article_title,journal_title,journal_abbre,article_date,abstract,article_type,pub_days,citation,abstract_clean,Breast Cancer,Lung Cancer,Leukemia,Prostate Cancer,Colorectal Cancer,Lymphoma,Bone Cancer,Melanoma,Liver Cancer,Kidney Cancer,Ovarian Cancer,Pancreatic Cancer,Brain Tumor,Head and Neck Cancer,Acute Myeloid Leukemia (AML),Multiple Myeloma,Sarcoma,Bladder Cancer,Skin Cancer,Gastric Cancer,Gastrointestinal Tumor,Endometrial Cancer,Acute Lymphoblastic Leukemia (ALL),Chronic Lymphocytic Leukemia (CLL),Cardiac Tumors,Cervical Cancer,Esophageal Cancer,Thyroid Cancer,Rectal Cancer,text_clean_seq,text_length,pmid,w2v_similarity_rank_cervical_cancer
The clinical course of deep vein thrombosis in patients with gynecologic cancer.,Gynecologic oncology,Gynecol. Oncol.,2002-01-01,"The aim of this study was to evaluate the survival of gynecologic cancer patients diagnosed with deep vein thrombosis. We retrospectively reviewed the charts of patients admitted to our institution with gynecologic malignancy who were diagnosed with deep vein thrombosis (DVT) between 1984 and 1995. Data were collected regarding site, stage, histology, treatment, and proximity of DVT to treatment with surgery, chemotherapy, and radiotherapy. This study was limited to cases of ovarian, uterine, and cervical cancer. Descriptive statistics were generated and the survival of patients from the time of DVT was calculated using the Kaplan and Meier method. Cases were then matched by site, stage, histology, and age to controls without DVT to evaluate the effect of DVT on survival. A Cox regression model was used to assess the effect of multiple variables on survival. A total of 74 cases were identified. Ovarian, uterine, and cervical cancer accounted for 45, 27, and 28% of cases, respectively. Approximately 64% of patients had stage III or greater disease. The median survival of all patients from the time of DVT diagnosis was 7.8 months, with only about 20% of patients surviving at 5 years. Patients with cervical cancer or patients who had radiation therapy within 3 months of DVT diagnosis had significantly lessened survival (P < 0.01) than other patients with DVT. The survival of patients from the time of cancer diagnosis with venous thrombosis was significantly worse than a matched control group without DVT (P < 0.001). On multivariate analysis, there was a twofold greater risk of dying in those patients with gynecologic cancer and DVT. The development of DVT in conjunction with a gynecologic malignancy connotes a poor prognosis, especially in patients with cervical cancer. It is possible that this poor prognosis is related to the pathophysiology that results in venous thrombosis and not just the presence of cancer.",Journal Article,6594.0,35.0,The aim of this study was to evaluate the survival of gynecologic cancer patients diagnosed with deep vein thrombosis We retrospectively reviewed the charts of patients admitted to our institution with gynecologic malignancy who were diagnosed with deep vein thrombosis DVT between 1984 and 1995 Data were collected regarding site stage histology treatment and proximity of DVT to treatment with surgery chemotherapy and radiotherapy This study was limited to cases of and cancer Descriptive statistics were generated and the survival of patients from the time of DVT was calculated using the Kaplan and Meier method Cases were then matched by site stage histology and age to controls without DVT to evaluate the effect of DVT on survival A Cox regression model was used to assess the effect of multiple variables on survival A total of 74 cases were identified and cancer accounted for 45 27 and 28 of cases respectively Approximately 64 of patients had stage III or greater disease The median survival of all patients from the time of DVT diagnosis was 7.8 months with only about 20 of patients surviving at 5 years Patients with cancer or patients who had radiation therapy within 3 months of DVT diagnosis had significantly lessened survival P 0.01 than other patients with DVT The survival of patients from the time of cancer diagnosis with venous thrombosis was significantly worse than a matched control group without DVT P 0.001 On multivariate analysis there was a twofold greater risk of dying in those patients with gynecologic cancer and DVT The development of DVT in conjunction with a gynecologic malignancy connotes a poor prognosis especially in patients with cancer It is possible that this poor prognosis is related to the pathophysiology that results in venous thrombosis and not just the presence of cancer,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 1130, 1, 26, 45, 10, 6, 376, 3, 25, 1, 1512, 12, 7, 265, 5, 2369, 2762, 2839, 21, 894, 446, 3, 4413, 1, 7, 4319, 6, 114, 731, 5, 1512, 710, 54, 11, 265, 5, 2369, 2762, 2839, 6311, 59, 6036, 2, 2323, 74, 11, 786, 666, 606, 82, 784, 24, 2, 6167, 1, 6311, 6, 24, 5, 152, 56, 2, 310, 26, 45, 10, 383, 6, 140, 1, 2, 12, 3778, 3065, 11, 1419, 2, 3, 25, 1, 7, 29, 3, 98, 1, 6311, 10, 981, 75, 3, 876, 2, 882, 596, 140, 11, 818, 655, 20, 606, 82, 784, 2, 89, 6, 535, 187, 6311, 6, 376, 3, 254, 1, 6311, 23, 25, 8, 418, 320, 202, 10, 95, 6, 423, 3, 254, 1, 232, 682, 23, 25, 8, 181, 1, 794, 140, 11, 108, 2, 12, 3688, 9, 512, 428, 2, 339, 1, 140, 106, 705, 660, 1, 7, 42, 82, 316, 15, 378, 34, 3, 52, 25, 1, 62, 7, 29, 3, 98, 1, 6311, 147, 10, 67, 66, 53, 5, 158, 545, 179, 1, 7, 3050, 28, 33, 60, 7, 5, 12, 15, 7, 54, 42, 121, 36, 262, 27, 53, 1, 6311, 147, 42, 97, 21933, 25, 19, 13, 355, 76, 127, 7, 5, 6311, 3, 25, 1, 7, 29, 3, 98, 1, 12, 147, 5, 2167, 2839, 10, 97, 639, 76, 8, 655, 182, 87, 187, 6311, 19, 13, 144, 23, 331, 65, 125, 10, 8, 8144, 378, 43, 1, 4536, 4, 135, 7, 5, 1512, 12, 2, 6311, 3, 193, 1, 6311, 4, 3357, 5, 8, 1512, 710, 33155, 8, 334, 356, 1093, 4, 7, 5, 12, 192, 16, 899, 17, 26, 334, 356, 16, 139, 6, 3, 4320, 17, 99, 4, 2167, 2839, 2, 44, 4673, 3, 463, 1, 12]",1826.0,11748979,792
Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival.,Gynecologic oncology,Gynecol. Oncol.,2002-01-01,"The incidence of cervical adenocarcinoma is increasing relative to squamous cell carcinoma and all cervical cancers. Few reports have described the outcome of patients with advanced cervical adenocarcinoma. The purpose of this study was to determine the prognostic factors and survival for patients with stage IIB-IVB disease. Institutional Review Board approval was obtained to perform a computerized search of all women diagnosed with cervical adenocarcinoma at our three institutions between 1982 and 2000. Medical records were retrospectively reviewed. Clinical follow-up was obtained from the SGO database and tumor registry and via correspondence with health care providers. Statistical analysis was performed using logistic regression for clinical variables and the log-rank test to compare Kaplan-Meier survival estimates. Eighty-three women with FIGO stage IIB-IVB cervical adenocarcinoma were identified. The median patient age was 53 years (range, 22-88). The median follow-up of 17 (20%) surviving patients was 33 months (range, 6-147); 66 (80%) died during the study interval. Stage IIB disease, young patient age, and grade 1 histology were independent variables having a favorable impact on survival (each P < 0.02). Stage IIB patients (n = 41) were more likely to be alive at 2 (64% vs 8%) and 5 years (30% vs 0%) than women with stage IIIA-IVB disease (n = 42; P < 0.01). Women diagnosed with advanced stage cervical adenocarcinoma have a poor prognosis. Prospective, multicenter trials of platinum-based chemoradiation or other novel therapies are urgently needed in the treatment of this highly lethal disease.",Journal Article,6594.0,47.0,The incidence of adenocarcinoma is increasing relative to squamous cell carcinoma and all cancers Few reports have described the outcome of patients with advanced adenocarcinoma The purpose of this study was to determine the prognostic factors and survival for patients with stage IIB-IVB disease Institutional Review Board approval was obtained to perform a computerized search of all women diagnosed with adenocarcinoma at our three institutions between 1982 and 2000 Medical records were retrospectively reviewed Clinical follow-up was obtained from the SGO database and tumor registry and via correspondence with health care providers Statistical analysis was performed using logistic regression for clinical variables and the log-rank test to compare Kaplan-Meier survival estimates Eighty-three women with FIGO stage IIB-IVB adenocarcinoma were identified The median patient age was 53 years range 22-88 The median follow-up of 17 20 surviving patients was 33 months range 6-147 66 80 died during the study interval Stage IIB disease young patient age and grade 1 histology were independent variables having a favorable impact on survival each P 0.02 Stage IIB patients n 41 were more likely to be alive at 2 64 vs 8 and 5 years 30 vs 0 than women with stage IIIA-IVB disease n 42 P 0.01 Women diagnosed with advanced stage adenocarcinoma have a poor prognosis Prospective multicenter trials of platinum-based chemoradiation or other novel therapies are urgently needed in the treatment of this highly lethal disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 287, 1, 449, 16, 602, 580, 6, 691, 31, 134, 2, 62, 163, 1021, 1198, 47, 1027, 3, 228, 1, 7, 5, 131, 449, 3, 743, 1, 26, 45, 10, 6, 223, 3, 177, 130, 2, 25, 9, 7, 5, 82, 3884, 7042, 34, 1115, 206, 2620, 1814, 10, 683, 6, 2715, 8, 4912, 1901, 1, 62, 117, 265, 5, 449, 28, 114, 169, 1764, 59, 6652, 2, 1081, 484, 1064, 11, 894, 446, 38, 166, 126, 10, 683, 29, 3, 12063, 609, 2, 30, 1608, 2, 847, 17597, 5, 341, 165, 1994, 1050, 65, 10, 173, 75, 812, 320, 9, 38, 682, 2, 3, 1066, 1026, 412, 6, 932, 876, 882, 25, 1423, 2207, 169, 117, 5, 3837, 82, 3884, 7042, 449, 11, 108, 3, 52, 69, 89, 10, 699, 60, 184, 350, 889, 3, 52, 166, 126, 1, 269, 179, 3050, 7, 10, 466, 53, 184, 49, 4961, 700, 493, 1016, 190, 3, 45, 268, 82, 3884, 34, 1169, 69, 89, 2, 88, 14, 784, 11, 306, 682, 1041, 8, 913, 345, 23, 25, 296, 19, 13, 588, 82, 3884, 7, 78, 605, 11, 80, 322, 6, 40, 1701, 28, 18, 660, 105, 66, 2, 33, 60, 201, 105, 13, 76, 117, 5, 82, 3164, 7042, 34, 78, 595, 19, 13, 355, 117, 265, 5, 131, 82, 449, 47, 8, 334, 356, 482, 1570, 143, 1, 828, 90, 975, 15, 127, 229, 235, 32, 5354, 575, 4, 3, 24, 1, 26, 561, 2266, 34]",1522.0,11748986,24
Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2002-01-01,"Recently, imaging-based tumor volume before, during, and after radiation therapy (RT) has been shown to predict tumor response in cervical cancer. However, the effectiveness of different methods and timing of imaging-based tumor size assessment have not been investigated. The purpose of this study was to compare the predictive value for treatment outcome derived from simple diameter-based ellipsoid tumor volume measurement using orthogonal diameters (with ellipsoid computation) with that derived from more complex contour tracing/region-of-interest (ROI) analysis 3D tumor volumetry. Serial magnetic resonance imaging (MRI) examinations were prospectively performed in 60 patients with advanced cervical cancer (Stages IB2-IVB/recurrent) at the start of RT, during early RT (20-25 Gy), mid-RT (45-50 Gy), and at follow-up (1-2 months after RT completion). ROI-based volumetry was derived by tracing the entire tumor region in each MR slice on the computer work station. For the diameter-based surrogate ""ellipsoid volume,"" the three orthogonal diameters (d1, d2, d3) were measured on film hard copies to calculate volume as an ellipsoid (d1 x d2 x d3 x pi/6). Serial tumor volumes and regression rates determined by each method were correlated with local control, disease-free and overall survival, and the results were compared between the two measuring methods. Median post-therapy follow-up was 4.9 years (range, 2.0-8.2 years). The best method and time point of tumor size measurement for the prediction of outcome was the tumor regression rate in the mid-therapy MRI examination (at 45-50 Gy) using 3D ROI volumetry. For the pre-RT measurement both the diameter-based method and ROI volumetry provided similar predictive accuracy, particularly for patients with small (<40 cm3) and large (> or =100 cm3) pre-RT tumor size. However, the pre-RT tumor size measured by either method had much less predictive value for the intermediate-size (40-99 cm3) tumors, which accounted for the majority of patients (55%). Tumor regression rate (fast vs. slow) obtained during mid-RT (45-50 Gy), which could only be appreciated by 3D ROI volumetry, had the best outcome prediction rate for local control (84% vs. 22%, p < 0.0001) and disease-free survival (63% vs. 20%, p = 0.0005). Within the difficult to classify intermediate pre-RT size group, slow ROI-based regression rate predicted all treatment failures (local control rate: 0% vs. 91%, p < 0.0001; disease-free survival: 0% vs. 73%, p < 0.0001). Mid-RT regression rate based on simple diameter measurement did not predict outcome. The early-RT and post-RT measurements were least useful with either measuring method. Our preliminary data suggest that for the prediction of treatment outcome in cervical cancer, initial tumor volume can be estimated by simple diameter-based measurement obtained from film hard copies. When initial tumor volume is in the intermediate size range, ROI volumetry and an additional MRI during RT are needed to quantitatively analyze tumor regression rate for the prediction of treatment outcome.",Journal Article,6594.0,125.0,Recently imaging-based tumor volume before during and after radiation therapy RT has been shown to predict tumor response in cancer However the effectiveness of different methods and timing of imaging-based tumor size assessment have not been investigated The purpose of this study was to compare the predictive value for treatment outcome derived from simple diameter-based ellipsoid tumor volume measurement using orthogonal diameters with ellipsoid computation with that derived from more complex contour tracing/region-of-interest ROI analysis 3D tumor volumetry Serial magnetic resonance imaging MRI examinations were prospectively performed in 60 patients with advanced cancer Stages IB2-IVB/recurrent at the start of RT during early RT 20-25 Gy mid-RT 45-50 Gy and at follow-up 1-2 months after RT completion ROI-based volumetry was derived by tracing the entire tumor region in each MR slice on the computer work station For the diameter-based surrogate `` ellipsoid volume '' the three orthogonal diameters d1 d2 d3 were measured on film hard copies to calculate volume as an ellipsoid d1 x d2 x d3 x pi/6 Serial tumor volumes and regression rates determined by each method were correlated with local control disease-free and overall survival and the results were compared between the two measuring methods Median post-therapy follow-up was 4.9 years range 2.0-8.2 years The best method and time point of tumor size measurement for the prediction of outcome was the tumor regression rate in the mid-therapy MRI examination at 45-50 Gy using 3D ROI volumetry For the pre-RT measurement both the diameter-based method and ROI volumetry provided similar predictive accuracy particularly for patients with small 40 cm3 and large or =100 cm3 pre-RT tumor size However the pre-RT tumor size measured by either method had much less predictive value for the intermediate-size 40-99 cm3 tumors which accounted for the majority of patients 55 Tumor regression rate fast vs. slow obtained during mid-RT 45-50 Gy which could only be appreciated by 3D ROI volumetry had the best outcome prediction rate for local control 84 vs. 22 p 0.0001 and disease-free survival 63 vs. 20 p 0.0005 Within the difficult to classify intermediate pre-RT size group slow ROI-based regression rate predicted all treatment failures local control rate 0 vs. 91 p 0.0001 disease-free survival 0 vs. 73 p 0.0001 Mid-RT regression rate based on simple diameter measurement did not predict outcome The early-RT and post-RT measurements were least useful with either measuring method Our preliminary data suggest that for the prediction of treatment outcome in cancer initial tumor volume can be estimated by simple diameter-based measurement obtained from film hard copies When initial tumor volume is in the intermediate size range ROI volumetry and an additional MRI during RT are needed to quantitatively analyze tumor regression rate for the prediction of treatment outcome,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[761, 270, 90, 30, 433, 348, 190, 2, 50, 121, 36, 240, 71, 85, 443, 6, 678, 30, 51, 4, 12, 137, 3, 1236, 1, 338, 636, 2, 1972, 1, 270, 90, 30, 444, 455, 47, 44, 85, 565, 3, 743, 1, 26, 45, 10, 6, 932, 3, 464, 549, 9, 24, 228, 526, 29, 2763, 2549, 90, 16180, 30, 433, 2204, 75, 9413, 10390, 5, 16180, 19417, 5, 17, 526, 29, 80, 840, 7523, 15457, 1053, 1, 1333, 9536, 65, 2265, 30, 14066, 2108, 1484, 1535, 270, 704, 4209, 11, 1143, 173, 4, 335, 7, 5, 131, 12, 1153, 9537, 7042, 387, 28, 3, 2435, 1, 240, 190, 191, 240, 179, 243, 381, 4863, 240, 512, 212, 381, 2, 28, 166, 126, 14, 18, 53, 50, 240, 1438, 9536, 90, 14066, 10, 526, 20, 15457, 3, 1797, 30, 1053, 4, 296, 1638, 10027, 23, 3, 4236, 1357, 15087, 9, 3, 2549, 90, 2592, 16180, 433, 522, 3, 169, 9413, 10390, 2146, 4171, 6037, 11, 644, 23, 9414, 9327, 5127, 6, 3232, 433, 22, 35, 16180, 2146, 1006, 4171, 1006, 6037, 1006, 2928, 49, 2108, 30, 2225, 2, 320, 151, 509, 20, 296, 596, 11, 438, 5, 293, 182, 34, 115, 2, 63, 25, 2, 3, 99, 11, 72, 59, 3, 100, 2978, 636, 52, 539, 36, 166, 126, 10, 39, 83, 60, 184, 18, 13, 66, 18, 60, 3, 824, 596, 2, 98, 741, 1, 30, 444, 2204, 9, 3, 1590, 1, 228, 10, 3, 30, 320, 116, 4, 3, 4863, 36, 704, 1385, 28, 512, 212, 381, 75, 2265, 9536, 14066, 9, 3, 671, 240, 2204, 110, 3, 2549, 90, 596, 2, 9536, 14066, 1052, 288, 464, 1190, 823, 9, 7, 5, 302, 327, 7397, 2, 375, 15, 394, 7397, 671, 240, 30, 444, 137, 3, 671, 240, 30, 444, 644, 20, 361, 596, 42, 1802, 299, 464, 549, 9, 3, 919, 444, 327, 1058, 7397, 57, 92, 3688, 9, 3, 686, 1, 7, 614, 30, 320, 116, 5830, 105, 3645, 683, 190, 4863, 240, 512, 212, 381, 92, 359, 158, 40, 7292, 20, 2265, 9536, 14066, 42, 3, 824, 228, 1590, 116, 9, 293, 182, 874, 105, 350, 19, 13, 488, 2, 34, 115, 25, 676, 105, 179, 19, 13, 4252, 262, 3, 1740, 6, 4896, 919, 671, 240, 444, 87, 3645, 9536, 90, 320, 116, 783, 62, 24, 3368, 293, 182, 116, 13, 105, 970, 19, 13, 488, 34, 115, 25, 13, 105, 803, 19, 13, 488, 4863, 240, 320, 116, 90, 23, 2763, 2549, 2204, 205, 44, 678, 228, 3, 191, 240, 2, 539, 240, 1685, 11, 506, 999, 5, 361, 2978, 596, 114, 1676, 74, 309, 17, 9, 3, 1590, 1, 24, 228, 4, 12, 388, 30, 433, 122, 40, 661, 20, 2763, 2549, 90, 2204, 683, 29, 9414, 9327, 5127, 198, 388, 30, 433, 16, 4, 3, 919, 444, 184, 9536, 14066, 2, 35, 402, 704, 190, 240, 32, 575, 6, 5889, 1992, 30, 320, 116, 9, 3, 1590, 1, 24, 228]",2949.0,11777618,6
An orthotopic nude mouse model of oral tongue squamous cell carcinoma.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2002-01-01,"Despite advances in our understanding, prevention, and treatment of head and neck squamous cell carcinoma (SCC), the 5-year survival rates for patients remain low. This poor prognosis for head and neck SCC and SCC of the oral tongue (SCCOT) in particular reflects a limited understanding of the mechanisms of local and regional metastasis, which accounts for a majority of deaths. To analyze the molecular and cellular mechanisms of metastasis, we have developed an orthotopic nude mouse model of SCCOT. Nude mice were injected submucosally in the tongue or subcutis with human squamous cell carcinoma of the oral cavity cell lines Tu159, Tu167, and MDA1986. The mice were necropsied and examined for the presence of primary tumors, and regional and systemic metastases. For all three of the squamous cell carcinoma of the oral cavity cell lines, tumors developed more readily in the orthotopic site, the tongue, than in the ectopic subcutis. MDA1986 cells were highly tumorigenic, particularly at the orthotopic site, with as few as 5 x 10(3) cells producing tumors in all of the mice. In contrast, s.c. tumor formation required at least 1 x 10(5) cells. The tumorigenicity observed between those mice given submucosal inoculation and those mice given s.c. inoculation (P < 0.0001). Regional metastases initially occurred in <10% of mice. To generate tumor lines of increased metastatic potential, regional metastases were isolated from cervical lymph nodes after the development of orthotopic tongue tumors. Serial passage of these lymph nodes resulted in a cell line more metastatic than its parental line. When injected into the tongues of mice, these cells metastasized to regional lymph nodes in 30% of mice and to the lungs in 20%. In this orthotopic murine model, oral tongue cancer recapitulates the behavior of human SCCOT, allowing for detailed studies of its biology and therapy.",Journal Article,6594.0,119.0,Despite advances in our understanding prevention and treatment of head and squamous cell carcinoma SCC the 5-year survival rates for patients remain low This poor prognosis for head and SCC and SCC of the oral tongue SCCOT in particular reflects a limited understanding of the mechanisms of local and regional metastasis which accounts for a majority of deaths To analyze the molecular and cellular mechanisms of metastasis we have developed an orthotopic nude mouse model of SCCOT Nude mice were injected submucosally in the tongue or subcutis with human squamous cell carcinoma of the oral cavity cell lines Tu159 Tu167 and MDA1986 The mice were necropsied and examined for the presence of primary tumors and regional and systemic metastases For all three of the squamous cell carcinoma of the oral cavity cell lines tumors developed more readily in the orthotopic site the tongue than in the ectopic subcutis MDA1986 cells were highly tumorigenic particularly at the orthotopic site with as few as 5 x 10 3 cells producing tumors in all of the mice In contrast s.c. tumor formation required at least 1 x 10 5 cells The tumorigenicity observed between those mice given submucosal inoculation and those mice given s.c. inoculation P 0.0001 Regional metastases initially occurred in 10 of mice To generate tumor lines of increased metastatic potential regional metastases were isolated from lymph nodes after the development of orthotopic tongue tumors Serial passage of these lymph nodes resulted in a cell line more metastatic than its parental line When injected into the tongues of mice these cells metastasized to regional lymph nodes in 30 of mice and to the lungs in 20 In this orthotopic murine model oral tongue cancer recapitulates the behavior of human SCCOT allowing for detailed studies of its biology and therapy,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[550, 954, 4, 114, 612, 1070, 2, 24, 1, 718, 2, 691, 31, 134, 1791, 3, 33, 111, 25, 151, 9, 7, 918, 154, 26, 334, 356, 9, 718, 2, 1791, 2, 1791, 1, 3, 518, 4391, 10948, 4, 1454, 5224, 8, 383, 612, 1, 3, 483, 1, 293, 2, 951, 278, 92, 4162, 9, 8, 686, 1, 1043, 6, 1992, 3, 219, 2, 763, 483, 1, 278, 21, 47, 276, 35, 2157, 2598, 830, 202, 1, 10948, 2598, 399, 11, 2651, 37075, 4, 3, 4391, 15, 15089, 5, 171, 691, 31, 134, 1, 3, 518, 2405, 31, 285, 27844, 20990, 2, 23073, 3, 399, 11, 42833, 2, 409, 9, 3, 463, 1, 86, 57, 2, 951, 2, 403, 196, 9, 62, 169, 1, 3, 691, 31, 134, 1, 3, 518, 2405, 31, 285, 57, 276, 80, 3860, 4, 3, 2157, 606, 3, 4391, 76, 4, 3, 3647, 15089, 23073, 37, 11, 561, 3795, 823, 28, 3, 2157, 606, 5, 22, 1021, 22, 33, 1006, 79, 27, 37, 3787, 57, 4, 62, 1, 3, 399, 4, 748, 695, 256, 30, 1264, 616, 28, 506, 14, 1006, 79, 33, 37, 3, 5538, 164, 59, 135, 399, 447, 9729, 9229, 2, 135, 399, 447, 695, 256, 9229, 19, 13, 488, 951, 196, 1625, 489, 4, 79, 1, 399, 6, 2562, 30, 285, 1, 101, 113, 174, 951, 196, 11, 1355, 29, 263, 502, 50, 3, 193, 1, 2157, 4391, 57, 2108, 7740, 1, 46, 263, 502, 627, 4, 8, 31, 328, 80, 113, 76, 211, 3418, 328, 198, 2651, 237, 3, 23074, 1, 399, 46, 37, 8486, 6, 951, 263, 502, 4, 201, 1, 399, 2, 6, 3, 4465, 4, 179, 4, 26, 2157, 1471, 202, 518, 4391, 12, 11076, 3, 1710, 1, 171, 10948, 2952, 9, 2455, 94, 1, 211, 891, 2, 36]",1826.0,11801572,56
Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection.,Gynecologic oncology,Gynecol. Oncol.,2002-02-01,"Previous reports suggest that cervical adenocarcinomas have a unique pattern of spread and are more apt to metastasize to para-aortic lymph nodes. The purpose of this study was to further define the node of para-aortic lymph node dissection in early-stage cervical adenocarcinoma treated by surgical intent. Institutional review board approval was obtained to perform a computerized search of the data of all women diagnosed with cervical adenocarcinoma between 1982 and 2000. Hospital charts were retrospectively reviewed. Follow-up was obtained from the tumor registry, medical records, and correspondence with health care providers. Three hundred (87%) of 345 early-stage (FIGO IA(1)-IIA) cervical adenocarcinoma patients were primarily treated by surgical intent. Two hundred seventy-six underwent pelvic and para-aortic node dissection (n = 69) or pelvic node dissection only (n = 207); 24 had no lymph node dissection. The median number of lymph nodes removed was 13 pelvic (range, 1-58) and 3 para-aortic (range, 1-17). Three (4%) of 69 patients had para-aortic nodal metastases. Each had either grossly evident para-aortic adenopathy (n = 2) or an adnexal metastasis. Thirty-six of 40 women developing recurrent disease had at least some component of pelvic recurrence; 4 had only extrapelvic disease. Three patients undergoing para-aortic node dissection developed an isolated extrapelvic recurrence despite originally negative para-aortic nodes (n = 2) or treatment by extended-field radiation for para-aortic metastases. One woman undergoing only pelvic node dissection had an isolated extrapelvic recurrence despite originally negative nodes. Early-stage cervical adenocarcinoma primarily treated by surgical intent has a very low risk of para-aortic metastases. These were detected only when there was gross evidence of nodal or adnexal disease.",Journal Article,6563.0,12.0,Previous reports suggest that adenocarcinomas have a unique pattern of spread and are more apt to metastasize to para-aortic lymph nodes The purpose of this study was to further define the node of para-aortic lymph node dissection in early-stage adenocarcinoma treated by surgical intent Institutional review board approval was obtained to perform a computerized search of the data of all women diagnosed with adenocarcinoma between 1982 and 2000 Hospital charts were retrospectively reviewed Follow-up was obtained from the tumor registry medical records and correspondence with health care providers Three hundred 87 of 345 early-stage FIGO IA 1 -IIA adenocarcinoma patients were primarily treated by surgical intent Two hundred seventy-six underwent pelvic and para-aortic node dissection n 69 or pelvic node dissection only n 207 24 had no lymph node dissection The median number of lymph nodes removed was 13 pelvic range 1-58 and 3 para-aortic range 1-17 Three 4 of 69 patients had para-aortic nodal metastases Each had either grossly evident para-aortic adenopathy n 2 or an adnexal metastasis Thirty-six of 40 women developing recurrent disease had at least some component of pelvic recurrence 4 had only extrapelvic disease Three patients undergoing para-aortic node dissection developed an isolated extrapelvic recurrence despite originally negative para-aortic nodes n 2 or treatment by extended-field radiation for para-aortic metastases One woman undergoing only pelvic node dissection had an isolated extrapelvic recurrence despite originally negative nodes Early-stage adenocarcinoma primarily treated by surgical intent has a very low risk of para-aortic metastases These were detected only when there was gross evidence of nodal or adnexal disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[698, 1198, 309, 17, 1586, 47, 8, 991, 1177, 1, 2579, 2, 32, 80, 15825, 6, 5769, 6, 4615, 3938, 263, 502, 3, 743, 1, 26, 45, 10, 6, 195, 1107, 3, 289, 1, 4615, 3938, 263, 289, 1161, 4, 191, 82, 449, 73, 20, 221, 1697, 1115, 206, 2620, 1814, 10, 683, 6, 2715, 8, 4912, 1901, 1, 3, 74, 1, 62, 117, 265, 5, 449, 59, 6652, 2, 1081, 702, 4413, 11, 894, 446, 166, 126, 10, 683, 29, 3, 30, 1608, 484, 1064, 2, 17597, 5, 341, 165, 1994, 169, 1128, 912, 1, 9005, 191, 82, 3837, 3302, 14, 4088, 449, 7, 11, 1561, 73, 20, 221, 1697, 100, 1128, 2073, 437, 208, 1110, 2, 4615, 3938, 289, 1161, 78, 790, 15, 1110, 289, 1161, 158, 78, 5292, 259, 42, 77, 263, 289, 1161, 3, 52, 207, 1, 263, 502, 2264, 10, 233, 1110, 184, 14, 717, 2, 27, 4615, 3938, 184, 14, 269, 169, 39, 1, 790, 7, 42, 4615, 3938, 779, 196, 296, 42, 361, 7185, 2853, 4615, 3938, 7741, 78, 18, 15, 35, 6462, 278, 977, 437, 1, 327, 117, 931, 387, 34, 42, 28, 506, 476, 1249, 1, 1110, 146, 39, 42, 158, 12070, 34, 169, 7, 479, 4615, 3938, 289, 1161, 276, 35, 1355, 12070, 146, 550, 5045, 199, 4615, 3938, 502, 78, 18, 15, 24, 20, 1747, 1067, 121, 9, 4615, 3938, 196, 104, 2854, 479, 158, 1110, 289, 1161, 42, 35, 1355, 12070, 146, 550, 5045, 199, 502, 191, 82, 449, 1561, 73, 20, 221, 1697, 71, 8, 923, 154, 43, 1, 4615, 3938, 196, 46, 11, 530, 158, 198, 125, 10, 1789, 241, 1, 779, 15, 6462, 34]",1764.0,11812088,514
Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2002-01-01,"Human papillomaviruses (HPVs) play a central role in the development of cervical carcinoma. Plasma DNA from 232 patients taken at diagnosis or after treatment for invasive cervical cancer (n = 175) or carcinoma in situ (n = 57) and 60 normal controls were examined for HPV-16 or HPV-18 E7 DNA by conventional and real-time quantitative PCR assays. We found HPV-16 or HPV-18 E7 DNA in 6.9% (11 of 175) of invasive cervical cancer cases (18.1% of cases positive for HPV-16 or HPV-18 at the genital tract), 1.8% (1 of 57) of carcinoma in situ, and 1.7% (1 of 60) of normal controls by conventional PCR. Quantitative PCR identified the highest concentrations of HPV DNA (copy number of HPV/ml of plasma) in patients with invasive cervical cancer (mean, 11,163; median, 183.5), followed by a level of 8 in the single carcinoma in situ case and 0 copies in the normal control initially positive by conventional PCR. HPV DNA can be detected in the plasma of some patients with HPV-positive cervical tumors. It remains to be demonstrated whether quantitative PCR analysis of HPV DNA in plasma may have utility in patients at high risk of recurrent disease.",Journal Article,6594.0,67.0,"Human papillomaviruses HPVs play a central role in the development of carcinoma Plasma DNA from 232 patients taken at diagnosis or after treatment for invasive cancer n 175 or carcinoma in situ n 57 and 60 normal controls were examined for HPV-16 or HPV-18 E7 DNA by conventional and real-time quantitative PCR assays We found HPV-16 or HPV-18 E7 DNA in 6.9 11 of 175 of invasive cancer cases 18.1 of cases positive for HPV-16 or HPV-18 at the genital tract 1.8 1 of 57 of carcinoma in situ and 1.7 1 of 60 of normal controls by conventional PCR Quantitative PCR identified the highest concentrations of HPV DNA copy number of HPV/ml of plasma in patients with invasive cancer mean 11,163 median 183.5 followed by a level of 8 in the single carcinoma in situ case and 0 copies in the normal control initially positive by conventional PCR HPV DNA can be detected in the plasma of some patients with HPV-positive tumors It remains to be demonstrated whether quantitative PCR analysis of HPV DNA in plasma may have utility in patients at high risk of recurrent disease",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 14731, 13477, 1343, 8, 854, 200, 4, 3, 193, 1, 134, 554, 261, 29, 7186, 7, 1633, 28, 147, 15, 50, 24, 9, 416, 12, 78, 3300, 15, 134, 4, 957, 78, 696, 2, 335, 295, 535, 11, 409, 9, 933, 245, 15, 933, 203, 4540, 261, 20, 809, 2, 1589, 98, 1156, 604, 1013, 21, 204, 933, 245, 15, 933, 203, 4540, 261, 4, 49, 83, 175, 1, 3300, 1, 416, 12, 140, 203, 14, 1, 140, 109, 9, 933, 245, 15, 933, 203, 28, 3, 8226, 1696, 14, 66, 14, 1, 696, 1, 134, 4, 957, 2, 14, 67, 14, 1, 335, 1, 295, 535, 20, 809, 604, 1156, 604, 108, 3, 1076, 1003, 1, 933, 261, 1337, 207, 1, 933, 542, 1, 554, 4, 7, 5, 416, 12, 313, 175, 5409, 52, 6348, 33, 370, 20, 8, 301, 1, 66, 4, 3, 226, 134, 4, 957, 473, 2, 13, 5127, 4, 3, 295, 182, 1625, 109, 20, 809, 604, 933, 261, 122, 40, 530, 4, 3, 554, 1, 476, 7, 5, 933, 109, 57, 192, 469, 6, 40, 264, 317, 1156, 604, 65, 1, 933, 261, 4, 554, 68, 47, 1207, 4, 7, 28, 64, 43, 1, 387, 34]",1065.0,11815394,260
Laparoscopic management of urolithiasis in a continent urostomy.,Gynecologic oncology,Gynecol. Oncol.,2002-03-01,"Urinary calculi formation is an infrequent but challenging late complication of continent urostomy. Percutaneous endoscopic management of two patients with symptomatic pouch urolithiasis is described. A 48-year-old woman with a history of cervical squamous cell carcinoma (SCC) treated with primary chemoradiotherapy presented with recurrent pain and urinary tract infections (pouchitis). She had undergone continent urostomy 4 years previously for management of a vesicovaginal fistula. A 59-year-old woman following exenteration with continent diversion for recurrent cervix SCC had a 6-month history of refractory pouchitis. In both women, multiple pouch urinary calculi were identified. Their continent reservoirs were, in part, created using titanium staplers. Percutaneous CO(2) endoscopy afforded identification and removal of their stones and staples without complication. Successful treatment of continent urostomy urolithiasis is accomplished by percutaneous endoscopy.",Case Reports,6535.0,6.0,Urinary calculi formation is an infrequent but challenging late complication of continent urostomy Percutaneous endoscopic management of two patients with symptomatic pouch urolithiasis is described A 48-year-old woman with a history of squamous cell carcinoma SCC treated with primary chemoradiotherapy presented with recurrent pain and urinary tract infections pouchitis She had undergone continent urostomy 4 years previously for management of a vesicovaginal fistula A 59-year-old woman following exenteration with continent diversion for recurrent cervix SCC had a 6-month history of refractory pouchitis In both women multiple pouch urinary calculi were identified Their continent reservoirs were in part created using titanium staplers Percutaneous CO 2 endoscopy afforded identification and removal of their stones and staples without complication Successful treatment of continent urostomy urolithiasis is accomplished by percutaneous endoscopy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1660, 37091, 1264, 16, 35, 4475, 84, 1950, 807, 1447, 1, 10396, 27852, 3720, 2056, 284, 1, 100, 7, 5, 1704, 15832, 42847, 16, 1027, 8, 576, 111, 1095, 2854, 5, 8, 532, 1, 691, 31, 134, 1791, 73, 5, 86, 1464, 917, 5, 387, 559, 2, 1660, 1696, 1875, 37092, 3109, 42, 1989, 10396, 27852, 39, 60, 373, 9, 284, 1, 8, 25979, 4920, 8, 728, 111, 1095, 2854, 366, 5668, 5, 10396, 6067, 9, 387, 3629, 1791, 42, 8, 49, 811, 532, 1, 430, 37092, 4, 110, 117, 232, 15832, 1660, 37091, 11, 108, 136, 10396, 17087, 11, 4, 760, 2466, 75, 33185, 33186, 3720, 1269, 18, 4199, 9150, 911, 2, 2829, 1, 136, 21948, 2, 42848, 187, 1447, 1401, 24, 1, 10396, 27852, 42847, 16, 5741, 20, 3720, 4199]",953.0,11855892,76
Magnetic resonance imaging findings in a case of cytarabine-induced myelopathy.,Military medicine,Mil Med,2002-02-01,"A 44-year-old white male with an isolated central nervous system relapse of acute lymphoblastic leukemia was treated with intrathecal cytarabine. He developed Staphylococcus epidermidis meningitis, which was treated successfully with intrathecal vancomycin. Four weeks after the initiation of intrathecal cytarabine, the patient developed progressive ascending paralysis to the upper cervical level. Initial magnetic resonance imaging of the brain and spine were normal, and cerebrospinal fluid evaluation showed no evidence of ongoing infection and clearance of lymphoblasts. Three weeks later, magnetic resonance imaging demonstrated marked edema and peripheral enhancement of the spinal cord, consistent with cytarabine toxicity.",Case Reports,6563.0,11.0,A 44-year-old white male with an isolated central nervous system relapse of acute lymphoblastic was treated with intrathecal cytarabine He developed Staphylococcus epidermidis meningitis which was treated successfully with intrathecal vancomycin Four weeks after the initiation of intrathecal cytarabine the patient developed progressive ascending paralysis to the upper level Initial magnetic resonance imaging of the brain and spine were normal and cerebrospinal fluid evaluation showed no evidence of ongoing infection and clearance of lymphoblasts Three weeks later magnetic resonance imaging demonstrated marked edema and peripheral enhancement of the spinal cord consistent with cytarabine toxicity,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,"[8, 584, 111, 1095, 886, 1045, 5, 35, 1355, 854, 1880, 398, 429, 1, 286, 1275, 10, 73, 5, 5126, 1855, 3174, 276, 14739, 42859, 10792, 92, 10, 73, 1878, 5, 5126, 9013, 294, 244, 50, 3, 1118, 1, 5126, 1855, 3, 69, 276, 1014, 14404, 11737, 6, 3, 1726, 301, 388, 1484, 1535, 270, 1, 3, 342, 2, 2342, 11, 295, 2, 5156, 2357, 451, 224, 77, 241, 1, 942, 930, 2, 1960, 1, 10521, 169, 244, 1559, 1484, 1535, 270, 264, 2003, 3306, 2, 672, 2461, 1, 3, 1499, 1885, 925, 5, 1855, 155]",704.0,11873541,322
Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation.,Human gene therapy,Hum. Gene Ther.,2002-03-01,"Herpes simplex virus type 1 (HSV-1)-based oncolytic treatment is a promising therapeutic approach for malignancy. Recombinant strains of HSV-1 containing mutations in the ICP 34.5 protein have been shown to replicate preferentially in rapidly proliferating malignant cells, resulting in a direct cytolytic effect. We assessed the efficacy of multimutated HSV-1 strains on human cervical cancer, and then used these viruses in combination with radiation therapy, the standard treatment for cervical cancer. The HSV-1 mutants 4009, 7020, 3616, and G207 induced significant lysis of three established human cervical cancer cell lines in vitro in a dose-dependent manner. G207 intratumoral treatment of established subcutaneous C33a tumors in severe combined immunodeficient (SCID) mice significantly reduced tumor burden by 50%. Weekly and triweekly treatments improved efficacy and inhibited flank tumor growth in an administration frequency-dependent manner without toxicity. Combination therapy of a low dose of radiation (1.5 or 3 Gy) and replication-selective HSV mutants infection exhibited increased antitumor effects against cervical cancer cells in vitro. The in vivo effect of G207 combined with low-dose radiation was studied in Me180 xenografts in athymic mice. Treatment of established Me180 tumor nodules with 3 Gy followed by intratumoral G207 administration greatly improved efficacy, resulting in 42% complete eradication of tumor. In conclusion, single and multiple intratumoral injections of G207 significantly reduced tumor burden in xenogeneic models of cervical cancer, and the addition of low-dose radiation further potentiated the effect. These results suggest that replication-selective HSV-1 mutants may be potent oncolytic agents for the treatment of cervical cancer.",Journal Article,6535.0,51.0,Herpes simplex virus type 1 HSV-1 -based oncolytic treatment is a promising therapeutic approach for malignancy Recombinant strains of HSV-1 containing mutations in the ICP 34.5 protein have been shown to replicate preferentially in rapidly proliferating malignant cells resulting in a direct cytolytic effect We assessed the efficacy of multimutated HSV-1 strains on human cancer and then used these viruses in combination with radiation therapy the standard treatment for cancer The HSV-1 mutants 4009 7020 3616 and G207 induced significant lysis of three established human cancer cell lines in vitro in a dose-dependent manner G207 intratumoral treatment of established subcutaneous C33a tumors in severe combined immunodeficient SCID mice significantly reduced tumor burden by 50 Weekly and triweekly treatments improved efficacy and inhibited flank tumor growth in an administration frequency-dependent manner without toxicity Combination therapy of a low dose of radiation 1.5 or 3 Gy and replication-selective HSV mutants infection exhibited increased antitumor effects against cancer cells in vitro The in vivo effect of G207 combined with low-dose radiation was studied in Me180 xenografts in athymic mice Treatment of established Me180 tumor nodules with 3 Gy followed by intratumoral G207 administration greatly improved efficacy resulting in 42 complete eradication of tumor In conclusion single and multiple intratumoral injections of G207 significantly reduced tumor burden in xenogeneic models of cancer and the addition of low-dose radiation further potentiated the effect These results suggest that replication-selective HSV-1 mutants may be potent oncolytic agents for the treatment of cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4716, 7241, 1450, 267, 14, 4702, 14, 90, 3236, 24, 16, 8, 721, 189, 353, 9, 710, 2835, 5175, 1, 4702, 14, 1101, 138, 4, 3, 24418, 562, 33, 178, 47, 85, 443, 6, 6423, 3509, 4, 1755, 5639, 393, 37, 1113, 4, 8, 1196, 6957, 254, 21, 275, 3, 209, 1, 42876, 4702, 14, 5175, 23, 171, 12, 2, 818, 95, 46, 4405, 4, 150, 5, 121, 36, 3, 260, 24, 9, 12, 3, 4702, 14, 3423, 42877, 42878, 37119, 2, 11552, 277, 93, 4783, 1, 169, 635, 171, 12, 31, 285, 4, 439, 4, 8, 61, 470, 1708, 11552, 2074, 24, 1, 635, 2529, 37059, 57, 4, 905, 397, 5031, 4129, 399, 97, 405, 30, 892, 20, 212, 709, 2, 33199, 640, 231, 209, 2, 879, 5564, 30, 129, 4, 35, 634, 675, 470, 1708, 187, 155, 150, 36, 1, 8, 154, 61, 1, 121, 14, 33, 15, 27, 381, 2, 2079, 1094, 4702, 3423, 930, 1416, 101, 579, 176, 480, 12, 37, 4, 439, 3, 4, 386, 254, 1, 11552, 397, 5, 154, 61, 121, 10, 656, 4, 42879, 1348, 4, 6396, 399, 24, 1, 635, 42879, 30, 2597, 5, 27, 381, 370, 20, 2074, 11552, 634, 3510, 231, 209, 1113, 4, 595, 236, 5173, 1, 30, 4, 1221, 226, 2, 232, 2074, 4344, 1, 11552, 97, 405, 30, 892, 4, 11240, 274, 1, 12, 2, 3, 352, 1, 154, 61, 121, 195, 6707, 3, 254, 46, 99, 309, 17, 2079, 1094, 4702, 14, 3423, 68, 40, 1157, 3236, 183, 9, 3, 24, 1, 12]",1710.0,11916486,433
Detection of female lower genital tract dysplasia using orally administered 5-aminolevulinic acid induced protoporphyrin IX: a preliminary study.,Gynecologic oncology,Gynecol. Oncol.,2002-04-01,"Previous studies have suggested that 5-aminolevulinic acid (ALA) may be used topically on the cervix to allow optical detection of cervical dysplasia, based on the fluorescence of protoporphyrin IX (PpIX) synthesized in situ from ALA. However, the uniformity of distribution of topically applied PpIX and the sensitivity and specificity of detection are not optimal. The current study was undertaken to demonstrate the feasibility of administering ALA by mouth (po) with the hypothesis that systemic administration might provide a more reliable diagnostic tool. Oral ALA was administered to 14 patients with abnormal Pap smears in a dose- and time-intensity design. Institutional review board approval was obtained. A starting dose of 10 mg/kg of po ALA was administered and colposcopy was performed in 3 patients at 1 h, 3 patients at 2 h, 6 patients at 3 h, and 2 patients at 4 h. The study was written with the intent to increase the dose in 10 mg/kg increments if fluorescence was not detected; however, fluorescence was detected at the first dose level. Liver function tests were checked pre and post ALA and follow-up telephone calls were made regarding possible side effects. Both white and blue light colposcopy examinations were performed by two blinded clinicians and biopsies of all abnormal areas were performed. All patients tolerated po ALA well, with no systemic side effects. At the 10 mg/kg dose there was no reported nausea or photosensitivity. Optimal fluorescence was achieved at the 3-h time point, with quenching noted at the 4-h time point. Excellent absorption was documented with fluorescence of the lip demonstrated with Wood's lamp. In some cases fluorescence correlated with dysplasia on biopsy. 5-ALA given via the po route and at the dose and time period studied is well tolerated and affords fluorescence of the cervix. Future study is needed to demonstrate the successful identification of dysplastic lesions, with the ultimate goal of treating dysplasia of the lower genital tract with 5-ALA and light therapy.",Clinical Trial,6504.0,10.0,Previous studies have suggested that 5-aminolevulinic acid ALA may be used topically on the cervix to allow optical detection of dysplasia based on the fluorescence of protoporphyrin IX PpIX synthesized in situ from ALA However the uniformity of distribution of topically applied PpIX and the sensitivity and specificity of detection are not optimal The current study was undertaken to demonstrate the feasibility of administering ALA by mouth po with the hypothesis that systemic administration might provide a more reliable diagnostic tool Oral ALA was administered to 14 patients with abnormal Pap smears in a dose- and time-intensity design Institutional review board approval was obtained A starting dose of 10 mg/kg of po ALA was administered and colposcopy was performed in 3 patients at 1 h 3 patients at 2 h 6 patients at 3 h and 2 patients at 4 h. The study was written with the intent to increase the dose in 10 mg/kg increments if fluorescence was not detected however fluorescence was detected at the first dose level function tests were checked pre and post ALA and follow-up telephone calls were made regarding possible side effects Both white and blue light colposcopy examinations were performed by two blinded clinicians and biopsies of all abnormal areas were performed All patients tolerated po ALA well with no systemic side effects At the 10 mg/kg dose there was no reported nausea or photosensitivity Optimal fluorescence was achieved at the 3-h time point with quenching noted at the 4-h time point Excellent absorption was documented with fluorescence of the lip demonstrated with Wood 's lamp In some cases fluorescence correlated with dysplasia on biopsy 5-ALA given via the po route and at the dose and time period studied is well tolerated and affords fluorescence of the cervix Future study is needed to demonstrate the successful identification of dysplastic lesions with the ultimate goal of treating dysplasia of the lower genital tract with 5-ALA and light therapy,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[698, 94, 47, 1148, 17, 33, 30218, 971, 8497, 68, 40, 95, 21012, 23, 3, 3629, 6, 1700, 4303, 638, 1, 2253, 90, 23, 3, 1591, 1, 33206, 8032, 21013, 5134, 4, 957, 29, 8497, 137, 3, 9338, 1, 1395, 1, 21012, 1498, 21013, 2, 3, 485, 2, 1121, 1, 638, 32, 44, 665, 3, 291, 45, 10, 2789, 6, 608, 3, 1437, 1, 5776, 8497, 20, 5831, 4826, 5, 3, 1492, 17, 403, 634, 822, 377, 8, 80, 2450, 752, 1515, 518, 8497, 10, 468, 6, 213, 7, 5, 1668, 4290, 8916, 4, 8, 61, 2, 98, 837, 771, 1115, 206, 2620, 1814, 10, 683, 8, 1723, 61, 1, 79, 81, 503, 1, 4826, 8497, 10, 468, 2, 9946, 10, 173, 4, 27, 7, 28, 14, 555, 27, 7, 28, 18, 555, 49, 7, 28, 27, 555, 2, 18, 7, 28, 39, 555, 3, 45, 10, 6538, 5, 3, 1697, 6, 344, 3, 61, 4, 79, 81, 503, 8225, 492, 1591, 10, 44, 530, 137, 1591, 10, 530, 28, 3, 157, 61, 301, 343, 895, 11, 14749, 671, 2, 539, 8497, 2, 166, 126, 4258, 6467, 11, 1229, 666, 899, 1152, 176, 110, 886, 2, 3352, 1691, 9946, 4209, 11, 173, 20, 100, 3288, 1490, 2, 1154, 1, 62, 1668, 1361, 11, 173, 62, 7, 421, 4826, 8497, 149, 5, 77, 403, 1152, 176, 28, 3, 79, 81, 503, 61, 125, 10, 77, 210, 1218, 15, 18142, 665, 1591, 10, 513, 28, 3, 27, 555, 98, 741, 5, 21964, 1051, 28, 3, 39, 555, 98, 741, 1503, 6125, 10, 1405, 5, 1591, 1, 3, 13489, 264, 5, 42884, 292, 30219, 4, 476, 140, 1591, 438, 5, 2253, 23, 411, 33, 8497, 447, 847, 3, 4826, 5841, 2, 28, 3, 61, 2, 98, 727, 656, 16, 149, 421, 2, 13485, 1591, 1, 3, 3629, 508, 45, 16, 575, 6, 608, 3, 1401, 911, 1, 6461, 406, 5, 3, 5768, 1326, 1, 1367, 2253, 1, 3, 280, 8226, 1696, 5, 33, 8497, 2, 1691, 36]",1998.0,11925131,129
Epstein-Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue.,Journal of pediatric hematology/oncology,J. Pediatr. Hematol. Oncol.,2002-02-01,"Epstein-Barr virus-associated lymphoproliferative disease (EBV-LPD) is a serious disorder seen in various states of immunodeficiency, often with a fatal outcome. In this article, a patient with EBV-lymphoma after autologous stem cell rescue for treatment of a nonhematologic solid tumor is described. The child, a 4-year-old boy, had unilateral retinoblastoma with metastatic spread to the central nervous system. He had previously received both local tumor bed and craniospinal radiation therapy together with intensive myeloablative alkylator chemotherapy before autologous stem cell rescue. Histologically confirmed lymphoma with evidence of active EBV proliferation developed within cervical lymph nodes 3 weeks after his first autologous stem cell rescue. A complete clinical remission of the lymphadenopathy was obtained after infusions of rituximab (an anti-CD20 monoclonal antibody), acyclovir, and high-titer anticytomegalovirus immunoglobulin. The patient died approximately 6 months later of persistent and progressive retinoblastoma without any clinical evidence of lymphoma. It is concluded that EBV-LPD should be included in the differential diagnosis in patients in whom lymphadenopathy develops after autologous stem cell rescue.",Case Reports,6563.0,11.0,Epstein-Barr virus-associated lymphoproliferative disease EBV-LPD is a serious disorder seen in various states of immunodeficiency often with a fatal outcome In this article a patient with EBV-lymphoma after autologous stem cell rescue for treatment of a nonhematologic solid tumor is described The child a 4-year-old boy had unilateral with metastatic spread to the central nervous system He had previously received both local tumor bed and craniospinal radiation therapy together with intensive myeloablative alkylator chemotherapy before autologous stem cell rescue Histologically confirmed with evidence of active EBV proliferation developed within lymph nodes 3 weeks after his first autologous stem cell rescue A complete clinical remission of the lymphadenopathy was obtained after infusions of rituximab an anti-CD20 monoclonal antibody acyclovir and high-titer anticytomegalovirus immunoglobulin The patient died approximately 6 months later of persistent and progressive without any clinical evidence of It is concluded that EBV-LPD should be included in the differential diagnosis in patients in whom lymphadenopathy develops after autologous stem cell rescue,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[5212, 5190, 1450, 41, 4192, 34, 2672, 8445, 16, 8, 1762, 2645, 527, 4, 747, 907, 1, 5323, 629, 5, 8, 3034, 228, 4, 26, 946, 8, 69, 5, 2672, 4763, 50, 1028, 452, 31, 4256, 9, 24, 1, 8, 3534, 537, 30, 16, 1027, 3, 2566, 8, 39, 111, 1095, 10802, 42, 3208, 5, 113, 2579, 6, 3, 854, 1880, 398, 3174, 42, 373, 103, 110, 293, 30, 2929, 2, 5748, 121, 36, 1162, 5, 1686, 3246, 9346, 56, 348, 1028, 452, 31, 4256, 2161, 557, 5, 241, 1, 544, 2672, 457, 276, 262, 263, 502, 27, 244, 50, 3224, 157, 1028, 452, 31, 4256, 8, 236, 38, 734, 1, 3, 4962, 10, 683, 50, 3435, 1, 855, 35, 312, 2198, 848, 548, 17606, 2, 64, 8444, 52883, 2593, 3, 69, 1016, 705, 49, 53, 1559, 1, 1882, 2, 1014, 187, 500, 38, 241, 1, 192, 16, 4724, 17, 2672, 8445, 257, 40, 159, 4, 3, 1777, 147, 4, 7, 4, 953, 4962, 4734, 50, 1028, 452, 31, 4256]",1170.0,11998794,524
Cervical subluxation after surgery and irradiation of childhood ependymoma.,Pediatric neurosurgery,Pediatr Neurosurg,2002-04-01,"Aggressive resection followed by postoperative radiation therapy directed at the tumor bed characterizes the treatment of childhood infratentorial ependymoma. Tumor resection often requires access to the upper portion of the cervical spinal canal, which places the patient at risk of complications, including destabilization. Two cases of cervical subluxation after surgery and irradiation for infratentorial ependymoma are presented and discussed to identify factors that may be responsible for this uncommon treatment complication. Cervical laminotomies, multiple surgeries, postoperative infection and the addition of radiation therapy may be contributory. Because second resection will be an important component of the next generation of cooperative group studies for infratentorial tumors, the incidence and severity of this treatment-related complication should be documented and efforts should be made to image the upper portion of the cervical spine during routine follow-up.",Case Reports,6504.0,1.0,Aggressive resection followed by postoperative radiation therapy directed at the tumor bed characterizes the treatment of childhood infratentorial ependymoma Tumor resection often requires access to the upper portion of the spinal canal which places the patient at risk of complications including destabilization Two cases of subluxation after surgery and irradiation for infratentorial ependymoma are presented and discussed to identify factors that may be responsible for this uncommon treatment complication laminotomies multiple surgeries postoperative infection and the addition of radiation therapy may be contributory Because second resection will be an important component of the next generation of cooperative group studies for infratentorial tumors the incidence and severity of this treatment-related complication should be documented and efforts should be made to image the upper portion of the spine during routine follow-up,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[571, 170, 370, 20, 573, 121, 36, 1166, 28, 3, 30, 2929, 9239, 3, 24, 1, 864, 10540, 4214, 30, 170, 629, 1706, 1655, 6, 3, 1726, 3206, 1, 3, 1499, 5614, 92, 14100, 3, 69, 28, 43, 1, 521, 141, 19459, 100, 140, 1, 27890, 50, 152, 2, 1104, 9, 10540, 4214, 32, 917, 2, 1588, 6, 255, 130, 17, 68, 40, 2327, 9, 26, 2052, 24, 1447, 52898, 232, 5305, 573, 930, 2, 3, 352, 1, 121, 36, 68, 40, 19445, 408, 419, 170, 303, 40, 35, 305, 1249, 1, 3, 1305, 914, 1, 1690, 87, 94, 9, 10540, 57, 3, 287, 2, 1702, 1, 26, 24, 139, 1447, 257, 40, 1405, 2, 1413, 257, 40, 1229, 6, 1482, 3, 1726, 3206, 1, 3, 2342, 190, 1311, 166, 126]",937.0,12006754,729
Radiation myelitis in a 5-year-old girl.,Journal of child neurology,J. Child Neurol.,2002-03-01,"Myelopathy is an uncommon complication of radiotherapy, particularly in the pediatric age group. A 5-year-old girl with acute lymphoblastic leukemia developed a severe but transient radiculopathy after intrathecal administration of methotrexate and cytarabine for an isolated central nervous system relapse. Chemotherapy was then given through an intraventricular catheter. Owing to a second central nervous system recurrence, she was treated with craniospinal radiation. The whole brain down to the level of C2 received a dose of 2400 cGy. Two months after completion of radiation, the child developed a progressive tetraparesis, and magnetic resonance imaging revealed an enhancing lesion involving the medulla and upper cervical cord. A biopsy was consistent with a treatment-related necrotizing leukoencephalopathy. This case suggests that patients who develop neurologic dysfunction when treated with methotrexate can also be particularly susceptible to radiation-related injury.",Case Reports,6535.0,8.0,Myelopathy is an uncommon complication of radiotherapy particularly in the pediatric age group A 5-year-old girl with acute lymphoblastic developed a severe but transient radiculopathy after intrathecal administration of methotrexate and cytarabine for an isolated central nervous system relapse Chemotherapy was then given through an intraventricular catheter Owing to a second central nervous system recurrence she was treated with craniospinal radiation The whole brain down to the level of C2 received a dose of 2400 cGy Two months after completion of radiation the child developed a progressive tetraparesis and magnetic resonance imaging revealed an enhancing lesion involving the medulla and upper cord A biopsy was consistent with a treatment-related necrotizing leukoencephalopathy This case suggests that patients who develop neurologic dysfunction when treated with methotrexate can also be particularly susceptible to radiation-related injury,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,"[10415, 16, 35, 2052, 1447, 1, 310, 823, 4, 3, 815, 89, 87, 8, 33, 111, 1095, 12079, 5, 286, 1275, 276, 8, 905, 84, 2473, 16642, 50, 5126, 634, 1, 2116, 2, 1855, 9, 35, 1355, 854, 1880, 398, 429, 56, 10, 818, 447, 298, 35, 7199, 3925, 3421, 6, 8, 419, 854, 1880, 398, 146, 3109, 10, 73, 5, 5748, 121, 3, 902, 342, 1328, 6, 3, 301, 1, 6706, 103, 8, 61, 1, 12518, 3071, 100, 53, 50, 1438, 1, 121, 3, 2566, 276, 8, 1014, 52917, 2, 1484, 1535, 270, 553, 35, 2430, 1180, 1267, 3, 20187, 2, 1726, 1885, 8, 411, 10, 925, 5, 8, 24, 139, 21974, 8744, 26, 473, 844, 17, 7, 54, 690, 2543, 1527, 198, 73, 5, 2116, 122, 120, 40, 823, 4012, 6, 121, 139, 2730]",954.0,12026238,543
Recurrent cervical cancer.,Current treatment options in oncology,Curr Treat Options Oncol,2002-04-01,"There are limited treatment options for patients with recurrent cervical carcinoma. Because of low response rates and a negligible impact on long-term survival, the use of chemotherapy in patients with unresectable recurrent disease should be considered palliative. Generally, radiation therapy in previously irradiated patients is considered palliative. For patients who develop recurrent disease after definitive surgery who have not received prior radiation therapy, salvage radiation therapy is the treatment of choice. Similarly, patients who have received definitive primary radiation therapy are candidates for surgical resection of their recurrence. However, there are specific criteria for surgical resection. Radical hysterectomy may be an option for the very rare patient with a small (<2 cm) centrally located recurrence in the cervix or vaginal fornices. However, for most patients, pelvic exenteration remains the only therapeutic option that offers the possibility of long-term survival. Patients who are candidates for exenteration are those with central local recurrences that have not extended to the pelvic sidewalls. The introduction of high-dose-rate intraoperative radiation therapy (HDR-IORT) combined with radical surgical resection has widened the scope of patients who may be offered surgery. Patients who in the past may not have been surgical candidates may benefit from radical surgical resection combined with HDR-IORT. All patients who are surgically fit and have undergone previous radiation therapy should be considered for surgical resection for centrally located recurrences. Patients whose recurrences extend close to the pelvic sidewalls should be referred to centers where HDR-IORT is available.",Journal Article,6504.0,40.0,There are limited treatment options for patients with recurrent carcinoma Because of low response rates and a negligible impact on long-term survival the use of chemotherapy in patients with unresectable recurrent disease should be considered palliative Generally radiation therapy in previously irradiated patients is considered palliative For patients who develop recurrent disease after definitive surgery who have not received prior radiation therapy salvage radiation therapy is the treatment of choice Similarly patients who have received definitive primary radiation therapy are candidates for surgical resection of their recurrence However there are specific criteria for surgical resection Radical hysterectomy may be an option for the very rare patient with a small 2 cm centrally located recurrence in the cervix or fornices However for most patients pelvic exenteration remains the only therapeutic option that offers the possibility of long-term survival Patients who are candidates for exenteration are those with central local recurrences that have not extended to the pelvic sidewalls The introduction of high-dose-rate intraoperative radiation therapy HDR-IORT combined with radical surgical resection has widened the scope of patients who may be offered surgery Patients who in the past may not have been surgical candidates may benefit from radical surgical resection combined with HDR-IORT All patients who are surgically fit and have undergone previous radiation therapy should be considered for surgical resection for centrally located recurrences Patients whose recurrences extend close to the pelvic sidewalls should be referred to centers where HDR-IORT is available,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[125, 32, 383, 24, 838, 9, 7, 5, 387, 134, 408, 1, 154, 51, 151, 2, 8, 6821, 345, 23, 319, 337, 25, 3, 119, 1, 56, 4, 7, 5, 1468, 387, 34, 257, 40, 515, 994, 1228, 121, 36, 4, 373, 2398, 7, 16, 515, 994, 9, 7, 54, 690, 387, 34, 50, 1057, 152, 54, 47, 44, 103, 324, 121, 36, 992, 121, 36, 16, 3, 24, 1, 1866, 1813, 7, 54, 47, 103, 1057, 86, 121, 36, 32, 1931, 9, 221, 170, 1, 136, 146, 137, 125, 32, 112, 371, 9, 221, 170, 711, 2622, 68, 40, 35, 1501, 9, 3, 923, 622, 69, 5, 8, 302, 18, 494, 4604, 2308, 146, 4, 3, 3629, 15, 52960, 137, 9, 96, 7, 1110, 5668, 469, 3, 158, 189, 1501, 17, 2339, 3, 2526, 1, 319, 337, 25, 7, 54, 32, 1931, 9, 5668, 32, 135, 5, 854, 293, 1593, 17, 47, 44, 1747, 6, 3, 1110, 42959, 3, 2456, 1, 64, 61, 116, 1720, 121, 36, 5309, 4158, 397, 5, 711, 221, 170, 71, 21990, 3, 7924, 1, 7, 54, 68, 40, 2216, 152, 7, 54, 4, 3, 1219, 68, 44, 47, 85, 221, 1931, 68, 247, 29, 711, 221, 170, 397, 5, 5309, 4158, 62, 7, 54, 32, 2350, 2975, 2, 47, 1989, 698, 121, 36, 257, 40, 515, 9, 221, 170, 9, 4604, 2308, 1593, 7, 1310, 1593, 4087, 2336, 6, 3, 1110, 42959, 257, 40, 1995, 6, 1168, 1257, 5309, 4158, 16, 390]",1691.0,12057073,173
Irinotecan for the treatment of cervical cancer.,"Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2002-05-01,"Topoisomerase inhibitors have been widely studied for the treatment of refractory or recurrent cervical cancer. Various schedules have been used, with response rates ranging from 13% to 20%. The combination of cisplatin and irinotecan (CPT-11, Camptosar) is being studied in cervical cancer. Hematologic and gastrointestinal toxicities have been observed. Gastrointestinal toxicities have been particularly problematic at high irinotecan doses. Further studies of irinotecan in combination with other drugs and radiotherapy are warranted.",Journal Article,6474.0,11.0,Topoisomerase inhibitors have been widely studied for the treatment of refractory or recurrent cancer Various schedules have been used with response rates ranging from 13 to 20 The combination of cisplatin and irinotecan CPT-11 Camptosar is being studied in cancer Hematologic and toxicities have been observed toxicities have been particularly problematic at high irinotecan doses Further studies of irinotecan in combination with other drugs and radiotherapy are warranted,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3999, 222, 47, 85, 1792, 656, 9, 3, 24, 1, 430, 15, 387, 12, 747, 2314, 47, 85, 95, 5, 51, 151, 2223, 29, 233, 6, 179, 3, 150, 1, 540, 2, 1071, 3361, 175, 13516, 16, 486, 656, 4, 12, 813, 2, 385, 47, 85, 164, 385, 47, 85, 823, 6594, 28, 64, 1071, 415, 195, 94, 1, 1071, 4, 150, 5, 127, 600, 2, 310, 32, 1197]",474.0,12109804,311
Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer.,Seminars in radiation oncology,Semin Radiat Oncol,2002-07-01,"Intensity-modulated radiotherapy (IMRT) offers technical advantages over conventional external beam radiotherapy (CXRT) that might prove clinically advantageous in the management of gynecologic malignancies. Especially in the case of locally advanced cervical cancer, IMRT provides an opportunity to improve the therapeutic ratio by allowing a selective combination of normal tissue dose reduction and/or concomitant integrated boost dose to the tumor. The clinical and biologic rationale for IMRT in this setting is presented here, and pertinent technical considerations such as the delineation of relevant clinical and planning target volumes are discussed. The capacity for IMRT-mediated normal tissue sparing is illustrated by example and review of the literature. Furthermore, for a small cohort of patients with locally advanced or recurrent cervical cancer treated with concomitant integrated boost IMRT and concurrent chemotherapy, preliminary clinical observations of toxicity and tumor response are presented. Concomitant integrated boost IMRT appears clinically tolerable and efficacious in this setting, and formal clinical investigation is warranted as a means of exploiting the fraction-size dependence of radiosensitizers in common clinical use.",Journal Article,6413.0,60.0,Intensity-modulated radiotherapy IMRT offers technical advantages over conventional external beam radiotherapy CXRT that might prove clinically advantageous in the management of gynecologic malignancies Especially in the case of locally advanced cancer IMRT provides an opportunity to improve the therapeutic ratio by allowing a selective combination of normal tissue dose reduction and/or concomitant integrated boost dose to the tumor The clinical and biologic rationale for IMRT in this setting is presented here and pertinent technical considerations such as the delineation of relevant clinical and planning target volumes are discussed The capacity for IMRT-mediated normal tissue sparing is illustrated by example and review of the literature Furthermore for a small cohort of patients with locally advanced or recurrent cancer treated with concomitant integrated boost IMRT and concurrent chemotherapy preliminary clinical observations of toxicity and tumor response are presented Concomitant integrated boost IMRT appears clinically tolerable and efficacious in this setting and formal clinical investigation is warranted as a means of exploiting the fraction-size dependence of radiosensitizers in common clinical use,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[837, 1757, 310, 964, 2339, 3359, 3126, 252, 809, 1455, 1345, 310, 7925, 17, 822, 4361, 505, 10650, 4, 3, 284, 1, 1512, 441, 1093, 4, 3, 473, 1, 795, 131, 12, 964, 777, 35, 2666, 6, 401, 3, 189, 197, 20, 2952, 8, 1094, 150, 1, 295, 246, 61, 628, 2, 15, 1781, 2102, 2569, 61, 6, 3, 30, 3, 38, 2, 1283, 1728, 9, 964, 4, 26, 546, 16, 917, 467, 2, 5799, 3359, 3891, 225, 22, 3, 5529, 1, 867, 38, 2, 1349, 283, 2225, 32, 1588, 3, 2162, 9, 964, 517, 295, 246, 1851, 16, 8508, 20, 2685, 2, 206, 1, 3, 789, 798, 9, 8, 302, 180, 1, 7, 5, 795, 131, 15, 387, 12, 73, 5, 1781, 2102, 2569, 964, 2, 750, 56, 1676, 38, 2172, 1, 155, 2, 30, 51, 32, 917, 1781, 2102, 2569, 964, 1233, 505, 2668, 2, 3289, 4, 26, 546, 2, 5057, 38, 940, 16, 1197, 22, 8, 2263, 1, 10060, 3, 1509, 444, 3721, 1, 11763, 4, 186, 38, 119]",1227.0,12118391,469
Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases.,Human gene therapy,Hum. Gene Ther.,2002-07-01,"Oncolytic herpesviruses have significant antitumoral effects in animal models when delivered directly to established tumors. Lymphatic metastases are a common occurrence for many tumor types. This study investigates the potential of an attenuated, replication-competent, oncolytic herpes simplex virus (NV1023) both to treat a primary tumor by direct injection and to travel through the lymphatic system to treat metastatic tumor within the lymph nodes draining lymph from the site of primary cancer. Isosulfan blue dye was injected into murine auricles to determine normal lymphatic drainage patterns and demonstrated consistent blue staining of a group of ipsilateral cervical lymph nodes. Auricular injections of NV1023 resulted in viral transit to these lymph nodes as measured by 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside histochemistry and viral plaque assay. An oncolytic herpesvirus (NV1066) expressing green fluorescent protein also demonstrated viral transit from the auricle to the cervical lymph nodes on fluorescence microscopy. Using the SCC VII cell line, a novel murine model of auricular squamous cell carcinoma was developed with an approximately 20% incidence of cervical lymph node metastases. Delivery of NV1023 or NV1066 to the surgical beds after excision of auricular SCC VII tumors resulted in successful viral infection of metastatic SCC VII cells within the cervical lymph nodes. After a 7-week follow-up, significantly enhanced locoregional control (p < 0.05, Fisher exact test) and disease-free survival (p < 0.05, log rank test) were evident with NV1023 treatment. This study demonstrates that the delivery of an oncolytic herpesvirus to a primary tumor site after surgical excision may have a significant impact on reducing both primary site recurrence and regional nodal metastases.",Journal Article,6413.0,59.0,Oncolytic herpesviruses have significant antitumoral effects in animal models when delivered directly to established tumors Lymphatic metastases are a common occurrence for many tumor types This study investigates the potential of an attenuated replication-competent oncolytic herpes simplex virus NV1023 both to treat a primary tumor by direct injection and to travel through the lymphatic system to treat metastatic tumor within the lymph nodes draining lymph from the site of primary cancer Isosulfan blue dye was injected into murine auricles to determine normal lymphatic drainage patterns and demonstrated consistent blue staining of a group of ipsilateral lymph nodes Auricular injections of NV1023 resulted in viral transit to these lymph nodes as measured by 5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside histochemistry and viral plaque assay An oncolytic herpesvirus NV1066 expressing green fluorescent protein also demonstrated viral transit from the auricle to the lymph nodes on fluorescence microscopy Using the SCC VII cell line a novel murine model of auricular squamous cell carcinoma was developed with an approximately 20 incidence of lymph node metastases Delivery of NV1023 or NV1066 to the surgical beds after excision of auricular SCC VII tumors resulted in successful viral infection of metastatic SCC VII cells within the lymph nodes After a 7-week follow-up significantly enhanced locoregional control p 0.05 Fisher exact test and disease-free survival p 0.05 log rank test were evident with NV1023 treatment This study demonstrates that the delivery of an oncolytic herpesvirus to a primary tumor site after surgical excision may have a significant impact on reducing both primary site recurrence and regional nodal metastases,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3236, 26036, 47, 93, 13808, 176, 4, 2026, 274, 198, 1623, 1606, 6, 635, 57, 2936, 196, 32, 8, 186, 2291, 9, 445, 30, 630, 26, 45, 7259, 3, 174, 1, 35, 2656, 2079, 6299, 3236, 4716, 7241, 1450, 9096, 110, 6, 943, 8, 86, 30, 20, 1196, 1754, 2, 6, 6793, 298, 3, 2936, 398, 6, 943, 113, 30, 262, 3, 263, 502, 7535, 263, 29, 3, 606, 1, 86, 12, 10267, 3352, 3796, 10, 2651, 237, 1471, 42998, 6, 223, 295, 2936, 3528, 764, 2, 264, 925, 3352, 1029, 1, 8, 87, 1, 2880, 263, 502, 24488, 4344, 1, 9096, 627, 4, 1667, 6432, 6, 46, 263, 502, 22, 644, 20, 33, 18196, 39, 14778, 27, 27934, 1090, 427, 42999, 27935, 2, 1667, 8506, 719, 35, 3236, 9329, 7748, 1046, 4658, 2910, 178, 120, 264, 1667, 6432, 29, 3, 53038, 6, 3, 263, 502, 23, 1591, 3804, 75, 3, 1791, 13809, 31, 328, 8, 229, 1471, 202, 1, 24488, 691, 31, 134, 10, 276, 5, 35, 705, 179, 287, 1, 263, 289, 196, 989, 1, 9096, 15, 7748, 6, 3, 221, 12737, 50, 1366, 1, 24488, 1791, 13809, 57, 627, 4, 1401, 1667, 930, 1, 113, 1791, 13809, 37, 262, 3, 263, 502, 50, 8, 67, 647, 166, 126, 97, 651, 1325, 182, 19, 13, 474, 3135, 2472, 412, 2, 34, 115, 25, 19, 13, 474, 1066, 1026, 412, 11, 2853, 5, 9096, 24, 26, 45, 1902, 17, 3, 989, 1, 35, 3236, 9329, 6, 8, 86, 30, 606, 50, 221, 1366, 68, 47, 8, 93, 345, 23, 1818, 110, 86, 606, 146, 2, 951, 779, 196]",1759.0,12133274,81
The human papilloma virus E7 oncoprotein inhibits transforming growth factor-beta signaling by blocking binding of the Smad complex to its target sequence.,The Journal of biological chemistry,J. Biol. Chem.,2002-07-26,"The human papillomavirus (HPV) oncoprotein E7 is implicated in the etiology of cervical cancer associated with infection by HPV. HPV-positive cells develop resistance to TGF-beta growth inhibitory activity through the inhibition of hypophosphorylation of pRb by papillomavirus type 16 E7 oncoprotein. In this study, we examined whether E7, in addition to its well known effects on pRb, might directly target the Smad proteins that mediate TGF-beta signaling. Here, we show that E7 significantly blocks both Smad transcriptional activity and the ability of TGF-beta to inhibit DNA synthesis. We found that E7 interacts constitutively with Smad2, Smad3, and Smad4. Confocal microscopic studies confirm that E7 and Smads co-localize in vivo. Using a canonical Smad DNA binding sequence, we found that E7 blocks Smad3 binding to its target sequence on DNA. These results suggest that suppression of Smad-mediated signaling by E7 may contribute to HPV-associated carcinogenesis.",Journal Article,6388.0,68.0,The human papillomavirus HPV oncoprotein E7 is implicated in the etiology of cancer associated with infection by HPV HPV-positive cells develop resistance to TGF-beta growth inhibitory activity through the inhibition of hypophosphorylation of pRb by papillomavirus type 16 E7 oncoprotein In this study we examined whether E7 in addition to its well known effects on pRb might directly target the Smad proteins that mediate TGF-beta signaling Here we show that E7 significantly blocks both Smad transcriptional activity and the ability of TGF-beta to inhibit DNA synthesis We found that E7 interacts constitutively with Smad2 Smad3 and Smad4 Confocal microscopic studies confirm that E7 and Smads co-localize in vivo Using a canonical Smad DNA binding sequence we found that E7 blocks Smad3 binding to its target sequence on DNA These results suggest that suppression of Smad-mediated signaling by E7 may contribute to HPV-associated carcinogenesis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 171, 3242, 933, 6159, 4540, 16, 1771, 4, 3, 2855, 1, 12, 41, 5, 930, 20, 933, 933, 109, 37, 690, 251, 6, 2387, 1090, 129, 1810, 128, 298, 3, 297, 1, 21052, 1, 8734, 20, 3242, 267, 245, 4540, 6159, 4, 26, 45, 21, 409, 317, 4540, 4, 352, 6, 211, 149, 440, 176, 23, 8734, 822, 1606, 283, 3, 8313, 652, 17, 3367, 2387, 1090, 314, 467, 21, 514, 17, 4540, 97, 2860, 110, 8313, 1431, 128, 2, 3, 801, 1, 2387, 1090, 6, 1433, 261, 2525, 21, 204, 17, 4540, 5528, 2818, 5, 10286, 10675, 2, 4248, 6541, 2984, 94, 1843, 17, 4540, 2, 22011, 1269, 8031, 4, 386, 75, 8, 4471, 8313, 261, 791, 1532, 21, 204, 17, 4540, 2860, 10675, 791, 6, 211, 283, 1532, 23, 261, 46, 99, 309, 17, 1332, 1, 8313, 517, 314, 20, 4540, 68, 1248, 6, 933, 41, 1719]",947.0,12145312,538
Cytologic and biopsy findings leading to conization in adenocarcinoma in situ of the cervix.,Obstetrics and gynecology,Obstet Gynecol,2002-08-01,"To investigate the utility of currently available screening tests in preoperatively detecting adenocarcinoma in situ of the cervix. Patients with a cone biopsy diagnosis of adenocarcinoma in situ from 1987 to 2000 at our institution were identified. Results from Papanicolaou smears, cervical biopsies, and endocervical curettages preceding the diagnostic cone biopsy were collected from medical records and referring providers. Fisher exact test (two-tail) was used for statistical analysis. The preoperative screening results preceding a cone biopsy containing adenocarcinoma in situ were available in 118 patients. Among 94 Papanicolaou smears, 65 (69%) glandular lesions and 29 (31%) squamous or unspecified lesions were reported. Biopsy and/or endocervical curettage after the 29 squamous or unspecified lesions on Papanicolaou smear detected 15 additional glandular lesions, totaling 80 (85%) of 94 cases of glandular disease detected before conization. Among all 118 cases with some form of preoperative data available, glandular disease was predicted in 100 cases (85%). In cases of suspected glandular disease, 86% were treated with cold knife cone compared with 22% in cases of suspected squamous abnormalities (P <.001). The sensitivity of detecting a glandular abnormality before a cone biopsy containing adenocarcinoma in situ is 69% with the Papanicolaou smear and 85% with the addition of biopsy and endocervical curettage. This underscores the importance of using preoperative assessment to appropriately plan treatment for a suspected glandular lesion.",Comparative Study,6382.0,14.0,To investigate the utility of currently available screening tests in preoperatively detecting adenocarcinoma in situ of the cervix Patients with a cone biopsy diagnosis of adenocarcinoma in situ from 1987 to 2000 at our institution were identified Results from Papanicolaou smears biopsies and endocervical curettages preceding the diagnostic cone biopsy were collected from medical records and referring providers Fisher exact test two-tail was used for statistical analysis The preoperative screening results preceding a cone biopsy containing adenocarcinoma in situ were available in 118 patients Among 94 Papanicolaou smears 65 69 glandular lesions and 29 31 squamous or unspecified lesions were reported Biopsy and/or endocervical curettage after the 29 squamous or unspecified lesions on Papanicolaou smear detected 15 additional glandular lesions totaling 80 85 of 94 cases of glandular disease detected before conization Among all 118 cases with some form of preoperative data available glandular disease was predicted in 100 cases 85 In cases of suspected glandular disease 86 were treated with cold knife cone compared with 22 in cases of suspected squamous abnormalities P .001 The sensitivity of detecting a glandular abnormality before a cone biopsy containing adenocarcinoma in situ is 69 with the Papanicolaou smear and 85 with the addition of biopsy and endocervical curettage This underscores the importance of using preoperative assessment to appropriately plan treatment for a suspected glandular lesion,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 963, 3, 1207, 1, 694, 390, 453, 895, 4, 3888, 2502, 449, 4, 957, 1, 3, 3629, 7, 5, 8, 6939, 411, 147, 1, 449, 4, 957, 29, 5450, 6, 1081, 28, 114, 731, 11, 108, 99, 29, 10416, 8916, 1154, 2, 10174, 53048, 5892, 3, 752, 6939, 411, 11, 786, 29, 484, 1064, 2, 8636, 1994, 3135, 2472, 412, 100, 5809, 10, 95, 9, 1050, 65, 3, 498, 453, 99, 5892, 8, 6939, 411, 1101, 449, 4, 957, 11, 390, 4, 4002, 7, 107, 960, 10416, 8916, 556, 790, 6170, 406, 2, 462, 456, 691, 15, 12288, 406, 11, 210, 411, 2, 15, 10174, 12529, 50, 3, 462, 691, 15, 12288, 406, 23, 10416, 8379, 530, 167, 402, 6170, 406, 12739, 493, 772, 1, 960, 140, 1, 6170, 34, 530, 348, 8755, 107, 62, 4002, 140, 5, 476, 1297, 1, 498, 74, 390, 6170, 34, 10, 783, 4, 394, 140, 772, 4, 140, 1, 2768, 6170, 34, 868, 11, 73, 5, 5945, 8045, 6939, 72, 5, 350, 4, 140, 1, 2768, 691, 1171, 19, 144, 3, 485, 1, 2502, 8, 6170, 3698, 348, 8, 6939, 411, 1101, 449, 4, 957, 16, 790, 5, 3, 10416, 8379, 2, 772, 5, 3, 352, 1, 411, 2, 10174, 12529, 26, 6926, 3, 1187, 1, 75, 498, 455, 6, 4544, 2242, 24, 9, 8, 2768, 6170, 1180]",1522.0,12151149,622
Photodynamic therapy of high-grade cervical intraepithelial neoplasia with 5-aminolevulinic acid.,Lasers in surgery and medicine,Lasers Surg Med,2002-01-01,"To determine the safety and efficacy of 5-aminolevulinic acid (ALA) as a topically applied photosensitizer for photodynamic therapy (PDT) of cervical intraepithelial neoplasia (CIN). Forty women, who were at least 18 years old with persistent biopsy-proven CIN 2 and CIN 3 within the previous 3 months of enrollment, underwent PDT in a phase I and II design. Five escalating radiant energies (increments of 25 J/cm(2), beginning at 50-150 J/cm(2)) using a Coherent Dye Model 920 argon pumped dye laser providing light at 630 nm (maximum output 0.8 W) were used to perform PDT with a fixed dose of ALA (200 mg/ml). ALA was placed in a cervical cap fitted to the cervix. After 90 minutes, the cap was removed and the ectocervix was illuminated for 5-16 minutes, depending on the irradiance. Success was defined as the absence of CIN on Pap smear or colposcopic examination at 12-months. Patients were monitored for toxicity. Thirty-two women (80%) completed the study with 1 year of follow-up. Sixty percent had CIN 3 and 40% CIN 2. Success rates at 4, 8, and 12 months were 51, 46, and 31%, respectively, and were not light-dose dependent. Three patients progressed from CIN 2 to CIN 3. Toxicity was tolerable and only consisted of spotting, vaginal discharge, mild cramping, and vaginal warmth. There was no apparent dose relationship to toxicity. PDT at this light and ALA dose is well tolerated but has minimal activity in the treatment of CIN 2 and CIN 3. Other doses and schedules of light and ALA or novel photosensitizers may improve efficacy.",Clinical Trial,6594.0,45.0,To determine the safety and efficacy of 5-aminolevulinic acid ALA as a topically applied photosensitizer for photodynamic therapy PDT of intraepithelial neoplasia CIN Forty women who were at least 18 years old with persistent biopsy-proven CIN 2 and CIN 3 within the previous 3 months of enrollment underwent PDT in a phase I and II design Five escalating radiant energies increments of 25 J/cm 2 beginning at 50-150 J/cm 2 using a Coherent Dye Model 920 argon pumped dye laser providing light at 630 nm maximum output 0.8 W were used to perform PDT with a fixed dose of ALA 200 mg/ml ALA was placed in a cap fitted to the cervix After 90 minutes the cap was removed and the ectocervix was illuminated for 5-16 minutes depending on the irradiance Success was defined as the absence of CIN on Pap smear or colposcopic examination at 12-months Patients were monitored for toxicity Thirty-two women 80 completed the study with 1 year of follow-up Sixty percent had CIN 3 and 40 CIN 2 Success rates at 4 8 and 12 months were 51 46 and 31 respectively and were not light-dose dependent Three patients progressed from CIN 2 to CIN 3 Toxicity was tolerable and only consisted of spotting discharge mild cramping and warmth There was no apparent dose relationship to toxicity PDT at this light and ALA dose is well tolerated but has minimal activity in the treatment of CIN 2 and CIN 3 Other doses and schedules of light and ALA or novel photosensitizers may improve efficacy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 367, 2, 209, 1, 33, 30218, 971, 8497, 22, 8, 21012, 1498, 10687, 9, 6910, 36, 3442, 1, 4153, 2298, 4652, 1213, 117, 54, 11, 28, 506, 203, 60, 1095, 5, 1882, 411, 1930, 4652, 18, 2, 4652, 27, 262, 3, 698, 27, 53, 1, 1798, 208, 3442, 4, 8, 124, 70, 2, 215, 771, 365, 2922, 11269, 24514, 8225, 1, 243, 3543, 494, 18, 2948, 28, 212, 1577, 3543, 494, 18, 75, 8, 22027, 3796, 202, 11533, 26069, 53141, 3796, 3555, 1736, 1691, 28, 10939, 2878, 689, 6911, 13, 66, 5444, 11, 95, 6, 2715, 3442, 5, 8, 1959, 61, 1, 8497, 1250, 81, 542, 8497, 10, 3295, 4, 8, 3204, 7315, 6, 3, 3629, 50, 424, 2511, 3, 3204, 10, 2264, 2, 3, 53142, 10, 22034, 9, 33, 245, 2511, 3221, 23, 3, 24515, 1825, 10, 395, 22, 3, 1127, 1, 4652, 23, 4290, 8379, 15, 14131, 1385, 28, 133, 53, 7, 11, 2909, 9, 155, 977, 100, 117, 493, 781, 3, 45, 5, 14, 111, 1, 166, 126, 1746, 714, 42, 4652, 27, 2, 327, 4652, 18, 1825, 151, 28, 39, 66, 2, 133, 53, 11, 725, 641, 2, 456, 106, 2, 11, 44, 1691, 61, 470, 169, 7, 1839, 29, 4652, 18, 6, 4652, 27, 155, 10, 2668, 2, 158, 1695, 1, 37278, 2993, 1980, 17149, 2, 27964, 125, 10, 77, 2235, 61, 858, 6, 155, 3442, 28, 26, 1691, 2, 8497, 61, 16, 149, 421, 84, 71, 1048, 128, 4, 3, 24, 1, 4652, 18, 2, 4652, 27, 127, 415, 2, 2314, 1, 1691, 2, 8497, 15, 229, 19499, 68, 401, 209]",1467.0,12355576,615
Relative risk of stroke in head and neck carcinoma patients treated with external cervical irradiation.,The Laryngoscope,Laryngoscope,2002-10-01,"To determine the rate of cerebrovascular events (stroke) in patients irradiated to high doses for squamous cell carcinoma of the head and neck. Retrospective chart review of 413 patients treated from 1987 to 2000 with squamous cell carcinoma of the head and neck was performed to determine the risk of stroke compared with the expected rate. Surgical, radiotherapeutic, radiological, and clinical or office records of 413 patients were analyzed, and data were collected regarding clinical risk factors for stroke, irradiation parameters, and follow-up on whether or not a stroke event occurred. The actuarial risk of stroke for this population was calculated and compared with expected risk from population-based data. Of the 413 patients, 20 had strokes in follow-up, occurring between 2 and 146 months after radiotherapy. The 5-year actuarial rate of stroke was 12%, which corresponded to a relative risk of 2.09 ( P=.0007) compared with the population-based ""expected"" data. Median radiation therapy dose was 64 Gy; there was no correlation between radiation therapy dose and stroke risk. No correlation was identified between surgery near the carotids and stroke risk. An association between high-dose cervical irradiation for squamous cell carcinoma of the head and neck and stroke is demonstrated. Although the relative risk is approximately doubled, the absolute risk is modest in comparison to the risk of cancer recurrence. Further study of this association and possible interventions is warranted.",Journal Article,6321.0,82.0,To determine the rate of cerebrovascular events stroke in patients irradiated to high doses for squamous cell carcinoma of the head and Retrospective chart review of 413 patients treated from 1987 to 2000 with squamous cell carcinoma of the head and was performed to determine the risk of stroke compared with the expected rate Surgical radiotherapeutic radiological and clinical or office records of 413 patients were analyzed and data were collected regarding clinical risk factors for stroke irradiation parameters and follow-up on whether or not a stroke event occurred The actuarial risk of stroke for this population was calculated and compared with expected risk from population-based data Of the 413 patients 20 had strokes in follow-up occurring between 2 and 146 months after radiotherapy The 5-year actuarial rate of stroke was 12 which corresponded to a relative risk of 2.09 P=.0007 compared with the population-based `` expected '' data Median radiation therapy dose was 64 Gy there was no correlation between radiation therapy dose and stroke risk No correlation was identified between surgery near the carotids and stroke risk An association between high-dose irradiation for squamous cell carcinoma of the head and and stroke is demonstrated Although the relative risk is approximately doubled the absolute risk is modest in comparison to the risk of cancer recurrence Further study of this association and possible interventions is warranted,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 116, 1, 9261, 281, 4408, 4, 7, 2398, 6, 64, 415, 9, 691, 31, 134, 1, 3, 718, 2, 459, 2937, 206, 1, 10436, 7, 73, 29, 5450, 6, 1081, 5, 691, 31, 134, 1, 3, 718, 2, 10, 173, 6, 223, 3, 43, 1, 4408, 72, 5, 3, 1336, 116, 221, 11924, 4298, 2, 38, 15, 6489, 1064, 1, 10436, 7, 11, 311, 2, 74, 11, 786, 666, 38, 43, 130, 9, 4408, 1104, 1038, 2, 166, 126, 23, 317, 15, 44, 8, 4408, 774, 489, 3, 2361, 43, 1, 4408, 9, 26, 266, 10, 981, 2, 72, 5, 1336, 43, 29, 266, 90, 74, 1, 3, 10436, 7, 179, 42, 17151, 4, 166, 126, 1821, 59, 18, 2, 4909, 53, 50, 310, 3, 33, 111, 2361, 116, 1, 4408, 10, 133, 92, 7254, 6, 8, 580, 43, 1, 18, 1730, 19, 6626, 72, 5, 3, 266, 90, 1336, 522, 74, 52, 121, 36, 61, 10, 660, 381, 125, 10, 77, 816, 59, 121, 36, 61, 2, 4408, 43, 77, 816, 10, 108, 59, 152, 1829, 3, 53149, 2, 4408, 43, 35, 248, 59, 64, 61, 1104, 9, 691, 31, 134, 1, 3, 718, 2, 2, 4408, 16, 264, 242, 3, 580, 43, 16, 705, 8431, 3, 1766, 43, 16, 1721, 4, 1155, 6, 3, 43, 1, 12, 146, 195, 45, 1, 26, 248, 2, 899, 1151, 16, 1197]",1459.0,12368635,841
Recurrent or persistent hyperparathyroidism.,Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research,J. Bone Miner. Res.,2002-11-01,"Approximately 90% of patients with primary hyperparathyroidism (PHPT) are cured by parathyroidectomy at the initial neck exploration. Those not cured either remain hypercalcemic in the immediate postoperative period or develop hypercalcemia after a long period of normocalcemia. Almost all cases of hypercalcemia after neck exploration for PHPT are evident early in the postoperative period and are caused either by an overlooked parathyroid adenoma or an incomplete resection of hyperplastic parathyroid tissue. Less commonly, the surgeon has failed to recognize, and adequately treat, parathyroid carcinoma, or the diagnosis of PHPT was incorrect and there is another cause of the hypercalcemia. A successful neck exploration for PHPT is primarily dependent on the experience of the operating surgeon, the anatomic location of the parathyroid glands, either in ""normal"" or ""ectopic"" sites, and the presence of a single enlarged parathyroid gland as opposed to multiglandular disease or parathyroid carcinoma. In cases where an enlarged parathyroid gland is not identified at operation, noninvasive or invasive radiographic imaging procedures are useful in localizing the gland. Currently, the most reliable and practical procedure is technetium 99m sestamibi scanning. This technique identifies an enlarged parathyroid gland in 65-80% of cases. Single photon emission computed tomography (SPECT) in association with sestamibi scanning increases the sensitivity of the procedure to 85%. These imaging procedures are least reliable in patients with multiglandular disease. Ultrasound and computed tomographic scanning are less sensitive; however, they are commonly used as confirmatory tests in association with sestamibi scanning. When noninvasive imaging procedures fail to identify an enlarged parathyroid gland, invasive procedures, such as selective arteriography, are performed. Whereas invasive procedures are useful, they are associated with significant morbidity. Reoperations for persistent or recurrent hyperparathyroidism, compared with the initial operations, are associated with higher complication rates. In 90% of cases, the abnormal pathology can be reached through a cervical incision. The success rate of the reoperation depends primarily on the results of the localization procedure and whether the patient has a single enlarged parathyroid gland or multiglandular disease. Resection of a single enlarged gland is curative in virtually all patients. If, however, the patient has multiple gland disease, the operation is successful less often, especially in those with certain familial endocrinopathies.",Journal Article,6290.0,46.0,Approximately 90 of patients with primary hyperparathyroidism PHPT are cured by parathyroidectomy at the initial exploration Those not cured either remain hypercalcemic in the immediate postoperative period or develop hypercalcemia after a long period of normocalcemia Almost all cases of hypercalcemia after exploration for PHPT are evident early in the postoperative period and are caused either by an overlooked adenoma or an incomplete resection of hyperplastic tissue Less commonly the surgeon has failed to recognize and adequately treat carcinoma or the diagnosis of PHPT was incorrect and there is another cause of the hypercalcemia A successful exploration for PHPT is primarily dependent on the experience of the operating surgeon the anatomic location of the glands either in `` normal '' or `` ectopic '' sites and the presence of a single enlarged gland as opposed to multiglandular disease or carcinoma In cases where an enlarged gland is not identified at operation noninvasive or invasive radiographic imaging procedures are useful in localizing the gland Currently the most reliable and practical procedure is technetium 99m sestamibi scanning This technique identifies an enlarged gland in 65-80 of cases Single photon emission computed tomography SPECT in association with sestamibi scanning increases the sensitivity of the procedure to 85 These imaging procedures are least reliable in patients with multiglandular disease Ultrasound and computed tomographic scanning are less sensitive however they are commonly used as confirmatory tests in association with sestamibi scanning When noninvasive imaging procedures fail to identify an enlarged gland invasive procedures such as selective arteriography are performed Whereas invasive procedures are useful they are associated with significant morbidity Reoperations for persistent or recurrent hyperparathyroidism compared with the initial operations are associated with higher complication rates In 90 of cases the abnormal pathology can be reached through a incision The success rate of the reoperation depends primarily on the results of the localization procedure and whether the patient has a single enlarged gland or multiglandular disease Resection of a single enlarged gland is curative in virtually all patients If however the patient has multiple gland disease the operation is successful less often especially in those with certain familial endocrinopathies,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[705, 424, 1, 7, 5, 86, 9630, 19512, 32, 3733, 20, 23116, 28, 3, 388, 3370, 135, 44, 3733, 361, 918, 24534, 4, 3, 2181, 573, 727, 15, 690, 6210, 50, 8, 319, 727, 1, 53190, 2214, 62, 140, 1, 6210, 50, 3370, 9, 19512, 32, 2853, 191, 4, 3, 573, 727, 2, 32, 1546, 361, 20, 35, 12549, 2434, 15, 35, 2610, 170, 1, 8179, 246, 299, 841, 3, 1897, 71, 1551, 6, 4237, 2, 4215, 943, 134, 15, 3, 147, 1, 19512, 10, 11774, 2, 125, 16, 1809, 708, 1, 3, 6210, 8, 1401, 3370, 9, 19512, 16, 1561, 470, 23, 3, 730, 1, 3, 2584, 1897, 3, 2745, 1147, 1, 3, 3966, 361, 4, 295, 522, 15, 3647, 522, 633, 2, 3, 463, 1, 8, 226, 7547, 2326, 22, 6101, 6, 33318, 34, 15, 134, 4, 140, 1257, 35, 7547, 2326, 16, 44, 108, 28, 2589, 2957, 15, 416, 1580, 270, 1369, 32, 999, 4, 14384, 3, 2326, 694, 3, 96, 2450, 2, 3320, 1299, 16, 11237, 6314, 11566, 3702, 26, 1312, 2953, 35, 7547, 2326, 4, 556, 493, 1, 140, 226, 4216, 1799, 1220, 872, 5817, 4, 248, 5, 11566, 3702, 1106, 3, 485, 1, 3, 1299, 6, 772, 46, 270, 1369, 32, 506, 2450, 4, 7, 5, 33318, 34, 1945, 2, 1220, 6158, 3702, 32, 299, 745, 137, 491, 32, 841, 95, 22, 5697, 895, 4, 248, 5, 11566, 3702, 198, 2957, 270, 1369, 4373, 6, 255, 35, 7547, 2326, 416, 1369, 225, 22, 1094, 53191, 32, 173, 547, 416, 1369, 32, 999, 491, 32, 41, 5, 93, 787, 10691, 9, 1882, 15, 387, 9630, 72, 5, 3, 388, 3867, 32, 41, 5, 142, 1447, 151, 4, 424, 1, 140, 3, 1668, 1117, 122, 40, 1300, 298, 8, 7538, 3, 1825, 116, 1, 3, 5077, 3828, 1561, 23, 3, 99, 1, 3, 2145, 1299, 2, 317, 3, 69, 71, 8, 226, 7547, 2326, 15, 33318, 34, 170, 1, 8, 226, 7547, 2326, 16, 1075, 4, 5860, 62, 7, 492, 137, 3, 69, 71, 232, 2326, 34, 3, 2589, 16, 1401, 299, 629, 1093, 4, 135, 5, 1840, 2200, 12081]",2438.0,12412795,94
Tumor above the spinal accessory nerve in papillary thyroid cancer that involves lateral neck nodes: a common occurrence.,Archives of otolaryngology--head & neck surgery,Arch. Otolaryngol. Head Neck Surg.,2002-11-01,"To describe the nature and extent of lateral neck node metastases from papillary thyroid cancer in relation to presenting physical examination and staging radiologic studies. Retrospective study. Tertiary referral cancer center. Consecutive patients who underwent comprehensive neck dissection with or without concurrent thyroidectomy for well-differentiated thyroid cancer between 1991 and 2001. Excluded were patients with well-differentiated thyroid cancer diagnosed incidentally at the time of treatment of other primary head and neck cancer, those with previous neck dissection for nonthyroid malignancies, and those undergoing surgery for medullary thyroid cancer. All pathology and operative and preoperative radiology reports for patients undergoing comprehensive neck dissection for well-differentiated thyroid malignancy were reviewed. Data were collected on previous procedures, preoperative evaluation, operative details, and pathologic findings. Identification of metastatic thyroid cancer in one or more nodes in anatomically defined drainage basins of the central and lateral neck. A total of 51 neck dissections were performed. All patients had preoperative evidence of metastatic disease. In addition to the usual comprehensive node dissection encompassing all lymphatic tissue in levels II through V, level I nodes and level II nodes above the spinal accessory nerve were labeled as distinct regions in 16 (31%) and 34 (67%) specimens, respectively. Disease was confined to a single nodal level in 20 (39%) of 51 specimens and was present in 4 or more levels in 7 (14%) of 50 neck dissections. There was cancer at 2 or 3 levels in 16 (31%) and 15 (29%) cases, respectively. Seven (21%) of the 34 patients undergoing separate analysis of nodes from above the spinal accessory nerve had cancer there. In 3 of the 34 it was the sole disease in level II. Tumor involvement at multiple nodal levels occurs in most cases when patients have lateral cervical node metastases. ""Skip"" metastases and cancer above the spinal accessory nerve are common. Neck dissections should include all node stations likely to be involved because selective node excision is likely to leave metastatic disease in situ.",Comparative Study,6290.0,59.0,To describe the nature and extent of lateral node metastases from papillary cancer in relation to presenting physical examination and staging radiologic studies Retrospective study Tertiary referral cancer center Consecutive patients who underwent comprehensive dissection with or without concurrent thyroidectomy for well-differentiated cancer between 1991 and 2001 Excluded were patients with well-differentiated cancer diagnosed incidentally at the time of treatment of other primary head and cancer those with previous dissection for nonthyroid malignancies and those undergoing surgery for medullary cancer All pathology and operative and preoperative radiology reports for patients undergoing comprehensive dissection for well-differentiated malignancy were reviewed Data were collected on previous procedures preoperative evaluation operative details and pathologic findings Identification of metastatic cancer in one or more nodes in anatomically defined drainage basins of the central and lateral A total of 51 dissections were performed All patients had preoperative evidence of metastatic disease In addition to the usual comprehensive node dissection encompassing all lymphatic tissue in levels II through V level I nodes and level II nodes above the spinal accessory nerve were labeled as distinct regions in 16 31 and 34 67 specimens respectively Disease was confined to a single nodal level in 20 39 of 51 specimens and was present in 4 or more levels in 7 14 of 50 dissections There was cancer at 2 or 3 levels in 16 31 and 15 29 cases respectively Seven 21 of the 34 patients undergoing separate analysis of nodes from above the spinal accessory nerve had cancer there In 3 of the 34 it was the sole disease in level II Tumor involvement at multiple nodal levels occurs in most cases when patients have lateral node metastases `` Skip '' metastases and cancer above the spinal accessory nerve are common dissections should include all node stations likely to be involved because selective node excision is likely to leave metastatic disease in situ,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[6, 897, 3, 2202, 2, 1039, 1, 3855, 289, 196, 29, 1796, 12, 4, 2191, 6, 1656, 900, 1385, 2, 632, 2812, 94, 459, 45, 2557, 2096, 12, 574, 935, 7, 54, 208, 949, 1161, 5, 15, 187, 750, 5949, 9, 149, 1442, 12, 59, 3372, 2, 1758, 1800, 11, 7, 5, 149, 1442, 12, 265, 5925, 28, 3, 98, 1, 24, 1, 127, 86, 718, 2, 12, 135, 5, 698, 1161, 9, 37315, 441, 2, 135, 479, 152, 9, 4564, 12, 62, 1117, 2, 1208, 2, 498, 4003, 1198, 9, 7, 479, 949, 1161, 9, 149, 1442, 710, 11, 446, 74, 11, 786, 23, 698, 1369, 498, 451, 1208, 3791, 2, 510, 272, 911, 1, 113, 12, 4, 104, 15, 80, 502, 4, 9622, 395, 3528, 7847, 1, 3, 854, 2, 3855, 8, 181, 1, 725, 6894, 11, 173, 62, 7, 42, 498, 241, 1, 113, 34, 4, 352, 6, 3, 3521, 949, 289, 1161, 6853, 62, 2936, 246, 4, 148, 215, 298, 603, 301, 70, 502, 2, 301, 215, 502, 2090, 3, 1499, 12082, 2476, 11, 2841, 22, 834, 1374, 4, 245, 456, 2, 562, 598, 623, 106, 34, 10, 2902, 6, 8, 226, 779, 301, 4, 179, 587, 1, 725, 623, 2, 10, 364, 4, 39, 15, 80, 148, 4, 67, 213, 1, 212, 6894, 125, 10, 12, 28, 18, 15, 27, 148, 4, 245, 456, 2, 167, 462, 140, 106, 648, 239, 1, 3, 562, 7, 479, 2282, 65, 1, 502, 29, 2090, 3, 1499, 12082, 2476, 42, 12, 125, 4, 27, 1, 3, 562, 192, 10, 3, 4991, 34, 4, 301, 215, 30, 799, 28, 232, 779, 148, 1780, 4, 96, 140, 198, 7, 47, 3855, 289, 196, 18833, 522, 196, 2, 12, 2090, 3, 1499, 12082, 2476, 32, 186, 6894, 257, 643, 62, 289, 9105, 322, 6, 40, 646, 408, 1094, 289, 1366, 16, 322, 6, 8678, 113, 34, 4, 957]",2065.0,12431169,197
"A stiff bristled, spiral-shaped ectocervical brush: a device for transepithelial tissue biopsy.",Obstetrics and gynecology,Obstet Gynecol,2002-12-01,"To compare a new spiral-shaped tissue-sampling brush with a standard cervical punch biopsy. Before large loop excision of the transformation zone, women with cervical intraepithelial neoplasia underwent a transepithelial brush biopsy of a portion of a colposcopically identified lesion, followed by a punch biopsy of the remaining portion. Brush biopsy samples were processed using liquid-based cytology and cell block techniques. Diagnoses were made using a consensus of three pathologists. Brush biopsy samples without basal cells were considered inadequate. The histological diagnosis was compared with the brush biopsy and punch biopsy samples. Patient-reported pain and physician-reported bleeding for punch and brush biopsies were compared. Fifty-two women were enrolled in the study; 47 successfully completed the study protocol. Eight brush biopsy specimens were inadequate. Thirty-nine women showed abnormal pathology (human papillomavirus/cervical intraepithelial neoplasia I or worse) on large loop excision of the transformation zone, and 32 women had high-grade (or worse) lesions. The punch biopsy correlated with high-grade disease in 53.1% of these women. The brush biopsy result correlated with high-grade disease in 79.3% of these women using a cell block technique and 76.7% using liquid cytology. There was significantly less pain (P <.001) and significantly less bleeding (P <.001) with the brush biopsy. When an adequate sample is collected, spiral brush biopsy is as good as a standard punch biopsy for detecting cervical pathology, with substantially less pain and bleeding. User training and guidelines for sampling are needed to assure that an adequate sample is collected.",Comparative Study,6260.0,5.0,To compare a new spiral-shaped tissue-sampling brush with a standard punch biopsy Before large loop excision of the transformation zone women with intraepithelial neoplasia underwent a transepithelial brush biopsy of a portion of a colposcopically identified lesion followed by a punch biopsy of the remaining portion Brush biopsy samples were processed using liquid-based cytology and cell block techniques Diagnoses were made using a consensus of three pathologists Brush biopsy samples without basal cells were considered inadequate The histological diagnosis was compared with the brush biopsy and punch biopsy samples Patient-reported pain and physician-reported bleeding for punch and brush biopsies were compared Fifty-two women were enrolled in the study 47 successfully completed the study protocol Eight brush biopsy specimens were inadequate Thirty-nine women showed abnormal pathology human papillomavirus/cervical intraepithelial neoplasia I or worse on large loop excision of the transformation zone and 32 women had high-grade or worse lesions The punch biopsy correlated with high-grade disease in 53.1 of these women The brush biopsy result correlated with high-grade disease in 79.3 of these women using a cell block technique and 76.7 using liquid cytology There was significantly less pain P .001 and significantly less bleeding P .001 with the brush biopsy When an adequate sample is collected spiral brush biopsy is as good as a standard punch biopsy for detecting pathology with substantially less pain and bleeding User training and guidelines for sampling are needed to assure that an adequate sample is collected,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 932, 8, 217, 18152, 8902, 246, 2874, 12556, 5, 8, 260, 12769, 411, 348, 375, 4432, 1366, 1, 3, 1392, 3614, 117, 5, 4153, 2298, 208, 8, 43102, 12556, 411, 1, 8, 3206, 1, 8, 26091, 108, 1180, 370, 20, 8, 12769, 411, 1, 3, 1844, 3206, 12556, 411, 347, 11, 5232, 75, 3165, 90, 2045, 2, 31, 2381, 1092, 2403, 11, 1229, 75, 8, 1391, 1, 169, 3354, 12556, 411, 347, 187, 2135, 37, 11, 515, 3358, 3, 1831, 147, 10, 72, 5, 3, 12556, 411, 2, 12769, 411, 347, 69, 210, 559, 2, 1473, 210, 2294, 9, 12769, 2, 12556, 1154, 11, 72, 1461, 100, 117, 11, 346, 4, 3, 45, 662, 1878, 781, 3, 45, 1182, 659, 12556, 411, 623, 11, 3358, 977, 762, 117, 224, 1668, 1117, 171, 3242, 18237, 4153, 2298, 70, 15, 639, 23, 375, 4432, 1366, 1, 3, 1392, 3614, 2, 531, 117, 42, 64, 88, 15, 639, 406, 3, 12769, 411, 438, 5, 64, 88, 34, 4, 699, 14, 1, 46, 117, 3, 12556, 411, 757, 438, 5, 64, 88, 34, 4, 842, 27, 1, 46, 117, 75, 8, 31, 2381, 1312, 2, 846, 67, 75, 3165, 2045, 125, 10, 97, 299, 559, 19, 144, 2, 97, 299, 2294, 19, 144, 5, 3, 12556, 411, 198, 35, 1658, 1000, 16, 786, 18152, 12556, 411, 16, 22, 1178, 22, 8, 260, 12769, 411, 9, 2502, 1117, 5, 2109, 299, 559, 2, 2294, 10188, 1741, 2, 677, 9, 2874, 32, 575, 6, 14799, 17, 35, 1658, 1000, 16, 786]",1638.0,12468174,879
Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ.,Gynecologic oncology,Gynecol. Oncol.,2002-10-01,"To determine if performing an endocervical curettage (ECC) at the time of conization is a useful diagnostic tool for predicting residual cervical adenocarcinoma in situ (AIS) among women who might wish to preserve their fertility. All patients diagnosed with AIS from 1995 to 2000 at four institutions were identified. Data were retrospectively extracted from clinical records. Women included in the statistical analysis were (1) younger than 40 years, (2) had an ECC performed at the time of the initial cone biopsy, (3) had a clearly demarcated surgical margin pathologically, and (4) underwent a second surgical procedure. Twenty-nine (24%) of 123 AIS patients met criteria for inclusion. The median age was 33 years (range, 17 to 39) and 13 (46%) were nulliparous. Initial surgery was a cold-knife conization (n = 17) or loop electrosurgical excision procedure (n = 12). Twelve (41%) ECCs and 15 (52%) cone margins were histologically positive. Sixteen patients underwent a repeat conization; 13 underwent hysterectomy. Thirteen (45%) patients had residual AIS at the time of their second surgical procedure. ECC had a superior positive predictive value (100% vs 47%; P < 0.01) and negative predictive value (94% vs 57%; P = 0.01) compared to cone margin in predicting residual AIS. None of the women undergoing fertility-sparing surgery developed recurrent AIS or adenocarcinoma. ECC performed at the time of conization may be a useful tool for predicting residual AIS in women considering fertility preservation.",Journal Article,6321.0,46.0,To determine if performing an endocervical curettage ECC at the time of conization is a useful diagnostic tool for predicting residual adenocarcinoma in situ AIS among women who might wish to preserve their fertility All patients diagnosed with AIS from 1995 to 2000 at four institutions were identified Data were retrospectively extracted from clinical records Women included in the statistical analysis were 1 younger than 40 years 2 had an ECC performed at the time of the initial cone biopsy 3 had a clearly demarcated surgical margin pathologically and 4 underwent a second surgical procedure Twenty-nine 24 of 123 AIS patients met criteria for inclusion The median age was 33 years range 17 to 39 and 13 46 were nulliparous Initial surgery was a cold-knife conization n 17 or loop electrosurgical excision procedure n 12 Twelve 41 ECCs and 15 52 cone margins were histologically positive Sixteen patients underwent a repeat conization 13 underwent hysterectomy Thirteen 45 patients had residual AIS at the time of their second surgical procedure ECC had a superior positive predictive value 100 vs 47 P 0.01 and negative predictive value 94 vs 57 P 0.01 compared to cone margin in predicting residual AIS None of the women undergoing fertility-sparing surgery developed recurrent AIS or adenocarcinoma ECC performed at the time of conization may be a useful tool for predicting residual AIS in women considering fertility preservation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 492, 3620, 35, 10174, 12529, 18238, 28, 3, 98, 1, 8755, 16, 8, 999, 752, 1515, 9, 1434, 753, 449, 4, 957, 3826, 107, 117, 54, 822, 11443, 6, 6783, 136, 2954, 62, 7, 265, 5, 3826, 29, 2323, 6, 1081, 28, 294, 1764, 11, 108, 74, 11, 894, 2484, 29, 38, 1064, 117, 159, 4, 3, 1050, 65, 11, 14, 773, 76, 327, 60, 18, 42, 35, 18238, 173, 28, 3, 98, 1, 3, 388, 6939, 411, 27, 42, 8, 2536, 23180, 221, 959, 2998, 2, 39, 208, 8, 419, 221, 1299, 737, 762, 259, 1, 2698, 3826, 7, 543, 371, 9, 1680, 3, 52, 89, 10, 466, 60, 184, 269, 6, 587, 2, 233, 641, 11, 9475, 388, 152, 10, 8, 5945, 8045, 8755, 78, 269, 15, 4432, 24548, 1366, 1299, 78, 133, 2544, 605, 43105, 2, 167, 653, 6939, 1012, 11, 2161, 109, 3228, 7, 208, 8, 2334, 8755, 233, 208, 2622, 3170, 512, 7, 42, 753, 3826, 28, 3, 98, 1, 136, 419, 221, 1299, 18238, 42, 8, 1123, 109, 464, 549, 394, 105, 662, 19, 13, 355, 2, 199, 464, 549, 960, 105, 696, 19, 13, 355, 72, 6, 6939, 959, 4, 1434, 753, 3826, 1292, 1, 3, 117, 479, 2954, 1851, 152, 276, 387, 3826, 15, 449, 18238, 173, 28, 3, 98, 1, 8755, 68, 40, 8, 999, 1515, 9, 1434, 753, 3826, 4, 117, 3075, 2954, 2224]",1440.0,12468353,596
Vaginal intraepithelial neoplasia: treatment by carbon dioxide laser and risk factors for failure.,"European journal of obstetrics, gynecology, and reproductive biology",Eur. J. Obstet. Gynecol. Reprod. Biol.,2003-01-01,"To evaluate the effectiveness of CO(2) laser ablation of vaginal intraepithelial neoplasia (VAIN) and to define prognostic factors. Medical records of 24 patients with VAIN II or III, treated by CO(2) laser ablation from 1990 to 1998 were reviewed. The grade, location, and focality of the lesions, the age, follow-up period and menopausal status of the patients, the power and duration of laser ablation, the presence of concurrent cervical or vulvar neoplasia or previous hysterectomy were evaluated as possible prognostic factors. Ablations of the VAIN were successfully accomplished in all of the patients with a mean period of 25.2+10.2 min, including additional simultaneous ablations of the cervix or vulva in eight (33.3%) patients. There was no early or late major complication. VAIN was completely eliminated in 17 (70.8%) patients after the first and in 19 (79.2%) patients after multiple episodes of ablation with a mean follow-up of 26.7+19.6 months. VAIN progressed to invasive vaginal carcinoma in one woman. None of the evaluated prognostic factors was found to be related to the persistence or recurrence. CO(2) laser ablation was a safe and effective method for the treatment of VAIN. However, since no prognostic factor was defined, all patients should be closely evaluated for persistence, recurrence or progression to invasion.",Clinical Trial,6229.0,36.0,To evaluate the effectiveness of CO 2 laser ablation of intraepithelial neoplasia VAIN and to define prognostic factors Medical records of 24 patients with VAIN II or III treated by CO 2 laser ablation from 1990 to 1998 were reviewed The grade location and focality of the lesions the age follow-up period and menopausal status of the patients the power and duration of laser ablation the presence of concurrent or neoplasia or previous hysterectomy were evaluated as possible prognostic factors Ablations of the VAIN were successfully accomplished in all of the patients with a mean period of 25.2+10.2 min including additional simultaneous ablations of the cervix or vulva in eight 33.3 patients There was no early or late major complication VAIN was completely eliminated in 17 70.8 patients after the first and in 19 79.2 patients after multiple episodes of ablation with a mean follow-up of 26.7+19.6 months VAIN progressed to invasive carcinoma in one woman None of the evaluated prognostic factors was found to be related to the persistence or recurrence CO 2 laser ablation was a safe and effective method for the treatment of VAIN However since no prognostic factor was defined all patients should be closely evaluated for persistence recurrence or progression to invasion,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 3, 1236, 1, 1269, 18, 3555, 1650, 1, 4153, 2298, 14802, 2, 6, 1107, 177, 130, 484, 1064, 1, 259, 7, 5, 14802, 215, 15, 316, 73, 20, 1269, 18, 3555, 1650, 29, 2289, 6, 1850, 11, 446, 3, 88, 1147, 2, 24553, 1, 3, 406, 3, 89, 166, 126, 727, 2, 3565, 156, 1, 3, 7, 3, 2349, 2, 654, 1, 3555, 1650, 3, 463, 1, 750, 15, 2298, 15, 698, 2622, 11, 194, 22, 899, 177, 130, 15894, 1, 3, 14802, 11, 1878, 5741, 4, 62, 1, 3, 7, 5, 8, 313, 727, 1, 243, 18, 79, 18, 1538, 141, 402, 2824, 15894, 1, 3, 3629, 15, 9263, 4, 659, 466, 27, 7, 125, 10, 77, 191, 15, 807, 458, 1447, 14802, 10, 2500, 6173, 4, 269, 431, 66, 7, 50, 3, 157, 2, 4, 326, 842, 18, 7, 50, 232, 3750, 1, 1650, 5, 8, 313, 166, 126, 1, 432, 67, 326, 49, 53, 14802, 1839, 6, 416, 134, 4, 104, 2854, 1292, 1, 3, 194, 177, 130, 10, 204, 6, 40, 139, 6, 3, 4108, 15, 146, 1269, 18, 3555, 1650, 10, 8, 1165, 2, 323, 596, 9, 3, 24, 1, 14802, 137, 1192, 77, 177, 161, 10, 395, 62, 7, 257, 40, 3210, 194, 9, 4108, 146, 15, 91, 6, 578]",1281.0,12475584,696
Development of an in vitro chemo-radiation response assay for cervical carcinoma.,Gynecologic oncology,Gynecol. Oncol.,2002-11-01,"To determine if synergistic effects of radiation (RT) and chemotherapy (chemo) on human cervical carcinoma cell lines and fresh tumor explants could be determined using an in vitro assay. In vitro radiation response was determined for 4 cell lines and 26 fresh tumor explants in an agar-based assay. Cells were exposed to increasing doses of RT with or without cisplatin (CDDP), carmustine (BCNU), buthionine sulfoximine (BSO), or paclitaxel (Tax). Cell suspensions were cultured for 5 days, with [(3)H]thymidine added on day 3 and proliferation was measured. Results were reported as the fraction of proliferation compared to control (FC). For each combination of irradiation and drug, synergy was tested using the Chou analysis, where a combination index (CI) <1 indicated synergistic interaction. In simple correlation analysis, an R value of >0.7 indicated cross-resistance. RT dose-dependent proliferation inhibition was observed for 2 of the 4 cell lines, and for all but 1 of the fresh specimens. Significant heterogeneity of tumor response to RT was seen. Four specimens that were 1 standard deviation below the median FC response after exposure to 300 cGy were classified as extremely radiation resistant. Twenty-one tumors were evaluated for synergistic response using the combination of chemo and RT with a median FC of 0.27 (+/-0.27) for 6.0 Gy of RT alone, 0.22 (+/-0.21) for CDDP alone, and 0.05 (+/-0.08) for the combination. A CI of 0.35 and an R value of 0.09 demonstrated synergy between chemo and RT without cross-resistance. Similar synergy without cross-resistance was found for RT in combination with BCNU, BSO, and TAX. Heterogeneous RT dose-response relationships in the in vitro assay were demonstrated. Explants were more sensitive to RT than cell lines. Unlike cell lines, fresh tumor cells consistently displayed synergy with RT and chemo. The synergy between RT and BSO suggests that glutathione depletion may enhance the effect of RT. The assay was feasible for examining fresh tumors and may be an important tool for studying RT or drug resistance. Clinical trials to evaluate this assay are indicated.",Journal Article,6290.0,9.0,To determine if synergistic effects of radiation RT and chemotherapy chemo on human carcinoma cell lines and fresh tumor explants could be determined using an in vitro assay In vitro radiation response was determined for 4 cell lines and 26 fresh tumor explants in an agar-based assay Cells were exposed to increasing doses of RT with or without cisplatin CDDP carmustine BCNU buthionine sulfoximine BSO or paclitaxel Tax Cell suspensions were cultured for 5 days with 3 H thymidine added on day 3 and proliferation was measured Results were reported as the fraction of proliferation compared to control FC For each combination of irradiation and drug synergy was tested using the Chou analysis where a combination index CI 1 indicated synergistic interaction In simple correlation analysis an R value of 0.7 indicated cross-resistance RT dose-dependent proliferation inhibition was observed for 2 of the 4 cell lines and for all but 1 of the fresh specimens Significant heterogeneity of tumor response to RT was seen Four specimens that were 1 standard deviation below the median FC response after exposure to 300 cGy were classified as extremely radiation resistant Twenty-one tumors were evaluated for synergistic response using the combination of chemo and RT with a median FC of 0.27 +/-0.27 for 6.0 Gy of RT alone 0.22 +/-0.21 for CDDP alone and 0.05 +/-0.08 for the combination A CI of 0.35 and an R value of 0.09 demonstrated synergy between chemo and RT without cross-resistance Similar synergy without cross-resistance was found for RT in combination with BCNU BSO and TAX Heterogeneous RT dose-response relationships in the in vitro assay were demonstrated Explants were more sensitive to RT than cell lines Unlike cell lines fresh tumor cells consistently displayed synergy with RT and chemo The synergy between RT and BSO suggests that glutathione depletion may enhance the effect of RT The assay was feasible for examining fresh tumors and may be an important tool for studying RT or drug resistance Clinical trials to evaluate this assay are indicated,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 492, 1806, 176, 1, 121, 240, 2, 56, 3341, 23, 171, 134, 31, 285, 2, 4329, 30, 9774, 359, 40, 509, 75, 35, 4, 439, 719, 4, 439, 121, 51, 10, 509, 9, 39, 31, 285, 2, 432, 4329, 30, 9774, 4, 35, 7491, 90, 719, 37, 11, 2234, 6, 602, 415, 1, 240, 5, 15, 187, 540, 5820, 5818, 4146, 24554, 24555, 9477, 15, 490, 8667, 31, 18240, 11, 3197, 9, 33, 162, 5, 27, 555, 6403, 1953, 23, 218, 27, 2, 457, 10, 644, 99, 11, 210, 22, 3, 1509, 1, 457, 72, 6, 182, 4127, 9, 296, 150, 1, 1104, 2, 234, 3439, 10, 650, 75, 3, 19520, 65, 1257, 8, 150, 558, 58, 14, 1103, 1806, 915, 4, 2763, 816, 65, 35, 668, 549, 1, 13, 67, 1103, 1383, 251, 240, 61, 470, 457, 297, 10, 164, 9, 18, 1, 3, 39, 31, 285, 2, 9, 62, 84, 14, 1, 3, 4329, 623, 93, 1144, 1, 30, 51, 6, 240, 10, 527, 294, 623, 17, 11, 14, 260, 3348, 2736, 3, 52, 4127, 51, 50, 645, 6, 2036, 3071, 11, 1373, 22, 2938, 121, 436, 737, 104, 57, 11, 194, 9, 1806, 51, 75, 3, 150, 1, 3341, 2, 240, 5, 8, 52, 4127, 1, 13, 428, 13, 428, 9, 49, 13, 381, 1, 240, 279, 13, 350, 13, 239, 9, 5820, 279, 2, 13, 474, 13, 1592, 9, 3, 150, 8, 58, 1, 13, 465, 2, 35, 668, 549, 1, 13, 1730, 264, 3439, 59, 3341, 2, 240, 187, 1383, 251, 288, 3439, 187, 1383, 251, 10, 204, 9, 240, 4, 150, 5, 4146, 9477, 2, 8667, 1564, 240, 61, 51, 2467, 4, 3, 4, 439, 719, 11, 264, 9774, 11, 80, 745, 6, 240, 76, 31, 285, 4246, 31, 285, 4329, 30, 37, 2433, 2507, 3439, 5, 240, 2, 3341, 3, 3439, 59, 240, 2, 9477, 844, 17, 4571, 2286, 68, 1304, 3, 254, 1, 240, 3, 719, 10, 1313, 9, 3282, 4329, 57, 2, 68, 40, 35, 305, 1515, 9, 4559, 240, 15, 234, 251, 38, 143, 6, 376, 26, 719, 32, 1103]",2066.0,12477451,869
ThinPrep detection of cervical and endometrial adenocarcinoma: a retrospective cohort study.,Cancer,Cancer,2002-12-01,"The current study was performed to compare the accuracy of the ThinPrep trade mark Papanicoloau (Pap) test with that of the conventionally prepared Pap smear in detecting cervical and endometrial adenocarcinomas. The subject group consisted of all ThinPrep cases of atypical glandular cells of undetermined significance (AGCUS) or adenocarcinoma diagnosed between March 1998 and March 2000. Conventional smears collected between January 1996 and January 1998, before laboratory conversion to the ThinPrep system, comprised the control group. Histologic follow-up was obtained. One hundred eighty-six (0.17%) of 112,058 ThinPrep Pap tests were interpreted as AGCUS/adenocarcinomas, compared with 77 (0.09%) of 83,464 conventional smears (P < 0.001). The overall sensitivity of a ThinPrep AGCUS/adenocarcinoma smear in detecting either cervical or endometrial adenocarcinoma was increased (72.0% vs. 41.5%; P < 0.001). The ThinPrep Pap test was more sensitive in detecting endometrial adenocarcinomas (65.2% vs. 38.6%; P = 0.010) and there was a trend for a higher sensitivity in detecting cervical adenocarcinomas (87.1% vs. 55.5%; P = 0.108). The ThinPrep Pap test is a more sensitive method of detecting cervical and endometrial adenocarcinomas than the conventional Pap smear.",Comparative Study,6260.0,75.0,"The current study was performed to compare the accuracy of the ThinPrep trade mark Papanicoloau Pap test with that of the conventionally prepared Pap smear in detecting and adenocarcinomas The subject group consisted of all ThinPrep cases of atypical glandular cells of undetermined significance AGCUS or adenocarcinoma diagnosed between March 1998 and March 2000 Conventional smears collected between January 1996 and January 1998 before laboratory conversion to the ThinPrep system comprised the control group Histologic follow-up was obtained One hundred eighty-six 0.17 of 112,058 ThinPrep Pap tests were interpreted as AGCUS/adenocarcinomas compared with 77 0.09 of 83,464 conventional smears P 0.001 The overall sensitivity of a ThinPrep AGCUS/adenocarcinoma smear in detecting either or adenocarcinoma was increased 72.0 vs. 41.5 P 0.001 The ThinPrep Pap test was more sensitive in detecting adenocarcinomas 65.2 vs. 38.6 P 0.010 and there was a trend for a higher sensitivity in detecting adenocarcinomas 87.1 vs. 55.5 P 0.108 The ThinPrep Pap test is a more sensitive method of detecting and adenocarcinomas than the conventional Pap smear",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 291, 45, 10, 173, 6, 932, 3, 1190, 1, 3, 12772, 10550, 8863, 53292, 4290, 412, 5, 17, 1, 3, 6846, 4421, 4290, 8379, 4, 2502, 2, 1586, 3, 2974, 87, 1695, 1, 62, 12772, 140, 1, 1973, 6170, 37, 1, 5206, 724, 37351, 15, 449, 265, 59, 2363, 1850, 2, 2363, 1081, 809, 8916, 786, 59, 1024, 2648, 2, 1024, 1850, 348, 1624, 3111, 6, 3, 12772, 398, 2603, 3, 182, 87, 884, 166, 126, 10, 683, 104, 1128, 2207, 437, 13, 269, 1, 3726, 10189, 12772, 4290, 895, 11, 5047, 22, 37351, 1586, 72, 5, 849, 13, 1730, 1, 852, 10288, 809, 8916, 19, 13, 144, 3, 63, 485, 1, 8, 12772, 37351, 449, 8379, 4, 2502, 361, 15, 449, 10, 101, 720, 13, 105, 605, 33, 19, 13, 144, 3, 12772, 4290, 412, 10, 80, 745, 4, 2502, 1586, 556, 18, 105, 519, 49, 19, 13, 4873, 2, 125, 10, 8, 853, 9, 8, 142, 485, 4, 2502, 1586, 912, 14, 105, 614, 33, 19, 13, 3590, 3, 12772, 4290, 412, 16, 8, 80, 745, 596, 1, 2502, 2, 1586, 76, 3, 809, 4290, 8379]",1148.0,12478681,418
New developments in the treatment of invasive cervical cancer.,Obstetrics and gynecology clinics of North America,Obstet. Gynecol. Clin. North Am.,2002-12-01,"Cervical cancer is a preventable disease that is curable when it is detected early. For advanced-stage cancer, the prognosis is worse. Over the years, much progress has been made in radiation therapy and in chemotherapy, but it took three decades for the arrival of concurrent chemoradiation therapy, which significantly improved the survival among women with advanced cervical cancer. This fact underscores the need and the importance for continuing efforts in clinical research. While current standards of therapy are being fine-tuned as more information is being gathered, great strides are being made in the areas of molecular and cancer biology. Novel treatments for cervical cancer appear to be imminent in the near future.",Journal Article,6260.0,18.0,cancer is a preventable disease that is curable when it is detected early For advanced-stage cancer the prognosis is worse Over the years much progress has been made in radiation therapy and in chemotherapy but it took three decades for the arrival of concurrent chemoradiation therapy which significantly improved the survival among women with advanced cancer This fact underscores the need and the importance for continuing efforts in clinical research While current standards of therapy are being fine-tuned as more information is being gathered great strides are being made in the areas of molecular and cancer biology Novel treatments for cancer appear to be imminent in the near future,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 8, 7936, 34, 17, 16, 4151, 198, 192, 16, 530, 191, 9, 131, 82, 12, 3, 356, 16, 639, 252, 3, 60, 1802, 1466, 71, 85, 1229, 4, 121, 36, 2, 4, 56, 84, 192, 5060, 169, 1968, 9, 3, 13286, 1, 750, 975, 36, 92, 97, 231, 3, 25, 107, 117, 5, 131, 12, 26, 1991, 6926, 3, 594, 2, 3, 1187, 9, 4346, 1413, 4, 38, 389, 369, 291, 3371, 1, 36, 32, 486, 2924, 22063, 22, 80, 487, 16, 486, 7546, 2797, 10698, 32, 486, 1229, 4, 3, 1361, 1, 219, 2, 12, 891, 229, 640, 9, 12, 1322, 6, 40, 21982, 4, 3, 1829, 508]",691.0,12509090,266
Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis.,Cancer,Cancer,2003-02-01,"The purpose of this study was to evaluate the clinical and pathologic factors associated with survival in patients with neuroendocrine (NE) cervical carcinoma. All patients with NE cervical carcinoma diagnosed between 1979-2001 were identified from tumor registry databases at two hospitals. Data were collected from hospital charts, office records, and tumor registry files. The impact of clinical and pathologic risk factors on the survival of patients with small cell NE carcinoma of the cervix was evaluated using Kaplan-Meier life table analyses and log-rank tests. The independent prognostic factors found to be predictive of survival in univariate analysis were evaluated using Cox regression. All tests were two-tailed with P values < 0.05 considered significant. Thirty-four patients (median age, 42 years) were diagnosed with neuroendocrine cervical carcinoma, which included 21 with International Federation of Gynecology and Obstetrics (FIGO) Stage I disease, 6 with FIGO Stage II disease, 5 with FIGO Stage III disease, and 2 with FIGO Stage IV disease. Seventeen patients underwent a radical and 6 patients underwent a simple hysterectomy. Fourteen women received adjuvant therapy with pelvic radiation and/or cisplatin-based chemotherapy. Ten women received primary radiotherapy with (n = 5) or without (n = 4) chemotherapy and the remaining patient refused therapy. Women with early-stage (Stage I-IIA) disease had median survival rates of 31 months compared with 10 months in the advanced-stage (Stage IIB-IVB) group (P = 0.002). In univariate analysis, advanced stage (P = 0.002), tumor size >2 cm (P = 0.02), margin involvement (P = 0.016), pure versus a mixed histologic pattern (P = 0.04), margin status (P = 0.016), and smoking (P = 0.04) were considered poor prognostic factors. In multivariate analysis, smoking for early-stage patients and stage of disease in the overall population remained as independent prognostic factors of survival. Smoking and advanced stage are reported to be poor prognostic factors for survival in patients with NE small cell carcinoma of the cervix. Only those with early lesions amenable to extirpation are cured. The role of primary or postoperative radiation with or without chemotherapy is unclear and yields uniformly poor results, particularly in patients with advanced lesions. Clinical trials are needed.",Journal Article,6198.0,129.0,The purpose of this study was to evaluate the clinical and pathologic factors associated with survival in patients with neuroendocrine NE carcinoma All patients with NE carcinoma diagnosed between 1979-2001 were identified from tumor registry databases at two hospitals Data were collected from hospital charts office records and tumor registry files The impact of clinical and pathologic risk factors on the survival of patients with small cell NE carcinoma of the cervix was evaluated using Kaplan-Meier life table analyses and log-rank tests The independent prognostic factors found to be predictive of survival in univariate analysis were evaluated using Cox regression All tests were two-tailed with P values 0.05 considered significant Thirty-four patients median age 42 years were diagnosed with neuroendocrine carcinoma which included 21 with International Federation of Gynecology and Obstetrics FIGO Stage I disease 6 with FIGO Stage II disease 5 with FIGO Stage III disease and 2 with FIGO Stage IV disease Seventeen patients underwent a radical and 6 patients underwent a simple hysterectomy Fourteen women received adjuvant therapy with pelvic radiation and/or cisplatin-based chemotherapy Ten women received primary radiotherapy with n 5 or without n 4 chemotherapy and the remaining patient refused therapy Women with early-stage Stage I-IIA disease had median survival rates of 31 months compared with 10 months in the advanced-stage Stage IIB-IVB group P 0.002 In univariate analysis advanced stage P 0.002 tumor size 2 cm P 0.02 margin involvement P 0.016 pure versus a mixed histologic pattern P 0.04 margin status P 0.016 and smoking P 0.04 were considered poor prognostic factors In multivariate analysis smoking for early-stage patients and stage of disease in the overall population remained as independent prognostic factors of survival Smoking and advanced stage are reported to be poor prognostic factors for survival in patients with NE small cell carcinoma of the cervix Only those with early lesions amenable to extirpation are cured The role of primary or postoperative radiation with or without chemotherapy is unclear and yields uniformly poor results particularly in patients with advanced lesions Clinical trials are needed,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 376, 3, 38, 2, 510, 130, 41, 5, 25, 4, 7, 5, 1542, 5876, 134, 62, 7, 5, 5876, 134, 265, 59, 9444, 1758, 11, 108, 29, 30, 1608, 2348, 28, 100, 1987, 74, 11, 786, 29, 702, 4413, 6489, 1064, 2, 30, 1608, 7530, 3, 345, 1, 38, 2, 510, 43, 130, 23, 3, 25, 1, 7, 5, 302, 31, 5876, 134, 1, 3, 3629, 10, 194, 75, 876, 882, 358, 7016, 318, 2, 1066, 1026, 895, 3, 306, 177, 130, 204, 6, 40, 464, 1, 25, 4, 880, 65, 11, 194, 75, 418, 320, 62, 895, 11, 100, 12119, 5, 19, 1030, 13, 474, 515, 93, 977, 294, 7, 52, 89, 595, 60, 11, 265, 5, 1542, 134, 92, 159, 239, 5, 944, 7303, 1, 6429, 2, 7407, 3837, 82, 70, 34, 49, 5, 3837, 82, 215, 34, 33, 5, 3837, 82, 316, 34, 2, 18, 5, 3837, 82, 478, 34, 3591, 7, 208, 8, 711, 2, 49, 7, 208, 8, 2763, 2622, 3225, 117, 103, 249, 36, 5, 1110, 121, 2, 15, 540, 90, 56, 1618, 117, 103, 86, 310, 5, 78, 33, 15, 187, 78, 39, 56, 2, 3, 1844, 69, 8237, 36, 117, 5, 191, 82, 82, 70, 4088, 34, 42, 52, 25, 151, 1, 456, 53, 72, 5, 79, 53, 4, 3, 131, 82, 82, 3884, 7042, 87, 19, 13, 1111, 4, 880, 65, 131, 82, 19, 13, 1111, 30, 444, 18, 494, 19, 13, 588, 959, 799, 19, 13, 3820, 3092, 185, 8, 1739, 884, 1177, 19, 13, 755, 959, 156, 19, 13, 3820, 2, 979, 19, 13, 755, 11, 515, 334, 177, 130, 4, 331, 65, 979, 9, 191, 82, 7, 2, 82, 1, 34, 4, 3, 63, 266, 958, 22, 306, 177, 130, 1, 25, 979, 2, 131, 82, 32, 210, 6, 40, 334, 177, 130, 9, 25, 4, 7, 5, 5876, 302, 31, 134, 1, 3, 3629, 158, 135, 5, 191, 406, 4070, 6, 11945, 32, 3733, 3, 200, 1, 86, 15, 573, 121, 5, 15, 187, 56, 16, 1200, 2, 4788, 4254, 334, 99, 823, 4, 7, 5, 131, 406, 38, 143, 32, 575]",2257.0,12548598,103
Cervical cancer rates and the supply of primary care physicians in Florida.,Family medicine,Fam Med,2003-01-01,"This study's aim was to determine if an increased supply of primary care physicians is associated with lower incidence and mortality rates for cervical cancer. We determined cervical cancer incidence and mortality rates for each of Florida's 67 counties over the 3-year period of 1993-1995 using data from Florida's population-based tumor registry. Data on physician supply were obtained from the 1994 American Medical Association Physician Masterfile. We used multiple linear regression analysis to examine the relationship between physician supply and cervical cancer incidence and mortality rates, adjusting for other county-level characteristics. In regression analysis that adjusted for other county-level characteristics, each increase in the supply of family physicians of one physician/10,000 persons was associated with a corresponding drop in the incidence rate of 1.5 cases/100,000 persons and a corresponding drop in mortality rate of .65 cases/100,000 persons. Our results indicate that a greater supply of primary care physicians is likely associated with a lower incidence of cervical cancer and a lower cervical cancer mortality rate. More studies are needed at the individual patient level to confirm this association.",Journal Article,6229.0,59.0,"This study 's aim was to determine if an increased supply of primary care physicians is associated with lower incidence and mortality rates for cancer We determined cancer incidence and mortality rates for each of Florida 's 67 counties over the 3-year period of 1993-1995 using data from Florida 's population-based tumor registry Data on physician supply were obtained from the 1994 American Medical Association Physician Masterfile We used multiple linear regression analysis to examine the relationship between physician supply and cancer incidence and mortality rates adjusting for other county-level characteristics In regression analysis that adjusted for other county-level characteristics each increase in the supply of family physicians of one physician/10,000 persons was associated with a corresponding drop in the incidence rate of 1.5 cases/100,000 persons and a corresponding drop in mortality rate of .65 cases/100,000 persons Our results indicate that a greater supply of primary care physicians is likely associated with a lower incidence of cancer and a lower cancer mortality rate More studies are needed at the individual patient level to confirm this association",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[26, 45, 292, 1130, 10, 6, 223, 492, 35, 101, 6296, 1, 86, 165, 1261, 16, 41, 5, 280, 287, 2, 282, 151, 9, 12, 21, 509, 12, 287, 2, 282, 151, 9, 296, 1, 10533, 292, 598, 8257, 252, 3, 27, 111, 727, 1, 3343, 2323, 75, 74, 29, 10533, 292, 266, 90, 30, 1608, 74, 23, 1473, 6296, 11, 683, 29, 3, 3023, 597, 484, 248, 1473, 24578, 21, 95, 232, 1646, 320, 65, 6, 1004, 3, 858, 59, 1473, 6296, 2, 12, 287, 2, 282, 151, 1358, 9, 127, 5152, 301, 374, 4, 320, 65, 17, 586, 9, 127, 5152, 301, 374, 296, 344, 4, 3, 6296, 1, 607, 1261, 1, 104, 1473, 79, 984, 4327, 10, 41, 5, 8, 1734, 7215, 4, 3, 287, 116, 1, 14, 33, 140, 394, 984, 4327, 2, 8, 1734, 7215, 4, 282, 116, 1, 556, 140, 394, 984, 4327, 114, 99, 1008, 17, 8, 378, 6296, 1, 86, 165, 1261, 16, 322, 41, 5, 8, 280, 287, 1, 12, 2, 8, 280, 12, 282, 116, 80, 94, 32, 575, 28, 3, 797, 69, 301, 6, 1843, 26, 248]",1184.0,12564867,753
Prognostic significance of microscopic and macroscopic extracapsular spread from metastatic tumor in the cervical lymph nodes.,Oral oncology,Oral Oncol.,2002-12-01,"It has been established that the presence or absence of cervical node metastases in patients with head and neck squamous cell carcinoma (HNSCC) is a powerful prognostic indicator. This report reviews the evolution of thinking over the past 70 years with regard to the import and detection of cervical nodal metastases which exhibit spread of tumor beyond the confines of the original encompassing nodal capsule. In the process, this discussion touches upon clinical examination, gross and microscopic pathologic examination, and radiographic imaging studies. In particular, the distinction between gross nodal extracapsular spread of tumor and microscopic nodal extracapsular spread of tumor has been drawn in recent reports; this raises the possibility that identification of microscopic breaching of the nodc capsule by tumor might provide clinically significant information which is not provided by the gross observation of an intact lymph node capsule. While it remains to be seen whether microscopic extracapsular spread alone will prove to be an important prognostic factor, it is recommended that selective neck dissection continue to be offered even in those patients with clinically negative necks; further studies should aid in defining the import of microscopic extracapsular tumor spread in patients with positive cervical nodes.",Journal Article,6260.0,131.0,It has been established that the presence or absence of node metastases in patients with head and squamous cell carcinoma HNSCC is a powerful prognostic indicator This report reviews the evolution of thinking over the past 70 years with regard to the import and detection of nodal metastases which exhibit spread of tumor beyond the confines of the original encompassing nodal capsule In the process this discussion touches upon clinical examination gross and microscopic pathologic examination and radiographic imaging studies In particular the distinction between gross nodal extracapsular spread of tumor and microscopic nodal extracapsular spread of tumor has been drawn in recent reports this raises the possibility that identification of microscopic breaching of the nodc capsule by tumor might provide clinically significant information which is not provided by the gross observation of an intact lymph node capsule While it remains to be seen whether microscopic extracapsular spread alone will prove to be an important prognostic factor it is recommended that selective dissection continue to be offered even in those patients with clinically negative necks further studies should aid in defining the import of microscopic extracapsular tumor spread in patients with positive nodes,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[192, 71, 85, 635, 17, 3, 463, 15, 1127, 1, 289, 196, 4, 7, 5, 718, 2, 691, 31, 134, 1209, 16, 8, 3757, 177, 3287, 26, 414, 2004, 3, 2554, 1, 12566, 252, 3, 1219, 431, 60, 5, 2539, 6, 3, 13849, 2, 638, 1, 779, 196, 92, 2239, 2579, 1, 30, 1654, 3, 23199, 1, 3, 2279, 6853, 779, 5474, 4, 3, 1129, 26, 2488, 26114, 1548, 38, 1385, 1789, 2, 2984, 510, 1385, 2, 1580, 270, 94, 4, 1454, 3, 6628, 59, 1789, 779, 5607, 2579, 1, 30, 2, 2984, 779, 5607, 2579, 1, 30, 71, 85, 5694, 4, 435, 1198, 26, 5789, 3, 2526, 17, 911, 1, 2984, 37385, 1, 3, 53360, 5474, 20, 30, 822, 377, 505, 93, 487, 92, 16, 44, 1052, 20, 3, 1789, 1664, 1, 35, 2964, 263, 289, 5474, 369, 192, 469, 6, 40, 527, 317, 2984, 5607, 2579, 279, 303, 4361, 6, 40, 35, 305, 177, 161, 192, 16, 793, 17, 1094, 1161, 1906, 6, 40, 2216, 871, 4, 135, 7, 5, 505, 199, 18251, 195, 94, 257, 2427, 4, 2847, 3, 13849, 1, 2984, 5607, 30, 2579, 4, 7, 5, 109, 502]",1290.0,12570052,73
Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia--a pilot study.,Gynecologic and obstetric investigation,Gynecol. Obstet. Invest.,2003-01-01,"Although many dysplastic cervical lesions regress spontaneously, treatment is common due to concern for progression. Lesions persist or progress in women whose immune systems are unable to clear infection by human papillomavirus (HPV). Dehydroepiandrosterone (DHEA) is an adrenal steroid that has both immune modulatory and tumor inhibitory activity. A pilot study was conducted to examine the feasibility, safety and potential efficacy of intravaginal DHEA in women with low-grade cervical dysplasia. Twelve women with low-grade dysplasia, confirmed by colposcopic exam, were given 150 mg of intravaginal micronized DHEA daily for up to 6 months. Follow-up evaluations of the cervix were done at 3 and 6 months of use. DHEA, DHEA-S, androstenedione and testosterone levels were also measured. By the end of the study period, 10 of the 12 women (83%) had no evidence of dysplasia; the remaining 2 had normal colposcopic exams but cytology showing atypical cells of undetermined significance. There were no serious side effects. Androstenedione levels were elevated at 3 months, whereas testosterone levels were unchanged over the course of treatment. The results suggest that intravaginal DHEA is safe and well tolerated and may promote regression of low-grade cervical lesions. Further study is needed to establish efficacy.",Clinical Trial,6229.0,16.0,Although many dysplastic lesions regress spontaneously treatment is common due to concern for progression Lesions persist or progress in women whose immune systems are unable to clear infection by human papillomavirus HPV Dehydroepiandrosterone DHEA is an adrenal steroid that has both immune modulatory and tumor inhibitory activity A pilot study was conducted to examine the feasibility safety and potential efficacy of intravaginal DHEA in women with low-grade dysplasia Twelve women with low-grade dysplasia confirmed by colposcopic exam were given 150 mg of intravaginal micronized DHEA daily for up to 6 months Follow-up evaluations of the cervix were done at 3 and 6 months of use DHEA DHEA-S androstenedione and testosterone levels were also measured By the end of the study period 10 of the 12 women 83 had no evidence of dysplasia the remaining 2 had normal colposcopic exams but cytology showing atypical cells of undetermined significance There were no serious side effects Androstenedione levels were elevated at 3 months whereas testosterone levels were unchanged over the course of treatment The results suggest that intravaginal DHEA is safe and well tolerated and may promote regression of low-grade lesions Further study is needed to establish efficacy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[242, 445, 6461, 406, 15824, 6459, 24, 16, 186, 520, 6, 2893, 9, 91, 406, 5589, 15, 1466, 4, 117, 1310, 250, 1530, 32, 4253, 6, 885, 930, 20, 171, 3242, 933, 12317, 10850, 16, 35, 2987, 3853, 17, 71, 110, 250, 11424, 2, 30, 1810, 128, 8, 2281, 45, 10, 426, 6, 1004, 3, 1437, 367, 2, 174, 209, 1, 16720, 10850, 4, 117, 5, 154, 88, 2253, 2544, 117, 5, 154, 88, 2253, 557, 20, 14131, 6747, 11, 447, 1577, 81, 1, 16720, 24414, 10850, 391, 9, 126, 6, 49, 53, 166, 126, 3816, 1, 3, 3629, 11, 1822, 28, 27, 2, 49, 53, 1, 119, 10850, 10850, 695, 10310, 2, 2660, 148, 11, 120, 644, 20, 3, 396, 1, 3, 45, 727, 79, 1, 3, 133, 117, 852, 42, 77, 241, 1, 2253, 3, 1844, 18, 42, 295, 14131, 12318, 84, 2045, 2069, 1973, 37, 1, 5206, 724, 125, 11, 77, 1762, 1152, 176, 10310, 148, 11, 804, 28, 27, 53, 547, 2660, 148, 11, 4639, 252, 3, 906, 1, 24, 3, 99, 309, 17, 16720, 10850, 16, 1165, 2, 149, 421, 2, 68, 1617, 320, 1, 154, 88, 406, 195, 45, 16, 575, 6, 1811, 209]",1270.0,12624548,215
Cervical adenocarcinoma survival among Hispanic and white women: a multicenter cohort study.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2003-03-01,"We compared the clinical outcome of cervical adenocarcinoma in Hispanic and white women to determine whether race was an independent predictor of survival. All women who were diagnosed with cervical adenocarcinoma at three institutions between 1982 and 2000 were identified. Medical records were reviewed retrospectively. Hispanic and white cohorts were matched 1:2 for age, stage of disease, date of diagnosis, tumor size, histologic subtype, grade, and invasive depth. The 65 Hispanic patients were more likely to be treated at the public hospital (71% vs 14%; P <.001) than the 122 matched white patients. Most Hispanic patients (72%) and white patients (76%) presented with early (stage IA-IIA), not advanced (IIB-IVB), disease. Early (81% vs 81%, P =.65), advanced (37% vs 26%, P =.21), and overall 5-year survival rates (67% vs 68%, P =.57) were similar among Hispanic and white patients, respectively. The relative risk of race on recurrence was 1.22 (95% CI, 0.56-2.42) and on survival was 0.72 (95% CI, 0.36-1.44). Hispanic race is not an independent predictor of survival in cervical adenocarcinoma.",Journal Article,6170.0,7.0,We compared the clinical outcome of adenocarcinoma in Hispanic and white women to determine whether race was an independent predictor of survival All women who were diagnosed with adenocarcinoma at three institutions between 1982 and 2000 were identified Medical records were reviewed retrospectively Hispanic and white cohorts were matched 1:2 for age stage of disease date of diagnosis tumor size histologic subtype grade and invasive depth The 65 Hispanic patients were more likely to be treated at the public hospital 71 vs 14 P .001 than the 122 matched white patients Most Hispanic patients 72 and white patients 76 presented with early stage IA-IIA not advanced IIB-IVB disease Early 81 vs 81 P =.65 advanced 37 vs 26 P =.21 and overall 5-year survival rates 67 vs 68 P =.57 were similar among Hispanic and white patients respectively The relative risk of race on recurrence was 1.22 95 CI 0.56-2.42 and on survival was 0.72 95 CI 0.36-1.44 Hispanic race is not an independent predictor of survival in adenocarcinoma,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 72, 3, 38, 228, 1, 449, 4, 1776, 2, 886, 117, 6, 223, 317, 1047, 10, 35, 306, 980, 1, 25, 62, 117, 54, 11, 265, 5, 449, 28, 169, 1764, 59, 6652, 2, 1081, 11, 108, 484, 1064, 11, 446, 894, 1776, 2, 886, 736, 11, 655, 14, 18, 9, 89, 82, 1, 34, 1244, 1, 147, 30, 444, 884, 875, 88, 2, 416, 2436, 3, 556, 1776, 7, 11, 80, 322, 6, 40, 73, 28, 3, 3067, 702, 792, 105, 213, 19, 144, 76, 3, 3285, 655, 886, 7, 96, 1776, 7, 720, 2, 886, 7, 846, 917, 5, 191, 82, 3302, 4088, 44, 131, 3884, 7042, 34, 191, 865, 105, 865, 19, 556, 131, 567, 105, 432, 19, 239, 2, 63, 33, 111, 25, 151, 598, 105, 806, 19, 696, 11, 288, 107, 1776, 2, 886, 7, 106, 3, 580, 43, 1, 1047, 23, 146, 10, 14, 350, 48, 58, 13, 664, 18, 595, 2, 23, 25, 10, 13, 720, 48, 58, 13, 511, 14, 584, 1776, 1047, 16, 44, 35, 306, 980, 1, 25, 4, 449]",1023.0,12634634,20
Adjuvant irradiation for cervical lymph node metastases from melanoma.,Cancer,Cancer,2003-04-01,"The risk of regional disease recurrence after surgery alone for lymph node metastases from melanoma is well documented. The role of adjuvant irradiation remains controversial. The medical records of 160 patients with cervical lymph node metastases from melanoma were reviewed retrospectively. Of these, 148 (93%) presented with clinically palpable lymph node metastases. All patients underwent surgery and radiation to a median dose of 30 grays (Gy) at 6 Gy per fraction delivered twice weekly. Surgical resection was either a selective neck dissection in 90 patients or local excision of the lymph node metastasis in 35 patients. Only 35 patients underwent a radical, modified radical, or functional neck dissection. At a median follow-up of 78 months, the actuarial local, regional, and locoregional control rates at 10 years were 94%, 94%, and 91%, respectively. Univariate analysis of patient, tumor, and treatment characteristics failed to reveal any association with the subsequent rate of local or regional control. The actuarial disease-specific (DSS), disease-free, and distant metastasis-free survival (DMFS) rates at 10 years were 48%, 42%, and 43%, respectively. Univariate and multivariate analyses revealed that patients with four or more involved lymph nodes had a significantly worse DSS and DMFS. Nine patients developed a treatment-related complication requiring medical management, resulting in a 5-year actuarial complication-free survival rate of 90%. Adjuvant radiotherapy resulted in a 10-year regional control rate of 94%. Complications for all patients were rare and manageable when they did occur. The authors recommend adjuvant irradiation for patients with extracapsular extension, lymph nodes measuring 3 cm in size or larger, the involvement of multiple lymph nodes, recurrent disease, or any patient having undergone a selective therapeutic neck dissection.",Journal Article,6139.0,79.0,The risk of regional disease recurrence after surgery alone for lymph node metastases from is well documented The role of adjuvant irradiation remains controversial The medical records of 160 patients with lymph node metastases from were reviewed retrospectively Of these 148 93 presented with clinically palpable lymph node metastases All patients underwent surgery and radiation to a median dose of 30 grays Gy at 6 Gy per fraction delivered twice weekly Surgical resection was either a selective dissection in 90 patients or local excision of the lymph node metastasis in 35 patients Only 35 patients underwent a radical modified radical or functional dissection At a median follow-up of 78 months the actuarial local regional and locoregional control rates at 10 years were 94 94 and 91 respectively Univariate analysis of patient tumor and treatment characteristics failed to reveal any association with the subsequent rate of local or regional control The actuarial disease-specific DSS disease-free and distant metastasis-free survival DMFS rates at 10 years were 48 42 and 43 respectively Univariate and multivariate analyses revealed that patients with four or more involved lymph nodes had a significantly worse DSS and DMFS Nine patients developed a treatment-related complication requiring medical management resulting in a 5-year actuarial complication-free survival rate of 90 Adjuvant radiotherapy resulted in a 10-year regional control rate of 94 Complications for all patients were rare and manageable when they did occur The authors recommend adjuvant irradiation for patients with extracapsular extension lymph nodes measuring 3 cm in size or larger the involvement of multiple lymph nodes recurrent disease or any patient having undergone a selective therapeutic dissection,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 43, 1, 951, 34, 146, 50, 152, 279, 9, 263, 289, 196, 29, 16, 149, 1405, 3, 200, 1, 249, 1104, 469, 2010, 3, 484, 1064, 1, 3457, 7, 5, 263, 289, 196, 29, 11, 446, 894, 1, 46, 4647, 966, 917, 5, 505, 4880, 263, 289, 196, 62, 7, 208, 152, 2, 121, 6, 8, 52, 61, 1, 201, 9864, 381, 28, 49, 381, 379, 1509, 1623, 936, 709, 221, 170, 10, 361, 8, 1094, 1161, 4, 424, 7, 15, 293, 1366, 1, 3, 263, 289, 278, 4, 465, 7, 158, 465, 7, 208, 8, 711, 1230, 711, 15, 583, 1161, 28, 8, 52, 166, 126, 1, 833, 53, 3, 2361, 293, 951, 2, 1325, 182, 151, 28, 79, 60, 11, 960, 960, 2, 970, 106, 880, 65, 1, 69, 30, 2, 24, 374, 1551, 6, 2396, 500, 248, 5, 3, 706, 116, 1, 293, 15, 951, 182, 3, 2361, 34, 112, 1788, 34, 115, 2, 626, 278, 115, 25, 5930, 151, 28, 79, 60, 11, 576, 595, 2, 601, 106, 880, 2, 331, 318, 553, 17, 7, 5, 294, 15, 80, 646, 263, 502, 42, 8, 97, 639, 1788, 2, 5930, 762, 7, 276, 8, 24, 139, 1447, 1888, 484, 284, 1113, 4, 8, 33, 111, 2361, 1447, 115, 25, 116, 1, 424, 249, 310, 627, 4, 8, 79, 111, 951, 182, 116, 1, 960, 521, 9, 62, 7, 11, 622, 2, 2808, 198, 491, 205, 1271, 3, 738, 2237, 249, 1104, 9, 7, 5, 5607, 2401, 263, 502, 2978, 27, 494, 4, 444, 15, 1077, 3, 799, 1, 232, 263, 502, 387, 34, 15, 500, 69, 1041, 1989, 8, 1094, 189, 1161]",1793.0,12655537,372
Laparoscopic identification of sentinel lymph nodes in early stage cervical cancer: prospective study using a combination of patent blue dye injection and technetium radiocolloid injection.,Gynecologic oncology,Gynecol. Oncol.,2003-04-01,"To determine the feasibility of intraoperative radioisotopic mapping using an endoscopic gamma probe associated with patent blue dye injection in patients with early stage cervical cancer. Between April 2001 and March 2002 a total of 12 patients underwent laparoscopic bilateral pelvic lymphadenectomy (squamous carcinoma in 10 cases, all stage FIGO IB1, and adenocarcinoma in 2 cases, stages IA2 and IB1). Lymphoscintigraphies were performed on the day before surgery to visualize sentinel lymph nodes, 31 +/- 22.5 and 174 +/- 34 min after injection of 200 microCi of technetium 99m rhenium sulfur colloid. The marker was injected at the 3, 6, 9, and 12 o'clock positions. The day of surgery 2 ml of patent blue dye plus 2 ml of physiological serum was injected in the cervix, at the same locations as the radioactive isotope injection. A total of 35 sentinel lymph nodes were detected. Eight sentinel lymph nodes were only detected by color, 8 sentinel lymph nodes were only detected by the endoscopic gamma probe, and 19 sentinel lymph nodes were ""hot and dyed."" We found 3 metastatic lymph nodes. In one case, bilateral positive sentinel nodes were only detected by the endoscopic gamma probe. Permanent section identified one inframillimetric micrometastasis in a lymph node that was neither blue nor hot intraoperatively (sensitivity = 66%, specificity = 100%, positive predictive value = 100%, negative predictive value = 90%). The identification of the sentinel lymph node with blue dye and radioisotope using an endoscopic gamma probe is feasible and improves detection rate. False negatives still occur, but the proportion is low even at the beginning of the learning curve. Isotopic imaging identifies nodes in areas outside the pelvis not routinely sampled in early cervical cancer patients.",Clinical Trial,6139.0,104.0,To determine the feasibility of intraoperative radioisotopic mapping using an endoscopic gamma probe associated with patent blue dye injection in patients with early stage cancer Between April 2001 and March 2002 a total of 12 patients underwent laparoscopic bilateral pelvic lymphadenectomy squamous carcinoma in 10 cases all stage FIGO IB1 and adenocarcinoma in 2 cases stages IA2 and IB1 Lymphoscintigraphies were performed on the day before surgery to visualize sentinel lymph nodes 31 +/- 22.5 and 174 +/- 34 min after injection of 200 microCi of technetium 99m rhenium sulfur colloid The marker was injected at the 3 6 9 and 12 o'clock positions The day of surgery 2 ml of patent blue dye plus 2 ml of physiological serum was injected in the cervix at the same locations as the radioactive isotope injection A total of 35 sentinel lymph nodes were detected Eight sentinel lymph nodes were only detected by color 8 sentinel lymph nodes were only detected by the endoscopic gamma probe and 19 sentinel lymph nodes were `` hot and dyed '' We found 3 metastatic lymph nodes In one case bilateral positive sentinel nodes were only detected by the endoscopic gamma probe Permanent section identified one inframillimetric micrometastasis in a lymph node that was neither blue nor hot intraoperatively sensitivity 66 specificity 100 positive predictive value 100 negative predictive value 90 The identification of the sentinel lymph node with blue dye and radioisotope using an endoscopic gamma probe is feasible and improves detection rate False negatives still occur but the proportion is low even at the beginning of the learning curve Isotopic imaging identifies nodes in areas outside the pelvis not routinely sampled in early cancer patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 1437, 1, 1720, 37433, 2568, 75, 35, 2056, 1705, 2888, 41, 5, 14172, 3352, 3796, 1754, 4, 7, 5, 191, 82, 12, 59, 2292, 1758, 2, 2363, 1544, 8, 181, 1, 133, 7, 208, 1964, 1607, 1110, 2048, 691, 134, 4, 79, 140, 62, 82, 3837, 8111, 2, 449, 4, 18, 140, 1153, 16725, 2, 8111, 53486, 11, 173, 23, 3, 218, 348, 152, 6, 9360, 1323, 263, 502, 456, 350, 33, 2, 5811, 562, 1538, 50, 1754, 1, 1250, 33413, 1, 11237, 6314, 37434, 10266, 7245, 3, 952, 10, 2651, 28, 3, 27, 49, 83, 2, 133, 28043, 7134, 3, 218, 1, 152, 18, 542, 1, 14172, 3352, 3796, 349, 18, 542, 1, 4733, 524, 10, 2651, 4, 3, 3629, 28, 3, 827, 4069, 22, 3, 4741, 9242, 1754, 8, 181, 1, 465, 1323, 263, 502, 11, 530, 659, 1323, 263, 502, 11, 158, 530, 20, 6052, 66, 1323, 263, 502, 11, 158, 530, 20, 3, 2056, 1705, 2888, 2, 326, 1323, 263, 502, 11, 2859, 2, 43227, 522, 21, 204, 27, 113, 263, 502, 4, 104, 473, 1607, 109, 1323, 502, 11, 158, 530, 20, 3, 2056, 1705, 2888, 4377, 2917, 108, 104, 53487, 10828, 4, 8, 263, 289, 17, 10, 2174, 3352, 2110, 2859, 6595, 485, 700, 1121, 394, 109, 464, 549, 394, 199, 464, 549, 424, 3, 911, 1, 3, 1323, 263, 289, 5, 3352, 3796, 2, 12477, 75, 35, 2056, 1705, 2888, 16, 1313, 2, 1804, 638, 116, 2133, 13508, 1234, 1271, 84, 3, 920, 16, 154, 871, 28, 3, 2948, 1, 3, 3434, 1496, 37435, 270, 2953, 502, 4, 1361, 2513, 3, 3270, 44, 3066, 5919, 4, 191, 12, 7]",1745.0,12694658,20
Quality of non-breast cancer health maintenance among elderly breast cancer survivors.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2003-04-01,"To assess the quality of preventive health care, the role of health care participation, and the patient and provider characteristics associated with high-quality care for breast cancer survivors. We analyzed the 1997 to 1998 Medicare data of elderly women who were diagnosed with nonmetastatic breast cancer in 1991 or 1992 while living in a Survival, Epidemiology, and End Results (SEER) tumor registry area and who survived to the end of 1998 without evidence of cancer recurrence. Controls were matched for age, race, and geographic location. The 5,965 breast cancer survivors received more preventive services (influenza vaccination, lipid testing, cervical and colon screening, and bone densitometry) than matched controls. Among both groups, those who were younger, non-African-American, of higher socioeconomic status, living in urban areas, and receiving care in a teaching center were most likely to receive high-quality health maintenance. Those survivors who continued to see oncology specialists were more likely to receive appropriate follow-up mammography for their cancer, but those who were monitored by primary care physicians were more likely to receive all other non-cancer-related preventive services. Those who saw both types of practitioners received more of both types of services. When the control group was restricted only to women actively undergoing mammographic screening before the study period, receipt of preventive services was similar. Breast cancer survivors receive high-quality preventive services, but disparities on the basis of nonmedical factors still exist. Cancer follow-up may provide regular contact with the health system, maximizing the likelihood of receiving appropriate general medical care.",Journal Article,6139.0,231.0,"To assess the quality of preventive health care the role of health care participation and the patient and provider characteristics associated with high-quality care for cancer survivors We analyzed the 1997 to 1998 Medicare data of elderly women who were diagnosed with nonmetastatic cancer in 1991 or 1992 while living in a Survival Epidemiology and End Results SEER tumor registry area and who survived to the end of 1998 without evidence of cancer recurrence Controls were matched for age race and geographic location The 5,965 cancer survivors received more preventive services influenza vaccination lipid testing and screening and densitometry than matched controls Among both groups those who were younger non-African-American of higher socioeconomic status living in urban areas and receiving care in a teaching center were most likely to receive high-quality health maintenance Those survivors who continued to see oncology specialists were more likely to receive appropriate follow-up mammography for their cancer but those who were monitored by primary care physicians were more likely to receive all other non-cancer-related preventive services Those who saw both types of practitioners received more of both types of services When the control group was restricted only to women actively undergoing mammographic screening before the study period receipt of preventive services was similar cancer survivors receive high-quality preventive services but disparities on the basis of nonmedical factors still exist Cancer follow-up may provide regular contact with the health system maximizing the likelihood of receiving appropriate general medical care",1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 423, 3, 372, 1, 3494, 341, 165, 3, 200, 1, 341, 165, 2599, 2, 3, 69, 2, 3094, 374, 41, 5, 64, 372, 165, 9, 12, 332, 21, 311, 3, 2341, 6, 1850, 1378, 74, 1, 1216, 117, 54, 11, 265, 5, 2683, 12, 4, 3372, 15, 2846, 369, 2798, 4, 8, 25, 1284, 2, 396, 99, 1605, 30, 1608, 965, 2, 54, 2996, 6, 3, 396, 1, 1850, 187, 241, 1, 12, 146, 535, 11, 655, 9, 89, 1047, 2, 3466, 1147, 3, 33, 15102, 12, 332, 103, 80, 3494, 2142, 7219, 1915, 3121, 471, 2, 453, 2, 18877, 76, 655, 535, 107, 110, 271, 135, 54, 11, 773, 220, 1410, 597, 1, 142, 3331, 156, 2798, 4, 5532, 1361, 2, 357, 165, 4, 8, 6292, 574, 11, 96, 322, 6, 560, 64, 372, 341, 1146, 135, 332, 54, 1351, 6, 3764, 413, 4409, 11, 80, 322, 6, 560, 870, 166, 126, 2446, 9, 136, 12, 84, 135, 54, 11, 2909, 20, 86, 165, 1261, 11, 80, 322, 6, 560, 62, 127, 220, 12, 139, 3494, 2142, 135, 54, 9257, 110, 630, 1, 6323, 103, 80, 1, 110, 630, 1, 2142, 198, 3, 182, 87, 10, 2016, 158, 6, 117, 4489, 479, 3806, 453, 348, 3, 45, 727, 1699, 1, 3494, 2142, 10, 288, 12, 332, 560, 64, 372, 3494, 2142, 84, 2227, 23, 3, 877, 1, 21137, 130, 1234, 1923, 12, 166, 126, 68, 377, 3316, 4393, 5, 3, 341, 398, 8260, 3, 1420, 1, 357, 870, 1083, 484, 165]",1660.0,12697865,9
Impact of individual physicians on enrollment of patients into clinical trials.,American journal of clinical oncology,Am. J. Clin. Oncol.,2003-04-01,"The National Cancer Institute is committed to increasing enrollment of cancer patients in clinical treatment trials. The factors that achieve successful results are poorly understood. This study analyzes the role of individual physicians in recruitment of patients in clinical trials. A retrospective review was undertaken of all patients with untreated endometrial, cervical, or ovarian cancer potentially eligible for a multi-institutional phase III trial cared for by the Section of Gynecologic Oncology at the University of Oklahoma from July 1, 1998 to September 30, 1999. Patient variables assessed included age, insurance status, cancer diagnosis, and enrollment onto clinical trial. There was no difference in faculty patients with regard to cancer type, age, or insurance status. There was a significant difference (p < 0.01) between faculty in offering protocol therapy and likelihood of successfully enrolling patients. Successful enrollment was correlated with faculty experience and principal investigator status. This study shows that availability of patients, patient variances, support staff, and institutional commitment are secondary to individual physician factors in determining successful enrollment of patients onto clinical trials.",Journal Article,6139.0,41.0,The National Cancer Institute is committed to increasing enrollment of cancer patients in clinical treatment trials The factors that achieve successful results are poorly understood This study analyzes the role of individual physicians in recruitment of patients in clinical trials A retrospective review was undertaken of all patients with untreated or cancer potentially eligible for a multi-institutional phase III trial cared for by the Section of Gynecologic Oncology at the University of Oklahoma from July 1 1998 to September 30 1999 Patient variables assessed included age insurance status cancer diagnosis and enrollment onto clinical trial There was no difference in faculty patients with regard to cancer type age or insurance status There was a significant difference p 0.01 between faculty in offering protocol therapy and likelihood of successfully enrolling patients Successful enrollment was correlated with faculty experience and principal investigator status This study shows that availability of patients patient variances support staff and institutional commitment are secondary to individual physician factors in determining successful enrollment of patients onto clinical trials,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 657, 12, 1377, 16, 9552, 6, 602, 1798, 1, 12, 7, 4, 38, 24, 143, 3, 130, 17, 1359, 1401, 99, 32, 1240, 1784, 26, 45, 11113, 3, 200, 1, 797, 1261, 4, 3202, 1, 7, 4, 38, 143, 8, 459, 206, 10, 2789, 1, 62, 7, 5, 1278, 15, 12, 751, 625, 9, 8, 1414, 1115, 124, 316, 160, 12743, 9, 20, 3, 2917, 1, 1512, 413, 28, 3, 1652, 1, 27850, 29, 2066, 14, 1850, 6, 2636, 201, 2043, 69, 682, 275, 159, 89, 1935, 156, 12, 147, 2, 1798, 3301, 38, 160, 125, 10, 77, 523, 4, 11137, 7, 5, 2539, 6, 12, 267, 89, 15, 1935, 156, 125, 10, 8, 93, 523, 19, 13, 355, 59, 11137, 4, 5846, 1182, 36, 2, 1420, 1, 1878, 6280, 7, 1401, 1798, 10, 438, 5, 11137, 730, 2, 4312, 3464, 156, 26, 45, 1949, 17, 2550, 1, 7, 69, 24607, 538, 5898, 2, 1115, 11082, 32, 568, 6, 797, 1473, 130, 4, 2196, 1401, 1798, 1, 7, 3301, 38, 143]",1200.0,12714890,670
Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.,Cancer gene therapy,Cancer Gene Ther.,2003-05-01,"The Herpes simplex virus 1 (HSV) thymidine kinase (tk) suicide gene together with ganciclovir (GCV) have been successfully used for the in vivo treatment of various solid tumors and for the ablation of unwanted transfused stem cells in recent clinical trials. With the aim of improving this therapeutic system, we compared the potential efficacy of adenoviral (Ad) vectors expressing enhanced tk mutants in vitro and in vivo. The previously created HSV-tk mutants dm30 and sr39, created by random sequence mutagenesis, were inserted into a standard Ad.RSV E1(-)E3(-) backbone using homologous recombination. GCV killing of Ad.HSV-tk, Ad.dm30-tk and Ad.sr39-tk was assessed in various tumor cell lines with a cell proliferation assay. Cells expressing the two TK mutants were two-to-five-fold more sensitive to GCV when compared with Ad.HSV-tk transduced cells in all cell lines tested (five human mesotheliomas, one human lung cancer, a human cervical carcinoma, a mouse fibrosarcoma, and a rat glioma line) at equal TK expression levels. Flank tumor models, including cell-mixing studies, assessed the in vivo efficacy of the engineered viruses in BALB/C and SCID mice. In all animal studies, Ad.dm30-tk and Ad.sr39-tk showed more tumor growth inhibition than Ad.HSV-tk when GCV was administered. The use of adenovirus-mediated gene transfer of both tk mutants dm30-tk and sr39-tk for cancer suicide gene therapy should provide a more effective and safer alternative to wild-type HSV-tk.",Journal Article,6109.0,46.0,The Herpes simplex virus 1 HSV thymidine kinase tk suicide gene together with ganciclovir GCV have been successfully used for the in vivo treatment of various solid tumors and for the ablation of unwanted transfused stem cells in recent clinical trials With the aim of improving this therapeutic system we compared the potential efficacy of adenoviral Ad vectors expressing enhanced tk mutants in vitro and in vivo The previously created HSV-tk mutants dm30 and sr39 created by random sequence mutagenesis were inserted into a standard Ad.RSV E1 E3 backbone using homologous recombination GCV killing of Ad.HSV-tk Ad.dm30-tk and Ad.sr39-tk was assessed in various tumor cell lines with a cell proliferation assay Cells expressing the two TK mutants were two-to-five-fold more sensitive to GCV when compared with Ad.HSV-tk transduced cells in all cell lines tested five human mesotheliomas one human cancer a human carcinoma a mouse fibrosarcoma and a rat glioma line at equal TK expression levels Flank tumor models including cell-mixing studies assessed the in vivo efficacy of the engineered viruses in BALB/C and SCID mice In all animal studies Ad.dm30-tk and Ad.sr39-tk showed more tumor growth inhibition than Ad.HSV-tk when GCV was administered The use of adenovirus-mediated gene transfer of both tk mutants dm30-tk and sr39-tk for cancer suicide gene therapy should provide a more effective and safer alternative to wild-type HSV-tk,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 4716, 7241, 1450, 14, 4702, 6403, 216, 5067, 7974, 145, 1162, 5, 18818, 15551, 47, 85, 1878, 95, 9, 3, 4, 386, 24, 1, 747, 537, 57, 2, 9, 3, 1650, 1, 16295, 12320, 452, 37, 4, 435, 38, 143, 5, 3, 1130, 1, 1673, 26, 189, 398, 21, 72, 3, 174, 209, 1, 4771, 1985, 5453, 1046, 651, 5067, 3423, 4, 439, 2, 4, 386, 3, 373, 2466, 4702, 5067, 3423, 33427, 2, 30402, 2466, 20, 2324, 1532, 8595, 11, 9882, 237, 8, 260, 1985, 17197, 6778, 7193, 7066, 75, 3894, 4017, 15551, 3003, 1, 1985, 4702, 5067, 1985, 33427, 5067, 2, 1985, 30402, 5067, 10, 275, 4, 747, 30, 31, 285, 5, 8, 31, 457, 719, 37, 1046, 3, 100, 5067, 3423, 11, 100, 6, 365, 1116, 80, 745, 6, 15551, 198, 72, 5, 1985, 4702, 5067, 5042, 37, 4, 62, 31, 285, 650, 365, 171, 11789, 104, 171, 12, 8, 171, 134, 8, 830, 8378, 2, 8, 4008, 945, 328, 28, 2997, 5067, 55, 148, 5564, 30, 274, 141, 31, 16296, 94, 275, 3, 4, 386, 209, 1, 3, 2794, 4405, 4, 8166, 256, 2, 4129, 399, 4, 62, 2026, 94, 1985, 33427, 5067, 2, 1985, 30402, 5067, 224, 80, 30, 129, 297, 76, 1985, 4702, 5067, 198, 15551, 10, 468, 3, 119, 1, 4488, 517, 145, 2602, 1, 110, 5067, 3423, 33427, 5067, 2, 30402, 5067, 9, 12, 7974, 145, 36, 257, 377, 8, 80, 323, 2, 9276, 1091, 6, 955, 267, 4702, 5067]",1440.0,12719705,480
"Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2003-05-01,"The epothilones are a novel class of nontaxane microtubule-stabilizing agents. BMS-247550 is a semisynthetic analog of the natural product epothilone B. We conducted a phase I study administering BMS-247550 as a 1-hour intravenous infusion daily for 5 consecutive days every 21 days. Twenty-one patients received BMS-247550 without filgrastim in the first cycle. An additional six patients were enrolled at a starting dose of 8 mg/m2/d with filgrastim support. Twenty-one of the 27 patients had received prior paclitaxel, docetaxel, or both. One hundred seven cycles were administered to 27 patients. The maximum-tolerated dose was 6 mg/m2 of BMS-247550 administered as a 1-hour intravenous infusion daily for 5 consecutive days every 21 days. Dose-limiting toxicity at a dose of 8 mg/m2/d was neutropenia with or without filgrastim support. Nonhematologic grade 3 toxicities included fatigue (seven cycles), stomatitis (two cycles), and anorexia (one cycle). The mean terminal half-life of BMS-247550 was 16.8 +/- 6.0 hours, the volume of distribution at steady-state was 798 +/- 375 L, and the clearance was 712 +/- 247 mL/min. Objective responses were observed in patients with breast, cervical, and basal cell cancer. Reductions in CA-125 levels were noted in patients with ovarian cancer. The recommended phase II dose of BMS-247550 on the daily schedule for 5 days is 6 mg/m2/d. Neutropenia was dose limiting, but higher doses were tolerated by a large fraction of patients with filgrastim support. Peripheral neuropathy was mild, even after multiple cycles of therapy, and was not dose limiting.",Clinical Trial,6109.0,124.0,The epothilones are a novel class of nontaxane microtubule-stabilizing agents BMS-247550 is a semisynthetic analog of the natural product epothilone B We conducted a phase I study administering BMS-247550 as a 1-hour intravenous infusion daily for 5 consecutive days every 21 days Twenty-one patients received BMS-247550 without filgrastim in the first cycle An additional six patients were enrolled at a starting dose of 8 mg/m2/d with filgrastim support Twenty-one of the 27 patients had received prior paclitaxel docetaxel or both One hundred seven cycles were administered to 27 patients The maximum-tolerated dose was 6 mg/m2 of BMS-247550 administered as a 1-hour intravenous infusion daily for 5 consecutive days every 21 days Dose-limiting toxicity at a dose of 8 mg/m2/d was neutropenia with or without filgrastim support Nonhematologic grade 3 toxicities included fatigue seven cycles stomatitis two cycles and anorexia one cycle The mean terminal half-life of BMS-247550 was 16.8 +/- 6.0 hours the volume of distribution at steady-state was 798 +/- 375 L and the clearance was 712 +/- 247 mL/min Objective responses were observed in patients with and basal cell cancer Reductions in CA-125 levels were noted in patients with cancer The recommended phase II dose of BMS-247550 on the daily schedule for 5 days is 6 mg/m2/d Neutropenia was dose limiting but higher doses were tolerated by a large fraction of patients with filgrastim support Peripheral neuropathy was mild even after multiple cycles of therapy and was not dose limiting,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 12129, 32, 8, 229, 1040, 1, 26161, 4621, 9116, 183, 3502, 11957, 16, 8, 18185, 3497, 1, 3, 1504, 2821, 10202, 132, 21, 426, 8, 124, 70, 45, 5776, 3502, 11957, 22, 8, 14, 2583, 1262, 904, 391, 9, 33, 935, 162, 454, 239, 162, 737, 104, 7, 103, 3502, 11957, 187, 5552, 4, 3, 157, 417, 35, 402, 437, 7, 11, 346, 28, 8, 1723, 61, 1, 66, 81, 821, 427, 5, 5552, 538, 737, 104, 1, 3, 428, 7, 42, 103, 324, 490, 621, 15, 110, 104, 1128, 648, 410, 11, 468, 6, 428, 7, 3, 689, 421, 61, 10, 49, 81, 821, 1, 3502, 11957, 468, 22, 8, 14, 2583, 1262, 904, 391, 9, 33, 935, 162, 454, 239, 162, 61, 817, 155, 28, 8, 61, 1, 66, 81, 821, 427, 10, 778, 5, 15, 187, 5552, 538, 3534, 88, 27, 385, 159, 613, 648, 410, 4486, 100, 410, 2, 3373, 104, 417, 3, 313, 2158, 1303, 358, 1, 3502, 11957, 10, 245, 66, 49, 13, 1459, 3, 433, 1, 1395, 28, 4152, 1309, 10, 13049, 4175, 805, 2, 3, 1960, 10, 13251, 7708, 542, 1538, 461, 253, 11, 164, 4, 7, 5, 2, 2135, 31, 12, 2153, 4, 1568, 1731, 148, 11, 1051, 4, 7, 5, 12, 3, 793, 124, 215, 61, 1, 3502, 11957, 23, 3, 391, 1055, 9, 33, 162, 16, 49, 81, 821, 427, 778, 10, 61, 817, 84, 142, 415, 11, 421, 20, 8, 375, 1509, 1, 7, 5, 5552, 538, 672, 1751, 10, 1980, 871, 50, 232, 410, 1, 36, 2, 10, 44, 61, 817]",1545.0,12721265,245
Current perspectives on anal cancer.,"Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2003-04-01,"Anal cancer accounts for 1.5% of digestive system malignancies in the United States. In the past 30 years, substantial progress has been made in understanding the pathophysiology and treatment of the disease. Anal cancer was once believed to be caused by chronic local inflammation of the perianal area, and treatment was abdominoperineal resection. From epidemiologic and clinical studies, we now know that the development of anal cancer is associated with human papillomavirus infection and that the disease has a pathophysiology similar to that of cervical cancer. Less invasive treatments have also been developed, and the majority of patients with anal cancer can now be cured with preservation of the anal sphincter using concurrent external-beam radiation therapy and fluorouracil (5-FU)/mitomycin (Mutamycin) chemotherapy. Current areas under investigation include the incorporation of platinum agents into the chemotherapy regimen and the use of cytologic screening studies for high-risk populations.",Journal Article,6139.0,6.0,cancer accounts for 1.5 of digestive system malignancies in the United States In the past 30 years substantial progress has been made in understanding the pathophysiology and treatment of the disease cancer was once believed to be caused by chronic local inflammation of the perianal area and treatment was abdominoperineal resection From epidemiologic and clinical studies we now know that the development of cancer is associated with human papillomavirus infection and that the disease has a pathophysiology similar to that of cancer Less invasive treatments have also been developed and the majority of patients with cancer can now be cured with preservation of the sphincter using concurrent external-beam radiation therapy and fluorouracil 5-FU /mitomycin Mutamycin chemotherapy Current areas under investigation include the incorporation of platinum agents into the chemotherapy regimen and the use of cytologic screening studies for high-risk populations,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 4162, 9, 14, 33, 1, 9117, 398, 441, 4, 3, 1088, 907, 4, 3, 1219, 201, 60, 1281, 1466, 71, 85, 1229, 4, 612, 3, 4320, 2, 24, 1, 3, 34, 12, 10, 1059, 3979, 6, 40, 1546, 20, 442, 293, 1815, 1, 3, 10855, 965, 2, 24, 10, 8177, 170, 29, 3609, 2, 38, 94, 21, 1134, 6572, 17, 3, 193, 1, 12, 16, 41, 5, 171, 3242, 930, 2, 17, 3, 34, 71, 8, 4320, 288, 6, 17, 1, 12, 299, 416, 640, 47, 120, 85, 276, 2, 3, 686, 1, 7, 5, 12, 122, 1134, 40, 3733, 5, 2224, 1, 3, 5400, 75, 750, 1455, 1345, 121, 36, 2, 1404, 33, 1296, 5837, 43240, 56, 291, 1361, 669, 940, 643, 3, 2838, 1, 828, 183, 237, 3, 56, 477, 2, 3, 119, 1, 4195, 453, 94, 9, 64, 43, 1184]",961.0,12735144,650
Development of endometrial cancer after radiation treatment for cervical carcinoma.,Obstetrics and gynecology,Obstet Gynecol,2003-05-01,"To detail the Memorial Sloan-Kettering Cancer Center and MD Anderson Cancer Center experience with 23 patients treated with radiation therapy for invasive cervical carcinoma who subsequently developed endometrial carcinoma. We conducted a retrospective chart and pathology review on patients diagnosed with endometrial cancer between 1976 and 2000 who had previously received definitive radiation treatment for cervical cancer. Abstracted data included patient demographics, type of radiation therapy, histological grade, histological subtype, and stage of endometrial cancer. The mean age at endometrial cancer diagnosis was 64.4 years (range 53-80), and the average latency period from initial therapy to development of endometrial carcinoma was 14 years (range 6-27). Distribution by stage, grade, and histology was as follows: stage I, five (22%); stage II, one (4%); stage III, nine (39%); stage IV, seven (30%); unknown stage, one (4%); grade 1, one (4%); grade 2, three (13%); grade 3, 17 (74%); unknown grade, two (9%); carcinosarcoma, eight (35%); endometrioid, four (17%); papillary serous, six (26%); clear cell, one (4%); mucinous, one (4%); undifferentiated, one (4%); and unknown histology, two (9%). The median survival was 24 months, and the 2- and 5-year survival rates were 50% (95% confidence interval [CI] 31.4%, 78.9%) and 21% (95% CI 8.1%, 56.3%), respectively. Patients treated with definitive radiation therapy for invasive cervical cancer may still have viable endometrium at risk for neoplasia. Endometrial cancers that develop after radiation treatment have a preponderance of high-risk histological subtypes and, consequently, a poor prognosis.",Journal Article,6109.0,30.0,To detail the Memorial Sloan-Kettering Cancer Center and MD Anderson Cancer Center experience with 23 patients treated with radiation therapy for invasive carcinoma who subsequently developed carcinoma We conducted a retrospective chart and pathology review on patients diagnosed with cancer between 1976 and 2000 who had previously received definitive radiation treatment for cancer Abstracted data included patient demographics type of radiation therapy histological grade histological subtype and stage of cancer The mean age at cancer diagnosis was 64.4 years range 53-80 and the average latency period from initial therapy to development of carcinoma was 14 years range 6-27 Distribution by stage grade and histology was as follows stage I five 22 stage II one 4 stage III nine 39 stage IV seven 30 unknown stage one 4 grade 1 one 4 grade 2 three 13 grade 3 17 74 unknown grade two 9 carcinosarcoma eight 35 endometrioid four 17 papillary serous six 26 clear cell one 4 mucinous one 4 undifferentiated one 4 and unknown histology two 9 The median survival was 24 months and the 2- and 5-year survival rates were 50 95 confidence interval CI 31.4 78.9 and 21 95 CI 8.1 56.3 respectively Patients treated with definitive radiation therapy for invasive cancer may still have viable at risk for neoplasia cancers that develop after radiation treatment have a preponderance of high-risk histological subtypes and consequently a poor prognosis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 5000, 3, 2563, 2783, 2784, 12, 574, 2, 2244, 1929, 12, 574, 730, 5, 382, 7, 73, 5, 121, 36, 9, 416, 134, 54, 1611, 276, 134, 21, 426, 8, 459, 2937, 2, 1117, 206, 23, 7, 265, 5, 12, 59, 8586, 2, 1081, 54, 42, 373, 103, 1057, 121, 24, 9, 12, 4106, 74, 159, 69, 2221, 267, 1, 121, 36, 1831, 88, 1831, 875, 2, 82, 1, 12, 3, 313, 89, 28, 12, 147, 10, 660, 39, 60, 184, 699, 493, 2, 3, 1011, 5301, 727, 29, 388, 36, 6, 193, 1, 134, 10, 213, 60, 184, 49, 428, 1395, 20, 82, 88, 2, 784, 10, 22, 2962, 82, 70, 365, 350, 82, 215, 104, 39, 82, 316, 762, 587, 82, 478, 648, 201, 860, 82, 104, 39, 88, 14, 104, 39, 88, 18, 169, 233, 88, 27, 269, 794, 860, 88, 100, 83, 5623, 659, 465, 3151, 294, 269, 1796, 1744, 437, 432, 885, 31, 104, 39, 2391, 104, 39, 4480, 104, 39, 2, 860, 784, 100, 83, 3, 52, 25, 10, 259, 53, 2, 3, 18, 2, 33, 111, 25, 151, 11, 212, 48, 307, 268, 58, 456, 39, 833, 83, 2, 239, 48, 58, 66, 14, 664, 27, 106, 7, 73, 5, 1057, 121, 36, 9, 416, 12, 68, 1234, 47, 2663, 28, 43, 9, 2298, 163, 17, 690, 50, 121, 24, 47, 8, 12531, 1, 64, 43, 1831, 814, 2, 3244, 8, 334, 356]",1442.0,12738155,136
Late stage cancers in a Medicaid-insured population.,Medical care,Med Care,2003-06-01,"Medicaid insurance promotes screening for early stage cancers. However, previous research suggests that Medicaid recipients are at risk for late stage disease. To identify differences in stage of diagnosis between cancer patients enrolled in Medicaid before versus after their disease was identified, as well as differences in diagnostic stage between Medicaid enrollees and other patients. Analyses of a linked database including information from the 1996 and 1997 Michigan Cancer Registry and Medicaid enrollment files. All persons ages 25 to 64 diagnosed with incident cases of breast, cervical, colorectal, or lung cancer (n = 5852). Patients enrolled in Medicaid before their cancer diagnosis and those enrolled in the same month or after their diagnosis were identified. Early (in situ, local) versus late (regional, distant, invasive/unknown) cancer stage at diagnosis was modeled using multivariate logistic regression. In each site of disease with the exception of breast, persons who enrolled in Medicaid after a cancer diagnosis were approximately 2 to 3 times more likely to have late stage disease compared with persons who were enrolled in Medicaid before the month of diagnosis. Odds ratios (OR) and 95% confidence intervals (C.I.) were: 1.28 (95% C.I. = 0.95, 1.67) for breast cancer, 2.96 (95% C.I. = 1.85, 4.75) for cervical cancer, 2.08 (95% C.I. = 1.30, 3.33) for colorectal cancer, and 3.40 (95% C.I. = 2.13, 5.43) for lung cancer. Relative to non-Medicaid enrollees, Medicaid enrollees were 2 to 5 times more likely to be diagnosed with late stage disease. Cancer patients enrolled in Medicaid after their diagnosis were disproportionately likely to have late stage disease relative to patients previously enrolled in Medicaid or non-Medicaid enrollees.",Comparative Study,6078.0,82.0,Medicaid insurance promotes screening for early stage cancers However previous research suggests that Medicaid recipients are at risk for late stage disease To identify differences in stage of diagnosis between cancer patients enrolled in Medicaid before versus after their disease was identified as well as differences in diagnostic stage between Medicaid enrollees and other patients Analyses of a linked database including information from the 1996 and 1997 Michigan Cancer Registry and Medicaid enrollment files All persons ages 25 to 64 diagnosed with incident cases of or cancer n 5852 Patients enrolled in Medicaid before their cancer diagnosis and those enrolled in the same month or after their diagnosis were identified Early in situ local versus late regional distant invasive/unknown cancer stage at diagnosis was modeled using multivariate logistic regression In each site of disease with the exception of persons who enrolled in Medicaid after a cancer diagnosis were approximately 2 to 3 times more likely to have late stage disease compared with persons who were enrolled in Medicaid before the month of diagnosis Odds ratios OR and 95 confidence intervals C.I were 1.28 95 C.I 0.95 1.67 for cancer 2.96 95 C.I 1.85 4.75 for cancer 2.08 95 C.I 1.30 3.33 for cancer and 3.40 95 C.I 2.13 5.43 for cancer Relative to non-Medicaid enrollees Medicaid enrollees were 2 to 5 times more likely to be diagnosed with late stage disease Cancer patients enrolled in Medicaid after their diagnosis were disproportionately likely to have late stage disease relative to patients previously enrolled in Medicaid or non-Medicaid enrollees,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2843, 1935, 2148, 453, 9, 191, 82, 163, 137, 698, 389, 844, 17, 2843, 2190, 32, 28, 43, 9, 807, 82, 34, 6, 255, 362, 4, 82, 1, 147, 59, 12, 7, 346, 4, 2843, 348, 185, 50, 136, 34, 10, 108, 22, 149, 22, 362, 4, 752, 82, 59, 2843, 9888, 2, 127, 7, 318, 1, 8, 1199, 609, 141, 487, 29, 3, 2648, 2, 2341, 9432, 12, 1608, 2, 2843, 1798, 7530, 62, 4327, 2165, 243, 6, 660, 265, 5, 2631, 140, 1, 15, 12, 78, 53549, 7, 346, 4, 2843, 348, 136, 12, 147, 2, 135, 346, 4, 3, 827, 811, 15, 50, 136, 147, 11, 108, 191, 4, 957, 293, 185, 807, 951, 626, 416, 860, 12, 82, 28, 147, 10, 4666, 75, 331, 812, 320, 4, 296, 606, 1, 34, 5, 3, 4188, 1, 4327, 54, 346, 4, 2843, 50, 8, 12, 147, 11, 705, 18, 6, 27, 1072, 80, 322, 6, 47, 807, 82, 34, 72, 5, 4327, 54, 11, 346, 4, 2843, 348, 3, 811, 1, 147, 610, 1137, 15, 2, 48, 307, 1582, 256, 70, 11, 14, 339, 48, 256, 70, 13, 48, 14, 598, 9, 12, 18, 921, 48, 256, 70, 14, 772, 39, 481, 9, 12, 18, 1592, 48, 256, 70, 14, 201, 27, 466, 9, 12, 2, 27, 327, 48, 256, 70, 18, 233, 33, 601, 9, 12, 580, 6, 220, 2843, 9888, 2843, 9888, 11, 18, 6, 33, 1072, 80, 322, 6, 40, 265, 5, 807, 82, 34, 12, 7, 346, 4, 2843, 50, 136, 147, 11, 10094, 322, 6, 47, 807, 82, 34, 580, 6, 7, 373, 346, 4, 2843, 15, 220, 2843, 9888]",1637.0,12773838,115
Cancer in the Minnesota Hmong population.,Cancer,Cancer,2003-06-01,"The Hmong are an isolated, agrarian people who settled in the mountainous regions of what today are Vietnam, Cambodia, and Laos. After the Vietnam War, many Hmong were relocated to the U.S. Minnesota has the second largest population (after California) of Hmong individuals. The objective of this study was to examine cancer incidence in this population, because it may indicate areas for targeted surveillance and intervention. The Minnesota Cancer Surveillance System database was screened for Hmong surnames, and proportional incidence ratios (PIRs) were calculated for the period 1988-1999. Compared with all Minnesotans, the Hmong population had increased PIRs for nasopharyngeal cancer (PIR, 39.39; 95% confidence interval [95% CI], 21.01-66.86), gastric cancer (PIR, 8.70; 95% CI, 5.39-13.25), hepatic cancer (PIR, 8.08; 95% CI, 3.88-14.71), and cervical cancer (PIR, 3.72; 95% CI, 2.04-6.20) and had decreased PIRs for prostate cancer, breast cancer, Hodgkin disease, and melanoma. The current observations have implications for cancer control interventions. In particular, an increased incidence of cervical cancer might be addressed in part by targeting culturally sensitive screening programs in the Hmong population.",Comparative Study,6078.0,31.0,The Hmong are an isolated agrarian people who settled in the mountainous regions of what today are Vietnam Cambodia and Laos After the Vietnam War many Hmong were relocated to the U.S. Minnesota has the second largest population after California of Hmong individuals The objective of this study was to examine cancer incidence in this population because it may indicate areas for targeted surveillance and intervention The Minnesota Cancer Surveillance System database was screened for Hmong surnames and proportional incidence ratios PIRs were calculated for the period 1988-1999 Compared with all Minnesotans the Hmong population had increased PIRs for cancer PIR 39.39 95 confidence interval 95 CI 21.01-66.86 cancer PIR 8.70 95 CI 5.39-13.25 hepatic cancer PIR 8.08 95 CI 3.88-14.71 and cancer PIR 3.72 95 CI 2.04-6.20 and had decreased PIRs for cancer cancer disease and The current observations have implications for cancer control interventions In particular an increased incidence of cancer might be addressed in part by targeting culturally sensitive screening programs in the Hmong population,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,"[3, 20295, 32, 35, 1355, 43259, 3788, 54, 37464, 4, 3, 43260, 1374, 1, 2067, 5665, 32, 28061, 43261, 2, 43262, 50, 3, 28061, 23228, 445, 20295, 11, 30426, 6, 3, 1767, 695, 8297, 71, 3, 419, 2166, 266, 50, 4355, 1, 20295, 869, 3, 461, 1, 26, 45, 10, 6, 1004, 12, 287, 4, 26, 266, 408, 192, 68, 1008, 1361, 9, 238, 617, 2, 788, 3, 8297, 12, 617, 398, 609, 10, 2261, 9, 20295, 53558, 2, 831, 287, 1137, 24616, 11, 981, 9, 3, 727, 3314, 2043, 72, 5, 62, 37465, 3, 20295, 266, 42, 101, 24616, 9, 12, 15567, 587, 587, 48, 307, 268, 48, 58, 239, 355, 700, 868, 12, 15567, 66, 431, 48, 58, 33, 587, 233, 243, 939, 12, 15567, 66, 1592, 48, 58, 27, 889, 213, 792, 2, 12, 15567, 27, 720, 48, 58, 18, 755, 49, 179, 2, 42, 340, 24616, 9, 12, 12, 34, 2, 3, 291, 2172, 47, 1268, 9, 12, 182, 1151, 4, 1454, 35, 101, 287, 1, 12, 822, 40, 2814, 4, 760, 20, 529, 15185, 745, 453, 2251, 4, 3, 20295, 266]",1102.0,12784344,332
A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer.,Investigational new drugs,Invest New Drugs,2003-02-01,"Pyrazoloacridine (PZA, NSC366140, PD115934) is an acridine derivative currently undergoing clinical evaluation. In preclinical testing, PZA has shown selectivity for solid tumor cell lines, activity in hypoxic, noncycling, and multidrug-resistant cell lines, and synergy with cisplatin in a variety of lung cancer cell lines. In early phase I clinical studies PZA has shown modest activity in ovarian, cervical, and colon cancer. The purpose of the present study was threefold: to determine the maximally tolerated doses of the combination of PZA (3-h infusion) and cisplatin administered with and without Filgrastim (G-CSF) (Amgen, Thousand Oaks, CA) every 3 weeks in untreated or minimally pretreated patients, to describe and quantify the clinical toxicities of combination chemotherapy with PZA and cisplatin, and to evaluate the effects of drug sequencing on the toxicity profile and pharmacologic behavior of PZA. The starting doses in this dose-escalation trial were PZA 400 mg/m2 as a 3-h intravenous infusion and cisplatin 50 mg/m2 as a 1 mg/min intravenous infusion. The sequence of drugs was alternated with each successive course in each patient treated. Twenty-one patients with refractory solid tumors received 43 courses of therapy through four dose levels. Neutropenia was dose-limiting and defined the maximum tolerated dose of PZA 400 mg/m2 and cisplatin 50 mg/m2 without G-CSF support. With G-CSF support, nausea and vomiting were dose-limiting. The maximum tolerated and recommended doses for further study of this combination are PZA 600 mg/m2 over 3 h and cisplatin 50 mg/m2 followed by G-CSF support. Pharmacokinetic analysis showed that sequence does not impact on the pharmacokinetics of PZA when given in combination with cisplatin.",Clinical Trial,6198.0,8.0,Pyrazoloacridine PZA NSC366140 PD115934 is an acridine derivative currently undergoing clinical evaluation In preclinical testing PZA has shown selectivity for solid tumor cell lines activity in hypoxic noncycling and multidrug-resistant cell lines and synergy with cisplatin in a variety of cancer cell lines In early phase I clinical studies PZA has shown modest activity in and cancer The purpose of the present study was threefold to determine the maximally tolerated doses of the combination of PZA 3-h infusion and cisplatin administered with and without Filgrastim G-CSF Amgen Thousand Oaks CA every 3 weeks in untreated or minimally pretreated patients to describe and quantify the clinical toxicities of combination chemotherapy with PZA and cisplatin and to evaluate the effects of drug sequencing on the toxicity profile and pharmacologic behavior of PZA The starting doses in this dose-escalation trial were PZA 400 mg/m2 as a 3-h intravenous infusion and cisplatin 50 mg/m2 as a 1 mg/min intravenous infusion The sequence of drugs was alternated with each successive course in each patient treated Twenty-one patients with refractory solid tumors received 43 courses of therapy through four dose levels Neutropenia was dose-limiting and defined the maximum tolerated dose of PZA 400 mg/m2 and cisplatin 50 mg/m2 without G-CSF support With G-CSF support nausea and vomiting were dose-limiting The maximum tolerated and recommended doses for further study of this combination are PZA 600 mg/m2 over 3 h and cisplatin 50 mg/m2 followed by G-CSF support Pharmacokinetic analysis showed that sequence does not impact on the pharmacokinetics of PZA when given in combination with cisplatin,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[18814, 14126, 53567, 53568, 16, 35, 19489, 4819, 694, 479, 38, 451, 4, 693, 471, 14126, 71, 443, 6072, 9, 537, 30, 31, 285, 128, 4, 4744, 33448, 2, 4814, 436, 31, 285, 2, 3439, 5, 540, 4, 8, 1362, 1, 12, 31, 285, 4, 191, 124, 70, 38, 94, 14126, 71, 443, 1721, 128, 4, 2, 12, 3, 743, 1, 3, 364, 45, 10, 10182, 6, 223, 3, 6402, 421, 415, 1, 3, 150, 1, 14126, 27, 555, 904, 2, 540, 468, 5, 2, 187, 5552, 499, 1211, 16736, 6161, 33449, 1568, 454, 27, 244, 4, 1278, 15, 2144, 2193, 7, 6, 897, 2, 3091, 3, 38, 385, 1, 150, 56, 5, 14126, 2, 540, 2, 6, 376, 3, 176, 1, 234, 615, 23, 3, 155, 800, 2, 2788, 1710, 1, 14126, 3, 1723, 415, 4, 26, 61, 1125, 160, 11, 14126, 1524, 81, 821, 22, 8, 27, 555, 1262, 904, 2, 540, 212, 81, 821, 22, 8, 14, 81, 1538, 1262, 904, 3, 1532, 1, 600, 10, 22110, 5, 296, 6808, 906, 4, 296, 69, 73, 737, 104, 7, 5, 430, 537, 57, 103, 601, 1993, 1, 36, 298, 294, 61, 148, 778, 10, 61, 817, 2, 395, 3, 689, 421, 61, 1, 14126, 1524, 81, 821, 2, 540, 212, 81, 821, 187, 499, 1211, 538, 5, 499, 1211, 538, 1218, 2, 1966, 11, 61, 817, 3, 689, 421, 2, 793, 415, 9, 195, 45, 1, 26, 150, 32, 14126, 2383, 81, 821, 252, 27, 555, 2, 540, 212, 81, 821, 370, 20, 499, 1211, 538, 1456, 65, 224, 17, 1532, 1097, 44, 345, 23, 3, 1159, 1, 14126, 198, 447, 4, 150, 5, 540]",1696.0,12795532,252
The role of novel oncogenes squamous cell carcinoma-related oncogene and phosphatidylinositol 3-kinase p110alpha in squamous cell carcinoma of the oral tongue.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2003-06-01,"Amplification at chromosome 3q26.3 is a common and crucial event in head and neck squamous cell carcinoma (HNSCC), impacting significantly on tumor progression and clinical outcome. Two novel oncogenes, namely squamous cell carcinoma (SCC)-related oncogene (SCCRO) and PIK3CA (gene encoding phosphatidylinositol-3 kinase catalytic alpha-polypeptide), have been identified as targets of 3q26.3 amplification. This study aimed to delineate the role of SCCRO and PIK3CA in the pathogenesis of oral tongue SCC. The association between gene copy number for SCCRO and PIK3CA measured by fluorescence in situ hybridization and level of mRNA expression quantitated by real-time reverse transcription-PCR was assessed in a panel of human HNSCC cell lines. In addition, gene expression in 49 consecutive primary SCCs of the oral tongue was determined and correlated with clinicopathological characteristics and outcome. The mRNA level of SCCRO and PIK3CA was significantly correlated to the gene copy number in nine HNSCC cell lines. In addition, the expression level of SCCRO and PIK3CA was significantly greater in malignant tissues compared with those in histologically normal mucosae (2.17- and 2.46-fold, respectively; P < 0.001). Matched tumor normal control analysis revealed that 24.5 and 69.4% of patients expressed high levels of SCCRO and PIK3CA, respectively. Univariate analyses demonstrated that SCCRO overexpression correlated with nodal metastases (P = 0.05) and advanced stage (P = 0.02), whereas PIK3CA overexpression was associated with vascular invasion (P = 0.04). Only SCCRO overexpression was associated with disease-specific (P = 0.04) and overall survival (P = 0.02). Furthermore, SCCRO overexpression remained an independent predictor for cervical nodal metastasis on multivariate regression analysis (chi(2) likelihood ratio = 4.38; P = 0.04). Although both SCCRO and PIK3CA may play a role in the pathogenesis of oral tongue SCC through amplification at 3q26, SCCRO appears to be a significant predictor of regional metastasis and may be a marker for tumor aggressiveness and clinical outcome.",Journal Article,6078.0,68.0,Amplification at chromosome 3q26.3 is a common and crucial event in head and squamous cell carcinoma HNSCC impacting significantly on tumor progression and clinical outcome Two novel oncogenes namely squamous cell carcinoma SCC -related oncogene SCCRO and PIK3CA gene encoding phosphatidylinositol-3 kinase catalytic alpha-polypeptide have been identified as targets of 3q26.3 amplification This study aimed to delineate the role of SCCRO and PIK3CA in the pathogenesis of oral tongue SCC The association between gene copy number for SCCRO and PIK3CA measured by fluorescence in situ hybridization and level of mRNA expression quantitated by real-time reverse transcription-PCR was assessed in a panel of human HNSCC cell lines In addition gene expression in 49 consecutive primary SCCs of the oral tongue was determined and correlated with clinicopathological characteristics and outcome The mRNA level of SCCRO and PIK3CA was significantly correlated to the gene copy number in nine HNSCC cell lines In addition the expression level of SCCRO and PIK3CA was significantly greater in malignant tissues compared with those in histologically normal mucosae 2.17- and 2.46-fold respectively P 0.001 Matched tumor normal control analysis revealed that 24.5 and 69.4 of patients expressed high levels of SCCRO and PIK3CA respectively Univariate analyses demonstrated that SCCRO overexpression correlated with nodal metastases P 0.05 and advanced stage P 0.02 whereas PIK3CA overexpression was associated with vascular invasion P 0.04 Only SCCRO overexpression was associated with disease-specific P 0.04 and overall survival P 0.02 Furthermore SCCRO overexpression remained an independent predictor for nodal metastasis on multivariate regression analysis chi 2 likelihood ratio 4.38 P 0.04 Although both SCCRO and PIK3CA may play a role in the pathogenesis of oral tongue SCC through amplification at 3q26 SCCRO appears to be a significant predictor of regional metastasis and may be a marker for tumor aggressiveness and clinical outcome,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1073, 28, 1170, 10678, 27, 16, 8, 186, 2, 2653, 774, 4, 718, 2, 691, 31, 134, 1209, 8661, 97, 23, 30, 91, 2, 38, 228, 100, 229, 3326, 5046, 691, 31, 134, 1791, 139, 1836, 13307, 2, 1506, 145, 2362, 3415, 27, 216, 4784, 950, 8720, 47, 85, 108, 22, 637, 1, 10678, 27, 1073, 26, 45, 1295, 6, 5092, 3, 200, 1, 13307, 2, 1506, 4, 3, 1384, 1, 518, 4391, 1791, 3, 248, 59, 145, 1337, 207, 9, 13307, 2, 1506, 644, 20, 1591, 4, 957, 1554, 2, 301, 1, 956, 55, 11773, 20, 1589, 98, 1772, 866, 604, 10, 275, 4, 8, 993, 1, 171, 1209, 31, 285, 4, 352, 145, 55, 4, 739, 935, 86, 6334, 1, 3, 518, 4391, 10, 509, 2, 438, 5, 2721, 374, 2, 228, 3, 956, 301, 1, 13307, 2, 1506, 10, 97, 438, 6, 3, 145, 1337, 207, 4, 762, 1209, 31, 285, 4, 352, 3, 55, 301, 1, 13307, 2, 1506, 10, 97, 378, 4, 393, 742, 72, 5, 135, 4, 2161, 295, 15568, 18, 269, 2, 18, 641, 1116, 106, 19, 13, 144, 655, 30, 295, 182, 65, 553, 17, 259, 33, 2, 790, 39, 1, 7, 570, 64, 148, 1, 13307, 2, 1506, 106, 880, 318, 264, 17, 13307, 851, 438, 5, 779, 196, 19, 13, 474, 2, 131, 82, 19, 13, 588, 547, 1506, 851, 10, 41, 5, 756, 578, 19, 13, 755, 158, 13307, 851, 10, 41, 5, 34, 112, 19, 13, 755, 2, 63, 25, 19, 13, 588, 798, 13307, 851, 958, 35, 306, 980, 9, 779, 278, 23, 331, 320, 65, 3163, 18, 1420, 197, 39, 519, 19, 13, 755, 242, 110, 13307, 2, 1506, 68, 1343, 8, 200, 4, 3, 1384, 1, 518, 4391, 1791, 298, 1073, 28, 10678, 13307, 1233, 6, 40, 8, 93, 980, 1, 951, 278, 2, 68, 40, 8, 952, 9, 30, 3908, 2, 38, 228]",2034.0,12796399,320
The use of MRI in the diagnosis and management of a bulky cervical carcinoma.,Gynecologic oncology,Gynecol. Oncol.,2003-06-01,"In the treatment of gynecologic cancer, surgical planning depends on the site and extent of disease. The evaluation of the origin of a large pelvic mass with combined pelvic examination and ultrasound is often adequate. However, the following case report illustrates the utility of magnetic resonance imaging (MRI) when sonographic findings are indeterminate and the origin of a pelvic mass is unclear. A 73-year-old woman presented for her first gynecologic exam in over 40 years. On speculum examination the cervix was not visible. A large, mobile pelvic mass was palpated during physical examination. Pelvic ultrasound revealed a large, cystic pelvic mass thought to be ovarian in origin. Surgery for presumed ovarian carcinoma was planned. Because a vaginal Pap smear revealed squamous-cell carcinoma, MRI was performed for further evaluation. MRI demonstrated a blood distended uterus with a large cervical tumor obstructing the endocervical os. After cervical dilatation under sonographic guidance, evacuation of the hematometrium was performed. Multiple biopsies of the cervix confirmed the diagnosis of a bulky Stage IIA squamous-cell carcinoma of the cervix. The patient was subsequently treated with concomitant chemotherapy and radiation therapy. Follow-up MRI demonstrated an excellent treatment response. Modified radical hysterectomy was performed demonstrating very small residual tumor. Magnetic resonance imaging, through multiplanar capabilities and high-contrast resolution, is a valuable tool that can assist the clinician in the evaluation, diagnosis, and management of challenging gynecologic malignancies.",Case Reports,6078.0,6.0,In the treatment of gynecologic cancer surgical planning depends on the site and extent of disease The evaluation of the origin of a large pelvic mass with combined pelvic examination and ultrasound is often adequate However the following case report illustrates the utility of magnetic resonance imaging MRI when sonographic findings are indeterminate and the origin of a pelvic mass is unclear A 73-year-old woman presented for her first gynecologic exam in over 40 years On speculum examination the cervix was not visible A large mobile pelvic mass was palpated during physical examination Pelvic ultrasound revealed a large cystic pelvic mass thought to be in origin Surgery for presumed carcinoma was planned Because a Pap smear revealed squamous-cell carcinoma MRI was performed for further evaluation MRI demonstrated a blood distended with a large tumor obstructing the endocervical os After dilatation under sonographic guidance evacuation of the hematometrium was performed Multiple biopsies of the cervix confirmed the diagnosis of a bulky Stage IIA squamous-cell carcinoma of the cervix The patient was subsequently treated with concomitant chemotherapy and radiation therapy Follow-up MRI demonstrated an excellent treatment response Modified radical hysterectomy was performed demonstrating very small residual tumor Magnetic resonance imaging through multiplanar capabilities and high-contrast resolution is a valuable tool that can assist the clinician in the evaluation diagnosis and management of challenging gynecologic malignancies,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[4, 3, 24, 1, 1512, 12, 221, 1349, 3828, 23, 3, 606, 2, 1039, 1, 34, 3, 451, 1, 3, 1938, 1, 8, 375, 1110, 782, 5, 397, 1110, 1385, 2, 1945, 16, 629, 1658, 137, 3, 366, 473, 414, 6342, 3, 1207, 1, 1484, 1535, 270, 704, 198, 9240, 272, 32, 5167, 2, 3, 1938, 1, 8, 1110, 782, 16, 1200, 8, 803, 111, 1095, 2854, 917, 9, 1084, 157, 1512, 6747, 4, 252, 327, 60, 23, 53572, 1385, 3, 3629, 10, 44, 4822, 8, 375, 7489, 1110, 782, 10, 28066, 190, 900, 1385, 1110, 1945, 553, 8, 375, 2965, 1110, 782, 2739, 6, 40, 4, 1938, 152, 9, 5472, 134, 10, 1465, 408, 8, 4290, 8379, 553, 691, 31, 134, 704, 10, 173, 9, 195, 451, 704, 264, 8, 315, 26178, 5, 8, 375, 30, 43269, 3, 10174, 118, 50, 12799, 669, 9240, 2753, 21156, 1, 3, 53573, 10, 173, 232, 1154, 1, 3, 3629, 557, 3, 147, 1, 8, 4112, 82, 4088, 691, 31, 134, 1, 3, 3629, 3, 69, 10, 1611, 73, 5, 1781, 56, 2, 121, 36, 166, 126, 704, 264, 35, 1503, 24, 51, 1230, 711, 2622, 10, 173, 2219, 923, 302, 753, 30, 1484, 1535, 270, 298, 17732, 8190, 2, 64, 748, 2125, 16, 8, 2926, 1515, 17, 122, 3425, 3, 3744, 4, 3, 451, 147, 2, 284, 1, 1950, 1512, 441]",1551.0,12798721,9
Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer.,Oral oncology,Oral Oncol.,2003-10-01,"We hypothesized that acquisition of resistance to anoikis is a critical step in oral cancer progression. To test this hypothesis, we compared a panel of cell lines derived from human oral tissues across the spectrum of tumor progression from oral keratinocytes (HOK-16B), invasive oral squamous cell carcinoma (Tu167), and finally metastatic carcinoma (TxCS-1, MDA1986) for their sensitivity to detachment from the extracellular matrix. The relationship between stage of tumor progression and anoikis resistance was demonstrated by the apoptotic fractions after 48 h in suspension culture which were 93.33, 61.6, 34.5, and 3.71%, respectively. To further demonstrate that anoikis resistance is important for tumor progression, we selected a highly anoikis resistant cell line, JMAR, by serial passage of the Tu167 cell line in suspension culture. Initially, the JMAR line, and clones derived from it, were characterized for anoikis resistance in vitro, and after 72 h in suspension culture the rates of anoikis in the Tu167 and JMAR lines were found to be 73 and 26%, respectively. The degree of anoikis resistance was found to correlate with survival of nude mice orthotopically injected with 5x10(5) Tu167 or JMAR cells. The JMAR mice had a median survival of 17 days versus over 30 days in mice implanted with the Tu167 line. Finally, we found that in vivo selection in the orthotopic model for a regionally metastatic cell line by implantation of Tu167 into the tongues of nude mice and harvesting and culturing cervical lymph nodes led to production of a cell line, Tu167LN1, which was found to be anoikis-resistant. This cell line had an apoptotic cell fraction of 16.2% (+/-3.14%) after 48 h in suspension culture.",Journal Article,5956.0,40.0,We hypothesized that acquisition of resistance to anoikis is a critical step in oral cancer progression To test this hypothesis we compared a panel of cell lines derived from human oral tissues across the spectrum of tumor progression from oral keratinocytes HOK-16B invasive oral squamous cell carcinoma Tu167 and finally metastatic carcinoma TxCS-1 MDA1986 for their sensitivity to detachment from the extracellular matrix The relationship between stage of tumor progression and anoikis resistance was demonstrated by the apoptotic fractions after 48 h in suspension culture which were 93.33 61.6 34.5 and 3.71 respectively To further demonstrate that anoikis resistance is important for tumor progression we selected a highly anoikis resistant cell line JMAR by serial passage of the Tu167 cell line in suspension culture Initially the JMAR line and clones derived from it were characterized for anoikis resistance in vitro and after 72 h in suspension culture the rates of anoikis in the Tu167 and JMAR lines were found to be 73 and 26 respectively The degree of anoikis resistance was found to correlate with survival of nude mice orthotopically injected with 5x10 5 Tu167 or JMAR cells The JMAR mice had a median survival of 17 days versus over 30 days in mice implanted with the Tu167 line Finally we found that in vivo selection in the orthotopic model for a regionally metastatic cell line by implantation of Tu167 into the tongues of nude mice and harvesting and culturing lymph nodes led to production of a cell line Tu167LN1 which was found to be anoikis-resistant This cell line had an apoptotic cell fraction of 16.2 +/-3.14 after 48 h in suspension culture,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 1237, 17, 3405, 1, 251, 6, 7817, 16, 8, 740, 2458, 4, 518, 12, 91, 6, 412, 26, 1492, 21, 72, 8, 993, 1, 31, 285, 526, 29, 171, 518, 742, 716, 3, 1873, 1, 30, 91, 29, 518, 9587, 53679, 43331, 416, 518, 691, 31, 134, 20990, 2, 1368, 113, 134, 53680, 14, 23073, 9, 136, 485, 6, 13252, 29, 3, 1976, 2248, 3, 858, 59, 82, 1, 30, 91, 2, 7817, 251, 10, 264, 20, 3, 1631, 1550, 50, 576, 555, 4, 9348, 2099, 92, 11, 966, 466, 713, 49, 562, 33, 2, 27, 792, 106, 6, 195, 608, 17, 7817, 251, 16, 305, 9, 30, 91, 21, 715, 8, 561, 7817, 436, 31, 328, 20314, 20, 2108, 7740, 1, 3, 20990, 31, 328, 4, 9348, 2099, 1625, 3, 20314, 328, 2, 2749, 526, 29, 192, 11, 765, 9, 7817, 251, 4, 439, 2, 50, 720, 555, 4, 9348, 2099, 3, 151, 1, 7817, 4, 3, 20990, 2, 20314, 285, 11, 204, 6, 40, 803, 2, 432, 106, 3, 1444, 1, 7817, 251, 10, 204, 6, 1513, 5, 25, 1, 2598, 399, 10806, 2651, 5, 24632, 33, 20990, 15, 20314, 37, 3, 20314, 399, 42, 8, 52, 25, 1, 269, 162, 185, 252, 201, 162, 4, 399, 3416, 5, 3, 20990, 328, 1368, 21, 204, 17, 4, 386, 881, 4, 3, 2157, 202, 9, 8, 8183, 113, 31, 328, 20, 4314, 1, 20990, 237, 3, 23074, 1, 2598, 399, 2, 17700, 2, 16316, 263, 502, 836, 6, 1529, 1, 8, 31, 328, 53681, 92, 10, 204, 6, 40, 7817, 436, 26, 31, 328, 42, 35, 1631, 31, 1509, 1, 245, 18, 27, 213, 50, 576, 555, 4, 9348, 2099]",1671.0,12907203,227
Radiotherapy in the management of giant cell tumor of bone.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2003-09-01,"To evaluate the outcomes of patients with giant cell tumor of bone (GCTB) treated with radiotherapy (RT) with or without surgical resection. We performed a retrospective review of the records from 25 consecutive patients with pathologically confirmed GCTB who had undergone RT between 1956 and 2000. Patients ranged in age from 11 to 69 years (median 32); 16 were female and 9 were male. The anatomic distribution of lesions was as follows: cervical spine, 3; temporal bone, 1; thoracic or lumbar spine, 9; sacrum, 8; ilium, 1, and humerus, radius, and thumb metacarpal, 1 each. Tumors ranged in size from 2 to 20 cm (median 9.5) at their maximal dimension. Thirteen patients had been referred for RT for primary GCTB and 12 had been referred with locally recurrent disease after having undergone one or more other treatments. Fourteen patients had undergone RT for gross disease, and the remaining 11 had been treated with RT after gross total resection. In 10 of these 11 patients, the treatment margins were positive or uncertain. Radiation doses ranged from 25 to 65 Gy (median 46). At a median follow-up of 8.8 years (range 0.67-34), 7 patients had developed isolated local recurrence, 2 had developed isolated distant recurrence, and 3 had developed both. The actuarial 5-year overall and disease-free survival rate was 91% and 58%, respectively, and the actuarial 5-year local control and distant metastasis-free survival rate was 62% and 81%, respectively. Univariate analysis suggested that treatment for recurrent disease correlated with a lower disease-free survival rate (83% vs. 33%, p = 0.06), distant metastasis-free survival rate (100% vs. 64%, p = 0.08), and local control rate (83% vs. 42%, p = 0.08) at 5 years. Of the 12 cases of recurrence, 7 were ultimately successfully treated with additional salvage therapy. In 4 of these patients, salvage therapy included interferon-alpha 2b. RT should be considered an adjuvant to surgery or as alternative therapy in cases of GCTB that are unresectable or in which excision would result in substantial functional deficits. When RT is used as primary therapy, the rate of local control seems to be satisfactory. In heavily pretreated patients, however, RT delivered as it was in this series can result in poor local control, and alternative therapies should be considered.",Journal Article,5986.0,93.0,To evaluate the outcomes of patients with giant cell tumor of GCTB treated with radiotherapy RT with or without surgical resection We performed a retrospective review of the records from 25 consecutive patients with pathologically confirmed GCTB who had undergone RT between 1956 and 2000 Patients ranged in age from 11 to 69 years median 32 16 were female and 9 were male The anatomic distribution of lesions was as follows spine 3 temporal 1 thoracic or lumbar spine 9 sacrum 8 ilium 1 and humerus radius and thumb metacarpal 1 each Tumors ranged in size from 2 to 20 cm median 9.5 at their maximal dimension Thirteen patients had been referred for RT for primary GCTB and 12 had been referred with locally recurrent disease after having undergone one or more other treatments Fourteen patients had undergone RT for gross disease and the remaining 11 had been treated with RT after gross total resection In 10 of these 11 patients the treatment margins were positive or uncertain Radiation doses ranged from 25 to 65 Gy median 46 At a median follow-up of 8.8 years range 0.67-34 7 patients had developed isolated local recurrence 2 had developed isolated distant recurrence and 3 had developed both The actuarial 5-year overall and disease-free survival rate was 91 and 58 respectively and the actuarial 5-year local control and distant metastasis-free survival rate was 62 and 81 respectively Univariate analysis suggested that treatment for recurrent disease correlated with a lower disease-free survival rate 83 vs. 33 p 0.06 distant metastasis-free survival rate 100 vs. 64 p 0.08 and local control rate 83 vs. 42 p 0.08 at 5 years Of the 12 cases of recurrence 7 were ultimately successfully treated with additional salvage therapy In 4 of these patients salvage therapy included interferon-alpha 2b RT should be considered an adjuvant to surgery or as alternative therapy in cases of GCTB that are unresectable or in which excision would result in substantial functional deficits When RT is used as primary therapy the rate of local control seems to be satisfactory In heavily pretreated patients however RT delivered as it was in this series can result in poor local control and alternative therapies should be considered,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 3, 123, 1, 7, 5, 6470, 31, 30, 1, 18294, 73, 5, 310, 240, 5, 15, 187, 221, 170, 21, 173, 8, 459, 206, 1, 3, 1064, 29, 243, 935, 7, 5, 2998, 557, 18294, 54, 42, 1989, 240, 59, 28098, 2, 1081, 7, 1869, 4, 89, 29, 175, 6, 790, 60, 52, 531, 245, 11, 1061, 2, 83, 11, 1045, 3, 2745, 1395, 1, 406, 10, 22, 2962, 2342, 27, 3264, 14, 2098, 15, 6187, 2342, 83, 11629, 66, 18295, 14, 2, 17746, 15862, 2, 53684, 43332, 14, 296, 57, 1869, 4, 444, 29, 18, 6, 179, 494, 52, 83, 33, 28, 136, 2725, 6384, 3170, 7, 42, 85, 1995, 9, 240, 9, 86, 18294, 2, 133, 42, 85, 1995, 5, 795, 387, 34, 50, 1041, 1989, 104, 15, 80, 127, 640, 3225, 7, 42, 1989, 240, 9, 1789, 34, 2, 3, 1844, 175, 42, 85, 73, 5, 240, 50, 1789, 181, 170, 4, 79, 1, 46, 175, 7, 3, 24, 1012, 11, 109, 15, 2717, 121, 415, 1869, 29, 243, 6, 556, 381, 52, 641, 28, 8, 52, 166, 126, 1, 66, 66, 60, 184, 13, 598, 562, 67, 7, 42, 276, 1355, 293, 146, 18, 42, 276, 1355, 626, 146, 2, 27, 42, 276, 110, 3, 2361, 33, 111, 63, 2, 34, 115, 25, 116, 10, 970, 2, 717, 106, 2, 3, 2361, 33, 111, 293, 182, 2, 626, 278, 115, 25, 116, 10, 744, 2, 865, 106, 880, 65, 1148, 17, 24, 9, 387, 34, 438, 5, 8, 280, 34, 115, 25, 116, 852, 105, 466, 19, 13, 1460, 626, 278, 115, 25, 116, 394, 105, 660, 19, 13, 1592, 2, 293, 182, 116, 852, 105, 595, 19, 13, 1592, 28, 33, 60, 1, 3, 133, 140, 1, 146, 67, 11, 2050, 1878, 73, 5, 402, 992, 36, 4, 39, 1, 46, 7, 992, 36, 159, 1688, 950, 3381, 240, 257, 40, 515, 35, 249, 6, 152, 15, 22, 1091, 36, 4, 140, 1, 18294, 17, 32, 1468, 15, 4, 92, 1366, 688, 757, 4, 1281, 583, 2752, 198, 240, 16, 95, 22, 86, 36, 3, 116, 1, 293, 182, 2744, 6, 40, 7972, 4, 2447, 2193, 7, 137, 240, 1623, 22, 192, 10, 4, 26, 988, 122, 757, 4, 334, 293, 182, 2, 1091, 235, 257, 40, 515]",2230.0,12909228,569
Early stage cervical cancers containing human papillomavirus type 18 DNA have more nodal metastasis and deeper stromal invasion.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2003-09-01,"To investigate the clinical and pathological factors which might explain the poor prognosis associated with early stage cervical cancers containing human papillomavirus (HPV) type 18 DNA. A clinical and pathological review of 144 patients with stage IB cervical cancer treated with radical hysterectomy and bilateral pelvic lymph node dissection was done. HPV genotyping was determined from fresh tumor specimens through PCR. Clinical-pathological information, sites of recurrence, use of adjuvant radiation, and survival data were analyzed. Thirty-three (23%) tumors contained HPV 18 DNA. These tumors did not differ from those which contained non-HPV 18 DNA with respect to tumor grade or size. However, HPV 18-containing cancers were more likely to be adenocarcinomas. A higher incidence of pelvic lymph node metastasis was noted among the HPV 18 group (48%) as compared with the non-HPV 18 group (28%), and deeper stromal invasion was more common in HPV 18-associated tumors. Although a slightly higher proportion of patients with HPV 18-containing tumors received adjuvant radiation (67%) than those with non-HPV 18 cancers (49%), recurrences were more common among HPV 18 patients. Eleven (33%) of HPV 18-containing cancers relapsed compared with 18 (16%) of non-HPV18-containing tumors. The explanation for the worse prognosis associated with stage IB cervical cancers containing HPV 18 DNA treated with radical hysterectomy and bilateral pelvic lymph node dissection appears to be related to deeper cervical stromal invasion and more nodal metastases. Despite an increased use of adjuvant radiation therapy, these cancers are still more likely to relapse.",Journal Article,5986.0,58.0,To investigate the clinical and pathological factors which might explain the poor prognosis associated with early stage cancers containing human papillomavirus HPV type 18 DNA A clinical and pathological review of 144 patients with stage IB cancer treated with radical hysterectomy and bilateral pelvic lymph node dissection was done HPV genotyping was determined from fresh tumor specimens through PCR Clinical-pathological information sites of recurrence use of adjuvant radiation and survival data were analyzed Thirty-three 23 tumors contained HPV 18 DNA These tumors did not differ from those which contained non-HPV 18 DNA with respect to tumor grade or size However HPV 18-containing cancers were more likely to be adenocarcinomas A higher incidence of pelvic lymph node metastasis was noted among the HPV 18 group 48 as compared with the non-HPV 18 group 28 and deeper stromal invasion was more common in HPV 18-associated tumors Although a slightly higher proportion of patients with HPV 18-containing tumors received adjuvant radiation 67 than those with non-HPV 18 cancers 49 recurrences were more common among HPV 18 patients Eleven 33 of HPV 18-containing cancers relapsed compared with 18 16 of non-HPV18-containing tumors The explanation for the worse prognosis associated with stage IB cancers containing HPV 18 DNA treated with radical hysterectomy and bilateral pelvic lymph node dissection appears to be related to deeper stromal invasion and more nodal metastases Despite an increased use of adjuvant radiation therapy these cancers are still more likely to relapse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,"[6, 963, 3, 38, 2, 1301, 130, 92, 822, 2943, 3, 334, 356, 41, 5, 191, 82, 163, 1101, 171, 3242, 933, 267, 203, 261, 8, 38, 2, 1301, 206, 1, 4415, 7, 5, 82, 3180, 12, 73, 5, 711, 2622, 2, 1607, 1110, 263, 289, 1161, 10, 1822, 933, 2686, 10, 509, 29, 4329, 30, 623, 298, 604, 38, 1301, 487, 633, 1, 146, 119, 1, 249, 121, 2, 25, 74, 11, 311, 977, 169, 382, 57, 3070, 933, 203, 261, 46, 57, 205, 44, 1505, 29, 135, 92, 3070, 220, 933, 203, 261, 5, 2184, 6, 30, 88, 15, 444, 137, 933, 203, 1101, 163, 11, 80, 322, 6, 40, 1586, 8, 142, 287, 1, 1110, 263, 289, 278, 10, 1051, 107, 3, 933, 203, 87, 576, 22, 72, 5, 3, 220, 933, 203, 87, 339, 2, 6029, 1126, 578, 10, 80, 186, 4, 933, 203, 41, 57, 242, 8, 3223, 142, 920, 1, 7, 5, 933, 203, 1101, 57, 103, 249, 121, 598, 76, 135, 5, 220, 933, 203, 163, 739, 1593, 11, 80, 186, 107, 933, 203, 7, 2627, 466, 1, 933, 203, 1101, 163, 591, 72, 5, 203, 245, 1, 220, 33514, 1101, 57, 3, 6603, 9, 3, 639, 356, 41, 5, 82, 3180, 163, 1101, 933, 203, 261, 73, 5, 711, 2622, 2, 1607, 1110, 263, 289, 1161, 1233, 6, 40, 139, 6, 6029, 1126, 578, 2, 80, 779, 196, 550, 35, 101, 119, 1, 249, 121, 36, 46, 163, 32, 1234, 80, 322, 6, 429]",1585.0,14519638,43
Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.,JAMA,JAMA,2003-10-01,"The effects of continuous combined hormone therapy on gynecologic cancers have not been investigated previously in a randomized trial setting. To determine the possible associations of estrogen plus progestin on gynecologic cancers and related diagnostic procedures. Randomized, double-blind, placebo-controlled trial of 16 608 postmenopausal women, who had not had a hysterectomy at baseline and who had been recruited from 40 US clinical centers between September 1993 and October 1998 (average follow-up, 5.6 years). One tablet per day containing 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate (n = 8506) or placebo (n = 8102). Incident invasive cancer of the ovary and endometrium. In 5.6 years of follow-up, there were 32 cases of invasive ovarian cancer, 58 cases of endometrial cancer, 1 case of nonendometrial uterine cancer, 13 cases of cervical cancer, and 7 cases of other gynecologic cancers. The hazard ratio (HR) for invasive ovarian cancer in women assigned to estrogen plus progestin compared with placebo was 1.58 (95% confidence interval [CI], 0.77-3.24). The HR for endometrial cancer was 0.81 (95% CI, 0.48-1.36). No appreciable differences were found in the distributions of tumor histology, stage, or grade for either cancer site. The incidence of other gynecologic cancers was low and did not differ by randomization assignment. More women taking estrogen plus progestin required endometrial biopsies (33% vs 6%; P<.001). This randomized trial suggests that continuous combined estrogen plus progestin therapy may increase the risk of ovarian cancer while producing endometrial cancer rates similar to placebo. The increased burden of endometrial biopsies required to assess vaginal bleeding further limits the acceptability of this regimen. These data provide additional support for caution in the use of continuous combined hormones.",Clinical Trial,5956.0,438.0,The effects of continuous combined hormone therapy on gynecologic cancers have not been investigated previously in a randomized trial setting To determine the possible associations of estrogen plus progestin on gynecologic cancers and related diagnostic procedures Randomized double-blind placebo-controlled trial of 16 608 postmenopausal women who had not had a hysterectomy at baseline and who had been recruited from 40 US clinical centers between September 1993 and October 1998 average follow-up 5.6 years One tablet per day containing 0.625 mg of conjugated equine estrogens plus 2.5 mg of medroxyprogesterone acetate n 8506 or placebo n 8102 Incident invasive cancer of the ovary and In 5.6 years of follow-up there were 32 cases of invasive cancer 58 cases of cancer 1 case of nonendometrial cancer 13 cases of cancer and 7 cases of other gynecologic cancers The hazard ratio HR for invasive cancer in women assigned to estrogen plus progestin compared with placebo was 1.58 95 confidence interval CI 0.77-3.24 The HR for cancer was 0.81 95 CI 0.48-1.36 No appreciable differences were found in the distributions of tumor histology stage or grade for either cancer site The incidence of other gynecologic cancers was low and did not differ by randomization assignment More women taking estrogen plus progestin required biopsies 33 vs 6 P .001 This randomized trial suggests that continuous combined estrogen plus progestin therapy may increase the risk of cancer while producing cancer rates similar to placebo The increased burden of biopsies required to assess bleeding further limits the acceptability of this regimen These data provide additional support for caution in the use of continuous combined hormones,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 176, 1, 1314, 397, 785, 36, 23, 1512, 163, 47, 44, 85, 565, 373, 4, 8, 384, 160, 546, 6, 223, 3, 899, 685, 1, 808, 349, 9370, 23, 1512, 163, 2, 139, 752, 1369, 384, 1627, 3142, 619, 1149, 160, 1, 245, 11768, 1679, 117, 54, 42, 44, 42, 8, 2622, 28, 330, 2, 54, 42, 85, 2619, 29, 327, 843, 38, 1168, 59, 2636, 3343, 2, 2551, 1850, 1011, 166, 126, 33, 49, 60, 104, 6977, 379, 218, 1101, 13, 9629, 81, 1, 3868, 17759, 6293, 349, 18, 33, 81, 1, 18815, 3424, 78, 43374, 15, 619, 78, 43375, 2631, 416, 12, 1, 3, 3631, 2, 4, 33, 49, 60, 1, 166, 126, 125, 11, 531, 140, 1, 416, 12, 717, 140, 1, 12, 14, 473, 1, 53767, 12, 233, 140, 1, 12, 2, 67, 140, 1, 127, 1512, 163, 3, 360, 197, 168, 9, 416, 12, 4, 117, 896, 6, 808, 349, 9370, 72, 5, 619, 10, 14, 717, 48, 307, 268, 58, 13, 849, 27, 259, 3, 168, 9, 12, 10, 13, 865, 48, 58, 13, 576, 14, 511, 77, 9371, 362, 11, 204, 4, 3, 4477, 1, 30, 784, 82, 15, 88, 9, 361, 12, 606, 3, 287, 1, 127, 1512, 163, 10, 154, 2, 205, 44, 1505, 20, 3644, 4392, 80, 117, 2727, 808, 349, 9370, 616, 1154, 466, 105, 49, 19, 144, 26, 384, 160, 844, 17, 1314, 397, 808, 349, 9370, 36, 68, 344, 3, 43, 1, 12, 369, 3787, 12, 151, 288, 6, 619, 3, 101, 892, 1, 1154, 616, 6, 423, 2294, 195, 3526, 3, 8065, 1, 26, 477, 46, 74, 377, 402, 538, 9, 5526, 4, 3, 119, 1, 1314, 397, 4927]",1721.0,14519708,166
Cervical cancer: issues of sexuality and fertility.,"Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2003-09-01,"Cervical cancer rates have fallen in the United States; regardless, the disease remains a significant concern for women, especially those who are premenopausal. The management of cervical cancer is dependent on stage of disease at diagnosis, and specific needs emerge for patients both during and following treatment. Over the past decade, the focus has been to maintain adequate tumor control while reducing long-term negative consequences. However, problems with sexuality and fertility persist for women treated for cervical cancer despite these advances. Sexual dysfunction following treatment for gynecologic cancer has been well documented in the literature, and recent studies demonstrate the success of brief psychosexual interventions. Treatment of sexual difficulties in cancer patients can be achieved through the provision of information, support, and symptom management, ideally as part of a sexual health program. Resources are not always available to develop such a program. However, medical professionals can identify individuals and organizations with expertise in treating sexual and fertility concerns, which can be provided to their patients, making help with these problems more accessible as needs arise.",Journal Article,5986.0,13.0,cancer rates have fallen in the United States regardless the disease remains a significant concern for women especially those who are premenopausal The management of cancer is dependent on stage of disease at diagnosis and specific needs emerge for patients both during and following treatment Over the past decade the focus has been to maintain adequate tumor control while reducing long-term negative consequences However problems with sexuality and fertility persist for women treated for cancer despite these advances Sexual dysfunction following treatment for gynecologic cancer has been well documented in the literature and recent studies demonstrate the success of brief psychosexual interventions Treatment of sexual difficulties in cancer patients can be achieved through the provision of information support and symptom management ideally as part of a sexual health program Resources are not always available to develop such a program However medical professionals can identify individuals and organizations with expertise in treating sexual and fertility concerns which can be provided to their patients making help with these problems more accessible as needs arise,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 151, 47, 18310, 4, 3, 1088, 907, 1583, 3, 34, 469, 8, 93, 2893, 9, 117, 1093, 135, 54, 32, 2710, 3, 284, 1, 12, 16, 470, 23, 82, 1, 34, 28, 147, 2, 112, 1891, 6371, 9, 7, 110, 190, 2, 366, 24, 252, 3, 1219, 2025, 3, 1222, 71, 85, 6, 3040, 1658, 30, 182, 369, 1818, 319, 337, 199, 3255, 137, 2408, 5, 18923, 2, 2954, 5589, 9, 117, 73, 9, 12, 550, 46, 954, 2232, 1527, 366, 24, 9, 1512, 12, 71, 85, 149, 1405, 4, 3, 789, 2, 435, 94, 608, 3, 1825, 1, 3190, 28131, 1151, 24, 1, 2232, 4679, 4, 12, 7, 122, 40, 513, 298, 3, 6832, 1, 487, 538, 2, 934, 284, 8160, 22, 760, 1, 8, 2232, 341, 1243, 2892, 32, 44, 3763, 390, 6, 690, 225, 8, 1243, 137, 484, 3409, 122, 255, 869, 2, 6283, 5, 4935, 4, 1367, 2232, 2, 2954, 2061, 92, 122, 40, 1052, 6, 136, 7, 1079, 987, 5, 46, 2408, 80, 5981, 22, 1891, 3043]",1178.0,14569851,503
Total laparoscopic radical hysterectomy with pelvic lymphadenectomy using the argon-beam coagulator: pilot data and comparison to laparotomy.,Gynecologic oncology,Gynecol. Oncol.,2003-11-01,"The aim of this study was to describe the feasibility and outcome of total laparoscopic radical hysterectomy with pelvic lymphadenectomy for stage I cervical cancer using the argon-beam coagulator. A retrospective review was performed of patients with FIGO stage IA1-IB1 cervical cancer who underwent a total laparoscopic approach for definitive surgical treatment. Comparison was made to a cohort of 195 patients who were treated with laparotomy. Between 12/2000 and 12/2002, 19 patients were offered the laparoscopic approach. The procedure was completed laparoscopically in 17 patients (89.5%). Two patients, in the beginning of the study, underwent conversion to laparotomy, 1 due to parametrial bleeding and 1 due to pelvic adhesions and cystotomy. Mean age was 42.6 years (range, 30-69 years); mean body mass index was 23.1 (range, 18-30); FIGO stage included IA1 with LVI (2), IA2 (6), IB1 (11). Mean pelvic lymph node count was 25.5 (range, 15-39), and 1 patient (5.3%) had positive nodes. Mean estimated blood loss was 301 cc (range, 75-1500 cc) compared to 693 cc in the laparotomy group (P < 0.01), mean operating time was 371 min (range, 230-600 min) compared to 295 min in the laparotomy group (P < 0.01), and mean hospital stay was 4.5 days (range, 3-11 days) compared to 9.7 days in the laparotomy group (P < 0.01). There were no ureteral injuries or fistula formation. All patients remain clinically disease free at the time of this report. Total laparoscopic radical hysterectomy with pelvic lymphadenectomy for selected patients with stage I cervical cancer is feasible, safe, and associated with a low morbidity in the pilot phase. Estimated blood loss and postoperative hospitalization appear shorter than historical controls, at the cost of longer operating time. Oncologic outcome requires longer follow-up.",Comparative Study,5925.0,160.0,The aim of this study was to describe the feasibility and outcome of total laparoscopic radical hysterectomy with pelvic lymphadenectomy for stage I cancer using the argon-beam coagulator A retrospective review was performed of patients with FIGO stage IA1-IB1 cancer who underwent a total laparoscopic approach for definitive surgical treatment Comparison was made to a cohort of 195 patients who were treated with laparotomy Between 12/2000 and 12/2002 19 patients were offered the laparoscopic approach The procedure was completed laparoscopically in 17 patients 89.5 Two patients in the beginning of the study underwent conversion to laparotomy 1 due to parametrial bleeding and 1 due to pelvic adhesions and cystotomy Mean age was 42.6 years range 30-69 years mean body mass index was 23.1 range 18-30 FIGO stage included IA1 with LVI 2 IA2 6 IB1 11 Mean pelvic lymph node count was 25.5 range 15-39 and 1 patient 5.3 had positive nodes Mean estimated blood loss was 301 cc range 75-1500 cc compared to 693 cc in the laparotomy group P 0.01 mean operating time was 371 min range 230-600 min compared to 295 min in the laparotomy group P 0.01 and mean hospital stay was 4.5 days range 3-11 days compared to 9.7 days in the laparotomy group P 0.01 There were no ureteral injuries or fistula formation All patients remain clinically disease free at the time of this report Total laparoscopic radical hysterectomy with pelvic lymphadenectomy for selected patients with stage I cancer is feasible safe and associated with a low morbidity in the pilot phase Estimated blood loss and postoperative hospitalization appear shorter than historical controls at the cost of longer operating time Oncologic outcome requires longer follow-up,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1130, 1, 26, 45, 10, 6, 897, 3, 1437, 2, 228, 1, 181, 1964, 711, 2622, 5, 1110, 2048, 9, 82, 70, 12, 75, 3, 26069, 1345, 43424, 8, 459, 206, 10, 173, 1, 7, 5, 3837, 82, 14517, 8111, 12, 54, 208, 8, 181, 1964, 353, 9, 1057, 221, 24, 1155, 10, 1229, 6, 8, 180, 1, 5786, 7, 54, 11, 73, 5, 3274, 59, 133, 1081, 2, 133, 1544, 326, 7, 11, 2216, 3, 1964, 353, 3, 1299, 10, 781, 11472, 4, 269, 7, 887, 33, 100, 7, 4, 3, 2948, 1, 3, 45, 208, 3111, 6, 3274, 14, 520, 6, 8726, 2294, 2, 14, 520, 6, 1110, 13233, 2, 37573, 313, 89, 10, 595, 49, 60, 184, 201, 790, 60, 313, 642, 782, 558, 10, 382, 14, 184, 203, 201, 3837, 82, 159, 14517, 5, 3327, 18, 16725, 49, 8111, 175, 313, 1110, 263, 289, 1276, 10, 243, 33, 184, 167, 587, 2, 14, 69, 33, 27, 42, 109, 502, 313, 661, 315, 407, 10, 5721, 1951, 184, 481, 7204, 1951, 72, 6, 13886, 1951, 4, 3, 3274, 87, 19, 13, 355, 313, 2584, 98, 10, 9196, 1538, 184, 6136, 2383, 1538, 72, 6, 7051, 1538, 4, 3, 3274, 87, 19, 13, 355, 2, 313, 702, 2020, 10, 39, 33, 162, 184, 27, 175, 162, 72, 6, 83, 67, 162, 4, 3, 3274, 87, 19, 13, 355, 125, 11, 77, 7213, 13063, 15, 4920, 1264, 62, 7, 918, 505, 34, 115, 28, 3, 98, 1, 26, 414, 181, 1964, 711, 2622, 5, 1110, 2048, 9, 715, 7, 5, 82, 70, 12, 16, 1313, 1165, 2, 41, 5, 8, 154, 787, 4, 3, 2281, 124, 661, 315, 407, 2, 573, 2826, 1322, 985, 76, 2252, 535, 28, 3, 835, 1, 589, 2584, 98, 1998, 228, 1706, 589, 166, 126]",1732.0,14599873,8
Cervical cancer.,Cancer,Cancer,2003-11-01,"Behavioral and psychosocial factors affect all aspects of cervical cancer control, from prevention to posttreatment rehabilitation. Behavioral scientists gathered at the Second International Conference on Cervical Cancer (Houston, TX, April 11-14, 2002) reviewed selected studies of behavioral factors related to cervical cancer, including women's receptivity to emerging cervical cancer screening and diagnostic technologies, factors that influence adherence to follow-up colposcopy recommendations, and cervical cancer survivors' quality of life. Researchers reported that reduced distress during examinations with new technology may improve adherence to cervical cancer screening recommendations. Until new technology becomes mainstream, research shows that distress is reduced and adherence improves when health care providers match interventions to patients' informational processing styles. Investigations of survivors' quality of life report conflicting findings, but studies indicate that survivors experience anger over reproductive loss, loss of interest in sex, and perhaps a greater vulnerability to sexual dysfunction compared with survivors of other cancers. Survivors also report a need for posttherapy support programs. Primary prevention of cervical cancer should remain a priority as research in behavioral interventions and barriers to screening, especially among vulnerable populations, moves forward.",Journal Article,5925.0,40.0,Behavioral and psychosocial factors affect all aspects of cancer control from prevention to posttreatment rehabilitation Behavioral scientists gathered at the Second International Conference on Cancer Houston TX April 11-14 2002 reviewed selected studies of behavioral factors related to cancer including women 's receptivity to emerging cancer screening and diagnostic technologies factors that influence adherence to follow-up colposcopy recommendations and cancer survivors quality of life Researchers reported that reduced distress during examinations with new technology may improve adherence to cancer screening recommendations Until new technology becomes mainstream research shows that distress is reduced and adherence improves when health care providers match interventions to patients informational processing styles Investigations of survivors quality of life report conflicting findings but studies indicate that survivors experience anger over reproductive loss loss of interest in sex and perhaps a greater vulnerability to sexual dysfunction compared with survivors of other cancers Survivors also report a need for posttherapy support programs Primary prevention of cancer should remain a priority as research in behavioral interventions and barriers to screening especially among vulnerable populations moves forward,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4166, 2, 2322, 130, 1158, 62, 2695, 1, 12, 182, 29, 1070, 6, 3149, 4182, 4166, 6868, 7546, 28, 3, 419, 944, 4180, 23, 12, 6212, 6614, 2292, 175, 213, 1544, 446, 715, 94, 1, 4166, 130, 139, 6, 12, 141, 117, 292, 28137, 6, 1478, 12, 453, 2, 752, 2590, 130, 17, 1054, 2149, 6, 166, 126, 9946, 883, 2, 12, 332, 372, 1, 358, 4211, 210, 17, 405, 1462, 190, 4209, 5, 217, 2033, 68, 401, 2149, 6, 12, 453, 883, 1100, 217, 2033, 5366, 18244, 389, 1949, 17, 1462, 16, 405, 2, 2149, 1804, 198, 341, 165, 1994, 5364, 1151, 6, 7, 12156, 3325, 15944, 2492, 1, 332, 372, 1, 358, 414, 4274, 272, 84, 94, 1008, 17, 332, 730, 28138, 252, 3705, 407, 407, 1, 1333, 4, 1035, 2, 4434, 8, 378, 7665, 6, 2232, 1527, 72, 5, 332, 1, 127, 163, 332, 120, 414, 8, 594, 9, 8163, 538, 2251, 86, 1070, 1, 12, 257, 918, 8, 4690, 22, 389, 4, 4166, 1151, 2, 2160, 6, 453, 1093, 107, 5017, 1184, 18926, 4674]",1334.0,14603537,44
Imaging in cervical cancer.,Cancer,Cancer,2003-11-01,"Cervical cancer traditionally has been staged clinically. Advances in imaging could improve the staging of cervical cancer by facilitating the detection of lymph node metastases and micrometastases in distant organs. Such progress could lead to improvements in treatment selection and therefore increase overall survival rates. At the Second International Conference on Clinical Cancer (Houston, TX, April 11-14, 2002), a panel composed of gynecologic oncologists, radiation oncologists, and diagnostic radiologists reviewed relevant technologies. Advances in lymphangiography, ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and lymphatic mapping were reviewed, along with the impact of these advances on the diagnosis, treatment, and survival of patients with cervical cancer. Few cancer centers still use lymphangiography, but the sensitivity of this method ranges from 28% to 83%, with specificity ranging from 47% to 100%. The roles of transabdominal and transvaginal ultrasonography in evaluating cervical cancer are expected to expand when new contrast agents increase the sensitivity of these techniques to parametrial invasion and lymph node metastases; meanwhile, ultrasonography's most significant contributions may involve the identification of uterine and cervical leiomyomas and the evaluation of urinary tract obstruction. Advances in CT have made it a rival technique to MRI, but limitations prevent CT from providing definitive information on certain parameters. MRI, which is valuable because of its superior soft tissue contrast resolution, multiplanar capabilities, and cost-effectiveness, is used to determine the size of the cervix and to detect certain types of invasion, characteristics of lymph nodes, and the presence of disease in the ureter, lung, and liver. PET with 2-[fluorine-18]fluoro-2-deoxy-D-glucose has been found to detect abnormal lymph node regions better than CT does but PET can also be used in conjunction with CT to measure tumor dimensions. PET also has become a method for identifying tumors that are unresponsive to chemoradiation. When used together with immunohistochemical and molecular techniques as well as conventional stains, sentinel lymph node mapping, an important development in the surgical management of solid tumors, is expected to improve gynecologic cancer management. Advances in imaging methods and in contrast agents, along with advances in the combined use of the two, are expected to make imaging technologies more valuable in cervical cancer assessment.",Journal Article,5925.0,93.0,cancer traditionally has been staged clinically Advances in imaging could improve the staging of cancer by facilitating the detection of lymph node metastases and micrometastases in distant organs Such progress could lead to improvements in treatment selection and therefore increase overall survival rates At the Second International Conference on Clinical Cancer Houston TX April 11-14 2002 a panel composed of gynecologic oncologists radiation oncologists and diagnostic radiologists reviewed relevant technologies Advances in lymphangiography ultrasonography computed tomography CT magnetic resonance imaging MRI positron emission tomography PET and lymphatic mapping were reviewed along with the impact of these advances on the diagnosis treatment and survival of patients with cancer Few cancer centers still use lymphangiography but the sensitivity of this method ranges from 28 to 83 with specificity ranging from 47 to 100 The roles of transabdominal and transvaginal ultrasonography in evaluating cancer are expected to expand when new contrast agents increase the sensitivity of these techniques to parametrial invasion and lymph node metastases meanwhile ultrasonography 's most significant contributions may involve the identification of and leiomyomas and the evaluation of urinary tract obstruction Advances in CT have made it a rival technique to MRI but limitations prevent CT from providing definitive information on certain parameters MRI which is valuable because of its superior soft tissue contrast resolution multiplanar capabilities and cost-effectiveness is used to determine the size of the cervix and to detect certain types of invasion characteristics of lymph nodes and the presence of disease in the ureter and PET with 2- fluorine-18 fluoro-2-deoxy-D-glucose has been found to detect abnormal lymph node regions better than CT does but PET can also be used in conjunction with CT to measure tumor dimensions PET also has become a method for identifying tumors that are unresponsive to chemoradiation When used together with immunohistochemical and molecular techniques as well as conventional stains sentinel lymph node mapping an important development in the surgical management of solid tumors is expected to improve gynecologic cancer management Advances in imaging methods and in contrast agents along with advances in the combined use of the two are expected to make imaging technologies more valuable in cancer assessment,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[12, 4206, 71, 85, 2930, 505, 954, 4, 270, 359, 401, 3, 632, 1, 12, 20, 5379, 3, 638, 1, 263, 289, 196, 2, 5485, 4, 626, 2285, 225, 1466, 359, 1122, 6, 1474, 4, 24, 881, 2, 673, 344, 63, 25, 151, 28, 3, 419, 944, 4180, 23, 38, 12, 6212, 6614, 2292, 175, 213, 1544, 8, 993, 3317, 1, 1512, 1339, 121, 1339, 2, 752, 3915, 446, 867, 2590, 954, 4, 37576, 4244, 1220, 872, 425, 1484, 1535, 270, 704, 1900, 1799, 872, 495, 2, 2936, 2568, 11, 446, 1510, 5, 3, 345, 1, 46, 954, 23, 3, 147, 24, 2, 25, 1, 7, 5, 12, 1021, 12, 1168, 1234, 119, 37576, 84, 3, 485, 1, 26, 596, 5632, 29, 339, 6, 852, 5, 1121, 2223, 29, 662, 6, 394, 3, 1790, 1, 16333, 2, 9487, 4244, 4, 1435, 12, 32, 1336, 6, 4082, 198, 217, 748, 183, 344, 3, 485, 1, 46, 1092, 6, 8726, 578, 2, 263, 289, 196, 8197, 4244, 292, 96, 93, 5621, 68, 3882, 3, 911, 1, 2, 12815, 2, 3, 451, 1, 1660, 1696, 3191, 954, 4, 425, 47, 1229, 192, 8, 43429, 1312, 6, 704, 84, 1939, 1682, 425, 29, 1736, 1057, 487, 23, 1840, 1038, 704, 92, 16, 2926, 408, 1, 211, 1123, 1214, 246, 748, 2125, 17732, 8190, 2, 835, 1236, 16, 95, 6, 223, 3, 444, 1, 3, 3629, 2, 6, 1426, 1840, 630, 1, 578, 374, 1, 263, 502, 2, 3, 463, 1, 34, 4, 3, 9775, 2, 495, 5, 18, 10190, 203, 6231, 18, 6149, 427, 2522, 71, 85, 204, 6, 1426, 1668, 263, 289, 1374, 380, 76, 425, 1097, 84, 495, 122, 120, 40, 95, 4, 3357, 5, 425, 6, 1463, 30, 6190, 495, 120, 71, 1417, 8, 596, 9, 1386, 57, 17, 32, 7244, 6, 975, 198, 95, 1162, 5, 1382, 2, 219, 1092, 22, 149, 22, 809, 7742, 1323, 263, 289, 2568, 35, 305, 193, 4, 3, 221, 284, 1, 537, 57, 16, 1336, 6, 401, 1512, 12, 284, 954, 4, 270, 636, 2, 4, 748, 183, 1510, 5, 954, 4, 3, 397, 119, 1, 3, 100, 32, 1336, 6, 2378, 270, 2590, 80, 2926, 4, 12, 455]",2458.0,14603539,238
"Cervical cancer chemoprevention, vaccines, and surrogate endpoint biomarkers.",Cancer,Cancer,2003-11-01,"At the Second International Conference on Cervical Cancer, held April 11-14, 2002, experts in cervical cancer prevention, detection, and treatment reviewed the need for more research in chemoprevention, including prophylactic and therapeutic vaccines, immunomodulators, peptides, and surrogate endpoint biomarkers. Investigators and clinicians noted the need for more rigorous Phase I randomized clinical trials, more attention to the risk factors that can affect study results in this patient population, and validation of optical technologies that will provide valuable quantitative information in real time regarding disease regression and progression. They discussed the role of the human papillomavirus (HPV) in cervical cancer development and the importance of developing strategies to suppress HPV persistence and progression. Results in Phase I randomized clinical trials have been disappointing because few have demonstrated statistically significant regression attributable to the agent tested. Researchers recommended using a transgenic mouse model to test and validate new compounds, initiating vaccine and immunomodulator trials, and developing immunologic surrogate endpoint biomarkers.",Journal Article,5925.0,13.0,At the Second International Conference on Cancer held April 11-14 2002 experts in cancer prevention detection and treatment reviewed the need for more research in chemoprevention including prophylactic and therapeutic vaccines immunomodulators peptides and surrogate endpoint biomarkers Investigators and clinicians noted the need for more rigorous Phase I randomized clinical trials more attention to the risk factors that can affect study results in this patient population and validation of optical technologies that will provide valuable quantitative information in real time regarding disease regression and progression They discussed the role of the human papillomavirus HPV in cancer development and the importance of developing strategies to suppress HPV persistence and progression Results in Phase I randomized clinical trials have been disappointing because few have demonstrated statistically significant regression attributable to the agent tested Researchers recommended using a transgenic mouse model to test and validate new compounds initiating vaccine and immunomodulator trials and developing immunologic surrogate endpoint biomarkers,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[28, 3, 419, 944, 4180, 23, 12, 4033, 2292, 175, 213, 1544, 3186, 4, 12, 1070, 638, 2, 24, 446, 3, 594, 9, 80, 389, 4, 2886, 141, 1862, 2, 189, 1842, 13888, 2491, 2, 2592, 1138, 582, 2394, 2, 1490, 1051, 3, 594, 9, 80, 6496, 124, 70, 384, 38, 143, 80, 2111, 6, 3, 43, 130, 17, 122, 1158, 45, 99, 4, 26, 69, 266, 2, 929, 1, 4303, 2590, 17, 303, 377, 2926, 1156, 487, 4, 1589, 98, 666, 34, 320, 2, 91, 491, 1588, 3, 200, 1, 3, 171, 3242, 933, 4, 12, 193, 2, 3, 1187, 1, 931, 422, 6, 3134, 933, 4108, 2, 91, 99, 4, 124, 70, 384, 38, 143, 47, 85, 5964, 408, 1021, 47, 264, 712, 93, 320, 2971, 6, 3, 420, 650, 4211, 793, 75, 8, 2862, 830, 202, 6, 412, 2, 2183, 217, 2411, 2637, 1274, 2, 21196, 143, 2, 931, 3042, 2592, 1138, 582]",1153.0,14603541,253
Expression of EphB4 in head and neck squamous cell carcinoma.,"Ear, nose, & throat journal",Ear Nose Throat J,2003-11-01,"EphB4 is a receptor tyrosine kinase that is expressed on epithelial cells during fetal life. It is also expressed on some venous endothelial cells. We conducted a study of six men with primary squamous cell carcinoma of the head and neck (HNSCC) that had metastasized to the cervical lymph nodes. Our goal was to determine if EphB4 is aberrantly expressed in cases of HNSCC and to determine if there is a qualitative difference between the expression of EphB4 on primary and metastatic tumors and its expression on normal mucosa adjacent to primary tumors. From each patient, we obtained specimens of the primary tumor, the nodal metastasis, and the adjacent normal mucosa, and we performed immunocytochemistry on each. We observed EphB4 expression in all primary and metastatic tumors and no expression in the normal tissue. In each of the six patients, expression was greater in the metastatic tumor than in the primary tumor. We conclude that EphB4 is a novel target in the treatment of HNSCC.",Journal Article,5925.0,19.0,EphB4 is a receptor tyrosine kinase that is expressed on epithelial cells during fetal life It is also expressed on some venous endothelial cells We conducted a study of six men with primary squamous cell carcinoma of the head and HNSCC that had metastasized to the lymph nodes Our goal was to determine if EphB4 is aberrantly expressed in cases of HNSCC and to determine if there is a qualitative difference between the expression of EphB4 on primary and metastatic tumors and its expression on normal mucosa adjacent to primary tumors From each patient we obtained specimens of the primary tumor the nodal metastasis and the adjacent normal mucosa and we performed immunocytochemistry on each We observed EphB4 expression in all primary and metastatic tumors and no expression in the normal tissue In each of the six patients expression was greater in the metastatic tumor than in the primary tumor We conclude that EphB4 is a novel target in the treatment of HNSCC,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4208, 16, 8, 153, 564, 216, 17, 16, 570, 23, 701, 37, 190, 6698, 358, 192, 16, 120, 570, 23, 476, 2167, 845, 37, 21, 426, 8, 45, 1, 437, 325, 5, 86, 691, 31, 134, 1, 3, 718, 2, 1209, 17, 42, 8486, 6, 3, 263, 502, 114, 1326, 10, 6, 223, 492, 4208, 16, 5619, 570, 4, 140, 1, 1209, 2, 6, 223, 492, 125, 16, 8, 3926, 523, 59, 3, 55, 1, 4208, 23, 86, 2, 113, 57, 2, 211, 55, 23, 295, 2713, 2086, 6, 86, 57, 29, 296, 69, 21, 683, 623, 1, 3, 86, 30, 3, 779, 278, 2, 3, 2086, 295, 2713, 2, 21, 173, 13290, 23, 296, 21, 164, 4208, 55, 4, 62, 86, 2, 113, 57, 2, 77, 55, 4, 3, 295, 246, 4, 296, 1, 3, 437, 7, 55, 10, 378, 4, 3, 113, 30, 76, 4, 3, 86, 30, 21, 2060, 17, 4208, 16, 8, 229, 283, 4, 3, 24, 1, 1209]",967.0,14661437,5
Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients.,Surgery,Surgery,2003-12-01,"The surgical management and follow-up strategy in patients with medullary thyroid carcinoma (MTC) remain controversial because of the lack of data on the natural history of these tumors and their patterns of progression. We reviewed the records of all patients who underwent a cervical operation for MTC between 1991 and 2002. Compartment-oriented surgery (COS) was performed to minimize the risk of cervical recurrence. We identified 92 consecutive patients who underwent a cervical operation for MTC: 80 had invasive MTC, and 12 had C-cell hyperplasia after prophylactic thyroidectomy for familial MTC. Ten (13%) of the 80 patients with invasive MTC presented with distant metastases and underwent COS to achieve local-regional control; cervical recurrence developed in none, but three have died of MTC. The remaining 70 patients underwent COS for primary (n=23) or recurrent (n=47) MTC. Disease recurred in 18 (26%) of these 70 patients at a median follow-up of 35 months, with 10 (14%) of the recurrences being cervical. Recurrent disease was associated with a basal calcitonin level of >250 pg/mL in all but four patients, two of whom showed tumor dedifferentiation. In contrast, only 5 (11%) patients without evidence of recurrence had basal calcitonin levels of >250 pg/mL at last follow-up. Complete COS minimizes cervical recurrence. Radiographic evidence of recurrent disease is unlikely when the calcitonin level is < or =250 pg/mL. These data could be used to develop a logical, cost-effective treatment and follow-up strategy for patients with MTC.",Journal Article,5895.0,58.0,The surgical management and follow-up strategy in patients with medullary carcinoma MTC remain controversial because of the lack of data on the natural history of these tumors and their patterns of progression We reviewed the records of all patients who underwent a operation for MTC between 1991 and 2002 Compartment-oriented surgery COS was performed to minimize the risk of recurrence We identified 92 consecutive patients who underwent a operation for MTC 80 had invasive MTC and 12 had C-cell hyperplasia after prophylactic thyroidectomy for familial MTC Ten 13 of the 80 patients with invasive MTC presented with distant metastases and underwent COS to achieve local-regional control recurrence developed in none but three have died of MTC The remaining 70 patients underwent COS for primary n=23 or recurrent n=47 MTC Disease recurred in 18 26 of these 70 patients at a median follow-up of 35 months with 10 14 of the recurrences being Recurrent disease was associated with a basal calcitonin level of 250 pg/mL in all but four patients two of whom showed tumor dedifferentiation In contrast only 5 11 patients without evidence of recurrence had basal calcitonin levels of 250 pg/mL at last follow-up Complete COS minimizes recurrence Radiographic evidence of recurrent disease is unlikely when the calcitonin level is or =250 pg/mL These data could be used to develop a logical cost-effective treatment and follow-up strategy for patients with MTC,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[3, 221, 284, 2, 166, 126, 692, 4, 7, 5, 4564, 134, 3959, 918, 2010, 408, 1, 3, 926, 1, 74, 23, 3, 1504, 532, 1, 46, 57, 2, 136, 764, 1, 91, 21, 446, 3, 1064, 1, 62, 7, 54, 208, 8, 2589, 9, 3959, 59, 3372, 2, 1544, 3616, 8095, 152, 18323, 10, 173, 6, 3241, 3, 43, 1, 146, 21, 108, 937, 935, 7, 54, 208, 8, 2589, 9, 3959, 493, 42, 416, 3959, 2, 133, 42, 256, 31, 3176, 50, 1862, 5949, 9, 2200, 3959, 1618, 233, 1, 3, 493, 7, 5, 416, 3959, 917, 5, 626, 196, 2, 208, 18323, 6, 1359, 293, 951, 182, 146, 276, 4, 1292, 84, 169, 47, 1016, 1, 3959, 3, 1844, 431, 7, 208, 18323, 9, 86, 78, 382, 15, 387, 78, 662, 3959, 34, 3363, 4, 203, 432, 1, 46, 431, 7, 28, 8, 52, 166, 126, 1, 465, 53, 5, 79, 213, 1, 3, 1593, 486, 387, 34, 10, 41, 5, 8, 2135, 11314, 301, 1, 2039, 3234, 542, 4, 62, 84, 294, 7, 100, 1, 953, 224, 30, 9496, 4, 748, 158, 33, 175, 7, 187, 241, 1, 146, 42, 2135, 11314, 148, 1, 2039, 3234, 542, 28, 1060, 166, 126, 236, 18323, 14527, 146, 1580, 241, 1, 387, 34, 16, 3568, 198, 3, 11314, 301, 16, 15, 2039, 3234, 542, 46, 74, 359, 40, 95, 6, 690, 8, 10405, 835, 323, 24, 2, 166, 126, 692, 9, 7, 5, 3959]",1455.0,14668720,551
Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer.,Surgery,Surgery,2003-12-01,"Cervical recurrence occurs in up to 30% of patients with differentiated thyroid carcinoma. We retrospectively compared preoperative transcutaneous ultrasonography and physical examination (PE) results in the detection of local-regional metastases (lymph node and soft tissue) in patients with thyroid cancer. Data were collected retrospectively from the medical records of patients with thyroid carcinoma who underwent preoperative ultrasonography. Patients were divided into 3 groups: group 1, those undergoing primary thyroid/neck surgery; group 2, those undergoing reoperation for persistent disease; and group 3, those undergoing reoperation for recurrent thyroid carcinoma. For each group, we recorded the frequencies with which ultrasonography detected disease in a neck compartment (central or lateral) that was normal on PE. Two hundred twelve patients underwent operation for primary, persistent, or recurrent papillary (n=130), medullary (n=61), or follicular/Hrthle cell (n=21) carcinoma. Ultrasonography detected additional sites of metastatic disease not appreciated on PE in 21 (20%) of 107 group 1 patients, 9 (32%) of 28 group 2 patients, and 52 (68%) of 77 group 3 patients. The surgical procedure performed was altered by the information obtained from preoperative ultrasonography in 82 (39%) of the 212 patients. Of the 107 group 1 patients, cervical recurrence has been detected in only 6 (6%) at a median follow-up of 36 months, in spite of 67 (63%) having tumors larger than 2 cm or lymph node metastases. Preoperative high-quality ultrasonography detected lymph node or soft-tissue metastases in neck compartments believed to be uninvolved by PE in 39% of patients. Ultrasound findings altered the operative procedure in these patients, facilitating complete resection of disease and potentially minimizing local-regional recurrence.",Comparative Study,5895.0,342.0,recurrence occurs in up to 30 of patients with differentiated carcinoma We retrospectively compared preoperative transcutaneous ultrasonography and physical examination PE results in the detection of local-regional metastases lymph node and soft tissue in patients with cancer Data were collected retrospectively from the medical records of patients with carcinoma who underwent preoperative ultrasonography Patients were divided into 3 groups group 1 those undergoing primary thyroid/neck surgery group 2 those undergoing reoperation for persistent disease and group 3 those undergoing reoperation for recurrent carcinoma For each group we recorded the frequencies with which ultrasonography detected disease in a compartment central or lateral that was normal on PE Two hundred twelve patients underwent operation for primary persistent or recurrent papillary n=130 medullary n=61 or follicular/Hrthle cell n=21 carcinoma Ultrasonography detected additional sites of metastatic disease not appreciated on PE in 21 20 of 107 group 1 patients 9 32 of 28 group 2 patients and 52 68 of 77 group 3 patients The surgical procedure performed was altered by the information obtained from preoperative ultrasonography in 82 39 of the 212 patients Of the 107 group 1 patients recurrence has been detected in only 6 6 at a median follow-up of 36 months in spite of 67 63 having tumors larger than 2 cm or lymph node metastases Preoperative high-quality ultrasonography detected lymph node or soft-tissue metastases in compartments believed to be uninvolved by PE in 39 of patients Ultrasound findings altered the operative procedure in these patients facilitating complete resection of disease and potentially minimizing local-regional recurrence,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[146, 1780, 4, 126, 6, 201, 1, 7, 5, 1442, 134, 21, 894, 72, 498, 33565, 4244, 2, 900, 1385, 4878, 99, 4, 3, 638, 1, 293, 951, 196, 263, 289, 2, 1214, 246, 4, 7, 5, 12, 74, 11, 786, 894, 29, 3, 484, 1064, 1, 7, 5, 134, 54, 208, 498, 4244, 7, 11, 2176, 237, 27, 271, 87, 14, 135, 479, 86, 11260, 4606, 152, 87, 18, 135, 479, 5077, 9, 1882, 34, 2, 87, 27, 135, 479, 5077, 9, 387, 134, 9, 296, 87, 21, 1872, 3, 2722, 5, 92, 4244, 530, 34, 4, 8, 3616, 854, 15, 3855, 17, 10, 295, 23, 4878, 100, 1128, 2544, 7, 208, 2589, 9, 86, 1882, 15, 387, 1796, 78, 3431, 4564, 78, 713, 15, 1974, 13545, 31, 78, 239, 134, 4244, 530, 402, 633, 1, 113, 34, 44, 7292, 23, 4878, 4, 239, 179, 1, 3650, 87, 14, 7, 83, 531, 1, 339, 87, 18, 7, 2, 653, 806, 1, 849, 87, 27, 7, 3, 221, 1299, 173, 10, 1495, 20, 3, 487, 683, 29, 498, 4244, 4, 878, 587, 1, 3, 6586, 7, 1, 3, 3650, 87, 14, 7, 146, 71, 85, 530, 4, 158, 49, 49, 28, 8, 52, 166, 126, 1, 511, 53, 4, 9018, 1, 598, 676, 1041, 57, 1077, 76, 18, 494, 15, 263, 289, 196, 498, 64, 372, 4244, 530, 263, 289, 15, 1214, 246, 196, 4, 6473, 3979, 6, 40, 7377, 20, 4878, 4, 587, 1, 7, 1945, 272, 1495, 3, 1208, 1299, 4, 46, 7, 5379, 236, 170, 1, 34, 2, 751, 4501, 293, 951, 146]",1738.0,14668727,304
Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma.,Gynecologic oncology,Gynecol. Oncol.,2003-12-01,"The purpose of this study was to identify poor prognostic factors of low-risk stage IB1 cervical adenocarcinoma . All women diagnosed with stage IB1 cervical adenocarcinoma between 1982 and 2002 were identified at our three institutions. Data were extracted from medical records. Patients were retrospectively assigned to a low- or intermediate/high-risk cohort based on the surgical-pathologic eligibility criteria of two randomized controlled trials of adjuvant therapy in early stage cervical cancer, Gynecologic Oncology Group protocols 92 and 109. Multivariate analysis was performed. Two hundred thirty women diagnosed with stage IB1 cervical adenocarcinoma had an overall 5-year survival of 89%. Adenosquamous cell type (P < 0.01) was the only independent risk factor of disease recurrence in the low-risk group (n = 178). The 5-year disease-free survival for low-risk adenosquamous patients was 79%, compared to 96% for other histologic subtypes (P < 0.01). Low-risk case subjects developed fewer disease recurrences than those in the intermediate/high-risk (n = 52) category (7% vs 46%; P < 0.01). The 5-year disease-free survival for intermediate/high-risk patients was 51% and no additional risk factors were identified. Adenosquamous histology is predictive of disease recurrence and decreased survival in low-risk stage IB1 cervical adenocarcinoma. This risk factor should be considered in future clinical trials of adjuvant therapy.",Journal Article,5895.0,36.0,The purpose of this study was to identify poor prognostic factors of low-risk stage IB1 adenocarcinoma All women diagnosed with stage IB1 adenocarcinoma between 1982 and 2002 were identified at our three institutions Data were extracted from medical records Patients were retrospectively assigned to a low- or intermediate/high-risk cohort based on the surgical-pathologic eligibility criteria of two randomized controlled trials of adjuvant therapy in early stage cancer Gynecologic Oncology Group protocols 92 and 109 Multivariate analysis was performed Two hundred thirty women diagnosed with stage IB1 adenocarcinoma had an overall 5-year survival of 89 Adenosquamous cell type P 0.01 was the only independent risk factor of disease recurrence in the low-risk group n 178 The 5-year disease-free survival for low-risk adenosquamous patients was 79 compared to 96 for other histologic subtypes P 0.01 Low-risk case subjects developed fewer disease recurrences than those in the intermediate/high-risk n 52 category 7 vs 46 P 0.01 The 5-year disease-free survival for intermediate/high-risk patients was 51 and no additional risk factors were identified Adenosquamous histology is predictive of disease recurrence and decreased survival in low-risk stage IB1 adenocarcinoma This risk factor should be considered in future clinical trials of adjuvant therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 255, 334, 177, 130, 1, 154, 43, 82, 8111, 449, 62, 117, 265, 5, 82, 8111, 449, 59, 6652, 2, 1544, 11, 108, 28, 114, 169, 1764, 74, 11, 2484, 29, 484, 1064, 7, 11, 894, 896, 6, 8, 154, 15, 919, 64, 43, 180, 90, 23, 3, 221, 510, 2317, 371, 1, 100, 384, 1149, 143, 1, 249, 36, 4, 191, 82, 12, 1512, 413, 87, 2189, 937, 2, 3486, 331, 65, 10, 173, 100, 1128, 977, 117, 265, 5, 82, 8111, 449, 42, 35, 63, 33, 111, 25, 1, 887, 8067, 31, 267, 19, 13, 355, 10, 3, 158, 306, 43, 161, 1, 34, 146, 4, 3, 154, 43, 87, 78, 7046, 3, 33, 111, 34, 115, 25, 9, 154, 43, 8067, 7, 10, 842, 72, 6, 921, 9, 127, 884, 814, 19, 13, 355, 154, 43, 473, 976, 276, 1497, 34, 1593, 76, 135, 4, 3, 919, 64, 43, 78, 653, 2169, 67, 105, 641, 19, 13, 355, 3, 33, 111, 34, 115, 25, 9, 919, 64, 43, 7, 10, 725, 2, 77, 402, 43, 130, 11, 108, 8067, 784, 16, 464, 1, 34, 146, 2, 340, 25, 4, 154, 43, 82, 8111, 449, 26, 43, 161, 257, 40, 515, 4, 508, 38, 143, 1, 249, 36]",1359.0,14675676,567
Management of atypical and low-grade cervical cytology.,"Cancer journal (Sudbury, Mass.)",Cancer J,,"The finding of atypical and low-grade cervical cytology on routine Papanicolaou test is considered problematic for gynecologists and pathologists. The interpretation and management of these cases can be difficult when Papanicolaou test results fall into the Bethesda 2001 categories of atypical squamous cells, atypical squamous cells--cannot rule out high-grade, atypical glandular cells, or low-grade squamous intraepithelial lesion. Although liquid-based Papanicolaou tests may have resulted in some improvement in detection, a large amount of variability in cytologic interpretations continues to exist. The recent approval of concurrent use of high-risk human papillomavirus DNA testing with cytology in the screening of women for cervical neoplasia adds a new dilemma to patient management: What should we do with women who are positive for high-risk human papillomavirus DNA but have negative cervical cytologic results?",Journal Article,,2.0,The finding of atypical and low-grade cytology on routine Papanicolaou test is considered problematic for gynecologists and pathologists The interpretation and management of these cases can be difficult when Papanicolaou test results fall into the Bethesda 2001 categories of atypical squamous cells atypical squamous cells -- can not rule out high-grade atypical glandular cells or low-grade squamous intraepithelial lesion Although liquid-based Papanicolaou tests may have resulted in some improvement in detection a large amount of variability in cytologic interpretations continues to exist The recent approval of concurrent use of high-risk human papillomavirus DNA testing with cytology in the screening of women for neoplasia adds a new dilemma to patient management What should we do with women who are positive for high-risk human papillomavirus DNA but have negative cytologic results,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1567, 1, 1973, 2, 154, 88, 2045, 23, 1311, 10416, 412, 16, 515, 6594, 9, 14854, 2, 3354, 3, 3037, 2, 284, 1, 46, 140, 122, 40, 1740, 198, 10416, 412, 99, 6712, 237, 3, 8222, 1758, 1996, 1, 1973, 691, 37, 1973, 691, 37, 122, 44, 5340, 1205, 64, 88, 1973, 6170, 37, 15, 154, 88, 691, 4153, 1180, 242, 3165, 90, 10416, 895, 68, 47, 627, 4, 476, 767, 4, 638, 8, 375, 3108, 1, 1982, 4, 4195, 11158, 2274, 6, 1923, 3, 435, 1814, 1, 750, 119, 1, 64, 43, 171, 3242, 261, 471, 5, 2045, 4, 3, 453, 1, 117, 9, 2298, 6659, 8, 217, 11554, 6, 69, 284, 2067, 257, 21, 1022, 5, 117, 54, 32, 109, 9, 64, 43, 171, 3242, 261, 84, 47, 199, 4195, 99]",894.0,14690312,402
Impact of intraoperative parathyroid hormone monitoring on the prediction of multiglandular parathyroid disease.,World journal of surgery,World J Surg,2004-01-08,"Optimal interpretation of the results of intraoperative parathyroid hormone (IOPTH) monitoring during neck exploration for primary hyperparathyroidism (pHPT) is still controversial. The reliability of the ""50% rule"" in multiglandular disease (MGD) is often disputed, mostly because of competing pathophysiologic paradigms. The aim of this study was to ascertain and corroborate the ability of IOPTH monitoring to detect MGD in a practice, combining conventional and alternative parathyroidectomy techniques. This is a retrospective single institution analysis of 69 consecutive patients undergoing cervical exploration for pHPT by various approaches. The IOPTH measurements were performed after induction of anesthesia but prior to skin incision and 10 minutes after excision of the first visualized enlarged parathyroid gland. In this series, 55 patients (80%) had single adenomas, and 14 patients (20%) had MGD. In 8 of the 14 patients with MGD, IOPTH levels were obtained sequentially after removal of every enlarged gland. Of these 8 patients, 6 (75%) had a false-positive decrease (decrease below 50% of baseline value in presence of another enlarged gland) failing to predict the presence of a second enlarged gland. In 2 cases IOPTH monitoring provided a true-negative result, correctly predicting MGD. If MGD is defined by gross morphologic criteria, IOPTH monitoring fails to predict the presence of MGD reliably. However, if MGD is defined by functional criteria, the course of these patients does not seem significantly affected. The importance of these findings must be further investigated, especially with regard to the outcome of minimally invasive parathyroid procedures.",Journal Article,5857.0,68.0,Optimal interpretation of the results of intraoperative hormone IOPTH monitoring during exploration for primary hyperparathyroidism pHPT is still controversial The reliability of the `` 50 rule '' in multiglandular disease MGD is often disputed mostly because of competing pathophysiologic paradigms The aim of this study was to ascertain and corroborate the ability of IOPTH monitoring to detect MGD in a practice combining conventional and alternative parathyroidectomy techniques This is a retrospective single institution analysis of 69 consecutive patients undergoing exploration for pHPT by various approaches The IOPTH measurements were performed after induction of anesthesia but prior to incision and 10 minutes after excision of the first visualized enlarged gland In this series 55 patients 80 had single adenomas and 14 patients 20 had MGD In 8 of the 14 patients with MGD IOPTH levels were obtained sequentially after removal of every enlarged gland Of these 8 patients 6 75 had a false-positive decrease decrease below 50 of baseline value in presence of another enlarged gland failing to predict the presence of a second enlarged gland In 2 cases IOPTH monitoring provided a true-negative result correctly predicting MGD If MGD is defined by gross morphologic criteria IOPTH monitoring fails to predict the presence of MGD reliably However if MGD is defined by functional criteria the course of these patients does not seem significantly affected The importance of these findings must be further investigated especially with regard to the outcome of minimally invasive procedures,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,"[665, 3037, 1, 3, 99, 1, 1720, 785, 28171, 1315, 190, 3370, 9, 86, 9630, 19512, 16, 1234, 2010, 3, 4217, 1, 3, 212, 5340, 522, 4, 33318, 34, 11809, 16, 629, 23085, 2754, 408, 1, 2573, 11575, 4887, 3, 1130, 1, 26, 45, 10, 6, 6040, 2, 14855, 3, 801, 1, 28171, 1315, 6, 1426, 11809, 4, 8, 758, 1525, 809, 2, 1091, 23116, 1092, 26, 16, 8, 459, 226, 731, 65, 1, 790, 935, 7, 479, 3370, 9, 19512, 20, 747, 611, 3, 28171, 1685, 11, 173, 50, 504, 1, 6433, 84, 324, 6, 7538, 2, 79, 2511, 50, 1366, 1, 3, 157, 6326, 7547, 2326, 4, 26, 988, 614, 7, 493, 42, 226, 2751, 2, 213, 7, 179, 42, 11809, 4, 66, 1, 3, 213, 7, 5, 11809, 28171, 148, 11, 683, 5455, 50, 2829, 1, 454, 7547, 2326, 1, 46, 66, 7, 49, 481, 42, 8, 2133, 109, 775, 775, 2736, 212, 1, 330, 549, 4, 463, 1, 1809, 7547, 2326, 7928, 6, 678, 3, 463, 1, 8, 419, 7547, 2326, 4, 18, 140, 28171, 1315, 1052, 8, 2501, 199, 757, 4911, 1434, 11809, 492, 11809, 16, 395, 20, 1789, 2815, 371, 28171, 1315, 7688, 6, 678, 3, 463, 1, 11809, 4092, 137, 492, 11809, 16, 395, 20, 583, 371, 3, 906, 1, 46, 7, 1097, 44, 3233, 97, 1424, 3, 1187, 1, 46, 272, 1642, 40, 195, 565, 1093, 5, 2539, 6, 3, 228, 1, 2144, 416, 1369]",1594.0,14708048,204
Rapid involution and mobility of carcinoma of the cervix.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2004-02-01,"To quantitatively describe the involution and mobility of carcinoma of the cervix while under treatment with chemoradiotherapy (both with external beam radiation [EBRT] and high-dose-rate [HDR] intracavitary therapy). These data have implications for conformal or intensity modulated radiation therapy boost to the cervix. Seventeen patients underwent HDR brachytherapy boost to the cervix and were evaluated by repeat clinical examinations. In most cases, 5 weekly HDR brachytherapy insertions were performed after approximately 2 to 3 weeks of the initiation of EBRT. Sequential clinical tumor sizes were recorded in the chart for each patient under treatment. Linear regression analyses were performed to analyze tumor size as a function of total dose of external beam plus brachytherapy and number of elapsed days during the treatment course. In addition, the mobility of the cervix was documented by placement of a uterine sleeve for HDR brachytherapy before the initiation of therapy, and changes in sleeve position were identified on portal films relative to the midline of the pubic symphysis, in three dimensions. The anatomic position of the cervix was also identified at the time of simulation for HDR brachytherapy. Seventeen patients were identified and selected to receive HDR brachytherapy at our institution. Sixteen of the 17 patients received concurrent chemotherapy. The median dose at which tumor was no longer clinically evident was 61.5 Gy (95% confidence interval [CI]: 50.7-72.3 Gy) by linear regression analysis. This indicates that the median dose to achieve a 50% reduction in tumor size is approximately 30.8 Gy. Similarly, the median number of elapsed days for a complete response was 42 days (95% CI: 34-50 elapsed days). This indicates that it takes 21 days to achieve a 50% clinical complete response for patients undergoing concurrent cisplatin-based chemoradiotherapy and HDR brachytherapy. In addition, the mobility of the cervix during EBRT was noted by serial measurements of the location of a metallic ring in the uterine sleeve, as seen on port films. The median and maximum ranges for change in the position of the cervix in the lateral (x), superior/inferior (y), and anterior/posterior (z) planes were 10, 8, and 16 mm and 24, 36, and 23 mm, respectively. Also, 85 brachytherapy procedures were performed, and the positions of the cervix on 170 orthogonal films were evaluated. The median and maximum ranges for the position of the cervix at the time of HDR brachytherapy in the lateral (x), superior/inferior (y), and anterior/posterior (z) planes were 5, 12, and 10 mm and 11, 25, and 32 mm, respectively. Carcinoma of the cervix involutes rapidly with EBRT, concurrent cisplatin-based chemotherapy, and HDR brachytherapy. The time for 50% tumor regression was calculated to be 21 days and occurs after 30.8 Gy. In addition, uterine sleeve placement allowed us to document the median and maximum ranges of cervical mobility during the treatment course of EBRT to be 8-16 mm and 23-36 mm, and at the time of HDR brachytherapy to be 5-12 mm and 11-32 mm, respectively. These data indicate that the cervix gross tumor volume changes rapidly in a systematic fashion during chemoradiotherapy and, together with the mobility of the cervix, urge caution in nonbrachytherapy boost planning.",Journal Article,5833.0,60.0,To quantitatively describe the involution and mobility of carcinoma of the cervix while under treatment with chemoradiotherapy both with external beam radiation EBRT and high-dose-rate HDR intracavitary therapy These data have implications for conformal or intensity modulated radiation therapy boost to the cervix Seventeen patients underwent HDR brachytherapy boost to the cervix and were evaluated by repeat clinical examinations In most cases 5 weekly HDR brachytherapy insertions were performed after approximately 2 to 3 weeks of the initiation of EBRT Sequential clinical tumor sizes were recorded in the chart for each patient under treatment Linear regression analyses were performed to analyze tumor size as a function of total dose of external beam plus brachytherapy and number of elapsed days during the treatment course In addition the mobility of the cervix was documented by placement of a sleeve for HDR brachytherapy before the initiation of therapy and changes in sleeve position were identified on portal films relative to the midline of the pubic symphysis in three dimensions The anatomic position of the cervix was also identified at the time of simulation for HDR brachytherapy Seventeen patients were identified and selected to receive HDR brachytherapy at our institution Sixteen of the 17 patients received concurrent chemotherapy The median dose at which tumor was no longer clinically evident was 61.5 Gy 95 confidence interval CI 50.7-72.3 Gy by linear regression analysis This indicates that the median dose to achieve a 50 reduction in tumor size is approximately 30.8 Gy Similarly the median number of elapsed days for a complete response was 42 days 95 CI 34-50 elapsed days This indicates that it takes 21 days to achieve a 50 clinical complete response for patients undergoing concurrent cisplatin-based chemoradiotherapy and HDR brachytherapy In addition the mobility of the cervix during EBRT was noted by serial measurements of the location of a metallic ring in the sleeve as seen on port films The median and maximum ranges for change in the position of the cervix in the lateral x superior/inferior y and anterior/posterior z planes were 10 8 and 16 mm and 24 36 and 23 mm respectively Also 85 brachytherapy procedures were performed and the positions of the cervix on 170 orthogonal films were evaluated The median and maximum ranges for the position of the cervix at the time of HDR brachytherapy in the lateral x superior/inferior y and anterior/posterior z planes were 5 12 and 10 mm and 11 25 and 32 mm respectively Carcinoma of the cervix involutes rapidly with EBRT concurrent cisplatin-based chemotherapy and HDR brachytherapy The time for 50 tumor regression was calculated to be 21 days and occurs after 30.8 Gy In addition sleeve placement allowed us to document the median and maximum ranges of mobility during the treatment course of EBRT to be 8-16 mm and 23-36 mm and at the time of HDR brachytherapy to be 5-12 mm and 11-32 mm respectively These data indicate that the cervix gross tumor volume changes rapidly in a systematic fashion during chemoradiotherapy and together with the mobility of the cervix urge caution in nonbrachytherapy boost planning,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 5889, 897, 3, 6658, 2, 5717, 1, 134, 1, 3, 3629, 369, 669, 24, 5, 1464, 110, 5, 1455, 1345, 121, 1883, 2, 64, 61, 116, 5309, 9122, 36, 46, 74, 47, 1268, 9, 2972, 15, 837, 1757, 121, 36, 2569, 6, 3, 3629, 3591, 7, 208, 5309, 1536, 2569, 6, 3, 3629, 2, 11, 194, 20, 2334, 38, 4209, 4, 96, 140, 33, 709, 5309, 1536, 6315, 11, 173, 50, 705, 18, 6, 27, 244, 1, 3, 1118, 1, 1883, 1787, 38, 30, 4131, 11, 1872, 4, 3, 2937, 9, 296, 69, 669, 24, 1646, 320, 318, 11, 173, 6, 1992, 30, 444, 22, 8, 343, 1, 181, 61, 1, 1455, 1345, 349, 1536, 2, 207, 1, 10670, 162, 190, 3, 24, 906, 4, 352, 3, 5717, 1, 3, 3629, 10, 1405, 20, 2613, 1, 8, 14536, 9, 5309, 1536, 348, 3, 1118, 1, 36, 2, 400, 4, 14536, 3559, 11, 108, 23, 3307, 12989, 580, 6, 3, 8677, 1, 3, 24676, 30540, 4, 169, 6190, 3, 2745, 3559, 1, 3, 3629, 10, 120, 108, 28, 3, 98, 1, 4026, 9, 5309, 1536, 3591, 7, 11, 108, 2, 715, 6, 560, 5309, 1536, 28, 114, 731, 3228, 1, 3, 269, 7, 103, 750, 56, 3, 52, 61, 28, 92, 30, 10, 77, 589, 505, 2853, 10, 713, 33, 381, 48, 307, 268, 58, 212, 67, 720, 27, 381, 20, 1646, 320, 65, 26, 2640, 17, 3, 52, 61, 6, 1359, 8, 212, 628, 4, 30, 444, 16, 705, 201, 66, 381, 1813, 3, 52, 207, 1, 10670, 162, 9, 8, 236, 51, 10, 595, 162, 48, 58, 562, 212, 10670, 162, 26, 2640, 17, 192, 8512, 239, 162, 6, 1359, 8, 212, 38, 236, 51, 9, 7, 479, 750, 540, 90, 1464, 2, 5309, 1536, 4, 352, 3, 5717, 1, 3, 3629, 190, 1883, 10, 1051, 20, 2108, 1685, 1, 3, 1147, 1, 8, 18950, 4091, 4, 3, 14536, 22, 527, 23, 3083, 12989, 3, 52, 2, 689, 5632, 9, 707, 4, 3, 3559, 1, 3, 3629, 4, 3, 3855, 1006, 1123, 1663, 2055, 2, 2882, 3028, 3905, 15959, 11, 79, 66, 2, 245, 321, 2, 259, 511, 2, 382, 321, 106, 120, 772, 1536, 1369, 11, 173, 2, 3, 7134, 1, 3, 3629, 23, 5248, 9413, 12989, 11, 194, 3, 52, 2, 689, 5632, 9, 3, 3559, 1, 3, 3629, 28, 3, 98, 1, 5309, 1536, 4, 3, 3855, 1006, 1123, 1663, 2055, 2, 2882, 3028, 3905, 15959, 11, 33, 133, 2, 79, 321, 2, 175, 243, 2, 531, 321, 106, 134, 1, 3, 3629, 53979, 1755, 5, 1883, 750, 540, 90, 56, 2, 5309, 1536, 3, 98, 9, 212, 30, 320, 10, 981, 6, 40, 239, 162, 2, 1780, 50, 201, 66, 381, 4, 352, 14536, 2613, 2313, 843, 6, 4753, 3, 52, 2, 689, 5632, 1, 5717, 190, 3, 24, 906, 1, 1883, 6, 40, 66, 245, 321, 2, 382, 511, 321, 2, 28, 3, 98, 1, 5309, 1536, 6, 40, 33, 133, 321, 2, 175, 531, 321, 106, 46, 74, 1008, 17, 3, 3629, 1789, 30, 433, 400, 1755, 4, 8, 1556, 3240, 190, 1464, 2, 1162, 5, 3, 5717, 1, 3, 3629, 24677, 5526, 4, 53980, 2569, 1349]",3210.0,14751536,595
Radiotherapy for cutaneous malignant melanoma: rationale and indications.,"Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2004-01-01,"The use of radiation as adjuvant therapy for patients with cutaneous malignant melanoma has been hindered by the unsubstantiated belief that melanoma cells are radioresistant. An abundance of literature has now demonstrated that locoregional relapse of melanoma is common after surgery alone when certain clinicopathologic features are present. Features associated with a high risk of primary tumor recurrence include desmoplastic subtype, positive microscopic margins, recurrent disease, and thick primary lesions with ulceration or statellitosis. Features associated with a high risk of nodal relapse include extracapsular extension, involvement of four or more lymph nodes, lymph nodes measuring at least 3 cm, cervical lymph node location, and recurrent disease. Numerous studies support the efficacy of adjuvant irradiation in these clinical situations. Although data in the literature remain sparse, evidence also indicates that elective irradiation is effective in eradicating subclinical nodal metastases after removal of the primary melanoma. Consequently, there may be an opportunity to integrate radiotherapy into the multimodality treatment of patients at high risk of subclinical nodal disease, particularly those with an involved sentinel lymph node. Such patients are known to have a low rate of additional lymph node involvement, and thus in this group, a short course of radiotherapy may be an adequate substitute for regional lymph node dissection. This will be the topic of future research.",Journal Article,5864.0,52.0,The use of radiation as adjuvant therapy for patients with cutaneous malignant has been hindered by the unsubstantiated belief that cells are radioresistant An abundance of literature has now demonstrated that locoregional relapse of is common after surgery alone when certain clinicopathologic features are present Features associated with a high risk of primary tumor recurrence include desmoplastic subtype positive microscopic margins recurrent disease and thick primary lesions with ulceration or statellitosis Features associated with a high risk of nodal relapse include extracapsular extension involvement of four or more lymph nodes lymph nodes measuring at least 3 cm lymph node location and recurrent disease Numerous studies support the efficacy of adjuvant irradiation in these clinical situations Although data in the literature remain sparse evidence also indicates that elective irradiation is effective in eradicating subclinical nodal metastases after removal of the primary Consequently there may be an opportunity to integrate radiotherapy into the multimodality treatment of patients at high risk of subclinical nodal disease particularly those with an involved sentinel lymph node Such patients are known to have a low rate of additional lymph node involvement and thus in this group a short course of radiotherapy may be an adequate substitute for regional lymph node dissection This will be the topic of future research,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 119, 1, 121, 22, 249, 36, 9, 7, 5, 1486, 393, 71, 85, 9981, 20, 3, 33608, 8862, 17, 37, 32, 7092, 35, 4778, 1, 789, 71, 1134, 264, 17, 1325, 429, 1, 16, 186, 50, 152, 279, 198, 1840, 1399, 404, 32, 364, 404, 41, 5, 8, 64, 43, 1, 86, 30, 146, 643, 5922, 875, 109, 2984, 1012, 387, 34, 2, 8494, 86, 406, 5, 5158, 15, 53998, 404, 41, 5, 8, 64, 43, 1, 779, 429, 643, 5607, 2401, 799, 1, 294, 15, 80, 263, 502, 263, 502, 2978, 28, 506, 27, 494, 263, 289, 1147, 2, 387, 34, 2331, 94, 538, 3, 209, 1, 249, 1104, 4, 46, 38, 5990, 242, 74, 4, 3, 789, 918, 7425, 241, 120, 2640, 17, 4700, 1104, 16, 323, 4, 11001, 7403, 779, 196, 50, 2829, 1, 3, 86, 3244, 125, 68, 40, 35, 2666, 6, 5671, 310, 237, 3, 2425, 24, 1, 7, 28, 64, 43, 1, 7403, 779, 34, 823, 135, 5, 35, 646, 1323, 263, 289, 225, 7, 32, 440, 6, 47, 8, 154, 116, 1, 402, 263, 289, 799, 2, 631, 4, 26, 87, 8, 978, 906, 1, 310, 68, 40, 35, 1658, 12577, 9, 951, 263, 289, 1161, 26, 303, 40, 3, 5463, 1, 508, 389]",1443.0,14768409,172
"Malignant mixed Mllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome.","International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2004-03-01,"To determine the survival outcomes, prognostic factors, and patterns of failure in patients with malignant mixed Mllerian tumor (MMMT) of the uterus. Between 1954 and 1998, 300 patients with clinical Stage I-III MMMT of the uterus were treated with curative intent at The University of Texas M. D. Anderson Cancer Center. Their hospital records were reviewed to obtain patient and tumor characteristics; details of surgery, radiotherapy (RT), and chemotherapy; and long-term outcome. Surviving patients were followed for a median of 109 months (range 15-138). Survival rates were calculated using the Kaplan-Meier method, with differences assessed by log-rank tests. Of the 300 patients, 113 (38%) were treated with surgery alone, 160 (53%) with surgery plus adjuvant EBRT or ICRT, and 27 (9%) with RT alone. Forty-eight patients received adjuvant chemotherapy. At 5 years, the overall rates of survival and cause-specific survival were 31% and 33%, respectively. Women who were postmenopausal or had a history of prior pelvic RT, pain at presentation, clinical Stage II-III disease, uterine enlargement (>/=12 weeks), or an abnormal Papanicolaou smear finding had a significantly poorer prognosis than the other patients in the series. Of the 273 patients who underwent surgery, those who had positive abdominal washings, uterine length >10 cm, or extrauterine spread of disease to the cervix, adnexa, or peritoneum had a significantly worse prognosis than the other patients. Factors found on multivariate analysis to have an independent adverse influence on cause-specific survival included postmenopausal status (p = 0.0007, relative risk [RR] 3.3), uterine length >10 cm (p = 0.0001, RR 2.2), cervical involvement (p = 0.002, RR 1.8), and peritoneal involvement (p = 0.0001, RR 4.3). At 5 years, the rates of pelvic and distant disease recurrence for the entire group of 300 patients were 38% and 57%, respectively. The most common site of distant recurrence was the peritoneal cavity. Patients treated with pelvic RT had a lower rate of pelvic recurrence than patients treated with surgery alone (28% vs. 48%, p = 0.0002), but the overall survival rates (36% vs. 27%, p = 0.10) and distant metastasis rates (57% vs. 54%, p = 0.96) were not significantly different. However, patients treated with pelvic RT had a longer mean time to any distant relapse (17.3 vs. 7.0 months, p = 0.001) than patients treated with surgery alone. The use of adjuvant chemotherapy did not correlate with the survival rate or rate of distant metastasis. Adjuvant pelvic RT decreased the risk of pelvic recurrence and may delay the appearance of distant metastases after hysterectomy for MMMT. However, the survival rates remain poor because of a high rate of distant recurrence. As more effective systemic chemotherapy is developed to control microscopic distant disease, the role of RT in controlling locoregional disease in the pelvis and abdomen may become more important. Future research should consider programs that integrate surgery, RT, and chemotherapy to maximize the probability of cure.",Journal Article,5804.0,161.0,To determine the survival outcomes prognostic factors and patterns of failure in patients with malignant mixed Mllerian tumor MMMT of the Between 1954 and 1998 300 patients with clinical Stage I-III MMMT of the were treated with curative intent at The University of Texas M. D. Anderson Cancer Center Their hospital records were reviewed to obtain patient and tumor characteristics details of surgery radiotherapy RT and chemotherapy and long-term outcome Surviving patients were followed for a median of 109 months range 15-138 Survival rates were calculated using the Kaplan-Meier method with differences assessed by log-rank tests Of the 300 patients 113 38 were treated with surgery alone 160 53 with surgery plus adjuvant EBRT or ICRT and 27 9 with RT alone Forty-eight patients received adjuvant chemotherapy At 5 years the overall rates of survival and cause-specific survival were 31 and 33 respectively Women who were postmenopausal or had a history of prior pelvic RT pain at presentation clinical Stage II-III disease enlargement /=12 weeks or an abnormal Papanicolaou smear finding had a significantly poorer prognosis than the other patients in the series Of the 273 patients who underwent surgery those who had positive abdominal washings length 10 cm or extrauterine spread of disease to the cervix adnexa or peritoneum had a significantly worse prognosis than the other patients Factors found on multivariate analysis to have an independent adverse influence on cause-specific survival included postmenopausal status p 0.0007 relative risk RR 3.3 length 10 cm p 0.0001 RR 2.2 involvement p 0.002 RR 1.8 and peritoneal involvement p 0.0001 RR 4.3 At 5 years the rates of pelvic and distant disease recurrence for the entire group of 300 patients were 38 and 57 respectively The most common site of distant recurrence was the peritoneal cavity Patients treated with pelvic RT had a lower rate of pelvic recurrence than patients treated with surgery alone 28 vs. 48 p 0.0002 but the overall survival rates 36 vs. 27 p 0.10 and distant metastasis rates 57 vs. 54 p 0.96 were not significantly different However patients treated with pelvic RT had a longer mean time to any distant relapse 17.3 vs. 7.0 months p 0.001 than patients treated with surgery alone The use of adjuvant chemotherapy did not correlate with the survival rate or rate of distant metastasis Adjuvant pelvic RT decreased the risk of pelvic recurrence and may delay the appearance of distant metastases after hysterectomy for MMMT However the survival rates remain poor because of a high rate of distant recurrence As more effective systemic chemotherapy is developed to control microscopic distant disease the role of RT in controlling locoregional disease in the pelvis and abdomen may become more important Future research should consider programs that integrate surgery RT and chemotherapy to maximize the probability of cure,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 223, 3, 25, 123, 177, 130, 2, 764, 1, 496, 4, 7, 5, 393, 1739, 9751, 30, 15861, 1, 3, 59, 22190, 2, 1850, 2036, 7, 5, 38, 82, 70, 316, 15861, 1, 3, 11, 73, 5, 1075, 1697, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 136, 702, 1064, 11, 446, 6, 3140, 69, 2, 30, 374, 3791, 1, 152, 310, 240, 2, 56, 2, 319, 337, 228, 3050, 7, 11, 370, 9, 8, 52, 1, 3486, 53, 184, 167, 4478, 25, 151, 11, 981, 75, 3, 876, 882, 596, 5, 362, 275, 20, 1066, 1026, 895, 1, 3, 2036, 7, 4259, 519, 11, 73, 5, 152, 279, 3457, 699, 5, 152, 349, 249, 1883, 15, 20350, 2, 428, 83, 5, 240, 279, 1213, 659, 7, 103, 249, 56, 28, 33, 60, 3, 63, 151, 1, 25, 2, 708, 112, 25, 11, 456, 2, 466, 106, 117, 54, 11, 1679, 15, 42, 8, 532, 1, 324, 1110, 240, 559, 28, 1031, 38, 82, 215, 316, 34, 9738, 133, 244, 15, 35, 1668, 10416, 8379, 1567, 42, 8, 97, 1769, 356, 76, 3, 127, 7, 4, 3, 988, 1, 3, 9385, 7, 54, 208, 152, 135, 54, 42, 109, 1467, 11161, 1318, 79, 494, 15, 12115, 2579, 1, 34, 6, 3, 3629, 17778, 15, 6699, 42, 8, 97, 639, 356, 76, 3, 127, 7, 130, 204, 23, 331, 65, 6, 47, 35, 306, 290, 1054, 23, 708, 112, 25, 159, 1679, 156, 19, 13, 6626, 580, 43, 861, 27, 27, 1318, 79, 494, 19, 13, 488, 861, 18, 18, 799, 19, 13, 1111, 861, 14, 66, 2, 1639, 799, 19, 13, 488, 861, 39, 27, 28, 33, 60, 3, 151, 1, 1110, 2, 626, 34, 146, 9, 3, 1797, 87, 1, 2036, 7, 11, 519, 2, 696, 106, 3, 96, 186, 606, 1, 626, 146, 10, 3, 1639, 2405, 7, 73, 5, 1110, 240, 42, 8, 280, 116, 1, 1110, 146, 76, 7, 73, 5, 152, 279, 339, 105, 576, 19, 13, 3531, 84, 3, 63, 25, 151, 511, 105, 428, 19, 13, 79, 2, 626, 278, 151, 696, 105, 667, 19, 13, 921, 11, 44, 97, 338, 137, 7, 73, 5, 1110, 240, 42, 8, 589, 313, 98, 6, 500, 626, 429, 269, 27, 105, 67, 13, 53, 19, 13, 144, 76, 7, 73, 5, 152, 279, 3, 119, 1, 249, 56, 205, 44, 1513, 5, 3, 25, 116, 15, 116, 1, 626, 278, 249, 1110, 240, 340, 3, 43, 1, 1110, 146, 2, 68, 1984, 3, 3592, 1, 626, 196, 50, 2622, 9, 15861, 137, 3, 25, 151, 918, 334, 408, 1, 8, 64, 116, 1, 626, 146, 22, 80, 323, 403, 56, 16, 276, 6, 182, 2984, 626, 34, 3, 200, 1, 240, 4, 1893, 1325, 34, 4, 3, 3270, 2, 4036, 68, 1417, 80, 305, 508, 389, 257, 2419, 2251, 17, 5671, 152, 240, 2, 56, 6, 4116, 3, 1320, 1, 1722]",2911.0,14967435,750
"Phase I trial of concomitant vinorelbine, cisplatin, and pelvic irradiation in cervical carcinoma and other advanced pelvic malignancies.",Gynecologic oncology,Gynecol. Oncol.,2004-03-01,"To determine the maximum tolerated dose (MTD) of vinorelbine in combination with weekly cisplatin and pelvic radiation therapy (RT). Eligible patients included those with bulky or locally advanced cervical cancer. Women with other advanced gynecologic malignancies were also eligible. All patients received cisplatin 40 mg/m(-2)/week (maximum dose, 70 mg) during pelvic RT. Vinorelbine was administered on the same day as cisplatin at a starting dose of 10 mg/m(-2)/week and escalated in 5 mg/m(-2)/week increments. Dose-limiting toxicity (DLT) was defined as: grade 3-4 non-hematologic toxicity, grade 4 hematologic toxicity, or any toxicity which required > or =1 week delay in RT or an omission of >1 dose of chemotherapy. Between April 2001 and September 2002, 12 women with pelvic malignancies (11 cervical, 1 recurrent ovarian) were enrolled. Cohorts of 3, 6, and 3 patients were treated at 10, 15, and 20 mg/m(-2)/week dose levels of vinorelbine. At the 20 mg/m2 level, DLT was observed. Two of three patients missed >1 cycle of chemotherapy secondary to predominantly hematologic toxicity. One patient at the 20 mg level developed a creatinine clearance <50 ml/min and missed 1 dose of cisplatin. Another developed transient grade 3 diarrhea. No grade 4 toxicities were observed. The MTD of vinorelbine in combination with cisplatin and pelvic RT in patients with cervical cancer is 15 mg/m(-2)/week.",Clinical Trial,5804.0,9.0,To determine the maximum tolerated dose MTD of vinorelbine in combination with weekly cisplatin and pelvic radiation therapy RT Eligible patients included those with bulky or locally advanced cancer Women with other advanced gynecologic malignancies were also eligible All patients received cisplatin 40 mg/m -2 /week maximum dose 70 mg during pelvic RT Vinorelbine was administered on the same day as cisplatin at a starting dose of 10 mg/m -2 /week and escalated in 5 mg/m -2 /week increments Dose-limiting toxicity DLT was defined as grade 3-4 non-hematologic toxicity grade 4 hematologic toxicity or any toxicity which required or =1 week delay in RT or an omission of 1 dose of chemotherapy Between April 2001 and September 2002 12 women with pelvic malignancies 11 1 recurrent were enrolled Cohorts of 3 6 and 3 patients were treated at 10 15 and 20 mg/m -2 /week dose levels of vinorelbine At the 20 mg/m2 level DLT was observed Two of three patients missed 1 cycle of chemotherapy secondary to predominantly hematologic toxicity One patient at the 20 mg level developed a creatinine clearance 50 ml/min and missed 1 dose of cisplatin Another developed transient grade 3 diarrhea No grade 4 toxicities were observed The MTD of vinorelbine in combination with cisplatin and pelvic RT in patients with cancer is 15 mg/m -2 /week,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 689, 421, 61, 961, 1, 3676, 4, 150, 5, 709, 540, 2, 1110, 121, 36, 240, 625, 7, 159, 135, 5, 4112, 15, 795, 131, 12, 117, 5, 127, 131, 1512, 441, 11, 120, 625, 62, 7, 103, 540, 327, 81, 188, 18, 647, 689, 61, 431, 81, 190, 1110, 240, 3676, 10, 468, 23, 3, 827, 218, 22, 540, 28, 8, 1723, 61, 1, 79, 81, 188, 18, 647, 2, 2842, 4, 33, 81, 188, 18, 647, 8225, 61, 817, 155, 2059, 10, 395, 22, 88, 27, 39, 220, 813, 155, 88, 39, 813, 155, 15, 500, 155, 92, 616, 15, 14, 647, 1984, 4, 240, 15, 35, 5736, 1, 14, 61, 1, 56, 59, 2292, 1758, 2, 2636, 1544, 133, 117, 5, 1110, 441, 175, 14, 387, 11, 346, 736, 1, 27, 49, 2, 27, 7, 11, 73, 28, 79, 167, 2, 179, 81, 188, 18, 647, 61, 148, 1, 3676, 28, 3, 179, 81, 821, 301, 2059, 10, 164, 100, 1, 169, 7, 5149, 14, 417, 1, 56, 568, 6, 2117, 813, 155, 104, 69, 28, 3, 179, 81, 301, 276, 8, 3177, 1960, 212, 542, 1538, 2, 5149, 14, 61, 1, 540, 1809, 276, 2473, 88, 27, 1172, 77, 88, 39, 385, 11, 164, 3, 961, 1, 3676, 4, 150, 5, 540, 2, 1110, 240, 4, 7, 5, 12, 16, 167, 81, 188, 18, 647]",1333.0,14984944,263
Adenocarcinoma of the cervix.,Current treatment options in oncology,Curr Treat Options Oncol,2004-04-01,"Cervical adenocarcinomas are increasing in incidence each year, comprising up to 25% of all cervical cancers diagnosed in the United States. This increase largely reflects the inherent difficulty in detecting glandular precursor lesions using current screening practices. However, there also appears to be a recent shift in the epidemiology of the disease process with younger women being diagnosed more frequently. Fertility-sparing surgery is an option for selected patients with adenocarcinoma in situ or stage IA(1) cervical adenocarcinoma. Simple hysterectomy should be performed at the completion of childbearing or when preserving fertility is not an issue. The treatment of choice for most women with stage IA(2) to IB(1) disease is radical hysterectomy. Fewer than 20% of patients will need adjuvant therapy and the cure rate is excellent. Primary radiation with weekly cisplatin may be the best option for patients with stage IB(2) to IIA cervical adenocarcinoma. Patients treated initially by primary radical surgery will almost certainly require postoperative chemoradiation because of high-risk surgical-pathologic features. Patients with stage IIB to IVA disease should also receive primary radiation with weekly cisplatin. Management of recurrence should be individualized, depending on the location of disease and the type of previous therapy.",Journal Article,5773.0,31.0,adenocarcinomas are increasing in incidence each year comprising up to 25 of all cancers diagnosed in the United States This increase largely reflects the inherent difficulty in detecting glandular precursor lesions using current screening practices However there also appears to be a recent shift in the epidemiology of the disease process with younger women being diagnosed more frequently Fertility-sparing surgery is an option for selected patients with adenocarcinoma in situ or stage IA 1 adenocarcinoma Simple hysterectomy should be performed at the completion of childbearing or when preserving fertility is not an issue The treatment of choice for most women with stage IA 2 to IB 1 disease is radical hysterectomy Fewer than 20 of patients will need adjuvant therapy and the cure rate is excellent Primary radiation with weekly cisplatin may be the best option for patients with stage IB 2 to IIA adenocarcinoma Patients treated initially by primary radical surgery will almost certainly require postoperative chemoradiation because of high-risk surgical-pathologic features Patients with stage IIB to IVA disease should also receive primary radiation with weekly cisplatin Management of recurrence should be individualized depending on the location of disease and the type of previous therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1586, 32, 602, 4, 287, 296, 111, 3538, 126, 6, 243, 1, 62, 163, 265, 4, 3, 1088, 907, 26, 344, 1733, 5224, 3, 4943, 4035, 4, 2502, 6170, 2765, 406, 75, 291, 453, 2634, 137, 125, 120, 1233, 6, 40, 8, 435, 3024, 4, 3, 1284, 1, 3, 34, 1129, 5, 773, 117, 486, 265, 80, 746, 2954, 1851, 152, 16, 35, 1501, 9, 715, 7, 5, 449, 4, 957, 15, 82, 3302, 14, 449, 2763, 2622, 257, 40, 173, 28, 3, 1438, 1, 10278, 15, 198, 4972, 2954, 16, 44, 35, 2537, 3, 24, 1, 1866, 9, 96, 117, 5, 82, 3302, 18, 6, 3180, 14, 34, 16, 711, 2622, 1497, 76, 179, 1, 7, 303, 594, 249, 36, 2, 3, 1722, 116, 16, 1503, 86, 121, 5, 709, 540, 68, 40, 3, 824, 1501, 9, 7, 5, 82, 3180, 18, 6, 4088, 449, 7, 73, 1625, 20, 86, 711, 152, 303, 2214, 13486, 1353, 573, 975, 408, 1, 64, 43, 221, 510, 404, 7, 5, 82, 3884, 6, 5900, 34, 257, 120, 560, 86, 121, 5, 709, 540, 284, 1, 146, 257, 40, 2596, 3221, 23, 3, 1147, 1, 34, 2, 3, 267, 1, 698, 36]",1303.0,14990206,751
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2004-03-01,"To report mature results of a randomized trial that compared extended-field radiotherapy (EFRT) versus pelvic radiotherapy with concomitant fluorouracil and cisplatin (CTRT) in women with locoregionally advanced carcinomas of the uterine cervix. Four hundred three women with cervical cancer were randomly assigned to receive either EFRT or CTRT. Patients were eligible if they had stage IIB to IVA disease, stage IB to IIA disease with a tumor diameter > or = 5 cm, or positive pelvic lymph nodes. Patients were stratified by stage and by method of lymph node evaluation. The median follow-up time for 228 surviving patients was 6.6 years. The overall survival rate for patients treated with CTRT was significantly greater than that for patients treated with EFRT (67% v 41% at 8 years; P <.0001). There was an overall reduction in the risk of disease recurrence of 51% (95% CI, 36% to 66%) for patients who received CTRT. Patients with stage IB to IIB disease who received CTRT had better overall and disease-free survival than those treated with EFRT (P <.0001); 116 patients with stage III to IVA disease had better disease-free survival (P =.05) and a trend toward better overall survival (P =.07) if they were randomly assigned to CTRT. The rate of serious late complications of treatment was similar for the two treatment arms. Mature analysis confirms that the addition of fluorouracil and cisplatin to radiotherapy significantly improved the survival rate of women with locally advanced cervical cancer without increasing the rate of late treatment-related side effects.",Clinical Trial,5804.0,677.0,To report mature results of a randomized trial that compared extended-field radiotherapy EFRT versus pelvic radiotherapy with concomitant fluorouracil and cisplatin CTRT in women with locoregionally advanced carcinomas of the cervix Four hundred three women with cancer were randomly assigned to receive either EFRT or CTRT Patients were eligible if they had stage IIB to IVA disease stage IB to IIA disease with a tumor diameter or 5 cm or positive pelvic lymph nodes Patients were stratified by stage and by method of lymph node evaluation The median follow-up time for 228 surviving patients was 6.6 years The overall survival rate for patients treated with CTRT was significantly greater than that for patients treated with EFRT 67 v 41 at 8 years P .0001 There was an overall reduction in the risk of disease recurrence of 51 95 CI 36 to 66 for patients who received CTRT Patients with stage IB to IIB disease who received CTRT had better overall and disease-free survival than those treated with EFRT P .0001 116 patients with stage III to IVA disease had better disease-free survival P =.05 and a trend toward better overall survival P =.07 if they were randomly assigned to CTRT The rate of serious late complications of treatment was similar for the two treatment arms Mature analysis confirms that the addition of fluorouracil and cisplatin to radiotherapy significantly improved the survival rate of women with locally advanced cancer without increasing the rate of late treatment-related side effects,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 414, 2908, 99, 1, 8, 384, 160, 17, 72, 1747, 1067, 310, 24685, 185, 1110, 310, 5, 1781, 1404, 2, 540, 10329, 4, 117, 5, 6410, 131, 826, 1, 3, 3629, 294, 1128, 169, 117, 5, 12, 11, 1108, 896, 6, 560, 361, 24685, 15, 10329, 7, 11, 625, 492, 491, 42, 82, 3884, 6, 5900, 34, 82, 3180, 6, 4088, 34, 5, 8, 30, 2549, 15, 33, 494, 15, 109, 1110, 263, 502, 7, 11, 1173, 20, 82, 2, 20, 596, 1, 263, 289, 451, 3, 52, 166, 126, 98, 9, 6736, 3050, 7, 10, 49, 49, 60, 3, 63, 25, 116, 9, 7, 73, 5, 10329, 10, 97, 378, 76, 17, 9, 7, 73, 5, 24685, 598, 603, 605, 28, 66, 60, 19, 488, 125, 10, 35, 63, 628, 4, 3, 43, 1, 34, 146, 1, 725, 48, 58, 511, 6, 700, 9, 7, 54, 103, 10329, 7, 5, 82, 3180, 6, 3884, 34, 54, 103, 10329, 42, 380, 63, 2, 34, 115, 25, 76, 135, 73, 5, 24685, 19, 488, 3790, 7, 5, 82, 316, 6, 5900, 34, 42, 380, 34, 115, 25, 19, 474, 2, 8, 853, 1317, 380, 63, 25, 19, 1615, 492, 491, 11, 1108, 896, 6, 10329, 3, 116, 1, 1762, 807, 521, 1, 24, 10, 288, 9, 3, 100, 24, 1335, 2908, 65, 5120, 17, 3, 352, 1, 1404, 2, 540, 6, 310, 97, 231, 3, 25, 116, 1, 117, 5, 795, 131, 12, 187, 602, 3, 116, 1, 807, 24, 139, 1152, 176]",1512.0,14990643,14
The diagnostic utility of human papillomavirus-testing in combination with immunohistochemistry in advanced gynaecologic pelvic tumours: a new diagnostic approach.,International journal of oncology,Int. J. Oncol.,2004-04-01,"Gynaecologic pelvic tumours comprise a range of histological entities that are highly variable with respect to their clinical behaviour. The distinction of these tumours can be extremely difficult. Accurate identification of the primary tumour site has significant impact on the treatment strategy and prognosis. In this study we investigated the diagnostic and clinical utility of HPV (Human Papillomavirus)-testing in combination with selected immunohistochemical markers in advanced pelvic tumours of unknown primary origin. Specimens of eight patients who presented with advanced gynaecologic pelvic tumour of unknown primary origin, 10 unequivocal cervical carcinomas with 10 corresponding metastases and 10 unequivocal endometrial carcinomas with 4 corresponding metastases were studied. All cases were analysed for HPV-infection by PCR. The expression of CEA, vimentin (VIM), estrogen receptor (ER) and progesterone receptor (PR) was studied by immunohistochemistry. HPV-DNA was exclusively detected in cervical carcinomas and their corresponding metastases but in none of the endometrial carcinomas (Fisher's exact test p<0.001). Endometrial carcinomas and their metastases were generally positive for ER (86%), PR (93%) and VIM (100%) but rarely positive for CEA (14%) and HPV (0%). Most cervical carcinomas and their corresponding metastases were positive for CEA (79%) and HPV (89%). They rarely expressed ER (5%), PR (5%) and VIM (10%). Among the eight patients with unknown primary tumour four patients were diagnosed with a cervical carcinoma and four with an endometrial carcinoma. In one case we could exclude an ovarian carcinoma. Immunohistochemical analysis of selected markers in combination with HPV-testing is simple and inexpensive. The detection of HPV-DNA seems to provide the most compelling evidence for the primary tumour site, when immunohistochemical analysis is less definitive. The proposed diagnostic approach is helpful in the identification and management of pelvic tumours of unknown primary origin.",Journal Article,5773.0,16.0,Gynaecologic pelvic tumours comprise a range of histological entities that are highly variable with respect to their clinical behaviour The distinction of these tumours can be extremely difficult Accurate identification of the primary tumour site has significant impact on the treatment strategy and prognosis In this study we investigated the diagnostic and clinical utility of HPV Human Papillomavirus -testing in combination with selected immunohistochemical markers in advanced pelvic tumours of unknown primary origin Specimens of eight patients who presented with advanced gynaecologic pelvic tumour of unknown primary origin 10 unequivocal carcinomas with 10 corresponding metastases and 10 unequivocal carcinomas with 4 corresponding metastases were studied All cases were analysed for HPV-infection by PCR The expression of CEA vimentin VIM estrogen receptor ER and progesterone receptor PR was studied by immunohistochemistry HPV-DNA was exclusively detected in carcinomas and their corresponding metastases but in none of the carcinomas Fisher 's exact test p 0.001 carcinomas and their metastases were generally positive for ER 86 PR 93 and VIM 100 but rarely positive for CEA 14 and HPV 0 Most carcinomas and their corresponding metastases were positive for CEA 79 and HPV 89 They rarely expressed ER 5 PR 5 and VIM 10 Among the eight patients with unknown primary tumour four patients were diagnosed with a carcinoma and four with an carcinoma In one case we could exclude an carcinoma Immunohistochemical analysis of selected markers in combination with HPV-testing is simple and inexpensive The detection of HPV-DNA seems to provide the most compelling evidence for the primary tumour site when immunohistochemical analysis is less definitive The proposed diagnostic approach is helpful in the identification and management of pelvic tumours of unknown primary origin,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[23316, 1110, 1319, 5238, 8, 184, 1, 1831, 4613, 17, 32, 561, 1347, 5, 2184, 6, 136, 38, 8173, 3, 6628, 1, 46, 1319, 122, 40, 2938, 1740, 1481, 911, 1, 3, 86, 770, 606, 71, 93, 345, 23, 3, 24, 692, 2, 356, 4, 26, 45, 21, 565, 3, 752, 2, 38, 1207, 1, 933, 171, 3242, 471, 4, 150, 5, 715, 1382, 525, 4, 131, 1110, 1319, 1, 860, 86, 1938, 623, 1, 659, 7, 54, 917, 5, 131, 23316, 1110, 770, 1, 860, 86, 1938, 79, 14775, 826, 5, 79, 1734, 196, 2, 79, 14775, 826, 5, 39, 1734, 196, 11, 656, 62, 140, 11, 3141, 9, 933, 930, 20, 604, 3, 55, 1, 3088, 4840, 18341, 808, 153, 516, 2, 2143, 153, 998, 10, 656, 20, 888, 933, 261, 10, 4437, 530, 4, 826, 2, 136, 1734, 196, 84, 4, 1292, 1, 3, 826, 3135, 292, 2472, 412, 19, 13, 144, 826, 2, 136, 196, 11, 1228, 109, 9, 516, 868, 998, 966, 2, 18341, 394, 84, 2416, 109, 9, 3088, 213, 2, 933, 13, 96, 826, 2, 136, 1734, 196, 11, 109, 9, 3088, 842, 2, 933, 887, 491, 2416, 570, 516, 33, 998, 33, 2, 18341, 79, 107, 3, 659, 7, 5, 860, 86, 770, 294, 7, 11, 265, 5, 8, 134, 2, 294, 5, 35, 134, 4, 104, 473, 21, 359, 6262, 35, 134, 1382, 65, 1, 715, 525, 4, 150, 5, 933, 471, 16, 2763, 2, 8168, 3, 638, 1, 933, 261, 2744, 6, 377, 3, 96, 6051, 241, 9, 3, 86, 770, 606, 198, 1382, 65, 16, 299, 1057, 3, 1587, 752, 353, 16, 3951, 4, 3, 911, 2, 284, 1, 1110, 1319, 1, 860, 86, 1938]",1883.0,15010819,6
P16 as a molecular biomarker of cervical adenocarcinoma.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2004-03-01,"Cervical adenocarcinomas are increasing in incidence each year. The aim of this study was to identify a molecular biomarker to improve early detection. Fifty-five in situ and invasive cervical adenocarcinomas were compared with 5 normal endocervical controls by immunohistochemical analysis of p16, p21, p27, cyclin D1, cyclin E, p53, and Ki-67. Expression was scored from 0 to 8 by using an automated imaging system. Western blotting and polymerase chain reaction-based human papillomavirus (HPV) testing were performed on 16 of the invasive cases having fresh-frozen tissue. P16 exhibited a higher mean expression score for in situ (7.4; P<.0001) and invasive cervical adenocarcinoma (6.6; P<.0001) versus controls (2.0). A cutoff p16 expression score of 5 had a sensitivity of 94.5% and a specificity of 100%. Western blotting confirmed p16 protein expression. Fourteen (88%) of 16 invasive cervical adenocarcinomas were HPV-positive. P16 is a putative molecular biomarker of cervical adenocarcinoma. Overexpression appears to primarily reflect HPV-induced cell cycle dysregulation.",Journal Article,5804.0,43.0,adenocarcinomas are increasing in incidence each year The aim of this study was to identify a molecular biomarker to improve early detection Fifty-five in situ and invasive adenocarcinomas were compared with 5 normal endocervical controls by immunohistochemical analysis of p16 p21 p27 cyclin D1 cyclin E p53 and Ki-67 Expression was scored from 0 to 8 by using an automated imaging system Western blotting and polymerase chain reaction-based human papillomavirus HPV testing were performed on 16 of the invasive cases having fresh-frozen tissue P16 exhibited a higher mean expression score for in situ 7.4 P .0001 and invasive adenocarcinoma 6.6 P .0001 versus controls 2.0 A cutoff p16 expression score of 5 had a sensitivity of 94.5 and a specificity of 100 Western blotting confirmed p16 protein expression Fourteen 88 of 16 invasive adenocarcinomas were HPV-positive P16 is a putative molecular biomarker of adenocarcinoma Overexpression appears to primarily reflect HPV-induced cell cycle dysregulation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1586, 32, 602, 4, 287, 296, 111, 3, 1130, 1, 26, 45, 10, 6, 255, 8, 219, 901, 6, 401, 191, 638, 1461, 365, 4, 957, 2, 416, 1586, 11, 72, 5, 33, 295, 10174, 535, 20, 1382, 65, 1, 1932, 2657, 2804, 1226, 2146, 1226, 563, 624, 2, 2311, 598, 55, 10, 3179, 29, 13, 6, 66, 20, 75, 35, 3235, 270, 398, 1521, 3661, 2, 1451, 1260, 1329, 90, 171, 3242, 933, 471, 11, 173, 23, 245, 1, 3, 416, 140, 1041, 4329, 3015, 246, 1932, 1416, 8, 142, 313, 55, 368, 9, 4, 957, 67, 39, 19, 488, 2, 416, 449, 49, 49, 19, 488, 185, 535, 18, 13, 8, 2779, 1932, 55, 368, 1, 33, 42, 8, 485, 1, 960, 33, 2, 8, 1121, 1, 394, 1521, 3661, 557, 1932, 178, 55, 3225, 889, 1, 245, 416, 1586, 11, 933, 109, 1932, 16, 8, 2743, 219, 901, 1, 449, 851, 1233, 6, 1561, 2694, 933, 277, 31, 417, 3935]",1008.0,15041997,334
Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2004-03-01,"The purpose of this study was to determine the association between active tobacco exposure and aberrant p16 promoter methylation in primary cervical squamous cell cancer and high-grade squamous cervical dysplasia. p16 methylation-specific polymerase chain reaction was performed on DNA that was extracted from 60 cervical cancers, 30 high-grade dysplasia specimens, and 78 normal cervical cytologic specimens. Patient data were obtained by medical record review or were collected prospectively. Aberrant p16 methylation was significantly higher in squamous cell cervical cancers (61%) than in squamous high-grade dysplasia (20%) or normal cytologic specimens (7.5%). Approximately one half the women with squamous cancer and one half of the women with high-grade dysplasia were active smokers. Aberrant p16 methylation was associated with active tobacco use in patients with squamous carcinoma (odds ratio, 20.6; 95% CI, 3.6-118; P<.001) and high-grade dysplasia (odds ratio, 4.57; 95% CI, 1.63-12.78; P=.002). Aberrant p16 methylation is associated strongly with active tobacco use in squamous cell cervical cancers and high-grade dysplasia.",Journal Article,5804.0,41.0,The purpose of this study was to determine the association between active tobacco exposure and aberrant p16 promoter methylation in primary squamous cell cancer and high-grade squamous dysplasia p16 methylation-specific polymerase chain reaction was performed on DNA that was extracted from 60 cancers 30 high-grade dysplasia specimens and 78 normal cytologic specimens Patient data were obtained by medical record review or were collected prospectively Aberrant p16 methylation was significantly higher in squamous cell cancers 61 than in squamous high-grade dysplasia 20 or normal cytologic specimens 7.5 Approximately one half the women with squamous cancer and one half of the women with high-grade dysplasia were active smokers Aberrant p16 methylation was associated with active tobacco use in patients with squamous carcinoma odds ratio 20.6 95 CI 3.6-118 P .001 and high-grade dysplasia odds ratio 4.57 95 CI 1.63-12.78 P=.002 Aberrant p16 methylation is associated strongly with active tobacco use in squamous cell cancers and high-grade dysplasia,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 223, 3, 248, 59, 544, 2607, 645, 2, 1898, 1932, 973, 569, 4, 86, 691, 31, 12, 2, 64, 88, 691, 2253, 1932, 569, 112, 1451, 1260, 1329, 10, 173, 23, 261, 17, 10, 2484, 29, 335, 163, 201, 64, 88, 2253, 623, 2, 833, 295, 4195, 623, 69, 74, 11, 683, 20, 484, 3237, 206, 15, 11, 786, 1143, 1898, 1932, 569, 10, 97, 142, 4, 691, 31, 163, 713, 76, 4, 691, 64, 88, 2253, 179, 15, 295, 4195, 623, 67, 33, 705, 104, 1303, 3, 117, 5, 691, 12, 2, 104, 1303, 1, 3, 117, 5, 64, 88, 2253, 11, 544, 1485, 1898, 1932, 569, 10, 41, 5, 544, 2607, 119, 4, 7, 5, 691, 134, 610, 197, 179, 49, 48, 58, 27, 49, 4002, 19, 144, 2, 64, 88, 2253, 610, 197, 39, 696, 48, 58, 14, 676, 133, 833, 19, 1111, 1898, 1932, 569, 16, 41, 1327, 5, 544, 2607, 119, 4, 691, 31, 163, 2, 64, 88, 2253]",1056.0,15041998,30
Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence.,Gynecologic oncology,Gynecol. Oncol.,2004-04-01,"To analyze the sites of relapse and overall survival in women with neuroendocrine marker-positive small cell carcinoma of the cervix. The records of all women who had their initial treatment for cervical cancer at The University of Texas M.D. Anderson Cancer Center between 1980 and 2000 were reviewed. Fifty-one patients had stages I-III cancers that were originally described as ""small cell"" or ""neuroendocrine."" Histological material was available for reexamination in 45 cases; of these, 21 were found to have small cell neuroendocrine carcinoma (SCNEC) as indicated by positive staining for chromogranin, synaptophysin, or CD56. Local treatment consisted of a radical hysterectomy in six patients and radiation therapy in 15. Thirteen patients received chemotherapy as part of their initial treatment. The median follow-up for surviving patients was 83 months (range, 25-209 months). Fourteen (66%) of the 21 patients had a relapse. The median time to first relapse from the initiation of treatment was 8.4 months (range, 3.6-28 months). Most patients developed hematogenous distant metastases before their death. Only 2 of 15 patients who were treated with radiation therapy had a recurrence within the radiation fields. However, five patients had a recurrence above the radiation fields in the paraaortic lymph nodes, and two patients had a recurrence distal to the pelvic fields in the vagina. No patient had brain metastases as the sole site of first recurrence. However, two patients developed brain metastases concurrently with lung metastases. The overall survival rate was 29% at 5 years; none of the patients who had disease more extensive than stage IB1 or clinical evidence of lymph node metastases survived their disease. Patients with small cell neuroendocrine cervical cancer have a poor prognosis. Their course is frequently characterized by the development of widespread hematogenous metastases; locoregional recurrence outside irradiated fields is also frequent. Brain metastases were seen only in patients who also had lung metastases, suggesting that prophylactic cranial irradiation would be of little benefit.",Journal Article,5773.0,156.0,To analyze the sites of relapse and overall survival in women with neuroendocrine marker-positive small cell carcinoma of the cervix The records of all women who had their initial treatment for cancer at The University of Texas M.D Anderson Cancer Center between 1980 and 2000 were reviewed Fifty-one patients had stages I-III cancers that were originally described as `` small cell '' or `` neuroendocrine '' Histological material was available for reexamination in 45 cases of these 21 were found to have small cell neuroendocrine carcinoma SCNEC as indicated by positive staining for chromogranin synaptophysin or CD56 Local treatment consisted of a radical hysterectomy in six patients and radiation therapy in 15 Thirteen patients received chemotherapy as part of their initial treatment The median follow-up for surviving patients was 83 months range 25-209 months Fourteen 66 of the 21 patients had a relapse The median time to first relapse from the initiation of treatment was 8.4 months range 3.6-28 months Most patients developed hematogenous distant metastases before their death Only 2 of 15 patients who were treated with radiation therapy had a recurrence within the radiation fields However five patients had a recurrence above the radiation fields in the paraaortic lymph nodes and two patients had a recurrence distal to the pelvic fields in the vagina No patient had brain metastases as the sole site of first recurrence However two patients developed brain metastases concurrently with metastases The overall survival rate was 29 at 5 years none of the patients who had disease more extensive than stage IB1 or clinical evidence of lymph node metastases survived their disease Patients with small cell neuroendocrine cancer have a poor prognosis Their course is frequently characterized by the development of widespread hematogenous metastases locoregional recurrence outside irradiated fields is also frequent Brain metastases were seen only in patients who also had metastases suggesting that prophylactic cranial irradiation would be of little benefit,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1992, 3, 633, 1, 429, 2, 63, 25, 4, 117, 5, 1542, 952, 109, 302, 31, 134, 1, 3, 3629, 3, 1064, 1, 62, 117, 54, 42, 136, 388, 24, 9, 12, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 59, 4376, 2, 1081, 11, 446, 1461, 104, 7, 42, 1153, 70, 316, 163, 17, 11, 5045, 1027, 22, 302, 31, 522, 15, 1542, 522, 1831, 3692, 10, 390, 9, 33636, 4, 512, 140, 1, 46, 239, 11, 204, 6, 47, 302, 31, 1542, 134, 24694, 22, 1103, 20, 109, 1029, 9, 8931, 12161, 15, 5803, 293, 24, 1695, 1, 8, 711, 2622, 4, 437, 7, 2, 121, 36, 4, 167, 3170, 7, 103, 56, 22, 760, 1, 136, 388, 24, 3, 52, 166, 126, 9, 3050, 7, 10, 852, 53, 184, 243, 5941, 53, 3225, 700, 1, 3, 239, 7, 42, 8, 429, 3, 52, 98, 6, 157, 429, 29, 3, 1118, 1, 24, 10, 66, 39, 53, 184, 27, 49, 339, 53, 96, 7, 276, 9792, 626, 196, 348, 136, 273, 158, 18, 1, 167, 7, 54, 11, 73, 5, 121, 36, 42, 8, 146, 262, 3, 121, 3130, 137, 365, 7, 42, 8, 146, 2090, 3, 121, 3130, 4, 3, 7401, 263, 502, 2, 100, 7, 42, 8, 146, 2107, 6, 3, 1110, 3130, 4, 3, 7553, 77, 69, 42, 342, 196, 22, 3, 4991, 606, 1, 157, 146, 137, 100, 7, 276, 342, 196, 3294, 5, 196, 3, 63, 25, 116, 10, 462, 28, 33, 60, 1292, 1, 3, 7, 54, 42, 34, 80, 1344, 76, 82, 8111, 15, 38, 241, 1, 263, 289, 196, 2996, 136, 34, 7, 5, 302, 31, 1542, 12, 47, 8, 334, 356, 136, 906, 16, 746, 765, 20, 3, 193, 1, 3029, 9792, 196, 1325, 146, 2513, 2398, 3130, 16, 120, 908, 342, 196, 11, 527, 158, 4, 7, 54, 120, 42, 196, 802, 17, 1862, 2565, 1104, 688, 40, 1, 1215, 247]",2074.0,15047210,447
Squamous cell carcinoma related oncogene regulates angiogenesis through vascular endothelial growth factor-A.,Annals of surgical oncology,Ann. Surg. Oncol.,2004-05-01,"Squamous cell carcinoma related oncogene expression (SCCRO) correlates with vascular endothelial growth factor-A expression. This data is validated in human lung tumors and provides a putative pathway for angiogenesis in a subset of squamous cell carcinomas. Squamous cell carcinoma related oncogene is a novel oncogene identified by positional cloning of a recurrent amplification at 3q26.3. It is over-expressed in 39.8% of lung, head and neck, cervical, and ovarian carcinomas. SCCRO imparts an aggressive phenotype to affected cancers, which may be related to increased angiogenesis due to SCCRO expression. Our previous work has demonstrated a link between SCCRO and vascular endothelial growth factor-A (VEGF-A) expression in vitro, suggesting a mechanism for SCCRO-induced angiogenesis. The present study aims to confirm and validate this link between SCCRO and VEGF-A expression in an ex vivo human tumor cohort. Fresh tissue was collected at Memorial Sloan-Kettering Cancer Center from 34 patients undergoing primary resection of lung squamous cell carcinomas. RNA was extracted from this tissue, reverse-transcribed, and real-time polymerase chain reaction (RT-PCR) was carried out using a BioRad iQ iCycler with SYBR green fluorophore. Microvessel counting was performed on the tumor specimens using CD34 immunohistochemistry. The expression of both SCCRO and VEGF-A mRNA varies widely in both tumor and normal tissue. SCCRO and VEGF-A co-expression was significantly correlated (R(2) = 0.63; P < 0.032). Microvessel counts were not associated with expression of SCCRO or VEGF-A and failed to significantly predict survival. VEGF-A expression in this patient group is a predictor of overall survival (P < 0.032). VEGF-A expression correlates with SCCRO expression in these primary human lung squamous cell carcinomas and is a predictor of clinical behavior. This data supports the association of SCRRO and VEGF-A in the induction of angiogenesis.",Journal Article,5743.0,17.0,Squamous cell carcinoma related oncogene expression SCCRO correlates with vascular endothelial growth factor-A expression This data is validated in human tumors and provides a putative pathway for angiogenesis in a subset of squamous cell carcinomas Squamous cell carcinoma related oncogene is a novel oncogene identified by positional cloning of a recurrent amplification at 3q26.3 It is over-expressed in 39.8 of head and and carcinomas SCCRO imparts an aggressive phenotype to affected cancers which may be related to increased angiogenesis due to SCCRO expression Our previous work has demonstrated a link between SCCRO and vascular endothelial growth factor-A VEGF-A expression in vitro suggesting a mechanism for SCCRO-induced angiogenesis The present study aims to confirm and validate this link between SCCRO and VEGF-A expression in an ex vivo human tumor cohort Fresh tissue was collected at Memorial Sloan-Kettering Cancer Center from 34 patients undergoing primary resection of squamous cell carcinomas RNA was extracted from this tissue reverse-transcribed and real-time polymerase chain reaction RT-PCR was carried out using a BioRad iQ iCycler with SYBR green fluorophore Microvessel counting was performed on the tumor specimens using CD34 immunohistochemistry The expression of both SCCRO and VEGF-A mRNA varies widely in both tumor and normal tissue SCCRO and VEGF-A co-expression was significantly correlated R 2 0.63 P 0.032 Microvessel counts were not associated with expression of SCCRO or VEGF-A and failed to significantly predict survival VEGF-A expression in this patient group is a predictor of overall survival P 0.032 VEGF-A expression correlates with SCCRO expression in these primary human squamous cell carcinomas and is a predictor of clinical behavior This data supports the association of SCRRO and VEGF-A in the induction of angiogenesis,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[691, 31, 134, 139, 1836, 55, 13307, 1871, 5, 756, 845, 129, 161, 8, 55, 26, 74, 16, 938, 4, 171, 57, 2, 777, 8, 2743, 308, 9, 1056, 4, 8, 697, 1, 691, 31, 826, 691, 31, 134, 139, 1836, 16, 8, 229, 1836, 108, 20, 16788, 11426, 1, 8, 387, 1073, 28, 10678, 27, 192, 16, 252, 570, 4, 587, 66, 1, 718, 2, 2, 826, 13307, 18351, 35, 571, 1005, 6, 1424, 163, 92, 68, 40, 139, 6, 101, 1056, 520, 6, 13307, 55, 114, 698, 1357, 71, 264, 8, 3460, 59, 13307, 2, 756, 845, 129, 161, 8, 618, 8, 55, 4, 439, 802, 8, 670, 9, 13307, 277, 1056, 3, 364, 45, 2970, 6, 1843, 2, 2183, 26, 3460, 59, 13307, 2, 618, 8, 55, 4, 35, 2581, 386, 171, 30, 180, 4329, 246, 10, 786, 28, 2563, 2783, 2784, 12, 574, 29, 562, 7, 479, 86, 170, 1, 691, 31, 826, 893, 10, 2484, 29, 26, 246, 1772, 10088, 2, 1589, 98, 1451, 1260, 1329, 240, 604, 10, 2629, 1205, 75, 8, 54142, 7666, 54143, 5, 43599, 4658, 18352, 4269, 9479, 10, 173, 23, 3, 30, 623, 75, 2215, 888, 3, 55, 1, 110, 13307, 2, 618, 8, 956, 4037, 1792, 4, 110, 30, 2, 295, 246, 13307, 2, 618, 8, 1269, 55, 10, 97, 438, 668, 18, 13, 676, 19, 13, 4708, 4269, 1911, 11, 44, 41, 5, 55, 1, 13307, 15, 618, 8, 2, 1551, 6, 97, 678, 25, 618, 8, 55, 4, 26, 69, 87, 16, 8, 980, 1, 63, 25, 19, 13, 4708, 618, 8, 55, 1871, 5, 13307, 55, 4, 46, 86, 171, 691, 31, 826, 2, 16, 8, 980, 1, 38, 1710, 26, 74, 2304, 3, 248, 1, 54144, 2, 618, 8, 4, 3, 504, 1, 1056]",1873.0,15123463,571
Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer.,Cancer research,Cancer Res.,2004-05-01,"Patients with advanced stage invasive cervical cancer (CC) exhibit highly complex genomic alterations and respond poorly to conventional treatment protocols. In our efforts to understand the molecular genetic basis of CC, we examined the role of Fanconi Anemia (FA)-BRCA pathway. Here, we show that FANCF gene is disrupted by either promoter hypermethylation and/or deregulated gene expression in a majority of CC. Inhibition of DNA methylation and histone deacetylases induces FANCF gene re-expression in CC cell lines. FANCF-deregulated CC cell lines also exhibit a chromosomal hypersensitivity phenotype after exposure to an alkylating agent, a characteristic of FA patients. We also show the involvement of BRCA1 gene by promoter hypermethylation or down-regulated expression in a small subset of CC patients. Thus, we have found inactivation of genes in the FA-BRCA pathway by epigenetic alterations in a high proportion of CC patients, suggesting a major role for this pathway in the development of cervical cancer. Thus, these results have important implications in understanding the molecular basis of CC tumorigenesis and clinical management in designing targeted experimental therapeutic protocols.",Journal Article,5743.0,152.0,Patients with advanced stage invasive cancer CC exhibit highly complex genomic alterations and respond poorly to conventional treatment protocols In our efforts to understand the molecular genetic basis of CC we examined the role of Fanconi Anemia FA -BRCA pathway Here we show that FANCF gene is disrupted by either promoter hypermethylation and/or deregulated gene expression in a majority of CC Inhibition of DNA methylation and histone deacetylases induces FANCF gene re-expression in CC cell lines FANCF-deregulated CC cell lines also exhibit a chromosomal hypersensitivity phenotype after exposure to an alkylating agent a characteristic of FA patients We also show the involvement of BRCA1 gene by promoter hypermethylation or down-regulated expression in a small subset of CC patients Thus we have found inactivation of genes in the FA-BRCA pathway by epigenetic alterations in a high proportion of CC patients suggesting a major role for this pathway in the development of cancer Thus these results have important implications in understanding the molecular basis of CC tumorigenesis and clinical management in designing targeted experimental therapeutic protocols,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[7, 5, 131, 82, 416, 12, 1951, 2239, 561, 840, 572, 593, 2, 1892, 1240, 6, 809, 24, 2189, 4, 114, 1413, 6, 1640, 3, 219, 336, 877, 1, 1951, 21, 409, 3, 200, 1, 8057, 1545, 4307, 1555, 308, 467, 21, 514, 17, 15910, 145, 16, 5576, 20, 361, 973, 2575, 2, 15, 5415, 145, 55, 4, 8, 686, 1, 1951, 297, 1, 261, 569, 2, 1508, 9758, 1516, 15910, 145, 1491, 55, 4, 1951, 31, 285, 15910, 5415, 1951, 31, 285, 120, 2239, 8, 1860, 4034, 1005, 50, 645, 6, 35, 3410, 420, 8, 2037, 1, 4307, 7, 21, 120, 514, 3, 799, 1, 766, 145, 20, 973, 2575, 15, 1328, 1065, 55, 4, 8, 302, 697, 1, 1951, 7, 631, 21, 47, 204, 2297, 1, 214, 4, 3, 4307, 1555, 308, 20, 1418, 593, 4, 8, 64, 920, 1, 1951, 7, 802, 8, 458, 200, 9, 26, 308, 4, 3, 193, 1, 12, 631, 46, 99, 47, 305, 1268, 4, 612, 3, 219, 877, 1, 1951, 1565, 2, 38, 284, 4, 5048, 238, 1560, 189, 2189]",1173.0,15126331,113
Prognostic significance of erythropoietin expression in human endometrial carcinoma.,Cancer,Cancer,2004-06-01,"Erythropoietin (Epo), which is induced by hypoxia, controls erythropoiesis and protects neurons from hypoxic damage. Hypoxia in malignant disease is associated with invasion, metastasis, and resistance to therapy. The authors recently demonstrated hypoxia-stimulated expression of Epo and Epo receptor (EpoR) in human breast and cervical carcinomas, suggesting a role for autocrine Epo signaling in the hypoxic adaptations of carcinomas. The authors characterized the expression of Epo, EpoR, hypoxia-inducible factor (HIF)-1alpha, estrogen receptor (ER), and progesterone receptor (PR) by immunohistochemical methods using endometrial carcinoma samples from 107 women and benign endometrial samples from 59 women in various phases of the menstrual cycle. They then analyzed potential correlations of Epo and EpoR immunostaining and clinicopathologic tumor features with outcome. In benign endometrial tissue samples, Epo and EpoR expression increased over the course of the cycle, with the highest levels observed in the late secretory phase. Epo expression in benign endometrial samples showed a negative correlation with ER and PR expression. The authors found Epo and EpoR expression in 95.3 % and 100% of endometrial carcinoma samples, respectively. Increased EpoR, but not Epo, expression in tumors was associated with advanced-stage disease, lymphovascular invasion, lymph node metastasis, and loss of ER expression. Increased Epo expression was observed in perinecrotic tumor regions in a pattern similar to the HIF-1alpha expression pattern. Increased Epo expression was significantly associated with adverse clinical outcome on both univariate and multivariate analysis. Hypoxia-inducible autocrine Epo signaling in endometrial carcinoma may contribute to tumor progression and increased aggressiveness. Increased Epo expression in endometrial carcinomas may be an independent prognostic and/or predictive factor.",Comparative Study,5712.0,87.0,Erythropoietin Epo which is induced by hypoxia controls erythropoiesis and protects neurons from hypoxic damage Hypoxia in malignant disease is associated with invasion metastasis and resistance to therapy The authors recently demonstrated hypoxia-stimulated expression of Epo and Epo receptor EpoR in human and carcinomas suggesting a role for autocrine Epo signaling in the hypoxic adaptations of carcinomas The authors characterized the expression of Epo EpoR hypoxia-inducible factor HIF -1alpha estrogen receptor ER and progesterone receptor PR by immunohistochemical methods using carcinoma samples from 107 women and benign samples from 59 women in various phases of the menstrual cycle They then analyzed potential correlations of Epo and EpoR immunostaining and clinicopathologic tumor features with outcome In benign tissue samples Epo and EpoR expression increased over the course of the cycle with the highest levels observed in the late secretory phase Epo expression in benign samples showed a negative correlation with ER and PR expression The authors found Epo and EpoR expression in 95.3 and 100 of carcinoma samples respectively Increased EpoR but not Epo expression in tumors was associated with advanced-stage disease lymphovascular invasion lymph node metastasis and loss of ER expression Increased Epo expression was observed in perinecrotic tumor regions in a pattern similar to the HIF-1alpha expression pattern Increased Epo expression was significantly associated with adverse clinical outcome on both univariate and multivariate analysis Hypoxia-inducible autocrine Epo signaling in carcinoma may contribute to tumor progression and increased aggressiveness Increased Epo expression in carcinomas may be an independent prognostic and/or predictive factor,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6266, 5423, 92, 16, 277, 20, 1823, 535, 10297, 2, 8170, 11930, 29, 4744, 1350, 1823, 4, 393, 34, 16, 41, 5, 578, 278, 2, 251, 6, 36, 3, 738, 761, 264, 1823, 2816, 55, 1, 5423, 2, 5423, 153, 12839, 4, 171, 2, 826, 802, 8, 200, 9, 5297, 5423, 314, 4, 3, 4744, 16278, 1, 826, 3, 738, 765, 3, 55, 1, 5423, 12839, 1823, 2877, 161, 2940, 5018, 808, 153, 516, 2, 2143, 153, 998, 20, 1382, 636, 75, 134, 347, 29, 3650, 117, 2, 1002, 347, 29, 728, 117, 4, 747, 3523, 1, 3, 8518, 417, 491, 818, 311, 174, 2553, 1, 5423, 2, 12839, 5027, 2, 1399, 30, 404, 5, 228, 4, 1002, 246, 347, 5423, 2, 12839, 55, 101, 252, 3, 906, 1, 3, 417, 5, 3, 1076, 148, 164, 4, 3, 807, 7106, 124, 5423, 55, 4, 1002, 347, 224, 8, 199, 816, 5, 516, 2, 998, 55, 3, 738, 204, 5423, 2, 12839, 55, 4, 48, 27, 2, 394, 1, 134, 347, 106, 101, 12839, 84, 44, 5423, 55, 4, 57, 10, 41, 5, 131, 82, 34, 2933, 578, 263, 289, 278, 2, 407, 1, 516, 55, 101, 5423, 55, 10, 164, 4, 26071, 30, 1374, 4, 8, 1177, 288, 6, 3, 2940, 5018, 55, 1177, 101, 5423, 55, 10, 97, 41, 5, 290, 38, 228, 23, 110, 880, 2, 331, 65, 1823, 2877, 5297, 5423, 314, 4, 134, 68, 1248, 6, 30, 91, 2, 101, 3908, 101, 5423, 55, 4, 826, 68, 40, 35, 306, 177, 2, 15, 464, 161]",1781.0,15160341,80
Coenzyme Q10 and lipid-related gene induction in HeLa cells.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2004-05-01,"Coenzyme Q10 is an antioxidant that may have a therapeutic role in cervical cancer. We investigated the cellular and molecular effects of 30 micromol/L Coenzyme Q10 in HeLa cells. Cell growth assays, fluorescence-activated cell sorting analyses, and Oil Red O staining were performed. Microarray experiments were performed in duplicate and analyzed on the basis of 2-fold changes in levels of gene expression. Coenzyme Q10 inhibited cell growth and led to apoptosis. Microarray analysis showed that 264 sequences were altered over time, with enrichment in lipid-related genes. Enhanced lipid accumulation was confirmed with Oil Red O staining. A lipid response to Coenzyme Q10 may affect mechanisms of growth inhibition in HeLa cells.",Journal Article,5743.0,13.0,Coenzyme Q10 is an antioxidant that may have a therapeutic role in cancer We investigated the cellular and molecular effects of 30 micromol/L Coenzyme Q10 in HeLa cells Cell growth assays fluorescence-activated cell sorting analyses and Oil Red O staining were performed Microarray experiments were performed in duplicate and analyzed on the basis of 2-fold changes in levels of gene expression Coenzyme Q10 inhibited cell growth and led to apoptosis Microarray analysis showed that 264 sequences were altered over time with enrichment in lipid-related genes Enhanced lipid accumulation was confirmed with Oil Red O staining A lipid response to Coenzyme Q10 may affect mechanisms of growth inhibition in HeLa cells,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[14411, 19649, 16, 35, 5536, 17, 68, 47, 8, 189, 200, 4, 12, 21, 565, 3, 763, 2, 219, 176, 1, 201, 6297, 805, 14411, 19649, 4, 8466, 37, 31, 129, 1013, 1591, 735, 31, 6751, 318, 2, 9481, 3422, 1990, 1029, 11, 173, 1727, 2332, 11, 173, 4, 13533, 2, 311, 23, 3, 877, 1, 18, 1116, 400, 4, 148, 1, 145, 55, 14411, 19649, 879, 31, 129, 2, 836, 6, 351, 1727, 65, 224, 17, 6528, 2866, 11, 1495, 252, 98, 5, 3020, 4, 3121, 139, 214, 651, 3121, 1835, 10, 557, 5, 9481, 3422, 1990, 1029, 8, 3121, 51, 6, 14411, 19649, 68, 1158, 483, 1, 129, 297, 4, 8466, 37]",714.0,15167860,87
Intraobserver variability in the MR determination of tumor volume in squamous cell carcinoma of the pharynx.,AJNR. American journal of neuroradiology,AJNR Am J Neuroradiol,,"If tumor volumes are to be used for evaluating responses to treatment and long-term outcomes of patients with primary pharyngeal carcinomas, the reproducibility of these measurements must be established. We determined the intraobserver variability of MR imaging-based volume measurements of these cancers and their regional metastases. We used an interactive computer program (IDL) that enables the extraction of tumor volumes from 3D MR data to obtain 202 volume measurements in 17 patients with pharyngeal carcinoma (two to five time points each). The primary cancer and largest nodal mass were manually outlined on every T2-weighted image of each MR study. The same neuroradiologist reanalyzed this MR dataset 2-41 weeks later. Measurement error and percentage measurement error (intraobserver variability) were determined. Differences in intraobserver variability between primary lesions and nodes, as well as between stages of treatment were tested with a Wilcoxon rank sum test. The mean and median percentage measurement errors, respectively, were 13% and 12% (range, 0-53%; 95% CI: 10%, 16%) for primary tumors and 9% and 7% (range, 0-37%; 95% CI: 7%, 12%) for nodal metastases. The difference in the percentage measurement error between primary lesions and cervical nodes approached statistical significance (P =.07). Differences in the variation of volume measurements based on the stage of therapy were significant (P =.01). Our results suggest that MR imaging-based tumor volumes are reliably reproducible. Such measurements may be important in predicting patient outcome, determining appropriate therapy, and conducting patient follow-up.",Journal Article,,30.0,If tumor volumes are to be used for evaluating responses to treatment and long-term outcomes of patients with primary carcinomas the reproducibility of these measurements must be established We determined the intraobserver variability of MR imaging-based volume measurements of these cancers and their regional metastases We used an interactive computer program IDL that enables the extraction of tumor volumes from 3D MR data to obtain 202 volume measurements in 17 patients with carcinoma two to five time points each The primary cancer and largest nodal mass were manually outlined on every T2-weighted image of each MR study The same neuroradiologist reanalyzed this MR dataset 2-41 weeks later Measurement error and percentage measurement error intraobserver variability were determined Differences in intraobserver variability between primary lesions and nodes as well as between stages of treatment were tested with a Wilcoxon rank sum test The mean and median percentage measurement errors respectively were 13 and 12 range 0-53 95 CI 10 16 for primary tumors and 9 and 7 range 0-37 95 CI 7 12 for nodal metastases The difference in the percentage measurement error between primary lesions and nodes approached statistical significance P =.07 Differences in the variation of volume measurements based on the stage of therapy were significant P =.01 Our results suggest that MR imaging-based tumor volumes are reliably reproducible Such measurements may be important in predicting patient outcome determining appropriate therapy and conducting patient follow-up,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[492, 30, 2225, 32, 6, 40, 95, 9, 1435, 253, 6, 24, 2, 319, 337, 123, 1, 7, 5, 86, 826, 3, 4688, 1, 46, 1685, 1642, 40, 635, 21, 509, 3, 13056, 1982, 1, 1638, 270, 90, 433, 1685, 1, 46, 163, 2, 136, 951, 196, 21, 95, 35, 4750, 4236, 1243, 30617, 17, 4843, 3, 5763, 1, 30, 2225, 29, 2265, 1638, 74, 6, 3140, 5918, 433, 1685, 4, 269, 7, 5, 134, 100, 6, 365, 98, 862, 296, 3, 86, 12, 2, 2166, 779, 782, 11, 8474, 6394, 23, 454, 1786, 2337, 1482, 1, 296, 1638, 45, 3, 827, 21256, 18359, 26, 1638, 3014, 18, 605, 244, 1559, 2204, 3444, 2, 1150, 2204, 3444, 13056, 1982, 11, 509, 362, 4, 13056, 1982, 59, 86, 406, 2, 502, 22, 149, 22, 59, 1153, 1, 24, 11, 650, 5, 8, 3896, 1026, 3216, 412, 3, 313, 2, 52, 1150, 2204, 4612, 106, 11, 233, 2, 133, 184, 13, 699, 48, 58, 79, 245, 9, 86, 57, 2, 83, 2, 67, 184, 13, 567, 48, 58, 67, 133, 9, 779, 196, 3, 523, 4, 3, 1150, 2204, 3444, 59, 86, 406, 2, 502, 5738, 1050, 724, 19, 1615, 362, 4, 3, 1380, 1, 433, 1685, 90, 23, 3, 82, 1, 36, 11, 93, 19, 355, 114, 99, 309, 17, 1638, 270, 90, 30, 2225, 32, 4092, 4172, 225, 1685, 68, 40, 305, 4, 1434, 69, 228, 2196, 870, 36, 2, 6018, 69, 166, 126]",1568.0,15205156,624
Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy.,Gynecologic oncology,Gynecol. Oncol.,2004-07-01,"To determine the outcome, complications and likelihood of requiring adjuvant therapy of patients with stage IB2 cervical cancer treated with primary radical hysterectomy and lymph node dissection. Clinical and pathologic data between 1985 and 1999 were reviewed. Associations between clinical and pathologic variables were tested using the Fisher's exact test. Survival was estimated using the Kaplan-Meier method with significance being calculated using the Log Rank test. Six hundred radical hysterectomies were performed during the study period. Fifty-eight of these women (9.6% of all radical hysterectomies) were diagnosed with FIGO stage IB2 cancers. Sixteen patients (28%) had positive pelvic lymph nodes. Forty-six patients (79%) had invasion involving the outer 1/3 of the cervical stroma, six had positive vaginal margins while five had occult parametrial extension. After retrospective review of the histopathologic data from this case series, criteria from two recently published prospective multicenter Gynecologic Oncology Group (GOG) trials were applied to this data set. According to criteria established by GOG protocol 92, 30 (52%) patients should have theoretically received adjuvant pelvic radiation while 21 (36%) would have qualified for adjuvant chemotherapy and radiation according to the results of GOG protocol 109. In actual fact, only 35 patients (60%) received adjuvant radiotherapy and one received adjuvant chemo-radiation. Severe toxicity was unusual with two developing urinary fistulae and one having a pulmonary embolism. Despite the lack of adjuvant therapy in most cases, only 21 women (38%) recurred of whom 11 failed on the pelvic wall, with an estimated 5-year survival of 62.1%. Radical hysterectomy and tailored adjuvant radiation therapy in stage IB2 cervical cancer is feasible. Even without the liberal use of adjuvant therapy, survival in this high-risk group compares favorably to primary chemotherapy and radiation. According to recently published randomized clinical trials, most patients should receive adjuvant postoperative therapy. The benefits of this multimodality approach require randomized study.",Journal Article,5682.0,64.0,To determine the outcome complications and likelihood of requiring adjuvant therapy of patients with stage IB2 cancer treated with primary radical hysterectomy and lymph node dissection Clinical and pathologic data between 1985 and 1999 were reviewed Associations between clinical and pathologic variables were tested using the Fisher 's exact test Survival was estimated using the Kaplan-Meier method with significance being calculated using the Log Rank test Six hundred radical hysterectomies were performed during the study period Fifty-eight of these women 9.6 of all radical hysterectomies were diagnosed with FIGO stage IB2 cancers Sixteen patients 28 had positive pelvic lymph nodes Forty-six patients 79 had invasion involving the outer 1/3 of the stroma six had positive margins while five had occult parametrial extension After retrospective review of the histopathologic data from this case series criteria from two recently published prospective multicenter Gynecologic Oncology Group GOG trials were applied to this data set According to criteria established by GOG protocol 92 30 52 patients should have theoretically received adjuvant pelvic radiation while 21 36 would have qualified for adjuvant chemotherapy and radiation according to the results of GOG protocol 109 In actual fact only 35 patients 60 received adjuvant radiotherapy and one received adjuvant chemo-radiation Severe toxicity was unusual with two developing urinary fistulae and one having a pulmonary embolism Despite the lack of adjuvant therapy in most cases only 21 women 38 recurred of whom 11 failed on the pelvic wall with an estimated 5-year survival of 62.1 Radical hysterectomy and tailored adjuvant radiation therapy in stage IB2 cancer is feasible Even without the liberal use of adjuvant therapy survival in this high-risk group compares favorably to primary chemotherapy and radiation According to recently published randomized clinical trials most patients should receive adjuvant postoperative therapy The benefits of this multimodality approach require randomized study,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 228, 521, 2, 1420, 1, 1888, 249, 36, 1, 7, 5, 82, 9537, 12, 73, 5, 86, 711, 2622, 2, 263, 289, 1161, 38, 2, 510, 74, 59, 4675, 2, 2043, 11, 446, 685, 59, 38, 2, 510, 682, 11, 650, 75, 3, 3135, 292, 2472, 412, 25, 10, 661, 75, 3, 876, 882, 596, 5, 724, 486, 981, 75, 3, 1066, 1026, 412, 437, 1128, 711, 15266, 11, 173, 190, 3, 45, 727, 1461, 659, 1, 46, 117, 83, 49, 1, 62, 711, 15266, 11, 265, 5, 3837, 82, 9537, 163, 3228, 7, 339, 42, 109, 1110, 263, 502, 1213, 437, 7, 842, 42, 578, 1267, 3, 7808, 14, 27, 1, 3, 2477, 437, 42, 109, 1012, 369, 365, 42, 2879, 8726, 2401, 50, 459, 206, 1, 3, 2630, 74, 29, 26, 473, 988, 371, 29, 100, 761, 983, 482, 1570, 1512, 413, 87, 4760, 143, 11, 1498, 6, 26, 74, 916, 768, 6, 371, 635, 20, 4760, 1182, 937, 201, 653, 7, 257, 47, 9662, 103, 249, 1110, 121, 369, 239, 511, 688, 47, 9575, 9, 249, 56, 2, 121, 768, 6, 3, 99, 1, 4760, 1182, 3486, 4, 3480, 1991, 158, 465, 7, 335, 103, 249, 310, 2, 104, 103, 249, 3341, 121, 905, 155, 10, 4015, 5, 100, 931, 1660, 17809, 2, 104, 1041, 8, 1087, 5475, 550, 3, 926, 1, 249, 36, 4, 96, 140, 158, 239, 117, 519, 3363, 1, 953, 175, 1551, 23, 3, 1110, 2397, 5, 35, 661, 33, 111, 25, 1, 744, 14, 711, 2622, 2, 3632, 249, 121, 36, 4, 82, 9537, 12, 16, 1313, 871, 187, 3, 23341, 119, 1, 249, 36, 25, 4, 26, 64, 43, 87, 5815, 5001, 6, 86, 56, 2, 121, 768, 6, 761, 983, 384, 38, 143, 96, 7, 257, 560, 249, 573, 36, 3, 1141, 1, 26, 2425, 353, 1353, 384, 45]",2070.0,15262120,9
Adenocarcinoma of the cervix and vagina in pediatric patients.,Pediatric blood & cancer,Pediatr Blood Cancer,2004-09-01,Here we report our combined analysis of vaginal mesonephric adenocarcinoma (MA) in a 13 years old treated at our institution and of reported vaginal or cervical MA and clear-cell adenocarcinoma in 37 patients 18 years old or younger. Tumors in 27 patients arose in the vagina; 8 (21%) had metastases at diagnosis. The predominant symptom was vaginal bleeding; 62% of patients were exposed to diethylstilbestrol in utero. The 3-year survival estimate was 71% +/- 11%. Surgical treatment and metastasis at diagnosis were significant predictors of survival. The association between tumor excision and excellent outcome suggests that radical hysterectomy or pelvic exenteration is unnecessary. Radiotherapy as an adjunct may have contributed to this outcome.,Journal Article,5620.0,17.0,Here we report our combined analysis of mesonephric adenocarcinoma MA in a 13 years old treated at our institution and of reported or MA and clear-cell adenocarcinoma in 37 patients 18 years old or younger Tumors in 27 patients arose in the vagina 8 21 had metastases at diagnosis The predominant symptom was bleeding 62 of patients were exposed to diethylstilbestrol in utero The 3-year survival estimate was 71 +/- 11 Surgical treatment and metastasis at diagnosis were significant predictors of survival The association between tumor excision and excellent outcome suggests that radical hysterectomy or pelvic exenteration is unnecessary Radiotherapy as an adjunct may have contributed to this outcome,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[467, 21, 414, 114, 397, 65, 1, 28259, 449, 3687, 4, 8, 233, 60, 1095, 73, 28, 114, 731, 2, 1, 210, 15, 3687, 2, 885, 31, 449, 4, 567, 7, 203, 60, 1095, 15, 773, 57, 4, 428, 7, 7268, 4, 3, 7553, 66, 239, 42, 196, 28, 147, 3, 2750, 934, 10, 2294, 744, 1, 7, 11, 2234, 6, 15522, 4, 13767, 3, 27, 111, 25, 1191, 10, 792, 175, 221, 24, 2, 278, 28, 147, 11, 93, 674, 1, 25, 3, 248, 59, 30, 1366, 2, 1503, 228, 844, 17, 711, 2622, 15, 1110, 5668, 16, 4224, 310, 22, 35, 5471, 68, 47, 3447, 6, 26, 228]",704.0,15266416,385
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?,Gynecologic oncology,Gynecol. Oncol.,2004-08-01,"To evaluate how the independent predictors of recurrence for stage IB2 cervical cancers treated with up-front radical hysterectomy apply to established risk models. Patients with IB2 cervical cancers diagnosed from 1990 to 2000 were identified from tumor registries of two institutions. Patients were classified into risk groups: high-risk (HR) (positive nodes, parametria, or margins), intermediate-risk (IR) (positive lymph vascular space involvement (LVSI) with any cervical stromal invasion (CSI), or (-) LVSI and > middle- CSI), or low-risk (LR) (absence of HR or IR characteristics). Disease-free survival (DFS) was estimated by Kaplan-Meier method and comparisons between subgroups were studied by log rank. A Cox proportional hazards model was used to determine independent predictors of recurrence. We identified 86 patients with stage IB2 tumors treated by RH. We found 34% of patients to be HR, 60% IR, and 6% LR. Of the 52 IR patients, 28 had (+) LVSI with superficial, middle, and outer 1/3 CSI, and 24 had (-) LVSI with middle or outer 1/3 invasion. Overall, postoperative adjuvant radiation (PRT) was used in 52% of the 86 patients, including 0/5 LR, 16/52 IR, and 29/29 HR patients. Univariate predictors of recurrence were pelvic nodal disease, (+) LVSI, (+) parametria, outer 1/3 CSI, and tumor size > 6 cm. Age, grade, histology, and the use of postoperative radiation were not associated with recurrence. Multivariate analysis identified LVSI as the only independent predictor of recurrence (RR 5.2, P = 0.03). Two-year DFS for LR, IR, and HR patients was 100%, 83%, and 60%, respectively. Only 4/24 (17%) IR patients with (-) LVSI got PRT compared with 12/28 (43%) of IR patients with (+) LVSI. The 2-year DFS for IR patients with (-) LVSI was 96%. IR (+) patients recurred more frequently with a 2-year DFS of 71%. Overall, 66% of patients with IB2 disease were classified as having low or intermediate-risk disease. IR patients with (-) LVSI and all LR patients did well with surgery alone. This study defines the independent importance of LVSI and questions the utility of published IR models when applied to stage IB2 cervical cancer.",Journal Article,5651.0,29.0,To evaluate how the independent predictors of recurrence for stage IB2 cancers treated with up-front radical hysterectomy apply to established risk models Patients with IB2 cancers diagnosed from 1990 to 2000 were identified from tumor registries of two institutions Patients were classified into risk groups high-risk HR positive nodes parametria or margins intermediate-risk IR positive lymph vascular space involvement LVSI with any stromal invasion CSI or LVSI and middle- CSI or low-risk LR absence of HR or IR characteristics Disease-free survival DFS was estimated by Kaplan-Meier method and comparisons between subgroups were studied by log rank A Cox proportional hazards model was used to determine independent predictors of recurrence We identified 86 patients with stage IB2 tumors treated by RH We found 34 of patients to be HR 60 IR and 6 LR Of the 52 IR patients 28 had LVSI with superficial middle and outer 1/3 CSI and 24 had LVSI with middle or outer 1/3 invasion Overall postoperative adjuvant radiation PRT was used in 52 of the 86 patients including 0/5 LR 16/52 IR and 29/29 HR patients Univariate predictors of recurrence were pelvic nodal disease LVSI parametria outer 1/3 CSI and tumor size 6 cm Age grade histology and the use of postoperative radiation were not associated with recurrence Multivariate analysis identified LVSI as the only independent predictor of recurrence RR 5.2 P 0.03 Two-year DFS for LR IR and HR patients was 100 83 and 60 respectively Only 4/24 17 IR patients with LVSI got PRT compared with 12/28 43 of IR patients with LVSI The 2-year DFS for IR patients with LVSI was 96 IR patients recurred more frequently with a 2-year DFS of 71 Overall 66 of patients with IB2 disease were classified as having low or intermediate-risk disease IR patients with LVSI and all LR patients did well with surgery alone This study defines the independent importance of LVSI and questions the utility of published IR models when applied to stage IB2 cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,"[6, 376, 832, 3, 306, 674, 1, 146, 9, 82, 9537, 163, 73, 5, 126, 3007, 711, 2622, 4930, 6, 635, 43, 274, 7, 5, 9537, 163, 265, 29, 2289, 6, 1081, 11, 108, 29, 30, 3768, 1, 100, 1764, 7, 11, 1373, 237, 43, 271, 64, 43, 168, 109, 502, 19585, 15, 1012, 919, 43, 2123, 109, 263, 756, 3865, 799, 8004, 5, 500, 1126, 578, 4293, 15, 8004, 2, 3897, 4293, 15, 154, 43, 2030, 1127, 1, 168, 15, 2123, 374, 34, 115, 25, 1010, 10, 661, 20, 876, 882, 596, 2, 2213, 59, 1453, 11, 656, 20, 1066, 1026, 8, 418, 831, 1017, 202, 10, 95, 6, 223, 306, 674, 1, 146, 21, 108, 868, 7, 5, 82, 9537, 57, 73, 20, 7240, 21, 204, 562, 1, 7, 6, 40, 168, 335, 2123, 2, 49, 2030, 1, 3, 653, 2123, 7, 339, 42, 8004, 5, 3562, 3897, 2, 7808, 14, 27, 4293, 2, 259, 42, 8004, 5, 3897, 15, 7808, 14, 27, 578, 63, 573, 249, 121, 8804, 10, 95, 4, 653, 1, 3, 868, 7, 141, 13, 33, 2030, 245, 653, 2123, 2, 462, 462, 168, 7, 880, 674, 1, 146, 11, 1110, 779, 34, 8004, 19585, 7808, 14, 27, 4293, 2, 30, 444, 49, 494, 89, 88, 784, 2, 3, 119, 1, 573, 121, 11, 44, 41, 5, 146, 331, 65, 108, 8004, 22, 3, 158, 306, 980, 1, 146, 861, 33, 18, 19, 13, 680, 100, 111, 1010, 9, 2030, 2123, 2, 168, 7, 10, 394, 852, 2, 335, 106, 158, 39, 259, 269, 2123, 7, 5, 8004, 23353, 8804, 72, 5, 133, 339, 601, 1, 2123, 7, 5, 8004, 3, 18, 111, 1010, 9, 2123, 7, 5, 8004, 10, 921, 2123, 7, 3363, 80, 746, 5, 8, 18, 111, 1010, 1, 792, 63, 700, 1, 7, 5, 9537, 34, 11, 1373, 22, 1041, 154, 15, 919, 43, 34, 2123, 7, 5, 8004, 2, 62, 2030, 7, 205, 149, 5, 152, 279, 26, 45, 5849, 3, 306, 1187, 1, 8004, 2, 1937, 3, 1207, 1, 983, 2123, 274, 198, 1498, 6, 82, 9537, 12]",1990.0,15297159,148
p16 expression in squamous lesions of the female genital tract.,Journal of molecular histology,J. Mol. Histol.,2004-02-01,"The aim of this study was to examine the role of p16 in the pathogenesis of squamous carcinoma of the gynecologic tract. Squamous carcinoma and carcinoma in situ from the female genital tract were examined for the expression of p16 by paraffin immunohistochemistry. About 74% (40/54) of cases showed p16 expression. By primary site, 77% (23/30) of cervical, 67% (6/9) of vaginal and 85% (11/13) of vulvar primaries expressed p16, but two endometrial primary squamous carcinomas were negative (0/2). In addition, p16 was not identified in non-dysplastic tissue and low grade dysplasia. In cases where there were matched vaginal or vulvar and cervical primaries in a given patient, there was concordant positive p16 expression. It is concluded that p16 is frequently expressed in squamous carcinoma of the cervix, vagina and vulva, but not seen in cases of benign and low grade lesions. It may be a marker of transformation from a low to a high grade lesion. More cases of endometrial primaries need to be studied to see if these evolve by a p16-independent pathway.",Journal Article,5833.0,8.0,The aim of this study was to examine the role of p16 in the pathogenesis of squamous carcinoma of the gynecologic tract Squamous carcinoma and carcinoma in situ from the female genital tract were examined for the expression of p16 by paraffin immunohistochemistry About 74 40/54 of cases showed p16 expression By primary site 77 23/30 of 67 6/9 of and 85 11/13 of primaries expressed p16 but two primary squamous carcinomas were negative 0/2 In addition p16 was not identified in non-dysplastic tissue and low grade dysplasia In cases where there were matched or and primaries in a given patient there was concordant positive p16 expression It is concluded that p16 is frequently expressed in squamous carcinoma of the cervix vagina and vulva but not seen in cases of benign and low grade lesions It may be a marker of transformation from a low to a high grade lesion More cases of primaries need to be studied to see if these evolve by a p16-independent pathway,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 1130, 1, 26, 45, 10, 6, 1004, 3, 200, 1, 1932, 4, 3, 1384, 1, 691, 134, 1, 3, 1512, 1696, 691, 134, 2, 134, 4, 957, 29, 3, 1061, 8226, 1696, 11, 409, 9, 3, 55, 1, 1932, 20, 2487, 888, 545, 794, 327, 667, 1, 140, 224, 1932, 55, 20, 86, 606, 849, 382, 201, 1, 598, 49, 83, 1, 2, 772, 175, 233, 1, 6183, 570, 1932, 84, 100, 86, 691, 826, 11, 199, 13, 18, 4, 352, 1932, 10, 44, 108, 4, 220, 6461, 246, 2, 154, 88, 2253, 4, 140, 1257, 125, 11, 655, 15, 2, 6183, 4, 8, 447, 69, 125, 10, 3610, 109, 1932, 55, 192, 16, 4724, 17, 1932, 16, 746, 570, 4, 691, 134, 1, 3, 3629, 7553, 2, 9263, 84, 44, 527, 4, 140, 1, 1002, 2, 154, 88, 406, 192, 68, 40, 8, 952, 1, 1392, 29, 8, 154, 6, 8, 64, 88, 1180, 80, 140, 1, 6183, 594, 6, 40, 656, 6, 3764, 492, 46, 4800, 20, 8, 1932, 306, 308]",962.0,15328914,575
BRCAPAP: feasibility of clinical BRCA testing on liquid-based cervical cytology: implications for biomarker development.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2004-09-01,"The study was designed to test the feasibility that lower genital tract cytology is a compatible medium for robust germ line genetic analyses. BRCA1 and/or BRCA2 gene mutational analysis was done on DNA isolated from liquid-based cervical or vaginal cytology taken from 17 consenting women (age 29-65 years) who previously had genetic counseling followed by BRACAnalysis (Myriad Genetics, Salt Lake City, UT) blood analyses. Eleven women had known mutations in either BRCA1 or BRCA2 (cases) and six had no identified mutations (controls) on entry into the study. Anonymized cytology samples were sent to Myriad Genetics with a request for testing that was limited to the degree of genomic testing previously done on the blood samples. One cervicovaginal specimen from a test-positive woman had inadequate cellular content that precluded gene sequencing and therefore was excluded from this analysis. For the 16 women with adequate cytologic specimens, there was 100% concordance for BRCA mutation test results between blood and genital tract cytology (kappa = 1.0; 95% confidence interval, 0.51-1.0). We have shown the feasibility of using liquid-based genital tract cytology as an alternative biospecimen to blood for germ line genetic analysis using a clinical approved assay. It needs to be emphasized that any type of testing for BRCA1 or BRCA2 mutation genotype should only be done in the setting of pretest and posttest counseling.",Journal Article,5620.0,1.0,The study was designed to test the feasibility that lower genital tract cytology is a compatible medium for robust germ line genetic analyses BRCA1 and/or BRCA2 gene mutational analysis was done on DNA isolated from liquid-based or cytology taken from 17 consenting women age 29-65 years who previously had genetic counseling followed by BRACAnalysis Myriad Genetics Salt Lake City UT blood analyses Eleven women had known mutations in either BRCA1 or BRCA2 cases and six had no identified mutations controls on entry into the study Anonymized cytology samples were sent to Myriad Genetics with a request for testing that was limited to the degree of genomic testing previously done on the blood samples One cervicovaginal specimen from a test-positive woman had inadequate cellular content that precluded gene sequencing and therefore was excluded from this analysis For the 16 women with adequate cytologic specimens there was 100 concordance for BRCA mutation test results between blood and genital tract cytology kappa 1.0 95 confidence interval 0.51-1.0 We have shown the feasibility of using liquid-based genital tract cytology as an alternative biospecimen to blood for germ line genetic analysis using a clinical approved assay It needs to be emphasized that any type of testing for BRCA1 or BRCA2 mutation genotype should only be done in the setting of pretest and posttest counseling,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 45, 10, 1114, 6, 412, 3, 1437, 17, 280, 8226, 1696, 2045, 16, 8, 7293, 3759, 9, 1922, 2280, 328, 336, 318, 766, 2, 15, 1167, 145, 1619, 65, 10, 1822, 23, 261, 1355, 29, 3165, 90, 15, 2045, 1633, 29, 269, 11932, 117, 89, 462, 556, 60, 54, 373, 42, 336, 2011, 370, 20, 30650, 8390, 2894, 11818, 37757, 7235, 13609, 315, 318, 2627, 117, 42, 440, 138, 4, 361, 766, 15, 1167, 140, 2, 437, 42, 77, 108, 138, 535, 23, 3001, 237, 3, 45, 23301, 2045, 347, 11, 6325, 6, 8390, 2894, 5, 8, 11660, 9, 471, 17, 10, 383, 6, 3, 1444, 1, 572, 471, 373, 1822, 23, 3, 315, 347, 104, 43708, 2360, 29, 8, 412, 109, 2854, 42, 3358, 763, 2457, 17, 8035, 145, 615, 2, 673, 10, 1800, 29, 26, 65, 9, 3, 245, 117, 5, 1658, 4195, 623, 125, 10, 394, 1827, 9, 1555, 258, 412, 99, 59, 315, 2, 8226, 1696, 2045, 3096, 14, 13, 48, 307, 268, 13, 725, 14, 13, 21, 47, 443, 3, 1437, 1, 75, 3165, 90, 8226, 1696, 2045, 22, 35, 1091, 13603, 6, 315, 9, 2280, 328, 336, 65, 75, 8, 38, 850, 719, 192, 1891, 6, 40, 8585, 17, 500, 267, 1, 471, 9, 766, 15, 1167, 258, 1183, 257, 158, 40, 1822, 4, 3, 546, 1, 12521, 2, 19504, 2011]",1393.0,15342457,760
HPV communication: review of existing research and recommendations for patient education.,CA: a cancer journal for clinicians,CA Cancer J Clin,,"The potential for human papillomavirus (HPV) DNA testing in cervical cancer prevention programs has been a topic at the forefront of cervical cancer policy discussions in recent years. To prevent some of the anxiety and psychological distress often experienced on HPV diagnosis and during the period of management, mass patient education must accompany the incorporation of HPV DNA testing into screening protocols. To contribute to a growing body of work that provides an empiric basis for development of effective counseling messages about HPV and HPV testing, this paper highlights women's most common information gaps and psychosocial concerns and describes the different perspectives offered by women's usual sources of information about HPV, including the crucial role of the clinical community in creating a shared decision making environment in which screening decisions and results can be discussed.",Journal Article,,119.0,The potential for human papillomavirus HPV DNA testing in cancer prevention programs has been a topic at the forefront of cancer policy discussions in recent years To prevent some of the anxiety and psychological distress often experienced on HPV diagnosis and during the period of management mass patient education must accompany the incorporation of HPV DNA testing into screening protocols To contribute to a growing body of work that provides an empiric basis for development of effective counseling messages about HPV and HPV testing this paper highlights women 's most common information gaps and psychosocial concerns and describes the different perspectives offered by women 's usual sources of information about HPV including the crucial role of the clinical community in creating a shared decision making environment in which screening decisions and results can be discussed,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 174, 9, 171, 3242, 933, 261, 471, 4, 12, 1070, 2251, 71, 85, 8, 5463, 28, 3, 11747, 1, 12, 4196, 3173, 4, 435, 60, 6, 1682, 476, 1, 3, 2021, 2, 2624, 1462, 629, 592, 23, 933, 147, 2, 190, 3, 727, 1, 284, 782, 69, 1848, 1642, 15982, 3, 2838, 1, 933, 261, 471, 237, 453, 2189, 6, 1248, 6, 8, 1921, 642, 1, 1357, 17, 777, 35, 7866, 877, 9, 193, 1, 323, 2011, 12610, 545, 933, 2, 933, 471, 26, 2817, 2527, 117, 292, 96, 186, 487, 5287, 2, 2322, 2061, 2, 2677, 3, 338, 5856, 2216, 20, 117, 292, 3521, 3375, 1, 487, 545, 933, 141, 3, 2653, 200, 1, 3, 38, 1714, 4, 6147, 8, 2664, 948, 1079, 3087, 4, 92, 453, 1526, 2, 99, 122, 40, 1588]",884.0,15371283,237
Malignant basomelanocytic tumor manifesting as metastatic melanoma.,The American journal of surgical pathology,Am. J. Surg. Pathol.,2004-10-01,"We report a case of an unusual basomelanocytic tumor from the scalp of a 56-year-old man. A 56-year-old white man presented with a scalp lesion that was biopsied and interpreted as a basal cell carcinoma. Fourteen months later, metastatic melanoma was discovered in a cervical lymph node and the liver. A subsequent biopsy from the area of the previously biopsied basal cell carcinoma of the scalp showed an invasive malignant melanoma. Immunohistochemical stains performed on the original scalp specimen showed biphasic immunohistochemical profile. A population of neoplastic cells was strongly positive for the melanocytic markers Melan-A, HMB-45, and tyrosinase and showed weak focal immunoreactivity for S-100. A second population of cells was strongly immunoreactive for keratin (wide-spectrum polyclonal antibody) and BerEp4. To our knowledge, this is the first description of a malignant basomelanocytic tumor complicated by metastatic melanoma.",Case Reports,5590.0,35.0,We report a case of an unusual basomelanocytic tumor from the scalp of a 56-year-old man A 56-year-old white man presented with a scalp lesion that was biopsied and interpreted as a basal cell carcinoma Fourteen months later metastatic was discovered in a lymph node and the A subsequent biopsy from the area of the previously biopsied basal cell carcinoma of the scalp showed an invasive malignant Immunohistochemical stains performed on the original scalp specimen showed biphasic immunohistochemical profile A population of neoplastic cells was strongly positive for the melanocytic markers Melan-A HMB-45 and tyrosinase and showed weak focal immunoreactivity for S-100 A second population of cells was strongly immunoreactive for keratin wide-spectrum polyclonal antibody and BerEp4 To our knowledge this is the first description of a malignant basomelanocytic tumor complicated by metastatic,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 414, 8, 473, 1, 35, 4015, 43719, 30, 29, 3, 5826, 1, 8, 664, 111, 1095, 3628, 8, 664, 111, 1095, 886, 3628, 917, 5, 8, 5826, 1180, 17, 10, 6775, 2, 5047, 22, 8, 2135, 31, 134, 3225, 53, 1559, 113, 10, 2747, 4, 8, 263, 289, 2, 3, 8, 706, 411, 29, 3, 965, 1, 3, 373, 6775, 2135, 31, 134, 1, 3, 5826, 224, 35, 416, 393, 1382, 7742, 173, 23, 3, 2279, 5826, 2360, 224, 7739, 1382, 800, 8, 266, 1, 2000, 37, 10, 1327, 109, 9, 3, 6123, 525, 12470, 8, 16740, 512, 2, 7624, 2, 224, 4241, 2137, 4900, 9, 695, 394, 8, 419, 266, 1, 37, 10, 1327, 10044, 9, 11535, 1019, 1873, 6350, 548, 2, 54363, 6, 114, 922, 26, 16, 3, 157, 5263, 1, 8, 393, 43719, 30, 4286, 20, 113]",896.0,15371958,30
A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?,Gynecologic oncology,Gynecol. Oncol.,2004-10-01,"To compare stages IB1 and IB2 cervical cancers treated with radical hysterectomy (RH) and to define predictors of nodal status and recurrence. Patients with stage IB cervical cancers undergoing RH between 1990 and 2000 were evaluated and clinicopathological variables were abstracted. The perioperative complication rate, estimated blood loss (EBL), and OR time were also tabulated. Variables were analyzed using X(2) and t tests. Disease-free survival (DFS) was calculated by Kaplan-Meier method. Multivariate analysis was performed via stepwise logistic regression. Cox-proportional hazards were used to identify independent predictors of recurrence. RH was performed on 109 stage IB1 and 86 stage IB2 patients. Mean age, EBL, and perioperative complication rates were similar. Overall, 38 patients (14 IB1 vs. 24 IB2) had positive nodes (P = 0.01) including 9 patients with positive para-aortic nodes (2 IB1 and 7 IB2). Parametrial involvement (PI) and outer 2/3 depth of invasion (DOI) were significantly more common in the IB2 tumors as well. Patients with IB2 disease received adjuvant radiation more frequently than IB1 patients (52% vs. 37%, P = 0.04). Univariate predictors of nodal status included lymphovascular space involvement (LVSI) (P = 0.001), DOI (P = 0.011), PI (P = 0.001), and stage (P = 0.011). Multivariate analysis identified only LVSI (OR 6.4, CI 2.4-17, P = 0. 0002) and PI (OR 8, CI 3.1-20, P = 0. 0001) as independent predictors of positive nodes. With a median follow-up of 35 months, estimates of DFS revealed tumor size (P = 0.008), nodal status (P = 0.0004), LVSI (P = 0.002), PI (P = 0.004), and DOI (P = 0.0004) as significant univariate predictors. Neoadjuvant chemotherapy, age, grade, histology, and adjuvant radiation were not associated with recurrence. The significant independent predictors of DFS were LVSI (ROR 5.7, CI 2-16, P = 0.0064) and outer 2/3 DOI (OR 5.8, CI 2-20, P = 0.0029). Neither tumor size nor nodal status was a significant predictor of DFS. The prognosis in stage IB cervical cancer seems to be most influenced by presence of LVSI and DOI and not by tumor size as the staging criteria would suggest. These factors are best determined pathologically after radical hysterectomy. This report contains the largest comparison of IB1 and IB2 patients managed by RH. Tumor size failed to predict recurrence or nodal status when stratified by LVSI, DOI, and PI. Treatment decisions based on tumor size alone should be reconsidered.",Journal Article,5590.0,48.0,To compare stages IB1 and IB2 cancers treated with radical hysterectomy RH and to define predictors of nodal status and recurrence Patients with stage IB cancers undergoing RH between 1990 and 2000 were evaluated and clinicopathological variables were abstracted The perioperative complication rate estimated blood loss EBL and OR time were also tabulated Variables were analyzed using X 2 and t tests Disease-free survival DFS was calculated by Kaplan-Meier method Multivariate analysis was performed via stepwise logistic regression Cox-proportional hazards were used to identify independent predictors of recurrence RH was performed on 109 stage IB1 and 86 stage IB2 patients Mean age EBL and perioperative complication rates were similar Overall 38 patients 14 IB1 vs. 24 IB2 had positive nodes P 0.01 including 9 patients with positive para-aortic nodes 2 IB1 and 7 IB2 Parametrial involvement PI and outer 2/3 depth of invasion DOI were significantly more common in the IB2 tumors as well Patients with IB2 disease received adjuvant radiation more frequently than IB1 patients 52 vs. 37 P 0.04 Univariate predictors of nodal status included lymphovascular space involvement LVSI P 0.001 DOI P 0.011 PI P 0.001 and stage P 0.011 Multivariate analysis identified only LVSI OR 6.4 CI 2.4-17 P 0 0002 and PI OR 8 CI 3.1-20 P 0 0001 as independent predictors of positive nodes With a median follow-up of 35 months estimates of DFS revealed tumor size P 0.008 nodal status P 0.0004 LVSI P 0.002 PI P 0.004 and DOI P 0.0004 as significant univariate predictors Neoadjuvant chemotherapy age grade histology and adjuvant radiation were not associated with recurrence The significant independent predictors of DFS were LVSI ROR 5.7 CI 2-16 P 0.0064 and outer 2/3 DOI OR 5.8 CI 2-20 P 0.0029 Neither tumor size nor nodal status was a significant predictor of DFS The prognosis in stage IB cancer seems to be most influenced by presence of LVSI and DOI and not by tumor size as the staging criteria would suggest These factors are best determined pathologically after radical hysterectomy This report contains the largest comparison of IB1 and IB2 patients managed by RH Tumor size failed to predict recurrence or nodal status when stratified by LVSI DOI and PI Treatment decisions based on tumor size alone should be reconsidered,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 932, 1153, 8111, 2, 9537, 163, 73, 5, 711, 2622, 7240, 2, 6, 1107, 674, 1, 779, 156, 2, 146, 7, 5, 82, 3180, 163, 479, 7240, 59, 2289, 2, 1081, 11, 194, 2, 2721, 682, 11, 4106, 3, 1547, 1447, 116, 661, 315, 407, 9541, 2, 15, 98, 11, 120, 9903, 682, 11, 311, 75, 1006, 18, 2, 102, 895, 34, 115, 25, 1010, 10, 981, 20, 876, 882, 596, 331, 65, 10, 173, 847, 5497, 812, 320, 418, 831, 1017, 11, 95, 6, 255, 306, 674, 1, 146, 7240, 10, 173, 23, 3486, 82, 8111, 2, 868, 82, 9537, 7, 313, 89, 9541, 2, 1547, 1447, 151, 11, 288, 63, 519, 7, 213, 8111, 105, 259, 9537, 42, 109, 502, 19, 13, 355, 141, 83, 7, 5, 109, 4615, 3938, 502, 18, 8111, 2, 67, 9537, 8726, 799, 2928, 2, 7808, 18, 27, 2436, 1, 578, 13105, 11, 97, 80, 186, 4, 3, 9537, 57, 22, 149, 7, 5, 9537, 34, 103, 249, 121, 80, 746, 76, 8111, 7, 653, 105, 567, 19, 13, 755, 880, 674, 1, 779, 156, 159, 2933, 3865, 799, 8004, 19, 13, 144, 13105, 19, 13, 3651, 2928, 19, 13, 144, 2, 82, 19, 13, 3651, 331, 65, 108, 158, 8004, 15, 49, 39, 58, 18, 39, 269, 19, 13, 3531, 2, 2928, 15, 66, 58, 27, 14, 179, 19, 13, 488, 22, 306, 674, 1, 109, 502, 5, 8, 52, 166, 126, 1, 465, 53, 1423, 1, 1010, 553, 30, 444, 19, 13, 2155, 779, 156, 19, 13, 5295, 8004, 19, 13, 1111, 2928, 19, 13, 1520, 2, 13105, 19, 13, 5295, 22, 93, 880, 674, 536, 56, 89, 88, 784, 2, 249, 121, 11, 44, 41, 5, 146, 3, 93, 306, 674, 1, 1010, 11, 8004, 17278, 33, 67, 58, 18, 245, 19, 13, 22080, 2, 7808, 18, 27, 13105, 15, 33, 66, 58, 18, 179, 19, 13, 16808, 2174, 30, 444, 2110, 779, 156, 10, 8, 93, 980, 1, 1010, 3, 356, 4, 82, 3180, 12, 2744, 6, 40, 96, 2574, 20, 463, 1, 8004, 2, 13105, 2, 44, 20, 30, 444, 22, 3, 632, 371, 688, 309, 46, 130, 32, 824, 509, 2998, 50, 711, 2622, 26, 414, 4862, 3, 2166, 1155, 1, 8111, 2, 9537, 7, 2231, 20, 7240, 30, 444, 1551, 6, 678, 146, 15, 779, 156, 198, 1173, 20, 8004, 13105, 2, 2928, 24, 1526, 90, 23, 30, 444, 279, 257, 40, 21277]",2324.0,15385112,579
Positron emission tomography with 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer.,Head & neck,Head Neck,2004-10-01,"Conventional imaging is limited in identifying persistent disease after organ-preserving therapy for patients with advanced squamous cell carcinoma of the head and neck (SCCHN). We studied the accuracy of positron emission tomography (PET) with (18)F-fluoro-2-deoxy-D-glucose (FDG-PET) in restaging disease in patients with SCCHN after they had undergone induction chemotherapy (ICT) followed by chemoradiotherapy (CRT). Forty patients with advanced SCCHN were treated with ICT followed by CRT. FDG-PET imaging was performed to assess for residual cancer at the primary site and in nodal metastases. Two nuclear medicine physicians interpreted PET scans in random sequence. Test characteristics were calculated with pathologic analysis or clinical recurrence as the standard. After induction chemotherapy, PET imaging had a sensitivity of 100% and specificity of 65% for detecting persistent disease at the primary tumor site. After ICT and CRT were completed, the sensitivity and specificity of PET imaging were 67% and 53%, respectively, for detecting occult disease in cervical lymph nodes. FDG-PET imaging showed some correlation with pathologic response after ICT and CRT in patients with advanced SCCHN. The use of FDG-PET warrants further investigation in this setting.",Journal Article,5590.0,82.0,Conventional imaging is limited in identifying persistent disease after organ-preserving therapy for patients with advanced squamous cell carcinoma of the head and SCCHN We studied the accuracy of positron emission tomography PET with 18 F-fluoro-2-deoxy-D-glucose FDG-PET in restaging disease in patients with SCCHN after they had undergone induction chemotherapy ICT followed by chemoradiotherapy CRT Forty patients with advanced SCCHN were treated with ICT followed by CRT FDG-PET imaging was performed to assess for residual cancer at the primary site and in nodal metastases Two nuclear medicine physicians interpreted PET scans in random sequence Test characteristics were calculated with pathologic analysis or clinical recurrence as the standard After induction chemotherapy PET imaging had a sensitivity of 100 and specificity of 65 for detecting persistent disease at the primary tumor site After ICT and CRT were completed the sensitivity and specificity of PET imaging were 67 and 53 respectively for detecting occult disease in lymph nodes FDG-PET imaging showed some correlation with pathologic response after ICT and CRT in patients with advanced SCCHN The use of FDG-PET warrants further investigation in this setting,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[809, 270, 16, 383, 4, 1386, 1882, 34, 50, 1259, 4972, 36, 9, 7, 5, 131, 691, 31, 134, 1, 3, 718, 2, 2999, 21, 656, 3, 1190, 1, 1900, 1799, 872, 495, 5, 203, 1068, 6231, 18, 6149, 427, 2522, 1285, 495, 4, 4275, 34, 4, 7, 5, 2999, 50, 491, 42, 1989, 504, 56, 10476, 370, 20, 1464, 1089, 1213, 7, 5, 131, 2999, 11, 73, 5, 10476, 370, 20, 1089, 1285, 495, 270, 10, 173, 6, 423, 9, 753, 12, 28, 3, 86, 606, 2, 4, 779, 196, 100, 928, 1807, 1261, 5047, 495, 1441, 4, 2324, 1532, 412, 374, 11, 981, 5, 510, 65, 15, 38, 146, 22, 3, 260, 50, 504, 56, 495, 270, 42, 8, 485, 1, 394, 2, 1121, 1, 556, 9, 2502, 1882, 34, 28, 3, 86, 30, 606, 50, 10476, 2, 1089, 11, 781, 3, 485, 2, 1121, 1, 495, 270, 11, 598, 2, 699, 106, 9, 2502, 2879, 34, 4, 263, 502, 1285, 495, 270, 224, 476, 816, 5, 510, 51, 50, 10476, 2, 1089, 4, 7, 5, 131, 2999, 3, 119, 1, 1285, 495, 2782, 195, 940, 4, 26, 546]",1233.0,15390197,100
Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix.,"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",Mod. Pathol.,2005-01-01,"Lymphatic invasion and nodal metastasis are predictors of shorter disease-free and overall survival in carcinoma of the uterine cervix. The monoclonal antibody D2-40, which reacts with the oncofetal membrane antigen M2A, is a new selective marker for lymphatic endothelium, and has been shown to be useful in identifying the presence of lymphatic invasion in various malignant neoplasms, including cervical carcinoma. However, the reactivity of the tumor cells with D2-40 has not yet been evaluated. In this study, we examined the pattern of D2-40 immunoreactivity in a series of 138 invasive squamous cell carcinomas of the uterine cervix. We correlated the presence and extent of D2-40 immunoreactivity in the tumor cells with various clinicopathologic features, the presence of lymphatic invasion, lymph node metastasis and outcome. Diffuse or focal D2-40 immunoreactivity was present in 17 (12%) and 81 (59%) tumors, respectively, while 40 (29%) tumors showed no immunoreactivity. Lymphatic invasion and nodal metastasis were present in 56 and 29% of tumors, respectively. Tumor emboli within lymphatic spaces and metastatic tumor foci in lymph nodes showed no immunoreactivity in 86 and 80% of the cases, respectively. Lymphatic invasion and nodal metastasis were significantly more common in tumors showing low D2-40 immunoreactivity (P<0.0001 and 0.022, respectively). D2-40 immunoreactivity showed no correlation with any other clinicopathologic features examined, including tumor size, grade and FIGO stage. In univariate analysis low D2-40 immunoreactivity was significantly associated with shorter recurrence-free, but not with overall survival. Our studies suggest that D2-40 immunostaining may serve as a marker for increased risk of lymphatic invasion and tumor recurrence in cervical biopsy material. Further study of the biological function of the M2A antigen may shed some light on the interaction of tumor cells with lymphatics.",Journal Article,5498.0,89.0,Lymphatic invasion and nodal metastasis are predictors of shorter disease-free and overall survival in carcinoma of the cervix The monoclonal antibody D2-40 which reacts with the oncofetal membrane antigen M2A is a new selective marker for lymphatic endothelium and has been shown to be useful in identifying the presence of lymphatic invasion in various malignant neoplasms including carcinoma However the reactivity of the tumor cells with D2-40 has not yet been evaluated In this study we examined the pattern of D2-40 immunoreactivity in a series of 138 invasive squamous cell carcinomas of the cervix We correlated the presence and extent of D2-40 immunoreactivity in the tumor cells with various clinicopathologic features the presence of lymphatic invasion lymph node metastasis and outcome Diffuse or focal D2-40 immunoreactivity was present in 17 12 and 81 59 tumors respectively while 40 29 tumors showed no immunoreactivity Lymphatic invasion and nodal metastasis were present in 56 and 29 of tumors respectively Tumor emboli within lymphatic spaces and metastatic tumor foci in lymph nodes showed no immunoreactivity in 86 and 80 of the cases respectively Lymphatic invasion and nodal metastasis were significantly more common in tumors showing low D2-40 immunoreactivity P 0.0001 and 0.022 respectively D2-40 immunoreactivity showed no correlation with any other clinicopathologic features examined including tumor size grade and FIGO stage In univariate analysis low D2-40 immunoreactivity was significantly associated with shorter recurrence-free but not with overall survival Our studies suggest that D2-40 immunostaining may serve as a marker for increased risk of lymphatic invasion and tumor recurrence in biopsy material Further study of the biological function of the M2A antigen may shed some light on the interaction of tumor cells with lymphatics,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[2936, 578, 2, 779, 278, 32, 674, 1, 985, 34, 115, 2, 63, 25, 4, 134, 1, 3, 3629, 3, 848, 548, 4171, 327, 92, 23374, 5, 3, 28288, 1905, 448, 43734, 16, 8, 217, 1094, 952, 9, 2936, 5300, 2, 71, 85, 443, 6, 40, 999, 4, 1386, 3, 463, 1, 2936, 578, 4, 747, 393, 1179, 141, 134, 137, 3, 4601, 1, 3, 30, 37, 5, 4171, 327, 71, 44, 1145, 85, 194, 4, 26, 45, 21, 409, 3, 1177, 1, 4171, 327, 4900, 4, 8, 988, 1, 4478, 416, 691, 31, 826, 1, 3, 3629, 21, 438, 3, 463, 2, 1039, 1, 4171, 327, 4900, 4, 3, 30, 37, 5, 747, 1399, 404, 3, 463, 1, 2936, 578, 263, 289, 278, 2, 228, 1388, 15, 2137, 4171, 327, 4900, 10, 364, 4, 269, 133, 2, 865, 728, 57, 106, 369, 327, 462, 57, 224, 77, 4900, 2936, 578, 2, 779, 278, 11, 364, 4, 664, 2, 462, 1, 57, 106, 30, 13259, 262, 2936, 11757, 2, 113, 30, 3340, 4, 263, 502, 224, 77, 4900, 4, 868, 2, 493, 1, 3, 140, 106, 2936, 578, 2, 779, 278, 11, 97, 80, 186, 4, 57, 2069, 154, 4171, 327, 4900, 19, 13, 488, 2, 13, 4773, 106, 4171, 327, 4900, 224, 77, 816, 5, 500, 127, 1399, 404, 409, 141, 30, 444, 88, 2, 3837, 82, 4, 880, 65, 154, 4171, 327, 4900, 10, 97, 41, 5, 985, 146, 115, 84, 44, 5, 63, 25, 114, 94, 309, 17, 4171, 327, 5027, 68, 1833, 22, 8, 952, 9, 101, 43, 1, 2936, 578, 2, 30, 146, 4, 411, 3692, 195, 45, 1, 3, 1037, 343, 1, 3, 43734, 448, 68, 5816, 476, 1691, 23, 3, 915, 1, 30, 37, 5, 9335]",1870.0,15467716,0
Cervical cancer screening.,Current oncology reports,Curr Oncol Rep,2004-11-01,"Although primary prevention of human papillomavirus (HPV) infections that are causally associated with invasive cervical cancer may be within our grasp, it is unlikely that these approaches will replace existing cervical cancer screening strategies for many years. Experts agree and data support periodic cytology screening for young-adult women using one of several technologies. Recent analyses of cost-effectiveness suggest that the addition of molecular HPV DNA testing for women aged over 30 years may allow the screening interval to be lengthened to 3 years for most women. Women at high risk for HPV infection and its associated cellular atypias warrant closer monitoring and follow-up. These patients would include organ transplant recipients, women exposed to diethylstilbestrol (DES), and HIV-infected women.",Journal Article,5559.0,13.0,Although primary prevention of human papillomavirus HPV infections that are causally associated with invasive cancer may be within our grasp it is unlikely that these approaches will replace existing cancer screening strategies for many years Experts agree and data support periodic cytology screening for young-adult women using one of several technologies Recent analyses of cost-effectiveness suggest that the addition of molecular HPV DNA testing for women aged over 30 years may allow the screening interval to be lengthened to 3 years for most women Women at high risk for HPV infection and its associated cellular atypias warrant closer monitoring and follow-up These patients would include organ transplant recipients women exposed to diethylstilbestrol DES and HIV-infected women,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[242, 86, 1070, 1, 171, 3242, 933, 1875, 17, 32, 12511, 41, 5, 416, 12, 68, 40, 262, 114, 43747, 192, 16, 3568, 17, 46, 611, 303, 7195, 1692, 12, 453, 422, 9, 445, 60, 3186, 10473, 2, 74, 538, 9086, 2045, 453, 9, 1169, 780, 117, 75, 104, 1, 392, 2590, 435, 318, 1, 835, 1236, 309, 17, 3, 352, 1, 219, 933, 261, 471, 9, 117, 1032, 252, 201, 60, 68, 1700, 3, 453, 268, 6, 40, 22009, 6, 27, 60, 9, 96, 117, 117, 28, 64, 43, 9, 933, 930, 2, 211, 41, 763, 30672, 2946, 6576, 1315, 2, 166, 126, 46, 7, 688, 643, 1259, 941, 2190, 117, 2234, 6, 15522, 8683, 2, 1942, 3369, 117]",788.0,15485621,224
Percutaneous CT-guided biopsy of osseous lesion of the spine in patients with known or suspected malignancy.,AJNR. American journal of neuroradiology,AJNR Am J Neuroradiol,2004-10-01,"CT-guided spinal biopsy (CTGSB) is considered a safe and accurate procedure. Our goal was to determine the accuracy of a CTGSB of osseous spinal lesions in patients with known or suspected underlying malignancy in reference to major variables such as the radiographic appearance of the biopsied lesion and its location within the spinal column. We retrospectively reviewed results of 410 consecutive percutaneous CTGSB procedures of osseous spinal lesions. Biopsy was determined to be adequate if diagnostic tissue was obtained (n = 401) or unsatisfactory (n = 9) if only blood without cellular elements was present on final pathologic-cytologic examination. The level of spinal biopsy was cervical in nine patients (2%), thoracic in 123 (31%), lumbar in 164 (42%), and sacral in 96 (25%). The overall diagnostic accuracy of CTGSB was 89%, with a false-negative rate of 11%. Biopsy of lytic lesions yielded an accurate diagnosis in 93% (220 of 236). Despite technical challenges inherent to biopsy of sclerotic lesions, diagnostic accuracy was 76% (63 of 83), although more importantly, 24% (20 of 83) of the results in sclerotic lesions were falsely negative. CTGSB of osseous spinal lesions is an important tool in the workup of patients with known or suspected underlying neoplastic disease. However, a negative result must be confirmed with either close follow-up or, preferably, open biopsy, especially in cases of sclerotic lesions for which diagnostic accuracy is decreased and the false-negative rate is high.",Journal Article,5590.0,104.0,CT-guided spinal biopsy CTGSB is considered a safe and accurate procedure Our goal was to determine the accuracy of a CTGSB of osseous spinal lesions in patients with known or suspected underlying malignancy in reference to major variables such as the radiographic appearance of the biopsied lesion and its location within the spinal column We retrospectively reviewed results of 410 consecutive percutaneous CTGSB procedures of osseous spinal lesions Biopsy was determined to be adequate if diagnostic tissue was obtained n 401 or unsatisfactory n 9 if only blood without cellular elements was present on final pathologic-cytologic examination The level of spinal biopsy was in nine patients 2 thoracic in 123 31 lumbar in 164 42 and sacral in 96 25 The overall diagnostic accuracy of CTGSB was 89 with a false-negative rate of 11 Biopsy of lytic lesions yielded an accurate diagnosis in 93 220 of 236 Despite technical challenges inherent to biopsy of sclerotic lesions diagnostic accuracy was 76 63 of 83 although more importantly 24 20 of 83 of the results in sclerotic lesions were falsely negative CTGSB of osseous spinal lesions is an important tool in the workup of patients with known or suspected underlying neoplastic disease However a negative result must be confirmed with either close follow-up or preferably open biopsy especially in cases of sclerotic lesions for which diagnostic accuracy is decreased and the false-negative rate is high,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[425, 1808, 1499, 411, 30681, 16, 515, 8, 1165, 2, 1481, 1299, 114, 1326, 10, 6, 223, 3, 1190, 1, 8, 30681, 1, 5230, 1499, 406, 4, 7, 5, 440, 15, 2768, 1181, 710, 4, 2482, 6, 458, 682, 225, 22, 3, 1580, 3592, 1, 3, 6775, 1180, 2, 211, 1147, 262, 3, 1499, 9004, 21, 894, 446, 99, 1, 7690, 935, 3720, 30681, 1369, 1, 5230, 1499, 406, 411, 10, 509, 6, 40, 1658, 492, 752, 246, 10, 683, 78, 7191, 15, 9573, 78, 83, 492, 158, 315, 187, 763, 2531, 10, 364, 23, 1457, 510, 4195, 1385, 3, 301, 1, 1499, 411, 10, 4, 762, 7, 18, 2098, 4, 2698, 456, 6187, 4, 5279, 595, 2, 7943, 4, 921, 243, 3, 63, 752, 1190, 1, 30681, 10, 887, 5, 8, 2133, 199, 116, 1, 175, 411, 1, 6148, 406, 2178, 35, 1481, 147, 4, 966, 6211, 1, 6383, 550, 3359, 1427, 4943, 6, 411, 1, 11969, 406, 752, 1190, 10, 846, 676, 1, 852, 242, 80, 1859, 259, 179, 1, 852, 1, 3, 99, 4, 11969, 406, 11, 16683, 199, 30681, 1, 5230, 1499, 406, 16, 35, 305, 1515, 4, 3, 4755, 1, 7, 5, 440, 15, 2768, 1181, 2000, 34, 137, 8, 199, 757, 1642, 40, 557, 5, 361, 2336, 166, 126, 15, 10590, 1020, 411, 1093, 4, 140, 1, 11969, 406, 9, 92, 752, 1190, 16, 340, 2, 3, 2133, 199, 116, 16, 64]",1454.0,15502142,109
Delayed hemorrhage after cervical conization unmasking severe factor XI deficiency.,Obstetrics and gynecology,Obstet Gynecol,2004-11-01,"Factor XI deficiency, a rare bleeding disorder found most commonly in patients of Ashkenazi Jewish background, may be present in patients with a history of abnormal bleeding after elective surgery. A patient of Ashkenazi Jewish descent presented 12 days after cervical conization for adenocarcinoma in situ with severe vaginal bleeding requiring multiple transfusions and uterine artery embolization. After a thorough workup, a severe factor XI deficiency was found. The patient ultimately required modified radical hysterectomy for treatment of early cervical cancer. With appropriate perioperative management, the patient underwent abdominal surgery without further bleeding complications. Factor XI deficiency can present with severe bleeding episodes after elective surgery. Adequate preoperative assessment and perioperative management are necessary to prevent bleeding complications in these patients.",Case Reports,5559.0,5.0,Factor XI deficiency a rare bleeding disorder found most commonly in patients of Ashkenazi Jewish background may be present in patients with a history of abnormal bleeding after elective surgery A patient of Ashkenazi Jewish descent presented 12 days after conization for adenocarcinoma in situ with severe bleeding requiring multiple transfusions and artery embolization After a thorough workup a severe factor XI deficiency was found The patient ultimately required modified radical hysterectomy for treatment of early cancer With appropriate perioperative management the patient underwent abdominal surgery without further bleeding complications Factor XI deficiency can present with severe bleeding episodes after elective surgery Adequate preoperative assessment and perioperative management are necessary to prevent bleeding complications in these patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[161, 15996, 2299, 8, 622, 2294, 2645, 204, 96, 841, 4, 7, 1, 5939, 5476, 2426, 68, 40, 364, 4, 7, 5, 8, 532, 1, 1668, 2294, 50, 4700, 152, 8, 69, 1, 5939, 5476, 9171, 917, 133, 162, 50, 8755, 9, 449, 4, 957, 5, 905, 2294, 1888, 232, 4987, 2, 2872, 4232, 50, 8, 5506, 4755, 8, 905, 161, 15996, 2299, 10, 204, 3, 69, 2050, 616, 1230, 711, 2622, 9, 24, 1, 191, 12, 5, 870, 1547, 284, 3, 69, 208, 1467, 152, 187, 195, 2294, 521, 161, 15996, 2299, 122, 364, 5, 905, 2294, 3750, 50, 4700, 152, 1658, 498, 455, 2, 1547, 284, 32, 1493, 6, 1682, 2294, 521, 4, 46, 7]",862.0,15516448,496
Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a patterns of care study.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2004-11-01,"To determine the influence of research findings and evolving technology on the practice of radiotherapy in patients with carcinoma of the cervix. Radiation oncology facilities were randomly selected from two strata: those that treated <500 and those that treated >/=500 new cancer patients annually. Patient records were randomly selected from lists of eligible patients treated between 1996 and 1999 at each institution. A total of 442 patient records were reviewed at 59 facilities (55 with eligible patients). National estimates were made using weights that reflected the relative contribution of each institution and of each patient within the sampled institutions. Most estimates were based on the 383 patients who had received their initial therapy at a surveyed facility (excluding the 59 patients who were referred for brachytherapy only after initial treatment at another facility). The estimates of brachytherapy practice were based on the 408 patients who had received their brachytherapy at a surveyed facility. The data were compared with those obtained from a similar 1992-1994 survey. Overall, 40.5%, 25.4%, and 33.9% of patients had Stage IA-IIA, IIB, or IIIA-IVA disease, respectively. CT was the most common method of nodal evaluation, with surgical evaluation performed in only 12% of patients. Of the 55 facilities with eligible patients, 32 had treated <==8 eligible patients during the 4-year study period. We estimated that 27.5% of patients were treated at facilities that treated <==2 patients with intact cervical cancer annually; 43% were treated at facilities that treated <500 new patients annually. Patients treated at small facilities were significantly more likely to have received a total dose to Point A of <80 Gy, to have had their treatment protracted to >70 days, and to have undergone adjuvant hysterectomy or chemotherapy. In large facilities, radiotherapy was less likely to be protracted to >70 days in the 1996-1999 survey than in the 1992-1994 survey (p < 0.0001); however, in small facilities, treatment was more likely to be protracted than in the earlier survey (p = 0.06), contributing to increasing disparities between the treatments given in large and small facilities. Overall, 92.4% of patients treated with nonpalliative intent were treated with brachytherapy. Of the patients who received brachytherapy, 16.4% had at least part of their brachytherapy delivered at a high dose rate; this was not significantly greater than the proportion treated with high-dose-rate brachytherapy in the 1992-1994 survey (9.1%; p = 0.3). The proportion of patients receiving chemotherapy as part of their initial treatment in 1996-1999 (34.6%) was not significantly different statistically from that in 1992-1994 (25.6%; p = 0.3). However, in 1999, 63% of patients had received chemotherapy compared with 19%, 28%, and 26% in 1996, 1997, and 1998, respectively. The details and confirmation of chemotherapy administration were rarely documented in the radiation oncology clinic notes and hospital records. The sharp increase in the use of chemotherapy in 1999 suggested rapid application of the results from randomized trials. However, considerable heterogeneity in practice patterns remains, particularly in the use of brachytherapy. The practice at small facilities appears to differ significantly from that at larger facilities in several respects, with a statistically significantly larger proportion of treatments at small facilities failing to meet current guidelines for optimal treatment.",Comparative Study,5559.0,106.0,To determine the influence of research findings and evolving technology on the practice of radiotherapy in patients with carcinoma of the cervix Radiation oncology facilities were randomly selected from two strata those that treated 500 and those that treated /=500 new cancer patients annually Patient records were randomly selected from lists of eligible patients treated between 1996 and 1999 at each institution A total of 442 patient records were reviewed at 59 facilities 55 with eligible patients National estimates were made using weights that reflected the relative contribution of each institution and of each patient within the sampled institutions Most estimates were based on the 383 patients who had received their initial therapy at a surveyed facility excluding the 59 patients who were referred for brachytherapy only after initial treatment at another facility The estimates of brachytherapy practice were based on the 408 patients who had received their brachytherapy at a surveyed facility The data were compared with those obtained from a similar 1992-1994 survey Overall 40.5 25.4 and 33.9 of patients had Stage IA-IIA IIB or IIIA-IVA disease respectively CT was the most common method of nodal evaluation with surgical evaluation performed in only 12 of patients Of the 55 facilities with eligible patients 32 had treated ==8 eligible patients during the 4-year study period We estimated that 27.5 of patients were treated at facilities that treated ==2 patients with intact cancer annually 43 were treated at facilities that treated 500 new patients annually Patients treated at small facilities were significantly more likely to have received a total dose to Point A of 80 Gy to have had their treatment protracted to 70 days and to have undergone adjuvant hysterectomy or chemotherapy In large facilities radiotherapy was less likely to be protracted to 70 days in the 1996-1999 survey than in the 1992-1994 survey p 0.0001 however in small facilities treatment was more likely to be protracted than in the earlier survey p 0.06 contributing to increasing disparities between the treatments given in large and small facilities Overall 92.4 of patients treated with nonpalliative intent were treated with brachytherapy Of the patients who received brachytherapy 16.4 had at least part of their brachytherapy delivered at a high dose rate this was not significantly greater than the proportion treated with high-dose-rate brachytherapy in the 1992-1994 survey 9.1 p 0.3 The proportion of patients receiving chemotherapy as part of their initial treatment in 1996-1999 34.6 was not significantly different statistically from that in 1992-1994 25.6 p 0.3 However in 1999 63 of patients had received chemotherapy compared with 19 28 and 26 in 1996 1997 and 1998 respectively The details and confirmation of chemotherapy administration were rarely documented in the radiation oncology clinic notes and hospital records The sharp increase in the use of chemotherapy in 1999 suggested rapid application of the results from randomized trials However considerable heterogeneity in practice patterns remains particularly in the use of brachytherapy The practice at small facilities appears to differ significantly from that at larger facilities in several respects with a statistically significantly larger proportion of treatments at small facilities failing to meet current guidelines for optimal treatment,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 1054, 1, 389, 272, 2, 3276, 2033, 23, 3, 758, 1, 310, 4, 7, 5, 134, 1, 3, 3629, 121, 413, 4351, 11, 1108, 715, 29, 100, 5758, 135, 17, 73, 1666, 2, 135, 17, 73, 1666, 217, 12, 7, 4226, 69, 1064, 11, 1108, 715, 29, 11471, 1, 625, 7, 73, 59, 2648, 2, 2043, 28, 296, 731, 8, 181, 1, 12186, 69, 1064, 11, 446, 28, 728, 4351, 614, 5, 625, 7, 657, 1423, 11, 1229, 75, 7966, 17, 4686, 3, 580, 2925, 1, 296, 731, 2, 1, 296, 69, 262, 3, 5919, 1764, 96, 1423, 11, 90, 23, 3, 10574, 7, 54, 42, 103, 136, 388, 36, 28, 8, 3696, 3483, 3207, 3, 728, 7, 54, 11, 1995, 9, 1536, 158, 50, 388, 24, 28, 1809, 3483, 3, 1423, 1, 1536, 758, 11, 90, 23, 3, 13356, 7, 54, 42, 103, 136, 1536, 28, 8, 3696, 3483, 3, 74, 11, 72, 5, 135, 683, 29, 8, 288, 2846, 3023, 1407, 63, 327, 33, 243, 39, 2, 466, 83, 1, 7, 42, 82, 3302, 4088, 3884, 15, 3164, 5900, 34, 106, 425, 10, 3, 96, 186, 596, 1, 779, 451, 5, 221, 451, 173, 4, 158, 133, 1, 7, 1, 3, 614, 4351, 5, 625, 7, 531, 42, 73, 66, 625, 7, 190, 3, 39, 111, 45, 727, 21, 661, 17, 428, 33, 1, 7, 11, 73, 28, 4351, 17, 73, 18, 7, 5, 2964, 12, 4226, 601, 11, 73, 28, 4351, 17, 73, 1666, 217, 7, 4226, 7, 73, 28, 302, 4351, 11, 97, 80, 322, 6, 47, 103, 8, 181, 61, 6, 741, 8, 1, 493, 381, 6, 47, 42, 136, 24, 7053, 6, 431, 162, 2, 6, 47, 1989, 249, 2622, 15, 56, 4, 375, 4351, 310, 10, 299, 322, 6, 40, 7053, 6, 431, 162, 4, 3, 2648, 2043, 1407, 76, 4, 3, 2846, 3023, 1407, 19, 13, 488, 137, 4, 302, 4351, 24, 10, 80, 322, 6, 40, 7053, 76, 4, 3, 1677, 1407, 19, 13, 1460, 3156, 6, 602, 2227, 59, 3, 640, 447, 4, 375, 2, 302, 4351, 63, 937, 39, 1, 7, 73, 5, 28002, 1697, 11, 73, 5, 1536, 1, 3, 7, 54, 103, 1536, 245, 39, 42, 28, 506, 760, 1, 136, 1536, 1623, 28, 8, 64, 61, 116, 26, 10, 44, 97, 378, 76, 3, 920, 73, 5, 64, 61, 116, 1536, 4, 3, 2846, 3023, 1407, 83, 14, 19, 13, 27, 3, 920, 1, 7, 357, 56, 22, 760, 1, 136, 388, 24, 4, 2648, 2043, 562, 49, 10, 44, 97, 338, 712, 29, 17, 4, 2846, 3023, 243, 49, 19, 13, 27, 137, 4, 2043, 676, 1, 7, 42, 103, 56, 72, 5, 326, 339, 2, 432, 4, 2648, 2341, 2, 1850, 106, 3, 3791, 2, 3551, 1, 56, 634, 11, 2416, 1405, 4, 3, 121, 413, 1188, 8192, 2, 702, 1064, 3, 9978, 344, 4, 3, 119, 1, 56, 4, 2043, 1148, 1321, 1581, 1, 3, 99, 29, 384, 143, 137, 2658, 1144, 4, 758, 764, 469, 823, 4, 3, 119, 1, 1536, 3, 758, 28, 302, 4351, 1233, 6, 1505, 97, 29, 17, 28, 1077, 4351, 4, 392, 24767, 5, 8, 712, 97, 1077, 920, 1, 640, 28, 302, 4351, 7928, 6, 3362, 291, 677, 9, 665, 24]",3423.0,15519786,8
Health care disparities and cervical cancer.,American journal of public health,Am J Public Health,2004-12-01,"We compared cervical cancer incidence, stage at diagnosis, and survival in Medicaid-insured and non-Medicaid-insured populations. We stratified the sample by age and used ordered logistic regression to predict stage at diagnosis and used Cox proportional hazards regression to predict survival. Medicaid insured nearly one quarter of women diagnosed with cervical cancer. The likelihood of late-stage disease was greatest for women who enrolled in Medicaid after diagnosis. Women younger than 65 years who enrolled in Medicaid after diagnosis were more likely to die from cervical cancer than were women who were not insured by Medicaid (hazard ratio=2.40, 95% confidence interval=1.49, 3.86). Our study underscores the importance of cervical cancer screening programs targeted at low-income women.",Journal Article,5529.0,35.0,We compared cancer incidence stage at diagnosis and survival in Medicaid-insured and non-Medicaid-insured populations We stratified the sample by age and used ordered logistic regression to predict stage at diagnosis and used Cox proportional hazards regression to predict survival Medicaid insured nearly one quarter of women diagnosed with cancer The likelihood of late-stage disease was greatest for women who enrolled in Medicaid after diagnosis Women younger than 65 years who enrolled in Medicaid after diagnosis were more likely to die from cancer than were women who were not insured by Medicaid hazard ratio=2.40 95 confidence interval=1.49 3.86 Our study underscores the importance of cancer screening programs targeted at low-income women,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 72, 12, 287, 82, 28, 147, 2, 25, 4, 2843, 4291, 2, 220, 2843, 4291, 1184, 21, 1173, 3, 1000, 20, 89, 2, 95, 7591, 812, 320, 6, 678, 82, 28, 147, 2, 95, 418, 831, 1017, 320, 6, 678, 25, 2843, 4291, 1857, 104, 8034, 1, 117, 265, 5, 12, 3, 1420, 1, 807, 82, 34, 10, 2199, 9, 117, 54, 346, 4, 2843, 50, 147, 117, 773, 76, 556, 60, 54, 346, 4, 2843, 50, 147, 11, 80, 322, 6, 3384, 29, 12, 76, 11, 117, 54, 11, 44, 4291, 20, 2843, 360, 197, 18, 327, 48, 307, 268, 14, 739, 27, 868, 114, 45, 6926, 3, 1187, 1, 12, 453, 2251, 238, 28, 154, 2306, 117]",749.0,15569960,654
Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma.,The Journal of clinical endocrinology and metabolism,J. Clin. Endocrinol. Metab.,2004-12-01,"The serum thyroglobulin (Tg) level is the most sensitive marker for detecting residual thyroid carcinoma. We hypothesized that the basal and TSH-stimulated Tg levels in patients with metastatic thyroid carcinoma would reflect tumor volume, histological subtype, and location of metastatic lesions. A retrospective review of 417 thyroid cancer survivors undergoing evaluation for residual disease with the assistance of recombinant human TSH (rhTSH) was performed. In 169 patients with metastatic disease, we found that the basal Tg level directly correlated with the number of lesions, and that it was highest in patients with follicular and lowest in those with papillary thyroid carcinoma. The basal Tg level was highest in patients with bone metastases and lowest in those with cervical metastases. The fold increase in the serum Tg after rhTSH treatment was highest in papillary thyroid carcinoma and lowest in Hurthle cell carcinoma. The fold increase in Tg was not influenced by tumor volume or by the site of metastatic lesions. Multivariate analysis showed multiple interactions between factors, but did not identify one factor that significantly influenced basal Tg or fold increase. We conclude that the location and volume of metastases influence basal Tg, but not its responsiveness to rhTSH, whereas the histological type of carcinoma influences both basal Tg and responsiveness to rhTSH.",Journal Article,5529.0,47.0,The serum thyroglobulin Tg level is the most sensitive marker for detecting residual carcinoma We hypothesized that the basal and TSH-stimulated Tg levels in patients with metastatic carcinoma would reflect tumor volume histological subtype and location of metastatic lesions A retrospective review of 417 cancer survivors undergoing evaluation for residual disease with the assistance of recombinant human TSH rhTSH was performed In 169 patients with metastatic disease we found that the basal Tg level directly correlated with the number of lesions and that it was highest in patients with follicular and lowest in those with papillary carcinoma The basal Tg level was highest in patients with metastases and lowest in those with metastases The fold increase in the serum Tg after rhTSH treatment was highest in papillary carcinoma and lowest in Hurthle cell carcinoma The fold increase in Tg was not influenced by tumor volume or by the site of metastatic lesions Multivariate analysis showed multiple interactions between factors but did not identify one factor that significantly influenced basal Tg or fold increase We conclude that the location and volume of metastases influence basal Tg but not its responsiveness to rhTSH whereas the histological type of carcinoma influences both basal Tg and responsiveness to rhTSH,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[3, 524, 8978, 5107, 301, 16, 3, 96, 745, 952, 9, 2502, 753, 134, 21, 1237, 17, 3, 2135, 2, 6581, 2816, 5107, 148, 4, 7, 5, 113, 134, 688, 2694, 30, 433, 1831, 875, 2, 1147, 1, 113, 406, 8, 459, 206, 1, 9947, 12, 332, 479, 451, 9, 753, 34, 5, 3, 6050, 1, 2835, 171, 6581, 12143, 10, 173, 4, 5436, 7, 5, 113, 34, 21, 204, 17, 3, 2135, 5107, 301, 1606, 438, 5, 3, 207, 1, 406, 2, 17, 192, 10, 1076, 4, 7, 5, 1974, 2, 2101, 4, 135, 5, 1796, 134, 3, 2135, 5107, 301, 10, 1076, 4, 7, 5, 196, 2, 2101, 4, 135, 5, 196, 3, 1116, 344, 4, 3, 524, 5107, 50, 12143, 24, 10, 1076, 4, 1796, 134, 2, 2101, 4, 18889, 31, 134, 3, 1116, 344, 4, 5107, 10, 44, 2574, 20, 30, 433, 15, 20, 3, 606, 1, 113, 406, 331, 65, 224, 232, 1286, 59, 130, 84, 205, 44, 255, 104, 161, 17, 97, 2574, 2135, 5107, 15, 1116, 344, 21, 2060, 17, 3, 1147, 2, 433, 1, 196, 1054, 2135, 5107, 84, 44, 211, 3642, 6, 12143, 547, 3, 1831, 267, 1, 134, 3859, 110, 2135, 5107, 2, 3642, 6, 12143]",1327.0,15579752,387
A fertility-sparing alternative to radical hysterectomy: how many patients may be eligible?,Gynecologic oncology,Gynecol. Oncol.,2004-12-01,"To determine the percentage of patients with early-stage cervical cancer who may be eligible for fertility preservation with laparoscopic radical vaginal trachelectomy (LRVT). We retrospectively reviewed the records of patients who underwent a radical hysterectomy for invasive cervical cancer at our institution from 12/85 to 8/01, before our use of LRVT at Memorial Sloan-Kettering Cancer Center. Institutional eligibility criteria for LRVT were applied. Patients > or =40 years of age were considered ineligible. We identified 435 patients who had undergone radical hysterectomy for cervical cancer; 186 were age < 40 at surgery and constituted our study population. Eighty-nine (48%) patients may have been eligible by our pathologic criteria. In 12 patients, LRVT may have been aborted or altered because of unexpected disease spread. A significant number of patients < 40 with early-stage cervical cancer may be pathologically eligible for LRVT and should be counseled on this preoperatively.",Journal Article,5529.0,,To determine the percentage of patients with early-stage cancer who may be eligible for fertility preservation with laparoscopic radical trachelectomy LRVT We retrospectively reviewed the records of patients who underwent a radical hysterectomy for invasive cancer at our institution from 12/85 to 8/01 before our use of LRVT at Memorial Sloan-Kettering Cancer Center Institutional eligibility criteria for LRVT were applied Patients or =40 years of age were considered ineligible We identified 435 patients who had undergone radical hysterectomy for cancer 186 were age 40 at surgery and constituted our study population Eighty-nine 48 patients may have been eligible by our pathologic criteria In 12 patients LRVT may have been aborted or altered because of unexpected disease spread A significant number of patients 40 with early-stage cancer may be pathologically eligible for LRVT and should be counseled on this preoperatively,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 1150, 1, 7, 5, 191, 82, 12, 54, 68, 40, 625, 9, 2954, 2224, 5, 1964, 711, 5760, 30696, 21, 894, 446, 3, 1064, 1, 7, 54, 208, 8, 711, 2622, 9, 416, 12, 28, 114, 731, 29, 133, 772, 6, 66, 355, 348, 114, 119, 1, 30696, 28, 2563, 2783, 2784, 12, 574, 1115, 2317, 371, 9, 30696, 11, 1498, 7, 15, 327, 60, 1, 89, 11, 515, 3773, 21, 108, 9002, 7, 54, 42, 1989, 711, 2622, 9, 12, 5869, 11, 89, 327, 28, 152, 2, 8917, 114, 45, 266, 2207, 762, 576, 7, 68, 47, 85, 625, 20, 114, 510, 371, 4, 133, 7, 30696, 68, 47, 85, 17083, 15, 1495, 408, 1, 3792, 34, 2579, 8, 93, 207, 1, 7, 327, 5, 191, 82, 12, 68, 40, 2998, 625, 9, 30696, 2, 257, 40, 10411, 23, 26, 3888]",932.0,15581959,28
A methodology to determine margins by EPID measurements of patient setup variation and motion as applied to immobilization devices.,Medical physics,Med Phys,2004-11-01,"Assessment of clinic and site specific margins are essential for the effective use of three-dimensional and intensity modulated radiation therapy. An electronic portal imaging device (EPID) based methodology is introduced which allows individual and population based CTV-to-PTV margins to be determined and compared with traditional margins prescribed during treatment. This method was applied to a patient cohort receiving external beam head and neck radiotherapy under an IRB approved protocol. Although the full study involved the use of an EPID-based method to assess the impact of (1) simulation technique, (2) immobilization, and (3) surgical intervention on inter- and intrafraction variations of individual and population-based CTV-to-PTV margins, the focus of the paper is on the technique. As an illustration, the methodology is utilized to examine the influence of two immobilization devices, the UON thermoplastic mask and the Type-S head/ neck shoulder immobilization system on margins. Daily through port images were acquired for selected fields for each patient with an EPID. To analyze these images, simulation films or digitally reconstructed radiographs (DRR's) were imported into the EPID software. Up to five anatomical landmarks were identified and outlined by the clinician and up to three of these structures were matched for each reference image. Once the individual based errors were quantified, the patient results were grouped into populations by matched anatomical structures and immobilization device. The variation within the subgroup was quantified by calculating the systematic and random errors (sigma(sub) and sigma(sub)). Individual patient margins were approximated as 1.65 times the individual-based random error and ranged from 1.1 to 6.3 mm (A-P) and 1.1 to 12.3 mm (S-I) for fields matched on skull and cervical structures, and 1.7 to 10.2 mm (L-R) and 2.0 to 13.8 mm (S-I) for supraclavicular fields. Population-based margins ranging from 5.1 to 6.6 mm (A-P) and 3.7 to 5.7 mm (S-I) were calculated for the corresponding skull/cervical field and 9.3 to 10.0 mm (L-R) and 6.3 to 6.6 mm (S-I) for the supraclavicular fields, respectively. The reported CTV-to-PTV margins are comparable to a value 7-15 mm based on traditional Mayo margins, but in some cases exceed the default values established in RTOG Head and Neck studies. The data suggests that the population-based margins provide sufficient coverage for the majority of the patients. However, the population-derived margins are excessive for some patients and insufficient for others, suggesting that a re-evaluation of current treatment margins for individual patients is warranted. Finally, this methodology provides direct evidence of treatment variation and thus can demonstrate with confidence, the superiority of one technique over another.",Clinical Trial,5559.0,24.0,Assessment of clinic and site specific margins are essential for the effective use of three-dimensional and intensity modulated radiation therapy An electronic portal imaging device EPID based methodology is introduced which allows individual and population based CTV-to-PTV margins to be determined and compared with traditional margins prescribed during treatment This method was applied to a patient cohort receiving external beam head and radiotherapy under an IRB approved protocol Although the full study involved the use of an EPID-based method to assess the impact of 1 simulation technique 2 immobilization and 3 surgical intervention on inter- and intrafraction variations of individual and population-based CTV-to-PTV margins the focus of the paper is on the technique As an illustration the methodology is utilized to examine the influence of two immobilization devices the UON thermoplastic mask and the Type-S head/ shoulder immobilization system on margins Daily through port images were acquired for selected fields for each patient with an EPID To analyze these images simulation films or digitally reconstructed radiographs DRR 's were imported into the EPID software Up to five anatomical landmarks were identified and outlined by the clinician and up to three of these structures were matched for each reference image Once the individual based errors were quantified the patient results were grouped into populations by matched anatomical structures and immobilization device The variation within the subgroup was quantified by calculating the systematic and random errors sigma sub and sigma sub Individual patient margins were approximated as 1.65 times the individual-based random error and ranged from 1.1 to 6.3 mm A-P and 1.1 to 12.3 mm S-I for fields matched on skull and structures and 1.7 to 10.2 mm L-R and 2.0 to 13.8 mm S-I for supraclavicular fields Population-based margins ranging from 5.1 to 6.6 mm A-P and 3.7 to 5.7 mm S-I were calculated for the corresponding skull/cervical field and 9.3 to 10.0 mm L-R and 6.3 to 6.6 mm S-I for the supraclavicular fields respectively The reported CTV-to-PTV margins are comparable to a value 7-15 mm based on traditional Mayo margins but in some cases exceed the default values established in RTOG Head and studies The data suggests that the population-based margins provide sufficient coverage for the majority of the patients However the population-derived margins are excessive for some patients and insufficient for others suggesting that a re-evaluation of current treatment margins for individual patients is warranted Finally this methodology provides direct evidence of treatment variation and thus can demonstrate with confidence the superiority of one technique over another,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[455, 1, 1188, 2, 606, 112, 1012, 32, 1452, 9, 3, 323, 119, 1, 169, 2201, 2, 837, 1757, 121, 36, 35, 3098, 3307, 270, 4472, 16814, 90, 3209, 16, 3955, 92, 2333, 797, 2, 266, 90, 3402, 6, 3303, 1012, 6, 40, 509, 2, 72, 5, 1847, 1012, 2746, 190, 24, 26, 596, 10, 1498, 6, 8, 69, 180, 357, 1455, 1345, 718, 2, 310, 669, 35, 5880, 850, 1182, 242, 3, 1647, 45, 646, 3, 119, 1, 35, 16814, 90, 596, 6, 423, 3, 345, 1, 14, 4026, 1312, 18, 10161, 2, 27, 221, 788, 23, 3606, 2, 10612, 2293, 1, 797, 2, 266, 90, 3402, 6, 3303, 1012, 3, 1222, 1, 3, 2817, 16, 23, 3, 1312, 22, 35, 20993, 3, 3209, 16, 2080, 6, 1004, 3, 1054, 1, 100, 10161, 6497, 3, 54525, 24618, 10878, 2, 3, 267, 695, 718, 13115, 10161, 398, 23, 1012, 391, 298, 3083, 1572, 11, 1294, 9, 715, 3130, 9, 296, 69, 5, 35, 16814, 6, 1992, 46, 1572, 4026, 12989, 15, 16815, 7267, 8921, 18382, 292, 11, 23391, 237, 3, 16814, 3639, 126, 6, 365, 5024, 12092, 11, 108, 2, 6394, 20, 3, 3744, 2, 126, 6, 169, 1, 46, 2414, 11, 655, 9, 296, 2482, 1482, 1059, 3, 797, 90, 4612, 11, 2790, 3, 69, 99, 11, 3706, 237, 1184, 20, 655, 5024, 2414, 2, 10161, 4472, 3, 1380, 262, 3, 1363, 10, 2790, 20, 8408, 3, 1556, 2, 2324, 4612, 22253, 551, 2, 22253, 551, 797, 69, 1012, 11, 11946, 22, 14, 556, 1072, 3, 797, 90, 2324, 3444, 2, 1869, 29, 14, 14, 6, 49, 27, 321, 8, 19, 2, 14, 14, 6, 133, 27, 321, 695, 70, 9, 3130, 655, 23, 5054, 2, 2414, 2, 14, 67, 6, 79, 18, 321, 805, 668, 2, 18, 13, 6, 233, 66, 321, 695, 70, 9, 5804, 3130, 266, 90, 1012, 2223, 29, 33, 14, 6, 49, 49, 321, 8, 19, 2, 27, 67, 6, 33, 67, 321, 695, 70, 11, 981, 9, 3, 1734, 5054, 18237, 1067, 2, 83, 27, 6, 79, 13, 321, 805, 668, 2, 49, 27, 6, 49, 49, 321, 695, 70, 9, 3, 5804, 3130, 106, 3, 210, 3402, 6, 3303, 1012, 32, 1279, 6, 8, 549, 67, 167, 321, 90, 23, 1847, 2486, 1012, 84, 4, 476, 140, 6818, 3, 22254, 1030, 635, 4, 3931, 718, 2, 94, 3, 74, 844, 17, 3, 266, 90, 1012, 377, 1952, 2139, 9, 3, 686, 1, 3, 7, 137, 3, 266, 526, 1012, 32, 4529, 9, 476, 7, 2, 3027, 9, 1749, 802, 17, 8, 1491, 451, 1, 291, 24, 1012, 9, 797, 7, 16, 1197, 1368, 26, 3209, 777, 1196, 241, 1, 24, 1380, 2, 631, 122, 608, 5, 307, 3, 5233, 1, 104, 1312, 252, 1809]",2759.0,15587650,15
"Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.",Gynecologic oncology,Gynecol. Oncol.,2005-01-01,"Standard primary treatment for locally advanced cervix cancer is radiation (RT) with concomitant platinum-based chemotherapy (CT). Incomplete local control and the appearance of distant disease herald poor survival and warrant evaluation of new primary strategies. Paclitaxel and carboplatin are active agents in recurrent cervical carcinoma, have potent, synergistic in vitro radiosensitization, and are cytotoxic in weekly schedules. This study was done to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of weekly paclitaxel/carboplatin chemoradiotherapy in locally advanced cervix cancer. Women with primary, previously untreated, squamous cell or adenocarcinoma of the cervix, FIGO stage IB(2) to IVA, negative para-aortic lymph nodes, adequate organ function and performance status were eligible. Pelvic RT (45 Gy over 5 weeks--180 cGy/day, four-field) was followed by two brachytherapy applications (Point A low dose rate (LDR): 90 Gy, high dose rate (HDR): 75 Gy). Concurrent weekly CT was paclitaxel 50 mg/m(2) and carboplatin, starting at AUC 1.5 and escalating in three-patient cohorts by AUC 0.5 (Max AUC 3.5). Dose escalation followed a 4-week observation period for toxicity. A grade III-IV toxicity prompted up to three additional patients per dose level. A second event defined DLT. CT was administered concurrently throughout brachytherapy. Fifteen patients were enrolled and treated over four dose levels until DLT was reached. Median age was 44 years (range, 23-70); stages: IB2: 1, IIB: 9, IIIA: 1, IIIB: 4. Median RT treatment time was 61 days (range, 55-79). Fourteen patients received brachytherapy (LDR: 8, HDR: 6), and one received external RT only due to cervical stenosis. The median number of weekly CT cycles was seven (range, 6-7). One CT dose was dropped in one patient for a grade II thrombocytopenia. One grade III ANC was observed at dose level II (AUC 2.0) but not seen in three additional patients. At dose level IV (AUC 3.0), two grade III-IV ANC toxicities were observed in two patients (DLT). Nine patients had grade II anemia. One patient had grade III anemia. Grade III/IV nonhematologic toxicity was rare (1/15 GI-nausea/vomiting, 1/15 pneumonia, 1/15 hypokalemia). The MTD of carboplatin is AUC 2.5 with paclitaxel 50 mg/m(2). Median follow-up is 17 months; three patients have recurred and two have died. The estimated 2-year PFS and OS are 80% and 86%. Weekly paclitaxel and carboplatin chemoradiation is feasible and active. The MTD for a phase II trial is 50 mg/m(2) and AUC 2.5, respectively.",Clinical Trial,5498.0,34.0,Standard primary treatment for locally advanced cervix cancer is radiation RT with concomitant platinum-based chemotherapy CT Incomplete local control and the appearance of distant disease herald poor survival and warrant evaluation of new primary strategies Paclitaxel and carboplatin are active agents in recurrent carcinoma have potent synergistic in vitro radiosensitization and are cytotoxic in weekly schedules This study was done to determine the maximum tolerated dose MTD and dose-limiting toxicity DLT of weekly paclitaxel/carboplatin chemoradiotherapy in locally advanced cervix cancer Women with primary previously untreated squamous cell or adenocarcinoma of the cervix FIGO stage IB 2 to IVA negative para-aortic lymph nodes adequate organ function and performance status were eligible Pelvic RT 45 Gy over 5 weeks -- 180 cGy/day four-field was followed by two brachytherapy applications Point A low dose rate LDR 90 Gy high dose rate HDR 75 Gy Concurrent weekly CT was paclitaxel 50 mg/m 2 and carboplatin starting at AUC 1.5 and escalating in three-patient cohorts by AUC 0.5 Max AUC 3.5 Dose escalation followed a 4-week observation period for toxicity A grade III-IV toxicity prompted up to three additional patients per dose level A second event defined DLT CT was administered concurrently throughout brachytherapy Fifteen patients were enrolled and treated over four dose levels until DLT was reached Median age was 44 years range 23-70 stages IB2 1 IIB 9 IIIA 1 IIIB 4 Median RT treatment time was 61 days range 55-79 Fourteen patients received brachytherapy LDR 8 HDR 6 and one received external RT only due to stenosis The median number of weekly CT cycles was seven range 6-7 One CT dose was dropped in one patient for a grade II thrombocytopenia One grade III ANC was observed at dose level II AUC 2.0 but not seen in three additional patients At dose level IV AUC 3.0 two grade III-IV ANC toxicities were observed in two patients DLT Nine patients had grade II anemia One patient had grade III anemia Grade III/IV nonhematologic toxicity was rare 1/15 GI-nausea/vomiting 1/15 pneumonia 1/15 hypokalemia The MTD of carboplatin is AUC 2.5 with paclitaxel 50 mg/m 2 Median follow-up is 17 months three patients have recurred and two have died The estimated 2-year PFS and OS are 80 and 86 Weekly paclitaxel and carboplatin chemoradiation is feasible and active The MTD for a phase II trial is 50 mg/m 2 and AUC 2.5 respectively,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[260, 86, 24, 9, 795, 131, 3629, 12, 16, 121, 240, 5, 1781, 828, 90, 56, 425, 2610, 293, 182, 2, 3, 3592, 1, 626, 34, 18383, 334, 25, 2, 2946, 451, 1, 217, 86, 422, 490, 2, 927, 32, 544, 183, 4, 387, 134, 47, 1157, 1806, 4, 439, 6738, 2, 32, 759, 4, 709, 2314, 26, 45, 10, 1822, 6, 223, 3, 689, 421, 61, 961, 2, 61, 817, 155, 2059, 1, 709, 490, 927, 1464, 4, 795, 131, 3629, 12, 117, 5, 86, 373, 1278, 691, 31, 15, 449, 1, 3, 3629, 3837, 82, 3180, 18, 6, 5900, 199, 4615, 3938, 263, 502, 1658, 1259, 343, 2, 528, 156, 11, 625, 1110, 240, 512, 381, 252, 33, 244, 3172, 3071, 218, 294, 1067, 10, 370, 20, 100, 1536, 2911, 741, 8, 154, 61, 116, 6962, 424, 381, 64, 61, 116, 5309, 481, 381, 750, 709, 425, 10, 490, 212, 81, 188, 18, 2, 927, 1723, 28, 1376, 14, 33, 2, 2922, 4, 169, 69, 736, 20, 1376, 13, 33, 2649, 1376, 27, 33, 61, 1125, 370, 8, 39, 647, 1664, 727, 9, 155, 8, 88, 316, 478, 155, 4140, 126, 6, 169, 402, 7, 379, 61, 301, 8, 419, 774, 395, 2059, 425, 10, 468, 3294, 2432, 1536, 3057, 7, 11, 346, 2, 73, 252, 294, 61, 148, 1100, 2059, 10, 1300, 52, 89, 10, 584, 60, 184, 382, 431, 1153, 9537, 14, 3884, 83, 3164, 14, 3036, 39, 52, 240, 24, 98, 10, 713, 162, 184, 614, 842, 3225, 7, 103, 1536, 6962, 66, 5309, 49, 2, 104, 103, 1455, 240, 158, 520, 6, 6935, 3, 52, 207, 1, 709, 425, 410, 10, 648, 184, 49, 67, 104, 425, 61, 10, 8801, 4, 104, 69, 9, 8, 88, 215, 1340, 104, 88, 316, 6486, 10, 164, 28, 61, 301, 215, 1376, 18, 13, 84, 44, 527, 4, 169, 402, 7, 28, 61, 301, 478, 1376, 27, 13, 100, 88, 316, 478, 6486, 385, 11, 164, 4, 100, 7, 2059, 762, 7, 42, 88, 215, 1545, 104, 69, 42, 88, 316, 1545, 88, 316, 478, 3534, 155, 10, 622, 14, 167, 2104, 1218, 1966, 14, 167, 3485, 14, 167, 7799, 3, 961, 1, 927, 16, 1376, 18, 33, 5, 490, 212, 81, 188, 18, 52, 166, 126, 16, 269, 53, 169, 7, 47, 3363, 2, 100, 47, 1016, 3, 661, 18, 111, 300, 2, 118, 32, 493, 2, 868, 709, 490, 2, 927, 975, 16, 1313, 2, 544, 3, 961, 9, 8, 124, 215, 160, 16, 212, 81, 188, 18, 2, 1376, 18, 33, 106]",2451.0,15589596,507
Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2004-12-01,"To evaluate the effect of surgical resection on the outcome of patients with clinical Stage II or III cancer of the esophagus treated with concurrent chemoradiotherapy. A retrospective review of 132 consecutive patients with clinical Stage II or III esophageal cancer treated with concurrent chemoradiotherapy between January 1990 and December 1998 was performed. Of the 132 patients, 60 underwent esophagectomy 6-8 weeks after chemoradiotherapy. The median radiation dose was 50 Gy (range, 30-64.8 Gy) in the definitive chemoradiation group and 45 Gy (range, 30-50.4 Gy) in the chemoradiation plus esophagectomy group. Statistically significant differences were found between the two groups in median age, histologic subtype, tumor location, and number of patients with T4 disease. Patients who underwent definitive chemoradiotherapy were older (p = 0.0004) and more likely to have squamous cell carcinoma than adenocarcinoma (p <0.000), upper thoracic or cervical esophageal tumors (p <0.000), and T4 tumors (p = 0.024). Patients treated with chemoradiation plus esophagectomy had statistically significant superior 5-year loco-regional control (67.1% vs. 22.1%, p <0.000), disease-free survival (40.7% vs. 9.9%, p < 0.000), and 5-year overall survival (52.6% vs. 6.5%, p < 0.000) rates and median survival time (62 vs. 12 months) compared with patients treated with chemoradiotherapy only. However, no statistically significant difference was found in the rate of distant metastasis-free survival between the two groups (67.5% vs. 65.8%, p = 0.3). Surgical resection of the tumor was an independent predictor of improved locoregional control and overall survival in both univariate and multivariate analyses. To reduce the effect of the selection bias on the outcome, 34 patients in each group with matched pretreatment characteristics were compared. The results showed statistically significant better overall survival, disease-free survival, and locoregional control in favor of the chemoradiotherapy plus esophagectomy group. No statistically significant difference in distant metastasis-free survival was found in this subgroup analysis. Locoregional control was better in clinical Stage II or III esophageal cancer patients treated with concurrent chemoradiation plus esophagectomy. An improvement in survival occurred in the chemoradiation plus esophagectomy group, although this observation may have reflected selection bias. The results from this study suggest the need for a randomized trial to compare chemoradiation with or without esophagectomy in the treatment of cancer of the esophagus.",Journal Article,5529.0,38.0,To evaluate the effect of surgical resection on the outcome of patients with clinical Stage II or III cancer of the treated with concurrent chemoradiotherapy A retrospective review of 132 consecutive patients with clinical Stage II or III cancer treated with concurrent chemoradiotherapy between January 1990 and December 1998 was performed Of the 132 patients 60 underwent esophagectomy 6-8 weeks after chemoradiotherapy The median radiation dose was 50 Gy range 30-64.8 Gy in the definitive chemoradiation group and 45 Gy range 30-50.4 Gy in the chemoradiation plus esophagectomy group Statistically significant differences were found between the two groups in median age histologic subtype tumor location and number of patients with T4 disease Patients who underwent definitive chemoradiotherapy were older p 0.0004 and more likely to have squamous cell carcinoma than adenocarcinoma p 0.000 upper thoracic or tumors p 0.000 and T4 tumors p 0.024 Patients treated with chemoradiation plus esophagectomy had statistically significant superior 5-year loco-regional control 67.1 vs. 22.1 p 0.000 disease-free survival 40.7 vs. 9.9 p 0.000 and 5-year overall survival 52.6 vs. 6.5 p 0.000 rates and median survival time 62 vs. 12 months compared with patients treated with chemoradiotherapy only However no statistically significant difference was found in the rate of distant metastasis-free survival between the two groups 67.5 vs. 65.8 p 0.3 Surgical resection of the tumor was an independent predictor of improved locoregional control and overall survival in both univariate and multivariate analyses To reduce the effect of the selection bias on the outcome 34 patients in each group with matched pretreatment characteristics were compared The results showed statistically significant better overall survival disease-free survival and locoregional control in favor of the chemoradiotherapy plus esophagectomy group No statistically significant difference in distant metastasis-free survival was found in this subgroup analysis Locoregional control was better in clinical Stage II or III cancer patients treated with concurrent chemoradiation plus esophagectomy An improvement in survival occurred in the chemoradiation plus esophagectomy group although this observation may have reflected selection bias The results from this study suggest the need for a randomized trial to compare chemoradiation with or without esophagectomy in the treatment of cancer of the,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[6, 376, 3, 254, 1, 221, 170, 23, 3, 228, 1, 7, 5, 38, 82, 215, 15, 316, 12, 1, 3, 73, 5, 750, 1464, 8, 459, 206, 1, 4255, 935, 7, 5, 38, 82, 215, 15, 316, 12, 73, 5, 750, 1464, 59, 1024, 2289, 2, 1397, 1850, 10, 173, 1, 3, 4255, 7, 335, 208, 3617, 49, 66, 244, 50, 1464, 3, 52, 121, 61, 10, 212, 381, 184, 201, 660, 66, 381, 4, 3, 1057, 975, 87, 2, 512, 381, 184, 201, 212, 39, 381, 4, 3, 975, 349, 3617, 87, 712, 93, 362, 11, 204, 59, 3, 100, 271, 4, 52, 89, 884, 875, 30, 1147, 2, 207, 1, 7, 5, 2463, 34, 7, 54, 208, 1057, 1464, 11, 434, 19, 13, 5295, 2, 80, 322, 6, 47, 691, 31, 134, 76, 449, 19, 13, 984, 1726, 2098, 15, 57, 19, 13, 984, 2, 2463, 57, 19, 13, 4247, 7, 73, 5, 975, 349, 3617, 42, 712, 93, 1123, 33, 111, 7214, 951, 182, 598, 14, 105, 350, 14, 19, 13, 984, 34, 115, 25, 327, 67, 105, 83, 83, 19, 13, 984, 2, 33, 111, 63, 25, 653, 49, 105, 49, 33, 19, 13, 984, 151, 2, 52, 25, 98, 744, 105, 133, 53, 72, 5, 7, 73, 5, 1464, 158, 137, 77, 712, 93, 523, 10, 204, 4, 3, 116, 1, 626, 278, 115, 25, 59, 3, 100, 271, 598, 33, 105, 556, 66, 19, 13, 27, 221, 170, 1, 3, 30, 10, 35, 306, 980, 1, 231, 1325, 182, 2, 63, 25, 4, 110, 880, 2, 331, 318, 6, 969, 3, 254, 1, 3, 881, 2947, 23, 3, 228, 562, 7, 4, 296, 87, 5, 655, 1194, 374, 11, 72, 3, 99, 224, 712, 93, 380, 63, 25, 34, 115, 25, 2, 1325, 182, 4, 4283, 1, 3, 1464, 349, 3617, 87, 77, 712, 93, 523, 4, 626, 278, 115, 25, 10, 204, 4, 26, 1363, 65, 1325, 182, 10, 380, 4, 38, 82, 215, 15, 316, 12, 7, 73, 5, 750, 975, 349, 3617, 35, 767, 4, 25, 489, 4, 3, 975, 349, 3617, 87, 242, 26, 1664, 68, 47, 4686, 881, 2947, 3, 99, 29, 26, 45, 309, 3, 594, 9, 8, 384, 160, 6, 932, 975, 5, 15, 187, 3617, 4, 3, 24, 1, 12, 1, 3]",2465.0,15590179,648
Preventable reoperations for persistent and recurrent papillary thyroid carcinoma.,Surgery,Surgery,2004-12-01,"Cervical recurrence occurs in up to 25% of patients with papillary thyroid carcinoma (PTC) due either to the aggressive biology of PTC or to inadequate treatment. This retrospective study was designed to determine the frequency of inadequate surgical or medical therapy as a cause of persistent or recurrent PTC. We identified all patients who underwent reoperation for persistent (within 6 months of initial or pre-referral operation) or recurrent (greater than 6 months after initial or pre-referral operation) PTC from 1992 to 2003. Medical records including initial preoperative imaging, operative, and histopathology reports were reviewed. The initial surgical procedure was considered incomplete if all gross neoplasm was not removed or if ""node plucking"" was performed, and a subsequent recurrence occurred in the same cervical compartment. Seventy-two consecutive patients underwent reoperation for persistent (17) or recurrent (55) PTC. Of the 17 patients with persistent PTC, reoperation was judged to have been possibly preventable in 14 (82%) due to inadequate preoperative imaging or incomplete initial surgery. Of the 55 patients with recurrent PTC, reoperation was judged to have been possibly preventable due to incomplete initial surgery in 14 (25%). Based on the National Comprehensive Cancer Network guidelines, 33 (46%) of 72 patients with persistent or recurrent PTC received inadequate initial local treatment. Reoperation in 28 (39%) of 72 patients with persistent or recurrent PTC was potentially preventable. Accurate preoperative staging and adherence to the suggested National Comprehensive Cancer Network treatment guidelines may minimize the need for cervical reoperation.",Journal Article,5529.0,,recurrence occurs in up to 25 of patients with papillary carcinoma PTC due either to the aggressive biology of PTC or to inadequate treatment This retrospective study was designed to determine the frequency of inadequate surgical or medical therapy as a cause of persistent or recurrent PTC We identified all patients who underwent reoperation for persistent within 6 months of initial or pre-referral operation or recurrent greater than 6 months after initial or pre-referral operation PTC from 1992 to 2003 Medical records including initial preoperative imaging operative and histopathology reports were reviewed The initial surgical procedure was considered incomplete if all gross neoplasm was not removed or if `` node plucking '' was performed and a subsequent recurrence occurred in the same compartment Seventy-two consecutive patients underwent reoperation for persistent 17 or recurrent 55 PTC Of the 17 patients with persistent PTC reoperation was judged to have been possibly preventable in 14 82 due to inadequate preoperative imaging or incomplete initial surgery Of the 55 patients with recurrent PTC reoperation was judged to have been possibly preventable due to incomplete initial surgery in 14 25 Based on the National Comprehensive Cancer Network guidelines 33 46 of 72 patients with persistent or recurrent PTC received inadequate initial local treatment Reoperation in 28 39 of 72 patients with persistent or recurrent PTC was potentially preventable Accurate preoperative staging and adherence to the suggested National Comprehensive Cancer Network treatment guidelines may minimize the need for reoperation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[146, 1780, 4, 126, 6, 243, 1, 7, 5, 1796, 134, 3748, 520, 361, 6, 3, 571, 891, 1, 3748, 15, 6, 3358, 24, 26, 459, 45, 10, 1114, 6, 223, 3, 675, 1, 3358, 221, 15, 484, 36, 22, 8, 708, 1, 1882, 15, 387, 3748, 21, 108, 62, 7, 54, 208, 5077, 9, 1882, 262, 49, 53, 1, 388, 15, 671, 2096, 2589, 15, 387, 378, 76, 49, 53, 50, 388, 15, 671, 2096, 2589, 3748, 29, 2846, 6, 1522, 484, 1064, 141, 388, 498, 270, 1208, 2, 3831, 1198, 11, 446, 3, 388, 221, 1299, 10, 515, 2610, 492, 62, 1789, 2131, 10, 44, 2264, 15, 492, 289, 43835, 522, 10, 173, 2, 8, 706, 146, 489, 4, 3, 827, 3616, 2073, 100, 935, 7, 208, 5077, 9, 1882, 269, 15, 387, 614, 3748, 1, 3, 269, 7, 5, 1882, 3748, 5077, 10, 7249, 6, 47, 85, 2150, 7936, 4, 213, 878, 520, 6, 3358, 498, 270, 15, 2610, 388, 152, 1, 3, 614, 7, 5, 387, 3748, 5077, 10, 7249, 6, 47, 85, 2150, 7936, 520, 6, 2610, 388, 152, 4, 213, 243, 90, 23, 3, 657, 949, 12, 1801, 677, 466, 641, 1, 720, 7, 5, 1882, 15, 387, 3748, 103, 3358, 388, 293, 24, 5077, 4, 339, 587, 1, 720, 7, 5, 1882, 15, 387, 3748, 10, 751, 7936, 1481, 498, 632, 2, 2149, 6, 3, 1148, 657, 949, 12, 1801, 24, 677, 68, 3241, 3, 594, 9, 5077]",1630.0,15657574,0
An educational program to increase cervical and breast cancer screening in Hispanic women: a Southwest Oncology Group study.,Cancer nursing,Cancer Nurs,,"We conducted a community-based pilot study to train Hispanic cancer survivors as promotoras (lay health educators) to encourage their social contacts to obtain breast and cervical cancer screening. Promotoras were recruited from a private oncologist's practice at a Minority-Based Community Clinical Oncology Program (MBCCOP). Five Hispanic women were trained to serve as promotoras by attending a 12-week course. They shared cancer screening information with family and social contacts and encouraged them to obtain Papanicolaou smears and/or mammograms. Study endpoints included the number of women recruited and trained to serve as promotoras, the number of contacts made per promotora, and the number of contacts who were screened; data were based on contact logs maintained for 1 year. Screening examinations were documented by a postcard returned by the contact or by review of community health clinic records. Five promotoras contacted 141 (range = 24-49 per promotora) women to share cancer screening information. Fifty Hispanic women obtained screening after contact with a promotora. Twenty-nine underwent mammography (ages 25-58) and 43 received a Papanicolaou smear (ages 23-62). Hispanic female cancer survivors can be trained as promotoras. Screening information conveyed by a promotora can successfully prompt Hispanic women to obtain mammography and Papanicolaou smears.",Journal Article,,73.0,We conducted a community-based pilot study to train Hispanic cancer survivors as promotoras lay health educators to encourage their social contacts to obtain and cancer screening Promotoras were recruited from a private oncologist 's practice at a Minority-Based Community Clinical Oncology Program MBCCOP Five Hispanic women were trained to serve as promotoras by attending a 12-week course They shared cancer screening information with family and social contacts and encouraged them to obtain Papanicolaou smears and/or mammograms Study endpoints included the number of women recruited and trained to serve as promotoras the number of contacts made per promotora and the number of contacts who were screened data were based on contact logs maintained for 1 year Screening examinations were documented by a postcard returned by the contact or by review of community health clinic records Five promotoras contacted 141 range 24-49 per promotora women to share cancer screening information Fifty Hispanic women obtained screening after contact with a promotora Twenty-nine underwent mammography ages 25-58 and 43 received a Papanicolaou smear ages 23-62 Hispanic female cancer survivors can be trained as promotoras Screening information conveyed by a promotora can successfully prompt Hispanic women to obtain mammography and Papanicolaou smears,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 426, 8, 1714, 90, 2281, 45, 6, 13619, 1776, 12, 332, 22, 28345, 9455, 341, 26362, 6, 7113, 136, 2032, 13291, 6, 3140, 2, 12, 453, 28345, 11, 2619, 29, 8, 4745, 2709, 292, 758, 28, 8, 2652, 90, 1714, 38, 413, 1243, 54587, 365, 1776, 117, 11, 5946, 6, 1833, 22, 28345, 20, 6895, 8, 133, 647, 906, 491, 2664, 12, 453, 487, 5, 607, 2, 2032, 13291, 2, 5865, 1370, 6, 3140, 10416, 8916, 2, 15, 6329, 45, 1387, 159, 3, 207, 1, 117, 2619, 2, 5946, 6, 1833, 22, 28345, 3, 207, 1, 13291, 1229, 379, 33809, 2, 3, 207, 1, 13291, 54, 11, 2261, 74, 11, 90, 23, 4393, 13527, 1955, 9, 14, 111, 453, 4209, 11, 1405, 20, 8, 54588, 5157, 20, 3, 4393, 15, 20, 206, 1, 1714, 341, 1188, 1064, 365, 28345, 8590, 4379, 184, 259, 739, 379, 33809, 117, 6, 4349, 12, 453, 487, 1461, 1776, 117, 683, 453, 50, 4393, 5, 8, 33809, 737, 762, 208, 2446, 2165, 243, 717, 2, 601, 103, 8, 10416, 8379, 2165, 382, 744, 1776, 1061, 12, 332, 122, 40, 5946, 22, 28345, 453, 487, 15887, 20, 8, 33809, 122, 1878, 4776, 1776, 117, 6, 3140, 2446, 2, 10416, 8916]",1345.0,15681982,103
Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial.,Gynecologic oncology,Gynecol. Oncol.,2005-03-01,"To retrospectively analyze data from a previously reported randomized trial of either pelvic radiation (RT) or RT + chemotherapy (CT) in patients undergoing radical hysterectomy and pelvic lymphadenectomy with positive pelvic lymph nodes, parametrial involvement, or surgical margins; to explore associations between RT + CT; and to investigate histopathologic and clinical factors which might be predictive of recurrence. Histopathologic sections from biopsies and hysterectomies and clinical data were reviewed from patients with stage IA2, IB, or IIA cervical cancer treated with RT or RT + CT (cisplatin 70 mg/m2 plus fluorouracil 1000 mg/m2 every 3 weeks for four cycles). A univariate analysis was performed because the relatively small sample size limited the interpretation of a multivariate analysis. Of the 268 enrolled women, 243 (RT = 116; RT + CT = 127) were evaluable. The beneficial effect of adjuvant CT was not strongly associated with patient age, histological type, or tumor grade. The prognostic significance of histological type, tumor size, number of positive nodes, and parametrial extension in the RT group was less apparent when CT was added. The absolute improvement in 5-year survival for adjuvant CT in patients with tumors < or =2 cm was only 5% (77% versus 82%), while for those with tumors >2 cm it was 19% (58% versus 77%). Similarly, the absolute 5-year survival benefit was less evident among patients with one nodal metastasis (79% versus 83%) than when at least two nodes were positive (55% versus 75%). In this exploratory, hypothesis-generating analysis, adding CT to RT after radical hysterectomy, appears to provide a smaller absolute benefit when only one node is positive or when the tumor size is < 2 cm. Further study of the role of CT after radical hysterectomy in patients with a low risk of recurrence may be warranted.",Clinical Trial,5439.0,122.0,To retrospectively analyze data from a previously reported randomized trial of either pelvic radiation RT or RT chemotherapy CT in patients undergoing radical hysterectomy and pelvic lymphadenectomy with positive pelvic lymph nodes parametrial involvement or surgical margins to explore associations between RT CT and to investigate histopathologic and clinical factors which might be predictive of recurrence Histopathologic sections from biopsies and hysterectomies and clinical data were reviewed from patients with stage IA2 IB or IIA cancer treated with RT or RT CT cisplatin 70 mg/m2 plus fluorouracil 1000 mg/m2 every 3 weeks for four cycles A univariate analysis was performed because the relatively small sample size limited the interpretation of a multivariate analysis Of the 268 enrolled women 243 RT 116 RT CT 127 were evaluable The beneficial effect of adjuvant CT was not strongly associated with patient age histological type or tumor grade The prognostic significance of histological type tumor size number of positive nodes and parametrial extension in the RT group was less apparent when CT was added The absolute improvement in 5-year survival for adjuvant CT in patients with tumors or =2 cm was only 5 77 versus 82 while for those with tumors 2 cm it was 19 58 versus 77 Similarly the absolute 5-year survival benefit was less evident among patients with one nodal metastasis 79 versus 83 than when at least two nodes were positive 55 versus 75 In this exploratory hypothesis-generating analysis adding CT to RT after radical hysterectomy appears to provide a smaller absolute benefit when only one node is positive or when the tumor size is 2 cm Further study of the role of CT after radical hysterectomy in patients with a low risk of recurrence may be warranted,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 894, 1992, 74, 29, 8, 373, 210, 384, 160, 1, 361, 1110, 121, 240, 15, 240, 56, 425, 4, 7, 479, 711, 2622, 2, 1110, 2048, 5, 109, 1110, 263, 502, 8726, 799, 15, 221, 1012, 6, 1645, 685, 59, 240, 425, 2, 6, 963, 2630, 2, 38, 130, 92, 822, 40, 464, 1, 146, 2630, 3013, 29, 1154, 2, 15266, 2, 38, 74, 11, 446, 29, 7, 5, 82, 16725, 3180, 15, 4088, 12, 73, 5, 240, 15, 240, 425, 540, 431, 81, 821, 349, 1404, 2345, 81, 821, 454, 27, 244, 9, 294, 410, 8, 880, 65, 10, 173, 408, 3, 1352, 302, 1000, 444, 383, 3, 3037, 1, 8, 331, 65, 1, 3, 8410, 346, 117, 6346, 240, 3790, 240, 425, 4080, 11, 859, 3, 2524, 254, 1, 249, 425, 10, 44, 1327, 41, 5, 69, 89, 1831, 267, 15, 30, 88, 3, 177, 724, 1, 1831, 267, 30, 444, 207, 1, 109, 502, 2, 8726, 2401, 4, 3, 240, 87, 10, 299, 2235, 198, 425, 10, 1953, 3, 1766, 767, 4, 33, 111, 25, 9, 249, 425, 4, 7, 5, 57, 15, 18, 494, 10, 158, 33, 849, 185, 878, 369, 9, 135, 5, 57, 18, 494, 192, 10, 326, 717, 185, 849, 1813, 3, 1766, 33, 111, 25, 247, 10, 299, 2853, 107, 7, 5, 104, 779, 278, 842, 185, 852, 76, 198, 28, 506, 100, 502, 11, 109, 614, 185, 481, 4, 26, 2386, 1492, 3997, 65, 2726, 425, 6, 240, 50, 711, 2622, 1233, 6, 377, 8, 2170, 1766, 247, 198, 158, 104, 289, 16, 109, 15, 198, 3, 30, 444, 16, 18, 494, 195, 45, 1, 3, 200, 1, 425, 50, 711, 2622, 4, 7, 5, 8, 154, 43, 1, 146, 68, 40, 1197]",1786.0,15721417,735
Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2005-03-01,"The purpose of this pilot study was to evaluate the efficacy of the clitoral therapy device (Eros Therapy) in alleviating sexual dysfunction in irradiated cervical cancer patients. Eligible patients had a history of cervical cancer treated with radiotherapy and self-reported sexual dysfunction of sexual arousal and/or orgasmic disorders. Patients used the noninvasive, nonpharmacologic clitoral therapy device using a hand-held, battery-powered vacuum to cause clitoral engorgement four times weekly for 3 months during foreplay and self-stimulation. Study instruments included the Female Sexual Function Index, Derogatis Interview for Sexual Functioning, and Dyadic Adjustment Scale. The outcome evaluation was performed at 3 months. Between 2001 and 2002, 15 women were enrolled and 13 completed the study. The median patient age and radiotherapy-enrollment interval was 43.5 years and 2 years, respectively. At baseline, all patients reported symptoms of sexual arousal and/or orgasmic disorders, and some also had sexual desire and pain disorders. At 3 months, statistically significant improvements were seen in all domains tested, including sexual desire, arousal, lubrication, orgasm, sexual satisfaction, and reduced pain. The median Female Sexual Function Index total score increased from 17 to 29.4 (maximal score, 36; p <0.001). The median Derogatis Interview for Sexual Functioning total raw score increased from 46 to 95 (maximal score, 118; p <0.001). At baseline, the Derogatis Interview for Sexual Functioning total T-score corresponded to the bottom 10th percentile of normal sexual functioning. At 3 months, the total T-score placed the patients at the normalcy cutoff. Gynecologic examinations revealed improved mucosal color and moisture and vaginal elasticity and decreased bleeding and ulceration. Our results from this pilot study suggest that the clitoral therapy device may alleviate sexual dysfunction in irradiated cervical cancer patients. A randomized, controlled trial is warranted to assess the full benefits of this approach.",Evaluation Study,5439.0,58.0,The purpose of this pilot study was to evaluate the efficacy of the clitoral therapy device Eros Therapy in alleviating sexual dysfunction in irradiated cancer patients Eligible patients had a history of cancer treated with radiotherapy and self-reported sexual dysfunction of sexual arousal and/or orgasmic disorders Patients used the noninvasive nonpharmacologic clitoral therapy device using a hand-held battery-powered vacuum to cause clitoral engorgement four times weekly for 3 months during foreplay and self-stimulation Study instruments included the Female Sexual Function Index Derogatis Interview for Sexual Functioning and Dyadic Adjustment Scale The outcome evaluation was performed at 3 months Between 2001 and 2002 15 women were enrolled and 13 completed the study The median patient age and radiotherapy-enrollment interval was 43.5 years and 2 years respectively At baseline all patients reported symptoms of sexual arousal and/or orgasmic disorders and some also had sexual desire and pain disorders At 3 months statistically significant improvements were seen in all domains tested including sexual desire arousal lubrication orgasm sexual satisfaction and reduced pain The median Female Sexual Function Index total score increased from 17 to 29.4 maximal score 36 p 0.001 The median Derogatis Interview for Sexual Functioning total raw score increased from 46 to 95 maximal score 118 p 0.001 At baseline the Derogatis Interview for Sexual Functioning total T-score corresponded to the bottom 10th percentile of normal sexual functioning At 3 months the total T-score placed the patients at the normalcy cutoff Gynecologic examinations revealed improved mucosal color and moisture and elasticity and decreased bleeding and ulceration Our results from this pilot study suggest that the clitoral therapy device may alleviate sexual dysfunction in irradiated cancer patients A randomized controlled trial is warranted to assess the full benefits of this approach,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 743, 1, 26, 2281, 45, 10, 6, 376, 3, 209, 1, 3, 24751, 36, 4472, 54664, 36, 4, 12956, 2232, 1527, 4, 2398, 12, 7, 625, 7, 42, 8, 532, 1, 12, 73, 5, 310, 2, 1074, 210, 2232, 1527, 1, 2232, 21313, 2, 15, 43878, 1997, 7, 95, 3, 2957, 11803, 24751, 36, 4472, 75, 8, 2833, 4033, 11665, 6855, 14519, 6, 708, 24751, 54665, 294, 1072, 709, 9, 27, 53, 190, 54666, 2, 1074, 2503, 45, 4730, 159, 3, 1061, 2232, 343, 558, 33840, 4313, 9, 2232, 2702, 2, 24799, 1852, 1124, 3, 228, 451, 10, 173, 28, 27, 53, 59, 1758, 2, 1544, 167, 117, 11, 346, 2, 233, 781, 3, 45, 3, 52, 69, 89, 2, 310, 1798, 268, 10, 601, 33, 60, 2, 18, 60, 106, 28, 330, 62, 7, 210, 507, 1, 2232, 21313, 2, 15, 43878, 1997, 2, 476, 120, 42, 2232, 5278, 2, 559, 1997, 28, 27, 53, 712, 93, 1474, 11, 527, 4, 62, 2703, 650, 141, 2232, 5278, 21313, 43879, 28363, 2232, 2885, 2, 405, 559, 3, 52, 1061, 2232, 343, 558, 181, 368, 101, 29, 269, 6, 462, 39, 2725, 368, 511, 19, 13, 144, 3, 52, 33840, 4313, 9, 2232, 2702, 181, 10170, 368, 101, 29, 641, 6, 48, 2725, 368, 4002, 19, 13, 144, 28, 330, 3, 33840, 4313, 9, 2232, 2702, 181, 102, 368, 7254, 6, 3, 9288, 14199, 6392, 1, 295, 2232, 2702, 28, 27, 53, 3, 181, 102, 368, 3295, 3, 7, 28, 3, 26124, 2779, 1512, 4209, 553, 231, 3068, 6052, 2, 54667, 2, 21314, 2, 340, 2294, 2, 5158, 114, 99, 29, 26, 2281, 45, 309, 17, 3, 24751, 36, 4472, 68, 8193, 2232, 1527, 4, 2398, 12, 7, 8, 384, 1149, 160, 16, 1197, 6, 423, 3, 1647, 1141, 1, 26, 353]",1978.0,15752887,632
Racial differences in the familial aggregation of breast cancer and other female cancers.,Breast cancer research and treatment,Breast Cancer Res. Treat.,2005-02-01,"Although breast cancer familial aggregation has been studied in Caucasians, information for African-Americans is scant. We used family cancer history from the Women's Contraceptive and Reproductive Experiences study to assess the aggregation of breast and gynecological cancers in African-American and Caucasian families. Information was available on 41,825 first and second-degree relatives of Caucasian and 28,956 relatives of African-American participants. We used a cohort approach in which the relative's cancer status was the outcome in unconditional logistic regression and adjusted for correlated data using generalized estimating equations. Race-specific models included a family history indicator, the relative's age, and type. Relative risk (RR) estimates for breast cancer were highest for first-degree relatives, and the overall RR for breast cancer among case relatives was 1.96 (95% CI = 1.68-2.30) for Caucasian and 1.78 (95% CI = 1.41-2.25) for African-Americans. The effect of CARE participants' reference age on their relatives' breast cancer risk was greatest among first-degree relatives of African-American patients with RRs (95% CI) for ages <45 and > or =45 of 2.97 (1.86-4.74) and 1.48 (1.14-1.92), respectively. Among Caucasians, first-degree relatives of case subjects were at greater risk for ovarian cancer, particularly relatives younger than 45 years (RR (95% CI) = 2.06 (1.02-4.12)), whereas African-American first-degree relatives of case subjects were at increased cervical cancer risk (RR (95% CI) = 2.17 (1.22-3.85). In conclusion, these racially distinct aggregation patterns may reflect different modes of inheritance and/or environmental factors that impact cancer risk.",Comparative Study,5467.0,8.0,"Although cancer familial aggregation has been studied in Caucasians information for African-Americans is scant We used family cancer history from the Women 's Contraceptive and Reproductive Experiences study to assess the aggregation of and gynecological cancers in African-American and Caucasian families Information was available on 41,825 first and second-degree relatives of Caucasian and 28,956 relatives of African-American participants We used a cohort approach in which the relative 's cancer status was the outcome in unconditional logistic regression and adjusted for correlated data using generalized estimating equations Race-specific models included a family history indicator the relative 's age and type Relative risk RR estimates for cancer were highest for first-degree relatives and the overall RR for cancer among case relatives was 1.96 95 CI 1.68-2.30 for Caucasian and 1.78 95 CI 1.41-2.25 for African-Americans The effect of CARE participants reference age on their relatives cancer risk was greatest among first-degree relatives of African-American patients with RRs 95 CI for ages 45 and or =45 of 2.97 1.86-4.74 and 1.48 1.14-1.92 respectively Among Caucasians first-degree relatives of case subjects were at greater risk for cancer particularly relatives younger than 45 years RR 95 CI 2.06 1.02-4.12 whereas African-American first-degree relatives of case subjects were at increased cancer risk RR 95 CI 2.17 1.22-3.85 In conclusion these racially distinct aggregation patterns may reflect different modes of inheritance and/or environmental factors that impact cancer risk",1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[242, 12, 2200, 6598, 71, 85, 656, 4, 5396, 487, 9, 1410, 2731, 16, 11578, 21, 95, 607, 12, 532, 29, 3, 117, 292, 6780, 2, 3705, 4031, 45, 6, 423, 3, 6598, 1, 2, 6324, 163, 4, 1410, 597, 2, 3229, 1954, 487, 10, 390, 23, 605, 9295, 157, 2, 419, 1444, 3335, 1, 3229, 2, 339, 14137, 3335, 1, 1410, 597, 776, 21, 95, 8, 180, 353, 4, 92, 3, 580, 292, 12, 156, 10, 3, 228, 4, 6438, 812, 320, 2, 586, 9, 438, 74, 75, 4169, 4563, 6799, 1047, 112, 274, 159, 8, 607, 532, 3287, 3, 580, 292, 89, 2, 267, 580, 43, 861, 1423, 9, 12, 11, 1076, 9, 157, 1444, 3335, 2, 3, 63, 861, 9, 12, 107, 473, 3335, 10, 14, 921, 48, 58, 14, 806, 18, 201, 9, 3229, 2, 14, 833, 48, 58, 14, 605, 18, 243, 9, 1410, 2731, 3, 254, 1, 165, 776, 2482, 89, 23, 136, 3335, 12, 43, 10, 2199, 107, 157, 1444, 3335, 1, 1410, 597, 7, 5, 4739, 48, 58, 9, 2165, 512, 2, 15, 512, 1, 18, 1015, 14, 868, 39, 794, 2, 14, 576, 14, 213, 14, 937, 106, 107, 5396, 157, 1444, 3335, 1, 473, 976, 11, 28, 378, 43, 9, 12, 823, 3335, 773, 76, 512, 60, 861, 48, 58, 18, 1460, 14, 588, 39, 133, 547, 1410, 597, 157, 1444, 3335, 1, 473, 976, 11, 28, 101, 12, 43, 861, 48, 58, 18, 269, 14, 350, 27, 772, 4, 1221, 46, 14908, 834, 6598, 764, 68, 2694, 338, 8256, 1, 10070, 2, 15, 3766, 130, 17, 345, 12, 43]",1601.0,15754120,429
Gynecologic cancer treatment and the impact of cancer-related infertility.,Gynecologic oncology,Gynecol. Oncol.,2005-04-01,"The objective of this study was to empirically assess the emotional and sexual impact of cancer-related infertility in women with a history of gynecologic cancer. Women with a history of gynecologic cancer were approached during their gynecologic oncology clinic appointment; they were provided a description of the study and asked to participate. All participants completed a one-time self-report survey. We present data acquired via the following methods: Center for Epidemiologic Studies-Depression Scale (CES-D), Impact of Events Scale (IES), Modified Inventory of Traumatic Grief (M-ITG), Female Sexual Function Index (FSFI), and the Menopausal Symptom Checklist. The study sample consisted of 20 women, ages 27 to 49 years (mean, approximately 40 years), who had undergone treatment for cervical (40%), ovarian (20%), or uterine (40%) cancer. Forty percent of the sample reported depressive symptoms as measured by the CES-D, with 35% of the women experiencing moderate to severe levels of distress as measured by the IES. The women in this sample experienced dissatisfaction with their overall sex lives (67%), pain during vaginal penetration (62%), and low levels of sexual desire (56%). The preliminary findings of this study indicated that feelings of depression, grief, stress, and sexual dysfunction are being experienced by women with a history of gynecologic cancer who have lost their fertility as a result of their cancer treatment.",Journal Article,5408.0,126.0,The objective of this study was to empirically assess the emotional and sexual impact of cancer-related infertility in women with a history of gynecologic cancer Women with a history of gynecologic cancer were approached during their gynecologic oncology clinic appointment they were provided a description of the study and asked to participate All participants completed a one-time self-report survey We present data acquired via the following methods Center for Epidemiologic Studies-Depression Scale CES-D Impact of Events Scale IES Modified Inventory of Traumatic Grief M-ITG Female Sexual Function Index FSFI and the Menopausal Symptom Checklist The study sample consisted of 20 women ages 27 to 49 years mean approximately 40 years who had undergone treatment for 40 20 or 40 cancer Forty percent of the sample reported depressive symptoms as measured by the CES-D with 35 of the women experiencing moderate to severe levels of distress as measured by the IES The women in this sample experienced dissatisfaction with their overall sex lives 67 pain during penetration 62 and low levels of sexual desire 56 The preliminary findings of this study indicated that feelings of depression grief stress and sexual dysfunction are being experienced by women with a history of gynecologic cancer who have lost their fertility as a result of their cancer treatment,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 461, 1, 26, 45, 10, 6, 9654, 423, 3, 2671, 2, 2232, 345, 1, 12, 139, 5901, 4, 117, 5, 8, 532, 1, 1512, 12, 117, 5, 8, 532, 1, 1512, 12, 11, 5738, 190, 136, 1512, 413, 1188, 9698, 491, 11, 1052, 8, 5263, 1, 3, 45, 2, 3732, 6, 3506, 62, 776, 781, 8, 104, 98, 1074, 414, 1407, 21, 364, 74, 1294, 847, 3, 366, 636, 574, 9, 3609, 94, 1774, 1124, 9979, 427, 345, 1, 281, 1124, 12331, 1230, 3818, 1, 11272, 11425, 188, 54697, 1061, 2232, 343, 558, 22278, 2, 3, 3565, 934, 9787, 3, 45, 1000, 1695, 1, 179, 117, 2165, 428, 6, 739, 60, 313, 705, 327, 60, 54, 42, 1989, 24, 9, 327, 179, 15, 327, 12, 1213, 714, 1, 3, 1000, 210, 4945, 507, 22, 644, 20, 3, 9979, 427, 5, 465, 1, 3, 117, 2985, 1163, 6, 905, 148, 1, 1462, 22, 644, 20, 3, 12331, 3, 117, 4, 26, 1000, 592, 12806, 5, 136, 63, 1035, 6407, 598, 559, 190, 4618, 744, 2, 154, 148, 1, 2232, 5278, 664, 3, 1676, 272, 1, 26, 45, 1103, 17, 12859, 1, 1774, 11425, 1531, 2, 2232, 1527, 32, 486, 592, 20, 117, 5, 8, 532, 1, 1512, 12, 54, 47, 3009, 136, 2954, 22, 8, 757, 1, 136, 12, 24]",1361.0,15790443,208
Pediatric radical abdominal trachelectomy for cervical clear cell carcinoma: a novel surgical approach.,Gynecologic oncology,Gynecol. Oncol.,2005-04-01,"Clear cell carcinoma of the cervix and vagina is rare in the pediatric population. Many of these tumors are associated with prior intrauterine diethylstilbestrol (DES) exposure. All DES-associated tumors are believed to contain microsatellite instability (MI). Historically, the recommended treatment is radical hysterectomy and pelvic lymphadenectomy, which result in infertility in all cases. Radical abdominal or vaginal trachelectomy and pelvic lymph node dissection is a new technique utilized in adult women with early cervical cancer who wish to retain fertility. This novel approach is also pertinent to the pediatric patient and is described in this report. A molecular analysis is also performed to determine if these are DES-associated tumors. Due to the narrow vaginal anatomy in pediatric patients, a vaginal approach is not possible, and an abdominal approach is performed. The resection includes the cervix, upper vagina, parametrium, and paracolpos. Pelvic lymphadenectomy is performed in a similar manner to the adult patient. Matched pairs of normal and tumor DNA from both cases were examined for evidence of MI using a consensus panel of microsatellite markers. Two girls aged 6 and 8 years and without history of DES exposure presented with vaginal bleeding. Vaginoscopy revealed cervical polyp in both cases. Biopsies demonstrated clear cell cancer stage IB1 in both patients. They underwent radical abdominal trachelectomy and bilateral pelvic lymph node dissection along with anastomosis of uterine isthmus to upper vagina. Intraoperative frozen-section analysis confirmed negative uterine and vaginal margins. No adjuvant treatment was given and both girls remain disease free. Neither tumor showed evidence for MI, confirming that these are not DES-associated tumors. To our knowledge, this is the first report of radical abdominal trachelectomy in the pediatric age group and it is likely to include the youngest patient with clear cell carcinoma of the uterine cervix not associated with DES exposure. This novel approach is feasible and appears safe in the pediatric age group.",Case Reports,5408.0,27.0,Clear cell carcinoma of the cervix and vagina is rare in the pediatric population Many of these tumors are associated with prior intrauterine diethylstilbestrol DES exposure All DES-associated tumors are believed to contain microsatellite instability MI Historically the recommended treatment is radical hysterectomy and pelvic lymphadenectomy which result in infertility in all cases Radical abdominal or trachelectomy and pelvic lymph node dissection is a new technique utilized in adult women with early cancer who wish to retain fertility This novel approach is also pertinent to the pediatric patient and is described in this report A molecular analysis is also performed to determine if these are DES-associated tumors Due to the narrow anatomy in pediatric patients a approach is not possible and an abdominal approach is performed The resection includes the cervix upper vagina parametrium and paracolpos Pelvic lymphadenectomy is performed in a similar manner to the adult patient Matched pairs of normal and tumor DNA from both cases were examined for evidence of MI using a consensus panel of microsatellite markers Two girls aged 6 and 8 years and without history of DES exposure presented with bleeding Vaginoscopy revealed polyp in both cases Biopsies demonstrated clear cell cancer stage IB1 in both patients They underwent radical abdominal trachelectomy and bilateral pelvic lymph node dissection along with anastomosis of isthmus to upper vagina Intraoperative frozen-section analysis confirmed negative and margins No adjuvant treatment was given and both girls remain disease free Neither tumor showed evidence for MI confirming that these are not DES-associated tumors To our knowledge this is the first report of radical abdominal trachelectomy in the pediatric age group and it is likely to include the youngest patient with clear cell carcinoma of the cervix not associated with DES exposure This novel approach is feasible and appears safe in the pediatric age group,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[885, 31, 134, 1, 3, 3629, 2, 7553, 16, 622, 4, 3, 815, 266, 445, 1, 46, 57, 32, 41, 5, 324, 18242, 15522, 8683, 645, 62, 8683, 41, 57, 32, 3979, 6, 3725, 2226, 1753, 6862, 3578, 3, 793, 24, 16, 711, 2622, 2, 1110, 2048, 92, 757, 4, 5901, 4, 62, 140, 711, 1467, 15, 5760, 2, 1110, 263, 289, 1161, 16, 8, 217, 1312, 2080, 4, 780, 117, 5, 191, 12, 54, 11443, 6, 6630, 2954, 26, 229, 353, 16, 120, 5799, 6, 3, 815, 69, 2, 16, 1027, 4, 26, 414, 8, 219, 65, 16, 120, 173, 6, 223, 492, 46, 32, 8683, 41, 57, 520, 6, 3, 6958, 5081, 4, 815, 7, 8, 353, 16, 44, 899, 2, 35, 1467, 353, 16, 173, 3, 170, 1920, 3, 3629, 1726, 7553, 30751, 2, 54700, 1110, 2048, 16, 173, 4, 8, 288, 1708, 6, 3, 780, 69, 655, 2773, 1, 295, 2, 30, 261, 29, 110, 140, 11, 409, 9, 241, 1, 6862, 75, 8, 1391, 993, 1, 2226, 525, 100, 5989, 1032, 49, 2, 66, 60, 2, 187, 532, 1, 8683, 645, 917, 5, 2294, 43902, 553, 6493, 4, 110, 140, 1154, 264, 885, 31, 12, 82, 8111, 4, 110, 7, 491, 208, 711, 1467, 5760, 2, 1607, 1110, 263, 289, 1161, 1510, 5, 5519, 1, 54701, 6, 1726, 7553, 1720, 3015, 2917, 65, 557, 199, 2, 1012, 77, 249, 24, 10, 447, 2, 110, 5989, 918, 34, 115, 2174, 30, 224, 241, 9, 6862, 5030, 17, 46, 32, 44, 8683, 41, 57, 6, 114, 922, 26, 16, 3, 157, 414, 1, 711, 1467, 5760, 4, 3, 815, 89, 87, 2, 192, 16, 322, 6, 643, 3, 13042, 69, 5, 885, 31, 134, 1, 3, 3629, 44, 41, 5, 8683, 645, 26, 229, 353, 16, 1313, 2, 1233, 1165, 4, 3, 815, 89, 87]",1991.0,15790482,480
Operative management of metastatic and malignant primary subaxial cervical tumors.,Journal of neurosurgery. Spine,J Neurosurg Spine,2005-03-01,"The authors describe the preoperative assessment, intraoperative strategies, and long-term outcomes in 41 consecutive patients who underwent spinal reconstruction after resection of subaxial cervical neoplasms. Thirty-three tumors were metastatic and eight were primary. Preoperative studies included direct laryngoscopy and vertebral artery (VA) balloon occlusion tests in selected patients. Based on the tumor location, approaches included 12 anterior, 13 posterior, and 16 combined. All patients underwent aggressive intralesional resection and spinal reconstruction. In 12 patients, the VA was dissected from the periphery of the tumor, two cases of which required ligation. Fibula allograft and an anterior rigid plate fixation were most commonly used for anterior reconstruction. Posterior reconstruction was initially performed using lateral mass plates (LMPs) in 13 patients and screw/rod systems in the remaining patients. At follow up, pain level improved to mild or was absent in 39 patients (95%) who had presented with moderate or severe pain. The American Spinal Injury Association (ASIA) Scale scores were stable in 25 patients who presented with ASIA Score E and improved in 14 patients (88%) who presented with ASIA Score B, C, or D. Functional radiculopathy significantly improved in 16 (94%) of 17 patients. Complications occurred in 10 patients (24%) and included three fixation failures requiring revision. Two fixation failures involved cervical LMP screw pullout. The overall mean survival duration was 8.6 months for patients with metastatic tumors and 33.4 months for primary tumors. Surgery for the treatment of subaxial spine neoplasms is effective for relieving pain, encouraging functional nerve root recovery, and preserving spinal cord function with acceptable complication rates.",Journal Article,5439.0,34.0,The authors describe the preoperative assessment intraoperative strategies and long-term outcomes in 41 consecutive patients who underwent spinal reconstruction after resection of subaxial neoplasms Thirty-three tumors were metastatic and eight were primary Preoperative studies included direct laryngoscopy and vertebral artery VA balloon occlusion tests in selected patients Based on the tumor location approaches included 12 anterior 13 posterior and 16 combined All patients underwent aggressive intralesional resection and spinal reconstruction In 12 patients the VA was dissected from the periphery of the tumor two cases of which required ligation Fibula allograft and an anterior rigid plate fixation were most commonly used for anterior reconstruction Posterior reconstruction was initially performed using lateral mass plates LMPs in 13 patients and screw/rod systems in the remaining patients At follow up pain level improved to mild or was absent in 39 patients 95 who had presented with moderate or severe pain The American Spinal Injury Association ASIA Scale scores were stable in 25 patients who presented with ASIA Score E and improved in 14 patients 88 who presented with ASIA Score B C or D. Functional radiculopathy significantly improved in 16 94 of 17 patients Complications occurred in 10 patients 24 and included three fixation failures requiring revision Two fixation failures involved LMP screw pullout The overall mean survival duration was 8.6 months for patients with metastatic tumors and 33.4 months for primary tumors Surgery for the treatment of subaxial spine neoplasms is effective for relieving pain encouraging functional nerve root recovery and preserving spinal cord function with acceptable complication rates,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 738, 897, 3, 498, 455, 1720, 422, 2, 319, 337, 123, 4, 605, 935, 7, 54, 208, 1499, 1470, 50, 170, 1, 43905, 1179, 977, 169, 57, 11, 113, 2, 659, 11, 86, 498, 94, 159, 1196, 25990, 2, 4731, 2872, 7057, 10725, 9742, 895, 4, 715, 7, 90, 23, 3, 30, 1147, 611, 159, 133, 2882, 233, 3028, 2, 245, 397, 62, 7, 208, 571, 7549, 170, 2, 1499, 1470, 4, 133, 7, 3, 7057, 10, 7973, 29, 3, 9668, 1, 3, 30, 100, 140, 1, 92, 616, 5307, 16797, 9568, 2, 35, 2882, 12782, 9656, 8574, 11, 96, 841, 95, 9, 2882, 1470, 3028, 1470, 10, 1625, 173, 75, 3855, 782, 18902, 43906, 4, 233, 7, 2, 14911, 14202, 1530, 4, 3, 1844, 7, 28, 166, 126, 559, 301, 231, 6, 1980, 15, 10, 3269, 4, 587, 7, 48, 54, 42, 917, 5, 1163, 15, 905, 559, 3, 597, 1499, 2730, 248, 5958, 1124, 703, 11, 585, 4, 243, 7, 54, 917, 5, 5958, 368, 563, 2, 231, 4, 213, 7, 889, 54, 917, 5, 5958, 368, 132, 256, 15, 427, 583, 16642, 97, 231, 4, 245, 960, 1, 269, 7, 521, 489, 4, 79, 7, 259, 2, 159, 169, 8574, 3368, 1888, 5646, 100, 8574, 3368, 646, 11786, 14911, 43907, 3, 63, 313, 25, 654, 10, 66, 49, 53, 9, 7, 5, 113, 57, 2, 466, 39, 53, 9, 86, 57, 152, 9, 3, 24, 1, 43905, 2342, 1179, 16, 323, 9, 13768, 559, 2269, 583, 2476, 8386, 1602, 2, 4972, 1499, 1885, 343, 5, 1595, 1447, 151]",1749.0,15796349,411
Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix.,Gynecologic oncology,Gynecol. Oncol.,2005-06-01,"To determine the efficacy and safety of capecitabine in women with inoperable, recurrent, or metastatic squamous cell cervical cancer. In a phase II IRB approved trial, capecitabine was given at a dosage of 2000 mg/m2/day orally in a divided dose daily for 14 days followed by a 7-day rest period. A standard dose modification scheme was used with one allowed dose reduction or dose escalation. National Cancer Institute criteria for progression, response, and toxicity were utilized. Quality of life data were obtained using the Memorial Symptom Assessment Scale and Functional Assessment for Cancer Therapy, which included a subscale for cervical cancer. Twenty of 23 enrolled patients were evaluable for response. Stable disease was noted in 5 patients, with a median duration of response of 3.5 months (range, 3-6.5 months). No partial or complete responses were seen. Common grade 3 toxicities were fatigue (30.4%); abdominal pain, constipation, hand-foot syndrome, nausea, and vomiting (8.7% each); as well as dyspnea, headache, and coagulopathy (4.3% each). There were no grade 4 toxicities. All patients with previous exposure to infused 5-FU had evidence of progression. No statistically significant changes in quality of life were noted from baseline to post-cycle 2. Single-agent capecitabine in patients with recurrent cervical cancer resulted in no objective responses. Although capecitabine is a well-tolerated regimen, as a single agent, it offers minimal benefit in a poor-prognosis cervical cancer population.",Clinical Trial,5347.0,15.0,To determine the efficacy and safety of capecitabine in women with inoperable recurrent or metastatic squamous cell cancer In a phase II IRB approved trial capecitabine was given at a dosage of 2000 mg/m2/day orally in a divided dose daily for 14 days followed by a 7-day rest period A standard dose modification scheme was used with one allowed dose reduction or dose escalation National Cancer Institute criteria for progression response and toxicity were utilized Quality of life data were obtained using the Memorial Symptom Assessment Scale and Functional Assessment for Cancer Therapy which included a subscale for cancer Twenty of 23 enrolled patients were evaluable for response Stable disease was noted in 5 patients with a median duration of response of 3.5 months range 3-6.5 months No partial or complete responses were seen Common grade 3 toxicities were fatigue 30.4 abdominal pain constipation hand-foot syndrome nausea and vomiting 8.7 each as well as dyspnea headache and coagulopathy 4.3 each There were no grade 4 toxicities All patients with previous exposure to infused 5-FU had evidence of progression No statistically significant changes in quality of life were noted from baseline to post-cycle 2 Single-agent capecitabine in patients with recurrent cancer resulted in no objective responses Although capecitabine is a well-tolerated regimen as a single agent it offers minimal benefit in a poor-prognosis cancer population,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 209, 2, 367, 1, 1629, 4, 117, 5, 3874, 387, 15, 113, 691, 31, 12, 4, 8, 124, 215, 5880, 850, 160, 1629, 10, 447, 28, 8, 3323, 1, 1081, 81, 821, 218, 1428, 4, 8, 2176, 61, 391, 9, 213, 162, 370, 20, 8, 67, 218, 3677, 727, 8, 260, 61, 2437, 4633, 10, 95, 5, 104, 2313, 61, 628, 15, 61, 1125, 657, 12, 1377, 371, 9, 91, 51, 2, 155, 11, 2080, 372, 1, 358, 74, 11, 683, 75, 3, 2563, 934, 455, 1124, 2, 583, 455, 9, 12, 36, 92, 159, 8, 5593, 9, 12, 737, 1, 382, 346, 7, 11, 859, 9, 51, 585, 34, 10, 1051, 4, 33, 7, 5, 8, 52, 654, 1, 51, 1, 27, 33, 53, 184, 27, 49, 33, 53, 77, 450, 15, 236, 253, 11, 527, 186, 88, 27, 385, 11, 613, 201, 39, 1467, 559, 4532, 2833, 4100, 681, 1218, 2, 1966, 66, 67, 296, 22, 149, 22, 2923, 4538, 2, 10029, 39, 27, 296, 125, 11, 77, 88, 39, 385, 62, 7, 5, 698, 645, 6, 4524, 33, 1296, 42, 241, 1, 91, 77, 712, 93, 400, 4, 372, 1, 358, 11, 1051, 29, 330, 6, 539, 417, 18, 226, 420, 1629, 4, 7, 5, 387, 12, 627, 4, 77, 461, 253, 242, 1629, 16, 8, 149, 421, 477, 22, 8, 226, 420, 192, 2339, 1048, 247, 4, 8, 334, 356, 12, 266]",1447.0,15882895,778
Management of cervical adenocarcinoma in situ during pregnancy.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2005-05-01,Adenocarcinoma in situ (AIS) is a precursor of invasive disease that is being more frequently diagnosed during the reproductive years. Few reports have described the treatment of this condition in gravid women. The purpose of this study was to review our collective experience managing cervical AIS during pregnancy. Retrospective medical record review of all women diagnosed with AIS during pregnancy from 1995 to 2004 at 3 academic institutions. Eleven women with a median age of 32 years were identified. Five who received a diagnosis in the early second trimester underwent uncomplicated cold knife conization (CKC) at 14 to 19 weeks' gestation. Six patients underwent postpartum CKC. All 11 women delivered at term. One patient undergoing postpartum CKC required radical hysterectomy for stage IB1 cervical adenocarcinoma. Four subsequent pregnancies occurred among patients having fertility-sparing surgery. Management of cervical AIS during pregnancy by early second trimester CKC is safe for mother and fetus.,Journal Article,5378.0,11.0,Adenocarcinoma in situ AIS is a precursor of invasive disease that is being more frequently diagnosed during the reproductive years Few reports have described the treatment of this condition in gravid women The purpose of this study was to review our collective experience managing AIS during pregnancy Retrospective medical record review of all women diagnosed with AIS during pregnancy from 1995 to 2004 at 3 academic institutions Eleven women with a median age of 32 years were identified Five who received a diagnosis in the early second trimester underwent uncomplicated cold knife conization CKC at 14 to 19 weeks gestation Six patients underwent postpartum CKC All 11 women delivered at term One patient undergoing postpartum CKC required radical hysterectomy for stage IB1 adenocarcinoma Four subsequent pregnancies occurred among patients having fertility-sparing surgery Management of AIS during pregnancy by early second trimester CKC is safe for mother and fetus,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[449, 4, 957, 3826, 16, 8, 2765, 1, 416, 34, 17, 16, 486, 80, 746, 265, 190, 3, 3705, 60, 1021, 1198, 47, 1027, 3, 24, 1, 26, 2850, 4, 30682, 117, 3, 743, 1, 26, 45, 10, 6, 206, 114, 9549, 730, 3969, 3826, 190, 2290, 459, 484, 3237, 206, 1, 62, 117, 265, 5, 3826, 190, 2290, 29, 2323, 6, 1131, 28, 27, 1916, 1764, 2627, 117, 5, 8, 52, 89, 1, 531, 60, 11, 108, 365, 54, 103, 8, 147, 4, 3, 191, 419, 12693, 208, 13863, 5945, 8045, 8755, 28403, 28, 213, 6, 326, 244, 13250, 437, 7, 208, 7830, 28403, 62, 175, 117, 1623, 28, 337, 104, 69, 479, 7830, 28403, 616, 711, 2622, 9, 82, 8111, 449, 294, 706, 8746, 489, 107, 7, 1041, 2954, 1851, 152, 284, 1, 3826, 190, 2290, 20, 191, 419, 12693, 28403, 16, 1165, 9, 9733, 2, 15083]",974.0,15902134,83
Effect of delivery route on natural history of cervical dysplasia.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2005-05-01,"This study was undertaken to determine the (1) impact of delivery route on the natural history of cervical dysplasia and (2) overall regression rates of cervical dysplasia in pregnant women. A retrospective analysis was performed on 705 pregnant women with abnormal Papanicolaou tests who presented for prenatal care at the Kapiolani Medical Center Women's Clinic in Honolulu, Hawaii, between 1991 and 2001. Data collection included demographics, delivery route, and cervical pathology. Two hundred one patients met the inclusion criteria. Regression rates for vaginal and cesarean section groups were as follows: atypical squamous cells (64% vs 70%, P = .32), low-grade squamous intraepithelial lesion (58% vs 42%, P = .073), and high-grade squamous intraepithelial lesion (53% vs 25%, P = .44). Of the total population, 30% of lesions persisted postpartum, 58% regressed, and 12% progressed. Mode of delivery does not influence the natural history of dysplastic lesions. Gravid and nongravid women have similar regression rates.",Journal Article,5378.0,14.0,This study was undertaken to determine the 1 impact of delivery route on the natural history of dysplasia and 2 overall regression rates of dysplasia in pregnant women A retrospective analysis was performed on 705 pregnant women with abnormal Papanicolaou tests who presented for prenatal care at the Kapiolani Medical Center Women 's Clinic in Honolulu Hawaii between 1991 and 2001 Data collection included demographics delivery route and pathology Two hundred one patients met the inclusion criteria Regression rates for and cesarean section groups were as follows atypical squamous cells 64 vs 70 P .32 low-grade squamous intraepithelial lesion 58 vs 42 P .073 and high-grade squamous intraepithelial lesion 53 vs 25 P .44 Of the total population 30 of lesions persisted postpartum 58 regressed and 12 progressed Mode of delivery does not influence the natural history of dysplastic lesions Gravid and nongravid women have similar regression rates,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[26, 45, 10, 2789, 6, 223, 3, 14, 345, 1, 989, 5841, 23, 3, 1504, 532, 1, 2253, 2, 18, 63, 320, 151, 1, 2253, 4, 6086, 117, 8, 459, 65, 10, 173, 23, 11303, 6086, 117, 5, 1668, 10416, 895, 54, 917, 9, 15621, 165, 28, 3, 37919, 484, 574, 117, 292, 1188, 4, 30774, 18301, 59, 3372, 2, 1758, 74, 2442, 159, 2221, 989, 5841, 2, 1117, 100, 1128, 104, 7, 543, 3, 1680, 371, 320, 151, 9, 2, 28385, 2917, 271, 11, 22, 2962, 1973, 691, 37, 660, 105, 431, 19, 531, 154, 88, 691, 4153, 1180, 717, 105, 595, 19, 14571, 2, 64, 88, 691, 4153, 1180, 699, 105, 243, 19, 584, 1, 3, 181, 266, 201, 1, 406, 3760, 7830, 717, 12579, 2, 133, 1839, 4530, 1, 989, 1097, 44, 1054, 3, 1504, 532, 1, 6461, 406, 30682, 2, 54824, 117, 47, 288, 320, 151]",950.0,15902135,353
Towards improved biomarker studies of cervical neoplasia: effects of precolposcopic procedures on gene expression patterns.,"Diagnostic molecular pathology : the American journal of surgical pathology, part B",Diagn. Mol. Pathol.,2005-06-01,"Among tumor sites, cervical cancer offers an ideal model for investigating differences in gene expression associated with transitions from normal to precancer and invasion to cancer. To evaluate the validity of assessing gene expression in cervical tissues acquired in a clinical setting, we investigated whether standard procedures, namely the application of acetic acid and/or Lugol's iodine, employed for the visualization of colposcopically directed biopsies, altered patterns in oligonucleotide (oligo) arrays. We compared microarray profiles from six women, each with three adjacent tissue samples removed from benign hysterectomy specimens and treated as follows: immediately frozen, acetic acid application only, acetic acid, and Lugol's iodine. Of the 22,464 original spots on the microarray, 4,850 spots were expressed at detectable levels for further evaluation upon data normalization and filtration. For each spot, the difference between topical applications was computed, and P values were calculated using a bivariate T2 test. Upon adjustment for multiple comparisons using both the Holm's and Hochberg's procedures as well as the False Discovery Rate (Benjamini-Hochberg and Benjamini-Yeuketili [BY]), we failed to identify genes differentially expressed and conclude that standard precolposcopic procedures do not substantially affect the overall gene expression patterns in the normal cervix.",Comparative Study,5347.0,5.0,"Among tumor sites cancer offers an ideal model for investigating differences in gene expression associated with transitions from normal to precancer and invasion to cancer To evaluate the validity of assessing gene expression in tissues acquired in a clinical setting we investigated whether standard procedures namely the application of acetic acid and/or Lugol 's iodine employed for the visualization of colposcopically directed biopsies altered patterns in oligonucleotide oligo arrays We compared microarray profiles from six women each with three adjacent tissue samples removed from benign hysterectomy specimens and treated as follows immediately frozen acetic acid application only acetic acid and Lugol 's iodine Of the 22,464 original spots on the microarray 4,850 spots were expressed at detectable levels for further evaluation upon data normalization and filtration For each spot the difference between topical applications was computed and P values were calculated using a bivariate T2 test Upon adjustment for multiple comparisons using both the Holm 's and Hochberg 's procedures as well as the False Discovery Rate Benjamini-Hochberg and Benjamini-Yeuketili BY we failed to identify genes differentially expressed and conclude that standard precolposcopic procedures do not substantially affect the overall gene expression patterns in the normal cervix",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[107, 30, 633, 12, 2339, 35, 3662, 202, 9, 3103, 362, 4, 145, 55, 41, 5, 7738, 29, 295, 6, 12380, 2, 578, 6, 12, 6, 376, 3, 3099, 1, 1977, 145, 55, 4, 742, 1294, 4, 8, 38, 546, 21, 565, 317, 260, 1369, 5046, 3, 1581, 1, 16812, 971, 2, 15, 37920, 292, 4287, 2516, 9, 3, 6234, 1, 26091, 1166, 1154, 1495, 764, 4, 4727, 11301, 3923, 21, 72, 1727, 1241, 29, 437, 117, 296, 5, 169, 2086, 246, 347, 2264, 29, 1002, 2622, 623, 2, 73, 22, 2962, 3467, 3015, 16812, 971, 1581, 158, 16812, 971, 2, 37920, 292, 4287, 1, 3, 350, 10288, 2279, 8382, 23, 3, 1727, 39, 8537, 8382, 11, 570, 28, 2083, 148, 9, 195, 451, 1548, 74, 5924, 2, 5779, 9, 296, 6901, 3, 523, 59, 5879, 2911, 10, 1220, 2, 19, 1030, 11, 981, 75, 8, 7686, 1786, 412, 1548, 1852, 9, 232, 2213, 75, 110, 3, 54830, 292, 2, 23448, 292, 1369, 22, 149, 22, 3, 2133, 1574, 116, 23449, 23448, 2, 23449, 54831, 20, 21, 1551, 6, 255, 214, 2478, 570, 2, 2060, 17, 260, 54832, 1369, 1022, 44, 2109, 1158, 3, 63, 145, 55, 764, 4, 3, 295, 3629]",1370.0,15905687,420
Methemoglobinemia induced by topical vaginal sulfanilamide cream in a patient with cervical cancer: a case report.,Gynecologic oncology,Gynecol. Oncol.,2005-06-01,"Methemoglobinemia is a rare disorder most commonly associated with the ingestion or topical application of an offending exogenous agent. The clinical consequences of acute methemoglobinemia can be devastating and include lethargy, headache, and dyspnea and, as methemoglobin concentrations rise, respiratory depression, confusion, seizures, and even death. Here we present a case of acute methemoglobinemia induced by exposure to topical vaginal sulfanilamide cream in a 36-year-old woman with a FIGO stage IIIB squamous cell cervical carcinoma. Although methemoglobinemia associated with topical anesthetics has been well documented, to our knowledge this is the first reported case of methemoglobinemia induced by exposure to topical sulfanilamide cream. Although patients undergoing intracavitary radiation treatment for cervical cancer are at risk for cyanosis due to the development of deep vein thromboses and pulmonary embolism, methemoglobinemia should be suspected in the setting of acute cyanosis with a normal arterial oxygen pressure.",Case Reports,5347.0,4.0,Methemoglobinemia is a rare disorder most commonly associated with the ingestion or topical application of an offending exogenous agent The clinical consequences of acute methemoglobinemia can be devastating and include lethargy headache and dyspnea and as methemoglobin concentrations rise respiratory depression confusion seizures and even death Here we present a case of acute methemoglobinemia induced by exposure to topical sulfanilamide cream in a 36-year-old woman with a FIGO stage IIIB squamous cell carcinoma Although methemoglobinemia associated with topical anesthetics has been well documented to our knowledge this is the first reported case of methemoglobinemia induced by exposure to topical sulfanilamide cream Although patients undergoing intracavitary radiation treatment for cancer are at risk for cyanosis due to the development of deep vein thromboses and pulmonary embolism methemoglobinemia should be suspected in the setting of acute cyanosis with a normal arterial oxygen pressure,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[20372, 16, 8, 622, 2645, 96, 841, 41, 5, 3, 17691, 15, 5879, 1581, 1, 35, 28093, 4181, 420, 3, 38, 3255, 1, 286, 20372, 122, 40, 5778, 2, 643, 18194, 4538, 2, 2923, 2, 22, 37921, 1003, 3693, 2718, 1774, 7399, 4448, 2, 871, 273, 467, 21, 364, 8, 473, 1, 286, 20372, 277, 20, 645, 6, 5879, 43973, 14572, 4, 8, 511, 111, 1095, 2854, 5, 8, 3837, 82, 3036, 691, 31, 134, 242, 20372, 41, 5, 5879, 43974, 71, 85, 149, 1405, 6, 114, 922, 26, 16, 3, 157, 210, 473, 1, 20372, 277, 20, 645, 6, 5879, 43973, 14572, 242, 7, 479, 9122, 121, 24, 9, 12, 32, 28, 43, 9, 33895, 520, 6, 3, 193, 1, 2369, 2762, 16267, 2, 1087, 5475, 20372, 257, 40, 2768, 4, 3, 546, 1, 286, 33895, 5, 8, 295, 3127, 2848, 3738]",1006.0,15907987,815
Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2005-05-23,"To prospectively assess the impact of treatment with cisplatin alone or in combination with topotecan (CT) on quality of life (QOL) in patients with advanced or recurrent cervical cancer, and to explore the prognostic value of baseline QOL scores. Patients entered on Gynecologic Oncology Group (GOG) Protocol 179 were expected to complete QOL assessments at four time points using Functional Assessment of Cancer Therapy-General (FACT-G), Cervix subscale (Cx subscale), FACT/GOG-Neurotoxicity subscale (NTX subscale), Brief Pain Inventory (BPI), and UNISCALE (UNI). Adjusting for patient age, baseline scores, and effects of time, we longitudinally examined treatment effect on QOL during and after chemotherapy. Among patients randomly allocated to receive cisplatin (n = 146) or CT (n = 147), there were no statistically significant differences in QOL up to 9 months after randomization despite more hematologic toxicity in the combination arm. QOL assessments were completed at rates of 98%, 85%, 68%, and 59%, respectively, for the four time points, with similar rates and reasons for nonparticipation between regimens. Baseline FACT-G (P = .0016) and BPI (P = .0001) scores were significantly associated with patient age; older patients had better QOL and less pain. Baseline UNI was positively correlated with FACT-G (r = 0.66; P < .001) and Cx subscale (r = 0.29; P < .001), and negatively related to BPI (r = -0.41; P < .0001). Baseline FACT-Cx (FACT-G + Cx subscale) was associated with survival. Despite increased toxicity, CT did not significantly reduce patient QOL when compared with cisplatin alone. Patient-reported QOL measures may be an important prognostic tool in advanced cervix cancer.",Clinical Trial,5356.0,112.0,To prospectively assess the impact of treatment with cisplatin alone or in combination with topotecan CT on quality of life QOL in patients with advanced or recurrent cancer and to explore the prognostic value of baseline QOL scores Patients entered on Gynecologic Oncology Group GOG Protocol 179 were expected to complete QOL assessments at four time points using Functional Assessment of Cancer Therapy-General FACT-G Cervix subscale Cx subscale FACT/GOG-Neurotoxicity subscale NTX subscale Brief Pain Inventory BPI and UNISCALE UNI Adjusting for patient age baseline scores and effects of time we longitudinally examined treatment effect on QOL during and after chemotherapy Among patients randomly allocated to receive cisplatin n 146 or CT n 147 there were no statistically significant differences in QOL up to 9 months after randomization despite more hematologic toxicity in the combination arm QOL assessments were completed at rates of 98 85 68 and 59 respectively for the four time points with similar rates and reasons for nonparticipation between regimens Baseline FACT-G P .0016 and BPI P .0001 scores were significantly associated with patient age older patients had better QOL and less pain Baseline UNI was positively correlated with FACT-G r 0.66 P .001 and Cx subscale r 0.29 P .001 and negatively related to BPI r -0.41 P .0001 Baseline FACT-Cx FACT-G Cx subscale was associated with survival Despite increased toxicity CT did not significantly reduce patient QOL when compared with cisplatin alone Patient-reported QOL measures may be an important prognostic tool in advanced cervix cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1143, 423, 3, 345, 1, 24, 5, 540, 279, 15, 4, 150, 5, 2129, 425, 23, 372, 1, 358, 1001, 4, 7, 5, 131, 15, 387, 12, 2, 6, 1645, 3, 177, 549, 1, 330, 1001, 703, 7, 2836, 23, 1512, 413, 87, 4760, 1182, 5977, 11, 1336, 6, 236, 1001, 2182, 28, 294, 98, 862, 75, 583, 455, 1, 12, 36, 1083, 1991, 499, 3629, 5593, 13627, 5593, 1991, 4760, 3561, 5593, 8110, 5593, 3190, 559, 3818, 9699, 2, 19021, 11024, 1358, 9, 69, 89, 330, 703, 2, 176, 1, 98, 21, 9278, 409, 24, 254, 23, 1001, 190, 2, 50, 56, 107, 7, 1108, 6682, 6, 560, 540, 78, 4909, 15, 425, 78, 4961, 125, 11, 77, 712, 93, 362, 4, 1001, 126, 6, 83, 53, 50, 3644, 550, 80, 813, 155, 4, 3, 150, 475, 1001, 2182, 11, 781, 28, 151, 1, 1096, 772, 806, 2, 728, 106, 9, 3, 294, 98, 862, 5, 288, 151, 2, 2325, 9, 33775, 59, 472, 330, 1991, 499, 19, 13230, 2, 9699, 19, 488, 703, 11, 97, 41, 5, 69, 89, 434, 7, 42, 380, 1001, 2, 299, 559, 330, 11024, 10, 2375, 438, 5, 1991, 499, 668, 13, 700, 19, 144, 2, 13627, 5593, 668, 13, 462, 19, 144, 2, 2723, 139, 6, 9699, 668, 13, 605, 19, 488, 330, 1991, 13627, 1991, 499, 13627, 5593, 10, 41, 5, 25, 550, 101, 155, 425, 205, 44, 97, 969, 69, 1001, 198, 72, 5, 540, 279, 69, 210, 1001, 1018, 68, 40, 35, 305, 177, 1515, 4, 131, 3629, 12]",1609.0,15911864,732
Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease?,Head & neck,Head Neck,2005-08-01,"Completion cervical lymphadenectomy is usually performed after excisional biopsy of nodal metastases from melanoma. Radiation (XRT) might be effective for some patients in lieu of formal lymph node dissection. Thirty-six patients with parotid or cervical node metastases from melanoma were treated with excision of nodal disease and postoperative XRT without formal lymph node dissection. Radiation was delivered to the primary site (if known), the site of nodal excision, and the undissected ipsilateral neck. With a median follow-up of 5.3 years, the disease recurred within the regional basin in two patients and at distant sites in 14 patients. The actuarial 5-year regional control and distant metastasis-free survival rates were 93% and 59%, respectively. Two patients had a clinically significant side effect develop. The results of this study suggest that selected patients may receive regional XRT after local excision of nodal disease from melanoma in lieu of formal lymph node dissection.",Journal Article,5286.0,38.0,Completion lymphadenectomy is usually performed after excisional biopsy of nodal metastases from Radiation XRT might be effective for some patients in lieu of formal lymph node dissection Thirty-six patients with parotid or node metastases from were treated with excision of nodal disease and postoperative XRT without formal lymph node dissection Radiation was delivered to the primary site if known the site of nodal excision and the undissected ipsilateral With a median follow-up of 5.3 years the disease recurred within the regional basin in two patients and at distant sites in 14 patients The actuarial 5-year regional control and distant metastasis-free survival rates were 93 and 59 respectively Two patients had a clinically significant side effect develop The results of this study suggest that selected patients may receive regional XRT after local excision of nodal disease from in lieu of formal lymph node dissection,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1438, 2048, 16, 2082, 173, 50, 6488, 411, 1, 779, 196, 29, 121, 3429, 822, 40, 323, 9, 476, 7, 4, 14575, 1, 5057, 263, 289, 1161, 977, 437, 7, 5, 5838, 15, 289, 196, 29, 11, 73, 5, 1366, 1, 779, 34, 2, 573, 3429, 187, 5057, 263, 289, 1161, 121, 10, 1623, 6, 3, 86, 606, 492, 440, 3, 606, 1, 779, 1366, 2, 3, 28415, 2880, 5, 8, 52, 166, 126, 1, 33, 27, 60, 3, 34, 3363, 262, 3, 951, 6969, 4, 100, 7, 2, 28, 626, 633, 4, 213, 7, 3, 2361, 33, 111, 951, 182, 2, 626, 278, 115, 25, 151, 11, 966, 2, 728, 106, 100, 7, 42, 8, 505, 93, 1152, 254, 690, 3, 99, 1, 26, 45, 309, 17, 715, 7, 68, 560, 951, 3429, 50, 293, 1366, 1, 779, 34, 29, 4, 14575, 1, 5057, 263, 289, 1161]",931.0,15952196,44
"Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology.",International journal of cancer,Int. J. Cancer,2005-12-01,"Oral contraceptive (OC) use, hormonal contraceptive use and multiparity are potential risk factors for cervical precancer, cervical intraepithelial neoplasia 3 (CIN3), but a limited number of studies have adequately accounted for possible confounding effect of oncogenic human papillomavirus (HPV) infection. To examine the relationships of these factors with CIN3, we conducted an analysis of women (n = 5,060) with minimally abnormal Pap smears who were enrolled in the ASCUS and LSIL Triage Study (ALTS), a clinical trial to evaluate management strategies. Cervical specimens collected at enrollment were tested for HPV DNA using 2 methods. Multivariate logistics regression models were used to assess associations (odds ratio [OR] with 95% confidence intervals [CI]) of the potential risk factors (e.g., OC use and parity) with testing oncogenic HPV positive among controls (<CIN2) (n = 4,114) and with rigorously reviewed cases of CIN3 identified throughout the study (n = 499) among women with oncogenic HPV (n = 3,126). Only former oral contraceptive use (OR = 1.3, 95% CI = 1.0-1.7) was associated marginally with having an oncogenic HPV infection among controls. Restricted to women with oncogenic HPV, current injectable hormonal contraceptive users were at an elevated risk of CIN3 (OR = 1.6, 95% CI = 1.2-2.1) compared to women who never used them. Similarly, restricted to women with HPV16 infection, current users of injectable contraceptives were at a marginally elevated risk of CIN3 (OR = 1.5, 95% CI = 1.0-2.3) compared to women who never used them. Oral contraceptive use, Norplant (implantable hormonal contraceptive) use, a history of pregnancy, age at first pregnancy, lifetime numbers of pregnancies and lifetime numbers of live births were not associated with CIN3. We conclude that only current injectable hormonal contraceptive use slightly elevated the risk (approximately 50%) of CIN3 in this young and low parity population of women with oncogenic HPV and minimally abnormal Pap smears but further confirmation of this relationship is needed.",Journal Article,5164.0,30.0,"Oral contraceptive OC use hormonal contraceptive use and multiparity are potential risk factors for precancer intraepithelial neoplasia 3 CIN3 but a limited number of studies have adequately accounted for possible confounding effect of oncogenic human papillomavirus HPV infection To examine the relationships of these factors with CIN3 we conducted an analysis of women n 5,060 with minimally abnormal Pap smears who were enrolled in the ASCUS and LSIL Triage Study ALTS a clinical trial to evaluate management strategies specimens collected at enrollment were tested for HPV DNA using 2 methods Multivariate logistics regression models were used to assess associations odds ratio OR with 95 confidence intervals CI of the potential risk factors e.g. OC use and parity with testing oncogenic HPV positive among controls CIN2 n 4,114 and with rigorously reviewed cases of CIN3 identified throughout the study n 499 among women with oncogenic HPV n 3,126 Only former oral contraceptive use OR 1.3 95 CI 1.0-1.7 was associated marginally with having an oncogenic HPV infection among controls Restricted to women with oncogenic HPV current injectable hormonal contraceptive users were at an elevated risk of CIN3 OR 1.6 95 CI 1.2-2.1 compared to women who never used them Similarly restricted to women with HPV16 infection current users of injectable contraceptives were at a marginally elevated risk of CIN3 OR 1.5 95 CI 1.0-2.3 compared to women who never used them Oral contraceptive use Norplant implantable hormonal contraceptive use a history of pregnancy age at first pregnancy lifetime numbers of pregnancies and lifetime numbers of live births were not associated with CIN3 We conclude that only current injectable hormonal contraceptive use slightly elevated the risk approximately 50 of CIN3 in this young and low parity population of women with oncogenic HPV and minimally abnormal Pap smears but further confirmation of this relationship is needed",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[518, 6780, 2950, 119, 1761, 6780, 119, 2, 28425, 32, 174, 43, 130, 9, 12380, 4153, 2298, 27, 10346, 84, 8, 383, 207, 1, 94, 47, 4215, 3688, 9, 899, 4339, 254, 1, 1302, 171, 3242, 933, 930, 6, 1004, 3, 2467, 1, 46, 130, 5, 10346, 21, 426, 35, 65, 1, 117, 78, 33, 9972, 5, 2144, 1668, 4290, 8916, 54, 11, 346, 4, 3, 21337, 2, 17849, 9059, 45, 26252, 8, 38, 160, 6, 376, 284, 422, 623, 786, 28, 1798, 11, 650, 9, 933, 261, 75, 18, 636, 331, 17179, 320, 274, 11, 95, 6, 423, 685, 610, 197, 15, 5, 48, 307, 1582, 58, 1, 3, 174, 43, 130, 563, 499, 2950, 119, 2, 5754, 5, 471, 1302, 933, 109, 107, 535, 12870, 78, 39, 3803, 2, 5, 10347, 446, 140, 1, 10346, 108, 2432, 3, 45, 78, 11673, 107, 117, 5, 1302, 933, 78, 27, 3927, 158, 3623, 518, 6780, 119, 15, 14, 27, 48, 58, 14, 13, 14, 67, 10, 41, 5007, 5, 1041, 35, 1302, 933, 930, 107, 535, 2016, 6, 117, 5, 1302, 933, 291, 11652, 1761, 6780, 2735, 11, 28, 35, 804, 43, 1, 10346, 15, 14, 49, 48, 58, 14, 18, 18, 14, 72, 6, 117, 54, 1737, 95, 1370, 1813, 2016, 6, 117, 5, 4048, 930, 291, 2735, 1, 11652, 9445, 11, 28, 8, 5007, 804, 43, 1, 10346, 15, 14, 33, 48, 58, 14, 13, 18, 27, 72, 6, 117, 54, 1737, 95, 1370, 518, 6780, 119, 54901, 14818, 1761, 6780, 119, 8, 532, 1, 2290, 89, 28, 157, 2290, 2898, 1870, 1, 8746, 2, 2898, 1870, 1, 3812, 9951, 11, 44, 41, 5, 10346, 21, 2060, 17, 158, 291, 11652, 1761, 6780, 119, 3223, 804, 3, 43, 705, 212, 1, 10346, 4, 26, 1169, 2, 154, 5754, 266, 1, 117, 5, 1302, 933, 2, 2144, 1668, 4290, 8916, 84, 195, 3551, 1, 26, 858, 16, 575]",1957.0,15986443,244
Intensity-modulated radiation therapy after hysterectomy: comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2005-07-01,"To determine the influence of target-volume expansion on the reduction in small-bowel dose achieved with use of intensity-modulated radiation therapy (IMRT) vs. standard conformal treatment of the pelvis after hysterectomy, and to investigate the influence of patient body habitus on the normal-tissue sparing achieved with use of IMRT. A clinical target volume (CTV) was contoured on each of 10 planning computed tomography scans of patients who had been treated for cervical or endometrial cancer after a hysterectomy. Treatment planning was based on vaginal CTVs and regional nodal CTVs. To account for internal motion, margins were added to form an initial planning target volume (PTVA) as follows: 0.0 mm were added to the regional nodal CTV; 10 mm were added anteriorly to the vaginal CTV; and 5 mm were added to the vaginal CTV in all other directions. Two further PTVs (PTVB and PTVC) were produced by a 5-mm expansion of PTVA to give PTVB and a further 5-mm expansion to give PTVC. Treatment plans for all 3 PTVs were produced by use of 2 conformal fields (2FC), 4 conformal fields (4FC), or IMRT to deliver 45 Gy to more than 97% of the PTV. The primary goal of IMRT was to spare small bowel. The change in sparing that accompanied the increase in margin size was assessed by comparison of dose-volume histograms that resulted from PTVA, PTVB, and PTVC. Measured patient dimensions were correlated with bowel sparing. Significantly less small bowel was irradiated by IMRT than by 2FC (p < 0.0001) or 4FC (p < 0.0001) for doses greater than 25 Gy. Significantly less rectum was irradiated by IMRT than by 2FC (p < 0.0001) or 4FC (p < 0.0001). Significantly less bladder was irradiated by IMRT than by 2FC (p < 0.0001). However, the magnitude of the sparing achieved by use of IMRT decreased as margins increased. In particular, the volume of small bowel spared by IMRT vs. 2FC or 4FC decreased as margin size increased (p = 0.0002 and p = 0.008 for 2FC and 4FC, respectively). The amount of normal-tissue sparing achieved by use of IMRT vs. 4FC was inversely correlated with patient body mass index. Because the small-bowel sparing achieved with use of IMRT is markedly reduced by relatively small expansions of the target volume, accurate target delineation, highly reproducible patient immobilization, and a clear understanding of internal-organ motion are needed to achieve optimal advantage in the use of IMRT over conventional methods of posthysterectomy pelvic radiation therapy.",Comparative Study,5317.0,106.0,To determine the influence of target-volume expansion on the reduction in small-bowel dose achieved with use of intensity-modulated radiation therapy IMRT vs. standard conformal treatment of the pelvis after hysterectomy and to investigate the influence of patient body habitus on the normal-tissue sparing achieved with use of IMRT A clinical target volume CTV was contoured on each of 10 planning computed tomography scans of patients who had been treated for or cancer after a hysterectomy Treatment planning was based on CTVs and regional nodal CTVs To account for internal motion margins were added to form an initial planning target volume PTVA as follows 0.0 mm were added to the regional nodal CTV 10 mm were added anteriorly to the CTV and 5 mm were added to the CTV in all other directions Two further PTVs PTVB and PTVC were produced by a 5-mm expansion of PTVA to give PTVB and a further 5-mm expansion to give PTVC Treatment plans for all 3 PTVs were produced by use of 2 conformal fields 2FC 4 conformal fields 4FC or IMRT to deliver 45 Gy to more than 97 of the PTV The primary goal of IMRT was to spare small bowel The change in sparing that accompanied the increase in margin size was assessed by comparison of dose-volume histograms that resulted from PTVA PTVB and PTVC Measured patient dimensions were correlated with bowel sparing Significantly less small bowel was irradiated by IMRT than by 2FC p 0.0001 or 4FC p 0.0001 for doses greater than 25 Gy Significantly less rectum was irradiated by IMRT than by 2FC p 0.0001 or 4FC p 0.0001 Significantly less was irradiated by IMRT than by 2FC p 0.0001 However the magnitude of the sparing achieved by use of IMRT decreased as margins increased In particular the volume of small bowel spared by IMRT vs. 2FC or 4FC decreased as margin size increased p 0.0002 and p 0.008 for 2FC and 4FC respectively The amount of normal-tissue sparing achieved by use of IMRT vs. 4FC was inversely correlated with patient body mass index Because the small-bowel sparing achieved with use of IMRT is markedly reduced by relatively small expansions of the target volume accurate target delineation highly reproducible patient immobilization and a clear understanding of internal-organ motion are needed to achieve optimal advantage in the use of IMRT over conventional methods of posthysterectomy pelvic radiation therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,"[6, 223, 3, 1054, 1, 283, 433, 1422, 23, 3, 628, 4, 302, 1659, 61, 513, 5, 119, 1, 837, 1757, 121, 36, 964, 105, 260, 2972, 24, 1, 3, 3270, 50, 2622, 2, 6, 963, 3, 1054, 1, 69, 642, 23459, 23, 3, 295, 246, 1851, 513, 5, 119, 1, 964, 8, 38, 283, 433, 3402, 10, 6476, 23, 296, 1, 79, 1349, 1220, 872, 1441, 1, 7, 54, 42, 85, 73, 9, 15, 12, 50, 8, 2622, 24, 1349, 10, 90, 23, 14256, 2, 951, 779, 14256, 6, 1967, 9, 2329, 2967, 1012, 11, 1953, 6, 1297, 35, 388, 1349, 283, 433, 37953, 22, 2962, 13, 13, 321, 11, 1953, 6, 3, 951, 779, 3402, 79, 321, 11, 1953, 22232, 6, 3, 3402, 2, 33, 321, 11, 1953, 6, 3, 3402, 4, 62, 127, 3540, 100, 195, 13631, 37954, 2, 37955, 11, 1687, 20, 8, 33, 321, 1422, 1, 37953, 6, 4978, 37954, 2, 8, 195, 33, 321, 1422, 6, 4978, 37955, 24, 1853, 9, 62, 27, 13631, 11, 1687, 20, 119, 1, 18, 2972, 3130, 26413, 39, 2972, 3130, 28426, 15, 964, 6, 3392, 512, 381, 6, 80, 76, 1015, 1, 3, 3303, 3, 86, 1326, 1, 964, 10, 6, 8539, 302, 1659, 3, 707, 4, 1851, 17, 2756, 3, 344, 4, 959, 444, 10, 275, 20, 1155, 1, 61, 433, 8638, 17, 627, 29, 37953, 37954, 2, 37955, 644, 69, 6190, 11, 438, 5, 1659, 1851, 97, 299, 302, 1659, 10, 2398, 20, 964, 76, 20, 26413, 19, 13, 488, 15, 28426, 19, 13, 488, 9, 415, 378, 76, 243, 381, 97, 299, 3660, 10, 2398, 20, 964, 76, 20, 26413, 19, 13, 488, 15, 28426, 19, 13, 488, 97, 299, 10, 2398, 20, 964, 76, 20, 26413, 19, 13, 488, 137, 3, 3131, 1, 3, 1851, 513, 20, 119, 1, 964, 340, 22, 1012, 101, 4, 1454, 3, 433, 1, 302, 1659, 6830, 20, 964, 105, 26413, 15, 28426, 340, 22, 959, 444, 101, 19, 13, 3531, 2, 19, 13, 2155, 9, 26413, 2, 28426, 106, 3, 3108, 1, 295, 246, 1851, 513, 20, 119, 1, 964, 105, 28426, 10, 2659, 438, 5, 69, 642, 782, 558, 408, 3, 302, 1659, 1851, 513, 5, 119, 1, 964, 16, 2195, 405, 20, 1352, 302, 12384, 1, 3, 283, 433, 1481, 283, 5529, 561, 4172, 69, 10161, 2, 8, 885, 612, 1, 2329, 1259, 2967, 32, 575, 6, 1359, 665, 1874, 4, 3, 119, 1, 964, 252, 809, 636, 1, 33916, 1110, 121, 36]",2371.0,15990017,723
Vaccines against human papillomavirus and cervical cancer: promises and challenges.,The oncologist,Oncologist,2005-08-01,"Cervical cancer and precancerous lesions of the genital tract are major threats to the health of women worldwide. The introduction of screening tests to detect cervical cancer precursor lesions has reduced cervical cancer rates in the developed world, but not in developing countries. Human papillomavirus (HPV) is the primary etiologic agent of cervical cancer and dysplasia. Thus, cervical cancer and other HPV-associated malignancies might be prevented or treated by HPV vaccines. Two vaccine strategies have been developed. First, prevention of HPV infection through induction of capsid-specific neutralizing antibodies has been studied in clinical trials. However, because the capsid proteins are not expressed at detectable levels by infected basal keratinocytes or in HPV-transformed cells, a second approach of developing therapeutic vaccines by targeting nonstructural early viral antigens has also been developed. Because two HPV oncogenic proteins, E6 and E7, are critical to the induction and maintenance of cellular transformation and are coexpressed in the majority of HPV-containing carcinomas, most therapeutic vaccines target one or both of these gene products. A variety of approaches is being tested in therapeutic vaccine clinical trials, whereby E6 and/or E7 are administered in live vectors, as peptides or protein, in nucleic acid form, or in cell-based vaccines. The paradigm of preventing HPV infection through vaccination has been tested, and two vaccines are currently in phase III clinical trials. However, current therapeutic vaccine trials are less mature with respect to disease clearance. A number of approaches have shown significant therapeutic benefit in preclinical papillomavirus models and await testing in patient populations to determine the most effective curative strategy.",Journal Article,5286.0,95.0,cancer and precancerous lesions of the genital tract are major threats to the health of women worldwide The introduction of screening tests to detect cancer precursor lesions has reduced cancer rates in the developed world but not in developing countries Human papillomavirus HPV is the primary etiologic agent of cancer and dysplasia Thus cancer and other HPV-associated malignancies might be prevented or treated by HPV vaccines Two vaccine strategies have been developed First prevention of HPV infection through induction of capsid-specific neutralizing antibodies has been studied in clinical trials However because the capsid proteins are not expressed at detectable levels by infected basal keratinocytes or in HPV-transformed cells a second approach of developing therapeutic vaccines by targeting nonstructural early viral antigens has also been developed Because two HPV oncogenic proteins E6 and E7 are critical to the induction and maintenance of cellular transformation and are coexpressed in the majority of HPV-containing carcinomas most therapeutic vaccines target one or both of these gene products A variety of approaches is being tested in therapeutic vaccine clinical trials whereby E6 and/or E7 are administered in live vectors as peptides or protein in nucleic acid form or in cell-based vaccines The paradigm of preventing HPV infection through vaccination has been tested and two vaccines are currently in phase III clinical trials However current therapeutic vaccine trials are less mature with respect to disease clearance A number of approaches have shown significant therapeutic benefit in preclinical papillomavirus models and await testing in patient populations to determine the most effective curative strategy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 2, 6605, 406, 1, 3, 8226, 1696, 32, 458, 22312, 6, 3, 341, 1, 117, 2358, 3, 2456, 1, 453, 895, 6, 1426, 12, 2765, 406, 71, 405, 12, 151, 4, 3, 276, 1956, 84, 44, 4, 931, 2115, 171, 3242, 933, 16, 3, 86, 6604, 420, 1, 12, 2, 2253, 631, 12, 2, 127, 933, 41, 441, 822, 40, 3902, 15, 73, 20, 933, 1842, 100, 1274, 422, 47, 85, 276, 157, 1070, 1, 933, 930, 298, 504, 1, 17237, 112, 5788, 890, 71, 85, 656, 4, 38, 143, 137, 408, 3, 17237, 652, 32, 44, 570, 28, 2083, 148, 20, 3369, 2135, 9587, 15, 4, 933, 2423, 37, 8, 419, 353, 1, 931, 189, 1842, 20, 529, 44072, 191, 1667, 1575, 71, 120, 85, 276, 408, 100, 933, 1302, 652, 4837, 2, 4540, 32, 740, 6, 3, 504, 2, 1146, 1, 763, 1392, 2, 32, 10185, 4, 3, 686, 1, 933, 1101, 826, 96, 189, 1842, 283, 104, 15, 110, 1, 46, 145, 2766, 8, 1362, 1, 611, 16, 486, 650, 4, 189, 1274, 38, 143, 6131, 4837, 2, 15, 4540, 32, 468, 4, 3812, 5453, 22, 2491, 15, 178, 4, 7895, 971, 1297, 15, 4, 31, 90, 1842, 3, 2431, 1, 3017, 933, 930, 298, 1915, 71, 85, 650, 2, 100, 1842, 32, 694, 4, 124, 316, 38, 143, 137, 291, 189, 1274, 143, 32, 299, 2908, 5, 2184, 6, 34, 1960, 8, 207, 1, 611, 47, 443, 93, 189, 247, 4, 693, 3242, 274, 2, 12095, 471, 4, 69, 1184, 6, 223, 3, 96, 323, 1075, 692]",1742.0,16079320,46
Gene expression profiling of in vitro radiation resistance in cervical carcinoma: a feasibility study.,Gynecologic oncology,Gynecol. Oncol.,2005-10-01,"To determine the feasibility of integrating an in vitro chemo-radiation response assay (IVRRA) with a gene microarray system to investigate the molecular patterns of expression that contribute to radiation resistance in cervical cancer. Viable primary untreated cervical cancer specimens were obtained and exposed to gamma irradiation at a dose of 3 Gy in the IVRRA to determine in vitro radiation sensitivity. RNA was purified for microarray analysis with the Affymetrix Human Genome U95A Array carrying more than 12,000 gene probes. Gene expression analysis was performed, and specimen transcript patterns were correlated with radiation response using an iteration analysis model and Pearson's correlation coefficient. A feasibility set of eight tumor specimens was studied. Tumors were classified into 4 extreme (ERR), 2 intermediate (IRR) and 2 low radiation resistance (LRR) categories. An intrinsic radiation response gene set of 54 genes transcripts with 100% accuracy for the classification of each tumor's radiation response category was identified. Gene sets associated with in vitro radiation response profiles in cervical cancer can be generated using the IVRRA and microarray technology. This has direct applications to the study of the biological pathways contributing to radiation resistance and may lead to the development of alternative treatment modalities. The potential of these technologies for cancers in which radiotherapy is employed warrants further investigation.",Journal Article,5225.0,17.0,"To determine the feasibility of integrating an in vitro chemo-radiation response assay IVRRA with a gene microarray system to investigate the molecular patterns of expression that contribute to radiation resistance in cancer Viable primary untreated cancer specimens were obtained and exposed to gamma irradiation at a dose of 3 Gy in the IVRRA to determine in vitro radiation sensitivity RNA was purified for microarray analysis with the Affymetrix Human Genome U95A Array carrying more than 12,000 gene probes Gene expression analysis was performed and specimen transcript patterns were correlated with radiation response using an iteration analysis model and Pearson 's correlation coefficient A feasibility set of eight tumor specimens was studied Tumors were classified into 4 extreme ERR 2 intermediate IRR and 2 low radiation resistance LRR categories An intrinsic radiation response gene set of 54 genes transcripts with 100 accuracy for the classification of each tumor 's radiation response category was identified Gene sets associated with in vitro radiation response profiles in cancer can be generated using the IVRRA and microarray technology This has direct applications to the study of the biological pathways contributing to radiation resistance and may lead to the development of alternative treatment modalities The potential of these technologies for cancers in which radiotherapy is employed warrants further investigation",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 1437, 1, 4568, 35, 4, 439, 3341, 121, 51, 719, 20461, 5, 8, 145, 1727, 398, 6, 963, 3, 219, 764, 1, 55, 17, 1248, 6, 121, 251, 4, 12, 2663, 86, 1278, 12, 623, 11, 683, 2, 2234, 6, 1705, 1104, 28, 8, 61, 1, 27, 381, 4, 3, 20461, 6, 223, 4, 439, 121, 485, 893, 10, 5963, 9, 1727, 65, 5, 3, 5318, 171, 898, 37445, 1926, 2934, 80, 76, 133, 984, 145, 3701, 145, 55, 65, 10, 173, 2, 2360, 3268, 764, 11, 438, 5, 121, 51, 75, 35, 21346, 65, 202, 2, 4720, 292, 816, 3200, 8, 1437, 916, 1, 659, 30, 623, 10, 656, 57, 11, 1373, 237, 39, 5611, 16839, 18, 919, 7824, 2, 18, 154, 121, 251, 2236, 1996, 35, 2354, 121, 51, 145, 916, 1, 667, 214, 2680, 5, 394, 1190, 9, 3, 947, 1, 296, 30, 292, 121, 51, 2169, 10, 108, 145, 2270, 41, 5, 4, 439, 121, 51, 1241, 4, 12, 122, 40, 1419, 75, 3, 20461, 2, 1727, 2033, 26, 71, 1196, 2911, 6, 3, 45, 1, 3, 1037, 460, 3156, 6, 121, 251, 2, 68, 1122, 6, 3, 193, 1, 1091, 24, 1558, 3, 174, 1, 46, 2590, 9, 163, 4, 92, 310, 16, 2516, 2782, 195, 940]",1443.0,16109440,684
"Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix.",Gynecologic oncology,Gynecol. Oncol.,2005-09-12,"To investigate prognostic significance of and correlations between HER1 (EGFR), HER2 (c-erb-B2), HER3 (c-erb-B3), HER4 (c-erb-B4), and phosphorylated Akt (P-Akt) in patients treated with radiation for cervical carcinoma. Fifty-five patients with stages I-IVA cervical carcinoma were treated with definitive radiotherapy. Tumor expression of each biomarker was quantitatively scored by an automated immunohistochemical imaging system. Parametric correlations were performed between biomarkers. Univariate and multivariate analysis was performed with disease-free survival (DFS) and overall survival (OS) as primary endpoints. Correlations were observed between expression of HER2 and HER4 (P = 0.003), and HER3 and HER4 (P = 0.004). Decreased HER2, HER4, and P-Akt expressions were significant for diminished DFS on univariate analysis (P = 0.04, P = 0.008, and P = 0.02, respectively). Increased EGFR, and diminished HER2, HER4, and P-Akt expression were significant or showed trends toward significance for diminished OS on univariate analysis (P = 0.07, P = 0.008, P = 0.09, and P = 0.08, respectively). After controlling for pretreatment factors, multivariate analysis revealed HER2 associated with improved OS (P = 0.05). These data emphasize that significant correlations exist between the differential expression of various HER family receptors. Multivariate analysis revealed only increased HER2 expression associated with improved OS after controlling for pretreatment clinical factors. These data emphasize the importance of continued basic and translational research on the HER family of receptors in cervical carcinoma.",Journal Article,5244.0,74.0,To investigate prognostic significance of and correlations between HER1 EGFR HER2 c-erb-B2 HER3 c-erb-B3 HER4 c-erb-B4 and phosphorylated Akt P-Akt in patients treated with radiation for carcinoma Fifty-five patients with stages I-IVA carcinoma were treated with definitive radiotherapy Tumor expression of each biomarker was quantitatively scored by an automated immunohistochemical imaging system Parametric correlations were performed between biomarkers Univariate and multivariate analysis was performed with disease-free survival DFS and overall survival OS as primary endpoints Correlations were observed between expression of HER2 and HER4 P 0.003 and HER3 and HER4 P 0.004 Decreased HER2 HER4 and P-Akt expressions were significant for diminished DFS on univariate analysis P 0.04 P 0.008 and P 0.02 respectively Increased EGFR and diminished HER2 HER4 and P-Akt expression were significant or showed trends toward significance for diminished OS on univariate analysis P 0.07 P 0.008 P 0.09 and P 0.08 respectively After controlling for pretreatment factors multivariate analysis revealed HER2 associated with improved OS P 0.05 These data emphasize that significant correlations exist between the differential expression of various HER family receptors Multivariate analysis revealed only increased HER2 expression associated with improved OS after controlling for pretreatment clinical factors These data emphasize the importance of continued basic and translational research on the HER family of receptors in carcinoma,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 963, 177, 724, 1, 2, 2553, 59, 9793, 227, 354, 256, 8460, 6617, 4885, 256, 8460, 12631, 13376, 256, 8460, 14476, 2, 2365, 649, 19, 649, 4, 7, 73, 5, 121, 9, 134, 1461, 365, 7, 5, 1153, 70, 5900, 134, 11, 73, 5, 1057, 310, 30, 55, 1, 296, 901, 10, 5889, 3179, 20, 35, 3235, 1382, 270, 398, 7590, 2553, 11, 173, 59, 582, 880, 2, 331, 65, 10, 173, 5, 34, 115, 25, 1010, 2, 63, 25, 118, 22, 86, 1387, 2553, 11, 164, 59, 55, 1, 354, 2, 13376, 19, 13, 1421, 2, 4885, 2, 13376, 19, 13, 1520, 340, 354, 13376, 2, 19, 649, 4249, 11, 93, 9, 2849, 1010, 23, 880, 65, 19, 13, 755, 19, 13, 2155, 2, 19, 13, 588, 106, 101, 227, 2, 2849, 354, 13376, 2, 19, 649, 55, 11, 93, 15, 224, 1963, 1317, 724, 9, 2849, 118, 23, 880, 65, 19, 13, 1615, 19, 13, 2155, 19, 13, 1730, 2, 19, 13, 1592, 106, 50, 1893, 9, 1194, 130, 331, 65, 553, 354, 41, 5, 231, 118, 19, 13, 474, 46, 74, 5560, 17, 93, 2553, 1923, 59, 3, 1777, 55, 1, 747, 1084, 607, 1186, 331, 65, 553, 158, 101, 354, 55, 41, 5, 231, 118, 50, 1893, 9, 1194, 38, 130, 46, 74, 5560, 3, 1187, 1, 1351, 2795, 2, 2460, 389, 23, 3, 1084, 607, 1, 1186, 4, 134]",1529.0,16157365,633
A three-dimensional computed tomography-assisted Monte Carlo evaluation of ovoid shielding on the dose to the bladder and rectum in intracavitary radiotherapy for cervical cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2005-10-01,"To determine the effects of Fletcher Suit Delclos ovoid shielding on dose to the bladder and rectum during intracavitary radiotherapy for cervical cancer. The Monte Carlo method was used to calculate the dose in 12 patients receiving low-dose-rate intracavitary radiotherapy with both shielded and unshielded ovoids. Cumulative dose-difference surface histograms were computed for the bladder and rectum. Doses to the 2-cm(3) and 5-cm(3) volumes of highest dose were computed for the bladder and rectum with and without shielding. Shielding affected dose to the 2-cm(3) and 5-cm(3) volumes of highest dose for the rectum (10.1% and 11.1% differences, respectively). Shielding did not have a major impact on the dose to the 2-cm(3) and 5-cm(3) volumes of highest dose for the bladder. The average dose reduction to 5% of the surface area of the bladder was 53 cGy. Reductions as large as 150 cGy were observed to 5% of the surface area of the bladder. The average dose reduction to 5% of the surface area of the rectum was 195 cGy. Reductions as large as 405 cGy were observed to 5% of the surface area of the rectum. Our data suggest that the ovoid shields can greatly reduce the radiation dose delivered to the rectum. We did not find the same degree of effect on the dose to the bladder. To calculate the dose accurately, however, the ovoid shields must be included in the dose model.",Evaluation Study,5225.0,13.0,To determine the effects of Fletcher Suit Delclos ovoid shielding on dose to the and rectum during intracavitary radiotherapy for cancer The Monte Carlo method was used to calculate the dose in 12 patients receiving low-dose-rate intracavitary radiotherapy with both shielded and unshielded ovoids Cumulative dose-difference surface histograms were computed for the and rectum Doses to the 2-cm 3 and 5-cm 3 volumes of highest dose were computed for the and rectum with and without shielding Shielding affected dose to the 2-cm 3 and 5-cm 3 volumes of highest dose for the rectum 10.1 and 11.1 differences respectively Shielding did not have a major impact on the dose to the 2-cm 3 and 5-cm 3 volumes of highest dose for the The average dose reduction to 5 of the surface area of the was 53 cGy Reductions as large as 150 cGy were observed to 5 of the surface area of the The average dose reduction to 5 of the surface area of the rectum was 195 cGy Reductions as large as 405 cGy were observed to 5 of the surface area of the rectum Our data suggest that the ovoid shields can greatly reduce the radiation dose delivered to the rectum We did not find the same degree of effect on the dose to the To calculate the dose accurately however the ovoid shields must be included in the dose model,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 176, 1, 28459, 24855, 55082, 15300, 16362, 23, 61, 6, 3, 2, 3660, 190, 9122, 310, 9, 12, 3, 7990, 7991, 596, 10, 95, 6, 3232, 3, 61, 4, 133, 7, 357, 154, 61, 116, 9122, 310, 5, 110, 17327, 2, 38032, 30845, 967, 61, 523, 1255, 8638, 11, 1220, 9, 3, 2, 3660, 415, 6, 3, 18, 494, 27, 2, 33, 494, 27, 2225, 1, 1076, 61, 11, 1220, 9, 3, 2, 3660, 5, 2, 187, 16362, 16362, 1424, 61, 6, 3, 18, 494, 27, 2, 33, 494, 27, 2225, 1, 1076, 61, 9, 3, 3660, 79, 14, 2, 175, 14, 362, 106, 16362, 205, 44, 47, 8, 458, 345, 23, 3, 61, 6, 3, 18, 494, 27, 2, 33, 494, 27, 2225, 1, 1076, 61, 9, 3, 3, 1011, 61, 628, 6, 33, 1, 3, 1255, 965, 1, 3, 10, 699, 3071, 2153, 22, 375, 22, 1577, 3071, 11, 164, 6, 33, 1, 3, 1255, 965, 1, 3, 3, 1011, 61, 628, 6, 33, 1, 3, 1255, 965, 1, 3, 3660, 10, 5786, 3071, 2153, 22, 375, 22, 9661, 3071, 11, 164, 6, 33, 1, 3, 1255, 965, 1, 3, 3660, 114, 74, 309, 17, 3, 15300, 20466, 122, 3510, 969, 3, 121, 61, 1623, 6, 3, 3660, 21, 205, 44, 2469, 3, 827, 1444, 1, 254, 23, 3, 61, 6, 3, 6, 3232, 3, 61, 2141, 137, 3, 15300, 20466, 1642, 40, 159, 4, 3, 61, 202]",1291.0,16168853,344
The nude rat as an orthotopic model for cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2005-09-26,"The purposes of this study were to establish intracervical tumors of the nude rat as an orthotopic experimental model for human cervical cancer and to preliminary evaluate the effects of the adenoviral vector, Ad5CMV-p53, on orthotopic cervical tumor size. Human cervical cancer SiHa and ME-180 cells were injected into the cervix of the nude rat. Four days later, 1 x 10(9) plaque forming units (PFU) of Ad5CMV-p53 were injected into the cervix. The rats were later sacrificed to determine cervical tumor size. Eight of ten nude rats developed SiHa cell tumors; all ten nude rats developed ME-180 cell tumors. Four of ten SiHa cell tumors metastasized to the pelvic cavity; no ME-180 cell tumors did. The growth of Ad5CMV-p53-infected cells was greatly suppressed. The ad5CMV-p53 treatment significantly reduced both cell tumor volumes in nude rat cervixes. The nude rat cervix grows tumors similar to human cervical cancer tumors and makes an excellent experimental model. Transfection of cervical cancer cells with the wild-type p53 gene via Ad5CMV-p53 is a potential therapeutic approach to cervical cancer.",Journal Article,5230.0,3.0,The purposes of this study were to establish intracervical tumors of the nude rat as an orthotopic experimental model for human cancer and to preliminary evaluate the effects of the adenoviral vector Ad5CMV-p53 on orthotopic tumor size Human cancer SiHa and ME-180 cells were injected into the cervix of the nude rat Four days later 1 x 10 9 plaque forming units PFU of Ad5CMV-p53 were injected into the cervix The rats were later sacrificed to determine tumor size Eight of ten nude rats developed SiHa cell tumors all ten nude rats developed ME-180 cell tumors Four of ten SiHa cell tumors metastasized to the pelvic cavity no ME-180 cell tumors did The growth of Ad5CMV-p53-infected cells was greatly suppressed The ad5CMV-p53 treatment significantly reduced both cell tumor volumes in nude rat cervixes The nude rat cervix grows tumors similar to human cancer tumors and makes an excellent experimental model Transfection of cancer cells with the wild-type p53 gene via Ad5CMV-p53 is a potential therapeutic approach to cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 4624, 1, 26, 45, 11, 6, 1811, 33970, 57, 1, 3, 2598, 4008, 22, 35, 2157, 1560, 202, 9, 171, 12, 2, 6, 1676, 376, 3, 176, 1, 3, 4771, 3374, 15873, 624, 23, 2157, 30, 444, 171, 12, 19043, 2, 4816, 3172, 37, 11, 2651, 237, 3, 3629, 1, 3, 2598, 4008, 294, 162, 1559, 14, 1006, 79, 83, 8506, 4525, 2960, 18154, 1, 15873, 624, 11, 2651, 237, 3, 3629, 3, 3765, 11, 1559, 15470, 6, 223, 30, 444, 659, 1, 1618, 2598, 3765, 276, 19043, 31, 57, 62, 1618, 2598, 3765, 276, 4816, 3172, 31, 57, 294, 1, 1618, 19043, 31, 57, 8486, 6, 3, 1110, 2405, 77, 4816, 3172, 31, 57, 205, 3, 129, 1, 15873, 624, 3369, 37, 10, 3510, 1908, 3, 15873, 624, 24, 97, 405, 110, 31, 30, 2225, 4, 2598, 4008, 55088, 3, 2598, 4008, 3629, 14884, 57, 288, 6, 171, 12, 57, 2, 4677, 35, 1503, 1560, 202, 3789, 1, 12, 37, 5, 3, 955, 267, 624, 145, 847, 15873, 624, 16, 8, 174, 189, 353, 6, 12]",1030.0,16185752,71
"Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.",Gynecologic oncology,Gynecol. Oncol.,2005-10-10,"The Gynecologic Oncology Group (GOG) compared methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) with topotecan and cisplatin (TC) or cisplatin alone (C) in advanced cervical cancer. The primary endpoint was overall survival (OS), with response rate, progression-free survival (PFS), and quality of life (QOL) as secondary objectives. Eligible patients were randomly allocated to receive either cisplatin 50 mg/m2 q 3 weeks (C) or cisplatin 50 mg/m2 day 1 and topotecan 0.75 mg/m2 days 1-3 q 3 weeks (TC) or methotrexate 30 mg/m2 days 1, 15, and 22, vinblastine 3 mg/m2 days 2, 15, and 22, doxorubicin 30 mg/m2 day 2, and cisplatin 70 mg/m2 day 2 q 4 weeks (MVAC). QOL was assessed at four time points using the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx), Neurotoxicity Subscale (FACT/GOG-NTX subscale), and Brief Pain Inventory (BPI). One hundred eighty-six patients (C = 60; TC = 63; MVAC = 63) were enrolled before MVAC was closed by the GOG Data Safety Monitoring Board after four treatment-related deaths occurred on that arm. MVAC produced a 22% overall response rate (95% CI: 0.13 to 0.34) and median PFS and OS of 4.4 months and 9.4 months, respectively. Compared with C and TC, there was more hematologic toxicity with MVAC. There were no appreciable differences in QOL scores after controlling for baseline scores. MVAC's clinical activity tended to be similar to that of TC but with an unacceptable risk of death from sepsis at this dose and schedule. Nevertheless, QOL, as measured by these instruments, was not substantially impaired by this regimen.",Journal Article,5216.0,26.0,The Gynecologic Oncology Group GOG compared methotrexate vinblastine doxorubicin and cisplatin MVAC with topotecan and cisplatin TC or cisplatin alone C in advanced cancer The primary endpoint was overall survival OS with response rate progression-free survival PFS and quality of life QOL as secondary objectives Eligible patients were randomly allocated to receive either cisplatin 50 mg/m2 q 3 weeks C or cisplatin 50 mg/m2 day 1 and topotecan 0.75 mg/m2 days 1-3 q 3 weeks TC or methotrexate 30 mg/m2 days 1 15 and 22 vinblastine 3 mg/m2 days 2 15 and 22 doxorubicin 30 mg/m2 day 2 and cisplatin 70 mg/m2 day 2 q 4 weeks MVAC QOL was assessed at four time points using the Functional Assessment of Cancer Therapy-Cervix FACT-Cx Neurotoxicity Subscale FACT/GOG-NTX subscale and Brief Pain Inventory BPI One hundred eighty-six patients C 60 TC 63 MVAC 63 were enrolled before MVAC was closed by the GOG Data Safety Monitoring Board after four treatment-related deaths occurred on that arm MVAC produced a 22 overall response rate 95 CI 0.13 to 0.34 and median PFS and OS of 4.4 months and 9.4 months respectively Compared with C and TC there was more hematologic toxicity with MVAC There were no appreciable differences in QOL scores after controlling for baseline scores MVAC 's clinical activity tended to be similar to that of TC but with an unacceptable risk of death from sepsis at this dose and schedule Nevertheless QOL as measured by these instruments was not substantially impaired by this regimen,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1512, 413, 87, 4760, 72, 2116, 5413, 856, 2, 540, 8238, 5, 2129, 2, 540, 3072, 15, 540, 279, 256, 4, 131, 12, 3, 86, 1138, 10, 63, 25, 118, 5, 51, 116, 91, 115, 25, 300, 2, 372, 1, 358, 1001, 22, 568, 2409, 625, 7, 11, 1108, 6682, 6, 560, 361, 540, 212, 81, 821, 4170, 27, 244, 256, 15, 540, 212, 81, 821, 218, 14, 2, 2129, 13, 481, 81, 821, 162, 14, 27, 4170, 27, 244, 3072, 15, 2116, 201, 81, 821, 162, 14, 167, 2, 350, 5413, 27, 81, 821, 162, 18, 167, 2, 350, 856, 201, 81, 821, 218, 18, 2, 540, 431, 81, 821, 218, 18, 4170, 39, 244, 8238, 1001, 10, 275, 28, 294, 98, 862, 75, 3, 583, 455, 1, 12, 36, 3629, 1991, 13627, 3561, 5593, 1991, 4760, 8110, 5593, 2, 3190, 559, 3818, 9699, 104, 1128, 2207, 437, 7, 256, 335, 3072, 676, 8238, 676, 11, 346, 348, 8238, 10, 3745, 20, 3, 4760, 74, 367, 1315, 2620, 50, 294, 24, 139, 1043, 489, 23, 17, 475, 8238, 1687, 8, 350, 63, 51, 116, 48, 58, 13, 233, 6, 13, 562, 2, 52, 300, 2, 118, 1, 39, 39, 53, 2, 83, 39, 53, 106, 72, 5, 256, 2, 3072, 125, 10, 80, 813, 155, 5, 8238, 125, 11, 77, 9371, 362, 4, 1001, 703, 50, 1893, 9, 330, 703, 8238, 292, 38, 128, 3886, 6, 40, 288, 6, 17, 1, 3072, 84, 5, 35, 3215, 43, 1, 273, 29, 4227, 28, 26, 61, 2, 1055, 3873, 1001, 22, 644, 20, 46, 4730, 10, 44, 2109, 2364, 20, 26, 477]",1508.0,16216315,118
Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer.,Current oncology reports,Curr Oncol Rep,2005-11-01,"Because only 16% of patients with metastatic cervical cancer are alive 5 years after diagnosis, the Gynecologic Oncology Group (GOG) has carefully designed and conducted many phase II studies to identify promising drugs. Cisplatin has emerged as the most active single agent with overall response rates of 19%. Recent phase III trials have documented response rates of 27% and 39% when cisplatin has been combined with either paclitaxel or topotecan, respectively. The comparison of cisplatin to cisplatin plus topotecan in GOG-179 has yielded the first study to show a statistically significant impact on the overall response rate, median progression-free survival, and median survival, with all outcome measures favoring the two-drug regimen. Despite these encouraging results, however, most of the responses are partial and of short duration. The need for novel combinations and the implementation of active biologic agents is implicit. The accumulated data in this disease setting, as evidenced by the experience of the GOG, are presented in this review.",Journal Article,5194.0,,Because only 16 of patients with metastatic cancer are alive 5 years after diagnosis the Gynecologic Oncology Group GOG has carefully designed and conducted many phase II studies to identify promising drugs Cisplatin has emerged as the most active single agent with overall response rates of 19 Recent phase III trials have documented response rates of 27 and 39 when cisplatin has been combined with either paclitaxel or topotecan respectively The comparison of cisplatin to cisplatin plus topotecan in GOG-179 has yielded the first study to show a statistically significant impact on the overall response rate median progression-free survival and median survival with all outcome measures favoring the two-drug regimen Despite these encouraging results however most of the responses are partial and of short duration The need for novel combinations and the implementation of active biologic agents is implicit The accumulated data in this disease setting as evidenced by the experience of the GOG are presented in this review,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[408, 158, 245, 1, 7, 5, 113, 12, 32, 1701, 33, 60, 50, 147, 3, 1512, 413, 87, 4760, 71, 3900, 1114, 2, 426, 445, 124, 215, 94, 6, 255, 721, 600, 540, 71, 2054, 22, 3, 96, 544, 226, 420, 5, 63, 51, 151, 1, 326, 435, 124, 316, 143, 47, 1405, 51, 151, 1, 428, 2, 587, 198, 540, 71, 85, 397, 5, 361, 490, 15, 2129, 106, 3, 1155, 1, 540, 6, 540, 349, 2129, 4, 4760, 5977, 71, 2178, 3, 157, 45, 6, 514, 8, 712, 93, 345, 23, 3, 63, 51, 116, 52, 91, 115, 25, 2, 52, 25, 5, 62, 228, 1018, 6238, 3, 100, 234, 477, 550, 46, 2269, 99, 137, 96, 1, 3, 253, 32, 450, 2, 1, 978, 654, 3, 594, 9, 229, 1247, 2, 3, 2393, 1, 544, 1283, 183, 16, 16849, 3, 6664, 74, 4, 26, 34, 546, 22, 4728, 20, 3, 730, 1, 3, 4760, 32, 917, 4, 26, 206]",1027.0,16221379,499
Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2005-10-17,"Concurrent chemoradiotherapy is the standard of care for locally advanced cervix cancer; the optimal chemotherapy regimen is not yet defined. This trial was designed to compare the outcome of protracted venous infusion (PVI) fluorouracil (FU) with standard weekly cisplatin and concurrent radiation therapy (RT). Patients with stage IIB, IIIB, and IVA cervical cancer with clinically negative aortic nodes were eligible. Pelvic RT dose was 45 Gy with a parametrial boost to involved sides of 5.4 to 9 Gy, and high- or low-dose rate intracavitary brachytherapy. Standard therapy was weekly cisplatin 40 mg/m2, and experimental therapy was PVI FU 225 mg/m2/d for 5 d/wk for six cycles during RT. The study was closed prematurely when a planned interim futility analysis indicated that PVI FU/RT had a higher treatment failure rate (35% higher) and would, most likely, not result in an improvement in progression-free survival compared with weekly cisplatin/RT. The PVI FU/RT arm continues to show a higher risk of treatment failure (relative risk [RR] unadjusted, 1.29) and a higher mortality rate (RR unadjusted, 1.37). There was no difference in pelvic treatment failure between regimens, but there was an increase in the failure rate at distant sites in the PVI FU arm. In this study, PVI FU does not show improved outcome over weekly cisplatin. Future research should explore combinations of FU with cisplatin, new radiosensitizers, and active drugs combined with RT to reduce the high rate of pelvic and distant treatment failure still seen in advanced cervix cancer.","Clinical Trial, Phase III",5209.0,136.0,Concurrent chemoradiotherapy is the standard of care for locally advanced cervix cancer the optimal chemotherapy regimen is not yet defined This trial was designed to compare the outcome of protracted venous infusion PVI fluorouracil FU with standard weekly cisplatin and concurrent radiation therapy RT Patients with stage IIB IIIB and IVA cancer with clinically negative aortic nodes were eligible Pelvic RT dose was 45 Gy with a parametrial boost to involved sides of 5.4 to 9 Gy and high- or low-dose rate intracavitary brachytherapy Standard therapy was weekly cisplatin 40 mg/m2 and experimental therapy was PVI FU 225 mg/m2/d for 5 d/wk for six cycles during RT The study was closed prematurely when a planned interim futility analysis indicated that PVI FU/RT had a higher treatment failure rate 35 higher and would most likely not result in an improvement in progression-free survival compared with weekly cisplatin/RT The PVI FU/RT arm continues to show a higher risk of treatment failure relative risk RR unadjusted 1.29 and a higher mortality rate RR unadjusted 1.37 There was no difference in pelvic treatment failure between regimens but there was an increase in the failure rate at distant sites in the PVI FU arm In this study PVI FU does not show improved outcome over weekly cisplatin Future research should explore combinations of FU with cisplatin new radiosensitizers and active drugs combined with RT to reduce the high rate of pelvic and distant treatment failure still seen in advanced cervix cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[750, 1464, 16, 3, 260, 1, 165, 9, 795, 131, 3629, 12, 3, 665, 56, 477, 16, 44, 1145, 395, 26, 160, 10, 1114, 6, 932, 3, 228, 1, 7053, 2167, 904, 16419, 1404, 1296, 5, 260, 709, 540, 2, 750, 121, 36, 240, 7, 5, 82, 3884, 3036, 2, 5900, 12, 5, 505, 199, 3938, 502, 11, 625, 1110, 240, 61, 10, 512, 381, 5, 8, 8726, 2569, 6, 646, 10958, 1, 33, 39, 6, 83, 381, 2, 64, 15, 154, 61, 116, 9122, 1536, 260, 36, 10, 709, 540, 327, 81, 821, 2, 1560, 36, 10, 16419, 1296, 4011, 81, 821, 427, 9, 33, 427, 3293, 9, 437, 410, 190, 240, 3, 45, 10, 3745, 9771, 198, 8, 1465, 2914, 7566, 65, 1103, 17, 16419, 1296, 240, 42, 8, 142, 24, 496, 116, 465, 142, 2, 688, 96, 322, 44, 757, 4, 35, 767, 4, 91, 115, 25, 72, 5, 709, 540, 240, 3, 16419, 1296, 240, 475, 2274, 6, 514, 8, 142, 43, 1, 24, 496, 580, 43, 861, 4487, 14, 462, 2, 8, 142, 282, 116, 861, 4487, 14, 567, 125, 10, 77, 523, 4, 1110, 24, 496, 59, 472, 84, 125, 10, 35, 344, 4, 3, 496, 116, 28, 626, 633, 4, 3, 16419, 1296, 475, 4, 26, 45, 16419, 1296, 1097, 44, 514, 231, 228, 252, 709, 540, 508, 389, 257, 1645, 1247, 1, 1296, 5, 540, 217, 11763, 2, 544, 600, 397, 5, 240, 6, 969, 3, 64, 116, 1, 1110, 2, 626, 24, 496, 1234, 527, 4, 131, 3629, 12]",1523.0,16230678,132
Quality of life and sexual functioning in cervical cancer survivors.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2005-10-01,"To compare quality of life and sexual functioning in cervical cancer survivors treated with either radical hysterectomy and lymph node dissection or radiotherapy. Women were interviewed at least 5 years after initial treatment for cervical cancer. Eligible women had squamous cell tumors smaller than 6 cm at diagnosis, were currently disease-free, and had either undergone surgery or radiotherapy, but not both. The two treatment groups were then compared using univariate analysis and multivariate linear regression with a control group of age- and race-matched women with no history of cancer. One hundred fourteen patients (37 surgery, 37 radiotherapy, 40 controls) were included for analysis. When compared with surgery patients and controls using univariate analysis, radiation patients had significantly poorer scores on standardized questionnaires measuring health-related quality of life (physical and mental health), psychosocial distress and sexual functioning. The disparity in sexual function remained significant in a multivariate analysis. Univariate and multivariate analyses did not show significant differences between radical hysterectomy patients and controls on any of the outcome measures. Cervical cancer survivors treated with radiotherapy had worse sexual functioning than did those treated with radical hysterectomy and lymph node dissection. In contrast, these data suggest that cervical cancer survivors treated with surgery alone can expect overall quality of life and sexual function not unlike that of peers without a history of cancer.",Comparative Study,5225.0,281.0,To compare quality of life and sexual functioning in cancer survivors treated with either radical hysterectomy and lymph node dissection or radiotherapy Women were interviewed at least 5 years after initial treatment for cancer Eligible women had squamous cell tumors smaller than 6 cm at diagnosis were currently disease-free and had either undergone surgery or radiotherapy but not both The two treatment groups were then compared using univariate analysis and multivariate linear regression with a control group of age- and race-matched women with no history of cancer One hundred fourteen patients 37 surgery 37 radiotherapy 40 controls were included for analysis When compared with surgery patients and controls using univariate analysis radiation patients had significantly poorer scores on standardized questionnaires measuring health-related quality of life physical and mental health psychosocial distress and sexual functioning The disparity in sexual function remained significant in a multivariate analysis Univariate and multivariate analyses did not show significant differences between radical hysterectomy patients and controls on any of the outcome measures cancer survivors treated with radiotherapy had worse sexual functioning than did those treated with radical hysterectomy and lymph node dissection In contrast these data suggest that cancer survivors treated with surgery alone can expect overall quality of life and sexual function not unlike that of peers without a history of cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 932, 372, 1, 358, 2, 2232, 2702, 4, 12, 332, 73, 5, 361, 711, 2622, 2, 263, 289, 1161, 15, 310, 117, 11, 6713, 28, 506, 33, 60, 50, 388, 24, 9, 12, 625, 117, 42, 691, 31, 57, 2170, 76, 49, 494, 28, 147, 11, 694, 34, 115, 2, 42, 361, 1989, 152, 15, 310, 84, 44, 110, 3, 100, 24, 271, 11, 818, 72, 75, 880, 65, 2, 331, 1646, 320, 5, 8, 182, 87, 1, 89, 2, 1047, 655, 117, 5, 77, 532, 1, 12, 104, 1128, 3225, 7, 567, 152, 567, 310, 327, 535, 11, 159, 9, 65, 198, 72, 5, 152, 7, 2, 535, 75, 880, 65, 121, 7, 42, 97, 1769, 703, 23, 1670, 2956, 2978, 341, 139, 372, 1, 358, 900, 2, 3031, 341, 2322, 1462, 2, 2232, 2702, 3, 4326, 4, 2232, 343, 958, 93, 4, 8, 331, 65, 880, 2, 331, 318, 205, 44, 514, 93, 362, 59, 711, 2622, 7, 2, 535, 23, 500, 1, 3, 228, 1018, 12, 332, 73, 5, 310, 42, 639, 2232, 2702, 76, 205, 135, 73, 5, 711, 2622, 2, 263, 289, 1161, 4, 748, 46, 74, 309, 17, 12, 332, 73, 5, 152, 279, 122, 8439, 63, 372, 1, 358, 2, 2232, 343, 44, 4246, 17, 1, 11187, 187, 8, 532, 1, 12]",1509.0,16234510,558
Utilization of diagnostic studies in the pretreatment evaluation of invasive cervical cancer in the United States: results of intergroup protocol ACRIN 6651/GOG 183.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2005-10-01,"To review the current utilization of diagnostic tests prescribed by the International Federation of Gynecology and Obstetrics (FIGO) clinical staging guidelines in the pretreatment work-up of invasive cervical cancer, and to compare the data with those of previous patterns of care studies. This interdisciplinary American College of Radiology Imaging Network/Gynecologic Oncology Group prospective clinical trial was conducted between March 1, 2000, and November 11, 2002. Twenty-five participating institutions, all from the United States, enrolled a total of 208 patients. Only patients scheduled for surgery with biopsy-confirmed cervical cancer of clinical FIGO stage IB or higher were eligible. The patterns of care data analysis was based on 197 patients who met all inclusion criteria. The conventional FIGO-recommended tests used for pre-enrollment FIGO clinical stage classification were at the discretion of the treating physician; overall frequency of use was tabulated for each test. Use of cystoscopy (8.1%) and sigmoidoscopy or proctoscopy (8.6%) was significantly lower than in 1988 to 1989 (P < .0001 in each instance). Intravenous urography was used in only 1% of patients as compared with 42% in 1988 to 1989 and 91% in 1983. No patient included in the data analysis had barium enema or lymphangiography. Only 26.9% of patients had examination under anesthesia for FIGO clinical staging. There is a large discrepancy between the diagnostic tests recommended by FIGO and the actual tests used for cervical cancer staging, suggesting a need to reassess the relevance of the FIGO guidelines to current clinical practice in the United States.",Comparative Study,5225.0,56.0,To review the current utilization of diagnostic tests prescribed by the International Federation of Gynecology and Obstetrics FIGO clinical staging guidelines in the pretreatment work-up of invasive cancer and to compare the data with those of previous patterns of care studies This interdisciplinary American College of Radiology Imaging Network/Gynecologic Oncology Group prospective clinical trial was conducted between March 1 2000 and November 11 2002 Twenty-five participating institutions all from the United States enrolled a total of 208 patients Only patients scheduled for surgery with biopsy-confirmed cancer of clinical FIGO stage IB or higher were eligible The patterns of care data analysis was based on 197 patients who met all inclusion criteria The conventional FIGO-recommended tests used for pre-enrollment FIGO clinical stage classification were at the discretion of the treating physician overall frequency of use was tabulated for each test Use of cystoscopy 8.1 and sigmoidoscopy or proctoscopy 8.6 was significantly lower than in 1988 to 1989 P .0001 in each instance Intravenous urography was used in only 1 of patients as compared with 42 in 1988 to 1989 and 91 in 1983 No patient included in the data analysis had barium enema or lymphangiography Only 26.9 of patients had examination under anesthesia for FIGO clinical staging There is a large discrepancy between the diagnostic tests recommended by FIGO and the actual tests used for cancer staging suggesting a need to reassess the relevance of the FIGO guidelines to current clinical practice in the United States,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 206, 3, 291, 1961, 1, 752, 895, 2746, 20, 3, 944, 7303, 1, 6429, 2, 7407, 3837, 38, 632, 677, 4, 3, 1194, 1357, 126, 1, 416, 12, 2, 6, 932, 3, 74, 5, 135, 1, 698, 764, 1, 165, 94, 26, 5911, 597, 2979, 1, 4003, 270, 1801, 1512, 413, 87, 482, 38, 160, 10, 426, 59, 2363, 14, 1081, 2, 2868, 175, 1544, 737, 365, 3052, 1764, 62, 29, 3, 1088, 907, 346, 8, 181, 1, 5920, 7, 158, 7, 4394, 9, 152, 5, 411, 557, 12, 1, 38, 3837, 82, 3180, 15, 142, 11, 625, 3, 764, 1, 165, 74, 65, 10, 90, 23, 6114, 7, 54, 543, 62, 1680, 371, 3, 809, 3837, 793, 895, 95, 9, 671, 1798, 3837, 38, 82, 947, 11, 28, 3, 7772, 1, 3, 1367, 1473, 63, 675, 1, 119, 10, 9903, 9, 296, 412, 119, 1, 4362, 66, 14, 2, 11607, 15, 21943, 66, 49, 10, 97, 280, 76, 4, 3314, 6, 3965, 19, 488, 4, 296, 10642, 1262, 55127, 10, 95, 4, 158, 14, 1, 7, 22, 72, 5, 595, 4, 3314, 6, 3965, 2, 970, 4, 6656, 77, 69, 159, 4, 3, 74, 65, 42, 17284, 26355, 15, 37576, 158, 432, 83, 1, 7, 42, 1385, 669, 6433, 9, 3837, 38, 632, 125, 16, 8, 375, 7916, 59, 3, 752, 895, 793, 20, 3837, 2, 3, 3480, 895, 95, 9, 12, 632, 802, 8, 594, 6, 19046, 3, 2088, 1, 3, 3837, 677, 6, 291, 38, 758, 4, 3, 1088, 907]",1595.0,16234512,716
Follicular lymphoma with bilateral testicular and epididymal involvement: case report and review of the literature.,Leukemia & lymphoma,Leuk. Lymphoma,2005-11-01,"Testicular involvement with indolent lymphoma is extremely rare, particularly in the absence of transformation to an aggressive histology. We report a case of a 64-year-old man who presented with cervical lymphadenopathy. Staging CT scans revealed extensive lymphadenopathy as well as bilateral testicular and epididymal masses. Histologic examination of lymph node, bone marrow, and testicular/epididymal biopsies revealed involvement with grade I follicular lymphoma. The patient was started on chemotherapy with cyclophosphamide, vincristine, prednisone, and rituximab in addition to intrathecal methotrexate and testicular radiation. He is now 6 months into therapy and responding well. A review of the literature demonstrated this to be the first confirmed case of testicular and epididymal involvement with grade I follicular lymphoma.",Case Reports,5194.0,2.0,involvement with indolent is extremely rare particularly in the absence of transformation to an aggressive histology We report a case of a 64-year-old man who presented with lymphadenopathy Staging CT scans revealed extensive lymphadenopathy as well as bilateral and epididymal masses Histologic examination of lymph node marrow and testicular/epididymal biopsies revealed involvement with grade I follicular The patient was started on chemotherapy with cyclophosphamide vincristine prednisone and rituximab in addition to intrathecal methotrexate and radiation He is now 6 months into therapy and responding well A review of the literature demonstrated this to be the first confirmed case of and epididymal involvement with grade I follicular,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[799, 5, 2316, 16, 2938, 622, 823, 4, 3, 1127, 1, 1392, 6, 35, 571, 784, 21, 414, 8, 473, 1, 8, 660, 111, 1095, 3628, 54, 917, 5, 4962, 632, 425, 1441, 553, 1344, 4962, 22, 149, 22, 1607, 2, 33987, 2692, 884, 1385, 1, 263, 289, 581, 2, 33267, 33987, 1154, 553, 799, 5, 88, 70, 1974, 3, 69, 10, 3461, 23, 56, 5, 1112, 2132, 1979, 2, 855, 4, 352, 6, 5126, 2116, 2, 121, 3174, 16, 1134, 49, 53, 237, 36, 2, 3261, 149, 8, 206, 1, 3, 789, 264, 26, 6, 40, 3, 157, 557, 473, 1, 2, 33987, 799, 5, 88, 70, 1974]",743.0,16236619,339
"Long-segment, supercharged, pedicled jejunal flap for total esophageal reconstruction.",The Journal of thoracic and cardiovascular surgery,J. Thorac. Cardiovasc. Surg.,2005-10-13,"Many patients with cancer have limited esophageal reconstruction options when the stomach is unavailable as a replacement conduit or when long-segment discontinuity exists. Jejunum has been used as an alternative conduit, both as a pedicled or free flap interposition; however, reports of this are usually limited to short-segment repairs. Microvascular augmentation of a pedicled jejunal flap allows creation of a longer conduit, making it possible to replace the entire esophagus with jejunum. Few reports describe this technique in patients with cancer. We report our initial experience with ""supercharged"" pedicled jejunum as an alternative conduit for total esophageal reconstruction. Review of a prospectively collected departmental database was performed to identify those patients who underwent total esophageal reconstruction with supercharged pedicled jejunum. Data regarding their perioperative course and postoperative function were gathered from the prospectively collected clinical data, review of hospital records, and patient interviews. Total esophageal reconstruction with supercharged pedicled jejunum was attempted in 26 patients (age range, 37-74 years) between March 2000 and April 2004. Twenty-four of 26 patients were ultimately discharged with an intact supercharged pedicled jejunum flap, for an overall success rate of 92.3%. One patient experienced intraoperative flap loss caused by technical difficulties harvesting the flap and never had the flap interposed. One other flap loss occurred in the early postoperative period in a patient who had multisystem organ failure after a prolonged reconstruction. Cervical anastomotic leaks occurred in 19.2% (5/26) of the patients. Two midconduit leaks occurred that were suspicious for iatrogenic perforation from nasogastric tube placement; one required reoperation. One additional early reoperation was performed for cecal ischemia. There were no mortalities. Functional results were available in 95.4% (21/22) of the patients receiving supercharged pedicled jejunum who survived at least 6 months after reconstruction. At the time of follow-up, 95% (20/21) of the patients were tolerating regular diet, and 76.2% (16/21) did not require any supplemental alimentation. Ninety-five percent (20/21) of the patients were free from reflux symptoms, and 80.9% (17/21) had no dumping symptoms. Only 1 patient required dilation of a midconduit stricture. One patient required late reoperation for conduit redundancy. Supercharged pedicled jejunum is a suitable alternative conduit for total esophageal replacement in patients with cancer with otherwise limited reconstructive options. Functional outcomes are excellent, despite the severity of disease and technical challenges in this patient population.",Journal Article,5213.0,49.0,Many patients with cancer have limited reconstruction options when the is unavailable as a replacement conduit or when long-segment discontinuity exists Jejunum has been used as an alternative conduit both as a pedicled or free flap interposition however reports of this are usually limited to short-segment repairs Microvascular augmentation of a pedicled jejunal flap allows creation of a longer conduit making it possible to replace the entire with jejunum Few reports describe this technique in patients with cancer We report our initial experience with `` supercharged '' pedicled jejunum as an alternative conduit for total reconstruction Review of a prospectively collected departmental database was performed to identify those patients who underwent total reconstruction with supercharged pedicled jejunum Data regarding their perioperative course and postoperative function were gathered from the prospectively collected clinical data review of hospital records and patient interviews Total reconstruction with supercharged pedicled jejunum was attempted in 26 patients age range 37-74 years between March 2000 and April 2004 Twenty-four of 26 patients were ultimately discharged with an intact supercharged pedicled jejunum flap for an overall success rate of 92.3 One patient experienced intraoperative flap loss caused by technical difficulties harvesting the flap and never had the flap interposed One other flap loss occurred in the early postoperative period in a patient who had multisystem organ failure after a prolonged reconstruction anastomotic leaks occurred in 19.2 5/26 of the patients Two midconduit leaks occurred that were suspicious for iatrogenic perforation from nasogastric tube placement one required reoperation One additional early reoperation was performed for cecal ischemia There were no mortalities Functional results were available in 95.4 21/22 of the patients receiving supercharged pedicled jejunum who survived at least 6 months after reconstruction At the time of follow-up 95 20/21 of the patients were tolerating regular diet and 76.2 16/21 did not require any supplemental alimentation Ninety-five percent 20/21 of the patients were free from reflux symptoms and 80.9 17/21 had no dumping symptoms Only 1 patient required dilation of a midconduit stricture One patient required late reoperation for conduit redundancy Supercharged pedicled jejunum is a suitable alternative conduit for total replacement in patients with cancer with otherwise limited reconstructive options Functional outcomes are excellent despite the severity of disease and technical challenges in this patient population,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,"[445, 7, 5, 12, 47, 383, 1470, 838, 198, 3, 16, 9098, 22, 8, 3892, 10439, 15, 198, 319, 4610, 33991, 2481, 16027, 71, 85, 95, 22, 35, 1091, 10439, 110, 22, 8, 11558, 15, 115, 3942, 16852, 137, 1198, 1, 26, 32, 2082, 383, 6, 978, 4610, 18439, 6466, 9047, 1, 8, 11558, 10835, 3942, 2333, 7560, 1, 8, 589, 10439, 1079, 192, 899, 6, 7195, 3, 1797, 5, 16027, 1021, 1198, 897, 26, 1312, 4, 7, 5, 12, 21, 414, 114, 388, 730, 5, 24868, 522, 11558, 16027, 22, 35, 1091, 10439, 9, 181, 1470, 206, 1, 8, 1143, 786, 14560, 609, 10, 173, 6, 255, 135, 7, 54, 208, 181, 1470, 5, 24868, 11558, 16027, 74, 666, 136, 1547, 906, 2, 573, 343, 11, 7546, 29, 3, 1143, 786, 38, 74, 206, 1, 702, 1064, 2, 69, 4053, 181, 1470, 5, 24868, 11558, 16027, 10, 4098, 4, 432, 7, 89, 184, 567, 794, 60, 59, 2363, 1081, 2, 2292, 1131, 737, 294, 1, 432, 7, 11, 2050, 6155, 5, 35, 2964, 24868, 11558, 16027, 3942, 9, 35, 63, 1825, 116, 1, 937, 27, 104, 69, 592, 1720, 3942, 407, 1546, 20, 3359, 4679, 17700, 3, 3942, 2, 1737, 42, 3, 3942, 55140, 104, 127, 3942, 407, 489, 4, 3, 191, 573, 727, 4, 8, 69, 54, 42, 17333, 1259, 496, 50, 8, 1069, 1470, 4818, 9674, 489, 4, 326, 18, 33, 432, 1, 3, 7, 100, 44144, 9674, 489, 17, 11, 3230, 9, 16401, 4854, 29, 26438, 2330, 2613, 104, 616, 5077, 104, 402, 191, 5077, 10, 173, 9, 19603, 5675, 125, 11, 77, 9743, 583, 99, 11, 390, 4, 48, 39, 239, 350, 1, 3, 7, 357, 24868, 11558, 16027, 54, 2996, 28, 506, 49, 53, 50, 1470, 28, 3, 98, 1, 166, 126, 48, 179, 239, 1, 3, 7, 11, 16003, 3316, 2453, 2, 846, 18, 245, 239, 205, 44, 1353, 500, 6303, 44145, 2493, 365, 714, 179, 239, 1, 3, 7, 11, 115, 29, 9657, 507, 2, 493, 83, 269, 239, 42, 77, 38057, 507, 158, 14, 69, 616, 8062, 1, 8, 44144, 6673, 104, 69, 616, 807, 5077, 9, 10439, 12589, 24868, 11558, 16027, 16, 8, 2884, 1091, 10439, 9, 181, 3892, 4, 7, 5, 12, 5, 2632, 383, 8060, 838, 583, 123, 32, 1503, 550, 3, 1702, 1, 34, 2, 3359, 1427, 4, 26, 69, 266]",2638.0,16256794,173
"Evaluating the risk of cervical precancer with a combination of cytologic, virologic, and visual methods.","Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2005-11-01,"Several test modalities (cytologic, molecular, and visual) may be used for cervical cancer screening, triage, and follow-up. Although no currently available single test for cervical neoplasia can detect disease with both high sensitivity and specificity, combinations of available tests allow for improved risk prediction. We therefore evaluated the combination of liquid-based cytology (LBC), human papillomavirus (HPV) DNA testing, and visual inspection (cervicography), taken at a single point in time, to predict risk of subsequent cervical intraepithelial neoplasia 3 (CIN3) or cancer developing within 2 years in a triage population of 5,060 women referred for equivocal or mildly abnormal cytology. The concurrent administration of all three test modalities showed that combinations of these test modalities permitted clear and distinct risk stratification. Among HPV-positive women with high-grade LBC and high-grade cervicography results, 79.1 % [95% confidence interval (95% CI), 64.0- 90.0] were diagnosed with histologic CIN3 or cancer within 2 years, supporting a ""see-and-treat"" clinical application. Conversely, only 1.4% (95% CI, 0.7-2.5) of women with a negative HPV, normal cervigram, and second normal cytology result developed CIN3 or cancer. Because this low absolute risk was largely attributable to the negative HPV test, our results suggest a lack of benefit for a secondary or tertiary test result given an HPV-negative test result. Within HPV-positive women, however, we observed a steadily increasing absolute risk for cervical precancer/cancer with increasing numbers and severity of abnormal test results. We conclude that the clear discrimination of cervical cancer risk provided by multiple test modalities is consistent with our understanding of cervical etiology related to HPV natural history.",Journal Article,5194.0,21.0,"Several test modalities cytologic molecular and visual may be used for cancer screening triage and follow-up Although no currently available single test for neoplasia can detect disease with both high sensitivity and specificity combinations of available tests allow for improved risk prediction We therefore evaluated the combination of liquid-based cytology LBC human papillomavirus HPV DNA testing and visual inspection cervicography taken at a single point in time to predict risk of subsequent intraepithelial neoplasia 3 CIN3 or cancer developing within 2 years in a triage population of 5,060 women referred for equivocal or mildly abnormal cytology The concurrent administration of all three test modalities showed that combinations of these test modalities permitted clear and distinct risk stratification Among HPV-positive women with high-grade LBC and high-grade cervicography results 79.1 95 confidence interval 95 CI 64.0- 90.0 were diagnosed with histologic CIN3 or cancer within 2 years supporting a `` see-and-treat '' clinical application Conversely only 1.4 95 CI 0.7-2.5 of women with a negative HPV normal cervigram and second normal cytology result developed CIN3 or cancer Because this low absolute risk was largely attributable to the negative HPV test our results suggest a lack of benefit for a secondary or tertiary test result given an HPV-negative test result Within HPV-positive women however we observed a steadily increasing absolute risk for precancer/cancer with increasing numbers and severity of abnormal test results We conclude that the clear discrimination of cancer risk provided by multiple test modalities is consistent with our understanding of etiology related to HPV natural history",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[392, 412, 1558, 4195, 219, 2, 3046, 68, 40, 95, 9, 12, 453, 9059, 2, 166, 126, 242, 77, 694, 390, 226, 412, 9, 2298, 122, 1426, 34, 5, 110, 64, 485, 2, 1121, 1247, 1, 390, 895, 1700, 9, 231, 43, 1590, 21, 673, 194, 3, 150, 1, 3165, 90, 2045, 28439, 171, 3242, 933, 261, 471, 2, 3046, 11746, 44156, 1633, 28, 8, 226, 741, 4, 98, 6, 678, 43, 1, 706, 4153, 2298, 27, 10346, 15, 12, 931, 262, 18, 60, 4, 8, 9059, 266, 1, 33, 9972, 117, 1995, 9, 5068, 15, 9443, 1668, 2045, 3, 750, 634, 1, 62, 169, 412, 1558, 224, 17, 1247, 1, 46, 412, 1558, 5449, 885, 2, 834, 43, 1541, 107, 933, 109, 117, 5, 64, 88, 28439, 2, 64, 88, 44156, 99, 842, 14, 48, 307, 268, 48, 58, 660, 13, 424, 13, 11, 265, 5, 884, 10346, 15, 12, 262, 18, 60, 1912, 8, 3764, 2, 943, 522, 38, 1581, 3154, 158, 14, 39, 48, 58, 13, 67, 18, 33, 1, 117, 5, 8, 199, 933, 295, 55160, 2, 419, 295, 2045, 757, 276, 10346, 15, 12, 408, 26, 154, 1766, 43, 10, 1733, 2971, 6, 3, 199, 933, 412, 114, 99, 309, 8, 926, 1, 247, 9, 8, 568, 15, 2557, 412, 757, 447, 35, 933, 199, 412, 757, 262, 933, 109, 117, 137, 21, 164, 8, 7025, 602, 1766, 43, 9, 12380, 12, 5, 602, 1870, 2, 1702, 1, 1668, 412, 99, 21, 2060, 17, 3, 885, 3520, 1, 12, 43, 1052, 20, 232, 412, 1558, 16, 925, 5, 114, 612, 1, 2855, 139, 6, 933, 1504, 532]",1727.0,16284394,43
A case-control study of methylenetetrahydrofolate reductase polymorphisms in cervical carcinogenesis.,Gynecologic oncology,Gynecol. Oncol.,2005-11-17,"Polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene are thought to be associated with a varying risk of cervical dysplasia. The purpose of this trial was to study the role of the two common functional MHTFR polymorphisms in a large multiracial population at risk for cervical dysplasia and cancer. This is a nested case-control study of 376 subjects obtained from cohorts enrolled in an ongoing prospective cervical carcinogenesis protocol. Cases included invasive cancers (n = 51), and high (n = 50) and low (n = 50) grade dysplasia. There were 225 normal controls. Functional MTHFR 677C-->T and 1298A-->C genotypes were identified. Follow-up cytology data were reviewed for the control subjects from the time of study entry until August 2004. There is a significant racial difference in allele frequency of the 677C-->T polymorphism (P < 0.005). African-American women had an extremely low prevalence of the 677T allele (8%). There was no significant difference in the frequency of the 677T allele between cases and controls. There is no racial difference in allele frequency of the 1298A-->C polymorphism. Also, no significant difference was found between cases and controls. Of the 51 cancers, no case was homozygous for both aberrant polymorphisms (677T, 1298C), and only 3 cases were heterozygous for both. Follow-up data were available for 129 of 225 control subjects (57%). Only 15 (12%) have had a subsequent abnormal pap, and there was no association with the 677C-->T polymorphism. We confirm a significant difference in the 677T allele frequencies among racial groups. However, there is no association of either the 677C-->T or 1298A-->C polymorphisms in cervical carcinogenesis. There is no role of the combined polymorphism effect in cervical cancer or evidence of prediction for future Pap abnormalities.",Journal Article,5178.0,17.0,Polymorphisms in the methylenetetrahydrofolate reductase MTHFR gene are thought to be associated with a varying risk of dysplasia The purpose of this trial was to study the role of the two common functional MHTFR polymorphisms in a large multiracial population at risk for dysplasia and cancer This is a nested case-control study of 376 subjects obtained from cohorts enrolled in an ongoing prospective carcinogenesis protocol Cases included invasive cancers n 51 and high n 50 and low n 50 grade dysplasia There were 225 normal controls Functional MTHFR 677C -- T and 1298A -- C genotypes were identified Follow-up cytology data were reviewed for the control subjects from the time of study entry until August 2004 There is a significant racial difference in allele frequency of the 677C -- T polymorphism P 0.005 African-American women had an extremely low prevalence of the 677T allele 8 There was no significant difference in the frequency of the 677T allele between cases and controls There is no racial difference in allele frequency of the 1298A -- C polymorphism Also no significant difference was found between cases and controls Of the 51 cancers no case was homozygous for both aberrant polymorphisms 677T 1298C and only 3 cases were heterozygous for both Follow-up data were available for 129 of 225 control subjects 57 Only 15 12 have had a subsequent abnormal pap and there was no association with the 677C -- T polymorphism We confirm a significant difference in the 677T allele frequencies among racial groups However there is no association of either the 677C -- T or 1298A -- C polymorphisms in carcinogenesis There is no role of the combined polymorphism effect in cancer or evidence of prediction for future Pap abnormalities,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1203, 4, 3, 15586, 4027, 8342, 145, 32, 2739, 6, 40, 41, 5, 8, 2990, 43, 1, 2253, 3, 743, 1, 26, 160, 10, 6, 45, 3, 200, 1, 3, 100, 186, 583, 55166, 1203, 4, 8, 375, 44164, 266, 28, 43, 9, 2253, 2, 12, 26, 16, 8, 4789, 473, 182, 45, 1, 9534, 976, 683, 29, 736, 346, 4, 35, 942, 482, 1719, 1182, 140, 159, 416, 163, 78, 725, 2, 64, 78, 212, 2, 154, 78, 212, 88, 2253, 125, 11, 4011, 295, 535, 583, 8342, 26205, 102, 2, 33536, 256, 2071, 11, 108, 166, 126, 2045, 74, 11, 446, 9, 3, 182, 976, 29, 3, 98, 1, 45, 3001, 1100, 2480, 1131, 125, 16, 8, 93, 2257, 523, 4, 1254, 675, 1, 3, 26205, 102, 1907, 19, 13, 1614, 1410, 597, 117, 42, 35, 2938, 154, 1078, 1, 3, 33999, 1254, 66, 125, 10, 77, 93, 523, 4, 3, 675, 1, 3, 33999, 1254, 59, 140, 2, 535, 125, 16, 77, 2257, 523, 4, 1254, 675, 1, 3, 33536, 256, 1907, 120, 77, 93, 523, 10, 204, 59, 140, 2, 535, 1, 3, 725, 163, 77, 473, 10, 3189, 9, 110, 1898, 1203, 33999, 55167, 2, 158, 27, 140, 11, 4167, 9, 110, 166, 126, 74, 11, 390, 9, 4649, 1, 4011, 182, 976, 696, 158, 167, 133, 47, 42, 8, 706, 1668, 4290, 2, 125, 10, 77, 248, 5, 3, 26205, 102, 1907, 21, 1843, 8, 93, 523, 4, 3, 33999, 1254, 2722, 107, 2257, 271, 137, 125, 16, 77, 248, 1, 361, 3, 26205, 102, 15, 33536, 256, 1203, 4, 1719, 125, 16, 77, 200, 1, 3, 397, 1907, 254, 4, 12, 15, 241, 1, 1590, 9, 508, 4290, 1171]",1745.0,16297972,27
Functional outcomes after laryngopharyngectomy with anterolateral thigh flap reconstruction.,Head & neck,Head Neck,2006-02-01,"We examined speech and swallowing outcomes and complications in patients with anterolateral thigh (ALT) flap reconstruction of cervical esophageal defects. We retrospectively reviewed 29 patients treated with laryngopharyngectomy and ALT flap reconstruction at The University of Texas M. D. Anderson Cancer Center from March 2002 to July 2004. We compared complication rates, nutritional intake, number of tracheoesophageal punctures (TEPs), speech fluency and use, operative defects, and radiotherapy effects. Twenty-two patients had circumferential defects, and seven had partial defects. Twenty-four patients had radiotherapy. Eleven patients underwent TEP. Higher complication rates in patients after TEP compared with those without TEP were not statistically significant (p = .268). Ninety percent of patients with TEP spoke fluently. Ninety percent of all patients returned to oral alimentation without significant effect from TEP (p = 1.00), complications (p = 1.00), radiation therapy (p = 1.00), or surgical defect (p = .56). The ALT flap successfully reconstructs laryngopharyngeal defects with excellent speech and swallowing results.",Journal Article,5102.0,35.0,We examined speech and swallowing outcomes and complications in patients with anterolateral thigh ALT flap reconstruction of defects We retrospectively reviewed 29 patients treated with laryngopharyngectomy and ALT flap reconstruction at The University of Texas M. D. Anderson Cancer Center from March 2002 to July 2004 We compared complication rates nutritional intake number of tracheoesophageal punctures TEPs speech fluency and use operative defects and radiotherapy effects Twenty-two patients had circumferential defects and seven had partial defects Twenty-four patients had radiotherapy Eleven patients underwent TEP Higher complication rates in patients after TEP compared with those without TEP were not statistically significant p .268 Ninety percent of patients with TEP spoke fluently Ninety percent of all patients returned to oral alimentation without significant effect from TEP p 1.00 complications p 1.00 radiation therapy p 1.00 or surgical defect p .56 The ALT flap successfully reconstructs laryngopharyngeal defects with excellent speech and swallowing results,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[21, 409, 9637, 2, 6129, 123, 2, 521, 4, 7, 5, 19622, 11674, 4548, 3942, 1470, 1, 2945, 21, 894, 446, 462, 7, 73, 5, 34000, 2, 4548, 3942, 1470, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 29, 2363, 1544, 6, 2066, 1131, 21, 72, 1447, 151, 5082, 1514, 207, 1, 26417, 22260, 38066, 9637, 20475, 2, 119, 1208, 2945, 2, 310, 176, 737, 100, 7, 42, 7937, 2945, 2, 648, 42, 450, 2945, 737, 294, 7, 42, 310, 2627, 7, 208, 28481, 142, 1447, 151, 4, 7, 50, 28481, 72, 5, 135, 187, 28481, 11, 44, 712, 93, 19, 8410, 2493, 714, 1, 7, 5, 28481, 24752, 55174, 2493, 714, 1, 62, 7, 5157, 6, 518, 44145, 187, 93, 254, 29, 28481, 19, 14, 2038, 521, 19, 14, 2038, 121, 36, 19, 14, 2038, 15, 221, 5398, 19, 664, 3, 4548, 3942, 1878, 44166, 43157, 2945, 5, 1503, 9637, 2, 6129, 99]",1082.0,16302192,64
Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2005-12-01,"Lymphatic invasion and nodal metastasis plays a major role in the spread of cervical cancer; however, little is known about the mechanisms whereby tumor cells enter the lymphatic system. We examined the intra- and peritumoral lymphatic vessel density (LVD) using D2-40 immunohistochemistry in 111 cervical squamous cell carcinomas and correlated them with vascular endothelial growth factor (VEGF)-C expression, clinicopathologic tumor features, and outcome. Compared with benign cervix, intratumoral and peritumoral LVD was significantly increased (P < 0.0001). Peritumoral LVD was significantly higher than intratumoral LVD (P = 0.009). High peritumoral, but not intratumoral, LVD showed significant correlation with high tumor stage, lymphatic invasion, and nodal metastasis. VEGF-C showed increased expression at the invasive edge compared with the center of tumors (P < 0.0001) and correlated with high peritumoral LVD, lymphatic invasion, and nodal metastasis. High peritumoral LVD and VEGF-C expression at the invasive edge of tumors were associated with poor overall and recurrence-free survival in univariate analysis. In multivariate analysis, peritumoral LVD was the only independent term predictive of overall survival. Our findings suggest a potential role for VEGF-C in tumor-induced lymphangiogenesis represented by high peritumoral LVD, which may be one of the mechanisms leading to lymphatic invasion and metastatic spread. High peritumoral LVD may be an independent prognostic factor in early-stage cervical cancer.",Journal Article,5164.0,156.0,Lymphatic invasion and nodal metastasis plays a major role in the spread of cancer however little is known about the mechanisms whereby tumor cells enter the lymphatic system We examined the intra- and peritumoral lymphatic vessel density LVD using D2-40 immunohistochemistry in 111 squamous cell carcinomas and correlated them with vascular endothelial growth factor VEGF -C expression clinicopathologic tumor features and outcome Compared with benign cervix intratumoral and peritumoral LVD was significantly increased P 0.0001 Peritumoral LVD was significantly higher than intratumoral LVD P 0.009 High peritumoral but not intratumoral LVD showed significant correlation with high tumor stage lymphatic invasion and nodal metastasis VEGF-C showed increased expression at the invasive edge compared with the center of tumors P 0.0001 and correlated with high peritumoral LVD lymphatic invasion and nodal metastasis High peritumoral LVD and VEGF-C expression at the invasive edge of tumors were associated with poor overall and recurrence-free survival in univariate analysis In multivariate analysis peritumoral LVD was the only independent term predictive of overall survival Our findings suggest a potential role for VEGF-C in tumor-induced lymphangiogenesis represented by high peritumoral LVD which may be one of the mechanisms leading to lymphatic invasion and metastatic spread High peritumoral LVD may be an independent prognostic factor in early-stage cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2936, 578, 2, 779, 278, 1698, 8, 458, 200, 4, 3, 2579, 1, 12, 137, 1215, 16, 440, 545, 3, 483, 6131, 30, 37, 7058, 3, 2936, 398, 21, 409, 3, 2392, 2, 5432, 2936, 3685, 1263, 13139, 75, 4171, 327, 888, 4, 3167, 691, 31, 826, 2, 438, 1370, 5, 756, 845, 129, 161, 618, 256, 55, 1399, 30, 404, 2, 228, 72, 5, 1002, 3629, 2074, 2, 5432, 13139, 10, 97, 101, 19, 13, 488, 5432, 13139, 10, 97, 142, 76, 2074, 13139, 19, 13, 2376, 64, 5432, 84, 44, 2074, 13139, 224, 93, 816, 5, 64, 30, 82, 2936, 578, 2, 779, 278, 618, 256, 224, 101, 55, 28, 3, 416, 7951, 72, 5, 3, 574, 1, 57, 19, 13, 488, 2, 438, 5, 64, 5432, 13139, 2936, 578, 2, 779, 278, 64, 5432, 13139, 2, 618, 256, 55, 28, 3, 416, 7951, 1, 57, 11, 41, 5, 334, 63, 2, 146, 115, 25, 4, 880, 65, 4, 331, 65, 5432, 13139, 10, 3, 158, 306, 337, 464, 1, 63, 25, 114, 272, 309, 8, 174, 200, 9, 618, 256, 4, 30, 277, 9916, 3324, 20, 64, 5432, 13139, 92, 68, 40, 104, 1, 3, 483, 1049, 6, 2936, 578, 2, 113, 2579, 64, 5432, 13139, 68, 40, 35, 306, 177, 161, 4, 191, 82, 12]",1468.0,16322297,106
Cancer characteristics in Swedish families fulfilling criteria for hereditary nonpolyposis colorectal cancer.,Gastroenterology,Gastroenterology,2005-12-01,"The present study quantified the prevalence of families that fulfill the Amsterdam or Bethesda criteria for hereditary nonpolyposis colorectal cancer (HNPCC) in the whole Swedish population and investigated the extent to which tumors in the classified families are HNPCC-related. The families of the Swedish Family-Cancer Database with at least 4 generations (N = 566,877) were classified according to the Amsterdam and the Bethesda criteria. Survival methods were used to assess the risk of cancer in the classified families, the prognosis of cancer patients, and the risk of subsequent malignancies after colorectal adenomas and after colorectal/endometrial adenocarcinomas. The Bethesda criteria identified 0.9% of all Swedish families and 11.2% of patients with colorectal cancer. Families that fulfilled the Bethesda criteria showed increased risks of cancer in the colorectum, endometrium, small bowel, ovary, stomach, bile ducts, renal pelvis, and ureter; members of Bethesda criteria families were at decreased risks of lung and cervical cancers. The prognosis of cancer in the ureter, renal pelvis, stomach, ovary, and colorectum, but not in the endometrium, was better in Bethesda criteria than in nonclassified families. Most malignancies in the classified families reflect typical features of HNPCC (association with subsequent malignancies, accelerated adenoma-carcinoma sequence, and better survival). The data presented in this study should help to define surveillance strategies for members of families that fulfill the criteria for HNPCC testing.",Journal Article,5164.0,33.0,"The present study quantified the prevalence of families that fulfill the Amsterdam or Bethesda criteria for hereditary nonpolyposis cancer HNPCC in the whole Swedish population and investigated the extent to which tumors in the classified families are HNPCC-related The families of the Swedish Family-Cancer Database with at least 4 generations N 566,877 were classified according to the Amsterdam and the Bethesda criteria Survival methods were used to assess the risk of cancer in the classified families the prognosis of cancer patients and the risk of subsequent malignancies after adenomas and after colorectal/endometrial adenocarcinomas The Bethesda criteria identified 0.9 of all Swedish families and 11.2 of patients with cancer Families that fulfilled the Bethesda criteria showed increased risks of cancer in the colorectum small bowel ovary ducts pelvis and ureter members of Bethesda criteria families were at decreased risks of and cancers The prognosis of cancer in the ureter pelvis ovary and colorectum but not in the was better in Bethesda criteria than in nonclassified families Most malignancies in the classified families reflect typical features of HNPCC association with subsequent malignancies accelerated adenoma-carcinoma sequence and better survival The data presented in this study should help to define surveillance strategies for members of families that fulfill the criteria for HNPCC testing",0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,"[3, 364, 45, 2790, 3, 1078, 1, 1954, 17, 11246, 3, 10531, 15, 8222, 371, 9, 2305, 10786, 12, 6232, 4, 3, 902, 14850, 266, 2, 565, 3, 1039, 6, 92, 57, 4, 3, 1373, 1954, 32, 6232, 139, 3, 1954, 1, 3, 14850, 607, 12, 609, 5, 28, 506, 39, 11083, 78, 14539, 17627, 11, 1373, 768, 6, 3, 10531, 2, 3, 8222, 371, 25, 636, 11, 95, 6, 423, 3, 43, 1, 12, 4, 3, 1373, 1954, 3, 356, 1, 12, 7, 2, 3, 43, 1, 706, 441, 50, 2751, 2, 50, 12863, 18442, 1586, 3, 8222, 371, 108, 13, 83, 1, 62, 14850, 1954, 2, 175, 18, 1, 7, 5, 12, 1954, 17, 9091, 3, 8222, 371, 224, 101, 1098, 1, 12, 4, 3, 12355, 302, 1659, 3631, 7310, 3270, 2, 9775, 1684, 1, 8222, 371, 1954, 11, 28, 340, 1098, 1, 2, 163, 3, 356, 1, 12, 4, 3, 9775, 3270, 3631, 2, 12355, 84, 44, 4, 3, 10, 380, 4, 8222, 371, 76, 4, 55198, 1954, 96, 441, 4, 3, 1373, 1954, 2694, 3476, 404, 1, 6232, 248, 5, 706, 441, 2241, 2434, 134, 1532, 2, 380, 25, 3, 74, 917, 4, 26, 45, 257, 987, 6, 1107, 617, 422, 9, 1684, 1, 1954, 17, 11246, 3, 371, 9, 6232, 471]",1423.0,16344057,93
A proposal for an international retinoblastoma staging system.,Pediatric blood & cancer,Pediatr Blood Cancer,2006-11-01,"Although intra-retinal tumor has long been staged presurgically according to the Reese-Ellsworth (R-E) system, retinoblastoma differs from other pediatric neoplasms in never having had a widely accepted classification system that encompasses the entire spectrum of the disease. Comparisons among studies that consider disease extension, risk factors for extra-ocular relapse, and response to therapy require a universally accepted staging system for extra-ocular disease. A committee of retinoblastoma experts from large centers worldwide has developed a consensus classification that can encompass all retinoblastoma cases and is presented herein. Patients are classified according to extent of disease and the presence of overt extra-ocular extension. In addition, a proposal for substaging considering histopathological features of enucleated specimens is presented to further discriminate between Stage I and II patients. The following is a summary of the classification system developed-Stage 0: Patients treated conservatively (subject to presurgical ophthalmologic classifications); Stage I: Eye enucleated, completely resected histologically; Stage II: Eye enucleated, microscopic residual tumor; Stage III: Regional extension [(a) overt orbital disease, (b) preauricular or cervical lymph node extension]; Stage IV: Metastatic disease [(a) hematogenous metastasis: (1) single lesion, (2) multiple lesions; (b) CNS extension: (1) prechiasmatic lesion, (2) CNS mass, (3) leptomeningeal disease]. A proposal is also presented for substaging of enucleated Stages I and II eyes. The proposed staging system is the product of an international effort to adopt a uniform staging system for patients with retinoblastoma to cover the whole spectrum of the disease.",Journal Article,4829.0,124.0,Although intra-retinal tumor has long been staged presurgically according to the Reese-Ellsworth R-E system differs from other pediatric neoplasms in never having had a widely accepted classification system that encompasses the entire spectrum of the disease Comparisons among studies that consider disease extension risk factors for extra-ocular relapse and response to therapy require a universally accepted staging system for extra-ocular disease A committee of experts from large centers worldwide has developed a consensus classification that can encompass all cases and is presented herein Patients are classified according to extent of disease and the presence of overt extra-ocular extension In addition a proposal for substaging considering histopathological features of enucleated specimens is presented to further discriminate between Stage I and II patients The following is a summary of the classification system developed-Stage 0 Patients treated conservatively subject to presurgical ophthalmologic classifications Stage I Eye enucleated completely resected histologically Stage II Eye enucleated microscopic residual tumor Stage III Regional extension a overt orbital disease b preauricular or lymph node extension Stage IV Metastatic disease a hematogenous metastasis 1 single lesion 2 multiple lesions b CNS extension 1 prechiasmatic lesion 2 CNS mass 3 leptomeningeal disease A proposal is also presented for substaging of enucleated Stages I and II eyes The proposed staging system is the product of an international effort to adopt a uniform staging system for patients with to cover the whole spectrum of the disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[242, 2392, 6831, 30, 71, 319, 85, 2930, 55204, 768, 6, 3, 16634, 16211, 668, 563, 398, 4990, 29, 127, 815, 1179, 4, 1737, 1041, 42, 8, 1792, 3058, 947, 398, 17, 9485, 3, 1797, 1873, 1, 3, 34, 2213, 107, 94, 17, 2419, 34, 2401, 43, 130, 9, 3420, 4345, 429, 2, 51, 6, 36, 1353, 8, 6813, 3058, 632, 398, 9, 3420, 4345, 34, 8, 2002, 1, 3186, 29, 375, 1168, 2358, 71, 276, 8, 1391, 947, 17, 122, 8454, 62, 140, 2, 16, 917, 1986, 7, 32, 1373, 768, 6, 1039, 1, 34, 2, 3, 463, 1, 7192, 3420, 4345, 2401, 4, 352, 8, 13383, 9, 23488, 3075, 4370, 404, 1, 12719, 623, 16, 917, 6, 195, 5696, 59, 82, 70, 2, 215, 7, 3, 366, 16, 8, 1962, 1, 3, 947, 398, 276, 82, 13, 7, 73, 10296, 2974, 6, 8851, 20190, 5787, 82, 70, 4922, 12719, 2500, 1133, 2161, 82, 215, 4922, 12719, 2984, 753, 30, 82, 316, 951, 2401, 8, 7192, 5549, 34, 132, 34010, 15, 263, 289, 2401, 82, 478, 113, 34, 8, 9792, 278, 14, 226, 1180, 18, 232, 406, 132, 1025, 2401, 14, 55205, 1180, 18, 1025, 782, 27, 4948, 34, 8, 13383, 16, 120, 917, 9, 23488, 1, 12719, 1153, 70, 2, 215, 3799, 3, 1587, 632, 398, 16, 3, 2821, 1, 35, 944, 2919, 6, 11462, 8, 3490, 632, 398, 9, 7, 5, 6, 8308, 3, 902, 1873, 1, 3, 34]",1638.0,16358310,35
Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2005-12-01,"To compare magnetic resonance imaging (MRI) and computed tomography (CT) with each other and to International Federation of Gynecology and Obstetrics (FIGO) clinical staging in the pretreatment evaluation of early invasive cervical cancer, using surgicopathologic findings as the reference standard. This prospective multicenter clinical study was conducted by the American College of Radiology Imaging Network and the Gynecologic Oncology Group from March 2000 to November 2002; 25 United States health centers enrolled 208 consecutive patients with biopsy-confirmed cervical cancer of FIGO stage > or = IB who were scheduled for surgery based on clinical assessment. Patients underwent FIGO clinical staging, helical CT, and MRI. Surgicopathologic findings constituted the reference standard for statistical analysis. Complete data were available for 172 patients; surgicopathologic findings were consistent with FIGO stages IA to IIA in 76% and stage > or = IIB in 21%. For the detection of advanced stage (> or = IIB), sensitivity was poor for FIGO clinical staging (29%), CT (42%), and MRI (53%); specificity was 99% for FIGO clinical staging, 82% for CT, and 74% for MRI; and negative predictive value was 84% for FIGO clinical staging, 84% for CT, and 85% for MRI. MRI (area under the receiver operating characteristic curve [AUC], 0.88) was significantly better than CT (AUC, 0.73) for detecting cervical tumors (P = .014). For 85% of patients, FIGO clinical staging forms were submitted after MRI and/or CT was performed. CT and MRI performed similarly; both had lower staging accuracy than in prior single-institution studies. Accuracy of FIGO clinical staging was higher than previously reported. The temporal data suggest that FIGO clinical staging was influenced by CT and MRI findings.",Clinical Trial,5164.0,150.0,To compare magnetic resonance imaging MRI and computed tomography CT with each other and to International Federation of Gynecology and Obstetrics FIGO clinical staging in the pretreatment evaluation of early invasive cancer using surgicopathologic findings as the reference standard This prospective multicenter clinical study was conducted by the American College of Radiology Imaging Network and the Gynecologic Oncology Group from March 2000 to November 2002 25 United States health centers enrolled 208 consecutive patients with biopsy-confirmed cancer of FIGO stage or IB who were scheduled for surgery based on clinical assessment Patients underwent FIGO clinical staging helical CT and MRI Surgicopathologic findings constituted the reference standard for statistical analysis Complete data were available for 172 patients surgicopathologic findings were consistent with FIGO stages IA to IIA in 76 and stage or IIB in 21 For the detection of advanced stage or IIB sensitivity was poor for FIGO clinical staging 29 CT 42 and MRI 53 specificity was 99 for FIGO clinical staging 82 for CT and 74 for MRI and negative predictive value was 84 for FIGO clinical staging 84 for CT and 85 for MRI MRI area under the receiver operating characteristic curve AUC 0.88 was significantly better than CT AUC 0.73 for detecting tumors P .014 For 85 of patients FIGO clinical staging forms were submitted after MRI and/or CT was performed CT and MRI performed similarly both had lower staging accuracy than in prior single-institution studies Accuracy of FIGO clinical staging was higher than previously reported The temporal data suggest that FIGO clinical staging was influenced by CT and MRI findings,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 932, 1484, 1535, 270, 704, 2, 1220, 872, 425, 5, 296, 127, 2, 6, 944, 7303, 1, 6429, 2, 7407, 3837, 38, 632, 4, 3, 1194, 451, 1, 191, 416, 12, 75, 30888, 272, 22, 3, 2482, 260, 26, 482, 1570, 38, 45, 10, 426, 20, 3, 597, 2979, 1, 4003, 270, 1801, 2, 3, 1512, 413, 87, 29, 2363, 1081, 6, 2868, 1544, 243, 1088, 907, 341, 1168, 346, 5920, 935, 7, 5, 411, 557, 12, 1, 3837, 82, 15, 3180, 54, 11, 4394, 9, 152, 90, 23, 38, 455, 7, 208, 3837, 38, 632, 6638, 425, 2, 704, 30888, 272, 8917, 3, 2482, 260, 9, 1050, 65, 236, 74, 11, 390, 9, 5312, 7, 30888, 272, 11, 925, 5, 3837, 1153, 3302, 6, 4088, 4, 846, 2, 82, 15, 3884, 4, 239, 9, 3, 638, 1, 131, 82, 15, 3884, 485, 10, 334, 9, 3837, 38, 632, 462, 425, 595, 2, 704, 699, 1121, 10, 1058, 9, 3837, 38, 632, 878, 9, 425, 2, 794, 9, 704, 2, 199, 464, 549, 10, 874, 9, 3837, 38, 632, 874, 9, 425, 2, 772, 9, 704, 704, 965, 669, 3, 3185, 2584, 2037, 1496, 1376, 13, 889, 10, 97, 380, 76, 425, 1376, 13, 803, 9, 2502, 57, 19, 3618, 9, 772, 1, 7, 3837, 38, 632, 2377, 11, 5118, 50, 704, 2, 15, 425, 10, 173, 425, 2, 704, 173, 1813, 110, 42, 280, 632, 1190, 76, 4, 324, 226, 731, 94, 1190, 1, 3837, 38, 632, 10, 142, 76, 373, 210, 3, 3264, 74, 309, 17, 3837, 38, 632, 10, 2574, 20, 425, 2, 704, 272]",1695.0,16361632,567
Mediastinal pancreatic pseudocyst with acute airway obstruction.,Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,J. Gastrointest. Surg.,2006-01-01,"Pancreatic pseudocysts are usually located in the peripancreatic area, but on rare occasion a pseudocyst can reach the mediastinum. The natural history of mediastinal pseudocysts is poorly understood and seldom reported in the literature. We treated a patient who presented with an acute airway obstruction from a mediastinal pancreatic pseudocyst. Initial acute airway management and stabilization proved successful. A staged cyst decompression via a cervical and abdominal transhiatal approach was ultimately required. The natural history, potential complications, and management of pancreatic mediastinal pseudocysts are reviewed.",Case Reports,5133.0,14.0,pseudocysts are usually located in the peripancreatic area but on rare occasion a pseudocyst can reach the mediastinum The natural history of mediastinal pseudocysts is poorly understood and seldom reported in the literature We treated a patient who presented with an acute airway obstruction from a mediastinal pseudocyst Initial acute airway management and stabilization proved successful A staged cyst decompression via a and abdominal transhiatal approach was ultimately required The natural history potential complications and management of mediastinal pseudocysts are reviewed,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[22035, 32, 2082, 2308, 4, 3, 19556, 965, 84, 23, 622, 18864, 8, 21365, 122, 3690, 3, 7156, 3, 1504, 532, 1, 2626, 22035, 16, 1240, 1784, 2, 10805, 210, 4, 3, 789, 21, 73, 8, 69, 54, 917, 5, 35, 286, 7627, 3191, 29, 8, 2626, 21365, 388, 286, 7627, 284, 2, 3184, 4328, 1401, 8, 2930, 3364, 7638, 847, 8, 2, 1467, 14120, 353, 10, 2050, 616, 3, 1504, 532, 174, 521, 2, 284, 1, 2626, 22035, 32, 446]",582.0,16368505,25
Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.,The Laryngoscope,Laryngoscope,2005-12-01,"Vascular endothelial growth factor (VEGF) is an important mediator in tumor vascularization, growth, and metastasis. We investigated whether blockade of the VEGF receptor (VEGF-R) signaling pathway by the tyrosine kinase inhibitor PTK787 combined with CPT-11, a semisynthetic camptothecin analogue, can inhibit the tumor growth and angiogenesis of squamous cell carcinoma of the oral tongue in an orthotopic nude mouse model. JMAR human oral squamous cell carcinoma cells were injected into the tongues of nude mice. Seven days later, the mice were randomized to receive a placebo, daily oral PTK787, weekly CPT-11 injection, or PTK787 plus CPT-11. After 4 weeks of treatment, the mice underwent necropsy, and the tongue tumors, cervical lymph nodes, and lungs were removed for immunohistochemical analyses. CPT-11, PTK787, and PTK787 plus CPT-11 significantly decreased tumor volumes and prolonged survival. The combination treatment group had the most significant decrease in volume and increase in survival. PTK787 alone or in combination with CPT-11 reduced the phosphorylation of VEGF-R in tumor cells and tumor-associated endothelial cells, was associated with decreased microvessel density, a decreased proliferative index, and an increased apoptotic index. PTK787 alone or the combination therapy resulted in apoptosis of both tumor cells and tumor-associated endothelial cells. These results suggest that targeting VEGF-R tyrosine kinase activity can be an effective therapeutic approach in squamous cell carcinoma of the oral tongue.",Comparative Study,5164.0,17.0,Vascular endothelial growth factor VEGF is an important mediator in tumor vascularization growth and metastasis We investigated whether blockade of the VEGF receptor VEGF-R signaling pathway by the tyrosine kinase inhibitor PTK787 combined with CPT-11 a semisynthetic camptothecin analogue can inhibit the tumor growth and angiogenesis of squamous cell carcinoma of the oral tongue in an orthotopic nude mouse model JMAR human oral squamous cell carcinoma cells were injected into the tongues of nude mice Seven days later the mice were randomized to receive a placebo daily oral PTK787 weekly CPT-11 injection or PTK787 plus CPT-11 After 4 weeks of treatment the mice underwent necropsy and the tongue tumors lymph nodes and lungs were removed for immunohistochemical analyses CPT-11 PTK787 and PTK787 plus CPT-11 significantly decreased tumor volumes and prolonged survival The combination treatment group had the most significant decrease in volume and increase in survival PTK787 alone or in combination with CPT-11 reduced the phosphorylation of VEGF-R in tumor cells and tumor-associated endothelial cells was associated with decreased microvessel density a decreased proliferative index and an increased apoptotic index PTK787 alone or the combination therapy resulted in apoptosis of both tumor cells and tumor-associated endothelial cells These results suggest that targeting VEGF-R tyrosine kinase activity can be an effective therapeutic approach in squamous cell carcinoma of the oral tongue,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[756, 845, 129, 161, 618, 16, 35, 305, 3810, 4, 30, 13342, 129, 2, 278, 21, 565, 317, 1189, 1, 3, 618, 153, 618, 668, 314, 308, 20, 3, 564, 216, 230, 12751, 397, 5, 3361, 175, 8, 18185, 6968, 4696, 122, 1433, 3, 30, 129, 2, 1056, 1, 691, 31, 134, 1, 3, 518, 4391, 4, 35, 2157, 2598, 830, 202, 20314, 171, 518, 691, 31, 134, 37, 11, 2651, 237, 3, 23074, 1, 2598, 399, 648, 162, 1559, 3, 399, 11, 384, 6, 560, 8, 619, 391, 518, 12751, 709, 3361, 175, 1754, 15, 12751, 349, 3361, 175, 50, 39, 244, 1, 24, 3, 399, 208, 16256, 2, 3, 4391, 57, 263, 502, 2, 4465, 11, 2264, 9, 1382, 318, 3361, 175, 12751, 2, 12751, 349, 3361, 175, 97, 340, 30, 2225, 2, 1069, 25, 3, 150, 24, 87, 42, 3, 96, 93, 775, 4, 433, 2, 344, 4, 25, 12751, 279, 15, 4, 150, 5, 3361, 175, 405, 3, 982, 1, 618, 668, 4, 30, 37, 2, 30, 41, 845, 37, 10, 41, 5, 340, 4269, 1263, 8, 340, 2441, 558, 2, 35, 101, 1631, 558, 12751, 279, 15, 3, 150, 36, 627, 4, 351, 1, 110, 30, 37, 2, 30, 41, 845, 37, 46, 99, 309, 17, 529, 618, 668, 564, 216, 128, 122, 40, 35, 323, 189, 353, 4, 691, 31, 134, 1, 3, 518, 4391]",1503.0,16369175,126
Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiation.,"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",Mod. Pathol.,2006-05-01,"Lymphatic invasion and nodal metastasis are predictors of poor outcome in cervix carcinoma. We have recently found that low podoplanin immunoreactivity in cervix carcinoma correlated with the presence of lymphatic invasion and nodal metastasis. In the current study, we examined whether podoplanin expression in pretreatment cervical biopsies can predict the presence lymphatic invasion, nodal metastasis, and outcome in advanced-stage tumors treated by nonsurgical means. Podoplanin expression was analyzed by immunohistochemistry in 48 cervical biopsies and corresponding hysterectomy specimens of early-stage invasive squamous cell carcinoma and in 74 pretreatment biopsies from advanced-stage tumors treated with primary radiation. We found a highly significant correlation between podoplanin expression obtained in biopsy and corresponding hysterectomy materials (r = 0.8962, P < 0.0001). Low podoplanin expression showed a significant correlation with lymphatic invasion (P < 0.0001) and nodal metastasis (P = 0.0058). Low podoplanin expression in pretreatment biopsy material showed a significant correlation with poor disease-free (P = 0.0009) and overall (P = 0.0002) survival in advanced-stage tumors. Our results suggest that in advanced-stage cervix carcinomas treated by radiation, when traditional prognostic indicators are not available and treatment decisions are based on biopsy material and clinical staging parameters, examination of podoplanin expression in pretreatment biopsy material may be a useful marker to predict lymphatic metastasis and patient outcome. Prospective studies involving larger numbers of patients are needed to further evaluate the clinical utility of examination of podoplanin expression in patients with cervix carcinoma.",Journal Article,5013.0,60.0,Lymphatic invasion and nodal metastasis are predictors of poor outcome in cervix carcinoma We have recently found that low podoplanin immunoreactivity in cervix carcinoma correlated with the presence of lymphatic invasion and nodal metastasis In the current study we examined whether podoplanin expression in pretreatment biopsies can predict the presence lymphatic invasion nodal metastasis and outcome in advanced-stage tumors treated by nonsurgical means Podoplanin expression was analyzed by immunohistochemistry in 48 biopsies and corresponding hysterectomy specimens of early-stage invasive squamous cell carcinoma and in 74 pretreatment biopsies from advanced-stage tumors treated with primary radiation We found a highly significant correlation between podoplanin expression obtained in biopsy and corresponding hysterectomy materials r 0.8962 P 0.0001 Low podoplanin expression showed a significant correlation with lymphatic invasion P 0.0001 and nodal metastasis P 0.0058 Low podoplanin expression in pretreatment biopsy material showed a significant correlation with poor disease-free P 0.0009 and overall P 0.0002 survival in advanced-stage tumors Our results suggest that in advanced-stage cervix carcinomas treated by radiation when traditional prognostic indicators are not available and treatment decisions are based on biopsy material and clinical staging parameters examination of podoplanin expression in pretreatment biopsy material may be a useful marker to predict lymphatic metastasis and patient outcome Prospective studies involving larger numbers of patients are needed to further evaluate the clinical utility of examination of podoplanin expression in patients with cervix carcinoma,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2936, 578, 2, 779, 278, 32, 674, 1, 334, 228, 4, 3629, 134, 21, 47, 761, 204, 17, 154, 16036, 4900, 4, 3629, 134, 438, 5, 3, 463, 1, 2936, 578, 2, 779, 278, 4, 3, 291, 45, 21, 409, 317, 16036, 55, 4, 1194, 1154, 122, 678, 3, 463, 2936, 578, 779, 278, 2, 228, 4, 131, 82, 57, 73, 20, 5544, 2263, 16036, 55, 10, 311, 20, 888, 4, 576, 1154, 2, 1734, 2622, 623, 1, 191, 82, 416, 691, 31, 134, 2, 4, 794, 1194, 1154, 29, 131, 82, 57, 73, 5, 86, 121, 21, 204, 8, 561, 93, 816, 59, 16036, 55, 683, 4, 411, 2, 1734, 2622, 5102, 668, 13, 55333, 19, 13, 488, 154, 16036, 55, 224, 8, 93, 816, 5, 2936, 578, 19, 13, 488, 2, 779, 278, 19, 13, 21380, 154, 16036, 55, 4, 1194, 411, 3692, 224, 8, 93, 816, 5, 334, 34, 115, 19, 13, 7946, 2, 63, 19, 13, 3531, 25, 4, 131, 82, 57, 114, 99, 309, 17, 4, 131, 82, 3629, 826, 73, 20, 121, 198, 1847, 177, 3539, 32, 44, 390, 2, 24, 1526, 32, 90, 23, 411, 3692, 2, 38, 632, 1038, 1385, 1, 16036, 55, 4, 1194, 411, 3692, 68, 40, 8, 999, 952, 6, 678, 2936, 278, 2, 69, 228, 482, 94, 1267, 1077, 1870, 1, 7, 32, 575, 6, 195, 376, 3, 38, 1207, 1, 1385, 1, 16036, 55, 4, 7, 5, 3629, 134]",1711.0,16528371,340
Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus.,Journal of the National Cancer Institute,J. Natl. Cancer Inst.,2006-05-01,"Conditionally replicating adenoviruses (CRAds) can be engineered to replicate selectively in cancer cells and cause cancer-specific cell lysis; thus they are considered a promising cancer therapy. To elucidate the mechanisms by which CRAds induce cancer-specific cell death, we infected normal human fibroblasts (MRC5, telomerase negative), human malignant glioma (U373-MG and U87-MG), human cervical cancer (HeLa), and human prostate cancer (PC3) cells (all telomerase positive) with CRAds regulated by the human telomerase reverse transcriptase promoter (hTERT-Ad) or control nonreplicating adenoviruses (Ad-GFP). Nonapoptotic autophagy was assessed in Ad-GFP- and hTERT-Ad-infected cells by examining cell morphology, the development of acidic vesicular organelles, and the conversion of microtubule-associated protein 1 light chain 3 from the cytoplasmic form to the autophagosome membrane form; signaling via mammalian target of rapamycin (mTOR), an autophagy-associated molecule, was monitored by western blot analysis. We also compared the growth of subcutaneous gliomas in nude mice that were treated by intratumoral injection with Ad-GFP or hTERT-Ad. Survival of athymic mice carrying intracranial gliomas treated by intratumoral injection with Ad-GFP or hTERT-Ad was compared by using the Kaplan-Meier method and the Cox-Mantel log-rank analysis. All statistical tests were two-sided. hTERT-Ad induced tumor-specific autophagic cell death in tumor cells and in subcutaneous gliomas. hTERT-Ad-induced autophagy was associated with hTERT-Ad infection kinetics. The mTOR signaling pathway was suppressed in tumor cells and in subcutaneous gliomas treated with hTERT-Ad compared with GFP-Ad or no treatment as shown by reduced phosphorylation of mTOR's downstream target p70S6 kinase (p70S6K). hTERT-Ad treatment of mice (n = 7) slowed growth of subcutaneous gliomas (mean tumor volume = 39 mm3, 95% confidence interval [CI] = 23 to 54 mm3) compared with GFP-Ad treatment (n = 7) (mean tumor volume = 200 mm3, 95% CI = 149 to 251 mm3) at day 7 (volume difference = 161 mm3, 95% CI = 126 to 197 mm3; P < .001). Mice carrying intracranial tumors that were treated with three intratumoral injections of hTERT-Ad survived longer (53 days) than after treatment with GFP-Ad (29 days) (seven mice per group, difference = 24 days, 95% CI = 20 to 28 days; P < .001). hTERT-Ad may kill telomerase-positive cancer cells by inducing autophagic cell death.",Journal Article,5013.0,127.0,Conditionally replicating adenoviruses CRAds can be engineered to replicate selectively in cancer cells and cause cancer-specific cell lysis thus they are considered a promising cancer therapy To elucidate the mechanisms by which CRAds induce cancer-specific cell death we infected normal human fibroblasts MRC5 telomerase negative human malignant glioma U373-MG and U87-MG human cancer HeLa and human cancer PC3 cells all telomerase positive with CRAds regulated by the human telomerase reverse transcriptase promoter hTERT-Ad or control nonreplicating adenoviruses Ad-GFP Nonapoptotic autophagy was assessed in Ad-GFP- and hTERT-Ad-infected cells by examining cell morphology the development of acidic vesicular organelles and the conversion of microtubule-associated protein 1 light chain 3 from the cytoplasmic form to the autophagosome membrane form signaling via mammalian target of rapamycin mTOR an autophagy-associated molecule was monitored by western blot analysis We also compared the growth of subcutaneous gliomas in nude mice that were treated by intratumoral injection with Ad-GFP or hTERT-Ad Survival of athymic mice carrying intracranial gliomas treated by intratumoral injection with Ad-GFP or hTERT-Ad was compared by using the Kaplan-Meier method and the Cox-Mantel log-rank analysis All statistical tests were two-sided hTERT-Ad induced tumor-specific autophagic cell death in tumor cells and in subcutaneous gliomas hTERT-Ad-induced autophagy was associated with hTERT-Ad infection kinetics The mTOR signaling pathway was suppressed in tumor cells and in subcutaneous gliomas treated with hTERT-Ad compared with GFP-Ad or no treatment as shown by reduced phosphorylation of mTOR 's downstream target p70S6 kinase p70S6K hTERT-Ad treatment of mice n 7 slowed growth of subcutaneous gliomas mean tumor volume 39 mm3 95 confidence interval CI 23 to 54 mm3 compared with GFP-Ad treatment n 7 mean tumor volume 200 mm3 95 CI 149 to 251 mm3 at day 7 volume difference 161 mm3 95 CI 126 to 197 mm3 P .001 Mice carrying intracranial tumors that were treated with three intratumoral injections of hTERT-Ad survived longer 53 days than after treatment with GFP-Ad 29 days seven mice per group difference 24 days 95 CI 20 to 28 days P .001 hTERT-Ad may kill telomerase-positive cancer cells by inducing autophagic cell death,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12704, 13012, 9470, 28163, 122, 40, 2794, 6, 6423, 2382, 4, 12, 37, 2, 708, 12, 112, 31, 4783, 631, 491, 32, 515, 8, 721, 12, 36, 6, 3061, 3, 483, 20, 92, 28163, 1290, 12, 112, 31, 273, 21, 3369, 295, 171, 3921, 55459, 3916, 199, 171, 393, 945, 21240, 81, 2, 6500, 81, 171, 12, 8466, 2, 171, 12, 4505, 37, 62, 3916, 109, 5, 28163, 1065, 20, 3, 171, 3916, 1772, 4456, 973, 6431, 1985, 15, 182, 34084, 9470, 1985, 4687, 26195, 2240, 10, 275, 4, 1985, 4687, 2, 6431, 1985, 3369, 37, 20, 3282, 31, 2567, 3, 193, 1, 8961, 11117, 16758, 2, 3, 3111, 1, 4621, 41, 178, 14, 1691, 1260, 27, 29, 3, 2828, 1297, 6, 3, 21388, 1905, 1297, 314, 847, 2359, 283, 1, 1620, 873, 35, 2240, 41, 1354, 10, 2909, 20, 1521, 2639, 65, 21, 120, 72, 3, 129, 1, 2529, 1287, 4, 2598, 399, 17, 11, 73, 20, 2074, 1754, 5, 1985, 4687, 15, 6431, 1985, 25, 1, 6396, 399, 2934, 2089, 1287, 73, 20, 2074, 1754, 5, 1985, 4687, 15, 6431, 1985, 10, 72, 20, 75, 3, 876, 882, 596, 2, 3, 418, 11618, 1066, 1026, 65, 62, 1050, 895, 11, 100, 1689, 6431, 1985, 277, 30, 112, 8810, 31, 273, 4, 30, 37, 2, 4, 2529, 1287, 6431, 1985, 277, 2240, 10, 41, 5, 6431, 1985, 930, 3839, 3, 873, 314, 308, 10, 1908, 4, 30, 37, 2, 4, 2529, 1287, 73, 5, 6431, 1985, 72, 5, 4687, 1985, 15, 77, 24, 22, 443, 20, 405, 982, 1, 873, 292, 1489, 283, 19756, 216, 8066, 6431, 1985, 24, 1, 399, 78, 67, 10673, 129, 1, 2529, 1287, 313, 30, 433, 587, 8434, 48, 307, 268, 58, 382, 6, 667, 8434, 72, 5, 4687, 1985, 24, 78, 67, 313, 30, 433, 1250, 8434, 48, 58, 4928, 6, 7288, 8434, 28, 218, 67, 433, 523, 5377, 8434, 48, 58, 3927, 6, 6114, 8434, 19, 144, 399, 2934, 2089, 57, 17, 11, 73, 5, 169, 2074, 4344, 1, 6431, 1985, 2996, 589, 699, 162, 76, 50, 24, 5, 4687, 1985, 462, 162, 648, 399, 379, 87, 523, 259, 162, 48, 58, 179, 6, 339, 162, 19, 144, 6431, 1985, 68, 5097, 3916, 109, 12, 37, 20, 1958, 8810, 31, 273]",2336.0,16670388,605
Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer.,Nature clinical practice. Oncology,Nat Clin Pract Oncol,2006-05-01,"From 1999-2000, each of five randomized trials demonstrated improved rates of survival and local control when concurrent cisplatin-based chemotherapy was added to radiation therapy in patients with loco-regionally advanced cervical cancer. These studies demonstrated that addition of chemotherapy to radiation therapy improved the outcome of patients treated with radiation therapy and hysterectomy or radiation therapy alone. Although concurrent chemotherapy increases the severity of acute side effects, it does not appear to increase the risk of late side effects of radiation therapy. A sixth randomized trial, published in 2002, failed to demonstrate improved outcome with concurrent weekly cisplatin over radiation therapy alone; however, the earlier trials demonstrated benefit with this chemoradiation regimen. In addition, three of the earlier randomized trials demonstrated improved outcome with combinations of cisplatin and 5-fluorouracil compared with radiation therapy alone. Although cisplatin-based chemoradiation is the most accepted standard, individual trials have suggested that other drugs, including mitomycin and epirubicin, might be beneficial. Randomized trials that investigated the administration of neoadjuvant chemotherapy before radiation therapy have failed to demonstrate a benefit of this approach. Although the evidence for benefit of concurrent chemotherapy is strong for otherwise healthy patients with newly diagnosed, loco-regionally advanced cervical cancers confined to the pelvis, the relative benefits and risks are not well understood for patients who are infirm or who require larger fields of radiation therapy. In such patients, the theoretical benefits and potential risks should be considered carefully before a treatment plan is prescribed.",Journal Article,5013.0,55.0,From 1999-2000 each of five randomized trials demonstrated improved rates of survival and local control when concurrent cisplatin-based chemotherapy was added to radiation therapy in patients with loco-regionally advanced cancer These studies demonstrated that addition of chemotherapy to radiation therapy improved the outcome of patients treated with radiation therapy and hysterectomy or radiation therapy alone Although concurrent chemotherapy increases the severity of acute side effects it does not appear to increase the risk of late side effects of radiation therapy A sixth randomized trial published in 2002 failed to demonstrate improved outcome with concurrent weekly cisplatin over radiation therapy alone however the earlier trials demonstrated benefit with this chemoradiation regimen In addition three of the earlier randomized trials demonstrated improved outcome with combinations of cisplatin and 5-fluorouracil compared with radiation therapy alone Although cisplatin-based chemoradiation is the most accepted standard individual trials have suggested that other drugs including mitomycin and epirubicin might be beneficial Randomized trials that investigated the administration of neoadjuvant chemotherapy before radiation therapy have failed to demonstrate a benefit of this approach Although the evidence for benefit of concurrent chemotherapy is strong for otherwise healthy patients with newly diagnosed loco-regionally advanced cancers confined to the pelvis the relative benefits and risks are not well understood for patients who are infirm or who require larger fields of radiation therapy In such patients the theoretical benefits and potential risks should be considered carefully before a treatment plan is prescribed,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[29, 2043, 1081, 296, 1, 365, 384, 143, 264, 231, 151, 1, 25, 2, 293, 182, 198, 750, 540, 90, 56, 10, 1953, 6, 121, 36, 4, 7, 5, 7214, 8183, 131, 12, 46, 94, 264, 17, 352, 1, 56, 6, 121, 36, 231, 3, 228, 1, 7, 73, 5, 121, 36, 2, 2622, 15, 121, 36, 279, 242, 750, 56, 1106, 3, 1702, 1, 286, 1152, 176, 192, 1097, 44, 1322, 6, 344, 3, 43, 1, 807, 1152, 176, 1, 121, 36, 8, 7462, 384, 160, 983, 4, 1544, 1551, 6, 608, 231, 228, 5, 750, 709, 540, 252, 121, 36, 279, 137, 3, 1677, 143, 264, 247, 5, 26, 975, 477, 4, 352, 169, 1, 3, 1677, 384, 143, 264, 231, 228, 5, 1247, 1, 540, 2, 33, 1404, 72, 5, 121, 36, 279, 242, 540, 90, 975, 16, 3, 96, 3058, 260, 797, 143, 47, 1148, 17, 127, 600, 141, 5837, 2, 5363, 822, 40, 2524, 384, 143, 17, 565, 3, 634, 1, 536, 56, 348, 121, 36, 47, 1551, 6, 608, 8, 247, 1, 26, 353, 242, 3, 241, 9, 247, 1, 750, 56, 16, 1082, 9, 2632, 1331, 7, 5, 732, 265, 7214, 8183, 131, 163, 2902, 6, 3, 3270, 3, 580, 1141, 2, 1098, 32, 44, 149, 1784, 9, 7, 54, 32, 33644, 15, 54, 1353, 1077, 3130, 1, 121, 36, 4, 225, 7, 3, 7060, 1141, 2, 174, 1098, 257, 40, 515, 3900, 348, 8, 24, 2242, 16, 2746]",1749.0,16683003,40
Chemotherapy in the management of cervical carcinoma.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2006-04-01,"Cervical carcinoma, although largely preventable, is one of the most prevalent cancers worldwide. Early-stage disease can be successfully treated with surgery alone, and women with locally advanced cervical carcinoma are treated with radiation and concurrent weekly cisplatin at a dose of 40 mg/m2 for six doses. For women with advanced, persistent, or recurrent disease not amenable to local resection or radiation, however, few treatment options exist. In this subset of patients, palliative cytotoxic chemotherapy is playing an ever-increasing role. Only the combination of topotecan and cisplatin has been shown to prolong survival in this setting and although the benefit of combination therapy is modest, there has been no decrease in quality of life when this doublet is compared to single-agent cisplatin. Newer innovative agents are needed to treat metastatic and recurrent cervical cancer.",Comparative Study,5043.0,13.0,carcinoma although largely preventable is one of the most prevalent cancers worldwide Early-stage disease can be successfully treated with surgery alone and women with locally advanced carcinoma are treated with radiation and concurrent weekly cisplatin at a dose of 40 mg/m2 for six doses For women with advanced persistent or recurrent disease not amenable to local resection or radiation however few treatment options exist In this subset of patients palliative cytotoxic chemotherapy is playing an ever-increasing role Only the combination of topotecan and cisplatin has been shown to prolong survival in this setting and although the benefit of combination therapy is modest there has been no decrease in quality of life when this doublet is compared to single-agent cisplatin Newer innovative agents are needed to treat metastatic and recurrent cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[134, 242, 1733, 7936, 16, 104, 1, 3, 96, 2485, 163, 2358, 191, 82, 34, 122, 40, 1878, 73, 5, 152, 279, 2, 117, 5, 795, 131, 134, 32, 73, 5, 121, 2, 750, 709, 540, 28, 8, 61, 1, 327, 81, 821, 9, 437, 415, 9, 117, 5, 131, 1882, 15, 387, 34, 44, 4070, 6, 293, 170, 15, 121, 137, 1021, 24, 838, 1923, 4, 26, 697, 1, 7, 994, 759, 56, 16, 12068, 35, 3353, 602, 200, 158, 3, 150, 1, 2129, 2, 540, 71, 85, 443, 6, 3615, 25, 4, 26, 546, 2, 242, 3, 247, 1, 150, 36, 16, 1721, 125, 71, 85, 77, 775, 4, 372, 1, 358, 198, 26, 4872, 16, 72, 6, 226, 420, 540, 2246, 4019, 183, 32, 575, 6, 943, 113, 2, 387, 12]",857.0,16728939,341
Advanced cervical cancer treatment in Harris County: pilot evaluation of factors that prevent optimal therapy.,Gynecologic oncology,Gynecol. Oncol.,2006-05-30,"To document obstacles to completing outpatient treatment faced by indigent patients with cervical cancer and compare treatment costs. A retrospective pilot case series study assessed all indigent Harris County residents referred from Lyndon Baines Johnson Hospital (LBJ) to The University of Texas M. D. Anderson Cancer Center (M. D. Anderson) for advanced cervical cancer treatment between February 2001 and April 2004. Twenty-seven patients required hospital admission during the expected course of outpatient treatment and were identified as the study group. Nine patients, drawn from the same cohort but able to successfully complete the expected course of treatment as outpatients, were selected as the control group. The median total treatment costs per patient in the study group (n = 27) was 28,892 US dollar more than the median treatment costs for the patients in the control group (n = 9) (P = 0.01). Median number of inpatient days in the study group was 19.6. Social factors identified as significantly different between the study and control groups included transportation difficulties (P = 0.006) and lack of social support (P = 0.08). Additional factors identified in the study group may have social significance such as accessible local housing (11% vs. 0%, P = 0.56) and noncompliance with treatment (37% vs. 11%, P = 0.22). A combination of the lack of adequate methods of transportation and social support may contribute to the high cost of treating indigent patients with cervical cancer in Harris County, Texas.",Journal Article,4984.0,11.0,"To document obstacles to completing outpatient treatment faced by indigent patients with cancer and compare treatment costs A retrospective pilot case series study assessed all indigent Harris County residents referred from Lyndon Baines Johnson Hospital LBJ to The University of Texas M. D. Anderson Cancer Center M. D. Anderson for advanced cancer treatment between February 2001 and April 2004 Twenty-seven patients required hospital admission during the expected course of outpatient treatment and were identified as the study group Nine patients drawn from the same cohort but able to successfully complete the expected course of treatment as outpatients were selected as the control group The median total treatment costs per patient in the study group n 27 was 28,892 US dollar more than the median treatment costs for the patients in the control group n 9 P 0.01 Median number of inpatient days in the study group was 19.6 Social factors identified as significantly different between the study and control groups included transportation difficulties P 0.006 and lack of social support P 0.08 Additional factors identified in the study group may have social significance such as accessible local housing 11 vs. 0 P 0.56 and noncompliance with treatment 37 vs. 11 P 0.22 A combination of the lack of adequate methods of transportation and social support may contribute to the high cost of treating indigent patients with cancer in Harris County Texas",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 4753, 7140, 6, 4144, 2379, 24, 6933, 20, 17892, 7, 5, 12, 2, 932, 24, 1201, 8, 459, 2281, 473, 988, 45, 275, 62, 17892, 28079, 5152, 5662, 1995, 29, 55518, 55519, 18915, 702, 55520, 6, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 188, 427, 1929, 9, 131, 12, 24, 59, 3010, 1758, 2, 2292, 1131, 737, 648, 7, 616, 702, 3411, 190, 3, 1336, 906, 1, 2379, 24, 2, 11, 108, 22, 3, 45, 87, 762, 7, 5694, 29, 3, 827, 180, 84, 1665, 6, 1878, 236, 3, 1336, 906, 1, 24, 22, 5698, 11, 715, 22, 3, 182, 87, 3, 52, 181, 24, 1201, 379, 69, 4, 3, 45, 87, 78, 428, 10, 339, 15571, 843, 28541, 80, 76, 3, 52, 24, 1201, 9, 3, 7, 4, 3, 182, 87, 78, 83, 19, 13, 355, 52, 207, 1, 2420, 162, 4, 3, 45, 87, 10, 326, 49, 2032, 130, 108, 22, 97, 338, 59, 3, 45, 2, 182, 271, 159, 13964, 4679, 19, 13, 1861, 2, 926, 1, 2032, 538, 19, 13, 1592, 402, 130, 108, 4, 3, 45, 87, 68, 47, 2032, 724, 225, 22, 5981, 293, 19050, 175, 105, 13, 19, 13, 664, 2, 13494, 5, 24, 567, 105, 175, 19, 13, 350, 8, 150, 1, 3, 926, 1, 1658, 636, 1, 13964, 2, 2032, 538, 68, 1248, 6, 3, 64, 835, 1, 1367, 17892, 7, 5, 12, 4, 28079, 5152, 2738]",1456.0,16730784,825
Cystoscopic temporary ureteral catheterization during radical vaginal and abdominal trachelectomy.,Gynecologic oncology,Gynecol. Oncol.,2006-06-06,"To describe the role of temporary retrograde ureteral catheterization at the time of fertility-sparing radical vaginal or abdominal trachelectomy in women with early-stage cervical cancer. We analyzed a prospectively maintained database of all patients with cervical cancer who were explored for radical vaginal or abdominal trachelectomy at our institution. Cystourethroscopy and ureteral catheterization were performed prior to the vaginal or abdominal operation in all patients, except two pediatric ones. Temporary bilateral retrograde ureteral catheters were planned for all patients as part of our routine procedure to facilitate identification of the distal ureters. 5Fr whistle-tip or open-ended catheters were used and usually advanced to approximately 20 cm. Catheters were removed at the end of the operation in all cases. All catheters were inserted by a gynecologic oncology fellow or attending. Between 11/01 and 12/05, 40 patients were taken to the operating room for planned fertility-sparing radical vaginal or abdominal trachelectomy. We previously reported on two pediatric patients; they are excluded from this report. The median age for adult patients was 32 years (mean, 31.6; range, 23-40). International Federation of Gynecology and Obstetrics (FIGO) stage included IB1 (26), IA2 (6), and IA1 with lymphovascular invasion (6). Thirty-four patients underwent radical vaginal trachelectomy and four underwent a radical abdominal trachelectomy. Two (5%) of 38 patients required immediate completion radical hysterectomy due to extensive endocervical disease (one in the vaginal group and one in the abdominal group). Bilateral ureteral catheters were inserted successfully in 37 (97%) of 38 patients and facilitated identification of the distal ureter during the dissection. In one case, the right ureteral orifice could not be successfully catheterized, and the case was completed with unilateral catheterization. The estimated time to perform this part of the operation was approximately 15-20 min. Twenty-eight patients (74%) had 5Fr whistle-tip ureteral catheters inserted, and 10 had open-ended catheters inserted. There were no intraoperative complications. Median hospital stay was 3 days (range, 3-7). Hematuria, evident in the drainage bag attached to the Foley catheter, usually resolved in 24-48 h. Two (20%) of 10 patients who had open-ended catheters inserted developed a transient rise in postoperative creatinine (1.7 and 3.5 mg/dl, respectively) compared to 0/28 patients who had whistle-tip catheters placed (P<0.001). Both were attributed to postoperative distal ureteral edema, and only one patient required reinsertion of temporary ureteral stents. No patient developed long-term urinary complications or fistulae. Cystourethroscopy and bilateral retrograde ureteral catheterization by gynecologic oncologists is a simple and quick procedure that may facilitate identifying the distal ureter during radical vaginal or abdominal trachelectomy. We favor using 5Fr whistle-tip catheters as they may be associated with less ureteral mucosal trauma and subsequent postoperative edema. The skills needed for this procedure should be available to fellows in gynecologic oncology training.",Journal Article,4977.0,22.0,To describe the role of temporary retrograde ureteral catheterization at the time of fertility-sparing radical or abdominal trachelectomy in women with early-stage cancer We analyzed a prospectively maintained database of all patients with cancer who were explored for radical or abdominal trachelectomy at our institution Cystourethroscopy and ureteral catheterization were performed prior to the or abdominal operation in all patients except two pediatric ones Temporary bilateral retrograde ureteral catheters were planned for all patients as part of our routine procedure to facilitate identification of the distal ureters 5Fr whistle-tip or open-ended catheters were used and usually advanced to approximately 20 cm Catheters were removed at the end of the operation in all cases All catheters were inserted by a gynecologic oncology fellow or attending Between 11/01 and 12/05 40 patients were taken to the operating room for planned fertility-sparing radical or abdominal trachelectomy We previously reported on two pediatric patients they are excluded from this report The median age for adult patients was 32 years mean 31.6 range 23-40 International Federation of Gynecology and Obstetrics FIGO stage included IB1 26 IA2 6 and IA1 with lymphovascular invasion 6 Thirty-four patients underwent radical trachelectomy and four underwent a radical abdominal trachelectomy Two 5 of 38 patients required immediate completion radical hysterectomy due to extensive endocervical disease one in the group and one in the abdominal group Bilateral ureteral catheters were inserted successfully in 37 97 of 38 patients and facilitated identification of the distal ureter during the dissection In one case the right ureteral orifice could not be successfully catheterized and the case was completed with unilateral catheterization The estimated time to perform this part of the operation was approximately 15-20 min Twenty-eight patients 74 had 5Fr whistle-tip ureteral catheters inserted and 10 had open-ended catheters inserted There were no intraoperative complications Median hospital stay was 3 days range 3-7 Hematuria evident in the drainage bag attached to the Foley catheter usually resolved in 24-48 h. Two 20 of 10 patients who had open-ended catheters inserted developed a transient rise in postoperative creatinine 1.7 and 3.5 mg/dl respectively compared to 0/28 patients who had whistle-tip catheters placed P 0.001 Both were attributed to postoperative distal ureteral edema and only one patient required reinsertion of temporary ureteral stents No patient developed long-term urinary complications or fistulae Cystourethroscopy and bilateral retrograde ureteral catheterization by gynecologic oncologists is a simple and quick procedure that may facilitate identifying the distal ureter during radical or abdominal trachelectomy We favor using 5Fr whistle-tip catheters as they may be associated with less ureteral mucosal trauma and subsequent postoperative edema The skills needed for this procedure should be available to fellows in gynecologic oncology training,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 897, 3, 200, 1, 7579, 10583, 7213, 15173, 28, 3, 98, 1, 2954, 1851, 711, 15, 1467, 5760, 4, 117, 5, 191, 82, 12, 21, 311, 8, 1143, 1955, 609, 1, 62, 7, 5, 12, 54, 11, 1443, 9, 711, 15, 1467, 5760, 28, 114, 731, 34100, 2, 7213, 15173, 11, 173, 324, 6, 3, 15, 1467, 2589, 4, 62, 7, 2187, 100, 815, 6737, 7579, 1607, 10583, 7213, 6722, 11, 1465, 9, 62, 7, 22, 760, 1, 114, 1311, 1299, 6, 1876, 911, 1, 3, 2107, 17796, 38188, 34101, 9372, 15, 1020, 8909, 6722, 11, 95, 2, 2082, 131, 6, 705, 179, 494, 6722, 11, 2264, 28, 3, 396, 1, 3, 2589, 4, 62, 140, 62, 6722, 11, 9882, 20, 8, 1512, 413, 10526, 15, 6895, 59, 175, 355, 2, 133, 474, 327, 7, 11, 1633, 6, 3, 2584, 4698, 9, 1465, 2954, 1851, 711, 15, 1467, 5760, 21, 373, 210, 23, 100, 815, 7, 491, 32, 1800, 29, 26, 414, 3, 52, 89, 9, 780, 7, 10, 531, 60, 313, 456, 49, 184, 382, 327, 944, 7303, 1, 6429, 2, 7407, 3837, 82, 159, 8111, 432, 16725, 49, 2, 14517, 5, 2933, 578, 49, 977, 294, 7, 208, 711, 5760, 2, 294, 208, 8, 711, 1467, 5760, 100, 33, 1, 519, 7, 616, 2181, 1438, 711, 2622, 520, 6, 1344, 10174, 34, 104, 4, 3, 87, 2, 104, 4, 3, 1467, 87, 1607, 7213, 6722, 11, 9882, 1878, 4, 567, 1015, 1, 519, 7, 2, 4667, 911, 1, 3, 2107, 9775, 190, 3, 1161, 4, 104, 473, 3, 1913, 7213, 30954, 359, 44, 40, 1878, 55546, 2, 3, 473, 10, 781, 5, 3208, 15173, 3, 661, 98, 6, 2715, 26, 760, 1, 3, 2589, 10, 705, 167, 179, 1538, 737, 659, 7, 794, 42, 38188, 34101, 9372, 7213, 6722, 9882, 2, 79, 42, 1020, 8909, 6722, 9882, 125, 11, 77, 1720, 521, 52, 702, 2020, 10, 27, 162, 184, 27, 67, 7798, 2853, 4, 3, 3528, 15260, 10409, 6, 3, 26513, 3925, 2082, 3862, 4, 259, 576, 555, 100, 179, 1, 79, 7, 54, 42, 1020, 8909, 6722, 9882, 276, 8, 2473, 3693, 4, 573, 3177, 14, 67, 2, 27, 33, 81, 1826, 106, 72, 6, 13, 339, 7, 54, 42, 34101, 9372, 6722, 3295, 19, 13, 144, 110, 11, 3073, 6, 573, 2107, 7213, 3306, 2, 158, 104, 69, 616, 44376, 1, 7579, 7213, 9910, 77, 69, 276, 319, 337, 1660, 521, 15, 17809, 34100, 2, 1607, 10583, 7213, 15173, 20, 1512, 1339, 16, 8, 2763, 2, 14431, 1299, 17, 68, 1876, 1386, 3, 2107, 9775, 190, 711, 15, 1467, 5760, 21, 4283, 75, 38188, 34101, 9372, 6722, 22, 491, 68, 40, 41, 5, 299, 7213, 3068, 11147, 2, 706, 573, 3306, 3, 5909, 575, 9, 26, 1299, 257, 40, 390, 6, 7813, 4, 1512, 413, 1741]",3077.0,16753202,469
Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2006-06-06,"To identify dosimetric parameters associated with acute hematologic toxicity (HT) and chemotherapy delivery in cervical cancer patients undergoing concurrent chemotherapy and intensity-modulated pelvic radiotherapy. We analyzed 37 cervical cancer patients receiving concurrent cisplatin (40 mg/m(2)/wk) and intensity-modulated pelvic radiotherapy. Pelvic bone marrow (BM) was contoured for each patient and divided into three subsites: lumbosacral spine, ilium, and lower pelvis. The volume of each region receiving 10, 20, 30, and > or =40 Gy (V(10), V(20), V(30), and V(40), respectively) was calculated. HT was graded according to the Radiation Therapy Oncology Group system. Multivariate regression models were used to test associations between dosimetric parameters and HT and chemotherapy delivery. Increased pelvic BM V(10) (BM-V(10)) was associated with an increased Grade 2 or worse leukopenia and neutropenia (odds ratio [OR], 2.09; 95% confidence interval [CI], 1.24-3.53; p = 0.006; and OR, 1.41; 95% CI, 1.02-1.94; p = 0.037, respectively). Patients with BM-V(10) > or =90% had higher rates of Grade 2 or worse leukopenia and neutropenia than did patients with BM-V(10) <90% (11.1% vs. 73.7%, p < 0.01; and 5.6% vs. 31.6%, p = 0.09) and were more likely to have chemotherapy held on univariate (16.7% vs. 47.4%, p = 0.08) and multivariate (OR, 32.2; 95% CI, 1.67-622; p = 0.02) analysis. No associations between HT and V(30) and V(40) were observed. Dosimetric parameters involving the lumbosacral spine and lower pelvis had stronger associations with HT than did those involving the ilium. The volume of pelvic BM receiving low-dose radiation is associated with HT and chemotherapy delivery in cervical cancer patients undergoing concurrent chemoradiotherapy.",Journal Article,4977.0,179.0,To identify dosimetric parameters associated with acute hematologic toxicity HT and chemotherapy delivery in cancer patients undergoing concurrent chemotherapy and intensity-modulated pelvic radiotherapy We analyzed 37 cancer patients receiving concurrent cisplatin 40 mg/m 2 /wk and intensity-modulated pelvic radiotherapy Pelvic marrow BM was contoured for each patient and divided into three subsites lumbosacral spine ilium and lower pelvis The volume of each region receiving 10 20 30 and or =40 Gy V 10 V 20 V 30 and V 40 respectively was calculated HT was graded according to the Radiation Therapy Oncology Group system Multivariate regression models were used to test associations between dosimetric parameters and HT and chemotherapy delivery Increased pelvic BM V 10 BM-V 10 was associated with an increased Grade 2 or worse leukopenia and neutropenia odds ratio OR 2.09 95 confidence interval CI 1.24-3.53 p 0.006 and OR 1.41 95 CI 1.02-1.94 p 0.037 respectively Patients with BM-V 10 or =90 had higher rates of Grade 2 or worse leukopenia and neutropenia than did patients with BM-V 10 90 11.1 vs. 73.7 p 0.01 and 5.6 vs. 31.6 p 0.09 and were more likely to have chemotherapy held on univariate 16.7 vs. 47.4 p 0.08 and multivariate OR 32.2 95 CI 1.67-622 p 0.02 analysis No associations between HT and V 30 and V 40 were observed Dosimetric parameters involving the lumbosacral spine and lower pelvis had stronger associations with HT than did those involving the ilium The volume of pelvic BM receiving low-dose radiation is associated with HT and chemotherapy delivery in cancer patients undergoing concurrent chemoradiotherapy,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 255, 3187, 1038, 41, 5, 286, 813, 155, 3152, 2, 56, 989, 4, 12, 7, 479, 750, 56, 2, 837, 1757, 1110, 310, 21, 311, 567, 12, 7, 357, 750, 540, 327, 81, 188, 18, 3293, 2, 837, 1757, 1110, 310, 1110, 581, 1246, 10, 6476, 9, 296, 69, 2, 2176, 237, 169, 11239, 15598, 2342, 18295, 2, 280, 3270, 3, 433, 1, 296, 1053, 357, 79, 179, 201, 2, 15, 327, 381, 603, 79, 603, 179, 603, 201, 2, 603, 327, 106, 10, 981, 3152, 10, 3468, 768, 6, 3, 121, 36, 413, 87, 398, 331, 320, 274, 11, 95, 6, 412, 685, 59, 3187, 1038, 2, 3152, 2, 56, 989, 101, 1110, 1246, 603, 79, 1246, 603, 79, 10, 41, 5, 35, 101, 88, 18, 15, 639, 3904, 2, 778, 610, 197, 15, 18, 1730, 48, 307, 268, 58, 14, 259, 27, 699, 19, 13, 1861, 2, 15, 14, 605, 48, 58, 14, 588, 14, 960, 19, 13, 5171, 106, 7, 5, 1246, 603, 79, 15, 424, 42, 142, 151, 1, 88, 18, 15, 639, 3904, 2, 778, 76, 205, 7, 5, 1246, 603, 79, 424, 175, 14, 105, 803, 67, 19, 13, 355, 2, 33, 49, 105, 456, 49, 19, 13, 1730, 2, 11, 80, 322, 6, 47, 56, 4033, 23, 880, 245, 67, 105, 662, 39, 19, 13, 1592, 2, 331, 15, 531, 18, 48, 58, 14, 598, 11011, 19, 13, 588, 65, 77, 685, 59, 3152, 2, 603, 201, 2, 603, 327, 11, 164, 3187, 1038, 1267, 3, 15598, 2342, 2, 280, 3270, 42, 3355, 685, 5, 3152, 76, 205, 135, 1267, 3, 18295, 3, 433, 1, 1110, 1246, 357, 154, 61, 121, 16, 41, 5, 3152, 2, 56, 989, 4, 12, 7, 479, 750, 1464]",1642.0,16757127,816
Recognition of a cervical cancer derived tumor cell line by a human papillomavirus type 16 E6 52-61-specific CD8 T cell clone.,Cancer immunity,Cancer Immun.,2006-06-30,"The E6 and E7 proteins of high-risk human papillomavirus (HPV) types are thought to be the ideal sources of antigens for immunotherapy for cervical cancer since they are expressed by the tumors and not by normal cells. We recently described new HPV 16 epitopes, including the E6 52-61 peptide restricted by HLA class I molecule B57. Primary tumor cell lines were established from three HLA-B57 positive, HPV 16 positive cervical cancer patients, and their recognition by a E6 52-61 specific CD8+ T cell clone was determined using a chromium release assay and an IFN-gamma enzyme-linked immunospot (ELISPOT) assay. The recognition of homologous epitopes contained in other high-risk HPV types (18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, and 73) was also examined at the peptide level. A low level of killing of two of the tumor cell lines derived from the three patients was demonstrated using a chromium release assay. The level of killing of one of these tumor cell lines was enhanced upon treatment with IFN-gamma and/or the addition of antigen. This tumor cell line also induced measurable IFN-gamma secretion. The recognition of homologous epitopes from HPV 35, 39, 45, 51, and 73 was detected in an ELISPOT assay. Therefore, the HPV 16 E6 52-61 epitope appears to be at least weakly expressed by tumor cell lines derived from cervical cancer, and the HPV 16 E6 52-61-specific T cell clone can recognize homologous peptides derived from other high risk HPV sequences.",Journal Article,4953.0,12.0,The E6 and E7 proteins of high-risk human papillomavirus HPV types are thought to be the ideal sources of antigens for immunotherapy for cancer since they are expressed by the tumors and not by normal cells We recently described new HPV 16 epitopes including the E6 52-61 peptide restricted by HLA class I molecule B57 Primary tumor cell lines were established from three HLA-B57 positive HPV 16 positive cancer patients and their recognition by a E6 52-61 specific CD8+ T cell clone was determined using a chromium release assay and an IFN-gamma enzyme-linked immunospot ELISPOT assay The recognition of homologous epitopes contained in other high-risk HPV types 18 31 33 35 39 45 51 52 56 58 59 68 and 73 was also examined at the peptide level A low level of killing of two of the tumor cell lines derived from the three patients was demonstrated using a chromium release assay The level of killing of one of these tumor cell lines was enhanced upon treatment with IFN-gamma and/or the addition of antigen This tumor cell line also induced measurable IFN-gamma secretion The recognition of homologous epitopes from HPV 35 39 45 51 and 73 was detected in an ELISPOT assay Therefore the HPV 16 E6 52-61 epitope appears to be at least weakly expressed by tumor cell lines derived from cancer and the HPV 16 E6 52-61-specific T cell clone can recognize homologous peptides derived from other high risk HPV sequences,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 4837, 2, 4540, 652, 1, 64, 43, 171, 3242, 933, 630, 32, 2739, 6, 40, 3, 3662, 3375, 1, 1575, 9, 726, 9, 12, 1192, 491, 32, 570, 20, 3, 57, 2, 44, 20, 295, 37, 21, 761, 1027, 217, 933, 245, 4915, 141, 3, 4837, 653, 713, 1389, 2016, 20, 1160, 1040, 70, 1354, 44400, 86, 30, 31, 285, 11, 635, 29, 169, 1160, 44400, 109, 933, 245, 109, 12, 7, 2, 136, 2335, 20, 8, 4837, 653, 713, 112, 968, 102, 31, 3910, 10, 509, 75, 8, 22168, 2008, 719, 2, 35, 1256, 1705, 1644, 1199, 11244, 7662, 719, 3, 2335, 1, 3894, 4915, 3070, 4, 127, 64, 43, 933, 630, 203, 456, 466, 465, 587, 512, 725, 653, 664, 717, 728, 806, 2, 803, 10, 120, 409, 28, 3, 1389, 301, 8, 154, 301, 1, 3003, 1, 100, 1, 3, 30, 31, 285, 526, 29, 3, 169, 7, 10, 264, 75, 8, 22168, 2008, 719, 3, 301, 1, 3003, 1, 104, 1, 46, 30, 31, 285, 10, 651, 1548, 24, 5, 1256, 1705, 2, 15, 3, 352, 1, 448, 26, 30, 31, 328, 120, 277, 1884, 1256, 1705, 2935, 3, 2335, 1, 3894, 4915, 29, 933, 465, 587, 512, 725, 2, 803, 10, 530, 4, 35, 7662, 719, 673, 3, 933, 245, 4837, 653, 713, 4430, 1233, 6, 40, 28, 506, 7348, 570, 20, 30, 31, 285, 526, 29, 12, 2, 3, 933, 245, 4837, 653, 713, 112, 102, 31, 3910, 122, 4237, 3894, 2491, 526, 29, 127, 64, 43, 933, 2866]",1413.0,16808432,405
Chemoradiotherapy in the treatment of cervical cancer.,Seminars in radiation oncology,Semin Radiat Oncol,2006-07-01,"The advantage of concurrent chemoradiotherapy over radiotherapy alone in patients with cervical cancer has now been well documented in a series of prospective randomized trials. Six of these trials compared a cisplatin-based regimen (either cisplatin alone administered weekly or a combination of cisplatin and 5-fluorouracil) with radiotherapy alone or radiotherapy plus another, less effective chemotherapy; 5 of these 6 trials showed a benefit with concurrent chemotherapy. Individual trials have also suggested that epirubicin and the combination of mitomycin plus 5-fluorouracil are effective when administered concurrently with radiotherapy. Other drugs, particularly biologic response modifiers, are currently being studied for their potential benefit in combination with radiation and cisplatin. Although the side effects of chemoradiotherapy with weekly cisplatin or cisplatin plus 5-fluorouracil are tolerable for most patients, the addition of concurrent chemotherapy to radiotherapy markedly increases hematologic and gastrointestinal side effects and adds to the overall complexity of treatment. Successful management requires particularly close monitoring of hematologic parameters, fluid balance, electrolyte levels, dietary condition, and social support. Careful coordination between caregivers is crucial. Although early publication of some trials precluded mature analysis of late radiation effects, available data suggest that the addition of concurrent chemotherapy does not markedly increase the risk of major late complications. Most women with locoregionally advanced cervical cancers (stage IB2 or greater or positive pelvic lymph nodes) that are confined to the pelvis are candidates for chemoradiotherapy. However, the benefit of adding concurrent chemotherapy to radiotherapy should always be weighed against the risk of serious acute side effects, particularly in patients who have serious coexisting medical conditions that would have precluded or discouraged enrollment in the prospective trials.",Journal Article,4952.0,59.0,The advantage of concurrent chemoradiotherapy over radiotherapy alone in patients with cancer has now been well documented in a series of prospective randomized trials Six of these trials compared a cisplatin-based regimen either cisplatin alone administered weekly or a combination of cisplatin and 5-fluorouracil with radiotherapy alone or radiotherapy plus another less effective chemotherapy 5 of these 6 trials showed a benefit with concurrent chemotherapy Individual trials have also suggested that epirubicin and the combination of mitomycin plus 5-fluorouracil are effective when administered concurrently with radiotherapy Other drugs particularly biologic response modifiers are currently being studied for their potential benefit in combination with radiation and cisplatin Although the side effects of chemoradiotherapy with weekly cisplatin or cisplatin plus 5-fluorouracil are tolerable for most patients the addition of concurrent chemotherapy to radiotherapy markedly increases hematologic and side effects and adds to the overall complexity of treatment Successful management requires particularly close monitoring of hematologic parameters fluid balance electrolyte levels dietary condition and social support Careful coordination between caregivers is crucial Although early publication of some trials precluded mature analysis of late radiation effects available data suggest that the addition of concurrent chemotherapy does not markedly increase the risk of major late complications Most women with locoregionally advanced cancers stage IB2 or greater or positive pelvic lymph nodes that are confined to the pelvis are candidates for chemoradiotherapy However the benefit of adding concurrent chemotherapy to radiotherapy should always be weighed against the risk of serious acute side effects particularly in patients who have serious coexisting medical conditions that would have precluded or discouraged enrollment in the prospective trials,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1874, 1, 750, 1464, 252, 310, 279, 4, 7, 5, 12, 71, 1134, 85, 149, 1405, 4, 8, 988, 1, 482, 384, 143, 437, 1, 46, 143, 72, 8, 540, 90, 477, 361, 540, 279, 468, 709, 15, 8, 150, 1, 540, 2, 33, 1404, 5, 310, 279, 15, 310, 349, 1809, 299, 323, 56, 33, 1, 46, 49, 143, 224, 8, 247, 5, 750, 56, 797, 143, 47, 120, 1148, 17, 5363, 2, 3, 150, 1, 5837, 349, 33, 1404, 32, 323, 198, 468, 3294, 5, 310, 127, 600, 823, 1283, 51, 5663, 32, 694, 486, 656, 9, 136, 174, 247, 4, 150, 5, 121, 2, 540, 242, 3, 1152, 176, 1, 1464, 5, 709, 540, 15, 540, 349, 33, 1404, 32, 2668, 9, 96, 7, 3, 352, 1, 750, 56, 6, 310, 2195, 1106, 813, 2, 1152, 176, 2, 6659, 6, 3, 63, 3082, 1, 24, 1401, 284, 1706, 823, 2336, 1315, 1, 813, 1038, 2357, 3459, 10834, 148, 2013, 2850, 2, 2032, 538, 3465, 6373, 59, 2771, 16, 2653, 242, 191, 4397, 1, 476, 143, 8035, 2908, 65, 1, 807, 121, 176, 390, 74, 309, 17, 3, 352, 1, 750, 56, 1097, 44, 2195, 344, 3, 43, 1, 458, 807, 521, 96, 117, 5, 6410, 131, 163, 82, 9537, 15, 378, 15, 109, 1110, 263, 502, 17, 32, 2902, 6, 3, 3270, 32, 1931, 9, 1464, 137, 3, 247, 1, 2726, 750, 56, 6, 310, 257, 3763, 40, 10271, 480, 3, 43, 1, 1762, 286, 1152, 176, 823, 4, 7, 54, 47, 1762, 8859, 484, 1298, 17, 688, 47, 8035, 15, 17899, 1798, 4, 3, 482, 143]",1965.0,16814159,655
Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study.,Gynecologic oncology,Gynecol. Oncol.,2006-07-03,"To determine if smoking, a known risk factor for a number of cancers including cervical cancer, is associated with poor prognosis in patients with locally advanced cervical carcinoma treated with chemoradiation. Patients with primary, previously untreated, histologically confirmed stage II-B, III-B or IV-A cervical carcinoma participated in a Gynecologic Oncology Group (GOG) phase III study (GOG 165) and were randomly allocated to receive radiation plus either cisplatin or 5-fluorouracil. Smoking behavior was ascertained using an administered questionnaire and by quantifying urine cotinine concentration. Disease progression was defined as a >or=50% increase in the cross product of the existing tumor compared with previous assessments. Patients were followed until death. Of 328 enrolled patients, 12 were ineligible, one was inevaluable for reported smoking status and 40 others were inevaluable for cotinine-derived smoking status. Among evaluable patients, 133 (42%) were reported smokers and 111 (40%) were cotinine-derived smokers. The kappa for agreement between the groups was 0.872 (P<0.01). Compared with non-smokers, median survival was 15 months shorter for reported smokers and 20 months shorter for cotinine-derived smokers (P<0.01). After adjusting for covariates, a significant increase in the risk of death (but not disease progression) was observed for reported smokers (hazard ratio [HR]: 1.51; 95% confidence interval [CI]: 1.01-2.27; P=0.04) and cotinine-derived smokers (HR: 1.57; 95% CI: 1.03-2.38; P=0.04). Smoking predicts worse overall survival in women with locally advanced cervical carcinoma treated with chemoradiation.",Journal Article,4950.0,44.0,To determine if smoking a known risk factor for a number of cancers including cancer is associated with poor prognosis in patients with locally advanced carcinoma treated with chemoradiation Patients with primary previously untreated histologically confirmed stage II-B III-B or IV-A carcinoma participated in a Gynecologic Oncology Group GOG phase III study GOG 165 and were randomly allocated to receive radiation plus either cisplatin or 5-fluorouracil Smoking behavior was ascertained using an administered questionnaire and by quantifying urine cotinine concentration Disease progression was defined as a or=50 increase in the cross product of the existing tumor compared with previous assessments Patients were followed until death Of 328 enrolled patients 12 were ineligible one was inevaluable for reported smoking status and 40 others were inevaluable for cotinine-derived smoking status Among evaluable patients 133 42 were reported smokers and 111 40 were cotinine-derived smokers The kappa for agreement between the groups was 0.872 P 0.01 Compared with non-smokers median survival was 15 months shorter for reported smokers and 20 months shorter for cotinine-derived smokers P 0.01 After adjusting for covariates a significant increase in the risk of death but not disease progression was observed for reported smokers hazard ratio HR 1.51 95 confidence interval CI 1.01-2.27 P=0.04 and cotinine-derived smokers HR 1.57 95 CI 1.03-2.38 P=0.04 Smoking predicts worse overall survival in women with locally advanced carcinoma treated with chemoradiation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 492, 979, 8, 440, 43, 161, 9, 8, 207, 1, 163, 141, 12, 16, 41, 5, 334, 356, 4, 7, 5, 795, 131, 134, 73, 5, 975, 7, 5, 86, 373, 1278, 2161, 557, 82, 215, 132, 316, 132, 15, 478, 8, 134, 3025, 4, 8, 1512, 413, 87, 4760, 124, 316, 45, 4760, 4966, 2, 11, 1108, 6682, 6, 560, 121, 349, 361, 540, 15, 33, 1404, 979, 1710, 10, 5240, 75, 35, 468, 1770, 2, 20, 6602, 2646, 13147, 1227, 34, 91, 10, 395, 22, 8, 15, 212, 344, 4, 3, 1383, 2821, 1, 3, 1692, 30, 72, 5, 698, 2182, 7, 11, 370, 1100, 273, 1, 8584, 346, 7, 133, 11, 3773, 104, 10, 19617, 9, 210, 979, 156, 2, 327, 1749, 11, 19617, 9, 13147, 526, 979, 156, 107, 859, 7, 5026, 595, 11, 210, 1485, 2, 3167, 327, 11, 13147, 526, 1485, 3, 3096, 9, 2024, 59, 3, 271, 10, 13, 17900, 19, 13, 355, 72, 5, 220, 1485, 52, 25, 10, 167, 53, 985, 9, 210, 1485, 2, 179, 53, 985, 9, 13147, 526, 1485, 19, 13, 355, 50, 1358, 9, 2489, 8, 93, 344, 4, 3, 43, 1, 273, 84, 44, 34, 91, 10, 164, 9, 210, 1485, 360, 197, 168, 14, 725, 48, 307, 268, 58, 14, 355, 18, 428, 19, 13, 755, 2, 13147, 526, 1485, 168, 14, 696, 48, 58, 14, 680, 18, 519, 19, 13, 755, 979, 2623, 639, 63, 25, 4, 117, 5, 795, 131, 134, 73, 5, 975]",1564.0,16815535,64
Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature.,Gynecologic oncology,Gynecol. Oncol.,2006-07-11,"Radical trachelectomy has emerged as a reasonable fertility-sparing operation for selected patients with stage I cervical cancer. The purpose of this report is to describe our technique of radical abdominal trachelectomy, a fertility-sparing operation in women with cervical cancer, and review the current literature on this procedure. A review of a prospectively maintained database of all fertility-sparing radical trachelectomy procedures performed at our institution. Between 11/01 and 3/06, we performed a total of 42 fertility-preserving radical trachelectomies with pelvic lymphadenectomy for women with invasive cervical cancer. We had previously reported on 2 pediatric abdominal trachelectomies, which are excluded from this report. Five of the remaining 40 cases had undergone a radical abdominal trachelectomy, and 35 cases were performed laparoscopically with a radical vaginal approach. The characteristics of the 5 adult patients who underwent abdominal radical trachelectomy included stage IB1 disease in all cases, a mean age of 36 years (range, 33-39), and a mean estimated blood loss of 280 ml (range, 50-400); 1 patient with squamous cell carcinoma needed completion radical hysterectomy at the time of trachelectomy due to disease extending into the endometrium, and 1 patient needed postoperative chemoradiation due to a positive parametrial lymph node. The remaining 3 patients resumed normal menstruation postoperatively. All patients remain disease-free at the time of this report. The only remaining uterine blood supply in these patients are the utero-ovarian vessels. There were no postoperative complications, and transurethral Foley catheters were removed in all cases within 2 weeks. Radical abdominal trachelectomy with pelvic lymphadenectomy is a feasible operation for selected women with stage I cervical cancer who desire to preserve reproductive function. Menstruation and reproductive function may be preserved after bilateral uterine vessel ligation. The procedure expands the inclusion criteria of radical vaginal trachelectomy to patients with distorted cervicovaginal anatomy in which the vaginal approach may not be feasible.",Journal Article,4942.0,113.0,Radical trachelectomy has emerged as a reasonable fertility-sparing operation for selected patients with stage I cancer The purpose of this report is to describe our technique of radical abdominal trachelectomy a fertility-sparing operation in women with cancer and review the current literature on this procedure A review of a prospectively maintained database of all fertility-sparing radical trachelectomy procedures performed at our institution Between 11/01 and 3/06 we performed a total of 42 fertility-preserving radical trachelectomies with pelvic lymphadenectomy for women with invasive cancer We had previously reported on 2 pediatric abdominal trachelectomies which are excluded from this report Five of the remaining 40 cases had undergone a radical abdominal trachelectomy and 35 cases were performed laparoscopically with a radical approach The characteristics of the 5 adult patients who underwent abdominal radical trachelectomy included stage IB1 disease in all cases a mean age of 36 years range 33-39 and a mean estimated blood loss of 280 ml range 50-400 1 patient with squamous cell carcinoma needed completion radical hysterectomy at the time of trachelectomy due to disease extending into the and 1 patient needed postoperative chemoradiation due to a positive parametrial lymph node The remaining 3 patients resumed normal menstruation postoperatively All patients remain disease-free at the time of this report The only remaining blood supply in these patients are the utero-ovarian vessels There were no postoperative complications and transurethral Foley catheters were removed in all cases within 2 weeks Radical abdominal trachelectomy with pelvic lymphadenectomy is a feasible operation for selected women with stage I cancer who desire to preserve reproductive function Menstruation and reproductive function may be preserved after bilateral vessel ligation The procedure expands the inclusion criteria of radical trachelectomy to patients with distorted cervicovaginal anatomy in which the approach may not be feasible,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[711, 5760, 71, 2054, 22, 8, 3203, 2954, 1851, 2589, 9, 715, 7, 5, 82, 70, 12, 3, 743, 1, 26, 414, 16, 6, 897, 114, 1312, 1, 711, 1467, 5760, 8, 2954, 1851, 2589, 4, 117, 5, 12, 2, 206, 3, 291, 789, 23, 26, 1299, 8, 206, 1, 8, 1143, 1955, 609, 1, 62, 2954, 1851, 711, 5760, 1369, 173, 28, 114, 731, 59, 175, 355, 2, 27, 1460, 21, 173, 8, 181, 1, 595, 2954, 4972, 711, 38216, 5, 1110, 2048, 9, 117, 5, 416, 12, 21, 42, 373, 210, 23, 18, 815, 1467, 38216, 92, 32, 1800, 29, 26, 414, 365, 1, 3, 1844, 327, 140, 42, 1989, 8, 711, 1467, 5760, 2, 465, 140, 11, 173, 11472, 5, 8, 711, 353, 3, 374, 1, 3, 33, 780, 7, 54, 208, 1467, 711, 5760, 159, 82, 8111, 34, 4, 62, 140, 8, 313, 89, 1, 511, 60, 184, 466, 587, 2, 8, 313, 661, 315, 407, 1, 5775, 542, 184, 212, 1524, 14, 69, 5, 691, 31, 134, 575, 1438, 711, 2622, 28, 3, 98, 1, 5760, 520, 6, 34, 4782, 237, 3, 2, 14, 69, 575, 573, 975, 520, 6, 8, 109, 8726, 263, 289, 3, 1844, 27, 7, 11294, 295, 23264, 3541, 62, 7, 918, 34, 115, 28, 3, 98, 1, 26, 414, 3, 158, 1844, 315, 6296, 4, 46, 7, 32, 3, 13767, 6301, 3102, 125, 11, 77, 573, 521, 2, 5079, 26513, 6722, 11, 2264, 4, 62, 140, 262, 18, 244, 711, 1467, 5760, 5, 1110, 2048, 16, 8, 1313, 2589, 9, 715, 117, 5, 82, 70, 12, 54, 5278, 6, 6783, 3705, 343, 23264, 2, 3705, 343, 68, 40, 5797, 50, 1607, 3685, 5307, 3, 1299, 9365, 3, 1680, 371, 1, 711, 5760, 6, 7, 5, 23534, 43708, 5081, 4, 92, 3, 353, 68, 44, 40, 1313]",2050.0,16837027,379
[The application of stapling device in surgery of carcinoma of the esophagus and cardia].,Zhonghua yi xue za zhi,Zhonghua Yi Xue Za Zhi,2006-06-01,"To evaluate the application of circular stapler in upper digestive tract reconstruction. We present a retrospective review of 3322 patients with Carcinoma of esophagus and cardia undergoing a stapled esophagogastric anastomosis from August 1980 to September 2004. There were 2642 males and 680 females with age ranged from 28 to 83 years old. Carcinoma of esophagus was present in 2312 patients and carcinoma of gastric cardia in 1010 patients. The anastomosis was performed in the cervical region in 102 cases, thoracic apex in 147 cases, up aortic in 1838 cases and below aortic in 1235 cases. Anastomotic leakage occurred in 18 patients with an overall incidence of 0.54%, including thoracic leakage in 11 cases and cervical leakage in 7 cases. nine patients were dead because of the thoracic leakage, and the mortality of thoracic leakage was 81.8%. Benign anastomotic stricture was found in 66 patients with a rate of 2.0%, and instrumental failure occurred in 36 patients with a rate of 1.1%. Circular stapler can be used safely and reliably in upper digestive tract surgery, and the stapled anastomosis is an effective technique to reduce the incidence of anastomotic leakage.",English Abstract,4982.0,2.0,To evaluate the application of circular stapler in upper digestive tract reconstruction We present a retrospective review of 3322 patients with Carcinoma of and cardia undergoing a stapled esophagogastric anastomosis from August 1980 to September 2004 There were 2642 males and 680 females with age ranged from 28 to 83 years old Carcinoma of was present in 2312 patients and carcinoma of cardia in 1010 patients The anastomosis was performed in the region in 102 cases thoracic apex in 147 cases up aortic in 1838 cases and below aortic in 1235 cases Anastomotic leakage occurred in 18 patients with an overall incidence of 0.54 including thoracic leakage in 11 cases and leakage in 7 cases nine patients were dead because of the thoracic leakage and the mortality of thoracic leakage was 81.8 Benign anastomotic stricture was found in 66 patients with a rate of 2.0 and instrumental failure occurred in 36 patients with a rate of 1.1 Circular stapler can be used safely and reliably in upper digestive tract surgery and the stapled anastomosis is an effective technique to reduce the incidence of anastomotic leakage,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,"[6, 376, 3, 1581, 1, 12388, 17868, 4, 1726, 9117, 1696, 1470, 21, 364, 8, 459, 206, 1, 55639, 7, 5, 134, 1, 2, 9791, 479, 8, 9911, 6330, 5519, 29, 2480, 4376, 6, 2636, 1131, 125, 11, 44418, 2296, 2, 9297, 2451, 5, 89, 1869, 29, 339, 6, 852, 60, 1095, 134, 1, 10, 364, 4, 37499, 7, 2, 134, 1, 9791, 4, 44419, 7, 3, 5519, 10, 173, 4, 3, 1053, 4, 2867, 140, 2098, 8670, 4, 4961, 140, 126, 3938, 4, 55640, 140, 2, 2736, 3938, 4, 30739, 140, 4818, 9256, 489, 4, 203, 7, 5, 35, 63, 287, 1, 13, 667, 141, 2098, 9256, 4, 175, 140, 2, 9256, 4, 67, 140, 762, 7, 11, 8311, 408, 1, 3, 2098, 9256, 2, 3, 282, 1, 2098, 9256, 10, 865, 66, 1002, 4818, 6673, 10, 204, 4, 700, 7, 5, 8, 116, 1, 18, 13, 2, 8307, 496, 489, 4, 511, 7, 5, 8, 116, 1, 14, 14, 12388, 17868, 122, 40, 95, 2268, 2, 4092, 4, 1726, 9117, 1696, 152, 2, 3, 9911, 5519, 16, 35, 323, 1312, 6, 969, 3, 287, 1, 4818, 9256]",1118.0,16842694,741
Will widespread human papillomavirus prophylactic vaccination change sexual practices of adolescent and young adult women in America?,Obstetrics and gynecology,Obstet Gynecol,2006-08-01,"Two virus-like particle human papillomavirus (HPV) vaccines have been shown to be nearly 100% effective in preventing type-specific persistent HPV infections and associated type-specific high-grade cervical intraepithelial neoplasia (CIN). Recently, it has been hypothesized that the administration of this vaccine to young girls in the United States might increase sexual promiscuity among adolescent women and/or young adults. Thus, it has been suggested that focused vaccine strategies either based on the risk of CIN or gender might be more rational or cost-effective. However, such strategies are unlikely to completely eradicate the burden of this disease and decrease the cost of cervical cancer screening. The suggestion that widespread vaccination will alter sexual practices is refuted and the rationale for the vaccination of all girls and boys is outlined.",Journal Article,4921.0,35.0,Two virus-like particle human papillomavirus HPV vaccines have been shown to be nearly 100 effective in preventing type-specific persistent HPV infections and associated type-specific high-grade intraepithelial neoplasia CIN Recently it has been hypothesized that the administration of this vaccine to young girls in the United States might increase sexual promiscuity among adolescent women and/or young adults Thus it has been suggested that focused vaccine strategies either based on the risk of CIN or gender might be more rational or cost-effective However such strategies are unlikely to completely eradicate the burden of this disease and decrease the cost of cancer screening The suggestion that widespread vaccination will alter sexual practices is refuted and the rationale for the vaccination of all girls and boys is outlined,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[100, 1450, 733, 5997, 171, 3242, 933, 1842, 47, 85, 443, 6, 40, 1857, 394, 323, 4, 3017, 267, 112, 1882, 933, 1875, 2, 41, 267, 112, 64, 88, 4153, 2298, 4652, 761, 192, 71, 85, 1237, 17, 3, 634, 1, 26, 1274, 6, 1169, 5989, 4, 3, 1088, 907, 822, 344, 2232, 30464, 107, 3678, 117, 2, 15, 1169, 857, 631, 192, 71, 85, 1148, 17, 1649, 1274, 422, 361, 90, 23, 3, 43, 1, 4652, 15, 1632, 822, 40, 80, 2696, 15, 835, 323, 137, 225, 422, 32, 3568, 6, 2500, 5650, 3, 892, 1, 26, 34, 2, 775, 3, 835, 1, 12, 453, 3, 8634, 17, 3029, 1915, 303, 2688, 2232, 2634, 16, 44431, 2, 3, 1728, 9, 3, 1915, 1, 62, 5989, 2, 12958, 16, 6394]",837.0,16880314,383
Medullary thyroid cancer.,Surgical oncology clinics of North America,Surg. Oncol. Clin. N. Am.,2006-07-01,"The goal in managing patients who have MTC is to detect and surgically remove disease at an early stage. Tumor marker-based biochemical screening and DNA-based genetic screening have created the opportunity for effective prophylactic surgery in patients at risk for hereditary MTC. Complete surgical resection is critical for cure because cervical reoperation for persistent or recurrent disease benefits only select patients. With the advent of therapies that target the RET-activated pathways, new hope may be emerging for patients who have locally advanced or metastatic disease.",Journal Article,4952.0,33.0,The goal in managing patients who have MTC is to detect and surgically remove disease at an early stage Tumor marker-based biochemical screening and DNA-based genetic screening have created the opportunity for effective prophylactic surgery in patients at risk for hereditary MTC Complete surgical resection is critical for cure because reoperation for persistent or recurrent disease benefits only select patients With the advent of therapies that target the RET-activated pathways new hope may be emerging for patients who have locally advanced or metastatic disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1326, 4, 3969, 7, 54, 47, 3959, 16, 6, 1426, 2, 2350, 7930, 34, 28, 35, 191, 82, 30, 952, 90, 1487, 453, 2, 261, 90, 336, 453, 47, 2466, 3, 2666, 9, 323, 1862, 152, 4, 7, 28, 43, 9, 2305, 3959, 236, 221, 170, 16, 740, 9, 1722, 408, 5077, 9, 1882, 15, 387, 34, 1141, 158, 1717, 7, 5, 3, 4114, 1, 235, 17, 283, 3, 2412, 735, 460, 217, 3045, 68, 40, 1478, 9, 7, 54, 47, 795, 131, 15, 113, 34]",568.0,16882502,574
Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group.,Gynecologic oncology,Gynecol. Oncol.,2006-08-04,"To determine the maximum tolerated dose (MTD) of weekly paclitaxel and cisplatin chemotherapy concurrent with whole pelvic irradiation in women with locally advanced cervical cancer. Consenting patients with stage IB2, IIA, IIB, IIIB and IVA carcinoma of the cervix (all cell types) were eligible for this phase I/II trial. Chemotherapy agents were administered in escalating doses to cohorts of three patients at each dose level, pending evaluation of toxicities from the previous dose level. Thirty-five eligible women were enrolled on this study, of whom 13 comprised the phase I component. The MTD was determined to be cisplatin 40 mg/m2 and paclitaxel 40 mg/m2 administered weekly for six cycles with external beam radiation therapy. An additional 21 patients were enrolled in the phase II component at the previously determined MTD, yielding a total of 22 patients at the MTD, of whom 19 were evaluable. Among the evaluable patients treated at the MTD, two had grade 3 or 4 gastrointestinal (GI) toxicities (representing 5 of 113 cycles administered to this cohort) and seven experienced grade 3 or 4 neutrophil toxicity, none occurring prior to the fourth cycle. Thrombocytopenia was rare. Radiation therapy was successfully completed in 52% of patients at 8 weeks and in 79% of patients at 9 weeks, with a median of 59 days. Paclitaxel and cisplatin combination chemotherapy concurrent with whole pelvic irradiation can be safely administered at the described MTD.","Clinical Trial, Phase I",4918.0,30.0,To determine the maximum tolerated dose MTD of weekly paclitaxel and cisplatin chemotherapy concurrent with whole pelvic irradiation in women with locally advanced cancer Consenting patients with stage IB2 IIA IIB IIIB and IVA carcinoma of the cervix all cell types were eligible for this phase I/II trial Chemotherapy agents were administered in escalating doses to cohorts of three patients at each dose level pending evaluation of toxicities from the previous dose level Thirty-five eligible women were enrolled on this study of whom 13 comprised the phase I component The MTD was determined to be cisplatin 40 mg/m2 and paclitaxel 40 mg/m2 administered weekly for six cycles with external beam radiation therapy An additional 21 patients were enrolled in the phase II component at the previously determined MTD yielding a total of 22 patients at the MTD of whom 19 were evaluable Among the evaluable patients treated at the MTD two had grade 3 or 4 GI toxicities representing 5 of 113 cycles administered to this cohort and seven experienced grade 3 or 4 neutrophil toxicity none occurring prior to the fourth cycle Thrombocytopenia was rare Radiation therapy was successfully completed in 52 of patients at 8 weeks and in 79 of patients at 9 weeks with a median of 59 days Paclitaxel and cisplatin combination chemotherapy concurrent with whole pelvic irradiation can be safely administered at the described MTD,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 689, 421, 61, 961, 1, 709, 490, 2, 540, 56, 750, 5, 902, 1110, 1104, 4, 117, 5, 795, 131, 12, 11932, 7, 5, 82, 9537, 4088, 3884, 3036, 2, 5900, 134, 1, 3, 3629, 62, 31, 630, 11, 625, 9, 26, 124, 70, 215, 160, 56, 183, 11, 468, 4, 2922, 415, 6, 736, 1, 169, 7, 28, 296, 61, 301, 9453, 451, 1, 385, 29, 3, 698, 61, 301, 977, 365, 625, 117, 11, 346, 23, 26, 45, 1, 953, 233, 2603, 3, 124, 70, 1249, 3, 961, 10, 509, 6, 40, 540, 327, 81, 821, 2, 490, 327, 81, 821, 468, 709, 9, 437, 410, 5, 1455, 1345, 121, 36, 35, 402, 239, 7, 11, 346, 4, 3, 124, 215, 1249, 28, 3, 373, 509, 961, 4949, 8, 181, 1, 350, 7, 28, 3, 961, 1, 953, 326, 11, 859, 107, 3, 859, 7, 73, 28, 3, 961, 100, 42, 88, 27, 15, 39, 2104, 385, 2861, 33, 1, 4259, 410, 468, 6, 26, 180, 2, 648, 592, 88, 27, 15, 39, 2595, 155, 1292, 1821, 324, 6, 3, 3608, 417, 1340, 10, 622, 121, 36, 10, 1878, 781, 4, 653, 1, 7, 28, 66, 244, 2, 4, 842, 1, 7, 28, 83, 244, 5, 8, 52, 1, 728, 162, 490, 2, 540, 150, 56, 750, 5, 902, 1110, 1104, 122, 40, 2268, 468, 28, 3, 1027, 961]",1416.0,16889823,474
Adenovirus-mediated transfer of human papillomavirus 16 E6/E7 antisense RNA and induction of apoptosis in cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2006-09-05,"In most cervical cancers, human papillomaviruses (HPVs) are identified. The E6 and E7 genes of HPVs encode proteins, that interfere with the function of the tumor suppressor proteins p53 and Rb. We are exploring the potential use of antisense HPV RNA transcripts for gene therapy for HPV-positive cervical cancers. Via a recombinant adenoviral vector, Ad5CMV-HPV 16 AS, we introduced the antisense RNA transcripts of the E6 and E7 genes of HPV type 16 into human cervical cancer SiHa cells harboring HPV 16. We then analyzed the effects of expression of these genes on cell and tumor growth. HPV 16 E6/E7 antisense RNA was detected for 14 days in Ad5CMV-HPV 16 AS-infected cells. After infection, E6 and E7 protein expression was suppressed, and p53 and Rb protein expression increased. The Ad5CMV-HPV 16 AS-infected cells underwent apoptosis in vitro and in vivo. Cell growth and tumorigenicity were greatly suppressed. Ad5CMV-HPV 16 AS treatment significantly reduced the volumes of established subcutaneous tumors. Transfection of cervical cancer cells with HPV 16 E6/E7 antisense RNA in a form such as Ad5CMV-HPV 16 AS might be a potentially useful approach to the therapy of HPV 16-positive cervical cancer.",Journal Article,4886.0,19.0,In most cancers human papillomaviruses HPVs are identified The E6 and E7 genes of HPVs encode proteins that interfere with the function of the tumor suppressor proteins p53 and Rb We are exploring the potential use of antisense HPV RNA transcripts for gene therapy for HPV-positive cancers Via a recombinant adenoviral vector Ad5CMV-HPV 16 AS we introduced the antisense RNA transcripts of the E6 and E7 genes of HPV type 16 into human cancer SiHa cells harboring HPV 16 We then analyzed the effects of expression of these genes on cell and tumor growth HPV 16 E6/E7 antisense RNA was detected for 14 days in Ad5CMV-HPV 16 AS-infected cells After infection E6 and E7 protein expression was suppressed and p53 and Rb protein expression increased The Ad5CMV-HPV 16 AS-infected cells underwent apoptosis in vitro and in vivo Cell growth and tumorigenicity were greatly suppressed Ad5CMV-HPV 16 AS treatment significantly reduced the volumes of established subcutaneous tumors Transfection of cancer cells with HPV 16 E6/E7 antisense RNA in a form such as Ad5CMV-HPV 16 AS might be a potentially useful approach to the therapy of HPV 16-positive cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4, 96, 163, 171, 14731, 13477, 32, 108, 3, 4837, 2, 4540, 214, 1, 13477, 6924, 652, 17, 6178, 5, 3, 343, 1, 3, 30, 1245, 652, 624, 2, 2955, 21, 32, 4378, 3, 174, 119, 1, 4645, 933, 893, 2680, 9, 145, 36, 9, 933, 109, 163, 847, 8, 2835, 4771, 3374, 15873, 933, 245, 22, 21, 3955, 3, 4645, 893, 2680, 1, 3, 4837, 2, 4540, 214, 1, 933, 267, 245, 237, 171, 12, 19043, 37, 2105, 933, 245, 21, 818, 311, 3, 176, 1, 55, 1, 46, 214, 23, 31, 2, 30, 129, 933, 245, 4837, 4540, 4645, 893, 10, 530, 9, 213, 162, 4, 15873, 933, 245, 22, 3369, 37, 50, 930, 4837, 2, 4540, 178, 55, 10, 1908, 2, 624, 2, 2955, 178, 55, 101, 3, 15873, 933, 245, 22, 3369, 37, 208, 351, 4, 439, 2, 4, 386, 31, 129, 2, 5538, 11, 3510, 1908, 15873, 933, 245, 22, 24, 97, 405, 3, 2225, 1, 635, 2529, 57, 3789, 1, 12, 37, 5, 933, 245, 4837, 4540, 4645, 893, 4, 8, 1297, 225, 22, 15873, 933, 245, 22, 822, 40, 8, 751, 999, 353, 6, 3, 36, 1, 933, 245, 109, 12]",1148.0,16908054,140
Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model.,Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2006-09-07,"Head and neck squamous cell carcinoma (HNSCC) is a leading cause of cancer mortality worldwide. Recent reports have associated a subset of HNSCC with high-risk human papillomaviruses (HPVs), particularly HPV16, the same subset of HPVs responsible for the majority of cervical and anogenital cancers. In this study we describe a mouse model for HPV-associated HNSCC that employs mice transgenic for the HPV16 oncogenes E6 and E7. In these mice, E6 and E7 induce aberrant epithelial proliferation and, in the presence of a chemical carcinogen, they increase dramatically the animal's susceptibility to HNSCC. The cancers arising in the HPV16-transgenic mice mirror the molecular and histopathological characteristics of human HPV-positive HNSCC that distinguish the latter from human HPV-negative HNSCC, including overexpression of p16 protein and formation of more basaloid cancers. This validated model of HPV-associated HNSCC provides the means to define the contributions of individual HPV oncogenes to HNSCC and to understand the molecular basis for the differing clinical properties of HPV-positive and HPV-negative human HNSCC. From this study, we identify minichromosome maintenance protein 7 (MCM7) and p16 as potentially useful biomarkers for HPV-positive head and neck cancer.",Journal Article,4884.0,98.0,Head and squamous cell carcinoma HNSCC is a leading cause of cancer mortality worldwide Recent reports have associated a subset of HNSCC with high-risk human papillomaviruses HPVs particularly HPV16 the same subset of HPVs responsible for the majority of and anogenital cancers In this study we describe a mouse model for HPV-associated HNSCC that employs mice transgenic for the HPV16 oncogenes E6 and E7 In these mice E6 and E7 induce aberrant epithelial proliferation and in the presence of a chemical carcinogen they increase dramatically the animal 's susceptibility to HNSCC The cancers arising in the HPV16-transgenic mice mirror the molecular and histopathological characteristics of human HPV-positive HNSCC that distinguish the latter from human HPV-negative HNSCC including overexpression of p16 protein and formation of more basaloid cancers This validated model of HPV-associated HNSCC provides the means to define the contributions of individual HPV oncogenes to HNSCC and to understand the molecular basis for the differing clinical properties of HPV-positive and HPV-negative human HNSCC From this study we identify minichromosome maintenance protein 7 MCM7 and p16 as potentially useful biomarkers for HPV-positive head and cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[718, 2, 691, 31, 134, 1209, 16, 8, 1049, 708, 1, 12, 282, 2358, 435, 1198, 47, 41, 8, 697, 1, 1209, 5, 64, 43, 171, 14731, 13477, 823, 4048, 3, 827, 697, 1, 13477, 2327, 9, 3, 686, 1, 2, 13836, 163, 4, 26, 45, 21, 897, 8, 830, 202, 9, 933, 41, 1209, 17, 15151, 399, 2862, 9, 3, 4048, 3326, 4837, 2, 4540, 4, 46, 399, 4837, 2, 4540, 1290, 1898, 701, 457, 2, 4, 3, 463, 1, 8, 3743, 7290, 491, 344, 2729, 3, 2026, 292, 1432, 6, 1209, 3, 163, 2635, 4, 3, 4048, 2862, 399, 15930, 3, 219, 2, 4370, 374, 1, 171, 933, 109, 1209, 17, 3081, 3, 3286, 29, 171, 933, 199, 1209, 141, 851, 1, 1932, 178, 2, 1264, 1, 80, 17247, 163, 26, 938, 202, 1, 933, 41, 1209, 777, 3, 2263, 6, 1107, 3, 5621, 1, 797, 933, 3326, 6, 1209, 2, 6, 1640, 3, 219, 877, 9, 3, 5276, 38, 1571, 1, 933, 109, 2, 933, 199, 171, 1209, 29, 26, 45, 21, 255, 44473, 1146, 178, 67, 55751, 2, 1932, 22, 751, 999, 582, 9, 933, 109, 718, 2, 12]",1247.0,16959885,155
Breaking down barriers to breast and cervical cancer screening: a university-based prevention program for Latinas.,Journal of health care for the poor and underserved,J Health Care Poor Underserved,2006-08-01,"The lower rate of utilization of mammography and cervical cancer screening observed for Latinas in the United States has been attributed to cultural, economic, and linguistic barriers they may encounter. A screening program was implemented offering cancer prevention education plus breast and cervical cancer screening to Latinas, as well as all necessary follow-up care, at no cost to the participant. In the first 6 years of this project, a total of 928 screening visits occurred; 53% were participants who had returned at least once for additional annual screening. Ninety-one percent of participants preferred speaking in Spanish to their health care providers; however, only 2% identified a primary care provider and 5% stated they had health care insurance. The participant characteristics and results of initial evaluation, as well as necessary follow-up studies, are presented. By removing economic concerns and by providing care and education through bilingual staff in a culturally sensitive environment, some of the barriers to cancer screening for Latinas were overcome. The success of the program is reflected by a high rate of return for additional annual screening by our participants.",Journal Article,4921.0,16.0,The lower rate of utilization of mammography and cancer screening observed for Latinas in the United States has been attributed to cultural economic and linguistic barriers they may encounter A screening program was implemented offering cancer prevention education plus and cancer screening to Latinas as well as all necessary follow-up care at no cost to the participant In the first 6 years of this project a total of 928 screening visits occurred 53 were participants who had returned at least once for additional annual screening Ninety-one percent of participants preferred speaking in Spanish to their health care providers however only 2 identified a primary care provider and 5 stated they had health care insurance The participant characteristics and results of initial evaluation as well as necessary follow-up studies are presented By removing economic concerns and by providing care and education through bilingual staff in a culturally sensitive environment some of the barriers to cancer screening for Latinas were overcome The success of the program is reflected by a high rate of return for additional annual screening by our participants,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 280, 116, 1, 1961, 1, 2446, 2, 12, 453, 164, 9, 10862, 4, 3, 1088, 907, 71, 85, 3073, 6, 8587, 3875, 2, 28586, 2160, 491, 68, 8650, 8, 453, 1243, 10, 3426, 5846, 12, 1070, 1848, 349, 2, 12, 453, 6, 10862, 22, 149, 22, 62, 1493, 166, 126, 165, 28, 77, 835, 6, 3, 5705, 4, 3, 157, 49, 60, 1, 26, 3105, 8, 181, 1, 15684, 453, 2690, 489, 699, 11, 776, 54, 42, 5157, 28, 506, 1059, 9, 402, 2114, 453, 2493, 104, 714, 1, 776, 2514, 8519, 4, 8733, 6, 136, 341, 165, 1994, 137, 158, 18, 108, 8, 86, 165, 3094, 2, 33, 8245, 491, 42, 341, 165, 1935, 3, 5705, 374, 2, 99, 1, 388, 451, 22, 149, 22, 1493, 166, 126, 94, 32, 917, 20, 9026, 3875, 2061, 2, 20, 1736, 165, 2, 1848, 298, 31003, 5898, 4, 8, 15185, 745, 3087, 476, 1, 3, 2160, 6, 12, 453, 9, 10862, 11, 1768, 3, 1825, 1, 3, 1243, 16, 4686, 20, 8, 64, 116, 1, 4656, 9, 402, 2114, 453, 20, 114, 776]",1154.0,16960319,530
KSHV/HHV8-associated primary cutaneous plasmablastic lymphoma in a patient with Castleman's disease and Kaposi's sarcoma.,Journal of cutaneous pathology,J. Cutan. Pathol.,2006-09-01,"We report a unique case of Kaposi's sarcoma (KS)-associated herpesvirus (KSHV)/human herpesvirus (HHV)8-associated lymphoma in a 56-year-old man with a history of acquired immune deficiency syndrome, Castleman's disease, KS, and idiopathic thrombocytopenic purpura. Three months following the diagnosis of KS affecting a left cervical lymph node and Castleman's disease with bone marrow involvement, he presented with a subcutaneous, tender lesion on his left arm. A skin biopsy demonstrated a superficial and deep, interstitial-nodular infiltrate of severely atypical lymphoid cells showing plasmacytoid features, numerous mitotic figures, and frequent individual apoptotic tumor cells. The morphologic features were those of plasmablastic lymphoma (PBL). Immunohistochemical study showed that the lymphoma cells strongly expressed CD45, CD30, and KSHV/HHV8 latency-associated nuclear antigen. KSHV/HHV8 was also detected in the biopsy sections of the patient's KS and Castleman's disease. Epstein-Barr virus in situ hybridization was diffusely positive. In situ hybridization demonstrated kappa-light chain restriction. Although KSHV/HHV8 has been individually associated with KS, Castleman's disease, and PBL, this appears to be the first reported case in which all three entities were present simultaneously in one person, suggesting a critical role of KSHV/HHV8 as a common denominator in the pathogenesis of these diseases.",Case Reports,4890.0,22.0,We report a unique case of Kaposi 's KS -associated herpesvirus KSHV /human herpesvirus HHV 8-associated in a 56-year-old man with a history of acquired immune deficiency syndrome Castleman 's disease KS and idiopathic thrombocytopenic purpura Three months following the diagnosis of KS affecting a left lymph node and Castleman 's disease with marrow involvement he presented with a subcutaneous tender lesion on his left arm A biopsy demonstrated a superficial and deep interstitial-nodular infiltrate of severely atypical lymphoid cells showing plasmacytoid features numerous mitotic figures and frequent individual apoptotic tumor cells The morphologic features were those of plasmablastic PBL Immunohistochemical study showed that the cells strongly expressed CD45 CD30 and KSHV/HHV8 latency-associated nuclear antigen KSHV/HHV8 was also detected in the biopsy sections of the patient 's KS and Castleman 's disease Epstein-Barr virus in situ hybridization was diffusely positive In situ hybridization demonstrated kappa-light chain restriction Although KSHV/HHV8 has been individually associated with KS Castleman 's disease and PBL this appears to be the first reported case in which all three entities were present simultaneously in one person suggesting a critical role of KSHV/HHV8 as a common denominator in the pathogenesis of these diseases,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,"[21, 414, 8, 991, 473, 1, 7574, 292, 5433, 41, 9329, 6863, 171, 9329, 11075, 66, 41, 4, 8, 664, 111, 1095, 3628, 5, 8, 532, 1, 1294, 250, 2299, 681, 11971, 292, 34, 5433, 2, 7540, 11908, 14174, 169, 53, 366, 3, 147, 1, 5433, 2319, 8, 1712, 263, 289, 2, 11971, 292, 34, 5, 581, 799, 3174, 917, 5, 8, 2529, 26533, 1180, 23, 3224, 1712, 475, 8, 411, 264, 8, 3562, 2, 2369, 4543, 4481, 5172, 1, 7207, 1973, 2303, 37, 2069, 7978, 404, 2331, 2346, 9446, 2, 908, 797, 1631, 30, 37, 3, 2815, 404, 11, 135, 1, 14433, 6172, 1382, 45, 224, 17, 3, 37, 1327, 570, 5280, 4541, 2, 6863, 15225, 5301, 41, 928, 448, 6863, 15225, 10, 120, 530, 4, 3, 411, 3013, 1, 3, 69, 292, 5433, 2, 11971, 292, 34, 5212, 5190, 1450, 4, 957, 1554, 10, 9333, 109, 4, 957, 1554, 264, 3096, 1691, 1260, 4575, 242, 6863, 15225, 71, 85, 4257, 41, 5, 5433, 11971, 292, 34, 2, 6172, 26, 1233, 6, 40, 3, 157, 210, 473, 4, 92, 62, 169, 4613, 11, 364, 3074, 4, 104, 2719, 802, 8, 740, 200, 1, 6863, 15225, 22, 8, 186, 26534, 4, 3, 1384, 1, 46, 1342]",1353.0,16972955,5
Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer.,World journal of gastroenterology,World J. Gastroenterol.,2006-09-01,"To evaluate the dosimetry, efficacy and toxicity of intensity-modulated radiation therapy (IMRT) and concurrent chemotherapy for patients with locally advanced cervical and upper thoracic esophageal cancer. A retrospective study was performed on 7 patients who were definitively treated with IMRT and concurrent chemotherapy. Patients who did not receive IMRT radiation and concurrent chemotherapy were not included in this analysis. IMRT plans were evaluated to assess the tumor coverage and normal tissue avoidance. Treatment response was evaluated and toxicities were assessed. Five- to nine-beam IMRT were used to deliver a total dose of 59.4-66 Gy (median: 64.8 Gy) to the primary tumor with 6-MV photons. The minimum dose received by the planning tumor volume (PTV) of the gross tumor volume boost was 91.2%-98.2% of the prescription dose (standard deviation [SD]: 3.7%-5.7%). The minimum dose received by the PTV of the clinical tumor volume was 93.8%-104.8% (SD: 4.3%-11.1%) of the prescribed dose. With a median follow-up of 15 mo (range: 3-21 mo), all 6 evaluable patients achieved complete response. Of them, 2 developed local recurrences and 2 had distant metastases, 3 survived with no evidence of disease. After treatment, 2 patients developed esophageal stricture requiring frequent dilation and 1 patient developed tracheal-esophageal fistula. Concurrent IMRT and chemotherapy resulted in an excellent early response in patients with locally advanced cervical and upper thoracic esophageal cancer. However, local and distant recurrence and toxicity remain to be a problem. Innovative approaches are needed to improve the outcome.",Journal Article,4890.0,37.0,To evaluate the dosimetry efficacy and toxicity of intensity-modulated radiation therapy IMRT and concurrent chemotherapy for patients with locally advanced and upper thoracic cancer A retrospective study was performed on 7 patients who were definitively treated with IMRT and concurrent chemotherapy Patients who did not receive IMRT radiation and concurrent chemotherapy were not included in this analysis IMRT plans were evaluated to assess the tumor coverage and normal tissue avoidance Treatment response was evaluated and toxicities were assessed Five- to nine-beam IMRT were used to deliver a total dose of 59.4-66 Gy median 64.8 Gy to the primary tumor with 6-MV photons The minimum dose received by the planning tumor volume PTV of the gross tumor volume boost was 91.2 -98.2 of the prescription dose standard deviation SD 3.7 -5.7 The minimum dose received by the PTV of the clinical tumor volume was 93.8 -104.8 SD 4.3 -11.1 of the prescribed dose With a median follow-up of 15 mo range 3-21 mo all 6 evaluable patients achieved complete response Of them 2 developed local recurrences and 2 had distant metastases 3 survived with no evidence of disease After treatment 2 patients developed stricture requiring frequent dilation and 1 patient developed tracheal-esophageal fistula Concurrent IMRT and chemotherapy resulted in an excellent early response in patients with locally advanced and upper thoracic cancer However local and distant recurrence and toxicity remain to be a problem Innovative approaches are needed to improve the outcome,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[6, 376, 3, 4113, 209, 2, 155, 1, 837, 1757, 121, 36, 964, 2, 750, 56, 9, 7, 5, 795, 131, 2, 1726, 2098, 12, 8, 459, 45, 10, 173, 23, 67, 7, 54, 11, 6008, 73, 5, 964, 2, 750, 56, 7, 54, 205, 44, 560, 964, 121, 2, 750, 56, 11, 44, 159, 4, 26, 65, 964, 1853, 11, 194, 6, 423, 3, 30, 2139, 2, 295, 246, 5863, 24, 51, 10, 194, 2, 385, 11, 275, 365, 6, 762, 1345, 964, 11, 95, 6, 3392, 8, 181, 61, 1, 728, 39, 700, 381, 52, 660, 66, 381, 6, 3, 86, 30, 5, 49, 3491, 7862, 3, 2499, 61, 103, 20, 3, 1349, 30, 433, 3303, 1, 3, 1789, 30, 433, 2569, 10, 970, 18, 1096, 18, 1, 3, 3584, 61, 260, 3348, 1270, 27, 67, 33, 67, 3, 2499, 61, 103, 20, 3, 3303, 1, 3, 38, 30, 433, 10, 966, 66, 3407, 66, 1270, 39, 27, 175, 14, 1, 3, 2746, 61, 5, 8, 52, 166, 126, 1, 167, 2035, 184, 27, 239, 2035, 62, 49, 859, 7, 513, 236, 51, 1, 1370, 18, 276, 293, 1593, 2, 18, 42, 626, 196, 27, 2996, 5, 77, 241, 1, 34, 50, 24, 18, 7, 276, 6673, 1888, 908, 8062, 2, 14, 69, 276, 12898, 12183, 4920, 750, 964, 2, 56, 627, 4, 35, 1503, 191, 51, 4, 7, 5, 795, 131, 2, 1726, 2098, 12, 137, 293, 2, 626, 146, 2, 155, 918, 6, 40, 8, 2497, 4019, 611, 32, 575, 6, 401, 3, 228]",1552.0,17006988,364
Intraoperative localization of lymph node metastases with a replication-competent herpes simplex virus.,The Journal of thoracic and cardiovascular surgery,J. Thorac. Cardiovasc. Surg.,2006-11-01,"Lymph node status is the most important prognostic factor determining recurrence and survival in patients with mesothelioma and other thoracic malignancies. Accurate localization of lymph node metastases is therefore necessary to improve selection of resectable and curable patients for surgical intervention. This study investigates the potential to identify lymph node metastases intraoperatively by using herpes-guided cancer cell-specific expression of green fluorescent protein. After infection with NV1066, a herpes simplex virus carrying green fluorescent protein transgene, human mesothelioma cancer cell lines were assessed for cancer cell-specific infection, green fluorescent protein expression, viral replication, and cytotoxicity. Murine models of lymphatic metastasis were established by means of surgical implantation of cancer cells into the preauricular (drainage to cervical lymph nodes) and pleural (mediastinal and retroperitoneal lymph nodes) spaces of athymic mice. Fluorescent thoracoscopy, laparoscopy, and stereomicroscopy were used to localize lymph node metastases that were confirmed by means of immunohistochemistry. In vitro NV1066 infected, replicated (5- to 17,000-fold), and expressed green fluorescent protein in all cancer cells, even when infected at a low ratio of one viral plaque-forming unit per 100 tumor cells. In vivo NV1066 injected into primary tumors was able to locate and infect lymph node metastases producing green fluorescent protein that was visualized by means of fluorescent imaging. Histology confirmed lymphatic metastases, and immunohistochemistry confirmed viral presence in regions that expressed green fluorescent protein. Herpes virus-guided cancer cell-specific production of green fluorescent protein can facilitate accurate localization of lymph node metastases. Fluorescent filters that detect green fluorescent protein can be incorporated into operative scopes to precisely localize and biopsy lymph node metastases.",Journal Article,4829.0,29.0,"Lymph node status is the most important prognostic factor determining recurrence and survival in patients with and other thoracic malignancies Accurate localization of lymph node metastases is therefore necessary to improve selection of resectable and curable patients for surgical intervention This study investigates the potential to identify lymph node metastases intraoperatively by using herpes-guided cancer cell-specific expression of green fluorescent protein After infection with NV1066 a herpes simplex virus carrying green fluorescent protein transgene human cancer cell lines were assessed for cancer cell-specific infection green fluorescent protein expression viral replication and cytotoxicity Murine models of lymphatic metastasis were established by means of surgical implantation of cancer cells into the preauricular drainage to lymph nodes and pleural mediastinal and retroperitoneal lymph nodes spaces of athymic mice Fluorescent thoracoscopy laparoscopy and stereomicroscopy were used to localize lymph node metastases that were confirmed by means of immunohistochemistry In vitro NV1066 infected replicated 5- to 17,000-fold and expressed green fluorescent protein in all cancer cells even when infected at a low ratio of one viral plaque-forming unit per 100 tumor cells In vivo NV1066 injected into primary tumors was able to locate and infect lymph node metastases producing green fluorescent protein that was visualized by means of fluorescent imaging Histology confirmed lymphatic metastases and immunohistochemistry confirmed viral presence in regions that expressed green fluorescent protein Herpes virus-guided cancer cell-specific production of green fluorescent protein can facilitate accurate localization of lymph node metastases Fluorescent filters that detect green fluorescent protein can be incorporated into operative scopes to precisely localize and biopsy lymph node metastases",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[263, 289, 156, 16, 3, 96, 305, 177, 161, 2196, 146, 2, 25, 4, 7, 5, 2, 127, 2098, 441, 1481, 2145, 1, 263, 289, 196, 16, 673, 1493, 6, 401, 881, 1, 1899, 2, 4151, 7, 9, 221, 788, 26, 45, 7259, 3, 174, 6, 255, 263, 289, 196, 6595, 20, 75, 4716, 1808, 12, 31, 112, 55, 1, 4658, 2910, 178, 50, 930, 5, 7748, 8, 4716, 7241, 1450, 2934, 4658, 2910, 178, 6632, 171, 12, 31, 285, 11, 275, 9, 12, 31, 112, 930, 4658, 2910, 178, 55, 1667, 2079, 2, 1408, 1471, 274, 1, 2936, 278, 11, 635, 20, 2263, 1, 221, 4314, 1, 12, 37, 237, 3, 34010, 3528, 6, 263, 502, 2, 2164, 2626, 2, 2591, 263, 502, 11757, 1, 6396, 399, 2910, 15153, 3553, 2, 55833, 11, 95, 6, 8031, 263, 289, 196, 17, 11, 557, 20, 2263, 1, 888, 4, 439, 7748, 3369, 6714, 33, 6, 269, 984, 1116, 2, 570, 4658, 2910, 178, 4, 62, 12, 37, 871, 198, 3369, 28, 8, 154, 197, 1, 104, 1667, 8506, 4525, 2712, 379, 394, 30, 37, 4, 386, 7748, 2651, 237, 86, 57, 10, 1665, 6, 15124, 2, 13510, 263, 289, 196, 3787, 4658, 2910, 178, 17, 10, 6326, 20, 2263, 1, 2910, 270, 784, 557, 2936, 196, 2, 888, 557, 1667, 463, 4, 1374, 17, 570, 4658, 2910, 178, 4716, 1450, 1808, 12, 31, 112, 1529, 1, 4658, 2910, 178, 122, 1876, 1481, 2145, 1, 263, 289, 196, 2910, 10788, 17, 1426, 4658, 2910, 178, 122, 40, 2449, 237, 1208, 55834, 6, 7428, 8031, 2, 411, 263, 289, 196]",1919.0,17059941,679
Primary lymphomas of the cervix and uterus: the University of Pennsylvania's experience and a review of the literature.,Leukemia & lymphoma,Leuk. Lymphoma,2006-09-01,"Primary lymphomas of the cervix and uterus are rare with approximately 150 cases reported in the world literature to date. Appropriate diagnosis is often delayed until the post-operative setting as clinical and radiographic presentations are non-specific. Several sub-types of lymphoma arising primarily in the cervix or uterus have been reported with diffuse large B-Cell lymphoma (DLBCL) being the most frequent. Due to the low incidence of this disease, no randomized clinical trials exist to help guide treatment. This study reports the experience of four patients with primary lymphomas of the uterus and cervix that reflect the heterogeneity of cases reported in the literature to date. The patients had a mean age at diagnosis of 46 (range 35 - 56) and presented with abnormal uterine bleeding. One patient was diagnosed by total abdominal hysterectomy (TAH), two patients were diagnosed by cervical biopsy and one patient was diagnosed by endometrial biopsy. Three patients had DLBCL and one patient had marginal zone lymphoma (MZL). All patients had stage IIE disease. Of the patients with DLBCL, one received chemotherapy followed by TAH and two received TAH followed by chemotherapy. Two of these three patients remain disease-free post-initial therapy with the third now disease-free post-salvage therapy and autologous stem cell transplant. The patient with MZL was treated with TAH alone and remains disease-free. Based on the case series and a review of available literature, primary lymphomas of the uterus or cervix are rare and require an individualized approach to treatment. In general, patients with limited stage disease should be treated with localized and systemic therapy to optimize chances of cure.",Case Reports,4890.0,39.0,Primary lymphomas of the cervix and are rare with approximately 150 cases reported in the world literature to date Appropriate diagnosis is often delayed until the post-operative setting as clinical and radiographic presentations are non-specific Several sub-types of arising primarily in the cervix or have been reported with diffuse large B-Cell DLBCL being the most frequent Due to the low incidence of this disease no randomized clinical trials exist to help guide treatment This study reports the experience of four patients with primary lymphomas of the and cervix that reflect the heterogeneity of cases reported in the literature to date The patients had a mean age at diagnosis of 46 range 35 56 and presented with abnormal bleeding One patient was diagnosed by total abdominal hysterectomy TAH two patients were diagnosed by biopsy and one patient was diagnosed by biopsy Three patients had DLBCL and one patient had marginal zone MZL All patients had stage IIE disease Of the patients with DLBCL one received chemotherapy followed by TAH and two received TAH followed by chemotherapy Two of these three patients remain disease-free post-initial therapy with the third now disease-free post-salvage therapy and autologous stem cell transplant The patient with MZL was treated with TAH alone and remains disease-free Based on the case series and a review of available literature primary lymphomas of the or cervix are rare and require an individualized approach to treatment In general patients with limited stage disease should be treated with localized and systemic therapy to optimize chances of cure,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[86, 1557, 1, 3, 3629, 2, 32, 622, 5, 705, 1577, 140, 210, 4, 3, 1956, 789, 6, 1244, 870, 147, 16, 629, 1612, 1100, 3, 539, 1208, 546, 22, 38, 2, 1580, 4261, 32, 220, 112, 392, 551, 630, 1, 2635, 1561, 4, 3, 3629, 15, 47, 85, 210, 5, 1388, 375, 132, 31, 1446, 486, 3, 96, 908, 520, 6, 3, 154, 287, 1, 26, 34, 77, 384, 38, 143, 1923, 6, 987, 1597, 24, 26, 45, 1198, 3, 730, 1, 294, 7, 5, 86, 1557, 1, 3, 2, 3629, 17, 2694, 3, 1144, 1, 140, 210, 4, 3, 789, 6, 1244, 3, 7, 42, 8, 313, 89, 28, 147, 1, 641, 184, 465, 664, 2, 917, 5, 1668, 2294, 104, 69, 10, 265, 20, 181, 1467, 2622, 16704, 100, 7, 11, 265, 20, 411, 2, 104, 69, 10, 265, 20, 411, 169, 7, 42, 1446, 2, 104, 69, 42, 3450, 3614, 8277, 62, 7, 42, 82, 26399, 34, 1, 3, 7, 5, 1446, 104, 103, 56, 370, 20, 16704, 2, 100, 103, 16704, 370, 20, 56, 100, 1, 46, 169, 7, 918, 34, 115, 539, 388, 36, 5, 3, 1282, 1134, 34, 115, 539, 992, 36, 2, 1028, 452, 31, 941, 3, 69, 5, 8277, 10, 73, 5, 16704, 279, 2, 469, 34, 115, 90, 23, 3, 473, 988, 2, 8, 206, 1, 390, 789, 86, 1557, 1, 3, 15, 3629, 32, 622, 2, 1353, 35, 2596, 353, 6, 24, 4, 1083, 7, 5, 383, 82, 34, 257, 40, 73, 5, 909, 2, 403, 36, 6, 2465, 10726, 1, 1722]",1612.0,17065003,778
A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2006-11-02,"To determine treatment-related acute toxicity rates in patients with locally advanced cervical cancer treated by oral celecoxib, i.v. cisplatin and 5-FU, and concurrent pelvic radiation therapy. Eligible patients on this RTOG Phase I-II study for advanced cervix cancer included FIGO Stage IIB-IVA or patients with FIGO Stage IB through IIA with biopsy proven pelvic node metastases or tumor size > or =5 cm. Patients were treated with pelvic radiotherapy and brachytherapy. Celecoxib was prescribed at 400 mg twice daily beginning on day 1 for 1 year. Cisplatin (75 mg/m2) and 5-FU (1g/m2 for 4 days) were administered every 3 weeks times 3. The primary end point of the study was treatment related toxicity. Between August 2001 and March 2004, 84 patients were accrued to the study and 77 patients were evaluable for toxicity. Regarding the primary end point, toxicities were observed in the following areas: blood/bone marrow (16), gastrointestinal (14), pain (7), renal/genitourinary (6), cardiovascular (3), hemorrhage (1), and neurologic (1). For the first 75 evaluable patients, a toxicity failure was identified in 36 patients for a rate of 48%. Celecoxib at 400 mg twice daily together with concurrent cisplatin and 5-FU and pelvic radiotherapy has a high incidence of acute toxicities. The most frequent toxicities were hematologic. Albeit, the toxicity was deemed excessive in this trial, the rate of toxicities was not too different compared to other recent experiences with concurrent chemoradiation for advanced cervix cancer.","Clinical Trial, Phase II",4828.0,34.0,To determine treatment-related acute toxicity rates in patients with locally advanced cancer treated by oral celecoxib i.v cisplatin and 5-FU and concurrent pelvic radiation therapy Eligible patients on this RTOG Phase I-II study for advanced cervix cancer included FIGO Stage IIB-IVA or patients with FIGO Stage IB through IIA with biopsy proven pelvic node metastases or tumor size or =5 cm Patients were treated with pelvic radiotherapy and brachytherapy Celecoxib was prescribed at 400 mg twice daily beginning on day 1 for 1 year Cisplatin 75 mg/m2 and 5-FU 1g/m2 for 4 days were administered every 3 weeks times 3 The primary end point of the study was treatment related toxicity Between August 2001 and March 2004 84 patients were accrued to the study and 77 patients were evaluable for toxicity Regarding the primary end point toxicities were observed in the following areas blood/bone marrow 16 14 pain 7 renal/genitourinary 6 cardiovascular 3 hemorrhage 1 and neurologic 1 For the first 75 evaluable patients a toxicity failure was identified in 36 patients for a rate of 48 Celecoxib at 400 mg twice daily together with concurrent cisplatin and 5-FU and pelvic radiotherapy has a high incidence of acute toxicities The most frequent toxicities were hematologic Albeit the toxicity was deemed excessive in this trial the rate of toxicities was not too different compared to other recent experiences with concurrent chemoradiation for advanced cervix cancer,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 24, 139, 286, 155, 151, 4, 7, 5, 795, 131, 12, 73, 20, 518, 2673, 70, 603, 540, 2, 33, 1296, 2, 750, 1110, 121, 36, 625, 7, 23, 26, 3931, 124, 70, 215, 45, 9, 131, 3629, 12, 159, 3837, 82, 3884, 5900, 15, 7, 5, 3837, 82, 3180, 298, 4088, 5, 411, 1930, 1110, 289, 196, 15, 30, 444, 15, 33, 494, 7, 11, 73, 5, 1110, 310, 2, 1536, 2673, 10, 2746, 28, 1524, 81, 936, 391, 2948, 23, 218, 14, 9, 14, 111, 540, 481, 81, 821, 2, 33, 1296, 18420, 821, 9, 39, 162, 11, 468, 454, 27, 244, 1072, 27, 3, 86, 396, 741, 1, 3, 45, 10, 24, 139, 155, 59, 2480, 1758, 2, 2363, 1131, 874, 7, 11, 3198, 6, 3, 45, 2, 849, 7, 11, 859, 9, 155, 666, 3, 86, 396, 741, 385, 11, 164, 4, 3, 366, 1361, 315, 3417, 581, 245, 213, 559, 67, 6117, 4109, 49, 2179, 27, 3599, 14, 2, 2543, 14, 9, 3, 157, 481, 859, 7, 8, 155, 496, 10, 108, 4, 511, 7, 9, 8, 116, 1, 576, 2673, 28, 1524, 81, 936, 391, 1162, 5, 750, 540, 2, 33, 1296, 2, 1110, 310, 71, 8, 64, 287, 1, 286, 385, 3, 96, 908, 385, 11, 813, 5993, 3, 155, 10, 3779, 4529, 4, 26, 160, 3, 116, 1, 385, 10, 44, 5044, 338, 72, 6, 127, 435, 4031, 5, 750, 975, 9, 131, 3629, 12]",1466.0,17084549,83
Recent advances in human papillomavirus vaccines.,Current oncology reports,Curr Oncol Rep,2006-11-01,"The human papillomavirus (HPV) is one of the most common sexually transmitted infections and the etiologic agent of cervical dysplasia and cancer. Recent research on the safety and efficacy of prophylactic vaccines against HPV has shown promising results with nearly 100% efficacy in preventing persistent infections and cervical dysplasia. Several approaches are being tested in therapeutic vaccine clinical trials whereby E6, E7, or both agents are administered in live viral vectors, as proteins, or in nucleic acid form. Cell-based therapeutic vaccines are also being tested. HPV vaccines have the potential to eradicate a major cancer and source of morbidity around the world.",Journal Article,4829.0,5.0,The human papillomavirus HPV is one of the most common sexually transmitted infections and the etiologic agent of dysplasia and cancer Recent research on the safety and efficacy of prophylactic vaccines against HPV has shown promising results with nearly 100 efficacy in preventing persistent infections and dysplasia Several approaches are being tested in therapeutic vaccine clinical trials whereby E6 E7 or both agents are administered in live viral vectors as proteins or in nucleic acid form Cell-based therapeutic vaccines are also being tested HPV vaccines have the potential to eradicate a major cancer and source of morbidity around the world,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 171, 3242, 933, 16, 104, 1, 3, 96, 186, 13588, 12959, 1875, 2, 3, 6604, 420, 1, 2253, 2, 12, 435, 389, 23, 3, 367, 2, 209, 1, 1862, 1842, 480, 933, 71, 443, 721, 99, 5, 1857, 394, 209, 4, 3017, 1882, 1875, 2, 2253, 392, 611, 32, 486, 650, 4, 189, 1274, 38, 143, 6131, 4837, 4540, 15, 110, 183, 32, 468, 4, 3812, 1667, 5453, 22, 652, 15, 4, 7895, 971, 1297, 31, 90, 189, 1842, 32, 120, 486, 650, 933, 1842, 47, 3, 174, 6, 5650, 8, 458, 12, 2, 2353, 1, 787, 3337, 3, 1956]",651.0,17091565,28
Survival and toxicity differences between 5-day and weekly cisplatin in patients with locally advanced cervical cancer.,Cancer,Cancer,2007-01-01,"Cisplatin (CDDP) administration concomitant with radiotherapy (RT) for the treatment of locally advanced cervical cancer has evolved from an inpatient 5-day every 21-day regimen to a weekly outpatient regimen. This study was designed to test for differences in progression-free survival (PFS) and toxicity between the 2 regimens. In all, 77 consecutive patients at a single institution with stage IB2-IV cervical cancer were included in this analysis (using the International Federation of Gynecologists and Obstetricians staging system). All patients were treated with CDDP, external beam RT, and 2 9-Gy high-dose-rate brachytherapy treatments. Two cohorts were compared: 1) 5-day, patients treated from 1995 to 2001 with CDDP 20 mg/m(2) x 5 days every 21 days concomitant with RT; 2) weekly, treated after May 2001 with CDDP 40 mg/m(2) weekly concomitant with RT. In all, 50 patients were treated with the 5-day regimen and 27 patients with the weekly regimen. There were no significant demographic differences between the groups. Overall 3-year PFS, controlling for stage, was 90% and 76% for 5-day and weekly groups, respectively (P = .01). Adjusting for stage, age, and completion of treatment, the risk of treatment failure among the weekly group was 3.46 times higher than the 5-day group (P = .02). The weekly group had a 3.43 times higher risk of developing acute toxicities than the 5-day group (P = .02) in advanced-stage patients. Patients who received weekly CDDP have a shorter 3-year PFS. Patients with advanced-stage cervical cancer who received weekly CDDP had significantly more acute toxicities. These data should be confirmed in a multi-institutional, randomized, controlled study.",Journal Article,4768.0,19.0,Cisplatin CDDP administration concomitant with radiotherapy RT for the treatment of locally advanced cancer has evolved from an inpatient 5-day every 21-day regimen to a weekly outpatient regimen This study was designed to test for differences in progression-free survival PFS and toxicity between the 2 regimens In all 77 consecutive patients at a single institution with stage IB2-IV cancer were included in this analysis using the International Federation of Gynecologists and Obstetricians staging system All patients were treated with CDDP external beam RT and 2 9-Gy high-dose-rate brachytherapy treatments Two cohorts were compared 1 5-day patients treated from 1995 to 2001 with CDDP 20 mg/m 2 x 5 days every 21 days concomitant with RT 2 weekly treated after May 2001 with CDDP 40 mg/m 2 weekly concomitant with RT In all 50 patients were treated with the 5-day regimen and 27 patients with the weekly regimen There were no significant demographic differences between the groups Overall 3-year PFS controlling for stage was 90 and 76 for 5-day and weekly groups respectively P .01 Adjusting for stage age and completion of treatment the risk of treatment failure among the weekly group was 3.46 times higher than the 5-day group P .02 The weekly group had a 3.43 times higher risk of developing acute toxicities than the 5-day group P .02 in advanced-stage patients Patients who received weekly CDDP have a shorter 3-year PFS Patients with advanced-stage cancer who received weekly CDDP had significantly more acute toxicities These data should be confirmed in a multi-institutional randomized controlled study,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[540, 5820, 634, 1781, 5, 310, 240, 9, 3, 24, 1, 795, 131, 12, 71, 3937, 29, 35, 2420, 33, 218, 454, 239, 218, 477, 6, 8, 709, 2379, 477, 26, 45, 10, 1114, 6, 412, 9, 362, 4, 91, 115, 25, 300, 2, 155, 59, 3, 18, 472, 4, 62, 849, 935, 7, 28, 8, 226, 731, 5, 82, 9537, 478, 12, 11, 159, 4, 26, 65, 75, 3, 944, 7303, 1, 14854, 2, 21015, 632, 398, 62, 7, 11, 73, 5, 5820, 1455, 1345, 240, 2, 18, 83, 381, 64, 61, 116, 1536, 640, 100, 736, 11, 72, 14, 33, 218, 7, 73, 29, 2323, 6, 1758, 5, 5820, 179, 81, 188, 18, 1006, 33, 162, 454, 239, 162, 1781, 5, 240, 18, 709, 73, 50, 68, 1758, 5, 5820, 327, 81, 188, 18, 709, 1781, 5, 240, 4, 62, 212, 7, 11, 73, 5, 3, 33, 218, 477, 2, 428, 7, 5, 3, 709, 477, 125, 11, 77, 93, 1540, 362, 59, 3, 271, 63, 27, 111, 300, 1893, 9, 82, 10, 424, 2, 846, 9, 33, 218, 2, 709, 271, 106, 19, 355, 1358, 9, 82, 89, 2, 1438, 1, 24, 3, 43, 1, 24, 496, 107, 3, 709, 87, 10, 27, 641, 1072, 142, 76, 3, 33, 218, 87, 19, 588, 3, 709, 87, 42, 8, 27, 601, 1072, 142, 43, 1, 931, 286, 385, 76, 3, 33, 218, 87, 19, 588, 4, 131, 82, 7, 7, 54, 103, 709, 5820, 47, 8, 985, 27, 111, 300, 7, 5, 131, 82, 12, 54, 103, 709, 5820, 42, 97, 80, 286, 385, 46, 74, 257, 40, 557, 4, 8, 1414, 1115, 384, 1149, 45]",1619.0,17123270,423
"Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2006-12-08,"A MESSAGE FROM ASCO's PRESIDENT For the second consecutive year, the American Society of Clinical Oncology (ASCO) is publishing Clinical Cancer Advances: Major Research Advances in Cancer Treatment, Prevention, and Screening, an annual review of the most significant cancer research presented or published over the past year. ASCO developed this report to demonstrate the enormous progress being made on the front lines of cancer research today. The report is intended to give all those with an interest in cancer care-the general public, cancer patients and physicians, policymakers, oncologists, and other medical professionals-an accessible summary of the year's most important cancer research advances. These pages report on new targeted therapies that are improving survival and response rates in hard-to-treat cancers such as kidney cancer, HER-2-positive breast cancer, head and neck cancer, and chronic myelogenous leukemia; the FDA's approval of the world's first preventive vaccine for human papillomavirus (HPV), which has the potential to dramatically reduce the global burden of cervical cancer; and advances in the fast-growing field of personalized medicine, including a new lung cancer test that could help physicians better target treatments and predict prognosis. These advances are only part of the landscape. Survival rates are on the rise, the number of cancer deaths in the United States began declining for the first time since 1930, and new research is showing that the rates of certain common cancers, such as those of the breast and colon, have stabilized, and may have even begun to decline. However, cancer research still faces a number of major obstacles. At a time of extraordinary scientific potential, declining federal funding of cancer research threatens to stall or even reverse recent progress. Such funding cuts have already led to fewer clinical trials, fewer talented young physicians entering the field, and a growing bottleneck of basic science discoveries waiting to be ""translated"" into useful therapies and diagnostics. In addition to highlighting the major research advances over the past year, this report also identifies key barriers to accelerating the pace of cancer research and outlines ASCO's recommendations for overcoming them. Despite these and other challenges, there is much good news on the front lines of cancer research. This report demonstrates the essential role of clinical cancer research in finding new and better ways to treat, diagnose, and prevent a group of diseases that strike half of men and one-third of women in the United States.",Journal Article,4792.0,94.0,A MESSAGE FROM ASCO 's PRESIDENT For the second consecutive year the American Society of Clinical Oncology ASCO is publishing Clinical Cancer Advances Major Research Advances in Cancer Treatment Prevention and Screening an annual review of the most significant cancer research presented or published over the past year ASCO developed this report to demonstrate the enormous progress being made on the front lines of cancer research today The report is intended to give all those with an interest in cancer care-the general public cancer patients and physicians policymakers oncologists and other medical professionals-an accessible summary of the year 's most important cancer research advances These pages report on new targeted therapies that are improving survival and response rates in hard-to-treat cancers such as cancer HER-2-positive cancer head and cancer and chronic myelogenous the FDA 's approval of the world 's first preventive vaccine for human papillomavirus HPV which has the potential to dramatically reduce the global burden of cancer and advances in the fast-growing field of personalized medicine including a new cancer test that could help physicians better target treatments and predict prognosis These advances are only part of the landscape Survival rates are on the rise the number of cancer deaths in the United States began declining for the first time since 1930 and new research is showing that the rates of certain common cancers such as those of the and have stabilized and may have even begun to decline However cancer research still faces a number of major obstacles At a time of extraordinary scientific potential declining federal funding of cancer research threatens to stall or even reverse recent progress Such funding cuts have already led to fewer clinical trials fewer talented young physicians entering the field and a growing bottleneck of basic science discoveries waiting to be `` translated '' into useful therapies and diagnostics In addition to highlighting the major research advances over the past year this report also identifies key barriers to accelerating the pace of cancer research and outlines ASCO 's recommendations for overcoming them Despite these and other challenges there is much good news on the front lines of cancer research This report demonstrates the essential role of clinical cancer research in finding new and better ways to treat diagnose and prevent a group of diseases that strike half of men and one-third of women in the United States,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[8, 10035, 29, 2697, 292, 15703, 9, 3, 419, 935, 111, 3, 597, 1174, 1, 38, 413, 2697, 16, 31038, 38, 12, 954, 458, 389, 954, 4, 12, 24, 1070, 2, 453, 35, 2114, 206, 1, 3, 96, 93, 12, 389, 917, 15, 983, 252, 3, 1219, 111, 2697, 276, 26, 414, 6, 608, 3, 8790, 1466, 486, 1229, 23, 3, 3007, 285, 1, 12, 389, 5665, 3, 414, 16, 4081, 6, 4978, 62, 135, 5, 35, 1333, 4, 12, 165, 3, 1083, 3067, 12, 7, 2, 1261, 16862, 1339, 2, 127, 484, 3409, 35, 5981, 1962, 1, 3, 111, 292, 96, 305, 12, 389, 954, 46, 14961, 414, 23, 217, 238, 235, 17, 32, 1673, 25, 2, 51, 151, 4, 9327, 6, 943, 163, 225, 22, 12, 1084, 18, 109, 12, 718, 2, 12, 2, 442, 2194, 3, 2078, 292, 1814, 1, 3, 1956, 292, 157, 3494, 1274, 9, 171, 3242, 933, 92, 71, 3, 174, 6, 2729, 969, 3, 1648, 892, 1, 12, 2, 954, 4, 3, 5830, 1921, 1067, 1, 2175, 1807, 141, 8, 217, 12, 412, 17, 359, 987, 1261, 380, 283, 640, 2, 678, 356, 46, 954, 32, 158, 760, 1, 3, 2801, 25, 151, 32, 23, 3, 3693, 3, 207, 1, 12, 1043, 4, 3, 1088, 907, 4603, 6896, 9, 3, 157, 98, 1192, 30582, 2, 217, 389, 16, 2069, 17, 3, 151, 1, 1840, 186, 163, 225, 22, 135, 1, 3, 2, 47, 7368, 2, 68, 47, 871, 6973, 6, 1858, 137, 12, 389, 1234, 19786, 8, 207, 1, 458, 7140, 28, 8, 98, 1, 17915, 3138, 174, 6896, 8536, 5468, 1, 12, 389, 24738, 6, 38315, 15, 871, 1772, 435, 1466, 225, 5468, 28471, 47, 3298, 836, 6, 1497, 38, 143, 1497, 38316, 1169, 1261, 7653, 3, 1067, 2, 8, 1921, 26563, 1, 2795, 3797, 5012, 7598, 6, 40, 5136, 522, 237, 999, 235, 2, 5197, 4, 352, 6, 4051, 3, 458, 389, 954, 252, 3, 1219, 111, 26, 414, 120, 2953, 825, 2160, 6, 13387, 3, 7265, 1, 12, 389, 2, 6510, 2697, 292, 883, 9, 5344, 1370, 550, 46, 2, 127, 1427, 125, 16, 1802, 1178, 8793, 23, 3, 3007, 285, 1, 12, 389, 26, 414, 1902, 3, 1452, 200, 1, 38, 12, 389, 4, 1567, 217, 2, 380, 4245, 6, 943, 6073, 2, 1682, 8, 87, 1, 1342, 17, 38317, 1303, 1, 325, 2, 104, 1282, 1, 117, 4, 3, 1088, 907]",2513.0,17158528,432
Reproductive concerns of women treated with radical trachelectomy for cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2006-12-22,"To report the reproductive concerns of women treated for stage I cervical cancer with fertility-preserving surgery. Newly diagnosed cervical cancer patients undergoing radical trachelectomy were enrolled in this study preoperatively and assessed over time. Preliminary data from the preoperative analysis and 3-month and 6-month assessment points addressing reproductive concerns are presented. Between February 2004 and June 2006, 29 patients were enrolled in the study. Three patients were excluded because they did not undergo the planned surgery and 6 patients were excluded because they required adjuvant therapy. Future childbearing was the main reason most women chose to undergo the procedure; however, treatment choice was also guided by conversations with their doctors (41%, n=12). Twenty-six (90%) initially expressed concern over future conception and childbearing, but this increased to all patients by 6 months. At enrollment, the majority of the patients had high expectations for future conception and childbearing but this declined over time. Despite this, patients' distress gradually decreased over time. Our results show that many women who have undergone a radical trachelectomy present with distress and reproductive concerns that persist for up to 6 months postoperatively. Concerns about conception appear to decrease following surgery; however, concerns about pregnancy appear to increase post trachelectomy itself. This pilot study reflects the first preliminary data from an active ongoing study prospectively collecting information over 2 years from newly diagnosed stage I cervical cancer patients undergoing radical trachelectomy.",Journal Article,4778.0,38.0,To report the reproductive concerns of women treated for stage I cancer with fertility-preserving surgery Newly diagnosed cancer patients undergoing radical trachelectomy were enrolled in this study preoperatively and assessed over time Preliminary data from the preoperative analysis and 3-month and 6-month assessment points addressing reproductive concerns are presented Between February 2004 and June 2006 29 patients were enrolled in the study Three patients were excluded because they did not undergo the planned surgery and 6 patients were excluded because they required adjuvant therapy Future childbearing was the main reason most women chose to undergo the procedure however treatment choice was also guided by conversations with their doctors 41 n=12 Twenty-six 90 initially expressed concern over future conception and childbearing but this increased to all patients by 6 months At enrollment the majority of the patients had high expectations for future conception and childbearing but this declined over time Despite this patients distress gradually decreased over time Our results show that many women who have undergone a radical trachelectomy present with distress and reproductive concerns that persist for up to 6 months postoperatively Concerns about conception appear to decrease following surgery however concerns about pregnancy appear to increase post trachelectomy itself This pilot study reflects the first preliminary data from an active ongoing study prospectively collecting information over 2 years from newly diagnosed stage I cancer patients undergoing radical trachelectomy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 414, 3, 3705, 2061, 1, 117, 73, 9, 82, 70, 12, 5, 2954, 4972, 152, 732, 265, 12, 7, 479, 711, 5760, 11, 346, 4, 26, 45, 3888, 2, 275, 252, 98, 1676, 74, 29, 3, 498, 65, 2, 27, 811, 2, 49, 811, 455, 862, 3432, 3705, 2061, 32, 917, 59, 3010, 1131, 2, 1924, 1324, 462, 7, 11, 346, 4, 3, 45, 169, 7, 11, 1800, 408, 491, 205, 44, 1251, 3, 1465, 152, 2, 49, 7, 11, 1800, 408, 491, 616, 249, 36, 508, 10278, 10, 3, 1895, 3852, 96, 117, 6177, 6, 1251, 3, 1299, 137, 24, 1866, 10, 120, 1808, 20, 7454, 5, 136, 13562, 605, 78, 133, 737, 437, 424, 1625, 570, 2893, 252, 508, 17273, 2, 10278, 84, 26, 101, 6, 62, 7, 20, 49, 53, 28, 1798, 3, 686, 1, 3, 7, 42, 64, 5591, 9, 508, 17273, 2, 10278, 84, 26, 3054, 252, 98, 550, 26, 7, 1462, 8092, 340, 252, 98, 114, 99, 514, 17, 445, 117, 54, 47, 1989, 8, 711, 5760, 364, 5, 1462, 2, 3705, 2061, 17, 5589, 9, 126, 6, 49, 53, 3541, 2061, 545, 17273, 1322, 6, 775, 366, 152, 137, 2061, 545, 2290, 1322, 6, 344, 539, 5760, 4045, 26, 2281, 45, 5224, 3, 157, 1676, 74, 29, 35, 544, 942, 45, 1143, 7251, 487, 252, 18, 60, 29, 732, 265, 82, 70, 12, 7, 479, 711, 5760]",1606.0,17188344,484
Topotecan in the management of cervical cancer.,Expert opinion on pharmacotherapy,Expert Opin Pharmacother,2007-02-01,"Topotecan, a semisynthetic camptothecin, exerts its cytotoxic effect through inhibition of DNA topoisomerase I. Single-agent topotecan has demonstrated activity against persistent, metastatic and recurrent cancer of the uterine cervix. When combined with cisplatin in Phase II trials, further improved response rates have been reported. The cisplatin/topotecan doublet subsequently proved to be the first regimen in a series of multiple Phase III studies to demonstrate improved disease-free and overall survival in this setting compared with cisplatin alone, thus leading to its third indication by both the US FDA and the European Medicines Agency in 2006. This survival advantage was achieved at the expense of an increase in grade 3-4 hematologic toxicity; however, there was no difference in patient-reported quality of life between the cisplatin/topotecan doublet and single-agent cisplatin. This article reviews the pharmacology of topotecan and its evolution as an active agent in advanced and metastatic cervical cancer that is not amenable to cure with surgery or radiotherapy.",Journal Article,4737.0,13.0,Topotecan a semisynthetic camptothecin exerts its cytotoxic effect through inhibition of DNA topoisomerase I. Single-agent topotecan has demonstrated activity against persistent metastatic and recurrent cancer of the cervix When combined with cisplatin in Phase II trials further improved response rates have been reported The cisplatin/topotecan doublet subsequently proved to be the first regimen in a series of multiple Phase III studies to demonstrate improved disease-free and overall survival in this setting compared with cisplatin alone thus leading to its third indication by both the US FDA and the European Medicines Agency in 2006 This survival advantage was achieved at the expense of an increase in grade 3-4 hematologic toxicity however there was no difference in patient-reported quality of life between the cisplatin/topotecan doublet and single-agent cisplatin This article reviews the pharmacology of topotecan and its evolution as an active agent in advanced and metastatic cancer that is not amenable to cure with surgery or radiotherapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[2129, 8, 18185, 6968, 5685, 211, 759, 254, 298, 297, 1, 261, 3999, 70, 226, 420, 2129, 71, 264, 128, 480, 1882, 113, 2, 387, 12, 1, 3, 3629, 198, 397, 5, 540, 4, 124, 215, 143, 195, 231, 51, 151, 47, 85, 210, 3, 540, 2129, 4872, 1611, 4328, 6, 40, 3, 157, 477, 4, 8, 988, 1, 232, 124, 316, 94, 6, 608, 231, 34, 115, 2, 63, 25, 4, 26, 546, 72, 5, 540, 279, 631, 1049, 6, 211, 1282, 3607, 20, 110, 3, 843, 2078, 2, 3, 1865, 11478, 8613, 4, 1324, 26, 25, 1874, 10, 513, 28, 3, 8563, 1, 35, 344, 4, 88, 27, 39, 813, 155, 137, 125, 10, 77, 523, 4, 69, 210, 372, 1, 358, 59, 3, 540, 2129, 4872, 2, 226, 420, 540, 26, 946, 2004, 3, 6852, 1, 2129, 2, 211, 2554, 22, 35, 544, 420, 4, 131, 2, 113, 12, 17, 16, 44, 4070, 6, 1722, 5, 152, 15, 310]",1058.0,17257092,203
Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials.,Gynecologic oncology,Gynecol. Oncol.,2007-02-02,"To explore clinical/pathologic factors associated with prognosis of patients with locally advanced cervical carcinoma treated with weekly cisplatin and pelvic radiation. We retrospectively reviewed data from 335 women who received weekly cisplatin and radiation while participating in similar arms of two GOG studies (protocols 120 and 165). Progression-free survival (PFS) and overall survival (OS) were evaluated for associations between clinical/pathologic factors and prognosis. Prognosis and selected toxicities were also compared between studies. Four-year PFS and OS for stage II patients were 64.2% and 68.1%, respectively for those treated on GOG 120 and 65.8% and 73.9% for those treated on GOG 165, compared to 51.4% and 55.4% for stage III/IV patients respectively treated on GOG 120 and 37.7% and 42.7% respectively for those treated on GOG 165. In multivariate analysis, stage, tumor grade, race and age were independently predictive of PFS and OS (for all, p<0.05). Prolonged (delayed for any cause) radiation was associated with poorer PFS (hazard ratio [HR], 1.98; 95% confidence interval [CI], 1.16-3.38; p=0.012) and OS (HR, 1.88; 95% CI, 1.08-3.26; p=0.024) in GOG 165 but not GOG 120. FIGO stage, tumor grade, race and age are prognostic in patients with locally advanced cervical carcinoma treated with concurrent cisplatin and radiation. This exploratory analysis has generated a hypothesis that clinical staging (as per GOG 165) is less sensitive in detecting aortic nodal metastases compared to surgical staging (as per GOG 120) and may be associated with poorer prognosis particularly when radiation is prolonged. Prospective clinical studies are needed to test this hypothesis.",Journal Article,4736.0,71.0,To explore clinical/pathologic factors associated with prognosis of patients with locally advanced carcinoma treated with weekly cisplatin and pelvic radiation We retrospectively reviewed data from 335 women who received weekly cisplatin and radiation while participating in similar arms of two GOG studies protocols 120 and 165 Progression-free survival PFS and overall survival OS were evaluated for associations between clinical/pathologic factors and prognosis Prognosis and selected toxicities were also compared between studies Four-year PFS and OS for stage II patients were 64.2 and 68.1 respectively for those treated on GOG 120 and 65.8 and 73.9 for those treated on GOG 165 compared to 51.4 and 55.4 for stage III/IV patients respectively treated on GOG 120 and 37.7 and 42.7 respectively for those treated on GOG 165 In multivariate analysis stage tumor grade race and age were independently predictive of PFS and OS for all p 0.05 Prolonged delayed for any cause radiation was associated with poorer PFS hazard ratio HR 1.98 95 confidence interval CI 1.16-3.38 p=0.012 and OS HR 1.88 95 CI 1.08-3.26 p=0.024 in GOG 165 but not GOG 120 FIGO stage tumor grade race and age are prognostic in patients with locally advanced carcinoma treated with concurrent cisplatin and radiation This exploratory analysis has generated a hypothesis that clinical staging as per GOG 165 is less sensitive in detecting aortic nodal metastases compared to surgical staging as per GOG 120 and may be associated with poorer prognosis particularly when radiation is prolonged Prospective clinical studies are needed to test this hypothesis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1645, 38, 510, 130, 41, 5, 356, 1, 7, 5, 795, 131, 134, 73, 5, 709, 540, 2, 1110, 121, 21, 894, 446, 74, 29, 9286, 117, 54, 103, 709, 540, 2, 121, 369, 3052, 4, 288, 1335, 1, 100, 4760, 94, 2189, 2031, 2, 4966, 91, 115, 25, 300, 2, 63, 25, 118, 11, 194, 9, 685, 59, 38, 510, 130, 2, 356, 356, 2, 715, 385, 11, 120, 72, 59, 94, 294, 111, 300, 2, 118, 9, 82, 215, 7, 11, 660, 18, 2, 806, 14, 106, 9, 135, 73, 23, 4760, 2031, 2, 556, 66, 2, 803, 83, 9, 135, 73, 23, 4760, 4966, 72, 6, 725, 39, 2, 614, 39, 9, 82, 316, 478, 7, 106, 73, 23, 4760, 2031, 2, 567, 67, 2, 595, 67, 106, 9, 135, 73, 23, 4760, 4966, 4, 331, 65, 82, 30, 88, 1047, 2, 89, 11, 1042, 464, 1, 300, 2, 118, 9, 62, 19, 13, 474, 1069, 1612, 9, 500, 708, 121, 10, 41, 5, 1769, 300, 360, 197, 168, 14, 1096, 48, 307, 268, 58, 14, 245, 27, 519, 19, 13, 3499, 2, 118, 168, 14, 889, 48, 58, 14, 1592, 27, 432, 19, 13, 4247, 4, 4760, 4966, 84, 44, 4760, 2031, 3837, 82, 30, 88, 1047, 2, 89, 32, 177, 4, 7, 5, 795, 131, 134, 73, 5, 750, 540, 2, 121, 26, 2386, 65, 71, 1419, 8, 1492, 17, 38, 632, 22, 379, 4760, 4966, 16, 299, 745, 4, 2502, 3938, 779, 196, 72, 6, 221, 632, 22, 379, 4760, 2031, 2, 68, 40, 41, 5, 1769, 356, 823, 198, 121, 16, 1069, 482, 38, 94, 32, 575, 6, 412, 26, 1492]",1628.0,17275889,263
Human papillomavirus vaccine: a new chance to prevent cervical cancer.,Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,Recent Results Cancer Res.,2007-01-01,"Human papillomavirus (HPV) is a significant source of morbidity and mortality throughout the world and is the most common sexually transmitted infection in the United States. HPV is the primary etiologic agent of cervical cancer and dysplasia. Thus, cervical cancer and other HPV-associated malignancies might be prevented or treated by HPV vaccines. Recent research on the safety and efficacy of candidate prophylactic vaccines against HPV have shown very promising results, with nearly 100% efficacy in preventing the development of persistent infections and cervical dysplasia. Questions remain, however, concerning the duration of protection, vaccine acceptability, and feasibility of vaccine delivery in the developing world. Screening recommendations might also be modified based on the longer-term follow-up data and cost-effectiveness considerations, but some level of screening is likely to be required for decades following the implementation of vaccine programs.",Journal Article,4768.0,7.0,Human papillomavirus HPV is a significant source of morbidity and mortality throughout the world and is the most common sexually transmitted infection in the United States HPV is the primary etiologic agent of cancer and dysplasia Thus cancer and other HPV-associated malignancies might be prevented or treated by HPV vaccines Recent research on the safety and efficacy of candidate prophylactic vaccines against HPV have shown very promising results with nearly 100 efficacy in preventing the development of persistent infections and dysplasia Questions remain however concerning the duration of protection vaccine acceptability and feasibility of vaccine delivery in the developing world Screening recommendations might also be modified based on the longer-term follow-up data and cost-effectiveness considerations but some level of screening is likely to be required for decades following the implementation of vaccine programs,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 3242, 933, 16, 8, 93, 2353, 1, 787, 2, 282, 2432, 3, 1956, 2, 16, 3, 96, 186, 13588, 12959, 930, 4, 3, 1088, 907, 933, 16, 3, 86, 6604, 420, 1, 12, 2, 2253, 631, 12, 2, 127, 933, 41, 441, 822, 40, 3902, 15, 73, 20, 933, 1842, 435, 389, 23, 3, 367, 2, 209, 1, 1609, 1862, 1842, 480, 933, 47, 443, 923, 721, 99, 5, 1857, 394, 209, 4, 3017, 3, 193, 1, 1882, 1875, 2, 2253, 1937, 918, 137, 4243, 3, 654, 1, 3525, 1274, 8065, 2, 1437, 1, 1274, 989, 4, 3, 931, 1956, 453, 883, 822, 120, 40, 1230, 90, 23, 3, 589, 337, 166, 126, 74, 2, 835, 1236, 3891, 84, 476, 301, 1, 453, 16, 322, 6, 40, 616, 9, 1968, 366, 3, 2393, 1, 1274, 2251]",930.0,17302188,43
"A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.",Gynecologic oncology,Gynecol. Oncol.,2007-02-14,"Cisplatin-based combination therapy produces higher response rates and improved survival, in comparison to single-agent cisplatin in the treatment of cervical cancer. Cisplatin and paclitaxel (PT) requires a prolonged infusion and is less convenient and more toxic than the combination of carboplatin and paclitaxel (CT) leading to more widespread use of CT. The objective of this study was to compare response rate and survival in patients with cervical cancer treated with PT or CT. A retrospective search of databases at the University of Oklahoma, Washington University-Barnes Jewish Christian Hospitals, Johns Hopkins University, and University of Alabama at Birmingham identified patients with stage IVB, recurrent or persistent cervical cancer who were treated with PT or CT. A total of 62 patients were identified. 14 were treated with PT and 48 with CT. There were no statistical differences between the groups in terms of demographics, prior radiation therapy, or median number of cycles. There was a trend toward a larger number of patients in the CT arm having received prior cisplatin/radiation (p=0.07). Objective responses occurred in 29% of patients receiving PT vs. 53% of patients receiving CT. With a median follow-up of 9 months, survival was not different with a median survival of 14 and 11 months, respectively. In this retrospective evaluation, CT compares favorably with PT and demonstrates a superior overall response rate. Because of its ease of administration and improved toxicity profile, CT should be considered in the treatment of advanced, recurrent or progressive cervical cancer.",Comparative Study,4724.0,62.0,Cisplatin-based combination therapy produces higher response rates and improved survival in comparison to single-agent cisplatin in the treatment of cancer Cisplatin and paclitaxel PT requires a prolonged infusion and is less convenient and more toxic than the combination of carboplatin and paclitaxel CT leading to more widespread use of CT The objective of this study was to compare response rate and survival in patients with cancer treated with PT or CT. A retrospective search of databases at the University of Oklahoma Washington University-Barnes Jewish Christian Hospitals Johns Hopkins University and University of Alabama at Birmingham identified patients with stage IVB recurrent or persistent cancer who were treated with PT or CT. A total of 62 patients were identified 14 were treated with PT and 48 with CT There were no statistical differences between the groups in terms of demographics prior radiation therapy or median number of cycles There was a trend toward a larger number of patients in the CT arm having received prior cisplatin/radiation p=0.07 Objective responses occurred in 29 of patients receiving PT vs. 53 of patients receiving CT. With a median follow-up of 9 months survival was not different with a median survival of 14 and 11 months respectively In this retrospective evaluation CT compares favorably with PT and demonstrates a superior overall response rate Because of its ease of administration and improved toxicity profile CT should be considered in the treatment of advanced recurrent or progressive cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[540, 90, 150, 36, 4042, 142, 51, 151, 2, 231, 25, 4, 1155, 6, 226, 420, 540, 4, 3, 24, 1, 12, 540, 2, 490, 3395, 1706, 8, 1069, 904, 2, 16, 299, 7048, 2, 80, 1812, 76, 3, 150, 1, 927, 2, 490, 425, 1049, 6, 80, 3029, 119, 1, 425, 3, 461, 1, 26, 45, 10, 6, 932, 51, 116, 2, 25, 4, 7, 5, 12, 73, 5, 3395, 15, 425, 8, 459, 1901, 1, 2348, 28, 3, 1652, 1, 27850, 10840, 1652, 56074, 5476, 31057, 1987, 5848, 5569, 1652, 2, 1652, 1, 24990, 28, 28531, 108, 7, 5, 82, 7042, 387, 15, 1882, 12, 54, 11, 73, 5, 3395, 15, 425, 8, 181, 1, 744, 7, 11, 108, 213, 11, 73, 5, 3395, 2, 576, 5, 425, 125, 11, 77, 1050, 362, 59, 3, 271, 4, 1794, 1, 2221, 324, 121, 36, 15, 52, 207, 1, 410, 125, 10, 8, 853, 1317, 8, 1077, 207, 1, 7, 4, 3, 425, 475, 1041, 103, 324, 540, 121, 19, 13, 1615, 461, 253, 489, 4, 462, 1, 7, 357, 3395, 105, 699, 1, 7, 357, 425, 5, 8, 52, 166, 126, 1, 83, 53, 25, 10, 44, 338, 5, 8, 52, 25, 1, 213, 2, 175, 53, 106, 4, 26, 459, 451, 425, 5815, 5001, 5, 3395, 2, 1902, 8, 1123, 63, 51, 116, 408, 1, 211, 7440, 1, 634, 2, 231, 155, 800, 425, 257, 40, 515, 4, 3, 24, 1, 131, 387, 15, 1014, 12]",1549.0,17303230,7
Supracervical hysterectomy in patients with advanced epithelial ovarian cancer.,Obstetrics and gynecology,Obstet Gynecol,2007-03-01,"To assess whether supracervical hysterectomy (SCH) is a reasonable alternative to total abdominal hysterectomy in patients with advanced ovarian cancer. We reviewed the records of patients with advanced ovarian cancer who underwent a SCH at one institution between 1993 and 2004 and a similar cohort who underwent total abdominal hysterectomy (TAH) at the same institution during the same period. Patients without complete surgical staging done at the institution were excluded. Independent-sample t tests, Fisher exact test, and log rank tests were used for statistical analysis. The study included 47 patients who underwent SCH (mean age, 59.6 years) and 190 who underwent TAH. There were no significant differences between the two groups in age (P=.51), preoperative CA 125 level (P=.55), or receipt of taxane-based and platinum-based chemotherapy (P=.84). Although limited by sample size, there were no significant differences between the two groups in rates of intraoperative complications (4 of 47 in the SCH group, or 8.5%, compared with 7 of 190 in the TAH group, or 3.7%; P=.24), vaginal or cervical recurrence (5 of 47 in the SCH group, or 10.6%, compared with 22 of 190 in the TAH group, or 11.6%; P=1.00), or in progression-free survival (SCH of 1.01 years compared with TAH of 1.19 years; P=.64) or overall survival (SCH of 3.28 years compared with TAH of 3.36 years; P=.12). Supracervical hysterectomy may be a reasonable alternative to TAH in patients with advanced ovarian cancer. II.",Comparative Study,4709.0,7.0,To assess whether supracervical hysterectomy SCH is a reasonable alternative to total abdominal hysterectomy in patients with advanced cancer We reviewed the records of patients with advanced cancer who underwent a SCH at one institution between 1993 and 2004 and a similar cohort who underwent total abdominal hysterectomy TAH at the same institution during the same period Patients without complete surgical staging done at the institution were excluded Independent-sample t tests Fisher exact test and log rank tests were used for statistical analysis The study included 47 patients who underwent SCH mean age 59.6 years and 190 who underwent TAH There were no significant differences between the two groups in age P=.51 preoperative CA 125 level P=.55 or receipt of taxane-based and platinum-based chemotherapy P=.84 Although limited by sample size there were no significant differences between the two groups in rates of intraoperative complications 4 of 47 in the SCH group or 8.5 compared with 7 of 190 in the TAH group or 3.7 P=.24 or recurrence 5 of 47 in the SCH group or 10.6 compared with 22 of 190 in the TAH group or 11.6 P=1.00 or in progression-free survival SCH of 1.01 years compared with TAH of 1.19 years P=.64 or overall survival SCH of 3.28 years compared with TAH of 3.36 years P=.12 Supracervical hysterectomy may be a reasonable alternative to TAH in patients with advanced cancer II,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 423, 317, 44642, 2622, 11047, 16, 8, 3203, 1091, 6, 181, 1467, 2622, 4, 7, 5, 131, 12, 21, 446, 3, 1064, 1, 7, 5, 131, 12, 54, 208, 8, 11047, 28, 104, 731, 59, 3343, 2, 1131, 2, 8, 288, 180, 54, 208, 181, 1467, 2622, 16704, 28, 3, 827, 731, 190, 3, 827, 727, 7, 187, 236, 221, 632, 1822, 28, 3, 731, 11, 1800, 306, 1000, 102, 895, 3135, 2472, 412, 2, 1066, 1026, 895, 11, 95, 9, 1050, 65, 3, 45, 159, 662, 7, 54, 208, 11047, 313, 89, 728, 49, 60, 2, 5974, 54, 208, 16704, 125, 11, 77, 93, 362, 59, 3, 100, 271, 4, 89, 19, 725, 498, 1568, 1731, 301, 19, 614, 15, 1699, 1, 1715, 90, 2, 828, 90, 56, 19, 874, 242, 383, 20, 1000, 444, 125, 11, 77, 93, 362, 59, 3, 100, 271, 4, 151, 1, 1720, 521, 39, 1, 662, 4, 3, 11047, 87, 15, 66, 33, 72, 5, 67, 1, 5974, 4, 3, 16704, 87, 15, 27, 67, 19, 259, 15, 146, 33, 1, 662, 4, 3, 11047, 87, 15, 79, 49, 72, 5, 350, 1, 5974, 4, 3, 16704, 87, 15, 175, 49, 19, 14, 2038, 15, 4, 91, 115, 25, 11047, 1, 14, 355, 60, 72, 5, 16704, 1, 14, 326, 60, 19, 660, 15, 63, 25, 11047, 1, 27, 339, 60, 72, 5, 16704, 1, 27, 511, 60, 19, 133, 44642, 2622, 68, 40, 8, 3203, 1091, 6, 16704, 4, 7, 5, 131, 12, 215]",1408.0,17329515,293
Unexpected long-term survival without evidence of disease after salvage chemotherapy for recurrent metastatic cervical cancer: a case series.,Gynecologic oncology,Gynecol. Oncol.,2007-03-23,"The prognosis of recurrent metastatic cervical cancer is extremely poor. Platinum-based palliative chemotherapy constitutes the mainstay of treatment. Cure is extremely rare. We present 3 cases of recurrent metastatic cervical cancer in which the patients remain disease-free many years after completing salvage chemotherapy and surgery. The patients remain with no evidence of disease at 6, 7, and 13 years, respectively, following recurrence. In rare cases, an unexpected complete clinical remission and long-term survival without evidence of disease may be achieved in patients with recurrent metastatic cervical cancer treated with multimodal therapy.",Case Reports,4687.0,7.0,The prognosis of recurrent metastatic cancer is extremely poor Platinum-based palliative chemotherapy constitutes the mainstay of treatment Cure is extremely rare We present 3 cases of recurrent metastatic cancer in which the patients remain disease-free many years after completing salvage chemotherapy and surgery The patients remain with no evidence of disease at 6 7 and 13 years respectively following recurrence In rare cases an unexpected complete clinical remission and long-term survival without evidence of disease may be achieved in patients with recurrent metastatic cancer treated with multimodal therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 356, 1, 387, 113, 12, 16, 2938, 334, 828, 90, 994, 56, 6788, 3, 4041, 1, 24, 1722, 16, 2938, 622, 21, 364, 27, 140, 1, 387, 113, 12, 4, 92, 3, 7, 918, 34, 115, 445, 60, 50, 4144, 992, 56, 2, 152, 3, 7, 918, 5, 77, 241, 1, 34, 28, 49, 67, 2, 233, 60, 106, 366, 146, 4, 622, 140, 35, 3792, 236, 38, 734, 2, 319, 337, 25, 187, 241, 1, 34, 68, 40, 513, 4, 7, 5, 387, 113, 12, 73, 5, 4122, 36]",617.0,17363045,279
Percutaneous biopsy of head and neck lesions with CT guidance: various approaches and relevant anatomic and technical considerations.,"Radiographics : a review publication of the Radiological Society of North America, Inc",Radiographics,,"Deep-seated head and neck lesions, which traditionally were evaluated by surgical means, are now accessible with less invasive computed tomography-guided percutaneous needle biopsy techniques. Major vessels, the trachea, and osseous structures like the maxilla, mandible, and vertebrae often preclude direct access to these lesions. It is important to understand the anatomy relevant to safe access route planning and the techniques, advantages, and limitations associated with various approaches used for percutaneous biopsy of head and neck lesions. For biopsy of suprahyoid head and neck lesions, including those of the skull base and upper cervical vertebrae, various approaches such as the subzygomatic, retromandibular, paramaxillary, submastoid, transoral, and posterior approaches can be used. Lesions in the infrahyoid portion of the neck and lower cervical vertebrae can be accessed with the anterolateral approach (between the airways and the carotid sheath), posterolateral approach (posterior to the carotid sheath), and direct posterior approach. The location and extent of the lesions and their relationship to adjacent structures influence the choice of the trajectory to use. Careful planning of the procedure and considerable familiarity with head and neck anatomy are necessary for a biopsy that is both precise and safe.",Journal Article,,49.0,Deep-seated head and lesions which traditionally were evaluated by surgical means are now accessible with less invasive computed tomography-guided percutaneous needle biopsy techniques Major vessels the trachea and osseous structures like the maxilla mandible and vertebrae often preclude direct access to these lesions It is important to understand the anatomy relevant to safe access route planning and the techniques advantages and limitations associated with various approaches used for percutaneous biopsy of head and lesions For biopsy of suprahyoid head and lesions including those of the skull base and upper vertebrae various approaches such as the subzygomatic retromandibular paramaxillary submastoid transoral and posterior approaches can be used Lesions in the infrahyoid portion of the and lower vertebrae can be accessed with the anterolateral approach between the airways and the carotid sheath posterolateral approach posterior to the carotid sheath and direct posterior approach The location and extent of the lesions and their relationship to adjacent structures influence the choice of the trajectory to use Careful planning of the procedure and considerable familiarity with head and anatomy are necessary for a biopsy that is both precise and safe,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2369, 21419, 718, 2, 406, 92, 4206, 11, 194, 20, 221, 2263, 32, 1134, 5981, 5, 299, 416, 1220, 872, 1808, 3720, 2177, 411, 1092, 458, 3102, 3, 15869, 2, 5230, 2414, 733, 3, 38399, 16845, 2, 7565, 629, 6064, 1196, 1655, 6, 46, 406, 192, 16, 305, 6, 1640, 3, 5081, 867, 6, 1165, 1655, 5841, 1349, 2, 3, 1092, 3126, 2, 1939, 41, 5, 747, 611, 95, 9, 3720, 411, 1, 718, 2, 406, 9, 411, 1, 56138, 718, 2, 406, 141, 135, 1, 3, 5054, 1782, 2, 1726, 7565, 747, 611, 225, 22, 3, 56139, 56140, 56141, 56142, 13959, 2, 3028, 611, 122, 40, 95, 406, 4, 3, 56143, 3206, 1, 3, 2, 280, 7565, 122, 40, 11276, 5, 3, 19622, 353, 59, 3, 21205, 2, 3, 8319, 7280, 13000, 353, 3028, 6, 3, 8319, 7280, 2, 1196, 3028, 353, 3, 1147, 2, 1039, 1, 3, 406, 2, 136, 858, 6, 2086, 2414, 1054, 3, 1866, 1, 3, 6118, 6, 119, 3465, 1349, 1, 3, 1299, 2, 2658, 10322, 5, 718, 2, 5081, 32, 1493, 9, 8, 411, 17, 16, 110, 3260, 2, 1165]",1269.0,17374859,4
Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer.,International journal of clinical oncology,Int. J. Clin. Oncol.,2007-02-25,"The purpose of this study was to evaluate the toxicity profile of weekly low-dose paclitaxel and carboplatin in patients with gynecologic malignancies. Patients had measurable disease defined by clinical examination or radiographic studies. Each cycle of treatment consisted of carboplatin at an AUC of 2 and paclitaxel at 80 mg/m2 on days 1, 8, and 15 of a 28-day cycle. Twenty-eight patients with advanced or recurrent cervical and endometrial cancers were included in this study. The overall response rate (ORR) was 39% (2 CR, 9 PR). Among the 15 cervical cancers the ORR was 20%, while the 13 endometrial cancers had a 62% ORR. Median time to progression and overall survival was 3.4 and 7.6 months for those with cervical cancer and 5.5 and 15.4 months for those with endometrial cancer. Grade 3 or 4 hematologic toxicity was uncommon (7% grade 3 anemia, 21% grade 3 or 4 neutropenia, 7% grade 3 or 4 thrombocytopenia). A regimen of weekly low-dose paclitaxel and carboplatin has an acceptable toxicity profile that is easily managed by dose adjustment and the use of erythropoietic therapy. This regimen appears to have activity in advanced or recurrent endometrial cancer which warrants further evaluation.",Journal Article,4713.0,28.0,The purpose of this study was to evaluate the toxicity profile of weekly low-dose paclitaxel and carboplatin in patients with gynecologic malignancies Patients had measurable disease defined by clinical examination or radiographic studies Each cycle of treatment consisted of carboplatin at an AUC of 2 and paclitaxel at 80 mg/m2 on days 1 8 and 15 of a 28-day cycle Twenty-eight patients with advanced or recurrent and cancers were included in this study The overall response rate ORR was 39 2 CR 9 PR Among the 15 cancers the ORR was 20 while the 13 cancers had a 62 ORR Median time to progression and overall survival was 3.4 and 7.6 months for those with cancer and 5.5 and 15.4 months for those with cancer Grade 3 or 4 hematologic toxicity was uncommon 7 grade 3 anemia 21 grade 3 or 4 neutropenia 7 grade 3 or 4 thrombocytopenia A regimen of weekly low-dose paclitaxel and carboplatin has an acceptable toxicity profile that is easily managed by dose adjustment and the use of erythropoietic therapy This regimen appears to have activity in advanced or recurrent cancer which warrants further evaluation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 376, 3, 155, 800, 1, 709, 154, 61, 490, 2, 927, 4, 7, 5, 1512, 441, 7, 42, 1884, 34, 395, 20, 38, 1385, 15, 1580, 94, 296, 417, 1, 24, 1695, 1, 927, 28, 35, 1376, 1, 18, 2, 490, 28, 493, 81, 821, 23, 162, 14, 66, 2, 167, 1, 8, 339, 218, 417, 737, 659, 7, 5, 131, 15, 387, 2, 163, 11, 159, 4, 26, 45, 3, 63, 51, 116, 1735, 10, 587, 18, 684, 83, 998, 107, 3, 167, 163, 3, 1735, 10, 179, 369, 3, 233, 163, 42, 8, 744, 1735, 52, 98, 6, 91, 2, 63, 25, 10, 27, 39, 2, 67, 49, 53, 9, 135, 5, 12, 2, 33, 33, 2, 167, 39, 53, 9, 135, 5, 12, 88, 27, 15, 39, 813, 155, 10, 2052, 67, 88, 27, 1545, 239, 88, 27, 15, 39, 778, 67, 88, 27, 15, 39, 1340, 8, 477, 1, 709, 154, 61, 490, 2, 927, 71, 35, 1595, 155, 800, 17, 16, 4697, 2231, 20, 61, 1852, 2, 3, 119, 1, 14276, 36, 26, 477, 1233, 6, 47, 128, 4, 131, 15, 387, 12, 92, 2782, 195, 451]",1110.0,17380438,521
Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience.,Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer,J Thorac Oncol,2006-03-01,"To characterize the treatment and outcome of patients with cervical and upper thoracic esophageal cancer, the authors retrospectively reviewed the 11-year experience from The University of Texas M. D. Anderson Cancer Center. Thirty-five patients with M0 cervical or upper thoracic esophageal cancer and treated with concurrent chemoradiotherapy were analyzed. Median radiation dose was 50.4 Gy (range, 24.5-64.8) Gy delivered with 1.8-Gy daily fractions over 5.5 weeks. Chemotherapy was 5-fluorouracil based. Response after treatment was evaluated on the basis of radiography, biopsy, or both. The survival rates were calculated by means of the Kaplan-Meier method. The median follow-up for the surviving patients was 39 months. The actuarial 5-year overall survival (OS), cause-specific survival, disease-free survival, local relapse-free survival, and distant metastasis-free survival rates were 18.6%, 27.6%, 22.4%, 47.7%, and 57.0%, respectively. Patients who received a radiation dose of greater than or equal to 50 Gy had a higher complete response rate than those who received less than 50 Gy (79.2% versus 27.3%; p = 0.003). On multivariate analysis, radiation dose was the only protective factor associated with the rates of OS (p = 0.006), cause-specific survival (p = 0.003), and local relapse-free survival (p = 0.001); tumor stage was the only factor associated with rate of disease-free survival (p = 0.007). Concurrent chemoradiotherapy is an effective treatment modality for patients with cervical and upper thoracic esophageal cancer. The authors' results suggest that a total radiation dose of 50 to 65 Gy with a concurrent chemotherapy regimen may improve local control and the OS rate in this rare type of esophageal cancer.",Journal Article,5074.0,50.0,To characterize the treatment and outcome of patients with and upper thoracic cancer the authors retrospectively reviewed the 11-year experience from The University of Texas M. D. Anderson Cancer Center Thirty-five patients with M0 or upper thoracic cancer and treated with concurrent chemoradiotherapy were analyzed Median radiation dose was 50.4 Gy range 24.5-64.8 Gy delivered with 1.8-Gy daily fractions over 5.5 weeks Chemotherapy was 5-fluorouracil based Response after treatment was evaluated on the basis of radiography biopsy or both The survival rates were calculated by means of the Kaplan-Meier method The median follow-up for the surviving patients was 39 months The actuarial 5-year overall survival OS cause-specific survival disease-free survival local relapse-free survival and distant metastasis-free survival rates were 18.6 27.6 22.4 47.7 and 57.0 respectively Patients who received a radiation dose of greater than or equal to 50 Gy had a higher complete response rate than those who received less than 50 Gy 79.2 versus 27.3 p 0.003 On multivariate analysis radiation dose was the only protective factor associated with the rates of OS p 0.006 cause-specific survival p 0.003 and local relapse-free survival p 0.001 tumor stage was the only factor associated with rate of disease-free survival p 0.007 Concurrent chemoradiotherapy is an effective treatment modality for patients with and upper thoracic cancer The authors results suggest that a total radiation dose of 50 to 65 Gy with a concurrent chemotherapy regimen may improve local control and the OS rate in this rare type of cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[6, 1507, 3, 24, 2, 228, 1, 7, 5, 2, 1726, 2098, 12, 3, 738, 894, 446, 3, 175, 111, 730, 29, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 977, 365, 7, 5, 4591, 15, 1726, 2098, 12, 2, 73, 5, 750, 1464, 11, 311, 52, 121, 61, 10, 212, 39, 381, 184, 259, 33, 660, 66, 381, 1623, 5, 14, 66, 381, 391, 1550, 252, 33, 33, 244, 56, 10, 33, 1404, 90, 51, 50, 24, 10, 194, 23, 3, 877, 1, 10647, 411, 15, 110, 3, 25, 151, 11, 981, 20, 2263, 1, 3, 876, 882, 596, 3, 52, 166, 126, 9, 3, 3050, 7, 10, 587, 53, 3, 2361, 33, 111, 63, 25, 118, 708, 112, 25, 34, 115, 25, 293, 429, 115, 25, 2, 626, 278, 115, 25, 151, 11, 203, 49, 428, 49, 350, 39, 662, 67, 2, 696, 13, 106, 7, 54, 103, 8, 121, 61, 1, 378, 76, 15, 2997, 6, 212, 381, 42, 8, 142, 236, 51, 116, 76, 135, 54, 103, 299, 76, 212, 381, 842, 18, 185, 428, 27, 19, 13, 1421, 23, 331, 65, 121, 61, 10, 3, 158, 2864, 161, 41, 5, 3, 151, 1, 118, 19, 13, 1861, 708, 112, 25, 19, 13, 1421, 2, 293, 429, 115, 25, 19, 13, 144, 30, 82, 10, 3, 158, 161, 41, 5, 116, 1, 34, 115, 25, 19, 13, 1999, 750, 1464, 16, 35, 323, 24, 1396, 9, 7, 5, 2, 1726, 2098, 12, 3, 738, 99, 309, 17, 8, 181, 121, 61, 1, 212, 6, 556, 381, 5, 8, 750, 56, 477, 68, 401, 293, 182, 2, 3, 118, 116, 4, 26, 622, 267, 1, 12]",1611.0,17409865,854
Is atypical squamous cells that cannot exclude high-grade squamous intraepithelial lesion clinically significant?,Journal of lower genital tract disease,J Low Genit Tract Dis,2007-04-01,"To determine the cumulative risk of cervical intraepithelial neoplasia (CIN) 2 or 3 in patients with atypical squamous cells, cannot exclude HSIL (ASC-H). A retrospective analysis was performed to identify patients referred to the dysplasia clinic with ASC-H. Initial evaluation included colposcopy, endocervical curettage, and an ectocervical biopsy, when indicated, in all the patients. A follow-up evaluation was performed at 6 and 12 months. Cumulative histological diagnosis of CIN 2 or 3 at 12 months served as the clinical end point. Two hundred twenty-nine patients with ASC-H and with a mean age of 32.8 years were evaluated. At the time of initial colposcopy, only 10.0% (23/229; 95% CI = 6.5%-15%) of the patients had histological evidence of CIN 2 or 3. The cumulative risk of CIN 2 or 3 was 12.2% (95% CI = 8%-17%). Evaluation of patients with ASC-H with colposcopy does lead to the detection of CIN 2 or 3 but perhaps at a rate lower than previously reported.",Journal Article,4678.0,25.0,To determine the cumulative risk of intraepithelial neoplasia CIN 2 or 3 in patients with atypical squamous cells can not exclude HSIL ASC-H A retrospective analysis was performed to identify patients referred to the dysplasia clinic with ASC-H Initial evaluation included colposcopy endocervical curettage and an ectocervical biopsy when indicated in all the patients A follow-up evaluation was performed at 6 and 12 months Cumulative histological diagnosis of CIN 2 or 3 at 12 months served as the clinical end point Two hundred twenty-nine patients with ASC-H and with a mean age of 32.8 years were evaluated At the time of initial colposcopy only 10.0 23/229 95 CI 6.5 -15 of the patients had histological evidence of CIN 2 or 3 The cumulative risk of CIN 2 or 3 was 12.2 95 CI 8 -17 Evaluation of patients with ASC-H with colposcopy does lead to the detection of CIN 2 or 3 but perhaps at a rate lower than previously reported,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 967, 43, 1, 4153, 2298, 4652, 18, 15, 27, 4, 7, 5, 1973, 691, 37, 122, 44, 6262, 16067, 5203, 555, 8, 459, 65, 10, 173, 6, 255, 7, 1995, 6, 3, 2253, 1188, 5, 5203, 555, 388, 451, 159, 9946, 10174, 12529, 2, 35, 44688, 411, 198, 1103, 4, 62, 3, 7, 8, 166, 126, 451, 10, 173, 28, 49, 2, 133, 53, 967, 1831, 147, 1, 4652, 18, 15, 27, 28, 133, 53, 5275, 22, 3, 38, 396, 741, 100, 1128, 737, 762, 7, 5, 5203, 555, 2, 5, 8, 313, 89, 1, 531, 66, 60, 11, 194, 28, 3, 98, 1, 388, 9946, 158, 79, 13, 382, 7584, 48, 58, 49, 33, 167, 1, 3, 7, 42, 1831, 241, 1, 4652, 18, 15, 27, 3, 967, 43, 1, 4652, 18, 15, 27, 10, 133, 18, 48, 58, 66, 269, 451, 1, 7, 5, 5203, 555, 5, 9946, 1097, 1122, 6, 3, 638, 1, 4652, 18, 15, 27, 84, 4434, 28, 8, 116, 280, 76, 373, 210]",931.0,17415112,705
Risk of colorectal cancer in women with a prior diagnosis of gynecologic malignancy.,Journal of clinical gastroenterology,J. Clin. Gastroenterol.,2007-03-01,"Earlier studies regarding the risk of colorectal cancer (CRC) in women with a prior diagnosis of gynecologic malignancies have revealed conflicting results. We sought to further clarify this association. A retrospective cohort study was performed using the General Practice Research Database of the United Kingdom. Patients with a prior diagnosis of ovarian, uterine, or cervical cancers were compared with control patients without a prior gynecologic malignancy. The primary outcome was a diagnosis of CRC. Poisson regression analysis was used to assess the effects of potential confounders. The study included 1995 ovarian, 1348 uterine, and 1101 cervical cancer patients and 7980, 5392, and 4404 matched control patients, respectively. The adjusted incidence rate ratio (IRR) of CRC among ovarian cancer patients was 2.90 [95% confidence intervals (CI) 1.45-5.82]. Five of 10 cases of CRC in ovarian cancer patients were diagnosed within 6 months of the cancer diagnosis with an adjusted IRR of 8.0 (95% CI 1.9-33.6). Excluding the initial 6 months of follow-up after the diagnosis of ovarian cancer, the adjusted IRR was 1.6 (95% CI 0.76-5.03). The adjusted IRR of CRC in patients with a prior diagnosis of uterine and cervical cancer was 0.79 (95% CI 0.24-2.61) and 1.50 (95% CI 0.43-5.21), respectively. Women with a prior diagnosis of ovarian cancer are at an increased risk of CRC. The risk of CRC was not increased among patients with a prior history of uterine and cervical cancer.",Journal Article,4709.0,7.0,Earlier studies regarding the risk of cancer CRC in women with a prior diagnosis of gynecologic malignancies have revealed conflicting results We sought to further clarify this association A retrospective cohort study was performed using the General Practice Research Database of the United Kingdom Patients with a prior diagnosis of or cancers were compared with control patients without a prior gynecologic malignancy The primary outcome was a diagnosis of CRC Poisson regression analysis was used to assess the effects of potential confounders The study included 1995 1348 and 1101 cancer patients and 7980 5392 and 4404 matched control patients respectively The adjusted incidence rate ratio IRR of CRC among cancer patients was 2.90 95 confidence intervals CI 1.45-5.82 Five of 10 cases of CRC in cancer patients were diagnosed within 6 months of the cancer diagnosis with an adjusted IRR of 8.0 95 CI 1.9-33.6 Excluding the initial 6 months of follow-up after the diagnosis of cancer the adjusted IRR was 1.6 95 CI 0.76-5.03 The adjusted IRR of CRC in patients with a prior diagnosis of and cancer was 0.79 95 CI 0.24-2.61 and 1.50 95 CI 0.43-5.21 respectively Women with a prior diagnosis of cancer are at an increased risk of CRC The risk of CRC was not increased among patients with a prior history of and cancer,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[1677, 94, 666, 3, 43, 1, 12, 590, 4, 117, 5, 8, 324, 147, 1, 1512, 441, 47, 553, 4274, 99, 21, 990, 6, 195, 3968, 26, 248, 8, 459, 180, 45, 10, 173, 75, 3, 1083, 758, 389, 609, 1, 3, 1088, 10782, 7, 5, 8, 324, 147, 1, 15, 163, 11, 72, 5, 182, 7, 187, 8, 324, 1512, 710, 3, 86, 228, 10, 8, 147, 1, 590, 7668, 320, 65, 10, 95, 6, 423, 3, 176, 1, 174, 4423, 3, 45, 159, 2323, 34253, 2, 15129, 12, 7, 2, 56200, 56201, 2, 44692, 655, 182, 7, 106, 3, 586, 287, 116, 197, 7824, 1, 590, 107, 12, 7, 10, 18, 424, 48, 307, 1582, 58, 14, 512, 33, 878, 365, 1, 79, 140, 1, 590, 4, 12, 7, 11, 265, 262, 49, 53, 1, 3, 12, 147, 5, 35, 586, 7824, 1, 66, 13, 48, 58, 14, 83, 466, 49, 3207, 3, 388, 49, 53, 1, 166, 126, 50, 3, 147, 1, 12, 3, 586, 7824, 10, 14, 49, 48, 58, 13, 846, 33, 680, 3, 586, 7824, 1, 590, 4, 7, 5, 8, 324, 147, 1, 2, 12, 10, 13, 842, 48, 58, 13, 259, 18, 713, 2, 14, 212, 48, 58, 13, 601, 33, 239, 106, 117, 5, 8, 324, 147, 1, 12, 32, 28, 35, 101, 43, 1, 590, 3, 43, 1, 590, 10, 44, 101, 107, 7, 5, 8, 324, 532, 1, 2, 12]",1321.0,17426469,438
Propensity-matched analysis of three techniques for intrathoracic esophagogastric anastomosis.,The Annals of thoracic surgery,Ann. Thorac. Surg.,2007-05-01,"A cervical side-to-side stapled esophagogastric anastomosis appears to decrease morbidity compared with traditional hand-sewn techniques. We evaluated our experience with this novel technique in intrathoracic anastomoses and compared the outcome with circular-stapled or hand-sewn techniques. All patients undergoing transthoracic esophagectomy from 1999 to 2005 for esophageal cancer with gastric replacement were reviewed. A prospective quality improvement database, telephone interview, and chart review were used to collect data. A side-to-side stapled anastomosis was done in 44 patients, circular-stapled anastomosis in 147, and hand-sewn anastomosis in 23. Propensity scores were generated from 14 variables, which were then used to generate 23 patient triplets. End points included leak, dysphagia, stricture, other major complications, and overall survival. Follow-up was available on all patients. For matched triplet comparison, no significant difference was noted in anastomotic leaks (8.7% with side-to-side stapled, 4.3% with circular-stapled, and 4.3% with hand-sewn; p = 0.78). Postoperative dysphagia was significantly higher in hand-sewn anastomoses at 56.5% versus 26.1% with side-to-side stapled and 21.7% with circular-stapled (p = 0.04). Stricture requiring esophageal dilation was also increased in hand-sewn at 34.8% versus 8.7% with side-to-side stapled and 8.7% with circular-stapled (p = 0.04). No difference was noted in perioperative mortality, long-term survival, or locoregional recurrences between techniques. In this carefully matched group of patients, intrathoracic use of the side-to-side stapled esophagogastric anastomosis in esophageal cancer patients is safe and effective. Postoperative dysphagia and need for stricture dilation may be decreased using a stapled compared with a traditional hand-sewn anastomosis.",Comparative Study,4648.0,59.0,A side-to-side stapled esophagogastric anastomosis appears to decrease morbidity compared with traditional hand-sewn techniques We evaluated our experience with this novel technique in intrathoracic anastomoses and compared the outcome with circular-stapled or hand-sewn techniques All patients undergoing transthoracic esophagectomy from 1999 to 2005 for cancer with replacement were reviewed A prospective quality improvement database telephone interview and chart review were used to collect data A side-to-side stapled anastomosis was done in 44 patients circular-stapled anastomosis in 147 and hand-sewn anastomosis in 23 Propensity scores were generated from 14 variables which were then used to generate 23 patient triplets End points included leak dysphagia stricture other major complications and overall survival Follow-up was available on all patients For matched triplet comparison no significant difference was noted in anastomotic leaks 8.7 with side-to-side stapled 4.3 with circular-stapled and 4.3 with hand-sewn p 0.78 Postoperative dysphagia was significantly higher in hand-sewn anastomoses at 56.5 versus 26.1 with side-to-side stapled and 21.7 with circular-stapled p 0.04 Stricture requiring dilation was also increased in hand-sewn at 34.8 versus 8.7 with side-to-side stapled and 8.7 with circular-stapled p 0.04 No difference was noted in perioperative mortality long-term survival or locoregional recurrences between techniques In this carefully matched group of patients intrathoracic use of the side-to-side stapled esophagogastric anastomosis in cancer patients is safe and effective Postoperative dysphagia and need for stricture dilation may be decreased using a stapled compared with a traditional hand-sewn anastomosis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,"[8, 1152, 6, 1152, 9911, 6330, 5519, 1233, 6, 775, 787, 72, 5, 1847, 2833, 19111, 1092, 21, 194, 114, 730, 5, 26, 229, 1312, 4, 7359, 13311, 2, 72, 3, 228, 5, 12388, 9911, 15, 2833, 19111, 1092, 62, 7, 479, 14806, 3617, 29, 2043, 6, 1242, 9, 12, 5, 3892, 11, 446, 8, 482, 372, 767, 609, 4258, 4313, 2, 2937, 206, 11, 95, 6, 6248, 74, 8, 1152, 6, 1152, 9911, 5519, 10, 1822, 4, 584, 7, 12388, 9911, 5519, 4, 4961, 2, 2833, 19111, 5519, 4, 382, 1925, 703, 11, 1419, 29, 213, 682, 92, 11, 818, 95, 6, 2562, 382, 69, 26037, 396, 862, 159, 4238, 4561, 6673, 127, 458, 521, 2, 63, 25, 166, 126, 10, 390, 23, 62, 7, 9, 655, 7706, 1155, 77, 93, 523, 10, 1051, 4, 4818, 9674, 66, 67, 5, 1152, 6, 1152, 9911, 39, 27, 5, 12388, 9911, 2, 39, 27, 5, 2833, 19111, 19, 13, 833, 573, 4561, 10, 97, 142, 4, 2833, 19111, 13311, 28, 664, 33, 185, 432, 14, 5, 1152, 6, 1152, 9911, 2, 239, 67, 5, 12388, 9911, 19, 13, 755, 6673, 1888, 8062, 10, 120, 101, 4, 2833, 19111, 28, 562, 66, 185, 66, 67, 5, 1152, 6, 1152, 9911, 2, 66, 67, 5, 12388, 9911, 19, 13, 755, 77, 523, 10, 1051, 4, 1547, 282, 319, 337, 25, 15, 1325, 1593, 59, 1092, 4, 26, 3900, 655, 87, 1, 7, 7359, 119, 1, 3, 1152, 6, 1152, 9911, 6330, 5519, 4, 12, 7, 16, 1165, 2, 323, 573, 4561, 2, 594, 9, 6673, 8062, 68, 40, 340, 75, 8, 9911, 72, 5, 8, 1847, 2833, 19111, 5519]",1752.0,17462404,289
A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration.,Gynecologic oncology,Gynecol. Oncol.,2007-05-02,"To determine the accuracy of (18)FDG PET in identifying sites of metastatic disease prior to pelvic exenteration or radical resection in patients (pts) with recurrent cervical or vaginal cancers. Pts with recurrent cervical or vaginal cancer being evaluated for surgical resection were enrolled in a prospective study approved by the institutional human subjects review board. All patients underwent (18)FDG PET scans as well as CT and/or MRI scans and were required to have pathologic confirmation of any sites suggestive of tumor recurrence. Between 1998 and 2002 a total of 27 pts were enrolled on the study. Seven patients did not complete all study requirements and are excluded from further analysis. All pts had undergone prior pelvic radiation therapy and five patients had also received chemotherapy. CT/MRI scans identified three patients with possible metastatic disease in the following sites: (1) iliac nodes (2 pts) and (2) lungs (1 pt). After surgical and pathological evaluation, only one of these sites, the lungs, was confirmed to have metastatic disease. PET scans identified possible metastatic disease in nine patients and included the following sites: (1) pelvic nodes (4 pts), (2) para-aortic nodes (2 pts), (3) axillary node (1 pt), (4) bowel wall (1 pt) and (5) lungs (1 pt). After surgical and pathologic evaluation metastatic disease was identified in five of these pts at the following sites: iliac nodes, 2; para-aortic nodes, 1; bowel wall, 1; and lungs, 1. Of the sites identified by PET scan as areas of metastasis CT scan only identified the pulmonary metastasis. (18)FDG PET was found to have a sensitivity of 100% and a specificity of 73% in detecting sites of extra-pelvic metastasis and may be the most accurate test to determine eligibility for pelvic exenteration.",Journal Article,4647.0,60.0,To determine the accuracy of 18 FDG PET in identifying sites of metastatic disease prior to pelvic exenteration or radical resection in patients pts with recurrent or cancers Pts with recurrent or cancer being evaluated for surgical resection were enrolled in a prospective study approved by the institutional human subjects review board All patients underwent 18 FDG PET scans as well as CT and/or MRI scans and were required to have pathologic confirmation of any sites suggestive of tumor recurrence Between 1998 and 2002 a total of 27 pts were enrolled on the study Seven patients did not complete all study requirements and are excluded from further analysis All pts had undergone prior pelvic radiation therapy and five patients had also received chemotherapy CT/MRI scans identified three patients with possible metastatic disease in the following sites 1 iliac nodes 2 pts and 2 lungs 1 pt After surgical and pathological evaluation only one of these sites the lungs was confirmed to have metastatic disease PET scans identified possible metastatic disease in nine patients and included the following sites 1 pelvic nodes 4 pts 2 para-aortic nodes 2 pts 3 axillary node 1 pt 4 bowel wall 1 pt and 5 lungs 1 pt After surgical and pathologic evaluation metastatic disease was identified in five of these pts at the following sites iliac nodes 2 para-aortic nodes 1 bowel wall 1 and lungs 1 Of the sites identified by PET scan as areas of metastasis CT scan only identified the pulmonary metastasis 18 FDG PET was found to have a sensitivity of 100 and a specificity of 73 in detecting sites of extra-pelvic metastasis and may be the most accurate test to determine eligibility for pelvic exenteration,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 1190, 1, 203, 1285, 495, 4, 1386, 633, 1, 113, 34, 324, 6, 1110, 5668, 15, 711, 170, 4, 7, 3637, 5, 387, 15, 163, 3637, 5, 387, 15, 12, 486, 194, 9, 221, 170, 11, 346, 4, 8, 482, 45, 850, 20, 3, 1115, 171, 976, 206, 2620, 62, 7, 208, 203, 1285, 495, 1441, 22, 149, 22, 425, 2, 15, 704, 1441, 2, 11, 616, 6, 47, 510, 3551, 1, 500, 633, 3832, 1, 30, 146, 59, 1850, 2, 1544, 8, 181, 1, 428, 3637, 11, 346, 23, 3, 45, 648, 7, 205, 44, 236, 62, 45, 4230, 2, 32, 1800, 29, 195, 65, 62, 3637, 42, 1989, 324, 1110, 121, 36, 2, 365, 7, 42, 120, 103, 56, 425, 704, 1441, 108, 169, 7, 5, 899, 113, 34, 4, 3, 366, 633, 14, 6692, 502, 18, 3637, 2, 18, 4465, 14, 3395, 50, 221, 2, 1301, 451, 158, 104, 1, 46, 633, 3, 4465, 10, 557, 6, 47, 113, 34, 495, 1441, 108, 899, 113, 34, 4, 762, 7, 2, 159, 3, 366, 633, 14, 1110, 502, 39, 3637, 18, 4615, 3938, 502, 18, 3637, 27, 1210, 289, 14, 3395, 39, 1659, 2397, 14, 3395, 2, 33, 4465, 14, 3395, 50, 221, 2, 510, 451, 113, 34, 10, 108, 4, 365, 1, 46, 3637, 28, 3, 366, 633, 6692, 502, 18, 4615, 3938, 502, 14, 1659, 2397, 14, 2, 4465, 14, 1, 3, 633, 108, 20, 495, 1657, 22, 1361, 1, 278, 425, 1657, 158, 108, 3, 1087, 278, 203, 1285, 495, 10, 204, 6, 47, 8, 485, 1, 394, 2, 8, 1121, 1, 803, 4, 2502, 633, 1, 3420, 1110, 278, 2, 68, 40, 3, 96, 1481, 412, 6, 223, 2317, 9, 1110, 5668]",1706.0,17477959,370
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2007-05-04,"To determine the efficacy and patterns of initial failure for oral celecoxib, intravenous cisplatin, and 5-fluorouracil and concurrent pelvic radiotherapy in patients with locally advanced cancer of the cervix. Patients were treated with concurrent 5-fluorouracil and cisplatin chemotherapy and pelvic radiotherapy and brachytherapy. Celecoxib was prescribed at a dose of 400 mg twice daily for 1 year beginning on the first day of radiotherapy. The overall and disease-free survival rates were determined. A total of 84 patients were accrued, of whom 78 were eligible. The estimated 2-year disease-free survival and overall survival rate was 69% and 83%, respectively. Of the 78 patients, 24 had treatment failure: 3 with persistent local disease, 9 local only, 2 regional, 4 distant, 1 regional and distant, 1 local and distant, and 2 with local, regional, and distant disease, and 1 had died of cervical cancer without a reported site of first failure and 1 without evidence of disease. At 2 years, the estimated disease-free survival and overall survival rate for patients with advanced cervical cancer who underwent a combination of chemoradiotherapy and celecoxib treatment was 69% and 83%, respectively. Recurrent disease developed in 24 patients, and, of those patients, 18 had a component of locoregional failure as a site of first failure. Thus, locoregional control continues to be problematic after chemoradiotherapy as delivered in our study. The identification of more active biologically targeted therapies is warranted for the treatment of advanced cancer of the cervix.","Clinical Trial, Phase II",4645.0,29.0,To determine the efficacy and patterns of initial failure for oral celecoxib intravenous cisplatin and 5-fluorouracil and concurrent pelvic radiotherapy in patients with locally advanced cancer of the cervix Patients were treated with concurrent 5-fluorouracil and cisplatin chemotherapy and pelvic radiotherapy and brachytherapy Celecoxib was prescribed at a dose of 400 mg twice daily for 1 year beginning on the first day of radiotherapy The overall and disease-free survival rates were determined A total of 84 patients were accrued of whom 78 were eligible The estimated 2-year disease-free survival and overall survival rate was 69 and 83 respectively Of the 78 patients 24 had treatment failure 3 with persistent local disease 9 local only 2 regional 4 distant 1 regional and distant 1 local and distant and 2 with local regional and distant disease and 1 had died of cancer without a reported site of first failure and 1 without evidence of disease At 2 years the estimated disease-free survival and overall survival rate for patients with advanced cancer who underwent a combination of chemoradiotherapy and celecoxib treatment was 69 and 83 respectively Recurrent disease developed in 24 patients and of those patients 18 had a component of locoregional failure as a site of first failure Thus locoregional control continues to be problematic after chemoradiotherapy as delivered in our study The identification of more active biologically targeted therapies is warranted for the treatment of advanced cancer of the cervix,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 209, 2, 764, 1, 388, 496, 9, 518, 2673, 1262, 540, 2, 33, 1404, 2, 750, 1110, 310, 4, 7, 5, 795, 131, 12, 1, 3, 3629, 7, 11, 73, 5, 750, 33, 1404, 2, 540, 56, 2, 1110, 310, 2, 1536, 2673, 10, 2746, 28, 8, 61, 1, 1524, 81, 936, 391, 9, 14, 111, 2948, 23, 3, 157, 218, 1, 310, 3, 63, 2, 34, 115, 25, 151, 11, 509, 8, 181, 1, 874, 7, 11, 3198, 1, 953, 833, 11, 625, 3, 661, 18, 111, 34, 115, 25, 2, 63, 25, 116, 10, 790, 2, 852, 106, 1, 3, 833, 7, 259, 42, 24, 496, 27, 5, 1882, 293, 34, 83, 293, 158, 18, 951, 39, 626, 14, 951, 2, 626, 14, 293, 2, 626, 2, 18, 5, 293, 951, 2, 626, 34, 2, 14, 42, 1016, 1, 12, 187, 8, 210, 606, 1, 157, 496, 2, 14, 187, 241, 1, 34, 28, 18, 60, 3, 661, 34, 115, 25, 2, 63, 25, 116, 9, 7, 5, 131, 12, 54, 208, 8, 150, 1, 1464, 2, 2673, 24, 10, 790, 2, 852, 106, 387, 34, 276, 4, 259, 7, 2, 1, 135, 7, 203, 42, 8, 1249, 1, 1325, 496, 22, 8, 606, 1, 157, 496, 631, 1325, 182, 2274, 6, 40, 6594, 50, 1464, 22, 1623, 4, 114, 45, 3, 911, 1, 80, 544, 2665, 238, 235, 16, 1197, 9, 3, 24, 1, 131, 12, 1, 3, 3629]",1532.0,17482376,1
Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2007-06-08,"To analyze the outcomes of therapy and identify prognostic factors for patients treated with surgery followed by intraoperative radiotherapy (IORT) for gynecologic malignancies at a single institution. We performed a retrospective review of 36 consecutive patients treated with IORT to 44 sites with mean follow-up of 50 months. The primary site was the cervix in 47%, endometrium in 31%, vulva in 14%, vagina in 6%, and fallopian tubes in 3%. Previous RT had failed in 72% of patients, and 89% had recurrent disease. Of 38 IORT sessions, 84% included maximal cytoreductive surgery, including 18% exenterations. The mean age was 52 years (range, 30-74), mean tumor size was 5 cm (range, 0.5-12), previous disease-free interval was 32 months (range, 0-177), and mean IORT dose was 1,152 cGy (range, 600-1,750). RT and systemic therapy after IORT were given to 53% and 24% of the cohort, respectively. The outcomes measured were locoregional control (LRC), distant metastasis-free survival (DMFS), disease-specific survival (DSS), and treatment-related complications. The Kaplan-Meier 5-year LRC, DMFS, and DSS probability for the whole group was 44%, 51%, and 47%, respectively. For cervical cancer patients, the Kaplan-Meier 5-year LRC, DMFS, and DSS estimate was 45%, 60%, and 46%, respectively. The prognostic factors found on multivariate analysis (p <or= 0.05) were the disease-free interval for LRC, tumor size for DMFS, and cervical primary, previous surgery, and locoregional relapse for DSS. Our cohort had 10 Grade 3-4 complications associated with treatment (surgery and IORT) and a Kaplan-Meier 5-year Grade 3-4 complication-free survival rate of 72%. Survival for pelvic recurrence of gynecologic cancer is poor (range, 0-25%). IORT after surgery seems to confer long-term local control in carefully selected patients.",Journal Article,4610.0,39.0,"To analyze the outcomes of therapy and identify prognostic factors for patients treated with surgery followed by intraoperative radiotherapy IORT for gynecologic malignancies at a single institution We performed a retrospective review of 36 consecutive patients treated with IORT to 44 sites with mean follow-up of 50 months The primary site was the cervix in 47 in 31 vulva in 14 vagina in 6 and tubes in 3 Previous RT had failed in 72 of patients and 89 had recurrent disease Of 38 IORT sessions 84 included maximal cytoreductive surgery including 18 exenterations The mean age was 52 years range 30-74 mean tumor size was 5 cm range 0.5-12 previous disease-free interval was 32 months range 0-177 and mean IORT dose was 1,152 cGy range 600-1,750 RT and systemic therapy after IORT were given to 53 and 24 of the cohort respectively The outcomes measured were locoregional control LRC distant metastasis-free survival DMFS disease-specific survival DSS and treatment-related complications The Kaplan-Meier 5-year LRC DMFS and DSS probability for the whole group was 44 51 and 47 respectively For cancer patients the Kaplan-Meier 5-year LRC DMFS and DSS estimate was 45 60 and 46 respectively The prognostic factors found on multivariate analysis p or= 0.05 were the disease-free interval for LRC tumor size for DMFS and primary previous surgery and locoregional relapse for DSS Our cohort had 10 Grade 3-4 complications associated with treatment surgery and IORT and a Kaplan-Meier 5-year Grade 3-4 complication-free survival rate of 72 Survival for pelvic recurrence of gynecologic cancer is poor range 0-25 IORT after surgery seems to confer long-term local control in carefully selected patients",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 1992, 3, 123, 1, 36, 2, 255, 177, 130, 9, 7, 73, 5, 152, 370, 20, 1720, 310, 4158, 9, 1512, 441, 28, 8, 226, 731, 21, 173, 8, 459, 206, 1, 511, 935, 7, 73, 5, 4158, 6, 584, 633, 5, 313, 166, 126, 1, 212, 53, 3, 86, 606, 10, 3, 3629, 4, 662, 4, 456, 9263, 4, 213, 7553, 4, 49, 2, 6193, 4, 27, 698, 240, 42, 1551, 4, 720, 1, 7, 2, 887, 42, 387, 34, 1, 519, 4158, 4390, 874, 159, 2725, 2604, 152, 141, 203, 44747, 3, 313, 89, 10, 653, 60, 184, 201, 794, 313, 30, 444, 10, 33, 494, 184, 13, 33, 133, 698, 34, 115, 268, 10, 531, 53, 184, 13, 4699, 2, 313, 4158, 61, 10, 14, 5370, 3071, 184, 2383, 14, 4506, 240, 2, 403, 36, 50, 4158, 11, 447, 6, 699, 2, 259, 1, 3, 180, 106, 3, 123, 644, 11, 1325, 182, 4000, 626, 278, 115, 25, 5930, 34, 112, 25, 1788, 2, 24, 139, 521, 3, 876, 882, 33, 111, 4000, 5930, 2, 1788, 1320, 9, 3, 902, 87, 10, 584, 725, 2, 662, 106, 9, 12, 7, 3, 876, 882, 33, 111, 4000, 5930, 2, 1788, 1191, 10, 512, 335, 2, 641, 106, 3, 177, 130, 204, 23, 331, 65, 19, 15, 13, 474, 11, 3, 34, 115, 268, 9, 4000, 30, 444, 9, 5930, 2, 86, 698, 152, 2, 1325, 429, 9, 1788, 114, 180, 42, 79, 88, 27, 39, 521, 41, 5, 24, 152, 2, 4158, 2, 8, 876, 882, 33, 111, 88, 27, 39, 1447, 115, 25, 116, 1, 720, 25, 9, 1110, 146, 1, 1512, 12, 16, 334, 184, 13, 243, 4158, 50, 152, 2744, 6, 2913, 319, 337, 293, 182, 4, 3900, 715, 7]",1700.0,17560736,207
Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma.,Gynecologic oncology,Gynecol. Oncol.,2007-06-11,"To evaluate the rate of vesicovaginal fistula formation and mortality in women with Stage IVA cervical carcinoma. Data were abstracted from the clinical records of women diagnosed with Stage IVA cervical cancer at the time of examination under anesthesia, cystoscopy, and proctoscopy (EUA/C/P) at a single institution from 1994 to 2004. Demographic and treatment characteristics were compared using either Fisher's exact test or Student's t-test, as appropriate. Survival was calculated using the Kaplan-Meier method. Twenty-three patients were diagnosed with Stage IVA cervical cancer. All were diagnosed with extension of disease into the bladder; one patient had rectal involvement as well. Concurrent chemotherapy and radiation was used in 60.8%, while 30.4% received radiation alone and 8.7% elected no treatment. Fifty-six percent of the patients were smokers. Eleven patients (47.8%) developed a fistula at a median time of 2.9 months from cancer diagnosis. Fistula formation was significantly increased among smokers as compared to non-smokers (73 vs 27%; p=0.03). Two patients (8.7%) are alive without evidence of disease at a median follow-up of 19 months. The disease-specific survival is 23.1 months. Patients who developed a vesicovaginal fistula had a median survival of 11.2 months after fistula formation. High rates of vesicovaginal fistula formation can be expected when treating women with extension of cervical cancer into the bladder, particularly among women who smoke. The routine use of EUA/C/P at the time of initial diagnosis aids in counseling women about the likelihood of this complication. Novel strategies for managing vesicovaginal fistulae after chemoradiation are needed.",Journal Article,4607.0,41.0,To evaluate the rate of vesicovaginal fistula formation and mortality in women with Stage IVA carcinoma Data were abstracted from the clinical records of women diagnosed with Stage IVA cancer at the time of examination under anesthesia cystoscopy and proctoscopy EUA/C/P at a single institution from 1994 to 2004 Demographic and treatment characteristics were compared using either Fisher 's exact test or Student 's t-test as appropriate Survival was calculated using the Kaplan-Meier method Twenty-three patients were diagnosed with Stage IVA cancer All were diagnosed with extension of disease into the one patient had involvement as well Concurrent chemotherapy and radiation was used in 60.8 while 30.4 received radiation alone and 8.7 elected no treatment Fifty-six percent of the patients were smokers Eleven patients 47.8 developed a fistula at a median time of 2.9 months from cancer diagnosis Fistula formation was significantly increased among smokers as compared to non-smokers 73 vs 27 p=0.03 Two patients 8.7 are alive without evidence of disease at a median follow-up of 19 months The disease-specific survival is 23.1 months Patients who developed a vesicovaginal fistula had a median survival of 11.2 months after fistula formation High rates of vesicovaginal fistula formation can be expected when treating women with extension of cancer into the particularly among women who smoke The routine use of EUA/C/P at the time of initial diagnosis aids in counseling women about the likelihood of this complication Novel strategies for managing vesicovaginal fistulae after chemoradiation are needed,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,"[6, 376, 3, 116, 1, 25979, 4920, 1264, 2, 282, 4, 117, 5, 82, 5900, 134, 74, 11, 4106, 29, 3, 38, 1064, 1, 117, 265, 5, 82, 5900, 12, 28, 3, 98, 1, 1385, 669, 6433, 4362, 2, 21943, 37087, 256, 19, 28, 8, 226, 731, 29, 3023, 6, 1131, 1540, 2, 24, 374, 11, 72, 75, 361, 3135, 292, 2472, 412, 15, 6390, 292, 102, 412, 22, 870, 25, 10, 981, 75, 3, 876, 882, 596, 737, 169, 7, 11, 265, 5, 82, 5900, 12, 62, 11, 265, 5, 2401, 1, 34, 237, 3, 104, 69, 42, 799, 22, 149, 750, 56, 2, 121, 10, 95, 4, 335, 66, 369, 201, 39, 103, 121, 279, 2, 66, 67, 9164, 77, 24, 1461, 437, 714, 1, 3, 7, 11, 1485, 2627, 7, 662, 66, 276, 8, 4920, 28, 8, 52, 98, 1, 18, 83, 53, 29, 12, 147, 4920, 1264, 10, 97, 101, 107, 1485, 22, 72, 6, 220, 1485, 803, 105, 428, 19, 13, 680, 100, 7, 66, 67, 32, 1701, 187, 241, 1, 34, 28, 8, 52, 166, 126, 1, 326, 53, 3, 34, 112, 25, 16, 382, 14, 53, 7, 54, 276, 8, 25979, 4920, 42, 8, 52, 25, 1, 175, 18, 53, 50, 4920, 1264, 64, 151, 1, 25979, 4920, 1264, 122, 40, 1336, 198, 1367, 117, 5, 2401, 1, 12, 237, 3, 823, 107, 117, 54, 6113, 3, 1311, 119, 1, 37087, 256, 19, 28, 3, 98, 1, 388, 147, 4174, 4, 2011, 117, 545, 3, 1420, 1, 26, 1447, 229, 422, 9, 3969, 25979, 17809, 50, 975, 32, 575]",1611.0,17561235,127
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2007-06-01,"To determine the toxicities, pharmacokinetics, and maximally tolerated doses of oxaliplatin in patients with hepatic impairment and to develop formal guidelines for oxaliplatin dosing in this patient population. Sixty adult cancer patients with variable hepatic function received i.v. oxaliplatin ranging from 60 to 130 mg/m(2) every 3 weeks. Patients were stratified by levels of total bilirubin, aspartate aminotransferase (AST), and alkaline phosphatase (AP) into five cohorts based on the degree of hepatic dysfunction: control group A [bilirubin, AST, and AP < or = upper limit of normal (ULN)], mild dysfunction group B (bilirubin < or = ULN, ULN < AST < or = 2.5 x ULN, or ULN < AP < or = 5 x ULN), moderate dysfunction group C (ULN < bilirubin < or = 3.0 mg/dL, AST > 2.5 x ULN, or AP > 5 x ULN), severe dysfunction group D (bilirubin > 3.0 mg/dL, any AST, and any AP), and liver transplantation group E (any bilirubin, any AST, and any AP). Doses were escalated in cohorts of three patients, and urine and plasma ultrafiltrates were assayed for platinum concentrations. Dose escalation of single-agent oxaliplatin to 130 mg/m(2) was well tolerated in all cohorts. Platinum clearance did not correlate with any liver function test. Two of 56 assessable patients with a diagnosis of laryngeal carcinoma and cervical adenocarcinoma experienced partial responses lasting 3 and 5.5 months. Oxaliplatin at 130 mg/m(2) every 3 weeks was well tolerated in all patients with impaired liver function. Dose reductions of single-agent oxaliplatin are not indicated in patients with hepatic dysfunction.",Clinical Trial,4617.0,44.0,To determine the toxicities pharmacokinetics and maximally tolerated doses of oxaliplatin in patients with hepatic impairment and to develop formal guidelines for oxaliplatin dosing in this patient population Sixty adult cancer patients with variable hepatic function received i.v oxaliplatin ranging from 60 to 130 mg/m 2 every 3 weeks Patients were stratified by levels of total bilirubin aspartate aminotransferase AST and alkaline phosphatase AP into five cohorts based on the degree of hepatic dysfunction control group A bilirubin AST and AP or upper limit of normal ULN mild dysfunction group B bilirubin or ULN ULN AST or 2.5 x ULN or ULN AP or 5 x ULN moderate dysfunction group C ULN bilirubin or 3.0 mg/dL AST 2.5 x ULN or AP 5 x ULN severe dysfunction group D bilirubin 3.0 mg/dL any AST and any AP and transplantation group E any bilirubin any AST and any AP Doses were escalated in cohorts of three patients and urine and plasma ultrafiltrates were assayed for platinum concentrations Dose escalation of single-agent oxaliplatin to 130 mg/m 2 was well tolerated in all cohorts Platinum clearance did not correlate with any function test Two of 56 assessable patients with a diagnosis of carcinoma and adenocarcinoma experienced partial responses lasting 3 and 5.5 months Oxaliplatin at 130 mg/m 2 every 3 weeks was well tolerated in all patients with impaired function Dose reductions of single-agent oxaliplatin are not indicated in patients with hepatic dysfunction,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 385, 1159, 2, 6402, 421, 415, 1, 1476, 4, 7, 5, 939, 2315, 2, 6, 690, 5057, 677, 9, 1476, 1280, 4, 26, 69, 266, 1746, 780, 12, 7, 5, 1347, 939, 343, 103, 70, 603, 1476, 2223, 29, 335, 6, 3431, 81, 188, 18, 454, 27, 244, 7, 11, 1173, 20, 148, 1, 181, 5009, 6308, 4597, 5759, 2, 5355, 2577, 2517, 237, 365, 736, 90, 23, 3, 1444, 1, 939, 1527, 182, 87, 8, 5009, 5759, 2, 2517, 15, 1726, 2385, 1, 295, 10628, 1980, 1527, 87, 132, 5009, 15, 10628, 10628, 5759, 15, 18, 33, 1006, 10628, 15, 10628, 2517, 15, 33, 1006, 10628, 1163, 1527, 87, 256, 10628, 5009, 15, 27, 13, 81, 1826, 5759, 18, 33, 1006, 10628, 15, 2517, 33, 1006, 10628, 905, 1527, 87, 427, 5009, 27, 13, 81, 1826, 500, 5759, 2, 500, 2517, 2, 497, 87, 563, 500, 5009, 500, 5759, 2, 500, 2517, 415, 11, 2842, 4, 736, 1, 169, 7, 2, 2646, 2, 554, 33477, 11, 4499, 9, 828, 1003, 61, 1125, 1, 226, 420, 1476, 6, 3431, 81, 188, 18, 10, 149, 421, 4, 62, 736, 828, 1960, 205, 44, 1513, 5, 500, 343, 412, 100, 1, 664, 3120, 7, 5, 8, 147, 1, 134, 2, 449, 592, 450, 253, 3443, 27, 2, 33, 33, 53, 1476, 28, 3431, 81, 188, 18, 454, 27, 244, 10, 149, 421, 4, 62, 7, 5, 2364, 343, 61, 2153, 1, 226, 420, 1476, 32, 44, 1103, 4, 7, 5, 939, 1527]",1481.0,17575231,137
Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis.,Cancer research,Cancer Res.,2007-07-01,"High-risk human papillomaviruses (HPVs), which cause the vast majority of cervical cancer, other anogenital cancers, and a subset of head and neck squamous cell carcinomas, encode three oncogenes: E5, E6, and E7. To determine the oncogenic properties of HPV16 E5 in vivo, we previously generated K14E5 transgenic mice, in which expression of E5 was directed to the basal compartment of stratified squamous epithelia. In these mice, E5 induced epidermal hyperplasia and spontaneous skin tumors. In the current study, we determined how E5 contributes to tumor formation in the skin using a multistage model for skin carcinogenesis that specifies the role of genes in three stages: initiation, promotion, and malignant progression. Both initiation and promotion are required steps for papilloma formation. K14E5 mice treated with the initiating agent 7,12-dimethylbenz(a)anthracene (DMBA) developed more papillomas than like-treated nontransgenic mice, whereas neither K14E5 nor nontransgenic mice treated with the promoting agent 12-O-tetradecanoylphorbol-13-acetate (TPA) developed papillomas. K14E5 mice treated with both DMBA and TPA to induce large numbers of papillomas had a higher incidence and earlier onset of carcinoma progression compared with like-treated nontransgenic mice. Thus, HPV16 E5 contributes to two stages of skin carcinogenesis: promotion and progression. The progressive neoplastic disease in K14E5 mice differed from that in nontransgenic mice in that benign tumors converted from exophytic to endophytic papillomas before progressing to carcinomas. Initial genetic and immunohistopathologic analyses did not determine the underlying basis for this distinct morphology, which correlates with a highly penetrant neoplastic phenotype.",Journal Article,4587.0,47.0,"High-risk human papillomaviruses HPVs which cause the vast majority of cancer other anogenital cancers and a subset of head and squamous cell carcinomas encode three oncogenes E5 E6 and E7 To determine the oncogenic properties of HPV16 E5 in vivo we previously generated K14E5 transgenic mice in which expression of E5 was directed to the basal compartment of stratified squamous epithelia In these mice E5 induced epidermal hyperplasia and spontaneous tumors In the current study we determined how E5 contributes to tumor formation in the using a multistage model for carcinogenesis that specifies the role of genes in three stages initiation promotion and malignant progression Both initiation and promotion are required steps for papilloma formation K14E5 mice treated with the initiating agent 7,12-dimethylbenz a anthracene DMBA developed more papillomas than like-treated nontransgenic mice whereas neither K14E5 nor nontransgenic mice treated with the promoting agent 12-O-tetradecanoylphorbol-13-acetate TPA developed papillomas K14E5 mice treated with both DMBA and TPA to induce large numbers of papillomas had a higher incidence and earlier onset of carcinoma progression compared with like-treated nontransgenic mice Thus HPV16 E5 contributes to two stages of carcinogenesis promotion and progression The progressive neoplastic disease in K14E5 mice differed from that in nontransgenic mice in that benign tumors converted from exophytic to endophytic papillomas before progressing to carcinomas Initial genetic and immunohistopathologic analyses did not determine the underlying basis for this distinct morphology which correlates with a highly penetrant neoplastic phenotype",0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,"[64, 43, 171, 14731, 13477, 92, 708, 3, 4337, 686, 1, 12, 127, 13836, 163, 2, 8, 697, 1, 718, 2, 691, 31, 826, 6924, 169, 3326, 16072, 4837, 2, 4540, 6, 223, 3, 1302, 1571, 1, 4048, 16072, 4, 386, 21, 373, 1419, 31131, 2862, 399, 4, 92, 55, 1, 16072, 10, 1166, 6, 3, 2135, 3616, 1, 1173, 691, 7743, 4, 46, 399, 16072, 277, 829, 3176, 2, 3280, 57, 4, 3, 291, 45, 21, 509, 832, 16072, 2444, 6, 30, 1264, 4, 3, 75, 8, 13509, 202, 9, 1719, 17, 38481, 3, 200, 1, 214, 4, 169, 1153, 1118, 5478, 2, 393, 91, 110, 1118, 2, 5478, 32, 616, 4022, 9, 7017, 1264, 31131, 399, 73, 5, 3, 2637, 420, 67, 133, 23309, 8, 22193, 12356, 276, 80, 14816, 76, 733, 73, 20194, 399, 547, 2174, 31131, 2110, 20194, 399, 73, 5, 3, 2388, 420, 133, 1990, 28692, 233, 3424, 11400, 276, 14816, 31131, 399, 73, 5, 110, 12356, 2, 11400, 6, 1290, 375, 1870, 1, 14816, 42, 8, 142, 287, 2, 1677, 1707, 1, 134, 91, 72, 5, 733, 73, 20194, 399, 631, 4048, 16072, 2444, 6, 100, 1153, 1, 1719, 5478, 2, 91, 3, 1014, 2000, 34, 4, 31131, 399, 2512, 29, 17, 4, 20194, 399, 4, 17, 1002, 57, 4764, 29, 12975, 6, 28693, 14816, 348, 4527, 6, 826, 388, 336, 2, 56380, 318, 205, 44, 223, 3, 1181, 877, 9, 26, 834, 2567, 92, 1871, 5, 8, 561, 10301, 2000, 1005]",1688.0,17616666,579
Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2007-07-01,"Globally, cervical cancer is the second most common cause of cancer-related mortality among women causing approximately 234,000 deaths annually among developing countries and killing 40,000 in developed nations. Most of these deaths occur in women with bulky or locally advanced cervical cancer, International Federation of Gynecology and Obstetrics (FIGO) stages IIB through IVA, when lesions are not amenable to high cure rates with surgery or radiation (RT). The standard prescription for RT used to treat locally advanced cervical cancer has been dictated by common practice and patterns of care studies. In contrast, the addition of concomitant chemotherapy to RT has been studied in a number of randomized prospective trials, which are discussed in detail. When added to RT, cisplatin reduces the relative risk of death from cervical carcinoma by approximately 50% by decreasing local/pelvic failure and distant metastases. In 1999, weekly intravenous cisplatin at 40 mg/m2 for 6 weeks in combination with RT was established as a new standard for the treatment of locally advanced cervical carcinoma. More recently, this recommendation has been expanded to include women with FIGO stage IB2 lesions as well as those with bulky stage IIA cancers. This monograph reviews the state of the art in treating locally advanced cervical cancer with combined chemotherapy and RT and discusses clinical and pathologic prognostic factors that impact cure. Quality of life during and after multimodality therapy is considered as well as ongoing clinical trials and future directions.",Journal Article,4587.0,149.0,"Globally cancer is the second most common cause of cancer-related mortality among women causing approximately 234,000 deaths annually among developing countries and killing 40,000 in developed nations Most of these deaths occur in women with bulky or locally advanced cancer International Federation of Gynecology and Obstetrics FIGO stages IIB through IVA when lesions are not amenable to high cure rates with surgery or radiation RT The standard prescription for RT used to treat locally advanced cancer has been dictated by common practice and patterns of care studies In contrast the addition of concomitant chemotherapy to RT has been studied in a number of randomized prospective trials which are discussed in detail When added to RT cisplatin reduces the relative risk of death from carcinoma by approximately 50 by decreasing local/pelvic failure and distant metastases In 1999 weekly intravenous cisplatin at 40 mg/m2 for 6 weeks in combination with RT was established as a new standard for the treatment of locally advanced carcinoma More recently this recommendation has been expanded to include women with FIGO stage IB2 lesions as well as those with bulky stage IIA cancers This monograph reviews the state of the art in treating locally advanced cancer with combined chemotherapy and RT and discusses clinical and pathologic prognostic factors that impact cure Quality of life during and after multimodality therapy is considered as well as ongoing clinical trials and future directions",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6873, 12, 16, 3, 419, 96, 186, 708, 1, 12, 139, 282, 107, 117, 3440, 705, 8049, 984, 1043, 4226, 107, 931, 2115, 2, 3003, 327, 984, 4, 276, 14456, 96, 1, 46, 1043, 1271, 4, 117, 5, 4112, 15, 795, 131, 12, 944, 7303, 1, 6429, 2, 7407, 3837, 1153, 3884, 298, 5900, 198, 406, 32, 44, 4070, 6, 64, 1722, 151, 5, 152, 15, 121, 240, 3, 260, 3584, 9, 240, 95, 6, 943, 795, 131, 12, 71, 85, 10575, 20, 186, 758, 2, 764, 1, 165, 94, 4, 748, 3, 352, 1, 1781, 56, 6, 240, 71, 85, 656, 4, 8, 207, 1, 384, 482, 143, 92, 32, 1588, 4, 5000, 198, 1953, 6, 240, 540, 2389, 3, 580, 43, 1, 273, 29, 134, 20, 705, 212, 20, 2777, 293, 1110, 496, 2, 626, 196, 4, 2043, 709, 1262, 540, 28, 327, 81, 821, 9, 49, 244, 4, 150, 5, 240, 10, 635, 22, 8, 217, 260, 9, 3, 24, 1, 795, 131, 134, 80, 761, 26, 3347, 71, 85, 2064, 6, 643, 117, 5, 3837, 82, 9537, 406, 22, 149, 22, 135, 5, 4112, 82, 4088, 163, 26, 17923, 2004, 3, 1309, 1, 3, 4363, 4, 1367, 795, 131, 12, 5, 397, 56, 2, 240, 2, 2759, 38, 2, 510, 177, 130, 17, 345, 1722, 372, 1, 358, 190, 2, 50, 2425, 36, 16, 515, 22, 149, 22, 942, 38, 143, 2, 508, 3540]",1500.0,17617527,502
Development of a macromolecular dual-modality MR-optical imaging for sentinel lymph node mapping.,Investigative radiology,Invest Radiol,2007-08-01,"To evaluate the effectiveness of a dual magnetic resonance-near infrared fluorescence optical imaging agent, poly(l-glutamic acid)-DTPA-Gd-NIR813, for both preoperative and intraoperative visualization and characterization of sentinel lymph nodes (SLN) in mice. Poly(L-glutamic acid) was conjugated with DTPA-Gd and NIR813 dye to obtain PG-DTPA-Gd-NIR813. To confirm drainage into the SLNs, this agent was injected subcutaneously into the front paw of nude mice followed by isosulfan blue (n = 6). Furthermore, PG-DTPA-Gd-NIR813 was injected subcutaneously at doses of 0.002 mmol Gd/kg (4.8 nmol eq. NIR813) and 0.02 mmol Gd/kg (48 nmol eq. NIR813) (n = 3/dose). To differentiate metastatic from nonmetastatic lymph nodes, nude mice bearing human oral squamous cell carcinoma (DM14) were injected intralingually with 0.02 mmol Gd/kg PG-DTPA-Gd-NIR813 (n = 3). Pre- and postcontrast images were taken using 4.7 T Bruker MRI scanner and Xenogen optical imaging system. The status of lymph nodes resected under the guidance of optical imaging was confirmed by histologic examinations. PG-DTPA-Gd-NIR813 colocalized with isosulfan blue, indicating drainage to the SLN. After subcutaneous injection, axiliary and branchial lymph nodes were clearly visualized with both T1-weighted MR and optical imaging within 3 minutes of contrast injection, even at the lowest dose tested (0.002 mmol Gd/kg). After intralingual injection in tumor-bearing mice, MR imaging identified 4 of the 6 superficial cervical lymph nodes, whereas near-infrared fluorescence (NIRF) optical imaging identified all 6 cervical nodes. The pattern of contrast enhancement of SLN visualized in MR images showed a characteristic ring-shaped appearance with a central filling defect, possibly resulting from nodal infiltration of metastatic lesions. Histopathologic examination of the SLNs resected under NIRF imaging guidance revealed micrometastases in all 6 SLNs identified by NIRF imaging. The dual modality imaging method demonstrated in this study represents an effective technique for localization and characterization of SLN.",Journal Article,4556.0,43.0,To evaluate the effectiveness of a dual magnetic resonance-near infrared fluorescence optical imaging agent poly l-glutamic acid -DTPA-Gd-NIR813 for both preoperative and intraoperative visualization and characterization of sentinel lymph nodes SLN in mice Poly L-glutamic acid was conjugated with DTPA-Gd and NIR813 dye to obtain PG-DTPA-Gd-NIR813 To confirm drainage into the SLNs this agent was injected subcutaneously into the front paw of nude mice followed by isosulfan blue n 6 Furthermore PG-DTPA-Gd-NIR813 was injected subcutaneously at doses of 0.002 mmol Gd/kg 4.8 nmol eq NIR813 and 0.02 mmol Gd/kg 48 nmol eq NIR813 n 3/dose To differentiate metastatic from nonmetastatic lymph nodes nude mice bearing human oral squamous cell carcinoma DM14 were injected intralingually with 0.02 mmol Gd/kg PG-DTPA-Gd-NIR813 n 3 Pre- and postcontrast images were taken using 4.7 T Bruker MRI scanner and Xenogen optical imaging system The status of lymph nodes resected under the guidance of optical imaging was confirmed by histologic examinations PG-DTPA-Gd-NIR813 colocalized with isosulfan blue indicating drainage to the SLN After subcutaneous injection axiliary and branchial lymph nodes were clearly visualized with both T1-weighted MR and optical imaging within 3 minutes of contrast injection even at the lowest dose tested 0.002 mmol Gd/kg After intralingual injection in tumor-bearing mice MR imaging identified 4 of the 6 superficial lymph nodes whereas near-infrared fluorescence NIRF optical imaging identified all 6 nodes The pattern of contrast enhancement of SLN visualized in MR images showed a characteristic ring-shaped appearance with a central filling defect possibly resulting from nodal infiltration of metastatic lesions Histopathologic examination of the SLNs resected under NIRF imaging guidance revealed micrometastases in all 6 SLNs identified by NIRF imaging The dual modality imaging method demonstrated in this study represents an effective technique for localization and characterization of SLN,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 3, 1236, 1, 8, 1828, 1484, 1535, 1829, 6765, 1591, 4303, 270, 420, 2699, 805, 12727, 971, 8435, 6661, 25017, 9, 110, 498, 2, 1720, 6234, 2, 2136, 1, 1323, 263, 502, 1099, 4, 399, 2699, 805, 12727, 971, 10, 3868, 5, 8435, 6661, 2, 25017, 3796, 6, 3140, 3234, 8435, 6661, 25017, 6, 1843, 3528, 237, 3, 2642, 26, 420, 10, 2651, 3928, 237, 3, 3007, 56393, 1, 2598, 399, 370, 20, 10267, 3352, 78, 49, 798, 3234, 8435, 6661, 25017, 10, 2651, 3928, 28, 415, 1, 13, 1111, 10645, 6661, 503, 39, 66, 4694, 6646, 25017, 2, 13, 588, 10645, 6661, 503, 576, 4694, 6646, 25017, 78, 27, 61, 6, 3723, 113, 29, 2683, 263, 502, 2598, 399, 1894, 171, 518, 691, 31, 134, 34296, 11, 2651, 56394, 5, 13, 588, 10645, 6661, 503, 3234, 8435, 6661, 25017, 78, 27, 671, 2, 16438, 1572, 11, 1633, 75, 39, 67, 102, 38486, 704, 10437, 2, 44335, 4303, 270, 398, 3, 156, 1, 263, 502, 1133, 669, 3, 2753, 1, 4303, 270, 10, 557, 20, 884, 4209, 3234, 8435, 6661, 25017, 16625, 5, 10267, 3352, 1716, 3528, 6, 3, 1099, 50, 2529, 1754, 56395, 2, 44776, 263, 502, 11, 2536, 6326, 5, 110, 1534, 2337, 1638, 2, 4303, 270, 262, 27, 2511, 1, 748, 1754, 871, 28, 3, 2101, 61, 650, 13, 1111, 10645, 6661, 503, 50, 56396, 1754, 4, 30, 1894, 399, 1638, 270, 108, 39, 1, 3, 49, 3562, 263, 502, 547, 1829, 6765, 1591, 15349, 4303, 270, 108, 62, 49, 502, 3, 1177, 1, 748, 2461, 1, 1099, 6326, 4, 1638, 1572, 224, 8, 2037, 4091, 8902, 3592, 5, 8, 854, 13930, 5398, 2150, 1113, 29, 779, 2084, 1, 113, 406, 2630, 1385, 1, 3, 2642, 1133, 669, 15349, 270, 2753, 553, 5485, 4, 62, 49, 2642, 108, 20, 15349, 270, 3, 1828, 1396, 270, 596, 264, 4, 26, 45, 1449, 35, 323, 1312, 9, 2145, 2, 2136, 1, 1099]",2025.0,17620940,73
Followup of patients with papillary thyroid cancer: in search of the optimal algorithm.,Journal of the American College of Surgeons,J. Am. Coll. Surg.,2007-06-18,"Cervical recurrence occurs in up to 30% of patients after surgical treatment for papillary thyroid cancer. This study sought to determine an appropriate algorithm for followup evaluation. Patients undergoing total thyroidectomy for papillary thyroid cancer were identified. Clinicopathologic data were recorded, as were the results of all followup evaluations including radioiodine scan, cervical ultrasonography, and serum thyroglobulin levels. The disease recurrence-free survival probability was estimated, and risk factors for recurrence were determined. Thyroidectomy with or without neck dissection was performed in 162 patients. We excluded 36 patients (followup less than 6 months in 26, extracervical disease at diagnosis in 4, unknown tumor size in 6) from the analysis. Of the remaining 126 patients, 109 (86.5%) had no evidence of disease, with serum thyroglobulin < 1 ng/mL at last followup; 4 (3.2%) had no evidence of disease (negative imaging), with serum thyroglobulin > 1 ng/mL, and 13 (10.3%) had recurrent disease. Cervical recurrence occurred in nine patients, all detected by routine ultrasonography. Pulmonary metastases occurred in four patients; three were diagnosed by chest CT and one by radioiodine scan. Thyroid stimulating hormone-suppressed thyroglobulin levels were available in 11 of the 13 patients and were elevated in 9. Patients with high T stage (extrathyroidal extension), or high N stage had an increased risk of recurrence. A followup strategy emphasizing routine cervical ultrasonography and unstimulated thyroglobulin is effective in identifying patients with recurrent papillary thyroid cancer, and may minimize the indiscriminate use of therapeutic radioiodine for radiographically occult disease. Surgery remains the optimal treatment of cervical recurrence, which is the dominant pattern of treatment failure.",Journal Article,4600.0,20.0,recurrence occurs in up to 30 of patients after surgical treatment for papillary cancer This study sought to determine an appropriate algorithm for followup evaluation Patients undergoing total thyroidectomy for papillary cancer were identified Clinicopathologic data were recorded as were the results of all followup evaluations including radioiodine scan ultrasonography and serum thyroglobulin levels The disease recurrence-free survival probability was estimated and risk factors for recurrence were determined Thyroidectomy with or without dissection was performed in 162 patients We excluded 36 patients followup less than 6 months in 26 extracervical disease at diagnosis in 4 unknown tumor size in 6 from the analysis Of the remaining 126 patients 109 86.5 had no evidence of disease with serum thyroglobulin 1 ng/mL at last followup 4 3.2 had no evidence of disease negative imaging with serum thyroglobulin 1 ng/mL and 13 10.3 had recurrent disease recurrence occurred in nine patients all detected by routine ultrasonography Pulmonary metastases occurred in four patients three were diagnosed by chest CT and one by radioiodine scan stimulating hormone-suppressed thyroglobulin levels were available in 11 of the 13 patients and were elevated in 9 Patients with high T stage extrathyroidal extension or high N stage had an increased risk of recurrence A followup strategy emphasizing routine ultrasonography and unstimulated thyroglobulin is effective in identifying patients with recurrent papillary cancer and may minimize the indiscriminate use of therapeutic radioiodine for radiographically occult disease Surgery remains the optimal treatment of recurrence which is the dominant pattern of treatment failure,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[146, 1780, 4, 126, 6, 201, 1, 7, 50, 221, 24, 9, 1796, 12, 26, 45, 990, 6, 223, 35, 870, 2124, 9, 3569, 451, 7, 479, 181, 5949, 9, 1796, 12, 11, 108, 1399, 74, 11, 1872, 22, 11, 3, 99, 1, 62, 3569, 3816, 141, 7211, 1657, 4244, 2, 524, 8978, 148, 3, 34, 146, 115, 25, 1320, 10, 661, 2, 43, 130, 9, 146, 11, 509, 5949, 5, 15, 187, 1161, 10, 173, 4, 5441, 7, 21, 1800, 511, 7, 3569, 299, 76, 49, 53, 4, 432, 38497, 34, 28, 147, 4, 39, 860, 30, 444, 4, 49, 29, 3, 65, 1, 3, 1844, 3927, 7, 3486, 868, 33, 42, 77, 241, 1, 34, 5, 524, 8978, 14, 997, 542, 28, 1060, 3569, 39, 27, 18, 42, 77, 241, 1, 34, 199, 270, 5, 524, 8978, 14, 997, 542, 2, 233, 79, 27, 42, 387, 34, 146, 489, 4, 762, 7, 62, 530, 20, 1311, 4244, 1087, 196, 489, 4, 294, 7, 169, 11, 265, 20, 1662, 425, 2, 104, 20, 7211, 1657, 2122, 785, 1908, 8978, 148, 11, 390, 4, 175, 1, 3, 233, 7, 2, 11, 804, 4, 83, 7, 5, 64, 102, 82, 18518, 2401, 15, 64, 78, 82, 42, 35, 101, 43, 1, 146, 8, 3569, 692, 6826, 1311, 4244, 2, 16781, 8978, 16, 323, 4, 1386, 7, 5, 387, 1796, 12, 2, 68, 3241, 3, 26618, 119, 1, 189, 7211, 9, 5770, 2879, 34, 152, 469, 3, 665, 24, 1, 146, 92, 16, 3, 2156, 1177, 1, 24, 496]",1724.0,17660070,198
Clinical proton radiation therapy research at the Francis H. Burr Proton Therapy Center.,Technology in cancer research & treatment,Technol. Cancer Res. Treat.,2007-08-01,"The Francis H. Burr Proton Therapy Center has a 230 MeV cyclotron from which proton beams are directed to two isocentric gantries, a stereotactic intracranial beam line, and an eye line. Because of improved physical dose distribution, proton radiotherapy allows dose escalation to improve local tumor control in anatomic sites and histologies where local control is suboptimal with photons. The improved dose localization also reduces normal-tissue doses with an anticipated reduction in acute and late toxicity. Clinical treatment protocols, developed to exploit the dosimetric advantages of protons over photons, have been grouped into two broad categories. In the first, dose is escalated for anatomic sites where local control with conventional radiation doses has been suboptimal. In the second, normal-tissue sparing with protons is designed to minimize acute and late toxicity. Treatment of patients on clinical research protocols has been encouraged. Patient treatments began on the first gantry in November 2001; on the eye line in April 2002; on the second gantry in May 2002; and on the stereotactic intracranial line in August 2006. The facility currently treats 60 patients per day, including up to six children daily under anesthesia. Dose-escalation studies have been completed for early stage prostate cancer (in conjunction with Loma Linda University) and sarcomas of the cervical spine/base of skull and thoracolumbosacral spine. Protocols are in progress or development for carcinoma of the nasopharynx, paranasal sinus carcinoma, non-small-cell lung carcinoma, locally advanced carcinoma of the prostate, hepatocellular carcinoma, and pancreatic cancer. Studies evaluating the use of protons for morbidity reduction include protocols for craniospinal irradiation in conjunction with systemic chemotherapy for medulloblastoma, retinoblastoma, pediatric rhabdomyosarcoma, other pediatric sarcomas, and accelerated, hypofractionated partial breast irradiation for T1N0 breast carcinomas. For pediatric patients, protons have also been accepted as an alternative to photons for children enrolled in Children's Oncology Group (COG) protocols. Treatment of patients on these studies has often required the development of new treatment techniques (i.e., matching abutting fields for craniospinal irradiation), respiratory gating, and development of appropriate clinical infrastructure support (i.e., increase in availability of pediatric anesthesia) to allow appropriate treatment. In addition, a clinical research infrastructure for protocol development and data management is required. Results to date indicate that proton radiation therapy offers several potential treatment advantages to patients that can be studied in the setting of clinical trials. Patients' willingness to enter these clinical trials seems to be quite high; accrual to selected studies has been favorable.",Journal Article,4556.0,17.0,The Francis H. Burr Proton Therapy Center has a 230 MeV cyclotron from which proton beams are directed to two isocentric gantries a stereotactic intracranial beam line and an eye line Because of improved physical dose distribution proton radiotherapy allows dose escalation to improve local tumor control in anatomic sites and histologies where local control is suboptimal with photons The improved dose localization also reduces normal-tissue doses with an anticipated reduction in acute and late toxicity Clinical treatment protocols developed to exploit the dosimetric advantages of protons over photons have been grouped into two broad categories In the first dose is escalated for anatomic sites where local control with conventional radiation doses has been suboptimal In the second normal-tissue sparing with protons is designed to minimize acute and late toxicity Treatment of patients on clinical research protocols has been encouraged Patient treatments began on the first gantry in November 2001 on the eye line in April 2002 on the second gantry in May 2002 and on the stereotactic intracranial line in August 2006 The facility currently treats 60 patients per day including up to six children daily under anesthesia Dose-escalation studies have been completed for early stage cancer in conjunction with Loma Linda University and sarcomas of the spine/base of skull and thoracolumbosacral spine Protocols are in progress or development for carcinoma of the nasopharynx paranasal sinus carcinoma non-small-cell carcinoma locally advanced carcinoma of the carcinoma and cancer Studies evaluating the use of protons for morbidity reduction include protocols for craniospinal irradiation in conjunction with systemic chemotherapy for medulloblastoma pediatric other pediatric sarcomas and accelerated hypofractionated partial irradiation for T1N0 carcinomas For pediatric patients protons have also been accepted as an alternative to photons for children enrolled in Children 's Oncology Group COG protocols Treatment of patients on these studies has often required the development of new treatment techniques i.e. matching abutting fields for craniospinal irradiation respiratory gating and development of appropriate clinical infrastructure support i.e. increase in availability of pediatric anesthesia to allow appropriate treatment In addition a clinical research infrastructure for protocol development and data management is required Results to date indicate that proton radiation therapy offers several potential treatment advantages to patients that can be studied in the setting of clinical trials Patients willingness to enter these clinical trials seems to be quite high accrual to selected studies has been favorable,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 37327, 555, 44795, 2095, 36, 574, 71, 8, 6136, 20375, 37078, 29, 92, 2095, 7821, 32, 1166, 6, 100, 38501, 56425, 8, 1729, 2089, 1345, 328, 2, 35, 4922, 328, 408, 1, 231, 900, 61, 1395, 2095, 310, 2333, 61, 1125, 6, 401, 293, 30, 182, 4, 2745, 633, 2, 3489, 1257, 293, 182, 16, 3291, 5, 7862, 3, 231, 61, 2145, 120, 2389, 295, 246, 415, 5, 35, 4078, 628, 4, 286, 2, 807, 155, 38, 24, 2189, 276, 6, 6109, 3, 3187, 3126, 1, 6684, 252, 7862, 47, 85, 3706, 237, 100, 2094, 1996, 4, 3, 157, 61, 16, 2842, 9, 2745, 633, 1257, 293, 182, 5, 809, 121, 415, 71, 85, 3291, 4, 3, 419, 295, 246, 1851, 5, 6684, 16, 1114, 6, 3241, 286, 2, 807, 155, 24, 1, 7, 23, 38, 389, 2189, 71, 85, 5865, 69, 640, 4603, 23, 3, 157, 13810, 4, 2868, 1758, 23, 3, 4922, 328, 4, 2292, 1544, 23, 3, 419, 13810, 4, 68, 1544, 2, 23, 3, 1729, 2089, 328, 4, 2480, 1324, 3, 3483, 694, 15886, 335, 7, 379, 218, 141, 126, 6, 437, 541, 391, 669, 6433, 61, 1125, 94, 47, 85, 781, 9, 191, 82, 12, 4, 3357, 5, 56426, 56427, 1652, 2, 1479, 1, 3, 2342, 1782, 1, 5054, 2, 56428, 2342, 2189, 32, 4, 1466, 15, 193, 9, 134, 1, 3, 13789, 12979, 5810, 134, 220, 302, 31, 134, 795, 131, 134, 1, 3, 134, 2, 12, 94, 1435, 3, 119, 1, 6684, 9, 787, 628, 643, 2189, 9, 5748, 1104, 4, 3357, 5, 403, 56, 9, 2714, 815, 127, 815, 1479, 2, 2241, 4479, 450, 1104, 9, 13404, 826, 9, 815, 7, 6684, 47, 120, 85, 3058, 22, 35, 1091, 6, 7862, 9, 541, 346, 4, 541, 292, 413, 87, 6377, 2189, 24, 1, 7, 23, 46, 94, 71, 629, 616, 3, 193, 1, 217, 24, 1092, 70, 563, 2616, 13245, 3130, 9, 5748, 1104, 2718, 11676, 2, 193, 1, 870, 38, 6219, 538, 70, 563, 344, 4, 2550, 1, 815, 6433, 6, 1700, 870, 24, 4, 352, 8, 38, 389, 6219, 9, 1182, 193, 2, 74, 284, 16, 616, 99, 6, 1244, 1008, 17, 2095, 121, 36, 2339, 392, 174, 24, 3126, 6, 7, 17, 122, 40, 656, 4, 3, 546, 1, 38, 143, 7, 5268, 6, 7058, 46, 38, 143, 2744, 6, 40, 6223, 64, 2262, 6, 715, 94, 71, 85, 913]",2736.0,17668954,97
Fertility-sparing surgery in 101 women with adenocarcinoma in situ of the cervix.,Gynecologic oncology,Gynecol. Oncol.,2007-08-08,"Cervical adenocarcinoma in situ (AIS) is a precursor of invasive disease that is increasing in incidence primarily among reproductive-age women of low parity. Conization is an alternative to hysterectomy that allows future pregnancy, but has an inherent risk of residual AIS. The purpose of this study was to determine the outcomes of patients treated by this fertility-sparing strategy over an extended period of surveillance. Women diagnosed with cervical AIS who underwent primary fertility-sparing surgery with either loop excision or cold knife conization between 1993 and 2001 were identified at three institutions. A retrospective medical record review was performed. Patients 40 years of age and older and those undergoing hysterectomy within 12 months of diagnosis were excluded. A total of 101 women underwent cone biopsy and expectant management. The median age was 29 years. Fifty-seven percent were nulliparous and 23% primiparous. Cold knife conization was most commonly performed (69 vs. 32 procedures) and had a higher efficacy of achieving negative margins (72% vs. 47%; P=0.036). Thirty-five women had a total of 49 pregnancies during a mean follow-up of 51 months. Thirty-five gestations were delivered at term. There were two preterm births, eight spontaneous miscarriages, three elective terminations, and one ectopic pregnancy. Thirty-six patients had a repeat cone biopsy. Five ultimately underwent hysterectomy. No invasive cervical adenocarcinomas were observed during the study interval. Fertility-sparing surgery enables women with cervical AIS to achieve pregnancy with minimal risk of developing invasive disease during surveillance.",Journal Article,4549.0,30.0,adenocarcinoma in situ AIS is a precursor of invasive disease that is increasing in incidence primarily among reproductive-age women of low parity Conization is an alternative to hysterectomy that allows future pregnancy but has an inherent risk of residual AIS The purpose of this study was to determine the outcomes of patients treated by this fertility-sparing strategy over an extended period of surveillance Women diagnosed with AIS who underwent primary fertility-sparing surgery with either loop excision or cold knife conization between 1993 and 2001 were identified at three institutions A retrospective medical record review was performed Patients 40 years of age and older and those undergoing hysterectomy within 12 months of diagnosis were excluded A total of 101 women underwent cone biopsy and expectant management The median age was 29 years Fifty-seven percent were nulliparous and 23 primiparous Cold knife conization was most commonly performed 69 vs. 32 procedures and had a higher efficacy of achieving negative margins 72 vs. 47 P=0.036 Thirty-five women had a total of 49 pregnancies during a mean follow-up of 51 months Thirty-five gestations were delivered at term There were two preterm births eight spontaneous miscarriages three elective terminations and one ectopic pregnancy Thirty-six patients had a repeat cone biopsy Five ultimately underwent hysterectomy No invasive adenocarcinomas were observed during the study interval Fertility-sparing surgery enables women with AIS to achieve pregnancy with minimal risk of developing invasive disease during surveillance,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[449, 4, 957, 3826, 16, 8, 2765, 1, 416, 34, 17, 16, 602, 4, 287, 1561, 107, 3705, 89, 117, 1, 154, 5754, 8755, 16, 35, 1091, 6, 2622, 17, 2333, 508, 2290, 84, 71, 35, 4943, 43, 1, 753, 3826, 3, 743, 1, 26, 45, 10, 6, 223, 3, 123, 1, 7, 73, 20, 26, 2954, 1851, 692, 252, 35, 1747, 727, 1, 617, 117, 265, 5, 3826, 54, 208, 86, 2954, 1851, 152, 5, 361, 4432, 1366, 15, 5945, 8045, 8755, 59, 3343, 2, 1758, 11, 108, 28, 169, 1764, 8, 459, 484, 3237, 206, 10, 173, 7, 327, 60, 1, 89, 2, 434, 2, 135, 479, 2622, 262, 133, 53, 1, 147, 11, 1800, 8, 181, 1, 2338, 117, 208, 6939, 411, 2, 16351, 284, 3, 52, 89, 10, 462, 60, 1461, 648, 714, 11, 9475, 2, 382, 37943, 5945, 8045, 8755, 10, 96, 841, 173, 790, 105, 531, 1369, 2, 42, 8, 142, 209, 1, 1785, 199, 1012, 720, 105, 662, 19, 13, 5395, 977, 365, 117, 42, 8, 181, 1, 739, 8746, 190, 8, 313, 166, 126, 1, 725, 53, 977, 365, 56461, 11, 1623, 28, 337, 125, 11, 100, 20525, 9951, 659, 3280, 22124, 169, 4700, 44812, 2, 104, 3647, 2290, 977, 437, 7, 42, 8, 2334, 6939, 411, 365, 2050, 208, 2622, 77, 416, 1586, 11, 164, 190, 3, 45, 268, 2954, 1851, 152, 4843, 117, 5, 3826, 6, 1359, 2290, 5, 1048, 43, 1, 931, 416, 34, 190, 617]",1595.0,17689593,279
Cervical adenocarcinoma in situ: the predictive value of conization margin status.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2007-08-01,"We evaluated the impact of conization margin status on outcomes of patients diagnosed with cervical adenocarcinoma in situ. A retrospective chart review identified patients at a University hospital from 1988-2006 with adenocarcinoma in situ (AIS) on conization. Seventy-four patients were included. Median follow-up was 26 months. Twenty-two of 74 patients (30%) had positive margins, 46 patients (62%) had negative margins, and 6 patients had indeterminate margins. Of patients with positive margins, 55% (12/22) were diagnosed with residual or recurrent disease, including 3 patients diagnosed with adenocarcinoma on hysterectomy. Thirteen percent of patients with negative conization margins (6/46) were diagnosed with residual or recurrent disease, including 2 patients diagnosed with adenocarcinoma during follow-up. Cold knife conization resulted in a significantly higher number of negative margins compared to other conization procedures (P = .013). Even with negative conization margins, women still face a risk of residual, recurrent, or invasive disease.",Journal Article,4556.0,26.0,We evaluated the impact of conization margin status on outcomes of patients diagnosed with adenocarcinoma in situ A retrospective chart review identified patients at a University hospital from 1988-2006 with adenocarcinoma in situ AIS on conization Seventy-four patients were included Median follow-up was 26 months Twenty-two of 74 patients 30 had positive margins 46 patients 62 had negative margins and 6 patients had indeterminate margins Of patients with positive margins 55 12/22 were diagnosed with residual or recurrent disease including 3 patients diagnosed with adenocarcinoma on hysterectomy Thirteen percent of patients with negative conization margins 6/46 were diagnosed with residual or recurrent disease including 2 patients diagnosed with adenocarcinoma during follow-up Cold knife conization resulted in a significantly higher number of negative margins compared to other conization procedures P .013 Even with negative conization margins women still face a risk of residual recurrent or invasive disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 194, 3, 345, 1, 8755, 959, 156, 23, 123, 1, 7, 265, 5, 449, 4, 957, 8, 459, 2937, 206, 108, 7, 28, 8, 1652, 702, 29, 3314, 1324, 5, 449, 4, 957, 3826, 23, 8755, 2073, 294, 7, 11, 159, 52, 166, 126, 10, 432, 53, 737, 100, 1, 794, 7, 201, 42, 109, 1012, 641, 7, 744, 42, 199, 1012, 2, 49, 7, 42, 5167, 1012, 1, 7, 5, 109, 1012, 614, 133, 350, 11, 265, 5, 753, 15, 387, 34, 141, 27, 7, 265, 5, 449, 23, 2622, 3170, 714, 1, 7, 5, 199, 8755, 1012, 49, 641, 11, 265, 5, 753, 15, 387, 34, 141, 18, 7, 265, 5, 449, 190, 166, 126, 5945, 8045, 8755, 627, 4, 8, 97, 142, 207, 1, 199, 1012, 72, 6, 127, 8755, 1369, 19, 3612, 871, 5, 199, 8755, 1012, 117, 1234, 3376, 8, 43, 1, 753, 387, 15, 416, 34]",1022.0,17689647,360
Metastasis of squamous cell carcinoma of the oral tongue.,Cancer metastasis reviews,Cancer Metastasis Rev.,2007-12-01,"Squamous cell carcinoma of the oral tongue (SCCOT) is one of the most prevalent tumors of the head and neck region. Despite advances in treatment, the survival of patients with SCCOT has not significantly improved over the past several decades. Most frequently, treatment failure takes the form of local and regional recurrences, but as disease control in these areas improves, SCCOT treatment failures are occurring more often as distant metastasis. The presence of cervical lymph node metastasis is the most reliable adverse prognostic factor in patients with SCCOT, and extracapsular spread (ECS) of cervical lymph nodes metastasis is a particularly reliable predictor of regional and distant recurrence and death from disease. Decisions regarding the elective and therapeutic management of cervical lymph node metastases are made mainly on clinical grounds as we cannot always predict cervical lymph node metastasis from the size and extent of invasion of the primary tumors. Therefore, the treatment of these metastases in the management of SCCOT remains controversial. The promise of basing treatment decisions on biomarkers has yet to be fully realized because of our poor understanding of the mechanisms of regional and distant metastases of SCCOT. Here we summarize the current status of investigations of SCCOT metastases and the potential of these studies to have a positive impact on the clinical management of SCCOT in the future.",Journal Article,4434.0,229.0,Squamous cell carcinoma of the oral tongue SCCOT is one of the most prevalent tumors of the head and region Despite advances in treatment the survival of patients with SCCOT has not significantly improved over the past several decades Most frequently treatment failure takes the form of local and regional recurrences but as disease control in these areas improves SCCOT treatment failures are occurring more often as distant metastasis The presence of lymph node metastasis is the most reliable adverse prognostic factor in patients with SCCOT and extracapsular spread ECS of lymph nodes metastasis is a particularly reliable predictor of regional and distant recurrence and death from disease Decisions regarding the elective and therapeutic management of lymph node metastases are made mainly on clinical grounds as we can not always predict lymph node metastasis from the size and extent of invasion of the primary tumors Therefore the treatment of these metastases in the management of SCCOT remains controversial The promise of basing treatment decisions on biomarkers has yet to be fully realized because of our poor understanding of the mechanisms of regional and distant metastases of SCCOT Here we summarize the current status of investigations of SCCOT metastases and the potential of these studies to have a positive impact on the clinical management of SCCOT in the future,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[691, 31, 134, 1, 3, 518, 4391, 10948, 16, 104, 1, 3, 96, 2485, 57, 1, 3, 718, 2, 1053, 550, 954, 4, 24, 3, 25, 1, 7, 5, 10948, 71, 44, 97, 231, 252, 3, 1219, 392, 1968, 96, 746, 24, 496, 8512, 3, 1297, 1, 293, 2, 951, 1593, 84, 22, 34, 182, 4, 46, 1361, 1804, 10948, 24, 3368, 32, 1821, 80, 629, 22, 626, 278, 3, 463, 1, 263, 289, 278, 16, 3, 96, 2450, 290, 177, 161, 4, 7, 5, 10948, 2, 5607, 2579, 5861, 1, 263, 502, 278, 16, 8, 823, 2450, 980, 1, 951, 2, 626, 146, 2, 273, 29, 34, 1526, 666, 3, 4700, 2, 189, 284, 1, 263, 289, 196, 32, 1229, 2615, 23, 38, 19479, 22, 21, 122, 44, 3763, 678, 263, 289, 278, 29, 3, 444, 2, 1039, 1, 578, 1, 3, 86, 57, 673, 3, 24, 1, 46, 196, 4, 3, 284, 1, 10948, 469, 2010, 3, 1783, 1, 25974, 24, 1526, 23, 582, 71, 1145, 6, 40, 1910, 8340, 408, 1, 114, 334, 612, 1, 3, 483, 1, 951, 2, 626, 196, 1, 10948, 467, 21, 2479, 3, 291, 156, 1, 2492, 1, 10948, 196, 2, 3, 174, 1, 46, 94, 6, 47, 8, 109, 345, 23, 3, 38, 284, 1, 10948, 4, 3, 508]",1385.0,17768600,235
Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis.,Gynecologic oncology,Gynecol. Oncol.,2007-09-12,"To evaluate whether histology (adenocarcinoma versus adenosquamous carcinoma) is an independent prognostic indicator in patients with stage IB1 cervical cancer after radical hysterectomy. All patients with adenocarcinoma or adenosquamous carcinoma who underwent radical hysterectomy between October 1990 and December 2006 at The University of Texas M. D. Anderson Cancer Center were evaluated. Clinico-pathological data collected included age, disease stage, tumor grade, lymph node status, parametrial involvement, depth of invasion, evidence of lymph-vascular space invasion (LVSI), and adjuvant therapy. Patients were categorized as having ""low-risk"" or ""high-risk"" disease depending on the final pathologic findings. We identified 126 patients with stage IB1 adenosquamous (n=29) or adenocarcinoma (n=97) cervical cancer. The median follow-up was 79 months (range 1.7-184.6). The median age was 40.3 years for patients with adenocarcinoma and 35.2 years for patients with adenosquamous carcinoma (P=0.88). Grade III histology and LVSI were more common in patients with adenosquamous tumors than in patients with adenocarcinoma (85% versus 16%; P<0.01 and 56.5% versus 32.8; P=0.04). Histology was not associated with lymph node or parametrial involvement. There was no difference in recurrence rates between the two histologic groups, but the time to recurrence was shorter for patients with adenosquamous carcinoma (7.9 months versus 15 months; P=0.01). There was no difference between cell types with regards to recurrence and recurrence-free survival rates in the low- and high-risk groups. We found no evidence that histologic subtype affects outcome; however, the median time to recurrence was shorter in patients with adenosquamous carcinoma. Our study suggests that in patients with stage IB1 adenosquamous carcinoma or adenocarcinoma, the presence of high-risk features is more important than histologic subtype.",Journal Article,4514.0,35.0,To evaluate whether histology adenocarcinoma versus adenosquamous carcinoma is an independent prognostic indicator in patients with stage IB1 cancer after radical hysterectomy All patients with adenocarcinoma or adenosquamous carcinoma who underwent radical hysterectomy between October 1990 and December 2006 at The University of Texas M. D. Anderson Cancer Center were evaluated Clinico-pathological data collected included age disease stage tumor grade lymph node status parametrial involvement depth of invasion evidence of lymph-vascular space invasion LVSI and adjuvant therapy Patients were categorized as having `` low-risk '' or `` high-risk '' disease depending on the final pathologic findings We identified 126 patients with stage IB1 adenosquamous n=29 or adenocarcinoma n=97 cancer The median follow-up was 79 months range 1.7-184.6 The median age was 40.3 years for patients with adenocarcinoma and 35.2 years for patients with adenosquamous carcinoma P=0.88 Grade III histology and LVSI were more common in patients with adenosquamous tumors than in patients with adenocarcinoma 85 versus 16 P 0.01 and 56.5 versus 32.8 P=0.04 Histology was not associated with lymph node or parametrial involvement There was no difference in recurrence rates between the two histologic groups but the time to recurrence was shorter for patients with adenosquamous carcinoma 7.9 months versus 15 months P=0.01 There was no difference between cell types with regards to recurrence and recurrence-free survival rates in the low- and high-risk groups We found no evidence that histologic subtype affects outcome however the median time to recurrence was shorter in patients with adenosquamous carcinoma Our study suggests that in patients with stage IB1 adenosquamous carcinoma or adenocarcinoma the presence of high-risk features is more important than histologic subtype,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 317, 784, 449, 185, 8067, 134, 16, 35, 306, 177, 3287, 4, 7, 5, 82, 8111, 12, 50, 711, 2622, 62, 7, 5, 449, 15, 8067, 134, 54, 208, 711, 2622, 59, 2551, 2289, 2, 1397, 1324, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 11, 194, 8688, 1301, 74, 786, 159, 89, 34, 82, 30, 88, 263, 289, 156, 8726, 799, 2436, 1, 578, 241, 1, 263, 756, 3865, 578, 8004, 2, 249, 36, 7, 11, 2320, 22, 1041, 154, 43, 522, 15, 64, 43, 522, 34, 3221, 23, 3, 1457, 510, 272, 21, 108, 3927, 7, 5, 82, 8111, 8067, 78, 462, 15, 449, 78, 1015, 12, 3, 52, 166, 126, 10, 842, 53, 184, 14, 67, 5894, 49, 3, 52, 89, 10, 327, 27, 60, 9, 7, 5, 449, 2, 465, 18, 60, 9, 7, 5, 8067, 134, 19, 13, 889, 88, 316, 784, 2, 8004, 11, 80, 186, 4, 7, 5, 8067, 57, 76, 4, 7, 5, 449, 772, 185, 245, 19, 13, 355, 2, 664, 33, 185, 531, 66, 19, 13, 755, 784, 10, 44, 41, 5, 263, 289, 15, 8726, 799, 125, 10, 77, 523, 4, 146, 151, 59, 3, 100, 884, 271, 84, 3, 98, 6, 146, 10, 985, 9, 7, 5, 8067, 134, 67, 83, 53, 185, 167, 53, 19, 13, 355, 125, 10, 77, 523, 59, 31, 630, 5, 8930, 6, 146, 2, 146, 115, 25, 151, 4, 3, 154, 2, 64, 43, 271, 21, 204, 77, 241, 17, 884, 875, 2561, 228, 137, 3, 52, 98, 6, 146, 10, 985, 4, 7, 5, 8067, 134, 114, 45, 844, 17, 4, 7, 5, 82, 8111, 8067, 134, 15, 449, 3, 463, 1, 64, 43, 404, 16, 80, 305, 76, 884, 875]",1868.0,17854872,45
Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2007-09-14,"To compare the treatment and outcomes of cervical cancer patients treated with concurrent chemoradiotherapy (CT-RT) in a multi-institutional trial or as standard care. We reviewed the records of 302 patients treated with CT-RT for locoregionally confined, intact cervical cancer between 1990 and 2005. Of the 302 patients, 76 were treated using cisplatin and 5-fluorouracil (C/F) on Radiation Therapy Oncology Group protocol 90-01 (CT-RT(90-01)); 226 underwent CT-RT as standard care with either C/F [CT-RT(SC(C/F)); n = 115] or weekly cisplatin [CT-RT(SC(WC)); n = 111). The CT-RT(90-01) patients more often had tumors >or=6 cm and were less often diabetic than were the CT-RT(SC) patients. The CT-RT(SC(WC)) patients were more likely than the CT-RT(SC(C/F)) patients to be >or=60 years old or to have Stage III-IV disease. During treatment, CT-RT(SC(C/F)) patients experienced more Grade 2-3 neutropenia and were, therefore, less likely to receive 200 mg/m(2) cisplatin than were either CT-RT(SC(WC)) or CT-RT(90-01) patients (52% vs. 77% vs. 85%, respectively; p <0.001). At 5 years, the disease-specific survival rates were greater for patients treated with C/F [CT-RT(SC(C/F)), 75%; CT-RT(90-01), 79%] than for those treated with CT-RT(SC(WC)) (58%; p = 0.02). On multivariate analysis, C/F chemotherapy, cisplatin dose >or=200 mg/m(2), Stage I-II disease, and negative pelvic lymph nodes were independent predictors of improved disease-specific survival. Even within a large comprehensive cancer center, the high rates of chemotherapy completion achieved on a multi-institutional trial can be difficult to reproduce in standard practice. Although C/F toxicity was greater in the standard care patients, their outcomes were similar to those of patients treated with C/F on Radiation Therapy Oncology Group protocol 90-01.",Comparative Study,4512.0,32.0,To compare the treatment and outcomes of cancer patients treated with concurrent chemoradiotherapy CT-RT in a multi-institutional trial or as standard care We reviewed the records of 302 patients treated with CT-RT for locoregionally confined intact cancer between 1990 and 2005 Of the 302 patients 76 were treated using cisplatin and 5-fluorouracil C/F on Radiation Therapy Oncology Group protocol 90-01 CT-RT 90-01 226 underwent CT-RT as standard care with either C/F CT-RT SC C/F n 115 or weekly cisplatin CT-RT SC WC n 111 The CT-RT 90-01 patients more often had tumors or=6 cm and were less often diabetic than were the CT-RT SC patients The CT-RT SC WC patients were more likely than the CT-RT SC C/F patients to be or=60 years old or to have Stage III-IV disease During treatment CT-RT SC C/F patients experienced more Grade 2-3 neutropenia and were therefore less likely to receive 200 mg/m 2 cisplatin than were either CT-RT SC WC or CT-RT 90-01 patients 52 vs. 77 vs. 85 respectively p 0.001 At 5 years the disease-specific survival rates were greater for patients treated with C/F CT-RT SC C/F 75 CT-RT 90-01 79 than for those treated with CT-RT SC WC 58 p 0.02 On multivariate analysis C/F chemotherapy cisplatin dose or=200 mg/m 2 Stage I-II disease and negative pelvic lymph nodes were independent predictors of improved disease-specific survival Even within a large comprehensive cancer center the high rates of chemotherapy completion achieved on a multi-institutional trial can be difficult to reproduce in standard practice Although C/F toxicity was greater in the standard care patients their outcomes were similar to those of patients treated with C/F on Radiation Therapy Oncology Group protocol 90-01,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 932, 3, 24, 2, 123, 1, 12, 7, 73, 5, 750, 1464, 425, 240, 4, 8, 1414, 1115, 160, 15, 22, 260, 165, 21, 446, 3, 1064, 1, 4952, 7, 73, 5, 425, 240, 9, 6410, 2902, 2964, 12, 59, 2289, 2, 1242, 1, 3, 4952, 7, 846, 11, 73, 75, 540, 2, 33, 1404, 256, 1068, 23, 121, 36, 413, 87, 1182, 424, 355, 425, 240, 424, 355, 7400, 208, 425, 240, 22, 260, 165, 5, 361, 256, 1068, 425, 240, 2969, 256, 1068, 78, 3670, 15, 709, 540, 425, 240, 2969, 13994, 78, 3167, 3, 425, 240, 424, 355, 7, 80, 629, 42, 57, 15, 49, 494, 2, 11, 299, 629, 5943, 76, 11, 3, 425, 240, 2969, 7, 3, 425, 240, 2969, 13994, 7, 11, 80, 322, 76, 3, 425, 240, 2969, 256, 1068, 7, 6, 40, 15, 335, 60, 1095, 15, 6, 47, 82, 316, 478, 34, 190, 24, 425, 240, 2969, 256, 1068, 7, 592, 80, 88, 18, 27, 778, 2, 11, 673, 299, 322, 6, 560, 1250, 81, 188, 18, 540, 76, 11, 361, 425, 240, 2969, 13994, 15, 425, 240, 424, 355, 7, 653, 105, 849, 105, 772, 106, 19, 13, 144, 28, 33, 60, 3, 34, 112, 25, 151, 11, 378, 9, 7, 73, 5, 256, 1068, 425, 240, 2969, 256, 1068, 481, 425, 240, 424, 355, 842, 76, 9, 135, 73, 5, 425, 240, 2969, 13994, 717, 19, 13, 588, 23, 331, 65, 256, 1068, 56, 540, 61, 15, 1250, 81, 188, 18, 82, 70, 215, 34, 2, 199, 1110, 263, 502, 11, 306, 674, 1, 231, 34, 112, 25, 871, 262, 8, 375, 949, 12, 574, 3, 64, 151, 1, 56, 1438, 513, 23, 8, 1414, 1115, 160, 122, 40, 1740, 6, 23141, 4, 260, 758, 242, 256, 1068, 155, 10, 378, 4, 3, 260, 165, 7, 136, 123, 11, 288, 6, 135, 1, 7, 73, 5, 256, 1068, 23, 121, 36, 413, 87, 1182, 424, 355]",1722.0,17869451,301
Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.,Journal of lower genital tract disease,J Low Genit Tract Dis,2007-10-01,"The purpose of this study was to demonstrate a methodology for auditing the impact of HCII testing on the direct cost of cervical cancer cytological screening, where the test is collected in all women screened and processed routinely in women age 30 years and older. After a policy change to screen all patients 30 years or older with both Pap smears and high-risk human papillomavirus (HR-HPV), as well as cocollection of HR-HPV in women younger than 30 years, all cytological, HPV, and histological data pertaining to cervical screening was collected retrospectively during a 2-month period. We documented the direct costs of performing these tests and estimated the necessary compliance rate for balanced cost-effectiveness. During the 2-month period, 8,300 women were screened with both Pap smear and HPV cocollection. Of the 'nonnormal' cytological findings, 5% of patients showed either atypical squamous cells (3.5%) or squamous intraepithelial abnormalities (1.5%). An additional 427 (5%) patients had the finding of positive HR-HPV with normal cytology. Six of these patients opted for immediate colposcopy, 2 of which were found to have cervical intraepithelial neoplasia 2. In women age 30 years and older, 900 patients per 1,000 screened would be eligible for a 2-year screening interval based on negative cytology and negative HR-HPV. Based on the direct costs associated with this cohort, no more than 164 women could request screening at an interval shorter than 3 years for the total costs of such a program to equal that of one without HR-HPV cocollection. By adding HCII collection to the Pap smear for our entire screening cohort, we intended to reduce the number of tests performed, which was impacted by its age distribution. Our findings indicate that at least 736 of the 900 double-negative patients (82%) would have to be screened at no less than 3 years for such a screening paradigm to be cost-effective in managing women 30 years and older.",Journal Article,4495.0,1.0,"The purpose of this study was to demonstrate a methodology for auditing the impact of HCII testing on the direct cost of cancer cytological screening where the test is collected in all women screened and processed routinely in women age 30 years and older After a policy change to screen all patients 30 years or older with both Pap smears and high-risk human papillomavirus HR-HPV as well as cocollection of HR-HPV in women younger than 30 years all cytological HPV and histological data pertaining to screening was collected retrospectively during a 2-month period We documented the direct costs of performing these tests and estimated the necessary compliance rate for balanced cost-effectiveness During the 2-month period 8,300 women were screened with both Pap smear and HPV cocollection Of the 'nonnormal cytological findings 5 of patients showed either atypical squamous cells 3.5 or squamous intraepithelial abnormalities 1.5 An additional 427 5 patients had the finding of positive HR-HPV with normal cytology Six of these patients opted for immediate colposcopy 2 of which were found to have intraepithelial neoplasia 2 In women age 30 years and older 900 patients per 1,000 screened would be eligible for a 2-year screening interval based on negative cytology and negative HR-HPV Based on the direct costs associated with this cohort no more than 164 women could request screening at an interval shorter than 3 years for the total costs of such a program to equal that of one without HR-HPV cocollection By adding HCII collection to the Pap smear for our entire screening cohort we intended to reduce the number of tests performed which was impacted by its age distribution Our findings indicate that at least 736 of the 900 double-negative patients 82 would have to be screened at no less than 3 years for such a screening paradigm to be cost-effective in managing women 30 years and older",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 608, 8, 3209, 9, 44891, 3, 345, 1, 44892, 471, 23, 3, 1196, 835, 1, 12, 9019, 453, 1257, 3, 412, 16, 786, 4, 62, 117, 2261, 2, 5232, 3066, 4, 117, 89, 201, 60, 2, 434, 50, 8, 4196, 707, 6, 2413, 62, 7, 201, 60, 15, 434, 5, 110, 4290, 8916, 2, 64, 43, 171, 3242, 168, 933, 22, 149, 22, 38566, 1, 168, 933, 4, 117, 773, 76, 201, 60, 62, 9019, 933, 2, 1831, 74, 6553, 6, 453, 10, 786, 894, 190, 8, 18, 811, 727, 21, 1405, 3, 1196, 1201, 1, 3620, 46, 895, 2, 661, 3, 1493, 3336, 116, 9, 4115, 835, 1236, 190, 3, 18, 811, 727, 66, 2036, 117, 11, 2261, 5, 110, 4290, 8379, 2, 933, 38566, 1, 3, 56597, 9019, 272, 33, 1, 7, 224, 361, 1973, 691, 37, 27, 33, 15, 691, 4153, 1171, 14, 33, 35, 402, 9749, 33, 7, 42, 3, 1567, 1, 109, 168, 933, 5, 295, 2045, 437, 1, 46, 7, 11807, 9, 2181, 9946, 18, 1, 92, 11, 204, 6, 47, 4153, 2298, 18, 4, 117, 89, 201, 60, 2, 434, 5310, 7, 379, 14, 984, 2261, 688, 40, 625, 9, 8, 18, 111, 453, 268, 90, 23, 199, 2045, 2, 199, 168, 933, 90, 23, 3, 1196, 1201, 41, 5, 26, 180, 77, 80, 76, 5279, 117, 359, 11660, 453, 28, 35, 268, 985, 76, 27, 60, 9, 3, 181, 1201, 1, 225, 8, 1243, 6, 2997, 17, 1, 104, 187, 168, 933, 38566, 20, 2726, 44892, 2442, 6, 3, 4290, 8379, 9, 114, 1797, 453, 180, 21, 4081, 6, 969, 3, 207, 1, 895, 173, 92, 10, 4619, 20, 211, 89, 1395, 114, 272, 1008, 17, 28, 506, 13953, 1, 3, 5310, 1627, 199, 7, 878, 688, 47, 6, 40, 2261, 28, 77, 299, 76, 27, 60, 9, 225, 8, 453, 2431, 6, 40, 835, 323, 4, 3969, 117, 201, 60, 2, 434]",1901.0,17917570,584
Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trial.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2007-10-24,"To look for possible associations between measurements of DNA index (DI), S-phase fraction (SPF), and tumor heterogeneity (TH) using flow cytometry and overall survival for patients with invasive cervical carcinoma treated with definitive irradiation. A total of 57 patients with International Federation of Obstetrics and Gynecology Stages IB(2) through IVB cervical carcinomas treated with definitive radiotherapy with or without concurrent chemotherapy were enrolled into this registry study that involved flow cytometric analysis of fresh tissue from each cervical cancer obtained by pretreatment biopsy. These specimens were evaluated for DNA aneuploidy (DI <or=1.5 vs. >1.5), SPF (<or=15% vs. >15%), and TH (uniploid vs. multiploid). In these analyses 27 of the patients were treated in Radiation Therapy Oncology Group protocol 9001, and an additional 30 were offered chemoradiation at a single institution. Forty-one patients had DI <or=1.5 and 16 DI >1.5. Twenty-nine patients had SPF <or=15%, 26 >15%, and 2 had no determinable SPF. Forty-three patients had uniploid and 14 multiploid tumors. The 4-year estimated overall survival rate for the entire study cohort was 62% (95% confidence interval 48%-74%). With a median follow-up of 3.7 years, there were no observable associations by univariate analysis for DI, SPF, or TH concerning patient survival. There were no statistically significant associations among DI, SPF, or TH and patient outcome. Additional studies are indicated to identify tumor biomarkers that could predict patients at risk for disseminated disease.",Journal Article,4472.0,5.0,To look for possible associations between measurements of DNA index DI S-phase fraction SPF and tumor heterogeneity TH using flow cytometry and overall survival for patients with invasive carcinoma treated with definitive irradiation A total of 57 patients with International Federation of Obstetrics and Gynecology Stages IB 2 through IVB carcinomas treated with definitive radiotherapy with or without concurrent chemotherapy were enrolled into this registry study that involved flow cytometric analysis of fresh tissue from each cancer obtained by pretreatment biopsy These specimens were evaluated for DNA aneuploidy DI or=1.5 vs. 1.5 SPF or=15 vs. 15 and TH uniploid vs. multiploid In these analyses 27 of the patients were treated in Radiation Therapy Oncology Group protocol 9001 and an additional 30 were offered chemoradiation at a single institution Forty-one patients had DI or=1.5 and 16 DI 1.5 Twenty-nine patients had SPF or=15 26 15 and 2 had no determinable SPF Forty-three patients had uniploid and 14 multiploid tumors The 4-year estimated overall survival rate for the entire study cohort was 62 95 confidence interval 48 -74 With a median follow-up of 3.7 years there were no observable associations by univariate analysis for DI SPF or TH concerning patient survival There were no statistically significant associations among DI SPF or TH and patient outcome Additional studies are indicated to identify tumor biomarkers that could predict patients at risk for disseminated disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 5316, 9, 899, 685, 59, 1685, 1, 261, 558, 6641, 695, 124, 1509, 20578, 2, 30, 1144, 4517, 75, 1412, 1914, 2, 63, 25, 9, 7, 5, 416, 134, 73, 5, 1057, 1104, 8, 181, 1, 696, 7, 5, 944, 7303, 1, 7407, 2, 6429, 1153, 3180, 18, 298, 7042, 826, 73, 5, 1057, 310, 5, 15, 187, 750, 56, 11, 346, 237, 26, 1608, 45, 17, 646, 1412, 6226, 65, 1, 4329, 246, 29, 296, 12, 683, 20, 1194, 411, 46, 623, 11, 194, 9, 261, 7437, 6641, 15, 14, 33, 105, 14, 33, 20578, 15, 167, 105, 167, 2, 4517, 44893, 105, 44894, 4, 46, 318, 428, 1, 3, 7, 11, 73, 4, 121, 36, 413, 87, 1182, 44895, 2, 35, 402, 201, 11, 2216, 975, 28, 8, 226, 731, 1213, 104, 7, 42, 6641, 15, 14, 33, 2, 245, 6641, 14, 33, 737, 762, 7, 42, 20578, 15, 167, 432, 167, 2, 18, 42, 77, 44178, 20578, 1213, 169, 7, 42, 44893, 2, 213, 44894, 57, 3, 39, 111, 661, 63, 25, 116, 9, 3, 1797, 45, 180, 10, 744, 48, 307, 268, 576, 794, 5, 8, 52, 166, 126, 1, 27, 67, 60, 125, 11, 77, 13793, 685, 20, 880, 65, 9, 6641, 20578, 15, 4517, 4243, 69, 25, 125, 11, 77, 712, 93, 685, 107, 6641, 20578, 15, 4517, 2, 69, 228, 402, 94, 32, 1103, 6, 255, 30, 582, 17, 359, 678, 7, 28, 43, 9, 3605, 34]",1502.0,17919835,657
Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2007-11-26,"To develop an atlas of the clinical target volume (CTV) definitions for postoperative radiotherapy of endometrial and cervical cancer to be used for planning pelvic intensity-modulated radiotherapy. The Radiation Therapy Oncology Group led an international collaboration of cooperative groups in the development of the atlas. The groups included the Radiation Therapy Oncology Group, Gynecologic Oncology Group, National Cancer Institute of Canada, European Society of Therapeutic Radiology and Oncology, and American College of Radiology Imaging Network. The members of the group were asked by questionnaire to define the areas that were to be included in the CTV and to outline theses areas on individual computed tomography images. The initial formulation of the group began in late 2004 and culminated with a formal consensus conference in June 2005. The committee achieved a consensus CTV definition for postoperative therapy for endometrial and cervical cancer. The CTV should include the common, external, and internal iliac lymph node regions. The upper 3.0 cm of the vagina and paravaginal soft tissue lateral to the vagina should also be included. For patients with cervical cancer, or endometrial cancer with cervical stromal invasion, it is also recommended that the CTV include the presacral lymph node region. This report serves as an international template for the definition of the CTV for postoperative intensity-modulated radiotherapy for endometrial and cervical cancer.",Consensus Development Conference,4439.0,223.0,To develop an atlas of the clinical target volume CTV definitions for postoperative radiotherapy of and cancer to be used for planning pelvic intensity-modulated radiotherapy The Radiation Therapy Oncology Group led an international collaboration of cooperative groups in the development of the atlas The groups included the Radiation Therapy Oncology Group Gynecologic Oncology Group National Cancer Institute of Canada European Society of Therapeutic Radiology and Oncology and American College of Radiology Imaging Network The members of the group were asked by questionnaire to define the areas that were to be included in the CTV and to outline theses areas on individual computed tomography images The initial formulation of the group began in late 2004 and culminated with a formal consensus conference in June 2005 The committee achieved a consensus CTV definition for postoperative therapy for and cancer The CTV should include the common external and internal iliac lymph node regions The upper 3.0 cm of the vagina and paravaginal soft tissue lateral to the vagina should also be included For patients with cancer or cancer with stromal invasion it is also recommended that the CTV include the presacral lymph node region This report serves as an international template for the definition of the CTV for postoperative intensity-modulated radiotherapy for and cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,"[6, 690, 35, 2643, 1, 3, 38, 283, 433, 3402, 3833, 9, 573, 310, 1, 2, 12, 6, 40, 95, 9, 1349, 1110, 837, 1757, 310, 3, 121, 36, 413, 87, 836, 35, 944, 4119, 1, 1690, 271, 4, 3, 193, 1, 3, 2643, 3, 271, 159, 3, 121, 36, 413, 87, 1512, 413, 87, 657, 12, 1377, 1, 4740, 1865, 1174, 1, 189, 4003, 2, 413, 2, 597, 2979, 1, 4003, 270, 1801, 3, 1684, 1, 3, 87, 11, 3732, 20, 1770, 6, 1107, 3, 1361, 17, 11, 6, 40, 159, 4, 3, 3402, 2, 6, 5277, 31130, 1361, 23, 797, 1220, 872, 1572, 3, 388, 3583, 1, 3, 87, 4603, 4, 807, 1131, 2, 17736, 5, 8, 5057, 1391, 4180, 4, 1924, 1242, 3, 2002, 513, 8, 1391, 3402, 2470, 9, 573, 36, 9, 2, 12, 3, 3402, 257, 643, 3, 186, 1455, 2, 2329, 6692, 263, 289, 1374, 3, 1726, 27, 13, 494, 1, 3, 7553, 2, 56687, 1214, 246, 3855, 6, 3, 7553, 257, 120, 40, 159, 9, 7, 5, 12, 15, 12, 5, 1126, 578, 192, 16, 120, 793, 17, 3, 3402, 643, 3, 13565, 263, 289, 1053, 26, 414, 4711, 22, 35, 944, 5932, 9, 3, 2470, 1, 3, 3402, 9, 573, 837, 1757, 310, 9, 2, 12]",1376.0,18037584,253
Reducing the burden of glandular carcinomas of the uterine cervix.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2007-12-01,"Widespread use of the Papanicolaou test for the screening of cervical cancers has lead to a significant decline in overall incidence and mortality rates over the past 3 decades. When different histologic types of cervical cancers are considered and trends are reexamined, it becomes apparent that observed declines are reflective of squamous cell carcinomas predominantly; the rates for adenocarcinomas continue to rise. This rise in incidence may be due to the greater difficulty in screening for glandular precursor lesions that often arise high within the endocervical canal. Reducing the incidence and mortality rates that are associated with adenocarcinomas can be accomplished by using improved screening techniques and large-scale implementation of cervical cancer vaccines that target the predominant oncogenic human papillomavirus types that are associated with adenocarcinoma.",Journal Article,4434.0,34.0,Widespread use of the Papanicolaou test for the screening of cancers has lead to a significant decline in overall incidence and mortality rates over the past 3 decades When different histologic types of cancers are considered and trends are reexamined it becomes apparent that observed declines are reflective of squamous cell carcinomas predominantly the rates for adenocarcinomas continue to rise This rise in incidence may be due to the greater difficulty in screening for glandular precursor lesions that often arise high within the endocervical canal Reducing the incidence and mortality rates that are associated with adenocarcinomas can be accomplished by using improved screening techniques and large-scale implementation of cancer vaccines that target the predominant oncogenic human papillomavirus types that are associated with adenocarcinoma,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3029, 119, 1, 3, 10416, 412, 9, 3, 453, 1, 163, 71, 1122, 6, 8, 93, 1858, 4, 63, 287, 2, 282, 151, 252, 3, 1219, 27, 1968, 198, 338, 884, 630, 1, 163, 32, 515, 2, 1963, 32, 20476, 192, 5366, 2235, 17, 164, 4264, 32, 11834, 1, 691, 31, 826, 2117, 3, 151, 9, 1586, 1906, 6, 3693, 26, 3693, 4, 287, 68, 40, 520, 6, 3, 378, 4035, 4, 453, 9, 6170, 2765, 406, 17, 629, 3043, 64, 262, 3, 10174, 5614, 1818, 3, 287, 2, 282, 151, 17, 32, 41, 5, 1586, 122, 40, 5741, 20, 75, 231, 453, 1092, 2, 375, 1124, 2393, 1, 12, 1842, 17, 283, 3, 2750, 1302, 171, 3242, 630, 17, 32, 41, 5, 449]",853.0,18060938,488
Cytologic findings after fertility-sparing radical trachelectomy.,Cancer,Cancer,2008-02-01,"Radical trachelectomy is a surgical procedure intended to preserve fertility in patients with early-stage cervical carcinoma in which the cervix is amputated in continuity with the parametrium and upper vagina, thereby sparing the uterus and adnexa. Follow-up is performed with periodic cytology specimens. The objective of the current study was to analyze the cytologic findings after this novel procedure. Isthmic and vaginal Papanicolaou-stained ThinPrep cytology specimens taken from patients after radical vaginal and abdominal trachelectomy were reviewed. The specimens were also analyzed for the presence of benign endocervical cells, lower uterine segment glandular cells, endometrial stromal cells, and endometrial cells. The findings were correlated with the original diagnosis and follow-up, which included subsequent cytology specimens and biopsies. Cytology specimens (n = 223) from 44 patients were included in this study. An endometrial component was identified in 131 of the cases (59%). Twenty-eight cases were diagnosed as abnormal in the original cytology examination. Twenty of these cases and 5 additional cases that were diagnosed cytologically as benign had subsequent biopsies. The biopsies confirmed the presence of a lesion in only 4 of 25 biopsies (3 low-grade squamous intraepithelial lesions and 1 adenosquamous carcinoma). All cases diagnosed as atypical glandular cells represented tubal metaplasia, lower uterine segment glandular cells, or endometrial stromal cells. Cytology specimens after trachelectomy frequently contain glandular cells from the lower uterine segment epithelium or endometrial stromal cells, which can lead to a misdiagnosis of atypical glandular cells of undetermined significance. Tubal metaplasia is also a potential pitfall in these specimens. Pathologists and gynecologic oncologists should be aware of the potential pitfalls in the surveillance of smears after trachelectomy.",Journal Article,4372.0,25.0,Radical trachelectomy is a surgical procedure intended to preserve fertility in patients with early-stage carcinoma in which the cervix is amputated in continuity with the parametrium and upper vagina thereby sparing the and adnexa Follow-up is performed with periodic cytology specimens The objective of the current study was to analyze the cytologic findings after this novel procedure Isthmic and Papanicolaou-stained ThinPrep cytology specimens taken from patients after radical and abdominal trachelectomy were reviewed The specimens were also analyzed for the presence of benign endocervical cells lower segment glandular cells stromal cells and cells The findings were correlated with the original diagnosis and follow-up which included subsequent cytology specimens and biopsies Cytology specimens n 223 from 44 patients were included in this study An component was identified in 131 of the cases 59 Twenty-eight cases were diagnosed as abnormal in the original cytology examination Twenty of these cases and 5 additional cases that were diagnosed cytologically as benign had subsequent biopsies The biopsies confirmed the presence of a lesion in only 4 of 25 biopsies 3 low-grade squamous intraepithelial lesions and 1 adenosquamous carcinoma All cases diagnosed as atypical glandular cells represented tubal metaplasia lower segment glandular cells or stromal cells Cytology specimens after trachelectomy frequently contain glandular cells from the lower segment epithelium or stromal cells which can lead to a misdiagnosis of atypical glandular cells of undetermined significance Tubal metaplasia is also a potential pitfall in these specimens Pathologists and gynecologic oncologists should be aware of the potential pitfalls in the surveillance of smears after trachelectomy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,"[711, 5760, 16, 8, 221, 1299, 4081, 6, 6783, 2954, 4, 7, 5, 191, 82, 134, 4, 92, 3, 3629, 16, 56761, 4, 12253, 5, 3, 30751, 2, 1726, 7553, 2267, 1851, 3, 2, 17778, 166, 126, 16, 173, 5, 9086, 2045, 623, 3, 461, 1, 3, 291, 45, 10, 6, 1992, 3, 4195, 272, 50, 26, 229, 1299, 44976, 2, 10416, 3386, 12772, 2045, 623, 1633, 29, 7, 50, 711, 2, 1467, 5760, 11, 446, 3, 623, 11, 120, 311, 9, 3, 463, 1, 1002, 10174, 37, 280, 4610, 6170, 37, 1126, 37, 2, 37, 3, 272, 11, 438, 5, 3, 2279, 147, 2, 166, 126, 92, 159, 706, 2045, 623, 2, 1154, 2045, 623, 78, 3907, 29, 584, 7, 11, 159, 4, 26, 45, 35, 1249, 10, 108, 4, 2229, 1, 3, 140, 728, 737, 659, 140, 11, 265, 22, 1668, 4, 3, 2279, 2045, 1385, 737, 1, 46, 140, 2, 33, 402, 140, 17, 11, 265, 8514, 22, 1002, 42, 706, 1154, 3, 1154, 557, 3, 463, 1, 8, 1180, 4, 158, 39, 1, 243, 1154, 27, 154, 88, 691, 4153, 406, 2, 14, 8067, 134, 62, 140, 265, 22, 1973, 6170, 37, 3324, 6674, 6054, 280, 4610, 6170, 37, 15, 1126, 37, 2045, 623, 50, 5760, 746, 3725, 6170, 37, 29, 3, 280, 4610, 2781, 15, 1126, 37, 92, 122, 1122, 6, 8, 13470, 1, 1973, 6170, 37, 1, 5206, 724, 6674, 6054, 16, 120, 8, 174, 28742, 4, 46, 623, 3354, 2, 1512, 1339, 257, 40, 4749, 1, 3, 174, 9631, 4, 3, 617, 1, 8916, 50, 5760]",1787.0,18085613,24
Vertebral body growth after craniospinal irradiation.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2007-12-31,"To estimate the effects of radiotherapy and clinical factors on vertebral growth in patients with medulloblastoma and supratentorial primitive neuroectodermal tumors treated with craniospinal irradiation (CSI) and chemotherapy. The height of eight individual or grouped vertebral bodies (C3, C3-C4, T4, T4-T5, C6-T3, T4-T7, L3, L1-L5) was measured before and after CSI (23.4 or 36-39.6 Gy) in 61 patients. Of the 61 patients, 40 were boys and 21 were girls (median age, 7 years; range, 3-13 years), treated between October 1996 and October 2003. Sagittal T(1)-weighted magnetic resonance images were used for the craniocaudal measurements. The measurements numbered 275 (median, 5/patient; range, 3-7). The median follow-up after CSI was 44.1 months (range, 13.8-74.9 months). Significant growth was observed in all measured vertebrae. Excluding C3-C4, the growth rate of the grouped vertebrae was affected by age, gender, and CSI dose (risk classification). The risk classification alone affected the growth rates of C3 (p = 0.002) and L3 (p = 0.02). Before CSI, the length of all vertebral bodies was an increasing function of age (p <0.0001). The C3 length before CSI was affected by gender and risk classification: C3 was longer for female (p = 0.07) and high-risk (p = 0.07) patients. All vertebrae grew significantly after CSI, with the vertebrae of the boys and younger patients growing at a rate greater than that of their counterparts. The effect of age was similar across all vertebrae, and gender had the greatest effect on the growth of the lower cervical and upper thoracic vertebrae. The effect of the risk classification was greatest in the lumbar spine by a factor of < or = 10.",Journal Article,4404.0,25.0,To estimate the effects of radiotherapy and clinical factors on vertebral growth in patients with medulloblastoma and supratentorial primitive neuroectodermal tumors treated with craniospinal irradiation CSI and chemotherapy The height of eight individual or grouped vertebral bodies C3 C3-C4 T4 T4-T5 C6-T3 T4-T7 L3 L1-L5 was measured before and after CSI 23.4 or 36-39.6 Gy in 61 patients Of the 61 patients 40 were boys and 21 were girls median age 7 years range 3-13 years treated between October 1996 and October 2003 Sagittal T 1 -weighted magnetic resonance images were used for the craniocaudal measurements The measurements numbered 275 median 5/patient range 3-7 The median follow-up after CSI was 44.1 months range 13.8-74.9 months Significant growth was observed in all measured vertebrae Excluding C3-C4 the growth rate of the grouped vertebrae was affected by age gender and CSI dose risk classification The risk classification alone affected the growth rates of C3 p 0.002 and L3 p 0.02 Before CSI the length of all vertebral bodies was an increasing function of age p 0.0001 The C3 length before CSI was affected by gender and risk classification C3 was longer for female p 0.07 and high-risk p 0.07 patients All vertebrae grew significantly after CSI with the vertebrae of the boys and younger patients growing at a rate greater than that of their counterparts The effect of age was similar across all vertebrae and gender had the greatest effect on the growth of the lower and upper thoracic vertebrae The effect of the risk classification was greatest in the lumbar spine by a factor of or 10,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1191, 3, 176, 1, 310, 2, 38, 130, 23, 4731, 129, 4, 7, 5, 2714, 2, 5716, 5594, 7160, 57, 73, 5, 5748, 1104, 4293, 2, 56, 3, 4594, 1, 659, 797, 15, 3706, 4731, 7442, 8732, 8732, 7752, 2463, 2463, 30493, 12267, 2065, 2463, 20192, 6869, 729, 24535, 10, 644, 348, 2, 50, 4293, 382, 39, 15, 511, 587, 49, 381, 4, 713, 7, 1, 3, 713, 7, 327, 11, 12958, 2, 239, 11, 5989, 52, 89, 67, 60, 184, 27, 233, 60, 73, 59, 2551, 2648, 2, 2551, 1522, 15902, 102, 14, 2337, 1484, 1535, 1572, 11, 95, 9, 3, 19456, 1685, 3, 1685, 16778, 5620, 52, 33, 69, 184, 27, 67, 3, 52, 166, 126, 50, 4293, 10, 584, 14, 53, 184, 233, 66, 794, 83, 53, 93, 129, 10, 164, 4, 62, 644, 7565, 3207, 8732, 7752, 3, 129, 116, 1, 3, 3706, 7565, 10, 1424, 20, 89, 1632, 2, 4293, 61, 43, 947, 3, 43, 947, 279, 1424, 3, 129, 151, 1, 8732, 19, 13, 1111, 2, 6869, 19, 13, 588, 348, 4293, 3, 1318, 1, 62, 4731, 7442, 10, 35, 602, 343, 1, 89, 19, 13, 488, 3, 8732, 1318, 348, 4293, 10, 1424, 20, 1632, 2, 43, 947, 8732, 10, 589, 9, 1061, 19, 13, 1615, 2, 64, 43, 19, 13, 1615, 7, 62, 7565, 8033, 97, 50, 4293, 5, 3, 7565, 1, 3, 12958, 2, 773, 7, 1921, 28, 8, 116, 378, 76, 17, 1, 136, 3953, 3, 254, 1, 89, 10, 288, 716, 62, 7565, 2, 1632, 42, 3, 2199, 254, 23, 3, 129, 1, 3, 280, 2, 1726, 2098, 7565, 3, 254, 1, 3, 43, 947, 10, 2199, 4, 3, 6187, 2342, 20, 8, 161, 1, 15, 79]",1611.0,18164830,692
Colorectal stents for palliation of large-bowel obstructions in recurrent gynecologic cancer: an updated series.,Gynecologic oncology,Gynecol. Oncol.,2008-01-10,"Malignant large-bowel obstruction in the acute setting is considered a surgical emergency. Surgical intervention has been the standard treatment for patients presenting with large-bowel obstruction. Surgery in severely ill patients, however, can be associated with significant morbidity and mortality. Our objective was to review and update our experience with colonic stent placement for patients presenting with a large-bowel obstruction due to recurrent gynecologic malignancy. We reviewed the records of all patients with gynecologic cancer who underwent colorectal stent placement for palliation of a large-bowel obstruction from January 2001 to October 2006. Thirty-five patients were identified--25 patients had recurrent ovarian cancer, 7 patients had recurrent endometrial cancer, 2 patients had primary peritoneal carcinoma, and 1 patient had recurrent cervical cancer. The median age at the time of stent placement was 54 years (range, 21-79). The median length of the large-bowel obstruction was 6.5 cm (range, 1-20 cm). Six patients had a lumen of 1 to 2 mm before stent placement, while 29 patients had complete obstruction and needed balloon dilatation before deployment of the stent. Twenty-seven patients (77%) underwent successful stent placement and immediate decompression at the time of colorectal stent placement. Of the patients who had successful stent placement, 9 (33%) underwent additional surgery to relieve obstruction-drainage gastrotomy, 3; colostomy, 4; and stent revision, 2. Eight patients (23%) had failed stent placement secondary to non-traversable strictures and angulation of the bowel. Of these 8 patients, 5 needed colostomy and 3 needed gastrotomy. Of the 27 patients who underwent successful stent placement, the median survival after placement was 7.7 months (95% CI, 3.19-11.9 months). In the management of patients with large-bowel obstructions due to recurrent gynecologic cancer, colonic stents appear to be a reasonable option that may enable patients to avoid major surgery.",Evaluation Study,4394.0,65.0,Malignant large-bowel obstruction in the acute setting is considered a surgical emergency Surgical intervention has been the standard treatment for patients presenting with large-bowel obstruction Surgery in severely ill patients however can be associated with significant morbidity and mortality Our objective was to review and update our experience with colonic stent placement for patients presenting with a large-bowel obstruction due to recurrent gynecologic malignancy We reviewed the records of all patients with gynecologic cancer who underwent stent placement for palliation of a large-bowel obstruction from January 2001 to October 2006 Thirty-five patients were identified -- 25 patients had recurrent cancer 7 patients had recurrent cancer 2 patients had primary peritoneal carcinoma and 1 patient had recurrent cancer The median age at the time of stent placement was 54 years range 21-79 The median length of the large-bowel obstruction was 6.5 cm range 1-20 cm Six patients had a lumen of 1 to 2 mm before stent placement while 29 patients had complete obstruction and needed balloon dilatation before deployment of the stent Twenty-seven patients 77 underwent successful stent placement and immediate decompression at the time of stent placement Of the patients who had successful stent placement 9 33 underwent additional surgery to relieve obstruction-drainage gastrotomy 3 colostomy 4 and stent revision 2 Eight patients 23 had failed stent placement secondary to non-traversable strictures and angulation of the bowel Of these 8 patients 5 needed colostomy and 3 needed gastrotomy Of the 27 patients who underwent successful stent placement the median survival after placement was 7.7 months 95 CI 3.19-11.9 months In the management of patients with large-bowel obstructions due to recurrent gynecologic cancer colonic stents appear to be a reasonable option that may enable patients to avoid major surgery,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[393, 375, 1659, 3191, 4, 3, 286, 546, 16, 515, 8, 221, 4605, 221, 788, 71, 85, 3, 260, 24, 9, 7, 1656, 5, 375, 1659, 3191, 152, 4, 7207, 4993, 7, 137, 122, 40, 41, 5, 93, 787, 2, 282, 114, 461, 10, 6, 206, 2, 2991, 114, 730, 5, 3663, 7601, 2613, 9, 7, 1656, 5, 8, 375, 1659, 3191, 520, 6, 387, 1512, 710, 21, 446, 3, 1064, 1, 62, 7, 5, 1512, 12, 54, 208, 7601, 2613, 9, 3695, 1, 8, 375, 1659, 3191, 29, 1024, 1758, 6, 2551, 1324, 977, 365, 7, 11, 108, 243, 7, 42, 387, 12, 67, 7, 42, 387, 12, 18, 7, 42, 86, 1639, 134, 2, 14, 69, 42, 387, 12, 3, 52, 89, 28, 3, 98, 1, 7601, 2613, 10, 667, 60, 184, 239, 842, 3, 52, 1318, 1, 3, 375, 1659, 3191, 10, 49, 33, 494, 184, 14, 179, 494, 437, 7, 42, 8, 10064, 1, 14, 6, 18, 321, 348, 7601, 2613, 369, 462, 7, 42, 236, 3191, 2, 575, 10725, 12799, 348, 13512, 1, 3, 7601, 737, 648, 7, 849, 208, 1401, 7601, 2613, 2, 2181, 7638, 28, 3, 98, 1, 7601, 2613, 1, 3, 7, 54, 42, 1401, 7601, 2613, 83, 466, 208, 402, 152, 6, 9635, 3191, 3528, 44994, 27, 7635, 39, 2, 7601, 5646, 18, 659, 7, 382, 42, 1551, 7601, 2613, 568, 6, 220, 56807, 7860, 2, 33234, 1, 3, 1659, 1, 46, 66, 7, 33, 575, 7635, 2, 27, 575, 44994, 1, 3, 428, 7, 54, 208, 1401, 7601, 2613, 3, 52, 25, 50, 2613, 10, 67, 67, 53, 48, 58, 27, 326, 175, 83, 53, 4, 3, 284, 1, 7, 5, 375, 1659, 17279, 520, 6, 387, 1512, 12, 3663, 9910, 1322, 6, 40, 8, 3203, 1501, 17, 68, 3047, 7, 6, 3085, 458, 152]",1926.0,18190953,83
Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes.,Gynecologic oncology,Gynecol. Oncol.,2008-01-14,"To examine surgico-pathologic outcomes following extraperitoneal para-aortic lymph node dissection (EPLND) via pfannenstiel compared to paramedian incision prior to radiation in patients with cervical cancer. At our institution, patients with locally advanced cervical cancer undergo, EPLND. From 1990 to 2000, EPLND was performed via paramedian incision (PM) primarily to identify positive para-aortic lymph nodes (PALN). From 2000 to present, a complete pelvic and para-aortic lymphadenectomy was performed via pfannenstiel incision (PF). Records for all patients undergoing EPLND were reviewed. Pathologic findings, post-operative complications, and time to initiation of radiation (TRT) were abstracted. 93 patients underwent EPLND, 48 via PF and 45 via PM incision. The mean age and body mass index did not differ between the two groups. Stage distribution was similar: IB2 8 vs. 0%; IIB 44 vs. 44%; IIIA/B 35 vs. 44%; IVA 13 vs. 11%, respectively. Positive PALN were identified in 44% of PF patients and 29% of PM patients (p=ns). TRT was not significantly different at 36.4 vs. 28.8 days, respectively. There were more complications among the PF group including cellulitis and lymphocyst formation. Pre-treatment computed tomography (CT) scan had positive and negative predictive values of only 86 and 66% for evaluation of PALN involvement. We present an extraperitoneal method for removal of the pelvic and para-aortic lymph nodes with acceptable complications and no significant delay to initiate chemoradiation. Accurate assessment of lymphatic metastases results in modification of the radiation field, which, along with surgical debulking, may impact overall survival.",Evaluation Study,4390.0,11.0,To examine surgico-pathologic outcomes following extraperitoneal para-aortic lymph node dissection EPLND via pfannenstiel compared to paramedian incision prior to radiation in patients with cancer At our institution patients with locally advanced cancer undergo EPLND From 1990 to 2000 EPLND was performed via paramedian incision PM primarily to identify positive para-aortic lymph nodes PALN From 2000 to present a complete pelvic and para-aortic lymphadenectomy was performed via pfannenstiel incision PF Records for all patients undergoing EPLND were reviewed Pathologic findings post-operative complications and time to initiation of radiation TRT were abstracted 93 patients underwent EPLND 48 via PF and 45 via PM incision The mean age and body mass index did not differ between the two groups Stage distribution was similar IB2 8 vs. 0 IIB 44 vs. 44 IIIA/B 35 vs. 44 IVA 13 vs. 11 respectively Positive PALN were identified in 44 of PF patients and 29 of PM patients p=ns TRT was not significantly different at 36.4 vs. 28.8 days respectively There were more complications among the PF group including cellulitis and lymphocyst formation Pre-treatment computed tomography CT scan had positive and negative predictive values of only 86 and 66 for evaluation of PALN involvement We present an extraperitoneal method for removal of the pelvic and para-aortic lymph nodes with acceptable complications and no significant delay to initiate chemoradiation Accurate assessment of lymphatic metastases results in modification of the radiation field which along with surgical debulking may impact overall survival,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1004, 44858, 510, 123, 366, 13087, 4615, 3938, 263, 289, 1161, 21492, 847, 44995, 72, 6, 44996, 7538, 324, 6, 121, 4, 7, 5, 12, 28, 114, 731, 7, 5, 795, 131, 12, 1251, 21492, 29, 2289, 6, 1081, 21492, 10, 173, 847, 44996, 7538, 3377, 1561, 6, 255, 109, 4615, 3938, 263, 502, 34400, 29, 1081, 6, 364, 8, 236, 1110, 2, 4615, 3938, 2048, 10, 173, 847, 44995, 7538, 3313, 1064, 9, 62, 7, 479, 21492, 11, 446, 510, 272, 539, 1208, 521, 2, 98, 6, 1118, 1, 121, 7778, 11, 4106, 966, 7, 208, 21492, 576, 847, 3313, 2, 512, 847, 3377, 7538, 3, 313, 89, 2, 642, 782, 558, 205, 44, 1505, 59, 3, 100, 271, 82, 1395, 10, 288, 9537, 66, 105, 13, 3884, 584, 105, 584, 3164, 132, 465, 105, 584, 5900, 233, 105, 175, 106, 109, 34400, 11, 108, 4, 584, 1, 3313, 7, 2, 462, 1, 3377, 7, 19, 4044, 7778, 10, 44, 97, 338, 28, 511, 39, 105, 339, 66, 162, 106, 125, 11, 80, 521, 107, 3, 3313, 87, 141, 11168, 2, 38114, 1264, 671, 24, 1220, 872, 425, 1657, 42, 109, 2, 199, 464, 1030, 1, 158, 868, 2, 700, 9, 451, 1, 34400, 799, 21, 364, 35, 13087, 596, 9, 2829, 1, 3, 1110, 2, 4615, 3938, 263, 502, 5, 1595, 521, 2, 77, 93, 1984, 6, 4565, 975, 1481, 455, 1, 2936, 196, 99, 4, 2437, 1, 3, 121, 1067, 92, 1510, 5, 221, 3556, 68, 345, 63, 25]",1611.0,18191994,92
Racial differences in cervical cancer survival in the Detroit metropolitan area.,Cancer,Cancer,2008-03-01,"African-American (AA) women have lower survival rates from cervical cancer compared with white women. The objective of this study was to examine the influence of socioeconomic status (SES) and other variables on racial disparities in overall survival among women with invasive cervical cancer. One thousand thirty-six women (705 white women and 331 AA women) who were diagnosed with primary invasive cancer of the cervix between 1988 and 1992 were identified through the Metropolitan Detroit Cancer Surveillance System (MDCSS), a registry in the Surveillance, Epidemiology, and End Results (SEER) database. Pathology, treatment, and survival data were obtained through SEER. SES was categorized by using occupation, poverty, and educational status at the census tract level. Cox proportional hazards models were used to compare overall survival between AA women and white women adjusting for sociodemographics, clinical presentation, and treatment. AA women were more likely to present at an older age (P<.001), with later stage disease (P<.001), and with squamous histology (P=.01), and they were more likely to reside in a census tract categorized as Working Poor (WP) (P<.001). After multivariate adjustment, race no longer had a significant impact on survival. Women who resided in a WP census tract had a higher risk of death than women from a Professional census tract (P=.05). There was a significant interaction between disease stage and time with the effect of stage on survival attenuated after 6 years. In this study, factors that affected access to medical care appeared to have a more important influence than race on the long-term survival of women with invasive cervical cancer.",Journal Article,4343.0,22.0,African-American AA women have lower survival rates from cancer compared with white women The objective of this study was to examine the influence of socioeconomic status SES and other variables on racial disparities in overall survival among women with invasive cancer One thousand thirty-six women 705 white women and 331 AA women who were diagnosed with primary invasive cancer of the cervix between 1988 and 1992 were identified through the Metropolitan Detroit Cancer Surveillance System MDCSS a registry in the Surveillance Epidemiology and End Results SEER database Pathology treatment and survival data were obtained through SEER SES was categorized by using occupation poverty and educational status at the census tract level Cox proportional hazards models were used to compare overall survival between AA women and white women adjusting for sociodemographics clinical presentation and treatment AA women were more likely to present at an older age P .001 with later stage disease P .001 and with squamous histology P=.01 and they were more likely to reside in a census tract categorized as Working Poor WP P .001 After multivariate adjustment race no longer had a significant impact on survival Women who resided in a WP census tract had a higher risk of death than women from a Professional census tract P=.05 There was a significant interaction between disease stage and time with the effect of stage on survival attenuated after 6 years In this study factors that affected access to medical care appeared to have a more important influence than race on the long-term survival of women with invasive cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1410, 597, 1519, 117, 47, 280, 25, 151, 29, 12, 72, 5, 886, 117, 3, 461, 1, 26, 45, 10, 6, 1004, 3, 1054, 1, 3331, 156, 5699, 2, 127, 682, 23, 2257, 2227, 4, 63, 25, 107, 117, 5, 416, 12, 104, 6161, 977, 437, 117, 11303, 886, 117, 2, 7558, 1519, 117, 54, 11, 265, 5, 86, 416, 12, 1, 3, 3629, 59, 3314, 2, 2846, 11, 108, 298, 3, 8737, 9085, 12, 617, 398, 24734, 8, 1608, 4, 3, 617, 1284, 2, 396, 99, 1605, 609, 1117, 24, 2, 25, 74, 11, 683, 298, 1605, 5699, 10, 2320, 20, 75, 16701, 7583, 2, 3624, 156, 28, 3, 7319, 1696, 301, 418, 831, 1017, 274, 11, 95, 6, 932, 63, 25, 59, 1519, 117, 2, 886, 117, 1358, 9, 16918, 38, 1031, 2, 24, 1519, 117, 11, 80, 322, 6, 364, 28, 35, 434, 89, 19, 144, 5, 1559, 82, 34, 19, 144, 2, 5, 691, 784, 19, 355, 2, 491, 11, 80, 322, 6, 10114, 4, 8, 7319, 1696, 2320, 22, 2644, 334, 9480, 19, 144, 50, 331, 1852, 1047, 77, 589, 42, 8, 93, 345, 23, 25, 117, 54, 13472, 4, 8, 9480, 7319, 1696, 42, 8, 142, 43, 1, 273, 76, 117, 29, 8, 5341, 7319, 1696, 19, 474, 125, 10, 8, 93, 915, 59, 34, 82, 2, 98, 5, 3, 254, 1, 82, 23, 25, 2656, 50, 49, 60, 4, 26, 45, 130, 17, 1424, 1655, 6, 484, 165, 2121, 6, 47, 8, 80, 305, 1054, 76, 1047, 23, 3, 319, 337, 25, 1, 117, 5, 416, 12]",1619.0,18257090,90
Evidence-based surgical management of substernal goiter.,World journal of surgery,World J Surg,2008-07-01,"A number of reports have been published concerning the surgical treatment of substernal goiters; however, there is yet to be a comprehensive review of this body of literature using evidence-based methodology. This article is a systematic review of the literature using evidence-based criteria and a review of unpublished data from our institution. Issue 1. Limited level III/IV data suggest that the incidence of cancer in substernal goiters is not higher than the incidence of cancer in cervical goiters. Risk factors for malignancy in substernal goiters may include a family history of thyroid pathology, a history of cervical radiation therapy, recurrent goiter, and the presence of cervical adenopathy (grade C recommendation). Issue 2. Prospective level V data suggest that, for most patients, expert endocrine surgeons utilize an extracervical approach approximately 2% of the time to remove a substernal goiter safely; a sternotomy or thoracotomy appears more likely in cases of a primary substernal goiter or a mass larger than the thoracic inlet (no recommendation). Issue 3. There may be a higher rate of permanent hypoparathyroidism and unintentional permanent recurrent laryngeal nerve injury when total thyroidectomy is performed for removal of a substernal goiter than for removal of a cervical goiter alone (grade C recommendation). Injury of the external branch of the superior laryngeal nerve was not specifically addressed and is almost certainly underreported. Issue 4. The presence of a substernal goiter, especially being present more than 5 years and causing significant tracheal compression, is likely a risk factor for tracheomalacia and tracheostomy (grade C recommendation). Tracheomalacia with substernal goiter is an infrequent occurrence, and many cases of tracheomalacia can be managed without tracheostomy (no recommendation). Issue 5. Prospective level V data suggest that about 5% to 10% of operations for substernal goiters are performed because of recurrent or persistent disease, although retrospective level V data report an even higher rate, up to 37%. The most common initial operations with recurrence or persistence appear to be subtotal or hemithyroidectomy (no recommendation). Evidence-based recommendations provide reliable information regarding the pathologic findings and operative management of substernal goiters in expert hands.",Journal Article,4221.0,126.0,A number of reports have been published concerning the surgical treatment of substernal goiters however there is yet to be a comprehensive review of this body of literature using evidence-based methodology This article is a systematic review of the literature using evidence-based criteria and a review of unpublished data from our institution Issue 1 Limited level III/IV data suggest that the incidence of cancer in substernal goiters is not higher than the incidence of cancer in goiters Risk factors for malignancy in substernal goiters may include a family history of pathology a history of radiation therapy recurrent goiter and the presence of adenopathy grade C recommendation Issue 2 Prospective level V data suggest that for most patients expert endocrine surgeons utilize an extracervical approach approximately 2 of the time to remove a substernal goiter safely a sternotomy or thoracotomy appears more likely in cases of a primary substernal goiter or a mass larger than the thoracic inlet no recommendation Issue 3 There may be a higher rate of permanent hypoparathyroidism and unintentional permanent recurrent nerve injury when total thyroidectomy is performed for removal of a substernal goiter than for removal of a goiter alone grade C recommendation Injury of the external branch of the superior nerve was not specifically addressed and is almost certainly underreported Issue 4 The presence of a substernal goiter especially being present more than 5 years and causing significant tracheal compression is likely a risk factor for tracheomalacia and tracheostomy grade C recommendation Tracheomalacia with substernal goiter is an infrequent occurrence and many cases of tracheomalacia can be managed without tracheostomy no recommendation Issue 5 Prospective level V data suggest that about 5 to 10 of operations for substernal goiters are performed because of recurrent or persistent disease although retrospective level V data report an even higher rate up to 37 The most common initial operations with recurrence or persistence appear to be subtotal or hemithyroidectomy no recommendation Evidence-based recommendations provide reliable information regarding the pathologic findings and operative management of substernal goiters in expert hands,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[8, 207, 1, 1198, 47, 85, 983, 4243, 3, 221, 24, 1, 19660, 25063, 137, 125, 16, 1145, 6, 40, 8, 949, 206, 1, 26, 642, 1, 789, 75, 241, 90, 3209, 26, 946, 16, 8, 1556, 206, 1, 3, 789, 75, 241, 90, 371, 2, 8, 206, 1, 16010, 74, 29, 114, 731, 2537, 14, 383, 301, 316, 478, 74, 309, 17, 3, 287, 1, 12, 4, 19660, 25063, 16, 44, 142, 76, 3, 287, 1, 12, 4, 25063, 43, 130, 9, 710, 4, 19660, 25063, 68, 643, 8, 607, 532, 1, 1117, 8, 532, 1, 121, 36, 387, 16309, 2, 3, 463, 1, 7741, 88, 256, 3347, 2537, 18, 482, 301, 603, 74, 309, 17, 9, 96, 7, 2005, 1293, 1613, 6391, 35, 38497, 353, 705, 18, 1, 3, 98, 6, 7930, 8, 19660, 16309, 2268, 8, 23295, 15, 6103, 1233, 80, 322, 4, 140, 1, 8, 86, 19660, 16309, 15, 8, 782, 1077, 76, 3, 2098, 22397, 77, 3347, 2537, 27, 125, 68, 40, 8, 142, 116, 1, 4377, 23587, 2, 17350, 4377, 387, 2476, 2730, 198, 181, 5949, 16, 173, 9, 2829, 1, 8, 19660, 16309, 76, 9, 2829, 1, 8, 16309, 279, 88, 256, 3347, 2730, 1, 3, 1455, 7769, 1, 3, 1123, 2476, 10, 44, 1225, 2814, 2, 16, 2214, 13486, 14900, 2537, 39, 3, 463, 1, 8, 19660, 16309, 1093, 486, 364, 80, 76, 33, 60, 2, 3440, 93, 12898, 3481, 16, 322, 8, 43, 161, 9, 38648, 2, 15648, 88, 256, 3347, 38648, 5, 19660, 16309, 16, 35, 4475, 2291, 2, 445, 140, 1, 38648, 122, 40, 2231, 187, 15648, 77, 3347, 2537, 33, 482, 301, 603, 74, 309, 17, 545, 33, 6, 79, 1, 3867, 9, 19660, 25063, 32, 173, 408, 1, 387, 15, 1882, 34, 242, 459, 301, 603, 74, 414, 35, 871, 142, 116, 126, 6, 567, 3, 96, 186, 388, 3867, 5, 146, 15, 4108, 1322, 6, 40, 5503, 15, 38649, 77, 3347, 241, 90, 883, 377, 2450, 487, 666, 3, 510, 272, 2, 1208, 284, 1, 19660, 25063, 4, 2005, 10648]",2268.0,18266028,273
Cyclooxygenase-2 in cervical neoplasia: a review.,Gynecologic oncology,Gynecol. Oncol.,2008-02-13,"Previous data demonstrate an association between cyclooxygenase activity and development of cervical cancer. This review investigates the role of cyclooxygenase-2 (COX-2) in the development of cervical cancer and potential therapeutic options targeting this pathway. A literature search was conducted using MEDLINE 1997-2007 utilizing the terms inflammation, cervical cancer, cyclooxygenase, COX-2, indomethacin, cervical intraepithelial neoplasia, and squamous cell cancer. Articles were included based on the quality of the study and pertinence to the topic. Other sources were culled from the references of the articles identified. Over 150 abstracts were reviewed for inclusion. Studies in vivo and in vitro confirm the role of COX-2 in the development of cervical cancer. In addition, COX-2 overexpression is associated with an increase in angiogenesis markers. Clinical correlation found that COX-2 overexpression in cervical cancer patients is a poor prognostic marker associated with increased risk for recurrent or metastatic disease. Despite early promise, two phase II trials in use of specific COX-2 inhibitors as radio-sensitizers in locally advanced cervical cancer demonstrated increased toxicity with no change in therapeutic effect. Results of studies using COX-2 inhibitors in pre-invasive cervical disease are encouraging. Treatment of cervical intraepithelial neoplasia with cyclooxygenase inhibitors may provide a medical alternative to surgical therapy.",Journal Article,4360.0,40.0,Previous data demonstrate an association between cyclooxygenase activity and development of cancer This review investigates the role of cyclooxygenase-2 COX-2 in the development of cancer and potential therapeutic options targeting this pathway A literature search was conducted using MEDLINE 1997-2007 utilizing the terms inflammation cancer cyclooxygenase COX-2 indomethacin intraepithelial neoplasia and squamous cell cancer Articles were included based on the quality of the study and pertinence to the topic Other sources were culled from the references of the articles identified Over 150 abstracts were reviewed for inclusion Studies in vivo and in vitro confirm the role of COX-2 in the development of cancer In addition COX-2 overexpression is associated with an increase in angiogenesis markers Clinical correlation found that COX-2 overexpression in cancer patients is a poor prognostic marker associated with increased risk for recurrent or metastatic disease Despite early promise two phase II trials in use of specific COX-2 inhibitors as radio-sensitizers in locally advanced cancer demonstrated increased toxicity with no change in therapeutic effect Results of studies using COX-2 inhibitors in pre-invasive disease are encouraging Treatment of intraepithelial neoplasia with cyclooxygenase inhibitors may provide a medical alternative to surgical therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[698, 74, 608, 35, 248, 59, 4043, 128, 2, 193, 1, 12, 26, 206, 7259, 3, 200, 1, 4043, 18, 418, 18, 4, 3, 193, 1, 12, 2, 174, 189, 838, 529, 26, 308, 8, 789, 1901, 10, 426, 75, 3388, 2341, 1307, 2600, 3, 1794, 1815, 12, 4043, 418, 18, 37365, 4153, 2298, 2, 691, 31, 12, 2384, 11, 159, 90, 23, 3, 372, 1, 3, 45, 2, 33923, 6, 3, 5463, 127, 3375, 11, 34419, 29, 3, 9241, 1, 3, 2384, 108, 252, 1577, 5159, 11, 446, 9, 1680, 94, 4, 386, 2, 4, 439, 1843, 3, 200, 1, 418, 18, 4, 3, 193, 1, 12, 4, 352, 418, 18, 851, 16, 41, 5, 35, 344, 4, 1056, 525, 38, 816, 204, 17, 418, 18, 851, 4, 12, 7, 16, 8, 334, 177, 952, 41, 5, 101, 43, 9, 387, 15, 113, 34, 550, 191, 1783, 100, 124, 215, 143, 4, 119, 1, 112, 418, 18, 222, 22, 6477, 19457, 4, 795, 131, 12, 264, 101, 155, 5, 77, 707, 4, 189, 254, 99, 1, 94, 75, 418, 18, 222, 4, 671, 416, 34, 32, 2269, 24, 1, 4153, 2298, 5, 4043, 222, 68, 377, 8, 484, 1091, 6, 221, 36]",1372.0,18275990,133
Social factors affecting treatment of cervical cancer: ethical issues and policy implications.,Obstetrics and gynecology,Obstet Gynecol,2008-03-01,"Health care in the United States has become a privilege rather than a right. Patients who have the greatest need are the ones most likely to be denied this privilege. Despite recent advances in disease detection and treatment, many patients do not receive even the bare minimum of care. The high complexity of the health care system in the setting of patients with low levels of health literacy significantly affects the ability to seek and receive treatment in a timely fashion. In addition, lack of insurance, transportation, and social support further complicate access to care. To truly provide a standard of care to all patients, regardless of resources, our health care system must evolve to address the needs of the population. In this paper, we report a tragic case where social factors affected the outcome of a single mother with advanced cervical cancer.",Case Reports,4343.0,13.0,Health care in the United States has become a privilege rather than a right Patients who have the greatest need are the ones most likely to be denied this privilege Despite recent advances in disease detection and treatment many patients do not receive even the bare minimum of care The high complexity of the health care system in the setting of patients with low levels of health literacy significantly affects the ability to seek and receive treatment in a timely fashion In addition lack of insurance transportation and social support further complicate access to care To truly provide a standard of care to all patients regardless of resources our health care system must evolve to address the needs of the population In this paper we report a tragic case where social factors affected the outcome of a single mother with advanced cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[341, 165, 4, 3, 1088, 907, 71, 1417, 8, 25067, 1832, 76, 8, 1913, 7, 54, 47, 3, 2199, 594, 32, 3, 6737, 96, 322, 6, 40, 12601, 26, 25067, 550, 435, 954, 4, 34, 638, 2, 24, 445, 7, 1022, 44, 560, 871, 3, 28770, 2499, 1, 165, 3, 64, 3082, 1, 3, 341, 165, 398, 4, 3, 546, 1, 7, 5, 154, 148, 1, 341, 9925, 97, 2561, 3, 801, 6, 6606, 2, 560, 24, 4, 8, 4225, 3240, 4, 352, 926, 1, 1935, 13964, 2, 2032, 538, 195, 11157, 1655, 6, 165, 6, 7260, 377, 8, 260, 1, 165, 6, 62, 7, 1583, 1, 2892, 114, 341, 165, 398, 1642, 4800, 6, 1539, 3, 1891, 1, 3, 266, 4, 26, 2817, 21, 414, 8, 38460, 473, 1257, 2032, 130, 1424, 3, 228, 1, 8, 226, 9733, 5, 131, 12]",842.0,18310380,242
Sensitivity of squamous cell carcinoma lymph node metastases to herpes oncolytic therapy.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2008-03-01,"Cancer metastases may have phenotypic and genetic differences from their primary cancers of origin. Engineered, replication-competent, attenuated viruses based on herpes simplex virus-1 (HSV-1) have shown potent oncolytic effects in treating primary tumors in animal tumor models, but their efficacy in treating lymph node metastases is poorly understood. We compared the efficacy of an attenuated oncolytic HSV-1 (NV1023) in treating a series of murine squamous carcinoma cell lines derived from serial implantation and harvest from metastatic lymph nodes. The auricles of C3H/HeJ mice were implanted with SCCVII. Cervical nodal metastases were isolated, expanded in vitro, and reimplanted into new mice. A series of cell lines (LN1-LN7) were generated through seven serial passages. Cells from higher LN passages showed consistent trends toward increased migratory and invasive ability, increased cell surface nectin-1 (an HSV-1 receptor) expression, and increased glycoprotein D binding. Exposure to NV1023 showed increased viral entry, replication, and cytotoxicity with higher LN passages. Intratumoral injection of NV1023 in a murine flank tumor model caused significantly greater tumor regression and increased viral infection of LN7 compared with SCCVII. These results show that lymph node metastases may undergo selection for characteristics, including increased nectin-1 expression, that make them more sensitive targets for herpes oncolytic therapy. These findings support the clinical application of these agents for the treatment of lymph node metastases.",Evaluation Study,4343.0,8.0,Cancer metastases may have phenotypic and genetic differences from their primary cancers of origin Engineered replication-competent attenuated viruses based on herpes simplex virus-1 HSV-1 have shown potent oncolytic effects in treating primary tumors in animal tumor models but their efficacy in treating lymph node metastases is poorly understood We compared the efficacy of an attenuated oncolytic HSV-1 NV1023 in treating a series of murine squamous carcinoma cell lines derived from serial implantation and harvest from metastatic lymph nodes The auricles of C3H/HeJ mice were implanted with SCCVII nodal metastases were isolated expanded in vitro and reimplanted into new mice A series of cell lines LN1-LN7 were generated through seven serial passages Cells from higher LN passages showed consistent trends toward increased migratory and invasive ability increased cell surface nectin-1 an HSV-1 receptor expression and increased glycoprotein D binding Exposure to NV1023 showed increased viral entry replication and cytotoxicity with higher LN passages Intratumoral injection of NV1023 in a murine flank tumor model caused significantly greater tumor regression and increased viral infection of LN7 compared with SCCVII These results show that lymph node metastases may undergo selection for characteristics including increased nectin-1 expression that make them more sensitive targets for herpes oncolytic therapy These findings support the clinical application of these agents for the treatment of lymph node metastases,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 196, 68, 47, 3290, 2, 336, 362, 29, 136, 86, 163, 1, 1938, 2794, 2079, 6299, 2656, 4405, 90, 23, 4716, 7241, 1450, 14, 4702, 14, 47, 443, 1157, 3236, 176, 4, 1367, 86, 57, 4, 2026, 30, 274, 84, 136, 209, 4, 1367, 263, 289, 196, 16, 1240, 1784, 21, 72, 3, 209, 1, 35, 2656, 3236, 4702, 14, 9096, 4, 1367, 8, 988, 1, 1471, 691, 134, 31, 285, 526, 29, 2108, 4314, 2, 10074, 29, 113, 263, 502, 3, 42998, 1, 16623, 33705, 399, 11, 3416, 5, 28337, 779, 196, 11, 1355, 2064, 4, 439, 2, 31248, 237, 217, 399, 8, 988, 1, 31, 285, 56942, 45063, 11, 1419, 298, 648, 2108, 14424, 37, 29, 142, 1763, 14424, 224, 925, 1963, 1317, 101, 7757, 2, 416, 801, 101, 31, 1255, 10758, 14, 35, 4702, 14, 153, 55, 2, 101, 4455, 427, 791, 645, 6, 9096, 224, 101, 1667, 3001, 2079, 2, 1408, 5, 142, 1763, 14424, 2074, 1754, 1, 9096, 4, 8, 1471, 5564, 30, 202, 1546, 97, 378, 30, 320, 2, 101, 1667, 930, 1, 45063, 72, 5, 28337, 46, 99, 514, 17, 263, 289, 196, 68, 1251, 881, 9, 374, 141, 101, 10758, 14, 55, 17, 2378, 1370, 80, 745, 637, 9, 4716, 3236, 36, 46, 272, 538, 3, 38, 1581, 1, 46, 183, 9, 3, 24, 1, 263, 289, 196]",1529.0,18347193,117
Perceived stress is associated with impaired T-cell response to HPV16 in women with cervical dysplasia.,Annals of behavioral medicine : a publication of the Society of Behavioral Medicine,Ann Behav Med,2008-02-13,"Infection with high-risk subtypes of human papillomavirus (HPV) is a central factor in the development of cervical neoplasia. Cell-mediated immunity against HPV16 plays an important role in the resolution of HPV infection and in controlling cervical disease progression. Research suggests that stress is associated with cervical disease progression, but few studies have examined the biological mechanisms that may be driving this association. This study examines whether stress is associated with immune response to HPV16 among women with cervical dysplasia. Seventy-four women presenting for colposcopy completed measures of health behaviors, stressful life events and perceived stress. A blood sample was obtained to evaluate proliferative T-cell response to HPV16, and a cervical sample was obtained during gynecologic exam for HPV-typing. More than 55% tested positive for one or more HPV subtypes. Women who did not show proliferative responses to HPV (i.e. non-responders) were more likely to be HPV(+) compared to women who had a response (i.e. responders). Consistent with study hypotheses, logistic regression revealed that higher levels of perceived stress were associated with a non-response to HPV16, controlling for relevant covariates. Stressful life events were not associated with T-cell response to HPV. Higher levels of perceived stress are associated with impaired HPV-specific immune response in women with cervical dysplasia, suggesting a potential mechanism by which stress may influence cervical disease progression.",Journal Article,4360.0,23.0,Infection with high-risk subtypes of human papillomavirus HPV is a central factor in the development of neoplasia Cell-mediated immunity against HPV16 plays an important role in the resolution of HPV infection and in controlling disease progression Research suggests that stress is associated with disease progression but few studies have examined the biological mechanisms that may be driving this association This study examines whether stress is associated with immune response to HPV16 among women with dysplasia Seventy-four women presenting for colposcopy completed measures of health behaviors stressful life events and perceived stress A blood sample was obtained to evaluate proliferative T-cell response to HPV16 and a sample was obtained during gynecologic exam for HPV-typing More than 55 tested positive for one or more HPV subtypes Women who did not show proliferative responses to HPV i.e non-responders were more likely to be HPV compared to women who had a response i.e responders Consistent with study hypotheses logistic regression revealed that higher levels of perceived stress were associated with a non-response to HPV16 controlling for relevant covariates Stressful life events were not associated with T-cell response to HPV Higher levels of perceived stress are associated with impaired HPV-specific immune response in women with dysplasia suggesting a potential mechanism by which stress may influence disease progression,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[930, 5, 64, 43, 814, 1, 171, 3242, 933, 16, 8, 854, 161, 4, 3, 193, 1, 2298, 31, 517, 1604, 480, 4048, 1698, 35, 305, 200, 4, 3, 2125, 1, 933, 930, 2, 4, 1893, 34, 91, 389, 844, 17, 1531, 16, 41, 5, 34, 91, 84, 1021, 94, 47, 409, 3, 1037, 483, 17, 68, 40, 4057, 26, 248, 26, 45, 4468, 317, 1531, 16, 41, 5, 250, 51, 6, 4048, 107, 117, 5, 2253, 2073, 294, 117, 1656, 9, 9946, 781, 1018, 1, 341, 3704, 15927, 358, 281, 2, 2588, 1531, 8, 315, 1000, 10, 683, 6, 376, 2441, 102, 31, 51, 6, 4048, 2, 8, 1000, 10, 683, 190, 1512, 6747, 9, 933, 10656, 80, 76, 614, 650, 109, 9, 104, 15, 80, 933, 814, 117, 54, 205, 44, 514, 2441, 253, 6, 933, 70, 563, 220, 1983, 11, 80, 322, 6, 40, 933, 72, 6, 117, 54, 42, 8, 51, 70, 563, 1983, 925, 5, 45, 6243, 812, 320, 553, 17, 142, 148, 1, 2588, 1531, 11, 41, 5, 8, 220, 51, 6, 4048, 1893, 9, 867, 2489, 15927, 358, 281, 11, 44, 41, 5, 102, 31, 51, 6, 933, 142, 148, 1, 2588, 1531, 32, 41, 5, 2364, 933, 112, 250, 51, 4, 117, 5, 2253, 802, 8, 174, 670, 20, 92, 1531, 68, 1054, 34, 91]",1448.0,18347908,34
"Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected].",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2008-04-01,"Cancer diagnosis and treatment imparts chronic stressors affecting quality of life (QOL) and basic physiology. However, the capacity to increase survival by improving QOL is controversial. Patients with cervical cancer, in particular, have severely compromised QOL, providing a population well-suited for the evaluation of novel psychosocial interventions and the exploration of mechanisms by which modulation of the psychoneuroimmune axis might result in improved clinical outcomes. A randomized clinical trial was conducted in cervical cancer survivors that were enrolled at >or=13 and <22 months after diagnosis (n=50), comparing a unique psychosocial telephone counseling (PTC) intervention to usual care. QOL and biological specimens (saliva and blood) were collected at baseline and 4 months post-enrollment. The PTC intervention yielded significantly improved QOL (P=0.011). Changes in QOL were significantly associated with a shift of immune system T helper type 1 and 2 (Th1/Th2) bias, as measured by IFN-gamma/interleukin-5 ELISpot T lymphocyte precursor frequency; improved QOL being associated with increased Th1 bias (P=0.012). Serum interleukin-10 and the neuroendocrine variables of cortisol and dehydroepiandrosterone revealed trends supporting this shift in immunologic stance and suggested a PTC-mediated decrease of the subject's chronic stress response. This study documents the utility of a unique PTC intervention and an association between changes in QOL and adaptive immunity (T helper class). These data support the integration of the chronic stress response into biobehavioral models of cancer survivorship and suggests a novel mechanistic hypotheses by which interventions leading to enhanced QOL could result in improved clinical outcome including survival.",Journal Article,4312.0,57.0,Cancer diagnosis and treatment imparts chronic stressors affecting quality of life QOL and basic physiology However the capacity to increase survival by improving QOL is controversial Patients with cancer in particular have severely compromised QOL providing a population well-suited for the evaluation of novel psychosocial interventions and the exploration of mechanisms by which modulation of the psychoneuroimmune axis might result in improved clinical outcomes A randomized clinical trial was conducted in cancer survivors that were enrolled at or=13 and 22 months after diagnosis n=50 comparing a unique psychosocial telephone counseling PTC intervention to usual care QOL and biological specimens saliva and blood were collected at baseline and 4 months post-enrollment The PTC intervention yielded significantly improved QOL P=0.011 Changes in QOL were significantly associated with a shift of immune system T helper type 1 and 2 Th1/Th2 bias as measured by IFN-gamma/interleukin-5 ELISpot T lymphocyte precursor frequency improved QOL being associated with increased Th1 bias P=0.012 Serum interleukin-10 and the neuroendocrine variables of cortisol and dehydroepiandrosterone revealed trends supporting this shift in immunologic stance and suggested a PTC-mediated decrease of the subject 's chronic stress response This study documents the utility of a unique PTC intervention and an association between changes in QOL and adaptive immunity T helper class These data support the integration of the chronic stress response into biobehavioral models of cancer survivorship and suggests a novel mechanistic hypotheses by which interventions leading to enhanced QOL could result in improved clinical outcome including survival,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 147, 2, 24, 18351, 442, 16335, 2319, 372, 1, 358, 1001, 2, 2795, 7206, 137, 3, 2162, 6, 344, 25, 20, 1673, 1001, 16, 2010, 7, 5, 12, 4, 1454, 47, 7207, 4867, 1001, 1736, 8, 266, 149, 7247, 9, 3, 451, 1, 229, 2322, 1151, 2, 3, 3370, 1, 483, 20, 92, 2356, 1, 3, 56975, 2310, 822, 757, 4, 231, 38, 123, 8, 384, 38, 160, 10, 426, 4, 12, 332, 17, 11, 346, 28, 15, 233, 2, 350, 53, 50, 147, 78, 212, 1430, 8, 991, 2322, 4258, 2011, 3748, 788, 6, 3521, 165, 1001, 2, 1037, 623, 10475, 2, 315, 11, 786, 28, 330, 2, 39, 53, 539, 1798, 3, 3748, 788, 2178, 97, 231, 1001, 19, 13, 3651, 400, 4, 1001, 11, 97, 41, 5, 8, 3024, 1, 250, 398, 102, 5539, 267, 14, 2, 18, 4714, 8358, 2947, 22, 644, 20, 1256, 1705, 1603, 33, 7662, 102, 1448, 2765, 675, 231, 1001, 486, 41, 5, 101, 4714, 2947, 19, 13, 3499, 524, 1603, 79, 2, 3, 1542, 682, 1, 9572, 2, 12317, 553, 1963, 1912, 26, 3024, 4, 3042, 34448, 2, 1148, 8, 3748, 517, 775, 1, 3, 2974, 292, 442, 1531, 51, 26, 45, 9337, 3, 1207, 1, 8, 991, 3748, 788, 2, 35, 248, 59, 400, 4, 1001, 2, 2454, 1604, 102, 5539, 1040, 46, 74, 538, 3, 2676, 1, 3, 442, 1531, 51, 237, 21332, 274, 1, 12, 2560, 2, 844, 8, 229, 2716, 6243, 20, 92, 1151, 1049, 6, 651, 1001, 359, 757, 4, 231, 38, 228, 141, 25]",1733.0,18381952,78
Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon.,Head & neck,Head Neck,2008-07-01,": Cystic lymph node metastases have been associated with tonsil cancer. A subset of oropharyngeal cancers contain human papillomavirus (HPV) DNA. The clinical and virologic associations of cystic nodal metastasis in head and neck cancer (HNSCC) were investigated. : A retrospective review of patients undergoing neck dissection between 2002 and 2004 identified patients with cystic lymph node metastases. Clinical and pathologic information was recorded. The presence of HPV DNA was analyzed using in situ hybridization in a subset of patients. : One hundred neck dissections were reviewed and 20 had cystic nodes. Seventeen of these patients had primary tumors arising in the palatine or lingual tonsil. Three were ""unknown primary."" HPV DNA was present in 11 of 13 patients with cystic metastases with tissue available for analysis (87%). No HPV DNA was identified in tumor from 21 patients with solid nodal metastasis (p <.0001). : Cystic cervical lymph node metastasis is strongly associated with HPV-related tonsillar HNSCC: (c) 2008 Wiley Periodicals, Inc. Head Neck 2008.",Journal Article,4221.0,247.0,Cystic lymph node metastases have been associated with tonsil cancer A subset of cancers contain human papillomavirus HPV DNA The clinical and virologic associations of cystic nodal metastasis in head and cancer HNSCC were investigated A retrospective review of patients undergoing dissection between 2002 and 2004 identified patients with cystic lymph node metastases Clinical and pathologic information was recorded The presence of HPV DNA was analyzed using in situ hybridization in a subset of patients One hundred dissections were reviewed and 20 had cystic nodes Seventeen of these patients had primary tumors arising in the palatine or lingual tonsil Three were `` unknown primary '' HPV DNA was present in 11 of 13 patients with cystic metastases with tissue available for analysis 87 No HPV DNA was identified in tumor from 21 patients with solid nodal metastasis p .0001 Cystic lymph node metastasis is strongly associated with HPV-related tonsillar HNSCC c 2008 Wiley Periodicals Inc. Head 2008,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2965, 263, 289, 196, 47, 85, 41, 5, 10226, 12, 8, 697, 1, 163, 3725, 171, 3242, 933, 261, 3, 38, 2, 22443, 685, 1, 2965, 779, 278, 4, 718, 2, 12, 1209, 11, 565, 8, 459, 206, 1, 7, 479, 1161, 59, 1544, 2, 1131, 108, 7, 5, 2965, 263, 289, 196, 38, 2, 510, 487, 10, 1872, 3, 463, 1, 933, 261, 10, 311, 75, 4, 957, 1554, 4, 8, 697, 1, 7, 104, 1128, 6894, 11, 446, 2, 179, 42, 2965, 502, 3591, 1, 46, 7, 42, 86, 57, 2635, 4, 3, 56978, 15, 43337, 10226, 169, 11, 860, 86, 522, 933, 261, 10, 364, 4, 175, 1, 233, 7, 5, 2965, 196, 5, 246, 390, 9, 65, 912, 77, 933, 261, 10, 108, 4, 30, 29, 239, 7, 5, 537, 779, 278, 19, 488, 2965, 263, 289, 278, 16, 1327, 41, 5, 933, 139, 13411, 1209, 256, 1375, 4692, 5493, 3479, 718, 1375]",1005.0,18383529,415
Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era.,Gynecologic oncology,Gynecol. Oncol.,2008-04-03,"To conduct an outcome analysis of patients with cervical clear cell carcinoma (CCCC) in the post-DES era. A retrospective review was conducted at 3 major gynecologic cancer centers of all primary CCCC between 1982 and 2004. CCCC was confirmed in 34 patients. Median age was 53 years. DES exposure was confirmed in 2 (6%) patients. A history of smoking was elicited in 22%, and of abnormal Pap smear 18% patients. Primary surgical resection was performed in all stage I or IIA patients (n=26); they displayed superior 3-year overall survival (OS) compared to advanced stage (n=8) patients (91% vs. 22%, p<0.001). Pelvic lymph node involvement was noted in 25%; all patients with positive para-aortic nodes (20% of patients sampled) had positive pelvic nodes. All node positive patients were treated with adjuvant radiation, but nevertheless displayed reduced progression free (31% vs 92%, p<0.001) and overall survival (80% vs. 100%, p=0.02). Adjuvant radiotherapy did not appear to impact OS in patients with negative lymph nodes. This series provides insight into the management of early stage CCCC in the post-DES era. Although these patients may be at slightly higher risk of nodal spread, clear cell histology by itself does not appear to portend a worse prognosis than squamous cell carcinoma of the cervix in the absence of traditional risk factors. Our data suggest that patients with low risk early stage CCCC may be managed with radical surgery alone, without the need for adjuvant chemotherapy or radiation.",Journal Article,4310.0,40.0,To conduct an outcome analysis of patients with clear cell carcinoma CCCC in the post-DES era A retrospective review was conducted at 3 major gynecologic cancer centers of all primary CCCC between 1982 and 2004 CCCC was confirmed in 34 patients Median age was 53 years DES exposure was confirmed in 2 6 patients A history of smoking was elicited in 22 and of abnormal Pap smear 18 patients Primary surgical resection was performed in all stage I or IIA patients n=26 they displayed superior 3-year overall survival OS compared to advanced stage n=8 patients 91 vs. 22 p 0.001 Pelvic lymph node involvement was noted in 25 all patients with positive para-aortic nodes 20 of patients sampled had positive pelvic nodes All node positive patients were treated with adjuvant radiation but nevertheless displayed reduced progression free 31 vs 92 p 0.001 and overall survival 80 vs. 100 p=0.02 Adjuvant radiotherapy did not appear to impact OS in patients with negative lymph nodes This series provides insight into the management of early stage CCCC in the post-DES era Although these patients may be at slightly higher risk of nodal spread clear cell histology by itself does not appear to portend a worse prognosis than squamous cell carcinoma of the cervix in the absence of traditional risk factors Our data suggest that patients with low risk early stage CCCC may be managed with radical surgery alone without the need for adjuvant chemotherapy or radiation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 4073, 35, 228, 65, 1, 7, 5, 885, 31, 134, 31262, 4, 3, 539, 8683, 1713, 8, 459, 206, 10, 426, 28, 27, 458, 1512, 12, 1168, 1, 62, 86, 31262, 59, 6652, 2, 1131, 31262, 10, 557, 4, 562, 7, 52, 89, 10, 699, 60, 8683, 645, 10, 557, 4, 18, 49, 7, 8, 532, 1, 979, 10, 5179, 4, 350, 2, 1, 1668, 4290, 8379, 203, 7, 86, 221, 170, 10, 173, 4, 62, 82, 70, 15, 4088, 7, 78, 432, 491, 2507, 1123, 27, 111, 63, 25, 118, 72, 6, 131, 82, 78, 66, 7, 970, 105, 350, 19, 13, 144, 1110, 263, 289, 799, 10, 1051, 4, 243, 62, 7, 5, 109, 4615, 3938, 502, 179, 1, 7, 5919, 42, 109, 1110, 502, 62, 289, 109, 7, 11, 73, 5, 249, 121, 84, 3873, 2507, 405, 91, 115, 456, 105, 937, 19, 13, 144, 2, 63, 25, 493, 105, 394, 19, 13, 588, 249, 310, 205, 44, 1322, 6, 345, 118, 4, 7, 5, 199, 263, 502, 26, 988, 777, 2670, 237, 3, 284, 1, 191, 82, 31262, 4, 3, 539, 8683, 1713, 242, 46, 7, 68, 40, 28, 3223, 142, 43, 1, 779, 2579, 885, 31, 784, 20, 4045, 1097, 44, 1322, 6, 11293, 8, 639, 356, 76, 691, 31, 134, 1, 3, 3629, 4, 3, 1127, 1, 1847, 43, 130, 114, 74, 309, 17, 7, 5, 154, 43, 191, 82, 31262, 68, 40, 2231, 5, 711, 152, 279, 187, 3, 594, 9, 249, 56, 15, 121]",1457.0,18394687,135
Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2008-05-01,"The purpose of this study was to investigate early gene expression changes after chemoradiation in a human solid tumor, allowing identification of chemoradiation-induced gene expression changes in the tumor as well as the tumor microenvironment. In addition we aimed to identify a gene expression profile that was associated with clinical outcome. Microarray experiments were performed on cervical cancer specimens obtained before and 48 h after chemoradiation from 12 patients with Stage IB2 to IIIB squamous cell carcinoma of the cervix treated between April 2001 and August 2002. A total of 262 genes were identified that were significantly changed after chemoradiation. Genes involved in DNA repair were identified including DDB2, ERCC4, GADD45A, and XPC. In addition, significantly regulated cell-to-cell signaling pathways included insulin-like growth factor-1 (IGF-1), interferon, and vascular endothelial growth factor signaling. At a median follow-up of 41 months, 5 of 12 patients had experienced either local or distant failure. Supervised clustering analysis identified a 58-gene set from the pretreatment samples that were differentially expressed between patients with and without recurrence. Genes involved in integrin signaling and apoptosis pathways were identified in this gene set. Immortalization-upregulated protein (IMUP), IGF-2, and ARHD had particularly marked differences in expression between patients with and without recurrence. Genetic profiling identified genes regulated by chemoradiation including DNA damage and cell-to-cell signaling pathways. Genes associated with recurrence were identified that will require validation in an independent patient data set to determine whether the 58-gene set associated with clinical outcome could be useful as a prognostic assay.",Journal Article,4282.0,28.0,The purpose of this study was to investigate early gene expression changes after chemoradiation in a human solid tumor allowing identification of chemoradiation-induced gene expression changes in the tumor as well as the tumor microenvironment In addition we aimed to identify a gene expression profile that was associated with clinical outcome Microarray experiments were performed on cancer specimens obtained before and 48 h after chemoradiation from 12 patients with Stage IB2 to IIIB squamous cell carcinoma of the cervix treated between April 2001 and August 2002 A total of 262 genes were identified that were significantly changed after chemoradiation Genes involved in DNA repair were identified including DDB2 ERCC4 GADD45A and XPC In addition significantly regulated cell-to-cell signaling pathways included insulin-like growth factor-1 IGF-1 interferon and vascular endothelial growth factor signaling At a median follow-up of 41 months 5 of 12 patients had experienced either local or distant failure Supervised clustering analysis identified a 58-gene set from the pretreatment samples that were differentially expressed between patients with and without recurrence Genes involved in integrin signaling and apoptosis pathways were identified in this gene set Immortalization-upregulated protein IMUP IGF-2 and ARHD had particularly marked differences in expression between patients with and without recurrence Genetic profiling identified genes regulated by chemoradiation including DNA damage and cell-to-cell signaling pathways Genes associated with recurrence were identified that will require validation in an independent patient data set to determine whether the 58-gene set associated with clinical outcome could be useful as a prognostic assay,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 963, 191, 145, 55, 400, 50, 975, 4, 8, 171, 537, 30, 2952, 911, 1, 975, 277, 145, 55, 400, 4, 3, 30, 22, 149, 22, 3, 30, 995, 4, 352, 21, 1295, 6, 255, 8, 145, 55, 800, 17, 10, 41, 5, 38, 228, 1727, 2332, 11, 173, 23, 12, 623, 683, 348, 2, 576, 555, 50, 975, 29, 133, 7, 5, 82, 9537, 6, 3036, 691, 31, 134, 1, 3, 3629, 73, 59, 2292, 1758, 2, 2480, 1544, 8, 181, 1, 7801, 214, 11, 108, 17, 11, 97, 2368, 50, 975, 214, 646, 4, 261, 972, 11, 108, 141, 12420, 13166, 30934, 2, 9522, 4, 352, 97, 1065, 31, 6, 31, 314, 460, 159, 1601, 733, 129, 161, 14, 1273, 14, 1688, 2, 756, 845, 129, 161, 314, 28, 8, 52, 166, 126, 1, 605, 53, 33, 1, 133, 7, 42, 592, 361, 293, 15, 626, 496, 7762, 3147, 65, 108, 8, 717, 145, 916, 29, 3, 1194, 347, 17, 11, 2478, 570, 59, 7, 5, 2, 187, 146, 214, 646, 4, 2876, 314, 2, 351, 460, 11, 108, 4, 26, 145, 916, 20169, 2684, 178, 56997, 1273, 18, 2, 56998, 42, 823, 2003, 362, 4, 55, 59, 7, 5, 2, 187, 146, 336, 1080, 108, 214, 1065, 20, 975, 141, 261, 1350, 2, 31, 6, 31, 314, 460, 214, 41, 5, 146, 11, 108, 17, 303, 1353, 929, 4, 35, 306, 69, 74, 916, 6, 223, 317, 3, 717, 145, 916, 41, 5, 38, 228, 359, 40, 999, 22, 8, 177, 719]",1764.0,18406887,255
p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers.,Cancer research,Cancer Res.,2008-04-01,"Whereas the tumor suppressor p53 gene is frequently mutated in most human cancers, this is not the case in human papillomavirus (HPV)-associated cancers, presumably because the viral E6 oncoprotein inactivates the p53 protein. The ability of E6 to transform cells in tissue culture and induce cancers in mice correlates in part with its ability to inactivate p53. In this study, we compared the expression of the HPV16 E6 oncogene to the conditional genetic disruption of p53 in the context of a mouse model for cervical cancer in which estrogen is a critical cofactor. Nearly all of the K14Crep53(f/f) mice treated with estrogen developed cervical cancer, a stark contrast to its complete absence in like-treated K14E6(WT)p53(f/f) mice, indicating that HPV16 E6 must only partially inactivate p53. p53-independent activities of E6 also contributed to carcinogenesis, but in the female reproductive tract, these activities were manifested only in the presence of the HPV16 E7 oncogene. Interestingly, treatment of K14Crep53(f/f) mice with estrogen also resulted in mammary tumors after only a short latency, many of which were positive for estrogen receptor alpha. The majority of these mammary tumors were of mixed cell types, suggestive of their originating from a multipotent progenitor. Furthermore, a subset of mammary tumors arising in the estrogen-treated, p53-deficient mammary glands exhibited evidence of an epithelial to mesenchymal transition. These data show the importance of the synergy between estrogen and p53 insufficiency in determining basic properties of carcinogenesis in hormone-responsive tissues, such as the breast and the reproductive tract.",Journal Article,4312.0,43.0,Whereas the tumor suppressor p53 gene is frequently mutated in most human cancers this is not the case in human papillomavirus HPV -associated cancers presumably because the viral E6 oncoprotein inactivates the p53 protein The ability of E6 to transform cells in tissue culture and induce cancers in mice correlates in part with its ability to inactivate p53 In this study we compared the expression of the HPV16 E6 oncogene to the conditional genetic disruption of p53 in the context of a mouse model for cancer in which estrogen is a critical cofactor Nearly all of the K14Crep53 f/f mice treated with estrogen developed cancer a stark contrast to its complete absence in like-treated K14E6 WT p53 f/f mice indicating that HPV16 E6 must only partially inactivate p53 p53-independent activities of E6 also contributed to carcinogenesis but in the female reproductive tract these activities were manifested only in the presence of the HPV16 E7 oncogene Interestingly treatment of K14Crep53 f/f mice with estrogen also resulted in mammary tumors after only a short latency many of which were positive for estrogen receptor alpha The majority of these mammary tumors were of mixed cell types suggestive of their originating from a multipotent progenitor Furthermore a subset of mammary tumors arising in the estrogen-treated p53-deficient mammary glands exhibited evidence of an epithelial to mesenchymal transition These data show the importance of the synergy between estrogen and p53 insufficiency in determining basic properties of carcinogenesis in hormone-responsive tissues such as the and the reproductive tract,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[547, 3, 30, 1245, 624, 145, 16, 746, 1185, 4, 96, 171, 163, 26, 16, 44, 3, 473, 4, 171, 3242, 933, 41, 163, 8682, 408, 3, 1667, 4837, 6159, 14521, 3, 624, 178, 3, 801, 1, 4837, 6, 7136, 37, 4, 246, 2099, 2, 1290, 163, 4, 399, 1871, 4, 760, 5, 211, 801, 6, 13772, 624, 4, 26, 45, 21, 72, 3, 55, 1, 3, 4048, 4837, 1836, 6, 3, 3212, 336, 3220, 1, 624, 4, 3, 1533, 1, 8, 830, 202, 9, 12, 4, 92, 808, 16, 8, 740, 17137, 1857, 62, 1, 3, 45088, 1068, 1068, 399, 73, 5, 808, 276, 12, 8, 16702, 748, 6, 211, 236, 1127, 4, 733, 73, 19516, 1820, 624, 1068, 1068, 399, 1716, 17, 4048, 4837, 1642, 158, 2995, 13772, 624, 624, 306, 2042, 1, 4837, 120, 3447, 6, 1719, 84, 4, 3, 1061, 3705, 1696, 46, 2042, 11, 6023, 158, 4, 3, 463, 1, 3, 4048, 4540, 1836, 2873, 24, 1, 45088, 1068, 1068, 399, 5, 808, 120, 627, 4, 1903, 57, 50, 158, 8, 978, 5301, 445, 1, 92, 11, 109, 9, 808, 153, 950, 3, 686, 1, 46, 1903, 57, 11, 1, 1739, 31, 630, 3832, 1, 136, 6794, 29, 8, 16392, 2520, 798, 8, 697, 1, 1903, 57, 2635, 4, 3, 808, 73, 624, 1971, 1903, 3966, 1416, 241, 1, 35, 701, 6, 1569, 1970, 46, 74, 514, 3, 1187, 1, 3, 3439, 59, 808, 2, 624, 4360, 4, 2196, 2795, 1571, 1, 1719, 4, 785, 2443, 742, 225, 22, 3, 2, 3, 3705, 1696]",1617.0,18413729,592
Cervical cancer in patients infected with the human immunodeficiency virus.,Cancer,Cancer,2008-06-01,"The objective of this study was to compare the human immunodeficiency virus (HIV) viral load (VL) and CD4 counts in patients infected with HIV with and without cervical cancer. The authors hypothesized that HIV-positive women with cervical cancer would have a greater risk of immune suppression. A case-control study was conducted that included all HIV-positive patients who were seen at the authors' institution from January 1, 1995 to April 20, 2006 with invasive cervical cancer (cases) and without invasive cervical cancer (controls). Patients were included only if they had a CD4 count recorded<6 months before or<3 months after their diagnosis of invasive cervical cancer (cases) or at their last gynecologic examination (controls). Controls were matched to cases on a 4:1 ratio according to current smoking history. Patients were considered immunocompetent if they had both a CD4 count>200 cells/microL and a VL<10,000 copies/mL. In total, 15 cases and 60 controls were identified. The median CD4 count for cases was 208 cells/microL (range, 18-1102 cells/microL) compared with 445 cells/microL (range, 20-1201 cells/microL) for controls (P=.03). The median VL was 16,918 copies/mL (range, 50-214,915 copies/mL) for cases compared with 1430 copies/mL (range, 50-571,000 copies/mL) for controls (P=.15). Only 1 of 14 cases (7%) was immunocompetent compared with 35 of 55 controls (64%; odds ratio, 0.04; 95% confidence interval, 0-0.37; P<.001). This significance was maintained after adjusting for other factors (P=.002). Women with HIV who were diagnosed with invasive cervical cancer appeared to have a much greater degree of immunosuppression than women with HIV without invasive cervical cancer.",Comparative Study,4251.0,16.0,"The objective of this study was to compare the human immunodeficiency virus HIV viral load VL and CD4 counts in patients infected with HIV with and without cancer The authors hypothesized that HIV-positive women with cancer would have a greater risk of immune suppression A case-control study was conducted that included all HIV-positive patients who were seen at the authors institution from January 1 1995 to April 20 2006 with invasive cancer cases and without invasive cancer controls Patients were included only if they had a CD4 count recorded 6 months before or 3 months after their diagnosis of invasive cancer cases or at their last gynecologic examination controls Controls were matched to cases on a 4:1 ratio according to current smoking history Patients were considered immunocompetent if they had both a CD4 count 200 cells/microL and a VL 10,000 copies/mL In total 15 cases and 60 controls were identified The median CD4 count for cases was 208 cells/microL range 18-1102 cells/microL compared with 445 cells/microL range 20-1201 cells/microL for controls P=.03 The median VL was 16,918 copies/mL range 50-214,915 copies/mL for cases compared with 1430 copies/mL range 50-571,000 copies/mL for controls P=.15 Only 1 of 14 cases 7 was immunocompetent compared with 35 of 55 controls 64 odds ratio 0.04 95 confidence interval 0-0.37 P .001 This significance was maintained after adjusting for other factors P=.002 Women with HIV who were diagnosed with invasive cancer appeared to have a much greater degree of immunosuppression than women with HIV without invasive cancer",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 461, 1, 26, 45, 10, 6, 932, 3, 171, 5323, 1450, 1942, 1667, 3800, 13660, 2, 1440, 1911, 4, 7, 3369, 5, 1942, 5, 2, 187, 12, 3, 738, 1237, 17, 1942, 109, 117, 5, 12, 688, 47, 8, 378, 43, 1, 250, 1332, 8, 473, 182, 45, 10, 426, 17, 159, 62, 1942, 109, 7, 54, 11, 527, 28, 3, 738, 731, 29, 1024, 14, 2323, 6, 2292, 179, 1324, 5, 416, 12, 140, 2, 187, 416, 12, 535, 7, 11, 159, 158, 492, 491, 42, 8, 1440, 1276, 1872, 49, 53, 348, 15, 27, 53, 50, 136, 147, 1, 416, 12, 140, 15, 28, 136, 1060, 1512, 1385, 535, 535, 11, 655, 6, 140, 23, 8, 39, 14, 197, 768, 6, 291, 979, 532, 7, 11, 515, 6749, 492, 491, 42, 110, 8, 1440, 1276, 1250, 37, 5128, 2, 8, 13660, 79, 984, 5127, 542, 4, 181, 167, 140, 2, 335, 535, 11, 108, 3, 52, 1440, 1276, 9, 140, 10, 5920, 37, 5128, 184, 203, 22475, 37, 5128, 72, 5, 9398, 37, 5128, 184, 179, 19100, 37, 5128, 9, 535, 19, 680, 3, 52, 13660, 10, 245, 17191, 5127, 542, 184, 212, 6900, 13644, 5127, 542, 9, 140, 72, 5, 38709, 5127, 542, 184, 212, 7846, 984, 5127, 542, 9, 535, 19, 167, 158, 14, 1, 213, 140, 67, 10, 6749, 72, 5, 465, 1, 614, 535, 660, 610, 197, 13, 755, 48, 307, 268, 13, 13, 567, 19, 144, 26, 724, 10, 1955, 50, 1358, 9, 127, 130, 19, 1111, 117, 5, 1942, 54, 11, 265, 5, 416, 12, 2121, 6, 47, 8, 1802, 378, 1444, 1, 3646, 76, 117, 5, 1942, 187, 416, 12]",1585.0,18438877,53
"Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.",Gynecologic oncology,Gynecol. Oncol.,2008-05-05,"To estimate the anti-tumor activity of pemetrexed in patients with advanced or recurrent carcinoma of the cervix that failed on higher priority treatment protocols and to determine the nature and degree of toxicity. A multicenter Phase II trial was conducted by the Gynecologic Oncology Group (GOG). Patients must have had advanced or recurrent measurable carcinoma of the cervix, and failed one prior chemotherapy regimen. Pemetrexed at a dose of 900 mg/m(2) was to be administered as an IV infusion over 10 min every 21 days. From July 6, 2004 to April 3, 2006, twenty-nine patients were entered by ten member institutions of the GOG. Two patients did not receive treatment and thus were inevaluable. A total of 128 cycles were administered with 37% of patients receiving six or more cycles. The treatment was well tolerated overall. More serious toxicities (grade 3 and 4) included anemia in 41%, leukopenia in 30%, neutropenia in 26%, and infection in 26%. No treatment related deaths were reported. Four patients (15%) had partial responses with a median response duration of 4.4 months. The response rate for non-radiated or radiated disease sites was 25% and 7% respectively. Sixteen patients (59%) had stable disease and seven (26%) patients had increasing disease. Median progression free survival (PFS) was 3.1 months and overall survival (OS) was 7.4 months. Pemetrexed at this dose and schedule showed moderate activity against advanced or recurrent cervical cancer that has failed prior chemotherapy. Data from other tumor sites has suggested synergy between pemetrexed and cisplatin and should be considered for further study.","Clinical Trial, Phase II",4278.0,32.0,To estimate the anti-tumor activity of pemetrexed in patients with advanced or recurrent carcinoma of the cervix that failed on higher priority treatment protocols and to determine the nature and degree of toxicity A multicenter Phase II trial was conducted by the Gynecologic Oncology Group GOG Patients must have had advanced or recurrent measurable carcinoma of the cervix and failed one prior chemotherapy regimen Pemetrexed at a dose of 900 mg/m 2 was to be administered as an IV infusion over 10 min every 21 days From July 6 2004 to April 3 2006 twenty-nine patients were entered by ten member institutions of the GOG Two patients did not receive treatment and thus were inevaluable A total of 128 cycles were administered with 37 of patients receiving six or more cycles The treatment was well tolerated overall More serious toxicities grade 3 and 4 included anemia in 41 leukopenia in 30 neutropenia in 26 and infection in 26 No treatment related deaths were reported Four patients 15 had partial responses with a median response duration of 4.4 months The response rate for non-radiated or radiated disease sites was 25 and 7 respectively Sixteen patients 59 had stable disease and seven 26 patients had increasing disease Median progression free survival PFS was 3.1 months and overall survival OS was 7.4 months Pemetrexed at this dose and schedule showed moderate activity against advanced or recurrent cancer that has failed prior chemotherapy Data from other tumor sites has suggested synergy between pemetrexed and cisplatin and should be considered for further study,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1191, 3, 312, 30, 128, 1, 2046, 4, 7, 5, 131, 15, 387, 134, 1, 3, 3629, 17, 1551, 23, 142, 4690, 24, 2189, 2, 6, 223, 3, 2202, 2, 1444, 1, 155, 8, 1570, 124, 215, 160, 10, 426, 20, 3, 1512, 413, 87, 4760, 7, 1642, 47, 42, 131, 15, 387, 1884, 134, 1, 3, 3629, 2, 1551, 104, 324, 56, 477, 2046, 28, 8, 61, 1, 5310, 81, 188, 18, 10, 6, 40, 468, 22, 35, 478, 904, 252, 79, 1538, 454, 239, 162, 29, 2066, 49, 1131, 6, 2292, 27, 1324, 737, 762, 7, 11, 2836, 20, 1618, 2693, 1764, 1, 3, 4760, 100, 7, 205, 44, 560, 24, 2, 631, 11, 19617, 8, 181, 1, 3990, 410, 11, 468, 5, 567, 1, 7, 357, 437, 15, 80, 410, 3, 24, 10, 149, 421, 63, 80, 1762, 385, 88, 27, 2, 39, 159, 1545, 4, 605, 3904, 4, 201, 778, 4, 432, 2, 930, 4, 432, 77, 24, 139, 1043, 11, 210, 294, 7, 167, 42, 450, 253, 5, 8, 52, 51, 654, 1, 39, 39, 53, 3, 51, 116, 9, 220, 10595, 15, 10595, 34, 633, 10, 243, 2, 67, 106, 3228, 7, 728, 42, 585, 34, 2, 648, 432, 7, 42, 602, 34, 52, 91, 115, 25, 300, 10, 27, 14, 53, 2, 63, 25, 118, 10, 67, 39, 53, 2046, 28, 26, 61, 2, 1055, 224, 1163, 128, 480, 131, 15, 387, 12, 17, 71, 1551, 324, 56, 74, 29, 127, 30, 633, 71, 1148, 3439, 59, 2046, 2, 540, 2, 257, 40, 515, 9, 195, 45]",1583.0,18455781,108
Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2008-05-28,"To evaluate early swallowing after intensity-modulated radiotherapy for head and neck squamous cell carcinoma and determine factors correlating with aspiration and/or stricture. Consecutive patients treated with intensity-modulated radiotherapy with or without chemotherapy between September 2004 and August 2006 at the Dana Farber Cancer Institute/Brigham and Women's Hospital were evaluated with institutional review board approval. Patients underwent swallowing evaluation after completion of therapy; including video swallow studies. The clinical- and treatment-related variables were examined for correlation with aspiration or strictures, as well as doses to the larynx, pharyngeal constrictor muscles, and cervical esophagus. The correlation was assessed with logistic regression analysis. A total of 96 patients were evaluated. Their median age was 55 years, and 79 (82%) were men. The primary site of cancer was the oropharynx in 43, hypopharynx/larynx in 17, oral cavity in 13, nasopharynx in 11, maxillary sinus in 2, and unknown primary in 10. Of the 96 patients, 85% underwent definitive RT and 15% postoperative RT. Also, 28 patients underwent induction chemotherapy followed by concurrent chemotherapy, 59 received concurrent chemotherapy, and 9 patients underwent RT alone. The median follow-up was 10 months. Of the 96 patients, 31 (32%) had clinically significant aspiration and 36 (37%) developed a stricture. The radiation dose-volume metrics, including the volume of the larynx receiving >or=50 Gy (p = 0.04 and p = 0.03, respectively) and volume of the inferior constrictor receiving >or=50 Gy (p = 0.05 and p = 0.02, respectively) were significantly associated with both aspiration and stricture. The mean larynx dose correlated with aspiration (p = 0.003). Smoking history was the only clinical factor to correlate with stricture (p = 0.05) but not aspiration. Aspiration and stricture are common side effects after intensity-modulated radiotherapy for head-and-neck squamous cell carcinoma. The dose given to the larynx and inferior constrictors correlated with these side effects.",Clinical Trial,4255.0,161.0,To evaluate early swallowing after intensity-modulated radiotherapy for head and squamous cell carcinoma and determine factors correlating with aspiration and/or stricture Consecutive patients treated with intensity-modulated radiotherapy with or without chemotherapy between September 2004 and August 2006 at the Dana Farber Cancer Institute/Brigham and Women 's Hospital were evaluated with institutional review board approval Patients underwent swallowing evaluation after completion of therapy including video swallow studies The clinical- and treatment-related variables were examined for correlation with aspiration or strictures as well as doses to the larynx constrictor muscles and The correlation was assessed with logistic regression analysis A total of 96 patients were evaluated Their median age was 55 years and 79 82 were men The primary site of cancer was the oropharynx in 43 hypopharynx/larynx in 17 oral cavity in 13 nasopharynx in 11 maxillary sinus in 2 and unknown primary in 10 Of the 96 patients 85 underwent definitive RT and 15 postoperative RT Also 28 patients underwent induction chemotherapy followed by concurrent chemotherapy 59 received concurrent chemotherapy and 9 patients underwent RT alone The median follow-up was 10 months Of the 96 patients 31 32 had clinically significant aspiration and 36 37 developed a stricture The radiation dose-volume metrics including the volume of the larynx receiving or=50 Gy p 0.04 and p 0.03 respectively and volume of the inferior constrictor receiving or=50 Gy p 0.05 and p 0.02 respectively were significantly associated with both aspiration and stricture The mean larynx dose correlated with aspiration p 0.003 Smoking history was the only clinical factor to correlate with stricture p 0.05 but not aspiration Aspiration and stricture are common side effects after intensity-modulated radiotherapy for head-and-neck squamous cell carcinoma The dose given to the larynx and inferior constrictors correlated with these side effects,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[6, 376, 191, 6129, 50, 837, 1757, 310, 9, 718, 2, 691, 31, 134, 2, 223, 130, 5637, 5, 3256, 2, 15, 6673, 935, 7, 73, 5, 837, 1757, 310, 5, 15, 187, 56, 59, 2636, 1131, 2, 2480, 1324, 28, 3, 4932, 4979, 12, 1377, 10543, 2, 117, 292, 702, 11, 194, 5, 1115, 206, 2620, 1814, 7, 208, 6129, 451, 50, 1438, 1, 36, 141, 4139, 11610, 94, 3, 38, 2, 24, 139, 682, 11, 409, 9, 816, 5, 3256, 15, 7860, 22, 149, 22, 415, 6, 3, 4308, 16456, 11784, 2, 3, 816, 10, 275, 5, 812, 320, 65, 8, 181, 1, 921, 7, 11, 194, 136, 52, 89, 10, 614, 60, 2, 842, 878, 11, 325, 3, 86, 606, 1, 12, 10, 3, 5333, 4, 601, 9395, 4308, 4, 269, 518, 2405, 4, 233, 13789, 4, 175, 11399, 5810, 4, 18, 2, 860, 86, 4, 79, 1, 3, 921, 7, 772, 208, 1057, 240, 2, 167, 573, 240, 120, 339, 7, 208, 504, 56, 370, 20, 750, 56, 728, 103, 750, 56, 2, 83, 7, 208, 240, 279, 3, 52, 166, 126, 10, 79, 53, 1, 3, 921, 7, 456, 531, 42, 505, 93, 3256, 2, 511, 567, 276, 8, 6673, 3, 121, 61, 433, 3589, 141, 3, 433, 1, 3, 4308, 357, 15, 212, 381, 19, 13, 755, 2, 19, 13, 680, 106, 2, 433, 1, 3, 1663, 16456, 357, 15, 212, 381, 19, 13, 474, 2, 19, 13, 588, 106, 11, 97, 41, 5, 110, 3256, 2, 6673, 3, 313, 4308, 61, 438, 5, 3256, 19, 13, 1421, 979, 532, 10, 3, 158, 38, 161, 6, 1513, 5, 6673, 19, 13, 474, 84, 44, 3256, 3256, 2, 6673, 32, 186, 1152, 176, 50, 837, 1757, 310, 9, 718, 2, 4606, 691, 31, 134, 3, 61, 447, 6, 3, 4308, 2, 1663, 31280, 438, 5, 46, 1152, 176]",2004.0,18468812,318
Initial lessons learned in HPV vaccination.,Gynecologic oncology,Gynecol. Oncol.,2008-05-01,"In the recent period following the approval of the first vaccine targeted against human papillomavirus, it is imperative that we re-evaluate the past, present, and future of cervical cancer prevention. It is clear that the subject of vaccinating young women against a sexually transmitted infection has incited a candid debate among all groups involved. Therefore, we must make the most appropriate and accurate information available to the public and medical communities. The development of vaccines targeted against oncogenic human papillomavirus (HPV) types has made it possible to eliminate approximately 70% of all invasive cervical cancers in women worldwide. However, knowledge about HPV infection and cervical cancer, as well as the need to vaccinate against oncogenic HPV infection, is still lacking among women and physicians. This deficiency could be a key reason why some parents continue to have reservations about vaccinating their daughters. In order for HPV vaccination programs to be highly successful, multiple barriers must be overcome. Review of lessons learned to date has demonstrated that continued tailored and targeted educational and awareness initiatives are required for healthcare professionals, media, patients, and parents. This article also examines the impact of the HPV vaccination awareness campaign on media and public policy dynamics.",Journal Article,4282.0,46.0,In the recent period following the approval of the first vaccine targeted against human papillomavirus it is imperative that we re-evaluate the past present and future of cancer prevention It is clear that the subject of vaccinating young women against a sexually transmitted infection has incited a candid debate among all groups involved Therefore we must make the most appropriate and accurate information available to the public and medical communities The development of vaccines targeted against oncogenic human papillomavirus HPV types has made it possible to eliminate approximately 70 of all invasive cancers in women worldwide However knowledge about HPV infection and cancer as well as the need to vaccinate against oncogenic HPV infection is still lacking among women and physicians This deficiency could be a key reason why some parents continue to have reservations about vaccinating their daughters In order for HPV vaccination programs to be highly successful multiple barriers must be overcome Review of lessons learned to date has demonstrated that continued tailored and targeted educational and awareness initiatives are required for healthcare professionals media patients and parents This article also examines the impact of the HPV vaccination awareness campaign on media and public policy dynamics,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4, 3, 435, 727, 366, 3, 1814, 1, 3, 157, 1274, 238, 480, 171, 3242, 192, 16, 6305, 17, 21, 1491, 376, 3, 1219, 364, 2, 508, 1, 12, 1070, 192, 16, 885, 17, 3, 2974, 1, 20348, 1169, 117, 480, 8, 13588, 12959, 930, 71, 57060, 8, 38722, 5220, 107, 62, 271, 646, 673, 21, 1642, 2378, 3, 96, 870, 2, 1481, 487, 390, 6, 3, 3067, 2, 484, 7651, 3, 193, 1, 1842, 238, 480, 1302, 171, 3242, 933, 630, 71, 1229, 192, 899, 6, 4964, 705, 431, 1, 62, 416, 163, 4, 117, 2358, 137, 922, 545, 933, 930, 2, 12, 22, 149, 22, 3, 594, 6, 25022, 480, 1302, 933, 930, 16, 1234, 1941, 107, 117, 2, 1261, 26, 2299, 359, 40, 8, 825, 3852, 5283, 476, 2418, 1906, 6, 47, 44146, 545, 20348, 136, 13099, 4, 1732, 9, 933, 1915, 2251, 6, 40, 561, 1401, 232, 2160, 1642, 40, 1768, 206, 1, 8268, 6426, 6, 1244, 71, 264, 17, 1351, 3632, 2, 238, 3624, 2, 3310, 6328, 32, 616, 9, 2819, 3409, 4769, 7, 2, 2418, 26, 946, 120, 4468, 3, 345, 1, 3, 933, 1915, 3310, 19155, 23, 4769, 2, 3067, 4196, 5193]",1321.0,18482557,37
Age considerations when vaccinating against HPV.,Gynecologic oncology,Gynecol. Oncol.,2008-05-01,"Human papillomavirus (HPV) vaccines have been shown to be both highly effective and safe, and there is now considerable enthusiasm among healthcare providers to use the vaccines to reduce the burden of HPV-associated disease in women. When considering who should be vaccinated, it is important that providers understand the complex relationships between age and HPV infections. HPV infections and cervical cancer have a widespread impact on society. Cervical cancer is the cause of a significant amount of morbidity and mortality throughout the world, making it crucial to implement prophylactic HPV vaccines to prevent cervical cancer. Nationally, the target group for vaccination is pre-adolescent females who have not been sexually active or who have recently become sexually active. In the United States, the Advisory Committee on Immunization Practices recommends HPV vaccination for females aged 11 to 12 years. ""Catch-up"" vaccination of females aged 13 to 26 years who have not been previously vaccinated or who have missed a vaccination is also recommended, as females within this age group have the highest prevalence of HPV infection. Vaccination can still benefit females over the age of 26 years who have not been previously exposed to HPV 6, 11, 16, or 18 and those who may have new sexual partners in the future. This review discusses the various considerations that should be addressed when making recommendations of who should be vaccinated against HPV.",Journal Article,4282.0,36.0,Human papillomavirus HPV vaccines have been shown to be both highly effective and safe and there is now considerable enthusiasm among healthcare providers to use the vaccines to reduce the burden of HPV-associated disease in women When considering who should be vaccinated it is important that providers understand the complex relationships between age and HPV infections HPV infections and cancer have a widespread impact on society cancer is the cause of a significant amount of morbidity and mortality throughout the world making it crucial to implement prophylactic HPV vaccines to prevent cancer Nationally the target group for vaccination is pre-adolescent females who have not been sexually active or who have recently become sexually active In the United States the Advisory Committee on Immunization Practices recommends HPV vaccination for females aged 11 to 12 years `` Catch-up '' vaccination of females aged 13 to 26 years who have not been previously vaccinated or who have missed a vaccination is also recommended as females within this age group have the highest prevalence of HPV infection Vaccination can still benefit females over the age of 26 years who have not been previously exposed to HPV 6 11 16 or 18 and those who may have new sexual partners in the future This review discusses the various considerations that should be addressed when making recommendations of who should be vaccinated against HPV,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 3242, 933, 1842, 47, 85, 443, 6, 40, 110, 561, 323, 2, 1165, 2, 125, 16, 1134, 2658, 8582, 107, 2819, 1994, 6, 119, 3, 1842, 6, 969, 3, 892, 1, 933, 41, 34, 4, 117, 198, 3075, 54, 257, 40, 5130, 192, 16, 305, 17, 1994, 1640, 3, 840, 2467, 59, 89, 2, 933, 1875, 933, 1875, 2, 12, 47, 8, 3029, 345, 23, 1174, 12, 16, 3, 708, 1, 8, 93, 3108, 1, 787, 2, 282, 2432, 3, 1956, 1079, 192, 2653, 6, 6207, 1862, 933, 1842, 6, 1682, 12, 7685, 3, 283, 87, 9, 1915, 16, 671, 3678, 2451, 54, 47, 44, 85, 13588, 544, 15, 54, 47, 761, 1417, 13588, 544, 4, 3, 1088, 907, 3, 12905, 2002, 23, 4835, 2634, 6716, 933, 1915, 9, 2451, 1032, 175, 6, 133, 60, 21074, 126, 522, 1915, 1, 2451, 1032, 233, 6, 432, 60, 54, 47, 44, 85, 373, 5130, 15, 54, 47, 5149, 8, 1915, 16, 120, 793, 22, 2451, 262, 26, 89, 87, 47, 3, 1076, 1078, 1, 933, 930, 1915, 122, 1234, 247, 2451, 252, 3, 89, 1, 432, 60, 54, 47, 44, 85, 373, 2234, 6, 933, 49, 175, 245, 15, 203, 2, 135, 54, 68, 47, 217, 2232, 4005, 4, 3, 508, 26, 206, 2759, 3, 747, 3891, 17, 257, 40, 2814, 198, 1079, 883, 1, 54, 257, 40, 5130, 480, 933]",1426.0,18482558,2
Cervical dysplasia among women over 35 years of age.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2008-05-19,"The objective of the study was to review the cytologic and histopathologic features among women 35 years of age or older with cervical dysplasia. Patients presenting between 2001 and 2005 were included. Patients were labeled as pre- (PRE) or postmenopausal (POST) based on age younger than or 50 years old or older. Statistics were performed using SAS 8.0. Three hundred fifty-nine patients were identified: 270 PRE and 89 POST. PRE and POST patients had similar referral cytology with atypical cells of undetermined significance (ASC)/low-grade squamous intraepithelial lesion (LSIL) in 60% and 65% and high-grade squamous intraepithelial lesion (HSIL) in 35% and 27%, respectively. Among patients with ASC/LSIL, POST had significantly more cervical intraepithelial neoplasia (CIN) 3 (41% vs 29%; P = .027) as well as more malignancies (17 vs 0%; P = .002). Among patients referred for loop electrical excisional procedure secondary to HSIL cytology not explained by colposcopy, CIN 2 or greater was identified more often in POST (71 vs 32%; P = .03). Our data demonstrate a high proportion of severe cervical dysplasia in age groups traditionally thought to have less risk than younger patients.",Journal Article,4264.0,12.0,The objective of the study was to review the cytologic and histopathologic features among women 35 years of age or older with dysplasia Patients presenting between 2001 and 2005 were included Patients were labeled as pre- PRE or postmenopausal POST based on age younger than or 50 years old or older Statistics were performed using SAS 8.0 Three hundred fifty-nine patients were identified 270 PRE and 89 POST PRE and POST patients had similar referral cytology with atypical cells of undetermined significance ASC /low-grade squamous intraepithelial lesion LSIL in 60 and 65 and high-grade squamous intraepithelial lesion HSIL in 35 and 27 respectively Among patients with ASC/LSIL POST had significantly more intraepithelial neoplasia CIN 3 41 vs 29 P .027 as well as more malignancies 17 vs 0 P .002 Among patients referred for loop electrical excisional procedure secondary to HSIL cytology not explained by colposcopy CIN 2 or greater was identified more often in POST 71 vs 32 P .03 Our data demonstrate a high proportion of severe dysplasia in age groups traditionally thought to have less risk than younger patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 461, 1, 3, 45, 10, 6, 206, 3, 4195, 2, 2630, 404, 107, 117, 465, 60, 1, 89, 15, 434, 5, 2253, 7, 1656, 59, 1758, 2, 1242, 11, 159, 7, 11, 2841, 22, 671, 671, 15, 1679, 539, 90, 23, 89, 773, 76, 15, 212, 60, 1095, 15, 434, 3065, 11, 173, 75, 8265, 66, 13, 169, 1128, 1461, 762, 7, 11, 108, 6666, 671, 2, 887, 539, 671, 2, 539, 7, 42, 288, 2096, 2045, 5, 1973, 37, 1, 5206, 724, 5203, 154, 88, 691, 4153, 1180, 17849, 4, 335, 2, 556, 2, 64, 88, 691, 4153, 1180, 16067, 4, 465, 2, 428, 106, 107, 7, 5, 5203, 17849, 539, 42, 97, 80, 4153, 2298, 4652, 27, 605, 105, 462, 19, 4523, 22, 149, 22, 80, 441, 269, 105, 13, 19, 1111, 107, 7, 1995, 9, 4432, 15921, 6488, 1299, 568, 6, 16067, 2045, 44, 3672, 20, 9946, 4652, 18, 15, 378, 10, 108, 80, 629, 4, 539, 792, 105, 531, 19, 680, 114, 74, 608, 8, 64, 920, 1, 905, 2253, 4, 89, 271, 4206, 2739, 6, 47, 299, 43, 76, 773, 7]",1123.0,18486088,690
Laparoscopic and robotic techniques for radical hysterectomy in patients with early-stage cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2008-05-19,"The goal of this review is to summarize the latest literature on the subject of laparoscopic and robotic approaches for radical hysterectomy in patients with early-stage cervical cancer. We analyzed the published literature in search of all articles addressing surgical techniques, intraoperative and perioperative outcomes in patient undergoing radical hysterectomy by the minimally invasive approach. Recurrence and overall survival rates in patients with early-stage cervical cancer are equivalent in patients who undergo laparoscopic radical hysterectomy and those who undergo surgery performed by laparotomy. There is growing evidence highlighting the benefits of robotic surgery in management of gynecologic malignancies. The advantages of the robotic system include three-dimensional vision, tremor reduction, seven degrees of intra-abdominal articulation, and motion scaling. Recent studies comparing radical hysterectomy performed through the open, laparoscopic, or robotics approach showed that there were no significant differences in intra- or postoperative complications among the three groups and no conversion in the robotic or laparoscopic groups. Total laparoscopic radical hysterectomy is a feasible and safe procedure that is associated with fewer intraoperative and postoperative complications than abdominal radical hysterectomy. We await results from additional series of radical hysterectomy performed by robotic surgery.",Journal Article,4264.0,47.0,The goal of this review is to summarize the latest literature on the subject of laparoscopic and robotic approaches for radical hysterectomy in patients with early-stage cancer We analyzed the published literature in search of all articles addressing surgical techniques intraoperative and perioperative outcomes in patient undergoing radical hysterectomy by the minimally invasive approach Recurrence and overall survival rates in patients with early-stage cancer are equivalent in patients who undergo laparoscopic radical hysterectomy and those who undergo surgery performed by laparotomy There is growing evidence highlighting the benefits of robotic surgery in management of gynecologic malignancies The advantages of the robotic system include three-dimensional vision tremor reduction seven degrees of intra-abdominal articulation and motion scaling Recent studies comparing radical hysterectomy performed through the open laparoscopic or robotics approach showed that there were no significant differences in intra- or postoperative complications among the three groups and no conversion in the robotic or laparoscopic groups Total laparoscopic radical hysterectomy is a feasible and safe procedure that is associated with fewer intraoperative and postoperative complications than abdominal radical hysterectomy We await results from additional series of radical hysterectomy performed by robotic surgery,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1326, 1, 26, 206, 16, 6, 2479, 3, 5923, 789, 23, 3, 2974, 1, 1964, 2, 2895, 611, 9, 711, 2622, 4, 7, 5, 191, 82, 12, 21, 311, 3, 983, 789, 4, 1901, 1, 62, 2384, 3432, 221, 1092, 1720, 2, 1547, 123, 4, 69, 479, 711, 2622, 20, 3, 2144, 416, 353, 146, 2, 63, 25, 151, 4, 7, 5, 191, 82, 12, 32, 2017, 4, 7, 54, 1251, 1964, 711, 2622, 2, 135, 54, 1251, 152, 173, 20, 3274, 125, 16, 1921, 241, 4051, 3, 1141, 1, 2895, 152, 4, 284, 1, 1512, 441, 3, 3126, 1, 3, 2895, 398, 643, 169, 2201, 5859, 14934, 628, 648, 4133, 1, 2392, 1467, 57075, 2, 2967, 17106, 435, 94, 1430, 711, 2622, 173, 298, 3, 1020, 1964, 15, 23681, 353, 224, 17, 125, 11, 77, 93, 362, 4, 2392, 15, 573, 521, 107, 3, 169, 271, 2, 77, 3111, 4, 3, 2895, 15, 1964, 271, 181, 1964, 711, 2622, 16, 8, 1313, 2, 1165, 1299, 17, 16, 41, 5, 1497, 1720, 2, 573, 521, 76, 1467, 711, 2622, 21, 12095, 99, 29, 402, 988, 1, 711, 2622, 173, 20, 2895, 152]",1412.0,18486966,9
The spectrum and clinical sequelae of human papillomavirus infection.,Gynecologic oncology,Gynecol. Oncol.,2007-11-01,"Infection with the human papillomavirus (HPV) is the most common sexually transmitted disease afflicting approximately 80% of the population. HPV infection is an essential factor in cervical carcinogenesis and cervical carcinoma is the second most common cause of cancer among women worldwide. In addition to cervical cancer, other malignancies in both men and women such as esophageal, oropharyngeal, and anal cancer have been causally associated with this virus. Other gender-specific HPV-related cancers include penile, vulvar and vaginal cancer. HPV-16 is the most common HPV type associated with a malignant phenotype regardless of organ of origin. HPV-16 together with HPV-18 accounts for approximately 70% of cervical cancers. Other non-oncogenic HPV types including HPV types 6 and 11 are associated with over 90% of benign HPV-related lesions such as genital warts and juvenile respiratory papillomatosis.",Journal Article,4464.0,62.0,Infection with the human papillomavirus HPV is the most common sexually transmitted disease afflicting approximately 80 of the population HPV infection is an essential factor in carcinogenesis and carcinoma is the second most common cause of cancer among women worldwide In addition to cancer other malignancies in both men and women such as and cancer have been causally associated with this virus Other gender-specific HPV-related cancers include and cancer HPV-16 is the most common HPV type associated with a malignant phenotype regardless of organ of origin HPV-16 together with HPV-18 accounts for approximately 70 of cancers Other non-oncogenic HPV types including HPV types 6 and 11 are associated with over 90 of benign HPV-related lesions such as genital warts and juvenile respiratory papillomatosis,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[930, 5, 3, 171, 3242, 933, 16, 3, 96, 186, 13588, 12959, 34, 45139, 705, 493, 1, 3, 266, 933, 930, 16, 35, 1452, 161, 4, 1719, 2, 134, 16, 3, 419, 96, 186, 708, 1, 12, 107, 117, 2358, 4, 352, 6, 12, 127, 441, 4, 110, 325, 2, 117, 225, 22, 2, 12, 47, 85, 12511, 41, 5, 26, 1450, 127, 1632, 112, 933, 139, 163, 643, 2, 12, 933, 245, 16, 3, 96, 186, 933, 267, 41, 5, 8, 393, 1005, 1583, 1, 1259, 1, 1938, 933, 245, 1162, 5, 933, 203, 4162, 9, 705, 431, 1, 163, 127, 220, 1302, 933, 630, 141, 933, 630, 49, 2, 175, 32, 41, 5, 252, 424, 1, 1002, 933, 139, 406, 225, 22, 8226, 19515, 2, 7857, 2718, 22118]",810.0,18499914,531
Fertility preservation in patients with early cervical cancer: radical trachelectomy.,Gynecologic oncology,Gynecol. Oncol.,2008-05-23,"The goal of this review is to summarize the latest literature on the subject of radical trachelectomy and fertility outcomes in patients with early-stage cervical cancer. We analyzed the published literature in search of all articles addressing surgical techniques, intraoperative and perioperative outcomes, and obstetrical results in patient undergoing radical trachelectomy for cervical cancer. It is estimated that 43% of all cases of cervical cancer in the United States are diagnosed in women younger than 45 years of age. As of 2007, a total of 520 patients had been reported to have undergone a radical vaginal trachelectomy. The majority of patients (60%) had a diagnosis of squamous cell carcinoma; adenocarcinoma was the second most common histologic subtype (40%). Data on outcomes after radical abdominal trachelectomy are less extensive-only approximately 50 cases have been reported worldwide. Approximately 43% of patients who undergo a radical trachelectomy subsequently attempt to become pregnant. Seventy percent of these women are successful at achieving a pregnancy. Radical trachelectomy is safe and feasible and pregnancy outcomes are very favorable. All patients interested in future fertility who are diagnosed with cervical cancer are encouraged to discuss radical trachelectomy with their physician.",Journal Article,4260.0,57.0,The goal of this review is to summarize the latest literature on the subject of radical trachelectomy and fertility outcomes in patients with early-stage cancer We analyzed the published literature in search of all articles addressing surgical techniques intraoperative and perioperative outcomes and obstetrical results in patient undergoing radical trachelectomy for cancer It is estimated that 43 of all cases of cancer in the United States are diagnosed in women younger than 45 years of age As of 2007 a total of 520 patients had been reported to have undergone a radical trachelectomy The majority of patients 60 had a diagnosis of squamous cell carcinoma adenocarcinoma was the second most common histologic subtype 40 Data on outcomes after radical abdominal trachelectomy are less extensive-only approximately 50 cases have been reported worldwide Approximately 43 of patients who undergo a radical trachelectomy subsequently attempt to become pregnant Seventy percent of these women are successful at achieving a pregnancy Radical trachelectomy is safe and feasible and pregnancy outcomes are very favorable All patients interested in future fertility who are diagnosed with cancer are encouraged to discuss radical trachelectomy with their physician,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1326, 1, 26, 206, 16, 6, 2479, 3, 5923, 789, 23, 3, 2974, 1, 711, 5760, 2, 2954, 123, 4, 7, 5, 191, 82, 12, 21, 311, 3, 983, 789, 4, 1901, 1, 62, 2384, 3432, 221, 1092, 1720, 2, 1547, 123, 2, 21031, 99, 4, 69, 479, 711, 5760, 9, 12, 192, 16, 661, 17, 601, 1, 62, 140, 1, 12, 4, 3, 1088, 907, 32, 265, 4, 117, 773, 76, 512, 60, 1, 89, 22, 1, 1307, 8, 181, 1, 9158, 7, 42, 85, 210, 6, 47, 1989, 8, 711, 5760, 3, 686, 1, 7, 335, 42, 8, 147, 1, 691, 31, 134, 449, 10, 3, 419, 96, 186, 884, 875, 327, 74, 23, 123, 50, 711, 1467, 5760, 32, 299, 1344, 158, 705, 212, 140, 47, 85, 210, 2358, 705, 601, 1, 7, 54, 1251, 8, 711, 5760, 1611, 3448, 6, 1417, 6086, 2073, 714, 1, 46, 117, 32, 1401, 28, 1785, 8, 2290, 711, 5760, 16, 1165, 2, 1313, 2, 2290, 123, 32, 923, 913, 62, 7, 7420, 4, 508, 2954, 54, 32, 265, 5, 12, 32, 5865, 6, 1139, 711, 5760, 5, 136, 1473]",1260.0,18501409,538
Lymphatic mapping and sentinel lymph node detection in women with cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2008-05-27,"Lymphatic mapping and sentinel node detection have been applied to almost every solid tumor and sentinel node status have become part of the American Joint Commission on Cancer (AJCC) staging criteria in both breast cancer and malignant melanoma. As the presence of metastatic disease in lymph nodes is the most important prognostic factor on survival in women with cervical cancer, the ability to reliably detect sentinel nodes might triage women to adjuvant radiotherapy without the need for full lymphadenectomies and their associated morbidity. To date, multiple international investigators have performed single institution investigations with promising results. Overall, 831 women have been undergoing lymphatic mapping and sentinel node detection as part of their cervical cancer therapy as reported in the literature. Combining results from all these studies, a sentinel node was identified in 90% of cases with an overall sensitivity of detecting metastatic disease of 92% with an 8% false negative rate. The overall negative predictive value was over 97%. There remain controversies in moving forward with accepting sentinel node biopsy as the standard in treating women cervical cancer including 1) determining an acceptable false-negative rate, 2) establishing the importance of micrometastatic disease or isolated tumor cells in sentinel nodes, and 3) discovering the minimum number of cases a surgeon needs to become proficient in mapping techniques. Large, multi-institutional studies in both Europe and the United States are nearing completion and their results should help guide the future direction for sentinel node technologies in the treatment of cervical cancer.",Journal Article,4256.0,40.0,Lymphatic mapping and sentinel node detection have been applied to almost every solid tumor and sentinel node status have become part of the American Joint Commission on Cancer AJCC staging criteria in both cancer and malignant As the presence of metastatic disease in lymph nodes is the most important prognostic factor on survival in women with cancer the ability to reliably detect sentinel nodes might triage women to adjuvant radiotherapy without the need for full lymphadenectomies and their associated morbidity To date multiple international investigators have performed single institution investigations with promising results Overall 831 women have been undergoing lymphatic mapping and sentinel node detection as part of their cancer therapy as reported in the literature Combining results from all these studies a sentinel node was identified in 90 of cases with an overall sensitivity of detecting metastatic disease of 92 with an 8 false negative rate The overall negative predictive value was over 97 There remain controversies in moving forward with accepting sentinel node biopsy as the standard in treating women cancer including 1 determining an acceptable false-negative rate 2 establishing the importance of micrometastatic disease or isolated tumor cells in sentinel nodes and 3 discovering the minimum number of cases a surgeon needs to become proficient in mapping techniques Large multi-institutional studies in both Europe and the United States are nearing completion and their results should help guide the future direction for sentinel node technologies in the treatment of cancer,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2936, 2568, 2, 1323, 289, 638, 47, 85, 1498, 6, 2214, 454, 537, 30, 2, 1323, 289, 156, 47, 1417, 760, 1, 3, 597, 2093, 7258, 23, 12, 2271, 632, 371, 4, 110, 12, 2, 393, 22, 3, 463, 1, 113, 34, 4, 263, 502, 16, 3, 96, 305, 177, 161, 23, 25, 4, 117, 5, 12, 3, 801, 6, 4092, 1426, 1323, 502, 822, 9059, 117, 6, 249, 310, 187, 3, 594, 9, 1647, 16322, 2, 136, 41, 787, 6, 1244, 232, 944, 2394, 47, 173, 226, 731, 2492, 5, 721, 99, 63, 13962, 117, 47, 85, 479, 2936, 2568, 2, 1323, 289, 638, 22, 760, 1, 136, 12, 36, 22, 210, 4, 3, 789, 1525, 99, 29, 62, 46, 94, 8, 1323, 289, 10, 108, 4, 424, 1, 140, 5, 35, 63, 485, 1, 2502, 113, 34, 1, 937, 5, 35, 66, 2133, 199, 116, 3, 63, 199, 464, 549, 10, 252, 1015, 125, 918, 6613, 4, 8324, 4674, 5, 19528, 1323, 289, 411, 22, 3, 260, 4, 1367, 117, 12, 141, 14, 2196, 35, 1595, 2133, 199, 116, 18, 4431, 3, 1187, 1, 7993, 34, 15, 1355, 30, 37, 4, 1323, 502, 2, 27, 10750, 3, 2499, 207, 1, 140, 8, 1897, 1891, 6, 1417, 5550, 4, 2568, 1092, 375, 1414, 1115, 94, 4, 110, 3934, 2, 3, 1088, 907, 32, 18901, 1438, 2, 136, 99, 257, 987, 1597, 3, 508, 4651, 9, 1323, 289, 2590, 4, 3, 24, 1, 12]",1608.0,18502488,205
Cervix regression and motion during the course of external beam chemoradiation for cervical cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2008-05-29,"To evaluate the magnitude of cervix regression and motion during external beam chemoradiation for cervical cancer. Sixteen patients with cervical cancer underwent computed tomography scanning before, weekly during, and after conventional chemoradiation. Cervix volumes were calculated to determine the extent of cervix regression. Changes in the center of mass and perimeter of the cervix between scans were used to determine the magnitude of cervix motion. Maximum cervix position changes were calculated for each patient, and mean maximum changes were calculated for the group. Mean cervical volumes before and after 45 Gy of external beam irradiation were 97.0 and 31.9 cc, respectively; mean volume reduction was 62.3%. Mean maximum changes in the center of mass of the cervix were 2.1, 1.6, and 0.82 cm in the superior-inferior, anterior-posterior, and right-left lateral dimensions, respectively. Mean maximum changes in the perimeter of the cervix were 2.3 and 1.3 cm in the superior and inferior, 1.7 and 1.8 cm in the anterior and posterior, and 0.76 and 0.94 cm in the right and left lateral directions, respectively. Cervix regression and internal organ motion contribute to marked interfraction variations in the intrapelvic position of the cervical target in patients receiving chemoradiation for cervical cancer. Failure to take these variations into account during the application of highly conformal external beam radiation techniques poses a theoretical risk of underdosing the target or overdosing adjacent critical structures.",Clinical Trial,4254.0,88.0,To evaluate the magnitude of cervix regression and motion during external beam chemoradiation for cancer Sixteen patients with cancer underwent computed tomography scanning before weekly during and after conventional chemoradiation Cervix volumes were calculated to determine the extent of cervix regression Changes in the center of mass and perimeter of the cervix between scans were used to determine the magnitude of cervix motion Maximum cervix position changes were calculated for each patient and mean maximum changes were calculated for the group Mean volumes before and after 45 Gy of external beam irradiation were 97.0 and 31.9 cc respectively mean volume reduction was 62.3 Mean maximum changes in the center of mass of the cervix were 2.1 1.6 and 0.82 cm in the superior-inferior anterior-posterior and right-left lateral dimensions respectively Mean maximum changes in the perimeter of the cervix were 2.3 and 1.3 cm in the superior and inferior 1.7 and 1.8 cm in the anterior and posterior and 0.76 and 0.94 cm in the right and left lateral directions respectively Cervix regression and internal organ motion contribute to marked interfraction variations in the intrapelvic position of the target in patients receiving chemoradiation for cancer Failure to take these variations into account during the application of highly conformal external beam radiation techniques poses a theoretical risk of underdosing the target or overdosing adjacent critical structures,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 3, 3131, 1, 3629, 320, 2, 2967, 190, 1455, 1345, 975, 9, 12, 3228, 7, 5, 12, 208, 1220, 872, 3702, 348, 709, 190, 2, 50, 809, 975, 3629, 2225, 11, 981, 6, 223, 3, 1039, 1, 3629, 320, 400, 4, 3, 574, 1, 782, 2, 31292, 1, 3, 3629, 59, 1441, 11, 95, 6, 223, 3, 3131, 1, 3629, 2967, 689, 3629, 3559, 400, 11, 981, 9, 296, 69, 2, 313, 689, 400, 11, 981, 9, 3, 87, 313, 2225, 348, 2, 50, 512, 381, 1, 1455, 1345, 1104, 11, 1015, 13, 2, 456, 83, 1951, 106, 313, 433, 628, 10, 744, 27, 313, 689, 400, 4, 3, 574, 1, 782, 1, 3, 3629, 11, 18, 14, 14, 49, 2, 13, 878, 494, 4, 3, 1123, 1663, 2882, 3028, 2, 1913, 1712, 3855, 6190, 106, 313, 689, 400, 4, 3, 31292, 1, 3, 3629, 11, 18, 27, 2, 14, 27, 494, 4, 3, 1123, 2, 1663, 14, 67, 2, 14, 66, 494, 4, 3, 2882, 2, 3028, 2, 13, 846, 2, 13, 960, 494, 4, 3, 1913, 2, 1712, 3855, 3540, 106, 3629, 320, 2, 2329, 1259, 2967, 1248, 6, 2003, 13610, 2293, 4, 3, 37103, 3559, 1, 3, 283, 4, 7, 357, 975, 9, 12, 496, 6, 3585, 46, 2293, 237, 1967, 190, 3, 1581, 1, 561, 2972, 1455, 1345, 121, 1092, 7056, 8, 7060, 43, 1, 24788, 3, 283, 15, 37851, 2086, 740, 2414]",1476.0,18513882,138
Involvement of Rac in fenretinide-induced apoptosis.,Cancer research,Cancer Res.,2008-06-01,"The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) has shown potential as a chemopreventive and therapeutic agent. The ability of 4HPR to enhance production of reactive oxygen species (ROS) leading to apoptosis has been suggested as a possible mechanism underlying these effects. We explored the possibility that ROS induction by 4HPR involves the small GTPase Ras-related C3 botulinum toxin substrate (Rac), a regulatory subunit of the NADPH oxidase complex. Rac was activated in human head and neck squamous cell carcinoma (HNSCC) cells as early as 5 minutes following 4HPR exposure. Moreover, inhibition of Rac activity or silencing of its expression by RNA interference decreased ROS generation in human head and neck, lung, and cervical cancer cells and murine melanoma cells. In HNSCC UMSCC-22B cells, this decrease correlated with reduction in apoptosis induction by 4HPR. Expression of a constitutive active mutant Rac increased basal and 4HPR-induced ROS generation and poly(ADP-ribose) polymerase cleavage. In addition, the metastatic DM14 cells exhibited higher Rac activation following 4HPR treatment compared with the primary Tu167-C2 cells. Furthermore, the metastatic cancer cells tested exhibited higher ROS generation and growth inhibition due to 4HPR exposure compared with their primary cancer cell counterparts. These findings show a preferential susceptibility of metastatic cells to the proapoptotic retinoid 4HPR through Rac activation and support the use of ROS-inducing agents such as 4HPR against metastatic cancer cells.",Journal Article,4251.0,20.0,The synthetic retinoid N- 4-hydroxyphenyl retinamide 4HPR has shown potential as a chemopreventive and therapeutic agent The ability of 4HPR to enhance production of reactive oxygen species ROS leading to apoptosis has been suggested as a possible mechanism underlying these effects We explored the possibility that ROS induction by 4HPR involves the small GTPase Ras-related C3 botulinum toxin substrate Rac a regulatory subunit of the NADPH oxidase complex Rac was activated in human head and squamous cell carcinoma HNSCC cells as early as 5 minutes following 4HPR exposure Moreover inhibition of Rac activity or silencing of its expression by RNA interference decreased ROS generation in human head and and cancer cells and murine cells In HNSCC UMSCC-22B cells this decrease correlated with reduction in apoptosis induction by 4HPR Expression of a constitutive active mutant Rac increased basal and 4HPR-induced ROS generation and poly ADP-ribose polymerase cleavage In addition the metastatic DM14 cells exhibited higher Rac activation following 4HPR treatment compared with the primary Tu167-C2 cells Furthermore the metastatic cancer cells tested exhibited higher ROS generation and growth inhibition due to 4HPR exposure compared with their primary cancer cell counterparts These findings show a preferential susceptibility of metastatic cells to the proapoptotic retinoid 4HPR through Rac activation and support the use of ROS-inducing agents such as 4HPR against metastatic cancer cells,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 3273, 6709, 78, 39, 26107, 28004, 14630, 71, 443, 174, 22, 8, 4401, 2, 189, 420, 3, 801, 1, 14630, 6, 1304, 1529, 1, 2163, 2848, 2915, 2609, 1049, 6, 351, 71, 85, 1148, 22, 8, 899, 670, 1181, 46, 176, 21, 1443, 3, 2526, 17, 2609, 504, 20, 14630, 2921, 3, 302, 9189, 1102, 139, 8732, 31295, 8848, 4235, 11173, 8, 1253, 3350, 1, 3, 16029, 10447, 840, 11173, 10, 735, 4, 171, 718, 2, 691, 31, 134, 1209, 37, 22, 191, 22, 33, 2511, 366, 14630, 645, 1393, 297, 1, 11173, 128, 15, 2077, 1, 211, 55, 20, 893, 3182, 340, 2609, 914, 4, 171, 718, 2, 2, 12, 37, 2, 1471, 37, 4, 1209, 57108, 57109, 37, 26, 775, 438, 5, 628, 4, 351, 504, 20, 14630, 55, 1, 8, 3178, 544, 620, 11173, 101, 2135, 2, 14630, 277, 2609, 914, 2, 2699, 3638, 3507, 1451, 3155, 4, 352, 3, 113, 34296, 37, 1416, 142, 11173, 363, 366, 14630, 24, 72, 5, 3, 86, 20990, 6706, 37, 798, 3, 113, 12, 37, 650, 1416, 142, 2609, 914, 2, 129, 297, 520, 6, 14630, 645, 72, 5, 136, 86, 12, 31, 3953, 46, 272, 514, 8, 6629, 1432, 1, 113, 37, 6, 3, 4118, 6709, 14630, 298, 11173, 363, 2, 538, 3, 119, 1, 2609, 1958, 183, 225, 22, 14630, 480, 113, 12, 37]",1497.0,18519704,729
"Lymphatic mapping and sentinel node biopsy in vulvar, vaginal, and cervical cancers.","Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2008-04-01,"Over the past 15 years, lymphatic mapping and sentinel lymph node biopsy in vulvar, vaginal, and cervical cancers have been explored by gynecologic oncologists around the world. Based on the results of multiple single-institution studies, most in our field are optimistic that these techniques will increase the rates of detection of lymph node metastasis while decreasing the morbidity associated with lymphadenectomy. Large validation studies are currently underway in both the United States and Europe. In this review article, we present the published data on mapping techniques and discuss future considerations for these technologies.",Journal Article,4312.0,9.0,Over the past 15 years lymphatic mapping and sentinel lymph node biopsy in and cancers have been explored by gynecologic oncologists around the world Based on the results of multiple single-institution studies most in our field are optimistic that these techniques will increase the rates of detection of lymph node metastasis while decreasing the morbidity associated with lymphadenectomy Large validation studies are currently underway in both the United States and Europe In this review article we present the published data on mapping techniques and discuss future considerations for these technologies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[252, 3, 1219, 167, 60, 2936, 2568, 2, 1323, 263, 289, 411, 4, 2, 163, 47, 85, 1443, 20, 1512, 1339, 3337, 3, 1956, 90, 23, 3, 99, 1, 232, 226, 731, 94, 96, 4, 114, 1067, 32, 9566, 17, 46, 1092, 303, 344, 3, 151, 1, 638, 1, 263, 289, 278, 369, 2777, 3, 787, 41, 5, 2048, 375, 929, 94, 32, 694, 3948, 4, 110, 3, 1088, 907, 2, 3934, 4, 26, 206, 946, 21, 364, 3, 983, 74, 23, 2568, 1092, 2, 1139, 508, 3891, 9, 46, 2590]",606.0,18533402,495
Alveolar soft part sarcoma of the cervix: case report and literature review.,Archives of gynecology and obstetrics,Arch. Gynecol. Obstet.,2008-06-12,"Alveolar soft part sarcoma (ASPS) is a rare mesenchymal malignancy typically found in the extremities or chest of young adults. We present a case of an alveolar soft part sarcoma arising in the endocervix of a 38-year-old premenopausal woman. This cancer was treated by extrafascial hysterectomy. No evidence of metastatic disease was found after extensive surgical staging. Since treatment, she has since remained disease-free for more than 5 years without additional therapy. This is the second case of ASPS arising in the endocervix of which we are aware. Our observations suggest simple hysterectomy suffices for optimal clinical management of cervical ASPS and that surgical staging of this disease offers little prognostic benefit.",Case Reports,4240.0,9.0,Alveolar soft part ASPS is a rare mesenchymal malignancy typically found in the extremities or chest of young adults We present a case of an alveolar soft part arising in the endocervix of a 38-year-old premenopausal woman This cancer was treated by extrafascial hysterectomy No evidence of metastatic disease was found after extensive surgical staging Since treatment she has since remained disease-free for more than 5 years without additional therapy This is the second case of ASPS arising in the endocervix of which we are aware Our observations suggest simple hysterectomy suffices for optimal clinical management of ASPS and that surgical staging of this disease offers little prognostic benefit,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,"[5641, 1214, 760, 8301, 16, 8, 622, 1569, 710, 1969, 204, 4, 3, 6387, 15, 1662, 1, 1169, 857, 21, 364, 8, 473, 1, 35, 5641, 1214, 760, 2635, 4, 3, 34486, 1, 8, 519, 111, 1095, 2710, 2854, 26, 12, 10, 73, 20, 25094, 2622, 77, 241, 1, 113, 34, 10, 204, 50, 1344, 221, 632, 1192, 24, 3109, 71, 1192, 958, 34, 115, 9, 80, 76, 33, 60, 187, 402, 36, 26, 16, 3, 419, 473, 1, 8301, 2635, 4, 3, 34486, 1, 92, 21, 32, 4749, 114, 2172, 309, 2763, 2622, 38749, 9, 665, 38, 284, 1, 8301, 2, 17, 221, 632, 1, 26, 34, 2339, 1215, 177, 247]",702.0,18548261,667
Drug-sensitive FGFR2 mutations in endometrial carcinoma.,Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2008-06-13,"Oncogenic activation of tyrosine kinases is a common mechanism of carcinogenesis and, given the druggable nature of these enzymes, an attractive target for anticancer therapy. Here, we show that somatic mutations of the fibroblast growth factor receptor 2 (FGFR2) tyrosine kinase gene, FGFR2, are present in 12% of endometrial carcinomas, with additional instances found in lung squamous cell carcinoma and cervical carcinoma. These FGFR2 mutations, many of which are identical to mutations associated with congenital craniofacial developmental disorders, are constitutively activated and oncogenic when ectopically expressed in NIH 3T3 cells. Inhibition of FGFR2 kinase activity in endometrial carcinoma cell lines bearing such FGFR2 mutations inhibits transformation and survival, implicating FGFR2 as a novel therapeutic target in endometrial carcinoma.",Journal Article,4239.0,253.0,Oncogenic activation of tyrosine kinases is a common mechanism of carcinogenesis and given the druggable nature of these enzymes an attractive target for anticancer therapy Here we show that somatic mutations of the fibroblast growth factor receptor 2 FGFR2 tyrosine kinase gene FGFR2 are present in 12 of carcinomas with additional instances found in squamous cell carcinoma and carcinoma These FGFR2 mutations many of which are identical to mutations associated with congenital craniofacial developmental disorders are constitutively activated and oncogenic when ectopically expressed in NIH 3T3 cells Inhibition of FGFR2 kinase activity in carcinoma cell lines bearing such FGFR2 mutations inhibits transformation and survival implicating FGFR2 as a novel therapeutic target in carcinoma,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[1302, 363, 1, 564, 1549, 16, 8, 186, 670, 1, 1719, 2, 447, 3, 9309, 2202, 1, 46, 3039, 35, 3059, 283, 9, 1475, 36, 467, 21, 514, 17, 1119, 138, 1, 3, 3758, 129, 161, 153, 18, 5273, 564, 216, 145, 5273, 32, 364, 4, 133, 1, 826, 5, 402, 5342, 204, 4, 691, 31, 134, 2, 134, 46, 5273, 138, 445, 1, 92, 32, 3038, 6, 138, 41, 5, 6711, 13493, 4566, 1997, 32, 2818, 735, 2, 1302, 198, 11744, 570, 4, 6833, 14796, 37, 297, 1, 5273, 216, 128, 4, 134, 31, 285, 1894, 225, 5273, 138, 1576, 1392, 2, 25, 7912, 5273, 22, 8, 229, 189, 283, 4, 134]",790.0,18552176,45
Cervical neoplasia in pregnancy. Part 1: screening and management of preinvasive disease.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2008-07-01,"Cervical cancer screening is an essential component of prenatal care. The diagnosis and management of cervical intraepithelial neoplasia (CIN) during pregnancy are challenging, and sufficient information does not exist to allow for a definitive evidence-based approach. The American Society for Colposcopy and Cervical Pathology has recently published guidelines regarding the evaluation of abnormal Papanicolaou tests and the treatment of CIN in this setting. Many techniques traditionally recommended in the evaluation of abnormal cervical cytology and the treatment of CIN in the nonpregnant woman, such as colposcopy, cervical biopsy, and electrosurgical excision, can be applied to the pregnant patient with important exceptions. The vascular cervix associated with the gravid condition and the risk of premature pregnancy loss mandates deviation from existing consensus guidelines in screening for cervical cancer in pregnancy and treating associated CIN. In the present review, current guidelines regarding cervical cancer screening are reviewed, and data from studies of pregnant populations are summarized.",Journal Article,4221.0,51.0,cancer screening is an essential component of prenatal care The diagnosis and management of intraepithelial neoplasia CIN during pregnancy are challenging and sufficient information does not exist to allow for a definitive evidence-based approach The American Society for Colposcopy and Pathology has recently published guidelines regarding the evaluation of abnormal Papanicolaou tests and the treatment of CIN in this setting Many techniques traditionally recommended in the evaluation of abnormal cytology and the treatment of CIN in the nonpregnant woman such as colposcopy biopsy and electrosurgical excision can be applied to the pregnant patient with important exceptions The vascular cervix associated with the gravid condition and the risk of premature pregnancy loss mandates deviation from existing consensus guidelines in screening for cancer in pregnancy and treating associated CIN In the present review current guidelines regarding cancer screening are reviewed and data from studies of pregnant populations are summarized,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 453, 16, 35, 1452, 1249, 1, 15621, 165, 3, 147, 2, 284, 1, 4153, 2298, 4652, 190, 2290, 32, 1950, 2, 1952, 487, 1097, 44, 1923, 6, 1700, 9, 8, 1057, 241, 90, 353, 3, 597, 1174, 9, 9946, 2, 1117, 71, 761, 983, 677, 666, 3, 451, 1, 1668, 10416, 895, 2, 3, 24, 1, 4652, 4, 26, 546, 445, 1092, 4206, 793, 4, 3, 451, 1, 1668, 2045, 2, 3, 24, 1, 4652, 4, 3, 16615, 2854, 225, 22, 9946, 411, 2, 24548, 1366, 122, 40, 1498, 6, 3, 6086, 69, 5, 305, 11084, 3, 756, 3629, 41, 5, 3, 30682, 2850, 2, 3, 43, 1, 5682, 2290, 407, 16176, 3348, 29, 1692, 1391, 677, 4, 453, 9, 12, 4, 2290, 2, 1367, 41, 4652, 4, 3, 364, 206, 291, 677, 666, 12, 453, 32, 446, 2, 74, 29, 94, 1, 6086, 1184, 32, 3989]",1037.0,18585520,367
Cervical neoplasia in pregnancy. Part 2: current treatment of invasive disease.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2008-07-01,"Although the incidence of cervical cancer in the United States has declined sharply, many young women are diagnosed with the disease every year. Naturally, coincident pregnancies will occur in this subset of reproductively active patients. Although the treatment of cervical cancer has evolved under the drive of multicenter, randomized trials, the same level of evidence does not exist for the treatment of this malignancy in pregnancy. Treatment algorithms are therefore proposed as a series of modifications to the guidelines intended for the nonpregnant patient, taking into account the tremendous social, ethical, and emotional dilemmas specific to each trimester at presentation.",Journal Article,4221.0,44.0,Although the incidence of cancer in the United States has declined sharply many young women are diagnosed with the disease every year Naturally coincident pregnancies will occur in this subset of reproductively active patients Although the treatment of cancer has evolved under the drive of multicenter randomized trials the same level of evidence does not exist for the treatment of this malignancy in pregnancy Treatment algorithms are therefore proposed as a series of modifications to the guidelines intended for the nonpregnant patient taking into account the tremendous social ethical and emotional dilemmas specific to each trimester at presentation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[242, 3, 287, 1, 12, 4, 3, 1088, 907, 71, 3054, 10833, 445, 1169, 117, 32, 265, 5, 3, 34, 454, 111, 6045, 9955, 8746, 303, 1271, 4, 26, 697, 1, 57210, 544, 7, 242, 3, 24, 1, 12, 71, 3937, 669, 3, 3279, 1, 1570, 384, 143, 3, 827, 301, 1, 241, 1097, 44, 1923, 9, 3, 24, 1, 26, 710, 4, 2290, 24, 3529, 32, 673, 1587, 22, 8, 988, 1, 2916, 6, 3, 677, 4081, 9, 3, 16615, 69, 2727, 237, 1967, 3, 6678, 2032, 7413, 2, 2671, 14222, 112, 6, 296, 12693, 28, 1031]",656.0,18585521,382
Robotic radical parametrectomy and pelvic lymphadenectomy in patients with invasive cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2008-07-18,"We describe a series of patients diagnosed with invasive cervical cancer after undergoing simple hysterectomy who subsequently underwent robotic radical parametrectomy and bilateral pelvic lymphadenectomy. The goal of this study is to report on the safety and feasibility of robotic radical parametrectomy. A retrospective review was performed of all patients who underwent robotic radical parametrectomy and bilateral pelvic lymphadenectomy at our institution during the period December 2006 to February 2008. We analyzed our data to evaluate the safety and feasibility of performing robotic radical parametrectomy. This analysis included 5 patients with invasive squamous cell carcinoma of the cervix. The median body mass index was 23.8 kg/m(2) (range, 17.7 to 26.5). The median operative time was 365 min (range, 331 to 430). The median estimated blood loss was 100 mL (range, 50 to 175). There were no conversions to laparotomy. There was 1 intraoperative complication--cystotomy. No patient required blood transfusion. The median length of hospital stay was 1 day (range, 1 to 2). One patient experienced two postoperative complications, a vesicovaginal fistula and a lymphocyst. No patient had residual tumor in the parametrectomy specimen, and no patient underwent adjuvant therapy. The median number of pelvic lymph nodes removed was 14 (range, 6 to 16). The median follow-up for all patients was 7.5 months (range, 1.3 to 13.8). There were no recurrences. Robotic radical parametrectomy and bilateral pelvic lymphadenectomy is feasible and safe and can be performed with an acceptable complication rate.",Journal Article,4204.0,33.0,We describe a series of patients diagnosed with invasive cancer after undergoing simple hysterectomy who subsequently underwent robotic radical parametrectomy and bilateral pelvic lymphadenectomy The goal of this study is to report on the safety and feasibility of robotic radical parametrectomy A retrospective review was performed of all patients who underwent robotic radical parametrectomy and bilateral pelvic lymphadenectomy at our institution during the period December 2006 to February 2008 We analyzed our data to evaluate the safety and feasibility of performing robotic radical parametrectomy This analysis included 5 patients with invasive squamous cell carcinoma of the cervix The median body mass index was 23.8 kg/m 2 range 17.7 to 26.5 The median operative time was 365 min range 331 to 430 The median estimated blood loss was 100 mL range 50 to 175 There were no conversions to laparotomy There was 1 intraoperative complication -- cystotomy No patient required blood transfusion The median length of hospital stay was 1 day range 1 to 2 One patient experienced two postoperative complications a vesicovaginal fistula and a lymphocyst No patient had residual tumor in the parametrectomy specimen and no patient underwent adjuvant therapy The median number of pelvic lymph nodes removed was 14 range 6 to 16 The median follow-up for all patients was 7.5 months range 1.3 to 13.8 There were no recurrences Robotic radical parametrectomy and bilateral pelvic lymphadenectomy is feasible and safe and can be performed with an acceptable complication rate,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 897, 8, 988, 1, 7, 265, 5, 416, 12, 50, 479, 2763, 2622, 54, 1611, 208, 2895, 711, 23693, 2, 1607, 1110, 2048, 3, 1326, 1, 26, 45, 16, 6, 414, 23, 3, 367, 2, 1437, 1, 2895, 711, 23693, 8, 459, 206, 10, 173, 1, 62, 7, 54, 208, 2895, 711, 23693, 2, 1607, 1110, 2048, 28, 114, 731, 190, 3, 727, 1397, 1324, 6, 3010, 1375, 21, 311, 114, 74, 6, 376, 3, 367, 2, 1437, 1, 3620, 2895, 711, 23693, 26, 65, 159, 33, 7, 5, 416, 691, 31, 134, 1, 3, 3629, 3, 52, 642, 782, 558, 10, 382, 66, 503, 188, 18, 184, 269, 67, 6, 432, 33, 3, 52, 1208, 98, 10, 7405, 1538, 184, 7558, 6, 10083, 3, 52, 661, 315, 407, 10, 394, 542, 184, 212, 6, 3300, 125, 11, 77, 13112, 6, 3274, 125, 10, 14, 1720, 1447, 37573, 77, 69, 616, 315, 2785, 3, 52, 1318, 1, 702, 2020, 10, 14, 218, 184, 14, 6, 18, 104, 69, 592, 100, 573, 521, 8, 25979, 4920, 2, 8, 38114, 77, 69, 42, 753, 30, 4, 3, 23693, 2360, 2, 77, 69, 208, 249, 36, 3, 52, 207, 1, 1110, 263, 502, 2264, 10, 213, 184, 49, 6, 245, 3, 52, 166, 126, 9, 62, 7, 10, 67, 33, 53, 184, 14, 27, 6, 233, 66, 125, 11, 77, 1593, 2895, 711, 23693, 2, 1607, 1110, 2048, 16, 1313, 2, 1165, 2, 122, 40, 173, 5, 35, 1595, 1447, 116]",1567.0,18639329,451
Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2008-08-01,"To compare bone marrow-sparing intensity-modulated pelvic radiotherapy (BMS-IMRT) with conventional (four-field box and anteroposterior-posteroanterior [AP-PA]) techniques in the treatment of cervical cancer. The data from 7 cervical cancer patients treated with concurrent chemotherapy and IMRT without BMS were analyzed and compared with data using four-field box and AP-PA techniques. All plans were normalized to cover the planning target volume with the 99% isodose line. The clinical target volume consisted of the pelvic and presacral lymph nodes, uterus and cervix, upper vagina, and parametrial tissue. Normal tissues included bowel, bladder, and pelvic bone marrow (PBM), which comprised the lumbosacral spine and ilium and the ischium, pubis, and proximal femora (lower pelvis bone marrow). Dose-volume histograms for the planning target volume and normal tissues were compared for BMS-IMRT vs. four-field box and AP-PA plans. BMS-IMRT was superior to the four-field box technique in reducing the dose to the PBM, small bowel, rectum, and bladder. Compared with AP-PA plans, BMS-IMRT reduced the PBM volume receiving a dose >16.4 Gy. BMS-IMRT reduced the volume of ilium, lower pelvis bone marrow, and bowel receiving a dose >27.7, >18.7, and >21.1 Gy, respectively, but increased dose below these thresholds compared with the AP-PA plans. BMS-IMRT reduced the volume of lumbosacral spine bone marrow, rectum, small bowel, and bladder at all dose levels in all 7 patients. BMS-IMRT reduced irradiation of PBM compared with the four-field box technique. Compared with the AP-PA technique, BMS-IMRT reduced lumbosacral spine bone marrow irradiation and reduced the volume of PBM irradiated to high doses. Therefore BMS-IMRT might reduce acute hematologic toxicity compared with conventional techniques.",Comparative Study,4190.0,125.0,To compare marrow-sparing intensity-modulated pelvic radiotherapy BMS-IMRT with conventional four-field box and anteroposterior-posteroanterior AP-PA techniques in the treatment of cancer The data from 7 cancer patients treated with concurrent chemotherapy and IMRT without BMS were analyzed and compared with data using four-field box and AP-PA techniques All plans were normalized to cover the planning target volume with the 99 isodose line The clinical target volume consisted of the pelvic and presacral lymph nodes and cervix upper vagina and parametrial tissue Normal tissues included bowel and pelvic marrow PBM which comprised the lumbosacral spine and ilium and the ischium pubis and proximal femora lower pelvis marrow Dose-volume histograms for the planning target volume and normal tissues were compared for BMS-IMRT vs. four-field box and AP-PA plans BMS-IMRT was superior to the four-field box technique in reducing the dose to the PBM small bowel rectum and Compared with AP-PA plans BMS-IMRT reduced the PBM volume receiving a dose 16.4 Gy BMS-IMRT reduced the volume of ilium lower pelvis marrow and bowel receiving a dose 27.7 18.7 and 21.1 Gy respectively but increased dose below these thresholds compared with the AP-PA plans BMS-IMRT reduced the volume of lumbosacral spine marrow rectum small bowel and at all dose levels in all 7 patients BMS-IMRT reduced irradiation of PBM compared with the four-field box technique Compared with the AP-PA technique BMS-IMRT reduced lumbosacral spine marrow irradiation and reduced the volume of PBM irradiated to high doses Therefore BMS-IMRT might reduce acute hematologic toxicity compared with conventional techniques,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,"[6, 932, 581, 1851, 837, 1757, 1110, 310, 3502, 964, 5, 809, 294, 1067, 4971, 2, 17418, 22374, 2517, 3118, 1092, 4, 3, 24, 1, 12, 3, 74, 29, 67, 12, 7, 73, 5, 750, 56, 2, 964, 187, 3502, 11, 311, 2, 72, 5, 74, 75, 294, 1067, 4971, 2, 2517, 3118, 1092, 62, 1853, 11, 4207, 6, 8308, 3, 1349, 283, 433, 5, 3, 1058, 8945, 328, 3, 38, 283, 433, 1695, 1, 3, 1110, 2, 13565, 263, 502, 2, 3629, 1726, 7553, 2, 8726, 246, 295, 742, 159, 1659, 2, 1110, 581, 9215, 92, 2603, 3, 15598, 2342, 2, 18295, 2, 3, 45207, 28361, 2, 2805, 31187, 280, 3270, 581, 61, 433, 8638, 9, 3, 1349, 283, 433, 2, 295, 742, 11, 72, 9, 3502, 964, 105, 294, 1067, 4971, 2, 2517, 3118, 1853, 3502, 964, 10, 1123, 6, 3, 294, 1067, 4971, 1312, 4, 1818, 3, 61, 6, 3, 9215, 302, 1659, 3660, 2, 72, 5, 2517, 3118, 1853, 3502, 964, 405, 3, 9215, 433, 357, 8, 61, 245, 39, 381, 3502, 964, 405, 3, 433, 1, 18295, 280, 3270, 581, 2, 1659, 357, 8, 61, 428, 67, 203, 67, 2, 239, 14, 381, 106, 84, 101, 61, 2736, 46, 4634, 72, 5, 3, 2517, 3118, 1853, 3502, 964, 405, 3, 433, 1, 15598, 2342, 581, 3660, 302, 1659, 2, 28, 62, 61, 148, 4, 62, 67, 7, 3502, 964, 405, 1104, 1, 9215, 72, 5, 3, 294, 1067, 4971, 1312, 72, 5, 3, 2517, 3118, 1312, 3502, 964, 405, 15598, 2342, 581, 1104, 2, 405, 3, 433, 1, 9215, 2398, 6, 64, 415, 673, 3502, 964, 822, 969, 286, 813, 155, 72, 5, 809, 1092]",1682.0,18640499,413
Cervical pharyngostomy: an old technique revisited.,Annals of surgery,Ann. Surg.,2008-08-01,"To review our experience with pharyngostomy tubes used to manage complications following foregut surgery and to discuss technical aspects of insertion. Cervical pharyngostomy tubes are percutaneously placed through the hypopharynx and directed into the stomach or small bowel. Historically, these tubes were placed during resection of head and neck cancer for postoperative nutrition. The technique may also be used to manage a variety of complications following esophagectomy or gastric surgery. A retrospective review identified all patients who underwent pharyngostomy tube placement at the University of Pittsburgh Medical Center from 1995 to 2007. Indications, procedure-related complications, and duration of tube placement were recorded. Thirty-eight patients were identified. Indications for tube placement were: access for enteral nutrition (n = 18), drainage of mediastinal abscess (n = 4), gastric decompression (n = 13), and other (n = 3). Procedure-related complications included: cellulitis (n = 1), esophagitis (n = 1), aspiration pneumonia (n = 1), and tube migration (n = 9). Duration of tube placement was 51 days (range 1-279). No major complications occurred. Pharyngostomy tubes may be useful in the management of complications following esophageal or gastric surgery. They are more comfortable than nasogastric tubes and may be kept in place for several months if necessary. Bleeding or other major complications have not occurred in our experience.",Journal Article,4190.0,13.0,To review our experience with pharyngostomy tubes used to manage complications following foregut surgery and to discuss technical aspects of insertion pharyngostomy tubes are percutaneously placed through the hypopharynx and directed into the or small bowel Historically these tubes were placed during resection of head and cancer for postoperative nutrition The technique may also be used to manage a variety of complications following esophagectomy or surgery A retrospective review identified all patients who underwent pharyngostomy tube placement at the University of Pittsburgh Medical Center from 1995 to 2007 Indications procedure-related complications and duration of tube placement were recorded Thirty-eight patients were identified Indications for tube placement were access for enteral nutrition n 18 drainage of mediastinal abscess n 4 decompression n 13 and other n 3 Procedure-related complications included cellulitis n 1 esophagitis n 1 aspiration pneumonia n 1 and tube migration n 9 Duration of tube placement was 51 days range 1-279 No major complications occurred Pharyngostomy tubes may be useful in the management of complications following or surgery They are more comfortable than nasogastric tubes and may be kept in place for several months if necessary Bleeding or other major complications have not occurred in our experience,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,"[6, 206, 114, 730, 5, 34515, 6193, 95, 6, 4001, 521, 366, 20481, 152, 2, 6, 1139, 3359, 2695, 1, 5099, 34515, 6193, 32, 18153, 3295, 298, 3, 9395, 2, 1166, 237, 3, 15, 302, 1659, 3578, 46, 6193, 11, 3295, 190, 170, 1, 718, 2, 12, 9, 573, 5260, 3, 1312, 68, 120, 40, 95, 6, 4001, 8, 1362, 1, 521, 366, 3617, 15, 152, 8, 459, 206, 108, 62, 7, 54, 208, 34515, 2330, 2613, 28, 3, 1652, 1, 12030, 484, 574, 29, 2323, 6, 1307, 2406, 1299, 139, 521, 2, 654, 1, 2330, 2613, 11, 1872, 977, 659, 7, 11, 108, 2406, 9, 2330, 2613, 11, 1655, 9, 14781, 5260, 78, 203, 3528, 1, 2626, 7979, 78, 39, 7638, 78, 233, 2, 127, 78, 27, 1299, 139, 521, 159, 11168, 78, 14, 5135, 78, 14, 3256, 3485, 78, 14, 2, 2330, 1381, 78, 83, 654, 1, 2330, 2613, 10, 725, 162, 184, 14, 8562, 77, 458, 521, 489, 34515, 6193, 68, 40, 999, 4, 3, 284, 1, 521, 366, 15, 152, 491, 32, 80, 11460, 76, 26438, 6193, 2, 68, 40, 11322, 4, 3536, 9, 392, 53, 492, 1493, 2294, 15, 127, 458, 521, 47, 44, 489, 4, 114, 730]",1355.0,18650628,846
Radical trachelectomy for cervical cancer: postoperative physical and emotional adjustment concerns.,Gynecologic oncology,Gynecol. Oncol.,2008-07-26,"To investigate the incidence of cervical stenosis and related emotional and sexual adjustment concerns in women treated with radical trachelectomy. Prospective data of 30 stage I cervical cancer patients enrolled in an ongoing study were evaluated in combination with a medical chart review. Eight patients (27%) did not have any stenosis of the neo-cervix postoperatively; 10 (33%) had clinically notable stenosis not requiring neo-cervical dilation to allow adequate sampling; moreover, 12 (40%) had sufficient stenosis requiring a neo-cervical dilation procedure, which proved to be safe and useful. The majority of the dilation procedures (n=8) were conducted under local anesthesia in the office. At preoperative baseline survey, women reported a high rate of sexual inactivity. Fear of intercourse and dyspareunia were reported prior to surgery; however, trends of adjustment and improvement were noted over time postoperatively. Overall, fear of sexual activity tended to lessen if the degree of dyspareunia decreased over time. Postoperative dyspareunia decreased over time, which could have been associated with the mechanical stretching due to vaginal dilator use or dilating benefit of intercourse. Postoperative concerns associated with radical trachelectomy may be greater than what has been reported in the literature; however, several adjustment trends were noted with intermediate/long-term follow-up. Office cervical dilation is a simple procedure, which is helpful in the management of neo-cervical stenosis. We are currently investigating the value of a physician checklist as a clinical care model to remind medical professionals to monitor and address important survivorship issues.",Journal Article,4196.0,51.0,To investigate the incidence of stenosis and related emotional and sexual adjustment concerns in women treated with radical trachelectomy Prospective data of 30 stage I cancer patients enrolled in an ongoing study were evaluated in combination with a medical chart review Eight patients 27 did not have any stenosis of the neo-cervix postoperatively 10 33 had clinically notable stenosis not requiring neo-cervical dilation to allow adequate sampling moreover 12 40 had sufficient stenosis requiring a neo-cervical dilation procedure which proved to be safe and useful The majority of the dilation procedures n=8 were conducted under local anesthesia in the office At preoperative baseline survey women reported a high rate of sexual inactivity Fear of intercourse and dyspareunia were reported prior to surgery however trends of adjustment and improvement were noted over time postoperatively Overall fear of sexual activity tended to lessen if the degree of dyspareunia decreased over time Postoperative dyspareunia decreased over time which could have been associated with the mechanical stretching due to dilator use or dilating benefit of intercourse Postoperative concerns associated with radical trachelectomy may be greater than what has been reported in the literature however several adjustment trends were noted with intermediate/long-term follow-up Office dilation is a simple procedure which is helpful in the management of neo-cervical stenosis We are currently investigating the value of a physician checklist as a clinical care model to remind medical professionals to monitor and address important survivorship issues,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 963, 3, 287, 1, 6935, 2, 139, 2671, 2, 2232, 1852, 2061, 4, 117, 73, 5, 711, 5760, 482, 74, 1, 201, 82, 70, 12, 7, 346, 4, 35, 942, 45, 11, 194, 4, 150, 5, 8, 484, 2937, 206, 659, 7, 428, 205, 44, 47, 500, 6935, 1, 3, 5357, 3629, 3541, 79, 466, 42, 505, 4090, 6935, 44, 1888, 5357, 18237, 8062, 6, 1700, 1658, 2874, 1393, 133, 327, 42, 1952, 6935, 1888, 8, 5357, 18237, 8062, 1299, 92, 4328, 6, 40, 1165, 2, 999, 3, 686, 1, 3, 8062, 1369, 78, 66, 11, 426, 669, 293, 6433, 4, 3, 6489, 28, 498, 330, 1407, 117, 210, 8, 64, 116, 1, 2232, 10050, 6443, 1, 12361, 2, 22098, 11, 210, 324, 6, 152, 137, 1963, 1, 1852, 2, 767, 11, 1051, 252, 98, 3541, 63, 6443, 1, 2232, 128, 3886, 6, 13763, 492, 3, 1444, 1, 22098, 340, 252, 98, 573, 22098, 340, 252, 98, 92, 359, 47, 85, 41, 5, 3, 6065, 15369, 520, 6, 17967, 119, 15, 57263, 247, 1, 12361, 573, 2061, 41, 5, 711, 5760, 68, 40, 378, 76, 2067, 71, 85, 210, 4, 3, 789, 137, 392, 1852, 1963, 11, 1051, 5, 919, 319, 337, 166, 126, 6489, 8062, 16, 8, 2763, 1299, 92, 16, 3951, 4, 3, 284, 1, 5357, 18237, 6935, 21, 32, 694, 3103, 3, 549, 1, 8, 1473, 9787, 22, 8, 38, 165, 202, 6, 37190, 484, 3409, 6, 3334, 2, 1539, 305, 2560, 1553]",1634.0,18662827,92
Ultrastaging improves detection of metastases in sentinel lymph nodes of uterine cervix squamous cell carcinoma.,The American journal of surgical pathology,Am. J. Surg. Pathol.,2008-09-01,"The technique of sentinel lymph node (SLN) detection is increasingly being applied in patients with uterine cervix carcinoma. This study presents the pathologic findings of SLNs in 48 such patients. The institutional pathology files were searched for all patients with a diagnosis of cervical squamous cell carcinoma who had SLNs reported. Patient age, follow-up, tumor size, presence/absence of lymphatic invasion, number and status of SLNs and non-SLNs, location of SLNs, and size of metastases in SLNs were recorded. All SLNs were sectioned in 2-mm slices perpendicular to the long axis and submitted entirely for microscopic examination. For all SLNs negative on the initial hematoxylin and eosin (H&E) stained slides, an ultrastaging protocol was performed consisting of 5 sets of slides at 40-mum intervals (1 H&E slide+2 unstained slides), representing an additional 5 intervals. Lymph nodes negative by the additional H&E intervals had immunohistochemistry for cytokeratin performed on 1 unstained slide. Forty-eight patients ranging from 25 to 62 years of age had a total of 208 SLNs removed. Fifteen (31%) patients had positive SLNs with 1 to 5 positive SLNs per case. The metastasis size ranged from a single cell to 27 mm. Twelve patients had metastasis detected by routine processing in 23 SLNs, whereas ultrastaging detected metastases in 3 SLNs of 3 additional patients. In 2 patients with metastasis detected by ultrastaging, the metastasis was detected by wide H&E intervals (level 2 for 1 patient; level 3 for 1 patient); in 1 patient, the metastasis was detected only by immunohistochemistry and consisted of a single cell. Of the 15 patients with positive SLNs, 3 patients had a total of 6 positive non-SLNs. All of the patients with a positive SLN are currently living. Thirty-three (69%) patients had negative SLNs. Of these, 1 patient had a single positive non-SLN for a false negative rate of 6.25%. Negative SLN predicts negative non-SLN. For most patients with a positive SLN, the SLN will be the only metastasis detected; a minority of patients with a positive SLN may have a positive non-SLN.",Journal Article,4159.0,46.0,The technique of sentinel lymph node SLN detection is increasingly being applied in patients with cervix carcinoma This study presents the pathologic findings of SLNs in 48 such patients The institutional pathology files were searched for all patients with a diagnosis of squamous cell carcinoma who had SLNs reported Patient age follow-up tumor size presence/absence of lymphatic invasion number and status of SLNs and non-SLNs location of SLNs and size of metastases in SLNs were recorded All SLNs were sectioned in 2-mm slices perpendicular to the long axis and submitted entirely for microscopic examination For all SLNs negative on the initial hematoxylin and eosin H E stained slides an ultrastaging protocol was performed consisting of 5 sets of slides at 40-mum intervals 1 H E slide+2 unstained slides representing an additional 5 intervals Lymph nodes negative by the additional H E intervals had immunohistochemistry for cytokeratin performed on 1 unstained slide Forty-eight patients ranging from 25 to 62 years of age had a total of 208 SLNs removed Fifteen 31 patients had positive SLNs with 1 to 5 positive SLNs per case The metastasis size ranged from a single cell to 27 mm Twelve patients had metastasis detected by routine processing in 23 SLNs whereas ultrastaging detected metastases in 3 SLNs of 3 additional patients In 2 patients with metastasis detected by ultrastaging the metastasis was detected by wide H E intervals level 2 for 1 patient level 3 for 1 patient in 1 patient the metastasis was detected only by immunohistochemistry and consisted of a single cell Of the 15 patients with positive SLNs 3 patients had a total of 6 positive non-SLNs All of the patients with a positive SLN are currently living Thirty-three 69 patients had negative SLNs Of these 1 patient had a single positive non-SLN for a false negative rate of 6.25 Negative SLN predicts negative non-SLN For most patients with a positive SLN the SLN will be the only metastasis detected a minority of patients with a positive SLN may have a positive non-SLN,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 1312, 1, 1323, 263, 289, 1099, 638, 16, 1635, 486, 1498, 4, 7, 5, 3629, 134, 26, 45, 2740, 3, 510, 272, 1, 2642, 4, 576, 225, 7, 3, 1115, 1117, 7530, 11, 3080, 9, 62, 7, 5, 8, 147, 1, 691, 31, 134, 54, 42, 2642, 210, 69, 89, 166, 126, 30, 444, 463, 1127, 1, 2936, 578, 207, 2, 156, 1, 2642, 2, 220, 2642, 1147, 1, 2642, 2, 444, 1, 196, 4, 2642, 11, 1872, 62, 2642, 11, 18302, 4, 18, 321, 12791, 13385, 6, 3, 319, 2310, 2, 5118, 6848, 9, 2984, 1385, 9, 62, 2642, 199, 23, 3, 388, 6209, 2, 5975, 555, 563, 3386, 3830, 35, 11338, 1182, 10, 173, 2273, 1, 33, 2270, 1, 3830, 28, 327, 10615, 1582, 14, 555, 563, 7911, 18, 17677, 3830, 2861, 35, 402, 33, 1582, 263, 502, 199, 20, 3, 402, 555, 563, 1582, 42, 888, 9, 4292, 173, 23, 14, 17677, 7911, 1213, 659, 7, 2223, 29, 243, 6, 744, 60, 1, 89, 42, 8, 181, 1, 5920, 2642, 2264, 3057, 456, 7, 42, 109, 2642, 5, 14, 6, 33, 109, 2642, 379, 473, 3, 278, 444, 1869, 29, 8, 226, 31, 6, 428, 321, 2544, 7, 42, 278, 530, 20, 1311, 3325, 4, 382, 2642, 547, 11338, 530, 196, 4, 27, 2642, 1, 27, 402, 7, 4, 18, 7, 5, 278, 530, 20, 11338, 3, 278, 10, 530, 20, 1019, 555, 563, 1582, 301, 18, 9, 14, 69, 301, 27, 9, 14, 69, 4, 14, 69, 3, 278, 10, 530, 158, 20, 888, 2, 1695, 1, 8, 226, 31, 1, 3, 167, 7, 5, 109, 2642, 27, 7, 42, 8, 181, 1, 49, 109, 220, 2642, 62, 1, 3, 7, 5, 8, 109, 1099, 32, 694, 2798, 977, 169, 790, 7, 42, 199, 2642, 1, 46, 14, 69, 42, 8, 226, 109, 220, 1099, 9, 8, 2133, 199, 116, 1, 49, 243, 199, 1099, 2623, 199, 220, 1099, 9, 96, 7, 5, 8, 109, 1099, 3, 1099, 303, 40, 3, 158, 278, 530, 8, 2652, 1, 7, 5, 8, 109, 1099, 68, 47, 8, 109, 220, 1099]",2053.0,18670356,89
"Cancer health disparities among Indian and Pakistani immigrants in the United States: a Surveillance, Epidemiology, and End Results-based study from 1988 to 2003.",Cancer,Cancer,2008-09-01,"Immigrants from India and Pakistan comprise about 1.5% of the total United States population. To the author' knowledge, this is the first study analyzing epidemiologic data on Indian and Pakistani patients with newly diagnosed cancer. The Surveillance, Epidemiology, and End Results (SEER) database has reported cancer incidence from 1973 to 2003. Since 1988, the Indian and Pakistani population has been reported separately under race and ethnicity. Frequency and survival analyses with SEER data were performed, and descriptive parameters were calculated along with overall survival in common cancers. In total, 6889 cases were reported between 1988 and 2003, and those cases included 51% men and 49% women (P = .821). Among men, 30% of cases were prostate cancers, 10% of cases were lung cancers, and 9% of cases were colorectal cancers. Among women, 38% of cases were breast cancers, 15% of cases were genital cancers, and 7% of cases were colorectal cancers. When overall survival with common cancer was compared between immigrants and non-Hispanic whites in the United States, it was better among Indian and Pakistani immigrants. In a United States-based Indian and Pakistani population, prostate and breast cancers were the most common malignancies in men and women, respectively. This differed from the incidence in India and Pakistan, where oral cavity cancer in men and breast and cervical cancers in women were the most common. These immigrant cancer patients also had better survival. This change in demographics may be attributed to multiple factors, and the current data have implications on cancer screening and intervention.",Journal Article,4159.0,11.0,Immigrants from India and Pakistan comprise about 1.5 of the total United States population To the author knowledge this is the first study analyzing epidemiologic data on Indian and Pakistani patients with newly diagnosed cancer The Surveillance Epidemiology and End Results SEER database has reported cancer incidence from 1973 to 2003 Since 1988 the Indian and Pakistani population has been reported separately under race and ethnicity Frequency and survival analyses with SEER data were performed and descriptive parameters were calculated along with overall survival in common cancers In total 6889 cases were reported between 1988 and 2003 and those cases included 51 men and 49 women P .821 Among men 30 of cases were cancers 10 of cases were cancers and 9 of cases were cancers Among women 38 of cases were cancers 15 of cases were genital cancers and 7 of cases were cancers When overall survival with common cancer was compared between immigrants and non-Hispanic whites in the United States it was better among Indian and Pakistani immigrants In a United States-based Indian and Pakistani population and cancers were the most common malignancies in men and women respectively This differed from the incidence in India and Pakistan where oral cavity cancer in men and and cancers in women were the most common These immigrant cancer patients also had better survival This change in demographics may be attributed to multiple factors and the current data have implications on cancer screening and intervention,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[14004, 29, 7776, 2, 38792, 5238, 545, 14, 33, 1, 3, 181, 1088, 907, 266, 6, 3, 11783, 922, 26, 16, 3, 157, 45, 4449, 3609, 74, 23, 7968, 2, 21526, 7, 5, 732, 265, 12, 3, 617, 1284, 2, 396, 99, 1605, 609, 71, 210, 12, 287, 29, 4756, 6, 1522, 1192, 3314, 3, 7968, 2, 21526, 266, 71, 85, 210, 3582, 669, 1047, 2, 2091, 675, 2, 25, 318, 5, 1605, 74, 11, 173, 2, 3778, 1038, 11, 981, 1510, 5, 63, 25, 4, 186, 163, 4, 181, 57281, 140, 11, 210, 59, 3314, 2, 1522, 2, 135, 140, 159, 725, 325, 2, 739, 117, 19, 10680, 107, 325, 201, 1, 140, 11, 163, 79, 1, 140, 11, 163, 2, 83, 1, 140, 11, 163, 107, 117, 519, 1, 140, 11, 163, 167, 1, 140, 11, 8226, 163, 2, 67, 1, 140, 11, 163, 198, 63, 25, 5, 186, 12, 10, 72, 59, 14004, 2, 220, 1776, 2556, 4, 3, 1088, 907, 192, 10, 380, 107, 7968, 2, 21526, 14004, 4, 8, 1088, 907, 90, 7968, 2, 21526, 266, 2, 163, 11, 3, 96, 186, 441, 4, 325, 2, 117, 106, 26, 2512, 29, 3, 287, 4, 7776, 2, 38792, 1257, 518, 2405, 12, 4, 325, 2, 2, 163, 4, 117, 11, 3, 96, 186, 46, 16931, 12, 7, 120, 42, 380, 25, 26, 707, 4, 2221, 68, 40, 3073, 6, 232, 130, 2, 3, 291, 74, 47, 1268, 23, 12, 453, 2, 788]",1518.0,18696716,83
Radiation treatment breaks and ulcerative mucositis in head and neck cancer.,The oncologist,Oncologist,2008-08-13,"Unplanned radiation treatment breaks and prolongation of the radiation treatment time are associated with lower survival and locoregional control rates when radiotherapy or concurrent chemoradiotherapy is used in the curative treatment of head and neck cancer. Treatment of head and neck cancer is intense, involving high-dose, continuous radiotherapy, and often adding chemotherapy to radiotherapy. As the intensity of treatment regimens has escalated in recent years, clinical outcomes generally have improved. However, more intensive therapy also increases the incidence of treatment-related toxicities, particularly those impacting the mucosal lining of the oral cavity, pharynx, and cervical esophagus, and results in varying degrees of ulcerative mucositis. Ulcerative mucositis is a root cause of unscheduled radiation treatment breaks, which prolongs the total radiation treatment time. Alterations in radiotherapy and chemotherapy, including the use of continuous (i.e., 7 days/week) radiotherapy to ensure constant negative proliferative pressure, may improve efficacy outcomes. However, these approaches also increase the incidence of ulcerative mucositis, thereby increasing the incidence of unplanned radiation treatment breaks. Conversely, the reduction of ulcerative mucositis to minimize unplanned breaks in radiotherapy may enhance not only tolerability, but also efficacy outcomes. Several strategies to prevent ulcerative mucositis in radiotherapy for head and neck cancer have been evaluated, but none have demonstrated strong efficacy. Continued investigation is needed to identify superior radiation treatment regimens, technology, and supportive care that reduce unplanned radiation treatment breaks with the goal of improving clinical outcomes in head and neck cancer.",Journal Article,4178.0,119.0,Unplanned radiation treatment breaks and prolongation of the radiation treatment time are associated with lower survival and locoregional control rates when radiotherapy or concurrent chemoradiotherapy is used in the curative treatment of head and cancer Treatment of head and cancer is intense involving high-dose continuous radiotherapy and often adding chemotherapy to radiotherapy As the intensity of treatment regimens has escalated in recent years clinical outcomes generally have improved However more intensive therapy also increases the incidence of treatment-related toxicities particularly those impacting the mucosal lining of the oral cavity pharynx and and results in varying degrees of ulcerative mucositis Ulcerative mucositis is a root cause of unscheduled radiation treatment breaks which prolongs the total radiation treatment time Alterations in radiotherapy and chemotherapy including the use of continuous i.e. 7 days/week radiotherapy to ensure constant negative proliferative pressure may improve efficacy outcomes However these approaches also increase the incidence of ulcerative mucositis thereby increasing the incidence of unplanned radiation treatment breaks Conversely the reduction of ulcerative mucositis to minimize unplanned breaks in radiotherapy may enhance not only tolerability but also efficacy outcomes Several strategies to prevent ulcerative mucositis in radiotherapy for head and cancer have been evaluated but none have demonstrated strong efficacy Continued investigation is needed to identify superior radiation treatment regimens technology and supportive care that reduce unplanned radiation treatment breaks with the goal of improving clinical outcomes in head and cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[5851, 121, 24, 4492, 2, 4464, 1, 3, 121, 24, 98, 32, 41, 5, 280, 25, 2, 1325, 182, 151, 198, 310, 15, 750, 1464, 16, 95, 4, 3, 1075, 24, 1, 718, 2, 12, 24, 1, 718, 2, 12, 16, 3933, 1267, 64, 61, 1314, 310, 2, 629, 2726, 56, 6, 310, 22, 3, 837, 1, 24, 472, 71, 2842, 4, 435, 60, 38, 123, 1228, 47, 231, 137, 80, 1686, 36, 120, 1106, 3, 287, 1, 24, 139, 385, 823, 135, 8661, 3, 3068, 10597, 1, 3, 518, 2405, 13958, 2, 2, 99, 4, 2990, 4133, 1, 11827, 2606, 11827, 2606, 16, 8, 8386, 708, 1, 13774, 121, 24, 4492, 92, 5613, 3, 181, 121, 24, 98, 593, 4, 310, 2, 56, 141, 3, 119, 1, 1314, 70, 563, 67, 162, 647, 310, 6, 3478, 4982, 199, 2441, 3738, 68, 401, 209, 123, 137, 46, 611, 120, 344, 3, 287, 1, 11827, 2606, 2267, 602, 3, 287, 1, 5851, 121, 24, 4492, 3154, 3, 628, 1, 11827, 2606, 6, 3241, 5851, 4492, 4, 310, 68, 1304, 44, 158, 1543, 84, 120, 209, 123, 392, 422, 6, 1682, 11827, 2606, 4, 310, 9, 718, 2, 12, 47, 85, 194, 84, 1292, 47, 264, 1082, 209, 1351, 940, 16, 575, 6, 255, 1123, 121, 24, 472, 2033, 2, 1877, 165, 17, 969, 5851, 121, 24, 4492, 5, 3, 1326, 1, 1673, 38, 123, 4, 718, 2, 12]",1721.0,18701763,52
Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2008-08-16,"To describe the surgical and pathologic findings of fertility-sparing radical abdominal trachelectomy using a standardized surgical technique, and report the rate of post-trachelectomy adjuvant therapy that results in permanent sterility. A prospectively maintained database of all patients with FIGO stage IB1 cervical cancer admitted to the operating room for planned fertility-sparing radical abdominal trachelectomy was analyzed. Sentinel node mapping was performed via cervical injection of Technetium and blue dye. Between 6/2005 and 5/2008, 22 consecutive patients with FIGO stage IB1 cervical cancer underwent laparotomy for planned fertility-sparing radical abdominal trachelectomy. Median age was 33 years (range, 23-43). Histology included 13 (59%) with adenocarcinoma and 9 (41%) with squamous carcinoma. Lymph-vascular invasion was seen in 9 (41%) cases. Only 3 (14%) needed immediate completion radical hysterectomy due to intraoperative findings (2 for positive nodes, 1 for positive endocervical margin). Median number of nodes evaluated was 23 (range, 11-44); and 6 (27%) patients had positive pelvic nodes on final pathology - all received postoperative chemoradiation. Sixteen (73%) patients agreed to participate in sentinel node mapping which yielded a detection rate of 100%, sensitivity of 83%, specificity of 100% and false-negative rate of 17%. Eighteen of 19 (95%) patients who completed trachelectomy had a cerclage placed, and 9/22 (41%) patients had no residual cervical carcinoma on final pathology. Median time in the operating room was 298 min (range, 180-425). Median estimated blood loss was 250 ml (range, 50-700), and median hospital stay was 4 days (range, 3-6). No recurrences were noted at the time of this report. Cervical adenocarcinoma and lymph-vascular invasion are common features of patients selected for radical abdominal trachelectomy. The majority of patients can undergo the operation successfully; however, nearly 32% of all selected cases will require hysterectomy or postoperative chemoradiation for oncologic reasons. Sentinel node mapping is useful but until lower false-negative rates are achieved total lymphadenectomy remains the gold standard. Investigating alternative fertility-sparing adjuvant therapy in node positive patients is needed.",Journal Article,4175.0,82.0,To describe the surgical and pathologic findings of fertility-sparing radical abdominal trachelectomy using a standardized surgical technique and report the rate of post-trachelectomy adjuvant therapy that results in permanent sterility A prospectively maintained database of all patients with FIGO stage IB1 cancer admitted to the operating room for planned fertility-sparing radical abdominal trachelectomy was analyzed Sentinel node mapping was performed via injection of Technetium and blue dye Between 6/2005 and 5/2008 22 consecutive patients with FIGO stage IB1 cancer underwent laparotomy for planned fertility-sparing radical abdominal trachelectomy Median age was 33 years range 23-43 Histology included 13 59 with adenocarcinoma and 9 41 with squamous carcinoma Lymph-vascular invasion was seen in 9 41 cases Only 3 14 needed immediate completion radical hysterectomy due to intraoperative findings 2 for positive nodes 1 for positive endocervical margin Median number of nodes evaluated was 23 range 11-44 and 6 27 patients had positive pelvic nodes on final pathology all received postoperative chemoradiation Sixteen 73 patients agreed to participate in sentinel node mapping which yielded a detection rate of 100 sensitivity of 83 specificity of 100 and false-negative rate of 17 Eighteen of 19 95 patients who completed trachelectomy had a cerclage placed and 9/22 41 patients had no residual carcinoma on final pathology Median time in the operating room was 298 min range 180-425 Median estimated blood loss was 250 ml range 50-700 and median hospital stay was 4 days range 3-6 No recurrences were noted at the time of this report adenocarcinoma and lymph-vascular invasion are common features of patients selected for radical abdominal trachelectomy The majority of patients can undergo the operation successfully however nearly 32 of all selected cases will require hysterectomy or postoperative chemoradiation for oncologic reasons Sentinel node mapping is useful but until lower false-negative rates are achieved total lymphadenectomy remains the gold standard Investigating alternative fertility-sparing adjuvant therapy in node positive patients is needed,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 897, 3, 221, 2, 510, 272, 1, 2954, 1851, 711, 1467, 5760, 75, 8, 1670, 221, 1312, 2, 414, 3, 116, 1, 539, 5760, 249, 36, 17, 99, 4, 4377, 30680, 8, 1143, 1955, 609, 1, 62, 7, 5, 3837, 82, 8111, 12, 4319, 6, 3, 2584, 4698, 9, 1465, 2954, 1851, 711, 1467, 5760, 10, 311, 1323, 289, 2568, 10, 173, 847, 1754, 1, 11237, 2, 3352, 3796, 59, 49, 1242, 2, 33, 1375, 350, 935, 7, 5, 3837, 82, 8111, 12, 208, 3274, 9, 1465, 2954, 1851, 711, 1467, 5760, 52, 89, 10, 466, 60, 184, 382, 601, 784, 159, 233, 728, 5, 449, 2, 83, 605, 5, 691, 134, 263, 756, 578, 10, 527, 4, 83, 605, 140, 158, 27, 213, 575, 2181, 1438, 711, 2622, 520, 6, 1720, 272, 18, 9, 109, 502, 14, 9, 109, 10174, 959, 52, 207, 1, 502, 194, 10, 382, 184, 175, 584, 2, 49, 428, 7, 42, 109, 1110, 502, 23, 1457, 1117, 62, 103, 573, 975, 3228, 803, 7, 4681, 6, 3506, 4, 1323, 289, 2568, 92, 2178, 8, 638, 116, 1, 394, 485, 1, 852, 1121, 1, 394, 2, 2133, 199, 116, 1, 269, 3195, 1, 326, 48, 7, 54, 781, 5760, 42, 8, 28830, 3295, 2, 83, 350, 605, 7, 42, 77, 753, 134, 23, 1457, 1117, 52, 98, 4, 3, 2584, 4698, 10, 8651, 1538, 184, 3172, 8544, 52, 661, 315, 407, 10, 2039, 542, 184, 212, 5692, 2, 52, 702, 2020, 10, 39, 162, 184, 27, 49, 77, 1593, 11, 1051, 28, 3, 98, 1, 26, 414, 449, 2, 263, 756, 578, 32, 186, 404, 1, 7, 715, 9, 711, 1467, 5760, 3, 686, 1, 7, 122, 1251, 3, 2589, 1878, 137, 1857, 531, 1, 62, 715, 140, 303, 1353, 2622, 15, 573, 975, 9, 1998, 2325, 1323, 289, 2568, 16, 999, 84, 1100, 280, 2133, 199, 151, 32, 513, 181, 2048, 469, 3, 4159, 260, 3103, 1091, 2954, 1851, 249, 36, 4, 289, 109, 7, 16, 575]",2179.0,18708244,394
A phase III randomized clinical trial comparing laparoscopic or robotic radical hysterectomy with abdominal radical hysterectomy in patients with early stage cervical cancer.,Journal of minimally invasive gynecology,J Minim Invasive Gynecol,,"Cervical cancer is a significant health problem in countries of the developing world. Although case series suggest advantages of total laparoscopic radical hysterectomy (TLRH) compared with total abdominal radical hysterectomy (TARH), no randomized controlled trial is currently available to establish TLRH as the new standard treatment. In this study, TLRH or total robotic radical hysterectomy (TRRH) will be performed without a vaginally assisted portion of the procedure. A biphasic randomized controlled trial was designed to test feasibility of recruitment and equivalence in regard to disease-free survival (Canadian Task Force classification I). Tertiary referral hospital. Patients with histologically confirmed invasive squamous cell carcinoma or adenocarcinoma of the cervix, stage IA1 (with lymphovascular space invasion), IA2, and IB1 are eligible. During the first phase, 100 patients will be randomized (1:1) to receive either TLRH/TRRH or TARH, with the primary end point being the rate of enrollment. During the second phase, recruitment will be extended by another 640 patients in a 1:1 TLRH/TRRH:TARH allocation, to determine equivalence with respect to disease-free survival with 80% power and alpha=0.05. Equivalence will be assumed if the difference in disease-free survival does not exceed 7% at 4 years. Secondary outcomes include treatment-related morbidity, costs and cost effectiveness, patterns of recurrence, quality of life, pelvic floor function, feasibility of intraoperative sentinel node sampling, and overall survival. All data from this multicenter study will be entered using online electronic case report forms, allowing real-time assessment of data completeness and patient follow-up. This prospective trial aims to show the equivalence of a TLRH/TRRH versus TARH approach for patients with early stage cervical cancer following a 2-phase protocol. This trial was developed and designed with the input and approval of the members of the Gynecologic Oncology Committee from the American Association of Gynecologic Laparoscopists.","Clinical Trial, Phase III",,121.0,cancer is a significant health problem in countries of the developing world Although case series suggest advantages of total laparoscopic radical hysterectomy TLRH compared with total abdominal radical hysterectomy TARH no randomized controlled trial is currently available to establish TLRH as the new standard treatment In this study TLRH or total robotic radical hysterectomy TRRH will be performed without a vaginally assisted portion of the procedure A biphasic randomized controlled trial was designed to test feasibility of recruitment and equivalence in regard to disease-free survival Canadian Task Force classification I Tertiary referral hospital Patients with histologically confirmed invasive squamous cell carcinoma or adenocarcinoma of the cervix stage IA1 with lymphovascular space invasion IA2 and IB1 are eligible During the first phase 100 patients will be randomized 1:1 to receive either TLRH/TRRH or TARH with the primary end point being the rate of enrollment During the second phase recruitment will be extended by another 640 patients in a 1:1 TLRH/TRRH TARH allocation to determine equivalence with respect to disease-free survival with 80 power and alpha=0.05 Equivalence will be assumed if the difference in disease-free survival does not exceed 7 at 4 years Secondary outcomes include treatment-related morbidity costs and cost effectiveness patterns of recurrence quality of life pelvic floor function feasibility of intraoperative sentinel node sampling and overall survival All data from this multicenter study will be entered using online electronic case report forms allowing real-time assessment of data completeness and patient follow-up This prospective trial aims to show the equivalence of a TLRH/TRRH versus TARH approach for patients with early stage cancer following a 2-phase protocol This trial was developed and designed with the input and approval of the members of the Gynecologic Oncology Committee from the American Association of Gynecologic Laparoscopists,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 8, 93, 341, 2497, 4, 2115, 1, 3, 931, 1956, 242, 473, 988, 309, 3126, 1, 181, 1964, 711, 2622, 28834, 72, 5, 181, 1467, 711, 2622, 34531, 77, 384, 1149, 160, 16, 694, 390, 6, 1811, 28834, 22, 3, 217, 260, 24, 4, 26, 45, 28834, 15, 181, 2895, 711, 2622, 34532, 303, 40, 173, 187, 8, 45239, 2927, 3206, 1, 3, 1299, 8, 7739, 384, 1149, 160, 10, 1114, 6, 412, 1437, 1, 3202, 2, 9779, 4, 2539, 6, 34, 115, 25, 7170, 3488, 4380, 947, 70, 2557, 2096, 702, 7, 5, 2161, 557, 416, 691, 31, 134, 15, 449, 1, 3, 3629, 82, 14517, 5, 2933, 3865, 578, 16725, 2, 8111, 32, 625, 190, 3, 157, 124, 394, 7, 303, 40, 384, 14, 14, 6, 560, 361, 28834, 34532, 15, 34531, 5, 3, 86, 396, 741, 486, 3, 116, 1, 1798, 190, 3, 419, 124, 3202, 303, 40, 1747, 20, 1809, 10972, 7, 4, 8, 14, 14, 28834, 34532, 34531, 6834, 6, 223, 9779, 5, 2184, 6, 34, 115, 25, 5, 493, 2349, 2, 950, 13, 474, 9779, 303, 40, 6719, 492, 3, 523, 4, 34, 115, 25, 1097, 44, 6818, 67, 28, 39, 60, 568, 123, 643, 24, 139, 787, 1201, 2, 835, 1236, 764, 1, 146, 372, 1, 358, 1110, 12557, 343, 1437, 1, 1720, 1323, 289, 2874, 2, 63, 25, 62, 74, 29, 26, 1570, 45, 303, 40, 2836, 75, 4123, 3098, 473, 414, 2377, 2952, 1589, 98, 455, 1, 74, 7507, 2, 69, 166, 126, 26, 482, 160, 2970, 6, 514, 3, 9779, 1, 8, 28834, 34532, 185, 34531, 353, 9, 7, 5, 191, 82, 12, 366, 8, 18, 124, 1182, 26, 160, 10, 276, 2, 1114, 5, 3, 5772, 2, 1814, 1, 3, 1684, 1, 3, 1512, 413, 2002, 29, 3, 597, 248, 1, 1512, 45240]",2006.0,18722970,592
Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma.,Gynecologic oncology,Gynecol. Oncol.,2008-08-27,"To compare the oncologic outcomes of women who underwent a fertility-sparing radical trachelectomy (RT) to those who underwent a radical hysterectomy (RH) for stage IB1 cervical carcinoma. We performed a case-control study of all patients with stage IB1 cervical carcinoma who underwent a vaginal or abdominal RT between 11/01 and 6/07. The control group consisted of patients with stage IB1 disease who underwent an RH between 11/91 and 6/07 and who would be considered candidates for fertility-sparing surgery. Information was extracted from a prospectively acquired database. Recurrence-free and disease-specific survival (RFS and DSS) were estimated using Kaplan-Meier estimates and compared with the log-rank test where indicated. Multivariate analysis was performed using the Cox regression method. Forty stage IB1 patients underwent an RT and 110 patients underwent an RH. There were no statistical differences between the two groups for the following prognostic variables: histology, median number of lymph nodes removed, node positive rate, lymph-vascular space involvement (LVSI), or deep stromal invasion (DSI). The median follow-up for the entire group was 44 months. The 5-year RFS rate was 96% (for the RT group compared to 86% for the RH group (P=NS). On multivariate analysis in this group of stage IB1 lesions, tumor size <2 cm was not an independent predictor of outcome, but both LVSI and DSI retained independent predictive value (P=0.033 and 0.005, respectively). For selected patients with stage IB1 cervical cancer, fertility-sparing radical trachelectomy appears to have a similar oncologic outcome to radical hysterectomy. LVSI and DSI appear to be more valuable predictors of outcome than tumor diameter in this subgroup of patients.",Journal Article,4164.0,136.0,To compare the oncologic outcomes of women who underwent a fertility-sparing radical trachelectomy RT to those who underwent a radical hysterectomy RH for stage IB1 carcinoma We performed a case-control study of all patients with stage IB1 carcinoma who underwent a or abdominal RT between 11/01 and 6/07 The control group consisted of patients with stage IB1 disease who underwent an RH between 11/91 and 6/07 and who would be considered candidates for fertility-sparing surgery Information was extracted from a prospectively acquired database Recurrence-free and disease-specific survival RFS and DSS were estimated using Kaplan-Meier estimates and compared with the log-rank test where indicated Multivariate analysis was performed using the Cox regression method Forty stage IB1 patients underwent an RT and 110 patients underwent an RH There were no statistical differences between the two groups for the following prognostic variables histology median number of lymph nodes removed node positive rate lymph-vascular space involvement LVSI or deep stromal invasion DSI The median follow-up for the entire group was 44 months The 5-year RFS rate was 96 for the RT group compared to 86 for the RH group P=NS On multivariate analysis in this group of stage IB1 lesions tumor size 2 cm was not an independent predictor of outcome but both LVSI and DSI retained independent predictive value P=0.033 and 0.005 respectively For selected patients with stage IB1 cancer fertility-sparing radical trachelectomy appears to have a similar oncologic outcome to radical hysterectomy LVSI and DSI appear to be more valuable predictors of outcome than tumor diameter in this subgroup of patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,"[6, 932, 3, 1998, 123, 1, 117, 54, 208, 8, 2954, 1851, 711, 5760, 240, 6, 135, 54, 208, 8, 711, 2622, 7240, 9, 82, 8111, 134, 21, 173, 8, 473, 182, 45, 1, 62, 7, 5, 82, 8111, 134, 54, 208, 8, 15, 1467, 240, 59, 175, 355, 2, 49, 1615, 3, 182, 87, 1695, 1, 7, 5, 82, 8111, 34, 54, 208, 35, 7240, 59, 175, 970, 2, 49, 1615, 2, 54, 688, 40, 515, 1931, 9, 2954, 1851, 152, 487, 10, 2484, 29, 8, 1143, 1294, 609, 146, 115, 2, 34, 112, 25, 1272, 2, 1788, 11, 661, 75, 876, 882, 1423, 2, 72, 5, 3, 1066, 1026, 412, 1257, 1103, 331, 65, 10, 173, 75, 3, 418, 320, 596, 1213, 82, 8111, 7, 208, 35, 240, 2, 3129, 7, 208, 35, 7240, 125, 11, 77, 1050, 362, 59, 3, 100, 271, 9, 3, 366, 177, 682, 784, 52, 207, 1, 263, 502, 2264, 289, 109, 116, 263, 756, 3865, 799, 8004, 15, 2369, 1126, 578, 38804, 3, 52, 166, 126, 9, 3, 1797, 87, 10, 584, 53, 3, 33, 111, 1272, 116, 10, 921, 9, 3, 240, 87, 72, 6, 868, 9, 3, 7240, 87, 19, 4044, 23, 331, 65, 4, 26, 87, 1, 82, 8111, 406, 30, 444, 18, 494, 10, 44, 35, 306, 980, 1, 228, 84, 110, 8004, 2, 38804, 3532, 306, 464, 549, 19, 13, 5254, 2, 13, 1614, 106, 9, 715, 7, 5, 82, 8111, 12, 2954, 1851, 711, 5760, 1233, 6, 47, 8, 288, 1998, 228, 6, 711, 2622, 8004, 2, 38804, 1322, 6, 40, 80, 2926, 674, 1, 228, 76, 30, 2549, 4, 26, 1363, 1, 7]",1684.0,18755500,320
Posterior stabilization strategies following resection of cervicothoracic junction tumors: review of 90 consecutive cases.,Journal of neurosurgery. Spine,J Neurosurg Spine,2008-08-01,"In this retrospective analysis the authors describe the assessment and outcomes of 90 patients who underwent placement of posterior instrumentation at the cervicothoracic junction following the resection of a primary or metastatic tumor during a 10-year period. All patients underwent a posterolateral laminectomy including uni- or bilateral facetectomy, and 44 patients additionally required vertebral body resection and reconstruction. In patients who underwent C-6 or C-7 decompression, the posterior instrumentation strategies changed from the use of lateral mass plate systems (LMPSs) to lateral mass screw/rod systems (LMSRSs). Similarly, for T1-3 tumor decompression, the strategy shifted from sublaminar hook/rod systems (SHRSs) to the use of pedicle screw systems (PSSs) in which the surgeon used either a 6.25-mm rod or dual-diameter rods with or without a connector. The overall surgical complication rate was 19% including fixation failure in 11 patients (12%), 6 of whom required reoperation. Fixation failure rates for cervical decompression decreased from 2 (29%) of 7 patients in the LMPS group to 0 (0%) of 8 in the LMSRS group (p = 0.2). The fixation failure rates for thoracic decompression were 7 (15%) of 48 patients in the SHRS group, and there was a decrease to 2 (7%) of 27 in the PSS group (p = 0.48). Neurological and functional outcomes including American Spinal Injury Association, Eastern Cooperative Oncology Group, and Medical Research Council muscle strength and pain scores remained stable or improved in 94, 96, 100, and 96% of patients, respectively. Current posterior instrumentation strategies involving LMSRSs and PSSs provide excellent and safe stabilization of the cervicothoracic junction following resection of primary or metastatic tumors.",Journal Article,4190.0,30.0,In this retrospective analysis the authors describe the assessment and outcomes of 90 patients who underwent placement of posterior instrumentation at the cervicothoracic junction following the resection of a primary or metastatic tumor during a 10-year period All patients underwent a posterolateral laminectomy including uni- or bilateral facetectomy and 44 patients additionally required vertebral body resection and reconstruction In patients who underwent C-6 or C-7 decompression the posterior instrumentation strategies changed from the use of lateral mass plate systems LMPSs to lateral mass screw/rod systems LMSRSs Similarly for T1-3 tumor decompression the strategy shifted from sublaminar hook/rod systems SHRSs to the use of pedicle screw systems PSSs in which the surgeon used either a 6.25-mm rod or dual-diameter rods with or without a connector The overall surgical complication rate was 19 including fixation failure in 11 patients 12 6 of whom required reoperation Fixation failure rates for decompression decreased from 2 29 of 7 patients in the LMPS group to 0 0 of 8 in the LMSRS group p 0.2 The fixation failure rates for thoracic decompression were 7 15 of 48 patients in the SHRS group and there was a decrease to 2 7 of 27 in the PSS group p 0.48 Neurological and functional outcomes including American Spinal Injury Association Eastern Cooperative Oncology Group and Medical Research Council muscle strength and pain scores remained stable or improved in 94 96 100 and 96 of patients respectively Current posterior instrumentation strategies involving LMSRSs and PSSs provide excellent and safe stabilization of the cervicothoracic junction following resection of primary or metastatic tumors,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4, 26, 459, 65, 3, 738, 897, 3, 455, 2, 123, 1, 424, 7, 54, 208, 2613, 1, 3028, 9166, 28, 3, 26738, 3322, 366, 3, 170, 1, 8, 86, 15, 113, 30, 190, 8, 79, 111, 727, 62, 7, 208, 8, 13000, 16891, 141, 11024, 15, 1607, 57328, 2, 584, 7, 1724, 616, 4731, 642, 170, 2, 1470, 4, 7, 54, 208, 256, 49, 15, 256, 67, 7638, 3, 3028, 9166, 422, 2368, 29, 3, 119, 1, 3855, 782, 9656, 1530, 57329, 6, 3855, 782, 14911, 14202, 1530, 45250, 1813, 9, 1534, 27, 30, 7638, 3, 692, 7289, 29, 57330, 38808, 14202, 1530, 57331, 6, 3, 119, 1, 9253, 14911, 1530, 45251, 4, 92, 3, 1897, 95, 361, 8, 49, 243, 321, 14202, 15, 1828, 2549, 25984, 5, 15, 187, 8, 57332, 3, 63, 221, 1447, 116, 10, 326, 141, 8574, 496, 4, 175, 7, 133, 49, 1, 953, 616, 5077, 8574, 496, 151, 9, 7638, 340, 29, 18, 462, 1, 67, 7, 4, 3, 43906, 87, 6, 13, 13, 1, 66, 4, 3, 57333, 87, 19, 13, 18, 3, 8574, 496, 151, 9, 2098, 7638, 11, 67, 167, 1, 576, 7, 4, 3, 34540, 87, 2, 125, 10, 8, 775, 6, 18, 67, 1, 428, 4, 3, 14929, 87, 19, 13, 576, 3622, 2, 583, 123, 141, 597, 1499, 2730, 248, 2118, 1690, 413, 87, 2, 484, 389, 9474, 1502, 3671, 2, 559, 703, 958, 585, 15, 231, 4, 960, 921, 394, 2, 921, 1, 7, 106, 291, 3028, 9166, 422, 1267, 45250, 2, 45251, 377, 1503, 2, 1165, 3184, 1, 3, 26738, 3322, 366, 170, 1, 86, 15, 113, 57]",1719.0,18764742,837
Treatment patterns of FIGO Stage IB2 cervical cancer: a single-institution experience of radical hysterectomy with individualized postoperative therapy and definitive radiation therapy.,Gynecologic oncology,Gynecol. Oncol.,2008-09-06,"The treatment of FIGO stage IB2 cervical cancer is controversial. Our aim was to assess treatment patterns, outcomes, and complications in patients with stage IB2 cervical cancer. A retrospective study of patients with stage IB2 cervical carcinoma at a single institution between January 1982 and September 2006 was performed. To adequately control treatment variables, we only included patients who underwent their entire treatment at our institution. Toxicity was assessed using NCI Common Toxicity Criteria (CTC). We identified 82 patients, of whom 47 met the strict inclusion criteria. Of these, 27 patients (57%) underwent primary radical hysterectomy (RH) and 20 (43%) were treated with definitive radiation/chemoradiation therapy (RT/CRT). Patients selected for RT/CRT had a higher American Society of Anesthesiologist (ASA) score than those selected for surgery (P=0.037). The 3-year progression free survival rate was 52% for the RH group and 55% for the RT/CRT group (P=0.977). The 3-year overall survival rates were 72% and 55%, respectively (P=0.161). Overall, 52% of patients in the RH group received postoperative radiation therapy as part of their adjuvant treatment. CTC grade 3, 4, and 5 complications affected 5 patients (19%) in the RH group and 3 (15%) in the RT/CRT group. Both RH and definitive RT/CRT are adequate management strategies for patients with FIGO stage IB2 cervical cancer. However, there was a subset of patients in whom RH as monotherapy was appropriate. Further studies are needed to evaluate the role of new preoperative models that will accurately identify these patients.",Journal Article,4154.0,30.0,The treatment of FIGO stage IB2 cancer is controversial Our aim was to assess treatment patterns outcomes and complications in patients with stage IB2 cancer A retrospective study of patients with stage IB2 carcinoma at a single institution between January 1982 and September 2006 was performed To adequately control treatment variables we only included patients who underwent their entire treatment at our institution Toxicity was assessed using NCI Common Toxicity Criteria CTC We identified 82 patients of whom 47 met the strict inclusion criteria Of these 27 patients 57 underwent primary radical hysterectomy RH and 20 43 were treated with definitive radiation/chemoradiation therapy RT/CRT Patients selected for RT/CRT had a higher American Society of Anesthesiologist ASA score than those selected for surgery P=0.037 The 3-year progression free survival rate was 52 for the RH group and 55 for the RT/CRT group P=0.977 The 3-year overall survival rates were 72 and 55 respectively P=0.161 Overall 52 of patients in the RH group received postoperative radiation therapy as part of their adjuvant treatment CTC grade 3 4 and 5 complications affected 5 patients 19 in the RH group and 3 15 in the RT/CRT group Both RH and definitive RT/CRT are adequate management strategies for patients with FIGO stage IB2 cancer However there was a subset of patients in whom RH as monotherapy was appropriate Further studies are needed to evaluate the role of new preoperative models that will accurately identify these patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 24, 1, 3837, 82, 9537, 12, 16, 2010, 114, 1130, 10, 6, 423, 24, 764, 123, 2, 521, 4, 7, 5, 82, 9537, 12, 8, 459, 45, 1, 7, 5, 82, 9537, 134, 28, 8, 226, 731, 59, 1024, 6652, 2, 2636, 1324, 10, 173, 6, 4215, 182, 24, 682, 21, 158, 159, 7, 54, 208, 136, 1797, 24, 28, 114, 731, 155, 10, 275, 75, 2580, 186, 155, 371, 1775, 21, 108, 878, 7, 1, 953, 662, 543, 3, 8043, 1680, 371, 1, 46, 428, 7, 696, 208, 86, 711, 2622, 7240, 2, 179, 601, 11, 73, 5, 1057, 121, 975, 36, 240, 1089, 7, 715, 9, 240, 1089, 42, 8, 142, 597, 1174, 1, 34544, 6453, 368, 76, 135, 715, 9, 152, 19, 13, 5171, 3, 27, 111, 91, 115, 25, 116, 10, 653, 9, 3, 7240, 87, 2, 614, 9, 3, 240, 1089, 87, 19, 13, 16407, 3, 27, 111, 63, 25, 151, 11, 720, 2, 614, 106, 19, 13, 5377, 63, 653, 1, 7, 4, 3, 7240, 87, 103, 573, 121, 36, 22, 760, 1, 136, 249, 24, 1775, 88, 27, 39, 2, 33, 521, 1424, 33, 7, 326, 4, 3, 7240, 87, 2, 27, 167, 4, 3, 240, 1089, 87, 110, 7240, 2, 1057, 240, 1089, 32, 1658, 284, 422, 9, 7, 5, 3837, 82, 9537, 12, 137, 125, 10, 8, 697, 1, 7, 4, 953, 7240, 22, 1411, 10, 870, 195, 94, 32, 575, 6, 376, 3, 200, 1, 217, 498, 274, 17, 303, 2141, 255, 46, 7]",1520.0,18774596,295
Radical hysterectomy in obese and morbidly obese women with cervical cancer.,Obstetrics and gynecology,Obstet Gynecol,2008-10-01,"To compare intraoperative and postoperative outcomes, pathologic findings, cancer recurrence, and death rates in normal-weight, overweight, obese, and morbidly obese women undergoing radical hysterectomy and pelvic lymphadenectomy for early-stage cervical cancer. A review of patients who underwent radical hysterectomy and pelvic lymphadenectomy for invasive cervical cancer between 1990 and 2006 was performed. On the basis of body mass index (BMI) (calculated as weight [kg]/[height (m)](2)), women were categorized as normal weight (BMI 18.5-24.9), overweight (BMI 25.0-29.9), obese (BMI 30.0-34.9), or morbidly obese (BMI at least 35.0). Four hundred eight women met the inclusion criteria. Of these, 155 (38%) were normal weight, 126 (31%) were overweight, 77 (19%) were obese, and 50 (12%) were morbidly obese. There were no statistically significant differences between these four groups in age, Charlson comorbidity score, smoking history, stage, histologic grade or subtype, tumor size, depth of invasion, transfusion rate, operative time, or intraoperative complications. Higher BMI was significantly correlated with higher estimated operative blood loss (P=.001). There were no statistically significant differences between the groups in pathologic findings, length of postoperative hospital stay, postoperative complications, readmission rate, or proportion of women receiving adjuvant radiotherapy. At a median follow-up time of 64 months, there were no differences between groups in rates of recurrence or death from disease. Radical hysterectomy and pelvic lymphadenectomy is feasible for obese and morbidly obese women with cervical cancer. Obesity alone should not be a contraindication to radical hysterectomy in women with cervical cancer.",Comparative Study,4129.0,23.0,To compare intraoperative and postoperative outcomes pathologic findings cancer recurrence and death rates in normal-weight overweight obese and morbidly obese women undergoing radical hysterectomy and pelvic lymphadenectomy for early-stage cancer A review of patients who underwent radical hysterectomy and pelvic lymphadenectomy for invasive cancer between 1990 and 2006 was performed On the basis of body mass index BMI calculated as weight kg height m 2 women were categorized as normal weight BMI 18.5-24.9 overweight BMI 25.0-29.9 obese BMI 30.0-34.9 or morbidly obese BMI at least 35.0 Four hundred eight women met the inclusion criteria Of these 155 38 were normal weight 126 31 were overweight 77 19 were obese and 50 12 were morbidly obese There were no statistically significant differences between these four groups in age Charlson comorbidity score smoking history stage histologic grade or subtype tumor size depth of invasion transfusion rate operative time or intraoperative complications Higher BMI was significantly correlated with higher estimated operative blood loss P=.001 There were no statistically significant differences between the groups in pathologic findings length of postoperative hospital stay postoperative complications readmission rate or proportion of women receiving adjuvant radiotherapy At a median follow-up time of 64 months there were no differences between groups in rates of recurrence or death from disease Radical hysterectomy and pelvic lymphadenectomy is feasible for obese and morbidly obese women with cancer Obesity alone should not be a contraindication to radical hysterectomy in women with cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 932, 1720, 2, 573, 123, 510, 272, 12, 146, 2, 273, 151, 4, 295, 924, 3566, 2209, 2, 9920, 2209, 117, 479, 711, 2622, 2, 1110, 2048, 9, 191, 82, 12, 8, 206, 1, 7, 54, 208, 711, 2622, 2, 1110, 2048, 9, 416, 12, 59, 2289, 2, 1324, 10, 173, 23, 3, 877, 1, 642, 782, 558, 1140, 981, 22, 924, 503, 4594, 188, 18, 117, 11, 2320, 22, 295, 924, 1140, 203, 33, 259, 83, 3566, 1140, 243, 13, 462, 83, 2209, 1140, 201, 13, 562, 83, 15, 9920, 2209, 1140, 28, 506, 465, 13, 294, 1128, 659, 117, 543, 3, 1680, 371, 1, 46, 3735, 519, 11, 295, 924, 3927, 456, 11, 3566, 849, 326, 11, 2209, 2, 212, 133, 11, 9920, 2209, 125, 11, 77, 712, 93, 362, 59, 46, 294, 271, 4, 89, 4670, 1879, 368, 979, 532, 82, 884, 88, 15, 875, 30, 444, 2436, 1, 578, 2785, 116, 1208, 98, 15, 1720, 521, 142, 1140, 10, 97, 438, 5, 142, 661, 1208, 315, 407, 19, 144, 125, 11, 77, 712, 93, 362, 59, 3, 271, 4, 510, 272, 1318, 1, 573, 702, 2020, 573, 521, 3146, 116, 15, 920, 1, 117, 357, 249, 310, 28, 8, 52, 166, 126, 98, 1, 660, 53, 125, 11, 77, 362, 59, 271, 4, 151, 1, 146, 15, 273, 29, 34, 711, 2622, 2, 1110, 2048, 16, 1313, 9, 2209, 2, 9920, 2209, 117, 5, 12, 1661, 279, 257, 44, 40, 8, 8363, 6, 711, 2622, 4, 117, 5, 12]",1651.0,18827134,24
The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease.,Gynecologic oncology,Gynecol. Oncol.,2008-10-16,"The aim was to describe the rate of laparoscopic trocar-related subcutaneous tumor implants in women with underlying malignant disease. An analysis of a prospective database of all patients undergoing transperitoneal laparoscopic procedures for malignant conditions performed by the gynecologic oncology service. Between July 1991 and April 2007, laparoscopic procedures were performed in 1694 patients with a malignant intraabdominal condition and in 505 breast cancer patients undergoing risk-reducing, diagnostic or therapeutic laparoscopic procedures without intraabdominal disease. Port-site metastases were documented in 20 of 1694 patients (1.18%) who underwent laparoscopic procedures for a malignant intraabdominal condition. Of these, 15 patients had a diagnosis of epithelial ovarian or fallopian tube carcinoma, 2 had breast cancer, 2 had cervical cancer, and 1 had uterine cancer. Nineteen of 20 patients (95%) had simultaneous carcinomatosis or metastases to other sites at the time of port-site metastasis. Patients who developed port-site metastases within 7 months from the laparoscopic procedure had a median survival of 12 months whereas patients who developed port-site metastasis >7 months had a median survival of 37 months (P=0.004). No port-site recurrence was documented in patients undergoing risk-reducing, diagnostic or therapeutic laparoscopic procedures for breast cancer without intraabdominal disease. The rate of port-site tumor implantation after laparoscopic procedures in women with malignant disease is low and almost always occurs in the setting of synchronous, advanced intraabdominal or distant metastatic disease. The presence of port-site implantation is a surrogate for advanced disease and should not be used as an argument against laparoscopic surgery in gynecologic malignancies.",Journal Article,4114.0,111.0,The aim was to describe the rate of laparoscopic trocar-related subcutaneous tumor implants in women with underlying malignant disease An analysis of a prospective database of all patients undergoing transperitoneal laparoscopic procedures for malignant conditions performed by the gynecologic oncology service Between July 1991 and April 2007 laparoscopic procedures were performed in 1694 patients with a malignant intraabdominal condition and in 505 cancer patients undergoing risk-reducing diagnostic or therapeutic laparoscopic procedures without intraabdominal disease Port-site metastases were documented in 20 of 1694 patients 1.18 who underwent laparoscopic procedures for a malignant intraabdominal condition Of these 15 patients had a diagnosis of epithelial or tube carcinoma 2 had cancer 2 had cancer and 1 had cancer Nineteen of 20 patients 95 had simultaneous carcinomatosis or metastases to other sites at the time of port-site metastasis Patients who developed port-site metastases within 7 months from the laparoscopic procedure had a median survival of 12 months whereas patients who developed port-site metastasis 7 months had a median survival of 37 months P=0.004 No port-site recurrence was documented in patients undergoing risk-reducing diagnostic or therapeutic laparoscopic procedures for cancer without intraabdominal disease The rate of port-site tumor implantation after laparoscopic procedures in women with malignant disease is low and almost always occurs in the setting of synchronous advanced intraabdominal or distant metastatic disease The presence of port-site implantation is a surrogate for advanced disease and should not be used as an argument against laparoscopic surgery in gynecologic malignancies,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 1130, 10, 6, 897, 3, 116, 1, 1964, 11980, 139, 2529, 30, 5966, 4, 117, 5, 1181, 393, 34, 35, 65, 1, 8, 482, 609, 1, 62, 7, 479, 12145, 1964, 1369, 9, 393, 1298, 173, 20, 3, 1512, 413, 3086, 59, 2066, 3372, 2, 2292, 1307, 1964, 1369, 11, 173, 4, 38839, 7, 5, 8, 393, 12723, 2850, 2, 4, 9766, 12, 7, 479, 43, 1818, 752, 15, 189, 1964, 1369, 187, 12723, 34, 3083, 606, 196, 11, 1405, 4, 179, 1, 38839, 7, 14, 203, 54, 208, 1964, 1369, 9, 8, 393, 12723, 2850, 1, 46, 167, 7, 42, 8, 147, 1, 701, 15, 2330, 134, 18, 42, 12, 18, 42, 12, 2, 14, 42, 12, 3498, 1, 179, 7, 48, 42, 2824, 5622, 15, 196, 6, 127, 633, 28, 3, 98, 1, 3083, 606, 278, 7, 54, 276, 3083, 606, 196, 262, 67, 53, 29, 3, 1964, 1299, 42, 8, 52, 25, 1, 133, 53, 547, 7, 54, 276, 3083, 606, 278, 67, 53, 42, 8, 52, 25, 1, 567, 53, 19, 13, 1520, 77, 3083, 606, 146, 10, 1405, 4, 7, 479, 43, 1818, 752, 15, 189, 1964, 1369, 9, 12, 187, 12723, 34, 3, 116, 1, 3083, 606, 30, 4314, 50, 1964, 1369, 4, 117, 5, 393, 34, 16, 154, 2, 2214, 3763, 1780, 4, 3, 546, 1, 2734, 131, 12723, 15, 626, 113, 34, 3, 463, 1, 3083, 606, 4314, 16, 8, 2592, 9, 131, 34, 2, 257, 44, 40, 95, 22, 35, 17140, 480, 1964, 152, 4, 1512, 441]",1742.0,18929404,34
"Effectiveness of decentralized community-based screening, detection, and treatment of breast cancer in low-income, uninsured women.",The American surgeon,Am Surg,2008-10-01,"Different systems exist currently in the provision of breast care to low-income, uninsured women. We assessed the efficacy of screening, diagnosis, and treatment of breast cancer in this patient population through a decentralized network of providers. We retrospectively reviewed charts of all patients referred for evaluation and treatment under the Cancer Detection Program: Every Woman Counts (CDP:EWC), the California equivalent of the National Breast and Cervical Cancer Detection and Prevention Program, in a suburban area of Los Angeles County. A total of 972 CDP:EWC screening mammograms was performed in the Antelope Valley during a 7-year study period (2000 to 2007). Sixty-two screened women aged 40 to 64 years were referred for further evaluation. Breast cancer detection rate per screening mammogram was 0.8 per cent; 80 per cent were early-stage breast cancer. The majority of the women (nine of 15) underwent breast conservation surgery. The axilla was staged using sentinel lymph node dissection and/or axillary lymph node dissection. Adjuvant chemotherapy and radiation were administered to all eligible patients. Compliance with published practice guidelines was high. This suggests that a decentralized community-based network of providers may be an effective model to deliver breast care to a low-income, uninsured patient population.",Comparative Study,4129.0,1.0,Different systems exist currently in the provision of care to low-income uninsured women We assessed the efficacy of screening diagnosis and treatment of cancer in this patient population through a decentralized network of providers We retrospectively reviewed charts of all patients referred for evaluation and treatment under the Cancer Detection Program Every Woman Counts CDP EWC the California equivalent of the National and Cancer Detection and Prevention Program in a suburban area of Los Angeles County A total of 972 CDP EWC screening mammograms was performed in the Antelope Valley during a 7-year study period 2000 to 2007 Sixty-two screened women aged 40 to 64 years were referred for further evaluation cancer detection rate per screening mammogram was 0.8 per cent 80 per cent were early-stage cancer The majority of the women nine of 15 underwent conservation surgery The axilla was staged using sentinel lymph node dissection and/or axillary lymph node dissection Adjuvant chemotherapy and radiation were administered to all eligible patients Compliance with published practice guidelines was high This suggests that a decentralized community-based network of providers may be an effective model to deliver care to a low-income uninsured patient population,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[338, 1530, 1923, 694, 4, 3, 6832, 1, 165, 6, 154, 2306, 4955, 117, 21, 275, 3, 209, 1, 453, 147, 2, 24, 1, 12, 4, 26, 69, 266, 298, 8, 33294, 1801, 1, 1994, 21, 894, 446, 4413, 1, 62, 7, 1995, 9, 451, 2, 24, 669, 3, 12, 638, 1243, 454, 2854, 1911, 19629, 45299, 3, 4355, 2017, 1, 3, 657, 2, 12, 638, 2, 1070, 1243, 4, 8, 38841, 965, 1, 3649, 6694, 5152, 8, 181, 1, 11959, 19629, 45299, 453, 6329, 10, 173, 4, 3, 57446, 17624, 190, 8, 67, 111, 45, 727, 1081, 6, 1307, 1746, 100, 2261, 117, 1032, 327, 6, 660, 60, 11, 1995, 9, 195, 451, 12, 638, 116, 379, 453, 5129, 10, 13, 66, 379, 6548, 493, 379, 6548, 11, 191, 82, 12, 3, 686, 1, 3, 117, 762, 1, 167, 208, 3351, 152, 3, 5053, 10, 2930, 75, 1323, 263, 289, 1161, 2, 15, 1210, 263, 289, 1161, 249, 56, 2, 121, 11, 468, 6, 62, 625, 7, 3336, 5, 983, 758, 677, 10, 64, 26, 844, 17, 8, 33294, 1714, 90, 1801, 1, 1994, 68, 40, 35, 323, 202, 6, 3392, 165, 6, 8, 154, 2306, 4955, 69, 266]",1272.0,18942635,268
Radical vaginal versus abdominal trachelectomy for stage IB1 cervical cancer: a comparison of surgical and pathologic outcomes.,Gynecologic oncology,Gynecol. Oncol.,2008-10-29,"To compare the surgical and pathologic outcomes utilizing two surgical approaches for fertility-sparing radical trachelectomy in patients with stage IB1 cervical cancer. A prospectively maintained database of vaginal radical trachelectomy (VRT) and abdominal radical trachelectomy (ART) procedures was analyzed. All procedures were performed in a standardized manner by the same surgical group. Parametrial measurements were recorded from the final pathology report. Standard statistical tests were used. Between 12/2001 and 7/2007, 43 adult patients with FIGO stage IB1 cervical cancer underwent surgery with the intent to perform a fertility-sparing radical trachelectomy. VRT was attempted in 28 patients (65%) and ART in 15 patients (35%). The median measured parametrial length in the VRT group was 1.45 cm compared to 3.97 cm in the ART group, P<0.0001. None of the parametrial specimens in the VRT group contained parametrial nodes. Parametrial nodes were detected in 8 (57.3%) of the ART specimens (P=0.0002). There was no difference in histologic subtypes, lymph vascular space invasion, or median total regional lymph nodes removed in the two groups. Median blood loss was greater but not clinically significant in the ART group, and median operating time was less in the ART group. The overall complication rate was not significantly different in the two groups. Using standardized techniques, radical abdominal trachelectomy provides similar surgical and pathologic outcomes with possibly a wider parametrial resection, including contiguous parametrial nodes, as compared to the radical vaginal approach.",Comparative Study,4101.0,81.0,To compare the surgical and pathologic outcomes utilizing two surgical approaches for fertility-sparing radical trachelectomy in patients with stage IB1 cancer A prospectively maintained database of radical trachelectomy VRT and abdominal radical trachelectomy ART procedures was analyzed All procedures were performed in a standardized manner by the same surgical group Parametrial measurements were recorded from the final pathology report Standard statistical tests were used Between 12/2001 and 7/2007 43 adult patients with FIGO stage IB1 cancer underwent surgery with the intent to perform a fertility-sparing radical trachelectomy VRT was attempted in 28 patients 65 and ART in 15 patients 35 The median measured parametrial length in the VRT group was 1.45 cm compared to 3.97 cm in the ART group P 0.0001 None of the parametrial specimens in the VRT group contained parametrial nodes Parametrial nodes were detected in 8 57.3 of the ART specimens P=0.0002 There was no difference in histologic subtypes lymph vascular space invasion or median total regional lymph nodes removed in the two groups Median blood loss was greater but not clinically significant in the ART group and median operating time was less in the ART group The overall complication rate was not significantly different in the two groups Using standardized techniques radical abdominal trachelectomy provides similar surgical and pathologic outcomes with possibly a wider parametrial resection including contiguous parametrial nodes as compared to the radical approach,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 932, 3, 221, 2, 510, 123, 2600, 100, 221, 611, 9, 2954, 1851, 711, 5760, 4, 7, 5, 82, 8111, 12, 8, 1143, 1955, 609, 1, 711, 5760, 26757, 2, 1467, 711, 5760, 4363, 1369, 10, 311, 62, 1369, 11, 173, 4, 8, 1670, 1708, 20, 3, 827, 221, 87, 8726, 1685, 11, 1872, 29, 3, 1457, 1117, 414, 260, 1050, 895, 11, 95, 59, 133, 1758, 2, 67, 1307, 601, 780, 7, 5, 3837, 82, 8111, 12, 208, 152, 5, 3, 1697, 6, 2715, 8, 2954, 1851, 711, 5760, 26757, 10, 4098, 4, 339, 7, 556, 2, 4363, 4, 167, 7, 465, 3, 52, 644, 8726, 1318, 4, 3, 26757, 87, 10, 14, 512, 494, 72, 6, 27, 1015, 494, 4, 3, 4363, 87, 19, 13, 488, 1292, 1, 3, 8726, 623, 4, 3, 26757, 87, 3070, 8726, 502, 8726, 502, 11, 530, 4, 66, 696, 27, 1, 3, 4363, 623, 19, 13, 3531, 125, 10, 77, 523, 4, 884, 814, 263, 756, 3865, 578, 15, 52, 181, 951, 263, 502, 2264, 4, 3, 100, 271, 52, 315, 407, 10, 378, 84, 44, 505, 93, 4, 3, 4363, 87, 2, 52, 2584, 98, 10, 299, 4, 3, 4363, 87, 3, 63, 1447, 116, 10, 44, 97, 338, 4, 3, 100, 271, 75, 1670, 1092, 711, 1467, 5760, 777, 288, 221, 2, 510, 123, 5, 2150, 8, 7771, 8726, 170, 141, 10941, 8726, 502, 22, 72, 6, 3, 711, 353]",1545.0,18973933,720
A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2008-11-01,"Topotecan improves response rate (RR), progression-free survival (PFS) and overall survival (OS) when added to cisplatin in treating metastatic and recurrent cervical cancer. The objective of this study was to assess the feasibility of adding weekly topotecan to cisplatin in patients with primary, locally advanced carcinoma of the cervix receiving pelvic irradiation. Patients with primary, previously untreated, histologically confirmed invasive squamous cell, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix, stages IB2-IVA were treated with external beam pelvic radiotherapy (45 Gy), intracavitary low dose rate brachytherapy (40 Gy) and a parametrial boost (5.4-9 Gy) with overall treatment time not to exceed 8 weeks. Concurrent chemotherapy was IV cisplatin 40 mg/m(2)plus IV topotecan 2 mg/m(2) on days 1, 8, 15, 22, 29 and once during parametrial boost for 6 cycles. Patients were monitored with history, physical examination, tumor measurement and laboratory evaluation before entering the study, before each cycle of chemotherapy, at study termination and every three months thereafter. The study met its accrual goal of 12 patients. With a median follow-up of 22 months, eleven patients completed treatment and ten are in long term follow up without evidence of recurrent disease. The 12th patient developed progressive disease during therapy. All patients completed at least 4 cycles of chemotherapy, with the majority (82%) completing 5 or more. Grade 2 or higher neutropenia delayed treatment in 54% of cycles. The median treatment delay was 1.5 cycles (range: 1 to 5 cycles). Median treatment time was 59 days (range 46 to 81 days). The complete RR was 92% (95% confidence interval, 55%-100%). The addition of weekly topotecan to cisplatin at this dose and schedule during pelvic irradiation for locally advanced cervical cancer appears to be feasible. Based on this primary treatment data and the activity of cisplatin-topotecan in the recurrent disease setting, phase II and III studies of this combination are warranted.",Clinical Trial,4098.0,14.0,Topotecan improves response rate RR progression-free survival PFS and overall survival OS when added to cisplatin in treating metastatic and recurrent cancer The objective of this study was to assess the feasibility of adding weekly topotecan to cisplatin in patients with primary locally advanced carcinoma of the cervix receiving pelvic irradiation Patients with primary previously untreated histologically confirmed invasive squamous cell adenocarcinoma or adenosquamous carcinoma of the cervix stages IB2-IVA were treated with external beam pelvic radiotherapy 45 Gy intracavitary low dose rate brachytherapy 40 Gy and a parametrial boost 5.4-9 Gy with overall treatment time not to exceed 8 weeks Concurrent chemotherapy was IV cisplatin 40 mg/m 2 plus IV topotecan 2 mg/m 2 on days 1 8 15 22 29 and once during parametrial boost for 6 cycles Patients were monitored with history physical examination tumor measurement and laboratory evaluation before entering the study before each cycle of chemotherapy at study termination and every three months thereafter The study met its accrual goal of 12 patients With a median follow-up of 22 months eleven patients completed treatment and ten are in long term follow up without evidence of recurrent disease The 12th patient developed progressive disease during therapy All patients completed at least 4 cycles of chemotherapy with the majority 82 completing 5 or more Grade 2 or higher neutropenia delayed treatment in 54 of cycles The median treatment delay was 1.5 cycles range 1 to 5 cycles Median treatment time was 59 days range 46 to 81 days The complete RR was 92 95 confidence interval 55 -100 The addition of weekly topotecan to cisplatin at this dose and schedule during pelvic irradiation for locally advanced cancer appears to be feasible Based on this primary treatment data and the activity of cisplatin-topotecan in the recurrent disease setting phase II and III studies of this combination are warranted,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[2129, 1804, 51, 116, 861, 91, 115, 25, 300, 2, 63, 25, 118, 198, 1953, 6, 540, 4, 1367, 113, 2, 387, 12, 3, 461, 1, 26, 45, 10, 6, 423, 3, 1437, 1, 2726, 709, 2129, 6, 540, 4, 7, 5, 86, 795, 131, 134, 1, 3, 3629, 357, 1110, 1104, 7, 5, 86, 373, 1278, 2161, 557, 416, 691, 31, 449, 15, 8067, 134, 1, 3, 3629, 1153, 9537, 5900, 11, 73, 5, 1455, 1345, 1110, 310, 512, 381, 9122, 154, 61, 116, 1536, 327, 381, 2, 8, 8726, 2569, 33, 39, 83, 381, 5, 63, 24, 98, 44, 6, 6818, 66, 244, 750, 56, 10, 478, 540, 327, 81, 188, 18, 349, 478, 2129, 18, 81, 188, 18, 23, 162, 14, 66, 167, 350, 462, 2, 1059, 190, 8726, 2569, 9, 49, 410, 7, 11, 2909, 5, 532, 900, 1385, 30, 2204, 2, 1624, 451, 348, 7653, 3, 45, 348, 296, 417, 1, 56, 28, 45, 7202, 2, 454, 169, 53, 3972, 3, 45, 543, 211, 2262, 1326, 1, 133, 7, 5, 8, 52, 166, 126, 1, 350, 53, 2627, 7, 781, 24, 2, 1618, 32, 4, 319, 337, 166, 126, 187, 241, 1, 387, 34, 3, 26659, 69, 276, 1014, 34, 190, 36, 62, 7, 781, 28, 506, 39, 410, 1, 56, 5, 3, 686, 878, 4144, 33, 15, 80, 88, 18, 15, 142, 778, 1612, 24, 4, 667, 1, 410, 3, 52, 24, 1984, 10, 14, 33, 410, 184, 14, 6, 33, 410, 52, 24, 98, 10, 728, 162, 184, 641, 6, 865, 162, 3, 236, 861, 10, 937, 48, 307, 268, 614, 394, 3, 352, 1, 709, 2129, 6, 540, 28, 26, 61, 2, 1055, 190, 1110, 1104, 9, 795, 131, 12, 1233, 6, 40, 1313, 90, 23, 26, 86, 24, 74, 2, 3, 128, 1, 540, 2129, 4, 3, 387, 34, 546, 124, 215, 2, 316, 94, 1, 26, 150, 32, 1197]",1969.0,18977518,120
A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a Gynecologic Oncology Group study.,Gynecologic oncology,Gynecol. Oncol.,2008-11-17,"To determine the maximum tolerated dose (MTD) of weekly paclitaxel and cisplatin chemotherapy concurrent with extended field irradiation in women with cervical cancer metastatic to the para-aortic nodes. Patients with carcinoma of the cervix and histologically documented para-aortic node metastases were eligible for this phase I/II trial. Chemotherapy agents were administered weekly concurrent with extended field radiation with escalating doses of paclitaxel from 30-50 mg/m(2) in each of three cohorts of three patients each. A phase II cohort was then evaluated at the selected maximum tolerated dose (MTD). The MTD was determined to be cisplatin 40 mg/m(2) (maximum dose of 70 mg) and paclitaxel 40 mg/m(2) administered weekly for six cycles concurrent with extended field radiation therapy. There were 19 evaluable patients for the phase II analysis of toxicity and efficacy. Grade three and four gastrointestinal toxicity was seen in 6 and neutropenia in 7. Radiation therapy was successfully completed in 36.8% of patients at eight weeks and in 68.4% of patients at nine weeks, with a median time to completion was 56 days. A total of 27 evaluable patients were enrolled, twelve are dead (mean survival of those deceased is 25 months), and 15 (56%) are alive, and have been followed for a mean of 48 months (range 25-68; median of 46 months). Paclitaxel and cisplatin combination chemotherapy concurrent with extended field pelvic para-aortic irradiation can be administered at the described MTD and shows a higher than previously reported disease-free survival in relation to historical data. The 56% survival to date, and 50% estimated 48 month survival, warrants validation in a larger prospective cohort. Central radiation dose reduction is being considered in the next trial to decrease late toxicity of regimen.","Clinical Trial, Phase I",4082.0,37.0,To determine the maximum tolerated dose MTD of weekly paclitaxel and cisplatin chemotherapy concurrent with extended field irradiation in women with cancer metastatic to the para-aortic nodes Patients with carcinoma of the cervix and histologically documented para-aortic node metastases were eligible for this phase I/II trial Chemotherapy agents were administered weekly concurrent with extended field radiation with escalating doses of paclitaxel from 30-50 mg/m 2 in each of three cohorts of three patients each A phase II cohort was then evaluated at the selected maximum tolerated dose MTD The MTD was determined to be cisplatin 40 mg/m 2 maximum dose of 70 mg and paclitaxel 40 mg/m 2 administered weekly for six cycles concurrent with extended field radiation therapy There were 19 evaluable patients for the phase II analysis of toxicity and efficacy Grade three and four toxicity was seen in 6 and neutropenia in 7 Radiation therapy was successfully completed in 36.8 of patients at eight weeks and in 68.4 of patients at nine weeks with a median time to completion was 56 days A total of 27 evaluable patients were enrolled twelve are dead mean survival of those deceased is 25 months and 15 56 are alive and have been followed for a mean of 48 months range 25-68 median of 46 months Paclitaxel and cisplatin combination chemotherapy concurrent with extended field pelvic para-aortic irradiation can be administered at the described MTD and shows a higher than previously reported disease-free survival in relation to historical data The 56 survival to date and 50 estimated 48 month survival warrants validation in a larger prospective cohort Central radiation dose reduction is being considered in the next trial to decrease late toxicity of regimen,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 689, 421, 61, 961, 1, 709, 490, 2, 540, 56, 750, 5, 1747, 1067, 1104, 4, 117, 5, 12, 113, 6, 3, 4615, 3938, 502, 7, 5, 134, 1, 3, 3629, 2, 2161, 1405, 4615, 3938, 289, 196, 11, 625, 9, 26, 124, 70, 215, 160, 56, 183, 11, 468, 709, 750, 5, 1747, 1067, 121, 5, 2922, 415, 1, 490, 29, 201, 212, 81, 188, 18, 4, 296, 1, 169, 736, 1, 169, 7, 296, 8, 124, 215, 180, 10, 818, 194, 28, 3, 715, 689, 421, 61, 961, 3, 961, 10, 509, 6, 40, 540, 327, 81, 188, 18, 689, 61, 1, 431, 81, 2, 490, 327, 81, 188, 18, 468, 709, 9, 437, 410, 750, 5, 1747, 1067, 121, 36, 125, 11, 326, 859, 7, 9, 3, 124, 215, 65, 1, 155, 2, 209, 88, 169, 2, 294, 155, 10, 527, 4, 49, 2, 778, 4, 67, 121, 36, 10, 1878, 781, 4, 511, 66, 1, 7, 28, 659, 244, 2, 4, 806, 39, 1, 7, 28, 762, 244, 5, 8, 52, 98, 6, 1438, 10, 664, 162, 8, 181, 1, 428, 859, 7, 11, 346, 2544, 32, 8311, 313, 25, 1, 135, 11956, 16, 243, 53, 2, 167, 664, 32, 1701, 2, 47, 85, 370, 9, 8, 313, 1, 576, 53, 184, 243, 806, 52, 1, 641, 53, 490, 2, 540, 150, 56, 750, 5, 1747, 1067, 1110, 4615, 3938, 1104, 122, 40, 468, 28, 3, 1027, 961, 2, 1949, 8, 142, 76, 373, 210, 34, 115, 25, 4, 2191, 6, 2252, 74, 3, 664, 25, 6, 1244, 2, 212, 661, 576, 811, 25, 2782, 929, 4, 8, 1077, 482, 180, 854, 121, 61, 628, 16, 486, 515, 4, 3, 1305, 160, 6, 775, 807, 155, 1, 477]",1762.0,19010522,296
Proteomics-based approach to elucidate the mechanism of antitumor effect of curcumin in cervical cancer.,"Prostaglandins, leukotrienes, and essential fatty acids",Prostaglandins Leukot. Essent. Fatty Acids,2008-12-05,"Cervical cancer is the second leading cause of cancer death for women in the world. A potential target for preventing and treating cervical cancer is cyclooxygenase-2 (cox-2). Curcumin is an anti-inflammatory agent that is known to have anti-cox-2 activity. In this study we examined the expression of cox-2 in cervical cancer and its precursors by immunohistochemistry. The effect of curcumin in inhibiting cervical cancer cells was determined via 2-dimensional gel electrophoresis, data analysis, and ingenuity pathway analysis. No significant differences in the expression of cox-2 in squamous cell carcinoma, and carcinoma in situ were observed. However, there was a statistically significant difference in the expression of cox-2 in adenocarcinoma in comparison to normal (p value=0.01) and squamous cell carcinoma (p value=0.02) tissues. Proteins associated with cancer and cell cycle were significantly altered in cultured cells. Curcumin may have antitumor effect in cervical cancer.",Journal Article,4064.0,28.0,cancer is the second leading cause of cancer death for women in the world A potential target for preventing and treating cancer is cyclooxygenase-2 cox-2 Curcumin is an anti-inflammatory agent that is known to have anti-cox-2 activity In this study we examined the expression of cox-2 in cancer and its precursors by immunohistochemistry The effect of curcumin in inhibiting cancer cells was determined via 2-dimensional gel electrophoresis data analysis and ingenuity pathway analysis No significant differences in the expression of cox-2 in squamous cell carcinoma and carcinoma in situ were observed However there was a statistically significant difference in the expression of cox-2 in adenocarcinoma in comparison to normal p value=0.01 and squamous cell carcinoma p value=0.02 tissues Proteins associated with cancer and cell cycle were significantly altered in cultured cells Curcumin may have antitumor effect in cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 3, 419, 1049, 708, 1, 12, 273, 9, 117, 4, 3, 1956, 8, 174, 283, 9, 3017, 2, 1367, 12, 16, 4043, 18, 418, 18, 3775, 16, 35, 312, 1291, 420, 17, 16, 440, 6, 47, 312, 418, 18, 128, 4, 26, 45, 21, 409, 3, 55, 1, 418, 18, 4, 12, 2, 211, 4881, 20, 888, 3, 254, 1, 3775, 4, 2062, 12, 37, 10, 509, 847, 18, 2201, 5916, 6777, 74, 65, 2, 12609, 308, 65, 77, 93, 362, 4, 3, 55, 1, 418, 18, 4, 691, 31, 134, 2, 134, 4, 957, 11, 164, 137, 125, 10, 8, 712, 93, 523, 4, 3, 55, 1, 418, 18, 4, 449, 4, 1155, 6, 295, 19, 549, 13, 355, 2, 691, 31, 134, 19, 549, 13, 588, 742, 652, 41, 5, 12, 2, 31, 417, 11, 97, 1495, 4, 3197, 37, 3775, 68, 47, 579, 254, 4, 12]",927.0,19058955,415
"Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.",Gynecologic oncology,Gynecol. Oncol.,2008-12-24,"To determine whether markers of tumor angiogenesis were associated with progression-free survival (PFS) and overall survival (OS) in women with high-risk, early-stage cervical cancer treated on a phase III trial. One hundred seventy-three tumor specimens were analyzed by semi-quantitative immunohistochemical (IHC) staining for vascular endothelial growth factor (VEGF, pro-angiogenesis factor), thrombospondin-1 (TSP-1, anti-angiogenesis factor), CD31 (non-specific endothelial marker), and CD105 (tumor-specific endothelial marker). Tumoral histoscores (HS) were calculated for VEGF using the formula: [% cells positivex(intensity+1)]. TSP-1 specimens were categorized as negative or positive. CD31 and CD105 microvessel density (MVD) ""hotspots"" were counted in three 20x high-power fields. Associations between angiogenesis markers and survival were evaluated. TSP-1 expression was observed in 65% of cases while 66% expressed high VEGF (>or=200), 34% exhibited high CD31 (CD31>or=110) and 66% displayed high CD105 (CD105>or=28). In univariate analyses CD31 MVD, but not tumor TSP-1, was associated with improved PFS (HR=0.37; 95% CI=0.18-0.76; p=0.007) and OS (HR=0.37; 95% CI=0.17-0.79; p=0.010). After adjusting for prognostic clinical covariates, high CD31 MVD, but not TSP-1, VEGF or CD105 MVD, was an independent prognostic factor for PFS (HR=0.36; 95% CI=0.17-0.75; p=0.006) and OS (HR=0.36; 95% CI=0.17-0.79; p=0.010). Tumor angiogenesis measured by CD31 MVD is an independent prognostic factor for both PFS and OS in high-risk, early-stage cervical cancer. We hypothesize that this finding may be explained by improved treatment response in well-vascularized, well-oxygenated tumors.","Clinical Trial, Phase III",4045.0,59.0,To determine whether markers of tumor angiogenesis were associated with progression-free survival PFS and overall survival OS in women with high-risk early-stage cancer treated on a phase III trial One hundred seventy-three tumor specimens were analyzed by semi-quantitative immunohistochemical IHC staining for vascular endothelial growth factor VEGF pro-angiogenesis factor thrombospondin-1 TSP-1 anti-angiogenesis factor CD31 non-specific endothelial marker and CD105 tumor-specific endothelial marker Tumoral histoscores HS were calculated for VEGF using the formula cells positivex intensity+1 TSP-1 specimens were categorized as negative or positive CD31 and CD105 microvessel density MVD `` hotspots '' were counted in three 20x high-power fields Associations between angiogenesis markers and survival were evaluated TSP-1 expression was observed in 65 of cases while 66 expressed high VEGF or=200 34 exhibited high CD31 CD31 or=110 and 66 displayed high CD105 CD105 or=28 In univariate analyses CD31 MVD but not tumor TSP-1 was associated with improved PFS HR=0.37 95 CI=0.18-0.76 p=0.007 and OS HR=0.37 95 CI=0.17-0.79 p=0.010 After adjusting for prognostic clinical covariates high CD31 MVD but not TSP-1 VEGF or CD105 MVD was an independent prognostic factor for PFS HR=0.36 95 CI=0.17-0.75 p=0.006 and OS HR=0.36 95 CI=0.17-0.79 p=0.010 Tumor angiogenesis measured by CD31 MVD is an independent prognostic factor for both PFS and OS in high-risk early-stage cancer We hypothesize that this finding may be explained by improved treatment response in well-vascularized well-oxygenated tumors,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 317, 525, 1, 30, 1056, 11, 41, 5, 91, 115, 25, 300, 2, 63, 25, 118, 4, 117, 5, 64, 43, 191, 82, 12, 73, 23, 8, 124, 316, 160, 104, 1128, 2073, 169, 30, 623, 11, 311, 20, 6399, 1156, 1382, 1289, 1029, 9, 756, 845, 129, 161, 618, 1805, 1056, 161, 12596, 14, 9545, 14, 312, 1056, 161, 6019, 220, 112, 845, 952, 2, 11822, 30, 112, 845, 952, 4204, 57600, 5871, 11, 981, 9, 618, 75, 3, 7986, 37, 57601, 837, 14, 9545, 14, 623, 11, 2320, 22, 199, 15, 109, 6019, 2, 11822, 4269, 1263, 6066, 11193, 522, 11, 12252, 4, 169, 45385, 64, 2349, 3130, 685, 59, 1056, 525, 2, 25, 11, 194, 9545, 14, 55, 10, 164, 4, 556, 1, 140, 369, 700, 570, 64, 618, 15, 1250, 562, 1416, 64, 6019, 6019, 15, 3129, 2, 700, 2507, 64, 11822, 11822, 15, 339, 4, 880, 318, 6019, 6066, 84, 44, 30, 9545, 14, 10, 41, 5, 231, 300, 168, 13, 567, 48, 58, 13, 203, 13, 846, 19, 13, 1999, 2, 118, 168, 13, 567, 48, 58, 13, 269, 13, 842, 19, 13, 4873, 50, 1358, 9, 177, 38, 2489, 64, 6019, 6066, 84, 44, 9545, 14, 618, 15, 11822, 6066, 10, 35, 306, 177, 161, 9, 300, 168, 13, 511, 48, 58, 13, 269, 13, 481, 19, 13, 1861, 2, 118, 168, 13, 511, 48, 58, 13, 269, 13, 842, 19, 13, 4873, 30, 1056, 644, 20, 6019, 6066, 16, 35, 306, 177, 161, 9, 110, 300, 2, 118, 4, 64, 43, 191, 82, 12, 21, 4919, 17, 26, 1567, 68, 40, 3672, 20, 231, 24, 51, 4, 149, 12266, 149, 31182, 57]",1601.0,19110305,773
Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2009-01-01,"Human papillomavirus (HPV) cofactors for cervical cancer include smoking, multiparity, and oral contraceptive use, but their mechanisms of action are not fully understood. It is also unknown whether cofactors vary by HPV genotypes. The Study to Understand Cervical Cancer Early Endpoints and Determinants (SUCCEED) is a cross-sectional study comprising women referred to the University of Oklahoma from November 2003 to September 2007 for abnormal cervical screening results. Detailed questionnaire data and liquid cytology specimens were collected and the latter was genotyped for HPV using the LINEAR ARRAY HPV Genotyping Test. The present analysis includes women with both questionnaire and HPV data and diagnosed with <CIN1 (n = 535), CIN1 (n = 497), CIN2 (n = 336), CIN3 (n = 292), and cancer (n = 80). We evaluated HPV types and cofactors among HPV-infected women by calculating odds ratios (OR) and 95% confidence intervals (95% CI) for CIN3 and CIN2 separately compared with <CIN2 using a polytomous logistic regression model; cancers were excluded from further analysis due to the substantially higher ages of these women. We found that HPV-infected women with minor histologic or cytologic abnormalities (e.g., CIN1, ASCUS, and LSIL) were indistinguishable from those with normal histology/cytology and were thus combined to form the referent group (<CIN2). Among women positive for oncogenic HPV, current smokers had a 2.5-fold increased risk for CIN3 (95% CI, 1.8-3.6) compared with nonsmokers. Among HPV16-infected women, current smokers had elevated risk for both CIN2 (OR, 1.9; 95% CI, 1.1-3.2) and CIN3 (OR, 2.7; 95% CI, 1.6-4.6). Our data suggest that non-HPV16-related CIN2 likely reflects a combination of CIN1 and CIN3 diagnosis, whereas HPV16-related CIN2 may indicate a precancerous state. Investigations on the molecular distinctions along the disease continuum of cervical pathogenesis by HPV type are needed.",Journal Article,4037.0,70.0,Human papillomavirus HPV cofactors for cancer include smoking multiparity and oral contraceptive use but their mechanisms of action are not fully understood It is also unknown whether cofactors vary by HPV genotypes The Study to Understand Cancer Early Endpoints and Determinants SUCCEED is a cross-sectional study comprising women referred to the University of Oklahoma from November 2003 to September 2007 for abnormal screening results Detailed questionnaire data and liquid cytology specimens were collected and the latter was genotyped for HPV using the LINEAR ARRAY HPV Genotyping Test The present analysis includes women with both questionnaire and HPV data and diagnosed with CIN1 n 535 CIN1 n 497 CIN2 n 336 CIN3 n 292 and cancer n 80 We evaluated HPV types and cofactors among HPV-infected women by calculating odds ratios OR and 95 confidence intervals 95 CI for CIN3 and CIN2 separately compared with CIN2 using a polytomous logistic regression model cancers were excluded from further analysis due to the substantially higher ages of these women We found that HPV-infected women with minor histologic or cytologic abnormalities e.g. CIN1 ASCUS and LSIL were indistinguishable from those with normal histology/cytology and were thus combined to form the referent group CIN2 Among women positive for oncogenic HPV current smokers had a 2.5-fold increased risk for CIN3 95 CI 1.8-3.6 compared with nonsmokers Among HPV16-infected women current smokers had elevated risk for both CIN2 OR 1.9 95 CI 1.1-3.2 and CIN3 OR 2.7 95 CI 1.6-4.6 Our data suggest that non-HPV16-related CIN2 likely reflects a combination of CIN1 and CIN3 diagnosis whereas HPV16-related CIN2 may indicate a precancerous state Investigations on the molecular distinctions along the disease continuum of pathogenesis by HPV type are needed,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 3242, 933, 14937, 9, 12, 643, 979, 28425, 2, 518, 6780, 119, 84, 136, 483, 1, 1578, 32, 44, 1910, 1784, 192, 16, 120, 860, 317, 14937, 2825, 20, 933, 2071, 3, 45, 6, 1640, 12, 191, 1387, 2, 3403, 15141, 16, 8, 1383, 2832, 45, 3538, 117, 1995, 6, 3, 1652, 1, 27850, 29, 2868, 1522, 6, 2636, 1307, 9, 1668, 453, 99, 2455, 1770, 74, 2, 3165, 2045, 623, 11, 786, 2, 3, 3286, 10, 3053, 9, 933, 75, 3, 1646, 1926, 933, 2686, 412, 3, 364, 65, 1920, 117, 5, 110, 1770, 2, 933, 74, 2, 265, 5, 23728, 78, 10528, 23728, 78, 11178, 12870, 78, 10047, 10346, 78, 8155, 2, 12, 78, 493, 21, 194, 933, 630, 2, 14937, 107, 933, 3369, 117, 20, 8408, 610, 1137, 15, 2, 48, 307, 1582, 48, 58, 9, 10346, 2, 12870, 3582, 72, 5, 12870, 75, 8, 13540, 812, 320, 202, 163, 11, 1800, 29, 195, 65, 520, 6, 3, 2109, 142, 2165, 1, 46, 117, 21, 204, 17, 933, 3369, 117, 5, 2278, 884, 15, 4195, 1171, 563, 499, 23728, 21337, 2, 17849, 11, 11112, 29, 135, 5, 295, 784, 2045, 2, 11, 631, 397, 6, 1297, 3, 9881, 87, 12870, 107, 117, 109, 9, 1302, 933, 291, 1485, 42, 8, 18, 33, 1116, 101, 43, 9, 10346, 48, 58, 14, 66, 27, 49, 72, 5, 8380, 107, 4048, 3369, 117, 291, 1485, 42, 804, 43, 9, 110, 12870, 15, 14, 83, 48, 58, 14, 14, 27, 18, 2, 10346, 15, 18, 67, 48, 58, 14, 49, 39, 49, 114, 74, 309, 17, 220, 4048, 139, 12870, 322, 5224, 8, 150, 1, 23728, 2, 10346, 147, 547, 4048, 139, 12870, 68, 1008, 8, 6605, 1309, 2492, 23, 3, 219, 16834, 1510, 3, 34, 7382, 1, 1384, 20, 933, 267, 32, 575]",1819.0,19124488,218
Abdominal radical trachelectomy: Success and pitfalls in a general gynecologic oncology practice.,Gynecologic oncology,Gynecol. Oncol.,2009-01-07,"To report our successes and complications with a series of abdominal radical trachelectomies performed to preserve fertility in young women at the Massachusetts General Hospital (MGH). Institutional review board (IRB) permission was obtained for retrospective record review. Data were collected regarding patient age and parity, tumor stage and histology, surgical time and complications, post-operative complications, follow-up, and pregnancy. Ten patients underwent radical abdominal trachelectomy, 9 by the same surgeon (LD). Surgery was essentially identical to that of radical hysterectomy with the exception of re-anastomosis of the uterine fundus to the vagina and placement of cerclage. Pre-operative evaluation and post operative follow-up was for the most part identical for all patients. Two patients achieved pregnancy, with 1 twin delivery and 1 patient had 2 pregnancies. Two patients experienced cervical stenosis with regular menses and the same 2 patients passed their abdominal cerclage vaginally. To date there have been no cancer recurrences. Pap smear follow-up has been complicated by difficulty in reading smears from the lower uterine segment (LUS). Radical abdominal trachelectomy can be successfully performed by any gynecologic oncologist who is trained in radical pelvic surgery. Pre-operative counseling is crucial in obtaining informed consent. Patients must be aware of potential post-operative complications, including pre-term delivery. Cytology department needs to be aware of potential pitfalls in reading Pap smears from the LUS.",Journal Article,4031.0,34.0,To report our successes and complications with a series of abdominal radical trachelectomies performed to preserve fertility in young women at the Massachusetts General Hospital MGH Institutional review board IRB permission was obtained for retrospective record review Data were collected regarding patient age and parity tumor stage and histology surgical time and complications post-operative complications follow-up and pregnancy Ten patients underwent radical abdominal trachelectomy 9 by the same surgeon LD Surgery was essentially identical to that of radical hysterectomy with the exception of re-anastomosis of the fundus to the vagina and placement of cerclage Pre-operative evaluation and post operative follow-up was for the most part identical for all patients Two patients achieved pregnancy with 1 twin delivery and 1 patient had 2 pregnancies Two patients experienced stenosis with regular menses and the same 2 patients passed their abdominal cerclage vaginally To date there have been no cancer recurrences Pap smear follow-up has been complicated by difficulty in reading smears from the lower segment LUS Radical abdominal trachelectomy can be successfully performed by any gynecologic oncologist who is trained in radical pelvic surgery Pre-operative counseling is crucial in obtaining informed consent Patients must be aware of potential post-operative complications including pre-term delivery Cytology department needs to be aware of potential pitfalls in reading Pap smears from the LUS,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 414, 114, 6697, 2, 521, 5, 8, 988, 1, 1467, 711, 38216, 173, 6, 6783, 2954, 4, 1169, 117, 28, 3, 5459, 1083, 702, 10704, 1115, 206, 2620, 5880, 20411, 10, 683, 9, 459, 3237, 206, 74, 11, 786, 666, 69, 89, 2, 5754, 30, 82, 2, 784, 221, 98, 2, 521, 539, 1208, 521, 166, 126, 2, 2290, 1618, 7, 208, 711, 1467, 5760, 83, 20, 3, 827, 1897, 5403, 152, 10, 7257, 3038, 6, 17, 1, 711, 2622, 5, 3, 4188, 1, 1491, 5519, 1, 3, 16869, 6, 3, 7553, 2, 2613, 1, 28830, 671, 1208, 451, 2, 539, 1208, 166, 126, 10, 9, 3, 96, 760, 3038, 9, 62, 7, 100, 7, 513, 2290, 5, 14, 13305, 989, 2, 14, 69, 42, 18, 8746, 100, 7, 592, 6935, 5, 3316, 15963, 2, 3, 827, 18, 7, 11814, 136, 1467, 28830, 45239, 6, 1244, 125, 47, 85, 77, 12, 1593, 4290, 8379, 166, 126, 71, 85, 4286, 20, 4035, 4, 7299, 8916, 29, 3, 280, 4610, 19550, 711, 1467, 5760, 122, 40, 1878, 173, 20, 500, 1512, 2709, 54, 16, 5946, 4, 711, 1110, 152, 671, 1208, 2011, 16, 2653, 4, 5244, 2767, 3844, 7, 1642, 40, 4749, 1, 174, 539, 1208, 521, 141, 671, 337, 989, 2045, 4271, 1891, 6, 40, 4749, 1, 174, 9631, 4, 7299, 4290, 8916, 29, 3, 19550]",1510.0,19131094,261
Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-01-12,"Vascular endothelial growth factor is a key promoter of tumor progression in cervical carcinoma. The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the efficacy and tolerability of bevacizumab, a recombinant humanized anti-vascular endothelial growth factor monoclonal antibody. Eligible patients had recurrent cervical cancer, measurable disease, and GOG performance status < or = 2. Treatment consisted of bevacizumab 15 mg/kg intravenously every 21 days until disease progression or prohibitive toxicity. Primary end points were progression-free survival (PFS) at 6 months and toxicity. Forty-six patients were enrolled (median age, 46 years); 38 patients (82.6%) received prior radiation as well as either one (n = 34, 73.9%) or two (n = 12, 26.1%) prior cytotoxic regimens for recurrent disease. Grade 3 or 4 adverse events at least possibly related to bevacizumab included hypertension (n = 7), thrombo-embolism (n = 5), GI (n = 4), anemia (n = 2), other cardiovascular (n = 2), vaginal bleeding (n = 1), neutropenia (n = 1), and fistula (n = 1). One grade 5 infection was observed. Eleven patients (23.9%; two-sided 90% CI, 14% to 37%) survived progression free for at least 6 months, and five patients (10.9%; two-sided 90% CI, 4% to 22%) had partial responses. The median response duration was 6.21 months (range, 2.83 to 8.28 months). The median PFS and overall survival times were 3.40 months (95% CI, 2.53 to 4.53 months) and 7.29 months (95% CI, 6.11 to 10.41 months), respectively. This compared favorably with historical phase II GOG trials in this setting. CONCLUSION Bevacizumab seems to be well tolerated and active in the second- and third-line treatment of patients with recurrent cervical cancer and merits phase III investigation.","Clinical Trial, Phase II",4026.0,218.0,Vascular endothelial growth factor is a key promoter of tumor progression in carcinoma The Gynecologic Oncology Group GOG conducted a phase II trial to assess the efficacy and tolerability of bevacizumab a recombinant humanized anti-vascular endothelial growth factor monoclonal antibody Eligible patients had recurrent cancer measurable disease and GOG performance status or 2 Treatment consisted of bevacizumab 15 mg/kg intravenously every 21 days until disease progression or prohibitive toxicity Primary end points were progression-free survival PFS at 6 months and toxicity Forty-six patients were enrolled median age 46 years 38 patients 82.6 received prior radiation as well as either one n 34 73.9 or two n 12 26.1 prior cytotoxic regimens for recurrent disease Grade 3 or 4 adverse events at least possibly related to bevacizumab included hypertension n 7 thrombo-embolism n 5 GI n 4 anemia n 2 other cardiovascular n 2 bleeding n 1 neutropenia n 1 and fistula n 1 One grade 5 infection was observed Eleven patients 23.9 two-sided 90 CI 14 to 37 survived progression free for at least 6 months and five patients 10.9 two-sided 90 CI 4 to 22 had partial responses The median response duration was 6.21 months range 2.83 to 8.28 months The median PFS and overall survival times were 3.40 months 95 CI 2.53 to 4.53 months and 7.29 months 95 CI 6.11 to 10.41 months respectively This compared favorably with historical phase II GOG trials in this setting CONCLUSION Bevacizumab seems to be well tolerated and active in the second- and third-line treatment of patients with recurrent cancer and merits phase III investigation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[756, 845, 129, 161, 16, 8, 825, 973, 1, 30, 91, 4, 134, 3, 1512, 413, 87, 4760, 426, 8, 124, 215, 160, 6, 423, 3, 209, 2, 1543, 1, 599, 8, 2835, 3619, 312, 756, 845, 129, 161, 848, 548, 625, 7, 42, 387, 12, 1884, 34, 2, 4760, 528, 156, 15, 18, 24, 1695, 1, 599, 167, 81, 503, 1672, 454, 239, 162, 1100, 34, 91, 15, 10784, 155, 86, 396, 862, 11, 91, 115, 25, 300, 28, 49, 53, 2, 155, 1213, 437, 7, 11, 346, 52, 89, 641, 60, 519, 7, 878, 49, 103, 324, 121, 22, 149, 22, 361, 104, 78, 562, 803, 83, 15, 100, 78, 133, 432, 14, 324, 759, 472, 9, 387, 34, 88, 27, 15, 39, 290, 281, 28, 506, 2150, 139, 6, 599, 159, 1824, 78, 67, 23453, 5475, 78, 33, 2104, 78, 39, 1545, 78, 18, 127, 2179, 78, 18, 2294, 78, 14, 778, 78, 14, 2, 4920, 78, 14, 104, 88, 33, 930, 10, 164, 2627, 7, 382, 83, 100, 1689, 424, 58, 213, 6, 567, 2996, 91, 115, 9, 28, 506, 49, 53, 2, 365, 7, 79, 83, 100, 1689, 424, 58, 39, 6, 350, 42, 450, 253, 3, 52, 51, 654, 10, 49, 239, 53, 184, 18, 852, 6, 66, 339, 53, 3, 52, 300, 2, 63, 25, 1072, 11, 27, 327, 53, 48, 58, 18, 699, 6, 39, 699, 53, 2, 67, 462, 53, 48, 58, 49, 175, 6, 79, 605, 53, 106, 26, 72, 5001, 5, 2252, 124, 215, 4760, 143, 4, 26, 546, 1221, 599, 2744, 6, 40, 149, 421, 2, 544, 4, 3, 419, 2, 1282, 328, 24, 1, 7, 5, 387, 12, 2, 4986, 124, 316, 940]",1629.0,19139430,355
The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma.,Gynecologic oncology,Gynecol. Oncol.,2009-01-13,"We sought to assess the accuracy of a preoperative grade 1 designation and role of lymphadenectomy in women with preoperative grade 1 endometrial cancer. A retrospective analysis of patients diagnosed with preoperative grade 1 endometrial cancer from 1970 to 2006 was conducted. Inclusion criteria were preoperative grade 1 disease and hysterectomy with or without surgical staging. 581 patients who underwent surgery for preoperative grade 1 cancer were identified. Lymphadenectomy was performed in 46%. Pelvic and aortic node metastases were identified in 5.4% and 3.2% patients who underwent lymphadenectomy. 9.7% were upgraded intraoperatively and 25% were upgraded on final pathology with 22% having grade 2 and 3% grade 3 disease. 22.5% with grade 1 disease intraoperatively were upgraded on final pathology, with 21.1% having grade 2 and 1.4% grade 3 disease. 9% had advanced stage disease. 20% of patients with disease limited to the uterus had adverse features including high risk histologic variants, grade 3 disease, myometrial invasion >1/2, and/or cervical involvement. After adjusting for risk factors there was no significant difference in OS (HR 1.00, p=0.992) or PFS (HR 0.96, p=0.815) between the patients who did or did not undergo surgical staging. A substantial number of patients with grade 1 endometrial cancer based on preoperative and intraoperative assessments have higher grade disease on final pathology. Although lymphadenectomy does not affect survival in this group it may identify patients with advanced disease and assist in tailoring adjuvant therapy for those with adverse risk factors.",Journal Article,4025.0,44.0,We sought to assess the accuracy of a preoperative grade 1 designation and role of lymphadenectomy in women with preoperative grade 1 cancer A retrospective analysis of patients diagnosed with preoperative grade 1 cancer from 1970 to 2006 was conducted Inclusion criteria were preoperative grade 1 disease and hysterectomy with or without surgical staging 581 patients who underwent surgery for preoperative grade 1 cancer were identified Lymphadenectomy was performed in 46 Pelvic and aortic node metastases were identified in 5.4 and 3.2 patients who underwent lymphadenectomy 9.7 were upgraded intraoperatively and 25 were upgraded on final pathology with 22 having grade 2 and 3 grade 3 disease 22.5 with grade 1 disease intraoperatively were upgraded on final pathology with 21.1 having grade 2 and 1.4 grade 3 disease 9 had advanced stage disease 20 of patients with disease limited to the had adverse features including high risk histologic variants grade 3 disease myometrial invasion 1/2 and/or involvement After adjusting for risk factors there was no significant difference in OS HR 1.00 p=0.992 or PFS HR 0.96 p=0.815 between the patients who did or did not undergo surgical staging A substantial number of patients with grade 1 cancer based on preoperative and intraoperative assessments have higher grade disease on final pathology Although lymphadenectomy does not affect survival in this group it may identify patients with advanced disease and assist in tailoring adjuvant therapy for those with adverse risk factors,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[21, 990, 6, 423, 3, 1190, 1, 8, 498, 88, 14, 8402, 2, 200, 1, 2048, 4, 117, 5, 498, 88, 14, 12, 8, 459, 65, 1, 7, 265, 5, 498, 88, 14, 12, 29, 4868, 6, 1324, 10, 426, 1680, 371, 11, 498, 88, 14, 34, 2, 2622, 5, 15, 187, 221, 632, 12482, 7, 54, 208, 152, 9, 498, 88, 14, 12, 11, 108, 2048, 10, 173, 4, 641, 1110, 2, 3938, 289, 196, 11, 108, 4, 33, 39, 2, 27, 18, 7, 54, 208, 2048, 83, 67, 11, 9162, 6595, 2, 243, 11, 9162, 23, 1457, 1117, 5, 350, 1041, 88, 18, 2, 27, 88, 27, 34, 350, 33, 5, 88, 14, 34, 6595, 11, 9162, 23, 1457, 1117, 5, 239, 14, 1041, 88, 18, 2, 14, 39, 88, 27, 34, 83, 42, 131, 82, 34, 179, 1, 7, 5, 34, 383, 6, 3, 42, 290, 404, 141, 64, 43, 884, 839, 88, 27, 34, 7327, 578, 14, 18, 2, 15, 799, 50, 1358, 9, 43, 130, 125, 10, 77, 93, 523, 4, 118, 168, 14, 2038, 19, 13, 13144, 15, 300, 168, 13, 921, 19, 13, 13535, 59, 3, 7, 54, 205, 15, 205, 44, 1251, 221, 632, 8, 1281, 207, 1, 7, 5, 88, 14, 12, 90, 23, 498, 2, 1720, 2182, 47, 142, 88, 34, 23, 1457, 1117, 242, 2048, 1097, 44, 1158, 25, 4, 26, 87, 192, 68, 255, 7, 5, 131, 34, 2, 3425, 4, 7101, 249, 36, 9, 135, 5, 290, 43, 130]",1533.0,19144394,675
[The expression and potentially clinical significance of heparanase in nasopharyngeal carcinoma].,"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery",Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,2008-11-01,"To investigate the expression of heparanase in nasopharyngeal carcinoma and the relationship between the expression of it and clinically pathological features of nasopharyngeal carcinoma. The expression of heparanase protein in 70 cases of nasopharyngeal carcinomas and 10 cases of normal nasopharyngeal tissues was detected by immunohistochemical staining. The date of expression combined clinical features, which included clinical stage, cervical lymph node metastasis rate, the rate of metastasis and recurrence, combination of, the 5-year survival rate, and other analysis, was analyzed. The positive rate of heparanase protein in cancerous tissues was 52.9% (37/70), while it was 0% in normal nasopharyngeal tissues. The positive rates of heparanase protein in patients were 30.0% (6/20) in stage I, 45.80% (11/24) in stage II, 70.6% (12/17) in stage III, 88.9% (8/9) in stage IV respectively. Heparanase positive tumors were associated with a higher incidence of lymph node metastasis (67.4%, 31/46) than heparanase negative ones (25.0%, 6/24). The rate of distant metastasis and regional recurrence in the heparanase positive group was 48.6% (18/37), but only 15.2% (5/ 33) in the heparanase negative group. The cumulative survival of patients in the heparanase negative group at 5 years was 78.8% (26/33), but only 24.3% (9/37) in the heparanase positive group. The clinical stage of disease, lymph node metastasis, the rate of distant metastasis and regional recurrence of nasopharyngeal carcinoma were correlated with positive expression of heparanase protein. The expression of HPA was associated with invasion and metastasis and prognosis of nasopharyngeal cancer, and it may be a new target for the anti-treatment of nasopharyngeal cancer. (P < 0.01), and heparanase expression level inversely correlated with the patient survival (P < 0.01). Heparanase may play important roles in the invasive infiltration, metastasis, and prognosis in nasopharyngeal carcinoma, clearly indicating that heparanase is a possible target for anticancer drug development.",English Abstract,4098.0,1.0,To investigate the expression of heparanase in carcinoma and the relationship between the expression of it and clinically pathological features of carcinoma The expression of heparanase protein in 70 cases of carcinomas and 10 cases of normal tissues was detected by immunohistochemical staining The date of expression combined clinical features which included clinical stage lymph node metastasis rate the rate of metastasis and recurrence combination of the 5-year survival rate and other analysis was analyzed The positive rate of heparanase protein in cancerous tissues was 52.9 37/70 while it was 0 in normal tissues The positive rates of heparanase protein in patients were 30.0 6/20 in stage I 45.80 11/24 in stage II 70.6 12/17 in stage III 88.9 8/9 in stage IV respectively Heparanase positive tumors were associated with a higher incidence of lymph node metastasis 67.4 31/46 than heparanase negative ones 25.0 6/24 The rate of distant metastasis and regional recurrence in the heparanase positive group was 48.6 18/37 but only 15.2 5/ 33 in the heparanase negative group The cumulative survival of patients in the heparanase negative group at 5 years was 78.8 26/33 but only 24.3 9/37 in the heparanase positive group The clinical stage of disease lymph node metastasis the rate of distant metastasis and regional recurrence of carcinoma were correlated with positive expression of heparanase protein The expression of HPA was associated with invasion and metastasis and prognosis of cancer and it may be a new target for the anti-treatment of cancer P 0.01 and heparanase expression level inversely correlated with the patient survival P 0.01 Heparanase may play important roles in the invasive infiltration metastasis and prognosis in carcinoma clearly indicating that heparanase is a possible target for anticancer drug development,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 963, 3, 55, 1, 15331, 4, 134, 2, 3, 858, 59, 3, 55, 1, 192, 2, 505, 1301, 404, 1, 134, 3, 55, 1, 15331, 178, 4, 431, 140, 1, 826, 2, 79, 140, 1, 295, 742, 10, 530, 20, 1382, 1029, 3, 1244, 1, 55, 397, 38, 404, 92, 159, 38, 82, 263, 289, 278, 116, 3, 116, 1, 278, 2, 146, 150, 1, 3, 33, 111, 25, 116, 2, 127, 65, 10, 311, 3, 109, 116, 1, 15331, 178, 4, 5483, 742, 10, 653, 83, 567, 431, 369, 192, 10, 13, 4, 295, 742, 3, 109, 151, 1, 15331, 178, 4, 7, 11, 201, 13, 49, 179, 4, 82, 70, 512, 493, 175, 259, 4, 82, 215, 431, 49, 133, 269, 4, 82, 316, 889, 83, 66, 83, 4, 82, 478, 106, 15331, 109, 57, 11, 41, 5, 8, 142, 287, 1, 263, 289, 278, 598, 39, 456, 641, 76, 15331, 199, 6737, 243, 13, 49, 259, 3, 116, 1, 626, 278, 2, 951, 146, 4, 3, 15331, 109, 87, 10, 576, 49, 203, 567, 84, 158, 167, 18, 33, 466, 4, 3, 15331, 199, 87, 3, 967, 25, 1, 7, 4, 3, 15331, 199, 87, 28, 33, 60, 10, 833, 66, 432, 466, 84, 158, 259, 27, 83, 567, 4, 3, 15331, 109, 87, 3, 38, 82, 1, 34, 263, 289, 278, 3, 116, 1, 626, 278, 2, 951, 146, 1, 134, 11, 438, 5, 109, 55, 1, 15331, 178, 3, 55, 1, 14513, 10, 41, 5, 578, 2, 278, 2, 356, 1, 12, 2, 192, 68, 40, 8, 217, 283, 9, 3, 312, 24, 1, 12, 19, 13, 355, 2, 15331, 55, 301, 2659, 438, 5, 3, 69, 25, 19, 13, 355, 15331, 68, 1343, 305, 1790, 4, 3, 416, 2084, 278, 2, 356, 4, 134, 2536, 1716, 17, 15331, 16, 8, 899, 283, 9, 1475, 234, 193]",1845.0,19157148,394
Evaluation of intervention to prevent hypomagnesemia in cervical cancer patients receiving combination cisplatin and radiation treatment.,Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,Support Care Cancer,2009-01-27,"The purpose of this study was to evaluate the impact of increasing the magnesium (Mg(2+)) supplementation in the pre- and posthydration of patients receiving cisplatin plus radiation (CisXRT) to prevent chemotherapy-induced hypomagnesemia (CIH) events. The study was conducted on newly diagnosed cervical cancer patients receiving CisXRT. The first prospective intervention to prevent CIH was to increase the pre- and posthydration Mg(2+) from 1 to 2 g. After completion of the first intervention, the analysis demonstrated the persistent occurrence of CIH on cycle 3, and later, a second intervention was implemented to increase Mg(2+) to 3 g in the pre- and posthydration. Patients that failed to complete at least five cycles or received cisplatin in combination with another chemotherapy regimen were excluded from the study. Baseline group included 70 patients that had received CisXRT prior to any changes in magnesium supplementation. There were 62.8% (44/70) and 32.6% (22/70) of patients with episodes of CIH in the baseline and first intervention groups, respectively (P = 0.007). In the second intervention group, a 49.6% decrease in the total number of episodes compared to control group was observed. Patients in the second intervention group showed a 100% improvement incidence of persistent CIH over the two other cohorts (P = 0.001). The increase of Mg(2+) to 2 g for the initial two cycles and then to 3 g with the third cycle of CisXRT therapy prevented episodes of CIH and decreased associated treatment delays.",Clinical Trial,4011.0,5.0,The purpose of this study was to evaluate the impact of increasing the magnesium Mg 2+ supplementation in the pre- and posthydration of patients receiving cisplatin plus radiation CisXRT to prevent chemotherapy-induced hypomagnesemia CIH events The study was conducted on newly diagnosed cancer patients receiving CisXRT The first prospective intervention to prevent CIH was to increase the pre- and posthydration Mg 2+ from 1 to 2 g. After completion of the first intervention the analysis demonstrated the persistent occurrence of CIH on cycle 3 and later a second intervention was implemented to increase Mg 2+ to 3 g in the pre- and posthydration Patients that failed to complete at least five cycles or received cisplatin in combination with another chemotherapy regimen were excluded from the study Baseline group included 70 patients that had received CisXRT prior to any changes in magnesium supplementation There were 62.8 44/70 and 32.6 22/70 of patients with episodes of CIH in the baseline and first intervention groups respectively P 0.007 In the second intervention group a 49.6 decrease in the total number of episodes compared to control group was observed Patients in the second intervention group showed a 100 improvement incidence of persistent CIH over the two other cohorts P 0.001 The increase of Mg 2+ to 2 g for the initial two cycles and then to 3 g with the third cycle of CisXRT therapy prevented episodes of CIH and decreased associated treatment delays,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 376, 3, 345, 1, 602, 3, 8089, 81, 18, 3890, 4, 3, 671, 2, 34268, 1, 7, 357, 540, 349, 121, 34628, 6, 1682, 56, 277, 10746, 28877, 281, 3, 45, 10, 426, 23, 732, 265, 12, 7, 357, 34628, 3, 157, 482, 788, 6, 1682, 28877, 10, 6, 344, 3, 671, 2, 34268, 81, 18, 29, 14, 6, 18, 499, 50, 1438, 1, 3, 157, 788, 3, 65, 264, 3, 1882, 2291, 1, 28877, 23, 417, 27, 2, 1559, 8, 419, 788, 10, 3426, 6, 344, 81, 18, 6, 27, 499, 4, 3, 671, 2, 34268, 7, 17, 1551, 6, 236, 28, 506, 365, 410, 15, 103, 540, 4, 150, 5, 1809, 56, 477, 11, 1800, 29, 3, 45, 330, 87, 159, 431, 7, 17, 42, 103, 34628, 324, 6, 500, 400, 4, 8089, 3890, 125, 11, 744, 66, 584, 431, 2, 531, 49, 350, 431, 1, 7, 5, 3750, 1, 28877, 4, 3, 330, 2, 157, 788, 271, 106, 19, 13, 1999, 4, 3, 419, 788, 87, 8, 739, 49, 775, 4, 3, 181, 207, 1, 3750, 72, 6, 182, 87, 10, 164, 7, 4, 3, 419, 788, 87, 224, 8, 394, 767, 287, 1, 1882, 28877, 252, 3, 100, 127, 736, 19, 13, 144, 3, 344, 1, 81, 18, 6, 18, 499, 9, 3, 388, 100, 410, 2, 818, 6, 27, 499, 5, 3, 1282, 417, 1, 34628, 36, 3902, 3750, 1, 28877, 2, 340, 41, 24, 3257]",1481.0,19172305,394
Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma?,Gynecologic oncology,Gynecol. Oncol.,2009-02-20,"To describe the accuracy of SLN mapping in patients with a preoperative diagnosis of grade 1 endometrial cancer. A prospective, non-randomized study of women with a preoperative diagnosis of endometrial cancer and clinical stage I disease was conducted. A subset analysis of patients with a preoperative diagnosis of grade 1 endometrial endometrioid cancer was performed. All patients had preoperative lymphoscintigraphy with Tc99m on the day of or day before surgery followed by an intraoperative injection of 2 cm(3) of isosulfan or methylene blue dye deep into the cervix or both cervix and fundus. All patients underwent hysterectomy, bilateral salpingo-oophorectomy, and regional nodal dissection. Hot and/or blue nodes were labeled as SLNs and sent for histopathological analysis. Forty-two patients with a preoperative diagnosis of grade 1 endometrial carcinoma treated from 3/06 to 8/08 were identified. Twenty-five (60%) had laparoscopic surgery; 17 (40%) were treated by laparotomy. Preoperative lymphoscintigraphy visualized SLNs in 30 patients (71%); intraoperative localization of the SLN was possible in 36 patients (86%). A median of 3 SLNs (range, 1-14) and 14.5 non-SLNs (range, 4-55) were examined. In all, 4/36 (11%) had positive SLNs-3 seen on H&E and 1 as cytokeratin-positive cells on IHC. All node-positive cases were picked up by the SLN; there were no false-negative cases. The sensitivity of the SLN procedure in the 36 patients who had an SLN identified was 100%. Sentinel lymph node mapping using a cervical injection with combined Tc and blue dye is feasible and accurate in patients with grade 1 endometrial cancer and may be a reasonable option for this select group of patients. Regional lymphadenectomy remains the gold standard in many practices, particularly for the approximately 15% of cases with failed SLN mapping.",Clinical Trial,3987.0,150.0,To describe the accuracy of SLN mapping in patients with a preoperative diagnosis of grade 1 cancer A prospective non-randomized study of women with a preoperative diagnosis of cancer and clinical stage I disease was conducted A subset analysis of patients with a preoperative diagnosis of grade 1 endometrioid cancer was performed All patients had preoperative lymphoscintigraphy with Tc99m on the day of or day before surgery followed by an intraoperative injection of 2 cm 3 of isosulfan or methylene blue dye deep into the cervix or both cervix and fundus All patients underwent hysterectomy bilateral salpingo-oophorectomy and regional nodal dissection Hot and/or blue nodes were labeled as SLNs and sent for histopathological analysis Forty-two patients with a preoperative diagnosis of grade 1 carcinoma treated from 3/06 to 8/08 were identified Twenty-five 60 had laparoscopic surgery 17 40 were treated by laparotomy Preoperative lymphoscintigraphy visualized SLNs in 30 patients 71 intraoperative localization of the SLN was possible in 36 patients 86 A median of 3 SLNs range 1-14 and 14.5 non-SLNs range 4-55 were examined In all 4/36 11 had positive SLNs-3 seen on H E and 1 as cytokeratin-positive cells on IHC All node-positive cases were picked up by the SLN there were no false-negative cases The sensitivity of the SLN procedure in the 36 patients who had an SLN identified was 100 Sentinel lymph node mapping using a injection with combined Tc and blue dye is feasible and accurate in patients with grade 1 cancer and may be a reasonable option for this select group of patients Regional lymphadenectomy remains the gold standard in many practices particularly for the approximately 15 of cases with failed SLN mapping,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 897, 3, 1190, 1, 1099, 2568, 4, 7, 5, 8, 498, 147, 1, 88, 14, 12, 8, 482, 220, 384, 45, 1, 117, 5, 8, 498, 147, 1, 12, 2, 38, 82, 70, 34, 10, 426, 8, 697, 65, 1, 7, 5, 8, 498, 147, 1, 88, 14, 3151, 12, 10, 173, 62, 7, 42, 498, 6849, 5, 45444, 23, 3, 218, 1, 15, 218, 348, 152, 370, 20, 35, 1720, 1754, 1, 18, 494, 27, 1, 10267, 15, 10256, 3352, 3796, 2369, 237, 3, 3629, 15, 110, 3629, 2, 16869, 62, 7, 208, 2622, 1607, 5690, 3470, 2, 951, 779, 1161, 2859, 2, 15, 3352, 502, 11, 2841, 22, 2642, 2, 6325, 9, 4370, 65, 1213, 100, 7, 5, 8, 498, 147, 1, 88, 14, 134, 73, 29, 27, 1460, 6, 66, 1592, 11, 108, 737, 365, 335, 42, 1964, 152, 269, 327, 11, 73, 20, 3274, 498, 6849, 6326, 2642, 4, 201, 7, 792, 1720, 2145, 1, 3, 1099, 10, 899, 4, 511, 7, 868, 8, 52, 1, 27, 2642, 184, 14, 213, 2, 213, 33, 220, 2642, 184, 39, 614, 11, 409, 4, 62, 39, 511, 175, 42, 109, 2642, 27, 527, 23, 555, 563, 2, 14, 22, 4292, 109, 37, 23, 1289, 62, 289, 109, 140, 11, 28724, 126, 20, 3, 1099, 125, 11, 77, 2133, 199, 140, 3, 485, 1, 3, 1099, 1299, 4, 3, 511, 7, 54, 42, 35, 1099, 108, 10, 394, 1323, 263, 289, 2568, 75, 8, 1754, 5, 397, 3072, 2, 3352, 3796, 16, 1313, 2, 1481, 4, 7, 5, 88, 14, 12, 2, 68, 40, 8, 3203, 1501, 9, 26, 1717, 87, 1, 7, 951, 2048, 469, 3, 4159, 260, 4, 445, 2634, 823, 9, 3, 705, 167, 1, 140, 5, 1551, 1099, 2568]",1737.0,19232699,229
Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland.,Cancer,Cancer,2009-05-01,"To the authors' knowledge, the indications for adjuvant treatment in acinic cell carcinoma (AciCC) of the parotid gland have not been elucidated to date. The aim of the current study was to determine patterns of failure and adverse prognostic features. Between March of 1989 and August of 2006, 35 patients underwent surgery at Memorial Sloan-Kettering Cancer Center for AciCC of the parotid gland and had their clinical and pathologic features retrospectively analyzed at the primary site. All cases were reviewed by 2 head and neck pathologists. Five-year estimates of survival outcomes were performed, followed by univariate analysis of potential prognostic features. The T classifications were as follows: T1 in 46% of patients, T2 in 23% of patients, T3 in 18% of patients, and T4 in 9% of patients. Three patients had cervical lymph node involvement. All patients underwent surgery as their primary treatment. Approximately 63% of patients (n = 22) received radiation treatment. The median follow-up time for surviving patients was 59.9 months. Five-year estimates of disease-free survival (DFS), overall survival (OS), and local control were 85%, 90%, and 90%, respectively. Of the clinical variables tested, clinical extracapsular extension (ECE), facial nerve sacrifice, and lymph node involvement were found to be significantly associated with a detriment in DFS and OS (P < .05). Positive surgical margins, histologic ECE, >2 mitoses per 10 high-power fields (HPF), atypical mitosis, vascular invasion, perineural invasion, pleomorphism, and necrosis were associated with adverse DFS (P < .05). All of these variables except for vascular invasion (P = .377) and perineural invasion (P = .07) were associated with OS. If high-grade tumors were defined on the basis of high mitotic activity (>2 mitoses/10 HPF) and/or tumor necrosis, high-grade carcinomas had a significantly lower DFS and OS (P = .001). AciCC had a low treatment failure rate, and a large number of patients could be considered candidates for surgery only. A histologic grading system was devised to help stratify patients for adjuvant treatment.",Journal Article,3917.0,55.0,To the authors knowledge the indications for adjuvant treatment in acinic cell carcinoma AciCC of the parotid gland have not been elucidated to date The aim of the current study was to determine patterns of failure and adverse prognostic features Between March of 1989 and August of 2006 35 patients underwent surgery at Memorial Sloan-Kettering Cancer Center for AciCC of the parotid gland and had their clinical and pathologic features retrospectively analyzed at the primary site All cases were reviewed by 2 head and pathologists Five-year estimates of survival outcomes were performed followed by univariate analysis of potential prognostic features The T classifications were as follows T1 in 46 of patients T2 in 23 of patients T3 in 18 of patients and T4 in 9 of patients Three patients had lymph node involvement All patients underwent surgery as their primary treatment Approximately 63 of patients n 22 received radiation treatment The median follow-up time for surviving patients was 59.9 months Five-year estimates of disease-free survival DFS overall survival OS and local control were 85 90 and 90 respectively Of the clinical variables tested clinical extracapsular extension ECE facial nerve sacrifice and lymph node involvement were found to be significantly associated with a detriment in DFS and OS P .05 Positive surgical margins histologic ECE 2 mitoses per 10 high-power fields HPF atypical mitosis vascular invasion perineural invasion pleomorphism and necrosis were associated with adverse DFS P .05 All of these variables except for vascular invasion P .377 and perineural invasion P .07 were associated with OS If high-grade tumors were defined on the basis of high mitotic activity 2 mitoses/10 HPF and/or tumor necrosis high-grade carcinomas had a significantly lower DFS and OS P .001 AciCC had a low treatment failure rate and a large number of patients could be considered candidates for surgery only A histologic grading system was devised to help stratify patients for adjuvant treatment,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 3, 738, 922, 3, 2406, 9, 249, 24, 4, 17375, 31, 134, 34657, 1, 3, 5838, 2326, 47, 44, 85, 3901, 6, 1244, 3, 1130, 1, 3, 291, 45, 10, 6, 223, 764, 1, 496, 2, 290, 177, 404, 59, 2363, 1, 3965, 2, 2480, 1, 1324, 465, 7, 208, 152, 28, 2563, 2783, 2784, 12, 574, 9, 34657, 1, 3, 5838, 2326, 2, 42, 136, 38, 2, 510, 404, 894, 311, 28, 3, 86, 606, 62, 140, 11, 446, 20, 18, 718, 2, 3354, 365, 111, 1423, 1, 25, 123, 11, 173, 370, 20, 880, 65, 1, 174, 177, 404, 3, 102, 5787, 11, 22, 2962, 1534, 4, 641, 1, 7, 1786, 4, 382, 1, 7, 2065, 4, 203, 1, 7, 2, 2463, 4, 83, 1, 7, 169, 7, 42, 263, 289, 799, 62, 7, 208, 152, 22, 136, 86, 24, 705, 676, 1, 7, 78, 350, 103, 121, 24, 3, 52, 166, 126, 98, 9, 3050, 7, 10, 728, 83, 53, 365, 111, 1423, 1, 34, 115, 25, 1010, 63, 25, 118, 2, 293, 182, 11, 772, 424, 2, 424, 106, 1, 3, 38, 682, 650, 38, 5607, 2401, 6508, 6825, 2476, 16670, 2, 263, 289, 799, 11, 204, 6, 40, 97, 41, 5, 8, 13334, 4, 1010, 2, 118, 19, 474, 109, 221, 1012, 884, 6508, 18, 7246, 379, 79, 64, 2349, 3130, 10457, 1973, 5624, 756, 578, 4917, 578, 14152, 2, 1523, 11, 41, 5, 290, 1010, 19, 474, 62, 1, 46, 682, 2187, 9, 756, 578, 19, 8211, 2, 4917, 578, 19, 1615, 11, 41, 5, 118, 492, 64, 88, 57, 11, 395, 23, 3, 877, 1, 64, 2346, 128, 18, 7246, 79, 10457, 2, 15, 30, 1523, 64, 88, 826, 42, 8, 97, 280, 1010, 2, 118, 19, 144, 34657, 42, 8, 154, 24, 496, 116, 2, 8, 375, 207, 1, 7, 359, 40, 515, 1931, 9, 152, 158, 8, 884, 3452, 398, 10, 10085, 6, 987, 3570, 7, 9, 249, 24]",2021.0,19309749,750
Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group.,Seminars in oncology,Semin. Oncol.,2009-04-01,"Following publication of five pivotal randomized trials of concurrent chemo-irradiation for patients with locally advanced cervical cancer (ie, International Federation of Gynecology and Oncology (FIGO] stages IB2-IVA) in 1999 and 2000, the National Cancer Institute issued a Clinical Alert advising that concurrent chemotherapy (typically, single-agent cisplatin) be incorporated into the treatment program of women scheduled to receive definitive pelvic radiotherapy. Although the adoption of this new standard has improved overall survival and decreased the recurrence rate by 50%, for those patients who do relapse, the prognosis is very poor and, ultimately, therapy in this setting is palliative in nature. The Gynecologic Oncology Group (GOG) has now completed eight randomized trials for metastatic and recurrent cervical cancer, all of which have studied cisplatin-based regimens. The eighth trial (protocol 204) compared four cisplatin-based doublets containing paclitaxel, topotecan, vinorelbine, or gemcitabine. Because the vast majority of patients are now expected to receive cisplatin ""up front"" as part of primary therapy with pelvic radiation, there are concerns for the development of drug-resistant clones in recurrences both inside and outside of the radiation field. The GOG has recently reported the results from a phase II trial evaluating the anti-vascular agent, bevacizumab, in women who were eligible for second-line or third-line therapy for metastatic and/or recurrent disease (protocol 227C). It becomes imperative that we continue to evaluate novel regimens for this disease.",Journal Article,3947.0,48.0,Following publication of five pivotal randomized trials of concurrent chemo-irradiation for patients with locally advanced cancer ie International Federation of Gynecology and Oncology FIGO stages IB2-IVA in 1999 and 2000 the National Cancer Institute issued a Clinical Alert advising that concurrent chemotherapy typically single-agent cisplatin be incorporated into the treatment program of women scheduled to receive definitive pelvic radiotherapy Although the adoption of this new standard has improved overall survival and decreased the recurrence rate by 50 for those patients who do relapse the prognosis is very poor and ultimately therapy in this setting is palliative in nature The Gynecologic Oncology Group GOG has now completed eight randomized trials for metastatic and recurrent cancer all of which have studied cisplatin-based regimens The eighth trial protocol 204 compared four cisplatin-based doublets containing paclitaxel topotecan vinorelbine or gemcitabine Because the vast majority of patients are now expected to receive cisplatin `` up front '' as part of primary therapy with pelvic radiation there are concerns for the development of drug-resistant clones in recurrences both inside and outside of the radiation field The GOG has recently reported the results from a phase II trial evaluating the anti-vascular agent bevacizumab in women who were eligible for second-line or third-line therapy for metastatic and/or recurrent disease protocol 227C It becomes imperative that we continue to evaluate novel regimens for this disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[366, 4397, 1, 365, 3754, 384, 143, 1, 750, 3341, 1104, 9, 7, 5, 795, 131, 12, 2523, 944, 7303, 1, 6429, 2, 413, 3837, 1153, 9537, 5900, 4, 2043, 2, 1081, 3, 657, 12, 1377, 13295, 8, 38, 12781, 22356, 17, 750, 56, 1969, 226, 420, 540, 40, 2449, 237, 3, 24, 1243, 1, 117, 4394, 6, 560, 1057, 1110, 310, 242, 3, 4350, 1, 26, 217, 260, 71, 231, 63, 25, 2, 340, 3, 146, 116, 20, 212, 9, 135, 7, 54, 1022, 429, 3, 356, 16, 923, 334, 2, 2050, 36, 4, 26, 546, 16, 994, 4, 2202, 3, 1512, 413, 87, 4760, 71, 1134, 781, 659, 384, 143, 9, 113, 2, 387, 12, 62, 1, 92, 47, 656, 540, 90, 472, 3, 7732, 160, 1182, 5996, 72, 294, 540, 90, 9097, 1101, 490, 2129, 3676, 15, 679, 408, 3, 4337, 686, 1, 7, 32, 1134, 1336, 6, 560, 540, 126, 3007, 522, 22, 760, 1, 86, 36, 5, 1110, 121, 125, 32, 2061, 9, 3, 193, 1, 234, 436, 2749, 4, 1593, 110, 8133, 2, 2513, 1, 3, 121, 1067, 3, 4760, 71, 761, 210, 3, 99, 29, 8, 124, 215, 160, 1435, 3, 312, 756, 420, 599, 4, 117, 54, 11, 625, 9, 419, 328, 15, 1282, 328, 36, 9, 113, 2, 15, 387, 34, 1182, 57771, 192, 5366, 6305, 17, 21, 1906, 6, 376, 229, 472, 9, 26, 34]",1558.0,19332251,166
Somatic LKB1 mutations promote cervical cancer progression.,PloS one,PLoS ONE,2009-04-02,"Human Papilloma Virus (HPV) is the etiologic agent for cervical cancer. Yet, infection with HPV is not sufficient to cause cervical cancer, because most infected women develop transient epithelial dysplasias that spontaneously regress. Progression to invasive cancer has been attributed to diverse host factors such as immune or hormonal status, as no recurrent genetic alterations have been identified in cervical cancers. Thus, the pressing question as to the biological basis of cervical cancer progression has remained unresolved, hampering the development of novel therapies and prognostic tests. Here we show that at least 20% of cervical cancers harbor somatically-acquired mutations in the LKB1 tumor suppressor. Approximately one-half of tumors with mutations harbored single nucleotide substitutions or microdeletions identifiable by exon sequencing, while the other half harbored larger monoallelic or biallelic deletions detectable by multiplex ligation probe amplification (MLPA). Biallelic mutations were identified in most cervical cancer cell lines; HeLa, the first human cell line, harbors a homozygous 25 kb deletion that occurred in vivo. LKB1 inactivation in primary tumors was associated with accelerated disease progression. Median survival was only 13 months for patients with LKB1-deficient tumors, but >100 months for patients with LKB1-wild type tumors (P = 0.015, log rank test; hazard ratio = 0.25, 95% CI = 0.083 to 0.77). LKB1 is thus a major cervical tumor suppressor, demonstrating that acquired genetic alterations drive progression of HPV-induced dysplasias to invasive, lethal cancers. Furthermore, LKB1 status can be exploited clinically to predict disease recurrence.",Journal Article,3946.0,184.0,Human Papilloma Virus HPV is the etiologic agent for cancer Yet infection with HPV is not sufficient to cause cancer because most infected women develop transient epithelial dysplasias that spontaneously regress Progression to invasive cancer has been attributed to diverse host factors such as immune or hormonal status as no recurrent genetic alterations have been identified in cancers Thus the pressing question as to the biological basis of cancer progression has remained unresolved hampering the development of novel therapies and prognostic tests Here we show that at least 20 of cancers harbor somatically-acquired mutations in the LKB1 tumor suppressor Approximately one-half of tumors with mutations harbored single nucleotide substitutions or microdeletions identifiable by exon sequencing while the other half harbored larger monoallelic or biallelic deletions detectable by multiplex ligation probe amplification MLPA Biallelic mutations were identified in most cancer cell lines HeLa the first human cell line harbors a homozygous 25 kb deletion that occurred in vivo LKB1 inactivation in primary tumors was associated with accelerated disease progression Median survival was only 13 months for patients with LKB1-deficient tumors but 100 months for patients with LKB1-wild type tumors P 0.015 log rank test hazard ratio 0.25 95 CI 0.083 to 0.77 LKB1 is thus a major tumor suppressor demonstrating that acquired genetic alterations drive progression of HPV-induced dysplasias to invasive lethal cancers Furthermore LKB1 status can be exploited clinically to predict disease recurrence,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 7017, 1450, 933, 16, 3, 6604, 420, 9, 12, 1145, 930, 5, 933, 16, 44, 1952, 6, 708, 12, 408, 96, 3369, 117, 690, 2473, 701, 19468, 17, 6459, 15824, 91, 6, 416, 12, 71, 85, 3073, 6, 1867, 1204, 130, 225, 22, 250, 15, 1761, 156, 22, 77, 387, 336, 593, 47, 85, 108, 4, 163, 631, 3, 11446, 2840, 22, 6, 3, 1037, 877, 1, 12, 91, 71, 958, 9420, 28896, 3, 193, 1, 229, 235, 2, 177, 895, 467, 21, 514, 17, 28, 506, 179, 1, 163, 2760, 12293, 1294, 138, 4, 3, 6336, 30, 1245, 705, 104, 1303, 1, 57, 5, 138, 3253, 226, 1579, 7646, 15, 23749, 6237, 20, 1725, 615, 369, 3, 127, 1303, 3253, 1077, 11950, 15, 6435, 2439, 2083, 20, 4908, 5307, 2888, 1073, 23750, 6435, 138, 11, 108, 4, 96, 12, 31, 285, 8466, 3, 157, 171, 31, 328, 8475, 8, 3189, 243, 5116, 1528, 17, 489, 4, 386, 6336, 2297, 4, 86, 57, 10, 41, 5, 2241, 34, 91, 52, 25, 10, 158, 233, 53, 9, 7, 5, 6336, 1971, 57, 84, 394, 53, 9, 7, 5, 6336, 955, 267, 57, 19, 13, 3433, 1066, 1026, 412, 360, 197, 13, 243, 48, 58, 13, 14291, 6, 13, 849, 6336, 16, 631, 8, 458, 30, 1245, 2219, 17, 1294, 336, 593, 3279, 91, 1, 933, 277, 19468, 6, 416, 2266, 163, 798, 6336, 156, 122, 40, 5177, 505, 6, 678, 34, 146]",1599.0,19340305,224
Pediatric radical abdominal trachelectomy for anaplastic embryonal rhabdomyosarcoma of the uterine cervix: an alternative to radical hysterectomy.,Journal of pediatric surgery,J. Pediatr. Surg.,2009-04-01,"Rhabdomyosarcoma arising in the female genital tract carries 5-year survival in excess of 80%, but lifelong infertility may be a consequence of local control strategies. We present the technique and outcome for a fertility-sparing, radical abdominal trachelectomy in a 12-year-old girl with anaplastic, embryonal rhabdomyosarcoma involving the uterine cervix. The patient had presented to our center after the piecemeal resection of a uterine cervical mass; because of concern about microscopic residual disease, we classified her as group II-A according to the Intergroup Rhabdomyosarcoma Study system. Staging studies excluded the presence of distant disease. The patient received 4 cycles of multiagent chemotherapy and then underwent radical abdominal trachelectomy, with removal of the uterine cervix, parametria, vaginal cuff, and regional lymph nodes. Microscopically, the specimen showed treatment effect and no residual tumor. Regional nodes were negative. Radical abdominal trachelectomy, which has not been previously reported for rhabdomyosarcoma, has appeared to secure local disease control in this case while preserving the patient's future fertility potential. In properly selected cases of rhabdomyosarcoma of the uterine cervix, where involvement of the uterus proper is not present, radical abdominal trachelectomy may be an attractive fertility-sparing alternative to radical hysterectomy.",Case Reports,3947.0,17.0,arising in the female genital tract carries 5-year survival in excess of 80 but lifelong infertility may be a consequence of local control strategies We present the technique and outcome for a fertility-sparing radical abdominal trachelectomy in a 12-year-old girl with anaplastic embryonal involving the cervix The patient had presented to our center after the piecemeal resection of a mass because of concern about microscopic residual disease we classified her as group II-A according to the Intergroup Study system Staging studies excluded the presence of distant disease The patient received 4 cycles of multiagent chemotherapy and then underwent radical abdominal trachelectomy with removal of the cervix parametria cuff and regional lymph nodes Microscopically the specimen showed treatment effect and no residual tumor Regional nodes were negative Radical abdominal trachelectomy which has not been previously reported for has appeared to secure local disease control in this case while preserving the patient 's future fertility potential In properly selected cases of of the cervix where involvement of the proper is not present radical abdominal trachelectomy may be an attractive fertility-sparing alternative to radical hysterectomy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[2635, 4, 3, 1061, 8226, 1696, 4942, 33, 111, 25, 4, 2612, 1, 493, 84, 9590, 5901, 68, 40, 8, 4177, 1, 293, 182, 422, 21, 364, 3, 1312, 2, 228, 9, 8, 2954, 1851, 711, 1467, 5760, 4, 8, 133, 111, 1095, 12079, 5, 1841, 5239, 1267, 3, 3629, 3, 69, 42, 917, 6, 114, 574, 50, 3, 28901, 170, 1, 8, 782, 408, 1, 2893, 545, 2984, 753, 34, 21, 1373, 1084, 22, 87, 215, 8, 768, 6, 3, 4839, 45, 398, 632, 94, 1800, 3, 463, 1, 626, 34, 3, 69, 103, 39, 410, 1, 7148, 56, 2, 818, 208, 711, 1467, 5760, 5, 2829, 1, 3, 3629, 19585, 11445, 2, 951, 263, 502, 7187, 3, 2360, 224, 24, 254, 2, 77, 753, 30, 951, 502, 11, 199, 711, 1467, 5760, 92, 71, 44, 85, 373, 210, 9, 71, 2121, 6, 14520, 293, 34, 182, 4, 26, 473, 369, 4972, 3, 69, 292, 508, 2954, 174, 4, 6785, 715, 140, 1, 1, 3, 3629, 1257, 799, 1, 3, 4576, 16, 44, 364, 711, 1467, 5760, 68, 40, 35, 3059, 2954, 1851, 1091, 6, 711, 2622]",1245.0,19361657,139
A prognostic index for predicting lymph node metastasis in minor salivary gland cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2010-01-01,"Large studies examining the clinical and pathological factors associated with nodal metastasis in minor salivary gland cancer are lacking in the literature. Using the Surveillance, Epidemiology, and End Results (SEER) database, we identified 2,667 minor salivary gland cancers with known lymph node status from 1988 to 2004. Univariate and multivariate analyses were conducted to identify factors associated with the use of neck dissection, the use of external beam radiation therapy, and the presence of cervical lymph node metastases. Four hundred twenty-six (16.0%) patients had neck nodal involvement. Factors associated with neck nodal involvement on univariate analysis included increasing age, male sex, increasing tumor size, high tumor grade, T3-T4 stage, adenocarcinoma or mucoepidermoid carcinomas, and pharyngeal site of primary malignancy. On multivariate analysis, four statistically significant factors were identified, including male sex, T3-T4 stage, pharyngeal site of primary malignancy, and high-grade adenocarcinoma or high-grade mucoepidermoid carcinomas. The proportions (and 95% confidence intervals) of patients with lymph node involvement for those with 0, 1, 2, 3, and 4 of these prognostic factors were 0.02 (0.01-0.03), 0.09 (0.07-0.11), 0.17 (0.14-0.21), 0.41 (0.33-0.49), and 0.70 (0.54-0.85), respectively. Grade was a significant predictor of metastasis for adenocarcinoma and mucoepidermoid carcinoma but not for adenoid cystic carcinoma. A prognostic index using the four clinicopathological factors listed here can effectively differentiate patients into risk groups of nodal metastasis. The precision of this index is subject to the limitations of SEER data and should be validated in further clinical studies.",Journal Article,3672.0,36.0,"Large studies examining the clinical and pathological factors associated with nodal metastasis in minor gland cancer are lacking in the literature Using the Surveillance Epidemiology and End Results SEER database we identified 2,667 minor gland cancers with known lymph node status from 1988 to 2004 Univariate and multivariate analyses were conducted to identify factors associated with the use of dissection the use of external beam radiation therapy and the presence of lymph node metastases Four hundred twenty-six 16.0 patients had nodal involvement Factors associated with nodal involvement on univariate analysis included increasing age male sex increasing tumor size high tumor grade T3-T4 stage adenocarcinoma or mucoepidermoid carcinomas and site of primary malignancy On multivariate analysis four statistically significant factors were identified including male sex T3-T4 stage site of primary malignancy and high-grade adenocarcinoma or high-grade mucoepidermoid carcinomas The proportions and 95 confidence intervals of patients with lymph node involvement for those with 0 1 2 3 and 4 of these prognostic factors were 0.02 0.01-0.03 0.09 0.07-0.11 0.17 0.14-0.21 0.41 0.33-0.49 and 0.70 0.54-0.85 respectively Grade was a significant predictor of metastasis for adenocarcinoma and mucoepidermoid carcinoma but not for adenoid cystic carcinoma A prognostic index using the four clinicopathological factors listed here can effectively differentiate patients into risk groups of nodal metastasis The precision of this index is subject to the limitations of SEER data and should be validated in further clinical studies",0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[375, 94, 3282, 3, 38, 2, 1301, 130, 41, 5, 779, 278, 4, 2278, 2326, 12, 32, 1941, 4, 3, 789, 75, 3, 617, 1284, 2, 396, 99, 1605, 609, 21, 108, 18, 10598, 2278, 2326, 163, 5, 440, 263, 289, 156, 29, 3314, 6, 1131, 880, 2, 331, 318, 11, 426, 6, 255, 130, 41, 5, 3, 119, 1, 1161, 3, 119, 1, 1455, 1345, 121, 36, 2, 3, 463, 1, 263, 289, 196, 294, 1128, 737, 437, 245, 13, 7, 42, 779, 799, 130, 41, 5, 779, 799, 23, 880, 65, 159, 602, 89, 1045, 1035, 602, 30, 444, 64, 30, 88, 2065, 2463, 82, 449, 15, 10832, 826, 2, 606, 1, 86, 710, 23, 331, 65, 294, 712, 93, 130, 11, 108, 141, 1045, 1035, 2065, 2463, 82, 606, 1, 86, 710, 2, 64, 88, 449, 15, 64, 88, 10832, 826, 3, 4117, 2, 48, 307, 1582, 1, 7, 5, 263, 289, 799, 9, 135, 5, 13, 14, 18, 27, 2, 39, 1, 46, 177, 130, 11, 13, 588, 13, 355, 13, 680, 13, 1730, 13, 1615, 13, 175, 13, 269, 13, 213, 13, 239, 13, 605, 13, 466, 13, 739, 2, 13, 431, 13, 667, 13, 772, 106, 88, 10, 8, 93, 980, 1, 278, 9, 449, 2, 10832, 134, 84, 44, 9, 8124, 2965, 134, 8, 177, 558, 75, 3, 294, 2721, 130, 8754, 467, 122, 1856, 3723, 7, 237, 43, 271, 1, 779, 278, 3, 2720, 1, 26, 558, 16, 2974, 6, 3, 1939, 1, 1605, 74, 2, 257, 40, 938, 4, 195, 38, 94]",1630.0,19386433,13
The fallen one: the inferior parathyroid gland that descends into the mediastinum.,Journal of the American College of Surgeons,J. Am. Coll. Surg.,2009-05-01,"Inferior parathyroid glands are located along the embryologic migration path of the thymus and can rest in the thyrothymic ligament or anterior mediastinum. Our nomenclature system designates these glands as ""fallen"" (type F) glands. This study reviews our experience with type F parathyroid glands to determine which can be retrieved successfully through a cervical incision. A retrospective review of patients who underwent parathyroidectomy between June 1998 and May 2008 was performed. Patient demographics, localization studies, and operative and pathologic reports were analyzed. Distance from the superior aspect of the clavicle to the target parathyroid gland was measured. Sixty (9.2%) patients had a type F parathyroid gland. Parathyroidectomy was performed through cervical incision in 54 (90%) patients and 6 (10%) required a thoracic approach. Preoperative imaging identified parathyroid glands located >or=6 cm below the superior aspect of the clavicle in eight patients. Of these, six (75%) required a thoracic approach and two (25%) were resected through a cervical incision with concomitant thymectomy. Parathyroidectomy was successfully performed through a cervical incision in all 52 (100%) patients in whom the target parathyroid gland was <6 cm below the superior aspect of the clavicle (Fisher's exact test, p < 0.001). A cervical approach allows successful retrieval of type F parathyroid glands located <6 cm below the superior aspect of the head of the clavicle in the anterior mediastinum. Parathyroidectomy for glands located >or=6 cm below the superior aspect of the clavicle can be attempted from the neck with concomitant thymectomy, but the majority will require a thoracic approach.",Journal Article,3917.0,12.0,Inferior glands are located along the embryologic migration path of the thymus and can rest in the thyrothymic ligament or anterior mediastinum Our nomenclature system designates these glands as `` fallen '' type F glands This study reviews our experience with type F glands to determine which can be retrieved successfully through a incision A retrospective review of patients who underwent parathyroidectomy between June 1998 and May 2008 was performed Patient demographics localization studies and operative and pathologic reports were analyzed Distance from the superior aspect of the clavicle to the target gland was measured Sixty 9.2 patients had a type F gland Parathyroidectomy was performed through incision in 54 90 patients and 6 10 required a thoracic approach Preoperative imaging identified glands located or=6 cm below the superior aspect of the clavicle in eight patients Of these six 75 required a thoracic approach and two 25 were resected through a incision with concomitant thymectomy Parathyroidectomy was successfully performed through a incision in all 52 100 patients in whom the target gland was 6 cm below the superior aspect of the clavicle Fisher 's exact test p 0.001 A approach allows successful retrieval of type F glands located 6 cm below the superior aspect of the head of the clavicle in the anterior mediastinum Parathyroidectomy for glands located or=6 cm below the superior aspect of the clavicle can be attempted from the with concomitant thymectomy but the majority will require a thoracic approach,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1663, 3966, 32, 2308, 1510, 3, 39002, 1381, 6361, 1, 3, 9468, 2, 122, 3677, 4, 3, 57928, 15908, 15, 2882, 7156, 114, 14925, 398, 34303, 46, 3966, 22, 18310, 522, 267, 1068, 3966, 26, 45, 2004, 114, 730, 5, 267, 1068, 3966, 6, 223, 92, 122, 40, 4539, 1878, 298, 8, 7538, 8, 459, 206, 1, 7, 54, 208, 23116, 59, 1924, 1850, 2, 68, 1375, 10, 173, 69, 2221, 2145, 94, 2, 1208, 2, 510, 1198, 11, 311, 3019, 29, 3, 1123, 7416, 1, 3, 21248, 6, 3, 283, 2326, 10, 644, 1746, 83, 18, 7, 42, 8, 267, 1068, 2326, 23116, 10, 173, 298, 7538, 4, 667, 424, 7, 2, 49, 79, 616, 8, 2098, 353, 498, 270, 108, 3966, 2308, 15, 49, 494, 2736, 3, 1123, 7416, 1, 3, 21248, 4, 659, 7, 1, 46, 437, 481, 616, 8, 2098, 353, 2, 100, 243, 11, 1133, 298, 8, 7538, 5, 1781, 14605, 23116, 10, 1878, 173, 298, 8, 7538, 4, 62, 653, 394, 7, 4, 953, 3, 283, 2326, 10, 49, 494, 2736, 3, 1123, 7416, 1, 3, 21248, 3135, 292, 2472, 412, 19, 13, 144, 8, 353, 2333, 1401, 8372, 1, 267, 1068, 3966, 2308, 49, 494, 2736, 3, 1123, 7416, 1, 3, 718, 1, 3, 21248, 4, 3, 2882, 7156, 23116, 9, 3966, 2308, 15, 49, 494, 2736, 3, 1123, 7416, 1, 3, 21248, 122, 40, 4098, 29, 3, 5, 1781, 14605, 84, 3, 686, 303, 1353, 8, 2098, 353]",1539.0,19476855,249
Anaplastic thyroid cancer manifesting as new-onset Horner syndrome.,Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,Endocr Pract,,"To report a case of Horner syndrome as the initial sign of locally advanced anaplastic thyroid cancer. We present a case report in conjunction with a retrospective review and evaluation of the English-language literature on Horner syndrome and thyroid pathologic conditions. Horner syndrome is a rare complication of thyroid disease most often occurring in the postoperative setting after resections. Preoperatively, Horner syndrome is usually caused by a benign intrathoracic goiter that compresses the sympathetic plexus as it exits the thoracic cavity to enter the neck. Malignant thyroid disease leading to Horner syndrome is less common than benign causes of the syndrome. Treatment of compressive lesions can lead to resolution of nerve compression. Horner syndrome is a rare complication of thyroid pathologic conditions. When present preoperatively, the majority of cases are due to benign compression of the cervical plexus. Therefore, Horner syndrome in the setting of a goiter does not necessarily portend a malignant process as one might suspect. Nonetheless, it still remains important that those patients who present with Horner syndrome undergo appropriate assessment for detection of mass lesions, underlying vascular etiologic factors, or other potentially treatable disorders causing sympathetic chain dysfunction.",Case Reports,,9.0,To report a case of Horner syndrome as the initial sign of locally advanced anaplastic cancer We present a case report in conjunction with a retrospective review and evaluation of the English-language literature on Horner syndrome and pathologic conditions Horner syndrome is a rare complication of disease most often occurring in the postoperative setting after resections Preoperatively Horner syndrome is usually caused by a benign intrathoracic goiter that compresses the sympathetic plexus as it exits the thoracic cavity to enter the Malignant disease leading to Horner syndrome is less common than benign causes of the syndrome Treatment of compressive lesions can lead to resolution of nerve compression Horner syndrome is a rare complication of pathologic conditions When present preoperatively the majority of cases are due to benign compression of the plexus Therefore Horner syndrome in the setting of a goiter does not necessarily portend a malignant process as one might suspect Nonetheless it still remains important that those patients who present with Horner syndrome undergo appropriate assessment for detection of mass lesions underlying vascular etiologic factors or other potentially treatable disorders causing sympathetic chain dysfunction,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[6, 414, 8, 473, 1, 23771, 681, 22, 3, 388, 7636, 1, 795, 131, 1841, 12, 21, 364, 8, 473, 414, 4, 3357, 5, 8, 459, 206, 2, 451, 1, 3, 4201, 4794, 789, 23, 23771, 681, 2, 510, 1298, 23771, 681, 16, 8, 622, 1447, 1, 34, 96, 629, 1821, 4, 3, 573, 546, 50, 2185, 3888, 23771, 681, 16, 2082, 1546, 20, 8, 1002, 7359, 16309, 17, 57939, 3, 11277, 9576, 22, 192, 45567, 3, 2098, 2405, 6, 7058, 3, 393, 34, 1049, 6, 23771, 681, 16, 299, 186, 76, 1002, 1626, 1, 3, 681, 24, 1, 33928, 406, 122, 1122, 6, 2125, 1, 2476, 3481, 23771, 681, 16, 8, 622, 1447, 1, 510, 1298, 198, 364, 3888, 3, 686, 1, 140, 32, 520, 6, 1002, 3481, 1, 3, 9576, 673, 23771, 681, 4, 3, 546, 1, 8, 16309, 1097, 44, 7766, 11293, 8, 393, 1129, 22, 104, 822, 17657, 4648, 192, 1234, 469, 305, 17, 135, 7, 54, 364, 5, 23771, 681, 1251, 870, 455, 9, 638, 1, 782, 406, 1181, 756, 6604, 130, 15, 127, 751, 9437, 1997, 3440, 11277, 1260, 1527]",1262.0,19491063,89
Cancer prevention: from 1727 to milestones of the past 100 years.,Cancer research,Cancer Res.,2009-06-02,"The rich, multidisciplinary history of cancer prevention recounted here begins with surgical and workplace recommendations of the 1700s and ends with 2009 results of the enormous (35,535 men) Selenium and Vitamin E [prostate] Cancer Prevention Trial (SELECT). This history comprises a fascinating array of chemopreventive, vaccine, surgical, and behavioral science research, both preclinical and clinical. Preclinical milestones of cancer prevention include the 1913 and 1916 mouse studies by Lathrop and Loeb of cancer development associated with pregnancy or cancer prevention through castration (oophorectomy), preventing chemically induced mouse carcinogenesis as early as 1929, energy restriction studies in the 1940s, the 1950s discoveries and later molecular characterizations of field cancerization and multistep carcinogenesis, and the effects of angiogenesis inhibition in genetically engineered mice reported in 2009. The extraordinary panoply of clinical research includes numerous large and smaller chemoprevention studies of nutritional supplements, other dietary approaches, a Bacillus Calmette-Gurin trial in 1976, molecular-targeted agents, and agents to prevent infection-related cancers such as hepatitis B virus vaccine to prevent liver cancer in 1984. Clinical surgical prevention includes removal of intraepithelial neoplasia detected by screening (including Pap testing developed in 1929 and culposcopy for cervical premalignancy and colonoscopy and polypectomy to prevent colorectal cancer begun in the 1960s) and prophylactic surgeries, such as in Lynch syndrome patients begun in 1977. Behavioral studies include smoking cessation and control beginning in the 1950s, obesity control rooted in studies of 1841, and genetic-counseling and cancer-survivorship studies. This history of pioneering events may help in better understanding who we are and what we want to achieve as cancer prevention researchers and practitioners.",Historical Article,3885.0,86.0,"The rich multidisciplinary history of cancer prevention recounted here begins with surgical and workplace recommendations of the 1700s and ends with 2009 results of the enormous 35,535 men Selenium and Vitamin E Cancer Prevention Trial SELECT This history comprises a fascinating array of chemopreventive vaccine surgical and behavioral science research both preclinical and clinical Preclinical milestones of cancer prevention include the 1913 and 1916 mouse studies by Lathrop and Loeb of cancer development associated with pregnancy or cancer prevention through castration oophorectomy preventing chemically induced mouse carcinogenesis as early as 1929 energy restriction studies in the 1940s the 1950s discoveries and later molecular characterizations of field cancerization and multistep carcinogenesis and the effects of angiogenesis inhibition in genetically engineered mice reported in 2009 The extraordinary panoply of clinical research includes numerous large and smaller chemoprevention studies of nutritional supplements other dietary approaches a Bacillus Calmette-Gurin trial in 1976 molecular-targeted agents and agents to prevent infection-related cancers such as hepatitis B virus vaccine to prevent cancer in 1984 Clinical surgical prevention includes removal of intraepithelial neoplasia detected by screening including Pap testing developed in 1929 and culposcopy for premalignancy and colonoscopy and polypectomy to prevent cancer begun in the 1960s and prophylactic surgeries such as in Lynch syndrome patients begun in 1977 Behavioral studies include smoking cessation and control beginning in the 1950s obesity control rooted in studies of 1841 and genetic-counseling and cancer-survivorship studies This history of pioneering events may help in better understanding who we are and what we want to achieve as cancer prevention researchers and practitioners",0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 3697, 1643, 532, 1, 12, 1070, 57942, 467, 12811, 5, 221, 2, 18331, 883, 1, 3, 57943, 2, 10894, 5, 1238, 99, 1, 3, 8790, 465, 10528, 325, 5037, 2, 1610, 563, 12, 1070, 160, 1717, 26, 532, 6704, 8, 34215, 1926, 1, 4401, 1274, 221, 2, 4166, 3797, 389, 110, 693, 2, 38, 693, 12118, 1, 12, 1070, 643, 3, 45569, 2, 34698, 830, 94, 20, 57944, 2, 57945, 1, 12, 193, 41, 5, 2290, 15, 12, 1070, 298, 1517, 3470, 3017, 9343, 277, 830, 1719, 22, 191, 22, 39006, 2803, 4575, 94, 4, 3, 34699, 3, 25016, 5012, 2, 1559, 219, 19668, 1, 1067, 18377, 2, 9417, 1719, 2, 3, 176, 1, 1056, 297, 4, 2301, 2794, 399, 210, 4, 1238, 3, 17915, 19878, 1, 38, 389, 1920, 2331, 375, 2, 2170, 2886, 94, 1, 5082, 6600, 127, 2013, 611, 8, 4947, 4803, 6365, 160, 4, 8586, 219, 238, 183, 2, 183, 6, 1682, 930, 139, 163, 225, 22, 3002, 132, 1450, 1274, 6, 1682, 12, 4, 6036, 38, 221, 1070, 1920, 2829, 1, 4153, 2298, 530, 20, 453, 141, 4290, 471, 276, 4, 39006, 2, 57946, 9, 21992, 2, 3996, 2, 11043, 6, 1682, 12, 6973, 4, 3, 22148, 2, 1862, 5305, 225, 22, 4, 3546, 681, 7, 6973, 4, 11792, 4166, 94, 643, 979, 3345, 2, 182, 2948, 4, 3, 25016, 1661, 182, 33684, 4, 94, 1, 57947, 2, 336, 2011, 2, 12, 2560, 94, 26, 532, 1, 25175, 281, 68, 987, 4, 380, 612, 54, 21, 32, 2, 2067, 21, 9651, 6, 1359, 22, 12, 1070, 4211, 2, 6323]",1882.0,19491253,291
Parametrial involvement in radical hysterectomy specimens for women with early-stage cervical cancer.,Obstetrics and gynecology,Obstet Gynecol,2009-07-01,"To estimate the incidence of parametrial involvement and to evaluate factors associated with parametrial spread in women with early-stage cervical cancer and to identify a cohort of patients at low risk for parametrial spread who may benefit from less radical surgery. We reviewed all patients who underwent radical hysterectomy and pelvic lymphadenectomy for invasive cervical cancer between 1990 and 2006. All women with squamous, adenocarcinoma, or adenosquamous disease, stage IA2-IB1, who underwent completed radical hysterectomy were included in the analysis. Normally distributed continuous variables were compared using Student's t-test for independent samples to analyze the outcome of positive or negative parametrial involvement. Three hundred fifty patients met the inclusion criteria. Overall, 27 women (7.7%) had parametrial involvement. The majority of specimens with parametrial involvement (52%) had tumor spread through direct microscopic extension. Patients with parametrial involvement were more likely to have a primary tumor size larger than 2 cm (larger than 2 cm: 14%, smaller than 2 cm: 4%, P=.001), higher histologic grade (grade 3: 12%, grades 1 and 2: 3%, P=.01), lymphovascular space invasion (positive: 12%, negative: 3%, P=.002), and metastasis to the pelvic lymph nodes (positive: 31%, negative: 4%, P<.001). One hundred twenty-five women (36%) had squamous, adenocarcinoma, or adenosquamous lesions, all grades, with primary tumor size 2 cm or smaller and no lymphovascular space invasion. In this group of patients, there was no pathologic evidence of parametrial involvement. We were able to retrospectively identify a cohort of women with early-stage cervical cancer who were at very low risk for parametrial involvement. If prospective application of these findings confirms our results, less radical surgery-such as simple hysterectomy, simple trachelectomy, or conization-with pelvic lymphadenectomy may be a reasonable therapeutic option for women with primary tumors 2 cm or smaller and no lymphovascular space invasion. III.",Journal Article,3856.0,129.0,To estimate the incidence of parametrial involvement and to evaluate factors associated with parametrial spread in women with early-stage cancer and to identify a cohort of patients at low risk for parametrial spread who may benefit from less radical surgery We reviewed all patients who underwent radical hysterectomy and pelvic lymphadenectomy for invasive cancer between 1990 and 2006 All women with squamous adenocarcinoma or adenosquamous disease stage IA2-IB1 who underwent completed radical hysterectomy were included in the analysis Normally distributed continuous variables were compared using Student 's t-test for independent samples to analyze the outcome of positive or negative parametrial involvement Three hundred fifty patients met the inclusion criteria Overall 27 women 7.7 had parametrial involvement The majority of specimens with parametrial involvement 52 had tumor spread through direct microscopic extension Patients with parametrial involvement were more likely to have a primary tumor size larger than 2 cm larger than 2 cm 14 smaller than 2 cm 4 P=.001 higher histologic grade grade 3 12 grades 1 and 2 3 P=.01 lymphovascular space invasion positive 12 negative 3 P=.002 and metastasis to the pelvic lymph nodes positive 31 negative 4 P .001 One hundred twenty-five women 36 had squamous adenocarcinoma or adenosquamous lesions all grades with primary tumor size 2 cm or smaller and no lymphovascular space invasion In this group of patients there was no pathologic evidence of parametrial involvement We were able to retrospectively identify a cohort of women with early-stage cancer who were at very low risk for parametrial involvement If prospective application of these findings confirms our results less radical surgery-such as simple hysterectomy simple trachelectomy or conization-with pelvic lymphadenectomy may be a reasonable therapeutic option for women with primary tumors 2 cm or smaller and no lymphovascular space invasion III,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1191, 3, 287, 1, 8726, 799, 2, 6, 376, 130, 41, 5, 8726, 2579, 4, 117, 5, 191, 82, 12, 2, 6, 255, 8, 180, 1, 7, 28, 154, 43, 9, 8726, 2579, 54, 68, 247, 29, 299, 711, 152, 21, 446, 62, 7, 54, 208, 711, 2622, 2, 1110, 2048, 9, 416, 12, 59, 2289, 2, 1324, 62, 117, 5, 691, 449, 15, 8067, 34, 82, 16725, 8111, 54, 208, 781, 711, 2622, 11, 159, 4, 3, 65, 6150, 4737, 1314, 682, 11, 72, 75, 6390, 292, 102, 412, 9, 306, 347, 6, 1992, 3, 228, 1, 109, 15, 199, 8726, 799, 169, 1128, 1461, 7, 543, 3, 1680, 371, 63, 428, 117, 67, 67, 42, 8726, 799, 3, 686, 1, 623, 5, 8726, 799, 653, 42, 30, 2579, 298, 1196, 2984, 2401, 7, 5, 8726, 799, 11, 80, 322, 6, 47, 8, 86, 30, 444, 1077, 76, 18, 494, 1077, 76, 18, 494, 213, 2170, 76, 18, 494, 39, 19, 144, 142, 884, 88, 88, 27, 133, 2276, 14, 2, 18, 27, 19, 355, 2933, 3865, 578, 109, 133, 199, 27, 19, 1111, 2, 278, 6, 3, 1110, 263, 502, 109, 456, 199, 39, 19, 144, 104, 1128, 737, 365, 117, 511, 42, 691, 449, 15, 8067, 406, 62, 2276, 5, 86, 30, 444, 18, 494, 15, 2170, 2, 77, 2933, 3865, 578, 4, 26, 87, 1, 7, 125, 10, 77, 510, 241, 1, 8726, 799, 21, 11, 1665, 6, 894, 255, 8, 180, 1, 117, 5, 191, 82, 12, 54, 11, 28, 923, 154, 43, 9, 8726, 799, 492, 482, 1581, 1, 46, 272, 5120, 114, 99, 299, 711, 152, 225, 22, 2763, 2622, 2763, 5760, 15, 8755, 5, 1110, 2048, 68, 40, 8, 3203, 189, 1501, 9, 117, 5, 86, 57, 18, 494, 15, 2170, 2, 77, 2933, 3865, 578, 316]",1970.0,19546764,62
Targeted in vivo imaging of integrin alphavbeta6 with an improved radiotracer and its relevance in a pancreatic tumor model.,Cancer research,Cancer Res.,2009-06-23,"The cell surface receptor alpha(v)beta(6) is epithelial specific, and its expression is tightly regulated; it is low or undetectable in adult tissues but has been shown to be increased in many different cancers, including pancreatic, cervical, lung, and colon cancers. Studies have described alpha(v)beta(6) as a prognostic biomarker linked to poor survival. We have recently shown the feasibility of imaging alpha(v)beta(6) in vivo by positron emission tomography (PET) using the peptide [(18)F]FBA-A20FMDV2. Here, we describe improved alpha(v)beta(6) imaging agents and test their efficacy in a mouse model with endogenous alpha(v)beta(6) expression. The modified compounds maintained high affinity for alpha(v)beta(6) and >1,000-fold selectivity over related integrins (by ELISA) and showed significantly improved alpha(v)beta(6)-dependent binding in cell-based assays (>60% binding versus <10% for [(18)F]FBA-A20FMDV2). In vivo studies using either a melanoma cell line (transduced alpha(v)beta(6) expression) or the BxPC-3 human pancreatic carcinoma cell line (endogenous alpha(v)beta(6) expression) revealed that the modified compounds showed significantly improved tumor retention. This, along with good clearance of nonspecifically bound activity, particularly for the new radiotracer [(18)F]FBA-PEG(28)-A20FMDV2, resulted in improved PET imaging. Tumor/pancreas and tumor/blood biodistribution ratios of >23:1 and >47:1, respectively, were achieved at 4 hours. Significantly, [(18)F]FBA-PEG(28)-A20FMDV2 was superior to 2-[(18)F]fluoro-2-deoxy-d-glucose ([(18)F]FDG) in imaging the BxPC-3 tumors. Pancreatic ductal adenocarcinoma is highly metastatic and current preoperative evaluation of resectability using noninvasive imaging has limited success, with most patients having metastases at time of surgery. The fact that these tumors express alpha(v)beta(6) suggests that this probe has significant potential for the in vivo detection of this malignancy, thus having important implications for patient care and therapy.",Journal Article,3864.0,61.0,"The cell surface receptor alpha v beta 6 is epithelial specific and its expression is tightly regulated it is low or undetectable in adult tissues but has been shown to be increased in many different cancers including and cancers Studies have described alpha v beta 6 as a prognostic biomarker linked to poor survival We have recently shown the feasibility of imaging alpha v beta 6 in vivo by positron emission tomography PET using the peptide 18 F FBA-A20FMDV2 Here we describe improved alpha v beta 6 imaging agents and test their efficacy in a mouse model with endogenous alpha v beta 6 expression The modified compounds maintained high affinity for alpha v beta 6 and 1,000-fold selectivity over related integrins by ELISA and showed significantly improved alpha v beta 6 -dependent binding in cell-based assays 60 binding versus 10 for 18 F FBA-A20FMDV2 In vivo studies using either a cell line transduced alpha v beta 6 expression or the BxPC-3 human carcinoma cell line endogenous alpha v beta 6 expression revealed that the modified compounds showed significantly improved tumor retention This along with good clearance of nonspecifically bound activity particularly for the new radiotracer 18 F FBA-PEG 28 -A20FMDV2 resulted in improved PET imaging Tumor/pancreas and tumor/blood biodistribution ratios of 23:1 and 47:1 respectively were achieved at 4 hours Significantly 18 F FBA-PEG 28 -A20FMDV2 was superior to 2- 18 F fluoro-2-deoxy-d-glucose 18 F FDG in imaging the BxPC-3 tumors ductal adenocarcinoma is highly metastatic and current preoperative evaluation of resectability using noninvasive imaging has limited success with most patients having metastases at time of surgery The fact that these tumors express alpha v beta 6 suggests that this probe has significant potential for the in vivo detection of this malignancy thus having important implications for patient care and therapy",0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 31, 1255, 153, 950, 603, 1090, 49, 16, 701, 112, 2, 211, 55, 16, 8507, 1065, 192, 16, 154, 15, 3920, 4, 780, 742, 84, 71, 85, 443, 6, 40, 101, 4, 445, 338, 163, 141, 2, 163, 94, 47, 1027, 950, 603, 1090, 49, 22, 8, 177, 901, 1199, 6, 334, 25, 21, 47, 761, 443, 3, 1437, 1, 270, 950, 603, 1090, 49, 4, 386, 20, 1900, 1799, 872, 495, 75, 3, 1389, 203, 1068, 31447, 17392, 467, 21, 897, 231, 950, 603, 1090, 49, 270, 183, 2, 412, 136, 209, 4, 8, 830, 202, 5, 2682, 950, 603, 1090, 49, 55, 3, 1230, 2411, 1955, 64, 3601, 9, 950, 603, 1090, 49, 2, 14, 984, 1116, 6072, 252, 139, 6593, 20, 3664, 2, 224, 97, 231, 950, 603, 1090, 49, 470, 791, 4, 31, 90, 1013, 335, 791, 185, 79, 9, 203, 1068, 31447, 17392, 4, 386, 94, 75, 361, 8, 31, 328, 5042, 950, 603, 1090, 49, 55, 15, 3, 13026, 27, 171, 134, 31, 328, 2682, 950, 603, 1090, 49, 55, 553, 17, 3, 1230, 2411, 224, 97, 231, 30, 3947, 26, 1510, 5, 1178, 1960, 1, 28705, 2951, 128, 823, 9, 3, 217, 7610, 203, 1068, 31447, 3145, 339, 17392, 627, 4, 231, 495, 270, 30, 15356, 2, 30, 315, 5250, 1137, 1, 382, 14, 2, 662, 14, 106, 11, 513, 28, 39, 1459, 97, 203, 1068, 31447, 3145, 339, 17392, 10, 1123, 6, 18, 203, 1068, 6231, 18, 6149, 427, 2522, 203, 1068, 1285, 4, 270, 3, 13026, 27, 57, 1258, 449, 16, 561, 113, 2, 291, 498, 451, 1, 5150, 75, 2957, 270, 71, 383, 1825, 5, 96, 7, 1041, 196, 28, 98, 1, 152, 3, 1991, 17, 46, 57, 1669, 950, 603, 1090, 49, 844, 17, 26, 2888, 71, 93, 174, 9, 3, 4, 386, 638, 1, 26, 710, 631, 1041, 305, 1268, 9, 69, 165, 2, 36]",1902.0,19549907,53
Limiting the morbidity of inguinal lymphadenectomy for metastatic melanoma.,Cancer control : journal of the Moffitt Cancer Center,Cancer Control,2009-07-01,"Surgery is currently the primary treatment modality for metastatic melanoma involving the inguinal lymph nodes. However, inguinal lymph node dissections are associated with substantial morbidity including infection, wound dehiscence, lymphedema, seroma, and deep venous thromboembolism (DVT). Improved understanding is needed regarding the factors predisposing patients to complications and the operative and perioperative maneuvers that can decrease morbidity. We reviewed recently published literature regarding the morbidity associated with lymphadenectomy in the treatment of inguinal metastatic melanoma. Where available, emphasis was focused on appropriately designed studies aimed at reducing treatment-related morbidity. When appropriate, the review was supplemented by our personal experience. Strategies to limit treatment-related morbidity involve optimizing the preoperative assessment, operative technique, and postoperative care. Establishing the diagnosis of nodal metastasis early using minimally invasive techniques is critical to reduce subsequent perioperative complications. Morbidity is higher for inguinal compared to cervical or axillary lymphadenectomy, and many variations in extent of inguinal lymphadenectomy and operative technique have been reported. The lack of definitive trials has led to controversy regarding surgical technique such as indications for pelvic lymphadenectomy (""deep"" node dissection), saphenous vein preservation, and sartorius transposition. In the postoperative period, the use of DVT and lymphedema prophylaxis should be considered to potentially improve patient outcomes. While the morbidity of inguinal lymphadenectomy can be substantial, several straightforward pre- and postoperative measures can be instituted to limit morbidity. Controversy persists regarding the indications for and benefit of pelvic lymphadenectomy, saphenous vein preservation, and sartorius muscle transposition. A multi-institutional trial is currently in progress to investigate the safety of avoiding lymphadenectomy in patients with microscopic metastases in the sentinel node.",Journal Article,3856.0,38.0,Surgery is currently the primary treatment modality for metastatic involving the inguinal lymph nodes However inguinal lymph node dissections are associated with substantial morbidity including infection wound dehiscence lymphedema seroma and deep venous thromboembolism DVT Improved understanding is needed regarding the factors predisposing patients to complications and the operative and perioperative maneuvers that can decrease morbidity We reviewed recently published literature regarding the morbidity associated with lymphadenectomy in the treatment of inguinal metastatic Where available emphasis was focused on appropriately designed studies aimed at reducing treatment-related morbidity When appropriate the review was supplemented by our personal experience Strategies to limit treatment-related morbidity involve optimizing the preoperative assessment operative technique and postoperative care Establishing the diagnosis of nodal metastasis early using minimally invasive techniques is critical to reduce subsequent perioperative complications Morbidity is higher for inguinal compared to or axillary lymphadenectomy and many variations in extent of inguinal lymphadenectomy and operative technique have been reported The lack of definitive trials has led to controversy regarding surgical technique such as indications for pelvic lymphadenectomy `` deep '' node dissection saphenous vein preservation and sartorius transposition In the postoperative period the use of DVT and lymphedema prophylaxis should be considered to potentially improve patient outcomes While the morbidity of inguinal lymphadenectomy can be substantial several straightforward pre- and postoperative measures can be instituted to limit morbidity Controversy persists regarding the indications for and benefit of pelvic lymphadenectomy saphenous vein preservation and sartorius muscle transposition A multi-institutional trial is currently in progress to investigate the safety of avoiding lymphadenectomy in patients with microscopic metastases in the sentinel node,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[152, 16, 694, 3, 86, 24, 1396, 9, 113, 1267, 3, 4907, 263, 502, 137, 4907, 263, 289, 6894, 32, 41, 5, 1281, 787, 141, 930, 2689, 11811, 3063, 11655, 2, 2369, 2167, 3501, 6311, 231, 612, 16, 575, 666, 3, 130, 6885, 7, 6, 521, 2, 3, 1208, 2, 1547, 21163, 17, 122, 775, 787, 21, 446, 761, 983, 789, 666, 3, 787, 41, 5, 2048, 4, 3, 24, 1, 4907, 113, 1257, 390, 3136, 10, 1649, 23, 4544, 1114, 94, 1295, 28, 1818, 24, 139, 787, 198, 870, 3, 206, 10, 7687, 20, 114, 3008, 730, 422, 6, 2385, 24, 139, 787, 3882, 4336, 3, 498, 455, 1208, 1312, 2, 573, 165, 4431, 3, 147, 1, 779, 278, 191, 75, 2144, 416, 1092, 16, 740, 6, 969, 706, 1547, 521, 787, 16, 142, 9, 4907, 72, 6, 15, 1210, 2048, 2, 445, 2293, 4, 1039, 1, 4907, 2048, 2, 1208, 1312, 47, 85, 210, 3, 926, 1, 1057, 143, 71, 836, 6, 4089, 666, 221, 1312, 225, 22, 2406, 9, 1110, 2048, 2369, 522, 289, 1161, 24877, 2762, 2224, 2, 39031, 19640, 4, 3, 573, 727, 3, 119, 1, 6311, 2, 3063, 2049, 257, 40, 515, 6, 751, 401, 69, 123, 369, 3, 787, 1, 4907, 2048, 122, 40, 1281, 392, 12753, 671, 2, 573, 1018, 122, 40, 12310, 6, 2385, 787, 4089, 8936, 666, 3, 2406, 9, 2, 247, 1, 1110, 2048, 24877, 2762, 2224, 2, 39031, 1502, 19640, 8, 1414, 1115, 160, 16, 694, 4, 1466, 6, 963, 3, 367, 1, 6048, 2048, 4, 7, 5, 2984, 196, 4, 3, 1323, 289]",2054.0,19556964,581
Patterns of regional recurrence after definitive radiotherapy for cervical cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2009-07-04,"To determine the patterns of regional recurrence in patients treated with definitive radiotherapy (RT) for cervical cancer. The records of 198 patients treated with definitive RT for cervical cancer between 1980 and 2000 who experienced a regional recurrence without a central or distal vaginal recurrence were reviewed. All patients received a combination of external-beam RT and intracavitary brachytherapy. In the 180 patients with a documented location of regional recurrence, the relationship between the recurrence and the radiation fields was determined. The median time to regional recurrence was 13 months (range, 2-85 months). Of the 180 patients who had an evaluable regional recurrence, 119 (66%) had a component of marginal failure; 71 patients recurred above-the-field, 2 patients occurred in the inguinal nodes, and 2 patients recurred above-the-field and in the inguinal nodes. In addition, 105 patients (58%) had a component of in-field failure; 59 patients recurred in-field only, 39 patients recurred in-field and above-the-field, 2 patients recurred in-field, above-the-field, and in the inguinal nodes, and 5 patients recurred in-field and in the inguinal nodes. The median survival after regional recurrence was 8 months (range, 0-194 months). Most regional recurrences after definitive RT for cervical cancer include a component of marginal failure, usually immediately superior to the radiation field. These recurrences suggest a deficiency in target volume. Recurrences also occur in-field, suggesting a deficiency in dose. Developments in pretreatment staging, field delineation, dose escalation, and posttreatment surveillance may help to improve outcome in these patients.",Journal Article,3853.0,54.0,To determine the patterns of regional recurrence in patients treated with definitive radiotherapy RT for cancer The records of 198 patients treated with definitive RT for cancer between 1980 and 2000 who experienced a regional recurrence without a central or distal recurrence were reviewed All patients received a combination of external-beam RT and intracavitary brachytherapy In the 180 patients with a documented location of regional recurrence the relationship between the recurrence and the radiation fields was determined The median time to regional recurrence was 13 months range 2-85 months Of the 180 patients who had an evaluable regional recurrence 119 66 had a component of marginal failure 71 patients recurred above-the-field 2 patients occurred in the inguinal nodes and 2 patients recurred above-the-field and in the inguinal nodes In addition 105 patients 58 had a component of in-field failure 59 patients recurred in-field only 39 patients recurred in-field and above-the-field 2 patients recurred in-field above-the-field and in the inguinal nodes and 5 patients recurred in-field and in the inguinal nodes The median survival after regional recurrence was 8 months range 0-194 months Most regional recurrences after definitive RT for cancer include a component of marginal failure usually immediately superior to the radiation field These recurrences suggest a deficiency in target volume Recurrences also occur in-field suggesting a deficiency in dose Developments in pretreatment staging field delineation dose escalation and posttreatment surveillance may help to improve outcome in these patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 764, 1, 951, 146, 4, 7, 73, 5, 1057, 310, 240, 9, 12, 3, 1064, 1, 6189, 7, 73, 5, 1057, 240, 9, 12, 59, 4376, 2, 1081, 54, 592, 8, 951, 146, 187, 8, 854, 15, 2107, 146, 11, 446, 62, 7, 103, 8, 150, 1, 1455, 1345, 240, 2, 9122, 1536, 4, 3, 3172, 7, 5, 8, 1405, 1147, 1, 951, 146, 3, 858, 59, 3, 146, 2, 3, 121, 3130, 10, 509, 3, 52, 98, 6, 951, 146, 10, 233, 53, 184, 18, 772, 53, 1, 3, 3172, 7, 54, 42, 35, 859, 951, 146, 4299, 700, 42, 8, 1249, 1, 3450, 496, 792, 7, 3363, 2090, 3, 1067, 18, 7, 489, 4, 3, 4907, 502, 2, 18, 7, 3363, 2090, 3, 1067, 2, 4, 3, 4907, 502, 4, 352, 3263, 7, 717, 42, 8, 1249, 1, 4, 1067, 496, 728, 7, 3363, 4, 1067, 158, 587, 7, 3363, 4, 1067, 2, 2090, 3, 1067, 18, 7, 3363, 4, 1067, 2090, 3, 1067, 2, 4, 3, 4907, 502, 2, 33, 7, 3363, 4, 1067, 2, 4, 3, 4907, 502, 3, 52, 25, 50, 951, 146, 10, 66, 53, 184, 13, 5434, 53, 96, 951, 1593, 50, 1057, 240, 9, 12, 643, 8, 1249, 1, 3450, 496, 2082, 3467, 1123, 6, 3, 121, 1067, 46, 1593, 309, 8, 2299, 4, 283, 433, 1593, 120, 1271, 4, 1067, 802, 8, 2299, 4, 61, 3703, 4, 1194, 632, 1067, 5529, 61, 1125, 2, 3149, 617, 68, 987, 6, 401, 228, 4, 46, 7]",1622.0,19581056,427
"Cervical cancer therapy: current, future and anti-angiogensis targeted treatment.",Expert review of anticancer therapy,Expert Rev Anticancer Ther,2009-07-01,"While the incidence of cervical cancer has declined significantly in the USA, ethnic disparities remain in terms of increased mortality and morbidity. Furthermore, this disease continues to be a significant burden on developing countries, with cervical cancer currently ranked as the second most common cause of cancer-related morbidity and the third most common cause of mortality worldwide. Treatment of cervical cancer has typically been viewed as surgical with possible adjuvant therapy versus initial radiotherapy and platinum-based chemotherapy. Prognosis and therapy for patients with recurrent disease is dependent upon the site of recurrence and ability to pursue curative therapy. This article will review the management of cervical cancer, including studies that have evaluated the treatment of distant metastasis or recurrent disease, as well as discussing the importance of angiogenesis and the use of therapies targeted against this phenomenon.",Journal Article,3856.0,38.0,While the incidence of cancer has declined significantly in the USA ethnic disparities remain in terms of increased mortality and morbidity Furthermore this disease continues to be a significant burden on developing countries with cancer currently ranked as the second most common cause of cancer-related morbidity and the third most common cause of mortality worldwide Treatment of cancer has typically been viewed as surgical with possible adjuvant therapy versus initial radiotherapy and platinum-based chemotherapy Prognosis and therapy for patients with recurrent disease is dependent upon the site of recurrence and ability to pursue curative therapy This article will review the management of cancer including studies that have evaluated the treatment of distant metastasis or recurrent disease as well as discussing the importance of angiogenesis and the use of therapies targeted against this phenomenon,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[369, 3, 287, 1, 12, 71, 3054, 97, 4, 3, 2706, 2871, 2227, 918, 4, 1794, 1, 101, 282, 2, 787, 798, 26, 34, 2274, 6, 40, 8, 93, 892, 23, 931, 2115, 5, 12, 694, 6441, 22, 3, 419, 96, 186, 708, 1, 12, 139, 787, 2, 3, 1282, 96, 186, 708, 1, 282, 2358, 24, 1, 12, 71, 1969, 85, 7879, 22, 221, 5, 899, 249, 36, 185, 388, 310, 2, 828, 90, 56, 356, 2, 36, 9, 7, 5, 387, 34, 16, 470, 1548, 3, 606, 1, 146, 2, 801, 6, 7874, 1075, 36, 26, 946, 303, 206, 3, 284, 1, 12, 141, 94, 17, 47, 194, 3, 24, 1, 626, 278, 15, 387, 34, 22, 149, 22, 6003, 3, 1187, 1, 1056, 2, 3, 119, 1, 235, 238, 480, 26, 3936]",912.0,19589029,91
Current understanding of risk factors for ovarian cancer.,Current treatment options in oncology,Curr Treat Options Oncol,2009-07-15,"Ovarian cancer is the deadliest gynecologic cancer. Unlike many cancers such as breast, cervical and colon cancers, there is no easily clinically identifiable pre-malignant phase of this malignancy making early identification difficult. Similarly, unlike lung, head and neck, and skin cancers, there is not easily identifiable risk factor making prevention short of oophorectomy difficult. Even so, theories as to the causative factors of ovarian cancer continue to evolve making our understanding of the genesis of ovarian cancer more clear. Genetics, parity, environment, hormonal factors, and inflammation all play an important and pivotal role in the development of ovarian cancer. The most current understanding of these elements and their respective contribution to the development of this cancer are presented in this chapter.",Journal Article,3842.0,59.0,cancer is the deadliest gynecologic cancer Unlike many cancers such as and cancers there is no easily clinically identifiable pre-malignant phase of this malignancy making early identification difficult Similarly unlike head and and cancers there is not easily identifiable risk factor making prevention short of oophorectomy difficult Even so theories as to the causative factors of cancer continue to evolve making our understanding of the genesis of cancer more clear Genetics parity environment hormonal factors and inflammation all play an important and pivotal role in the development of cancer The most current understanding of these elements and their respective contribution to the development of this cancer are presented in this chapter,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,"[12, 16, 3, 13255, 1512, 12, 4246, 445, 163, 225, 22, 2, 163, 125, 16, 77, 4697, 505, 6237, 671, 393, 124, 1, 26, 710, 1079, 191, 911, 1740, 1813, 4246, 718, 2, 2, 163, 125, 16, 44, 4697, 6237, 43, 161, 1079, 1070, 978, 1, 3470, 1740, 871, 1743, 18219, 22, 6, 3, 8088, 130, 1, 12, 1906, 6, 4800, 1079, 114, 612, 1, 3, 9110, 1, 12, 80, 885, 2894, 5754, 3087, 1761, 130, 2, 1815, 62, 1343, 35, 305, 2, 3754, 200, 4, 3, 193, 1, 12, 3, 96, 291, 612, 1, 46, 2531, 2, 136, 3847, 2925, 6, 3, 193, 1, 26, 12, 32, 917, 4, 26, 6366]",747.0,19603272,76
Dysplastic cells in cytological cervical samples show a high incidence of chromosomal abnormalities.,Diagnostic cytopathology,Diagn. Cytopathol.,2010-01-01,Chromosomal abnormalities are frequent in most cervical cancers. Amplifications of both the 3q26 (TERC) and 8q24 (MYC) loci have been shown to be prevalent in both high-grade lesions and invasive cervical carcinoma. Most of these studies have looked at either the histological sample or at the entire cytological population of cells. We have developed a Papanicolaou (Pap) destaining method that allows for the accurate analysis of individual cells that were previously identified by cytopathology as dysplastic. The application of fluorescence in situ hybridization (FISH) was then implemented to determine the chromosomal status of the dysplastic cells in the samples and correlate the two events. Chromosomal abnormality is over a thousand times more frequent in dysplastic cells compared with their morphologically normal counterparts.,Journal Article,3672.0,3.0,Chromosomal abnormalities are frequent in most cancers Amplifications of both the 3q26 TERC and 8q24 MYC loci have been shown to be prevalent in both high-grade lesions and invasive carcinoma Most of these studies have looked at either the histological sample or at the entire cytological population of cells We have developed a Papanicolaou Pap destaining method that allows for the accurate analysis of individual cells that were previously identified by cytopathology as dysplastic The application of fluorescence in situ hybridization FISH was then implemented to determine the chromosomal status of the dysplastic cells in the samples and correlate the two events Chromosomal abnormality is over a thousand times more frequent in dysplastic cells compared with their morphologically normal counterparts,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1860, 1171, 32, 908, 4, 96, 163, 4877, 1, 110, 3, 10678, 18432, 2, 6069, 1371, 2012, 47, 85, 443, 6, 40, 2485, 4, 110, 64, 88, 406, 2, 416, 134, 96, 1, 46, 94, 47, 13058, 28, 361, 3, 1831, 1000, 15, 28, 3, 1797, 9019, 266, 1, 37, 21, 47, 276, 8, 10416, 4290, 58091, 596, 17, 2333, 9, 3, 1481, 65, 1, 797, 37, 17, 11, 373, 108, 20, 21569, 22, 6461, 3, 1581, 1, 1591, 4, 957, 1554, 1277, 10, 818, 3426, 6, 223, 3, 1860, 156, 1, 3, 6461, 37, 4, 3, 347, 2, 1513, 3, 100, 281, 1860, 3698, 16, 252, 8, 6161, 1072, 80, 908, 4, 6461, 37, 72, 5, 136, 6204, 295, 3953]",807.0,19626623,134
Node-positive adenocarcinoma of the endometrium: outcome and patterns of recurrence with and without external beam irradiation.,Gynecologic oncology,Gynecol. Oncol.,2009-07-25,"To evaluate treatment outcomes and patterns of recurrence in patients with node-positive (International Federation of Obstetrics and Gynecology stage IIIC) adenocarcinoma of the uterus without serous or clear cell differentiation. The records of 71 women who were treated for stage IIIC endometrial adenocarcinoma at our institution between 1984 and 2005 were reviewed. All patients underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy. Fifty patients received definitive pelvic or extended-field radiotherapy with or without systemic therapy (regional RT group). Eighteen received adjuvant systemic platinum-based chemotherapy or hormonal therapy without external beam RT. The median follow-up for patients not dying of disease was 67 months. Survival rates were calculated using the Kaplan-Meier method; differences were assessed using log-rank tests. Thirty-nine percent (28/71) of patients had involved paraaortic lymph nodes while 61% (43/71) had only pelvic lymph nodes. Five- and 10-year disease-specific survival (DSS) rates were 63% and 54%, respectively; corresponding overall survival rates were 60% and 47%. Grade was strongly associated with DSS (76% vs 46% at 5 years for low-grade vs high-grade tumors, P=0.004). Cervical or adnexal involvement was associated with decreased DSS, but lymph-vascular space invasion, age, race, body mass index, and number and location of positive nodes were not. Five-year pelvic-relapse-free survival (98% vs 61%, P=0.001), DSS (78% vs 39%, P=0.01), and overall survival (73% vs 40%, P=0.03) were significantly better for the regional RT group than the systemic therapy group. In patients treated without regional RT, the most common site of relapse was the pelvis. DSS was not significantly correlated with number of nodes removed in the regional RT group but was in patients treated without regional RT (P=0.001). Patients treated without regional RT had a high rate of locoregional recurrence. Patients with stage IIIC endometrial adenocarcinoma who underwent surgical staging followed by external beam irradiation had a high rate of cure. Relapses in patients treated with EBRT primarily occurred in patients with grade 3 cancer who may be most likely to benefit from combined-chemoradiation treatment.",Journal Article,3832.0,85.0,To evaluate treatment outcomes and patterns of recurrence in patients with node-positive International Federation of Obstetrics and Gynecology stage IIIC adenocarcinoma of the without serous or clear cell differentiation The records of 71 women who were treated for stage IIIC adenocarcinoma at our institution between 1984 and 2005 were reviewed All patients underwent total abdominal hysterectomy bilateral salpingo-oophorectomy and lymphadenectomy Fifty patients received definitive pelvic or extended-field radiotherapy with or without systemic therapy regional RT group Eighteen received adjuvant systemic platinum-based chemotherapy or hormonal therapy without external beam RT The median follow-up for patients not dying of disease was 67 months Survival rates were calculated using the Kaplan-Meier method differences were assessed using log-rank tests Thirty-nine percent 28/71 of patients had involved paraaortic lymph nodes while 61 43/71 had only pelvic lymph nodes Five- and 10-year disease-specific survival DSS rates were 63 and 54 respectively corresponding overall survival rates were 60 and 47 Grade was strongly associated with DSS 76 vs 46 at 5 years for low-grade vs high-grade tumors P=0.004 or adnexal involvement was associated with decreased DSS but lymph-vascular space invasion age race body mass index and number and location of positive nodes were not Five-year pelvic-relapse-free survival 98 vs 61 P=0.001 DSS 78 vs 39 P=0.01 and overall survival 73 vs 40 P=0.03 were significantly better for the regional RT group than the systemic therapy group In patients treated without regional RT the most common site of relapse was the pelvis DSS was not significantly correlated with number of nodes removed in the regional RT group but was in patients treated without regional RT P=0.001 Patients treated without regional RT had a high rate of locoregional recurrence Patients with stage IIIC adenocarcinoma who underwent surgical staging followed by external beam irradiation had a high rate of cure Relapses in patients treated with EBRT primarily occurred in patients with grade 3 cancer who may be most likely to benefit from combined-chemoradiation treatment,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 376, 24, 123, 2, 764, 1, 146, 4, 7, 5, 289, 109, 944, 7303, 1, 7407, 2, 6429, 82, 3842, 449, 1, 3, 187, 1744, 15, 885, 31, 910, 3, 1064, 1, 792, 117, 54, 11, 73, 9, 82, 3842, 449, 28, 114, 731, 59, 6036, 2, 1242, 11, 446, 62, 7, 208, 181, 1467, 2622, 1607, 5690, 3470, 2, 2048, 1461, 7, 103, 1057, 1110, 15, 1747, 1067, 310, 5, 15, 187, 403, 36, 951, 240, 87, 3195, 103, 249, 403, 828, 90, 56, 15, 1761, 36, 187, 1455, 1345, 240, 3, 52, 166, 126, 9, 7, 44, 4536, 1, 34, 10, 598, 53, 25, 151, 11, 981, 75, 3, 876, 882, 596, 362, 11, 275, 75, 1066, 1026, 895, 977, 762, 714, 339, 792, 1, 7, 42, 646, 7401, 263, 502, 369, 713, 601, 792, 42, 158, 1110, 263, 502, 365, 2, 79, 111, 34, 112, 25, 1788, 151, 11, 676, 2, 667, 106, 1734, 63, 25, 151, 11, 335, 2, 662, 88, 10, 1327, 41, 5, 1788, 846, 105, 641, 28, 33, 60, 9, 154, 88, 105, 64, 88, 57, 19, 13, 1520, 15, 6462, 799, 10, 41, 5, 340, 1788, 84, 263, 756, 3865, 578, 89, 1047, 642, 782, 558, 2, 207, 2, 1147, 1, 109, 502, 11, 44, 365, 111, 1110, 429, 115, 25, 1096, 105, 713, 19, 13, 144, 1788, 833, 105, 587, 19, 13, 355, 2, 63, 25, 803, 105, 327, 19, 13, 680, 11, 97, 380, 9, 3, 951, 240, 87, 76, 3, 403, 36, 87, 4, 7, 73, 187, 951, 240, 3, 96, 186, 606, 1, 429, 10, 3, 3270, 1788, 10, 44, 97, 438, 5, 207, 1, 502, 2264, 4, 3, 951, 240, 87, 84, 10, 4, 7, 73, 187, 951, 240, 19, 13, 144, 7, 73, 187, 951, 240, 42, 8, 64, 116, 1, 1325, 146, 7, 5, 82, 3842, 449, 54, 208, 221, 632, 370, 20, 1455, 1345, 1104, 42, 8, 64, 116, 1, 1722, 3713, 4, 7, 73, 5, 1883, 1561, 489, 4, 7, 5, 88, 27, 12, 54, 68, 40, 96, 322, 6, 247, 29, 397, 975, 24]",2187.0,19632709,698
Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.,"European journal of cancer (Oxford, England : 1990)",Eur. J. Cancer,2009-07-31,"Cancer staging systems aim to identify patient cohorts with different outcomes based on clinically relevant prognostic factors. Uterine leiomyosarcoma (ULMS) is classified using the FIGO staging system developed for epithelial malignancies; other sarcomas use the AJCC staging system. Neither has been validated in ULMS. We critically evaluated both systems to determine if either identified patient groups with distinct outcomes. We staged 230 ULMS patients by the FIGO and AJCC systems. Progression-free survival (PFS) and overall survival (OS) rates were calculated; statistical pairwise comparisons were performed. The number of stages I and III patients varied by staging system. There were few stage II patients by either system. Using the FIGO system, PFS was better in stage I patients versus stage III or IV patients, and OS was better in stage I patients versus stage IV patients. Using the AJCC system, PFS and OS were better in stage I patients (low grade) versus stage II, III or IV patients, and OS was better in stage III patients versus stage IV patients. Prognosis of patients with serosal involvement (FIGO III) was similar to that of patients with metastases (FIGO IV). Neither system classifies ULMS patients into four clinically meaningful, non-overlapping stages predictive of PFS and OS. This analysis highlights the relevance of certain factors (low grade, serosal involvement) and rarity of others (FIGO stage II, cervical invasion). Once identified, prognostic factors relevant to this malignancy should be incorporated into a new staging system in an effort to identify appropriate cohorts for different treatments.",Evaluation Study,3826.0,33.0,Cancer staging systems aim to identify patient cohorts with different outcomes based on clinically relevant prognostic factors leiomyosarcoma ULMS is classified using the FIGO staging system developed for epithelial malignancies other sarcomas use the AJCC staging system Neither has been validated in ULMS We critically evaluated both systems to determine if either identified patient groups with distinct outcomes We staged 230 ULMS patients by the FIGO and AJCC systems Progression-free survival PFS and overall survival OS rates were calculated statistical pairwise comparisons were performed The number of stages I and III patients varied by staging system There were few stage II patients by either system Using the FIGO system PFS was better in stage I patients versus stage III or IV patients and OS was better in stage I patients versus stage IV patients Using the AJCC system PFS and OS were better in stage I patients low grade versus stage II III or IV patients and OS was better in stage III patients versus stage IV patients Prognosis of patients with serosal involvement FIGO III was similar to that of patients with metastases FIGO IV Neither system classifies ULMS patients into four clinically meaningful non-overlapping stages predictive of PFS and OS This analysis highlights the relevance of certain factors low grade serosal involvement and rarity of others FIGO stage II invasion Once identified prognostic factors relevant to this malignancy should be incorporated into a new staging system in an effort to identify appropriate cohorts for different treatments,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,"[12, 632, 1530, 1130, 6, 255, 69, 736, 5, 338, 123, 90, 23, 505, 867, 177, 130, 3717, 7038, 16, 1373, 75, 3, 3837, 632, 398, 276, 9, 701, 441, 127, 1479, 119, 3, 2271, 632, 398, 2174, 71, 85, 938, 4, 7038, 21, 4331, 194, 110, 1530, 6, 223, 492, 361, 108, 69, 271, 5, 834, 123, 21, 2930, 6136, 7038, 7, 20, 3, 3837, 2, 2271, 1530, 91, 115, 25, 300, 2, 63, 25, 118, 151, 11, 981, 1050, 8716, 2213, 11, 173, 3, 207, 1, 1153, 70, 2, 316, 7, 2051, 20, 632, 398, 125, 11, 1021, 82, 215, 7, 20, 361, 398, 75, 3, 3837, 398, 300, 10, 380, 4, 82, 70, 7, 185, 82, 316, 15, 478, 7, 2, 118, 10, 380, 4, 82, 70, 7, 185, 82, 478, 7, 75, 3, 2271, 398, 300, 2, 118, 11, 380, 4, 82, 70, 7, 154, 88, 185, 82, 215, 316, 15, 478, 7, 2, 118, 10, 380, 4, 82, 316, 7, 185, 82, 478, 7, 356, 1, 7, 5, 17169, 799, 3837, 316, 10, 288, 6, 17, 1, 7, 5, 196, 3837, 478, 2174, 398, 15295, 7038, 7, 237, 294, 505, 2538, 220, 4551, 1153, 464, 1, 300, 2, 118, 26, 65, 2527, 3, 2088, 1, 1840, 130, 154, 88, 17169, 799, 2, 4989, 1, 1749, 3837, 82, 215, 578, 1059, 108, 177, 130, 867, 6, 26, 710, 257, 40, 2449, 237, 8, 217, 632, 398, 4, 35, 2919, 6, 255, 870, 736, 9, 338, 640]",1584.0,19647426,151
Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.,International journal of cancer,Int. J. Cancer,2009-11-01,"High-risk human papillomavirus (H-HPV) infection is strongly linked to cervical neoplasia, but its role in detecting glandular lesions (GLs) is unclear. In the cervix, carbonic anhydrase IX (CA-IX) is expressed in cervical neoplasia, but rarely in the benign cervix. The diagnostic utility of these biomarkers was evaluated in women with a cytologic diagnosis of atypical glandular cells (AGC). H-HPV was detected using hybrid capture 2 (HC2) in liquid-based cytology, and CA-IX immunoreactivity was studied on conventional Pap smears. Of 403 patients, 111 (28%) were positive for significant cervical lesions (SCLs) including CIN2, CIN3, adenocarcinoma in situ or invasive carcinoma. CA-IX testing alone (n = 403) had a sensitivity of 75, 95 or 65% for SCLs, significant GLs or squamous lesions (SLs), respectively, with a specificity of 88% and a false negative rate (FNR defined as 1 minus negative predictive value) of 10%. Testing for H-HPV (n = 122) had a sensitivity of 97, 100 or 96% for SCLs, GLs or SLs, respectively, with a specificity of 87% and a FNR of 1%. The combination of CA-IX and H-HPV testing (n = 122), collectively, had the same sensitivity, specificity and FNR for SCLs, GLs or SLs as H-HPV testing alone. The conclusions of our study are that both H-HPV and CA-IX testing are useful diagnostic markers for GLs. However, H-HPV testing is a better diagnostic marker for SLs. The combination of CA-IX with H-HPV testing does not improve the diagnostic accuracy for cervical neoplasia in women with AGC diagnosis over that of H-HPV testing alone.",Journal Article,3733.0,18.0,High-risk human papillomavirus H-HPV infection is strongly linked to neoplasia but its role in detecting glandular lesions GLs is unclear In the cervix carbonic anhydrase IX CA-IX is expressed in neoplasia but rarely in the benign cervix The diagnostic utility of these biomarkers was evaluated in women with a cytologic diagnosis of atypical glandular cells AGC H-HPV was detected using hybrid capture 2 HC2 in liquid-based cytology and CA-IX immunoreactivity was studied on conventional Pap smears Of 403 patients 111 28 were positive for significant lesions SCLs including CIN2 CIN3 adenocarcinoma in situ or invasive carcinoma CA-IX testing alone n 403 had a sensitivity of 75 95 or 65 for SCLs significant GLs or squamous lesions SLs respectively with a specificity of 88 and a false negative rate FNR defined as 1 minus negative predictive value of 10 Testing for H-HPV n 122 had a sensitivity of 97 100 or 96 for SCLs GLs or SLs respectively with a specificity of 87 and a FNR of 1 The combination of CA-IX and H-HPV testing n 122 collectively had the same sensitivity specificity and FNR for SCLs GLs or SLs as H-HPV testing alone The conclusions of our study are that both H-HPV and CA-IX testing are useful diagnostic markers for GLs However H-HPV testing is a better diagnostic marker for SLs The combination of CA-IX with H-HPV testing does not improve the diagnostic accuracy for neoplasia in women with AGC diagnosis over that of H-HPV testing alone,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[64, 43, 171, 3242, 555, 933, 930, 16, 1327, 1199, 6, 2298, 84, 211, 200, 4, 2502, 6170, 406, 16515, 16, 1200, 4, 3, 3629, 11190, 11191, 8032, 1568, 8032, 16, 570, 4, 2298, 84, 2416, 4, 3, 1002, 3629, 3, 752, 1207, 1, 46, 582, 10, 194, 4, 117, 5, 8, 4195, 147, 1, 1973, 6170, 37, 10490, 555, 933, 10, 530, 75, 4542, 2891, 18, 16516, 4, 3165, 90, 2045, 2, 1568, 8032, 4900, 10, 656, 23, 809, 4290, 8916, 1, 10836, 7, 3167, 339, 11, 109, 9, 93, 406, 34737, 141, 12870, 10346, 449, 4, 957, 15, 416, 134, 1568, 8032, 471, 279, 78, 10836, 42, 8, 485, 1, 481, 48, 15, 556, 9, 34737, 93, 16515, 15, 691, 406, 19205, 106, 5, 8, 1121, 1, 889, 2, 8, 2133, 199, 116, 9310, 395, 22, 14, 12297, 199, 464, 549, 1, 79, 471, 9, 555, 933, 78, 3285, 42, 8, 485, 1, 1015, 394, 15, 921, 9, 34737, 16515, 15, 19205, 106, 5, 8, 1121, 1, 912, 2, 8, 9310, 1, 14, 3, 150, 1, 1568, 8032, 2, 555, 933, 471, 78, 3285, 2535, 42, 3, 827, 485, 1121, 2, 9310, 9, 34737, 16515, 15, 19205, 22, 555, 933, 471, 279, 3, 2130, 1, 114, 45, 32, 17, 110, 555, 933, 2, 1568, 8032, 471, 32, 999, 752, 525, 9, 16515, 137, 555, 933, 471, 16, 8, 380, 752, 952, 9, 19205, 3, 150, 1, 1568, 8032, 5, 555, 933, 471, 1097, 44, 401, 3, 752, 1190, 9, 2298, 4, 117, 5, 10490, 147, 252, 17, 1, 555, 933, 471, 279]",1463.0,19670419,865
Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma.,The Annals of thoracic surgery,Ann. Thorac. Surg.,2009-09-01,"Radical surgery for malignant pleural mesothelioma does not improve survival in patients with nodal metastases. Imaging is poor at predicting nodal involvement and mediastinoscopy, though frequently used, is of low sensitivity. As endobronchial ultrasound (EBUS) and esophageal endoscopic ultrasound (EUS) are accurate for nodal staging of lung cancer, we hypothesized that they would be at least as sensitive as cervical video-mediastinoscopy for nodal staging of mesothelioma. Eighty-five patients with mesothelioma who were potential candidates for radical surgery underwent preoperative staging with mediastinoscopy (n = 50) or EBUS (n = 38). Eleven patients also underwent EUS. Diagnostic yield (specimens containing lymphocytes or tumor cells) was 100% for mediastinoscopy and 84% for EBUS (p < 0.001). Mediastinoscopy identified 7 of 50 (14%) patients with nodal metastases. Thirty-eight (76%) mediastinoscopy-negative patients underwent surgery with nodal sampling and there were 18 false negatives. Endobronchial ultrasound identified 13 of 38 (34%) patients with nodal metastases. Twenty-two (58%) EBUS-negative patients underwent surgery with nodal sampling and there were 10 false negatives. Sensitivity and negative predictive value for mediastinoscopy were 28% and 49%, and 59% and 57% for EBUS. Eleven patients had EUS preoperatively, which revealed infradiaphragmatic nodal metastases in 5 patients. Although this study is retrospective, EBUS had higher sensitivity than either mediastinoscopy or imaging studies for detection of nodal metastases. Nevertheless, the ability to accurately identify nodal involvement preoperatively in patients with mesothelioma remains suboptimal. Esophageal ultrasound may complement EBUS particularly in cases where infradiaphragmatic nodal metastases are suspected.",Comparative Study,3794.0,44.0,Radical surgery for malignant pleural does not improve survival in patients with nodal metastases Imaging is poor at predicting nodal involvement and mediastinoscopy though frequently used is of low sensitivity As endobronchial ultrasound EBUS and endoscopic ultrasound EUS are accurate for nodal staging of cancer we hypothesized that they would be at least as sensitive as video-mediastinoscopy for nodal staging of Eighty-five patients with who were potential candidates for radical surgery underwent preoperative staging with mediastinoscopy n 50 or EBUS n 38 Eleven patients also underwent EUS Diagnostic yield specimens containing lymphocytes or tumor cells was 100 for mediastinoscopy and 84 for EBUS p 0.001 Mediastinoscopy identified 7 of 50 14 patients with nodal metastases Thirty-eight 76 mediastinoscopy-negative patients underwent surgery with nodal sampling and there were 18 false negatives Endobronchial ultrasound identified 13 of 38 34 patients with nodal metastases Twenty-two 58 EBUS-negative patients underwent surgery with nodal sampling and there were 10 false negatives Sensitivity and negative predictive value for mediastinoscopy were 28 and 49 and 59 and 57 for EBUS Eleven patients had EUS preoperatively which revealed infradiaphragmatic nodal metastases in 5 patients Although this study is retrospective EBUS had higher sensitivity than either mediastinoscopy or imaging studies for detection of nodal metastases Nevertheless the ability to accurately identify nodal involvement preoperatively in patients with remains suboptimal ultrasound may complement EBUS particularly in cases where infradiaphragmatic nodal metastases are suspected,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[711, 152, 9, 393, 2164, 1097, 44, 401, 25, 4, 7, 5, 779, 196, 270, 16, 334, 28, 1434, 779, 799, 2, 9856, 2471, 746, 95, 16, 1, 154, 485, 22, 11087, 1945, 7080, 2, 2056, 1945, 3626, 32, 1481, 9, 779, 632, 1, 12, 21, 1237, 17, 491, 688, 40, 28, 506, 22, 745, 22, 4139, 9856, 9, 779, 632, 1, 2207, 365, 7, 5, 54, 11, 174, 1931, 9, 711, 152, 208, 498, 632, 5, 9856, 78, 212, 15, 7080, 78, 519, 2627, 7, 120, 208, 3626, 752, 2309, 623, 1101, 1594, 15, 30, 37, 10, 394, 9, 9856, 2, 874, 9, 7080, 19, 13, 144, 9856, 108, 67, 1, 212, 213, 7, 5, 779, 196, 977, 659, 846, 9856, 199, 7, 208, 152, 5, 779, 2874, 2, 125, 11, 203, 2133, 13508, 11087, 1945, 108, 233, 1, 519, 562, 7, 5, 779, 196, 737, 100, 717, 7080, 199, 7, 208, 152, 5, 779, 2874, 2, 125, 11, 79, 2133, 13508, 485, 2, 199, 464, 549, 9, 9856, 11, 339, 2, 739, 2, 728, 2, 696, 9, 7080, 2627, 7, 42, 3626, 3888, 92, 553, 30476, 779, 196, 4, 33, 7, 242, 26, 45, 16, 459, 7080, 42, 142, 485, 76, 361, 9856, 15, 270, 94, 9, 638, 1, 779, 196, 3873, 3, 801, 6, 2141, 255, 779, 799, 3888, 4, 7, 5, 469, 3291, 1945, 68, 3731, 7080, 823, 4, 140, 1257, 30476, 779, 196, 32, 2768]",1670.0,19699913,579
"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-08-31,"Assess toxicity and efficacy of cisplatin (Cis) doublet combinations in advanced and recurrent cervical carcinoma. Patients were randomly assigned to paclitaxel 135 mg/m(2) over 24 hours plus Cis 50 mg/m(2) day 2 every 3 weeks (PC, reference arm); vinorelbine 30 mg/m(2) days 1 and 8 plus Cis 50 mg/m(2) day 1 every 3 weeks (VC); gemcitabine 1,000 mg/m(2) day 1 and 8 plus Cis 50 mg/m(2) day 1 every 3 weeks (GC); or topotecan 0.75 mg/m(2) days 1, 2, and 3 plus Cis 50 mg/m(2) day 1 every 3 weeks (TC). Survival was the primary end point with a 33% improvement relative to PC considered important (85% power, alpha = 5%). Quality-of-life data were prospectively collected. A total of 513 patients were enrolled when a planned interim analysis recommended early closure for futility. The experimental-to-PC hazard ratios of death were 1.15 (95% CI, 0.79 to 1.67) for VC, 1.32 (95% CI, 0.91 to 1.92) for GC, and 1.26 (95% CI, 0.86 to 1.82) for TC. The hazard ratios for progression-free survival (PFS) were 1.36 (95% CI, 0.97 to 1.90) for VC, 1.39 (95% CI, 0.99 to 1.96) for GC, and 1.27 (95% CI, 0.90 to 1.78) for TC. Response rates (RRs) for PC, VC, GC, and TC were 29.1%, 25.9%, 22.3%, and 23.4%, respectively. The arms were comparable with respect to toxicity except for leucopenia, neutropenia, infection, and alopecia. VC, GC, and TC are not superior to PC in terms of overall survival (OS). However, the trend in RR, PFS, and OS favors PC. Differences in chemotherapy scheduling, pre-existing morbidity, and toxicity are important in individualizing therapy.","Clinical Trial, Phase III",3795.0,358.0,"Assess toxicity and efficacy of cisplatin Cis doublet combinations in advanced and recurrent carcinoma Patients were randomly assigned to paclitaxel 135 mg/m 2 over 24 hours plus Cis 50 mg/m 2 day 2 every 3 weeks PC reference arm vinorelbine 30 mg/m 2 days 1 and 8 plus Cis 50 mg/m 2 day 1 every 3 weeks VC gemcitabine 1,000 mg/m 2 day 1 and 8 plus Cis 50 mg/m 2 day 1 every 3 weeks GC or topotecan 0.75 mg/m 2 days 1 2 and 3 plus Cis 50 mg/m 2 day 1 every 3 weeks TC Survival was the primary end point with a 33 improvement relative to PC considered important 85 power alpha 5 Quality-of-life data were prospectively collected A total of 513 patients were enrolled when a planned interim analysis recommended early closure for futility The experimental-to-PC hazard ratios of death were 1.15 95 CI 0.79 to 1.67 for VC 1.32 95 CI 0.91 to 1.92 for GC and 1.26 95 CI 0.86 to 1.82 for TC The hazard ratios for progression-free survival PFS were 1.36 95 CI 0.97 to 1.90 for VC 1.39 95 CI 0.99 to 1.96 for GC and 1.27 95 CI 0.90 to 1.78 for TC Response rates RRs for PC VC GC and TC were 29.1 25.9 22.3 and 23.4 respectively The arms were comparable with respect to toxicity except for leucopenia neutropenia infection and alopecia VC GC and TC are not superior to PC in terms of overall survival OS However the trend in RR PFS and OS favors PC Differences in chemotherapy scheduling pre-existing morbidity and toxicity are important in individualizing therapy",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[423, 155, 2, 209, 1, 540, 1927, 4872, 1247, 4, 131, 2, 387, 134, 7, 11, 1108, 896, 6, 490, 3978, 81, 188, 18, 252, 259, 1459, 349, 1927, 212, 81, 188, 18, 218, 18, 454, 27, 244, 1341, 2482, 475, 3676, 201, 81, 188, 18, 162, 14, 2, 66, 349, 1927, 212, 81, 188, 18, 218, 14, 454, 27, 244, 11468, 679, 14, 984, 81, 188, 18, 218, 14, 2, 66, 349, 1927, 212, 81, 188, 18, 218, 14, 454, 27, 244, 1709, 15, 2129, 13, 481, 81, 188, 18, 162, 14, 18, 2, 27, 349, 1927, 212, 81, 188, 18, 218, 14, 454, 27, 244, 3072, 25, 10, 3, 86, 396, 741, 5, 8, 466, 767, 580, 6, 1341, 515, 305, 772, 2349, 950, 33, 372, 1, 358, 74, 11, 1143, 786, 8, 181, 1, 11895, 7, 11, 346, 198, 8, 1465, 2914, 65, 793, 191, 4830, 9, 7566, 3, 1560, 6, 1341, 360, 1137, 1, 273, 11, 14, 167, 48, 58, 13, 842, 6, 14, 598, 9, 11468, 14, 531, 48, 58, 13, 970, 6, 14, 937, 9, 1709, 2, 14, 432, 48, 58, 13, 868, 6, 14, 878, 9, 3072, 3, 360, 1137, 9, 91, 115, 25, 300, 11, 14, 511, 48, 58, 13, 1015, 6, 14, 424, 9, 11468, 14, 587, 48, 58, 13, 1058, 6, 14, 921, 9, 1709, 2, 14, 428, 48, 58, 13, 424, 6, 14, 833, 9, 3072, 51, 151, 4739, 9, 1341, 11468, 1709, 2, 3072, 11, 462, 14, 243, 83, 350, 27, 2, 382, 39, 106, 3, 1335, 11, 1279, 5, 2184, 6, 155, 2187, 9, 10317, 778, 930, 2, 5691, 11468, 1709, 2, 3072, 32, 44, 1123, 6, 1341, 4, 1794, 1, 63, 25, 118, 137, 3, 853, 4, 861, 300, 2, 118, 13054, 1341, 362, 4, 56, 8122, 671, 1692, 787, 2, 155, 32, 305, 4, 12747, 36]",1455.0,19720909,601
Improving sentinel lymph node detection rates in endometrial cancer: how many cases are needed?,Gynecologic oncology,Gynecol. Oncol.,2009-09-19,"To describe sentinel lymph node (SLN) detection rates in endometrial cancer and estimate how many cases are needed to achieve >90% SLN detection. We conducted a prospective study of patients undergoing primary surgery for endometrial cancer between September 2005 and March 2009. Lymph node mapping was performed using blue dye injection into the cervix in all cases. Additional injection methods included blue dye injection in the uterine fundus, and cervical injection of Tc99m. SLNs were identified and removed, followed by regional lymph node dissection. The results were analyzed according to two study periods: an ""early"" phase (September 2005-December 2007) and a ""late"" phase (January 2008-March 2009). One hundred and fifteen patients with endometrial cancer were included. The cervix was the only site of injection in 82 cases (71%), while a combined cervical and fundal injection was performed in 33 cases (29%). Overall, SLN detection was achieved in 98 (85%) cases. In the initial 27 months of the study, a SLN was identified in 50 of 64 cases (78%), with 2 false negative cases. In the subsequent 15 months, successful mapping was achieved in 48 of 51 cases (94%) with no false negative cases. When examining an individual provider's performance, after the first 30 cases, the rate of successful mapping significantly increased from 77% to 94% (P=0.033). Sentinel node mapping in uterine cancer requires a dedicated effort to achieve high detection rates. Surgeons should determine their individual detection rates and false negative rates. Our data demonstrate that high SLN detection rates can be achieved in women with uterine cancer and increasing surgical volume (30 cases) is associated with significantly increased detection rates.",Journal Article,3776.0,82.0,To describe sentinel lymph node SLN detection rates in cancer and estimate how many cases are needed to achieve 90 SLN detection We conducted a prospective study of patients undergoing primary surgery for cancer between September 2005 and March 2009 Lymph node mapping was performed using blue dye injection into the cervix in all cases Additional injection methods included blue dye injection in the fundus and injection of Tc99m SLNs were identified and removed followed by regional lymph node dissection The results were analyzed according to two study periods an `` early '' phase September 2005-December 2007 and a `` late '' phase January 2008-March 2009 One hundred and fifteen patients with cancer were included The cervix was the only site of injection in 82 cases 71 while a combined and fundal injection was performed in 33 cases 29 Overall SLN detection was achieved in 98 85 cases In the initial 27 months of the study a SLN was identified in 50 of 64 cases 78 with 2 false negative cases In the subsequent 15 months successful mapping was achieved in 48 of 51 cases 94 with no false negative cases When examining an individual provider 's performance after the first 30 cases the rate of successful mapping significantly increased from 77 to 94 P=0.033 Sentinel node mapping in cancer requires a dedicated effort to achieve high detection rates Surgeons should determine their individual detection rates and false negative rates Our data demonstrate that high SLN detection rates can be achieved in women with cancer and increasing surgical volume 30 cases is associated with significantly increased detection rates,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 897, 1323, 263, 289, 1099, 638, 151, 4, 12, 2, 1191, 832, 445, 140, 32, 575, 6, 1359, 424, 1099, 638, 21, 426, 8, 482, 45, 1, 7, 479, 86, 152, 9, 12, 59, 2636, 1242, 2, 2363, 1238, 263, 289, 2568, 10, 173, 75, 3352, 3796, 1754, 237, 3, 3629, 4, 62, 140, 402, 1754, 636, 159, 3352, 3796, 1754, 4, 3, 16869, 2, 1754, 1, 45444, 2642, 11, 108, 2, 2264, 370, 20, 951, 263, 289, 1161, 3, 99, 11, 311, 768, 6, 100, 45, 3338, 35, 191, 522, 124, 2636, 1242, 1397, 1307, 2, 8, 807, 522, 124, 1024, 1375, 2363, 1238, 104, 1128, 2, 3057, 7, 5, 12, 11, 159, 3, 3629, 10, 3, 158, 606, 1, 1754, 4, 878, 140, 792, 369, 8, 397, 2, 38245, 1754, 10, 173, 4, 466, 140, 462, 63, 1099, 638, 10, 513, 4, 1096, 772, 140, 4, 3, 388, 428, 53, 1, 3, 45, 8, 1099, 10, 108, 4, 212, 1, 660, 140, 833, 5, 18, 2133, 199, 140, 4, 3, 706, 167, 53, 1401, 2568, 10, 513, 4, 576, 1, 725, 140, 960, 5, 77, 2133, 199, 140, 198, 3282, 35, 797, 3094, 292, 528, 50, 3, 157, 201, 140, 3, 116, 1, 1401, 2568, 97, 101, 29, 849, 6, 960, 19, 13, 5254, 1323, 289, 2568, 4, 12, 1706, 8, 4827, 2919, 6, 1359, 64, 638, 151, 1613, 257, 223, 136, 797, 638, 151, 2, 2133, 199, 151, 114, 74, 608, 17, 64, 1099, 638, 151, 122, 40, 513, 4, 117, 5, 12, 2, 602, 221, 433, 201, 140, 16, 41, 5, 97, 101, 638, 151]",1629.0,19767064,45
"High risk human papillomavirus testing: guidelines for use in screening, triage, and follow-up for the prevention and early detection of cervical cancer.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2004-11-01,"The changes in cervical cytology characterization agreed on by the Bethesda committee meeting in 2001 created a category of atypical findings that has caused some management confusion. By description, the characterization of cervical cytology as only atypical implies a less worrisome prognosis. However, more than 40% of high-grade (CIN II or III or cancer) will be discovered within this category. The development and Food and Drug Administration approval of the Hybrid Capture 2 (HC-2; Digene Corporation, Gaithersburg, MD) for detecting high-risk human papillomavirus (HR-HPV) subtypes and the subsequent level I evidence supporting use of this test in the triage of women with atypical cytology has revolutionized the management of this cytology. With this success has come numerous additional uses for HR-HPV testing in the treatment and follow-up of women with a variety of cytologic abnormalities. This article reviews the literature on uses of HR-HPV testing in this population, with reference to currently accepted guidelines.",Journal Article,5559.0,4.0,The changes in cytology characterization agreed on by the Bethesda committee meeting in 2001 created a category of atypical findings that has caused some management confusion By description the characterization of cytology as only atypical implies a less worrisome prognosis However more than 40 of high-grade CIN II or III or cancer will be discovered within this category The development and Food and Drug Administration approval of the Hybrid Capture 2 HC-2 Digene Corporation Gaithersburg MD for detecting high-risk human papillomavirus HR-HPV subtypes and the subsequent level I evidence supporting use of this test in the triage of women with atypical cytology has revolutionized the management of this cytology With this success has come numerous additional uses for HR-HPV testing in the treatment and follow-up of women with a variety of cytologic abnormalities This article reviews the literature on uses of HR-HPV testing in this population with reference to currently accepted guidelines,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 400, 4, 2045, 2136, 4681, 23, 20, 3, 8222, 2002, 2238, 4, 1758, 2466, 8, 2169, 1, 1973, 272, 17, 71, 1546, 476, 284, 7399, 20, 5263, 3, 2136, 1, 2045, 22, 158, 1973, 10441, 8, 299, 13155, 356, 137, 80, 76, 327, 1, 64, 88, 4652, 215, 15, 316, 15, 12, 303, 40, 2747, 262, 26, 2169, 3, 193, 2, 1773, 2, 234, 634, 1814, 1, 3, 4542, 2891, 18, 7487, 18, 58284, 14089, 33588, 2244, 9, 2502, 64, 43, 171, 3242, 168, 933, 814, 2, 3, 706, 301, 70, 241, 1912, 119, 1, 26, 412, 4, 3, 9059, 1, 117, 5, 1973, 2045, 71, 5746, 3, 284, 1, 26, 2045, 5, 26, 1825, 71, 6235, 2331, 402, 4025, 9, 168, 933, 471, 4, 3, 24, 2, 166, 126, 1, 117, 5, 8, 1362, 1, 4195, 1171, 26, 946, 2004, 3, 789, 23, 4025, 1, 168, 933, 471, 4, 26, 266, 5, 2482, 6, 694, 3058, 677]",999.0,19780302,314
Role of postoperative irradiation for patients with bilateral cervical nodal metastases from cutaneous melanoma: a critical assessment.,Head & neck,Head Neck,2010-06-01,"The aim of this study was to evaluate the role of regional nodal radiation therapy (RT) for patients with bilateral cervical nodal metastases from melanoma. Between 1998 and 2008, 16 patients with bilateral cervical metastases without distant metastases were treated with postoperative RT (30 Gy in 5 fractions delivered twice weekly). Median follow-up was 5 months (range, 1-34 months). Median survival was 9 months (95% confidence interval [CI], 0-23 months). Overall survival was 68%, 50%, and 27% at 6, 12, and 24 months, respectively. Regional nodal control was 74% and 64% at 6 and 12 months, respectively. Rates of development of distant metastasis were 60%, 70%, and 90% at 6, 12, and 18 months, respectively. The actuarial rate of RT-related complications was 49% at 12 months. The limited life expectancy of patients observed with this disease combined with the high rate of RT-related complications argue against the routine use of adjuvant RT for regional nodal disease in this setting.",Journal Article,3521.0,3.0,The aim of this study was to evaluate the role of regional nodal radiation therapy RT for patients with bilateral nodal metastases from Between 1998 and 2008 16 patients with bilateral metastases without distant metastases were treated with postoperative RT 30 Gy in 5 fractions delivered twice weekly Median follow-up was 5 months range 1-34 months Median survival was 9 months 95 confidence interval CI 0-23 months Overall survival was 68 50 and 27 at 6 12 and 24 months respectively Regional nodal control was 74 and 64 at 6 and 12 months respectively Rates of development of distant metastasis were 60 70 and 90 at 6 12 and 18 months respectively The actuarial rate of RT-related complications was 49 at 12 months The limited life expectancy of patients observed with this disease combined with the high rate of RT-related complications argue against the routine use of adjuvant RT for regional nodal disease in this setting,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1130, 1, 26, 45, 10, 6, 376, 3, 200, 1, 951, 779, 121, 36, 240, 9, 7, 5, 1607, 779, 196, 29, 59, 1850, 2, 1375, 245, 7, 5, 1607, 196, 187, 626, 196, 11, 73, 5, 573, 240, 201, 381, 4, 33, 1550, 1623, 936, 709, 52, 166, 126, 10, 33, 53, 184, 14, 562, 53, 52, 25, 10, 83, 53, 48, 307, 268, 58, 13, 382, 53, 63, 25, 10, 806, 212, 2, 428, 28, 49, 133, 2, 259, 53, 106, 951, 779, 182, 10, 794, 2, 660, 28, 49, 2, 133, 53, 106, 151, 1, 193, 1, 626, 278, 11, 335, 431, 2, 424, 28, 49, 133, 2, 203, 53, 106, 3, 2361, 116, 1, 240, 139, 521, 10, 739, 28, 133, 53, 3, 383, 358, 3399, 1, 7, 164, 5, 26, 34, 397, 5, 3, 64, 116, 1, 240, 139, 521, 7004, 480, 3, 1311, 119, 1, 249, 240, 9, 951, 779, 34, 4, 26, 546]",928.0,19787786,448
Human papillomavirus vaccination in survivors of childhood cancer.,Cancer,Cancer,2009-12-01,"Effective vaccination is now available to prevent human papillomavirus (HPV), the most common sexually transmitted infection and the cause of cervical cancer, which is the second most common cancer among women worldwide. HPV vaccine uptake is particularly important for females surviving cancer, some of whom are at high risk for HPV complications because of the direct and indirect effects of cancer treatment. Thus, version 3.0 of the Children's Oncology Group's Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancer recommends HPV vaccination for all eligible females surviving childhood cancer. Because this vaccine was only approved by the US Food and Drug Administration in 2006, little is known regarding the complexity of vaccination uptake among those surviving cancer. The purpose of this article was to describe the HPV vaccine and its usefulness in the survivorship population, provide a rationale for describing cancer survivors as being at increased risk for HPV complications, identify factors associated with HPV vaccination, and discuss the utilization of these predictors in designing strategies to promote adherence to HPV vaccination recommendations within the survivorship context.",Journal Article,3703.0,30.0,Effective vaccination is now available to prevent human papillomavirus HPV the most common sexually transmitted infection and the cause of cancer which is the second most common cancer among women worldwide HPV vaccine uptake is particularly important for females surviving cancer some of whom are at high risk for HPV complications because of the direct and indirect effects of cancer treatment Thus version 3.0 of the Children 's Oncology Group 's Long-Term Follow-Up Guidelines for Survivors of Childhood Adolescent and Young Adult Cancer recommends HPV vaccination for all eligible females surviving childhood cancer Because this vaccine was only approved by the US Food and Drug Administration in 2006 little is known regarding the complexity of vaccination uptake among those surviving cancer The purpose of this article was to describe the HPV vaccine and its usefulness in the survivorship population provide a rationale for describing cancer survivors as being at increased risk for HPV complications identify factors associated with HPV vaccination and discuss the utilization of these predictors in designing strategies to promote adherence to HPV vaccination recommendations within the survivorship context,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[323, 1915, 16, 1134, 390, 6, 1682, 171, 3242, 933, 3, 96, 186, 13588, 12959, 930, 2, 3, 708, 1, 12, 92, 16, 3, 419, 96, 186, 12, 107, 117, 2358, 933, 1274, 1135, 16, 823, 305, 9, 2451, 3050, 12, 476, 1, 953, 32, 28, 64, 43, 9, 933, 521, 408, 1, 3, 1196, 2, 6110, 176, 1, 12, 24, 631, 2256, 27, 13, 1, 3, 541, 292, 413, 87, 292, 319, 337, 166, 126, 677, 9, 332, 1, 864, 3678, 2, 1169, 780, 12, 6716, 933, 1915, 9, 62, 625, 2451, 3050, 864, 12, 408, 26, 1274, 10, 158, 850, 20, 3, 843, 1773, 2, 234, 634, 4, 1324, 1215, 16, 440, 666, 3, 3082, 1, 1915, 1135, 107, 135, 3050, 12, 3, 743, 1, 26, 946, 10, 6, 897, 3, 933, 1274, 2, 211, 5235, 4, 3, 2560, 266, 377, 8, 1728, 9, 4950, 12, 332, 22, 486, 28, 101, 43, 9, 933, 521, 255, 130, 41, 5, 933, 1915, 2, 1139, 3, 1961, 1, 46, 674, 4, 5048, 422, 6, 1617, 2149, 6, 933, 1915, 883, 262, 3, 2560, 1533]",1218.0,19813272,3
Concurrent chemoradiation in the routine management of patients with cervical cancer: does marital status matter?,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2009-08-01,"The aim of this study was to investigate the relationship between marital status and outcome in women treated with concurrent chemoradiation (CT-RT) for locally advanced cervical cancer. We reviewed the records of all women who received CT-RT for squamous or adenocarcinomas of the cervix at the M. D. Anderson Cancer Center between 1998 and 2005. Patients with extrapelvic disease, prior hysterectomy, concurrent second malignancies, or prior pelvic radiation therapy or chemotherapy were excluded. All patients received external beam and intracavitary radiation therapy with concurrent weekly cisplatin or cisplatin and 5-fluorouracil. Of 226 women, 117 were married (MPs; median follow-up, 41 months) and 109 were single, divorced, or separated (SPs; median follow-up, 42 months). The SPs were more likely to be African American (P < 0.001), be medically indigent (P < 0.001), and have used illicit drugs (P = 0.01). Married patients were more likely to have traveled to Houston for care; SPs were more likely to be permanent residents of Houston (61% vs 29.1%, P < 0.001). The SPs more often presented with tumors of 6.0 cm or more (P = 0.01) and stage II to IVA disease (P = 0.02). There were no other significant between-group differences in patient or tumor characteristics or CT-RT compliance. At 3 years, there were no significant between-group differences in disease-specific (80% in MPs vs 78% in SPs, P = 0.61) or pelvic relapse-free survival rates (88% in MPs vs 86% in SPs, P = 0.62). Despite patient and tumor characteristics traditionally associated with poorer outcomes, SPs do not have significantly poorer treatment completion rates or outcomes after CT-RT. Further studies are needed to determine whether these trends hold true in other practice settings.",Evaluation Study,3825.0,5.0,The aim of this study was to investigate the relationship between marital status and outcome in women treated with concurrent chemoradiation CT-RT for locally advanced cancer We reviewed the records of all women who received CT-RT for squamous or adenocarcinomas of the cervix at the M. D. Anderson Cancer Center between 1998 and 2005 Patients with extrapelvic disease prior hysterectomy concurrent second malignancies or prior pelvic radiation therapy or chemotherapy were excluded All patients received external beam and intracavitary radiation therapy with concurrent weekly cisplatin or cisplatin and 5-fluorouracil Of 226 women 117 were married MPs median follow-up 41 months and 109 were single divorced or separated SPs median follow-up 42 months The SPs were more likely to be African American P 0.001 be medically indigent P 0.001 and have used illicit drugs P 0.01 Married patients were more likely to have traveled to Houston for care SPs were more likely to be permanent residents of Houston 61 vs 29.1 P 0.001 The SPs more often presented with tumors of 6.0 cm or more P 0.01 and stage II to IVA disease P 0.02 There were no other significant between-group differences in patient or tumor characteristics or CT-RT compliance At 3 years there were no significant between-group differences in disease-specific 80 in MPs vs 78 in SPs P 0.61 or pelvic relapse-free survival rates 88 in MPs vs 86 in SPs P 0.62 Despite patient and tumor characteristics traditionally associated with poorer outcomes SPs do not have significantly poorer treatment completion rates or outcomes after CT-RT Further studies are needed to determine whether these trends hold true in other practice settings,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1130, 1, 26, 45, 10, 6, 963, 3, 858, 59, 5345, 156, 2, 228, 4, 117, 73, 5, 750, 975, 425, 240, 9, 795, 131, 12, 21, 446, 3, 1064, 1, 62, 117, 54, 103, 425, 240, 9, 691, 15, 1586, 1, 3, 3629, 28, 3, 188, 427, 1929, 12, 574, 59, 1850, 2, 1242, 7, 5, 12070, 34, 324, 2622, 750, 419, 441, 15, 324, 1110, 121, 36, 15, 56, 11, 1800, 62, 7, 103, 1455, 1345, 2, 9122, 121, 36, 5, 750, 709, 540, 15, 540, 2, 33, 1404, 1, 7400, 117, 3843, 11, 5365, 17444, 52, 166, 126, 605, 53, 2, 3486, 11, 226, 14310, 15, 4910, 8818, 52, 166, 126, 595, 53, 3, 8818, 11, 80, 322, 6, 40, 1410, 597, 19, 13, 144, 40, 4381, 17892, 19, 13, 144, 2, 47, 95, 15747, 600, 19, 13, 355, 5365, 7, 11, 80, 322, 6, 47, 12590, 6, 6212, 9, 165, 8818, 11, 80, 322, 6, 40, 4377, 5662, 1, 6212, 713, 105, 462, 14, 19, 13, 144, 3, 8818, 80, 629, 917, 5, 57, 1, 49, 13, 494, 15, 80, 19, 13, 355, 2, 82, 215, 6, 5900, 34, 19, 13, 588, 125, 11, 77, 127, 93, 59, 87, 362, 4, 69, 15, 30, 374, 15, 425, 240, 3336, 28, 27, 60, 125, 11, 77, 93, 59, 87, 362, 4, 34, 112, 493, 4, 17444, 105, 833, 4, 8818, 19, 13, 713, 15, 1110, 429, 115, 25, 151, 889, 4, 17444, 105, 868, 4, 8818, 19, 13, 744, 550, 69, 2, 30, 374, 4206, 41, 5, 1769, 123, 8818, 1022, 44, 47, 97, 1769, 24, 1438, 151, 15, 123, 50, 425, 240, 195, 94, 32, 575, 6, 223, 317, 46, 1963, 4164, 2501, 4, 127, 758, 1947]",1692.0,19820377,279
Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study.,Gynecologic oncology,Gynecol. Oncol.,2009-10-22,"Cisplatin-based combination chemotherapy is considered standard treatment for advanced/recurrent cervical carcinoma; however, the majority of patients do not respond. This study was undertaken to identify the prognostic factors and develop a model predictive of (non-) response to chemotherapy. Four-hundred twenty-eight patients with advanced cervical cancer who received a cisplatin-containing combination in three Gynecologic Oncology Group (GOG) protocols (110, 169 and 179) were evaluated for baseline clinical characteristics and multivariate analysis was conducted to identify factors independently prognostic predictive of response using a Logistic regression model. A predictive model was developed and externally validated using an independent GOG protocol (149) data. Multivariate analysis identified five factors (African-American, performance status [PS] >0, pelvic disease, prior radiosensitizer and time interval from diagnosis to first recurrence <1 year) independently prognostic of poor response. A simple prognostic index was derived based on the total number of risk factors. When patients were classified into three risk groups (low risk: 0-1 factor; mid risk: 2-3 factors; high risk: 4-5 factors), patients with 4-5 risk factors were estimated to have a response rate of only 13%, and median progression-free and overall survival of 2.8 months and 5.5 months, respectively. The accuracy of the index was supported by both internal and external datasets. A simple index based on five prognostic factors may have utility in clinical practice to identify the women who are not likely to respond to the cisplatin-containing regimens. This subgroup of patients should be considered for non-cisplatin chemotherapy or investigational trials.",Journal Article,3743.0,92.0,Cisplatin-based combination chemotherapy is considered standard treatment for advanced/recurrent carcinoma however the majority of patients do not respond This study was undertaken to identify the prognostic factors and develop a model predictive of non- response to chemotherapy Four-hundred twenty-eight patients with advanced cancer who received a cisplatin-containing combination in three Gynecologic Oncology Group GOG protocols 110 169 and 179 were evaluated for baseline clinical characteristics and multivariate analysis was conducted to identify factors independently prognostic predictive of response using a Logistic regression model A predictive model was developed and externally validated using an independent GOG protocol 149 data Multivariate analysis identified five factors African-American performance status PS 0 pelvic disease prior radiosensitizer and time interval from diagnosis to first recurrence 1 year independently prognostic of poor response A simple prognostic index was derived based on the total number of risk factors When patients were classified into three risk groups low risk 0-1 factor mid risk 2-3 factors high risk 4-5 factors patients with 4-5 risk factors were estimated to have a response rate of only 13 and median progression-free and overall survival of 2.8 months and 5.5 months respectively The accuracy of the index was supported by both internal and external datasets A simple index based on five prognostic factors may have utility in clinical practice to identify the women who are not likely to respond to the cisplatin-containing regimens This subgroup of patients should be considered for non-cisplatin chemotherapy or investigational trials,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[540, 90, 150, 56, 16, 515, 260, 24, 9, 131, 387, 134, 137, 3, 686, 1, 7, 1022, 44, 1892, 26, 45, 10, 2789, 6, 255, 3, 177, 130, 2, 690, 8, 202, 464, 1, 220, 51, 6, 56, 294, 1128, 737, 659, 7, 5, 131, 12, 54, 103, 8, 540, 1101, 150, 4, 169, 1512, 413, 87, 4760, 2189, 3129, 5436, 2, 5977, 11, 194, 9, 330, 38, 374, 2, 331, 65, 10, 426, 6, 255, 130, 1042, 177, 464, 1, 51, 75, 8, 812, 320, 202, 8, 464, 202, 10, 276, 2, 7753, 938, 75, 35, 306, 4760, 1182, 4928, 74, 331, 65, 108, 365, 130, 1410, 597, 528, 156, 1511, 13, 1110, 34, 324, 8853, 2, 98, 268, 29, 147, 6, 157, 146, 14, 111, 1042, 177, 1, 334, 51, 8, 2763, 177, 558, 10, 526, 90, 23, 3, 181, 207, 1, 43, 130, 198, 7, 11, 1373, 237, 169, 43, 271, 154, 43, 13, 14, 161, 4863, 43, 18, 27, 130, 64, 43, 39, 33, 130, 7, 5, 39, 33, 43, 130, 11, 661, 6, 47, 8, 51, 116, 1, 158, 233, 2, 52, 91, 115, 2, 63, 25, 1, 18, 66, 53, 2, 33, 33, 53, 106, 3, 1190, 1, 3, 558, 10, 2708, 20, 110, 2329, 2, 1455, 3455, 8, 2763, 558, 90, 23, 365, 177, 130, 68, 47, 1207, 4, 38, 758, 6, 255, 3, 117, 54, 32, 44, 322, 6, 1892, 6, 3, 540, 1101, 472, 26, 1363, 1, 7, 257, 40, 515, 9, 220, 540, 56, 15, 3093, 143]",1697.0,19853287,2
Anti-angiogenesis agents in metastatic or recurrent cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2009-10-27,"While the incidence of cervical cancer has declined significantly in the United States, it still remains a serious American health threat. When detected early, cervical cancer is generally curable. Early lesions are treated surgically, and locally advanced lesions are managed with concurrent cisplatin chemotherapy and pelvic radiation. Metastatic disease or recurrent lesions not amenable to radical local excision or regional radiation are treated with palliative chemotherapy. Current chemotherapeutic regimens are associated with significant side effects and only limited activity making the identification of active and tolerable novel targeted agents a high priority. Angiogenesis is central to cervical cancer development and progression. The dominant role of angiogenesis in cervical cancer seems to be directly related to HPV inhibition of p53 and stabilization of HIF-1 alpha, both of which increase VEGF. Bevacizumab binding and subsequent inactivation of VEGF seem to shrink cervical tumors and delay progression without appreciable toxicity, and are therefore being studied in a Gynecologic Oncology Group (GOG) phase III trial. Other intracellular tyrosine kinase inhibitors (TKIs) of angiogenesis such as pazopanib are also encouraging, especially in lieu of their oral administration. Further study of angiogenesis and its inhibition are ongoing.",Journal Article,3738.0,59.0,While the incidence of cancer has declined significantly in the United States it still remains a serious American health threat When detected early cancer is generally curable Early lesions are treated surgically and locally advanced lesions are managed with concurrent cisplatin chemotherapy and pelvic radiation Metastatic disease or recurrent lesions not amenable to radical local excision or regional radiation are treated with palliative chemotherapy Current chemotherapeutic regimens are associated with significant side effects and only limited activity making the identification of active and tolerable novel targeted agents a high priority Angiogenesis is central to cancer development and progression The dominant role of angiogenesis in cancer seems to be directly related to HPV inhibition of p53 and stabilization of HIF-1 alpha both of which increase VEGF Bevacizumab binding and subsequent inactivation of VEGF seem to shrink tumors and delay progression without appreciable toxicity and are therefore being studied in a Gynecologic Oncology Group GOG phase III trial Other intracellular tyrosine kinase inhibitors TKIs of angiogenesis such as pazopanib are also encouraging especially in lieu of their oral administration Further study of angiogenesis and its inhibition are ongoing,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[369, 3, 287, 1, 12, 71, 3054, 97, 4, 3, 1088, 907, 192, 1234, 469, 8, 1762, 597, 341, 10965, 198, 530, 191, 12, 16, 1228, 4151, 191, 406, 32, 73, 2350, 2, 795, 131, 406, 32, 2231, 5, 750, 540, 56, 2, 1110, 121, 113, 34, 15, 387, 406, 44, 4070, 6, 711, 293, 1366, 15, 951, 121, 32, 73, 5, 994, 56, 291, 1573, 472, 32, 41, 5, 93, 1152, 176, 2, 158, 383, 128, 1079, 3, 911, 1, 544, 2, 2668, 229, 238, 183, 8, 64, 4690, 1056, 16, 854, 6, 12, 193, 2, 91, 3, 2156, 200, 1, 1056, 4, 12, 2744, 6, 40, 1606, 139, 6, 933, 297, 1, 624, 2, 3184, 1, 2940, 14, 950, 110, 1, 92, 344, 618, 599, 791, 2, 706, 2297, 1, 618, 3233, 6, 22572, 57, 2, 1984, 91, 187, 9371, 155, 2, 32, 673, 486, 656, 4, 8, 1512, 413, 87, 4760, 124, 316, 160, 127, 2087, 564, 216, 222, 1671, 1, 1056, 225, 22, 2576, 32, 120, 2269, 1093, 4, 14575, 1, 136, 518, 634, 195, 45, 1, 1056, 2, 211, 297, 32, 942]",1298.0,19861227,179
Radical abdominal trachelectomy for stage IB1 cervical cancer at 15-week gestation.,Gynecologic oncology,Gynecol. Oncol.,2009-10-29,"The management of stage IB1 cervical cancer at 15 weeks pregnancy remains a significant challenge from both the oncologic and obstetrical standpoints. Abdominal trachelectomy has been recently described as a potential option in patients who have a very strong desire to attempt preservation of pregnancy and treat the cancer without delay. A 37-year-old female, presented for prenatal care in the first trimester and was diagnosed with a FIGO stage IB1 poorly differentiated lymphoepithelioma like cervical cancer on conization. After extensive counseling she underwent a radical abdominal trachelectomy with pelvic lymphadenectomy and placement of permanent cerclage at 15 weeks gestation. Final trachelectomy pathology revealed 7/19 mm invasion with no lymphovascular invasion, negative margins and nodes. She successfully carried the pregnancy to 39 weeks gestation and delivered a healthy female infant by elective planned cesarean hysterectomy. The patient remains without evidence of disease at the time of this report. Recent advances in fertility-sparing surgery for stage IB1 cervical cancer lead to the successful utilization of radical abdominal trachelectomy during the early second trimester of pregnancy. This approach in early gestation is feasible and resulted in a favorable oncologic and obstetrical outcome. Radical trachelectomy may broaden the treatment options for pregnant women with stage IB1 cervical cancer who have a strong desire to avoid definitive pregnancy termination and commence treatment without delay.",Case Reports,3736.0,42.0,The management of stage IB1 cancer at 15 weeks pregnancy remains a significant challenge from both the oncologic and obstetrical standpoints Abdominal trachelectomy has been recently described as a potential option in patients who have a very strong desire to attempt preservation of pregnancy and treat the cancer without delay A 37-year-old female presented for prenatal care in the first trimester and was diagnosed with a FIGO stage IB1 poorly differentiated lymphoepithelioma like cancer on conization After extensive counseling she underwent a radical abdominal trachelectomy with pelvic lymphadenectomy and placement of permanent cerclage at 15 weeks gestation Final trachelectomy pathology revealed 7/19 mm invasion with no lymphovascular invasion negative margins and nodes She successfully carried the pregnancy to 39 weeks gestation and delivered a healthy female infant by elective planned cesarean hysterectomy The patient remains without evidence of disease at the time of this report Recent advances in fertility-sparing surgery for stage IB1 cancer lead to the successful utilization of radical abdominal trachelectomy during the early second trimester of pregnancy This approach in early gestation is feasible and resulted in a favorable oncologic and obstetrical outcome Radical trachelectomy may broaden the treatment options for pregnant women with stage IB1 cancer who have a strong desire to avoid definitive pregnancy termination and commence treatment without delay,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 284, 1, 82, 8111, 12, 28, 167, 244, 2290, 469, 8, 93, 1745, 29, 110, 3, 1998, 2, 21031, 45749, 1467, 5760, 71, 85, 761, 1027, 22, 8, 174, 1501, 4, 7, 54, 47, 8, 923, 1082, 5278, 6, 3448, 2224, 1, 2290, 2, 943, 3, 12, 187, 1984, 8, 567, 111, 1095, 1061, 917, 9, 15621, 165, 4, 3, 157, 12693, 2, 10, 265, 5, 8, 3837, 82, 8111, 1240, 1442, 28091, 733, 12, 23, 8755, 50, 1344, 2011, 3109, 208, 8, 711, 1467, 5760, 5, 1110, 2048, 2, 2613, 1, 4377, 28830, 28, 167, 244, 13250, 1457, 5760, 1117, 553, 67, 326, 321, 578, 5, 77, 2933, 578, 199, 1012, 2, 502, 3109, 1878, 2629, 3, 2290, 6, 587, 244, 13250, 2, 1623, 8, 1331, 1061, 8027, 20, 4700, 1465, 28385, 2622, 3, 69, 469, 187, 241, 1, 34, 28, 3, 98, 1, 26, 414, 435, 954, 4, 2954, 1851, 152, 9, 82, 8111, 12, 1122, 6, 3, 1401, 1961, 1, 711, 1467, 5760, 190, 3, 191, 419, 12693, 1, 2290, 26, 353, 4, 191, 13250, 16, 1313, 2, 627, 4, 8, 913, 1998, 2, 21031, 228, 711, 5760, 68, 12338, 3, 24, 838, 9, 6086, 117, 5, 82, 8111, 12, 54, 47, 8, 1082, 5278, 6, 3085, 1057, 2290, 7202, 2, 31535, 24, 187, 1984]",1489.0,19878979,62
Conference Report: Seventh Annual AACR International Conference on Frontiers in Cancer Prevention Research.,"Cancer prevention research (Philadelphia, Pa.)",Cancer Prev Res (Phila),2009-11-01,"In November, 2008 the AACR held the Seventh Annual Frontiers in Cancer Prevention Research meeting in Washington, DC. At this meeting, a wide range of cutting-edge cancer prevention research was presented. This summary highlights some of the most impactful presentations with a focus on the interaction between inflammation, infections, the immune system, and tumor microenvironment in promoting cancer. Several of these presentations described targeting host-tumor interactions as a means for cancer prevention. As discussed below, this meeting continues to represent all phases of cancer prevention research including epidemiologic studies, behavioral and lifestyle interventions, carcinogenesis research, preclinical studies testing novel preventive interventions, and the results of early- and late-phase cancer prevention trials. Major advances presented at the 2008 meeting included studies showing that immune cells can be either protumorigenic or antitumorigenic, efforts to develop more comprehensive human papillomavirus vaccines to more effectively prevent cervical cancer and other human papillomavirus-related cancers, controversial studies of vitamin D and cancer risk, and studies of single-nucleotide polymorphisms to better assess cancer risk. These and the other presentations at this meeting continue to provide strong support for the concept that cancer will be most effectively controlled by applying modern cancer prevention strategies.",Congress,3733.0,1.0,In November 2008 the AACR held the Seventh Annual Frontiers in Cancer Prevention Research meeting in Washington DC At this meeting a wide range of cutting-edge cancer prevention research was presented This summary highlights some of the most impactful presentations with a focus on the interaction between inflammation infections the immune system and tumor microenvironment in promoting cancer Several of these presentations described targeting host-tumor interactions as a means for cancer prevention As discussed below this meeting continues to represent all phases of cancer prevention research including epidemiologic studies behavioral and lifestyle interventions carcinogenesis research preclinical studies testing novel preventive interventions and the results of early- and late-phase cancer prevention trials Major advances presented at the 2008 meeting included studies showing that immune cells can be either protumorigenic or antitumorigenic efforts to develop more comprehensive human papillomavirus vaccines to more effectively prevent cancer and other human papillomavirus-related cancers controversial studies of vitamin D and cancer risk and studies of single-nucleotide polymorphisms to better assess cancer risk These and the other presentations at this meeting continue to provide strong support for the concept that cancer will be most effectively controlled by applying modern cancer prevention strategies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4, 2868, 1375, 3, 1630, 4033, 3, 8114, 2114, 24656, 4, 12, 1070, 389, 2238, 4, 10840, 2321, 28, 26, 2238, 8, 1019, 184, 1, 13360, 7951, 12, 1070, 389, 10, 917, 26, 1962, 2527, 476, 1, 3, 96, 17993, 4261, 5, 8, 1222, 23, 3, 915, 59, 1815, 1875, 3, 250, 398, 2, 30, 995, 4, 2388, 12, 392, 1, 46, 4261, 1027, 529, 1204, 30, 1286, 22, 8, 2263, 9, 12, 1070, 22, 1588, 2736, 26, 2238, 2274, 6, 1231, 62, 3523, 1, 12, 1070, 389, 141, 3609, 94, 4166, 2, 3487, 1151, 1719, 389, 693, 94, 471, 229, 3494, 1151, 2, 3, 99, 1, 191, 2, 807, 124, 12, 1070, 143, 458, 954, 917, 28, 3, 1375, 2238, 159, 94, 2069, 17, 250, 37, 122, 40, 361, 11840, 15, 15958, 1413, 6, 690, 80, 949, 171, 3242, 1842, 6, 80, 1856, 1682, 12, 2, 127, 171, 3242, 139, 163, 2010, 94, 1, 1610, 427, 2, 12, 43, 2, 94, 1, 226, 1579, 1203, 6, 380, 423, 12, 43, 46, 2, 3, 127, 4261, 28, 26, 2238, 1906, 6, 377, 1082, 538, 9, 3, 2545, 17, 12, 303, 40, 96, 1856, 1149, 20, 4798, 2366, 12, 1070, 422]",1428.0,19892666,277
Dynamic jaws and dynamic couch in helical tomotherapy.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2009-11-10,"To investigate the next generation of helical tomotherapy delivery with dynamic jaw and dynamic couch movements. The new technique of dynamic jaw and dynamic couch movements is described, and a comparative planning study is performed. Ten nasopharyngeal cancer patients with skull base infiltration were chosen for this comparison of longitudinal dose profiles using regular tomotherapy delivery, running-start-stop treatment, and dynamic jaw and dynamic couch delivery. A multifocal simultaneous integrated boost concept was used (70.4Gy to the primary tumor and involved lymph nodes; 57.4Gy to the bilateral cervical lymphatic drainage pathways, 32 fractions). Target coverage, conformity, homogeneity, sparing of organs at risk, integral dose, and radiation delivery time were evaluated. Mean parotid dose for all different deliveries was between 24.8 and 26.1Gy, without significant differences. The mean integral dose was lowered by 6.3% by using the dynamic technique, in comparison with a 2.5-cm-field width for regular delivery and 16.7% with 5-cm-field width for regular delivery. Dynamic jaw and couch movements reduced the calculated radiation time by 66% of the time required with regular 2.5-cm-field width delivery (199 sec vs. 595 sec, p < 0.001). The current delivery mode of helical tomotherapy produces dose distributions with conformal avoidance of parotid glands, brain stem, and spinal cord. The new technology with dynamic jaw and couch movements improves the plan quality by reducing the dose penumbra and thereby reducing the integral dose. In addition, radiation time is reduced by 66% of the regular delivery time.",Comparative Study,3724.0,45.0,To investigate the next generation of helical tomotherapy delivery with dynamic jaw and dynamic couch movements The new technique of dynamic jaw and dynamic couch movements is described and a comparative planning study is performed Ten cancer patients with skull base infiltration were chosen for this comparison of longitudinal dose profiles using regular tomotherapy delivery running-start-stop treatment and dynamic jaw and dynamic couch delivery A multifocal simultaneous integrated boost concept was used 70.4Gy to the primary tumor and involved lymph nodes 57.4Gy to the bilateral lymphatic drainage pathways 32 fractions Target coverage conformity homogeneity sparing of organs at risk integral dose and radiation delivery time were evaluated Mean parotid dose for all different deliveries was between 24.8 and 26.1Gy without significant differences The mean integral dose was lowered by 6.3 by using the dynamic technique in comparison with a 2.5-cm-field width for regular delivery and 16.7 with 5-cm-field width for regular delivery Dynamic jaw and couch movements reduced the calculated radiation time by 66 of the time required with regular 2.5-cm-field width delivery 199 sec vs. 595 sec p 0.001 The current delivery mode of helical tomotherapy produces dose distributions with conformal avoidance of parotid glands brain stem and spinal cord The new technology with dynamic jaw and couch movements improves the plan quality by reducing the dose penumbra and thereby reducing the integral dose In addition radiation time is reduced by 66 of the regular delivery time,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 963, 3, 1305, 914, 1, 6638, 7731, 989, 5, 2540, 7670, 2, 2540, 11986, 13564, 3, 217, 1312, 1, 2540, 7670, 2, 2540, 11986, 13564, 16, 1027, 2, 8, 2352, 1349, 45, 16, 173, 1618, 12, 7, 5, 5054, 1782, 2084, 11, 4695, 9, 26, 1155, 1, 2380, 61, 1241, 75, 3316, 7731, 989, 18585, 2435, 7142, 24, 2, 2540, 7670, 2, 2540, 11986, 989, 8, 3492, 2824, 2102, 2569, 2545, 10, 95, 431, 17384, 6, 3, 86, 30, 2, 646, 263, 502, 696, 17384, 6, 3, 1607, 2936, 3528, 460, 531, 1550, 283, 2139, 8693, 7502, 1851, 1, 2285, 28, 43, 4450, 61, 2, 121, 989, 98, 11, 194, 313, 5838, 61, 9, 62, 338, 26092, 10, 59, 259, 66, 2, 432, 45762, 187, 93, 362, 3, 313, 4450, 61, 10, 7238, 20, 49, 27, 20, 75, 3, 2540, 1312, 4, 1155, 5, 8, 18, 33, 494, 1067, 5195, 9, 3316, 989, 2, 245, 67, 5, 33, 494, 1067, 5195, 9, 3316, 989, 2540, 7670, 2, 11986, 13564, 405, 3, 981, 121, 98, 20, 700, 1, 3, 98, 616, 5, 3316, 18, 33, 494, 1067, 5195, 989, 5840, 13678, 105, 11442, 13678, 19, 13, 144, 3, 291, 989, 4530, 1, 6638, 7731, 4042, 61, 4477, 5, 2972, 5863, 1, 5838, 3966, 342, 452, 2, 1499, 1885, 3, 217, 2033, 5, 2540, 7670, 2, 11986, 13564, 1804, 3, 2242, 372, 20, 1818, 3, 61, 20675, 2, 2267, 1818, 3, 4450, 61, 4, 352, 121, 98, 16, 405, 20, 700, 1, 3, 3316, 989, 98]",1579.0,19910128,512
"Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study.",Gynecologic oncology,Gynecol. Oncol.,2009-11-13,"This study aimed to determine whether carbonic anhydrase-IX (CA-IX) was associated with progression-free survival (PFS) and overall survival (OS) in women with high-risk, early-stage cervical cancer treated with adjuvant pelvic radiotherapy with or without radiosensitizing chemotherapy. CA-IX expression was detected using an immunohistochemistry assay and categorized as low when <or=80% of tumor cells exhibited CA-IX staining and high when >80% tumor cells display CA-IX staining. Associations between CA-IX expression and clinical characteristics, angiogenesis marker expression, and clinical outcome were evaluated. High CA-IX expression was observed in 35/166 (21.1%) of cases. CA-IX expression was not associated with age, race, stage, cell type, grade, positive margins, parametrial extensions, positive lymph nodes, or lymphovascular space invasion but was associated with tumor size categorized as <2 , 2-2.9 , or >or=3 cm (high expression: 4.7% vs. 23.2% vs. 32.5%, P=0.003) and cervical invasion confined to the inner two-thirds compared with the outer third of the cervix (high expression: 6.1% vs. 23.7%, P=0.028). CA-IX expression was not associated with immunohistochemical expression of p53, CD31, CD105, thrombospondin-1, or vascular endothelial growth factor-A. Women with high versus low CA-IX expression had similar PFS (P=0.053) and significantly worse OS (P=0.044). After adjusting for prognostic clinical covariates, high CA-IX expression was an independent prognostic factor for PFS (hazard ratio [HR]=2.12; 95% confidence interval [CI]=1.13-3.95; P=0.019) and OS (HR=2.41; 95% CI=1.24-4.68; P=0.009). Tumor hypoxia measured by immunohistochemical expression of CA-IX is an independent prognostic factor for both PFS and OS in high-risk, early-stage cervical cancer.","Clinical Trial, Phase III",3721.0,45.0,This study aimed to determine whether carbonic anhydrase-IX CA-IX was associated with progression-free survival PFS and overall survival OS in women with high-risk early-stage cancer treated with adjuvant pelvic radiotherapy with or without radiosensitizing chemotherapy CA-IX expression was detected using an immunohistochemistry assay and categorized as low when or=80 of tumor cells exhibited CA-IX staining and high when 80 tumor cells display CA-IX staining Associations between CA-IX expression and clinical characteristics angiogenesis marker expression and clinical outcome were evaluated High CA-IX expression was observed in 35/166 21.1 of cases CA-IX expression was not associated with age race stage cell type grade positive margins parametrial extensions positive lymph nodes or lymphovascular space invasion but was associated with tumor size categorized as 2 2-2.9 or or=3 cm high expression 4.7 vs. 23.2 vs. 32.5 P=0.003 and invasion confined to the inner two-thirds compared with the outer third of the cervix high expression 6.1 vs. 23.7 P=0.028 CA-IX expression was not associated with immunohistochemical expression of p53 CD31 CD105 thrombospondin-1 or vascular endothelial growth factor-A Women with high versus low CA-IX expression had similar PFS P=0.053 and significantly worse OS P=0.044 After adjusting for prognostic clinical covariates high CA-IX expression was an independent prognostic factor for PFS hazard ratio HR =2.12 95 confidence interval CI =1.13-3.95 P=0.019 and OS HR=2.41 95 CI=1.24-4.68 P=0.009 Tumor hypoxia measured by immunohistochemical expression of CA-IX is an independent prognostic factor for both PFS and OS in high-risk early-stage cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[26, 45, 1295, 6, 223, 317, 11190, 11191, 8032, 1568, 8032, 10, 41, 5, 91, 115, 25, 300, 2, 63, 25, 118, 4, 117, 5, 64, 43, 191, 82, 12, 73, 5, 249, 1110, 310, 5, 15, 187, 8384, 56, 1568, 8032, 55, 10, 530, 75, 35, 888, 719, 2, 2320, 22, 154, 198, 15, 493, 1, 30, 37, 1416, 1568, 8032, 1029, 2, 64, 198, 493, 30, 37, 3640, 1568, 8032, 1029, 685, 59, 1568, 8032, 55, 2, 38, 374, 1056, 952, 55, 2, 38, 228, 11, 194, 64, 1568, 8032, 55, 10, 164, 4, 465, 5812, 239, 14, 1, 140, 1568, 8032, 55, 10, 44, 41, 5, 89, 1047, 82, 31, 267, 88, 109, 1012, 8726, 23146, 109, 263, 502, 15, 2933, 3865, 578, 84, 10, 41, 5, 30, 444, 2320, 22, 18, 18, 18, 83, 15, 15, 27, 494, 64, 55, 39, 67, 105, 382, 18, 105, 531, 33, 19, 13, 1421, 2, 578, 2902, 6, 3, 7938, 100, 5438, 72, 5, 3, 7808, 1282, 1, 3, 3629, 64, 55, 49, 14, 105, 382, 67, 19, 13, 4836, 1568, 8032, 55, 10, 44, 41, 5, 1382, 55, 1, 624, 6019, 11822, 12596, 14, 15, 756, 845, 129, 161, 8, 117, 5, 64, 185, 154, 1568, 8032, 55, 42, 288, 300, 19, 13, 9948, 2, 97, 639, 118, 19, 13, 6194, 50, 1358, 9, 177, 38, 2489, 64, 1568, 8032, 55, 10, 35, 306, 177, 161, 9, 300, 360, 197, 168, 18, 133, 48, 307, 268, 58, 14, 233, 27, 48, 19, 13, 4049, 2, 118, 168, 18, 605, 48, 58, 14, 259, 39, 806, 19, 13, 2376, 30, 1823, 644, 20, 1382, 55, 1, 1568, 8032, 16, 35, 306, 177, 161, 9, 110, 300, 2, 118, 4, 64, 43, 191, 82, 12]",1691.0,19913895,244
Acceptance of human papillomavirus vaccination among first year female university students in Hong Kong.,Sexual health,Sex Health,2009-12-01,"The present study assessed sexual behaviour, knowledge and attitudes among first year university students in order to identify factors that may affect their acceptance of human papillomavirus (HPV) vaccination. A cross-sectional survey was conducted at the Chinese University of Hong Kong in August 2006. The survey was a self-administered questionnaire comprising questions regarding general health, sexual behaviour, knowledge about HPV and cervical cancer, and attitudes towards vaccination. chi2, anova and logistic regression tests were used to identify associations between categories. Of 992 students, 63 (6.5%) reported having had sexual intercourse, 22.4% of whom had had more than one sexual partner and 36.5% had had unprotected sexual intercourse. A total of 70.8% of participants were willing to accept the HPV vaccine, with 'willingness' independently associated with age, having had sexual intercourse and beliefs regarding the effectiveness of vaccination (P < 0.05). Understanding the role of these influences can aid in the design of successful HPV education, prevention and vaccination programs.",Journal Article,3703.0,11.0,The present study assessed sexual behaviour knowledge and attitudes among first year university students in order to identify factors that may affect their acceptance of human papillomavirus HPV vaccination A cross-sectional survey was conducted at the Chinese University of Hong Kong in August 2006 The survey was a self-administered questionnaire comprising questions regarding general health sexual behaviour knowledge about HPV and cancer and attitudes towards vaccination chi2 anova and logistic regression tests were used to identify associations between categories Of 992 students 63 6.5 reported having had sexual intercourse 22.4 of whom had had more than one sexual partner and 36.5 had had unprotected sexual intercourse A total of 70.8 of participants were willing to accept the HPV vaccine with 'willingness independently associated with age having had sexual intercourse and beliefs regarding the effectiveness of vaccination P 0.05 Understanding the role of these influences can aid in the design of successful HPV education prevention and vaccination programs,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 364, 45, 275, 2232, 8173, 922, 2, 4555, 107, 157, 111, 1652, 15593, 4, 1732, 6, 255, 130, 17, 68, 1158, 136, 5080, 1, 171, 3242, 933, 1915, 8, 1383, 2832, 1407, 10, 426, 28, 3, 3656, 1652, 1, 20678, 20679, 4, 2480, 1324, 3, 1407, 10, 8, 1074, 468, 1770, 3538, 1937, 666, 1083, 341, 2232, 8173, 922, 545, 933, 2, 12, 2, 4555, 3113, 1915, 12474, 9008, 2, 812, 320, 895, 11, 95, 6, 255, 685, 59, 1996, 1, 13144, 15593, 676, 49, 33, 210, 1041, 42, 2232, 12361, 350, 39, 1, 953, 42, 42, 80, 76, 104, 2232, 4852, 2, 511, 33, 42, 42, 28637, 2232, 12361, 8, 181, 1, 431, 66, 1, 776, 11, 7820, 6, 11485, 3, 933, 1274, 5, 58422, 1042, 41, 5, 89, 1041, 42, 2232, 12361, 2, 5059, 666, 3, 1236, 1, 1915, 19, 13, 474, 612, 3, 200, 1, 46, 3859, 122, 2427, 4, 3, 771, 1, 1401, 933, 1848, 1070, 2, 1915, 2251]",1075.0,19917193,92
Predicting residual neck disease in patients with oropharyngeal squamous cell carcinoma treated with radiation therapy: utility of p16 status.,Archives of otolaryngology--head & neck surgery,Arch. Otolaryngol. Head Neck Surg.,2009-11-01,"To identify factors that predict complete response of cervical nodal disease to radiation therapy (RT) in patients with oropharyngeal squamous cell carcinoma (OP-SCCA). Histologic analysis of prospectively collected specimens and retrospective medical chart review. Tertiary referral center. Sixty-nine patients with OP-SCCA treated from January 1, 2002, through June 1, 2008. Definitive RT, with or without chemotherapy and with or without neck dissection (ND). Presence of a viable tumor in post-RT ND specimen. Tissue specimens from 69 patients with OP-SCCA treated primarily with RT, with or without chemotherapy, were evaluated. Of these, 47 (68.1%) were strongly and diffusely positive for p16 expression by immunohistochemical analysis, signifying human papillomavirus positivity. Patients with p16-positive and p16-negative tumors (hereinafter, p16+ and p16-, respectively) had similarly sized primary tumors on presentation, but p16+ primary tumors were associated with more advanced neck disease (nodal stages N2c-N3; 31.9% vs 4.5% for p16- tumors) and more contralateral nodes (27.7% vs 4.5% for p16- tumors). Forty-seven patients (59.0%) underwent planned posttreatment ND (a total of 55 NDs). The NDs performed for p16- tumors were significantly more likely to have viable tumor in the specimen (50.0% vs 18.0% for p16+ tumors; P = .02). In addition, p16+ necks with residual viable cancer were characterized by incomplete response on post-RT imaging, tobacco and alcohol use, and extracapsular spread on pretreatment imaging. In conjunction with other clinical parameters, p16 status can help predict the need for post-RT ND in patients with OP-SCCA. Although close observation may be warranted in selected patients with p16+ tumors, patients with p16- tumors are at much higher risk for residual neck disease, even when initial nodal disease is less advanced.",Comparative Study,3733.0,17.0,To identify factors that predict complete response of nodal disease to radiation therapy RT in patients with squamous cell carcinoma OP-SCCA Histologic analysis of prospectively collected specimens and retrospective medical chart review Tertiary referral center Sixty-nine patients with OP-SCCA treated from January 1 2002 through June 1 2008 Definitive RT with or without chemotherapy and with or without dissection ND Presence of a viable tumor in post-RT ND specimen Tissue specimens from 69 patients with OP-SCCA treated primarily with RT with or without chemotherapy were evaluated Of these 47 68.1 were strongly and diffusely positive for p16 expression by immunohistochemical analysis signifying human papillomavirus positivity Patients with p16-positive and p16-negative tumors hereinafter p16+ and p16- respectively had similarly sized primary tumors on presentation but p16+ primary tumors were associated with more advanced disease nodal stages N2c-N3 31.9 vs 4.5 for p16- tumors and more contralateral nodes 27.7 vs 4.5 for p16- tumors Forty-seven patients 59.0 underwent planned posttreatment ND a total of 55 NDs The NDs performed for p16- tumors were significantly more likely to have viable tumor in the specimen 50.0 vs 18.0 for p16+ tumors P .02 In addition p16+ necks with residual viable cancer were characterized by incomplete response on post-RT imaging tobacco and alcohol use and extracapsular spread on pretreatment imaging In conjunction with other clinical parameters p16 status can help predict the need for post-RT ND in patients with OP-SCCA Although close observation may be warranted in selected patients with p16+ tumors patients with p16- tumors are at much higher risk for residual disease even when initial nodal disease is less advanced,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 255, 130, 17, 678, 236, 51, 1, 779, 34, 6, 121, 36, 240, 4, 7, 5, 691, 31, 134, 9209, 6372, 884, 65, 1, 1143, 786, 623, 2, 459, 484, 2937, 206, 2557, 2096, 574, 1746, 762, 7, 5, 9209, 6372, 73, 29, 1024, 14, 1544, 298, 1924, 14, 1375, 1057, 240, 5, 15, 187, 56, 2, 5, 15, 187, 1161, 7175, 463, 1, 8, 2663, 30, 4, 539, 240, 7175, 2360, 246, 623, 29, 790, 7, 5, 9209, 6372, 73, 1561, 5, 240, 5, 15, 187, 56, 11, 194, 1, 46, 662, 806, 14, 11, 1327, 2, 9333, 109, 9, 1932, 55, 20, 1382, 65, 20487, 171, 3242, 1887, 7, 5, 1932, 109, 2, 1932, 199, 57, 45769, 1932, 2, 1932, 106, 42, 1813, 8568, 86, 57, 23, 1031, 84, 1932, 86, 57, 11, 41, 5, 80, 131, 34, 779, 1153, 21233, 5749, 456, 83, 105, 39, 33, 9, 1932, 57, 2, 80, 2138, 502, 428, 67, 105, 39, 33, 9, 1932, 57, 1213, 648, 7, 728, 13, 208, 1465, 3149, 7175, 8, 181, 1, 614, 30830, 3, 30830, 173, 9, 1932, 57, 11, 97, 80, 322, 6, 47, 2663, 30, 4, 3, 2360, 212, 13, 105, 203, 13, 9, 1932, 57, 19, 588, 4, 352, 1932, 18251, 5, 753, 2663, 12, 11, 765, 20, 2610, 51, 23, 539, 240, 270, 2607, 2, 2197, 119, 2, 5607, 2579, 23, 1194, 270, 4, 3357, 5, 127, 38, 1038, 1932, 156, 122, 987, 678, 3, 594, 9, 539, 240, 7175, 4, 7, 5, 9209, 6372, 242, 2336, 1664, 68, 40, 1197, 4, 715, 7, 5, 1932, 57, 7, 5, 1932, 57, 32, 28, 1802, 142, 43, 9, 753, 34, 871, 198, 388, 779, 34, 16, 299, 131]",1773.0,19917926,402
Selective versus comprehensive neck dissection after chemoradiation for advanced oropharyngeal squamous cell carcinoma.,Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery,Otolaryngol Head Neck Surg,2009-12-01,"To determine whether a comprehensive neck dissection (CND) or a selective neck dissection (SND) is indicated as planned post-primary chemoradiation treatment (CRT) for patients with advanced oropharyngeal squamous cell carcinoma (OPSCC). Case series with chart review. A community teaching hospital. Patients with advanced OPSCC who received a uniform CRT protocol at Greater Baltimore Medical Center (GBMC). Medical records of patients treated with primary CRT for locoregionally advanced OPSCC at GBMC between 2001 and 2007 were reviewed. All patients received 7000 to 7500, 6000, and 5000 cGy to primary disease sites, involved cervical lymphatics, and uninvolved cervical and supraclavicular lymphatics, respectively, with concomitant cisplatin (12 mg/m(2)/1 h) and 5-fluorouracil (600 mg/m(2)/20 h) given on days one through five and 29 through 33. Seventy-six patients received CRT, and 41 met the criteria for neck dissection. Forty-eight neck dissections were performed (34 unilateral and 7 bilateral), of which 23 (48%) were CNDs and 25 (52%) were SNDs. Residual carcinoma was found in six (26%) of the CND and five (20%) of the SND heminecks. The CND group had six (26%) complications, whereas the SND group had two (8%). The high rate of residual disease demonstrated in this study supports the need for post-CRT neck dissection. Although complication rates were not significantly different between the two groups, the trend in this study indicates that SND results in less morbidity. The presumed reduced morbidity and equivalent regional control rate suggest that SND is an appropriate surgical option for OPSCC patients after primary CRT.",Comparative Study,3703.0,19.0,To determine whether a comprehensive dissection CND or a selective dissection SND is indicated as planned post-primary chemoradiation treatment CRT for patients with advanced squamous cell carcinoma OPSCC Case series with chart review A community teaching hospital Patients with advanced OPSCC who received a uniform CRT protocol at Greater Baltimore Medical Center GBMC Medical records of patients treated with primary CRT for locoregionally advanced OPSCC at GBMC between 2001 and 2007 were reviewed All patients received 7000 to 7500 6000 and 5000 cGy to primary disease sites involved lymphatics and uninvolved and supraclavicular lymphatics respectively with concomitant cisplatin 12 mg/m 2 /1 h and 5-fluorouracil 600 mg/m 2 /20 h given on days one through five and 29 through 33 Seventy-six patients received CRT and 41 met the criteria for dissection Forty-eight dissections were performed 34 unilateral and 7 bilateral of which 23 48 were CNDs and 25 52 were SNDs Residual carcinoma was found in six 26 of the CND and five 20 of the SND heminecks The CND group had six 26 complications whereas the SND group had two 8 The high rate of residual disease demonstrated in this study supports the need for post-CRT dissection Although complication rates were not significantly different between the two groups the trend in this study indicates that SND results in less morbidity The presumed reduced morbidity and equivalent regional control rate suggest that SND is an appropriate surgical option for OPSCC patients after primary CRT,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 317, 8, 949, 1161, 14287, 15, 8, 1094, 1161, 15314, 16, 1103, 22, 1465, 539, 86, 975, 24, 1089, 9, 7, 5, 131, 691, 31, 134, 5205, 473, 988, 5, 2937, 206, 8, 1714, 6292, 702, 7, 5, 131, 5205, 54, 103, 8, 3490, 1089, 1182, 28, 378, 16884, 484, 574, 45776, 484, 1064, 1, 7, 73, 5, 86, 1089, 9, 6410, 131, 5205, 28, 45776, 59, 1758, 2, 1307, 11, 446, 62, 7, 103, 23358, 6, 33288, 16187, 2, 10410, 3071, 6, 86, 34, 633, 646, 9335, 2, 7377, 2, 5804, 9335, 106, 5, 1781, 540, 133, 81, 188, 18, 14, 555, 2, 33, 1404, 2383, 81, 188, 18, 179, 555, 447, 23, 162, 104, 298, 365, 2, 462, 298, 466, 2073, 437, 7, 103, 1089, 2, 605, 543, 3, 371, 9, 1161, 1213, 659, 6894, 11, 173, 562, 3208, 2, 67, 1607, 1, 92, 382, 576, 11, 58428, 2, 243, 653, 11, 58429, 753, 134, 10, 204, 4, 437, 432, 1, 3, 14287, 2, 365, 179, 1, 3, 15314, 26681, 3, 14287, 87, 42, 437, 432, 521, 547, 3, 15314, 87, 42, 100, 66, 3, 64, 116, 1, 753, 34, 264, 4, 26, 45, 2304, 3, 594, 9, 539, 1089, 1161, 242, 1447, 151, 11, 44, 97, 338, 59, 3, 100, 271, 3, 853, 4, 26, 45, 2640, 17, 15314, 99, 4, 299, 787, 3, 5472, 405, 787, 2, 2017, 951, 182, 116, 309, 17, 15314, 16, 35, 870, 221, 1501, 9, 5205, 7, 50, 86, 1089]",1538.0,19932847,366
Pelvic fractures after radiotherapy for cervical cancer: implications for survivors.,Cancer,Cancer,2010-02-01,"The incidence of pelvic fractures and associated risk factors was determined in women treated with curative-intent radiotherapy for cervical cancer. The records of 516 women treated with curative-intent radiotherapy for cervical cancer between 2001 and 2006 at the University of Texas M. D. Anderson Cancer Center were reviewed. Among these, 300 patients had at least 1 post-treatment computed tomography scan or magnetic resonance imaging study available for review, and they comprised our study population. All imaging studies were re-reviewed by a single radiologist to evaluate for fractures. Pelvic fractures were noted in 29 of 300 patients (9.7%). Fracture sites included sacrum (n = 24; 83%), sacrum and pubis (n = 3; 10%), iliac crest (n = 1; 3%), and sacrum and acetabulum (n = 1; 3%). Thirteen patients (45%) were symptomatic, with pain being the most common presenting symptom. The median time from the completion of radiotherapy to the detection of fractures on imaging studies was 14.1 months (range, 2.1-63.1 months), with 38% of patients diagnosed within 1 year and 83% diagnosed within 2 years of completing therapy. The median age of the patients at diagnosis was higher in the women who developed a fracture compared with the women who did not (56.5 years vs 46.7 years; P = .04). A higher number of women with a fracture were postmenopausal (62% vs 37%; P = .03). The median body mass index was lower in the women who had a fracture (26.0 kg/m2 vs 28.0 kg/m2; P = .03). Pelvic fractures were detected in a substantial proportion of women after radiotherapy for cervical cancer. Bone mineral density screening and pharmacologic intervention should be considered in these women.",Journal Article,3641.0,67.0,The incidence of pelvic fractures and associated risk factors was determined in women treated with curative-intent radiotherapy for cancer The records of 516 women treated with curative-intent radiotherapy for cancer between 2001 and 2006 at the University of Texas M. D. Anderson Cancer Center were reviewed Among these 300 patients had at least 1 post-treatment computed tomography scan or magnetic resonance imaging study available for review and they comprised our study population All imaging studies were re-reviewed by a single radiologist to evaluate for fractures Pelvic fractures were noted in 29 of 300 patients 9.7 Fracture sites included sacrum n 24 83 sacrum and pubis n 3 10 iliac crest n 1 3 and sacrum and acetabulum n 1 3 Thirteen patients 45 were symptomatic with pain being the most common presenting symptom The median time from the completion of radiotherapy to the detection of fractures on imaging studies was 14.1 months range 2.1-63.1 months with 38 of patients diagnosed within 1 year and 83 diagnosed within 2 years of completing therapy The median age of the patients at diagnosis was higher in the women who developed a fracture compared with the women who did not 56.5 years vs 46.7 years P .04 A higher number of women with a fracture were postmenopausal 62 vs 37 P .03 The median body mass index was lower in the women who had a fracture 26.0 kg/m2 vs 28.0 kg/m2 P .03 Pelvic fractures were detected in a substantial proportion of women after radiotherapy for cancer mineral density screening and pharmacologic intervention should be considered in these women,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 287, 1, 1110, 3909, 2, 41, 43, 130, 10, 509, 4, 117, 73, 5, 1075, 1697, 310, 9, 12, 3, 1064, 1, 11780, 117, 73, 5, 1075, 1697, 310, 9, 12, 59, 1758, 2, 1324, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 11, 446, 107, 46, 2036, 7, 42, 28, 506, 14, 539, 24, 1220, 872, 1657, 15, 1484, 1535, 270, 45, 390, 9, 206, 2, 491, 2603, 114, 45, 266, 62, 270, 94, 11, 1491, 446, 20, 8, 226, 6247, 6, 376, 9, 3909, 1110, 3909, 11, 1051, 4, 462, 1, 2036, 7, 83, 67, 3956, 633, 159, 11629, 78, 259, 852, 11629, 2, 28361, 78, 27, 79, 6692, 10686, 78, 14, 27, 2, 11629, 2, 28172, 78, 14, 27, 3170, 7, 512, 11, 1704, 5, 559, 486, 3, 96, 186, 1656, 934, 3, 52, 98, 29, 3, 1438, 1, 310, 6, 3, 638, 1, 3909, 23, 270, 94, 10, 213, 14, 53, 184, 18, 14, 676, 14, 53, 5, 519, 1, 7, 265, 262, 14, 111, 2, 852, 265, 262, 18, 60, 1, 4144, 36, 3, 52, 89, 1, 3, 7, 28, 147, 10, 142, 4, 3, 117, 54, 276, 8, 3956, 72, 5, 3, 117, 54, 205, 44, 664, 33, 60, 105, 641, 67, 60, 19, 755, 8, 142, 207, 1, 117, 5, 8, 3956, 11, 1679, 744, 105, 567, 19, 680, 3, 52, 642, 782, 558, 10, 280, 4, 3, 117, 54, 42, 8, 3956, 432, 13, 503, 821, 105, 339, 13, 503, 821, 19, 680, 1110, 3909, 11, 530, 4, 8, 1281, 920, 1, 117, 50, 310, 9, 12, 5033, 1263, 453, 2, 2788, 788, 257, 40, 515, 4, 46, 117]",1592.0,20052724,554
Development of prototype shielded cervical intracavitary brachytherapy applicators compatible with CT and MR imaging.,Medical physics,Med Phys,2009-12-01,"Intracavitary brachytherapy (ICBT) is an integral part of the treatment regimen for cervical cancer and, generally, outcome in terms of local disease control and complications is a function of dose to the disease bed and critical structures, respectively. Therefore, it is paramount to accurately determine the dose given via ICBT to the tumor bed as well as critical structures. This is greatly facilitated through the use of advanced three-dimensional imaging modalities, such as CT and MR, to delineate critical and target structures with an ICBT applicator inserted in vivo. These methods are not possible when using a shielded applicator due to the image artifacts generated by interovoid shielding. The authors present two prototype shielded ICBT applicators that can be utilized for artifact-free CT image acquisition. They also investigate the MR amenability and dosimetry of a novel tungsten-alloy shielding material to extend the functionality of these devices. To accomplish artifact-free CT image acquisition, a ""step-and-shoot"" (S&S) methodology was utilized, which exploits the prototype applicators movable interovoid shielding. Both prototypes were placed in imaging phantoms that positioned the applicators in clinically applicable orientations. CT image sets were acquired of the prototype applicators as well as a shielded Fletcher-Williamson (sFW) ovoid. Artifacts present in each CT image set were qualitatively compared for each prototype applicator following the S&S methodology and the sFW. To test the novel tungsten-alloy shielding material's MR amenability, they constructed a phantom applicator that mimics the basic components of an ICBT ovoid. This phantom applicator positions the MR-compatible shields in orientations equivalent to the sFW bladder and rectal shields. MR images were acquired within a gadopentetate dimeglumine-doped water tank using standard pulse sequences and examined for artifacts. In addition, Monte Carlo simulations were performed to match the attenuation due to the thickness of this new shield type with current, clinically utilized ovoid shields and a 192Ir HDR/PDR source. Artifact-free CT images could be acquired of both generation applicators in a clinically applicable geometry using the S&S method. MR images were acquired of the phantom applicator containing shields, which contained minimal, clinically relevant artifacts. The thickness required to match the dosimetry of the MR-compatible and sFW rectal shields was determined using Monte Carlo simulations. Utilizing a S&S imaging method in conjunction with prototype applicators that feature movable interovoid shields, they were able to acquire artifact-free CT image sets in a clinically applicable geometry. MR images were acquired of a phantom applicator that contained shields composed of a novel tungsten alloy. Artifacts were largely limited to regions within the ovoid cap and are of no clinical interest. The second generation A3 utilizes this material for interovoid shielding.",Journal Article,3703.0,,Intracavitary brachytherapy ICBT is an integral part of the treatment regimen for cancer and generally outcome in terms of local disease control and complications is a function of dose to the disease bed and critical structures respectively Therefore it is paramount to accurately determine the dose given via ICBT to the tumor bed as well as critical structures This is greatly facilitated through the use of advanced three-dimensional imaging modalities such as CT and MR to delineate critical and target structures with an ICBT applicator inserted in vivo These methods are not possible when using a shielded applicator due to the image artifacts generated by interovoid shielding The authors present two prototype shielded ICBT applicators that can be utilized for artifact-free CT image acquisition They also investigate the MR amenability and dosimetry of a novel tungsten-alloy shielding material to extend the functionality of these devices To accomplish artifact-free CT image acquisition a `` step-and-shoot '' S S methodology was utilized which exploits the prototype applicators movable interovoid shielding Both prototypes were placed in imaging phantoms that positioned the applicators in clinically applicable orientations CT image sets were acquired of the prototype applicators as well as a shielded Fletcher-Williamson sFW ovoid Artifacts present in each CT image set were qualitatively compared for each prototype applicator following the S S methodology and the sFW To test the novel tungsten-alloy shielding material 's MR amenability they constructed a phantom applicator that mimics the basic components of an ICBT ovoid This phantom applicator positions the MR-compatible shields in orientations equivalent to the sFW and shields MR images were acquired within a gadopentetate dimeglumine-doped water tank using standard pulse sequences and examined for artifacts In addition Monte Carlo simulations were performed to match the attenuation due to the thickness of this new shield type with current clinically utilized ovoid shields and a 192Ir HDR/PDR source Artifact-free CT images could be acquired of both generation applicators in a clinically applicable geometry using the S S method MR images were acquired of the phantom applicator containing shields which contained minimal clinically relevant artifacts The thickness required to match the dosimetry of the MR-compatible and sFW shields was determined using Monte Carlo simulations Utilizing a S S imaging method in conjunction with prototype applicators that feature movable interovoid shields they were able to acquire artifact-free CT image sets in a clinically applicable geometry MR images were acquired of a phantom applicator that contained shields composed of a novel tungsten alloy Artifacts were largely limited to regions within the ovoid cap and are of no clinical interest The second generation A3 utilizes this material for interovoid shielding,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,"[9122, 1536, 23808, 16, 35, 4450, 760, 1, 3, 24, 477, 9, 12, 2, 1228, 228, 4, 1794, 1, 293, 34, 182, 2, 521, 16, 8, 343, 1, 61, 6, 3, 34, 2929, 2, 740, 2414, 106, 673, 192, 16, 7640, 6, 2141, 223, 3, 61, 447, 847, 23808, 6, 3, 30, 2929, 22, 149, 22, 740, 2414, 26, 16, 3510, 4667, 298, 3, 119, 1, 131, 169, 2201, 270, 1558, 225, 22, 425, 2, 1638, 6, 5092, 740, 2, 283, 2414, 5, 35, 23808, 8789, 9882, 4, 386, 46, 636, 32, 44, 899, 198, 75, 8, 17327, 8789, 520, 6, 3, 1482, 10567, 1419, 20, 34823, 16362, 3, 738, 364, 100, 8743, 17327, 23808, 11800, 17, 122, 40, 2080, 9, 14759, 115, 425, 1482, 3405, 491, 120, 963, 3, 1638, 31568, 2, 4113, 1, 8, 229, 31524, 34773, 16362, 3692, 6, 4087, 3, 8592, 1, 46, 6497, 6, 12976, 14759, 115, 425, 1482, 3405, 8, 2458, 2, 18428, 522, 695, 695, 3209, 10, 2080, 92, 15213, 3, 8743, 11800, 39215, 34823, 16362, 110, 45522, 11, 3295, 4, 270, 14546, 17, 14240, 3, 11800, 4, 505, 3801, 26877, 425, 1482, 2270, 11, 1294, 1, 3, 8743, 11800, 22, 149, 22, 8, 17327, 28459, 39216, 34824, 15300, 10567, 364, 4, 296, 425, 1482, 916, 11, 8040, 72, 9, 296, 8743, 8789, 366, 3, 695, 695, 3209, 2, 3, 34824, 6, 412, 3, 229, 31524, 34773, 16362, 3692, 292, 1638, 31568, 491, 2776, 8, 6755, 8789, 17, 7557, 3, 2795, 1628, 1, 35, 23808, 15300, 26, 6755, 8789, 7134, 3, 1638, 7293, 20466, 4, 26877, 2017, 6, 3, 34824, 2, 20466, 1638, 1572, 11, 1294, 262, 8, 33173, 25970, 34825, 4388, 16107, 75, 260, 7877, 2866, 2, 409, 9, 10567, 4, 352, 7990, 7991, 7490, 11, 173, 6, 5364, 3, 5349, 520, 6, 3, 2903, 1, 26, 217, 21581, 267, 5, 291, 505, 2080, 15300, 20466, 2, 8, 28360, 5309, 16467, 2353, 14759, 115, 425, 1572, 359, 40, 1294, 1, 110, 914, 11800, 4, 8, 505, 3801, 12337, 75, 3, 695, 695, 596, 1638, 1572, 11, 1294, 1, 3, 6755, 8789, 1101, 20466, 92, 3070, 1048, 505, 867, 10567, 3, 2903, 616, 6, 5364, 3, 4113, 1, 3, 1638, 7293, 2, 34824, 20466, 10, 509, 75, 7990, 7991, 7490, 2600, 8, 695, 695, 270, 596, 4, 3357, 5, 8743, 11800, 17, 2705, 39215, 34823, 20466, 491, 11, 1665, 6, 6206, 14759, 115, 425, 1482, 2270, 4, 8, 505, 3801, 12337, 1638, 1572, 11, 1294, 1, 8, 6755, 8789, 17, 3070, 20466, 3317, 1, 8, 229, 31524, 34773, 10567, 11, 1733, 383, 6, 1374, 262, 3, 15300, 3204, 2, 32, 1, 77, 38, 1333, 3, 419, 914, 7024, 9639, 26, 3692, 9, 34823, 16362]",2940.0,20095264,723
Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation.,The Annals of thoracic surgery,Ann. Thorac. Surg.,2010-01-01,"We studied the clinical characteristics and outcomes of patients undergoing pneumonectomy after preoperative concurrent chemoradiation for non-small cell lung cancer. Clinical records of patients with non-small cell lung cancer who underwent pneumonectomy at our institution between 1995 and 2005 after preoperative concurrent chemoradiation were reviewed retrospectively. Twenty-nine patients underwent pneumonectomy after preoperative concurrent chemoradiation. Of the 21 men and 8 women who were treated, 1 had stage IIB (T3N0M0) and the remainder had stage IIIA or IIIB non-small cell lung cancer. Mean patient age at surgery was 53.4 years. There were 15 right pneumonectomies, of which 2 were for pancoast tumors. All patients received concurrent preoperative chemoradiation. Mean total radiation dose was 61.1 Gy. All patients went on to have complete (R0) resection by pneumonectomy. Pathologic complete response was found in 16 patients (55.2%). All patients were discharged alive from the hospital after pneumonectomy. Median hospital length of stay was 5 days (mean 8.6). Ninety-day mortality after surgery was 3.4% (n = 1). Recurrences have been found in 11 patients (38%), including brain metastases (n = 6), bone metastases (n = 4), liver metastases (n = 2), and cervical lymph node metastases (n = 2). One patient had a contralateral new primary lung cancer develop 70 months after undergoing pneumonectomy. Estimated 5-year disease-free survival is 48%. Median survival time has not been reached. Pneumonectomy can be performed safely after preoperative concurrent chemoradiation, even with high-dose radiation. The frequency of disease recurrence in the brain underscores the need to evaluate the role of prophylactic cranial radiation in non-small cell lung cancer.",Comparative Study,3672.0,35.0,We studied the clinical characteristics and outcomes of patients undergoing pneumonectomy after preoperative concurrent chemoradiation for cell cancer Clinical records of patients with cell cancer who underwent pneumonectomy at our institution between 1995 and 2005 after preoperative concurrent chemoradiation were reviewed retrospectively Twenty-nine patients underwent pneumonectomy after preoperative concurrent chemoradiation Of the 21 men and 8 women who were treated 1 had stage IIB T3N0M0 and the remainder had stage IIIA or IIIB cell cancer Mean patient age at surgery was 53.4 years There were 15 right pneumonectomies of which 2 were for pancoast tumors All patients received concurrent preoperative chemoradiation Mean total radiation dose was 61.1 Gy All patients went on to have complete R0 resection by pneumonectomy Pathologic complete response was found in 16 patients 55.2 All patients were discharged alive from the hospital after pneumonectomy Median hospital length of stay was 5 days mean 8.6 Ninety-day mortality after surgery was 3.4 n 1 Recurrences have been found in 11 patients 38 including brain metastases n 6 metastases n 4 metastases n 2 and lymph node metastases n 2 One patient had a contralateral new primary cancer develop 70 months after undergoing pneumonectomy Estimated 5-year disease-free survival is 48 Median survival time has not been reached Pneumonectomy can be performed safely after preoperative concurrent chemoradiation even with high-dose radiation The frequency of disease recurrence in the brain underscores the need to evaluate the role of prophylactic cranial radiation in cell cancer,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 656, 3, 38, 374, 2, 123, 1, 7, 479, 4853, 50, 498, 750, 975, 9, 31, 12, 38, 1064, 1, 7, 5, 31, 12, 54, 208, 4853, 28, 114, 731, 59, 2323, 2, 1242, 50, 498, 750, 975, 11, 446, 894, 737, 762, 7, 208, 4853, 50, 498, 750, 975, 1, 3, 239, 325, 2, 66, 117, 54, 11, 73, 14, 42, 82, 3884, 18769, 2, 3, 7095, 42, 82, 3164, 15, 3036, 31, 12, 313, 69, 89, 28, 152, 10, 699, 39, 60, 125, 11, 167, 1913, 16376, 1, 92, 18, 11, 9, 19533, 57, 62, 7, 103, 750, 498, 975, 313, 181, 121, 61, 10, 713, 14, 381, 62, 7, 7109, 23, 6, 47, 236, 2328, 170, 20, 4853, 510, 236, 51, 10, 204, 4, 245, 7, 614, 18, 62, 7, 11, 6155, 1701, 29, 3, 702, 50, 4853, 52, 702, 1318, 1, 2020, 10, 33, 162, 313, 66, 49, 2493, 218, 282, 50, 152, 10, 27, 39, 78, 14, 1593, 47, 85, 204, 4, 175, 7, 519, 141, 342, 196, 78, 49, 196, 78, 39, 196, 78, 18, 2, 263, 289, 196, 78, 18, 104, 69, 42, 8, 2138, 217, 86, 12, 690, 431, 53, 50, 479, 4853, 661, 33, 111, 34, 115, 25, 16, 576, 52, 25, 98, 71, 44, 85, 1300, 4853, 122, 40, 173, 2268, 50, 498, 750, 975, 871, 5, 64, 61, 121, 3, 675, 1, 34, 146, 4, 3, 342, 6926, 3, 594, 6, 376, 3, 200, 1, 1862, 2565, 121, 4, 31, 12]",1638.0,20103235,40
Single photon emission computed tomography SPECT-CT improves sentinel node detection and localization in cervical and uterine malignancy.,Gynecologic oncology,Gynecol. Oncol.,2010-02-01,"Planar lymphoscintigraphy (LSG) is frequently performed for the assessment of the sentinel lymph nodes (SLN) in gynecologic malignancies. Planar imaging helps to localize hot nodes but lacks accuracy of the anatomic location of those nodes. In this study, we compared SPECT-CT to planar LSG in endometrial and cervical cancer to assess its ability to localize SLN. We conducted a prospective nonrandomized study of SLN mapping in women with endometrial and cervical cancer. Forty patients with endometrial cancer and 10 with cervical cancer underwent pre-operative LSG with 1 or 4 mCi of (99m)Tc sulfur colloid administered as injections into the cervix. All patients were scanned immediately with planar LSG obtained in the anterior and lateral views. SPECT-CT imaging was obtained following the planar imaging. Planar LSG alone localized SLN in 30/40 (75%) endometrial cancer patients while SPECT-CT localized SLN in all 40 patients (100%). In the 10 cases where SLN was not identified with planar imaging, SPECT-CT localized nodes in the external iliac, internal iliac, common iliac and obturator groups. In cervical cancer, planar LSG alone localized sentinel lymph nodes in 8/10 patients (80%) as compared to SPECT-CT, which localized nodes in all 10 patients (100%). SPECT-CT imaging was especially useful in delineating external iliac versus internal iliac or obturator nodes, and the parametrial nodal uptake. SPECT-CT appears to improve sentinel lymph node detection and anatomic localization as compared to planar imaging in cervical and uterine cancer.",Clinical Trial,3641.0,61.0,Planar lymphoscintigraphy LSG is frequently performed for the assessment of the sentinel lymph nodes SLN in gynecologic malignancies Planar imaging helps to localize hot nodes but lacks accuracy of the anatomic location of those nodes In this study we compared SPECT-CT to planar LSG in and cancer to assess its ability to localize SLN We conducted a prospective nonrandomized study of SLN mapping in women with and cancer Forty patients with cancer and 10 with cancer underwent pre-operative LSG with 1 or 4 mCi of 99m Tc sulfur colloid administered as injections into the cervix All patients were scanned immediately with planar LSG obtained in the anterior and lateral views SPECT-CT imaging was obtained following the planar imaging Planar LSG alone localized SLN in 30/40 75 cancer patients while SPECT-CT localized SLN in all 40 patients 100 In the 10 cases where SLN was not identified with planar imaging SPECT-CT localized nodes in the external iliac internal iliac common iliac and obturator groups In cancer planar LSG alone localized sentinel lymph nodes in 8/10 patients 80 as compared to SPECT-CT which localized nodes in all 10 patients 100 SPECT-CT imaging was especially useful in delineating external iliac versus internal iliac or obturator nodes and the parametrial nodal uptake SPECT-CT appears to improve sentinel lymph node detection and anatomic localization as compared to planar imaging in and cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[9042, 6849, 14948, 16, 746, 173, 9, 3, 455, 1, 3, 1323, 263, 502, 1099, 4, 1512, 441, 9042, 270, 6484, 6, 8031, 2859, 502, 84, 6856, 1190, 1, 3, 2745, 1147, 1, 135, 502, 4, 26, 45, 21, 72, 5817, 425, 6, 9042, 14948, 4, 2, 12, 6, 423, 211, 801, 6, 8031, 1099, 21, 426, 8, 482, 5666, 45, 1, 1099, 2568, 4, 117, 5, 2, 12, 1213, 7, 5, 12, 2, 79, 5, 12, 208, 671, 1208, 14948, 5, 14, 15, 39, 4076, 1, 6314, 3072, 10266, 7245, 468, 22, 4344, 237, 3, 3629, 62, 7, 11, 9555, 3467, 5, 9042, 14948, 683, 4, 3, 2882, 2, 3855, 9512, 5817, 425, 270, 10, 683, 366, 3, 9042, 270, 9042, 14948, 279, 909, 1099, 4, 201, 327, 481, 12, 7, 369, 5817, 425, 909, 1099, 4, 62, 327, 7, 394, 4, 3, 79, 140, 1257, 1099, 10, 44, 108, 5, 9042, 270, 5817, 425, 909, 502, 4, 3, 1455, 6692, 2329, 6692, 186, 6692, 2, 12698, 271, 4, 12, 9042, 14948, 279, 909, 1323, 263, 502, 4, 66, 79, 7, 493, 22, 72, 6, 5817, 425, 92, 909, 502, 4, 62, 79, 7, 394, 5817, 425, 270, 10, 1093, 999, 4, 11025, 1455, 6692, 185, 2329, 6692, 15, 12698, 502, 2, 3, 8726, 779, 1135, 5817, 425, 1233, 6, 401, 1323, 263, 289, 638, 2, 2745, 2145, 22, 72, 6, 9042, 270, 4, 2, 12]",1426.0,20117827,643
Cancer-related infertility in survivorship.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2010-01-01,"To empirically assess and describe the emotional, sexual, and physical impact of cancer-related infertility on gynecologic cancer survivors. The study was composed of 88 survivors of cervical, endometrial/uterine, ovarian cancer, and gestational trophoblastic disease who experienced impaired or loss of fertility as a result of treatment. Patient age ranged from 21 to 49 years. Participants completed a 1-time self-report survey, including medical and demographic information and empirical measures of mood (Center for Epidemiologic Studies Depression Scale), distress (Impact of Event Scale), sexual function (Female Sexual Function Index), and menopause (Menopausal Symptom Checklist). Eighty-four (96%) of the 88 enrolled patients had undergone a surgical intervention as part of their cancer treatment. Sixty-three patients (77%) reported clinically significant levels of distress in relation to loss of fertility or impaired fertility. Survivors' levels of distress (P < 0.0001) and depression (P < 0.0001) were associated with the severity and number of menopausal symptoms reported. Patients who retained functioning ovaries (partial fertility) (41%, n = 36) reported being less bothered by menopausal symptoms (P = 0.01) and having higher sexual functioning than those with ovarian failure (P < 0.0001). The emotional and physical impact of impaired or loss of fertility can be complex and long lasting, with women experiencing high levels of distress, menopausal symptoms, and changes in sexual function persisting into survivorship. Future research should focus on the development of strategies to identify, monitor, and address, in a clinical care setting, the issues these cancer survivors face. Alternate family-building strategies should also be explored before treatment and/or upon treatment completion when feasible.",Journal Article,3672.0,54.0,To empirically assess and describe the emotional sexual and physical impact of cancer-related infertility on gynecologic cancer survivors The study was composed of 88 survivors of endometrial/uterine cancer and gestational trophoblastic disease who experienced impaired or loss of fertility as a result of treatment Patient age ranged from 21 to 49 years Participants completed a 1-time self-report survey including medical and demographic information and empirical measures of mood Center for Epidemiologic Studies Depression Scale distress Impact of Event Scale sexual function Female Sexual Function Index and menopause Menopausal Symptom Checklist Eighty-four 96 of the 88 enrolled patients had undergone a surgical intervention as part of their cancer treatment Sixty-three patients 77 reported clinically significant levels of distress in relation to loss of fertility or impaired fertility Survivors levels of distress P 0.0001 and depression P 0.0001 were associated with the severity and number of menopausal symptoms reported Patients who retained functioning ovaries partial fertility 41 n 36 reported being less bothered by menopausal symptoms P 0.01 and having higher sexual functioning than those with failure P 0.0001 The emotional and physical impact of impaired or loss of fertility can be complex and long lasting with women experiencing high levels of distress menopausal symptoms and changes in sexual function persisting into survivorship Future research should focus on the development of strategies to identify monitor and address in a clinical care setting the issues these cancer survivors face Alternate family-building strategies should also be explored before treatment and/or upon treatment completion when feasible,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 9654, 423, 2, 897, 3, 2671, 2232, 2, 900, 345, 1, 12, 139, 5901, 23, 1512, 12, 332, 3, 45, 10, 3317, 1, 889, 332, 1, 18442, 16369, 12, 2, 9383, 11355, 34, 54, 592, 2364, 15, 407, 1, 2954, 22, 8, 757, 1, 24, 69, 89, 1869, 29, 239, 6, 739, 60, 776, 781, 8, 14, 98, 1074, 414, 1407, 141, 484, 2, 1540, 487, 2, 7273, 1018, 1, 5234, 574, 9, 3609, 94, 1774, 1124, 1462, 345, 1, 774, 1124, 2232, 343, 1061, 2232, 343, 558, 2, 5034, 3565, 934, 9787, 2207, 294, 921, 1, 3, 889, 346, 7, 42, 1989, 8, 221, 788, 22, 760, 1, 136, 12, 24, 1746, 169, 7, 849, 210, 505, 93, 148, 1, 1462, 4, 2191, 6, 407, 1, 2954, 15, 2364, 2954, 332, 148, 1, 1462, 19, 13, 488, 2, 1774, 19, 13, 488, 11, 41, 5, 3, 1702, 2, 207, 1, 3565, 507, 210, 7, 54, 3532, 2702, 7262, 450, 2954, 605, 78, 511, 210, 486, 299, 23784, 20, 3565, 507, 19, 13, 355, 2, 1041, 142, 2232, 2702, 76, 135, 5, 496, 19, 13, 488, 3, 2671, 2, 900, 345, 1, 2364, 15, 407, 1, 2954, 122, 40, 840, 2, 319, 3443, 5, 117, 2985, 64, 148, 1, 1462, 3565, 507, 2, 400, 4, 2232, 343, 12099, 237, 2560, 508, 389, 257, 1222, 23, 3, 193, 1, 422, 6, 255, 3334, 2, 1539, 4, 8, 38, 165, 546, 3, 1553, 46, 12, 332, 3376, 4689, 607, 5808, 422, 257, 120, 40, 1443, 348, 24, 2, 15, 1548, 24, 1438, 198, 1313]",1744.0,20130497,547
Sentinel lymph node biopsy accurately stages the regional lymph nodes for T1-T2 oral squamous cell carcinomas: results of a prospective multi-institutional trial.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-02-08,"The validity of sentinel lymph node biopsy (SLNB) for T1 or T2, clinically N0, oral cancer was tested by correlation of sentinel node pathologic status with that of nodes within the completion neck dissection. This prospective, cooperative group trial involved 25 institutions over a 3-year period. One hundred forty patients with invasive oral cancers, stage T1 and T2, N0 including 95 cancers of the tongue, 26 of the floor of mouth, and 19 other oral cancers were studied. The study excluded lesions with diameter smaller than 6 mm or minimal invasion. Imaging was used to exclude nonpalpable gross nodal disease. Patients underwent injection of the lesion with (99m)Tc-sulfur colloid, nuclear imaging, narrow-exposure SLNB, and completion selective neck dissection. The major end point was the negative-predictive value (NPV) of SLNB. In the 106 SLNBs, which were found to be pathologically and clinically node-negative by routine hematoxylin and eosin stain, 100 patients were found to have no other pathologically positive nodes, corresponding to a NPV of 94%. With additional sectioning and immunohistochemistry, NPV was improved to 96%. In the forty patients with proven cervical metastases, the true-positive rate was 90.2% and was superior for tongue tumors relative to floor of mouth. For T1 lesions, metastases were correctly identified in 100%. For T1 or T2 N0 oral squamous cell carcinoma, SLNB with step sectioning and immunohistochemistry, performed by surgeons of mixed experience levels, correctly predicted a pathologically negative neck in 96% of patients (NPV, 96%).",Comparative Study,3634.0,195.0,The validity of sentinel lymph node biopsy SLNB for T1 or T2 clinically N0 oral cancer was tested by correlation of sentinel node pathologic status with that of nodes within the completion dissection This prospective cooperative group trial involved 25 institutions over a 3-year period One hundred forty patients with invasive oral cancers stage T1 and T2 N0 including 95 cancers of the tongue 26 of the floor of mouth and 19 other oral cancers were studied The study excluded lesions with diameter smaller than 6 mm or minimal invasion Imaging was used to exclude nonpalpable gross nodal disease Patients underwent injection of the lesion with 99m Tc-sulfur colloid nuclear imaging narrow-exposure SLNB and completion selective dissection The major end point was the negative-predictive value NPV of SLNB In the 106 SLNBs which were found to be pathologically and clinically node-negative by routine hematoxylin and eosin stain 100 patients were found to have no other pathologically positive nodes corresponding to a NPV of 94 With additional sectioning and immunohistochemistry NPV was improved to 96 In the forty patients with proven metastases the true-positive rate was 90.2 and was superior for tongue tumors relative to floor of mouth For T1 lesions metastases were correctly identified in 100 For T1 or T2 N0 oral squamous cell carcinoma SLNB with step sectioning and immunohistochemistry performed by surgeons of mixed experience levels correctly predicted a pathologically negative in 96 of patients NPV 96,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 3099, 1, 1323, 263, 289, 411, 2272, 9, 1534, 15, 1786, 505, 3394, 518, 12, 10, 650, 20, 816, 1, 1323, 289, 510, 156, 5, 17, 1, 502, 262, 3, 1438, 1161, 26, 482, 1690, 87, 160, 646, 243, 1764, 252, 8, 27, 111, 727, 104, 1128, 1213, 7, 5, 416, 518, 163, 82, 1534, 2, 1786, 3394, 141, 48, 163, 1, 3, 4391, 432, 1, 3, 12557, 1, 5831, 2, 326, 127, 518, 163, 11, 656, 3, 45, 1800, 406, 5, 2549, 2170, 76, 49, 321, 15, 1048, 578, 270, 10, 95, 6, 6262, 11734, 1789, 779, 34, 7, 208, 1754, 1, 3, 1180, 5, 6314, 3072, 10266, 7245, 928, 270, 6958, 645, 2272, 2, 1438, 1094, 1161, 3, 458, 396, 741, 10, 3, 199, 464, 549, 6771, 1, 2272, 4, 3, 3251, 24889, 92, 11, 204, 6, 40, 2998, 2, 505, 289, 199, 20, 1311, 6209, 2, 5975, 8763, 394, 7, 11, 204, 6, 47, 77, 127, 2998, 109, 502, 1734, 6, 8, 6771, 1, 960, 5, 402, 12969, 2, 888, 6771, 10, 231, 6, 921, 4, 3, 1213, 7, 5, 1930, 196, 3, 2501, 109, 116, 10, 424, 18, 2, 10, 1123, 9, 4391, 57, 580, 6, 12557, 1, 5831, 9, 1534, 406, 196, 11, 4911, 108, 4, 394, 9, 1534, 15, 1786, 3394, 518, 691, 31, 134, 2272, 5, 2458, 12969, 2, 888, 173, 20, 1613, 1, 1739, 730, 148, 4911, 783, 8, 2998, 199, 4, 921, 1, 7, 6771, 921]",1518.0,20142602,660
"Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2010-02-09,"This study assessed the safety/tolerability, pharmacokinetics, and clinical activity of three times weekly i.v. 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in combination with once-weekly i.v. cisplatin and daily pelvic radiation in patients with gynecologic malignancies. 3-AP is a novel small-molecule inhibitor of ribonucleotide reductase (RNR) and is being tested as a potential radiosensitizer and chemosensitizer. Patients with stage IB2 to IVB cervical cancer (n = 10) or recurrent uterine sarcoma (n = 1) were assigned to dose-finding cohorts of 2-hour 3-AP infusions during 5 weeks of cisplatin chemoradiation. Pharmacokinetic and methemoglobin samples and tumor biopsy for RNR activity were obtained on day 1 and day 10. Clinical response was assessed. The maximum tolerated 3-AP dose was 25 mg/m(2) given three times weekly during cisplatin and pelvic radiation. Two patients experienced manageable 3-AP-related grade 3 or 4 electrolyte abnormalities. 3-AP pharmacokinetics showed a 2-hour half-life, with median peak plasma concentrations of 277 ng/mL (25 mg/m(2)) and 467 ng/mL (50 mg/m(2)). Median methemoglobin levels peaked at 1% (25 mg/m(2)) and 6% (50 mg/m(2)) at 4 hours after initiating 3-AP infusions. No change in RNR activity was found on day 1 versus day 10 in six early complete responders, whereas elevated RNR activity was seen on day 10 as compared with day 1 in four late complete responders (P = 0.02). Ten (100%) patients with stage IB2 to IVB cervical cancer achieved complete clinical response and remained without disease relapse with a median 18 months of follow-up (6-32 months). 3-AP was well tolerated at a three times weekly i.v. 25 mg/m(2) dose during cisplatin and pelvic radiation. Clin Cancer Res; 16(4); 1298-306.","Clinical Trial, Phase I",3633.0,70.0,This study assessed the safety/tolerability pharmacokinetics and clinical activity of three times weekly i.v 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 3-AP NSC 663249 in combination with once-weekly i.v cisplatin and daily pelvic radiation in patients with gynecologic malignancies 3-AP is a novel small-molecule inhibitor of ribonucleotide reductase RNR and is being tested as a potential radiosensitizer and chemosensitizer Patients with stage IB2 to IVB cancer n 10 or recurrent n 1 were assigned to dose-finding cohorts of 2-hour 3-AP infusions during 5 weeks of cisplatin chemoradiation Pharmacokinetic and methemoglobin samples and tumor biopsy for RNR activity were obtained on day 1 and day 10 Clinical response was assessed The maximum tolerated 3-AP dose was 25 mg/m 2 given three times weekly during cisplatin and pelvic radiation Two patients experienced manageable 3-AP-related grade 3 or 4 electrolyte abnormalities 3-AP pharmacokinetics showed a 2-hour half-life with median peak plasma concentrations of 277 ng/mL 25 mg/m 2 and 467 ng/mL 50 mg/m 2 Median methemoglobin levels peaked at 1 25 mg/m 2 and 6 50 mg/m 2 at 4 hours after initiating 3-AP infusions No change in RNR activity was found on day 1 versus day 10 in six early complete responders whereas elevated RNR activity was seen on day 10 as compared with day 1 in four late complete responders P 0.02 Ten 100 patients with stage IB2 to IVB cancer achieved complete clinical response and remained without disease relapse with a median 18 months of follow-up 6-32 months 3-AP was well tolerated at a three times weekly i.v 25 mg/m 2 dose during cisplatin and pelvic radiation Clin Cancer Res 16 4 1298-306,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,"[26, 45, 275, 3, 367, 1543, 1159, 2, 38, 128, 1, 169, 1072, 709, 70, 603, 27, 23330, 18, 23331, 24704, 27, 2517, 10073, 58650, 4, 150, 5, 1059, 709, 70, 603, 540, 2, 391, 1110, 121, 4, 7, 5, 1512, 441, 27, 2517, 16, 8, 229, 302, 1354, 230, 1, 7050, 4027, 18376, 2, 16, 486, 650, 22, 8, 174, 8853, 2, 23796, 7, 5, 82, 9537, 6, 7042, 12, 78, 79, 15, 387, 78, 14, 11, 896, 6, 61, 1567, 736, 1, 18, 2583, 27, 2517, 3435, 190, 33, 244, 1, 540, 975, 1456, 2, 37921, 347, 2, 30, 411, 9, 18376, 128, 11, 683, 23, 218, 14, 2, 218, 79, 38, 51, 10, 275, 3, 689, 421, 27, 2517, 61, 10, 243, 81, 188, 18, 447, 169, 1072, 709, 190, 540, 2, 1110, 121, 100, 7, 592, 2808, 27, 2517, 139, 88, 27, 15, 39, 10834, 1171, 27, 2517, 1159, 224, 8, 18, 2583, 1303, 358, 5, 52, 2944, 554, 1003, 1, 7996, 997, 542, 243, 81, 188, 18, 2, 10993, 997, 542, 212, 81, 188, 18, 52, 37921, 148, 11095, 28, 14, 243, 81, 188, 18, 2, 49, 212, 81, 188, 18, 28, 39, 1459, 50, 2637, 27, 2517, 3435, 77, 707, 4, 18376, 128, 10, 204, 23, 218, 14, 185, 218, 79, 4, 437, 191, 236, 1983, 547, 804, 18376, 128, 10, 527, 23, 218, 79, 22, 72, 5, 218, 14, 4, 294, 807, 236, 1983, 19, 13, 588, 1618, 394, 7, 5, 82, 9537, 6, 7042, 12, 513, 236, 38, 51, 2, 958, 187, 34, 429, 5, 8, 52, 203, 53, 1, 166, 126, 49, 531, 53, 27, 2517, 10, 149, 421, 28, 8, 169, 1072, 709, 70, 603, 243, 81, 188, 18, 61, 190, 540, 2, 1110, 121, 2459, 12, 1936, 245, 39, 26913, 9974]",1688.0,20145183,559
Metastases to the craniovertebral junction.,Neurosurgery,Neurosurgery,2010-03-01,"This study reviews the relevant literature regarding the management of craniovertebral junction (CVJ) metastases. These rare tumors present significant diagnostic and treatment challenges. A PubMed search of cervical spine, cervical spine metastasis, craniovertebral junction, atlantoaxial spine, and metastasis radiation was conducted to define the epidemiology, imaging, and treatment protocols in the management of metastatic CVJ tumors. CVJ tumors represent less than 1% of spinal metastases, and the literature is limited to small case series. CVJ tumors present with flexion, extension, and rotational pain, often associated with occipital neuralgia. Magnetic resonance imaging is the most sensitive imaging modality for the detection of spinal metastases, but plain x-rays, computed tomography, and [18F]2-fluoro-2-deoxy-D-glucose play a role in diagnosis and management. Conventional external beam radiation therapy or stereotactic radiosurgery effectively treat the majority of patients with normal spinal alignment or minimal fracture subluxations. Surgery should be considered in patients with fracture subluxations greater than 5 mm, or 3.5 mm subluxation with 11-degree angulation. The palliative goals for surgery favor posterior approaches only including laminectomy for decompression, without the need for anterior approaches with the associated morbidity. Occipitocervical instrumentation using screw-rod systems are effective for irreducible subluxations, but posterior strategies using C1-C2 or C1-C3 can be used for patients with reducible subluxations. Effective management of CVJ tumors using radiation and/or surgery results in significant pain and functional improvement in properly selected patients. Advanced surgical techniques and stereotactic radiation may improve outcomes with less morbidity.",Journal Article,3613.0,24.0,This study reviews the relevant literature regarding the management of craniovertebral junction CVJ metastases These rare tumors present significant diagnostic and treatment challenges A PubMed search of spine spine metastasis craniovertebral junction atlantoaxial spine and metastasis radiation was conducted to define the epidemiology imaging and treatment protocols in the management of metastatic CVJ tumors CVJ tumors represent less than 1 of spinal metastases and the literature is limited to small case series CVJ tumors present with flexion extension and rotational pain often associated with occipital neuralgia Magnetic resonance imaging is the most sensitive imaging modality for the detection of spinal metastases but plain x-rays computed tomography and 18F 2-fluoro-2-deoxy-D-glucose play a role in diagnosis and management Conventional external beam radiation therapy or stereotactic radiosurgery effectively treat the majority of patients with normal spinal alignment or minimal fracture subluxations Surgery should be considered in patients with fracture subluxations greater than 5 mm or 3.5 mm subluxation with 11-degree angulation The palliative goals for surgery favor posterior approaches only including laminectomy for decompression without the need for anterior approaches with the associated morbidity Occipitocervical instrumentation using screw-rod systems are effective for irreducible subluxations but posterior strategies using C1-C2 or C1-C3 can be used for patients with reducible subluxations Effective management of CVJ tumors using radiation and/or surgery results in significant pain and functional improvement in properly selected patients Advanced surgical techniques and stereotactic radiation may improve outcomes with less morbidity,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[26, 45, 2004, 3, 867, 789, 666, 3, 284, 1, 31589, 3322, 19219, 196, 46, 622, 57, 364, 93, 752, 2, 24, 1427, 8, 3161, 1901, 1, 2342, 2342, 278, 31589, 3322, 30244, 2342, 2, 278, 121, 10, 426, 6, 1107, 3, 1284, 270, 2, 24, 2189, 4, 3, 284, 1, 113, 19219, 57, 19219, 57, 1231, 299, 76, 14, 1, 1499, 196, 2, 3, 789, 16, 383, 6, 302, 473, 988, 19219, 57, 364, 5, 45005, 2401, 2, 9499, 559, 629, 41, 5, 17945, 33218, 1484, 1535, 270, 16, 3, 96, 745, 270, 1396, 9, 3, 638, 1, 1499, 196, 84, 15858, 1006, 8558, 1220, 872, 2, 4751, 18, 6231, 18, 6149, 427, 2522, 1343, 8, 200, 4, 147, 2, 284, 809, 1455, 1345, 121, 36, 15, 1729, 2192, 1856, 943, 3, 686, 1, 7, 5, 295, 1499, 8097, 15, 1048, 3956, 26004, 152, 257, 40, 515, 4, 7, 5, 3956, 26004, 378, 76, 33, 321, 15, 27, 33, 321, 27890, 5, 175, 1444, 33234, 3, 994, 2802, 9, 152, 4283, 3028, 611, 158, 141, 16891, 9, 7638, 187, 3, 594, 9, 2882, 611, 5, 3, 41, 787, 39250, 9166, 75, 14911, 14202, 1530, 32, 323, 9, 58679, 26004, 84, 3028, 422, 75, 6801, 6706, 15, 6801, 8732, 122, 40, 95, 9, 7, 5, 44176, 26004, 323, 284, 1, 19219, 57, 75, 121, 2, 15, 152, 99, 4, 93, 559, 2, 583, 767, 4, 6785, 715, 7, 131, 221, 1092, 2, 1729, 121, 68, 401, 123, 5, 299, 787]",1773.0,20173512,553
Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2010-03-06,"Conventional therapy for cervical node squamous cell carcinoma metastases from an unknown primary can cause considerable toxicity owing to the volume of tissues to be irradiated. In the present study, hypothesizing that using intensity-modulated radiotherapy (IMRT) would provide effective treatment with minimal toxicity, we reviewed the outcomes and patterns of failure for head-and-neck unknown primary cancer at a single tertiary cancer center. We retrospectively reviewed the records of 52 patients who had undergone IMRT for an unknown primary at M.D. Anderson Cancer Center between 1998 and 2005. The patient and treatment characteristics were extracted and the survival rates calculated using the Kaplan-Meier method. Of the 52 patients, 5 presented with Stage N1, 11 with Stage N2a, 23 with Stage N2b, 6 with Stage N2c, 4 with Stage N3, and 3 with Stage Nx disease. A total of 26 patients had undergone neck dissection, 13 before and 13 after IMRT; 14 patients had undergone excisional biopsy and presented for IMRT without evidence of disease. Finally, 14 patients had received systemic chemotherapy. All patients underwent IMRT to targets on both sides of the neck and pharyngeal axis. The median follow-up time for the surviving patients was 3.7 years. The 5-year actuarial rate of primary mucosal tumor control and regional control was 98% and 94%, respectively. Only 3 patients developed distant metastasis with locoregional control. The 5-year actuarial disease-free and overall survival rate was 88% and 89%, respectively. The most severe toxicity was Grade 3 dysphagia/esophageal stricture, experienced by 2 patients. The results of our study have shown that IMRT can produce excellent outcomes for patients who present with cervical node squamous cell carcinoma metastases from an unknown head-and-neck primary tumor. Severe late complications were uncommon.",Evaluation Study,3608.0,53.0,Conventional therapy for node squamous cell carcinoma metastases from an unknown primary can cause considerable toxicity owing to the volume of tissues to be irradiated In the present study hypothesizing that using intensity-modulated radiotherapy IMRT would provide effective treatment with minimal toxicity we reviewed the outcomes and patterns of failure for head-and-neck unknown primary cancer at a single tertiary cancer center We retrospectively reviewed the records of 52 patients who had undergone IMRT for an unknown primary at M.D Anderson Cancer Center between 1998 and 2005 The patient and treatment characteristics were extracted and the survival rates calculated using the Kaplan-Meier method Of the 52 patients 5 presented with Stage N1 11 with Stage N2a 23 with Stage N2b 6 with Stage N2c 4 with Stage N3 and 3 with Stage Nx disease A total of 26 patients had undergone dissection 13 before and 13 after IMRT 14 patients had undergone excisional biopsy and presented for IMRT without evidence of disease Finally 14 patients had received systemic chemotherapy All patients underwent IMRT to targets on both sides of the and axis The median follow-up time for the surviving patients was 3.7 years The 5-year actuarial rate of primary mucosal tumor control and regional control was 98 and 94 respectively Only 3 patients developed distant metastasis with locoregional control The 5-year actuarial disease-free and overall survival rate was 88 and 89 respectively The most severe toxicity was Grade 3 dysphagia/esophageal stricture experienced by 2 patients The results of our study have shown that IMRT can produce excellent outcomes for patients who present with node squamous cell carcinoma metastases from an unknown head-and-neck primary tumor Severe late complications were uncommon,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[809, 36, 9, 289, 691, 31, 134, 196, 29, 35, 860, 86, 122, 708, 2658, 155, 3421, 6, 3, 433, 1, 742, 6, 40, 2398, 4, 3, 364, 45, 16664, 17, 75, 837, 1757, 310, 964, 688, 377, 323, 24, 5, 1048, 155, 21, 446, 3, 123, 2, 764, 1, 496, 9, 718, 2, 4606, 860, 86, 12, 28, 8, 226, 2557, 12, 574, 21, 894, 446, 3, 1064, 1, 653, 7, 54, 42, 1989, 964, 9, 35, 860, 86, 28, 188, 427, 1929, 12, 574, 59, 1850, 2, 1242, 3, 69, 2, 24, 374, 11, 2484, 2, 3, 25, 151, 981, 75, 3, 876, 882, 596, 1, 3, 653, 7, 33, 917, 5, 82, 3192, 175, 5, 82, 14262, 382, 5, 82, 14540, 49, 5, 82, 21233, 39, 5, 82, 5749, 2, 27, 5, 82, 13285, 34, 8, 181, 1, 432, 7, 42, 1989, 1161, 233, 348, 2, 233, 50, 964, 213, 7, 42, 1989, 6488, 411, 2, 917, 9, 964, 187, 241, 1, 34, 1368, 213, 7, 42, 103, 403, 56, 62, 7, 208, 964, 6, 637, 23, 110, 10958, 1, 3, 2, 2310, 3, 52, 166, 126, 98, 9, 3, 3050, 7, 10, 27, 67, 60, 3, 33, 111, 2361, 116, 1, 86, 3068, 30, 182, 2, 951, 182, 10, 1096, 2, 960, 106, 158, 27, 7, 276, 626, 278, 5, 1325, 182, 3, 33, 111, 2361, 34, 115, 2, 63, 25, 116, 10, 889, 2, 887, 106, 3, 96, 905, 155, 10, 88, 27, 4561, 12183, 6673, 592, 20, 18, 7, 3, 99, 1, 114, 45, 47, 443, 17, 964, 122, 2410, 1503, 123, 9, 7, 54, 364, 5, 289, 691, 31, 134, 196, 29, 35, 860, 718, 2, 4606, 86, 30, 905, 807, 521, 11, 2052]",1801.0,20207504,415
"Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening.",CA: a cancer journal for clinicians,CA Cancer J Clin,,"Each year the American Cancer Society (ACS) publishes a summary of its recommendations for early cancer detection, a report on data and trends in cancer screening rates, and select issues related to cancer screening. In 2010, the ACS updated its guidelines for testing for early prostate cancer detection, and during 2009 there were several newsworthy updates in the cancer screening guidelines from other organizations. In this article, the current ACS guidelines and recent issues are summarized, updates of guidelines for testing for early breast cancer detection by the US Preventive Services Task Force and for prevention and early detection of cervical cancer from the American College of Obstetricians and Gynecologists are addressed, and the most recent data from the National Health Interview Survey pertaining to participation rates in cancer screening are described.",Journal Article,,345.0,Each year the American Cancer Society ACS publishes a summary of its recommendations for early cancer detection a report on data and trends in cancer screening rates and select issues related to cancer screening In 2010 the ACS updated its guidelines for testing for early cancer detection and during 2009 there were several newsworthy updates in the cancer screening guidelines from other organizations In this article the current ACS guidelines and recent issues are summarized updates of guidelines for testing for early cancer detection by the US Preventive Services Task Force and for prevention and early detection of cancer from the American College of Obstetricians and Gynecologists are addressed and the most recent data from the National Health Interview Survey pertaining to participation rates in cancer screening are described,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[296, 111, 3, 597, 12, 1174, 6004, 22457, 8, 1962, 1, 211, 883, 9, 191, 12, 638, 8, 414, 23, 74, 2, 1963, 4, 12, 453, 151, 2, 1717, 1553, 139, 6, 12, 453, 4, 1120, 3, 6004, 2939, 211, 677, 9, 471, 9, 191, 12, 638, 2, 190, 1238, 125, 11, 392, 58745, 5454, 4, 3, 12, 453, 677, 29, 127, 6283, 4, 26, 946, 3, 291, 6004, 677, 2, 435, 1553, 32, 3989, 5454, 1, 677, 9, 471, 9, 191, 12, 638, 20, 3, 843, 3494, 2142, 3488, 4380, 2, 9, 1070, 2, 191, 638, 1, 12, 29, 3, 597, 2979, 1, 21015, 2, 14854, 32, 2814, 2, 3, 96, 435, 74, 29, 3, 657, 341, 4313, 1407, 6553, 6, 2599, 151, 4, 12, 453, 32, 1027]",840.0,20228384,0
Expression of nuclear transcription factor kappa B in locally advanced human cervical cancer treated with definitive chemoradiation.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2010-03-16,"Nuclear factor kappa B (NF-B), a transcriptional factor that has been shown to be constitutively active in cervical cancer, is part of an important pathway leading to treatment resistance in many tumor types. The purpose of our study was to determine whether expression of NF-B in pretreatment specimens and specimens taken shortly after treatment initiation correlated with outcome in cervical cancer patients treated with definitive chemoradiation. Eighteen patients with locally advanced cervical cancer were enrolled in a study in which cervical biopsy specimens were obtained before radiation therapy and 48 h after treatment initiation. Matched biopsy specimens from 16 of these patients were available and evaluated for the nuclear expression of NF-B protein by immunohistochemical staining. After a median follow-up of 43 months, there were 9 total treatment failures. Nuclear staining for NF-B was positive in 3 of 16 pretreatment biopsy specimens (19%) and 5 of 16 postradiation biopsy specimens (31%). Pretreatment expression of NF-B nuclear staining correlated with increased rates of local-regional failure (100% vs. 23%, p = 0.01), distant failure (100% vs. 38%, p = 0.055), disease-specific mortality (100% vs. 31%, p = 0.03), and overall mortality (100% vs. 38%, p = 0.055). Our data suggest that pretreatment nuclear expression of NF-B may be associated with a poor outcome for cervical cancer patients treated with chemoradiation. Although these data require validation in a larger group of patients, the results support the continued study of the relationship between NF-B and outcome in patients treated for carcinoma of the cervix.",Journal Article,3598.0,15.0,Nuclear factor kappa B NF-B a transcriptional factor that has been shown to be constitutively active in cancer is part of an important pathway leading to treatment resistance in many tumor types The purpose of our study was to determine whether expression of NF-B in pretreatment specimens and specimens taken shortly after treatment initiation correlated with outcome in cancer patients treated with definitive chemoradiation Eighteen patients with locally advanced cancer were enrolled in a study in which biopsy specimens were obtained before radiation therapy and 48 h after treatment initiation Matched biopsy specimens from 16 of these patients were available and evaluated for the nuclear expression of NF-B protein by immunohistochemical staining After a median follow-up of 43 months there were 9 total treatment failures Nuclear staining for NF-B was positive in 3 of 16 pretreatment biopsy specimens 19 and 5 of 16 postradiation biopsy specimens 31 Pretreatment expression of NF-B nuclear staining correlated with increased rates of local-regional failure 100 vs. 23 p 0.01 distant failure 100 vs. 38 p 0.055 disease-specific mortality 100 vs. 31 p 0.03 and overall mortality 100 vs. 38 p 0.055 Our data suggest that pretreatment nuclear expression of NF-B may be associated with a poor outcome for cancer patients treated with chemoradiation Although these data require validation in a larger group of patients the results support the continued study of the relationship between NF-B and outcome in patients treated for carcinoma of the cervix,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[928, 161, 3096, 132, 1365, 2448, 8, 1431, 161, 17, 71, 85, 443, 6, 40, 2818, 544, 4, 12, 16, 760, 1, 35, 305, 308, 1049, 6, 24, 251, 4, 445, 30, 630, 3, 743, 1, 114, 45, 10, 6, 223, 317, 55, 1, 1365, 2448, 4, 1194, 623, 2, 623, 1633, 6961, 50, 24, 1118, 438, 5, 228, 4, 12, 7, 73, 5, 1057, 975, 3195, 7, 5, 795, 131, 12, 11, 346, 4, 8, 45, 4, 92, 411, 623, 11, 683, 348, 121, 36, 2, 576, 555, 50, 24, 1118, 655, 411, 623, 29, 245, 1, 46, 7, 11, 390, 2, 194, 9, 3, 928, 55, 1, 1365, 2448, 178, 20, 1382, 1029, 50, 8, 52, 166, 126, 1, 601, 53, 125, 11, 83, 181, 24, 3368, 928, 1029, 9, 1365, 2448, 10, 109, 4, 27, 1, 245, 1194, 411, 623, 326, 2, 33, 1, 245, 12802, 411, 623, 456, 1194, 55, 1, 1365, 2448, 928, 1029, 438, 5, 101, 151, 1, 293, 951, 496, 394, 105, 382, 19, 13, 355, 626, 496, 394, 105, 519, 19, 13, 9186, 34, 112, 282, 394, 105, 456, 19, 13, 680, 2, 63, 282, 394, 105, 519, 19, 13, 9186, 114, 74, 309, 17, 1194, 928, 55, 1, 1365, 2448, 68, 40, 41, 5, 8, 334, 228, 9, 12, 7, 73, 5, 975, 242, 46, 74, 1353, 929, 4, 8, 1077, 87, 1, 7, 3, 99, 538, 3, 1351, 45, 1, 3, 858, 59, 1365, 2448, 2, 228, 4, 7, 73, 9, 134, 1, 3, 3629]",1562.0,20231067,531
A role for HPV16 E5 in cervical carcinogenesis.,Cancer research,Cancer Res.,2010-03-23,"A subset of the mucosotropic human papillomaviruses (HPV), including HPV16, are etiologic agents for the vast majority of cervical cancers, other anogenital cancers, and a subset of head and neck squamous cell carcinomas. HPV16 encodes three oncogenes: E5, E6, and E7. Although E6 and E7 have been well-studied and clearly shown to be important contributors to these cancers, less is known about E5. In this study, we used E5 transgenic mice to investigate the role of E5 in cervical cancer. When treated for 6 months with estrogen, a cofactor for cervical carcinogenesis, E5 transgenic mice developed more severe neoplastic cervical disease than similarly treated nontransgenic mice, although no frank cancers were detected. In addition, E5 when combined with either E6 or E7 induced more severe neoplastic disease than seen in mice expressing only one viral oncogene. Prolonged treatment of E5 transgenic mice with exogenous estrogen uncovered an ability of E5 to cause frank cancer. These data indicate that E5 acts as an oncogene in the reproductive tracts of female mice.",Journal Article,3591.0,67.0,A subset of the mucosotropic human papillomaviruses HPV including HPV16 are etiologic agents for the vast majority of cancers other anogenital cancers and a subset of head and squamous cell carcinomas HPV16 encodes three oncogenes E5 E6 and E7 Although E6 and E7 have been well-studied and clearly shown to be important contributors to these cancers less is known about E5 In this study we used E5 transgenic mice to investigate the role of E5 in cancer When treated for 6 months with estrogen a cofactor for carcinogenesis E5 transgenic mice developed more severe neoplastic disease than similarly treated nontransgenic mice although no frank cancers were detected In addition E5 when combined with either E6 or E7 induced more severe neoplastic disease than seen in mice expressing only one viral oncogene Prolonged treatment of E5 transgenic mice with exogenous estrogen uncovered an ability of E5 to cause frank cancer These data indicate that E5 acts as an oncogene in the reproductive tracts of female mice,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[8, 697, 1, 3, 58773, 171, 14731, 933, 141, 4048, 32, 6604, 183, 9, 3, 4337, 686, 1, 163, 127, 13836, 163, 2, 8, 697, 1, 718, 2, 691, 31, 826, 4048, 4322, 169, 3326, 16072, 4837, 2, 4540, 242, 4837, 2, 4540, 47, 85, 149, 656, 2, 2536, 443, 6, 40, 305, 9680, 6, 46, 163, 299, 16, 440, 545, 16072, 4, 26, 45, 21, 95, 16072, 2862, 399, 6, 963, 3, 200, 1, 16072, 4, 12, 198, 73, 9, 49, 53, 5, 808, 8, 17137, 9, 1719, 16072, 2862, 399, 276, 80, 905, 2000, 34, 76, 1813, 73, 20194, 399, 242, 77, 15252, 163, 11, 530, 4, 352, 16072, 198, 397, 5, 361, 4837, 15, 4540, 277, 80, 905, 2000, 34, 76, 527, 4, 399, 1046, 158, 104, 1667, 1836, 1069, 24, 1, 16072, 2862, 399, 5, 4181, 808, 5601, 35, 801, 1, 16072, 6, 708, 15252, 12, 46, 74, 1008, 17, 16072, 4459, 22, 35, 1836, 4, 3, 3705, 10950, 1, 1061, 399]",1012.0,20332225,360
A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies.,Gynecologic oncology,Gynecol. Oncol.,2010-03-28,"The mTOR inhibitor, temsirolimus, has clinical activity in the treatment of gynecologic malignancies, particularly endometrial cancer. We sought to determine the tolerability of the combination of weekly topotecan with weekly temsirolimus. Women with a history of advanced or recurrent gynecologic malignancy refractory to curative therapy were enrolled. A starting dose of 1mg/m(2) of intravenous topotecan days 1, 8 and 15 was combined with 25mg temsirolimus days 1, 8, 15 and 22 of a 28 day cycle. Patients with and without prior pelvic radiotherapy (RT) were dose-escalated in separate cohorts. Fifteen patients were treated on study. Forty-three cycles were administered, with between 1 and 7 cycles received per patient. Patient characteristics included ovarian cancer (n=7), endometrial cancer (n=3), uterine carcinosarcoma (n=3), and cervical cancer (n=2); performance status 0 (n=10) and 1 (n=5); prior chemotherapy regimens one (n=8), two (n=4), and three (n=3). Dose-limiting toxicity included asymptomatic neutropenia and thrombocytopenia. Four patients without prior pelvic RT were successfully treated with 1mg/m(2) topotecan with 25mg temsirolimus, days 1, 8, and 15 of a 28 day cycle. The combination was not tolerated in patients with a history of pelvic RT. Dose-limiting toxicity for the combination of temsirolimus with topotecan was myelosuppression. The regimen may be safe in women who have not previously received radiation, but full doses of each agent could not be administered in combination.","Clinical Trial, Phase I",3586.0,58.0,The mTOR inhibitor temsirolimus has clinical activity in the treatment of gynecologic malignancies particularly cancer We sought to determine the tolerability of the combination of weekly topotecan with weekly temsirolimus Women with a history of advanced or recurrent gynecologic malignancy refractory to curative therapy were enrolled A starting dose of 1mg/m 2 of intravenous topotecan days 1 8 and 15 was combined with 25mg temsirolimus days 1 8 15 and 22 of a 28 day cycle Patients with and without prior pelvic radiotherapy RT were dose-escalated in separate cohorts Fifteen patients were treated on study Forty-three cycles were administered with between 1 and 7 cycles received per patient Patient characteristics included cancer n=7 cancer n=3 carcinosarcoma n=3 and cancer n=2 performance status 0 n=10 and 1 n=5 prior chemotherapy regimens one n=8 two n=4 and three n=3 Dose-limiting toxicity included asymptomatic neutropenia and thrombocytopenia Four patients without prior pelvic RT were successfully treated with 1mg/m 2 topotecan with 25mg temsirolimus days 1 8 and 15 of a 28 day cycle The combination was not tolerated in patients with a history of pelvic RT Dose-limiting toxicity for the combination of temsirolimus with topotecan was myelosuppression The regimen may be safe in women who have not previously received radiation but full doses of each agent could not be administered in combination,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 873, 230, 2831, 71, 38, 128, 4, 3, 24, 1, 1512, 441, 823, 12, 21, 990, 6, 223, 3, 1543, 1, 3, 150, 1, 709, 2129, 5, 709, 2831, 117, 5, 8, 532, 1, 131, 15, 387, 1512, 710, 430, 6, 1075, 36, 11, 346, 8, 1723, 61, 1, 25247, 188, 18, 1, 1262, 2129, 162, 14, 66, 2, 167, 10, 397, 5, 15905, 2831, 162, 14, 66, 167, 2, 350, 1, 8, 339, 218, 417, 7, 5, 2, 187, 324, 1110, 310, 240, 11, 61, 2842, 4, 2282, 736, 3057, 7, 11, 73, 23, 45, 1213, 169, 410, 11, 468, 5, 59, 14, 2, 67, 410, 103, 379, 69, 69, 374, 159, 12, 78, 67, 12, 78, 27, 5623, 78, 27, 2, 12, 78, 18, 528, 156, 13, 78, 79, 2, 14, 78, 33, 324, 56, 472, 104, 78, 66, 100, 78, 39, 2, 169, 78, 27, 61, 817, 155, 159, 2100, 778, 2, 1340, 294, 7, 187, 324, 1110, 240, 11, 1878, 73, 5, 25247, 188, 18, 2129, 5, 15905, 2831, 162, 14, 66, 2, 167, 1, 8, 339, 218, 417, 3, 150, 10, 44, 421, 4, 7, 5, 8, 532, 1, 1110, 240, 61, 817, 155, 9, 3, 150, 1, 2831, 5, 2129, 10, 2858, 3, 477, 68, 40, 1165, 4, 117, 54, 47, 44, 373, 103, 121, 84, 1647, 415, 1, 296, 420, 359, 44, 40, 468, 4, 150]",1417.0,20347480,3
The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2010-02-01,"Ongoing drug discovery and synergy in cytotoxic combinations have served as the dominant theme for clinical research in women with metastatic and recurrent cervical cancer. The results of the most recent phase III randomized clinical trials conducted by the Gynecologic Oncology Group in this population evaluated the tolerability and efficacy of cisplatin-based chemotherapy doublets. Possibly as a consequence of the increasing use of radiosensitizing cisplatin with concurrent pelvic radiotherapy for treatment of locally advanced disease prior to recurrence, the response rates obtained with platinum-based regimens have decreased with each successive trial. There is clearly a need for a re-appraisal of therapeutic options for women with recurrent and metastatic cervical cancer, many of whom may harbor platinum-resistant clones. In this article we will provide a rationale for the use of non-platinum-based chemotherapy doublets for this patient population.",Journal Article,3641.0,21.0,Ongoing drug discovery and synergy in cytotoxic combinations have served as the dominant theme for clinical research in women with metastatic and recurrent cancer The results of the most recent phase III randomized clinical trials conducted by the Gynecologic Oncology Group in this population evaluated the tolerability and efficacy of cisplatin-based chemotherapy doublets Possibly as a consequence of the increasing use of radiosensitizing cisplatin with concurrent pelvic radiotherapy for treatment of locally advanced disease prior to recurrence the response rates obtained with platinum-based regimens have decreased with each successive trial There is clearly a need for a re-appraisal of therapeutic options for women with recurrent and metastatic cancer many of whom may harbor platinum-resistant clones In this article we will provide a rationale for the use of non-platinum-based chemotherapy doublets for this patient population,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[942, 234, 1574, 2, 3439, 4, 759, 1247, 47, 5275, 22, 3, 2156, 10293, 9, 38, 389, 4, 117, 5, 113, 2, 387, 12, 3, 99, 1, 3, 96, 435, 124, 316, 384, 38, 143, 426, 20, 3, 1512, 413, 87, 4, 26, 266, 194, 3, 1543, 2, 209, 1, 540, 90, 56, 9097, 2150, 22, 8, 4177, 1, 3, 602, 119, 1, 8384, 540, 5, 750, 1110, 310, 9, 24, 1, 795, 131, 34, 324, 6, 146, 3, 51, 151, 683, 5, 828, 90, 472, 47, 340, 5, 296, 6808, 160, 125, 16, 2536, 8, 594, 9, 8, 1491, 10477, 1, 189, 838, 9, 117, 5, 387, 2, 113, 12, 445, 1, 953, 68, 2760, 828, 436, 2749, 4, 26, 946, 21, 303, 377, 8, 1728, 9, 3, 119, 1, 220, 828, 90, 56, 9097, 9, 26, 69, 266]",940.0,20386532,146
Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity.,Cancer research,Cancer Res.,2010-04-01,"Tumor immune escape is a major obstacle in cancer immunotherapy, but the mechanisms involved remain poorly understood. We have previously developed an immune evasion tumor model using an in vivo immune selection strategy and revealed Akt-mediated immune resistance to antitumor immunity induced by various cancer immunotherapeutic agents. In the current study, we used microarray gene analysis to identify an Akt-activating candidate molecule overexpressed in immune-resistant tumors compared with parental tumors. X-linked lymphocyte-regulated protein pM1 (XLR) gene was the most upregulated in immune-resistant tumors compared with parental tumor cells. Furthermore, the retroviral transduction of XLR in parental tumor cells led to activation of Akt, resulting in upregulation of antiapoptotic proteins and the induction of immune resistance phenotype in parental tumor cells. In addition, we found that transduction of parental tumor cells with other homologous genes from the mouse XLR family, such as synaptonemal complex protein 3 (SCP3) and XLR-related, meiosis-regulated protein (XMR) and its human counterpart of SCP3 (hSCP3), also led to activation of Akt, resulting in the upregulation of antiapoptotic proteins and induction of immune resistance phenotype. Importantly, characterization of a panel of human cervical cancers revealed relatively higher expression levels of hSCP3 in human cervical cancer tissue compared with normal cervical tissue. Thus, our data indicate that ectopic expression of XLR and its homologues in tumor cells represents a potentially important mechanism for tumor immune evasion and serves as a promising molecular target for cancer immunotherapy.",Journal Article,3582.0,16.0,Tumor immune escape is a major obstacle in cancer immunotherapy but the mechanisms involved remain poorly understood We have previously developed an immune evasion tumor model using an in vivo immune selection strategy and revealed Akt-mediated immune resistance to antitumor immunity induced by various cancer immunotherapeutic agents In the current study we used microarray gene analysis to identify an Akt-activating candidate molecule overexpressed in immune-resistant tumors compared with parental tumors X-linked lymphocyte-regulated protein pM1 XLR gene was the most upregulated in immune-resistant tumors compared with parental tumor cells Furthermore the retroviral transduction of XLR in parental tumor cells led to activation of Akt resulting in upregulation of antiapoptotic proteins and the induction of immune resistance phenotype in parental tumor cells In addition we found that transduction of parental tumor cells with other homologous genes from the mouse XLR family such as synaptonemal complex protein 3 SCP3 and XLR-related meiosis-regulated protein XMR and its human counterpart of SCP3 hSCP3 also led to activation of Akt resulting in the upregulation of antiapoptotic proteins and induction of immune resistance phenotype Importantly characterization of a panel of human cancers revealed relatively higher expression levels of hSCP3 in human cancer tissue compared with normal tissue Thus our data indicate that ectopic expression of XLR and its homologues in tumor cells represents a potentially important mechanism for tumor immune evasion and serves as a promising molecular target for cancer immunotherapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[30, 250, 3776, 16, 8, 458, 7414, 4, 12, 726, 84, 3, 483, 646, 918, 1240, 1784, 21, 47, 373, 276, 35, 250, 5351, 30, 202, 75, 35, 4, 386, 250, 881, 692, 2, 553, 649, 517, 250, 251, 6, 579, 1604, 277, 20, 747, 12, 3222, 183, 4, 3, 291, 45, 21, 95, 1727, 145, 65, 6, 255, 35, 649, 1616, 1609, 1354, 1711, 4, 250, 436, 57, 72, 5, 3418, 57, 1006, 1199, 1448, 1065, 178, 45977, 31611, 145, 10, 3, 96, 2684, 4, 250, 436, 57, 72, 5, 3418, 30, 37, 798, 3, 8658, 2761, 1, 31611, 4, 3418, 30, 37, 836, 6, 363, 1, 649, 1113, 4, 2218, 1, 4176, 652, 2, 3, 504, 1, 250, 251, 1005, 4, 3418, 30, 37, 4, 352, 21, 204, 17, 2761, 1, 3418, 30, 37, 5, 127, 3894, 214, 29, 3, 830, 31611, 607, 225, 22, 58849, 840, 178, 27, 45978, 2, 31611, 139, 33676, 1065, 178, 58850, 2, 211, 171, 10423, 1, 45978, 45979, 120, 836, 6, 363, 1, 649, 1113, 4, 3, 2218, 1, 4176, 652, 2, 504, 1, 250, 251, 1005, 1859, 2136, 1, 8, 993, 1, 171, 163, 553, 1352, 142, 55, 148, 1, 45979, 4, 171, 12, 246, 72, 5, 295, 246, 631, 114, 74, 1008, 17, 3647, 55, 1, 31611, 2, 211, 22169, 4, 30, 37, 1449, 8, 751, 305, 670, 9, 30, 250, 5351, 2, 4711, 22, 8, 721, 219, 283, 9, 12, 726]",1634.0,20395201,255
Normal tissue complication probability modeling of acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2010-04-17,"To test the hypothesis that increased pelvic bone marrow (BM) irradiation is associated with increased hematologic toxicity (HT) in cervical cancer patients undergoing chemoradiotherapy and to develop a normal tissue complication probability (NTCP) model for HT. We tested associations between hematologic nadirs during chemoradiotherapy and the volume of BM receiving10 and 20 Gy (V10 and V20) using a previously developed linear regression model. The validation cohort consisted of 44 cervical cancer patients treated with concurrent cisplatin and pelvic radiotherapy. Subsequently, these data were pooled with data from 37 identically treated patients from a previous study, forming a cohort of 81 patients for normal tissue complication probability analysis. Generalized linear modeling was used to test associations between hematologic nadirs and dosimetric parameters, adjusting for body mass index. Receiver operating characteristic curves were used to derive optimal dosimetric planning constraints. In the validation cohort, significant negative correlations were observed between white blood cell count nadir and V10 (regression coefficient ()=-0.060, p=0.009) and V20 (=-0.044, p=0.010). In the combined cohort, the (adjusted)  estimates for log (white blood cell) vs. V10 and V20 were as follows: -0.022 (p=0.025) and -0.021 (p=0.002), respectively. Patients with V1095% were more likely to experience Grade3 leukopenia (68.8% vs. 24.6%, p<0.001) than were patients with V20>76% (57.7% vs. 21.8%, p=0.001). These findings support the hypothesis that HT increases with increasing pelvic BM volume irradiated. Efforts to maintain V10<95% and V20<76% may reduce HT.",Journal Article,3566.0,83.0,To test the hypothesis that increased pelvic marrow BM irradiation is associated with increased hematologic toxicity HT in cancer patients undergoing chemoradiotherapy and to develop a normal tissue complication probability NTCP model for HT We tested associations between hematologic nadirs during chemoradiotherapy and the volume of BM receiving10 and 20 Gy V10 and V20 using a previously developed linear regression model The validation cohort consisted of 44 cancer patients treated with concurrent cisplatin and pelvic radiotherapy Subsequently these data were pooled with data from 37 identically treated patients from a previous study forming a cohort of 81 patients for normal tissue complication probability analysis Generalized linear modeling was used to test associations between hematologic nadirs and dosimetric parameters adjusting for body mass index Receiver operating characteristic curves were used to derive optimal dosimetric planning constraints In the validation cohort significant negative correlations were observed between white blood cell count nadir and V10 regression coefficient =-0.060 p=0.009 and V20 =-0.044 p=0.010 In the combined cohort the adjusted estimates for log white blood cell vs. V10 and V20 were as follows -0.022 p=0.025 and -0.021 p=0.002 respectively Patients with V1095 were more likely to experience Grade3 leukopenia 68.8 vs. 24.6 p 0.001 than were patients with V20 76 57.7 vs. 21.8 p=0.001 These findings support the hypothesis that HT increases with increasing pelvic BM volume irradiated Efforts to maintain V10 95 and V20 76 may reduce HT,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 412, 3, 1492, 17, 101, 1110, 581, 1246, 1104, 16, 41, 5, 101, 813, 155, 3152, 4, 12, 7, 479, 1464, 2, 6, 690, 8, 295, 246, 1447, 1320, 13479, 202, 9, 3152, 21, 650, 685, 59, 813, 13866, 190, 1464, 2, 3, 433, 1, 1246, 58857, 2, 179, 381, 10724, 2, 8120, 75, 8, 373, 276, 1646, 320, 202, 3, 929, 180, 1695, 1, 584, 12, 7, 73, 5, 750, 540, 2, 1110, 310, 1611, 46, 74, 11, 1830, 5, 74, 29, 567, 20330, 73, 7, 29, 8, 698, 45, 4525, 8, 180, 1, 865, 7, 9, 295, 246, 1447, 1320, 65, 4169, 1646, 2057, 10, 95, 6, 412, 685, 59, 813, 13866, 2, 3187, 1038, 1358, 9, 642, 782, 558, 3185, 2584, 2037, 2400, 11, 95, 6, 3823, 665, 3187, 1349, 4879, 4, 3, 929, 180, 93, 199, 2553, 11, 164, 59, 886, 315, 31, 1276, 3686, 2, 10724, 320, 3200, 13, 9972, 19, 13, 2376, 2, 8120, 1458, 13, 6194, 19, 13, 4873, 4, 3, 397, 180, 3, 586, 1423, 9, 1066, 886, 315, 31, 105, 10724, 2, 8120, 11, 22, 2962, 13, 4773, 19, 13, 4067, 2, 13, 4630, 19, 13, 1111, 106, 7, 5, 58858, 11, 80, 322, 6, 730, 14659, 3904, 806, 66, 105, 259, 49, 19, 13, 144, 76, 11, 7, 5, 8120, 846, 696, 67, 105, 239, 66, 19, 13, 144, 46, 272, 538, 3, 1492, 17, 3152, 1106, 5, 602, 1110, 1246, 433, 2398, 1413, 6, 3040, 10724, 48, 2, 8120, 846, 68, 969, 3152]",1598.0,20400238,795
Pazopanib: Clinical development of a potent anti-angiogenic drug.,Critical reviews in oncology/hematology,Crit. Rev. Oncol. Hematol.,2010-04-24,"Pazopanib is an oral, multi-targeted, tyrosine kinase inhibitor (TKI) that binds to the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and several other key proteins responsible for angiogenesis, tumor growth and cell survival. Pazopanib exhibited in vivo and in vitro activity against tumor growth and, in early clinical trials, was well tolerated with the main side effects being hypertension, fatigue and gastrointestinal disorders. Pazopanib showed clinical activity in several tumors including renal cell cancer (RCC), breast cancer, soft tissue sarcoma, thyroid cancer, hepatocellular cancer and cervical cancer. A phase III clinical trial in metastatic RCC patients showed a significant improvement in progression-free survival, leading to its approval in the US. In metastatic breast cancer, the combination of pazopanib with lapatinib was more effective than lapatinib alone. At the time of the current publication, pazopanib is being evaluated in more than 35 phase II and III trials.",Journal Article,3559.0,84.0,Pazopanib is an oral multi-targeted tyrosine kinase inhibitor TKI that binds to the vascular endothelial growth factor receptor VEGFR platelet-derived growth factor receptor PDGFR and several other key proteins responsible for angiogenesis tumor growth and cell survival Pazopanib exhibited in vivo and in vitro activity against tumor growth and in early clinical trials was well tolerated with the main side effects being hypertension fatigue and disorders Pazopanib showed clinical activity in several tumors including cell cancer RCC cancer soft tissue cancer cancer and cancer A phase III clinical trial in metastatic RCC patients showed a significant improvement in progression-free survival leading to its approval in the US In metastatic cancer the combination of pazopanib with lapatinib was more effective than lapatinib alone At the time of the current publication pazopanib is being evaluated in more than 35 phase II and III trials,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,"[2576, 16, 35, 518, 1414, 238, 564, 216, 230, 1379, 17, 3333, 6, 3, 756, 845, 129, 161, 153, 2134, 1596, 526, 129, 161, 153, 4103, 2, 392, 127, 825, 652, 2327, 9, 1056, 30, 129, 2, 31, 25, 2576, 1416, 4, 386, 2, 4, 439, 128, 480, 30, 129, 2, 4, 191, 38, 143, 10, 149, 421, 5, 3, 1895, 1152, 176, 486, 1824, 613, 2, 1997, 2576, 224, 38, 128, 4, 392, 57, 141, 31, 12, 796, 12, 1214, 246, 12, 12, 2, 12, 8, 124, 316, 38, 160, 4, 113, 796, 7, 224, 8, 93, 767, 4, 91, 115, 25, 1049, 6, 211, 1814, 4, 3, 843, 4, 113, 12, 3, 150, 1, 2576, 5, 2076, 10, 80, 323, 76, 2076, 279, 28, 3, 98, 1, 3, 291, 4397, 2576, 16, 486, 194, 4, 80, 76, 465, 124, 215, 2, 316, 143]",943.0,20456972,246
Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional data.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2010-05-14,"To study the effects of increasing pelvic bone marrow (BM) radiation dose on acute hematologic toxicity in patients undergoing chemoradiotherapy, using a novel modeling approach to preserve the local spatial dose information. The study included 37 cervical cancer patients treated with concurrent weekly cisplatin and pelvic radiation therapy. The white blood cell count nadir during treatment was used as the indicator for acute hematologic toxicity. Pelvic BM radiation dose distributions were standardized across patients by registering the pelvic BM volumes to a common template, followed by dose remapping using deformable image registration, resulting in a dose array. Principal component (PC) analysis was applied to the dose array, and the significant eigenvectors were identified by linear regression on the PCs. The coefficients for PC regression and significant eigenvectors were represented in three dimensions to identify critical BM subregions where dose accumulation is associated with hematologic toxicity. We identified five PCs associated with acute hematologic toxicity. PC analysis regression modeling explained a high proportion of the variation in acute hematologicity (adjusted R(2), 0.49). Three-dimensional rendering of a linear combination of the significant eigenvectors revealed patterns consistent with anatomical distributions of hematopoietically active BM. We have developed a novel approach that preserves spatial dose information to model effects of radiation dose on toxicity, which may be useful in optimizing radiation techniques to avoid critical subregions of normal tissues. Further validation of this approach in a large cohort is ongoing.",Journal Article,3539.0,28.0,To study the effects of increasing pelvic marrow BM radiation dose on acute hematologic toxicity in patients undergoing chemoradiotherapy using a novel modeling approach to preserve the local spatial dose information The study included 37 cancer patients treated with concurrent weekly cisplatin and pelvic radiation therapy The white blood cell count nadir during treatment was used as the indicator for acute hematologic toxicity Pelvic BM radiation dose distributions were standardized across patients by registering the pelvic BM volumes to a common template followed by dose remapping using deformable image registration resulting in a dose array Principal component PC analysis was applied to the dose array and the significant eigenvectors were identified by linear regression on the PCs The coefficients for PC regression and significant eigenvectors were represented in three dimensions to identify critical BM subregions where dose accumulation is associated with hematologic toxicity We identified five PCs associated with acute hematologic toxicity PC analysis regression modeling explained a high proportion of the variation in acute hematologicity adjusted R 2 0.49 Three-dimensional rendering of a linear combination of the significant eigenvectors revealed patterns consistent with anatomical distributions of hematopoietically active BM We have developed a novel approach that preserves spatial dose information to model effects of radiation dose on toxicity which may be useful in optimizing radiation techniques to avoid critical subregions of normal tissues Further validation of this approach in a large cohort is ongoing,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 45, 3, 176, 1, 602, 1110, 581, 1246, 121, 61, 23, 286, 813, 155, 4, 7, 479, 1464, 75, 8, 229, 2057, 353, 6, 6783, 3, 293, 5104, 61, 487, 3, 45, 159, 567, 12, 7, 73, 5, 750, 709, 540, 2, 1110, 121, 36, 3, 886, 315, 31, 1276, 3686, 190, 24, 10, 95, 22, 3, 3287, 9, 286, 813, 155, 1110, 1246, 121, 61, 4477, 11, 1670, 716, 7, 20, 39326, 3, 1110, 1246, 2225, 6, 8, 186, 5932, 370, 20, 61, 58951, 75, 10491, 1482, 3169, 1113, 4, 8, 61, 1926, 4312, 1249, 1341, 65, 10, 1498, 6, 3, 61, 1926, 2, 3, 93, 26941, 11, 108, 20, 1646, 320, 23, 3, 4270, 3, 5161, 9, 1341, 320, 2, 93, 26941, 11, 3324, 4, 169, 6190, 6, 255, 740, 1246, 22613, 1257, 61, 1835, 16, 41, 5, 813, 155, 21, 108, 365, 4270, 41, 5, 286, 813, 155, 1341, 65, 320, 2057, 3672, 8, 64, 920, 1, 3, 1380, 4, 286, 58952, 586, 668, 18, 13, 739, 169, 2201, 9535, 1, 8, 1646, 150, 1, 3, 93, 26941, 553, 764, 925, 5, 5024, 4477, 1, 58953, 544, 1246, 21, 47, 276, 8, 229, 353, 17, 16221, 5104, 61, 487, 6, 202, 176, 1, 121, 61, 23, 155, 92, 68, 40, 999, 4, 4336, 121, 1092, 6, 3085, 740, 22613, 1, 295, 742, 195, 929, 1, 26, 353, 4, 8, 375, 180, 16, 942]",1642.0,20472344,328
Predictive value of endocervical curettage at cervical conization and provider practices in management of high-grade cervical dysplasia.,The Journal of reproductive medicine,J Reprod Med,,"To determine the utility of endocervical curettage (ECC) at cervical conization for predicting residual or recurrent dysplasia and to evaluate differences in management between general gynecologists and gynecologic oncologists. From February 1999 to November 2007, 192 patients with high-grade dysplasia on conization were retrospectively identified. Data were analyzed for 54 patients who underwent repeat conization or hysterectomy to evaluate predictors of disease. Data for all patients were analyzed based on provider. Among patients who underwent secondary procedures, 68.5% (37/54) had residual or recurrent disease. Eighty-six percent of patients with a positive ECC had residual or recurrent disease compared to 48% of patients with a negative ECC (OR 6.91, CI 1.595-30.00, p=0.01). Among all patients, 77% (148/192) were managed by a generalist, and 23% (44/192) by a gynecologic oncologist. Oncologists were significantly more likely to perform a hysterectomy (45.5% vs. 14.2%, OR 5.04, CI 2.38-10.69, p<0.0001). Endocervical curettage at the time of conization with high-grade dysplasia is a simple and reliable predictor of residual or recurrent disease and should be performed routinely. Gynecologic oncologists are more likely than general gynecologists to perform a hysterectomy in the management of high-grade dysplasia on conization.",Journal Article,,1.0,To determine the utility of endocervical curettage ECC at conization for predicting residual or recurrent dysplasia and to evaluate differences in management between general gynecologists and gynecologic oncologists From February 1999 to November 2007 192 patients with high-grade dysplasia on conization were retrospectively identified Data were analyzed for 54 patients who underwent repeat conization or hysterectomy to evaluate predictors of disease Data for all patients were analyzed based on provider Among patients who underwent secondary procedures 68.5 37/54 had residual or recurrent disease Eighty-six percent of patients with a positive ECC had residual or recurrent disease compared to 48 of patients with a negative ECC OR 6.91 CI 1.595-30.00 p=0.01 Among all patients 77 148/192 were managed by a generalist and 23 44/192 by a gynecologic oncologist Oncologists were significantly more likely to perform a hysterectomy 45.5 vs. 14.2 OR 5.04 CI 2.38-10.69 p 0.0001 Endocervical curettage at the time of conization with high-grade dysplasia is a simple and reliable predictor of residual or recurrent disease and should be performed routinely Gynecologic oncologists are more likely than general gynecologists to perform a hysterectomy in the management of high-grade dysplasia on conization,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 1207, 1, 10174, 12529, 18238, 28, 8755, 9, 1434, 753, 15, 387, 2253, 2, 6, 376, 362, 4, 284, 59, 1083, 14854, 2, 1512, 1339, 29, 3010, 2043, 6, 2868, 1307, 5016, 7, 5, 64, 88, 2253, 23, 8755, 11, 894, 108, 74, 11, 311, 9, 667, 7, 54, 208, 2334, 8755, 15, 2622, 6, 376, 674, 1, 34, 74, 9, 62, 7, 11, 311, 90, 23, 3094, 107, 7, 54, 208, 568, 1369, 806, 33, 567, 667, 42, 753, 15, 387, 34, 2207, 437, 714, 1, 7, 5, 8, 109, 18238, 42, 753, 15, 387, 34, 72, 6, 576, 1, 7, 5, 8, 199, 18238, 15, 49, 970, 58, 14, 11442, 201, 2038, 19, 13, 355, 107, 62, 7, 849, 4647, 5016, 11, 2231, 20, 8, 39338, 2, 382, 584, 5016, 20, 8, 1512, 2709, 1339, 11, 97, 80, 322, 6, 2715, 8, 2622, 512, 33, 105, 213, 18, 15, 33, 755, 58, 18, 519, 79, 790, 19, 13, 488, 10174, 12529, 28, 3, 98, 1, 8755, 5, 64, 88, 2253, 16, 8, 2763, 2, 2450, 980, 1, 753, 15, 387, 34, 2, 257, 40, 173, 3066, 1512, 1339, 32, 80, 322, 76, 1083, 14854, 6, 2715, 8, 2622, 4, 3, 284, 1, 64, 88, 2253, 23, 8755]",1305.0,20506673,757
Surgical management of cervical lymph nodes in differentiated thyroid cancer.,Otolaryngologic clinics of North America,Otolaryngol. Clin. North Am.,2010-04-01,"Well-differentiated thyroid cancer (DTC) carries an excellent prognosis. Although long-term survival rates are high, regional lymph node metastases are common. Surgical management of cervical lymph nodes is integral to the comprehensive treatment of DTC, but data from large randomized trials do not exist to define optimal treatment. Therapy is thus guided by observational data, and founded on an understanding of the behavior of lymphatic metastases in DTC. This article focuses on the significance of lymph node metastases in thyroid cancer, and the strategy for surgical management.",Journal Article,3582.0,22.0,Well-differentiated cancer DTC carries an excellent prognosis Although long-term survival rates are high regional lymph node metastases are common Surgical management of lymph nodes is integral to the comprehensive treatment of DTC but data from large randomized trials do not exist to define optimal treatment Therapy is thus guided by observational data and founded on an understanding of the behavior of lymphatic metastases in DTC This article focuses on the significance of lymph node metastases in cancer and the strategy for surgical management,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[149, 1442, 12, 5201, 4942, 35, 1503, 356, 242, 319, 337, 25, 151, 32, 64, 951, 263, 289, 196, 32, 186, 221, 284, 1, 263, 502, 16, 4450, 6, 3, 949, 24, 1, 5201, 84, 74, 29, 375, 384, 143, 1022, 44, 1923, 6, 1107, 665, 24, 36, 16, 631, 1808, 20, 2495, 74, 2, 13497, 23, 35, 612, 1, 3, 1710, 1, 2936, 196, 4, 5201, 26, 946, 3026, 23, 3, 724, 1, 263, 289, 196, 4, 12, 2, 3, 692, 9, 221, 284]",551.0,20510715,419
"Racial/ethnic and socioeconomic disparities in mortality among women diagnosed with cervical cancer in New York City, 1995-2006.",Cancer causes & control : CCC,Cancer Causes Control,2010-06-03,"Though cervical cancer rates have declined due to Pap screening, racial and socioeconomic disparities in cervical cancer incidence and mortality persist. This study assesses the relative impact of race/ethnicity and neighborhood poverty on cervical cancer incidence and mortality in New York City (NYC). Invasive cervical cancer cases in NYC from 1995 to 2006 were identified along with demographic and socioeconomic measures. Odds ratios (OR) of late stage diagnosis were estimated using logistic regression. Hazard ratios (HR) of death were calculated using Cox proportional hazards regression. From 1995 to 2006 cervical cancer incidence and mortality rates decreased in NYC, though black and Hispanic women had higher incidence and mortality rates than white women. Puerto Ricans (OR=1.55, 95% CI=1.20-2.01) and blacks (OR=1.34, 95% CI=1.15-1.57) were more likely to be diagnosed with late stage disease than whites. In multivariate analysis, blacks had similar mortality risk (HR 1.07, 95% CI=0.95-1.20) to whites while Puerto Ricans had increased risk (HR=1.31, 95% CI=1.10-1.55), and non-Puerto Rican Hispanics (HR=0.54, 95% CI=0.45-0.63) and Asian/PIs (HR=0.64, 95% CI=0.52-0.78) had reduced risk. Women living in high poverty neighborhoods had higher mortality than women in higher income neighborhoods (HR=1.32, 95% CI=1.16-1.52). Black and Puerto Rican women in NYC are at greatest risk of dying from cervical cancer. Race/ethnicity is predictive of late stage diagnosis, while both race/ethnicity and neighborhood poverty are important predictors of cervical cancer mortality.",Journal Article,3519.0,45.0,Though cancer rates have declined due to Pap screening racial and socioeconomic disparities in cancer incidence and mortality persist This study assesses the relative impact of race/ethnicity and neighborhood poverty on cancer incidence and mortality in New York City NYC Invasive cancer cases in NYC from 1995 to 2006 were identified along with demographic and socioeconomic measures Odds ratios OR of late stage diagnosis were estimated using logistic regression Hazard ratios HR of death were calculated using Cox proportional hazards regression From 1995 to 2006 cancer incidence and mortality rates decreased in NYC though black and Hispanic women had higher incidence and mortality rates than white women Puerto Ricans OR 1.55 95 CI 1.20-2.01 and blacks OR 1.34 95 CI 1.15-1.57 were more likely to be diagnosed with late stage disease than whites In multivariate analysis blacks had similar mortality risk HR 1.07 95 CI 0.95-1.20 to whites while Puerto Ricans had increased risk HR 1.31 95 CI 1.10-1.55 and non-Puerto Rican Hispanics HR 0.54 95 CI 0.45-0.63 and Asian/PIs HR 0.64 95 CI 0.52-0.78 had reduced risk Women living in high poverty neighborhoods had higher mortality than women in higher income neighborhoods HR 1.32 95 CI 1.16-1.52 Black and Puerto Rican women in NYC are at greatest risk of dying from cancer Race/ethnicity is predictive of late stage diagnosis while both race/ethnicity and neighborhood poverty are important predictors of cancer mortality,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2471, 12, 151, 47, 3054, 520, 6, 4290, 453, 2257, 2, 3331, 2227, 4, 12, 287, 2, 282, 5589, 26, 45, 7777, 3, 580, 345, 1, 1047, 2091, 2, 10985, 7583, 23, 12, 287, 2, 282, 4, 217, 5050, 7235, 34912, 416, 12, 140, 4, 34912, 29, 2323, 6, 1324, 11, 108, 1510, 5, 1540, 2, 3331, 1018, 610, 1137, 15, 1, 807, 82, 147, 11, 661, 75, 812, 320, 360, 1137, 168, 1, 273, 11, 981, 75, 418, 831, 1017, 320, 29, 2323, 6, 1324, 12, 287, 2, 282, 151, 340, 4, 34912, 2471, 1445, 2, 1776, 117, 42, 142, 287, 2, 282, 151, 76, 886, 117, 15247, 34913, 15, 14, 614, 48, 58, 14, 179, 18, 355, 2, 3544, 15, 14, 562, 48, 58, 14, 167, 14, 696, 11, 80, 322, 6, 40, 265, 5, 807, 82, 34, 76, 2556, 4, 331, 65, 3544, 42, 288, 282, 43, 168, 14, 1615, 48, 58, 13, 48, 14, 179, 6, 2556, 369, 15247, 34913, 42, 101, 43, 168, 14, 456, 48, 58, 14, 79, 14, 614, 2, 220, 15247, 39343, 3850, 168, 13, 667, 48, 58, 13, 512, 13, 676, 2, 2399, 7034, 168, 13, 660, 48, 58, 13, 653, 13, 833, 42, 405, 43, 117, 2798, 4, 64, 7583, 22360, 42, 142, 282, 76, 117, 4, 142, 2306, 22360, 168, 14, 531, 48, 58, 14, 245, 14, 653, 1445, 2, 15247, 39343, 117, 4, 34912, 32, 28, 2199, 43, 1, 4536, 29, 12, 1047, 2091, 16, 464, 1, 807, 82, 147, 369, 110, 1047, 2091, 2, 10985, 7583, 32, 305, 674, 1, 12, 282]",1475.0,20521091,213
Cervical dysplasia in pregnancy: a multi-institutional evaluation.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2010-06-03,"This study was undertaken to identify the prognostic indicators associated with postpartum regression of cervical dysplasia diagnosed in pregnancy. A retrospective cohort study of pregnant women referred for colposcopy from 2004-2007 at four academic centers. One thousand seventy-nine patients were identified. Colposcopic impression by cervical cytology is detailed later in the text. Of patients who underwent biopsy, results correlated with or were less severe than colposcopic impression in 83% with CIN 1 and 56% with CIN 2/3. Fifty-seven percent had follow-up postpartum, with 61% reverting to normal. Resolution of cervical dysplasia was inversely associated with smoking (P = .002). No progression to cancer occurred during pregnancy. Colposcopic impression in pregnancy correlated with cervical biopsy results and postpartum colposcopic findings when performed by expert colposcopists. A high proportion of cervical dysplasia regressed postpartum. Cervical biopsies in pregnancy may not be necessary unless invasive cancer is suspected.",Evaluation Study,3519.0,33.0,This study was undertaken to identify the prognostic indicators associated with postpartum regression of dysplasia diagnosed in pregnancy A retrospective cohort study of pregnant women referred for colposcopy from 2004-2007 at four academic centers One thousand seventy-nine patients were identified Colposcopic impression by cytology is detailed later in the text Of patients who underwent biopsy results correlated with or were less severe than colposcopic impression in 83 with CIN 1 and 56 with CIN 2/3 Fifty-seven percent had follow-up postpartum with 61 reverting to normal Resolution of dysplasia was inversely associated with smoking P .002 No progression to cancer occurred during pregnancy Colposcopic impression in pregnancy correlated with biopsy results and postpartum colposcopic findings when performed by expert colposcopists A high proportion of dysplasia regressed postpartum biopsies in pregnancy may not be necessary unless invasive cancer is suspected,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[26, 45, 10, 2789, 6, 255, 3, 177, 3539, 41, 5, 7830, 320, 1, 2253, 265, 4, 2290, 8, 459, 180, 45, 1, 6086, 117, 1995, 9, 9946, 29, 1131, 1307, 28, 294, 1916, 1168, 104, 6161, 2073, 762, 7, 11, 108, 14131, 8925, 20, 2045, 16, 2455, 1559, 4, 3, 6153, 1, 7, 54, 208, 411, 99, 438, 5, 15, 11, 299, 905, 76, 14131, 8925, 4, 852, 5, 4652, 14, 2, 664, 5, 4652, 18, 27, 1461, 648, 714, 42, 166, 126, 7830, 5, 713, 31639, 6, 295, 2125, 1, 2253, 10, 2659, 41, 5, 979, 19, 1111, 77, 91, 6, 12, 489, 190, 2290, 14131, 8925, 4, 2290, 438, 5, 411, 99, 2, 7830, 14131, 272, 198, 173, 20, 2005, 59028, 8, 64, 920, 1, 2253, 12579, 7830, 1154, 4, 2290, 68, 44, 40, 1493, 6179, 416, 12, 16, 2768]",972.0,20522409,522
E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice.,Cancer research,Cancer Res.,2010-06-08,"High-risk human papillomaviruses (HPV) cause certain anogenital and head and neck cancers. E6, one of three potent HPV oncogenes that contribute to the development of these malignancies, is a multifunctional protein with many biochemical activities. Among these activities are its ability to bind and inactivate the cellular tumor suppressor p53, induce expression of telomerase, and bind to various other proteins, including Bak, E6BP1, and E6TP1, and proteins that contain PDZ domains, such as hScrib and hDlg. Many of these activities are thought to contribute to the role of E6 in carcinogenesis. The interaction of E6 with many of these cellular proteins, including p53, leads to their destabilization. This property is mediated at least in part through the ability of E6 to recruit the ubiquitin ligase E6-associated protein (E6AP) into complexes with these cellular proteins, resulting in their ubiquitin-mediated degradation by the proteasome. In this study, we address the requirement for E6AP in mediating acute and oncogenic phenotypes of E6, including induction of epithelial hyperplasia, abrogation of DNA damage response, and induction of cervical cancer. Loss of E6AP had no discernible effect on the ability of E6 to induce hyperplasia or abrogate DNA damage responses, akin to what we had earlier observed in the mouse epidermis. Nevertheless, in cervical carcinogenesis studies, there was a complete loss of the oncogenic potential of E6 in mice nulligenic for E6AP. Thus, E6AP is absolutely required for E6 to cause cervical cancer.",Journal Article,3514.0,41.0,High-risk human papillomaviruses HPV cause certain anogenital and head and cancers E6 one of three potent HPV oncogenes that contribute to the development of these malignancies is a multifunctional protein with many biochemical activities Among these activities are its ability to bind and inactivate the cellular tumor suppressor p53 induce expression of telomerase and bind to various other proteins including Bak E6BP1 and E6TP1 and proteins that contain PDZ domains such as hScrib and hDlg Many of these activities are thought to contribute to the role of E6 in carcinogenesis The interaction of E6 with many of these cellular proteins including p53 leads to their destabilization This property is mediated at least in part through the ability of E6 to recruit the ubiquitin ligase E6-associated protein E6AP into complexes with these cellular proteins resulting in their ubiquitin-mediated degradation by the proteasome In this study we address the requirement for E6AP in mediating acute and oncogenic phenotypes of E6 including induction of epithelial hyperplasia abrogation of DNA damage response and induction of cancer Loss of E6AP had no discernible effect on the ability of E6 to induce hyperplasia or abrogate DNA damage responses akin to what we had earlier observed in the mouse epidermis Nevertheless in carcinogenesis studies there was a complete loss of the oncogenic potential of E6 in mice nulligenic for E6AP Thus E6AP is absolutely required for E6 to cause cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[64, 43, 171, 14731, 933, 708, 1840, 13836, 2, 718, 2, 163, 4837, 104, 1, 169, 1157, 933, 3326, 17, 1248, 6, 3, 193, 1, 46, 441, 16, 8, 7354, 178, 5, 445, 1487, 2042, 107, 46, 2042, 32, 211, 801, 6, 4060, 2, 13772, 3, 763, 30, 1245, 624, 1290, 55, 1, 3916, 2, 4060, 6, 747, 127, 652, 141, 5599, 59046, 2, 59047, 2, 652, 17, 3725, 23840, 2703, 225, 22, 59048, 2, 59049, 445, 1, 46, 2042, 32, 2739, 6, 1248, 6, 3, 200, 1, 4837, 4, 1719, 3, 915, 1, 4837, 5, 445, 1, 46, 763, 652, 141, 624, 1940, 6, 136, 19459, 26, 9267, 16, 517, 28, 506, 4, 760, 298, 3, 801, 1, 4837, 6, 8973, 3, 4213, 5839, 4837, 41, 178, 18232, 237, 3817, 5, 46, 763, 652, 1113, 4, 136, 4213, 517, 2373, 20, 3, 1694, 4, 26, 45, 21, 1539, 3, 4701, 9, 18232, 4, 3941, 286, 2, 1302, 2618, 1, 4837, 141, 504, 1, 701, 3176, 8589, 1, 261, 1350, 51, 2, 504, 1, 12, 407, 1, 18232, 42, 77, 19070, 254, 23, 3, 801, 1, 4837, 6, 1290, 3176, 15, 8581, 261, 1350, 253, 16693, 6, 2067, 21, 42, 1677, 164, 4, 3, 830, 18141, 3873, 4, 1719, 94, 125, 10, 8, 236, 407, 1, 3, 1302, 174, 1, 4837, 4, 399, 59050, 9, 18232, 631, 18232, 16, 22105, 616, 9, 4837, 6, 708, 12]",1485.0,20530688,729
High-throughput profiling of the humoral immune responses against thirteen human papillomavirus types by proteome microarrays.,Virology,Virology,2010-06-15,"We have developed microarrays with all eight proteins encoded by 13 different human papillomavirus types associated with anogenital cancer (HPV-16, -18, -31, -33, -35, -45, and -53), genital warts (HPV-6 and -11), or skin lesions (HPV-1, -2, -4, and -5). We analyzed the seroprevalence of antibodies in 546 patients, which had either cervical carcinomas, or precursor lesions, or which were asymptomatic. All patient groups contained sera ranging from high reactivity against multiple HPV proteins to low or no reactivity. Computational analyses showed the E7 proteins of carcinogenic HPV types as significantly more reactive in cancer patients compared to asymptomatic individuals and discriminating between cancer and HSIL or LSIL patients. Antibodies against E4 and E5 had the highest seroprevalence but did not exhibit differential reactivity relative to pathology. Our study introduces a new approach to future evaluation of the overall antigenicity of HPV proteins and cross-reaction between homologous proteins.",Journal Article,3507.0,30.0,We have developed microarrays with all eight proteins encoded by 13 different human papillomavirus types associated with anogenital cancer HPV-16 -18 -31 -33 -35 -45 and -53 genital warts HPV-6 and -11 or lesions HPV-1 -2 -4 and -5 We analyzed the seroprevalence of antibodies in 546 patients which had either carcinomas or precursor lesions or which were asymptomatic All patient groups contained sera ranging from high reactivity against multiple HPV proteins to low or no reactivity Computational analyses showed the E7 proteins of carcinogenic HPV types as significantly more reactive in cancer patients compared to asymptomatic individuals and discriminating between cancer and HSIL or LSIL patients Antibodies against E4 and E5 had the highest seroprevalence but did not exhibit differential reactivity relative to pathology Our study introduces a new approach to future evaluation of the overall antigenicity of HPV proteins and cross-reaction between homologous proteins,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,"[21, 47, 276, 2774, 5, 62, 659, 652, 4587, 20, 233, 338, 171, 3242, 630, 41, 5, 13836, 12, 933, 245, 203, 456, 466, 465, 512, 2, 699, 8226, 19515, 933, 49, 2, 175, 15, 406, 933, 14, 18, 39, 2, 33, 21, 311, 3, 26784, 1, 890, 4, 11912, 7, 92, 42, 361, 826, 15, 2765, 406, 15, 92, 11, 2100, 62, 69, 271, 3070, 4210, 2223, 29, 64, 4601, 480, 232, 933, 652, 6, 154, 15, 77, 4601, 5368, 318, 224, 3, 4540, 652, 1, 7483, 933, 630, 22, 97, 80, 2163, 4, 12, 7, 72, 6, 2100, 869, 2, 8059, 59, 12, 2, 16067, 15, 17849, 7, 890, 480, 22245, 2, 16072, 42, 3, 1076, 26784, 84, 205, 44, 2239, 1777, 4601, 580, 6, 1117, 114, 45, 13090, 8, 217, 353, 6, 508, 451, 1, 3, 63, 21995, 1, 933, 652, 2, 1383, 1329, 59, 3894, 652]",978.0,20554302,804
Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer: a population-based analysis.,American journal of surgery,Am. J. Surg.,2010-06-18,"The increasing incidence of thyroid cancer may be an artifact of increased diagnostic scrutiny, permitting detection of smaller, subclinical thyroid cancers. Our objective was to examine trends in the incidence of well-differentiated thyroid cancers with large size and adverse pathological features. Detailed population-based analysis of incidence trends in well-differentiated thyroid carcinoma (1973-2006) in the Surveillance Epidemiology and End Results (SEER) cancer registry, using weighted least squares and Joinpoint regression models. The incidence of well-differentiated thyroid cancer (WDTC) in the United States has tripled since 1973 (P < .0001). Incidence trends differ significantly between geographic regions and racial groups. Large WDTCs, including those >4 cm or >6 cm, have more than doubled in incidence (P < .0001). Cancers with extrathyroidal extension and with cervical metastases have also more than doubled in incidence (P < .0001). While the model of improving screening does explain increased diagnoses of small thyroid cancers, significant rises in the incidence of large cancers, and cancers with clinically significant pathological adverse features, are harder to explain. Alternative hypotheses, including a true increase in cancer incidence, would seem to merit exploration.",Comparative Study,3504.0,103.0,The increasing incidence of cancer may be an artifact of increased diagnostic scrutiny permitting detection of smaller subclinical cancers Our objective was to examine trends in the incidence of well-differentiated cancers with large size and adverse pathological features Detailed population-based analysis of incidence trends in well-differentiated carcinoma 1973-2006 in the Surveillance Epidemiology and End Results SEER cancer registry using weighted least squares and Joinpoint regression models The incidence of well-differentiated cancer WDTC in the United States has tripled since 1973 P .0001 Incidence trends differ significantly between geographic regions and racial groups Large WDTCs including those 4 cm or 6 cm have more than doubled in incidence P .0001 Cancers with extrathyroidal extension and with metastases have also more than doubled in incidence P .0001 While the model of improving screening does explain increased diagnoses of small cancers significant rises in the incidence of large cancers and cancers with clinically significant pathological adverse features are harder to explain Alternative hypotheses including a true increase in cancer incidence would seem to merit exploration,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[3, 602, 287, 1, 12, 68, 40, 35, 14759, 1, 101, 752, 11323, 9621, 638, 1, 2170, 7403, 163, 114, 461, 10, 6, 1004, 1963, 4, 3, 287, 1, 149, 1442, 163, 5, 375, 444, 2, 290, 1301, 404, 2455, 266, 90, 65, 1, 287, 1963, 4, 149, 1442, 134, 4756, 1324, 4, 3, 617, 1284, 2, 396, 99, 1605, 12, 1608, 75, 2337, 506, 11938, 2, 16025, 320, 274, 3, 287, 1, 149, 1442, 12, 14663, 4, 3, 1088, 907, 71, 18261, 1192, 4756, 19, 488, 287, 1963, 1505, 97, 59, 3466, 1374, 2, 2257, 271, 375, 59084, 141, 135, 39, 494, 15, 49, 494, 47, 80, 76, 8431, 4, 287, 19, 488, 163, 5, 18518, 2401, 2, 5, 196, 47, 120, 80, 76, 8431, 4, 287, 19, 488, 369, 3, 202, 1, 1673, 453, 1097, 2943, 101, 2403, 1, 302, 163, 93, 13502, 4, 3, 287, 1, 375, 163, 2, 163, 5, 505, 93, 1301, 290, 404, 32, 39354, 6, 2943, 1091, 6243, 141, 8, 2501, 344, 4, 12, 287, 688, 3233, 6, 7062, 3370]",1211.0,20561605,9
"Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-07-06,"Pazopanib and lapatinib are tyrosine kinase inhibitors that target vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit or epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/neu), respectively. In cervical cancer, EGFR and HER2/neu overexpression and high microvascular density correlate with survival. Patients with measurable stage IVB persistent/recurrent cervical carcinoma not amenable to curative therapy and at least one prior regimen in the metastatic setting were randomly assigned in a ratio of 1:1:1 to pazopanib at 800 mg once daily, lapatinib at 1,500 mg once daily, or lapatinib plus pazopanib combination therapy (lapatinib at 1,000 mg plus pazopanib at 400 mg once daily or lapatinib at 1,500 mg plus pazopanib at 800 mg once daily). Therapy continued until progression or withdrawal because of adverse events (AEs). Primary end point was progression-free survival (PFS), and secondary end points were overall survival (OS), response rate (RR), and safety. The futility boundary was crossed at the planned interim analysis for combination therapy compared with lapatinib therapy, and the combination was discontinued. Of 230 patients enrolled, 152 were randomly assigned to the monotherapy arms: pazopanib (n = 74) or lapatinib (n = 78). Most patients (62%) had recurrent cancer. Pazopanib improved PFS (hazard ratio [HR], 0.66; 90% CI, 0.48 to 0.91; P = .013) and OS (HR, 0.67; 90% CI, 0.46 to 0.99; P = .045). Median OS was 50.7 weeks and 39.1 weeks and RRs were 9% and 5% for pazopanib and lapatinib, respectively. The only grade 3 AE > 10% was diarrhea (11% pazopanib and 13% lapatinib). Grade 4 AEs were 9% (lapatinib) and 12% (pazopanib). This study confirms the activity of antiangiogenesis agents in advanced and recurrent cervical cancer and demonstrates the benefit of pazopanib based on the prolonged PFS and favorable toxicity profile.","Clinical Trial, Phase II",3486.0,160.0,"Pazopanib and lapatinib are tyrosine kinase inhibitors that target vascular endothelial growth factor receptor platelet-derived growth factor receptor and c-Kit or epidermal growth factor receptor EGFR and human epidermal growth factor receptor 2 HER2/neu respectively In cancer EGFR and HER2/neu overexpression and high microvascular density correlate with survival Patients with measurable stage IVB persistent/recurrent carcinoma not amenable to curative therapy and at least one prior regimen in the metastatic setting were randomly assigned in a ratio of 1:1:1 to pazopanib at 800 mg once daily lapatinib at 1,500 mg once daily or lapatinib plus pazopanib combination therapy lapatinib at 1,000 mg plus pazopanib at 400 mg once daily or lapatinib at 1,500 mg plus pazopanib at 800 mg once daily Therapy continued until progression or withdrawal because of adverse events AEs Primary end point was progression-free survival PFS and secondary end points were overall survival OS response rate RR and safety The futility boundary was crossed at the planned interim analysis for combination therapy compared with lapatinib therapy and the combination was discontinued Of 230 patients enrolled 152 were randomly assigned to the monotherapy arms pazopanib n 74 or lapatinib n 78 Most patients 62 had recurrent cancer Pazopanib improved PFS hazard ratio HR 0.66 90 CI 0.48 to 0.91 P .013 and OS HR 0.67 90 CI 0.46 to 0.99 P .045 Median OS was 50.7 weeks and 39.1 weeks and RRs were 9 and 5 for pazopanib and lapatinib respectively The only grade 3 AE 10 was diarrhea 11 pazopanib and 13 lapatinib Grade 4 AEs were 9 lapatinib and 12 pazopanib This study confirms the activity of antiangiogenesis agents in advanced and recurrent cancer and demonstrates the benefit of pazopanib based on the prolonged PFS and favorable toxicity profile",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2576, 2, 2076, 32, 564, 216, 222, 17, 283, 756, 845, 129, 161, 153, 1596, 526, 129, 161, 153, 2, 256, 1164, 15, 829, 129, 161, 153, 227, 2, 171, 829, 129, 161, 153, 18, 354, 1637, 106, 4, 12, 227, 2, 354, 1637, 851, 2, 64, 6466, 1263, 1513, 5, 25, 7, 5, 1884, 82, 7042, 1882, 387, 134, 44, 4070, 6, 1075, 36, 2, 28, 506, 104, 324, 477, 4, 3, 113, 546, 11, 1108, 896, 4, 8, 197, 1, 14, 14, 14, 6, 2576, 28, 2796, 81, 1059, 391, 2076, 28, 14, 1666, 81, 1059, 391, 15, 2076, 349, 2576, 150, 36, 2076, 28, 14, 984, 81, 349, 2576, 28, 1524, 81, 1059, 391, 15, 2076, 28, 14, 1666, 81, 349, 2576, 28, 2796, 81, 1059, 391, 36, 1351, 1100, 91, 15, 3683, 408, 1, 290, 281, 1477, 86, 396, 741, 10, 91, 115, 25, 300, 2, 568, 396, 862, 11, 63, 25, 118, 51, 116, 861, 2, 367, 3, 7566, 8920, 10, 7023, 28, 3, 1465, 2914, 65, 9, 150, 36, 72, 5, 2076, 36, 2, 3, 150, 10, 2402, 1, 6136, 7, 346, 5370, 11, 1108, 896, 6, 3, 1411, 1335, 2576, 78, 794, 15, 2076, 78, 833, 96, 7, 744, 42, 387, 12, 2576, 231, 300, 360, 197, 168, 13, 700, 424, 58, 13, 576, 6, 13, 970, 19, 3612, 2, 118, 168, 13, 598, 424, 58, 13, 641, 6, 13, 1058, 19, 4918, 52, 118, 10, 212, 67, 244, 2, 587, 14, 244, 2, 4739, 11, 83, 2, 33, 9, 2576, 2, 2076, 106, 3, 158, 88, 27, 3633, 79, 10, 1172, 175, 2576, 2, 233, 2076, 88, 39, 1477, 11, 83, 2076, 2, 133, 2576, 26, 45, 5120, 3, 128, 1, 7351, 183, 4, 131, 2, 387, 12, 2, 1902, 3, 247, 1, 2576, 90, 23, 3, 1069, 300, 2, 913, 155, 800]",1833.0,20606083,0
Proton radiotherapy: the biological effect of treating alternating subsets of fields for different treatment fractions.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2010-08-02,"Common practice in proton radiotherapy is to deliver a subset of all fields in the treatment plan on any given treatment day. We investigate using biological modeling if the resulting variation in daily dose to normal tissues has a relevant detrimental biological effect. For four patient groups, the cumulative normalized total dose (NTD) was determined for normal tissues (OARs) of each patient using the clinically delivered fractionation schedule (FS(clin)), and for hypothetical fractionation schedules delivering all fields every day (FS(all)) or only a single field each day (FS(single)). Cumulative three-dimensional NTD distributions were summarized using the generalized equivalent uniform dose (gEUD) model. For the skull base/cervical spine chordoma group, the largest effect is a 4-Gy increase in gEUD of the chiasm when treating only a subset of fields on any day. For lung cancer and pancreatic cancer patients, the variation in the gEUD of normal tissues is <0.2 Gy. For the prostate group, FS(clin) increases the gEUD of the femoral heads by 9 Gy compared with FS(all). Use of FS(single) resulted in the highest NTD to normal tissues for any patient. FS(all) resulted in an integral NTD to the patient that is on average 5% lower than FS(clin) and 10% lower than FS(single). The effects of field set of the day treatment delivery depend on the tumor site and number of fields treated each day. Modeling these effects may be important for accurate risk assessment.",Journal Article,3459.0,8.0,Common practice in proton radiotherapy is to deliver a subset of all fields in the treatment plan on any given treatment day We investigate using biological modeling if the resulting variation in daily dose to normal tissues has a relevant detrimental biological effect For four patient groups the cumulative normalized total dose NTD was determined for normal tissues OARs of each patient using the clinically delivered fractionation schedule FS clin and for hypothetical fractionation schedules delivering all fields every day FS all or only a single field each day FS single Cumulative three-dimensional NTD distributions were summarized using the generalized equivalent uniform dose gEUD model For the skull base/cervical spine chordoma group the largest effect is a 4-Gy increase in gEUD of the chiasm when treating only a subset of fields on any day For cancer and cancer patients the variation in the gEUD of normal tissues is 0.2 Gy For the group FS clin increases the gEUD of the femoral heads by 9 Gy compared with FS all Use of FS single resulted in the highest NTD to normal tissues for any patient FS all resulted in an integral NTD to the patient that is on average 5 lower than FS clin and 10 lower than FS single The effects of field set of the day treatment delivery depend on the tumor site and number of fields treated each day Modeling these effects may be important for accurate risk assessment,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[186, 758, 4, 2095, 310, 16, 6, 3392, 8, 697, 1, 62, 3130, 4, 3, 24, 2242, 23, 500, 447, 24, 218, 21, 963, 75, 1037, 2057, 492, 3, 1113, 1380, 4, 391, 61, 6, 295, 742, 71, 8, 867, 6227, 1037, 254, 9, 294, 69, 271, 3, 967, 4207, 181, 61, 21397, 10, 509, 9, 295, 742, 8617, 1, 296, 69, 75, 3, 505, 1623, 3519, 1055, 4110, 2459, 2, 9, 7045, 3519, 2314, 4790, 62, 3130, 454, 218, 4110, 62, 15, 158, 8, 226, 1067, 296, 218, 4110, 226, 967, 169, 2201, 21397, 4477, 11, 3989, 75, 3, 4169, 2017, 3490, 61, 16974, 202, 9, 3, 5054, 1782, 18237, 2342, 3911, 87, 3, 2166, 254, 16, 8, 39, 381, 344, 4, 16974, 1, 3, 14583, 198, 1367, 158, 8, 697, 1, 3130, 23, 500, 218, 9, 12, 2, 12, 7, 3, 1380, 4, 3, 16974, 1, 295, 742, 16, 13, 18, 381, 9, 3, 87, 4110, 2459, 1106, 3, 16974, 1, 3, 7649, 26969, 20, 83, 381, 72, 5, 4110, 62, 119, 1, 4110, 226, 627, 4, 3, 1076, 21397, 6, 295, 742, 9, 500, 69, 4110, 62, 627, 4, 35, 4450, 21397, 6, 3, 69, 17, 16, 23, 1011, 33, 280, 76, 4110, 2459, 2, 79, 280, 76, 4110, 226, 3, 176, 1, 1067, 916, 1, 3, 218, 24, 989, 4533, 23, 3, 30, 606, 2, 207, 1, 3130, 73, 296, 218, 2057, 46, 176, 68, 40, 305, 9, 1481, 43, 455]",1415.0,20675067,221
Epitrochlear lymph node dissection.,Annals of surgical oncology,Ann. Surg. Oncol.,2010-08-03,"Epitrochlear node involvement occurs in a small minority of patients with forearm or hand melanoma. Although in-transit sentinel lymph nodes are identified infrequently, they contain metastatic disease at nearly the same frequency as sentinel lymph nodes in cervical, axillary, and inguinal nodal basins. Positive in-transit sentinel lymph nodes are likely to be the only site of nodal metastasis. Therefore, detailed preoperative lymphoscintigraphy and meticulous intraoperative search for in-transit nodes should be performed. The recovery of nodes from in-transit nodal areas is low; however, there appears to be an increase in the performance of these dissections since the advent of lymphatic mapping and sentinel lymph node biopsy. This streaming video demonstrates the incidence of epitrochlear lymph node involvement and technical considerations associated with epitrochlear lymph node dissection.",Journal Article,3458.0,3.0,Epitrochlear node involvement occurs in a small minority of patients with forearm or hand Although in-transit sentinel lymph nodes are identified infrequently they contain metastatic disease at nearly the same frequency as sentinel lymph nodes in axillary and inguinal nodal basins Positive in-transit sentinel lymph nodes are likely to be the only site of nodal metastasis Therefore detailed preoperative lymphoscintigraphy and meticulous intraoperative search for in-transit nodes should be performed The recovery of nodes from in-transit nodal areas is low however there appears to be an increase in the performance of these dissections since the advent of lymphatic mapping and sentinel lymph node biopsy This streaming video demonstrates the incidence of epitrochlear lymph node involvement and technical considerations associated with epitrochlear lymph node dissection,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[27931, 289, 799, 1780, 4, 8, 302, 2652, 1, 7, 5, 18396, 15, 2833, 242, 4, 6432, 1323, 263, 502, 32, 108, 6440, 491, 3725, 113, 34, 28, 1857, 3, 827, 675, 22, 1323, 263, 502, 4, 1210, 2, 4907, 779, 7847, 109, 4, 6432, 1323, 263, 502, 32, 322, 6, 40, 3, 158, 606, 1, 779, 278, 673, 2455, 498, 6849, 2, 13764, 1720, 1901, 9, 4, 6432, 502, 257, 40, 173, 3, 1602, 1, 502, 29, 4, 6432, 779, 1361, 16, 154, 137, 125, 1233, 6, 40, 35, 344, 4, 3, 528, 1, 46, 6894, 1192, 3, 4114, 1, 2936, 2568, 2, 1323, 263, 289, 411, 26, 59228, 4139, 1902, 3, 287, 1, 27931, 263, 289, 799, 2, 3359, 3891, 41, 5, 27931, 263, 289, 1161]",875.0,20680692,296
Assessment of fluorescence in situ hybridization and hybrid capture 2 analyses of cervical cytology specimens diagnosed as low grade squamous intraepithelial lesion for the detection of high grade cervical intraepithelial neoplasia.,Analytical and quantitative cytology and histology,Anal. Quant. Cytol. Histol.,2010-06-01,"To assess Hybrid Capture 2 (HC2) and fluorescence in situ hybridization (FISH) for the detection of cervical intraepithelial neoplasia 2 or worse (CIN 2+) in patients with a cytologic diagnosis of low grade squamous intraepithelial lesion (LSIL). Residual samples from 115 LSIL-diagnosed cervical cytology specimens were evaluated by high-risk human papillomavirus (HR-HPV) HC2 testing and FISH using biotin-labeled probes to HR-HPV and chromosomal probes to 3q26 (TERC) and 8q24 (CMYC). A cervical biopsy diagnosis of CIN 2+ was considered as evidence of high grade disease. The positive and negative predictive values of HC2 and FISH for detecting patients with CIN 2+ were 32% vs. 37% and 100% vs. 93%, respectively. The sensitivities of HC2 and FISH for CIN 2+ were not significantly different (100% vs. 90%, p = 0.25), while the specificity of HC2 was significantly lower than that of FISH (28% vs. 48%, p=0.003). FISH diagnosed fewer specimens as positive as compared to HC2 (62% vs. 79%). These preliminary data suggest that FISH testing may be useful for determining which patients with LSIL are most likely to have CIN 2+ on clinical follow-up.",Comparative Study,3521.0,9.0,To assess Hybrid Capture 2 HC2 and fluorescence in situ hybridization FISH for the detection of intraepithelial neoplasia 2 or worse CIN 2+ in patients with a cytologic diagnosis of low grade squamous intraepithelial lesion LSIL Residual samples from 115 LSIL-diagnosed cytology specimens were evaluated by high-risk human papillomavirus HR-HPV HC2 testing and FISH using biotin-labeled probes to HR-HPV and chromosomal probes to 3q26 TERC and 8q24 CMYC A biopsy diagnosis of CIN 2+ was considered as evidence of high grade disease The positive and negative predictive values of HC2 and FISH for detecting patients with CIN 2+ were 32 vs. 37 and 100 vs. 93 respectively The sensitivities of HC2 and FISH for CIN 2+ were not significantly different 100 vs. 90 p 0.25 while the specificity of HC2 was significantly lower than that of FISH 28 vs. 48 p=0.003 FISH diagnosed fewer specimens as positive as compared to HC2 62 vs. 79 These preliminary data suggest that FISH testing may be useful for determining which patients with LSIL are most likely to have CIN 2+ on clinical follow-up,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 423, 4542, 2891, 18, 16516, 2, 1591, 4, 957, 1554, 1277, 9, 3, 638, 1, 4153, 2298, 18, 15, 639, 4652, 18, 4, 7, 5, 8, 4195, 147, 1, 154, 88, 691, 4153, 1180, 17849, 753, 347, 29, 3670, 17849, 265, 2045, 623, 11, 194, 20, 64, 43, 171, 3242, 168, 933, 16516, 471, 2, 1277, 75, 12713, 2841, 3701, 6, 168, 933, 2, 1860, 3701, 6, 10678, 18432, 2, 6069, 16357, 8, 411, 147, 1, 4652, 18, 10, 515, 22, 241, 1, 64, 88, 34, 3, 109, 2, 199, 464, 1030, 1, 16516, 2, 1277, 9, 2502, 7, 5, 4652, 18, 11, 531, 105, 567, 2, 394, 105, 966, 106, 3, 6202, 1, 16516, 2, 1277, 9, 4652, 18, 11, 44, 97, 338, 394, 105, 424, 19, 13, 243, 369, 3, 1121, 1, 16516, 10, 97, 280, 76, 17, 1, 1277, 339, 105, 576, 19, 13, 1421, 1277, 265, 1497, 623, 22, 109, 22, 72, 6, 16516, 744, 105, 842, 46, 1676, 74, 309, 17, 1277, 471, 68, 40, 999, 9, 2196, 92, 7, 5, 17849, 32, 96, 322, 6, 47, 4652, 18, 23, 38, 166, 126]",1083.0,20701064,812
Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for uterine or cervical cancers.,Gynecologic oncology,Gynecol. Oncol.,2010-08-12,"A prior analysis of patients undergoing laparotomy for ovarian malignancies at our institution revealed an increased rate of intra-abdominal collections using HA-CMC film during debulking surgery. The primary objective of the current study was to determine whether the use of HA-CMC is associated with the development of postoperative intra-abdominal collections in patients undergoing laparotomy for uterine or cervical malignancies. We retrospectively identified all laparotomies performed for these malignancies from 3/1/05 to 12/31/07. We identified cases involving the use of HA-CMC via billing records and operative reports. Intra-abdominal collections were defined as localized intraperitoneal fluid accumulations in the absence of re-accumulating ascites. We noted incidences of intra-abdominal collections, as well as other complications. Appropriate statistical tests were applied using SPSS 15.0. We identified 169 laparotomies in which HA-CMC was used and 347 in which HA-CMC was not used. The following were statistically similar in both cohorts: age, body mass index (BMI), primary site, surgery for recurrent disease, prior intraperitoneal surgery, and extent of current surgery. Intra-abdominal collections were seen in 6 (3.6%) of 169 HA-CMC cases compared to 10 (2.9%) of 347 non-HA-CMC cases (p=0.7). The rate of infected collections was similar in both groups (1.2% vs. 1.4%). In the subgroup that underwent tumor debulking, intra-abdominal collections were seen in 3 (11.5%) of 26 HA-CMC cases compared to 2 (5.4%) of 37 non-HA-CMC cases (p=0.6). HA-CMC use does not appear to be associated with postoperative intra-abdominal collections in patients undergoing laparotomy for uterine or cervical cancer.",Journal Article,3449.0,7.0,A prior analysis of patients undergoing laparotomy for malignancies at our institution revealed an increased rate of intra-abdominal collections using HA-CMC film during debulking surgery The primary objective of the current study was to determine whether the use of HA-CMC is associated with the development of postoperative intra-abdominal collections in patients undergoing laparotomy for or malignancies We retrospectively identified all laparotomies performed for these malignancies from 3/1/05 to 12/31/07 We identified cases involving the use of HA-CMC via billing records and operative reports Intra-abdominal collections were defined as localized intraperitoneal fluid accumulations in the absence of re-accumulating ascites We noted incidences of intra-abdominal collections as well as other complications Appropriate statistical tests were applied using SPSS 15.0 We identified 169 laparotomies in which HA-CMC was used and 347 in which HA-CMC was not used The following were statistically similar in both cohorts age body mass index BMI primary site surgery for recurrent disease prior intraperitoneal surgery and extent of current surgery Intra-abdominal collections were seen in 6 3.6 of 169 HA-CMC cases compared to 10 2.9 of 347 non-HA-CMC cases p=0.7 The rate of infected collections was similar in both groups 1.2 vs. 1.4 In the subgroup that underwent tumor debulking intra-abdominal collections were seen in 3 11.5 of 26 HA-CMC cases compared to 2 5.4 of 37 non-HA-CMC cases p=0.6 HA-CMC use does not appear to be associated with postoperative intra-abdominal collections in patients undergoing laparotomy for or cancer,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[8, 324, 65, 1, 7, 479, 3274, 9, 441, 28, 114, 731, 553, 35, 101, 116, 1, 2392, 1467, 8394, 75, 4812, 9505, 9414, 190, 3556, 152, 3, 86, 461, 1, 3, 291, 45, 10, 6, 223, 317, 3, 119, 1, 4812, 9505, 16, 41, 5, 3, 193, 1, 573, 2392, 1467, 8394, 4, 7, 479, 3274, 9, 15, 441, 21, 894, 108, 62, 18839, 173, 9, 46, 441, 29, 27, 14, 474, 6, 133, 456, 1615, 21, 108, 140, 1267, 3, 119, 1, 4812, 9505, 847, 10827, 1064, 2, 1208, 1198, 2392, 1467, 8394, 11, 395, 22, 909, 3339, 2357, 39101, 4, 3, 1127, 1, 1491, 6233, 3819, 21, 1051, 3981, 1, 2392, 1467, 8394, 22, 149, 22, 127, 521, 870, 1050, 895, 11, 1498, 75, 11461, 167, 13, 21, 108, 5436, 18839, 4, 92, 4812, 9505, 10, 95, 2, 10745, 4, 92, 4812, 9505, 10, 44, 95, 3, 366, 11, 712, 288, 4, 110, 736, 89, 642, 782, 558, 1140, 86, 606, 152, 9, 387, 34, 324, 3339, 152, 2, 1039, 1, 291, 152, 2392, 1467, 8394, 11, 527, 4, 49, 27, 49, 1, 5436, 4812, 9505, 140, 72, 6, 79, 18, 83, 1, 10745, 220, 4812, 9505, 140, 19, 13, 67, 3, 116, 1, 3369, 8394, 10, 288, 4, 110, 271, 14, 18, 105, 14, 39, 4, 3, 1363, 17, 208, 30, 3556, 2392, 1467, 8394, 11, 527, 4, 27, 175, 33, 1, 432, 4812, 9505, 140, 72, 6, 18, 33, 39, 1, 567, 220, 4812, 9505, 140, 19, 13, 49, 4812, 9505, 119, 1097, 44, 1322, 6, 40, 41, 5, 573, 2392, 1467, 8394, 4, 7, 479, 3274, 9, 15, 12]",1639.0,20708225,575
Conservative surgery in early-stage cervical cancer: what percentage of patients may be eligible for conization and lymphadenectomy?,Gynecologic oncology,Gynecol. Oncol.,2010-08-12,"To determine the proportion of young patients with early-stage invasive cervical cancer treated with radical hysterectomy who may have been eligible for fertility-sparing surgery consisting of cervical conization with pelvic lymph node dissection. We retrospectively identified all patients with early-stage cervical cancer (stages IA1-IB1) who underwent a radical hysterectomy at The University of Texas M. D. Anderson Cancer Center between 1990 and 2009. We reviewed these patients' records to identify patients who were <40 years who had not previously undergone tubal ligation and who would have been considered candidates for cold-knife conization with pelvic lymph node dissection-i.e., women with tumors smaller than 2 cm, low-risk histology (squamous, adenocarcinoma, or adenosquamous), and no lymphovascular space invasion (LVSI). A total of 507 patients with early-stage cervical cancer were identified who underwent radical hysterectomy during the review period. Of these women, 277 (55%) were 40 years or younger. Of these 277 patients, 75 (27%) had had a previous tubal ligation and 202 (73%) had not. Of these 202 patients potentially interested in fertility preserving surgery, 53 (26%) had favorable pathologic characteristics including low-risk histology, tumors 2 cm in size and no LVSI present. Of these 53 patients, none had parametrial involvement or positive lymph nodes. Among 202 women with age younger than 40 years and no previous tubal ligation who underwent radical hysterectomy, 53 (26%) may have been eligible for fertility-sparing surgery such as cold-knife conization with pelvic lymph node dissection.",Journal Article,3449.0,29.0,To determine the proportion of young patients with early-stage invasive cancer treated with radical hysterectomy who may have been eligible for fertility-sparing surgery consisting of conization with pelvic lymph node dissection We retrospectively identified all patients with early-stage cancer stages IA1-IB1 who underwent a radical hysterectomy at The University of Texas M. D. Anderson Cancer Center between 1990 and 2009 We reviewed these patients records to identify patients who were 40 years who had not previously undergone tubal ligation and who would have been considered candidates for cold-knife conization with pelvic lymph node dissection-i.e. women with tumors smaller than 2 cm low-risk histology squamous adenocarcinoma or adenosquamous and no lymphovascular space invasion LVSI A total of 507 patients with early-stage cancer were identified who underwent radical hysterectomy during the review period Of these women 277 55 were 40 years or younger Of these 277 patients 75 27 had had a previous tubal ligation and 202 73 had not Of these 202 patients potentially interested in fertility preserving surgery 53 26 had favorable pathologic characteristics including low-risk histology tumors 2 cm in size and no LVSI present Of these 53 patients none had parametrial involvement or positive lymph nodes Among 202 women with age younger than 40 years and no previous tubal ligation who underwent radical hysterectomy 53 26 may have been eligible for fertility-sparing surgery such as cold-knife conization with pelvic lymph node dissection,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 920, 1, 1169, 7, 5, 191, 82, 416, 12, 73, 5, 711, 2622, 54, 68, 47, 85, 625, 9, 2954, 1851, 152, 2273, 1, 8755, 5, 1110, 263, 289, 1161, 21, 894, 108, 62, 7, 5, 191, 82, 12, 1153, 14517, 8111, 54, 208, 8, 711, 2622, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 59, 2289, 2, 1238, 21, 446, 46, 7, 1064, 6, 255, 7, 54, 11, 327, 60, 54, 42, 44, 373, 1989, 6674, 5307, 2, 54, 688, 47, 85, 515, 1931, 9, 5945, 8045, 8755, 5, 1110, 263, 289, 1161, 70, 563, 117, 5, 57, 2170, 76, 18, 494, 154, 43, 784, 691, 449, 15, 8067, 2, 77, 2933, 3865, 578, 8004, 8, 181, 1, 12257, 7, 5, 191, 82, 12, 11, 108, 54, 208, 711, 2622, 190, 3, 206, 727, 1, 46, 117, 7996, 614, 11, 327, 60, 15, 773, 1, 46, 7996, 7, 481, 428, 42, 42, 8, 698, 6674, 5307, 2, 5918, 803, 42, 44, 1, 46, 5918, 7, 751, 7420, 4, 2954, 4972, 152, 699, 432, 42, 913, 510, 374, 141, 154, 43, 784, 57, 6006, 494, 4, 444, 2, 77, 8004, 364, 1, 46, 699, 7, 1292, 42, 8726, 799, 15, 109, 263, 502, 107, 5918, 117, 5, 89, 773, 76, 327, 60, 2, 77, 698, 6674, 5307, 54, 208, 711, 2622, 699, 432, 68, 47, 85, 625, 9, 2954, 1851, 152, 225, 22, 5945, 8045, 8755, 5, 1110, 263, 289, 1161]",1556.0,20708227,163
Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2010-08-12,"To evaluate disease outcomes and toxicity in cervical cancer patients treated with pelvic intensity-modulated radiation therapy (IMRT). We included all patients with Stage I-IVA cervical carcinoma treated with IMRT at three different institutions from 2000-2007. Patients treated with extended field or conventional techniques were excluded. Intensity-modulated radiation therapy plans were designed to deliver 45 Gy in 1.8-Gy daily fractions to the planning target volume while minimizing dose to the bowel, bladder, and rectum. Toxicity was graded according to the Radiation Therapy Oncology Group system. Overall survival and disease-free survival were estimated by use of the Kaplan-Meier method. Pelvic failure, distant failure, and late toxicity were estimated by use of cumulative incidence functions. The study included 111 patients. Of these, 22 were treated with postoperative IMRT, 8 with IMRT followed by intracavitary brachytherapy and adjuvant hysterectomy, and 81 with IMRT followed by planned intracavitary brachytherapy. Of the patients, 63 had Stage I-IIA disease and 48 had Stage IIB-IVA disease. The median follow-up time was 27 months. The 3-year overall survival rate and the disease-free survival rate were 78% (95% confidence interval [CI], 68-88%) and 69% (95% CI, 59-81%), respectively. The 3-year pelvic failure rate and the distant failure rate were 14% (95% CI, 6-22%) and 17% (95% CI, 8-25%), respectively. Estimates of acute and late Grade 3 toxicity or higher were 2% (95% CI, 0-7%) and 7% (95% CI, 2-13%), respectively. Intensity-modulated radiation therapy is associated with low toxicity and favorable outcomes, supporting its safety and efficacy for cervical cancer. Prospective clinical trials are needed to evaluate the comparative efficacy of IMRT vs. conventional techniques.",Journal Article,3449.0,108.0,To evaluate disease outcomes and toxicity in cancer patients treated with pelvic intensity-modulated radiation therapy IMRT We included all patients with Stage I-IVA carcinoma treated with IMRT at three different institutions from 2000-2007 Patients treated with extended field or conventional techniques were excluded Intensity-modulated radiation therapy plans were designed to deliver 45 Gy in 1.8-Gy daily fractions to the planning target volume while minimizing dose to the bowel and rectum Toxicity was graded according to the Radiation Therapy Oncology Group system Overall survival and disease-free survival were estimated by use of the Kaplan-Meier method Pelvic failure distant failure and late toxicity were estimated by use of cumulative incidence functions The study included 111 patients Of these 22 were treated with postoperative IMRT 8 with IMRT followed by intracavitary brachytherapy and adjuvant hysterectomy and 81 with IMRT followed by planned intracavitary brachytherapy Of the patients 63 had Stage I-IIA disease and 48 had Stage IIB-IVA disease The median follow-up time was 27 months The 3-year overall survival rate and the disease-free survival rate were 78 95 confidence interval CI 68-88 and 69 95 CI 59-81 respectively The 3-year pelvic failure rate and the distant failure rate were 14 95 CI 6-22 and 17 95 CI 8-25 respectively Estimates of acute and late Grade 3 toxicity or higher were 2 95 CI 0-7 and 7 95 CI 2-13 respectively Intensity-modulated radiation therapy is associated with low toxicity and favorable outcomes supporting its safety and efficacy for cancer Prospective clinical trials are needed to evaluate the comparative efficacy of IMRT vs. conventional techniques,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 34, 123, 2, 155, 4, 12, 7, 73, 5, 1110, 837, 1757, 121, 36, 964, 21, 159, 62, 7, 5, 82, 70, 5900, 134, 73, 5, 964, 28, 169, 338, 1764, 29, 1081, 1307, 7, 73, 5, 1747, 1067, 15, 809, 1092, 11, 1800, 837, 1757, 121, 36, 1853, 11, 1114, 6, 3392, 512, 381, 4, 14, 66, 381, 391, 1550, 6, 3, 1349, 283, 433, 369, 4501, 61, 6, 3, 1659, 2, 3660, 155, 10, 3468, 768, 6, 3, 121, 36, 413, 87, 398, 63, 25, 2, 34, 115, 25, 11, 661, 20, 119, 1, 3, 876, 882, 596, 1110, 496, 626, 496, 2, 807, 155, 11, 661, 20, 119, 1, 967, 287, 1681, 3, 45, 159, 3167, 7, 1, 46, 350, 11, 73, 5, 573, 964, 66, 5, 964, 370, 20, 9122, 1536, 2, 249, 2622, 2, 865, 5, 964, 370, 20, 1465, 9122, 1536, 1, 3, 7, 676, 42, 82, 70, 4088, 34, 2, 576, 42, 82, 3884, 5900, 34, 3, 52, 166, 126, 98, 10, 428, 53, 3, 27, 111, 63, 25, 116, 2, 3, 34, 115, 25, 116, 11, 833, 48, 307, 268, 58, 806, 889, 2, 790, 48, 58, 728, 865, 106, 3, 27, 111, 1110, 496, 116, 2, 3, 626, 496, 116, 11, 213, 48, 58, 49, 350, 2, 269, 48, 58, 66, 243, 106, 1423, 1, 286, 2, 807, 88, 27, 155, 15, 142, 11, 18, 48, 58, 13, 67, 2, 67, 48, 58, 18, 233, 106, 837, 1757, 121, 36, 16, 41, 5, 154, 155, 2, 913, 123, 1912, 211, 367, 2, 209, 9, 12, 482, 38, 143, 32, 575, 6, 376, 3, 2352, 209, 1, 964, 105, 809, 1092]",1712.0,20708346,42
Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice.,Virology,Virology,2010-08-24,"High-risk human papillomaviruses (HPVs) contribute to cervical and other anogenital cancers, and they are also linked etiologically to a subset of head and neck squamous cell carcinomas (HNSCC). We previously established a model for HPV-associated HNSCC in which we treated transgenic mice expressing the papillomaviral oncoproteins with the chemical carcinogen 4-nitroquinoline-1-oxide (4-NQO). We found that the HPV-16 E7 oncoprotein was highly potent in causing HNSCC, and its dominance masked any potential oncogenic contribution of E6, a second papillomaviral oncoprotein commonly expressed in human cancers. In the current study, we shortened the duration of treatment with 4-NQO to reduce the incidence of cancers and discovered a striking synergy between E6 and E7 in causing HNSCC. Comparing the oncogenic properties of wild-type versus mutant E6 genes in this model for HNSCC uncovered a role for some but not other cellular targets of E6 previously shown to contribute to cervical cancer.",Journal Article,3437.0,35.0,High-risk human papillomaviruses HPVs contribute to and other anogenital cancers and they are also linked etiologically to a subset of head and squamous cell carcinomas HNSCC We previously established a model for HPV-associated HNSCC in which we treated transgenic mice expressing the papillomaviral oncoproteins with the chemical carcinogen 4-nitroquinoline-1-oxide 4-NQO We found that the HPV-16 E7 oncoprotein was highly potent in causing HNSCC and its dominance masked any potential oncogenic contribution of E6 a second papillomaviral oncoprotein commonly expressed in human cancers In the current study we shortened the duration of treatment with 4-NQO to reduce the incidence of cancers and discovered a striking synergy between E6 and E7 in causing HNSCC Comparing the oncogenic properties of wild-type versus mutant E6 genes in this model for HNSCC uncovered a role for some but not other cellular targets of E6 previously shown to contribute to cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[64, 43, 171, 14731, 13477, 1248, 6, 2, 127, 13836, 163, 2, 491, 32, 120, 1199, 17225, 6, 8, 697, 1, 718, 2, 691, 31, 826, 1209, 21, 373, 635, 8, 202, 9, 933, 41, 1209, 4, 92, 21, 73, 2862, 399, 1046, 3, 46191, 8241, 5, 3, 3743, 7290, 39, 26979, 14, 6608, 39, 21620, 21, 204, 17, 3, 933, 245, 4540, 6159, 10, 561, 1157, 4, 3440, 1209, 2, 211, 16402, 7415, 500, 174, 1302, 2925, 1, 4837, 8, 419, 46191, 6159, 841, 570, 4, 171, 163, 4, 3, 291, 45, 21, 6151, 3, 654, 1, 24, 5, 39, 21620, 6, 969, 3, 287, 1, 163, 2, 2747, 8, 5133, 3439, 59, 4837, 2, 4540, 4, 3440, 1209, 1430, 3, 1302, 1571, 1, 955, 267, 185, 620, 4837, 214, 4, 26, 202, 9, 1209, 5601, 8, 200, 9, 476, 84, 44, 127, 763, 637, 1, 4837, 373, 443, 6, 1248, 6, 12]",961.0,20797753,325
Assessment and significance of quality of life in women with gynecologic cancer.,"Future oncology (London, England)",Future Oncol,2010-08-01,"In the design of randomized clinical trials, quality of life (QOL) has become an important component across multiple cancer types. QOL includes the measurement of patient-reported outcomes, mostly described as the physical, social, emotional and functional wellbeing of the patient. These realms of wellbeing are reported by the patient themself and are thought to be a subjective measurement of response to treatment and/or treatment outcomes. Therapeutic interventions such as chemotherapy and/or radiation can thus be monitored from a patient perspective. In addition, while researchers and oncologists may recognize the futility of advanced and/or recurrent cancer therapy in the setting of reduced QOL, patients may have difficulty with discontinuing therapy. QOL research adds to the literature by introducing a patient perspective into the decision to treat aggressively. Specifically, in gynecologic cancers, there is a wide range of outcomes and patient characteristics to be considered. All three cancer settings - endometrial, cervical and ovarian - are remarkable in the QOL literature as this is a relatively new field with room to create interventions targeted towards improving QOL in often challenging clinical and life situations.",Journal Article,3460.0,21.0,In the design of randomized clinical trials quality of life QOL has become an important component across multiple cancer types QOL includes the measurement of patient-reported outcomes mostly described as the physical social emotional and functional wellbeing of the patient These realms of wellbeing are reported by the patient themself and are thought to be a subjective measurement of response to treatment and/or treatment outcomes Therapeutic interventions such as chemotherapy and/or radiation can thus be monitored from a patient perspective In addition while researchers and oncologists may recognize the futility of advanced and/or recurrent cancer therapy in the setting of reduced QOL patients may have difficulty with discontinuing therapy QOL research adds to the literature by introducing a patient perspective into the decision to treat aggressively Specifically in gynecologic cancers there is a wide range of outcomes and patient characteristics to be considered All three cancer settings and are remarkable in the QOL literature as this is a relatively new field with room to create interventions targeted towards improving QOL in often challenging clinical and life situations,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[4, 3, 771, 1, 384, 38, 143, 372, 1, 358, 1001, 71, 1417, 35, 305, 1249, 716, 232, 12, 630, 1001, 1920, 3, 2204, 1, 69, 210, 123, 2754, 1027, 22, 3, 900, 2032, 2671, 2, 583, 19915, 1, 3, 69, 46, 59291, 1, 19915, 32, 210, 20, 3, 69, 59292, 2, 32, 2739, 6, 40, 8, 5571, 2204, 1, 51, 6, 24, 2, 15, 24, 123, 189, 1151, 225, 22, 56, 2, 15, 121, 122, 631, 40, 2909, 29, 8, 69, 3727, 4, 352, 369, 4211, 2, 1339, 68, 4237, 3, 7566, 1, 131, 2, 15, 387, 12, 36, 4, 3, 546, 1, 405, 1001, 7, 68, 47, 4035, 5, 7971, 36, 1001, 389, 6659, 6, 3, 789, 20, 11165, 8, 69, 3727, 237, 3, 948, 6, 943, 8503, 1225, 4, 1512, 163, 125, 16, 8, 1019, 184, 1, 123, 2, 69, 374, 6, 40, 515, 62, 169, 12, 1947, 2, 32, 3813, 4, 3, 1001, 789, 22, 26, 16, 8, 1352, 217, 1067, 5, 4698, 6, 3736, 1151, 238, 3113, 1673, 1001, 4, 629, 1950, 38, 2, 358, 5990]",1195.0,20799874,184
Reliability analysis of the epidural spinal cord compression scale.,Journal of neurosurgery. Spine,J Neurosurg Spine,2010-09-01,"The evolution of imaging techniques, along with highly effective radiation options has changed the way metastatic epidural tumors are treated. While high-grade epidural spinal cord compression (ESCC) frequently serves as an indication for surgical decompression, no consensus exists in the literature about the precise definition of this term. The advancement of the treatment paradigms in patients with metastatic tumors for the spine requires a clear grading scheme of ESCC. The degree of ESCC often serves as a major determinant in the decision to operate or irradiate. The purpose of this study was to determine the reliability and validity of a 6-point, MR imaging-based grading system for ESCC. To determine the reliability of the grading scale, a survey was distributed to 7 spine surgeons who participate in the Spine Oncology Study Group. The MR images of 25 cervical or thoracic spinal tumors were distributed consisting of 1 sagittal image and 3 axial images at the identical level including T1-weighted, T2-weighted, and Gd-enhanced T1-weighted images. The survey was administered 3 times at 2-week intervals. The inter- and intrarater reliability was assessed. The inter- and intrarater reliability ranged from good to excellent when surgeons were asked to rate the degree of spinal cord compression using T2-weighted axial images. The T2-weighted images were superior indicators of ESCC compared with T1-weighted images with and without Gd. The ESCC scale provides a valid and reliable instrument that may be used to describe the degree of ESCC based on T2-weighted MR images. This scale accounts for recent advances in the treatment of spinal metastases and may be used to provide an ESCC classification scheme for multicenter clinical trial and outcome studies.",Journal Article,3429.0,177.0,The evolution of imaging techniques along with highly effective radiation options has changed the way metastatic epidural tumors are treated While high-grade epidural spinal cord compression ESCC frequently serves as an indication for surgical decompression no consensus exists in the literature about the precise definition of this term The advancement of the treatment paradigms in patients with metastatic tumors for the spine requires a clear grading scheme of ESCC The degree of ESCC often serves as a major determinant in the decision to operate or irradiate The purpose of this study was to determine the reliability and validity of a 6-point MR imaging-based grading system for ESCC To determine the reliability of the grading scale a survey was distributed to 7 spine surgeons who participate in the Spine Oncology Study Group The MR images of 25 or thoracic spinal tumors were distributed consisting of 1 sagittal image and 3 axial images at the identical level including T1-weighted T2-weighted and Gd-enhanced T1-weighted images The survey was administered 3 times at 2-week intervals The inter- and intrarater reliability was assessed The inter- and intrarater reliability ranged from good to excellent when surgeons were asked to rate the degree of spinal cord compression using T2-weighted axial images The T2-weighted images were superior indicators of ESCC compared with T1-weighted images with and without Gd The ESCC scale provides a valid and reliable instrument that may be used to describe the degree of ESCC based on T2-weighted MR images This scale accounts for recent advances in the treatment of spinal metastases and may be used to provide an ESCC classification scheme for multicenter clinical trial and outcome studies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 2554, 1, 270, 1092, 1510, 5, 561, 323, 121, 838, 71, 2368, 3, 2255, 113, 5844, 57, 32, 73, 369, 64, 88, 5844, 1499, 1885, 3481, 5681, 746, 4711, 22, 35, 3607, 9, 221, 7638, 77, 1391, 2481, 4, 3, 789, 545, 3, 3260, 2470, 1, 26, 337, 3, 7496, 1, 3, 24, 4887, 4, 7, 5, 113, 57, 9, 3, 2342, 1706, 8, 885, 3452, 4633, 1, 5681, 3, 1444, 1, 5681, 629, 4711, 22, 8, 458, 4372, 4, 3, 948, 6, 15680, 15, 24641, 3, 743, 1, 26, 45, 10, 6, 223, 3, 4217, 2, 3099, 1, 8, 49, 741, 1638, 270, 90, 3452, 398, 9, 5681, 6, 223, 3, 4217, 1, 3, 3452, 1124, 8, 1407, 10, 4737, 6, 67, 2342, 1613, 54, 3506, 4, 3, 2342, 413, 45, 87, 3, 1638, 1572, 1, 243, 15, 2098, 1499, 57, 11, 4737, 2273, 1, 14, 15902, 1482, 2, 27, 5229, 1572, 28, 3, 3038, 301, 141, 1534, 2337, 1786, 2337, 2, 6661, 651, 1534, 2337, 1572, 3, 1407, 10, 468, 27, 1072, 28, 18, 647, 1582, 3, 3606, 2, 28622, 4217, 10, 275, 3, 3606, 2, 28622, 4217, 1869, 29, 1178, 6, 1503, 198, 1613, 11, 3732, 6, 116, 3, 1444, 1, 1499, 1885, 3481, 75, 1786, 2337, 5229, 1572, 3, 1786, 2337, 1572, 11, 1123, 3539, 1, 5681, 72, 5, 1534, 2337, 1572, 5, 2, 187, 6661, 3, 5681, 1124, 777, 8, 4406, 2, 2450, 3877, 17, 68, 40, 95, 6, 897, 3, 1444, 1, 5681, 90, 23, 1786, 2337, 1638, 1572, 26, 1124, 4162, 9, 435, 954, 4, 3, 24, 1, 1499, 196, 2, 68, 40, 95, 6, 377, 35, 5681, 947, 4633, 9, 1570, 38, 160, 2, 228, 94]",1747.0,20809724,79
"A 2-year prospective study assessing the emotional, sexual, and quality of life concerns of women undergoing radical trachelectomy versus radical hysterectomy for treatment of early-stage cervical cancer.",Gynecologic oncology,Gynecol. Oncol.,2010-11-01,"To prospectively assess and describe the emotional, sexual, and QOL concerns of women with early-stage cervical cancer undergoing radical surgery. Seventy-one women who were consented for radical trachelectomy (RT) or radical hysterectomy (RH) were enrolled preoperatively in this 2-year study; 52 women (33 RT; 19 RH) were actively followed. Patients completed self-report surveys composed of 4 empirical measures in addition to exploratory items. Data analyses for the 2 years of prospective data are presented. At preoperative assessment, women choosing RH reported greater concern about cancer recurrence (x=7.27 [scale from 0 to 10]) than women choosing RT (x=5.66) (P=0.008). Forty-eight percent undergoing RH compared to 8.6% undergoing RT reported having adequate ""time to complete childbearing"" (P<0.001). Both groups demonstrated scores suggestive of depression (based on the CES-D scale) and distress (based on the IES scale) preoperatively; over time, however, CES-D and IES scores generally improved. Scores on the Female Sexual Functioning Inventory (FSFI) for the total sample were below the mean cut-off (26.55), suggestive of sexual dysfunction; however, the means increased from 16.79 preoperatively to 23.78 by 12 months and 22.20 at 24 months. Measurements of mood, distress, sexual function, and QOL did not differ significantly by surgical type, and instead reflect the challenges faced by young cervical cancer patients treated by RT or RH without adjuvant treatment. Points of vulnerability were identified in which patients may benefit from preoperative consultation or immediate postoperative support. Overall, patients improved during the first year, reaching a plateau between Year-1 and Year-2, which may reflect a new level of functioning in survivorship.",Journal Article,3368.0,73.0,To prospectively assess and describe the emotional sexual and QOL concerns of women with early-stage cancer undergoing radical surgery Seventy-one women who were consented for radical trachelectomy RT or radical hysterectomy RH were enrolled preoperatively in this 2-year study 52 women 33 RT 19 RH were actively followed Patients completed self-report surveys composed of 4 empirical measures in addition to exploratory items Data analyses for the 2 years of prospective data are presented At preoperative assessment women choosing RH reported greater concern about cancer recurrence x=7.27 scale from 0 to 10 than women choosing RT x=5.66 P=0.008 Forty-eight percent undergoing RH compared to 8.6 undergoing RT reported having adequate `` time to complete childbearing '' P 0.001 Both groups demonstrated scores suggestive of depression based on the CES-D scale and distress based on the IES scale preoperatively over time however CES-D and IES scores generally improved Scores on the Female Sexual Functioning Inventory FSFI for the total sample were below the mean cut-off 26.55 suggestive of sexual dysfunction however the means increased from 16.79 preoperatively to 23.78 by 12 months and 22.20 at 24 months Measurements of mood distress sexual function and QOL did not differ significantly by surgical type and instead reflect the challenges faced by young cancer patients treated by RT or RH without adjuvant treatment Points of vulnerability were identified in which patients may benefit from preoperative consultation or immediate postoperative support Overall patients improved during the first year reaching a plateau between Year-1 and Year-2 which may reflect a new level of functioning in survivorship,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1143, 423, 2, 897, 3, 2671, 2232, 2, 1001, 2061, 1, 117, 5, 191, 82, 12, 479, 711, 152, 2073, 104, 117, 54, 11, 8199, 9, 711, 5760, 240, 15, 711, 2622, 7240, 11, 346, 3888, 4, 26, 18, 111, 45, 653, 117, 466, 240, 326, 7240, 11, 4489, 370, 7, 781, 1074, 414, 3666, 3317, 1, 39, 7273, 1018, 4, 352, 6, 2386, 2980, 74, 318, 9, 3, 18, 60, 1, 482, 74, 32, 917, 28, 498, 455, 117, 5065, 7240, 210, 378, 2893, 545, 12, 146, 1006, 67, 428, 1124, 29, 13, 6, 79, 76, 117, 5065, 240, 1006, 33, 700, 19, 13, 2155, 1213, 659, 714, 479, 7240, 72, 6, 66, 49, 479, 240, 210, 1041, 1658, 98, 6, 236, 10278, 522, 19, 13, 144, 110, 271, 264, 703, 3832, 1, 1774, 90, 23, 3, 9979, 427, 1124, 2, 1462, 90, 23, 3, 12331, 1124, 3888, 252, 98, 137, 9979, 427, 2, 12331, 703, 1228, 231, 703, 23, 3, 1061, 2232, 2702, 3818, 22278, 9, 3, 181, 1000, 11, 2736, 3, 313, 3554, 1889, 432, 614, 3832, 1, 2232, 1527, 137, 3, 2263, 101, 29, 245, 842, 3888, 6, 382, 833, 20, 133, 53, 2, 350, 179, 28, 259, 53, 1685, 1, 5234, 1462, 2232, 343, 2, 1001, 205, 44, 1505, 97, 20, 221, 267, 2, 3496, 2694, 3, 1427, 6933, 20, 1169, 12, 7, 73, 20, 240, 15, 7240, 187, 249, 24, 862, 1, 7665, 11, 108, 4, 92, 7, 68, 247, 29, 498, 2981, 15, 2181, 573, 538, 63, 7, 231, 190, 3, 157, 111, 6168, 8, 6133, 59, 111, 14, 2, 111, 18, 92, 68, 2694, 8, 217, 301, 1, 2702, 4, 2560]",1717.0,20817227,55
Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2010-09-15,"Patients with micrometastasis to para-aortic lymph nodes may benefit from extended field chemoradiation. To determine the rate of para-aortic node micrometastasis in patients with locally advanced cervical cancer undergoing laparoscopic extraperitoneal para-aortic lymphadenectomy. We prospectively identified consecutive patients diagnosed with stage IB2-IVA biopsy-proven cervical cancer. Eligible patients included those who were candidates for treatment with radiotherapy and concurrent chemotherapy and had no evidence of para-aortic lymphadenopathy (all lymph nodes< 2 cm in diameter) by preoperative computed tomography or magnetic resonance imaging. All patients underwent preoperative positron emission tomography/computed tomography and laparoscopic extraperitoneal para-aortic lymphadenectomy. All lymph nodes were assessed for metastasis by routine hematoxylin-eosin (H&E) staining. Ultrastaging (serial sectioning) and immunohistochemical analysis were performed in H&E-negative specimens. Thirteen (22%) of 60 consecutive patients had para-aortic lymph node metastases detected on routine H&E staining. Of the remaining 47 patients, one (2.1%) had evidence of micrometastasis, which was detected by ultrastaging. This patient completed whole pelvic radiotherapy and chemotherapy but had a recurrence 27 months after completion of therapy. The rate of para-aortic node micrometastasis in patients with locally advanced cervical cancer is low. The role of routine ultrastaging and immunohistochemical analysis in such patients remains uncertain. Future studies are needed to determine the clinical impact of para-aortic node micrometastasis in patients with locally advanced cervical cancer.",Clinical Trial,3415.0,25.0,Patients with micrometastasis to para-aortic lymph nodes may benefit from extended field chemoradiation To determine the rate of para-aortic node micrometastasis in patients with locally advanced cancer undergoing laparoscopic extraperitoneal para-aortic lymphadenectomy We prospectively identified consecutive patients diagnosed with stage IB2-IVA biopsy-proven cancer Eligible patients included those who were candidates for treatment with radiotherapy and concurrent chemotherapy and had no evidence of para-aortic lymphadenopathy all lymph nodes 2 cm in diameter by preoperative computed tomography or magnetic resonance imaging All patients underwent preoperative positron emission tomography/computed tomography and laparoscopic extraperitoneal para-aortic lymphadenectomy All lymph nodes were assessed for metastasis by routine hematoxylin-eosin H E staining Ultrastaging serial sectioning and immunohistochemical analysis were performed in H E-negative specimens Thirteen 22 of 60 consecutive patients had para-aortic lymph node metastases detected on routine H E staining Of the remaining 47 patients one 2.1 had evidence of micrometastasis which was detected by ultrastaging This patient completed whole pelvic radiotherapy and chemotherapy but had a recurrence 27 months after completion of therapy The rate of para-aortic node micrometastasis in patients with locally advanced cancer is low The role of routine ultrastaging and immunohistochemical analysis in such patients remains uncertain Future studies are needed to determine the clinical impact of para-aortic node micrometastasis in patients with locally advanced cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[7, 5, 10828, 6, 4615, 3938, 263, 502, 68, 247, 29, 1747, 1067, 975, 6, 223, 3, 116, 1, 4615, 3938, 289, 10828, 4, 7, 5, 795, 131, 12, 479, 1964, 13087, 4615, 3938, 2048, 21, 1143, 108, 935, 7, 265, 5, 82, 9537, 5900, 411, 1930, 12, 625, 7, 159, 135, 54, 11, 1931, 9, 24, 5, 310, 2, 750, 56, 2, 42, 77, 241, 1, 4615, 3938, 4962, 62, 263, 502, 18, 494, 4, 2549, 20, 498, 1220, 872, 15, 1484, 1535, 270, 62, 7, 208, 498, 1900, 1799, 872, 1220, 872, 2, 1964, 13087, 4615, 3938, 2048, 62, 263, 502, 11, 275, 9, 278, 20, 1311, 6209, 5975, 555, 563, 1029, 11338, 2108, 12969, 2, 1382, 65, 11, 173, 4, 555, 563, 199, 623, 3170, 350, 1, 335, 935, 7, 42, 4615, 3938, 263, 289, 196, 530, 23, 1311, 555, 563, 1029, 1, 3, 1844, 662, 7, 104, 18, 14, 42, 241, 1, 10828, 92, 10, 530, 20, 11338, 26, 69, 781, 902, 1110, 310, 2, 56, 84, 42, 8, 146, 428, 53, 50, 1438, 1, 36, 3, 116, 1, 4615, 3938, 289, 10828, 4, 7, 5, 795, 131, 12, 16, 154, 3, 200, 1, 1311, 11338, 2, 1382, 65, 4, 225, 7, 469, 2717, 508, 94, 32, 575, 6, 223, 3, 38, 345, 1, 4615, 3938, 289, 10828, 4, 7, 5, 795, 131, 12]",1639.0,20837355,681
Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.,Gynecologic oncology,Gynecol. Oncol.,2010-09-15,"To assess the differences in health-related quality of life (HRQL) of 4 cisplatin containing doublet chemotherapy combinations in women with advanced/recurrent cervical carcinoma. Patients were randomized to three-week cycles of paclitaxel + cisplatin (PC); vinorelbine + C (VC); gemcitabine + C (GC); or topotecan + C (TC). We report HRQL results from data available on 434 eligible patients enrolled into this 513 patient trial. HRQL was assessed with the Functional Assessment of Cancer Therapy-Cervix (FACT-Cx) the FACT/Gynecologic Oncology Group (FACT/GOG) four-item neurotoxicity scale, and the 0-10 ""worst pain"" item from the Brief Pain Inventory, at baseline (pre-treatment), prior to beginning cycle 2, prior to beginning cycle 5, and at 9 months after enrollment. As reported by Monk et al. (2009) [13] VC, GC and TC were found not to be superior to PC with regard to progression-free survival or overall survival. The trial was terminated early due to planned interim futility analysis, reducing power for HRQL analysis from 85% to 55%. Patients receiving VC, GC and TC doublets did not report significantly different HRQL, neuropathy, or pain from those who received the PC (control) doublet. Patients receiving PC tended to report worse neuropathy during treatment than patients who received other doublets (especially GC and TC), but the differences were not statistically significant. None of the 3 experimental doublets was different from PC in terms of HRQL during treatment. Long-term toxicity data are inconclusive. Except where patients may wish to reduce their risk of worsening pre-treatment neuropathy, PC remains the standard of care for this disease.",Journal Article,3415.0,26.0,To assess the differences in health-related quality of life HRQL of 4 cisplatin containing doublet chemotherapy combinations in women with advanced/recurrent carcinoma Patients were randomized to three-week cycles of paclitaxel cisplatin PC vinorelbine C VC gemcitabine C GC or topotecan C TC We report HRQL results from data available on 434 eligible patients enrolled into this 513 patient trial HRQL was assessed with the Functional Assessment of Cancer Therapy-Cervix FACT-Cx the FACT/Gynecologic Oncology Group FACT/GOG four-item neurotoxicity scale and the 0-10 `` worst pain '' item from the Brief Pain Inventory at baseline pre-treatment prior to beginning cycle 2 prior to beginning cycle 5 and at 9 months after enrollment As reported by Monk et al 2009 13 VC GC and TC were found not to be superior to PC with regard to progression-free survival or overall survival The trial was terminated early due to planned interim futility analysis reducing power for HRQL analysis from 85 to 55 Patients receiving VC GC and TC doublets did not report significantly different HRQL neuropathy or pain from those who received the PC control doublet Patients receiving PC tended to report worse neuropathy during treatment than patients who received other doublets especially GC and TC but the differences were not statistically significant None of the 3 experimental doublets was different from PC in terms of HRQL during treatment Long-term toxicity data are inconclusive Except where patients may wish to reduce their risk of worsening pre-treatment neuropathy PC remains the standard of care for this disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 423, 3, 362, 4, 341, 139, 372, 1, 358, 7332, 1, 39, 540, 1101, 4872, 56, 1247, 4, 117, 5, 131, 387, 134, 7, 11, 384, 6, 169, 647, 410, 1, 490, 540, 1341, 3676, 256, 11468, 679, 256, 1709, 15, 2129, 256, 3072, 21, 414, 7332, 99, 29, 74, 390, 23, 11483, 625, 7, 346, 237, 26, 11895, 69, 160, 7332, 10, 275, 5, 3, 583, 455, 1, 12, 36, 3629, 1991, 13627, 3, 1991, 1512, 413, 87, 1991, 4760, 294, 3471, 3561, 1124, 2, 3, 13, 79, 4066, 559, 522, 3471, 29, 3, 3190, 559, 3818, 28, 330, 671, 24, 324, 6, 2948, 417, 18, 324, 6, 2948, 417, 33, 2, 28, 83, 53, 50, 1798, 22, 210, 20, 59325, 2022, 2171, 1238, 233, 11468, 1709, 2, 3072, 11, 204, 44, 6, 40, 1123, 6, 1341, 5, 2539, 6, 91, 115, 25, 15, 63, 25, 3, 160, 10, 5640, 191, 520, 6, 1465, 2914, 7566, 65, 1818, 2349, 9, 7332, 65, 29, 772, 6, 614, 7, 357, 11468, 1709, 2, 3072, 9097, 205, 44, 414, 97, 338, 7332, 1751, 15, 559, 29, 135, 54, 103, 3, 1341, 182, 4872, 7, 357, 1341, 3886, 6, 414, 639, 1751, 190, 24, 76, 7, 54, 103, 127, 9097, 1093, 1709, 2, 3072, 84, 3, 362, 11, 44, 712, 93, 1292, 1, 3, 27, 1560, 9097, 10, 338, 29, 1341, 4, 1794, 1, 7332, 190, 24, 319, 337, 155, 74, 32, 6791, 2187, 1257, 7, 68, 11443, 6, 969, 136, 43, 1, 4323, 671, 24, 1751, 1341, 469, 3, 260, 1, 165, 9, 26, 34]",1609.0,20837359,42
Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study.,Annals of internal medicine,Ann. Intern. Med.,2010-10-01,"Survivors of childhood cancer may develop a second malignant neoplasm during adulthood and therefore require regular surveillance. To examine adherence to population cancer screening guidelines by survivors at average risk for a second malignant neoplasm and adherence to cancer surveillance guidelines by survivors at high risk for a second malignant neoplasm. Retrospective cohort study. The Childhood Cancer Survivor Study (CCSS), a 26-center study of long-term survivors of childhood cancer that was diagnosed between 1970 and 1986. 4329 male and 4018 female survivors of childhood cancer who completed a CCSS questionnaire assessing screening and surveillance for new cases of cancer. Patient-reported receipt and timing of mammography, Papanicolaou smear, colonoscopy, or skin examination was categorized as adherent to the U.S. Preventive Services Task Force guidelines for survivors at average risk for breast or cervical cancer or the Children's Oncology Group guidelines for survivors at high risk for breast, colorectal, or skin cancer as a result of cancer therapy. In average-risk female survivors, 2743 of 3392 (80.9%) reported having a Papanicolaou smear within the recommended period, and 140 of 209 (67.0%) reported mammography within the recommended period. In high-risk survivors, rates of recommended mammography among women were only 241 of 522 (46.2%) and the rates of colonoscopy and complete skin examinations among both sexes were 91 of 794 (11.5%) and 1290 of 4850 (26.6%), respectively. Data were self-reported. Participants in the CCSS are a selected group of survivors, and their adherence may not be representative of all survivors of childhood cancer. Female survivors at average risk for a second malignant neoplasm show reasonable rates of screening for cervical and breast cancer. However, surveillance for new cases of cancer is very low in survivors at the highest risk for colon, breast, or skin cancer, suggesting that survivors and their physicians need education about their risks and recommended surveillance. The National Cancer Institute, National Institutes of Health, and the American Lebanese Syrian Associated Charities.",Journal Article,3399.0,69.0,Survivors of childhood cancer may develop a second malignant neoplasm during adulthood and therefore require regular surveillance To examine adherence to population cancer screening guidelines by survivors at average risk for a second malignant neoplasm and adherence to cancer surveillance guidelines by survivors at high risk for a second malignant neoplasm Retrospective cohort study The Childhood Cancer Survivor Study CCSS a 26-center study of long-term survivors of childhood cancer that was diagnosed between 1970 and 1986 4329 male and 4018 female survivors of childhood cancer who completed a CCSS questionnaire assessing screening and surveillance for new cases of cancer Patient-reported receipt and timing of mammography Papanicolaou smear colonoscopy or examination was categorized as adherent to the U.S. Preventive Services Task Force guidelines for survivors at average risk for or cancer or the Children 's Oncology Group guidelines for survivors at high risk for or cancer as a result of cancer therapy In average-risk female survivors 2743 of 3392 80.9 reported having a Papanicolaou smear within the recommended period and 140 of 209 67.0 reported mammography within the recommended period In high-risk survivors rates of recommended mammography among women were only 241 of 522 46.2 and the rates of colonoscopy and complete examinations among both sexes were 91 of 794 11.5 and 1290 of 4850 26.6 respectively Data were self-reported Participants in the CCSS are a selected group of survivors and their adherence may not be representative of all survivors of childhood cancer Female survivors at average risk for a second malignant neoplasm show reasonable rates of screening for and cancer However surveillance for new cases of cancer is very low in survivors at the highest risk for or cancer suggesting that survivors and their physicians need education about their risks and recommended surveillance The National Cancer Institute National Institutes of Health and the American Lebanese Syrian Associated Charities,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,"[332, 1, 864, 12, 68, 690, 8, 419, 393, 2131, 190, 6002, 2, 673, 1353, 3316, 617, 6, 1004, 2149, 6, 266, 12, 453, 677, 20, 332, 28, 1011, 43, 9, 8, 419, 393, 2131, 2, 2149, 6, 12, 617, 677, 20, 332, 28, 64, 43, 9, 8, 419, 393, 2131, 459, 180, 45, 3, 864, 12, 2628, 45, 4657, 8, 432, 574, 45, 1, 319, 337, 332, 1, 864, 12, 17, 10, 265, 59, 4868, 2, 3751, 46260, 1045, 2, 59418, 1061, 332, 1, 864, 12, 54, 781, 8, 4657, 1770, 1977, 453, 2, 617, 9, 217, 140, 1, 12, 69, 210, 1699, 2, 1972, 1, 2446, 10416, 8379, 3996, 15, 1385, 10, 2320, 22, 7010, 6, 3, 1767, 695, 3494, 2142, 3488, 4380, 677, 9, 332, 28, 1011, 43, 9, 15, 12, 15, 3, 541, 292, 413, 87, 677, 9, 332, 28, 64, 43, 9, 15, 12, 22, 8, 757, 1, 12, 36, 4, 1011, 43, 1061, 332, 59419, 1, 46261, 493, 83, 210, 1041, 8, 10416, 8379, 262, 3, 793, 727, 2, 3304, 1, 5941, 598, 13, 210, 2446, 262, 3, 793, 727, 4, 64, 43, 332, 151, 1, 793, 2446, 107, 117, 11, 158, 7086, 1, 9741, 641, 18, 2, 3, 151, 1, 3996, 2, 236, 4209, 107, 110, 13771, 11, 970, 1, 13085, 175, 33, 2, 24957, 1, 59420, 432, 49, 106, 74, 11, 1074, 210, 776, 4, 3, 4657, 32, 8, 715, 87, 1, 332, 2, 136, 2149, 68, 44, 40, 3724, 1, 62, 332, 1, 864, 12, 1061, 332, 28, 1011, 43, 9, 8, 419, 393, 2131, 514, 3203, 151, 1, 453, 9, 2, 12, 137, 617, 9, 217, 140, 1, 12, 16, 923, 154, 4, 332, 28, 3, 1076, 43, 9, 15, 12, 802, 17, 332, 2, 136, 1261, 594, 1848, 545, 136, 1098, 2, 793, 617, 3, 657, 12, 1377, 657, 5973, 1, 341, 2, 3, 597, 14666, 13671, 41, 14667]",2038.0,20921543,59
"Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs.",Nutrition and cancer,Nutr Cancer,2010-01-01,"Curcumin (diferuloylmethane), the yellow pigment in Indian saffron (Curcuma longa; also called turmeric, haldi, or haridara in the East and curry powder in the West), has been consumed by people for centuries as a dietary component and for a variety of proinflammatory ailments. Extensive research within the last decade in cell culture and in rodents has revealed that curcumin can sensitize tumors to different chemotherapeutic agents including doxorubicin, 5-FU, paclitaxel, vincristine, melphalan, butyrate, cisplatin, celecoxib, vinorelbine, gemcitabine, oxaliplatin, etoposide, sulfinosine, thalidomide, and bortezomib. Chemosensitization has been observed in cancers of the breast, colon, pancreas, gastric, liver, blood, lung, prostate, bladder, cervix, ovary, head and neck, and brain and in multiple myeloma, leukemia, and lymphoma. Similar studies have also revealed that this agent can sensitize a variety of tumors to gamma radiation including glioma, neuroblastoma, cervical carcinoma, epidermal carcinoma, prostate cancer, and colon cancer. How curcumin acts as a chemosensitizer and radiosensitizer has also been studied extensively. For example, it downregulates various growth regulatory pathways and specific genetic targets including genes for NF-B, STAT3, COX2, Akt, antiapoptotic proteins, growth factor receptors, and multidrug-resistance proteins. Although it acts as a chemosensitizer and radiosensitizer for tumors in some cases, curcumin has also been shown to protect normal organs such as liver, kidney, oral mucosa, and heart from chemotherapy and radiotherapy-induced toxicity. The protective effects of curcumin appear to be mediated through its ability to induce the activation of NRF2 and induce the expression of antioxidant enzymes (e.g., hemeoxygenase-1, glutathione peroxidase, modulatory subunit of gamma-glutamyl-cysteine ligase, and NAD(P)H:quinone oxidoreductase 1, increase glutathione (a product of the modulatory subunit of gamma-glutamyl-cysteine ligase), directly quench free radicals, and inhibit p300 HAT activity. These preclinical studies are expected to lead to clinical trials to prove the potential of this age-old golden spice for treating cancer patients.",Journal Article,3672.0,303.0,Curcumin diferuloylmethane the yellow pigment in Indian saffron Curcuma longa also called turmeric haldi or haridara in the East and curry powder in the West has been consumed by people for centuries as a dietary component and for a variety of proinflammatory ailments Extensive research within the last decade in cell culture and in rodents has revealed that curcumin can sensitize tumors to different chemotherapeutic agents including doxorubicin 5-FU paclitaxel vincristine melphalan butyrate cisplatin celecoxib vinorelbine gemcitabine oxaliplatin etoposide sulfinosine thalidomide and bortezomib Chemosensitization has been observed in cancers of the blood cervix ovary head and and brain and in multiple and Similar studies have also revealed that this agent can sensitize a variety of tumors to gamma radiation including glioma carcinoma epidermal carcinoma cancer and cancer How curcumin acts as a chemosensitizer and radiosensitizer has also been studied extensively For example it downregulates various growth regulatory pathways and specific genetic targets including genes for NF-B STAT3 COX2 Akt antiapoptotic proteins growth factor receptors and multidrug-resistance proteins Although it acts as a chemosensitizer and radiosensitizer for tumors in some cases curcumin has also been shown to protect normal organs such as oral mucosa and from chemotherapy and radiotherapy-induced toxicity The protective effects of curcumin appear to be mediated through its ability to induce the activation of NRF2 and induce the expression of antioxidant enzymes e.g. hemeoxygenase-1 glutathione peroxidase modulatory subunit of gamma-glutamyl-cysteine ligase and NAD P H quinone oxidoreductase 1 increase glutathione a product of the modulatory subunit of gamma-glutamyl-cysteine ligase directly quench free radicals and inhibit p300 HAT activity These preclinical studies are expected to lead to clinical trials to prove the potential of this age-old golden spice for treating cancer patients,1,1,1,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,"[3775, 24733, 3, 17826, 14524, 4, 7968, 59423, 39071, 39072, 120, 3472, 19471, 46266, 15, 59424, 4, 3, 6633, 2, 34232, 9984, 4, 3, 7261, 71, 85, 8028, 20, 3788, 9, 22509, 22, 8, 2013, 1249, 2, 9, 8, 1362, 1, 5767, 29072, 1344, 389, 262, 3, 1060, 2025, 4, 31, 2099, 2, 4, 16696, 71, 553, 17, 3775, 122, 5745, 57, 6, 338, 1573, 183, 141, 856, 33, 1296, 490, 2132, 2370, 12285, 540, 2673, 3676, 679, 1476, 1934, 59425, 2159, 2, 819, 13594, 71, 85, 164, 4, 163, 1, 3, 315, 3629, 3631, 718, 2, 2, 342, 2, 4, 232, 2, 288, 94, 47, 120, 553, 17, 26, 420, 122, 5745, 8, 1362, 1, 57, 6, 1705, 121, 141, 945, 134, 829, 134, 12, 2, 12, 832, 3775, 4459, 22, 8, 23796, 2, 8853, 71, 120, 85, 656, 3576, 9, 2685, 192, 11265, 747, 129, 1253, 460, 2, 112, 336, 637, 141, 214, 9, 1365, 2448, 1439, 8069, 649, 4176, 652, 129, 161, 1186, 2, 4814, 251, 652, 242, 192, 4459, 22, 8, 23796, 2, 8853, 9, 57, 4, 476, 140, 3775, 71, 120, 85, 443, 6, 4869, 295, 2285, 225, 22, 518, 2713, 2, 29, 56, 2, 310, 277, 155, 3, 2864, 176, 1, 3775, 1322, 6, 40, 517, 298, 211, 801, 6, 1290, 3, 363, 1, 5731, 2, 1290, 3, 55, 1, 5536, 3039, 563, 499, 59426, 14, 4571, 14747, 11424, 3350, 1, 1705, 15867, 6943, 5839, 2, 11597, 19, 555, 19517, 18836, 14, 344, 4571, 8, 2821, 1, 3, 11424, 3350, 1, 1705, 15867, 6943, 5839, 1606, 46267, 115, 18292, 2, 1433, 10685, 18347, 128, 46, 693, 94, 32, 1336, 6, 1122, 6, 38, 143, 6, 4361, 3, 174, 1, 26, 89, 1095, 28387, 26028, 9, 1367, 12, 7]",1994.0,20924967,157
Anti-carcinogenic effects of sulforaphane in association with its apoptosis-inducing and anti-inflammatory properties in human cervical cancer cells.,Cancer epidemiology,Cancer Epidemiol,2010-10-16,"The multistep process of carcinogenesis is characterized by progressive disorganization and occurrence of initiation, promotion, and progression events. Several new strategies such as chemoprevention are being developed for treatment and prevention at various stages of carcinogenesis. Sulforaphane, a potential chemopreventive agent, possesses anti-proliferative, anti-inflammatory, anti-oxidant and anti-cancer activities and has attracted extensive interest for better cancer management. We evaluated the effect of sulforaphane alone or in combination with gemcitabine on HeLa cells by cell viability assay and confirmed the results by apoptosis assay. Further we analyzed the effect of sulforaphane on the expression of Bcl-2, COX-2 and IL-1 by RT-PCR on HeLa cells. In the present study, sulforaphane was found to induce dose-dependent selective cytotoxicity in HeLa cells in comparison to normal cells pointing to its safe cytotoxicity profile. Additionally, a combination of sulforaphane and gemcitabine was found to increase the growth inhibition in a synergistic manner in HeLa cells compared to the individual drugs. Also, the expression analysis of genes involved in apoptosis and inflammation revealed significant downregulation of Bcl-2, COX-2 and IL-1 upon treatment with sulforaphane. Our results suggest that sulforaphane exerts its anticancer activities via apoptosis induction and anti-inflammatory properties and provides the first evidence demonstrating synergism between sulforaphane and gemcitabine which may enhance the therapeutic index of prevention and/or treatment of cervical cancer.",Journal Article,3384.0,31.0,The multistep process of carcinogenesis is characterized by progressive disorganization and occurrence of initiation promotion and progression events Several new strategies such as chemoprevention are being developed for treatment and prevention at various stages of carcinogenesis Sulforaphane a potential chemopreventive agent possesses anti-proliferative anti-inflammatory anti-oxidant and anti-cancer activities and has attracted extensive interest for better cancer management We evaluated the effect of sulforaphane alone or in combination with gemcitabine on HeLa cells by cell viability assay and confirmed the results by apoptosis assay Further we analyzed the effect of sulforaphane on the expression of Bcl-2 COX-2 and IL-1 by RT-PCR on HeLa cells In the present study sulforaphane was found to induce dose-dependent selective cytotoxicity in HeLa cells in comparison to normal cells pointing to its safe cytotoxicity profile Additionally a combination of sulforaphane and gemcitabine was found to increase the growth inhibition in a synergistic manner in HeLa cells compared to the individual drugs Also the expression analysis of genes involved in apoptosis and inflammation revealed significant downregulation of Bcl-2 COX-2 and IL-1 upon treatment with sulforaphane Our results suggest that sulforaphane exerts its anticancer activities via apoptosis induction and anti-inflammatory properties and provides the first evidence demonstrating synergism between sulforaphane and gemcitabine which may enhance the therapeutic index of prevention and/or treatment of cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 9417, 1129, 1, 1719, 16, 765, 20, 1014, 39452, 2, 2291, 1, 1118, 5478, 2, 91, 281, 392, 217, 422, 225, 22, 2886, 32, 486, 276, 9, 24, 2, 1070, 28, 747, 1153, 1, 1719, 9510, 8, 174, 4401, 420, 9857, 312, 2441, 312, 1291, 312, 13322, 2, 312, 12, 2042, 2, 71, 14439, 1344, 1333, 9, 380, 12, 284, 21, 194, 3, 254, 1, 9510, 279, 15, 4, 150, 5, 679, 23, 8466, 37, 20, 31, 2120, 719, 2, 557, 3, 99, 20, 351, 719, 195, 21, 311, 3, 254, 1, 9510, 23, 3, 55, 1, 1044, 18, 418, 18, 2, 501, 8215, 20, 240, 604, 23, 8466, 37, 4, 3, 364, 45, 9510, 10, 204, 6, 1290, 61, 470, 1094, 1408, 4, 8466, 37, 4, 1155, 6, 295, 37, 11548, 6, 211, 1165, 1408, 800, 1724, 8, 150, 1, 9510, 2, 679, 10, 204, 6, 344, 3, 129, 297, 4, 8, 1806, 1708, 4, 8466, 37, 72, 6, 3, 797, 600, 120, 3, 55, 65, 1, 214, 646, 4, 351, 2, 1815, 553, 93, 2475, 1, 1044, 18, 418, 18, 2, 501, 8215, 1548, 24, 5, 9510, 114, 99, 309, 17, 9510, 5685, 211, 1475, 2042, 847, 351, 504, 2, 312, 1291, 1571, 2, 777, 3, 157, 241, 2219, 6494, 59, 9510, 2, 679, 92, 68, 1304, 3, 189, 558, 1, 1070, 2, 15, 24, 1, 12]",1584.0,20956097,525
The presence of human papillomavirus or p16 in six cases of retroperitoneal carcinoma.,Obstetrics and gynecology,Obstet Gynecol,2010-11-01,"To describe six cases of unknown primary carcinoma of the retroperitoneum that were positive for human papillomavirus (HPV), a surrogate molecular marker for high-risk HPV (p16), or both. Using the MD Anderson pathology database, females with confirmed HPV or p16 expression within retroperitoneal carcinomas of unknown primary were identified. Clinical data were collected by retrospective chart review. One pathologist reviewed all histology. Individuals with known primary were excluded. Data regarding individual demographics, presentation, Pap test history, pathology, HPV and p16 positivity, and outcome were analyzed using descriptive statistics. Six individuals were identified. The median age of the individuals was 43.5 years (range 27-54). Three malignancies (50%) were squamous and three (50%) were undifferentiated. Median follow-up was 12 months (range 6-48 months). Two of the six (33%) individuals had remote histories (more than 10 years) of abnormal Pap test results. All had normal gynecologic examination and Pap test results at diagnosis. Four tumors were HPV-positive (66%) and six were p16-positive (100%). All samples that were HPV-positive were also p16-positive. All individuals underwent treatment with chemotherapy, radiation, or both. One individual underwent initial attempt at resection that was unsuccessful. Two individuals are without evidence of disease, two have had progression of disease, and two have died of their disease. Pelvic masses of unknown primary may be HPV-related despite normal cervical examinations. III.",Journal Article,3368.0,4.0,To describe six cases of unknown primary carcinoma of the retroperitoneum that were positive for human papillomavirus HPV a surrogate molecular marker for high-risk HPV p16 or both Using the MD Anderson pathology database females with confirmed HPV or p16 expression within retroperitoneal carcinomas of unknown primary were identified Clinical data were collected by retrospective chart review One pathologist reviewed all histology Individuals with known primary were excluded Data regarding individual demographics presentation Pap test history pathology HPV and p16 positivity and outcome were analyzed using descriptive statistics Six individuals were identified The median age of the individuals was 43.5 years range 27-54 Three malignancies 50 were squamous and three 50 were undifferentiated Median follow-up was 12 months range 6-48 months Two of the six 33 individuals had remote histories more than 10 years of abnormal Pap test results All had normal gynecologic examination and Pap test results at diagnosis Four tumors were HPV-positive 66 and six were p16-positive 100 All samples that were HPV-positive were also p16-positive All individuals underwent treatment with chemotherapy radiation or both One individual underwent initial attempt at resection that was unsuccessful Two individuals are without evidence of disease two have had progression of disease and two have died of their disease Pelvic masses of unknown primary may be HPV-related despite normal examinations III,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 897, 437, 140, 1, 860, 86, 134, 1, 3, 7765, 17, 11, 109, 9, 171, 3242, 933, 8, 2592, 219, 952, 9, 64, 43, 933, 1932, 15, 110, 75, 3, 2244, 1929, 1117, 609, 2451, 5, 557, 933, 15, 1932, 55, 262, 2591, 826, 1, 860, 86, 11, 108, 38, 74, 11, 786, 20, 459, 2937, 206, 104, 5093, 446, 62, 784, 869, 5, 440, 86, 11, 1800, 74, 666, 797, 2221, 1031, 4290, 412, 532, 1117, 933, 2, 1932, 1887, 2, 228, 11, 311, 75, 3778, 3065, 437, 869, 11, 108, 3, 52, 89, 1, 3, 869, 10, 601, 33, 60, 184, 428, 667, 169, 441, 212, 11, 691, 2, 169, 212, 11, 4480, 52, 166, 126, 10, 133, 53, 184, 49, 576, 53, 100, 1, 3, 437, 466, 869, 42, 9879, 5329, 80, 76, 79, 60, 1, 1668, 4290, 412, 99, 62, 42, 295, 1512, 1385, 2, 4290, 412, 99, 28, 147, 294, 57, 11, 933, 109, 700, 2, 437, 11, 1932, 109, 394, 62, 347, 17, 11, 933, 109, 11, 120, 1932, 109, 62, 869, 208, 24, 5, 56, 121, 15, 110, 104, 797, 208, 388, 3448, 28, 170, 17, 10, 7581, 100, 869, 32, 187, 241, 1, 34, 100, 47, 42, 91, 1, 34, 2, 100, 47, 1016, 1, 136, 34, 1110, 2692, 1, 860, 86, 68, 40, 933, 139, 550, 295, 4209, 316]",1492.0,20966687,730
Chemoradiotherapy for cervical cancer in 2010.,Current oncology reports,Curr Oncol Rep,2011-02-01,"The introduction of concurrent chemotherapy and radiotherapy for the definitive treatment of cervical cancer constituted a major advance in the management of cervical cancer, resulting in a significant improvement in local control, progression-free survival, and overall survival. Since the publication of the results of seminal trials demonstrating the benefits of platinum-based chemotherapy, investigations of new cytotoxic and targeting agents have continued. The success of these studies has been limited in part because the side effects of standard platinum-based chemoradiation regimens already approach the limits of tolerability. Future progress will depend on identifying new agents without overlapping toxic effects, improving supportive care, and minimizing the toxic effects of radiation.",Journal Article,3276.0,30.0,The introduction of concurrent chemotherapy and radiotherapy for the definitive treatment of cancer constituted a major advance in the management of cancer resulting in a significant improvement in local control progression-free survival and overall survival Since the publication of the results of seminal trials demonstrating the benefits of platinum-based chemotherapy investigations of new cytotoxic and targeting agents have continued The success of these studies has been limited in part because the side effects of standard platinum-based chemoradiation regimens already approach the limits of tolerability Future progress will depend on identifying new agents without overlapping toxic effects improving supportive care and minimizing the toxic effects of radiation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 2456, 1, 750, 56, 2, 310, 9, 3, 1057, 24, 1, 12, 8917, 8, 458, 3148, 4, 3, 284, 1, 12, 1113, 4, 8, 93, 767, 4, 293, 182, 91, 115, 25, 2, 63, 25, 1192, 3, 4397, 1, 3, 99, 1, 4786, 143, 2219, 3, 1141, 1, 828, 90, 56, 2492, 1, 217, 759, 2, 529, 183, 47, 1351, 3, 1825, 1, 46, 94, 71, 85, 383, 4, 760, 408, 3, 1152, 176, 1, 260, 828, 90, 975, 472, 3298, 353, 3, 3526, 1, 1543, 508, 1466, 303, 4533, 23, 1386, 217, 183, 187, 4551, 1812, 176, 1673, 1877, 165, 2, 4501, 3, 1812, 176, 1, 121]",773.0,21042887,162
Limited utility of magnetic resonance imaging in determining the primary site of disease in patients with inconclusive endometrial biopsy.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2010-11-01,"To evaluate the utility of preoperative magnetic resonance imaging (MRI) in determining whether primary disease site is cervical or endometrial in patients with inconclusive preoperative endometrial biopsy. We retrospectively identified all patients who underwent pelvic MRI and who had a preoperative diagnosis of cervical or endometrial cancer at MD Anderson Cancer Center between 1990 and 2006. The subset in which endometrial biopsy did not clarify the primary disease site was analyzed. Magnetic resonance imaging results were compared with postoperative histopathologic findings. A total of 168 patients who underwent MRI who had a preoperative diagnosis of cervical or endometrial cancer were identified. Of these patients, 51 had an inconclusive endometrial biopsy. Magnetic resonance imaging suggested an endometrial primary tumor without cervical invasion in 28 patients, of whom 21 (75%) actually had such a tumor and 7 had an endometrial primary tumor with cervical invasion. Magnetic resonance imaging suggested an endometrial primary tumor with cervical invasion in 3 patients, all of whom had such a tumor. Magnetic resonance imaging suggested a cervical primary tumor in 6 patients, of whom 5 had such a tumor and 1 had an endometrial primary tumor without cervical invasion. Magnetic resonance imaging was inconclusive (did not clarify primary disease site or no lesion visualized) in 14 (27%) of 51 patients, 6 of whom had an endocervical primary tumor or an endometrial tumor with cervical involvement. Overall, preoperative MRI was either inaccurate or unhelpful in 22 (43%) of 51 patients. Preoperative MRI in patients with inconclusive endometrial biopsy is inaccurate or unhelpful in nearly half of patients.",Comparative Study,3368.0,6.0,To evaluate the utility of preoperative magnetic resonance imaging MRI in determining whether primary disease site is or in patients with inconclusive preoperative biopsy We retrospectively identified all patients who underwent pelvic MRI and who had a preoperative diagnosis of or cancer at MD Anderson Cancer Center between 1990 and 2006 The subset in which biopsy did not clarify the primary disease site was analyzed Magnetic resonance imaging results were compared with postoperative histopathologic findings A total of 168 patients who underwent MRI who had a preoperative diagnosis of or cancer were identified Of these patients 51 had an inconclusive biopsy Magnetic resonance imaging suggested an primary tumor without invasion in 28 patients of whom 21 75 actually had such a tumor and 7 had an primary tumor with invasion Magnetic resonance imaging suggested an primary tumor with invasion in 3 patients all of whom had such a tumor Magnetic resonance imaging suggested a primary tumor in 6 patients of whom 5 had such a tumor and 1 had an primary tumor without invasion Magnetic resonance imaging was inconclusive did not clarify primary disease site or no lesion visualized in 14 27 of 51 patients 6 of whom had an endocervical primary tumor or an tumor with involvement Overall preoperative MRI was either inaccurate or unhelpful in 22 43 of 51 patients Preoperative MRI in patients with inconclusive biopsy is inaccurate or unhelpful in nearly half of patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 376, 3, 1207, 1, 498, 1484, 1535, 270, 704, 4, 2196, 317, 86, 34, 606, 16, 15, 4, 7, 5, 6791, 498, 411, 21, 894, 108, 62, 7, 54, 208, 1110, 704, 2, 54, 42, 8, 498, 147, 1, 15, 12, 28, 2244, 1929, 12, 574, 59, 2289, 2, 1324, 3, 697, 4, 92, 411, 205, 44, 3968, 3, 86, 34, 606, 10, 311, 1484, 1535, 270, 99, 11, 72, 5, 573, 2630, 272, 8, 181, 1, 5359, 7, 54, 208, 704, 54, 42, 8, 498, 147, 1, 15, 12, 11, 108, 1, 46, 7, 725, 42, 35, 6791, 411, 1484, 1535, 270, 1148, 35, 86, 30, 187, 578, 4, 339, 7, 1, 953, 239, 481, 6742, 42, 225, 8, 30, 2, 67, 42, 35, 86, 30, 5, 578, 1484, 1535, 270, 1148, 35, 86, 30, 5, 578, 4, 27, 7, 62, 1, 953, 42, 225, 8, 30, 1484, 1535, 270, 1148, 8, 86, 30, 4, 49, 7, 1, 953, 33, 42, 225, 8, 30, 2, 14, 42, 35, 86, 30, 187, 578, 1484, 1535, 270, 10, 6791, 205, 44, 3968, 86, 34, 606, 15, 77, 1180, 6326, 4, 213, 428, 1, 725, 7, 49, 1, 953, 42, 35, 10174, 86, 30, 15, 35, 30, 5, 799, 63, 498, 704, 10, 361, 8791, 15, 35002, 4, 350, 601, 1, 725, 7, 498, 704, 4, 7, 5, 6791, 411, 16, 8791, 15, 35002, 4, 1857, 1303, 1, 7]",1475.0,21051975,657
Dosimetric comparison study between intensity modulated radiation therapy and three-dimensional conformal proton therapy for pelvic bone marrow sparing in the treatment of cervical cancer.,Journal of applied clinical medical physics,J Appl Clin Med Phys,2010-08-15,"The objective was to compare intensity-modulated radiation therapy (IMRT) with 3D conformal proton therapy (3DCPT) in the treatment of cervical cancer. In particular, each technique's ability to spare pelvic bone marrow (PBM) was of primary interest in this study. A total of six cervical cancer patients (3 postoperative and 3 intact) were planned and analyzed. All plans had uniform 1.0 cm CTV-PTV margin and satisfied the 95% PTV with 100% isodose (prescription dose = 45 Gy) coverage. Dose-volume histograms (DVH) were analyzed for comparison. The overall PTV and PBM volumes were 1035.9  192.2 cc and 1151.4  198.3 cc, respectively. In terms of PTV dose conformity index (DCI) and dose homogeneity index (DHI), 3DCPT was slightly superior to IMRT with 1.00  0.001, 1.01  0.02, and 1.10  0.02, 1.13  0.01, respectively. In addition, 3DCPT demonstrated superiority in reducing lower doses (i.e., V30 or less) to PBM, small bowel and bladder. Particularly in PBM, average V10 and V20 reductions of 10.8% and 7.4% (p = 0.001 and 0.04), respectively, were observed. However, in the higher dose range, IMRT provided better sparing (> V30). For example, in small bowel and PBM, average reductions in V45 of 4.9% and 10.0% (p = 0.048 and 0.008), respectively, were observed. Due to its physical characteristics such as low entrance dose, spread-out Bragg peak and finite particle range of protons, 3DCPT illustrated superior target coverage uniformity and sparing of the lower doses in PBM and other organs. Further studies are, however, needed to fully exploit the benefits of protons for general use in cervical cancer.",Comparative Study,3446.0,20.0,The objective was to compare intensity-modulated radiation therapy IMRT with 3D conformal proton therapy 3DCPT in the treatment of cancer In particular each technique 's ability to spare pelvic marrow PBM was of primary interest in this study A total of six cancer patients 3 postoperative and 3 intact were planned and analyzed All plans had uniform 1.0 cm CTV-PTV margin and satisfied the 95 PTV with 100 isodose prescription dose 45 Gy coverage Dose-volume histograms DVH were analyzed for comparison The overall PTV and PBM volumes were 1035.9  192.2 cc and 1151.4  198.3 cc respectively In terms of PTV dose conformity index DCI and dose homogeneity index DHI 3DCPT was slightly superior to IMRT with 1.00  0.001 1.01  0.02 and 1.10  0.02 1.13  0.01 respectively In addition 3DCPT demonstrated superiority in reducing lower doses i.e. V30 or less to PBM small bowel and Particularly in PBM average V10 and V20 reductions of 10.8 and 7.4 p 0.001 and 0.04 respectively were observed However in the higher dose range IMRT provided better sparing V30 For example in small bowel and PBM average reductions in V45 of 4.9 and 10.0 p 0.048 and 0.008 respectively were observed Due to its physical characteristics such as low entrance dose spread-out Bragg peak and finite particle range of protons 3DCPT illustrated superior target coverage uniformity and sparing of the lower doses in PBM and other organs Further studies are however needed to fully exploit the benefits of protons for general use in cancer,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,"[3, 461, 10, 6, 932, 837, 1757, 121, 36, 964, 5, 2265, 2972, 2095, 36, 35008, 4, 3, 24, 1, 12, 4, 1454, 296, 1312, 292, 801, 6, 8539, 1110, 581, 9215, 10, 1, 86, 1333, 4, 26, 45, 8, 181, 1, 437, 12, 7, 27, 573, 2, 27, 2964, 11, 1465, 2, 311, 62, 1853, 42, 3490, 14, 13, 494, 3402, 3303, 959, 2, 7411, 3, 48, 3303, 5, 394, 8945, 3584, 61, 512, 381, 2139, 61, 433, 8638, 8255, 11, 311, 9, 1155, 3, 63, 3303, 2, 9215, 2225, 11, 28784, 83, 810, 5016, 18, 1951, 2, 39474, 39, 810, 6189, 27, 1951, 106, 4, 1794, 1, 3303, 61, 8693, 558, 59546, 2, 61, 7502, 558, 59547, 35008, 10, 3223, 1123, 6, 964, 5, 14, 2038, 810, 13, 144, 14, 355, 810, 13, 588, 2, 14, 79, 810, 13, 588, 14, 233, 810, 13, 355, 106, 4, 352, 35008, 264, 5233, 4, 1818, 280, 415, 70, 563, 14613, 15, 299, 6, 9215, 302, 1659, 2, 823, 4, 9215, 1011, 10724, 2, 8120, 2153, 1, 79, 66, 2, 67, 39, 19, 13, 144, 2, 13, 755, 106, 11, 164, 137, 4, 3, 142, 61, 184, 964, 1052, 380, 1851, 14613, 9, 2685, 4, 302, 1659, 2, 9215, 1011, 2153, 4, 16984, 1, 39, 83, 2, 79, 13, 19, 13, 4969, 2, 13, 2155, 106, 11, 164, 520, 6, 211, 900, 374, 225, 22, 154, 22540, 61, 2579, 1205, 31700, 2944, 2, 14612, 5997, 184, 1, 6684, 35008, 8508, 1123, 283, 2139, 9338, 2, 1851, 1, 3, 280, 415, 4, 9215, 2, 127, 2285, 195, 94, 32, 137, 575, 6, 1910, 6109, 3, 1141, 1, 6684, 9, 1083, 119, 4, 12]",1511.0,21081882,819
Daily online cone beam computed tomography to assess interfractional motion in patients with intact cervical cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2010-11-23,"To quantify interfraction motion in patients with intact cervical cancer and assess implications for clinical target volume (CTV) coverage and required planning margins. We analyzed 10 patients undergoing external beam radiotherapy using online cone beam computed tomography (CBCT) before each fraction. CTVs were contoured on the planning CT and on each CBCT. Each CBCT was rigidly registered to the planning CT with respect to bony anatomy. The CTV from each CBCT was projected onto the planning CT and compared to the CTV from the planning CT. Uniform three-dimensional expansions were applied to the planning CTV to assess required planning margins. For each fraction, the minimum margin required to encompass the CTV was calculated, and the volume of CTV (on the CBCT) encompassed by the PTV was determined as a function of margin size. A uniform CTV planning treatment volume margin of 15 mm would have failed to encompass the CTV in 32% of fractions. The mean volume of CTV missed, however, was small (4 cc). The mean planning margin (across patients and fractions) required to encompass the CTV was 15 mm. Variation in margin estimates was high, with interpatient variation being the predominant component. Increased rectal volume was associated with posterior (p < 0.0001) and superior (p = 0.0004) shifts in the CTV, whereas increased bladder volume was associated with superior shifts (p < 0.0001). Interfraction motion results in a high probability of missing the CTV using conventional planning margins, but the volume of CTV missed is small. Adaptive radiotherapy approaches are needed to improve treatment accuracy.",Journal Article,3346.0,46.0,To quantify interfraction motion in patients with intact cancer and assess implications for clinical target volume CTV coverage and required planning margins We analyzed 10 patients undergoing external beam radiotherapy using online cone beam computed tomography CBCT before each fraction CTVs were contoured on the planning CT and on each CBCT Each CBCT was rigidly registered to the planning CT with respect to bony anatomy The CTV from each CBCT was projected onto the planning CT and compared to the CTV from the planning CT Uniform three-dimensional expansions were applied to the planning CTV to assess required planning margins For each fraction the minimum margin required to encompass the CTV was calculated and the volume of CTV on the CBCT encompassed by the PTV was determined as a function of margin size A uniform CTV planning treatment volume margin of 15 mm would have failed to encompass the CTV in 32 of fractions The mean volume of CTV missed however was small 4 cc The mean planning margin across patients and fractions required to encompass the CTV was 15 mm Variation in margin estimates was high with interpatient variation being the predominant component Increased volume was associated with posterior p 0.0001 and superior p 0.0004 shifts in the CTV whereas increased volume was associated with superior shifts p 0.0001 Interfraction motion results in a high probability of missing the CTV using conventional planning margins but the volume of CTV missed is small Adaptive radiotherapy approaches are needed to improve treatment accuracy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,"[6, 3091, 13610, 2967, 4, 7, 5, 2964, 12, 2, 423, 1268, 9, 38, 283, 433, 3402, 2139, 2, 616, 1349, 1012, 21, 311, 79, 7, 479, 1455, 1345, 310, 75, 4123, 6939, 1345, 1220, 872, 5187, 348, 296, 1509, 14256, 11, 6476, 23, 3, 1349, 425, 2, 23, 296, 5187, 296, 5187, 10, 39481, 1653, 6, 3, 1349, 425, 5, 2184, 6, 6552, 5081, 3, 3402, 29, 296, 5187, 10, 5633, 3301, 3, 1349, 425, 2, 72, 6, 3, 3402, 29, 3, 1349, 425, 3490, 169, 2201, 12384, 11, 1498, 6, 3, 1349, 3402, 6, 423, 616, 1349, 1012, 9, 296, 1509, 3, 2499, 959, 616, 6, 8454, 3, 3402, 10, 981, 2, 3, 433, 1, 3402, 23, 3, 5187, 9226, 20, 3, 3303, 10, 509, 22, 8, 343, 1, 959, 444, 8, 3490, 3402, 1349, 24, 433, 959, 1, 167, 321, 688, 47, 1551, 6, 8454, 3, 3402, 4, 531, 1, 1550, 3, 313, 433, 1, 3402, 5149, 137, 10, 302, 39, 1951, 3, 313, 1349, 959, 716, 7, 2, 1550, 616, 6, 8454, 3, 3402, 10, 167, 321, 1380, 4, 959, 1423, 10, 64, 5, 7423, 1380, 486, 3, 2750, 1249, 101, 433, 10, 41, 5, 3028, 19, 13, 488, 2, 1123, 19, 13, 5295, 5906, 4, 3, 3402, 547, 101, 433, 10, 41, 5, 1123, 5906, 19, 13, 488, 13610, 2967, 99, 4, 8, 64, 1320, 1, 4593, 3, 3402, 75, 809, 1349, 1012, 84, 3, 433, 1, 3402, 5149, 16, 302, 2454, 310, 611, 32, 575, 6, 401, 24, 1190]",1562.0,21109360,696
Biologics in cervical cancer therapy.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2010-12-01,"Though cervical cancer incidence and prevalence have decreased in the United States, the disease remains a very important cause of morbidity and mortality worldwide. Current therapy for early-stage disease is surgical with adjuvant therapy being administered according to histopathologic findings. Pelvic radiation with concomitant platinum-based chemotherapy is used to treat locally advanced disease, whereas metastatic and recurrent lesions continue to be difficult to effectively treat and cure. Clinical trials in this latter scenario have suggested that clinical benefit may be associated with biologic therapies. This article focuses on the use of targeted therapies in cervical cancer, specifically evaluating antiangiogenesis and endothelial growth factor receptor-related treatments.",Journal Article,3338.0,,Though cancer incidence and prevalence have decreased in the United States the disease remains a very important cause of morbidity and mortality worldwide Current therapy for early-stage disease is surgical with adjuvant therapy being administered according to histopathologic findings Pelvic radiation with concomitant platinum-based chemotherapy is used to treat locally advanced disease whereas metastatic and recurrent lesions continue to be difficult to effectively treat and cure Clinical trials in this latter scenario have suggested that clinical benefit may be associated with biologic therapies This article focuses on the use of targeted therapies in cancer specifically evaluating antiangiogenesis and endothelial growth factor receptor-related treatments,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2471, 12, 287, 2, 1078, 47, 340, 4, 3, 1088, 907, 3, 34, 469, 8, 923, 305, 708, 1, 787, 2, 282, 2358, 291, 36, 9, 191, 82, 34, 16, 221, 5, 249, 36, 486, 468, 768, 6, 2630, 272, 1110, 121, 5, 1781, 828, 90, 56, 16, 95, 6, 943, 795, 131, 34, 547, 113, 2, 387, 406, 1906, 6, 40, 1740, 6, 1856, 943, 2, 1722, 38, 143, 4, 26, 3286, 5456, 47, 1148, 17, 38, 247, 68, 40, 41, 5, 1283, 235, 26, 946, 3026, 23, 3, 119, 1, 238, 235, 4, 12, 1225, 1435, 7351, 2, 845, 129, 161, 153, 139, 640]",767.0,21147904,335
Fertility-sparing surgery in early-stage cervical cancer: indications and applications.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2010-12-01,"This article describes the surgical and pathologic findings of fertility-sparing radical trachelectomy using a standardized surgical technique, and reports the rate of posttrachelectomy outcomes. The authors analyzed a prospectively maintained database of all patients with FIGO stage IA1-IB1 cervical cancer admitted to the operating room for planned fertility-sparing radical abdominal trachelectomy. Sentinel node mapping was performed through cervical injection. Between November 2001 and May 2010, 98 consecutive patients with FIGO stage IA1-IB1 cervical cancer and a median age of 32 years (range, 6-45 years) underwent a fertility-sparing radical trachelectomy. The most common histology was adenocarcinoma in 54 patients (55%) and squamous carcinoma in 42 (43%). Lymph-vascular invasion was seen in 38 patients (39%). FIGO stages included IA1 (with lymph-vascular invasion) in 10 patients (10%), IA2 in 9 (9%), and IB1 in 79 (81%). Only 15 (15%) needed immediate completion radical hysterectomy because of intraoperative findings. Median number of nodes evaluated was 22 (range, 3-54), and 16 (16%) patients had positive pelvic nodes on final pathology. Final trachelectomy pathology showed no residual disease in 44 (45%) cases, dysplasia in 5 (5%), and adenocarcinoma in situ in 3 (3%). Overall, 27 (27%) patients needed hysterectomy or adjuvant pelvic radiation postoperatively. One (1%) documented recurrence was fatal at the time of this report. Cervical adenocarcinoma and lymph-vascular invasion are common features of patients selected for radical trachelectomy. Most patients can undergo the operation successfully with many having no residual invasive disease; however, nearly 27% of all selected cases will require hysterectomy or postoperative chemoradiation for oncologic reasons. Investigation into alternative fertility-sparing adjuvant therapy in patients with node-positive disease is needed.",Journal Article,3338.0,,This article describes the surgical and pathologic findings of fertility-sparing radical trachelectomy using a standardized surgical technique and reports the rate of posttrachelectomy outcomes The authors analyzed a prospectively maintained database of all patients with FIGO stage IA1-IB1 cancer admitted to the operating room for planned fertility-sparing radical abdominal trachelectomy Sentinel node mapping was performed through injection Between November 2001 and May 2010 98 consecutive patients with FIGO stage IA1-IB1 cancer and a median age of 32 years range 6-45 years underwent a fertility-sparing radical trachelectomy The most common histology was adenocarcinoma in 54 patients 55 and squamous carcinoma in 42 43 Lymph-vascular invasion was seen in 38 patients 39 FIGO stages included IA1 with lymph-vascular invasion in 10 patients 10 IA2 in 9 9 and IB1 in 79 81 Only 15 15 needed immediate completion radical hysterectomy because of intraoperative findings Median number of nodes evaluated was 22 range 3-54 and 16 16 patients had positive pelvic nodes on final pathology Final trachelectomy pathology showed no residual disease in 44 45 cases dysplasia in 5 5 and adenocarcinoma in situ in 3 3 Overall 27 27 patients needed hysterectomy or adjuvant pelvic radiation postoperatively One 1 documented recurrence was fatal at the time of this report adenocarcinoma and lymph-vascular invasion are common features of patients selected for radical trachelectomy Most patients can undergo the operation successfully with many having no residual invasive disease however nearly 27 of all selected cases will require hysterectomy or postoperative chemoradiation for oncologic reasons Investigation into alternative fertility-sparing adjuvant therapy in patients with node-positive disease is needed,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[26, 946, 2677, 3, 221, 2, 510, 272, 1, 2954, 1851, 711, 5760, 75, 8, 1670, 221, 1312, 2, 1198, 3, 116, 1, 59626, 123, 3, 738, 311, 8, 1143, 1955, 609, 1, 62, 7, 5, 3837, 82, 14517, 8111, 12, 4319, 6, 3, 2584, 4698, 9, 1465, 2954, 1851, 711, 1467, 5760, 1323, 289, 2568, 10, 173, 298, 1754, 59, 2868, 1758, 2, 68, 1120, 1096, 935, 7, 5, 3837, 82, 14517, 8111, 12, 2, 8, 52, 89, 1, 531, 60, 184, 49, 512, 60, 208, 8, 2954, 1851, 711, 5760, 3, 96, 186, 784, 10, 449, 4, 667, 7, 614, 2, 691, 134, 4, 595, 601, 263, 756, 578, 10, 527, 4, 519, 7, 587, 3837, 1153, 159, 14517, 5, 263, 756, 578, 4, 79, 7, 79, 16725, 4, 83, 83, 2, 8111, 4, 842, 865, 158, 167, 167, 575, 2181, 1438, 711, 2622, 408, 1, 1720, 272, 52, 207, 1, 502, 194, 10, 350, 184, 27, 667, 2, 245, 245, 7, 42, 109, 1110, 502, 23, 1457, 1117, 1457, 5760, 1117, 224, 77, 753, 34, 4, 584, 512, 140, 2253, 4, 33, 33, 2, 449, 4, 957, 4, 27, 27, 63, 428, 428, 7, 575, 2622, 15, 249, 1110, 121, 3541, 104, 14, 1405, 146, 10, 3034, 28, 3, 98, 1, 26, 414, 449, 2, 263, 756, 578, 32, 186, 404, 1, 7, 715, 9, 711, 5760, 96, 7, 122, 1251, 3, 2589, 1878, 5, 445, 1041, 77, 753, 416, 34, 137, 1857, 428, 1, 62, 715, 140, 303, 1353, 2622, 15, 573, 975, 9, 1998, 2325, 940, 237, 1091, 2954, 1851, 249, 36, 4, 7, 5, 289, 109, 34, 16, 575]",1808.0,21147906,246
Outcomes of patients undergoing radical hysterectomy for cervical cancer of high-risk histological subtypes.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2011-01-01,"The most common types of cervical cancer are squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma, referred to here collectively as SA cervical cancer. Other types of cervical cancer, referred to here collectively as nonsquamous/nonadenocarcinoma (NSNA) cervical cancer, include neuroendocrine, small cell, clear cell, sarcomatoid, and serous tumors. Anecdotally, NSNA tumors seem to have a worse prognosis than their SA counterparts. We sought to determine whether patients with early-stage NSNA have a worse prognosis than those with early-stage SA cervical cancer. We retrospectively reviewed charts of women with stage IA1-IB2 NSNA cervical cancer treated by radical hysterectomy and lymph node staging at M. D. Anderson Cancer Center from 1990 to 2006. The NSNA patients were matched 1:2 to patients with grade 3 SA lesions on the basis of stage, age at diagnosis, tumor size, and date of diagnosis. Eighteen patients with NSNA primary cervical cancer subtypes (neuroendocrine [n = 7], small cell [n = 5], clear cell [n = 4], papillary serous [n = 1], and sarcomatoid [n = 1]) were matched to 36 patients with grade 3 SA lesions. There were no differences between the 2 groups in age, body mass index, clinical stage, or lesion size. The 2 groups also did not differ with respect to number of nodes resected, lymphovascular space invasion, margin status, lymph node metastasis, or adjuvant radiation therapy or chemotherapy. At a median follow-up of 44 months, median progression-free and overall survivals had not been reached; however, both progression-free survival (P = 0.018) and overall survival (P = 0.028) were worse for the NSNA group. The 5-year progression-free and overall survival rates were 61.2% and 67.6%, respectively, for the NSNA group, compared with 90.1% and 88.3%, respectively, for the SA group. Patients with early-stage NSNA cervical cancer undergoing radical hysterectomy and pelvic lymphadenectomy have a worse prognosis than patients with grade 3 SA lesions. Patients with NSNA tumors may require a multimodality approach to their cancer care.",Journal Article,3307.0,10.0,The most common types of cancer are squamous cell carcinoma adenocarcinoma and adenosquamous carcinoma referred to here collectively as SA cancer Other types of cancer referred to here collectively as nonsquamous/nonadenocarcinoma NSNA cancer include neuroendocrine small cell clear cell sarcomatoid and serous tumors Anecdotally NSNA tumors seem to have a worse prognosis than their SA counterparts We sought to determine whether patients with early-stage NSNA have a worse prognosis than those with early-stage SA cancer We retrospectively reviewed charts of women with stage IA1-IB2 NSNA cancer treated by radical hysterectomy and lymph node staging at M. D. Anderson Cancer Center from 1990 to 2006 The NSNA patients were matched 1:2 to patients with grade 3 SA lesions on the basis of stage age at diagnosis tumor size and date of diagnosis Eighteen patients with NSNA primary cancer subtypes neuroendocrine n 7 small cell n 5 clear cell n 4 papillary serous n 1 and sarcomatoid n 1 were matched to 36 patients with grade 3 SA lesions There were no differences between the 2 groups in age body mass index clinical stage or lesion size The 2 groups also did not differ with respect to number of nodes resected lymphovascular space invasion margin status lymph node metastasis or adjuvant radiation therapy or chemotherapy At a median follow-up of 44 months median progression-free and overall survivals had not been reached however both progression-free survival P 0.018 and overall survival P 0.028 were worse for the NSNA group The 5-year progression-free and overall survival rates were 61.2 and 67.6 respectively for the NSNA group compared with 90.1 and 88.3 respectively for the SA group Patients with early-stage NSNA cancer undergoing radical hysterectomy and pelvic lymphadenectomy have a worse prognosis than patients with grade 3 SA lesions Patients with NSNA tumors may require a multimodality approach to their cancer care,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 96, 186, 630, 1, 12, 32, 691, 31, 134, 449, 2, 8067, 134, 1995, 6, 467, 2535, 22, 4913, 12, 127, 630, 1, 12, 1995, 6, 467, 2535, 22, 6218, 16946, 22647, 12, 643, 1542, 302, 31, 885, 31, 3912, 2, 1744, 57, 17876, 22647, 57, 3233, 6, 47, 8, 639, 356, 76, 136, 4913, 3953, 21, 990, 6, 223, 317, 7, 5, 191, 82, 22647, 47, 8, 639, 356, 76, 135, 5, 191, 82, 4913, 12, 21, 894, 446, 4413, 1, 117, 5, 82, 14517, 9537, 22647, 12, 73, 20, 711, 2622, 2, 263, 289, 632, 28, 188, 427, 1929, 12, 574, 29, 2289, 6, 1324, 3, 22647, 7, 11, 655, 14, 18, 6, 7, 5, 88, 27, 4913, 406, 23, 3, 877, 1, 82, 89, 28, 147, 30, 444, 2, 1244, 1, 147, 3195, 7, 5, 22647, 86, 12, 814, 1542, 78, 67, 302, 31, 78, 33, 885, 31, 78, 39, 1796, 1744, 78, 14, 2, 3912, 78, 14, 11, 655, 6, 511, 7, 5, 88, 27, 4913, 406, 125, 11, 77, 362, 59, 3, 18, 271, 4, 89, 642, 782, 558, 38, 82, 15, 1180, 444, 3, 18, 271, 120, 205, 44, 1505, 5, 2184, 6, 207, 1, 502, 1133, 2933, 3865, 578, 959, 156, 263, 289, 278, 15, 249, 121, 36, 15, 56, 28, 8, 52, 166, 126, 1, 584, 53, 52, 91, 115, 2, 63, 3794, 42, 44, 85, 1300, 137, 110, 91, 115, 25, 19, 13, 4047, 2, 63, 25, 19, 13, 4836, 11, 639, 9, 3, 22647, 87, 3, 33, 111, 91, 115, 2, 63, 25, 151, 11, 713, 18, 2, 598, 49, 106, 9, 3, 22647, 87, 72, 5, 424, 14, 2, 889, 27, 106, 9, 3, 4913, 87, 7, 5, 191, 82, 22647, 12, 479, 711, 2622, 2, 1110, 2048, 47, 8, 639, 356, 76, 7, 5, 88, 27, 4913, 406, 7, 5, 22647, 57, 68, 1353, 8, 2425, 353, 6, 136, 12, 165]",1939.0,21178574,461
Glioneuronal tumor with neuropil-like islands of the spinal cord with diffuse leptomeningeal neuraxis dissemination.,Journal of neuro-oncology,J. Neurooncol.,2010-12-25,"A 54-year-old Caucasian female presented with a 1year history of intermittent numbness of the left leg progressing to bilateral, lower extremity sensory loss that advanced to include impaired vibration and proprioception. The subsequent thoracic spine magnetic resonance imaging (MRI) scan revealed a heterogeneous, avidly enhancing, centrally situated spinal cord mass involving T7 through T10 in association with thick linear enhancement of the anterior and posterior cord surfaces extending both superiorly and inferiorly. Both the cervical and lumbar spine MRI demonstrated diffuse leptomeningeal disease as well. A brain MRI revealed focal leptomeningeal enhancement in the left and right sylvian fissures, the suprasellar cistern, and the posterior fossa; a pattern consistent with metastatic disease. The patient underwent a T6-T10 laminectomy for tumor biopsy and debulking. Histology revealed a WHO grade III glioneuronal tumor with rosetted neuropil-like islands. Synaptophysin and neurofilament (NF) positive staining was noted within the neural appearing component, whereas, glial fibrillary acidic protein (GFAP) immunopositivity was evident in the fibrillary astrocytoma component of the tumor. The Ki-67 labeling index was 7%. This tumor pattern, now included in the 2007 World Health Organization (WHO) classification of central nervous system tumours as a pattern variation of anaplastic astrocytoma (Kleihues et al. In: Louis et al. (eds) WHO classification of tumours of the central nervous system, 2007), was first described in a four-case series by Teo et al. in 1999. The majority of subsequently reported cases described them as primary tumors of the cerebrum. Herein, we report a unique example of a spinal glioneuronal tumor with neuropil-like islands with associated leptomeningeal dissemination involving the entire craniospinal axis.",Case Reports,3314.0,14.0,A 54-year-old Caucasian female presented with a 1 year history of intermittent numbness of the left leg progressing to bilateral lower extremity sensory loss that advanced to include impaired vibration and proprioception The subsequent thoracic spine magnetic resonance imaging MRI scan revealed a heterogeneous avidly enhancing centrally situated spinal cord mass involving T7 through T10 in association with thick linear enhancement of the anterior and posterior cord surfaces extending both superiorly and inferiorly Both the and lumbar spine MRI demonstrated diffuse leptomeningeal disease as well A brain MRI revealed focal leptomeningeal enhancement in the left and right sylvian fissures the suprasellar cistern and the posterior fossa a pattern consistent with metastatic disease The patient underwent a T6-T10 laminectomy for tumor biopsy and debulking Histology revealed a WHO grade III glioneuronal tumor with rosetted neuropil-like islands Synaptophysin and neurofilament NF positive staining was noted within the neural appearing component whereas glial fibrillary acidic protein GFAP immunopositivity was evident in the fibrillary astrocytoma component of the tumor The Ki-67 labeling index was 7 This tumor pattern now included in the 2007 World Health Organization WHO classification of central nervous system tumours as a pattern variation of anaplastic astrocytoma Kleihues et al In Louis et al eds WHO classification of tumours of the central nervous system 2007 was first described in a four-case series by Teo et al in 1999 The majority of subsequently reported cases described them as primary tumors of the cerebrum Herein we report a unique example of a spinal glioneuronal tumor with neuropil-like islands with associated leptomeningeal dissemination involving the entire craniospinal axis,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[8, 667, 111, 1095, 3229, 1061, 917, 5, 8, 14, 111, 532, 1, 4102, 8655, 1, 3, 1712, 10873, 4527, 6, 1607, 280, 2678, 4148, 407, 17, 131, 6, 643, 2364, 46381, 2, 46382, 3, 706, 2098, 2342, 1484, 1535, 270, 704, 1657, 553, 8, 1564, 26558, 2430, 4604, 18207, 1499, 1885, 782, 1267, 20192, 298, 19625, 4, 248, 5, 8494, 1646, 2461, 1, 3, 2882, 2, 3028, 1885, 8835, 4782, 110, 25125, 2, 25313, 110, 3, 2, 6187, 2342, 704, 264, 1388, 4948, 34, 22, 149, 8, 342, 704, 553, 2137, 4948, 2461, 4, 3, 1712, 2, 1913, 59681, 38741, 3, 13122, 39504, 2, 3, 3028, 5100, 8, 1177, 925, 5, 113, 34, 3, 69, 208, 8, 46383, 19625, 16891, 9, 30, 411, 2, 3556, 784, 553, 8, 54, 88, 316, 16411, 30, 5, 59682, 26815, 733, 6046, 12161, 2, 20495, 1365, 109, 1029, 10, 1051, 262, 3, 3922, 6536, 1249, 547, 6944, 19106, 8961, 178, 13154, 18964, 10, 2853, 4, 3, 19106, 3822, 1249, 1, 3, 30, 3, 2311, 598, 3383, 558, 10, 67, 26, 30, 1177, 1134, 159, 4, 3, 1307, 1956, 341, 2533, 54, 947, 1, 854, 1880, 398, 1319, 22, 8, 1177, 1380, 1, 1841, 3822, 59683, 2022, 2171, 4, 34853, 2022, 2171, 18017, 54, 947, 1, 1319, 1, 3, 854, 1880, 398, 1307, 10, 157, 1027, 4, 8, 294, 473, 988, 20, 59684, 2022, 2171, 4, 2043, 3, 686, 1, 1611, 210, 140, 1027, 1370, 22, 86, 57, 1, 3, 20722, 1986, 21, 414, 8, 991, 2685, 1, 8, 1499, 16411, 30, 5, 26815, 733, 6046, 5, 41, 4948, 3430, 1267, 3, 1797, 5748, 2310]",1813.0,21188469,159
Sentinel lymph node biopsy in the management of early-stage cervical carcinoma.,Gynecologic oncology,Gynecol. Oncol.,2011-01-08,"We aimed to determine the sentinel lymph node detection rates, accuracy in predicting the status of lymph node metastasis, and if pathologic ultrastaging improves the detection of micrometastases and isolated tumor cells at the time of primary surgery for cervical cancer. A prospective, non-randomized study of women with early-stage (FIGO stage IA1 with lymphovascular space involvement--IIA) cervical carcinoma was conducted from June 2003 to August 2009. All patients underwent an intraoperative intracervical blue dye injection. Patients who underwent a preoperative lymphoscintigraphy received a 99m Tc sulfur colloid injection in addition. All patients underwent sentinel lymph node (SLN) identification followed by a complete pelvic node and parametrial dissection. SLN were evaluated using our institutional protocol that included pathologic ultrastaging. SLN mapping was successful in 77 (95%) of 81 patients. A total of 316 SLN were identified, with a median of 3 SLN per patient (range, 0-10 SLN). The majority (85%) of SLN were located at three main sites: the external iliac (35%); internal iliac (30%); and obturator (20%). Positive lymph nodes (LN) were identified in 26 (32%) patients, including 21 patients with positive SLN. Fifteen of 21 patients (71%) had SLN metastasis detected on routine processing. SLN ultrastaging detected metastasis in an additional 6/21 patients (29%). Two patients had grossly positive LN at exploration, and mapping was abandoned. Three of 26 (12%) patients had successful SLN mapping; however, the SLN failed to identify the metastatic LN. Of these 3 false negative cases, 2 patients had a metastatic parametrial node as the only positive LN with multiple negative pelvic nodes including negative SLN. One patient with stage IA1 disease and lymphovascular invasion had unilateral SLN mapping and a metastatic common iliac LN identified on completion lymphadenectomy of the contralateral side that did not map. The 4 (5%) patients with unsuccessful mapping included 1 who had grossly positive nodes identified at the time of laparotomy; the remaining 3 occurred during each surgeon's initial SLN mapping learning phase. SLN mapping in early-stage cervical carcinoma yields high detection rates. Ultrastaging improves micrometastasis detection. Parametrectomy and side-specific lymphadenectomy (in cases of failed mapping) remain important components of the surgical management of selected cases.",Journal Article,3300.0,49.0,We aimed to determine the sentinel lymph node detection rates accuracy in predicting the status of lymph node metastasis and if pathologic ultrastaging improves the detection of micrometastases and isolated tumor cells at the time of primary surgery for cancer A prospective non-randomized study of women with early-stage FIGO stage IA1 with lymphovascular space involvement -- IIA carcinoma was conducted from June 2003 to August 2009 All patients underwent an intraoperative intracervical blue dye injection Patients who underwent a preoperative lymphoscintigraphy received a 99m Tc sulfur colloid injection in addition All patients underwent sentinel lymph node SLN identification followed by a complete pelvic node and parametrial dissection SLN were evaluated using our institutional protocol that included pathologic ultrastaging SLN mapping was successful in 77 95 of 81 patients A total of 316 SLN were identified with a median of 3 SLN per patient range 0-10 SLN The majority 85 of SLN were located at three main sites the external iliac 35 internal iliac 30 and obturator 20 Positive lymph nodes LN were identified in 26 32 patients including 21 patients with positive SLN Fifteen of 21 patients 71 had SLN metastasis detected on routine processing SLN ultrastaging detected metastasis in an additional 6/21 patients 29 Two patients had grossly positive LN at exploration and mapping was abandoned Three of 26 12 patients had successful SLN mapping however the SLN failed to identify the metastatic LN Of these 3 false negative cases 2 patients had a metastatic parametrial node as the only positive LN with multiple negative pelvic nodes including negative SLN One patient with stage IA1 disease and lymphovascular invasion had unilateral SLN mapping and a metastatic common iliac LN identified on completion lymphadenectomy of the contralateral side that did not map The 4 5 patients with unsuccessful mapping included 1 who had grossly positive nodes identified at the time of laparotomy the remaining 3 occurred during each surgeon 's initial SLN mapping learning phase SLN mapping in early-stage carcinoma yields high detection rates Ultrastaging improves micrometastasis detection Parametrectomy and side-specific lymphadenectomy in cases of failed mapping remain important components of the surgical management of selected cases,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 1295, 6, 223, 3, 1323, 263, 289, 638, 151, 1190, 4, 1434, 3, 156, 1, 263, 289, 278, 2, 492, 510, 11338, 1804, 3, 638, 1, 5485, 2, 1355, 30, 37, 28, 3, 98, 1, 86, 152, 9, 12, 8, 482, 220, 384, 45, 1, 117, 5, 191, 82, 3837, 82, 14517, 5, 2933, 3865, 799, 4088, 134, 10, 426, 29, 1924, 1522, 6, 2480, 1238, 62, 7, 208, 35, 1720, 33970, 3352, 3796, 1754, 7, 54, 208, 8, 498, 6849, 103, 8, 6314, 3072, 10266, 7245, 1754, 4, 352, 62, 7, 208, 1323, 263, 289, 1099, 911, 370, 20, 8, 236, 1110, 289, 2, 8726, 1161, 1099, 11, 194, 75, 114, 1115, 1182, 17, 159, 510, 11338, 1099, 2568, 10, 1401, 4, 849, 48, 1, 865, 7, 8, 181, 1, 8500, 1099, 11, 108, 5, 8, 52, 1, 27, 1099, 379, 69, 184, 13, 79, 1099, 3, 686, 772, 1, 1099, 11, 2308, 28, 169, 1895, 633, 3, 1455, 6692, 465, 2329, 6692, 201, 2, 12698, 179, 109, 263, 502, 1763, 11, 108, 4, 432, 531, 7, 141, 239, 7, 5, 109, 1099, 3057, 1, 239, 7, 792, 42, 1099, 278, 530, 23, 1311, 3325, 1099, 11338, 530, 278, 4, 35, 402, 49, 239, 7, 462, 100, 7, 42, 7185, 109, 1763, 28, 3370, 2, 2568, 10, 13015, 169, 1, 432, 133, 7, 42, 1401, 1099, 2568, 137, 3, 1099, 1551, 6, 255, 3, 113, 1763, 1, 46, 27, 2133, 199, 140, 18, 7, 42, 8, 113, 8726, 289, 22, 3, 158, 109, 1763, 5, 232, 199, 1110, 502, 141, 199, 1099, 104, 69, 5, 82, 14517, 34, 2, 2933, 578, 42, 3208, 1099, 2568, 2, 8, 113, 186, 6692, 1763, 108, 23, 1438, 2048, 1, 3, 2138, 1152, 17, 205, 44, 3771, 3, 39, 33, 7, 5, 7581, 2568, 159, 14, 54, 42, 7185, 109, 502, 108, 28, 3, 98, 1, 3274, 3, 1844, 27, 489, 190, 296, 1897, 292, 388, 1099, 2568, 3434, 124, 1099, 2568, 4, 191, 82, 134, 4788, 64, 638, 151, 11338, 1804, 10828, 638, 23693, 2, 1152, 112, 2048, 4, 140, 1, 1551, 2568, 918, 305, 1628, 1, 3, 221, 284, 1, 715, 140]",2345.0,21216450,25
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.,Molecular cancer therapeutics,Mol. Cancer Ther.,2011-01-07,"Preclinical data suggest that PIK3CA mutations predict response to PI3K/AKT/mTOR inhibitors. Concomitant KRAS or BRAF mutations may mediate resistance. Therefore, tumors from patients referred to the phase I program for targeted therapy starting in October 2008 were analyzed for PIK3CA mutations using PCR-based DNA sequencing of exons 9 and 20. Consecutive patients with diverse tumor types and PIK3CA mutation were treated whenever possible with agents targeting the PI3K/AKT/mTOR pathway. Overall, PIK3CA mutations were detected in 25 of 217 patients (11.5%; exon 9, n = 11; exon 20, n = 14). In tumor types with more than 10 patients tested, PIK3CA mutations were most frequent in endometrial (3 of 14, 21%), ovarian (5 of 30, 17%), colorectal (9 of 54, 17%), breast (2 of 14, 14%), cervical (2 of 15, 13%), and squamous cell cancer of the head and neck (1 of 11, 9%). Of the 25 patients with PIK3CA mutations, 17 (68%) were treated on a protocol that included a PI3K/AKT/mTOR pathway inhibitor, and 6 (35%) achieved a partial response. In contrast, only 15 of 241 patients (6%) without documented PIK3CA mutations treated on the same protocols responded (P = 0.001). Of the 17 patients with PIK3CA mutations, 6 (35%) had simultaneous KRAS or BRAF mutations (colorectal, n = 4; ovarian, n = 2). Colorectal cancer patients with PIK3CA and KRAS mutations did not respond to therapy, whereas both ovarian cancer patients with PIK3CA and KRAS or BRAF mutations did. In conclusion, PIK3CA mutations were detected in 11.5% of patients with diverse solid tumors. The response rate was significantly higher for patients with PIK3CA mutations treated with PI3K/AKT/mTOR pathway inhibitors than for those without documented mutations.",Journal Article,3301.0,254.0,Preclinical data suggest that PIK3CA mutations predict response to PI3K/AKT/mTOR inhibitors Concomitant KRAS or BRAF mutations may mediate resistance Therefore tumors from patients referred to the phase I program for targeted therapy starting in October 2008 were analyzed for PIK3CA mutations using PCR-based DNA sequencing of exons 9 and 20 Consecutive patients with diverse tumor types and PIK3CA mutation were treated whenever possible with agents targeting the PI3K/AKT/mTOR pathway Overall PIK3CA mutations were detected in 25 of 217 patients 11.5 exon 9 n 11 exon 20 n 14 In tumor types with more than 10 patients tested PIK3CA mutations were most frequent in 3 of 14 21 5 of 30 17 9 of 54 17 2 of 14 14 2 of 15 13 and squamous cell cancer of the head and 1 of 11 9 Of the 25 patients with PIK3CA mutations 17 68 were treated on a protocol that included a PI3K/AKT/mTOR pathway inhibitor and 6 35 achieved a partial response In contrast only 15 of 241 patients 6 without documented PIK3CA mutations treated on the same protocols responded P 0.001 Of the 17 patients with PIK3CA mutations 6 35 had simultaneous KRAS or BRAF mutations n 4 n 2 cancer patients with PIK3CA and KRAS mutations did not respond to therapy whereas both cancer patients with PIK3CA and KRAS or BRAF mutations did In conclusion PIK3CA mutations were detected in 11.5 of patients with diverse solid tumors The response rate was significantly higher for patients with PIK3CA mutations treated with PI3K/AKT/mTOR pathway inhibitors than for those without documented mutations,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[693, 74, 309, 17, 1506, 138, 678, 51, 6, 974, 649, 873, 222, 1781, 723, 15, 566, 138, 68, 3367, 251, 673, 57, 29, 7, 1995, 6, 3, 124, 70, 1243, 9, 238, 36, 1723, 4, 2551, 1375, 11, 311, 9, 1506, 138, 75, 604, 90, 261, 615, 1, 3885, 83, 2, 179, 935, 7, 5, 1867, 30, 630, 2, 1506, 258, 11, 73, 8395, 899, 5, 183, 529, 3, 974, 649, 873, 308, 63, 1506, 138, 11, 530, 4, 243, 1, 6499, 7, 175, 33, 1725, 83, 78, 175, 1725, 179, 78, 213, 4, 30, 630, 5, 80, 76, 79, 7, 650, 1506, 138, 11, 96, 908, 4, 27, 1, 213, 239, 33, 1, 201, 269, 83, 1, 667, 269, 18, 1, 213, 213, 18, 1, 167, 233, 2, 691, 31, 12, 1, 3, 718, 2, 14, 1, 175, 83, 1, 3, 243, 7, 5, 1506, 138, 269, 806, 11, 73, 23, 8, 1182, 17, 159, 8, 974, 649, 873, 308, 230, 2, 49, 465, 513, 8, 450, 51, 4, 748, 158, 167, 1, 7086, 7, 49, 187, 1405, 1506, 138, 73, 23, 3, 827, 2189, 2211, 19, 13, 144, 1, 3, 269, 7, 5, 1506, 138, 49, 465, 42, 2824, 723, 15, 566, 138, 78, 39, 78, 18, 12, 7, 5, 1506, 2, 723, 138, 205, 44, 1892, 6, 36, 547, 110, 12, 7, 5, 1506, 2, 723, 15, 566, 138, 205, 4, 1221, 1506, 138, 11, 530, 4, 175, 33, 1, 7, 5, 1867, 537, 57, 3, 51, 116, 10, 97, 142, 9, 7, 5, 1506, 138, 73, 5, 974, 649, 873, 308, 222, 76, 9, 135, 187, 1405, 138]",1552.0,21216929,809
Evidence-based mini-review: the role of alkylating agents in the initial treatment of chronic lymphocytic leukemia patients with the 11q deletion.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2010-01-01,"A 55-year-old man presented with fever, night sweats, and weight loss of about 20 lbs. in the prior 6 months. Physical examination revealed multiple cervical, axillary, and inguinal lymphadenopathy. The spleen was enlarged. A complete blood count revealed leukocytosis with absolute lymphocytosis: 30,000/L. Peripheral blood-flow cytometric analysis showed a clonal lymphocyte population with immunophenotypes positive for CD5, CD20(dim), and monotypic kappa light chain. Fluorescence in situ hybridization (FISH) analysis revealed del(11q22.3), but negative for t(11:14). What should be used to treat his chronic lymphocytic leukemia (CLL) disease?",Journal Article,3672.0,15.0,"A 55-year-old man presented with fever night sweats and weight loss of about 20 lbs in the prior 6 months Physical examination revealed multiple axillary and inguinal lymphadenopathy The spleen was enlarged A complete blood count revealed leukocytosis with absolute lymphocytosis 30,000/L Peripheral blood-flow cytometric analysis showed a clonal lymphocyte population with immunophenotypes positive for CD5 CD20 dim and monotypic kappa light chain Fluorescence in situ hybridization FISH analysis revealed del 11q22.3 but negative for t 11:14 What should be used to treat his chronic lymphocytic CLL disease",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,"[8, 614, 111, 1095, 3628, 917, 5, 2775, 8955, 13298, 2, 924, 407, 1, 545, 179, 35044, 4, 3, 324, 49, 53, 900, 1385, 553, 232, 1210, 2, 4907, 4962, 3, 4071, 10, 7547, 8, 236, 315, 1276, 553, 7463, 5, 1766, 8125, 201, 984, 5513, 672, 315, 1412, 6226, 65, 224, 8, 1946, 1448, 266, 5, 16679, 109, 9, 6349, 2198, 8657, 2, 30771, 3096, 1691, 1260, 1591, 4, 957, 1554, 1277, 65, 553, 3084, 12647, 27, 84, 199, 9, 102, 175, 213, 2067, 257, 40, 95, 6, 943, 3224, 442, 1193, 552, 34]",609.0,21239776,539
"Allocating cancer-directed expenditures: tensions between prevention, early detection and treatment is unnecessary.",Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer,Recent Results Cancer Res.,2011-01-01,"In most countries, the allocation of financial resources for cancer prevention, early detection, and treatment come from different nonrelated ""silos."" Primary prevention benefits have the greatest economic return since the cancer benefits are intertwined with other major health conditions. Smoking alone accounts for about one-third cancer deaths. In most affluent countries, vaccines for selected viral caused cancers are (wisely) widely available if not optimally utilized. Estimating the additional cancer burden from obesity is still evolving. Age-targeted, less frequent but higher rates of participation in early detection of cervical, breast, and colorectal cancer will likely be prudent expenditures.The last 20 years in high-income countries, there has seen an explosion in demand and the costs of cancer drug or biologic therapy, a modest growth in some forms of radiation, yet minimal or declining surgical costs for primary disease control. Expenditures for cancer drugs are now the world leader of any medication category. While a few have truly led to marked benefits, all have been priced at levels that strain or break budgets. We comment on ten steps or principles that can be applied in most countries that can meaningfully reduce cancer care costs with minimal impact on survival and maintain or enhance quality of patient's life especially with advanced disease. We emphasize limiting systemic therapies for metastatic disease to fully ambulatory patients, those who previously responded to therapy, and earlier initiation of palliative care. Changing behaviors, incentives, expectations, and the framing of treatment effects are necessary to ""bend"" the current unrelenting cancer care cost curve.",Journal Article,3307.0,1.0,In most countries the allocation of financial resources for cancer prevention early detection and treatment come from different nonrelated `` silos '' Primary prevention benefits have the greatest economic return since the cancer benefits are intertwined with other major health conditions Smoking alone accounts for about one-third cancer deaths In most affluent countries vaccines for selected viral caused cancers are wisely widely available if not optimally utilized Estimating the additional cancer burden from obesity is still evolving Age-targeted less frequent but higher rates of participation in early detection of and cancer will likely be prudent expenditures.The last 20 years in high-income countries there has seen an explosion in demand and the costs of cancer drug or biologic therapy a modest growth in some forms of radiation yet minimal or declining surgical costs for primary disease control Expenditures for cancer drugs are now the world leader of any medication category While a few have truly led to marked benefits all have been priced at levels that strain or break budgets We comment on ten steps or principles that can be applied in most countries that can meaningfully reduce cancer care costs with minimal impact on survival and maintain or enhance quality of patient 's life especially with advanced disease We emphasize limiting systemic therapies for metastatic disease to fully ambulatory patients those who previously responded to therapy and earlier initiation of palliative care Changing behaviors incentives expectations and the framing of treatment effects are necessary to `` bend '' the current unrelenting cancer care cost curve,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4, 96, 2115, 3, 6834, 1, 3021, 2892, 9, 12, 1070, 191, 638, 2, 24, 6235, 29, 338, 59751, 39527, 522, 86, 1070, 1141, 47, 3, 2199, 3875, 4656, 1192, 3, 12, 1141, 32, 22377, 5, 127, 458, 341, 1298, 979, 279, 4162, 9, 545, 104, 1282, 12, 1043, 4, 96, 24537, 2115, 1842, 9, 715, 1667, 1546, 163, 32, 19253, 1792, 390, 492, 44, 5074, 2080, 4563, 3, 402, 12, 892, 29, 1661, 16, 1234, 3276, 89, 238, 299, 908, 84, 142, 151, 1, 2599, 4, 191, 638, 1, 2, 12, 303, 322, 40, 10263, 8728, 3, 1060, 179, 60, 4, 64, 2306, 2115, 125, 71, 527, 35, 10983, 4, 6645, 2, 3, 1201, 1, 12, 234, 15, 1283, 36, 8, 1721, 129, 4, 476, 2377, 1, 121, 1145, 1048, 15, 6896, 221, 1201, 9, 86, 34, 182, 8728, 9, 12, 600, 32, 1134, 3, 1956, 16860, 1, 500, 3012, 2169, 369, 8, 1021, 47, 7260, 836, 6, 2003, 1141, 62, 47, 85, 35048, 28, 148, 17, 5041, 15, 4338, 26656, 21, 11745, 23, 1618, 4022, 15, 4650, 17, 122, 40, 1498, 4, 96, 2115, 17, 122, 14625, 969, 12, 165, 1201, 5, 1048, 345, 23, 25, 2, 3040, 15, 1304, 372, 1, 69, 292, 358, 1093, 5, 131, 34, 21, 5560, 817, 403, 235, 9, 113, 34, 6, 1910, 4154, 7, 135, 54, 373, 2211, 6, 36, 2, 1677, 1118, 1, 994, 165, 3600, 3704, 12564, 5591, 2, 3, 31317, 1, 24, 176, 32, 1493, 6, 46420, 522, 3, 291, 59752, 12, 165, 835, 1496]",1671.0,21253785,168
Conservative management of early stage cervical cancer: is there a role for less radical surgery?,Gynecologic oncology,Gynecol. Oncol.,2011-03-01,"The utility of parametrial resection in women with early stage cervical cancer is controversial. In patients with favorable pathologic characteristics such as tumor size <2cm and the absence of lymphovascular space invasion, the rate of parametrial involvement is very low. More conservative surgical approaches have therefore been suggested. The objective of this report is to review the existing literature in this area and to describe an ongoing prospective study evaluating the safety and efficacy of conservative surgery in women with early stage cervical cancer. We performed a search of PubMed for English language articles published between 1970 and 2010 using the MeSH terms ""cervical cancer"", ""conservative surgery"", and ""cone biopsy"". Several retrospective studies have shown that <1% of patients with early stage cervical cancer with favorable pathologic characteristics have parametrial involvement. In addition, approximately 60% of patients undergoing radical trachelectomy have no residual disease in the final pathologic specimen. Recent studies have reported on the feasibility and safety of performing less radical surgery consisting of pelvic lymphadenectomy with cone biopsy, simple trachelectomy or simple hysterectomy in women with stage IA1 to IB1 cervical carcinoma. In addition, a prospective, multi-center, international trial is currently being performed to evaluate the outcomes of performing pelvic lymphadenectomy with conservative surgery (simple hysterectomy or cervical conization) in patients with favorable pathologic characteristics. Neoadjuvant chemotherapy followed by conservative surgery is also being explored as an option for patients with larger tumors and other pathologic characteristics that do not meet the criteria to perform conservative surgery alone. The rate of parametrial involvement in women with early stage cervical cancer with favorable pathologic characteristics is low. Should the results of ongoing studies be favorable, conservative surgery could become the standard of care for certain women with early stage cervical cancer.",Journal Article,3248.0,86.0,The utility of parametrial resection in women with early stage cancer is controversial In patients with favorable pathologic characteristics such as tumor size 2cm and the absence of lymphovascular space invasion the rate of parametrial involvement is very low More conservative surgical approaches have therefore been suggested The objective of this report is to review the existing literature in this area and to describe an ongoing prospective study evaluating the safety and efficacy of conservative surgery in women with early stage cancer We performed a search of PubMed for English language articles published between 1970 and 2010 using the MeSH terms `` cancer '' `` conservative surgery '' and `` cone biopsy '' Several retrospective studies have shown that 1 of patients with early stage cancer with favorable pathologic characteristics have parametrial involvement In addition approximately 60 of patients undergoing radical trachelectomy have no residual disease in the final pathologic specimen Recent studies have reported on the feasibility and safety of performing less radical surgery consisting of pelvic lymphadenectomy with cone biopsy simple trachelectomy or simple hysterectomy in women with stage IA1 to IB1 carcinoma In addition a prospective multi-center international trial is currently being performed to evaluate the outcomes of performing pelvic lymphadenectomy with conservative surgery simple hysterectomy or conization in patients with favorable pathologic characteristics Neoadjuvant chemotherapy followed by conservative surgery is also being explored as an option for patients with larger tumors and other pathologic characteristics that do not meet the criteria to perform conservative surgery alone The rate of parametrial involvement in women with early stage cancer with favorable pathologic characteristics is low Should the results of ongoing studies be favorable conservative surgery could become the standard of care for certain women with early stage cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1207, 1, 8726, 170, 4, 117, 5, 191, 82, 12, 16, 2010, 4, 7, 5, 913, 510, 374, 225, 22, 30, 444, 26562, 2, 3, 1127, 1, 2933, 3865, 578, 3, 116, 1, 8726, 799, 16, 923, 154, 80, 4476, 221, 611, 47, 673, 85, 1148, 3, 461, 1, 26, 414, 16, 6, 206, 3, 1692, 789, 4, 26, 965, 2, 6, 897, 35, 942, 482, 45, 1435, 3, 367, 2, 209, 1, 4476, 152, 4, 117, 5, 191, 82, 12, 21, 173, 8, 1901, 1, 3161, 9, 4201, 4794, 2384, 983, 59, 4868, 2, 1120, 75, 3, 11332, 1794, 12, 522, 4476, 152, 522, 2, 6939, 411, 522, 392, 459, 94, 47, 443, 17, 14, 1, 7, 5, 191, 82, 12, 5, 913, 510, 374, 47, 8726, 799, 4, 352, 705, 335, 1, 7, 479, 711, 5760, 47, 77, 753, 34, 4, 3, 1457, 510, 2360, 435, 94, 47, 210, 23, 3, 1437, 2, 367, 1, 3620, 299, 711, 152, 2273, 1, 1110, 2048, 5, 6939, 411, 2763, 5760, 15, 2763, 2622, 4, 117, 5, 82, 14517, 6, 8111, 134, 4, 352, 8, 482, 1414, 574, 944, 160, 16, 694, 486, 173, 6, 376, 3, 123, 1, 3620, 1110, 2048, 5, 4476, 152, 2763, 2622, 15, 8755, 4, 7, 5, 913, 510, 374, 536, 56, 370, 20, 4476, 152, 16, 120, 486, 1443, 22, 35, 1501, 9, 7, 5, 1077, 57, 2, 127, 510, 374, 17, 1022, 44, 3362, 3, 371, 6, 2715, 4476, 152, 279, 3, 116, 1, 8726, 799, 4, 117, 5, 191, 82, 12, 5, 913, 510, 374, 16, 154, 257, 3, 99, 1, 942, 94, 40, 913, 4476, 152, 359, 1417, 3, 260, 1, 165, 9, 1840, 117, 5, 191, 82, 12]",2002.0,21320670,18
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2011-02-24,"We investigated whether vandetanib, an inhibitor of the tyrosine kinase activities of vascular endothelial growth factor receptor-2 (VEGFR-2), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET), could augment the antitumor activity of radiation with or without cisplatin in preclinical in vitro and in vivo models of human head and neck squamous cell carcinoma (HNSCC). OSC-19 and HN5 HNSCC cells that were cisplatin and radioresistant were treated with vandetanib, cisplatin, and radiation alone or in combination in vitro and in vivo using an orthotopic nude mouse model. Treatment effects were assessed using clonogenic survival assay, tumor volume, bioluminescence imaging, tumor growth delay, survival, microvessel density, tumor and endothelial cell apoptosis, and EGFR and Akt phosphorylation data. Vandetanib plus cisplatin radiosensitized HNSCC cells in vitro and in vivo. The combination treatment with vandetanib, cisplatin, and radiation was superior to the rest of treatments (including the double combinations) in antitumoral effects, prolonging survival, decreasing cervical lymph node metastases in vivo. It also increased both tumor and tumor-associated endothelial cell apoptosis and decreased microvessel density in vivo. An analysis of tumor growth delay data revealed that vandetanib plus cisplatin enhanced radioresponse in vivo. All vandetanib-containing treatments inhibited EGFR and Akt phosphorylation in vitro and in vivo. The addition of vandetanib to combination therapy with cisplatin and radiation was able to effectively overcome cisplatin and radioresistance in in vitro and in vivo models of HNSCC. Further study of this regimen in clinical trials may be warranted.",Journal Article,3253.0,49.0,We investigated whether vandetanib an inhibitor of the tyrosine kinase activities of vascular endothelial growth factor receptor-2 VEGFR-2 epidermal growth factor receptor EGFR and rearranged during transfection RET could augment the antitumor activity of radiation with or without cisplatin in preclinical in vitro and in vivo models of human head and squamous cell carcinoma HNSCC OSC-19 and HN5 HNSCC cells that were cisplatin and radioresistant were treated with vandetanib cisplatin and radiation alone or in combination in vitro and in vivo using an orthotopic nude mouse model Treatment effects were assessed using clonogenic survival assay tumor volume bioluminescence imaging tumor growth delay survival microvessel density tumor and endothelial cell apoptosis and EGFR and Akt phosphorylation data Vandetanib plus cisplatin radiosensitized HNSCC cells in vitro and in vivo The combination treatment with vandetanib cisplatin and radiation was superior to the rest of treatments including the double combinations in antitumoral effects prolonging survival decreasing lymph node metastases in vivo It also increased both tumor and tumor-associated endothelial cell apoptosis and decreased microvessel density in vivo An analysis of tumor growth delay data revealed that vandetanib plus cisplatin enhanced radioresponse in vivo All vandetanib-containing treatments inhibited EGFR and Akt phosphorylation in vitro and in vivo The addition of vandetanib to combination therapy with cisplatin and radiation was able to effectively overcome cisplatin and radioresistance in in vitro and in vivo models of HNSCC Further study of this regimen in clinical trials may be warranted,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 565, 317, 3493, 35, 230, 1, 3, 564, 216, 2042, 1, 756, 845, 129, 161, 153, 18, 2134, 18, 829, 129, 161, 153, 227, 2, 3201, 190, 3789, 2412, 359, 4369, 3, 579, 128, 1, 121, 5, 15, 187, 540, 4, 693, 4, 439, 2, 4, 386, 274, 1, 171, 718, 2, 691, 31, 134, 1209, 16077, 326, 2, 28892, 1209, 37, 17, 11, 540, 2, 7092, 11, 73, 5, 3493, 540, 2, 121, 279, 15, 4, 150, 4, 439, 2, 4, 386, 75, 35, 2157, 2598, 830, 202, 24, 176, 11, 275, 75, 3798, 25, 719, 30, 433, 7956, 270, 30, 129, 1984, 25, 4269, 1263, 30, 2, 845, 31, 351, 2, 227, 2, 649, 982, 74, 3493, 349, 540, 13830, 1209, 37, 4, 439, 2, 4, 386, 3, 150, 24, 5, 3493, 540, 2, 121, 10, 1123, 6, 3, 3677, 1, 640, 141, 3, 1627, 1247, 4, 13808, 176, 5559, 25, 2777, 263, 289, 196, 4, 386, 192, 120, 101, 110, 30, 2, 30, 41, 845, 31, 351, 2, 340, 4269, 1263, 4, 386, 35, 65, 1, 30, 129, 1984, 74, 553, 17, 3493, 349, 540, 651, 33884, 4, 386, 62, 3493, 1101, 640, 879, 227, 2, 649, 982, 4, 439, 2, 4, 386, 3, 352, 1, 3493, 6, 150, 36, 5, 540, 2, 121, 10, 1665, 6, 1856, 1768, 540, 2, 7052, 4, 4, 439, 2, 4, 386, 274, 1, 1209, 195, 45, 1, 26, 477, 4, 38, 143, 68, 40, 1197]",1679.0,21350000,15
Recruitment and retention results for a population-based cervical cancer biobehavioral clinical trial.,Gynecologic oncology,Gynecol. Oncol.,2011-03-12,"Minority and low-income cancer patients are underrepresented in clinical trials, contributing to diminished access to state-of-the-art care and disparities in cancer outcomes including survivorship issues. In cervical cancer, there is a disproportionate disease burden among minority and underserved women and persistent quality of life disruption. We encountered significant challenges in both recruitment and retention in a randomized biobehavioral clinical trial for cervical cancer survivors, identified through California Cancer Registries, leading to this investigation. To determine differential rates of accrual and retention, data from our trial are analyzed using descriptive statistics, logistic regression and multivariate analysis of variance. Ethnic differences in associations between covariables and attrition rates were tested by interaction factors. Process evaluation and focus group data were obtained to inform improvement strategies. Of eligible subjects with viable phone numbers, 29% enrolled and 71% actively or passively refused. Enrolled Hispanic women were more likely to have less education (p<0.001), lower income (p=0.003), and more children (p=0.028). The dropout rate was associated with less education (p=0.012), foreign-birth (p=0.061), speaking Spanish in the home (p=0.012). Reported reasons for active refusal were 'too busy' for all women, 'too emotional' for non-Hispanic women, 'too ill' and phlebotomy for Hispanic women. Subsequent focus groups identified specific strategies to improve study materials. Although population-based recruitment of minority and underserved cancer patients continues to be a challenge, specific sociodemographic and disease variables can predict accrual difficulties. The information herein, taken together with disease and culturally relevant strategies, can be useful when recruiting underserved cancer survivors.",Journal Article,3237.0,12.0,Minority and low-income cancer patients are underrepresented in clinical trials contributing to diminished access to state-of-the-art care and disparities in cancer outcomes including survivorship issues In cancer there is a disproportionate disease burden among minority and underserved women and persistent quality of life disruption We encountered significant challenges in both recruitment and retention in a randomized biobehavioral clinical trial for cancer survivors identified through California Cancer Registries leading to this investigation To determine differential rates of accrual and retention data from our trial are analyzed using descriptive statistics logistic regression and multivariate analysis of variance Ethnic differences in associations between covariables and attrition rates were tested by interaction factors Process evaluation and focus group data were obtained to inform improvement strategies Of eligible subjects with viable phone numbers 29 enrolled and 71 actively or passively refused Enrolled Hispanic women were more likely to have less education p 0.001 lower income p=0.003 and more children p=0.028 The dropout rate was associated with less education p=0.012 foreign-birth p=0.061 speaking Spanish in the home p=0.012 Reported reasons for active refusal were 'too busy for all women 'too emotional for non-Hispanic women 'too ill and phlebotomy for Hispanic women Subsequent focus groups identified specific strategies to improve study materials Although population-based recruitment of minority and underserved cancer patients continues to be a challenge specific sociodemographic and disease variables can predict accrual difficulties The information herein taken together with disease and culturally relevant strategies can be useful when recruiting underserved cancer survivors,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2652, 2, 154, 2306, 12, 7, 32, 9900, 4, 38, 143, 3156, 6, 2849, 1655, 6, 1309, 1, 3, 4363, 165, 2, 2227, 4, 12, 123, 141, 2560, 1553, 4, 12, 125, 16, 8, 14156, 34, 892, 107, 2652, 2, 6960, 117, 2, 1882, 372, 1, 358, 3220, 21, 3903, 93, 1427, 4, 110, 3202, 2, 3947, 4, 8, 384, 21332, 38, 160, 9, 12, 332, 108, 298, 4355, 12, 3768, 1049, 6, 26, 940, 6, 223, 1777, 151, 1, 2262, 2, 3947, 74, 29, 114, 160, 32, 311, 75, 3778, 3065, 812, 320, 2, 331, 65, 1, 4446, 2871, 362, 4, 685, 59, 21498, 2, 9174, 151, 11, 650, 20, 915, 130, 1129, 451, 2, 1222, 87, 74, 11, 683, 6, 2295, 767, 422, 1, 625, 976, 5, 2663, 8772, 1870, 462, 346, 2, 792, 4489, 15, 16075, 8237, 346, 1776, 117, 11, 80, 322, 6, 47, 299, 1848, 19, 13, 144, 280, 2306, 19, 13, 1421, 2, 80, 541, 19, 13, 4836, 3, 13929, 116, 10, 41, 5, 299, 1848, 19, 13, 3499, 9950, 3809, 19, 13, 13500, 8519, 8733, 4, 3, 3249, 19, 13, 3499, 210, 2325, 9, 544, 8104, 11, 39586, 19706, 9, 62, 117, 39586, 2671, 9, 220, 1776, 117, 39586, 4993, 2, 14014, 9, 1776, 117, 706, 1222, 271, 108, 112, 422, 6, 401, 45, 5102, 242, 266, 90, 3202, 1, 2652, 2, 6960, 12, 7, 2274, 6, 40, 8, 1745, 112, 4221, 2, 34, 682, 122, 678, 2262, 4679, 3, 487, 1986, 1633, 1162, 5, 34, 2, 15185, 867, 422, 122, 40, 999, 198, 9200, 6960, 12, 332]",1823.0,21402400,358
"A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors.",Investigational new drugs,Invest New Drugs,2011-03-22,"The kinesin spindle protein (KSP) is essential for separation of spindle poles during mitosis. Its inhibition results in mitotic arrest. This phase I trial examined safety, tolerability, dose-limiting toxicity (DLT), maximum tolerated dose (MTD), pharmacokinetic parameters, and anti-tumor activity of MK-0731, a potent inhibitor of KSP. In part 1, patients with advanced solid tumors received MK-0731 intravenously over 24 h every 21 days starting at 6 mg/m(2), escalating until MTD was reached. In part 2, patients with taxane-resistant tumors received the MTD. Plasma samples were collected to analyze the pharmacokinetics of MK-0731. Tumor response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) v1.0. In part 1, 21 patients (median age 63 years) were treated with MK-0731 at doses ranging from 6 to 48 mg/m(2)/24 h for median four cycles. The dose-limiting toxicity was neutropenia and the MTD was 17 mg/m(2)/24 h. At the MTD, AUC (SD) was 10.5 (7.3) M  hour, clearance (SD) was 153 mL/min (84), and t(1/2) was 5.9 h. In part 2, 22 patients received the MTD and there were no DLTs. Although there were no objective tumor responses, four patients (with cervical, non-small cell lung, and ovarian cancers) had prolonged stable disease. MK-0731 at the MTD of 17 mg/m(2)/day every 21 days in patients with solid tumors had few grade 3 and 4 toxicities with the major DLTs at higher doses being myelosuppression. Anti-tumor efficacy was suggested by the length of stable disease in selected patients with taxane-resistant tumors.","Clinical Trial, Phase I",3227.0,35.0,The kinesin spindle protein KSP is essential for separation of spindle poles during mitosis Its inhibition results in mitotic arrest This phase I trial examined safety tolerability dose-limiting toxicity DLT maximum tolerated dose MTD pharmacokinetic parameters and anti-tumor activity of MK-0731 a potent inhibitor of KSP In part 1 patients with advanced solid tumors received MK-0731 intravenously over 24 h every 21 days starting at 6 mg/m 2 escalating until MTD was reached In part 2 patients with taxane-resistant tumors received the MTD Plasma samples were collected to analyze the pharmacokinetics of MK-0731 Tumor response was evaluated using Response Evaluation Criteria in Solid Tumors RECIST v1.0 In part 1 21 patients median age 63 years were treated with MK-0731 at doses ranging from 6 to 48 mg/m 2 /24 h for median four cycles The dose-limiting toxicity was neutropenia and the MTD was 17 mg/m 2 /24 h. At the MTD AUC SD was 10.5 7.3 M hour clearance SD was 153 mL/min 84 and t 1/2 was 5.9 h. In part 2 22 patients received the MTD and there were no DLTs Although there were no objective tumor responses four patients with cell and cancers had prolonged stable disease MK-0731 at the MTD of 17 mg/m 2 /day every 21 days in patients with solid tumors had few grade 3 and 4 toxicities with the major DLTs at higher doses being myelosuppression Anti-tumor efficacy was suggested by the length of stable disease in selected patients with taxane-resistant tumors,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 14193, 4052, 178, 21532, 16, 1452, 9, 5422, 1, 4052, 59948, 190, 5624, 211, 297, 99, 4, 2346, 1854, 26, 124, 70, 160, 409, 367, 1543, 61, 817, 155, 2059, 689, 421, 61, 961, 1456, 1038, 2, 312, 30, 128, 1, 3558, 31776, 8, 1157, 230, 1, 21532, 4, 760, 14, 7, 5, 131, 537, 57, 103, 3558, 31776, 1672, 252, 259, 555, 454, 239, 162, 1723, 28, 49, 81, 188, 18, 2922, 1100, 961, 10, 1300, 4, 760, 18, 7, 5, 1715, 436, 57, 103, 3, 961, 554, 347, 11, 786, 6, 1992, 3, 1159, 1, 3558, 31776, 30, 51, 10, 194, 75, 51, 451, 371, 4, 537, 57, 1834, 7673, 13, 4, 760, 14, 239, 7, 52, 89, 676, 60, 11, 73, 5, 3558, 31776, 28, 415, 2223, 29, 49, 6, 576, 81, 188, 18, 259, 555, 9, 52, 294, 410, 3, 61, 817, 155, 10, 778, 2, 3, 961, 10, 269, 81, 188, 18, 259, 555, 28, 3, 961, 1376, 22658, 10, 79, 33, 17459, 27, 4810, 2583, 1960, 22658, 10, 4251, 542, 1538, 59949, 2, 102, 14, 18, 10, 33, 83, 555, 4, 760, 18, 350, 7, 103, 3, 961, 2, 125, 11, 77, 2506, 242, 125, 11, 77, 461, 30, 253, 294, 7, 5, 31, 2, 163, 42, 1069, 585, 34, 3558, 31776, 28, 3, 961, 1, 269, 81, 188, 18, 218, 454, 239, 162, 4, 7, 5, 537, 57, 42, 1021, 88, 27, 2, 39, 385, 5, 3, 458, 2506, 28, 142, 415, 486, 2858, 312, 30, 209, 10, 1148, 20, 3, 1318, 1, 585, 34, 4, 715, 7, 5, 1715, 436, 57]",1477.0,21424701,217
Central neck dissection for papillary thyroid cancer.,Cancer control : journal of the Moffitt Cancer Center,Cancer Control,2011-04-01,"Central compartment lymph node dissection is a common adjunct to thyroidectomy in the treatment of papillary thyroid cancer. The indications, surgical technique, potential benefits, and operative risks of this procedure should be clearly defined in order to provide optimal care to these patients. A systematic review of the literature and an analysis of evidence-based recommendations were performed regarding central neck node dissection for patients with papillary thyroid carcinoma. Cervical nodal metastasis in papillary thyroid cancer is a common occurrence. The presence of metastasis is associated with increased recurrence rates and may decrease survival. Detection of central and lateral neck nodal metastasis preoperatively with clinical examination and cervical ultrasound is important in determining the appropriate initial surgical management. Level VI neck dissection and central neck dissection are terms often used interchangeably to describe surgical excision of all lymph nodes from the hyoid bone to the sternal notch between the carotid arteries, but the addition of the superior mediastinal lymph nodes in compartment VII should be included in the central neck dissection. Due to improved recurrence rates and survival, therapeutic central neck dissection is recommended for all patients with nodal involvement detected pre- or intraoperatively. Prophylactic central neck dissection in patients without detectable nodal disease remains a controversial topic due to a lack of definitive evidence of improved recurrence rates or survival and the possibility of higher complication rates compared to total thyroidectomy alone. Reoperative central nodal dissection can be a challenging procedure with increased complication rates but with good outcomes in experienced centers. Central neck lymph node dissection plays an important role in the appropriate treatment of papillary thyroid cancer at initial presentation and in cases of recurrent disease. Surgeons caring for this group of patients should have familiarity and skill with this procedure.",Journal Article,3217.0,45.0,Central compartment lymph node dissection is a common adjunct to thyroidectomy in the treatment of papillary cancer The indications surgical technique potential benefits and operative risks of this procedure should be clearly defined in order to provide optimal care to these patients A systematic review of the literature and an analysis of evidence-based recommendations were performed regarding central node dissection for patients with papillary carcinoma nodal metastasis in papillary cancer is a common occurrence The presence of metastasis is associated with increased recurrence rates and may decrease survival Detection of central and lateral nodal metastasis preoperatively with clinical examination and ultrasound is important in determining the appropriate initial surgical management Level VI dissection and central dissection are terms often used interchangeably to describe surgical excision of all lymph nodes from the hyoid to the sternal notch between the carotid arteries but the addition of the superior mediastinal lymph nodes in compartment VII should be included in the central dissection Due to improved recurrence rates and survival therapeutic central dissection is recommended for all patients with nodal involvement detected pre- or intraoperatively Prophylactic central dissection in patients without detectable nodal disease remains a controversial topic due to a lack of definitive evidence of improved recurrence rates or survival and the possibility of higher complication rates compared to total thyroidectomy alone Reoperative central nodal dissection can be a challenging procedure with increased complication rates but with good outcomes in experienced centers Central lymph node dissection plays an important role in the appropriate treatment of papillary cancer at initial presentation and in cases of recurrent disease Surgeons caring for this group of patients should have familiarity and skill with this procedure,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[854, 3616, 263, 289, 1161, 16, 8, 186, 5471, 6, 5949, 4, 3, 24, 1, 1796, 12, 3, 2406, 221, 1312, 174, 1141, 2, 1208, 1098, 1, 26, 1299, 257, 40, 2536, 395, 4, 1732, 6, 377, 665, 165, 6, 46, 7, 8, 1556, 206, 1, 3, 789, 2, 35, 65, 1, 241, 90, 883, 11, 173, 666, 854, 289, 1161, 9, 7, 5, 1796, 134, 779, 278, 4, 1796, 12, 16, 8, 186, 2291, 3, 463, 1, 278, 16, 41, 5, 101, 146, 151, 2, 68, 775, 25, 638, 1, 854, 2, 3855, 779, 278, 3888, 5, 38, 1385, 2, 1945, 16, 305, 4, 2196, 3, 870, 388, 221, 284, 301, 7149, 1161, 2, 854, 1161, 32, 1794, 629, 95, 35088, 6, 897, 221, 1366, 1, 62, 263, 502, 29, 3, 59972, 6, 3, 15004, 3193, 59, 3, 8319, 10166, 84, 3, 352, 1, 3, 1123, 2626, 263, 502, 4, 3616, 13809, 257, 40, 159, 4, 3, 854, 1161, 520, 6, 231, 146, 151, 2, 25, 189, 854, 1161, 16, 793, 9, 62, 7, 5, 779, 799, 530, 671, 15, 6595, 1862, 854, 1161, 4, 7, 187, 2083, 779, 34, 469, 8, 2010, 5463, 520, 6, 8, 926, 1, 1057, 241, 1, 231, 146, 151, 15, 25, 2, 3, 2526, 1, 142, 1447, 151, 72, 6, 181, 5949, 279, 11250, 854, 779, 1161, 122, 40, 8, 1950, 1299, 5, 101, 1447, 151, 84, 5, 1178, 123, 4, 592, 1168, 854, 263, 289, 1161, 1698, 35, 305, 200, 4, 3, 870, 24, 1, 1796, 12, 28, 388, 1031, 2, 4, 140, 1, 387, 34, 1613, 6571, 9, 26, 87, 1, 7, 257, 47, 10322, 2, 11180, 5, 26, 1299]",1955.0,21451450,289
Minimally invasive esophagectomy is safe and effective following neoadjuvant chemoradiation therapy.,Annals of surgical oncology,Ann. Surg. Oncol.,2011-04-09,"Minimally invasive esophagectomy (MIE) is technically demanding, and implementation has been hindered by a steep learning curve. Despite widespread concern about the successful performance of this procedure following neoadjuvant chemoradiotherapy (NACR) treatment, we hypothesized that safe and effective MIE could be performed in this setting. We reviewed our prospective database of patients undergoing MIE for esophageal cancer at our institution between January 2008 and February 2010. We analyzed the association of NACR on perioperative outcomes and compared them with those patients undergoing MIE without NACR. NACR was used in T2 or N+ tumors. A total of 61 consecutive patients underwent a planned MIE. A complete MIE or hybrid procedure was performed in 58 patients (95%), while 3 patients were unresectable. Median age was 67 years (range 38-85). Anastomoses were performed in the cervical region in 47 patients (81%) while 11 patients had an anastomosis in the right chest. Serious complications included: 3 cervical anastomotic leaks (5%), 2 thoracic duct leaks (4%), 12 pneumonias (21%), 10 atrial fibrillations (18%), and 1 death in a patient not undergoing NACR. NACR was used in 41 patients. There was no significant difference in estimated blood loss (EBL), complications, or negative pathologic margins in patients undergoing NACR with MIE vs. MIE alone (P=NS). Median number of lymph nodes excised and PostOp LOS was 15 and 11 in patients undergoing NACR compared with 13 and 9 in those undergoing MIE alone (P=NS). MIE is safe following NACR. Excellent results can be achieved with this operation in patients with advanced tumors.",Journal Article,3209.0,26.0,Minimally invasive esophagectomy MIE is technically demanding and implementation has been hindered by a steep learning curve Despite widespread concern about the successful performance of this procedure following neoadjuvant chemoradiotherapy NACR treatment we hypothesized that safe and effective MIE could be performed in this setting We reviewed our prospective database of patients undergoing MIE for cancer at our institution between January 2008 and February 2010 We analyzed the association of NACR on perioperative outcomes and compared them with those patients undergoing MIE without NACR NACR was used in T2 or N+ tumors A total of 61 consecutive patients underwent a planned MIE A complete MIE or hybrid procedure was performed in 58 patients 95 while 3 patients were unresectable Median age was 67 years range 38-85 Anastomoses were performed in the region in 47 patients 81 while 11 patients had an anastomosis in the right chest Serious complications included 3 anastomotic leaks 5 2 thoracic duct leaks 4 12 pneumonias 21 10 atrial fibrillations 18 and 1 death in a patient not undergoing NACR NACR was used in 41 patients There was no significant difference in estimated blood loss EBL complications or negative pathologic margins in patients undergoing NACR with MIE vs. MIE alone P=NS Median number of lymph nodes excised and PostOp LOS was 15 and 11 in patients undergoing NACR compared with 13 and 9 in those undergoing MIE alone P=NS MIE is safe following NACR Excellent results can be achieved with this operation in patients with advanced tumors,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[2144, 416, 3617, 7336, 16, 6093, 14562, 2, 2393, 71, 85, 9981, 20, 8, 17786, 3434, 1496, 550, 3029, 2893, 545, 3, 1401, 528, 1, 26, 1299, 366, 536, 1464, 23905, 24, 21, 1237, 17, 1165, 2, 323, 7336, 359, 40, 173, 4, 26, 546, 21, 446, 114, 482, 609, 1, 7, 479, 7336, 9, 12, 28, 114, 731, 59, 1024, 1375, 2, 3010, 1120, 21, 311, 3, 248, 1, 23905, 23, 1547, 123, 2, 72, 1370, 5, 135, 7, 479, 7336, 187, 23905, 23905, 10, 95, 4, 46530, 15, 78, 57, 8, 181, 1, 713, 935, 7, 208, 8, 1465, 7336, 8, 236, 7336, 15, 4542, 1299, 10, 173, 4, 717, 7, 48, 369, 27, 7, 11, 1468, 52, 89, 10, 598, 60, 184, 519, 772, 13311, 11, 173, 4, 3, 1053, 4, 662, 7, 865, 369, 175, 7, 42, 35, 5519, 4, 3, 1913, 1662, 1762, 521, 159, 27, 4818, 9674, 33, 18, 2098, 2920, 9674, 39, 133, 34957, 239, 79, 7658, 60012, 203, 2, 14, 273, 4, 8, 69, 44, 479, 23905, 23905, 10, 95, 4, 605, 7, 125, 10, 77, 93, 523, 4, 661, 315, 407, 9541, 521, 15, 199, 510, 1012, 4, 7, 479, 23905, 5, 7336, 105, 7336, 279, 19, 4044, 52, 207, 1, 263, 502, 5076, 2, 17670, 3649, 10, 167, 2, 175, 4, 7, 479, 23905, 72, 5, 233, 2, 83, 4, 135, 479, 7336, 279, 19, 4044, 7336, 16, 1165, 366, 23905, 1503, 99, 122, 40, 513, 5, 26, 2589, 4, 7, 5, 131, 57]",1569.0,21479689,734
Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy.,"Journal of immunotherapy (Hagerstown, Md. : 1997)",J. Immunother.,2011-05-01,"Patients with glioblastoma multiforme (GBM) are profoundly immunosuppressed and may benefit from restoration of an antitumor immune response in combination with conventional radiation therapy and temozolomide (TMZ). The optimal strategies to evaluate clinically relevant immune responses to treatment have yet to be determined. The primary objective of our study was to determine immunologic response to cervical intranodal vaccination with autologous tumor lysate-loaded dendritic cells (DCs) in patients with GBM after radiation therapy and TMZ. We used a novel hierarchical clustering analysis of immune parameters measured before and after vaccination. Secondary objectives were to assess treatment feasibility and to correlate immune response with progression-free survival (PFS) and overall survival. Ten eligible patients received vaccination. Tumor-specific cytotoxic T-cell response measured after vaccination was enhanced for the precursor frequency of CD4+ T and CD4+ interferon -producing cells. Hierarchical clustering analysis of multiple functional outcomes discerned 2 groups of patients according to their immune response, and additionally showed that patients in the top quintile for at least one immune function parameter had improved survival. There were no serious adverse events related to DC vaccination. All patients were alive at 6 months after diagnosis and the 6-month PFS was 90%. The median PFS was 9.5 months and overall survival was 28 months. In patients with GBM, immune therapy with DC vaccination after radiation and TMZ resulted in tumor-specific immune responses that were associated with prolonged survival. Our data suggest that DC vaccination in combination with radiation and chemotherapy in patients with GBM is feasible, safe, and may induce tumor-specific immune responses.",Clinical Trial,3187.0,101.0,Patients with glioblastoma multiforme GBM are profoundly immunosuppressed and may benefit from restoration of an antitumor immune response in combination with conventional radiation therapy and temozolomide TMZ The optimal strategies to evaluate clinically relevant immune responses to treatment have yet to be determined The primary objective of our study was to determine immunologic response to intranodal vaccination with autologous tumor lysate-loaded dendritic cells DCs in patients with GBM after radiation therapy and TMZ We used a novel hierarchical clustering analysis of immune parameters measured before and after vaccination Secondary objectives were to assess treatment feasibility and to correlate immune response with progression-free survival PFS and overall survival Ten eligible patients received vaccination Tumor-specific cytotoxic T-cell response measured after vaccination was enhanced for the precursor frequency of CD4+ T and CD4+ interferon -producing cells Hierarchical clustering analysis of multiple functional outcomes discerned 2 groups of patients according to their immune response and additionally showed that patients in the top quintile for at least one immune function parameter had improved survival There were no serious adverse events related to DC vaccination All patients were alive at 6 months after diagnosis and the 6-month PFS was 90 The median PFS was 9.5 months and overall survival was 28 months In patients with GBM immune therapy with DC vaccination after radiation and TMZ resulted in tumor-specific immune responses that were associated with prolonged survival Our data suggest that DC vaccination in combination with radiation and chemotherapy in patients with GBM is feasible safe and may induce tumor-specific immune responses,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[7, 5, 996, 3238, 1136, 32, 8802, 12749, 2, 68, 247, 29, 5194, 1, 35, 579, 250, 51, 4, 150, 5, 809, 121, 36, 2, 1537, 2081, 3, 665, 422, 6, 376, 505, 867, 250, 253, 6, 24, 47, 1145, 6, 40, 509, 3, 86, 461, 1, 114, 45, 10, 6, 223, 3042, 51, 6, 22154, 1915, 5, 1028, 30, 8758, 4805, 2464, 37, 3110, 4, 7, 5, 1136, 50, 121, 36, 2, 2081, 21, 95, 8, 229, 4466, 3147, 65, 1, 250, 1038, 644, 348, 2, 50, 1915, 568, 2409, 11, 6, 423, 24, 1437, 2, 6, 1513, 250, 51, 5, 91, 115, 25, 300, 2, 63, 25, 1618, 625, 7, 103, 1915, 30, 112, 759, 102, 31, 51, 644, 50, 1915, 10, 651, 9, 3, 2765, 675, 1, 1440, 102, 2, 1440, 1688, 2655, 3787, 37, 4466, 3147, 65, 1, 232, 583, 123, 19767, 18, 271, 1, 7, 768, 6, 136, 250, 51, 2, 1724, 224, 17, 7, 4, 3, 3150, 5950, 9, 28, 506, 104, 250, 343, 4219, 42, 231, 25, 125, 11, 77, 1762, 290, 281, 139, 6, 2321, 1915, 62, 7, 11, 1701, 28, 49, 53, 50, 147, 2, 3, 49, 811, 300, 10, 424, 3, 52, 300, 10, 83, 33, 53, 2, 63, 25, 10, 339, 53, 4, 7, 5, 1136, 250, 36, 5, 2321, 1915, 50, 121, 2, 2081, 627, 4, 30, 112, 250, 253, 17, 11, 41, 5, 1069, 25, 114, 74, 309, 17, 2321, 1915, 4, 150, 5, 121, 2, 56, 4, 7, 5, 1136, 16, 1313, 1165, 2, 68, 1290, 30, 112, 250, 253]",1783.0,21499132,588
Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings.,Cancer,Cancer,2010-11-16,"Failure to detect metastasis to para-aortic nodes in patients with locally advanced cervical cancer leads to suboptimal treatment. No previous studies have prospectively compared positron emission tomography (PET)/computed tomography (CT) with laparoscopic extraperitoneal staging in the evaluation of para-aortic lymph nodes. Sixty-five patients were enrolled; 60 were available for analysis. Patients with stage IB2-IVA cervical cancer without evidence of para-aortic lymphadenopathy on preoperative CT or magnetic resonance imaging (MRI) were prospectively enrolled. All patients underwent preoperative PET/CT. Laparoscopic extraperitoneal lymphadenectomy was performed from the common iliac vessels to the left renal vein. The median age at diagnosis was 48 years (range, 23-84). The median operative time was 140 minutes (range, 89-252). The median blood loss was 22.5 mL (range, 5-150). The median length of hospital stay was 1 day (range, 0-4). The median number of lymph nodes retrieved was 11 (range, 1-39). Fourteen (23%) patients had histopathologically positive para-aortic nodes. Of the 26 patients with negative pelvic and para-aortic nodes on PET/CT, 3 (12%) had histopathologically positive para-aortic nodes. Of the 27 patients with positive pelvic but negative para-aortic nodes on PET/CT, 6 (22%) had histopathologically positive para-aortic nodes. The sensitivity and specificity of PET/CT in detecting positive para-aortic nodes when nodes were negative on CT or MRI were 36% and 96%, respectively. Eleven (18.3%) patients had a treatment modification based on surgical findings. Laparoscopic extraperitoneal para-aortic lymphadenectomy is safe and feasible. Surgical staging of patients with locally advanced cervical cancer should be considered before planned radiation and chemotherapy.",Clinical Trial,3353.0,110.0,Failure to detect metastasis to para-aortic nodes in patients with locally advanced cancer leads to suboptimal treatment No previous studies have prospectively compared positron emission tomography PET /computed tomography CT with laparoscopic extraperitoneal staging in the evaluation of para-aortic lymph nodes Sixty-five patients were enrolled 60 were available for analysis Patients with stage IB2-IVA cancer without evidence of para-aortic lymphadenopathy on preoperative CT or magnetic resonance imaging MRI were prospectively enrolled All patients underwent preoperative PET/CT Laparoscopic extraperitoneal lymphadenectomy was performed from the common iliac vessels to the left vein The median age at diagnosis was 48 years range 23-84 The median operative time was 140 minutes range 89-252 The median blood loss was 22.5 mL range 5-150 The median length of hospital stay was 1 day range 0-4 The median number of lymph nodes retrieved was 11 range 1-39 Fourteen 23 patients had histopathologically positive para-aortic nodes Of the 26 patients with negative pelvic and para-aortic nodes on PET/CT 3 12 had histopathologically positive para-aortic nodes Of the 27 patients with positive pelvic but negative para-aortic nodes on PET/CT 6 22 had histopathologically positive para-aortic nodes The sensitivity and specificity of PET/CT in detecting positive para-aortic nodes when nodes were negative on CT or MRI were 36 and 96 respectively Eleven 18.3 patients had a treatment modification based on surgical findings Laparoscopic extraperitoneal para-aortic lymphadenectomy is safe and feasible Surgical staging of patients with locally advanced cancer should be considered before planned radiation and chemotherapy,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[496, 6, 1426, 278, 6, 4615, 3938, 502, 4, 7, 5, 795, 131, 12, 1940, 6, 3291, 24, 77, 698, 94, 47, 1143, 72, 1900, 1799, 872, 495, 1220, 872, 425, 5, 1964, 13087, 632, 4, 3, 451, 1, 4615, 3938, 263, 502, 1746, 365, 7, 11, 346, 335, 11, 390, 9, 65, 7, 5, 82, 9537, 5900, 12, 187, 241, 1, 4615, 3938, 4962, 23, 498, 425, 15, 1484, 1535, 270, 704, 11, 1143, 346, 62, 7, 208, 498, 495, 425, 1964, 13087, 2048, 10, 173, 29, 3, 186, 6692, 3102, 6, 3, 1712, 2762, 3, 52, 89, 28, 147, 10, 576, 60, 184, 382, 874, 3, 52, 1208, 98, 10, 3304, 2511, 184, 887, 6951, 3, 52, 315, 407, 10, 350, 33, 542, 184, 33, 1577, 3, 52, 1318, 1, 702, 2020, 10, 14, 218, 184, 13, 39, 3, 52, 207, 1, 263, 502, 4539, 10, 175, 184, 14, 587, 3225, 382, 7, 42, 8631, 109, 4615, 3938, 502, 1, 3, 432, 7, 5, 199, 1110, 2, 4615, 3938, 502, 23, 495, 425, 27, 133, 42, 8631, 109, 4615, 3938, 502, 1, 3, 428, 7, 5, 109, 1110, 84, 199, 4615, 3938, 502, 23, 495, 425, 49, 350, 42, 8631, 109, 4615, 3938, 502, 3, 485, 2, 1121, 1, 495, 425, 4, 2502, 109, 4615, 3938, 502, 198, 502, 11, 199, 23, 425, 15, 704, 11, 511, 2, 921, 106, 2627, 203, 27, 7, 42, 8, 24, 2437, 90, 23, 221, 272, 1964, 13087, 4615, 3938, 2048, 16, 1165, 2, 1313, 221, 632, 1, 7, 5, 795, 131, 12, 257, 40, 515, 348, 1465, 121, 2, 56]",1721.0,21509770,543
Establishing a sentinel lymph node mapping algorithm for the treatment of early cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2011-05-13,"To establish an algorithm that incorporates sentinel lymph node (SLN) mapping to the surgical treatment of early cervical cancer, ensuring that lymph node (LN) metastases are accurately detected but minimizing the need for complete lymphadenectomy (LND). A prospectively maintained database of all patients who underwent SLN procedure followed by a complete bilateral pelvic LND for cervical cancer (FIGO stages IA1 with LVI to IIA) from 03/2003 to 09/2010 was analyzed. The surgical algorithm we evaluated included the following: 1. SLNs are removed and submitted to ultrastaging; 2. any suspicious LN is removed regardless of mapping; 3. if only unilateral mapping is noted, a contralateral side-specific pelvic LND is performed (including inter-iliac nodes); and 4. parametrectomy en bloc with primary tumor resection is done in all cases. We retrospectively applied the algorithm to determine how it would have performed. One hundred twenty-two patients were included. Median SLN count was 3 and median total LN count was 20. At least one SLN was identified in 93% of cases (114/122), while optimal (bilateral) mapping was achieved in 75% of cases (91/122). SLN correctly diagnosed 21 of 25 patients with nodal spread. When the algorithm was applied, all patients with LN metastasis were detected; with optimal mapping, bilateral pelvic LND could have been avoided in 75% of cases. In the surgical treatment of early cervical cancer, the algorithm we propose allows for comprehensive detection of all patients with nodal disease and spares complete LND in the majority of cases.",Journal Article,3175.0,79.0,To establish an algorithm that incorporates sentinel lymph node SLN mapping to the surgical treatment of early cancer ensuring that lymph node LN metastases are accurately detected but minimizing the need for complete lymphadenectomy LND A prospectively maintained database of all patients who underwent SLN procedure followed by a complete bilateral pelvic LND for cancer FIGO stages IA1 with LVI to IIA from 03/2003 to 09/2010 was analyzed The surgical algorithm we evaluated included the following 1 SLNs are removed and submitted to ultrastaging 2. any suspicious LN is removed regardless of mapping 3. if only unilateral mapping is noted a contralateral side-specific pelvic LND is performed including inter-iliac nodes and 4. parametrectomy en bloc with primary tumor resection is done in all cases We retrospectively applied the algorithm to determine how it would have performed One hundred twenty-two patients were included Median SLN count was 3 and median total LN count was 20 At least one SLN was identified in 93 of cases 114/122 while optimal bilateral mapping was achieved in 75 of cases 91/122 SLN correctly diagnosed 21 of 25 patients with nodal spread When the algorithm was applied all patients with LN metastasis were detected with optimal mapping bilateral pelvic LND could have been avoided in 75 of cases In the surgical treatment of early cancer the algorithm we propose allows for comprehensive detection of all patients with nodal disease and spares complete LND in the majority of cases,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1811, 35, 2124, 17, 6175, 1323, 263, 289, 1099, 2568, 6, 3, 221, 24, 1, 191, 12, 8397, 17, 263, 289, 1763, 196, 32, 2141, 530, 84, 4501, 3, 594, 9, 236, 2048, 3400, 8, 1143, 1955, 609, 1, 62, 7, 54, 208, 1099, 1299, 370, 20, 8, 236, 1607, 1110, 3400, 9, 12, 3837, 1153, 14517, 5, 3327, 6, 4088, 29, 680, 1522, 6, 1730, 1120, 10, 311, 3, 221, 2124, 21, 194, 159, 3, 366, 14, 2642, 32, 2264, 2, 5118, 6, 11338, 18, 500, 3230, 1763, 16, 2264, 1583, 1, 2568, 27, 492, 158, 3208, 2568, 16, 1051, 8, 2138, 1152, 112, 1110, 3400, 16, 173, 141, 3606, 6692, 502, 2, 39, 23693, 4375, 5590, 5, 86, 30, 170, 16, 1822, 4, 62, 140, 21, 894, 1498, 3, 2124, 6, 223, 832, 192, 688, 47, 173, 104, 1128, 737, 100, 7, 11, 159, 52, 1099, 1276, 10, 27, 2, 52, 181, 1763, 1276, 10, 179, 28, 506, 104, 1099, 10, 108, 4, 966, 1, 140, 3803, 3285, 369, 665, 1607, 2568, 10, 513, 4, 481, 1, 140, 970, 3285, 1099, 4911, 265, 239, 1, 243, 7, 5, 779, 2579, 198, 3, 2124, 10, 1498, 62, 7, 5, 1763, 278, 11, 530, 5, 665, 2568, 1607, 1110, 3400, 359, 47, 85, 5617, 4, 481, 1, 140, 4, 3, 221, 24, 1, 191, 12, 3, 2124, 21, 2548, 2333, 9, 949, 638, 1, 62, 7, 5, 779, 34, 2, 21114, 236, 3400, 4, 3, 686, 1, 140]",1514.0,21570713,40
"Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity.",Molecular cancer therapeutics,Mol. Cancer Ther.,2011-05-13,"Because liver involvement in patients with metastatic cancer has limited options and poor outcomes, we conducted a phase I study to determine the safety, activity, and pharmacokinetic characteristics of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel (HAI nab-paclitaxel). Cohorts of three patients having predominant hepatic metastases received HAI nab-paclitaxel at three dose levels (180, 220, and 260 mg/m(2), respectively) infused for more than 1 hour every 3 weeks (3 + 3 design). Some patients participated in comparative pharmacokinetic studies (i.v. vs. HAI), receiving their first course i.v., to determine peak concentrations and effect of first-pass hepatic extraction compared with subsequent courses administered by HAI. The highest dose level was expanded to determine the safety and activity of HAI nab-paclitaxel. Thirty-eight patients were treated. There were no dose-limiting toxicities at doses up to 260 mg/m(2). Common adverse events included alopecia, fatigue, myelosuppresion, nausea, and vomiting. Three patients had stable disease for 4 or more months and 2 patients (1 of 12 with breast cancer and 1 of 1 with cervical cancer) achieved a partial response lasting for 5 and 15 months, respectively. Peak concentrations were lower (50%) with greater hepatic extraction of drug (42%) following HAI than i.v. infusion based on area under the curve comparison of drug exposure. HAI nab-paclitaxel showed partial hepatic extraction. At doses 260 mg/m(2) or less given for 1 hour every 3 weeks, the treatment was well-tolerated and showed activity in advanced cancer patients with predominant liver metastases.","Clinical Trial, Phase I",3175.0,13.0,Because involvement in patients with metastatic cancer has limited options and poor outcomes we conducted a phase I study to determine the safety activity and pharmacokinetic characteristics of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel HAI nab-paclitaxel Cohorts of three patients having predominant hepatic metastases received HAI nab-paclitaxel at three dose levels 180 220 and 260 mg/m 2 respectively infused for more than 1 hour every 3 weeks 3 3 design Some patients participated in comparative pharmacokinetic studies i.v vs. HAI receiving their first course i.v. to determine peak concentrations and effect of first-pass hepatic extraction compared with subsequent courses administered by HAI The highest dose level was expanded to determine the safety and activity of HAI nab-paclitaxel Thirty-eight patients were treated There were no dose-limiting toxicities at doses up to 260 mg/m 2 Common adverse events included alopecia fatigue myelosuppresion nausea and vomiting Three patients had stable disease for 4 or more months and 2 patients 1 of 12 with cancer and 1 of 1 with cancer achieved a partial response lasting for 5 and 15 months respectively Peak concentrations were lower 50 with greater hepatic extraction of drug 42 following HAI than i.v infusion based on area under the curve comparison of drug exposure HAI nab-paclitaxel showed partial hepatic extraction At doses 260 mg/m 2 or less given for 1 hour every 3 weeks the treatment was well-tolerated and showed activity in advanced cancer patients with predominant metastases,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[408, 799, 4, 7, 5, 113, 12, 71, 383, 838, 2, 334, 123, 21, 426, 8, 124, 70, 45, 6, 223, 3, 367, 128, 2, 1456, 374, 1, 939, 3127, 904, 1, 4483, 2799, 2951, 490, 4382, 3139, 490, 736, 1, 169, 7, 1041, 2750, 939, 196, 103, 4382, 3139, 490, 28, 169, 61, 148, 3172, 6211, 2, 6398, 81, 188, 18, 106, 4524, 9, 80, 76, 14, 2583, 454, 27, 244, 27, 27, 771, 476, 7, 3025, 4, 2352, 1456, 94, 70, 603, 105, 4382, 357, 136, 157, 906, 70, 603, 6, 223, 2944, 1003, 2, 254, 1, 157, 10152, 939, 5763, 72, 5, 706, 1993, 468, 20, 4382, 3, 1076, 61, 301, 10, 2064, 6, 223, 3, 367, 2, 128, 1, 4382, 3139, 490, 977, 659, 7, 11, 73, 125, 11, 77, 61, 817, 385, 28, 415, 126, 6, 6398, 81, 188, 18, 186, 290, 281, 159, 5691, 613, 39065, 1218, 2, 1966, 169, 7, 42, 585, 34, 9, 39, 15, 80, 53, 2, 18, 7, 14, 1, 133, 5, 12, 2, 14, 1, 14, 5, 12, 513, 8, 450, 51, 3443, 9, 33, 2, 167, 53, 106, 2944, 1003, 11, 280, 23911, 5, 378, 939, 5763, 1, 234, 60124, 366, 4382, 76, 70, 603, 904, 90, 23, 965, 669, 3, 1496, 1155, 1, 234, 645, 4382, 3139, 490, 224, 450, 939, 5763, 28, 415, 6398, 81, 188, 18, 15, 299, 447, 9, 14, 2583, 454, 27, 244, 3, 24, 10, 149, 421, 2, 224, 128, 4, 131, 12, 7, 5, 2750, 196]",1575.0,21571911,693
Rate of port-site metastasis is uncommon in patients undergoing robotic surgery for gynecological malignancies.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2011-07-01,"To describe the rate of port-site metastasis in patients who underwent robotic surgery for suspected gynecological malignancy. Using a prospective database, we identified all patients who underwent robotic surgery performed by the Gynecologic Oncology service at 1 institution between December 2006 and March 2010. Records of patients with confirmed malignancy were reviewed for clinicopathological data and information about port-site metastasis. One hundred eighty-one patients met the inclusion criteria. The median age was 55.4 years (range, 19-82 years), and the median body mass index was 29.6 kg/m (range, 17.9-70.7 kg/m). Port-site metastases were detected in 2 patients (1.1%) at 3 weeks (patient 1) and 11 months (patient 2) after surgery. Patient 1 underwent surgery for an adnexal mass, and pathological examination revealed gallbladder adenocarcinoma metastatic to the ovary. She had a recurrence in the right lateral abdominal wall robotic trocar site with concurrent metastases in the gallbladder fossa and liver. Patient 2 was diagnosed with adenocarcinoma of unclear (cervical vs endometrial) origin. Imaging showed metastases in pelvic and para-aortic lymph nodes. She underwent laparoscopy and was found intraoperatively to have gross disease on the right ovary. The patient underwent right salpingo-oophorectomy and chemoradiation. She had residual disease in the cervix and subsequently underwent robotic hysterectomy and left salpingo-oophorectomy. Pathological examination revealed endometrial cancer. She had a recurrence at the transumbilical trocar site concurrent with retroperitoneal lymphadenopathy and carcinomatosis. There were no cases of isolated port-site metastasis. The rate of port-site metastasis after robotic surgery in women with gynecological cancer is low and similar to the rate for laparoscopic procedures.",Evaluation Study,3126.0,30.0,To describe the rate of port-site metastasis in patients who underwent robotic surgery for suspected gynecological malignancy Using a prospective database we identified all patients who underwent robotic surgery performed by the Gynecologic Oncology service at 1 institution between December 2006 and March 2010 Records of patients with confirmed malignancy were reviewed for clinicopathological data and information about port-site metastasis One hundred eighty-one patients met the inclusion criteria The median age was 55.4 years range 19-82 years and the median body mass index was 29.6 kg/m range 17.9-70.7 kg/m Port-site metastases were detected in 2 patients 1.1 at 3 weeks patient 1 and 11 months patient 2 after surgery Patient 1 underwent surgery for an adnexal mass and pathological examination revealed adenocarcinoma metastatic to the ovary She had a recurrence in the right lateral abdominal wall robotic trocar site with concurrent metastases in the fossa and Patient 2 was diagnosed with adenocarcinoma of unclear vs origin Imaging showed metastases in pelvic and para-aortic lymph nodes She underwent laparoscopy and was found intraoperatively to have gross disease on the right ovary The patient underwent right salpingo-oophorectomy and chemoradiation She had residual disease in the cervix and subsequently underwent robotic hysterectomy and left salpingo-oophorectomy Pathological examination revealed cancer She had a recurrence at the transumbilical trocar site concurrent with retroperitoneal lymphadenopathy and carcinomatosis There were no cases of isolated port-site metastasis The rate of port-site metastasis after robotic surgery in women with gynecological cancer is low and similar to the rate for laparoscopic procedures,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 897, 3, 116, 1, 3083, 606, 278, 4, 7, 54, 208, 2895, 152, 9, 2768, 6324, 710, 75, 8, 482, 609, 21, 108, 62, 7, 54, 208, 2895, 152, 173, 20, 3, 1512, 413, 3086, 28, 14, 731, 59, 1397, 1324, 2, 2363, 1120, 1064, 1, 7, 5, 557, 710, 11, 446, 9, 2721, 74, 2, 487, 545, 3083, 606, 278, 104, 1128, 2207, 104, 7, 543, 3, 1680, 371, 3, 52, 89, 10, 614, 39, 60, 184, 326, 878, 60, 2, 3, 52, 642, 782, 558, 10, 462, 49, 503, 4709, 184, 269, 83, 431, 67, 503, 4709, 3083, 606, 196, 11, 530, 4, 18, 7, 14, 14, 28, 27, 244, 69, 14, 2, 175, 53, 69, 18, 50, 152, 69, 14, 208, 152, 9, 35, 6462, 782, 2, 1301, 1385, 553, 449, 113, 6, 3, 3631, 3109, 42, 8, 146, 4, 3, 1913, 3855, 1467, 2397, 2895, 11980, 606, 5, 750, 196, 4, 3, 5100, 2, 69, 18, 10, 265, 5, 449, 1, 1200, 105, 1938, 270, 224, 196, 4, 1110, 2, 4615, 3938, 263, 502, 3109, 208, 3553, 2, 10, 204, 6595, 6, 47, 1789, 34, 23, 3, 1913, 3631, 3, 69, 208, 1913, 5690, 3470, 2, 975, 3109, 42, 753, 34, 4, 3, 3629, 2, 1611, 208, 2895, 2622, 2, 1712, 5690, 3470, 1301, 1385, 553, 12, 3109, 42, 8, 146, 28, 3, 60186, 11980, 606, 750, 5, 2591, 4962, 2, 5622, 125, 11, 77, 140, 1, 1355, 3083, 606, 278, 3, 116, 1, 3083, 606, 278, 50, 2895, 152, 4, 117, 5, 6324, 12, 16, 154, 2, 288, 6, 3, 116, 9, 1964, 1369]",1755.0,21633306,78
ACR appropriateness criteria adjuvant therapy for resected squamous cell carcinoma of the head and neck.,Oral oncology,Oral Oncol.,2011-06-12,"Locoregional recurrence following surgical resection alone for stage III/IV head and neck cancer is common. Adjuvant radiotherapy has been shown to improve post-operative locoregional control when compared to pre-operative radiotherapy for head and neck cancers. Following surgical resection, adverse pathological features determine the need for adjuvant therapy. High-risk pathologic features include extranodal tumor spread and involved surgical margins. Other adverse pathologic features include T 3-4 tumors, perineural invasion, lymphovascular space invasion, low neck adenopathy, and multiple tumor involved cervical lymph nodes. The standard adjuvant therapies are post-operative radiation therapy or post-operative chemoradiotherapy. Post-operative chemoradiotherapy yields superior locoregional control, progression-free survival, and in some studies, overall survival compared to post-operative radiotherapy for high-risk patients in multiple randomized studies. Pooled analyses of randomized data demonstrate that post-operative concurrent chemoradiotherapy is associated with overall survival benefits for patients with involved surgical margins as well as those with extranodal tumor spread. Post-operative radiotherapy concurrent with cisplatin at 100 mg/m(2) every 21 days is the current standard chemoradiotherapy platform adjuvant head and neck cancer treatment. Post-operative radiotherapy and post-operative chemoradiotherapy radiation treatment volumes are not standardized and should be designed based on the risk of recurrence and clinically occult involvement of head and neck subsites and nodal regions. Evidence supports a post-operative radiotherapy and chemoradiotherapy radiation dose of at least 63 Gy for high-risk patients and at least 57 Gy for low risk patients.",Journal Article,3145.0,,Locoregional recurrence following surgical resection alone for stage III/IV head and cancer is common Adjuvant radiotherapy has been shown to improve post-operative locoregional control when compared to pre-operative radiotherapy for head and cancers Following surgical resection adverse pathological features determine the need for adjuvant therapy High-risk pathologic features include extranodal tumor spread and involved surgical margins Other adverse pathologic features include T 3-4 tumors perineural invasion lymphovascular space invasion low adenopathy and multiple tumor involved lymph nodes The standard adjuvant therapies are post-operative radiation therapy or post-operative chemoradiotherapy Post-operative chemoradiotherapy yields superior locoregional control progression-free survival and in some studies overall survival compared to post-operative radiotherapy for high-risk patients in multiple randomized studies Pooled analyses of randomized data demonstrate that post-operative concurrent chemoradiotherapy is associated with overall survival benefits for patients with involved surgical margins as well as those with extranodal tumor spread Post-operative radiotherapy concurrent with cisplatin at 100 mg/m 2 every 21 days is the current standard chemoradiotherapy platform adjuvant head and cancer treatment Post-operative radiotherapy and post-operative chemoradiotherapy radiation treatment volumes are not standardized and should be designed based on the risk of recurrence and clinically occult involvement of head and subsites and nodal regions Evidence supports a post-operative radiotherapy and chemoradiotherapy radiation dose of at least 63 Gy for high-risk patients and at least 57 Gy for low risk patients,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1325, 146, 366, 221, 170, 279, 9, 82, 316, 478, 718, 2, 12, 16, 186, 249, 310, 71, 85, 443, 6, 401, 539, 1208, 1325, 182, 198, 72, 6, 671, 1208, 310, 9, 718, 2, 163, 366, 221, 170, 290, 1301, 404, 223, 3, 594, 9, 249, 36, 64, 43, 510, 404, 643, 4093, 30, 2579, 2, 646, 221, 1012, 127, 290, 510, 404, 643, 102, 27, 39, 57, 4917, 578, 2933, 3865, 578, 154, 7741, 2, 232, 30, 646, 263, 502, 3, 260, 249, 235, 32, 539, 1208, 121, 36, 15, 539, 1208, 1464, 539, 1208, 1464, 4788, 1123, 1325, 182, 91, 115, 25, 2, 4, 476, 94, 63, 25, 72, 6, 539, 1208, 310, 9, 64, 43, 7, 4, 232, 384, 94, 1830, 318, 1, 384, 74, 608, 17, 539, 1208, 750, 1464, 16, 41, 5, 63, 25, 1141, 9, 7, 5, 646, 221, 1012, 22, 149, 22, 135, 5, 4093, 30, 2579, 539, 1208, 310, 750, 5, 540, 28, 394, 81, 188, 18, 454, 239, 162, 16, 3, 291, 260, 1464, 2243, 249, 718, 2, 12, 24, 539, 1208, 310, 2, 539, 1208, 1464, 121, 24, 2225, 32, 44, 1670, 2, 257, 40, 1114, 90, 23, 3, 43, 1, 146, 2, 505, 2879, 799, 1, 718, 2, 11239, 2, 779, 1374, 241, 2304, 8, 539, 1208, 310, 2, 1464, 121, 61, 1, 28, 506, 676, 381, 9, 64, 43, 7, 2, 28, 506, 696, 381, 9, 154, 43, 7]",1741.0,21664857,806
Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.,Gynecologic oncology,Gynecol. Oncol.,2011-09-01,"The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the efficacy and tolerability of the anti-EGFR antibody cetuximab, in persistent or recurrent carcinoma of the cervix. Eligible patients had cervical cancer, measurable disease, and GOG performance status 2. Treatment consisted of cetuximab 400 mg/m(2) initial dose followed by 250 mg/m(2) weekly until disease progression or prohibitive toxicity. The primary endpoints were progression-free survival (PFS) at 6 months and response. The study used a 2-stage group sequential design. Thirty-eight patients were entered with 3 exclusions, leaving 35 evaluable for analysis. Thirty-one patients (88.6%) received prior radiation as well as either 1 (n=25, 71.4%) or 2 (n=10) prior cytotoxic regimens. Twenty-four patients (68.6%) had a squamous cell carcinoma. Grade 3 adverse events possibly related to cetuximab included dermatologic (n=5), GI (n=4), anemia (n=2), constitutional (n=3), infection (n=2), vascular (n=2), pain (n=2), and pulmonary, neurological, vomiting and metabolic (n=1 each). No clinical responses were detected. Five patients (14.3%; two-sided 90% CI, 5.8% to 30%) survived without progression for at least 6 months. The median PFS and overall survival (OS) times were 1.97 and 6.7 months, respectively. In this study, all patients with PFS at 6 months harbored tumors with squamous cell histology. Cetuximab is well tolerated but has limited activity in this population. Cetuximab activity may be limited to patients with squamous cell histology.","Clinical Trial, Phase II",3064.0,78.0,The Gynecologic Oncology Group GOG conducted a phase II trial to assess the efficacy and tolerability of the anti-EGFR antibody cetuximab in persistent or recurrent carcinoma of the cervix Eligible patients had cancer measurable disease and GOG performance status 2 Treatment consisted of cetuximab 400 mg/m 2 initial dose followed by 250 mg/m 2 weekly until disease progression or prohibitive toxicity The primary endpoints were progression-free survival PFS at 6 months and response The study used a 2-stage group sequential design Thirty-eight patients were entered with 3 exclusions leaving 35 evaluable for analysis Thirty-one patients 88.6 received prior radiation as well as either 1 n=25 71.4 or 2 n=10 prior cytotoxic regimens Twenty-four patients 68.6 had a squamous cell carcinoma Grade 3 adverse events possibly related to cetuximab included dermatologic n=5 GI n=4 anemia n=2 constitutional n=3 infection n=2 vascular n=2 pain n=2 and pulmonary neurological vomiting and metabolic n=1 each No clinical responses were detected Five patients 14.3 two-sided 90 CI 5.8 to 30 survived without progression for at least 6 months The median PFS and overall survival OS times were 1.97 and 6.7 months respectively In this study all patients with PFS at 6 months harbored tumors with squamous cell histology Cetuximab is well tolerated but has limited activity in this population Cetuximab activity may be limited to patients with squamous cell histology,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1512, 413, 87, 4760, 426, 8, 124, 215, 160, 6, 423, 3, 209, 2, 1543, 1, 3, 312, 227, 548, 1175, 4, 1882, 15, 387, 134, 1, 3, 3629, 625, 7, 42, 12, 1884, 34, 2, 4760, 528, 156, 6006, 24, 1695, 1, 1175, 1524, 81, 188, 18, 388, 61, 370, 20, 2039, 81, 188, 18, 709, 1100, 34, 91, 15, 10784, 155, 3, 86, 1387, 11, 91, 115, 25, 300, 28, 49, 53, 2, 51, 3, 45, 95, 8, 18, 82, 87, 1787, 771, 977, 659, 7, 11, 2836, 5, 27, 17835, 7806, 465, 859, 9, 65, 977, 104, 7, 889, 49, 103, 324, 121, 22, 149, 22, 361, 14, 78, 243, 792, 39, 15, 18, 78, 79, 324, 759, 472, 737, 294, 7, 806, 49, 42, 8, 691, 31, 134, 88, 27, 290, 281, 2150, 139, 6, 1175, 159, 4722, 78, 33, 2104, 78, 39, 1545, 78, 18, 5962, 78, 27, 930, 78, 18, 756, 78, 18, 559, 78, 18, 2, 1087, 3622, 1966, 2, 1436, 78, 14, 296, 77, 38, 253, 11, 530, 365, 7, 213, 27, 100, 1689, 424, 58, 33, 66, 6, 201, 2996, 187, 91, 9, 28, 506, 49, 53, 3, 52, 300, 2, 63, 25, 118, 1072, 11, 14, 1015, 2, 49, 67, 53, 106, 4, 26, 45, 62, 7, 5, 300, 28, 49, 53, 3253, 57, 5, 691, 31, 784, 1175, 16, 149, 421, 84, 71, 383, 128, 4, 26, 266, 1175, 128, 68, 40, 383, 6, 7, 5, 691, 31, 784]",1458.0,21684583,524
Differentiating squamous cell carcinoma of the cervix and epithelioid trophoblastic tumor.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2011-07-01,"Epithelioid trophoblastic tumor (ETT) is a recently described subtype of gestational trophoblastic neoplasia (GTN). Its diagnosis requires a high level of suspicion because it is often mistaken for more common cervical or uterine corpus epithelial neoplasms. This is a 39-year-old woman who presented with a cervical mass and positive human chorionic gonadotropin and was diagnosed with both locally advanced squamous cell cervical carcinoma and nonmetastatic GTN. She was treated unsuccessfully with concurrent intravenous cisplatin plus pelvic radiation and single-agent intravenous methotrexate. A retrospective review of the cervical biopsy using immunohistochemistry as well as genotyping of the tumor changed the original diagnosis to ETT. It is known that ETT is relatively unresponsive to chemotherapy compared with most other types of GTN; therefore, surgery would have been the optimal treatment. She died despite multiple salvage chemotherapies. Malignant GTN is one of the most curable gynecologic malignancies; however, its correct diagnosis is critical for the appropriate treatment. It can be easily misdiagnosed as a carcinoma because of their morphologic similarity. Genetic fingerprinting and immunohistochemistry are potentially valuable tools to confirm the diagnosis of ETT.",Case Reports,3126.0,12.0,Epithelioid trophoblastic tumor ETT is a recently described subtype of gestational trophoblastic neoplasia GTN Its diagnosis requires a high level of suspicion because it is often mistaken for more common or corpus epithelial neoplasms This is a 39-year-old woman who presented with a mass and positive human chorionic gonadotropin and was diagnosed with both locally advanced squamous cell carcinoma and nonmetastatic GTN She was treated unsuccessfully with concurrent intravenous cisplatin plus pelvic radiation and single-agent intravenous methotrexate A retrospective review of the biopsy using immunohistochemistry as well as genotyping of the tumor changed the original diagnosis to ETT It is known that ETT is relatively unresponsive to chemotherapy compared with most other types of GTN therefore surgery would have been the optimal treatment She died despite multiple salvage chemotherapies Malignant GTN is one of the most curable gynecologic malignancies however its correct diagnosis is critical for the appropriate treatment It can be easily misdiagnosed as a carcinoma because of their morphologic similarity Genetic fingerprinting and immunohistochemistry are potentially valuable tools to confirm the diagnosis of ETT,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3838, 11355, 30, 26871, 16, 8, 761, 1027, 875, 1, 9383, 11355, 2298, 12448, 211, 147, 1706, 8, 64, 301, 1, 5782, 408, 192, 16, 629, 16214, 9, 80, 186, 15, 7758, 701, 1179, 26, 16, 8, 587, 111, 1095, 2854, 54, 917, 5, 8, 782, 2, 109, 171, 10420, 6501, 2, 10, 265, 5, 110, 795, 131, 691, 31, 134, 2, 2683, 12448, 3109, 10, 73, 26546, 5, 750, 1262, 540, 349, 1110, 121, 2, 226, 420, 1262, 2116, 8, 459, 206, 1, 3, 411, 75, 888, 22, 149, 22, 2686, 1, 3, 30, 2368, 3, 2279, 147, 6, 26871, 192, 16, 440, 17, 26871, 16, 1352, 7244, 6, 56, 72, 5, 96, 127, 630, 1, 12448, 673, 152, 688, 47, 85, 3, 665, 24, 3109, 1016, 550, 232, 992, 4203, 393, 12448, 16, 104, 1, 3, 96, 4151, 1512, 441, 137, 211, 4883, 147, 16, 740, 9, 3, 870, 24, 192, 122, 40, 4697, 10688, 22, 8, 134, 408, 1, 136, 2815, 6700, 336, 21030, 2, 888, 32, 751, 2926, 1896, 6, 1843, 3, 147, 1, 26871]",1233.0,21697681,13
Cancer screening practices among Amish and non-Amish adults living in Ohio Appalachia.,The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association,J Rural Health,2010-11-15,"The Amish, a unique community living in Ohio Appalachia, have lower cancer incidence rates than non-Amish living in Ohio Appalachia. The purpose of this study was to examine cancer screening rates among Amish compared to non-Amish adults living in Ohio Appalachia and a national sample of adults of the same race and ethnicity in an effort to explain cancer patterns. Face-to-face interviews focusing on perception of risk, cancer screening behaviors, and screening barriers were conducted among Amish (n = 134) and non-Amish (n = 154) adults living in Ohio Appalachia. Cancer screening rates were calculated and then compared to a national sample of adults. More Ohio Appalachia non-Amish males (35.9% vs 14.5%; P= .022) and females (33.3% vs 12.5%; P= .008) reported that they would probably develop cancer in the future compared to Amish males and females. Amish adults had significantly lower prostate (13.5% vs 63.1% vs 44.6%; P < .001), colorectal (males: 10.3% vs 40.0% vs 37.2%, females: 8.6% vs 31.6% vs 42.9%; P < .001), cervical (48.0% vs 84.0% vs 80.0%; P < .001), and female breast (24.8% vs 53.7% vs 56.9%; P < .05) cancer screening rates compared to Ohio Appalachia non-Amish participants and a national sample of adults, respectively. Barriers to cancer screening were similar among the 2 Ohio groups; however, Amish males reported that prostate cancer screening was not necessary more often than did Ohio Appalachia non-Amish males (78.6% vs 16.7%; P= .003). Lower rates of cancer screening were documented among the Amish and may be a contributing factor to the reduced cancer incidence rates reported among this population.",Comparative Study,3354.0,11.0,The Amish a unique community living in Ohio Appalachia have lower cancer incidence rates than non-Amish living in Ohio Appalachia The purpose of this study was to examine cancer screening rates among Amish compared to non-Amish adults living in Ohio Appalachia and a national sample of adults of the same race and ethnicity in an effort to explain cancer patterns Face-to-face interviews focusing on perception of risk cancer screening behaviors and screening barriers were conducted among Amish n 134 and non-Amish n 154 adults living in Ohio Appalachia Cancer screening rates were calculated and then compared to a national sample of adults More Ohio Appalachia non-Amish males 35.9 vs 14.5 P= .022 and females 33.3 vs 12.5 P= .008 reported that they would probably develop cancer in the future compared to Amish males and females Amish adults had significantly lower 13.5 vs 63.1 vs 44.6 P .001 males 10.3 vs 40.0 vs 37.2 females 8.6 vs 31.6 vs 42.9 P .001 48.0 vs 84.0 vs 80.0 P .001 and female 24.8 vs 53.7 vs 56.9 P .05 cancer screening rates compared to Ohio Appalachia non-Amish participants and a national sample of adults respectively Barriers to cancer screening were similar among the 2 Ohio groups however Amish males reported that cancer screening was not necessary more often than did Ohio Appalachia non-Amish males 78.6 vs 16.7 P= .003 Lower rates of cancer screening were documented among the Amish and may be a contributing factor to the reduced cancer incidence rates reported among this population,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 11213, 8, 991, 1714, 2798, 4, 10009, 25368, 47, 280, 12, 287, 151, 76, 220, 11213, 2798, 4, 10009, 25368, 3, 743, 1, 26, 45, 10, 6, 1004, 12, 453, 151, 107, 11213, 72, 6, 220, 11213, 857, 2798, 4, 10009, 25368, 2, 8, 657, 1000, 1, 857, 1, 3, 827, 1047, 2, 2091, 4, 35, 2919, 6, 2943, 12, 764, 3376, 6, 3376, 4053, 3312, 23, 4886, 1, 43, 12, 453, 3704, 2, 453, 2160, 11, 426, 107, 11213, 78, 4842, 2, 220, 11213, 78, 4838, 857, 2798, 4, 10009, 25368, 12, 453, 151, 11, 981, 2, 818, 72, 6, 8, 657, 1000, 1, 857, 80, 10009, 25368, 220, 11213, 2296, 465, 83, 105, 213, 33, 19, 4773, 2, 2451, 466, 27, 105, 133, 33, 19, 2155, 210, 17, 491, 688, 4061, 690, 12, 4, 3, 508, 72, 6, 11213, 2296, 2, 2451, 11213, 857, 42, 97, 280, 233, 33, 105, 676, 14, 105, 584, 49, 19, 144, 2296, 79, 27, 105, 327, 13, 105, 567, 18, 2451, 66, 49, 105, 456, 49, 105, 595, 83, 19, 144, 576, 13, 105, 874, 13, 105, 493, 13, 19, 144, 2, 1061, 259, 66, 105, 699, 67, 105, 664, 83, 19, 474, 12, 453, 151, 72, 6, 10009, 25368, 220, 11213, 776, 2, 8, 657, 1000, 1, 857, 106, 2160, 6, 12, 453, 11, 288, 107, 3, 18, 10009, 271, 137, 11213, 2296, 210, 17, 12, 453, 10, 44, 1493, 80, 629, 76, 205, 10009, 25368, 220, 11213, 2296, 833, 49, 105, 245, 67, 19, 1421, 280, 151, 1, 12, 453, 11, 1405, 107, 3, 11213, 2, 68, 40, 8, 3156, 161, 6, 3, 405, 12, 287, 151, 210, 107, 26, 266]",1518.0,21729158,32
Tumor size and presence of calcifications on ultrasonography are pre-operative predictors of lymph node metastases in patients with papillary thyroid cancer.,Journal of surgical oncology,J Surg Oncol,2011-07-08,"Lymph node metastases in papillary thyroid cancer (PTC) are common and their presence can significantly alter the treatment for patients with PTC. We therefore sought to identify pre-operative predictors of lymph node metastases in patients with PTC. A thyroid tumor database was queried to identify patients with a pre-operative diagnosis of PTC and underwent thyroidectomy between January 2006 and August 2009. One hundred and three patients who had a pre-operative ultrasound and had lymph nodes surgically resected were identified. Clinical factors and tumor ultrasound characteristics were recorded. The pre-operative ultrasound results, type of operation, and final pathology results were also recorded. Of the 103 patients, 74 (72%) were women and 29 (28%) were men with an age range of 15-78 years (median age of 43). Of the ultrasound characteristics evaluated only calcifications (P=0.007) and size (P=0.003) were statistically associated with positive cervical lymph nodes. None of the other demographic or clinical factors were significantly associated with lymph node metastases. Thyroid nodule size and presence of calcifications on ultrasound were found to have a statistically significant association with lymph node metastases in patients with PTC. This information could be used to guide the surgical management of these patients.",Journal Article,3119.0,14.0,Lymph node metastases in papillary cancer PTC are common and their presence can significantly alter the treatment for patients with PTC We therefore sought to identify pre-operative predictors of lymph node metastases in patients with PTC A tumor database was queried to identify patients with a pre-operative diagnosis of PTC and underwent thyroidectomy between January 2006 and August 2009 One hundred and three patients who had a pre-operative ultrasound and had lymph nodes surgically resected were identified Clinical factors and tumor ultrasound characteristics were recorded The pre-operative ultrasound results type of operation and final pathology results were also recorded Of the 103 patients 74 72 were women and 29 28 were men with an age range of 15-78 years median age of 43 Of the ultrasound characteristics evaluated only calcifications P 0.007 and size P 0.003 were statistically associated with positive lymph nodes None of the other demographic or clinical factors were significantly associated with lymph node metastases nodule size and presence of calcifications on ultrasound were found to have a statistically significant association with lymph node metastases in patients with PTC This information could be used to guide the surgical management of these patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[263, 289, 196, 4, 1796, 12, 3748, 32, 186, 2, 136, 463, 122, 97, 2688, 3, 24, 9, 7, 5, 3748, 21, 673, 990, 6, 255, 671, 1208, 674, 1, 263, 289, 196, 4, 7, 5, 3748, 8, 30, 609, 10, 3547, 6, 255, 7, 5, 8, 671, 1208, 147, 1, 3748, 2, 208, 5949, 59, 1024, 1324, 2, 2480, 1238, 104, 1128, 2, 169, 7, 54, 42, 8, 671, 1208, 1945, 2, 42, 263, 502, 2350, 1133, 11, 108, 38, 130, 2, 30, 1945, 374, 11, 1872, 3, 671, 1208, 1945, 99, 267, 1, 2589, 2, 1457, 1117, 99, 11, 120, 1872, 1, 3, 3283, 7, 794, 720, 11, 117, 2, 462, 339, 11, 325, 5, 35, 89, 184, 1, 167, 833, 60, 52, 89, 1, 601, 1, 3, 1945, 374, 194, 158, 6740, 19, 13, 1999, 2, 444, 19, 13, 1421, 11, 712, 41, 5, 109, 263, 502, 1292, 1, 3, 127, 1540, 15, 38, 130, 11, 97, 41, 5, 263, 289, 196, 5072, 444, 2, 463, 1, 6740, 23, 1945, 11, 204, 6, 47, 8, 712, 93, 248, 5, 263, 289, 196, 4, 7, 5, 3748, 26, 487, 359, 40, 95, 6, 1597, 3, 221, 284, 1, 46, 7]",1287.0,21744345,14
Application of the hybrid capture 2 assay to squamous cell carcinomas of the head and neck: a convenient liquid-phase approach for the reliable determination of human papillomavirus status.,Cancer cytopathology,Cancer Cytopathol,2011-07-12,"A growing proportion of head and neck squamous cell carcinoma (HNSCC) is caused by the human papillomavirus (HPV). In light of the unique natural history and prognosis of HPV-related HNSCCs, routine HPV testing is being incorporated into diagnostic protocols. Accordingly, there is an escalating demand for an optimal detection strategy that is sensitive and specific, transferrable to the diagnostic laboratory, standardized across laboratories, cost-effective, and amenable to broad application across specimen types including cytologic preparations. Cytologic preparations (fine-needle aspirates [FNAs] and brushes) were obtained from surgically resected HNSCCs and evaluated for the presence of high-risk HPV using the Hybrid Capture 2 assay. HPV analysis was also performed on the corresponding tissue sections using HPV in situ hybridization and p16 immunohistochemistry. In cases in which the immunohistochemical and in situ hybridization results were discordant, HPV status was determined by real-time polymerase chain reaction detection of E7 expression. HPV status in the tissues and corresponding cytologic samples was compared. Based on benchmark HPV testing of the tissue sections, 14 HNSCCs were classified as HPV positive and 10 as HPV negative. All corresponding cytologic preparations were correctly classified using the Hybrid Capture 2 assay. The Hybrid Capture 2 strategy, already widely used for the detection of high-risk HPV in cervical brushes, is readily transferrable to HNSCCs. Consistent accuracy in cytologic preparation suggests its potential application in FNAs from patients who present with lymph node metastases, and may eliminate the need to obtain tissue solely for the purpose of HPV testing.",Evaluation Study,3115.0,45.0,A growing proportion of head and squamous cell carcinoma HNSCC is caused by the human papillomavirus HPV In light of the unique natural history and prognosis of HPV-related HNSCCs routine HPV testing is being incorporated into diagnostic protocols Accordingly there is an escalating demand for an optimal detection strategy that is sensitive and specific transferrable to the diagnostic laboratory standardized across laboratories cost-effective and amenable to broad application across specimen types including cytologic preparations Cytologic preparations fine-needle aspirates FNAs and brushes were obtained from surgically resected HNSCCs and evaluated for the presence of high-risk HPV using the Hybrid Capture 2 assay HPV analysis was also performed on the corresponding tissue sections using HPV in situ hybridization and p16 immunohistochemistry In cases in which the immunohistochemical and in situ hybridization results were discordant HPV status was determined by real-time polymerase chain reaction detection of E7 expression HPV status in the tissues and corresponding cytologic samples was compared Based on benchmark HPV testing of the tissue sections 14 HNSCCs were classified as HPV positive and 10 as HPV negative All corresponding cytologic preparations were correctly classified using the Hybrid Capture 2 assay The Hybrid Capture 2 strategy already widely used for the detection of high-risk HPV in brushes is readily transferrable to HNSCCs Consistent accuracy in cytologic preparation suggests its potential application in FNAs from patients who present with lymph node metastases and may eliminate the need to obtain tissue solely for the purpose of HPV testing,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[8, 1921, 920, 1, 718, 2, 691, 31, 134, 1209, 16, 1546, 20, 3, 171, 3242, 933, 4, 1691, 1, 3, 991, 1504, 532, 2, 356, 1, 933, 139, 9691, 1311, 933, 471, 16, 486, 2449, 237, 752, 2189, 4705, 125, 16, 35, 2922, 6645, 9, 35, 665, 638, 692, 17, 16, 745, 2, 112, 46671, 6, 3, 752, 1624, 1670, 716, 4884, 835, 323, 2, 4070, 6, 2094, 1581, 716, 2360, 630, 141, 4195, 7791, 4195, 7791, 2924, 2177, 7493, 18785, 2, 31307, 11, 683, 29, 2350, 1133, 9691, 2, 194, 9, 3, 463, 1, 64, 43, 933, 75, 3, 4542, 2891, 18, 719, 933, 65, 10, 120, 173, 23, 3, 1734, 246, 3013, 75, 933, 4, 957, 1554, 2, 1932, 888, 4, 140, 4, 92, 3, 1382, 2, 4, 957, 1554, 99, 11, 4570, 933, 156, 10, 509, 20, 1589, 98, 1451, 1260, 1329, 638, 1, 4540, 55, 933, 156, 4, 3, 742, 2, 1734, 4195, 347, 10, 72, 90, 23, 7330, 933, 471, 1, 3, 246, 3013, 213, 9691, 11, 1373, 22, 933, 109, 2, 79, 22, 933, 199, 62, 1734, 4195, 7791, 11, 4911, 1373, 75, 3, 4542, 2891, 18, 719, 3, 4542, 2891, 18, 692, 3298, 1792, 95, 9, 3, 638, 1, 64, 43, 933, 4, 31307, 16, 3860, 46671, 6, 9691, 925, 1190, 4, 4195, 4824, 844, 211, 174, 1581, 4, 18785, 29, 7, 54, 364, 5, 263, 289, 196, 2, 68, 4964, 3, 594, 6, 3140, 246, 5558, 9, 3, 743, 1, 933, 471]",1685.0,21751428,94
GRIM-19 disrupts E6/E6AP complex to rescue p53 and induce apoptosis in cervical cancers.,PloS one,PLoS ONE,2011-07-12,"Our previous studies showed a down-regulation of GRIM-19 in primary human cervical cancers, and restoration of GRIM-19 induced tumor regression. The induction of tumor suppressor protein p53 ubiquitination and degradation by E6 oncoportein of high risk-HPV through forming a stable complex with E6AP is considered as a critical mechanism for cervical tumor development. The aims of this study were to determine the potential role of GRIM-19 in rescuing p53 protein and inducing cervical cancer cell apoptosis. The protein levels of GRIM-19 and p53 were detected in normal cervical tissues from 45 patients who underwent hysterectomy for reasons other than neoplasias of either the cervix or endometrium, and cervical cancer tissues from 60 patients with non-metastatic squamous epithelial carcinomas. Coimmunoprecipitation and GST pull-down assay were performed to examine the interaction of GRIM-19 with 18E6 and E6AP in vivo and in vitro respectively. The competition of 18E6 with E6AP in binding GRIM-19 by performing competition pull-down assays was designed to examine the disruption of E6/E6AP complex by GRIM-19. The augment of E6AP ubiquitination by GRIM-19 was detected in vivo and in vitro ubiquitination assay. The effects of GRIM-19-dependent p53 accumulation on cell proliferation, cell cycle, apoptosis were explored by MTT, flow cytometry and transmission electron microscopy respectively. The tumor suppression was detected by xenograft mouse model. The levels of GRIM-19 and p53 were concurrently down regulated in cervical cancers. The restoration of GRIM-19 can induce ubiquitination and degradation of E6AP, and disrupt the E6/E6AP complex through the interaction of N-terminus of GRIM-19 with both E6 and E6AP, which protected p53 from degradation and promoted cell apoptosis. Tumor xenograft studies also revealed the suppression of p53 degradation in presence of GRIM-19. These data suggest that GRIM-19 can block E6/E6AP complex; and synergistically suppress cervical tumor growth with p53.",Journal Article,3115.0,17.0,Our previous studies showed a down-regulation of GRIM-19 in primary human cancers and restoration of GRIM-19 induced tumor regression The induction of tumor suppressor protein p53 ubiquitination and degradation by E6 oncoportein of high risk-HPV through forming a stable complex with E6AP is considered as a critical mechanism for tumor development The aims of this study were to determine the potential role of GRIM-19 in rescuing p53 protein and inducing cancer cell apoptosis The protein levels of GRIM-19 and p53 were detected in normal tissues from 45 patients who underwent hysterectomy for reasons other than neoplasias of either the cervix or and cancer tissues from 60 patients with non-metastatic squamous epithelial carcinomas Coimmunoprecipitation and GST pull-down assay were performed to examine the interaction of GRIM-19 with 18E6 and E6AP in vivo and in vitro respectively The competition of 18E6 with E6AP in binding GRIM-19 by performing competition pull-down assays was designed to examine the disruption of E6/E6AP complex by GRIM-19 The augment of E6AP ubiquitination by GRIM-19 was detected in vivo and in vitro ubiquitination assay The effects of GRIM-19-dependent p53 accumulation on cell proliferation cell cycle apoptosis were explored by MTT flow cytometry and transmission electron microscopy respectively The tumor suppression was detected by xenograft mouse model The levels of GRIM-19 and p53 were concurrently down regulated in cancers The restoration of GRIM-19 can induce ubiquitination and degradation of E6AP and disrupt the E6/E6AP complex through the interaction of N-terminus of GRIM-19 with both E6 and E6AP which protected p53 from degradation and promoted cell apoptosis Tumor xenograft studies also revealed the suppression of p53 degradation in presence of GRIM-19 These data suggest that GRIM-19 can block E6/E6AP complex and synergistically suppress tumor growth with p53,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[114, 698, 94, 224, 8, 1328, 863, 1, 11282, 326, 4, 86, 171, 163, 2, 5194, 1, 11282, 326, 277, 30, 320, 3, 504, 1, 30, 1245, 178, 624, 8258, 2, 2373, 20, 4837, 60360, 1, 64, 43, 933, 298, 4525, 8, 585, 840, 5, 18232, 16, 515, 22, 8, 740, 670, 9, 30, 193, 3, 2970, 1, 26, 45, 11, 6, 223, 3, 174, 200, 1, 11282, 326, 4, 31159, 624, 178, 2, 1958, 12, 31, 351, 3, 178, 148, 1, 11282, 326, 2, 624, 11, 530, 4, 295, 742, 29, 512, 7, 54, 208, 2622, 9, 2325, 127, 76, 8235, 1, 361, 3, 3629, 15, 2, 12, 742, 29, 335, 7, 5, 220, 113, 691, 701, 826, 15888, 2, 5645, 18171, 1328, 719, 11, 173, 6, 1004, 3, 915, 1, 11282, 326, 5, 46678, 2, 18232, 4, 386, 2, 4, 439, 106, 3, 12809, 1, 46678, 5, 18232, 4, 791, 11282, 326, 20, 3620, 12809, 18171, 1328, 1013, 10, 1114, 6, 1004, 3, 3220, 1, 4837, 18232, 840, 20, 11282, 326, 3, 4369, 1, 18232, 8258, 20, 11282, 326, 10, 530, 4, 386, 2, 4, 439, 8258, 719, 3, 176, 1, 11282, 326, 470, 624, 1835, 23, 31, 457, 31, 417, 351, 11, 1443, 20, 4988, 1412, 1914, 2, 8151, 4560, 3804, 106, 3, 30, 1332, 10, 530, 20, 1330, 830, 202, 3, 148, 1, 11282, 326, 2, 624, 11, 3294, 1328, 1065, 4, 163, 3, 5194, 1, 11282, 326, 122, 1290, 8258, 2, 2373, 1, 18232, 2, 6619, 3, 4837, 18232, 840, 298, 3, 915, 1, 78, 9114, 1, 11282, 326, 5, 110, 4837, 2, 18232, 92, 5541, 624, 29, 2373, 2, 2992, 31, 351, 30, 1330, 94, 120, 553, 3, 1332, 1, 624, 2373, 4, 463, 1, 11282, 326, 46, 74, 309, 17, 11282, 326, 122, 2381, 4837, 18232, 840, 2, 4240, 3134, 30, 129, 5, 624]",1918.0,21765936,68
Risk of occult malignancy in morcellated hysterectomy: a case series.,International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists,Int. J. Gynecol. Pathol.,2011-09-01,"Uterine morcellation is performed only when significant neoplasia is not anticipated. In this study, we aimed to determine the prevalence of unexpected pathology in a series of low-risk morcellated hysterectomies. We reviewed a series consisting of all patients undergoing hysterectomy with morcellation at a tertiary-care hospital over a 4-yr period (n=101). Patient records were reviewed to retrieve demographics, details of preoperative evaluation (Pap smear, endometrial biopsy, imaging), and surgical pathology diagnoses. The median number of blocks submitted for histology was 6. On final pathology, endometrium was detected in 99% of all cases. No endometrial, myometrial, or cervical neoplasia other than leiomyoma (numerous cases) was present in the morcellated uteri, but in 1 case an atypical trophoblastic nodule with necrosis and myometrial infiltration, suspected to represent epithelioid trophoblastic tumor, was inadvertently morcellated. From this series, the prospective risk of occult malignancy in a low-risk population undergoing morcellation is estimated at 1% (95% confidence interval, <0.01%-5.94%). A subgroup analysis of patients who participated in what we propose as a complete preoperative workup, consisting of nonconcerning Pap smear, endometrial biopsy, and ultrasound or magnetic resonance imaging, showed no significant findings on final histology. Even with a complete workup, however, morcellation of occult uterine malignancy remains a possibility. This risk should be discussed as part of informed consent before morcellation.",Case Reports,3064.0,50.0,morcellation is performed only when significant neoplasia is not anticipated In this study we aimed to determine the prevalence of unexpected pathology in a series of low-risk morcellated hysterectomies We reviewed a series consisting of all patients undergoing hysterectomy with morcellation at a tertiary-care hospital over a 4-yr period n=101 Patient records were reviewed to retrieve demographics details of preoperative evaluation Pap smear biopsy imaging and surgical pathology diagnoses The median number of blocks submitted for histology was 6 On final pathology was detected in 99 of all cases No myometrial or neoplasia other than leiomyoma numerous cases was present in the morcellated uteri but in 1 case an atypical trophoblastic nodule with necrosis and myometrial infiltration suspected to represent epithelioid trophoblastic tumor was inadvertently morcellated From this series the prospective risk of occult malignancy in a low-risk population undergoing morcellation is estimated at 1 95 confidence interval 0.01 -5.94 A subgroup analysis of patients who participated in what we propose as a complete preoperative workup consisting of nonconcerning Pap smear biopsy and ultrasound or magnetic resonance imaging showed no significant findings on final histology Even with a complete workup however morcellation of occult malignancy remains a possibility This risk should be discussed as part of informed consent before morcellation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[13125, 16, 173, 158, 198, 93, 2298, 16, 44, 4078, 4, 26, 45, 21, 1295, 6, 223, 3, 1078, 1, 3792, 1117, 4, 8, 988, 1, 154, 43, 27084, 15266, 21, 446, 8, 988, 2273, 1, 62, 7, 479, 2622, 5, 13125, 28, 8, 2557, 165, 702, 252, 8, 39, 2830, 727, 78, 2338, 69, 1064, 11, 446, 6, 18193, 2221, 3791, 1, 498, 451, 4290, 8379, 411, 270, 2, 221, 1117, 2403, 3, 52, 207, 1, 2860, 5118, 9, 784, 10, 49, 23, 1457, 1117, 10, 530, 4, 1058, 1, 62, 140, 77, 7327, 15, 2298, 127, 76, 12390, 2331, 140, 10, 364, 4, 3, 27084, 18980, 84, 4, 14, 473, 35, 1973, 11355, 5072, 5, 1523, 2, 7327, 2084, 2768, 6, 1231, 3838, 11355, 30, 10, 23154, 27084, 29, 26, 988, 3, 482, 43, 1, 2879, 710, 4, 8, 154, 43, 266, 479, 13125, 16, 661, 28, 14, 48, 307, 268, 13, 355, 33, 960, 8, 1363, 65, 1, 7, 54, 3025, 4, 2067, 21, 2548, 22, 8, 236, 498, 4755, 2273, 1, 60413, 4290, 8379, 411, 2, 1945, 15, 1484, 1535, 270, 224, 77, 93, 272, 23, 1457, 784, 871, 5, 8, 236, 4755, 137, 13125, 1, 2879, 710, 469, 8, 2526, 26, 43, 257, 40, 1588, 22, 760, 1, 2767, 3844, 348, 13125]",1448.0,21804400,100
Candida albicans cervical lymphadenitis in patients who have acute myeloid leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2011-08-01,We describe two patients with acute myelogenous leukemia who developed cervical lymphadenitis and chronic disseminated infection due to Candida albicans. Candida albicans infection should be considered in leukemic patients with acute lymphadenitis. Evaluation for visceral dissemination is warranted even in the absence of fungemia.,Case Reports,3095.0,2.0,We describe two patients with acute myelogenous who developed lymphadenitis and chronic disseminated infection due to Candida albicans Candida albicans infection should be considered in leukemic patients with acute lymphadenitis Evaluation for visceral dissemination is warranted even in the absence of fungemia,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 897, 100, 7, 5, 286, 2194, 54, 276, 25375, 2, 442, 3605, 930, 520, 6, 13321, 24644, 13321, 24644, 930, 257, 40, 515, 4, 2015, 7, 5, 286, 25375, 451, 9, 2737, 3430, 16, 1197, 871, 4, 3, 1127, 1, 34088]",311.0,21816377,12
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.,PloS one,PLoS ONE,2011-07-29,"Oncogenic mutations of PIK3CA, RAS (KRAS, NRAS), and BRAF have been identified in various malignancies, and activate the PI3K/AKT/mTOR and RAS/RAF/MEK pathways, respectively. Both pathways are critical drivers of tumorigenesis. Tumor tissues from 504 patients with diverse cancers referred to the Clinical Center for Targeted Therapy at MD Anderson Cancer Center starting in October 2008 were analyzed for PIK3CA, RAS (KRAS, NRAS), and BRAF mutations using polymerase chain reaction-based DNA sequencing. PIK3CA mutations were found in 54 (11%) of 504 patients tested; KRAS in 69 (19%) of 367; NRAS in 19 (8%) of 225; and BRAF in 31 (9%) of 361 patients. PIK3CA mutations were most frequent in squamous cervical (5/14, 36%), uterine (7/28, 25%), breast (6/29, 21%), and colorectal cancers (18/105, 17%); KRAS in pancreatic (5/9, 56%), colorectal (49/97, 51%), and uterine cancers (3/20, 15%); NRAS in melanoma (12/40, 30%), and uterine cancer (2/11, 18%); BRAF in melanoma (23/52, 44%), and colorectal cancer (5/88, 6%). Regardless of histology, KRAS mutations were found in 38% of patients with PIK3CA mutations compared to 16% of patients with wild-type (wt)PIK3CA (p=0.001). In total, RAS (KRAS, NRAS) or BRAF mutations were found in 47% of patients with PIK3CA mutations vs. 24% of patients wtPIK3CA (p=0.001). PIK3CA mutations were found in 28% of patients with KRAS mutations compared to 10% with wtKRAS (p=0.001) and in 20% of patients with RAS (KRAS, NRAS) or BRAF mutations compared to 8% with wtRAS (KRAS, NRAS) or wtBRAF (p=0.001). PIK3CA, RAS (KRAS, NRAS), and BRAF mutations are frequent in diverse tumors. In a wide variety of tumors, PIK3CA mutations coexist with RAS (KRAS, NRAS) and BRAF mutations.",Journal Article,3098.0,123.0,Oncogenic mutations of PIK3CA RAS KRAS NRAS and BRAF have been identified in various malignancies and activate the PI3K/AKT/mTOR and RAS/RAF/MEK pathways respectively Both pathways are critical drivers of tumorigenesis Tumor tissues from 504 patients with diverse cancers referred to the Clinical Center for Targeted Therapy at MD Anderson Cancer Center starting in October 2008 were analyzed for PIK3CA RAS KRAS NRAS and BRAF mutations using polymerase chain reaction-based DNA sequencing PIK3CA mutations were found in 54 11 of 504 patients tested KRAS in 69 19 of 367 NRAS in 19 8 of 225 and BRAF in 31 9 of 361 patients PIK3CA mutations were most frequent in squamous 5/14 36 7/28 25 6/29 21 and cancers 18/105 17 KRAS in 5/9 56 49/97 51 and cancers 3/20 15 NRAS in 12/40 30 and cancer 2/11 18 BRAF in 23/52 44 and cancer 5/88 6 Regardless of histology KRAS mutations were found in 38 of patients with PIK3CA mutations compared to 16 of patients with wild-type wt PIK3CA p 0.001 In total RAS KRAS NRAS or BRAF mutations were found in 47 of patients with PIK3CA mutations vs. 24 of patients wtPIK3CA p 0.001 PIK3CA mutations were found in 28 of patients with KRAS mutations compared to 10 with wtKRAS p 0.001 and in 20 of patients with RAS KRAS NRAS or BRAF mutations compared to 8 with wtRAS KRAS NRAS or wtBRAF p 0.001 PIK3CA RAS KRAS NRAS and BRAF mutations are frequent in diverse tumors In a wide variety of tumors PIK3CA mutations coexist with RAS KRAS NRAS and BRAF mutations,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[1302, 138, 1, 1506, 1102, 723, 2845, 2, 566, 47, 85, 108, 4, 747, 441, 2, 2977, 3, 974, 649, 873, 2, 1102, 2212, 1693, 460, 106, 110, 460, 32, 740, 3391, 1, 1565, 30, 742, 29, 8362, 7, 5, 1867, 163, 1995, 6, 3, 38, 574, 9, 238, 36, 28, 2244, 1929, 12, 574, 1723, 4, 2551, 1375, 11, 311, 9, 1506, 1102, 723, 2845, 2, 566, 138, 75, 1451, 1260, 1329, 90, 261, 615, 1506, 138, 11, 204, 4, 667, 175, 1, 8362, 7, 650, 723, 4, 790, 326, 1, 10720, 2845, 4, 326, 66, 1, 4011, 2, 566, 4, 456, 83, 1, 9234, 7, 1506, 138, 11, 96, 908, 4, 691, 33, 213, 511, 67, 339, 243, 49, 462, 239, 2, 163, 203, 3263, 269, 723, 4, 33, 83, 664, 739, 1015, 725, 2, 163, 27, 179, 167, 2845, 4, 133, 327, 201, 2, 12, 18, 175, 203, 566, 4, 382, 653, 584, 2, 12, 33, 889, 49, 1583, 1, 784, 723, 138, 11, 204, 4, 519, 1, 7, 5, 1506, 138, 72, 6, 245, 1, 7, 5, 955, 267, 1820, 1506, 19, 13, 144, 4, 181, 1102, 723, 2845, 15, 566, 138, 11, 204, 4, 662, 1, 7, 5, 1506, 138, 105, 259, 1, 7, 60445, 19, 13, 144, 1506, 138, 11, 204, 4, 339, 1, 7, 5, 723, 138, 72, 6, 79, 5, 16140, 19, 13, 144, 2, 4, 179, 1, 7, 5, 1102, 723, 2845, 15, 566, 138, 72, 6, 66, 5, 25095, 723, 2845, 15, 29191, 19, 13, 144, 1506, 1102, 723, 2845, 2, 566, 138, 32, 908, 4, 1867, 57, 4, 8, 1019, 1362, 1, 57, 1506, 138, 15707, 5, 1102, 723, 2845, 2, 566, 138]",1485.0,21829508,762
CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend.,"Cancer immunology, immunotherapy : CII",Cancer Immunol. Immunother.,2011-08-13,"The association between the CD8+ T-cell responses to human papillomavirus type 16 (HPV-16) E6 protein and a favorable clinical trend has been demonstrated previously. The roles of human papillomavirus (HPV)-specific CD4+ T-cell responses and of regulatory T-cells (Tregs) were examined. Subjects with a recent history of abnormal Papanicolaou smear were eligible, and colposcopy-guided biopsy was performed at enrollment. Interferon- enzyme-linked immunospot assay and fluorescent-activated cell sorter analysis to measure the frequencies of Tregs were performed. Subjects with histological diagnoses of cervical intraepithelial neoplasia 1, 2, or 3 were considered to have short-term persistence of cervical abnormality and were called ""persistors"" (n=51) while those of normal histology were designated to be ""regressors"" (n=33). A significantly higher percentage CD4+ T-cell response was detected in the regressors (15/33 or 45.5%) compared with the persistors (10/51 or 19.6%) (P=.015) for the E6 peptides but not for the E7 peptides. The CD4+ responses to certain E6 regions [E6(16-40), E6(91-115), E6(106-130), and E6(136-158)] were also significantly higher in the regressors. Although there was no difference in the frequencies of Tregs between the two groups, low frequencies of Tregs were significantly associated with positive CD4+ T-cell responses within certain E6 regions [E6(16-40), E6(31-55), E6(76-100), E6(91-115), and E6(106-130)]. The CD4+ and CD8+ T-cell responses to the HPV-16 E6 protein are associated with a favorable clinical trend. The HPV-16 E6 protein should be incorporated in the design of an HPV therapeutic vaccine.",Journal Article,3083.0,16.0,The association between the CD8+ T-cell responses to human papillomavirus type 16 HPV-16 E6 protein and a favorable clinical trend has been demonstrated previously The roles of human papillomavirus HPV -specific CD4+ T-cell responses and of regulatory T-cells Tregs were examined Subjects with a recent history of abnormal Papanicolaou smear were eligible and colposcopy-guided biopsy was performed at enrollment Interferon- enzyme-linked immunospot assay and fluorescent-activated cell sorter analysis to measure the frequencies of Tregs were performed Subjects with histological diagnoses of intraepithelial neoplasia 1 2 or 3 were considered to have short-term persistence of abnormality and were called `` persistors '' n 51 while those of normal histology were designated to be `` regressors '' n 33 A significantly higher percentage CD4+ T-cell response was detected in the regressors 15/33 or 45.5 compared with the persistors 10/51 or 19.6 P .015 for the E6 peptides but not for the E7 peptides The CD4+ responses to certain E6 regions E6 16-40 E6 91-115 E6 106-130 and E6 136-158 were also significantly higher in the regressors Although there was no difference in the frequencies of Tregs between the two groups low frequencies of Tregs were significantly associated with positive CD4+ T-cell responses within certain E6 regions E6 16-40 E6 31-55 E6 76-100 E6 91-115 and E6 106-130 The CD4+ and CD8+ T-cell responses to the HPV-16 E6 protein are associated with a favorable clinical trend The HPV-16 E6 protein should be incorporated in the design of an HPV therapeutic vaccine,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 248, 59, 3, 968, 102, 31, 253, 6, 171, 3242, 267, 245, 933, 245, 4837, 178, 2, 8, 913, 38, 853, 71, 85, 264, 373, 3, 1790, 1, 171, 3242, 933, 112, 1440, 102, 31, 253, 2, 1, 1253, 102, 37, 3975, 11, 409, 976, 5, 8, 435, 532, 1, 1668, 10416, 8379, 11, 625, 2, 9946, 1808, 411, 10, 173, 28, 1798, 1688, 2655, 1644, 1199, 11244, 719, 2, 2910, 735, 31, 20221, 65, 6, 1463, 3, 2722, 1, 3975, 11, 173, 976, 5, 1831, 2403, 1, 4153, 2298, 14, 18, 15, 27, 11, 515, 6, 47, 978, 337, 4108, 1, 3698, 2, 11, 3472, 46725, 522, 78, 725, 369, 135, 1, 295, 784, 11, 4107, 6, 40, 39734, 522, 78, 466, 8, 97, 142, 1150, 1440, 102, 31, 51, 10, 530, 4, 3, 39734, 167, 466, 15, 512, 33, 72, 5, 3, 46725, 79, 725, 15, 326, 49, 19, 3433, 9, 3, 4837, 2491, 84, 44, 9, 3, 4540, 2491, 3, 1440, 253, 6, 1840, 4837, 1374, 4837, 245, 327, 4837, 970, 3670, 4837, 3251, 3431, 2, 4837, 4829, 5162, 11, 120, 97, 142, 4, 3, 39734, 242, 125, 10, 77, 523, 4, 3, 2722, 1, 3975, 59, 3, 100, 271, 154, 2722, 1, 3975, 11, 97, 41, 5, 109, 1440, 102, 31, 253, 262, 1840, 4837, 1374, 4837, 245, 327, 4837, 456, 614, 4837, 846, 394, 4837, 970, 3670, 2, 4837, 3251, 3431, 3, 1440, 2, 968, 102, 31, 253, 6, 3, 933, 245, 4837, 178, 32, 41, 5, 8, 913, 38, 853, 3, 933, 245, 4837, 178, 257, 40, 2449, 4, 3, 771, 1, 35, 933, 189, 1274]",1588.0,21842207,684
Pathways for cervical metastasis in malignant neoplasms of the head and neck region.,"Clinical anatomy (New York, N.Y.)",Clin Anat,2011-08-18,"There have been significant changes in the evaluation and management of lymphatic metastases in the neck during the past several decades, and knowledge of the functional anatomy of the cervical lymphatics is fundamental to the clinical management of metastasis in this region. This review provides a comprehensive description of the cervical lymphatics and discusses how this knowledge is used in the modern management of the neck lymphatics in the setting of common cancers of the head and neck. The patterns of tumor spread can be delineated based on the well-studied functional anatomy of the lymphatic networks in the cervical region. The characteristics and patterns of metastatic spread for two common cancers found in this region, squamous cell carcinoma and cutaneous malignant melanoma, are discussed in this review. Significant improvements in clinical care, namely, selective neck dissection and sentinel lymph node biopsy aided by lymphoscintigraphy, have been developed and are based upon detailed studies of the pathways of metastatic spread. These advances have significantly decreased the morbidity associated with the evaluation and treatment of metastatic disease to the neck.",Journal Article,3078.0,17.0,There have been significant changes in the evaluation and management of lymphatic metastases in the during the past several decades and knowledge of the functional anatomy of the lymphatics is fundamental to the clinical management of metastasis in this region This review provides a comprehensive description of the lymphatics and discusses how this knowledge is used in the modern management of the lymphatics in the setting of common cancers of the head and The patterns of tumor spread can be delineated based on the well-studied functional anatomy of the lymphatic networks in the region The characteristics and patterns of metastatic spread for two common cancers found in this region squamous cell carcinoma and cutaneous malignant are discussed in this review Significant improvements in clinical care namely selective dissection and sentinel lymph node biopsy aided by lymphoscintigraphy have been developed and are based upon detailed studies of the pathways of metastatic spread These advances have significantly decreased the morbidity associated with the evaluation and treatment of metastatic disease to the,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[125, 47, 85, 93, 400, 4, 3, 451, 2, 284, 1, 2936, 196, 4, 3, 190, 3, 1219, 392, 1968, 2, 922, 1, 3, 583, 5081, 1, 3, 9335, 16, 4595, 6, 3, 38, 284, 1, 278, 4, 26, 1053, 26, 206, 777, 8, 949, 5263, 1, 3, 9335, 2, 2759, 832, 26, 922, 16, 95, 4, 3, 2366, 284, 1, 3, 9335, 4, 3, 546, 1, 186, 163, 1, 3, 718, 2, 3, 764, 1, 30, 2579, 122, 40, 5610, 90, 23, 3, 149, 656, 583, 5081, 1, 3, 2936, 3991, 4, 3, 1053, 3, 374, 2, 764, 1, 113, 2579, 9, 100, 186, 163, 204, 4, 26, 1053, 691, 31, 134, 2, 1486, 393, 32, 1588, 4, 26, 206, 93, 1474, 4, 38, 165, 5046, 1094, 1161, 2, 1323, 263, 289, 411, 8783, 20, 6849, 47, 85, 276, 2, 32, 90, 1548, 2455, 94, 1, 3, 460, 1, 113, 2579, 46, 954, 47, 97, 340, 3, 787, 41, 5, 3, 451, 2, 24, 1, 113, 34, 6, 3]",1121.0,21853469,7
Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2011-09-08,"To characterize tumor growth and metastatic potential in head and neck squamous cell carcinoma (HNSCC) cell lines in an orthotopic murine model of oral tongue cancer and to correlate TP53 mutation status with these findings. Cells from each of 48 HNSCC cell lines were orthotopically injected into the oral tongues of nude mice. Tumor volume, cervical lymph node metastasis, and mouse survival were recorded. Direct sequencing of the TP53 gene and Western blot analysis for the p53 protein after induction with 5-fluorouracil was conducted. Cell lines were categorized as either mutant TP53 or wild-type TP53, and lines with TP53 mutation were further categorized on the basis of type of mutation (disruptive or nondisruptive) and level of p53 protein expression. The behavior of tumors in these different groups was compared. These 48 HNSCC cell lines showed a wide range of behavior from highly aggressive and metastatic to no tumor formation. Mice injected with cells harboring disruptive TP53 mutations had faster tumor growth, greater incidence of cervical lymph node metastasis, and shorter survival than mice injected with cells lacking these mutations. HNSCC cell lines display a wide spectrum of behavior in an orthotopic model of oral cancer. Cell lines with disruptive TP53 mutations are more aggressive in this system, corroborating clinical reports that have linked these mutations to poor patient outcome.",Journal Article,3057.0,54.0,To characterize tumor growth and metastatic potential in head and squamous cell carcinoma HNSCC cell lines in an orthotopic murine model of oral tongue cancer and to correlate TP53 mutation status with these findings Cells from each of 48 HNSCC cell lines were orthotopically injected into the oral tongues of nude mice Tumor volume lymph node metastasis and mouse survival were recorded Direct sequencing of the TP53 gene and Western blot analysis for the p53 protein after induction with 5-fluorouracil was conducted Cell lines were categorized as either mutant TP53 or wild-type TP53 and lines with TP53 mutation were further categorized on the basis of type of mutation disruptive or nondisruptive and level of p53 protein expression The behavior of tumors in these different groups was compared These 48 HNSCC cell lines showed a wide range of behavior from highly aggressive and metastatic to no tumor formation Mice injected with cells harboring disruptive TP53 mutations had faster tumor growth greater incidence of lymph node metastasis and shorter survival than mice injected with cells lacking these mutations HNSCC cell lines display a wide spectrum of behavior in an orthotopic model of oral cancer Cell lines with disruptive TP53 mutations are more aggressive in this system corroborating clinical reports that have linked these mutations to poor patient outcome,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1507, 30, 129, 2, 113, 174, 4, 718, 2, 691, 31, 134, 1209, 31, 285, 4, 35, 2157, 1471, 202, 1, 518, 4391, 12, 2, 6, 1513, 1206, 258, 156, 5, 46, 272, 37, 29, 296, 1, 576, 1209, 31, 285, 11, 10806, 2651, 237, 3, 518, 23074, 1, 2598, 399, 30, 433, 263, 289, 278, 2, 830, 25, 11, 1872, 1196, 615, 1, 3, 1206, 145, 2, 1521, 2639, 65, 9, 3, 624, 178, 50, 504, 5, 33, 1404, 10, 426, 31, 285, 11, 2320, 22, 361, 620, 1206, 15, 955, 267, 1206, 2, 285, 5, 1206, 258, 11, 195, 2320, 23, 3, 877, 1, 267, 1, 258, 12217, 15, 34394, 2, 301, 1, 624, 178, 55, 3, 1710, 1, 57, 4, 46, 338, 271, 10, 72, 46, 576, 1209, 31, 285, 224, 8, 1019, 184, 1, 1710, 29, 561, 571, 2, 113, 6, 77, 30, 1264, 399, 2651, 5, 37, 2105, 12217, 1206, 138, 42, 5308, 30, 129, 378, 287, 1, 263, 289, 278, 2, 985, 25, 76, 399, 2651, 5, 37, 1941, 46, 138, 1209, 31, 285, 3640, 8, 1019, 1873, 1, 1710, 4, 35, 2157, 202, 1, 518, 12, 31, 285, 5, 12217, 1206, 138, 32, 80, 571, 4, 26, 398, 22256, 38, 1198, 17, 47, 1199, 46, 138, 6, 334, 69, 228]",1376.0,21903770,312
Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2011-07-13,"Human papillomavirus (HPV) infection is a major risk factor for cervical cancer. Imiquimod is a topical medication that enhances the immune response to HPV-induced genital warts. This study evaluated cervical application of imiquimod as an adjunct to standard treatment for cervical dysplasia. Fifty-six patients were randomized to standard excisional/ablative treatment vs applications of imiquimod followed by standard treatment. The primary endpoint was dysplasia recurrence within 2 years. There were no differences in dysplasia recurrence between the 2 groups. Treatment was well tolerated, with side effects being mild but significantly worse in women receiving imiquimod for, chills, fatigue, fever, headache, myalgias, and vaginal discharge. This trial does not support the hypothesis that imiquimod, as used in this trial, has an impact on recurrence of cervical dysplasia, but the adequacy of findings are limited by sample size. The trial does support the feasibility and acceptability of the use of imiquimod on the cervix.",Journal Article,3114.0,,Human papillomavirus HPV infection is a major risk factor for cancer Imiquimod is a topical medication that enhances the immune response to HPV-induced genital warts This study evaluated application of imiquimod as an adjunct to standard treatment for dysplasia Fifty-six patients were randomized to standard excisional/ablative treatment vs applications of imiquimod followed by standard treatment The primary endpoint was dysplasia recurrence within 2 years There were no differences in dysplasia recurrence between the 2 groups Treatment was well tolerated with side effects being mild but significantly worse in women receiving imiquimod for chills fatigue fever headache myalgias and discharge This trial does not support the hypothesis that imiquimod as used in this trial has an impact on recurrence of dysplasia but the adequacy of findings are limited by sample size The trial does support the feasibility and acceptability of the use of imiquimod on the cervix,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 3242, 933, 930, 16, 8, 458, 43, 161, 9, 12, 11823, 16, 8, 5879, 3012, 17, 2519, 3, 250, 51, 6, 933, 277, 8226, 19515, 26, 45, 194, 1581, 1, 11823, 22, 35, 5471, 6, 260, 24, 9, 2253, 1461, 437, 7, 11, 384, 6, 260, 6488, 4504, 24, 105, 2911, 1, 11823, 370, 20, 260, 24, 3, 86, 1138, 10, 2253, 146, 262, 18, 60, 125, 11, 77, 362, 4, 2253, 146, 59, 3, 18, 271, 24, 10, 149, 421, 5, 1152, 176, 486, 1980, 84, 97, 639, 4, 117, 357, 11823, 9, 9730, 613, 2775, 4538, 11571, 2, 2993, 26, 160, 1097, 44, 538, 3, 1492, 17, 11823, 22, 95, 4, 26, 160, 71, 35, 345, 23, 146, 1, 2253, 84, 3, 6760, 1, 272, 32, 383, 20, 1000, 444, 3, 160, 1097, 538, 3, 1437, 2, 8065, 1, 3, 119, 1, 11823, 23, 3, 3629]",970.0,21907959,11
The role of frozen section in surgical staging of low risk endometrial cancer.,PloS one,PLoS ONE,2011-09-01,"The role of frozen section (FS) in intraoperative decision making for surgical staging of endometrial cancer is controversial. Objective of this study is to assess the agreement rate between the FS and paraffin section (PS); and the potential impact of the role of FS in the intra-operative decision making for the complete surgical staging in low risk endometrial cancer. This is a retrospective analysis of patients diagnosed with intra-operative FS stage I, grade I or II endometrial cancer from 1995-2004. FS results were compared with final pathology results with regard to tumor grade, depth of myometrial invasion, cervical involvement, lymphovascular invasion, and lymph node involvement. Agreement statistic with kappa was calculated using SPSS statistical software. Categorical variables were tested using chi-square test with p value of 0.05 being statistically significant. Of the 457 patients with endometrial cancer, 146 were evaluated by intra-operative FS and met inclusion criteria. FS results were in disagreement with permanent section in 35% for the grade (kappa 0.58, p=0.003), 28% for depth of myometrial invasion (kappa 0.61, p<0.0001), 13% for cervical involvement (kappa 0.78, p=0.002), and 32% for lymphovascular invasion (kappa 0.6, p=0.01). Permanent pathology upstaged 31.9% & 23.2% of FS stage IA, & IB specimen respectively. Lymph node dissection was done in 56.8%. Lymph node metastasis was identified in 8.4%. Use of intraoperative FS would have resulted in suboptimal surgical treatment in 13% stage IA and 6.6% of stage IB patients respectively by foregoing lymphadenectomy. A significant number of patients with low risk endometrial cancer by FS were upstaged and upgraded on final pathology. Before placing absolute reliance on intraoperative FS to undertake complete surgical staging, the inherent limitation of the same in predicting final stage and grade highlighted by our data need to be carefully considered.",Journal Article,3064.0,60.0,The role of frozen section FS in intraoperative decision making for surgical staging of cancer is controversial Objective of this study is to assess the agreement rate between the FS and paraffin section PS and the potential impact of the role of FS in the intra-operative decision making for the complete surgical staging in low risk cancer This is a retrospective analysis of patients diagnosed with intra-operative FS stage I grade I or II cancer from 1995-2004 FS results were compared with final pathology results with regard to tumor grade depth of myometrial invasion involvement lymphovascular invasion and lymph node involvement Agreement statistic with kappa was calculated using SPSS statistical software Categorical variables were tested using chi-square test with p value of 0.05 being statistically significant Of the 457 patients with cancer 146 were evaluated by intra-operative FS and met inclusion criteria FS results were in disagreement with permanent section in 35 for the grade kappa 0.58 p 0.003 28 for depth of myometrial invasion kappa 0.61 p 0.0001 13 for involvement kappa 0.78 p 0.002 and 32 for lymphovascular invasion kappa 0.6 p 0.01 Permanent pathology upstaged 31.9 23.2 of FS stage IA IB specimen respectively Lymph node dissection was done in 56.8 Lymph node metastasis was identified in 8.4 Use of intraoperative FS would have resulted in suboptimal surgical treatment in 13 stage IA and 6.6 of stage IB patients respectively by foregoing lymphadenectomy A significant number of patients with low risk cancer by FS were upstaged and upgraded on final pathology Before placing absolute reliance on intraoperative FS to undertake complete surgical staging the inherent limitation of the same in predicting final stage and grade highlighted by our data need to be carefully considered,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 200, 1, 3015, 2917, 4110, 4, 1720, 948, 1079, 9, 221, 632, 1, 12, 16, 2010, 461, 1, 26, 45, 16, 6, 423, 3, 2024, 116, 59, 3, 4110, 2, 2487, 2917, 1511, 2, 3, 174, 345, 1, 3, 200, 1, 4110, 4, 3, 2392, 1208, 948, 1079, 9, 3, 236, 221, 632, 4, 154, 43, 12, 26, 16, 8, 459, 65, 1, 7, 265, 5, 2392, 1208, 4110, 82, 70, 88, 70, 15, 215, 12, 29, 2323, 1131, 4110, 99, 11, 72, 5, 1457, 1117, 99, 5, 2539, 6, 30, 88, 2436, 1, 7327, 578, 799, 2933, 578, 2, 263, 289, 799, 2024, 4502, 5, 3096, 10, 981, 75, 11461, 1050, 3639, 5982, 682, 11, 650, 75, 3163, 3219, 412, 5, 19, 549, 1, 8710, 474, 486, 712, 93, 1, 3, 13372, 7, 5, 12, 4909, 11, 194, 20, 2392, 1208, 4110, 2, 543, 1680, 371, 4110, 99, 11, 4, 10212, 5, 4377, 2917, 4, 465, 9, 3, 88, 3096, 13, 717, 19, 13, 1421, 339, 9, 2436, 1, 7327, 578, 3096, 13, 713, 19, 13, 488, 233, 9, 799, 3096, 13, 833, 19, 13, 1111, 2, 531, 9, 2933, 578, 3096, 13, 49, 19, 13, 355, 4377, 1117, 7250, 456, 83, 382, 18, 1, 4110, 82, 3302, 3180, 2360, 106, 263, 289, 1161, 10, 1822, 4, 664, 66, 263, 289, 278, 10, 108, 4, 66, 39, 119, 1, 1720, 4110, 688, 47, 627, 4, 3291, 221, 24, 4, 233, 82, 3302, 2, 49, 49, 1, 82, 3180, 7, 106, 20, 34596, 2048, 8, 93, 207, 1, 7, 5, 154, 43, 12, 20, 4110, 11, 7250, 2, 9162, 23, 1457, 1117, 348, 11815, 1766, 9007, 23, 1720, 4110, 6, 18765, 236, 221, 632, 3, 4943, 5039, 1, 3, 827, 4, 1434, 1457, 82, 2, 88, 3681, 20, 114, 74, 594, 6, 40, 3900, 515]",1818.0,21912633,566
Eugenol enhances the chemotherapeutic potential of gemcitabine and induces anticarcinogenic and anti-inflammatory activity in human cervical cancer cells.,Cancer biotherapy & radiopharmaceuticals,Cancer Biother. Radiopharm.,2011-09-22,"Administration of natural or synthetic agents to inhibit, delay, block, or reverse the initiation and promotional events associated with carcinogenesis opens a new avenue for cancer prevention and treatment to reduce cancer morbidity and mortality. Eugenol, a potential chemopreventive agent, is a component of clove and several other spices such as basil, cinnamon, and bay leaves. A number of reports have shown that eugenol possesses antiseptic, analgesic, antibacterial, and anticancer properties. The present study was undertaken to evaluate the chemopreventive potential of eugenol alone and in combination with a chemotherapeutic agent such as gemcitabine. Eugenol showed dose-dependent selective cytotoxicity toward HeLa cells in comparison to normal cells, pointing to its safe cytotoxicity profile. A combination of eugenol and gemcitabine induced growth inhibition and apoptosis at lower concentrations, compared with the individual drugs. The analysis of the data using a combination index showed combination index values of <1 indicating strong synergistic interaction. The combination thus may enhance the efficacy of gemcitabine at lower doses and minimize the toxicity on normal cells. In addition, the expression analysis of genes involved in apoptosis and inflammation revealed significant downregulation of Bcl-2, COX-2, and IL-1 on treatment with eugenol. Thus, the results suggest that eugenol exerts its anticancer activities via apoptosis induction and anti-inflammatory properties and also provide the first evidence demonstrating synergism between eugenol and gemcitabine, which may enhance the therapeutic index of prevention and/or treatment of cervical cancer.",Journal Article,3043.0,49.0,Administration of natural or synthetic agents to inhibit delay block or reverse the initiation and promotional events associated with carcinogenesis opens a new avenue for cancer prevention and treatment to reduce cancer morbidity and mortality Eugenol a potential chemopreventive agent is a component of clove and several other spices such as basil cinnamon and bay leaves A number of reports have shown that eugenol possesses antiseptic analgesic antibacterial and anticancer properties The present study was undertaken to evaluate the chemopreventive potential of eugenol alone and in combination with a chemotherapeutic agent such as gemcitabine Eugenol showed dose-dependent selective cytotoxicity toward HeLa cells in comparison to normal cells pointing to its safe cytotoxicity profile A combination of eugenol and gemcitabine induced growth inhibition and apoptosis at lower concentrations compared with the individual drugs The analysis of the data using a combination index showed combination index values of 1 indicating strong synergistic interaction The combination thus may enhance the efficacy of gemcitabine at lower doses and minimize the toxicity on normal cells In addition the expression analysis of genes involved in apoptosis and inflammation revealed significant downregulation of Bcl-2 COX-2 and IL-1 on treatment with eugenol Thus the results suggest that eugenol exerts its anticancer activities via apoptosis induction and anti-inflammatory properties and also provide the first evidence demonstrating synergism between eugenol and gemcitabine which may enhance the therapeutic index of prevention and/or treatment of cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[634, 1, 1504, 15, 3273, 183, 6, 1433, 1984, 2381, 15, 1772, 3, 1118, 2, 23743, 281, 41, 5, 1719, 12701, 8, 217, 10537, 9, 12, 1070, 2, 24, 6, 969, 12, 787, 2, 282, 20743, 8, 174, 4401, 420, 16, 8, 1249, 1, 46783, 2, 392, 127, 60579, 225, 22, 60580, 60581, 2, 7444, 15229, 8, 207, 1, 1198, 47, 443, 17, 20743, 9857, 35202, 5954, 15002, 2, 1475, 1571, 3, 364, 45, 10, 2789, 6, 376, 3, 4401, 174, 1, 20743, 279, 2, 4, 150, 5, 8, 1573, 420, 225, 22, 679, 20743, 224, 61, 470, 1094, 1408, 1317, 8466, 37, 4, 1155, 6, 295, 37, 11548, 6, 211, 1165, 1408, 800, 8, 150, 1, 20743, 2, 679, 277, 129, 297, 2, 351, 28, 280, 1003, 72, 5, 3, 797, 600, 3, 65, 1, 3, 74, 75, 8, 150, 558, 224, 150, 558, 1030, 1, 14, 1716, 1082, 1806, 915, 3, 150, 631, 68, 1304, 3, 209, 1, 679, 28, 280, 415, 2, 3241, 3, 155, 23, 295, 37, 4, 352, 3, 55, 65, 1, 214, 646, 4, 351, 2, 1815, 553, 93, 2475, 1, 1044, 18, 418, 18, 2, 501, 8215, 23, 24, 5, 20743, 631, 3, 99, 309, 17, 20743, 5685, 211, 1475, 2042, 847, 351, 504, 2, 312, 1291, 1571, 2, 120, 377, 3, 157, 241, 2219, 6494, 59, 20743, 2, 679, 92, 68, 1304, 3, 189, 558, 1, 1070, 2, 15, 24, 1, 12]",1652.0,21939359,52
Predictors of survival and recurrence after temporal bone resection for cancer.,Head & neck,Head Neck,2011-09-23,"The purpose of this study was to identify factors predictive of outcome in patients undergoing temporal bone resection (TBR) for head and neck cancer. This was a retrospective study of 72 patients undergoing TBR. Factors associated with survival and recurrence were identified on multivariable regression. Most tumors were epithelial (81%), commonly (69%) involving critical structures. Cervical metastases were uncommon (6%). Squamous cell carcinoma (SCC) of the external auditory canal carried a high rate of parotid invasion (25%) and parotid nodal metastases (43%). The 5-year rate of overall survival (OS) was 62%; disease-specific survival (DSS), 70%; recurrence-free survival (RFS), 46%. Factors independently associated with outcome on multivariable analysis were margin status and extratemporal spread of disease to the parotid, mandible, or regional nodes. Recurrence was common (72%) in cT3-4 tumors. Margin status and extratemporal disease spread are the strongest independent predictors of survival and recurrence. In SCC of the external auditory canal, high rates of parotid involvement support adjunctive parotidectomy. Risk of recurrence in T3-T4 tumors may support a role for adjuvant therapy.",Journal Article,3042.0,42.0,The purpose of this study was to identify factors predictive of outcome in patients undergoing temporal resection TBR for head and cancer This was a retrospective study of 72 patients undergoing TBR Factors associated with survival and recurrence were identified on multivariable regression Most tumors were epithelial 81 commonly 69 involving critical structures metastases were uncommon 6 Squamous cell carcinoma SCC of the external auditory canal carried a high rate of parotid invasion 25 and parotid nodal metastases 43 The 5-year rate of overall survival OS was 62 disease-specific survival DSS 70 recurrence-free survival RFS 46 Factors independently associated with outcome on multivariable analysis were margin status and extratemporal spread of disease to the parotid mandible or regional nodes Recurrence was common 72 in cT3-4 tumors Margin status and extratemporal disease spread are the strongest independent predictors of survival and recurrence In SCC of the external auditory canal high rates of parotid involvement support adjunctive parotidectomy Risk of recurrence in T3-T4 tumors may support a role for adjuvant therapy,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 255, 130, 464, 1, 228, 4, 7, 479, 3264, 170, 12886, 9, 718, 2, 12, 26, 10, 8, 459, 45, 1, 720, 7, 479, 12886, 130, 41, 5, 25, 2, 146, 11, 108, 23, 658, 320, 96, 57, 11, 701, 865, 841, 790, 1267, 740, 2414, 196, 11, 2052, 49, 691, 31, 134, 1791, 1, 3, 1455, 11991, 5614, 2629, 8, 64, 116, 1, 5838, 578, 243, 2, 5838, 779, 196, 601, 3, 33, 111, 116, 1, 63, 25, 118, 10, 744, 34, 112, 25, 1788, 431, 146, 115, 25, 1272, 641, 130, 1042, 41, 5, 228, 23, 658, 65, 11, 959, 156, 2, 46799, 2579, 1, 34, 6, 3, 5838, 16845, 15, 951, 502, 146, 10, 186, 720, 4, 11036, 39, 57, 959, 156, 2, 46799, 34, 2579, 32, 3, 3311, 306, 674, 1, 25, 2, 146, 4, 1791, 1, 3, 1455, 11991, 5614, 64, 151, 1, 5838, 799, 538, 7402, 16416, 43, 1, 146, 4, 2065, 2463, 57, 68, 538, 8, 200, 9, 249, 36]",1140.0,21953902,148
Cervical juxtafacet cyst after anterior cervical discectomy and fusion.,Neurosurgical focus,Neurosurg Focus,2011-10-01,"Anterior cervical discectomy and fusion (ACDF) is a common neurosurgical procedure, and the benefits, long-term outcomes, and complications are well described in the literature. The development of a juxtafacet joint cyst resulting in radiculopathy is a rare outcome after ACDF and merits further description. The authors describe a patient in whom a juxtafacet joint cyst developed after ACDF procedures, resulting in surgical intervention. When a juxtafacet joint cyst develops after ACDF, symptoms can include radiculopathy, neck pain, and neurological symptoms such as paresthesias and motor weakness. The presence of a juxtafacet joint cyst implies instability in that region of the spine. Patients with this pathological entity may require decompression of neural elements and fusion across the segment involved with the cyst.",Case Reports,3034.0,3.0,Anterior discectomy and fusion ACDF is a common neurosurgical procedure and the benefits long-term outcomes and complications are well described in the literature The development of a juxtafacet joint cyst resulting in radiculopathy is a rare outcome after ACDF and merits further description The authors describe a patient in whom a juxtafacet joint cyst developed after ACDF procedures resulting in surgical intervention When a juxtafacet joint cyst develops after ACDF symptoms can include radiculopathy pain and neurological symptoms such as paresthesias and motor weakness The presence of a juxtafacet joint cyst implies instability in that region of the spine Patients with this pathological entity may require decompression of neural elements and fusion across the segment involved with the cyst,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2882, 60601, 2, 1212, 35205, 16, 8, 186, 10338, 1299, 2, 3, 1141, 319, 337, 123, 2, 521, 32, 149, 1027, 4, 3, 789, 3, 193, 1, 8, 35206, 2093, 3364, 1113, 4, 16642, 16, 8, 622, 228, 50, 35205, 2, 4986, 195, 5263, 3, 738, 897, 8, 69, 4, 953, 8, 35206, 2093, 3364, 276, 50, 35205, 1369, 1113, 4, 221, 788, 198, 8, 35206, 2093, 3364, 4734, 50, 35205, 507, 122, 643, 16642, 559, 2, 3622, 507, 225, 22, 20321, 2, 3482, 6408, 3, 463, 1, 8, 35206, 2093, 3364, 10441, 1753, 4, 17, 1053, 1, 3, 2342, 7, 5, 26, 1301, 2983, 68, 1353, 7638, 1, 3922, 2531, 2, 1212, 716, 3, 4610, 646, 5, 3, 3364]",802.0,21961863,771
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2011-10-03,"The clinical course for patients with chronic lymphocytic leukemia (CLL) is diverse; some patients have indolent disease, never needing treatment, whereas others have aggressive disease requiring early treatment. We continue to use criteria for active disease to initiate therapy. Multivariable analysis was performed to identify prognostic factors independently associated with time to first treatment for patients with CLL. Traditional laboratory, clinical prognostic, and newer prognostic factors such as fluorescent in situ hybridization (FISH), IGHV mutation status, and ZAP-70 expression evaluated at first patient visit to MD Anderson Cancer Center were correlated by multivariable analysis with time to first treatment. This multivariable model was used to develop a nomogram-a weighted tool to calculate 2- and 4-year probability of treatment and estimate median time to first treatment. There were 930 previously untreated patients who had traditional and new prognostic factors evaluated; they did not have active CLL requiring initiation of treatment within 3 months of first visit and were observed for time to first treatment. The following were independently associated with shorter time to first treatment: three involved lymph node sites, increased size of cervical lymph nodes, presence of 17p deletion or 11q deletion by FISH, increased serum lactate dehydrogenase, and unmutated IGHV mutation status. We developed a multivariable model that incorporates traditional and newer prognostic factors to identify patients at high risk for progression to treatment. This model may be useful to identify patients for early interventional trials.",Journal Article,3032.0,85.0,The clinical course for patients with chronic lymphocytic CLL is diverse some patients have indolent disease never needing treatment whereas others have aggressive disease requiring early treatment We continue to use criteria for active disease to initiate therapy Multivariable analysis was performed to identify prognostic factors independently associated with time to first treatment for patients with CLL Traditional laboratory clinical prognostic and newer prognostic factors such as fluorescent in situ hybridization FISH IGHV mutation status and ZAP-70 expression evaluated at first patient visit to MD Anderson Cancer Center were correlated by multivariable analysis with time to first treatment This multivariable model was used to develop a nomogram-a weighted tool to calculate 2- and 4-year probability of treatment and estimate median time to first treatment There were 930 previously untreated patients who had traditional and new prognostic factors evaluated they did not have active CLL requiring initiation of treatment within 3 months of first visit and were observed for time to first treatment The following were independently associated with shorter time to first treatment three involved lymph node sites increased size of lymph nodes presence of 17p deletion or 11q deletion by FISH increased serum lactate dehydrogenase and unmutated IGHV mutation status We developed a multivariable model that incorporates traditional and newer prognostic factors to identify patients at high risk for progression to treatment This model may be useful to identify patients for early interventional trials,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,"[3, 38, 906, 9, 7, 5, 442, 1193, 552, 16, 1867, 476, 7, 47, 2316, 34, 1737, 12864, 24, 547, 1749, 47, 571, 34, 1888, 191, 24, 21, 1906, 6, 119, 371, 9, 544, 34, 6, 4565, 36, 658, 65, 10, 173, 6, 255, 177, 130, 1042, 41, 5, 98, 6, 157, 24, 9, 7, 5, 552, 1847, 1624, 38, 177, 2, 2246, 177, 130, 225, 22, 2910, 4, 957, 1554, 1277, 6220, 258, 156, 2, 6251, 431, 55, 194, 28, 157, 69, 2807, 6, 2244, 1929, 12, 574, 11, 438, 20, 658, 65, 5, 98, 6, 157, 24, 26, 658, 202, 10, 95, 6, 690, 8, 1981, 8, 2337, 1515, 6, 3232, 18, 2, 39, 111, 1320, 1, 24, 2, 1191, 52, 98, 6, 157, 24, 125, 11, 13416, 373, 1278, 7, 54, 42, 1847, 2, 217, 177, 130, 194, 491, 205, 44, 47, 544, 552, 1888, 1118, 1, 24, 262, 27, 53, 1, 157, 2807, 2, 11, 164, 9, 98, 6, 157, 24, 3, 366, 11, 1042, 41, 5, 985, 98, 6, 157, 24, 169, 646, 263, 289, 633, 101, 444, 1, 263, 502, 463, 1, 4135, 1528, 15, 7203, 1528, 20, 1277, 101, 524, 3330, 2374, 2, 7216, 6220, 258, 156, 21, 276, 8, 658, 202, 17, 6175, 1847, 2, 2246, 177, 130, 6, 255, 7, 28, 64, 43, 9, 91, 6, 24, 26, 202, 68, 40, 999, 6, 255, 7, 9, 191, 6182, 143]",1613.0,21969505,231
Small lymphocytic lymphoma in a patient with CREST syndrome.,Hematology/oncology and stem cell therapy,Hematol Oncol Stem Cell Ther,2011-01-01,"We report a case of a 61-year-old man with a history of CREST syndrome (calcinosis cutis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia) who presented for evaluation of thrombocytopenia. He had evident cervical adenopathy and lymph node biopsy showed small lymphocytic lymphoma (SLL) with evident systemic adenopathy and bone marrow involvement. The patient achieved a complete remission with FCR (fludarabine/cyclophosphamide/rituximab) chemotherapy. About 30 cases of lymphomas are reported in the literature in association with systemic sclerosis. To our knowledge, there are no reports of a small lymphocytic lymphoma (SLL) in association with limited cutaneous systemic sclerosis with classic features of the CREST syndrome.",Case Reports,3307.0,,We report a case of a 61-year-old man with a history of CREST syndrome calcinosis cutis Raynaud phenomenon dysmotility sclerodactyly and telangiectasia who presented for evaluation of thrombocytopenia He had evident adenopathy and lymph node biopsy showed small lymphocytic SLL with evident systemic adenopathy and marrow involvement The patient achieved a complete remission with FCR fludarabine/cyclophosphamide/rituximab chemotherapy About 30 cases of lymphomas are reported in the literature in association with systemic sclerosis To our knowledge there are no reports of a small lymphocytic SLL in association with limited cutaneous systemic sclerosis with classic features of the CREST syndrome,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[21, 414, 8, 473, 1, 8, 713, 111, 1095, 3628, 5, 8, 532, 1, 10686, 681, 35067, 25273, 28452, 3936, 33792, 46467, 2, 8524, 54, 917, 9, 451, 1, 1340, 3174, 42, 2853, 7741, 2, 263, 289, 411, 224, 302, 1193, 5302, 5, 2853, 403, 7741, 2, 581, 799, 3, 69, 513, 8, 236, 734, 5, 4953, 2027, 1112, 855, 56, 545, 201, 140, 1, 1557, 32, 210, 4, 3, 789, 4, 248, 5, 403, 7426, 6, 114, 922, 125, 32, 77, 1198, 1, 8, 302, 1193, 5302, 4, 248, 5, 383, 1486, 403, 7426, 5, 3168, 404, 1, 3, 10686, 681]",700.0,21982887,47
Fertility sparing surgery for treatment of early-stage cervical cancer: open vs. robotic radical trachelectomy.,Gynecologic oncology,Gynecol. Oncol.,2011-10-27,"To compare the open versus robotic surgical approaches and provide surgical outcome data on patients who have undergone radical trachelectomy (RT). We identified patients who underwent open (ORT) or robotic radical trachelectomy (RRT) between September 2005 and June 2011. Tumor characteristics, perioperative, operative and obstetrical outcomes were analyzed. Thirty-seven patients with early stage cervical cancer that desired future fertility underwent attempted radical trachelectomy, and 32 patients (20 with 1B1, 11 with 1A2, and 5 with 1A1 with LVSI/poorly differentiated histology) had successful completion of RT. Five (1 open/4 robotic) underwent conversion to radical hysterectomy secondary to close (<5mm) endocervical margin (p=0.08). The median age at diagnosis was 28.9 years (range; 21.4-37.2), 70% were nulliparous, and 9 had a visible lesion. Twenty-five patients (68%) underwent ORT and 12 (32%) underwent RRT. RRT was associated with less blood loss (62.5 mL vs. 300 mL, p=0.0001) and decreased length of postoperative stay (1 vs. 4 days, p<0.001), with no difference in operative time or histopathologic outcomes. Twenty-three patients (62%) had no residual cervical disease on final pathology. Common long-term morbidities were irregular menstrual bleeding or amenorrhea (25%), cerclage erosion (13%), or cervical stenosis (9%). Although there was a higher rate of conversion to hysterectomy in the robotic surgery cohort, rates of serious morbidities among the cohorts were comparable (robotic: 33% vs. open: 24%, p=0.70). Eleven (36%) patients are actively attempting pregnancy and three have achieved pregnancy. The median time of follow up is 17.0 months (range 0.30-64.9 months). There are no documented recurrences. RRT results in less blood loss and decreased length of hospital stay with no compromise in histopathologic outcomes.",Comparative Study,3008.0,62.0,To compare the open versus robotic surgical approaches and provide surgical outcome data on patients who have undergone radical trachelectomy RT We identified patients who underwent open ORT or robotic radical trachelectomy RRT between September 2005 and June 2011 Tumor characteristics perioperative operative and obstetrical outcomes were analyzed Thirty-seven patients with early stage cancer that desired future fertility underwent attempted radical trachelectomy and 32 patients 20 with 1B1 11 with 1A2 and 5 with 1A1 with LVSI/poorly differentiated histology had successful completion of RT Five 1 open/4 robotic underwent conversion to radical hysterectomy secondary to close 5mm endocervical margin p=0.08 The median age at diagnosis was 28.9 years range 21.4-37.2 70 were nulliparous and 9 had a visible lesion Twenty-five patients 68 underwent ORT and 12 32 underwent RRT RRT was associated with less blood loss 62.5 mL vs. 300 mL p=0.0001 and decreased length of postoperative stay 1 vs. 4 days p 0.001 with no difference in operative time or histopathologic outcomes Twenty-three patients 62 had no residual disease on final pathology Common long-term morbidities were irregular menstrual bleeding or amenorrhea 25 cerclage erosion 13 or stenosis 9 Although there was a higher rate of conversion to hysterectomy in the robotic surgery cohort rates of serious morbidities among the cohorts were comparable robotic 33 vs. open 24 p=0.70 Eleven 36 patients are actively attempting pregnancy and three have achieved pregnancy The median time of follow up is 17.0 months range 0.30-64.9 months There are no documented recurrences RRT results in less blood loss and decreased length of hospital stay with no compromise in histopathologic outcomes,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 932, 3, 1020, 185, 2895, 221, 611, 2, 377, 221, 228, 74, 23, 7, 54, 47, 1989, 711, 5760, 240, 21, 108, 7, 54, 208, 1020, 19957, 15, 2895, 711, 5760, 17964, 59, 2636, 1242, 2, 1924, 1132, 30, 374, 1547, 1208, 2, 21031, 123, 11, 311, 977, 648, 7, 5, 191, 82, 12, 17, 6115, 508, 2954, 208, 4098, 711, 5760, 2, 531, 7, 179, 5, 25014, 175, 5, 30797, 2, 33, 5, 18885, 5, 8004, 1240, 1442, 784, 42, 1401, 1438, 1, 240, 365, 14, 1020, 39, 2895, 208, 3111, 6, 711, 2622, 568, 6, 2336, 18584, 10174, 959, 19, 13, 1592, 3, 52, 89, 28, 147, 10, 339, 83, 60, 184, 239, 39, 567, 18, 431, 11, 9475, 2, 83, 42, 8, 4822, 1180, 737, 365, 7, 806, 208, 19957, 2, 133, 531, 208, 17964, 17964, 10, 41, 5, 299, 315, 407, 744, 33, 542, 105, 2036, 542, 19, 13, 488, 2, 340, 1318, 1, 573, 2020, 14, 105, 39, 162, 19, 13, 144, 5, 77, 523, 4, 1208, 98, 15, 2630, 123, 737, 169, 7, 744, 42, 77, 753, 34, 23, 1457, 1117, 186, 319, 337, 5655, 11, 8685, 8518, 2294, 15, 9373, 243, 28830, 14547, 233, 15, 6935, 83, 242, 125, 10, 8, 142, 116, 1, 3111, 6, 2622, 4, 3, 2895, 152, 180, 151, 1, 1762, 5655, 107, 3, 736, 11, 1279, 2895, 466, 105, 1020, 259, 19, 13, 431, 2627, 511, 7, 32, 4489, 9632, 2290, 2, 169, 47, 513, 2290, 3, 52, 98, 1, 166, 126, 16, 269, 13, 53, 184, 13, 201, 660, 83, 53, 125, 32, 77, 1405, 1593, 17964, 99, 4, 299, 315, 407, 2, 340, 1318, 1, 702, 2020, 5, 77, 4665, 4, 2630, 123]",1752.0,22035808,365
Sensitivity of Raman spectroscopy to normal patient variability.,Journal of biomedical optics,J Biomed Opt,2011-11-01,"Many groups have used Raman spectroscopy for diagnosing cervical dysplasia; however, there have been few studies looking at the effect of normal physiological variations on Raman spectra. We assess four patient variables that may affect normal Raman spectra: Race/ethnicity, body mass index (BMI), parity, and socioeconomic status. Raman spectra were acquired from a diverse population of 75 patients undergoing routine screening for cervical dysplasia. Classification of Raman spectra from patients with a normal cervix is performed using sparse multinomial logistic regression (SMLR) to determine if any of these variables has a significant effect. Results suggest that BMI and parity have the greatest impact, whereas race/ethnicity and socioeconomic status have a limited effect. Incorporating BMI and obstetric history into classification algorithms may increase sensitivity and specificity rates of disease classification using Raman spectroscopy. Studies are underway to assess the effect of these variables on disease.",Journal Article,3003.0,21.0,Many groups have used Raman spectroscopy for diagnosing dysplasia however there have been few studies looking at the effect of normal physiological variations on Raman spectra We assess four patient variables that may affect normal Raman spectra Race/ethnicity body mass index BMI parity and socioeconomic status Raman spectra were acquired from a diverse population of 75 patients undergoing routine screening for dysplasia Classification of Raman spectra from patients with a normal cervix is performed using sparse multinomial logistic regression SMLR to determine if any of these variables has a significant effect Results suggest that BMI and parity have the greatest impact whereas race/ethnicity and socioeconomic status have a limited effect Incorporating BMI and obstetric history into classification algorithms may increase sensitivity and specificity rates of disease classification using Raman spectroscopy Studies are underway to assess the effect of these variables on disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[445, 271, 47, 95, 14683, 5326, 9, 5798, 2253, 137, 125, 47, 85, 1021, 94, 9095, 28, 3, 254, 1, 295, 4733, 2293, 23, 14683, 7683, 21, 423, 294, 69, 682, 17, 68, 1158, 295, 14683, 7683, 1047, 2091, 642, 782, 558, 1140, 5754, 2, 3331, 156, 14683, 7683, 11, 1294, 29, 8, 1867, 266, 1, 481, 7, 479, 1311, 453, 9, 2253, 947, 1, 14683, 7683, 29, 7, 5, 8, 295, 3629, 16, 173, 75, 7425, 10907, 812, 320, 60814, 6, 223, 492, 500, 1, 46, 682, 71, 8, 93, 254, 99, 309, 17, 1140, 2, 5754, 47, 3, 2199, 345, 547, 1047, 2091, 2, 3331, 156, 47, 8, 383, 254, 2570, 1140, 2, 24695, 532, 237, 947, 3529, 68, 344, 485, 2, 1121, 151, 1, 34, 947, 75, 14683, 5326, 94, 32, 3948, 6, 423, 3, 254, 1, 46, 682, 23, 34]",990.0,22112136,461
"Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.",International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists,Int. J. Gynecol. Pathol.,2012-01-01,"NOL7 is a putative tumor suppressor gene localized to 6p23, a region with frequent loss of heterozygosity in a number of cancers, including cervical cancer (CC). We have previously demonstrated that reintroduction of NOL7 into CC cells altered the angiogenic phenotype and suppressed tumor growth in vivo by 95%. Therefore, to understand its mechanism of inactivation in CC, we investigated the genetic and epigenetic regulation of NOL7. NOL7 mRNA and protein levels were assessed in 13 CC cell lines and 23 consecutive CC specimens by real-time quantitative polymerase chain reaction, western blotting, and immunohistochemistry. Methylation of the NOL7 promoter was analyzed by bisulfite sequencing and mutations were identified through direct sequencing. A CpG island with multiple CpG dinucleotides spanned the 5' untranslated region and first exon of NOL7. However, bisulfite sequencing failed to identify persistent sites of methylation. Mutational sequencing revealed that 40% of the CC specimens and 31% of the CC cell lines harbored somatic mutations that may affect the in vivo function of NOL7. Endogenous NOL7 mRNA and protein expression in CC cell lines were significantly decreased in 46% of the CC cell lines. Finally, immunohistochemistry demonstrated strong NOL7 nucleolar staining in normal tissues that decreased with histologic progression toward CC. NOL7 is inactivated in CC in accordance with the Knudson 2-hit hypothesis through loss of heterozygosity and mutation. Together with evidence of its in vivo tumor suppression, these data support the hypothesis that NOL7 is the legitimate tumor suppressor gene located on 6p23.",Journal Article,2942.0,6.0,NOL7 is a putative tumor suppressor gene localized to 6p23 a region with frequent loss of heterozygosity in a number of cancers including cancer CC We have previously demonstrated that reintroduction of NOL7 into CC cells altered the angiogenic phenotype and suppressed tumor growth in vivo by 95 Therefore to understand its mechanism of inactivation in CC we investigated the genetic and epigenetic regulation of NOL7 NOL7 mRNA and protein levels were assessed in 13 CC cell lines and 23 consecutive CC specimens by real-time quantitative polymerase chain reaction western blotting and immunohistochemistry Methylation of the NOL7 promoter was analyzed by bisulfite sequencing and mutations were identified through direct sequencing A CpG island with multiple CpG dinucleotides spanned the 5 untranslated region and first exon of NOL7 However bisulfite sequencing failed to identify persistent sites of methylation Mutational sequencing revealed that 40 of the CC specimens and 31 of the CC cell lines harbored somatic mutations that may affect the in vivo function of NOL7 Endogenous NOL7 mRNA and protein expression in CC cell lines were significantly decreased in 46 of the CC cell lines Finally immunohistochemistry demonstrated strong NOL7 nucleolar staining in normal tissues that decreased with histologic progression toward CC NOL7 is inactivated in CC in accordance with the Knudson 2-hit hypothesis through loss of heterozygosity and mutation Together with evidence of its in vivo tumor suppression these data support the hypothesis that NOL7 is the legitimate tumor suppressor gene located on 6p23,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21694, 16, 8, 2743, 30, 1245, 145, 909, 6, 39827, 8, 1053, 5, 908, 407, 1, 3963, 4, 8, 207, 1, 163, 141, 12, 1951, 21, 47, 373, 264, 17, 14721, 1, 21694, 237, 1951, 37, 1495, 3, 2068, 1005, 2, 1908, 30, 129, 4, 386, 20, 48, 673, 6, 1640, 211, 670, 1, 2297, 4, 1951, 21, 565, 3, 336, 2, 1418, 863, 1, 21694, 21694, 956, 2, 178, 148, 11, 275, 4, 233, 1951, 31, 285, 2, 382, 935, 1951, 623, 20, 1589, 98, 1156, 1451, 1260, 1329, 1521, 3661, 2, 888, 569, 1, 3, 21694, 973, 10, 311, 20, 6181, 615, 2, 138, 11, 108, 298, 1196, 615, 8, 2075, 3454, 5, 232, 2075, 21270, 16363, 3, 33, 7379, 1053, 2, 157, 1725, 1, 21694, 137, 6181, 615, 1551, 6, 255, 1882, 633, 1, 569, 1619, 615, 553, 17, 327, 1, 3, 1951, 623, 2, 456, 1, 3, 1951, 31, 285, 3253, 1119, 138, 17, 68, 1158, 3, 4, 386, 343, 1, 21694, 2682, 21694, 956, 2, 178, 55, 4, 1951, 31, 285, 11, 97, 340, 4, 641, 1, 3, 1951, 31, 285, 1368, 888, 264, 1082, 21694, 11328, 1029, 4, 295, 742, 17, 340, 5, 884, 91, 1317, 1951, 21694, 16, 5458, 4, 1951, 4, 8934, 5, 3, 46905, 18, 6519, 1492, 298, 407, 1, 3963, 2, 258, 1162, 5, 241, 1, 211, 4, 386, 30, 1332, 46, 74, 538, 3, 1492, 17, 21694, 16, 3, 23149, 30, 1245, 145, 2308, 23, 39827]",1609.0,22123719,236
Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: a Gynecologic Oncology Group study.,Gynecologic oncology,Gynecol. Oncol.,2011-12-08,"To determine whether the number of positive pelvic nodes (PPN), cervical stromal involvement (CSI), and/or lymphovascular space involvement (LVSI) were prognostic factors among women with advanced endometrial carcinoma treated with adriamycin plus cisplatin (AP) or whole abdominal irradiation (WAI). Data were abstracted from records of patients treated with adjuvant WAI or AP in a GOG randomized trial. Cox proportional hazards models were used to estimate the association of CSI and PPN with differences in PFS and OS while adjusting for treatment and previously studied factors. WAI was randomly allocated to 202 and AP to 194 eligible patients. CSI (n=93 total) was associated with a 44% increase in risk of progression and a 33% increase in risk of death. There was a trend for increasing number PPN being associated with a 7% per positive node increase in risk of progression/death. For CSI, the estimated unadjusted treatment hazard ratios (HRs) were: PFS 0.85 (0.53, 1.38); OS 0.81 (0.50, 1.33). For metastatic disease limited to a single PPN (n=25), the unadjusted HRs were: PFS 0.96 (0.34, 2.74); OS 0.73 (0.24, 2.18). The test of homogeneity of treatment effect (ie., AP vs WAI) across subgroups (CSI, number of positive pelvic nodes) was not statistically significant for either endpoint, thus supporting the superiority of chemotherapy as reported in the original manuscript. The presence of CSI and increasing number of PPN were associated with poor prognosis. On average, patients with CSI experienced improved PFS and OS when treated with AP relative to WAI.",Journal Article,2966.0,14.0,To determine whether the number of positive pelvic nodes PPN stromal involvement CSI and/or lymphovascular space involvement LVSI were prognostic factors among women with advanced carcinoma treated with adriamycin plus cisplatin AP or whole abdominal irradiation WAI Data were abstracted from records of patients treated with adjuvant WAI or AP in a GOG randomized trial Cox proportional hazards models were used to estimate the association of CSI and PPN with differences in PFS and OS while adjusting for treatment and previously studied factors WAI was randomly allocated to 202 and AP to 194 eligible patients CSI n=93 total was associated with a 44 increase in risk of progression and a 33 increase in risk of death There was a trend for increasing number PPN being associated with a 7 per positive node increase in risk of progression/death For CSI the estimated unadjusted treatment hazard ratios HRs were PFS 0.85 0.53 1.38 OS 0.81 0.50 1.33 For metastatic disease limited to a single PPN n=25 the unadjusted HRs were PFS 0.96 0.34 2.74 OS 0.73 0.24 2.18 The test of homogeneity of treatment effect ie. AP vs WAI across subgroups CSI number of positive pelvic nodes was not statistically significant for either endpoint thus supporting the superiority of chemotherapy as reported in the original manuscript The presence of CSI and increasing number of PPN were associated with poor prognosis On average patients with CSI experienced improved PFS and OS when treated with AP relative to WAI,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,"[6, 223, 317, 3, 207, 1, 109, 1110, 502, 31895, 1126, 799, 4293, 2, 15, 2933, 3865, 799, 8004, 11, 177, 130, 107, 117, 5, 131, 134, 73, 5, 7700, 349, 540, 2517, 15, 902, 1467, 1104, 21531, 74, 11, 4106, 29, 1064, 1, 7, 73, 5, 249, 21531, 15, 2517, 4, 8, 4760, 384, 160, 418, 831, 1017, 274, 11, 95, 6, 1191, 3, 248, 1, 4293, 2, 31895, 5, 362, 4, 300, 2, 118, 369, 1358, 9, 24, 2, 373, 656, 130, 21531, 10, 1108, 6682, 6, 5918, 2, 2517, 6, 5434, 625, 7, 4293, 78, 966, 181, 10, 41, 5, 8, 584, 344, 4, 43, 1, 91, 2, 8, 466, 344, 4, 43, 1, 273, 125, 10, 8, 853, 9, 602, 207, 31895, 486, 41, 5, 8, 67, 379, 109, 289, 344, 4, 43, 1, 91, 273, 9, 4293, 3, 661, 4487, 24, 360, 1137, 2733, 11, 300, 13, 772, 13, 699, 14, 519, 118, 13, 865, 13, 212, 14, 466, 9, 113, 34, 383, 6, 8, 226, 31895, 78, 243, 3, 4487, 2733, 11, 300, 13, 921, 13, 562, 18, 794, 118, 13, 803, 13, 259, 18, 203, 3, 412, 1, 7502, 1, 24, 254, 2523, 2517, 105, 21531, 716, 1453, 4293, 207, 1, 109, 1110, 502, 10, 44, 712, 93, 9, 361, 1138, 631, 1912, 3, 5233, 1, 56, 22, 210, 4, 3, 2279, 5825, 3, 463, 1, 4293, 2, 602, 207, 1, 31895, 11, 41, 5, 334, 356, 23, 1011, 7, 5, 4293, 592, 231, 300, 2, 118, 198, 73, 5, 2517, 580, 6, 21531]",1497.0,22155678,529
A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study.,Gynecologic oncology,Gynecol. Oncol.,2011-12-22,"To determine the maximum tolerated dose (MTD) and acute dose-limiting toxicities (DLT) of intravenous topotecan administered with weekly cisplatin during pelvic radiation therapy in patients with locally advanced cervical cancer. Patients were treated at one of two dose levels receiving intravenous topotecan at 0.5mg/m(2) and cisplatin at either 30 or 40 mg/m(2) given weekly for 6 weeks concurrently with pelvic radiation and intracavitary brachytherapy. The primary endpoint for the escalation study was acute dose-limiting toxicities occurring within 30 days of completing radiation therapy. Eleven patients were enrolled. Dose-limiting toxicity consisting of Grade 3 nausea and vomiting lasting >24h in one patient and grade 3 febrile neutropenia in another patient occurred at the first dose level of weekly topotecan 0.5mg/m(2) and cisplatin 40 mg/m(2). This necessitated de-escalation to weekly cisplatin 30 mg/m(2) in combination with topotecan 0.5mg/m(2) and pelvic radiation. This dose level was tolerable in 6 evaluable patients with only one DLT consisting of grade 4 thrombocytopenia, grade 3 abdominal pain and grade 3 elevated gamma glutamyl transpeptidase (GGT). In women with locally advanced cervical cancer, intravenous topotecan 0.5mg/m(2) and cisplatin 30 mg/m(2) given weekly for 6 weeks with concurrent pelvic radiation and intracavitary brachytherapy were tolerable. Further expansion of the feasibility cohort of this study was suspended based on the results of a phase 3 trial comparing the efficacy of platinum combinations in advanced and recurrent cervical cancer.","Clinical Trial, Phase I",2952.0,15.0,To determine the maximum tolerated dose MTD and acute dose-limiting toxicities DLT of intravenous topotecan administered with weekly cisplatin during pelvic radiation therapy in patients with locally advanced cancer Patients were treated at one of two dose levels receiving intravenous topotecan at 0.5mg/m 2 and cisplatin at either 30 or 40 mg/m 2 given weekly for 6 weeks concurrently with pelvic radiation and intracavitary brachytherapy The primary endpoint for the escalation study was acute dose-limiting toxicities occurring within 30 days of completing radiation therapy Eleven patients were enrolled Dose-limiting toxicity consisting of Grade 3 nausea and vomiting lasting 24h in one patient and grade 3 febrile neutropenia in another patient occurred at the first dose level of weekly topotecan 0.5mg/m 2 and cisplatin 40 mg/m 2 This necessitated de-escalation to weekly cisplatin 30 mg/m 2 in combination with topotecan 0.5mg/m 2 and pelvic radiation This dose level was tolerable in 6 evaluable patients with only one DLT consisting of grade 4 thrombocytopenia grade 3 abdominal pain and grade 3 elevated gamma glutamyl transpeptidase GGT In women with locally advanced cancer intravenous topotecan 0.5mg/m 2 and cisplatin 30 mg/m 2 given weekly for 6 weeks with concurrent pelvic radiation and intracavitary brachytherapy were tolerable Further expansion of the feasibility cohort of this study was suspended based on the results of a phase 3 trial comparing the efficacy of platinum combinations in advanced and recurrent cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 689, 421, 61, 961, 2, 286, 61, 817, 385, 2059, 1, 1262, 2129, 468, 5, 709, 540, 190, 1110, 121, 36, 4, 7, 5, 795, 131, 12, 7, 11, 73, 28, 104, 1, 100, 61, 148, 357, 1262, 2129, 28, 13, 11356, 188, 18, 2, 540, 28, 361, 201, 15, 327, 81, 188, 18, 447, 709, 9, 49, 244, 3294, 5, 1110, 121, 2, 9122, 1536, 3, 86, 1138, 9, 3, 1125, 45, 10, 286, 61, 817, 385, 1821, 262, 201, 162, 1, 4144, 121, 36, 2627, 7, 11, 346, 61, 817, 155, 2273, 1, 88, 27, 1218, 2, 1966, 3443, 12551, 4, 104, 69, 2, 88, 27, 2498, 778, 4, 1809, 69, 489, 28, 3, 157, 61, 301, 1, 709, 2129, 13, 11356, 188, 18, 2, 540, 327, 81, 188, 18, 26, 14727, 1566, 1125, 6, 709, 540, 201, 81, 188, 18, 4, 150, 5, 2129, 13, 11356, 188, 18, 2, 1110, 121, 26, 61, 301, 10, 2668, 4, 49, 859, 7, 5, 158, 104, 2059, 2273, 1, 88, 39, 1340, 88, 27, 1467, 559, 2, 88, 27, 804, 1705, 15867, 34756, 17995, 4, 117, 5, 795, 131, 12, 1262, 2129, 13, 11356, 188, 18, 2, 540, 201, 81, 188, 18, 447, 709, 9, 49, 244, 5, 750, 1110, 121, 2, 9122, 1536, 11, 2668, 195, 1422, 1, 3, 1437, 180, 1, 26, 45, 10, 14903, 90, 23, 3, 99, 1, 8, 124, 27, 160, 1430, 3, 209, 1, 828, 1247, 4, 131, 2, 387, 12]",1542.0,22198338,220
Pocket proteins suppress head and neck cancer.,Cancer research,Cancer Res.,2012-01-11,"Head and neck squamous cell carcinomas (HNSCC) is a common cancer in humans long known to be caused by tobacco and alcohol use, but now an increasing percentage of HNSCC is recognized to be caused by the same human papillomaviruses (HPV) that cause cervical and other anogenital cancers. HPV-positive HNSCCs differ remarkably from HPV-negative HNSCCs in their clinical response and molecular properties. From studies in mice, we know that E7 is the dominant HPV oncoprotein in head and neck cancer. E7 is best known for its ability to inactivate pRb, the product of the retinoblastoma tumor susceptibility gene. However, loss of pRb function does not fully account for potency of E7 in causing head and neck cancer. In this study, we characterized the cancer susceptibility of mice deficient in the expression of pRb and either of two related ""pocket"" proteins, p107 and p130, that are also inactivated by E7. pRb/p107-deficient mice developed head and neck cancer as frequently as do HPV-16 E7 transgenic mice. The head and neck epithelia of the pRb/p107-deficient mice also displayed the same acute phenotypes and biomarker readouts as observed in the epithelia of E7 transgenic mice. Mice deficient for pRb and p130 in their head and neck epithelia showed intermediate acute and tumor phenotypes. We conclude that pRb and p107 act together to efficiently suppress head and neck cancer and are, therefore, highly relevant targets of HPV-16 E7 in its contribution to HPV-positive HNSCC.",Journal Article,2932.0,15.0,Head and squamous cell carcinomas HNSCC is a common cancer in humans long known to be caused by tobacco and alcohol use but now an increasing percentage of HNSCC is recognized to be caused by the same human papillomaviruses HPV that cause and other anogenital cancers HPV-positive HNSCCs differ remarkably from HPV-negative HNSCCs in their clinical response and molecular properties From studies in mice we know that E7 is the dominant HPV oncoprotein in head and cancer E7 is best known for its ability to inactivate pRb the product of the tumor susceptibility gene However loss of pRb function does not fully account for potency of E7 in causing head and cancer In this study we characterized the cancer susceptibility of mice deficient in the expression of pRb and either of two related `` pocket '' proteins p107 and p130 that are also inactivated by E7 pRb/p107-deficient mice developed head and cancer as frequently as do HPV-16 E7 transgenic mice The head and epithelia of the pRb/p107-deficient mice also displayed the same acute phenotypes and biomarker readouts as observed in the epithelia of E7 transgenic mice Mice deficient for pRb and p130 in their head and epithelia showed intermediate acute and tumor phenotypes We conclude that pRb and p107 act together to efficiently suppress head and cancer and are therefore highly relevant targets of HPV-16 E7 in its contribution to HPV-positive HNSCC,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[718, 2, 691, 31, 826, 1209, 16, 8, 186, 12, 4, 3218, 319, 440, 6, 40, 1546, 20, 2607, 2, 2197, 119, 84, 1134, 35, 602, 1150, 1, 1209, 16, 1904, 6, 40, 1546, 20, 3, 827, 171, 14731, 933, 17, 708, 2, 127, 13836, 163, 933, 109, 9691, 1505, 4856, 29, 933, 199, 9691, 4, 136, 38, 51, 2, 219, 1571, 29, 94, 4, 399, 21, 6572, 17, 4540, 16, 3, 2156, 933, 6159, 4, 718, 2, 12, 4540, 16, 824, 440, 9, 211, 801, 6, 13772, 8734, 3, 2821, 1, 3, 30, 1432, 145, 137, 407, 1, 8734, 343, 1097, 44, 1910, 1967, 9, 3593, 1, 4540, 4, 3440, 718, 2, 12, 4, 26, 45, 21, 765, 3, 12, 1432, 1, 399, 1971, 4, 3, 55, 1, 8734, 2, 361, 1, 100, 139, 6575, 522, 652, 16865, 2, 15206, 17, 32, 120, 5458, 20, 4540, 8734, 16865, 1971, 399, 276, 718, 2, 12, 22, 746, 22, 1022, 933, 245, 4540, 2862, 399, 3, 718, 2, 7743, 1, 3, 8734, 16865, 1971, 399, 120, 2507, 3, 827, 286, 2618, 2, 901, 19040, 22, 164, 4, 3, 7743, 1, 4540, 2862, 399, 399, 1971, 9, 8734, 2, 15206, 4, 136, 718, 2, 7743, 224, 919, 286, 2, 30, 2618, 21, 2060, 17, 8734, 2, 16865, 2559, 1162, 6, 4143, 3134, 718, 2, 12, 2, 32, 673, 561, 867, 637, 1, 933, 245, 4540, 4, 211, 2925, 6, 933, 109, 1209]",1409.0,22237625,309
Short hairpin RNA targeting Twist1 suppresses cell proliferation and             improves chemosensitivity to cisplatin in HeLa human cervical cancer cells.,Oncology reports,Oncol. Rep.,2012-01-12,"Development of multidrug resistance (MDR) remains a major hurdle to successful cancer chemotherapy and MDR1/P-gp overexpression is believed to be mainly responsible for MDR of tumor cells. Twist1, which is a highly conserved transcription factor that belongs to the family of basic helix-loop-helix proteins, has been shown to be a major regulator of the epithelial-mesenchymal transition (EMT), and therefore promotes carcinoma metastasis. Recently, a novel function of Twist1 was reported to confer radioresistance or chemoresistance in cervical cancer. However, mechanisms of such efficacy are not completely elucidated. In the present study, we firstly analyzed the relationship between Twist1 and MDR1/P-gp expression in human cervical cancer specimens and demonstrated a positive correlation between Twist1 and MDR1/P-gp expression in the same patient. Additionally, we provide the first evidence that silencing of Twist1 by RNAi downregulated MDR1/P-gp expression in HeLa cervical cancer cells, suppressed the cell proliferation, inhibited Rhodamine123 efflux activity of cells and sensitized cells to cisplatin treatment. Collectively, these ndings suggest that Twist1-mediated modulation of MDR1/P-gp expression plays an important role in sensitization of cervical cancer cells to cisplatin, and also indicate a novel therapeutic strategy to overcome drug resistance through inactivation of Twist1 expression in cervical cancer.",Journal Article,2931.0,34.0,Development of multidrug resistance MDR remains a major hurdle to successful cancer chemotherapy and MDR1/P-gp overexpression is believed to be mainly responsible for MDR of tumor cells Twist1 which is a highly conserved transcription factor that belongs to the family of basic helix-loop-helix proteins has been shown to be a major regulator of the epithelial-mesenchymal transition EMT and therefore promotes carcinoma metastasis Recently a novel function of Twist1 was reported to confer radioresistance or chemoresistance in cancer However mechanisms of such efficacy are not completely elucidated In the present study we firstly analyzed the relationship between Twist1 and MDR1/P-gp expression in human cancer specimens and demonstrated a positive correlation between Twist1 and MDR1/P-gp expression in the same patient Additionally we provide the first evidence that silencing of Twist1 by RNAi downregulated MDR1/P-gp expression in HeLa cancer cells suppressed the cell proliferation inhibited Rhodamine123 efflux activity of cells and sensitized cells to cisplatin treatment Collectively these ndings suggest that Twist1-mediated modulation of MDR1/P-gp expression plays an important role in sensitization of cancer cells to cisplatin and also indicate a novel therapeutic strategy to overcome drug resistance through inactivation of Twist1 expression in cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[193, 1, 4814, 251, 4186, 469, 8, 458, 14232, 6, 1401, 12, 56, 2, 5921, 19, 5407, 851, 16, 3979, 6, 40, 2615, 2327, 9, 4186, 1, 30, 37, 5446, 92, 16, 8, 561, 5547, 866, 161, 17, 14815, 6, 3, 607, 1, 2795, 8861, 4432, 8861, 652, 71, 85, 443, 6, 40, 8, 458, 2452, 1, 3, 701, 1569, 1970, 2208, 2, 673, 2148, 134, 278, 761, 8, 229, 343, 1, 5446, 10, 210, 6, 2913, 7052, 15, 3782, 4, 12, 137, 483, 1, 225, 209, 32, 44, 2500, 3901, 4, 3, 364, 45, 21, 16535, 311, 3, 858, 59, 5446, 2, 5921, 19, 5407, 55, 4, 171, 12, 623, 2, 264, 8, 109, 816, 59, 5446, 2, 5921, 19, 5407, 55, 4, 3, 827, 69, 1724, 21, 377, 3, 157, 241, 17, 2077, 1, 5446, 20, 5881, 3315, 5921, 19, 5407, 55, 4, 8466, 12, 37, 1908, 3, 31, 457, 879, 60992, 7043, 128, 1, 37, 2, 4242, 37, 6, 540, 24, 2535, 46, 46986, 309, 17, 5446, 517, 2356, 1, 5921, 19, 5407, 55, 1698, 35, 305, 200, 4, 6272, 1, 12, 37, 6, 540, 2, 120, 1008, 8, 229, 189, 692, 6, 1768, 234, 251, 298, 2297, 1, 5446, 55, 4, 12]",1371.0,22245869,497
Clinical and pathological heterogeneity of cervical intraepithelial neoplasia grade 3.,PloS one,PLoS ONE,2012-01-13,"Cervical intraepithelial neoplasia grade 3 (CIN3), the immediate cervical cancer precursor, is a target of cervical cancer prevention. However, less than half of CIN3s will progress to cancer. Routine treatment of all CIN3s and the majority of CIN2s may lead to overtreatment of many lesions that would not progress. To improve our understanding of CIN3 natural history, we performed a detailed characterization of CIN3 heterogeneity in a large referral population in the US. We examined 309 CIN3 cases in the SUCCEED, a large population-based study of women with abnormal cervical cancer screening results. Histology information for 12 individual loop electrosurgical excision procedure (LEEP) segments was evaluated for each woman. We performed case-case comparisons of CIN3s to analyze determinants of heterogeneity and screening test performance. CIN3 cases varied substantially by size (1-10 LEEP segments) and by presentation with concomitant CIN2 and CIN1. All grades of CINs were equally distributed over the cervical surface. In half of the women, CIN3 lesions were found as multiple distinct lesions on the cervix. Women with large and solitary CIN3 lesions were more likely to be older, have longer sexual activity span, and have fewer multiple high risk HPV infections. Screening frequency, but not HPV16 positivity, was an important predictor of CIN3 size. Large CIN3 lesions were also characterized by high-grade clinical test results. We demonstrate substantial heterogeneity in clinical and pathological presentation of CIN3 in a US population. Time since sexual debut and participation in screening were predictors of CIN3 size. We did not observe a preferential site of CIN3 on the cervical surface that could serve as a target for cervical biopsy. Cervical cancer screening procedures were more likely to detect larger CIN3s, suggesting that CIN3s detected by multiple independent diagnostic tests may represent cases with increased risk of invasion.",Journal Article,2930.0,10.0,intraepithelial neoplasia grade 3 CIN3 the immediate cancer precursor is a target of cancer prevention However less than half of CIN3s will progress to cancer Routine treatment of all CIN3s and the majority of CIN2s may lead to overtreatment of many lesions that would not progress To improve our understanding of CIN3 natural history we performed a detailed characterization of CIN3 heterogeneity in a large referral population in the US We examined 309 CIN3 cases in the SUCCEED a large population-based study of women with abnormal cancer screening results Histology information for 12 individual loop electrosurgical excision procedure LEEP segments was evaluated for each woman We performed case-case comparisons of CIN3s to analyze determinants of heterogeneity and screening test performance CIN3 cases varied substantially by size 1-10 LEEP segments and by presentation with concomitant CIN2 and CIN1 All grades of CINs were equally distributed over the surface In half of the women CIN3 lesions were found as multiple distinct lesions on the cervix Women with large and solitary CIN3 lesions were more likely to be older have longer sexual activity span and have fewer multiple high risk HPV infections Screening frequency but not HPV16 positivity was an important predictor of CIN3 size Large CIN3 lesions were also characterized by high-grade clinical test results We demonstrate substantial heterogeneity in clinical and pathological presentation of CIN3 in a US population Time since sexual debut and participation in screening were predictors of CIN3 size We did not observe a preferential site of CIN3 on the surface that could serve as a target for biopsy cancer screening procedures were more likely to detect larger CIN3s suggesting that CIN3s detected by multiple independent diagnostic tests may represent cases with increased risk of invasion,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4153, 2298, 88, 27, 10346, 3, 2181, 12, 2765, 16, 8, 283, 1, 12, 1070, 137, 299, 76, 1303, 1, 31905, 303, 1466, 6, 12, 1311, 24, 1, 62, 31905, 2, 3, 686, 1, 61008, 68, 1122, 6, 7720, 1, 445, 406, 17, 688, 44, 1466, 6, 401, 114, 612, 1, 10346, 1504, 532, 21, 173, 8, 2455, 2136, 1, 10346, 1144, 4, 8, 375, 2096, 266, 4, 3, 843, 21, 409, 9440, 10346, 140, 4, 3, 15141, 8, 375, 266, 90, 45, 1, 117, 5, 1668, 12, 453, 99, 784, 487, 9, 133, 797, 4432, 24548, 1366, 1299, 19966, 5138, 10, 194, 9, 296, 2854, 21, 173, 473, 473, 2213, 1, 31905, 6, 1992, 3403, 1, 1144, 2, 453, 412, 528, 10346, 140, 2051, 2109, 20, 444, 14, 79, 19966, 5138, 2, 20, 1031, 5, 1781, 12870, 2, 23728, 62, 2276, 1, 61009, 11, 4142, 4737, 252, 3, 1255, 4, 1303, 1, 3, 117, 10346, 406, 11, 204, 22, 232, 834, 406, 23, 3, 3629, 117, 5, 375, 2, 3144, 10346, 406, 11, 80, 322, 6, 40, 434, 47, 589, 2232, 128, 7165, 2, 47, 1497, 232, 64, 43, 933, 1875, 453, 675, 84, 44, 4048, 1887, 10, 35, 305, 980, 1, 10346, 444, 375, 10346, 406, 11, 120, 765, 20, 64, 88, 38, 412, 99, 21, 608, 1281, 1144, 4, 38, 2, 1301, 1031, 1, 10346, 4, 8, 843, 266, 98, 1192, 2232, 46998, 2, 2599, 4, 453, 11, 674, 1, 10346, 444, 21, 205, 44, 4635, 8, 6629, 606, 1, 10346, 23, 3, 1255, 17, 359, 1833, 22, 8, 283, 9, 411, 12, 453, 1369, 11, 80, 322, 6, 1426, 1077, 31905, 802, 17, 31905, 530, 20, 232, 306, 752, 895, 68, 1231, 140, 5, 101, 43, 1, 578]",1863.0,22253702,102
Infant ectopic cervical thymus one case report: diagnostic and management difficulties.,Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery,J Craniomaxillofac Surg,2012-01-23,"Cervical ectopic thymus (CET), an embryological anomaly detected incidentally at autopsy, is rarely described in clinical patients. Furthermore, aberrant cervical thymic tissue is an infrequently reported cause of neck masses, and especially for pediatric patients. However, according to clinical work, it should be included in the differential diagnosis of neck masses, particularly for children patients. Thymic tissue rests can be found all along the route of thymic descent from the neck into the anterior mediastinum. In routine practice, the preoperative diagnosis of ectopic cervical thymus is seldom considered and it is often misdiagnosed as a possible tumor or as a lymph node, which leads to biopsy or surgical removal. Here, a case of ectopic thymic tissue was presented in the neck misdiagnosed as cystic hydroma (one type of lymphatic malformation). Our misdiagnosis was introduced, the literature about diagnosis and management controversy were reviewed in recent years.",Case Reports,2920.0,1.0,ectopic thymus CET an embryological anomaly detected incidentally at autopsy is rarely described in clinical patients Furthermore aberrant thymic tissue is an infrequently reported cause of masses and especially for pediatric patients However according to clinical work it should be included in the differential diagnosis of masses particularly for children patients Thymic tissue rests can be found all along the route of thymic descent from the into the anterior mediastinum In routine practice the preoperative diagnosis of ectopic thymus is seldom considered and it is often misdiagnosed as a possible tumor or as a lymph node which leads to biopsy or surgical removal Here a case of ectopic thymic tissue was presented in the misdiagnosed as cystic hydroma one type of lymphatic malformation Our misdiagnosis was introduced the literature about diagnosis and management controversy were reviewed in recent years,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3647, 9468, 18646, 35, 31912, 17085, 530, 5925, 28, 6270, 16, 2416, 1027, 4, 38, 7, 798, 1898, 3572, 246, 16, 35, 6440, 210, 708, 1, 2692, 2, 1093, 9, 815, 7, 137, 768, 6, 38, 1357, 192, 257, 40, 159, 4, 3, 1777, 147, 1, 2692, 823, 9, 541, 7, 3572, 246, 14405, 122, 40, 204, 62, 1510, 3, 5841, 1, 3572, 9171, 29, 3, 237, 3, 2882, 7156, 4, 1311, 758, 3, 498, 147, 1, 3647, 9468, 16, 10805, 515, 2, 192, 16, 629, 10688, 22, 8, 899, 30, 15, 22, 8, 263, 289, 92, 1940, 6, 411, 15, 221, 2829, 467, 8, 473, 1, 3647, 3572, 246, 10, 917, 4, 3, 10688, 22, 2965, 61023, 104, 267, 1, 2936, 14595, 114, 13470, 10, 3955, 3, 789, 545, 147, 2, 284, 4089, 11, 446, 4, 435, 60]",916.0,22266225,639
Optimized planning target volume for intact cervical cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2012-01-21,"To model interfraction clinical target volume (CTV) variation in patients with intact cervical cancer and design a planning target volume (PTV) that minimizes normal tissue dose while maximizing CTV coverage. We analyzed 50 patients undergoing external-beam radiotherapy for intact cervical cancer using daily online cone-beam computed tomography (CBCT). The CBCTs (n = 972) for each patient were rigidly registered to the planning CT. The CTV was delineated on the planning CT (CTV(0)) and the set of CBCTs ({CTV(1)-CTV(25)}). Manual (n = 98) and automated (n = 668) landmarks were placed over the surface of CTV(0) with reference to defined anatomic structures. Normal vectors were extended from each landmark, and the minimum length required for a given probability of encompassing CTV(1)-CTV(25) was computed. The resulting expansions were used to generate an optimized PTV. The mean (SD; range) normal vector length to ensure 95% coverage was 4.3 mm (2.7 mm; 1-16 mm). The uniform expansion required to ensure 95% probability of CTV coverage was 13 mm. An anisotropic margin of 20 mm anteriorly and posteriorly and 10 mm superiorly, inferiorly, and laterally also would have ensured a 95% probability of CTV coverage. The volume of the 95% optimized PTV (1470 cm(3)) was significantly lower than both the anisotropic PTV (2220 cm(3)) and the uniformly expanded PTV (2110 cm(3)) (p < 0.001). For a 95% probability of CTV coverage, normal lengths of 1-3 mm were found along the superior and lateral regions of CTV(0), 5-10 mm along the interfaces of CTV(0) with the bladder and rectum, and 10-14 mm along the anterior surface of CTV(0) at the level of the uterus. Optimizing PTV definition according to surface landmarking resulted in a high probability of CTV coverage with reduced PTV volumes. Our results provide data justifying planning margins to use in practice and clinical trials.",Journal Article,2922.0,20.0,To model interfraction clinical target volume CTV variation in patients with intact cancer and design a planning target volume PTV that minimizes normal tissue dose while maximizing CTV coverage We analyzed 50 patients undergoing external-beam radiotherapy for intact cancer using daily online cone-beam computed tomography CBCT The CBCTs n 972 for each patient were rigidly registered to the planning CT The CTV was delineated on the planning CT CTV 0 and the set of CBCTs CTV 1 -CTV 25 Manual n 98 and automated n 668 landmarks were placed over the surface of CTV 0 with reference to defined anatomic structures Normal vectors were extended from each landmark and the minimum length required for a given probability of encompassing CTV 1 -CTV 25 was computed The resulting expansions were used to generate an optimized PTV The mean SD range normal vector length to ensure 95 coverage was 4.3 mm 2.7 mm 1-16 mm The uniform expansion required to ensure 95 probability of CTV coverage was 13 mm An anisotropic margin of 20 mm anteriorly and posteriorly and 10 mm superiorly inferiorly and laterally also would have ensured a 95 probability of CTV coverage The volume of the 95 optimized PTV 1470 cm 3 was significantly lower than both the anisotropic PTV 2220 cm 3 and the uniformly expanded PTV 2110 cm 3 p 0.001 For a 95 probability of CTV coverage normal lengths of 1-3 mm were found along the superior and lateral regions of CTV 0 5-10 mm along the interfaces of CTV 0 with the and rectum and 10-14 mm along the anterior surface of CTV 0 at the level of the Optimizing PTV definition according to surface landmarking resulted in a high probability of CTV coverage with reduced PTV volumes Our results provide data justifying planning margins to use in practice and clinical trials,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,"[6, 202, 13610, 38, 283, 433, 3402, 1380, 4, 7, 5, 2964, 12, 2, 771, 8, 1349, 283, 433, 3303, 17, 14527, 295, 246, 61, 369, 8260, 3402, 2139, 21, 311, 212, 7, 479, 1455, 1345, 310, 9, 2964, 12, 75, 391, 4123, 6939, 1345, 1220, 872, 5187, 3, 19237, 78, 11959, 9, 296, 69, 11, 39481, 1653, 6, 3, 1349, 425, 3, 3402, 10, 5610, 23, 3, 1349, 425, 3402, 13, 2, 3, 916, 1, 19237, 3402, 14, 3402, 243, 4590, 78, 1096, 2, 3235, 78, 13642, 12092, 11, 3295, 252, 3, 1255, 1, 3402, 13, 5, 2482, 6, 395, 2745, 2414, 295, 5453, 11, 1747, 29, 296, 3829, 2, 3, 2499, 1318, 616, 9, 8, 447, 1320, 1, 6853, 3402, 14, 3402, 243, 10, 1220, 3, 1113, 12384, 11, 95, 6, 2562, 35, 4039, 3303, 3, 313, 1270, 184, 295, 3374, 1318, 6, 3478, 48, 2139, 10, 39, 27, 321, 18, 67, 321, 14, 245, 321, 3, 3490, 1422, 616, 6, 3478, 48, 1320, 1, 3402, 2139, 10, 233, 321, 35, 31913, 959, 1, 179, 321, 22232, 2, 21488, 2, 79, 321, 25125, 25313, 2, 17800, 120, 688, 47, 23296, 8, 48, 1320, 1, 3402, 2139, 3, 433, 1, 3, 48, 4039, 3303, 30342, 494, 27, 10, 97, 280, 76, 110, 3, 31913, 3303, 47014, 494, 27, 2, 3, 4254, 2064, 3303, 47015, 494, 27, 19, 13, 144, 9, 8, 48, 1320, 1, 3402, 2139, 295, 7443, 1, 14, 27, 321, 11, 204, 1510, 3, 1123, 2, 3855, 1374, 1, 3402, 13, 33, 79, 321, 1510, 3, 29246, 1, 3402, 13, 5, 3, 2, 3660, 2, 79, 213, 321, 1510, 3, 2882, 1255, 1, 3402, 13, 28, 3, 301, 1, 3, 4336, 3303, 2470, 768, 6, 1255, 61032, 627, 4, 8, 64, 1320, 1, 3402, 2139, 5, 405, 3303, 2225, 114, 99, 377, 74, 13579, 1349, 1012, 6, 119, 4, 758, 2, 38, 143]",1783.0,22270167,28
Correlation between radiation dose to F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2012-01-21,"To test the hypothesis that radiation dose to (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET)-defined active bone marrow (BM(ACT)) subregions is correlated with hematologic toxicity in cervical cancer patients treated with chemoradiotherapy. The conditions of 26 women with cervical cancer who underwent (18)F-FDG-PET before treatment with concurrent cisplatin and intensity-modulated radiation therapy were analyzed. BM(ACT) was defined as the subregion of total bone marrow (BM(TOT)) with a standardized uptake value (SUV) equal to or above the mean for that individual. Inactive bone marrow (BM(INACT)) was defined as BM(TOT) - BM(ACT). Generalized linear modeling was used to test the correlation between BM(ACT) and BM(INACT) dose-volume metrics and hematologic nadirs, particularly white blood cell count (WBC) and absolute neutrophil count (ANC). Increased BM(ACT) mean dose was significantly associated with decreased log(WBC) nadir ( = -0.04; 95% CI, -0.07 to -0.01; p = 0.009), decreased log(ANC) nadir ( = -0.05; 95% CI, -0.08 to -0.02; p = 0.006), decreased hemoglobin nadir ( = -0.16; 95% CI, -0.27 to -0.05; p = 0.010), and decreased platelet nadir ( = -6.16; 95% CI, -9.37 to -2.96; p < 0.001). By contrast, there was no association between BM(INACT) mean dose and log(WBC) nadir ( = -0.01; 95% CI, -0.06 to 0.05; p = 0.84), log(ANC) nadir ( = -0.03; 95% CI, -0.10 to 0.04; p = 0.40), hemoglobin nadir ( = -0.09; 95% CI, -0.31 to 0.14; p = 0.452), or platelet nadir ( = -3.47; 95% CI, -10.44 to 3.50; p = 0.339). Irradiation of BM subregions with higher (18)F-FDG-PET activity was associated with hematologic toxicity, supporting the hypothesis that reducing dose to BM(ACT) subregions could mitigate hematologic toxicity. Future investigation should seek to confirm these findings and to identify optimal SUV thresholds to define BM(ACT).",Journal Article,2922.0,60.0,To test the hypothesis that radiation dose to 18 F-fluorodeoxyglucose positron emission tomography 18 F-FDG-PET -defined active marrow BM ACT subregions is correlated with hematologic toxicity in cancer patients treated with chemoradiotherapy The conditions of 26 women with cancer who underwent 18 F-FDG-PET before treatment with concurrent cisplatin and intensity-modulated radiation therapy were analyzed BM ACT was defined as the subregion of total marrow BM TOT with a standardized uptake value SUV equal to or above the mean for that individual Inactive marrow BM INACT was defined as BM TOT BM ACT Generalized linear modeling was used to test the correlation between BM ACT and BM INACT dose-volume metrics and hematologic nadirs particularly white blood cell count WBC and absolute neutrophil count ANC Increased BM ACT mean dose was significantly associated with decreased log WBC nadir -0.04 95 CI -0.07 to -0.01 p 0.009 decreased log ANC nadir -0.05 95 CI -0.08 to -0.02 p 0.006 decreased hemoglobin nadir -0.16 95 CI -0.27 to -0.05 p 0.010 and decreased platelet nadir -6.16 95 CI -9.37 to -2.96 p 0.001 By contrast there was no association between BM INACT mean dose and log WBC nadir -0.01 95 CI -0.06 to 0.05 p 0.84 log ANC nadir -0.03 95 CI -0.10 to 0.04 p 0.40 hemoglobin nadir -0.09 95 CI -0.31 to 0.14 p 0.452 or platelet nadir -3.47 95 CI -10.44 to 3.50 p 0.339 Irradiation of BM subregions with higher 18 F-FDG-PET activity was associated with hematologic toxicity supporting the hypothesis that reducing dose to BM ACT subregions could mitigate hematologic toxicity Future investigation should seek to confirm these findings and to identify optimal SUV thresholds to define BM ACT,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 412, 3, 1492, 17, 121, 61, 6, 203, 1068, 4085, 1900, 1799, 872, 203, 1068, 1285, 495, 395, 544, 581, 1246, 2559, 22613, 16, 438, 5, 813, 155, 4, 12, 7, 73, 5, 1464, 3, 1298, 1, 432, 117, 5, 12, 54, 208, 203, 1068, 1285, 495, 348, 24, 5, 750, 540, 2, 837, 1757, 121, 36, 11, 311, 1246, 2559, 10, 395, 22, 3, 31914, 1, 181, 581, 1246, 19958, 5, 8, 1670, 1135, 549, 2217, 2997, 6, 15, 2090, 3, 313, 9, 17, 797, 5002, 581, 1246, 39879, 10, 395, 22, 1246, 19958, 1246, 2559, 4169, 1646, 2057, 10, 95, 6, 412, 3, 816, 59, 1246, 2559, 2, 1246, 39879, 61, 433, 3589, 2, 813, 13866, 823, 886, 315, 31, 1276, 4685, 2, 1766, 2595, 1276, 6486, 101, 1246, 2559, 313, 61, 10, 97, 41, 5, 340, 1066, 4685, 3686, 13, 755, 48, 58, 13, 1615, 6, 13, 355, 19, 13, 2376, 340, 1066, 6486, 3686, 13, 474, 48, 58, 13, 1592, 6, 13, 588, 19, 13, 1861, 340, 2222, 3686, 13, 245, 48, 58, 13, 428, 6, 13, 474, 19, 13, 4873, 2, 340, 1596, 3686, 49, 245, 48, 58, 83, 567, 6, 18, 921, 19, 13, 144, 20, 748, 125, 10, 77, 248, 59, 1246, 39879, 313, 61, 2, 1066, 4685, 3686, 13, 355, 48, 58, 13, 1460, 6, 13, 474, 19, 13, 874, 1066, 6486, 3686, 13, 680, 48, 58, 13, 79, 6, 13, 755, 19, 13, 327, 2222, 3686, 13, 1730, 48, 58, 13, 456, 6, 13, 213, 19, 13, 12638, 15, 1596, 3686, 27, 662, 48, 58, 79, 584, 6, 27, 212, 19, 13, 7881, 1104, 1, 1246, 22613, 5, 142, 203, 1068, 1285, 495, 128, 10, 41, 5, 813, 155, 1912, 3, 1492, 17, 1818, 61, 6, 1246, 2559, 22613, 359, 5626, 813, 155, 508, 940, 257, 6606, 6, 1843, 46, 272, 2, 6, 255, 665, 2217, 4634, 6, 1107, 1246, 2559]",1702.0,22270171,622
Merkel cell carcinoma of unknown primary origin.,Annals of surgical oncology,Ann. Surg. Oncol.,2012-01-21,"Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin. MCC from an unknown primary origin (MCCUP) can present a diagnostic and therapeutic challenge. We describe our single-institution experience with the diagnosis and management of MCCUP presenting as metastases to lymph nodes. After institutional review board approval, our institutional database spanning the years 1998-2010 was queried for patients with MCCUP. Clinicopathologic variables and outcomes were assessed. From a database of 321 patients with MCC, 38 (12%) were identified as having nodal MCCUP. Median age was 67years, and 79% were men. Nodal basins involved at presentation were cervical (58%), axillary/epitrochlear (21%), or inguinal/iliac (21%). CK20 staining was positive in 93% of tumors tested, and all were negative for thyroid transcription factor-1. Twenty-nine patients (76%) underwent complete regional lymph node dissection (LND): 3 had LND alone, ten had LND and adjuvant radiotherapy, and 16 underwent LND followed by chemoradiotherapy. Definitive chemoradiotherapy without surgery was provided to six patients (16%), while radiotherapy alone was provided to three (8%). Recurrence was observed in 34% of patients. Median recurrence-free survival was 35months. Ten patients (26%) died, five of disease and five of other causes. The median overall survival was 104months. Nodal MCCUP is a rare disease affecting primarily elderly white men. Recurrence is observed in approximately one-third of patients, with a 104month median overall survival after a multimodal treatment approach consisting of surgery along with adjuvant chemotherapy and radiotherapy in the majority of patients.",Clinical Trial,2922.0,35.0,Merkel cell carcinoma MCC is a rare neuroendocrine tumor of the MCC from an unknown primary origin MCCUP can present a diagnostic and therapeutic challenge We describe our single-institution experience with the diagnosis and management of MCCUP presenting as metastases to lymph nodes After institutional review board approval our institutional database spanning the years 1998-2010 was queried for patients with MCCUP Clinicopathologic variables and outcomes were assessed From a database of 321 patients with MCC 38 12 were identified as having nodal MCCUP Median age was 67 years and 79 were men Nodal basins involved at presentation were 58 axillary/epitrochlear 21 or inguinal/iliac 21 CK20 staining was positive in 93 of tumors tested and all were negative for transcription factor-1 Twenty-nine patients 76 underwent complete regional lymph node dissection LND 3 had LND alone ten had LND and adjuvant radiotherapy and 16 underwent LND followed by chemoradiotherapy Definitive chemoradiotherapy without surgery was provided to six patients 16 while radiotherapy alone was provided to three 8 Recurrence was observed in 34 of patients Median recurrence-free survival was 35 months Ten patients 26 died five of disease and five of other causes The median overall survival was 104 months Nodal MCCUP is a rare disease affecting primarily elderly white men Recurrence is observed in approximately one-third of patients with a 104 month median overall survival after a multimodal treatment approach consisting of surgery along with adjuvant chemotherapy and radiotherapy in the majority of patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,"[5855, 31, 134, 4384, 16, 8, 622, 1542, 30, 1, 3, 4384, 29, 35, 860, 86, 1938, 27131, 122, 364, 8, 752, 2, 189, 1745, 21, 897, 114, 226, 731, 730, 5, 3, 147, 2, 284, 1, 27131, 1656, 22, 196, 6, 263, 502, 50, 1115, 206, 2620, 1814, 114, 1115, 609, 7155, 3, 60, 1850, 1120, 10, 3547, 9, 7, 5, 27131, 1399, 682, 2, 123, 11, 275, 29, 8, 609, 1, 9976, 7, 5, 4384, 519, 133, 11, 108, 22, 1041, 779, 27131, 52, 89, 10, 598, 60, 2, 842, 11, 325, 779, 7847, 646, 28, 1031, 11, 717, 1210, 27931, 239, 15, 4907, 6692, 239, 10821, 1029, 10, 109, 4, 966, 1, 57, 650, 2, 62, 11, 199, 9, 866, 161, 14, 737, 762, 7, 846, 208, 236, 951, 263, 289, 1161, 3400, 27, 42, 3400, 279, 1618, 42, 3400, 2, 249, 310, 2, 245, 208, 3400, 370, 20, 1464, 1057, 1464, 187, 152, 10, 1052, 6, 437, 7, 245, 369, 310, 279, 10, 1052, 6, 169, 66, 146, 10, 164, 4, 562, 1, 7, 52, 146, 115, 25, 10, 465, 53, 1618, 7, 432, 1016, 365, 1, 34, 2, 365, 1, 127, 1626, 3, 52, 63, 25, 10, 3407, 53, 779, 27131, 16, 8, 622, 34, 2319, 1561, 1216, 886, 325, 146, 16, 164, 4, 705, 104, 1282, 1, 7, 5, 8, 3407, 811, 52, 63, 25, 50, 8, 4122, 24, 353, 2273, 1, 152, 1510, 5, 249, 56, 2, 310, 4, 3, 686, 1, 7]",1600.0,22271206,580
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-01-23,"Mutations of the PIK3CA gene may predict response to phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) inhibitors. Concomitant mutations in the mitogen-activated protein kinase (MAPK) pathway may mediate resistance. Tumors from patients with breast, cervical, endometrial, and ovarian cancer referred to the Clinical Center for Targeted Therapy (Phase I Program) were analyzed for PIK3CA, KRAS, NRAS, and BRAF mutations. Patients with PIK3CA mutations were treated, whenever feasible, with agents targeting the PI3K/AKT/mTOR pathway. Of 140 patients analyzed, 25 (18%) had PIK3CA mutations, including five of 14 patients with squamous cell cervical, seven of 29 patients with endometrial, six of 29 patients with breast, and seven of 60 patients with ovarian cancers. Of the 25 patients with PIK3CA mutations, 23 (median of two prior therapies) were treated on a protocol that included a PI3K/AKT/mTOR pathway inhibitor. Two (9%) of 23 patients had stable disease for more than 6 months, and seven patients (30%) had a partial response. In comparison, only seven (10%) of 70 patients with the same disease types but with wild-type PIK3CA treated on the same protocols responded (P = .04). Seven patients (30%) with PIK3CA mutations had coexisting MAPK pathway (KRAS, NRAS, BRAF) mutations (ovarian cancer, n = 5; endometrial cancer, n = 2), and two of these patients (ovarian cancer) achieved a response. PIK3CA mutations were detected in 18% of tested patients. Patients with PIK3CA mutations treated with PI3K/AKT/mTOR inhibitors demonstrated a higher response rate than patients without mutations. A subset of patients with ovarian cancer with simultaneous PIK3CA and MAPK mutations responded to PI3K/AKT/mTOR inhibitors, suggesting that not all patients demonstrate resistance when the MAPK pathway is concomitantly activated.",Journal Article,2920.0,326.0,Mutations of the PIK3CA gene may predict response to phosphatidylinositol 3-kinase PI3K /AKT/mammalian target of rapamycin mTOR inhibitors Concomitant mutations in the mitogen-activated protein kinase MAPK pathway may mediate resistance Tumors from patients with and cancer referred to the Clinical Center for Targeted Therapy Phase I Program were analyzed for PIK3CA KRAS NRAS and BRAF mutations Patients with PIK3CA mutations were treated whenever feasible with agents targeting the PI3K/AKT/mTOR pathway Of 140 patients analyzed 25 18 had PIK3CA mutations including five of 14 patients with squamous cell seven of 29 patients with six of 29 patients with and seven of 60 patients with cancers Of the 25 patients with PIK3CA mutations 23 median of two prior therapies were treated on a protocol that included a PI3K/AKT/mTOR pathway inhibitor Two 9 of 23 patients had stable disease for more than 6 months and seven patients 30 had a partial response In comparison only seven 10 of 70 patients with the same disease types but with wild-type PIK3CA treated on the same protocols responded P .04 Seven patients 30 with PIK3CA mutations had coexisting MAPK pathway KRAS NRAS BRAF mutations cancer n 5 cancer n 2 and two of these patients cancer achieved a response PIK3CA mutations were detected in 18 of tested patients Patients with PIK3CA mutations treated with PI3K/AKT/mTOR inhibitors demonstrated a higher response rate than patients without mutations A subset of patients with cancer with simultaneous PIK3CA and MAPK mutations responded to PI3K/AKT/mTOR inhibitors suggesting that not all patients demonstrate resistance when the MAPK pathway is concomitantly activated,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[138, 1, 3, 1506, 145, 68, 678, 51, 6, 3415, 27, 216, 974, 649, 2359, 283, 1, 1620, 873, 222, 1781, 138, 4, 3, 2625, 735, 178, 216, 1748, 308, 68, 3367, 251, 57, 29, 7, 5, 2, 12, 1995, 6, 3, 38, 574, 9, 238, 36, 124, 70, 1243, 11, 311, 9, 1506, 723, 2845, 2, 566, 138, 7, 5, 1506, 138, 11, 73, 8395, 1313, 5, 183, 529, 3, 974, 649, 873, 308, 1, 3304, 7, 311, 243, 203, 42, 1506, 138, 141, 365, 1, 213, 7, 5, 691, 31, 648, 1, 462, 7, 5, 437, 1, 462, 7, 5, 2, 648, 1, 335, 7, 5, 163, 1, 3, 243, 7, 5, 1506, 138, 382, 52, 1, 100, 324, 235, 11, 73, 23, 8, 1182, 17, 159, 8, 974, 649, 873, 308, 230, 100, 83, 1, 382, 7, 42, 585, 34, 9, 80, 76, 49, 53, 2, 648, 7, 201, 42, 8, 450, 51, 4, 1155, 158, 648, 79, 1, 431, 7, 5, 3, 827, 34, 630, 84, 5, 955, 267, 1506, 73, 23, 3, 827, 2189, 2211, 19, 755, 648, 7, 201, 5, 1506, 138, 42, 8859, 1748, 308, 723, 2845, 566, 138, 12, 78, 33, 12, 78, 18, 2, 100, 1, 46, 7, 12, 513, 8, 51, 1506, 138, 11, 530, 4, 203, 1, 650, 7, 7, 5, 1506, 138, 73, 5, 974, 649, 873, 222, 264, 8, 142, 51, 116, 76, 7, 187, 138, 8, 697, 1, 7, 5, 12, 5, 2824, 1506, 2, 1748, 138, 2211, 6, 974, 649, 873, 222, 802, 17, 44, 62, 7, 608, 251, 198, 3, 1748, 308, 16, 6485, 735]",1676.0,22271473,183
Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study.,Gynecologic oncology,Gynecol. Oncol.,2012-02-01,"To determine associations between pretreatment health-related quality of life subscales with progression-free (PFS) and overall survival (OS) in advanced and recurrent cervical cancer. Patients included those participating in Gynecologic Oncology Group advanced or recurrent cervical cancer phase III treatment trials who completed the Functional Assessment of Cancer Therapy for patients with cervical cancer (FACT-Cx) and a single-item pain scale at study entry. The FACT-Cx includes five domains: physical (PWB), emotional (EWB), social (SWB), functional well being (FWB), and cervix cancer subscale (CCS). A high quality of life (QoL) score reflects better QoL. After stratifying by protocol and adjusting for patient and disease characteristics, a Cox proportional hazards model was fitted for each subscale as a continuous variable. If statistically significant, (p<0.05), an analysis on mean item scores (MIS) was performed. Nine-hundred-ninety-one patients were enrolled from 1997 to 2007. The majority (87%) had recurrent disease. After adjustment for covariates and predictors, only the PWB domain (better physical QoL) was associated with improved OS [HR 0.96 95% CI 0.95-0.98; p<0.001]. When classifying patients based on the MIS of each subscale, the patients with the lowest risk of death were likely to report less compromised QoL (MIS>3) for PWB [HR 0.44 (0.33-0.58) P<0.001], FWB [0.49 (0.38-0.62) P<0.001], and CCS [0.48 (0.38-0.61) P<0.001]. The pretreatment patient-reported PWB as measured by the PWB subscale of the FACT-Cx, is significantly associated with survival in advanced cervical cancer trials, even after controlling for known prognostic factors.",Journal Article,2911.0,21.0,To determine associations between pretreatment health-related quality of life subscales with progression-free PFS and overall survival OS in advanced and recurrent cancer Patients included those participating in Gynecologic Oncology Group advanced or recurrent cancer phase III treatment trials who completed the Functional Assessment of Cancer Therapy for patients with cancer FACT-Cx and a single-item pain scale at study entry The FACT-Cx includes five domains physical PWB emotional EWB social SWB functional well being FWB and cervix cancer subscale CCS A high quality of life QoL score reflects better QoL After stratifying by protocol and adjusting for patient and disease characteristics a Cox proportional hazards model was fitted for each subscale as a continuous variable If statistically significant p 0.05 an analysis on mean item scores MIS was performed Nine-hundred-ninety-one patients were enrolled from 1997 to 2007 The majority 87 had recurrent disease After adjustment for covariates and predictors only the PWB domain better physical QoL was associated with improved OS HR 0.96 95 CI 0.95-0.98 p 0.001 When classifying patients based on the MIS of each subscale the patients with the lowest risk of death were likely to report less compromised QoL MIS 3 for PWB HR 0.44 0.33-0.58 P 0.001 FWB 0.49 0.38-0.62 P 0.001 and CCS 0.48 0.38-0.61 P 0.001 The pretreatment patient-reported PWB as measured by the PWB subscale of the FACT-Cx is significantly associated with survival in advanced cancer trials even after controlling for known prognostic factors,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 685, 59, 1194, 341, 139, 372, 1, 358, 6472, 5, 91, 115, 300, 2, 63, 25, 118, 4, 131, 2, 387, 12, 7, 159, 135, 3052, 4, 1512, 413, 87, 131, 15, 387, 12, 124, 316, 24, 143, 54, 781, 3, 583, 455, 1, 12, 36, 9, 7, 5, 12, 1991, 13627, 2, 8, 226, 3471, 559, 1124, 28, 45, 3001, 3, 1991, 13627, 1920, 365, 2703, 900, 16517, 2671, 18276, 2032, 15716, 583, 149, 486, 14332, 2, 3629, 12, 5593, 5688, 8, 64, 372, 1, 358, 1001, 368, 5224, 380, 1001, 50, 5035, 20, 1182, 2, 1358, 9, 69, 2, 34, 374, 8, 418, 831, 1017, 202, 10, 7315, 9, 296, 5593, 22, 8, 1314, 1347, 492, 712, 93, 19, 13, 474, 35, 65, 23, 313, 3471, 703, 4386, 10, 173, 762, 1128, 2493, 104, 7, 11, 346, 29, 2341, 6, 1307, 3, 686, 912, 42, 387, 34, 50, 1852, 9, 2489, 2, 674, 158, 3, 16517, 1398, 380, 900, 1001, 10, 41, 5, 231, 118, 168, 13, 921, 48, 58, 13, 48, 13, 1096, 19, 13, 144, 198, 8681, 7, 90, 23, 3, 4386, 1, 296, 5593, 3, 7, 5, 3, 2101, 43, 1, 273, 11, 322, 6, 414, 299, 4867, 1001, 4386, 27, 9, 16517, 168, 13, 584, 13, 466, 13, 717, 19, 13, 144, 14332, 13, 739, 13, 519, 13, 744, 19, 13, 144, 2, 5688, 13, 576, 13, 519, 13, 713, 19, 13, 144, 3, 1194, 69, 210, 16517, 22, 644, 20, 3, 16517, 5593, 1, 3, 1991, 13627, 16, 97, 41, 5, 25, 4, 131, 12, 143, 871, 50, 1893, 9, 440, 177, 130]",1571.0,22307062,522
Genetic variation in RTN4 3'-UTR and susceptibility to cervical squamous cell carcinoma.,DNA and cell biology,DNA Cell Biol.,2012-02-09,"Recent studies have suggested that RTN4 is a multifunctional gene, including inhibition of axonal regeneration, vascular remodeling, apoptosis, and tumor suppression. The TATC and CAA insertion/deletion polymorphisms of RTN4 3'-UTR have been linked to schizophrenia, depression, and dilated cardiomyopathy. To test whether these two polymorphisms are associated with cervical squamous cell carcinoma (CSCC), in this research, by using polymerase chain reaction-polyacrylamide gel electrophoresis, we determined the genotypes of the TATC and CAA polymorphisms in 336 CSCC patients and 450 unrelated control subjects. Allele frequencies of TATC and CAA polymorphisms were not significantly different between CSCC patients and control subjects (odds ratio [OR]=1.22, 95% confidence interval [CI]=0.98-1.50 for TATC; OR=0.95, 95% CI=0.76-1.18 for CAA). Decreased CSCC risk was associated with TATC polymorphism in a recessive model (OR=0.49, 95% CI=0.30-0.77), while no significant association was observed between CAA polymorphism and CSCC in different genetic models. Results of stratified analysis revealed that both TATC and CAA polymorphisms were associated with high clinical stage, and CAA polymorphism was also associated with positive parametrial invasion (OR=0.69, 95% CI=0.48-0.98). The present study provides evidence that TATC and CAA insertion/deletion polymorphisms are associated with CSCC, indicating that genetic variation in RTN4 3'-UTR contributes to the susceptibility to CSCC. It is necessary to confirm these findings in ethnically different populations and with a larger sample.",Journal Article,2903.0,7.0,Recent studies have suggested that RTN4 is a multifunctional gene including inhibition of axonal regeneration vascular remodeling apoptosis and tumor suppression The TATC and CAA insertion/deletion polymorphisms of RTN4 3'-UTR have been linked to schizophrenia depression and dilated cardiomyopathy To test whether these two polymorphisms are associated with squamous cell carcinoma CSCC in this research by using polymerase chain reaction-polyacrylamide gel electrophoresis we determined the genotypes of the TATC and CAA polymorphisms in 336 CSCC patients and 450 unrelated control subjects Allele frequencies of TATC and CAA polymorphisms were not significantly different between CSCC patients and control subjects odds ratio OR =1.22 95 confidence interval CI =0.98-1.50 for TATC OR=0.95 95 CI=0.76-1.18 for CAA Decreased CSCC risk was associated with TATC polymorphism in a recessive model OR=0.49 95 CI=0.30-0.77 while no significant association was observed between CAA polymorphism and CSCC in different genetic models Results of stratified analysis revealed that both TATC and CAA polymorphisms were associated with high clinical stage and CAA polymorphism was also associated with positive parametrial invasion OR=0.69 95 CI=0.48-0.98 The present study provides evidence that TATC and CAA insertion/deletion polymorphisms are associated with CSCC indicating that genetic variation in RTN4 3'-UTR contributes to the susceptibility to CSCC It is necessary to confirm these findings in ethnically different populations and with a larger sample,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[435, 94, 47, 1148, 17, 39892, 16, 8, 7354, 145, 141, 297, 1, 17257, 7888, 756, 4429, 351, 2, 30, 1332, 3, 27143, 2, 15753, 5099, 1528, 1203, 1, 39892, 5435, 8196, 47, 85, 1199, 6, 17950, 1774, 2, 11536, 6460, 6, 412, 317, 46, 100, 1203, 32, 41, 5, 691, 31, 134, 8015, 4, 26, 389, 20, 75, 1451, 1260, 1329, 26147, 5916, 6777, 21, 509, 3, 2071, 1, 3, 27143, 2, 15753, 1203, 4, 10047, 8015, 7, 2, 5669, 2092, 182, 976, 1254, 2722, 1, 27143, 2, 15753, 1203, 11, 44, 97, 338, 59, 8015, 7, 2, 182, 976, 610, 197, 15, 14, 350, 48, 307, 268, 58, 13, 1096, 14, 212, 9, 27143, 15, 13, 48, 48, 58, 13, 846, 14, 203, 9, 15753, 340, 8015, 43, 10, 41, 5, 27143, 1907, 4, 8, 9724, 202, 15, 13, 739, 48, 58, 13, 201, 13, 849, 369, 77, 93, 248, 10, 164, 59, 15753, 1907, 2, 8015, 4, 338, 336, 274, 99, 1, 1173, 65, 553, 17, 110, 27143, 2, 15753, 1203, 11, 41, 5, 64, 38, 82, 2, 15753, 1907, 10, 120, 41, 5, 109, 8726, 578, 15, 13, 790, 48, 58, 13, 576, 13, 1096, 3, 364, 45, 777, 241, 17, 27143, 2, 15753, 5099, 1528, 1203, 32, 41, 5, 8015, 1716, 17, 336, 1380, 4, 39892, 5435, 8196, 2444, 6, 3, 1432, 6, 8015, 192, 16, 1493, 6, 1843, 46, 272, 4, 12771, 338, 1184, 2, 5, 8, 1077, 1000]",1550.0,22320844,757
Stereotactic body radiation therapy in spinal metastases.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2012-02-11,"Based on reports of safety and efficacy, stereotactic body radiotherapy (SBRT) for treatment of malignant spinal tumors was initiated at our institution. We report prospective results of this population at Mayo Clinic. Between April 2008 and December 2010, 85 lesions in 66 patients were treated with SBRT for spinal metastases. Twenty-two lesions (25.8%) were treated for recurrence after prior radiotherapy (RT). The mean age of patients was 56.8  13.4 years. Patients were treated to a median dose of 24 Gy (range, 10-40 Gy) in a median of three fractions (range, 1-5). Radiation was delivered with intensity-modulated radiotherapy (IMRT) and prescribed to cover 80% of the planning target volume (PTV) with organs at risk such as the spinal cord taking priority over PTV coverage. Tumor sites included 48, 22, 12, and 3 in the thoracic, lumbar, cervical, and sacral spine, respectively. The mean actuarial survival at 12 months was 52.2%. A total of 7 patients had both local and marginal failure, 1 patient experienced marginal but not local failure, and 1 patient had local failure only. Actuarial local control at 1 year was 83.3% and 91.2% in patients with and without prior RT. The median dose delivered to patients who experienced local/marginal failure was 24 Gy (range, 18-30 Gy) in a median of three fractions (range, 1-5). No cases of Grade 4 toxicity were reported. In 1 of 2 patients experiencing Grade 3 toxicity, SBRT was given after previous radiation. The results indicate SBRT to be an effective measure to achieve local control in spinal metastases. Toxicity of treatment was rare, including those previously irradiated. Our results appear comparable to previous reports analyzing spine SBRT. Further research is needed to determine optimum dose and fractionation to further improve local control and prevent toxicity.",Journal Article,2901.0,71.0,Based on reports of safety and efficacy stereotactic body radiotherapy SBRT for treatment of malignant spinal tumors was initiated at our institution We report prospective results of this population at Mayo Clinic Between April 2008 and December 2010 85 lesions in 66 patients were treated with SBRT for spinal metastases Twenty-two lesions 25.8 were treated for recurrence after prior radiotherapy RT The mean age of patients was 56.8  13.4 years Patients were treated to a median dose of 24 Gy range 10-40 Gy in a median of three fractions range 1-5 Radiation was delivered with intensity-modulated radiotherapy IMRT and prescribed to cover 80 of the planning target volume PTV with organs at risk such as the spinal cord taking priority over PTV coverage Tumor sites included 48 22 12 and 3 in the thoracic lumbar and sacral spine respectively The mean actuarial survival at 12 months was 52.2 A total of 7 patients had both local and marginal failure 1 patient experienced marginal but not local failure and 1 patient had local failure only Actuarial local control at 1 year was 83.3 and 91.2 in patients with and without prior RT The median dose delivered to patients who experienced local/marginal failure was 24 Gy range 18-30 Gy in a median of three fractions range 1-5 No cases of Grade 4 toxicity were reported In 1 of 2 patients experiencing Grade 3 toxicity SBRT was given after previous radiation The results indicate SBRT to be an effective measure to achieve local control in spinal metastases Toxicity of treatment was rare including those previously irradiated Our results appear comparable to previous reports analyzing spine SBRT Further research is needed to determine optimum dose and fractionation to further improve local control and prevent toxicity,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[90, 23, 1198, 1, 367, 2, 209, 1729, 642, 310, 1415, 9, 24, 1, 393, 1499, 57, 10, 1917, 28, 114, 731, 21, 414, 482, 99, 1, 26, 266, 28, 2486, 1188, 59, 2292, 1375, 2, 1397, 1120, 772, 406, 4, 700, 7, 11, 73, 5, 1415, 9, 1499, 196, 737, 100, 406, 243, 66, 11, 73, 9, 146, 50, 324, 310, 240, 3, 313, 89, 1, 7, 10, 664, 66, 810, 233, 39, 60, 7, 11, 73, 6, 8, 52, 61, 1, 259, 381, 184, 79, 327, 381, 4, 8, 52, 1, 169, 1550, 184, 14, 33, 121, 10, 1623, 5, 837, 1757, 310, 964, 2, 2746, 6, 8308, 493, 1, 3, 1349, 283, 433, 3303, 5, 2285, 28, 43, 225, 22, 3, 1499, 1885, 2727, 4690, 252, 3303, 2139, 30, 633, 159, 576, 350, 133, 2, 27, 4, 3, 2098, 6187, 2, 7943, 2342, 106, 3, 313, 2361, 25, 28, 133, 53, 10, 653, 18, 8, 181, 1, 67, 7, 42, 110, 293, 2, 3450, 496, 14, 69, 592, 3450, 84, 44, 293, 496, 2, 14, 69, 42, 293, 496, 158, 2361, 293, 182, 28, 14, 111, 10, 852, 27, 2, 970, 18, 4, 7, 5, 2, 187, 324, 240, 3, 52, 61, 1623, 6, 7, 54, 592, 293, 3450, 496, 10, 259, 381, 184, 203, 201, 381, 4, 8, 52, 1, 169, 1550, 184, 14, 33, 77, 140, 1, 88, 39, 155, 11, 210, 4, 14, 1, 18, 7, 2985, 88, 27, 155, 1415, 10, 447, 50, 698, 121, 3, 99, 1008, 1415, 6, 40, 35, 323, 1463, 6, 1359, 293, 182, 4, 1499, 196, 155, 1, 24, 10, 622, 141, 135, 373, 2398, 114, 99, 1322, 1279, 6, 698, 1198, 4449, 2342, 1415, 195, 389, 16, 575, 6, 223, 6357, 61, 2, 3519, 6, 195, 401, 293, 182, 2, 1682, 155]",1774.0,22330988,402
A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2012-02-16,"Concurrent cisplatin-based chemoradiotherapy (CRT) is the standard treatment for locally advanced cervical cancer. RTOG 0417 was a Phase II study exploring the safety and efficacy of the addition of bevacizumab to standard CRT. Eligible patients with bulky tumors (Stage IB-IIIB) were treated with once-weekly cisplatin (40 mg/m(2)) chemotherapy and standard pelvic radiotherapy and brachytherapy. Bevacizumab was administered at 10 mg/kg intravenously every 2 weeks for three cycles. Treatment-related serious adverse event (SAE) and other adverse event (AE) rates within the first 90 days from treatment start were determined. Treatment-related SAEs were defined as any Grade  4 vaginal bleeding or thrombotic event or Grade  3 arterial event, gastrointestinal (GI) bleeding, or bowel/bladder perforation, or any Grade 5 treatment-related death. Treatment-related AEs included all SAEs and Grade 3 or 4 GI toxicity persisting for >2 weeks despite medical intervention, Grade 4 neutropenia or leukopenia persisting for >7 days, febrile neutropenia, Grade 3 or 4 other hematologic toxicity, and Grade 3 or 4 GI, renal, cardiac, pulmonary, hepatic, or neurologic AEs. All AEs were scored using the National Cancer Institute Common Terminology Criteria (CTCAE) v 3.0 (MedDRA version 6.0). A total of 60 patients from 28 institutions were enrolled between 2006 and 2009, and of these, 49 patients were evaluable. The median follow-up was 12.4 months (range, 4.6-31.4 months).The median age was 45 years (range, 22-80 years). Most patients had FIGO Stage IIB (63%) and were of Zubrod performance status of 0 (67%). 80% of cases were squamous. There were no treatment-related SAEs. There were 15 (31%) protocol-specified treatment-related AEs within 90 days of treatment start; the most common were hematologic (12/15; 80%). 18 (37%) occurred during treatment or follow-up at any time. 37 of the 49 patients (76%) had cisplatin and bevacizumab administered per protocol, and 46 of the 49 (94%) had both external beam and brachytherapy administered per protocol or with acceptable variation. Bevacizumab in addition to standard pelvic chemoradiotherapy for locally advanced cervical cancer is feasible and safe with respect to the protocol-specified treatment-related SAEs and AEs.","Clinical Trial, Phase II",2896.0,57.0,Concurrent cisplatin-based chemoradiotherapy CRT is the standard treatment for locally advanced cancer RTOG 0417 was a Phase II study exploring the safety and efficacy of the addition of bevacizumab to standard CRT Eligible patients with bulky tumors Stage IB-IIIB were treated with once-weekly cisplatin 40 mg/m 2 chemotherapy and standard pelvic radiotherapy and brachytherapy Bevacizumab was administered at 10 mg/kg intravenously every 2 weeks for three cycles Treatment-related serious adverse event SAE and other adverse event AE rates within the first 90 days from treatment start were determined Treatment-related SAEs were defined as any Grade  4 bleeding or thrombotic event or Grade  3 arterial event GI bleeding or bowel/bladder perforation or any Grade 5 treatment-related death Treatment-related AEs included all SAEs and Grade 3 or 4 GI toxicity persisting for 2 weeks despite medical intervention Grade 4 neutropenia or leukopenia persisting for 7 days febrile neutropenia Grade 3 or 4 other hematologic toxicity and Grade 3 or 4 GI pulmonary hepatic or neurologic AEs All AEs were scored using the National Cancer Institute Common Terminology Criteria CTCAE v 3.0 MedDRA version 6.0 A total of 60 patients from 28 institutions were enrolled between 2006 and 2009 and of these 49 patients were evaluable The median follow-up was 12.4 months range 4.6-31.4 months .The median age was 45 years range 22-80 years Most patients had FIGO Stage IIB 63 and were of Zubrod performance status of 0 67 80 of cases were squamous There were no treatment-related SAEs There were 15 31 protocol-specified treatment-related AEs within 90 days of treatment start the most common were hematologic 12/15 80 18 37 occurred during treatment or follow-up at any time 37 of the 49 patients 76 had cisplatin and bevacizumab administered per protocol and 46 of the 49 94 had both external beam and brachytherapy administered per protocol or with acceptable variation Bevacizumab in addition to standard pelvic chemoradiotherapy for locally advanced cancer is feasible and safe with respect to the protocol-specified treatment-related SAEs and AEs,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,"[750, 540, 90, 1464, 1089, 16, 3, 260, 24, 9, 795, 131, 12, 3931, 31404, 10, 8, 124, 215, 45, 4378, 3, 367, 2, 209, 1, 3, 352, 1, 599, 6, 260, 1089, 625, 7, 5, 4112, 57, 82, 3180, 3036, 11, 73, 5, 1059, 709, 540, 327, 81, 188, 18, 56, 2, 260, 1110, 310, 2, 1536, 599, 10, 468, 28, 79, 81, 503, 1672, 454, 18, 244, 9, 169, 410, 24, 139, 1762, 290, 774, 29193, 2, 127, 290, 774, 3633, 151, 262, 3, 157, 424, 162, 29, 24, 2435, 11, 509, 24, 139, 11499, 11, 395, 22, 500, 88, 749, 39, 2294, 15, 6108, 774, 15, 88, 749, 27, 3127, 774, 2104, 2294, 15, 1659, 9685, 4854, 15, 500, 88, 33, 24, 139, 273, 24, 139, 1477, 159, 62, 11499, 2, 88, 27, 15, 39, 2104, 155, 12099, 9, 18, 244, 550, 484, 788, 88, 39, 778, 15, 3904, 12099, 9, 67, 162, 2498, 778, 88, 27, 15, 39, 127, 813, 155, 2, 88, 27, 15, 39, 2104, 1087, 939, 15, 2543, 1477, 62, 1477, 11, 3179, 75, 3, 657, 12, 1377, 186, 3462, 371, 3898, 603, 27, 13, 35303, 2256, 49, 13, 8, 181, 1, 335, 7, 29, 339, 1764, 11, 346, 59, 1324, 2, 1238, 2, 1, 46, 739, 7, 11, 859, 3, 52, 166, 126, 10, 133, 39, 53, 184, 39, 49, 456, 39, 53, 3, 52, 89, 10, 512, 60, 184, 350, 493, 60, 96, 7, 42, 3837, 82, 3884, 676, 2, 11, 1, 10672, 528, 156, 1, 13, 598, 493, 1, 140, 11, 691, 125, 11, 77, 24, 139, 11499, 125, 11, 167, 456, 1182, 3575, 24, 139, 1477, 262, 424, 162, 1, 24, 2435, 3, 96, 186, 11, 813, 133, 167, 493, 203, 567, 489, 190, 24, 15, 166, 126, 28, 500, 98, 567, 1, 3, 739, 7, 846, 42, 540, 2, 599, 468, 379, 1182, 2, 641, 1, 3, 739, 960, 42, 110, 1455, 1345, 2, 1536, 468, 379, 1182, 15, 5, 1595, 1380, 599, 4, 352, 6, 260, 1110, 1464, 9, 795, 131, 12, 16, 1313, 2, 1165, 5, 2184, 6, 3, 1182, 3575, 24, 139, 11499, 2, 1477]",2140.0,22342094,621
Identification of nm23-H1 as a metastatic suppressor and prognostic factor in nasopharyngeal carcinoma by proteomic analysis.,Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences,Zhong Nan Da Xue Xue Bao Yi Xue Ban,2012-01-01,"To identify proteins associated with nasopharyngeal carcinoma (NPC) metastasis, and provide scientific basis for the prevention and cure of NPC. A two-dimensional gel electrophoresis and mass spectrometry were performed to screen for differential proteins between highly metastatic 5-8F and non-metastatic 6-10B NPC cell lines. Western blot was used to confirm the differential proteins. We siRNA used to inhibit the expression of differential protein nm23-H1 to determine the association of nm23-H1 with NPC in vitro invasive ability. Immunohistochemistry and statistics were used to evaluate the correlation of nm23-H1 expression with clinicopathological features and clinical outcomes in paraffin-embedded archival tissues including 93 cases of primary NPC and 20 cases of cervical lymphonode metastatic NPC (LMNPC). A total of 15 differential proteins in the 2 cell lines were identified by a proteomic approach, and 3 differential proteins were selectively confirmed. Downregulation of nm23-H1 by siRNA significantly increased the in vitro invasive ability of 6-10B. Significant nm23-H1 downregulation was observed in LMNPC compared with primary NPC. nm23-H1 downregulation in primary NPC was positively correlated with lymphonode and distant metastasis, advanced clinical stage and recurrence. Survival curves showed that patients with nm23-H1 downregulation in primary NPC had a poor prognosis. Multivariate analysis confirmed that nm23-H1 expression level in primary NPC was an independent prognostic indicator. nm23-H1 behaves as a metastasis suppressor in NPC, and nm23-H1 downregulation in the is a biomarker for poor NPC prognosis.",Journal Article,2942.0,6.0,To identify proteins associated with carcinoma NPC metastasis and provide scientific basis for the prevention and cure of NPC A two-dimensional gel electrophoresis and mass spectrometry were performed to screen for differential proteins between highly metastatic 5-8F and non-metastatic 6-10B NPC cell lines Western blot was used to confirm the differential proteins We siRNA used to inhibit the expression of differential protein nm23-H1 to determine the association of nm23-H1 with NPC in vitro invasive ability Immunohistochemistry and statistics were used to evaluate the correlation of nm23-H1 expression with clinicopathological features and clinical outcomes in paraffin-embedded archival tissues including 93 cases of primary NPC and 20 cases of lymphonode metastatic NPC LMNPC A total of 15 differential proteins in the 2 cell lines were identified by a proteomic approach and 3 differential proteins were selectively confirmed Downregulation of nm23-H1 by siRNA significantly increased the in vitro invasive ability of 6-10B Significant nm23-H1 downregulation was observed in LMNPC compared with primary NPC nm23-H1 downregulation in primary NPC was positively correlated with lymphonode and distant metastasis advanced clinical stage and recurrence Survival curves showed that patients with nm23-H1 downregulation in primary NPC had a poor prognosis Multivariate analysis confirmed that nm23-H1 expression level in primary NPC was an independent prognostic indicator nm23-H1 behaves as a metastasis suppressor in NPC and nm23-H1 downregulation in the is a biomarker for poor NPC prognosis,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 255, 652, 41, 5, 134, 5330, 278, 2, 377, 3138, 877, 9, 3, 1070, 2, 1722, 1, 5330, 8, 100, 2201, 5916, 6777, 2, 782, 3680, 11, 173, 6, 2413, 9, 1777, 652, 59, 561, 113, 33, 20666, 2, 220, 113, 49, 9930, 5330, 31, 285, 1521, 2639, 10, 95, 6, 1843, 3, 1777, 652, 21, 1919, 95, 6, 1433, 3, 55, 1, 1777, 178, 21713, 5199, 6, 223, 3, 248, 1, 21713, 5199, 5, 5330, 4, 439, 416, 801, 888, 2, 3065, 11, 95, 6, 376, 3, 816, 1, 21713, 5199, 55, 5, 2721, 404, 2, 38, 123, 4, 2487, 2505, 3967, 742, 141, 966, 140, 1, 86, 5330, 2, 179, 140, 1, 47064, 113, 5330, 47065, 8, 181, 1, 167, 1777, 652, 4, 3, 18, 31, 285, 11, 108, 20, 8, 3784, 353, 2, 27, 1777, 652, 11, 2382, 557, 2475, 1, 21713, 5199, 20, 1919, 97, 101, 3, 4, 439, 416, 801, 1, 49, 9930, 93, 21713, 5199, 2475, 10, 164, 4, 47065, 72, 5, 86, 5330, 21713, 5199, 2475, 4, 86, 5330, 10, 2375, 438, 5, 47064, 2, 626, 278, 131, 38, 82, 2, 146, 25, 2400, 224, 17, 7, 5, 21713, 5199, 2475, 4, 86, 5330, 42, 8, 334, 356, 331, 65, 557, 17, 21713, 5199, 55, 301, 4, 86, 5330, 10, 35, 306, 177, 3287, 21713, 5199, 16771, 22, 8, 278, 1245, 4, 5330, 2, 21713, 5199, 2475, 4, 3, 16, 8, 901, 9, 334, 5330, 356]",1599.0,22349375,320
The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes.,Gynecologic oncology,Gynecol. Oncol.,2012-02-22,"To determine the false-negative rate of a surgical sentinel lymph node (SLN) mapping algorithm that incorporates more than just removing SLNs in detecting metastatic endometrial cancer. A prospective database of all patients who underwent lymphatic mapping for endometrial cancer was reviewed. Cervical injection of blue dye was used in all cases. The surgical algorithm is as follows: 1) peritoneal and serosal evaluation and washings; 2) retroperitoneal evaluation including excision of all mapped SLNs and suspicious nodes regardless of mapping; and 3) if there is no mapping on a hemi-pelvis, a side-specific pelvic, common iliac, and interiliac lymph node dissection (LND) is performed. Paraaortic LND is performed at the attendings' discretion. The algorithm was retrospectively applied. From 9/2005 to 4/2011, 498 patients received a blue dye cervical injection for SLN mapping. At least one LN was removed in 95% of cases (474/498); at least one SLN was identified in 81% (401/498). SLN correctly diagnosed 40/47 patients with nodal metastases who had at least one SLN mapped, resulting in a 15% false-negative rate. After applying the algorithm, the false-negative rate dropped to 2%. Only one patient, whose LN spread would not have been caught by the algorithm, had an isolated positive right paraaortic LN with a negative ipsilateral SLN and pelvic LND. Satisfactory SLN mapping in endometrial cancer requires adherence to a surgical SLN algorithm and goes beyond just the removal of blue SLNs. Removal of any suspicious node along with side-specific lymphadenectomy for failed mapping are an integral part of this algorithm. Further validation of the false-negative rate of this algorithm is necessary.",Journal Article,2890.0,181.0,To determine the false-negative rate of a surgical sentinel lymph node SLN mapping algorithm that incorporates more than just removing SLNs in detecting metastatic cancer A prospective database of all patients who underwent lymphatic mapping for cancer was reviewed injection of blue dye was used in all cases The surgical algorithm is as follows 1 peritoneal and serosal evaluation and washings 2 retroperitoneal evaluation including excision of all mapped SLNs and suspicious nodes regardless of mapping and 3 if there is no mapping on a hemi-pelvis a side-specific pelvic common iliac and interiliac lymph node dissection LND is performed Paraaortic LND is performed at the attendings discretion The algorithm was retrospectively applied From 9/2005 to 4/2011 498 patients received a blue dye injection for SLN mapping At least one LN was removed in 95 of cases 474/498 at least one SLN was identified in 81 401/498 SLN correctly diagnosed 40/47 patients with nodal metastases who had at least one SLN mapped resulting in a 15 false-negative rate After applying the algorithm the false-negative rate dropped to 2 Only one patient whose LN spread would not have been caught by the algorithm had an isolated positive right paraaortic LN with a negative ipsilateral SLN and pelvic LND Satisfactory SLN mapping in cancer requires adherence to a surgical SLN algorithm and goes beyond just the removal of blue SLNs Removal of any suspicious node along with side-specific lymphadenectomy for failed mapping are an integral part of this algorithm Further validation of the false-negative rate of this algorithm is necessary,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 223, 3, 2133, 199, 116, 1, 8, 221, 1323, 263, 289, 1099, 2568, 2124, 17, 6175, 80, 76, 4673, 9026, 2642, 4, 2502, 113, 12, 8, 482, 609, 1, 62, 7, 54, 208, 2936, 2568, 9, 12, 10, 446, 1754, 1, 3352, 3796, 10, 95, 4, 62, 140, 3, 221, 2124, 16, 22, 2962, 14, 1639, 2, 17169, 451, 2, 11161, 18, 2591, 451, 141, 1366, 1, 62, 6224, 2642, 2, 3230, 502, 1583, 1, 2568, 2, 27, 492, 125, 16, 77, 2568, 23, 8, 16784, 3270, 8, 1152, 112, 1110, 186, 6692, 2, 61174, 263, 289, 1161, 3400, 16, 173, 7401, 3400, 16, 173, 28, 3, 35311, 7772, 3, 2124, 10, 894, 1498, 29, 83, 1242, 6, 39, 1132, 8928, 7, 103, 8, 3352, 3796, 1754, 9, 1099, 2568, 28, 506, 104, 1763, 10, 2264, 4, 48, 1, 140, 10282, 8928, 28, 506, 104, 1099, 10, 108, 4, 865, 7191, 8928, 1099, 4911, 265, 327, 662, 7, 5, 779, 196, 54, 42, 28, 506, 104, 1099, 6224, 1113, 4, 8, 167, 2133, 199, 116, 50, 4798, 3, 2124, 3, 2133, 199, 116, 8801, 6, 18, 158, 104, 69, 1310, 1763, 2579, 688, 44, 47, 85, 38005, 20, 3, 2124, 42, 35, 1355, 109, 1913, 7401, 1763, 5, 8, 199, 2880, 1099, 2, 1110, 3400, 7972, 1099, 2568, 4, 12, 1706, 2149, 6, 8, 221, 1099, 2124, 2, 23967, 1654, 4673, 3, 2829, 1, 3352, 2642, 2829, 1, 500, 3230, 289, 1510, 5, 1152, 112, 2048, 9, 1551, 2568, 32, 35, 4450, 760, 1, 26, 2124, 195, 929, 1, 3, 2133, 199, 116, 1, 26, 2124, 16, 1493]",1619.0,22366409,409
Early postoperative epidermal growth factor receptor inhibition: safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo.,Head & neck,Head Neck,2012-02-24,"The local-regional failure of advanced oral squamous cell carcinoma (OSCC) after surgery results from the regrowth of residual tumor cells that may be stimulated by epidermal growth factor receptor (EGFR) ligands during the wound healing process. The level of EGFR ligands in human drain fluids (DFs) from OSCC resection and remote flap donor site were determined. A mouse model of microscopic residual OSCC was established and treated with cetuximab to measure tumor growth, survival, and cervical lymph node metastases. A mouse model of wound healing was also established to assess the effect of an EGFR antibody on the wound healing process. EGFR ligands are found in sites from OSCC resection. EGFR targeted therapy can delay tumor regrowth in a microscopic residual disease model of OSCC without significant effects on local wound healing. These results provide a strong rationale for clinical evaluation of this approach to treat patients with local-regionally advanced OSCC.",Journal Article,2888.0,8.0,The local-regional failure of advanced oral squamous cell carcinoma OSCC after surgery results from the regrowth of residual tumor cells that may be stimulated by epidermal growth factor receptor EGFR ligands during the wound healing process The level of EGFR ligands in human drain fluids DFs from OSCC resection and remote flap donor site were determined A mouse model of microscopic residual OSCC was established and treated with cetuximab to measure tumor growth survival and lymph node metastases A mouse model of wound healing was also established to assess the effect of an EGFR antibody on the wound healing process EGFR ligands are found in sites from OSCC resection EGFR targeted therapy can delay tumor regrowth in a microscopic residual disease model of OSCC without significant effects on local wound healing These results provide a strong rationale for clinical evaluation of this approach to treat patients with local-regionally advanced OSCC,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 293, 951, 496, 1, 131, 518, 691, 31, 134, 3785, 50, 152, 99, 29, 3, 8673, 1, 753, 30, 37, 17, 68, 40, 2816, 20, 829, 129, 161, 153, 227, 3123, 190, 3, 2689, 4706, 1129, 3, 301, 1, 227, 3123, 4, 171, 9203, 9332, 1010, 29, 3785, 170, 2, 9879, 3942, 1488, 606, 11, 509, 8, 830, 202, 1, 2984, 753, 3785, 10, 635, 2, 73, 5, 1175, 6, 1463, 30, 129, 25, 2, 263, 289, 196, 8, 830, 202, 1, 2689, 4706, 10, 120, 635, 6, 423, 3, 254, 1, 35, 227, 548, 23, 3, 2689, 4706, 1129, 227, 3123, 32, 204, 4, 633, 29, 3785, 170, 227, 238, 36, 122, 1984, 30, 8673, 4, 8, 2984, 753, 34, 202, 1, 3785, 187, 93, 176, 23, 293, 2689, 4706, 46, 99, 377, 8, 1082, 1728, 9, 38, 451, 1, 26, 353, 6, 943, 7, 5, 293, 8183, 131, 3785]",957.0,22367702,785
Biological predictors of cervical cancer response to radiation therapy.,Seminars in radiation oncology,Semin Radiat Oncol,2012-04-01,"The addition of cisplatin-based chemotherapy to standard radiation therapy reduces the risk of recurrence and disease-related death rates from locally advanced cervical cancers by as much as 50%. However, the absolute gains are relatively small for patients with early tumors, many of whom would have been cured with radiation alone, and recurrence rates are still high for patients who have very large or advanced-stage tumors. As a result, there is a pressing need for more accurate predictors of radiocurability. A variety of types of biomarkers have been shown to correlate with cervical cancer response to radiation therapy. These include traditional clinical and morphologic predictors, non-molecular biomarkers, including hypoxia and fluorodeoxyglucose-positron emission tomography (FDG-PET) avidity, as well as molecular biomarkers, which include single-gene markers or array-based multigene predictors. Multi-gene predictors of response remain immature in cervical cancer, but studies thus far have paved the way for future studies to validate these findings. Methods will need to be standardized and markers will need to be validated on homogeneous patient populations and treatment approaches before they can become useful tools for clinical decision making. In addition, new biomarkers will be of major value only if they add to the predictive value of traditional clinical and morphologic predictors. Ultimately, the most useful biomarkers will identify patients who will benefit from specific molecularly targeted agents in addition to radiation therapy or perhaps identify patient who are at low risk for recurrence, for whom the dose of radiation or chemotherapy can be reduced.",Journal Article,2851.0,23.0,The addition of cisplatin-based chemotherapy to standard radiation therapy reduces the risk of recurrence and disease-related death rates from locally advanced cancers by as much as 50 However the absolute gains are relatively small for patients with early tumors many of whom would have been cured with radiation alone and recurrence rates are still high for patients who have very large or advanced-stage tumors As a result there is a pressing need for more accurate predictors of radiocurability A variety of types of biomarkers have been shown to correlate with cancer response to radiation therapy These include traditional clinical and morphologic predictors non-molecular biomarkers including hypoxia and fluorodeoxyglucose-positron emission tomography FDG-PET avidity as well as molecular biomarkers which include single-gene markers or array-based multigene predictors Multi-gene predictors of response remain immature in cancer but studies thus far have paved the way for future studies to validate these findings Methods will need to be standardized and markers will need to be validated on homogeneous patient populations and treatment approaches before they can become useful tools for clinical decision making In addition new biomarkers will be of major value only if they add to the predictive value of traditional clinical and morphologic predictors Ultimately the most useful biomarkers will identify patients who will benefit from specific molecularly targeted agents in addition to radiation therapy or perhaps identify patient who are at low risk for recurrence for whom the dose of radiation or chemotherapy can be reduced,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 352, 1, 540, 90, 56, 6, 260, 121, 36, 2389, 3, 43, 1, 146, 2, 34, 139, 273, 151, 29, 795, 131, 163, 20, 22, 1802, 22, 212, 137, 3, 1766, 3849, 32, 1352, 302, 9, 7, 5, 191, 57, 445, 1, 953, 688, 47, 85, 3733, 5, 121, 279, 2, 146, 151, 32, 1234, 64, 9, 7, 54, 47, 923, 375, 15, 131, 82, 57, 22, 8, 757, 125, 16, 8, 11446, 594, 9, 80, 1481, 674, 1, 61195, 8, 1362, 1, 630, 1, 582, 47, 85, 443, 6, 1513, 5, 12, 51, 6, 121, 36, 46, 643, 1847, 38, 2, 2815, 674, 220, 219, 582, 141, 1823, 2, 4085, 1900, 1799, 872, 1285, 495, 6071, 22, 149, 22, 219, 582, 92, 643, 226, 145, 525, 15, 1926, 90, 6339, 674, 1414, 145, 674, 1, 51, 918, 5733, 4, 12, 84, 94, 631, 3272, 47, 15288, 3, 2255, 9, 508, 94, 6, 2183, 46, 272, 636, 303, 594, 6, 40, 1670, 2, 525, 303, 594, 6, 40, 938, 23, 5642, 69, 1184, 2, 24, 611, 348, 491, 122, 1417, 999, 1896, 9, 38, 948, 1079, 4, 352, 217, 582, 303, 40, 1, 458, 549, 158, 492, 491, 4178, 6, 3, 464, 549, 1, 1847, 38, 2, 2815, 674, 2050, 3, 96, 999, 582, 303, 255, 7, 54, 303, 247, 29, 112, 2372, 238, 183, 4, 352, 6, 121, 36, 15, 4434, 255, 69, 54, 32, 28, 154, 43, 9, 146, 9, 953, 3, 61, 1, 121, 15, 56, 122, 40, 405]",1643.0,22385921,216
Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.,Current pharmaceutical design,Curr. Pharm. Des.,2012-01-01,"Gynecologic cancer is a major burden in both developed and developing countries. Almost a half million deaths from gynecologic cancer are reported each year. Understanding the molecular biology of cancer is a principle resource leading to the identification of new potential therapeutic targets, which may be parlayed into novel therapeutic options in gynecologic cancer. Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase, which plays a pivotal role in many aspects of malignant growth including cancer cell survival, migration, invasion, angiogenesis and metastasis. Various human cancer tissues have demonstrated high expression of FAK or activated FAK, which has been correlated with survival of cancer patients. Among gynecologic cancers, reports have emerged demonstrating that FAK is involved in the pathogenesis of ovarian, endometrial, and cervical cancers. In addition, the polycomb group protein enhancer of Zeste homologue 2 (EZH2), Dll4/notch and EphA2 has also emerged as important regulators of endothelial cell biology and angiogenesis. Herein, we review the role of these new targets in tumor angiogenesis and the rationale for further clinical development.",Journal Article,2942.0,,Gynecologic cancer is a major burden in both developed and developing countries Almost a half million deaths from gynecologic cancer are reported each year Understanding the molecular biology of cancer is a principle resource leading to the identification of new potential therapeutic targets which may be parlayed into novel therapeutic options in gynecologic cancer Focal adhesion kinase FAK is a non-receptor tyrosine kinase which plays a pivotal role in many aspects of malignant growth including cancer cell survival migration invasion angiogenesis and metastasis Various human cancer tissues have demonstrated high expression of FAK or activated FAK which has been correlated with survival of cancer patients Among gynecologic cancers reports have emerged demonstrating that FAK is involved in the pathogenesis of and cancers In addition the polycomb group protein enhancer of Zeste homologue 2 EZH2 Dll4/notch and EphA2 has also emerged as important regulators of endothelial cell biology and angiogenesis Herein we review the role of these new targets in tumor angiogenesis and the rationale for further clinical development,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[1512, 12, 16, 8, 458, 892, 4, 110, 276, 2, 931, 2115, 2214, 8, 1303, 3346, 1043, 29, 1512, 12, 32, 210, 296, 111, 612, 3, 219, 891, 1, 12, 16, 8, 4968, 3069, 1049, 6, 3, 911, 1, 217, 174, 189, 637, 92, 68, 40, 61202, 237, 229, 189, 838, 4, 1512, 12, 2137, 2128, 216, 3248, 16, 8, 220, 153, 564, 216, 92, 1698, 8, 3754, 200, 4, 445, 2695, 1, 393, 129, 141, 12, 31, 25, 1381, 578, 1056, 2, 278, 747, 171, 12, 742, 47, 264, 64, 55, 1, 3248, 15, 735, 3248, 92, 71, 85, 438, 5, 25, 1, 12, 7, 107, 1512, 163, 1198, 47, 2054, 2219, 17, 3248, 16, 646, 4, 3, 1384, 1, 2, 163, 4, 352, 3, 8666, 87, 178, 4239, 1, 11270, 7907, 18, 3755, 8481, 3193, 2, 5511, 71, 120, 2054, 22, 305, 3196, 1, 845, 31, 891, 2, 1056, 1986, 21, 206, 3, 200, 1, 46, 217, 637, 4, 30, 1056, 2, 3, 1728, 9, 195, 38, 193]",1132.0,22390757,290
Sexual function after intracavitary vaginal brachytherapy for early-stage endometrial carcinoma.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2012-05-01,"To describe the effects of intracavitary brachytherapy (IVB) on sexual function and quality of life of women with early-stage endometrial cancer. Women with International Federation of Gynecology and Obstetrics stage I to stage II endometrial cancer treated surgically with or without IVB were identified and mailed questionnaires. Quality of life and sexual function were measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the cervical cancer disease-specific module. Pertinent data from prior surgery and radiation treatments were abstracted retrospectively. Linear transformation of the survey subscale scores was conducted per European Organization for Research and Treatment of Cancer guidelines. Sixteen women in the IVB arm and 53 in the surgery-alone group completed the survey. Of the sexually active patients, 33% of the IVB patients and 42% of the surgery-alone patients felt their vagina was dry during sexual activity (P = 0.804) and 17% versus 20% felt their vagina was short (P = 0.884). Seventeen percent of patients in the IVB group felt their vagina was tight compared to 29% in the surgery-alone group (P = 0.891) and 0% versus 14% of patients reported pain during intercourse (P = 0.808). There was no statistically significant difference in sexual/vaginal functioning, sexual worry, or sexual enjoyment between the 2 groups. Although both groups report vaginal changes that may affect sexual function, the patients treated with IVB reported similar outcomes on a sexual function questionnaire compared to patients treated with surgery alone.",Journal Article,2821.0,22.0,To describe the effects of intracavitary brachytherapy IVB on sexual function and quality of life of women with early-stage cancer Women with International Federation of Gynecology and Obstetrics stage I to stage II cancer treated surgically with or without IVB were identified and mailed questionnaires Quality of life and sexual function were measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the cancer disease-specific module Pertinent data from prior surgery and radiation treatments were abstracted retrospectively Linear transformation of the survey subscale scores was conducted per European Organization for Research and Treatment of Cancer guidelines Sixteen women in the IVB arm and 53 in the surgery-alone group completed the survey Of the sexually active patients 33 of the IVB patients and 42 of the surgery-alone patients felt their vagina was dry during sexual activity P 0.804 and 17 versus 20 felt their vagina was short P 0.884 Seventeen percent of patients in the IVB group felt their vagina was tight compared to 29 in the surgery-alone group P 0.891 and 0 versus 14 of patients reported pain during intercourse P 0.808 There was no statistically significant difference in sexual/vaginal functioning sexual worry or sexual enjoyment between the 2 groups Although both groups report changes that may affect sexual function the patients treated with IVB reported similar outcomes on a sexual function questionnaire compared to patients treated with surgery alone,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 897, 3, 176, 1, 9122, 1536, 7042, 23, 2232, 343, 2, 372, 1, 358, 1, 117, 5, 191, 82, 12, 117, 5, 944, 7303, 1, 6429, 2, 7407, 82, 70, 6, 82, 215, 12, 73, 2350, 5, 15, 187, 7042, 11, 108, 2, 6703, 2956, 372, 1, 358, 2, 2232, 343, 11, 644, 75, 3, 1865, 2533, 9, 389, 2, 24, 1, 12, 372, 1, 358, 1770, 1793, 201, 2, 3, 12, 34, 112, 5980, 5799, 74, 29, 324, 152, 2, 121, 640, 11, 4106, 894, 1646, 1392, 1, 3, 1407, 5593, 703, 10, 426, 379, 1865, 2533, 9, 389, 2, 24, 1, 12, 677, 3228, 117, 4, 3, 7042, 475, 2, 699, 4, 3, 152, 279, 87, 781, 3, 1407, 1, 3, 13588, 544, 7, 466, 1, 3, 7042, 7, 2, 595, 1, 3, 152, 279, 7, 5284, 136, 7553, 10, 7922, 190, 2232, 128, 19, 13, 10853, 2, 269, 185, 179, 5284, 136, 7553, 10, 978, 19, 13, 14511, 3591, 714, 1, 7, 4, 3, 7042, 87, 5284, 136, 7553, 10, 12523, 72, 6, 462, 4, 3, 152, 279, 87, 19, 13, 14416, 2, 13, 185, 213, 1, 7, 210, 559, 190, 12361, 19, 13, 15341, 125, 10, 77, 712, 93, 523, 4, 2232, 18982, 2702, 2232, 6309, 15, 2232, 24426, 59, 3, 18, 271, 242, 110, 271, 414, 400, 17, 68, 1158, 2232, 343, 3, 7, 73, 5, 7042, 210, 288, 123, 23, 8, 2232, 343, 1770, 72, 6, 7, 73, 5, 152, 279]",1551.0,22398710,413
mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2012-03-12,"The incidence of head and neck squamous cell carcinomas (HNSCC) associated with human papillomavirus (HPV) infection has increased over the past decades in the United States. We aimed at examining the global impact of HPV-associated HNSCC and whether the established key role of mTOR activation in HNSCC is also observed in HPV(+) HNSCC lesions, thereby providing novel treatment options for HPV-associated HNSCC patients. An international HNSCC tissue microarray (TMA) was used to analyze the expression of p16(INK4A), a surrogate for HPV infection, and Akt-mTOR pathway activation. Results were confirmed in a large collection of HPV(-) and HPV(+) HNSCC cases and in a cervical cancer (CCSCC) TMA. Observations were validated in HNSCC and CCSCC-derived cell lines, which were xenografted into immunodeficient mice for tumorigenesis assays. Approximately 20% of all HNSCC lesions could be classified as HPV(+), irrespective of their country of origin. mTOR pathway activation was observed in most HPV(+) HNSCC and CCSCC lesions and cell lines. The preclinical efficacy of mTOR inhibition by rapamycin and RAD001 was explored in HPV(+) HNSCC and CCSCC tumor xenografts. Both mTOR inhibitors effectively decreased mTOR activity in vivo and caused a remarkable decrease in tumor burden. These results emphasize the emerging global impact of HPV-related HNSCCs and indicate that the activation of the mTOR pathway is a widespread event in both HPV(-) and HPV-associated HNSCC and CCSCC lesions. The emerging results may provide a rationale for the clinical evaluation of mTOR inhibitors as a molecular targeted approach for the treatment of HPV-associated malignancies.",Comparative Study,2871.0,109.0,The incidence of head and squamous cell carcinomas HNSCC associated with human papillomavirus HPV infection has increased over the past decades in the United States We aimed at examining the global impact of HPV-associated HNSCC and whether the established key role of mTOR activation in HNSCC is also observed in HPV HNSCC lesions thereby providing novel treatment options for HPV-associated HNSCC patients An international HNSCC tissue microarray TMA was used to analyze the expression of p16 INK4A a surrogate for HPV infection and Akt-mTOR pathway activation Results were confirmed in a large collection of HPV and HPV HNSCC cases and in a cancer CCSCC TMA Observations were validated in HNSCC and CCSCC-derived cell lines which were xenografted into immunodeficient mice for tumorigenesis assays Approximately 20 of all HNSCC lesions could be classified as HPV irrespective of their country of origin mTOR pathway activation was observed in most HPV HNSCC and CCSCC lesions and cell lines The preclinical efficacy of mTOR inhibition by rapamycin and RAD001 was explored in HPV HNSCC and CCSCC tumor xenografts Both mTOR inhibitors effectively decreased mTOR activity in vivo and caused a remarkable decrease in tumor burden These results emphasize the emerging global impact of HPV-related HNSCCs and indicate that the activation of the mTOR pathway is a widespread event in both HPV and HPV-associated HNSCC and CCSCC lesions The emerging results may provide a rationale for the clinical evaluation of mTOR inhibitors as a molecular targeted approach for the treatment of HPV-associated malignancies,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 287, 1, 718, 2, 691, 31, 826, 1209, 41, 5, 171, 3242, 933, 930, 71, 101, 252, 3, 1219, 1968, 4, 3, 1088, 907, 21, 1295, 28, 3282, 3, 1648, 345, 1, 933, 41, 1209, 2, 317, 3, 635, 825, 200, 1, 873, 363, 4, 1209, 16, 120, 164, 4, 933, 1209, 406, 2267, 1736, 229, 24, 838, 9, 933, 41, 1209, 7, 35, 944, 1209, 246, 1727, 5501, 10, 95, 6, 1992, 3, 55, 1, 1932, 6276, 8, 2592, 9, 933, 930, 2, 649, 873, 308, 363, 99, 11, 557, 4, 8, 375, 2442, 1, 933, 2, 933, 1209, 140, 2, 4, 8, 12, 31939, 5501, 2172, 11, 938, 4, 1209, 2, 31939, 526, 31, 285, 92, 11, 8047, 237, 5031, 399, 9, 1565, 1013, 705, 179, 1, 62, 1209, 406, 359, 40, 1373, 22, 933, 3500, 1, 136, 5978, 1, 1938, 873, 308, 363, 10, 164, 4, 96, 933, 1209, 2, 31939, 406, 2, 31, 285, 3, 693, 209, 1, 873, 297, 20, 1620, 2, 7027, 10, 1443, 4, 933, 1209, 2, 31939, 30, 1348, 110, 873, 222, 1856, 340, 873, 128, 4, 386, 2, 1546, 8, 3813, 775, 4, 30, 892, 46, 99, 5560, 3, 1478, 1648, 345, 1, 933, 139, 9691, 2, 1008, 17, 3, 363, 1, 3, 873, 308, 16, 8, 3029, 774, 4, 110, 933, 2, 933, 41, 1209, 2, 31939, 406, 3, 1478, 99, 68, 377, 8, 1728, 9, 3, 38, 451, 1, 873, 222, 22, 8, 219, 238, 353, 9, 3, 24, 1, 933, 41, 441]",1605.0,22409888,13
"Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy.",Endocrinology,Endocrinology,2012-03-13,"More than 90% of ovarian cancers have been thought to arise from epithelial cells that cover the ovarian surface or, more frequently, line subserosal cysts. Recent studies suggest that histologically similar cancers can arise from the fimbriae of Fallopian tubes and from deposits of endometriosis. Different histotypes are observed that resemble epithelial cells from the normal Fallopian tube (serous), endometrium (endometrioid), cervical glands (mucinous), and vaginal rests (clear cell) and that share expression of relevant HOX genes which drive normal gynecological differentiation. Two groups of epithelial ovarian cancers have been distinguished: type I low-grade cancers that present in early stage, grow slowly, and resist conventional chemotherapy but may respond to hormonal manipulation; and type II high-grade cancers that are generally diagnosed in advanced stage and grow aggressively but respond to chemotherapy. Type I cancers have wild-type p53 and BRCA1/2, but have frequent mutations of Ras and Raf as well as expression of IGFR and activation of the phosphatidylinositol-3-kinase (PI3K) pathway. Virtually all type II cancers have mutations of p53, and almost half have mutation or dysfunction of BRCA1/2, but other mutations are rare, and oncogenesis appears to be driven by amplification of several growth-regulatory genes that activate the Ras/MAPK and PI3K pathways. Cytoreductive surgery and combination chemotherapy with platinum compounds and taxanes have improved 5-yr survival, but less than 40% of all stages can be cured. Novel therapies are being developed that target high-grade serous cancer cells with PI3Kness or BRCAness as well as the tumor vasculature. Both in silico and animal models are needed that more closely resemble type I and type II cancers to facilitate the identification of novel targets and to predict response to combinations of new agents.",Journal Article,2870.0,177.0,More than 90 of cancers have been thought to arise from epithelial cells that cover the surface or more frequently line subserosal cysts Recent studies suggest that histologically similar cancers can arise from the fimbriae of tubes and from deposits of endometriosis Different histotypes are observed that resemble epithelial cells from the normal tube serous endometrioid glands mucinous and rests clear cell and that share expression of relevant HOX genes which drive normal gynecological differentiation Two groups of epithelial cancers have been distinguished type I low-grade cancers that present in early stage grow slowly and resist conventional chemotherapy but may respond to hormonal manipulation and type II high-grade cancers that are generally diagnosed in advanced stage and grow aggressively but respond to chemotherapy Type I cancers have wild-type p53 and BRCA1/2 but have frequent mutations of Ras and Raf as well as expression of IGFR and activation of the phosphatidylinositol-3-kinase PI3K pathway Virtually all type II cancers have mutations of p53 and almost half have mutation or dysfunction of BRCA1/2 but other mutations are rare and oncogenesis appears to be driven by amplification of several growth-regulatory genes that activate the Ras/MAPK and PI3K pathways Cytoreductive surgery and combination chemotherapy with platinum compounds and taxanes have improved 5-yr survival but less than 40 of all stages can be cured Novel therapies are being developed that target high-grade serous cancer cells with PI3Kness or BRCAness as well as the tumor vasculature Both in silico and animal models are needed that more closely resemble type I and type II cancers to facilitate the identification of novel targets and to predict response to combinations of new agents,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[80, 76, 424, 1, 163, 47, 85, 2739, 6, 3043, 29, 701, 37, 17, 8308, 3, 1255, 15, 80, 746, 328, 23477, 4395, 435, 94, 309, 17, 2161, 288, 163, 122, 3043, 29, 3, 61226, 1, 6193, 2, 29, 7626, 1, 7915, 338, 13101, 32, 164, 17, 8247, 701, 37, 29, 3, 295, 2330, 1744, 3151, 3966, 2391, 2, 14405, 885, 31, 2, 17, 4349, 55, 1, 867, 14722, 214, 92, 3279, 295, 6324, 910, 100, 271, 1, 701, 163, 47, 85, 4735, 267, 70, 154, 88, 163, 17, 364, 4, 191, 82, 6265, 7681, 2, 13010, 809, 56, 84, 68, 1892, 6, 1761, 6239, 2, 267, 215, 64, 88, 163, 17, 32, 1228, 265, 4, 131, 82, 2, 6265, 8503, 84, 1892, 6, 56, 267, 70, 163, 47, 955, 267, 624, 2, 766, 18, 84, 47, 908, 138, 1, 1102, 2, 2212, 22, 149, 22, 55, 1, 35049, 2, 363, 1, 3, 3415, 27, 216, 974, 308, 5860, 62, 267, 215, 163, 47, 138, 1, 624, 2, 2214, 1303, 47, 258, 15, 1527, 1, 766, 18, 84, 127, 138, 32, 622, 2, 4503, 1233, 6, 40, 1621, 20, 1073, 1, 392, 129, 1253, 214, 17, 2977, 3, 1102, 1748, 2, 974, 460, 2604, 152, 2, 150, 56, 5, 828, 2411, 2, 2961, 47, 231, 33, 2830, 25, 84, 299, 76, 327, 1, 62, 1153, 122, 40, 3733, 229, 235, 32, 486, 276, 17, 283, 64, 88, 1744, 12, 37, 5, 47123, 15, 16971, 22, 149, 22, 3, 30, 3805, 110, 4, 6648, 2, 2026, 274, 32, 575, 17, 80, 3210, 8247, 267, 70, 2, 267, 215, 163, 6, 1876, 3, 911, 1, 229, 637, 2, 6, 678, 51, 6, 1247, 1, 217, 183]",1789.0,22416079,95
Impact of heterogeneity-based dose calculation using a deterministic grid-based Boltzmann equation solver for intracavitary brachytherapy.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2012-03-19,"To investigate the dosimetric impact of the heterogeneity dose calculation Acuros (Transpire Inc., Gig Harbor, WA), a grid-based Boltzmann equation solver (GBBS), for brachytherapy in a cohort of cervical cancer patients. The impact of heterogeneities was retrospectively assessed in treatment plans for 26 patients who had previously received (192)Ir intracavitary brachytherapy for cervical cancer with computed tomography (CT)/magnetic resonance-compatible tandems and unshielded colpostats. The GBBS models sources, patient boundaries, applicators, and tissue heterogeneities. Multiple GBBS calculations were performed with and without solid model applicator, with and without overriding the patient contour to 1 g/cm(3) muscle, and with and without overriding contrast materials to muscle or 2.25 g/cm(3) bone. Impact of source and boundary modeling, applicator, tissue heterogeneities, and sensitivity of CT-to-material mapping of contrast were derived from the multiple calculations. American Association of Physicists in Medicine Task Group 43 (TG-43) guidelines and the GBBS were compared for the following clinical dosimetric parameters: Manchester points A and B, International Commission on Radiation Units and Measurements (ICRU) report 38 rectal and bladder points, three and nine o'clock, and (D2cm3) to the bladder, rectum, and sigmoid. Points A and B, D(2) cm(3) bladder, ICRU bladder, and three and nine o'clock were within 5% of TG-43 for all GBBS calculations. The source and boundary and applicator account for most of the differences between the GBBS and TG-43 guidelines. The D(2cm3) rectum (n = 3), D(2cm3) sigmoid (n = 1), and ICRU rectum (n = 6) had differences of >5% from TG-43 for the worst case incorrect mapping of contrast to bone. Clinical dosimetric parameters were within 5% of TG-43 when rectal and balloon contrast were mapped to bone and radiopaque packing was not overridden. The GBBS has minimal impact on clinical parameters for this cohort of patients with unshielded applicators. The incorrect mapping of rectal and balloon contrast does not have a significant impact on clinical parameters. Rectal parameters may be sensitive to the mapping of radiopaque packing.",Journal Article,2864.0,25.0,To investigate the dosimetric impact of the heterogeneity dose calculation Acuros Transpire Inc. Gig Harbor WA a grid-based Boltzmann equation solver GBBS for brachytherapy in a cohort of cancer patients The impact of heterogeneities was retrospectively assessed in treatment plans for 26 patients who had previously received 192 Ir intracavitary brachytherapy for cancer with computed tomography CT /magnetic resonance-compatible tandems and unshielded colpostats The GBBS models sources patient boundaries applicators and tissue heterogeneities Multiple GBBS calculations were performed with and without solid model applicator with and without overriding the patient contour to 1 g/cm 3 muscle and with and without overriding contrast materials to muscle or 2.25 g/cm 3 Impact of source and boundary modeling applicator tissue heterogeneities and sensitivity of CT-to-material mapping of contrast were derived from the multiple calculations American Association of Physicists in Medicine Task Group 43 TG-43 guidelines and the GBBS were compared for the following clinical dosimetric parameters Manchester points A and B International Commission on Radiation Units and Measurements ICRU report 38 and points three and nine o'clock and D2cm3 to the rectum and sigmoid Points A and B D 2 cm 3 ICRU and three and nine o'clock were within 5 of TG-43 for all GBBS calculations The source and boundary and applicator account for most of the differences between the GBBS and TG-43 guidelines The D 2cm3 rectum n 3 D 2cm3 sigmoid n 1 and ICRU rectum n 6 had differences of 5 from TG-43 for the worst case incorrect mapping of contrast to Clinical dosimetric parameters were within 5 of TG-43 when and balloon contrast were mapped to and radiopaque packing was not overridden The GBBS has minimal impact on clinical parameters for this cohort of patients with unshielded applicators The incorrect mapping of and balloon contrast does not have a significant impact on clinical parameters parameters may be sensitive to the mapping of radiopaque packing,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,"[6, 963, 3, 3187, 345, 1, 3, 1144, 61, 6333, 39932, 61259, 3479, 61260, 2760, 15846, 8, 17491, 90, 47138, 5747, 39933, 21720, 9, 1536, 4, 8, 180, 1, 12, 7, 3, 345, 1, 19168, 10, 894, 275, 4, 24, 1853, 9, 432, 7, 54, 42, 373, 103, 5016, 2123, 9122, 1536, 9, 12, 5, 1220, 872, 425, 1484, 1535, 7293, 61261, 2, 38032, 47139, 3, 21720, 274, 3375, 69, 9692, 11800, 2, 246, 19168, 232, 21720, 8229, 11, 173, 5, 2, 187, 537, 202, 8789, 5, 2, 187, 23487, 3, 69, 7523, 6, 14, 499, 494, 27, 1502, 2, 5, 2, 187, 23487, 748, 5102, 6, 1502, 15, 18, 243, 499, 494, 27, 345, 1, 2353, 2, 8920, 2057, 8789, 246, 19168, 2, 485, 1, 425, 6, 3692, 2568, 1, 748, 11, 526, 29, 3, 232, 8229, 597, 248, 1, 23777, 4, 1807, 3488, 87, 601, 5107, 601, 677, 2, 3, 21720, 11, 72, 9, 3, 366, 38, 3187, 1038, 24918, 862, 8, 2, 132, 944, 7258, 23, 121, 2960, 2, 1685, 19015, 414, 519, 2, 862, 169, 2, 762, 28043, 2, 61262, 6, 3, 3660, 2, 9356, 862, 8, 2, 132, 427, 18, 494, 27, 19015, 2, 169, 2, 762, 28043, 11, 262, 33, 1, 5107, 601, 9, 62, 21720, 8229, 3, 2353, 2, 8920, 2, 8789, 1967, 9, 96, 1, 3, 362, 59, 3, 21720, 2, 5107, 601, 677, 3, 427, 47140, 3660, 78, 27, 427, 47140, 9356, 78, 14, 2, 19015, 3660, 78, 49, 42, 362, 1, 33, 29, 5107, 601, 9, 3, 4066, 473, 11774, 2568, 1, 748, 6, 38, 3187, 1038, 11, 262, 33, 1, 5107, 601, 198, 2, 10725, 748, 11, 6224, 6, 2, 18893, 18479, 10, 44, 34006, 3, 21720, 71, 1048, 345, 23, 38, 1038, 9, 26, 180, 1, 7, 5, 38032, 11800, 3, 11774, 2568, 1, 2, 10725, 748, 1097, 44, 47, 8, 93, 345, 23, 38, 1038, 1038, 68, 40, 745, 6, 3, 2568, 1, 18893, 18479]",2044.0,22436788,809
Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2012-05-01,"To test the hypothesis that increased bowel radiation dose is associated with acute gastrointestinal (GI) toxicity in cervical cancer patients undergoing concurrent chemotherapy and intensity-modulated radiation therapy (IMRT), using a previously derived normal tissue complication probability (NTCP) model. Fifty patients with Stage I-III cervical cancer undergoing IMRT and concurrent weekly cisplatin were analyzed. Acute GI toxicity was graded using the Radiation Therapy Oncology Group scale, excluding upper GI events. A logistic model was used to test correlations between acute GI toxicity and bowel dosimetric parameters. The primary objective was to test the association between Grade 2 GI toxicity and the volume of bowel receiving 45 Gy (V(45)) using the logistic model. Twenty-three patients (46%) had Grade 2 GI toxicity. The mean (SD) V(45) was 143 mL (99). The mean V(45) values for patients with and without Grade 2 GI toxicity were 176 vs. 115 mL, respectively. Twenty patients (40%) had V(45) >150 mL. The proportion of patients with Grade 2 GI toxicity with and without V(45) >150 mL was 65% vs. 33% (p = 0.03). Logistic model parameter estimates V50 and  were 161 mL (95% confidence interval [CI] 60-399) and 0.31 (95% CI 0.04-0.63), respectively. On multivariable logistic regression, increased V(45) was associated with an increased odds of Grade 2 GI toxicity (odds ratio 2.19 per 100 mL, 95% CI 1.04-4.63, p = 0.04). Our results support the hypothesis that increasing bowel V(45) is correlated with increased GI toxicity in cervical cancer patients undergoing IMRT and concurrent cisplatin. Reducing bowel V(45) could reduce the risk of Grade 2 GI toxicity by approximately 50% per 100 mL of bowel spared.",Journal Article,2821.0,29.0,To test the hypothesis that increased bowel radiation dose is associated with acute GI toxicity in cancer patients undergoing concurrent chemotherapy and intensity-modulated radiation therapy IMRT using a previously derived normal tissue complication probability NTCP model Fifty patients with Stage I-III cancer undergoing IMRT and concurrent weekly cisplatin were analyzed Acute GI toxicity was graded using the Radiation Therapy Oncology Group scale excluding upper GI events A logistic model was used to test correlations between acute GI toxicity and bowel dosimetric parameters The primary objective was to test the association between Grade 2 GI toxicity and the volume of bowel receiving 45 Gy V 45 using the logistic model Twenty-three patients 46 had Grade 2 GI toxicity The mean SD V 45 was 143 mL 99 The mean V 45 values for patients with and without Grade 2 GI toxicity were 176 vs. 115 mL respectively Twenty patients 40 had V 45 150 mL The proportion of patients with Grade 2 GI toxicity with and without V 45 150 mL was 65 vs. 33 p 0.03 Logistic model parameter estimates V50 and  were 161 mL 95 confidence interval CI 60-399 and 0.31 95 CI 0.04-0.63 respectively On multivariable logistic regression increased V 45 was associated with an increased odds of Grade 2 GI toxicity odds ratio 2.19 per 100 mL 95 CI 1.04-4.63 p 0.04 Our results support the hypothesis that increasing bowel V 45 is correlated with increased GI toxicity in cancer patients undergoing IMRT and concurrent cisplatin Reducing bowel V 45 could reduce the risk of Grade 2 GI toxicity by approximately 50 per 100 mL of bowel spared,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 412, 3, 1492, 17, 101, 1659, 121, 61, 16, 41, 5, 286, 2104, 155, 4, 12, 7, 479, 750, 56, 2, 837, 1757, 121, 36, 964, 75, 8, 373, 526, 295, 246, 1447, 1320, 13479, 202, 1461, 7, 5, 82, 70, 316, 12, 479, 964, 2, 750, 709, 540, 11, 311, 286, 2104, 155, 10, 3468, 75, 3, 121, 36, 413, 87, 1124, 3207, 1726, 2104, 281, 8, 812, 202, 10, 95, 6, 412, 2553, 59, 286, 2104, 155, 2, 1659, 3187, 1038, 3, 86, 461, 10, 6, 412, 3, 248, 59, 88, 3107, 2104, 155, 2, 3, 433, 1, 1659, 357, 19939, 381, 603, 512, 75, 3, 812, 202, 737, 169, 7, 641, 42, 88, 3107, 2104, 155, 3, 313, 1270, 603, 512, 10, 4400, 542, 1058, 3, 313, 603, 512, 1030, 9, 7, 5, 2, 187, 88, 3107, 2104, 155, 11, 5800, 105, 3670, 542, 106, 737, 7, 327, 42, 603, 512, 1577, 542, 3, 920, 1, 7, 5, 88, 3107, 2104, 155, 5, 2, 187, 603, 512, 1577, 542, 10, 556, 105, 466, 19, 13, 680, 812, 202, 4219, 1423, 23541, 2, 2655, 11, 5377, 542, 48, 307, 268, 58, 335, 9623, 2, 13, 456, 48, 58, 13, 755, 13, 676, 106, 23, 658, 812, 320, 101, 603, 512, 10, 41, 5, 35, 101, 610, 1, 88, 3107, 2104, 155, 610, 197, 18, 326, 379, 394, 542, 48, 58, 14, 755, 39, 676, 19, 13, 755, 114, 99, 538, 3, 1492, 17, 602, 1659, 603, 512, 16, 438, 5, 101, 2104, 155, 4, 12, 7, 479, 964, 2, 750, 540, 1818, 1659, 603, 512, 359, 969, 3, 43, 1, 88, 3107, 2104, 155, 20, 705, 212, 379, 394, 542, 1, 1659, 6830]",1625.0,22516388,680
Selective neck dissection in node-positive squamous cell carcinoma of the head and neck.,Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery,Otolaryngol Head Neck Surg,2012-04-18,"The optimal type of neck dissection in head and neck squamous cell carcinoma (SCC) with clinical cervical metastases has not been determined. The following study was performed to determine the rate of regional control with selective neck dissection (SND) in these patients. Case series with planned data collection. Single institution, cancer center. Patients with cervical lymph node metastases from mucosal cancers of the head and neck who were treated with SND from 2000 to 2010 were selected. Demographics, tumor characteristics, extent of neck dissection, adjuvant treatments, locoregional control, and survival were recorded. Recurrence in the neck and disease-specific survival (DSS) were primary and secondary end points. One hundred eight patients underwent SND. Sixty-nine (64%) were male. Median age was 62 (20-89) years. The most common primary site was the oral cavity (71.3%). Ninety-five (88%) received adjuvant treatment. Median follow-up was 21 months. Six patients (5.5%) had isolated recurrence in the dissected neck. Patients with N2C disease had poorer neck recurrence-free survival. At the end of study, 64 (59.3%) patients had no evidence of disease, and 23 (21.3%) had died of disease. Two-year DSS was 76.9%. Number of positive nodes (P = .026) and positive surgical margins (P = .001), among others, were predictors of poorer DSS. In a highly selected group of patients with cervical lymph node metastases from head and neck SCC, selective neck dissection is effective in controlling the disease in the neck when performed in the setting of a multimodality treatment, including adjuvant radiotherapy or radiochemotherapy.",Journal Article,2834.0,16.0,The optimal type of dissection in head and squamous cell carcinoma SCC with clinical metastases has not been determined The following study was performed to determine the rate of regional control with selective dissection SND in these patients Case series with planned data collection Single institution cancer center Patients with lymph node metastases from mucosal cancers of the head and who were treated with SND from 2000 to 2010 were selected Demographics tumor characteristics extent of dissection adjuvant treatments locoregional control and survival were recorded Recurrence in the and disease-specific survival DSS were primary and secondary end points One hundred eight patients underwent SND Sixty-nine 64 were male Median age was 62 20-89 years The most common primary site was the oral cavity 71.3 Ninety-five 88 received adjuvant treatment Median follow-up was 21 months Six patients 5.5 had isolated recurrence in the dissected Patients with N2C disease had poorer recurrence-free survival At the end of study 64 59.3 patients had no evidence of disease and 23 21.3 had died of disease Two-year DSS was 76.9 Number of positive nodes P .026 and positive surgical margins P .001 among others were predictors of poorer DSS In a highly selected group of patients with lymph node metastases from head and SCC selective dissection is effective in controlling the disease in the when performed in the setting of a multimodality treatment including adjuvant radiotherapy or radiochemotherapy,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 665, 267, 1, 1161, 4, 718, 2, 691, 31, 134, 1791, 5, 38, 196, 71, 44, 85, 509, 3, 366, 45, 10, 173, 6, 223, 3, 116, 1, 951, 182, 5, 1094, 1161, 15314, 4, 46, 7, 473, 988, 5, 1465, 74, 2442, 226, 731, 12, 574, 7, 5, 263, 289, 196, 29, 3068, 163, 1, 3, 718, 2, 54, 11, 73, 5, 15314, 29, 1081, 6, 1120, 11, 715, 2221, 30, 374, 1039, 1, 1161, 249, 640, 1325, 182, 2, 25, 11, 1872, 146, 4, 3, 2, 34, 112, 25, 1788, 11, 86, 2, 568, 396, 862, 104, 1128, 659, 7, 208, 15314, 1746, 762, 660, 11, 1045, 52, 89, 10, 744, 179, 887, 60, 3, 96, 186, 86, 606, 10, 3, 518, 2405, 792, 27, 2493, 365, 889, 103, 249, 24, 52, 166, 126, 10, 239, 53, 437, 7, 33, 33, 42, 1355, 146, 4, 3, 7973, 7, 5, 21233, 34, 42, 1769, 146, 115, 25, 28, 3, 396, 1, 45, 660, 728, 27, 7, 42, 77, 241, 1, 34, 2, 382, 239, 27, 42, 1016, 1, 34, 100, 111, 1788, 10, 846, 83, 207, 1, 109, 502, 19, 4554, 2, 109, 221, 1012, 19, 144, 107, 1749, 11, 674, 1, 1769, 1788, 4, 8, 561, 715, 87, 1, 7, 5, 263, 289, 196, 29, 718, 2, 1791, 1094, 1161, 16, 323, 4, 1893, 3, 34, 4, 3, 198, 173, 4, 3, 546, 1, 8, 2425, 24, 141, 249, 310, 15, 6836]",1499.0,22517013,480
Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin.,Annals of surgical oncology,Ann. Surg. Oncol.,2012-04-24,"Papillary thyroid cancer (PTC) has an excellent prognosis with current treatment methods. However, the rates of locoregional recurrence after initial surgical management remain significant. This study evaluates the effect of reoperative neck dissection for locoregional recurrence of PTC after initial total thyroidectomy and radioiodine therapy on the incidence of cervical recurrence and postoperative serum thyroglobulin (Tg) levels. This is a retrospective cohort study conducted in a single academic medical center of patients with recurrent or persistent PTC isolated to the neck after previous total thyroidectomy with or without lymph node dissection and adjuvant I(131) therapy who were treated with reoperative lymph node dissection. Outcomes including operative complications, pathologic findings, and effect of surgery on Tg levels and rates of recurrent disease were analyzed. From 2001 to 2010, a total of 61 patients had reoperative neck dissections for recurrent cervical PTC with a complication rate of 5 %. Seventy-two percent of patients were clinically free of detectable disease, and 28 % of patients had recurrent, persistent, or newly metastatic disease detected during the follow-up period. All patients had significant decreases in Tg levels, with a median 98 % reduction in preoperative levels. However, only 21 % of patients had an undetectable stimulated Tg (<0.5 ng/mL) during the follow-up period of 15.5 months. Reoperative treatment of recurrent or persistent PTC can be performed with low complication rates, and Tg levels greatly decrease in most patients; however, few achieve undetectable stimulated Tg.",Journal Article,2828.0,34.0,Papillary cancer PTC has an excellent prognosis with current treatment methods However the rates of locoregional recurrence after initial surgical management remain significant This study evaluates the effect of reoperative dissection for locoregional recurrence of PTC after initial total thyroidectomy and radioiodine therapy on the incidence of recurrence and postoperative serum thyroglobulin Tg levels This is a retrospective cohort study conducted in a single academic medical center of patients with recurrent or persistent PTC isolated to the after previous total thyroidectomy with or without lymph node dissection and adjuvant I 131 therapy who were treated with reoperative lymph node dissection Outcomes including operative complications pathologic findings and effect of surgery on Tg levels and rates of recurrent disease were analyzed From 2001 to 2010 a total of 61 patients had reoperative dissections for recurrent PTC with a complication rate of 5 Seventy-two percent of patients were clinically free of detectable disease and 28 of patients had recurrent persistent or newly metastatic disease detected during the follow-up period All patients had significant decreases in Tg levels with a median 98 reduction in preoperative levels However only 21 of patients had an undetectable stimulated Tg 0.5 ng/mL during the follow-up period of 15.5 months Reoperative treatment of recurrent or persistent PTC can be performed with low complication rates and Tg levels greatly decrease in most patients however few achieve undetectable stimulated Tg,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[1796, 12, 3748, 71, 35, 1503, 356, 5, 291, 24, 636, 137, 3, 151, 1, 1325, 146, 50, 388, 221, 284, 918, 93, 26, 45, 4941, 3, 254, 1, 11250, 1161, 9, 1325, 146, 1, 3748, 50, 388, 181, 5949, 2, 7211, 36, 23, 3, 287, 1, 146, 2, 573, 524, 8978, 5107, 148, 26, 16, 8, 459, 180, 45, 426, 4, 8, 226, 1916, 484, 574, 1, 7, 5, 387, 15, 1882, 3748, 1355, 6, 3, 50, 698, 181, 5949, 5, 15, 187, 263, 289, 1161, 2, 249, 70, 2229, 36, 54, 11, 73, 5, 11250, 263, 289, 1161, 123, 141, 1208, 521, 510, 272, 2, 254, 1, 152, 23, 5107, 148, 2, 151, 1, 387, 34, 11, 311, 29, 1758, 6, 1120, 8, 181, 1, 713, 7, 42, 11250, 6894, 9, 387, 3748, 5, 8, 1447, 116, 1, 33, 2073, 100, 714, 1, 7, 11, 505, 115, 1, 2083, 34, 2, 339, 1, 7, 42, 387, 1882, 15, 732, 113, 34, 530, 190, 3, 166, 126, 727, 62, 7, 42, 93, 2140, 4, 5107, 148, 5, 8, 52, 1096, 628, 4, 498, 148, 137, 158, 239, 1, 7, 42, 35, 3920, 2816, 5107, 13, 33, 997, 542, 190, 3, 166, 126, 727, 1, 167, 33, 53, 11250, 24, 1, 387, 15, 1882, 3748, 122, 40, 173, 5, 154, 1447, 151, 2, 5107, 148, 3510, 775, 4, 96, 7, 137, 1021, 1359, 3920, 2816, 5107]",1560.0,22526913,413
Minimally invasive esophagectomy with cervical esophagogastric anastomosis.,Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,J. Gastrointest. Surg.,2012-05-02,"Thoracoscopic dissection of the esophagus and laparoscopic dissection of the stomach with cervical esophagogastric anastomosis is a safe method for resection of esophageal and gastroesophageal junction malignancy. The setting was at University Tertiary Care Center. Subjects are patients with esophageal or gastroesophageal junction malignancy undergoing minimally invasive esophagectomy with cervical esophagogastric anastomosis. Technique of a 6-cm side-to-side stapled cervical esophagogastric anastomosis is described. The technique of minimally invasive esophagectomy with side-to-side stapled cervical esophagogastric anastomosis is described. Thoracoscopic dissection of the esophagus, laparoscopic dissection of the stomach, and a side-to-side stapled cervical esophagogastric anastomosis is safe, oncologically appropriate, and provides excellent functional results.",Journal Article,2820.0,24.0,Thoracoscopic dissection of the and laparoscopic dissection of the with esophagogastric anastomosis is a safe method for resection of and gastroesophageal junction malignancy The setting was at University Tertiary Care Center Subjects are patients with or gastroesophageal junction malignancy undergoing minimally invasive esophagectomy with esophagogastric anastomosis Technique of a 6-cm side-to-side stapled esophagogastric anastomosis is described The technique of minimally invasive esophagectomy with side-to-side stapled esophagogastric anastomosis is described Thoracoscopic dissection of the laparoscopic dissection of the and a side-to-side stapled esophagogastric anastomosis is safe oncologically appropriate and provides excellent functional results,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,"[5752, 1161, 1, 3, 2, 1964, 1161, 1, 3, 5, 6330, 5519, 16, 8, 1165, 596, 9, 170, 1, 2, 3227, 3322, 710, 3, 546, 10, 28, 1652, 2557, 165, 574, 976, 32, 7, 5, 15, 3227, 3322, 710, 479, 2144, 416, 3617, 5, 6330, 5519, 1312, 1, 8, 49, 494, 1152, 6, 1152, 9911, 6330, 5519, 16, 1027, 3, 1312, 1, 2144, 416, 3617, 5, 1152, 6, 1152, 9911, 6330, 5519, 16, 1027, 5752, 1161, 1, 3, 1964, 1161, 1, 3, 2, 8, 1152, 6, 1152, 9911, 6330, 5519, 16, 1165, 10854, 870, 2, 777, 1503, 583, 99]",762.0,22549264,574
Cancer prevention and screening practices of siblings of childhood cancer survivors: a report from the Childhood Cancer Survivor Study.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2012-05-10,"To compare the skin and breast/cervical cancer prevention/screening practices of adult siblings of childhood cancer survivors with controls and to identify modifying factors for these practices. Cross-sectional, self-report data from 2,588 adult siblings of 5+ year survivors of childhood cancer were analyzed to assess cancer prevention/screening practices. Two age, sex, and race/ethnicity-matched samples (N = 5,915 and N = 37,789) of the Behavioral Risk Factor Surveillance System participants served as the comparison populations. Sociodemographic and cancer-related data were explored as modifying factors for sibling cancer prevention/screening practices through multivariable logistic regression. Compared with controls, siblings were more likely to practice skin cancer prevention behaviors: use of protective clothing [OR, 2.85; 95% confidence interval (CI), 2.39-3.39], use of shade (OR, 2.11; 95% CI, 1.88-2.36), use of sunscreen (OR, 1.27; 95% CI, 1.14-1.40), and wearing a hat (OR, 1.77; 95% CI, 1.58-1.98). No differences were noted for breast/cervical cancer screening including mammography and Pap testing. Having less than a high school education and lack of health insurance were associated with diminished cancer prevention/screening behaviors. Survivor diagnosis, treatment intensity, adverse health, chronic health conditions, and second cancers were not associated with sibling cancer prevention/screening behaviors. Siblings of cancer survivors report greater skin cancer prevention practices when compared with controls; however, no differences were noted for breast/cervical cancer screening practices. Access to care and lack of education may be associated with decreased cancer prevention/screening behaviors. Interventions are needed to address these barriers. Research should be directed at understanding the impact of the cancer experience on sibling health behaviors.",Comparative Study,2812.0,3.0,"To compare the and breast/cervical cancer prevention/screening practices of adult siblings of childhood cancer survivors with controls and to identify modifying factors for these practices Cross-sectional self-report data from 2,588 adult siblings of 5+ year survivors of childhood cancer were analyzed to assess cancer prevention/screening practices Two age sex and race/ethnicity-matched samples N 5,915 and N 37,789 of the Behavioral Risk Factor Surveillance System participants served as the comparison populations Sociodemographic and cancer-related data were explored as modifying factors for sibling cancer prevention/screening practices through multivariable logistic regression Compared with controls siblings were more likely to practice cancer prevention behaviors use of protective clothing OR 2.85 95 confidence interval CI 2.39-3.39 use of shade OR 2.11 95 CI 1.88-2.36 use of sunscreen OR 1.27 95 CI 1.14-1.40 and wearing a hat OR 1.77 95 CI 1.58-1.98 No differences were noted for breast/cervical cancer screening including mammography and Pap testing Having less than a high school education and lack of health insurance were associated with diminished cancer prevention/screening behaviors Survivor diagnosis treatment intensity adverse health chronic health conditions and second cancers were not associated with sibling cancer prevention/screening behaviors Siblings of cancer survivors report greater cancer prevention practices when compared with controls however no differences were noted for breast/cervical cancer screening practices Access to care and lack of education may be associated with decreased cancer prevention/screening behaviors Interventions are needed to address these barriers Research should be directed at understanding the impact of the cancer experience on sibling health behaviors",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,"[6, 932, 3, 2, 1678, 18237, 12, 1070, 453, 2634, 1, 780, 2758, 1, 864, 12, 332, 5, 535, 2, 6, 255, 4898, 130, 9, 46, 2634, 1383, 2832, 1074, 414, 74, 29, 18, 14064, 780, 2758, 1, 33, 111, 332, 1, 864, 12, 11, 311, 6, 423, 12, 1070, 453, 2634, 100, 89, 1035, 2, 1047, 2091, 655, 347, 78, 33, 13644, 2, 78, 567, 16464, 1, 3, 4166, 43, 161, 617, 398, 776, 5275, 22, 3, 1155, 1184, 4221, 2, 12, 139, 74, 11, 1443, 22, 4898, 130, 9, 3684, 12, 1070, 453, 2634, 298, 658, 812, 320, 72, 5, 535, 2758, 11, 80, 322, 6, 758, 12, 1070, 3704, 119, 1, 2864, 19250, 15, 18, 772, 48, 307, 268, 58, 18, 587, 27, 587, 119, 1, 26305, 15, 18, 175, 48, 58, 14, 889, 18, 511, 119, 1, 16481, 15, 14, 428, 48, 58, 14, 213, 14, 327, 2, 35360, 8, 18347, 15, 14, 849, 48, 58, 14, 717, 14, 1096, 77, 362, 11, 1051, 9, 1678, 18237, 12, 453, 141, 2446, 2, 4290, 471, 1041, 299, 76, 8, 64, 5953, 1848, 2, 926, 1, 341, 1935, 11, 41, 5, 2849, 12, 1070, 453, 3704, 2628, 147, 24, 837, 290, 341, 442, 341, 1298, 2, 419, 163, 11, 44, 41, 5, 3684, 12, 1070, 453, 3704, 2758, 1, 12, 332, 414, 378, 12, 1070, 2634, 198, 72, 5, 535, 137, 77, 362, 11, 1051, 9, 1678, 18237, 12, 453, 2634, 1655, 6, 165, 2, 926, 1, 1848, 68, 40, 41, 5, 340, 12, 1070, 453, 3704, 1151, 32, 575, 6, 1539, 46, 2160, 389, 257, 40, 1166, 28, 612, 3, 345, 1, 3, 12, 730, 23, 3684, 341, 3704]",1826.0,22576363,160
Robotic surgery in gynecologic oncology.,Current opinion in oncology,Curr Opin Oncol,2012-09-01,"The objective of this article is to review the recently published literature on the use of robotic surgery in the management of gynecologic malignancies. Retrospective data collected from many institutions support the use of robotic surgery in the management of cervical, endometrial, and early-stage ovarian cancer. Benefits to robotic surgery include decreased blood loss, fewer perioperative complications, and decreased length of hospital stay, especially when compared to an open cohort. Disadvantages include costs associated with the robotic system and disposable equipment, accessibility to robotic surgical systems, loss of haptic sensation with the device, and lack of prospective trials validating its use in gynecologic oncology. Current evidence establishes a role for the use of robotic surgery in the treatment of gynecologic malignancies. Further research should be implemented to validate the use of robotic surgery in gynecologic malignancies and to compare its outcomes to those of open and laparoscopic surgery.",Journal Article,2698.0,25.0,The objective of this article is to review the recently published literature on the use of robotic surgery in the management of gynecologic malignancies Retrospective data collected from many institutions support the use of robotic surgery in the management of and early-stage cancer Benefits to robotic surgery include decreased blood loss fewer perioperative complications and decreased length of hospital stay especially when compared to an open cohort Disadvantages include costs associated with the robotic system and disposable equipment accessibility to robotic surgical systems loss of haptic sensation with the device and lack of prospective trials validating its use in gynecologic oncology Current evidence establishes a role for the use of robotic surgery in the treatment of gynecologic malignancies Further research should be implemented to validate the use of robotic surgery in gynecologic malignancies and to compare its outcomes to those of open and laparoscopic surgery,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 461, 1, 26, 946, 16, 6, 206, 3, 761, 983, 789, 23, 3, 119, 1, 2895, 152, 4, 3, 284, 1, 1512, 441, 459, 74, 786, 29, 445, 1764, 538, 3, 119, 1, 2895, 152, 4, 3, 284, 1, 2, 191, 82, 12, 1141, 6, 2895, 152, 643, 340, 315, 407, 1497, 1547, 521, 2, 340, 1318, 1, 702, 2020, 1093, 198, 72, 6, 35, 1020, 180, 8787, 643, 1201, 41, 5, 3, 2895, 398, 2, 47201, 12583, 9571, 6, 2895, 221, 1530, 407, 1, 61442, 12516, 5, 3, 4472, 2, 926, 1, 482, 143, 6897, 211, 119, 4, 1512, 413, 291, 241, 7410, 8, 200, 9, 3, 119, 1, 2895, 152, 4, 3, 24, 1, 1512, 441, 195, 389, 257, 40, 3426, 6, 2183, 3, 119, 1, 2895, 152, 4, 1512, 441, 2, 6, 932, 211, 123, 6, 135, 1, 1020, 2, 1964, 152]",988.0,22581356,231
Rhabdomyosarcoma of the cervix in adult women and younger patients.,Gynecologic oncology,Gynecol. Oncol.,2012-05-15,"Cervical rhabdomyosarcoma is extremely rare, and there is a paucity of literature on the subject. The purpose of this study was to describe the clinical and pathologic features of cervical rhabdomyosarcoma. We retrospectively reviewed all patients with cervical rhabdomyosarcoma who presented to our institution from 1980 to 2010. We reviewed pathologic, demographic, and clinical information. During the study period, 11 females presented with cervical rhabdomyosarcoma. The median age at presentation was 18.4 years, and 6 patients were <19 years old at diagnosis. Vaginal bleeding was the most common presenting symptom, and a vaginal mass was often a co-presenting symptom. Eight patients (73%) presented with stage IB disease, and 8 (73%) presented with the embryonal (botryoid) histologic subtype. Nine patients (82%) received multimodal therapy consisting of surgery with chemotherapy, radiation therapy, or both. All patients were without evidence of disease after completion of primary therapy, but 3 patients experienced local recurrence. At a median follow-up of 23 months, 6 patients (55%) were without evidence of disease, 1 (9%) was alive with disease, 1 (9%) had died of disease, and 3 (27%) had died of other causes. Three patients (27%) had other primary malignancies in addition to rhabdomyosarcoma-1 had a Sertoli-Leydig tumor, 1 had a Sertoli-Leydig tumor and a pinealoblastoma, and 1 had thyroid cancer and a parotid adenocarcinoma. With multimodal therapy, cervical rhabdomyosarcoma appears to be associated with a good prognosis. Favorable prognostic factors such as early stage at diagnosis and a favorable histologic subtype may contribute to the excellent observed survival.",Journal Article,2807.0,16.0,is extremely rare and there is a paucity of literature on the subject The purpose of this study was to describe the clinical and pathologic features of We retrospectively reviewed all patients with who presented to our institution from 1980 to 2010 We reviewed pathologic demographic and clinical information During the study period 11 females presented with The median age at presentation was 18.4 years and 6 patients were 19 years old at diagnosis bleeding was the most common presenting symptom and a mass was often a co-presenting symptom Eight patients 73 presented with stage IB disease and 8 73 presented with the embryonal botryoid histologic subtype Nine patients 82 received multimodal therapy consisting of surgery with chemotherapy radiation therapy or both All patients were without evidence of disease after completion of primary therapy but 3 patients experienced local recurrence At a median follow-up of 23 months 6 patients 55 were without evidence of disease 1 9 was alive with disease 1 9 had died of disease and 3 27 had died of other causes Three patients 27 had other primary malignancies in addition to rhabdomyosarcoma-1 had a Sertoli-Leydig tumor 1 had a Sertoli-Leydig tumor and a pinealoblastoma and 1 had cancer and a parotid adenocarcinoma With multimodal therapy appears to be associated with a good prognosis Favorable prognostic factors such as early stage at diagnosis and a favorable histologic subtype may contribute to the excellent observed survival,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[16, 2938, 622, 2, 125, 16, 8, 4832, 1, 789, 23, 3, 2974, 3, 743, 1, 26, 45, 10, 6, 897, 3, 38, 2, 510, 404, 1, 21, 894, 446, 62, 7, 5, 54, 917, 6, 114, 731, 29, 4376, 6, 1120, 21, 446, 510, 1540, 2, 38, 487, 190, 3, 45, 727, 175, 2451, 917, 5, 3, 52, 89, 28, 1031, 10, 203, 39, 60, 2, 49, 7, 11, 326, 60, 1095, 28, 147, 2294, 10, 3, 96, 186, 1656, 934, 2, 8, 782, 10, 629, 8, 1269, 1656, 934, 659, 7, 803, 917, 5, 82, 3180, 34, 2, 66, 803, 917, 5, 3, 5239, 35369, 884, 875, 762, 7, 878, 103, 4122, 36, 2273, 1, 152, 5, 56, 121, 36, 15, 110, 62, 7, 11, 187, 241, 1, 34, 50, 1438, 1, 86, 36, 84, 27, 7, 592, 293, 146, 28, 8, 52, 166, 126, 1, 382, 53, 49, 7, 614, 11, 187, 241, 1, 34, 14, 83, 10, 1701, 5, 34, 14, 83, 42, 1016, 1, 34, 2, 27, 428, 42, 1016, 1, 127, 1626, 169, 7, 428, 42, 127, 86, 441, 4, 352, 6, 22050, 14, 42, 8, 31032, 23505, 30, 14, 42, 8, 31032, 23505, 30, 2, 8, 61478, 2, 14, 42, 12, 2, 8, 5838, 449, 5, 4122, 36, 1233, 6, 40, 41, 5, 8, 1178, 356, 913, 177, 130, 225, 22, 191, 82, 28, 147, 2, 8, 913, 884, 875, 68, 1248, 6, 3, 1503, 164, 25]",1488.0,22609112,378
Prognostic value of lymph node ratio and clinicopathologic parameters in patients diagnosed with stage IIIC endometrial cancer.,Obstetrics and gynecology,Obstet Gynecol,2012-06-01,"To estimate the prognostic significance of lymph node ratio with respect to clinicopathologic characteristics in stage IIIC endometrial cancer patients. Using data from medical records and surgery notes, we identified all consecutive patients with stage IIIC endometrial cancer who received primary surgical treatment between 1993 and 2008. Lymph node ratio is the number of metastatic lymph nodes to the total number of removed lymph nodes. Survival analyses were performed using Kaplan-Meier and Cox proportional hazard methods. Two hundred sixteen patients with stage IIIC endometrial cancer were included in this multicenter study. Age, number of metastatic lymph nodes, lymph node ratio, grossly suspicious lymph nodes, histologic subtype, and cervical metastasis were associated with progression-free survival and overall survival, respectively. Patients with lymph node ratios 10% or less, more than 10-50%, and more than 50% had 5-year overall survival rates of 79.0%, 60.6%, and 35.8%, respectively (P<.001). In multivariable analysis, only lymph node ratio was associated with both progression-free survival and overall survival, respectively. Total number of removed lymph nodes and number of metastatic lymph nodes did not correlate with overall survival in the group with grossly suspicious lymph nodes, whereas lymph node ratio did. In the subgroup of 123 (56.9%) patients who had pelvic and aortic lymphadenectomies with a minimum of 10 lymph nodes removed, age and lymph node ratio were still associated with progression-free survival and overall survival, whereas total lymph nodes removed was not. Stratification based on lymph node ratio is useful when comprehensive lymphadenectomy is routinely performed and likely reflects metastatic nodal tumor burden. These data provide another prognostic variable in the heterogenic group of women with stage IIIC endometrial cancer. II.",Journal Article,2790.0,20.0,To estimate the prognostic significance of lymph node ratio with respect to clinicopathologic characteristics in stage IIIC cancer patients Using data from medical records and surgery notes we identified all consecutive patients with stage IIIC cancer who received primary surgical treatment between 1993 and 2008 Lymph node ratio is the number of metastatic lymph nodes to the total number of removed lymph nodes Survival analyses were performed using Kaplan-Meier and Cox proportional hazard methods Two hundred sixteen patients with stage IIIC cancer were included in this multicenter study Age number of metastatic lymph nodes lymph node ratio grossly suspicious lymph nodes histologic subtype and metastasis were associated with progression-free survival and overall survival respectively Patients with lymph node ratios 10 or less more than 10-50 and more than 50 had 5-year overall survival rates of 79.0 60.6 and 35.8 respectively P .001 In multivariable analysis only lymph node ratio was associated with both progression-free survival and overall survival respectively Total number of removed lymph nodes and number of metastatic lymph nodes did not correlate with overall survival in the group with grossly suspicious lymph nodes whereas lymph node ratio did In the subgroup of 123 56.9 patients who had pelvic and aortic lymphadenectomies with a minimum of 10 lymph nodes removed age and lymph node ratio were still associated with progression-free survival and overall survival whereas total lymph nodes removed was not Stratification based on lymph node ratio is useful when comprehensive lymphadenectomy is routinely performed and likely reflects metastatic nodal tumor burden These data provide another prognostic variable in the heterogenic group of women with stage IIIC cancer II,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 1191, 3, 177, 724, 1, 263, 289, 197, 5, 2184, 6, 1399, 374, 4, 82, 3842, 12, 7, 75, 74, 29, 484, 1064, 2, 152, 8192, 21, 108, 62, 935, 7, 5, 82, 3842, 12, 54, 103, 86, 221, 24, 59, 3343, 2, 1375, 263, 289, 197, 16, 3, 207, 1, 113, 263, 502, 6, 3, 181, 207, 1, 2264, 263, 502, 25, 318, 11, 173, 75, 876, 882, 2, 418, 831, 360, 636, 100, 1128, 3228, 7, 5, 82, 3842, 12, 11, 159, 4, 26, 1570, 45, 89, 207, 1, 113, 263, 502, 263, 289, 197, 7185, 3230, 263, 502, 884, 875, 2, 278, 11, 41, 5, 91, 115, 25, 2, 63, 25, 106, 7, 5, 263, 289, 1137, 79, 15, 299, 80, 76, 79, 212, 2, 80, 76, 212, 42, 33, 111, 63, 25, 151, 1, 842, 13, 335, 49, 2, 465, 66, 106, 19, 144, 4, 658, 65, 158, 263, 289, 197, 10, 41, 5, 110, 91, 115, 25, 2, 63, 25, 106, 181, 207, 1, 2264, 263, 502, 2, 207, 1, 113, 263, 502, 205, 44, 1513, 5, 63, 25, 4, 3, 87, 5, 7185, 3230, 263, 502, 547, 263, 289, 197, 205, 4, 3, 1363, 1, 2698, 664, 83, 7, 54, 42, 1110, 2, 3938, 16322, 5, 8, 2499, 1, 79, 263, 502, 2264, 89, 2, 263, 289, 197, 11, 1234, 41, 5, 91, 115, 25, 2, 63, 25, 547, 181, 263, 502, 2264, 10, 44, 1541, 90, 23, 263, 289, 197, 16, 999, 198, 949, 2048, 16, 3066, 173, 2, 322, 5224, 113, 779, 30, 892, 46, 74, 377, 1809, 177, 1347, 4, 3, 43300, 87, 1, 117, 5, 82, 3842, 12, 215]",1798.0,22617586,739
Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients.,Abdominal imaging,Abdom Imaging,2013-04-01,"To present the gastrointestinal (GI) complications associated with bevacizumab therapy and their findings on abdominal imaging studies. A computerized search identified 11 patients with GI complications of bevacizumab therapy on abdominal CT (n = 11) and fluoroscopic GI contrast studies (n = 4) who met our study criteria (including five patients with ovarian cancer, five with colon cancer, and one with cervical cancer). The medical records and imaging studies were reviewed to determine the clinical and radiographic findings in these patients. All 11 patients had findings of GI perforation on CT, or CT and GI contrast studies. CT revealed a localized extraluminal collection containing gas, fluid, and/or contrast material in eight patients (73%) with focal perforation, and free abdominal air and fluid in three (27%) with free perforation The imaging studies also revealed seven fistulas, including two colovaginal, one rectovaginal, one enterocutaneous, one colocutaneous, one gastrocolic, and one colorectal fistula. Eight (73%) of the 11 patients died within 1 year of the development of GI perforation, and the perforation was felt to be the cause of death in four patients (36%). Abdominal CT and fluoroscopic GI contrast studies are useful imaging tests for the diagnosis of potentially life-threatening GI perforation as a complication of bevacizumab therapy. When GI perforation is detected on abdominal imaging studies, treatment with bevacizumab should immediately be discontinued.",Journal Article,2486.0,11.0,To present the GI complications associated with bevacizumab therapy and their findings on abdominal imaging studies A computerized search identified 11 patients with GI complications of bevacizumab therapy on abdominal CT n 11 and fluoroscopic GI contrast studies n 4 who met our study criteria including five patients with cancer five with cancer and one with cancer The medical records and imaging studies were reviewed to determine the clinical and radiographic findings in these patients All 11 patients had findings of GI perforation on CT or CT and GI contrast studies CT revealed a localized extraluminal collection containing gas fluid and/or contrast material in eight patients 73 with focal perforation and free abdominal air and fluid in three 27 with free perforation The imaging studies also revealed seven fistulas including two colovaginal one rectovaginal one enterocutaneous one colocutaneous one gastrocolic and one fistula Eight 73 of the 11 patients died within 1 year of the development of GI perforation and the perforation was felt to be the cause of death in four patients 36 Abdominal CT and fluoroscopic GI contrast studies are useful imaging tests for the diagnosis of potentially life-threatening GI perforation as a complication of bevacizumab therapy When GI perforation is detected on abdominal imaging studies treatment with bevacizumab should immediately be discontinued,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 364, 3, 2104, 521, 41, 5, 599, 36, 2, 136, 272, 23, 1467, 270, 94, 8, 4912, 1901, 108, 175, 7, 5, 2104, 521, 1, 599, 36, 23, 1467, 425, 78, 175, 2, 21407, 2104, 748, 94, 78, 39, 54, 543, 114, 45, 371, 141, 365, 7, 5, 12, 365, 5, 12, 2, 104, 5, 12, 3, 484, 1064, 2, 270, 94, 11, 446, 6, 223, 3, 38, 2, 1580, 272, 4, 46, 7, 62, 175, 7, 42, 272, 1, 2104, 4854, 23, 425, 15, 425, 2, 2104, 748, 94, 425, 553, 8, 909, 39998, 2442, 1101, 5577, 2357, 2, 15, 748, 3692, 4, 659, 7, 803, 5, 2137, 4854, 2, 115, 1467, 6909, 2, 2357, 4, 169, 428, 5, 115, 4854, 3, 270, 94, 120, 553, 648, 13244, 141, 100, 61492, 104, 22569, 104, 30657, 104, 61493, 104, 39999, 2, 104, 4920, 659, 803, 1, 3, 175, 7, 1016, 262, 14, 111, 1, 3, 193, 1, 2104, 4854, 2, 3, 4854, 10, 5284, 6, 40, 3, 708, 1, 273, 4, 294, 7, 511, 1467, 425, 2, 21407, 2104, 748, 94, 32, 999, 270, 895, 9, 3, 147, 1, 751, 358, 3691, 2104, 4854, 22, 8, 1447, 1, 599, 36, 198, 2104, 4854, 16, 530, 23, 1467, 270, 94, 24, 5, 599, 257, 3467, 40, 2402]",1403.0,22627832,88
Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2012-06-01,"Gemcitabine is active in several gynecologic malignancies including ovarian cancer, cervical cancer, and uterine leiomyosarcoma. It has been used in an off-label setting for the treatment of advanced endometrial cancer, despite lack of published data showing efficacy. We performed a retrospective study to determine the progression-free survival and response rate of endometrial cancer patients treated with gemcitabine at Memorial Sloan-Kettering Cancer Center. Eligible patients had histologically confirmed advanced (stage IV or recurrent) endometrial cancer that was treated with single-agent gemcitabine at Memorial Sloan-Kettering Cancer Center between 1999 and 2009. Response to therapy was determined by review of computed tomography imaging by Response Evaluation Criteria in Solid Tumors 1.1 criteria. Forty-six patients were included in the analysis. Median age was 66 years (range, 52-87 years). All patients were previously treated with chemotherapy. The median number of prior lines of chemotherapy was 2 (range, 1-8). Median dose of gemcitabine administered was 800 mg/m infused on days 1 and 8 of a 21-day cycle. Predominant histology was endometrioid (48%, n = 22) followed by serous (35%, n = 16), clear cell (15%, n = 7), and undifferentiated (2%, n = 1). Overall response rate was 10.9% (95% confidence interval, 1.9%-19.9%); 5 patients (11%) achieved a partial response. Thirteen patients (28%) displayed stable disease lasting at least 3 months. Of note, 5 (71%) of the 7 patients with clear cell histology displayed stable disease or partial response (n = 5). The median progression-free survival was 3.0 months (95% confidence interval, 2.1-3.3 months). Nonhematologic grades 3 and 4 toxicities were rare. Ten patients (22%) were treated with granulocyte colony-stimulating factor during treatment. Grade 3 thrombocytopenia was seen in 4 patients (9%). There were no cases of grade 4 thrombocytopenia. In a mixed population of patients with previously treated advanced endometrial cancer, gemcitabine was well tolerated and showed modest activity. Patients with clear cell histology appeared to have greater likelihood of benefit.",Journal Article,2790.0,8.0,Gemcitabine is active in several gynecologic malignancies including cancer cancer and leiomyosarcoma It has been used in an off-label setting for the treatment of advanced cancer despite lack of published data showing efficacy We performed a retrospective study to determine the progression-free survival and response rate of cancer patients treated with gemcitabine at Memorial Sloan-Kettering Cancer Center Eligible patients had histologically confirmed advanced stage IV or recurrent cancer that was treated with single-agent gemcitabine at Memorial Sloan-Kettering Cancer Center between 1999 and 2009 Response to therapy was determined by review of computed tomography imaging by Response Evaluation Criteria in Solid Tumors 1.1 criteria Forty-six patients were included in the analysis Median age was 66 years range 52-87 years All patients were previously treated with chemotherapy The median number of prior lines of chemotherapy was 2 range 1-8 Median dose of gemcitabine administered was 800 mg/m infused on days 1 and 8 of a 21-day cycle Predominant histology was endometrioid 48 n 22 followed by serous 35 n 16 clear cell 15 n 7 and undifferentiated 2 n 1 Overall response rate was 10.9 95 confidence interval 1.9 -19.9 5 patients 11 achieved a partial response Thirteen patients 28 displayed stable disease lasting at least 3 months Of note 5 71 of the 7 patients with clear cell histology displayed stable disease or partial response n 5 The median progression-free survival was 3.0 months 95 confidence interval 2.1-3.3 months Nonhematologic grades 3 and 4 toxicities were rare Ten patients 22 were treated with granulocyte colony-stimulating factor during treatment Grade 3 thrombocytopenia was seen in 4 patients 9 There were no cases of grade 4 thrombocytopenia In a mixed population of patients with previously treated advanced cancer gemcitabine was well tolerated and showed modest activity Patients with clear cell histology appeared to have greater likelihood of benefit,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[679, 16, 544, 4, 392, 1512, 441, 141, 12, 12, 2, 3717, 192, 71, 85, 95, 4, 35, 1889, 1756, 546, 9, 3, 24, 1, 131, 12, 550, 926, 1, 983, 74, 2069, 209, 21, 173, 8, 459, 45, 6, 223, 3, 91, 115, 25, 2, 51, 116, 1, 12, 7, 73, 5, 679, 28, 2563, 2783, 2784, 12, 574, 625, 7, 42, 2161, 557, 131, 82, 478, 15, 387, 12, 17, 10, 73, 5, 226, 420, 679, 28, 2563, 2783, 2784, 12, 574, 59, 2043, 2, 1238, 51, 6, 36, 10, 509, 20, 206, 1, 1220, 872, 270, 20, 51, 451, 371, 4, 537, 57, 14, 14, 371, 1213, 437, 7, 11, 159, 4, 3, 65, 52, 89, 10, 700, 60, 184, 653, 912, 60, 62, 7, 11, 373, 73, 5, 56, 3, 52, 207, 1, 324, 285, 1, 56, 10, 18, 184, 14, 66, 52, 61, 1, 679, 468, 10, 2796, 81, 188, 4524, 23, 162, 14, 2, 66, 1, 8, 239, 218, 417, 2750, 784, 10, 3151, 576, 78, 350, 370, 20, 1744, 465, 78, 245, 885, 31, 167, 78, 67, 2, 4480, 18, 78, 14, 63, 51, 116, 10, 79, 83, 48, 307, 268, 14, 83, 326, 83, 33, 7, 175, 513, 8, 450, 51, 3170, 7, 339, 2507, 585, 34, 3443, 28, 506, 27, 53, 1, 5739, 33, 792, 1, 3, 67, 7, 5, 885, 31, 784, 2507, 585, 34, 15, 450, 51, 78, 33, 3, 52, 91, 115, 25, 10, 27, 13, 53, 48, 307, 268, 18, 14, 27, 27, 53, 3534, 2276, 27, 2, 39, 385, 11, 622, 1618, 7, 350, 11, 73, 5, 2764, 1975, 2122, 161, 190, 24, 88, 27, 1340, 10, 527, 4, 39, 7, 83, 125, 11, 77, 140, 1, 88, 39, 1340, 4, 8, 1739, 266, 1, 7, 5, 373, 73, 131, 12, 679, 10, 149, 421, 2, 224, 1721, 128, 7, 5, 885, 31, 784, 2121, 6, 47, 378, 1420, 1, 247]",1992.0,22635030,339
Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2012-06-06,"Cytology-based screening has limited sensitivity to detect prevalent cervical precancers. Human papilloma virus (HPV) DNA testing is highly sensitive and provides a high, long-term reassurance of low risk of cervical cancer. However, the specificity of HPV DNA testing is limited, requiring additional, more disease-specific markers for efficient screening approaches. Liquid-based cytology samples were collected from 625 women referred to colposcopy. A slide was stained using the CINtec plus cytology assay. Pap cytology and HPV genotyping were conducted from the same vial. Clinical performance characteristics were calculated for all women, stratified by age, and for women referred with a low-grade squamous intraepithelial lesion (LSIL) Pap. p16/Ki-67 positivity increased with histologic severity, from 26.8% in normal histology, 46.5% in CIN1, 82.8% in CIN2 to 92.8% in CIN3. Among women with CIN3, p16/Ki-67 positivity increased from 77.8% for women younger than 30 years without HPV16 to 100% for women 30 years and older with HPV16. The sensitivity and specificity to detect CIN3+ were 93.2% and 46.1%, respectively, and increased to 97.2% and 60.0% among women 30 years and older. In women with high-risk (HR)-HPV-positive atypical squamous cells of undetermined significance (ASC-US) and LSIL, sensitivity and specificity for detection of CIN3 were 90.6% and 48.6%, respectively. p16/Ki-67 testing could reduce referral to colposcopy by almost half while detecting the most severe cases of CIN3. The high sensitivity of p16/Ki-67 with significantly improved specificity compared with HPV testing makes p16/Ki-67 a viable option for LSIL triage. Further studies are required to evaluate p16/Ki-67 as triage marker in HPV-based screening strategies.",Journal Article,2785.0,127.0,Cytology-based screening has limited sensitivity to detect prevalent precancers Human papilloma virus HPV DNA testing is highly sensitive and provides a high long-term reassurance of low risk of cancer However the specificity of HPV DNA testing is limited requiring additional more disease-specific markers for efficient screening approaches Liquid-based cytology samples were collected from 625 women referred to colposcopy A slide was stained using the CINtec plus cytology assay Pap cytology and HPV genotyping were conducted from the same vial Clinical performance characteristics were calculated for all women stratified by age and for women referred with a low-grade squamous intraepithelial lesion LSIL Pap p16/Ki-67 positivity increased with histologic severity from 26.8 in normal histology 46.5 in CIN1 82.8 in CIN2 to 92.8 in CIN3 Among women with CIN3 p16/Ki-67 positivity increased from 77.8 for women younger than 30 years without HPV16 to 100 for women 30 years and older with HPV16 The sensitivity and specificity to detect CIN3+ were 93.2 and 46.1 respectively and increased to 97.2 and 60.0 among women 30 years and older In women with high-risk HR -HPV-positive atypical squamous cells of undetermined significance ASC-US and LSIL sensitivity and specificity for detection of CIN3 were 90.6 and 48.6 respectively p16/Ki-67 testing could reduce referral to colposcopy by almost half while detecting the most severe cases of CIN3 The high sensitivity of p16/Ki-67 with significantly improved specificity compared with HPV testing makes p16/Ki-67 a viable option for LSIL triage Further studies are required to evaluate p16/Ki-67 as triage marker in HPV-based screening strategies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2045, 90, 453, 71, 383, 485, 6, 1426, 2485, 18753, 171, 7017, 1450, 933, 261, 471, 16, 561, 745, 2, 777, 8, 64, 319, 337, 14491, 1, 154, 43, 1, 12, 137, 3, 1121, 1, 933, 261, 471, 16, 383, 1888, 402, 80, 34, 112, 525, 9, 2547, 453, 611, 3165, 90, 2045, 347, 11, 786, 29, 9629, 117, 1995, 6, 9946, 8, 7911, 10, 3386, 75, 3, 47229, 349, 2045, 719, 4290, 2045, 2, 933, 2686, 11, 426, 29, 3, 827, 29225, 38, 528, 374, 11, 981, 9, 62, 117, 1173, 20, 89, 2, 9, 117, 1995, 5, 8, 154, 88, 691, 4153, 1180, 17849, 4290, 1932, 2311, 598, 1887, 101, 5, 884, 1702, 29, 432, 66, 4, 295, 784, 641, 33, 4, 23728, 878, 66, 4, 12870, 6, 937, 66, 4, 10346, 107, 117, 5, 10346, 1932, 2311, 598, 1887, 101, 29, 849, 66, 9, 117, 773, 76, 201, 60, 187, 4048, 6, 394, 9, 117, 201, 60, 2, 434, 5, 4048, 3, 485, 2, 1121, 6, 1426, 10346, 11, 966, 18, 2, 641, 14, 106, 2, 101, 6, 1015, 18, 2, 335, 13, 107, 117, 201, 60, 2, 434, 4, 117, 5, 64, 43, 168, 933, 109, 1973, 691, 37, 1, 5206, 724, 5203, 843, 2, 17849, 485, 2, 1121, 9, 638, 1, 10346, 11, 424, 49, 2, 576, 49, 106, 1932, 2311, 598, 471, 359, 969, 2096, 6, 9946, 20, 2214, 1303, 369, 2502, 3, 96, 905, 140, 1, 10346, 3, 64, 485, 1, 1932, 2311, 598, 5, 97, 231, 1121, 72, 5, 933, 471, 4677, 1932, 2311, 598, 8, 2663, 1501, 9, 17849, 9059, 195, 94, 32, 616, 6, 376, 1932, 2311, 598, 22, 9059, 952, 4, 933, 90, 453, 422]",1696.0,22675168,723
Cervical cancers require the continuous expression of the human papillomavirus type 16 E7 oncoprotein even in the presence of the viral E6 oncoprotein.,Cancer research,Cancer Res.,2012-06-13,"High-risk human papillomaviruses (HPV), such as HPV-16, are etiologic agents of a variety of anogenital and oral malignancies, including nearly all cases of cervical cancer. Cervical cancers arising in transgenic mice that express HPV-16 E7 in an inducible manner require the continuous expression of E7 for their maintenance. However, in HPV-associated cancers in vivo, E6 and E7 invariably are coexpressed. In this study, we investigated whether cervical cancers rely on the continuous expression of E7 in the context of constitutively expressed E6. We placed the inducible HPV-16 E7 transgene onto a background in which HPV-16 E6 was constitutively expressed. In transgenic mice with high-grade cervical dysplastic lesions and cervical cancer, repressing the expression of E7 led to the regression of all cancers and the vast majority of high-grade dysplastic lesions. In addition, cervical cancers were occasionally observed in transgenic mice in which E7 was repressed and then reexpressed. Our findings indicate that even in the presence of constitutively expressed E6, the continuous expression of E7 is required for the maintenance of cervical cancers and most precancerous lesions. These data have important implications for the potential clinical use of drugs designed to inhibit the expression and/or function of E7 to treat HPV-associated cancers.",Journal Article,2778.0,32.0,High-risk human papillomaviruses HPV such as HPV-16 are etiologic agents of a variety of anogenital and oral malignancies including nearly all cases of cancer cancers arising in transgenic mice that express HPV-16 E7 in an inducible manner require the continuous expression of E7 for their maintenance However in HPV-associated cancers in vivo E6 and E7 invariably are coexpressed In this study we investigated whether cancers rely on the continuous expression of E7 in the context of constitutively expressed E6 We placed the inducible HPV-16 E7 transgene onto a background in which HPV-16 E6 was constitutively expressed In transgenic mice with high-grade dysplastic lesions and cancer repressing the expression of E7 led to the regression of all cancers and the vast majority of high-grade dysplastic lesions In addition cancers were occasionally observed in transgenic mice in which E7 was repressed and then reexpressed Our findings indicate that even in the presence of constitutively expressed E6 the continuous expression of E7 is required for the maintenance of cancers and most precancerous lesions These data have important implications for the potential clinical use of drugs designed to inhibit the expression and/or function of E7 to treat HPV-associated cancers,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[64, 43, 171, 14731, 933, 225, 22, 933, 245, 32, 6604, 183, 1, 8, 1362, 1, 13836, 2, 518, 441, 141, 1857, 62, 140, 1, 12, 163, 2635, 4, 2862, 399, 17, 1669, 933, 245, 4540, 4, 35, 2877, 1708, 1353, 3, 1314, 55, 1, 4540, 9, 136, 1146, 137, 4, 933, 41, 163, 4, 386, 4837, 2, 4540, 6912, 32, 10185, 4, 26, 45, 21, 565, 317, 163, 5533, 23, 3, 1314, 55, 1, 4540, 4, 3, 1533, 1, 2818, 570, 4837, 21, 3295, 3, 2877, 933, 245, 4540, 6632, 3301, 8, 2426, 4, 92, 933, 245, 4837, 10, 2818, 570, 4, 2862, 399, 5, 64, 88, 6461, 406, 2, 12, 13803, 3, 55, 1, 4540, 836, 6, 3, 320, 1, 62, 163, 2, 3, 4337, 686, 1, 64, 88, 6461, 406, 4, 352, 163, 11, 6319, 164, 4, 2862, 399, 4, 92, 4540, 10, 6654, 2, 818, 43127, 114, 272, 1008, 17, 871, 4, 3, 463, 1, 2818, 570, 4837, 3, 1314, 55, 1, 4540, 16, 616, 9, 3, 1146, 1, 163, 2, 96, 6605, 406, 46, 74, 47, 305, 1268, 9, 3, 174, 38, 119, 1, 600, 1114, 6, 1433, 3, 55, 2, 15, 343, 1, 4540, 6, 943, 933, 41, 163]",1276.0,22700879,50
A microRNA expression signature for the prognosis of oropharyngeal squamous cell carcinoma.,Cancer,Cancer,2012-06-26,"Oropharyngeal squamous cell carcinoma (SCC) rates have been increasing significantly in recent years, despite a decreasing incidence of head and neck cancer in general. Oropharyngeal SCC has many characteristics that are distinct from other head and neck cancers, and thus it is important to focus specifically on cancers arising in this region, with the goal of improving patient outcomes. One important goal is to identify those patients who are likely to fail standard therapy and who could potentially benefit from alternative or targeted treatments. In the current study, the prognostic value of microRNAs (miRNAs) was evaluated in patients with oropharyngeal SCC. miRNAs are small, noncoding RNAs that are master regulators of many important biological processes. In total, 150 oropharyngeal tumors were analyzed using the recently developed quantitative polymerase chain reaction-based method for miRNA expression profiling. In addition, the expression of miRNAs was also compared with human papillomavirus (HPV) transcriptional activities. The current study identified 6 miRNAs that were found to be significantly associated with cancer survival. A combined expression signature of these miRNAs was prognostic of oropharyngeal SCC, independent of common clinical features or HPV status. This new miRNA signature was experimentally validated in an independent oropharyngeal SCC cohort. Furthermore, 5 HPV-related miRNAs were identified, which may help to characterize HPV-induced cancers including both oropharyngeal and cervical SCC.",Journal Article,2765.0,48.0,squamous cell carcinoma SCC rates have been increasing significantly in recent years despite a decreasing incidence of head and cancer in general SCC has many characteristics that are distinct from other head and cancers and thus it is important to focus specifically on cancers arising in this region with the goal of improving patient outcomes One important goal is to identify those patients who are likely to fail standard therapy and who could potentially benefit from alternative or targeted treatments In the current study the prognostic value of microRNAs miRNAs was evaluated in patients with SCC miRNAs are small noncoding RNAs that are master regulators of many important biological processes In total 150 tumors were analyzed using the recently developed quantitative polymerase chain reaction-based method for miRNA expression profiling In addition the expression of miRNAs was also compared with human papillomavirus HPV transcriptional activities The current study identified 6 miRNAs that were found to be significantly associated with cancer survival A combined expression signature of these miRNAs was prognostic of SCC independent of common clinical features or HPV status This new miRNA signature was experimentally validated in an independent SCC cohort Furthermore 5 HPV-related miRNAs were identified which may help to characterize HPV-induced cancers including both and SCC,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[691, 31, 134, 1791, 151, 47, 85, 602, 97, 4, 435, 60, 550, 8, 2777, 287, 1, 718, 2, 12, 4, 1083, 1791, 71, 445, 374, 17, 32, 834, 29, 127, 718, 2, 163, 2, 631, 192, 16, 305, 6, 1222, 1225, 23, 163, 2635, 4, 26, 1053, 5, 3, 1326, 1, 1673, 69, 123, 104, 305, 1326, 16, 6, 255, 135, 7, 54, 32, 322, 6, 4373, 260, 36, 2, 54, 359, 751, 247, 29, 1091, 15, 238, 640, 4, 3, 291, 45, 3, 177, 549, 1, 3515, 2028, 10, 194, 4, 7, 5, 1791, 2028, 32, 302, 6420, 4550, 17, 32, 7561, 3196, 1, 445, 305, 1037, 1849, 4, 181, 1577, 57, 11, 311, 75, 3, 761, 276, 1156, 1451, 1260, 1329, 90, 596, 9, 2053, 55, 1080, 4, 352, 3, 55, 1, 2028, 10, 120, 72, 5, 171, 3242, 933, 1431, 2042, 3, 291, 45, 108, 49, 2028, 17, 11, 204, 6, 40, 97, 41, 5, 12, 25, 8, 397, 55, 1651, 1, 46, 2028, 10, 177, 1, 1791, 306, 1, 186, 38, 404, 15, 933, 156, 26, 217, 2053, 1651, 10, 8593, 938, 4, 35, 306, 1791, 180, 798, 33, 933, 139, 2028, 11, 108, 92, 68, 987, 6, 1507, 933, 277, 163, 141, 110, 2, 1791]",1397.0,22736309,224
The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy.,Cancer,Cancer,2012-07-17,"This study sought to determine if treatment time impacts pelvic failure (PF), distant failure (DF), or disease-specific mortality (DSM) in patients undergoing concurrent chemoradiotherapy (CCRT). A retrospective review was performed of 113 consecutive eligible patients with stage IB2 to IIIB cervical cancer. All patients received whole-pelvis radiation with concurrent chemotherapy and consolidative intracavitary brachytherapy (BT) to the cervix, followed by an external beam parametrial boost when appropriate. The effect of treatment time on PF, DF, and DSM was examined with univariate and multivariate analyses. Characteristics of patients with and without treatment prolongation were compared to explore reasons for treatment prolongation. The median time to completion of BT was 60 days, and the median time to complete all RT was 68 days. The 3-year cumulative incidence of PF, DF, and DSM were 18%, 23%, and 26%, respectively. On multivariate analysis, time to completion of BT >56 days was associated with increased PF (hazard ratio, 3.8; 95% confidence interval, 1.2-16; P = .02). The 3-year PF for >56 days versus 56 days was 26% versus 9% (P = .04). Treatment time was not associated with DF or DSM. Treatment prolongation was found to be associated with delay in starting BT and higher incidence of acute grade 3/4 toxicities. In the setting of CCRT, treatment time >56 days is detrimental to pelvic control but is not associated with an increase in DF or DSM. To maximize pelvic control, we recommend completing BT in 8 weeks or less.",Journal Article,2744.0,54.0,This study sought to determine if treatment time impacts pelvic failure PF distant failure DF or disease-specific mortality DSM in patients undergoing concurrent chemoradiotherapy CCRT A retrospective review was performed of 113 consecutive eligible patients with stage IB2 to IIIB cancer All patients received whole-pelvis radiation with concurrent chemotherapy and consolidative intracavitary brachytherapy BT to the cervix followed by an external beam parametrial boost when appropriate The effect of treatment time on PF DF and DSM was examined with univariate and multivariate analyses Characteristics of patients with and without treatment prolongation were compared to explore reasons for treatment prolongation The median time to completion of BT was 60 days and the median time to complete all RT was 68 days The 3-year cumulative incidence of PF DF and DSM were 18 23 and 26 respectively On multivariate analysis time to completion of BT 56 days was associated with increased PF hazard ratio 3.8 95 confidence interval 1.2-16 P .02 The 3-year PF for 56 days versus 56 days was 26 versus 9 P .04 Treatment time was not associated with DF or DSM Treatment prolongation was found to be associated with delay in starting BT and higher incidence of acute grade 3/4 toxicities In the setting of CCRT treatment time 56 days is detrimental to pelvic control but is not associated with an increase in DF or DSM To maximize pelvic control we recommend completing BT in 8 weeks or less,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[26, 45, 990, 6, 223, 492, 24, 98, 4719, 1110, 496, 3313, 626, 496, 6687, 15, 34, 112, 282, 17022, 4, 7, 479, 750, 1464, 6255, 8, 459, 206, 10, 173, 1, 4259, 935, 625, 7, 5, 82, 9537, 6, 3036, 12, 62, 7, 103, 902, 3270, 121, 5, 750, 56, 2, 6618, 9122, 1536, 3641, 6, 3, 3629, 370, 20, 35, 1455, 1345, 8726, 2569, 198, 870, 3, 254, 1, 24, 98, 23, 3313, 6687, 2, 17022, 10, 409, 5, 880, 2, 331, 318, 374, 1, 7, 5, 2, 187, 24, 4464, 11, 72, 6, 1645, 2325, 9, 24, 4464, 3, 52, 98, 6, 1438, 1, 3641, 10, 335, 162, 2, 3, 52, 98, 6, 236, 62, 240, 10, 806, 162, 3, 27, 111, 967, 287, 1, 3313, 6687, 2, 17022, 11, 203, 382, 2, 432, 106, 23, 331, 65, 98, 6, 1438, 1, 3641, 664, 162, 10, 41, 5, 101, 3313, 360, 197, 27, 66, 48, 307, 268, 14, 18, 245, 19, 588, 3, 27, 111, 3313, 9, 664, 162, 185, 61678, 162, 10, 432, 185, 83, 19, 755, 24, 98, 10, 44, 41, 5, 6687, 15, 17022, 24, 4464, 10, 204, 6, 40, 41, 5, 1984, 4, 1723, 3641, 2, 142, 287, 1, 286, 88, 27, 39, 385, 4, 3, 546, 1, 6255, 24, 98, 664, 162, 16, 6227, 6, 1110, 182, 84, 16, 44, 41, 5, 35, 344, 4, 6687, 15, 17022, 6, 4116, 1110, 182, 21, 2237, 4144, 3641, 4, 66, 244, 15, 299]",1485.0,22806897,400
Anatomic location of PET-positive aortocaval nodes in patients with locally advanced cervical cancer: implications for surgical staging.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2012-09-01,"Pathologic evaluation of aortocaval nodes in patients with locally advanced cervical cancer in an effort to better tailor radiotherapy has gained popularity. We sought to determine which aortocaval nodes should be sampled during surgical staging procedures. From 2004 to 2011, 246 patients with locally advanced cervical cancer underwent positron emission tomography (PET) before definitive chemoradiation. We reviewed the imaging studies to determine the location of PET-positive aortocaval nodes in relationship to the inferior mesenteric artery (IMA). Forty-two patients (17%) had PET images suggesting aortocaval metastasis. Ten patients had stage IB, 1 had stage IIA, 13 had stage IIB, 13 had stage IIIB, and 5 had stage IV disease. Of these 42 patients, 39 (93%) had FDG-avid pelvic nodes, 1 (2%) had PET-negative pelvic nodes but FDG-avid common iliac nodes, and 2 (5%) had direct spread to the aortocaval nodes. Three patients (7%) had FDG-avid aortocaval nodes above the IMA without FDG-avid nodes between the aortic bifurcation and IMA. All 3 of these patients also had FDG-avid nodes in the pelvis. Nineteen patients (45%) had FDG-avid nodes above and below the IMA, and 20 (48%) had FDG-avid nodes below the IMA only. This hypothesis-generating study revealed that a small number of patients have PET-positive aortocaval nodes above the IMA only. For patients undergoing surgical staging for locally advanced cervical cancer, dissection to the renal vessels may be necessary. A future international, randomized study will prospectively evaluate the locations of pathologically positive aortocaval lymph nodes.",Journal Article,2698.0,5.0,Pathologic evaluation of aortocaval nodes in patients with locally advanced cancer in an effort to better tailor radiotherapy has gained popularity We sought to determine which aortocaval nodes should be sampled during surgical staging procedures From 2004 to 2011 246 patients with locally advanced cancer underwent positron emission tomography PET before definitive chemoradiation We reviewed the imaging studies to determine the location of PET-positive aortocaval nodes in relationship to the inferior mesenteric artery IMA Forty-two patients 17 had PET images suggesting aortocaval metastasis Ten patients had stage IB 1 had stage IIA 13 had stage IIB 13 had stage IIIB and 5 had stage IV disease Of these 42 patients 39 93 had FDG-avid pelvic nodes 1 2 had PET-negative pelvic nodes but FDG-avid common iliac nodes and 2 5 had direct spread to the aortocaval nodes Three patients 7 had FDG-avid aortocaval nodes above the IMA without FDG-avid nodes between the aortic bifurcation and IMA All 3 of these patients also had FDG-avid nodes in the pelvis Nineteen patients 45 had FDG-avid nodes above and below the IMA and 20 48 had FDG-avid nodes below the IMA only This hypothesis-generating study revealed that a small number of patients have PET-positive aortocaval nodes above the IMA only For patients undergoing surgical staging for locally advanced cancer dissection to the vessels may be necessary A future international randomized study will prospectively evaluate the locations of pathologically positive aortocaval lymph nodes,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[510, 451, 1, 17414, 502, 4, 7, 5, 795, 131, 12, 4, 35, 2919, 6, 380, 6585, 310, 71, 3711, 11393, 21, 990, 6, 223, 92, 17414, 502, 257, 40, 5919, 190, 221, 632, 1369, 29, 1131, 6, 1132, 6907, 7, 5, 795, 131, 12, 208, 1900, 1799, 872, 495, 348, 1057, 975, 21, 446, 3, 270, 94, 6, 223, 3, 1147, 1, 495, 109, 17414, 502, 4, 858, 6, 3, 1663, 5719, 2872, 15572, 1213, 100, 7, 269, 42, 495, 1572, 802, 17414, 278, 1618, 7, 42, 82, 3180, 14, 42, 82, 4088, 233, 42, 82, 3884, 233, 42, 82, 3036, 2, 33, 42, 82, 478, 34, 1, 46, 595, 7, 587, 966, 42, 1285, 5189, 1110, 502, 14, 18, 42, 495, 199, 1110, 502, 84, 1285, 5189, 186, 6692, 502, 2, 18, 33, 42, 1196, 2579, 6, 3, 17414, 502, 169, 7, 67, 42, 1285, 5189, 17414, 502, 2090, 3, 15572, 187, 1285, 5189, 502, 59, 3, 3938, 18788, 2, 15572, 62, 27, 1, 46, 7, 120, 42, 1285, 5189, 502, 4, 3, 3270, 3498, 7, 512, 42, 1285, 5189, 502, 2090, 2, 2736, 3, 15572, 2, 179, 576, 42, 1285, 5189, 502, 2736, 3, 15572, 158, 26, 1492, 3997, 45, 553, 17, 8, 302, 207, 1, 7, 47, 495, 109, 17414, 502, 2090, 3, 15572, 158, 9, 7, 479, 221, 632, 9, 795, 131, 12, 1161, 6, 3, 3102, 68, 40, 1493, 8, 508, 944, 384, 45, 303, 1143, 376, 3, 4069, 1, 2998, 109, 17414, 263, 502]",1539.0,22810967,6
A novel RT-PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis.,International journal of cancer,Int. J. Cancer,2012-09-07,"Oropharyngeal squamous cell carcinoma (SCC) is strongly associated with human papillomavirus (HPV) infection, which is distinctively different from most other head and neck cancers. However, a robust quantitative reverse transcription PCR (RT-qPCR) method for comprehensive expression profiling of HPV genes in routinely fixed tissues has not been reported. To address this issue, we have established a new real-time RT-PCR method for the expression profiling of the E6 and E7 oncogenes from 13 high-risk HPV types. This method was validated in cervical cancer and by comparison with another HPV RNA detection method (in situ hybridization) in oropharyngeal tumors. In addition, the expression profiles of selected HPV-related human genes were also analyzed. HPV E6 and E7 expression profiles were then analyzed in 150 archived oropharyngeal SCC samples and compared with other variables and with patient outcomes. Our study showed that RT-qPCR and RNA in situ hybridization were 100% concordant in determining HPV status. HPV transcriptional activity was found in most oropharyngeal SCC (81.3%), a prevalence that is higher than in previous studies. Besides HPV16, three other HPV types were also detected, including 33, 35 and 18. Furthermore, HPV and p16 had essentially identical expression signatures, and both HPV and p16 were prognostic biomarkers for the prediction of disease outcome. Thus, p16 mRNA or protein expression signature is a sensitive and specific surrogate marker for HPV transcriptional activity (all genotypes combined).",Journal Article,2692.0,56.0,squamous cell carcinoma SCC is strongly associated with human papillomavirus HPV infection which is distinctively different from most other head and cancers However a robust quantitative reverse transcription PCR RT-qPCR method for comprehensive expression profiling of HPV genes in routinely fixed tissues has not been reported To address this issue we have established a new real-time RT-PCR method for the expression profiling of the E6 and E7 oncogenes from 13 high-risk HPV types This method was validated in cancer and by comparison with another HPV RNA detection method in situ hybridization in tumors In addition the expression profiles of selected HPV-related human genes were also analyzed HPV E6 and E7 expression profiles were then analyzed in 150 archived SCC samples and compared with other variables and with patient outcomes Our study showed that RT-qPCR and RNA in situ hybridization were 100 concordant in determining HPV status HPV transcriptional activity was found in most SCC 81.3 a prevalence that is higher than in previous studies Besides HPV16 three other HPV types were also detected including 33 35 and 18 Furthermore HPV and p16 had essentially identical expression signatures and both HPV and p16 were prognostic biomarkers for the prediction of disease outcome Thus p16 mRNA or protein expression signature is a sensitive and specific surrogate marker for HPV transcriptional activity all genotypes combined,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[691, 31, 134, 1791, 16, 1327, 41, 5, 171, 3242, 933, 930, 92, 16, 26680, 338, 29, 96, 127, 718, 2, 163, 137, 8, 1922, 1156, 1772, 866, 604, 240, 6162, 596, 9, 949, 55, 1080, 1, 933, 214, 4, 3066, 1959, 742, 71, 44, 85, 210, 6, 1539, 26, 2537, 21, 47, 635, 8, 217, 1589, 98, 240, 604, 596, 9, 3, 55, 1080, 1, 3, 4837, 2, 4540, 3326, 29, 233, 64, 43, 933, 630, 26, 596, 10, 938, 4, 12, 2, 20, 1155, 5, 1809, 933, 893, 638, 596, 4, 957, 1554, 4, 57, 4, 352, 3, 55, 1241, 1, 715, 933, 139, 171, 214, 11, 120, 311, 933, 4837, 2, 4540, 55, 1241, 11, 818, 311, 4, 1577, 6282, 1791, 347, 2, 72, 5, 127, 682, 2, 5, 69, 123, 114, 45, 224, 17, 240, 6162, 2, 893, 4, 957, 1554, 11, 394, 3610, 4, 2196, 933, 156, 933, 1431, 128, 10, 204, 4, 96, 1791, 865, 27, 8, 1078, 17, 16, 142, 76, 4, 698, 94, 7301, 4048, 169, 127, 933, 630, 11, 120, 530, 141, 466, 465, 2, 203, 798, 933, 2, 1932, 42, 7257, 3038, 55, 2210, 2, 110, 933, 2, 1932, 11, 177, 582, 9, 3, 1590, 1, 34, 228, 631, 1932, 956, 15, 178, 55, 1651, 16, 8, 745, 2, 112, 2592, 952, 9, 933, 1431, 128, 62, 2071, 397]",1438.0,22821242,49
Utility of conization with frozen section for intraoperative triage prior to definitive hysterectomy.,Gynecologic oncology,Gynecol. Oncol.,2012-07-26,"To review our experience with conization with intraoperative frozen section analysis and to compare results from our tertiary cancer center with those from 2 community hospitals. The records of all women who underwent conization with intraoperative frozen section analysis from January 1, 1997, through April 30, 2011, at The University of Texas MD Anderson Cancer Center and 2 community hospitals-The Woman's Hospital of Texas and St. Luke's Episcopal Hospital-were reviewed. Findings on pathologic analysis of frozen sections, permanent loop electrosurgical excisional procedure/conization specimens, and hysterectomy specimens were compared for each patient, and the results from the cancer center were compared to those from the community hospitals. One hundred fifty-three patients met the inclusion criteria. Rates of accuracy of conization with frozen section analysis in predicting definitive pathologic findings were as follows: cervix with no residual disease after prior extirpative procedure, 96.5% (95% CI 86.9-100%); cervical squamous carcinoma in situ, 95.4% (95% CI 84.5-100%); cervical adenocarcinoma in situ, 98.7% (95% CI 92.7-100%); microinvasive carcinoma, 97.4% (95% CI 90.1-100%); and invasive carcinoma3 mm, 100%. Most importantly, conization with frozen section analysis was 100% accurate for triaging patients to simple or radical hysterectomy. Finally, this approach performed equally well in the cancer center with subspecialized pathologists and the 2 community hospitals with general pathologists. Conization with frozen section analysis is an effective technique for intraoperative triage of patients to immediate simple or radical hysterectomy and can be accurately performed in both academic and community hospitals.",Comparative Study,2735.0,1.0,To review our experience with conization with intraoperative frozen section analysis and to compare results from our tertiary cancer center with those from 2 community hospitals The records of all women who underwent conization with intraoperative frozen section analysis from January 1 1997 through April 30 2011 at The University of Texas MD Anderson Cancer Center and 2 community hospitals-The Woman 's Hospital of Texas and St. Luke 's Episcopal Hospital-were reviewed Findings on pathologic analysis of frozen sections permanent loop electrosurgical excisional procedure/conization specimens and hysterectomy specimens were compared for each patient and the results from the cancer center were compared to those from the community hospitals One hundred fifty-three patients met the inclusion criteria Rates of accuracy of conization with frozen section analysis in predicting definitive pathologic findings were as follows cervix with no residual disease after prior extirpative procedure 96.5 95 CI 86.9-100 squamous carcinoma in situ 95.4 95 CI 84.5-100 adenocarcinoma in situ 98.7 95 CI 92.7-100 microinvasive carcinoma 97.4 95 CI 90.1-100 and invasive carcinoma3 mm 100 Most importantly conization with frozen section analysis was 100 accurate for triaging patients to simple or radical hysterectomy Finally this approach performed equally well in the cancer center with subspecialized pathologists and the 2 community hospitals with general pathologists Conization with frozen section analysis is an effective technique for intraoperative triage of patients to immediate simple or radical hysterectomy and can be accurately performed in both academic and community hospitals,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 206, 114, 730, 5, 8755, 5, 1720, 3015, 2917, 65, 2, 6, 932, 99, 29, 114, 2557, 12, 574, 5, 135, 29, 18, 1714, 1987, 3, 1064, 1, 62, 117, 54, 208, 8755, 5, 1720, 3015, 2917, 65, 29, 1024, 14, 2341, 298, 2292, 201, 1132, 28, 3, 1652, 1, 2738, 2244, 1929, 12, 574, 2, 18, 1714, 1987, 3, 2854, 292, 702, 1, 2738, 2, 3062, 40061, 292, 61712, 702, 11, 446, 272, 23, 510, 65, 1, 3015, 3013, 4377, 4432, 24548, 6488, 1299, 8755, 623, 2, 2622, 623, 11, 72, 9, 296, 69, 2, 3, 99, 29, 3, 12, 574, 11, 72, 6, 135, 29, 3, 1714, 1987, 104, 1128, 1461, 169, 7, 543, 3, 1680, 371, 151, 1, 1190, 1, 8755, 5, 3015, 2917, 65, 4, 1434, 1057, 510, 272, 11, 22, 2962, 3629, 5, 77, 753, 34, 50, 324, 13349, 1299, 921, 33, 48, 58, 868, 83, 394, 691, 134, 4, 957, 48, 39, 48, 58, 874, 33, 394, 449, 4, 957, 1096, 67, 48, 58, 937, 67, 394, 16477, 134, 1015, 39, 48, 58, 424, 14, 394, 2, 416, 61713, 321, 394, 96, 1859, 8755, 5, 3015, 2917, 65, 10, 394, 1481, 9, 22450, 7, 6, 2763, 15, 711, 2622, 1368, 26, 353, 173, 4142, 149, 4, 3, 12, 574, 5, 47314, 3354, 2, 3, 18, 1714, 1987, 5, 1083, 3354, 8755, 5, 3015, 2917, 65, 16, 35, 323, 1312, 9, 1720, 9059, 1, 7, 6, 2181, 2763, 15, 711, 2622, 2, 122, 40, 2141, 173, 4, 110, 1916, 2, 1714, 1987]",1685.0,22842126,724
Tubal ligation frequency in Oklahoma women with cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2012-07-31,"Infrequent Pap screening is an important risk factor for cervical cancer. We studied the association between contraceptive methods, screening frequency, and cancer. Women (n=2004) enrolled in the cross-sectional Study to Understand Cervical Cancer Endpoints and Determinants (SUCCEED) underwent colposcopy to evaluate an abnormal Pap test. Questionnaire data were compared between those with cervical intraepithelial neoplasia (CIN) 3/adenocarcinoma in situ (AIS) and those with invasive cancer to identify factors associated with cancer. Logistic regression was used to calculate age-stratified measures of association between contraceptive method and Pap frequency as well as tubal ligation (TL) and cancer risk. In all age groups, women with TL were more likely to have had no Pap screening in the previous 5 years compared to women using other contraception: 26-35 years (OR 4.6, 95% CI 2.4-8.6; p<0.001), 36-45 years (OR 3.8, 95% CI 2.1-7.0; p<0.001), and 46-55 years (OR 2.2, 95% CI 1.0-4.9; p=0.050). Subjects with cancer (n=163) were more likely to have had a TL (41% vs. 21%, p<0.001) than those with CIN 3/AIS (n=370). Age-stratified analyses showed increased odds of tubal ligation in women with cancer versus those with CIN 3/AIS between 25 and 45 years, with a significant increase in women 26 to 35 years old (OR 3.3, 95% CI 1.4-8.1; p=0.009). Adjusting for Pap frequency changed the effect only slightly, suggesting that increased risk was not fully mediated by lack of screening. Contraceptive type is associated with Pap screening. Women with TLs obtain less frequent Pap testing and may be at an increased risk for cervical cancer.",Journal Article,2730.0,4.0,Infrequent Pap screening is an important risk factor for cancer We studied the association between contraceptive methods screening frequency and cancer Women n=2004 enrolled in the cross-sectional Study to Understand Cancer Endpoints and Determinants SUCCEED underwent colposcopy to evaluate an abnormal Pap test Questionnaire data were compared between those with intraepithelial neoplasia CIN 3/adenocarcinoma in situ AIS and those with invasive cancer to identify factors associated with cancer Logistic regression was used to calculate age-stratified measures of association between contraceptive method and Pap frequency as well as tubal ligation TL and cancer risk In all age groups women with TL were more likely to have had no Pap screening in the previous 5 years compared to women using other contraception 26-35 years OR 4.6 95 CI 2.4-8.6 p 0.001 36-45 years OR 3.8 95 CI 2.1-7.0 p 0.001 and 46-55 years OR 2.2 95 CI 1.0-4.9 p=0.050 Subjects with cancer n=163 were more likely to have had a TL 41 vs. 21 p 0.001 than those with CIN 3/AIS n=370 Age-stratified analyses showed increased odds of tubal ligation in women with cancer versus those with CIN 3/AIS between 25 and 45 years with a significant increase in women 26 to 35 years old OR 3.3 95 CI 1.4-8.1 p=0.009 Adjusting for Pap frequency changed the effect only slightly suggesting that increased risk was not fully mediated by lack of screening Contraceptive type is associated with Pap screening Women with TLs obtain less frequent Pap testing and may be at an increased risk for cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4475, 4290, 453, 16, 35, 305, 43, 161, 9, 12, 21, 656, 3, 248, 59, 6780, 636, 453, 675, 2, 12, 117, 78, 1131, 346, 4, 3, 1383, 2832, 45, 6, 1640, 12, 1387, 2, 3403, 15141, 208, 9946, 6, 376, 35, 1668, 4290, 412, 1770, 74, 11, 72, 59, 135, 5, 4153, 2298, 4652, 27, 449, 4, 957, 3826, 2, 135, 5, 416, 12, 6, 255, 130, 41, 5, 12, 812, 320, 10, 95, 6, 3232, 89, 1173, 1018, 1, 248, 59, 6780, 596, 2, 4290, 675, 22, 149, 22, 6674, 5307, 6828, 2, 12, 43, 4, 62, 89, 271, 117, 5, 6828, 11, 80, 322, 6, 47, 42, 77, 4290, 453, 4, 3, 698, 33, 60, 72, 6, 117, 75, 127, 21441, 432, 465, 60, 15, 39, 49, 48, 58, 18, 39, 66, 49, 19, 13, 144, 511, 512, 60, 15, 27, 66, 48, 58, 18, 14, 67, 13, 19, 13, 144, 2, 641, 614, 60, 15, 18, 18, 48, 58, 14, 13, 39, 83, 19, 13, 10801, 976, 5, 12, 78, 5409, 11, 80, 322, 6, 47, 42, 8, 6828, 605, 105, 239, 19, 13, 144, 76, 135, 5, 4652, 27, 3826, 78, 8156, 89, 1173, 318, 224, 101, 610, 1, 6674, 5307, 4, 117, 5, 12, 185, 135, 5, 4652, 27, 3826, 59, 243, 2, 512, 60, 5, 8, 93, 344, 4, 117, 432, 6, 465, 60, 1095, 15, 27, 27, 48, 58, 14, 39, 66, 14, 19, 13, 2376, 1358, 9, 4290, 675, 2368, 3, 254, 158, 3223, 802, 17, 101, 43, 10, 44, 1910, 517, 20, 926, 1, 453, 6780, 267, 16, 41, 5, 4290, 453, 117, 5, 8778, 3140, 299, 908, 4290, 471, 2, 68, 40, 28, 35, 101, 43, 9, 12]",1555.0,22858904,692
Treatment of metastatic cervical cancer: future directions involving targeted agents.,Critical reviews in oncology/hematology,Crit. Rev. Oncol. Hematol.,2012-08-09,"Cervical cancer is the third most common cause of female cancer mortality, and it remains a major health problem in populations with limited economic resources. Metastatic disease or recurrent lesions not amenable to radical local excision or regional radiation have a poor prognosis, and are treated with palliative platinum-based chemotherapy. There are few effective therapeutic options for patients who progressed after first-line chemotherapy. Future advances in the treatment of metastatic or recurrent disease may rely on more effective and better-tolerated therapies, and molecularly driven targeted agents could represent an attractive option. Inhibition of tumor angiogenesis and epidermal growth factor receptor directed therapies have focused the most recent clinical research efforts. A thorough molecular characterization of cervical cancer remains crucial for a rationale implementation of targeted agents and companion biomarkers. Alternative clinical trial designs may also be necessary to optimize the clinical development of new drugs for metastatic cervical cancer.",Journal Article,2721.0,44.0,cancer is the third most common cause of female cancer mortality and it remains a major health problem in populations with limited economic resources Metastatic disease or recurrent lesions not amenable to radical local excision or regional radiation have a poor prognosis and are treated with palliative platinum-based chemotherapy There are few effective therapeutic options for patients who progressed after first-line chemotherapy Future advances in the treatment of metastatic or recurrent disease may rely on more effective and better-tolerated therapies and molecularly driven targeted agents could represent an attractive option Inhibition of tumor angiogenesis and epidermal growth factor receptor directed therapies have focused the most recent clinical research efforts A thorough molecular characterization of cancer remains crucial for a rationale implementation of targeted agents and companion biomarkers Alternative clinical trial designs may also be necessary to optimize the clinical development of new drugs for metastatic cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 3, 1282, 96, 186, 708, 1, 1061, 12, 282, 2, 192, 469, 8, 458, 341, 2497, 4, 1184, 5, 383, 3875, 2892, 113, 34, 15, 387, 406, 44, 4070, 6, 711, 293, 1366, 15, 951, 121, 47, 8, 334, 356, 2, 32, 73, 5, 994, 828, 90, 56, 125, 32, 1021, 323, 189, 838, 9, 7, 54, 1839, 50, 157, 328, 56, 508, 954, 4, 3, 24, 1, 113, 15, 387, 34, 68, 5533, 23, 80, 323, 2, 380, 421, 235, 2, 2372, 1621, 238, 183, 359, 1231, 35, 3059, 1501, 297, 1, 30, 1056, 2, 829, 129, 161, 153, 1166, 235, 47, 1649, 3, 96, 435, 38, 389, 1413, 8, 5506, 219, 2136, 1, 12, 469, 2653, 9, 8, 1728, 2393, 1, 238, 183, 2, 6639, 582, 1091, 38, 160, 4120, 68, 120, 40, 1493, 6, 2465, 3, 38, 193, 1, 217, 600, 9, 113, 12]",1048.0,22883215,613
Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: an inter-era analysis.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2012-08-14,"To compare rates of severe late toxicities following concomitant chemoradiotherapy and radiotherapy alone for cervical cancer. Patients with cervical cancer were treated at a single institution with radiotherapy alone or concomitant chemoradiotherapy for curative intent. Severe late toxicity was defined as grade3 vaginal, urologic, or gastrointestinal toxicity or any pelvic fracture, using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE), occurring 6 months from treatment completion and predating any salvage therapy. Severe late toxicity rates were compared after adjusting for pertinent covariates. At 3 years, probability of vaginal severe late toxicity was 20.2% for radiotherapy alone and 35.1% for concomitant chemoradiotherapy (P=.026). At 3 years, probability of skeletal severe late toxicity was 1.6% for radiotherapy alone and 7.5% for concomitant chemoradiotherapy (P=.010). After adjustment for case mix, concomitant chemoradiotherapy was associated with higher vaginal (hazard ratio [HR] 3.0, 95% confidence interval [CI], 1.7-5.2, P<.001), and skeletal (HR 7.0, 95% CI 1.4-34.1, P=.016) severe late toxicity. Compared to high dilator compliance, moderate (HR 3.6, 95% CI 2.0-6.5, P<.001) and poor (HR 8.5, 95% CI 4.3-16.9, P<.001) dilator compliance was associated with higher vaginal severe late toxicity. Age>50 was associated with higher vaginal (HR 1.8, 95% CI 1.1-3.0, P=.013) and skeletal (HR 5.7, 95% CI 1.2-27.0, P=.028) severe late toxicity. Concomitant chemoradiotherapy was not associated with higher gastrointestinal (P=.886) or urologic (unadjusted, P=.053; adjusted, P=.063) severe late toxicity. Compared to radiotherapy alone, concomitant chemoradiotherapy is associated with higher rates of severe vaginal and skeletal late toxicities. Other predictive factors include dilator compliance for severe vaginal late toxicity and age for severe vaginal and skeletal late toxicities.",Comparative Study,2716.0,58.0,To compare rates of severe late toxicities following concomitant chemoradiotherapy and radiotherapy alone for cancer Patients with cancer were treated at a single institution with radiotherapy alone or concomitant chemoradiotherapy for curative intent Severe late toxicity was defined as grade3 urologic or toxicity or any pelvic fracture using Common Terminology Criteria for Adverse Events version 4.0 CTCAE occurring 6 months from treatment completion and predating any salvage therapy Severe late toxicity rates were compared after adjusting for pertinent covariates At 3 years probability of severe late toxicity was 20.2 for radiotherapy alone and 35.1 for concomitant chemoradiotherapy P=.026 At 3 years probability of skeletal severe late toxicity was 1.6 for radiotherapy alone and 7.5 for concomitant chemoradiotherapy P=.010 After adjustment for case mix concomitant chemoradiotherapy was associated with higher hazard ratio HR 3.0 95 confidence interval CI 1.7-5.2 P .001 and skeletal HR 7.0 95 CI 1.4-34.1 P=.016 severe late toxicity Compared to high dilator compliance moderate HR 3.6 95 CI 2.0-6.5 P .001 and poor HR 8.5 95 CI 4.3-16.9 P .001 dilator compliance was associated with higher severe late toxicity Age 50 was associated with higher HR 1.8 95 CI 1.1-3.0 P=.013 and skeletal HR 5.7 95 CI 1.2-27.0 P=.028 severe late toxicity Concomitant chemoradiotherapy was not associated with higher P=.886 or urologic unadjusted P=.053 adjusted P=.063 severe late toxicity Compared to radiotherapy alone concomitant chemoradiotherapy is associated with higher rates of severe and skeletal late toxicities Other predictive factors include dilator compliance for severe late toxicity and age for severe and skeletal late toxicities,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 932, 151, 1, 905, 807, 385, 366, 1781, 1464, 2, 310, 279, 9, 12, 7, 5, 12, 11, 73, 28, 8, 226, 731, 5, 310, 279, 15, 1781, 1464, 9, 1075, 1697, 905, 807, 155, 10, 395, 22, 14659, 7178, 15, 155, 15, 500, 1110, 3956, 75, 186, 3462, 371, 9, 290, 281, 2256, 39, 13, 3898, 1821, 6258, 53, 29, 24, 1438, 2, 29135, 500, 992, 36, 905, 807, 155, 151, 11, 72, 50, 1358, 9, 5799, 2489, 28, 27, 60, 1320, 1, 905, 807, 155, 10, 179, 18, 9, 310, 279, 2, 465, 14, 9, 1781, 1464, 19, 4554, 28, 27, 60, 1320, 1, 2621, 905, 807, 155, 10, 14, 49, 9, 310, 279, 2, 67, 33, 9, 1781, 1464, 19, 4873, 50, 1852, 9, 473, 8842, 1781, 1464, 10, 41, 5, 142, 360, 197, 168, 27, 13, 48, 307, 268, 58, 14, 67, 33, 18, 19, 144, 2, 2621, 168, 67, 13, 48, 58, 14, 39, 562, 14, 19, 3820, 905, 807, 155, 72, 6, 64, 17967, 3336, 1163, 168, 27, 49, 48, 58, 18, 13, 49, 33, 19, 144, 2, 334, 168, 66, 33, 48, 58, 39, 27, 245, 83, 19, 144, 17967, 3336, 10, 41, 5, 142, 905, 807, 155, 89, 212, 10, 41, 5, 142, 168, 14, 66, 48, 58, 14, 14, 27, 13, 19, 3612, 2, 2621, 168, 33, 67, 48, 58, 14, 18, 428, 13, 19, 4836, 905, 807, 155, 1781, 1464, 10, 44, 41, 5, 142, 19, 14577, 15, 7178, 4487, 19, 9948, 586, 19, 10592, 905, 807, 155, 72, 6, 310, 279, 1781, 1464, 16, 41, 5, 142, 151, 1, 905, 2, 2621, 807, 385, 127, 464, 130, 643, 17967, 3336, 9, 905, 807, 155, 2, 89, 9, 905, 2, 2621, 807, 385]",1743.0,22898381,234
"""Triple injection"" lymphatic mapping technique to determine if parametrial nodes are the true sentinel lymph nodes in women with cervical cancer.",Gynecologic oncology,Gynecol. Oncol.,2012-08-19,"Lymphatic mapping studies in women with cervical cancer typically identify sentinel nodes (SLNs) in the pelvis and not the parametrium. We added India ink as a mapping agent to determine whether this would allow us to pathologically identify sentinel parametrial nodes and to test our hypothesis that the parametrial nodes are the true SLNs in women with cervical cancer. We performed lymphatic mapping and SLN biopsy in 20 women with early-stage cervical cancer undergoing radical hysterectomy or trachelectomy using a ""triple injection"" technique with blue dye, radiocolloid, and India ink. Pathologic processing of parametrium and nodal tissue was then performed to identify India ink in specimens. On pathology review, 15 (75%) patients had a parametrial node identified, and 9 patients (45%) had bilateral parametrial nodes identified; the median number of parametrial nodes identified was 2 (range, 0-7). India ink was seen in at least 1 parametrial node in 13 (87%) of the 15 patients with a parametrial node identified pathologically. Of the 9 patients with bilateral parametrial nodes identified pathologically, only 5 (54%) had bilateral parametrial nodes containing India ink. India ink was found in 26 (44%) of 59 SLNs and only 1 (0.3%) of 289 non-SLNs. In 5 patients, India ink was seen in a SLN on the same side of the pelvis where a parametrial node was identified but not microscopically black. There appears to be direct drainage of cervical lesions to pelvic nodal basins bypassing small parametrial nodes. Parametrial nodes, therefore, may not always be the SLNs in women with cervical cancer.",Journal Article,2711.0,9.0,Lymphatic mapping studies in women with cancer typically identify sentinel nodes SLNs in the pelvis and not the parametrium We added India ink as a mapping agent to determine whether this would allow us to pathologically identify sentinel parametrial nodes and to test our hypothesis that the parametrial nodes are the true SLNs in women with cancer We performed lymphatic mapping and SLN biopsy in 20 women with early-stage cancer undergoing radical hysterectomy or trachelectomy using a `` triple injection '' technique with blue dye radiocolloid and India ink Pathologic processing of parametrium and nodal tissue was then performed to identify India ink in specimens On pathology review 15 75 patients had a parametrial node identified and 9 patients 45 had bilateral parametrial nodes identified the median number of parametrial nodes identified was 2 range 0-7 India ink was seen in at least 1 parametrial node in 13 87 of the 15 patients with a parametrial node identified pathologically Of the 9 patients with bilateral parametrial nodes identified pathologically only 5 54 had bilateral parametrial nodes containing India ink India ink was found in 26 44 of 59 SLNs and only 1 0.3 of 289 non-SLNs In 5 patients India ink was seen in a SLN on the same side of the pelvis where a parametrial node was identified but not microscopically black There appears to be direct drainage of lesions to pelvic nodal basins bypassing small parametrial nodes Parametrial nodes therefore may not always be the SLNs in women with cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2936, 2568, 94, 4, 117, 5, 12, 1969, 255, 1323, 502, 2642, 4, 3, 3270, 2, 44, 3, 30751, 21, 1953, 7776, 8054, 22, 8, 2568, 420, 6, 223, 317, 26, 688, 1700, 843, 6, 2998, 255, 1323, 8726, 502, 2, 6, 412, 114, 1492, 17, 3, 8726, 502, 32, 3, 2501, 2642, 4, 117, 5, 12, 21, 173, 2936, 2568, 2, 1099, 411, 4, 179, 117, 5, 191, 82, 12, 479, 711, 2622, 15, 5760, 75, 8, 1500, 1754, 522, 1312, 5, 3352, 3796, 11921, 2, 7776, 8054, 510, 3325, 1, 30751, 2, 779, 246, 10, 818, 173, 6, 255, 7776, 8054, 4, 623, 23, 1117, 206, 167, 481, 7, 42, 8, 8726, 289, 108, 2, 83, 7, 512, 42, 1607, 8726, 502, 108, 3, 52, 207, 1, 8726, 502, 108, 10, 18, 184, 13, 67, 7776, 8054, 10, 527, 4, 28, 506, 14, 8726, 289, 4, 233, 912, 1, 3, 167, 7, 5, 8, 8726, 289, 108, 2998, 1, 3, 83, 7, 5, 1607, 8726, 502, 108, 2998, 158, 33, 667, 42, 1607, 8726, 502, 1101, 7776, 8054, 7776, 8054, 10, 204, 4, 432, 584, 1, 728, 2642, 2, 158, 14, 13, 27, 1, 9080, 220, 2642, 4, 33, 7, 7776, 8054, 10, 527, 4, 8, 1099, 23, 3, 827, 1152, 1, 3, 3270, 1257, 8, 8726, 289, 10, 108, 84, 44, 7187, 1445, 125, 1233, 6, 40, 1196, 3528, 1, 406, 6, 1110, 779, 7847, 16301, 302, 8726, 502, 8726, 502, 673, 68, 44, 3763, 40, 3, 2642, 4, 117, 5, 12]",1528.0,22910691,20
A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study.,Gynecologic oncology,Gynecol. Oncol.,2012-09-07,"Epithelial growth factor receptor over-expression correlates with poor outcomes in cervical cancer. This study assessed the safety of chemoradiation with cetuximab in the treatment of women with newly diagnosed locally advanced cervical cancer. Patients received weekly cisplatin 30 and 40 mg/m(2) [dose level (DL) 1 and 2] and cetuximab 400mg/m(2) loading dose and then 250 mg/m(2) for a total of six weeks with radiotherapy (RT). Patients with nodal metastases received extended field radiation therapy (EFRT). At the maximum tolerated dose, feasibility was evaluated in a 20 patient two-stage, sequential design. In patients receiving pelvic RT, seven were treated at DL 1 with one dose-limiting toxicity (DLT) (febrile neutropenia with grade 3 diarrhea) and three at DL 2 with two DLTs (grade 3 rash and delay in RT >8 weeks). The feasibility phase was opened at DL1. Of the 21 patients treated there was one DLT (grade 4 CVA). Median RT duration was 50 days (range, 42-70). In patients receiving EFRT, nine were treated at DL 1 with 1 DLT (grade 3 mucositis) and 24 in the feasibility phase with eight DLTs [delay in RT >8 weeks due to toxicity (2) and one each with grade 3 or 4 small bowel obstruction, embolism, mucositis, mucositis with hypokalemia, pain with headache, and platelets with mucositis and headache]. Median EFRT duration was 56 days (range, 36-74). For patients receiving pelvic RT, cisplatin and cetuximab were feasible. For patients receiving EFRT, combination of cisplatin and cetuximab was not feasible.","Clinical Trial, Phase I",2692.0,27.0,Epithelial growth factor receptor over-expression correlates with poor outcomes in cancer This study assessed the safety of chemoradiation with cetuximab in the treatment of women with newly diagnosed locally advanced cancer Patients received weekly cisplatin 30 and 40 mg/m 2 dose level DL 1 and 2 and cetuximab 400mg/m 2 loading dose and then 250 mg/m 2 for a total of six weeks with radiotherapy RT Patients with nodal metastases received extended field radiation therapy EFRT At the maximum tolerated dose feasibility was evaluated in a 20 patient two-stage sequential design In patients receiving pelvic RT seven were treated at DL 1 with one dose-limiting toxicity DLT febrile neutropenia with grade 3 diarrhea and three at DL 2 with two DLTs grade 3 rash and delay in RT 8 weeks The feasibility phase was opened at DL1 Of the 21 patients treated there was one DLT grade 4 CVA Median RT duration was 50 days range 42-70 In patients receiving EFRT nine were treated at DL 1 with 1 DLT grade 3 mucositis and 24 in the feasibility phase with eight DLTs delay in RT 8 weeks due to toxicity 2 and one each with grade 3 or 4 small bowel obstruction embolism mucositis mucositis with hypokalemia pain with headache and platelets with mucositis and headache Median EFRT duration was 56 days range 36-74 For patients receiving pelvic RT cisplatin and cetuximab were feasible For patients receiving EFRT combination of cisplatin and cetuximab was not feasible,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[701, 129, 161, 153, 252, 55, 1871, 5, 334, 123, 4, 12, 26, 45, 275, 3, 367, 1, 975, 5, 1175, 4, 3, 24, 1, 117, 5, 732, 265, 795, 131, 12, 7, 103, 709, 540, 201, 2, 327, 81, 188, 18, 61, 301, 1826, 14, 2, 18, 2, 1175, 14632, 188, 18, 4717, 61, 2, 818, 2039, 81, 188, 18, 9, 8, 181, 1, 437, 244, 5, 310, 240, 7, 5, 779, 196, 103, 1747, 1067, 121, 36, 24685, 28, 3, 689, 421, 61, 1437, 10, 194, 4, 8, 179, 69, 100, 82, 1787, 771, 4, 7, 357, 1110, 240, 648, 11, 73, 28, 1826, 14, 5, 104, 61, 817, 155, 2059, 2498, 778, 5, 88, 27, 1172, 2, 169, 28, 1826, 18, 5, 100, 2506, 88, 27, 1641, 2, 1984, 4, 240, 66, 244, 3, 1437, 124, 10, 8543, 28, 13436, 1, 3, 239, 7, 73, 125, 10, 104, 2059, 88, 39, 30920, 52, 240, 654, 10, 212, 162, 184, 595, 431, 4, 7, 357, 24685, 762, 11, 73, 28, 1826, 14, 5, 14, 2059, 88, 27, 2606, 2, 259, 4, 3, 1437, 124, 5, 659, 2506, 1984, 4, 240, 66, 244, 520, 6, 155, 18, 2, 104, 296, 5, 88, 27, 15, 39, 302, 1659, 3191, 5475, 2606, 2606, 5, 7799, 559, 5, 4538, 2, 4407, 5, 2606, 2, 4538, 52, 24685, 654, 10, 664, 162, 184, 511, 794, 9, 7, 357, 1110, 240, 540, 2, 1175, 11, 1313, 9, 7, 357, 24685, 150, 1, 540, 2, 1175, 10, 44, 1313]",1455.0,22960004,373
Parameningeal rhabdomyosarcoma: outcomes and opportunities.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2012-09-25,"To examine patterns of failure in patients with parameningeal rhabdomyosarcoma (PM-RMS) treated with intensity modulated radiation therapy (IMRT). Forty-seven patients with PM-RMS received chemotherapy and IMRT for definitive treatment. The median age was 9 years (range, 0.5-35 years). The high-risk features were as follows: 40% alveolar histology, 72% group III and 26% group IV disease, 57% either intracranial extension (ICE) (n=25) or cranial neuropathy (n=21). The median time to RT from the start of chemotherapy was 15 weeks (range, 2-54 weeks). Patients received 50.4 Gy in 1.8-Gy fractions to the primary tumor by use of IMRT. Thirteen patients aged14 years with alveolar histology received 36 Gy prophylactic nodal irradiation (PNI) to bilateral cervical nodes. Events were defined as local, regional (nodal), central nervous system (CNS), or distant failures. With a median follow-up time of 3.3 years (range, 0.5-12.8 years), 18 patients experienced failure: 5 local, 2 regional, 6 distant, and 7 CNS. The 5-year local failure-free survival was 86%. Age, histology, and time to RT did not influence the risk of local failure. The 5-year regional failure-free survival was 92%: 100% for embryonal and 74% for alveolar (P=.03). However, there were no lymph node failures in patients with alveolar histology who were given PNI. The 5-year CNS failure-free survival was 83%: 100% without and 70% with ICE (P=.01); 95% without and 69% with cranial neuropathy (P=.02). The estimated 5-year event-free survival and overall survival were 61% for group III and 58% for group IV patients. Distant failure was the most common type of failure among group IV patients. Patients with alveolar histology seem to benefit from PNI. The presence of ICE or cranial neuropathy portends a high risk of CNS failure, the most common pattern of failure among non-group IV patients. These patients may benefit from the addition of novel CNS-directed therapy.",Journal Article,2674.0,17.0,To examine patterns of failure in patients with parameningeal PM-RMS treated with intensity modulated radiation therapy IMRT Forty-seven patients with PM-RMS received chemotherapy and IMRT for definitive treatment The median age was 9 years range 0.5-35 years The high-risk features were as follows 40 alveolar histology 72 group III and 26 group IV disease 57 either intracranial extension ICE n=25 or cranial neuropathy n=21 The median time to RT from the start of chemotherapy was 15 weeks range 2-54 weeks Patients received 50.4 Gy in 1.8-Gy fractions to the primary tumor by use of IMRT Thirteen patients aged14 years with alveolar histology received 36 Gy prophylactic nodal irradiation PNI to bilateral nodes Events were defined as local regional nodal central nervous system CNS or distant failures With a median follow-up time of 3.3 years range 0.5-12.8 years 18 patients experienced failure 5 local 2 regional 6 distant and 7 CNS The 5-year local failure-free survival was 86 Age histology and time to RT did not influence the risk of local failure The 5-year regional failure-free survival was 92 100 for embryonal and 74 for alveolar P=.03 However there were no lymph node failures in patients with alveolar histology who were given PNI The 5-year CNS failure-free survival was 83 100 without and 70 with ICE P=.01 95 without and 69 with cranial neuropathy P=.02 The estimated 5-year event-free survival and overall survival were 61 for group III and 58 for group IV patients Distant failure was the most common type of failure among group IV patients Patients with alveolar histology seem to benefit from PNI The presence of ICE or cranial neuropathy portends a high risk of CNS failure the most common pattern of failure among non-group IV patients These patients may benefit from the addition of novel CNS-directed therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1004, 764, 1, 496, 4, 7, 5, 14441, 3377, 3413, 73, 5, 837, 1757, 121, 36, 964, 1213, 648, 7, 5, 3377, 3413, 103, 56, 2, 964, 9, 1057, 24, 3, 52, 89, 10, 83, 60, 184, 13, 33, 465, 60, 3, 64, 43, 404, 11, 22, 2962, 327, 5641, 784, 720, 87, 316, 2, 432, 87, 478, 34, 696, 361, 2089, 2401, 5995, 78, 243, 15, 2565, 1751, 78, 239, 3, 52, 98, 6, 240, 29, 3, 2435, 1, 56, 10, 167, 244, 184, 18, 667, 244, 7, 103, 212, 39, 381, 4, 14, 66, 381, 1550, 6, 3, 86, 30, 20, 119, 1, 964, 3170, 7, 61927, 60, 5, 5641, 784, 103, 511, 381, 1862, 779, 1104, 5109, 6, 1607, 502, 281, 11, 395, 22, 293, 951, 779, 854, 1880, 398, 1025, 15, 626, 3368, 5, 8, 52, 166, 126, 98, 1, 27, 27, 60, 184, 13, 33, 133, 66, 60, 203, 7, 592, 496, 33, 293, 18, 951, 49, 626, 2, 67, 1025, 3, 33, 111, 293, 496, 115, 25, 10, 868, 89, 784, 2, 98, 6, 240, 205, 44, 1054, 3, 43, 1, 293, 496, 3, 33, 111, 951, 496, 115, 25, 10, 937, 394, 9, 5239, 2, 794, 9, 5641, 19, 680, 137, 125, 11, 77, 263, 289, 3368, 4, 7, 5, 5641, 784, 54, 11, 447, 5109, 3, 33, 111, 1025, 496, 115, 25, 10, 852, 394, 187, 2, 431, 5, 5995, 19, 355, 48, 187, 2, 790, 5, 2565, 1751, 19, 588, 3, 661, 33, 111, 774, 115, 25, 2, 63, 25, 11, 713, 9, 87, 316, 2, 717, 9, 87, 478, 7, 626, 496, 10, 3, 96, 186, 267, 1, 496, 107, 87, 478, 7, 7, 5, 5641, 784, 3233, 6, 247, 29, 5109, 3, 463, 1, 5995, 15, 2565, 1751, 8745, 8, 64, 43, 1, 1025, 496, 3, 96, 186, 1177, 1, 496, 107, 220, 87, 478, 7, 46, 7, 68, 247, 29, 3, 352, 1, 229, 1025, 1166, 36]",1839.0,23021437,704
The MBD4 Glu346Lys polymorphism is associated with the risk of cervical cancer in a Chinese population.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2012-11-01,"Methyl-CpG binding domain 4 (MBD4) protein functions as a DNA repair enzyme and plays an important role in maintaining genome integrity and carcinogenesis. The polymorphisms in the MBD4 gene may be associated with differences in DNA repair capacity and thereby influence an individual's susceptibility to cervical cancer. To verify this hypothesis, we examined the potential association between the MBD4 Glu346Lys polymorphism (rs140693, G>A) and the risk of cervical cancer in a Chinese population. We genotyped the MBD4 Glu346Lys polymorphism in 146 cervical cancer cases and 320 healthy female subjects using polymerase chain reaction-based restriction fragment length polymorphism method. Unconditional logistic regression analysis was used to estimate the association between the genotypes and the risk of cervical cancer. We observed a significantly decreased risk of cervical cancer associated with the heterozygous Lys/Glu genotype (odds ratio [OR], 0.60; 95% confidence interval [CI], 0.36-0.99; P = 0.046) and the homozygous Glu/Glu genotype (OR, 0.52; 95% CI, 0.30-0.89; P = 0.018), compared with the Lys/Lys homozygotes. Moreover, the reduced cervical cancer risk was more predominant among younger subjects or human papillomavirus-positive individuals carrying Glu/Glu genotypes (OR, 0.33; 95% CI, 0.14-0.78, P = 0.011; and OR, 0.27; 95% CI, 0.09-0.75, P = 0.013, respectively). The MBD4 codon 346 polymorphism may play a role in cervical cancer susceptibility in the Chinese population. Further larger case-control and functional studies are needed to validate these findings.",Journal Article,2637.0,9.0,Methyl-CpG binding domain 4 MBD4 protein functions as a DNA repair enzyme and plays an important role in maintaining genome integrity and carcinogenesis The polymorphisms in the MBD4 gene may be associated with differences in DNA repair capacity and thereby influence an individual 's susceptibility to cancer To verify this hypothesis we examined the potential association between the MBD4 Glu346Lys polymorphism rs140693 G A and the risk of cancer in a Chinese population We genotyped the MBD4 Glu346Lys polymorphism in 146 cancer cases and 320 healthy female subjects using polymerase chain reaction-based restriction fragment length polymorphism method Unconditional logistic regression analysis was used to estimate the association between the genotypes and the risk of cancer We observed a significantly decreased risk of cancer associated with the heterozygous Lys/Glu genotype odds ratio OR 0.60 95 confidence interval CI 0.36-0.99 P 0.046 and the homozygous Glu/Glu genotype OR 0.52 95 CI 0.30-0.89 P 0.018 compared with the Lys/Lys homozygotes Moreover the reduced cancer risk was more predominant among younger subjects or human papillomavirus-positive individuals carrying Glu/Glu genotypes OR 0.33 95 CI 0.14-0.78 P 0.011 and OR 0.27 95 CI 0.09-0.75 P 0.013 respectively The MBD4 codon 346 polymorphism may play a role in cancer susceptibility in the Chinese population Further larger case-control and functional studies are needed to validate these findings,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[5228, 2075, 791, 1398, 39, 26119, 178, 1681, 22, 8, 261, 972, 1644, 2, 1698, 35, 305, 200, 4, 3284, 898, 4797, 2, 1719, 3, 1203, 4, 3, 26119, 145, 68, 40, 41, 5, 362, 4, 261, 972, 2162, 2, 2267, 1054, 35, 797, 292, 1432, 6, 12, 6, 6355, 26, 1492, 21, 409, 3, 174, 248, 59, 3, 26119, 47422, 1907, 61937, 499, 8, 2, 3, 43, 1, 12, 4, 8, 3656, 266, 21, 3053, 3, 26119, 47422, 1907, 4, 4909, 12, 140, 2, 5904, 1331, 1061, 976, 75, 1451, 1260, 1329, 90, 4575, 5245, 1318, 1907, 596, 6438, 812, 320, 65, 10, 95, 6, 1191, 3, 248, 59, 3, 2071, 2, 3, 43, 1, 12, 21, 164, 8, 97, 340, 43, 1, 12, 41, 5, 3, 4167, 8288, 13496, 1183, 610, 197, 15, 13, 335, 48, 307, 268, 58, 13, 511, 13, 1058, 19, 13, 4902, 2, 3, 3189, 13496, 13496, 1183, 15, 13, 653, 48, 58, 13, 201, 13, 887, 19, 13, 4047, 72, 5, 3, 8288, 8288, 13067, 1393, 3, 405, 12, 43, 10, 80, 2750, 107, 773, 976, 15, 171, 3242, 109, 869, 2934, 13496, 13496, 2071, 15, 13, 466, 48, 58, 13, 213, 13, 833, 19, 13, 3651, 2, 15, 13, 428, 48, 58, 13, 1730, 13, 481, 19, 13, 3612, 106, 3, 26119, 3673, 9184, 1907, 68, 1343, 8, 200, 4, 12, 1432, 4, 3, 3656, 266, 195, 1077, 473, 182, 2, 583, 94, 32, 575, 6, 2183, 46, 272]",1471.0,23027038,11
Analgesic and antiemetic requirements after minimally invasive surgery for early cervical cancer: a comparison between laparoscopy and robotic surgery.,Annals of surgical oncology,Ann. Surg. Oncol.,2012-10-05,"Women with early cervical cancer undergoing radical hysterectomy via minimally invasive surgery (MIS) have decreased blood loss and a shorter hospital stay compared with laparotomy. It remains unclear whether there is a difference in benefit to the patient between robotic surgery and traditional laparoscopy. We sought to compare postoperative analgesic and antiemetic requirements between the two approaches. After institutional review board approval, the medication administration records of all patients who underwent MIS radical hysterectomy for cervical cancer at MD Anderson Cancer Center were reviewed. Analgesic and antiemetic medication use as well as visual pain scores was recorded. Descriptive statistics and nonparametric tests were used to compare the groups undergoing laparoscopy (LRH) and robotic surgery (RRH). A total of 85 patients underwent MIS for early cervical cancer, 55 LRH and 30 RRH. Median age was older in the RRH (42 vs. 52years, p=0.001). There was no difference in median body mass index (26.9 vs. 26.8kg/m(2), p=0.71). Length of stay was significantly shorter in the RRH (2 vs. 1day, p=0.005). Total intravenous opioids administered were significantly higher in the LRH (26.7mg morphine equivalents) compared with the RRH (10.7mg morphine equivalents) (p=0.001). There was no difference in visual pain scores or antiemetics given. Intravenous opioids administered were significantly less for RRH compared to LRH; however, there was no difference in visual pain scores. Prospective studies are being performed to evaluate quality of life in patients undergoing MIS for gynecologic cancers.",Comparative Study,2664.0,28.0,Women with early cancer undergoing radical hysterectomy via minimally invasive surgery MIS have decreased blood loss and a shorter hospital stay compared with laparotomy It remains unclear whether there is a difference in benefit to the patient between robotic surgery and traditional laparoscopy We sought to compare postoperative analgesic and antiemetic requirements between the two approaches After institutional review board approval the medication administration records of all patients who underwent MIS radical hysterectomy for cancer at MD Anderson Cancer Center were reviewed Analgesic and antiemetic medication use as well as visual pain scores was recorded Descriptive statistics and nonparametric tests were used to compare the groups undergoing laparoscopy LRH and robotic surgery RRH A total of 85 patients underwent MIS for early cancer 55 LRH and 30 RRH Median age was older in the RRH 42 vs. 52 years p 0.001 There was no difference in median body mass index 26.9 vs. 26.8 kg/m 2 p 0.71 Length of stay was significantly shorter in the RRH 2 vs. 1 day p 0.005 Total intravenous opioids administered were significantly higher in the LRH 26.7 mg morphine equivalents compared with the RRH 10.7 mg morphine equivalents p 0.001 There was no difference in visual pain scores or antiemetics given Intravenous opioids administered were significantly less for RRH compared to LRH however there was no difference in visual pain scores Prospective studies are being performed to evaluate quality of life in patients undergoing MIS for gynecologic cancers,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[117, 5, 191, 12, 479, 711, 2622, 847, 2144, 416, 152, 4386, 47, 340, 315, 407, 2, 8, 985, 702, 2020, 72, 5, 3274, 192, 469, 1200, 317, 125, 16, 8, 523, 4, 247, 6, 3, 69, 59, 2895, 152, 2, 1847, 3553, 21, 990, 6, 932, 573, 5954, 2, 7367, 4230, 59, 3, 100, 611, 50, 1115, 206, 2620, 1814, 3, 3012, 634, 1064, 1, 62, 7, 54, 208, 4386, 711, 2622, 9, 12, 28, 2244, 1929, 12, 574, 11, 446, 5954, 2, 7367, 3012, 119, 22, 149, 22, 3046, 559, 703, 10, 1872, 3778, 3065, 2, 8310, 895, 11, 95, 6, 932, 3, 271, 479, 3553, 19053, 2, 2895, 152, 21738, 8, 181, 1, 772, 7, 208, 4386, 9, 191, 12, 614, 19053, 2, 201, 21738, 52, 89, 10, 434, 4, 3, 21738, 595, 105, 653, 60, 19, 13, 144, 125, 10, 77, 523, 4, 52, 642, 782, 558, 432, 83, 105, 432, 66, 503, 188, 18, 19, 13, 792, 1318, 1, 2020, 10, 97, 985, 4, 3, 21738, 18, 105, 14, 218, 19, 13, 1614, 181, 1262, 4353, 468, 11, 97, 142, 4, 3, 19053, 432, 67, 81, 5896, 13263, 72, 5, 3, 21738, 79, 67, 81, 5896, 13263, 19, 13, 144, 125, 10, 77, 523, 4, 3046, 559, 703, 15, 10962, 447, 1262, 4353, 468, 11, 97, 299, 9, 21738, 72, 6, 19053, 137, 125, 10, 77, 523, 4, 3046, 559, 703, 482, 94, 32, 486, 173, 6, 376, 372, 1, 358, 4, 7, 479, 4386, 9, 1512, 163]",1561.0,23054117,249
A modified Latent Class Model assessment of human papillomavirus-based screening tests for cervical lesions in women with atypical glandular cells: a Gynecologic Oncology Group study.,Cancer causes & control : CCC,Cancer Causes Control,2012-10-17,"In the absence of gold standard diagnoses, we estimate age-specific false-positive and false-negative prediction rates of HPV-, cytology-, and histology-based tests for significant cervical lesions (SCL) in US women with AGC-NOS Pap smear diagnoses. Modified Latent Class Model (LCM) analyses, with prevalence of SCL modeled as a function of age, were applied to GOG-0171 study data (n = 122). The accuracies of several HPV-based tests, including Hybrid Capture II high-risk HPV (HC2 H-HPV); carbonic anhydrase IX (CA-IX); and invasive histological diagnosis, were compared. 1-PPV and 1-NPV were written as functions of sensitivity, specificity, and prevalence to obtain age-specific false-positive and false-negative rates. The histology-based test was nearly perfect (sensitivity = 1.00, CI = 0.98-1.00; specificity = 0.99, CI = 0.96-1.00). Otherwise, HC2 H-HPV performed best (sensitivity = 1.00, CI = 1.00-1.00; specificity = 0.87, CI = 0.79-0.94). The false-positive detection rates (1-PPV) for HC2 H-HPV were high (>17 %) at each age, while those of the histological diagnoses were low (<5 % at ages 60 and <17 % overall ages). False-negative prediction rates (1-NPV) for HC2 H-HPV were <0.11 % at each age and were uniformly lower than those of other tests, including the histology-based test (<0.25 %). CA-IX together with HC2 H-HPV did not improve performance. Women with negative HC2 H-HPV can safely forego invasive treatment (i.e., cone or LEEP biopsy, hysterectomy) in favor of observational follow-up. Additional biomarkers must be found for use in combination with HC2 H-HPV to reduce false-positive rates. This novel application of a modified LCM exemplifies methods for potential use in future cancer screening studies when gold standard diagnoses are not available.",Journal Article,2652.0,3.0,In the absence of gold standard diagnoses we estimate age-specific false-positive and false-negative prediction rates of HPV- cytology- and histology-based tests for significant lesions SCL in US women with AGC-NOS Pap smear diagnoses Modified Latent Class Model LCM analyses with prevalence of SCL modeled as a function of age were applied to GOG-0171 study data n 122 The accuracies of several HPV-based tests including Hybrid Capture II high-risk HPV HC2 H-HPV carbonic anhydrase IX CA-IX and invasive histological diagnosis were compared 1-PPV and 1-NPV were written as functions of sensitivity specificity and prevalence to obtain age-specific false-positive and false-negative rates The histology-based test was nearly perfect sensitivity 1.00 CI 0.98-1.00 specificity 0.99 CI 0.96-1.00 Otherwise HC2 H-HPV performed best sensitivity 1.00 CI 1.00-1.00 specificity 0.87 CI 0.79-0.94 The false-positive detection rates 1-PPV for HC2 H-HPV were high 17 at each age while those of the histological diagnoses were low 5 at ages 60 and 17 overall ages False-negative prediction rates 1-NPV for HC2 H-HPV were 0.11 at each age and were uniformly lower than those of other tests including the histology-based test 0.25 CA-IX together with HC2 H-HPV did not improve performance Women with negative HC2 H-HPV can safely forego invasive treatment i.e. cone or LEEP biopsy hysterectomy in favor of observational follow-up Additional biomarkers must be found for use in combination with HC2 H-HPV to reduce false-positive rates This novel application of a modified LCM exemplifies methods for potential use in future cancer screening studies when gold standard diagnoses are not available,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4, 3, 1127, 1, 4159, 260, 2403, 21, 1191, 89, 112, 2133, 109, 2, 2133, 199, 1590, 151, 1, 933, 2045, 2, 784, 90, 895, 9, 93, 406, 17194, 4, 843, 117, 5, 10490, 6306, 4290, 8379, 2403, 1230, 6011, 1040, 202, 12376, 318, 5, 1078, 1, 17194, 4666, 22, 8, 343, 1, 89, 11, 1498, 6, 4760, 47455, 45, 74, 78, 3285, 3, 15320, 1, 392, 933, 90, 895, 141, 4542, 2891, 215, 64, 43, 933, 16516, 555, 933, 11190, 11191, 8032, 1568, 8032, 2, 416, 1831, 147, 11, 72, 14, 4998, 2, 14, 6771, 11, 6538, 22, 1681, 1, 485, 1121, 2, 1078, 6, 3140, 89, 112, 2133, 109, 2, 2133, 199, 151, 3, 784, 90, 412, 10, 1857, 8954, 485, 14, 2038, 58, 13, 1096, 14, 2038, 1121, 13, 1058, 58, 13, 921, 14, 2038, 2632, 16516, 555, 933, 173, 824, 485, 14, 2038, 58, 14, 2038, 14, 2038, 1121, 13, 912, 58, 13, 842, 13, 960, 3, 2133, 109, 638, 151, 14, 4998, 9, 16516, 555, 933, 11, 64, 269, 28, 296, 89, 369, 135, 1, 3, 1831, 2403, 11, 154, 33, 28, 2165, 12236, 2, 269, 63, 2165, 2133, 199, 1590, 151, 14, 6771, 9, 16516, 555, 933, 11, 13, 175, 28, 296, 89, 2, 11, 4254, 280, 76, 135, 1, 127, 895, 141, 3, 784, 90, 412, 13, 243, 1568, 8032, 1162, 5, 16516, 555, 933, 205, 44, 401, 528, 117, 5, 199, 16516, 555, 933, 122, 2268, 19176, 416, 24, 70, 563, 6939, 15, 19966, 411, 2622, 4, 4283, 1, 2495, 166, 126, 402, 582, 1642, 40, 204, 9, 119, 4, 150, 5, 16516, 555, 933, 6, 969, 2133, 109, 151, 26, 229, 1581, 1, 8, 1230, 12376, 24934, 636, 9, 174, 119, 4, 508, 12, 453, 94, 198, 4159, 260, 2403, 32, 44, 390]",1682.0,23073789,859
The zinc finger protein ZNF268 is overexpressed in human cervical cancer and contributes to tumorigenesis via enhancing NF-B signaling.,The Journal of biological chemistry,J. Biol. Chem.,2012-10-22,"Cervical cancer is one of the most common tumors affecting women's health worldwide. Although human papillomavirus can be detected in nearly all cases, the mechanism of cervical carcinogenesis remains to be further addressed. Here, we demonstrated that ZNF268, a Krppel-associated box-containing zinc finger protein, might contribute to the development of cervical cancer. We found that ZNF268b2, an isoform of ZNF268, was overexpressed in human squamous cervical cancer specimens. Knockdown of ZNF268 in cervical cancer cells caused cell cycle arrest at the G(0)/G(1) phase, reduced colony formation, and increased sensitivity to TNF-induced apoptosis. In addition, HeLa cell growth in xenograft nude mice was suppressed by ZNF268 knockdown, with increased apoptosis. Furthermore, ZNF268b2 was shown to increase NF-B signaling in vitro and in vivo. Reconstitution of NF-B activity restored proliferation in ZNF268 knockdown HeLa cells. Of note, we observed a high frequency of NF-B activation in ZNF268-overexpressing cervical cancer tissues, suggesting a pathological coincidence of ZNF268b2 overexpression and NF-B activation. Taken together, our results reveal a novel role of ZNF268b2 that contributes to cervical carcinogenesis in part through enhancing NF-B signaling.",Journal Article,2647.0,15.0,cancer is one of the most common tumors affecting women 's health worldwide Although human papillomavirus can be detected in nearly all cases the mechanism of carcinogenesis remains to be further addressed Here we demonstrated that ZNF268 a Krppel-associated box-containing zinc finger protein might contribute to the development of cancer We found that ZNF268b2 an isoform of ZNF268 was overexpressed in human squamous cancer specimens Knockdown of ZNF268 in cancer cells caused cell cycle arrest at the G 0 /G 1 phase reduced colony formation and increased sensitivity to TNF-induced apoptosis In addition HeLa cell growth in xenograft nude mice was suppressed by ZNF268 knockdown with increased apoptosis Furthermore ZNF268b2 was shown to increase NF-B signaling in vitro and in vivo Reconstitution of NF-B activity restored proliferation in ZNF268 knockdown HeLa cells Of note we observed a high frequency of NF-B activation in ZNF268-overexpressing cancer tissues suggesting a pathological coincidence of ZNF268b2 overexpression and NF-B activation Taken together our results reveal a novel role of ZNF268b2 that contributes to carcinogenesis in part through enhancing NF-B signaling,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 104, 1, 3, 96, 186, 57, 2319, 117, 292, 341, 2358, 242, 171, 3242, 122, 40, 530, 4, 1857, 62, 140, 3, 670, 1, 1719, 469, 6, 40, 195, 2814, 467, 21, 264, 17, 29364, 8, 23429, 41, 4971, 1101, 5988, 8079, 178, 822, 1248, 6, 3, 193, 1, 12, 21, 204, 17, 35461, 35, 3995, 1, 29364, 10, 1711, 4, 171, 691, 12, 623, 1563, 1, 29364, 4, 12, 37, 1546, 31, 417, 1854, 28, 3, 499, 13, 499, 14, 124, 405, 1975, 1264, 2, 101, 485, 6, 8713, 277, 351, 4, 352, 8466, 31, 129, 4, 1330, 2598, 399, 10, 1908, 20, 29364, 1563, 5, 101, 351, 798, 35461, 10, 443, 6, 344, 1365, 2448, 314, 4, 439, 2, 4, 386, 5616, 1, 1365, 2448, 128, 4138, 457, 4, 29364, 1563, 8466, 37, 1, 5739, 21, 164, 8, 64, 675, 1, 1365, 2448, 363, 4, 29364, 2810, 12, 742, 802, 8, 1301, 26006, 1, 35461, 851, 2, 1365, 2448, 363, 1633, 1162, 114, 99, 2396, 8, 229, 200, 1, 35461, 17, 2444, 6, 1719, 4, 760, 298, 2430, 1365, 2448, 314]",1195.0,23091055,84
Preventing cervical cancer globally.,"Cancer prevention research (Philadelphia, Pa.)",Cancer Prev Res (Phila),2012-11-01,"Cervical cancer is one of the leading causes of cancer and cancer-related deaths among women worldwide. More than 85% of cases and deaths occur in the developing world where the availability of effective screening is limited. In this issue of the journal, Pierce and colleagues (beginning on page 1273) describe a novel technique using a high-resolution microendoscope (HRME) to diagnose cervical dysplasia. This perspective reviews the limitations of existing cervical cancer screening methods currently in use in low-resource settings and the potential for HRME imaging to contribute to cervical cancer prevention in the developing world.",Journal Article,2637.0,2.0,cancer is one of the leading causes of cancer and cancer-related deaths among women worldwide More than 85 of cases and deaths occur in the developing world where the availability of effective screening is limited In this issue of the journal Pierce and colleagues beginning on page 1273 describe a novel technique using a high-resolution microendoscope HRME to diagnose dysplasia This perspective reviews the limitations of existing cancer screening methods currently in use in low-resource settings and the potential for HRME imaging to contribute to cancer prevention in the developing world,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 104, 1, 3, 1049, 1626, 1, 12, 2, 12, 139, 1043, 107, 117, 2358, 80, 76, 772, 1, 140, 2, 1043, 1271, 4, 3, 931, 1956, 1257, 3, 2550, 1, 323, 453, 16, 383, 4, 26, 2537, 1, 3, 6685, 62086, 2, 6367, 2948, 23, 9430, 29126, 897, 8, 229, 1312, 75, 8, 64, 2125, 19487, 12049, 6, 6073, 2253, 26, 3727, 2004, 3, 1939, 1, 1692, 12, 453, 636, 694, 4, 119, 4, 154, 3069, 1947, 2, 3, 174, 9, 12049, 270, 6, 1248, 6, 12, 1070, 4, 3, 931, 1956]",594.0,23129579,153
"A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2012-11-07,"This study was designed to establish the maximum tolerated dose (MTD) and to evaluate tolerability, pharmacokinetics, and antitumor activity of etirinotecan pegol. Patients with refractory solid malignancies were enrolled and assigned to escalating-dose cohorts. Patients received 1 infusion of etirinotecan pegol weekly 3 times every 4 weeks (w  3q4w), or every 14 days (q14d), or every 21 days (q21d), with MTD as the primary end point using a standard 3 + 3 design. Seventy-six patients were entered onto 3 dosing schedules (58-245 mg/m(2)). The MTD was 115 mg/m(2) for the w  3q4w schedule and 145 mg/m(2) for both the q14d and q21d schedules. Most adverse events related to study drug were gastrointestinal disorders and were more frequent at higher doses of etirinotecan pegol. Late onset diarrhea was observed in some patients, the frequency of which generally correlated with dose density. Cholinergic diarrhea commonly seen with irinotecan treatment did not occur in patients treated with etirinotecan pegol. Etirinotecan pegol administration resulted in sustained and controlled systemic exposure to SN-38, which had a mean half-life of approximately 50 days. Overall, the pharmacokinetics of etirinotecan pegol are predictable and do not require complex dosing adjustments. Confirmed partial responses were observed in 8 patients with breast, colon, lung (small and squamous cell), bladder, cervical, and neuroendocrine cancer. Etirinotecan pegol showed substantial antitumor activity in patients with various solid tumors and a somewhat different safety profile compared with the irinotecan historical profile. The MTD recommended for phase II clinical trials is 145 mg/m(2) q14d or q21d.","Clinical Trial, Phase I",2631.0,40.0,This study was designed to establish the maximum tolerated dose MTD and to evaluate tolerability pharmacokinetics and antitumor activity of etirinotecan pegol Patients with refractory solid malignancies were enrolled and assigned to escalating-dose cohorts Patients received 1 infusion of etirinotecan pegol weekly 3 times every 4 weeks w 3q4w or every 14 days q14d or every 21 days q21d with MTD as the primary end point using a standard 3 3 design Seventy-six patients were entered onto 3 dosing schedules 58-245 mg/m 2 The MTD was 115 mg/m 2 for the w 3q4w schedule and 145 mg/m 2 for both the q14d and q21d schedules Most adverse events related to study drug were disorders and were more frequent at higher doses of etirinotecan pegol Late onset diarrhea was observed in some patients the frequency of which generally correlated with dose density Cholinergic diarrhea commonly seen with irinotecan treatment did not occur in patients treated with etirinotecan pegol Etirinotecan pegol administration resulted in sustained and controlled systemic exposure to SN-38 which had a mean half-life of approximately 50 days Overall the pharmacokinetics of etirinotecan pegol are predictable and do not require complex dosing adjustments Confirmed partial responses were observed in 8 patients with small and squamous cell and neuroendocrine cancer Etirinotecan pegol showed substantial antitumor activity in patients with various solid tumors and a somewhat different safety profile compared with the irinotecan historical profile The MTD recommended for phase II clinical trials is 145 mg/m 2 q14d or q21d,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,"[26, 45, 10, 1114, 6, 1811, 3, 689, 421, 61, 961, 2, 6, 376, 1543, 1159, 2, 579, 128, 1, 12461, 12462, 7, 5, 430, 537, 441, 11, 346, 2, 896, 6, 2922, 61, 736, 7, 103, 14, 904, 1, 12461, 12462, 709, 27, 1072, 454, 39, 244, 5444, 47482, 15, 454, 213, 162, 28482, 15, 454, 239, 162, 22333, 5, 961, 22, 3, 86, 396, 741, 75, 8, 260, 27, 27, 771, 2073, 437, 7, 11, 2836, 3301, 27, 1280, 2314, 717, 7373, 81, 188, 18, 3, 961, 10, 3670, 81, 188, 18, 9, 3, 5444, 47482, 1055, 2, 4058, 81, 188, 18, 9, 110, 3, 28482, 2, 22333, 2314, 96, 290, 281, 139, 6, 45, 234, 11, 1997, 2, 11, 80, 908, 28, 142, 415, 1, 12461, 12462, 807, 1707, 1172, 10, 164, 4, 476, 7, 3, 675, 1, 92, 1228, 438, 5, 61, 1263, 62090, 1172, 841, 527, 5, 1071, 24, 205, 44, 1271, 4, 7, 73, 5, 12461, 12462, 12461, 12462, 634, 627, 4, 2275, 2, 1149, 403, 645, 6, 3133, 519, 92, 42, 8, 313, 1303, 358, 1, 705, 212, 162, 63, 3, 1159, 1, 12461, 12462, 32, 7639, 2, 1022, 44, 1353, 840, 1280, 6017, 557, 450, 253, 11, 164, 4, 66, 7, 5, 302, 2, 691, 31, 2, 1542, 12, 12461, 12462, 224, 1281, 579, 128, 4, 7, 5, 747, 537, 57, 2, 8, 6122, 338, 367, 800, 72, 5, 3, 1071, 2252, 800, 3, 961, 793, 9, 124, 215, 38, 143, 16, 4058, 81, 188, 18, 28482, 15, 22333]",1602.0,23136196,130
Amygdalin induces apoptosis in human cervical cancer cell line HeLa cells.,Immunopharmacology and immunotoxicology,Immunopharmacol Immunotoxicol,2013-02-01,"Amygdalin, a naturally occurring substance, has been suggested to be efficacious as an anticancer substance. The effect of amygdalin on cervical cancer cells has never been studied. In this study, we found that the viability of human cervical cancer HeLa cell line was significantly inhibited by amygdalin. 4,6-Diamino-2-phenyl indole (DAPI) staining showed that amygdalin-treated HeLa cells developed typical apoptotic changes. The development of apoptosis in the amygdalin-treated HeLa cells were confirmed by double staining of amygdalin-treated HeLa cells with annexin V-FITC and propidium iodide (PI) along with increase in caspase-3 activity in these cells. Further studies indicated that antiapoptotic protein Bcl-2 was downregulated whereas proapoptotic Bax protein was upregulated in the amygdalin-treated HeLa cells implying involvement of the intrinsic pathway of apoptosis. In vivo, amygdalin administration inhibited the growth of HeLa cell xenografts through a mechanism of apoptosis. The results in the present study suggest that amygdalin may offer a new therapeutic option for patients with cervical cancer.",Journal Article,2545.0,42.0,"Amygdalin a naturally occurring substance has been suggested to be efficacious as an anticancer substance The effect of amygdalin on cancer cells has never been studied In this study we found that the viability of human cancer HeLa cell line was significantly inhibited by amygdalin 4,6-Diamino-2-phenyl indole DAPI staining showed that amygdalin-treated HeLa cells developed typical apoptotic changes The development of apoptosis in the amygdalin-treated HeLa cells were confirmed by double staining of amygdalin-treated HeLa cells with annexin V-FITC and propidium iodide PI along with increase in caspase-3 activity in these cells Further studies indicated that antiapoptotic protein Bcl-2 was downregulated whereas proapoptotic Bax protein was upregulated in the amygdalin-treated HeLa cells implying involvement of the intrinsic pathway of apoptosis In vivo amygdalin administration inhibited the growth of HeLa cell xenografts through a mechanism of apoptosis The results in the present study suggest that amygdalin may offer a new therapeutic option for patients with cancer",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[24019, 8, 6045, 1821, 9448, 71, 85, 1148, 6, 40, 3289, 22, 35, 1475, 9448, 3, 254, 1, 24019, 23, 12, 37, 71, 1737, 85, 656, 4, 26, 45, 21, 204, 17, 3, 2120, 1, 171, 12, 8466, 31, 328, 10, 97, 879, 20, 24019, 39, 49, 62091, 18, 14594, 24020, 15769, 1029, 224, 17, 24019, 73, 8466, 37, 276, 3476, 1631, 400, 3, 193, 1, 351, 4, 3, 24019, 73, 8466, 37, 11, 557, 20, 1627, 1029, 1, 24019, 73, 8466, 37, 5, 4850, 603, 12990, 2, 10839, 8456, 2928, 1510, 5, 344, 4, 1469, 27, 128, 4, 46, 37, 195, 94, 1103, 17, 4176, 178, 1044, 18, 10, 3315, 547, 4118, 3119, 178, 10, 2684, 4, 3, 24019, 73, 8466, 37, 7885, 799, 1, 3, 2354, 308, 1, 351, 4, 386, 24019, 634, 879, 3, 129, 1, 8466, 31, 1348, 298, 8, 670, 1, 351, 3, 99, 4, 3, 364, 45, 309, 17, 24019, 68, 1918, 8, 217, 189, 1501, 9, 7, 5, 12]",1081.0,23137229,125
The impact of close surgical margins after radical hysterectomy for early-stage cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2012-11-05,"While it is known that positive surgical margins increase the risk of cervical cancer recurrence, little is known about the effect of close surgical margins (CSM). Therefore, we set out to determine the impact of margin status on recurrence and survival in patients with early-stage cervical cancer. A retrospective review was conducted of patients undergoing radical hysterectomy from 2000 to 2010 with Stage IA2-IIA cervical cancer. CSM were defined as 5mm; association with other clinicopathologic factors as well as recurrence and survival was evaluated. Of the 119 patients, 75 (63%) with CSM had a recurrence rate of 24% compared to 9% without CSM. Though not independently associated with recurrence, CSM were significantly associated with positive lymph nodes (44% vs. 18%), positive parametria (33.3% vs. 2.3%), larger tumors (3.5 vs. 2.5cm), greater depth of stromal invasion (DOI) (84% vs. 33%), and lymphovascular space invasion (LVSI) (61.3% vs. 34.1%). We failed to find an association between adjuvant therapy and recurrence in those with CSM. Exploratory analysis revealed that a surgical margin of 2mm was significantly associated with an increased risk of overall recurrence (36% vs. 9%, p=0.009) as well as loco-regional recurrence (22% vs. 4%, p=0.0034). Surgical margins of 5mm on radical hysterectomy specimens are often associated with other high or intermediate risk factors for recurrence. While not a proven independent risk factor, the distance to surgical margin may warrant further investigation as an intermediate risk factor along with tumor size, DOI and LVSI.",Journal Article,2633.0,17.0,While it is known that positive surgical margins increase the risk of cancer recurrence little is known about the effect of close surgical margins CSM Therefore we set out to determine the impact of margin status on recurrence and survival in patients with early-stage cancer A retrospective review was conducted of patients undergoing radical hysterectomy from 2000 to 2010 with Stage IA2-IIA cancer CSM were defined as 5mm association with other clinicopathologic factors as well as recurrence and survival was evaluated Of the 119 patients 75 63 with CSM had a recurrence rate of 24 compared to 9 without CSM Though not independently associated with recurrence CSM were significantly associated with positive lymph nodes 44 vs. 18 positive parametria 33.3 vs. 2.3 larger tumors 3.5 vs. 2.5cm greater depth of stromal invasion DOI 84 vs. 33 and lymphovascular space invasion LVSI 61.3 vs. 34.1 We failed to find an association between adjuvant therapy and recurrence in those with CSM Exploratory analysis revealed that a surgical margin of 2mm was significantly associated with an increased risk of overall recurrence 36 vs. 9 p=0.009 as well as loco-regional recurrence 22 vs. 4 p=0.0034 Surgical margins of 5mm on radical hysterectomy specimens are often associated with other high or intermediate risk factors for recurrence While not a proven independent risk factor the distance to surgical margin may warrant further investigation as an intermediate risk factor along with tumor size DOI and LVSI,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,"[369, 192, 16, 440, 17, 109, 221, 1012, 344, 3, 43, 1, 12, 146, 1215, 16, 440, 545, 3, 254, 1, 2336, 221, 1012, 7079, 673, 21, 916, 1205, 6, 223, 3, 345, 1, 959, 156, 23, 146, 2, 25, 4, 7, 5, 191, 82, 12, 8, 459, 206, 10, 426, 1, 7, 479, 711, 2622, 29, 1081, 6, 1120, 5, 82, 16725, 4088, 12, 7079, 11, 395, 22, 40169, 248, 5, 127, 1399, 130, 22, 149, 22, 146, 2, 25, 10, 194, 1, 3, 4299, 7, 481, 676, 5, 7079, 42, 8, 146, 116, 1, 259, 72, 6, 83, 187, 7079, 2471, 44, 1042, 41, 5, 146, 7079, 11, 97, 41, 5, 109, 263, 502, 584, 105, 203, 109, 19585, 466, 27, 105, 18, 27, 1077, 57, 27, 33, 105, 18, 18615, 378, 2436, 1, 1126, 578, 13105, 874, 105, 466, 2, 2933, 3865, 578, 8004, 713, 27, 105, 562, 14, 21, 1551, 6, 2469, 35, 248, 59, 249, 36, 2, 146, 4, 135, 5, 7079, 2386, 65, 553, 17, 8, 221, 959, 1, 62094, 10, 97, 41, 5, 35, 101, 43, 1, 63, 146, 511, 105, 83, 19, 13, 2376, 22, 149, 22, 7214, 951, 146, 350, 105, 39, 19, 13, 19746, 221, 1012, 1, 40169, 23, 711, 2622, 623, 32, 629, 41, 5, 127, 64, 15, 919, 43, 130, 9, 146, 369, 44, 8, 1930, 306, 43, 161, 3, 3019, 6, 221, 959, 68, 2946, 195, 940, 22, 35, 919, 43, 161, 1510, 5, 30, 444, 13105, 2, 8004]",1508.0,23138134,565
Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2012-11-15,"According to national surveys, the use of intensity-modulated radiation therapy (IMRT) in gynecologic cancers is on the rise, yet there is still some reluctance to adopt adjuvant IMRT as standard practice. The purpose of this study is to report a single-institution experience using postoperative pelvic IMRT with concurrent chemotherapy in intermediate- and high-risk early stage cervical cancer. From 1/2004 to 12/2009, 34 patients underwent radical hysterectomy and pelvic lymph node dissection (28 median nodes were removed) for early stage cervical cancer. Median dose of postoperative pelvic IMRT was 50.4 Gy (range, 45-50.4). All patients received concurrent cisplatin. With a median follow-up of 44 months, 3 patients have recurred; 1 vaginal recurrence, 1 regional and distant, and 1 distant. The 3- and 5-year disease-free survival (DFS) was 91.2% (95% CI, 81.4-100%) and overall survival (OS) was 91.1% (95% CI, 81.3-100%). All failures and all deaths were in the high-risk group (n=3/26). There was 32.3% G3-4 hematologic toxicity, 2.9% acute G3 gastrointestinal toxicity, and no acute G3 or higher genitourinary toxicity. There were no chronic G3 or higher toxicities. Oncologic outcomes with postoperative IMRT were very good, with DFS and OS rates of >90% at median follow-up of 44 months, despite a preponderance (76.5%) of high-risk features. Toxicity was minimal even in the setting of an aggressive trimodality approach. Data from this study and emerging data from the Phase II RTOG study (0418) demonstrate the advantages of postoperative IMRT in early stage cervical cancer.",Journal Article,2623.0,46.0,According to national surveys the use of intensity-modulated radiation therapy IMRT in gynecologic cancers is on the rise yet there is still some reluctance to adopt adjuvant IMRT as standard practice The purpose of this study is to report a single-institution experience using postoperative pelvic IMRT with concurrent chemotherapy in intermediate- and high-risk early stage cancer From 1/2004 to 12/2009 34 patients underwent radical hysterectomy and pelvic lymph node dissection 28 median nodes were removed for early stage cancer Median dose of postoperative pelvic IMRT was 50.4 Gy range 45-50.4 All patients received concurrent cisplatin With a median follow-up of 44 months 3 patients have recurred 1 recurrence 1 regional and distant and 1 distant The 3- and 5-year disease-free survival DFS was 91.2 95 CI 81.4-100 and overall survival OS was 91.1 95 CI 81.3-100 All failures and all deaths were in the high-risk group n=3/26 There was 32.3 G3-4 hematologic toxicity 2.9 acute G3 toxicity and no acute G3 or higher genitourinary toxicity There were no chronic G3 or higher toxicities Oncologic outcomes with postoperative IMRT were very good with DFS and OS rates of 90 at median follow-up of 44 months despite a preponderance 76.5 of high-risk features Toxicity was minimal even in the setting of an aggressive trimodality approach Data from this study and emerging data from the Phase II RTOG study 0418 demonstrate the advantages of postoperative IMRT in early stage cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[768, 6, 657, 3666, 3, 119, 1, 837, 1757, 121, 36, 964, 4, 1512, 163, 16, 23, 3, 3693, 1145, 125, 16, 1234, 476, 13872, 6, 11462, 249, 964, 22, 260, 758, 3, 743, 1, 26, 45, 16, 6, 414, 8, 226, 731, 730, 75, 573, 1110, 964, 5, 750, 56, 4, 919, 2, 64, 43, 191, 82, 12, 29, 14, 1131, 6, 133, 1238, 562, 7, 208, 711, 2622, 2, 1110, 263, 289, 1161, 339, 52, 502, 11, 2264, 9, 191, 82, 12, 52, 61, 1, 573, 1110, 964, 10, 212, 39, 381, 184, 512, 212, 39, 62, 7, 103, 750, 540, 5, 8, 52, 166, 126, 1, 584, 53, 27, 7, 47, 3363, 14, 146, 14, 951, 2, 626, 2, 14, 626, 3, 27, 2, 33, 111, 34, 115, 25, 1010, 10, 970, 18, 48, 58, 865, 39, 394, 2, 63, 25, 118, 10, 970, 14, 48, 58, 865, 27, 394, 62, 3368, 2, 62, 1043, 11, 4, 3, 64, 43, 87, 78, 27, 432, 125, 10, 531, 27, 5578, 39, 813, 155, 18, 83, 286, 5578, 155, 2, 77, 286, 5578, 15, 142, 4109, 155, 125, 11, 77, 442, 5578, 15, 142, 385, 1998, 123, 5, 573, 964, 11, 923, 1178, 5, 1010, 2, 118, 151, 1, 424, 28, 52, 166, 126, 1, 584, 53, 550, 8, 12531, 846, 33, 1, 64, 43, 404, 155, 10, 1048, 871, 4, 3, 546, 1, 35, 571, 4625, 353, 74, 29, 26, 45, 2, 1478, 74, 29, 3, 124, 215, 3931, 45, 31487, 608, 3, 3126, 1, 573, 964, 4, 191, 82, 12]",1485.0,23159818,193
"Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases-equivalent efficacy, less toxicity, more convenient: a subset analysis of Radiation Therapy Oncology Group trial 97-14.",Cancer,Cancer,2012-11-16,"The Radiation Therapy Oncology Group (RTOG) trial 97-14 revealed no difference between radiation delivered for painful bone metastases at a dose of 8 gray (Gy) in 1 fraction (single-fraction radiotherapy [SFRT]) and 30 Gy in 10 fractions (multifraction radiotherapy [MFRT]) in pain relief or narcotic use 3 months after randomization. SFRT for painful vertebral bone metastases (PVBM) has not been well accepted, possibly because of concerns about efficacy and toxicity. In the current study, the authors evaluated the subset of patients that was treated specifically for patients with PVBM. PVBM included the cervical, thoracic, and/or lumbar spine regions. Among patients with PVBM, differences in retreatment rates and in pain relief, narcotic use, and toxicity 3 months after randomization were evaluated. Of 909 eligible patients, 235 (26%) had PVBM. Patients with and without PVBM differed in terms of the percentage of men (55% vs 47%, respectively; P = .03) and the proportion of patients with multiple painful sites (57% vs 38%, respectively; P < .01). Among those with PVBM, more patients who received MFRT had multiple sites treated (65% vs 49% for MFRT vs SFRT, respectively; P = .02). There were no statistically significant treatment differences in terms of pain relief (62% vs 70% for MFRT vs SFRT, respectively; P = .59) or freedom from narcotic use (24% vs 27%, respectively; P = .76) at 3 months. Significant differences in acute grade 2 through 4 toxicity (20% vs 10% for MFRT vs SFRT, respectively; P = .01) and acute grade 2 through 4 gastrointestinal toxicity (14% vs 6%, respectively; P = .01) were observed at 3 months, with lower toxicities seen in the patients treated with SFRT. Late toxicity was rare. No myelopathy was recorded. SFRT produced higher 3-year retreatment rates (5% vs 15%; P = .01). Results for the subset of patients with PVBM in the RTOG 94-17 randomized controlled trial were comparable to those for the entire population. SFRT produced less acute toxicity and a higher rate of retreatment than MFRT. SFRT and MFRT resulted in comparable pain relief and narcotic use at 3 months.",Journal Article,2622.0,66.0,The Radiation Therapy Oncology Group RTOG trial 97-14 revealed no difference between radiation delivered for painful metastases at a dose of 8 gray Gy in 1 fraction single-fraction radiotherapy SFRT and 30 Gy in 10 fractions multifraction radiotherapy MFRT in pain relief or narcotic use 3 months after randomization SFRT for painful vertebral metastases PVBM has not been well accepted possibly because of concerns about efficacy and toxicity In the current study the authors evaluated the subset of patients that was treated specifically for patients with PVBM PVBM included the thoracic and/or lumbar spine regions Among patients with PVBM differences in retreatment rates and in pain relief narcotic use and toxicity 3 months after randomization were evaluated Of 909 eligible patients 235 26 had PVBM Patients with and without PVBM differed in terms of the percentage of men 55 vs 47 respectively P .03 and the proportion of patients with multiple painful sites 57 vs 38 respectively P .01 Among those with PVBM more patients who received MFRT had multiple sites treated 65 vs 49 for MFRT vs SFRT respectively P .02 There were no statistically significant treatment differences in terms of pain relief 62 vs 70 for MFRT vs SFRT respectively P .59 or freedom from narcotic use 24 vs 27 respectively P .76 at 3 months Significant differences in acute grade 2 through 4 toxicity 20 vs 10 for MFRT vs SFRT respectively P .01 and acute grade 2 through 4 toxicity 14 vs 6 respectively P .01 were observed at 3 months with lower toxicities seen in the patients treated with SFRT Late toxicity was rare No myelopathy was recorded SFRT produced higher 3-year retreatment rates 5 vs 15 P .01 Results for the subset of patients with PVBM in the RTOG 94-17 randomized controlled trial were comparable to those for the entire population SFRT produced less acute toxicity and a higher rate of retreatment than MFRT SFRT and MFRT resulted in comparable pain relief and narcotic use at 3 months,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 121, 36, 413, 87, 3931, 160, 1015, 213, 553, 77, 523, 59, 121, 1623, 9, 7041, 196, 28, 8, 61, 1, 66, 4163, 381, 4, 14, 1509, 226, 1509, 310, 17027, 2, 201, 381, 4, 79, 1550, 40183, 310, 27234, 4, 559, 4586, 15, 10703, 119, 27, 53, 50, 3644, 17027, 9, 7041, 4731, 196, 25482, 71, 44, 85, 149, 3058, 2150, 408, 1, 2061, 545, 209, 2, 155, 4, 3, 291, 45, 3, 738, 194, 3, 697, 1, 7, 17, 10, 73, 1225, 9, 7, 5, 25482, 25482, 159, 3, 2098, 2, 15, 6187, 2342, 1374, 107, 7, 5, 25482, 362, 4, 6291, 151, 2, 4, 559, 4586, 10703, 119, 2, 155, 27, 53, 50, 3644, 11, 194, 1, 16804, 625, 7, 6465, 432, 42, 25482, 7, 5, 2, 187, 25482, 2512, 4, 1794, 1, 3, 1150, 1, 325, 614, 105, 662, 106, 19, 680, 2, 3, 920, 1, 7, 5, 232, 7041, 633, 696, 105, 519, 106, 19, 355, 107, 135, 5, 25482, 80, 7, 54, 103, 27234, 42, 232, 633, 73, 556, 105, 739, 9, 27234, 105, 17027, 106, 19, 588, 125, 11, 77, 712, 93, 24, 362, 4, 1794, 1, 559, 4586, 744, 105, 431, 9, 27234, 105, 17027, 106, 19, 728, 15, 3060, 29, 10703, 119, 259, 105, 428, 106, 19, 846, 28, 27, 53, 93, 362, 4, 286, 88, 18, 298, 39, 155, 179, 105, 79, 9, 27234, 105, 17027, 106, 19, 355, 2, 286, 88, 18, 298, 39, 155, 213, 105, 49, 106, 19, 355, 11, 164, 28, 27, 53, 5, 280, 385, 527, 4, 3, 7, 73, 5, 17027, 807, 155, 10, 622, 77, 10415, 10, 1872, 17027, 1687, 142, 27, 111, 6291, 151, 33, 105, 167, 19, 355, 99, 9, 3, 697, 1, 7, 5, 25482, 4, 3, 3931, 960, 269, 384, 1149, 160, 11, 1279, 6, 135, 9, 3, 1797, 266, 17027, 1687, 299, 286, 155, 2, 8, 142, 116, 1, 6291, 76, 27234, 17027, 2, 27234, 627, 4, 1279, 559, 4586, 2, 10703, 119, 28, 27, 53]",1983.0,23165743,106
(-)-Epigallocatechin-3-gallate induces apoptosis and inhibits invasion and migration of human cervical cancer cells.,Asian Pacific journal of cancer prevention : APJCP,Asian Pac. J. Cancer Prev.,2012-01-01,"Invasion and metastasis are the major causes of cancer-related death. Pharmacological or therapeutic interventions such as chemoprevention of the progression stages of neoplastic development could result in substantial reduction in the incidence of cancer mortality. (-)-Epigallocatechin-3-gallate (EGCG), a promising chemopreventive agent, has attracted extensive interest for cancer therapy utilizing its antioxidant, anti- proliferative and inhibitory effects on angiogenesis and tumor cell invasion. In this study, we assessed the influence of EGCG on the proliferative potential of HeLa cells by cell viability assay and authenticated the results by nuclear morphological examination, DNA laddering assay and cell cycle analysis. Further we analyzed the anti-invasive properties of EGCG by wound migration assay and gene expression of MMP-9 and TIMP-1 in HeLa cells. Our results indicated that EGCG induced growth inhibition of HeLa cells in a dose- and time- dependent manner. It was observed that cell death mediated by EGCG was through apoptosis. Interestingly, EGCG effectively inhibited invasion and migration of HeLa cells and modulated the expression of related genes (MMP-9 and TIMP-1) . These results indicate that EGCG may effectively suppress promotion and progression stages of cervical cancer development.",Journal Article,2942.0,,Invasion and metastasis are the major causes of cancer-related death Pharmacological or therapeutic interventions such as chemoprevention of the progression stages of neoplastic development could result in substantial reduction in the incidence of cancer mortality -Epigallocatechin-3-gallate EGCG a promising chemopreventive agent has attracted extensive interest for cancer therapy utilizing its antioxidant anti- proliferative and inhibitory effects on angiogenesis and tumor cell invasion In this study we assessed the influence of EGCG on the proliferative potential of HeLa cells by cell viability assay and authenticated the results by nuclear morphological examination DNA laddering assay and cell cycle analysis Further we analyzed the anti-invasive properties of EGCG by wound migration assay and gene expression of MMP-9 and TIMP-1 in HeLa cells Our results indicated that EGCG induced growth inhibition of HeLa cells in a dose- and time- dependent manner It was observed that cell death mediated by EGCG was through apoptosis Interestingly EGCG effectively inhibited invasion and migration of HeLa cells and modulated the expression of related genes MMP-9 and TIMP-1 These results indicate that EGCG may effectively suppress promotion and progression stages of cancer development,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[578, 2, 278, 32, 3, 458, 1626, 1, 12, 139, 273, 3419, 15, 189, 1151, 225, 22, 2886, 1, 3, 91, 1153, 1, 2000, 193, 359, 757, 4, 1281, 628, 4, 3, 287, 1, 12, 282, 15613, 27, 15965, 7729, 8, 721, 4401, 420, 71, 14439, 1344, 1333, 9, 12, 36, 2600, 211, 5536, 312, 2441, 2, 1810, 176, 23, 1056, 2, 30, 31, 578, 4, 26, 45, 21, 275, 3, 1054, 1, 7729, 23, 3, 2441, 174, 1, 8466, 37, 20, 31, 2120, 719, 2, 29111, 3, 99, 20, 928, 4268, 1385, 261, 33768, 719, 2, 31, 417, 65, 195, 21, 311, 3, 312, 416, 1571, 1, 7729, 20, 2689, 1381, 719, 2, 145, 55, 1, 2151, 83, 2, 5272, 14, 4, 8466, 37, 114, 99, 1103, 17, 7729, 277, 129, 297, 1, 8466, 37, 4, 8, 61, 2, 98, 470, 1708, 192, 10, 164, 17, 31, 273, 517, 20, 7729, 10, 298, 351, 2873, 7729, 1856, 879, 578, 2, 1381, 1, 8466, 37, 2, 1757, 3, 55, 1, 139, 214, 2151, 83, 2, 5272, 14, 46, 99, 1008, 17, 7729, 68, 1856, 3134, 5478, 2, 91, 1153, 1, 12, 193]",1291.0,23167425,366
"Molecular diagnostics, personalized medicine, and the evolving role of the cytotechnologist: an institutional experience.",Acta cytologica,Acta Cytol.,2012-11-24,"The role of cytotechnologists has focused primarily on the microscopic examination of cytologic specimens for diagnosing disease. Cytotechnologists currently evaluate a wide assortment of both gynecological and nongynecological cytology specimens. However, the Pap test remains the primary test for most cytology laboratories. Recently, human papillomavirus testing and newer cervical cancer screening guidelines have reduced the number of Pap tests, resulting in some anxiety and concern among the cytology community. However, as Pap test volumes continue to decrease, molecular oncology and ancillary testing volumes continue to increase with the advent of new biomarkers and associated personalized therapies. This change in clinical practice has resulted in evolving roles for many cytotechnologists. Cytotechnologists have skills based not only in morphology but also in understanding concepts of disease including neoplasia. These skills allow cytotechnologists to excel in many other types of laboratory testing. This article discusses how the roles of the cytotechnologist have recently expanded at our institution to include involvement in DNA ploidy analysis, quantitative immunohistochemistry, fluorescence in situ hybridization, circulating tumor cells, and molecular oncology testing. Lastly, this article discusses how these newer roles benefit both the cytotechnologist and the clinical laboratory.",Journal Article,2614.0,10.0,The role of cytotechnologists has focused primarily on the microscopic examination of cytologic specimens for diagnosing disease Cytotechnologists currently evaluate a wide assortment of both gynecological and nongynecological cytology specimens However the Pap test remains the primary test for most cytology laboratories Recently human papillomavirus testing and newer cancer screening guidelines have reduced the number of Pap tests resulting in some anxiety and concern among the cytology community However as Pap test volumes continue to decrease molecular oncology and ancillary testing volumes continue to increase with the advent of new biomarkers and associated personalized therapies This change in clinical practice has resulted in evolving roles for many cytotechnologists Cytotechnologists have skills based not only in morphology but also in understanding concepts of disease including neoplasia These skills allow cytotechnologists to excel in many other types of laboratory testing This article discusses how the roles of the cytotechnologist have recently expanded at our institution to include involvement in DNA ploidy analysis quantitative immunohistochemistry fluorescence in situ hybridization circulating tumor cells and molecular oncology testing Lastly this article discusses how these newer roles benefit both the cytotechnologist and the clinical laboratory,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 200, 1, 28820, 71, 1649, 1561, 23, 3, 2984, 1385, 1, 4195, 623, 9, 5798, 34, 28820, 694, 376, 8, 1019, 33289, 1, 110, 6324, 2, 47520, 2045, 623, 137, 3, 4290, 412, 469, 3, 86, 412, 9, 96, 2045, 4884, 761, 171, 3242, 471, 2, 2246, 12, 453, 677, 47, 405, 3, 207, 1, 4290, 895, 1113, 4, 476, 2021, 2, 2893, 107, 3, 2045, 1714, 137, 22, 4290, 412, 2225, 1906, 6, 775, 219, 413, 2, 8496, 471, 2225, 1906, 6, 344, 5, 3, 4114, 1, 217, 582, 2, 41, 2175, 235, 26, 707, 4, 38, 758, 71, 627, 4, 3276, 1790, 9, 445, 28820, 28820, 47, 5909, 90, 44, 158, 4, 2567, 84, 120, 4, 612, 5101, 1, 34, 141, 2298, 46, 5909, 1700, 28820, 6, 27851, 4, 445, 127, 630, 1, 1624, 471, 26, 946, 2759, 832, 3, 1790, 1, 3, 34506, 47, 761, 2064, 28, 114, 731, 6, 643, 799, 4, 261, 9032, 65, 1156, 888, 1591, 4, 957, 1554, 1033, 30, 37, 2, 219, 413, 471, 6354, 26, 946, 2759, 832, 46, 2246, 1790, 247, 110, 3, 34506, 2, 3, 38, 1624]",1384.0,23207447,584
Tumor suppressor function of the plasma glutathione peroxidase gpx3 in colitis-associated carcinoma.,Cancer research,Cancer Res.,2012-12-05,"The glutathione peroxidases, a family of selenocysteine-containing redox enzymes, play pivotal roles in balancing the signaling, immunomodulatory, and deleterious effects of reactive oxygen species (ROS). The glutathione peroxidase GPX3 is the only extracellular member of this family, suggesting it may defend cells against ROS in the extracellular environment. Notably, GPX3 hypermethylation and underexpression occur commonly in prostate, gastric, cervical, thyroid, and colon cancers. We took a reverse genetics approach to investigate whether GPX3 would augment inflammatory colonic tumorigenesis, a process characterized by oxidative stress and inflammation, comparing Gpx3(-/-) mice in an established two-stage model of inflammatory colon carcinogenesis. Gpx3-deficient mice exhibited an increased tumor number, though not size, along with a higher degree of dysplasia. In addition, they exhibited increased inflammation with redistribution toward protumorigenic M2 macrophage subsets, increased proliferation, hyperactive WNT signaling, and increased DNA damage. To determine the impact of acute gene loss in an established colon cancer line, we silenced GPX3 in human Caco2 cells, resulting in increased ROS production, DNA damage and apoptosis in response to oxidative stress, combined with decreased contact-independent growth. Taken together, our results suggested an immunomodulatory role for GPX3 that limits the development of colitis-associated carcinoma.",Journal Article,2603.0,69.0,The glutathione peroxidases a family of selenocysteine-containing redox enzymes play pivotal roles in balancing the signaling immunomodulatory and deleterious effects of reactive oxygen species ROS The glutathione peroxidase GPX3 is the only extracellular member of this family suggesting it may defend cells against ROS in the extracellular environment Notably GPX3 hypermethylation and underexpression occur commonly in and cancers We took a reverse genetics approach to investigate whether GPX3 would augment inflammatory colonic tumorigenesis a process characterized by oxidative stress and inflammation comparing Gpx3 -/- mice in an established two-stage model of inflammatory carcinogenesis Gpx3-deficient mice exhibited an increased tumor number though not size along with a higher degree of dysplasia In addition they exhibited increased inflammation with redistribution toward protumorigenic M2 macrophage subsets increased proliferation hyperactive WNT signaling and increased DNA damage To determine the impact of acute gene loss in an established cancer line we silenced GPX3 in human Caco2 cells resulting in increased ROS production DNA damage and apoptosis in response to oxidative stress combined with decreased contact-independent growth Taken together our results suggested an immunomodulatory role for GPX3 that limits the development of colitis-associated carcinoma,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,"[3, 4571, 62179, 8, 607, 1, 32054, 1101, 7237, 3039, 1343, 3754, 1790, 4, 13013, 3, 314, 2555, 2, 3586, 176, 1, 2163, 2848, 2915, 2609, 3, 4571, 14747, 18037, 16, 3, 158, 1976, 2693, 1, 26, 607, 802, 192, 68, 38012, 37, 480, 2609, 4, 3, 1976, 3087, 2552, 18037, 2575, 2, 22250, 1271, 841, 4, 2, 163, 21, 5060, 8, 1772, 2894, 353, 6, 963, 317, 18037, 688, 4369, 1291, 3663, 1565, 8, 1129, 765, 20, 3495, 1531, 2, 1815, 1430, 18037, 399, 4, 35, 635, 100, 82, 202, 1, 1291, 1719, 18037, 1971, 399, 1416, 35, 101, 30, 207, 2471, 44, 444, 1510, 5, 8, 142, 1444, 1, 2253, 4, 352, 491, 1416, 101, 1815, 5, 12507, 1317, 11840, 821, 2674, 1890, 101, 457, 11802, 2112, 314, 2, 101, 261, 1350, 6, 223, 3, 345, 1, 286, 145, 407, 4, 35, 635, 12, 328, 21, 5442, 18037, 4, 171, 26171, 37, 1113, 4, 101, 2609, 1529, 261, 1350, 2, 351, 4, 51, 6, 3495, 1531, 397, 5, 340, 4393, 306, 129, 1633, 1162, 114, 99, 1148, 35, 2555, 200, 9, 18037, 17, 3526, 3, 193, 1, 4132, 41, 134]",1385.0,23221387,31
The role of human papillomavirus in nongenital cancers.,CA: a cancer journal for clinicians,CA Cancer J Clin,2012-12-19,"Human papillomavirus (HPV), one of the most common sexually transmitted diseases worldwide, has an established role in the pathogenesis of genital malignancies such as cervical cancer. The virus has also been implicated in the oncogenesis of nongenital cancers including head and neck malignancies (specifically oropharyngeal cancers) as well as anal cancer. There is less clarity regarding its role in lung and esophageal cancers. Worldwide, the incidence and prevalence of HPV-associated oropharyngeal cancer has been increasing over time. These patients have improved outcomes compared with those with HPV-negative oropharyngeal cancers, and there is continued interest in designing treatments specifically for this HPV-positive subgroup. Clinicians continue to gain an understanding of HPV in anal cancers and the risk factors associated with infection and progression to malignancy. This has potential implications for the eventual screening of high-risk groups. While HPV vaccination is currently approved for the prevention of cervical cancer, it also has potential in the prevention of all HPV-associated malignancies. In this review, current understanding of the role of HPV in nongenital cancers is discussed, as well as future implications for treatment and prevention.",Journal Article,2589.0,127.0,Human papillomavirus HPV one of the most common sexually transmitted diseases worldwide has an established role in the pathogenesis of genital malignancies such as cancer The virus has also been implicated in the oncogenesis of nongenital cancers including head and malignancies specifically cancers as well as cancer There is less clarity regarding its role in and cancers Worldwide the incidence and prevalence of HPV-associated cancer has been increasing over time These patients have improved outcomes compared with those with HPV-negative cancers and there is continued interest in designing treatments specifically for this HPV-positive subgroup Clinicians continue to gain an understanding of HPV in cancers and the risk factors associated with infection and progression to malignancy This has potential implications for the eventual screening of high-risk groups While HPV vaccination is currently approved for the prevention of cancer it also has potential in the prevention of all HPV-associated malignancies In this review current understanding of the role of HPV in nongenital cancers is discussed as well as future implications for treatment and prevention,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[171, 3242, 933, 104, 1, 3, 96, 186, 13588, 12959, 1342, 2358, 71, 35, 635, 200, 4, 3, 1384, 1, 8226, 441, 225, 22, 12, 3, 1450, 71, 120, 85, 1771, 4, 3, 4503, 1, 40204, 163, 141, 718, 2, 441, 1225, 163, 22, 149, 22, 12, 125, 16, 299, 12901, 666, 211, 200, 4, 2, 163, 2358, 3, 287, 2, 1078, 1, 933, 41, 12, 71, 85, 602, 252, 98, 46, 7, 47, 231, 123, 72, 5, 135, 5, 933, 199, 163, 2, 125, 16, 1351, 1333, 4, 5048, 640, 1225, 9, 26, 933, 109, 1363, 1490, 1906, 6, 1803, 35, 612, 1, 933, 4, 163, 2, 3, 43, 130, 41, 5, 930, 2, 91, 6, 710, 26, 71, 174, 1268, 9, 3, 6956, 453, 1, 64, 43, 271, 369, 933, 1915, 16, 694, 850, 9, 3, 1070, 1, 12, 192, 120, 71, 174, 4, 3, 1070, 1, 62, 933, 41, 441, 4, 26, 206, 291, 612, 1, 3, 200, 1, 933, 4, 40204, 163, 16, 1588, 22, 149, 22, 508, 1268, 9, 24, 2, 1070]",1169.0,23258613,145
Pelvic insufficiency fractures in patients with cervical and endometrial cancer treated with postoperative pelvic radiation.,Gynecologic oncology,Gynecol. Oncol.,2012-12-20,"There is an increased awareness of pelvic insufficiency fractures (PIF) as a potential morbidity of pelvic radiotherapy (RT). The purpose of this study was to determine the incidence of PIF and assess prognostic factors, including intensity-modulated RT (IMRT), in gynecologic oncology patients treated with postoperative pelvic RT. We performed a retrospective review of all patients with endometrial or cervical carcinoma who received postoperative pelvic RT at our institution during 2000-2008. Patients who received definitive or palliative RT were excluded. A total of 222 patients were identified, of whom 11 (5%) developed PIF at a median time of 11.5months (range, 5.5-87.3months) from RT completion. The 5-year actuarial rate was 5.1% (95% CI 3.3-6.9). In patients with osteoporosis, the 5-year rate was 15.6% compared with 2.9% for those without (P=0.01). Similarly, patients who were on prior hormone-replacement therapy (HRT) had a higher rate (14.8% vs 4.1%, P=0.009). The median body-mass index (BMI) for patients who developed PIF was significantly lower than those who didn't (25.9 vs 27.2, P=0.016). The rate of PIF was 4.9% whether patients received IMRT or conventional RT. The 5-year risk of PIF for postoperative pelvic RT in cervical and endometrial cancer is 5.1%. Women with history of osteoporosis, prior HRT, or low BMI need to be counseled about the risk of PIF. The use of IMRT did not decrease PIF, but further studies are needed to determine if a dose/volume relationship exists between RT and PIF.",Journal Article,2588.0,36.0,There is an increased awareness of pelvic insufficiency fractures PIF as a potential morbidity of pelvic radiotherapy RT The purpose of this study was to determine the incidence of PIF and assess prognostic factors including intensity-modulated RT IMRT in gynecologic oncology patients treated with postoperative pelvic RT We performed a retrospective review of all patients with or carcinoma who received postoperative pelvic RT at our institution during 2000-2008 Patients who received definitive or palliative RT were excluded A total of 222 patients were identified of whom 11 5 developed PIF at a median time of 11.5months range 5.5-87.3months from RT completion The 5-year actuarial rate was 5.1 95 CI 3.3-6.9 In patients with osteoporosis the 5-year rate was 15.6 compared with 2.9 for those without P=0.01 Similarly patients who were on prior hormone-replacement therapy HRT had a higher rate 14.8 vs 4.1 P=0.009 The median body-mass index BMI for patients who developed PIF was significantly lower than those who did n't 25.9 vs 27.2 P=0.016 The rate of PIF was 4.9 whether patients received IMRT or conventional RT The 5-year risk of PIF for postoperative pelvic RT in and cancer is 5.1 Women with history of osteoporosis prior HRT or low BMI need to be counseled about the risk of PIF The use of IMRT did not decrease PIF but further studies are needed to determine if a dose/volume relationship exists between RT and PIF,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[125, 16, 35, 101, 3310, 1, 1110, 4360, 3909, 22770, 22, 8, 174, 787, 1, 1110, 310, 240, 3, 743, 1, 26, 45, 10, 6, 223, 3, 287, 1, 22770, 2, 423, 177, 130, 141, 837, 1757, 240, 964, 4, 1512, 413, 7, 73, 5, 573, 1110, 240, 21, 173, 8, 459, 206, 1, 62, 7, 5, 15, 134, 54, 103, 573, 1110, 240, 28, 114, 731, 190, 1081, 1375, 7, 54, 103, 1057, 15, 994, 240, 11, 1800, 8, 181, 1, 5647, 7, 11, 108, 1, 953, 175, 33, 276, 22770, 28, 8, 52, 98, 1, 175, 15029, 184, 33, 33, 912, 18669, 29, 240, 1438, 3, 33, 111, 2361, 116, 10, 33, 14, 48, 58, 27, 27, 49, 83, 4, 7, 5, 4970, 3, 33, 111, 116, 10, 167, 49, 72, 5, 18, 83, 9, 135, 187, 19, 13, 355, 1813, 7, 54, 11, 23, 324, 785, 3892, 36, 5315, 42, 8, 142, 116, 213, 66, 105, 39, 14, 19, 13, 2376, 3, 52, 642, 782, 558, 1140, 9, 7, 54, 276, 22770, 10, 97, 280, 76, 135, 54, 205, 12408, 243, 83, 105, 428, 18, 19, 13, 3820, 3, 116, 1, 22770, 10, 39, 83, 317, 7, 103, 964, 15, 809, 240, 3, 33, 111, 43, 1, 22770, 9, 573, 1110, 240, 4, 2, 12, 16, 33, 14, 117, 5, 532, 1, 4970, 324, 5315, 15, 154, 1140, 594, 6, 40, 10411, 545, 3, 43, 1, 22770, 3, 119, 1, 964, 205, 44, 775, 22770, 84, 195, 94, 32, 575, 6, 223, 492, 8, 61, 433, 858, 2481, 59, 240, 2, 22770]",1432.0,23262211,266
Outcomes for patients with cervical cancer treated with extended-field intensity-modulated radiation therapy and concurrent cisplatin.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2013-01-01,"To evaluate disease outcomes and toxicity in patients with cervical cancer treated with extended-field intensity-modulated radiotherapy. We included all patients treated with extended-field intensity-modulated radiotherapy and concurrent weekly cisplatin from 2003 to 2010 at 2 institutions. Overall survival and disease-free survival were estimated using Kaplan-Meier method. Locoregional failure (LRF), distant failure, and competing mortality were calculated using cumulative incidence functions. Acute and late toxicity were graded using Common Terminology Criteria for Adverse Events (CTCAE) and Radiation Therapy Oncology Group late radiation morbidity scoring criteria, respectively. The study included 21 patients, 14 and 20 of which had positive para-aortic and pelvic nodes, respectively. The median follow-up was 22 months. Eighteen-month overall survival and disease-free survival were 59.7% (95% confidence interval [CI], 41.2%-86.4%) and 42.9% (95% CI, 26.2%-70.2%). Eighteen-month cumulative incidences of LRF, distant failure, and competing mortality were 9.5% (95% CI, 1.5-26.8%), 42.9% (95% CI, 21.3-62.9%), and 4.8% (95% CI, 0.3-20.2%), respectively. Eighteen-month cumulative incidences of late grade 3 or higher-grade genitourinary and gastrointestinal toxicity were 4.8% (95% CI, 0.2%-20.3%) and 0%, respectively. Intensity-modulated extended-field radiotherapy was associated with low rates of late toxicity and LRF. High rates of distant failure indicate that this group of patients could benefit from intensified systemic therapy.",Evaluation Study,2576.0,22.0,To evaluate disease outcomes and toxicity in patients with cancer treated with extended-field intensity-modulated radiotherapy We included all patients treated with extended-field intensity-modulated radiotherapy and concurrent weekly cisplatin from 2003 to 2010 at 2 institutions Overall survival and disease-free survival were estimated using Kaplan-Meier method Locoregional failure LRF distant failure and competing mortality were calculated using cumulative incidence functions Acute and late toxicity were graded using Common Terminology Criteria for Adverse Events CTCAE and Radiation Therapy Oncology Group late radiation morbidity scoring criteria respectively The study included 21 patients 14 and 20 of which had positive para-aortic and pelvic nodes respectively The median follow-up was 22 months Eighteen-month overall survival and disease-free survival were 59.7 95 confidence interval CI 41.2 -86.4 and 42.9 95 CI 26.2 -70.2 Eighteen-month cumulative incidences of LRF distant failure and competing mortality were 9.5 95 CI 1.5-26.8 42.9 95 CI 21.3-62.9 and 4.8 95 CI 0.3-20.2 respectively Eighteen-month cumulative incidences of late grade 3 or higher-grade genitourinary and toxicity were 4.8 95 CI 0.2 -20.3 and 0 respectively Intensity-modulated extended-field radiotherapy was associated with low rates of late toxicity and LRF High rates of distant failure indicate that this group of patients could benefit from intensified systemic therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 34, 123, 2, 155, 4, 7, 5, 12, 73, 5, 1747, 1067, 837, 1757, 310, 21, 159, 62, 7, 73, 5, 1747, 1067, 837, 1757, 310, 2, 750, 709, 540, 29, 1522, 6, 1120, 28, 18, 1764, 63, 25, 2, 34, 115, 25, 11, 661, 75, 876, 882, 596, 1325, 496, 6482, 626, 496, 2, 2573, 282, 11, 981, 75, 967, 287, 1681, 286, 2, 807, 155, 11, 3468, 75, 186, 3462, 371, 9, 290, 281, 3898, 2, 121, 36, 413, 87, 807, 121, 787, 2504, 371, 106, 3, 45, 159, 239, 7, 213, 2, 179, 1, 92, 42, 109, 4615, 3938, 2, 1110, 502, 106, 3, 52, 166, 126, 10, 350, 53, 3195, 811, 63, 25, 2, 34, 115, 25, 11, 728, 67, 48, 307, 268, 58, 605, 18, 868, 39, 2, 595, 83, 48, 58, 432, 18, 431, 18, 3195, 811, 967, 3981, 1, 6482, 626, 496, 2, 2573, 282, 11, 83, 33, 48, 58, 14, 33, 432, 66, 595, 83, 48, 58, 239, 27, 744, 83, 2, 39, 66, 48, 58, 13, 27, 179, 18, 106, 3195, 811, 967, 3981, 1, 807, 88, 27, 15, 142, 88, 4109, 2, 155, 11, 39, 66, 48, 58, 13, 18, 179, 27, 2, 13, 106, 837, 1757, 1747, 1067, 310, 10, 41, 5, 154, 151, 1, 807, 155, 2, 6482, 64, 151, 1, 626, 496, 1008, 17, 26, 87, 1, 7, 359, 247, 29, 7311, 403, 36]",1463.0,23262521,695
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.,Science translational medicine,Sci Transl Med,2013-01-01,"Papanicolaou (Pap) smears have revolutionized the management of patients with cervical cancers by permitting the detection of early, surgically curable tumors and their precursors. In recent years, the traditional Pap smear has been replaced by a liquid-based method, which allows not only cytologic evaluation but also collection of DNA for detection of human papillomavirus, the causative agent of cervical cancer. We reasoned that this routinely collected DNA could be exploited to detect somatic mutations present in rare tumor cells that accumulate in the cervix once shed from endometrial or ovarian cancers. A panel of genes that are commonly mutated in endometrial and ovarian cancers was assembled with new whole-exome sequencing data from 22 endometrial cancers and previously published data on other tumor types. We used this panel to search for mutations in 24 endometrial and 22 ovarian cancers and identified mutations in all 46 samples. With a sensitive massively parallel sequencing method, we were able to identify the same mutations in the DNA from liquid Pap smear specimens in 100% of endometrial cancers (24 of 24) and in 41% of ovarian cancers (9 of 22). Prompted by these findings, we developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear specimen without previous knowledge of the tumor's genotype. When applied to 14 samples selected from the positive cases described above, the expected tumor-specific mutations were identified. These results demonstrate that DNA from most endometrial and a fraction of ovarian cancers can be detected in a standard liquid-based Pap smear specimen obtained during routine pelvic examination. Although improvements need to be made before applying this test in a routine clinical manner, it represents a promising step toward a broadly applicable screening methodology for the early detection of gynecologic malignancies.",Evaluation Study,2576.0,161.0,Papanicolaou Pap smears have revolutionized the management of patients with cancers by permitting the detection of early surgically curable tumors and their precursors In recent years the traditional Pap smear has been replaced by a liquid-based method which allows not only cytologic evaluation but also collection of DNA for detection of human papillomavirus the causative agent of cancer We reasoned that this routinely collected DNA could be exploited to detect somatic mutations present in rare tumor cells that accumulate in the cervix once shed from or cancers A panel of genes that are commonly mutated in and cancers was assembled with new whole-exome sequencing data from 22 cancers and previously published data on other tumor types We used this panel to search for mutations in 24 and 22 cancers and identified mutations in all 46 samples With a sensitive massively parallel sequencing method we were able to identify the same mutations in the DNA from liquid Pap smear specimens in 100 of cancers 24 of 24 and in 41 of cancers 9 of 22 Prompted by these findings we developed a sequence-based method to query mutations in 12 genes in a single liquid Pap smear specimen without previous knowledge of the tumor 's genotype When applied to 14 samples selected from the positive cases described above the expected tumor-specific mutations were identified These results demonstrate that DNA from most and a fraction of cancers can be detected in a standard liquid-based Pap smear specimen obtained during routine pelvic examination Although improvements need to be made before applying this test in a routine clinical manner it represents a promising step toward a broadly applicable screening methodology for the early detection of gynecologic malignancies,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[10416, 4290, 8916, 47, 5746, 3, 284, 1, 7, 5, 163, 20, 9621, 3, 638, 1, 191, 2350, 4151, 57, 2, 136, 4881, 4, 435, 60, 3, 1847, 4290, 8379, 71, 85, 6928, 20, 8, 3165, 90, 596, 92, 2333, 44, 158, 4195, 451, 84, 120, 2442, 1, 261, 9, 638, 1, 171, 3242, 3, 8088, 420, 1, 12, 21, 15577, 17, 26, 3066, 786, 261, 359, 40, 5177, 6, 1426, 1119, 138, 364, 4, 622, 30, 37, 17, 7859, 4, 3, 3629, 1059, 5816, 29, 15, 163, 8, 993, 1, 214, 17, 32, 841, 1185, 4, 2, 163, 10, 6154, 5, 217, 902, 2865, 615, 74, 29, 350, 163, 2, 373, 983, 74, 23, 127, 30, 630, 21, 95, 26, 993, 6, 1901, 9, 138, 4, 259, 2, 350, 163, 2, 108, 138, 4, 62, 641, 347, 5, 8, 745, 7284, 2755, 615, 596, 21, 11, 1665, 6, 255, 3, 827, 138, 4, 3, 261, 29, 3165, 4290, 8379, 623, 4, 394, 1, 163, 259, 1, 259, 2, 4, 605, 1, 163, 83, 1, 350, 4140, 20, 46, 272, 21, 276, 8, 1532, 90, 596, 6, 12259, 138, 4, 133, 214, 4, 8, 226, 3165, 4290, 8379, 2360, 187, 698, 922, 1, 3, 30, 292, 1183, 198, 1498, 6, 213, 347, 715, 29, 3, 109, 140, 1027, 2090, 3, 1336, 30, 112, 138, 11, 108, 46, 99, 608, 17, 261, 29, 96, 2, 8, 1509, 1, 163, 122, 40, 530, 4, 8, 260, 3165, 90, 4290, 8379, 2360, 683, 190, 1311, 1110, 1385, 242, 1474, 594, 6, 40, 1229, 348, 4798, 26, 412, 4, 8, 1311, 38, 1708, 192, 1449, 8, 721, 2458, 1317, 8, 5482, 3801, 453, 3209, 9, 3, 191, 638, 1, 1512, 441]",1764.0,23303603,642
Laparoscopic radical trachelectomy.,JSLS : Journal of the Society of Laparoendoscopic Surgeons,JSLS,,"The standard treatment for patients with early-stage cervical cancer has been radical hysterectomy. However, for women interested in future fertility, radical trachelectomy is now considered a safe and feasible option. The use of minimally invasive surgical techniques  to perform this procedure has recently been reported. We report the first case of a laparoscopic radical trachelectomy performed in a developing country. The patient is a nulligravid, 30-y-old female with stage IB1 adenocarcinoma of the cervix who desired future  fertility. She underwent a laparoscopic radical trachelectomy and bilateral pelvic lymph node dissection. The operative time was 340 min, and the estimated blood loss was 100mL. There were no intraoperative or postoperative complications. The final pathology showed no evidence of residual  disease, and all pelvic lymph nodes were negative. At 20 mo of follow-up, the patient is having regular menses but has not yet attempted to become pregnant. There is no evidence of recurrence. Laparoscopic radical trachelectomy with pelvic lymphadenectomy in a young  woman who desires future fertility may also be an alternative technique in the treatment of early cervical cancer in developing countries.",Case Reports,,8.0,The standard treatment for patients with early-stage cancer has been radical hysterectomy However for women interested in future fertility radical trachelectomy is now considered a safe and feasible option The use of minimally invasive surgical techniques to perform this procedure has recently been reported We report the first case of a laparoscopic radical trachelectomy performed in a developing country The patient is a nulligravid 30-y-old female with stage IB1 adenocarcinoma of the cervix who desired future fertility She underwent a laparoscopic radical trachelectomy and bilateral pelvic lymph node dissection The operative time was 340 min and the estimated blood loss was 100mL There were no intraoperative or postoperative complications The final pathology showed no evidence of residual disease and all pelvic lymph nodes were negative At 20 mo of follow-up the patient is having regular menses but has not yet attempted to become pregnant There is no evidence of recurrence Laparoscopic radical trachelectomy with pelvic lymphadenectomy in a young woman who desires future fertility may also be an alternative technique in the treatment of early cancer in developing countries,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 260, 24, 9, 7, 5, 191, 82, 12, 71, 85, 711, 2622, 137, 9, 117, 7420, 4, 508, 2954, 711, 5760, 16, 1134, 515, 8, 1165, 2, 1313, 1501, 3, 119, 1, 2144, 416, 221, 1092, 6, 2715, 26, 1299, 71, 761, 85, 210, 21, 414, 3, 157, 473, 1, 8, 1964, 711, 5760, 173, 4, 8, 931, 5978, 3, 69, 16, 8, 37147, 201, 2055, 1095, 1061, 5, 82, 8111, 449, 1, 3, 3629, 54, 6115, 508, 2954, 3109, 208, 8, 1964, 711, 5760, 2, 1607, 1110, 263, 289, 1161, 3, 1208, 98, 10, 7264, 1538, 2, 3, 661, 315, 407, 10, 44279, 125, 11, 77, 1720, 15, 573, 521, 3, 1457, 1117, 224, 77, 241, 1, 753, 34, 2, 62, 1110, 263, 502, 11, 199, 28, 179, 2035, 1, 166, 126, 3, 69, 16, 1041, 3316, 15963, 84, 71, 44, 1145, 4098, 6, 1417, 6086, 125, 16, 77, 241, 1, 146, 1964, 711, 5760, 5, 1110, 2048, 4, 8, 1169, 2854, 54, 27248, 508, 2954, 68, 120, 40, 35, 1091, 1312, 4, 3, 24, 1, 191, 12, 4, 931, 2115]",1191.0,23318085,599
Anatomic distribution of fluorodeoxyglucose-avid para-aortic lymph nodes in patients with cervical cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2013-01-17,"Conformal treatment of para-aortic lymph nodes (PAN) in cervical cancer allows dose escalation and reduces normal tissue toxicity. Currently, data documenting the precise location of involved PAN are lacking. We define the spatial distribution of this high-risk nodal volume by analyzing fluorodeoxyglucose (FDG)-avid lymph nodes (LNs) on positron emission tomography/computed tomography (PET/CT) scans in patients with cervical cancer. We identified 72 PANs on pretreatment PET/CT of 30 patients with newly diagnosed stage IB-IVA cervical cancer treated with definitive chemoradiation. LNs were classified as left-lateral para-aortic (LPA), aortocaval (AC), or right paracaval (RPC). Distances from the LN center to the closest vessel and adjacent vertebral body were calculated. Using deformable image registration, nodes were mapped to a template computed tomogram to provide a visual impression of nodal frequencies and anatomic distribution. We identified 72 PET-positive para-aortic lymph nodes (37 LPA, 32 AC, 3 RPC). All RPC lymph nodes were in the inferior third of the para-aortic region. The mean distance from aorta for all lymph nodes was 8.3 mm (range, 3-17 mm), and from the inferior vena cava was 5.6 mm (range, 2-10 mm). Of the 72 lymph nodes, 60% were in the inferior third, 36% were in the middle third, and 4% were in the upper third of the para-aortic region. In all, 29 of 30 patients also had FDG-avid pelvic lymph nodes. A total of 96% of PET positive nodes were adjacent to the aorta; PET positive nodes to the right of the IVC were rare and were all located distally, within 3 cm of the aortic bifurcation. Our findings suggest that circumferential margins around the vessels do not accurately define the nodal region at risk. Instead, the anatomical extent of the nodal basin should be contoured on each axial image to provide optimal coverage of the para-aortic nodal compartment.",Journal Article,2560.0,13.0,Conformal treatment of para-aortic lymph nodes PAN in cancer allows dose escalation and reduces normal tissue toxicity Currently data documenting the precise location of involved PAN are lacking We define the spatial distribution of this high-risk nodal volume by analyzing fluorodeoxyglucose FDG -avid lymph nodes LNs on positron emission tomography/computed tomography PET/CT scans in patients with cancer We identified 72 PANs on pretreatment PET/CT of 30 patients with newly diagnosed stage IB-IVA cancer treated with definitive chemoradiation LNs were classified as left-lateral para-aortic LPA aortocaval AC or right paracaval RPC Distances from the LN center to the closest vessel and adjacent vertebral body were calculated Using deformable image registration nodes were mapped to a template computed tomogram to provide a visual impression of nodal frequencies and anatomic distribution We identified 72 PET-positive para-aortic lymph nodes 37 LPA 32 AC 3 RPC All RPC lymph nodes were in the inferior third of the para-aortic region The mean distance from aorta for all lymph nodes was 8.3 mm range 3-17 mm and from the inferior vena cava was 5.6 mm range 2-10 mm Of the 72 lymph nodes 60 were in the inferior third 36 were in the middle third and 4 were in the upper third of the para-aortic region In all 29 of 30 patients also had FDG-avid pelvic lymph nodes A total of 96 of PET positive nodes were adjacent to the aorta PET positive nodes to the right of the IVC were rare and were all located distally within 3 cm of the aortic bifurcation Our findings suggest that circumferential margins around the vessels do not accurately define the nodal region at risk Instead the anatomical extent of the nodal basin should be contoured on each axial image to provide optimal coverage of the para-aortic nodal compartment,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2972, 24, 1, 4615, 3938, 263, 502, 3055, 4, 12, 2333, 61, 1125, 2, 2389, 295, 246, 155, 694, 74, 9255, 3, 3260, 1147, 1, 646, 3055, 32, 1941, 21, 1107, 3, 5104, 1395, 1, 26, 64, 43, 779, 433, 20, 4449, 4085, 1285, 5189, 263, 502, 2704, 23, 1900, 1799, 872, 1220, 872, 495, 425, 1441, 4, 7, 5, 12, 21, 108, 720, 22776, 23, 1194, 495, 425, 1, 201, 7, 5, 732, 265, 82, 3180, 5900, 12, 73, 5, 1057, 975, 2704, 11, 1373, 22, 1712, 3855, 4615, 3938, 7504, 17414, 1948, 15, 1913, 38371, 30698, 11022, 29, 3, 1763, 574, 6, 3, 12197, 3685, 2, 2086, 4731, 642, 11, 981, 75, 10491, 1482, 3169, 502, 11, 6224, 6, 8, 5932, 1220, 46015, 6, 377, 8, 3046, 8925, 1, 779, 2722, 2, 2745, 1395, 21, 108, 720, 495, 109, 4615, 3938, 263, 502, 567, 7504, 531, 1948, 27, 30698, 62, 30698, 263, 502, 11, 4, 3, 1663, 1282, 1, 3, 4615, 3938, 1053, 3, 313, 3019, 29, 14164, 9, 62, 263, 502, 10, 66, 27, 321, 184, 27, 269, 321, 2, 29, 3, 1663, 6693, 7294, 10, 33, 49, 321, 184, 18, 79, 321, 1, 3, 720, 263, 502, 335, 11, 4, 3, 1663, 1282, 511, 11, 4, 3, 3897, 1282, 2, 39, 11, 4, 3, 1726, 1282, 1, 3, 4615, 3938, 1053, 4, 62, 462, 1, 201, 7, 120, 42, 1285, 5189, 1110, 263, 502, 8, 181, 1, 921, 1, 495, 109, 502, 11, 2086, 6, 3, 14164, 495, 109, 502, 6, 3, 1913, 1, 3, 7818, 11, 622, 2, 11, 62, 2308, 17743, 262, 27, 494, 1, 3, 3938, 18788, 114, 272, 309, 17, 7937, 1012, 3337, 3, 3102, 1022, 44, 2141, 1107, 3, 779, 1053, 28, 43, 3496, 3, 5024, 1039, 1, 3, 779, 6969, 257, 40, 6476, 23, 296, 5229, 1482, 6, 377, 665, 2139, 1, 3, 4615, 3938, 779, 3616]",1827.0,23332221,378
Cervical cancer screening and prevention in low-resource settings.,Clinical obstetrics and gynecology,Clin Obstet Gynecol,2013-03-01,"Cervical cancer is both preventable and curable, yet it remains one of the leading causes of mortality in women worldwide. Approximately 88% of cervical cancer cases are diagnosed in low-resource countries, yet very few resources are allocated to prevention and treatment programs. In fact, it is estimated that only 5% of women in low-resources countries are screened appropriately for cervical cancer. Cytology-based programs are not feasible because of lack of healthcare infrastructure and cost, thus alternative methods of cancer screening, such as visual inspection with acetic acid and HPV-DNA testing, have been intensively studied and are reviewed in this article.",Journal Article,2517.0,36.0,cancer is both preventable and curable yet it remains one of the leading causes of mortality in women worldwide Approximately 88 of cancer cases are diagnosed in low-resource countries yet very few resources are allocated to prevention and treatment programs In fact it is estimated that only 5 of women in low-resources countries are screened appropriately for cancer Cytology-based programs are not feasible because of lack of healthcare infrastructure and cost thus alternative methods of cancer screening such as visual inspection with acetic acid and HPV-DNA testing have been intensively studied and are reviewed in this article,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 110, 7936, 2, 4151, 1145, 192, 469, 104, 1, 3, 1049, 1626, 1, 282, 4, 117, 2358, 705, 889, 1, 12, 140, 32, 265, 4, 154, 3069, 2115, 1145, 923, 1021, 2892, 32, 6682, 6, 1070, 2, 24, 2251, 4, 1991, 192, 16, 661, 17, 158, 33, 1, 117, 4, 154, 2892, 2115, 32, 2261, 4544, 9, 12, 2045, 90, 2251, 32, 44, 1313, 408, 1, 926, 1, 2819, 6219, 2, 835, 631, 1091, 636, 1, 12, 453, 225, 22, 3046, 11746, 5, 16812, 971, 2, 933, 261, 471, 47, 85, 13240, 656, 2, 32, 446, 4, 26, 946]",634.0,23337844,149
Neuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease.,Gynecologic oncology,Gynecol. Oncol.,2013-01-26,"Neuroendocrine carcinomas (NECs) of the cervix comprise only 2% of all cervical cancers. Prospective data is limited and treatment guidelines rely on retrospective reviews and literature from lung NEC. The objective of this study was to report our experience in the management of this rare disease. This was an IRB-approved retrospective review. Study criteria included patients with cervical NEC diagnosed between 1990 and 2012. Demographic, treatment and survival data was collected. Progression free survival (PFS) and overall survival (OS) were assessed. Twenty-six patients met inclusion criteria. Advanced-stage disease (II-IV) was diagnosed in 58% (n=15) of patients. Of the eleven patients with stage I disease, five were treated with platinum-based neoadjuvant chemotherapy (NACT), six with initial radical surgery, and seven received adjuvant therapy including chemotherapy and/or radiation. Nine patients (82%) are currently without evidence of disease (NED). Patients with stage I disease had significantly improved PFS and OS compared to stages II-IV with a median OS that was not reached and 12.1 months, respectively (p=0.0013). The majority of stage I patients with lymph node metastasis and large tumors achieved durable remission with triple-modality therapy including NACT and surgery followed by adjuvant therapy. Cervical NEC is an aggressive disease associated with a high mortality rate. Patients with advanced-stage disease have a poor prognosis regardless of therapy. However, multimodality with consideration of triple-modality therapy in early-stage disease has the potential for complete response and long-term survival, supporting the goal of curative intent in these patients.",Journal Article,2551.0,22.0,Neuroendocrine carcinomas NECs of the cervix comprise only 2 of all cancers Prospective data is limited and treatment guidelines rely on retrospective reviews and literature from NEC The objective of this study was to report our experience in the management of this rare disease This was an IRB-approved retrospective review Study criteria included patients with NEC diagnosed between 1990 and 2012 Demographic treatment and survival data was collected Progression free survival PFS and overall survival OS were assessed Twenty-six patients met inclusion criteria Advanced-stage disease II-IV was diagnosed in 58 n=15 of patients Of the eleven patients with stage I disease five were treated with platinum-based neoadjuvant chemotherapy NACT six with initial radical surgery and seven received adjuvant therapy including chemotherapy and/or radiation Nine patients 82 are currently without evidence of disease NED Patients with stage I disease had significantly improved PFS and OS compared to stages II-IV with a median OS that was not reached and 12.1 months respectively p=0.0013 The majority of stage I patients with lymph node metastasis and large tumors achieved durable remission with triple-modality therapy including NACT and surgery followed by adjuvant therapy NEC is an aggressive disease associated with a high mortality rate Patients with advanced-stage disease have a poor prognosis regardless of therapy However multimodality with consideration of triple-modality therapy in early-stage disease has the potential for complete response and long-term survival supporting the goal of curative intent in these patients,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1542, 826, 11717, 1, 3, 3629, 5238, 158, 18, 1, 62, 163, 482, 74, 16, 383, 2, 24, 677, 5533, 23, 459, 2004, 2, 789, 29, 7176, 3, 461, 1, 26, 45, 10, 6, 414, 114, 730, 4, 3, 284, 1, 26, 622, 34, 26, 10, 35, 5880, 850, 459, 206, 45, 371, 159, 7, 5, 7176, 265, 59, 2289, 2, 1195, 1540, 24, 2, 25, 74, 10, 786, 91, 115, 25, 300, 2, 63, 25, 118, 11, 275, 737, 437, 7, 543, 1680, 371, 131, 82, 34, 215, 478, 10, 265, 4, 717, 78, 167, 1, 7, 1, 3, 2627, 7, 5, 82, 70, 34, 365, 11, 73, 5, 828, 90, 536, 56, 4365, 437, 5, 388, 711, 152, 2, 648, 103, 249, 36, 141, 56, 2, 15, 121, 762, 7, 878, 32, 694, 187, 241, 1, 34, 7466, 7, 5, 82, 70, 34, 42, 97, 231, 300, 2, 118, 72, 6, 1153, 215, 478, 5, 8, 52, 118, 17, 10, 44, 1300, 2, 133, 14, 53, 106, 19, 13, 11534, 3, 686, 1, 82, 70, 7, 5, 263, 289, 278, 2, 375, 57, 513, 1480, 734, 5, 1500, 1396, 36, 141, 4365, 2, 152, 370, 20, 249, 36, 7176, 16, 35, 571, 34, 41, 5, 8, 64, 282, 116, 7, 5, 131, 82, 34, 47, 8, 334, 356, 1583, 1, 36, 137, 2425, 5, 2415, 1, 1500, 1396, 36, 4, 191, 82, 34, 71, 3, 174, 9, 236, 51, 2, 319, 337, 25, 1912, 3, 1326, 1, 1075, 1697, 4, 46, 7]",1630.0,23357610,831
Clinical and pathologic characteristics of serous carcinoma confined to the endometrium: a multi-institutional study.,International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists,Int. J. Gynecol. Pathol.,2013-03-01,"The objective of this study was to analyze the clinical and pathologic factors in patients with uterine serous carcinoma confined to the endometrium. A total of 236 uterine serous carcinoma patients from the pathology databases of 4 large academic institutions were included in the study. Clinical and pathologic variables were analyzed, including patient demographics, tumor size (2 vs. >2 cm), myometrial invasion, lymphovascular invasion, lymph node status, tumor location (endometrium vs. polyp), cervical involvement, lower uterine segment involvement, FIGO stage, pelvic washings, recurrence, overall survival, and progression-free survival. Of 236 patients, 55 (23%) had tumors limited to the endometrium. Forty-four patients (80%) had Stage IA tumors. The tumor was confined to a polyp in 17 (30.9%) patients. Twenty patients (36.4%) had tumor sizes >2 cm and 12 (21.8%) exhibited lymphovascular invasion. Only 3 patients (5.4 %) had cervical stromal involvement. Thirty-three (66%) patients underwent pelvic and para-aortic lymphadenectomy with 2 positive para-aortic lymph nodes identified. Seven (12.7%) patients had positive washings, whereas 8 patients (14.5 %) had disease recurrence. At a median follow-up of 46 months, there was no difference in overall survival (P = 0.216) or progression-free survival (P=0.063) between patients with tumors confined to a polyp, patients with tumors confined to the endometrium, and patients with tumors present in both polyp and the endometrium. Uterine serous carcinoma with only endometrial involvement, even when confined to a polyp, can be associated with poor prognosis, further stressing the importance of complete surgical staging and adjuvant treatment in this setting.",Journal Article,2517.0,19.0,The objective of this study was to analyze the clinical and pathologic factors in patients with serous carcinoma confined to the A total of 236 serous carcinoma patients from the pathology databases of 4 large academic institutions were included in the study Clinical and pathologic variables were analyzed including patient demographics tumor size 2 vs. 2 cm myometrial invasion lymphovascular invasion lymph node status tumor location vs. polyp involvement lower segment involvement FIGO stage pelvic washings recurrence overall survival and progression-free survival Of 236 patients 55 23 had tumors limited to the Forty-four patients 80 had Stage IA tumors The tumor was confined to a polyp in 17 30.9 patients Twenty patients 36.4 had tumor sizes 2 cm and 12 21.8 exhibited lymphovascular invasion Only 3 patients 5.4 had stromal involvement Thirty-three 66 patients underwent pelvic and para-aortic lymphadenectomy with 2 positive para-aortic lymph nodes identified Seven 12.7 patients had positive washings whereas 8 patients 14.5 had disease recurrence At a median follow-up of 46 months there was no difference in overall survival P 0.216 or progression-free survival P=0.063 between patients with tumors confined to a polyp patients with tumors confined to the and patients with tumors present in both polyp and the serous carcinoma with only involvement even when confined to a polyp can be associated with poor prognosis further stressing the importance of complete surgical staging and adjuvant treatment in this setting,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,"[3, 461, 1, 26, 45, 10, 6, 1992, 3, 38, 2, 510, 130, 4, 7, 5, 1744, 134, 2902, 6, 3, 8, 181, 1, 6383, 1744, 134, 7, 29, 3, 1117, 2348, 1, 39, 375, 1916, 1764, 11, 159, 4, 3, 45, 38, 2, 510, 682, 11, 311, 141, 69, 2221, 30, 444, 6006, 105, 18, 494, 7327, 578, 2933, 578, 263, 289, 156, 30, 1147, 105, 6493, 799, 280, 4610, 799, 3837, 82, 1110, 11161, 146, 63, 25, 2, 91, 115, 25, 1, 6383, 7, 614, 382, 42, 57, 383, 6, 3, 1213, 294, 7, 493, 42, 82, 3302, 57, 3, 30, 10, 2902, 6, 8, 6493, 4, 269, 201, 83, 7, 737, 7, 511, 39, 42, 30, 4131, 18, 494, 2, 133, 239, 66, 1416, 2933, 578, 158, 27, 7, 33, 39, 42, 1126, 799, 977, 169, 700, 7, 208, 1110, 2, 4615, 3938, 2048, 5, 18, 109, 4615, 3938, 263, 502, 108, 648, 133, 67, 7, 42, 109, 11161, 547, 66, 7, 213, 33, 42, 34, 146, 28, 8, 52, 166, 126, 1, 641, 53, 125, 10, 77, 523, 4, 63, 25, 19, 13, 6287, 15, 91, 115, 25, 19, 13, 10592, 59, 7, 5, 57, 2902, 6, 8, 6493, 7, 5, 57, 2902, 6, 3, 2, 7, 5, 57, 364, 4, 110, 6493, 2, 3, 1744, 134, 5, 158, 799, 871, 198, 2902, 6, 8, 6493, 122, 40, 41, 5, 334, 356, 195, 22281, 3, 1187, 1, 236, 221, 632, 2, 249, 24, 4, 26, 546]",1534.0,23370657,785
"Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening.",CA: a cancer journal for clinicians,CA Cancer J Clin,2013-02-01,"Each year the American Cancer Society (ACS) publishes a summary of its recommendations for early cancer detection, a report on data and trends in cancer screening rates, and select issues related to cancer screening. In this issue of the journal, current ACS cancer screening guidelines are summarized, as are updated guidelines on cervical cancer screening and lung cancer screening with low-dose helical computed tomography. The latest data on the use of cancer screening from the National Health Interview Survey also are described, as are several issues related to screening coverage under the Patient Protection and Affordable Care Act of 2010.",Journal Article,2545.0,212.0,Each year the American Cancer Society ACS publishes a summary of its recommendations for early cancer detection a report on data and trends in cancer screening rates and select issues related to cancer screening In this issue of the journal current ACS cancer screening guidelines are summarized as are updated guidelines on cancer screening and cancer screening with low-dose helical computed tomography The latest data on the use of cancer screening from the National Health Interview Survey also are described as are several issues related to screening coverage under the Patient Protection and Affordable Care Act of 2010,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[296, 111, 3, 597, 12, 1174, 6004, 22457, 8, 1962, 1, 211, 883, 9, 191, 12, 638, 8, 414, 23, 74, 2, 1963, 4, 12, 453, 151, 2, 1717, 1553, 139, 6, 12, 453, 4, 26, 2537, 1, 3, 6685, 291, 6004, 12, 453, 677, 32, 3989, 22, 32, 2939, 677, 23, 12, 453, 2, 12, 453, 5, 154, 61, 6638, 1220, 872, 3, 5923, 74, 23, 3, 119, 1, 12, 453, 29, 3, 657, 341, 4313, 1407, 120, 32, 1027, 22, 32, 392, 1553, 139, 6, 453, 2139, 669, 3, 69, 3525, 2, 8216, 165, 2559, 1, 1120]",625.0,23378235,27
Intraoperative ultrasound guidance during intracavitary brachytherapy applicator placement in cervical cancer: the University of Alabama at Birmingham experience.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2013-03-01,"The objective of this study was to evaluate the University of Alabama at Birmingham experience with routine intraoperative ultrasound (IUS)-guided tandem placement for cervical cancer. Between 1999 and 2008, 243 cervical cancer patients underwent IUS-guided tandem placement. One hundred thirty-nine patients received low-dose-rate brachytherapy, and 104 received high-dose-rate brachytherapy. Three hundred fifty-six IUS-guided procedures were performed. Clinical and imaging data were retrospectively analyzed to evaluate complications requiring reinsertion of tandem placement in the context of IUS. All 243 cervical cancer patients completed intracavitary brachytherapy. Five (1.4%) of 356 IUS-guided applicator placements resulted in uterine perforation. All of these patients underwent successful tandem insertion on the second attempt, and no significant clinical sequelae occurred. Intraoperative ultrasound enabled direct uterine visualization and facilitated real-time feedback for selection of a suitable tandem length and curvature; no suboptimal placements requiring return to the operating room occurred (excluding perforation). In this large series, IUS guidance substantially increased the rate of successful applicator placement and diminished the rate of uterine perforation relative to historical controls. We strongly recommend the use of IUS guidance during operative intrauterine tandem placement for cervical cancer.",Journal Article,2517.0,19.0,The objective of this study was to evaluate the University of Alabama at Birmingham experience with routine intraoperative ultrasound IUS -guided tandem placement for cancer Between 1999 and 2008 243 cancer patients underwent IUS-guided tandem placement One hundred thirty-nine patients received low-dose-rate brachytherapy and 104 received high-dose-rate brachytherapy Three hundred fifty-six IUS-guided procedures were performed Clinical and imaging data were retrospectively analyzed to evaluate complications requiring reinsertion of tandem placement in the context of IUS All 243 cancer patients completed intracavitary brachytherapy Five 1.4 of 356 IUS-guided applicator placements resulted in perforation All of these patients underwent successful tandem insertion on the second attempt and no significant clinical sequelae occurred Intraoperative ultrasound enabled direct visualization and facilitated real-time feedback for selection of a suitable tandem length and curvature no suboptimal placements requiring return to the operating room occurred excluding perforation In this large series IUS guidance substantially increased the rate of successful applicator placement and diminished the rate of perforation relative to historical controls We strongly recommend the use of IUS guidance during operative intrauterine tandem placement for cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 461, 1, 26, 45, 10, 6, 376, 3, 1652, 1, 24990, 28, 28531, 730, 5, 1311, 1720, 1945, 18670, 1808, 2905, 2613, 9, 12, 59, 2043, 2, 1375, 6346, 12, 7, 208, 18670, 1808, 2905, 2613, 104, 1128, 977, 762, 7, 103, 154, 61, 116, 1536, 2, 3407, 103, 64, 61, 116, 1536, 169, 1128, 1461, 437, 18670, 1808, 1369, 11, 173, 38, 2, 270, 74, 11, 894, 311, 6, 376, 521, 1888, 44376, 1, 2905, 2613, 4, 3, 1533, 1, 18670, 62, 6346, 12, 7, 781, 9122, 1536, 365, 14, 39, 1, 8664, 18670, 1808, 8789, 25197, 627, 4, 4854, 62, 1, 46, 7, 208, 1401, 2905, 5099, 23, 3, 419, 3448, 2, 77, 93, 38, 4156, 489, 1720, 1945, 4387, 1196, 6234, 2, 4667, 1589, 98, 3983, 9, 881, 1, 8, 2884, 2905, 1318, 2, 30953, 77, 3291, 25197, 1888, 4656, 6, 3, 2584, 4698, 489, 3207, 4854, 4, 26, 375, 988, 18670, 2753, 2109, 101, 3, 116, 1, 1401, 8789, 2613, 2, 2849, 3, 116, 1, 4854, 580, 6, 2252, 535, 21, 1327, 2237, 3, 119, 1, 18670, 2753, 190, 1208, 18242, 2905, 2613, 9, 12]",1357.0,23385283,443
Radical surgery with individualized postoperative radiation for stage IB cervical cancer: oncologic outcomes and severe complications.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2013-03-01,"The objective of this study was to compare morbidity and outcome following radical surgery with or without adjuvant radiation therapy (RT) in the treatment of stages IB1-IB2 cervical carcinoma. We retrospectively identified 222 patients with stages IB1-IB2 cervical carcinoma treated initially with radical hysterectomy or radical trachelectomy with or without adjuvant RT from February 2000 to November 2009. All grade 3 or higher complications-those requiring interventional radiology, endoscopic evaluation, or operative intervention-were documented. One hundred fifty-eight patients (71%) underwent radical hysterectomy; 64 (29%) underwent radical trachelectomy. One hundred fifty-three patients (69%) underwent surgery alone; 69 (31%) received adjuvant radiation with or without chemosensitization. There was a statistically significant difference in the rate of total grades 1 to 5 late complications between the surgery-alone and surgery + RT groups (12% vs 32%, respectively; P < 0.001); however, the rate of grade 3 or higher complications was similar (5% vs 4%, respectively; P = 0.999). The progression-free and overall survival rates of the entire cohort were both 95%. The 5-year progression-free survival rates for the surgery-alone and surgery + RT groups were 93% and 90% (P = 0.172). The overall survival rates were 96% and 91%, respectively (P = 0.332). The majority of women with stages IB1-IB2 cervical cancer undergoing radical surgery do not require adjuvant RT, have excellent oncologic outcome, and have low severe complication rates. Nearly one third of our patients required postoperative radiation, with no statistically significant increase in severe complication rate and with similar oncologic outcomes compared with the surgery-only cohort. These data support the continued practice of radical surgery with individualized postoperative radiation for these patients.",Journal Article,2517.0,6.0,The objective of this study was to compare morbidity and outcome following radical surgery with or without adjuvant radiation therapy RT in the treatment of stages IB1-IB2 carcinoma We retrospectively identified 222 patients with stages IB1-IB2 carcinoma treated initially with radical hysterectomy or radical trachelectomy with or without adjuvant RT from February 2000 to November 2009 All grade 3 or higher complications-those requiring interventional radiology endoscopic evaluation or operative intervention-were documented One hundred fifty-eight patients 71 underwent radical hysterectomy 64 29 underwent radical trachelectomy One hundred fifty-three patients 69 underwent surgery alone 69 31 received adjuvant radiation with or without chemosensitization There was a statistically significant difference in the rate of total grades 1 to 5 late complications between the surgery-alone and surgery RT groups 12 vs 32 respectively P 0.001 however the rate of grade 3 or higher complications was similar 5 vs 4 respectively P 0.999 The progression-free and overall survival rates of the entire cohort were both 95 The 5-year progression-free survival rates for the surgery-alone and surgery RT groups were 93 and 90 P 0.172 The overall survival rates were 96 and 91 respectively P 0.332 The majority of women with stages IB1-IB2 cancer undergoing radical surgery do not require adjuvant RT have excellent oncologic outcome and have low severe complication rates Nearly one third of our patients required postoperative radiation with no statistically significant increase in severe complication rate and with similar oncologic outcomes compared with the surgery-only cohort These data support the continued practice of radical surgery with individualized postoperative radiation for these patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 461, 1, 26, 45, 10, 6, 932, 787, 2, 228, 366, 711, 152, 5, 15, 187, 249, 121, 36, 240, 4, 3, 24, 1, 1153, 8111, 9537, 134, 21, 894, 108, 5647, 7, 5, 1153, 8111, 9537, 134, 73, 1625, 5, 711, 2622, 15, 711, 5760, 5, 15, 187, 249, 240, 29, 3010, 1081, 6, 2868, 1238, 62, 88, 27, 15, 142, 521, 135, 1888, 6182, 4003, 2056, 451, 15, 1208, 788, 11, 1405, 104, 1128, 1461, 659, 7, 792, 208, 711, 2622, 660, 462, 208, 711, 5760, 104, 1128, 1461, 169, 7, 790, 208, 152, 279, 790, 456, 103, 249, 121, 5, 15, 187, 13594, 125, 10, 8, 712, 93, 523, 4, 3, 116, 1, 181, 2276, 14, 6, 33, 807, 521, 59, 3, 152, 279, 2, 152, 240, 271, 133, 105, 531, 106, 19, 13, 144, 137, 3, 116, 1, 88, 27, 15, 142, 521, 10, 288, 33, 105, 39, 106, 19, 13, 10323, 3, 91, 115, 2, 63, 25, 151, 1, 3, 1797, 180, 11, 110, 48, 3, 33, 111, 91, 115, 25, 151, 9, 3, 152, 279, 2, 152, 240, 271, 11, 966, 2, 424, 19, 13, 5312, 3, 63, 25, 151, 11, 921, 2, 970, 106, 19, 13, 10651, 3, 686, 1, 117, 5, 1153, 8111, 9537, 12, 479, 711, 152, 1022, 44, 1353, 249, 240, 47, 1503, 1998, 228, 2, 47, 154, 905, 1447, 151, 1857, 104, 1282, 1, 114, 7, 616, 573, 121, 5, 77, 712, 93, 344, 4, 905, 1447, 116, 2, 5, 288, 1998, 123, 72, 5, 3, 152, 158, 180, 46, 74, 538, 3, 1351, 758, 1, 711, 152, 5, 2596, 573, 121, 9, 46, 7]",1800.0,23392402,84
External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.,Cancer,Cancer,2013-03-01,"There is no validated system to identify prognostically distinct cohorts of women with uterine leiomyosarcoma (ULMS). By using an independent, pooled, multi-institutional, international patient cohort, the authors validated a recently proposed ULMS nomogram. The ULMS nomogram incorporated 7 clinical characteristics (age, tumor size, tumor grade, cervical involvement, locoregional metastases, distant metastases, and mitotic index (per 10 high-power fields) to predict overall survival (OS) after primary surgery. Independent cohorts from 2 sarcoma centers were included. Eligible women, at minimum, underwent a hysterectomy for primary, locally advanced, or metastatic ULMS and received part of their care at 1 of the centers between 1994 and 2010. In total, 187 women with ULMS were identified who met the above criteria described above (median age, 51 years; median tumor size, 9 cm; median mitotic index, 20 per 10 high-power fields). Tumors generally were high grade (88%), FIGO stage I or II (61%) without cervical involvement (93%) and without locoregional metastases (77%) or distant metastases (83%). The median OS and the 5-year OS rate were 4.5 years (95% confidence interval, 3.2-5.3 years) and 46%, respectively; and 65 women (35%) remained alive at last follow-up. The nomogram concordance index was 0.67(standard error, 0.02), which was as high as the concordance index from the initial cohort used for nomogram development. The concordance between actual OS and nomogram predictions suggests excellent calibration because predictions were within 1% of actual 5-year OS rates for patients with a predicted 5-year OS of less than 0.68. The ULMS nomogram was externally validated using independent cohorts. These findings support the international use of the ULMS nomogram prognostic of OS in ULMS.",Journal Article,2517.0,32.0,There is no validated system to identify prognostically distinct cohorts of women with leiomyosarcoma ULMS By using an independent pooled multi-institutional international patient cohort the authors validated a recently proposed ULMS nomogram The ULMS nomogram incorporated 7 clinical characteristics age tumor size tumor grade involvement locoregional metastases distant metastases and mitotic index per 10 high-power fields to predict overall survival OS after primary surgery Independent cohorts from 2 centers were included Eligible women at minimum underwent a hysterectomy for primary locally advanced or metastatic ULMS and received part of their care at 1 of the centers between 1994 and 2010 In total 187 women with ULMS were identified who met the above criteria described above median age 51 years median tumor size 9 cm median mitotic index 20 per 10 high-power fields Tumors generally were high grade 88 FIGO stage I or II 61 without involvement 93 and without locoregional metastases 77 or distant metastases 83 The median OS and the 5-year OS rate were 4.5 years 95 confidence interval 3.2-5.3 years and 46 respectively and 65 women 35 remained alive at last follow-up The nomogram concordance index was 0.67 standard error 0.02 which was as high as the concordance index from the initial cohort used for nomogram development The concordance between actual OS and nomogram predictions suggests excellent calibration because predictions were within 1 of actual 5-year OS rates for patients with a predicted 5-year OS of less than 0.68 The ULMS nomogram was externally validated using independent cohorts These findings support the international use of the ULMS nomogram prognostic of OS in ULMS,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,"[125, 16, 77, 938, 398, 6, 255, 7848, 834, 736, 1, 117, 5, 3717, 7038, 20, 75, 35, 306, 1830, 1414, 1115, 944, 69, 180, 3, 738, 938, 8, 761, 1587, 7038, 1981, 3, 7038, 1981, 2449, 67, 38, 374, 89, 30, 444, 30, 88, 799, 1325, 196, 626, 196, 2, 2346, 558, 379, 79, 64, 2349, 3130, 6, 678, 63, 25, 118, 50, 86, 152, 306, 736, 29, 18, 1168, 11, 159, 625, 117, 28, 2499, 208, 8, 2622, 9, 86, 795, 131, 15, 113, 7038, 2, 103, 760, 1, 136, 165, 28, 14, 1, 3, 1168, 59, 3023, 2, 1120, 4, 181, 5568, 117, 5, 7038, 11, 108, 54, 543, 3, 2090, 371, 1027, 2090, 52, 89, 725, 60, 52, 30, 444, 83, 494, 52, 2346, 558, 179, 379, 79, 64, 2349, 3130, 57, 1228, 11, 64, 88, 889, 3837, 82, 70, 15, 215, 713, 187, 799, 966, 2, 187, 1325, 196, 849, 15, 626, 196, 852, 3, 52, 118, 2, 3, 33, 111, 118, 116, 11, 39, 33, 60, 48, 307, 268, 27, 18, 33, 27, 60, 2, 641, 106, 2, 556, 117, 465, 958, 1701, 28, 1060, 166, 126, 3, 1981, 1827, 558, 10, 13, 598, 260, 3444, 13, 588, 92, 10, 22, 64, 22, 3, 1827, 558, 29, 3, 388, 180, 95, 9, 1981, 193, 3, 1827, 59, 3480, 118, 2, 1981, 4340, 844, 1503, 4821, 408, 4340, 11, 262, 14, 1, 3480, 33, 111, 118, 151, 9, 7, 5, 8, 783, 33, 111, 118, 1, 299, 76, 13, 806, 3, 7038, 1981, 10, 7753, 938, 75, 306, 736, 46, 272, 538, 3, 944, 119, 1, 3, 7038, 1981, 177, 1, 118, 4, 7038]",1708.0,23456762,623
Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2013-02-22,"Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults, and radiation is one of the main treatment modalities. However, cure rates remain low despite best available therapies. Immunotherapy is a promising modality that could work synergistically with radiation, which has been shown to increase antigen presentation and promote a proinflammatory tumor microenvironment. Programmed-death-1 (PD-1) is a surface receptor expressed on activated and exhausted T cells, which mediate T cell inhibition upon binding with its ligand PD-L1, expressed on many tumor types including human GBMs. We tested the combination of anti-PD-1 immunotherapy with stereotactic radiosurgery in a mouse orthotopic GBM model. We performed intracranial implantation of mouse glioma cell line GL261 transfected with luciferase into C57BL/6 mice. Mice were stratified into 4 treatment groups: (1) control; (2) radiation only; (3) anti-PD-1 antibody only; and (4) radiation plus anti-PD-1 antibody. Overall survival was quantified. The mice were killed on day 21 after implantation to assess immunologic parameters in the brain/tumor, cervical lymph nodes, and spleen. Improved survival was demonstrated with combination anti-PD-1 therapy plus radiation compared with either modality alone: median survival was 25 days in the control arm, 27 days in the anti-PD-1 antibody arm, 28 days in the radiation arm, and 53 days in the radiation plus anti-PD-1 therapy arm (P<.05 by log-rank Mantle-Cox). Long-term survival was seen only in the combined treatment arm, with a fraction (15%-40%) of animals alive at day 180+ after treatment. Immunologic data on day 21 after implantation showed increased tumor infiltration by cytotoxic T cells (CD8+/interferon-+/tumor necrosis factor-+) and decreased regulatory T cells (CD4+/FOXP3) in the combined treatment group compared with the single modality arms. The combination of PD-1 blockade and localized radiation therapy results in long-term survival in mice with orthotopic brain tumors. These studies provide strong preclinical evidence to support combination trials in patients with GBM.",Journal Article,2524.0,380.0,Glioblastoma multiforme GBM is the most common primary brain tumor in adults and radiation is one of the main treatment modalities However cure rates remain low despite best available therapies Immunotherapy is a promising modality that could work synergistically with radiation which has been shown to increase antigen presentation and promote a proinflammatory tumor microenvironment Programmed-death-1 PD-1 is a surface receptor expressed on activated and exhausted T cells which mediate T cell inhibition upon binding with its ligand PD-L1 expressed on many tumor types including human GBMs We tested the combination of anti-PD-1 immunotherapy with stereotactic radiosurgery in a mouse orthotopic GBM model We performed intracranial implantation of mouse glioma cell line GL261 transfected with luciferase into C57BL/6 mice Mice were stratified into 4 treatment groups 1 control 2 radiation only 3 anti-PD-1 antibody only and 4 radiation plus anti-PD-1 antibody Overall survival was quantified The mice were killed on day 21 after implantation to assess immunologic parameters in the brain/tumor lymph nodes and spleen Improved survival was demonstrated with combination anti-PD-1 therapy plus radiation compared with either modality alone median survival was 25 days in the control arm 27 days in the anti-PD-1 antibody arm 28 days in the radiation arm and 53 days in the radiation plus anti-PD-1 therapy arm P .05 by log-rank Mantle-Cox Long-term survival was seen only in the combined treatment arm with a fraction 15 -40 of animals alive at day 180+ after treatment Immunologic data on day 21 after implantation showed increased tumor infiltration by cytotoxic T cells CD8+/interferon-+/tumor necrosis factor-+ and decreased regulatory T cells CD4+/FOXP3 in the combined treatment group compared with the single modality arms The combination of PD-1 blockade and localized radiation therapy results in long-term survival in mice with orthotopic brain tumors These studies provide strong preclinical evidence to support combination trials in patients with GBM,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[996, 3238, 1136, 16, 3, 96, 186, 86, 342, 30, 4, 857, 2, 121, 16, 104, 1, 3, 1895, 24, 1558, 137, 1722, 151, 918, 154, 550, 824, 390, 235, 726, 16, 8, 721, 1396, 17, 359, 1357, 4240, 5, 121, 92, 71, 85, 443, 6, 344, 448, 1031, 2, 1617, 8, 5767, 30, 995, 1846, 273, 14, 333, 14, 16, 8, 1255, 153, 570, 23, 735, 2, 9584, 102, 37, 92, 3367, 102, 31, 297, 1548, 791, 5, 211, 1232, 333, 729, 570, 23, 445, 30, 630, 141, 171, 5556, 21, 650, 3, 150, 1, 312, 333, 14, 726, 5, 1729, 2192, 4, 8, 830, 2157, 1136, 202, 21, 173, 2089, 4314, 1, 830, 945, 31, 328, 16083, 3245, 5, 3864, 237, 7049, 49, 399, 399, 11, 1173, 237, 39, 24, 271, 14, 182, 18, 121, 158, 27, 312, 333, 14, 548, 158, 2, 39, 121, 349, 312, 333, 14, 548, 63, 25, 10, 2790, 3, 399, 11, 8239, 23, 218, 239, 50, 4314, 6, 423, 3042, 1038, 4, 3, 342, 30, 263, 502, 2, 4071, 231, 25, 10, 264, 5, 150, 312, 333, 14, 36, 349, 121, 72, 5, 361, 1396, 279, 52, 25, 10, 243, 162, 4, 3, 182, 475, 428, 162, 4, 3, 312, 333, 14, 548, 475, 339, 162, 4, 3, 121, 475, 2, 699, 162, 4, 3, 121, 349, 312, 333, 14, 36, 475, 19, 474, 20, 1066, 1026, 2757, 418, 319, 337, 25, 10, 527, 158, 4, 3, 397, 24, 475, 5, 8, 1509, 167, 327, 1, 2258, 1701, 28, 218, 3172, 50, 24, 3042, 74, 23, 218, 239, 50, 4314, 224, 101, 30, 2084, 20, 759, 102, 37, 968, 1688, 2655, 30, 1523, 161, 2014, 2, 340, 1253, 102, 37, 1440, 3548, 4, 3, 397, 24, 87, 72, 5, 3, 226, 1396, 1335, 3, 150, 1, 333, 14, 1189, 2, 909, 121, 36, 99, 4, 319, 337, 25, 4, 399, 5, 2157, 342, 57, 46, 94, 377, 1082, 693, 241, 6, 538, 150, 143, 4, 7, 5, 1136]",2068.0,23462419,706
Cervical cancer.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2013-03-01,"These NCCN Clinical Practice Guidelines in Oncology for Cervical Cancer focus on early-stage disease, because it occurs more frequently in the United States. After careful clinical evaluation and staging, the primary treatment of early-stage cervical cancer is either surgery or radiotherapy. These guidelines include fertility-sparing and non-fertility-sparing treatment for those with early-stage disease, which is disease confined to the uterus. A new fertility-sparing algorithm was added for select patients with stage IA and IB1 disease..",Journal Article,2517.0,91.0,These NCCN Clinical Practice Guidelines in Oncology for Cancer focus on early-stage disease because it occurs more frequently in the United States After careful clinical evaluation and staging the primary treatment of early-stage cancer is either surgery or radiotherapy These guidelines include fertility-sparing and non-fertility-sparing treatment for those with early-stage disease which is disease confined to the A new fertility-sparing algorithm was added for select patients with stage IA and IB1 disease..,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[46, 1944, 38, 758, 677, 4, 413, 9, 12, 1222, 23, 191, 82, 34, 408, 192, 1780, 80, 746, 4, 3, 1088, 907, 50, 3465, 38, 451, 2, 632, 3, 86, 24, 1, 191, 82, 12, 16, 361, 152, 15, 310, 46, 677, 643, 2954, 1851, 2, 220, 2954, 1851, 24, 9, 135, 5, 191, 82, 34, 92, 16, 34, 2902, 6, 3, 8, 217, 2954, 1851, 2124, 10, 1953, 9, 1717, 7, 5, 82, 3302, 2, 8111, 34]",513.0,23486458,857
"Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas.",Gynecologic oncology,Gynecol. Oncol.,2013-03-25,"The objective of this study is to assess effects of clinicopathologic risk factors and contemporary therapeutic interventions on high-risk uterine epithelial carcinoma outcomes. Patient-, disease-, and treatment-specific variables were annotated. Survival was estimated via the Kaplan-Meier method. Associations were evaluated with Cox proportional hazard regression and summarized using hazard ratios. From 1999 through 2008, therapy with curative intent was initiated for 119 grade 3 endometrioid (G3EC), 211 serous (USC), and 40 clear cell (CCC) carcinomas. Although clinicopathologic risk factors varied among the histologic subtypes, overall survival (OS) did not differ statistically between subtypes (P=.10) or in stage-for-stage comparative analyses (stage I/II, P=.45; stage III, P=.46; stage IV, P=.65). The 5-year cause-specific survival in stage I/II was 84.8%, 89.8%, and 83.9% for G3EC, USC, and CCC, respectively; multivariable modeling identified lymphovascular space involvement (LVSI) as the only independent prognostic factor (P=.02). For stage III, 5-year OS was 49.2% and 40.0% for G3EC and USC, respectively; multivariable modeling identified age (P<.001), LVSI (P<.001), unresectable nodal disease (P=.03), and regional radiotherapy (P=.01) as independent prognostic factors. For stage IV, 5-year OS was 8.7% and 12.1% for G3EC and USC, respectively; multivariable modeling identified LVSI (P=.002), cervical stromal invasion (P=.02), and adjuvant chemotherapy (P=.02) but not residual disease as independent prognostic factors. When controlled for disease stage, outcomes did not differ among high-risk histologic subtypes. LVSI was a significant adverse prognostic factor within all stages. The lack of improved outcomes with contemporary therapy suggests that more innovative therapeutic approaches should be given higher priority.",Comparative Study,2493.0,58.0,The objective of this study is to assess effects of clinicopathologic risk factors and contemporary therapeutic interventions on high-risk epithelial carcinoma outcomes Patient- disease- and treatment-specific variables were annotated Survival was estimated via the Kaplan-Meier method Associations were evaluated with Cox proportional hazard regression and summarized using hazard ratios From 1999 through 2008 therapy with curative intent was initiated for 119 grade 3 endometrioid G3EC 211 serous USC and 40 clear cell CCC carcinomas Although clinicopathologic risk factors varied among the histologic subtypes overall survival OS did not differ statistically between subtypes P=.10 or in stage-for-stage comparative analyses stage I/II P=.45 stage III P=.46 stage IV P=.65 The 5-year cause-specific survival in stage I/II was 84.8 89.8 and 83.9 for G3EC USC and CCC respectively multivariable modeling identified lymphovascular space involvement LVSI as the only independent prognostic factor P=.02 For stage III 5-year OS was 49.2 and 40.0 for G3EC and USC respectively multivariable modeling identified age P .001 LVSI P .001 unresectable nodal disease P=.03 and regional radiotherapy P=.01 as independent prognostic factors For stage IV 5-year OS was 8.7 and 12.1 for G3EC and USC respectively multivariable modeling identified LVSI P=.002 stromal invasion P=.02 and adjuvant chemotherapy P=.02 but not residual disease as independent prognostic factors When controlled for disease stage outcomes did not differ among high-risk histologic subtypes LVSI was a significant adverse prognostic factor within all stages The lack of improved outcomes with contemporary therapy suggests that more innovative therapeutic approaches should be given higher priority,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,"[3, 461, 1, 26, 45, 16, 6, 423, 176, 1, 1399, 43, 130, 2, 2667, 189, 1151, 23, 64, 43, 701, 134, 123, 69, 34, 2, 24, 112, 682, 11, 6196, 25, 10, 661, 847, 3, 876, 882, 596, 685, 11, 194, 5, 418, 831, 360, 320, 2, 3989, 75, 360, 1137, 29, 2043, 298, 1375, 36, 5, 1075, 1697, 10, 1917, 9, 4299, 88, 27, 3151, 21754, 5905, 1744, 8423, 2, 327, 885, 31, 5730, 826, 242, 1399, 43, 130, 2051, 107, 3, 884, 814, 63, 25, 118, 205, 44, 1505, 712, 59, 814, 19, 79, 15, 4, 82, 9, 82, 2352, 318, 82, 70, 215, 19, 512, 82, 316, 19, 641, 82, 478, 19, 556, 3, 33, 111, 708, 112, 25, 4, 82, 70, 215, 10, 874, 66, 887, 66, 2, 852, 83, 9, 21754, 8423, 2, 5730, 106, 658, 2057, 108, 2933, 3865, 799, 8004, 22, 3, 158, 306, 177, 161, 19, 588, 9, 82, 316, 33, 111, 118, 10, 739, 18, 2, 327, 13, 9, 21754, 2, 8423, 106, 658, 2057, 108, 89, 19, 144, 8004, 19, 144, 1468, 779, 34, 19, 680, 2, 951, 310, 19, 355, 22, 306, 177, 130, 9, 82, 478, 33, 111, 118, 10, 66, 67, 2, 133, 14, 9, 21754, 2, 8423, 106, 658, 2057, 108, 8004, 19, 1111, 1126, 578, 19, 588, 2, 249, 56, 19, 588, 84, 44, 753, 34, 22, 306, 177, 130, 198, 1149, 9, 34, 82, 123, 205, 44, 1505, 107, 64, 43, 884, 814, 8004, 10, 8, 93, 290, 177, 161, 262, 62, 1153, 3, 926, 1, 231, 123, 5, 2667, 36, 844, 17, 80, 4019, 189, 611, 257, 40, 447, 142, 4690]",1762.0,23535279,827
Risk of residual disease and invasive carcinoma in women treated for adenocarcinoma in situ of the cervix.,Gynecologic oncology,Gynecol. Oncol.,2013-03-28,"Cervical adenocarcinoma in situ (AIS) is increasing in incidence among reproductive-age women. Cervical conization is an alternative to hysterectomy that allows future fertility, however reports regarding the risk of residual AIS and underlying adenocarcinoma are conflicting. The purpose of this study was to determine the outcomes of a large cohort of women treated for AIS. The medical records of 180 women with cervical AIS evaluated at the University of Texas MD Anderson Cancer Center and its outlying clinics between 1983 and 2011 were reviewed for demographic information, treatment history, pathologic findings and outcomes. The mean age at diagnosis was 33.8years (range 17.6-76.1years). 172 of the 180 women had at least one cone biopsy performed, with 110 (64.0%) undergoing a cold knife cone (CKC), and 62 (36.0%) undergoing a loop electrosurgical excision procedure (LEEP) as their initial method of treatment. Positive margins were noted in 35.0% of patients undergoing CKC compared with 55.6% undergoing LEEP (p=0.017). 71 patients ultimately underwent hysterectomy with residual disease noted in 10 patients (14.1%), 8 patients (11.3%) with residual AIS and 2 patients (2.8%) with invasive carcinoma. Of the 101 patients who did not undergo hysterectomy, 2 patients (2.0%) developed recurrent AIS at a median of 27.5months (range 18-37months) from the last cone, and none developed invasive carcinoma. Patients undergoing conservative management for AIS with cervical conization alone should be monitored closely and counseled regarding the potential risks of residual and recurrent disease, even when negative cone margins are obtained.",Journal Article,2490.0,19.0,adenocarcinoma in situ AIS is increasing in incidence among reproductive-age women conization is an alternative to hysterectomy that allows future fertility however reports regarding the risk of residual AIS and underlying adenocarcinoma are conflicting The purpose of this study was to determine the outcomes of a large cohort of women treated for AIS The medical records of 180 women with AIS evaluated at the University of Texas MD Anderson Cancer Center and its outlying clinics between 1983 and 2011 were reviewed for demographic information treatment history pathologic findings and outcomes The mean age at diagnosis was 33.8years range 17.6-76.1years 172 of the 180 women had at least one cone biopsy performed with 110 64.0 undergoing a cold knife cone CKC and 62 36.0 undergoing a loop electrosurgical excision procedure LEEP as their initial method of treatment Positive margins were noted in 35.0 of patients undergoing CKC compared with 55.6 undergoing LEEP p=0.017 71 patients ultimately underwent hysterectomy with residual disease noted in 10 patients 14.1 8 patients 11.3 with residual AIS and 2 patients 2.8 with invasive carcinoma Of the 101 patients who did not undergo hysterectomy 2 patients 2.0 developed recurrent AIS at a median of 27.5months range 18-37months from the last cone and none developed invasive carcinoma Patients undergoing conservative management for AIS with conization alone should be monitored closely and counseled regarding the potential risks of residual and recurrent disease even when negative cone margins are obtained,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[449, 4, 957, 3826, 16, 602, 4, 287, 107, 3705, 89, 117, 8755, 16, 35, 1091, 6, 2622, 17, 2333, 508, 2954, 137, 1198, 666, 3, 43, 1, 753, 3826, 2, 1181, 449, 32, 4274, 3, 743, 1, 26, 45, 10, 6, 223, 3, 123, 1, 8, 375, 180, 1, 117, 73, 9, 3826, 3, 484, 1064, 1, 3172, 117, 5, 3826, 194, 28, 3, 1652, 1, 2738, 2244, 1929, 12, 574, 2, 211, 44048, 4736, 59, 6656, 2, 1132, 11, 446, 9, 1540, 487, 24, 532, 510, 272, 2, 123, 3, 313, 89, 28, 147, 10, 466, 29418, 184, 269, 49, 846, 29147, 5312, 1, 3, 3172, 117, 42, 28, 506, 104, 6939, 411, 173, 5, 3129, 660, 13, 479, 8, 5945, 8045, 6939, 28403, 2, 744, 511, 13, 479, 8, 4432, 24548, 1366, 1299, 19966, 22, 136, 388, 596, 1, 24, 109, 1012, 11, 1051, 4, 465, 13, 1, 7, 479, 28403, 72, 5, 614, 49, 479, 19966, 19, 13, 3825, 792, 7, 2050, 208, 2622, 5, 753, 34, 1051, 4, 79, 7, 213, 14, 66, 7, 175, 27, 5, 753, 3826, 2, 18, 7, 18, 66, 5, 416, 134, 1, 3, 2338, 7, 54, 205, 44, 1251, 2622, 18, 7, 18, 13, 276, 387, 3826, 28, 8, 52, 1, 428, 15029, 184, 203, 62656, 29, 3, 1060, 6939, 2, 1292, 276, 416, 134, 7, 479, 4476, 284, 9, 3826, 5, 8755, 279, 257, 40, 2909, 3210, 2, 10411, 666, 3, 174, 1098, 1, 753, 2, 387, 34, 871, 198, 199, 6939, 1012, 32, 683]",1567.0,23541795,480
Intraoperative Electron Beam Radiotherapy (IOERT) in the management of locally advanced or recurrent cervical cancer.,"Radiation oncology (London, England)",Radiat Oncol,2013-04-08,"To report outcomes in women with locally recurrent or advanced cervical cancer who received intraoperative electron beam radiotherapy (IOERT) as a component of therapy. From 1983 to 2010, 86 patients with locally recurrent (n=73, 85%) or primary advanced (n=13, 15%) cervical cancer received IOERT following surgery. Common surgeries included pelvic exenteration (n=26; 30%) or sidewall resection (n=22; 26%). The median IOERT dose was 15 Gy (range, 6.25-25 Gy). Sixty-one patients (71%) received perioperative external beam radiotherapy (EBRT; median dose, 45 Gy). Forty-one patients (48%) received perioperative chemotherapy. Median follow-up was 2.7 years (range, 0.1-25.5 years). Resections were classified as R0 (n=35, 41%), R1 (n=30, 35%), or R2 (n=21, 24%). Cumulative incidences of central (within the IOERT field) and locoregional relapse at 3 years were 23 and 38%, respectively. The 3-year cumulative incidence of distant relapse was 43%. Median survival was 15 months, and 3-year Kaplan-Meier estimates of cause-specific (CSS) and overall survival (OS) were 31 and 25%, respectively. On multivariate analysis, pelvic exenteration (p=0.02) and perioperative EBRT (p=0.009) were associated with improved central control in patients with recurrent disease. Recurrence within 6 months of initial therapy was associated with reduced CSS (p=0.001). Common IOERT-related toxicities included peripheral neuropathy (n=16), ureteral stenosis (n=4), and bowel fistula/perforation (n=4). Eleven of 16 patients with neuropathy required long-term pain medication. Long-term survival is possible with combined modality therapy including IOERT for advanced cervical cancer. Distant relapse is common, yet a significant number of patients experienced local progression in spite of aggressive treatment. In addition to consideration of disease- and treatment-related morbidity, other factors to be considered when selecting patients for this approach include the time interval from initial therapy to recurrence and whether the patient is able to receive perioperative EBRT and pelvic exenteration in addition to IOERT.",Journal Article,2479.0,22.0,To report outcomes in women with locally recurrent or advanced cancer who received intraoperative electron beam radiotherapy IOERT as a component of therapy From 1983 to 2010 86 patients with locally recurrent n 73 85 or primary advanced n 13 15 cancer received IOERT following surgery Common surgeries included pelvic exenteration n 26 30 or sidewall resection n 22 26 The median IOERT dose was 15 Gy range 6.25-25 Gy Sixty-one patients 71 received perioperative external beam radiotherapy EBRT median dose 45 Gy Forty-one patients 48 received perioperative chemotherapy Median follow-up was 2.7 years range 0.1-25.5 years Resections were classified as R0 n 35 41 R1 n 30 35 or R2 n 21 24 Cumulative incidences of central within the IOERT field and locoregional relapse at 3 years were 23 and 38 respectively The 3-year cumulative incidence of distant relapse was 43 Median survival was 15 months and 3-year Kaplan-Meier estimates of cause-specific CSS and overall survival OS were 31 and 25 respectively On multivariate analysis pelvic exenteration p 0.02 and perioperative EBRT p 0.009 were associated with improved central control in patients with recurrent disease Recurrence within 6 months of initial therapy was associated with reduced CSS p 0.001 Common IOERT-related toxicities included peripheral neuropathy n 16 ureteral stenosis n 4 and bowel fistula/perforation n 4 Eleven of 16 patients with neuropathy required long-term pain medication Long-term survival is possible with combined modality therapy including IOERT for advanced cancer Distant relapse is common yet a significant number of patients experienced local progression in spite of aggressive treatment In addition to consideration of disease- and treatment-related morbidity other factors to be considered when selecting patients for this approach include the time interval from initial therapy to recurrence and whether the patient is able to receive perioperative EBRT and pelvic exenteration in addition to IOERT,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 414, 123, 4, 117, 5, 795, 387, 15, 131, 12, 54, 103, 1720, 4560, 1345, 310, 8366, 22, 8, 1249, 1, 36, 29, 6656, 6, 1120, 868, 7, 5, 795, 387, 78, 803, 772, 15, 86, 131, 78, 233, 167, 12, 103, 8366, 366, 152, 186, 5305, 159, 1110, 5668, 78, 432, 201, 15, 12599, 170, 78, 350, 432, 3, 52, 8366, 61, 10, 167, 381, 184, 49, 243, 243, 381, 1746, 104, 7, 792, 103, 1547, 1455, 1345, 310, 1883, 52, 61, 512, 381, 1213, 104, 7, 576, 103, 1547, 56, 52, 166, 126, 10, 18, 67, 60, 184, 13, 14, 243, 33, 60, 2185, 11, 1373, 22, 2328, 78, 465, 605, 3239, 78, 201, 465, 15, 4332, 78, 239, 259, 967, 3981, 1, 854, 262, 3, 8366, 1067, 2, 1325, 429, 28, 27, 60, 11, 382, 2, 519, 106, 3, 27, 111, 967, 287, 1, 626, 429, 10, 601, 52, 25, 10, 167, 53, 2, 27, 111, 876, 882, 1423, 1, 708, 112, 2687, 2, 63, 25, 118, 11, 456, 2, 243, 106, 23, 331, 65, 1110, 5668, 19, 13, 588, 2, 1547, 1883, 19, 13, 2376, 11, 41, 5, 231, 854, 182, 4, 7, 5, 387, 34, 146, 262, 49, 53, 1, 388, 36, 10, 41, 5, 405, 2687, 19, 13, 144, 186, 8366, 139, 385, 159, 672, 1751, 78, 245, 7213, 6935, 78, 39, 2, 1659, 4920, 4854, 78, 39, 2627, 1, 245, 7, 5, 1751, 616, 319, 337, 559, 3012, 319, 337, 25, 16, 899, 5, 397, 1396, 36, 141, 8366, 9, 131, 12, 626, 429, 16, 186, 1145, 8, 93, 207, 1, 7, 592, 293, 91, 4, 9018, 1, 571, 24, 4, 352, 6, 2415, 1, 34, 2, 24, 139, 787, 127, 130, 6, 40, 515, 198, 3675, 7, 9, 26, 353, 643, 3, 98, 268, 29, 388, 36, 6, 146, 2, 317, 3, 69, 16, 1665, 6, 560, 1547, 1883, 2, 1110, 5668, 4, 352, 6, 8366]",1990.0,23566444,206
Hematologic toxicity in RTOG 0418: a phase 2 study of postoperative IMRT for gynecologic cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2013-05-01,"Intensity modulated radiation therapy (IMRT), compared with conventional 4-field treatment, can reduce the volume of bone marrow irradiated. Pelvic bone marrow sparing has produced a clinically significant reduction in hematologic toxicity (HT). This analysis investigated HT in Radiation Therapy Oncology Group (RTOG) 0418, a prospective study to test the feasibility of delivering postoperative IMRT for cervical and endometrial cancer in a multiinstitutional setting. Patients in the RTOG 0418 study were treated with postoperative IMRT to 50.4 Gy to the pelvic lymphatics and vagina. Endometrial cancer patients received IMRT alone, whereas patients with cervical cancer received IMRT and weekly cisplatin (40 mg/m(2)). Pelvic bone marrow was defined within the treatment field by using a computed tomography density-based autocontouring algorithm. The volume of bone marrow receiving 10, 20, 30, and 40 Gy and the median dose to bone marrow were correlated with HT, graded by Common Terminology Criteria for Adverse Events, version 3.0, criteria. Eighty-three patients were eligible for analysis (43 with endometrial cancer and 40 with cervical cancer). Patients with cervical cancer treated with weekly cisplatin and pelvic IMRT had grades 1-5 HT (23%, 33%, 25%, 0%, and 0% of patients, respectively). Among patients with cervical cancer, 83% received 5 or more cycles of cisplatin, and 90% received at least 4 cycles of cisplatin. The median percentage volume of bone marrow receiving 10, 20, 30, and 40 Gy in all 83 patients, respectively, was 96%, 84%, 61%, and 37%. Among cervical cancer patients with a V40 >37%, 75% had grade 2 or higher HT compared with 40% of patients with a V40 less than or equal to 37% (P =.025). Cervical cancer patients with a median bone marrow dose of >34.2 Gy also had higher rates of grade  2 HT than did those with a dose of  34.2 Gy (74% vs 43%, P=.049). Pelvic IMRT with weekly cisplatin is associated with low rates of HT and high rates of weekly cisplatin use. The volume of bone marrow receiving 40 Gy and the median dose to bone marrow correlated with higher rates of grade  2 toxicity among patients receiving weekly cisplatin (cervical cancer patients). Evaluation and limitation of the volume of bone marrow treated with pelvic IMRT is warranted in patients receiving concurrent chemotherapy.","Clinical Trial, Phase II",2456.0,93.0,Intensity modulated radiation therapy IMRT compared with conventional 4-field treatment can reduce the volume of marrow irradiated Pelvic marrow sparing has produced a clinically significant reduction in hematologic toxicity HT This analysis investigated HT in Radiation Therapy Oncology Group RTOG 0418 a prospective study to test the feasibility of delivering postoperative IMRT for and cancer in a multiinstitutional setting Patients in the RTOG 0418 study were treated with postoperative IMRT to 50.4 Gy to the pelvic lymphatics and vagina cancer patients received IMRT alone whereas patients with cancer received IMRT and weekly cisplatin 40 mg/m 2 Pelvic marrow was defined within the treatment field by using a computed tomography density-based autocontouring algorithm The volume of marrow receiving 10 20 30 and 40 Gy and the median dose to marrow were correlated with HT graded by Common Terminology Criteria for Adverse Events version 3.0 criteria Eighty-three patients were eligible for analysis 43 with cancer and 40 with cancer Patients with cancer treated with weekly cisplatin and pelvic IMRT had grades 1-5 HT 23 33 25 0 and 0 of patients respectively Among patients with cancer 83 received 5 or more cycles of cisplatin and 90 received at least 4 cycles of cisplatin The median percentage volume of marrow receiving 10 20 30 and 40 Gy in all 83 patients respectively was 96 84 61 and 37 Among cancer patients with a V40 37 75 had grade 2 or higher HT compared with 40 of patients with a V40 less than or equal to 37 P =.025 cancer patients with a median marrow dose of 34.2 Gy also had higher rates of grade  2 HT than did those with a dose of  34.2 Gy 74 vs 43 P=.049 Pelvic IMRT with weekly cisplatin is associated with low rates of HT and high rates of weekly cisplatin use The volume of marrow receiving 40 Gy and the median dose to marrow correlated with higher rates of grade  2 toxicity among patients receiving weekly cisplatin cancer patients Evaluation and limitation of the volume of marrow treated with pelvic IMRT is warranted in patients receiving concurrent chemotherapy,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[837, 1757, 121, 36, 964, 72, 5, 809, 39, 1067, 24, 122, 969, 3, 433, 1, 581, 2398, 1110, 581, 1851, 71, 1687, 8, 505, 93, 628, 4, 813, 155, 3152, 26, 65, 565, 3152, 4, 121, 36, 413, 87, 3931, 31487, 8, 482, 45, 6, 412, 3, 1437, 1, 4790, 573, 964, 9, 2, 12, 4, 8, 13781, 546, 7, 4, 3, 3931, 31487, 45, 11, 73, 5, 573, 964, 6, 212, 39, 381, 6, 3, 1110, 9335, 2, 7553, 12, 7, 103, 964, 279, 547, 7, 5, 12, 103, 964, 2, 709, 540, 327, 81, 188, 18, 1110, 581, 10, 395, 262, 3, 24, 1067, 20, 75, 8, 1220, 872, 1263, 90, 46268, 2124, 3, 433, 1, 581, 357, 79, 179, 201, 2, 327, 381, 2, 3, 52, 61, 6, 581, 11, 438, 5, 3152, 3468, 20, 186, 3462, 371, 9, 290, 281, 2256, 27, 13, 371, 2207, 169, 7, 11, 625, 9, 65, 601, 5, 12, 2, 327, 5, 12, 7, 5, 12, 73, 5, 709, 540, 2, 1110, 964, 42, 2276, 14, 33, 3152, 382, 466, 243, 13, 2, 13, 1, 7, 106, 107, 7, 5, 12, 852, 103, 33, 15, 80, 410, 1, 540, 2, 424, 103, 28, 506, 39, 410, 1, 540, 3, 52, 1150, 433, 1, 581, 357, 79, 179, 201, 2, 327, 381, 4, 62, 852, 7, 106, 10, 921, 874, 713, 2, 567, 107, 12, 7, 5, 8, 12454, 567, 481, 42, 88, 18, 15, 142, 3152, 72, 5, 327, 1, 7, 5, 8, 12454, 299, 76, 15, 2997, 6, 567, 19, 4067, 12, 7, 5, 8, 52, 581, 61, 1, 562, 18, 381, 120, 42, 142, 151, 1, 88, 749, 18, 3152, 76, 205, 135, 5, 8, 61, 1, 1552, 562, 18, 381, 794, 105, 601, 19, 5121, 1110, 964, 5, 709, 540, 16, 41, 5, 154, 151, 1, 3152, 2, 64, 151, 1, 709, 540, 119, 3, 433, 1, 581, 357, 327, 381, 2, 3, 52, 61, 6, 581, 438, 5, 142, 151, 1, 88, 749, 18, 155, 107, 7, 357, 709, 540, 12, 7, 451, 2, 5039, 1, 3, 433, 1, 581, 73, 5, 1110, 964, 16, 1197, 4, 7, 357, 750, 56]",2106.0,23582248,725
Altered drainage patterns in patients with melanoma and previous axillary dissection.,The Journal of dermatology,J. Dermatol.,2013-04-17,"The incidence of melanoma is increasing rapidly in the United States. Sentinel lymph node biopsy is an important diagnostic tool in the treatment and staging of melanoma. However, many patients with melanoma will have had lymph node surgery for previous melanoma or breast cancer. We set out to examine alterations in drainage patterns in patients with previous axillary dissection for breast cancer. We reviewed four patients with truncal and/or extremity melanomas and examined their lymphoscintigraphy and drainage patterns. Three patients with truncal melanoma mapped to cervical lymph nodes and a fourth patient with an arm melanoma mapped to her previously dissected axilla. Sentinel lymph node mapping is still an important adjunct in patients with melanoma despite previous axillary dissection. ",Case Reports,2470.0,2.0,The incidence of is increasing rapidly in the United States Sentinel lymph node biopsy is an important diagnostic tool in the treatment and staging of However many patients with will have had lymph node surgery for previous or cancer We set out to examine alterations in drainage patterns in patients with previous axillary dissection for cancer We reviewed four patients with truncal and/or extremity melanomas and examined their lymphoscintigraphy and drainage patterns Three patients with truncal mapped to lymph nodes and a fourth patient with an arm mapped to her previously dissected axilla Sentinel lymph node mapping is still an important adjunct in patients with despite previous axillary dissection,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 287, 1, 16, 602, 1755, 4, 3, 1088, 907, 1323, 263, 289, 411, 16, 35, 305, 752, 1515, 4, 3, 24, 2, 632, 1, 137, 445, 7, 5, 303, 47, 42, 263, 289, 152, 9, 698, 15, 12, 21, 916, 1205, 6, 1004, 593, 4, 3528, 764, 4, 7, 5, 698, 1210, 1161, 9, 12, 21, 446, 294, 7, 5, 9170, 2, 15, 2678, 1965, 2, 409, 136, 6849, 2, 3528, 764, 169, 7, 5, 9170, 6224, 6, 263, 502, 2, 8, 3608, 69, 5, 35, 475, 6224, 6, 1084, 373, 7973, 5053, 1323, 263, 289, 2568, 16, 1234, 35, 305, 5471, 4, 7, 5, 550, 698, 1210, 1161]",708.0,23594177,491
"Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.",Gynecologic oncology,Gynecol. Oncol.,2013-04-18,"Cervical and vaginal cancers have virally-mediated or mutated defects in DNA damage repair responses, making these cancers sensible targets for ribonucleotide reductase inhibition during radiochemotherapy. We conducted a phase II study evaluating 3 weekly 2-hour intravenous 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, 25 mg/m(2)) co-administered with 1 weekly intravenous cisplatin (40 mg/m(2)) and daily pelvic radiation (45 Gy) in women with stage I(B2)-IV(B) cervical (n=22) or stage II-IV vaginal (n=3) cancers. Brachytherapy followed (40 Gy). Toxicity was monitored by common terminology criteria for adverse events (version 3.0). The primary end point of response was assessed by 3-month posttherapy 2-[(18)F] fluoro-2-deoxy-d-glucose positron emission tomography (PET/CT) and clinical examination. 3-AP radiochemotherapy achieved clinical responses in 24 (96% [95% confidence interval: 80-99%]) of 25 patients (median follow-up 20 months, range 2-35 months). 23 (96% [95% confidence interval: 80-99%]) of 24 patients had 3-month posttherapy PET/CT scans that recorded metabolic activity in the cervix or vagina equal or less than that of the cardiac blood pool, suggesting complete metabolic responses. The most frequent 3-AP radiochemotherapy-related adverse events included fatigue, nausea, diarrhea, and reversible hematological and electrolyte abnormalities. The addition of 3-AP to cisplatin radiochemotherapy was tolerable and produced high rates of clinical and metabolic responses in women with cervical and vaginal cancers. Future randomized phase II and III clinical trials of 3-AP radiochemotherapy are warranted.","Clinical Trial, Phase II",2469.0,54.0,and cancers have virally-mediated or mutated defects in DNA damage repair responses making these cancers sensible targets for ribonucleotide reductase inhibition during radiochemotherapy We conducted a phase II study evaluating 3 weekly 2-hour intravenous 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 3-AP 25 mg/m 2 co-administered with 1 weekly intravenous cisplatin 40 mg/m 2 and daily pelvic radiation 45 Gy in women with stage I B2 -IV B n=22 or stage II-IV n=3 cancers Brachytherapy followed 40 Gy Toxicity was monitored by common terminology criteria for adverse events version 3.0 The primary end point of response was assessed by 3-month posttherapy 2- 18 F fluoro-2-deoxy-d-glucose positron emission tomography PET/CT and clinical examination 3-AP radiochemotherapy achieved clinical responses in 24 96 95 confidence interval 80-99 of 25 patients median follow-up 20 months range 2-35 months 23 96 95 confidence interval 80-99 of 24 patients had 3-month posttherapy PET/CT scans that recorded metabolic activity in the cervix or vagina equal or less than that of the blood pool suggesting complete metabolic responses The most frequent 3-AP radiochemotherapy-related adverse events included fatigue nausea diarrhea and reversible hematological and electrolyte abnormalities The addition of 3-AP to cisplatin radiochemotherapy was tolerable and produced high rates of clinical and metabolic responses in women with and cancers Future randomized phase II and III clinical trials of 3-AP radiochemotherapy are warranted,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,"[2, 163, 47, 18811, 517, 15, 1185, 2945, 4, 261, 1350, 972, 253, 1079, 46, 163, 22365, 637, 9, 7050, 4027, 297, 190, 6836, 21, 426, 8, 124, 215, 45, 1435, 22635, 709, 18, 2583, 1262, 27, 23330, 18, 23331, 24704, 27, 2517, 243, 81, 188, 18, 1269, 468, 5, 40336, 709, 1262, 540, 327, 81, 188, 18, 2, 391, 1110, 121, 512, 381, 4, 117, 5, 82, 70, 6617, 478, 132, 78, 350, 15, 82, 215, 478, 78, 27, 163, 1536, 370, 327, 381, 155, 10, 2909, 20, 186, 3462, 371, 9, 290, 281, 2256, 27, 13, 3, 86, 396, 741, 1, 51, 10, 275, 20, 27, 811, 8163, 18, 203, 1068, 6231, 18, 6149, 427, 2522, 1900, 1799, 872, 495, 425, 2, 38, 1385, 27, 2517, 6836, 513, 38, 253, 4, 259, 921, 48, 307, 268, 493, 1058, 1, 243, 7, 52, 166, 126, 179, 53, 184, 18, 465, 53, 382, 921, 48, 307, 268, 493, 1058, 1, 259, 7, 42, 27, 811, 8163, 495, 425, 1441, 17, 1872, 1436, 128, 4, 3, 3629, 15, 7553, 2997, 15, 299, 76, 17, 1, 3, 315, 6545, 802, 236, 1436, 253, 3, 96, 908, 27, 2517, 6836, 139, 290, 281, 159, 613, 1218, 1172, 2, 2786, 2890, 2, 10834, 1171, 3, 352, 1, 27, 2517, 6, 540, 6836, 10, 2668, 2, 1687, 64, 151, 1, 38, 2, 1436, 253, 4, 117, 5, 2, 163, 508, 384, 124, 215, 2, 316, 38, 143, 1, 27, 2517, 6836, 32, 1197]",1533.0,23603372,228
Differential cytotoxicity and particle action of hydroxyapatite nanoparticles in human cancer cells.,"Nanomedicine (London, England)",Nanomedicine (Lond),2013-04-24,"While hydroxyapatite nanoparticles (HAPNs) have been reported to exhibit anticancer effects on several types of human cancer cells, no investigation has been performed to compare their cytotoxicity with different types of cancer cells. The objective of the present study is to investigate the cytotoxic action of HAPNs in different types of human cancer cell and to explore the possible mechanisms involved. Rod-shaped HAPNs were prepared by the aqueous precipitation method and then labeled with fluorescein isothiocyanate to visualize the cellular uptake and distribution. Their cytotoxicity to three human carcinoma cell lines (gastric cancer cells [MGC80-3], cervical adenocarcinoma epithelial cells [HeLa] and hepatoma cells [HepG2], as well as to normal human hepatocyte cells [L-02]) was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Cell apoptosis was characterized by the changes in nuclear morphology with 4',6-diamidino-2-phenylindole staining and by flow cytometric analysis with Annexin V-fluorescein isothiocyanate/propidium iodide double staining. Furthermore, the activity of apoptotic proteins (caspase-3, -8 and -9), intracellular reactive oxygen species and glutathione levels were analyzed in HAPN-treated cells. The cellular uptake of HAPNs was studied using flow cytometry analysis, and changes in intracellular calcium levels were investigated using the Ca(2+)-sensitive fluorescent dye, fluo-3 AM. HAPNs significantly inhibited cell proliferation and induced apoptosis of cancer cells with an order of MGC80-3 > HepG2 > HeLa, but had no impact on normal hepatic cells (L-02). The increase in apoptosis was accompanied by the activation of caspase-3 and -9, but not activation of caspase-8. Moreover, HAPN treatment led to reactive oxygen species generation and decreased intracellular glutathione in cancer cells, with the most remarkable reactive oxygen species burst in HeLa cells. The degree of cytotoxicity did not correlate with the cellular uptake efficiency of HAPNs. However, more HAPNs were found inside the nucleus of MGC80-3 cells, and an increase in the intracellular calcium level was observed in all cancer cells, with the highest level also detected in MGC80-3. Varying cytotoxicity of HAPNs was observed in different cancer cell types. Our results suggest that possible mechanisms of cytotoxicity in various types of cancer cells could be different. The elevated calcium concentration and nuclear localization of the particles might be the main mechanism of growth inhibition by HAPNs in cancer cells.",Comparative Study,2463.0,39.0,"While hydroxyapatite nanoparticles HAPNs have been reported to exhibit anticancer effects on several types of human cancer cells no investigation has been performed to compare their cytotoxicity with different types of cancer cells The objective of the present study is to investigate the cytotoxic action of HAPNs in different types of human cancer cell and to explore the possible mechanisms involved Rod-shaped HAPNs were prepared by the aqueous precipitation method and then labeled with fluorescein isothiocyanate to visualize the cellular uptake and distribution Their cytotoxicity to three human carcinoma cell lines cancer cells MGC80-3 adenocarcinoma epithelial cells HeLa and hepatoma cells HepG2 as well as to normal human cells L-02 was assessed using the 3- 4,5-dimethylthiazol-2-yl -2,5-diphenyltetrazolium bromide assay Cell apoptosis was characterized by the changes in nuclear morphology with 4',6-diamidino-2-phenylindole staining and by flow cytometric analysis with Annexin V-fluorescein isothiocyanate/propidium iodide double staining Furthermore the activity of apoptotic proteins caspase-3 -8 and -9 intracellular reactive oxygen species and glutathione levels were analyzed in HAPN-treated cells The cellular uptake of HAPNs was studied using flow cytometry analysis and changes in intracellular calcium levels were investigated using the Ca 2+ -sensitive fluorescent dye fluo-3 AM HAPNs significantly inhibited cell proliferation and induced apoptosis of cancer cells with an order of MGC80-3 HepG2 HeLa but had no impact on normal hepatic cells L-02 The increase in apoptosis was accompanied by the activation of caspase-3 and -9 but not activation of caspase-8 Moreover HAPN treatment led to reactive oxygen species generation and decreased intracellular glutathione in cancer cells with the most remarkable reactive oxygen species burst in HeLa cells The degree of cytotoxicity did not correlate with the cellular uptake efficiency of HAPNs However more HAPNs were found inside the nucleus of MGC80-3 cells and an increase in the intracellular calcium level was observed in all cancer cells with the highest level also detected in MGC80-3 Varying cytotoxicity of HAPNs was observed in different cancer cell types Our results suggest that possible mechanisms of cytotoxicity in various types of cancer cells could be different The elevated calcium concentration and nuclear localization of the particles might be the main mechanism of growth inhibition by HAPNs in cancer cells",0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,"[369, 27279, 2889, 13725, 47, 85, 210, 6, 2239, 1475, 176, 23, 392, 630, 1, 171, 12, 37, 77, 940, 71, 85, 173, 6, 932, 136, 1408, 5, 338, 630, 1, 12, 37, 3, 461, 1, 3, 364, 45, 16, 6, 963, 3, 759, 1578, 1, 13725, 4, 338, 630, 1, 171, 12, 31, 2, 6, 1645, 3, 899, 483, 646, 14202, 8902, 13725, 11, 4421, 20, 3, 13152, 18912, 596, 2, 818, 2841, 5, 14425, 13790, 6, 9360, 3, 763, 1135, 2, 1395, 136, 1408, 6, 169, 171, 134, 31, 285, 12, 37, 29429, 27, 449, 701, 37, 8466, 2, 13822, 37, 8286, 22, 149, 22, 6, 295, 171, 37, 805, 588, 10, 275, 75, 3, 27, 39, 33, 12094, 18, 7983, 18, 33, 12525, 10168, 719, 31, 351, 10, 765, 20, 3, 400, 4, 928, 2567, 5, 14401, 49, 19425, 18, 19426, 1029, 2, 20, 1412, 6226, 65, 5, 4850, 603, 14425, 13790, 10839, 8456, 1627, 1029, 798, 3, 128, 1, 1631, 652, 1469, 27, 66, 2, 83, 2087, 2163, 2848, 2915, 2, 4571, 148, 11, 311, 4, 20006, 73, 37, 3, 763, 1135, 1, 13725, 10, 656, 75, 1412, 1914, 65, 2, 400, 4, 2087, 3299, 148, 11, 565, 75, 3, 1568, 18, 745, 2910, 3796, 62727, 27, 5886, 13725, 97, 879, 31, 457, 2, 277, 351, 1, 12, 37, 5, 35, 1732, 1, 29429, 27, 8286, 8466, 84, 42, 77, 345, 23, 295, 939, 37, 805, 588, 3, 344, 4, 351, 10, 2756, 20, 3, 363, 1, 1469, 27, 2, 83, 84, 44, 363, 1, 1469, 66, 1393, 20006, 24, 836, 6, 2163, 2848, 2915, 914, 2, 340, 2087, 4571, 4, 12, 37, 5, 3, 96, 3813, 2163, 2848, 2915, 18192, 4, 8466, 37, 3, 1444, 1, 1408, 205, 44, 1513, 5, 3, 763, 1135, 2904, 1, 13725, 137, 80, 13725, 11, 204, 8133, 3, 4262, 1, 29429, 27, 37, 2, 35, 344, 4, 3, 2087, 3299, 301, 10, 164, 4, 62, 12, 37, 5, 3, 1076, 301, 120, 530, 4, 29429, 27, 2990, 1408, 1, 13725, 10, 164, 4, 338, 12, 31, 630, 114, 99, 309, 17, 899, 483, 1, 1408, 4, 747, 630, 1, 12, 37, 359, 40, 338, 3, 804, 3299, 1227, 2, 928, 2145, 1, 3, 6095, 822, 40, 3, 1895, 670, 1, 129, 297, 20, 13725, 4, 12, 37]",2504.0,23614636,345
Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2013-04-29,"A 69-year-old woman was referred for further evaluation and management of relapsed angioimmunoblastic T-cell lymphoma. At diagnosis, she received six cycles of dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) and achieved a complete response (CR). Her first surveillance computed tomography scan 3 months later demonstrated enlarging cervical lymphadenopathy. A lymph node excision confirmed relapsed angioimmunoblastic T-cell lymphoma with atypical lymphocytes expressing CD3, CD4, CD10, PD-1, and EBER, with loss of CD5 (Fig 1). A clonal T-cell receptor beta and gamma rearrangement by polymerase chain reaction was identical to that in her initial diagnostic biopsy. At our initial consultation, options for standard as well as investigational therapies were discussed, and HLA typing was initiated. The patient was enrolled onto an investigational phase II study; however, she developed progressive disease after two cycles. She was then treated with romidepsin 14 mg/m(2) administered intravenously for 3 consecutive weeks with 1 week off. After two cycles, she achieved a partial response, and after four additional cycles, she maintained her response without further improvement. We discussed additional treatment options.",Case Reports,2458.0,17.0,A 69-year-old woman was referred for further evaluation and management of relapsed angioimmunoblastic T-cell At diagnosis she received six cycles of dose-adjusted EPOCH etoposide prednisone vincristine cyclophosphamide and doxorubicin and achieved a complete response CR Her first surveillance computed tomography scan 3 months later demonstrated enlarging lymphadenopathy A lymph node excision confirmed relapsed angioimmunoblastic T-cell with atypical lymphocytes expressing CD3 CD4 CD10 PD-1 and EBER with loss of CD5 Fig 1 A clonal T-cell receptor beta and gamma rearrangement by polymerase chain reaction was identical to that in her initial diagnostic biopsy At our initial consultation options for standard as well as investigational therapies were discussed and HLA typing was initiated The patient was enrolled onto an investigational phase II study however she developed progressive disease after two cycles She was then treated with romidepsin 14 mg/m 2 administered intravenously for 3 consecutive weeks with 1 week off After two cycles she achieved a partial response and after four additional cycles she maintained her response without further improvement We discussed additional treatment options,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[8, 790, 111, 1095, 2854, 10, 1995, 9, 195, 451, 2, 284, 1, 591, 10722, 102, 31, 28, 147, 3109, 103, 437, 410, 1, 61, 586, 7959, 1934, 1979, 2132, 1112, 2, 856, 2, 513, 8, 236, 51, 684, 1084, 157, 617, 1220, 872, 1657, 27, 53, 1559, 264, 11961, 4962, 8, 263, 289, 1366, 557, 591, 10722, 102, 31, 5, 1973, 1594, 1046, 3117, 1440, 6289, 333, 14, 2, 12345, 5, 407, 1, 6349, 14197, 14, 8, 1946, 102, 31, 153, 1090, 2, 1705, 2675, 20, 1451, 1260, 1329, 10, 3038, 6, 17, 4, 1084, 388, 752, 411, 28, 114, 388, 2981, 838, 9, 260, 22, 149, 22, 3093, 235, 11, 1588, 2, 1160, 10656, 10, 1917, 3, 69, 10, 346, 3301, 35, 3093, 124, 215, 45, 137, 3109, 276, 1014, 34, 50, 100, 410, 3109, 10, 818, 73, 5, 6256, 213, 81, 188, 18, 468, 1672, 9, 27, 935, 244, 5, 14, 647, 1889, 50, 100, 410, 3109, 513, 8, 450, 51, 2, 50, 294, 402, 410, 3109, 1955, 1084, 51, 187, 195, 767, 21, 1588, 402, 24, 838]",1211.0,23630204,503
Galectin-7 levels predict radiation response in squamous cell carcinoma of the cervix.,Gynecologic oncology,Gynecol. Oncol.,2013-04-30,"We previously found that galectin-7 was upregulated in patients with cervical cancer who remained recurrence-free after chemoradiation. We hypothesized that pretreatment levels of galectin-7 predict radiation response in patients with squamous cell carcinoma (SCC) of the cervix. Galectin-7 expression was assessed by immunohistochemical staining of a tissue microarray of paraffin-embedded specimens from 161 patients with cervical SCC treated with definitive radiation therapy in 1980-1999. Galectin-7 expression was scored as absent or present. Distant metastasis-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS) were computed using the Kaplan-Meier method and log-rank tests. The median age at diagnosis was 45 years (range 21-85) and median follow-up interval was 71 months (range 0-285). Of the 161 patients, 105 (65%) had FIGO stage IB disease, 18 (11%) stage IIA, and 38 (24%) stage IIB. Median tumor diameter was 5.5 cm (range 3.5-8). Seven patients (4%) received concurrent chemotherapy; 139 patients (86%) had galectin-7-positive tumors and 22 (14%) galectin-7-negative tumors. Five-year DMFS rates for patients with galectin-7-positive versus -negative tumors were 73% and 55% (p=0.05); DSS, 65% and 36% (p=0.004); and OS, 64% and 36% (p=0.005). In multivariate analysis adjusting for age, stage, and tumor diameter, galectin-7 expression remained a significant predictor of DMFS (hazard ratio [HR]=0.43, p=0.03), DSS (HR=0.34, p=0.001), and OS (HR=0.34, p=0.001). Elevated galectin-7 expression is associated with improved outcomes after radiation therapy for cervical cancer. Further studies are required to validate these findings and clarify the role of galectin-7 in disease progression and radiation response.",Journal Article,2457.0,19.0,We previously found that galectin-7 was upregulated in patients with cancer who remained recurrence-free after chemoradiation We hypothesized that pretreatment levels of galectin-7 predict radiation response in patients with squamous cell carcinoma SCC of the cervix Galectin-7 expression was assessed by immunohistochemical staining of a tissue microarray of paraffin-embedded specimens from 161 patients with SCC treated with definitive radiation therapy in 1980-1999 Galectin-7 expression was scored as absent or present Distant metastasis-free survival DMFS disease-specific survival DSS and overall survival OS were computed using the Kaplan-Meier method and log-rank tests The median age at diagnosis was 45 years range 21-85 and median follow-up interval was 71 months range 0-285 Of the 161 patients 105 65 had FIGO stage IB disease 18 11 stage IIA and 38 24 stage IIB Median tumor diameter was 5.5 cm range 3.5-8 Seven patients 4 received concurrent chemotherapy 139 patients 86 had galectin-7-positive tumors and 22 14 galectin-7-negative tumors Five-year DMFS rates for patients with galectin-7-positive versus -negative tumors were 73 and 55 p=0.05 DSS 65 and 36 p=0.004 and OS 64 and 36 p=0.005 In multivariate analysis adjusting for age stage and tumor diameter galectin-7 expression remained a significant predictor of DMFS hazard ratio HR =0.43 p=0.03 DSS HR=0.34 p=0.001 and OS HR=0.34 p=0.001 Elevated galectin-7 expression is associated with improved outcomes after radiation therapy for cancer Further studies are required to validate these findings and clarify the role of galectin-7 in disease progression and radiation response,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 373, 204, 17, 8063, 67, 10, 2684, 4, 7, 5, 12, 54, 958, 146, 115, 50, 975, 21, 1237, 17, 1194, 148, 1, 8063, 67, 678, 121, 51, 4, 7, 5, 691, 31, 134, 1791, 1, 3, 3629, 8063, 67, 55, 10, 275, 20, 1382, 1029, 1, 8, 246, 1727, 1, 2487, 2505, 623, 29, 5377, 7, 5, 1791, 73, 5, 1057, 121, 36, 4, 4376, 2043, 8063, 67, 55, 10, 3179, 22, 3269, 15, 364, 626, 278, 115, 25, 5930, 34, 112, 25, 1788, 2, 63, 25, 118, 11, 1220, 75, 3, 876, 882, 596, 2, 1066, 1026, 895, 3, 52, 89, 28, 147, 10, 512, 60, 184, 239, 772, 2, 52, 166, 126, 268, 10, 792, 53, 184, 13, 8121, 1, 3, 5377, 7, 3263, 556, 42, 3837, 82, 3180, 34, 203, 175, 82, 4088, 2, 519, 259, 82, 3884, 52, 30, 2549, 10, 33, 33, 494, 184, 27, 33, 66, 648, 7, 39, 103, 750, 56, 4929, 7, 868, 42, 8063, 67, 109, 57, 2, 350, 213, 8063, 67, 199, 57, 365, 111, 5930, 151, 9, 7, 5, 8063, 67, 109, 185, 199, 57, 11, 803, 2, 614, 19, 13, 474, 1788, 556, 2, 511, 19, 13, 1520, 2, 118, 660, 2, 511, 19, 13, 1614, 4, 331, 65, 1358, 9, 89, 82, 2, 30, 2549, 8063, 67, 55, 958, 8, 93, 980, 1, 5930, 360, 197, 168, 13, 601, 19, 13, 680, 1788, 168, 13, 562, 19, 13, 144, 2, 118, 168, 13, 562, 19, 13, 144, 804, 8063, 67, 55, 16, 41, 5, 231, 123, 50, 121, 36, 9, 12, 195, 94, 32, 616, 6, 2183, 46, 272, 2, 3968, 3, 200, 1, 8063, 67, 4, 34, 91, 2, 121, 51]",1650.0,23643871,225
The Patient Protection and Affordable Care Act: impact on the care of gynecologic oncology patients in the absence of Medicaid expansion in central Virginia.,Gynecologic oncology,Gynecol. Oncol.,2013-05-03,"Many gynecologic oncology (GO) patients in Virginia are low income and their care is supplemented by Disproportionate Share Hospital (DSH) funds. Our objective is to estimate how many new GO patients may lose access to care if the state forgoes Medicaid expansion. New patients referred to the GO service between July 1, 2010 and July 1, 2012 were identified. Data were collected regarding age, race, referral diagnosis, payor, and state pay scale. Pay scale 1 (PS1) is equal to the federal poverty level (FPL). Assumptions included the following: (1) pay scale is a surrogate for income, (2) PS1 patients will be ineligible for discounted insurance through the exchanges, and (3) decreasing DSH funds will result in a reduction of the free-care pool. There were 1623 referrals to the GO service and the majority (83%) was Caucasian. The payor distribution was 44% commercial insurance, 5.6% Medicaid, 31% Medicare, and 10.4% uninsured. Among the 361 women who were PS1, 32% were uninsured. Thirty percent of PS1 patients were minorities and 47.4% had a malignancy. Of note, 52% of new patients with cervical cancer were PS1. Seven percent of new GO patients are PS1 and uninsured. This population contains a disproportionate number of minorities and women with cancer. These women will have difficulty affording care as DSH funding decreases, particularly in states with lean Medicaid that opt out of Medicaid expansion. The burden of lack of access to care will be shouldered by an unfortunate few.",Journal Article,2454.0,5.0,Many gynecologic oncology GO patients in Virginia are low income and their care is supplemented by Disproportionate Share Hospital DSH funds Our objective is to estimate how many new GO patients may lose access to care if the state forgoes Medicaid expansion New patients referred to the GO service between July 1 2010 and July 1 2012 were identified Data were collected regarding age race referral diagnosis payor and state pay scale Pay scale 1 PS1 is equal to the federal poverty level FPL Assumptions included the following 1 pay scale is a surrogate for income 2 PS1 patients will be ineligible for discounted insurance through the exchanges and 3 decreasing DSH funds will result in a reduction of the free-care pool There were 1623 referrals to the GO service and the majority 83 was Caucasian The payor distribution was 44 commercial insurance 5.6 Medicaid 31 Medicare and 10.4 uninsured Among the 361 women who were PS1 32 were uninsured Thirty percent of PS1 patients were minorities and 47.4 had a malignancy Of note 52 of new patients with cancer were PS1 Seven percent of new GO patients are PS1 and uninsured This population contains a disproportionate number of minorities and women with cancer These women will have difficulty affording care as DSH funding decreases particularly in states with lean Medicaid that opt out of Medicaid expansion The burden of lack of access to care will be shouldered by an unfortunate few,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[445, 1512, 413, 3537, 7, 4, 11457, 32, 154, 2306, 2, 136, 165, 16, 7687, 20, 14156, 4349, 702, 40356, 20478, 114, 461, 16, 6, 1191, 832, 445, 217, 3537, 7, 68, 11027, 1655, 6, 165, 492, 3, 1309, 62775, 2843, 1422, 217, 7, 1995, 6, 3, 3537, 3086, 59, 2066, 14, 1120, 2, 2066, 14, 1195, 11, 108, 74, 11, 786, 666, 89, 1047, 2096, 147, 27092, 2, 1309, 6974, 1124, 6974, 1124, 14, 26894, 16, 2997, 6, 3, 8536, 7583, 301, 19329, 8387, 159, 3, 366, 14, 6974, 1124, 16, 8, 2592, 9, 2306, 18, 26894, 7, 303, 40, 3773, 9, 15123, 1935, 298, 3, 25236, 2, 27, 2777, 40356, 20478, 303, 757, 4, 8, 628, 1, 3, 115, 165, 6545, 125, 11, 29312, 6902, 6, 3, 3537, 3086, 2, 3, 686, 852, 10, 3229, 3, 27092, 1395, 10, 584, 4860, 1935, 33, 49, 2843, 456, 1378, 2, 79, 39, 4955, 107, 3, 9234, 117, 54, 11, 26894, 531, 11, 4955, 977, 714, 1, 26894, 7, 11, 6727, 2, 662, 39, 42, 8, 710, 1, 5739, 653, 1, 217, 7, 5, 12, 11, 26894, 648, 714, 1, 217, 3537, 7, 32, 26894, 2, 4955, 26, 266, 4862, 8, 14156, 207, 1, 6727, 2, 117, 5, 12, 46, 117, 303, 47, 4035, 18887, 165, 22, 40356, 5468, 2140, 823, 4, 907, 5, 6949, 2843, 17, 8966, 1205, 1, 2843, 1422, 3, 892, 1, 926, 1, 1655, 6, 165, 303, 40, 62776, 20, 35, 30763, 1021]",1437.0,23648470,72
Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2013-06-01,"To describe the incidence of low-volume ultrastage-detected metastases in sentinel lymph nodes (SLNs) identified at surgical staging for endometrial carcinoma and to correlate it with depth of myoinvasion and tumor grade. We reviewed all patients who underwent primary surgery for endometrial carcinoma with successful mapping of at least one SLN at our institution from September 2005 to December 2011. All patients underwent a cervical injection for mapping. The SLN ultrastaging protocol involved cutting an additional 2 adjacent 5-m sections at each of 2 levels, 50-m apart, from each paraffin block lacking metastatic carcinoma on routine hematoxylin and eosin (H&E) staining. At each level, one slide was stained with H&E and with immunohistochemistry (IHC) using anticytokeratin AE1:AE3.Micrometastases (tumor deposits >0.2 mm and 2 mm) and isolated tumor cells (0.2 mm) were classified as low-volume ultrastage-detected metastases if pathologic ultrastaging was the only method allowing detection of such nodal disease. Of 508 patients with successful mapping, 413 patients (81.3%) had endometrioid carcinoma. Sixty-four (12.6%) of the 508 patients had positive nodes: routine H&E detected 35 patients (6.9%), ultrastaging detected an additional 23 patients (4.5%) who would have otherwise been missed (4 micrometastases and 19 isolated tumor cells), and 6 patients (1.2%) had metastatic disease in their non-SLNs. The incidence rates of low-volume ultrastage-detected nodal metastases in patients with grades 1, 2, and 3 tumors were 3.8%, 3.4%, and 6.9%, respectively. The frequency rates of low-volume ultrastage-detected metastases in patients with a depth of myoinvasion of 0, less than 50%, and 50% or more were 0.8%, 8.0%, and 7.4%, respectively. Lymphovascular invasion was present in 20 (87%) of the cases containing low-volume ultrastage-detected metastases in the lymph nodes. Sentinel lymph node mapping with pathologic ultrastaging in endometrial carcinoma detects additional low-volume metastases (4.5%) that would otherwise go undetected with routine evaluations. Our data support the incorporation of pathologic ultrastaging of SLNs in endometrial carcinoma with any degree of myoinvasion. The oncologic significance of low-volume nodal metastases requires long-term follow-up.",Journal Article,2425.0,112.0,To describe the incidence of low-volume ultrastage-detected metastases in sentinel lymph nodes SLNs identified at surgical staging for carcinoma and to correlate it with depth of myoinvasion and tumor grade We reviewed all patients who underwent primary surgery for carcinoma with successful mapping of at least one SLN at our institution from September 2005 to December 2011 All patients underwent a injection for mapping The SLN ultrastaging protocol involved cutting an additional 2 adjacent 5-m sections at each of 2 levels 50-m apart from each paraffin block lacking metastatic carcinoma on routine hematoxylin and eosin H E staining At each level one slide was stained with H E and with immunohistochemistry IHC using anticytokeratin AE1 AE3.Micrometastases tumor deposits 0.2 mm and 2 mm and isolated tumor cells 0.2 mm were classified as low-volume ultrastage-detected metastases if pathologic ultrastaging was the only method allowing detection of such nodal disease Of 508 patients with successful mapping 413 patients 81.3 had endometrioid carcinoma Sixty-four 12.6 of the 508 patients had positive nodes routine H E detected 35 patients 6.9 ultrastaging detected an additional 23 patients 4.5 who would have otherwise been missed 4 micrometastases and 19 isolated tumor cells and 6 patients 1.2 had metastatic disease in their non-SLNs The incidence rates of low-volume ultrastage-detected nodal metastases in patients with grades 1 2 and 3 tumors were 3.8 3.4 and 6.9 respectively The frequency rates of low-volume ultrastage-detected metastases in patients with a depth of myoinvasion of 0 less than 50 and 50 or more were 0.8 8.0 and 7.4 respectively Lymphovascular invasion was present in 20 87 of the cases containing low-volume ultrastage-detected metastases in the lymph nodes Sentinel lymph node mapping with pathologic ultrastaging in carcinoma detects additional low-volume metastases 4.5 that would otherwise go undetected with routine evaluations Our data support the incorporation of pathologic ultrastaging of SLNs in carcinoma with any degree of myoinvasion The oncologic significance of low-volume nodal metastases requires long-term follow-up,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 897, 3, 287, 1, 154, 433, 29437, 530, 196, 4, 1323, 263, 502, 2642, 108, 28, 221, 632, 9, 134, 2, 6, 1513, 192, 5, 2436, 1, 19166, 2, 30, 88, 21, 446, 62, 7, 54, 208, 86, 152, 9, 134, 5, 1401, 2568, 1, 28, 506, 104, 1099, 28, 114, 731, 29, 2636, 1242, 6, 1397, 1132, 62, 7, 208, 8, 1754, 9, 2568, 3, 1099, 11338, 1182, 646, 13360, 35, 402, 18, 2086, 33, 4810, 3013, 28, 296, 1, 18, 148, 212, 4810, 5461, 29, 296, 2487, 2381, 1941, 113, 134, 23, 1311, 6209, 2, 5975, 555, 563, 1029, 28, 296, 301, 104, 7911, 10, 3386, 5, 555, 563, 2, 5, 888, 1289, 75, 33293, 20204, 20168, 5485, 30, 7626, 13, 18, 321, 2, 6006, 321, 2, 1355, 30, 37, 8710, 18, 321, 11, 1373, 22, 154, 433, 29437, 530, 196, 492, 510, 11338, 10, 3, 158, 596, 2952, 638, 1, 225, 779, 34, 1, 11598, 7, 5, 1401, 2568, 10436, 7, 865, 27, 42, 3151, 134, 1746, 294, 133, 49, 1, 3, 11598, 7, 42, 109, 502, 1311, 555, 563, 530, 465, 7, 49, 83, 11338, 530, 35, 402, 382, 7, 39, 33, 54, 688, 47, 2632, 85, 5149, 39, 5485, 2, 326, 1355, 30, 37, 2, 49, 7, 14, 18, 42, 113, 34, 4, 136, 220, 2642, 3, 287, 151, 1, 154, 433, 29437, 530, 779, 196, 4, 7, 5, 2276, 14, 18, 2, 27, 57, 11, 27, 66, 27, 39, 2, 49, 83, 106, 3, 675, 151, 1, 154, 433, 29437, 530, 196, 4, 7, 5, 8, 2436, 1, 19166, 1, 13, 299, 76, 212, 2, 212, 15, 80, 11, 13, 66, 66, 13, 2, 67, 39, 106, 2933, 578, 10, 364, 4, 179, 912, 1, 3, 140, 1101, 154, 433, 29437, 530, 196, 4, 3, 263, 502, 1323, 263, 289, 2568, 5, 510, 11338, 4, 134, 6887, 402, 154, 433, 196, 39, 33, 17, 688, 2632, 3537, 11449, 5, 1311, 3816, 114, 74, 538, 3, 2838, 1, 510, 11338, 1, 2642, 4, 134, 5, 500, 1444, 1, 19166, 3, 1998, 724, 1, 154, 433, 779, 196, 1706, 319, 337, 166, 126]",2175.0,23694985,54
Expanding the indications for radical trachelectomy: a report on 29 patients with stage IB1 tumors measuring 2 to 4 centimeters.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2013-07-01,"Radical trachelectomy has enabled select women with stage I cervical cancer to maintain fertility after treatment. Tumor size greater than 2 cm has been considered a contraindication, and those patients denied trachelectomy. We report our trachelectomy experience with tumors measuring 2 to 4 cm. We retrospectively reviewed the medical records of all patients planned for fertility-sparing radical trachelectomy. Largest tumor dimension was determined by physical examination, preoperative magnetic resonance imaging, or pathologic evaluation. No patient received neoadjuvant chemotherapy. Twenty-nine (26%) of 110 patients had stage IB1 disease with tumors 2 to 4 cm. Median age was 31 years (range, 22-40 years), and 83% were nulliparous. Thirteen patients (45%) had squamous cell carcinoma, 12 patients (41%) had adenocarcinoma, and 4 patients (14%) had adenosquamous carcinoma. Thirteen (45%) of 29 patients had positive pelvic nodes. All para-aortic nodes were negative. Owing to intraoperative frozen section, 13 patients (45%) underwent immediate hysterectomy and 1 patient (3%) definitive chemoradiation. Owing to high-risk features on final pathology, 6 patients (21%) who had retained their uterus received chemoradiation. Nine patients (31%) underwent a fertility-sparing procedure. At a median follow-up of 44 months (range, 1-90 months), there was one recurrence. Expanding radical trachelectomy inclusion criteria to women with 2- to 4-cm tumors allows for a fertility-sparing procedure in 30% of patients who would otherwise have been denied the option, with no compromise in oncologic outcome.",Clinical Trial,2395.0,41.0,Radical trachelectomy has enabled select women with stage I cancer to maintain fertility after treatment Tumor size greater than 2 cm has been considered a contraindication and those patients denied trachelectomy We report our trachelectomy experience with tumors measuring 2 to 4 cm We retrospectively reviewed the medical records of all patients planned for fertility-sparing radical trachelectomy Largest tumor dimension was determined by physical examination preoperative magnetic resonance imaging or pathologic evaluation No patient received neoadjuvant chemotherapy Twenty-nine 26 of 110 patients had stage IB1 disease with tumors 2 to 4 cm Median age was 31 years range 22-40 years and 83 were nulliparous Thirteen patients 45 had squamous cell carcinoma 12 patients 41 had adenocarcinoma and 4 patients 14 had adenosquamous carcinoma Thirteen 45 of 29 patients had positive pelvic nodes All para-aortic nodes were negative Owing to intraoperative frozen section 13 patients 45 underwent immediate hysterectomy and 1 patient 3 definitive chemoradiation Owing to high-risk features on final pathology 6 patients 21 who had retained their received chemoradiation Nine patients 31 underwent a fertility-sparing procedure At a median follow-up of 44 months range 1-90 months there was one recurrence Expanding radical trachelectomy inclusion criteria to women with 2- to 4-cm tumors allows for a fertility-sparing procedure in 30 of patients who would otherwise have been denied the option with no compromise in oncologic outcome,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[711, 5760, 71, 4387, 1717, 117, 5, 82, 70, 12, 6, 3040, 2954, 50, 24, 30, 444, 378, 76, 18, 494, 71, 85, 515, 8, 8363, 2, 135, 7, 12601, 5760, 21, 414, 114, 5760, 730, 5, 57, 2978, 18, 6, 39, 494, 21, 894, 446, 3, 484, 1064, 1, 62, 7, 1465, 9, 2954, 1851, 711, 5760, 2166, 30, 6384, 10, 509, 20, 900, 1385, 498, 1484, 1535, 270, 15, 510, 451, 77, 69, 103, 536, 56, 737, 762, 432, 1, 3129, 7, 42, 82, 8111, 34, 5, 57, 18, 6, 39, 494, 52, 89, 10, 456, 60, 184, 350, 327, 60, 2, 852, 11, 9475, 3170, 7, 512, 42, 691, 31, 134, 133, 7, 605, 42, 449, 2, 39, 7, 213, 42, 8067, 134, 3170, 512, 1, 462, 7, 42, 109, 1110, 502, 62, 4615, 3938, 502, 11, 199, 3421, 6, 1720, 3015, 2917, 233, 7, 512, 208, 2181, 2622, 2, 14, 69, 27, 1057, 975, 3421, 6, 64, 43, 404, 23, 1457, 1117, 49, 7, 239, 54, 42, 3532, 136, 103, 975, 762, 7, 456, 208, 8, 2954, 1851, 1299, 28, 8, 52, 166, 126, 1, 584, 53, 184, 14, 424, 53, 125, 10, 104, 146, 4304, 711, 5760, 1680, 371, 6, 117, 5, 18, 6, 39, 494, 57, 2333, 9, 8, 2954, 1851, 1299, 4, 201, 1, 7, 54, 688, 2632, 47, 85, 12601, 3, 1501, 5, 77, 4665, 4, 1998, 228]",1533.0,23714706,133
Clinical characteristics of patients with multiple potentially human papillomavirus-related malignancies.,Head & neck,Head Neck,2013-09-02,"Human papillomavirus (HPV) is a causative factor in squamous cell carcinomas of the anus, penis, vagina, vulva, and head and neck, and adenocarcinoma of the cervix. We examined the demographics, clinical characteristics, and timing of multiple potentially HPV-related cancers in individual patients. One hundred forty-three patients were identified with 300 potentially HPV-related cancers. The median follow-up from index and second cancer was 18.5 years and 3.2 years, respectively. Median age at index and second cancer was 45 and 60.5 years of age, respectively, with a median interval of 11 years. Cervical cancer was the most common initial diagnosis (61.7%), whereas head and neck squamous cell carcinoma (HNSCC) was the most common second cancer (57.6%). These data suggest differential patterns for development of multiple HPV-related cancers based upon clinical characteristics. Prospective longitudinal and population-based studies are warranted to understand the impact of these findings and opportunities for intervention and screening.",Comparative Study,2332.0,2.0,Human papillomavirus HPV is a causative factor in squamous cell carcinomas of the anus penis vagina vulva and head and and adenocarcinoma of the cervix We examined the demographics clinical characteristics and timing of multiple potentially HPV-related cancers in individual patients One hundred forty-three patients were identified with 300 potentially HPV-related cancers The median follow-up from index and second cancer was 18.5 years and 3.2 years respectively Median age at index and second cancer was 45 and 60.5 years of age respectively with a median interval of 11 years cancer was the most common initial diagnosis 61.7 whereas head and squamous cell carcinoma HNSCC was the most common second cancer 57.6 These data suggest differential patterns for development of multiple HPV-related cancers based upon clinical characteristics Prospective longitudinal and population-based studies are warranted to understand the impact of these findings and opportunities for intervention and screening,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 3242, 933, 16, 8, 8088, 161, 4, 691, 31, 826, 1, 3, 15178, 10954, 7553, 9263, 2, 718, 2, 2, 449, 1, 3, 3629, 21, 409, 3, 2221, 38, 374, 2, 1972, 1, 232, 751, 933, 139, 163, 4, 797, 7, 104, 1128, 1213, 169, 7, 11, 108, 5, 2036, 751, 933, 139, 163, 3, 52, 166, 126, 29, 558, 2, 419, 12, 10, 203, 33, 60, 2, 27, 18, 60, 106, 52, 89, 28, 558, 2, 419, 12, 10, 512, 2, 335, 33, 60, 1, 89, 106, 5, 8, 52, 268, 1, 175, 60, 12, 10, 3, 96, 186, 388, 147, 713, 67, 547, 718, 2, 691, 31, 134, 1209, 10, 3, 96, 186, 419, 12, 696, 49, 46, 74, 309, 1777, 764, 9, 193, 1, 232, 933, 139, 163, 90, 1548, 38, 374, 482, 2380, 2, 266, 90, 94, 32, 1197, 6, 1640, 3, 345, 1, 46, 272, 2, 2605, 9, 788, 2, 453]",1001.0,23720126,564
Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis.,Thyroid : official journal of the American Thyroid Association,Thyroid,2013-09-04,"Serum thyrotropin (TSH) concentration and thyroid autoimmunity may be of prognostic importance in differentiated thyroid cancer (DTC). Preoperative serum TSH level has been associated with higher DTC stage in cross-sectional studies; data are contradictory on the significance of thyroid autoimmunity at the time of diagnosis. We sought to assess whether preoperative serum TSH and perioperative antithyroglobulin antibodies (TgAb) were associated with thyroid cancer stage and outcome in DTC patients followed by the National Thyroid Cancer Treatment Cooperative Study, a large multicenter thyroid cancer registry. Patients registered after 1996 with available preoperative serum TSH (n=617; the TSH cohort) or perioperative TgAb status (n=1770; the TgAb cohort) were analyzed for tumor stage, persistent disease, recurrence, and overall survival (OS; median follow-up, 5.5 years). Parametric tests assessed log-transformed TSH, and categorical variables were tested with chi square. Disease-free survival (DFS) and OS was assessed with Cox models. Geometric mean serum TSH levels were higher in patients with higher-stage disease (Stage III/IV=1.48 vs. 1.02mU/L for Stages I/II; p=0.006). The relationship persisted in those aged 45 years after adjusting for sex (p=0.01). Gross extrathyroidal extension (p=0.03) and presence of cervical lymph node metastases (p=0.003) were also significantly associated with higher serum TSH. Disease recurrence and all-cause mortality occurred in 37 and 38 TSH cohort patients respectively, which limited the power for survival analysis. Positive TgAb was associated with lower stage on univariate analysis (positive TgAb in 23.4% vs. 17.8% of Stage I/II vs. III/IV patients, respectively; p=0.01), although the relationship lost significance when adjusting for age and sex (p=0.34). Perioperative TgAb was not an independent predictor of DFS (hazard ratio=1.12 [95% confidence interval=0.74-1.69]) or OS (hazard ratio=0.98 [95% confidence interval=0.56-1.72]). Preoperative serum TSH level is associated with higher DTC stage, gross extrathyroidal extension, and neck node metastases. Perioperative TgAb is not an independent predictor of DTC prognosis. A larger cohort is required to assess whether preoperative serum TSH level predicts recurrence or mortality.",Journal Article,2330.0,59.0,Serum thyrotropin TSH concentration and autoimmunity may be of prognostic importance in differentiated cancer DTC Preoperative serum TSH level has been associated with higher DTC stage in cross-sectional studies data are contradictory on the significance of autoimmunity at the time of diagnosis We sought to assess whether preoperative serum TSH and perioperative antithyroglobulin antibodies TgAb were associated with cancer stage and outcome in DTC patients followed by the National Cancer Treatment Cooperative Study a large multicenter cancer registry Patients registered after 1996 with available preoperative serum TSH n=617 the TSH cohort or perioperative TgAb status n=1770 the TgAb cohort were analyzed for tumor stage persistent disease recurrence and overall survival OS median follow-up 5.5 years Parametric tests assessed log-transformed TSH and categorical variables were tested with chi square Disease-free survival DFS and OS was assessed with Cox models Geometric mean serum TSH levels were higher in patients with higher-stage disease Stage III/IV=1.48 vs. 1.02 mU/L for Stages I/II p=0.006 The relationship persisted in those aged 45 years after adjusting for sex p=0.01 Gross extrathyroidal extension p=0.03 and presence of lymph node metastases p=0.003 were also significantly associated with higher serum TSH Disease recurrence and all-cause mortality occurred in 37 and 38 TSH cohort patients respectively which limited the power for survival analysis Positive TgAb was associated with lower stage on univariate analysis positive TgAb in 23.4 vs. 17.8 of Stage I/II vs. III/IV patients respectively p=0.01 although the relationship lost significance when adjusting for age and sex p=0.34 Perioperative TgAb was not an independent predictor of DFS hazard ratio=1.12 95 confidence interval=0.74-1.69 or OS hazard ratio=0.98 95 confidence interval=0.56-1.72 Preoperative serum TSH level is associated with higher DTC stage gross extrathyroidal extension and node metastases Perioperative TgAb is not an independent predictor of DTC prognosis A larger cohort is required to assess whether preoperative serum TSH level predicts recurrence or mortality,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[524, 16665, 6581, 1227, 2, 7628, 68, 40, 1, 177, 1187, 4, 1442, 12, 5201, 498, 524, 6581, 301, 71, 85, 41, 5, 142, 5201, 82, 4, 1383, 2832, 94, 74, 32, 11782, 23, 3, 724, 1, 7628, 28, 3, 98, 1, 147, 21, 990, 6, 423, 317, 498, 524, 6581, 2, 1547, 62889, 890, 27293, 11, 41, 5, 12, 82, 2, 228, 4, 5201, 7, 370, 20, 3, 657, 12, 24, 1690, 45, 8, 375, 1570, 12, 1608, 7, 1653, 50, 2648, 5, 390, 498, 524, 6581, 78, 12379, 3, 6581, 180, 15, 1547, 27293, 156, 78, 47616, 3, 27293, 180, 11, 311, 9, 30, 82, 1882, 34, 146, 2, 63, 25, 118, 52, 166, 126, 33, 33, 60, 7590, 895, 275, 1066, 2423, 6581, 2, 5982, 682, 11, 650, 5, 3163, 3219, 34, 115, 25, 1010, 2, 118, 10, 275, 5, 418, 274, 8570, 313, 524, 6581, 148, 11, 142, 4, 7, 5, 142, 82, 34, 82, 316, 478, 14, 576, 105, 14, 588, 6601, 805, 9, 1153, 70, 215, 19, 13, 1861, 3, 858, 3760, 4, 135, 1032, 19939, 60, 50, 1358, 9, 1035, 19, 13, 355, 1789, 18518, 2401, 19, 13, 680, 2, 463, 1, 263, 289, 196, 19, 13, 1421, 11, 120, 97, 41, 5, 142, 524, 6581, 34, 146, 2, 62, 708, 282, 489, 4, 567, 2, 519, 6581, 180, 7, 106, 92, 383, 3, 2349, 9, 25, 65, 109, 27293, 10, 41, 5, 280, 82, 23, 880, 65, 109, 27293, 4, 382, 39, 105, 269, 66, 1, 82, 70, 215, 105, 316, 478, 7, 106, 19, 13, 355, 242, 3, 858, 3009, 724, 198, 1358, 9, 89, 2, 1035, 19, 13, 562, 1547, 27293, 10, 44, 35, 306, 980, 1, 1010, 360, 197, 14, 133, 48, 307, 268, 13, 794, 14, 790, 15, 118, 360, 197, 13, 1096, 48, 307, 268, 13, 664, 14, 720, 498, 524, 6581, 301, 16, 41, 5, 142, 5201, 82, 1789, 18518, 2401, 2, 289, 196, 1547, 27293, 16, 44, 35, 306, 980, 1, 5201, 356, 8, 1077, 180, 16, 616, 6, 423, 317, 498, 524, 6581, 301, 2623, 146, 15, 282]",2171.0,23731273,608
"Distance traveled for treatment of cervical cancer: who travels the farthest, and does it impact outcome?",International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2013-07-01,"To evaluate the impact of distance from residence to treatment center on disease characteristics and recurrence of cervical cancer. A single-institution retrospective chart review of patients treated for cervical cancer during 2006-2011 was performed. Demographic, socioeconomic, and clinicopathologic characteristics were recorded. Distance traveled from home to treatment facility was calculated and categorized. Recurrence and follow-up data were extracted; progression-free survival and overall survival were calculated. SAS version 9.2 was used for statistical analysis. Two hundred nineteen patients met the study criteria; 75% were Caucasian. Forty-nine percent used tobacco. Twenty-five percent had stage III/IV disease. Insurance type was 46% private, 25% Medicaid, 20% Medicare, and 9% uninsured. Distance between residence and hospital was less than 15 miles (29%), 15 to 30 miles (21%), 30 to 50 miles (17%), and more than 50 miles (33%). Median follow-up period was 23 months (range, 1-65). Caucasians were more likely to travel more than 30 miles to a treatment center (P = 0.018) Non-Caucasians were less likely to have private insurance (P = 0.0005) and more likely to recur (P = 0.0045). Recurrence was highest (50%) in African Americans. Travel of more than 30 miles was not associated with age, stage, histology, tobacco abuse, employment, clinical trial enrollment, primary chemoradiation for stage IB disease, or delayed radiation. Travel of more than 30 miles was associated with government insurance (P = 0.029) and a trend toward unemployment (P = 0.059). Four-year progression-free survival (53% vs 52%; P = 0.992) and overall survival (57% vs 62%; P = 0.73) were similar between less than or more than 30-mile travel. Fifty percent of the patients reside more than 30 miles from treating hospital. Despite farther travel, stage of disease, clinical trial enrollment, treatment type, radiation completion, and recurrence rates were similar among patients with cervical cancer. Non-Caucasians are less likely to travel more than 30 miles.",Clinical Trial,2395.0,16.0,To evaluate the impact of distance from residence to treatment center on disease characteristics and recurrence of cancer A single-institution retrospective chart review of patients treated for cancer during 2006-2011 was performed Demographic socioeconomic and clinicopathologic characteristics were recorded Distance traveled from home to treatment facility was calculated and categorized Recurrence and follow-up data were extracted progression-free survival and overall survival were calculated SAS version 9.2 was used for statistical analysis Two hundred nineteen patients met the study criteria 75 were Caucasian Forty-nine percent used tobacco Twenty-five percent had stage III/IV disease Insurance type was 46 private 25 Medicaid 20 Medicare and 9 uninsured Distance between residence and hospital was less than 15 miles 29 15 to 30 miles 21 30 to 50 miles 17 and more than 50 miles 33 Median follow-up period was 23 months range 1-65 Caucasians were more likely to travel more than 30 miles to a treatment center P 0.018 Non-Caucasians were less likely to have private insurance P 0.0005 and more likely to recur P 0.0045 Recurrence was highest 50 in African Americans Travel of more than 30 miles was not associated with age stage histology tobacco abuse employment clinical trial enrollment primary chemoradiation for stage IB disease or delayed radiation Travel of more than 30 miles was associated with government insurance P 0.029 and a trend toward unemployment P 0.059 Four-year progression-free survival 53 vs 52 P 0.992 and overall survival 57 vs 62 P 0.73 were similar between less than or more than 30-mile travel Fifty percent of the patients reside more than 30 miles from treating hospital Despite farther travel stage of disease clinical trial enrollment treatment type radiation completion and recurrence rates were similar among patients with cancer Non-Caucasians are less likely to travel more than 30 miles,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 3, 345, 1, 3019, 29, 5562, 6, 24, 574, 23, 34, 374, 2, 146, 1, 12, 8, 226, 731, 459, 2937, 206, 1, 7, 73, 9, 12, 190, 1324, 1132, 10, 173, 1540, 3331, 2, 1399, 374, 11, 1872, 3019, 12590, 29, 3249, 6, 24, 3483, 10, 981, 2, 2320, 146, 2, 166, 126, 74, 11, 2484, 91, 115, 25, 2, 63, 25, 11, 981, 8265, 2256, 83, 18, 10, 95, 9, 1050, 65, 100, 1128, 3498, 7, 543, 3, 45, 371, 481, 11, 3229, 1213, 762, 714, 95, 2607, 737, 365, 714, 42, 82, 316, 478, 34, 1935, 267, 10, 641, 4745, 243, 2843, 179, 1378, 2, 83, 4955, 3019, 59, 5562, 2, 702, 10, 299, 76, 167, 7886, 462, 167, 6, 201, 7886, 239, 201, 6, 212, 7886, 269, 2, 80, 76, 212, 7886, 466, 52, 166, 126, 727, 10, 382, 53, 184, 14, 556, 5396, 11, 80, 322, 6, 6793, 80, 76, 201, 7886, 6, 8, 24, 574, 19, 13, 4047, 220, 5396, 11, 299, 322, 6, 47, 4745, 1935, 19, 13, 4252, 2, 80, 322, 6, 5609, 19, 13, 16053, 146, 10, 1076, 212, 4, 1410, 2731, 6793, 1, 80, 76, 201, 7886, 10, 44, 41, 5, 89, 82, 784, 2607, 10847, 5141, 38, 160, 1798, 86, 975, 9, 82, 3180, 34, 15, 1612, 121, 6793, 1, 80, 76, 201, 7886, 10, 41, 5, 7608, 1935, 19, 13, 4770, 2, 8, 853, 1317, 11966, 19, 13, 11795, 294, 111, 91, 115, 25, 699, 105, 653, 19, 13, 13144, 2, 63, 25, 696, 105, 744, 19, 13, 803, 11, 288, 59, 299, 76, 15, 80, 76, 201, 24857, 6793, 1461, 714, 1, 3, 7, 10114, 80, 76, 201, 7886, 29, 1367, 702, 550, 17799, 6793, 82, 1, 34, 38, 160, 1798, 24, 267, 121, 1438, 2, 146, 151, 11, 288, 107, 7, 5, 12, 220, 5396, 32, 299, 322, 6, 6793, 80, 76, 201, 7886]",1936.0,23765207,254
Human papillomavirus knowledge and awareness among Vietnamese mothers.,Journal of community health,J Community Health,2013-12-01,"Human papillomavirus (HPV) is the most common sexually transmitted disease in the US and the primary cause of cervical cancer. Vietnamese American women have the highest incidence rates of cervical cancer but one of the lowest HPV vaccination rates. Parental knowledge is an important predictor of HPV vaccination; however, little is known about HPV knowledge in the Vietnamese American community. We aimed to describe the HPV knowledge of Vietnamese mothers in Houston, Texas and their intention to vaccinate their daughters. We conducted face-to-face interviews with Vietnamese mothers who had daughters aged 9-26 years. We collected data on demographics, acculturation, HPV knowledge, and vaccination intention. Knowledge scores (0-5) were calculated using 5 knowledge questions. We used logistic regression to identify predictors of HPV knowledge. Participants had low levels of acculturation by report of reading (31%) and writing (23%) English well. Less than 50% of participants (n = 47) had heard of HPV, and among these, the mean HPV knowledge score was 4. Although only 1 in 3 had discussed HPV with their medical provider, nearly 86% of participants who had not heard of HPV would vaccinate their daughter if their doctor had recommended it. Good written English skills and belief that the HPV vaccine was not expensive were predictors of HPV awareness. HPV awareness is low among less acculturated Vietnamese mothers in Houston. Future educational efforts about the role of HPV vaccine in preventing cervical cancer should be made in their language when targeting parents of a high risk Vietnamese population.",Journal Article,2242.0,13.0,Human papillomavirus HPV is the most common sexually transmitted disease in the US and the primary cause of cancer Vietnamese American women have the highest incidence rates of cancer but one of the lowest HPV vaccination rates Parental knowledge is an important predictor of HPV vaccination however little is known about HPV knowledge in the Vietnamese American community We aimed to describe the HPV knowledge of Vietnamese mothers in Houston Texas and their intention to vaccinate their daughters We conducted face-to-face interviews with Vietnamese mothers who had daughters aged 9-26 years We collected data on demographics acculturation HPV knowledge and vaccination intention Knowledge scores 0-5 were calculated using 5 knowledge questions We used logistic regression to identify predictors of HPV knowledge Participants had low levels of acculturation by report of reading 31 and writing 23 English well Less than 50 of participants n 47 had heard of HPV and among these the mean HPV knowledge score was 4 Although only 1 in 3 had discussed HPV with their medical provider nearly 86 of participants who had not heard of HPV would vaccinate their daughter if their doctor had recommended it Good written English skills and belief that the HPV vaccine was not expensive were predictors of HPV awareness HPV awareness is low among less acculturated Vietnamese mothers in Houston Future educational efforts about the role of HPV vaccine in preventing cancer should be made in their language when targeting parents of a high risk Vietnamese population,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 3242, 933, 16, 3, 96, 186, 13588, 12959, 34, 4, 3, 843, 2, 3, 86, 708, 1, 12, 20689, 597, 117, 47, 3, 1076, 287, 151, 1, 12, 84, 104, 1, 3, 2101, 933, 1915, 151, 3418, 922, 16, 35, 305, 980, 1, 933, 1915, 137, 1215, 16, 440, 545, 933, 922, 4, 3, 20689, 597, 1714, 21, 1295, 6, 897, 3, 933, 922, 1, 20689, 8605, 4, 6212, 2738, 2, 136, 3205, 6, 25022, 136, 13099, 21, 426, 3376, 6, 3376, 4053, 5, 20689, 8605, 54, 42, 13099, 1032, 83, 432, 60, 21, 786, 74, 23, 2221, 16497, 933, 922, 2, 1915, 3205, 922, 703, 13, 33, 11, 981, 75, 33, 922, 1937, 21, 95, 812, 320, 6, 255, 674, 1, 933, 922, 776, 42, 154, 148, 1, 16497, 20, 414, 1, 7299, 456, 2, 9461, 382, 4201, 149, 299, 76, 212, 1, 776, 78, 662, 42, 14638, 1, 933, 2, 107, 46, 3, 313, 933, 922, 368, 10, 39, 242, 158, 14, 4, 27, 42, 1588, 933, 5, 136, 484, 3094, 1857, 868, 1, 776, 54, 42, 44, 14638, 1, 933, 688, 25022, 136, 15254, 492, 136, 9350, 42, 793, 192, 1178, 6538, 4201, 5909, 2, 8862, 17, 3, 933, 1274, 10, 44, 6038, 11, 674, 1, 933, 3310, 933, 3310, 16, 154, 107, 299, 21528, 20689, 8605, 4, 6212, 508, 3624, 1413, 545, 3, 200, 1, 933, 1274, 4, 3017, 12, 257, 40, 1229, 4, 136, 4794, 198, 529, 2418, 1, 8, 64, 43, 20689, 266]",1555.0,23775032,65
Stage IB1 cervical cancer: role of preoperative MR imaging in selection of patients for fertility-sparing radical trachelectomy.,Radiology,Radiology,2013-06-20,"To determine whether magnetic resonance (MR) imaging evaluation of key morphologic tumor characteristics can improve patient selection for radical trachelectomy. The institutional review board approved and waived informed consent for this study of 62 patients (mean age, 32 years; age range, 23-42 years) with International Federation of Gynecology and Obstetrics stage IB1 cervical carcinoma who underwent attempted radical trachelectomy between November 2001 and January 2011 and had preoperative MR imaging. Retrospectively, two radiologists reviewed MR images for tumor presence and size, distance between tumor and internal os, and presence of deep cervical stromal invasion. Associations between MR imaging findings and surgery type were tested. Sensitivity and specificity of tumor detection were, respectively, 87% and 100% (reader 1) and 76% and 95% (reader 2). Six of six patients with negative cone biopsy margins and no tumor at postconization MR imaging were without tumor at trachelectomy pathologic analysis. Mean differences between MR imaging and histologic tumor sizes were 0.7 mm (range, -15 to 11 mm) for reader 1 and 2.2 mm (range, -9 to 15 mm) for reader 2. Sensitivities for deep cervical stromal invasion were 75% (reader 1) and 50% (reader 2). For each reader, nine of nine (100%) patients with tumor 5 mm or less from the internal os and three of five (60%) patients with tumor 6-9 mm from the internal os at MR imaging needed radical hysterectomy. For both readers, tumor size of 2 cm or larger (P < .001) and deep cervical stromal invasion (P  .003) at MR imaging were associated with increased chance of radical hysterectomy. Pretrachelectomy MR imaging can help identify high-risk patients likely to need radical hysterectomy or confirm the absence of residual tumor in the cervix after a cone biopsy with negative margins.",Clinical Trial,2406.0,41.0,To determine whether magnetic resonance MR imaging evaluation of key morphologic tumor characteristics can improve patient selection for radical trachelectomy The institutional review board approved and waived informed consent for this study of 62 patients mean age 32 years age range 23-42 years with International Federation of Gynecology and Obstetrics stage IB1 carcinoma who underwent attempted radical trachelectomy between November 2001 and January 2011 and had preoperative MR imaging Retrospectively two radiologists reviewed MR images for tumor presence and size distance between tumor and internal os and presence of deep stromal invasion Associations between MR imaging findings and surgery type were tested Sensitivity and specificity of tumor detection were respectively 87 and 100 reader 1 and 76 and 95 reader 2 Six of six patients with negative cone biopsy margins and no tumor at postconization MR imaging were without tumor at trachelectomy pathologic analysis Mean differences between MR imaging and histologic tumor sizes were 0.7 mm range -15 to 11 mm for reader 1 and 2.2 mm range -9 to 15 mm for reader 2 Sensitivities for deep stromal invasion were 75 reader 1 and 50 reader 2 For each reader nine of nine 100 patients with tumor 5 mm or less from the internal os and three of five 60 patients with tumor 6-9 mm from the internal os at MR imaging needed radical hysterectomy For both readers tumor size of 2 cm or larger P .001 and deep stromal invasion P  .003 at MR imaging were associated with increased chance of radical hysterectomy Pretrachelectomy MR imaging can help identify high-risk patients likely to need radical hysterectomy or confirm the absence of residual tumor in the cervix after a cone biopsy with negative margins,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,"[6, 223, 317, 1484, 1535, 1638, 270, 451, 1, 825, 2815, 30, 374, 122, 401, 69, 881, 9, 711, 5760, 3, 1115, 206, 2620, 850, 2, 12855, 2767, 3844, 9, 26, 45, 1, 744, 7, 313, 89, 531, 60, 89, 184, 382, 595, 60, 5, 944, 7303, 1, 6429, 2, 7407, 82, 8111, 134, 54, 208, 4098, 711, 5760, 59, 2868, 1758, 2, 1024, 1132, 2, 42, 498, 1638, 270, 894, 100, 3915, 446, 1638, 1572, 9, 30, 463, 2, 444, 3019, 59, 30, 2, 2329, 118, 2, 463, 1, 2369, 1126, 578, 685, 59, 1638, 270, 272, 2, 152, 267, 11, 650, 485, 2, 1121, 1, 30, 638, 11, 106, 912, 2, 394, 4924, 14, 2, 846, 2, 48, 4924, 18, 437, 1, 437, 7, 5, 199, 6939, 411, 1012, 2, 77, 30, 28, 35603, 1638, 270, 11, 187, 30, 28, 5760, 510, 65, 313, 362, 59, 1638, 270, 2, 884, 30, 4131, 11, 13, 67, 321, 184, 167, 6, 175, 321, 9, 4924, 14, 2, 18, 18, 321, 184, 83, 6, 167, 321, 9, 4924, 18, 6202, 9, 2369, 1126, 578, 11, 481, 4924, 14, 2, 212, 4924, 18, 9, 296, 4924, 762, 1, 762, 394, 7, 5, 30, 33, 321, 15, 299, 29, 3, 2329, 118, 2, 169, 1, 365, 335, 7, 5, 30, 49, 83, 321, 29, 3, 2329, 118, 28, 1638, 270, 575, 711, 2622, 9, 110, 5439, 30, 444, 1, 18, 494, 15, 1077, 19, 144, 2, 2369, 1126, 578, 19, 1552, 1421, 28, 1638, 270, 11, 41, 5, 101, 3477, 1, 711, 2622, 62965, 1638, 270, 122, 987, 255, 64, 43, 7, 322, 6, 594, 711, 2622, 15, 1843, 3, 1127, 1, 753, 30, 4, 3, 3629, 50, 8, 6939, 411, 5, 199, 1012]",1761.0,23788721,542
Minimally invasive esophagectomy is safe in patients with previous gastric bypass.,Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery,Surg Obes Relat Dis,2013-04-22,"The prevalence of morbid obesity in the United States has been steadily increasing, and there is an established relationship between obesity and the risk of developing certain cancers. Patients who have undergone prior gastric bypass (GB) and present with newly diagnosed esophageal cancer represent a new and challenging cohort for surgical resection of their disease. We present our case series of consecutive patients with previous GB who underwent minimally invasive esophagectomy (MIE). Retrospective review of consecutive patients with a history of GB who underwent a MIE for esophageal cancer between July 2010 and August 2012. Five patients were identified with a mean age of 57 years. Mean follow-up was 9.1 months. Four patients had undergone laparoscopic GB, and 1 patient had an open GB. Two patients received neoadjuvant chemoradiation therapy for locally advanced disease. Minimally invasive procedures were thoracoscopic/laparoscopic esophagectomy with cervical anastomosis in 4 patients and colonic interposition in 1 patient. Mean operative time was 6 hours and 52 minutes. Median length of stay was 7 days. There was no mortality. Postoperative complications occurred in 3 patients and included pneumonia/respiratory failure, recurrent laryngeal nerve injury, and pyloric stenosis. All patients are alive and disease free at last follow-up. Minimally invasive esophagectomy after prior GB is well tolerated, is technically feasible, and has acceptable oncologic and perioperative outcomes. We conclude that precise endoscopic evaluation before bariatric surgery in patients with gastroesophageal reflux disease is essential, as is the necessity for continuing postsurgical surveillance in patients with known Barrett's esophagitis and for early evaluation in patients who develop new symptoms of gastroesophageal reflux disease after bariatric surgery.",Journal Article,2465.0,9.0,The prevalence of morbid obesity in the United States has been steadily increasing and there is an established relationship between obesity and the risk of developing certain cancers Patients who have undergone prior bypass GB and present with newly diagnosed cancer represent a new and challenging cohort for surgical resection of their disease We present our case series of consecutive patients with previous GB who underwent minimally invasive esophagectomy MIE Retrospective review of consecutive patients with a history of GB who underwent a MIE for cancer between July 2010 and August 2012 Five patients were identified with a mean age of 57 years Mean follow-up was 9.1 months Four patients had undergone laparoscopic GB and 1 patient had an open GB Two patients received neoadjuvant chemoradiation therapy for locally advanced disease Minimally invasive procedures were thoracoscopic/laparoscopic esophagectomy with anastomosis in 4 patients and colonic interposition in 1 patient Mean operative time was 6 hours and 52 minutes Median length of stay was 7 days There was no mortality Postoperative complications occurred in 3 patients and included pneumonia/respiratory failure recurrent nerve injury and pyloric stenosis All patients are alive and disease free at last follow-up Minimally invasive esophagectomy after prior GB is well tolerated is technically feasible and has acceptable oncologic and perioperative outcomes We conclude that precise endoscopic evaluation before bariatric surgery in patients with gastroesophageal reflux disease is essential as is the necessity for continuing postsurgical surveillance in patients with known Barrett 's esophagitis and for early evaluation in patients who develop new symptoms of gastroesophageal reflux disease after bariatric surgery,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,"[3, 1078, 1, 8188, 1661, 4, 3, 1088, 907, 71, 85, 7025, 602, 2, 125, 16, 35, 635, 858, 59, 1661, 2, 3, 43, 1, 931, 1840, 163, 7, 54, 47, 1989, 324, 5481, 7832, 2, 364, 5, 732, 265, 12, 1231, 8, 217, 2, 1950, 180, 9, 221, 170, 1, 136, 34, 21, 364, 114, 473, 988, 1, 935, 7, 5, 698, 7832, 54, 208, 2144, 416, 3617, 7336, 459, 206, 1, 935, 7, 5, 8, 532, 1, 7832, 54, 208, 8, 7336, 9, 12, 59, 2066, 1120, 2, 2480, 1195, 365, 7, 11, 108, 5, 8, 313, 89, 1, 696, 60, 313, 166, 126, 10, 83, 14, 53, 294, 7, 42, 1989, 1964, 7832, 2, 14, 69, 42, 35, 1020, 7832, 100, 7, 103, 536, 975, 36, 9, 795, 131, 34, 2144, 416, 1369, 11, 5752, 1964, 3617, 5, 5519, 4, 39, 7, 2, 3663, 16852, 4, 14, 69, 313, 1208, 98, 10, 49, 1459, 2, 653, 2511, 52, 1318, 1, 2020, 10, 67, 162, 125, 10, 77, 282, 573, 521, 489, 4, 27, 7, 2, 159, 3485, 2718, 496, 387, 2476, 2730, 2, 26862, 6935, 62, 7, 32, 1701, 2, 34, 115, 28, 1060, 166, 126, 2144, 416, 3617, 50, 324, 7832, 16, 149, 421, 16, 6093, 1313, 2, 71, 1595, 1998, 2, 1547, 123, 21, 2060, 17, 3260, 2056, 451, 348, 15033, 152, 4, 7, 5, 3227, 9657, 34, 16, 1452, 22, 16, 3, 7378, 9, 4346, 6891, 617, 4, 7, 5, 440, 4366, 292, 5135, 2, 9, 191, 451, 4, 7, 54, 690, 217, 507, 1, 3227, 9657, 34, 50, 15033, 152]",1795.0,23791535,372
Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.,Gynecologic oncology,Gynecol. Oncol.,2013-06-22,"The optimal adjuvant therapy in advanced endometrial cancer is controversial. One regimen is concurrent external beam pelvic irradiation (RT) and cisplatin, then carboplatin/paclitaxel. This study reports an institutional experience using this approach in stage III (FIGO 2009) endometrial cancer. Patients with stage III (FIGO 2009) endometrial cancer who underwent total hysterectomy and bilateral salpingo-oophorectomy at a single institution from 01/2004 to 12/2009 were identified retrospectively. Those treated with adjuvant RT/cisplatin, followed by carboplatin/paclitaxel comprised the study population. Of the 40 eligible patients, 7 (18%) were stage IIIA and 33 (82%) IIIC. Nineteen patients (48%) were  60 years of age. Twenty-three (58%) had  50% myometrial invasion, 30 (75%) lymphovascular invasion, 11 (28%) cervical stromal invasion, and 5 (12%) positive peritoneal cytology. Histology was endometrioid in 32 (80%), serous in 6 (15%), and clear cell in 2 (5%). At a median follow-up of 49 months, the 5-year freedom from relapse was 79% and overall survival 85%. The 5-year rate of vaginal recurrence was 3%, non-vaginal pelvic recurrence 3%, para-aortic recurrence 11%, peritoneal recurrence 5%, and other distant recurrence 11%. Thirty-one patients (78%) were able to complete the planned RT/cisplatin and 4 cycles of carboplatin/paclitaxel. Acute grade 3 toxicity occurred in 10 patients (4 neutropenia, 2 anemia, 1 fatigue, 2 diarrhea). No late toxicity was grade  3. These favorable outcomes corroborate those of RTOG 9708. Until prospective data that compare adjuvant therapy regimens mature, concurrent chemoradiation should be strongly considered in stage III endometrial cancer.",Journal Article,2404.0,23.0,The optimal adjuvant therapy in advanced cancer is controversial One regimen is concurrent external beam pelvic irradiation RT and cisplatin then carboplatin/paclitaxel This study reports an institutional experience using this approach in stage III FIGO 2009 cancer Patients with stage III FIGO 2009 cancer who underwent total hysterectomy and bilateral salpingo-oophorectomy at a single institution from 01/2004 to 12/2009 were identified retrospectively Those treated with adjuvant RT/cisplatin followed by carboplatin/paclitaxel comprised the study population Of the 40 eligible patients 7 18 were stage IIIA and 33 82 IIIC Nineteen patients 48 were  60 years of age Twenty-three 58 had  50 myometrial invasion 30 75 lymphovascular invasion 11 28 stromal invasion and 5 12 positive peritoneal cytology Histology was endometrioid in 32 80 serous in 6 15 and clear cell in 2 5 At a median follow-up of 49 months the 5-year freedom from relapse was 79 and overall survival 85 The 5-year rate of recurrence was 3 non-vaginal pelvic recurrence 3 para-aortic recurrence 11 peritoneal recurrence 5 and other distant recurrence 11 Thirty-one patients 78 were able to complete the planned RT/cisplatin and 4 cycles of carboplatin/paclitaxel Acute grade 3 toxicity occurred in 10 patients 4 neutropenia 2 anemia 1 fatigue 2 diarrhea No late toxicity was grade  3 These favorable outcomes corroborate those of RTOG 9708 Until prospective data that compare adjuvant therapy regimens mature concurrent chemoradiation should be strongly considered in stage III cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,"[3, 665, 249, 36, 4, 131, 12, 16, 2010, 104, 477, 16, 750, 1455, 1345, 1110, 1104, 240, 2, 540, 818, 927, 490, 26, 45, 1198, 35, 1115, 730, 75, 26, 353, 4, 82, 316, 3837, 1238, 12, 7, 5, 82, 316, 3837, 1238, 12, 54, 208, 181, 2622, 2, 1607, 5690, 3470, 28, 8, 226, 731, 29, 355, 1131, 6, 133, 1238, 11, 108, 894, 135, 73, 5, 249, 240, 540, 370, 20, 927, 490, 2603, 3, 45, 266, 1, 3, 327, 625, 7, 67, 203, 11, 82, 3164, 2, 466, 878, 3842, 3498, 7, 576, 11, 749, 335, 60, 1, 89, 737, 169, 717, 42, 749, 212, 7327, 578, 201, 481, 2933, 578, 175, 339, 1126, 578, 2, 33, 133, 109, 1639, 2045, 784, 10, 3151, 4, 531, 493, 1744, 4, 49, 167, 2, 885, 31, 4, 18, 33, 28, 8, 52, 166, 126, 1, 739, 53, 3, 33, 111, 3060, 29, 429, 10, 842, 2, 63, 25, 772, 3, 33, 111, 116, 1, 146, 10, 27, 220, 18982, 1110, 146, 27, 4615, 3938, 146, 175, 1639, 146, 33, 2, 127, 626, 146, 175, 977, 104, 7, 833, 11, 1665, 6, 236, 3, 1465, 240, 540, 2, 39, 410, 1, 927, 490, 286, 88, 27, 155, 489, 4, 79, 7, 39, 778, 18, 1545, 14, 613, 18, 1172, 77, 807, 155, 10, 88, 749, 27, 46, 913, 123, 14855, 135, 1, 3931, 62988, 1100, 482, 74, 17, 932, 249, 36, 472, 2908, 750, 975, 257, 40, 1327, 515, 4, 82, 316, 12]",1559.0,23800696,420
Evaluation of a multiplex panel of immune-related markers in cervical secretions: a methodologic study.,International journal of cancer,Int. J. Cancer,2013-07-30,"Although persistent carcinogenic human papillomavirus (HPV) infection is necessary for cervical carcinogenesis, the cofactors involved in HPV persistence and disease progression are poorly understood. Chronic cervical inflammation may increase risk, but few studies have measured immune markers (cytokines, chemokines and soluble receptors) in cervical secretions. We evaluated the performance of 74 multiplexed, bead-based immune markers in cervical secretions from three groups of women with biopsy evaluation of cervical intraepithelial neoplasia (CIN), (i) <CIN1, HPV-negative (n = 24), (ii) <CIN1, carcinogenic HPV-positive (n = 24) and (iii) CIN2/3, carcinogenic HPV-positive (n = 48), matched on time since last period and smoking status. We considered markers with >25% detectability and >80% interclass correlation coefficients (ICCs) acceptable for epidemiologic studies. Within-batch coefficients of variation (CVs) of 25% indicated room for assay improvement. Secondarily, we explored associations between marker levels and CIN/HPV status adjusted for matching variables, assay batch, age and number of sexual partners. Sixty-two markers (84%) had >25% detectability and ICCs > 80%. Of those, 53 (85%) had CVs < 25%. Using these preliminary data, we found that HPV positivity was associated with increased eotaxin-1 [odds ratio (OR): 15.63, 95% confidence interval (CI): 1.26-200.00] and G-CSF (OR: 12.99, 95% CI: 1.10-142.86) among CIN-negative women. There was suggestive evidence that higher chemoattractant marker levels were associated with CIN2/3 (e.g., MIP-1delta, OR: 4.48, 95% CI: 0.87-23.04 versus <CIN1/HPV-positive). More than 70% of markers were reliably measured. This assay may be used to evaluate associations of immune-related markers with CIN and HPV status. ",Journal Article,2366.0,11.0,Although persistent carcinogenic human papillomavirus HPV infection is necessary for carcinogenesis the cofactors involved in HPV persistence and disease progression are poorly understood Chronic inflammation may increase risk but few studies have measured immune markers cytokines chemokines and soluble receptors in secretions We evaluated the performance of 74 multiplexed bead-based immune markers in secretions from three groups of women with biopsy evaluation of intraepithelial neoplasia CIN i CIN1 HPV-negative n 24 ii CIN1 carcinogenic HPV-positive n 24 and iii CIN2/3 carcinogenic HPV-positive n 48 matched on time since last period and smoking status We considered markers with 25 detectability and 80 interclass correlation coefficients ICCs acceptable for epidemiologic studies Within-batch coefficients of variation CVs of 25 indicated room for assay improvement Secondarily we explored associations between marker levels and CIN/HPV status adjusted for matching variables assay batch age and number of sexual partners Sixty-two markers 84 had 25 detectability and ICCs 80 Of those 53 85 had CVs 25 Using these preliminary data we found that HPV positivity was associated with increased eotaxin-1 odds ratio OR 15.63 95 confidence interval CI 1.26-200.00 and G-CSF OR 12.99 95 CI 1.10-142.86 among CIN-negative women There was suggestive evidence that higher chemoattractant marker levels were associated with CIN2/3 e.g. MIP-1delta OR 4.48 95 CI 0.87-23.04 versus CIN1/HPV-positive More than 70 of markers were reliably measured This assay may be used to evaluate associations of immune-related markers with CIN and HPV status,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[242, 1882, 7483, 171, 3242, 933, 930, 16, 1493, 9, 1719, 3, 14937, 646, 4, 933, 4108, 2, 34, 91, 32, 1240, 1784, 442, 1815, 68, 344, 43, 84, 1021, 94, 47, 644, 250, 525, 1886, 4906, 2, 2968, 1186, 4, 28208, 21, 194, 3, 528, 1, 794, 7734, 9921, 90, 250, 525, 4, 28208, 29, 169, 271, 1, 117, 5, 411, 451, 1, 4153, 2298, 4652, 70, 23728, 933, 199, 78, 259, 215, 23728, 7483, 933, 109, 78, 259, 2, 316, 12870, 27, 7483, 933, 109, 78, 576, 655, 23, 98, 1192, 1060, 727, 2, 979, 156, 21, 515, 525, 5, 243, 23248, 2, 493, 38163, 816, 5161, 17417, 1595, 9, 3609, 94, 262, 18009, 5161, 1, 1380, 14723, 1, 11056, 1103, 4698, 9, 719, 767, 12974, 21, 1443, 685, 59, 952, 148, 2, 4652, 933, 156, 586, 9, 2616, 682, 719, 18009, 89, 2, 207, 1, 2232, 4005, 1746, 100, 525, 874, 42, 243, 23248, 2, 17417, 493, 1, 135, 699, 772, 42, 14723, 243, 75, 46, 1676, 74, 21, 204, 17, 933, 1887, 10, 41, 5, 101, 21511, 14, 610, 197, 15, 167, 676, 48, 307, 268, 58, 14, 432, 1250, 2038, 2, 499, 1211, 15, 133, 1058, 48, 58, 14, 79, 4785, 868, 107, 4652, 199, 117, 125, 10, 3832, 241, 17, 142, 12187, 952, 148, 11, 41, 5, 12870, 27, 563, 499, 7076, 63021, 15, 39, 576, 48, 58, 13, 912, 382, 755, 185, 23728, 933, 109, 80, 76, 431, 1, 525, 11, 4092, 644, 26, 719, 68, 40, 95, 6, 376, 685, 1, 250, 139, 525, 5, 4652, 2, 933, 156]",1642.0,23824624,85
Commissioning of a grid-based Boltzmann solver for cervical cancer brachytherapy treatment planning with shielded colpostats.,Brachytherapy,Brachytherapy,2013-07-24,"We sought to commission a gynecologic shielded colpostat analytic model provided from a treatment planning system (TPS) library. We have reported retrospectively the dosimetric impact of this applicator model in a cohort of patients. A commercial TPS with a grid-based Boltzmann solver (GBBS) was commissioned for (192)Ir high-dose-rate (HDR) brachytherapy for cervical cancer with stainless steel-shielded colpostats. Verification of the colpostat analytic model was verified using a radiograph and vendor schematics. MCNPX v2.6 Monte Carlo simulations were performed to compare dose distributions around the applicator in water with the TPS GBBS dose predictions. Retrospectively, the dosimetric impact was assessed over 24 cervical cancer patients' HDR plans. Applicator (TPS ID #AL13122005) shield dimensions were within 0.4mm of the independent shield dimensions verification. GBBS profiles in planes bisecting the cap around the applicator agreed with Monte Carlo simulations within 2% at most locations; differing screw representations resulted in differences of up to 9%. For the retrospective study, the GBBS doses differed from TG-43 as follows (meanvalue standard deviation [min, max]): International Commission on Radiation units [ICRU]rectum (-8.42.5% [-14.1, -4.1%]), ICRUbladder (-7.23.6% [-15.7, -2.1%]), D2cc-rectum (-6.22.6% [-11.9, -0.8%]), D2cc-sigmoid (-5.62.6% [-9.3, -2.0%]), and D2cc-bladder (-3.41.9% [-7.2, -1.1%]). As brachytherapy TPSs implement advanced model-based dose calculations, the analytic applicator models stored in TPSs should be independently validated before clinical use. For this cohort, clinically meaningful differences (>5%) from TG-43 were observed. Accurate dosimetric modeling of shielded applicators may help to refine organ toxicity studies.",Journal Article,2372.0,12.0,We sought to commission a gynecologic shielded colpostat analytic model provided from a treatment planning system TPS library We have reported retrospectively the dosimetric impact of this applicator model in a cohort of patients A commercial TPS with a grid-based Boltzmann solver GBBS was commissioned for 192 Ir high-dose-rate HDR brachytherapy for cancer with stainless steel-shielded colpostats Verification of the colpostat analytic model was verified using a radiograph and vendor schematics MCNPX v2.6 Monte Carlo simulations were performed to compare dose distributions around the applicator in water with the TPS GBBS dose predictions Retrospectively the dosimetric impact was assessed over 24 cancer patients HDR plans Applicator TPS ID AL13122005 shield dimensions were within 0.4 mm of the independent shield dimensions verification GBBS profiles in planes bisecting the cap around the applicator agreed with Monte Carlo simulations within 2 at most locations differing screw representations resulted in differences of up to 9 For the retrospective study the GBBS doses differed from TG-43 as follows mean value  standard deviation min max International Commission on Radiation units ICRU rectum -8.4  2.5 -14.1 -4.1 ICRUbladder -7.2  3.6 -15.7 -2.1 D2cc-rectum -6.2  2.6 -11.9 -0.8 D2cc-sigmoid -5.6  2.6 -9.3 -2.0 and D2cc-bladder -3.4  1.9 -7.2 -1.1 As brachytherapy TPSs implement advanced model-based dose calculations the analytic applicator models stored in TPSs should be independently validated before clinical use For this cohort clinically meaningful differences 5 from TG-43 were observed Accurate dosimetric modeling of shielded applicators may help to refine organ toxicity studies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,"[21, 990, 6, 7258, 8, 1512, 17327, 35627, 5146, 202, 1052, 29, 8, 24, 1349, 398, 11796, 4157, 21, 47, 210, 894, 3, 3187, 345, 1, 26, 8789, 202, 4, 8, 180, 1, 7, 8, 4860, 11796, 5, 8, 17491, 90, 47138, 39933, 21720, 10, 19823, 9, 5016, 2123, 64, 61, 116, 5309, 1536, 9, 12, 5, 38071, 38072, 17327, 47139, 6720, 1, 3, 35627, 5146, 202, 10, 4815, 75, 8, 12295, 2, 16121, 63133, 26878, 15333, 49, 7990, 7991, 7490, 11, 173, 6, 932, 61, 4477, 3337, 3, 8789, 4, 4388, 5, 3, 11796, 21720, 61, 4340, 894, 3, 3187, 345, 10, 275, 252, 259, 12, 7, 5309, 1853, 8789, 11796, 4937, 63134, 21581, 6190, 11, 262, 13, 39, 321, 1, 3, 306, 21581, 6190, 6720, 21720, 1241, 4, 15959, 45217, 3, 3204, 3337, 3, 8789, 4681, 5, 7990, 7991, 7490, 262, 18, 28, 96, 4069, 5276, 14911, 19641, 627, 4, 362, 1, 126, 6, 83, 9, 3, 459, 45, 3, 21720, 415, 2512, 29, 5107, 601, 22, 2962, 313, 549, 810, 260, 3348, 1538, 2649, 944, 7258, 23, 121, 2960, 19015, 3660, 66, 39, 810, 18, 33, 213, 14, 39, 14, 63135, 67, 18, 810, 27, 49, 167, 67, 18, 14, 40431, 3660, 49, 18, 810, 18, 49, 175, 83, 13, 66, 40431, 9356, 33, 49, 810, 18, 49, 83, 27, 18, 13, 2, 40431, 9685, 27, 39, 810, 14, 83, 67, 18, 14, 14, 22, 1536, 21745, 6207, 131, 202, 90, 61, 8229, 3, 5146, 8789, 274, 9744, 4, 21745, 257, 40, 1042, 938, 348, 38, 119, 9, 26, 180, 505, 2538, 362, 33, 29, 5107, 601, 11, 164, 1481, 3187, 2057, 1, 17327, 11800, 68, 987, 6, 5003, 1259, 155, 94]",1714.0,23891341,412
Racial disparities in cervical cancer survival over time.,Cancer,Cancer,2013-07-31,"The purpose of this study is to examine changes over time in survival for African American (AA) and white women diagnosed with cervical cancer (CC). Surveillance, Epidemiology, and End Results (SEER) Program data from 1985 to 2009 were used for this analysis. Racial differences in survival were evaluated between African American (AA) and white women. Kaplan-Meier and Cox proportional hazards survival methods were used to assess differences in survival by race at 5-year intervals. The study sample included 23,368 women, including 3886 (16.6%) who were AA and 19,482 (83.4%) who were white. AA women were older (51.4 versus 48.9 years; P<.001) and had a higher rate of regional (38.3% versus 31.8%; P<.001) and distant metastasis (10.7% versus 8.7%; P<.001). AA less frequently received cancer-directed surgery (32.4% versus 46%; P<.001), and more frequently radiotherapy (36.3% versus 26.4%; P<.001). Overall, AA women had a hazard ratio (HR) of 1.41 (95% confidence interval=1.32-1.51) of cervical cancer (CC) mortality compared with whites. Adjusting for SEER registry, marital status, stage, age, treatment, grade, and histology, AA women had an HR of 1.13 (95% confidence interval=1.05-1.22) of CC-related mortality. After adjusting for the same variables, there was a significant difference in CC-specific mortality between 1985 to 1989 and 1990 to 1994, but not after 1995. After adjusting for race, SEER registry, marital status, stage, age, treatment, grade, and histology, there was a significant difference in CC-specific mortality between 1985 to 1989 and 1990 to 1994, but not after 1995.",Comparative Study,2365.0,30.0,"The purpose of this study is to examine changes over time in survival for African American AA and white women diagnosed with cancer CC Surveillance Epidemiology and End Results SEER Program data from 1985 to 2009 were used for this analysis Racial differences in survival were evaluated between African American AA and white women Kaplan-Meier and Cox proportional hazards survival methods were used to assess differences in survival by race at 5-year intervals The study sample included 23,368 women including 3886 16.6 who were AA and 19,482 83.4 who were white AA women were older 51.4 versus 48.9 years P .001 and had a higher rate of regional 38.3 versus 31.8 P .001 and distant metastasis 10.7 versus 8.7 P .001 AA less frequently received cancer-directed surgery 32.4 versus 46 P .001 and more frequently radiotherapy 36.3 versus 26.4 P .001 Overall AA women had a hazard ratio HR of 1.41 95 confidence interval=1.32-1.51 of cancer CC mortality compared with whites Adjusting for SEER registry marital status stage age treatment grade and histology AA women had an HR of 1.13 95 confidence interval=1.05-1.22 of CC-related mortality After adjusting for the same variables there was a significant difference in CC-specific mortality between 1985 to 1989 and 1990 to 1994 but not after 1995 After adjusting for race SEER registry marital status stage age treatment grade and histology there was a significant difference in CC-specific mortality between 1985 to 1989 and 1990 to 1994 but not after 1995",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 743, 1, 26, 45, 16, 6, 1004, 400, 252, 98, 4, 25, 9, 1410, 597, 1519, 2, 886, 117, 265, 5, 12, 1951, 617, 1284, 2, 396, 99, 1605, 1243, 74, 29, 4675, 6, 1238, 11, 95, 9, 26, 65, 2257, 362, 4, 25, 11, 194, 59, 1410, 597, 1519, 2, 886, 117, 876, 882, 2, 418, 831, 1017, 25, 636, 11, 95, 6, 423, 362, 4, 25, 20, 1047, 28, 33, 111, 1582, 3, 45, 1000, 159, 382, 9074, 117, 141, 40434, 245, 49, 54, 11, 1519, 2, 326, 10560, 852, 39, 54, 11, 886, 1519, 117, 11, 434, 725, 39, 185, 576, 83, 60, 19, 144, 2, 42, 8, 142, 116, 1, 951, 519, 27, 185, 456, 66, 19, 144, 2, 626, 278, 79, 67, 185, 66, 67, 19, 144, 1519, 299, 746, 103, 12, 1166, 152, 531, 39, 185, 641, 19, 144, 2, 80, 746, 310, 511, 27, 185, 432, 39, 19, 144, 63, 1519, 117, 42, 8, 360, 197, 168, 1, 14, 605, 48, 307, 268, 14, 531, 14, 725, 1, 12, 1951, 282, 72, 5, 2556, 1358, 9, 1605, 1608, 5345, 156, 82, 89, 24, 88, 2, 784, 1519, 117, 42, 35, 168, 1, 14, 233, 48, 307, 268, 14, 474, 14, 350, 1, 1951, 139, 282, 50, 1358, 9, 3, 827, 682, 125, 10, 8, 93, 523, 4, 1951, 112, 282, 59, 4675, 6, 3965, 2, 2289, 6, 3023, 84, 44, 50, 2323, 50, 1358, 9, 1047, 1605, 1608, 5345, 156, 82, 89, 24, 88, 2, 784, 125, 10, 8, 93, 523, 4, 1951, 112, 282, 59, 4675, 6, 3965, 2, 2289, 6, 3023, 84, 44, 50, 2323]",1506.0,23913530,174
Paget Cells in Endometrial and Endocervical Curettings in a Patient With Recurrent Vulvar Paget's Disease.,International journal of surgical pathology,Int. J. Surg. Pathol.,2013-08-05,"Paget's disease of the vulva is a rare malignancy primarily affecting Caucasian women in their seventh to eighth decades. Most patients experience an indolent disease course and undergo surgical excision for disease control. Although progression to invasive adenocarcinoma is rare, recurrence is common because of the difficulty of achieving negative surgical margins. We report a case of a 73-year-old woman with a long-standing history of recurrent vulvar Paget's disease who presented with postmenopausal bleeding. Workup revealed extensive endocervical involvement by Paget's disease, resulting in Paget cells on endocervical curettage, as well as endometrial curettage (because of cervical contamination). Extensive endocervical involvement by vulvar Paget's disease can occur despite multiple reexcisions and topical therapy. The presence of Paget cells on endometrial and endocervical curettings, particularly in patients without visible vulvar or cervical lesions, should raise suspicion of endocervical involvement and prompt further evaluation of disease extension.",Case Reports,2360.0,1.0,Paget 's disease of the vulva is a rare malignancy primarily affecting Caucasian women in their seventh to eighth decades Most patients experience an indolent disease course and undergo surgical excision for disease control Although progression to invasive adenocarcinoma is rare recurrence is common because of the difficulty of achieving negative surgical margins We report a case of a 73-year-old woman with a long-standing history of recurrent Paget 's disease who presented with postmenopausal bleeding Workup revealed extensive endocervical involvement by Paget 's disease resulting in Paget cells on endocervical curettage as well as curettage because of contamination Extensive endocervical involvement by Paget 's disease can occur despite multiple reexcisions and topical therapy The presence of Paget cells on and endocervical curettings particularly in patients without visible or lesions should raise suspicion of endocervical involvement and prompt further evaluation of disease extension,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[7497, 292, 34, 1, 3, 9263, 16, 8, 622, 710, 1561, 2319, 3229, 117, 4, 136, 8114, 6, 7732, 1968, 96, 7, 730, 35, 2316, 34, 906, 2, 1251, 221, 1366, 9, 34, 182, 242, 91, 6, 416, 449, 16, 622, 146, 16, 186, 408, 1, 3, 4035, 1, 1785, 199, 221, 1012, 21, 414, 8, 473, 1, 8, 803, 111, 1095, 2854, 5, 8, 319, 10909, 532, 1, 387, 7497, 292, 34, 54, 917, 5, 1679, 2294, 4755, 553, 1344, 10174, 799, 20, 7497, 292, 34, 1113, 4, 7497, 37, 23, 10174, 12529, 22, 149, 22, 12529, 408, 1, 9866, 1344, 10174, 799, 20, 7497, 292, 34, 122, 1271, 550, 232, 34594, 2, 5879, 36, 3, 463, 1, 7497, 37, 23, 2, 10174, 63187, 823, 4, 7, 187, 4822, 15, 406, 257, 5008, 5782, 1, 10174, 799, 2, 4776, 195, 451, 1, 34, 2401]",1002.0,23918905,3
Risk factors for non-initiation of the human papillomavirus vaccine among adolescent survivors of childhood cancer.,"Cancer prevention research (Philadelphia, Pa.)",Cancer Prev Res (Phila),2013-08-27,"Effective vaccination is now available to prevent human papillomavirus (HPV), the most common sexually transmitted infection and cause of cervical cancer. This study aimed to estimate the prevalence of HPV vaccination among childhood cancer survivors and identify factors associated with HPV vaccine initiation and completion. Mothers of daughters of ages 9 to 17 years with/without a history of childhood cancer (n = 235, Mage = 13.2 years, SD = 2.69; n = 70, Mage = 13.3 years, SD = 2.47, respectively) completed surveys querying HPV vaccination initiation and completion along with sociodemographic, medical, HPV knowledge and communication, and health belief factors, which may relate to vaccination outcomes. Multivariate logistic regression was used to identify factors that associate with HPV vaccination initiation and completion. Among cancer survivors, 32.6% initiated and 17.9% completed the three-dose vaccine series, whereas 34.3% and 20.0% of controls initiated and completed, respectively. Univariate analyses indicated no differences between cancer/no cancer groups on considered risk factors. Among all participants, multivariate logistic regression analyses found vaccine initiation associated with older age of daughter and physician recommendation, whereas increased perceived barriers associated with a decreased likelihood of initiation (all P < 0.05). Among those having initiated, risk factors for noncompletion included being non-White, increased perceived severity of HPV, and increased perceived barriers to vaccination (all P < 0.05). A minority of adolescents surviving childhood cancer has completed vaccination despite their increased risk for HPV-related complication. These results inform the prioritization of strategies to be included in vaccine promotion efforts.",Journal Article,2338.0,16.0,Effective vaccination is now available to prevent human papillomavirus HPV the most common sexually transmitted infection and cause of cancer This study aimed to estimate the prevalence of HPV vaccination among childhood cancer survivors and identify factors associated with HPV vaccine initiation and completion Mothers of daughters of ages 9 to 17 years with/without a history of childhood cancer n 235 Mage 13.2 years SD 2.69 n 70 Mage 13.3 years SD 2.47 respectively completed surveys querying HPV vaccination initiation and completion along with sociodemographic medical HPV knowledge and communication and health belief factors which may relate to vaccination outcomes Multivariate logistic regression was used to identify factors that associate with HPV vaccination initiation and completion Among cancer survivors 32.6 initiated and 17.9 completed the three-dose vaccine series whereas 34.3 and 20.0 of controls initiated and completed respectively Univariate analyses indicated no differences between cancer/no cancer groups on considered risk factors Among all participants multivariate logistic regression analyses found vaccine initiation associated with older age of daughter and physician recommendation whereas increased perceived barriers associated with a decreased likelihood of initiation all P 0.05 Among those having initiated risk factors for noncompletion included being non-White increased perceived severity of HPV and increased perceived barriers to vaccination all P 0.05 A minority of adolescents surviving childhood cancer has completed vaccination despite their increased risk for HPV-related complication These results inform the prioritization of strategies to be included in vaccine promotion efforts,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[323, 1915, 16, 1134, 390, 6, 1682, 171, 3242, 933, 3, 96, 186, 13588, 12959, 930, 2, 708, 1, 12, 26, 45, 1295, 6, 1191, 3, 1078, 1, 933, 1915, 107, 864, 12, 332, 2, 255, 130, 41, 5, 933, 1274, 1118, 2, 1438, 8605, 1, 13099, 1, 2165, 83, 6, 269, 60, 5, 187, 8, 532, 1, 864, 12, 78, 6465, 4871, 233, 18, 60, 1270, 18, 790, 78, 431, 4871, 233, 27, 60, 1270, 18, 662, 106, 781, 3666, 22483, 933, 1915, 1118, 2, 1438, 1510, 5, 4221, 484, 933, 922, 2, 2063, 2, 341, 8862, 130, 92, 68, 6509, 6, 1915, 123, 331, 812, 320, 10, 95, 6, 255, 130, 17, 6446, 5, 933, 1915, 1118, 2, 1438, 107, 12, 332, 531, 49, 1917, 2, 269, 83, 781, 3, 169, 61, 1274, 988, 547, 562, 27, 2, 179, 13, 1, 535, 1917, 2, 781, 106, 880, 318, 1103, 77, 362, 59, 12, 77, 12, 271, 23, 515, 43, 130, 107, 62, 776, 331, 812, 320, 318, 204, 1274, 1118, 41, 5, 434, 89, 1, 15254, 2, 1473, 3347, 547, 101, 2588, 2160, 41, 5, 8, 340, 1420, 1, 1118, 62, 19, 13, 474, 107, 135, 1041, 1917, 43, 130, 9, 31736, 159, 486, 220, 886, 101, 2588, 1702, 1, 933, 2, 101, 2588, 2160, 6, 1915, 62, 19, 13, 474, 8, 2652, 1, 3101, 3050, 864, 12, 71, 781, 1915, 550, 136, 101, 43, 9, 933, 139, 1447, 46, 99, 2295, 3, 10343, 1, 422, 6, 40, 159, 4, 1274, 5478, 1413]",1733.0,23983087,36
Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.,Cancer,Cancer,2013-08-23,"Cervical cancer is the second leading cause of cancer deaths among women worldwide. The objective of this study was to describe the most common oncogenic mutations in cervical cancers and to explore genomic differences between the 2 most common histologic subtypes: adenocarcinoma and squamous cell carcinoma. A high-throughput genotyping platform, termed Oncomap, was used to interrogate 80 cervical tumors for 1250 known mutations in 139 cancer genes. Samples were analyzed using a mass spectrometry-based genotyping platform and were validated using orthogonal chemistry. Epidermal growth factor receptor (EGFR) mutations were further validated by massive parallel sequencing. Human papilloma virus (HPV) genotyping also was performed. Validated mutations were detected in 48 of 80 tumors (60%) examined. The highest mutation rates were in the genes phosphatidylinositol 3-kinase, catalytic subunit  (PIK3CA) (31.3%); Kirsten rat sarcoma viral oncogene homolog (KRAS) (8.8%); and EGFR (3.8%). PIK3CA mutation rates did not differ significantly between adenocarcinomas and squamous cell carcinomas (25% vs 37.5%, respectively; P = .33). In contrast, KRAS mutations were identified only in adenocarcinomas (17.5% vs 0%; P = .01), and a novel EGFR mutation was detected only in squamous cell carcinomas (0% vs 7.5%; P = .24). There were no associations between HPV-16 or HPV-18 and somatic mutations or overall survival. In adjusted analyses, PIK3CA mutations were associated with shorter survival (67.1 months vs 90.3 months; hazard ratio, 9.1; 95% confidence interval, 2.8-29.5 months; P < .001). Cervical cancers harbor high rates of potentially targetable oncogenic mutations. In addition, cervical squamous cell carcinoma and adenocarcinoma have distinct molecular profiles, suggesting that clinical outcomes may be improved with the use of more tailored treatment strategies, including PI3K and MEK inhibitors.",Comparative Study,2342.0,128.0,cancer is the second leading cause of cancer deaths among women worldwide The objective of this study was to describe the most common oncogenic mutations in cancers and to explore genomic differences between the 2 most common histologic subtypes adenocarcinoma and squamous cell carcinoma A high-throughput genotyping platform termed Oncomap was used to interrogate 80 tumors for 1250 known mutations in 139 cancer genes Samples were analyzed using a mass spectrometry-based genotyping platform and were validated using orthogonal chemistry Epidermal growth factor receptor EGFR mutations were further validated by massive parallel sequencing Human papilloma virus HPV genotyping also was performed Validated mutations were detected in 48 of 80 tumors 60 examined The highest mutation rates were in the genes phosphatidylinositol 3-kinase catalytic subunit PIK3CA 31.3 Kirsten rat viral oncogene homolog KRAS 8.8 and EGFR 3.8 PIK3CA mutation rates did not differ significantly between adenocarcinomas and squamous cell carcinomas 25 vs 37.5 respectively P .33 In contrast KRAS mutations were identified only in adenocarcinomas 17.5 vs 0 P .01 and a novel EGFR mutation was detected only in squamous cell carcinomas 0 vs 7.5 P .24 There were no associations between HPV-16 or HPV-18 and somatic mutations or overall survival In adjusted analyses PIK3CA mutations were associated with shorter survival 67.1 months vs 90.3 months hazard ratio 9.1 95 confidence interval 2.8-29.5 months P .001 cancers harbor high rates of potentially targetable oncogenic mutations In addition squamous cell carcinoma and adenocarcinoma have distinct molecular profiles suggesting that clinical outcomes may be improved with the use of more tailored treatment strategies including PI3K and MEK inhibitors,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 3, 419, 1049, 708, 1, 12, 1043, 107, 117, 2358, 3, 461, 1, 26, 45, 10, 6, 897, 3, 96, 186, 1302, 138, 4, 163, 2, 6, 1645, 572, 362, 59, 3, 18, 96, 186, 884, 814, 449, 2, 691, 31, 134, 8, 64, 3643, 2686, 2243, 4183, 16141, 10, 95, 6, 8415, 493, 57, 9, 11551, 440, 138, 4, 4929, 12, 214, 347, 11, 311, 75, 8, 782, 3680, 90, 2686, 2243, 2, 11, 938, 75, 9413, 9352, 829, 129, 161, 153, 227, 138, 11, 195, 938, 20, 7929, 2755, 615, 171, 7017, 1450, 933, 2686, 120, 10, 173, 938, 138, 11, 530, 4, 576, 1, 493, 57, 335, 409, 3, 1076, 258, 151, 11, 4, 3, 214, 3415, 27, 216, 4784, 3350, 1506, 456, 27, 10618, 4008, 1667, 1836, 3412, 723, 66, 66, 2, 227, 27, 66, 1506, 258, 151, 205, 44, 1505, 97, 59, 1586, 2, 691, 31, 826, 243, 105, 567, 33, 106, 19, 466, 4, 748, 723, 138, 11, 108, 158, 4, 1586, 269, 33, 105, 13, 19, 355, 2, 8, 229, 227, 258, 10, 530, 158, 4, 691, 31, 826, 13, 105, 67, 33, 19, 259, 125, 11, 77, 685, 59, 933, 245, 15, 933, 203, 2, 1119, 138, 15, 63, 25, 4, 586, 318, 1506, 138, 11, 41, 5, 985, 25, 598, 14, 53, 105, 424, 27, 53, 360, 197, 83, 14, 48, 307, 268, 18, 66, 462, 33, 53, 19, 144, 163, 2760, 64, 151, 1, 751, 3985, 1302, 138, 4, 352, 691, 31, 134, 2, 449, 47, 834, 219, 1241, 802, 17, 38, 123, 68, 40, 231, 5, 3, 119, 1, 80, 3632, 24, 422, 141, 974, 2, 1693, 222]",1784.0,24037752,0
"Management of low-risk early-stage cervical cancer: should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care?",Gynecologic oncology,Gynecol. Oncol.,2013-09-14,"The standard treatment for women with early-stage cervical cancer (IA2-IB1) remains radical hysterectomy with pelvic lymphadenectomy. In select patients interested in future fertility, the option of radical trachelectomy with pelvic lymphadenectomy is also considered a viable option. The possibility of less radical surgery may be appropriate not only for patients desiring to preserve fertility but also for all patients with low-risk early-stage cervical cancer. Recently, a number of studies have explored less radical surgical options for early-stage cervical cancer, including simple hysterectomy, simple trachelectomy, and cervical conization with or without sentinel lymph node biopsy and pelvic lymph node dissection. Such options may be available for patients with low-risk early-stage cervical cancer. Criteria that define this low-risk group include: squamous carcinoma, adenocarcinoma, or adenosquamous carcinoma, tumor size <2 cm, stromal invasion <10mm, and no lymph-vascular space invasion. In this report, we provide a review of the existing literature on the conservative management of cervical cancer and describe ongoing multi-institutional trials evaluating the role of conservative surgery in selected patients with early-stage cervical cancer.",Journal Article,2320.0,98.0,The standard treatment for women with early-stage cancer IA2-IB1 remains radical hysterectomy with pelvic lymphadenectomy In select patients interested in future fertility the option of radical trachelectomy with pelvic lymphadenectomy is also considered a viable option The possibility of less radical surgery may be appropriate not only for patients desiring to preserve fertility but also for all patients with low-risk early-stage cancer Recently a number of studies have explored less radical surgical options for early-stage cancer including simple hysterectomy simple trachelectomy and conization with or without sentinel lymph node biopsy and pelvic lymph node dissection Such options may be available for patients with low-risk early-stage cancer Criteria that define this low-risk group include squamous carcinoma adenocarcinoma or adenosquamous carcinoma tumor size 2 cm stromal invasion 10mm and no lymph-vascular space invasion In this report we provide a review of the existing literature on the conservative management of cancer and describe ongoing multi-institutional trials evaluating the role of conservative surgery in selected patients with early-stage cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,"[3, 260, 24, 9, 117, 5, 191, 82, 12, 16725, 8111, 469, 711, 2622, 5, 1110, 2048, 4, 1717, 7, 7420, 4, 508, 2954, 3, 1501, 1, 711, 5760, 5, 1110, 2048, 16, 120, 515, 8, 2663, 1501, 3, 2526, 1, 299, 711, 152, 68, 40, 870, 44, 158, 9, 7, 20520, 6, 6783, 2954, 84, 120, 9, 62, 7, 5, 154, 43, 191, 82, 12, 761, 8, 207, 1, 94, 47, 1443, 299, 711, 221, 838, 9, 191, 82, 12, 141, 2763, 2622, 2763, 5760, 2, 8755, 5, 15, 187, 1323, 263, 289, 411, 2, 1110, 263, 289, 1161, 225, 838, 68, 40, 390, 9, 7, 5, 154, 43, 191, 82, 12, 371, 17, 1107, 26, 154, 43, 87, 643, 691, 134, 449, 15, 8067, 134, 30, 444, 18, 494, 1126, 578, 16557, 2, 77, 263, 756, 3865, 578, 4, 26, 414, 21, 377, 8, 206, 1, 3, 1692, 789, 23, 3, 4476, 284, 1, 12, 2, 897, 942, 1414, 1115, 143, 1435, 3, 200, 1, 4476, 152, 4, 715, 7, 5, 191, 82, 12]",1180.0,24041877,726
"Limitations of lymph node ratio, evidence-based benchmarks, and the importance of a thorough lymph node dissection in melanoma.",Annals of surgical oncology,Ann. Surg. Oncol.,2013-09-18,"Stage III melanoma is currently stratified by number of lymph nodes (LNs) involved. However, given the variability of LN retrieval counts we hypothesize that lymph node ratio (LNR) may also provide prognostic information. Retrospective cohort study of 411 patients with stage III melanoma were divided into two groups based on LNR (<0.15, n = 291 and 0.15, n = 120). In multivariate analysis N stage (N3 vs. N1, hazard ratio [HR] = 2.13, p < 0.001), extranodal extension (HR = 1.92, p = 0.002), macrometastasis (HR = 1.70, p = 0.005), non-SLN involvement (HR = 1.65, p = 0.005), risk of N2 disease exceeding 35 % (HR = 1.51, p = 0.03), and LNR 0.15 (HR = 1.46, p = 0.03) were associated with overall survival (OS). LNR failed to further stratify stage III melanoma; however, the number of LNs examined was an independent prognostic factor. Patients who had >8 inguinal, >15 axillary, or >20 cervical LNs examined had fewer same nodal basin recurrences (26 [8 %] vs. 20 [20 %], p = 0.0009) and for N1 patients an improved OS (3-year OS 84 % vs. 76 %, 10-year OS 53 % vs. 34 %, p = 0.06) compared with N1 patients who had fewer LNs examined. LNR is an important prognostic factor in stage III melanoma; however, it was not independent over the current AJCC TNM staging system. Diligence by the surgeon and pathologist to retrieve and examine >8 inguinal, >15 axillary, or >20 cervical LNs is associated with fewer same nodal basin recurrences and improved survival and is critical to reliable prognostication.",Clinical Trial,2316.0,20.0,Stage III is currently stratified by number of lymph nodes LNs involved However given the variability of LN retrieval counts we hypothesize that lymph node ratio LNR may also provide prognostic information Retrospective cohort study of 411 patients with stage III were divided into two groups based on LNR 0.15 n 291 and 0.15 n 120 In multivariate analysis N stage N3 vs. N1 hazard ratio HR 2.13 p 0.001 extranodal extension HR 1.92 p 0.002 macrometastasis HR 1.70 p 0.005 non-SLN involvement HR 1.65 p 0.005 risk of N2 disease exceeding 35 HR 1.51 p 0.03 and LNR 0.15 HR 1.46 p 0.03 were associated with overall survival OS LNR failed to further stratify stage III however the number of LNs examined was an independent prognostic factor Patients who had 8 inguinal 15 axillary or 20 LNs examined had fewer same nodal basin recurrences 26 8 vs. 20 20 p 0.0009 and for N1 patients an improved OS 3-year OS 84 vs. 76 10-year OS 53 vs. 34 p 0.06 compared with N1 patients who had fewer LNs examined LNR is an important prognostic factor in stage III however it was not independent over the current AJCC TNM staging system Diligence by the surgeon and pathologist to retrieve and examine 8 inguinal 15 axillary or 20 LNs is associated with fewer same nodal basin recurrences and improved survival and is critical to reliable prognostication,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[82, 316, 16, 694, 1173, 20, 207, 1, 263, 502, 2704, 646, 137, 447, 3, 1982, 1, 1763, 8372, 1911, 21, 4919, 17, 263, 289, 197, 4732, 68, 120, 377, 177, 487, 459, 180, 45, 1, 9619, 7, 5, 82, 316, 11, 2176, 237, 100, 271, 90, 23, 4732, 13, 167, 78, 8253, 2, 8898, 167, 78, 2031, 4, 331, 65, 78, 82, 5749, 105, 3192, 360, 197, 168, 18, 233, 19, 13, 144, 4093, 2401, 168, 14, 937, 19, 13, 1111, 16991, 168, 14, 431, 19, 13, 1614, 220, 1099, 799, 168, 14, 556, 19, 13, 1614, 43, 1, 3473, 34, 5178, 465, 168, 14, 725, 19, 13, 680, 2, 4732, 8898, 167, 168, 14, 641, 19, 13, 680, 11, 41, 5, 63, 25, 118, 4732, 1551, 6, 195, 3570, 82, 316, 137, 3, 207, 1, 2704, 409, 10, 35, 306, 177, 161, 7, 54, 42, 66, 4907, 167, 1210, 15, 179, 2704, 409, 42, 1497, 827, 779, 6969, 1593, 432, 66, 105, 179, 179, 19, 13, 7946, 2, 9, 3192, 7, 35, 231, 118, 27, 111, 118, 874, 105, 846, 79, 111, 118, 699, 105, 562, 19, 13, 1460, 72, 5, 3192, 7, 54, 42, 1497, 2704, 409, 4732, 16, 35, 305, 177, 161, 4, 82, 316, 137, 192, 10, 44, 306, 252, 3, 291, 2271, 2918, 632, 398, 33710, 20, 3, 1897, 2, 5093, 6, 18193, 2, 1004, 66, 4907, 167, 1210, 15, 179, 2704, 16, 41, 5, 1497, 827, 779, 6969, 1593, 2, 231, 25, 2, 16, 740, 6, 2450, 4260]",1338.0,24046102,790
Comparative morbidity and mortality from cervical or thoracic esophageal anastomoses.,Journal of surgical oncology,J Surg Oncol,2013-09-21,"In the modern era of esophagectomy, we hypothesized that perioperative morbidity and mortality from cervical or thoracic sites of anastomoses would not be different. We used the American College of Surgeons National Surgical Quality Improvement Program database to identify patients who underwent esophagectomy for lower esophageal or gastroesophageal (GE) junction malignancies from 2005 to 2010. Patients were categorized as having either a cervical or thoracic anastomosis based on CPT codes. There were 601 (66%) cervical and 308 (34%) thoracic anastomoses. Cervical anastomoses were associated with greater than 2 units of blood transfusion in a higher proportion of patients (10% vs. 3%, P=0.001), and higher superficial surgical site infections (13% vs. 7%, P=0.003). There were no difference in rates of organ/space infections (6% vs. 7%, P=0.70), overall morbidity (38% vs. 39%, P=0.84), or mortality (3% vs. 4%, P=0.34). Median length of stay was similar (11.5 days cervical vs. 11 days thoracic, P=0.89), even among patients with organ/space infections (18 days cervical vs. 21 days thoracic, P=0.49). On multivariate analysis thoracic anastomosis was not a significant predictor of increased overall morbidity (OR 1.13: 95%CI 0.83-1.54). After esophagectomy, the site of anastomosis does not predict an increased risk of perioperative morbidity or mortality.",Journal Article,2313.0,8.0,In the modern era of esophagectomy we hypothesized that perioperative morbidity and mortality from or thoracic sites of anastomoses would not be different We used the American College of Surgeons National Surgical Quality Improvement Program database to identify patients who underwent esophagectomy for lower or gastroesophageal GE junction malignancies from 2005 to 2010 Patients were categorized as having either a or thoracic anastomosis based on CPT codes There were 601 66 and 308 34 thoracic anastomoses anastomoses were associated with greater than 2 units of blood transfusion in a higher proportion of patients 10 vs. 3 P 0.001 and higher superficial surgical site infections 13 vs. 7 P 0.003 There were no difference in rates of organ/space infections 6 vs. 7 P 0.70 overall morbidity 38 vs. 39 P 0.84 or mortality 3 vs. 4 P 0.34 Median length of stay was similar 11.5 days vs. 11 days thoracic P 0.89 even among patients with organ/space infections 18 days vs. 21 days thoracic P 0.49 On multivariate analysis thoracic anastomosis was not a significant predictor of increased overall morbidity OR 1.13 95 CI 0.83-1.54 After esophagectomy the site of anastomosis does not predict an increased risk of perioperative morbidity or mortality,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[4, 3, 2366, 1713, 1, 3617, 21, 1237, 17, 1547, 787, 2, 282, 29, 15, 2098, 633, 1, 13311, 688, 44, 40, 338, 21, 95, 3, 597, 2979, 1, 1613, 657, 221, 372, 767, 1243, 609, 6, 255, 7, 54, 208, 3617, 9, 280, 15, 3227, 9489, 3322, 441, 29, 1242, 6, 1120, 7, 11, 2320, 22, 1041, 361, 8, 15, 2098, 5519, 90, 23, 3361, 5271, 125, 11, 10488, 700, 2, 7786, 562, 2098, 13311, 13311, 11, 41, 5, 378, 76, 18, 2960, 1, 315, 2785, 4, 8, 142, 920, 1, 7, 79, 105, 27, 19, 13, 144, 2, 142, 3562, 221, 606, 1875, 233, 105, 67, 19, 13, 1421, 125, 11, 77, 523, 4, 151, 1, 1259, 3865, 1875, 49, 105, 67, 19, 13, 431, 63, 787, 519, 105, 587, 19, 13, 874, 15, 282, 27, 105, 39, 19, 13, 562, 52, 1318, 1, 2020, 10, 288, 175, 33, 162, 105, 175, 162, 2098, 19, 13, 887, 871, 107, 7, 5, 1259, 3865, 1875, 203, 162, 105, 239, 162, 2098, 19, 13, 739, 23, 331, 65, 2098, 5519, 10, 44, 8, 93, 980, 1, 101, 63, 787, 15, 14, 233, 48, 58, 13, 852, 14, 667, 50, 3617, 3, 606, 1, 5519, 1097, 44, 678, 35, 101, 43, 1, 1547, 787, 15, 282]",1248.0,24108568,204
"The Sequencing Bead Array (SBA), a next-generation digital suspension array.",PloS one,PLoS ONE,2013-10-07,"Here we describe the novel Sequencing Bead Array (SBA), a complete assay for molecular diagnostics and typing applications. SBA is a digital suspension array using Next-Generation Sequencing (NGS), to replace conventional optical readout platforms. The technology allows for reducing the number of instruments required in a laboratory setting, where the same NGS instrument could be employed from whole-genome and targeted sequencing to SBA broad-range biomarker detection and genotyping. As proof-of-concept, a model assay was designed that could distinguish ten Human Papillomavirus (HPV) genotypes associated with cervical cancer progression. SBA was used to genotype 20 cervical tumor samples and, when compared with amplicon pyrosequencing, was able to detect two additional co-infections due to increased sensitivity. We also introduce in-house software Sphix, enabling easy accessibility and interpretation of results. The technology offers a multi-parallel, rapid, robust, and scalable system that is readily adaptable for a multitude of microarray diagnostic and typing applications, e.g. genetic signatures, single nucleotide polymorphisms (SNPs), structural variations, and immunoassays. SBA has the potential to dramatically change the way we perform probe-based applications, and allow for a smooth transition towards the technology offered by genomic sequencing. ",Journal Article,2297.0,3.0,Here we describe the novel Sequencing Bead Array SBA a complete assay for molecular diagnostics and typing applications SBA is a digital suspension array using Next-Generation Sequencing NGS to replace conventional optical readout platforms The technology allows for reducing the number of instruments required in a laboratory setting where the same NGS instrument could be employed from whole-genome and targeted sequencing to SBA broad-range biomarker detection and genotyping As proof-of-concept a model assay was designed that could distinguish ten Human Papillomavirus HPV genotypes associated with cancer progression SBA was used to genotype 20 tumor samples and when compared with amplicon pyrosequencing was able to detect two additional co-infections due to increased sensitivity We also introduce in-house software Sphix enabling easy accessibility and interpretation of results The technology offers a multi-parallel rapid robust and scalable system that is readily adaptable for a multitude of microarray diagnostic and typing applications e.g genetic signatures single nucleotide polymorphisms SNPs structural variations and immunoassays SBA has the potential to dramatically change the way we perform probe-based applications and allow for a smooth transition towards the technology offered by genomic sequencing,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[467, 21, 897, 3, 229, 615, 9921, 1926, 9715, 8, 236, 719, 9, 219, 5197, 2, 10656, 2911, 9715, 16, 8, 3271, 9348, 1926, 75, 1305, 914, 615, 2650, 6, 7195, 809, 4303, 18589, 4364, 3, 2033, 2333, 9, 1818, 3, 207, 1, 4730, 616, 4, 8, 1624, 546, 1257, 3, 827, 2650, 3877, 359, 40, 2516, 29, 902, 898, 2, 238, 615, 6, 9715, 2094, 184, 901, 638, 2, 2686, 22, 3840, 1, 2545, 8, 202, 719, 10, 1114, 17, 359, 3081, 1618, 171, 3242, 933, 2071, 41, 5, 12, 91, 9715, 10, 95, 6, 1183, 179, 30, 347, 2, 198, 72, 5, 9161, 6031, 10, 1665, 6, 1426, 100, 402, 1269, 1875, 520, 6, 101, 485, 21, 120, 7630, 4, 10087, 3639, 63494, 5257, 6261, 9571, 2, 3037, 1, 99, 3, 2033, 2339, 8, 1414, 2755, 1321, 1922, 2, 17510, 398, 17, 16, 3860, 16474, 9, 8, 9540, 1, 1727, 752, 2, 10656, 2911, 563, 499, 336, 2210, 226, 1579, 1203, 1109, 3281, 2293, 2, 14785, 9715, 71, 3, 174, 6, 2729, 707, 3, 2255, 21, 2715, 2888, 90, 2911, 2, 1700, 9, 8, 5774, 1970, 3113, 3, 2033, 2216, 20, 572, 615]",1326.0,24116138,22
Outcomes in patients with mucosal melanomas.,Journal of surgical oncology,J Surg Oncol,2013-10-16,"Our goal was to evaluate the different subtypes of mucosal melanoma and describe specific variables that predict outcomes. Prospective review of two tertiary care center databases identified 76 mucosal melanoma patients; 73 with complete records were included. Demographic and clinical data were analyzed. Cox regression determined variables impacting recurrence and survival. In the 73 patients, the mean age was 64 years, and 74% were female. Sixty-seven percent presented with lymph node involvement, and 73% had ulcerated tumors. Major sites affected were nasal/palate/oral (36%), vulvar/vaginal/cervical (48%), and anorectal (15%). Mean overall and disease-free survival were 56.9 and 27.2 months. Variables associated with decreased survival included: lymphovascular invasion (HR17.70, P=0.0093), Caucasian race (HR3.02, P=0.0362), nasal/palate/oral sub-group (HR1.85, P=0.026), Breslow thickness (HR1.23, P=0.00004), T stage (HR1.34, P=0.0075), M stage (HR3.03, P=0.0039), and chemotherapy (HR3.13, P=0.0002). The worst prognosis was seen in the nasal/palate/oral sub-group, with a median overall survival of 9.7 months and recurrence-free time of 4.5 months. This subtype also demonstrated high lymph node positivity, ulceration, and larger tumor size. The nasal, palate, oral subtype has the worst prognosis compared to other mucosal melanoma locations. Studies are ongoing to evaluate pathologic and genomic variables that may predict outcomes.",Journal Article,2288.0,23.0,Our goal was to evaluate the different subtypes of mucosal and describe specific variables that predict outcomes Prospective review of two tertiary care center databases identified 76 mucosal patients 73 with complete records were included Demographic and clinical data were analyzed Cox regression determined variables impacting recurrence and survival In the 73 patients the mean age was 64 years and 74 were female Sixty-seven percent presented with lymph node involvement and 73 had ulcerated tumors Major sites affected were nasal/palate/oral 36 vulvar/vaginal/cervical 48 and anorectal 15 Mean overall and disease-free survival were 56.9 and 27.2 months Variables associated with decreased survival included lymphovascular invasion HR17.70 P 0.0093 Caucasian race HR3.02 P 0.0362 nasal/palate/oral sub-group HR1.85 P 0.026 Breslow thickness HR1.23 P 0.00004 T stage HR1.34 P 0.0075 M stage HR3.03 P 0.0039 and chemotherapy HR3.13 P 0.0002 The worst prognosis was seen in the nasal/palate/oral sub-group with a median overall survival of 9.7 months and recurrence-free time of 4.5 months This subtype also demonstrated high lymph node positivity ulceration and larger tumor size The nasal palate oral subtype has the worst prognosis compared to other mucosal locations Studies are ongoing to evaluate pathologic and genomic variables that may predict outcomes,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[114, 1326, 10, 6, 376, 3, 338, 814, 1, 3068, 2, 897, 112, 682, 17, 678, 123, 482, 206, 1, 100, 2557, 165, 574, 2348, 108, 846, 3068, 7, 803, 5, 236, 1064, 11, 159, 1540, 2, 38, 74, 11, 311, 418, 320, 509, 682, 8661, 146, 2, 25, 4, 3, 803, 7, 3, 313, 89, 10, 660, 60, 2, 794, 11, 1061, 1746, 648, 714, 917, 5, 263, 289, 799, 2, 803, 42, 13571, 57, 458, 633, 1424, 11, 6743, 10988, 518, 511, 48010, 18982, 18237, 576, 2, 9778, 167, 313, 63, 2, 34, 115, 25, 11, 664, 83, 2, 428, 18, 53, 682, 41, 5, 340, 25, 159, 2933, 578, 63528, 431, 19, 13, 26813, 3229, 1047, 40512, 588, 19, 13, 40227, 6743, 10988, 518, 551, 87, 25099, 772, 19, 13, 4554, 6931, 2903, 25099, 382, 19, 13, 30815, 102, 82, 25099, 562, 19, 13, 23345, 188, 82, 40512, 680, 19, 13, 20518, 2, 56, 40512, 233, 19, 13, 3531, 3, 4066, 356, 10, 527, 4, 3, 6743, 10988, 518, 551, 87, 5, 8, 52, 63, 25, 1, 83, 67, 53, 2, 146, 115, 98, 1, 39, 33, 53, 26, 875, 120, 264, 64, 263, 289, 1887, 5158, 2, 1077, 30, 444, 3, 6743, 10988, 518, 875, 71, 3, 4066, 356, 72, 6, 127, 3068, 4069, 94, 32, 942, 6, 376, 510, 2, 572, 682, 17, 68, 678, 123]",1364.0,24132665,757
PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions.,AJR. American journal of roentgenology,AJR Am J Roentgenol,2013-11-01,"Hypoxia is a characteristic of many tumors and portends a worse prognosis in lung, cervical, prostate, and rectal cancers. Unlike the others, lung cancers present a unique challenge in measuring hypoxia, with invasive biopsies and higher rates of complications. Noninvasive imaging studies detecting hypoxia using isotopes of copper-diacetyl-bis(N4-methylthiosemicarbazone) ((62)Cu-ATSM) have predicted prognosis and treatment outcomes in some small feasibility trials. These images, however, may not identify all areas of hypoxia. Hence, we hypothesize that the addition of another PET imaging agent, copper-pyruvaldehyde-bis(N4-methylthiosemicarbazone) ((62)Cu-PTSM), which can detect areas of perfusion, can augment the information obtained in (62)Cu-ATSM PET scans. To characterize tumors on the basis of both perfusion and hypoxia, 10 patients were studied using both (62)Cu-ATSM and (62)Cu-PTSM PET scans. In addition, proteomic arrays looking at specific proangiogenic, survival, and proinflammatory targets were assessed. Six of 10 patients had evaluable PET scans. Our initial experience of characterizing lung tumor hypoxia using (62)Cu-ATSM and (62)Cu-PTSM PET scans showed that visualization of areas with hypoxia normalized for perfusion is feasible. All studied tumors exhibited some hypoxia. Despite the small sample size, a positive relationship was noted between epidermal growth factor levels and (62)Cu-ATSM-detected hypoxia. This initial series of (62)Cu-ATSM and (62)Cu-PTSM PET scans shows that evaluating lung masses by visualizing hypoxia and perfusion is a feasible and novel technique to provide more information. Further investigation is warranted to assess the potential role of (62)Cu-ATSM and (62)Cu-PTSM PET techniques combined with proteomics as alternatives to invasive biopsy techniques in clinical care.",Journal Article,2272.0,12.0,Hypoxia is a characteristic of many tumors and portends a worse prognosis in and cancers Unlike the others cancers present a unique challenge in measuring hypoxia with invasive biopsies and higher rates of complications Noninvasive imaging studies detecting hypoxia using isotopes of copper-diacetyl-bis N4-methylthiosemicarbazone 62 Cu-ATSM have predicted prognosis and treatment outcomes in some small feasibility trials These images however may not identify all areas of hypoxia Hence we hypothesize that the addition of another PET imaging agent copper-pyruvaldehyde-bis N4-methylthiosemicarbazone 62 Cu-PTSM which can detect areas of perfusion can augment the information obtained in 62 Cu-ATSM PET scans To characterize tumors on the basis of both perfusion and hypoxia 10 patients were studied using both 62 Cu-ATSM and 62 Cu-PTSM PET scans In addition proteomic arrays looking at specific proangiogenic survival and proinflammatory targets were assessed Six of 10 patients had evaluable PET scans Our initial experience of characterizing tumor hypoxia using 62 Cu-ATSM and 62 Cu-PTSM PET scans showed that visualization of areas with hypoxia normalized for perfusion is feasible All studied tumors exhibited some hypoxia Despite the small sample size a positive relationship was noted between epidermal growth factor levels and 62 Cu-ATSM-detected hypoxia This initial series of 62 Cu-ATSM and 62 Cu-PTSM PET scans shows that evaluating masses by visualizing hypoxia and perfusion is a feasible and novel technique to provide more information Further investigation is warranted to assess the potential role of 62 Cu-ATSM and 62 Cu-PTSM PET techniques combined with proteomics as alternatives to invasive biopsy techniques in clinical care,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,"[1823, 16, 8, 2037, 1, 445, 57, 2, 8745, 8, 639, 356, 4, 2, 163, 4246, 3, 1749, 163, 364, 8, 991, 1745, 4, 2978, 1823, 5, 416, 1154, 2, 142, 151, 1, 521, 2957, 270, 94, 2502, 1823, 75, 16210, 1, 10289, 48014, 7200, 33541, 40518, 744, 6119, 22818, 47, 783, 356, 2, 24, 123, 4, 476, 302, 1437, 143, 46, 1572, 137, 68, 44, 255, 62, 1361, 1, 1823, 3665, 21, 4919, 17, 3, 352, 1, 1809, 495, 270, 420, 10289, 63543, 7200, 33541, 40518, 744, 6119, 32198, 92, 122, 1426, 1361, 1, 3018, 122, 4369, 3, 487, 683, 4, 744, 6119, 22818, 495, 1441, 6, 1507, 57, 23, 3, 877, 1, 110, 3018, 2, 1823, 79, 7, 11, 656, 75, 110, 744, 6119, 22818, 2, 744, 6119, 32198, 495, 1441, 4, 352, 3784, 3923, 9095, 28, 112, 8571, 25, 2, 5767, 637, 11, 275, 437, 1, 79, 7, 42, 859, 495, 1441, 114, 388, 730, 1, 5723, 30, 1823, 75, 744, 6119, 22818, 2, 744, 6119, 32198, 495, 1441, 224, 17, 6234, 1, 1361, 5, 1823, 4207, 9, 3018, 16, 1313, 62, 656, 57, 1416, 476, 1823, 550, 3, 302, 1000, 444, 8, 109, 858, 10, 1051, 59, 829, 129, 161, 148, 2, 744, 6119, 22818, 530, 1823, 26, 388, 988, 1, 744, 6119, 22818, 2, 744, 6119, 32198, 495, 1441, 1949, 17, 1435, 2692, 20, 21396, 1823, 2, 3018, 16, 8, 1313, 2, 229, 1312, 6, 377, 80, 487, 195, 940, 16, 1197, 6, 423, 3, 174, 200, 1, 744, 6119, 22818, 2, 744, 6119, 32198, 495, 1092, 397, 5, 6478, 22, 6295, 6, 416, 411, 1092, 4, 38, 165]",1746.0,24147499,315
Costs and outcomes evaluation of patient navigation after abnormal cancer screening: evidence from the Patient Navigation Research Program.,Cancer,Cancer,2013-10-25,"Navigators can facilitate timely access to cancer services, but to the authors' knowledge there are little data available regarding their economic impact. The authors conducted a cost-consequence analysis of navigation versus usual care among 10,521 individuals with abnormal breast, cervical, colorectal, or prostate cancer screening results who enrolled in the Patient Navigation Research Program study from January 1, 2006 to March 31, 2010. Navigation costs included diagnostic evaluation, patient and staff time, materials, and overhead. Consequences or outcomes were time to diagnostic resolution and probability of resolution. Differences in costs and outcomes were evaluated using multilevel, mixed-effects regression modeling adjusting for age, race/ethnicity, language, marital status, insurance status, cancer, and site clustering. The majority of individuals were members of a minority (70.7%) and uninsured or publically insured (72.7%). Diagnostic resolution was higher for navigation versus usual care at 180 days (56.2% vs 53.8%; P =.008) and 270 days (70.0% vs 68.2%; P <.001). Although there were no differences in the average number of days to resolution between the 2 groups (110 days vs 109 days; P =.63), the probability of ever having diagnostic resolution was higher for the navigation group versus the usual-care group (84.5% vs 79.6%; P <.001). The added cost of navigation versus usual care was $275 per patient (95% confidence interval, $260-$290; P <.001). There was no significant difference in stage distribution among the 12.4% of patients in the navigation group vs 11% of the usual-care patients diagnosed with cancer. Navigation adds costs and modestly increases the probability of diagnostic resolution among patients with abnormal screening test results. Navigation is only likely to be cost-effective if improved resolution translates into an earlier cancer stage at the time of diagnosis.",Journal Article,2279.0,26.0,"Navigators can facilitate timely access to cancer services but to the authors knowledge there are little data available regarding their economic impact The authors conducted a cost-consequence analysis of navigation versus usual care among 10,521 individuals with abnormal or cancer screening results who enrolled in the Patient Navigation Research Program study from January 1 2006 to March 31 2010 Navigation costs included diagnostic evaluation patient and staff time materials and overhead Consequences or outcomes were time to diagnostic resolution and probability of resolution Differences in costs and outcomes were evaluated using multilevel mixed-effects regression modeling adjusting for age race/ethnicity language marital status insurance status cancer and site clustering The majority of individuals were members of a minority 70.7 and uninsured or publically insured 72.7 Diagnostic resolution was higher for navigation versus usual care at 180 days 56.2 vs 53.8 P .008 and 270 days 70.0 vs 68.2 P .001 Although there were no differences in the average number of days to resolution between the 2 groups 110 days vs 109 days P .63 the probability of ever having diagnostic resolution was higher for the navigation group versus the usual-care group 84.5 vs 79.6 P .001 The added cost of navigation versus usual care was 275 per patient 95 confidence interval 260- 290 P .001 There was no significant difference in stage distribution among the 12.4 of patients in the navigation group vs 11 of the usual-care patients diagnosed with cancer Navigation adds costs and modestly increases the probability of diagnostic resolution among patients with abnormal screening test results Navigation is only likely to be cost-effective if improved resolution translates into an earlier cancer stage at the time of diagnosis",1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[15368, 122, 1876, 4225, 1655, 6, 12, 2142, 84, 6, 3, 738, 922, 125, 32, 1215, 74, 390, 666, 136, 3875, 345, 3, 738, 426, 8, 835, 4177, 65, 1, 5604, 185, 3521, 165, 107, 79, 11925, 869, 5, 1668, 15, 12, 453, 99, 54, 346, 4, 3, 69, 5604, 389, 1243, 45, 29, 1024, 14, 1324, 6, 2363, 456, 1120, 5604, 1201, 159, 752, 451, 69, 2, 5898, 98, 5102, 2, 40523, 3255, 15, 123, 11, 98, 6, 752, 2125, 2, 1320, 1, 2125, 362, 4, 1201, 2, 123, 11, 194, 75, 10913, 1739, 176, 320, 2057, 1358, 9, 89, 1047, 2091, 4794, 5345, 156, 1935, 156, 12, 2, 606, 3147, 3, 686, 1, 869, 11, 1684, 1, 8, 2652, 431, 67, 2, 4955, 15, 15614, 4291, 720, 67, 752, 2125, 10, 142, 9, 5604, 185, 3521, 165, 28, 3172, 162, 664, 18, 105, 699, 66, 19, 2155, 2, 6666, 162, 431, 13, 105, 806, 18, 19, 144, 242, 125, 11, 77, 362, 4, 3, 1011, 207, 1, 162, 6, 2125, 59, 3, 18, 271, 3129, 162, 105, 3486, 162, 19, 676, 3, 1320, 1, 3353, 1041, 752, 2125, 10, 142, 9, 3, 5604, 87, 185, 3, 3521, 165, 87, 874, 33, 105, 842, 49, 19, 144, 3, 1953, 835, 1, 5604, 185, 3521, 165, 10, 5620, 379, 69, 48, 307, 268, 6398, 9027, 19, 144, 125, 10, 77, 93, 523, 4, 82, 1395, 107, 3, 133, 39, 1, 7, 4, 3, 5604, 87, 105, 175, 1, 3, 3521, 165, 7, 265, 5, 12, 5604, 6659, 1201, 2, 5588, 1106, 3, 1320, 1, 752, 2125, 107, 7, 5, 1668, 453, 412, 99, 5604, 16, 158, 322, 6, 40, 835, 323, 492, 231, 2125, 10328, 237, 35, 1677, 12, 82, 28, 3, 98, 1, 147]",1823.0,24166217,116
Variable impact of intracavitary brachytherapy fractionation schedule onbiologically effective dose to organs at risk in patients with cervicalcancer.,Brachytherapy,Brachytherapy,2013-11-01,"To determine the effect of intracavitary brachytherapy (ICBT) fractionation schedule on biologically effective dose to organs at risk. We reviewed records from 26 patients who had CT imaging during ICBT for International Federation of Gynecology and Obstetrics stage IB2-IVA cervical cancer. Using /=10, we calculated hypothetical nominal doses to achieve a biologically effective dose at 2Gy per fraction (EQD2/=10) of 40Gy to Point A for high-dose-rate ICBT with 1-15 fractions. Corresponding minimum EQD2/=3s to the maximally irradiated 2 cc of rectum, bladder, and sigmoid were calculated for each fractionation scheme and added to EQD2/=3 from external beam radiotherapy. Total EQD2/=3s were compared with American Brachytherapy Society suggested dose constraints (rectum/sigmoid, 75Gy; bladder, 90Gy). Except for rectal EQD2/=3 in three patients, the rectal, bladder, and sigmoid EQD2/=3s decreased with increasing fractionation in all patients. Although the total rectal EQD2/=3s were less than the American Brachytherapy Society rectal dose constraint in all patients at all fractionation schedules, the total bladder EQD2/=3s routinely exceeded the bladder dose constraint, even at maximum fractionation. By contrast, increasing fractionation decreased the number of patients with doses exceeding the sigmoid dose constraint by 48%. The relationship between ICBT fractionation schedule and relative EQD2/=3s to rectum, bladder, and sigmoid depends on individual anatomy. Fractionation optimization can improve therapeutic ratios by minimizing the risk or severity of toxic effects. For patients in whom many fractions optimize the therapeutic ratio, low-dose-rate or pulsed-dose-rate brachytherapy may be preferred.",Journal Article,2272.0,1.0,To determine the effect of intracavitary brachytherapy ICBT fractionation schedule on biologically effective dose to organs at risk We reviewed records from 26 patients who had CT imaging during ICBT for International Federation of Gynecology and Obstetrics stage IB2-IVA cancer Using /=10 we calculated hypothetical nominal doses to achieve a biologically effective dose at 2 Gy per fraction EQD2/=10 of 40 Gy to Point A for high-dose-rate ICBT with 1-15 fractions Corresponding minimum EQD2/=3s to the maximally irradiated 2 cc of rectum and sigmoid were calculated for each fractionation scheme and added to EQD2/=3 from external beam radiotherapy Total EQD2/=3s were compared with American Brachytherapy Society suggested dose constraints rectum/sigmoid 75 Gy 90 Gy Except for EQD2/=3 in three patients the and sigmoid EQD2/=3s decreased with increasing fractionation in all patients Although the total EQD2/=3s were less than the American Brachytherapy Society dose constraint in all patients at all fractionation schedules the total EQD2/=3s routinely exceeded the dose constraint even at maximum fractionation By contrast increasing fractionation decreased the number of patients with doses exceeding the sigmoid dose constraint by 48 The relationship between ICBT fractionation schedule and relative EQD2/=3s to rectum and sigmoid depends on individual anatomy Fractionation optimization can improve therapeutic ratios by minimizing the risk or severity of toxic effects For patients in whom many fractions optimize the therapeutic ratio low-dose-rate or pulsed-dose-rate brachytherapy may be preferred,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,"[6, 223, 3, 254, 1, 9122, 1536, 23808, 3519, 1055, 23, 2665, 323, 61, 6, 2285, 28, 43, 21, 446, 1064, 29, 432, 7, 54, 42, 425, 270, 190, 23808, 9, 944, 7303, 1, 6429, 2, 7407, 82, 9537, 5900, 12, 75, 2014, 1458, 79, 21, 981, 7045, 8948, 415, 6, 1359, 8, 2665, 323, 61, 28, 18, 381, 379, 1509, 24088, 1458, 79, 1, 327, 381, 6, 741, 8, 9, 64, 61, 116, 23808, 5, 14, 167, 1550, 1734, 2499, 24088, 1458, 19813, 6, 3, 6402, 2398, 18, 1951, 1, 3660, 2, 9356, 11, 981, 9, 296, 3519, 4633, 2, 1953, 6, 24088, 1458, 27, 29, 1455, 1345, 310, 181, 24088, 1458, 19813, 11, 72, 5, 597, 1536, 1174, 1148, 61, 4879, 3660, 9356, 40469, 381, 25286, 381, 2187, 9, 24088, 1458, 27, 4, 169, 7, 3, 2, 9356, 24088, 1458, 19813, 340, 5, 602, 3519, 4, 62, 7, 242, 3, 181, 24088, 1458, 19813, 11, 299, 76, 3, 597, 1536, 1174, 61, 11482, 4, 62, 7, 28, 62, 3519, 2314, 3, 181, 24088, 1458, 19813, 3066, 4726, 3, 61, 11482, 871, 28, 689, 3519, 20, 748, 602, 3519, 340, 3, 207, 1, 7, 5, 415, 5178, 3, 9356, 61, 11482, 20, 576, 3, 858, 59, 23808, 3519, 1055, 2, 580, 24088, 1458, 19813, 6, 3660, 2, 9356, 3828, 23, 797, 5081, 3519, 3980, 122, 401, 189, 1137, 20, 4501, 3, 43, 15, 1702, 1, 1812, 176, 9, 7, 4, 953, 445, 1550, 2465, 3, 189, 197, 154, 61, 116, 15, 5695, 61, 116, 1536, 68, 40, 2514]",1632.0,24188993,799
Chemoradiation for esophageal cancer.,Thoracic surgery clinics,Thorac Surg Clin,2013-11-01,"Esophageal cancer management is based on baseline clinical stage, location of the tumor, and associated comorbid conditions. In patients with localized esophageal cancer (LEC) with technically resectable tumors and who are medically fit for surgery, the current recommendation is trimodality therapy (chemoradiation followed by surgery). Bimodality therapy (definitive chemoradiation) is reserved for patients with cervical esophageal tumors, technically unresectable tumors, for patients who cannot be recommended surgery due to medical comorbidities, or those who decline surgery. Prospective data from 2 studies suggest that definitive chemoradiation may be sufficient for LEC with squamous cell histology; a definite answer, however, is unclear. ",Journal Article,2272.0,9.0,cancer management is based on baseline clinical stage location of the tumor and associated comorbid conditions In patients with localized cancer LEC with technically resectable tumors and who are medically fit for surgery the current recommendation is trimodality therapy chemoradiation followed by surgery Bimodality therapy definitive chemoradiation is reserved for patients with tumors technically unresectable tumors for patients who can not be recommended surgery due to medical comorbidities or those who decline surgery Prospective data from 2 studies suggest that definitive chemoradiation may be sufficient for LEC with squamous cell histology a definite answer however is unclear,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[12, 284, 16, 90, 23, 330, 38, 82, 1147, 1, 3, 30, 2, 41, 3952, 1298, 4, 7, 5, 909, 12, 12370, 5, 6093, 1899, 57, 2, 54, 32, 4381, 2975, 9, 152, 3, 291, 3347, 16, 4625, 36, 975, 370, 20, 152, 18050, 36, 1057, 975, 16, 6468, 9, 7, 5, 57, 6093, 1468, 57, 9, 7, 54, 122, 44, 40, 793, 152, 520, 6, 484, 1909, 15, 135, 54, 1858, 152, 482, 74, 29, 18, 94, 309, 17, 1057, 975, 68, 40, 1952, 9, 12370, 5, 691, 31, 784, 8, 8442, 6634, 137, 16, 1200]",689.0,24199704,87
Implications for human papillomavirus in penile cancer.,Urologic oncology,Urol. Oncol.,2013-11-13,"Human papillomavirus infection (HPV) has been implicated in penile cancer, and although the annual incidence is estimated to be 1,570 in the United States, there are areas of the world in which the incidence is as much as 20-fold higher. Ample data in the literature support testing and vaccination against HPV-related cervical cancer, but for men and penile cancer, these data are lacking. However, some preliminary data would suggest that HPV not only plays an important role in a significant subset of patients with penile cancer but also may be a target for penile cancer prevention as well via initiation of a vaccination program in high-risk male populations. ",Journal Article,2260.0,30.0,"Human papillomavirus infection HPV has been implicated in cancer and although the annual incidence is estimated to be 1,570 in the United States there are areas of the world in which the incidence is as much as 20-fold higher Ample data in the literature support testing and vaccination against HPV-related cancer but for men and cancer these data are lacking However some preliminary data would suggest that HPV not only plays an important role in a significant subset of patients with cancer but also may be a target for cancer prevention as well via initiation of a vaccination program in high-risk male populations",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 3242, 930, 933, 71, 85, 1771, 4, 12, 2, 242, 3, 2114, 287, 16, 661, 6, 40, 14, 11316, 4, 3, 1088, 907, 125, 32, 1361, 1, 3, 1956, 4, 92, 3, 287, 16, 22, 1802, 22, 179, 1116, 142, 17814, 74, 4, 3, 789, 538, 471, 2, 1915, 480, 933, 139, 12, 84, 9, 325, 2, 12, 46, 74, 32, 1941, 137, 476, 1676, 74, 688, 309, 17, 933, 44, 158, 1698, 35, 305, 200, 4, 8, 93, 697, 1, 7, 5, 12, 84, 120, 68, 40, 8, 283, 9, 12, 1070, 22, 149, 847, 1118, 1, 8, 1915, 1243, 4, 64, 43, 1045, 1184]",618.0,24239463,116
Prospective study of symptom assessment among patients with cervical cancer during concurrent chemoradiotherapy with weekly cisplatin or every-3-week cisplatin and 5-fluorouracil.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2013-10-01,"In this prospective study, symptoms were assessed in patients with locally advanced cervical cancer undergoing concurrent chemoradiotherapy (CTRT) with either weekly cisplatin (WP) or every-3-week cisplatin/5-fluorouracil (PF). Patients with 1994 International Federation of Gynecology and Obstetrics stage IIB to IVA disease, biopsy-proven involved pelvic nodes, or gross tumor size greater than 5 cm were eligible. Patients requiring paraaortic radiotherapy were excluded. With the use of a modified Edmonton Symptom Assessment Scale, patients reported symptom severity on an 11-point scale 3 times per week during CTRT and at the first follow-up. The Wilcoxon rank sum test and multilevel mixed-effects linear regression were used to assess the effect of chemotherapy regimen on symptoms. Among the 52 patients included in the final analysis, 37 received WP, 13 received PF, and 2 received 1 cycle of PF followed by WP. Overall compliance with completion of Edmonton Symptom Assessment Scale questionnaires was 75%. There were significant differences in symptom scores for well-being, anorexia, fatigue, diarrhea, and stomatitis favoring the WP regimen. All symptoms except diarrhea were stable and of low intensity in the WP group. In the PF group, symptoms had a cyclical pattern with an initial rise followed by a gradual fall during the 3-week period after chemotherapy. For the 29 patients (56%) who completed the follow-up surveys, scores for all symptoms improved to baseline levels 4 to 6 weeks after treatment. This analysis provides important patient-reported data regarding the rates and timing of acute symptoms during CTRT that can help clinicians better manage symptoms that impact patients' quality of life.",Comparative Study,2303.0,2.0,In this prospective study symptoms were assessed in patients with locally advanced cancer undergoing concurrent chemoradiotherapy CTRT with either weekly cisplatin WP or every-3-week cisplatin/5-fluorouracil PF Patients with 1994 International Federation of Gynecology and Obstetrics stage IIB to IVA disease biopsy-proven involved pelvic nodes or gross tumor size greater than 5 cm were eligible Patients requiring paraaortic radiotherapy were excluded With the use of a modified Edmonton Symptom Assessment Scale patients reported symptom severity on an 11-point scale 3 times per week during CTRT and at the first follow-up The Wilcoxon rank sum test and multilevel mixed-effects linear regression were used to assess the effect of chemotherapy regimen on symptoms Among the 52 patients included in the final analysis 37 received WP 13 received PF and 2 received 1 cycle of PF followed by WP Overall compliance with completion of Edmonton Symptom Assessment Scale questionnaires was 75 There were significant differences in symptom scores for well-being anorexia fatigue diarrhea and stomatitis favoring the WP regimen All symptoms except diarrhea were stable and of low intensity in the WP group In the PF group symptoms had a cyclical pattern with an initial rise followed by a gradual fall during the 3-week period after chemotherapy For the 29 patients 56 who completed the follow-up surveys scores for all symptoms improved to baseline levels 4 to 6 weeks after treatment This analysis provides important patient-reported data regarding the rates and timing of acute symptoms during CTRT that can help clinicians better manage symptoms that impact patients quality of life,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4, 26, 482, 45, 507, 11, 275, 4, 7, 5, 795, 131, 12, 479, 750, 1464, 10329, 5, 361, 709, 540, 9480, 15, 454, 27, 647, 540, 33, 1404, 3313, 7, 5, 3023, 944, 7303, 1, 6429, 2, 7407, 82, 3884, 6, 5900, 34, 411, 1930, 646, 1110, 502, 15, 1789, 30, 444, 378, 76, 33, 494, 11, 625, 7, 1888, 7401, 310, 11, 1800, 5, 3, 119, 1, 8, 1230, 5656, 934, 455, 1124, 7, 210, 934, 1702, 23, 35, 175, 741, 1124, 27, 1072, 379, 647, 190, 10329, 2, 28, 3, 157, 166, 126, 3, 3896, 1026, 3216, 412, 2, 10913, 1739, 176, 1646, 320, 11, 95, 6, 423, 3, 254, 1, 56, 477, 23, 507, 107, 3, 653, 7, 159, 4, 3, 1457, 65, 567, 103, 9480, 233, 103, 3313, 2, 18, 103, 14, 417, 1, 3313, 370, 20, 9480, 63, 3336, 5, 1438, 1, 5656, 934, 455, 1124, 2956, 10, 481, 125, 11, 93, 362, 4, 934, 703, 9, 149, 486, 3373, 613, 1172, 2, 4486, 6238, 3, 9480, 477, 62, 507, 2187, 1172, 11, 585, 2, 1, 154, 837, 4, 3, 9480, 87, 4, 3, 3313, 87, 507, 42, 8, 19179, 1177, 5, 35, 388, 3693, 370, 20, 8, 11268, 6712, 190, 3, 27, 647, 727, 50, 56, 9, 3, 462, 7, 664, 54, 781, 3, 166, 126, 3666, 703, 9, 62, 507, 231, 6, 330, 148, 39, 6, 49, 244, 50, 24, 26, 65, 777, 305, 69, 210, 74, 666, 3, 151, 2, 1972, 1, 286, 507, 190, 10329, 17, 122, 987, 1490, 380, 4001, 507, 17, 345, 7, 372, 1, 358]",1680.0,24257567,579
Pelvic exenteration: impact of age on surgical and oncologic outcomes.,Gynecologic oncology,Gynecol. Oncol.,2013-11-18,"To evaluate whether preoperative age impacts surgical outcomes, complication rates, and/or recurrence in women undergoing pelvic exenteration. All women who underwent a pelvic exenteration for any gynecologic indication at our institution from 1993 to 2010 were included. Women were stratified into groups based on age in years (young:  50, middle: 51-64, and senior:  65). Baseline characteristics, surgical outcomes, early (<60 days) and late ( 60 days) postoperative complications, and recurrence/survival outcomes were ascertained. Fisher's exact test or Kruskal-Wallis test was performed. Kaplan-Meier survival curves were compared. 161 patients were included (58 young, 62 in the middle, and 41 senior). Women in the young group predominately had a diagnosis of cervical cancer (82.8%) while women in the senior group primarily had a diagnosis of vulvar or vaginal cancer (70.7%). Senior women were also more likely to have hypertension (p < 0.0001) and pulmonary disease (p = 0.040). Operative time was significantly shorter for women in the senior group (8.5h) compared with the middle (9.5h) and young group (10.1h) (p = 0.0089). There were no significant differences in early or late complications when stratified by age. The overall survival did not differ between age groups (p = 0.3760). Although hypertension and pulmonary disease were more frequent in the senior age group, duration of surgery, blood loss, length of hospital stay and complication rates did not increase with age. Advanced chronological age should not be considered a contraindication to a potentially curative surgical procedure.",Journal Article,2255.0,16.0,To evaluate whether preoperative age impacts surgical outcomes complication rates and/or recurrence in women undergoing pelvic exenteration All women who underwent a pelvic exenteration for any gynecologic indication at our institution from 1993 to 2010 were included Women were stratified into groups based on age in years young  50 middle 51-64 and senior  65 Baseline characteristics surgical outcomes early 60 days and late  60 days postoperative complications and recurrence/survival outcomes were ascertained Fisher 's exact test or Kruskal-Wallis test was performed Kaplan-Meier survival curves were compared 161 patients were included 58 young 62 in the middle and 41 senior Women in the young group predominately had a diagnosis of cancer 82.8 while women in the senior group primarily had a diagnosis of or cancer 70.7 Senior women were also more likely to have hypertension p 0.0001 and pulmonary disease p 0.040 Operative time was significantly shorter for women in the senior group 8.5h compared with the middle 9.5h and young group 10.1h p 0.0089 There were no significant differences in early or late complications when stratified by age The overall survival did not differ between age groups p 0.3760 Although hypertension and pulmonary disease were more frequent in the senior age group duration of surgery blood loss length of hospital stay and complication rates did not increase with age Advanced chronological age should not be considered a contraindication to a potentially curative surgical procedure,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 317, 498, 89, 4719, 221, 123, 1447, 151, 2, 15, 146, 4, 117, 479, 1110, 5668, 62, 117, 54, 208, 8, 1110, 5668, 9, 500, 1512, 3607, 28, 114, 731, 29, 3343, 6, 1120, 11, 159, 117, 11, 1173, 237, 271, 90, 23, 89, 4, 60, 1169, 1552, 212, 3897, 725, 660, 2, 10898, 749, 556, 330, 374, 221, 123, 191, 335, 162, 2, 807, 749, 335, 162, 573, 521, 2, 146, 25, 123, 11, 5240, 3135, 292, 2472, 412, 15, 8800, 8875, 412, 10, 173, 876, 882, 25, 2400, 11, 72, 5377, 7, 11, 159, 717, 1169, 744, 4, 3, 3897, 2, 605, 10898, 117, 4, 3, 1169, 87, 11583, 42, 8, 147, 1, 12, 878, 66, 369, 117, 4, 3, 10898, 87, 1561, 42, 8, 147, 1, 15, 12, 431, 67, 10898, 117, 11, 120, 80, 322, 6, 47, 1824, 19, 13, 488, 2, 1087, 34, 19, 13, 6824, 1208, 98, 10, 97, 985, 9, 117, 4, 3, 10898, 87, 66, 38494, 72, 5, 3, 3897, 83, 38494, 2, 1169, 87, 79, 10147, 19, 13, 21191, 125, 11, 77, 93, 362, 4, 191, 15, 807, 521, 198, 1173, 20, 89, 3, 63, 25, 205, 44, 1505, 59, 89, 271, 19, 13, 40545, 242, 1824, 2, 1087, 34, 11, 80, 908, 4, 3, 10898, 89, 87, 654, 1, 152, 315, 407, 1318, 1, 702, 2020, 2, 1447, 151, 205, 44, 344, 5, 89, 131, 14921, 89, 257, 44, 40, 515, 8, 8363, 6, 8, 751, 1075, 221, 1299]",1526.0,24262877,280
Impact of facility volume on therapy and survival for locally advanced cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2013-12-12,"Chemosensitizing radiation with brachytherapy is standard of care for treatment of locally advanced cervical cancer, an increasingly rare disease. Treatment facility volume has been correlated with outcome in many diseases. Treatment outcome and likelihood of receiving standard therapy in locally advanced cervical cancer based on facility volume were examined using a large national cancer database. The National Cancer Data Base was queried for patients with stage IIB - IIIB cervical cancer from 1/1998 through 12/2010. Facility volumes were tallied. Overall survival was estimated using Kaplan-Meier method. Univariate and multivariable analyses were performed to determine variables affecting survival, receiving standard therapy, and total duration of radiotherapy. We identified a total of 27,660 patients who were treated at 1361 facilities. Thirty of the facilities (2.2%) treated the highest quartile volume of patients (>9.4 patients annually) while 1072 facilities (78.8%) treated <2.4 patients annually. The median age of patients was 53, the majority were Caucasian, treated in a metropolitan area, and of squamous cell histology. Median survival of patients treated at lowest- and highest-volume centers were 42.3 months (95% CI 39.8-44.8) and 53.8 months (50.1-57.5), respectively (p < 0.001). The proportions of patients receiving brachytherapy and chemotherapy were 54.8% and 79.9%, respectively. On multivariable analysis, higher facility volume independently predicted improved survival (p = 0.022), increased likelihood of receiving brachytherapy (p < 0.0005) and chemotherapy (p = 0.013), and shorter time to radiotherapy completion (p < 0.0005). Patients with locally advanced cervical cancer treated at high volume centers are more likely to receive standard therapy, complete therapy sooner, and experience better survival.",Journal Article,2231.0,37.0,"Chemosensitizing radiation with brachytherapy is standard of care for treatment of locally advanced cancer an increasingly rare disease Treatment facility volume has been correlated with outcome in many diseases Treatment outcome and likelihood of receiving standard therapy in locally advanced cancer based on facility volume were examined using a large national cancer database The National Cancer Data Base was queried for patients with stage IIB IIIB cancer from 1/1998 through 12/2010 Facility volumes were tallied Overall survival was estimated using Kaplan-Meier method Univariate and multivariable analyses were performed to determine variables affecting survival receiving standard therapy and total duration of radiotherapy We identified a total of 27,660 patients who were treated at 1361 facilities Thirty of the facilities 2.2 treated the highest quartile volume of patients 9.4 patients annually while 1072 facilities 78.8 treated 2.4 patients annually The median age of patients was 53 the majority were Caucasian treated in a metropolitan area and of squamous cell histology Median survival of patients treated at lowest- and highest-volume centers were 42.3 months 95 CI 39.8-44.8 and 53.8 months 50.1-57.5 respectively p 0.001 The proportions of patients receiving brachytherapy and chemotherapy were 54.8 and 79.9 respectively On multivariable analysis higher facility volume independently predicted improved survival p 0.022 increased likelihood of receiving brachytherapy p 0.0005 and chemotherapy p 0.013 and shorter time to radiotherapy completion p 0.0005 Patients with locally advanced cancer treated at high volume centers are more likely to receive standard therapy complete therapy sooner and experience better survival",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[16829, 121, 5, 1536, 16, 260, 1, 165, 9, 24, 1, 795, 131, 12, 35, 1635, 622, 34, 24, 3483, 433, 71, 85, 438, 5, 228, 4, 445, 1342, 24, 228, 2, 1420, 1, 357, 260, 36, 4, 795, 131, 12, 90, 23, 3483, 433, 11, 409, 75, 8, 375, 657, 12, 609, 3, 657, 12, 74, 1782, 10, 3547, 9, 7, 5, 82, 3884, 3036, 12, 29, 14, 1850, 298, 133, 1120, 3483, 2225, 11, 37395, 63, 25, 10, 661, 75, 876, 882, 596, 880, 2, 658, 318, 11, 173, 6, 223, 682, 2319, 25, 357, 260, 36, 2, 181, 654, 1, 310, 21, 108, 8, 181, 1, 428, 10639, 7, 54, 11, 73, 28, 35070, 4351, 977, 1, 3, 4351, 18, 18, 73, 3, 1076, 3708, 433, 1, 7, 83, 39, 7, 4226, 369, 27101, 4351, 833, 66, 73, 18, 39, 7, 4226, 3, 52, 89, 1, 7, 10, 699, 3, 686, 11, 3229, 73, 4, 8, 8737, 965, 2, 1, 691, 31, 784, 52, 25, 1, 7, 73, 28, 2101, 2, 1076, 433, 1168, 11, 595, 27, 53, 48, 58, 587, 66, 584, 66, 2, 699, 66, 53, 212, 14, 696, 33, 106, 19, 13, 144, 3, 4117, 1, 7, 357, 1536, 2, 56, 11, 667, 66, 2, 842, 83, 106, 23, 658, 65, 142, 3483, 433, 1042, 783, 231, 25, 19, 13, 4773, 101, 1420, 1, 357, 1536, 19, 13, 4252, 2, 56, 19, 13, 3612, 2, 985, 98, 6, 310, 1438, 19, 13, 4252, 7, 5, 795, 131, 12, 73, 28, 64, 433, 1168, 32, 80, 322, 6, 560, 260, 36, 236, 36, 13546, 2, 730, 380, 25]",1747.0,24333361,51
Cervical conization and sentinel lymph node mapping in the treatment of stage I cervical cancer: is less enough?,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2014-01-01,"This study aimed to determine the feasibility of cervical conization and sentinel lymph node (SLN) mapping as a fertility-sparing strategy to treat stage I cervical cancer and to estimate the tumor margin status needed to achieve no residual carcinoma in the cervix. We identified all patients who desired fertility preservation and underwent SLN mapping with cervical conization for stage I cervical cancer from September 2005 to August 2012. Relevant demographic, clinical, and pathologic information was collected. Ten patients were identified. Median age was 28 years (range, 18-36 years). None of the patients had a grossly visible tumor. The initial diagnosis of invasive carcinoma was made either on a loop electrosurgical excision procedure or cone biopsy. All patients underwent preoperative radiologic evaluation (magnetic resonance imaging and positron emission tomography-computed tomography). None of the patients had evidence of gross tumor or suspicion of lymph node metastasis on imaging. Stage distribution included 7 (70%) patients with stage IA1 cervical cancer with lymphovascular invasion and 3 (30%) patients with microscopic IB1. Histologic diagnosis included 8 (80%) patients with squamous cell carcinoma, 1 (10%) patient with adenocarcinoma, and 1 (10%) patient with clear cell carcinoma. Nine patients underwent repeat cervical conization with SLN mapping, and 1 patient underwent postconization cervical biopsies and SLN mapping. None of the patients had residual tumor identified on the final specimen. The median distance from the invasive carcinoma to the endocervical margin was 2.25 mm, and the distance from the invasive carcinoma to the ectocervical margin was 1.9 mm. All collected lymph nodes were negative for metastasis. After a median follow-up of 17 months (range, 1-83 months), none of the patients' conditions were diagnosed with recurrent disease and 3 (30%) patients achieved pregnancy. Cervical conization and SLN mapping seems to be an acceptable treatment strategy for selected patients with small-volume stage I cervical cancer. Tumor clearance of 2 mm and above seems to correlate well with no residual on repeat conization. A larger sample size and longer follow-up is needed to establish the long-term outcomes of this procedure.",Journal Article,2211.0,25.0,This study aimed to determine the feasibility of conization and sentinel lymph node SLN mapping as a fertility-sparing strategy to treat stage I cancer and to estimate the tumor margin status needed to achieve no residual carcinoma in the cervix We identified all patients who desired fertility preservation and underwent SLN mapping with conization for stage I cancer from September 2005 to August 2012 Relevant demographic clinical and pathologic information was collected Ten patients were identified Median age was 28 years range 18-36 years None of the patients had a grossly visible tumor The initial diagnosis of invasive carcinoma was made either on a loop electrosurgical excision procedure or cone biopsy All patients underwent preoperative radiologic evaluation magnetic resonance imaging and positron emission tomography-computed tomography None of the patients had evidence of gross tumor or suspicion of lymph node metastasis on imaging Stage distribution included 7 70 patients with stage IA1 cancer with lymphovascular invasion and 3 30 patients with microscopic IB1 Histologic diagnosis included 8 80 patients with squamous cell carcinoma 1 10 patient with adenocarcinoma and 1 10 patient with clear cell carcinoma Nine patients underwent repeat conization with SLN mapping and 1 patient underwent postconization biopsies and SLN mapping None of the patients had residual tumor identified on the final specimen The median distance from the invasive carcinoma to the endocervical margin was 2.25 mm and the distance from the invasive carcinoma to the ectocervical margin was 1.9 mm All collected lymph nodes were negative for metastasis After a median follow-up of 17 months range 1-83 months none of the patients conditions were diagnosed with recurrent disease and 3 30 patients achieved pregnancy conization and SLN mapping seems to be an acceptable treatment strategy for selected patients with small-volume stage I cancer Tumor clearance of 2 mm and above seems to correlate well with no residual on repeat conization A larger sample size and longer follow-up is needed to establish the long-term outcomes of this procedure,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[26, 45, 1295, 6, 223, 3, 1437, 1, 8755, 2, 1323, 263, 289, 1099, 2568, 22, 8, 2954, 1851, 692, 6, 943, 82, 70, 12, 2, 6, 1191, 3, 30, 959, 156, 575, 6, 1359, 77, 753, 134, 4, 3, 3629, 21, 108, 62, 7, 54, 6115, 2954, 2224, 2, 208, 1099, 2568, 5, 8755, 9, 82, 70, 12, 29, 2636, 1242, 6, 2480, 1195, 867, 1540, 38, 2, 510, 487, 10, 786, 1618, 7, 11, 108, 52, 89, 10, 339, 60, 184, 203, 511, 60, 1292, 1, 3, 7, 42, 8, 7185, 4822, 30, 3, 388, 147, 1, 416, 134, 10, 1229, 361, 23, 8, 4432, 24548, 1366, 1299, 15, 6939, 411, 62, 7, 208, 498, 2812, 451, 1484, 1535, 270, 2, 1900, 1799, 872, 1220, 872, 1292, 1, 3, 7, 42, 241, 1, 1789, 30, 15, 5782, 1, 263, 289, 278, 23, 270, 82, 1395, 159, 67, 431, 7, 5, 82, 14517, 12, 5, 2933, 578, 2, 27, 201, 7, 5, 2984, 8111, 884, 147, 159, 66, 493, 7, 5, 691, 31, 134, 14, 79, 69, 5, 449, 2, 14, 79, 69, 5, 885, 31, 134, 762, 7, 208, 2334, 8755, 5, 1099, 2568, 2, 14, 69, 208, 35603, 1154, 2, 1099, 2568, 1292, 1, 3, 7, 42, 753, 30, 108, 23, 3, 1457, 2360, 3, 52, 3019, 29, 3, 416, 134, 6, 3, 10174, 959, 10, 18, 243, 321, 2, 3, 3019, 29, 3, 416, 134, 6, 3, 44688, 959, 10, 14, 83, 321, 62, 786, 263, 502, 11, 199, 9, 278, 50, 8, 52, 166, 126, 1, 269, 53, 184, 14, 852, 53, 1292, 1, 3, 7, 1298, 11, 265, 5, 387, 34, 2, 27, 201, 7, 513, 2290, 8755, 2, 1099, 2568, 2744, 6, 40, 35, 1595, 24, 692, 9, 715, 7, 5, 302, 433, 82, 70, 12, 30, 1960, 1, 18, 321, 2, 2090, 2744, 6, 1513, 149, 5, 77, 753, 23, 2334, 8755, 8, 1077, 1000, 444, 2, 589, 166, 126, 16, 575, 6, 1811, 3, 319, 337, 123, 1, 26, 1299]",2144.0,24335661,423
Socioeconomic factors and the risk for sarcoma.,European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP),Eur. J. Cancer Prev.,2014-11-01,"Sarcomas are a heterogeneous group of rare malignancies arising from mesenchymal tissue. Although several occupational exposures have been evaluated in association with sarcoma, little is known about the role of socioeconomic indicators such as education. Socioeconomic status has been found to be associated with risk of development of several types of cancers, primarily lung, gastric, and cervical cancers. We conducted a hospital-based case-control study to evaluate the association of socioeconomic level with the risk for sarcoma. A total of 371 incident cases of sarcoma were matched in terms of age, sex, and year of enrollment in the study with 742 cancer-free controls. Education and income levels were evaluated as the indicators of socioeconomic status. Higher education (college level) was associated with a significantly lower risk for sarcoma [odds ratio (OR)=0.48, 95% confidence interval (CI)=0.29-0.80], even after adjusting for important confounders. After stratifying by sex, significantly lower risk for sarcoma was observed among men who had college level education compared with men with a level of education of eighth grade or lower (OR=0.38, 95% CI=0.19-0.74). A significant association between education and the risk for sarcoma remained after stratifying by income (OR=0.49, 95% CI=0.28-0.86, among the low income group). When analyzed as a composite exposure, individuals with high education and high income status had significantly lower risk for sarcoma compared with those with low income and low education status (OR=0.41, 95% CI=0.23-0.71). Thus, socioeconomic factors may play a significant role in determining the risk for sarcoma and should be explored further to elucidate the underlying factors that may explain these sociodemographic inequalities related to sarcoma. ",Journal Article,1907.0,2.0,Sarcomas are a heterogeneous group of rare malignancies arising from mesenchymal tissue Although several occupational exposures have been evaluated in association with little is known about the role of socioeconomic indicators such as education Socioeconomic status has been found to be associated with risk of development of several types of cancers primarily and cancers We conducted a hospital-based case-control study to evaluate the association of socioeconomic level with the risk for A total of 371 incident cases of were matched in terms of age sex and year of enrollment in the study with 742 cancer-free controls Education and income levels were evaluated as the indicators of socioeconomic status Higher education college level was associated with a significantly lower risk for odds ratio OR =0.48 95 confidence interval CI =0.29-0.80 even after adjusting for important confounders After stratifying by sex significantly lower risk for was observed among men who had college level education compared with men with a level of education of eighth grade or lower OR=0.38 95 CI=0.19-0.74 A significant association between education and the risk for remained after stratifying by income OR=0.49 95 CI=0.28-0.86 among the low income group When analyzed as a composite exposure individuals with high education and high income status had significantly lower risk for compared with those with low income and low education status OR=0.41 95 CI=0.23-0.71 Thus socioeconomic factors may play a significant role in determining the risk for and should be explored further to elucidate the underlying factors that may explain these sociodemographic inequalities related to,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,"[1479, 32, 8, 1564, 87, 1, 622, 441, 2635, 29, 1569, 246, 242, 392, 10318, 3401, 47, 85, 194, 4, 248, 5, 1215, 16, 440, 545, 3, 200, 1, 3331, 3539, 225, 22, 1848, 3331, 156, 71, 85, 204, 6, 40, 41, 5, 43, 1, 193, 1, 392, 630, 1, 163, 1561, 2, 163, 21, 426, 8, 702, 90, 473, 182, 45, 6, 376, 3, 248, 1, 3331, 301, 5, 3, 43, 9, 8, 181, 1, 9196, 2631, 140, 1, 11, 655, 4, 1794, 1, 89, 1035, 2, 111, 1, 1798, 4, 3, 45, 5, 12585, 12, 115, 535, 1848, 2, 2306, 148, 11, 194, 22, 3, 3539, 1, 3331, 156, 142, 1848, 2979, 301, 10, 41, 5, 8, 97, 280, 43, 9, 610, 197, 15, 13, 576, 48, 307, 268, 58, 13, 462, 13, 493, 871, 50, 1358, 9, 305, 4423, 50, 5035, 20, 1035, 97, 280, 43, 9, 10, 164, 107, 325, 54, 42, 2979, 301, 1848, 72, 5, 325, 5, 8, 301, 1, 1848, 1, 7732, 88, 15, 280, 15, 13, 519, 48, 58, 13, 326, 13, 794, 8, 93, 248, 59, 1848, 2, 3, 43, 9, 958, 50, 5035, 20, 2306, 15, 13, 739, 48, 58, 13, 339, 13, 868, 107, 3, 154, 2306, 87, 198, 311, 22, 8, 3308, 645, 869, 5, 64, 1848, 2, 64, 2306, 156, 42, 97, 280, 43, 9, 72, 5, 135, 5, 154, 2306, 2, 154, 1848, 156, 15, 13, 605, 48, 58, 13, 382, 13, 792, 631, 3331, 130, 68, 1343, 8, 93, 200, 4, 2196, 3, 43, 9, 2, 257, 40, 1443, 195, 6, 3061, 3, 1181, 130, 17, 68, 2943, 46, 4221, 28859, 139, 6]",1669.0,24356343,142
"Prevalence of human papillomavirus infection in esophageal and cervical cancers in the high incidence area for the two diseases from 2007 to 2009 in Linzhou of Henan Province, Northern China.",Archives of virology,Arch. Virol.,2014-01-03,"The etiological role of human papillomavirus (HPV) in cervical cancer has been well established. However, it is inconclusive whether HPV plays the same role in esophageal carcinogenesis. In this study, we detected HPV infection in 145 frozen esophageal tissues, including 30 normal epithelium (ENOR), 37 dysplasia (DYS) and 78 invasive squamous cell carcinoma (ESCC), and in 143 frozen cervical tissues composed of 30 normal epithelium (CNOR), 38 intraepithelial neoplasia (CIN) and 75 invasive squamous cell carcinoma (CSCC). The patients and symptom-free subjects enrolled in this study were from a high-incidence area for both ESCC and CSCC, Linzhou City, Northern China, from 2007 to 2009. The HPV infection analysis was conducted by using an HPV GenoArray Test Kit. We found that the high-risk HPV types accounted for more than 90 % of the HPV-positive lesions of esophagus and cervix tissues. The prevalence of high-risk HPV types increased significantly during the progression of both esophageal and cervical carcinogenesis (positive rate in esophageal tissues: 33 % ENOR, 70 % in DYS and 69 % in ESCC; positive rate in cervical tissues: 27 % in CNOR, 82 % in CIN and 88 % in CSCC; P < 0.001, respectively). Infection with the high-risk HPV types increased the risk for both DYS and ESCC by 4-fold (DYS vs. ENOR: OR = 4.73, 95 %CI = 1.68-13.32; ESCC vs. ENOR: OR = 4.50, 95 %CI = 1.83-11.05) and increased the risk for both CIN and CSCC by 12-fold and 20-fold (CIN vs. CNOR: OR = 12.18, 95 %CI = 3.85-38.55; CSCC vs. CNOR: OR = 20.17, 95 %CI = 6.93-58.65), respectively. The prevalence of high-risk types in ESCC patients was lower than that in CSCC patients (P = 0.005) and was significantly associated with the degree of ESCC tumor infiltration (P = 0.001). HPV 16 was the most prevalent subtype in both esophageal and cervical tissues. Single HPV infection increased significantly along with the progression of ESCC and maintained a high level in cervical tissues, regardless of whether they were CNOR or CSCC tissues. Our results showed that infection with HPV, especially the high-risk types, was positively associated with both esophageal and cervical cancers, suggesting that HPV also plays a role in the etiology of ESCC in the high-incidence area.",Journal Article,2209.0,10.0,The etiological role of human papillomavirus HPV in cancer has been well established However it is inconclusive whether HPV plays the same role in carcinogenesis In this study we detected HPV infection in 145 frozen tissues including 30 normal epithelium ENOR 37 dysplasia DYS and 78 invasive squamous cell carcinoma ESCC and in 143 frozen tissues composed of 30 normal epithelium CNOR 38 intraepithelial neoplasia CIN and 75 invasive squamous cell carcinoma CSCC The patients and symptom-free subjects enrolled in this study were from a high-incidence area for both ESCC and CSCC Linzhou City Northern China from 2007 to 2009 The HPV infection analysis was conducted by using an HPV GenoArray Test Kit We found that the high-risk HPV types accounted for more than 90 of the HPV-positive lesions of and cervix tissues The prevalence of high-risk HPV types increased significantly during the progression of both and carcinogenesis positive rate in tissues 33 ENOR 70 in DYS and 69 in ESCC positive rate in tissues 27 in CNOR 82 in CIN and 88 in CSCC P 0.001 respectively Infection with the high-risk HPV types increased the risk for both DYS and ESCC by 4-fold DYS vs. ENOR OR 4.73 95 CI 1.68-13.32 ESCC vs. ENOR OR 4.50 95 CI 1.83-11.05 and increased the risk for both CIN and CSCC by 12-fold and 20-fold CIN vs. CNOR OR 12.18 95 CI 3.85-38.55 CSCC vs. CNOR OR 20.17 95 CI 6.93-58.65 respectively The prevalence of high-risk types in ESCC patients was lower than that in CSCC patients P 0.005 and was significantly associated with the degree of ESCC tumor infiltration P 0.001 HPV 16 was the most prevalent subtype in both and tissues Single HPV infection increased significantly along with the progression of ESCC and maintained a high level in tissues regardless of whether they were CNOR or CSCC tissues Our results showed that infection with HPV especially the high-risk types was positively associated with both and cancers suggesting that HPV also plays a role in the etiology of ESCC in the high-incidence area,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[3, 13813, 200, 1, 171, 3242, 933, 4, 12, 71, 85, 149, 635, 137, 192, 16, 6791, 317, 933, 1698, 3, 827, 200, 4, 1719, 4, 26, 45, 21, 530, 933, 930, 4, 4058, 3015, 742, 141, 201, 295, 2781, 35733, 567, 2253, 21219, 2, 833, 416, 691, 31, 134, 5681, 2, 4, 4400, 3015, 742, 3317, 1, 201, 295, 2781, 32219, 519, 4153, 2298, 4652, 2, 481, 416, 691, 31, 134, 8015, 3, 7, 2, 934, 115, 976, 346, 4, 26, 45, 11, 29, 8, 64, 287, 965, 9, 110, 5681, 2, 8015, 63787, 7235, 7088, 5055, 29, 1307, 6, 1238, 3, 933, 930, 65, 10, 426, 20, 75, 35, 933, 63788, 412, 1164, 21, 204, 17, 3, 64, 43, 933, 630, 3688, 9, 80, 76, 424, 1, 3, 933, 109, 406, 1, 2, 3629, 742, 3, 1078, 1, 64, 43, 933, 630, 101, 97, 190, 3, 91, 1, 110, 2, 1719, 109, 116, 4, 742, 466, 35733, 431, 4, 21219, 2, 790, 4, 5681, 109, 116, 4, 742, 428, 4, 32219, 878, 4, 4652, 2, 889, 4, 8015, 19, 13, 144, 106, 930, 5, 3, 64, 43, 933, 630, 101, 3, 43, 9, 110, 21219, 2, 5681, 20, 39, 1116, 21219, 105, 35733, 15, 39, 803, 48, 58, 14, 806, 233, 531, 5681, 105, 35733, 15, 39, 212, 48, 58, 14, 852, 175, 474, 2, 101, 3, 43, 9, 110, 4652, 2, 8015, 20, 133, 1116, 2, 179, 1116, 4652, 105, 32219, 15, 133, 203, 48, 58, 27, 772, 519, 614, 8015, 105, 32219, 15, 179, 269, 48, 58, 49, 966, 717, 556, 106, 3, 1078, 1, 64, 43, 630, 4, 5681, 7, 10, 280, 76, 17, 4, 8015, 7, 19, 13, 1614, 2, 10, 97, 41, 5, 3, 1444, 1, 5681, 30, 2084, 19, 13, 144, 933, 245, 10, 3, 96, 2485, 875, 4, 110, 2, 742, 226, 933, 930, 101, 97, 1510, 5, 3, 91, 1, 5681, 2, 1955, 8, 64, 301, 4, 742, 1583, 1, 317, 491, 11, 32219, 15, 8015, 742, 114, 99, 224, 17, 930, 5, 933, 1093, 3, 64, 43, 630, 10, 2375, 41, 5, 110, 2, 163, 802, 17, 933, 120, 1698, 8, 200, 4, 3, 2855, 1, 5681, 4, 3, 64, 287, 965]",2017.0,24385156,65
Outcomes of total thyroidectomy with therapeutic central and lateral neck dissection with a single dose of radioiodine in the treatment of regionally advanced papillary thyroid cancer and effects on serum thyroglobulin.,Annals of surgical oncology,Ann. Surg. Oncol.,2014-01-03,"Achieving an undetectable serum thyroglobulin (Tg) level (<1.0 ng/mL) after surgical and radioiodine treatment for papillary thyroid cancer (PTC) is associated with low recurrence rates and has been termed biochemical remission. This study aimed to determine the effectiveness of total thyroidectomy with therapeutic central and lateral neck dissection for regionally advanced (T1-4bN1bM0) PTC with regard to posttreatment Tg levels. This is a single-institution retrospective cohort study of patients with regionally advanced PTC initially treated with total thyroidectomy and therapeutic levels 2-7 neck dissection from 2002 to 2012. Pathologic findings, complications, serum Tg levels, and outcomes were analyzed. Sixty-one patients were initially treated with total thyroidectomy and therapeutic central and lateral neck dissection for PTC involving the lateral cervical nodes (N1b). The median number of lymph nodes excised and positive was 27 (range 5-112) and 9 (range 1-67), respectively. Extranodal extension occurred in 48 %. Radioiodine was administered after surgery with a median total dose of 150 mCi (range 30-244 mCi). Recurrent or persistent cervical disease occurred in 8 (13 %) and 3 (5 %) patients, respectively, and required additional radioiodine treatment in 2 and reoperative neck dissection in 10. Three patients developed new distant metastasis, and 1 died during the median follow-up of 20 months (range 1-109 months). Undetectable unstimulated Tg (<1.0 ng/mL) without clinically detectable recurrence was experienced in 68 % of patients with initial treatment. Biochemical remission can be experienced in most patients presenting with regionally advanced PTC with total thyroidectomy and compartment based therapeutic neck dissection followed by a single dose of radioiodine.",Journal Article,2209.0,12.0,Achieving an undetectable serum thyroglobulin Tg level 1.0 ng/mL after surgical and radioiodine treatment for papillary cancer PTC is associated with low recurrence rates and has been termed biochemical remission This study aimed to determine the effectiveness of total thyroidectomy with therapeutic central and lateral dissection for regionally advanced T1-4bN1bM0 PTC with regard to posttreatment Tg levels This is a single-institution retrospective cohort study of patients with regionally advanced PTC initially treated with total thyroidectomy and therapeutic levels 2-7 dissection from 2002 to 2012 Pathologic findings complications serum Tg levels and outcomes were analyzed Sixty-one patients were initially treated with total thyroidectomy and therapeutic central and lateral dissection for PTC involving the lateral nodes N1b The median number of lymph nodes excised and positive was 27 range 5-112 and 9 range 1-67 respectively Extranodal extension occurred in 48 Radioiodine was administered after surgery with a median total dose of 150 mCi range 30-244 mCi Recurrent or persistent disease occurred in 8 13 and 3 5 patients respectively and required additional radioiodine treatment in 2 and reoperative dissection in 10 Three patients developed new distant metastasis and 1 died during the median follow-up of 20 months range 1-109 months Undetectable unstimulated Tg 1.0 ng/mL without clinically detectable recurrence was experienced in 68 of patients with initial treatment Biochemical remission can be experienced in most patients presenting with regionally advanced PTC with total thyroidectomy and compartment based therapeutic dissection followed by a single dose of radioiodine,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[1785, 35, 3920, 524, 8978, 5107, 301, 14, 13, 997, 542, 50, 221, 2, 7211, 24, 9, 1796, 12, 3748, 16, 41, 5, 154, 146, 151, 2, 71, 85, 4183, 1487, 734, 26, 45, 1295, 6, 223, 3, 1236, 1, 181, 5949, 5, 189, 854, 2, 3855, 1161, 9, 8183, 131, 1534, 63789, 3748, 5, 2539, 6, 3149, 5107, 148, 26, 16, 8, 226, 731, 459, 180, 45, 1, 7, 5, 8183, 131, 3748, 1625, 73, 5, 181, 5949, 2, 189, 148, 18, 67, 1161, 29, 1544, 6, 1195, 510, 272, 521, 524, 5107, 148, 2, 123, 11, 311, 1746, 104, 7, 11, 1625, 73, 5, 181, 5949, 2, 189, 854, 2, 3855, 1161, 9, 3748, 1267, 3, 3855, 502, 24912, 3, 52, 207, 1, 263, 502, 5076, 2, 109, 10, 428, 184, 33, 3726, 2, 83, 184, 14, 598, 106, 4093, 2401, 489, 4, 576, 7211, 10, 468, 50, 152, 5, 8, 52, 181, 61, 1, 1577, 4076, 184, 201, 6567, 4076, 387, 15, 1882, 34, 489, 4, 66, 233, 2, 27, 33, 7, 106, 2, 616, 402, 7211, 24, 4, 18, 2, 11250, 1161, 4, 79, 169, 7, 276, 217, 626, 278, 2, 14, 1016, 190, 3, 52, 166, 126, 1, 179, 53, 184, 14, 3486, 53, 3920, 16781, 5107, 14, 13, 997, 542, 187, 505, 2083, 146, 10, 592, 4, 806, 1, 7, 5, 388, 24, 1487, 734, 122, 40, 592, 4, 96, 7, 1656, 5, 8183, 131, 3748, 5, 181, 5949, 2, 3616, 90, 189, 1161, 370, 20, 8, 226, 61, 1, 7211]",1699.0,24385210,243
Landscape of genomic alterations in cervical carcinomas.,Nature,Nature,2013-12-25,"Cervical cancer is responsible for 10-15% of cancer-related deaths in women worldwide. The aetiological role of infection with high-risk human papilloma viruses (HPVs) in cervical carcinomas is well established. Previous studies have also implicated somatic mutations in PIK3CA, PTEN, TP53, STK11 and KRAS as well as several copy-number alterations in the pathogenesis of cervical carcinomas. Here we report whole-exome sequencing analysis of 115 cervical carcinoma-normal paired samples, transcriptome sequencing of 79 cases and whole-genome sequencing of 14 tumour-normal pairs. Previously unknown somatic mutations in 79 primary squamous cell carcinomas include recurrent E322K substitutions in the MAPK1 gene (8%), inactivating mutations in the HLA-B gene (9%), and mutations in EP300 (16%), FBXW7 (15%), NFE2L2 (4%), TP53 (5%) and ERBB2 (6%). We also observe somatic ELF3 (13%) and CBFB (8%) mutations in 24 adenocarcinomas. Squamous cell carcinomas have higher frequencies of somatic nucleotide substitutions occurring at cytosines preceded by thymines (Tp*C sites) than adenocarcinomas. Gene expression levels at HPV integration sites were statistically significantly higher in tumours with HPV integration compared with expression of the same genes in tumours without viral integration at the same site. These data demonstrate several recurrent genomic alterations in cervical carcinomas that suggest new strategies to combat this disease. ",Journal Article,2218.0,366.0,cancer is responsible for 10-15 of cancer-related deaths in women worldwide The aetiological role of infection with high-risk human papilloma viruses HPVs in carcinomas is well established Previous studies have also implicated somatic mutations in PIK3CA PTEN TP53 STK11 and KRAS as well as several copy-number alterations in the pathogenesis of carcinomas Here we report whole-exome sequencing analysis of 115 carcinoma-normal paired samples transcriptome sequencing of 79 cases and whole-genome sequencing of 14 tumour-normal pairs Previously unknown somatic mutations in 79 primary squamous cell carcinomas include recurrent E322K substitutions in the MAPK1 gene 8 inactivating mutations in the HLA-B gene 9 and mutations in EP300 16 FBXW7 15 NFE2L2 4 TP53 5 and ERBB2 6 We also observe somatic ELF3 13 and CBFB 8 mutations in 24 adenocarcinomas Squamous cell carcinomas have higher frequencies of somatic nucleotide substitutions occurring at cytosines preceded by thymines Tp*C sites than adenocarcinomas Gene expression levels at HPV integration sites were statistically significantly higher in tumours with HPV integration compared with expression of the same genes in tumours without viral integration at the same site These data demonstrate several recurrent genomic alterations in carcinomas that suggest new strategies to combat this disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 2327, 9, 79, 167, 1, 12, 139, 1043, 4, 117, 2358, 3, 33737, 200, 1, 930, 5, 64, 43, 171, 7017, 4405, 13477, 4, 826, 16, 149, 635, 698, 94, 47, 120, 1771, 1119, 138, 4, 1506, 820, 1206, 9675, 2, 723, 22, 149, 22, 392, 1337, 207, 593, 4, 3, 1384, 1, 826, 467, 21, 414, 902, 2865, 615, 65, 1, 3670, 134, 295, 2355, 347, 3917, 615, 1, 842, 140, 2, 902, 898, 615, 1, 213, 770, 295, 2773, 373, 860, 1119, 138, 4, 842, 86, 691, 31, 826, 643, 387, 35734, 7646, 4, 3, 16563, 145, 66, 6096, 138, 4, 3, 1160, 132, 145, 83, 2, 138, 4, 15423, 245, 8352, 167, 16969, 39, 1206, 33, 2, 2186, 49, 21, 120, 4635, 1119, 22041, 233, 2, 14598, 66, 138, 4, 259, 1586, 691, 31, 826, 47, 142, 2722, 1, 1119, 1579, 7646, 1821, 28, 23365, 6083, 20, 63795, 5907, 256, 633, 76, 1586, 145, 55, 148, 28, 933, 2676, 633, 11, 712, 97, 142, 4, 1319, 5, 933, 2676, 72, 5, 55, 1, 3, 827, 214, 4, 1319, 187, 1667, 2676, 28, 3, 827, 606, 46, 74, 608, 392, 387, 572, 593, 4, 826, 17, 309, 217, 422, 6, 10584, 26, 34]",1352.0,24390348,350
Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.,Gynecologic oncology,Gynecol. Oncol.,2014-01-07,"To review the extent of health disparities in gynecologic cancer care and outcomes and to propose recommendations to help counteract the disparities. We searched the electronic databases PubMed and the Cochrane Library. We included studies demonstrating quantifiable differences by race and ethnicity in the incidence, treatment, and survival of gynecologic cancers in the United States (US). Most studies relied on retrospective data. We focused on differences between Black and White women, because of the limited number of studies on non-Black women. White women have a higher incidence of ovarian cancer compared to Black women. However, the all-cause ovarian cancer mortality in Black women is 1.3 times higher than that of White women. Endometrial and cervical cancer mortality in Black women is twice that of White women. The etiology of these disparities is multifaceted. However, much of the evidence suggests that equal care leads to equal outcomes for Black women diagnosed with gynecologic cancers. Underlying molecular factors may play an additional role in aggressive tumor biology and endometrial cancer disparities. Gynecologic cancer disparities exist between Black and White women. The literature is limited by the lack of large prospective trials and adequate numbers of non-Black racial and ethnic groups. We conclude with recommendations for continued research and a multifaceted approach to eliminate gynecologic cancer disparities.",Journal Article,2205.0,70.0,To review the extent of health disparities in gynecologic cancer care and outcomes and to propose recommendations to help counteract the disparities We searched the electronic databases PubMed and the Cochrane Library We included studies demonstrating quantifiable differences by race and ethnicity in the incidence treatment and survival of gynecologic cancers in the United States US Most studies relied on retrospective data We focused on differences between Black and White women because of the limited number of studies on non-Black women White women have a higher incidence of cancer compared to Black women However the all-cause cancer mortality in Black women is 1.3 times higher than that of White women and cancer mortality in Black women is twice that of White women The etiology of these disparities is multifaceted However much of the evidence suggests that equal care leads to equal outcomes for Black women diagnosed with gynecologic cancers Underlying molecular factors may play an additional role in aggressive tumor biology and cancer disparities Gynecologic cancer disparities exist between Black and White women The literature is limited by the lack of large prospective trials and adequate numbers of non-Black racial and ethnic groups We conclude with recommendations for continued research and a multifaceted approach to eliminate gynecologic cancer disparities,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 206, 3, 1039, 1, 341, 2227, 4, 1512, 12, 165, 2, 123, 2, 6, 2548, 883, 6, 987, 12141, 3, 2227, 21, 3080, 3, 3098, 2348, 3161, 2, 3, 4956, 4157, 21, 159, 94, 2219, 11639, 362, 20, 1047, 2, 2091, 4, 3, 287, 24, 2, 25, 1, 1512, 163, 4, 3, 1088, 907, 843, 96, 94, 9896, 23, 459, 74, 21, 1649, 23, 362, 59, 1445, 2, 886, 117, 408, 1, 3, 383, 207, 1, 94, 23, 220, 1445, 117, 886, 117, 47, 8, 142, 287, 1, 12, 72, 6, 1445, 117, 137, 3, 62, 708, 12, 282, 4, 1445, 117, 16, 14, 27, 1072, 142, 76, 17, 1, 886, 117, 2, 12, 282, 4, 1445, 117, 16, 936, 17, 1, 886, 117, 3, 2855, 1, 46, 2227, 16, 10076, 137, 1802, 1, 3, 241, 844, 17, 2997, 165, 1940, 6, 2997, 123, 9, 1445, 117, 265, 5, 1512, 163, 1181, 219, 130, 68, 1343, 35, 402, 200, 4, 571, 30, 891, 2, 12, 2227, 1512, 12, 2227, 1923, 59, 1445, 2, 886, 117, 3, 789, 16, 383, 20, 3, 926, 1, 375, 482, 143, 2, 1658, 1870, 1, 220, 1445, 2257, 2, 2871, 271, 21, 2060, 5, 883, 9, 1351, 389, 2, 8, 10076, 353, 6, 4964, 1512, 12, 2227]",1384.0,24406291,172
Sentinel lymph node evaluation in women with cervical cancer.,Journal of minimally invasive gynecology,J Minim Invasive Gynecol,2014-01-07,"Lymph node status is the most important prognosticator of survival in women with early stage cervical cancer. Thus many patients with cervical cancer will undergo pelvic lymphadenectomy as part of the treatment. This procedure is associated with substantial morbidity. Use of the sentinel lymph node technique in women with cervical cancer has the potential to decrease this morbidity. Multiple studies have suggested that sentinel lymph node mapping in these patients is feasible, with excellent detection rates and sensitivity. This review examines the current body of literature about sentinel lymph node biopsy in women with cervical cancer. ",Journal Article,2205.0,28.0,Lymph node status is the most important prognosticator of survival in women with early stage cancer Thus many patients with cancer will undergo pelvic lymphadenectomy as part of the treatment This procedure is associated with substantial morbidity Use of the sentinel lymph node technique in women with cancer has the potential to decrease this morbidity Multiple studies have suggested that sentinel lymph node mapping in these patients is feasible with excellent detection rates and sensitivity This review examines the current body of literature about sentinel lymph node biopsy in women with cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[263, 289, 156, 16, 3, 96, 305, 9655, 1, 25, 4, 117, 5, 191, 82, 12, 631, 445, 7, 5, 12, 303, 1251, 1110, 2048, 22, 760, 1, 3, 24, 26, 1299, 16, 41, 5, 1281, 787, 119, 1, 3, 1323, 263, 289, 1312, 4, 117, 5, 12, 71, 3, 174, 6, 775, 26, 787, 232, 94, 47, 1148, 17, 1323, 263, 289, 2568, 4, 46, 7, 16, 1313, 5, 1503, 638, 151, 2, 485, 26, 206, 4468, 3, 291, 642, 1, 789, 545, 1323, 263, 289, 411, 4, 117, 5, 12]",602.0,24407177,315
Patterns of radiation therapy practice for patients treated for intact cervical cancer in 2005 to 2007: a quality research in radiation oncology study.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2014-01-07,"To assess practice patterns and compliance with clinical performance measures for radiation therapy (RT) for patients with intact carcinoma of the cervix. Trained research associates reviewed the records of 261 randomly selected patients who received RT for cervix carcinoma between 2005 and 2007 from 45 facilities randomly selected after stratification by practice type. National estimates of patient and treatment characteristics were calculated from survey data using SUDAAN statistical software. From the survey data, we estimated that only 8% of US facilities treated on average more than 3 eligible patients per year. No small or medium nonacademic facilities in the survey treated more than 3 eligible patients per year. Approximately 65.5% of patients began treatment in a facility that treated 3 or fewer eligible patients per year. Although 87.5% of patients had brachytherapy as part of their treatment, the proportion treated with external beam RT only was about double that estimated from the 1996 to 1999 survey. The use of high-dose-rate brachytherapy sharply increased, particularly in small nonacademic facilities. Overall, patients treated in nonacademic facilities were more likely to have incomplete or protracted treatment; 43% of patients treated in small nonacademic facilities did not have treatment completed within 10 weeks. Also, patients treated in facilities that treated 3 or fewer eligible patients per year were significantly less likely to receive concurrent chemotherapy than were patients treated in other facilities. Survey results indicate a disturbingly high rate of noncompliance with established criteria for high-quality care of patients with cervical cancer. Noncompliance rates are particularly high in nonacademic facilities, especially those that treat relatively few patients with intact cervical cancer.",Evaluation Study,2205.0,55.0,To assess practice patterns and compliance with clinical performance measures for radiation therapy RT for patients with intact carcinoma of the cervix Trained research associates reviewed the records of 261 randomly selected patients who received RT for cervix carcinoma between 2005 and 2007 from 45 facilities randomly selected after stratification by practice type National estimates of patient and treatment characteristics were calculated from survey data using SUDAAN statistical software From the survey data we estimated that only 8 of US facilities treated on average more than 3 eligible patients per year No small or medium nonacademic facilities in the survey treated more than 3 eligible patients per year Approximately 65.5 of patients began treatment in a facility that treated 3 or fewer eligible patients per year Although 87.5 of patients had brachytherapy as part of their treatment the proportion treated with external beam RT only was about double that estimated from the 1996 to 1999 survey The use of high-dose-rate brachytherapy sharply increased particularly in small nonacademic facilities Overall patients treated in nonacademic facilities were more likely to have incomplete or protracted treatment 43 of patients treated in small nonacademic facilities did not have treatment completed within 10 weeks Also patients treated in facilities that treated 3 or fewer eligible patients per year were significantly less likely to receive concurrent chemotherapy than were patients treated in other facilities Survey results indicate a disturbingly high rate of noncompliance with established criteria for high-quality care of patients with cancer Noncompliance rates are particularly high in nonacademic facilities especially those that treat relatively few patients with intact cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 423, 758, 764, 2, 3336, 5, 38, 528, 1018, 9, 121, 36, 240, 9, 7, 5, 2964, 134, 1, 3, 3629, 5946, 389, 7326, 446, 3, 1064, 1, 7007, 1108, 715, 7, 54, 103, 240, 9, 3629, 134, 59, 1242, 2, 1307, 29, 512, 4351, 1108, 715, 50, 1541, 20, 758, 267, 657, 1423, 1, 69, 2, 24, 374, 11, 981, 29, 1407, 74, 75, 28667, 1050, 3639, 29, 3, 1407, 74, 21, 661, 17, 158, 66, 1, 843, 4351, 73, 23, 1011, 80, 76, 27, 625, 7, 379, 111, 77, 302, 15, 3759, 13913, 4351, 4, 3, 1407, 73, 80, 76, 27, 625, 7, 379, 111, 705, 556, 33, 1, 7, 4603, 24, 4, 8, 3483, 17, 73, 27, 15, 1497, 625, 7, 379, 111, 242, 912, 33, 1, 7, 42, 1536, 22, 760, 1, 136, 24, 3, 920, 73, 5, 1455, 1345, 240, 158, 10, 545, 1627, 17, 661, 29, 3, 2648, 6, 2043, 1407, 3, 119, 1, 64, 61, 116, 1536, 10833, 101, 823, 4, 302, 13913, 4351, 63, 7, 73, 4, 13913, 4351, 11, 80, 322, 6, 47, 2610, 15, 7053, 24, 601, 1, 7, 73, 4, 302, 13913, 4351, 205, 44, 47, 24, 781, 262, 79, 244, 120, 7, 73, 4, 4351, 17, 73, 27, 15, 1497, 625, 7, 379, 111, 11, 97, 299, 322, 6, 560, 750, 56, 76, 11, 7, 73, 4, 127, 4351, 1407, 99, 1008, 8, 63818, 64, 116, 1, 13494, 5, 635, 371, 9, 64, 372, 165, 1, 7, 5, 12, 13494, 151, 32, 823, 64, 4, 13913, 4351, 1093, 135, 17, 943, 1352, 1021, 7, 5, 2964, 12]",1808.0,24411621,24
Simultaneous characterization of somatic events and HPV-18 integration in a metastatic cervical carcinoma patient using DNA and RNA sequencing.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2014-02-01,"Integration of carcinogenic human papillomaviruses (HPVs) into the host genome is a significant tumorigenic factor in specific cancers including cervical carcinoma. Although major strides have been made with respect to HPV diagnosis and prevention, identification and development of efficacious treatments for cervical cancer patients remains a goal and thus requires additional detailed characterization of both somatic events and HPV integration. Given this need, the goal of this study was to use the next generation sequencing to simultaneously evaluate somatic alterations and expression changes in a patient's cervical squamous carcinoma lesion metastatic to the lung and to detect and analyze HPV infection in the same sample. We performed tumor and normal exome, tumor and normal shallow whole-genome sequencing, and RNA sequencing of the patient's lung metastasis. We generated over 1.2 billion mapped reads and identified 130 somatic point mutations and indels, 21 genic translocations, 16 coding regions demonstrating copy number changes, and over 36 genes demonstrating altered expression in the tumor (corrected P < 0.05). Sequencing also revealed the HPV type 18 (HPV-18) integration in the metastasis. Using both DNA and RNA reads, we pinpointed 3 major events indicating HPV-18 integration into an intronic region of chromosome 6p25.1 in the patient's tumor and validated these events with Sanger sequencing. This integration site has not been reported for HPV-18. We demonstrate that DNA and RNA sequencing can be used to concurrently characterize somatic alterations and expression changes in a biopsy and delineate HPV integration at base resolution in cervical cancer. Further sequencing will allow us to better understand the molecular basis of cervical cancer pathogenesis.",Case Reports,2180.0,12.0,Integration of carcinogenic human papillomaviruses HPVs into the host genome is a significant tumorigenic factor in specific cancers including carcinoma Although major strides have been made with respect to HPV diagnosis and prevention identification and development of efficacious treatments for cancer patients remains a goal and thus requires additional detailed characterization of both somatic events and HPV integration Given this need the goal of this study was to use the next generation sequencing to simultaneously evaluate somatic alterations and expression changes in a patient 's squamous carcinoma lesion metastatic to the and to detect and analyze HPV infection in the same sample We performed tumor and normal exome tumor and normal shallow whole-genome sequencing and RNA sequencing of the patient 's metastasis We generated over 1.2 billion mapped reads and identified 130 somatic point mutations and indels 21 genic translocations 16 coding regions demonstrating copy number changes and over 36 genes demonstrating altered expression in the tumor corrected P 0.05 Sequencing also revealed the HPV type 18 HPV-18 integration in the metastasis Using both DNA and RNA reads we pinpointed 3 major events indicating HPV-18 integration into an intronic region of chromosome 6p25.1 in the patient 's tumor and validated these events with Sanger sequencing This integration site has not been reported for HPV-18 We demonstrate that DNA and RNA sequencing can be used to concurrently characterize somatic alterations and expression changes in a biopsy and delineate HPV integration at base resolution in cancer Further sequencing will allow us to better understand the molecular basis of cancer pathogenesis,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2676, 1, 7483, 171, 14731, 13477, 237, 3, 1204, 898, 16, 8, 93, 3795, 161, 4, 112, 163, 141, 134, 242, 458, 10698, 47, 85, 1229, 5, 2184, 6, 933, 147, 2, 1070, 911, 2, 193, 1, 3289, 640, 9, 12, 7, 469, 8, 1326, 2, 631, 1706, 402, 2455, 2136, 1, 110, 1119, 281, 2, 933, 2676, 447, 26, 594, 3, 1326, 1, 26, 45, 10, 6, 119, 3, 1305, 914, 615, 6, 3074, 376, 1119, 593, 2, 55, 400, 4, 8, 69, 292, 691, 134, 1180, 113, 6, 3, 2, 6, 1426, 2, 1992, 933, 930, 4, 3, 827, 1000, 21, 173, 30, 2, 295, 2865, 30, 2, 295, 31400, 902, 898, 615, 2, 893, 615, 1, 3, 69, 292, 278, 21, 1419, 252, 14, 18, 10243, 6224, 11062, 2, 108, 3431, 1119, 741, 138, 2, 13721, 239, 26978, 3262, 245, 3097, 1374, 2219, 1337, 207, 400, 2, 252, 511, 214, 2219, 1495, 55, 4, 3, 30, 3848, 19, 13, 474, 615, 120, 553, 3, 933, 267, 203, 933, 203, 2676, 4, 3, 278, 75, 110, 261, 2, 893, 11062, 21, 38762, 27, 458, 281, 1716, 933, 203, 2676, 237, 35, 7998, 1053, 1, 1170, 20717, 14, 4, 3, 69, 292, 30, 2, 938, 46, 281, 5, 7285, 615, 26, 2676, 606, 71, 44, 85, 210, 9, 933, 203, 21, 608, 17, 261, 2, 893, 615, 122, 40, 95, 6, 3294, 1507, 1119, 593, 2, 55, 400, 4, 8, 411, 2, 5092, 933, 2676, 28, 1782, 2125, 4, 12, 195, 615, 303, 1700, 843, 6, 380, 1640, 3, 219, 877, 1, 12, 1384]",1717.0,24418928,376
"""Trap-door"" and ""clamshell"" surgical approaches for the management of pediatric tumors of the cervicothoracic junction and mediastinum.",Journal of pediatric surgery,J. Pediatr. Surg.,2013-10-05,"For pediatric tumors of the cervicothoracic junction, an isolated cervical or thoracic surgical approach provides insufficient exposure for achieving complete resection. We retrospectively examined ""trap-door"" and ""clamshell"" pediatric thoracotomies as a surgical approach to these tumors. We searched our database for pediatric patients with cervicothoracic tumors who underwent clamshell or trap-door thoracotomy between 1991 and 2013, reviewing tumor characteristics, surgical technique, completeness of resection, morbidity, and outcome. Trap-door (n=13) and clamshell (n=4) thoracotomies were performed for neuroblastoma (n=9), non-rhabdomyosarcoma soft tissue sarcoma (n=4), germ cell tumor (n=2), rhabdomyosarcoma (n=1), and neuroendocrine small cell carcinoma (n=1). Fourteen of these cervicothoracic tumors were primary, and three were metastatic. Gross total resection was achieved in 15 patients (94%). Operative complications included vocal cord paralysis (n=2), mild upper-extremity neuropraxia (n=2), and hemidiaphragm paralysis (n=1), All but one involved encased nerves. Overall survival was 61% for the series and 80% for patients with primary tumors. Eleven (73%) of 15 patients who underwent gross total resection had no evidence of recurrence. Three patients with metastatic disease died of distant progression within 1.3years. Gross total resection of primary cervicothoracic tumors can be accomplished with specialized exposure in pediatric patients with minimal morbidity.",Comparative Study,2299.0,6.0,For pediatric tumors of the cervicothoracic junction an isolated or thoracic surgical approach provides insufficient exposure for achieving complete resection We retrospectively examined `` trap-door '' and `` clamshell '' pediatric thoracotomies as a surgical approach to these tumors We searched our database for pediatric patients with cervicothoracic tumors who underwent clamshell or trap-door thoracotomy between 1991 and 2013 reviewing tumor characteristics surgical technique completeness of resection morbidity and outcome Trap-door n=13 and clamshell n=4 thoracotomies were performed for n=9 non-rhabdomyosarcoma soft tissue n=4 germ cell tumor n=2 n=1 and neuroendocrine small cell carcinoma n=1 Fourteen of these cervicothoracic tumors were primary and three were metastatic Gross total resection was achieved in 15 patients 94 Operative complications included vocal cord paralysis n=2 mild upper-extremity neuropraxia n=2 and hemidiaphragm paralysis n=1 All but one involved encased nerves Overall survival was 61 for the series and 80 for patients with primary tumors Eleven 73 of 15 patients who underwent gross total resection had no evidence of recurrence Three patients with metastatic disease died of distant progression within 1.3years Gross total resection of primary cervicothoracic tumors can be accomplished with specialized exposure in pediatric patients with minimal morbidity,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,"[9, 815, 57, 1, 3, 26738, 3322, 35, 1355, 15, 2098, 221, 353, 777, 3027, 645, 9, 1785, 236, 170, 21, 894, 409, 8281, 16512, 522, 2, 32224, 522, 815, 15525, 22, 8, 221, 353, 6, 46, 57, 21, 3080, 114, 609, 9, 815, 7, 5, 26738, 57, 54, 208, 32224, 15, 8281, 16512, 6103, 59, 3372, 2, 1346, 6979, 30, 374, 221, 1312, 7507, 1, 170, 787, 2, 228, 8281, 16512, 78, 233, 2, 32224, 78, 39, 15525, 11, 173, 9, 78, 83, 220, 22050, 1214, 246, 78, 39, 2280, 31, 30, 78, 18, 78, 14, 2, 1542, 302, 31, 134, 78, 14, 3225, 1, 46, 26738, 57, 11, 86, 2, 169, 11, 113, 1789, 181, 170, 10, 513, 4, 167, 7, 960, 1208, 521, 159, 11738, 1885, 11737, 78, 18, 1980, 1726, 2678, 46584, 78, 18, 2, 63847, 11737, 78, 14, 62, 84, 104, 646, 34820, 6721, 63, 25, 10, 713, 9, 3, 988, 2, 493, 9, 7, 5, 86, 57, 2627, 803, 1, 167, 7, 54, 208, 1789, 181, 170, 42, 77, 241, 1, 146, 169, 7, 5, 113, 34, 1016, 1, 626, 91, 262, 14, 20695, 1789, 181, 170, 1, 86, 26738, 57, 122, 40, 5741, 5, 4791, 645, 4, 815, 7, 5, 1048, 787]",1402.0,24439604,194
Barriers reported among patients with breast and cervical abnormalities in the patient navigation research program: impact on timely care.,Women's health issues : official publication of the Jacobs Institute of Women's Health,Womens Health Issues,,"Patient navigation (PN) is a system-level strategy to decrease cancer mortality rates by reducing barriers to cancer care. Barriers to resolution among participants in the PN intervention arm with a breast or cervical abnormality in the Patient Navigation Research Program and navigators' actions to address those barriers were examined. Data from seven institutions (2005-2010) included 1,995 breast and 1,194 cervical patients. A stratified Cox proportional hazards regression model was used to examine the effects of barriers on time to resolution of an abnormal screening test or clinical finding. The range of unique barriers was 0 to 12 and 0 to 7 among participants with breast and cervical abnormalities, respectively. About two thirds of breast and one half of cervical participants had at least one barrier resulting in longer time to diagnostic resolution among breast (adjusted hazard ratio [HR], 0.744; p<.001) and cervical (adjusted HR,0.792; p<.001) participants. Patient- and system-level barriers were most common. Frequent navigator actions were making arrangements, scheduling appointments, referrals, and education. Having a barrier resulted in a delay in diagnostic resolution of an abnormal screening test or clinical finding. Health care systems can use these findings to improve existing PN programs or when developing new programs.",Journal Article,,22.0,"Patient navigation PN is a system-level strategy to decrease cancer mortality rates by reducing barriers to cancer care Barriers to resolution among participants in the PN intervention arm with a or abnormality in the Patient Navigation Research Program and navigators actions to address those barriers were examined Data from seven institutions 2005-2010 included 1,995 and 1,194 patients A stratified Cox proportional hazards regression model was used to examine the effects of barriers on time to resolution of an abnormal screening test or clinical finding The range of unique barriers was 0 to 12 and 0 to 7 among participants with and abnormalities respectively About two thirds of and one half of participants had at least one barrier resulting in longer time to diagnostic resolution among adjusted hazard ratio HR 0.744 p .001 and adjusted HR 0.792 p .001 participants Patient- and system-level barriers were most common Frequent navigator actions were making arrangements scheduling appointments referrals and education Having a barrier resulted in a delay in diagnostic resolution of an abnormal screening test or clinical finding Health care systems can use these findings to improve existing PN programs or when developing new programs",1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[69, 5604, 2700, 16, 8, 398, 301, 692, 6, 775, 12, 282, 151, 20, 1818, 2160, 6, 12, 165, 2160, 6, 2125, 107, 776, 4, 3, 2700, 788, 475, 5, 8, 15, 3698, 4, 3, 69, 5604, 389, 1243, 2, 15368, 5592, 6, 1539, 135, 2160, 11, 409, 74, 29, 648, 1764, 1242, 1120, 159, 14, 13563, 2, 14, 5434, 7, 8, 1173, 418, 831, 1017, 320, 202, 10, 95, 6, 1004, 3, 176, 1, 2160, 23, 98, 6, 2125, 1, 35, 1668, 453, 412, 15, 38, 1567, 3, 184, 1, 991, 2160, 10, 13, 6, 133, 2, 13, 6, 67, 107, 776, 5, 2, 1171, 106, 545, 100, 5438, 1, 2, 104, 1303, 1, 776, 42, 28, 506, 104, 3318, 1113, 4, 589, 98, 6, 752, 2125, 107, 586, 360, 197, 168, 13, 12614, 19, 144, 2, 586, 168, 13, 13760, 19, 144, 776, 69, 2, 398, 301, 2160, 11, 96, 186, 908, 18560, 5592, 11, 1079, 14551, 8122, 9829, 6902, 2, 1848, 1041, 8, 3318, 627, 4, 8, 1984, 4, 752, 2125, 1, 35, 1668, 453, 412, 15, 38, 1567, 341, 165, 1530, 122, 119, 46, 272, 6, 401, 1692, 2700, 2251, 15, 198, 931, 217, 2251]",1248.0,24439942,291
Lifestyle modification in cervical cancer survivors: an ongoing need.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2014-03-01,"With the introduction of multimodality therapy for cervical cancer, many women will be long-term survivors in need of comprehensive surveillance care. Our goals were to evaluate patterns of obesity and smoking in a cohort of cervical cancer survivors and to assess the potential influence of these comorbidities on subsequent follow-up. We reviewed the records of patients treated for invasive cervical cancer at our institution from 2000 to 2003 who had no evidence of disease for 3 or more years. Demographic and clinical data were collected, including smoking history and anthropometric measurements. Body mass index (BMI) was categorized according to World Health Organization criteria. Logistic regression and Wilcoxon rank sum analyses were performed. Two hundred ninety-eight women had complete follow-up data at 3 years. The median age at diagnosis was 43.5 years (range, 17.6-87.1 years). At diagnosis, 31.9% had a normal BMI, 28.2% were overweight, and 34.6% were obese compared with 31.7%, 21.1%, and 30.2% at 3 years, respectively. Of the 51 women whose BMI categorization changed, 33 (64.7%) had weight gain, and 18 (35.3%) had weight loss. By paired analyses, increase in BMI was significant over the 3-year interval (P < 0.001). Seventy patients actively smoked at diagnosis. Compared with nonsmokers, current smokers had a greater odds of referral to the pain service (odds ratio [OR], 6.56; confidence interval [CI], 6.26-16.43; P < 0.001), physical therapy (OR, 4.74; CI, 1.29-17.36; P = 0.02), and gastroenterology (OR, 2.25; CI, 1.14-4.24; P = 0.02). Obesity and smoking are significant comorbidities that may complicate care in cervical cancer survivors. Interventions aimed at modifying these risk factors should be routinely undertaken in this population.",Journal Article,2152.0,5.0,With the introduction of multimodality therapy for cancer many women will be long-term survivors in need of comprehensive surveillance care Our goals were to evaluate patterns of obesity and smoking in a cohort of cancer survivors and to assess the potential influence of these comorbidities on subsequent follow-up We reviewed the records of patients treated for invasive cancer at our institution from 2000 to 2003 who had no evidence of disease for 3 or more years Demographic and clinical data were collected including smoking history and anthropometric measurements Body mass index BMI was categorized according to World Health Organization criteria Logistic regression and Wilcoxon rank sum analyses were performed Two hundred ninety-eight women had complete follow-up data at 3 years The median age at diagnosis was 43.5 years range 17.6-87.1 years At diagnosis 31.9 had a normal BMI 28.2 were overweight and 34.6 were obese compared with 31.7 21.1 and 30.2 at 3 years respectively Of the 51 women whose BMI categorization changed 33 64.7 had weight gain and 18 35.3 had weight loss By paired analyses increase in BMI was significant over the 3-year interval P 0.001 Seventy patients actively smoked at diagnosis Compared with nonsmokers current smokers had a greater odds of referral to the pain service odds ratio OR 6.56 confidence interval CI 6.26-16.43 P 0.001 physical therapy OR 4.74 CI 1.29-17.36 P 0.02 and gastroenterology OR 2.25 CI 1.14-4.24 P 0.02 Obesity and smoking are significant comorbidities that may complicate care in cancer survivors Interventions aimed at modifying these risk factors should be routinely undertaken in this population,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[5, 3, 2456, 1, 2425, 36, 9, 12, 445, 117, 303, 40, 319, 337, 332, 4, 594, 1, 949, 617, 165, 114, 2802, 11, 6, 376, 764, 1, 1661, 2, 979, 4, 8, 180, 1, 12, 332, 2, 6, 423, 3, 174, 1054, 1, 46, 1909, 23, 706, 166, 126, 21, 446, 3, 1064, 1, 7, 73, 9, 416, 12, 28, 114, 731, 29, 1081, 6, 1522, 54, 42, 77, 241, 1, 34, 9, 27, 15, 80, 60, 1540, 2, 38, 74, 11, 786, 141, 979, 532, 2, 15307, 1685, 642, 782, 558, 1140, 10, 2320, 768, 6, 1956, 341, 2533, 371, 812, 320, 2, 3896, 1026, 3216, 318, 11, 173, 100, 1128, 2493, 659, 117, 42, 236, 166, 126, 74, 28, 27, 60, 3, 52, 89, 28, 147, 10, 601, 33, 60, 184, 269, 49, 912, 14, 60, 28, 147, 456, 83, 42, 8, 295, 1140, 339, 18, 11, 3566, 2, 562, 49, 11, 2209, 72, 5, 456, 67, 239, 14, 2, 201, 18, 28, 27, 60, 106, 1, 3, 725, 117, 1310, 1140, 8872, 2368, 466, 660, 67, 42, 924, 1803, 2, 203, 465, 27, 42, 924, 407, 20, 2355, 318, 344, 4, 1140, 10, 93, 252, 3, 27, 111, 268, 19, 13, 144, 2073, 7, 4489, 7047, 28, 147, 72, 5, 8380, 291, 1485, 42, 8, 378, 610, 1, 2096, 6, 3, 559, 3086, 610, 197, 15, 49, 664, 307, 268, 58, 49, 432, 245, 601, 19, 13, 144, 900, 36, 15, 39, 794, 58, 14, 462, 269, 511, 19, 13, 588, 2, 13118, 15, 18, 243, 58, 14, 213, 39, 259, 19, 13, 588, 1661, 2, 979, 32, 93, 1909, 17, 68, 11157, 165, 4, 12, 332, 1151, 1295, 28, 4898, 46, 43, 130, 257, 40, 3066, 2789, 4, 26, 266]",1664.0,24469324,297
Incidental detection of late subsequent intracranial neoplasms with magnetic resonance imaging among adult survivors of childhood cancer.,Journal of cancer survivorship : research and practice,J Cancer Surviv,2014-02-02,"Survivors of childhood cancer are at an increased risk of developing subsequent neoplasms. In long-term survivors of childhood malignancies treated with and without cranial radiation therapy (CRT), undergoing unenhanced magnetic resonance imaging (MRI) of the brain, we estimated detection of intracranial neoplasms. To investigate neurocognitive outcomes, 219 survivors of childhood cancer underwent unenhanced screening MRI of the brain. Of the survivors, 164 had been treated for acute lymphoblastic leukemia (ALL) (125 received CRT) and 55 for Hodgkin lymphoma (HL) (none received CRT). MRI examinations were reviewed and systematically coded by a single neuroradiologist. Demographic and treatment characteristics were compared for survivors with and without subsequent neoplasms. Nineteen of the 219 survivors (8.7 %) had a total of 31 subsequent intracranial neoplasms identified by neuroimaging at a median time of 25 years (range 12-46 years) from diagnosis. All neoplasms occurred after CRT, except for a single vestibular schwannoma within the cervical radiation field in a HL survivor. The prevalence of subsequent neoplasms after CRT exposure was 14.4 % (18 of 125). By noncontrast MRI, intracranial neoplasms were most suggestive of meningiomas. Most patients presented with no specific, localizing neurological complaints. In addition to the schwannoma, six tumors were resected based on results of MRI screening, all of which were meningiomas on histologic review. Unenhanced brain MRI of long-term survivors of childhood cancer detected a substantial number of intracranial neoplasms. Screening for early detection of intracranial neoplasms among aging survivors of childhood cancer who received CRT should be evaluated. The high prevalence of incidentally detected subsequent intracranial neoplasms after CRT in long-term survivors of childhood cancer and the minimal symptoms reported by those with intracranial tumors in our study indicate that brain MRI screening of long-term survivors who received CRT may be warranted. Prospective studies of such screening are needed.",Journal Article,2179.0,6.0,Survivors of childhood cancer are at an increased risk of developing subsequent neoplasms In long-term survivors of childhood malignancies treated with and without cranial radiation therapy CRT undergoing unenhanced magnetic resonance imaging MRI of the brain we estimated detection of intracranial neoplasms To investigate neurocognitive outcomes 219 survivors of childhood cancer underwent unenhanced screening MRI of the brain Of the survivors 164 had been treated for acute lymphoblastic ALL 125 received CRT and 55 for HL none received CRT MRI examinations were reviewed and systematically coded by a single neuroradiologist Demographic and treatment characteristics were compared for survivors with and without subsequent neoplasms Nineteen of the 219 survivors 8.7 had a total of 31 subsequent intracranial neoplasms identified by neuroimaging at a median time of 25 years range 12-46 years from diagnosis All neoplasms occurred after CRT except for a single vestibular schwannoma within the radiation field in a HL survivor The prevalence of subsequent neoplasms after CRT exposure was 14.4 18 of 125 By noncontrast MRI intracranial neoplasms were most suggestive of meningiomas Most patients presented with no specific localizing neurological complaints In addition to the schwannoma six tumors were resected based on results of MRI screening all of which were meningiomas on histologic review Unenhanced brain MRI of long-term survivors of childhood cancer detected a substantial number of intracranial neoplasms Screening for early detection of intracranial neoplasms among aging survivors of childhood cancer who received CRT should be evaluated The high prevalence of incidentally detected subsequent intracranial neoplasms after CRT in long-term survivors of childhood cancer and the minimal symptoms reported by those with intracranial tumors in our study indicate that brain MRI screening of long-term survivors who received CRT may be warranted Prospective studies of such screening are needed,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,"[332, 1, 864, 12, 32, 28, 35, 101, 43, 1, 931, 706, 1179, 4, 319, 337, 332, 1, 864, 441, 73, 5, 2, 187, 2565, 121, 36, 1089, 479, 23920, 1484, 1535, 270, 704, 1, 3, 342, 21, 661, 638, 1, 2089, 1179, 6, 963, 2958, 123, 6679, 332, 1, 864, 12, 208, 23920, 453, 704, 1, 3, 342, 1, 3, 332, 5279, 42, 85, 73, 9, 286, 1275, 62, 1731, 103, 1089, 2, 614, 9, 1718, 1292, 103, 1089, 704, 4209, 11, 446, 2, 3390, 8259, 20, 8, 226, 21256, 1540, 2, 24, 374, 11, 72, 9, 332, 5, 2, 187, 706, 1179, 3498, 1, 3, 6679, 332, 66, 67, 42, 8, 181, 1, 456, 706, 2089, 1179, 108, 20, 7468, 28, 8, 52, 98, 1, 243, 60, 184, 133, 641, 60, 29, 147, 62, 1179, 489, 50, 1089, 2187, 9, 8, 226, 9633, 9601, 262, 3, 121, 1067, 4, 8, 1718, 2628, 3, 1078, 1, 706, 1179, 50, 1089, 645, 10, 213, 39, 203, 1, 1731, 20, 35381, 704, 2089, 1179, 11, 96, 3832, 1, 3718, 96, 7, 917, 5, 77, 112, 14384, 3622, 6938, 4, 352, 6, 3, 9601, 437, 57, 11, 1133, 90, 23, 99, 1, 704, 453, 62, 1, 92, 11, 3718, 23, 884, 206, 23920, 342, 704, 1, 319, 337, 332, 1, 864, 12, 530, 8, 1281, 207, 1, 2089, 1179, 453, 9, 191, 638, 1, 2089, 1179, 107, 4220, 332, 1, 864, 12, 54, 103, 1089, 257, 40, 194, 3, 64, 1078, 1, 5925, 530, 706, 2089, 1179, 50, 1089, 4, 319, 337, 332, 1, 864, 12, 2, 3, 1048, 507, 210, 20, 135, 5, 2089, 57, 4, 114, 45, 1008, 17, 342, 704, 453, 1, 319, 337, 332, 54, 103, 1089, 68, 40, 1197, 482, 94, 1, 225, 453, 32, 575]",2010.0,24488818,63
HPV-associated lung cancers: an international pooled analysis.,Carcinogenesis,Carcinogenesis,2014-02-12,"Human papillomavirus (HPV) is the etiologic risk factor for cervical cancer. Some studies have suggested an association with a subset of lung tumors, but the etiologic link has not been firmly established. We performed an international pooled analysis of cross-sectional studies (27 datasets, n = 3249 patients) to evaluate HPV DNA prevalence in lung cancer and to investigate viral presence according to clinical and demographic characteristics. HPV16/18 were the most commonly detected, but with substantial variation in viral prevalence between geographic regions. The highest prevalence of HPV16/18 was observed in South and Central America, followed by Asia, North America and Europe (adjusted prevalence rates = 22, 5, 4 and 3%, respectively). Higher HPV16 prevalence was noted in each geographic region compared with HPV18, except in North America. HPV16/18-positive lung cancer was less likely observed among White race (adjusted odds ratio [OR] = 0.33, 95% confidence interval [CI] = 0.12-0.90), whereas no associations were observed with gender, smoking history, age, histology or stage. Comparisons between tumor and normal lung tissue show that HPV was more likely to be present in lung cancer rather than normal lung tissues (OR = 3.86, 95% CI = 2.87-5.19). Among a subset of patients with HPV16-positive tumors, integration was primarily among female patients (93%, 13/14), while the physical status in male cases (N = 14) was inconsistent. Our findings confirm that HPV DNA is present in a small fraction of lung tumors, with large geographic variations. Further comprehensive analysis is needed to assess whether this association reflects a causal relationship.",Journal Article,2169.0,38.0,Human papillomavirus HPV is the etiologic risk factor for cancer Some studies have suggested an association with a subset of tumors but the etiologic link has not been firmly established We performed an international pooled analysis of cross-sectional studies 27 datasets n 3249 patients to evaluate HPV DNA prevalence in cancer and to investigate viral presence according to clinical and demographic characteristics HPV16/18 were the most commonly detected but with substantial variation in viral prevalence between geographic regions The highest prevalence of HPV16/18 was observed in South and Central America followed by Asia North America and Europe adjusted prevalence rates 22 5 4 and 3 respectively Higher HPV16 prevalence was noted in each geographic region compared with HPV18 except in North America HPV16/18-positive cancer was less likely observed among White race adjusted odds ratio OR 0.33 95 confidence interval CI 0.12-0.90 whereas no associations were observed with gender smoking history age histology or stage Comparisons between tumor and normal tissue show that HPV was more likely to be present in cancer rather than normal tissues OR 3.86 95 CI 2.87-5.19 Among a subset of patients with HPV16-positive tumors integration was primarily among female patients 93 13/14 while the physical status in male cases N 14 was inconsistent Our findings confirm that HPV DNA is present in a small fraction of tumors with large geographic variations Further comprehensive analysis is needed to assess whether this association reflects a causal relationship,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 3242, 933, 16, 3, 6604, 43, 161, 9, 12, 476, 94, 47, 1148, 35, 248, 5, 8, 697, 1, 57, 84, 3, 6604, 3460, 71, 44, 85, 12971, 635, 21, 173, 35, 944, 1830, 65, 1, 1383, 2832, 94, 428, 3455, 78, 40615, 7, 6, 376, 933, 261, 1078, 4, 12, 2, 6, 963, 1667, 463, 768, 6, 38, 2, 1540, 374, 4048, 203, 11, 3, 96, 841, 530, 84, 5, 1281, 1380, 4, 1667, 1078, 59, 3466, 1374, 3, 1076, 1078, 1, 4048, 203, 10, 164, 4, 5452, 2, 854, 4010, 370, 20, 5958, 2669, 4010, 2, 3934, 586, 1078, 151, 350, 33, 39, 2, 27, 106, 142, 4048, 1078, 10, 1051, 4, 296, 3466, 1053, 72, 5, 33514, 2187, 4, 2669, 4010, 4048, 203, 109, 12, 10, 299, 322, 164, 107, 886, 1047, 586, 610, 197, 15, 13, 466, 48, 307, 268, 58, 13, 133, 13, 424, 547, 77, 685, 11, 164, 5, 1632, 979, 532, 89, 784, 15, 82, 2213, 59, 30, 2, 295, 246, 514, 17, 933, 10, 80, 322, 6, 40, 364, 4, 12, 1832, 76, 295, 742, 15, 27, 868, 48, 58, 18, 912, 33, 326, 107, 8, 697, 1, 7, 5, 4048, 109, 57, 2676, 10, 1561, 107, 1061, 7, 966, 233, 213, 369, 3, 900, 156, 4, 1045, 140, 78, 213, 10, 4923, 114, 272, 1843, 17, 933, 261, 16, 364, 4, 8, 302, 1509, 1, 57, 5, 375, 3466, 2293, 195, 949, 65, 16, 575, 6, 423, 317, 26, 248, 5224, 8, 5163, 858]",1567.0,24523449,268
Improved survival with bevacizumab in advanced cervical cancer.,The New England journal of medicine,N. Engl. J. Med.,2014-02-01,"Vascular endothelial growth factor (VEGF) promotes angiogenesis, a mediator of disease progression in cervical cancer. Bevacizumab, a humanized anti-VEGF monoclonal antibody, has single-agent activity in previously treated, recurrent disease. Most patients in whom recurrent cervical cancer develops have previously received cisplatin with radiation therapy, which reduces the effectiveness of cisplatin at the time of recurrence. We evaluated the effectiveness of bevacizumab and nonplatinum combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer. Using a 2-by-2 factorial design, we randomly assigned 452 patients to chemotherapy with or without bevacizumab at a dose of 15 mg per kilogram of body weight. Chemotherapy consisted of cisplatin at a dose of 50 mg per square meter of body-surface area, plus paclitaxel at a dose of 135 or 175 mg per square meter or topotecan at a dose of 0.75 mg per square meter on days 1 to 3, plus paclitaxel at a dose of 175 mg per square meter on day 1. Cycles were repeated every 21 days until disease progression, the development of unacceptable toxic effects, or a complete response was documented. The primary end point was overall survival; a reduction of 30% in the hazard ratio for death was considered clinically important. Groups were well balanced with respect to age, histologic findings, performance status, previous use or nonuse of a radiosensitizing platinum agent, and disease status. Topotecan-paclitaxel was not superior to cisplatin-paclitaxel (hazard ratio for death, 1.20). With the data for the two chemotherapy regimens combined, the addition of bevacizumab to chemotherapy was associated with increased overall survival (17.0 months vs. 13.3 months; hazard ratio for death, 0.71; 98% confidence interval, 0.54 to 0.95; P=0.004 in a one-sided test) and higher response rates (48% vs. 36%, P=0.008). Bevacizumab, as compared with chemotherapy alone, was associated with an increased incidence of hypertension of grade 2 or higher (25% vs. 2%), thromboembolic events of grade 3 or higher (8% vs. 1%), and gastrointestinal fistulas of grade 3 or higher (3% vs. 0%). The addition of bevacizumab to combination chemotherapy in patients with recurrent, persistent, or metastatic cervical cancer was associated with an improvement of 3.7 months in median overall survival. (Funded by the National Cancer Institute; GOG 240 ClinicalTrials.gov number, NCT00803062.).","Clinical Trial, Phase III",2180.0,,Vascular endothelial growth factor VEGF promotes angiogenesis a mediator of disease progression in cancer Bevacizumab a humanized anti-VEGF monoclonal antibody has single-agent activity in previously treated recurrent disease Most patients in whom recurrent cancer develops have previously received cisplatin with radiation therapy which reduces the effectiveness of cisplatin at the time of recurrence We evaluated the effectiveness of bevacizumab and nonplatinum combination chemotherapy in patients with recurrent persistent or metastatic cancer Using a 2-by-2 factorial design we randomly assigned 452 patients to chemotherapy with or without bevacizumab at a dose of 15 mg per kilogram of body weight Chemotherapy consisted of cisplatin at a dose of 50 mg per square meter of body-surface area plus paclitaxel at a dose of 135 or 175 mg per square meter or topotecan at a dose of 0.75 mg per square meter on days 1 to 3 plus paclitaxel at a dose of 175 mg per square meter on day 1 Cycles were repeated every 21 days until disease progression the development of unacceptable toxic effects or a complete response was documented The primary end point was overall survival a reduction of 30 in the hazard ratio for death was considered clinically important Groups were well balanced with respect to age histologic findings performance status previous use or nonuse of a radiosensitizing platinum agent and disease status Topotecan-paclitaxel was not superior to cisplatin-paclitaxel hazard ratio for death 1.20 With the data for the two chemotherapy regimens combined the addition of bevacizumab to chemotherapy was associated with increased overall survival 17.0 months vs. 13.3 months hazard ratio for death 0.71 98 confidence interval 0.54 to 0.95 P=0.004 in a one-sided test and higher response rates 48 vs. 36 P=0.008 Bevacizumab as compared with chemotherapy alone was associated with an increased incidence of hypertension of grade 2 or higher 25 vs. 2 thromboembolic events of grade 3 or higher 8 vs. 1 and fistulas of grade 3 or higher 3 vs. 0 The addition of bevacizumab to combination chemotherapy in patients with recurrent persistent or metastatic cancer was associated with an improvement of 3.7 months in median overall survival Funded by the National Cancer Institute GOG 240 ClinicalTrials.gov number NCT00803062,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[756, 845, 129, 161, 618, 2148, 1056, 8, 3810, 1, 34, 91, 4, 12, 599, 8, 3619, 312, 618, 848, 548, 71, 226, 420, 128, 4, 373, 73, 387, 34, 96, 7, 4, 953, 387, 12, 4734, 47, 373, 103, 540, 5, 121, 36, 92, 2389, 3, 1236, 1, 540, 28, 3, 98, 1, 146, 21, 194, 3, 1236, 1, 599, 2, 10815, 150, 56, 4, 7, 5, 387, 1882, 15, 113, 12, 75, 8, 18, 20, 18, 11613, 771, 21, 1108, 896, 12638, 7, 6, 56, 5, 15, 187, 599, 28, 8, 61, 1, 167, 81, 379, 6543, 1, 642, 924, 56, 1695, 1, 540, 28, 8, 61, 1, 212, 81, 379, 3219, 8591, 1, 642, 1255, 965, 349, 490, 28, 8, 61, 1, 3978, 15, 3300, 81, 379, 3219, 8591, 15, 2129, 28, 8, 61, 1, 13, 481, 81, 379, 3219, 8591, 23, 162, 14, 6, 27, 349, 490, 28, 8, 61, 1, 3300, 81, 379, 3219, 8591, 23, 218, 14, 410, 11, 2113, 454, 239, 162, 1100, 34, 91, 3, 193, 1, 3215, 1812, 176, 15, 8, 236, 51, 10, 1405, 3, 86, 396, 741, 10, 63, 25, 8, 628, 1, 201, 4, 3, 360, 197, 9, 273, 10, 515, 505, 305, 271, 11, 149, 4115, 5, 2184, 6, 89, 884, 272, 528, 156, 698, 119, 15, 18509, 1, 8, 8384, 828, 420, 2, 34, 156, 2129, 490, 10, 44, 1123, 6, 540, 490, 360, 197, 9, 273, 14, 179, 5, 3, 74, 9, 3, 100, 56, 472, 397, 3, 352, 1, 599, 6, 56, 10, 41, 5, 101, 63, 25, 269, 13, 53, 105, 233, 27, 53, 360, 197, 9, 273, 13, 792, 1096, 307, 268, 13, 667, 6, 13, 48, 19, 13, 1520, 4, 8, 104, 1689, 412, 2, 142, 51, 151, 576, 105, 511, 19, 13, 2155, 599, 22, 72, 5, 56, 279, 10, 41, 5, 35, 101, 287, 1, 1824, 1, 88, 18, 15, 142, 243, 105, 18, 4703, 281, 1, 88, 27, 15, 142, 66, 105, 14, 2, 13244, 1, 88, 27, 15, 142, 27, 105, 13, 3, 352, 1, 599, 6, 150, 56, 4, 7, 5, 387, 1882, 15, 113, 12, 10, 41, 5, 35, 767, 1, 27, 67, 53, 4, 52, 63, 25, 3827, 20, 3, 657, 12, 1377, 4760, 4263, 1252, 1239, 207, 40623]",2331.0,24552320,177
Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies.,Gynecologic oncology,Gynecol. Oncol.,2014-02-28,"Our primary objective was to assess the detection rate of sentinel lymph nodes (SLNs) using indocyanine green (ICG) and near-infrared (NIR) fluorescence imaging for uterine and cervical malignancies. NIR fluorescence imaging for the robotic platform was obtained at our institution in 12/2011. We identified all cases planned for SLN mapping using fluorescence imaging from 12/2011-4/2013. Intracervical ICG was the fluorophobe in all cases. Four cc (1.25mg/mL) of ICG was injected into the cervix alone divided into the 3- and 9-o'clock positions, with 1 cc deep into the stroma and 1 cc submucosally before initiating laparoscopic entry. Blue dye was concurrently injected in some cases. Two hundred twenty-seven cases were performed. Median age was 60 years (range, 28-90 years). Median BMI was 30.2 kg/m(2) (range, 18-60 kg/m(2)). The median SLN count was 3 (range, 1-23). An SLN was identified in 216 cases (95%), with bilateral pelvic mapping in 179 (79%). An aortic SLN was identified in 21 (10%) of the 216 mapped cases. When ICG alone was used to map cases, 188/197 patients mapped, for a 95% detection rate compared to 93% (28/30) in cases in which both dyes were used (P=NS). Bilateral mapping was seen in 156/197 (79%) ICG-only cases and 23/30 (77%) ICG and blue dye cases (P=NS). NIR fluorescence imaging with intracervical ICG injection using the robotic platform has a high bilateral SLN detection rate and appears favorable to using blue dye alone and/or other modalities. Combined use of ICG and blue dye appears unnecessary.",Journal Article,2153.0,132.0,Our primary objective was to assess the detection rate of sentinel lymph nodes SLNs using indocyanine green ICG and near-infrared NIR fluorescence imaging for and malignancies NIR fluorescence imaging for the robotic platform was obtained at our institution in 12/2011 We identified all cases planned for SLN mapping using fluorescence imaging from 12/2011-4/2013 Intracervical ICG was the fluorophobe in all cases Four cc 1.25mg/mL of ICG was injected into the cervix alone divided into the 3- and 9-o'clock positions with 1 cc deep into the stroma and 1 cc submucosally before initiating laparoscopic entry Blue dye was concurrently injected in some cases Two hundred twenty-seven cases were performed Median age was 60 years range 28-90 years Median BMI was 30.2 kg/m 2 range 18-60 kg/m 2 The median SLN count was 3 range 1-23 An SLN was identified in 216 cases 95 with bilateral pelvic mapping in 179 79 An aortic SLN was identified in 21 10 of the 216 mapped cases When ICG alone was used to map cases 188/197 patients mapped for a 95 detection rate compared to 93 28/30 in cases in which both dyes were used P=NS Bilateral mapping was seen in 156/197 79 ICG-only cases and 23/30 77 ICG and blue dye cases P=NS NIR fluorescence imaging with intracervical ICG injection using the robotic platform has a high bilateral SLN detection rate and appears favorable to using blue dye alone and/or other modalities Combined use of ICG and blue dye appears unnecessary,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[114, 86, 461, 10, 6, 423, 3, 638, 116, 1, 1323, 263, 502, 2642, 75, 18903, 4658, 9118, 2, 1829, 6765, 6479, 1591, 270, 9, 2, 441, 6479, 1591, 270, 9, 3, 2895, 2243, 10, 683, 28, 114, 731, 4, 133, 1132, 21, 108, 62, 140, 1465, 9, 1099, 2568, 75, 1591, 270, 29, 133, 1132, 39, 1346, 33970, 9118, 10, 3, 64006, 4, 62, 140, 294, 1951, 14, 15905, 542, 1, 9118, 10, 2651, 237, 3, 3629, 279, 2176, 237, 3, 27, 2, 83, 28043, 7134, 5, 14, 1951, 2369, 237, 3, 2477, 2, 14, 1951, 37075, 348, 2637, 1964, 3001, 3352, 3796, 10, 3294, 2651, 4, 476, 140, 100, 1128, 737, 648, 140, 11, 173, 52, 89, 10, 335, 60, 184, 339, 424, 60, 52, 1140, 10, 201, 18, 503, 188, 18, 184, 203, 335, 503, 188, 18, 3, 52, 1099, 1276, 10, 27, 184, 14, 382, 35, 1099, 10, 108, 4, 6287, 140, 48, 5, 1607, 1110, 2568, 4, 5977, 842, 35, 3938, 1099, 10, 108, 4, 239, 79, 1, 3, 6287, 6224, 140, 198, 9118, 279, 10, 95, 6, 3771, 140, 5664, 6114, 7, 6224, 9, 8, 48, 638, 116, 72, 6, 966, 339, 201, 4, 140, 4, 92, 110, 19011, 11, 95, 19, 4044, 1607, 2568, 10, 527, 4, 5693, 6114, 842, 9118, 158, 140, 2, 382, 201, 849, 9118, 2, 3352, 3796, 140, 19, 4044, 6479, 1591, 270, 5, 33970, 9118, 1754, 75, 3, 2895, 2243, 71, 8, 64, 1607, 1099, 638, 116, 2, 1233, 913, 6, 75, 3352, 3796, 279, 2, 15, 127, 1558, 397, 119, 1, 9118, 2, 3352, 3796, 1233, 4224]",1463.0,24582865,826
Human papillomavirus status of head and neck cancer as determined in cytologic specimens using the hybrid-capture 2 assay.,Oral oncology,Oral Oncol.,2014-03-12,"A standardized assay to determine the HPV status of head and neck squamous cell carcinoma (HNSCC) specimens has not yet been established, particularly for cytologic samples. The goal of this study was to determine whether the hybrid capture-2 (HC-2) assay, already widely used for the detection of high risk HPV in cervical brushings, is applicable to cytologic specimens obtained from patients with suspected HNSCCs. Fine needle aspirates (FNA) of cervical lymph nodes were pre-operatively obtained from patients with suspected HNSCCs and evaluated for the presence of HPV using the HC-2 assay. HPV analysis was performed on the corresponding resected tissue specimens using p16 immunohistochemistry (IHC) and HR-HPV in situ hybridization (ISH). A cost analysis was performed using the Center for Medicare & Medicaid Services. HPV status of the cervical lymph node metastases was correctly classified using the HC-2 assay in 84% (21/25) of cases. Accuracy was improved to 100% when cytologic evaluation confirmed the presence of cancer cells in the test samples. The estimated cost savings to CMS using the HC-2 assay ranged from $113.74 to $364.63 per patient. HC-2 is a reliable method for determining the HPV status of HNSCCs. Its application to HNSCCs may reduce costs by helping to localize the primary site during the diagnostic work-up as well as decrease the interval time of determining the HPV status which would be relevant for providing prognostic information to the patient as well as determining eligibility for clinical trials targeting this unique patient population.",Journal Article,2141.0,23.0,A standardized assay to determine the HPV status of head and squamous cell carcinoma HNSCC specimens has not yet been established particularly for cytologic samples The goal of this study was to determine whether the hybrid capture-2 HC-2 assay already widely used for the detection of high risk HPV in brushings is applicable to cytologic specimens obtained from patients with suspected HNSCCs Fine needle aspirates FNA of lymph nodes were pre-operatively obtained from patients with suspected HNSCCs and evaluated for the presence of HPV using the HC-2 assay HPV analysis was performed on the corresponding resected tissue specimens using p16 immunohistochemistry IHC and HR-HPV in situ hybridization ISH A cost analysis was performed using the Center for Medicare Medicaid Services HPV status of the lymph node metastases was correctly classified using the HC-2 assay in 84 21/25 of cases Accuracy was improved to 100 when cytologic evaluation confirmed the presence of cancer cells in the test samples The estimated cost savings to CMS using the HC-2 assay ranged from 113.74 to 364.63 per patient HC-2 is a reliable method for determining the HPV status of HNSCCs Its application to HNSCCs may reduce costs by helping to localize the primary site during the diagnostic work-up as well as decrease the interval time of determining the HPV status which would be relevant for providing prognostic information to the patient as well as determining eligibility for clinical trials targeting this unique patient population,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[8, 1670, 719, 6, 223, 3, 933, 156, 1, 718, 2, 691, 31, 134, 1209, 623, 71, 44, 1145, 85, 635, 823, 9, 4195, 347, 3, 1326, 1, 26, 45, 10, 6, 223, 317, 3, 4542, 2891, 18, 7487, 18, 719, 3298, 1792, 95, 9, 3, 638, 1, 64, 43, 933, 4, 14515, 16, 3801, 6, 4195, 623, 683, 29, 7, 5, 2768, 9691, 2924, 2177, 7493, 4064, 1, 263, 502, 11, 671, 9433, 683, 29, 7, 5, 2768, 9691, 2, 194, 9, 3, 463, 1, 933, 75, 3, 7487, 18, 719, 933, 65, 10, 173, 23, 3, 1734, 1133, 246, 623, 75, 1932, 888, 1289, 2, 168, 933, 4, 957, 1554, 6321, 8, 835, 65, 10, 173, 75, 3, 574, 9, 1378, 2843, 2142, 933, 156, 1, 3, 263, 289, 196, 10, 4911, 1373, 75, 3, 7487, 18, 719, 4, 874, 239, 243, 1, 140, 1190, 10, 231, 6, 394, 198, 4195, 451, 557, 3, 463, 1, 12, 37, 4, 3, 412, 347, 3, 661, 835, 7003, 6, 9914, 75, 3, 7487, 18, 719, 1869, 29, 4259, 794, 6, 10106, 676, 379, 69, 7487, 18, 16, 8, 2450, 596, 9, 2196, 3, 933, 156, 1, 9691, 211, 1581, 6, 9691, 68, 969, 1201, 20, 7188, 6, 8031, 3, 86, 606, 190, 3, 752, 1357, 126, 22, 149, 22, 775, 3, 268, 98, 1, 2196, 3, 933, 156, 92, 688, 40, 867, 9, 1736, 177, 487, 6, 3, 69, 22, 149, 22, 2196, 2317, 9, 38, 143, 529, 26, 991, 69, 266]",1521.0,24630260,243
Surgical site infection in women undergoing surgery for gynecologic cancer.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2014-05-01,"The objectives of this study were to describe the rate and predictors of surgical site infection (SSI) after gynecologic cancer surgery and identify any association between SSI and postoperative outcome. Patients with endometrial, cervical, or ovarian cancers from 2005 to 2011 were identified from the American College of Surgeons National Surgical Quality Improvement Program. The extent of surgical intervention was categorized into modified surgical complexity scoring (MSCS) system. Univariate and multivariate logistic regression analyses were used. Odds ratios were adjusted for patient demographics, comorbidities, preoperative laboratory values, and operative factors. Of 6854 patients, 369 (5.4%) were diagnosed with SSI. Surgical site infection after laparotomy was 3.5 times higher compared with minimally invasive surgery (7% vs 2%; P < 0.001). Among laparotomy group, independent predictors of SSI included endometrial cancer diagnosis, obesity, ascites, preoperative anemia, American Society of Anesthesiologists class greater than or equal to 3, MSCS greater than or equal to 3, and perioperative blood transfusion. Among laparoscopic cases, independent predictors of SSI included only preoperative leukocytosis and overweight. For patients with deep or organ space SSI, significant predictors included hypoalbuminemia, preoperative weight loss, respiratory comorbidities, MSCS greater than 4, and perioperative blood transfusion for laparotomy and only preoperative leukocytosis for minimally invasive surgery. Surgical site infection was associated with longer mean hospital stay and higher rate of reoperation, sepsis, and wound dehiscence. Surgical site infection was not associated with increased risk of acute renal failure or 30-day mortality. These findings were consistent in subset of patients with deep or organ space SSI. Seven percent of patients undergoing laparotomy for gynecologic malignancy developed SSI. Surgical site infection is associated with longer hospital stay and more than 5-fold increased risk of reoperation. In this study, we identified several risk factors for developing SSI among gynecologic cancer patients. These findings may contribute toward identification of patients at risk for SSI and the development of strategies to reduce SSI rate and potentially reduce the cost of care in gynecologic cancer surgery.",Journal Article,2091.0,24.0,The objectives of this study were to describe the rate and predictors of surgical site infection SSI after gynecologic cancer surgery and identify any association between SSI and postoperative outcome Patients with or cancers from 2005 to 2011 were identified from the American College of Surgeons National Surgical Quality Improvement Program The extent of surgical intervention was categorized into modified surgical complexity scoring MSCS system Univariate and multivariate logistic regression analyses were used Odds ratios were adjusted for patient demographics comorbidities preoperative laboratory values and operative factors Of 6854 patients 369 5.4 were diagnosed with SSI Surgical site infection after laparotomy was 3.5 times higher compared with minimally invasive surgery 7 vs 2 P 0.001 Among laparotomy group independent predictors of SSI included cancer diagnosis obesity ascites preoperative anemia American Society of Anesthesiologists class greater than or equal to 3 MSCS greater than or equal to 3 and perioperative blood transfusion Among laparoscopic cases independent predictors of SSI included only preoperative leukocytosis and overweight For patients with deep or organ space SSI significant predictors included hypoalbuminemia preoperative weight loss respiratory comorbidities MSCS greater than 4 and perioperative blood transfusion for laparotomy and only preoperative leukocytosis for minimally invasive surgery Surgical site infection was associated with longer mean hospital stay and higher rate of reoperation sepsis and wound dehiscence Surgical site infection was not associated with increased risk of acute failure or 30-day mortality These findings were consistent in subset of patients with deep or organ space SSI Seven percent of patients undergoing laparotomy for gynecologic malignancy developed SSI Surgical site infection is associated with longer hospital stay and more than 5-fold increased risk of reoperation In this study we identified several risk factors for developing SSI among gynecologic cancer patients These findings may contribute toward identification of patients at risk for SSI and the development of strategies to reduce SSI rate and potentially reduce the cost of care in gynecologic cancer surgery,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 2409, 1, 26, 45, 11, 6, 897, 3, 116, 2, 674, 1, 221, 606, 930, 6837, 50, 1512, 12, 152, 2, 255, 500, 248, 59, 6837, 2, 573, 228, 7, 5, 15, 163, 29, 1242, 6, 1132, 11, 108, 29, 3, 597, 2979, 1, 1613, 657, 221, 372, 767, 1243, 3, 1039, 1, 221, 788, 10, 2320, 237, 1230, 221, 3082, 2504, 4460, 398, 880, 2, 331, 812, 320, 318, 11, 95, 610, 1137, 11, 586, 9, 69, 2221, 1909, 498, 1624, 1030, 2, 1208, 130, 1, 64135, 7, 8718, 33, 39, 11, 265, 5, 6837, 221, 606, 930, 50, 3274, 10, 27, 33, 1072, 142, 72, 5, 2144, 416, 152, 67, 105, 18, 19, 13, 144, 107, 3274, 87, 306, 674, 1, 6837, 159, 12, 147, 1661, 3819, 498, 1545, 597, 1174, 1, 9558, 1040, 378, 76, 15, 2997, 6, 27, 4460, 378, 76, 15, 2997, 6, 27, 2, 1547, 315, 2785, 107, 1964, 140, 306, 674, 1, 6837, 159, 158, 498, 7463, 2, 3566, 9, 7, 5, 2369, 15, 1259, 3865, 6837, 93, 674, 159, 11667, 498, 924, 407, 2718, 1909, 4460, 378, 76, 39, 2, 1547, 315, 2785, 9, 3274, 2, 158, 498, 7463, 9, 2144, 416, 152, 221, 606, 930, 10, 41, 5, 589, 313, 702, 2020, 2, 142, 116, 1, 5077, 4227, 2, 2689, 11811, 221, 606, 930, 10, 44, 41, 5, 101, 43, 1, 286, 496, 15, 201, 218, 282, 46, 272, 11, 925, 4, 697, 1, 7, 5, 2369, 15, 1259, 3865, 6837, 648, 714, 1, 7, 479, 3274, 9, 1512, 710, 276, 6837, 221, 606, 930, 16, 41, 5, 589, 702, 2020, 2, 80, 76, 33, 1116, 101, 43, 1, 5077, 4, 26, 45, 21, 108, 392, 43, 130, 9, 931, 6837, 107, 1512, 12, 7, 46, 272, 68, 1248, 1317, 911, 1, 7, 28, 43, 9, 6837, 2, 3, 193, 1, 422, 6, 969, 6837, 116, 2, 751, 969, 3, 835, 1, 165, 4, 1512, 12, 152]",2263.0,24681712,257
Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy.,Journal of clinical microbiology,J. Clin. Microbiol.,2014-04-09,"High-risk human papillomavirus (hrHPV) testing is now being introduced as a potential primary screening test for improved detection of cervical precancer and cancer. Current U.S. Food and Drug Administration-approved tests are batch tests that take several hours to complete. A rapid, non-batch test might permit point-of-care (POC) testing, which can facilitate same-day screen and management strategies. For a non-batch, random-access platform (GeneXpert; Cepheid, Sunnyvale, CA), a prototype hrHPV assay (Xpert) has been developed where testing for 14 hrHPV types can be completed in 1 h. In the first clinical evaluation, Xpert was compared to two validated hrHPV tests, the cobas HPV test (cobas, Roche Molecular Systems) and Hybrid Capture 2 (hc2, Qiagen), and to histologic outcomes using specimens from colposcopy referral populations at 7 clinical sites in the United States (n = 697). The sensitivity of Xpert for cervical intraepithelial neoplasia grade 2 or more severe diagnoses (CIN2+) (n = 141) was equal to that of cobas (90.8% versus 90.8%, P = 1) and greater than that of hc2 (90.8% versus 81.6%, P = 0.004). Xpert was more specific than cobas (42.6% versus 39.6%, P = 0.02) and less specific than hc2 (42.6% versus 47.7%, P < 0.001). Similar results were observed for cervical intraepithelial neoplasia grade 3 or higher (CIN3+) (n = 91). HPV16 detection by Xpert identified 41.8% of the CIN2+ specimens with a positive predictive value (PPV) of 54.6%. By comparison, HPV16 detection by cobas identified 42.6% of the CIN2+ specimens with a PPV of 55.0%. hrHPV detection by the Xpert demonstrated excellent clinical performance for identifying women with CIN2+ and CIN3+ that was comparable to that of currently available clinically validated tests. ",Comparative Study,2113.0,39.0,High-risk human papillomavirus hrHPV testing is now being introduced as a potential primary screening test for improved detection of precancer and cancer Current U.S. Food and Drug Administration-approved tests are batch tests that take several hours to complete A rapid non-batch test might permit point-of-care POC testing which can facilitate same-day screen and management strategies For a non-batch random-access platform GeneXpert Cepheid Sunnyvale CA a prototype hrHPV assay Xpert has been developed where testing for 14 hrHPV types can be completed in 1 h. In the first clinical evaluation Xpert was compared to two validated hrHPV tests the cobas HPV test cobas Roche Molecular Systems and Hybrid Capture 2 hc2 Qiagen and to histologic outcomes using specimens from colposcopy referral populations at 7 clinical sites in the United States n 697 The sensitivity of Xpert for intraepithelial neoplasia grade 2 or more severe diagnoses CIN2+ n 141 was equal to that of cobas 90.8 versus 90.8 P 1 and greater than that of hc2 90.8 versus 81.6 P 0.004 Xpert was more specific than cobas 42.6 versus 39.6 P 0.02 and less specific than hc2 42.6 versus 47.7 P 0.001 Similar results were observed for intraepithelial neoplasia grade 3 or higher CIN3+ n 91 HPV16 detection by Xpert identified 41.8 of the CIN2+ specimens with a positive predictive value PPV of 54.6 By comparison HPV16 detection by cobas identified 42.6 of the CIN2+ specimens with a PPV of 55.0 hrHPV detection by the Xpert demonstrated excellent clinical performance for identifying women with CIN2+ and CIN3+ that was comparable to that of currently available clinically validated tests,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[64, 43, 171, 3242, 17544, 471, 16, 1134, 486, 3955, 22, 8, 174, 86, 453, 412, 9, 231, 638, 1, 12380, 2, 12, 291, 1767, 695, 1773, 2, 234, 634, 850, 895, 32, 18009, 895, 17, 3585, 392, 1459, 6, 236, 8, 1321, 220, 18009, 412, 822, 5634, 741, 1, 165, 12224, 471, 92, 122, 1876, 827, 218, 2413, 2, 284, 422, 9, 8, 220, 18009, 2324, 1655, 2243, 40680, 48296, 26466, 1568, 8, 8743, 17544, 719, 20039, 71, 85, 276, 1257, 471, 9, 213, 17544, 630, 122, 40, 781, 4, 14, 555, 4, 3, 157, 38, 451, 20039, 10, 72, 6, 100, 938, 17544, 895, 3, 12053, 933, 412, 12053, 9777, 219, 1530, 2, 4542, 2891, 18, 16516, 22599, 2, 6, 884, 123, 75, 623, 29, 9946, 2096, 1184, 28, 67, 38, 633, 4, 3, 1088, 907, 78, 11989, 3, 485, 1, 20039, 9, 4153, 2298, 88, 18, 15, 80, 905, 2403, 12870, 78, 4379, 10, 2997, 6, 17, 1, 12053, 424, 66, 185, 424, 66, 19, 14, 2, 378, 76, 17, 1, 16516, 424, 66, 185, 865, 49, 19, 13, 1520, 20039, 10, 80, 112, 76, 12053, 595, 49, 185, 587, 49, 19, 13, 588, 2, 299, 112, 76, 16516, 595, 49, 185, 662, 67, 19, 13, 144, 288, 99, 11, 164, 9, 4153, 2298, 88, 27, 15, 142, 10346, 78, 970, 4048, 638, 20, 20039, 108, 605, 66, 1, 3, 12870, 623, 5, 8, 109, 464, 549, 4998, 1, 667, 49, 20, 1155, 4048, 638, 20, 12053, 108, 595, 49, 1, 3, 12870, 623, 5, 8, 4998, 1, 614, 13, 17544, 638, 20, 3, 20039, 264, 1503, 38, 528, 9, 1386, 117, 5, 12870, 2, 10346, 17, 10, 1279, 6, 17, 1, 694, 390, 505, 938, 895]",1655.0,24719440,208
Normalization of lymphocyte count after high ablative dose of I-131 in a patient with chronic lymphoid leukemia and secondary papillary carcinoma of the thyroid. Case report.,"Einstein (Sao Paulo, Brazil)",Einstein (Sao Paulo),,"The authors report the case of a 70-year-old male patient with chronic lymphoid leukemia who presented subsequently a papillary carcinoma of the thyroid with metastases to regional lymph nodes. The patient was treated with surgical thyroidectomy with regional and cervical lymph node excision and radioiodine therapy (I-131). The protocolar control scintigraphy 4 days after the radioactive dose showed I-131 uptake in both axillae and even in the inguinal regions. PET/CT showed faint FDG-F-18 uptake in one lymph node of the left axilla. An ultrasound guided fine needle biopsy of this lymph node identified by I-131 SPECT/CT and FDG-F-18 PET/CT revealed lymphoma cells and was negative for thyroid tissue and thyroglobulin content. The sequential blood counts done routinely after radiation treatment showed a marked fall until return to normal values of leucocytes and lymphocytes (absolute and relative), which were still normal in the last control 19 months after the radioiodine administration. Chest computed tomography showed a decrease in size of axillary and para-aortic lymph nodes. By immunohistochemistry, cells of the lymphoid B lineage decreased from 52% before radioiodine therapy to 5% after the procedure. The authors speculate about a possible sodium iodide symporter expression by the cells of this lymphoma, similar to some other non-thyroid tumors, such as breast cancer cells. ",Case Reports,,0.0,The authors report the case of a 70-year-old male patient with chronic lymphoid who presented subsequently a papillary carcinoma of the with metastases to regional lymph nodes The patient was treated with surgical thyroidectomy with regional and lymph node excision and radioiodine therapy I-131 The protocolar control scintigraphy 4 days after the radioactive dose showed I-131 uptake in both axillae and even in the inguinal regions PET/CT showed faint FDG-F-18 uptake in one lymph node of the left axilla An ultrasound guided fine needle biopsy of this lymph node identified by I-131 SPECT/CT and FDG-F-18 PET/CT revealed cells and was negative for tissue and thyroglobulin content The sequential blood counts done routinely after radiation treatment showed a marked fall until return to normal values of leucocytes and lymphocytes absolute and relative which were still normal in the last control 19 months after the radioiodine administration Chest computed tomography showed a decrease in size of axillary and para-aortic lymph nodes By immunohistochemistry cells of the lymphoid B lineage decreased from 52 before radioiodine therapy to 5 after the procedure The authors speculate about a possible sodium iodide symporter expression by the cells of this similar to some other non-thyroid tumors such as cancer cells,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[3, 738, 414, 3, 473, 1, 8, 431, 111, 1095, 1045, 69, 5, 442, 2303, 54, 917, 1611, 8, 1796, 134, 1, 3, 5, 196, 6, 951, 263, 502, 3, 69, 10, 73, 5, 221, 5949, 5, 951, 2, 263, 289, 1366, 2, 7211, 36, 70, 2229, 3, 64203, 182, 7577, 39, 162, 50, 3, 4741, 61, 224, 70, 2229, 1135, 4, 110, 26121, 2, 871, 4, 3, 4907, 1374, 495, 425, 224, 24755, 1285, 1068, 203, 1135, 4, 104, 263, 289, 1, 3, 1712, 5053, 35, 1945, 1808, 2924, 2177, 411, 1, 26, 263, 289, 108, 20, 70, 2229, 5817, 425, 2, 1285, 1068, 203, 495, 425, 553, 37, 2, 10, 199, 9, 246, 2, 8978, 2457, 3, 1787, 315, 1911, 1822, 3066, 50, 121, 24, 224, 8, 2003, 6712, 1100, 4656, 6, 295, 1030, 1, 40419, 2, 1594, 1766, 2, 580, 92, 11, 1234, 295, 4, 3, 1060, 182, 326, 53, 50, 3, 7211, 634, 1662, 1220, 872, 224, 8, 775, 4, 444, 1, 1210, 2, 4615, 3938, 263, 502, 20, 888, 37, 1, 3, 2303, 132, 2542, 340, 29, 653, 348, 7211, 36, 6, 33, 50, 3, 1299, 3, 738, 11778, 545, 8, 899, 4682, 8456, 20641, 55, 20, 3, 37, 1, 26, 288, 6, 476, 127, 220, 11260, 57, 225, 22, 12, 37]",1322.0,24728254,115
The feasibility and safety of same-day discharge after robotic-assisted hysterectomy alone or with other procedures for benign and malignant indications.,Gynecologic oncology,Gynecol. Oncol.,2014-04-13,"This study aimed to report the feasibility and safety of same-day discharge after robotic-assisted hysterectomy. Same-day discharge after robotic-assisted hysterectomy was initiated 07/2010. All cases from then through 12/2012 were captured for quality assessment monitoring. The distance from the hospital to patients' homes was determined using http://maps.google.com. Procedures were categorized as simple (TLH+/-BSO) or complex (TLH+/-BSO with sentinel node mapping, pelvic and/or aortic nodal dissection, appendectomy, or omentectomy). Urgent care center (UCC) visits and readmissions within 30days of surgery were captured, and time to the visit was determined from the initial surgical date. Same-day discharge was planned in 200 cases. Median age was 52years (range, 30-78), BMI was 26.8kg/m(2) (range, 17.4-56.8), and ASA was class 2 (range, 1-3). Median distance traveled was 31.5miles (range, 0.2-149). Procedures were simple in 109 (55%) and complex in 91 (45%) cases. The indication for surgery was: endometrial cancer (n=82; 41%), ovarian cancer (n=5; 2.5%), cervical cancer (n=8; 4%), and non-gynecologic cancer/benign (n=105; 53%). One hundred fifty-seven (78%) had successful same-day discharge. Median time for discharge for these cases was 4.8h (range, 2.4-10.3). Operative time, case ending before 6pm, and use of intraoperative ketorolac were associated with successful same-day discharge. UCC visits occurred in 8/157 (5.1%) same-day discharge cases compared to 5/43 (11.6%) requiring admission (P=.08). Readmission was necessary in 4/157 (2.5%) same-day discharge cases compared to 3/43 (7.0%) requiring admission (P=.02). Same-day discharge after robotic-assisted hysterectomy for benign and malignant conditions is feasible and safe.",Journal Article,2109.0,36.0,This study aimed to report the feasibility and safety of same-day discharge after robotic-assisted hysterectomy Same-day discharge after robotic-assisted hysterectomy was initiated 07/2010 All cases from then through 12/2012 were captured for quality assessment monitoring The distance from the hospital to patients homes was determined using http //maps.google.com Procedures were categorized as simple TLH+/-BSO or complex TLH+/-BSO with sentinel node mapping pelvic and/or aortic nodal dissection appendectomy or omentectomy Urgent care center UCC visits and readmissions within 30days of surgery were captured and time to the visit was determined from the initial surgical date Same-day discharge was planned in 200 cases Median age was 52years range 30-78 BMI was 26.8kg/m 2 range 17.4-56.8 and ASA was class 2 range 1-3 Median distance traveled was 31.5miles range 0.2-149 Procedures were simple in 109 55 and complex in 91 45 cases The indication for surgery was cancer n=82 41 cancer n=5 2.5 cancer n=8 4 and non-gynecologic cancer/benign n=105 53 One hundred fifty-seven 78 had successful same-day discharge Median time for discharge for these cases was 4.8h range 2.4-10.3 Operative time case ending before 6pm and use of intraoperative ketorolac were associated with successful same-day discharge UCC visits occurred in 8/157 5.1 same-day discharge cases compared to 5/43 11.6 requiring admission P=.08 Readmission was necessary in 4/157 2.5 same-day discharge cases compared to 3/43 7.0 requiring admission P=.02 Same-day discharge after robotic-assisted hysterectomy for benign and malignant conditions is feasible and safe,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[26, 45, 1295, 6, 414, 3, 1437, 2, 367, 1, 827, 218, 2993, 50, 2895, 2927, 2622, 827, 218, 2993, 50, 2895, 2927, 2622, 10, 1917, 1615, 1120, 62, 140, 29, 818, 298, 133, 1195, 11, 4954, 9, 372, 455, 1315, 3, 3019, 29, 3, 702, 6, 7, 19609, 10, 509, 75, 5196, 5845, 11897, 8264, 1369, 11, 2320, 22, 2763, 48304, 9477, 15, 840, 48304, 9477, 5, 1323, 289, 2568, 1110, 2, 15, 3938, 779, 1161, 14590, 15, 20196, 5013, 165, 574, 15424, 2690, 2, 5319, 262, 20849, 1, 152, 11, 4954, 2, 98, 6, 3, 2807, 10, 509, 29, 3, 388, 221, 1244, 827, 218, 2993, 10, 1465, 4, 1250, 140, 52, 89, 10, 64209, 184, 201, 833, 1140, 10, 432, 48305, 188, 18, 184, 269, 39, 664, 66, 2, 6453, 10, 1040, 18, 184, 14, 27, 52, 3019, 12590, 10, 456, 64210, 184, 13, 18, 4928, 1369, 11, 2763, 4, 3486, 614, 2, 840, 4, 970, 512, 140, 3, 3607, 9, 152, 10, 12, 78, 878, 605, 12, 78, 33, 18, 33, 12, 78, 66, 39, 2, 220, 1512, 12, 1002, 78, 3263, 699, 104, 1128, 1461, 648, 833, 42, 1401, 827, 218, 2993, 52, 98, 9, 2993, 9, 46, 140, 10, 39, 37912, 184, 18, 39, 79, 27, 1208, 98, 473, 16412, 348, 64211, 2, 119, 1, 1720, 26263, 11, 41, 5, 1401, 827, 218, 2993, 15424, 2690, 489, 4, 66, 5311, 33, 14, 827, 218, 2993, 140, 72, 6, 33, 601, 175, 49, 1888, 3411, 19, 1592, 3146, 10, 1493, 4, 39, 5311, 18, 33, 827, 218, 2993, 140, 72, 6, 27, 601, 67, 13, 1888, 3411, 19, 588, 827, 218, 2993, 50, 2895, 2927, 2622, 9, 1002, 2, 393, 1298, 16, 1313, 2, 1165]",1636.0,24736022,19
The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline.,Practical radiation oncology,Pract Radiat Oncol,2014-03-31,"To present evidence-based guidelines for adjuvant radiation in the treatment of endometrial cancer. Key clinical questions to be addressed in this evidence-based guideline on endometrial cancer were identified. A comprehensive literature review was performed to identify studies that included no adjuvant therapy, or pelvic radiation or vaginal brachytherapy with or without systemic chemotherapy. Outcomes included local control, survival rates, and overall assessment of quality of life. Patients with grade 1 or 2 cancers with either no invasion or <50% myometrial invasion (MI), especially when no other high risk features are present, can be safely observed after hysterectomy. Vaginal cuff brachytherapy is as effective as pelvic radiation therapy at preventing vaginal recurrence for patients with grade 1 or 2 cancers with 50% MI or grade 3 tumors with <50% MI. Patients with grade 3 cancer with 50% MI or cervical stroma invasion may benefit from pelvic radiation to reduce the risk of pelvic recurrence. There is limited evidence for a benefit to vaginal cuff brachytherapy following pelvic radiation. Multimodality treatment is recommended for patients with positive nodes or involved uterine serosa, ovaries or fallopian tubes, vagina, bladder, or rectum. External beam and vaginal brachytherapy remain integral aspects of adjuvant therapy for endometrial cancer.",Journal Article,2122.0,95.0,To present evidence-based guidelines for adjuvant radiation in the treatment of cancer Key clinical questions to be addressed in this evidence-based guideline on cancer were identified A comprehensive literature review was performed to identify studies that included no adjuvant therapy or pelvic radiation or brachytherapy with or without systemic chemotherapy Outcomes included local control survival rates and overall assessment of quality of life Patients with grade 1 or 2 cancers with either no invasion or 50 myometrial invasion MI especially when no other high risk features are present can be safely observed after hysterectomy cuff brachytherapy is as effective as pelvic radiation therapy at preventing recurrence for patients with grade 1 or 2 cancers with 50 MI or grade 3 tumors with 50 MI Patients with grade 3 cancer with 50 MI or stroma invasion may benefit from pelvic radiation to reduce the risk of pelvic recurrence There is limited evidence for a benefit to cuff brachytherapy following pelvic radiation Multimodality treatment is recommended for patients with positive nodes or involved serosa ovaries or tubes vagina or rectum External beam and brachytherapy remain integral aspects of adjuvant therapy for cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,"[6, 364, 241, 90, 677, 9, 249, 121, 4, 3, 24, 1, 12, 825, 38, 1937, 6, 40, 2814, 4, 26, 241, 90, 2009, 23, 12, 11, 108, 8, 949, 789, 206, 10, 173, 6, 255, 94, 17, 159, 77, 249, 36, 15, 1110, 121, 15, 1536, 5, 15, 187, 403, 56, 123, 159, 293, 182, 25, 151, 2, 63, 455, 1, 372, 1, 358, 7, 5, 88, 14, 15, 18, 163, 5, 361, 77, 578, 15, 212, 7327, 578, 6862, 1093, 198, 77, 127, 64, 43, 404, 32, 364, 122, 40, 2268, 164, 50, 2622, 11445, 1536, 16, 22, 323, 22, 1110, 121, 36, 28, 3017, 146, 9, 7, 5, 88, 14, 15, 18, 163, 5, 5660, 6862, 15, 88, 27, 57, 5, 212, 6862, 7, 5, 88, 27, 12, 5, 5660, 6862, 15, 2477, 578, 68, 247, 29, 1110, 121, 6, 969, 3, 43, 1, 1110, 146, 125, 16, 383, 241, 9, 8, 247, 6, 11445, 1536, 366, 1110, 121, 2425, 24, 16, 793, 9, 7, 5, 109, 502, 15, 646, 23561, 7262, 15, 6193, 7553, 15, 3660, 1455, 1345, 2, 1536, 918, 4450, 2695, 1, 249, 36, 9, 12]",1239.0,24766678,325
Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2014-04-28,"To better understand oral human papillomavirus (HPV) infection and cancer risk among long-term sexual partners of patients with HPV-positive oropharyngeal cancer (HPV-OPC). An oral rinse sample, risk factor survey, cancer history, and oral examination (partners only) were collected from patients with HPV-OPC and their partners. Oral rinse samples were evaluated for 36 types of HPV DNA using PGMY 09/11 primers and line-blot hybridization and HPV16 copy number using quantitative polymerase chain reaction. Oral HPV prevalence was compared with infection among those age 45 to 65 years using National Health and Nutrition Examination Survey (NHANES) 2009-2010. A total of 164 patients with HPV-OPC and 93 of their partners were enrolled. Patients were primarily men (90%), were never-smokers (51%), and had performed oral sex (97%), with a median age of 56 years; they had a high prevalence of oncogenic oral HPV DNA (61%) and oral HPV16 DNA (54%) at enrollment. Female partners had comparable oncogenic oral HPV prevalence compared with members of the general population of the same age (1.2% v 1.3%). Among the six male partners, no oncogenic oral HPV infections were detected. No precancers or cancers were identified during partner oral cancer screening examinations. However, a history of cervical disease was reported by nine partners (10.3%) and two female patients (11.8%), and three patients (2.0%) reported a previous partner who developed invasive cervical cancer. Oral HPV16 DNA is commonly detected among patients with HPV-OPC at diagnosis, but not among their partners. Partners of patients with HPV-OPC do not seem to have elevated oral HPV infection compared with the general population.",Journal Article,2094.0,88.0,To better understand oral human papillomavirus HPV infection and cancer risk among long-term sexual partners of patients with HPV-positive cancer HPV-OPC An oral rinse sample risk factor survey cancer history and oral examination partners only were collected from patients with HPV-OPC and their partners Oral rinse samples were evaluated for 36 types of HPV DNA using PGMY 09/11 primers and line-blot hybridization and HPV16 copy number using quantitative polymerase chain reaction Oral HPV prevalence was compared with infection among those age 45 to 65 years using National Health and Nutrition Examination Survey NHANES 2009-2010 A total of 164 patients with HPV-OPC and 93 of their partners were enrolled Patients were primarily men 90 were never-smokers 51 and had performed oral sex 97 with a median age of 56 years they had a high prevalence of oncogenic oral HPV DNA 61 and oral HPV16 DNA 54 at enrollment Female partners had comparable oncogenic oral HPV prevalence compared with members of the general population of the same age 1.2 v 1.3 Among the six male partners no oncogenic oral HPV infections were detected No precancers or cancers were identified during partner oral cancer screening examinations However a history of disease was reported by nine partners 10.3 and two female patients 11.8 and three patients 2.0 reported a previous partner who developed invasive cancer Oral HPV16 DNA is commonly detected among patients with HPV-OPC at diagnosis but not among their partners Partners of patients with HPV-OPC do not seem to have elevated oral HPV infection compared with the general population,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 380, 1640, 518, 171, 3242, 933, 930, 2, 12, 43, 107, 319, 337, 2232, 4005, 1, 7, 5, 933, 109, 12, 933, 4654, 35, 518, 19339, 1000, 43, 161, 1407, 12, 532, 2, 518, 1385, 4005, 158, 11, 786, 29, 7, 5, 933, 4654, 2, 136, 4005, 518, 19339, 347, 11, 194, 9, 511, 630, 1, 933, 261, 75, 64281, 1730, 175, 10031, 2, 328, 2639, 1554, 2, 4048, 1337, 207, 75, 1156, 1451, 1260, 1329, 518, 933, 1078, 10, 72, 5, 930, 107, 135, 89, 512, 6, 556, 60, 75, 657, 341, 2, 5260, 1385, 1407, 25529, 1238, 1120, 8, 181, 1, 5279, 7, 5, 933, 4654, 2, 966, 1, 136, 4005, 11, 346, 7, 11, 1561, 325, 424, 11, 1737, 1485, 725, 2, 42, 173, 518, 1035, 1015, 5, 8, 52, 89, 1, 664, 60, 491, 42, 8, 64, 1078, 1, 1302, 518, 933, 261, 713, 2, 518, 4048, 261, 667, 28, 1798, 1061, 4005, 42, 1279, 1302, 518, 933, 1078, 72, 5, 1684, 1, 3, 1083, 266, 1, 3, 827, 89, 14, 18, 603, 14, 27, 107, 3, 437, 1045, 4005, 77, 1302, 518, 933, 1875, 11, 530, 77, 18753, 15, 163, 11, 108, 190, 4852, 518, 12, 453, 4209, 137, 8, 532, 1, 34, 10, 210, 20, 762, 4005, 79, 27, 2, 100, 1061, 7, 175, 66, 2, 169, 7, 18, 13, 210, 8, 698, 4852, 54, 276, 416, 12, 518, 4048, 261, 16, 841, 530, 107, 7, 5, 933, 4654, 28, 147, 84, 44, 107, 136, 4005, 4005, 1, 7, 5, 933, 4654, 1022, 44, 3233, 6, 47, 804, 518, 933, 930, 72, 5, 3, 1083, 266]",1614.0,24778397,95
Metastatic cervical carcinoma from an unknown primary: literature review.,"Ear, nose, & throat journal",Ear Nose Throat J,,"Carcinoma of an unknown primary (CUP) encompasses a heterogeneous group of tumors for which no primary site can be detected following a thorough history, physical examination, and noninvasive and invasive testing. CUP presenting with metastasis to the neck (metastatic cervical carcinoma from an unknown primary [MCCUP]) has been an enigma since von Volkmann first described it in 1882 as a cancer arising in a branchial cleft cyst. Genetic studies have shed some light on this unusual entity. In most cases, clinical features, imaging studies, and a meticulous assessment of the upper aerodigestive tract should assist in identifying the source of disease. Molecular testing of cytologic specimens for Epstein-Barr virus and human papillomavirus (HPV) can facilitate identification of the primary site in the nasopharynx and oropharynx. At least 25% of MCCUPs are directly attributable to HPV-related malignancies, and this number can be expected to increase. Minimally invasive transoral mucosal sampling can identify an otherwise clinically and radiologically occult cancer. We performed a literature review with the objective of discussing the history, epidemiology, clinical presentation, diagnostic workup, and management of MCCUP. ",Journal Article,,9.0,Carcinoma of an unknown primary CUP encompasses a heterogeneous group of tumors for which no primary site can be detected following a thorough history physical examination and noninvasive and invasive testing CUP presenting with metastasis to the metastatic carcinoma from an unknown primary MCCUP has been an enigma since von Volkmann first described it in 1882 as a cancer arising in a branchial cleft cyst Genetic studies have shed some light on this unusual entity In most cases clinical features imaging studies and a meticulous assessment of the upper aerodigestive tract should assist in identifying the source of disease Molecular testing of cytologic specimens for Epstein-Barr virus and human papillomavirus HPV can facilitate identification of the primary site in the nasopharynx and oropharynx At least 25 of MCCUPs are directly attributable to HPV-related malignancies and this number can be expected to increase Minimally invasive transoral mucosal sampling can identify an otherwise clinically and radiologically occult cancer We performed a literature review with the objective of discussing the history epidemiology clinical presentation diagnostic workup and management of MCCUP,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[134, 1, 35, 860, 86, 7121, 9485, 8, 1564, 87, 1, 57, 9, 92, 77, 86, 606, 122, 40, 530, 366, 8, 5506, 532, 900, 1385, 2, 2957, 2, 416, 471, 7121, 1656, 5, 278, 6, 3, 113, 134, 29, 35, 860, 86, 27131, 71, 85, 35, 19048, 1192, 6430, 64328, 157, 1027, 192, 4, 48349, 22, 8, 12, 2635, 4, 8, 44776, 26847, 3364, 336, 94, 47, 5816, 476, 1691, 23, 26, 4015, 2983, 4, 96, 140, 38, 404, 270, 94, 2, 8, 13764, 455, 1, 3, 1726, 11006, 1696, 257, 3425, 4, 1386, 3, 2353, 1, 34, 219, 471, 1, 4195, 623, 9, 5212, 5190, 1450, 2, 171, 3242, 933, 122, 1876, 911, 1, 3, 86, 606, 4, 3, 13789, 2, 5333, 28, 506, 243, 1, 64329, 32, 1606, 2971, 6, 933, 139, 441, 2, 26, 207, 122, 40, 1336, 6, 344, 2144, 416, 13959, 3068, 2874, 122, 255, 35, 2632, 505, 2, 9579, 2879, 12, 21, 173, 8, 789, 206, 5, 3, 461, 1, 6003, 3, 532, 1284, 38, 1031, 752, 4755, 2, 284, 1, 27131]",1196.0,24817234,421
Cultural sensitivity and health education: essential components to the success of the early detection cancer screening program for Latinas at MedStar Georgetown University Hospital.,Journal of health care for the poor and underserved,J Health Care Poor Underserved,2014-05-01,"Over 13 years, the Celebremos la Vida (CLV) program has offered free breast examinations, mammograms, and cervical cancer screenings to uninsured Latinas residing in the Northern Virginia suburbs of Washington, D.C. The CLV program aims to educate participants on the importance of breast self-examination and regular cancer screening for the early detection of breast and cervical cancer.",Journal Article,2091.0,1.0,Over 13 years the Celebremos la Vida CLV program has offered free examinations mammograms and cancer screenings to uninsured Latinas residing in the Northern Virginia suburbs of Washington D.C The CLV program aims to educate participants on the importance of self-examination and regular cancer screening for the early detection of and cancer,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[252, 233, 60, 3, 64412, 4608, 64413, 48386, 1243, 71, 2216, 115, 4209, 6329, 2, 12, 14317, 6, 4955, 10862, 8230, 4, 3, 7088, 11457, 64414, 1, 10840, 427, 256, 3, 48386, 1243, 2970, 6, 10407, 776, 23, 3, 1187, 1, 1074, 1385, 2, 3316, 12, 453, 9, 3, 191, 638, 1, 2, 12]",342.0,24858861,595
Younger age distribution of cervical cancer incidence among survivors of pediatric and young adult cancers.,Gynecologic oncology,Gynecol. Oncol.,2014-05-27,"Pediatric and young adult (PAYA) cancer survivors may have an earlier onset of chronic diseases compared with the general population. We compared the age at cervical cancer diagnosis between PAYA cancer survivors and females in the general US population. We used longitudinal data from 9 population-based registries of the Surveillance, Epidemiology, and End Results program collected between 1973 and 2010. PAYA cancer survivors were females diagnosed with any cancer before age 30 years, survived at least 5 years post-diagnosis, and were subsequently diagnosed with invasive cervical cancer (n=46). The general US population comprised females who were diagnosed with invasive cervical cancer as the primary malignancy (n=26,956). We estimated the difference in median age at diagnosis () and bootstrap 95% confidence limits (CL) of invasive cervical cancer after adjustment for year of diagnosis and race. The median age at diagnosis of invasive cervical cancer was 33 years for female PAYA cancer survivors and 40 years for females in the general US population (50=-7.0, 95% CL: -11, -3.2). Similar differences were observed across subgroups of stage and histologic subtype of invasive cervical cancer. Our results suggest that PAYA cancer survivors are diagnosed with invasive cervical cancer at a substantially younger age compared with females without a prior cancer diagnosis in the general US population. This issue warrants further study, and could have implications for determining age at initiation or frequency of cervical cancer screening if younger age at diagnosis is attributable to an underlying biological phenomenon.",Journal Article,2065.0,5.0,"Pediatric and young adult PAYA cancer survivors may have an earlier onset of chronic diseases compared with the general population We compared the age at cancer diagnosis between PAYA cancer survivors and females in the general US population We used longitudinal data from 9 population-based registries of the Surveillance Epidemiology and End Results program collected between 1973 and 2010 PAYA cancer survivors were females diagnosed with any cancer before age 30 years survived at least 5 years post-diagnosis and were subsequently diagnosed with invasive cancer n=46 The general US population comprised females who were diagnosed with invasive cancer as the primary malignancy n=26,956 We estimated the difference in median age at diagnosis  and bootstrap 95 confidence limits CL of invasive cancer after adjustment for year of diagnosis and race The median age at diagnosis of invasive cancer was 33 years for female PAYA cancer survivors and 40 years for females in the general US population 50=-7.0 95 CL -11 -3.2 Similar differences were observed across subgroups of stage and histologic subtype of invasive cancer Our results suggest that PAYA cancer survivors are diagnosed with invasive cancer at a substantially younger age compared with females without a prior cancer diagnosis in the general US population This issue warrants further study and could have implications for determining age at initiation or frequency of cancer screening if younger age at diagnosis is attributable to an underlying biological phenomenon",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[815, 2, 1169, 780, 21798, 12, 332, 68, 47, 35, 1677, 1707, 1, 442, 1342, 72, 5, 3, 1083, 266, 21, 72, 3, 89, 28, 12, 147, 59, 21798, 12, 332, 2, 2451, 4, 3, 1083, 843, 266, 21, 95, 2380, 74, 29, 83, 266, 90, 3768, 1, 3, 617, 1284, 2, 396, 99, 1243, 786, 59, 4756, 2, 1120, 21798, 12, 332, 11, 2451, 265, 5, 500, 12, 348, 89, 201, 60, 2996, 28, 506, 33, 60, 539, 147, 2, 11, 1611, 265, 5, 416, 12, 78, 641, 3, 1083, 843, 266, 2603, 2451, 54, 11, 265, 5, 416, 12, 22, 3, 86, 710, 78, 432, 14137, 21, 661, 3, 523, 4, 52, 89, 28, 147, 64430, 2, 8086, 48, 307, 3526, 5192, 1, 416, 12, 50, 1852, 9, 111, 1, 147, 2, 1047, 3, 52, 89, 28, 147, 1, 416, 12, 10, 466, 60, 9, 1061, 21798, 12, 332, 2, 327, 60, 9, 2451, 4, 3, 1083, 843, 266, 64431, 67, 13, 48, 5192, 175, 27, 18, 288, 362, 11, 164, 716, 1453, 1, 82, 2, 884, 875, 1, 416, 12, 114, 99, 309, 17, 21798, 12, 332, 32, 265, 5, 416, 12, 28, 8, 2109, 773, 89, 72, 5, 2451, 187, 8, 324, 12, 147, 4, 3, 1083, 843, 266, 26, 2537, 2782, 195, 45, 2, 359, 47, 1268, 9, 2196, 89, 28, 1118, 15, 675, 1, 12, 453, 492, 773, 89, 28, 147, 16, 2971, 6, 35, 1181, 1037, 3936]",1536.0,24875121,46
Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic.,Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,J. Clin. Virol.,2014-05-02,"Human papillomavirus (HPV) testing in urine offers a convenient approach for cervical cancer screening but has previously suffered from limited clinical sensitivity. We evaluated clinical performance of the prototype Trovagene HPV test, a novel polymerase chain reaction assay that targets the E1 region of the HPV genome and detects and amplifies short fragments of cell-free HPV DNA in urine. We conducted a pilot study among 72 women referred to colposcopy following abnormal screening. Participants provided a urine sample prior to clinician-collected cervical sampling and colposcopically-directed punch biopsy. Trovagene HPV test results on urine samples were compared with cervical and urine testing by Linear Array HPV Genotyping Test (LA-HPV) for detection of histologically-confirmed cervical precancerous lesions. There was high concordance between urine samples tested by the Trovagene HPV test and corresponding cervical (87.5%) and urine (81.9%) samples tested by LA-HPV. The Trovagene HPV test had high sensitivity (92.3% for detecting CIN2/3, and 100% for CIN3), comparable to LA-HPV testing on cervical samples (96.0% and 100%, respectively), and higher than LA-HPV testing on urine samples (80.8% and 90.0%, respectively). In this referral population, the specificity of the Trovagene urine HPV test was non-significantly lower (29% for CIN2/3 and 25% for CIN3) than corresponding estimates of LA-HPV testing on cervical (36% and 28%, respectively) and urine (42% and 38%, respectively) samples. This pilot study suggests that the Trovagene HPV test has high sensitivity for urine-based detection of cervical precancer and merits evaluation in larger studies.",Journal Article,2090.0,8.0,Human papillomavirus HPV testing in urine offers a convenient approach for cancer screening but has previously suffered from limited clinical sensitivity We evaluated clinical performance of the prototype Trovagene HPV test a novel polymerase chain reaction assay that targets the E1 region of the HPV genome and detects and amplifies short fragments of cell-free HPV DNA in urine We conducted a pilot study among 72 women referred to colposcopy following abnormal screening Participants provided a urine sample prior to clinician-collected sampling and colposcopically-directed punch biopsy Trovagene HPV test results on urine samples were compared with and urine testing by Linear Array HPV Genotyping Test LA-HPV for detection of histologically-confirmed precancerous lesions There was high concordance between urine samples tested by the Trovagene HPV test and corresponding 87.5 and urine 81.9 samples tested by LA-HPV The Trovagene HPV test had high sensitivity 92.3 for detecting CIN2/3 and 100 for CIN3 comparable to LA-HPV testing on samples 96.0 and 100 respectively and higher than LA-HPV testing on urine samples 80.8 and 90.0 respectively In this referral population the specificity of the Trovagene urine HPV test was non-significantly lower 29 for CIN2/3 and 25 for CIN3 than corresponding estimates of LA-HPV testing on 36 and 28 respectively and urine 42 and 38 respectively samples This pilot study suggests that the Trovagene HPV test has high sensitivity for urine-based detection of precancer and merits evaluation in larger studies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 3242, 933, 471, 4, 2646, 2339, 8, 7048, 353, 9, 12, 453, 84, 71, 373, 6388, 29, 383, 38, 485, 21, 194, 38, 528, 1, 3, 8743, 29572, 933, 412, 8, 229, 1451, 1260, 1329, 719, 17, 637, 3, 6778, 1053, 1, 3, 933, 898, 2, 6887, 2, 19051, 978, 5843, 1, 31, 115, 933, 261, 4, 2646, 21, 426, 8, 2281, 45, 107, 720, 117, 1995, 6, 9946, 366, 1668, 453, 776, 1052, 8, 2646, 1000, 324, 6, 3744, 786, 2874, 2, 26091, 1166, 12769, 411, 29572, 933, 412, 99, 23, 2646, 347, 11, 72, 5, 2, 2646, 471, 20, 1646, 1926, 933, 2686, 412, 4608, 933, 9, 638, 1, 2161, 557, 6605, 406, 125, 10, 64, 1827, 59, 2646, 347, 650, 20, 3, 29572, 933, 412, 2, 1734, 912, 33, 2, 2646, 865, 83, 347, 650, 20, 4608, 933, 3, 29572, 933, 412, 42, 64, 485, 937, 27, 9, 2502, 12870, 27, 2, 394, 9, 10346, 1279, 6, 4608, 933, 471, 23, 347, 921, 13, 2, 394, 106, 2, 142, 76, 4608, 933, 471, 23, 2646, 347, 493, 66, 2, 424, 13, 106, 4, 26, 2096, 266, 3, 1121, 1, 3, 29572, 2646, 933, 412, 10, 220, 97, 280, 462, 9, 12870, 27, 2, 243, 9, 10346, 76, 1734, 1423, 1, 4608, 933, 471, 23, 511, 2, 339, 106, 2, 2646, 595, 2, 519, 106, 347, 26, 2281, 45, 844, 17, 3, 29572, 933, 412, 71, 64, 485, 9, 2646, 90, 638, 1, 12380, 2, 4986, 451, 4, 1077, 94]",1553.0,24881489,7
Factors associated with reduced accuracy in Papanicolaou tests for patients with invasive cervical cancer.,Cancer cytopathology,Cancer Cytopathol,2014-05-28,"Recent proposals to lengthen the interval in cervical cancer screening highlight the importance of the accurate interpretation of screening tests. Tumor debris present in Papanicolaou (Pap) tests from women with invasive cancer is known to hamper interpretation. The current study evaluated limiting factors in Pap tests from women with invasive cervical cancer. A total of 3003 women with the spectrum of cervical lesions who had ThinPrep (Hologic Inc, Marlborough, Mass) Pap and human papillomavirus (HPV) genotyping tests performed were grouped by their most severe histologic diagnosis. Cytologic and HPV results were analyzed by cross-sectional analysis. The unsatisfactory rate of cytology specimens from patients with cancer (3.1%) was significantly higher than those from patients with cervical intraepithelial neoplasia of type 3 or less (0.8%) (P < .001). The percentage of samples with qualified adequacy was 34.8% in specimens from patients with cancer compared with only 3.6% from specimens from those without cancer (P < .001). The unsatisfactory and qualified adequacy rates were higher in squamous cancers compared with adenocarcinomas. However, adenocarcinomas were identified less frequently than squamous cancers (37.0% vs 61.7%) in the Pap tests. HPV tests were positive in 84.4% of unsatisfactory cases including 8 of 9 cancer cases, although 8.5% of cancers tested negative for HPV. Unsatisfactory and suboptimal ThinPrep Pap tests were increased in cancer cases compared with lesser histologic diagnoses. This was found to be particularly true for squamous cancers. Specimens from adenocarcinomas had fewer adequacy problems but were less frequently recognized as malignant. HPV tests were positive in the majority of unsatisfactory Pap tests in women with carcinoma, suggesting that HPV testing in women aged > 30 years can help to identify high-risk women with unsatisfactory Pap tests.",Journal Article,2064.0,9.0,Recent proposals to lengthen the interval in cancer screening highlight the importance of the accurate interpretation of screening tests Tumor debris present in Papanicolaou Pap tests from women with invasive cancer is known to hamper interpretation The current study evaluated limiting factors in Pap tests from women with invasive cancer A total of 3003 women with the spectrum of lesions who had ThinPrep Hologic Inc Marlborough Mass Pap and human papillomavirus HPV genotyping tests performed were grouped by their most severe histologic diagnosis Cytologic and HPV results were analyzed by cross-sectional analysis The unsatisfactory rate of cytology specimens from patients with cancer 3.1 was significantly higher than those from patients with intraepithelial neoplasia of type 3 or less 0.8 P .001 The percentage of samples with qualified adequacy was 34.8 in specimens from patients with cancer compared with only 3.6 from specimens from those without cancer P .001 The unsatisfactory and qualified adequacy rates were higher in squamous cancers compared with adenocarcinomas However adenocarcinomas were identified less frequently than squamous cancers 37.0 vs 61.7 in the Pap tests HPV tests were positive in 84.4 of unsatisfactory cases including 8 of 9 cancer cases although 8.5 of cancers tested negative for HPV Unsatisfactory and suboptimal ThinPrep Pap tests were increased in cancer cases compared with lesser histologic diagnoses This was found to be particularly true for squamous cancers Specimens from adenocarcinomas had fewer adequacy problems but were less frequently recognized as malignant HPV tests were positive in the majority of unsatisfactory Pap tests in women with carcinoma suggesting that HPV testing in women aged 30 years can help to identify high-risk women with unsatisfactory Pap tests,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[435, 11913, 6, 26232, 3, 268, 4, 12, 453, 1817, 3, 1187, 1, 3, 1481, 3037, 1, 453, 895, 30, 24639, 364, 4, 10416, 4290, 895, 29, 117, 5, 416, 12, 16, 440, 6, 19705, 3037, 3, 291, 45, 194, 817, 130, 4, 4290, 895, 29, 117, 5, 416, 12, 8, 181, 1, 30496, 117, 5, 3, 1873, 1, 406, 54, 42, 12772, 64445, 3479, 34521, 782, 4290, 2, 171, 3242, 933, 2686, 895, 173, 11, 3706, 20, 136, 96, 905, 884, 147, 4195, 2, 933, 99, 11, 311, 20, 1383, 2832, 65, 3, 9573, 116, 1, 2045, 623, 29, 7, 5, 12, 27, 14, 10, 97, 142, 76, 135, 29, 7, 5, 4153, 2298, 1, 267, 27, 15, 299, 13, 66, 19, 144, 3, 1150, 1, 347, 5, 9575, 6760, 10, 562, 66, 4, 623, 29, 7, 5, 12, 72, 5, 158, 27, 49, 29, 623, 29, 135, 187, 12, 19, 144, 3, 9573, 2, 9575, 6760, 151, 11, 142, 4, 691, 163, 72, 5, 1586, 137, 1586, 11, 108, 299, 746, 76, 691, 163, 567, 13, 105, 713, 67, 4, 3, 4290, 895, 933, 895, 11, 109, 4, 874, 39, 1, 9573, 140, 141, 66, 1, 83, 12, 140, 242, 66, 33, 1, 163, 650, 199, 9, 933, 9573, 2, 3291, 12772, 4290, 895, 11, 101, 4, 12, 140, 72, 5, 5191, 884, 2403, 26, 10, 204, 6, 40, 823, 2501, 9, 691, 163, 623, 29, 1586, 42, 1497, 6760, 2408, 84, 11, 299, 746, 1904, 22, 393, 933, 895, 11, 109, 4, 3, 686, 1, 9573, 4290, 895, 4, 117, 5, 134, 802, 17, 933, 471, 4, 117, 1032, 201, 60, 122, 987, 6, 255, 64, 43, 117, 5, 9573, 4290, 895]",1826.0,24888458,507
Patient preferences for side effects associated with cervical cancer treatment.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2014-07-01,"The aim of this study was to assess patient preferences regarding side effects associated with cervical cancer treatment. The visual analog scale (VAS) and modified standard gamble (SG) were used to elicit preferences of women with no evidence of disease after primary treatment of cervical cancer. Higher scores on VAS and SG indicated more favorable ratings for a given health state. Health states (HS) included vaginal shortening, diarrhea, dietary changes, menopause, moderate nausea/vomiting, rectal bleeding, sexual dysfunction, and urinary self-catheterization. Descriptive statistics, Kruskal-Wallis, Mann-Whitney U, and Wilcoxon signed-ranks tests and correlation coefficients were used for statistical analysis. Seventy-eight patients participated in the study. Median age was 44.1 years (range, 24.9-67.8 years). Median time since treatment completion was 31.2 months (range, 1.0-113.3 months). The HSs rated as most favorable by VAS were also rated as most favorable by SG. Increasing age was associated with higher VAS scores for menopause and vaginal shortening (P = 0.04 and 0.036). African Americans had higher VAS scores for dietary changes (P = 0.05), sexual dysfunction (P = 0.028), and diarrhea (P = 0.05) when compared with Hispanic and non-Hispanic white patients. Women receiving radiation had more favorable VAS scores for menopause compared with women undergoing radical hysterectomy (P = 0.05). Women receiving chemotherapy rated urinary self-catheterization less favorably by VAS score compared with those not receiving chemotherapy (P = 0.045). Multiple demographic and clinical factors influence the severity of treatment-related adverse effects perceived by women surviving cervical cancer. A better understanding of factors influencing patient preferences regarding treatment side effects will allow providers to formulate care better tailored to the individual desires of each patient.",Journal Article,2030.0,5.0,The aim of this study was to assess patient preferences regarding side effects associated with cancer treatment The visual analog scale VAS and modified standard gamble SG were used to elicit preferences of women with no evidence of disease after primary treatment of cancer Higher scores on VAS and SG indicated more favorable ratings for a given health state Health states HS included shortening diarrhea dietary changes menopause moderate nausea/vomiting bleeding sexual dysfunction and urinary self-catheterization Descriptive statistics Kruskal-Wallis Mann-Whitney U and Wilcoxon signed-ranks tests and correlation coefficients were used for statistical analysis Seventy-eight patients participated in the study Median age was 44.1 years range 24.9-67.8 years Median time since treatment completion was 31.2 months range 1.0-113.3 months The HSs rated as most favorable by VAS were also rated as most favorable by SG Increasing age was associated with higher VAS scores for menopause and shortening P 0.04 and 0.036 African Americans had higher VAS scores for dietary changes P 0.05 sexual dysfunction P 0.028 and diarrhea P 0.05 when compared with Hispanic and non-Hispanic white patients Women receiving radiation had more favorable VAS scores for menopause compared with women undergoing radical hysterectomy P 0.05 Women receiving chemotherapy rated urinary self-catheterization less favorably by VAS score compared with those not receiving chemotherapy P 0.045 Multiple demographic and clinical factors influence the severity of treatment-related adverse effects perceived by women surviving cancer A better understanding of factors influencing patient preferences regarding treatment side effects will allow providers to formulate care better tailored to the individual desires of each patient,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,"[3, 1130, 1, 26, 45, 10, 6, 423, 69, 2875, 666, 1152, 176, 41, 5, 12, 24, 3, 3046, 3497, 1124, 8458, 2, 1230, 260, 19561, 7995, 11, 95, 6, 5487, 2875, 1, 117, 5, 77, 241, 1, 34, 50, 86, 24, 1, 12, 142, 703, 23, 8458, 2, 7995, 1103, 80, 913, 5548, 9, 8, 447, 341, 1309, 341, 907, 5871, 159, 9245, 1172, 2013, 400, 5034, 1163, 1218, 1966, 2294, 2232, 1527, 2, 1660, 1074, 15173, 3778, 3065, 8800, 8875, 7470, 7471, 1767, 2, 3896, 7717, 14740, 895, 2, 816, 5161, 11, 95, 9, 1050, 65, 2073, 659, 7, 3025, 4, 3, 45, 52, 89, 10, 584, 14, 60, 184, 259, 83, 598, 66, 60, 52, 98, 1192, 24, 1438, 10, 456, 18, 53, 184, 14, 13, 4259, 27, 53, 3, 64475, 3982, 22, 96, 913, 20, 8458, 11, 120, 3982, 22, 96, 913, 20, 7995, 602, 89, 10, 41, 5, 142, 8458, 703, 9, 5034, 2, 9245, 19, 13, 755, 2, 13, 5395, 1410, 2731, 42, 142, 8458, 703, 9, 2013, 400, 19, 13, 474, 2232, 1527, 19, 13, 4836, 2, 1172, 19, 13, 474, 198, 72, 5, 1776, 2, 220, 1776, 886, 7, 117, 357, 121, 42, 80, 913, 8458, 703, 9, 5034, 72, 5, 117, 479, 711, 2622, 19, 13, 474, 117, 357, 56, 3982, 1660, 1074, 15173, 299, 5001, 20, 8458, 368, 72, 5, 135, 44, 357, 56, 19, 13, 4918, 232, 1540, 2, 38, 130, 1054, 3, 1702, 1, 24, 139, 290, 176, 2588, 20, 117, 3050, 12, 8, 380, 612, 1, 130, 4743, 69, 2875, 666, 24, 1152, 176, 303, 1700, 1994, 6, 10992, 165, 380, 3632, 6, 3, 797, 27248, 1, 296, 69]",1804.0,24905618,262
Impact of patient navigation on timely cancer care: the Patient Navigation Research Program.,Journal of the National Cancer Institute,J. Natl. Cancer Inst.,2014-06-17,"Patient navigation is a promising intervention to address cancer disparities but requires a multisite controlled trial to assess its effectiveness. The Patient Navigation Research Program compared patient navigation with usual care on time to diagnosis or treatment for participants with breast, cervical, colorectal, or prostate screening abnormalities and/or cancers between 2007 and 2010. Patient navigators developed individualized strategies to address barriers to care, with the focus on preventing delays in care. To assess timeliness of diagnostic resolution, we conducted a meta-analysis of center- and cancer-specific adjusted hazard ratios (aHRs) comparing patient navigation vs usual care. To assess initiation of cancer therapy, we calculated a single aHR, pooling data across all centers and cancer types. We conducted a metaregression to evaluate variability across centers. All statistical tests were two-sided. The 10521 participants with abnormal screening tests and 2105 with a cancer or precancer diagnosis were predominantly from racial/ethnic minority groups (73%) and publically insured (40%) or uninsured (31%). There was no benefit during the first 90 days of care, but a benefit of navigation was seen from 91 to 365 days for both diagnostic resolution (aHR = 1.51; 95% confidence interval [CI] = 1.23 to 1.84; P < .001)) and treatment initiation (aHR = 1.43; 95% CI = 1.10 to 1.86; P < .007). Metaregression revealed that navigation had its greatest benefits within centers with the greatest delays in follow-up under usual care. Patient navigation demonstrated a moderate benefit in improving timely cancer care. These results support adoption of patient navigation in settings that serve populations at risk of being lost to follow-up.",Journal Article,2044.0,103.0,Patient navigation is a promising intervention to address cancer disparities but requires a multisite controlled trial to assess its effectiveness The Patient Navigation Research Program compared patient navigation with usual care on time to diagnosis or treatment for participants with or screening abnormalities and/or cancers between 2007 and 2010 Patient navigators developed individualized strategies to address barriers to care with the focus on preventing delays in care To assess timeliness of diagnostic resolution we conducted a meta-analysis of center- and cancer-specific adjusted hazard ratios aHRs comparing patient navigation vs usual care To assess initiation of cancer therapy we calculated a single aHR pooling data across all centers and cancer types We conducted a metaregression to evaluate variability across centers All statistical tests were two-sided The 10521 participants with abnormal screening tests and 2105 with a cancer or precancer diagnosis were predominantly from racial/ethnic minority groups 73 and publically insured 40 or uninsured 31 There was no benefit during the first 90 days of care but a benefit of navigation was seen from 91 to 365 days for both diagnostic resolution aHR 1.51 95 confidence interval CI 1.23 to 1.84 P .001 and treatment initiation aHR 1.43 95 CI 1.10 to 1.86 P .007 Metaregression revealed that navigation had its greatest benefits within centers with the greatest delays in follow-up under usual care Patient navigation demonstrated a moderate benefit in improving timely cancer care These results support adoption of patient navigation in settings that serve populations at risk of being lost to follow-up,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[69, 5604, 16, 8, 721, 788, 6, 1539, 12, 2227, 84, 1706, 8, 9030, 1149, 160, 6, 423, 211, 1236, 3, 69, 5604, 389, 1243, 72, 69, 5604, 5, 3521, 165, 23, 98, 6, 147, 15, 24, 9, 776, 5, 15, 453, 1171, 2, 15, 163, 59, 1307, 2, 1120, 69, 15368, 276, 2596, 422, 6, 1539, 2160, 6, 165, 5, 3, 1222, 23, 3017, 3257, 4, 165, 6, 423, 11680, 1, 752, 2125, 21, 426, 8, 1742, 65, 1, 574, 2, 12, 112, 586, 360, 1137, 40758, 1430, 69, 5604, 105, 3521, 165, 6, 423, 1118, 1, 12, 36, 21, 981, 8, 226, 3657, 9419, 74, 716, 62, 1168, 2, 12, 630, 21, 426, 8, 25623, 6, 376, 1982, 716, 1168, 62, 1050, 895, 11, 100, 1689, 3, 64526, 776, 5, 1668, 453, 895, 2, 26421, 5, 8, 12, 15, 12380, 147, 11, 2117, 29, 2257, 2871, 2652, 271, 803, 2, 15614, 4291, 327, 15, 4955, 456, 125, 10, 77, 247, 190, 3, 157, 424, 162, 1, 165, 84, 8, 247, 1, 5604, 10, 527, 29, 970, 6, 7405, 162, 9, 110, 752, 2125, 3657, 14, 725, 48, 307, 268, 58, 14, 382, 6, 14, 874, 19, 144, 2, 24, 1118, 3657, 14, 601, 48, 58, 14, 79, 6, 14, 868, 19, 1999, 25623, 553, 17, 5604, 42, 211, 2199, 1141, 262, 1168, 5, 3, 2199, 3257, 4, 166, 126, 669, 3521, 165, 69, 5604, 264, 8, 1163, 247, 4, 1673, 4225, 12, 165, 46, 99, 538, 4350, 1, 69, 5604, 4, 1947, 17, 1833, 1184, 28, 43, 1, 486, 3009, 6, 166, 126]",1672.0,24938303,433
Fat composition changes in bone marrow during chemotherapy and radiation therapy.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2014-07-08,"To quantify changes in bone marrow fat fraction and determine associations with peripheral blood cell counts. In this prospective study, 19 patients received either highly myelotoxic treatment (radiation therapy plus cisplatin, 5-fluorouracil mitomycin C [FU/MMC], or cisplatin/5-FU/cetuximab) or less myelotoxic treatment (capecitabine-radiation therapy or no concurrent chemotherapy). Patients underwent MR imaging and venipuncture at baseline, midtreatment, and posttreatment visits. We performed mixed effects modeling of the mean proton density fat fraction (PDFF[%]) by linear time, treatment, and vertebral column region (lumbar [L]4-sacral [S]2 vs thoracic [T]10-L3 vs cervical[C]3-T9), while controlling for cumulative mean dose and other confounders. Spearman rank correlations were performed by white blood cell (WBC) counts versus the differences in PDFF(%) before and after treatment. Cumulative mean dose was associated with a 0.43% per Gy (P=.004) increase in PDFF(%). In the highly myelotoxic group, we observed significant changes in PDFF(%) per visit within L4-S2 (10.1%, P<.001) and within T10-L3 (3.93%, P=.01), relative to the reference C3-T9. In the less myelotoxic group, we did not observe significant changes in PDFF(%) per visit according to region. Within L4-S2, we observed a significant difference between treatment groups in the change in PDFF(%) per visit (5.36%, P=.04). Rank correlations of the inverse log differences in WBC versus the differences in PDFF(%) overall and within T10-S2 ranged from 0.69 to 0.78 (P<.05). Rank correlations of the inverse log differences in absolute neutrophil counts versus the differences in PDFF(%) overall and within L4-S2 ranged from 0.79 to 0.81 (P<.05). Magnetic resonance imaging fat quantification is sensitive to marrow composition changes that result from chemoradiation therapy. These changes are associated with peripheral blood cell counts. This study supports a rationale for bone marrow-sparing treatment planning to reduce the risk of hematologic toxicity.",Journal Article,2023.0,31.0,To quantify changes in marrow fat fraction and determine associations with peripheral blood cell counts In this prospective study 19 patients received either highly myelotoxic treatment radiation therapy plus cisplatin 5-fluorouracil mitomycin C FU/MMC or cisplatin/5-FU/cetuximab or less myelotoxic treatment capecitabine-radiation therapy or no concurrent chemotherapy Patients underwent MR imaging and venipuncture at baseline midtreatment and posttreatment visits We performed mixed effects modeling of the mean proton density fat fraction PDFF by linear time treatment and vertebral column region lumbar L 4-sacral S 2 vs thoracic T 10-L3 vs C 3-T9 while controlling for cumulative mean dose and other confounders Spearman rank correlations were performed by white blood cell WBC counts versus the differences in PDFF before and after treatment Cumulative mean dose was associated with a 0.43 per Gy P=.004 increase in PDFF In the highly myelotoxic group we observed significant changes in PDFF per visit within L4-S2 10.1 P .001 and within T10-L3 3.93 P=.01 relative to the reference C3-T9 In the less myelotoxic group we did not observe significant changes in PDFF per visit according to region Within L4-S2 we observed a significant difference between treatment groups in the change in PDFF per visit 5.36 P=.04 Rank correlations of the inverse log differences in WBC versus the differences in PDFF overall and within T10-S2 ranged from 0.69 to 0.78 P .05 Rank correlations of the inverse log differences in absolute neutrophil counts versus the differences in PDFF overall and within L4-S2 ranged from 0.79 to 0.81 P .05 Magnetic resonance imaging fat quantification is sensitive to marrow composition changes that result from chemoradiation therapy These changes are associated with peripheral blood cell counts This study supports a rationale for marrow-sparing treatment planning to reduce the risk of hematologic toxicity,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 3091, 400, 4, 581, 2300, 1509, 2, 223, 685, 5, 672, 315, 31, 1911, 4, 26, 482, 45, 326, 7, 103, 361, 561, 20470, 24, 121, 36, 349, 540, 33, 1404, 5837, 256, 1296, 6370, 15, 540, 33, 1296, 1175, 15, 299, 20470, 24, 1629, 121, 36, 15, 77, 750, 56, 7, 208, 1638, 270, 2, 33783, 28, 330, 19803, 2, 3149, 2690, 21, 173, 1739, 176, 2057, 1, 3, 313, 2095, 1263, 2300, 1509, 25627, 20, 1646, 98, 24, 2, 4731, 9004, 1053, 6187, 805, 39, 7943, 695, 18, 105, 2098, 102, 79, 6869, 105, 256, 27, 33888, 369, 1893, 9, 967, 313, 61, 2, 127, 4423, 5061, 1026, 2553, 11, 173, 20, 886, 315, 31, 4685, 1911, 185, 3, 362, 4, 25627, 348, 2, 50, 24, 967, 313, 61, 10, 41, 5, 8, 13, 601, 379, 381, 19, 1520, 344, 4, 25627, 4, 3, 561, 20470, 87, 21, 164, 93, 400, 4, 25627, 379, 2807, 262, 17614, 10355, 79, 14, 19, 144, 2, 262, 19625, 6869, 27, 966, 19, 355, 580, 6, 3, 2482, 8732, 33888, 4, 3, 299, 20470, 87, 21, 205, 44, 4635, 93, 400, 4, 25627, 379, 2807, 768, 6, 1053, 262, 17614, 10355, 21, 164, 8, 93, 523, 59, 24, 271, 4, 3, 707, 4, 25627, 379, 2807, 33, 511, 19, 755, 1026, 2553, 1, 3, 2931, 1066, 362, 4, 4685, 185, 3, 362, 4, 25627, 63, 2, 262, 19625, 10355, 1869, 29, 13, 790, 6, 13, 833, 19, 474, 1026, 2553, 1, 3, 2931, 1066, 362, 4, 1766, 2595, 1911, 185, 3, 362, 4, 25627, 63, 2, 262, 17614, 10355, 1869, 29, 13, 842, 6, 13, 865, 19, 474, 1484, 1535, 270, 2300, 4752, 16, 745, 6, 581, 3761, 400, 17, 757, 29, 975, 36, 46, 400, 32, 41, 5, 672, 315, 31, 1911, 26, 45, 2304, 8, 1728, 9, 581, 1851, 24, 1349, 6, 969, 3, 43, 1, 813, 155]",1934.0,25015207,404
Optimization of MR imaging for pretreatment evaluation of patients with endometrial and cervical cancer.,"Radiographics : a review publication of the Radiological Society of North America, Inc",Radiographics,,"Endometrial and cervical cancer are the most common gynecologic malignancies in the world. Accurate staging of cervical and endometrial cancer is essential to determine the correct treatment approach. The current International Federation of Gynecology and Obstetrics (FIGO) staging system does not include modern imaging modalities. However, magnetic resonance (MR) imaging has proved to be the most accurate noninvasive modality for staging endometrial and cervical carcinomas and often helps with risk stratification and making treatment decisions. Multiparametric MR imaging is increasingly being used to evaluate the female pelvis, an approach that combines anatomic T2-weighted imaging with functional imaging (ie, dynamic contrast material-enhanced and diffusion-weighted imaging). MR imaging helps guide treatment decisions by depicting the depth of myometrial invasion and cervical stromal involvement in patients with endometrial cancer and tumor size and parametrial invasion in those with cervical cancer. However, its accuracy for local staging depends on technique and image quality, namely thin-section high-resolution multiplanar T2-weighted imaging with simple modifications, such as double oblique T2-weighting supplemented by diffusion weighting and contrast enhancement.",Journal Article,,37.0,and cancer are the most common gynecologic malignancies in the world Accurate staging of and cancer is essential to determine the correct treatment approach The current International Federation of Gynecology and Obstetrics FIGO staging system does not include modern imaging modalities However magnetic resonance MR imaging has proved to be the most accurate noninvasive modality for staging and carcinomas and often helps with risk stratification and making treatment decisions Multiparametric MR imaging is increasingly being used to evaluate the female pelvis an approach that combines anatomic T2-weighted imaging with functional imaging ie dynamic contrast material-enhanced and diffusion-weighted imaging MR imaging helps guide treatment decisions by depicting the depth of myometrial invasion and stromal involvement in patients with cancer and tumor size and parametrial invasion in those with cancer However its accuracy for local staging depends on technique and image quality namely thin-section high-resolution multiplanar T2-weighted imaging with simple modifications such as double oblique T2-weighting supplemented by diffusion weighting and contrast enhancement,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,"[2, 12, 32, 3, 96, 186, 1512, 441, 4, 3, 1956, 1481, 632, 1, 2, 12, 16, 1452, 6, 223, 3, 4883, 24, 353, 3, 291, 944, 7303, 1, 6429, 2, 7407, 3837, 632, 398, 1097, 44, 643, 2366, 270, 1558, 137, 1484, 1535, 1638, 270, 71, 4328, 6, 40, 3, 96, 1481, 2957, 1396, 9, 632, 2, 826, 2, 629, 6484, 5, 43, 1541, 2, 1079, 24, 1526, 8347, 1638, 270, 16, 1635, 486, 95, 6, 376, 3, 1061, 3270, 35, 353, 17, 6705, 2745, 1786, 2337, 270, 5, 583, 270, 2523, 2540, 748, 3692, 651, 2, 3438, 2337, 270, 1638, 270, 6484, 1597, 24, 1526, 20, 18956, 3, 2436, 1, 7327, 578, 2, 1126, 799, 4, 7, 5, 12, 2, 30, 444, 2, 8726, 578, 4, 135, 5, 12, 137, 211, 1190, 9, 293, 632, 3828, 23, 1312, 2, 1482, 372, 5046, 5648, 2917, 64, 2125, 17732, 1786, 2337, 270, 5, 2763, 2916, 225, 22, 1627, 19506, 1786, 7775, 7687, 20, 3438, 7775, 2, 748, 2461]",1177.0,25019443,479
Transcervical wedge resection after transcervical extended mediastinal lymphadenectomy.,"Innovations (Philadelphia, Pa.)",Innovations (Phila),,"Transcervical extended mediastinal lymphadenectomy (TEMLA) has been shown to be feasible and safe. This approach may be underrecognized for providing excellent access to the pleural space. We present a 60-year-old woman who had a clinical stage T2b N0 M0 adenocarcinoma of her right lower lobe and several ground glass opacities throughout her upper lobes bilaterally. She underwent a TEMLA to confirm absence of lymph node involvement in her mediastinum. During the same anesthetic setting, a transpleural right upper lobe wedge resection via the cervical approach was performed as an extension of her TEMLA. The pathology from this wedge resection demonstrated atypical adenomatous hyperplasia. Ultimately, she underwent a thoracoscopic right lower lobectomy that confirmed that she had a pathologic T2b N0 M0 (5.0  4.0  3.0 cm) adenocarcinoma. There were no perioperative adverse events with either operation. Transcervical extended mediastinal lymphadenectomy and transcervical lung resections may be performed safely during the same anesthetic setting. ",Case Reports,,0.0,Transcervical extended mediastinal lymphadenectomy TEMLA has been shown to be feasible and safe This approach may be underrecognized for providing excellent access to the pleural space We present a 60-year-old woman who had a clinical stage T2b N0 M0 adenocarcinoma of her right lower lobe and several ground glass opacities throughout her upper lobes bilaterally She underwent a TEMLA to confirm absence of lymph node involvement in her mediastinum During the same anesthetic setting a transpleural right upper lobe wedge resection via the approach was performed as an extension of her TEMLA The pathology from this wedge resection demonstrated atypical adenomatous hyperplasia Ultimately she underwent a thoracoscopic right lower lobectomy that confirmed that she had a pathologic T2b N0 M0 5.0 4.0 3.0 cm adenocarcinoma There were no perioperative adverse events with either operation Transcervical extended mediastinal lymphadenectomy and transcervical resections may be performed safely during the same anesthetic setting,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21802, 1747, 2626, 2048, 18083, 71, 85, 443, 6, 40, 1313, 2, 1165, 26, 353, 68, 40, 16739, 9, 1736, 1503, 1655, 6, 3, 2164, 3865, 21, 364, 8, 335, 111, 1095, 2854, 54, 42, 8, 38, 82, 9023, 3394, 4591, 449, 1, 1084, 1913, 280, 4940, 2, 392, 9808, 9428, 19736, 2432, 1084, 1726, 9231, 17679, 3109, 208, 8, 18083, 6, 1843, 1127, 1, 263, 289, 799, 4, 1084, 7156, 190, 3, 827, 14926, 546, 8, 64701, 1913, 1726, 4940, 8246, 170, 847, 3, 353, 10, 173, 22, 35, 2401, 1, 1084, 18083, 3, 1117, 29, 26, 8246, 170, 264, 1973, 4865, 3176, 2050, 3109, 208, 8, 5752, 1913, 280, 3258, 17, 557, 17, 3109, 42, 8, 510, 9023, 3394, 4591, 33, 13, 39, 13, 27, 13, 494, 449, 125, 11, 77, 1547, 290, 281, 5, 361, 2589, 21802, 1747, 2626, 2048, 2, 21802, 2185, 68, 40, 173, 2268, 190, 3, 827, 14926, 546]",1026.0,25084246,647
"Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?",Gynecologic oncology,Gynecol. Oncol.,2014-07-30,"To determine whether intra-operative radiation therapy (IORT) at the time of pelvic exenteration (PE) or laterally extended endopelvic resection (LEER) improves progression-free survival (PFS) in patients with recurrent, previously irradiated gynecologic cancers. We conducted a single institution retrospective review of patients who had undergone a complete PE for locally recurrent gynecologic cancer. Demographic and clinicopathologic data were collected. 32 patients were identified (2000-2012); 21 (66%) cervical cancer, 8 (25%) vaginal, and 3 (9%) vulvar cancer. All patients were previously irradiated. Twenty-one (66%) received IORT. Mean age was 51. Eight patients had a LEER, all with IORT. Median PFS and OS, respectively, for those with PE alone was 33 and 41 vs. 10 and 10 months for PE+IORT compared to 9 and 17 months for LEER+IORT (P=.04). Increasing tumor size negatively impacted PFS (hazard ratio 1.3; 95%CI 1.12-1.52). Margin status was not associated with survival. No patients undergoing LEER+IORT recurred only locally whereas 62% recurred with a distant component (+/- local). Patients with PE alone had mainly local (36%) and few (9%) distant recurrences compared to 31% local and 38% distant (+/- local) recurrences for those with PE+IORT. We failed to demonstrate that IORT changes survival and recurrence outcomes. However, patients with clinical indications for IORT at the time of PE have worse prognosis compared to those who do not require IORT. If the need for IORT is anticipated, the surgeon may consider performing a LEER to decrease local recurrence if cure is the goal or consider palliative treatment options.",Journal Article,2001.0,15.0,To determine whether intra-operative radiation therapy IORT at the time of pelvic exenteration PE or laterally extended endopelvic resection LEER improves progression-free survival PFS in patients with recurrent previously irradiated gynecologic cancers We conducted a single institution retrospective review of patients who had undergone a complete PE for locally recurrent gynecologic cancer Demographic and clinicopathologic data were collected 32 patients were identified 2000-2012 21 66 cancer 8 25 and 3 9 cancer All patients were previously irradiated Twenty-one 66 received IORT Mean age was 51 Eight patients had a LEER all with IORT Median PFS and OS respectively for those with PE alone was 33 and 41 vs. 10 and 10 months for PE+IORT compared to 9 and 17 months for LEER+IORT P=.04 Increasing tumor size negatively impacted PFS hazard ratio 1.3 95 CI 1.12-1.52 Margin status was not associated with survival No patients undergoing LEER+IORT recurred only locally whereas 62 recurred with a distant component +/- local Patients with PE alone had mainly local 36 and few 9 distant recurrences compared to 31 local and 38 distant +/- local recurrences for those with PE+IORT We failed to demonstrate that IORT changes survival and recurrence outcomes However patients with clinical indications for IORT at the time of PE have worse prognosis compared to those who do not require IORT If the need for IORT is anticipated the surgeon may consider performing a LEER to decrease local recurrence if cure is the goal or consider palliative treatment options,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 317, 2392, 1208, 121, 36, 4158, 28, 3, 98, 1, 1110, 5668, 4878, 15, 17800, 1747, 64703, 170, 32313, 1804, 91, 115, 25, 300, 4, 7, 5, 387, 373, 2398, 1512, 163, 21, 426, 8, 226, 731, 459, 206, 1, 7, 54, 42, 1989, 8, 236, 4878, 9, 795, 387, 1512, 12, 1540, 2, 1399, 74, 11, 786, 531, 7, 11, 108, 1081, 1195, 239, 700, 12, 66, 243, 2, 27, 83, 12, 62, 7, 11, 373, 2398, 737, 104, 700, 103, 4158, 313, 89, 10, 725, 659, 7, 42, 8, 32313, 62, 5, 4158, 52, 300, 2, 118, 106, 9, 135, 5, 4878, 279, 10, 466, 2, 605, 105, 79, 2, 79, 53, 9, 4878, 4158, 72, 6, 83, 2, 269, 53, 9, 32313, 4158, 19, 755, 602, 30, 444, 2723, 4619, 300, 360, 197, 14, 27, 48, 58, 14, 133, 14, 653, 959, 156, 10, 44, 41, 5, 25, 77, 7, 479, 32313, 4158, 3363, 158, 795, 547, 744, 3363, 5, 8, 626, 1249, 293, 7, 5, 4878, 279, 42, 2615, 293, 511, 2, 1021, 83, 626, 1593, 72, 6, 456, 293, 2, 519, 626, 293, 1593, 9, 135, 5, 4878, 4158, 21, 1551, 6, 608, 17, 4158, 400, 25, 2, 146, 123, 137, 7, 5, 38, 2406, 9, 4158, 28, 3, 98, 1, 4878, 47, 639, 356, 72, 6, 135, 54, 1022, 44, 1353, 4158, 492, 3, 594, 9, 4158, 16, 4078, 3, 1897, 68, 2419, 3620, 8, 32313, 6, 775, 293, 146, 492, 1722, 16, 3, 1326, 15, 2419, 994, 24, 838]",1560.0,25084510,283
"Mucinous differentiation does not impact stage or risk of recurrence among patients with grade 1, endometrioid type, endometrial carcinoma.",Gynecologic oncology,Gynecol. Oncol.,2014-08-01,"To evaluate whether the presence of mucinous differentiation influences histopathologic findings, stage distribution, or rate of recurrence among women with grade 1, endometrioid type, endometrial carcinoma. This was a retrospective cohort study of all patients with grade 1, endometrioid type, endometrial carcinoma between January 2005 and December 2012. Patients were separated by the presence or absence of mucinous differentiation and then compared. Of 655 patients, mucinous differentiation was present in 137 (20.9%) and absent in 518 (79.1%) patients. Compared to the group without mucinous differentiation, the group containing mucinous differentiation was older at diagnosis (mean: 61.1 vs. 58.5 years, OR, 95% CI; 1.03, 1.01-1.05) and more likely to have myometrial invasion (61.3% vs. 51.5%, OR, 95% CI; 1.49, 1.01-2.19). Additional histopathologic findings including: tumor size, cervical stromal invasion, adnexal involvement, LVI and/or the presence of positive lymph nodes were similar between groups. Mucinous differentiation did not affect stage distribution, as most patients were stage 1A (85.4% vs. 86.3%). The median PFS for the entire group has yet to be reached. The mean PFS for the entire study sample was 94.7 months. There was no difference in mean PFS when comparing the group with mucinous differentiation to the group without mucinous differentiation (98 vs. 93.4 months, p=0.07). In the setting of grade 1, endometrioid type, endometrial carcinoma, mucinous differentiation is more common in older patients and is associated with an increased likelihood of myometrial invasion. However, stage distribution and risk of recurrence are not affected.",Journal Article,1999.0,0.0,To evaluate whether the presence of mucinous differentiation influences histopathologic findings stage distribution or rate of recurrence among women with grade 1 endometrioid type carcinoma This was a retrospective cohort study of all patients with grade 1 endometrioid type carcinoma between January 2005 and December 2012 Patients were separated by the presence or absence of mucinous differentiation and then compared Of 655 patients mucinous differentiation was present in 137 20.9 and absent in 518 79.1 patients Compared to the group without mucinous differentiation the group containing mucinous differentiation was older at diagnosis mean 61.1 vs. 58.5 years OR 95 CI 1.03 1.01-1.05 and more likely to have myometrial invasion 61.3 vs. 51.5 OR 95 CI 1.49 1.01-2.19 Additional histopathologic findings including tumor size stromal invasion adnexal involvement LVI and/or the presence of positive lymph nodes were similar between groups Mucinous differentiation did not affect stage distribution as most patients were stage 1A 85.4 vs. 86.3 The median PFS for the entire group has yet to be reached The mean PFS for the entire study sample was 94.7 months There was no difference in mean PFS when comparing the group with mucinous differentiation to the group without mucinous differentiation 98 vs. 93.4 months p=0.07 In the setting of grade 1 endometrioid type carcinoma mucinous differentiation is more common in older patients and is associated with an increased likelihood of myometrial invasion However stage distribution and risk of recurrence are not affected,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,"[6, 376, 317, 3, 463, 1, 2391, 910, 3859, 2630, 272, 82, 1395, 15, 116, 1, 146, 107, 117, 5, 88, 14, 3151, 267, 134, 26, 10, 8, 459, 180, 45, 1, 62, 7, 5, 88, 14, 3151, 267, 134, 59, 1024, 1242, 2, 1397, 1195, 7, 11, 4910, 20, 3, 463, 15, 1127, 1, 2391, 910, 2, 818, 72, 1, 10458, 7, 2391, 910, 10, 364, 4, 4352, 179, 83, 2, 3269, 4, 10978, 842, 14, 7, 72, 6, 3, 87, 187, 2391, 910, 3, 87, 1101, 2391, 910, 10, 434, 28, 147, 313, 713, 14, 105, 717, 33, 60, 15, 48, 58, 14, 680, 14, 355, 14, 474, 2, 80, 322, 6, 47, 7327, 578, 713, 27, 105, 725, 33, 15, 48, 58, 14, 739, 14, 355, 18, 326, 402, 2630, 272, 141, 30, 444, 1126, 578, 6462, 799, 3327, 2, 15, 3, 463, 1, 109, 263, 502, 11, 288, 59, 271, 2391, 910, 205, 44, 1158, 82, 1395, 22, 96, 7, 11, 82, 6345, 772, 39, 105, 868, 27, 3, 52, 300, 9, 3, 1797, 87, 71, 1145, 6, 40, 1300, 3, 313, 300, 9, 3, 1797, 45, 1000, 10, 960, 67, 53, 125, 10, 77, 523, 4, 313, 300, 198, 1430, 3, 87, 5, 2391, 910, 6, 3, 87, 187, 2391, 910, 1096, 105, 966, 39, 53, 19, 13, 1615, 4, 3, 546, 1, 88, 14, 3151, 267, 134, 2391, 910, 16, 80, 186, 4, 434, 7, 2, 16, 41, 5, 35, 101, 1420, 1, 7327, 578, 137, 82, 1395, 2, 43, 1, 146, 32, 44, 1424]",1574.0,25088333,167
New strategies in advanced cervical cancer: from angiogenesis blockade to immunotherapy.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2014-08-07,"Cervical cancer remains unique among solid tumor malignancies. Persistent infection with oncogenic subtypes of the human papillomavirus (HPV) results in carcinogenesis, predominantly occurring at the cervical transformation zone where endocervical columnar cells undergo metaplasia to a stratified squamous epithelium. The molecular cascade involving viral oncoproteins, E6 and E7 and their degradative interactions with cellular tumor suppressor gene products, p53 and pRb, respectively, has been precisely delineated. The precursor state of cervical neoplasia may last for years allowing for ready detection through successful screening programs in developed countries using cervical cytology and/or high-risk HPV DNA testing. Prophylactic HPV L1 capsid protein vaccines using virus-like-particle technology have been developed to prevent primary infection by the most common high-risk HPVs (16 and 18). Women who lack access to health care and those who undergo sporadic screening remain at risk. Although radical surgery (including fertility-sparing surgery) is available for patients with early-stage cancers, and chemoradiation plus high-dose-rate brachytherapy can cure the majority of those with locally advanced disease, patients with metastatic and nonoperable recurrent cervical cancer constitute a high-risk population with an unmet clinical need. On August 14, 2014, the FDA approved the antiangiogenesis drug bevacizumab for women with advanced cervical cancer. This review will highlight advances in translational science, antiangiogenesis therapy and immunotherapy for advanced disease.",Journal Article,1993.0,36.0,cancer remains unique among solid tumor malignancies Persistent infection with oncogenic subtypes of the human papillomavirus HPV results in carcinogenesis predominantly occurring at the transformation zone where endocervical columnar cells undergo metaplasia to a stratified squamous epithelium The molecular cascade involving viral oncoproteins E6 and E7 and their degradative interactions with cellular tumor suppressor gene products p53 and pRb respectively has been precisely delineated The precursor state of neoplasia may last for years allowing for ready detection through successful screening programs in developed countries using cytology and/or high-risk HPV DNA testing Prophylactic HPV L1 capsid protein vaccines using virus-like-particle technology have been developed to prevent primary infection by the most common high-risk HPVs 16 and 18 Women who lack access to health care and those who undergo sporadic screening remain at risk Although radical surgery including fertility-sparing surgery is available for patients with early-stage cancers and chemoradiation plus high-dose-rate brachytherapy can cure the majority of those with locally advanced disease patients with metastatic and nonoperable recurrent cancer constitute a high-risk population with an unmet clinical need On August 14 2014 the FDA approved the antiangiogenesis drug bevacizumab for women with advanced cancer This review will highlight advances in translational science antiangiogenesis therapy and immunotherapy for advanced disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 469, 991, 107, 537, 30, 441, 1882, 930, 5, 1302, 814, 1, 3, 171, 3242, 933, 99, 4, 1719, 2117, 1821, 28, 3, 1392, 3614, 1257, 10174, 16500, 37, 1251, 6054, 6, 8, 1173, 691, 2781, 3, 219, 4678, 1267, 1667, 8241, 4837, 2, 4540, 2, 136, 27986, 1286, 5, 763, 30, 1245, 145, 2766, 624, 2, 8734, 106, 71, 85, 7428, 5610, 3, 2765, 1309, 1, 2298, 68, 1060, 9, 60, 2952, 9, 11307, 638, 298, 1401, 453, 2251, 4, 276, 2115, 75, 2045, 2, 15, 64, 43, 933, 261, 471, 1862, 933, 729, 17237, 178, 1842, 75, 1450, 733, 5997, 2033, 47, 85, 276, 6, 1682, 86, 930, 20, 3, 96, 186, 64, 43, 13477, 245, 2, 203, 117, 54, 926, 1655, 6, 341, 165, 2, 135, 54, 1251, 1928, 453, 918, 28, 43, 242, 711, 152, 141, 2954, 1851, 152, 16, 390, 9, 7, 5, 191, 82, 163, 2, 975, 349, 64, 61, 116, 1536, 122, 1722, 3, 686, 1, 135, 5, 795, 131, 34, 7, 5, 113, 2, 31566, 387, 12, 4999, 8, 64, 43, 266, 5, 35, 3715, 38, 594, 23, 2480, 213, 1409, 3, 2078, 850, 3, 7351, 234, 599, 9, 117, 5, 131, 12, 26, 206, 303, 1817, 954, 4, 2460, 3797, 7351, 36, 2, 726, 9, 131, 34]",1523.0,25104084,130
Same-day discharge is feasible and safe in patients undergoing minimally invasive staging for gynecologic malignancies.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2014-08-14,"The objective of the study was to evaluate the feasibility and safety of same-day discharge of patients undergoing minimally invasive comprehensive surgical staging for endometrial and cervical cancer. We performed a retrospective review of consecutive patients from January 2008 to December 2011 undergoing comprehensive staging for endometrial or cervical cancer by traditional laparoscopy or robotic-assisted laparoscopy and intended for same-day discharge. Patients accomplishing same-day discharge were compared with those who required admission. Clinical and demographic data, perioperative outcomes, and postoperative patient contacts within 6 weeks were collected. Multivariate logistic regression modeling was used to determine factors associated with admission and unscheduled patient contacts within 2 weeks of surgery. A total of 141 patients were identified. One hundred eighteen patients (83.7%) underwent same-day discharge and 23 (16.3%) required overnight admission. The variables that significantly predicted overnight admission were severe pain in the postanesthesia care unit (odds ratio [OR], 6.81; 95% confidence interval [CI], 1.74-26.6; P = .006), delayed ability to tolerate oral intake (OR, 9.3; 95% CI, 2.25-38.6, P = .002), traditional laparoscopic vs robotic-assisted surgical approach (OR, 9.05; 95% CI, 2.34-35.1; P = .001), and surgery start time at 2:00 pm or later (OR, 36.8; 95% CI, 6.19-219.3; P < .0001). There was no difference in the readmission rate between patients undergoing same-day discharge compared with overnight admission (11% vs 17%, P = .48). No variables significantly predicted unscheduled patient contact within 2 weeks of surgery at P < .01. Same-day discharge for patients undergoing laparoscopic or robotic-assisted laparoscopic staging for endometrial or cervical cancer is feasible and safe. There are low complication rates and few readmissions or unscheduled patient contacts within 2 weeks of surgery.",Journal Article,1986.0,25.0,The objective of the study was to evaluate the feasibility and safety of same-day discharge of patients undergoing minimally invasive comprehensive surgical staging for and cancer We performed a retrospective review of consecutive patients from January 2008 to December 2011 undergoing comprehensive staging for or cancer by traditional laparoscopy or robotic-assisted laparoscopy and intended for same-day discharge Patients accomplishing same-day discharge were compared with those who required admission Clinical and demographic data perioperative outcomes and postoperative patient contacts within 6 weeks were collected Multivariate logistic regression modeling was used to determine factors associated with admission and unscheduled patient contacts within 2 weeks of surgery A total of 141 patients were identified One hundred eighteen patients 83.7 underwent same-day discharge and 23 16.3 required overnight admission The variables that significantly predicted overnight admission were severe pain in the postanesthesia care unit odds ratio OR 6.81 95 confidence interval CI 1.74-26.6 P .006 delayed ability to tolerate oral intake OR 9.3 95 CI 2.25-38.6 P .002 traditional laparoscopic vs robotic-assisted surgical approach OR 9.05 95 CI 2.34-35.1 P .001 and surgery start time at 2:00 pm or later OR 36.8 95 CI 6.19-219.3 P .0001 There was no difference in the readmission rate between patients undergoing same-day discharge compared with overnight admission 11 vs 17 P .48 No variables significantly predicted unscheduled patient contact within 2 weeks of surgery at P .01 Same-day discharge for patients undergoing laparoscopic or robotic-assisted laparoscopic staging for or cancer is feasible and safe There are low complication rates and few readmissions or unscheduled patient contacts within 2 weeks of surgery,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 461, 1, 3, 45, 10, 6, 376, 3, 1437, 2, 367, 1, 827, 218, 2993, 1, 7, 479, 2144, 416, 949, 221, 632, 9, 2, 12, 21, 173, 8, 459, 206, 1, 935, 7, 29, 1024, 1375, 6, 1397, 1132, 479, 949, 632, 9, 15, 12, 20, 1847, 3553, 15, 2895, 2927, 3553, 2, 4081, 9, 827, 218, 2993, 7, 22021, 827, 218, 2993, 11, 72, 5, 135, 54, 616, 3411, 38, 2, 1540, 74, 1547, 123, 2, 573, 69, 13291, 262, 49, 244, 11, 786, 331, 812, 320, 2057, 10, 95, 6, 223, 130, 41, 5, 3411, 2, 13774, 69, 13291, 262, 18, 244, 1, 152, 8, 181, 1, 4379, 7, 11, 108, 104, 1128, 3195, 7, 852, 67, 208, 827, 218, 2993, 2, 382, 245, 27, 616, 18409, 3411, 3, 682, 17, 97, 783, 18409, 3411, 11, 905, 559, 4, 3, 33549, 165, 2712, 610, 197, 15, 49, 865, 48, 307, 268, 58, 14, 794, 432, 49, 19, 1861, 1612, 801, 6, 5010, 518, 1514, 15, 83, 27, 48, 58, 18, 243, 519, 49, 19, 1111, 1847, 1964, 105, 2895, 2927, 221, 353, 15, 83, 474, 48, 58, 18, 562, 465, 14, 19, 144, 2, 152, 2435, 98, 28, 18, 2038, 3377, 15, 1559, 15, 511, 66, 48, 58, 49, 326, 6679, 27, 19, 488, 125, 10, 77, 523, 4, 3, 3146, 116, 59, 7, 479, 827, 218, 2993, 72, 5, 18409, 3411, 175, 105, 269, 19, 576, 77, 682, 97, 783, 13774, 69, 4393, 262, 18, 244, 1, 152, 28, 19, 355, 827, 218, 2993, 9, 7, 479, 1964, 15, 2895, 2927, 1964, 632, 9, 15, 12, 16, 1313, 2, 1165, 125, 32, 154, 1447, 151, 2, 1021, 5319, 15, 13774, 69, 13291, 262, 18, 244, 1, 152]",1828.0,25132462,494
Cancer screening rates in individuals with different life expectancies.,JAMA internal medicine,JAMA Intern Med,2014-10-01,"Routine cancer screening has unproven net benefit for patients with limited life expectancy. To examine the patterns of prostate, breast, cervical, and colorectal cancer screening in the United States in individuals with different life expectancies. Data from the population-based National Health Interview Survey (NHIS) from 2000 through 2010 were used and included 27404 participants aged 65 years or older. Using a validated mortality index specific for NHIS, participants were grouped into those with low (<25%), intermediate (25%-49%), high (50%-74%), and very high (75%) risks of 9-year mortality. Rates of prostate, breast, cervical, and colorectal cancer screening. In participants with very high mortality risk, 31% to 55% received recent cancer screening, with prostate cancer screening being most common (55%). For women who had a hysterectomy for benign reasons, 34% to 56% had a Papanicolaou test within the past 3 years. On multivariate analysis, very high vs low mortality risk was associated with less screening for prostate (odds ratio [OR], 0.65 [95% CI, 0.50-0.85]), breast (OR, 0.43 [95% CI, 0.35-0.53]), and cervical (OR, 0.50 [95% CI, 0.36-0.70]) cancers. There was less screening for prostate and cervical cancers in more recent years compared with 2000, and there was no significant interaction between calendar year and mortality risk for any cancer screening (P>.05 for all cancers). Our sensitivity analysis showed that screening was also common in individuals with less than 5-year life expectancy. A substantial proportion of the US population with limited life expectancy received prostate, breast, cervical, and colorectal cancer screening that is unlikely to provide net benefit. These results suggest that overscreening is common in both men and women, which not only increases health care expenditure but can lead to net patient harm.",Journal Article,1938.0,79.0,Routine cancer screening has unproven net benefit for patients with limited life expectancy To examine the patterns of and cancer screening in the United States in individuals with different life expectancies Data from the population-based National Health Interview Survey NHIS from 2000 through 2010 were used and included 27 404 participants aged 65 years or older Using a validated mortality index specific for NHIS participants were grouped into those with low 25 intermediate 25 -49 high 50 -74 and very high 75 risks of 9-year mortality Rates of and cancer screening In participants with very high mortality risk 31 to 55 received recent cancer screening with cancer screening being most common 55 For women who had a hysterectomy for benign reasons 34 to 56 had a Papanicolaou test within the past 3 years On multivariate analysis very high vs low mortality risk was associated with less screening for odds ratio OR 0.65 95 CI 0.50-0.85 OR 0.43 95 CI 0.35-0.53 and OR 0.50 95 CI 0.36-0.70 cancers There was less screening for and cancers in more recent years compared with 2000 and there was no significant interaction between calendar year and mortality risk for any cancer screening P .05 for all cancers Our sensitivity analysis showed that screening was also common in individuals with less than 5-year life expectancy A substantial proportion of the US population with limited life expectancy received and cancer screening that is unlikely to provide net benefit These results suggest that overscreening is common in both men and women which not only increases health care expenditure but can lead to net patient harm,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1311, 12, 453, 71, 10048, 2587, 247, 9, 7, 5, 383, 358, 3399, 6, 1004, 3, 764, 1, 2, 12, 453, 4, 3, 1088, 907, 4, 869, 5, 338, 358, 15505, 74, 29, 3, 266, 90, 657, 341, 4313, 1407, 20612, 29, 1081, 298, 1120, 11, 95, 2, 159, 428, 10315, 776, 1032, 556, 60, 15, 434, 75, 8, 938, 282, 558, 112, 9, 20612, 776, 11, 3706, 237, 135, 5, 154, 243, 919, 243, 739, 64, 212, 794, 2, 923, 64, 8999, 1098, 1, 83, 111, 282, 151, 1, 2, 12, 453, 4, 776, 5, 923, 64, 282, 43, 456, 6, 614, 103, 435, 12, 453, 5, 12, 453, 486, 96, 186, 614, 9, 117, 54, 42, 8, 2622, 9, 1002, 2325, 562, 6, 664, 42, 8, 10416, 412, 262, 3, 1219, 27, 60, 23, 331, 65, 923, 64, 105, 154, 282, 43, 10, 41, 5, 299, 453, 9, 610, 197, 15, 13, 556, 48, 58, 13, 212, 13, 772, 15, 13, 601, 48, 58, 13, 465, 13, 699, 2, 15, 13, 212, 48, 58, 13, 511, 13, 431, 163, 125, 10, 299, 453, 9, 2, 163, 4, 80, 435, 60, 72, 5, 1081, 2, 125, 10, 77, 93, 915, 59, 11236, 111, 2, 282, 43, 9, 500, 12, 453, 19, 474, 9, 62, 163, 114, 485, 65, 224, 17, 453, 10, 120, 186, 4, 869, 5, 299, 76, 33, 111, 358, 3399, 8, 1281, 920, 1, 3, 843, 266, 5, 383, 358, 3399, 103, 2, 12, 453, 17, 16, 3568, 6, 377, 2587, 247, 46, 99, 309, 17, 64781, 16, 186, 4, 110, 325, 2, 117, 92, 44, 158, 1106, 341, 165, 8699, 84, 122, 1122, 6, 2587, 69, 7158]",1630.0,25133746,314
Moderate hypothermia for intradural spinal tumor resection: a cohort comparison and feasibility study.,Therapeutic hypothermia and temperature management,Ther Hypothermia Temp Manag,2014-09-01,"To evaluate the safety and feasibility of modest hypothermia as a potential strategy for intraoperative neuroprotection during the removal of intradural spinal tumors. A retrospective review was performed for two groups of patients of a single surgeon who underwent intradural extrameduallary and intramedullary spinal tumor resection of tumors located between cervical level 1 and lumbar 2 over a 10-year period between 2001 and 2010. One cohort received intraoperative moderate hypothermia (33C) via intravascular catheter cooling during tumor surgery and the second cohort, a historical control group of the same surgeon, underwent surgery at normothermia (36C). The main outcome measured was safety as determined by surgical, medical, and neurological complications. The hypothermia (n=38) and nonhypothermia (n=34) groups were homogenous for patient demographics and baseline comorbidities. There were no differences between the groups regarding tumor level (p=0.51), tumor pathology, or intramedullary versus intradural extramedullary location (p=0.11). The hypothermia group had a lower mean body temperature (33.7C0.72 vs. 36.6C0.7, p0.001) longer postoperative hospital stays (10.814.0 vs. 7.34.72, p<0.001), but there were no significant differences in operative and perioperative variables such as, total anesthetic time (8.22.4 vs. 7.82.7 hours, p=0.45), total surgical time (5.92.1 vs. 5.72.5 hours, p=0.58), or estimated blood loss (483420 vs. 420314mL, p=0.65). There were no statistically significant differences between the two groups with respect to the rate of surgical (3 vs. 2, p=1.0), medical (4 vs. 3, p=1.0), neurological (3 vs. 4, p=0.7), or overall complications (10 vs. 9, p=1.0). In this study, moderate hypothermia via intravascular cooling catheters was successfully performed during 38 intradural spinal tumor surgeries. Compared to the historical control group, the hypothermia patients had longer hospital stays, but did not have higher complication rates. Intraoperative moderate hypothermia during spinal tumor resection is feasible and appeared safe in this limited cohort; however, further studies with larger cohorts will be needed to determine whether peri-operative hypothermia is an effective neuroprotectant strategy in spinal tumor surgery.",Comparative Study,1968.0,0.0,To evaluate the safety and feasibility of modest hypothermia as a potential strategy for intraoperative neuroprotection during the removal of intradural spinal tumors A retrospective review was performed for two groups of patients of a single surgeon who underwent intradural extrameduallary and intramedullary spinal tumor resection of tumors located between level 1 and lumbar 2 over a 10-year period between 2001 and 2010 One cohort received intraoperative moderate hypothermia 33C via intravascular catheter cooling during tumor surgery and the second cohort a historical control group of the same surgeon underwent surgery at normothermia 36C The main outcome measured was safety as determined by surgical medical and neurological complications The hypothermia n=38 and nonhypothermia n=34 groups were homogenous for patient demographics and baseline comorbidities There were no differences between the groups regarding tumor level p=0.51 tumor pathology or intramedullary versus intradural extramedullary location p=0.11 The hypothermia group had a lower mean body temperature 33.7C0.72 vs. 36.6C0.7 p0.001 longer postoperative hospital stays 10.814.0 vs. 7.34.72 p 0.001 but there were no significant differences in operative and perioperative variables such as total anesthetic time 8.22.4 vs. 7.82.7 hours p=0.45 total surgical time 5.92.1 vs. 5.72.5 hours p=0.58 or estimated blood loss 483420 vs. 420314 mL p=0.65 There were no statistically significant differences between the two groups with respect to the rate of surgical 3 vs. 2 p=1.0 medical 4 vs. 3 p=1.0 neurological 3 vs. 4 p=0.7 or overall complications 10 vs. 9 p=1.0 In this study moderate hypothermia via intravascular cooling catheters was successfully performed during 38 intradural spinal tumor surgeries Compared to the historical control group the hypothermia patients had longer hospital stays but did not have higher complication rates Intraoperative moderate hypothermia during spinal tumor resection is feasible and appeared safe in this limited cohort however further studies with larger cohorts will be needed to determine whether peri-operative hypothermia is an effective neuroprotectant strategy in spinal tumor surgery,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 3, 367, 2, 1437, 1, 1721, 19251, 22, 8, 174, 692, 9, 1720, 40818, 190, 3, 2829, 1, 14288, 1499, 57, 8, 459, 206, 10, 173, 9, 100, 271, 1, 7, 1, 8, 226, 1897, 54, 208, 14288, 64867, 2, 8686, 1499, 30, 170, 1, 57, 2308, 59, 301, 14, 2, 6187, 18, 252, 8, 79, 111, 727, 59, 1758, 2, 1120, 104, 180, 103, 1720, 1163, 19251, 64868, 847, 8741, 3925, 8946, 190, 30, 152, 2, 3, 419, 180, 8, 2252, 182, 87, 1, 3, 827, 1897, 208, 152, 28, 64869, 64870, 3, 1895, 228, 644, 10, 367, 22, 509, 20, 221, 484, 2, 3622, 521, 3, 19251, 78, 519, 2, 64871, 78, 562, 271, 11, 10408, 9, 69, 2221, 2, 330, 1909, 125, 11, 77, 362, 59, 3, 271, 666, 30, 301, 19, 13, 725, 30, 1117, 15, 8686, 185, 14288, 5508, 1147, 19, 13, 175, 3, 19251, 87, 42, 8, 280, 313, 642, 6882, 466, 64872, 720, 105, 511, 64873, 67, 12444, 144, 589, 573, 702, 10472, 79, 64874, 13, 105, 67, 46050, 720, 19, 13, 144, 84, 125, 11, 77, 93, 362, 4, 1208, 2, 1547, 682, 225, 22, 181, 14926, 98, 66, 64875, 39, 105, 67, 40819, 67, 1459, 19, 13, 512, 181, 221, 98, 33, 64876, 14, 105, 33, 48561, 33, 1459, 19, 13, 717, 15, 661, 315, 407, 64877, 105, 64878, 542, 19, 13, 556, 125, 11, 77, 712, 93, 362, 59, 3, 100, 271, 5, 2184, 6, 3, 116, 1, 221, 27, 105, 18, 19, 14, 13, 484, 39, 105, 27, 19, 14, 13, 3622, 27, 105, 39, 19, 13, 67, 15, 63, 521, 79, 105, 83, 19, 14, 13, 4, 26, 45, 1163, 19251, 847, 8741, 8946, 6722, 10, 1878, 173, 190, 519, 14288, 1499, 30, 5305, 72, 6, 3, 2252, 182, 87, 3, 19251, 7, 42, 589, 702, 10472, 84, 205, 44, 47, 142, 1447, 151, 1720, 1163, 19251, 190, 1499, 30, 170, 16, 1313, 2, 2121, 1165, 4, 26, 383, 180, 137, 195, 94, 5, 1077, 736, 303, 40, 575, 6, 223, 317, 6164, 1208, 19251, 16, 35, 323, 39506, 692, 4, 1499, 30, 152]",2223.0,25184750,573
Factors associated with poor quality of life among cervical cancer survivors: implications for clinical care and clinical trials.,Gynecologic oncology,Gynecol. Oncol.,2014-09-03,"The purpose of this study is to identify factors that are associated with poor quality of life (QOL) among cervical cancer survivors. Patients identified through the California Cancer Registry were recruited to participate in a randomized counseling intervention. Patient-reported outcomes (PROs) were collected at study baseline (9-30 months post-diagnosis) and subsequent to the intervention. Multivariable linear models were used to identify independent factors associated with poor baseline QOL. Non-Hispanic (N=121) and Hispanic (N=83) women aged 22-73 completed baseline measures. Approximately 50% of participants received radiation therapy with or without chemotherapy. Compared to the US population, cervical cancer patients reported lower QOL and significantly higher levels of depression and anxiety (26% and 28% >1 SD above the general population means, respectively). Among those in the lowest quartile for QOL, 63% had depression levels >1 SD above the mean. In addition, treatment with radiationchemotherapy (p=0.014), and self-reported comorbidities predating the cancer diagnosis (p<0.001) were associated with lower QOL. Sociodemographic characteristics explained only a small portion of variance in QOL (r(2)=0.23). Persistent gynecologic problems, low social support, depression, somatization, less adaptive coping, comorbidities, sleep problems and low education were all independently associated with low QOL in multivariate analysis (r(2)=0.74). We have identified key psychological and physical health factors that contribute significantly to poor quality of life subsequent to definitive cancer treatment. The majority of these factors are amenable to supportive care interventions and should be evaluated at the time of primary treatment.",Journal Article,1966.0,35.0,The purpose of this study is to identify factors that are associated with poor quality of life QOL among cancer survivors Patients identified through the California Cancer Registry were recruited to participate in a randomized counseling intervention Patient-reported outcomes PROs were collected at study baseline 9-30 months post-diagnosis and subsequent to the intervention Multivariable linear models were used to identify independent factors associated with poor baseline QOL Non-Hispanic N=121 and Hispanic N=83 women aged 22-73 completed baseline measures Approximately 50 of participants received radiation therapy with or without chemotherapy Compared to the US population cancer patients reported lower QOL and significantly higher levels of depression and anxiety 26 and 28 1 SD above the general population means respectively Among those in the lowest quartile for QOL 63 had depression levels 1 SD above the mean In addition treatment with radiationchemotherapy p=0.014 and self-reported comorbidities predating the cancer diagnosis p 0.001 were associated with lower QOL Sociodemographic characteristics explained only a small portion of variance in QOL r 2 =0.23 Persistent gynecologic problems low social support depression somatization less adaptive coping comorbidities sleep problems and low education were all independently associated with low QOL in multivariate analysis r 2 =0.74 We have identified key psychological and physical health factors that contribute significantly to poor quality of life subsequent to definitive cancer treatment The majority of these factors are amenable to supportive care interventions and should be evaluated at the time of primary treatment,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 743, 1, 26, 45, 16, 6, 255, 130, 17, 32, 41, 5, 334, 372, 1, 358, 1001, 107, 12, 332, 7, 108, 298, 3, 4355, 12, 1608, 11, 2619, 6, 3506, 4, 8, 384, 2011, 788, 69, 210, 123, 4660, 11, 786, 28, 45, 330, 83, 201, 53, 539, 147, 2, 706, 6, 3, 788, 658, 1646, 274, 11, 95, 6, 255, 306, 130, 41, 5, 334, 330, 1001, 220, 1776, 78, 4141, 2, 1776, 78, 852, 117, 1032, 350, 803, 781, 330, 1018, 705, 212, 1, 776, 103, 121, 36, 5, 15, 187, 56, 72, 6, 3, 843, 266, 12, 7, 210, 280, 1001, 2, 97, 142, 148, 1, 1774, 2, 2021, 432, 2, 339, 14, 1270, 2090, 3, 1083, 266, 2263, 106, 107, 135, 4, 3, 2101, 3708, 9, 1001, 676, 42, 1774, 148, 14, 1270, 2090, 3, 313, 4, 352, 24, 5, 40824, 19, 13, 3618, 2, 1074, 210, 1909, 29135, 3, 12, 147, 19, 13, 144, 11, 41, 5, 280, 1001, 4221, 374, 3672, 158, 8, 302, 3206, 1, 4446, 4, 1001, 668, 18, 13, 382, 1882, 1512, 2408, 154, 2032, 538, 1774, 13589, 299, 2454, 4276, 1909, 2494, 2408, 2, 154, 1848, 11, 62, 1042, 41, 5, 154, 1001, 4, 331, 65, 668, 18, 13, 794, 21, 47, 108, 825, 2624, 2, 900, 341, 130, 17, 1248, 97, 6, 334, 372, 1, 358, 706, 6, 1057, 12, 24, 3, 686, 1, 46, 130, 32, 4070, 6, 1877, 165, 1151, 2, 257, 40, 194, 28, 3, 98, 1, 86, 24]",1697.0,25192629,545
Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria.,Gynecologic oncology,Gynecol. Oncol.,2014-09-09,"For locally-advanced uterine cancer clinically extending to the cervix, two treatment paradigms exist: surgical staging radical hysterectomy with tailored adjuvant therapy or neoadjuvant therapy followed by a less extensive simple hysterectomy. Currently, insufficient data exists to guide consensus guidelines and practical application of preoperative radiotherapy. Retrospective IRB approved cohort study from 1999 to 2014 of 36 endometrial cancer patients with clinical involvement of cervixparametria treated with neoadjuvant external beam radiotherapy (45-50.4Gy in 25-28 fractions) and image-based HDR brachytherapy (5-5.5Gy times 3-4 fractions)chemotherapy followed by extrafascial hysterectomy performed at a median of 6weeks after radiotherapy. All patients had clinical cervical extension, 50% also had parametria extension, and 31% had nodal involvement. At the time of surgery 91% had no clinical cervical involvement, 58% had no pathologic cervical involvement, and all had margin negative resection. The pathologic complete response rate was 24%. Median follow-up from the time of surgery was 20months (range: 0-153). The 3-year local control, regional control, distant control, disease free survival and overall survival rates were 96%, 89%, 84%, 73%, and 100%. The 3-year rate of grade 3 complications was 11%, with no grade 4+ toxicity. Neoadjuvant radiation therapychemotherapy followed by extrafascial hysterectomy appears to be a viable option for patients with endometrial cancer clinically extending to the cervix and parametria. The HDR brachytherapy schema of 5-5.5Gy times 3-4 fractions, for a cumulative EQD2 of 60-70Gy, is well tolerated with high rates of clinical and pathological response.",Journal Article,1960.0,13.0,For locally-advanced cancer clinically extending to the cervix two treatment paradigms exist surgical staging radical hysterectomy with tailored adjuvant therapy or neoadjuvant therapy followed by a less extensive simple hysterectomy Currently insufficient data exists to guide consensus guidelines and practical application of preoperative radiotherapy Retrospective IRB approved cohort study from 1999 to 2014 of 36 cancer patients with clinical involvement of cervixparametria treated with neoadjuvant external beam radiotherapy 45-50.4Gy in 25-28 fractions and image-based HDR brachytherapy 5-5.5Gy times 3-4 fractions chemotherapy followed by extrafascial hysterectomy performed at a median of 6weeks after radiotherapy All patients had clinical extension 50 also had parametria extension and 31 had nodal involvement At the time of surgery 91 had no clinical involvement 58 had no pathologic involvement and all had margin negative resection The pathologic complete response rate was 24 Median follow-up from the time of surgery was 20months range 0-153 The 3-year local control regional control distant control disease free survival and overall survival rates were 96 89 84 73 and 100 The 3-year rate of grade 3 complications was 11 with no grade 4+ toxicity Neoadjuvant radiation therapychemotherapy followed by extrafascial hysterectomy appears to be a viable option for patients with cancer clinically extending to the cervix and parametria The HDR brachytherapy schema of 5-5.5Gy times 3-4 fractions for a cumulative EQD2 of 60-70Gy is well tolerated with high rates of clinical and pathological response,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[9, 795, 131, 12, 505, 4782, 6, 3, 3629, 100, 24, 4887, 1923, 221, 632, 711, 2622, 5, 3632, 249, 36, 15, 536, 36, 370, 20, 8, 299, 1344, 2763, 2622, 694, 3027, 74, 2481, 6, 1597, 1391, 677, 2, 3320, 1581, 1, 498, 310, 459, 5880, 850, 180, 45, 29, 2043, 6, 1409, 1, 511, 12, 7, 5, 38, 799, 1, 64915, 73, 5, 536, 1455, 1345, 310, 512, 212, 17384, 4, 243, 339, 1550, 2, 1482, 90, 5309, 1536, 33, 33, 19227, 1072, 27, 39, 1550, 48580, 370, 20, 25094, 2622, 173, 28, 8, 52, 1, 40836, 50, 310, 62, 7, 42, 38, 2401, 212, 120, 42, 19585, 2401, 2, 456, 42, 779, 799, 28, 3, 98, 1, 152, 970, 42, 77, 38, 799, 717, 42, 77, 510, 799, 2, 62, 42, 959, 199, 170, 3, 510, 236, 51, 116, 10, 259, 52, 166, 126, 29, 3, 98, 1, 152, 10, 48581, 184, 13, 4251, 3, 27, 111, 293, 182, 951, 182, 626, 182, 34, 115, 25, 2, 63, 25, 151, 11, 921, 887, 874, 803, 2, 394, 3, 27, 111, 116, 1, 88, 27, 521, 10, 175, 5, 77, 88, 39, 155, 536, 121, 64916, 370, 20, 25094, 2622, 1233, 6, 40, 8, 2663, 1501, 9, 7, 5, 12, 505, 4782, 6, 3, 3629, 2, 19585, 3, 5309, 1536, 8371, 1, 33, 33, 19227, 1072, 27, 39, 1550, 9, 8, 967, 10010, 1, 335, 26282, 16, 149, 421, 5, 64, 151, 1, 38, 2, 1301, 51]",1618.0,25218303,0
Differences between nurse practitioner and physician care providers on rates of secondary cancer screening and discussion of lifestyle changes among breast cancer survivors.,Journal of cancer survivorship : research and practice,J Cancer Surviv,2014-10-09,"Breast cancer survivorship care is provided by surgical and medical oncologists, primary care physicians (PCPs), and nurse practitioner survivorship specialists (NPs). The study objective was to identify whether frequency of cancer screening and discussion of healthy lifestyles differed across these provider types. We also determined differences by provider in survivor reported follow through with lifestyle recommendations. Breast cancer survivors completed surveys regarding the type of health-care provider they most recently saw, cancer screening, discussion, and self-reported lifestyle change since their breast cancer diagnosis. Seven hundred fifty-nine breast cancer survivors (78.7 % of those invited) completed the survey; 51.8 % indicated that their last visit was with a medical oncologist. There was no difference in rates of cancer screening (colon, cervical, and breast) among types of providers. A significantly larger proportion of patients who last saw an NP reported that they had discussed physical activity (78.6 %) as compared to medical oncologist 54.4 %, surgeon 43.1 %, radiation oncologist 64.1 %, and PCP 61.3 % (p<0.001). Similar observations were observed for discussion of nutrition and weight (NP 70.0 %, medical oncologist 36.5 %, surgeon 25.7 %, radiation oncologist 48.7 %, PCP 35.5 %; p<0.001). There was no significant difference across provider type in self-reported implementation of change in physical activity or diet. Our data indicate that a visit to the NP was related to comparable screening rates, but despite that NPs are more often discussing lifestyle modification, self-reported change in nutrition and physical exercise did not differ across provider type. NPs perform favorably with respect to lifestyle recommendations. Given the reported lack of lifestyle change, it is important to triage to providers who specialize in lifestyle modification and, if plausible, learn and provide actual evidence-based approaches to achieve positive outcomes in this area.",Comparative Study,1930.0,6.0,cancer survivorship care is provided by surgical and medical oncologists primary care physicians PCPs and nurse practitioner survivorship specialists NPs The study objective was to identify whether frequency of cancer screening and discussion of healthy lifestyles differed across these provider types We also determined differences by provider in survivor reported follow through with lifestyle recommendations cancer survivors completed surveys regarding the type of health-care provider they most recently saw cancer screening discussion and self-reported lifestyle change since their cancer diagnosis Seven hundred fifty-nine cancer survivors 78.7 of those invited completed the survey 51.8 indicated that their last visit was with a medical oncologist There was no difference in rates of cancer screening and among types of providers A significantly larger proportion of patients who last saw an NP reported that they had discussed physical activity 78.6 as compared to medical oncologist 54.4 surgeon 43.1 radiation oncologist 64.1 and PCP 61.3 p 0.001 Similar observations were observed for discussion of nutrition and weight NP 70.0 medical oncologist 36.5 surgeon 25.7 radiation oncologist 48.7 PCP 35.5 p 0.001 There was no significant difference across provider type in self-reported implementation of change in physical activity or diet Our data indicate that a visit to the NP was related to comparable screening rates but despite that NPs are more often discussing lifestyle modification self-reported change in nutrition and physical exercise did not differ across provider type NPs perform favorably with respect to lifestyle recommendations Given the reported lack of lifestyle change it is important to triage to providers who specialize in lifestyle modification and if plausible learn and provide actual evidence-based approaches to achieve positive outcomes in this area,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 2560, 165, 16, 1052, 20, 221, 2, 484, 1339, 86, 165, 1261, 8640, 2, 6756, 11929, 2560, 4409, 4655, 3, 45, 461, 10, 6, 255, 317, 675, 1, 12, 453, 2, 2488, 1, 1331, 28885, 2512, 716, 46, 3094, 630, 21, 120, 509, 362, 20, 3094, 4, 2628, 210, 166, 298, 5, 3487, 883, 12, 332, 781, 3666, 666, 3, 267, 1, 341, 165, 3094, 491, 96, 761, 9257, 12, 453, 2488, 2, 1074, 210, 3487, 707, 1192, 136, 12, 147, 648, 1128, 1461, 762, 12, 332, 833, 67, 1, 135, 7594, 781, 3, 1407, 725, 66, 1103, 17, 136, 1060, 2807, 10, 5, 8, 484, 2709, 125, 10, 77, 523, 4, 151, 1, 12, 453, 2, 107, 630, 1, 1994, 8, 97, 1077, 920, 1, 7, 54, 1060, 9257, 35, 3769, 210, 17, 491, 42, 1588, 900, 128, 833, 49, 22, 72, 6, 484, 2709, 667, 39, 1897, 601, 14, 121, 2709, 660, 14, 2, 8135, 713, 27, 19, 13, 144, 288, 2172, 11, 164, 9, 2488, 1, 5260, 2, 924, 3769, 431, 13, 484, 2709, 511, 33, 1897, 243, 67, 121, 2709, 576, 67, 8135, 465, 33, 19, 13, 144, 125, 10, 77, 93, 523, 716, 3094, 267, 4, 1074, 210, 2393, 1, 707, 4, 900, 128, 15, 2453, 114, 74, 1008, 17, 8, 2807, 6, 3, 3769, 10, 139, 6, 1279, 453, 151, 84, 550, 17, 4655, 32, 80, 629, 6003, 3487, 2437, 1074, 210, 707, 4, 5260, 2, 900, 2277, 205, 44, 1505, 716, 3094, 267, 4655, 2715, 5001, 5, 2184, 6, 3487, 883, 447, 3, 210, 926, 1, 3487, 707, 192, 16, 305, 6, 9059, 6, 1994, 54, 26572, 4, 3487, 2437, 2, 492, 7761, 7586, 2, 377, 3480, 241, 90, 611, 6, 1359, 109, 123, 4, 26, 965]",1891.0,25297542,2
"Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.",International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2014-11-01,"Overexpression of bcl-2 is a mechanism of drug resistance in cervical cancer. Agents that down-regulate bcl-2 may decrease tumor cell threshold and sensitize tumor cells to chemotherapy. The objective of this multi-institutional phase 2 trial was to evaluate the efficacy and toxicity of paclitaxel and bcl-2 modulators (13-cis retinoic acid and interferon alfa-2b) in patients with advanced-stage or recurrent cervical cancer. Patients had biopsy-proven metastatic, first relapse, or persistent cervical cancer with no prior chemotherapy except for chemosensitizing agents. The treatment consisted of oral 13-cis retinoic acid, 1 mg/kg, and subcutaneous interferon alfa-2b, 6 mU/m, days 1 to 4, and intravenous paclitaxel, 175 mg/m, day 4 until disease progression or adverse events prohibited treatment. The primary endpoint was overall response rate. Thirty-three patients were enrolled between March 2001 and June 2009. Thirty-one patients were eligible for evaluation of treatment response. Twenty-seven patients (82%) received prior concurrent chemoradiation or radiotherapy alone before study enrollment. The overall response rate was 30% (6 complete responses and 4 partial responses). Furthermore, 7 patients (21%) had stable disease. Grade 3 or 4 adverse events included neutropenia (n =16 [48%]), febrile neutropenia (n = 1 [3%]), and anemia (n = 1 [3%]). There were no treatment-related deaths. The median progression-free survival was 3.4 months (95% confidence interval, 2.0-7.4 months), and overall survival was 11.2 months (95% confidence interval, 7.5-26.2 months). Of 6 patients with complete responses, 5 patients survived more than 2 years. Combination therapy with paclitaxel, 13-cis retinoic acid, and interferon alfa-2b is feasible and safe in treating patients with advanced and recurrent cervical cancer.","Clinical Trial, Phase II",1907.0,5.0,Overexpression of bcl-2 is a mechanism of drug resistance in cancer Agents that down-regulate bcl-2 may decrease tumor cell threshold and sensitize tumor cells to chemotherapy The objective of this multi-institutional phase 2 trial was to evaluate the efficacy and toxicity of paclitaxel and bcl-2 modulators 13-cis retinoic acid and interferon alfa-2b in patients with advanced-stage or recurrent cancer Patients had biopsy-proven metastatic first relapse or persistent cancer with no prior chemotherapy except for chemosensitizing agents The treatment consisted of oral 13-cis retinoic acid 1 mg/kg and subcutaneous interferon alfa-2b 6 mU/m days 1 to 4 and intravenous paclitaxel 175 mg/m day 4 until disease progression or adverse events prohibited treatment The primary endpoint was overall response rate Thirty-three patients were enrolled between March 2001 and June 2009 Thirty-one patients were eligible for evaluation of treatment response Twenty-seven patients 82 received prior concurrent chemoradiation or radiotherapy alone before study enrollment The overall response rate was 30 6 complete responses and 4 partial responses Furthermore 7 patients 21 had stable disease Grade 3 or 4 adverse events included neutropenia n =16 48 febrile neutropenia n 1 3 and anemia n 1 3 There were no treatment-related deaths The median progression-free survival was 3.4 months 95 confidence interval 2.0-7.4 months and overall survival was 11.2 months 95 confidence interval 7.5-26.2 months Of 6 patients with complete responses 5 patients survived more than 2 years Combination therapy with paclitaxel 13-cis retinoic acid and interferon alfa-2b is feasible and safe in treating patients with advanced and recurrent cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[851, 1, 1044, 18, 16, 8, 670, 1, 234, 251, 4, 12, 183, 17, 1328, 2288, 1044, 18, 68, 775, 30, 31, 2390, 2, 5745, 30, 37, 6, 56, 3, 461, 1, 26, 1414, 1115, 124, 18, 160, 10, 6, 376, 3, 209, 2, 155, 1, 490, 2, 1044, 18, 5014, 233, 1927, 3887, 971, 2, 1688, 4443, 3381, 4, 7, 5, 131, 82, 15, 387, 12, 7, 42, 411, 1930, 113, 157, 429, 15, 1882, 12, 5, 77, 324, 56, 2187, 9, 16829, 183, 3, 24, 1695, 1, 518, 233, 1927, 3887, 971, 14, 81, 503, 2, 2529, 1688, 4443, 3381, 49, 6601, 188, 162, 14, 6, 39, 2, 1262, 490, 3300, 81, 188, 218, 39, 1100, 34, 91, 15, 290, 281, 19105, 24, 3, 86, 1138, 10, 63, 51, 116, 977, 169, 7, 11, 346, 59, 2363, 1758, 2, 1924, 1238, 977, 104, 7, 11, 625, 9, 451, 1, 24, 51, 737, 648, 7, 878, 103, 324, 750, 975, 15, 310, 279, 348, 45, 1798, 3, 63, 51, 116, 10, 201, 49, 236, 253, 2, 39, 450, 253, 798, 67, 7, 239, 42, 585, 34, 88, 27, 15, 39, 290, 281, 159, 778, 78, 245, 576, 2498, 778, 78, 14, 27, 2, 1545, 78, 14, 27, 125, 11, 77, 24, 139, 1043, 3, 52, 91, 115, 25, 10, 27, 39, 53, 48, 307, 268, 18, 13, 67, 39, 53, 2, 63, 25, 10, 175, 18, 53, 48, 307, 268, 67, 33, 432, 18, 53, 1, 49, 7, 5, 236, 253, 33, 7, 2996, 80, 76, 18, 60, 150, 36, 5, 490, 233, 1927, 3887, 971, 2, 1688, 4443, 3381, 16, 1313, 2, 1165, 4, 1367, 7, 5, 131, 2, 387, 12]",1723.0,25304678,143
Comparison and consensus guidelines for delineation of clinical target volume for CT- and MR-based brachytherapy in locally advanced cervical cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2014-10-01,"To create and compare consensus clinical target volume (CTV) contours for computed tomography (CT) and 3-Tesla (3-T) magnetic resonance (MR) image-based cervical-cancer brachytherapy. Twenty-three experts in gynecologic radiation oncology contoured the same 3 cervical cancer brachytherapy cases: 1 stage IIB near-complete response (CR) case with a tandem and ovoid, 1 stage IIB partial response (PR) case with tandem and ovoid with needles, and 1 stage IB2 CR case with a tandem and ring applicator. The CT contours were completed before the MRI contours. These were analyzed for consistency and clarity of target delineation using an expectation maximization algorithm for simultaneous truth and performance level estimation (STAPLE), with  statistics as a measure of agreement between participants. The conformity index was calculated for each of the 6 data sets. Dice coefficients were generated to compare the CT and MR contours of the same case. For all 3 cases, the mean tumor volume was smaller on MR than on CT (P<.001). The  and conformity index estimates were slightly higher for CT, indicating a higher level of agreement on CT. The Dice coefficients were 89% for the stage IB2 case with a CR, 74% for the stage IIB case with a PR, and 57% for the stage IIB case with a CR. In a comparison of MR-contoured with CT-contoured CTV volumes, the higher level of agreement on CT may be due to the more distinct contrast medium visible on the images at the time of brachytherapy. MR at the time of brachytherapy may be of greatest benefit in patients with large tumors with parametrial extension that have a partial or complete response to external beam. On the basis of these results, a 95% consensus volume was generated for CT and for MR. Online contouring atlases are available for instruction at http://www.nrgoncology.org/Resources/ContouringAtlases/GYNCervicalBrachytherapy.aspx.",Comparative Study,1938.0,69.0,To create and compare consensus clinical target volume CTV contours for computed tomography CT and 3-Tesla 3-T magnetic resonance MR image-based cervical-cancer brachytherapy Twenty-three experts in gynecologic radiation oncology contoured the same 3 cancer brachytherapy cases 1 stage IIB near-complete response CR case with a tandem and ovoid 1 stage IIB partial response PR case with tandem and ovoid with needles and 1 stage IB2 CR case with a tandem and ring applicator The CT contours were completed before the MRI contours These were analyzed for consistency and clarity of target delineation using an expectation maximization algorithm for simultaneous truth and performance level estimation STAPLE with  statistics as a measure of agreement between participants The conformity index was calculated for each of the 6 data sets Dice coefficients were generated to compare the CT and MR contours of the same case For all 3 cases the mean tumor volume was smaller on MR than on CT P .001 The  and conformity index estimates were slightly higher for CT indicating a higher level of agreement on CT The Dice coefficients were 89 for the stage IB2 case with a CR 74 for the stage IIB case with a PR and 57 for the stage IIB case with a CR In a comparison of MR-contoured with CT-contoured CTV volumes the higher level of agreement on CT may be due to the more distinct contrast medium visible on the images at the time of brachytherapy MR at the time of brachytherapy may be of greatest benefit in patients with large tumors with parametrial extension that have a partial or complete response to external beam On the basis of these results a 95 consensus volume was generated for CT and for MR. Online contouring atlases are available for instruction at http //www.nrgoncology.org/Resources/ContouringAtlases/GYNCervicalBrachytherapy.aspx,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 3736, 2, 932, 1391, 38, 283, 433, 3402, 6137, 9, 1220, 872, 425, 2, 27, 22173, 27, 102, 1484, 1535, 1638, 1482, 90, 18237, 12, 1536, 737, 169, 3186, 4, 1512, 121, 413, 6476, 3, 827, 27, 12, 1536, 140, 14, 82, 3884, 1829, 236, 51, 684, 473, 5, 8, 2905, 2, 15300, 14, 82, 3884, 450, 51, 998, 473, 5, 2905, 2, 15300, 5, 14393, 2, 14, 82, 9537, 684, 473, 5, 8, 2905, 2, 4091, 8789, 3, 425, 6137, 11, 781, 348, 3, 704, 6137, 46, 11, 311, 9, 5358, 2, 12901, 1, 283, 5529, 75, 35, 9988, 16318, 2124, 9, 2824, 14660, 2, 528, 301, 4470, 14259, 5, 4627, 3065, 22, 8, 1463, 1, 2024, 59, 776, 3, 8693, 558, 10, 981, 9, 296, 1, 3, 49, 74, 2270, 13685, 5161, 11, 1419, 6, 932, 3, 425, 2, 1638, 6137, 1, 3, 827, 473, 9, 62, 27, 140, 3, 313, 30, 433, 10, 2170, 23, 1638, 76, 23, 425, 19, 144, 3, 4627, 2, 8693, 558, 1423, 11, 3223, 142, 9, 425, 1716, 8, 142, 301, 1, 2024, 23, 425, 3, 13685, 5161, 11, 887, 9, 3, 82, 9537, 473, 5, 8, 684, 794, 9, 3, 82, 3884, 473, 5, 8, 998, 2, 696, 9, 3, 82, 3884, 473, 5, 8, 684, 4, 8, 1155, 1, 1638, 6476, 5, 425, 6476, 3402, 2225, 3, 142, 301, 1, 2024, 23, 425, 68, 40, 520, 6, 3, 80, 834, 748, 3759, 4822, 23, 3, 1572, 28, 3, 98, 1, 1536, 1638, 28, 3, 98, 1, 1536, 68, 40, 1, 2199, 247, 4, 7, 5, 375, 57, 5, 8726, 2401, 17, 47, 8, 450, 15, 236, 51, 6, 1455, 1345, 23, 3, 877, 1, 46, 99, 8, 48, 1391, 433, 10, 1419, 9, 425, 2, 9, 1638, 4123, 7997, 20639, 32, 390, 9, 19661, 28, 5196, 3064, 65063, 5598, 2892, 65064, 65065, 65066]",1842.0,25304792,733
A multicenter phase 1 study of  -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors.,Investigational new drugs,Invest New Drugs,2014-10-17,"RO4929097 is an oral inhibitor of  -secretase that results in Notch signaling inhibition. Prior work has demonstrated that Notch signaling inhibition enhances chemotherapy sensitivity of cancer cells. This phase I study was conducted to determine maximum tolerated dose (MTD), toxicities and efficacy of RO4929097 and capecitabine in advanced solid tumors. Patients with refractory solid tumors received capecitabine at a fixed dose of 1,000 mg/m(2) twice daily with escalating doses of RO4929097 on a 21-day cycle in a 3+3 design. Capecitabine was administered for 14 days and the RO49029097 once daily, 3 days per week, both for a 21 day cycle. Thirty patients were treated on six dose levels (20 to 150 mg). The maximally tolerated dose was not reached. One dose limiting toxicity was observed at each level 3 through 6 (hypophosphatemia, fatigue, and nausea/vomiting). Three confirmed partial responses were observed: two patients with fluoropyrimide-refractory colon cancer and one patient with cervical cancer. Autoinduction of RO4929097 was demonstrated with increasing dose levels and duration. The recommended phase 2 dose is capecitabine 1,000 mg/m(2) orally twice daily on days 1 through 14 with RO4929097 20 mg orally once daily on days 1-3, 8-10 and 15-17 with a 21 day cycle. Clinical benefit was observed in cervical and colon cancer. Autoinduction of RO4929097 was seen both with increasing cycle number and increasing dose. Plasma concentrations of RO4929097 were above those needed for Notch inhibition.","Clinical Trial, Phase I",1922.0,24.0,"RO4929097 is an oral inhibitor of  -secretase that results in Notch signaling inhibition Prior work has demonstrated that Notch signaling inhibition enhances chemotherapy sensitivity of cancer cells This phase I study was conducted to determine maximum tolerated dose MTD toxicities and efficacy of RO4929097 and capecitabine in advanced solid tumors Patients with refractory solid tumors received capecitabine at a fixed dose of 1,000 mg/m 2 twice daily with escalating doses of RO4929097 on a 21-day cycle in a 3 3 design Capecitabine was administered for 14 days and the RO49029097 once daily 3 days per week both for a 21 day cycle Thirty patients were treated on six dose levels 20 to 150 mg The maximally tolerated dose was not reached One dose limiting toxicity was observed at each level 3 through 6 hypophosphatemia fatigue and nausea/vomiting Three confirmed partial responses were observed two patients with fluoropyrimide-refractory cancer and one patient with cancer Autoinduction of RO4929097 was demonstrated with increasing dose levels and duration The recommended phase 2 dose is capecitabine 1,000 mg/m 2 orally twice daily on days 1 through 14 with RO4929097 20 mg orally once daily on days 1-3 8-10 and 15-17 with a 21 day cycle Clinical benefit was observed in and cancer Autoinduction of RO4929097 was seen both with increasing cycle number and increasing dose Plasma concentrations of RO4929097 were above those needed for Notch inhibition",0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[10507, 16, 35, 518, 230, 1, 2655, 10014, 17, 99, 4, 3193, 314, 297, 324, 1357, 71, 264, 17, 3193, 314, 297, 2519, 56, 485, 1, 12, 37, 26, 124, 70, 45, 10, 426, 6, 223, 689, 421, 61, 961, 385, 2, 209, 1, 10507, 2, 1629, 4, 131, 537, 57, 7, 5, 430, 537, 57, 103, 1629, 28, 8, 1959, 61, 1, 14, 984, 81, 188, 18, 936, 391, 5, 2922, 415, 1, 10507, 23, 8, 239, 218, 417, 4, 8, 27, 27, 771, 1629, 10, 468, 9, 213, 162, 2, 3, 65081, 1059, 391, 27, 162, 379, 647, 110, 9, 8, 239, 218, 417, 977, 7, 11, 73, 23, 437, 61, 148, 179, 6, 1577, 81, 3, 6402, 421, 61, 10, 44, 1300, 104, 61, 817, 155, 10, 164, 28, 296, 301, 27, 298, 49, 8021, 613, 2, 1218, 1966, 169, 557, 450, 253, 11, 164, 100, 7, 5, 65082, 430, 12, 2, 104, 69, 5, 12, 33281, 1, 10507, 10, 264, 5, 602, 61, 148, 2, 654, 3, 793, 124, 18, 61, 16, 1629, 14, 984, 81, 188, 18, 1428, 936, 391, 23, 162, 14, 298, 213, 5, 10507, 179, 81, 1428, 1059, 391, 23, 162, 14, 27, 66, 79, 2, 167, 269, 5, 8, 239, 218, 417, 38, 247, 10, 164, 4, 2, 12, 33281, 1, 10507, 10, 527, 110, 5, 602, 417, 207, 2, 602, 61, 554, 1003, 1, 10507, 11, 2090, 135, 575, 9, 3193, 297]",1463.0,25318436,174
Hydronephrosis in patients with cervical cancer: an assessment of morbidity and survival.,Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,Support Care Cancer,2014-10-23,"Hydronephrosis is a frequently observed but understudied complication in patients with cervical cancer. To better characterize hydronephrosis in cervical cancer patients, the current study sought (1) to describe hydronephrosis-associated morbidity and (2) to analyze the prognostic effect of hydronephrosis in patients with a broad range of cancer stages over time. The Mayo Clinic Tumor Registry was interrogated for all invasive cervical cancer patients seen at the Mayo Clinic from 2008 through 2013 in Rochester, Minnesota; these patients' medical records were then reviewed in detail. Two hundred seventy-nine cervical cancer patients with a median age of 49 years and a range of cancer stages were included. Sixty-five patients (23 %) were diagnosed with hydronephrosis at some point during their disease course. In univariate analyses, hydronephrosis was associated with advanced cancer stage (p<0.0001), squamous histology (p=0.0079), and nonsurgical cancer treatment (p=0.0039). In multivariate analyses, stage and tumor histology were associated with hydronephrosis. All but one patient underwent stent placement or urinary diversion; hydronephrosis-related morbidity included pain, urinary tract infections, nausea and vomiting, renal failure, and urinary tract bleeding. In landmark univariate survival analyses, hydronephrosis was associated with worse survival at all time points. In landmark multivariate analyses (adjusted for patient age, stage, cancer treatment, and tumor histology), hydronephrosis was associated with a trend toward worse survival over time (hazard ratios ranged from 1.47 to 4.69). Hydronephrosis in cervical cancer patients is associated with notable morbidity. It is also associated with trends toward worse survival-even if it occurs after the original cancer diagnosis.",Journal Article,1916.0,13.0,Hydronephrosis is a frequently observed but understudied complication in patients with cancer To better characterize hydronephrosis in cancer patients the current study sought 1 to describe hydronephrosis-associated morbidity and 2 to analyze the prognostic effect of hydronephrosis in patients with a broad range of cancer stages over time The Mayo Clinic Tumor Registry was interrogated for all invasive cancer patients seen at the Mayo Clinic from 2008 through 2013 in Rochester Minnesota these patients medical records were then reviewed in detail Two hundred seventy-nine cancer patients with a median age of 49 years and a range of cancer stages were included Sixty-five patients 23 were diagnosed with hydronephrosis at some point during their disease course In univariate analyses hydronephrosis was associated with advanced cancer stage p 0.0001 squamous histology p 0.0079 and nonsurgical cancer treatment p 0.0039 In multivariate analyses stage and tumor histology were associated with hydronephrosis All but one patient underwent stent placement or urinary diversion hydronephrosis-related morbidity included pain urinary tract infections nausea and vomiting failure and urinary tract bleeding In landmark univariate survival analyses hydronephrosis was associated with worse survival at all time points In landmark multivariate analyses adjusted for patient age stage cancer treatment and tumor histology hydronephrosis was associated with a trend toward worse survival over time hazard ratios ranged from 1.47 to 4.69 Hydronephrosis in cancer patients is associated with notable morbidity It is also associated with trends toward worse survival-even if it occurs after the original cancer diagnosis,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[11977, 16, 8, 746, 164, 84, 8207, 1447, 4, 7, 5, 12, 6, 380, 1507, 11977, 4, 12, 7, 3, 291, 45, 990, 14, 6, 897, 11977, 41, 787, 2, 18, 6, 1992, 3, 177, 254, 1, 11977, 4, 7, 5, 8, 2094, 184, 1, 12, 1153, 252, 98, 3, 2486, 1188, 30, 1608, 10, 7227, 9, 62, 416, 12, 7, 527, 28, 3, 2486, 1188, 29, 1375, 298, 1346, 4, 5801, 8297, 46, 7, 484, 1064, 11, 818, 446, 4, 5000, 100, 1128, 2073, 762, 12, 7, 5, 8, 52, 89, 1, 739, 60, 2, 8, 184, 1, 12, 1153, 11, 159, 1746, 365, 7, 382, 11, 265, 5, 11977, 28, 476, 741, 190, 136, 34, 906, 4, 880, 318, 11977, 10, 41, 5, 131, 12, 82, 19, 13, 488, 691, 784, 19, 13, 23407, 2, 5544, 12, 24, 19, 13, 20518, 4, 331, 318, 82, 2, 30, 784, 11, 41, 5, 11977, 62, 84, 104, 69, 208, 7601, 2613, 15, 1660, 6067, 11977, 139, 787, 159, 559, 1660, 1696, 1875, 1218, 2, 1966, 496, 2, 1660, 1696, 2294, 4, 3829, 880, 25, 318, 11977, 10, 41, 5, 639, 25, 28, 62, 98, 862, 4, 3829, 331, 318, 586, 9, 69, 89, 82, 12, 24, 2, 30, 784, 11977, 10, 41, 5, 8, 853, 1317, 639, 25, 252, 98, 360, 1137, 1869, 29, 14, 662, 6, 39, 790, 11977, 4, 12, 7, 16, 41, 5, 4090, 787, 192, 16, 120, 41, 5, 1963, 1317, 639, 25, 871, 492, 192, 1780, 50, 3, 2279, 12, 147]",1712.0,25339620,259
Factors associated with grade 3 or 4 treatment-related toxicity in women with advanced or recurrent cervical cancer: an exploratory analysis of NRG Oncology/Gynecologic Oncology Group trials 179 and 204.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2015-02-01,"This study aimed to describe pretreatment patient characteristics and baseline quality-of-life scores as they relate to the development of grade 3 or 4 toxicity in patients receiving chemotherapy for advanced/recurrent cervical cancer. The study sample was drawn from Gynecologic Oncology Group protocols 179 and 204. Grade 3 or 4 toxicities were considered in 4 specified categories as follows: peripheral neuropathy, fatigue, hematological, and gastrointestinal (GI). The data variables explored included age, stage, pretreatment radiation, performance status (PS) at treatment initiation, and baseline Functional Assessment of Cancer Therapy-Cervix (FACT-Cx) score. A logistic regression model was developed with various adverse events as binary (0/1) outcomes. Six hundred seventy-three patient-reported questionnaires were used in the analyses. At baseline, pain was the most severe patient-reported symptom. Baseline line-item patient concerns did demonstrate specific correlations with the development of individual toxicities. In 401 patients who were enrolled on Gynecologic Oncology Group 204 (fatigue not measured on 179), a worse PS predicted the development of grade 3 or 4 fatigue (odds ratio, 2.78; 95% confidence interval, 1.66-4.68). Exposure to previous radiation, treatment regimen, and a worse FACT-Cx score were associated with the reporting of both grade 3 or 4 leukopenia (P < 0.05) and anemia (P < 0.0005). Performance status and treatment regimen (P < 0.05) were associated with the development of grade 3 or 4 thrombocytopenia. Age and treatment regimen (P < 0.05) were associated with the development of grade 3 or 4 neutropenia. The FACT-Cx score (P = 0.0016) predicted grade 3 or 4 GI toxicity. The development of fatigue, hematological, and GI toxicity might be predictable based on factors other than treatment assignment such as age, PS, and patient-reported quality-of-life measurement.",Journal Article,1815.0,3.0,This study aimed to describe pretreatment patient characteristics and baseline quality-of-life scores as they relate to the development of grade 3 or 4 toxicity in patients receiving chemotherapy for advanced/recurrent cancer The study sample was drawn from Gynecologic Oncology Group protocols 179 and 204 Grade 3 or 4 toxicities were considered in 4 specified categories as follows peripheral neuropathy fatigue hematological and GI The data variables explored included age stage pretreatment radiation performance status PS at treatment initiation and baseline Functional Assessment of Cancer Therapy-Cervix FACT-Cx score A logistic regression model was developed with various adverse events as binary 0/1 outcomes Six hundred seventy-three patient-reported questionnaires were used in the analyses At baseline pain was the most severe patient-reported symptom Baseline line-item patient concerns did demonstrate specific correlations with the development of individual toxicities In 401 patients who were enrolled on Gynecologic Oncology Group 204 fatigue not measured on 179 a worse PS predicted the development of grade 3 or 4 fatigue odds ratio 2.78 95 confidence interval 1.66-4.68 Exposure to previous radiation treatment regimen and a worse FACT-Cx score were associated with the reporting of both grade 3 or 4 leukopenia P 0.05 and anemia P 0.0005 Performance status and treatment regimen P 0.05 were associated with the development of grade 3 or 4 thrombocytopenia Age and treatment regimen P 0.05 were associated with the development of grade 3 or 4 neutropenia The FACT-Cx score P 0.0016 predicted grade 3 or 4 GI toxicity The development of fatigue hematological and GI toxicity might be predictable based on factors other than treatment assignment such as age PS and patient-reported quality-of-life measurement,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[26, 45, 1295, 6, 897, 1194, 69, 374, 2, 330, 372, 1, 358, 703, 22, 491, 6509, 6, 3, 193, 1, 88, 27, 15, 39, 155, 4, 7, 357, 56, 9, 131, 387, 12, 3, 45, 1000, 10, 5694, 29, 1512, 413, 87, 2189, 5977, 2, 5996, 88, 27, 15, 39, 385, 11, 515, 4, 39, 3575, 1996, 22, 2962, 672, 1751, 613, 2890, 2, 2104, 3, 74, 682, 1443, 159, 89, 82, 1194, 121, 528, 156, 1511, 28, 24, 1118, 2, 330, 583, 455, 1, 12, 36, 3629, 1991, 13627, 368, 8, 812, 320, 202, 10, 276, 5, 747, 290, 281, 22, 6405, 13, 14, 123, 437, 1128, 2073, 169, 69, 210, 2956, 11, 95, 4, 3, 318, 28, 330, 559, 10, 3, 96, 905, 69, 210, 934, 330, 328, 3471, 69, 2061, 205, 608, 112, 2553, 5, 3, 193, 1, 797, 385, 4, 7191, 7, 54, 11, 346, 23, 1512, 413, 87, 5996, 613, 44, 644, 23, 5977, 8, 639, 1511, 783, 3, 193, 1, 88, 27, 15, 39, 613, 610, 197, 18, 833, 48, 307, 268, 14, 700, 39, 806, 645, 6, 698, 121, 24, 477, 2, 8, 639, 1991, 13627, 368, 11, 41, 5, 3, 1760, 1, 110, 88, 27, 15, 39, 3904, 19, 13, 474, 2, 1545, 19, 13, 4252, 528, 156, 2, 24, 477, 19, 13, 474, 11, 41, 5, 3, 193, 1, 88, 27, 15, 39, 1340, 89, 2, 24, 477, 19, 13, 474, 11, 41, 5, 3, 193, 1, 88, 27, 15, 39, 778, 3, 1991, 13627, 368, 19, 13, 13230, 783, 88, 27, 15, 39, 2104, 155, 3, 193, 1, 613, 2890, 2, 2104, 155, 822, 40, 7639, 90, 23, 130, 127, 76, 24, 4392, 225, 22, 89, 1511, 2, 69, 210, 372, 1, 358, 2204]",1827.0,25405577,143
"Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.",Cancer,Cancer,2014-11-19,"The current phase 1, open-label, dose escalation study was conducted to establish the safety, tolerability, pharmacokinetic profile, and preliminary antitumor activity of the novel mitochondrial inhibitor ME-344 in patients with refractory solid tumors. Patients with refractory solid tumors were treated in a 3 + 3 dose escalation design. ME-344 was administered via intravenous infusion on days 1, 8, and 15 of the first 28-day cycle and weekly thereafter. Pharmacokinetics was assessed on days 1 and 15 of the first cycle. A total of 30 patients (median age, 65 years; 67% of whom were female) received ME-344. There were 5 dose-limiting toxicities reported. Four patients developed grade 3 neuropathy (2 patients each at doses of 15 mg/kg and 20 mg/kg) and 1 patient treated at a dose of 10 mg/kg developed a grade 3 acute myocardial infarction (toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.03]). The maximum tolerated dose (MTD) was defined as 10 mg/kg weekly. The most common adverse events were nausea, dizziness, and fatigue. At the MTD of 10 mg/kg, the maximal plasma concentration (Cmax) was 25.8 g/mL and the area under the concentration curve from time zero to infinity was 25.9 hour*g/mL. One patient with small cell lung cancer achieved a partial response for  52 weeks. Four patients had prolonged stable disease (1 patient each with urothelial carcinoma [47 weeks], carcinoid tumor [ 40 weeks], cervical leiomyosarcoma [39 weeks], and cervical cancer [ 31 weeks]). The once-weekly administration of ME-344 was generally well tolerated in the current study, a first-in-human study; dose-limiting neuropathy was noted, but not at the MTD. Exposures at the 10-mg/kg dose level suggest a sufficient therapeutic index. The preliminary clinical activity as a monotherapy supports the further clinical development of ME-344 in combination with chemotherapy.","Clinical Trial, Phase I",1889.0,13.0,The current phase 1 open-label dose escalation study was conducted to establish the safety tolerability pharmacokinetic profile and preliminary antitumor activity of the novel mitochondrial inhibitor ME-344 in patients with refractory solid tumors Patients with refractory solid tumors were treated in a 3 3 dose escalation design ME-344 was administered via intravenous infusion on days 1 8 and 15 of the first 28-day cycle and weekly thereafter Pharmacokinetics was assessed on days 1 and 15 of the first cycle A total of 30 patients median age 65 years 67 of whom were female received ME-344 There were 5 dose-limiting toxicities reported Four patients developed grade 3 neuropathy 2 patients each at doses of 15 mg/kg and 20 mg/kg and 1 patient treated at a dose of 10 mg/kg developed a grade 3 acute myocardial infarction toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 The maximum tolerated dose MTD was defined as 10 mg/kg weekly The most common adverse events were nausea dizziness and fatigue At the MTD of 10 mg/kg the maximal plasma concentration Cmax was 25.8 g/mL and the area under the concentration curve from time zero to infinity was 25.9 hour*g/mL One patient with small cell cancer achieved a partial response for  52 weeks Four patients had prolonged stable disease 1 patient each with urothelial carcinoma 47 weeks tumor  40 weeks leiomyosarcoma 39 weeks and cancer  31 weeks The once-weekly administration of ME-344 was generally well tolerated in the current study a first-in-human study dose-limiting neuropathy was noted but not at the MTD Exposures at the 10-mg/kg dose level suggest a sufficient therapeutic index The preliminary clinical activity as a monotherapy supports the further clinical development of ME-344 in combination with chemotherapy,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 291, 124, 14, 1020, 1756, 61, 1125, 45, 10, 426, 6, 1811, 3, 367, 1543, 1456, 800, 2, 1676, 579, 128, 1, 3, 229, 2019, 230, 4816, 6993, 4, 7, 5, 430, 537, 57, 7, 5, 430, 537, 57, 11, 73, 4, 8, 27, 27, 61, 1125, 771, 4816, 6993, 10, 468, 847, 1262, 904, 23, 162, 14, 66, 2, 167, 1, 3, 157, 339, 218, 417, 2, 709, 3972, 1159, 10, 275, 23, 162, 14, 2, 167, 1, 3, 157, 417, 8, 181, 1, 201, 7, 52, 89, 556, 60, 598, 1, 953, 11, 1061, 103, 4816, 6993, 125, 11, 33, 61, 817, 385, 210, 294, 7, 276, 88, 27, 1751, 18, 7, 296, 28, 415, 1, 167, 81, 503, 2, 179, 81, 503, 2, 14, 69, 73, 28, 8, 61, 1, 79, 81, 503, 276, 8, 88, 27, 286, 5098, 6124, 155, 10, 3468, 768, 6, 3, 657, 12, 1377, 186, 3462, 371, 9, 290, 281, 2256, 39, 680, 3, 689, 421, 61, 961, 10, 395, 22, 79, 81, 503, 709, 3, 96, 186, 290, 281, 11, 1218, 11489, 2, 613, 28, 3, 961, 1, 79, 81, 503, 3, 2725, 554, 1227, 9818, 10, 243, 66, 7570, 542, 2, 3, 965, 669, 3, 1227, 1496, 29, 98, 5115, 6, 12290, 10, 243, 83, 2583, 7570, 542, 104, 69, 5, 302, 31, 12, 513, 8, 450, 51, 9, 749, 653, 244, 294, 7, 42, 1069, 585, 34, 14, 69, 296, 5, 1472, 134, 662, 244, 30, 749, 327, 244, 3717, 587, 244, 2, 12, 749, 456, 244, 3, 1059, 709, 634, 1, 4816, 6993, 10, 1228, 149, 421, 4, 3, 291, 45, 8, 157, 4, 171, 45, 61, 817, 1751, 10, 1051, 84, 44, 28, 3, 961, 3401, 28, 3, 79, 81, 503, 61, 301, 309, 8, 1952, 189, 558, 3, 1676, 38, 128, 22, 8, 1411, 2304, 3, 195, 38, 193, 1, 4816, 6993, 4, 150, 5, 56]",1856.0,25411085,211
Morbid obesity as an independent risk factor for disease-specific mortality in women with cervical cancer.,Obstetrics and gynecology,Obstet Gynecol,2014-12-01,"To assess whether obesity is an independent predictor of mortality in women with cervical cancer. This retrospective cohort study of patients with stages IB1-IVA cervical cancer treated with curative intent at MD Anderson Cancer Center from 1980 through 2007 categorized these women as underweight, normal weight, overweight, obese, or morbidly obese according to National Institutes of Health definitions. In addition to weight category, known prognostic factors for survival after a diagnosis of cervical cancer were included in a multivariate model. These known prognostic factors included age, smoking status, race or ethnicity (self-reported), socioeconomic status, comorbidities, tumor histologic subtype, tumor stage, tumor size, presence or absence of hydronephrosis, radiologic evidence of nodal metastasis, and the addition of concurrent chemotherapy with definitive radiation. A total of 3,086 patients met the inclusion criteria. The median survival for the entire cohort was 81 months (range 0-365 months). The presence of lymph node spread and advancing stage were the most significant predictors of survival. Compared with normal-weight women, morbidly obese women had a significantly higher hazard ratio for both all-cause death (hazard ratio 1.26, 95% confidence interval [CI] 1.10-1.45) and disease-specific death (hazard ratio 1.24, 95% CI 1.06-1.47). Underweight, overweight, and obese women did not have an increased risk for death compared with normal-weight women. After controlling for all previously known prognostic factors, morbid obesity remains an independent risk factor for death from cervical cancer. Overweight and obese women have the same prognosis as normal-weight women.",Journal Article,1877.0,22.0,"To assess whether obesity is an independent predictor of mortality in women with cancer This retrospective cohort study of patients with stages IB1-IVA cancer treated with curative intent at MD Anderson Cancer Center from 1980 through 2007 categorized these women as underweight normal weight overweight obese or morbidly obese according to National Institutes of Health definitions In addition to weight category known prognostic factors for survival after a diagnosis of cancer were included in a multivariate model These known prognostic factors included age smoking status race or ethnicity self-reported socioeconomic status comorbidities tumor histologic subtype tumor stage tumor size presence or absence of hydronephrosis radiologic evidence of nodal metastasis and the addition of concurrent chemotherapy with definitive radiation A total of 3,086 patients met the inclusion criteria The median survival for the entire cohort was 81 months range 0-365 months The presence of lymph node spread and advancing stage were the most significant predictors of survival Compared with normal-weight women morbidly obese women had a significantly higher hazard ratio for both all-cause death hazard ratio 1.26 95 confidence interval CI 1.10-1.45 and disease-specific death hazard ratio 1.24 95 CI 1.06-1.47 Underweight overweight and obese women did not have an increased risk for death compared with normal-weight women After controlling for all previously known prognostic factors morbid obesity remains an independent risk factor for death from cancer Overweight and obese women have the same prognosis as normal-weight women",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 423, 317, 1661, 16, 35, 306, 980, 1, 282, 4, 117, 5, 12, 26, 459, 180, 45, 1, 7, 5, 1153, 8111, 5900, 12, 73, 5, 1075, 1697, 28, 2244, 1929, 12, 574, 29, 4376, 298, 1307, 2320, 46, 117, 22, 8094, 295, 924, 3566, 2209, 15, 9920, 2209, 768, 6, 657, 5973, 1, 341, 3833, 4, 352, 6, 924, 2169, 440, 177, 130, 9, 25, 50, 8, 147, 1, 12, 11, 159, 4, 8, 331, 202, 46, 440, 177, 130, 159, 89, 979, 156, 1047, 15, 2091, 1074, 210, 3331, 156, 1909, 30, 884, 875, 30, 82, 30, 444, 463, 15, 1127, 1, 11977, 2812, 241, 1, 779, 278, 2, 3, 352, 1, 750, 56, 5, 1057, 121, 8, 181, 1, 27, 16798, 7, 543, 3, 1680, 371, 3, 52, 25, 9, 3, 1797, 180, 10, 865, 53, 184, 13, 7405, 53, 3, 463, 1, 263, 289, 2579, 2, 5155, 82, 11, 3, 96, 93, 674, 1, 25, 72, 5, 295, 924, 117, 9920, 2209, 117, 42, 8, 97, 142, 360, 197, 9, 110, 62, 708, 273, 360, 197, 14, 432, 48, 307, 268, 58, 14, 79, 14, 512, 2, 34, 112, 273, 360, 197, 14, 259, 48, 58, 14, 1460, 14, 662, 8094, 3566, 2, 2209, 117, 205, 44, 47, 35, 101, 43, 9, 273, 72, 5, 295, 924, 117, 50, 1893, 9, 62, 373, 440, 177, 130, 8188, 1661, 469, 35, 306, 43, 161, 9, 273, 29, 12, 3566, 2, 2209, 117, 47, 3, 827, 356, 22, 295, 924, 117]",1627.0,25415160,408
Multiple biopsies and detection of cervical cancer precursors at colposcopy.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2014-11-24,"Women with abnormal cervical cancer screening results are referred to colposcopy and biopsy for diagnosis of cervical cancer precursors (high-grade squamous intraepithelial lesions [HSILs]). Colposcopy with a single biopsy can miss identification of HSILs. No systematic study has quantified the improved detection of HSIL by taking multiple lesion-directed biopsies. The Biopsy Study was an observational study of 690 women referred to colposcopy after abnormal cervical cancer screening results. Up to four directed biopsies were taken from distinct acetowhite lesions and ranked by colposcopic impression. A nondirected biopsy of a normal-appearing area was added if fewer than four directed biopsies were taken. HSIL identified by any biopsy was the reference standard of disease used to evaluate the incremental yield and sensitivity of multiple biopsies. In the overall population, sensitivities for detecting HSIL increased from 60.6% (95% CI, 54.8% to 66.6%) from a single biopsy to 85.6% (95% CI, 80.3% to 90.2%) after two biopsies and to 95.6% (95% CI, 91.3% to 99.2%) after three biopsies. A significant increase in sensitivity of multiple biopsies was observed in all subgroups. The highest increase in yield of HSIL was observed for women with a high-grade colposcopic impression, HSIL cytology, and human papillomavirus (HPV) type 16 positivity. Only 2% of all HSILs diagnosed in the participants were detected by biopsies of normal-appearing transformation zone. Collection of additional lesion-directed biopsies during colposcopy increased detection of histologic HSIL, regardless of patient characteristics. Taking additional biopsies when multiple lesions are present should become the standard practice of colposcopic biopsy.",Journal Article,1884.0,69.0,Women with abnormal cancer screening results are referred to colposcopy and biopsy for diagnosis of cancer precursors high-grade squamous intraepithelial lesions HSILs Colposcopy with a single biopsy can miss identification of HSILs No systematic study has quantified the improved detection of HSIL by taking multiple lesion-directed biopsies The Biopsy Study was an observational study of 690 women referred to colposcopy after abnormal cancer screening results Up to four directed biopsies were taken from distinct acetowhite lesions and ranked by colposcopic impression A nondirected biopsy of a normal-appearing area was added if fewer than four directed biopsies were taken HSIL identified by any biopsy was the reference standard of disease used to evaluate the incremental yield and sensitivity of multiple biopsies In the overall population sensitivities for detecting HSIL increased from 60.6 95 CI 54.8 to 66.6 from a single biopsy to 85.6 95 CI 80.3 to 90.2 after two biopsies and to 95.6 95 CI 91.3 to 99.2 after three biopsies A significant increase in sensitivity of multiple biopsies was observed in all subgroups The highest increase in yield of HSIL was observed for women with a high-grade colposcopic impression HSIL cytology and human papillomavirus HPV type 16 positivity Only 2 of all HSILs diagnosed in the participants were detected by biopsies of normal-appearing transformation zone Collection of additional lesion-directed biopsies during colposcopy increased detection of histologic HSIL regardless of patient characteristics Taking additional biopsies when multiple lesions are present should become the standard practice of colposcopic biopsy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[117, 5, 1668, 12, 453, 99, 32, 1995, 6, 9946, 2, 411, 9, 147, 1, 12, 4881, 64, 88, 691, 4153, 406, 40904, 9946, 5, 8, 226, 411, 122, 11070, 911, 1, 40904, 77, 1556, 45, 71, 2790, 3, 231, 638, 1, 16067, 20, 2727, 232, 1180, 1166, 1154, 3, 411, 45, 10, 35, 2495, 45, 1, 11648, 117, 1995, 6, 9946, 50, 1668, 12, 453, 99, 126, 6, 294, 1166, 1154, 11, 1633, 29, 834, 48696, 406, 2, 6441, 20, 14131, 8925, 8, 28346, 411, 1, 8, 295, 6536, 965, 10, 1953, 492, 1497, 76, 294, 1166, 1154, 11, 1633, 16067, 108, 20, 500, 411, 10, 3, 2482, 260, 1, 34, 95, 6, 376, 3, 3648, 2309, 2, 485, 1, 232, 1154, 4, 3, 63, 266, 6202, 9, 2502, 16067, 101, 29, 335, 49, 48, 58, 667, 66, 6, 700, 49, 29, 8, 226, 411, 6, 772, 49, 48, 58, 493, 27, 6, 424, 18, 50, 100, 1154, 2, 6, 48, 49, 48, 58, 970, 27, 6, 1058, 18, 50, 169, 1154, 8, 93, 344, 4, 485, 1, 232, 1154, 10, 164, 4, 62, 1453, 3, 1076, 344, 4, 2309, 1, 16067, 10, 164, 9, 117, 5, 8, 64, 88, 14131, 8925, 16067, 2045, 2, 171, 3242, 933, 267, 245, 1887, 158, 18, 1, 62, 40904, 265, 4, 3, 776, 11, 530, 20, 1154, 1, 295, 6536, 1392, 3614, 2442, 1, 402, 1180, 1166, 1154, 190, 9946, 101, 638, 1, 884, 16067, 1583, 1, 69, 374, 2727, 402, 1154, 198, 232, 406, 32, 364, 257, 1417, 3, 260, 758, 1, 14131, 411]",1672.0,25422481,555
Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.,Oncotarget,Oncotarget,2014-11-01,"Activated PI3K/AKT/mTOR pathway frequently occurs in metastatic or recurrent cervical carcinomas. However, the clinical benefits of matched therapy, a therapeutic approach targeting a specific mutational abnormality, have not yet been established. We analyzed the outcomes of patients with metastatic or recurrent cervical carcinomas who had a test for PIK3CA mutation and/or PTEN loss/mutation, and received 1 phase I therapeutic regimen between January 2006 and June 2013. Patients with adenocarcinoma had fewer PIK3CA mutations (14%), and survived longer (median, 14.2 months) than those with squamous cell carcinoma (48% and 7.2 months; p = 0.016, and 0.001, respectively). Matched therapy targeting the activated PI3K/AKT/mTOR pathway led to a favorable rate of SD  6 months/CR/PR (53%) and significantly longer progression-free survival (median, 6.0 months) than non-matched therapy (11% and 1.5 months; p = 0.08 and 0.026; respectively). In patients with squamous cell carcinoma of the cervix, the presence of PIK3CA mutations was associated with a significantly longer overall survival (median, 9.4 months) than the absence of PIK3CA mutations (median, 4.2 months; p = 0.019). Matched therapy targeting the activated PI3K/AKT/mTOR pathway provided meaningful clinical benefits. Thus, further evaluation of PI3K/AKT/mTOR pathway targeted therapy is warranted, especially in metastatic or recurrent squamous cell carcinoma.","Clinical Trial, Phase I",1907.0,31.0,Activated PI3K/AKT/mTOR pathway frequently occurs in metastatic or recurrent carcinomas However the clinical benefits of matched therapy a therapeutic approach targeting a specific mutational abnormality have not yet been established We analyzed the outcomes of patients with metastatic or recurrent carcinomas who had a test for PIK3CA mutation and/or PTEN loss/mutation and received 1 phase I therapeutic regimen between January 2006 and June 2013 Patients with adenocarcinoma had fewer PIK3CA mutations 14 and survived longer median 14.2 months than those with squamous cell carcinoma 48 and 7.2 months p 0.016 and 0.001 respectively Matched therapy targeting the activated PI3K/AKT/mTOR pathway led to a favorable rate of SD  6 months/CR/PR 53 and significantly longer progression-free survival median 6.0 months than non-matched therapy 11 and 1.5 months p 0.08 and 0.026 respectively In patients with squamous cell carcinoma of the cervix the presence of PIK3CA mutations was associated with a significantly longer overall survival median 9.4 months than the absence of PIK3CA mutations median 4.2 months p 0.019 Matched therapy targeting the activated PI3K/AKT/mTOR pathway provided meaningful clinical benefits Thus further evaluation of PI3K/AKT/mTOR pathway targeted therapy is warranted especially in metastatic or recurrent squamous cell carcinoma,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[735, 974, 649, 873, 308, 746, 1780, 4, 113, 15, 387, 826, 137, 3, 38, 1141, 1, 655, 36, 8, 189, 353, 529, 8, 112, 1619, 3698, 47, 44, 1145, 85, 635, 21, 311, 3, 123, 1, 7, 5, 113, 15, 387, 826, 54, 42, 8, 412, 9, 1506, 258, 2, 15, 820, 407, 258, 2, 103, 3567, 124, 70, 189, 477, 59, 1024, 1324, 2, 1924, 1346, 7, 5, 449, 42, 1497, 1506, 138, 213, 2, 2996, 589, 52, 213, 18, 53, 76, 135, 5, 691, 31, 134, 576, 2, 67, 18, 53, 19, 13, 3820, 2, 13, 144, 106, 655, 36, 529, 3, 735, 974, 649, 873, 308, 836, 6, 8, 913, 116, 1, 1270, 749, 49, 53, 684, 998, 699, 2, 97, 589, 91, 115, 25, 52, 49, 13, 53, 76, 220, 655, 36, 175, 2, 14, 33, 53, 19, 13, 1592, 2, 13, 4554, 106, 4, 7, 5, 691, 31, 134, 1, 3, 3629, 3, 463, 1, 1506, 138, 10, 41, 5, 8, 97, 589, 63, 25, 52, 83, 39, 53, 76, 3, 1127, 1, 1506, 138, 52, 39, 18, 53, 19, 13, 4049, 655, 36, 529, 3, 735, 974, 649, 873, 308, 1052, 2538, 38, 1141, 631, 195, 451, 1, 974, 649, 873, 308, 238, 36, 16, 1197, 1093, 4, 113, 15, 387, 691, 31, 134]",1361.0,25426553,410
"Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.",Trials,Trials,2014-11-29,"Over 50% of patients with head and neck squamous cell carcinoma (HNSCC) present with locoregionally advanced disease. Those at intermediate-to-high risk of recurrence after definitive therapy exhibit advanced disease based on tumour size or lymph node involvement, non-oropharynx primary sites, human papillomavirus (HPV)-negative oropharyngeal cancer, or HPV-positive oropharynx cancer with smoking history (>10-pack-years). Non-surgical approaches include concurrent chemoradiotherapy, induction chemotherapy followed by definitive radiotherapy or chemoradiotherapy, or radiotherapy alone. Following locoregional therapies (including surgical salvage of residual cervical nodes), no standard intervention exists. Overexpression of epidermal growth factor receptor (EGFR), an ErbB family member, is associated with poor prognosis in HNSCC. EGFR-targeted cetuximab is the only targeted therapy that impacts overall survival and is approved for HNSCC in the USA or Europe. However, resistance often occurs, and new approaches, such as targeting multiple ErbB family members, may be required. Afatinib, an irreversible ErbB family blocker, demonstrated antiproliferative activity in preclinical models and comparable clinical efficacy with cetuximab in a randomized phase II trial in recurrent or metastatic HNSCC. LUX-Head & Neck 2, a phase III study, will assess adjuvant afatinib versus placebo following chemoradiotherapy in primary unresected locoregionally advanced intermediate-to-high-risk HNSCC. Patients with primary unresected locoregionally advanced HNSCC, in good clinical condition with unfavourable risk of recurrence, and no evidence of disease after chemoradiotherapy will be randomized 2:1 to oral once-daily afatinib (40 mg starting dose) or placebo. As HPV status will not be determined for eligibility, unfavourable risk is defined as non-oropharynx primary site or oropharynx cancer in patients with a smoking history (>10 pack-years). Treatment will continue for 18 months or until recurrence or unacceptable adverse events occur. The primary endpoint measure is duration of disease-free survival; secondary endpoint measures are disease-free survival rate at 2 years, overall survival, health-related quality of life and safety. Given the unmet need in the adjuvant treatment of intermediate-to-high-risk HNSCC patients, it is expected that LUX-Head & Neck 2 will provide new insights into treatment in this setting and might demonstrate the ability of afatinib to significantly improve disease-free survival, compared with placebo. ClinicalTrials.gov NCT01345669.","Clinical Trial, Phase III",1879.0,18.0,Over 50 of patients with head and squamous cell carcinoma HNSCC present with locoregionally advanced disease Those at intermediate-to-high risk of recurrence after definitive therapy exhibit advanced disease based on tumour size or lymph node involvement non-oropharynx primary sites human papillomavirus HPV -negative cancer or HPV-positive oropharynx cancer with smoking history 10-pack-years Non-surgical approaches include concurrent chemoradiotherapy induction chemotherapy followed by definitive radiotherapy or chemoradiotherapy or radiotherapy alone Following locoregional therapies including surgical salvage of residual nodes no standard intervention exists Overexpression of epidermal growth factor receptor EGFR an ErbB family member is associated with poor prognosis in HNSCC EGFR-targeted cetuximab is the only targeted therapy that impacts overall survival and is approved for HNSCC in the USA or Europe However resistance often occurs and new approaches such as targeting multiple ErbB family members may be required Afatinib an irreversible ErbB family blocker demonstrated antiproliferative activity in preclinical models and comparable clinical efficacy with cetuximab in a randomized phase II trial in recurrent or metastatic HNSCC LUX-Head 2 a phase III study will assess adjuvant afatinib versus placebo following chemoradiotherapy in primary unresected locoregionally advanced intermediate-to-high-risk HNSCC Patients with primary unresected locoregionally advanced HNSCC in good clinical condition with unfavourable risk of recurrence and no evidence of disease after chemoradiotherapy will be randomized 2:1 to oral once-daily afatinib 40 mg starting dose or placebo As HPV status will not be determined for eligibility unfavourable risk is defined as non-oropharynx primary site or oropharynx cancer in patients with a smoking history 10 pack-years Treatment will continue for 18 months or until recurrence or unacceptable adverse events occur The primary endpoint measure is duration of disease-free survival secondary endpoint measures are disease-free survival rate at 2 years overall survival health-related quality of life and safety Given the unmet need in the adjuvant treatment of intermediate-to-high-risk HNSCC patients it is expected that LUX-Head 2 will provide new insights into treatment in this setting and might demonstrate the ability of afatinib to significantly improve disease-free survival compared with placebo ClinicalTrials.gov NCT01345669,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[252, 212, 1, 7, 5, 718, 2, 691, 31, 134, 1209, 364, 5, 6410, 131, 34, 135, 28, 919, 6, 64, 43, 1, 146, 50, 1057, 36, 2239, 131, 34, 90, 23, 770, 444, 15, 263, 289, 799, 220, 5333, 86, 633, 171, 3242, 933, 199, 12, 15, 933, 109, 5333, 12, 5, 979, 532, 79, 4668, 60, 220, 221, 611, 643, 750, 1464, 504, 56, 370, 20, 1057, 310, 15, 1464, 15, 310, 279, 366, 1325, 235, 141, 221, 992, 1, 753, 502, 77, 260, 788, 2481, 851, 1, 829, 129, 161, 153, 227, 35, 4205, 607, 2693, 16, 41, 5, 334, 356, 4, 1209, 227, 238, 1175, 16, 3, 158, 238, 36, 17, 4719, 63, 25, 2, 16, 850, 9, 1209, 4, 3, 2706, 15, 3934, 137, 251, 629, 1780, 2, 217, 611, 225, 22, 529, 232, 4205, 607, 1684, 68, 40, 616, 3729, 35, 4422, 4205, 607, 8411, 264, 3669, 128, 4, 693, 274, 2, 1279, 38, 209, 5, 1175, 4, 8, 384, 124, 215, 160, 4, 387, 15, 113, 1209, 9502, 718, 18, 8, 124, 316, 45, 303, 423, 249, 3729, 185, 619, 366, 1464, 4, 86, 8096, 6410, 131, 919, 6, 64, 43, 1209, 7, 5, 86, 8096, 6410, 131, 1209, 4, 1178, 38, 2850, 5, 13879, 43, 1, 146, 2, 77, 241, 1, 34, 50, 1464, 303, 40, 384, 18, 14, 6, 518, 1059, 391, 3729, 327, 81, 1723, 61, 15, 619, 22, 933, 156, 303, 44, 40, 509, 9, 2317, 13879, 43, 16, 395, 22, 220, 5333, 86, 606, 15, 5333, 12, 4, 7, 5, 8, 979, 532, 79, 4668, 60, 24, 303, 1906, 9, 203, 53, 15, 1100, 146, 15, 3215, 290, 281, 1271, 3, 86, 1138, 1463, 16, 654, 1, 34, 115, 25, 568, 1138, 1018, 32, 34, 115, 25, 116, 28, 18, 60, 63, 25, 341, 139, 372, 1, 358, 2, 367, 447, 3, 3715, 594, 4, 3, 249, 24, 1, 919, 6, 64, 43, 1209, 7, 192, 16, 1336, 17, 9502, 718, 18, 303, 377, 217, 1957, 237, 24, 4, 26, 546, 2, 822, 608, 3, 801, 1, 3729, 6, 97, 401, 34, 115, 25, 72, 5, 619, 1252, 1239, 65220]",2489.0,25432788,707
State Medicaid expansion decisions and disparities in women's cancer screening.,American journal of preventive medicine,Am J Prev Med,2014-10-30,"There are substantial disparities in breast and cervical cancer screening that stem from lack of health insurance. Although the Affordable Care Act (ACA) expands insurance coverage to many Americans, there are differences in availability of Medicaid coverage across states. To understand the potential impact of Medicaid expansions on disparities in preventive care for low-income women by assessing pre-ACA breast and cervical cancer screening across states currently expanding and not expanding Medicaid to low-income adults. Data from the 2012 Behavioral Risk Factor Surveillance System (analyzed in 2014) were used to consider differences in demographics among women for whom screening is recommended, including income and race/ethnicity, across expansion and nonexpansion states. Self-reported screening was compared by state expansion status overall, for the uninsured, and for low-income women. Logistic regressions were estimated to assess differences in self-reported screening across expansion and nonexpansion states controlling for demographics. Women in states that are not expanding Medicaid had significantly lower odds of receiving recommended mammograms (OR=0.87, 95% CI=0.79, 0.95) or Pap tests (OR=0.87, 95% CI=0.79, 0.95). The difference was larger among the uninsured (OR=0.72, 95% CI=0.56, 0.91 for mammography; OR=0.78, 95% CI=0.65, 0.94 for Pap tests). As women in nonexpansion states remain uninsured and others gain coverage, existing disparities in cancer screening by race and socioeconomic status are likely to widen. Health risks and associated costs to underserved populations must be taken into account in ongoing debates over expansion.",Comparative Study,1909.0,35.0,There are substantial disparities in and cancer screening that stem from lack of health insurance Although the Affordable Care Act ACA expands insurance coverage to many Americans there are differences in availability of Medicaid coverage across states To understand the potential impact of Medicaid expansions on disparities in preventive care for low-income women by assessing pre-ACA and cancer screening across states currently expanding and not expanding Medicaid to low-income adults Data from the 2012 Behavioral Risk Factor Surveillance System analyzed in 2014 were used to consider differences in demographics among women for whom screening is recommended including income and race/ethnicity across expansion and nonexpansion states Self-reported screening was compared by state expansion status overall for the uninsured and for low-income women Logistic regressions were estimated to assess differences in self-reported screening across expansion and nonexpansion states controlling for demographics Women in states that are not expanding Medicaid had significantly lower odds of receiving recommended mammograms OR=0.87 95 CI=0.79 0.95 or Pap tests OR=0.87 95 CI=0.79 0.95 The difference was larger among the uninsured OR=0.72 95 CI=0.56 0.91 for mammography OR=0.78 95 CI=0.65 0.94 for Pap tests As women in nonexpansion states remain uninsured and others gain coverage existing disparities in cancer screening by race and socioeconomic status are likely to widen Health risks and associated costs to underserved populations must be taken into account in ongoing debates over expansion,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[125, 32, 1281, 2227, 4, 2, 12, 453, 17, 452, 29, 926, 1, 341, 1935, 242, 3, 8216, 165, 2559, 6285, 9365, 1935, 2139, 6, 445, 2731, 125, 32, 362, 4, 2550, 1, 2843, 2139, 716, 907, 6, 1640, 3, 174, 345, 1, 2843, 12384, 23, 2227, 4, 3494, 165, 9, 154, 2306, 117, 20, 1977, 671, 6285, 2, 12, 453, 716, 907, 694, 4304, 2, 44, 4304, 2843, 6, 154, 2306, 857, 74, 29, 3, 1195, 4166, 43, 161, 617, 398, 311, 4, 1409, 11, 95, 6, 2419, 362, 4, 2221, 107, 117, 9, 953, 453, 16, 793, 141, 2306, 2, 1047, 2091, 716, 1422, 2, 18692, 907, 1074, 210, 453, 10, 72, 20, 1309, 1422, 156, 63, 9, 3, 4955, 2, 9, 154, 2306, 117, 812, 5142, 11, 661, 6, 423, 362, 4, 1074, 210, 453, 716, 1422, 2, 18692, 907, 1893, 9, 2221, 117, 4, 907, 17, 32, 44, 4304, 2843, 42, 97, 280, 610, 1, 357, 793, 6329, 15, 13, 912, 48, 58, 13, 842, 13, 48, 15, 4290, 895, 15, 13, 912, 48, 58, 13, 842, 13, 48, 3, 523, 10, 1077, 107, 3, 4955, 15, 13, 720, 48, 58, 13, 664, 13, 970, 9, 2446, 15, 13, 833, 48, 58, 13, 556, 13, 960, 9, 4290, 895, 22, 117, 4, 18692, 907, 918, 4955, 2, 1749, 1803, 2139, 1692, 2227, 4, 12, 453, 20, 1047, 2, 3331, 156, 32, 322, 6, 22288, 341, 1098, 2, 41, 1201, 6, 6960, 1184, 1642, 40, 1633, 237, 1967, 4, 942, 26100, 252, 1422]",1598.0,25441234,85
Relationship between low hemoglobin levels and outcomes after treatment with radiation or chemoradiation in patients with cervical cancer: has the impact of anemia been overstated?,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2014-10-25,"Previous reports have suggested that anemia increases rates of recurrence after radiation therapy for cervical cancer. However, these studies may not have fully corrected for confounding risk factors. Using a well-characterized cohort of cervical cancer patients, we examined the association between anemia and outcomes before and after the introduction of chemoradiation as standard of care. We reviewed the records of 2454 patients who underwent definitive radiation therapy from 1980 through 2011. Minimum hemoglobin level (Hgbmin) was recorded for 2359 patients (96%). Endpoints included freedom from central recurrence (FFCR), freedom from distant metastasis (FFDM), and disease-specific survival (DSS). For the entire cohort, hemoglobin concentrations of 9, 10, and 12 g/dL before and during radiation were all significantly associated with FFCR, FFDM, and DSS (all P<.001) on univariate analysis. However, on multivariate analysis, only Hgbmin less than 10 g/dL during RT (RT-Hgb<10) remained significant, and it was correlated with lower DSS (P=.02, hazard ratio [HR] = 1.28) and FFDM (P=.03, HR = 1.33) but not with FFCR. In a subset analysis of patients receiving chemoradiation (n=678), RT-Hgb<10 was associated only with DSS (P=.008, HR = 1.49), not with FFCR or FFDM. In this subgroup, despite an association between RT-Hgb<10 and DSS, the use of transfusion was not correlated with benefit. No evidence was found supporting anemia as an independent predictor of central recurrence in patients treated with definitive radiation therapy with or without chemotherapy. Less emphasis on correcting anemia in cervical cancer patients may be warranted.",Journal Article,1914.0,14.0,Previous reports have suggested that anemia increases rates of recurrence after radiation therapy for cancer However these studies may not have fully corrected for confounding risk factors Using a well-characterized cohort of cancer patients we examined the association between anemia and outcomes before and after the introduction of chemoradiation as standard of care We reviewed the records of 2454 patients who underwent definitive radiation therapy from 1980 through 2011 Minimum hemoglobin level Hgbmin was recorded for 2359 patients 96 Endpoints included freedom from central recurrence FFCR freedom from distant metastasis FFDM and disease-specific survival DSS For the entire cohort hemoglobin concentrations of 9 10 and 12 g/dL before and during radiation were all significantly associated with FFCR FFDM and DSS all P .001 on univariate analysis However on multivariate analysis only Hgbmin less than 10 g/dL during RT RT-Hgb 10 remained significant and it was correlated with lower DSS P=.02 hazard ratio HR 1.28 and FFDM P=.03 HR 1.33 but not with FFCR In a subset analysis of patients receiving chemoradiation n=678 RT-Hgb 10 was associated only with DSS P=.008 HR 1.49 not with FFCR or FFDM In this subgroup despite an association between RT-Hgb 10 and DSS the use of transfusion was not correlated with benefit No evidence was found supporting anemia as an independent predictor of central recurrence in patients treated with definitive radiation therapy with or without chemotherapy Less emphasis on correcting anemia in cancer patients may be warranted,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[698, 1198, 47, 1148, 17, 1545, 1106, 151, 1, 146, 50, 121, 36, 9, 12, 137, 46, 94, 68, 44, 47, 1910, 3848, 9, 4339, 43, 130, 75, 8, 149, 765, 180, 1, 12, 7, 21, 409, 3, 248, 59, 1545, 2, 123, 348, 2, 50, 3, 2456, 1, 975, 22, 260, 1, 165, 21, 446, 3, 1064, 1, 48711, 7, 54, 208, 1057, 121, 36, 29, 4376, 298, 1132, 2499, 2222, 301, 48712, 10, 1872, 9, 48713, 7, 921, 1387, 159, 3060, 29, 854, 146, 35932, 3060, 29, 626, 278, 19303, 2, 34, 112, 25, 1788, 9, 3, 1797, 180, 2222, 1003, 1, 83, 79, 2, 133, 499, 1826, 348, 2, 190, 121, 11, 62, 97, 41, 5, 35932, 19303, 2, 1788, 62, 19, 144, 23, 880, 65, 137, 23, 331, 65, 158, 48712, 299, 76, 79, 499, 1826, 190, 240, 240, 8938, 79, 958, 93, 2, 192, 10, 438, 5, 280, 1788, 19, 588, 360, 197, 168, 14, 339, 2, 19303, 19, 680, 168, 14, 466, 84, 44, 5, 35932, 4, 8, 697, 65, 1, 7, 357, 975, 78, 14892, 240, 8938, 79, 10, 41, 158, 5, 1788, 19, 2155, 168, 14, 739, 44, 5, 35932, 15, 19303, 4, 26, 1363, 550, 35, 248, 59, 240, 8938, 79, 2, 1788, 3, 119, 1, 2785, 10, 44, 438, 5, 247, 77, 241, 10, 204, 1912, 1545, 22, 35, 306, 980, 1, 854, 146, 4, 7, 73, 5, 1057, 121, 36, 5, 15, 187, 56, 299, 3136, 23, 11154, 1545, 4, 12, 7, 68, 40, 1197]",1570.0,25446609,600
Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2014-11-18,"The ratio of positive to negative lymph nodes, or lymph node ratio (LNR), is an important prognostic factor in several solid tumors. The objective of this study was to determine if LNR can be used to define a high-risk category of patients with node-positive early stage cervical cancer. We performed a retrospective review of patients diagnosed with node-positive stage I or II cervical cancer who underwent radical hysterectomy and pelvic +/- para-aortic lymphadenectomy at MD Anderson from January 1990 to December 2011. Univariate and multivariate analyses were used to identify prognostic factors for progression-free (PFS) and overall survival (OS). Ninety-five patients met the inclusion criteria and were included in the analysis. Median total nodes removed were 19 (range 1-58), and median number of positive nodes was 1 (range 1-12). Fifty-eight patients (61%) received radiation with concurrent cisplatin and 27 patients (28%) received radiotherapy alone. Twenty-one (22%) patients recurred. On multivariate analysis, a LNR > 6.6% was associated with a worse PFS (HR = 2.97, 95% CI 1.26-7.02, p = 0.01), and a LNR > 7.6% with a worse OS (HR = 3.96, 95% CI 1.31-11.98, p = 0.01). On multivariate analysis, positive margins were associated with worse PFS (p = 0.001) and OS (p = 0.002), and adjuvant radiotherapy (p = 0.01) with improved OS. LNR appears to be a useful tool to identify patients with worse prognosis in node-positive early stage cervical cancer. LNR may be used in addition to pathologic risk factors to tailor adjuvant treatment in this population.",Journal Article,1890.0,32.0,The ratio of positive to negative lymph nodes or lymph node ratio LNR is an important prognostic factor in several solid tumors The objective of this study was to determine if LNR can be used to define a high-risk category of patients with node-positive early stage cancer We performed a retrospective review of patients diagnosed with node-positive stage I or II cancer who underwent radical hysterectomy and pelvic +/- para-aortic lymphadenectomy at MD Anderson from January 1990 to December 2011 Univariate and multivariate analyses were used to identify prognostic factors for progression-free PFS and overall survival OS Ninety-five patients met the inclusion criteria and were included in the analysis Median total nodes removed were 19 range 1-58 and median number of positive nodes was 1 range 1-12 Fifty-eight patients 61 received radiation with concurrent cisplatin and 27 patients 28 received radiotherapy alone Twenty-one 22 patients recurred On multivariate analysis a LNR 6.6 was associated with a worse PFS HR 2.97 95 CI 1.26-7.02 p 0.01 and a LNR 7.6 with a worse OS HR 3.96 95 CI 1.31-11.98 p 0.01 On multivariate analysis positive margins were associated with worse PFS p 0.001 and OS p 0.002 and adjuvant radiotherapy p 0.01 with improved OS LNR appears to be a useful tool to identify patients with worse prognosis in node-positive early stage cancer LNR may be used in addition to pathologic risk factors to tailor adjuvant treatment in this population,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 197, 1, 109, 6, 199, 263, 502, 15, 263, 289, 197, 4732, 16, 35, 305, 177, 161, 4, 392, 537, 57, 3, 461, 1, 26, 45, 10, 6, 223, 492, 4732, 122, 40, 95, 6, 1107, 8, 64, 43, 2169, 1, 7, 5, 289, 109, 191, 82, 12, 21, 173, 8, 459, 206, 1, 7, 265, 5, 289, 109, 82, 70, 15, 215, 12, 54, 208, 711, 2622, 2, 1110, 4615, 3938, 2048, 28, 2244, 1929, 29, 1024, 2289, 6, 1397, 1132, 880, 2, 331, 318, 11, 95, 6, 255, 177, 130, 9, 91, 115, 300, 2, 63, 25, 118, 2493, 365, 7, 543, 3, 1680, 371, 2, 11, 159, 4, 3, 65, 52, 181, 502, 2264, 11, 326, 184, 14, 717, 2, 52, 207, 1, 109, 502, 10, 14, 184, 14, 133, 1461, 659, 7, 713, 103, 121, 5, 750, 540, 2, 428, 7, 339, 103, 310, 279, 737, 104, 350, 7, 3363, 23, 331, 65, 8, 4732, 49, 49, 10, 41, 5, 8, 639, 300, 168, 18, 1015, 48, 58, 14, 432, 67, 588, 19, 13, 355, 2, 8, 4732, 67, 49, 5, 8, 639, 118, 168, 27, 921, 48, 58, 14, 456, 175, 1096, 19, 13, 355, 23, 331, 65, 109, 1012, 11, 41, 5, 639, 300, 19, 13, 144, 2, 118, 19, 13, 1111, 2, 249, 310, 19, 13, 355, 5, 231, 118, 4732, 1233, 6, 40, 8, 999, 1515, 6, 255, 7, 5, 639, 356, 4, 289, 109, 191, 82, 12, 4732, 68, 40, 95, 4, 352, 6, 510, 43, 130, 6, 6585, 249, 24, 4, 26, 266]",1473.0,25451695,17
Supratentorial extraventricular anaplastic ependymoma with extracranial metastasis.,Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,J Clin Neurosci,2014-10-31,"Ependymoma is a relatively rare malignancy accounting for 2.0% of all primary central nervous system tumors in adults. Extracranial metastasis is a very uncommon complication of gliomas, especially of anaplastic ependymomas. The objective of this paper is to show that ependymomas can metastasize to soft tissue and lymph nodes as well as to share our approach to this challenge. We report a male patient with anaplastic ependymoma that recurred, metastasizing to the neck and lymph nodes. Metastatic disease was diagnosed based on clinical presentation of a palpable nodule on the right neck and diffuse cervical lymphadenopathies. A biopsy was obtained and pathology revealed anaplastic ependymoma. Whole-body fluorodeoxyglucose positron emission tomography scan showed metastatic disease in the right mastoid region with diffuse uptake in the cervical lymph nodes. Clinical and radiologic response was achieved after three chemotherapy cycles of etoposide, cisplatin, vincristine, and cyclophosphamide. This case highlights extracranial metastasis to the soft tissue as an atypical presentation of recurrent anaplastic ependymoma. Other reported instances of extracranial metastatic ependymoma with this presentation are discussed. The possible metastatic pathways of intracranial disease are discussed. It also illustrates how extracranial disease remains stable with systemic chemotherapy. ",Case Reports,1908.0,5.0,Ependymoma is a relatively rare malignancy accounting for 2.0 of all primary central nervous system tumors in adults Extracranial metastasis is a very uncommon complication of gliomas especially of anaplastic ependymomas The objective of this paper is to show that ependymomas can metastasize to soft tissue and lymph nodes as well as to share our approach to this challenge We report a male patient with anaplastic ependymoma that recurred metastasizing to the and lymph nodes Metastatic disease was diagnosed based on clinical presentation of a palpable nodule on the right and diffuse lymphadenopathies A biopsy was obtained and pathology revealed anaplastic ependymoma Whole-body fluorodeoxyglucose positron emission tomography scan showed metastatic disease in the right mastoid region with diffuse uptake in the lymph nodes Clinical and radiologic response was achieved after three chemotherapy cycles of etoposide cisplatin vincristine and cyclophosphamide This case highlights extracranial metastasis to the soft tissue as an atypical presentation of recurrent anaplastic ependymoma Other reported instances of extracranial metastatic ependymoma with this presentation are discussed The possible metastatic pathways of intracranial disease are discussed It also illustrates how extracranial disease remains stable with systemic chemotherapy,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4214, 16, 8, 1352, 622, 710, 3116, 9, 18, 13, 1, 62, 86, 854, 1880, 398, 57, 4, 857, 4202, 278, 16, 8, 923, 2052, 1447, 1, 1287, 1093, 1, 1841, 8839, 3, 461, 1, 26, 2817, 16, 6, 514, 17, 8839, 122, 5769, 6, 1214, 246, 2, 263, 502, 22, 149, 22, 6, 4349, 114, 353, 6, 26, 1745, 21, 414, 8, 1045, 69, 5, 1841, 4214, 17, 3363, 16240, 6, 3, 2, 263, 502, 113, 34, 10, 265, 90, 23, 38, 1031, 1, 8, 4880, 5072, 23, 3, 1913, 2, 1388, 39022, 8, 411, 10, 683, 2, 1117, 553, 1841, 4214, 902, 642, 4085, 1900, 1799, 872, 1657, 224, 113, 34, 4, 3, 1913, 27408, 1053, 5, 1388, 1135, 4, 3, 263, 502, 38, 2, 2812, 51, 10, 513, 50, 169, 56, 410, 1, 1934, 540, 2132, 2, 1112, 26, 473, 2527, 4202, 278, 6, 3, 1214, 246, 22, 35, 1973, 1031, 1, 387, 1841, 4214, 127, 210, 5342, 1, 4202, 113, 4214, 5, 26, 1031, 32, 1588, 3, 899, 113, 460, 1, 2089, 34, 32, 1588, 192, 120, 6342, 832, 4202, 34, 469, 585, 5, 403, 56]",1348.0,25455735,636
Significance of lymphovascular space invasion in uterine serous carcinoma: what matters more; extent or presence?,International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists,Int. J. Gynecol. Pathol.,2015-01-01,"To analyze the clinical significance of the extent of lymphovascular space invasion (LVI) in patients with uterine serous carcinoma. After IRB approval, 232 patients with uterine serous carcinoma from the pathology databases of 4 large academic institutions were included. Patients were divided into 3 groups based on extent of LVI. Extensive LVI (E-LVI) was defined as 3 vessel involvement; low LVI (L-LVI) was defined <3 vessel involvement; and the third group consisted of tumors with no LVI (A-LVI). The association between LVI and myometrial invasion, cervical involvement, lower uterine segment involvement, positive peritoneal washings, lymph node involvement, stage, and survival were analyzed. Of 232 patients, 47 had E-LVI (20.3%), 83 had L-LVI (35.8%), and 102 had A-LVI (44%). A total of 9.8% of the patients with A-LVI had lymph node involvement as compared with 18.1% in the L-LVI group and 55.4% in the E-LVI group (P<0.0001). Fifty-nine percent of the patients in A-LVI, 85% in L-LVI, and 100% in the E-LVI group demonstrated myometrial invasion (P<0.0001). Cervical involvement was noted in 23%, 43%, 66% (P<0.0001) and lower uterine segment involvement involvement in 31%, 43%, and 42% of A-LVI, L-LVI, and E-LVI (P<0.0001), respectively. Stage III and IV disease were seen in 29%, 38%, and 79% of the patients with A-LVI, L-LVI, and E-LVI, respectively (P<0.0001). The median overall survival was 172, 95, and 39 mo for the A-LVI, L-LVI, and E-LVI groups, respectively (P<0.0001). The racial distribution was significant with African American patients demonstrating significantly more L-LVI (27.8%) and E-LVI (40.4%) when compared with A-LVI (19.6%) (P=0.040). In a subgroup analysis including patients with Stage I and II (n=123) revealed median survivals of 172, 169, and 38 mo in the A-LVI, L-LVI, and E-LVI groups, respectively (P<0.0001). Fifty percent of these patients with E-LVI, 20% in L-LVI group, and 15% in A-LVI group had disease recurrence (P=0.040). The extent of LVI was associated with multiple pathologic factors and was found to be a negative prognostic factor for overall survival and disease recurrence. ",Journal Article,1846.0,11.0,To analyze the clinical significance of the extent of lymphovascular space invasion LVI in patients with serous carcinoma After IRB approval 232 patients with serous carcinoma from the pathology databases of 4 large academic institutions were included Patients were divided into 3 groups based on extent of LVI Extensive LVI E-LVI was defined as 3 vessel involvement low LVI L-LVI was defined 3 vessel involvement and the third group consisted of tumors with no LVI A-LVI The association between LVI and myometrial invasion involvement lower segment involvement positive peritoneal washings lymph node involvement stage and survival were analyzed Of 232 patients 47 had E-LVI 20.3 83 had L-LVI 35.8 and 102 had A-LVI 44 A total of 9.8 of the patients with A-LVI had lymph node involvement as compared with 18.1 in the L-LVI group and 55.4 in the E-LVI group P 0.0001 Fifty-nine percent of the patients in A-LVI 85 in L-LVI and 100 in the E-LVI group demonstrated myometrial invasion P 0.0001 involvement was noted in 23 43 66 P 0.0001 and lower segment involvement involvement in 31 43 and 42 of A-LVI L-LVI and E-LVI P 0.0001 respectively Stage III and IV disease were seen in 29 38 and 79 of the patients with A-LVI L-LVI and E-LVI respectively P 0.0001 The median overall survival was 172 95 and 39 mo for the A-LVI L-LVI and E-LVI groups respectively P 0.0001 The racial distribution was significant with African American patients demonstrating significantly more L-LVI 27.8 and E-LVI 40.4 when compared with A-LVI 19.6 P=0.040 In a subgroup analysis including patients with Stage I and II n=123 revealed median survivals of 172 169 and 38 mo in the A-LVI L-LVI and E-LVI groups respectively P 0.0001 Fifty percent of these patients with E-LVI 20 in L-LVI group and 15 in A-LVI group had disease recurrence P=0.040 The extent of LVI was associated with multiple pathologic factors and was found to be a negative prognostic factor for overall survival and disease recurrence,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 1992, 3, 38, 724, 1, 3, 1039, 1, 2933, 3865, 578, 3327, 4, 7, 5, 1744, 134, 50, 5880, 1814, 7186, 7, 5, 1744, 134, 29, 3, 1117, 2348, 1, 39, 375, 1916, 1764, 11, 159, 7, 11, 2176, 237, 27, 271, 90, 23, 1039, 1, 3327, 1344, 3327, 563, 3327, 10, 395, 22, 2608, 3685, 799, 154, 3327, 805, 3327, 10, 395, 27, 3685, 799, 2, 3, 1282, 87, 1695, 1, 57, 5, 77, 3327, 8, 3327, 3, 248, 59, 3327, 2, 7327, 578, 799, 280, 4610, 799, 109, 1639, 11161, 263, 289, 799, 82, 2, 25, 11, 311, 1, 7186, 7, 662, 42, 563, 3327, 179, 27, 852, 42, 805, 3327, 465, 66, 2, 2867, 42, 8, 3327, 584, 8, 181, 1, 83, 66, 1, 3, 7, 5, 8, 3327, 42, 263, 289, 799, 22, 72, 5, 203, 14, 4, 3, 805, 3327, 87, 2, 614, 39, 4, 3, 563, 3327, 87, 19, 13, 488, 1461, 762, 714, 1, 3, 7, 4, 8, 3327, 772, 4, 805, 3327, 2, 394, 4, 3, 563, 3327, 87, 264, 7327, 578, 19, 13, 488, 799, 10, 1051, 4, 382, 601, 700, 19, 13, 488, 2, 280, 4610, 799, 799, 4, 456, 601, 2, 595, 1, 8, 3327, 805, 3327, 2, 563, 3327, 19, 13, 488, 106, 82, 316, 2, 478, 34, 11, 527, 4, 462, 519, 2, 842, 1, 3, 7, 5, 8, 3327, 805, 3327, 2, 563, 3327, 106, 19, 13, 488, 3, 52, 63, 25, 10, 5312, 48, 2, 587, 2035, 9, 3, 8, 3327, 805, 3327, 2, 563, 3327, 271, 106, 19, 13, 488, 3, 2257, 1395, 10, 93, 5, 1410, 597, 7, 2219, 97, 80, 805, 3327, 428, 66, 2, 563, 3327, 327, 39, 198, 72, 5, 8, 3327, 326, 49, 19, 13, 6824, 4, 8, 1363, 65, 141, 7, 5, 82, 70, 2, 215, 78, 2698, 553, 52, 3794, 1, 5312, 5436, 2, 519, 2035, 4, 3, 8, 3327, 805, 3327, 2, 563, 3327, 271, 106, 19, 13, 488, 1461, 714, 1, 46, 7, 5, 563, 3327, 179, 4, 805, 3327, 87, 2, 167, 4, 8, 3327, 87, 42, 34, 146, 19, 13, 6824, 3, 1039, 1, 3327, 10, 41, 5, 232, 510, 130, 2, 10, 204, 6, 40, 8, 199, 177, 161, 9, 63, 25, 2, 34, 146]",1978.0,25473753,857
ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen.,Human vaccines & immunotherapeutics,Hum Vaccin Immunother,2014-01-01,"Listeria monocytogenes is a bacterium that can be genetically modified to express fusion proteins with antigens specific to certain cancer models. This technology has been harnessed to develop ADXS11-001, a vaccine that aims to elicit an immune response against human papillomavirus (HPV) oncoprotein E7.Pre-clinical studies assessing the efficacy of recombinant Listeria vaccination targeting this same oncoprotein have consistently demonstrated successful reduction of in vivo tumor burden among animal cancer models. Several clinical trials are underway to assess the efficacy of ADXS11-001 in eliciting both immune and clinical responses against HPV-related human cervical, oropharyngeal and anal cancers. ",Journal Article,2211.0,34.0,Listeria monocytogenes is a bacterium that can be genetically modified to express fusion proteins with antigens specific to certain cancer models This technology has been harnessed to develop ADXS11-001 a vaccine that aims to elicit an immune response against human papillomavirus HPV oncoprotein E7 Pre-clinical studies assessing the efficacy of recombinant Listeria vaccination targeting this same oncoprotein have consistently demonstrated successful reduction of in vivo tumor burden among animal cancer models Several clinical trials are underway to assess the efficacy of ADXS11-001 in eliciting both immune and clinical responses against HPV-related human and cancers,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[14582, 16023, 16, 8, 16832, 17, 122, 40, 2301, 1230, 6, 1669, 1212, 652, 5, 1575, 112, 6, 1840, 12, 274, 26, 2033, 71, 85, 16522, 6, 690, 20057, 144, 8, 1274, 17, 2970, 6, 5487, 35, 250, 51, 480, 171, 3242, 933, 6159, 4540, 671, 38, 94, 1977, 3, 209, 1, 2835, 14582, 1915, 529, 26, 827, 6159, 47, 2433, 264, 1401, 628, 1, 4, 386, 30, 892, 107, 2026, 12, 274, 392, 38, 143, 32, 3948, 6, 423, 3, 209, 1, 20057, 144, 4, 10299, 110, 250, 2, 38, 253, 480, 933, 139, 171, 2, 163]",674.0,25483687,358
Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population.,American journal of clinical pathology,Am. J. Clin. Pathol.,2015-01-01,"The Xpert HPV Assay (Xpert; Cepheid, Sunnyvale, CA) was developed for the multianalytic GeneXpert platform. In a colposcopy referral population of 708 women living in the United States, two cervical specimens, A and B, were collected, and both were tested by the Xpert assay for high-risk human papillomavirus (hrHPV) DNA, permitting an evaluation of its test reliability. Specimen B was also tested by Hybrid Capture 2 (hc2; Qiagen, Germantown, MD) and the cobas HPV Test (cobas; Roche Molecular Systems, Pleasanton, CA). The  and percent agreement for any hrHPV for the two Xpert results were 0.88 and 94.5%, respectively. There was no statistical difference in testing positive on both specimens by Xpert (P = .62). The sensitivity for detection of cervical intraepithelial neoplasia grade 2 or more severe (CIN2+) was 89.0% using specimen A and 90.4% using specimen B for Xpert, 90.4% for cobas, and 81.6% for hc2. The Xpert assay was sensitive and reliable for the detection of hrHPV and the identification of women with CIN2+.",Journal Article,1846.0,21.0,The Xpert HPV Assay Xpert Cepheid Sunnyvale CA was developed for the multianalytic GeneXpert platform In a colposcopy referral population of 708 women living in the United States two specimens A and B were collected and both were tested by the Xpert assay for high-risk human papillomavirus hrHPV DNA permitting an evaluation of its test reliability Specimen B was also tested by Hybrid Capture 2 hc2 Qiagen Germantown MD and the cobas HPV Test cobas Roche Molecular Systems Pleasanton CA The  and percent agreement for any hrHPV for the two Xpert results were 0.88 and 94.5 respectively There was no statistical difference in testing positive on both specimens by Xpert P .62 The sensitivity for detection of intraepithelial neoplasia grade 2 or more severe CIN2+ was 89.0 using specimen A and 90.4 using specimen B for Xpert 90.4 for cobas and 81.6 for hc2 The Xpert assay was sensitive and reliable for the detection of hrHPV and the identification of women with CIN2+,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 20039, 933, 719, 20039, 48296, 26466, 1568, 10, 276, 9, 3, 48744, 40680, 2243, 4, 8, 9946, 2096, 266, 1, 9687, 117, 2798, 4, 3, 1088, 907, 100, 623, 8, 2, 132, 11, 786, 2, 110, 11, 650, 20, 3, 20039, 719, 9, 64, 43, 171, 3242, 17544, 261, 9621, 35, 451, 1, 211, 412, 4217, 2360, 132, 10, 120, 650, 20, 4542, 2891, 18, 16516, 22599, 65336, 2244, 2, 3, 12053, 933, 412, 12053, 9777, 219, 1530, 35476, 1568, 3, 4627, 2, 714, 2024, 9, 500, 17544, 9, 3, 100, 20039, 99, 11, 13, 889, 2, 960, 33, 106, 125, 10, 77, 1050, 523, 4, 471, 109, 23, 110, 623, 20, 20039, 19, 744, 3, 485, 9, 638, 1, 4153, 2298, 88, 18, 15, 80, 905, 12870, 10, 887, 13, 75, 2360, 8, 2, 424, 39, 75, 2360, 132, 9, 20039, 424, 39, 9, 12053, 2, 865, 49, 9, 16516, 3, 20039, 719, 10, 745, 2, 2450, 9, 3, 638, 1, 17544, 2, 3, 911, 1, 117, 5, 12870]",972.0,25511151,31
Establishing translational and clinical cancer research collaborations between high- and low-income countries.,Annals of surgical oncology,Ann. Surg. Oncol.,2015-01-09,"Both infectious and noninfectious related malignancies are a growing problem in low- and middle-income countries (LMIC). It is difficult to extrapolate data and guidelines regarding cancer care from high-income countries (HIC) to cancer patients in LMIC. Due to the rise in noncommunicable cancer rates, there is a widening gap between the need for evidence-based treatments for cancer control plans and existing research capabilities. Surgeons frequently provide all surgical and medical oncology treatments for patients in LMIC for diseases, such as breast, gastric, cervical, and colorectal cancers. Surgical oncology clinical and translational research collaborations, however, are lacking. There are several successful consortiums that focus on HIV- and infectious-related malignancies. These collaborations can be used as an example for future surgical research efforts. The Memorial Sloan Kettering Cancer Center-Nigerian collaboration that is concentrating on colorectal cancer is used as an example of how to initiate a research collaboration that can build research infrastructure and provide the necessary data to generate realistic treatment guidelines. The need for expanded surgical oncology research and the growing population of patients with noninfectious-related malignancies in LMIC has created a unique opportunity for surgeons to initiate and lead clinical and translational research collaborations between HIC and LMIC. ",Journal Article,1838.0,14.0,Both infectious and noninfectious related malignancies are a growing problem in low- and middle-income countries LMIC It is difficult to extrapolate data and guidelines regarding cancer care from high-income countries HIC to cancer patients in LMIC Due to the rise in noncommunicable cancer rates there is a widening gap between the need for evidence-based treatments for cancer control plans and existing research capabilities Surgeons frequently provide all surgical and medical oncology treatments for patients in LMIC for diseases such as and cancers Surgical oncology clinical and translational research collaborations however are lacking There are several successful consortiums that focus on HIV- and infectious-related malignancies These collaborations can be used as an example for future surgical research efforts The Memorial Sloan Kettering Cancer Center-Nigerian collaboration that is concentrating on cancer is used as an example of how to initiate a research collaboration that can build research infrastructure and provide the necessary data to generate realistic treatment guidelines The need for expanded surgical oncology research and the growing population of patients with noninfectious-related malignancies in LMIC has created a unique opportunity for surgeons to initiate and lead clinical and translational research collaborations between HIC and LMIC,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,"[110, 3398, 2, 13602, 139, 441, 32, 8, 1921, 2497, 4, 154, 2, 3897, 2306, 2115, 12950, 192, 16, 1740, 6, 19750, 74, 2, 677, 666, 12, 165, 29, 64, 2306, 2115, 13390, 6, 12, 7, 4, 12950, 520, 6, 3, 3693, 4, 32375, 12, 151, 125, 16, 8, 23486, 5285, 59, 3, 594, 9, 241, 90, 640, 9, 12, 182, 1853, 2, 1692, 389, 8190, 1613, 746, 377, 62, 221, 2, 484, 413, 640, 9, 7, 4, 12950, 9, 1342, 225, 22, 2, 163, 221, 413, 38, 2, 2460, 389, 10493, 137, 32, 1941, 125, 32, 392, 1401, 35947, 17, 1222, 23, 1942, 2, 3398, 139, 441, 46, 10493, 122, 40, 95, 22, 35, 2685, 9, 508, 221, 389, 1413, 3, 2563, 2783, 2784, 12, 574, 24134, 4119, 17, 16, 22052, 23, 12, 16, 95, 22, 35, 2685, 1, 832, 6, 4565, 8, 389, 4119, 17, 122, 5867, 389, 6219, 2, 377, 3, 1493, 74, 6, 2562, 7661, 24, 677, 3, 594, 9, 2064, 221, 413, 389, 2, 3, 1921, 266, 1, 7, 5, 13602, 139, 441, 4, 12950, 71, 2466, 8, 991, 2666, 9, 1613, 6, 4565, 2, 1122, 38, 2, 2460, 389, 10493, 59, 13390, 2, 12950]",1375.0,25572682,7
Are we appropriately selecting therapy for patients with cervical cancer? Longitudinal patterns-of-care analysis for stage IB-IIB cervical cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2014-10-18,"We performed a patterns-of-care analysis evaluating the effects of newer technology and recent research findings on treatment decisions over 26 years to determine whether patients with cervical cancer are being appropriately selected for treatment to optimize the therapeutic ratio. A retrospective analysis was conducted using the Surveillance, Epidemiology and End Results (SEER) program from 1983 to 2009. We identified 10,933 women with stage IB-IIB cervical carcinoma. Of the 10,933 subjects identified, 40.1% received surgery, 26.8% received radiation (RT), and 33.1% received surgery plus RT. RT use increased after 2000 compared to prior to 2000, with a corresponding decrease in surgery and surgery plus RT. Among patients with risk factors including tumor size >4 cm, positive parametria, and positive lymph nodes, declining use of surgery plus RT was observed. However, 23% of patients with tumors >4 cm, 20% of patients with positive parametria, and 55% of node-positive patients continued to receive surgery plus RT as of 2009. Factors associated with increased use of surgery plus RT included patient age <50 and node-positive status. In this largest patterns-of-care analysis to date for patients with locally advanced cervical cancer, we found a substantial proportion of patients continue to undergo surgery followed by radiation, despite randomized data supporting the use of definitive radiation therapy, with lower morbidity than surgery and radiation.",Journal Article,1921.0,14.0,"We performed a patterns-of-care analysis evaluating the effects of newer technology and recent research findings on treatment decisions over 26 years to determine whether patients with cancer are being appropriately selected for treatment to optimize the therapeutic ratio A retrospective analysis was conducted using the Surveillance Epidemiology and End Results SEER program from 1983 to 2009 We identified 10,933 women with stage IB-IIB carcinoma Of the 10,933 subjects identified 40.1 received surgery 26.8 received radiation RT and 33.1 received surgery plus RT RT use increased after 2000 compared to prior to 2000 with a corresponding decrease in surgery and surgery plus RT Among patients with risk factors including tumor size 4 cm positive parametria and positive lymph nodes declining use of surgery plus RT was observed However 23 of patients with tumors 4 cm 20 of patients with positive parametria and 55 of node-positive patients continued to receive surgery plus RT as of 2009 Factors associated with increased use of surgery plus RT included patient age 50 and node-positive status In this largest patterns-of-care analysis to date for patients with locally advanced cancer we found a substantial proportion of patients continue to undergo surgery followed by radiation despite randomized data supporting the use of definitive radiation therapy with lower morbidity than surgery and radiation",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 173, 8, 764, 1, 165, 65, 1435, 3, 176, 1, 2246, 2033, 2, 435, 389, 272, 23, 24, 1526, 252, 432, 60, 6, 223, 317, 7, 5, 12, 32, 486, 4544, 715, 9, 24, 6, 2465, 3, 189, 197, 8, 459, 65, 10, 426, 75, 3, 617, 1284, 2, 396, 99, 1605, 1243, 29, 6656, 6, 1238, 21, 108, 79, 17986, 117, 5, 82, 3180, 3884, 134, 1, 3, 79, 17986, 976, 108, 327, 14, 103, 152, 432, 66, 103, 121, 240, 2, 466, 14, 103, 152, 349, 240, 240, 119, 101, 50, 1081, 72, 6, 324, 6, 1081, 5, 8, 1734, 775, 4, 152, 2, 152, 349, 240, 107, 7, 5, 43, 130, 141, 30, 444, 39, 494, 109, 19585, 2, 109, 263, 502, 6896, 119, 1, 152, 349, 240, 10, 164, 137, 382, 1, 7, 5, 57, 39, 494, 179, 1, 7, 5, 109, 19585, 2, 614, 1, 289, 109, 7, 1351, 6, 560, 152, 349, 240, 22, 1, 1238, 130, 41, 5, 101, 119, 1, 152, 349, 240, 159, 69, 89, 212, 2, 289, 109, 156, 4, 26, 2166, 764, 1, 165, 65, 6, 1244, 9, 7, 5, 795, 131, 12, 21, 204, 8, 1281, 920, 1, 7, 1906, 6, 1251, 152, 370, 20, 121, 550, 384, 74, 1912, 3, 119, 1, 1057, 121, 36, 5, 280, 787, 76, 152, 2, 121]",1409.0,25585782,181
[Proliferation inhibition and apoptosis induction of Juglone on human cervical cancer Caski cells].,Wei sheng yan jiu = Journal of hygiene research,Wei Sheng Yan Jiu,2014-11-01,"To explore the effects of Juglone on proliferation and apoptosis of human cervical cancer Caski cells, and to further study the related mechanism of cell apoptosis. Cultured Caski cells were incubated with 20, 40, 60, 80 and 100 mol/L juglone for 24 h. The proliferation of Caski cells was detected by methyl thiazolyl tetrazolium (MTT) assay. The cell apoptosis were detected by transmission electron microscope. The expression of Bcl-2 and Bax were detected by Western blot. MTT results showed that in different doses of juglone groups, the Caski cell growth was greatly inhibited (P < 0.05, P < 0.01) and showed dose dependent when compared with control group except 20 mol/L. The IC50 of juglone was 42.4 mol/L. After treatment on Caski cells with 40 mol/L juglone, typical apoptosis characteristics was observed by transmission electronmicro scope. The expression of Bcl-2 was decreased while the expression of Bax was increased significantly when compared with control group (P < 0.05). Juglone significantly inhibits the proliferation and induces the apoptosis of Caski cells in vitro.",Journal Article,1907.0,3.0,To explore the effects of Juglone on proliferation and apoptosis of human cancer Caski cells and to further study the related mechanism of cell apoptosis Cultured Caski cells were incubated with 20 40 60 80 and 100 mol/L juglone for 24 h. The proliferation of Caski cells was detected by methyl thiazolyl tetrazolium MTT assay The cell apoptosis were detected by transmission electron microscope The expression of Bcl-2 and Bax were detected by Western blot MTT results showed that in different doses of juglone groups the Caski cell growth was greatly inhibited P 0.05 P 0.01 and showed dose dependent when compared with control group except 20 mol/L The IC50 of juglone was 42.4 mol/L After treatment on Caski cells with 40 mol/L juglone typical apoptosis characteristics was observed by transmission electronmicro scope The expression of Bcl-2 was decreased while the expression of Bax was increased significantly when compared with control group P 0.05 Juglone significantly inhibits the proliferation and induces the apoptosis of Caski cells in vitro,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1645, 3, 176, 1, 20059, 23, 457, 2, 351, 1, 171, 12, 27417, 37, 2, 6, 195, 45, 3, 139, 670, 1, 31, 351, 3197, 27417, 37, 11, 8303, 5, 179, 327, 335, 493, 2, 394, 7674, 805, 20059, 9, 259, 555, 3, 457, 1, 27417, 37, 10, 530, 20, 5228, 21466, 11915, 4988, 719, 3, 31, 351, 11, 530, 20, 8151, 4560, 13061, 3, 55, 1, 1044, 18, 2, 3119, 11, 530, 20, 1521, 2639, 4988, 99, 224, 17, 4, 338, 415, 1, 20059, 271, 3, 27417, 31, 129, 10, 3510, 879, 19, 13, 474, 19, 13, 355, 2, 224, 61, 470, 198, 72, 5, 182, 87, 2187, 179, 7674, 805, 3, 5211, 1, 20059, 10, 595, 39, 7674, 805, 50, 24, 23, 27417, 37, 5, 327, 7674, 805, 20059, 3476, 351, 374, 10, 164, 20, 8151, 65509, 7924, 3, 55, 1, 1044, 18, 10, 340, 369, 3, 55, 1, 3119, 10, 101, 97, 198, 72, 5, 182, 87, 19, 13, 474, 20059, 97, 1576, 3, 457, 2, 1516, 3, 351, 1, 27417, 37, 4, 439]",1059.0,25603606,878
"Escalation of oncologic services at the end of life among patients with gynecologic cancer at an urban, public hospital.",Journal of oncology practice,J Oncol Pract,2015-01-20,"Use of oncology-related services is increasingly scrutinized, yet precisely which services are actually rendered to patients, particularly at the end of life, is unknown. This study characterizes the end-of-life use of medical services by patients with gynecologic cancer at a safety-net hospital. Oncologic history and metrics of medical use (eg, hospitalizations, chemotherapy infusions, procedures) for patients with gynecologic oncology who died between December 2006 and February 2012 were evaluated. Mixed-effect regression models were used to test time effects and construct usage summaries. Among 116 subjects, cervical cancer accounted for the most deaths (42%). The median age at diagnosis was 55 years; 63% were Hispanic, and 65% had advanced disease. Only 34% died in hospice care. The median times from do not resuscitate/do not intubate documentation and from last therapeutic intervention to death were 9 days and 55 days, respectively. Significant time effects for all services (eg, hospitalizations, diagnostics, procedures, treatments, clinic appointments) were detected during the patient's final year (P < .001), with the most dramatic changes occurring during the last 2 months. Patients with longer duration of continuity of care used significantly fewer resources toward the end of life. To our knowledge, this is the first report enumerating medical services obtained by patients with gynecologic cancer in a large, public hospital during the end of life. Marked changes in interventions in the patient's final 2 months highlight the need for cost-effective, evidence-based metrics for delivering cancer care. Our data emphasize continuity of care as a significant determinant of oncologic resource use during this critical period.",Journal Article,1827.0,7.0,Use of oncology-related services is increasingly scrutinized yet precisely which services are actually rendered to patients particularly at the end of life is unknown This study characterizes the end-of-life use of medical services by patients with gynecologic cancer at a safety-net hospital Oncologic history and metrics of medical use eg hospitalizations chemotherapy infusions procedures for patients with gynecologic oncology who died between December 2006 and February 2012 were evaluated Mixed-effect regression models were used to test time effects and construct usage summaries Among 116 subjects cancer accounted for the most deaths 42 The median age at diagnosis was 55 years 63 were Hispanic and 65 had advanced disease Only 34 died in hospice care The median times from do not resuscitate/do not intubate documentation and from last therapeutic intervention to death were 9 days and 55 days respectively Significant time effects for all services eg hospitalizations diagnostics procedures treatments clinic appointments were detected during the patient 's final year P .001 with the most dramatic changes occurring during the last 2 months Patients with longer duration of continuity of care used significantly fewer resources toward the end of life To our knowledge this is the first report enumerating medical services obtained by patients with gynecologic cancer in a large public hospital during the end of life Marked changes in interventions in the patient 's final 2 months highlight the need for cost-effective evidence-based metrics for delivering cancer care Our data emphasize continuity of care as a significant determinant of oncologic resource use during this critical period,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[119, 1, 413, 139, 2142, 16, 1635, 21084, 1145, 7428, 92, 2142, 32, 6742, 6021, 6, 7, 823, 28, 3, 396, 1, 358, 16, 860, 26, 45, 9239, 3, 396, 1, 358, 119, 1, 484, 2142, 20, 7, 5, 1512, 12, 28, 8, 367, 2587, 702, 1998, 532, 2, 3589, 1, 484, 119, 2887, 4888, 56, 3435, 1369, 9, 7, 5, 1512, 413, 54, 1016, 59, 1397, 1324, 2, 3010, 1195, 11, 194, 1739, 254, 320, 274, 11, 95, 6, 412, 98, 176, 2, 3883, 5015, 15168, 107, 3790, 976, 12, 3688, 9, 3, 96, 1043, 595, 3, 52, 89, 28, 147, 10, 614, 60, 676, 11, 1776, 2, 556, 42, 131, 34, 158, 562, 1016, 4, 2490, 165, 3, 52, 1072, 29, 1022, 44, 12509, 1022, 44, 65513, 4965, 2, 29, 1060, 189, 788, 6, 273, 11, 83, 162, 2, 614, 162, 106, 93, 98, 176, 9, 62, 2142, 2887, 4888, 5197, 1369, 640, 1188, 9829, 11, 530, 190, 3, 69, 292, 1457, 111, 19, 144, 5, 3, 96, 3079, 400, 1821, 190, 3, 1060, 18, 53, 7, 5, 589, 654, 1, 12253, 1, 165, 95, 97, 1497, 2892, 1317, 3, 396, 1, 358, 6, 114, 922, 26, 16, 3, 157, 414, 21029, 484, 2142, 683, 20, 7, 5, 1512, 12, 4, 8, 375, 3067, 702, 190, 3, 396, 1, 358, 2003, 400, 4, 1151, 4, 3, 69, 292, 1457, 18, 53, 1817, 3, 594, 9, 835, 323, 241, 90, 3589, 9, 4790, 12, 165, 114, 74, 5560, 12253, 1, 165, 22, 8, 93, 4372, 1, 1998, 3069, 119, 190, 26, 740, 727]",1702.0,25604595,450
Optimizing packing contrast for MRI-based intracavitary brachytherapy planning for cervical cancer.,Brachytherapy,Brachytherapy,2015-01-22,"We prospectively tested five variations in vaginal gauze packing in an effort to improve contrast between the packing, cervix, and applicator for MRI-based intracavitary brachytherapy planning. Five patients enrolled on a prospective study from May 2013 to October 2013 received MRI-based intracavitary brachytherapy for cervical cancer with variations of impregnated gauze packing. Substances tested included antibiotic cream alone, antibiotic cream mixed with ultrasound gel, conjugated estrogens cream mixed with ultrasound gel, ultrasound gel alone, and gadolinium. Images from the T2-weighted pelvic MRI were used to obtain signal intensity measurements at points within the packing, cervix, and applicator. Signal intensity values were normalized using the signal-to-noise ratio and compared using an unpaired t-test. Ultrasound gel-impregnated gauze allowed for the greatest contrast between the packing and the cervix with a difference in mean normalized signal intensity of 38.2 (p < 0.01). Conjugated estrogens cream mixed with ultrasound gel and gadolinium also provided contrast when compared with cervix, with differences in mean normalized signal intensity of 25.3 and -16.2, respectively (p < 0.01 for both). For all variations but gadolinium, the normalized mean signal intensity of the packing was found to be significantly different from the applicator, with the ultrasound gel again demonstrating the greatest contrast with a difference of 42.5 (p < 0.01). Gauze impregnated with ultrasound gel, conjugated estrogens cream mixed with ultrasound gel, and gadolinium allowed for a significant difference in MRI signal intensity between the packing and the cervix. With respect to both the cervix and the applicator, ultrasoundgel-impregnated gauze provided the best contrast overall.",Journal Article,1825.0,1.0,We prospectively tested five variations in gauze packing in an effort to improve contrast between the packing cervix and applicator for MRI-based intracavitary brachytherapy planning Five patients enrolled on a prospective study from May 2013 to October 2013 received MRI-based intracavitary brachytherapy for cancer with variations of impregnated gauze packing Substances tested included antibiotic cream alone antibiotic cream mixed with ultrasound gel conjugated estrogens cream mixed with ultrasound gel ultrasound gel alone and gadolinium Images from the T2-weighted pelvic MRI were used to obtain signal intensity measurements at points within the packing cervix and applicator Signal intensity values were normalized using the signal-to-noise ratio and compared using an unpaired t-test Ultrasound gel-impregnated gauze allowed for the greatest contrast between the packing and the cervix with a difference in mean normalized signal intensity of 38.2 p 0.01 Conjugated estrogens cream mixed with ultrasound gel and gadolinium also provided contrast when compared with cervix with differences in mean normalized signal intensity of 25.3 and -16.2 respectively p 0.01 for both For all variations but gadolinium the normalized mean signal intensity of the packing was found to be significantly different from the applicator with the ultrasound gel again demonstrating the greatest contrast with a difference of 42.5 p 0.01 Gauze impregnated with ultrasound gel conjugated estrogens cream mixed with ultrasound gel and gadolinium allowed for a significant difference in MRI signal intensity between the packing and the cervix With respect to both the cervix and the applicator ultrasoundgel-impregnated gauze provided the best contrast overall,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 1143, 650, 365, 2293, 4, 28291, 18479, 4, 35, 2919, 6, 401, 748, 59, 3, 18479, 3629, 2, 8789, 9, 704, 90, 9122, 1536, 1349, 365, 7, 346, 23, 8, 482, 45, 29, 68, 1346, 6, 2551, 1346, 103, 704, 90, 9122, 1536, 9, 12, 5, 2293, 1, 23215, 28291, 18479, 17124, 650, 159, 5210, 14572, 279, 5210, 14572, 1739, 5, 1945, 5916, 3868, 6293, 14572, 1739, 5, 1945, 5916, 1945, 5916, 279, 2, 7295, 1572, 29, 3, 1786, 2337, 1110, 704, 11, 95, 6, 3140, 1235, 837, 1685, 28, 862, 262, 3, 18479, 3629, 2, 8789, 1235, 837, 1030, 11, 4207, 75, 3, 1235, 6, 7556, 197, 2, 72, 75, 35, 16248, 102, 412, 1945, 5916, 23215, 28291, 2313, 9, 3, 2199, 748, 59, 3, 18479, 2, 3, 3629, 5, 8, 523, 4, 313, 4207, 1235, 837, 1, 519, 18, 19, 13, 355, 3868, 6293, 14572, 1739, 5, 1945, 5916, 2, 7295, 120, 1052, 748, 198, 72, 5, 3629, 5, 362, 4, 313, 4207, 1235, 837, 1, 243, 27, 2, 245, 18, 106, 19, 13, 355, 9, 110, 9, 62, 2293, 84, 7295, 3, 4207, 313, 1235, 837, 1, 3, 18479, 10, 204, 6, 40, 97, 338, 29, 3, 8789, 5, 3, 1945, 5916, 5089, 2219, 3, 2199, 748, 5, 8, 523, 1, 595, 33, 19, 13, 355, 28291, 23215, 5, 1945, 5916, 3868, 6293, 14572, 1739, 5, 1945, 5916, 2, 7295, 2313, 9, 8, 93, 523, 4, 704, 1235, 837, 59, 3, 18479, 2, 3, 3629, 5, 2184, 6, 110, 3, 3629, 2, 3, 8789, 65537, 23215, 28291, 1052, 3, 824, 748, 63]",1746.0,25620163,355
Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women.,International journal of cancer,Int. J. Cancer,2015-02-13,"Although the rates of cervical squamous cell carcinoma have been declining, the rates of cervical adenocarcinoma are increasing in some countries. Outcomes for advanced cervical adenocarcinoma remain poor. Precision mapping of genetic alterations in cervical adenocarcinoma may enable better selection of therapies and deliver improved outcomes when combined with new sequencing diagnostics. We present whole-exome sequencing results from 15 cervical adenocarcinomas and paired normal samples from Hong Kong Chinese women. These data revealed a heterogeneous mutation spectrum and identified several frequently altered genes including FAT1, ARID1A, ERBB2 and PIK3CA. Exome sequencing identified human papillomavirus (HPV) sequences in 13 tumors in which the HPV genome might have integrated into and hence disrupted the functions of certain exons, raising the possibility that HPV integration can alter pathways other than p53 and pRb. Together, these provisionary data suggest the potential for individualized therapies for cervical adenocarcinoma based on genomic information. ",Journal Article,1803.0,21.0,Although the rates of squamous cell carcinoma have been declining the rates of adenocarcinoma are increasing in some countries Outcomes for advanced adenocarcinoma remain poor Precision mapping of genetic alterations in adenocarcinoma may enable better selection of therapies and deliver improved outcomes when combined with new sequencing diagnostics We present whole-exome sequencing results from 15 adenocarcinomas and paired normal samples from Hong Kong Chinese women These data revealed a heterogeneous mutation spectrum and identified several frequently altered genes including FAT1 ARID1A ERBB2 and PIK3CA Exome sequencing identified human papillomavirus HPV sequences in 13 tumors in which the HPV genome might have integrated into and hence disrupted the functions of certain exons raising the possibility that HPV integration can alter pathways other than p53 and pRb Together these provisionary data suggest the potential for individualized therapies for adenocarcinoma based on genomic information,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[242, 3, 151, 1, 691, 31, 134, 47, 85, 6896, 3, 151, 1, 449, 32, 602, 4, 476, 2115, 123, 9, 131, 449, 918, 334, 2720, 2568, 1, 336, 593, 4, 449, 68, 3047, 380, 881, 1, 235, 2, 3392, 231, 123, 198, 397, 5, 217, 615, 5197, 21, 364, 902, 2865, 615, 99, 29, 167, 1586, 2, 2355, 295, 347, 29, 20678, 20679, 3656, 117, 46, 74, 553, 8, 1564, 258, 1873, 2, 108, 392, 746, 1495, 214, 141, 13203, 5430, 2186, 2, 1506, 2865, 615, 108, 171, 3242, 933, 2866, 4, 233, 57, 4, 92, 3, 933, 898, 822, 47, 2102, 237, 2, 3665, 5576, 3, 1681, 1, 1840, 3885, 6627, 3, 2526, 17, 933, 2676, 122, 2688, 460, 127, 76, 624, 2, 8734, 1162, 46, 65548, 74, 309, 3, 174, 9, 2596, 235, 9, 449, 90, 23, 572, 487]",1010.0,25626421,400
High-resolution microendoscope for the detection of cervical neoplasia.,"Methods in molecular biology (Clifton, N.J.)",Methods Mol. Biol.,2015-01-01,"Cervical cancer causes 275,000 deaths each year with 85 % of these deaths occurring in the developing world. One of the primary reasons for the concentration of deaths in developing countries is a lack of effective screening methods suited for the infrastructure of these countries. In order to address this need, we have developed a high-resolution microendoscope (HRME). The HRME is a fiber-based fluorescence microscope with subcellular resolution. Using the vital stain proflavine, we are able to image cell nuclei in vivo and evaluate metrics such as nuclear-to-cytoplasmic ratio, critical to identifying precancerous epithelial regions. In this chapter, we detail the materials and methods necessary to build this system from commercially available parts.",Journal Article,1846.0,2.0,"cancer causes 275,000 deaths each year with 85 of these deaths occurring in the developing world One of the primary reasons for the concentration of deaths in developing countries is a lack of effective screening methods suited for the infrastructure of these countries In order to address this need we have developed a high-resolution microendoscope HRME The HRME is a fiber-based fluorescence microscope with subcellular resolution Using the vital stain proflavine we are able to image cell nuclei in vivo and evaluate metrics such as nuclear-to-cytoplasmic ratio critical to identifying precancerous epithelial regions In this chapter we detail the materials and methods necessary to build this system from commercially available parts",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 1626, 5620, 984, 1043, 296, 111, 5, 772, 1, 46, 1043, 1821, 4, 3, 931, 1956, 104, 1, 3, 86, 2325, 9, 3, 1227, 1, 1043, 4, 931, 2115, 16, 8, 926, 1, 323, 453, 636, 7247, 9, 3, 6219, 1, 46, 2115, 4, 1732, 6, 1539, 26, 594, 21, 47, 276, 8, 64, 2125, 19487, 12049, 3, 12049, 16, 8, 5554, 90, 1591, 13061, 5, 7153, 2125, 75, 3, 3511, 8763, 20769, 21, 32, 1665, 6, 1482, 31, 4725, 4, 386, 2, 376, 3589, 225, 22, 928, 6, 2828, 197, 740, 6, 1386, 6605, 701, 1374, 4, 26, 6366, 21, 5000, 3, 5102, 2, 636, 1493, 6, 5867, 26, 398, 29, 5262, 390, 6532]",738.0,25626555,297
Postoperative proton therapy for chordomas and chondrosarcomas of the spine: adjuvant versus salvage radiation therapy.,Spine,Spine,2015-04-01,"Retrospective comparative cohort series. The aim of this study was to evaluate patients treated with proton therapy for chordoma and chondrosarcoma of the spine in the postoperative setting and to report local control, relapse-free, and overall survival outcomes. Margin-negative resection of spinal chordomas and chondrosarcomas can be challenging, so adjuvant radiotherapy is often recommended. However, delivery of adequate radiotherapy is complicated by the relative radioresistance of these tumors, necessitating high doses, as well as the proximity of the spinal cord and exiting nerve roots increasing the risk for toxicity. Proton radiotherapy has favorable physical properties for avoiding nearby nontarget structures and is increasingly used for such lesions. Nineteen patients who underwent postoperative proton therapy at a single institution from 2006 to 2012 were identified including 13 with chordoma and 6 with chondrosarcoma. Surgical approach varied by tumor location in the cervical (n = 3), thoracic (n = 1), lumbar (n = 2), or sacral (n = 13) spine. Eight patients were categorized as receiving ""early adjuvant"" and 11 patients as receiving ""salvage"" treatment, as determined by initiation of radiation therapy after primary surgery or local recurrence, respectively. The median radiation dose delivered was 70 Gy relative biologic effectiveness (range: 56-78 Gy relative biologic effectiveness). For the entire cohort, 2-year local control, relapse-free survival, and overall survival were 58%, 51.9%, and 93.3%, respectively. The early adjuvant group had significantly higher 2-year local control (80% vs. 45.5%; P = 0.024). Patients referred early for primary adjuvant radiation therapy after surgery had higher rates of disease control than those referred for salvage treatment of recurrent disease. Recurrence rates in our cohort were higher overall than other published series, indicating that even higher radiation doses may be helpful for further improving local control in the presence of gross or recurrent disease. 3.",Comparative Study,1756.0,43.0,Retrospective comparative cohort series The aim of this study was to evaluate patients treated with proton therapy for chordoma and chondrosarcoma of the spine in the postoperative setting and to report local control relapse-free and overall survival outcomes Margin-negative resection of spinal chordomas and chondrosarcomas can be challenging so adjuvant radiotherapy is often recommended However delivery of adequate radiotherapy is complicated by the relative radioresistance of these tumors necessitating high doses as well as the proximity of the spinal cord and exiting nerve roots increasing the risk for toxicity Proton radiotherapy has favorable physical properties for avoiding nearby nontarget structures and is increasingly used for such lesions Nineteen patients who underwent postoperative proton therapy at a single institution from 2006 to 2012 were identified including 13 with chordoma and 6 with chondrosarcoma Surgical approach varied by tumor location in the n 3 thoracic n 1 lumbar n 2 or sacral n 13 spine Eight patients were categorized as receiving `` early adjuvant '' and 11 patients as receiving `` salvage '' treatment as determined by initiation of radiation therapy after primary surgery or local recurrence respectively The median radiation dose delivered was 70 Gy relative biologic effectiveness range 56-78 Gy relative biologic effectiveness For the entire cohort 2-year local control relapse-free survival and overall survival were 58 51.9 and 93.3 respectively The early adjuvant group had significantly higher 2-year local control 80 vs. 45.5 P 0.024 Patients referred early for primary adjuvant radiation therapy after surgery had higher rates of disease control than those referred for salvage treatment of recurrent disease Recurrence rates in our cohort were higher overall than other published series indicating that even higher radiation doses may be helpful for further improving local control in the presence of gross or recurrent disease 3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[459, 2352, 180, 988, 3, 1130, 1, 26, 45, 10, 6, 376, 7, 73, 5, 2095, 36, 9, 3911, 2, 6116, 1, 3, 2342, 4, 3, 573, 546, 2, 6, 414, 293, 182, 429, 115, 2, 63, 25, 123, 959, 199, 170, 1, 1499, 6790, 2, 11960, 122, 40, 1950, 1743, 249, 310, 16, 629, 793, 137, 989, 1, 1658, 310, 16, 4286, 20, 3, 580, 7052, 1, 46, 57, 8365, 64, 415, 22, 149, 22, 3, 6167, 1, 3, 1499, 1885, 2, 35957, 2476, 19672, 602, 3, 43, 9, 155, 2095, 310, 71, 913, 900, 1571, 9, 6048, 10789, 12756, 2414, 2, 16, 1635, 95, 9, 225, 406, 3498, 7, 54, 208, 573, 2095, 36, 28, 8, 226, 731, 29, 1324, 6, 1195, 11, 108, 141, 233, 5, 3911, 2, 49, 5, 6116, 221, 353, 2051, 20, 30, 1147, 4, 3, 78, 27, 2098, 78, 14, 6187, 78, 18, 15, 7943, 78, 233, 2342, 659, 7, 11, 2320, 22, 357, 191, 249, 522, 2, 175, 7, 22, 357, 992, 522, 24, 22, 509, 20, 1118, 1, 121, 36, 50, 86, 152, 15, 293, 146, 106, 3, 52, 121, 61, 1623, 10, 431, 381, 580, 1283, 1236, 184, 664, 833, 381, 580, 1283, 1236, 9, 3, 1797, 180, 18, 111, 293, 182, 429, 115, 25, 2, 63, 25, 11, 717, 725, 83, 2, 966, 27, 106, 3, 191, 249, 87, 42, 97, 142, 18, 111, 293, 182, 493, 105, 512, 33, 19, 13, 4247, 7, 1995, 191, 9, 86, 249, 121, 36, 50, 152, 42, 142, 151, 1, 34, 182, 76, 135, 1995, 9, 992, 24, 1, 387, 34, 146, 151, 4, 114, 180, 11, 142, 63, 76, 127, 983, 988, 1716, 17, 871, 142, 121, 415, 68, 40, 3951, 9, 195, 1673, 293, 182, 4, 3, 463, 1, 1789, 15, 387, 34, 27]",1987.0,25627289,106
"Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).",The Lancet. Oncology,Lancet Oncol.,2015-01-29,"GOG 240 was a practice-changing randomised phase 3 trial that concluded that chemotherapy plus bevacizumab for advanced cervical cancer significantly improves overall and progression-free survival, and the proportion of patients achieving an overall objective response, compared with chemotherapy alone. In this study, we aimed to analyse patient-reported outcomes in GOG 240. Eligible adult participants (aged 18 years) had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease and GOG performance status of 0-1. Participants were randomly assigned by web-based permuted block randomisation (block size 4) in a 1:1:1:1 ratio to the four treatment groups: cisplatin (50 mg/m(2) intravenously on day 1 or 2 of the treatment cycle) and paclitaxel (135 mg/m(2) intravenously over 24 h or 175 mg/m(2) intravenously over 3 h on day 1), with or without bevacizumab (15 mg/kg intravenously on day 1 or 2), or paclitaxel (175 mg/m(2) over 3 h on day 1) and topotecan (075 mg/m(2) for 30 min on days 1-3) with or without bevacizumab (15 mg/kg intravenously on day 1). Treatment assignment was concealed at randomisation (everyone was masked to treatment assignment, achieved by the use of a computer encrypted numbering system at the National Cancer Institute) and became open-label when each patient was registered to the trial. Treatment cycles were repeated every 21 days until disease progression or unacceptable toxicity, whichever occurred first. The coprimary endpoints of the trial were overall survival and safety; the primary quality-of-life endpoint was the score on the Functional Assessment of Cancer Therapy-Cervix Trial Outcome Index (FACT-Cx TOI). For our analysis of patient-reported outcomes, participants were assessed before treatment cycles 1, 2, and 5, and at 6 and 9 months after the start of cycle 1, with the FACT-Cx TOI, items from the FACT-GOG-Neurotoxicity subscale, and a worst pain item from the Brief Pain Inventory. All patients who completed baseline quality-of-life assessments and at least one further follow-up assessment were evaluable for quality-of-life outcomes. This study is registered with ClinicalTrials.gov, number NCT00803062. Between April 6, 2009, and Jan 3, 2012, a total of 452 patients were enrolled in the trial, of whom 390 completed baseline quality-of-life assessment and at least one further assessment and were therefore evaluable for quality-of-life outcomes. In these patients, patient-reported outcome completion declined from 426 (94%) of 452 (at baseline) to 193 (63%) of 307 (9 months post-cycle 1), but completion rates did not differ significantly between treatment regimens (p=078). The baseline FACT-Cx TOI scores did not differ significantly between patients who received bevacizumab versus those who did not (p=027). Compared with patients who received chemotherapy alone, patients who received chemotherapy plus bevacizumab reported FACT-Cx TOI scores that were an average of 12 points lower (9875% CI -41 to 17; p=030). Improvements in overall survival and progression-free survival attributed to the incorporation of bevacizumab into the treatment of advanced cervical cancer were not accompanied by any significant deterioration in health-related quality of life. Patients responding to anti-angiogenesis therapy who maintain an acceptable quality of life could be suitable at progression for treatment with other novel therapies that might confer additional benefit. National Institutes of Health.","Clinical Trial, Phase III",1818.0,67.0,GOG 240 was a practice-changing randomised phase 3 trial that concluded that chemotherapy plus bevacizumab for advanced cancer significantly improves overall and progression-free survival and the proportion of patients achieving an overall objective response compared with chemotherapy alone In this study we aimed to analyse patient-reported outcomes in GOG 240 Eligible adult participants aged 18 years had primary stage IVB or recurrent or persistent carcinoma of the cervix with measurable disease and GOG performance status of 0-1 Participants were randomly assigned by web-based permuted block randomisation block size 4 in a 1:1:1:1 ratio to the four treatment groups cisplatin 50 mg/m 2 intravenously on day 1 or 2 of the treatment cycle and paclitaxel 135 mg/m 2 intravenously over 24 h or 175 mg/m 2 intravenously over 3 h on day 1 with or without bevacizumab 15 mg/kg intravenously on day 1 or 2 or paclitaxel 175 mg/m 2 over 3 h on day 1 and topotecan 075 mg/m 2 for 30 min on days 1-3 with or without bevacizumab 15 mg/kg intravenously on day 1 Treatment assignment was concealed at randomisation everyone was masked to treatment assignment achieved by the use of a computer encrypted numbering system at the National Cancer Institute and became open-label when each patient was registered to the trial Treatment cycles were repeated every 21 days until disease progression or unacceptable toxicity whichever occurred first The coprimary endpoints of the trial were overall survival and safety the primary quality-of-life endpoint was the score on the Functional Assessment of Cancer Therapy-Cervix Trial Outcome Index FACT-Cx TOI For our analysis of patient-reported outcomes participants were assessed before treatment cycles 1 2 and 5 and at 6 and 9 months after the start of cycle 1 with the FACT-Cx TOI items from the FACT-GOG-Neurotoxicity subscale and a worst pain item from the Brief Pain Inventory All patients who completed baseline quality-of-life assessments and at least one further follow-up assessment were evaluable for quality-of-life outcomes This study is registered with ClinicalTrials.gov number NCT00803062 Between April 6 2009 and Jan 3 2012 a total of 452 patients were enrolled in the trial of whom 390 completed baseline quality-of-life assessment and at least one further assessment and were therefore evaluable for quality-of-life outcomes In these patients patient-reported outcome completion declined from 426 94 of 452 at baseline to 193 63 of 307 9 months post-cycle 1 but completion rates did not differ significantly between treatment regimens p=078 The baseline FACT-Cx TOI scores did not differ significantly between patients who received bevacizumab versus those who did not p=027 Compared with patients who received chemotherapy alone patients who received chemotherapy plus bevacizumab reported FACT-Cx TOI scores that were an average of 12 points lower 9875 CI -41 to 17 p=030 Improvements in overall survival and progression-free survival attributed to the incorporation of bevacizumab into the treatment of advanced cancer were not accompanied by any significant deterioration in health-related quality of life Patients responding to anti-angiogenesis therapy who maintain an acceptable quality of life could be suitable at progression for treatment with other novel therapies that might confer additional benefit National Institutes of Health,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4760, 4263, 10, 8, 758, 3600, 2827, 124, 27, 160, 17, 4724, 17, 56, 349, 599, 9, 131, 12, 97, 1804, 63, 2, 91, 115, 25, 2, 3, 920, 1, 7, 1785, 35, 63, 461, 51, 72, 5, 56, 279, 4, 26, 45, 21, 1295, 6, 10305, 69, 210, 123, 4, 4760, 4263, 625, 780, 776, 1032, 6624, 60, 42, 86, 82, 7042, 15, 387, 15, 1882, 134, 1, 3, 3629, 5, 1884, 34, 2, 4760, 528, 156, 1, 13, 14, 776, 11, 1108, 896, 20, 3469, 90, 10496, 2381, 5204, 2381, 444, 39, 4, 8, 14, 14, 14, 14, 197, 6, 3, 294, 24, 271, 540, 212, 81, 188, 18, 1672, 23, 218, 14, 15, 18, 1, 3, 24, 417, 2, 490, 3978, 81, 188, 18, 1672, 252, 259, 555, 15, 3300, 81, 188, 18, 1672, 252, 27, 555, 23, 218, 14, 5, 15, 187, 599, 167, 81, 503, 1672, 23, 218, 14, 15, 18, 15, 490, 3300, 81, 188, 18, 252, 27, 555, 23, 218, 14, 2, 2129, 16992, 81, 188, 18, 9, 201, 1538, 23, 162, 14, 27, 5, 15, 187, 599, 167, 81, 503, 1672, 23, 218, 14, 24, 4392, 10, 40977, 28, 5204, 31309, 10, 7415, 6, 24, 4392, 513, 20, 3, 119, 1, 8, 4236, 39419, 38840, 398, 28, 3, 657, 12, 1377, 2, 3451, 1020, 1756, 198, 296, 69, 10, 1653, 6, 3, 160, 24, 410, 11, 2113, 454, 239, 162, 1100, 34, 91, 15, 3215, 155, 12867, 489, 157, 3, 10740, 1387, 1, 3, 160, 11, 63, 25, 2, 367, 3, 86, 372, 1, 358, 1138, 10, 3, 368, 23, 3, 583, 455, 1, 12, 36, 3629, 160, 228, 558, 1991, 13627, 12329, 9, 114, 65, 1, 69, 210, 123, 776, 11, 275, 348, 24, 410, 14, 18, 2, 33, 2, 28, 49, 2, 83, 53, 50, 3, 2435, 1, 417, 14, 5, 3, 1991, 13627, 12329, 2980, 29, 3, 1991, 4760, 3561, 5593, 2, 8, 4066, 559, 3471, 29, 3, 3190, 559, 3818, 62, 7, 54, 781, 330, 372, 1, 358, 2182, 2, 28, 506, 104, 195, 166, 126, 455, 11, 859, 9, 372, 1, 358, 123, 26, 45, 16, 1653, 5, 1252, 1239, 207, 40623, 59, 2292, 49, 1238, 2, 7555, 27, 1195, 8, 181, 1, 12638, 7, 11, 346, 4, 3, 160, 1, 953, 7992, 781, 330, 372, 1, 358, 455, 2, 28, 506, 104, 195, 455, 2, 11, 673, 859, 9, 372, 1, 358, 123, 4, 46, 7, 69, 210, 228, 1438, 3054, 29, 12114, 960, 1, 12638, 28, 330, 6, 5744, 676, 1, 9682, 83, 53, 539, 417, 14, 84, 1438, 151, 205, 44, 1505, 97, 59, 24, 472, 19, 17513, 3, 330, 1991, 13627, 12329, 703, 205, 44, 1505, 97, 59, 7, 54, 103, 599, 185, 135, 54, 205, 44, 19, 29311, 72, 5, 7, 54, 103, 56, 279, 7, 54, 103, 56, 349, 599, 210, 1991, 13627, 12329, 703, 17, 11, 35, 1011, 1, 14363, 862, 280, 65563, 58, 19269, 6, 15768, 19, 20762, 1474, 4, 63, 25, 2, 91, 115, 25, 3073, 6, 3, 2838, 1, 599, 237, 3, 24, 1, 131, 12, 11, 44, 2756, 20, 500, 93, 4451, 4, 341, 139, 372, 1, 358, 7, 3261, 6, 312, 1056, 36, 54, 3040, 35, 1595, 372, 1, 358, 359, 40, 2884, 28, 91, 9, 24, 5, 127, 229, 235, 17, 822, 2913, 402, 247, 657, 5973, 1, 341]",3407.0,25638326,286
[Juglone inhibits proliferation and induces apoptosis of human cervical squamous cancer SiHa cells].,Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology,Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi,2015-02-01,"To explore the effect of juglone on proliferation and apoptosis of human cervical squamous cancer SiHa cells. Cultured SiHa cells in the exponential growth phase were grouped into blank control group and 10, 20, 50, 80 and 100 mol/L juglone treatment groups. Methyl thiazolyl tetrazolium (MTT) assay was adopted to observe the inhibitory effect of juglone on the proliferation of SiHa cells, and then 50% inhibitory concentration (IC50) was calculated through formula. Annexin V-FITC/PI double staining and flow cytometry were used to detect the effect of 20 mol/L juglone on SiHa cell apoptosis. Western blot was applied to determine the expressions of Bcl-2 and Bax. MTT assay showed that, compared with the control group, treatment groups all showed significant inhibitory effects on SiHa cell growth, and IC50 was 20.4 mol/L. Flow cytometry demonstrated that early apoptosis rate of SiHa cells in the control group was (2.46  0.37)%, and after treatment with 20 mol/L Juglone for 12 hours, the apoptosis rate was raised to (18.47  2.26)%; Western blot analysis showed that the expression of Bcl-2 decreased while the expression of Bax increased significantly in SiHa cells treated with 20 mol/L juglone. Juglone could significantly inhibit the proliferation and induce the apoptosis of SiHa cells.",English Abstract,1815.0,7.0,To explore the effect of juglone on proliferation and apoptosis of human squamous cancer SiHa cells Cultured SiHa cells in the exponential growth phase were grouped into blank control group and 10 20 50 80 and 100 mol/L juglone treatment groups Methyl thiazolyl tetrazolium MTT assay was adopted to observe the inhibitory effect of juglone on the proliferation of SiHa cells and then 50 inhibitory concentration IC50 was calculated through formula Annexin V-FITC/PI double staining and flow cytometry were used to detect the effect of 20 mol/L juglone on SiHa cell apoptosis Western blot was applied to determine the expressions of Bcl-2 and Bax MTT assay showed that compared with the control group treatment groups all showed significant inhibitory effects on SiHa cell growth and IC50 was 20.4 mol/L Flow cytometry demonstrated that early apoptosis rate of SiHa cells in the control group was 2.46  0.37 and after treatment with 20 mol/L Juglone for 12 hours the apoptosis rate was raised to 18.47  2.26 Western blot analysis showed that the expression of Bcl-2 decreased while the expression of Bax increased significantly in SiHa cells treated with 20 mol/L juglone Juglone could significantly inhibit the proliferation and induce the apoptosis of SiHa cells,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1645, 3, 254, 1, 20059, 23, 457, 2, 351, 1, 171, 691, 12, 19043, 37, 3197, 19043, 37, 4, 3, 9379, 129, 124, 11, 3706, 237, 16024, 182, 87, 2, 79, 179, 212, 493, 2, 394, 7674, 805, 20059, 24, 271, 5228, 21466, 11915, 4988, 719, 10, 4457, 6, 4635, 3, 1810, 254, 1, 20059, 23, 3, 457, 1, 19043, 37, 2, 818, 212, 1810, 1227, 5211, 10, 981, 298, 7986, 4850, 603, 12990, 2928, 1627, 1029, 2, 1412, 1914, 11, 95, 6, 1426, 3, 254, 1, 179, 7674, 805, 20059, 23, 19043, 31, 351, 1521, 2639, 10, 1498, 6, 223, 3, 4249, 1, 1044, 18, 2, 3119, 4988, 719, 224, 17, 72, 5, 3, 182, 87, 24, 271, 62, 224, 93, 1810, 176, 23, 19043, 31, 129, 2, 5211, 10, 179, 39, 7674, 805, 1412, 1914, 264, 17, 191, 351, 116, 1, 19043, 37, 4, 3, 182, 87, 10, 18, 641, 810, 13, 567, 2, 50, 24, 5, 179, 7674, 805, 20059, 9, 133, 1459, 3, 351, 116, 10, 5673, 6, 203, 662, 810, 18, 432, 1521, 2639, 65, 224, 17, 3, 55, 1, 1044, 18, 340, 369, 3, 55, 1, 3119, 101, 97, 4, 19043, 37, 73, 5, 179, 7674, 805, 20059, 20059, 359, 97, 1433, 3, 457, 2, 1290, 3, 351, 1, 19043, 37]",1270.0,25652859,848
Development of a platform for systemic antiangiogenesis therapy for advanced cervical cancer.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2014-11-01,"Women with metastatic, recurrent, or persistent cervical carcinoma historically have had extremely limited treatment options. Systemic chemotherapy in these settings is predominantly palliative and has been associated with platinum resistance, nondurable responses, rapid progression of disease with deterioration in quality of life, and early death. At the cooperative group level, efforts to breach this clinical impasse have focused on incorporation of antiangiogenesis therapy, medical optimization, and identification of less toxic regimens. Gynecologic Oncology Group protocols 204 and 240, along with the Japanese Clinical Oncology Group protocol 0505, make up the pivotal phase 3 clinical trials that have provided 3 distinct treatment options. These options incorporate the antiangiogenesis humanized monoclonal antibody bevacizumab in combination with either a platinum-based or nonplatinum-based chemotherapy doublet. This review will highlight the development of bevacizumab in advanced cervical cancer and address the relevance of the survival gain obtained using antiangiogenesis therapy in this high-risk population. ",Journal Article,1907.0,6.0,Women with metastatic recurrent or persistent carcinoma historically have had extremely limited treatment options Systemic chemotherapy in these settings is predominantly palliative and has been associated with platinum resistance nondurable responses rapid progression of disease with deterioration in quality of life and early death At the cooperative group level efforts to breach this clinical impasse have focused on incorporation of antiangiogenesis therapy medical optimization and identification of less toxic regimens Gynecologic Oncology Group protocols 204 and 240 along with the Japanese Clinical Oncology Group protocol 0505 make up the pivotal phase 3 clinical trials that have provided 3 distinct treatment options These options incorporate the antiangiogenesis humanized monoclonal antibody bevacizumab in combination with either a platinum-based or nonplatinum-based chemotherapy doublet This review will highlight the development of bevacizumab in advanced cancer and address the relevance of the survival gain obtained using antiangiogenesis therapy in this high-risk population,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[117, 5, 113, 387, 15, 1882, 134, 3578, 47, 42, 2938, 383, 24, 838, 403, 56, 4, 46, 1947, 16, 2117, 994, 2, 71, 85, 41, 5, 828, 251, 65611, 253, 1321, 91, 1, 34, 5, 4451, 4, 372, 1, 358, 2, 191, 273, 28, 3, 1690, 87, 301, 1413, 6, 32046, 26, 38, 48849, 47, 1649, 23, 2838, 1, 7351, 36, 484, 3980, 2, 911, 1, 299, 1812, 472, 1512, 413, 87, 2189, 5996, 2, 4263, 1510, 5, 3, 5256, 38, 413, 87, 1182, 48850, 2378, 126, 3, 3754, 124, 27, 38, 143, 17, 47, 1052, 27, 834, 24, 838, 46, 838, 3360, 3, 7351, 3619, 848, 548, 599, 4, 150, 5, 361, 8, 828, 90, 15, 10815, 90, 56, 4872, 26, 206, 303, 1817, 3, 193, 1, 599, 4, 131, 12, 2, 1539, 3, 2088, 1, 3, 25, 1803, 683, 75, 7351, 36, 4, 26, 64, 43, 266]",1097.0,25674713,300
Radical Trachelectomy for Early-Stage Cervical Cancer: A Survey of the Society of Gynecologic Oncology and Gynecologic Oncology Fellows-in-Training.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2015-05-01,"The aim of this study was to survey gynecologic oncologists and fellows-in-training regarding the role of radical trachelectomy (RT) and conservative surgery in patients with early-stage cervical cancer. From June 2012 to September 2012, the Society of Gynecologic Oncology member practitioners (n = 1353) and gynecologic oncology fellows (n = 156) were sent group-specific surveys investigating current practice, training, and the future of RT for early-stage cervical cancer management. Twenty-two percent of practitioners (n = 303) and 24.4% of fellows (n = 38) completed the surveys. Of the practitioners, 50% (n = 148) report performing RT, 98% (n = 269) support RT as treatment for squamous carcinoma, and 71% (n = 195) confirm the use of RT for adenocarcinoma. Most practitioners offer RT treatment for stages IA2 to IB1 smaller than 2 cm (n = 209, 76.8%) regardless of grade (77.7%) or lymph vascular space invasion (n = 211, 79.3%). Only 8% (n = 23) of practitioners feel that RT is appropriate for stage IBI larger than 2 cm. Respectively, both practitioners and fellows most frequently perform robotic-assisted (47.0%, n = 101 and 59.1%, n = 13) and abdominal (40.5%, n = 87 and 68.2%, n = 15) RT approaches. After training, fellows project the use of robotic-assisted (71%, n = 22) or abdominal methods (58.1%, n = 18). Overall, 75% (n = 227) of practitioners and 60% (n = 23) of fellows speculate that over the next 5 years, less radical procedures will be used to manage early-stage cervical cancer. Our findings suggest that practitioners and fellows believe RT remains an option for early-stage cervical cancer patients. However, a significant proportion of all respondents believe that less radical surgery may be a future consideration for patients with low-risk early-stage cervical cancer.",Journal Article,1726.0,5.0,The aim of this study was to survey gynecologic oncologists and fellows-in-training regarding the role of radical trachelectomy RT and conservative surgery in patients with early-stage cancer From June 2012 to September 2012 the Society of Gynecologic Oncology member practitioners n 1353 and gynecologic oncology fellows n 156 were sent group-specific surveys investigating current practice training and the future of RT for early-stage cancer management Twenty-two percent of practitioners n 303 and 24.4 of fellows n 38 completed the surveys Of the practitioners 50 n 148 report performing RT 98 n 269 support RT as treatment for squamous carcinoma and 71 n 195 confirm the use of RT for adenocarcinoma Most practitioners offer RT treatment for stages IA2 to IB1 smaller than 2 cm n 209 76.8 regardless of grade 77.7 or lymph vascular space invasion n 211 79.3 Only 8 n 23 of practitioners feel that RT is appropriate for stage IBI larger than 2 cm Respectively both practitioners and fellows most frequently perform robotic-assisted 47.0 n 101 and 59.1 n 13 and abdominal 40.5 n 87 and 68.2 n 15 RT approaches After training fellows project the use of robotic-assisted 71 n 22 or abdominal methods 58.1 n 18 Overall 75 n 227 of practitioners and 60 n 23 of fellows speculate that over the next 5 years less radical procedures will be used to manage early-stage cancer Our findings suggest that practitioners and fellows believe RT remains an option for early-stage cancer patients However a significant proportion of all respondents believe that less radical surgery may be a future consideration for patients with low-risk early-stage cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1130, 1, 26, 45, 10, 6, 1407, 1512, 1339, 2, 7813, 4, 1741, 666, 3, 200, 1, 711, 5760, 240, 2, 4476, 152, 4, 7, 5, 191, 82, 12, 29, 1924, 1195, 6, 2636, 1195, 3, 1174, 1, 1512, 413, 2693, 6323, 78, 35964, 2, 1512, 413, 7813, 78, 5693, 11, 6325, 87, 112, 3666, 3103, 291, 758, 1741, 2, 3, 508, 1, 240, 9, 191, 82, 12, 284, 737, 100, 714, 1, 6323, 78, 9044, 2, 259, 39, 1, 7813, 78, 519, 781, 3, 3666, 1, 3, 6323, 212, 78, 4647, 414, 3620, 240, 1096, 78, 8639, 538, 240, 22, 24, 9, 691, 134, 2, 792, 78, 5786, 1843, 3, 119, 1, 240, 9, 449, 96, 6323, 1918, 240, 24, 9, 1153, 16725, 6, 8111, 2170, 76, 18, 494, 78, 5941, 846, 66, 1583, 1, 88, 849, 67, 15, 263, 756, 3865, 578, 78, 5905, 842, 27, 158, 66, 78, 382, 1, 6323, 9993, 17, 240, 16, 870, 9, 82, 65614, 1077, 76, 18, 494, 106, 110, 6323, 2, 7813, 96, 746, 2715, 2895, 2927, 662, 13, 78, 2338, 2, 728, 14, 78, 233, 2, 1467, 327, 33, 78, 912, 2, 806, 18, 78, 167, 240, 611, 50, 1741, 7813, 3105, 3, 119, 1, 2895, 2927, 792, 78, 350, 15, 1467, 636, 717, 14, 78, 203, 63, 481, 78, 7132, 1, 6323, 2, 335, 78, 382, 1, 7813, 11778, 17, 252, 3, 1305, 33, 60, 299, 711, 1369, 303, 40, 95, 6, 4001, 191, 82, 12, 114, 272, 309, 17, 6323, 2, 7813, 4629, 240, 469, 35, 1501, 9, 191, 82, 12, 7, 137, 8, 93, 920, 1, 62, 3122, 4629, 17, 299, 711, 152, 68, 40, 8, 508, 2415, 9, 7, 5, 154, 43, 191, 82, 12]",1646.0,25675042,464
MRI-guided high-dose-rate intracavitary brachytherapy for treatment of cervical cancer: the University of Pittsburgh experience.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2015-01-30,"Image-based brachytherapy is increasingly used for gynecologic malignancies. We report early outcomes of magnetic resonance imaging (MRI)-guided brachytherapy. Consecutive patient cases with FIGO stage IB1 to IVA cervical cancer treated at a single institution were retrospectively reviewed. All patients received concurrent cisplatin with external beam radiation therapy along with interdigitated high-dose-rate intracavitary brachytherapy. Computed tomography or MRI was completed after each application, the latter acquired for at least 1 fraction. High-risk clinical target volume (HRCTV) and organs at risk were identified by Groupe Europen de Curiethrapie and European SocieTy for Radiotherapy and Oncology guidelines. Doses were converted to equivalent 2-Gy doses (EQD2) with planned HRCTV doses of 75 to 85 Gy. From 2007 to 2013, 128 patients, median 52 years of age, were treated. Predominant characteristics included stage IIB disease (58.6%) with a median tumor size of 5 cm, squamous histology (82.8%), and no radiographic nodal involvement (53.1%). Most patients (67.2%) received intensity modulated radiation therapy (IMRT) at a median dose of 45 Gy, followed by a median brachytherapy dose of 27.5 Gy (range, 25-30 Gy) in 5 fractions. At a median follow up of 24.4 months (range, 2.1-77.2 months), estimated 2-year local control, disease-free survival, and cancer-specific survival rates were 91.6%, 81.8%, and 87.6%, respectively. Predictors of local failure included adenocarcinoma histology (P<.01) and clinical response at 3 months (P<.01). Among the adenocarcinoma subset, receiving HRCTV D90 EQD2 84 Gy was associated with improved local control (2-year local control rate 100% vs 54.5%, P=.03). Grade 3 or greater gastrointestinal or genitourinary late toxicity occurred at a 2-year actuarial rate of 0.9%. This study constitutes one of the largest reported series of MRI-guided brachytherapy in North America, demonstrating excellent local control with acceptable morbidity. Dose escalation may be warranted when feasible for adenocarcinomas to offset the risk of local failure.",Journal Article,1817.0,67.0,Image-based brachytherapy is increasingly used for gynecologic malignancies We report early outcomes of magnetic resonance imaging MRI -guided brachytherapy Consecutive patient cases with FIGO stage IB1 to IVA cancer treated at a single institution were retrospectively reviewed All patients received concurrent cisplatin with external beam radiation therapy along with interdigitated high-dose-rate intracavitary brachytherapy Computed tomography or MRI was completed after each application the latter acquired for at least 1 fraction High-risk clinical target volume HRCTV and organs at risk were identified by Groupe Europen de Curiethrapie and European SocieTy for Radiotherapy and Oncology guidelines Doses were converted to equivalent 2-Gy doses EQD2 with planned HRCTV doses of 75 to 85 Gy From 2007 to 2013 128 patients median 52 years of age were treated Predominant characteristics included stage IIB disease 58.6 with a median tumor size of 5 cm squamous histology 82.8 and no radiographic nodal involvement 53.1 Most patients 67.2 received intensity modulated radiation therapy IMRT at a median dose of 45 Gy followed by a median brachytherapy dose of 27.5 Gy range 25-30 Gy in 5 fractions At a median follow up of 24.4 months range 2.1-77.2 months estimated 2-year local control disease-free survival and cancer-specific survival rates were 91.6 81.8 and 87.6 respectively Predictors of local failure included adenocarcinoma histology P .01 and clinical response at 3 months P .01 Among the adenocarcinoma subset receiving HRCTV D90 EQD2 84 Gy was associated with improved local control 2-year local control rate 100 vs 54.5 P=.03 Grade 3 or greater or genitourinary late toxicity occurred at a 2-year actuarial rate of 0.9 This study constitutes one of the largest reported series of MRI-guided brachytherapy in North America demonstrating excellent local control with acceptable morbidity Dose escalation may be warranted when feasible for adenocarcinomas to offset the risk of local failure,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1482, 90, 1536, 16, 1635, 95, 9, 1512, 441, 21, 414, 191, 123, 1, 1484, 1535, 270, 704, 1808, 1536, 935, 69, 140, 5, 3837, 82, 8111, 6, 5900, 12, 73, 28, 8, 226, 731, 11, 894, 446, 62, 7, 103, 750, 540, 5, 1455, 1345, 121, 36, 1510, 5, 22119, 64, 61, 116, 9122, 1536, 1220, 872, 15, 704, 10, 781, 50, 296, 1581, 3, 3286, 1294, 9, 28, 506, 14, 1509, 64, 43, 38, 283, 433, 29650, 2, 2285, 28, 43, 11, 108, 20, 29011, 65634, 1566, 65635, 2, 1865, 1174, 9, 310, 2, 413, 677, 415, 11, 4764, 6, 2017, 18, 381, 415, 10010, 5, 1465, 29650, 415, 1, 481, 6, 772, 381, 29, 1307, 6, 1346, 3990, 7, 52, 653, 60, 1, 89, 11, 73, 2750, 374, 159, 82, 3884, 34, 717, 49, 5, 8, 52, 30, 444, 1, 33, 494, 691, 784, 878, 66, 2, 77, 1580, 779, 799, 699, 14, 96, 7, 598, 18, 103, 837, 1757, 121, 36, 964, 28, 8, 52, 61, 1, 512, 381, 370, 20, 8, 52, 1536, 61, 1, 428, 33, 381, 184, 243, 201, 381, 4, 33, 1550, 28, 8, 52, 166, 126, 1, 259, 39, 53, 184, 18, 14, 849, 18, 53, 661, 18, 111, 293, 182, 34, 115, 25, 2, 12, 112, 25, 151, 11, 970, 49, 865, 66, 2, 912, 49, 106, 674, 1, 293, 496, 159, 449, 784, 19, 355, 2, 38, 51, 28, 27, 53, 19, 355, 107, 3, 449, 697, 357, 29650, 13040, 10010, 65636, 381, 10, 41, 5, 231, 293, 182, 18, 111, 293, 182, 116, 394, 105, 667, 33, 19, 680, 88, 27, 15, 378, 15, 4109, 807, 155, 489, 28, 8, 18, 111, 2361, 116, 1, 13, 83, 26, 45, 6788, 104, 1, 3, 2166, 210, 988, 1, 704, 1808, 1536, 4, 2669, 4010, 2219, 1503, 293, 182, 5, 1595, 787, 61, 1125, 68, 40, 1197, 198, 1313, 9, 1586, 6, 9500, 3, 43, 1, 293, 496]",2009.0,25680598,492
The Impact of Near-Universal Insurance Coverage on Breast and Cervical Cancer Screening: Evidence from Massachusetts.,Health economics,Health Econ,2015-02-18,"This paper investigates the effect of expansion to near-universal health insurance coverage in Massachusetts on breast and cervical cancer screening. We use data from 2002 to 2010 to compare changes in receipt of mammograms and Pap tests in Massachusetts relative to other New England states. We also consider the effect specifically among low-income women. We find positive effects of Massachusetts health reform on cancer screening, suggesting a 4 to 5% increase in mammograms and 6 to 7% increase in Pap tests annually. Increases in both breast and cervical cancer screening are larger 3 years after the implementation of reform than in the year immediately following, suggesting that there may be an adjustment or learning period. Low-income women experience greater increases in breast and cervical cancer screening than the overall population; among women with household income less than 250% of the federal poverty level, mammograms increase by approximately 8% and Pap tests by 9%. Overall, Massachusetts health reform appears to have increased breast and cervical cancer screening, particularly among low-income women. Our results suggest that reform was successful in promoting preventive care among targeted populations.",Journal Article,1798.0,14.0,This paper investigates the effect of expansion to near-universal health insurance coverage in Massachusetts on and cancer screening We use data from 2002 to 2010 to compare changes in receipt of mammograms and Pap tests in Massachusetts relative to other New England states We also consider the effect specifically among low-income women We find positive effects of Massachusetts health reform on cancer screening suggesting a 4 to 5 increase in mammograms and 6 to 7 increase in Pap tests annually Increases in both and cancer screening are larger 3 years after the implementation of reform than in the year immediately following suggesting that there may be an adjustment or learning period Low-income women experience greater increases in and cancer screening than the overall population among women with household income less than 250 of the federal poverty level mammograms increase by approximately 8 and Pap tests by 9 Overall Massachusetts health reform appears to have increased and cancer screening particularly among low-income women Our results suggest that reform was successful in promoting preventive care among targeted populations,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[26, 2817, 7259, 3, 254, 1, 1422, 6, 1829, 4967, 341, 1935, 2139, 4, 5459, 23, 2, 12, 453, 21, 119, 74, 29, 1544, 6, 1120, 6, 932, 400, 4, 1699, 1, 6329, 2, 4290, 895, 4, 5459, 580, 6, 127, 217, 12578, 907, 21, 120, 2419, 3, 254, 1225, 107, 154, 2306, 117, 21, 2469, 109, 176, 1, 5459, 341, 12227, 23, 12, 453, 802, 8, 39, 6, 33, 344, 4, 6329, 2, 49, 6, 67, 344, 4, 4290, 895, 4226, 1106, 4, 110, 2, 12, 453, 32, 1077, 27, 60, 50, 3, 2393, 1, 12227, 76, 4, 3, 111, 3467, 366, 802, 17, 125, 68, 40, 35, 1852, 15, 3434, 727, 154, 2306, 117, 730, 378, 1106, 4, 2, 12, 453, 76, 3, 63, 266, 107, 117, 5, 7353, 2306, 299, 76, 2039, 1, 3, 8536, 7583, 301, 6329, 344, 20, 705, 66, 2, 4290, 895, 20, 83, 63, 5459, 341, 12227, 1233, 6, 47, 101, 2, 12, 453, 823, 107, 154, 2306, 117, 114, 99, 309, 17, 12227, 10, 1401, 4, 2388, 3494, 165, 107, 238, 1184]",1148.0,25693869,568
Psychosocial telephone counseling for survivors of cervical cancer: results of a randomized biobehavioral trial.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2015-02-23,"Survivors of cervical cancer experience quality-of-life (QOL) disruptions that persist years after treatment. This study examines the effect of a psychosocial telephone counseling (PTC) intervention on QOL domains and associations with biomarkers. We conducted a randomized clinical trial in survivors of cervical cancer, who were  9 and less than 30 months from diagnosis (n = 204), to compare PTC to usual care (UC). PTC included five weekly sessions and a 1-month booster. Patient-reported outcomes (PROs) and biospecimens were collected at baseline and 4 and 9 months after enrollment. Changes in PROs over time and associations with longitudinal change in cytokines as categorical variables were analyzed using multivariable analysis of variance for repeated measures. Participant mean age was 43 years; 40% of women were Hispanic, and 51% were non-Hispanic white. Adjusting for age and baseline scores, participants receiving PTC had significantly improved depression and improved gynecologic and cancer-specific concerns at 4 months compared with UC participants (all P < .05); significant differences in gynecologic and cancer-specific concerns (P < .05) were sustained at 9 months. Longitudinal change in overall QOL and anxiety did not reach statistical significance. Participants with decreasing interleukin (IL) -4, IL-5, IL-10, and IL-13 had significantly greater improvement in QOL than those with increasing cytokine levels. This trial confirms that PTC benefits mood and QOL cancer-specific and gynecologic concerns for a multiethnic underserved population of survivors of cancer. The improvement in PROs with decreases in T-helper type 2 and counter-regulatory cytokines supports a potential biobehavioral pathway relevant to cancer survivorship.",Journal Article,1793.0,17.0,Survivors of cancer experience quality-of-life QOL disruptions that persist years after treatment This study examines the effect of a psychosocial telephone counseling PTC intervention on QOL domains and associations with biomarkers We conducted a randomized clinical trial in survivors of cancer who were  9 and less than 30 months from diagnosis n 204 to compare PTC to usual care UC PTC included five weekly sessions and a 1-month booster Patient-reported outcomes PROs and biospecimens were collected at baseline and 4 and 9 months after enrollment Changes in PROs over time and associations with longitudinal change in cytokines as categorical variables were analyzed using multivariable analysis of variance for repeated measures Participant mean age was 43 years 40 of women were Hispanic and 51 were non-Hispanic white Adjusting for age and baseline scores participants receiving PTC had significantly improved depression and improved gynecologic and cancer-specific concerns at 4 months compared with UC participants all P .05 significant differences in gynecologic and cancer-specific concerns P .05 were sustained at 9 months Longitudinal change in overall QOL and anxiety did not reach statistical significance Participants with decreasing interleukin IL -4 IL-5 IL-10 and IL-13 had significantly greater improvement in QOL than those with increasing cytokine levels This trial confirms that PTC benefits mood and QOL cancer-specific and gynecologic concerns for a multiethnic underserved population of survivors of cancer The improvement in PROs with decreases in T-helper type 2 and counter-regulatory cytokines supports a potential biobehavioral pathway relevant to cancer survivorship,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[332, 1, 12, 730, 372, 1, 358, 1001, 11594, 17, 5589, 60, 50, 24, 26, 45, 4468, 3, 254, 1, 8, 2322, 4258, 2011, 3748, 788, 23, 1001, 2703, 2, 685, 5, 582, 21, 426, 8, 384, 38, 160, 4, 332, 1, 12, 54, 11, 749, 83, 2, 299, 76, 201, 53, 29, 147, 78, 5996, 6, 932, 3748, 6, 3521, 165, 2417, 3748, 159, 365, 709, 4390, 2, 8, 14, 811, 11640, 69, 210, 123, 4660, 2, 12419, 11, 786, 28, 330, 2, 39, 2, 83, 53, 50, 1798, 400, 4, 4660, 252, 98, 2, 685, 5, 2380, 707, 4, 1886, 22, 5982, 682, 11, 311, 75, 658, 65, 1, 4446, 9, 2113, 1018, 5705, 313, 89, 10, 601, 60, 327, 1, 117, 11, 1776, 2, 725, 11, 220, 1776, 886, 1358, 9, 89, 2, 330, 703, 776, 357, 3748, 42, 97, 231, 1774, 2, 231, 1512, 2, 12, 112, 2061, 28, 39, 53, 72, 5, 2417, 776, 62, 19, 474, 93, 362, 4, 1512, 2, 12, 112, 2061, 19, 474, 11, 2275, 28, 83, 53, 2380, 707, 4, 63, 1001, 2, 2021, 205, 44, 3690, 1050, 724, 776, 5, 2777, 1603, 501, 39, 501, 33, 501, 79, 2, 501, 233, 42, 97, 378, 767, 4, 1001, 76, 135, 5, 602, 1675, 148, 26, 160, 5120, 17, 3748, 1141, 5234, 2, 1001, 12, 112, 2, 1512, 2061, 9, 8, 17756, 6960, 266, 1, 332, 1, 12, 3, 767, 4, 4660, 5, 2140, 4, 102, 5539, 267, 18, 2, 10259, 1253, 1886, 2304, 8, 174, 21332, 308, 867, 6, 12, 2560]",1701.0,25713429,338
[The clinical value of sentinel lymph node detection in laryngeal and hypopharyngeal carcinoma patients with clinically negative neck by methylene blue method and radiolabeled tracer method].,"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery",Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi,2014-11-01,"To investigate the clinical value of sentinel lymph node (SLN) detection in laryngeal and hypopharyngeal carcinoma patients with clinically negative neck (cN0) by methylene blue method, radiolabeled tracer method and combination of these two methods. Thirty-three patients with cN0 laryngeal carcinoma and six patients with cN0 hypopharyngeal carcinoma underwent SLN detection using both of methylene blue and radiolabeled tracer method. All these patients were accepted received the injection of radioactive isotope 99 Tc(m)-sulfur colloid (SC) and methylene blue into the carcinoma before surgery, then all these patients underwent intraopertive lymphatic mapping with a handheld gamma-detecting probe and blue-dyed SLN. After the mapping of SLN, selected neck dissections and tumor resections were peformed. The results of SLN detection by radiolabeled tracer, dye and combination of both methods were compared. The detection rate of SLN by radiolabeled tracer, methylene blue and combined method were 89.7%, 79.5%, 92.3% respectively. The number of detected SLN was significantly different between radiolabeled tracer method and combined method, and also between methylene blue method and combined method. The detection rate of methylene blue and radiolabeled tracer method were significantly different from combined method (P < 0.05). Nine patients were found to have lymph node metastasis by final pathological examination. The accuracy and negative rate of SLN detection of the combined method were 97.2% and 11.1%. The combined method using radiolabeled tracer and methylene blue can improve the detection rate and accuracy of sentinel lymph node detection. Furthermore, sentinel lymph node detection can accurately represent the cervical lymph node status in cN0 laryngeal and hypopharyngeal carcinoma.",Journal Article,1907.0,0.0,To investigate the clinical value of sentinel lymph node SLN detection in and carcinoma patients with clinically negative cN0 by methylene blue method radiolabeled tracer method and combination of these two methods Thirty-three patients with cN0 carcinoma and six patients with cN0 carcinoma underwent SLN detection using both of methylene blue and radiolabeled tracer method All these patients were accepted received the injection of radioactive isotope 99 Tc m -sulfur colloid SC and methylene blue into the carcinoma before surgery then all these patients underwent intraopertive lymphatic mapping with a handheld gamma-detecting probe and blue-dyed SLN After the mapping of SLN selected dissections and tumor resections were peformed The results of SLN detection by radiolabeled tracer dye and combination of both methods were compared The detection rate of SLN by radiolabeled tracer methylene blue and combined method were 89.7 79.5 92.3 respectively The number of detected SLN was significantly different between radiolabeled tracer method and combined method and also between methylene blue method and combined method The detection rate of methylene blue and radiolabeled tracer method were significantly different from combined method P 0.05 Nine patients were found to have lymph node metastasis by final pathological examination The accuracy and negative rate of SLN detection of the combined method were 97.2 and 11.1 The combined method using radiolabeled tracer and methylene blue can improve the detection rate and accuracy of sentinel lymph node detection Furthermore sentinel lymph node detection can accurately represent the lymph node status in cN0 and carcinoma,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 963, 3, 38, 549, 1, 1323, 263, 289, 1099, 638, 4, 2, 134, 7, 5, 505, 199, 8115, 20, 10256, 3352, 596, 5740, 6160, 596, 2, 150, 1, 46, 100, 636, 977, 169, 7, 5, 8115, 134, 2, 437, 7, 5, 8115, 134, 208, 1099, 638, 75, 110, 1, 10256, 3352, 2, 5740, 6160, 596, 62, 46, 7, 11, 3058, 103, 3, 1754, 1, 4741, 9242, 1058, 3072, 188, 10266, 7245, 2969, 2, 10256, 3352, 237, 3, 134, 348, 152, 818, 62, 46, 7, 208, 65711, 2936, 2568, 5, 8, 15463, 1705, 2502, 2888, 2, 3352, 43227, 1099, 50, 3, 2568, 1, 1099, 715, 6894, 2, 30, 2185, 11, 65712, 3, 99, 1, 1099, 638, 20, 5740, 6160, 3796, 2, 150, 1, 110, 636, 11, 72, 3, 638, 116, 1, 1099, 20, 5740, 6160, 10256, 3352, 2, 397, 596, 11, 887, 67, 842, 33, 937, 27, 106, 3, 207, 1, 530, 1099, 10, 97, 338, 59, 5740, 6160, 596, 2, 397, 596, 2, 120, 59, 10256, 3352, 596, 2, 397, 596, 3, 638, 116, 1, 10256, 3352, 2, 5740, 6160, 596, 11, 97, 338, 29, 397, 596, 19, 13, 474, 762, 7, 11, 204, 6, 47, 263, 289, 278, 20, 1457, 1301, 1385, 3, 1190, 2, 199, 116, 1, 1099, 638, 1, 3, 397, 596, 11, 1015, 18, 2, 175, 14, 3, 397, 596, 75, 5740, 6160, 2, 10256, 3352, 122, 401, 3, 638, 116, 2, 1190, 1, 1323, 263, 289, 638, 798, 1323, 263, 289, 638, 122, 2141, 1231, 3, 263, 289, 156, 4, 8115, 2, 134]",1681.0,25735093,765
A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2015-03-10,"To evaluate the cost-effectiveness of bevacizumab in recurrent/persistent and metastatic cervical cancer using recently reported updated survival and toxicology data. A Markov decision tree based on the Gynecologic Oncology Group 240 randomized trial was created. The 2013 MediCare Services Drug Payment Table and Physician Fee Schedule provided costs. In the 5-year model subjects transitioned through the following states: response, progression, minor complications, severe complications, and death. Patients experiencing a health utility per month according to treatment effectiveness were calculated. Because cervical cancer survival is measured in months rather than years, results were reported in both quality adjusted cervical cancer life months and years (QALmonth, QALY), adjusted from a baseline of having advanced cervical cancer during a month. The estimated total cost of therapy with bevacizumab is approximately 13.2 times that for chemotherapy alone, adding $73,791 per 3.5months (0.29year) of life gained, resulting in an incremental cost-effectiveness ratio (ICER) of $21.083 per month of added life. The ICER increased to $5775 per month of added life and $24,597/QALmonth ($295,164/QALY) due to the smaller difference in QALmonths. With 75% bevacizumab cost reduction, the ICER is $6737/QALmonth ($80,844/QALY), which translates to $23,580 for the 3.5month (0.29year) gain in OS. Increased costs are primarily related to the cost of drug and not the management of bevacizumab-induced complications. Cost reductions in bevacizumab result in dramatic declines in the ICER, suggesting that cost reconciliation in advanced cervical cancer may be possible through the availability of biosimilars, and/or less expensive, equally efficacious anti-angiogenesis agents.",Journal Article,1778.0,33.0,"To evaluate the cost-effectiveness of bevacizumab in recurrent/persistent and metastatic cancer using recently reported updated survival and toxicology data A Markov decision tree based on the Gynecologic Oncology Group 240 randomized trial was created The 2013 MediCare Services Drug Payment Table and Physician Fee Schedule provided costs In the 5-year model subjects transitioned through the following states response progression minor complications severe complications and death Patients experiencing a health utility per month according to treatment effectiveness were calculated Because cancer survival is measured in months rather than years results were reported in both quality adjusted cancer life months and years QALmonth QALY adjusted from a baseline of having advanced cancer during a month The estimated total cost of therapy with bevacizumab is approximately 13.2 times that for chemotherapy alone adding 73,791 per 3.5months 0.29year of life gained resulting in an incremental cost-effectiveness ratio ICER of 21.083 per month of added life The ICER increased to 5775 per month of added life and 24,597/QALmonth 295,164/QALY due to the smaller difference in QALmonths With 75 bevacizumab cost reduction the ICER is 6737/QALmonth 80,844/QALY which translates to 23,580 for the 3.5month 0.29year gain in OS Increased costs are primarily related to the cost of drug and not the management of bevacizumab-induced complications Cost reductions in bevacizumab result in dramatic declines in the ICER suggesting that cost reconciliation in advanced cancer may be possible through the availability of biosimilars and/or less expensive equally efficacious anti-angiogenesis agents",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 3, 835, 1236, 1, 599, 4, 387, 1882, 2, 113, 12, 75, 761, 210, 2939, 25, 2, 18174, 74, 8, 6516, 948, 4899, 90, 23, 3, 1512, 413, 87, 4263, 384, 160, 10, 2466, 3, 1346, 1378, 2142, 234, 9066, 7016, 2, 1473, 8270, 1055, 1052, 1201, 4, 3, 33, 111, 202, 976, 13987, 298, 3, 366, 907, 51, 91, 2278, 521, 905, 521, 2, 273, 7, 2985, 8, 341, 1207, 379, 811, 768, 6, 24, 1236, 11, 981, 408, 12, 25, 16, 644, 4, 53, 1832, 76, 60, 99, 11, 210, 4, 110, 372, 586, 12, 358, 53, 2, 60, 41023, 4124, 586, 29, 8, 330, 1, 1041, 131, 12, 190, 8, 811, 3, 661, 181, 835, 1, 36, 5, 599, 16, 705, 233, 18, 1072, 17, 9, 56, 279, 2726, 803, 14482, 379, 27, 15029, 13, 48899, 1, 358, 3711, 1113, 4, 35, 3648, 835, 1236, 197, 6463, 1, 239, 14291, 379, 811, 1, 1953, 358, 3, 6463, 101, 6, 65751, 379, 811, 1, 1953, 358, 2, 259, 14507, 41023, 7051, 5279, 4124, 520, 6, 3, 2170, 523, 4, 65752, 5, 481, 599, 835, 628, 3, 6463, 16, 65753, 41023, 493, 15617, 4124, 92, 10328, 6, 382, 10624, 9, 3, 27, 65754, 13, 48899, 1803, 4, 118, 101, 1201, 32, 1561, 139, 6, 3, 835, 1, 234, 2, 44, 3, 284, 1, 599, 277, 521, 835, 2153, 4, 599, 757, 4, 3079, 4264, 4, 3, 6463, 802, 17, 835, 41024, 4, 131, 12, 68, 40, 899, 298, 3, 2550, 1, 13212, 2, 15, 299, 6038, 4142, 3289, 312, 1056, 183]",1689.0,25766118,278
Global health perspective on gynecologic oncology.,Gynecologic oncology,Gynecol. Oncol.,2015-03-14,"To describe challenges faced by low-middle income countries (LMICs) across the cancer spectrum, with specific focus on gynecologic cancers. MEDLINE was searched for research articles published in English between January 1, 2000 and February 1, 2015 which reported on global health efforts in LMICs. An estimated 80% of global cancer burden and only 5% of global cancer spending affect LMICs. The overwhelming majority of cervical cancer cases and related deaths occur in LMICs. The charge to close this cancer divide is at the center of global health efforts. Prevention is central to global health efforts to close the cancer divide. The gynecologic oncology community is well positioned to lead efforts in global health by partnering with institutions, professional societies and advocacy groups.",Journal Article,1774.0,9.0,To describe challenges faced by low-middle income countries LMICs across the cancer spectrum with specific focus on gynecologic cancers MEDLINE was searched for research articles published in English between January 1 2000 and February 1 2015 which reported on global health efforts in LMICs An estimated 80 of global cancer burden and only 5 of global cancer spending affect LMICs The overwhelming majority of cancer cases and related deaths occur in LMICs The charge to close this cancer divide is at the center of global health efforts Prevention is central to global health efforts to close the cancer divide The gynecologic oncology community is well positioned to lead efforts in global health by partnering with institutions professional societies and advocacy groups,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 897, 1427, 6933, 20, 154, 3897, 2306, 2115, 13457, 716, 3, 12, 1873, 5, 112, 1222, 23, 1512, 163, 3388, 10, 3080, 9, 389, 2384, 983, 4, 4201, 59, 1024, 14, 1081, 2, 3010, 14, 1483, 92, 210, 23, 1648, 341, 1413, 4, 13457, 35, 661, 493, 1, 1648, 12, 892, 2, 158, 33, 1, 1648, 12, 6985, 1158, 13457, 3, 10075, 686, 1, 12, 140, 2, 139, 1043, 1271, 4, 13457, 3, 11812, 6, 2336, 26, 12, 15901, 16, 28, 3, 574, 1, 1648, 341, 1413, 1070, 16, 854, 6, 1648, 341, 1413, 6, 2336, 3, 12, 15901, 3, 1512, 413, 1714, 16, 149, 14240, 6, 1122, 1413, 4, 1648, 341, 20, 33956, 5, 1764, 5341, 10600, 2, 8368, 271]",774.0,25782635,769
Longitudinal study of acute haematologic toxicity in cervical cancer patients treated with chemoradiotherapy.,Journal of medical imaging and radiation oncology,J Med Imaging Radiat Oncol,2015-04-01,"Acute hematologic toxicity (HT) limits optimal delivery of concurrent chemoradiotherapy (CRT) for patients with pelvic malignancies. We tested the hypothesis that pelvic bone marrow (PBM) dose-volume metrics were associated with weekly reductions in peripheral blood cell counts in cervical cancer patients undergoing CRT. We included 102 cervical cancer patients treated with concurrent cisplatin (40mg/m(2) /week) and pelvic radiotherapy treated at three US centres. No patient received granulocyte-monocyte colony stimulating factor (GM-CSF) or platelet transfusions. Using linear-mixed effects modelling, we analysed weekly reductions in log-transformed peripheral blood cell counts as a function of time (weeks), mean PBM dose and the PBM volume receiving 10Gy (V(10)), 20Gy (V(20)), 30Gy (V(30)) and 40Gy (V(40)). Increases in mean PBM radiation dose, V(20), V(30) and V(40) were all significantly associated with a greater weekly reduction in white blood cell (WBC) and absolute neutrophil counts (ANCs). We estimated that with every 1Gy increase in mean PBM dose, ln(ANC) was reduced by 9.6/L per week (95% confidence interval, 1.9-17.3, P=0.015). Subregion analysis also identified significant associations between weekly reductions in ln(WBC) and ln(ANC) within lumbosacral spine, ischium and proximal femora, as opposed to ilium. PBM radiation dose-volume metrics are significantly associated with weekly reductions in peripheral blood cell counts in cervical cancer patients undergoing CRT, particularly within the lower pelvis and lumbosacral spine.",Journal Article,1756.0,13.0,Acute hematologic toxicity HT limits optimal delivery of concurrent chemoradiotherapy CRT for patients with pelvic malignancies We tested the hypothesis that pelvic marrow PBM dose-volume metrics were associated with weekly reductions in peripheral blood cell counts in cancer patients undergoing CRT We included 102 cancer patients treated with concurrent cisplatin 40 mg/m 2 /week and pelvic radiotherapy treated at three US centres No patient received granulocyte-monocyte colony stimulating factor GM-CSF or platelet transfusions Using linear-mixed effects modelling we analysed weekly reductions in log-transformed peripheral blood cell counts as a function of time weeks mean PBM dose and the PBM volume receiving 10 Gy V 10 20 Gy V 20 30 Gy V 30 and 40 Gy V 40 Increases in mean PBM radiation dose V 20 V 30 and V 40 were all significantly associated with a greater weekly reduction in white blood cell WBC and absolute neutrophil counts ANCs We estimated that with every 1 Gy increase in mean PBM dose ln ANC was reduced by 9.6/L per week 95 confidence interval 1.9-17.3 P 0.015 Subregion analysis also identified significant associations between weekly reductions in ln WBC and ln ANC within lumbosacral spine ischium and proximal femora as opposed to ilium PBM radiation dose-volume metrics are significantly associated with weekly reductions in peripheral blood cell counts in cancer patients undergoing CRT particularly within the lower pelvis and lumbosacral spine,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[286, 813, 155, 3152, 3526, 665, 989, 1, 750, 1464, 1089, 9, 7, 5, 1110, 441, 21, 650, 3, 1492, 17, 1110, 581, 9215, 61, 433, 3589, 11, 41, 5, 709, 2153, 4, 672, 315, 31, 1911, 4, 12, 7, 479, 1089, 21, 159, 2867, 12, 7, 73, 5, 750, 540, 327, 81, 188, 18, 647, 2, 1110, 310, 73, 28, 169, 843, 4496, 77, 69, 103, 2764, 5231, 1975, 2122, 161, 2147, 1211, 15, 1596, 4987, 75, 1646, 1739, 176, 10812, 21, 3141, 709, 2153, 4, 1066, 2423, 672, 315, 31, 1911, 22, 8, 343, 1, 98, 244, 313, 9215, 61, 2, 3, 9215, 433, 357, 4556, 381, 603, 79, 179, 381, 603, 179, 201, 381, 603, 201, 2, 327, 381, 603, 327, 1106, 4, 313, 9215, 121, 61, 603, 179, 603, 201, 2, 603, 327, 11, 62, 97, 41, 5, 8, 378, 709, 628, 4, 886, 315, 31, 4685, 2, 1766, 2595, 1911, 19084, 21, 661, 17, 5, 454, 14, 381, 344, 4, 313, 9215, 61, 1763, 6486, 10, 405, 20, 83, 49, 5513, 379, 647, 48, 307, 268, 14, 83, 269, 27, 19, 13, 3433, 31914, 65, 120, 108, 93, 685, 59, 709, 2153, 4, 1763, 4685, 2, 1763, 6486, 262, 15598, 2342, 45207, 2, 2805, 31187, 22, 6101, 6, 18295, 9215, 121, 61, 433, 3589, 32, 97, 41, 5, 709, 2153, 4, 672, 315, 31, 1911, 4, 12, 7, 479, 1089, 823, 262, 3, 280, 3270, 2, 15598, 2342]",1479.0,25828068,331
CDC Grand Rounds: the future of cancer screening.,MMWR. Morbidity and mortality weekly report,MMWR Morb. Mortal. Wkly. Rep.,2015-04-01,"Cancer is the second leading cause of death in the United States, with 52% of deaths caused by cancers of the lung and bronchus, female breast, uterine cervix, colon and rectum, oral cavity and pharynx, prostate, and skin (melanoma). In the 1930s, uterine cancer, including cancer of the uterine cervix, was the leading cause of cancer deaths among women in the United States. With the advent of the Papanicolaou (Pap) test in the 1950s to detect cellular level changes in the cervix, cervical cancer death rates declined significantly. Since this first cancer screening test, others have been developed that detect the presence of cancer through imaging procedures (e.g., mammography, endoscopy, and computed tomography) and laboratory tests (e.g., fecal occult blood tests). ",Journal Article,1756.0,6.0,Cancer is the second leading cause of death in the United States with 52 of deaths caused by cancers of the and bronchus female cervix and rectum oral cavity and pharynx and In the 1930s cancer including cancer of the cervix was the leading cause of cancer deaths among women in the United States With the advent of the Papanicolaou Pap test in the 1950s to detect cellular level changes in the cervix cancer death rates declined significantly Since this first cancer screening test others have been developed that detect the presence of cancer through imaging procedures e.g. mammography endoscopy and computed tomography and laboratory tests e.g. fecal occult blood tests,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,"[12, 16, 3, 419, 1049, 708, 1, 273, 4, 3, 1088, 907, 5, 653, 1, 1043, 1546, 20, 163, 1, 3, 2, 16472, 1061, 3629, 2, 3660, 518, 2405, 2, 13958, 2, 4, 3, 65888, 12, 141, 12, 1, 3, 3629, 10, 3, 1049, 708, 1, 12, 1043, 107, 117, 4, 3, 1088, 907, 5, 3, 4114, 1, 3, 10416, 4290, 412, 4, 3, 25016, 6, 1426, 763, 301, 400, 4, 3, 3629, 12, 273, 151, 3054, 97, 1192, 26, 157, 12, 453, 412, 1749, 47, 85, 276, 17, 1426, 3, 463, 1, 12, 298, 270, 1369, 563, 499, 2446, 4199, 2, 1220, 872, 2, 1624, 895, 563, 499, 6784, 2879, 315, 895]",673.0,25837243,341
NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer.,Cancer,Cancer,2015-04-06,"The current study was conducted to assess acute and late adverse events (AEs), overall survival (OS), pelvic failure, regional failure, distant failure, and disease-free survival in a prospective phase 2 clinical trial of bevacizumab and pelvic intensity-modulated radiotherapy (IMRT) with chemotherapy in patients with high-risk endometrial cancer. Patients underwent a hysterectomy and lymph node removal, and had 1 of the following high-risk factors: grade 3 carcinoma with >50% myometrial invasion, grade 2 or 3 disease with any cervical stromal invasion, or known extrauterine extension confined to the pelvis. Treatment included pelvic IMRT and concurrent cisplatin on days 1 and 29 of radiation and bevacizumab (at a dose of 5 mg/kg on days 1, 15, and 29 of radiation) followed by adjuvant carboplatin and paclitaxel for 4 cycles. The primary endpoint was grade 3 AEs occurring within the first 90 days (toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0]). A total of 34 patients were accrued from November 2009 through December 2011, 30 of whom were eligible and received study treatment. Seven of 30 patients (23.3%; 1-sided 95% confidence interval, 10.6%-36.0%) developed grade 3 treatment-related nonhematologic toxicities within 90 days; an additional 6 patients experienced grade 3 toxicities between 90 and 365 days after treatment. The 2-year OS rate was 96.7% and the disease-free survival rate was 79.1%. No patient developed a within-field pelvic failure and no patients with International Federation of Gynecology and Obstetrics stage I to IIIA disease developed disease recurrence after a median follow-up of 26 months. Postoperative bevacizumab added to chemotherapy and pelvic IMRT appears to be well tolerated and results in high OS rates at 2 years for patients with high-risk endometrial carcinoma.","Clinical Trial, Phase II",1751.0,12.0,The current study was conducted to assess acute and late adverse events AEs overall survival OS pelvic failure regional failure distant failure and disease-free survival in a prospective phase 2 clinical trial of bevacizumab and pelvic intensity-modulated radiotherapy IMRT with chemotherapy in patients with high-risk cancer Patients underwent a hysterectomy and lymph node removal and had 1 of the following high-risk factors grade 3 carcinoma with 50 myometrial invasion grade 2 or 3 disease with any stromal invasion or known extrauterine extension confined to the pelvis Treatment included pelvic IMRT and concurrent cisplatin on days 1 and 29 of radiation and bevacizumab at a dose of 5 mg/kg on days 1 15 and 29 of radiation followed by adjuvant carboplatin and paclitaxel for 4 cycles The primary endpoint was grade 3 AEs occurring within the first 90 days toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 A total of 34 patients were accrued from November 2009 through December 2011 30 of whom were eligible and received study treatment Seven of 30 patients 23.3 1-sided 95 confidence interval 10.6 -36.0 developed grade 3 treatment-related nonhematologic toxicities within 90 days an additional 6 patients experienced grade 3 toxicities between 90 and 365 days after treatment The 2-year OS rate was 96.7 and the disease-free survival rate was 79.1 No patient developed a within-field pelvic failure and no patients with International Federation of Gynecology and Obstetrics stage I to IIIA disease developed disease recurrence after a median follow-up of 26 months Postoperative bevacizumab added to chemotherapy and pelvic IMRT appears to be well tolerated and results in high OS rates at 2 years for patients with high-risk carcinoma,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,"[3, 291, 45, 10, 426, 6, 423, 286, 2, 807, 290, 281, 1477, 63, 25, 118, 1110, 496, 951, 496, 626, 496, 2, 34, 115, 25, 4, 8, 482, 124, 18, 38, 160, 1, 599, 2, 1110, 837, 1757, 310, 964, 5, 56, 4, 7, 5, 64, 43, 12, 7, 208, 8, 2622, 2, 263, 289, 2829, 2, 42, 3567, 1, 3, 366, 64, 43, 130, 88, 27, 134, 5, 212, 7327, 578, 88, 18, 15, 27, 34, 5, 500, 1126, 578, 15, 440, 12115, 2401, 2902, 6, 3, 3270, 24, 159, 1110, 964, 2, 750, 540, 23, 162, 14, 2, 462, 1, 121, 2, 599, 28, 8, 61, 1, 33, 81, 503, 23, 162, 14, 167, 2, 462, 1, 121, 370, 20, 249, 927, 2, 490, 9, 39, 410, 3, 86, 1138, 10, 88, 2608, 1477, 1821, 262, 3, 157, 424, 162, 155, 10, 3468, 768, 6, 3, 657, 12, 1377, 186, 3462, 371, 9, 290, 281, 2256, 39, 13, 8, 181, 1, 562, 7, 11, 3198, 29, 2868, 1238, 298, 1397, 1132, 201, 1, 953, 11, 625, 2, 103, 45, 24, 648, 1, 201, 7, 382, 27, 14, 1689, 48, 307, 268, 79, 49, 511, 13, 276, 88, 2608, 24, 139, 3534, 385, 262, 424, 162, 35, 402, 49, 7, 592, 88, 2608, 385, 59, 424, 2, 7405, 162, 50, 24, 3, 18, 111, 118, 116, 10, 921, 67, 2, 3, 34, 115, 25, 116, 10, 842, 14, 77, 69, 276, 8, 262, 1067, 1110, 496, 2, 77, 7, 5, 944, 7303, 1, 6429, 2, 7407, 82, 70, 6, 3164, 34, 276, 34, 146, 50, 8, 52, 166, 126, 1, 432, 53, 573, 599, 1953, 6, 56, 2, 1110, 964, 1233, 6, 40, 149, 421, 2, 99, 4, 64, 118, 151, 28, 18, 60, 9, 7, 5, 64, 43, 134]",1822.0,25847373,739
Aloe vera inhibits proliferation of human breast and cervical cancer cells and acts synergistically with cisplatin.,Asian Pacific journal of cancer prevention : APJCP,Asian Pac. J. Cancer Prev.,2015-01-01,"Many of the anti-cancer agents currently used have an origin in natural sources including plants. Aloe vera is one such plant being studied extensively for its diverse health benefits, including cancer prevention. In this study, the cytotoxic potential of Aloe vera crude extract (ACE) alone or in combination with cisplatin in human breast (MCF-7) and cervical (HeLa) cancer cells was studied by cell viability assay, nuclear morphological examination and cell cycle analysis. Effects were correlated with modulation of expression of genes involved in cell cycle regulation, apoptosis and drug metabolism by RT-PCR. Exposure of cells to ACE resulted in considerable loss of cell viability in a dose- and time-dependent fashion, which was found to be mediated by through the apoptotic pathway as evidenced by changes in the nuclear morphology and the distribution of cells in the different phases of the cell cycle. Interestingly, ACE did not have any significant cytotoxicity towards normal cells, thus placing it in the category of safe chemopreventive agent. Further, the effects were correlated with the downregulation of cyclin D1, CYP 1A1, CYP 1A2 and increased expression of bax and p21 in MCF-7 and HeLa cells. In addition, low dose combination of ACE and cisplatin showed a combination index less than 1, indicating synergistic growth inhibition compared to the agents applied individually. In conclusion, these results signify that Aloe vera may be an effective anti-neoplastic agent to inhibit cancer cell growth and increase the therapeutic efficacy of conventional drugs like cispolatin. Thus promoting the development of plant-derived therapeutic agents appears warranted for novel cancer treatment strategies. ",Journal Article,1846.0,10.0,Many of the anti-cancer agents currently used have an origin in natural sources including plants Aloe vera is one such plant being studied extensively for its diverse health benefits including cancer prevention In this study the cytotoxic potential of Aloe vera crude extract ACE alone or in combination with cisplatin in human MCF-7 and HeLa cancer cells was studied by cell viability assay nuclear morphological examination and cell cycle analysis Effects were correlated with modulation of expression of genes involved in cell cycle regulation apoptosis and drug metabolism by RT-PCR Exposure of cells to ACE resulted in considerable loss of cell viability in a dose- and time-dependent fashion which was found to be mediated by through the apoptotic pathway as evidenced by changes in the nuclear morphology and the distribution of cells in the different phases of the cell cycle Interestingly ACE did not have any significant cytotoxicity towards normal cells thus placing it in the category of safe chemopreventive agent Further the effects were correlated with the downregulation of cyclin D1 CYP 1A1 CYP 1A2 and increased expression of bax and p21 in MCF-7 and HeLa cells In addition low dose combination of ACE and cisplatin showed a combination index less than 1 indicating synergistic growth inhibition compared to the agents applied individually In conclusion these results signify that Aloe vera may be an effective anti-neoplastic agent to inhibit cancer cell growth and increase the therapeutic efficacy of conventional drugs like cispolatin Thus promoting the development of plant-derived therapeutic agents appears warranted for novel cancer treatment strategies,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[445, 1, 3, 312, 12, 183, 694, 95, 47, 35, 1938, 4, 1504, 3375, 141, 20406, 41057, 5756, 16, 104, 225, 9045, 486, 656, 3576, 9, 211, 1867, 341, 1141, 141, 12, 1070, 4, 26, 45, 3, 759, 174, 1, 41057, 5756, 6622, 7164, 11057, 279, 15, 4, 150, 5, 540, 4, 171, 3252, 67, 2, 8466, 12, 37, 10, 656, 20, 31, 2120, 719, 928, 4268, 1385, 2, 31, 417, 65, 176, 11, 438, 5, 2356, 1, 55, 1, 214, 646, 4, 31, 417, 863, 351, 2, 234, 1600, 20, 240, 604, 645, 1, 37, 6, 11057, 627, 4, 2658, 407, 1, 31, 2120, 4, 8, 61, 2, 98, 470, 3240, 92, 10, 204, 6, 40, 517, 20, 298, 3, 1631, 308, 22, 4728, 20, 400, 4, 3, 928, 2567, 2, 3, 1395, 1, 37, 4, 3, 338, 3523, 1, 3, 31, 417, 2873, 11057, 205, 44, 47, 500, 93, 1408, 3113, 295, 37, 631, 11815, 192, 4, 3, 2169, 1, 1165, 4401, 420, 195, 3, 176, 11, 438, 5, 3, 2475, 1, 1226, 2146, 9495, 18885, 9495, 30797, 2, 101, 55, 1, 3119, 2, 2657, 4, 3252, 67, 2, 8466, 37, 4, 352, 154, 61, 150, 1, 11057, 2, 540, 224, 8, 150, 558, 299, 76, 14, 1716, 1806, 129, 297, 72, 6, 3, 183, 1498, 4257, 4, 1221, 46, 99, 19016, 17, 41057, 5756, 68, 40, 35, 323, 312, 2000, 420, 6, 1433, 12, 31, 129, 2, 344, 3, 189, 209, 1, 809, 600, 733, 65925, 631, 2388, 3, 193, 1, 9045, 526, 189, 183, 1233, 1197, 9, 229, 12, 24, 422]",1679.0,25854386,411
"Cervical Cancer, Version 2.2015.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2015-04-01,"The NCCN Guidelines for Cervical Cancer provide interdisciplinary recommendations for treating cervical cancer. These NCCN Guidelines Insights summarize the NCCN Cervical Cancer Panel's discussion and major guideline updates from 2014 and 2015. The recommended systemic therapy options for recurrent and metastatic cervical cancer were amended upon panel review of new survival data and the FDA's approval of bevacizumab for treating late-stage cervical cancer. This article outlines relevant data and provides insight into panel decisions regarding various combination regimens. Additionally, a new section was added to provide additional guidance on key principles of evaluation and surgical staging in cervical cancer. This article highlights 2 areas of active investigation and debate from this new section: sentinel lymph node mapping and fertility-sparing treatment approaches.",Journal Article,1756.0,154.0,The NCCN Guidelines for Cancer provide interdisciplinary recommendations for treating cancer These NCCN Guidelines Insights summarize the NCCN Cancer Panel 's discussion and major guideline updates from 2014 and 2015 The recommended systemic therapy options for recurrent and metastatic cancer were amended upon panel review of new survival data and the FDA 's approval of bevacizumab for treating late-stage cancer This article outlines relevant data and provides insight into panel decisions regarding various combination regimens Additionally a new section was added to provide additional guidance on key principles of evaluation and surgical staging in cancer This article highlights 2 areas of active investigation and debate from this new section sentinel lymph node mapping and fertility-sparing treatment approaches,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1944, 677, 9, 12, 377, 5911, 883, 9, 1367, 12, 46, 1944, 677, 1957, 2479, 3, 1944, 12, 993, 292, 2488, 2, 458, 2009, 5454, 29, 1409, 2, 1483, 3, 793, 403, 36, 838, 9, 387, 2, 113, 12, 11, 7595, 1548, 993, 206, 1, 217, 25, 74, 2, 3, 2078, 292, 1814, 1, 599, 9, 1367, 807, 82, 12, 26, 946, 6510, 867, 74, 2, 777, 2670, 237, 993, 1526, 666, 747, 150, 472, 1724, 8, 217, 2917, 10, 1953, 6, 377, 402, 2753, 23, 825, 4650, 1, 451, 2, 221, 632, 4, 12, 26, 946, 2527, 18, 1361, 1, 544, 940, 2, 5220, 29, 26, 217, 2917, 1323, 263, 289, 2568, 2, 2954, 1851, 24, 611]",823.0,25870376,83
Medical and sociodemographic factors associated with human papillomavirus (HPV) vaccination adherence among female survivors of childhood cancer.,Pediatric blood & cancer,Pediatr Blood Cancer,2015-04-20,"Among those 9-26 years of age, vaccination can prevent specific types of genital human papillomavirus (HPV), the most common sexually transmitted infection and cause of cervical and other cancers. The objective of this study was to estimate the prevalence of and factors associated with HPV vaccine initiation and completion among females surviving childhood cancer. One-hundred fourteen young adults and 230 mothers with daughters surviving childhood cancer completed surveys querying HPV vaccination history along with medical and sociodemographic factors potentially associated with vaccination outcomes. Vaccination rate differences by age necessitated analysis of outcomes by age group: 9-13 years (preadolescents), 14-17 years (adolescents), and 18-26 years (young adults). Multivariable logistic regression was utilized to identify factors associated with HPV vaccination outcomes. Overall, 34.6% (119/344) of survivors initiated and 20.9% (72/344) completed HPV vaccination. Preadolescents were least likely to have initiated vaccination (P<0.001). Physician recommendation was associated with initiation across age groups (OR=6.81-11.96, Ps<0.001-.01), whereas older age at diagnosis (12 years of age) was associated with lower vaccination initiation among young adults only (OR=0.28; 95%CI, 0.10-0.76, P=0.012). Physician recommendation (OR=7.54; 95%CI, 1.19-47.69, P=0.032; adolescent group) and greater treatment intensity (OR=5.25; 95%CI, 1.00-27.61, P=0.050; young adult group) were associated with vaccine completion, whereas being non-White was associated with decreased vaccination completion (OR=0.17; 95%CI, 0.05-0.66, P=0.010; adolescent group). A minority of youths surviving childhood cancer have initiated or completed HPV vaccination. Strategies to increase vaccination among survivors are discussed.",Journal Article,1737.0,5.0,Among those 9-26 years of age vaccination can prevent specific types of genital human papillomavirus HPV the most common sexually transmitted infection and cause of and other cancers The objective of this study was to estimate the prevalence of and factors associated with HPV vaccine initiation and completion among females surviving childhood cancer One-hundred fourteen young adults and 230 mothers with daughters surviving childhood cancer completed surveys querying HPV vaccination history along with medical and sociodemographic factors potentially associated with vaccination outcomes Vaccination rate differences by age necessitated analysis of outcomes by age group 9-13 years preadolescents 14-17 years adolescents and 18-26 years young adults Multivariable logistic regression was utilized to identify factors associated with HPV vaccination outcomes Overall 34.6 119/344 of survivors initiated and 20.9 72/344 completed HPV vaccination Preadolescents were least likely to have initiated vaccination P 0.001 Physician recommendation was associated with initiation across age groups OR 6.81-11.96 Ps 0.001-.01 whereas older age at diagnosis 12 years of age was associated with lower vaccination initiation among young adults only OR 0.28 95 CI 0.10-0.76 P 0.012 Physician recommendation OR 7.54 95 CI 1.19-47.69 P 0.032 adolescent group and greater treatment intensity OR 5.25 95 CI 1.00-27.61 P 0.050 young adult group were associated with vaccine completion whereas being non-White was associated with decreased vaccination completion OR 0.17 95 CI 0.05-0.66 P 0.010 adolescent group A minority of youths surviving childhood cancer have initiated or completed HPV vaccination Strategies to increase vaccination among survivors are discussed,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[107, 135, 83, 432, 60, 1, 89, 1915, 122, 1682, 112, 630, 1, 8226, 171, 3242, 933, 3, 96, 186, 13588, 12959, 930, 2, 708, 1, 2, 127, 163, 3, 461, 1, 26, 45, 10, 6, 1191, 3, 1078, 1, 2, 130, 41, 5, 933, 1274, 1118, 2, 1438, 107, 2451, 3050, 864, 12, 104, 1128, 3225, 1169, 857, 2, 6136, 8605, 5, 13099, 3050, 864, 12, 781, 3666, 22483, 933, 1915, 532, 1510, 5, 484, 2, 4221, 130, 751, 41, 5, 1915, 123, 1915, 116, 362, 20, 89, 14727, 65, 1, 123, 20, 89, 87, 83, 233, 60, 49008, 213, 269, 60, 3101, 2, 203, 432, 60, 1169, 857, 658, 812, 320, 10, 2080, 6, 255, 130, 41, 5, 933, 1915, 123, 63, 562, 49, 4299, 6993, 1, 332, 1917, 2, 179, 83, 720, 6993, 781, 933, 1915, 49008, 11, 506, 322, 6, 47, 1917, 1915, 19, 13, 144, 1473, 3347, 10, 41, 5, 1118, 716, 89, 271, 15, 49, 865, 175, 921, 1511, 13, 144, 355, 547, 434, 89, 28, 147, 9612, 60, 1, 89, 10, 41, 5, 280, 1915, 1118, 107, 1169, 857, 158, 15, 13, 339, 48, 58, 13, 79, 13, 846, 19, 13, 3499, 1473, 3347, 15, 67, 667, 48, 58, 14, 326, 662, 790, 19, 13, 4708, 3678, 87, 2, 378, 24, 837, 15, 33, 243, 48, 58, 14, 2038, 428, 713, 19, 13, 10801, 1169, 780, 87, 11, 41, 5, 1274, 1438, 547, 486, 220, 886, 10, 41, 5, 340, 1915, 1438, 15, 13, 269, 48, 58, 13, 474, 13, 700, 19, 13, 4873, 3678, 87, 8, 2652, 1, 49009, 3050, 864, 12, 47, 1917, 15, 781, 933, 1915, 422, 6, 344, 1915, 107, 332, 32, 1588]",1753.0,25900433,34
Association Study of Single-Nucleotide Polymorphisms of STAT2/STAT3/IFN- Genes in Cervical Cancer in Southern Chinese Han Women.,Asian Pacific journal of cancer prevention : APJCP,Asian Pac. J. Cancer Prev.,2015-01-01,"Interferon- (IFN-) and signal transducers and activators of transcription (STATs) each play an important role in carcinogenesis associated with viral infection. Cervical cancer is almost invariably associated with infection by human papillomavirus (HPV), and previous studies suggested that dysregulation of the signal pathway involved in IFN- and STATs is associated. Our objective was to evaluate the association of SNPs in STAT2, STAT3, and IFN- with cervical cancer susceptibility in Chinese Han women in Hunan province. Genomic DNA was extracted from peripheral blood samples of 234 cervical cancer patients and 216 healthy female controls. STAT2 and STAT3 genotyping was performed using polymerase chain reaction-restriction enzyme (PCR-RE) analysis. IFN- genotyping was detected by PCR-amplification of specific allele (PASA). For STAT2 rs2066807 polymorphisms, there was no significant difference of genotype distribution (P=0.827) and allele frequencies (P=0.830, OR=1.09, 95% CI: 0.51-2.31) between cases and controls. For STAT3 rs957970 polymorphisms, there was no significant difference of genotype distribution (P=0.455) and allele frequencies (P=0.560, OR=0.92, 95% CI: 0.71-1.20) between cases and controls. For IFN- +874A/T polymorphisms, there was no significant difference of genotype distribution (P=0.652) and allele frequencies (P=0.527, OR=1.12, 95% CI: 0.79-1.59) between cases and controls. These results suggest that polymorphisms in STAT2, STAT3 and IFN- genes are not likely to be strong predictors of cervical cancer in Han women in southern China.",Comparative Study,1846.0,1.0,Interferon- IFN- and signal transducers and activators of transcription STATs each play an important role in carcinogenesis associated with viral infection cancer is almost invariably associated with infection by human papillomavirus HPV and previous studies suggested that dysregulation of the signal pathway involved in IFN- and STATs is associated Our objective was to evaluate the association of SNPs in STAT2 STAT3 and IFN- with cancer susceptibility in Chinese Han women in Hunan province Genomic DNA was extracted from peripheral blood samples of 234 cancer patients and 216 healthy female controls STAT2 and STAT3 genotyping was performed using polymerase chain reaction-restriction enzyme PCR-RE analysis IFN- genotyping was detected by PCR-amplification of specific allele PASA For STAT2 rs2066807 polymorphisms there was no significant difference of genotype distribution P=0.827 and allele frequencies P=0.830 OR=1.09 95 CI 0.51-2.31 between cases and controls For STAT3 rs957970 polymorphisms there was no significant difference of genotype distribution P=0.455 and allele frequencies P=0.560 OR=0.92 95 CI 0.71-1.20 between cases and controls For IFN- +874A/T polymorphisms there was no significant difference of genotype distribution P=0.652 and allele frequencies P=0.527 OR=1.12 95 CI 0.79-1.59 between cases and controls These results suggest that polymorphisms in STAT2 STAT3 and IFN- genes are not likely to be strong predictors of cancer in Han women in southern China,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1688, 2655, 1256, 2655, 2, 1235, 11439, 2, 7751, 1, 866, 23274, 296, 1343, 35, 305, 200, 4, 1719, 41, 5, 1667, 930, 12, 16, 2214, 6912, 41, 5, 930, 20, 171, 3242, 933, 2, 698, 94, 1148, 17, 3935, 1, 3, 1235, 308, 646, 4, 1256, 2655, 2, 23274, 16, 41, 114, 461, 10, 6, 376, 3, 248, 1, 1109, 4, 21148, 1439, 2, 1256, 2655, 5, 12, 1432, 4, 3656, 16374, 117, 4, 66044, 20174, 572, 261, 10, 2484, 29, 672, 315, 347, 1, 8049, 12, 7, 2, 6287, 1331, 1061, 535, 21148, 2, 1439, 2686, 10, 173, 75, 1451, 1260, 1329, 4575, 1644, 604, 1491, 65, 1256, 2655, 2686, 10, 530, 20, 604, 1073, 1, 112, 1254, 66045, 9, 21148, 66046, 1203, 125, 10, 77, 93, 523, 1, 1183, 1395, 19, 13, 13947, 2, 1254, 2722, 19, 13, 12400, 15, 14, 1730, 48, 58, 13, 725, 18, 456, 59, 140, 2, 535, 9, 1439, 66047, 1203, 125, 10, 77, 93, 523, 1, 1183, 1395, 19, 13, 10997, 2, 1254, 2722, 19, 13, 7356, 15, 13, 937, 48, 58, 13, 792, 14, 179, 59, 140, 2, 535, 9, 1256, 2655, 66048, 102, 1203, 125, 10, 77, 93, 523, 1, 1183, 1395, 19, 13, 14167, 2, 1254, 2722, 19, 13, 14254, 15, 14, 133, 48, 58, 13, 842, 14, 728, 59, 140, 2, 535, 46, 99, 309, 17, 1203, 4, 21148, 1439, 2, 1256, 2655, 214, 32, 44, 322, 6, 40, 1082, 674, 1, 12, 4, 16374, 117, 4, 7525, 5055]",1496.0,25921106,193
"Trends in the quality of treatment for patients with intact cervical cancer in the United States, 1999 through 2011.","International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2015-06-01,"High-quality treatment for intact cervical cancer requires external radiation therapy, brachytherapy, and chemotherapy, carefully sequenced and completed without delays. We sought to determine how frequently current treatment meets quality benchmarks and whether new technologies have influenced patterns of care. By searching diagnosis and procedure claims in MarketScan, an employment-based health care claims database, we identified 1508 patients with nonmetastatic, intact cervical cancer treated from 1999 to 2011, who were <65 years of age and received >10 fractions of radiation. Treatments received were identified using procedure codes and compared with 3 quality benchmarks: receipt of brachytherapy, receipt of chemotherapy, and radiation treatment duration not exceeding 63 days. The Cochran-Armitage test was used to evaluate temporal trends. Seventy-eight percent of patients (n=1182) received brachytherapy, with brachytherapy receipt stable over time (Cochran-Armitage Ptrend=.15). Among patients who received brachytherapy, 66% had high-dose rate and 34% had low-dose rate treatment, although use of high-dose rate brachytherapy steadily increased to 75% by 2011 (Ptrend<.001). Eighteen percent of patients (n=278) received intensity modulated radiation therapy (IMRT), and IMRT receipt increased to 37% by 2011 (Ptrend<.001). Only 2.5% of patients (n=38) received IMRT in the setting of brachytherapy omission. Overall, 79% of patients (n=1185) received chemotherapy, and chemotherapy receipt increased to 84% by 2011 (Ptrend<.001). Median radiation treatment duration was 56 days (interquartile range, 47-65 days); however, duration exceeded 63 days in 36% of patients (n=543). Although 98% of patients received at least 1 benchmark treatment, only 44% received treatment that met all 3 benchmarks. With more stringent indicators (brachytherapy, 4 chemotherapy cycles, and duration not exceeding 56 days), only 25% of patients received treatment that met all benchmarks. In this cohort, most cervical cancer patients received treatment that did not comply with all 3 benchmarks for quality treatment. In contrast to increasing receipt of newer radiation technologies, there was little improvement in receipt of essential treatment benchmarks.",Journal Article,1695.0,29.0,High-quality treatment for intact cancer requires external radiation therapy brachytherapy and chemotherapy carefully sequenced and completed without delays We sought to determine how frequently current treatment meets quality benchmarks and whether new technologies have influenced patterns of care By searching diagnosis and procedure claims in MarketScan an employment-based health care claims database we identified 1508 patients with nonmetastatic intact cancer treated from 1999 to 2011 who were 65 years of age and received 10 fractions of radiation Treatments received were identified using procedure codes and compared with 3 quality benchmarks receipt of brachytherapy receipt of chemotherapy and radiation treatment duration not exceeding 63 days The Cochran-Armitage test was used to evaluate temporal trends Seventy-eight percent of patients n=1182 received brachytherapy with brachytherapy receipt stable over time Cochran-Armitage Ptrend=.15 Among patients who received brachytherapy 66 had high-dose rate and 34 had low-dose rate treatment although use of high-dose rate brachytherapy steadily increased to 75 by 2011 Ptrend .001 Eighteen percent of patients n=278 received intensity modulated radiation therapy IMRT and IMRT receipt increased to 37 by 2011 Ptrend .001 Only 2.5 of patients n=38 received IMRT in the setting of brachytherapy omission Overall 79 of patients n=1185 received chemotherapy and chemotherapy receipt increased to 84 by 2011 Ptrend .001 Median radiation treatment duration was 56 days interquartile range 47-65 days however duration exceeded 63 days in 36 of patients n=543 Although 98 of patients received at least 1 benchmark treatment only 44 received treatment that met all 3 benchmarks With more stringent indicators brachytherapy 4 chemotherapy cycles and duration not exceeding 56 days only 25 of patients received treatment that met all benchmarks In this cohort most cancer patients received treatment that did not comply with all 3 benchmarks for quality treatment In contrast to increasing receipt of newer radiation technologies there was little improvement in receipt of essential treatment benchmarks,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[64, 372, 24, 9, 2964, 12, 1706, 1455, 121, 36, 1536, 2, 56, 3900, 4040, 2, 781, 187, 3257, 21, 990, 6, 223, 832, 746, 291, 24, 13400, 372, 9945, 2, 317, 217, 2590, 47, 2574, 764, 1, 165, 20, 10082, 147, 2, 1299, 2770, 4, 10246, 35, 5141, 90, 341, 165, 2770, 609, 21, 108, 28520, 7, 5, 2683, 2964, 12, 73, 29, 2043, 6, 1132, 54, 11, 556, 60, 1, 89, 2, 103, 79, 1550, 1, 121, 640, 103, 11, 108, 75, 1299, 5271, 2, 72, 5, 27, 372, 9945, 1699, 1, 1536, 1699, 1, 56, 2, 121, 24, 654, 44, 5178, 676, 162, 3, 12211, 14314, 412, 10, 95, 6, 376, 3264, 1963, 2073, 659, 714, 1, 7, 78, 34153, 103, 1536, 5, 1536, 1699, 585, 252, 98, 12211, 14314, 6197, 167, 107, 7, 54, 103, 1536, 700, 42, 64, 61, 116, 2, 562, 42, 154, 61, 116, 24, 242, 119, 1, 64, 61, 116, 1536, 7025, 101, 6, 481, 20, 1132, 6197, 144, 3195, 714, 1, 7, 78, 9128, 103, 837, 1757, 121, 36, 964, 2, 964, 1699, 101, 6, 567, 20, 1132, 6197, 144, 158, 18, 33, 1, 7, 78, 519, 103, 964, 4, 3, 546, 1, 1536, 5736, 63, 842, 1, 7, 78, 32435, 103, 56, 2, 56, 1699, 101, 6, 874, 20, 1132, 6197, 144, 52, 121, 24, 654, 10, 664, 162, 2899, 184, 662, 556, 162, 137, 654, 4726, 676, 162, 4, 511, 1, 7, 78, 11943, 242, 1096, 1, 7, 103, 28, 506, 14, 7330, 24, 158, 584, 103, 24, 17, 543, 62, 27, 9945, 5, 80, 6763, 3539, 1536, 5915, 56, 410, 2, 654, 44, 5178, 664, 162, 158, 243, 1, 7, 103, 24, 17, 543, 62, 9945, 4, 26, 180, 96, 12, 7, 103, 24, 17, 205, 44, 20193, 5, 62, 27, 9945, 9, 372, 24, 4, 748, 6, 602, 1699, 1, 2246, 121, 2590, 125, 10, 1215, 767, 4, 1699, 1, 1452, 24, 9945]",2158.0,25968823,615
Minimally Invasive Esophagectomy with Cervical Anastomosis.,Annals of surgical oncology,Ann. Surg. Oncol.,2015-06-17,"This video demonstrates our technique for a minimally invasive esophagectomy with side-to-side stapled cervical esophagogastric anastomosis. This technique is routinely utilized in most patients undergoing esophagectomy for esophageal or gastroesophageal junction malignancy, excluding type III gastroesophageal junction tumors. Absolute contraindications include significant tumor involvement of the fundus which may necessitate an intrathoracic anastomosis. Relative contraindications include poor pulmonary function or prior extensive surgical history that may either preclude surgery altogether or prevent the ability of the conduit from reaching the cervical region, or could preclude utilization of a minimally invasive approach. We have not found large body habitus to be an absolute contraindication for this approach. The technique involves thoracoscopic mobilization of the esophagus, laparoscopic dissection of the stomach and creation of gastric conduit, and creation of a 6 cm side-to-side stapled cervical esophagogastric anastomosis. The pylorus is treated with a botox injection; routine pyloroplasty is not performed. In our experience, this technique is safe, oncologically appropriate, and provides excellent functional results.",Journal Article,1679.0,1.0,This video demonstrates our technique for a minimally invasive esophagectomy with side-to-side stapled esophagogastric anastomosis This technique is routinely utilized in most patients undergoing esophagectomy for or gastroesophageal junction malignancy excluding type III gastroesophageal junction tumors Absolute contraindications include significant tumor involvement of the fundus which may necessitate an intrathoracic anastomosis Relative contraindications include poor pulmonary function or prior extensive surgical history that may either preclude surgery altogether or prevent the ability of the conduit from reaching the region or could preclude utilization of a minimally invasive approach We have not found large body habitus to be an absolute contraindication for this approach The technique involves thoracoscopic mobilization of the laparoscopic dissection of the and creation of conduit and creation of a 6 cm side-to-side stapled esophagogastric anastomosis The pylorus is treated with a botox injection routine pyloroplasty is not performed In our experience this technique is safe oncologically appropriate and provides excellent functional results,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,"[26, 4139, 1902, 114, 1312, 9, 8, 2144, 416, 3617, 5, 1152, 6, 1152, 9911, 6330, 5519, 26, 1312, 16, 3066, 2080, 4, 96, 7, 479, 3617, 9, 15, 3227, 3322, 710, 3207, 267, 316, 3227, 3322, 57, 1766, 8511, 643, 93, 30, 799, 1, 3, 16869, 92, 68, 12084, 35, 7359, 5519, 580, 8511, 643, 334, 1087, 343, 15, 324, 1344, 221, 532, 17, 68, 361, 6064, 152, 6767, 15, 1682, 3, 801, 1, 3, 10439, 29, 6168, 3, 1053, 15, 359, 6064, 1961, 1, 8, 2144, 416, 353, 21, 47, 44, 204, 375, 642, 23459, 6, 40, 35, 1766, 8363, 9, 26, 353, 3, 1312, 2921, 5752, 4030, 1, 3, 1964, 1161, 1, 3, 2, 7560, 1, 10439, 2, 7560, 1, 8, 49, 494, 1152, 6, 1152, 9911, 6330, 5519, 3, 26077, 16, 73, 5, 8, 66308, 1754, 1311, 27453, 16, 44, 173, 4, 114, 730, 26, 1312, 16, 1165, 10854, 870, 2, 777, 1503, 583, 99]",1167.0,26082198,459
Radical trachelectomy in early-stage cervical cancer: A comparison of laparotomy and minimally invasive surgery.,Gynecologic oncology,Gynecol. Oncol.,2015-06-18,"Radical trachelectomy is considered standard of care in patients with early-stage cervical cancer interested in future fertility. The goal of this study was to compare operative, oncologic, and fertility outcomes in patients with early-stage cervical cancer undergoing open vs. minimally invasive radical trachelectomy. A retrospective review was performed of patients from four institutions who underwent radical trachelectomy for early-stage cervical cancer from June 2002 to July 2013. Perioperative, oncologic, and fertility outcomes were compared between patients undergoing open vs. minimally invasive surgery. A total of 100 patients were included in the analysis. Fifty-eight patients underwent open radical trachelectomy and 42 patients underwent minimally invasive surgery (MIS=laparoscopic or robotic). There were no differences in patient age, body mass index, race, histology, lymph vascular space invasion, or stage between the two groups. The median surgical time for MIS was 272min [range, 130-441min] compared with 270min [range, 150-373min] for open surgery (p=0.78). Blood loss was significantly lower for MIS vs. laparotomy (50mL [range, 10-225mL] vs. 300mL [50-1100mL]) (p<0.0001). Nine patients required blood transfusion, all in the open surgery group (p=0.010). Length of hospitalization was shorter for MIS than for laparotomy (1day [1-3 days] vs. 4days [1-9 days]) (p<0.0001). Three intraoperative complications occurred (3%): 1 bladder injury, and 1 fallopian tube injury requiring unilateral salpingectomy in the MIS group and 1 vascular injury in the open surgery group. The median lymph node count was 17 (range, 5-47) for MIS vs. 22 (range, 7-48) for open surgery (p=0.03). There were no differences in the rate of postoperative complications (30% MIS vs. 31% open surgery). Among 83 patients who preserved their fertility (33 MIS vs. 50 open surgery), 34 (41%) patients attempted to get pregnant. Sixteen (47%) patients were able to do so (MIS: 2 vs. laparotomy: 14, p=0.01). The pregnancy rate was higher in the open surgery group when compared to the MIS group (51% vs. 28%, p=0.018). However, median follow-up was shorter is the MIS group compared with the open surgery group (25months [range, 10-69] vs. 66months [range, 11-147]). To date, there has been one recurrence in the laparotomy group and none in the MIS group. Our results suggest that radical trachelectomy via MIS results in less blood loss and a shorter hospital stay. Fertility rates appear higher in patients undergoing open radical trachelectomy.",Journal Article,1678.0,32.0,Radical trachelectomy is considered standard of care in patients with early-stage cancer interested in future fertility The goal of this study was to compare operative oncologic and fertility outcomes in patients with early-stage cancer undergoing open vs. minimally invasive radical trachelectomy A retrospective review was performed of patients from four institutions who underwent radical trachelectomy for early-stage cancer from June 2002 to July 2013 Perioperative oncologic and fertility outcomes were compared between patients undergoing open vs. minimally invasive surgery A total of 100 patients were included in the analysis Fifty-eight patients underwent open radical trachelectomy and 42 patients underwent minimally invasive surgery MIS=laparoscopic or robotic There were no differences in patient age body mass index race histology lymph vascular space invasion or stage between the two groups The median surgical time for MIS was 272min range 130-441min compared with 270min range 150-373min for open surgery p=0.78 Blood loss was significantly lower for MIS vs. laparotomy 50mL range 10-225mL vs. 300mL 50-1100mL p 0.0001 Nine patients required blood transfusion all in the open surgery group p=0.010 Length of hospitalization was shorter for MIS than for laparotomy 1day 1-3 days vs. 4days 1-9 days p 0.0001 Three intraoperative complications occurred 3 1 injury and 1 tube injury requiring unilateral salpingectomy in the MIS group and 1 vascular injury in the open surgery group The median lymph node count was 17 range 5-47 for MIS vs. 22 range 7-48 for open surgery p=0.03 There were no differences in the rate of postoperative complications 30 MIS vs. 31 open surgery Among 83 patients who preserved their fertility 33 MIS vs. 50 open surgery 34 41 patients attempted to get pregnant Sixteen 47 patients were able to do so MIS 2 vs. laparotomy 14 p=0.01 The pregnancy rate was higher in the open surgery group when compared to the MIS group 51 vs. 28 p=0.018 However median follow-up was shorter is the MIS group compared with the open surgery group 25months range 10-69 vs. 66months range 11-147 To date there has been one recurrence in the laparotomy group and none in the MIS group Our results suggest that radical trachelectomy via MIS results in less blood loss and a shorter hospital stay Fertility rates appear higher in patients undergoing open radical trachelectomy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,"[711, 5760, 16, 515, 260, 1, 165, 4, 7, 5, 191, 82, 12, 7420, 4, 508, 2954, 3, 1326, 1, 26, 45, 10, 6, 932, 1208, 1998, 2, 2954, 123, 4, 7, 5, 191, 82, 12, 479, 1020, 105, 2144, 416, 711, 5760, 8, 459, 206, 10, 173, 1, 7, 29, 294, 1764, 54, 208, 711, 5760, 9, 191, 82, 12, 29, 1924, 1544, 6, 2066, 1346, 1547, 1998, 2, 2954, 123, 11, 72, 59, 7, 479, 1020, 105, 2144, 416, 152, 8, 181, 1, 394, 7, 11, 159, 4, 3, 65, 1461, 659, 7, 208, 1020, 711, 5760, 2, 595, 7, 208, 2144, 416, 152, 4386, 1964, 15, 2895, 125, 11, 77, 362, 4, 69, 89, 642, 782, 558, 1047, 784, 263, 756, 3865, 578, 15, 82, 59, 3, 100, 271, 3, 52, 221, 98, 9, 4386, 10, 66321, 184, 3431, 66322, 72, 5, 66323, 184, 1577, 66324, 9, 1020, 152, 19, 13, 833, 315, 407, 10, 97, 280, 9, 4386, 105, 3274, 48368, 184, 79, 66325, 105, 66326, 212, 66327, 19, 13, 488, 762, 7, 616, 315, 2785, 62, 4, 3, 1020, 152, 87, 19, 13, 4873, 1318, 1, 2826, 10, 985, 9, 4386, 76, 9, 3274, 29690, 14, 27, 162, 105, 49139, 14, 83, 162, 19, 13, 488, 169, 1720, 521, 489, 27, 14, 2730, 2, 14, 2330, 2730, 1888, 3208, 15290, 4, 3, 4386, 87, 2, 14, 756, 2730, 4, 3, 1020, 152, 87, 3, 52, 263, 289, 1276, 10, 269, 184, 33, 662, 9, 4386, 105, 350, 184, 67, 576, 9, 1020, 152, 19, 13, 680, 125, 11, 77, 362, 4, 3, 116, 1, 573, 521, 201, 4386, 105, 456, 1020, 152, 107, 852, 7, 54, 5797, 136, 2954, 466, 4386, 105, 212, 1020, 152, 562, 605, 7, 4098, 6, 10743, 6086, 3228, 662, 7, 11, 1665, 6, 1022, 1743, 4386, 18, 105, 3274, 213, 19, 13, 355, 3, 2290, 116, 10, 142, 4, 3, 1020, 152, 87, 198, 72, 6, 3, 4386, 87, 725, 105, 339, 19, 13, 4047, 137, 52, 166, 126, 10, 985, 16, 3, 4386, 87, 72, 5, 3, 1020, 152, 87, 49140, 184, 79, 790, 105, 66328, 184, 175, 4961, 6, 1244, 125, 71, 85, 104, 146, 4, 3, 3274, 87, 2, 1292, 4, 3, 4386, 87, 114, 99, 309, 17, 711, 5760, 847, 4386, 99, 4, 299, 315, 407, 2, 8, 985, 702, 2020, 2954, 151, 1322, 142, 4, 7, 479, 1020, 711, 5760]",2397.0,26095894,453
HPV testing as a screen for cervical cancer.,BMJ (Clinical research ed.),BMJ,2015-06-30,"Human papillomavirus (HPV) has been identified as a necessary factor in the development of pre-invasive and invasive cancers of the lower genital tract, of which cervical cancer is the most prevalent. A molecular understanding of malignant transformation and epidemiologic information has led to the development of many strategies for detection and early intervention. Newer tests for oncogenic subtypes of HPV have made it possible to predict the risk of future development of cervical cancer. This review summarizes the current understanding of HPV related disease and examines the role of HPV testing as a screening tool for cervical cancer. It summarizes the data from prospective and randomized controlled trials on HPV screening from Europe and North America and includes smaller studies from low and middle income countries where cervical cancer is the most common cancer in women. ",Journal Article,1666.0,53.0,Human papillomavirus HPV has been identified as a necessary factor in the development of pre-invasive and invasive cancers of the lower genital tract of which cancer is the most prevalent A molecular understanding of malignant transformation and epidemiologic information has led to the development of many strategies for detection and early intervention Newer tests for oncogenic subtypes of HPV have made it possible to predict the risk of future development of cancer This review summarizes the current understanding of HPV related disease and examines the role of HPV testing as a screening tool for cancer It summarizes the data from prospective and randomized controlled trials on HPV screening from Europe and North America and includes smaller studies from low and middle income countries where cancer is the most common cancer in women,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 3242, 933, 71, 85, 108, 22, 8, 1493, 161, 4, 3, 193, 1, 671, 416, 2, 416, 163, 1, 3, 280, 8226, 1696, 1, 92, 12, 16, 3, 96, 2485, 8, 219, 612, 1, 393, 1392, 2, 3609, 487, 71, 836, 6, 3, 193, 1, 445, 422, 9, 638, 2, 191, 788, 2246, 895, 9, 1302, 814, 1, 933, 47, 1229, 192, 899, 6, 678, 3, 43, 1, 508, 193, 1, 12, 26, 206, 2869, 3, 291, 612, 1, 933, 139, 34, 2, 4468, 3, 200, 1, 933, 471, 22, 8, 453, 1515, 9, 12, 192, 2869, 3, 74, 29, 482, 2, 384, 1149, 143, 23, 933, 453, 29, 3934, 2, 2669, 4010, 2, 1920, 2170, 94, 29, 154, 2, 3897, 2306, 2115, 1257, 12, 16, 3, 96, 186, 12, 4, 117]",844.0,26126623,80
Clinical Outcomes of Computed Tomography-Based Volumetric Brachytherapy Planning for Cervical Cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2015-05-04,"A report of clinical outcomes of a computed tomography (CT)-based image guided brachytherapy (IGBT) technique for treatment of cervical cancer. Seventy-six women with International Federation of Gynecology and Obstetrics stage IB to IVA cervical carcinoma diagnosed between 2007 and 2014 were treated with definitive external beam radiation therapy (EBRT) with or without concurrent chemotherapy followed by high-dose-rate (HDR) IGBT. All patients underwent planning CT simulation at each implantation. A high-risk clinical target volume (HRCTV) encompassing any visible tumor and the entire cervix was contoured on the simulation CT. When available, magnetic resonance imaging (MRI) was performed at implantation to assist with tumor delineation. The prescription dose was prescribed to the HRCTV. The median follow-up time was 17 months. Thirteen patients (17%) had an MRI done before brachytherapy, and 16 patients (21%) were treated without MRI guidance. The mean EBRT/IGBT sum 2-Gy equivalent dose (EQD2) delivered to the 90% volume of the HRCTV was 86.3 Gy. The mean maximum EQD2s delivered to 2 cm(3) of the rectum, sigmoid, and bladder were 67.5 Gy, 66.2 Gy, and 75.3 Gy, respectively. The 2-year cumulative incidences of local, locoregional, and distant failure were 5.8% (95% confidence interval [CI]: 1.4%-14.8%), 15.1% (95% CI: 5.4%-29.4%), and 24.3% (95% CI: 12.1%-38.9%), respectively. The 2-year overall and disease-free survival rates were 75% (95% CI, 61%-91%) and 73% (95% CI, 60%-90%), respectively. Twenty-nine patients (38%) experienced grade  2 acute toxicity, with 5 cases of acute grade 3 toxicity and no grade  4 toxicities. One patient experienced grade 3 gastrointestinal toxicity. No other late grade  3 events were observed. This is the largest report to date of CT/MRI-based IGBT for the treatment of cervical cancer. The results are promising, with excellent local control and acceptable toxicity. Further investigation is needed to assess the long-term safety and efficacy of this treatment.",Journal Article,1723.0,25.0,A report of clinical outcomes of a computed tomography CT -based image guided brachytherapy IGBT technique for treatment of cancer Seventy-six women with International Federation of Gynecology and Obstetrics stage IB to IVA carcinoma diagnosed between 2007 and 2014 were treated with definitive external beam radiation therapy EBRT with or without concurrent chemotherapy followed by high-dose-rate HDR IGBT All patients underwent planning CT simulation at each implantation A high-risk clinical target volume HRCTV encompassing any visible tumor and the entire cervix was contoured on the simulation CT When available magnetic resonance imaging MRI was performed at implantation to assist with tumor delineation The prescription dose was prescribed to the HRCTV The median follow-up time was 17 months Thirteen patients 17 had an MRI done before brachytherapy and 16 patients 21 were treated without MRI guidance The mean EBRT/IGBT sum 2-Gy equivalent dose EQD2 delivered to the 90 volume of the HRCTV was 86.3 Gy The mean maximum EQD2s delivered to 2 cm 3 of the rectum sigmoid and were 67.5 Gy 66.2 Gy and 75.3 Gy respectively The 2-year cumulative incidences of local locoregional and distant failure were 5.8 95 confidence interval CI 1.4 -14.8 15.1 95 CI 5.4 -29.4 and 24.3 95 CI 12.1 -38.9 respectively The 2-year overall and disease-free survival rates were 75 95 CI 61 -91 and 73 95 CI 60 -90 respectively Twenty-nine patients 38 experienced grade  2 acute toxicity with 5 cases of acute grade 3 toxicity and no grade  4 toxicities One patient experienced grade 3 toxicity No other late grade  3 events were observed This is the largest report to date of CT/MRI-based IGBT for the treatment of cancer The results are promising with excellent local control and acceptable toxicity Further investigation is needed to assess the long-term safety and efficacy of this treatment,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,"[8, 414, 1, 38, 123, 1, 8, 1220, 872, 425, 90, 1482, 1808, 1536, 36056, 1312, 9, 24, 1, 12, 2073, 437, 117, 5, 944, 7303, 1, 6429, 2, 7407, 82, 3180, 6, 5900, 134, 265, 59, 1307, 2, 1409, 11, 73, 5, 1057, 1455, 1345, 121, 36, 1883, 5, 15, 187, 750, 56, 370, 20, 64, 61, 116, 5309, 36056, 62, 7, 208, 1349, 425, 4026, 28, 296, 4314, 8, 64, 43, 38, 283, 433, 29650, 6853, 500, 4822, 30, 2, 3, 1797, 3629, 10, 6476, 23, 3, 4026, 425, 198, 390, 1484, 1535, 270, 704, 10, 173, 28, 4314, 6, 3425, 5, 30, 5529, 3, 3584, 61, 10, 2746, 6, 3, 29650, 3, 52, 166, 126, 98, 10, 269, 53, 3170, 7, 269, 42, 35, 704, 1822, 348, 1536, 2, 245, 7, 239, 11, 73, 187, 704, 2753, 3, 313, 1883, 36056, 3216, 18, 381, 2017, 61, 10010, 1623, 6, 3, 424, 433, 1, 3, 29650, 10, 868, 27, 381, 3, 313, 689, 66376, 1623, 6, 18, 494, 27, 1, 3, 3660, 9356, 2, 11, 598, 33, 381, 700, 18, 381, 2, 481, 27, 381, 106, 3, 18, 111, 967, 3981, 1, 293, 1325, 2, 626, 496, 11, 33, 66, 48, 307, 268, 58, 14, 39, 213, 66, 167, 14, 48, 58, 33, 39, 462, 39, 2, 259, 27, 48, 58, 133, 14, 519, 83, 106, 3, 18, 111, 63, 2, 34, 115, 25, 151, 11, 481, 48, 58, 713, 970, 2, 803, 48, 58, 335, 424, 106, 737, 762, 7, 519, 592, 88, 749, 18, 286, 155, 5, 33, 140, 1, 286, 88, 27, 155, 2, 77, 88, 749, 39, 385, 104, 69, 592, 88, 27, 155, 77, 127, 807, 88, 749, 27, 281, 11, 164, 26, 16, 3, 2166, 414, 6, 1244, 1, 425, 704, 90, 36056, 9, 3, 24, 1, 12, 3, 99, 32, 721, 5, 1503, 293, 182, 2, 1595, 155, 195, 940, 16, 575, 6, 423, 3, 319, 337, 367, 2, 209, 1, 26, 24]",1885.0,26130230,264
Postoperative Radiation Therapy for Endometrial Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2015-07-06,"To provide guidance on the role of adjuvant radiation therapy in the treatment of endometrial cancer. ""The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline"" by Klopp et al, published in 2014 in Practical Radiation Oncology, was reviewed for developmental rigor by methodologists. The American Society for Radiation Oncology (ASTRO) guideline content and recommendations were further reviewed by the American Society of Clinical Oncology (ASCO) Endorsement Panel. The ASCO Endorsement Panel determined that the recommendations from the ASTRO guideline are clear, thorough, and based on the most relevant scientific evidence. ASCO endorsed the ASTRO guideline with several qualifying statements. Surveillance without adjuvant radiation therapy is a reasonable option for women without residual disease in the hysterectomy specimen and for women with grade 1 or 2 cancer and < 50% myometrial invasion, especially when no other high-risk features are present. For women with grade 1 or 2 cancer and  50% myometrial invasion or grade 3 cancer and < 50% myometrial invasion, vaginal brachytherapy is as effective as pelvic radiation therapy at preventing vaginal recurrence and is preferred. Patients with grade 3 cancer and  50% myometrial invasion or cervical stroma invasion may benefit from pelvic radiation to prevent pelvic recurrence. For women with high-risk early-stage disease and advanced disease, the ASCO Endorsement Panel added qualifying statements to the ASTRO recommendations to provide stronger statements in favor of chemotherapy (with or without radiation therapy).",Journal Article,1660.0,45.0,To provide guidance on the role of adjuvant radiation therapy in the treatment of cancer `` The Role of Postoperative Radiation Therapy for Cancer An ASTRO Evidence-Based Guideline '' by Klopp et al published in 2014 in Practical Radiation Oncology was reviewed for developmental rigor by methodologists The American Society for Radiation Oncology ASTRO guideline content and recommendations were further reviewed by the American Society of Clinical Oncology ASCO Endorsement Panel The ASCO Endorsement Panel determined that the recommendations from the ASTRO guideline are clear thorough and based on the most relevant scientific evidence ASCO endorsed the ASTRO guideline with several qualifying statements Surveillance without adjuvant radiation therapy is a reasonable option for women without residual disease in the hysterectomy specimen and for women with grade 1 or 2 cancer and 50 myometrial invasion especially when no other high-risk features are present For women with grade 1 or 2 cancer and  50 myometrial invasion or grade 3 cancer and 50 myometrial invasion brachytherapy is as effective as pelvic radiation therapy at preventing recurrence and is preferred Patients with grade 3 cancer and  50 myometrial invasion or stroma invasion may benefit from pelvic radiation to prevent pelvic recurrence For women with high-risk early-stage disease and advanced disease the ASCO Endorsement Panel added qualifying statements to the ASTRO recommendations to provide stronger statements in favor of chemotherapy with or without radiation therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 377, 2753, 23, 3, 200, 1, 249, 121, 36, 4, 3, 24, 1, 12, 3, 200, 1, 573, 121, 36, 9, 12, 35, 7709, 241, 90, 2009, 522, 20, 66420, 2022, 2171, 983, 4, 1409, 4, 3320, 121, 413, 10, 446, 9, 4566, 13117, 20, 19827, 3, 597, 1174, 9, 121, 413, 7709, 2009, 2457, 2, 883, 11, 195, 446, 20, 3, 597, 1174, 1, 38, 413, 2697, 11049, 993, 3, 2697, 11049, 993, 509, 17, 3, 883, 29, 3, 7709, 2009, 32, 885, 5506, 2, 90, 23, 3, 96, 867, 3138, 241, 2697, 6864, 3, 7709, 2009, 5, 392, 14646, 7072, 617, 187, 249, 121, 36, 16, 8, 3203, 1501, 9, 117, 187, 753, 34, 4, 3, 2622, 2360, 2, 9, 117, 5, 88, 14, 15, 18, 12, 2, 212, 7327, 578, 1093, 198, 77, 127, 64, 43, 404, 32, 364, 9, 117, 5, 88, 14, 15, 18, 12, 2, 749, 212, 7327, 578, 15, 88, 27, 12, 2, 212, 7327, 578, 1536, 16, 22, 323, 22, 1110, 121, 36, 28, 3017, 146, 2, 16, 2514, 7, 5, 88, 27, 12, 2, 749, 212, 7327, 578, 15, 2477, 578, 68, 247, 29, 1110, 121, 6, 1682, 1110, 146, 9, 117, 5, 64, 43, 191, 82, 34, 2, 131, 34, 3, 2697, 11049, 993, 1953, 14646, 7072, 6, 3, 7709, 883, 6, 377, 3355, 7072, 4, 4283, 1, 56, 5, 15, 187, 121, 36]",1554.0,26150442,609
HIV Testing in Patients With Cancer at the Initiation of Therapy at a Large US Comprehensive Cancer Center.,Journal of oncology practice,J Oncol Pract,2015-08-04,"To determine the rates of HIV testing and infection among patients with cancer at initiation of systemic cancer therapy. We conducted a retrospective cohort study of adults with cancer who registered at a comprehensive cancer center from January 2004 through April 2011 and received systemic cancer therapy. We determined rates of HIV-1/2 and/or Western blot testing and HIV positivity at initiation of systemic cancer therapy. Multivariable logistic regression was used to determine predictors of HIV testing. Of 18,874 patients with cancer who received systemic cancer therapy during the study period, 3,514 (18.6%) were tested for HIV at initiation of cancer therapy. The prevalence of positive HIV test results was 1.2% (41 of 3,514), and the prevalence of newly diagnosed HIV was 0.3% (12 of 3,514). The HIV testing rate was lower in black than in white patients (13.7% v 19.2%), but the prevalence of positive test results was higher in black patients (4.5%) than in any other racial/ethnic group. Among patients with AIDS-defining cancers (eg, non-Hodgkin lymphoma and cervical cancer), predictors of HIV testing were history of non-Hodgkin lymphoma, younger age, and registration after 2006. Among patients with non-AIDS-defining cancers, predictors of HIV testing were younger age, registration after 2006, male sex, history of illicit drug use or sexually transmitted disease, having a hematologic malignancy, and black race. The prevalence of HIV infection among patients with cancer was 1.2%, higher than the 0.1% prevalence threshold above which national guidelines recommend routine opt-out testing; however, the overall HIV testing rate was low.",Journal Article,1631.0,7.0,"To determine the rates of HIV testing and infection among patients with cancer at initiation of systemic cancer therapy We conducted a retrospective cohort study of adults with cancer who registered at a comprehensive cancer center from January 2004 through April 2011 and received systemic cancer therapy We determined rates of HIV-1/2 and/or Western blot testing and HIV positivity at initiation of systemic cancer therapy Multivariable logistic regression was used to determine predictors of HIV testing Of 18,874 patients with cancer who received systemic cancer therapy during the study period 3,514 18.6 were tested for HIV at initiation of cancer therapy The prevalence of positive HIV test results was 1.2 41 of 3,514 and the prevalence of newly diagnosed HIV was 0.3 12 of 3,514 The HIV testing rate was lower in black than in white patients 13.7 v 19.2 but the prevalence of positive test results was higher in black patients 4.5 than in any other racial/ethnic group Among patients with AIDS-defining cancers eg and cancer predictors of HIV testing were history of younger age and registration after 2006 Among patients with non-AIDS-defining cancers predictors of HIV testing were younger age registration after 2006 male sex history of illicit drug use or sexually transmitted disease having a hematologic malignancy and black race The prevalence of HIV infection among patients with cancer was 1.2 higher than the 0.1 prevalence threshold above which national guidelines recommend routine opt-out testing however the overall HIV testing rate was low",0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 151, 1, 1942, 471, 2, 930, 107, 7, 5, 12, 28, 1118, 1, 403, 12, 36, 21, 426, 8, 459, 180, 45, 1, 857, 5, 12, 54, 1653, 28, 8, 949, 12, 574, 29, 1024, 1131, 298, 2292, 1132, 2, 103, 403, 12, 36, 21, 509, 151, 1, 1942, 14, 18, 2, 15, 1521, 2639, 471, 2, 1942, 1887, 28, 1118, 1, 403, 12, 36, 658, 812, 320, 10, 95, 6, 223, 674, 1, 1942, 471, 1, 203, 15746, 7, 5, 12, 54, 103, 403, 12, 36, 190, 3, 45, 727, 27, 13539, 203, 49, 11, 650, 9, 1942, 28, 1118, 1, 12, 36, 3, 1078, 1, 109, 1942, 412, 99, 10, 14, 18, 605, 1, 27, 13539, 2, 3, 1078, 1, 732, 265, 1942, 10, 13, 27, 133, 1, 27, 13539, 3, 1942, 471, 116, 10, 280, 4, 1445, 76, 4, 886, 7, 233, 67, 603, 326, 18, 84, 3, 1078, 1, 109, 412, 99, 10, 142, 4, 1445, 7, 39, 33, 76, 4, 500, 127, 2257, 2871, 87, 107, 7, 5, 4174, 2847, 163, 2887, 2, 12, 674, 1, 1942, 471, 11, 532, 1, 773, 89, 2, 3169, 50, 1324, 107, 7, 5, 220, 4174, 2847, 163, 674, 1, 1942, 471, 11, 773, 89, 3169, 50, 1324, 1045, 1035, 532, 1, 15747, 234, 119, 15, 13588, 12959, 34, 1041, 8, 813, 710, 2, 1445, 1047, 3, 1078, 1, 1942, 930, 107, 7, 5, 12, 10, 14, 18, 142, 76, 3, 13, 14, 1078, 2390, 2090, 92, 657, 677, 2237, 1311, 8966, 1205, 471, 137, 3, 63, 1942, 471, 116, 10, 154]",1563.0,26243649,7
Survivors of gynecologic malignancies: impact of treatment on health and well-being.,Journal of cancer survivorship : research and practice,J Cancer Surviv,2015-08-06,"While overall survival from gynecologic malignancies has greatly improved over the last three decades, required treatments can lead to multiple health issues for survivors. Our objective was to identify health concerns that gynecologic cancer survivors face. A systematic, stratified sample of women with gynecologic malignancies was surveyed for 18 health issues occurring before, during, or after treatment. The impact of clinical features and treatment modality on health issues was assessed through multivariate logistic regression models. Of 2,546 surveys mailed, 622 were not received by eligible subjects secondary to invalid address, incorrect diagnosis, or death. Thus, 1924 survivors potentially received surveys. Of the 1,029 surveys (53.5%) completed, median age was 59 years; diagnoses included 29% cervical, 26% endometrial, 26% ovarian/primary peritoneal/fallopian tube, 12.1% vulvar, and 5.4% vaginal cancers. The most frequently reported health issues included fatigue (60.6%), sleep disturbance (54.9%), urinary difficulties (50.9%), sexual dysfunction (48.4%), neurologic issues (45.4%), bowel complaints (42.0%), depression (41.3%), and memory problems (41.2%). These rankings were consistent with patients' self-reported rankings of ""highest impact"" personal issues. After controlling for demographic and clinical variables, multivariate analyses revealed that treatment modality impacted the odds of experiencing a given health issue. Our study demonstrates that gynecologic cancer survivors experience a high frequency of health conditions and highlights the association between treatment modality and specific health concerns. The study findings highlight the multiple health concerns experienced by gynecologic cancer survivors and suggest the potential for developing interventions to mitigate these concerns in survivorship.",Journal Article,1629.0,17.0,"While overall survival from gynecologic malignancies has greatly improved over the last three decades required treatments can lead to multiple health issues for survivors Our objective was to identify health concerns that gynecologic cancer survivors face A systematic stratified sample of women with gynecologic malignancies was surveyed for 18 health issues occurring before during or after treatment The impact of clinical features and treatment modality on health issues was assessed through multivariate logistic regression models Of 2,546 surveys mailed 622 were not received by eligible subjects secondary to invalid address incorrect diagnosis or death Thus 1924 survivors potentially received surveys Of the 1,029 surveys 53.5 completed median age was 59 years diagnoses included 29 26 26 ovarian/primary peritoneal/fallopian tube 12.1 and 5.4 cancers The most frequently reported health issues included fatigue 60.6 sleep disturbance 54.9 urinary difficulties 50.9 sexual dysfunction 48.4 neurologic issues 45.4 bowel complaints 42.0 depression 41.3 and memory problems 41.2 These rankings were consistent with patients self-reported rankings of `` highest impact '' personal issues After controlling for demographic and clinical variables multivariate analyses revealed that treatment modality impacted the odds of experiencing a given health issue Our study demonstrates that gynecologic cancer survivors experience a high frequency of health conditions and highlights the association between treatment modality and specific health concerns The study findings highlight the multiple health concerns experienced by gynecologic cancer survivors and suggest the potential for developing interventions to mitigate these concerns in survivorship",0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[369, 63, 25, 29, 1512, 441, 71, 3510, 231, 252, 3, 1060, 169, 1968, 616, 640, 122, 1122, 6, 232, 341, 1553, 9, 332, 114, 461, 10, 6, 255, 341, 2061, 17, 1512, 12, 332, 3376, 8, 1556, 1173, 1000, 1, 117, 5, 1512, 441, 10, 3696, 9, 203, 341, 1553, 1821, 348, 190, 15, 50, 24, 3, 345, 1, 38, 404, 2, 24, 1396, 23, 341, 1553, 10, 275, 298, 331, 812, 320, 274, 1, 18, 11912, 3666, 6703, 11011, 11, 44, 103, 20, 625, 976, 568, 6, 25008, 1539, 11774, 147, 15, 273, 631, 36079, 332, 751, 103, 3666, 1, 3, 14, 4770, 3666, 699, 33, 781, 52, 89, 10, 728, 60, 2403, 159, 462, 432, 432, 6301, 86, 1639, 25234, 2330, 133, 14, 2, 33, 39, 163, 3, 96, 746, 210, 341, 1553, 159, 613, 335, 49, 2494, 6663, 667, 83, 1660, 4679, 212, 83, 2232, 1527, 576, 39, 2543, 1553, 512, 39, 1659, 6938, 595, 13, 1774, 605, 27, 2, 2407, 2408, 605, 18, 46, 17820, 11, 925, 5, 7, 1074, 210, 17820, 1, 1076, 345, 522, 3008, 1553, 50, 1893, 9, 1540, 2, 38, 682, 331, 318, 553, 17, 24, 1396, 4619, 3, 610, 1, 2985, 8, 447, 341, 2537, 114, 45, 1902, 17, 1512, 12, 332, 730, 8, 64, 675, 1, 341, 1298, 2, 2527, 3, 248, 59, 24, 1396, 2, 112, 341, 2061, 3, 45, 272, 1817, 3, 232, 341, 2061, 592, 20, 1512, 12, 332, 2, 309, 3, 174, 9, 931, 1151, 6, 5626, 46, 2061, 4, 2560]",1752.0,26245979,69
Barriers to health care contribute to delays in follow-up among women with abnormal cancer screening: Data from the Patient Navigation Research Program.,Cancer,Cancer,2015-08-19,"There is limited understanding of the association between barriers to care and clinical outcomes within patient navigation programs. Secondary analyses of data from the intervention arms of the Patient Navigation Research Program were performed, which included navigated participants with abnormal breast and cervical cancer screening tests from 2007 to 2010. Independent variables were: 1) the number of unique barriers to care (0, 1, 2, or 3) documented during patient navigation encounters; and 2) the presence of socio-legal barriers originating from social policy (yes/no). The median time to diagnostic resolution of index screening abnormalities was estimated using Kaplan-Meier cumulative incidence curves. Multivariable Cox proportional hazards regression examined the impact of barriers on time to resolution, controlling for sociodemographics and stratifying by study center. Among 2600 breast screening participants, approximately 75% had barriers to care documented (25% had 1 barrier, 16% had 2 barriers, and 34% had 3 barriers). Among 1387 cervical screening participants, greater than one-half had barriers documented (31% had 1 barrier, 11% had 2 barriers, and 13% had 3 barriers). Among breast screening participants, the presence of barriers was associated with less timely resolution for any number of barriers compared with no barriers. Among cervical screening participants, only the presence of 2 barriers was found to be associated with less timely resolution. Both types of barriers, socio-legal and other barriers, were found to be associated with delay among breast and cervical screening participants. Navigated women with barriers resolved cancer screening abnormalities at a slower rate compared with navigated women with no barriers. Further innovations in navigation care are necessary to maximize the impact of patient navigation programs nationwide.",Journal Article,1616.0,10.0,There is limited understanding of the association between barriers to care and clinical outcomes within patient navigation programs Secondary analyses of data from the intervention arms of the Patient Navigation Research Program were performed which included navigated participants with abnormal and cancer screening tests from 2007 to 2010 Independent variables were 1 the number of unique barriers to care 0 1 2 or 3 documented during patient navigation encounters and 2 the presence of socio-legal barriers originating from social policy yes/no The median time to diagnostic resolution of index screening abnormalities was estimated using Kaplan-Meier cumulative incidence curves Multivariable Cox proportional hazards regression examined the impact of barriers on time to resolution controlling for sociodemographics and stratifying by study center Among 2600 screening participants approximately 75 had barriers to care documented 25 had 1 barrier 16 had 2 barriers and 34 had 3 barriers Among 1387 screening participants greater than one-half had barriers documented 31 had 1 barrier 11 had 2 barriers and 13 had 3 barriers Among screening participants the presence of barriers was associated with less timely resolution for any number of barriers compared with no barriers Among screening participants only the presence of 2 barriers was found to be associated with less timely resolution Both types of barriers socio-legal and other barriers were found to be associated with delay among and screening participants Navigated women with barriers resolved cancer screening abnormalities at a slower rate compared with navigated women with no barriers Further innovations in navigation care are necessary to maximize the impact of patient navigation programs nationwide,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[125, 16, 383, 612, 1, 3, 248, 59, 2160, 6, 165, 2, 38, 123, 262, 69, 5604, 2251, 568, 318, 1, 74, 29, 3, 788, 1335, 1, 3, 69, 5604, 389, 1243, 11, 173, 92, 159, 15373, 776, 5, 1668, 2, 12, 453, 895, 29, 1307, 6, 1120, 306, 682, 11, 14, 3, 207, 1, 991, 2160, 6, 165, 13, 14, 18, 15, 2608, 1405, 190, 69, 5604, 8525, 2, 18, 3, 463, 1, 13370, 12281, 2160, 6794, 29, 2032, 4196, 7073, 77, 3, 52, 98, 6, 752, 2125, 1, 558, 453, 1171, 10, 661, 75, 876, 882, 967, 287, 2400, 658, 418, 831, 1017, 320, 409, 3, 345, 1, 2160, 23, 98, 6, 2125, 1893, 9, 16918, 2, 5035, 20, 45, 574, 107, 28221, 453, 776, 705, 481, 42, 2160, 6, 165, 1405, 243, 42, 14, 3318, 245, 42, 18, 2160, 2, 562, 42, 2608, 2160, 107, 66822, 453, 776, 378, 76, 104, 1303, 42, 2160, 1405, 456, 42, 14, 3318, 175, 42, 18, 2160, 2, 233, 42, 2608, 2160, 107, 453, 776, 3, 463, 1, 2160, 10, 41, 5, 299, 4225, 2125, 9, 500, 207, 1, 2160, 72, 5, 77, 2160, 107, 453, 776, 158, 3, 463, 1, 3107, 2160, 10, 204, 6, 40, 41, 5, 299, 4225, 2125, 110, 630, 1, 2160, 13370, 12281, 2, 127, 2160, 11, 204, 6, 40, 41, 5, 1984, 107, 2, 453, 776, 15373, 117, 5, 2160, 3862, 12, 453, 1171, 28, 8, 6715, 116, 72, 5, 15373, 117, 5, 77, 2160, 195, 10081, 4, 5604, 165, 32, 1493, 6, 4116, 3, 345, 1, 69, 5604, 2251, 5405]",1777.0,26385420,36
Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2015-09-30,"The objective of this study was to delineate and measure the symptom distress experienced by patients with advanced cervical cancer at the time of palliative care (PC) referral. A total of 156 patients with advanced cervical cancer were referred to PC from 2010 to 2012. Of these, 88 patients had completed the Edmonton Symptom Assessment System (ESAS) and were included in the analysis. The mean age was 45years (25-76), 47% were white, 18% were African American, and 33% were Hispanic. Fifty-one percent were married, 64% had no advance directives, and 75% had recurrent disease. Clinically significant symptoms recorded by patient reported outcome measurement (defined as ESAS scores 4) were pain (81%), anorexia (72%), a poor feeling of well-being (70%), fatigue (69%), and insomnia (54%). The chief complaint recorded for the visit was pain in 94% of patients. According to the PC specialists' assessment, pain (96%), emotional distress (77%), and constipation (50%) were predominant symptoms. Various PC interventions including opioids, laxatives, and expressive supportive counseling were provided. Clinically significant symptoms including nausea, depression, anxiety, and feeling of well-being were significantly improved at follow-up visits. More than half of patients with advanced cervical cancer were significantly burdened with pain, anorexia, a poor feeling of well-being, fatigue, insomnia, and constipation at the time of PC referral. This research is an integral step towards developing a standardized tool for assessing symptoms in women diagnosed with cervical cancer and thus maximizing effectiveness of patient centered care.",Journal Article,1574.0,11.0,The objective of this study was to delineate and measure the symptom distress experienced by patients with advanced cancer at the time of palliative care PC referral A total of 156 patients with advanced cancer were referred to PC from 2010 to 2012 Of these 88 patients had completed the Edmonton Symptom Assessment System ESAS and were included in the analysis The mean age was 45years 25-76 47 were white 18 were African American and 33 were Hispanic Fifty-one percent were married 64 had no advance directives and 75 had recurrent disease Clinically significant symptoms recorded by patient reported outcome measurement defined as ESAS scores 4 were pain 81 anorexia 72 a poor feeling of well-being 70 fatigue 69 and insomnia 54 The chief complaint recorded for the visit was pain in 94 of patients According to the PC specialists assessment pain 96 emotional distress 77 and constipation 50 were predominant symptoms Various PC interventions including opioids laxatives and expressive supportive counseling were provided Clinically significant symptoms including nausea depression anxiety and feeling of well-being were significantly improved at follow-up visits More than half of patients with advanced cancer were significantly burdened with pain anorexia a poor feeling of well-being fatigue insomnia and constipation at the time of PC referral This research is an integral step towards developing a standardized tool for assessing symptoms in women diagnosed with cancer and thus maximizing effectiveness of patient centered care,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 461, 1, 26, 45, 10, 6, 5092, 2, 1463, 3, 934, 1462, 592, 20, 7, 5, 131, 12, 28, 3, 98, 1, 994, 165, 1341, 2096, 8, 181, 1, 5693, 7, 5, 131, 12, 11, 1995, 6, 1341, 29, 1120, 6, 1195, 1, 46, 889, 7, 42, 781, 3, 5656, 934, 455, 398, 3243, 2, 11, 159, 4, 3, 65, 3, 313, 89, 10, 66871, 243, 846, 662, 11, 886, 203, 11, 1410, 597, 2, 466, 11, 1776, 1461, 104, 714, 11, 5365, 660, 42, 77, 3148, 9129, 2, 481, 42, 387, 34, 505, 93, 507, 1872, 20, 69, 210, 228, 2204, 395, 22, 3243, 703, 5915, 11, 559, 865, 3373, 720, 8, 334, 8001, 1, 149, 486, 431, 613, 790, 2, 8055, 667, 3, 14557, 13332, 1872, 9, 3, 2807, 10, 559, 4, 960, 1, 7, 768, 6, 3, 1341, 4409, 455, 559, 921, 2671, 1462, 849, 2, 4532, 212, 11, 2750, 507, 747, 1341, 1151, 141, 4353, 28379, 2, 15497, 1877, 2011, 11, 1052, 505, 93, 507, 141, 1218, 1774, 2021, 2, 8001, 1, 149, 486, 11, 97, 231, 28, 166, 126, 2690, 80, 76, 1303, 1, 7, 5, 131, 12, 11, 97, 21450, 5, 559, 3373, 8, 334, 8001, 1, 149, 486, 613, 8055, 2, 4532, 28, 3, 98, 1, 1341, 2096, 26, 389, 16, 35, 4450, 2458, 3113, 931, 8, 1670, 1515, 9, 1977, 507, 4, 117, 265, 5, 12, 2, 631, 8260, 1236, 1, 69, 4846, 165]",1538.0,26432043,449
"Impact of Insurance Status on Radiation Treatment Modality Selection Among Potential Candidates for Prostate, Breast, or Gynecologic Brachytherapy.","International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2015-08-28,"The Patient Protection and Affordable Care Act looks to expand both private and Medicaid insurance. To evaluate how these changes may affect the field of radiation oncology, we evaluated the association of insurance status with the use of brachytherapy in cancers for which this treatment technique is used. A total of 190,467 patients met the inclusion criteria, of whom 95,292 (50.0%) had breast cancer, 61,096 (32.1%) had prostate cancer, 28,194 (14.8%) had endometrial cancer, and 5885 (3.1%) had cervical cancer. A multivariate logistic regression model was used to determine the association between insurance status and receipt of brachytherapy among patients treated definitively for prostate and cervical cancer or postoperatively for breast and endometrial cancer. The rates of non-Medicaid insurance were 49.9% (cervical), 85.3% (endometrial), 87.4% (breast), and 90.9% (prostate) (P<.001). In a logistic regression, patients who received radiation therapy were less likely to receive brachytherapy if they had Medicaid coverage (odds ratio [OR] 0.57, 95% confidence interval [CI] 0.53-0.61, P<.001) or did not have insurance coverage (OR 0.50, 95% CI 0.45-0.56, P<.001) compared with those with non-Medicaid insurance. On subset analysis, patients with Medicaid coverage or without insurance coverage were significantly less likely to receive brachytherapy than were those with non-Medicaid insurance for all 4 sites, except for patients with endometrial cancer. Despite being a cost-effective treatment modality, brachytherapy is less often used in the definitive or postoperative management of cancer in patients with Medicaid coverage or without insurance. Upcoming health policy changes resulting in the expansion of private insurance and Medicaid will likely increase access to and demand for brachytherapy.",Journal Article,1607.0,14.0,"The Patient Protection and Affordable Care Act looks to expand both private and Medicaid insurance To evaluate how these changes may affect the field of radiation oncology we evaluated the association of insurance status with the use of brachytherapy in cancers for which this treatment technique is used A total of 190,467 patients met the inclusion criteria of whom 95,292 50.0 had cancer 61,096 32.1 had cancer 28,194 14.8 had cancer and 5885 3.1 had cancer A multivariate logistic regression model was used to determine the association between insurance status and receipt of brachytherapy among patients treated definitively for and cancer or postoperatively for and cancer The rates of non-Medicaid insurance were 49.9 85.3 87.4 and 90.9 P .001 In a logistic regression patients who received radiation therapy were less likely to receive brachytherapy if they had Medicaid coverage odds ratio OR 0.57 95 confidence interval CI 0.53-0.61 P .001 or did not have insurance coverage OR 0.50 95 CI 0.45-0.56 P .001 compared with those with non-Medicaid insurance On subset analysis patients with Medicaid coverage or without insurance coverage were significantly less likely to receive brachytherapy than were those with non-Medicaid insurance for all 4 sites except for patients with cancer Despite being a cost-effective treatment modality brachytherapy is less often used in the definitive or postoperative management of cancer in patients with Medicaid coverage or without insurance Upcoming health policy changes resulting in the expansion of private insurance and Medicaid will likely increase access to and demand for brachytherapy",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 69, 3525, 2, 8216, 165, 2559, 18362, 6, 4082, 110, 4745, 2, 2843, 1935, 6, 376, 832, 46, 400, 68, 1158, 3, 1067, 1, 121, 413, 21, 194, 3, 248, 1, 1935, 156, 5, 3, 119, 1, 1536, 4, 163, 9, 92, 26, 24, 1312, 16, 95, 8, 181, 1, 5974, 10993, 7, 543, 3, 1680, 371, 1, 953, 48, 8155, 212, 13, 42, 12, 713, 13894, 531, 14, 42, 12, 339, 5434, 213, 66, 42, 12, 2, 66929, 27, 14, 42, 12, 8, 331, 812, 320, 202, 10, 95, 6, 223, 3, 248, 59, 1935, 156, 2, 1699, 1, 1536, 107, 7, 73, 6008, 9, 2, 12, 15, 3541, 9, 2, 12, 3, 151, 1, 220, 2843, 1935, 11, 739, 83, 772, 27, 912, 39, 2, 424, 83, 19, 144, 4, 8, 812, 320, 7, 54, 103, 121, 36, 11, 299, 322, 6, 560, 1536, 492, 491, 42, 2843, 2139, 610, 197, 15, 13, 696, 48, 307, 268, 58, 13, 699, 13, 713, 19, 144, 15, 205, 44, 47, 1935, 2139, 15, 13, 212, 48, 58, 13, 512, 13, 664, 19, 144, 72, 5, 135, 5, 220, 2843, 1935, 23, 697, 65, 7, 5, 2843, 2139, 15, 187, 1935, 2139, 11, 97, 299, 322, 6, 560, 1536, 76, 11, 135, 5, 220, 2843, 1935, 9, 62, 39, 633, 2187, 9, 7, 5, 12, 550, 486, 8, 835, 323, 24, 1396, 1536, 16, 299, 629, 95, 4, 3, 1057, 15, 573, 284, 1, 12, 4, 7, 5, 2843, 2139, 15, 187, 1935, 11974, 341, 4196, 400, 1113, 4, 3, 1422, 1, 4745, 1935, 2, 2843, 303, 322, 344, 1655, 6, 2, 6645, 9, 1536]",1639.0,26452570,483
Avoidable tragedies: Disparities in healthcare access among medically underserved women diagnosed with cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2015-10-21,"The purpose was to identify barriers including logistical and health belief correlates of late stage presentation of cervical cancer (CxCa) among medically underserved women presenting to a safety net health care system. Women presenting with newly diagnosed CxCa were asked to complete a detailed health belief survey that included questions about barriers to care and their knowledge of CxCa. All information was collected prior to initiating cancer treatment. Comparisons were made among women diagnosed at early stages of disease amendable to surgical treatment (IB1) and those diagnosed at a stage requiring local-regional or systemic/palliative treatment (IB2). Among the 138 women, 21.7% were diagnosed with lB1 disease, while 78.3% were diagnosed with IB2 disease. Late-stage diagnosis was associated with a greater number of emergency room (ER) visits (p<.001) and blood transfusions (p<.001) prior to diagnosis. Compared to 88% with lB1 disease, only 53% of patients with IB2 disease had a car (p=.003). Women with IB2 disease were more likely to be without a primary care provider (75.0% vs. 42.3%, p=.001). Access to transportation and lack of a regular primary care provider or a medical home are associated with late-stage of CxCa at diagnosis. Many medically underserved women continue to use the ER as their primary source of health care, and as a result their CxCa is diagnosed in advanced stages, with higher medical costs and lower chances of cure. The lack of Medicaid expansion in Texas may result in a worsening of this situation.",Journal Article,1553.0,14.0,The purpose was to identify barriers including logistical and health belief correlates of late stage presentation of cancer CxCa among medically underserved women presenting to a safety net health care system Women presenting with newly diagnosed CxCa were asked to complete a detailed health belief survey that included questions about barriers to care and their knowledge of CxCa All information was collected prior to initiating cancer treatment Comparisons were made among women diagnosed at early stages of disease amendable to surgical treatment IB1 and those diagnosed at a stage requiring local-regional or systemic/palliative treatment IB2 Among the 138 women 21.7 were diagnosed with lB1 disease while 78.3 were diagnosed with IB2 disease Late-stage diagnosis was associated with a greater number of emergency room ER visits p .001 and blood transfusions p .001 prior to diagnosis Compared to 88 with lB1 disease only 53 of patients with IB2 disease had a car p=.003 Women with IB2 disease were more likely to be without a primary care provider 75.0 vs. 42.3 p=.001 Access to transportation and lack of a regular primary care provider or a medical home are associated with late-stage of CxCa at diagnosis Many medically underserved women continue to use the ER as their primary source of health care and as a result their CxCa is diagnosed in advanced stages with higher medical costs and lower chances of cure The lack of Medicaid expansion in Texas may result in a worsening of this situation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 743, 10, 6, 255, 2160, 141, 9773, 2, 341, 8862, 1871, 1, 807, 82, 1031, 1, 12, 27479, 107, 4381, 6960, 117, 1656, 6, 8, 367, 2587, 341, 165, 398, 117, 1656, 5, 732, 265, 27479, 11, 3732, 6, 236, 8, 2455, 341, 8862, 1407, 17, 159, 1937, 545, 2160, 6, 165, 2, 136, 922, 1, 27479, 62, 487, 10, 786, 324, 6, 2637, 12, 24, 2213, 11, 1229, 107, 117, 265, 28, 191, 1153, 1, 34, 35866, 6, 221, 24, 67038, 2, 135, 265, 28, 8, 82, 1888, 293, 951, 15, 403, 994, 24, 36124, 107, 3, 4478, 117, 239, 67, 11, 265, 5, 49361, 34, 369, 833, 27, 11, 265, 5, 36124, 34, 807, 82, 147, 10, 41, 5, 8, 378, 207, 1, 4605, 4698, 516, 2690, 19, 144, 2, 315, 4987, 19, 144, 324, 6, 147, 72, 6, 889, 5, 49361, 34, 158, 699, 1, 7, 5, 36124, 34, 42, 8, 1881, 19, 1421, 117, 5, 36124, 34, 11, 80, 322, 6, 40, 187, 8, 86, 165, 3094, 481, 13, 105, 595, 27, 19, 144, 1655, 6, 13964, 2, 926, 1, 8, 3316, 86, 165, 3094, 15, 8, 484, 3249, 32, 41, 5, 807, 82, 1, 27479, 28, 147, 445, 4381, 6960, 117, 1906, 6, 119, 3, 516, 22, 136, 86, 2353, 1, 341, 165, 2, 22, 8, 757, 136, 27479, 16, 265, 4, 131, 1153, 5, 142, 484, 1201, 2, 280, 10726, 1, 1722, 3, 926, 1, 2843, 1422, 4, 2738, 68, 757, 4, 8, 4323, 1, 26, 7747]",1511.0,26498912,829
Role of Indocyanine Green in Sentinel Node Mapping in Gynecologic Cancer: Is Fluorescence Imaging the New Standard?,Journal of minimally invasive gynecology,J Minim Invasive Gynecol,2015-10-28,"Sentinel lymph node biopsy has proven safe and feasible in a number of gynecologic cancers such as vulvar cancer, cervical cancer, and endometrial cancer. The proposed aim of lymphatic mapping and sentinel node identification is to decrease the associated morbidity of a complete lymphadenectomy, particularly the rate of lymphedema, while also increasing the detection of small tumor deposits in the node. Different tracers have been shown to be useful, including technetium-99 and blue dye, with a detection reported in 66% to 86%. Recently, there has been increasing interest in the use of fluorescent dies such as indocyanine green (ICG). In this report we provide a review of the existing literature regarding the use of ICG in cervical or endometrial cancer with the goal to provide details on its utility and compare it with other tracers. ",Journal Article,1546.0,28.0,Sentinel lymph node biopsy has proven safe and feasible in a number of gynecologic cancers such as cancer cancer and cancer The proposed aim of lymphatic mapping and sentinel node identification is to decrease the associated morbidity of a complete lymphadenectomy particularly the rate of lymphedema while also increasing the detection of small tumor deposits in the node Different tracers have been shown to be useful including technetium-99 and blue dye with a detection reported in 66 to 86 Recently there has been increasing interest in the use of fluorescent dies such as indocyanine green ICG In this report we provide a review of the existing literature regarding the use of ICG in or cancer with the goal to provide details on its utility and compare it with other tracers,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[1323, 263, 289, 411, 71, 1930, 1165, 2, 1313, 4, 8, 207, 1, 1512, 163, 225, 22, 12, 12, 2, 12, 3, 1587, 1130, 1, 2936, 2568, 2, 1323, 289, 911, 16, 6, 775, 3, 41, 787, 1, 8, 236, 2048, 823, 3, 116, 1, 3063, 369, 120, 602, 3, 638, 1, 302, 30, 7626, 4, 3, 289, 338, 10089, 47, 85, 443, 6, 40, 999, 141, 11237, 1058, 2, 3352, 3796, 5, 8, 638, 210, 4, 700, 6, 868, 761, 125, 71, 85, 602, 1333, 4, 3, 119, 1, 2910, 67058, 225, 22, 18903, 4658, 9118, 4, 26, 414, 21, 377, 8, 206, 1, 3, 1692, 789, 666, 3, 119, 1, 9118, 4, 15, 12, 5, 3, 1326, 6, 377, 3791, 23, 211, 1207, 2, 932, 192, 5, 127, 10089]",781.0,26518716,215
"Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.",Cancer immunology research,Cancer Immunol Res,2015-11-06,"Inhibition of immune checkpoints, including cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), and its ligand PD-L1, has demonstrated exciting and durable remissions across a spectrum of malignancies. Combinatorial regimens blocking complementary immune checkpoints further enhance the therapeutic benefit. The activity of these agents for patients with glioblastoma, a generally lethal primary brain tumor associated with significant systemic and microenvironmental immunosuppression, is not known. We therefore systematically evaluated the antitumor efficacy of murine antibodies targeting a broad panel of immune checkpoint molecules, including CTLA-4, PD-1, PD-L1, and PD-L2 when administered as single-agent therapy and in combinatorial regimens against an orthotopic, immunocompetent murine glioblastoma model. In these experiments, we observed long-term tumor-free survival following single-agent anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy in 50%, 20%, and 15% of treated animals, respectively. Combination therapy of anti-CTLA-4 plus anti-PD-1 cured 75% of the animals, even against advanced, later-stage tumors. In long-term survivors, tumor growth was not seen upon intracranial tumor rechallenge, suggesting that tumor-specific immune memory responses were generated. Inhibitory immune checkpoint blockade quantitatively increased activated CD8(+) and natural killer cells and decreased suppressive immune cells in the tumor microenvironment and draining cervical lymph nodes. Our results support prioritizing the clinical evaluation of PD-1, PD-L1, and CTLA-4 single-agent targeted therapy as well as combination therapy of CTLA-4 plus PD-1 blockade for patients with glioblastoma.",Journal Article,1537.0,105.0,Inhibition of immune checkpoints including cytotoxic T-lymphocyte antigen-4 CTLA-4 programmed death-1 PD-1 and its ligand PD-L1 has demonstrated exciting and durable remissions across a spectrum of malignancies Combinatorial regimens blocking complementary immune checkpoints further enhance the therapeutic benefit The activity of these agents for patients with glioblastoma a generally lethal primary brain tumor associated with significant systemic and microenvironmental immunosuppression is not known We therefore systematically evaluated the antitumor efficacy of murine antibodies targeting a broad panel of immune checkpoint molecules including CTLA-4 PD-1 PD-L1 and PD-L2 when administered as single-agent therapy and in combinatorial regimens against an orthotopic immunocompetent murine glioblastoma model In these experiments we observed long-term tumor-free survival following single-agent anti-PD-1 anti-PD-L1 or anti-CTLA-4 therapy in 50 20 and 15 of treated animals respectively Combination therapy of anti-CTLA-4 plus anti-PD-1 cured 75 of the animals even against advanced later-stage tumors In long-term survivors tumor growth was not seen upon intracranial tumor rechallenge suggesting that tumor-specific immune memory responses were generated Inhibitory immune checkpoint blockade quantitatively increased activated CD8 and natural killer cells and decreased suppressive immune cells in the tumor microenvironment and draining lymph nodes Our results support prioritizing the clinical evaluation of PD-1 PD-L1 and CTLA-4 single-agent targeted therapy as well as combination therapy of CTLA-4 plus PD-1 blockade for patients with glioblastoma,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[297, 1, 250, 4704, 141, 759, 102, 1448, 448, 39, 2127, 39, 1846, 273, 14, 333, 14, 2, 211, 1232, 333, 729, 71, 264, 4963, 2, 1480, 3166, 716, 8, 1873, 1, 441, 3866, 472, 2521, 3380, 250, 4704, 195, 1304, 3, 189, 247, 3, 128, 1, 46, 183, 9, 7, 5, 996, 8, 1228, 2266, 86, 342, 30, 41, 5, 93, 403, 2, 9300, 3646, 16, 44, 440, 21, 673, 3390, 194, 3, 579, 209, 1, 1471, 890, 529, 8, 2094, 993, 1, 250, 986, 1598, 141, 2127, 39, 333, 14, 333, 729, 2, 333, 5111, 198, 468, 22, 226, 420, 36, 2, 4, 3866, 472, 480, 35, 2157, 6749, 1471, 996, 202, 4, 46, 2332, 21, 164, 319, 337, 30, 115, 25, 366, 226, 420, 312, 333, 14, 312, 333, 729, 15, 312, 2127, 39, 36, 4, 212, 179, 2, 167, 1, 73, 2258, 106, 150, 36, 1, 312, 2127, 39, 349, 312, 333, 14, 3733, 481, 1, 3, 2258, 871, 480, 131, 1559, 82, 57, 4, 319, 337, 332, 30, 129, 10, 44, 527, 1548, 2089, 30, 9423, 802, 17, 30, 112, 250, 2407, 253, 11, 1419, 1810, 250, 986, 1189, 5889, 101, 735, 968, 2, 1504, 3458, 37, 2, 340, 3707, 250, 37, 4, 3, 30, 995, 2, 7535, 263, 502, 114, 99, 538, 14234, 3, 38, 451, 1, 333, 14, 333, 729, 2, 2127, 39, 226, 420, 238, 36, 22, 149, 22, 150, 36, 1, 2127, 39, 349, 333, 14, 1189, 9, 7, 5, 996]",1663.0,26546453,136
Advances and Concepts in Cervical Cancer Trials: A Road Map for the Future.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2016-01-01,"Cervical cancer is responsible for more than a quarter of a million deaths globally each year, mostly in developing countries, making therapeutic advances in all health care settings a top priority. The Gynecologic Cancer InterGroup (GCIG) is a worldwide collaboration of leading national research groups that develops and promotes multinational trials in gynecologic cancer. In recognition of the pressing need for action, the GCIG convened an international meeting with expert representation from the GCIG groups and selected large sites in low- and middle-income countries. The focus was to develop a consensus on several concepts for future clinical trials, which would be developed and promoted by the GCIG and launched with major international participation. The first half of the meeting was devoted to a resume of the current state of the knowledge and identifying the gaps in need of new evidence, validating control arms for present and future clinical trials and identifying national and international barriers for studies of cervix cancers. The second half of the meeting was concerned with achieving consensus on a path forward. There were 5 principal outcomes as follows: first, a proposal to expand fertility-preserving options with neoadjuvant chemotherapy; second, validation of the assessment of sentinel lymph nodes using minimally invasive surgery with an emphasis on identification and management of low-volume metastasis, such as isolated tumor cells and micrometastasis; third, evaluation of hypofractionation for palliative and curative radiation under the umbrella of the GCIG Cervix Cancer Research Network; fourth, adding to the advances in antiangiogenesis therapy in the setting of metastatic disease; and fifth, developing a maintenance study among women at high risk of relapse. The latter 2 systemic interventions could study PI3K (phosphatidylinositol-3-kinase) inhibitors, immunotherapy, anti-human papillomavirus approaches, or novel antiangiogenic agents/combinations.",Consensus Development Conference,1481.0,19.0,cancer is responsible for more than a quarter of a million deaths globally each year mostly in developing countries making therapeutic advances in all health care settings a top priority The Gynecologic Cancer InterGroup GCIG is a worldwide collaboration of leading national research groups that develops and promotes multinational trials in gynecologic cancer In recognition of the pressing need for action the GCIG convened an international meeting with expert representation from the GCIG groups and selected large sites in low- and middle-income countries The focus was to develop a consensus on several concepts for future clinical trials which would be developed and promoted by the GCIG and launched with major international participation The first half of the meeting was devoted to a resume of the current state of the knowledge and identifying the gaps in need of new evidence validating control arms for present and future clinical trials and identifying national and international barriers for studies of cervix cancers The second half of the meeting was concerned with achieving consensus on a path forward There were 5 principal outcomes as follows first a proposal to expand fertility-preserving options with neoadjuvant chemotherapy second validation of the assessment of sentinel lymph nodes using minimally invasive surgery with an emphasis on identification and management of low-volume metastasis such as isolated tumor cells and micrometastasis third evaluation of hypofractionation for palliative and curative radiation under the umbrella of the GCIG Cervix Cancer Research Network fourth adding to the advances in antiangiogenesis therapy in the setting of metastatic disease and fifth developing a maintenance study among women at high risk of relapse The latter 2 systemic interventions could study PI3K phosphatidylinositol-3-kinase inhibitors immunotherapy anti-human papillomavirus approaches or novel antiangiogenic agents/combinations,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 2327, 9, 80, 76, 8, 8034, 1, 8, 3346, 1043, 6873, 296, 111, 2754, 4, 931, 2115, 1079, 189, 954, 4, 62, 341, 165, 1947, 8, 3150, 4690, 3, 1512, 12, 4839, 21695, 16, 8, 2358, 4119, 1, 1049, 657, 389, 271, 17, 4734, 2, 2148, 8243, 143, 4, 1512, 12, 4, 2335, 1, 3, 11446, 594, 9, 1578, 3, 21695, 4440, 35, 944, 2238, 5, 2005, 7768, 29, 3, 21695, 271, 2, 715, 375, 633, 4, 154, 2, 3897, 2306, 2115, 3, 1222, 10, 6, 690, 8, 1391, 23, 392, 5101, 9, 508, 38, 143, 92, 688, 40, 276, 2, 2992, 20, 3, 21695, 2, 13234, 5, 458, 944, 2599, 3, 157, 1303, 1, 3, 2238, 10, 12985, 6, 8, 23726, 1, 3, 291, 1309, 1, 3, 922, 2, 1386, 3, 5287, 4, 594, 1, 217, 241, 6897, 182, 1335, 9, 364, 2, 508, 38, 143, 2, 1386, 657, 2, 944, 2160, 9, 94, 1, 3629, 163, 3, 419, 1303, 1, 3, 2238, 10, 9415, 5, 1785, 1391, 23, 8, 6361, 4674, 125, 11, 33, 4312, 123, 22, 2962, 157, 8, 13383, 6, 4082, 2954, 4972, 838, 5, 536, 56, 419, 929, 1, 3, 455, 1, 1323, 263, 502, 75, 2144, 416, 152, 5, 35, 3136, 23, 911, 2, 284, 1, 154, 433, 278, 225, 22, 1355, 30, 37, 2, 10828, 1282, 451, 1, 7614, 9, 994, 2, 1075, 121, 669, 3, 22449, 1, 3, 21695, 3629, 12, 389, 1801, 3608, 2726, 6, 3, 954, 4, 7351, 36, 4, 3, 546, 1, 113, 34, 2, 5780, 931, 8, 1146, 45, 107, 117, 28, 64, 43, 1, 429, 3, 3286, 18, 403, 1151, 359, 45, 974, 3415, 27, 216, 222, 726, 312, 171, 3242, 611, 15, 229, 2168, 183, 1247]",1964.0,26569057,411
Prevalence and predictors of human papillomavirus (HPV) vaccination among young women surviving childhood cancer.,Journal of cancer survivorship : research and practice,J Cancer Surviv,2015-11-16,"Human papillomavirus (HPV) is a sexually transmitted infection and the cause of cervical and other cancers. Vaccination is available to protect against genital HPV and is recommended for individuals aged 9-26years. This study aimed to estimate the prevalence of HPV vaccination among childhood cancer survivors and to identify factors associated with vaccine outcomes. Young adult females with (n=114; M age=21.18years, SD=2.48) and without (n=98; M age=20.65years, SD=2.29) a childhood cancer history completed surveys querying HPV vaccination initiation/completion, as well as sociodemographic, medical, and health belief factors. Multivariable logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for vaccine outcomes. Among survivors, 38.6% (44/114) and 26.3% (30/114) initiated or completed vaccination compared to 44.9% (44/98) and 28.6% (28/98) among controls, respectively. In the combined survivor/control group, physician recommendation (OR=11.24, 95% CI 3.15-40.14) and familial HPV communication (OR=7.28, 95% CI 1.89-28.05) associated with vaccine initiation. Perceptions of vaccine benefit associated with vaccine completion (OR=10.55, 95% CI 1.59-69.92), whereas perceptions of HPV-related severity associated with non-completion (OR=0.14, 95% CI 0.03-0.71). Despite their increased risk for HPV-related complication, a minority of childhood cancer survivors have initiated or completed HPV vaccination. Modifiable factors associated with vaccine outcomes were identified. HPV vaccination is a useful tool for cancer prevention in survivorship, and interventions to increase vaccine uptake are warranted.",Journal Article,1527.0,3.0,Human papillomavirus HPV is a sexually transmitted infection and the cause of and other cancers Vaccination is available to protect against genital HPV and is recommended for individuals aged 9-26 years This study aimed to estimate the prevalence of HPV vaccination among childhood cancer survivors and to identify factors associated with vaccine outcomes Young adult females with n 114 M age 21.18 years SD 2.48 and without n 98 M age 20.65 years SD 2.29 a childhood cancer history completed surveys querying HPV vaccination initiation/completion as well as sociodemographic medical and health belief factors Multivariable logistic regression was used to calculate odds ratios ORs and 95 confidence intervals CIs for vaccine outcomes Among survivors 38.6 44/114 and 26.3 30/114 initiated or completed vaccination compared to 44.9 44/98 and 28.6 28/98 among controls respectively In the combined survivor/control group physician recommendation OR 11.24 95 CI 3.15-40.14 and familial HPV communication OR 7.28 95 CI 1.89-28.05 associated with vaccine initiation Perceptions of vaccine benefit associated with vaccine completion OR 10.55 95 CI 1.59-69.92 whereas perceptions of HPV-related severity associated with non-completion OR 0.14 95 CI 0.03-0.71 Despite their increased risk for HPV-related complication a minority of childhood cancer survivors have initiated or completed HPV vaccination Modifiable factors associated with vaccine outcomes were identified HPV vaccination is a useful tool for cancer prevention in survivorship and interventions to increase vaccine uptake are warranted,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 3242, 933, 16, 8, 13588, 12959, 930, 2, 3, 708, 1, 2, 127, 163, 1915, 16, 390, 6, 4869, 480, 8226, 933, 2, 16, 793, 9, 869, 1032, 83, 432, 60, 26, 45, 1295, 6, 1191, 3, 1078, 1, 933, 1915, 107, 864, 12, 332, 2, 6, 255, 130, 41, 5, 1274, 123, 1169, 780, 2451, 5, 78, 3803, 188, 89, 239, 203, 60, 1270, 18, 576, 2, 187, 78, 1096, 188, 89, 179, 556, 60, 1270, 18, 462, 8, 864, 12, 532, 781, 3666, 22483, 933, 1915, 1118, 1438, 22, 149, 22, 4221, 484, 2, 341, 8862, 130, 658, 812, 320, 10, 95, 6, 3232, 610, 1137, 3694, 2, 48, 307, 1582, 1927, 9, 1274, 123, 107, 332, 519, 49, 584, 3803, 2, 432, 27, 201, 3803, 1917, 15, 781, 1915, 72, 6, 584, 83, 584, 1096, 2, 339, 49, 339, 1096, 107, 535, 106, 4, 3, 397, 2628, 182, 87, 1473, 3347, 15, 175, 259, 48, 58, 27, 167, 327, 213, 2, 2200, 933, 2063, 15, 67, 339, 48, 58, 14, 887, 339, 474, 41, 5, 1274, 1118, 3746, 1, 1274, 247, 41, 5, 1274, 1438, 15, 79, 614, 48, 58, 14, 728, 790, 937, 547, 3746, 1, 933, 139, 1702, 41, 5, 220, 1438, 15, 13, 213, 48, 58, 13, 680, 13, 792, 550, 136, 101, 43, 9, 933, 139, 1447, 8, 2652, 1, 864, 12, 332, 47, 1917, 15, 781, 933, 1915, 5222, 130, 41, 5, 1274, 123, 11, 108, 933, 1915, 16, 8, 999, 1515, 9, 12, 1070, 4, 2560, 2, 1151, 6, 344, 1274, 1135, 32, 1197]",1592.0,26572902,4
Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods.,BMC infectious diseases,BMC Infect. Dis.,2015-11-25,"Identification of human papillomavirus (HPV) DNA in cervical tissue is important for understanding cervical carcinogenesis and for evaluating cervical cancer prevention approaches. However, HPV genotyping using formalin-fixed, paraffin-embedded (FFPE) tissues is technically challenging. We evaluated the performance of four commonly used genotyping methods on FFPE cervical specimens conducted in different laboratories and compared to genotyping results from cytological samples. We included 60 pairs of exfoliated-cell and FFPE specimens from women with histologically confirmed cervical intraepithelial lesions grade 2 or 3. Cytology specimens were genotyped using the Linear Array assay. Four expert laboratories processed tissue specimens using different preparation methods and then genotyped the resultant sample preparations using four different HPV genotyping methods: SPF10-PCR DEIA LiPA25 (version 1), Inno-LiPA, Linear Array and the Onclarity assay. Percentage agreement, kappa statistics and McNemar's chi-square were calculated for each comparison of different methods and specimen types. Overall agreement with respect to carcinogenic HPV status for FFPE samples between different methods was: 81.7, 86.7 and 91.7% for Onclarity versus Inno-LiPA, Linear Array and SPF-LiPA25, respectively; 81.7 and 85.0% for Linear Array versus Inno-LiPA and SPF-LiPA25, respectively; and 86.7% for SPF-LiPA25 versus Inno-LiPA. Type-specific agreement was >88.3% for all pair-wise comparisons. Comparisons with cytology specimens resulted in overall agreements from 80 to 95% depending on the method and type-specific agreement was >90% for most comparisons. Our data demonstrate that the four genotyping methods run by expert laboratories reliably detect HPV DNA in FFPE specimens with some variation in genotype-specific detection.",Comparative Study,1518.0,24.0,Identification of human papillomavirus HPV DNA in tissue is important for understanding carcinogenesis and for evaluating cancer prevention approaches However HPV genotyping using formalin-fixed paraffin-embedded FFPE tissues is technically challenging We evaluated the performance of four commonly used genotyping methods on FFPE specimens conducted in different laboratories and compared to genotyping results from cytological samples We included 60 pairs of exfoliated-cell and FFPE specimens from women with histologically confirmed intraepithelial lesions grade 2 or 3 Cytology specimens were genotyped using the Linear Array assay Four expert laboratories processed tissue specimens using different preparation methods and then genotyped the resultant sample preparations using four different HPV genotyping methods SPF10-PCR DEIA LiPA25 version 1 Inno-LiPA Linear Array and the Onclarity assay Percentage agreement kappa statistics and McNemar 's chi-square were calculated for each comparison of different methods and specimen types Overall agreement with respect to carcinogenic HPV status for FFPE samples between different methods was 81.7 86.7 and 91.7 for Onclarity versus Inno-LiPA Linear Array and SPF-LiPA25 respectively 81.7 and 85.0 for Linear Array versus Inno-LiPA and SPF-LiPA25 respectively and 86.7 for SPF-LiPA25 versus Inno-LiPA Type-specific agreement was 88.3 for all pair-wise comparisons Comparisons with cytology specimens resulted in overall agreements from 80 to 95 depending on the method and type-specific agreement was 90 for most comparisons Our data demonstrate that the four genotyping methods run by expert laboratories reliably detect HPV DNA in FFPE specimens with some variation in genotype-specific detection,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[911, 1, 171, 3242, 933, 261, 4, 246, 16, 305, 9, 612, 1719, 2, 9, 1435, 12, 1070, 611, 137, 933, 2686, 75, 3265, 1959, 2487, 2505, 4412, 742, 16, 6093, 1950, 21, 194, 3, 528, 1, 294, 841, 95, 2686, 636, 23, 4412, 623, 426, 4, 338, 4884, 2, 72, 6, 2686, 99, 29, 9019, 347, 21, 159, 335, 2773, 1, 24604, 31, 2, 4412, 623, 29, 117, 5, 2161, 557, 4153, 406, 88, 18, 15, 27, 2045, 623, 11, 3053, 75, 3, 1646, 1926, 719, 294, 2005, 4884, 5232, 246, 623, 75, 338, 4824, 636, 2, 818, 3053, 3, 6099, 1000, 7791, 75, 294, 338, 933, 2686, 636, 67230, 604, 67231, 36145, 2256, 14, 23580, 31795, 1646, 1926, 2, 3, 49433, 719, 1150, 2024, 3096, 3065, 2, 10665, 292, 3163, 3219, 11, 981, 9, 296, 1155, 1, 338, 636, 2, 2360, 630, 63, 2024, 5, 2184, 6, 7483, 933, 156, 9, 4412, 347, 59, 338, 636, 10, 865, 67, 868, 67, 2, 970, 67, 9, 49433, 185, 23580, 31795, 1646, 1926, 2, 20578, 36145, 106, 865, 67, 2, 772, 13, 9, 1646, 1926, 185, 23580, 31795, 2, 20578, 36145, 106, 2, 868, 67, 9, 20578, 36145, 185, 23580, 31795, 267, 112, 2024, 10, 889, 27, 9, 62, 4767, 11663, 2213, 2213, 5, 2045, 623, 627, 4, 63, 15739, 29, 493, 6, 48, 3221, 23, 3, 596, 2, 267, 112, 2024, 10, 424, 9, 96, 2213, 114, 74, 608, 17, 3, 294, 2686, 636, 7726, 20, 2005, 4884, 4092, 1426, 933, 261, 4, 4412, 623, 5, 476, 1380, 4, 1183, 112, 638]",1751.0,26607224,479
Impact of Patient Navigation Interventions on Timely Diagnostic Follow Up for Abnormal Cervical Screening.,Journal of women's health (2002),J Womens Health (Larchmt),2015-12-01,"As part of the Patient Navigation Research Program, we examined the effect of patient navigation versus usual care on timely diagnostic follow-up, defined as clinical management for women with cervical abnormalities within accepted time frames. Participants from four Patient Navigation Research Program centers were divided into low- and high-risk abnormality groups and analyzed separately. Low-risk participants (n=2088) were those who enrolled with an initial Pap test finding of atypical squamous cells of undetermined significance (ASCUS) with a positive high-risk human papillomavirus (HPV) serotype, atypical glandular cells, or low-grade squamous intraepithelial lesion (LGSIL). High-risk participants were those with an initial finding of high-grade squamous intraepithelial lesion (HGSIL) (n=229). A dichotomous outcome of timely diagnostic follow-up within 180 days was used for the low-risk abnormality group and timely diagnostic follow-up within 60 days for the high-risk group, consistent with treatment guidelines. A logistic mixed-effects regression model was used to evaluate the intervention effect using a random effect for study arm within an institution. A backward selection process was used for multivariable model building, considering the impact of each predictor on the intervention effect. Low-risk women in the patient navigation arm showed an improvement in the odds of timely diagnostic follow-up across all racial groups, but statistically significant effects were only observed in non-English-speaking Hispanics (OR 5.88, 95% CI 2.81-12.29). No effect was observed among high-risk women. These results suggest that patient navigation can improve timely diagnostic follow-up among women with low-risk cervical abnormalities, particularly in non-English-speaking Hispanic women.",Journal Article,1512.0,5.0,As part of the Patient Navigation Research Program we examined the effect of patient navigation versus usual care on timely diagnostic follow-up defined as clinical management for women with abnormalities within accepted time frames Participants from four Patient Navigation Research Program centers were divided into low- and high-risk abnormality groups and analyzed separately Low-risk participants n 2088 were those who enrolled with an initial Pap test finding of atypical squamous cells of undetermined significance ASCUS with a positive high-risk human papillomavirus HPV serotype atypical glandular cells or low-grade squamous intraepithelial lesion LGSIL High-risk participants were those with an initial finding of high-grade squamous intraepithelial lesion HGSIL n 229 A dichotomous outcome of timely diagnostic follow-up within 180 days was used for the low-risk abnormality group and timely diagnostic follow-up within 60 days for the high-risk group consistent with treatment guidelines A logistic mixed-effects regression model was used to evaluate the intervention effect using a random effect for study arm within an institution A backward selection process was used for multivariable model building considering the impact of each predictor on the intervention effect Low-risk women in the patient navigation arm showed an improvement in the odds of timely diagnostic follow-up across all racial groups but statistically significant effects were only observed in non-English-speaking Hispanics OR 5.88 95 CI 2.81-12.29 No effect was observed among high-risk women These results suggest that patient navigation can improve timely diagnostic follow-up among women with low-risk abnormalities particularly in non-English-speaking Hispanic women,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[22, 760, 1, 3, 69, 5604, 389, 1243, 21, 409, 3, 254, 1, 69, 5604, 185, 3521, 165, 23, 4225, 752, 166, 126, 395, 22, 38, 284, 9, 117, 5, 1171, 262, 3058, 98, 13302, 776, 29, 294, 69, 5604, 389, 1243, 1168, 11, 2176, 237, 154, 2, 64, 43, 3698, 271, 2, 311, 3582, 154, 43, 776, 78, 67254, 11, 135, 54, 346, 5, 35, 388, 4290, 412, 1567, 1, 1973, 691, 37, 1, 5206, 724, 21337, 5, 8, 109, 64, 43, 171, 3242, 933, 18590, 1973, 6170, 37, 15, 154, 88, 691, 4153, 1180, 67255, 64, 43, 776, 11, 135, 5, 35, 388, 1567, 1, 64, 88, 691, 4153, 1180, 67256, 78, 7584, 8, 14455, 228, 1, 4225, 752, 166, 126, 262, 3172, 162, 10, 95, 9, 3, 154, 43, 3698, 87, 2, 4225, 752, 166, 126, 262, 335, 162, 9, 3, 64, 43, 87, 925, 5, 24, 677, 8, 812, 1739, 176, 320, 202, 10, 95, 6, 376, 3, 788, 254, 75, 8, 2324, 254, 9, 45, 475, 262, 35, 731, 8, 10877, 881, 1129, 10, 95, 9, 658, 202, 5808, 3075, 3, 345, 1, 296, 980, 23, 3, 788, 254, 154, 43, 117, 4, 3, 69, 5604, 475, 224, 35, 767, 4, 3, 610, 1, 4225, 752, 166, 126, 716, 62, 2257, 271, 84, 712, 93, 176, 11, 158, 164, 4, 220, 4201, 8519, 3850, 15, 33, 889, 48, 58, 18, 865, 133, 462, 77, 254, 10, 164, 107, 64, 43, 117, 46, 99, 309, 17, 69, 5604, 122, 401, 4225, 752, 166, 126, 107, 117, 5, 154, 43, 1171, 823, 4, 220, 4201, 8519, 1776, 117]",1758.0,26625131,565
High-resolution microendoscopy: a point-of-care diagnostic for cervical dysplasia in low-resource settings.,European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP),Eur. J. Cancer Prev.,2017-01-01,"Cervical cancer is the third leading cause of cancer-related death among women in low-to-middle income countries. Pap testing and pathological services are difficult to implement under these settings. Alternative techniques for the diagnosis of cervical precancer in these settings are needed to reduce the burden of the disease. The objective of this study was to evaluate the diagnostic accuracy of a low-cost, high-resolution microendoscope imaging system in identifying precancerous lesions of the cervix in vivo. A retrospective study of 59 patients undergoing colposcopy for an abnormal Pap test was performed at Hospital de Cncer de Barretos in Brazil. All patients underwent colposcopy as per standard of care, and acetowhite lesions were recorded. High-resolution microendoscopy (HRME) images were obtained from one colposcopically normal region and from all lesions observed on colposcopy. Biopsies of abnormal areas were obtained and reviewed by three independent, blinded pathologists and compared with HRME findings. The mean nuclear area and the median nuclear eccentricity were calculated from HRME images acquired from each site. A diagnostic algorithm to distinguish histopathologically diagnosed cervical intraepithelial neoplasias of grade 2 or more severe lesions (high grade) from less severe lesions (low grade) was developed using these parameters. A test of trend was used to analyze the relationship between HRME positivity and severity of histopathogical diagnosis. Fisher's exact test was used to analyze differences in HRME positivity between high-grade and low-grade lesions. Evaluable images were obtained from 108 of 143 discrete sites. Of these, 71 sites were colposcopically normal or low grade according to histopathology and 37 were diagnosed as high grade on the basis of histopathology. Using the mean nuclear area and the median nuclear eccentricity, HRME images from 59 colposcopically abnormal sites were classified as high grade or low grade with 92% sensitivity and 77% specificity compared with histopathological findings. Increasing HRME positivity showed a significant trend with increasing severity of diagnosis (Ptrend<0.001). We found a strong association (P<0.001) between HRME positivity and a histopathological diagnosis of cervical intraepithelial neoplasia of grade 2 or higher. HRME demonstrated an accurate in-situ diagnosis of high-grade dysplasia. In low-resource settings in which colposcopy and histopathology services are severely limited or unavailable, HRME may provide a low-cost, accurate method for diagnosis of cervical precancer without the need for biopsy, allowing for a single 'screen-and-treat' approach.",Journal Article,1115.0,12.0,cancer is the third leading cause of cancer-related death among women in low-to-middle income countries Pap testing and pathological services are difficult to implement under these settings Alternative techniques for the diagnosis of precancer in these settings are needed to reduce the burden of the disease The objective of this study was to evaluate the diagnostic accuracy of a low-cost high-resolution microendoscope imaging system in identifying precancerous lesions of the cervix in vivo A retrospective study of 59 patients undergoing colposcopy for an abnormal Pap test was performed at Hospital de Cncer de Barretos in Brazil All patients underwent colposcopy as per standard of care and acetowhite lesions were recorded High-resolution microendoscopy HRME images were obtained from one colposcopically normal region and from all lesions observed on colposcopy Biopsies of abnormal areas were obtained and reviewed by three independent blinded pathologists and compared with HRME findings The mean nuclear area and the median nuclear eccentricity were calculated from HRME images acquired from each site A diagnostic algorithm to distinguish histopathologically diagnosed intraepithelial neoplasias of grade 2 or more severe lesions high grade from less severe lesions low grade was developed using these parameters A test of trend was used to analyze the relationship between HRME positivity and severity of histopathogical diagnosis Fisher 's exact test was used to analyze differences in HRME positivity between high-grade and low-grade lesions Evaluable images were obtained from 108 of 143 discrete sites Of these 71 sites were colposcopically normal or low grade according to histopathology and 37 were diagnosed as high grade on the basis of histopathology Using the mean nuclear area and the median nuclear eccentricity HRME images from 59 colposcopically abnormal sites were classified as high grade or low grade with 92 sensitivity and 77 specificity compared with histopathological findings Increasing HRME positivity showed a significant trend with increasing severity of diagnosis Ptrend 0.001 We found a strong association P 0.001 between HRME positivity and a histopathological diagnosis of intraepithelial neoplasia of grade 2 or higher HRME demonstrated an accurate in-situ diagnosis of high-grade dysplasia In low-resource settings in which colposcopy and histopathology services are severely limited or unavailable HRME may provide a low-cost accurate method for diagnosis of precancer without the need for biopsy allowing for a single 'screen-and-treat approach,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 3, 1282, 1049, 708, 1, 12, 139, 273, 107, 117, 4, 154, 6, 3897, 2306, 2115, 4290, 471, 2, 1301, 2142, 32, 1740, 6, 6207, 669, 46, 1947, 1091, 1092, 9, 3, 147, 1, 12380, 4, 46, 1947, 32, 575, 6, 969, 3, 892, 1, 3, 34, 3, 461, 1, 26, 45, 10, 6, 376, 3, 752, 1190, 1, 8, 154, 835, 64, 2125, 19487, 270, 398, 4, 1386, 6605, 406, 1, 3, 3629, 4, 386, 8, 459, 45, 1, 728, 7, 479, 9946, 9, 35, 1668, 4290, 412, 10, 173, 28, 702, 1566, 67271, 1566, 32336, 4, 10452, 62, 7, 208, 9946, 22, 379, 260, 1, 165, 2, 48696, 406, 11, 1872, 64, 2125, 24180, 12049, 1572, 11, 683, 29, 104, 26091, 295, 1053, 2, 29, 62, 406, 164, 23, 9946, 1154, 1, 1668, 1361, 11, 683, 2, 446, 20, 169, 306, 3288, 3354, 2, 72, 5, 12049, 272, 3, 313, 928, 965, 2, 3, 52, 928, 40163, 11, 981, 29, 12049, 1572, 1294, 29, 296, 606, 8, 752, 2124, 6, 3081, 8631, 265, 4153, 8235, 1, 88, 18, 15, 80, 905, 406, 64, 88, 29, 299, 905, 406, 154, 88, 10, 276, 75, 46, 1038, 8, 412, 1, 853, 10, 95, 6, 1992, 3, 858, 59, 12049, 1887, 2, 1702, 1, 40734, 147, 3135, 292, 2472, 412, 10, 95, 6, 1992, 362, 4, 12049, 1887, 59, 64, 88, 2, 154, 88, 406, 859, 1572, 11, 683, 29, 3590, 1, 4400, 5447, 633, 1, 46, 792, 633, 11, 26091, 295, 15, 154, 88, 768, 6, 3831, 2, 567, 11, 265, 22, 64, 88, 23, 3, 877, 1, 3831, 75, 3, 313, 928, 965, 2, 3, 52, 928, 40163, 12049, 1572, 29, 728, 26091, 1668, 633, 11, 1373, 22, 64, 88, 15, 154, 88, 5, 937, 485, 2, 849, 1121, 72, 5, 4370, 272, 602, 12049, 1887, 224, 8, 93, 853, 5, 602, 1702, 1, 147, 6197, 13, 144, 21, 204, 8, 1082, 248, 19, 13, 144, 59, 12049, 1887, 2, 8, 4370, 147, 1, 4153, 2298, 1, 88, 18, 15, 142, 12049, 264, 35, 1481, 4, 957, 147, 1, 64, 88, 2253, 4, 154, 3069, 1947, 4, 92, 9946, 2, 3831, 2142, 32, 7207, 383, 15, 9098, 12049, 68, 377, 8, 154, 835, 1481, 596, 9, 147, 1, 12380, 187, 3, 594, 9, 411, 2952, 9, 8, 226, 67272, 2, 943, 353]",2592.0,26637074,45
Documentation of Pregnancy Risk Assessment and Pregnancy Among Women Presenting for Gynecologic Oncology Consultation.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2016-01-01,"The aim of the study was to describe pregnancy risk assessment, reproductive goals, and incidence of pregnancy among the reproductive age population seen by gynecologic oncologists at a tertiary care center. A retrospective chart review was conducted among 18- to 45-year-old women evaluated by a gynecologic oncologist from January 2000 to December 2011. Data abstracted included the following: diagnosis, cancer treatment, parity, pregnancy risk factors (eg, menstrual patterns, sexual activity, and use of contraception), reproductive goals, type of referral, and pregnancy. Descriptive statistics were used to describe the characteristics of the population. Five hundred seventeen women were eligible and included in the review. Median age was 31 years with most common diagnoses being cervical cancer, endometrial cancer, and premalignant disease. Most patients are multiparous. Seventy percent were treated surgically, with 58% experiencing surgical sterility. Completeness of reproductive data documented at initial visit included the following: 47% with a contraception plan, 54% sexual activity/practices, and 37% with personal reproductive goals reviewed. Fifteen patients were pregnant at the initial visit, and 21 patients pregnant during follow-up, representing 43 pregnancies (9 patients had more than 1 pregnancy). For those maintaining fertility after the initial visit, there was a median (range) of 2 (0-25) visits with 32% documenting a contraception plan at follow-up visits. A patient's reproductive goals and risk factors for pregnancy are inconsistently addressed during initial consultation with the gynecologic oncologist. This lack of consistency potentially increases patients' risk for unplanned pregnancy during evaluation and treatment of a gynecologic cancer diagnosis and potentially results in a missed opportunity for fertility preservation. Planned and unplanned pregnancy occurs in this population at a rate similar to that of US women of reproductive age, underscoring the need for reproductive counseling in this population.",Journal Article,1481.0,2.0,The aim of the study was to describe pregnancy risk assessment reproductive goals and incidence of pregnancy among the reproductive age population seen by gynecologic oncologists at a tertiary care center A retrospective chart review was conducted among 18- to 45-year-old women evaluated by a gynecologic oncologist from January 2000 to December 2011 Data abstracted included the following diagnosis cancer treatment parity pregnancy risk factors eg menstrual patterns sexual activity and use of contraception reproductive goals type of referral and pregnancy Descriptive statistics were used to describe the characteristics of the population Five hundred seventeen women were eligible and included in the review Median age was 31 years with most common diagnoses being cancer cancer and premalignant disease Most patients are multiparous Seventy percent were treated surgically with 58 experiencing surgical sterility Completeness of reproductive data documented at initial visit included the following 47 with a contraception plan 54 sexual activity/practices and 37 with personal reproductive goals reviewed Fifteen patients were pregnant at the initial visit and 21 patients pregnant during follow-up representing 43 pregnancies 9 patients had more than 1 pregnancy For those maintaining fertility after the initial visit there was a median range of 2 0-25 visits with 32 documenting a contraception plan at follow-up visits A patient 's reproductive goals and risk factors for pregnancy are inconsistently addressed during initial consultation with the gynecologic oncologist This lack of consistency potentially increases patients risk for unplanned pregnancy during evaluation and treatment of a gynecologic cancer diagnosis and potentially results in a missed opportunity for fertility preservation Planned and unplanned pregnancy occurs in this population at a rate similar to that of US women of reproductive age underscoring the need for reproductive counseling in this population,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 1130, 1, 3, 45, 10, 6, 897, 2290, 43, 455, 3705, 2802, 2, 287, 1, 2290, 107, 3, 3705, 89, 266, 527, 20, 1512, 1339, 28, 8, 2557, 165, 574, 8, 459, 2937, 206, 10, 426, 107, 203, 6, 512, 111, 1095, 117, 194, 20, 8, 1512, 2709, 29, 1024, 1081, 6, 1397, 1132, 74, 4106, 159, 3, 366, 147, 12, 24, 5754, 2290, 43, 130, 2887, 8518, 764, 2232, 128, 2, 119, 1, 21441, 3705, 2802, 267, 1, 2096, 2, 2290, 3778, 3065, 11, 95, 6, 897, 3, 374, 1, 3, 266, 365, 1128, 3591, 117, 11, 625, 2, 159, 4, 3, 206, 52, 89, 10, 456, 60, 5, 96, 186, 2403, 486, 12, 12, 2, 4343, 34, 96, 7, 32, 40038, 2073, 714, 11, 73, 2350, 5, 717, 2985, 221, 30680, 7507, 1, 3705, 74, 1405, 28, 388, 2807, 159, 3, 366, 662, 5, 8, 21441, 2242, 667, 2232, 128, 2634, 2, 567, 5, 3008, 3705, 2802, 446, 3057, 7, 11, 6086, 28, 3, 388, 2807, 2, 239, 7, 6086, 190, 166, 126, 2861, 601, 8746, 83, 7, 42, 80, 76, 14, 2290, 9, 135, 3284, 2954, 50, 3, 388, 2807, 125, 10, 8, 52, 184, 1, 18, 13, 243, 2690, 5, 531, 9255, 8, 21441, 2242, 28, 166, 126, 2690, 8, 69, 292, 3705, 2802, 2, 43, 130, 9, 2290, 32, 12399, 2814, 190, 388, 2981, 5, 3, 1512, 2709, 26, 926, 1, 5358, 751, 1106, 7, 43, 9, 5851, 2290, 190, 451, 2, 24, 1, 8, 1512, 12, 147, 2, 751, 99, 4, 8, 5149, 2666, 9, 2954, 2224, 1465, 2, 5851, 2290, 1780, 4, 26, 266, 28, 8, 116, 288, 6, 17, 1, 843, 117, 1, 3705, 89, 8369, 3, 594, 9, 3705, 2011, 4, 26, 266]",1992.0,26658364,442
Effectiveness of Chinese herbal medicine for cancer palliative care: overview of systematic reviews with meta-analyses.,Scientific reports,Sci Rep,2015-12-16,"Chinese herbal medicines (CHM) are often used in managing cancer related symptoms but their effectiveness and safety is controversial. We conducted this overview of meta-analyses to summarize evidence on CHM for cancer palliative care. We included systematic reviews (SRs) with meta-analyses of CHM clinical trials on patients diagnosed with any type of cancer. Methodological quality of included meta-analyses was assessed with the Methodological Quality of Systematic Reviews (AMSTAR) Instrument. Fifty-one SRs with meta-analyses were included. They covered patients with lung (20SRs), gastric (8SRs), colorectal (6SRs), liver (6SRs), breast (2SRs), cervical (1SR), esophageal (1SR), and nasopharyngeal (1SR) cancers. Six SRs summarized evidence on various types of cancer. Methodological quality of included meta-analyses was not satisfactory. Overall, favorable therapeutic effects in improving quality of life among cancer patients have been reported. Conflicting evidence exists for the effectiveness of CHM in prolonging survival and in reducing chemotherapy and/or radiotherapy related toxicities. No serious adverse effects were reported in all included studies. Evidence indicated that CHM could be considered as an option for improving quality of life among patients receiving palliative care. It is unclear if CHM may increase survival, or reduce therapy related toxicities. ",Journal Article,1497.0,15.0,Chinese herbal medicines CHM are often used in managing cancer related symptoms but their effectiveness and safety is controversial We conducted this overview of meta-analyses to summarize evidence on CHM for cancer palliative care We included systematic reviews SRs with meta-analyses of CHM clinical trials on patients diagnosed with any type of cancer Methodological quality of included meta-analyses was assessed with the Methodological Quality of Systematic Reviews AMSTAR Instrument Fifty-one SRs with meta-analyses were included They covered patients with 20 SRs 8 SRs 6 SRs 6 SRs 2 SRs 1 SR 1 SR and 1 SR cancers Six SRs summarized evidence on various types of cancer Methodological quality of included meta-analyses was not satisfactory Overall favorable therapeutic effects in improving quality of life among cancer patients have been reported Conflicting evidence exists for the effectiveness of CHM in prolonging survival and in reducing chemotherapy and/or radiotherapy related toxicities No serious adverse effects were reported in all included studies Evidence indicated that CHM could be considered as an option for improving quality of life among patients receiving palliative care It is unclear if CHM may increase survival or reduce therapy related toxicities,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,"[3656, 10146, 11478, 13460, 32, 629, 95, 4, 3969, 12, 139, 507, 84, 136, 1236, 2, 367, 16, 2010, 21, 426, 26, 2901, 1, 1742, 318, 6, 2479, 241, 23, 13460, 9, 12, 994, 165, 21, 159, 1556, 2004, 1429, 5, 1742, 318, 1, 13460, 38, 143, 23, 7, 265, 5, 500, 267, 1, 12, 8470, 372, 1, 159, 1742, 318, 10, 275, 5, 3, 8470, 372, 1, 1556, 2004, 49001, 3877, 1461, 104, 1429, 5, 1742, 318, 11, 159, 491, 4306, 7, 5, 179, 1429, 66, 1429, 49, 1429, 49, 1429, 18, 1429, 14, 7460, 14, 7460, 2, 14, 7460, 163, 437, 1429, 3989, 241, 23, 747, 630, 1, 12, 8470, 372, 1, 159, 1742, 318, 10, 44, 7972, 63, 913, 189, 176, 4, 1673, 372, 1, 358, 107, 12, 7, 47, 85, 210, 4274, 241, 2481, 9, 3, 1236, 1, 13460, 4, 5559, 25, 2, 4, 1818, 56, 2, 15, 310, 139, 385, 77, 1762, 290, 176, 11, 210, 4, 62, 159, 94, 241, 1103, 17, 13460, 359, 40, 515, 22, 35, 1501, 9, 1673, 372, 1, 358, 107, 7, 357, 994, 165, 192, 16, 1200, 492, 13460, 68, 344, 25, 15, 969, 36, 139, 385]",1278.0,26669761,99
Cervical cancer control in Latin America: A call to action.,Cancer,Cancer,2015-12-15,"Cervical cancer (CC) is second most common cause of cancer in Latin America and is a leading cause of cancer mortality among women. In 2015, an estimated 74,488 women will be diagnosed with CC in Latin America and 31,303 will die of the disease. CC mortality is projected to increase by 45% by 2030 despite human papillomavirus (HPV) vaccination and screening efforts. In this setting, the goal was of the current study was to examine CC control efforts in Latin America and identify deficiencies in these efforts that could be addressed to reduce CC incidence and mortality. The authors found that HPV vaccination has been introduced in the majority of Latin American countries, and there is now a need to monitor the success (or shortcomings) of these programs and to ensure that these programs are sustainable. This topic was also reviewed in light of emerging data demonstrating that visual inspection with acetic acid and HPV DNA testing without Papanicolaou tests have efficacy from a screening perspective and are good alternatives to cytology-based screening programs. Overall, there is a need to build capacity for CC control in Latin America and the best strategy will depend on the country/region and must be tailored to meet the needs of the population as well as available resources.",Journal Article,1498.0,18.0,"cancer CC is second most common cause of cancer in Latin America and is a leading cause of cancer mortality among women In 2015 an estimated 74,488 women will be diagnosed with CC in Latin America and 31,303 will die of the disease CC mortality is projected to increase by 45 by 2030 despite human papillomavirus HPV vaccination and screening efforts In this setting the goal was of the current study was to examine CC control efforts in Latin America and identify deficiencies in these efforts that could be addressed to reduce CC incidence and mortality The authors found that HPV vaccination has been introduced in the majority of Latin American countries and there is now a need to monitor the success or shortcomings of these programs and to ensure that these programs are sustainable This topic was also reviewed in light of emerging data demonstrating that visual inspection with acetic acid and HPV DNA testing without Papanicolaou tests have efficacy from a screening perspective and are good alternatives to cytology-based screening programs Overall there is a need to build capacity for CC control in Latin America and the best strategy will depend on the country/region and must be tailored to meet the needs of the population as well as available resources",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 1951, 16, 419, 96, 186, 708, 1, 12, 4, 10870, 4010, 2, 16, 8, 1049, 708, 1, 12, 282, 107, 117, 4, 1483, 35, 661, 794, 9620, 117, 303, 40, 265, 5, 1951, 4, 10870, 4010, 2, 456, 9044, 303, 3384, 1, 3, 34, 1951, 282, 16, 5633, 6, 344, 20, 512, 20, 15976, 550, 171, 3242, 933, 1915, 2, 453, 1413, 4, 26, 546, 3, 1326, 10, 1, 3, 291, 45, 10, 6, 1004, 1951, 182, 1413, 4, 10870, 4010, 2, 255, 7159, 4, 46, 1413, 17, 359, 40, 2814, 6, 969, 1951, 287, 2, 282, 3, 738, 204, 17, 933, 1915, 71, 85, 3955, 4, 3, 686, 1, 10870, 597, 2115, 2, 125, 16, 1134, 8, 594, 6, 3334, 3, 1825, 15, 12023, 1, 46, 2251, 2, 6, 3478, 17, 46, 2251, 32, 13226, 26, 5463, 10, 120, 446, 4, 1691, 1, 1478, 74, 2219, 17, 3046, 11746, 5, 16812, 971, 2, 933, 261, 471, 187, 10416, 895, 47, 209, 29, 8, 453, 3727, 2, 32, 1178, 6295, 6, 2045, 90, 453, 2251, 63, 125, 16, 8, 594, 6, 5867, 2162, 9, 1951, 182, 4, 10870, 4010, 2, 3, 824, 692, 303, 4533, 23, 3, 5978, 1053, 2, 1642, 40, 3632, 6, 3362, 3, 1891, 1, 3, 266, 22, 149, 22, 390, 2892]",1269.0,26670695,607
Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2015-12-01,"In the randomized phase III trial, Gynecologic Oncology Group (GOG) protocol 240, the incorporation of bevacizumab with chemotherapy significantly increased overall survival (OS) in women with advanced cervical cancer. A major objective of GOG-240 was to prospectively analyze previously identified pooled clinical prognostic factors known as the Moore criteria. Potential negative factors included black race, performance status 1, pelvic disease, prior cisplatin, and progression-free interval <365 days. Risk categories included low-risk (0-1 factor), mid-risk (2-3 factors), and high-risk (4-5 factors). Each test of association was conducted at the 5% level of significance. Logistic regression and survival analysis was used to determine whether factors were prognostic or could be used to guide therapy. For the entire population (n = 452), high-risk patients had significantly worse OS (P < 0.0001). The HRs of death for treating with topotecan in low-risk, mid-risk, and high-risk subsets are 1.18 [95% confidence interval (CI), 0.63-2.24], 1.11 (95% CI, 0.82-1.5), and 0.84 (95% CI, 0.50-1.42), respectively. The HRs of death for treating with bevacizumab in low-risk, mid-risk, and high-risk subsets are 0.96 (95% CI, 0.51-1.83; P = 0.9087), 0.673 (95% CI, 0.5-0.91; P = 0.0094), and 0.536 (95% CI, 0.32-0.905; P = 0.0196), respectively. This is the first prospectively validated scoring system in cervical cancer. The Moore criteria have real-world clinical applicability. Toxicity concerns may justify omission of bevacizumab in some low-risk patients where survival benefit is small. The benefit to receiving bevacizumab appears to be greatest in the moderate- and high-risk subgroups (5.8-month increase in median OS). Clin Cancer Res; 21(24); 5480-7. 2015 AACR.","Clinical Trial, Phase III",1512.0,27.0,In the randomized phase III trial Gynecologic Oncology Group GOG protocol 240 the incorporation of bevacizumab with chemotherapy significantly increased overall survival OS in women with advanced cancer A major objective of GOG-240 was to prospectively analyze previously identified pooled clinical prognostic factors known as the Moore criteria Potential negative factors included black race performance status 1 pelvic disease prior cisplatin and progression-free interval 365 days Risk categories included low-risk 0-1 factor mid-risk 2-3 factors and high-risk 4-5 factors Each test of association was conducted at the 5 level of significance Logistic regression and survival analysis was used to determine whether factors were prognostic or could be used to guide therapy For the entire population n 452 high-risk patients had significantly worse OS P 0.0001 The HRs of death for treating with topotecan in low-risk mid-risk and high-risk subsets are 1.18 95 confidence interval CI 0.63-2.24 1.11 95 CI 0.82-1.5 and 0.84 95 CI 0.50-1.42 respectively The HRs of death for treating with bevacizumab in low-risk mid-risk and high-risk subsets are 0.96 95 CI 0.51-1.83 P 0.9087 0.673 95 CI 0.5-0.91 P 0.0094 and 0.536 95 CI 0.32-0.905 P 0.0196 respectively This is the first prospectively validated scoring system in cancer The Moore criteria have real-world clinical applicability Toxicity concerns may justify omission of bevacizumab in some low-risk patients where survival benefit is small The benefit to receiving bevacizumab appears to be greatest in the moderate- and high-risk subgroups 5.8-month increase in median OS Clin Cancer Res 21 24 5480-7 2015 AACR,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4, 3, 384, 124, 316, 160, 1512, 413, 87, 4760, 1182, 4263, 3, 2838, 1, 599, 5, 56, 97, 101, 63, 25, 118, 4, 117, 5, 131, 12, 8, 458, 461, 1, 4760, 4263, 10, 6, 1143, 1992, 373, 108, 1830, 38, 177, 130, 440, 22, 3, 41289, 371, 174, 199, 130, 159, 1445, 1047, 528, 156, 14, 1110, 34, 324, 540, 2, 91, 115, 268, 7405, 162, 43, 1996, 159, 154, 43, 13, 14, 161, 4863, 43, 18, 27, 130, 2, 64, 43, 39, 33, 130, 296, 412, 1, 248, 10, 426, 28, 3, 33, 301, 1, 724, 812, 320, 2, 25, 65, 10, 95, 6, 223, 317, 130, 11, 177, 15, 359, 40, 95, 6, 1597, 36, 9, 3, 1797, 266, 78, 12638, 64, 43, 7, 42, 97, 639, 118, 19, 13, 488, 3, 2733, 1, 273, 9, 1367, 5, 2129, 4, 154, 43, 4863, 43, 2, 64, 43, 1890, 32, 14, 203, 48, 307, 268, 58, 13, 676, 18, 259, 14, 175, 48, 58, 13, 878, 14, 33, 2, 13, 874, 48, 58, 13, 212, 14, 595, 106, 3, 2733, 1, 273, 9, 1367, 5, 599, 4, 154, 43, 4863, 43, 2, 64, 43, 1890, 32, 13, 921, 48, 58, 13, 725, 14, 852, 19, 13, 44052, 13, 14267, 48, 58, 13, 33, 13, 970, 19, 13, 28383, 2, 13, 11274, 48, 58, 13, 531, 13, 13300, 19, 13, 30957, 106, 26, 16, 3, 157, 1143, 938, 2504, 398, 4, 12, 3, 41289, 371, 47, 1589, 1956, 38, 5412, 155, 2061, 68, 6665, 5736, 1, 599, 4, 476, 154, 43, 7, 1257, 25, 247, 16, 302, 3, 247, 6, 357, 599, 1233, 6, 40, 2199, 4, 3, 1163, 2, 64, 43, 1453, 33, 66, 811, 344, 4, 52, 118, 2459, 12, 1936, 239, 259, 67313, 67, 18091, 1630]",1666.0,26672085,144
When to Treat Adults Like Children: Optimizing Therapy for Lymphoblastic Lymphoma in Young Adults.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2015-12-23,"A 23-year-old man was urgently referred for evaluation of rapidly enlarging cervical lymphadenopathy, progressive dyspnea, fatigue, night sweats, and an unintentional weight loss of 25 pounds. A computed tomography scan of the neck performed 30 days before referral revealed bilateral cervical and supraclavicular lymphadenopathy (6  5 cm). A fine-needle aspirate of nasopharyngeal tissue demonstrated fibroadipose tissue. Tissue collected by core needle biopsy of a left internal jugular lymph node demonstrated a reactive lymph node but no malignancy. The patient was admitted to an academic medical center hospital. His physical examination was remarkable for bulky cervical and supraclavicular lymphadenopathy. A testicular examination was normal. The patient's lactate dehydrogenase concentration was 327 U/L (normal range, 118-225 U/L). A positron emission tomography scan revealed bilateral cervical and supraclavicular lymphadenopathy (6  5 cm with a standardized uptake value [SUV] of 14), a 1.3-cm subcutaneous nodule in the left thigh (SUV 16), and two 2.7-cm liver lesions (SUV 14). He underwent an excisional lymph node biopsy. The lymph node revealed effacement of the architecture by an interfollicular infiltrate of lymphoid cells (Fig 1). Mitotic figures were abundant (Ki-67 stain 80% to 90% positive) and there were multiple foci of tissue necrosis. The lymphoblasts were examined by flow cytometry and immunohistochemistry and expressed the T-cell markers CD2, CD3, CD4, and terminal deoxynucleotidyl transferase. A subpopulation of T cells was positive for both CD4 and CD8. Polymerase chain reaction studies revealed a clonal rearrangement of the T-cell receptor  gene. A marrow aspirate and biopsy revealed normal trilineage hematopoiesis with no evidence of lymphoma and a normal male karyotype (46, XY). A lumbar puncture sample did not contain lymphoma cells. The patient's diagnosis was T-lymphoblastic lymphoma.",Case Reports,1490.0,2.0,A 23-year-old man was urgently referred for evaluation of rapidly enlarging lymphadenopathy progressive dyspnea fatigue night sweats and an unintentional weight loss of 25 pounds A computed tomography scan of the performed 30 days before referral revealed bilateral and supraclavicular lymphadenopathy 6 5 cm A fine-needle aspirate of tissue demonstrated fibroadipose tissue Tissue collected by core needle biopsy of a left internal jugular lymph node demonstrated a reactive lymph node but no malignancy The patient was admitted to an academic medical center hospital His physical examination was remarkable for bulky and supraclavicular lymphadenopathy A examination was normal The patient 's lactate dehydrogenase concentration was 327 U/L normal range 118-225 U/L A positron emission tomography scan revealed bilateral and supraclavicular lymphadenopathy 6 5 cm with a standardized uptake value SUV of 14 a 1.3-cm subcutaneous nodule in the left thigh SUV 16 and two 2.7-cm lesions SUV 14 He underwent an excisional lymph node biopsy The lymph node revealed effacement of the architecture by an interfollicular infiltrate of lymphoid cells Fig 1 Mitotic figures were abundant Ki-67 stain 80 to 90 positive and there were multiple foci of tissue necrosis The lymphoblasts were examined by flow cytometry and immunohistochemistry and expressed the T-cell markers CD2 CD3 CD4 and terminal deoxynucleotidyl transferase A subpopulation of T cells was positive for both CD4 and CD8 Polymerase chain reaction studies revealed a clonal rearrangement of the T-cell receptor  gene A marrow aspirate and biopsy revealed normal trilineage hematopoiesis with no evidence of and a normal male karyotype 46 XY A lumbar puncture sample did not contain cells The patient 's diagnosis was T-lymphoblastic,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[8, 382, 111, 1095, 3628, 10, 5354, 1995, 9, 451, 1, 1755, 11961, 4962, 1014, 2923, 613, 8955, 13298, 2, 35, 17350, 924, 407, 1, 243, 16715, 8, 1220, 872, 1657, 1, 3, 173, 201, 162, 348, 2096, 553, 1607, 2, 5804, 4962, 49, 33, 494, 8, 2924, 2177, 8022, 1, 246, 264, 30479, 246, 246, 786, 20, 1793, 2177, 411, 1, 8, 1712, 2329, 21384, 263, 289, 264, 8, 2163, 263, 289, 84, 77, 710, 3, 69, 10, 4319, 6, 35, 1916, 484, 574, 702, 3224, 900, 1385, 10, 3813, 9, 4112, 2, 5804, 4962, 8, 1385, 10, 295, 3, 69, 292, 3330, 2374, 1227, 10, 7749, 1767, 805, 295, 184, 4002, 4011, 1767, 805, 8, 1900, 1799, 872, 1657, 553, 1607, 2, 5804, 4962, 49, 33, 494, 5, 8, 1670, 1135, 549, 2217, 1, 213, 8, 14, 27, 494, 2529, 5072, 4, 3, 1712, 11674, 2217, 245, 2, 100, 18, 67, 494, 406, 2217, 213, 3174, 208, 35, 6488, 263, 289, 411, 3, 263, 289, 553, 29097, 1, 3, 4447, 20, 35, 30633, 5172, 1, 2303, 37, 14197, 14, 2346, 9446, 11, 4834, 2311, 598, 8763, 493, 6, 424, 109, 2, 125, 11, 232, 3340, 1, 246, 1523, 3, 10521, 11, 409, 20, 1412, 1914, 2, 888, 2, 570, 3, 102, 31, 525, 11048, 3117, 1440, 2, 2158, 10655, 4402, 8, 5518, 1, 102, 37, 10, 109, 9, 110, 1440, 2, 968, 1451, 1260, 1329, 94, 553, 8, 1946, 2675, 1, 3, 102, 31, 153, 2655, 145, 8, 581, 8022, 2, 411, 553, 295, 21950, 5114, 5, 77, 241, 1, 2, 8, 295, 1045, 3385, 641, 26388, 8, 6187, 12104, 1000, 205, 44, 3725, 37, 3, 69, 292, 147, 10, 102, 1275]",1791.0,26700121,300
Dying well: How equal is end of life care among gynecologic oncology patients?,Gynecologic oncology,Gynecol. Oncol.,2015-12-17,"To identify disparities in utilization of end of life (EoL) resources by gynecologic oncology (GO) patients. This retrospective analysis of the medical records of GO patients treated 1/2007-12/2011 and deceased 1/2012-8/2014 evaluated patient demographics, disease characteristics, and utilization of EoL resources. Chi-square, Fisher's exact test, Mann Whitney and Kruskal-Wallis tests were used for statistical analysis. Of 189 patients analyzed, 113 (60%) were white, 38 (20%) Hispanic, 31 (16%) black, and seven (4%) Asian. Ninety-five (48%) had ovarian cancer, 51 (26%) uterine, 47 (23%) cervical, seven (3%) vulvar/vaginal. In the last 30days of life (DoL), 18 (10%) had multiple hospital admissions, 10 (5%) admitted to the Intensive Care Unit (ICU), 30 (16%) multiple Emergency Room (ER) visits, 45 (24%) received aggressive medical care and eight (4%) received chemotherapy in the final 14 DoL. Furthermore, 54 (29%) had no Supportive Care referral and 29 (15%) no hospice referral. Only 46 (24%) had a Medical Power of Attorney (PoA) or Living Will (LW) on file. Non-white race was associated with increased odds of dying without hospice (OR 3.07; 95%CI [1.27, 2.46], p=0.013). However, non-white patients who enrolled in hospice did so earlier than white patients (42 v. 27days before death, p=0.054). Non-white patients were also significantly less likely to have PoA/LW documentation (24% v. 76%, p=0.009) even if enrolled in hospice (12% v. 31%, p=0.007). Significant racial disparities in hospice enrollment and PoA/LW documentation were seen in GO patients. This warrants further study to identify barriers to use of EoL resources.",Journal Article,1496.0,9.0,To identify disparities in utilization of end of life EoL resources by gynecologic oncology GO patients This retrospective analysis of the medical records of GO patients treated 1/2007-12/2011 and deceased 1/2012-8/2014 evaluated patient demographics disease characteristics and utilization of EoL resources Chi-square Fisher 's exact test Mann Whitney and Kruskal-Wallis tests were used for statistical analysis Of 189 patients analyzed 113 60 were white 38 20 Hispanic 31 16 black and seven 4 Asian Ninety-five 48 had cancer 51 26 47 23 seven 3 vulvar/vaginal In the last 30days of life DoL 18 10 had multiple hospital admissions 10 5 admitted to the Intensive Care Unit ICU 30 16 multiple Emergency Room ER visits 45 24 received aggressive medical care and eight 4 received chemotherapy in the final 14 DoL Furthermore 54 29 had no Supportive Care referral and 29 15 no hospice referral Only 46 24 had a Medical Power of Attorney PoA or Living Will LW on file Non-white race was associated with increased odds of dying without hospice OR 3.07 95 CI 1.27 2.46 p=0.013 However non-white patients who enrolled in hospice did so earlier than white patients 42 v. 27days before death p=0.054 Non-white patients were also significantly less likely to have PoA/LW documentation 24 v. 76 p=0.009 even if enrolled in hospice 12 v. 31 p=0.007 Significant racial disparities in hospice enrollment and PoA/LW documentation were seen in GO patients This warrants further study to identify barriers to use of EoL resources,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 255, 2227, 4, 1961, 1, 396, 1, 358, 3946, 2892, 20, 1512, 413, 3537, 7, 26, 459, 65, 1, 3, 484, 1064, 1, 3537, 7, 73, 14, 1307, 133, 1132, 2, 11956, 14, 1195, 66, 1409, 194, 69, 2221, 34, 374, 2, 1961, 1, 3946, 2892, 3163, 3219, 3135, 292, 2472, 412, 7470, 7471, 2, 8800, 8875, 895, 11, 95, 9, 1050, 65, 1, 5899, 7, 311, 4259, 335, 11, 886, 519, 179, 1776, 456, 245, 1445, 2, 648, 39, 2399, 2493, 365, 576, 42, 12, 725, 432, 662, 382, 648, 27, 48010, 18982, 4, 3, 1060, 20849, 1, 358, 49483, 203, 79, 42, 232, 702, 5565, 79, 33, 4319, 6, 3, 1686, 165, 2712, 6195, 201, 245, 232, 4605, 4698, 516, 2690, 512, 259, 103, 571, 484, 165, 2, 659, 39, 103, 56, 4, 3, 1457, 213, 49483, 798, 667, 462, 42, 77, 1877, 165, 2096, 2, 462, 167, 77, 2490, 2096, 158, 641, 259, 42, 8, 484, 2349, 1, 21034, 20078, 15, 2798, 303, 36164, 23, 12339, 220, 886, 1047, 10, 41, 5, 101, 610, 1, 4536, 187, 2490, 15, 27, 1615, 48, 58, 14, 428, 18, 641, 19, 13, 3612, 137, 220, 886, 7, 54, 346, 4, 2490, 205, 1743, 1677, 76, 886, 7, 595, 603, 49085, 348, 273, 19, 13, 9546, 220, 886, 7, 11, 120, 97, 299, 322, 6, 47, 20078, 36164, 4965, 259, 603, 846, 19, 13, 2376, 871, 492, 346, 4, 2490, 133, 603, 456, 19, 13, 1999, 93, 2257, 2227, 4, 2490, 1798, 2, 20078, 36164, 4965, 11, 527, 4, 3537, 7, 26, 2782, 195, 45, 6, 255, 2160, 6, 119, 1, 3946, 2892]",1511.0,26706661,626
External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society.,Head & neck,Head Neck,2015-12-30,"The use of external-beam radiotherapy (EBRT) in differentiated thyroid cancer (DTC) is debated because of a lack of prospective clinical data, but recent retrospective studies have reported benefits in selected patients. The Endocrine Surgery Committee of the American Head and Neck Society provides 4 recommendations regarding EBRT for locoregional control in DTC, based on review of literature and expert opinion of the authors. (1) EBRT is recommended for patients with gross residual or unresectable locoregional disease, except for patients <45 years old with limited gross disease that is radioactive iodine (RAI)-avid. (2) EBRT should not be routinely used as adjuvant therapy after complete resection of gross disease. (3) After complete resection, EBRT may be considered in select patients >45 years old with high likelihood of microscopic residual disease and low likelihood of responding to RAI. (4) Cervical lymph node involvement alone should not be an indication for adjuvant EBRT.",Journal Article,1483.0,19.0,The use of external-beam radiotherapy EBRT in differentiated cancer DTC is debated because of a lack of prospective clinical data but recent retrospective studies have reported benefits in selected patients The Endocrine Surgery Committee of the American Head and Society provides 4 recommendations regarding EBRT for locoregional control in DTC based on review of literature and expert opinion of the authors 1 EBRT is recommended for patients with gross residual or unresectable locoregional disease except for patients 45 years old with limited gross disease that is radioactive iodine RAI -avid 2 EBRT should not be routinely used as adjuvant therapy after complete resection of gross disease 3 After complete resection EBRT may be considered in select patients 45 years old with high likelihood of microscopic residual disease and low likelihood of responding to RAI 4 lymph node involvement alone should not be an indication for adjuvant EBRT,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[3, 119, 1, 1455, 1345, 310, 1883, 4, 1442, 12, 5201, 16, 7755, 408, 1, 8, 926, 1, 482, 38, 74, 84, 435, 459, 94, 47, 210, 1141, 4, 715, 7, 3, 1293, 152, 2002, 1, 3, 597, 718, 2, 1174, 777, 39, 883, 666, 1883, 9, 1325, 182, 4, 5201, 90, 23, 206, 1, 789, 2, 2005, 3564, 1, 3, 738, 14, 1883, 16, 793, 9, 7, 5, 1789, 753, 15, 1468, 1325, 34, 2187, 9, 7, 512, 60, 1095, 5, 383, 1789, 34, 17, 16, 4741, 4287, 4121, 5189, 18, 1883, 257, 44, 40, 3066, 95, 22, 249, 36, 50, 236, 170, 1, 1789, 34, 27, 50, 236, 170, 1883, 68, 40, 515, 4, 1717, 7, 512, 60, 1095, 5, 64, 1420, 1, 2984, 753, 34, 2, 154, 1420, 1, 3261, 6, 4121, 39, 263, 289, 799, 279, 257, 44, 40, 35, 3607, 9, 249, 1883]",948.0,26716601,281
Impact of Widespread Cervical Cancer Screening: Number of Cancers Prevented and Changes in Race-specific Incidence.,American journal of clinical oncology,Am. J. Clin. Oncol.,2018-03-01,"With recent approval of standalone HPV testing and increasing uptake of HPV vaccination, some have postulated that we are moving toward a ""post-Pap"" era of cervical cancer prevention. However, the total number cases that have been prevented by Pap smear screening as well as its impact on racial disparities are unknown. We estimated national cervical cancer incidence from 1976 to 2009 using the Surveillance, Epidemiology, and End Result database. Screening data were obtained from the literature and National Cancer Institute Progress Reports. We examined early, late, and race-specific trends in cancer incidence, and calculated the estimated number of cancers prevented over the past 3 decades. From 1976 to 2009, there was a significant decrease in the incidence of early-stage cervical cancer, from 9.8 to 4.9 cases per 100,000 women (P<0.001). Late-stage disease incidence also decreased, from 5.3 to 3.7 cases per 100,000 women (P<0.001). The incidence among black women decreased from 26.9 to 9.7 cases per 100,000 women (P<0.001), a greater decline compared with that of white women and women of other races. After adjusting for ""prescreening era"" rates of cervical cancer, we estimate that Pap smears were associated with a reduction of between 105,000 and 492,000 cases of cervical cancer over the past 3 decades in the United States. A large number of early-stage and late-stage cervical cancers were prevented and racial disparity in cancer rates were reduced during an era of widespread Pap smear screening.",Journal Article,691.0,6.0,"With recent approval of standalone HPV testing and increasing uptake of HPV vaccination some have postulated that we are moving toward a `` post-Pap '' era of cancer prevention However the total number cases that have been prevented by Pap smear screening as well as its impact on racial disparities are unknown We estimated national cancer incidence from 1976 to 2009 using the Surveillance Epidemiology and End Result database Screening data were obtained from the literature and National Cancer Institute Progress Reports We examined early late and race-specific trends in cancer incidence and calculated the estimated number of cancers prevented over the past 3 decades From 1976 to 2009 there was a significant decrease in the incidence of early-stage cancer from 9.8 to 4.9 cases per 100,000 women P 0.001 Late-stage disease incidence also decreased from 5.3 to 3.7 cases per 100,000 women P 0.001 The incidence among black women decreased from 26.9 to 9.7 cases per 100,000 women P 0.001 a greater decline compared with that of white women and women of other races After adjusting for `` prescreening era '' rates of cancer we estimate that Pap smears were associated with a reduction of between 105,000 and 492,000 cases of cancer over the past 3 decades in the United States A large number of early-stage and late-stage cancers were prevented and racial disparity in cancer rates were reduced during an era of widespread Pap smear screening",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[5, 435, 1814, 1, 27306, 933, 471, 2, 602, 1135, 1, 933, 1915, 476, 47, 6507, 17, 21, 32, 8324, 1317, 8, 539, 4290, 522, 1713, 1, 12, 1070, 137, 3, 181, 207, 140, 17, 47, 85, 3902, 20, 4290, 8379, 453, 22, 149, 22, 211, 345, 23, 2257, 2227, 32, 860, 21, 661, 657, 12, 287, 29, 8586, 6, 1238, 75, 3, 617, 1284, 2, 396, 757, 609, 453, 74, 11, 683, 29, 3, 789, 2, 657, 12, 1377, 1466, 1198, 21, 409, 191, 807, 2, 1047, 112, 1963, 4, 12, 287, 2, 981, 3, 661, 207, 1, 163, 3902, 252, 3, 1219, 27, 1968, 29, 8586, 6, 1238, 125, 10, 8, 93, 775, 4, 3, 287, 1, 191, 82, 12, 29, 83, 66, 6, 39, 83, 140, 379, 394, 984, 117, 19, 13, 144, 807, 82, 34, 287, 120, 340, 29, 33, 27, 6, 27, 67, 140, 379, 394, 984, 117, 19, 13, 144, 3, 287, 107, 1445, 117, 340, 29, 432, 83, 6, 83, 67, 140, 379, 394, 984, 117, 19, 13, 144, 8, 378, 1858, 72, 5, 17, 1, 886, 117, 2, 117, 1, 127, 9290, 50, 1358, 9, 21638, 1713, 522, 151, 1, 12, 21, 1191, 17, 4290, 8916, 11, 41, 5, 8, 628, 1, 59, 3263, 984, 2, 11628, 984, 140, 1, 12, 252, 3, 1219, 27, 1968, 4, 3, 1088, 907, 8, 375, 207, 1, 191, 82, 2, 807, 82, 163, 11, 3902, 2, 2257, 4326, 4, 12, 151, 11, 405, 190, 35, 1713, 1, 3029, 4290, 8379, 453]",1449.0,26808257,28
Surgical Outcomes of Patients Undergoing Extrafascial Hysterectomy After Neoadjuvant Radiotherapy With or Without Chemotherapy for Locally Advanced Endometrial Cancer Clinically Extending to the Cervix or Parametria.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2017-07-01,"Recent data have shown high rates of clinical and pathologic responses to neoadjuvant radiation therapy for locally advanced endometrial cancer. There are limited data on the surgical outcomes of these patients in the era of modern radiation and surgical techniques. We sought to characterize surgical outcomes after extrafascial hysterectomy in this population. Patients with endometrial cancer of all histologies clinically involving the cervix or parametria treated with neoadjuvant brachytherapy followed by extrafascial hysterectomy from 1999 to 2014 were identified. Patient charts were reviewed for data regarding treatment characteristics and postoperative outcomes. Pearson  and logistic regression analyses were used to assess correlations between surgical complications and treatment-related variables. Twenty-nine patients met inclusion criteria. Mean operating time for the cohort was 115 minutes. Mean estimated blood loss was 100 mL. No visceral injuries occurred. Mean length of hospital stay was 1 and 4 days for the minimally invasive and laparotomy groups, respectively. Rates of postoperative ileus, blood transfusion, wound infection, and readmission were 3%, 3%, 6%, and 3%, respectively. No case of prolonged urodynamic dysfunction was noted. The rate of vaginal complications was significantly higher in the group of patients who underwent minimally invasive surgery as compared with laparotomy (33% vs 5%, P < 0.041). These data support adjuvant extrafascial hysterectomy after neoadjuvant radiotherapy for endometrial cancer with cervical or parametrial involvement as a safe and viable procedure, with low rates of postoperative complications. Extra care should be taken when closing the vaginal cuff to reduce the risk of vaginal cuff complications.",Journal Article,934.0,3.0,Recent data have shown high rates of clinical and pathologic responses to neoadjuvant radiation therapy for locally advanced cancer There are limited data on the surgical outcomes of these patients in the era of modern radiation and surgical techniques We sought to characterize surgical outcomes after extrafascial hysterectomy in this population Patients with cancer of all histologies clinically involving the cervix or parametria treated with neoadjuvant brachytherapy followed by extrafascial hysterectomy from 1999 to 2014 were identified Patient charts were reviewed for data regarding treatment characteristics and postoperative outcomes Pearson  and logistic regression analyses were used to assess correlations between surgical complications and treatment-related variables Twenty-nine patients met inclusion criteria Mean operating time for the cohort was 115 minutes Mean estimated blood loss was 100 mL No visceral injuries occurred Mean length of hospital stay was 1 and 4 days for the minimally invasive and laparotomy groups respectively Rates of postoperative ileus blood transfusion wound infection and readmission were 3 3 6 and 3 respectively No case of prolonged urodynamic dysfunction was noted The rate of complications was significantly higher in the group of patients who underwent minimally invasive surgery as compared with laparotomy 33 vs 5 P 0.041 These data support adjuvant extrafascial hysterectomy after neoadjuvant radiotherapy for cancer with or parametrial involvement as a safe and viable procedure with low rates of postoperative complications Extra care should be taken when closing the cuff to reduce the risk of cuff complications,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[435, 74, 47, 443, 64, 151, 1, 38, 2, 510, 253, 6, 536, 121, 36, 9, 795, 131, 12, 125, 32, 383, 74, 23, 3, 221, 123, 1, 46, 7, 4, 3, 1713, 1, 2366, 121, 2, 221, 1092, 21, 990, 6, 1507, 221, 123, 50, 25094, 2622, 4, 26, 266, 7, 5, 12, 1, 62, 3489, 505, 1267, 3, 3629, 15, 19585, 73, 5, 536, 1536, 370, 20, 25094, 2622, 29, 2043, 6, 1409, 11, 108, 69, 4413, 11, 446, 9, 74, 666, 24, 374, 2, 573, 123, 4720, 5112, 2, 812, 320, 318, 11, 95, 6, 423, 2553, 59, 221, 521, 2, 24, 139, 682, 737, 762, 7, 543, 1680, 371, 313, 2584, 98, 9, 3, 180, 10, 3670, 2511, 313, 661, 315, 407, 10, 394, 542, 77, 2737, 13063, 489, 313, 1318, 1, 702, 2020, 10, 14, 2, 39, 162, 9, 3, 2144, 416, 2, 3274, 271, 106, 151, 1, 573, 9843, 315, 2785, 2689, 930, 2, 3146, 11, 27, 27, 49, 2, 27, 106, 77, 473, 1, 1069, 39950, 1527, 10, 1051, 3, 116, 1, 521, 10, 97, 142, 4, 3, 87, 1, 7, 54, 208, 2144, 416, 152, 22, 72, 5, 3274, 466, 105, 33, 19, 13, 5937, 46, 74, 538, 249, 25094, 2622, 50, 536, 310, 9, 12, 5, 15, 8726, 799, 22, 8, 1165, 2, 2663, 1299, 5, 154, 151, 1, 573, 521, 3420, 165, 257, 40, 1633, 198, 21257, 3, 11445, 6, 969, 3, 43, 1, 11445, 521]",1673.0,26825835,15
Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2016-02-04,"First-in-human phase I trial to determine the safety, pharmacokinetics, and antitumor activity of BIND-014, a novel, tumor prostate-specific membrane antigen (PSMA)-targeted nanoparticle, containing docetaxel. Patients with advanced solid tumors received BIND-014 every three weeks (n = 28) or weekly (n = 27), with dose levels ranging from 3.5 to 75 mg/m(2) and 15 to 45 mg/m(2), respectively. BIND-014 was generally well tolerated, with no unexpected toxicities. The most common drug-related toxicities (>20% of patients) on either schedule included neutropenia, fatigue, anemia, alopecia, and diarrhea. BIND-014 demonstrated a dose-linear pharmacokinetic profile, distinct from docetaxel, with prolonged persistence of docetaxel-encapsulated circulating nanoparticles. Of the 52 patients evaluable for response, one had a complete response (cervical cancer on the every three week schedule) and five had partial responses (ampullary adenocarcinoma, non-small cell lung, and prostate cancers on the every-three-week schedule, and breast and gastroesophageal cancers on the weekly schedule). Responses were noted in both PSMA-detectable and -undetectable tumors. BIND-014 was generally well tolerated, with predictable and manageable toxicity and a unique pharmacokinetic profile compared with conventional docetaxel. Clinical activity was noted in multiple tumor types. The recommended phase II dose of BIND-014 is 60 mg/m(2) every three weeks or 40 mg/m(2) weekly. Clin Cancer Res; 22(13); 3157-63. 2016 AACR.","Clinical Trial, Phase I",1447.0,80.0,First-in-human phase I trial to determine the safety pharmacokinetics and antitumor activity of BIND-014 a novel tumor prostate-specific membrane antigen PSMA -targeted nanoparticle containing docetaxel Patients with advanced solid tumors received BIND-014 every three weeks n 28 or weekly n 27 with dose levels ranging from 3.5 to 75 mg/m 2 and 15 to 45 mg/m 2 respectively BIND-014 was generally well tolerated with no unexpected toxicities The most common drug-related toxicities 20 of patients on either schedule included neutropenia fatigue anemia alopecia and diarrhea BIND-014 demonstrated a dose-linear pharmacokinetic profile distinct from docetaxel with prolonged persistence of docetaxel-encapsulated circulating nanoparticles Of the 52 patients evaluable for response one had a complete response cancer on the every three week schedule and five had partial responses ampullary adenocarcinoma cell and cancers on the every-three-week schedule and and gastroesophageal cancers on the weekly schedule Responses were noted in both PSMA-detectable and -undetectable tumors BIND-014 was generally well tolerated with predictable and manageable toxicity and a unique pharmacokinetic profile compared with conventional docetaxel Clinical activity was noted in multiple tumor types The recommended phase II dose of BIND-014 is 60 mg/m 2 every three weeks or 40 mg/m 2 weekly Clin Cancer Res 22 13 3157-63 2016 AACR,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[157, 4, 171, 124, 70, 160, 6, 223, 3, 367, 1159, 2, 579, 128, 1, 4060, 3618, 8, 229, 30, 1364, 112, 1905, 448, 3588, 238, 4483, 1101, 621, 7, 5, 131, 537, 57, 103, 4060, 3618, 454, 169, 244, 78, 339, 15, 709, 78, 428, 5, 61, 148, 2223, 29, 27, 33, 6, 481, 81, 188, 18, 2, 167, 6, 512, 81, 188, 18, 106, 4060, 3618, 10, 1228, 149, 421, 5, 77, 3792, 385, 3, 96, 186, 234, 139, 385, 179, 1, 7, 23, 361, 1055, 159, 778, 613, 1545, 5691, 2, 1172, 4060, 3618, 264, 8, 61, 1646, 1456, 800, 834, 29, 621, 5, 1069, 4108, 1, 621, 7431, 1033, 2889, 1, 3, 653, 7, 859, 9, 51, 104, 42, 8, 236, 51, 12, 23, 3, 454, 169, 647, 1055, 2, 365, 42, 450, 253, 6762, 449, 31, 2, 163, 23, 3, 454, 169, 647, 1055, 2, 2, 3227, 163, 23, 3, 709, 1055, 253, 11, 1051, 4, 110, 3588, 2083, 2, 3920, 57, 4060, 3618, 10, 1228, 149, 421, 5, 7639, 2, 2808, 155, 2, 8, 991, 1456, 800, 72, 5, 809, 621, 38, 128, 10, 1051, 4, 232, 30, 630, 3, 793, 124, 215, 61, 1, 4060, 3618, 16, 335, 81, 188, 18, 454, 169, 244, 15, 327, 81, 188, 18, 709, 2459, 12, 1936, 350, 233, 67587, 676, 3456, 1630]",1418.0,26847057,79
Stage I and II Endometrial Adenocarcinoma: Analysis of 2009 FIGO Staging Revision and Impact on Survival by Adjuvant Therapy.,American journal of clinical oncology,Am. J. Clin. Oncol.,2018-03-01,"In 2009, the International Federation of Gynecology and Obstetrics revised the staging classification for endometrial cancer. Mucosal cervical involvement was eliminated from the criteria and only those with stromal cervical involvement were considered stage II. We examined the implications of the staging changes and the survival impact of adjuvant therapy in stage I to II endometrial adenocarcinoma. Data were obtained from the National Oncology Data Alliance. Stage I to II endometrial adenocarcinoma patients diagnosed between 1988 and 2008 were identified and grouped according to the 1988 International Federation of Gynecology and Obstetrics staging. Multivariate analysis (MVA) was performed using proportional hazards model; comparison of Kaplan-Meier survival curves was based on the log-rank statistic. A total of 14,158 patients with stage I to II endometrial adenocarcinoma were identified with a median follow-up of 41 months. Adjuvant external-beam radiation therapy (EBRT) and adjuvant vaginal brachytherapy (VB) were positive predictors for overall survival (OS) only in IC, IIA, and IIB. On MVA, stages IA and IB OS did not differ (P=0.17), IIA had worse OS compared with IC (P<0.05), and IIA OS did not differ from IIB (P=0.57). Neither IA nor IB benefited from adjuvant radiotherapy on MVA. However, both IC and IIA had OS improvements with VBEBRT (P<0.05) with the greatest impact from the VB. Mucosal cervical involvement represents a risk factor and should be considered when determining adjuvant therapy. Adjuvant therapy provided no survival benefit in 1988 stage IA or IB; however, adjuvant radiotherapy is recommended in the management of IC, IIA, and IIB.",Journal Article,691.0,2.0,"In 2009 the International Federation of Gynecology and Obstetrics revised the staging classification for cancer Mucosal involvement was eliminated from the criteria and only those with stromal involvement were considered stage II We examined the implications of the staging changes and the survival impact of adjuvant therapy in stage I to II adenocarcinoma Data were obtained from the National Oncology Data Alliance Stage I to II adenocarcinoma patients diagnosed between 1988 and 2008 were identified and grouped according to the 1988 International Federation of Gynecology and Obstetrics staging Multivariate analysis MVA was performed using proportional hazards model comparison of Kaplan-Meier survival curves was based on the log-rank statistic A total of 14,158 patients with stage I to II adenocarcinoma were identified with a median follow-up of 41 months Adjuvant external-beam radiation therapy EBRT and adjuvant brachytherapy VB were positive predictors for overall survival OS only in IC IIA and IIB On MVA stages IA and IB OS did not differ P=0.17 IIA had worse OS compared with IC P 0.05 and IIA OS did not differ from IIB P=0.57 Neither IA nor IB benefited from adjuvant radiotherapy on MVA However both IC and IIA had OS improvements with VBEBRT P 0.05 with the greatest impact from the VB Mucosal involvement represents a risk factor and should be considered when determining adjuvant therapy Adjuvant therapy provided no survival benefit in 1988 stage IA or IB however adjuvant radiotherapy is recommended in the management of IC IIA and IIB",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,"[4, 1238, 3, 944, 7303, 1, 6429, 2, 7407, 4218, 3, 632, 947, 9, 12, 3068, 799, 10, 6173, 29, 3, 371, 2, 158, 135, 5, 1126, 799, 11, 515, 82, 215, 21, 409, 3, 1268, 1, 3, 632, 400, 2, 3, 25, 345, 1, 249, 36, 4, 82, 70, 6, 215, 449, 74, 11, 683, 29, 3, 657, 413, 74, 7127, 82, 70, 6, 215, 449, 7, 265, 59, 3314, 2, 1375, 11, 108, 2, 3706, 768, 6, 3, 3314, 944, 7303, 1, 6429, 2, 7407, 632, 331, 65, 5320, 10, 173, 75, 831, 1017, 202, 1155, 1, 876, 882, 25, 2400, 10, 90, 23, 3, 1066, 1026, 4502, 8, 181, 1, 213, 5162, 7, 5, 82, 70, 6, 215, 449, 11, 108, 5, 8, 52, 166, 126, 1, 605, 53, 249, 1455, 1345, 121, 36, 1883, 2, 249, 1536, 9464, 11, 109, 674, 9, 63, 25, 118, 158, 4, 2340, 4088, 2, 3884, 23, 5320, 1153, 3302, 2, 3180, 118, 205, 44, 1505, 19, 13, 269, 4088, 42, 639, 118, 72, 5, 2340, 19, 13, 474, 2, 4088, 118, 205, 44, 1505, 29, 3884, 19, 13, 696, 2174, 3302, 2110, 3180, 7067, 29, 249, 310, 23, 5320, 137, 110, 2340, 2, 4088, 42, 118, 1474, 5, 67654, 19, 13, 474, 5, 3, 2199, 345, 29, 3, 9464, 3068, 799, 1449, 8, 43, 161, 2, 257, 40, 515, 198, 2196, 249, 36, 249, 36, 1052, 77, 25, 247, 4, 3314, 82, 3302, 15, 3180, 137, 249, 310, 16, 793, 4, 3, 284, 1, 2340, 4088, 2, 3884]",1562.0,26886945,31
The cost-utility of integrated cervical cancer prevention strategies in the Ontario setting - Can we do better?,Vaccine,Vaccine,2016-02-15,"A universal, publicly funded, school-based human papillomavirus (HPV) vaccination program in grade eight girls was initiated in Ontario in 2007. We present a cost-utility analysis of integrated cervical cancer prevention programs from the healthcare payer perspective. Our analysis was based on linked HPV transmission and disease history models. We obtained data from the literature, provincial surveys and Ontario population-based linked health administrative datasets. We modeled combinations of vaccination and screening strategies. We considered vaccination based on the Ontario experience, as well as conservative and optimistic scenarios, varying coverage, vaccine effectiveness and duration of protection. We considered 900 screening scenarios (screening start age: 21-70 years, screening interval: 3-20 years; 1-year time steps). The current schedule screens every 3 years starting at age 21 years. We examined (1) first vaccinated cohort (low herd-immunity), and (2) steady state, i.e. all cohorts were vaccinated (high herd-immunity). Adding vaccination to the current screening schedule was cost-effective (<C$10,000/quality-adjusted life year (QALY)) across all scenarios. Delaying screening start and/or extending screening intervals increased both expected QALYs and cost, and increased overall NHB for screening schedules with a start age of 25-35 years and 3-10-year intervals for most scenarios. Delaying screening start age and/or extending screening intervals in vaccinated cohorts is likely to be cost-effective. Consideration should be given to both the short- and long-term implications of health policy decisions, particularly for infectious disease interventions that require long time intervals to reach steady state.",Journal Article,1436.0,4.0,"A universal publicly funded school-based human papillomavirus HPV vaccination program in grade eight girls was initiated in Ontario in 2007 We present a cost-utility analysis of integrated cancer prevention programs from the healthcare payer perspective Our analysis was based on linked HPV transmission and disease history models We obtained data from the literature provincial surveys and Ontario population-based linked health administrative datasets We modeled combinations of vaccination and screening strategies We considered vaccination based on the Ontario experience as well as conservative and optimistic scenarios varying coverage vaccine effectiveness and duration of protection We considered 900 screening scenarios screening start age 21-70 years screening interval 3-20 years 1-year time steps The current schedule screens every 3 years starting at age 21 years We examined 1 first vaccinated cohort low herd-immunity and 2 steady state i.e all cohorts were vaccinated high herd-immunity Adding vaccination to the current screening schedule was cost-effective C 10,000/quality-adjusted life year QALY across all scenarios Delaying screening start and/or extending screening intervals increased both expected QALYs and cost and increased overall NHB for screening schedules with a start age of 25-35 years and 3-10-year intervals for most scenarios Delaying screening start age and/or extending screening intervals in vaccinated cohorts is likely to be cost-effective Consideration should be given to both the short- and long-term implications of health policy decisions particularly for infectious disease interventions that require long time intervals to reach steady state",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[8, 4967, 6878, 3827, 5953, 90, 171, 3242, 933, 1915, 1243, 4, 88, 659, 5989, 10, 1917, 4, 8498, 4, 1307, 21, 364, 8, 835, 1207, 65, 1, 2102, 12, 1070, 2251, 29, 3, 2819, 7433, 3727, 114, 65, 10, 90, 23, 1199, 933, 8151, 2, 34, 532, 274, 21, 683, 74, 29, 3, 789, 31087, 3666, 2, 8498, 266, 90, 1199, 341, 6723, 3455, 21, 4666, 1247, 1, 1915, 2, 453, 422, 21, 515, 1915, 90, 23, 3, 8498, 730, 22, 149, 22, 4476, 2, 9566, 3964, 2990, 2139, 1274, 1236, 2, 654, 1, 3525, 21, 515, 5310, 453, 3964, 453, 2435, 89, 239, 431, 60, 453, 268, 27, 179, 60, 14, 111, 98, 4022, 3, 291, 1055, 7508, 454, 27, 60, 1723, 28, 89, 239, 60, 21, 409, 14, 157, 5130, 180, 154, 32560, 1604, 2, 18, 4152, 1309, 70, 563, 62, 736, 11, 5130, 64, 32560, 1604, 2726, 1915, 6, 3, 291, 453, 1055, 10, 835, 323, 256, 79, 984, 372, 586, 358, 111, 4124, 716, 62, 3964, 7151, 453, 2435, 2, 15, 4782, 453, 1582, 101, 110, 1336, 6764, 2, 835, 2, 101, 63, 12467, 9, 453, 2314, 5, 8, 2435, 89, 1, 243, 465, 60, 2, 27, 79, 111, 1582, 9, 96, 3964, 7151, 453, 2435, 89, 2, 15, 4782, 453, 1582, 4, 5130, 736, 16, 322, 6, 40, 835, 323, 2415, 257, 40, 447, 6, 110, 3, 978, 2, 319, 337, 1268, 1, 341, 4196, 1526, 823, 9, 3398, 34, 1151, 17, 1353, 319, 98, 1582, 6, 3690, 4152, 1309]",1689.0,26892739,59
Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery.,Annals of surgical oncology,Ann. Surg. Oncol.,2016-02-23,"The aim of this study was to determine the impact of obesity on the rate of successful sentinel lymph node (SLN) mapping in patients with uterine cancer undergoing robotic surgery, and compare SLN detection rates using indocyanine green (ICG) versus blue dye. We reviewed robotic cases undergoing SLN mapping with a cervical injection from January 2011 to December 2013 using either blue dye or ICG with near-infrared (NIR) fluorescence imaging. Data were stratified by body mass index (BMI) and the dye used. Appropriate statistical tests were applied. Overall, 472 cases were identified. Bilateral mapping was successful in 352 cases (75%), and unilateral mapping was successful in 73 cases (15%). Bilateral mapping was achieved in 266 (85%) of 312 ICG cases compared with 86 (54%) of 160 blue-dye cases (p<0.001). Cases with successful bilateral mapping had a median BMI of 29.8kg/m(2) (range 16.3-65.3kg/m(2)); cases with no mapping had a median BMI of 34.7kg/m(2) (range 21.4-60.4kg/m(2)) (p=0.001). With increasing BMI, there was a significant decrease in successful bilateral mapping rates for both the ICG (p<0.001) and blue-dye groups (p=0.041); however, the use of ICG resulted in better bilateral (p=0.002) and overall (p=0.011) mapping rates compared with the use of blue dye in all BMI groups. ICG results in a higher overall and bilateral SLN detection than blue dye in women with uterine cancer. Successful mapping decreases with increasing BMI irrespective of the dye used; however, it is significantly improved with the use of ICG and NIR fluorescence imaging compared with blue dye.",Comparative Study,1428.0,28.0,The aim of this study was to determine the impact of obesity on the rate of successful sentinel lymph node SLN mapping in patients with cancer undergoing robotic surgery and compare SLN detection rates using indocyanine green ICG versus blue dye We reviewed robotic cases undergoing SLN mapping with a injection from January 2011 to December 2013 using either blue dye or ICG with near-infrared NIR fluorescence imaging Data were stratified by body mass index BMI and the dye used Appropriate statistical tests were applied Overall 472 cases were identified Bilateral mapping was successful in 352 cases 75 and unilateral mapping was successful in 73 cases 15 Bilateral mapping was achieved in 266 85 of 312 ICG cases compared with 86 54 of 160 blue-dye cases p 0.001 Cases with successful bilateral mapping had a median BMI of 29.8 kg/m 2 range 16.3-65.3 kg/m 2 cases with no mapping had a median BMI of 34.7 kg/m 2 range 21.4-60.4 kg/m 2 p 0.001 With increasing BMI there was a significant decrease in successful bilateral mapping rates for both the ICG p 0.001 and blue-dye groups p 0.041 however the use of ICG resulted in better bilateral p 0.002 and overall p 0.011 mapping rates compared with the use of blue dye in all BMI groups ICG results in a higher overall and bilateral SLN detection than blue dye in women with cancer Successful mapping decreases with increasing BMI irrespective of the dye used however it is significantly improved with the use of ICG and NIR fluorescence imaging compared with blue dye,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 1130, 1, 26, 45, 10, 6, 223, 3, 345, 1, 1661, 23, 3, 116, 1, 1401, 1323, 263, 289, 1099, 2568, 4, 7, 5, 12, 479, 2895, 152, 2, 932, 1099, 638, 151, 75, 18903, 4658, 9118, 185, 3352, 3796, 21, 446, 2895, 140, 479, 1099, 2568, 5, 8, 1754, 29, 1024, 1132, 6, 1397, 1346, 75, 361, 3352, 3796, 15, 9118, 5, 1829, 6765, 6479, 1591, 270, 74, 11, 1173, 20, 642, 782, 558, 1140, 2, 3, 3796, 95, 870, 1050, 895, 11, 1498, 63, 10887, 140, 11, 108, 1607, 2568, 10, 1401, 4, 9550, 140, 481, 2, 3208, 2568, 10, 1401, 4, 803, 140, 167, 1607, 2568, 10, 513, 4, 8786, 772, 1, 8187, 9118, 140, 72, 5, 868, 667, 1, 3457, 3352, 3796, 140, 19, 13, 144, 140, 5, 1401, 1607, 2568, 42, 8, 52, 1140, 1, 462, 66, 503, 188, 18, 184, 245, 27, 556, 27, 503, 188, 18, 140, 5, 77, 2568, 42, 8, 52, 1140, 1, 562, 67, 503, 188, 18, 184, 239, 39, 335, 39, 503, 188, 18, 19, 13, 144, 5, 602, 1140, 125, 10, 8, 93, 775, 4, 1401, 1607, 2568, 151, 9, 110, 3, 9118, 19, 13, 144, 2, 3352, 3796, 271, 19, 13, 5937, 137, 3, 119, 1, 9118, 627, 4, 380, 1607, 19, 13, 1111, 2, 63, 19, 13, 3651, 2568, 151, 72, 5, 3, 119, 1, 3352, 3796, 4, 62, 1140, 271, 9118, 99, 4, 8, 142, 63, 2, 1607, 1099, 638, 76, 3352, 3796, 4, 117, 5, 12, 1401, 2568, 2140, 5, 602, 1140, 3500, 1, 3, 3796, 95, 137, 192, 16, 97, 231, 5, 3, 119, 1, 9118, 2, 6479, 1591, 270, 72, 5, 3352, 3796]",1519.0,26905542,90
Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.,JAMA oncology,JAMA Oncol,2016-04-01,"Patients with squamous cell carcinoma (SCC) of the cervix or vulva have limited therapeutic options, and the potential for immunotherapy for this population has not been evaluated. Recent trials suggest that tumors with a genetic basis for PD-1 (programmed cell death protein 1) ligand expression are highly sensitive to therapeutic antibodies targeting PD-1. To determine the genetic status of CD274 (encoding PD-L1 [programmed cell death 1 ligand 1]) and PDCD1LG2 (encoding PD-L2 [programmed cell death 1 ligand 2]) in SCCs of the cervix and vulva and to correlate the findings with PD-L1 protein expression. We performed fluorescence in situ hybridization (FISH) using probes targeting CD274, PDCD1LG2, and the centromeric portion of chromosome 9, and immunohistochemistry (IHC) using an antibody recognizing PD-L1 on formalin-fixed, paraffin-embedded (FFPE) biopsy specimens from 48 cervical SCCs and 23 vulvar SCCs. Tumors were categorized according to the genetic abnormality in CD274 and PDCD1LG2 (coamplification>cogain>polysomy>disomy) as detected by FISH, and evaluated on a semiquantitative scale (modified H score, the product of the percentage of tumor cells with positive staining and the maximum intensity of positive staining) for PD-L1 protein expression as detected by IHC. Overall, 71 samples of FFPE tissue from cases of cervical SCCs (n=48) and vulvar SCCs (n=23) were retrieved from the archives of Brigham and Women's Hospital and included in this study. We observed cogain or coamplification of CD274 and PDCD1LG2 in 32 of 48 cervical SCCs (67%) and 10 of 23 vulvar SCCs (43%). Median PD-L1 protein expression was highest among tumors with CD274 and PDCD1LG2 coamplification and lowest among tumors with disomy. Recurrent copy number gain of the genes encoding the PD-1 ligands provides a genetic basis for PD-L1 expression in a subset of cervical and vulvar SCCs and identifies a class of patients that are rational candidates for therapies targeting PD-1.",Journal Article,1390.0,59.0,Patients with squamous cell carcinoma SCC of the cervix or vulva have limited therapeutic options and the potential for immunotherapy for this population has not been evaluated Recent trials suggest that tumors with a genetic basis for PD-1 programmed cell death protein 1 ligand expression are highly sensitive to therapeutic antibodies targeting PD-1 To determine the genetic status of CD274 encoding PD-L1 programmed cell death 1 ligand 1 and PDCD1LG2 encoding PD-L2 programmed cell death 1 ligand 2 in SCCs of the cervix and vulva and to correlate the findings with PD-L1 protein expression We performed fluorescence in situ hybridization FISH using probes targeting CD274 PDCD1LG2 and the centromeric portion of chromosome 9 and immunohistochemistry IHC using an antibody recognizing PD-L1 on formalin-fixed paraffin-embedded FFPE biopsy specimens from 48 SCCs and 23 SCCs Tumors were categorized according to the genetic abnormality in CD274 and PDCD1LG2 coamplification cogain polysomy disomy as detected by FISH and evaluated on a semiquantitative scale modified H score the product of the percentage of tumor cells with positive staining and the maximum intensity of positive staining for PD-L1 protein expression as detected by IHC Overall 71 samples of FFPE tissue from cases of SCCs n 48 and SCCs n 23 were retrieved from the archives of Brigham and Women 's Hospital and included in this study We observed cogain or coamplification of CD274 and PDCD1LG2 in 32 of 48 SCCs 67 and 10 of 23 SCCs 43 Median PD-L1 protein expression was highest among tumors with CD274 and PDCD1LG2 coamplification and lowest among tumors with disomy Recurrent copy number gain of the genes encoding the PD-1 ligands provides a genetic basis for PD-L1 expression in a subset of and SCCs and identifies a class of patients that are rational candidates for therapies targeting PD-1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[7, 5, 691, 31, 134, 1791, 1, 3, 3629, 15, 9263, 47, 383, 189, 838, 2, 3, 174, 9, 726, 9, 26, 266, 71, 44, 85, 194, 435, 143, 309, 17, 57, 5, 8, 336, 877, 9, 333, 14, 1846, 31, 273, 178, 14, 1232, 55, 32, 561, 745, 6, 189, 890, 529, 333, 14, 6, 223, 3, 336, 156, 1, 10511, 2362, 333, 729, 1846, 31, 273, 14, 1232, 14, 2, 14047, 2362, 333, 5111, 1846, 31, 273, 14, 1232, 18, 4, 6334, 1, 3, 3629, 2, 9263, 2, 6, 1513, 3, 272, 5, 333, 729, 178, 55, 21, 173, 1591, 4, 957, 1554, 1277, 75, 3701, 529, 10511, 14047, 2, 3, 15531, 3206, 1, 1170, 83, 2, 888, 1289, 75, 35, 548, 5842, 333, 729, 23, 3265, 1959, 2487, 2505, 4412, 411, 623, 29, 576, 6334, 2, 382, 6334, 57, 11, 2320, 768, 6, 3, 336, 3698, 4, 10511, 2, 14047, 17912, 49585, 5882, 13983, 22, 530, 20, 1277, 2, 194, 23, 8, 8942, 1124, 1230, 555, 368, 3, 2821, 1, 3, 1150, 1, 30, 37, 5, 109, 1029, 2, 3, 689, 837, 1, 109, 1029, 9, 333, 729, 178, 55, 22, 530, 20, 1289, 63, 792, 347, 1, 4412, 246, 29, 140, 1, 6334, 78, 576, 2, 6334, 78, 382, 11, 4539, 29, 3, 12810, 1, 10543, 2, 117, 292, 702, 2, 159, 4, 26, 45, 21, 164, 49585, 15, 17912, 1, 10511, 2, 14047, 4, 531, 1, 576, 6334, 598, 2, 79, 1, 382, 6334, 601, 52, 333, 729, 178, 55, 10, 1076, 107, 57, 5, 10511, 2, 14047, 17912, 2, 2101, 107, 57, 5, 13983, 387, 1337, 207, 1803, 1, 3, 214, 2362, 3, 333, 14, 3123, 777, 8, 336, 877, 9, 333, 729, 55, 4, 8, 697, 1, 2, 6334, 2, 2953, 8, 1040, 1, 7, 17, 32, 2696, 1931, 9, 235, 529, 333, 14]",1869.0,26913631,313
Health Behaviors in Cervical Cancer Survivors and Associations with Quality of Life.,Clinical therapeutics,Clin Ther,2016-02-27,"Improvement in health behaviors following cancer diagnosis may contribute to better prognosis and well-being. This study examines the prevalence of health behaviors in cervical cancer survivors who have completed treatment, and associations between health behaviors and quality of life (QOL). We recruited 204 women who had completed treatment for cervical cancer to participate in a randomized counseling intervention. Participants provided information on health behaviors (smoking, physical activity, and alcohol consumption); QOL (Functional Assessment of Cancer Therapy-Cervical questionnaire); and depression (Patient-Reported Outcomes Measurement Information System), anxiety (Patient-Reported Outcomes Measurement Information System), and distress (Brief Symptom Inventory) at baseline (9-30 months after diagnosis) and subsequent to the intervention. Data were analyzed using multivariate general linear models. Participants ranged in age from 20 to 72 years at diagnosis (mean = 43 years), 41% were Hispanic, and 52% were non-Hispanic white. Three-fourths were stage 1 at diagnosis and 51% were treated with radiation with or without chemotherapy. At baseline, 15% of patients were current smokers, 4% reported alcohol consumption of >10 drinks per week, and 63% reported exercising <3 hours per week. Overall, 67.4% of cervical cancer survivors did not meet recommended national guidelines for at least 1 of these health behaviors. QOL scores were significantly higher for patients with greater physical activity (128 vs 118; P = 0.002) and increased with the number of recommended guidelines met (P for trend = 0.030). Associations between patient-reported outcomes and smoking and alcohol consumption did not reach statistical significance. Participants who met guidelines for all health behaviors also had less depression (P = 0.008), anxiety (P = 0.051), and distress (P = 0.142). Participants who improved their aggregate health behaviors during the 4-month follow-up experienced a greater improvement in QOL than those who did not improve their health behaviors (10.8 vs 4.5; P = 0.026). Results indicate that two-thirds of cervical cancer survivors are not meeting national guidelines for smoking, physical activity, and alcohol consumption following completion of definitive treatment. These adverse health behaviors were associated with impaired QOL and higher levels of depression and distress. Positive changes in health behaviors are associated with significant improvement in QOL.",Journal Article,1424.0,6.0,Improvement in health behaviors following cancer diagnosis may contribute to better prognosis and well-being This study examines the prevalence of health behaviors in cancer survivors who have completed treatment and associations between health behaviors and quality of life QOL We recruited 204 women who had completed treatment for cancer to participate in a randomized counseling intervention Participants provided information on health behaviors smoking physical activity and alcohol consumption QOL Functional Assessment of Cancer Therapy-Cervical questionnaire and depression Patient-Reported Outcomes Measurement Information System anxiety Patient-Reported Outcomes Measurement Information System and distress Brief Symptom Inventory at baseline 9-30 months after diagnosis and subsequent to the intervention Data were analyzed using multivariate general linear models Participants ranged in age from 20 to 72 years at diagnosis mean 43 years 41 were Hispanic and 52 were non-Hispanic white Three-fourths were stage 1 at diagnosis and 51 were treated with radiation with or without chemotherapy At baseline 15 of patients were current smokers 4 reported alcohol consumption of 10 drinks per week and 63 reported exercising 3 hours per week Overall 67.4 of cancer survivors did not meet recommended national guidelines for at least 1 of these health behaviors QOL scores were significantly higher for patients with greater physical activity 128 vs 118 P 0.002 and increased with the number of recommended guidelines met P for trend 0.030 Associations between patient-reported outcomes and smoking and alcohol consumption did not reach statistical significance Participants who met guidelines for all health behaviors also had less depression P 0.008 anxiety P 0.051 and distress P 0.142 Participants who improved their aggregate health behaviors during the 4-month follow-up experienced a greater improvement in QOL than those who did not improve their health behaviors 10.8 vs 4.5 P 0.026 Results indicate that two-thirds of cancer survivors are not meeting national guidelines for smoking physical activity and alcohol consumption following completion of definitive treatment These adverse health behaviors were associated with impaired QOL and higher levels of depression and distress Positive changes in health behaviors are associated with significant improvement in QOL,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[767, 4, 341, 3704, 366, 12, 147, 68, 1248, 6, 380, 356, 2, 149, 486, 26, 45, 4468, 3, 1078, 1, 341, 3704, 4, 12, 332, 54, 47, 781, 24, 2, 685, 59, 341, 3704, 2, 372, 1, 358, 1001, 21, 2619, 5996, 117, 54, 42, 781, 24, 9, 12, 6, 3506, 4, 8, 384, 2011, 788, 776, 1052, 487, 23, 341, 3704, 979, 900, 128, 2, 2197, 2421, 1001, 583, 455, 1, 12, 36, 18237, 1770, 2, 1774, 69, 210, 123, 2204, 487, 398, 2021, 69, 210, 123, 2204, 487, 398, 2, 1462, 3190, 934, 3818, 28, 330, 83, 201, 53, 50, 147, 2, 706, 6, 3, 788, 74, 11, 311, 75, 331, 1083, 1646, 274, 776, 1869, 4, 89, 29, 179, 6, 720, 60, 28, 147, 313, 601, 60, 605, 11, 1776, 2, 653, 11, 220, 1776, 886, 169, 17246, 11, 82, 14, 28, 147, 2, 725, 11, 73, 5, 121, 5, 15, 187, 56, 28, 330, 167, 1, 7, 11, 291, 1485, 39, 210, 2197, 2421, 1, 79, 12112, 379, 647, 2, 676, 210, 18455, 27, 1459, 379, 647, 63, 598, 39, 1, 12, 332, 205, 44, 3362, 793, 657, 677, 9, 28, 506, 14, 1, 46, 341, 3704, 1001, 703, 11, 97, 142, 9, 7, 5, 378, 900, 128, 3990, 105, 4002, 19, 13, 1111, 2, 101, 5, 3, 207, 1, 793, 677, 543, 19, 9, 853, 13, 6542, 685, 59, 69, 210, 123, 2, 979, 2, 2197, 2421, 205, 44, 3690, 1050, 724, 776, 54, 543, 677, 9, 62, 341, 3704, 120, 42, 299, 1774, 19, 13, 2155, 2021, 19, 13, 9891, 2, 1462, 19, 13, 4785, 776, 54, 231, 136, 7494, 341, 3704, 190, 3, 39, 811, 166, 126, 592, 8, 378, 767, 4, 1001, 76, 135, 54, 205, 44, 401, 136, 341, 3704, 79, 66, 105, 39, 33, 19, 13, 4554, 99, 1008, 17, 100, 5438, 1, 12, 332, 32, 44, 2238, 657, 677, 9, 979, 900, 128, 2, 2197, 2421, 366, 1438, 1, 1057, 24, 46, 290, 341, 3704, 11, 41, 5, 2364, 1001, 2, 142, 148, 1, 1774, 2, 1462, 109, 400, 4, 341, 3704, 32, 41, 5, 93, 767, 4, 1001]",2381.0,26926320,232
Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer.,Clinical therapeutics,Clin Ther,2016-02-28,"The purpose of this study was to provide an overview of current and up and coming targeted therapies in cervical cancer with or without chemotherapy. We reviewed the literature using search terms cervical cancer AND immunotherapy, immune therapy, vaccines, bevacizumab, anti-angiogenic therapy, and PARP inhibitors on PubMed. We included all review articles and prospective trials. We also reviewed ClinicalTrials.gov for trials in progress. The addition of bevacizumab has improved the overall survival of women with advanced or recurrent cervical cancer when compared with cytotoxic therapy alone. This advancement has sparked an interest in other anti-angiogenic agents. Additionally, targeted therapies, including tyrosine kinase inhibitors, immunotherapy, and vaccine therapy, are also being evaluated. Another exciting area of study is the role of poly (ADP-ribose) polymerase inhibition in cervical cancer. Though the results are promising, the data are preliminary and additional studies evaluating the proper combination of therapy, dosing, and schedules will help inform the ideal regimen.",Journal Article,1423.0,30.0,The purpose of this study was to provide an overview of current and up and coming targeted therapies in cancer with or without chemotherapy We reviewed the literature using search terms cancer AND immunotherapy immune therapy vaccines bevacizumab anti-angiogenic therapy and PARP inhibitors on PubMed We included all review articles and prospective trials We also reviewed ClinicalTrials.gov for trials in progress The addition of bevacizumab has improved the overall survival of women with advanced or recurrent cancer when compared with cytotoxic therapy alone This advancement has sparked an interest in other anti-angiogenic agents Additionally targeted therapies including tyrosine kinase inhibitors immunotherapy and vaccine therapy are also being evaluated Another exciting area of study is the role of poly ADP-ribose polymerase inhibition in cancer Though the results are promising the data are preliminary and additional studies evaluating the proper combination of therapy dosing and schedules will help inform the ideal regimen,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 377, 35, 2901, 1, 291, 2, 126, 2, 10671, 238, 235, 4, 12, 5, 15, 187, 56, 21, 446, 3, 789, 75, 1901, 1794, 12, 2, 726, 250, 36, 1842, 599, 312, 2068, 36, 2, 2041, 222, 23, 3161, 21, 159, 62, 206, 2384, 2, 482, 143, 21, 120, 446, 1252, 1239, 9, 143, 4, 1466, 3, 352, 1, 599, 71, 231, 3, 63, 25, 1, 117, 5, 131, 15, 387, 12, 198, 72, 5, 759, 36, 279, 26, 7496, 71, 19720, 35, 1333, 4, 127, 312, 2068, 183, 1724, 238, 235, 141, 564, 216, 222, 726, 2, 1274, 36, 32, 120, 486, 194, 1809, 4963, 965, 1, 45, 16, 3, 200, 1, 2699, 3638, 3507, 1451, 297, 4, 12, 2471, 3, 99, 32, 721, 3, 74, 32, 1676, 2, 402, 94, 1435, 3, 4576, 150, 1, 36, 1280, 2, 2314, 303, 987, 2295, 3, 3662, 477]",1039.0,26926322,55
"Next-Generation Sequencing-Based HPV Genotyping Assay Validated in Formalin-Fixed, Paraffin-Embedded Oropharyngeal and Cervical Cancer Specimens.",Journal of biomolecular techniques : JBT,J Biomol Tech,2016-03-07,"Available clinical human papilloma virus (HPV) diagnostics for head and neck cancer have limited sensitivity and/or fail to define the HPV genotype. Common HPV genotyping assays are costly and labor intensive. We sought to develop a next-generation sequencing (NGS)-based HPV genotyping assay that was sensitive enough to work on formalin-fixed paraffin-embedded (FFPE) samples. We developed an ion torrent NGS HPV genotyping assay using barcoded HPV PCR broad-spectrum general primers 5(+)/6(+) (BSGP)5(+)/6(+). To validate genotype specificity and use in archived clinical FFPE tumor samples, we compared NGS HPV genotyping at 2 sequencing centers with typing by Roche Linear Array assay in 42 oropharyngeal and cervical cancer specimens representing 10 HPV genotypes, as well as HPV-negative cases. To demonstrate the detection of a broad range of HPV genotypes, we genotyped a cohort of 266 cervical cancers. A comparison of NGS genotyping of FFPE cancer specimens with genotyping by Linear Array showed concordant results in 34/37 samples (92%) at sequencing site 1 and 39/42 samples (93%) at sequencing site 2. Concordance between sites was 92%. Designed for use with 10 ng genomic DNA, the assay detected HPV using as little as 1.25 ng FFPE-derived genomic DNA. In 266 cervical cancer specimens, the NGS assay identified 20 different HPV genotypes, including all 13 carcinogenic genotypes. This novel NGS assay provides a sensitive and specific high-throughput method to detect and genotype HPV in a range of clinical specimens derived from FFPE with low per-sample cost.",Journal Article,1415.0,14.0,Available clinical human papilloma virus HPV diagnostics for head and cancer have limited sensitivity and/or fail to define the HPV genotype Common HPV genotyping assays are costly and labor intensive We sought to develop a next-generation sequencing NGS -based HPV genotyping assay that was sensitive enough to work on formalin-fixed paraffin-embedded FFPE samples We developed an ion torrent NGS HPV genotyping assay using barcoded HPV PCR broad-spectrum general primers 5 /6 BSGP 5 /6 To validate genotype specificity and use in archived clinical FFPE tumor samples we compared NGS HPV genotyping at 2 sequencing centers with typing by Roche Linear Array assay in 42 and cancer specimens representing 10 HPV genotypes as well as HPV-negative cases To demonstrate the detection of a broad range of HPV genotypes we genotyped a cohort of 266 cancers A comparison of NGS genotyping of FFPE cancer specimens with genotyping by Linear Array showed concordant results in 34/37 samples 92 at sequencing site 1 and 39/42 samples 93 at sequencing site 2 Concordance between sites was 92 Designed for use with 10 ng genomic DNA the assay detected HPV using as little as 1.25 ng FFPE-derived genomic DNA In 266 cancer specimens the NGS assay identified 20 different HPV genotypes including all 13 carcinogenic genotypes This novel NGS assay provides a sensitive and specific high-throughput method to detect and genotype HPV in a range of clinical specimens derived from FFPE with low per-sample cost,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[390, 38, 171, 7017, 1450, 933, 5197, 9, 718, 2, 12, 47, 383, 485, 2, 15, 4373, 6, 1107, 3, 933, 1183, 186, 933, 2686, 1013, 32, 6288, 2, 9557, 1686, 21, 990, 6, 690, 8, 1305, 914, 615, 2650, 90, 933, 2686, 719, 17, 10, 745, 5151, 6, 1357, 23, 3265, 1959, 2487, 2505, 4412, 347, 21, 276, 35, 7714, 20837, 2650, 933, 2686, 719, 75, 32367, 933, 604, 2094, 1873, 1083, 10031, 33, 49, 67854, 33, 49, 6, 2183, 1183, 1121, 2, 119, 4, 6282, 38, 4412, 30, 347, 21, 72, 2650, 933, 2686, 28, 18, 615, 1168, 5, 10656, 20, 9777, 1646, 1926, 719, 4, 595, 2, 12, 623, 2861, 79, 933, 2071, 22, 149, 22, 933, 199, 140, 6, 608, 3, 638, 1, 8, 2094, 184, 1, 933, 2071, 21, 3053, 8, 180, 1, 8786, 163, 8, 1155, 1, 2650, 2686, 1, 4412, 12, 623, 5, 2686, 20, 1646, 1926, 224, 3610, 99, 4, 562, 567, 347, 937, 28, 615, 606, 14, 2, 587, 595, 347, 966, 28, 615, 606, 18, 1827, 59, 633, 10, 937, 1114, 9, 119, 5, 79, 997, 572, 261, 3, 719, 530, 933, 75, 22, 1215, 22, 14, 243, 997, 4412, 526, 572, 261, 4, 8786, 12, 623, 3, 2650, 719, 108, 179, 338, 933, 2071, 141, 62, 233, 7483, 2071, 26, 229, 2650, 719, 777, 8, 745, 2, 112, 64, 3643, 596, 6, 1426, 2, 1183, 933, 4, 8, 184, 1, 38, 623, 526, 29, 4412, 5, 154, 379, 1000, 835]",1492.0,27006646,3
Disparities in the management and outcome of cervical cancer in the United States according to health insurance status.,Gynecologic oncology,Gynecol. Oncol.,2016-03-25,"Our study sought to characterize the presentation, local management and outcomes of invasive cervical cancer with regard to patient insurance status. We queried the NCI-SEER database for invasive cervical cancer cases in patients aged 18-64 from 2007 to 2011. We analyzed clinical and socioeconomic data with regard insurance status (insured, Medicaid, or uninsured). We tested for associations between patient insurance status and treatment with definitive surgery for FIGO IA2-IB1 patients, and treatment with suboptimal radiation therapy (RT) for FIGO IB2-IVA patients (other than combination external beam and brachytherapy). We evaluated overall and cause specific survival according to insurance status. 11,714 cases were analyzed: 60% insured, 31% Medicaid, and 9% uninsured. FIGO III/IV stage at presentation was more frequent with Medicaid (40%) and uninsured (42%) compared to insured patients (28%) (p<0.001). For FIGO IA2-IB1 patients, receipt of definitive surgery was inversely associated with uninsured status (OR [95%CI]=0.65 [0.47-0.90], p<0.001) in univariable analysis; however the relationship lost significance after multivariable adjustment. For FIGO IB2-IVA patients, the use of suboptimal RT was associated with uninsured status (OR [95%CI]=1.33 [1.07-1.65], p=0.011) in adjusted analyses. Among all patients, overall mortality was increased with Medicaid (HR [95%CI]=1.16 [1.05-1.28], p=0.003) and uninsured status (HR [95%CI]=1.17 [1.01-1.34], p=0.031) in multivariable analysis. Cancer specific mortality survival trended towards significance in multivariable analyses for both Medicaid (HR [95%CI]=1.11 [1.00-1.24] and uninsured status (HR [95%CI]=1.14 [0.98-1.33]). Disparities in cervical cancer treatment with regard to insurance status are apparent in a recent cohort of American patients. Later stage at presentation and differences in management partially account for the inferior prognostic outcomes associated with Medicaid and uninsured status.",Journal Article,1397.0,17.0,"Our study sought to characterize the presentation local management and outcomes of invasive cancer with regard to patient insurance status We queried the NCI-SEER database for invasive cancer cases in patients aged 18-64 from 2007 to 2011 We analyzed clinical and socioeconomic data with regard insurance status insured Medicaid or uninsured We tested for associations between patient insurance status and treatment with definitive surgery for FIGO IA2-IB1 patients and treatment with suboptimal radiation therapy RT for FIGO IB2-IVA patients other than combination external beam and brachytherapy We evaluated overall and cause specific survival according to insurance status 11,714 cases were analyzed 60 insured 31 Medicaid and 9 uninsured FIGO III/IV stage at presentation was more frequent with Medicaid 40 and uninsured 42 compared to insured patients 28 p 0.001 For FIGO IA2-IB1 patients receipt of definitive surgery was inversely associated with uninsured status OR 95 CI =0.65 0.47-0.90 p 0.001 in univariable analysis however the relationship lost significance after multivariable adjustment For FIGO IB2-IVA patients the use of suboptimal RT was associated with uninsured status OR 95 CI =1.33 1.07-1.65 p=0.011 in adjusted analyses Among all patients overall mortality was increased with Medicaid HR 95 CI =1.16 1.05-1.28 p=0.003 and uninsured status HR 95 CI =1.17 1.01-1.34 p=0.031 in multivariable analysis Cancer specific mortality survival trended towards significance in multivariable analyses for both Medicaid HR 95 CI =1.11 1.00-1.24 and uninsured status HR 95 CI =1.14 0.98-1.33 Disparities in cancer treatment with regard to insurance status are apparent in a recent cohort of American patients Later stage at presentation and differences in management partially account for the inferior prognostic outcomes associated with Medicaid and uninsured status",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[114, 45, 990, 6, 1507, 3, 1031, 293, 284, 2, 123, 1, 416, 12, 5, 2539, 6, 69, 1935, 156, 21, 3547, 3, 2580, 1605, 609, 9, 416, 12, 140, 4, 7, 1032, 203, 660, 29, 1307, 6, 1132, 21, 311, 38, 2, 3331, 74, 5, 2539, 1935, 156, 4291, 2843, 15, 4955, 21, 650, 9, 685, 59, 69, 1935, 156, 2, 24, 5, 1057, 152, 9, 3837, 16725, 8111, 7, 2, 24, 5, 3291, 121, 36, 240, 9, 3837, 9537, 5900, 7, 127, 76, 150, 1455, 1345, 2, 1536, 21, 194, 63, 2, 708, 112, 25, 768, 6, 1935, 156, 175, 14189, 140, 11, 311, 335, 4291, 456, 2843, 2, 83, 4955, 3837, 316, 478, 82, 28, 1031, 10, 80, 908, 5, 2843, 327, 2, 4955, 595, 72, 6, 4291, 7, 339, 19, 13, 144, 9, 3837, 16725, 8111, 7, 1699, 1, 1057, 152, 10, 2659, 41, 5, 4955, 156, 15, 48, 58, 13, 556, 13, 662, 13, 424, 19, 13, 144, 4, 4084, 65, 137, 3, 858, 3009, 724, 50, 658, 1852, 9, 3837, 9537, 5900, 7, 3, 119, 1, 3291, 240, 10, 41, 5, 4955, 156, 15, 48, 58, 14, 466, 14, 1615, 14, 556, 19, 13, 3651, 4, 586, 318, 107, 62, 7, 63, 282, 10, 101, 5, 2843, 168, 48, 58, 14, 245, 14, 474, 14, 339, 19, 13, 1421, 2, 4955, 156, 168, 48, 58, 14, 269, 14, 355, 14, 562, 19, 13, 5304, 4, 658, 65, 12, 112, 282, 25, 6374, 3113, 724, 4, 658, 318, 9, 110, 2843, 168, 48, 58, 14, 175, 14, 2038, 14, 259, 2, 4955, 156, 168, 48, 58, 14, 213, 13, 1096, 14, 466, 2227, 4, 12, 24, 5, 2539, 6, 1935, 156, 32, 2235, 4, 8, 435, 180, 1, 597, 7, 1559, 82, 28, 1031, 2, 362, 4, 284, 2995, 1967, 9, 3, 1663, 177, 123, 41, 5, 2843, 2, 4955, 156]",1877.0,27012428,463
Comparison of Colposcopic Impression Based on Live Colposcopy and Evaluation of Static Digital Images.,Journal of lower genital tract disease,J Low Genit Tract Dis,2016-04-01,"The aim of the study was to evaluate the agreement and compare diagnostic accuracy of colposcopic impressions from live colposcopy versus evaluation of static digital images. Live impressions and corresponding static images obtained during colposcopy of 690 women were independently compared. Diagnostic accuracy was calculated for colposcopic impressions from both methods, varying hypothetical thresholds for colposcopically directed cervical biopsies (acetowhitening or worse, low grade or worse, high grade or worse). Stratified analyses investigated the impact of referral cytology, human papillomavirus 16 infection, and age on colposcopic impression. Overall agreement between live and static colposcopic visualization was 43.0% ( = 0.20; 95% CI = 0.14-0.26) over normal, acetowhitening, low-grade, and high-grade impressions. Classification of acetowhitening or worse impressions showed the highest agreement (92.2%;  = 0.39; 95% CI = 0.21-0.57); both methods achieved more than 95% sensitivity for CIN 2+. Agreement between live and static colposcopic visualization was 69.3% for rating low-grade or worse impressions ( = 0.23; 95% CI = 0.14-0.33) and 71% when rating high-grade impressions ( = 0.33; 95% CI = 0.24-0.42). Live colposcopic impressions were more likely to be rated low grade or worse (p < .01; odds ratio = 3.5; 95% CI = 2.4-5.0), yielding higher sensitivity for CIN 2+ at this threshold than static image assessment (95.4% vs 79.8%, p < .01). Overall, colposcopic impressions were more likely rated high grade on live assessment among women referred with high-grade cytology (odds ratio = 3.3; 95% CI = 1.8-6.4), significantly improving the sensitivity for CIN 2+ (66.3% vs 48.5%, p < .01). Colposcopic impressions of acetowhitening or worse are highly sensitive for identifying cervical precancers and reproducible on static image-based pattern recognition.",Comparative Study,1390.0,6.0,The aim of the study was to evaluate the agreement and compare diagnostic accuracy of colposcopic impressions from live colposcopy versus evaluation of static digital images Live impressions and corresponding static images obtained during colposcopy of 690 women were independently compared Diagnostic accuracy was calculated for colposcopic impressions from both methods varying hypothetical thresholds for colposcopically directed biopsies acetowhitening or worse low grade or worse high grade or worse Stratified analyses investigated the impact of referral cytology human papillomavirus 16 infection and age on colposcopic impression Overall agreement between live and static colposcopic visualization was 43.0  0.20 95 CI 0.14-0.26 over normal acetowhitening low-grade and high-grade impressions Classification of acetowhitening or worse impressions showed the highest agreement 92.2  0.39 95 CI 0.21-0.57 both methods achieved more than 95 sensitivity for CIN 2+ Agreement between live and static colposcopic visualization was 69.3 for rating low-grade or worse impressions  0.23 95 CI 0.14-0.33 and 71 when rating high-grade impressions  0.33 95 CI 0.24-0.42 Live colposcopic impressions were more likely to be rated low grade or worse p .01 odds ratio 3.5 95 CI 2.4-5.0 yielding higher sensitivity for CIN 2+ at this threshold than static image assessment 95.4 vs 79.8 p .01 Overall colposcopic impressions were more likely rated high grade on live assessment among women referred with high-grade cytology odds ratio 3.3 95 CI 1.8-6.4 significantly improving the sensitivity for CIN 2+ 66.3 vs 48.5 p .01 Colposcopic impressions of acetowhitening or worse are highly sensitive for identifying precancers and reproducible on static image-based pattern recognition,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1130, 1, 3, 45, 10, 6, 376, 3, 2024, 2, 932, 752, 1190, 1, 14131, 16250, 29, 3812, 9946, 185, 451, 1, 9708, 3271, 1572, 3812, 16250, 2, 1734, 9708, 1572, 683, 190, 9946, 1, 11648, 117, 11, 1042, 72, 752, 1190, 10, 981, 9, 14131, 16250, 29, 110, 636, 2990, 7045, 4634, 9, 26091, 1166, 1154, 32581, 15, 639, 154, 88, 15, 639, 64, 88, 15, 639, 1173, 318, 565, 3, 345, 1, 2096, 2045, 171, 3242, 245, 930, 2, 89, 23, 14131, 8925, 63, 2024, 59, 3812, 2, 9708, 14131, 6234, 10, 601, 13, 4627, 13, 179, 48, 58, 13, 213, 13, 432, 252, 295, 32581, 154, 88, 2, 64, 88, 16250, 947, 1, 32581, 15, 639, 16250, 224, 3, 1076, 2024, 937, 18, 4627, 13, 587, 48, 58, 13, 239, 13, 696, 110, 636, 513, 80, 76, 48, 485, 9, 4652, 18, 2024, 59, 3812, 2, 9708, 14131, 6234, 10, 790, 27, 9, 5477, 154, 88, 15, 639, 16250, 4627, 13, 382, 48, 58, 13, 213, 13, 466, 2, 792, 198, 5477, 64, 88, 16250, 4627, 13, 466, 48, 58, 13, 259, 13, 595, 3812, 14131, 16250, 11, 80, 322, 6, 40, 3982, 154, 88, 15, 639, 19, 355, 610, 197, 27, 33, 48, 58, 18, 39, 33, 13, 4949, 142, 485, 9, 4652, 18, 28, 26, 2390, 76, 9708, 1482, 455, 48, 39, 105, 842, 66, 19, 355, 63, 14131, 16250, 11, 80, 322, 3982, 64, 88, 23, 3812, 455, 107, 117, 1995, 5, 64, 88, 2045, 610, 197, 27, 27, 48, 58, 14, 66, 49, 39, 97, 1673, 3, 485, 9, 4652, 18, 700, 27, 105, 576, 33, 19, 355, 14131, 16250, 1, 32581, 15, 639, 32, 561, 745, 9, 1386, 18753, 2, 4172, 23, 9708, 1482, 90, 1177, 2335]",1774.0,27015261,49
Initiation of a formalized precision medicine program in gynecologic oncology.,Gynecologic oncology,Gynecol. Oncol.,2016-04-01,"In an effort to better incorporate precision medicine into clinical practice, we initiated a pilot project to screen, discuss, and genetically characterize patients with metastatic or recurrent gynecologic malignancies for whom no curative standard of care exists. In 7/2014, we initiated a multi-disciplinary Precision Medicine Board (PMB) whose purpose was to apply molecular profiling to select and prioritize early phase clinical trial enrollment for high-risk gynecologic malignancies. Additional objectives were to record outcomes and enable scientific discussions of mutations which may foster local translational research. FoundationOne was the preferred genomic platform; results were reviewed by a team comprised of disease site specialists, phase I trialists, and basic and translational scientists affiliated with the Gynecologic Cancer Program. A detailed database for each patient was created and is followed prospectively for treatment use and resultant outcomes. To date, we have presented 62 cases with interpretable FoundationOne testing on 60 tumor samples (31 ovarian, 18 uterine, 9 cervical, and 4 other female genital tract). Significant genomic alterations were commonly found in all tumor types (median: 3); TP53 (45%) and PIK3CA (27%) were the most frequently noted mutations; however, molecular profiling resulted in identification of few actionable mutations (6%). To date, we have matched 4 patients on therapies based on actionable mutations. The predominant function of our PMB is establishment of a forum to enhance research while providing clinical care for refractory malignancies. We have matched patients with specific mutations to ongoing trials and are developing investigator-initiated studies based on trends within genomic profiling results. Longer-term follow up will be required to determine the success of this strategy.",Journal Article,1390.0,7.0,In an effort to better incorporate precision medicine into clinical practice we initiated a pilot project to screen discuss and genetically characterize patients with metastatic or recurrent gynecologic malignancies for whom no curative standard of care exists In 7/2014 we initiated a multi-disciplinary Precision Medicine Board PMB whose purpose was to apply molecular profiling to select and prioritize early phase clinical trial enrollment for high-risk gynecologic malignancies Additional objectives were to record outcomes and enable scientific discussions of mutations which may foster local translational research FoundationOne was the preferred genomic platform results were reviewed by a team comprised of disease site specialists phase I trialists and basic and translational scientists affiliated with the Gynecologic Cancer Program A detailed database for each patient was created and is followed prospectively for treatment use and resultant outcomes To date we have presented 62 cases with interpretable FoundationOne testing on 60 tumor samples 31 18 9 and 4 other female genital tract Significant genomic alterations were commonly found in all tumor types median 3 TP53 45 and PIK3CA 27 were the most frequently noted mutations however molecular profiling resulted in identification of few actionable mutations 6 To date we have matched 4 patients on therapies based on actionable mutations The predominant function of our PMB is establishment of a forum to enhance research while providing clinical care for refractory malignancies We have matched patients with specific mutations to ongoing trials and are developing investigator-initiated studies based on trends within genomic profiling results Longer-term follow up will be required to determine the success of this strategy,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[4, 35, 2919, 6, 380, 3360, 2720, 1807, 237, 38, 758, 21, 1917, 8, 2281, 3105, 6, 2413, 1139, 2, 2301, 1507, 7, 5, 113, 15, 387, 1512, 441, 9, 953, 77, 1075, 260, 1, 165, 2481, 4, 67, 1409, 21, 1917, 8, 1414, 15726, 2720, 1807, 2620, 34433, 1310, 743, 10, 6, 4930, 219, 1080, 6, 1717, 2, 7716, 191, 124, 38, 160, 1798, 9, 64, 43, 1512, 441, 402, 2409, 11, 6, 3237, 123, 2, 3047, 3138, 3173, 1, 138, 92, 68, 9899, 293, 2460, 389, 15437, 10, 3, 2514, 572, 2243, 99, 11, 446, 20, 8, 2870, 2603, 1, 34, 606, 4409, 124, 70, 19497, 2, 2795, 2, 2460, 6868, 9048, 5, 3, 1512, 12, 1243, 8, 2455, 609, 9, 296, 69, 10, 2466, 2, 16, 370, 1143, 9, 24, 119, 2, 6099, 123, 6, 1244, 21, 47, 917, 744, 140, 5, 19606, 15437, 471, 23, 335, 30, 347, 456, 203, 83, 2, 39, 127, 1061, 8226, 1696, 93, 572, 593, 11, 841, 204, 4, 62, 30, 630, 52, 27, 1206, 512, 2, 1506, 428, 11, 3, 96, 746, 1051, 138, 137, 219, 1080, 627, 4, 911, 1, 1021, 2856, 138, 49, 6, 1244, 21, 47, 655, 39, 7, 23, 235, 90, 23, 2856, 138, 3, 2750, 343, 1, 114, 34433, 16, 5346, 1, 8, 8037, 6, 1304, 389, 369, 1736, 38, 165, 9, 430, 441, 21, 47, 655, 7, 5, 112, 138, 6, 942, 143, 2, 32, 931, 3464, 1917, 94, 90, 23, 1963, 262, 572, 1080, 99, 589, 337, 166, 126, 303, 40, 616, 6, 223, 3, 1825, 1, 26, 692]",1796.0,27016225,65
Preoperative catheter spinal angiography and embolization of cervical spinal tumors: Outcomes from a single center.,"Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences",Interv Neuroradiol,2016-03-27,"The existing literature regarding preoperative cervical spinal tumor embolization is sparse, with few discussions on the indications, risks, and best techniques. We present our experience with the preoperative endovascular management of hypervascular cervical spinal tumors. We performed a retrospective review of all patients who underwent preoperative spinal angiography (regardless of whether tumor embolization was performed) at our institution (from 2002 to 2012) for primary and metastatic cervical spinal tumors. Tumor vascularity was graded from 0 (tumor blush equal to the normal adjacent vertebral body) to 3 (intense tumor blush with arteriovenous shunting). Tumors were considered ""hypervascular"" if they had a tumor vascular grade from 1 to 3. Embolic materials included particles, liquid embolics, and detachable coils. The main embolization technique was superselective catheterization of an arterial tumor feeder followed by injection of embolic material. This technique could be used alone or supplemented with occlusion of dangerous anastomoses of the vertebral artery as needed to prevent inadvertent embolization of the vertebrobasilar system. In cases when superselective catheterization of the tumoral feeder was not feasible, embolization was performed from a proximal catheter position after occlusion of branches supplying areas other than the tumor (""flow diversion""). A total of 47 patients with 49 cervical spinal tumors were included in this study. Of the 49 total tumors, 41 demonstrated increased vascularity (vascularity score>0). The most common tumor pathology in our series was renal cell carcinoma (RCC) (N=16; 32.7% of all tumors) followed by thyroid carcinoma (N=7; 14.3% of all tumors).Tumor embolization was undertaken in 25 hypervascular tumors resulting in complete, near-complete, and partial embolization in 36.0% (N=9), 44.0% (N=11), and 20.0% (N=5) of embolized tumors, respectively. We embolized 42 tumor feeders in 25 tumors. The most commonly embolized tumor feeders were branches of the vertebral artery (19.0%; N=8), the deep cervical artery (19.0%; N=8), and the ascending cervical artery (19.0%; N=8). Sixteen hypervascular tumors were not embolized because of minimal hypervascularity (8/16), unacceptably high risk of spinal cord or vertebrobasilar ischemia (4/16), failed superselective catheterization of tumor feeder (3/16), and cancellation of surgery (1/16). Vertebral artery occlusion was performed in 20% of embolizations. There were no new post-procedure neurological deficits or any serious adverse events. Estimated blood loss data from this cohort show a significant decrease in operative blood loss for embolized tumors of moderate and significant hypervascularity. Preoperative embolization of cervical spinal tumors can be performed safely and effectively in centers with significant experience and a standardized approach.",Journal Article,1395.0,3.0,The existing literature regarding preoperative spinal tumor embolization is sparse with few discussions on the indications risks and best techniques We present our experience with the preoperative endovascular management of hypervascular spinal tumors We performed a retrospective review of all patients who underwent preoperative spinal angiography regardless of whether tumor embolization was performed at our institution from 2002 to 2012 for primary and metastatic spinal tumors Tumor vascularity was graded from 0 tumor blush equal to the normal adjacent vertebral body to 3 intense tumor blush with arteriovenous shunting Tumors were considered `` hypervascular '' if they had a tumor vascular grade from 1 to 3 Embolic materials included particles liquid embolics and detachable coils The main embolization technique was superselective catheterization of an arterial tumor feeder followed by injection of embolic material This technique could be used alone or supplemented with occlusion of dangerous anastomoses of the vertebral artery as needed to prevent inadvertent embolization of the vertebrobasilar system In cases when superselective catheterization of the tumoral feeder was not feasible embolization was performed from a proximal catheter position after occlusion of branches supplying areas other than the tumor `` flow diversion '' A total of 47 patients with 49 spinal tumors were included in this study Of the 49 total tumors 41 demonstrated increased vascularity vascularity score 0 The most common tumor pathology in our series was cell carcinoma RCC N 16 32.7 of all tumors followed by carcinoma N 7 14.3 of all tumors .Tumor embolization was undertaken in 25 hypervascular tumors resulting in complete near-complete and partial embolization in 36.0 N 9 44.0 N 11 and 20.0 N 5 of embolized tumors respectively We embolized 42 tumor feeders in 25 tumors The most commonly embolized tumor feeders were branches of the vertebral artery 19.0 N 8 the deep artery 19.0 N 8 and the ascending artery 19.0 N 8 Sixteen hypervascular tumors were not embolized because of minimal hypervascularity 8/16 unacceptably high risk of spinal cord or vertebrobasilar ischemia 4/16 failed superselective catheterization of tumor feeder 3/16 and cancellation of surgery 1/16 Vertebral artery occlusion was performed in 20 of embolizations There were no new post-procedure neurological deficits or any serious adverse events Estimated blood loss data from this cohort show a significant decrease in operative blood loss for embolized tumors of moderate and significant hypervascularity Preoperative embolization of spinal tumors can be performed safely and effectively in centers with significant experience and a standardized approach,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[3, 1692, 789, 666, 498, 1499, 30, 4232, 16, 7425, 5, 1021, 3173, 23, 3, 2406, 1098, 2, 824, 1092, 21, 364, 114, 730, 5, 3, 498, 30942, 284, 1, 13855, 1499, 57, 21, 173, 8, 459, 206, 1, 62, 7, 54, 208, 498, 1499, 8078, 1583, 1, 317, 30, 4232, 10, 173, 28, 114, 731, 29, 1544, 6, 1195, 9, 86, 2, 113, 1499, 57, 30, 7093, 10, 3468, 29, 13, 30, 21711, 2997, 6, 3, 295, 2086, 4731, 642, 6, 27, 3933, 30, 21711, 5, 15732, 14158, 57, 11, 515, 13855, 522, 492, 491, 42, 8, 30, 756, 88, 29, 14, 6, 27, 15510, 5102, 159, 6095, 3165, 47951, 2, 40492, 20418, 3, 1895, 4232, 1312, 10, 22086, 15173, 1, 35, 3127, 30, 23825, 370, 20, 1754, 1, 15510, 3692, 26, 1312, 359, 40, 95, 279, 15, 7687, 5, 9742, 1, 22026, 13311, 1, 3, 4731, 2872, 22, 575, 6, 1682, 18344, 4232, 1, 3, 49646, 398, 4, 140, 198, 22086, 15173, 1, 3, 4204, 23825, 10, 44, 1313, 4232, 10, 173, 29, 8, 2805, 3925, 3559, 50, 9742, 1, 13873, 31254, 1361, 127, 76, 3, 30, 1412, 6067, 522, 8, 181, 1, 662, 7, 5, 739, 1499, 57, 11, 159, 4, 26, 45, 1, 3, 739, 181, 57, 605, 264, 101, 7093, 7093, 368, 13, 3, 96, 186, 30, 1117, 4, 114, 988, 10, 31, 134, 796, 78, 245, 531, 67, 1, 62, 57, 370, 20, 134, 78, 67, 213, 27, 1, 62, 57, 30, 4232, 10, 2789, 4, 243, 13855, 57, 1113, 4, 236, 1829, 236, 2, 450, 4232, 4, 511, 13, 78, 83, 584, 13, 78, 175, 2, 179, 13, 78, 33, 1, 18975, 57, 106, 21, 18975, 595, 30, 24129, 4, 243, 57, 3, 96, 841, 18975, 30, 24129, 11, 13873, 1, 3, 4731, 2872, 326, 13, 78, 66, 3, 2369, 2872, 326, 13, 78, 66, 2, 3, 14404, 2872, 326, 13, 78, 66, 3228, 13855, 57, 11, 44, 18975, 408, 1, 1048, 28033, 66, 245, 11934, 64, 43, 1, 1499, 1885, 15, 49646, 5675, 39, 245, 1551, 22086, 15173, 1, 30, 23825, 27, 245, 2, 43874, 1, 152, 14, 245, 4731, 2872, 9742, 10, 173, 4, 179, 1, 24902, 125, 11, 77, 217, 539, 1299, 3622, 2752, 15, 500, 1762, 290, 281, 661, 315, 407, 74, 29, 26, 180, 514, 8, 93, 775, 4, 1208, 315, 407, 9, 18975, 57, 1, 1163, 2, 93, 28033, 498, 4232, 1, 1499, 57, 122, 40, 173, 2268, 2, 1856, 4, 1168, 5, 93, 730, 2, 8, 1670, 353]",2736.0,27020696,233
Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2016-04-15,"Small cell cervical cancer is a rare malignancy with limited treatment options for recurrent disease. We sought to determine if tumor specimens of small cell cervical cancer harbor common somatic mutations and if any of these are actionable. Using a registry of patients with neuroendocrine cervical cancer, we identified 44 patients with pure or mixed small cell cervical cancer who had undergone mutational analysis. Mutations had been detected using next generation sequencing of mutational hotspots in 50 cancer-related genes. Thirty-five mutations were identified in 24 patients (55%). Fifteen of these 24 patients (63%) had 1 mutation, 7 patients (29%) had 2 mutations, and 2 patients (8%) had 3 mutations. In all 44 patients, the most commonly seen mutations were mutations in PIK3CA (8 patients; 18%), KRAS (6 patients; 14%), and TP53 (5 patients; 11%). No other mutation was found in >7% of specimens. Of the 24 patients who had a mutation, 21 (88%) had at least 1 alteration for which there currently exists a class of biological agents targeting that mutation. In the entire cohort of 44 patients, 48% had at least 1 actionable mutation. Although no single mutation was found in the majority of patients with small cell cervical cancer, almost half had at least 1 actionable mutation. As treatment options for patients with recurrent small cell cervical cancer are currently very limited, molecular testing for targetable mutations, which may suggest potential therapeutic strategies, may be useful for clinicians and patients.",Journal Article,1376.0,13.0,Small cell cancer is a rare malignancy with limited treatment options for recurrent disease We sought to determine if tumor specimens of small cell cancer harbor common somatic mutations and if any of these are actionable Using a registry of patients with neuroendocrine cancer we identified 44 patients with pure or mixed small cell cancer who had undergone mutational analysis Mutations had been detected using next generation sequencing of mutational hotspots in 50 cancer-related genes Thirty-five mutations were identified in 24 patients 55 Fifteen of these 24 patients 63 had 1 mutation 7 patients 29 had 2 mutations and 2 patients 8 had 3 mutations In all 44 patients the most commonly seen mutations were mutations in PIK3CA 8 patients 18 KRAS 6 patients 14 and TP53 5 patients 11 No other mutation was found in 7 of specimens Of the 24 patients who had a mutation 21 88 had at least 1 alteration for which there currently exists a class of biological agents targeting that mutation In the entire cohort of 44 patients 48 had at least 1 actionable mutation Although no single mutation was found in the majority of patients with small cell cancer almost half had at least 1 actionable mutation As treatment options for patients with recurrent small cell cancer are currently very limited molecular testing for targetable mutations which may suggest potential therapeutic strategies may be useful for clinicians and patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[302, 31, 12, 16, 8, 622, 710, 5, 383, 24, 838, 9, 387, 34, 21, 990, 6, 223, 492, 30, 623, 1, 302, 31, 12, 2760, 186, 1119, 138, 2, 492, 500, 1, 46, 32, 2856, 75, 8, 1608, 1, 7, 5, 1542, 12, 21, 108, 584, 7, 5, 3092, 15, 1739, 302, 31, 12, 54, 42, 1989, 1619, 65, 138, 42, 85, 530, 75, 1305, 914, 615, 1, 1619, 11193, 4, 212, 12, 139, 214, 977, 365, 138, 11, 108, 4, 259, 7, 614, 3057, 1, 46, 259, 7, 676, 42, 14, 258, 67, 7, 462, 42, 18, 138, 2, 18, 7, 66, 42, 27, 138, 4, 62, 584, 7, 3, 96, 841, 527, 138, 11, 138, 4, 1506, 66, 7, 203, 723, 49, 7, 213, 2, 1206, 33, 7, 175, 77, 127, 258, 10, 204, 4, 67, 1, 623, 1, 3, 259, 7, 54, 42, 8, 258, 239, 889, 42, 28, 506, 14, 2611, 9, 92, 125, 694, 2481, 8, 1040, 1, 1037, 183, 529, 17, 258, 4, 3, 1797, 180, 1, 584, 7, 576, 42, 28, 506, 14, 2856, 258, 242, 77, 226, 258, 10, 204, 4, 3, 686, 1, 7, 5, 302, 31, 12, 2214, 1303, 42, 28, 506, 14, 2856, 258, 22, 24, 838, 9, 7, 5, 387, 302, 31, 12, 32, 694, 923, 383, 219, 471, 9, 3985, 138, 92, 68, 309, 174, 189, 422, 68, 40, 999, 9, 1490, 2, 7]",1430.0,27079212,430
Programmable protein arrays for immunoprofiling HPV-associated cancers.,Proteomics,Proteomics,2016-04-04,"Over 600,000 cancers each year are attributed to the human papillomavirus (HPV), including cervical, anogenital and oropharyngeal cancers (OPC). A key challenge in understanding HPV immunobiology is the diversity of oncogenic HPV types and the need for multiplexed display of HPV antigens to measure antibody responses. We have generated custom HPV protein microarrays displaying 98 proteins as C-terminal GST fusion proteins, representing eight antigens of two low-risk HPV types (HPV6 and 11) and ten oncogenic high-risk HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52 and 58). We demonstrate robust and reproducible protein expression of 96/98 of the antigens using a human cell lysate expression system. The target epitopes and specificities of four monoclonal antibodies were identified. Using sera from ten patients with newly diagnosed OPC and ten controls, we demonstrate specific IgG seroreactivity to HPV16 E1, E2, and E7 (a fold increase of 1.52, 2.19 and 1.35 in cases vs. controls, respectively, all p < 0.005), confirming our prior data on an ELISA platform. We also detect HPV52 E7 Abs in serum from a patient with cervical cancer. The HPV protein array has potential for rapid identification of serologic responses to 12 HPV types.",Journal Article,1387.0,8.0,"Over 600,000 cancers each year are attributed to the human papillomavirus HPV including anogenital and cancers OPC A key challenge in understanding HPV immunobiology is the diversity of oncogenic HPV types and the need for multiplexed display of HPV antigens to measure antibody responses We have generated custom HPV protein microarrays displaying 98 proteins as C-terminal GST fusion proteins representing eight antigens of two low-risk HPV types HPV6 and 11 and ten oncogenic high-risk HPV types HPV16 18 31 33 35 39 45 51 52 and 58 We demonstrate robust and reproducible protein expression of 96/98 of the antigens using a human cell lysate expression system The target epitopes and specificities of four monoclonal antibodies were identified Using sera from ten patients with newly diagnosed OPC and ten controls we demonstrate specific IgG seroreactivity to HPV16 E1 E2 and E7 a fold increase of 1.52 2.19 and 1.35 in cases vs. controls respectively all p 0.005 confirming our prior data on an ELISA platform We also detect HPV52 E7 Abs in serum from a patient with cancer The HPV protein array has potential for rapid identification of serologic responses to 12 HPV types",0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[252, 2383, 984, 163, 296, 111, 32, 3073, 6, 3, 171, 3242, 933, 141, 13836, 2, 163, 4654, 8, 825, 1745, 4, 612, 933, 18842, 16, 3, 3653, 1, 1302, 933, 630, 2, 3, 594, 9, 7734, 3640, 1, 933, 1575, 6, 1463, 548, 253, 21, 47, 1419, 6980, 933, 178, 2774, 6609, 1096, 652, 22, 256, 2158, 5645, 1212, 652, 2861, 659, 1575, 1, 100, 154, 43, 933, 630, 41407, 2, 175, 2, 1618, 1302, 64, 43, 933, 630, 4048, 203, 456, 466, 465, 587, 512, 725, 653, 2, 717, 21, 608, 1922, 2, 4172, 178, 55, 1, 921, 1096, 1, 3, 1575, 75, 8, 171, 31, 8758, 55, 398, 3, 283, 4915, 2, 10571, 1, 294, 848, 890, 11, 108, 75, 4210, 29, 1618, 7, 5, 732, 265, 4654, 2, 1618, 535, 21, 608, 112, 3630, 22268, 6, 4048, 6778, 5036, 2, 4540, 8, 1116, 344, 1, 14, 653, 18, 326, 2, 14, 465, 4, 140, 105, 535, 106, 62, 19, 13, 1614, 5030, 114, 324, 74, 23, 35, 3664, 2243, 21, 120, 1426, 41408, 4540, 7723, 4, 524, 29, 8, 69, 5, 12, 3, 933, 178, 1926, 71, 174, 9, 1321, 911, 1, 7850, 253, 6, 133, 933, 630]",1178.0,27089055,653
Adjuvant radiotherapy versus concurrent chemoradiotherapy for the management of high-risk salivary gland carcinomas.,Head & neck,Head Neck,2016-04-21,"Given the aggressive behavior of advanced salivary malignancies, the purpose of the current study was to explore the utility of adjuvant chemoradiotherapy (CRT) in this population. A retrospective study of salivary carcinomas treated from 1998 to 2013 with postoperative CRT (37 patients) or radiotherapy (RT; 103 patients) was completed. The decision to utilize adjuvant CRT versus RT was influenced by tumor grade and histology, cervical lymph node status, surgical margins, and perineural invasion. In both treatment cohorts, high locoregional control rates were obtained (79% for CRT vs 91% for RT; p = .031). Multivariate Cox regression analysis did not identify a difference in 3-year progression-free survival (PFS) with the use of CRT versus RT (hazard ratio [HR] = 0.783; 95% confidence interval [CI] = 0.396-1.549; p = .482). Until prospective evidence is available, such as from Radiation Therapy Oncology Group 1008, the standard use of CRT for advanced salivary malignancies cannot be recommended.  2016 Wiley Periodicals, Inc. Head Neck 38: 1708-1716, 2016.",Comparative Study,1370.0,19.0,Given the aggressive behavior of advanced malignancies the purpose of the current study was to explore the utility of adjuvant chemoradiotherapy CRT in this population A retrospective study of carcinomas treated from 1998 to 2013 with postoperative CRT 37 patients or radiotherapy RT 103 patients was completed The decision to utilize adjuvant CRT versus RT was influenced by tumor grade and histology lymph node status surgical margins and perineural invasion In both treatment cohorts high locoregional control rates were obtained 79 for CRT vs 91 for RT p .031 Multivariate Cox regression analysis did not identify a difference in 3-year progression-free survival PFS with the use of CRT versus RT hazard ratio HR 0.783 95 confidence interval CI 0.396-1.549 p .482 Until prospective evidence is available such as from Radiation Therapy Oncology Group 1008 the standard use of CRT for advanced malignancies can not be recommended  2016 Wiley Periodicals Inc. Head 38 1708-1716 2016,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[447, 3, 571, 1710, 1, 131, 441, 3, 743, 1, 3, 291, 45, 10, 6, 1645, 3, 1207, 1, 249, 1464, 1089, 4, 26, 266, 8, 459, 45, 1, 826, 73, 29, 1850, 6, 1346, 5, 573, 1089, 567, 7, 15, 310, 240, 3283, 7, 10, 781, 3, 948, 6, 6391, 249, 1089, 185, 240, 10, 2574, 20, 30, 88, 2, 784, 263, 289, 156, 221, 1012, 2, 4917, 578, 4, 110, 24, 736, 64, 1325, 182, 151, 11, 683, 842, 9, 1089, 105, 970, 9, 240, 19, 5304, 331, 418, 320, 65, 205, 44, 255, 8, 523, 4, 27, 111, 91, 115, 25, 300, 5, 3, 119, 1, 1089, 185, 240, 360, 197, 168, 13, 14149, 48, 307, 268, 58, 13, 9987, 14, 10224, 19, 10560, 1100, 482, 241, 16, 390, 225, 22, 29, 121, 36, 413, 87, 24658, 3, 260, 119, 1, 1089, 9, 131, 441, 122, 44, 40, 793, 2206, 1390, 4692, 5493, 3479, 718, 519, 68032, 68033, 1390]",984.0,27098984,18
Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.,Pituitary,Pituitary,2016-08-01,"Pituitary carcinomas (PC) are uncommon neuroendocrine tumors, accounting for 0.1% of all pituitary tumors. The diagnosis of PC is based on the presence of metastases from a pituitary adenoma, and not by local invasion or pathological features alone. PC is typically resistant to therapy, with a median overall survival of only 31months. There is no standard treatment for PC, but maximal safe resection and radiation are performed when possible. Encouraging preliminary data on the use of temozolomide (TMZ)-based therapy has been previously reported. We report the response to therapy and safety of radiation with concurrent temozolomide (RT/TMZ) in 2 adult patients with heavily pretreated PC and extraneural metastases. Both patients had prior history of pituitary macroadenoma. At the time of diagnosis of PC, Ki-67% was 24.2 and 10%, with positive p53 staining in one case. Metastatic sites included lymph nodes, liver and bone. Case-1 received RT/TMZ to the tumor bed in the skull base and to the metastases in the cervical lymph nodes. Case-2 received RT/TMZ to recurrent tumor involving portacaval lymph nodes. Both patients achieved excellent long-term control of the sites of treated extraneural metastases, with no significant acute or delayed toxicity. RT/TMZ was safely delivered and might provide sustained control of extraneural metastases in PC. Although this retrospective report has limitations, RT/TMZ can be considered as a therapeutic option for the management of extraneural metastases in PC.",Case Reports,1268.0,8.0,carcinomas PC are uncommon neuroendocrine tumors accounting for 0.1 of all tumors The diagnosis of PC is based on the presence of metastases from a adenoma and not by local invasion or pathological features alone PC is typically resistant to therapy with a median overall survival of only 31 months There is no standard treatment for PC but maximal safe resection and radiation are performed when possible Encouraging preliminary data on the use of temozolomide TMZ -based therapy has been previously reported We report the response to therapy and safety of radiation with concurrent temozolomide RT/TMZ in 2 adult patients with heavily pretreated PC and extraneural metastases Both patients had prior history of macroadenoma At the time of diagnosis of PC Ki-67 was 24.2 and 10 with positive p53 staining in one case Metastatic sites included lymph nodes and Case-1 received RT/TMZ to the tumor bed in the skull base and to the metastases in the lymph nodes Case-2 received RT/TMZ to recurrent tumor involving portacaval lymph nodes Both patients achieved excellent long-term control of the sites of treated extraneural metastases with no significant acute or delayed toxicity RT/TMZ was safely delivered and might provide sustained control of extraneural metastases in PC Although this retrospective report has limitations RT/TMZ can be considered as a therapeutic option for the management of extraneural metastases in PC,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[826, 1341, 32, 2052, 1542, 57, 3116, 9, 13, 14, 1, 62, 57, 3, 147, 1, 1341, 16, 90, 23, 3, 463, 1, 196, 29, 8, 2434, 2, 44, 20, 293, 578, 15, 1301, 404, 279, 1341, 16, 1969, 436, 6, 36, 5, 8, 52, 63, 25, 1, 158, 456, 53, 125, 16, 77, 260, 24, 9, 1341, 84, 2725, 1165, 170, 2, 121, 32, 173, 198, 899, 2269, 1676, 74, 23, 3, 119, 1, 1537, 2081, 90, 36, 71, 85, 373, 210, 21, 414, 3, 51, 6, 36, 2, 367, 1, 121, 5, 750, 1537, 240, 2081, 4, 18, 780, 7, 5, 2447, 2193, 1341, 2, 16431, 196, 110, 7, 42, 324, 532, 1, 27905, 28, 3, 98, 1, 147, 1, 1341, 2311, 598, 10, 259, 18, 2, 79, 5, 109, 624, 1029, 4, 104, 473, 113, 633, 159, 263, 502, 2, 473, 14, 103, 240, 2081, 6, 3, 30, 2929, 4, 3, 5054, 1782, 2, 6, 3, 196, 4, 3, 263, 502, 473, 18, 103, 240, 2081, 6, 387, 30, 1267, 46882, 263, 502, 110, 7, 513, 1503, 319, 337, 182, 1, 3, 633, 1, 73, 16431, 196, 5, 77, 93, 286, 15, 1612, 155, 240, 2081, 10, 2268, 1623, 2, 822, 377, 2275, 182, 1, 16431, 196, 4, 1341, 242, 26, 459, 414, 71, 1939, 240, 2081, 122, 40, 515, 22, 8, 189, 1501, 9, 3, 284, 1, 16431, 196, 4, 1341]",1424.0,27106209,262
"Primary NK/T-cell lymphoma of the larynx: Report of 2 cases and review of the English-, Japanese-, and Chinese-language literature.","Ear, nose, & throat journal",Ear Nose Throat J,,"Natural killer/T (NK/T) -cell lymphoma in the larynx is extremely rare, as only 29 cases have been previously reported in the English-language, Japanese-language, and Chinese-language literature. Its characteristics have never been systematically illustrated. We report 2 new cases of laryngeal NK/T-cell lymphoma, and we discuss the process of the diagnosis of this disease, the choice of treatment, and treatment outcomes. We also summarize all 31 cases reported thus far. Symptoms of laryngeal NK/T-cell lymphoma are difficult to differentiate from those of other laryngeal diseases. The most common laryngeal subsite in the reported cases was the supraglottis, and roughly one-third of these cases involved the cervical lymph nodes. Because of our limited experience with this disease and the difficulties encountered in interpreting the pathologic findings, most patients required multiple biopsies over a few months before their diagnosis was confirmed. The outcome of treatment was generally poor. Radiotherapy, alone or combined with chemotherapy, was superior to chemotherapy alone in treating this disease in its early stages. In view of the frequency of local lymph node metastasis, irradiation fields should cover the entire cervical area. We believe that prompt diagnosis and treatment with radiotherapy are both critical to improving survival for patients with laryngeal NK/T-cell lymphoma. ",Case Reports,,3.0,Natural killer/T NK/T -cell in the larynx is extremely rare as only 29 cases have been previously reported in the English-language Japanese-language and Chinese-language literature Its characteristics have never been systematically illustrated We report 2 new cases of NK/T-cell and we discuss the process of the diagnosis of this disease the choice of treatment and treatment outcomes We also summarize all 31 cases reported thus far Symptoms of NK/T-cell are difficult to differentiate from those of other diseases The most common subsite in the reported cases was the supraglottis and roughly one-third of these cases involved the lymph nodes Because of our limited experience with this disease and the difficulties encountered in interpreting the pathologic findings most patients required multiple biopsies over a few months before their diagnosis was confirmed The outcome of treatment was generally poor Radiotherapy alone or combined with chemotherapy was superior to chemotherapy alone in treating this disease in its early stages In view of the frequency of local lymph node metastasis irradiation fields should cover the entire area We believe that prompt diagnosis and treatment with radiotherapy are both critical to improving survival for patients with NK/T-cell,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1504, 3458, 102, 1765, 102, 31, 4, 3, 4308, 16, 2938, 622, 22, 158, 462, 140, 47, 85, 373, 210, 4, 3, 4201, 4794, 5256, 4794, 2, 3656, 4794, 789, 211, 374, 47, 1737, 85, 3390, 8508, 21, 414, 18, 217, 140, 1, 1765, 102, 31, 2, 21, 1139, 3, 1129, 1, 3, 147, 1, 26, 34, 3, 1866, 1, 24, 2, 24, 123, 21, 120, 2479, 62, 456, 140, 210, 631, 3272, 507, 1, 1765, 102, 31, 32, 1740, 6, 3723, 29, 135, 1, 127, 1342, 3, 96, 186, 9483, 4, 3, 210, 140, 10, 3, 68097, 2, 7954, 104, 1282, 1, 46, 140, 646, 3, 263, 502, 408, 1, 114, 383, 730, 5, 26, 34, 2, 3, 4679, 3903, 4, 8876, 3, 510, 272, 96, 7, 616, 232, 1154, 252, 8, 1021, 53, 348, 136, 147, 10, 557, 3, 228, 1, 24, 10, 1228, 334, 310, 279, 15, 397, 5, 56, 10, 1123, 6, 56, 279, 4, 1367, 26, 34, 4, 211, 191, 1153, 4, 3811, 1, 3, 675, 1, 293, 263, 289, 278, 1104, 3130, 257, 8308, 3, 1797, 965, 21, 4629, 17, 4776, 147, 2, 24, 5, 310, 32, 110, 740, 6, 1673, 25, 9, 7, 5, 1765, 102, 31]",1276.0,27140022,12
Loss of Dependence on Continued Expression of the Human Papillomavirus 16 E7 Oncogene in Cervical Cancers and Precancerous Lesions Arising in Fanconi Anemia Pathway-Deficient Mice.,mBio,mBio,2016-05-17,"Fanconi anemia (FA) is a rare genetic disorder caused by defects in DNA damage repair. FA patients often develop squamous cell carcinoma (SCC) at sites where high-risk human papillomaviruses (HPVs) are known to cause cancer, including the cervix. However, SCCs found in human FA patients are often HPV negative, even though the majority of female FA patients with anogenital cancers had preexisting HPV-positive dysplasia. We hypothesize that HPVs contribute to the development of SCCs in FA patients but that the continued expression of HPV oncogenes is not required for the maintenance of the cancer state because FA deficiency leads to an accumulation of mutations in cellular genes that render the cancer no longer dependent upon viral oncogenes. We tested this hypothesis, making use of Bi-L E7 transgenic mice in which we temporally controlled expression of HPV16 E7, the dominant viral oncogene in HPV-associated cancers. As seen before, the persistence of cervical neoplastic disease was highly dependent upon the continued expression of HPV16 E7 in FA-sufficient mice. However, in mice with FA deficiency, cervical cancers persisted in a large fraction of the mice after HPV16 E7 expression was turned off, indicating that these cancers had escaped from their dependency on E7. Furthermore, the severity of precancerous lesions also failed to be reduced significantly in the mice with FA deficiency upon turning off expression of E7. These findings confirm our hypothesis and may explain the fact that, while FA patients have a high frequency of infections by HPVs and HPV-induced precancerous lesions, the cancers are frequently HPV negative. IMPORTANCE: Fanconi anemia (FA) patients are at high risk for developing squamous cell carcinoma (SCC) at sites where high-risk human papillomaviruses (HPVs) frequently cause cancer. Yet these SCCs are often HPV negative. FA patients have a genetic defect in their capacity to repair damaged DNA. HPV oncogenes cause an accumulation of DNA damage. We hypothesize, therefore, that DNA damage induced by HPV leads to an accumulation of mutations in patients with FA deficiency and that such mutations allow HPV-driven cancers to become independent of the viral oncogenes. Consistent with this hypothesis, we found that cervical cancers arising in HPV16 transgenic mice with FA deficiency frequently escape from dependency on the HPV16 oncogene that drove its development. Our report provides further support for vaccination of FA patients against HPVs and argues for the need to define mutational profiles of SCCs arising in FA patients in order to inform precision medicine-based approaches to treating these patients.",Journal Article,1344.0,10.0,Fanconi anemia FA is a rare genetic disorder caused by defects in DNA damage repair FA patients often develop squamous cell carcinoma SCC at sites where high-risk human papillomaviruses HPVs are known to cause cancer including the cervix However SCCs found in human FA patients are often HPV negative even though the majority of female FA patients with anogenital cancers had preexisting HPV-positive dysplasia We hypothesize that HPVs contribute to the development of SCCs in FA patients but that the continued expression of HPV oncogenes is not required for the maintenance of the cancer state because FA deficiency leads to an accumulation of mutations in cellular genes that render the cancer no longer dependent upon viral oncogenes We tested this hypothesis making use of Bi-L E7 transgenic mice in which we temporally controlled expression of HPV16 E7 the dominant viral oncogene in HPV-associated cancers As seen before the persistence of neoplastic disease was highly dependent upon the continued expression of HPV16 E7 in FA-sufficient mice However in mice with FA deficiency cancers persisted in a large fraction of the mice after HPV16 E7 expression was turned off indicating that these cancers had escaped from their dependency on E7 Furthermore the severity of precancerous lesions also failed to be reduced significantly in the mice with FA deficiency upon turning off expression of E7 These findings confirm our hypothesis and may explain the fact that while FA patients have a high frequency of infections by HPVs and HPV-induced precancerous lesions the cancers are frequently HPV negative IMPORTANCE Fanconi anemia FA patients are at high risk for developing squamous cell carcinoma SCC at sites where high-risk human papillomaviruses HPVs frequently cause cancer Yet these SCCs are often HPV negative FA patients have a genetic defect in their capacity to repair damaged DNA HPV oncogenes cause an accumulation of DNA damage We hypothesize therefore that DNA damage induced by HPV leads to an accumulation of mutations in patients with FA deficiency and that such mutations allow HPV-driven cancers to become independent of the viral oncogenes Consistent with this hypothesis we found that cancers arising in HPV16 transgenic mice with FA deficiency frequently escape from dependency on the HPV16 oncogene that drove its development Our report provides further support for vaccination of FA patients against HPVs and argues for the need to define mutational profiles of SCCs arising in FA patients in order to inform precision medicine-based approaches to treating these patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[8057, 1545, 4307, 16, 8, 622, 336, 2645, 1546, 20, 2945, 4, 261, 1350, 972, 4307, 7, 629, 690, 691, 31, 134, 1791, 28, 633, 1257, 64, 43, 171, 14731, 13477, 32, 440, 6, 708, 12, 141, 3, 3629, 137, 6334, 204, 4, 171, 4307, 7, 32, 629, 933, 199, 871, 2471, 3, 686, 1, 1061, 4307, 7, 5, 13836, 163, 42, 5004, 933, 109, 2253, 21, 4919, 17, 13477, 1248, 6, 3, 193, 1, 6334, 4, 4307, 7, 84, 17, 3, 1351, 55, 1, 933, 3326, 16, 44, 616, 9, 3, 1146, 1, 3, 12, 1309, 408, 4307, 2299, 1940, 6, 35, 1835, 1, 138, 4, 763, 214, 17, 7873, 3, 12, 77, 589, 470, 1548, 1667, 3326, 21, 650, 26, 1492, 1079, 119, 1, 3984, 805, 4540, 2862, 399, 4, 92, 21, 11114, 1149, 55, 1, 4048, 4540, 3, 2156, 1667, 1836, 4, 933, 41, 163, 22, 527, 348, 3, 4108, 1, 2000, 34, 10, 561, 470, 1548, 3, 1351, 55, 1, 4048, 4540, 4, 4307, 1952, 399, 137, 4, 399, 5, 4307, 2299, 163, 3760, 4, 8, 375, 1509, 1, 3, 399, 50, 4048, 4540, 55, 10, 13017, 1889, 1716, 17, 46, 163, 42, 22186, 29, 136, 6359, 23, 4540, 798, 3, 1702, 1, 6605, 406, 120, 1551, 6, 40, 405, 97, 4, 3, 399, 5, 4307, 2299, 1548, 18525, 1889, 55, 1, 4540, 46, 272, 1843, 114, 1492, 2, 68, 2943, 3, 1991, 17, 369, 4307, 7, 47, 8, 64, 675, 1, 1875, 20, 13477, 2, 933, 277, 6605, 406, 3, 163, 32, 746, 933, 199, 1187, 8057, 1545, 4307, 7, 32, 28, 64, 43, 9, 931, 691, 31, 134, 1791, 28, 633, 1257, 64, 43, 171, 14731, 13477, 746, 708, 12, 1145, 46, 6334, 32, 629, 933, 199, 4307, 7, 47, 8, 336, 5398, 4, 136, 2162, 6, 972, 9884, 261, 933, 3326, 708, 35, 1835, 1, 261, 1350, 21, 4919, 673, 17, 261, 1350, 277, 20, 933, 1940, 6, 35, 1835, 1, 138, 4, 7, 5, 4307, 2299, 2, 17, 225, 138, 1700, 933, 1621, 163, 6, 1417, 306, 1, 3, 1667, 3326, 925, 5, 26, 1492, 21, 204, 17, 163, 2635, 4, 4048, 2862, 399, 5, 4307, 2299, 746, 3776, 29, 6359, 23, 3, 4048, 1836, 17, 14751, 211, 193, 114, 414, 777, 195, 538, 9, 1915, 1, 4307, 7, 480, 13477, 2, 14473, 9, 3, 594, 6, 1107, 1619, 1241, 1, 6334, 2635, 4, 4307, 7, 4, 1732, 6, 2295, 2720, 1807, 90, 611, 6, 1367, 46, 7]",2599.0,27190216,654
Cancer and the world's poor: What's a gynecologic cancer specialist to do?,Gynecologic oncology,Gynecol. Oncol.,2016-05-24,"Women in low- and middle-income countries (LMICs) face a drastically increased burden of cervical cancer and the same burden of other gynecologic cancers as do women in high-income countries, yet there are few resources or specialists to meet their needs. 85% of deaths from cervical cancer occur in LMICs. As the population of these regions age, and as death from infectious diseases decrease, this burden will increase further without strong intervention. There are few cancer specialists in LMICs and training in gynecologic cancer care is rare. Gynecologic cancer specialists are uniquely positioned to meet this challenge as advocates, educators and experts. On behalf of the SGO International Committee, we call on our colleagues to meet this historic challenge.",Editorial,1337.0,2.0,Women in low- and middle-income countries LMICs face a drastically increased burden of cancer and the same burden of other gynecologic cancers as do women in high-income countries yet there are few resources or specialists to meet their needs 85 of deaths from cancer occur in LMICs As the population of these regions age and as death from infectious diseases decrease this burden will increase further without strong intervention There are few cancer specialists in LMICs and training in gynecologic cancer care is rare Gynecologic cancer specialists are uniquely positioned to meet this challenge as advocates educators and experts On behalf of the SGO International Committee we call on our colleagues to meet this historic challenge,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[117, 4, 154, 2, 3897, 2306, 2115, 13457, 3376, 8, 11900, 101, 892, 1, 12, 2, 3, 827, 892, 1, 127, 1512, 163, 22, 1022, 117, 4, 64, 2306, 2115, 1145, 125, 32, 1021, 2892, 15, 4409, 6, 3362, 136, 1891, 772, 1, 1043, 29, 12, 1271, 4, 13457, 22, 3, 266, 1, 46, 1374, 89, 2, 22, 273, 29, 3398, 1342, 775, 26, 892, 303, 344, 195, 187, 1082, 788, 125, 32, 1021, 12, 4409, 4, 13457, 2, 1741, 4, 1512, 12, 165, 16, 622, 1512, 12, 4409, 32, 7089, 14240, 6, 3362, 26, 1745, 22, 7781, 26362, 2, 3186, 23, 14968, 1, 3, 12063, 944, 2002, 21, 7715, 23, 114, 6367, 6, 3362, 26, 6875, 1745]",736.0,27210817,15
"The influence of marital status on the use of breast, cervical, and colorectal cancer screening.",Preventive medicine,Prev Med,2016-05-20,"To examine the impact of marital status on the use of screening for breast, cervical, and colorectal cancer. We relied on 2012 Behavioral Risk Factor Surveillance System Survey age-appropriate screening cohorts. Appropriate screening for breast, cervical, and colorectal cancer was determined according to United States Preventive Services Task Force recommendations in effect at the time of the 2012 survey. Complex samples logistic regression models were performed to examine the effect of marital status on cancer screening. Overall, 81.6, 83.9, and 68.9% of married participants underwent breast, cervical, and colorectal cancer, respectively, relative to 74.2, 75.1, and 60.9% for divorced/widowed/separated, individuals, and 74.7, 78.7, and 53.4% for never married individuals. Marital status (married vs. never married) was an independent predictor of screening for all cancers examined: breast cancer, odds ratio (OR): 1.42 (95% confidence interval [CI]: 1.25-1.61); cervical cancer, OR: 1.29 (95% CI: 1.16-1.43); colorectal cancer, OR: 1.63 (95% CI: 1.51-1.77). Gender-specific subgroup analyses for colorectal cancer suggests that marital status may exert a greater effect in men, relative to women (married men: OR 1.75, 95% CI: 1.56-1.96; married women: OR: 1.52, 95% CI: 1.35-1.70). Being married is associated with increased utilization of breast, cervical, and colorectal cancer screening. The influence of marital status was greater in men relative to women eligible for colorectal cancer screening. Our results emphasize the importance of social determinants of health-seeking behaviors.",Journal Article,1341.0,18.0,To examine the impact of marital status on the use of screening for and cancer We relied on 2012 Behavioral Risk Factor Surveillance System Survey age-appropriate screening cohorts Appropriate screening for and cancer was determined according to United States Preventive Services Task Force recommendations in effect at the time of the 2012 survey Complex samples logistic regression models were performed to examine the effect of marital status on cancer screening Overall 81.6 83.9 and 68.9 of married participants underwent and cancer respectively relative to 74.2 75.1 and 60.9 for divorced/widowed/separated individuals and 74.7 78.7 and 53.4 for never married individuals Marital status married vs. never married was an independent predictor of screening for all cancers examined cancer odds ratio OR 1.42 95 confidence interval CI 1.25-1.61 cancer OR 1.29 95 CI 1.16-1.43 cancer OR 1.63 95 CI 1.51-1.77 Gender-specific subgroup analyses for cancer suggests that marital status may exert a greater effect in men relative to women married men OR 1.75 95 CI 1.56-1.96 married women OR 1.52 95 CI 1.35-1.70 Being married is associated with increased utilization of and cancer screening The influence of marital status was greater in men relative to women eligible for cancer screening Our results emphasize the importance of social determinants of health-seeking behaviors,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1004, 3, 345, 1, 5345, 156, 23, 3, 119, 1, 453, 9, 2, 12, 21, 9896, 23, 1195, 4166, 43, 161, 617, 398, 1407, 89, 870, 453, 736, 870, 453, 9, 2, 12, 10, 509, 768, 6, 1088, 907, 3494, 2142, 3488, 4380, 883, 4, 254, 28, 3, 98, 1, 3, 1195, 1407, 840, 347, 812, 320, 274, 11, 173, 6, 1004, 3, 254, 1, 5345, 156, 23, 12, 453, 63, 865, 49, 852, 83, 2, 806, 83, 1, 5365, 776, 208, 2, 12, 106, 580, 6, 794, 18, 481, 14, 2, 335, 83, 9, 14310, 21491, 4910, 869, 2, 794, 67, 833, 67, 2, 699, 39, 9, 1737, 5365, 869, 5345, 156, 5365, 105, 1737, 5365, 10, 35, 306, 980, 1, 453, 9, 62, 163, 409, 12, 610, 197, 15, 14, 595, 48, 307, 268, 58, 14, 243, 14, 713, 12, 15, 14, 462, 48, 58, 14, 245, 14, 601, 12, 15, 14, 676, 48, 58, 14, 725, 14, 849, 1632, 112, 1363, 318, 9, 12, 844, 17, 5345, 156, 68, 5448, 8, 378, 254, 4, 325, 580, 6, 117, 5365, 325, 15, 14, 481, 48, 58, 14, 664, 14, 921, 5365, 117, 15, 14, 653, 48, 58, 14, 465, 14, 431, 486, 5365, 16, 41, 5, 101, 1961, 1, 2, 12, 453, 3, 1054, 1, 5345, 156, 10, 378, 4, 325, 580, 6, 117, 625, 9, 12, 453, 114, 99, 5560, 3, 1187, 1, 2032, 3403, 1, 341, 5734, 3704]",1375.0,27215758,134
Role of cervical cytology in surveillance after radical trachelectomy for cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2016-06-06,"There are currently no standard guidelines on the use of Papanicolaou (Pap) tests for surveillance after radical trachelectomy for cervical cancer. The goal of this study was to determine the usefulness of Pap tests in routine surveillance after radical trachelectomy for cervical cancer. Cervical cancer patients who underwent radical trachelectomy from January 2004 through October 2015 and subsequently had at least one Pap test were retrospectively identified. Demographic and clinical characteristics were described and compared between patients with and without at least one abnormal Pap test. The Kaplan-Meier method was used to estimate time to first abnormal Pap test. Forty-one patients met inclusion criteria. Of these, 30 (73%) had at least one year in which more than one Pap test per year was obtained. Twenty-four (59%) had at least one abnormal Pap test. Of 238 total Pap tests collected, 44 (18%) were abnormal. The most common abnormality was ASCUS (52%, n=23). Other findings included LSIL (20%, n=9), HSIL (2%, n=1), and AGUS (25%, n=11). Median time from radical trachelectomy to first abnormal Pap test was 17.2months (range, 11.8-86.3). No patient had disease recurrence. Surgery type (laparoscopic, open, or robotic), trachelectomy specimen size, histology, device for stenosis prevention (pediatric Foley catheter or Smit Sleeve), and cerclage placement were not significant predictors of an abnormal Pap test. The rate of abnormal Pap tests after radical trachelectomy is high; however, the clinical significance of such abnormalities appears limited. The routine use of cervical cytology as surveillance after radical trachelectomy does not appear to substantially impact management decisions.",Journal Article,1324.0,6.0,There are currently no standard guidelines on the use of Papanicolaou Pap tests for surveillance after radical trachelectomy for cancer The goal of this study was to determine the usefulness of Pap tests in routine surveillance after radical trachelectomy for cancer cancer patients who underwent radical trachelectomy from January 2004 through October 2015 and subsequently had at least one Pap test were retrospectively identified Demographic and clinical characteristics were described and compared between patients with and without at least one abnormal Pap test The Kaplan-Meier method was used to estimate time to first abnormal Pap test Forty-one patients met inclusion criteria Of these 30 73 had at least one year in which more than one Pap test per year was obtained Twenty-four 59 had at least one abnormal Pap test Of 238 total Pap tests collected 44 18 were abnormal The most common abnormality was ASCUS 52 n=23 Other findings included LSIL 20 n=9 HSIL 2 n=1 and AGUS 25 n=11 Median time from radical trachelectomy to first abnormal Pap test was 17.2months range 11.8-86.3 No patient had disease recurrence Surgery type laparoscopic open or robotic trachelectomy specimen size histology device for stenosis prevention pediatric Foley catheter or Smit Sleeve and cerclage placement were not significant predictors of an abnormal Pap test The rate of abnormal Pap tests after radical trachelectomy is high however the clinical significance of such abnormalities appears limited The routine use of cytology as surveillance after radical trachelectomy does not appear to substantially impact management decisions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[125, 32, 694, 77, 260, 677, 23, 3, 119, 1, 10416, 4290, 895, 9, 617, 50, 711, 5760, 9, 12, 3, 1326, 1, 26, 45, 10, 6, 223, 3, 5235, 1, 4290, 895, 4, 1311, 617, 50, 711, 5760, 9, 12, 12, 7, 54, 208, 711, 5760, 29, 1024, 1131, 298, 2551, 1483, 2, 1611, 42, 28, 506, 104, 4290, 412, 11, 894, 108, 1540, 2, 38, 374, 11, 1027, 2, 72, 59, 7, 5, 2, 187, 28, 506, 104, 1668, 4290, 412, 3, 876, 882, 596, 10, 95, 6, 1191, 98, 6, 157, 1668, 4290, 412, 1213, 104, 7, 543, 1680, 371, 1, 46, 201, 803, 42, 28, 506, 104, 111, 4, 92, 80, 76, 104, 4290, 412, 379, 111, 10, 683, 737, 294, 728, 42, 28, 506, 104, 1668, 4290, 412, 1, 6883, 181, 4290, 895, 786, 584, 203, 11, 1668, 3, 96, 186, 3698, 10, 21337, 653, 78, 382, 127, 272, 159, 17849, 179, 78, 83, 16067, 18, 78, 14, 2, 68296, 243, 78, 175, 52, 98, 29, 711, 5760, 6, 157, 1668, 4290, 412, 10, 269, 15030, 184, 175, 66, 868, 27, 77, 69, 42, 34, 146, 152, 267, 1964, 1020, 15, 2895, 5760, 2360, 444, 784, 4472, 9, 6935, 1070, 815, 26513, 3925, 15, 68297, 14536, 2, 28830, 2613, 11, 44, 93, 674, 1, 35, 1668, 4290, 412, 3, 116, 1, 1668, 4290, 895, 50, 711, 5760, 16, 64, 137, 3, 38, 724, 1, 225, 1171, 1233, 383, 3, 1311, 119, 1, 2045, 22, 617, 50, 711, 5760, 1097, 44, 1322, 6, 2109, 345, 284, 1526]",1622.0,27246304,806
Risk of Venous Thromboembolism After Laparoscopic Surgery for Gynecologic Malignancy.,Journal of minimally invasive gynecology,J Minim Invasive Gynecol,2016-06-21,"To determine the incidence of venous thromboembolism (VTE) after laparoscopic surgery for gynecologic cancer. Retrospective analysis of the ACS-NSQIP database (Canadian Task Force Classification II.1). Academic and community healthcare institutions across the United States. Women who underwent at least 1 major laparoscopic surgery for uterine, ovarian, and cervical cancers. Data were collected on surgical procedures, patient demographic variables, type of malignancy and VTE, and mortality outcomes within 30days of surgery. VTE was defined as deep venous thrombosis requiring therapy and pulmonary embolism confirmed by imaging or autopsy within 30days of surgery. Of the 2219 patients included in the final analysis, 15 patients (.7%) were diagnosed with VTE within 30days after surgery. Six patients (.3%) were diagnosed before discharge, and 9 patients (.4%) were diagnosed after discharge. The median time from surgery to diagnosis was 6days (range, 0-28days). Although most patients included in the study had uterine cancer (86%, n=1913), no difference was noted based on the site of cancer (.5% for cervical cancer, .7% for endometrial cancer, and .8% for ovarian cancer; p=.95). There was no difference in rate of VTE when stratified by age (p=.10), body mass index (p=.68), diabetes (p=.22), smoking (p=.60), respiratory morbidities (p=.55), cardiac disease (p=.22), hypertension (p=.13), preoperative blood transfusion (p=.90), or American Society of Anesthesiologistsclass (p=.10). There was a trend toward higher risk of VTE among patients with disseminated cancer compared with those with early cancers (3.6% vs .6%, p=.05). No difference was found in the risk of VTE based on operative time (.7% for <2hours, .6% for 2-3hours, and .7% for >3hours; p=.96). No difference was noted in the risk of VTE among those who underwent lymphadenectomy compared with those who did not (.9% vs .5%, p=.35). In multivariable logistic regression analysis adjusting age (p=.12), body mass index (p=.90), operative time (p=.71), and lymphadenectomy (p=.30), none of these variables was significantly associated with risk of VTE. In multivariable analysis adjusting for other confounders, VTE within 30days was a significant predictor of higher 30-day mortality (OR, 26.0; 95% CI, 2.2-306.9; p=.01). The rate of VTE is low after major laparoscopic surgery for gynecologic cancers but is associated with increased 30-day mortality. Universal or extended thromboprophylaxis does not appear to be indicated for all patients. Further studies are needed to identify patients at high risk for postoperative VTE who may benefit from pharmacologic prophylaxis.",Journal Article,1309.0,9.0,To determine the incidence of venous thromboembolism VTE after laparoscopic surgery for gynecologic cancer Retrospective analysis of the ACS-NSQIP database Canadian Task Force Classification II.1 Academic and community healthcare institutions across the United States Women who underwent at least 1 major laparoscopic surgery for and cancers Data were collected on surgical procedures patient demographic variables type of malignancy and VTE and mortality outcomes within 30 days of surgery VTE was defined as deep venous thrombosis requiring therapy and pulmonary embolism confirmed by imaging or autopsy within 30 days of surgery Of the 2219 patients included in the final analysis 15 patients .7 were diagnosed with VTE within 30 days after surgery Six patients .3 were diagnosed before discharge and 9 patients .4 were diagnosed after discharge The median time from surgery to diagnosis was 6 days range 0-28 days Although most patients included in the study had cancer 86 n 1913 no difference was noted based on the site of cancer .5 for cancer .7 for cancer and .8 for cancer p .95 There was no difference in rate of VTE when stratified by age p .10 body mass index p .68 diabetes p .22 smoking p .60 respiratory morbidities p .55 disease p .22 hypertension p .13 preoperative blood transfusion p .90 or American Society of Anesthesiologists class p .10 There was a trend toward higher risk of VTE among patients with disseminated cancer compared with those with early cancers 3.6 vs .6 p .05 No difference was found in the risk of VTE based on operative time .7 for 2 hours .6 for 2-3 hours and .7 for 3 hours p .96 No difference was noted in the risk of VTE among those who underwent lymphadenectomy compared with those who did not .9 vs .5 p .35 In multivariable logistic regression analysis adjusting age p .12 body mass index p .90 operative time p .71 and lymphadenectomy p .30 none of these variables was significantly associated with risk of VTE In multivariable analysis adjusting for other confounders VTE within 30 days was a significant predictor of higher 30-day mortality OR 26.0 95 CI 2.2-306.9 p .01 The rate of VTE is low after major laparoscopic surgery for gynecologic cancers but is associated with increased 30-day mortality Universal or extended thromboprophylaxis does not appear to be indicated for all patients Further studies are needed to identify patients at high risk for postoperative VTE who may benefit from pharmacologic prophylaxis,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,"[6, 223, 3, 287, 1, 2167, 3501, 1779, 50, 1964, 152, 9, 1512, 12, 459, 65, 1, 3, 6004, 8280, 609, 7170, 3488, 4380, 947, 215, 14, 1916, 2, 1714, 2819, 1764, 716, 3, 1088, 907, 117, 54, 208, 28, 506, 14, 458, 1964, 152, 9, 2, 163, 74, 11, 786, 23, 221, 1369, 69, 1540, 682, 267, 1, 710, 2, 1779, 2, 282, 123, 262, 201, 162, 1, 152, 1779, 10, 395, 22, 2369, 2167, 2839, 1888, 36, 2, 1087, 5475, 557, 20, 270, 15, 6270, 262, 201, 162, 1, 152, 1, 3, 49100, 7, 159, 4, 3, 1457, 65, 167, 7, 67, 11, 265, 5, 1779, 262, 201, 162, 50, 152, 437, 7, 27, 11, 265, 348, 2993, 2, 83, 7, 39, 11, 265, 50, 2993, 3, 52, 98, 29, 152, 6, 147, 10, 49, 162, 184, 13, 339, 162, 242, 96, 7, 159, 4, 3, 45, 42, 12, 868, 78, 45569, 77, 523, 10, 1051, 90, 23, 3, 606, 1, 12, 33, 9, 12, 67, 9, 12, 2, 66, 9, 12, 19, 48, 125, 10, 77, 523, 4, 116, 1, 1779, 198, 1173, 20, 89, 19, 79, 642, 782, 558, 19, 806, 1978, 19, 350, 979, 19, 335, 2718, 5655, 19, 614, 34, 19, 350, 1824, 19, 233, 498, 315, 2785, 19, 424, 15, 597, 1174, 1, 9558, 1040, 19, 79, 125, 10, 8, 853, 1317, 142, 43, 1, 1779, 107, 7, 5, 3605, 12, 72, 5, 135, 5, 191, 163, 27, 49, 105, 49, 19, 474, 77, 523, 10, 204, 4, 3, 43, 1, 1779, 90, 23, 1208, 98, 67, 9, 18, 1459, 49, 9, 18, 27, 1459, 2, 67, 9, 27, 1459, 19, 921, 77, 523, 10, 1051, 4, 3, 43, 1, 1779, 107, 135, 54, 208, 2048, 72, 5, 135, 54, 205, 44, 83, 105, 33, 19, 465, 4, 658, 812, 320, 65, 1358, 89, 19, 133, 642, 782, 558, 19, 424, 1208, 98, 19, 792, 2, 2048, 19, 201, 1292, 1, 46, 682, 10, 97, 41, 5, 43, 1, 1779, 4, 658, 65, 1358, 9, 127, 4423, 1779, 262, 201, 162, 10, 8, 93, 980, 1, 142, 201, 218, 282, 15, 432, 13, 48, 58, 18, 18, 9974, 83, 19, 355, 3, 116, 1, 1779, 16, 154, 50, 458, 1964, 152, 9, 1512, 163, 84, 16, 41, 5, 101, 201, 218, 282, 4967, 15, 1747, 8008, 1097, 44, 1322, 6, 40, 1103, 9, 62, 7, 195, 94, 32, 575, 6, 255, 7, 28, 64, 43, 9, 573, 1779, 54, 68, 247, 29, 2788, 2049]",2471.0,27353413,189
Determinants of cancer screening in Asian-Americans.,Cancer causes & control : CCC,Cancer Causes Control,2016-07-02,"Recent data suggest that Asian-Americans (AsAs) are more likely to present with advanced disease when diagnosed with cancer. We sought to determine whether AsAs are under-utilizing recommended cancer screening. Cross-sectional analysis of the 2012 Behavioral Risk Factor Surveillance System comprising of AsAs and non-Hispanic White (NHW) community-dwelling individuals (English and Spanish speaking) eligible for colorectal, breast, cervical, or prostate cancer screening according to the United States Preventive Services Task Force recommendations. Age, education and income level, residence location, marital status, health insurance, regular access to healthcare provider, and screening were extracted. Complex samples logistic regression models quantified the effect of race on odds of undergoing appropriate screening. Data were analyzed in 2015. Weighted samples of 63.3, 33.3, 47.9, and 30.3 million individuals eligible for colorectal, breast, cervical, and prostate cancer screening identified, respectively. In general, AsAs were more educated, more often married, had higher levels of income, and lived in urban/suburban residencies as compared to NHWs (all p<0.05). In multivariable analyses, AsAs had lower odds of undergoing colorectal (odds ratio [OR] 0.78, 95% confidence interval [CI] 0.63-0.96), cervical (OR 0.45, 95% CI 0.36-0.55), and prostate cancer (OR 0.55, 95% CI 0.39-0.78) screening and similar odds of undergoing breast cancer (OR 1.29, 95% CI 0.92-1.82) screening as compared to NHWs. AsAs are less likely to undergo appropriate screening for colorectal, cervical, and prostate cancer. Contributing reasons include limitations in healthcare access, differing cultural beliefs on cancer screening and treatment, and potential physician biases. Interventions such as increasing healthcare access and literacy may improve screening rates.",Journal Article,1298.0,8.0,Recent data suggest that Asian-Americans AsAs are more likely to present with advanced disease when diagnosed with cancer We sought to determine whether AsAs are under-utilizing recommended cancer screening Cross-sectional analysis of the 2012 Behavioral Risk Factor Surveillance System comprising of AsAs and non-Hispanic White NHW community-dwelling individuals English and Spanish speaking eligible for or cancer screening according to the United States Preventive Services Task Force recommendations Age education and income level residence location marital status health insurance regular access to healthcare provider and screening were extracted Complex samples logistic regression models quantified the effect of race on odds of undergoing appropriate screening Data were analyzed in 2015 Weighted samples of 63.3 33.3 47.9 and 30.3 million individuals eligible for and cancer screening identified respectively In general AsAs were more educated more often married had higher levels of income and lived in urban/suburban residencies as compared to NHWs all p 0.05 In multivariable analyses AsAs had lower odds of undergoing odds ratio OR 0.78 95 confidence interval CI 0.63-0.96 OR 0.45 95 CI 0.36-0.55 and cancer OR 0.55 95 CI 0.39-0.78 screening and similar odds of undergoing cancer OR 1.29 95 CI 0.92-1.82 screening as compared to NHWs AsAs are less likely to undergo appropriate screening for and cancer Contributing reasons include limitations in healthcare access differing cultural beliefs on cancer screening and treatment and potential physician biases Interventions such as increasing healthcare access and literacy may improve screening rates,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[435, 74, 309, 17, 2399, 2731, 23772, 32, 80, 322, 6, 364, 5, 131, 34, 198, 265, 5, 12, 21, 990, 6, 223, 317, 23772, 32, 669, 2600, 793, 12, 453, 1383, 2832, 65, 1, 3, 1195, 4166, 43, 161, 617, 398, 3538, 1, 23772, 2, 220, 1776, 886, 7510, 1714, 24883, 869, 4201, 2, 8733, 8519, 625, 9, 15, 12, 453, 768, 6, 3, 1088, 907, 3494, 2142, 3488, 4380, 883, 89, 1848, 2, 2306, 301, 5562, 1147, 5345, 156, 341, 1935, 3316, 1655, 6, 2819, 3094, 2, 453, 11, 2484, 840, 347, 812, 320, 274, 2790, 3, 254, 1, 1047, 23, 610, 1, 479, 870, 453, 74, 11, 311, 4, 1483, 2337, 347, 1, 676, 27, 466, 27, 662, 83, 2, 201, 27, 3346, 869, 625, 9, 2, 12, 453, 108, 106, 4, 1083, 23772, 11, 80, 9031, 80, 629, 5365, 42, 142, 148, 1, 2306, 2, 4813, 4, 5532, 38841, 68516, 22, 72, 6, 16080, 62, 19, 13, 474, 4, 658, 318, 23772, 42, 280, 610, 1, 479, 610, 197, 15, 13, 833, 48, 307, 268, 58, 13, 676, 13, 921, 15, 13, 512, 48, 58, 13, 511, 13, 614, 2, 12, 15, 13, 614, 48, 58, 13, 587, 13, 833, 453, 2, 288, 610, 1, 479, 12, 15, 14, 462, 48, 58, 13, 937, 14, 878, 453, 22, 72, 6, 16080, 23772, 32, 299, 322, 6, 1251, 870, 453, 9, 2, 12, 3156, 2325, 643, 1939, 4, 2819, 1655, 5276, 8587, 5059, 23, 12, 453, 2, 24, 2, 174, 1473, 8232, 1151, 225, 22, 602, 2819, 1655, 2, 9925, 68, 401, 453, 151]",1662.0,27372292,263
Application of flat panel OLED display technology for the point-of-care detection of circulating cancer biomarkers.,Scientific reports,Sci Rep,2016-07-04,"Point-of-care molecular diagnostics can provide efficient and cost-effective medical care, and they have the potential to fundamentally change our approach to global health. However, most existing approaches are not scalable to include multiple biomarkers. As a solution, we have combined commercial flat panel OLED display technology with protein microarray technology to enable high-density fluorescent, programmable, multiplexed biorecognition in a compact and disposable configuration with clinical-level sensitivity. Our approach leverages advances in commercial display technology to reduce pre-functionalized biosensor substrate costs to pennies per cm(2). Here, we demonstrate quantitative detection of IgG antibodies to multiple viral antigens in patient serum samples with detection limits for human IgG in the 10pg/mL range. We also demonstrate multiplexed detection of antibodies to the HPV16 proteins E2, E6, and E7, which are circulating biomarkers for cervical as well as head and neck cancers.",Journal Article,1296.0,17.0,Point-of-care molecular diagnostics can provide efficient and cost-effective medical care and they have the potential to fundamentally change our approach to global health However most existing approaches are not scalable to include multiple biomarkers As a solution we have combined commercial flat panel OLED display technology with protein microarray technology to enable high-density fluorescent programmable multiplexed biorecognition in a compact and disposable configuration with clinical-level sensitivity Our approach leverages advances in commercial display technology to reduce pre-functionalized biosensor substrate costs to pennies per cm 2 Here we demonstrate quantitative detection of IgG antibodies to multiple viral antigens in patient serum samples with detection limits for human IgG in the 10 pg/mL range We also demonstrate multiplexed detection of antibodies to the HPV16 proteins E2 E6 and E7 which are circulating biomarkers for as well as head and cancers,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[741, 1, 165, 219, 5197, 122, 377, 2547, 2, 835, 323, 484, 165, 2, 491, 47, 3, 174, 6, 13933, 707, 114, 353, 6, 1648, 341, 137, 96, 1692, 611, 32, 44, 17510, 6, 643, 232, 582, 22, 8, 5829, 21, 47, 397, 4860, 7767, 993, 68519, 3640, 2033, 5, 178, 1727, 2033, 6, 3047, 64, 1263, 2910, 13410, 7734, 49862, 4, 8, 19916, 2, 47201, 13796, 5, 38, 301, 485, 114, 353, 29443, 954, 4, 4860, 3640, 2033, 6, 969, 671, 12962, 20088, 4235, 1201, 6, 68520, 379, 494, 18, 467, 21, 608, 1156, 638, 1, 3630, 890, 6, 232, 1667, 1575, 4, 69, 524, 347, 5, 638, 3526, 9, 171, 3630, 4, 3, 79, 3234, 542, 184, 21, 120, 608, 7734, 638, 1, 890, 6, 3, 4048, 652, 5036, 4837, 2, 4540, 92, 32, 1033, 582, 9, 22, 149, 22, 718, 2, 163]",980.0,27374875,406
Transthoracic Anastomotic Leak After Esophagectomy: Current Trends.,Annals of surgical oncology,Ann. Surg. Oncol.,2016-07-12,"Leaks from intrathoracic esophagogastric anastomosis are thought to be associated with higher rates of morbidity and mortality than leaks from cervical anastomosis. We challenge this assumption and hypothesize that there is no significant difference in mortality based on the location of the esophagogastric anastomosis. A systematic literature search was conducted using PubMed and Embase databases on all studies published from January 2000 to June 2015, comparing transthoracic (TTE) and transhiatal (THE) esophagectomies. Studies using jejunal or colonic interposition were excluded. Outcomes analyzed were leak rate, leak-associated mortality, overall 30-day mortality, and overall morbidity. Meta-analyses were performed using Mantel-Haenszel statistical analyses on studies reporting leak rates of both approaches. Nominal data are presented as frequency and interquartile range (IQR); measures of the association between treatments and outcomes are presented as odds ratio (OR) with 95% confidence interval. Twenty-one studies (3 randomized controlled trials) were analyzed comprising of 7167 patients (54% TTE). TTE approach yields a lower anastomotic leak rate (9.8%; IQR 6.0-12.2%) than THE (12%; IQR 11.6-22.1%; OR 0.56 [0.34-0.92]), without any significant difference in leak associated mortality (7.1% TTE vs. 4.6% THE: OR 1.83 [0.39-8.52]). There was no difference in overall 30-day mortality (3.9% TTE vs. 4.3% THE; OR 0.86 [0.66-1.13]) and morbidity (59.0% TTE vs. 66.6% THE; OR 0.76 [0.37-1.59]). Based on meta-analysis, TTE is associated with alower leak rate and does not result in higher morbidity or mortality than THE. The previously assumed higher rate of transthoracic anastomotic leak-associated mortality is overstated, thus supporting surgeon discretion and other factors to influence the choice of thoracic versus cervical anastomosis.",Journal Article,1288.0,16.0,Leaks from intrathoracic esophagogastric anastomosis are thought to be associated with higher rates of morbidity and mortality than leaks from anastomosis We challenge this assumption and hypothesize that there is no significant difference in mortality based on the location of the esophagogastric anastomosis A systematic literature search was conducted using PubMed and Embase databases on all studies published from January 2000 to June 2015 comparing transthoracic TTE and transhiatal THE esophagectomies Studies using jejunal or colonic interposition were excluded Outcomes analyzed were leak rate leak-associated mortality overall 30-day mortality and overall morbidity Meta-analyses were performed using Mantel-Haenszel statistical analyses on studies reporting leak rates of both approaches Nominal data are presented as frequency and interquartile range IQR measures of the association between treatments and outcomes are presented as odds ratio OR with 95 confidence interval Twenty-one studies 3 randomized controlled trials were analyzed comprising of 7167 patients 54 TTE TTE approach yields a lower anastomotic leak rate 9.8 IQR 6.0-12.2 than THE 12 IQR 11.6-22.1 OR 0.56 0.34-0.92 without any significant difference in leak associated mortality 7.1 TTE vs. 4.6 THE OR 1.83 0.39-8.52 There was no difference in overall 30-day mortality 3.9 TTE vs. 4.3 THE OR 0.86 0.66-1.13 and morbidity 59.0 TTE vs. 66.6 THE OR 0.76 0.37-1.59 Based on meta-analysis TTE is associated with a lower leak rate and does not result in higher morbidity or mortality than THE The previously assumed higher rate of transthoracic anastomotic leak-associated mortality is overstated thus supporting surgeon discretion and other factors to influence the choice of thoracic versus anastomosis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[9674, 29, 7359, 6330, 5519, 32, 2739, 6, 40, 41, 5, 142, 151, 1, 787, 2, 282, 76, 9674, 29, 5519, 21, 1745, 26, 8739, 2, 4919, 17, 125, 16, 77, 93, 523, 4, 282, 90, 23, 3, 1147, 1, 3, 6330, 5519, 8, 1556, 789, 1901, 10, 426, 75, 3161, 2, 4995, 2348, 23, 62, 94, 983, 29, 1024, 1081, 6, 1924, 1483, 1430, 14806, 15728, 2, 14120, 3, 25338, 94, 75, 10835, 15, 3663, 16852, 11, 1800, 123, 311, 11, 4238, 116, 4238, 41, 282, 63, 201, 218, 282, 2, 63, 787, 1742, 318, 11, 173, 75, 11618, 14496, 1050, 318, 23, 94, 1760, 4238, 151, 1, 110, 611, 8948, 74, 32, 917, 22, 675, 2, 2899, 184, 2245, 1018, 1, 3, 248, 59, 640, 2, 123, 32, 917, 22, 610, 197, 15, 5, 48, 307, 268, 737, 104, 94, 27, 384, 1149, 143, 11, 311, 3538, 1, 68566, 7, 667, 15728, 15728, 353, 4788, 8, 280, 4818, 4238, 116, 83, 66, 2245, 49, 13, 133, 18, 76, 3, 133, 2245, 175, 49, 350, 14, 15, 13, 664, 13, 562, 13, 937, 187, 500, 93, 523, 4, 4238, 41, 282, 67, 14, 15728, 105, 39, 49, 3, 15, 14, 852, 13, 587, 66, 653, 125, 10, 77, 523, 4, 63, 201, 218, 282, 27, 83, 15728, 105, 39, 27, 3, 15, 13, 868, 13, 700, 14, 233, 2, 787, 728, 13, 15728, 105, 700, 49, 3, 15, 13, 846, 13, 567, 14, 728, 90, 23, 1742, 65, 15728, 16, 41, 5, 8, 280, 4238, 116, 2, 1097, 44, 757, 4, 142, 787, 15, 282, 76, 3, 3, 373, 6719, 142, 116, 1, 14806, 4818, 4238, 41, 282, 16, 34481, 631, 1912, 1897, 7772, 2, 127, 130, 6, 1054, 3, 1866, 1, 2098, 185, 5519]",1779.0,27406098,51
Impact of postoperative intensity-modulated radiation therapy (IMRT) on the rate of bowel obstruction in gynecologic malignancy.,Gynecologic oncology,Gynecol. Oncol.,2016-07-30,"The purpose was to determine the potential impact of IMRT on the rate of bowel obstruction (BO), in patients with gynecologic malignancies undergoing postoperative pelvic RT. We performed a retrospective review of all patients with endometrial or cervical cancer who received postoperative pelvic RT at our institution from 2000 to 2012. Patients who received definitive or palliative RT, or those with BO due to disease progression, were excluded. Standard two-sided statistical tests were used to evaluate for associated risk factors. Kaplan-Meier, Log rank and Cox proportional hazards regression analysis tests were performed for actuarial analysis. A total of 224 patients were identified, 120 (54%) received postoperative pelvic IMRT and 104 (46%) 3-dimentional (3-D) RT. Median follow-up time was 67months. BO was grade 1 (asymptomatic) in 2/228 (0.9%), grade 2 (conservative management) in 4 (1.8%), and grade 3 in 4 (1.8%). Overall, the 5-year actuarial rate of BO was 4.8%. The 5-year rate of BO in the IMRT group was 0.9% compared to 9.3% for 3-D RT (p=0.006). Patients with BMI30kg/m(2) were less likely to develop BO (2.6% vs. 8.3; p=0.03). On multivariate analysis, only IMRT retained its significance as an independent predictor of less BO (p=0.022). The use of postoperative IMRT for cervical and endometrial cancer was associated with significant reduction in the rate of bowel obstruction. This difference maintained its statistical significance on multivariate analysis. Such finding if confirmed by others will help further solidify the benefit of IMRT in gynecologic cancers.",Journal Article,1270.0,5.0,The purpose was to determine the potential impact of IMRT on the rate of bowel obstruction BO in patients with gynecologic malignancies undergoing postoperative pelvic RT We performed a retrospective review of all patients with or cancer who received postoperative pelvic RT at our institution from 2000 to 2012 Patients who received definitive or palliative RT or those with BO due to disease progression were excluded Standard two-sided statistical tests were used to evaluate for associated risk factors Kaplan-Meier Log rank and Cox proportional hazards regression analysis tests were performed for actuarial analysis A total of 224 patients were identified 120 54 received postoperative pelvic IMRT and 104 46 3-dimentional 3-D RT Median follow-up time was 67months BO was grade 1 asymptomatic in 2/228 0.9 grade 2 conservative management in 4 1.8 and grade 3 in 4 1.8 Overall the 5-year actuarial rate of BO was 4.8 The 5-year rate of BO in the IMRT group was 0.9 compared to 9.3 for 3-D RT p=0.006 Patients with BMI30kg/m 2 were less likely to develop BO 2.6 vs. 8.3 p=0.03 On multivariate analysis only IMRT retained its significance as an independent predictor of less BO p=0.022 The use of postoperative IMRT for and cancer was associated with significant reduction in the rate of bowel obstruction This difference maintained its statistical significance on multivariate analysis Such finding if confirmed by others will help further solidify the benefit of IMRT in gynecologic cancers,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 743, 10, 6, 223, 3, 174, 345, 1, 964, 23, 3, 116, 1, 1659, 3191, 17998, 4, 7, 5, 1512, 441, 479, 573, 1110, 240, 21, 173, 8, 459, 206, 1, 62, 7, 5, 15, 12, 54, 103, 573, 1110, 240, 28, 114, 731, 29, 1081, 6, 1195, 7, 54, 103, 1057, 15, 994, 240, 15, 135, 5, 17998, 520, 6, 34, 91, 11, 1800, 260, 100, 1689, 1050, 895, 11, 95, 6, 376, 9, 41, 43, 130, 876, 882, 1066, 1026, 2, 418, 831, 1017, 320, 65, 895, 11, 173, 9, 2361, 65, 8, 181, 1, 5908, 7, 11, 108, 2031, 667, 103, 573, 1110, 964, 2, 3407, 641, 27, 68711, 27, 427, 240, 52, 166, 126, 98, 10, 41174, 17998, 10, 88, 14, 2100, 4, 18, 6736, 13, 83, 88, 18, 4476, 284, 4, 39, 14, 66, 2, 88, 68712, 4, 39, 14, 66, 63, 3, 33, 111, 2361, 116, 1, 17998, 10, 39, 66, 3, 33, 111, 116, 1, 17998, 4, 3, 964, 87, 10, 13, 83, 72, 6, 83, 27, 9, 27, 427, 240, 19, 13, 1861, 7, 5, 49445, 188, 18, 11, 299, 322, 6, 690, 17998, 18, 49, 105, 66, 27, 19, 13, 680, 23, 331, 65, 158, 964, 3532, 211, 724, 22, 35, 306, 980, 1, 299, 17998, 19, 13, 4773, 3, 119, 1, 573, 964, 9, 2, 12, 10, 41, 5, 93, 628, 4, 3, 116, 1, 1659, 3191, 26, 523, 1955, 211, 1050, 724, 23, 331, 65, 225, 1567, 492, 557, 20, 1749, 303, 987, 195, 24631, 3, 247, 1, 964, 4, 1512, 163]",1497.0,27486131,615
Mixed Mesonephric Adenocarcinoma and High-grade Neuroendocrine Carcinoma of the Uterine Cervix: Case Description of a Previously Unreported Entity With Insights Into Its Molecular Pathogenesis.,International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists,Int. J. Gynecol. Pathol.,2017-01-01,"Human papillomavirus (HPV)-negative cervical carcinomas are uncommon and typically encompass unusual histologic subtypes. Mesonephric adenocarcinoma is one such subtype. Mesonephric tumors in the female genital tract are thought to arise from Wolffian remnants, and are extremely rare tumors with widely variable morphology. Sarcomatoid dedifferentiation has been previously described in a few cases, but other forms of dedifferentiation have not been reported. Neuroendocrine carcinoma of the cervix (e.g. small cell carcinoma) is associated with HPV infection, typically HPV 18. These tumors often arise in association with a conventional epithelial component such as squamous cell carcinoma or usual-type endocervical adenocarcinoma. We describe a case of mesonephric adenocarcinoma of the uterine cervix associated with an HPV-negative high-grade neuroendocrine carcinoma at the morphologic and immunophenotypic level, for which we performed targeted massively parallel sequencing analysis of the 2 elements. Both components shared identical mutations in U2AF1 p.R156H (c.467G>A) and GATA3 p.M422fs (c.1263dupG), as well as MYCN amplification. In addition, the neuroendocrine carcinoma harbored TP53 and MST1R mutations not present in the mesonephric carcinoma. Our data suggest a clonal origin of the 2 components of this rare entity, rather than a collision tumor.",Case Reports,1115.0,12.0,Human papillomavirus HPV -negative carcinomas are uncommon and typically encompass unusual histologic subtypes Mesonephric adenocarcinoma is one such subtype Mesonephric tumors in the female genital tract are thought to arise from Wolffian remnants and are extremely rare tumors with widely variable morphology Sarcomatoid dedifferentiation has been previously described in a few cases but other forms of dedifferentiation have not been reported Neuroendocrine carcinoma of the cervix e.g small cell carcinoma is associated with HPV infection typically HPV 18 These tumors often arise in association with a conventional epithelial component such as squamous cell carcinoma or usual-type endocervical adenocarcinoma We describe a case of mesonephric adenocarcinoma of the cervix associated with an HPV-negative high-grade neuroendocrine carcinoma at the morphologic and immunophenotypic level for which we performed targeted massively parallel sequencing analysis of the 2 elements Both components shared identical mutations in U2AF1 p.R156H c.467G A and GATA3 p.M422fs c.1263dupG as well as MYCN amplification In addition the neuroendocrine carcinoma harbored TP53 and MST1R mutations not present in the mesonephric carcinoma Our data suggest a clonal origin of the 2 components of this rare entity rather than a collision tumor,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[171, 3242, 933, 199, 826, 32, 2052, 2, 1969, 8454, 4015, 884, 814, 28259, 449, 16, 104, 225, 875, 28259, 57, 4, 3, 1061, 8226, 1696, 32, 2739, 6, 3043, 29, 31852, 15733, 2, 32, 2938, 622, 57, 5, 1792, 1347, 2567, 3912, 9496, 71, 85, 373, 1027, 4, 8, 1021, 140, 84, 127, 2377, 1, 9496, 47, 44, 85, 210, 1542, 134, 1, 3, 3629, 563, 499, 302, 31, 134, 16, 41, 5, 933, 930, 1969, 933, 203, 46, 57, 629, 3043, 4, 248, 5, 8, 809, 701, 1249, 225, 22, 691, 31, 134, 15, 3521, 267, 10174, 449, 21, 897, 8, 473, 1, 28259, 449, 1, 3, 3629, 41, 5, 35, 933, 199, 64, 88, 1542, 134, 28, 3, 2815, 2, 6599, 301, 9, 92, 21, 173, 238, 7284, 2755, 615, 65, 1, 3, 18, 2531, 110, 1628, 2664, 3038, 138, 4, 11522, 19, 68798, 256, 68799, 8, 2, 8140, 19, 68800, 256, 68801, 22, 149, 22, 4068, 1073, 4, 352, 3, 1542, 134, 3253, 1206, 2, 29632, 138, 44, 364, 4, 3, 28259, 134, 114, 74, 309, 8, 1946, 1938, 1, 3, 18, 1628, 1, 26, 622, 2983, 1832, 76, 8, 21549, 30]",1328.0,27532149,230
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis.,Gynecologic oncology,Gynecol. Oncol.,2016-08-17,"To determine the effect of age on completion of and toxicities following treatment of local regionally advanced cervical cancer (LACC) on Gynecologic Oncology Group (GOG) Phase I-III trials. An ancillary data analysis of GOG protocols 113, 120, 165, 219 data was performed. Wilcoxon, Pearson, and Kruskal-Wallis tests were used for univariate and multivariate analysis. Log rank tests were used to compare survival lengths. One-thousand-three-hundred-nineteen women were included; 60.7% were Caucasian, 15% were age 60-70years and an additional 5% were >70; 87% had squamous histology, 55% had stage IIB disease and 34% had IIIB disease. Performance status declined with age (p=0.006). Histology and tumor stage did not significantly differ. Number of cycles of chemotherapy received, radiation treatment time, nor dose modifications varied with age. Notably, radiation protocol deviations and failure to complete brachytherapy (BT) did increase with age (p=0.022 and p<0.001 respectively). Only all grade lymphatic (p=0.006) and grade3 cardiovascular toxicities (p=0.019) were found to vary with age. A 2% increase in the risk of death for every year increase >50 for all-cause mortality (HR 1.02; 95% CI, 1.01-1.04) was found, but no association between age and disease specific mortality was found. This represents a large analysis of patients treated for LACC with chemo/radiation, approximately 20% of whom were >60years of age. Older patients, had higher rates of incomplete brachytherapy which is not explained by collected toxicity data. Age did not adversely impact completion of chemotherapy and radiation or toxicities.",Journal Article,1252.0,15.0,To determine the effect of age on completion of and toxicities following treatment of local regionally advanced cancer LACC on Gynecologic Oncology Group GOG Phase I-III trials An ancillary data analysis of GOG protocols 113 120 165 219 data was performed Wilcoxon Pearson and Kruskal-Wallis tests were used for univariate and multivariate analysis Log rank tests were used to compare survival lengths One-thousand-three-hundred-nineteen women were included 60.7 were Caucasian 15 were age 60-70years and an additional 5 were 70 87 had squamous histology 55 had stage IIB disease and 34 had IIIB disease Performance status declined with age p=0.006 Histology and tumor stage did not significantly differ Number of cycles of chemotherapy received radiation treatment time nor dose modifications varied with age Notably radiation protocol deviations and failure to complete brachytherapy BT did increase with age p=0.022 and p 0.001 respectively Only all grade lymphatic p=0.006 and grade3 cardiovascular toxicities p=0.019 were found to vary with age A 2 increase in the risk of death for every year increase 50 for all-cause mortality HR 1.02 95 CI 1.01-1.04 was found but no association between age and disease specific mortality was found This represents a large analysis of patients treated for LACC with chemo/radiation approximately 20 of whom were 60years of age Older patients had higher rates of incomplete brachytherapy which is not explained by collected toxicity data Age did not adversely impact completion of chemotherapy and radiation or toxicities,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 254, 1, 89, 23, 1438, 1, 2, 385, 366, 24, 1, 293, 8183, 131, 12, 24255, 23, 1512, 413, 87, 4760, 124, 70, 316, 143, 35, 8496, 74, 65, 1, 4760, 2189, 4259, 2031, 4966, 6679, 74, 10, 173, 3896, 4720, 2, 8800, 8875, 895, 11, 95, 9, 880, 2, 331, 65, 1066, 1026, 895, 11, 95, 6, 932, 25, 7443, 104, 6161, 169, 1128, 3498, 117, 11, 159, 335, 67, 11, 3229, 167, 11, 89, 335, 32318, 2, 35, 402, 33, 11, 431, 912, 42, 691, 784, 614, 42, 82, 3884, 34, 2, 562, 42, 3036, 34, 528, 156, 3054, 5, 89, 19, 13, 1861, 784, 2, 30, 82, 205, 44, 97, 1505, 207, 1, 410, 1, 56, 103, 121, 24, 98, 2110, 61, 2916, 2051, 5, 89, 2552, 121, 1182, 7810, 2, 496, 6, 236, 1536, 3641, 205, 344, 5, 89, 19, 13, 4773, 2, 19, 13, 144, 106, 158, 62, 88, 2936, 19, 13, 1861, 2, 14659, 2179, 385, 19, 13, 4049, 11, 204, 6, 2825, 5, 89, 8, 18, 344, 4, 3, 43, 1, 273, 9, 454, 111, 344, 212, 9, 62, 708, 282, 168, 14, 588, 48, 58, 14, 355, 14, 755, 10, 204, 84, 77, 248, 59, 89, 2, 34, 112, 282, 10, 204, 26, 1449, 8, 375, 65, 1, 7, 73, 9, 24255, 5, 3341, 121, 705, 179, 1, 953, 11, 32094, 1, 89, 434, 7, 42, 142, 151, 1, 2610, 1536, 92, 16, 44, 3672, 20, 786, 155, 74, 89, 205, 44, 4311, 345, 1438, 1, 56, 2, 121, 15, 385]",1563.0,27542967,689
Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study.,Salud publica de Mexico,Salud Publica Mex,2016-04-01,"This paper describes the study design and baseline characteristics of the study population, including the first 30 829 women who enrolled in the Forwarding Research for Improved Detection and Access for Cervical Cancer Screening and Triage (FRIDA Study). This is a large population based study that is evaluating the performance and cost-effectiveness of different triage strategies for high-risk HPV (hrHPV) positive women in Mexico. The target population is more than 100 000 women aged 30 to 64 years who attend the Cervical Cancer Screening Program in 100 health centers in the state of Tlaxcala, Mexico. Since August 2013, all women in the region have been invited to enroll in the study. The study participants are evaluated to determine hrHPV infection using the Cobas 4800 HPV test. The HPV-16/18 genotyping and cytology triage strategies are performed as reflex tests in all hrHPV-positive participants. Women with a positive HPV-16/18 test and/or abnormal cytology (atypical squamous cells of undetermined significance or worse, ASCUS+) are referred for colposcopy evaluation, where a minimum of four biopsies and an endocervical sample are systematically collected. Histologic confirmation is performed by a standardized panel of pathologists. Among the 30 829 women who have been screened, the overall prevalence of hrHPV is 11.0%. The overall prevalence of HPV16 and HPV18 are 1.5% and 0.7%, respectively. Cytological abnormalities (ASCUS+) were detected in 11.8% of the hrHPV-positive women. A total of 27.0% (920/3,401) of the hrHPV-positive women were referred to colposcopy because of a positive HPV16/18 test and/or abnormal reflex cytology, (31.6% had only ASCUS+, 53.6% were HPV16/18 positive with a normal cytology result, and 9.5% were positive to both triage tests). The results of this study will help policy makers and health service providers establish the best practices for triage in cervical cancer screening in Mexico and other countries.",Journal Article,1390.0,13.0,"This paper describes the study design and baseline characteristics of the study population including the first 30 829 women who enrolled in the Forwarding Research for Improved Detection and Access for Cancer Screening and Triage FRIDA Study This is a large population based study that is evaluating the performance and cost-effectiveness of different triage strategies for high-risk HPV hrHPV positive women in Mexico The target population is more than 100 000 women aged 30 to 64 years who attend the Cancer Screening Program in 100 health centers in the state of Tlaxcala Mexico Since August 2013 all women in the region have been invited to enroll in the study The study participants are evaluated to determine hrHPV infection using the Cobas 4800 HPV test The HPV-16/18 genotyping and cytology triage strategies are performed as reflex tests in all hrHPV-positive participants Women with a positive HPV-16/18 test and/or abnormal cytology atypical squamous cells of undetermined significance or worse ASCUS+ are referred for colposcopy evaluation where a minimum of four biopsies and an endocervical sample are systematically collected Histologic confirmation is performed by a standardized panel of pathologists Among the 30 829 women who have been screened the overall prevalence of hrHPV is 11.0 The overall prevalence of HPV16 and HPV18 are 1.5 and 0.7 respectively Cytological abnormalities ASCUS+ were detected in 11.8 of the hrHPV-positive women A total of 27.0 920/3,401 of the hrHPV-positive women were referred to colposcopy because of a positive HPV16/18 test and/or abnormal reflex cytology 31.6 had only ASCUS+ 53.6 were HPV16/18 positive with a normal cytology result and 9.5 were positive to both triage tests The results of this study will help policy makers and health service providers establish the best practices for triage in cancer screening in Mexico and other countries",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[26, 2817, 2677, 3, 45, 771, 2, 330, 374, 1, 3, 45, 266, 141, 3, 157, 201, 13904, 117, 54, 346, 4, 3, 68849, 389, 9, 231, 638, 2, 1655, 9, 12, 453, 2, 9059, 68850, 45, 26, 16, 8, 375, 266, 90, 45, 17, 16, 1435, 3, 528, 2, 835, 1236, 1, 338, 9059, 422, 9, 64, 43, 933, 17544, 109, 117, 4, 10109, 3, 283, 266, 16, 80, 76, 394, 984, 117, 1032, 201, 6, 660, 60, 54, 14166, 3, 12, 453, 1243, 4, 394, 341, 1168, 4, 3, 1309, 1, 68851, 10109, 1192, 2480, 1346, 62, 117, 4, 3, 1053, 47, 85, 7594, 6, 6559, 4, 3, 45, 3, 45, 776, 32, 194, 6, 223, 17544, 930, 75, 3, 12053, 26153, 933, 412, 3, 933, 245, 203, 2686, 2, 2045, 9059, 422, 32, 173, 22, 10265, 895, 4, 62, 17544, 109, 776, 117, 5, 8, 109, 933, 245, 203, 412, 2, 15, 1668, 2045, 1973, 691, 37, 1, 5206, 724, 15, 639, 21337, 32, 1995, 9, 9946, 451, 1257, 8, 2499, 1, 294, 1154, 2, 35, 10174, 1000, 32, 3390, 786, 884, 3551, 16, 173, 20, 8, 1670, 993, 1, 3354, 107, 3, 201, 13904, 117, 54, 47, 85, 2261, 3, 63, 1078, 1, 17544, 16, 175, 13, 3, 63, 1078, 1, 4048, 2, 33514, 32, 14, 33, 2, 13, 67, 106, 9019, 1171, 21337, 11, 530, 4, 175, 66, 1, 3, 17544, 109, 117, 8, 181, 1, 428, 13, 11533, 27, 7191, 1, 3, 17544, 109, 117, 11, 1995, 6, 9946, 408, 1, 8, 109, 4048, 203, 412, 2, 15, 1668, 10265, 2045, 456, 49, 42, 158, 21337, 699, 49, 11, 4048, 203, 109, 5, 8, 295, 2045, 757, 2, 83, 33, 11, 109, 6, 110, 9059, 895, 3, 99, 1, 26, 45, 303, 987, 4196, 10888, 2, 341, 3086, 1994, 1811, 3, 824, 2634, 9, 9059, 4, 12, 453, 4, 10109, 2, 127, 2115]",1898.0,27557378,604
Association between Time since Cancer Diagnosis and Health-Related Quality of Life: A Population-Level Analysis.,Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research,Value Health,2016-04-07,"To examine the association between time since cancer diagnosis and health-related quality of life (HRQOL) among cancer survivors in remission. Analyzing data from 3,610 cancer survivors and 59,539 individuals without cancer in the Medical Expenditure Panel Survey, we examined the relationship between time since cancer diagnosis and HRQOL, taking remission status into account and controlling for patients' demographic characteristics and comorbidities. HRQOL measurements included the six-dimensional health state short form (derived from 36-item short form health survey) (SF-6D) utility scores, the physical component summary score, and the mental component summary score. The relationship between time since cancer diagnosis and HRQOL varied substantially across cancer types. Compared with individuals without cancer, survivors of breast, prostate, or poor-prognosis cancer had statistically lower SF-6D scores within 2 years of diagnosis (-0.044, -0.062, and -0.088, respectively). Breast cancer survivors had SF-6D scores similar to those of individuals without cancer after 2 years, as did patients with poor-prognosis cancer after 5 years. Nevertheless, even after a period of 10 years, survivors of prostate or cervical cancer had a lower level of SF-6D scores (-0.027 and -0.042, respectively). The comparisons of physical health between cancer survivors and individuals without cancer were similar to those of SF-6D. In contrast, most cancer survivors did not experience poorer mental health; survivors of prostate or cervical cancer, however, had lower mental component summary scores after 10 years of diagnosis. The level of HRQOL among cancer survivors depends on time since cancer diagnosis and cancer type. Some cancer survivors have lower HRQOL after a decade of diagnosis, even in remission.",Journal Article,1384.0,13.0,"To examine the association between time since cancer diagnosis and health-related quality of life HRQOL among cancer survivors in remission Analyzing data from 3,610 cancer survivors and 59,539 individuals without cancer in the Medical Expenditure Panel Survey we examined the relationship between time since cancer diagnosis and HRQOL taking remission status into account and controlling for patients demographic characteristics and comorbidities HRQOL measurements included the six-dimensional health state short form derived from 36-item short form health survey SF-6D utility scores the physical component summary score and the mental component summary score The relationship between time since cancer diagnosis and HRQOL varied substantially across cancer types Compared with individuals without cancer survivors of or poor-prognosis cancer had statistically lower SF-6D scores within 2 years of diagnosis -0.044 -0.062 and -0.088 respectively cancer survivors had SF-6D scores similar to those of individuals without cancer after 2 years as did patients with poor-prognosis cancer after 5 years Nevertheless even after a period of 10 years survivors of or cancer had a lower level of SF-6D scores -0.027 and -0.042 respectively The comparisons of physical health between cancer survivors and individuals without cancer were similar to those of SF-6D In contrast most cancer survivors did not experience poorer mental health survivors of or cancer however had lower mental component summary scores after 10 years of diagnosis The level of HRQOL among cancer survivors depends on time since cancer diagnosis and cancer type Some cancer survivors have lower HRQOL after a decade of diagnosis even in remission",1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1004, 3, 248, 59, 98, 1192, 12, 147, 2, 341, 139, 372, 1, 358, 2534, 107, 12, 332, 4, 734, 4449, 74, 29, 27, 11302, 12, 332, 2, 728, 11416, 869, 187, 12, 4, 3, 484, 8699, 993, 1407, 21, 409, 3, 858, 59, 98, 1192, 12, 147, 2, 2534, 2727, 734, 156, 237, 1967, 2, 1893, 9, 7, 1540, 374, 2, 1909, 2534, 1685, 159, 3, 437, 2201, 341, 1309, 978, 1297, 526, 29, 511, 3471, 978, 1297, 341, 1407, 4086, 13451, 1207, 703, 3, 900, 1249, 1962, 368, 2, 3, 3031, 1249, 1962, 368, 3, 858, 59, 98, 1192, 12, 147, 2, 2534, 2051, 2109, 716, 12, 630, 72, 5, 869, 187, 12, 332, 1, 15, 334, 356, 12, 42, 712, 280, 4086, 13451, 703, 262, 18, 60, 1, 147, 13, 6194, 13, 12139, 2, 13, 13848, 106, 12, 332, 42, 4086, 13451, 703, 288, 6, 135, 1, 869, 187, 12, 50, 18, 60, 22, 205, 7, 5, 334, 356, 12, 50, 33, 60, 3873, 871, 50, 8, 727, 1, 79, 60, 332, 1, 15, 12, 42, 8, 280, 301, 1, 4086, 13451, 703, 13, 4523, 2, 13, 5606, 106, 3, 2213, 1, 900, 341, 59, 12, 332, 2, 869, 187, 12, 11, 288, 6, 135, 1, 4086, 13451, 4, 748, 96, 12, 332, 205, 44, 730, 1769, 3031, 341, 332, 1, 15, 12, 137, 42, 280, 3031, 1249, 1962, 703, 50, 79, 60, 1, 147, 3, 301, 1, 2534, 107, 12, 332, 3828, 23, 98, 1192, 12, 147, 2, 12, 267, 476, 12, 332, 47, 280, 2534, 50, 8, 2025, 1, 147, 871, 4, 734]",1712.0,27565280,725
"Differences in sex distribution, anatomic location and MR imaging appearance of pediatric compared to adult chordomas.",BMC medical imaging,BMC Med Imaging,2016-09-08,"Chordomas are rare malignancies that primarily affect adults, but also rarely affect pediatric patients. We compared the imaging appearance, demographic and anatomic distributions of adult and pediatric chordomas in a large cohort. We performed a retrospective review of medical records of 220 subjects with histologically confirmed chordomas of the axial skeleton and pre-treatment magnetic resonance imaging studies. Age, sex, type of chordoma (conventional, chondroid or dedifferentiated), the anatomic location of the chordoma, as well as whether the lesion was primarily extra-osseous were recorded. Pediatric subjects were less than 21years at the time of diagnosis. Binomial two-sample tests of proportions and Fisher's exact tests were used to compare proportions between the pediatric and adult subjects. Fifty six pediatric subjects (58.9% female) and 164 adult subjects (42.1% female) were identified. The proportion of female subjects with chordomas was significantly higher in the pediatric cohort compared to the adult cohort (P=0.04). Most chordomas occur in Caucasians, however African-Americans were more represented in the pediatric cohort than in the adult cohort (P=0.01). 69.6% (39/56) of the pediatric chordomas involved the clivus/skull base and cervical spine compared to 29.3% (48/164) of the adult chordomas (P=1.9910(-7)). Only 1.8% (1/56) of the pediatric chordomas was in the sacrococcygeal region compared to 36.0% (59/164) of the adult chordomas (P=2.5510(-8)). In cases where pre-treatment imaging was available, 93.8% (16/17) of pediatric chordomas were predominantly extra-osseous compared to 76.7% (46/60) of adult chordomas (P=0.17). Pediatric chordomas more often affect females and occur most frequently at the craniocervical junction with decrease in incidence distally in the spine, whereas adult chordomas most frequently involve the craniocervical and sacrococcygeal regions.",Comparative Study,1230.0,3.0,Chordomas are rare malignancies that primarily affect adults but also rarely affect pediatric patients We compared the imaging appearance demographic and anatomic distributions of adult and pediatric chordomas in a large cohort We performed a retrospective review of medical records of 220 subjects with histologically confirmed chordomas of the axial skeleton and pre-treatment magnetic resonance imaging studies Age sex type of chordoma conventional chondroid or dedifferentiated the anatomic location of the chordoma as well as whether the lesion was primarily extra-osseous were recorded Pediatric subjects were less than 21 years at the time of diagnosis Binomial two-sample tests of proportions and Fisher 's exact tests were used to compare proportions between the pediatric and adult subjects Fifty six pediatric subjects 58.9 female and 164 adult subjects 42.1 female were identified The proportion of female subjects with chordomas was significantly higher in the pediatric cohort compared to the adult cohort P 0.04 Most chordomas occur in Caucasians however African-Americans were more represented in the pediatric cohort than in the adult cohort P 0.01 69.6 39/56 of the pediatric chordomas involved the clivus/skull base and spine compared to 29.3 48/164 of the adult chordomas P 1.99 10 -7 Only 1.8 1/56 of the pediatric chordomas was in the sacrococcygeal region compared to 36.0 59/164 of the adult chordomas P 2.55 10 -8 In cases where pre-treatment imaging was available 93.8 16/17 of pediatric chordomas were predominantly extra-osseous compared to 76.7 46/60 of adult chordomas P 0.17 Pediatric chordomas more often affect females and occur most frequently at the craniocervical junction with decrease in incidence distally in the spine whereas adult chordomas most frequently involve the craniocervical and sacrococcygeal regions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6790, 32, 622, 441, 17, 1561, 1158, 857, 84, 120, 2416, 1158, 815, 7, 21, 72, 3, 270, 3592, 1540, 2, 2745, 4477, 1, 780, 2, 815, 6790, 4, 8, 375, 180, 21, 173, 8, 459, 206, 1, 484, 1064, 1, 6211, 976, 5, 2161, 557, 6790, 1, 3, 5229, 9160, 2, 671, 24, 1484, 1535, 270, 94, 89, 1035, 267, 1, 3911, 809, 15590, 15, 6275, 3, 2745, 1147, 1, 3, 3911, 22, 149, 22, 317, 3, 1180, 10, 1561, 3420, 5230, 11, 1872, 815, 976, 11, 299, 76, 239, 60, 28, 3, 98, 1, 147, 8538, 100, 1000, 895, 1, 4117, 2, 3135, 292, 2472, 895, 11, 95, 6, 932, 4117, 59, 3, 815, 2, 780, 976, 1461, 437, 815, 976, 717, 83, 1061, 2, 5279, 780, 976, 595, 14, 1061, 11, 108, 3, 920, 1, 1061, 976, 5, 6790, 10, 97, 142, 4, 3, 815, 180, 72, 6, 3, 780, 180, 19, 13, 755, 96, 6790, 1271, 4, 5396, 137, 1410, 2731, 11, 80, 3324, 4, 3, 815, 180, 76, 4, 3, 780, 180, 19, 13, 355, 790, 49, 587, 664, 1, 3, 815, 6790, 646, 3, 29835, 5054, 1782, 2, 2342, 72, 6, 462, 27, 576, 5279, 1, 3, 780, 6790, 19, 14, 1058, 79, 67, 158, 14, 66, 14, 664, 1, 3, 815, 6790, 10, 4, 3, 24260, 1053, 72, 6, 511, 13, 728, 5279, 1, 3, 780, 6790, 19, 18, 614, 79, 66, 4, 140, 1257, 671, 24, 270, 10, 390, 966, 66, 245, 269, 1, 815, 6790, 11, 2117, 3420, 5230, 72, 6, 846, 67, 641, 335, 1, 780, 6790, 19, 13, 269, 815, 6790, 80, 629, 1158, 2451, 2, 1271, 96, 746, 28, 3, 32650, 3322, 5, 775, 4, 287, 17743, 4, 3, 2342, 547, 780, 6790, 96, 746, 3882, 3, 32650, 2, 24260, 1374]",1851.0,27609115,64
New Strategies for Multimodality Therapy in Treating Locally Advanced Cervix Cancer.,Seminars in radiation oncology,Semin Radiat Oncol,2016-05-26,"Cervical cancer is the fourth most common cause of cancer of women worldwide. In the developing world, it comprises 12% of all cancers of women. Since 1999, the mainstay of treatment for locally advanced cervical cancer (LACC) has been concurrent cisplatin-based chemoradiation. However, outcomes in this disease remain suboptimal, with long-term progression-free survival and overall survival rates of approximately 60%. There are several new strategies of combined modality treatment under evaluation in LACC, including chemotherapy before and after treatment as well as novel agents such as poly-adenosine diphosphate ribose polymerase inhibitors, antiangiogenic blockage, and immunotherapy. We provide a brief overview of these strategies and their potential in the treatment of women with LACC.",Journal Article,1335.0,10.0,cancer is the fourth most common cause of cancer of women worldwide In the developing world it comprises 12 of all cancers of women Since 1999 the mainstay of treatment for locally advanced cancer LACC has been concurrent cisplatin-based chemoradiation However outcomes in this disease remain suboptimal with long-term progression-free survival and overall survival rates of approximately 60 There are several new strategies of combined modality treatment under evaluation in LACC including chemotherapy before and after treatment as well as novel agents such as poly-adenosine diphosphate ribose polymerase inhibitors antiangiogenic blockage and immunotherapy We provide a brief overview of these strategies and their potential in the treatment of women with LACC,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 3, 3608, 96, 186, 708, 1, 12, 1, 117, 2358, 4, 3, 931, 1956, 192, 6704, 133, 1, 62, 163, 1, 117, 1192, 2043, 3, 4041, 1, 24, 9, 795, 131, 12, 24255, 71, 85, 750, 540, 90, 975, 137, 123, 4, 26, 34, 918, 3291, 5, 319, 337, 91, 115, 25, 2, 63, 25, 151, 1, 705, 335, 125, 32, 392, 217, 422, 1, 397, 1396, 24, 669, 451, 4, 24255, 141, 56, 348, 2, 50, 24, 22, 149, 22, 229, 183, 225, 22, 2699, 4938, 8762, 3507, 1451, 222, 2168, 12501, 2, 726, 21, 377, 8, 3190, 2901, 1, 46, 422, 2, 136, 174, 4, 3, 24, 1, 117, 5, 24255]",764.0,27619255,137
Menopausal hormone therapy in cancer survivors: A narrative review of the literature.,Maturitas,Maturitas,2016-07-27,"Decision making regarding the use of menopausal hormone therapy (MHT) for the treatment of bothersome menopausal symptoms in a cancer survivor can be complex, and includes assessment of its impact on disease-free or overall survival. Estrogen receptors are present in several cancer types, but this does not always result in estrogen-mediated tumor proliferation and adverse cancer-related outcomes. Estrogen may even be protective against certain cancers. Menopausal hormone therapy is associated with an increased risk of recurrence and mortality after diagnosis of some cancer types, but not others. We provide a narrative review of the medical literature regarding the risk of cancer recurrence and associated mortality with initiation of MHT after the diagnosis of breast, gynecologic, lung, colorectal, hematologic cancers, and melanoma. Menopausal hormone therapy may be considered for management of bothersome menopausal symptoms in women with some cancer types (e.g., colorectal and hematologic cancer, localized melanoma, and most cervical, vulvar and vaginal cancers), while nonhormonal treatment options may be preferred for others (e.g., breast cancer). In women with other cancer types, recommendations are less straightforward, and the use of MHT must be individualized. ",Journal Article,1273.0,12.0,Decision making regarding the use of menopausal hormone therapy MHT for the treatment of bothersome menopausal symptoms in a cancer survivor can be complex and includes assessment of its impact on disease-free or overall survival Estrogen receptors are present in several cancer types but this does not always result in estrogen-mediated tumor proliferation and adverse cancer-related outcomes Estrogen may even be protective against certain cancers Menopausal hormone therapy is associated with an increased risk of recurrence and mortality after diagnosis of some cancer types but not others We provide a narrative review of the medical literature regarding the risk of cancer recurrence and associated mortality with initiation of MHT after the diagnosis of gynecologic hematologic cancers and Menopausal hormone therapy may be considered for management of bothersome menopausal symptoms in women with some cancer types e.g. and hematologic cancer localized and most and cancers while nonhormonal treatment options may be preferred for others e.g. cancer In women with other cancer types recommendations are less straightforward and the use of MHT must be individualized,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[948, 1079, 666, 3, 119, 1, 3565, 785, 36, 10381, 9, 3, 24, 1, 14768, 3565, 507, 4, 8, 12, 2628, 122, 40, 840, 2, 1920, 455, 1, 211, 345, 23, 34, 115, 15, 63, 25, 808, 1186, 32, 364, 4, 392, 12, 630, 84, 26, 1097, 44, 3763, 757, 4, 808, 517, 30, 457, 2, 290, 12, 139, 123, 808, 68, 871, 40, 2864, 480, 1840, 163, 3565, 785, 36, 16, 41, 5, 35, 101, 43, 1, 146, 2, 282, 50, 147, 1, 476, 12, 630, 84, 44, 1749, 21, 377, 8, 8963, 206, 1, 3, 484, 789, 666, 3, 43, 1, 12, 146, 2, 41, 282, 5, 1118, 1, 10381, 50, 3, 147, 1, 1512, 813, 163, 2, 3565, 785, 36, 68, 40, 515, 9, 284, 1, 14768, 3565, 507, 4, 117, 5, 476, 12, 630, 563, 499, 2, 813, 12, 909, 2, 96, 2, 163, 369, 16196, 24, 838, 68, 40, 2514, 9, 1749, 563, 499, 12, 4, 117, 5, 127, 12, 630, 883, 32, 299, 12753, 2, 3, 119, 1, 10381, 1642, 40, 2596]",1173.0,27621244,605
Leveraging premalignant biology for immune-based cancer prevention.,Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2016-09-16,"Prevention is an essential component of cancer eradication. Next-generation sequencing of cancer genomes and epigenomes has defined large numbers of driver mutations and molecular subgroups, leading to therapeutic advances. By comparison, there is a relative paucity of such knowledge in premalignant neoplasia, which inherently limits the potential to develop precision prevention strategies. Studies on the interplay between germ-line and somatic events have elucidated genetic processes underlying premalignant progression and preventive targets. Emerging data hint at the immune system's ability to intercept premalignancy and prevent cancer. Genetically engineered mouse models have identified mechanisms by which genetic drivers and other somatic alterations recruit inflammatory cells and induce changes in normal cells to create and interact with the premalignant tumor microenvironment to promote oncogenesis and immune evasion. These studies are currently limited to only a few lesion types and patients. In this Perspective, we advocate a large-scale collaborative effort to systematically map the biology of premalignancy and the surrounding cellular response. By bringing together scientists from diverse disciplines (e.g., biochemistry, omics, and computational biology; microbiology, immunology, and medical genetics; engineering, imaging, and synthetic chemistry; and implementation science), we can drive a concerted effort focused on cancer vaccines to reprogram the immune response to prevent, detect, and reject premalignancy. Lynch syndrome, clonal hematopoiesis, and cervical intraepithelial neoplasia which also serve as models for inherited syndromes, blood, and viral premalignancies, are ideal scenarios in which to launch this initiative.",Journal Article,1222.0,23.0,Prevention is an essential component of cancer eradication Next-generation sequencing of cancer genomes and epigenomes has defined large numbers of driver mutations and molecular subgroups leading to therapeutic advances By comparison there is a relative paucity of such knowledge in premalignant neoplasia which inherently limits the potential to develop precision prevention strategies Studies on the interplay between germ-line and somatic events have elucidated genetic processes underlying premalignant progression and preventive targets Emerging data hint at the immune system 's ability to intercept premalignancy and prevent cancer Genetically engineered mouse models have identified mechanisms by which genetic drivers and other somatic alterations recruit inflammatory cells and induce changes in normal cells to create and interact with the premalignant tumor microenvironment to promote oncogenesis and immune evasion These studies are currently limited to only a few lesion types and patients In this Perspective we advocate a large-scale collaborative effort to systematically map the biology of premalignancy and the surrounding cellular response By bringing together scientists from diverse disciplines e.g. biochemistry omics and computational biology microbiology immunology and medical genetics engineering imaging and synthetic chemistry and implementation science we can drive a concerted effort focused on cancer vaccines to reprogram the immune response to prevent detect and reject premalignancy Lynch syndrome clonal hematopoiesis and intraepithelial neoplasia which also serve as models for inherited syndromes blood and viral premalignancies are ideal scenarios in which to launch this initiative,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1070, 16, 35, 1452, 1249, 1, 12, 5173, 1305, 914, 615, 1, 12, 5085, 2, 29484, 71, 395, 375, 1870, 1, 2228, 138, 2, 219, 1453, 1049, 6, 189, 954, 20, 1155, 125, 16, 8, 580, 4832, 1, 225, 922, 4, 4343, 2298, 92, 11183, 3526, 3, 174, 6, 690, 2720, 1070, 422, 94, 23, 3, 5709, 59, 2280, 328, 2, 1119, 281, 47, 3901, 336, 1849, 1181, 4343, 91, 2, 3494, 637, 1478, 74, 34074, 28, 3, 250, 398, 292, 801, 6, 17862, 21992, 2, 1682, 12, 2301, 2794, 830, 274, 47, 108, 483, 20, 92, 336, 3391, 2, 127, 1119, 593, 8973, 1291, 37, 2, 1290, 400, 4, 295, 37, 6, 3736, 2, 4491, 5, 3, 4343, 30, 995, 6, 1617, 4503, 2, 250, 5351, 46, 94, 32, 694, 383, 6, 158, 8, 1021, 1180, 630, 2, 7, 4, 26, 3727, 21, 8912, 8, 375, 1124, 3737, 2919, 6, 3390, 3771, 3, 891, 1, 21992, 2, 3, 2976, 763, 51, 20, 12548, 1162, 6868, 29, 1867, 9102, 563, 499, 16776, 15363, 2, 5368, 891, 26476, 6534, 2, 484, 2894, 6717, 270, 2, 3273, 9352, 2, 2393, 3797, 21, 122, 3279, 8, 12645, 2919, 1649, 23, 12, 1842, 6, 14947, 3, 250, 51, 6, 1682, 1426, 2, 13784, 21992, 3546, 681, 1946, 5114, 2, 4153, 2298, 92, 120, 1833, 22, 274, 9, 2986, 2040, 315, 2, 1667, 69005, 32, 3662, 3964, 4, 92, 6, 18480, 26, 4439]",1723.0,27638202,435
Disparities in standard of care treatment and associated survival decrement in patients with locally advanced cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2016-09-16,"Standard of care (SOC) treatment for locally advanced cervical cancer includes pelvic external beam radiation (EBRT) with chemotherapy and interdigitated brachytherapy. We evaluated national utilization trends and factors associated with receiving SOC therapy. We utilized the National Cancer Database (NCDB) to identify women with locally advanced cervical cancer treated with definitive radiation or chemoradiation therapy and stratified these patients by treatment received. We identified 15,194 patients. Only 44.3% of patients received SOC treatment and this group had significantly improved OS. High volume centers, academic centers, comprehensive community cancer centers, private insurance, and higher income, were all associated with an increased likelihood of receiving SOC, whereas Black patients were less likely to receive SOC. We found 26.8% of patients received no radiation boost, 23.8% received an EBRT boost only, and 49.5% of patients received EBRT with brachytherapy. Although an EBRT boost was advantageous over no boost at all (HR 0.720, p<0.001), OS was superior in patients who received brachytherapy (HR 0.554, p<0.001). Patients were more likely to receive no radiotherapy boost if they had lower incomes, Medicaid, were treated at low volume centers, or were treated at non-comprehensive community cancer centers. SOC for locally advanced cervical cancer offers superior outcomes, yet less than half of patients receive SOC and there are disparities in which patients receive SOC treatment. No additional treatment, including sophisticated EBRT techniques including IMRT or SBRT, can make up for the survival decrement from lack of brachytherapy as a component of definitive care.",Journal Article,1222.0,37.0,"Standard of care SOC treatment for locally advanced cancer includes pelvic external beam radiation EBRT with chemotherapy and interdigitated brachytherapy We evaluated national utilization trends and factors associated with receiving SOC therapy We utilized the National Cancer Database NCDB to identify women with locally advanced cancer treated with definitive radiation or chemoradiation therapy and stratified these patients by treatment received We identified 15,194 patients Only 44.3 of patients received SOC treatment and this group had significantly improved OS High volume centers academic centers comprehensive community cancer centers private insurance and higher income were all associated with an increased likelihood of receiving SOC whereas Black patients were less likely to receive SOC We found 26.8 of patients received no radiation boost 23.8 received an EBRT boost only and 49.5 of patients received EBRT with brachytherapy Although an EBRT boost was advantageous over no boost at all HR 0.720 p 0.001 OS was superior in patients who received brachytherapy HR 0.554 p 0.001 Patients were more likely to receive no radiotherapy boost if they had lower incomes Medicaid were treated at low volume centers or were treated at non-comprehensive community cancer centers SOC for locally advanced cancer offers superior outcomes yet less than half of patients receive SOC and there are disparities in which patients receive SOC treatment No additional treatment including sophisticated EBRT techniques including IMRT or SBRT can make up for the survival decrement from lack of brachytherapy as a component of definitive care",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[260, 1, 165, 7615, 24, 9, 795, 131, 12, 1920, 1110, 1455, 1345, 121, 1883, 5, 56, 2, 22119, 1536, 21, 194, 657, 1961, 1963, 2, 130, 41, 5, 357, 7615, 36, 21, 2080, 3, 657, 12, 609, 4315, 6, 255, 117, 5, 795, 131, 12, 73, 5, 1057, 121, 15, 975, 36, 2, 1173, 46, 7, 20, 24, 103, 21, 108, 167, 5434, 7, 158, 584, 27, 1, 7, 103, 7615, 24, 2, 26, 87, 42, 97, 231, 118, 64, 433, 1168, 1916, 1168, 949, 1714, 12, 1168, 4745, 1935, 2, 142, 2306, 11, 62, 41, 5, 35, 101, 1420, 1, 357, 7615, 547, 1445, 7, 11, 299, 322, 6, 560, 7615, 21, 204, 432, 66, 1, 7, 103, 77, 121, 2569, 382, 66, 103, 35, 1883, 2569, 158, 2, 739, 33, 1, 7, 103, 1883, 5, 1536, 242, 35, 1883, 2569, 10, 10650, 252, 77, 2569, 28, 62, 168, 13, 9746, 19, 13, 144, 118, 10, 1123, 4, 7, 54, 103, 1536, 168, 13, 13345, 19, 13, 144, 7, 11, 80, 322, 6, 560, 77, 310, 2569, 492, 491, 42, 280, 16762, 2843, 11, 73, 28, 154, 433, 1168, 15, 11, 73, 28, 220, 949, 1714, 12, 1168, 7615, 9, 795, 131, 12, 2339, 1123, 123, 1145, 299, 76, 1303, 1, 7, 560, 7615, 2, 125, 32, 2227, 4, 92, 7, 560, 7615, 24, 77, 402, 24, 141, 8023, 1883, 1092, 141, 964, 15, 1415, 122, 2378, 126, 9, 3, 25, 15951, 29, 926, 1, 1536, 22, 8, 1249, 1, 1057, 165]",1638.0,27640961,124
Patterns of recurrence and survival in neuroendocrine cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2016-09-16,"To analyze patterns of recurrence and survival and identify prognostic factors in women with neuroendocrine cervical cancer (NECC). We reviewed patients with International Federation of Gynecology and Obstetrics stage I-IVA NECC who were enrolled in the Neuroendocrine Cervical Tumor Registry and treated with curative intent. Event-free survival (EFS) and overall survival (OS) according to disease and treatment characteristics were analyzed using the Kaplan-Meier method. Among 40 patients with NECC, 25 (62%) had small cell NECC, eight (20%) had large cell NECC, and seven (18%) had unspecified neuroendocrine histology. With a median follow-up of 21.5months, 32 patients (80%) experienced progression, and 28 (70%) died. For all patients, the 5-year EFS rate was 20%, and the 5-year OS rate was 27%. Patients with large cell NECC had significantly better median EFS (median not reached vs. 10.0months, p=0.02) and showed a trend toward better median OS (153months vs. 21months, p=0.08) than patients with other histologic types. In patients with early-stage clinically node-negative disease, chemoradiation was associated with significantly better median EFS than surgery (median not reached vs. 18.0months, p=0.04). Patients with large cell NECC have better outcomes than patients with other subtypes of NECC. In early-stage node-negative NECC, chemoradiation yields better EFS than surgery. Most patients with NECC, even those with no evidence of nodal disease at diagnosis, rapidly develop widespread hematogenous metastases and die of their disease.",Journal Article,1222.0,7.0,To analyze patterns of recurrence and survival and identify prognostic factors in women with neuroendocrine cancer NECC We reviewed patients with International Federation of Gynecology and Obstetrics stage I-IVA NECC who were enrolled in the Neuroendocrine Tumor Registry and treated with curative intent Event-free survival EFS and overall survival OS according to disease and treatment characteristics were analyzed using the Kaplan-Meier method Among 40 patients with NECC 25 62 had small cell NECC eight 20 had large cell NECC and seven 18 had unspecified neuroendocrine histology With a median follow-up of 21.5months 32 patients 80 experienced progression and 28 70 died For all patients the 5-year EFS rate was 20 and the 5-year OS rate was 27 Patients with large cell NECC had significantly better median EFS median not reached vs. 10.0months p=0.02 and showed a trend toward better median OS 153months vs. 21months p=0.08 than patients with other histologic types In patients with early-stage clinically node-negative disease chemoradiation was associated with significantly better median EFS than surgery median not reached vs. 18.0months p=0.04 Patients with large cell NECC have better outcomes than patients with other subtypes of NECC In early-stage node-negative NECC chemoradiation yields better EFS than surgery Most patients with NECC even those with no evidence of nodal disease at diagnosis rapidly develop widespread hematogenous metastases and die of their disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1992, 764, 1, 146, 2, 25, 2, 255, 177, 130, 4, 117, 5, 1542, 12, 21863, 21, 446, 7, 5, 944, 7303, 1, 6429, 2, 7407, 82, 70, 5900, 21863, 54, 11, 346, 4, 3, 1542, 30, 1608, 2, 73, 5, 1075, 1697, 774, 115, 25, 1683, 2, 63, 25, 118, 768, 6, 34, 2, 24, 374, 11, 311, 75, 3, 876, 882, 596, 107, 327, 7, 5, 21863, 243, 744, 42, 302, 31, 21863, 659, 179, 42, 375, 31, 21863, 2, 648, 203, 42, 12288, 1542, 784, 5, 8, 52, 166, 126, 1, 239, 15029, 531, 7, 493, 592, 91, 2, 339, 431, 1016, 9, 62, 7, 3, 33, 111, 1683, 116, 10, 179, 2, 3, 33, 111, 118, 116, 10, 428, 7, 5, 375, 31, 21863, 42, 97, 380, 52, 1683, 52, 44, 1300, 105, 79, 20846, 19, 13, 588, 2, 224, 8, 853, 1317, 380, 52, 118, 69019, 105, 50013, 19, 13, 1592, 76, 7, 5, 127, 884, 630, 4, 7, 5, 191, 82, 505, 289, 199, 34, 975, 10, 41, 5, 97, 380, 52, 1683, 76, 152, 52, 44, 1300, 105, 203, 20846, 19, 13, 755, 7, 5, 375, 31, 21863, 47, 380, 123, 76, 7, 5, 127, 814, 1, 21863, 4, 191, 82, 289, 199, 21863, 975, 4788, 380, 1683, 76, 152, 96, 7, 5, 21863, 871, 135, 5, 77, 241, 1, 779, 34, 28, 147, 1755, 690, 3029, 9792, 196, 2, 3384, 1, 136, 34]",1486.0,27645621,308
Relation of comorbidities and patient navigation with the time to diagnostic resolution after abnormal cancer screening.,Cancer,Cancer,2016-09-20,"Whether patient navigation improves outcomes for patients with comorbidities is unknown. The aims of this study were to determine the effect of comorbidities on the time to diagnostic resolution after an abnormal cancer screening test and to examine whether patient navigation improves the timeliness and likelihood of diagnostic resolution for patients with comorbidities in comparison with no navigation. A secondary analysis of comorbidity data collected by Patient Navigation Research Program sites using the Charlson Comorbidity Index (CCI) was conducted. The participants were 6,349 patients with abnormal breast, cervical, colon, or prostate cancer screening tests between 2007 and 2011. The intervention was patient navigation or usual care. The CCI data were highly skewed across projects and cancer sites, and the CCI scores were categorized as 0 (CCI score of 0 or no comorbidities identified; 76% of cases); 1 (CCI score of 1; 16% of cases), or 2 (CCI score2; 8% of cases). Separate adjusted hazard ratios for each site and cancer type were obtained, and then they were pooled with a meta-analysis random effects methodology. Patients with a CCI score2 had delayed diagnostic resolution after an abnormal cancer screening test in comparison with those with no comorbidities. Patient navigation reduced delays in diagnostic resolution, with the greatest benefits seen for those with a CCI score2. Persons with a CCI score2 experienced significant delays in timely diagnostic care in comparison with patients without comorbidities. Patient navigation was effective in reducing delays in diagnostic resolution among those with CCI scores>1. Cancer 2017;123:312-318.  2016 American Cancer Society.",Journal Article,1218.0,6.0,"Whether patient navigation improves outcomes for patients with comorbidities is unknown The aims of this study were to determine the effect of comorbidities on the time to diagnostic resolution after an abnormal cancer screening test and to examine whether patient navigation improves the timeliness and likelihood of diagnostic resolution for patients with comorbidities in comparison with no navigation A secondary analysis of comorbidity data collected by Patient Navigation Research Program sites using the Charlson Comorbidity Index CCI was conducted The participants were 6,349 patients with abnormal or cancer screening tests between 2007 and 2011 The intervention was patient navigation or usual care The CCI data were highly skewed across projects and cancer sites and the CCI scores were categorized as 0 CCI score of 0 or no comorbidities identified 76 of cases 1 CCI score of 1 16 of cases or 2 CCI score  2 8 of cases Separate adjusted hazard ratios for each site and cancer type were obtained and then they were pooled with a meta-analysis random effects methodology Patients with a CCI score  2 had delayed diagnostic resolution after an abnormal cancer screening test in comparison with those with no comorbidities Patient navigation reduced delays in diagnostic resolution with the greatest benefits seen for those with a CCI score  2 Persons with a CCI score  2 experienced significant delays in timely diagnostic care in comparison with patients without comorbidities Patient navigation was effective in reducing delays in diagnostic resolution among those with CCI scores 1 Cancer 2017 123:312-318  2016 American Cancer Society",1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[317, 69, 5604, 1804, 123, 9, 7, 5, 1909, 16, 860, 3, 2970, 1, 26, 45, 11, 6, 223, 3, 254, 1, 1909, 23, 3, 98, 6, 752, 2125, 50, 35, 1668, 12, 453, 412, 2, 6, 1004, 317, 69, 5604, 1804, 3, 11680, 2, 1420, 1, 752, 2125, 9, 7, 5, 1909, 4, 1155, 5, 77, 5604, 8, 568, 65, 1, 1879, 74, 786, 20, 69, 5604, 389, 1243, 633, 75, 3, 4670, 1879, 558, 4934, 10, 426, 3, 776, 11, 49, 9043, 7, 5, 1668, 15, 12, 453, 895, 59, 1307, 2, 1132, 3, 788, 10, 69, 5604, 15, 3521, 165, 3, 4934, 74, 11, 561, 16082, 716, 9663, 2, 12, 633, 2, 3, 4934, 703, 11, 2320, 22, 13, 4934, 368, 1, 13, 15, 77, 1909, 108, 846, 1, 140, 14, 4934, 368, 1, 14, 245, 1, 140, 15, 18, 4934, 368, 749, 18, 66, 1, 140, 2282, 586, 360, 1137, 9, 296, 606, 2, 12, 267, 11, 683, 2, 818, 491, 11, 1830, 5, 8, 1742, 65, 2324, 176, 3209, 7, 5, 8, 4934, 368, 749, 18, 42, 1612, 752, 2125, 50, 35, 1668, 12, 453, 412, 4, 1155, 5, 135, 5, 77, 1909, 69, 5604, 405, 3257, 4, 752, 2125, 5, 3, 2199, 1141, 527, 9, 135, 5, 8, 4934, 368, 749, 18, 4327, 5, 8, 4934, 368, 749, 18, 592, 93, 3257, 4, 4225, 752, 165, 4, 1155, 5, 7, 187, 1909, 69, 5604, 10, 323, 4, 1818, 3257, 4, 752, 2125, 107, 135, 5, 4934, 703, 14, 12, 1759, 2698, 8187, 8797, 2206, 1390, 597, 12, 1174]",1652.0,27648520,140
"Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix.",Oncotarget,Oncotarget,2016-11-01,"Immune checkpoints are emerging treatment targets, but mechanisms underlying checkpoint expression are poorly understood. Since alterations in DNA repair genes have been connected to the efficacy of checkpoint inhibitors, we investigated associations between methylation of DNA repair genes and CTLA4 and CD274 (PD-L1) expression.A list of DNA repair genes (179 genes) was selected from the literature, methylation status and expression of inflammation-associated genes (The Cancer Genome Atlas data) was correlated in head and neck squamous cell carcinoma (HNSCC), cervical and lung squamous cell carcinoma.A significant positive correlation of the methylation status of 15, 3 and 2 genes with checkpoint expression was identified, respectively. RAD51B methylation was identified in all cancer subtypes. In HNSCC and cervical cancer, there was significant enrichment for homologous recombination genes. Methylation of the candidate genes was also associated with expression of other checkpoints, ligands, MHC- and T-cell associated genes as well as an interferon-inflammatory immune gene signature, predictive for the efficacy of PD-1 inhibition in HNSCC.Homologous recombination deficiency might therefore be mediated by DNA repair gene hypermethylation and linked to an immune-evasive phenotype in SCC. The methylation status of these genes could represent a new predictive biomarker for immune checkpoint inhibition.",Journal Article,1176.0,14.0,Immune checkpoints are emerging treatment targets but mechanisms underlying checkpoint expression are poorly understood Since alterations in DNA repair genes have been connected to the efficacy of checkpoint inhibitors we investigated associations between methylation of DNA repair genes and CTLA4 and CD274 PD-L1 expression.A list of DNA repair genes 179 genes was selected from the literature methylation status and expression of inflammation-associated genes The Cancer Genome Atlas data was correlated in head and squamous cell carcinoma HNSCC and squamous cell carcinoma.A significant positive correlation of the methylation status of 15 3 and 2 genes with checkpoint expression was identified respectively RAD51B methylation was identified in all cancer subtypes In HNSCC and cancer there was significant enrichment for homologous recombination genes Methylation of the candidate genes was also associated with expression of other checkpoints ligands MHC- and T-cell associated genes as well as an interferon-inflammatory immune gene signature predictive for the efficacy of PD-1 inhibition in HNSCC.Homologous recombination deficiency might therefore be mediated by DNA repair gene hypermethylation and linked to an immune-evasive phenotype in SCC The methylation status of these genes could represent a new predictive biomarker for immune checkpoint inhibition,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[250, 4704, 32, 1478, 24, 637, 84, 483, 1181, 986, 55, 32, 1240, 1784, 1192, 593, 4, 261, 972, 214, 47, 85, 13150, 6, 3, 209, 1, 986, 222, 21, 565, 685, 59, 569, 1, 261, 972, 214, 2, 5427, 2, 10511, 333, 729, 55, 8, 4754, 1, 261, 972, 214, 5977, 214, 10, 715, 29, 3, 789, 569, 156, 2, 55, 1, 1815, 41, 214, 3, 12, 898, 2643, 74, 10, 438, 4, 718, 2, 691, 31, 134, 1209, 2, 691, 31, 134, 8, 93, 109, 816, 1, 3, 569, 156, 1, 167, 27, 2, 18, 214, 5, 986, 55, 10, 108, 106, 20744, 569, 10, 108, 4, 62, 12, 814, 4, 1209, 2, 12, 125, 10, 93, 3020, 9, 3894, 4017, 214, 569, 1, 3, 1609, 214, 10, 120, 41, 5, 55, 1, 127, 4704, 3123, 3658, 2, 102, 31, 41, 214, 22, 149, 22, 35, 1688, 1291, 250, 145, 1651, 464, 9, 3, 209, 1, 333, 14, 297, 4, 1209, 3894, 4017, 2299, 822, 673, 40, 517, 20, 261, 972, 145, 2575, 2, 1199, 6, 35, 250, 29310, 1005, 4, 1791, 3, 569, 156, 1, 46, 214, 359, 1231, 8, 217, 464, 901, 9, 250, 986, 297]",1368.0,27683114,29
Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy.,Cancer discovery,Cancer Discov,2016-09-28,"We present the case of a patient with a left frontal glioblastoma with primitive neuroectodermal tumor features and hypermutated genotype in the setting of a POLE germline alteration. During standard-of-care chemoradiation, the patient developed a cervical spine metastasis and was subsequently treated with pembrolizumab. Shortly thereafter, the patient developed an additional metastatic spinal lesion. Using whole-exome DNA sequencing and clonal analysis, we report changes in the subclonal architecture throughout treatment. Furthermore, a persistently high neoantigen load was observed within all tumors. Interestingly, following initiation of pembrolizumab, brisk lymphocyte infiltration was observed in the subsequently resected metastatic spinal lesion and an objective radiographic response was noted in a progressive intracranial lesion, suggestive of active central nervous system (CNS) immunosurveillance following checkpoint blockade therapy. It is unclear whether hypermutated glioblastomas are susceptible to checkpoint blockade in adults. Herein, we provide proof of principle that glioblastomas with DNA-repair defects treated with checkpoint blockade may result in CNS immune activation, leading to clinically and immunologically significant responses. These patients may represent a genomically stratified group for whom immunotherapy could be considered. Cancer Discov; 6(11); 1230-6. 2016 AACR.See related commentary by Snyder and Wolchok, p. 1210This article is highlighted in the In This Issue feature, p. 1197.",Case Reports,1210.0,104.0,We present the case of a patient with a left frontal glioblastoma with primitive neuroectodermal tumor features and hypermutated genotype in the setting of a POLE germline alteration During standard-of-care chemoradiation the patient developed a spine metastasis and was subsequently treated with pembrolizumab Shortly thereafter the patient developed an additional metastatic spinal lesion Using whole-exome DNA sequencing and clonal analysis we report changes in the subclonal architecture throughout treatment Furthermore a persistently high neoantigen load was observed within all tumors Interestingly following initiation of pembrolizumab brisk lymphocyte infiltration was observed in the subsequently resected metastatic spinal lesion and an objective radiographic response was noted in a progressive intracranial lesion suggestive of active central nervous system CNS immunosurveillance following checkpoint blockade therapy It is unclear whether hypermutated glioblastomas are susceptible to checkpoint blockade in adults Herein we provide proof of principle that glioblastomas with DNA-repair defects treated with checkpoint blockade may result in CNS immune activation leading to clinically and immunologically significant responses These patients may represent a genomically stratified group for whom immunotherapy could be considered Cancer Discov 6 11 1230-6 2016 AACR.See related commentary by Snyder and Wolchok p. 1210This article is highlighted in the In This Issue feature p. 1197,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 364, 3, 473, 1, 8, 69, 5, 8, 1712, 8082, 996, 5, 5594, 7160, 30, 404, 2, 13585, 1183, 4, 3, 546, 1, 8, 9119, 1009, 2611, 190, 260, 1, 165, 975, 3, 69, 276, 8, 2342, 278, 2, 10, 1611, 73, 5, 2233, 6961, 3972, 3, 69, 276, 35, 402, 113, 1499, 1180, 75, 902, 2865, 261, 615, 2, 1946, 65, 21, 414, 400, 4, 3, 9210, 4447, 2432, 24, 798, 8, 8684, 64, 6921, 3800, 10, 164, 262, 62, 57, 2873, 366, 1118, 1, 2233, 15216, 1448, 2084, 10, 164, 4, 3, 1611, 1133, 113, 1499, 1180, 2, 35, 461, 1580, 51, 10, 1051, 4, 8, 1014, 2089, 1180, 3832, 1, 544, 854, 1880, 398, 1025, 15169, 366, 986, 1189, 36, 192, 16, 1200, 317, 13585, 4729, 32, 4012, 6, 986, 1189, 4, 857, 1986, 21, 377, 3840, 1, 4968, 17, 4729, 5, 261, 972, 2945, 73, 5, 986, 1189, 68, 757, 4, 1025, 250, 363, 1049, 6, 505, 2, 9841, 93, 253, 46, 7, 68, 1231, 8, 7218, 1173, 87, 9, 953, 726, 359, 40, 515, 12, 7183, 49, 175, 26050, 49, 3456, 1630, 3764, 139, 4662, 20, 69091, 2, 35816, 19, 69092, 946, 16, 3681, 4, 3, 4, 26, 2537, 2705, 19, 34954]",1499.0,27683556,173
Brachytherapy should not be omitted when treating locally advanced neuroendocrine cervical cancer with definitive chemoradiation therapy.,Brachytherapy,Brachytherapy,2016-10-04,"Neuroendocrine cervical cancer is a rare malignancy with a poor prognosis, yet there is a paucity of data to guide treatment decisions when managing patients with this diagnosis. Specifically, there are little data to aid practitioners in deciding if there is added value to brachytherapy given the additional time, cost, discomfort, and toxicity to patients. We used the National Cancer Data Base to identify women with locally advanced neuroendocrine cervical cancer treated with definitive chemoradiotherapy to determine if the addition of brachytherapy improves outcomes in this disease. We also assessed outcomes based on chemotherapy timing in this cohort. We identified 100 patients with locally advanced nonmetastatic neuroendocrine cervical cancer that were treated with definitive chemoradiotherapy between 2004 and 2012. There was a substantial improvement in overall survival when brachytherapy was administered in addition to external beam radiotherapy. In multivariate analysis, the addition of brachytherapy, compared with external beam radiotherapy alone, was associated with an improved median survival of 48.6 vs. 21.6months (hazard ratio (HR), 0.475; 95% CI, 0.255-0.883; p= 0.019). We observed no difference in overall survival for patients treated with neoadjuvant chemotherapy compared with the group who received chemotherapy started concurrently with radiation (HR, 0.851; 95% CI, 0.483-1.500; p= 0.578). Brachytherapy should be considered an essential component of definitive chemoradiotherapy for the treatment of neuroendocrine cervical cancer. Chemotherapy timing, however, does not impact outcome.",Journal Article,1204.0,8.0,Neuroendocrine cancer is a rare malignancy with a poor prognosis yet there is a paucity of data to guide treatment decisions when managing patients with this diagnosis Specifically there are little data to aid practitioners in deciding if there is added value to brachytherapy given the additional time cost discomfort and toxicity to patients We used the National Cancer Data Base to identify women with locally advanced neuroendocrine cancer treated with definitive chemoradiotherapy to determine if the addition of brachytherapy improves outcomes in this disease We also assessed outcomes based on chemotherapy timing in this cohort We identified 100 patients with locally advanced nonmetastatic neuroendocrine cancer that were treated with definitive chemoradiotherapy between 2004 and 2012 There was a substantial improvement in overall survival when brachytherapy was administered in addition to external beam radiotherapy In multivariate analysis the addition of brachytherapy compared with external beam radiotherapy alone was associated with an improved median survival of 48.6 vs. 21.6 months hazard ratio HR 0.475 95 CI 0.255-0.883 p 0.019 We observed no difference in overall survival for patients treated with neoadjuvant chemotherapy compared with the group who received chemotherapy started concurrently with radiation HR 0.851 95 CI 0.483-1.500 p 0.578 Brachytherapy should be considered an essential component of definitive chemoradiotherapy for the treatment of neuroendocrine cancer Chemotherapy timing however does not impact outcome,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1542, 12, 16, 8, 622, 710, 5, 8, 334, 356, 1145, 125, 16, 8, 4832, 1, 74, 6, 1597, 24, 1526, 198, 3969, 7, 5, 26, 147, 1225, 125, 32, 1215, 74, 6, 2427, 6323, 4, 10160, 492, 125, 16, 1953, 549, 6, 1536, 447, 3, 402, 98, 835, 7381, 2, 155, 6, 7, 21, 95, 3, 657, 12, 74, 1782, 6, 255, 117, 5, 795, 131, 1542, 12, 73, 5, 1057, 1464, 6, 223, 492, 3, 352, 1, 1536, 1804, 123, 4, 26, 34, 21, 120, 275, 123, 90, 23, 56, 1972, 4, 26, 180, 21, 108, 394, 7, 5, 795, 131, 2683, 1542, 12, 17, 11, 73, 5, 1057, 1464, 59, 1131, 2, 1195, 125, 10, 8, 1281, 767, 4, 63, 25, 198, 1536, 10, 468, 4, 352, 6, 1455, 1345, 310, 4, 331, 65, 3, 352, 1, 1536, 72, 5, 1455, 1345, 310, 279, 10, 41, 5, 35, 231, 52, 25, 1, 576, 49, 105, 239, 49, 53, 360, 197, 168, 13, 9201, 48, 58, 13, 7826, 13, 14748, 19, 13, 4049, 21, 164, 77, 523, 4, 63, 25, 9, 7, 73, 5, 536, 56, 72, 5, 3, 87, 54, 103, 56, 3461, 3294, 5, 121, 168, 13, 14733, 48, 58, 13, 10661, 14, 1666, 19, 13, 10431, 1536, 257, 40, 515, 35, 1452, 1249, 1, 1057, 1464, 9, 3, 24, 1, 1542, 12, 56, 1972, 137, 1097, 44, 345, 228]",1553.0,27720204,170
Impact of treatment year on survival and adverse effects in patients with cervical cancer and paraortic lymph node metastases treated with definitive extended-field radiation therapy.,Practical radiation oncology,Pract Radiat Oncol,2016-09-07,"Treatment for locoregionally advanced cervical cancer has changed dramatically since 2000. In that year, delivery of radiation therapy with concurrent chemotherapy became standard, and in the early 2000s, use of intensity modulated RT (IMRT) and positron emission tomography (PET) became more prevalent. We sought to determine the impact of these changes on disease-specific survival (DSS) and treatment-related adverse effects in patients with cervical cancer with para-aortic lymph node (PAN) metastases treated with definitive extended-field radiation therapy. We reviewed the medical records of 103 patients with cervical cancer with PAN metastases treated with curative intent at our institution during 2000 to 2013. DSS, disease control in PANs, and treatment-associated adverse effects were compared between patient groups defined by treatment year. The 5-year DSS rate was 23% (95% confidence interval, 9%-38%) for the 34 patients treated from 2000 to 2004, and 47% (95% confidence interval, 36%-59%) for the 69 patients treated from 2005 to 2013 (P = .005). Factors associated with improved DSS included concurrent chemoradiation (P = .001), baseline PET imaging (P = .01), and treatment of PANs with IMRT (P = .02). Only 3 patients (4%) treated from 2005 to 2013 versus 6 patients (18%) treated from 2000 to 2004 had recurrence in PANs (P = .03). Most recurrences in patients treated from 2005 to 2013 were at distant sites. The crude rate of grade 3 or higher late treatment-related adverse effects was 17%; of the 18 patients who developed serious adverse effects, 8 were being treated for recurrent disease at the time. Adverse effects most frequently involved the gastrointestinal and genitourinary systems. Outcomes for patients with cervical cancer with PAN metastases have improved concurrently with advances in treatment, including PET and IMRT. Future studies should focus on ways to improve systemic treatments and reduce late adverse effects without compromising local control.",Journal Article,1231.0,7.0,Treatment for locoregionally advanced cancer has changed dramatically since 2000 In that year delivery of radiation therapy with concurrent chemotherapy became standard and in the early 2000s use of intensity modulated RT IMRT and positron emission tomography PET became more prevalent We sought to determine the impact of these changes on disease-specific survival DSS and treatment-related adverse effects in patients with cancer with para-aortic lymph node PAN metastases treated with definitive extended-field radiation therapy We reviewed the medical records of 103 patients with cancer with PAN metastases treated with curative intent at our institution during 2000 to 2013 DSS disease control in PANs and treatment-associated adverse effects were compared between patient groups defined by treatment year The 5-year DSS rate was 23 95 confidence interval 9 -38 for the 34 patients treated from 2000 to 2004 and 47 95 confidence interval 36 -59 for the 69 patients treated from 2005 to 2013 P .005 Factors associated with improved DSS included concurrent chemoradiation P .001 baseline PET imaging P .01 and treatment of PANs with IMRT P .02 Only 3 patients 4 treated from 2005 to 2013 versus 6 patients 18 treated from 2000 to 2004 had recurrence in PANs P .03 Most recurrences in patients treated from 2005 to 2013 were at distant sites The crude rate of grade 3 or higher late treatment-related adverse effects was 17 of the 18 patients who developed serious adverse effects 8 were being treated for recurrent disease at the time Adverse effects most frequently involved the and genitourinary systems Outcomes for patients with cancer with PAN metastases have improved concurrently with advances in treatment including PET and IMRT Future studies should focus on ways to improve systemic treatments and reduce late adverse effects without compromising local control,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[24, 9, 6410, 131, 12, 71, 2368, 2729, 1192, 1081, 4, 17, 111, 989, 1, 121, 36, 5, 750, 56, 3451, 260, 2, 4, 3, 191, 17373, 119, 1, 837, 1757, 240, 964, 2, 1900, 1799, 872, 495, 3451, 80, 2485, 21, 990, 6, 223, 3, 345, 1, 46, 400, 23, 34, 112, 25, 1788, 2, 24, 139, 290, 176, 4, 7, 5, 12, 5, 4615, 3938, 263, 289, 3055, 196, 73, 5, 1057, 1747, 1067, 121, 36, 21, 446, 3, 484, 1064, 1, 3283, 7, 5, 12, 5, 3055, 196, 73, 5, 1075, 1697, 28, 114, 731, 190, 1081, 6, 1346, 1788, 34, 182, 4, 22776, 2, 24, 41, 290, 176, 11, 72, 59, 69, 271, 395, 20, 24, 111, 3, 33, 111, 1788, 116, 10, 382, 48, 307, 268, 83, 519, 9, 3, 562, 7, 73, 29, 1081, 6, 1131, 2, 662, 48, 307, 268, 511, 728, 9, 3, 790, 7, 73, 29, 1242, 6, 1346, 19, 1614, 130, 41, 5, 231, 1788, 159, 750, 975, 19, 144, 330, 495, 270, 19, 355, 2, 24, 1, 22776, 5, 964, 19, 588, 158, 27, 7, 39, 73, 29, 1242, 6, 1346, 185, 49, 7, 203, 73, 29, 1081, 6, 1131, 42, 146, 4, 22776, 19, 680, 96, 1593, 4, 7, 73, 29, 1242, 6, 1346, 11, 28, 626, 633, 3, 6622, 116, 1, 88, 27, 15, 142, 807, 24, 139, 290, 176, 10, 269, 1, 3, 203, 7, 54, 276, 1762, 290, 176, 66, 11, 486, 73, 9, 387, 34, 28, 3, 98, 290, 176, 96, 746, 646, 3, 2, 4109, 1530, 123, 9, 7, 5, 12, 5, 3055, 196, 47, 231, 3294, 5, 954, 4, 24, 141, 495, 2, 964, 508, 94, 257, 1222, 23, 4245, 6, 401, 403, 640, 2, 969, 807, 290, 176, 187, 6102, 293, 182]",1874.0,27743802,333
"Awareness and knowledge of Human Papillomavirus (HPV), HPV-related cancers, and HPV vaccines in an uninsured adult clinic population.",Cancer medicine,Cancer Med,2016-10-17,"Human papillomavirus (HPV) vaccines offer primary prevention of cervical cancer and protection against other HPV-associated cancers. HPV vaccine coverage in the United States (U.S.) remains low, particularly among older adolescents/young adults, and the uninsured. We assessed awareness and knowledge of HPV disease, HPV-related cancers, and HPV vaccines among working, uninsured adults. Data from the 2014 Health Information National Trends Survey (HINTS 4, Cycle 4) were used as a benchmark. Patients were surveyed in late 2014 at the Volunteers in Medicine free clinic in Duval County, Florida. Surveys contained validated measures of HPV disease and vaccine knowledge; HPV-related cancer knowledge was also assessed. Two-hundred and ninety-six surveys were analyzable with an 84% participation rate. Half (50.3%) of participants had heard of HPV, and 32.1% had heard of the HPV vaccine; in HINTS, these estimates were 63.6% and 62.7%, respectively (both P<0.0001). In adjusted models, high HPV disease knowledge was associated with white race and increased education; high vaccine knowledge was associated with white race, increased education, and female sex. Recognition of HPV as a causative agent was 43.9% for cervical, 9.1% for anal, and 11.1% for throat cancers. For all HPV-associated cancers, participants had lower knowledge/recognition relative to HINTS. The uninsured, socioeconomically disadvantaged adults we surveyed were unaware of a ubiquitous virus that can cause cancer and the existence of a vaccine to protect against it. These findings point to settings and populations in which initiatives to promote HPV vaccination as a cancer prevention tool remain critical.",Journal Article,1191.0,11.0,Human papillomavirus HPV vaccines offer primary prevention of cancer and protection against other HPV-associated cancers HPV vaccine coverage in the United States U.S. remains low particularly among older adolescents/young adults and the uninsured We assessed awareness and knowledge of HPV disease HPV-related cancers and HPV vaccines among working uninsured adults Data from the 2014 Health Information National Trends Survey HINTS 4 Cycle 4 were used as a benchmark Patients were surveyed in late 2014 at the Volunteers in Medicine free clinic in Duval County Florida Surveys contained validated measures of HPV disease and vaccine knowledge HPV-related cancer knowledge was also assessed Two-hundred and ninety-six surveys were analyzable with an 84 participation rate Half 50.3 of participants had heard of HPV and 32.1 had heard of the HPV vaccine in HINTS these estimates were 63.6 and 62.7 respectively both P 0.0001 In adjusted models high HPV disease knowledge was associated with white race and increased education high vaccine knowledge was associated with white race increased education and female sex Recognition of HPV as a causative agent was 43.9 for 9.1 for and 11.1 for throat cancers For all HPV-associated cancers participants had lower knowledge/recognition relative to HINTS The uninsured socioeconomically disadvantaged adults we surveyed were unaware of a ubiquitous virus that can cause cancer and the existence of a vaccine to protect against it These findings point to settings and populations in which initiatives to promote HPV vaccination as a cancer prevention tool remain critical,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 3242, 933, 1842, 1918, 86, 1070, 1, 12, 2, 3525, 480, 127, 933, 41, 163, 933, 1274, 2139, 4, 3, 1088, 907, 1767, 695, 469, 154, 823, 107, 434, 3101, 1169, 857, 2, 3, 4955, 21, 275, 3310, 2, 922, 1, 933, 34, 933, 139, 163, 2, 933, 1842, 107, 2644, 4955, 857, 74, 29, 3, 1409, 341, 487, 657, 1963, 1407, 19573, 39, 417, 39, 11, 95, 22, 8, 7330, 7, 11, 3696, 4, 807, 1409, 28, 3, 5495, 4, 1807, 115, 1188, 4, 69180, 5152, 10533, 3666, 3070, 938, 1018, 1, 933, 34, 2, 1274, 922, 933, 139, 12, 922, 10, 120, 275, 100, 1128, 2, 2493, 437, 3666, 11, 9860, 5, 35, 874, 2599, 116, 1303, 212, 27, 1, 776, 42, 14638, 1, 933, 2, 531, 14, 42, 14638, 1, 3, 933, 1274, 4, 19573, 46, 1423, 11, 676, 49, 2, 744, 67, 106, 110, 19, 13, 488, 4, 586, 274, 64, 933, 34, 922, 10, 41, 5, 886, 1047, 2, 101, 1848, 64, 1274, 922, 10, 41, 5, 886, 1047, 101, 1848, 2, 1061, 1035, 2335, 1, 933, 22, 8, 8088, 420, 10, 601, 83, 9, 83, 14, 9, 2, 175, 14, 9, 14896, 163, 9, 62, 933, 41, 163, 776, 42, 280, 922, 2335, 580, 6, 19573, 3, 4955, 27228, 16700, 857, 21, 3696, 11, 12505, 1, 8, 8577, 1450, 17, 122, 708, 12, 2, 3, 5335, 1, 8, 1274, 6, 4869, 480, 192, 46, 272, 741, 6, 1947, 2, 1184, 4, 92, 6328, 6, 1617, 933, 1915, 22, 8, 12, 1070, 1515, 918, 740]",1613.0,27748078,11
Comparison of Computed Tomography- and Magnetic Resonance Imaging-based Clinical Target Volume Contours at Brachytherapy forCervical Cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2016-07-30,"We prospectively compared computed tomography (CT)- and magnetic resonance imaging (MRI)-based high-risk clinical target volume (HR-CTV) contours at the time of brachytherapy for cervical cancer in an effort to identify patients who might benefit most from MRI-based planning. Thirty-seven patients who had undergone a pretreatment diagnostic MRI scan were included in the analysis. We delineated the HR-CTV on the brachytherapy CT and brachytherapy MRI scans independently for each patient. We then calculated the absolute volumes for each HR-CTV and the Dice coefficient of similarity (DC, a measure of spatial agreement) for the HR-CTV contours. We identified the clinical and tumor factors associated with (1) a discrepancy in volume between the CT HR-CTV and MRI HR-CTV contours; and (2) DC. The mean values were compared using 1-way analysis of variance or paired or unpaired t tests, as appropriate. Simple and multivariable linear regression analyses were used to model the effects of covariates on the outcomes. Patients with International Federation of Gynecology and Obstetrics stage IB to IVA cervical cancer were treated with intracavitary brachytherapy using tandem and ovoid (n=33) or tandem and cylinder (n=4) applicators. The mean CT HR-CTV volume (44.1cm<sup>3</sup>) was larger than the mean MRI HR-CTV volume (35.1cm<sup>3</sup>; P<.0001, paired t test). On multivariable analysis, a higher body mass index (BMI) and tumor size 5cm with parametrial invasion on the MRI scan at diagnosis were associated with an increased discrepancy in volume between the HR-CTV contours (P<.02 for both). In addition, the spatial agreement (as measured by DC) between the HR-CTV contours decreased with an increasing BMI (P=.013). We recommend MRI-based brachytherapy planning for patients with tumors >5cm and parametrial invasion on MRI at diagnosis and for those with a high BMI.",Comparative Study,1270.0,11.0,We prospectively compared computed tomography CT and magnetic resonance imaging MRI -based high-risk clinical target volume HR-CTV contours at the time of brachytherapy for cancer in an effort to identify patients who might benefit most from MRI-based planning Thirty-seven patients who had undergone a pretreatment diagnostic MRI scan were included in the analysis We delineated the HR-CTV on the brachytherapy CT and brachytherapy MRI scans independently for each patient We then calculated the absolute volumes for each HR-CTV and the Dice coefficient of similarity DC a measure of spatial agreement for the HR-CTV contours We identified the clinical and tumor factors associated with 1 a discrepancy in volume between the CT HR-CTV and MRI HR-CTV contours and 2 DC The mean values were compared using 1-way analysis of variance or paired or unpaired t tests as appropriate Simple and multivariable linear regression analyses were used to model the effects of covariates on the outcomes Patients with International Federation of Gynecology and Obstetrics stage IB to IVA cancer were treated with intracavitary brachytherapy using tandem and ovoid n=33 or tandem and cylinder n=4 applicators The mean CT HR-CTV volume 44.1 cm sup 3 /sup was larger than the mean MRI HR-CTV volume 35.1 cm sup 3 /sup P .0001 paired t test On multivariable analysis a higher body mass index BMI and tumor size 5 cm with parametrial invasion on the MRI scan at diagnosis were associated with an increased discrepancy in volume between the HR-CTV contours P .02 for both In addition the spatial agreement as measured by DC between the HR-CTV contours decreased with an increasing BMI P=.013 We recommend MRI-based brachytherapy planning for patients with tumors 5 cm and parametrial invasion on MRI at diagnosis and for those with a high BMI,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 1143, 72, 1220, 872, 425, 2, 1484, 1535, 270, 704, 90, 64, 43, 38, 283, 433, 168, 3402, 6137, 28, 3, 98, 1, 1536, 9, 12, 4, 35, 2919, 6, 255, 7, 54, 822, 247, 96, 29, 704, 90, 1349, 977, 648, 7, 54, 42, 1989, 8, 1194, 752, 704, 1657, 11, 159, 4, 3, 65, 21, 5610, 3, 168, 3402, 23, 3, 1536, 425, 2, 1536, 704, 1441, 1042, 9, 296, 69, 21, 818, 981, 3, 1766, 2225, 9, 296, 168, 3402, 2, 3, 13685, 3200, 1, 6700, 2321, 8, 1463, 1, 5104, 2024, 9, 3, 168, 3402, 6137, 21, 108, 3, 38, 2, 30, 130, 41, 5, 14, 8, 7916, 4, 433, 59, 3, 425, 168, 3402, 2, 704, 168, 3402, 6137, 2, 18, 2321, 3, 313, 1030, 11, 72, 75, 14, 2255, 65, 1, 4446, 15, 2355, 15, 16248, 102, 895, 22, 870, 2763, 2, 658, 1646, 320, 318, 11, 95, 6, 202, 3, 176, 1, 2489, 23, 3, 123, 7, 5, 944, 7303, 1, 6429, 2, 7407, 82, 3180, 6, 5900, 12, 11, 73, 5, 9122, 1536, 75, 2905, 2, 15300, 78, 466, 15, 2905, 2, 23326, 78, 39, 11800, 3, 313, 425, 168, 3402, 433, 584, 14, 494, 172, 27, 172, 10, 1077, 76, 3, 313, 704, 168, 3402, 433, 465, 14, 494, 172, 27, 172, 19, 488, 2355, 102, 412, 23, 658, 65, 8, 142, 642, 782, 558, 1140, 2, 30, 444, 4126, 494, 5, 8726, 578, 23, 3, 704, 1657, 28, 147, 11, 41, 5, 35, 101, 7916, 4, 433, 59, 3, 168, 3402, 6137, 19, 588, 9, 110, 4, 352, 3, 5104, 2024, 22, 644, 20, 2321, 59, 3, 168, 3402, 6137, 340, 5, 35, 602, 1140, 19, 3612, 21, 2237, 704, 90, 1536, 1349, 9, 7, 5, 57, 33, 494, 2, 8726, 578, 23, 704, 28, 147, 2, 9, 135, 5, 8, 64, 1140]",1823.0,27788952,83
Prospective Validation of a High Dimensional Shape Model for Organ Motion in Intact Cervical Cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2016-08-22,"Validated models are needed to justify strategies to define planning target volumes (PTVs) for intact cervical cancer used in clinical practice. Our objective was to independently validate a previously published shape model, using data collected prospectively from clinical trials. We analyzed 42 patients with intact cervical cancer treated with daily fractionated pelvic intensity modulated radiation therapy and concurrent chemotherapy in one of 2 prospective clinical trials. We collected online cone beam computed tomography (CBCT) scans before each fraction. Clinical target volume (CTV) structures from the planning computed tomography scan were cast onto each CBCT scan after rigid registration and manually redrawn to account for organ motion and deformation. We applied the 95% isodose cloud from the planning computed tomography scan to each CBCT scan and computed any CTV outside the 95% isodose cloud. The primary aim was to determine the proportion of CTVs that were encompassed within the 95% isodose volume. A 1-sample t test was used to test the hypothesis that the probability of complete coverage was different from 95%. We used mixed-effects logistic regression to assess effects of time and patient variability. The 95% isodose line completely encompassed 92.3% of all CTVs (95% confidence interval, 88.3%-96.4%), not significantly different from the 95% probability anticipated a priori (P=.19). The overall proportion of missed CTVs was small: the grand mean of covered CTVs was 99.9%, and 95.2% of misses were located in the anterior body of the uterus. Time did not affect coverage probability (P=.71). With the clinical implementation of a previously proposed PTV definition strategy based on a shape model for intact cervical cancer, the probability of CTV coverage was high and the volume of CTV missed was low. This PTV expansion strategy is acceptable for clinical trials and practice; however, we recommend daily image guidance to avoid systematic large misses in select patients.",Journal Article,1247.0,2.0,Validated models are needed to justify strategies to define planning target volumes PTVs for intact cancer used in clinical practice Our objective was to independently validate a previously published shape model using data collected prospectively from clinical trials We analyzed 42 patients with intact cancer treated with daily fractionated pelvic intensity modulated radiation therapy and concurrent chemotherapy in one of 2 prospective clinical trials We collected online cone beam computed tomography CBCT scans before each fraction Clinical target volume CTV structures from the planning computed tomography scan were cast onto each CBCT scan after rigid registration and manually redrawn to account for organ motion and deformation We applied the 95 isodose cloud from the planning computed tomography scan to each CBCT scan and computed any CTV outside the 95 isodose cloud The primary aim was to determine the proportion of CTVs that were encompassed within the 95 isodose volume A 1-sample t test was used to test the hypothesis that the probability of complete coverage was different from 95 We used mixed-effects logistic regression to assess effects of time and patient variability The 95 isodose line completely encompassed 92.3 of all CTVs 95 confidence interval 88.3 -96.4 not significantly different from the 95 probability anticipated a priori P=.19 The overall proportion of missed CTVs was small the grand mean of covered CTVs was 99.9 and 95.2 of misses were located in the anterior body of the Time did not affect coverage probability P=.71 With the clinical implementation of a previously proposed PTV definition strategy based on a shape model for intact cancer the probability of CTV coverage was high and the volume of CTV missed was low This PTV expansion strategy is acceptable for clinical trials and practice however we recommend daily image guidance to avoid systematic large misses in select patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[938, 274, 32, 575, 6, 6665, 422, 6, 1107, 1349, 283, 2225, 13631, 9, 2964, 12, 95, 4, 38, 758, 114, 461, 10, 6, 1042, 2183, 8, 373, 983, 5465, 202, 75, 74, 786, 1143, 29, 38, 143, 21, 311, 595, 7, 5, 2964, 12, 73, 5, 391, 3950, 1110, 837, 1757, 121, 36, 2, 750, 56, 4, 104, 1, 18, 482, 38, 143, 21, 786, 4123, 6939, 1345, 1220, 872, 5187, 1441, 348, 296, 1509, 38, 283, 433, 3402, 2414, 29, 3, 1349, 1220, 872, 1657, 11, 14394, 3301, 296, 5187, 1657, 50, 12782, 3169, 2, 8474, 69262, 6, 1967, 9, 1259, 2967, 2, 16377, 21, 1498, 3, 48, 8945, 27237, 29, 3, 1349, 1220, 872, 1657, 6, 296, 5187, 1657, 2, 1220, 500, 3402, 2513, 3, 48, 8945, 27237, 3, 86, 1130, 10, 6, 223, 3, 920, 1, 14256, 17, 11, 9226, 262, 3, 48, 8945, 433, 8, 14, 1000, 102, 412, 10, 95, 6, 412, 3, 1492, 17, 3, 1320, 1, 236, 2139, 10, 338, 29, 48, 21, 95, 1739, 176, 812, 320, 6, 423, 176, 1, 98, 2, 69, 1982, 3, 48, 8945, 328, 2500, 9226, 937, 27, 1, 62, 14256, 48, 307, 268, 889, 27, 921, 39, 44, 97, 338, 29, 3, 48, 1320, 4078, 8, 7499, 19, 326, 3, 63, 920, 1, 5149, 14256, 10, 302, 3, 20904, 313, 1, 4306, 14256, 10, 1058, 83, 2, 48, 18, 1, 21940, 11, 2308, 4, 3, 2882, 642, 1, 3, 98, 205, 44, 1158, 2139, 1320, 19, 792, 5, 3, 38, 2393, 1, 8, 373, 1587, 3303, 2470, 692, 90, 23, 8, 5465, 202, 9, 2964, 12, 3, 1320, 1, 3402, 2139, 10, 64, 2, 3, 433, 1, 3402, 5149, 10, 154, 26, 3303, 1422, 692, 16, 1595, 9, 38, 143, 2, 758, 137, 21, 2237, 391, 1482, 2753, 6, 3085, 1556, 375, 21940, 4, 1717, 7]",1932.0,27788953,174
Cervical metastasis in squamous cell carcinoma of the hard palate and maxillary alveolus.,"Ear, nose, & throat journal",Ear Nose Throat J,,"We conducted a retrospective study to determine the incidence and treatment outcomes of neck metastases in patients with squamous cell carcinoma (SCC) of the hard palate and/or maxillary alveolus after surgical excision of the primary tumor. We also sought to identify any risk factors for recurrence. Our study population was made up of 20 patients-9 men and 11 women, aged 46 to 88 years (mean: 72.6)-who had undergone excision of an SCC of the hard palate and/or maxillary alveolus at a tertiary care cancer center over a 7-year period. Half of all patients were former tobacco users. Of the 20 tumors, 10 involved the maxillary alveolus, 4 involved the hard palate, and 6 involved both sites. Three patients were clinically categorized as T1, 9 as T2, 6 as T3, and 2 as T4; pathologically, 8 tumors were categorized as T4a. In addition to maxillectomy, a neck dissection was performed in 7 patients-4 therapeutically and 3 electively. Eight of 20 patients experienced a recurrence: 4 local, 6 regional, and 2 distant (several patients had a recurrence at more than one site). Univariate analysis identified perineural invasion (p = 0.04) as a statistically significant risk factor for recurrence. Of 14 patients with a clinicopathologically negative neck, 5 (36%) developed a cervical recurrence, and 4 of them died of their disease. An advanced stage (T4 vs. <T4) was not significantly correlated with the risk of regional metastasis (p = 0.58). The rate of occult nodal metastasis in clinically and radiologically N0 necks was high. Clinical and radiologic understaging was common, and regional recurrences frequently resulted in death. We conclude that elective nodal evaluation and treatment of the neck warrants strong consideration for most patients with cancer of the hard palate and/or maxillary alveolus.",Journal Article,,1.0,We conducted a retrospective study to determine the incidence and treatment outcomes of metastases in patients with squamous cell carcinoma SCC of the hard palate and/or maxillary alveolus after surgical excision of the primary tumor We also sought to identify any risk factors for recurrence Our study population was made up of 20 patients-9 men and 11 women aged 46 to 88 years mean 72.6 -who had undergone excision of an SCC of the hard palate and/or maxillary alveolus at a tertiary care cancer center over a 7-year period Half of all patients were former tobacco users Of the 20 tumors 10 involved the maxillary alveolus 4 involved the hard palate and 6 involved both sites Three patients were clinically categorized as T1 9 as T2 6 as T3 and 2 as T4 pathologically 8 tumors were categorized as T4a In addition to maxillectomy a dissection was performed in 7 patients-4 therapeutically and 3 electively Eight of 20 patients experienced a recurrence 4 local 6 regional and 2 distant several patients had a recurrence at more than one site Univariate analysis identified perineural invasion p 0.04 as a statistically significant risk factor for recurrence Of 14 patients with a clinicopathologically negative 5 36 developed a recurrence and 4 of them died of their disease An advanced stage T4 vs. T4 was not significantly correlated with the risk of regional metastasis p 0.58 The rate of occult nodal metastasis in clinically and radiologically N0 necks was high Clinical and radiologic understaging was common and regional recurrences frequently resulted in death We conclude that elective nodal evaluation and treatment of the warrants strong consideration for most patients with cancer of the hard palate and/or maxillary alveolus,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 426, 8, 459, 45, 6, 223, 3, 287, 2, 24, 123, 1, 196, 4, 7, 5, 691, 31, 134, 1791, 1, 3, 9327, 10988, 2, 15, 11399, 19919, 50, 221, 1366, 1, 3, 86, 30, 21, 120, 990, 6, 255, 500, 43, 130, 9, 146, 114, 45, 266, 10, 1229, 126, 1, 179, 7, 83, 325, 2, 175, 117, 1032, 641, 6, 889, 60, 313, 720, 49, 54, 42, 1989, 1366, 1, 35, 1791, 1, 3, 9327, 10988, 2, 15, 11399, 19919, 28, 8, 2557, 165, 12, 574, 252, 8, 67, 111, 727, 1303, 1, 62, 7, 11, 3623, 2607, 2735, 1, 3, 179, 57, 79, 646, 3, 11399, 19919, 39, 646, 3, 9327, 10988, 2, 49, 646, 110, 633, 169, 7, 11, 505, 2320, 22, 1534, 83, 22, 1786, 49, 22, 2065, 2, 18, 22, 2463, 2998, 66, 57, 11, 2320, 22, 10626, 4, 352, 6, 28001, 8, 1161, 10, 173, 4, 67, 7, 39, 4602, 2, 27, 17683, 659, 1, 179, 7, 592, 8, 146, 39, 293, 49, 951, 2, 18, 626, 392, 7, 42, 8, 146, 28, 80, 76, 104, 606, 880, 65, 108, 4917, 578, 19, 13, 755, 22, 8, 712, 93, 43, 161, 9, 146, 1, 213, 7, 5, 8, 30923, 199, 33, 511, 276, 8, 146, 2, 39, 1, 1370, 1016, 1, 136, 34, 35, 131, 82, 2463, 105, 2463, 10, 44, 97, 438, 5, 3, 43, 1, 951, 278, 19, 13, 717, 3, 116, 1, 2879, 779, 278, 4, 505, 2, 9579, 3394, 18251, 10, 64, 38, 2, 2812, 18228, 10, 186, 2, 951, 1593, 746, 627, 4, 273, 21, 2060, 17, 4700, 779, 451, 2, 24, 1, 3, 2782, 1082, 2415, 9, 96, 7, 5, 12, 1, 3, 9327, 10988, 2, 15, 11399, 19919]",1738.0,27792826,431
Management and outcome of cervical cancer diagnosed inpregnancy.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2016-10-31,"Cervical cancer is the third most common gynecologic malignancy in the United States. Approximately 1-3% of cervical cancers will be diagnosed in pregnant and peripartum women; optimal management in the setting of pregnancy is not always clear. We sought to describe the management of patients with cervical cancer diagnosed in pregnancy and compare their outcomes to nonpregnant women with similar baseline characteristics. We conducted a retrospective chart review of all patients diagnosed with cervical cancer in pregnancy and matched them 1:2 with contemporaneous nonpregnant women of the same age diagnosed with cervical cancer of the same stage. Patients were identified using International Classification of Diseases, Ninth Revision codes and the Dana-Farber/Massachusetts General Hospital Cancer Registry. Data were analyzed using Stata, Version 10.1 (College Station, TX). In all, 28 women diagnosed with cervical cancer during pregnancy were identified from 1997 through 2013. The majority were Stage IB1. In all, 25% (7/28) of women terminated the pregnancy; these women were more likely to be diagnosed earlier in pregnancy (10.9 vs 19.7 weeks, P= .006). For those who did not terminate, mean gestational age at delivery was 36.1 weeks. Pregnancy complications were uncommon. Complication rates in pregnant women undergoing radical hysterectomy were similar to those outside of pregnancy. Time to treatment was significantly longer for pregnant women compared to nonpregnant patients (20.8 vs 7.9 weeks, P= .0014) but there was no survival difference between groups (89.3% vs 95.2%, P= .08). Women who underwent gravid radical hysterectomy had significantly higher estimated blood loss than those who had a radical hysterectomy in the postpartum period (2033 vs 425 mL, P= .0064), but operative characteristics were otherwise similar. None of the pregnant women who died delayed treatment due to pregnancy. Gestational age at diagnosis is an important determinant of management of cervical cancer in pregnancy, underscoring the need for expeditious workup of abnormal cervical cytology. Of women who choose to continue the pregnancy, most delivered in the late preterm period without significant obstetric complications. For women undergoing radical hysterectomy in the peripartum period, complication rates are similar to nonpregnant women undergoing this procedure. Women who died were more likely to have advanced stage disease at the time of diagnosis. This information may be useful in counseling women facing the diagnosis of cervical cancer in pregnancy.",Journal Article,1177.0,6.0,cancer is the third most common gynecologic malignancy in the United States Approximately 1-3 of cancers will be diagnosed in pregnant and peripartum women optimal management in the setting of pregnancy is not always clear We sought to describe the management of patients with cancer diagnosed in pregnancy and compare their outcomes to nonpregnant women with similar baseline characteristics We conducted a retrospective chart review of all patients diagnosed with cancer in pregnancy and matched them 1:2 with contemporaneous nonpregnant women of the same age diagnosed with cancer of the same stage Patients were identified using International Classification of Diseases Ninth Revision codes and the Dana-Farber/Massachusetts General Hospital Cancer Registry Data were analyzed using Stata Version 10.1 College Station TX In all 28 women diagnosed with cancer during pregnancy were identified from 1997 through 2013 The majority were Stage IB1 In all 25 7/28 of women terminated the pregnancy these women were more likely to be diagnosed earlier in pregnancy 10.9 vs 19.7 weeks P .006 For those who did not terminate mean gestational age at delivery was 36.1 weeks Pregnancy complications were uncommon Complication rates in pregnant women undergoing radical hysterectomy were similar to those outside of pregnancy Time to treatment was significantly longer for pregnant women compared to nonpregnant patients 20.8 vs 7.9 weeks P .0014 but there was no survival difference between groups 89.3 vs 95.2 P .08 Women who underwent gravid radical hysterectomy had significantly higher estimated blood loss than those who had a radical hysterectomy in the postpartum period 2033 vs 425 mL P .0064 but operative characteristics were otherwise similar None of the pregnant women who died delayed treatment due to pregnancy Gestational age at diagnosis is an important determinant of management of cancer in pregnancy underscoring the need for expeditious workup of abnormal cytology Of women who choose to continue the pregnancy most delivered in the late preterm period without significant obstetric complications For women undergoing radical hysterectomy in the peripartum period complication rates are similar to nonpregnant women undergoing this procedure Women who died were more likely to have advanced stage disease at the time of diagnosis This information may be useful in counseling women facing the diagnosis of cancer in pregnancy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 3, 1282, 96, 186, 1512, 710, 4, 3, 1088, 907, 705, 14, 27, 1, 163, 303, 40, 265, 4, 6086, 2, 21399, 117, 665, 284, 4, 3, 546, 1, 2290, 16, 44, 3763, 885, 21, 990, 6, 897, 3, 284, 1, 7, 5, 12, 265, 4, 2290, 2, 932, 136, 123, 6, 16615, 117, 5, 288, 330, 374, 21, 426, 8, 459, 2937, 206, 1, 62, 7, 265, 5, 12, 4, 2290, 2, 655, 1370, 14, 18, 5, 11633, 16615, 117, 1, 3, 827, 89, 265, 5, 12, 1, 3, 827, 82, 7, 11, 108, 75, 944, 947, 1, 1342, 13544, 5646, 5271, 2, 3, 4932, 4979, 5459, 1083, 702, 12, 1608, 74, 11, 311, 75, 32096, 2256, 79, 14, 2979, 15087, 6614, 4, 62, 339, 117, 265, 5, 12, 190, 2290, 11, 108, 29, 2341, 298, 1346, 3, 686, 11, 82, 8111, 4, 62, 243, 67, 339, 1, 117, 5640, 3, 2290, 46, 117, 11, 80, 322, 6, 40, 265, 1677, 4, 2290, 79, 83, 105, 326, 67, 244, 19, 1861, 9, 135, 54, 205, 44, 20373, 313, 9383, 89, 28, 989, 10, 511, 14, 244, 2290, 521, 11, 2052, 1447, 151, 4, 6086, 117, 479, 711, 2622, 11, 288, 6, 135, 2513, 1, 2290, 98, 6, 24, 10, 97, 589, 9, 6086, 117, 72, 6, 16615, 7, 179, 66, 105, 67, 83, 244, 19, 11408, 84, 125, 10, 77, 25, 523, 59, 271, 887, 27, 105, 48, 18, 19, 1592, 117, 54, 208, 30682, 711, 2622, 42, 97, 142, 661, 315, 407, 76, 135, 54, 42, 8, 711, 2622, 4, 3, 7830, 727, 39566, 105, 8544, 542, 19, 22080, 84, 1208, 374, 11, 2632, 288, 1292, 1, 3, 6086, 117, 54, 1016, 1612, 24, 520, 6, 2290, 9383, 89, 28, 147, 16, 35, 305, 4372, 1, 284, 1, 12, 4, 2290, 8369, 3, 594, 9, 32667, 4755, 1, 1668, 2045, 1, 117, 54, 6009, 6, 1906, 3, 2290, 96, 1623, 4, 3, 807, 20525, 727, 187, 93, 24695, 521, 9, 117, 479, 711, 2622, 4, 3, 21399, 727, 1447, 151, 32, 288, 6, 16615, 117, 479, 26, 1299, 117, 54, 1016, 11, 80, 322, 6, 47, 131, 82, 34, 28, 3, 98, 1, 147, 26, 487, 68, 40, 999, 4, 2011, 117, 7917, 3, 147, 1, 12, 4, 2290]",2437.0,27810552,523
Esophageal adenocarcinoma and Barrett esophagus in a neurologically impaired teenager.,Pediatrics international : official journal of the Japan Pediatric Society,Pediatr Int,2016-11-01,"Esophageal adenocarcinoma (EAC) accompanied by Barrett esophagus (BE) is rare in patients younger than 20years old. EAC in the upper esophagus is also rare. We report a rare case of EAC with BE that developed in the upper esophagus after chronic, untreated gastroesophageal reflux disease in a neurologically impaired teenager. A 19-year-old neurologically impaired man underwent endoscopy for evaluation of dysphagia and vomiting, and was diagnosed with EAC with BE. He underwent transthoracic esophagectomy, extensive lymph node dissection, and cervical esophagogastric anastomosis, but the prognosis was poor. Pathology indicated poorly differentiated adenocarcinoma with BE.",Case Reports,1176.0,0.0,adenocarcinoma EAC accompanied by Barrett BE is rare in patients younger than 20 years old EAC in the upper is also rare We report a rare case of EAC with BE that developed in the upper after chronic untreated gastroesophageal reflux disease in a neurologically impaired teenager A 19-year-old neurologically impaired man underwent endoscopy for evaluation of dysphagia and vomiting and was diagnosed with EAC with BE He underwent transthoracic esophagectomy extensive lymph node dissection and esophagogastric anastomosis but the prognosis was poor Pathology indicated poorly differentiated adenocarcinoma with BE,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[449, 3378, 2756, 20, 4366, 40, 16, 622, 4, 7, 773, 76, 179, 60, 1095, 3378, 4, 3, 1726, 16, 120, 622, 21, 414, 8, 622, 473, 1, 3378, 5, 40, 17, 276, 4, 3, 1726, 50, 442, 1278, 3227, 9657, 34, 4, 8, 17139, 2364, 29220, 8, 326, 111, 1095, 17139, 2364, 3628, 208, 4199, 9, 451, 1, 4561, 2, 1966, 2, 10, 265, 5, 3378, 5, 40, 3174, 208, 14806, 3617, 1344, 263, 289, 1161, 2, 6330, 5519, 84, 3, 356, 10, 334, 1117, 1103, 1240, 1442, 449, 5, 40]",614.0,27882742,58
Less radical surgery for early-stage cervical cancer: Can conization specimens help identify patients at low risk for parametrial involvement?,Gynecologic oncology,Gynecol. Oncol.,2016-11-21,"Radical hysterectomy for cervical cancer is associated with increased morbidity over an extrafascial hysterectomy. The goal of this study was to determine incidence of and risk factors for parametrial involvement (PI) based on conization specimen (CS) and to potentially identify candidates for less radical surgery. Patients with FIGO IA2-IIA cervical cancer treated with radical hysterectomy and pelvic lymph node dissection (RH) from 2000 to 2010 were retrospectively identified. Data was extracted from operative and pathology reports. Statistical analyses were performed using Fisher's exact test, t-test, and asymptotic logistic regression. Of 267 RH patients identified, 118 (44%) had conization prior to RH. The incidence of PI was 15.7% overall and 7.5% in patients treated with conization prior to RH. There was no association between PI and histology, stage, grade, or tumor size. Conization patients with PI were more likely to have LVSI on CS (77.8% vs. 29.4%) and positive lymph nodes (LNP) (66.7% vs. 8.3%). Of patients with positive endocervical curettage, a modest 12% had PI, which was not statistically significant. Tumor size, depth of invasion, and margin status on CS were not statistically associated with PI. In logistic regression analysis, LNP alone or LNP+LVSI were predictive of PI. The incidence of PI in early-stage cervical cancer is significant. Only LVSI on CS and LNP were predictors of PI in the current study. While there may be select patients with early stage cervical cancer who can be spared parametrectomy, additional research is warranted.",Journal Article,1156.0,7.0,Radical hysterectomy for cancer is associated with increased morbidity over an extrafascial hysterectomy The goal of this study was to determine incidence of and risk factors for parametrial involvement PI based on conization specimen CS and to potentially identify candidates for less radical surgery Patients with FIGO IA2-IIA cancer treated with radical hysterectomy and pelvic lymph node dissection RH from 2000 to 2010 were retrospectively identified Data was extracted from operative and pathology reports Statistical analyses were performed using Fisher 's exact test t-test and asymptotic logistic regression Of 267 RH patients identified 118 44 had conization prior to RH The incidence of PI was 15.7 overall and 7.5 in patients treated with conization prior to RH There was no association between PI and histology stage grade or tumor size Conization patients with PI were more likely to have LVSI on CS 77.8 vs. 29.4 and positive lymph nodes LNP 66.7 vs. 8.3 Of patients with positive endocervical curettage a modest 12 had PI which was not statistically significant Tumor size depth of invasion and margin status on CS were not statistically associated with PI In logistic regression analysis LNP alone or LNP+LVSI were predictive of PI The incidence of PI in early-stage cancer is significant Only LVSI on CS and LNP were predictors of PI in the current study While there may be select patients with early stage cancer who can be spared parametrectomy additional research is warranted,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[711, 2622, 9, 12, 16, 41, 5, 101, 787, 252, 35, 25094, 2622, 3, 1326, 1, 26, 45, 10, 6, 223, 287, 1, 2, 43, 130, 9, 8726, 799, 2928, 90, 23, 8755, 2360, 2188, 2, 6, 751, 255, 1931, 9, 299, 711, 152, 7, 5, 3837, 16725, 4088, 12, 73, 5, 711, 2622, 2, 1110, 263, 289, 1161, 7240, 29, 1081, 6, 1120, 11, 894, 108, 74, 10, 2484, 29, 1208, 2, 1117, 1198, 1050, 318, 11, 173, 75, 3135, 292, 2472, 412, 102, 412, 2, 24880, 812, 320, 1, 7559, 7240, 7, 108, 4002, 584, 42, 8755, 324, 6, 7240, 3, 287, 1, 2928, 10, 167, 67, 63, 2, 67, 33, 4, 7, 73, 5, 8755, 324, 6, 7240, 125, 10, 77, 248, 59, 2928, 2, 784, 82, 88, 15, 30, 444, 8755, 7, 5, 2928, 11, 80, 322, 6, 47, 8004, 23, 2188, 849, 66, 105, 462, 39, 2, 109, 263, 502, 13204, 700, 67, 105, 66, 27, 1, 7, 5, 109, 10174, 12529, 8, 1721, 133, 42, 2928, 92, 10, 44, 712, 93, 30, 444, 2436, 1, 578, 2, 959, 156, 23, 2188, 11, 44, 712, 41, 5, 2928, 4, 812, 320, 65, 13204, 279, 15, 13204, 8004, 11, 464, 1, 2928, 3, 287, 1, 2928, 4, 191, 82, 12, 16, 93, 158, 8004, 23, 2188, 2, 13204, 11, 674, 1, 2928, 4, 3, 291, 45, 369, 125, 68, 40, 1717, 7, 5, 191, 82, 12, 54, 122, 40, 6830, 23693, 402, 389, 16, 1197]",1497.0,27884514,344
Revisiting Milan cervical cancer study: Do the original findings hold in the era of chemotherapy?,Gynecologic oncology,Gynecol. Oncol.,2016-11-26,"The primary treatment of early stage cervical carcinoma (IB-IIA) is either surgery or radiation therapy based on the pivotal Milan randomized study published twenty years ago. In the presence of high-risk features, the gold standard treatment is concurrent chemotherapy and radiation therapy (CRT) whether it is the in the postoperative or the definitive setting. Using the National Cancer Data Base (NCDB), the goal of our study is to compare the outcomes of surgery and radiation therapy in the chemotherapy era. Between 2004 and 2013, 5478 patients diagnosed with early stage cervical cancer were divided into 2 groups based on their primary treatment: non-surgical (n=1980) and surgical groups (n=3498). The distribution of patient/tumor characteristics and treatment variables with their relation to overall survival and proportional regression models were assessed to investigate the superiority of one approach over the other. Propensity score analysis adjusted for imbalance of covariates to create a well-matched-patient cohort. At 46months median follow-up, the 5-year overall survival was similar between both groups (738% vs. 75.7%; p=0.619) after applying propensity score analysis. On multivariate analysis, high Charlson comorbidity score, stage IIA disease, larger tumor size, positive lymph nodes and high-grade disease were significant predictors of poor outcome while older age and treatment approach were not. Our analysis suggests that surgery (followed by adjuvant RT or CRT) and definitive radiotherapy (with or without chemotherapy) result in equivalent survival. Prospective studies are warranted to establish this paradigm in the chemotherapy era.",Journal Article,1151.0,1.0,The primary treatment of early stage carcinoma IB-IIA is either surgery or radiation therapy based on the pivotal Milan randomized study published twenty years ago In the presence of high-risk features the gold standard treatment is concurrent chemotherapy and radiation therapy CRT whether it is the in the postoperative or the definitive setting Using the National Cancer Data Base NCDB the goal of our study is to compare the outcomes of surgery and radiation therapy in the chemotherapy era Between 2004 and 2013 5478 patients diagnosed with early stage cancer were divided into 2 groups based on their primary treatment non-surgical n=1980 and surgical groups n=3498 The distribution of patient/tumor characteristics and treatment variables with their relation to overall survival and proportional regression models were assessed to investigate the superiority of one approach over the other Propensity score analysis adjusted for imbalance of covariates to create a well-matched-patient cohort At 46months median follow-up the 5-year overall survival was similar between both groups 738 vs. 75.7 p=0.619 after applying propensity score analysis On multivariate analysis high Charlson comorbidity score stage IIA disease larger tumor size positive lymph nodes and high-grade disease were significant predictors of poor outcome while older age and treatment approach were not Our analysis suggests that surgery followed by adjuvant RT or CRT and definitive radiotherapy with or without chemotherapy result in equivalent survival Prospective studies are warranted to establish this paradigm in the chemotherapy era,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 86, 24, 1, 191, 82, 134, 3180, 4088, 16, 361, 152, 15, 121, 36, 90, 23, 3, 3754, 10610, 384, 45, 983, 737, 60, 5028, 4, 3, 463, 1, 64, 43, 404, 3, 4159, 260, 24, 16, 750, 56, 2, 121, 36, 1089, 317, 192, 16, 3, 4, 3, 573, 15, 3, 1057, 546, 75, 3, 657, 12, 74, 1782, 4315, 3, 1326, 1, 114, 45, 16, 6, 932, 3, 123, 1, 152, 2, 121, 36, 4, 3, 56, 1713, 59, 1131, 2, 1346, 69411, 7, 265, 5, 191, 82, 12, 11, 2176, 237, 18, 271, 90, 23, 136, 86, 24, 220, 221, 78, 4376, 2, 221, 271, 78, 69412, 3, 1395, 1, 69, 30, 374, 2, 24, 682, 5, 136, 2191, 6, 63, 25, 2, 831, 320, 274, 11, 275, 6, 963, 3, 5233, 1, 104, 353, 252, 3, 127, 1925, 368, 65, 586, 9, 6088, 1, 2489, 6, 3736, 8, 149, 655, 69, 180, 28, 50075, 52, 166, 126, 3, 33, 111, 63, 25, 10, 288, 59, 110, 271, 50119, 105, 481, 67, 19, 13, 14277, 50, 4798, 1925, 368, 65, 23, 331, 65, 64, 4670, 1879, 368, 82, 4088, 34, 1077, 30, 444, 109, 263, 502, 2, 64, 88, 34, 11, 93, 674, 1, 334, 228, 369, 434, 89, 2, 24, 353, 11, 44, 114, 65, 844, 17, 152, 370, 20, 249, 240, 15, 1089, 2, 1057, 310, 5, 15, 187, 56, 757, 4, 2017, 25, 482, 94, 32, 1197, 6, 1811, 26, 2431, 4, 3, 56, 1713]",1618.0,27899201,338
Carcinogenic human papillomavirus infection.,Nature reviews. Disease primers,Nat Rev Dis Primers,2016-12-01,"Infections with human papillomavirus (HPV) are common and transmitted by direct contact. Although the great majority of infections resolve within 2 years, 13 phylogenetically related, sexually transmitted HPV genotypes, notably HPV16, cause - if not controlled immunologically or by screening - virtually all cervical cancers worldwide, a large fraction of other anogenital cancers and an increasing proportion of oropharyngeal cancers. The carcinogenicity of these HPV types results primarily from the activity of the oncoproteins E6 and E7, which impair growth regulatory pathways. Persistent high-risk HPVs can transition from a productive (virion-producing) to an abortive or transforming infection, after which cancer can result after typically slow accumulation of host genetic mutations. However, which precancerous lesions progress and which do not is unclear; the majority of screening-detected precancers are treated, leading to overtreatment. The discovery of HPV as a carcinogen led to the development of effective preventive vaccines and sensitive HPV DNA and RNA tests. Together, vaccination programmes (the ultimate long-term preventive strategy) and screening using HPV tests could dramatically alter the landscape of HPV-related cancers. HPV testing will probably replace cytology-based cervical screening owing to greater reassurance when the test is negative. However, the effective implementation of HPV vaccination and screening globally remains a challenge.",Journal Article,1146.0,140.0,Infections with human papillomavirus HPV are common and transmitted by direct contact Although the great majority of infections resolve within 2 years 13 phylogenetically related sexually transmitted HPV genotypes notably HPV16 cause if not controlled immunologically or by screening virtually all cancers worldwide a large fraction of other anogenital cancers and an increasing proportion of cancers The carcinogenicity of these HPV types results primarily from the activity of the oncoproteins E6 and E7 which impair growth regulatory pathways Persistent high-risk HPVs can transition from a productive virion-producing to an abortive or transforming infection after which cancer can result after typically slow accumulation of host genetic mutations However which precancerous lesions progress and which do not is unclear the majority of screening-detected precancers are treated leading to overtreatment The discovery of HPV as a carcinogen led to the development of effective preventive vaccines and sensitive HPV DNA and RNA tests Together vaccination programmes the ultimate long-term preventive strategy and screening using HPV tests could dramatically alter the landscape of HPV-related cancers HPV testing will probably replace cytology-based screening owing to greater reassurance when the test is negative However the effective implementation of HPV vaccination and screening globally remains a challenge,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1875, 5, 171, 3242, 933, 32, 186, 2, 12959, 20, 1196, 4393, 242, 3, 2797, 686, 1, 1875, 8244, 262, 18, 60, 233, 47185, 139, 13588, 12959, 933, 2071, 2552, 4048, 708, 492, 44, 1149, 9841, 15, 20, 453, 5860, 62, 163, 2358, 8, 375, 1509, 1, 127, 13836, 163, 2, 35, 602, 920, 1, 163, 3, 33443, 1, 46, 933, 630, 99, 1561, 29, 3, 128, 1, 3, 8241, 4837, 2, 4540, 92, 6267, 129, 1253, 460, 1882, 64, 43, 13477, 122, 1970, 29, 8, 10110, 26060, 3787, 6, 35, 33849, 15, 3621, 930, 50, 92, 12, 122, 757, 50, 1969, 3645, 1835, 1, 1204, 336, 138, 137, 92, 6605, 406, 1466, 2, 92, 1022, 44, 16, 1200, 3, 686, 1, 453, 530, 18753, 32, 73, 1049, 6, 7720, 3, 1574, 1, 933, 22, 8, 7290, 836, 6, 3, 193, 1, 323, 3494, 1842, 2, 745, 933, 261, 2, 893, 895, 1162, 1915, 12861, 3, 5768, 319, 337, 3494, 692, 2, 453, 75, 933, 895, 359, 2729, 2688, 3, 2801, 1, 933, 139, 163, 933, 471, 303, 4061, 7195, 2045, 90, 453, 3421, 6, 378, 14491, 198, 3, 412, 16, 199, 137, 3, 323, 2393, 1, 933, 1915, 2, 453, 6873, 469, 8, 1745]",1416.0,27905473,242
Does para-aortic irradiation reduce the risk of distant metastasis in advanced cervical cancer? A systematic review and meta-analysis of randomized clinical trials.,Gynecologic oncology,Gynecol. Oncol.,2016-11-28,"To evaluate the impact of the extension of the radiotherapy field cranially toward para-aortic lymph nodes (EF-RT) in advanced cervical cancer. A systematic search of databases (PubMed, CENTRAL, Clinical Trials) was performed and included studies that were published between 1960 and November 2015 without language restrictions. All randomized clinical trials (RCTs) were analyzed further. All patients must have undergone pelvic radiotherapy and the same systemic therapy in both arms. The primary endpoints were locoregional failure, incidence of distant metastasis, para-aortic failure, and cancer related death. The Mantel-Haenszel method was used in the meta-analysis. The risk of bias analysis was determined using the 7-domain method per the Cochrane Handbook for Systematic Reviews of Interventions V5.1.0. A review of the treatment technique and toxicity was also performed. A total of 1309 studies were evaluated, 4 RCTs of which met the inclusion criteria; 506 patients were allocated to standard pelvic irradiation, and 494 underwent EF-RT. The risk of bias was considered to be low in nearly 80% of the domains. EF-RT significantly reduced the rate of para-aortic failure (HR 0.35, 95% CI 0.19-0.64; p<0.01) and the incidence of other distant metastases (HR 0.69, 95% CI 0.50-0.96; p=0.03). Locoregional failure and cancer-related death were not significantly altered (OR 1.06 [0.80-1.42]; p=0.67, and 0.68 [0.45-1.01]; p=0.06, respectively). The radiotherapy technique was conventional in 3 studies and conformational in 1 study. In total, 10 treatment-related deaths occurred-4 in pelvic radiation and 6 in EF-RT (OR 2.12 [0.71-6.27]; p=0.18). EF-RT that targets the para-aortic lymphatic chain reduces distant metastatic events, but its impact on survival is unknown. Future studies should examine the value of EF-RT using modern radiation techniques.",Journal Article,1149.0,13.0,To evaluate the impact of the extension of the radiotherapy field cranially toward para-aortic lymph nodes EF-RT in advanced cancer A systematic search of databases PubMed CENTRAL Clinical Trials was performed and included studies that were published between 1960 and November 2015 without language restrictions All randomized clinical trials RCTs were analyzed further All patients must have undergone pelvic radiotherapy and the same systemic therapy in both arms The primary endpoints were locoregional failure incidence of distant metastasis para-aortic failure and cancer related death The Mantel-Haenszel method was used in the meta-analysis The risk of bias analysis was determined using the 7-domain method per the Cochrane Handbook for Systematic Reviews of Interventions V5.1.0 A review of the treatment technique and toxicity was also performed A total of 1309 studies were evaluated 4 RCTs of which met the inclusion criteria 506 patients were allocated to standard pelvic irradiation and 494 underwent EF-RT The risk of bias was considered to be low in nearly 80 of the domains EF-RT significantly reduced the rate of para-aortic failure HR 0.35 95 CI 0.19-0.64 p 0.01 and the incidence of other distant metastases HR 0.69 95 CI 0.50-0.96 p=0.03 Locoregional failure and cancer-related death were not significantly altered OR 1.06 0.80-1.42 p=0.67 and 0.68 0.45-1.01 p=0.06 respectively The radiotherapy technique was conventional in 3 studies and conformational in 1 study In total 10 treatment-related deaths occurred-4 in pelvic radiation and 6 in EF-RT OR 2.12 0.71-6.27 p=0.18 EF-RT that targets the para-aortic lymphatic chain reduces distant metastatic events but its impact on survival is unknown Future studies should examine the value of EF-RT using modern radiation techniques,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 3, 345, 1, 3, 2401, 1, 3, 310, 1067, 35442, 1317, 4615, 3938, 263, 502, 5580, 240, 4, 131, 12, 8, 1556, 1901, 1, 2348, 3161, 854, 38, 143, 10, 173, 2, 159, 94, 17, 11, 983, 59, 10391, 2, 2868, 1483, 187, 4794, 9999, 62, 384, 38, 143, 4335, 11, 311, 195, 62, 7, 1642, 47, 1989, 1110, 310, 2, 3, 827, 403, 36, 4, 110, 1335, 3, 86, 1387, 11, 1325, 496, 287, 1, 626, 278, 4615, 3938, 496, 2, 12, 139, 273, 3, 11618, 14496, 596, 10, 95, 4, 3, 1742, 65, 3, 43, 1, 2947, 65, 10, 509, 75, 3, 67, 1398, 596, 379, 3, 4956, 31882, 9, 1556, 2004, 1, 1151, 10234, 14, 13, 8, 206, 1, 3, 24, 1312, 2, 155, 10, 120, 173, 8, 181, 1, 27106, 94, 11, 194, 39, 4335, 1, 92, 543, 3, 1680, 371, 9454, 7, 11, 6682, 6, 260, 1110, 1104, 2, 10919, 208, 5580, 240, 3, 43, 1, 2947, 10, 515, 6, 40, 154, 4, 1857, 493, 1, 3, 2703, 5580, 240, 97, 405, 3, 116, 1, 4615, 3938, 496, 168, 13, 465, 48, 58, 13, 326, 13, 660, 19, 13, 355, 2, 3, 287, 1, 127, 626, 196, 168, 13, 790, 48, 58, 13, 212, 13, 921, 19, 13, 680, 1325, 496, 2, 12, 139, 273, 11, 44, 97, 1495, 15, 14, 1460, 13, 493, 14, 595, 19, 13, 598, 2, 13, 806, 13, 512, 14, 355, 19, 13, 1460, 106, 3, 310, 1312, 10, 809, 4, 27, 94, 2, 9011, 4, 14, 45, 4, 181, 79, 24, 139, 1043, 489, 39, 4, 1110, 121, 2, 49, 4, 5580, 240, 15, 18, 133, 13, 792, 49, 428, 19, 13, 203, 5580, 240, 17, 637, 3, 4615, 3938, 2936, 1260, 2389, 626, 113, 281, 84, 211, 345, 23, 25, 16, 860, 508, 94, 257, 1004, 3, 549, 1, 5580, 240, 75, 2366, 121, 1092]",1800.0,27908530,563
First-line therapy for young patients with CLL.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2016-12-01,"A 61-year-old man with a history of chronic lymphocytic leukemia (CLL) presents with complaints of worsening fatigue and night sweats. He was diagnosed with CLL 3 years ago on routine blood count testing. He has no major medical comorbidities. On examination, he has several 2- to 3-cm lymph nodes in the cervical and axillary area. Spleen is palpable 5 cm below the costal margin. Blood counts show lymphocytosis with thrombocytopenia and anemia. Prognostic markers include deletion 13q by fluorescence in situ hybridization analysis and mutated IGHV You are asked by the hematology fellow you are supervising about the best treatment of this patient.",Case Reports,1146.0,0.0,A 61-year-old man with a history of chronic lymphocytic CLL presents with complaints of worsening fatigue and night sweats He was diagnosed with CLL 3 years ago on routine blood count testing He has no major medical comorbidities On examination he has several 2- to 3-cm lymph nodes in the and axillary area Spleen is palpable 5 cm below the costal margin Blood counts show lymphocytosis with thrombocytopenia and anemia Prognostic markers include deletion 13q by fluorescence in situ hybridization analysis and mutated IGHV You are asked by the hematology fellow you are supervising about the best treatment of this patient,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,"[8, 713, 111, 1095, 3628, 5, 8, 532, 1, 442, 1193, 552, 2740, 5, 6938, 1, 4323, 613, 2, 8955, 13298, 3174, 10, 265, 5, 552, 27, 60, 5028, 23, 1311, 315, 1276, 471, 3174, 71, 77, 458, 484, 1909, 23, 1385, 3174, 71, 392, 18, 6, 27, 494, 263, 502, 4, 3, 2, 1210, 965, 4071, 16, 4880, 33, 494, 2736, 3, 50133, 959, 315, 1911, 514, 8125, 5, 1340, 2, 1545, 177, 525, 643, 1528, 8453, 20, 1591, 4, 957, 1554, 65, 2, 1185, 6220, 10342, 32, 3732, 20, 3, 6216, 10526, 10342, 32, 69438, 545, 3, 824, 24, 1, 26, 69]",624.0,27913473,80
"Highly Efficient Training, Refinement, and Validation of a Knowledge-based Planning Quality-Control System for Radiation Therapy Clinical Trials.","International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2016-10-13,"To demonstrate an efficient method for training and validation of a knowledge-based planning (KBP) system as a radiation therapy clinical trial plan quality-control system. We analyzed 86 patients with stage IB through IVA cervical cancer treated with intensity modulated radiation therapy at 2 institutions according to the standards of the INTERTECC (International Evaluation of Radiotherapy Technology Effectiveness in Cervical Cancer, National Clinical Trials Network identifier: 01554397) protocol.The protocol used a planning target volume and 2 primary organs at risk: pelvic bone marrow (PBM) and bowel. Secondary organs at risk were rectum and bladder. Initial unfiltered dose-volume histogram (DVH) estimation models were trained using all 86 plans. Refined training sets were created by removing sub-optimal plans from the unfiltered sample, and DVH estimation models and DVH estimation models were constructed by identifying 30 of 86 plans emphasizing PBM sparing (comparing protocol-specified dosimetric cutpoints V<sub>10</sub> (percentage volume of PBM receiving at least 10 Gy dose) and V<sub>20</sub> (percentage volume of PBM receiving at least 20 Gy dose) with unfiltered predictions) and another 30 of 86 plans emphasizing bowel sparing (comparing V<sub>40</sub> (absolute volume of bowel receiving at least 40 Gy dose) and V<sub>45</sub> (absolute volume of bowel receiving at least 45 Gy dose), 9 in common with the PBM set).To obtain deliverable KBP plans, refined models must inform patient-specific optimization objectives and/or priorities (an auto-planning ""routine""). Four candidate routines emphasizing different tradeoffs were composed, and a script was developed to automatically re-plan multiple patients with each routine. After selection of the routine that best met protocol objectives in the 51-patient training sample (KBP<sub>FINAL</sub>), protocol-specific DVH metrics and normal tissue complication probability were compared for original versus KBP<sub>FINAL</sub> plans across the 35-patient validation set. Paired t tests were used to test differences between planning sets. KBP<sub>FINAL</sub> plans outperformed manual planning across the validation set in all protocol-specific DVH cutpoints. The mean normal tissue complication probability for gastrointestinal toxicity was lower for KBP<sub>FINAL</sub> versus validation-set plans (48.7% vs 53.8%, P<.001). Similarly, the estimated mean white blood cell count nadir was higher (2.77 vs 2.49 k/mL, P<.001) with KBP<sub>FINAL</sub> plans, indicating lowered probability of hematologic toxicity. This work demonstrates that a KBP system can be efficiently trained and refined for use in radiation therapy clinical trials with minimal effort. This patient-specific plan quality control resulted in improvements on protocol-specific dosimetric endpoints.",Journal Article,1195.0,25.0,To demonstrate an efficient method for training and validation of a knowledge-based planning KBP system as a radiation therapy clinical trial plan quality-control system We analyzed 86 patients with stage IB through IVA cancer treated with intensity modulated radiation therapy at 2 institutions according to the standards of the INTERTECC International Evaluation of Radiotherapy Technology Effectiveness in Cancer National Clinical Trials Network identifier 01554397 protocol The protocol used a planning target volume and 2 primary organs at risk pelvic marrow PBM and bowel Secondary organs at risk were rectum and Initial unfiltered dose-volume histogram DVH estimation models were trained using all 86 plans Refined training sets were created by removing sub-optimal plans from the unfiltered sample and DVH estimation models and DVH estimation models were constructed by identifying 30 of 86 plans emphasizing PBM sparing comparing protocol-specified dosimetric cutpoints V sub 10 /sub percentage volume of PBM receiving at least 10 Gy dose and V sub 20 /sub percentage volume of PBM receiving at least 20 Gy dose with unfiltered predictions and another 30 of 86 plans emphasizing bowel sparing comparing V sub 40 /sub absolute volume of bowel receiving at least 40 Gy dose and V sub 45 /sub absolute volume of bowel receiving at least 45 Gy dose 9 in common with the PBM set To obtain deliverable KBP plans refined models must inform patient-specific optimization objectives and/or priorities an auto-planning `` routine '' Four candidate routines emphasizing different tradeoffs were composed and a script was developed to automatically re-plan multiple patients with each routine After selection of the routine that best met protocol objectives in the 51-patient training sample KBP sub FINAL /sub protocol-specific DVH metrics and normal tissue complication probability were compared for original versus KBP sub FINAL /sub plans across the 35-patient validation set Paired t tests were used to test differences between planning sets KBP sub FINAL /sub plans outperformed manual planning across the validation set in all protocol-specific DVH cutpoints The mean normal tissue complication probability for toxicity was lower for KBP sub FINAL /sub versus validation-set plans 48.7 vs 53.8 P .001 Similarly the estimated mean white blood cell count nadir was higher 2.77 vs 2.49 k/mL P .001 with KBP sub FINAL /sub plans indicating lowered probability of hematologic toxicity This work demonstrates that a KBP system can be efficiently trained and refined for use in radiation therapy clinical trials with minimal effort This patient-specific plan quality control resulted in improvements on protocol-specific dosimetric endpoints,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,"[6, 608, 35, 2547, 596, 9, 1741, 2, 929, 1, 8, 922, 90, 1349, 24273, 398, 22, 8, 121, 36, 38, 160, 2242, 372, 182, 398, 21, 311, 868, 7, 5, 82, 3180, 298, 5900, 12, 73, 5, 837, 1757, 121, 36, 28, 18, 1764, 768, 6, 3, 3371, 1, 3, 69495, 944, 451, 1, 310, 2033, 1236, 4, 12, 657, 38, 143, 1801, 3719, 69496, 1182, 3, 1182, 95, 8, 1349, 283, 433, 2, 18, 86, 2285, 28, 43, 1110, 581, 9215, 2, 1659, 568, 2285, 28, 43, 11, 3660, 2, 388, 30308, 61, 433, 8261, 8255, 4470, 274, 11, 5946, 75, 62, 868, 1853, 5332, 1741, 2270, 11, 2466, 20, 9026, 551, 665, 1853, 29, 3, 30308, 1000, 2, 8255, 4470, 69497, 2, 8255, 4470, 274, 11, 2776, 20, 1386, 201, 1, 868, 1853, 6826, 9215, 1851, 1430, 1182, 3575, 3187, 17790, 603, 551, 79, 551, 1150, 433, 1, 9215, 357, 28, 506, 79, 381, 61, 2, 603, 551, 179, 551, 1150, 433, 1, 9215, 357, 28, 506, 179, 381, 61, 5, 30308, 4340, 2, 1809, 201, 1, 868, 1853, 6826, 1659, 1851, 1430, 603, 551, 327, 551, 1766, 433, 1, 1659, 357, 28, 506, 327, 381, 61, 2, 603, 551, 512, 551, 1766, 433, 1, 1659, 357, 28, 506, 512, 381, 61, 83, 4, 186, 5, 3, 9215, 916, 6, 3140, 28320, 24273, 1853, 5332, 274, 1642, 2295, 69, 112, 3980, 2409, 2, 15, 6513, 35, 3005, 1349, 1311, 522, 294, 1609, 28560, 6826, 338, 16748, 11, 3317, 2, 8, 46372, 10, 276, 6, 10111, 1491, 2242, 232, 7, 5, 296, 1311, 50, 881, 1, 3, 1311, 17, 824, 543, 1182, 2409, 4, 3, 725, 69, 1741, 1000, 24273, 551, 1457, 551, 1182, 112, 8255, 3589, 2, 295, 246, 1447, 1320, 11, 72, 9, 2279, 185, 24273, 551, 1457, 551, 1853, 716, 3, 465, 69, 929, 916, 2355, 102, 895, 11, 95, 6, 412, 362, 59, 1349, 2270, 24273, 551, 1457, 551, 1853, 9504, 4590, 1349, 716, 3, 929, 916, 4, 62, 1182, 112, 8255, 17790, 3, 313, 295, 246, 1447, 1320, 9, 155, 10, 280, 9, 24273, 551, 1457, 551, 185, 929, 916, 1853, 576, 67, 105, 699, 66, 19, 144, 1813, 3, 661, 313, 886, 315, 31, 1276, 3686, 10, 142, 18, 849, 105, 18, 739, 1634, 542, 19, 144, 5, 24273, 551, 1457, 551, 1853, 1716, 7238, 1320, 1, 813, 155, 26, 1357, 1902, 17, 8, 24273, 398, 122, 40, 4143, 5946, 2, 5332, 9, 119, 4, 121, 36, 38, 143, 5, 1048, 2919, 26, 69, 112, 2242, 372, 182, 627, 4, 1474, 23, 1182, 112, 3187, 1387]",2739.0,27979445,456
"A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.",The Lancet. Oncology,Lancet Oncol.,2016-12-18,"Despite its common use in cancer treatment, radiotherapy has not yet entered the era of precision medicine, and there have been no approaches to adjust dose based on biological differences between or within tumours. We aimed to assess whether a patient-specific molecular signature of radiation sensitivity could be used to identify the optimum radiotherapy dose. We used the gene-expression-based radiation-sensitivity index and the linear quadratic model to derive the genomic-adjusted radiation dose (GARD). A high GARD value predicts for high therapeutic effect for radiotherapy; which we postulate would relate to clinical outcome. Using data from the prospective, observational Total Cancer Care (TCC) protocol, we calculated GARD for primary tumours from 20 disease sites treated using standard radiotherapy doses for each disease type. We also used multivariable Cox modelling to assess whether GARD was independently associated with clinical outcome in five clinical cohorts: Erasmus Breast Cancer Cohort (n=263); Karolinska Breast Cancer Cohort (n=77); Moffitt Lung Cancer Cohort (n=60); Moffitt Pancreas Cancer Cohort (n=40); and The Cancer Genome Atlas Glioblastoma Patient Cohort (n=98). We calculated GARD for 8271 tissue samples from the TCC cohort. There was a wide range of GARD values (range 166-1724) across the TCC cohort despite assignment of uniform radiotherapy doses within disease types. Median GARD values were lowest for gliomas and sarcomas and highest for cervical cancer and oropharyngeal head and neck cancer. There was a wide range of GARD values within tumour type groups. GARD independently predicted clinical outcome in breast cancer, lung cancer, glioblastoma, and pancreatic cancer. In the Erasmus Breast Cancer Cohort, 5-year distant-metastasis-free survival was longer in patients with high GARD values than in those with low GARD values (hazard ratio 211, 95% 113-394, p=0018). A GARD-based clinical model could allow the individualisation of radiotherapy dose to tumour radiosensitivity and could provide a framework to design genomically-guided clinical trials in radiation oncology. None.",Journal Article,1129.0,117.0,Despite its common use in cancer treatment radiotherapy has not yet entered the era of precision medicine and there have been no approaches to adjust dose based on biological differences between or within tumours We aimed to assess whether a patient-specific molecular signature of radiation sensitivity could be used to identify the optimum radiotherapy dose We used the gene-expression-based radiation-sensitivity index and the linear quadratic model to derive the genomic-adjusted radiation dose GARD A high GARD value predicts for high therapeutic effect for radiotherapy which we postulate would relate to clinical outcome Using data from the prospective observational Total Cancer Care TCC protocol we calculated GARD for primary tumours from 20 disease sites treated using standard radiotherapy doses for each disease type We also used multivariable Cox modelling to assess whether GARD was independently associated with clinical outcome in five clinical cohorts Erasmus Cancer Cohort n=263 Karolinska Cancer Cohort n=77 Moffitt Cancer Cohort n=60 Moffitt Cancer Cohort n=40 and The Cancer Genome Atlas Glioblastoma Patient Cohort n=98 We calculated GARD for 8271 tissue samples from the TCC cohort There was a wide range of GARD values range 166-1724 across the TCC cohort despite assignment of uniform radiotherapy doses within disease types Median GARD values were lowest for gliomas and sarcomas and highest for cancer and head and cancer There was a wide range of GARD values within tumour type groups GARD independently predicted clinical outcome in cancer cancer glioblastoma and cancer In the Erasmus Cancer Cohort 5-year distant-metastasis-free survival was longer in patients with high GARD values than in those with low GARD values hazard ratio 211 95 113-394 p=0018 A GARD-based clinical model could allow the individualisation of radiotherapy dose to tumour radiosensitivity and could provide a framework to design genomically-guided clinical trials in radiation oncology None,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,"[550, 211, 186, 119, 4, 12, 24, 310, 71, 44, 1145, 2836, 3, 1713, 1, 2720, 1807, 2, 125, 47, 85, 77, 611, 6, 6611, 61, 90, 23, 1037, 362, 59, 15, 262, 1319, 21, 1295, 6, 423, 317, 8, 69, 112, 219, 1651, 1, 121, 485, 359, 40, 95, 6, 255, 3, 6357, 310, 61, 21, 95, 3, 145, 55, 90, 121, 485, 558, 2, 3, 1646, 14231, 202, 6, 3823, 3, 572, 586, 121, 61, 18717, 8, 64, 18717, 549, 2623, 9, 64, 189, 254, 9, 310, 92, 21, 12071, 688, 6509, 6, 38, 228, 75, 74, 29, 3, 482, 2495, 181, 12, 165, 4901, 1182, 21, 981, 18717, 9, 86, 1319, 29, 179, 34, 633, 73, 75, 260, 310, 415, 9, 296, 34, 267, 21, 120, 95, 658, 418, 10812, 6, 423, 317, 18717, 10, 1042, 41, 5, 38, 228, 4, 365, 38, 736, 50150, 12, 180, 78, 6098, 69514, 12, 180, 78, 849, 9054, 12, 180, 78, 335, 9054, 12, 180, 78, 327, 2, 3, 12, 898, 2643, 996, 69, 180, 78, 1096, 21, 981, 18717, 9, 48430, 246, 347, 29, 3, 4901, 180, 125, 10, 8, 1019, 184, 1, 18717, 1030, 184, 41628, 69515, 716, 3, 4901, 180, 550, 4392, 1, 3490, 310, 415, 262, 34, 630, 52, 18717, 1030, 11, 2101, 9, 1287, 2, 1479, 2, 1076, 9, 12, 2, 718, 2, 12, 125, 10, 8, 1019, 184, 1, 18717, 1030, 262, 770, 267, 271, 18717, 1042, 783, 38, 228, 4, 12, 12, 996, 2, 12, 4, 3, 50150, 12, 180, 33, 111, 626, 278, 115, 25, 10, 589, 4, 7, 5, 64, 18717, 1030, 76, 4, 135, 5, 154, 18717, 1030, 360, 197, 31677, 48, 22728, 69516, 19, 31873, 8, 18717, 90, 38, 202, 359, 1700, 3, 69517, 1, 310, 61, 6, 770, 5850, 2, 359, 377, 8, 2586, 6, 771, 7218, 1808, 38, 143, 4, 121, 413, 1292]",2002.0,27993569,1
Diffusion-Weighted Magnetic Resonance Imaging as a Predictor of Outcome in Cervical Cancer After Chemoradiation.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2016-11-17,"Todetermine whether apparent diffusion coefficient (ADC) value is predictive of survival after definitive chemoradiation for cervical cancer independent of established imaging and clinical prognostic factors. Between 2011 and 2013, the pretreatment MRI scans for 69 patients treated with definitive chemoradiation for newly diagnosed cervical cancer were retrieved. Scans were acquired with a 1.5-T magnetic resonance scanner, including diffusion-weighted imaging sequences. Mean ADC value was measured within a region of interest in the primary cervical cancer on the baseline MRI scan. Baseline tumor maximum standardized uptake value on positron emission tomography/computed tomography was determined by the reading radiologist. Treatment included external beam radiation therapy to the pelvis followed by brachytherapy in 97%, and with concurrent weekly cisplatin in 99% of patients. Univariate and multivariate analyses were done to investigate the association of clinical and imaging variables with disease control and survival endpoints using a Cox proportional hazard test. Median follow-up was 16.7months (range, 3.1-44.2months). The 1-year overall survival, locoregional recurrence-free survival, and disease-free survival rates were 91%, 86%, and 74%, respectively. The median ADC value was 0.94110<sup>-3</sup>mm<sup>2</sup>/s (range, 0.256-1.50810<sup>-3</sup>mm<sup>2</sup>/s). The median standardized uptake value in the primary tumor was 15 (range, 6.2-43.4). In multivariate analysis, higher ADC value (hazard ratio [HR] 0.36, 95% confidence interval [CI] 0.15-0.85, P=.02), higher stage (HR 2.4, 95% CI 1.1-5.5, P=.033), and nonsquamous histology (HR 0.23, 95% CI 0.07-0.82, P=.024) were independent predictors of disease-free survival. The mean ADC value of the primary tumor on pretreatment MRI was the only imaging feature that was an independent predictor of disease-free survival in cervical cancer patients treated with chemoradiation. Further validation will be needed to determine whether ADC values may prove useful in identifying cervical patients at high risk of recurrence.",Journal Article,1160.0,18.0,To determine whether apparent diffusion coefficient ADC value is predictive of survival after definitive chemoradiation for cancer independent of established imaging and clinical prognostic factors Between 2011 and 2013 the pretreatment MRI scans for 69 patients treated with definitive chemoradiation for newly diagnosed cancer were retrieved Scans were acquired with a 1.5-T magnetic resonance scanner including diffusion-weighted imaging sequences Mean ADC value was measured within a region of interest in the primary cancer on the baseline MRI scan Baseline tumor maximum standardized uptake value on positron emission tomography/computed tomography was determined by the reading radiologist Treatment included external beam radiation therapy to the pelvis followed by brachytherapy in 97 and with concurrent weekly cisplatin in 99 of patients Univariate and multivariate analyses were done to investigate the association of clinical and imaging variables with disease control and survival endpoints using a Cox proportional hazard test Median follow-up was 16.7 months range 3.1-44.2 months The 1-year overall survival locoregional recurrence-free survival and disease-free survival rates were 91 86 and 74 respectively The median ADC value was 0.941 10 sup -3 /sup mm sup 2 /sup /s range 0.256-1.508 10 sup -3 /sup mm sup 2 /sup /s The median standardized uptake value in the primary tumor was 15 range 6.2-43.4 In multivariate analysis higher ADC value hazard ratio HR 0.36 95 confidence interval CI 0.15-0.85 P=.02 higher stage HR 2.4 95 CI 1.1-5.5 P=.033 and nonsquamous histology HR 0.23 95 CI 0.07-0.82 P=.024 were independent predictors of disease-free survival The mean ADC value of the primary tumor on pretreatment MRI was the only imaging feature that was an independent predictor of disease-free survival in cancer patients treated with chemoradiation Further validation will be needed to determine whether ADC values may prove useful in identifying patients at high risk of recurrence,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 317, 2235, 3438, 3200, 3309, 549, 16, 464, 1, 25, 50, 1057, 975, 9, 12, 306, 1, 635, 270, 2, 38, 177, 130, 59, 1132, 2, 1346, 3, 1194, 704, 1441, 9, 790, 7, 73, 5, 1057, 975, 9, 732, 265, 12, 11, 4539, 1441, 11, 1294, 5, 8, 14, 33, 102, 1484, 1535, 10437, 141, 3438, 2337, 270, 2866, 313, 3309, 549, 10, 644, 262, 8, 1053, 1, 1333, 4, 3, 86, 12, 23, 3, 330, 704, 1657, 330, 30, 689, 1670, 1135, 549, 23, 1900, 1799, 872, 1220, 872, 10, 509, 20, 3, 7299, 6247, 24, 159, 1455, 1345, 121, 36, 6, 3, 3270, 370, 20, 1536, 4, 1015, 2, 5, 750, 709, 540, 4, 1058, 1, 7, 880, 2, 331, 318, 11, 1822, 6, 963, 3, 248, 1, 38, 2, 270, 682, 5, 34, 182, 2, 25, 1387, 75, 8, 418, 831, 360, 412, 52, 166, 126, 10, 245, 67, 53, 184, 27, 14, 584, 18, 53, 3, 14, 111, 63, 25, 1325, 146, 115, 25, 2, 34, 115, 25, 151, 11, 970, 868, 2, 794, 106, 3, 52, 3309, 549, 10, 13, 13164, 79, 172, 27, 172, 321, 172, 18, 172, 695, 184, 13, 7162, 14, 11598, 79, 172, 27, 172, 321, 172, 18, 172, 695, 3, 52, 1670, 1135, 549, 4, 3, 86, 30, 10, 167, 184, 49, 18, 601, 39, 4, 331, 65, 142, 3309, 549, 360, 197, 168, 13, 511, 48, 307, 268, 58, 13, 167, 13, 772, 19, 588, 142, 82, 168, 18, 39, 48, 58, 14, 14, 33, 33, 19, 5254, 2, 6218, 784, 168, 13, 382, 48, 58, 13, 1615, 13, 878, 19, 4247, 11, 306, 674, 1, 34, 115, 25, 3, 313, 3309, 549, 1, 3, 86, 30, 23, 1194, 704, 10, 3, 158, 270, 2705, 17, 10, 35, 306, 980, 1, 34, 115, 25, 4, 12, 7, 73, 5, 975, 195, 929, 303, 40, 575, 6, 223, 317, 3309, 1030, 68, 4361, 999, 4, 1386, 7, 28, 64, 43, 1, 146]",2003.0,28011045,799
ACR appropriateness criteria<sup></sup> nasal cavity and paranasal sinus cancers.,Head & neck,Head Neck,2016-12-29,"The American College of Radiology (ACR) Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment. Here, we present the Appropriateness Criteria for cancers arising in the nasal cavity and paranasal sinuses (maxillary, sphenoid, and ethmoid sinuses). This includes clinical presentation, prognostic factors, principles of management, and treatment outcomes. Controversies regarding management of cervical lymph nodes are discussed. Rare and unusual nasal cavity cancers, such as esthesioneuroblastoma and sinonasal undifferentiated carcinomas, are included.  2016 American College of Radiology. Head Neck, 2016  2016 Wiley Periodicals, Inc. Head Neck 39: 407-418, 2017.",Journal Article,1118.0,3.0,The American College of Radiology ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel The guideline development and revision include an extensive analysis of current medical literature from peer-reviewed journals and the application of well-established methodologies RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment Development and Evaluation or GRADE to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios In those instances where evidence is lacking or equivocal expert opinion may supplement the available evidence to recommend imaging or treatment Here we present the Appropriateness Criteria for cancers arising in the nasal cavity and paranasal sinuses maxillary sphenoid and ethmoid sinuses This includes clinical presentation prognostic factors principles of management and treatment outcomes Controversies regarding management of lymph nodes are discussed Rare and unusual nasal cavity cancers such as and sinonasal undifferentiated carcinomas are included  2016 American College of Radiology Head 2016  2016 Wiley Periodicals Inc. Head 39 407-418 2017,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 597, 2979, 1, 4003, 11020, 4473, 371, 32, 241, 90, 677, 9, 112, 38, 1298, 17, 32, 446, 4226, 20, 8, 1643, 2005, 993, 3, 2009, 193, 2, 5646, 643, 35, 1344, 65, 1, 291, 484, 789, 29, 5084, 446, 6871, 2, 3, 1581, 1, 149, 635, 6616, 15549, 12158, 4473, 596, 2, 3452, 1, 883, 455, 193, 2, 451, 15, 88, 6, 116, 3, 4473, 1, 270, 2, 24, 1369, 9, 112, 38, 3964, 4, 135, 5342, 1257, 241, 16, 1941, 15, 5068, 2005, 3564, 68, 5836, 3, 390, 241, 6, 2237, 270, 15, 24, 467, 21, 364, 3, 4473, 371, 9, 163, 2635, 4, 3, 6743, 2405, 2, 12979, 16658, 11399, 18779, 2, 34563, 16658, 26, 1920, 38, 1031, 177, 130, 4650, 1, 284, 2, 24, 123, 6613, 666, 284, 1, 263, 502, 32, 1588, 622, 2, 4015, 6743, 2405, 163, 225, 22, 2, 7605, 4480, 826, 32, 159, 2206, 1390, 597, 2979, 1, 4003, 718, 1390, 2206, 1390, 4692, 5493, 3479, 718, 587, 11595, 10387, 1759]",1233.0,28032679,74
The American College of Radiology and the American Brachytherapy Society practice parameter for the performance of low-dose-rate brachytherapy.,Brachytherapy,Brachytherapy,,"Brachytherapy is the use of radionuclides to treat malignancies or benign conditions by means of a radiation source placed close to or into the tumor or treatment site. This practice parameter refers only to the use of radionuclide brachytherapy. Brachytherapy alone or combined with external beam therapy plays an important role in the management and treatment of patients with cancer. Low-dose-rate (LDR) brachytherapy has traditionally been used for treating prostate, head and neck, breast, cervical, and endometrial cancers as well as obstructive bile duct, esophageal, or bronchial lesions. It has been practiced for over a century with a variety of sources including radium-226, cesium-137, and, more recently, iridium- 192, iodine-125, and palladium-103. Low-dose-rate (LDR) brachytherapy can be given as interstitial, intracavitary, intraluminal, and/or plesiotherapy to a wide variety of treatment sites. This practice parameter addresses sealed sources as they are used for LDR brachytherapy. It is recognized that unsealed sources (e.g., yttrium-90) are also a form of LDR brachytherapy.",Journal Article,,4.0,Brachytherapy is the use of radionuclides to treat malignancies or benign conditions by means of a radiation source placed close to or into the tumor or treatment site This practice parameter refers only to the use of radionuclide brachytherapy Brachytherapy alone or combined with external beam therapy plays an important role in the management and treatment of patients with cancer Low-dose-rate LDR brachytherapy has traditionally been used for treating head and and cancers as well as obstructive duct or lesions It has been practiced for over a century with a variety of sources including radium-226 cesium-137 and more recently iridium- 192 iodine-125 and palladium-103 Low-dose-rate LDR brachytherapy can be given as interstitial intracavitary intraluminal and/or plesiotherapy to a wide variety of treatment sites This practice parameter addresses sealed sources as they are used for LDR brachytherapy It is recognized that unsealed sources e.g. yttrium-90 are also a form of LDR brachytherapy,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,"[1536, 16, 3, 119, 1, 14396, 6, 943, 441, 15, 1002, 1298, 20, 2263, 1, 8, 121, 2353, 3295, 2336, 6, 15, 237, 3, 30, 15, 24, 606, 26, 758, 4219, 11312, 158, 6, 3, 119, 1, 7967, 1536, 1536, 279, 15, 397, 5, 1455, 1345, 36, 1698, 35, 305, 200, 4, 3, 284, 2, 24, 1, 7, 5, 12, 154, 61, 116, 6962, 1536, 71, 4206, 85, 95, 9, 1367, 718, 2, 2, 163, 22, 149, 22, 6937, 2920, 15, 406, 192, 71, 85, 11121, 9, 252, 8, 7981, 5, 8, 1362, 1, 3375, 141, 6650, 7400, 31158, 4352, 2, 80, 761, 22134, 5016, 4287, 1731, 2, 22221, 3283, 154, 61, 116, 6962, 1536, 122, 40, 447, 22, 4543, 9122, 19960, 2, 15, 69700, 6, 8, 1019, 1362, 1, 24, 633, 26, 758, 4219, 5437, 31855, 3375, 22, 491, 32, 95, 9, 6962, 1536, 192, 16, 1904, 17, 46648, 3375, 563, 499, 7190, 424, 32, 120, 8, 1297, 1, 6962, 1536]",1001.0,28109633,47
Bone Marrow-sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin For Stage IB-IVA Cervical Cancer: An International Multicenter Phase II Clinical Trial (INTERTECC-2).,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2016-11-23,"To test the hypothesis that intensity modulated radiation therapy (IMRT) reduces acute hematologic and gastrointestinal (GI) toxicity for patients with locoregionally advanced cervical cancer. We enrolled patients with stage IB-IVA cervical carcinoma in a single-arm phase II trial involving 8 centers internationally. All patients received weekly cisplatin concurrently with once-daily IMRT, followed by intracavitary brachytherapy, as indicated. The primary endpoint was the occurrence of either acute grade 3 neutropenia or clinically significant GI toxicity within 30days of completing chemoradiation therapy. A preplanned subgroup analysis tested the hypothesis that positron emission tomography-based image-guided IMRT (IG-IMRT) would lower the risk of acute neutropenia. We also longitudinally assessed patients' changes in quality of life. From October 2011 to April 2015, 83 patients met the eligibility criteria and initiated protocol therapy. The median follow-up was 26.0months. The incidence of any primary event was 26.5% (95% confidence interval [CI] 18.2%-36.9%), significantly lower than the 40% incidence hypothesized a priori from historical data (P=.012). The incidence of grade 3 neutropenia and clinically significant GI toxicity was 19.3% (95% CI 12.2%-29.0%) and 12.0% (95% CI 6.7%-20.8%), respectively. Compared with patients treated without IG-IMRT (n=48), those treated with IG-IMRT (n=35) had a significantly lower incidence of grade 3 neutropenia (8.6% vs 27.1%; 2-sided <sup>2</sup>P=.035) and nonsignificantly lower incidence of grade 3 leukopenia (25.7% vs 41.7%; P=.13) and any grade 3 hematologic toxicity (31.4% vs 43.8%; P=.25). IMRT reduces acute hematologic and GI toxicity compared with standard treatment, with promising therapeutic outcomes. Positron emission tomography IG-IMRT reduces the incidence of acute neutropenia.","Clinical Trial, Phase II",1154.0,42.0,To test the hypothesis that intensity modulated radiation therapy IMRT reduces acute hematologic and GI toxicity for patients with locoregionally advanced cancer We enrolled patients with stage IB-IVA carcinoma in a single-arm phase II trial involving 8 centers internationally All patients received weekly cisplatin concurrently with once-daily IMRT followed by intracavitary brachytherapy as indicated The primary endpoint was the occurrence of either acute grade 3 neutropenia or clinically significant GI toxicity within 30 days of completing chemoradiation therapy A preplanned subgroup analysis tested the hypothesis that positron emission tomography-based image-guided IMRT IG-IMRT would lower the risk of acute neutropenia We also longitudinally assessed patients changes in quality of life From October 2011 to April 2015 83 patients met the eligibility criteria and initiated protocol therapy The median follow-up was 26.0 months The incidence of any primary event was 26.5 95 confidence interval CI 18.2 -36.9 significantly lower than the 40 incidence hypothesized a priori from historical data P=.012 The incidence of grade 3 neutropenia and clinically significant GI toxicity was 19.3 95 CI 12.2 -29.0 and 12.0 95 CI 6.7 -20.8 respectively Compared with patients treated without IG-IMRT n=48 those treated with IG-IMRT n=35 had a significantly lower incidence of grade 3 neutropenia 8.6 vs 27.1 2-sided  sup 2 /sup P=.035 and nonsignificantly lower incidence of grade 3 leukopenia 25.7 vs 41.7 P=.13 and any grade 3 hematologic toxicity 31.4 vs 43.8 P=.25 IMRT reduces acute hematologic and GI toxicity compared with standard treatment with promising therapeutic outcomes Positron emission tomography IG-IMRT reduces the incidence of acute neutropenia,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 412, 3, 1492, 17, 837, 1757, 121, 36, 964, 2389, 286, 813, 2, 2104, 155, 9, 7, 5, 6410, 131, 12, 21, 346, 7, 5, 82, 3180, 5900, 134, 4, 8, 226, 475, 124, 215, 160, 1267, 66, 1168, 12828, 62, 7, 103, 709, 540, 3294, 5, 1059, 391, 964, 370, 20, 9122, 1536, 22, 1103, 3, 86, 1138, 10, 3, 2291, 1, 361, 286, 88, 2608, 778, 15, 505, 93, 2104, 155, 262, 201, 162, 1, 4144, 975, 36, 8, 9817, 1363, 65, 650, 3, 1492, 17, 1900, 1799, 872, 90, 1482, 1808, 964, 4200, 964, 688, 280, 3, 43, 1, 286, 778, 21, 120, 9278, 275, 7, 400, 4, 372, 1, 358, 29, 2551, 1132, 6, 2292, 1483, 852, 7, 543, 3, 2317, 371, 2, 1917, 1182, 36, 3, 52, 166, 126, 10, 432, 13, 53, 3, 287, 1, 500, 86, 774, 10, 432, 33, 48, 307, 268, 58, 203, 18, 511, 83, 97, 280, 76, 3, 327, 287, 1237, 8, 7499, 29, 2252, 74, 19, 3499, 3, 287, 1, 88, 2608, 778, 2, 505, 93, 2104, 155, 10, 326, 27, 48, 58, 133, 18, 462, 13, 2, 133, 13, 48, 58, 49, 67, 179, 66, 106, 72, 5, 7, 73, 187, 4200, 964, 78, 576, 135, 73, 5, 4200, 964, 78, 465, 42, 8, 97, 280, 287, 1, 88, 2608, 778, 66, 49, 105, 428, 14, 18, 1689, 5112, 172, 18, 172, 19, 4514, 2, 17078, 280, 287, 1, 88, 2608, 3904, 243, 67, 105, 605, 67, 19, 233, 2, 500, 88, 2608, 813, 155, 456, 39, 105, 601, 66, 19, 243, 964, 2389, 286, 813, 2, 2104, 155, 72, 5, 260, 24, 5, 721, 189, 123, 1900, 1799, 872, 4200, 964, 2389, 3, 287, 1, 286, 778]",1770.0,28126303,439
Cervical cancer prevention and treatment in Latin America.,Journal of surgical oncology,J Surg Oncol,2017-02-07,"Cervical cancer is a preventable disease with a known etiology (human papillomavirus), effective preventive vaccines, excellent screening methods, and a treatable pre-invasive phase. Surgery is the primary treatment for pre-invasive and early-stage disease and can safely be performed in many low-resource settings. However, cervical cancer rates remain high in many areas of Latin America. This article presents a number of evidence-based strategies being implemented to improve cervical cancer outcomes in Latin America.",Journal Article,1078.0,10.0,cancer is a preventable disease with a known etiology human papillomavirus effective preventive vaccines excellent screening methods and a treatable pre-invasive phase Surgery is the primary treatment for pre-invasive and early-stage disease and can safely be performed in many low-resource settings However cancer rates remain high in many areas of Latin America This article presents a number of evidence-based strategies being implemented to improve cancer outcomes in Latin America,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 8, 7936, 34, 5, 8, 440, 2855, 171, 3242, 323, 3494, 1842, 1503, 453, 636, 2, 8, 9437, 671, 416, 124, 152, 16, 3, 86, 24, 9, 671, 416, 2, 191, 82, 34, 2, 122, 2268, 40, 173, 4, 445, 154, 3069, 1947, 137, 12, 151, 918, 64, 4, 445, 1361, 1, 10870, 4010, 26, 946, 2740, 8, 207, 1, 241, 90, 422, 486, 3426, 6, 401, 12, 123, 4, 10870, 4010]",485.0,28168717,3
Sensitivity and negative predictive value for sentinel lymph node biopsy in women with early-stage cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2017-02-08,"The role of sentinel lymph node (SLN) biopsy alone for staging of early-stage cervical cancer remains controversial. We aimed to determine the validity of this technique in women with early-stage cervical cancer. We retrospectively reviewed women with early-stage cervical cancer who underwent SLN mapping followed by complete pelvic lymphadenectomy as part of initial surgical management from August 1997 through October 2015. All modes of surgical approach were included. Lymphatic mapping was performed using blue dye, technetium-99m sulfur colloid (Tc-99), and/or indocyanine green (ICG). We determined SLN detection rates, sensitivity and negative predictive value. One hundred eighty-eight patients were included, and 35 (19%) had lymph node metastases. At least one SLN was identified in 170 patients (90%), and bilateral SLNs were identified in 117 patients (62%). The majority of SLNs (83%) were found in the pelvis. There was no difference in detection rates between mapping agents, surgical approach, patients with and without prior conization or between patients with tumors <2cm and 2cm. The detection rate for bilateral SLNs was significantly lower in women with body mass index (BMI)>30kg/m<sup>2</sup> than in women with lower BMI (p=0.03). Metastatic disease in sentinel nodes was detected by H&E staining in 78% of cases and required ultrastaging/immunohistochemistry in 22% of cases. Only one patient had a false-negative result, yielding a sensitivity of 96.4% (95% CI 79.8%-99.8%) and negative predictive value of 99.3% (95% CI 95.6%-100%). The false-negative rate was 3.6%. In these women with early-stage cervical cancer, SLN biopsy had very high sensitivity and negative predictive value. We believe it is time to change the standard of care for women with early-stage cervical cancer to SLN biopsy only.",Journal Article,1077.0,53.0,The role of sentinel lymph node SLN biopsy alone for staging of early-stage cancer remains controversial We aimed to determine the validity of this technique in women with early-stage cancer We retrospectively reviewed women with early-stage cancer who underwent SLN mapping followed by complete pelvic lymphadenectomy as part of initial surgical management from August 1997 through October 2015 All modes of surgical approach were included Lymphatic mapping was performed using blue dye technetium-99m sulfur colloid Tc-99 and/or indocyanine green ICG We determined SLN detection rates sensitivity and negative predictive value One hundred eighty-eight patients were included and 35 19 had lymph node metastases At least one SLN was identified in 170 patients 90 and bilateral SLNs were identified in 117 patients 62 The majority of SLNs 83 were found in the pelvis There was no difference in detection rates between mapping agents surgical approach patients with and without prior conization or between patients with tumors 2cm and 2cm The detection rate for bilateral SLNs was significantly lower in women with body mass index BMI 30kg/m sup 2 /sup than in women with lower BMI p=0.03 Metastatic disease in sentinel nodes was detected by H E staining in 78 of cases and required ultrastaging/immunohistochemistry in 22 of cases Only one patient had a false-negative result yielding a sensitivity of 96.4 95 CI 79.8 -99.8 and negative predictive value of 99.3 95 CI 95.6 -100 The false-negative rate was 3.6 In these women with early-stage cancer SLN biopsy had very high sensitivity and negative predictive value We believe it is time to change the standard of care for women with early-stage cancer to SLN biopsy only,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 200, 1, 1323, 263, 289, 1099, 411, 279, 9, 632, 1, 191, 82, 12, 469, 2010, 21, 1295, 6, 223, 3, 3099, 1, 26, 1312, 4, 117, 5, 191, 82, 12, 21, 894, 446, 117, 5, 191, 82, 12, 54, 208, 1099, 2568, 370, 20, 236, 1110, 2048, 22, 760, 1, 388, 221, 284, 29, 2480, 2341, 298, 2551, 1483, 62, 8256, 1, 221, 353, 11, 159, 2936, 2568, 10, 173, 75, 3352, 3796, 11237, 6314, 10266, 7245, 3072, 1058, 2, 15, 18903, 4658, 9118, 21, 509, 1099, 638, 151, 485, 2, 199, 464, 549, 104, 1128, 2207, 659, 7, 11, 159, 2, 465, 326, 42, 263, 289, 196, 28, 506, 104, 1099, 10, 108, 4, 5248, 7, 424, 2, 1607, 2642, 11, 108, 4, 3843, 7, 744, 3, 686, 1, 2642, 852, 11, 204, 4, 3, 3270, 125, 10, 77, 523, 4, 638, 151, 59, 2568, 183, 221, 353, 7, 5, 2, 187, 324, 8755, 15, 59, 7, 5, 57, 26562, 2, 69869, 3, 638, 116, 9, 1607, 2642, 10, 97, 280, 4, 117, 5, 642, 782, 558, 1140, 50233, 188, 172, 18, 172, 76, 4, 117, 5, 280, 1140, 19, 13, 680, 113, 34, 4, 1323, 502, 10, 530, 20, 555, 563, 1029, 4, 833, 1, 140, 2, 616, 11338, 888, 4, 350, 1, 140, 158, 104, 69, 42, 8, 2133, 199, 757, 4949, 8, 485, 1, 921, 39, 48, 58, 842, 66, 1058, 66, 2, 199, 464, 549, 1, 1058, 27, 48, 58, 48, 49, 394, 3, 2133, 199, 116, 10, 27, 49, 4, 46, 117, 5, 191, 82, 12, 1099, 411, 42, 923, 64, 485, 2, 199, 464, 549, 21, 4629, 192, 16, 98, 6, 707, 3, 260, 1, 165, 9, 117, 5, 191, 82, 12, 6, 1099, 411, 158]",1722.0,28188015,264
Potential immunotherapy targets in recurrent cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2017-02-21,"Our objective was to characterize the intra and peritumoral immune profile in recurrent cervical cancers to identify rational immunotherapy targets. Archival pelvic exenteration specimens were examined using a validated multiplex immuno-fluorescent panel of antibodies against cluster of differentiation 8 (CD8), cluster of differentiation 68 (CD68), forkhead box P3 (FoxP3), programmed cell death protein 1 (PD1), and programmed death-ligand 1 (PD-L1, N=28). Clinical data were abstracted from the electronic medical record. Cytotoxic T cells, macrophages, and regulatory T cells were found in higher densities in peritumoral stroma (CD8+ density 497.7 vs 83.5, p<0.0001, CD68+ density 345.0 vs 196.7, p=0.04, FoxP3+ density 214.5 vs 35.6, p<0.0001). Antigen experienced T cells (PD1+) were higher in peritumoral compared to tumor tissue (median normalized fluorescence intensity 0.05 vs 0.0085, p<0.001). Although there was a higher median density of intratumoral cytotoxic T cells and macrophages compared to regulatory T cells (median density CD8+ 83.5 vs 35.6, p<0.05, median density 196.7 vs 35.6, p<0.05), the presence of macrophages correlated with the presence of regulatory T cells in tumors (r=0.58, p=0.001). While cytotoxic T cells are present in tumor tissue to varying degrees, their density is lower than in peritumoral stroma, suggesting intratumoral exclusion or destruction of T cells. Higher densities of intratumoral macrophages compared to regulatory T cells suggest macrophages may be important contributors to the immunosuppressive tumor environment. Future directions for combination therapy include altering T cell trafficking and targeting tumor associated macrophages (TAMs) to enhance intratumoral activated T cell density and effect a more robust immune response.",Journal Article,1064.0,9.0,Our objective was to characterize the intra and peritumoral immune profile in recurrent cancers to identify rational immunotherapy targets Archival pelvic exenteration specimens were examined using a validated multiplex immuno-fluorescent panel of antibodies against cluster of differentiation 8 CD8 cluster of differentiation 68 CD68 forkhead box P3 FoxP3 programmed cell death protein 1 PD1 and programmed death-ligand 1 PD-L1 N=28 Clinical data were abstracted from the electronic medical record Cytotoxic T cells macrophages and regulatory T cells were found in higher densities in peritumoral stroma CD8+ density 497.7 vs 83.5 p 0.0001 CD68+ density 345.0 vs 196.7 p=0.04 FoxP3+ density 214.5 vs 35.6 p 0.0001 Antigen experienced T cells PD1+ were higher in peritumoral compared to tumor tissue median normalized fluorescence intensity 0.05 vs 0.0085 p 0.001 Although there was a higher median density of intratumoral cytotoxic T cells and macrophages compared to regulatory T cells median density CD8+ 83.5 vs 35.6 p 0.05 median density 196.7 vs 35.6 p 0.05 the presence of macrophages correlated with the presence of regulatory T cells in tumors r=0.58 p=0.001 While cytotoxic T cells are present in tumor tissue to varying degrees their density is lower than in peritumoral stroma suggesting intratumoral exclusion or destruction of T cells Higher densities of intratumoral macrophages compared to regulatory T cells suggest macrophages may be important contributors to the immunosuppressive tumor environment Future directions for combination therapy include altering T cell trafficking and targeting tumor associated macrophages TAMs to enhance intratumoral activated T cell density and effect a more robust immune response,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[114, 461, 10, 6, 1507, 3, 2392, 2, 5432, 250, 800, 4, 387, 163, 6, 255, 2696, 726, 637, 3967, 1110, 5668, 623, 11, 409, 75, 8, 938, 4908, 7644, 2910, 993, 1, 890, 480, 3132, 1, 910, 66, 968, 3132, 1, 910, 806, 6439, 8106, 4971, 9306, 3548, 1846, 31, 273, 178, 14, 4893, 2, 1846, 273, 1232, 14, 333, 729, 78, 339, 38, 74, 11, 4106, 29, 3, 3098, 484, 3237, 759, 102, 37, 2748, 2, 1253, 102, 37, 11, 204, 4, 142, 6908, 4, 5432, 2477, 968, 1263, 11178, 67, 105, 852, 33, 19, 13, 488, 6439, 1263, 9005, 13, 105, 6369, 67, 19, 13, 755, 3548, 1263, 6900, 33, 105, 465, 49, 19, 13, 488, 448, 592, 102, 37, 4893, 11, 142, 4, 5432, 72, 6, 30, 246, 52, 4207, 1591, 837, 13, 474, 105, 13, 18749, 19, 13, 144, 242, 125, 10, 8, 142, 52, 1263, 1, 2074, 759, 102, 37, 2, 2748, 72, 6, 1253, 102, 37, 52, 1263, 968, 852, 33, 105, 465, 49, 19, 13, 474, 52, 1263, 6369, 67, 105, 465, 49, 19, 13, 474, 3, 463, 1, 2748, 438, 5, 3, 463, 1, 1253, 102, 37, 4, 57, 668, 13, 717, 19, 13, 144, 369, 759, 102, 37, 32, 364, 4, 30, 246, 6, 2990, 4133, 136, 1263, 16, 280, 76, 4, 5432, 2477, 802, 2074, 4721, 15, 4572, 1, 102, 37, 142, 6908, 1, 2074, 2748, 72, 6, 1253, 102, 37, 309, 2748, 68, 40, 305, 9680, 6, 3, 2989, 30, 3087, 508, 3540, 9, 150, 36, 643, 4831, 102, 31, 6105, 2, 529, 30, 41, 2748, 7790, 6, 1304, 2074, 735, 102, 31, 1263, 2, 254, 8, 80, 1922, 250, 51]",1733.0,28233576,704
Longitudinal Changes in Active Bone Marrow for Cervical Cancer Patients Treated With Concurrent Chemoradiation Therapy.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2016-11-29,"To quantify longitudinal changes in active bone marrow (ABM) distributions within unirradiated (extrapelvic) and irradiated (pelvic) bone marrow (BM) in cervical cancer patients treated with concurrent chemoradiation therapy (CRT). We sampled 39 cervical cancer patients treated with CRT, of whom 25 were treated with concurrent cisplatin (40mg/m<sup>2</sup>) and 14 were treated with cisplatin (40mg/m<sup>2</sup>) plus gemcitabine (50-125mg/m<sup>2</sup>) (C/G). Patients underwent <sup>18</sup>F-fluorodeoxyglucose positron emission tomographic/computed tomographic imaging at baseline and 1.5 to 6.0months after treatment. ABM was defined as the subvolume of bone with standardized uptake value (SUV) above the mean SUV of the total bone. The primary aim was to measure the compensatory response, defined as the change in the log of the ratio of extrapelvic versus pelvic ABM percentage from baseline to after treatment. We also quantified the change in the proportion of ABM and mean SUV in pelvic and extrapelvic BM using a 2-sided paired t test. We observed a significant increase in the overall extrapelvic compensatory response after CRT (0.381; 95% confidence interval [CI]: 0.312, 0.449) and separately in patients treated with cisplatin (0.429; 95% CI: 0.340, 0.517) and C/G (0.294; 95% CI: 0.186, 0.402). We observed a trend toward higher compensatory response in patients treated with cisplatin compared with C/G (P=.057). Pelvic ABM percentage was reduced after CRT both in patients receiving cisplatin (P<.001) and in those receiving C/G (P<.001), whereas extrapelvic ABM percentage was increased in patients receiving cisplatin (P<.001) and C/G (P<.001). The mean SUV in pelvic structures was lower after CRT with both cisplatin (P<.001) and C/G (P<.001). The mean SUV appeared lower in extrapelvic structures after CRT in patients treated with C/G (P=.076) but not with cisplatin (P=.942). We also observed that older age and more intense chemotherapy regimens were correlated with a decreased compensatory response on multivariable analysis. In patients treated with C/G, mean pelvic bone marrow dose was found to be negatively correlated with the compensatory response. Patients have differing subacute compensatory responses after CRT, owing to variable recovery in unirradiated marrow. Intensive chemotherapy regimens appear to decrease the extrapelvic compensatory response, which may lead to increased hematologic toxicity.",Controlled Clinical Trial,1148.0,9.0,To quantify longitudinal changes in active marrow ABM distributions within unirradiated extrapelvic and irradiated pelvic marrow BM in cancer patients treated with concurrent chemoradiation therapy CRT We sampled 39 cancer patients treated with CRT of whom 25 were treated with concurrent cisplatin 40 mg/m sup 2 /sup and 14 were treated with cisplatin 40 mg/m sup 2 /sup plus gemcitabine 50-125 mg/m sup 2 /sup C/G Patients underwent sup 18 /sup F-fluorodeoxyglucose positron emission tomographic/computed tomographic imaging at baseline and 1.5 to 6.0 months after treatment ABM was defined as the subvolume of with standardized uptake value SUV above the mean SUV of the total The primary aim was to measure the compensatory response defined as the change in the log of the ratio of extrapelvic versus pelvic ABM percentage from baseline to after treatment We also quantified the change in the proportion of ABM and mean SUV in pelvic and extrapelvic BM using a 2-sided paired t test We observed a significant increase in the overall extrapelvic compensatory response after CRT 0.381 95 confidence interval CI 0.312 0.449 and separately in patients treated with cisplatin 0.429 95 CI 0.340 0.517 and C/G 0.294 95 CI 0.186 0.402 We observed a trend toward higher compensatory response in patients treated with cisplatin compared with C/G P=.057 Pelvic ABM percentage was reduced after CRT both in patients receiving cisplatin P .001 and in those receiving C/G P .001 whereas extrapelvic ABM percentage was increased in patients receiving cisplatin P .001 and C/G P .001 The mean SUV in pelvic structures was lower after CRT with both cisplatin P .001 and C/G P .001 The mean SUV appeared lower in extrapelvic structures after CRT in patients treated with C/G P=.076 but not with cisplatin P=.942 We also observed that older age and more intense chemotherapy regimens were correlated with a decreased compensatory response on multivariable analysis In patients treated with C/G mean pelvic marrow dose was found to be negatively correlated with the compensatory response Patients have differing subacute compensatory responses after CRT owing to variable recovery in unirradiated marrow Intensive chemotherapy regimens appear to decrease the extrapelvic compensatory response which may lead to increased hematologic toxicity,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 3091, 2380, 400, 4, 544, 581, 14380, 4477, 262, 11306, 12070, 2, 2398, 1110, 581, 1246, 4, 12, 7, 73, 5, 750, 975, 36, 1089, 21, 5919, 587, 12, 7, 73, 5, 1089, 1, 953, 243, 11, 73, 5, 750, 540, 327, 81, 188, 172, 18, 172, 2, 213, 11, 73, 5, 540, 327, 81, 188, 172, 18, 172, 349, 679, 212, 1731, 81, 188, 172, 18, 172, 256, 499, 7, 208, 172, 203, 172, 1068, 4085, 1900, 1799, 6158, 1220, 6158, 270, 28, 330, 2, 14, 33, 6, 49, 13, 53, 50, 24, 14380, 10, 395, 22, 3, 24103, 1, 5, 1670, 1135, 549, 2217, 2090, 3, 313, 2217, 1, 3, 181, 3, 86, 1130, 10, 6, 1463, 3, 7084, 51, 395, 22, 3, 707, 4, 3, 1066, 1, 3, 197, 1, 12070, 185, 1110, 14380, 1150, 29, 330, 6, 50, 24, 21, 120, 2790, 3, 707, 4, 3, 920, 1, 14380, 2, 313, 2217, 4, 1110, 2, 12070, 1246, 75, 8, 18, 1689, 2355, 102, 412, 21, 164, 8, 93, 344, 4, 3, 63, 12070, 7084, 51, 50, 1089, 13, 10155, 48, 307, 268, 58, 13, 8187, 13, 8865, 2, 3582, 4, 7, 73, 5, 540, 13, 8406, 48, 58, 13, 7264, 13, 11100, 2, 256, 499, 13, 8375, 48, 58, 13, 5869, 13, 9422, 21, 164, 8, 853, 1317, 142, 7084, 51, 4, 7, 73, 5, 540, 72, 5, 256, 499, 19, 10807, 1110, 14380, 1150, 10, 405, 50, 1089, 110, 4, 7, 357, 540, 19, 144, 2, 4, 135, 357, 256, 499, 19, 144, 547, 12070, 14380, 1150, 10, 101, 4, 7, 357, 540, 19, 144, 2, 256, 499, 19, 144, 3, 313, 2217, 4, 1110, 2414, 10, 280, 50, 1089, 5, 110, 540, 19, 144, 2, 256, 499, 19, 144, 3, 313, 2217, 2121, 280, 4, 12070, 2414, 50, 1089, 4, 7, 73, 5, 256, 499, 19, 13973, 84, 44, 5, 540, 19, 19784, 21, 120, 164, 17, 434, 89, 2, 80, 3933, 56, 472, 11, 438, 5, 8, 340, 7084, 51, 23, 658, 65, 4, 7, 73, 5, 256, 499, 313, 1110, 581, 61, 10, 204, 6, 40, 2723, 438, 5, 3, 7084, 51, 7, 47, 5276, 15181, 7084, 253, 50, 1089, 3421, 6, 1347, 1602, 4, 11306, 581, 1686, 56, 472, 1322, 6, 775, 3, 12070, 7084, 51, 92, 68, 1122, 6, 101, 813, 155]",2325.0,28244416,117
Peripheral nervous system injury after high-dose single-fraction image-guided stereotactic radiosurgery for spine tumors.,Neurosurgical focus,Neurosurg Focus,2017-03-01,"OBJECTIVE The object of this study was to determine the percentage of high-dose (1800-2600 cGy) single-fraction stereotactic radiosurgery (SF-SRS) treatments to the spine that result in peripheral nervous system (PNS) injury. METHODS All patients treated with SF-SRS for primary or metastatic spine tumors between January 2004 and May 2013 and referred to the Rehabilitation Medicine Service for evaluation and treatment of neuromuscular, musculoskeletal, or functional impairments or pain were retrospectively identified. RESULTS Five hundred fifty-seven SF-SRS treatments in 447 patients resulted in 14 PNS injuries in 13 patients. All injures resulted from SF-SRS delivered to the cervical or lumbosacral spine at 2400 cGy. The overall percentage of SF-SRS treatments resulting in PNS injury was 2.5%, increasing to 4.5% when the thoracic spine was excluded from analysis. The median time to symptom onset following SF-SRS was 10 months (range 4-32 months). The plexus (cervical, brachial, and/or lumbosacral) was affected clinically and/or electrophysiologically in 12 (86%) of 14 cases, the nerve root in 2 (14%) of 14, and both in 6 (43%) of 14 cases. All patients experienced pain and most (93%) developed weakness. Peripheral nervous system injuries were CTCAE Grade 1 in 14% of cases, 2 in 64%, and 3 in 21%. No dose relationship between SF-SRS dose and PNS injury was detected. CONCLUSIONS Single-fraction SRS to the spine can result in PNS injury with major implications for function and quality of life.",Journal Article,1056.0,17.0,OBJECTIVE The object of this study was to determine the percentage of high-dose 1800-2600 cGy single-fraction stereotactic radiosurgery SF-SRS treatments to the spine that result in peripheral nervous system PNS injury METHODS All patients treated with SF-SRS for primary or metastatic spine tumors between January 2004 and May 2013 and referred to the Rehabilitation Medicine Service for evaluation and treatment of neuromuscular musculoskeletal or functional impairments or pain were retrospectively identified RESULTS Five hundred fifty-seven SF-SRS treatments in 447 patients resulted in 14 PNS injuries in 13 patients All injures resulted from SF-SRS delivered to the or lumbosacral spine at 2400 cGy The overall percentage of SF-SRS treatments resulting in PNS injury was 2.5 increasing to 4.5 when the thoracic spine was excluded from analysis The median time to symptom onset following SF-SRS was 10 months range 4-32 months The plexus brachial and/or lumbosacral was affected clinically and/or electrophysiologically in 12 86 of 14 cases the nerve root in 2 14 of 14 and both in 6 43 of 14 cases All patients experienced pain and most 93 developed weakness Peripheral nervous system injuries were CTCAE Grade 1 in 14 of cases 2 in 64 and 3 in 21 No dose relationship between SF-SRS dose and PNS injury was detected CONCLUSIONS Single-fraction SRS to the spine can result in PNS injury with major implications for function and quality of life,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[461, 3, 12381, 1, 26, 45, 10, 6, 223, 3, 1150, 1, 64, 61, 13507, 28221, 3071, 226, 1509, 1729, 2192, 4086, 1429, 640, 6, 3, 2342, 17, 757, 4, 672, 1880, 398, 9137, 2730, 636, 62, 7, 73, 5, 4086, 1429, 9, 86, 15, 113, 2342, 57, 59, 1024, 1131, 2, 68, 1346, 2, 1995, 6, 3, 4182, 1807, 3086, 9, 451, 2, 24, 1, 14209, 5701, 15, 583, 6948, 15, 559, 11, 894, 108, 99, 365, 1128, 1461, 648, 4086, 1429, 640, 4, 9472, 7, 627, 4, 213, 9137, 13063, 4, 233, 7, 62, 43660, 627, 29, 4086, 1429, 1623, 6, 3, 15, 15598, 2342, 28, 12518, 3071, 3, 63, 1150, 1, 4086, 1429, 640, 1113, 4, 9137, 2730, 10, 18, 33, 602, 6, 39, 33, 198, 3, 2098, 2342, 10, 1800, 29, 65, 3, 52, 98, 6, 934, 1707, 366, 4086, 1429, 10, 79, 53, 184, 39, 531, 53, 3, 9576, 10975, 2, 15, 15598, 10, 1424, 505, 2, 15, 69966, 4, 133, 868, 1, 213, 140, 3, 2476, 8386, 4, 18, 213, 1, 213, 2, 110, 4, 49, 601, 1, 213, 140, 62, 7, 592, 559, 2, 96, 966, 276, 6408, 672, 1880, 398, 13063, 11, 3898, 88, 14, 4, 213, 1, 140, 18, 4, 660, 2, 27, 4, 239, 77, 61, 858, 59, 4086, 1429, 61, 2, 9137, 2730, 10, 530, 2130, 226, 1509, 1429, 6, 3, 2342, 122, 757, 4, 9137, 2730, 5, 458, 1268, 9, 343, 2, 372, 1, 358]",1450.0,28245730,16
TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.,Cancer,Cancer,2017-03-13,"The incidence of human papillomavirus (HPV)-associated (HPV-positive) head and neck squamous cell carcinoma (HNSCC) of the oropharynx has dramatically increased over the last decade and continues to rise. Newly diagnosed HPV-positive HNSCCs in the United States currently outnumber any other HPV-associated cancers, including cervical cancer. Despite introduction of the HPV vaccine, the epidemic of HPV-positive HNSCC is expected to continue for approximately 60 years. Compared with patients who have tobacco-associated HNSCC, those who have HPV-positive HNSCC have better overall survival and response to treatment. Current treatment, including chemotherapy and radiation therapy, is associated with lifelong morbidity, and there are limited treatments and no curative options for patients who develop recurrent metastatic disease. Therapeutic de-escalation (decreased radiation dose) is being tested through clinical trials; however, those studies select patients based solely on tumor and patient smoking characteristics. Mechanisms of HPV-driven carcinogenesis in HNSCC are not well understood, which limits new therapeutic strategies and hinders the appropriate selection of patients for de-escalation therapy. The authors analyzed HNSCC data from The Cancer Genome Atlas to identify molecular characteristics that correlate with outcomes and integration status of the HPV genome. The current investigations identified a subset of HPV-positive HNSCCs with mutations in the genes TRAF3 (tumor necrosis factor receptor-associated factor 3) and CYLD (cylindromatosis lysine 63 deubiquitinase). Defects in TRAF3 and CYLD correlated with the activation of transcriptional factor nuclear factor B, episomal HPV status of tumors, and improved patient survival. Defects in TRAF3/CYLD were accompanied with the activation of nuclear factor B signaling and maintenance of episomal HPV in tumors, suggesting that these mutations may support an alternative mechanism of HPV tumorigenesis in head and neck tumors. Cancer 2017;123:1778-1790.  2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.",Journal Article,1044.0,34.0,The incidence of human papillomavirus HPV -associated HPV-positive head and squamous cell carcinoma HNSCC of the oropharynx has dramatically increased over the last decade and continues to rise Newly diagnosed HPV-positive HNSCCs in the United States currently outnumber any other HPV-associated cancers including cancer Despite introduction of the HPV vaccine the epidemic of HPV-positive HNSCC is expected to continue for approximately 60 years Compared with patients who have tobacco-associated HNSCC those who have HPV-positive HNSCC have better overall survival and response to treatment Current treatment including chemotherapy and radiation therapy is associated with lifelong morbidity and there are limited treatments and no curative options for patients who develop recurrent metastatic disease Therapeutic de-escalation decreased radiation dose is being tested through clinical trials however those studies select patients based solely on tumor and patient smoking characteristics Mechanisms of HPV-driven carcinogenesis in HNSCC are not well understood which limits new therapeutic strategies and hinders the appropriate selection of patients for de-escalation therapy The authors analyzed HNSCC data from The Cancer Genome Atlas to identify molecular characteristics that correlate with outcomes and integration status of the HPV genome The current investigations identified a subset of HPV-positive HNSCCs with mutations in the genes TRAF3 tumor necrosis factor receptor-associated factor 3 and CYLD cylindromatosis lysine 63 deubiquitinase Defects in TRAF3 and CYLD correlated with the activation of transcriptional factor nuclear factor B episomal HPV status of tumors and improved patient survival Defects in TRAF3/CYLD were accompanied with the activation of nuclear factor B signaling and maintenance of episomal HPV in tumors suggesting that these mutations may support an alternative mechanism of HPV tumorigenesis in head and tumors Cancer 2017 123:1778-1790  2017 The Authors Cancer published by Wiley Periodicals Inc. on behalf of American Cancer Society This is an open access article under the terms of the Creative Commons Attribution NonCommercial License which permits use distribution and reproduction in any medium provided the original work is properly cited and is not used for commercial purposes,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 287, 1, 171, 3242, 933, 41, 933, 109, 718, 2, 691, 31, 134, 1209, 1, 3, 5333, 71, 2729, 101, 252, 3, 1060, 2025, 2, 2274, 6, 3693, 732, 265, 933, 109, 9691, 4, 3, 1088, 907, 694, 31036, 500, 127, 933, 41, 163, 141, 12, 550, 2456, 1, 3, 933, 1274, 3, 12515, 1, 933, 109, 1209, 16, 1336, 6, 1906, 9, 705, 335, 60, 72, 5, 7, 54, 47, 2607, 41, 1209, 135, 54, 47, 933, 109, 1209, 47, 380, 63, 25, 2, 51, 6, 24, 291, 24, 141, 56, 2, 121, 36, 16, 41, 5, 9590, 787, 2, 125, 32, 383, 640, 2, 77, 1075, 838, 9, 7, 54, 690, 387, 113, 34, 189, 1566, 1125, 340, 121, 61, 16, 486, 650, 298, 38, 143, 137, 135, 94, 1717, 7, 90, 5558, 23, 30, 2, 69, 979, 374, 483, 1, 933, 1621, 1719, 4, 1209, 32, 44, 149, 1784, 92, 3526, 217, 189, 422, 2, 21066, 3, 870, 881, 1, 7, 9, 1566, 1125, 36, 3, 738, 311, 1209, 74, 29, 3, 12, 898, 2643, 6, 255, 219, 374, 17, 1513, 5, 123, 2, 2676, 156, 1, 3, 933, 898, 3, 291, 2492, 108, 8, 697, 1, 933, 109, 9691, 5, 138, 4, 3, 214, 23619, 30, 1523, 161, 153, 41, 161, 27, 2, 26430, 44094, 6041, 676, 18627, 2945, 4, 23619, 2, 26430, 438, 5, 3, 363, 1, 1431, 161, 928, 161, 2448, 26345, 933, 156, 1, 57, 2, 231, 69, 25, 2945, 4, 23619, 26430, 11, 2756, 5, 3, 363, 1, 928, 161, 2448, 314, 2, 1146, 1, 26345, 933, 4, 57, 802, 17, 46, 138, 68, 538, 35, 1091, 670, 1, 933, 1565, 4, 718, 2, 57, 12, 1759, 2698, 29460, 27839, 2206, 1759, 3, 738, 12, 983, 20, 4692, 5493, 3479, 23, 14968, 1, 597, 12, 1174, 26, 16, 35, 1020, 1655, 946, 669, 3, 1794, 1, 3, 18607, 18108, 12076, 25752, 15289, 92, 8504, 119, 1395, 2, 17209, 4, 500, 3759, 1052, 3, 2279, 1357, 16, 6785, 7068, 2, 16, 44, 95, 9, 4860, 4624]",2333.0,28295222,599
miR-519 suppresses nasopharyngeal carcinoma cell proliferation by targeting oncogene URG4/URGCP.,Life sciences,Life Sci.,2017-03-16,"Nasopharyngeal carcinoma (NPC) is one of the most common malignant tumor in Southeast Asia, its regulatory mechanism is still to be understood. miR-519 inhibits the progression of several tumors, including cervical cancer, ovarian cancer and gastric cancer. But its role in NPC hasn't been studied. In present study, we found miR-519 was downregulated in NPC cells, its overexpression inhibited NPC cell proliferation and arrested cell cycle at G0/G1 phase, while its knockdown promoted NPC cell proliferation and cell cycle progression. An oncogene URG4/URGCP (upregulated gene-4/upregulator of cell proliferation) was the target of miR-519, URG4 was upregulated in NPC cells, miR-519 inhibited URG4 expression by directly binding to the 3'UTR of URG4. miR-519 inhibited Cyclin D1 expression and the phosphorylation level of Rb, and increased p21 and p27 expression, confirming miR-519 blocked G1/S transition. Moreover, miR-519 level was negative correlated with URG4 level in NPC tissues. In summary, we found miR-519 NPC cell proliferation by inhibiting URG4.",Journal Article,1041.0,8.0,carcinoma NPC is one of the most common malignant tumor in Southeast Asia its regulatory mechanism is still to be understood miR-519 inhibits the progression of several tumors including cancer cancer and cancer But its role in NPC has n't been studied In present study we found miR-519 was downregulated in NPC cells its overexpression inhibited NPC cell proliferation and arrested cell cycle at G0/G1 phase while its knockdown promoted NPC cell proliferation and cell cycle progression An oncogene URG4/URGCP upregulated gene-4/upregulator of cell proliferation was the target of miR-519 URG4 was upregulated in NPC cells miR-519 inhibited URG4 expression by directly binding to the 3'UTR of URG4 miR-519 inhibited Cyclin D1 expression and the phosphorylation level of Rb and increased p21 and p27 expression confirming miR-519 blocked G1/S transition Moreover miR-519 level was negative correlated with URG4 level in NPC tissues In summary we found miR-519 NPC cell proliferation by inhibiting URG4,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,"[134, 5330, 16, 104, 1, 3, 96, 186, 393, 30, 4, 21377, 5958, 211, 1253, 670, 16, 1234, 6, 40, 1784, 722, 11992, 1576, 3, 91, 1, 392, 57, 141, 12, 12, 2, 12, 84, 211, 200, 4, 5330, 71, 12408, 85, 656, 4, 364, 45, 21, 204, 722, 11992, 10, 3315, 4, 5330, 37, 211, 851, 879, 5330, 31, 457, 2, 9762, 31, 417, 28, 8588, 3344, 124, 369, 211, 1563, 2992, 5330, 31, 457, 2, 31, 417, 91, 35, 1836, 29877, 70067, 2684, 145, 39, 70068, 1, 31, 457, 10, 3, 283, 1, 722, 11992, 29877, 10, 2684, 4, 5330, 37, 722, 11992, 879, 29877, 55, 20, 1606, 791, 6, 3, 9990, 1, 29877, 722, 11992, 879, 1226, 2146, 55, 2, 3, 982, 301, 1, 2955, 2, 101, 2657, 2, 2804, 55, 5030, 722, 11992, 2582, 3344, 695, 1970, 1393, 722, 11992, 301, 10, 199, 438, 5, 29877, 301, 4, 5330, 742, 4, 1962, 21, 204, 722, 11992, 5330, 31, 457, 20, 2062, 29877]",1000.0,28315691,111
"Stabilization of Tumor-Associated Craniovertebral Junction Instability: Indications, Operative Variables, and Outcomes.",Neurosurgery,Neurosurgery,2017-08-01,"Whether primary or metastatic, tumors of the craniovertebral junction (CVJ) are rare and challenging. To examine the surgical indications, operative variables, and outcomes in patients with tumors of the CVJ undergoing occipitocervical (OC) stabilization. A single-institution, retrospective case series was performed from a prospectively maintained spine database. Patients with primary or metastatic tumors of the CVJ who underwent OC stabilization were identified. Out of 46 patients who underwent OC fusion, 39 were for tumor. Paired t -tests and Wilcoxon rank-sum tests were performed to assess for postoperative changes. Ten patients (26%) harbored primary tumors, and the remaining 29 (74%) had metastatic disease. Of the metastatic patients, 14 had a neurological deficit, 10 had severe neck pain, and 5 were deemed mechanically unstable. Postoperative visual analog pain scores were significantly reduced at all 3 follow-up times ( P < .001, 95% confidence interval [CI; 3.2, 6.0]; P = .001, 95% CI [2.6, 7.7]; P = .020, 95% CI [0.6, 5.5]). The percentage of patients who were ambulatory and neurologically improved or intact remained stable postoperatively with no significant declines. There were 2 perioperative mortalities (5%), and 13 patients (33%) experienced a major complication. In patients with primary or metastatic tumor of the CVJ, OC stabilization using a cervical screw-rod system affixed to a midline-keel buttress plate, with or without posterior decompression, is a reliable method for CVJ stabilization in the oncologic setting. Improvement in pain and preservation of neurological function was seen.",Journal Article,903.0,,Whether primary or metastatic tumors of the craniovertebral junction CVJ are rare and challenging To examine the surgical indications operative variables and outcomes in patients with tumors of the CVJ undergoing occipitocervical OC stabilization A single-institution retrospective case series was performed from a prospectively maintained spine database Patients with primary or metastatic tumors of the CVJ who underwent OC stabilization were identified Out of 46 patients who underwent OC fusion 39 were for tumor Paired t -tests and Wilcoxon rank-sum tests were performed to assess for postoperative changes Ten patients 26 harbored primary tumors and the remaining 29 74 had metastatic disease Of the metastatic patients 14 had a neurological deficit 10 had severe pain and 5 were deemed mechanically unstable Postoperative visual analog pain scores were significantly reduced at all 3 follow-up times P .001 95 confidence interval CI 3.2 6.0 P .001 95 CI 2.6 7.7 P .020 95 CI 0.6 5.5 The percentage of patients who were ambulatory and neurologically improved or intact remained stable postoperatively with no significant declines There were 2 perioperative mortalities 5 and 13 patients 33 experienced a major complication In patients with primary or metastatic tumor of the CVJ OC stabilization using a screw-rod system affixed to a midline-keel buttress plate with or without posterior decompression is a reliable method for CVJ stabilization in the oncologic setting Improvement in pain and preservation of neurological function was seen,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[317, 86, 15, 113, 57, 1, 3, 31589, 3322, 19219, 32, 622, 2, 1950, 6, 1004, 3, 221, 2406, 1208, 682, 2, 123, 4, 7, 5, 57, 1, 3, 19219, 479, 39250, 2950, 3184, 8, 226, 731, 459, 473, 988, 10, 173, 29, 8, 1143, 1955, 2342, 609, 7, 5, 86, 15, 113, 57, 1, 3, 19219, 54, 208, 2950, 3184, 11, 108, 1205, 1, 641, 7, 54, 208, 2950, 1212, 587, 11, 9, 30, 2355, 102, 895, 2, 3896, 1026, 3216, 895, 11, 173, 6, 423, 9, 573, 400, 1618, 7, 432, 3253, 86, 57, 2, 3, 1844, 462, 794, 42, 113, 34, 1, 3, 113, 7, 213, 42, 8, 3622, 6819, 79, 42, 905, 559, 2, 33, 11, 3779, 22431, 7705, 573, 3046, 3497, 559, 703, 11, 97, 405, 28, 62, 27, 166, 126, 1072, 19, 144, 48, 307, 268, 58, 27, 18, 49, 13, 19, 144, 48, 58, 18, 49, 67, 67, 19, 5743, 48, 58, 13, 49, 33, 33, 3, 1150, 1, 7, 54, 11, 4154, 2, 17139, 231, 15, 2964, 958, 585, 3541, 5, 77, 93, 4264, 125, 11, 18, 1547, 9743, 33, 2, 233, 7, 466, 592, 8, 458, 1447, 4, 7, 5, 86, 15, 113, 30, 1, 3, 19219, 2950, 3184, 75, 8, 14911, 14202, 398, 49427, 6, 8, 8677, 70129, 70130, 9656, 5, 15, 187, 3028, 7638, 16, 8, 2450, 596, 9, 19219, 3184, 4, 3, 1998, 546, 767, 4, 559, 2, 2224, 1, 3622, 343, 10, 527]",1546.0,28368478,387
Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.,Cancer,Cancer,2017-05-02,"Patients with resectable esophageal cancer (rEC) are managed with either concurrent chemoradiotherapy followed by surgery (CRSx) or concurrent chemoradiotherapy alone (cCR). To the authors' knowledge, there is insufficient evidence comparing the overall survival of patients treated with these 2 options. The National Cancer Data Base was queried for rEC cases diagnosed from 2003 through 2011. Patients with previous cancers, cervical rEC, clinical stage T1N0 disease, or metastasis were excluded. cCR was defined as radiotherapy administered within 30 days of chemotherapy. CRSx was defined as cCR followed by esophagectomy within 90 days. Overall survival was compared using Kaplan-Meier methods, propensity score matching, and extended Cox proportional hazards models. Of the 11,122 eligible patients, 8091 (72.7%) received cCR and 3031 (27.3%) received CRSx. The odds of receiving CRSx were higher among patients with American Joint Committee on Cancer stage II disease (vs stage III), adenocarcinoma (vs squamous cell carcinoma), lesions of the lower one-third of the esophagus, private insurance, and those living >25 miles from the treating facility or in areas with a higher median income or a greater percentage of high school-educated residents. Patients aged >70 years, female patients, African-American patients, those with 2 comorbidities, or those treated at community programs were more likely to receive cCR. After propensity score matching, the median and 10-year survival rates were found to be significantly better with CRSx (32.5 months [95% confidence interval (95% CI), 29.6-34.8 months] and 23.8% months [95% CI, 20.0-27.9 months], respectively) compared with cCR (14.2 months [95% CI, 13.4-15.5 months] and 6.1% months [95% CI, 3.9-9.0 months], respectively). Data from the National Cancer Data Base support the inclusion of surgery after concurrent chemoradiotherapy for patients with locally advanced rEC. Cancer 2017;123:3476-85.  2017 American Cancer Society.",Comparative Study,994.0,12.0,"Patients with resectable cancer rEC are managed with either concurrent chemoradiotherapy followed by surgery CRSx or concurrent chemoradiotherapy alone cCR To the authors knowledge there is insufficient evidence comparing the overall survival of patients treated with these 2 options The National Cancer Data Base was queried for rEC cases diagnosed from 2003 through 2011 Patients with previous cancers rEC clinical stage T1N0 disease or metastasis were excluded cCR was defined as radiotherapy administered within 30 days of chemotherapy CRSx was defined as cCR followed by esophagectomy within 90 days Overall survival was compared using Kaplan-Meier methods propensity score matching and extended Cox proportional hazards models Of the 11,122 eligible patients 8091 72.7 received cCR and 3031 27.3 received CRSx The odds of receiving CRSx were higher among patients with American Joint Committee on Cancer stage II disease vs stage III adenocarcinoma vs squamous cell carcinoma lesions of the lower one-third of the private insurance and those living 25 miles from the treating facility or in areas with a higher median income or a greater percentage of high school-educated residents Patients aged 70 years female patients African-American patients those with 2 comorbidities or those treated at community programs were more likely to receive cCR After propensity score matching the median and 10-year survival rates were found to be significantly better with CRSx 32.5 months 95 confidence interval 95 CI 29.6-34.8 months and 23.8 months 95 CI 20.0-27.9 months respectively compared with cCR 14.2 months 95 CI 13.4-15.5 months and 6.1 months 95 CI 3.9-9.0 months respectively Data from the National Cancer Data Base support the inclusion of surgery after concurrent chemoradiotherapy for patients with locally advanced rEC Cancer 2017 123:3476-85  2017 American Cancer Society",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[7, 5, 1899, 12, 29795, 32, 2231, 5, 361, 750, 1464, 370, 20, 152, 32731, 15, 750, 1464, 279, 4992, 6, 3, 738, 922, 125, 16, 3027, 241, 1430, 3, 63, 25, 1, 7, 73, 5, 46, 18, 838, 3, 657, 12, 74, 1782, 10, 3547, 9, 29795, 140, 265, 29, 1522, 298, 1132, 7, 5, 698, 163, 29795, 38, 82, 13404, 34, 15, 278, 11, 1800, 4992, 10, 395, 22, 310, 468, 262, 201, 162, 1, 56, 32731, 10, 395, 22, 4992, 370, 20, 3617, 262, 424, 162, 63, 25, 10, 72, 75, 876, 882, 636, 1925, 368, 2616, 2, 1747, 418, 831, 1017, 274, 1, 3, 175, 3285, 625, 7, 70319, 720, 67, 103, 4992, 2, 50296, 428, 27, 103, 32731, 3, 610, 1, 357, 32731, 11, 142, 107, 7, 5, 597, 2093, 2002, 23, 12, 82, 215, 34, 105, 82, 316, 449, 105, 691, 31, 134, 406, 1, 3, 280, 104, 1282, 1, 3, 4745, 1935, 2, 135, 2798, 243, 7886, 29, 3, 1367, 3483, 15, 4, 1361, 5, 8, 142, 52, 2306, 15, 8, 378, 1150, 1, 64, 5953, 9031, 5662, 7, 1032, 431, 60, 1061, 7, 1410, 597, 7, 135, 5, 3107, 1909, 15, 135, 73, 28, 1714, 2251, 11, 80, 322, 6, 560, 4992, 50, 1925, 368, 2616, 3, 52, 2, 79, 111, 25, 151, 11, 204, 6, 40, 97, 380, 5, 32731, 531, 33, 53, 48, 307, 268, 48, 58, 462, 49, 562, 66, 53, 2, 382, 66, 53, 48, 58, 179, 13, 428, 83, 53, 106, 72, 5, 4992, 213, 18, 53, 48, 58, 233, 39, 167, 33, 53, 2, 49, 14, 53, 48, 58, 27, 83, 83, 13, 53, 106, 74, 29, 3, 657, 12, 74, 1782, 538, 3, 1680, 1, 152, 50, 750, 1464, 9, 7, 5, 795, 131, 29795, 12, 1759, 2698, 39595, 772, 2206, 1759, 597, 12, 1174]",1884.0,28464264,374
Opportunities and Challenges: Human Papillomavirus and Cancer.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2017-05-01,"Mucosal exposure to human papillomavirus (HPV) can lead to anogenital and head and neck (H&N) cancer. Vaccination at a young age can be almost 100% effective in preventing HPV infection with the viral subtypes in both men and women, at least for disease in the anogenital tract. Therapeutic strategies targeting HPV in cervical dysplasia and cancer are showing promise as well in regressing dysplasia and controlling disease. That HPV-positive H&N cancer is a different disease from HPV-negative disease, with different molecular and clinical features and prognosis, is becoming better appreciated. At this time, however, the NCCN Guidelines for H&N Cancers do not distinguish between the types. This is expected to change.",Journal Article,995.0,1.0,Mucosal exposure to human papillomavirus HPV can lead to anogenital and head and H N cancer Vaccination at a young age can be almost 100 effective in preventing HPV infection with the viral subtypes in both men and women at least for disease in the anogenital tract Therapeutic strategies targeting HPV in dysplasia and cancer are showing promise as well in regressing dysplasia and controlling disease That HPV-positive H N cancer is a different disease from HPV-negative disease with different molecular and clinical features and prognosis is becoming better appreciated At this time however the NCCN Guidelines for H N Cancers do not distinguish between the types This is expected to change,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3068, 645, 6, 171, 3242, 933, 122, 1122, 6, 13836, 2, 718, 2, 555, 78, 12, 1915, 28, 8, 1169, 89, 122, 40, 2214, 394, 323, 4, 3017, 933, 930, 5, 3, 1667, 814, 4, 110, 325, 2, 117, 28, 506, 9, 34, 4, 3, 13836, 1696, 189, 422, 529, 933, 4, 2253, 2, 12, 32, 2069, 1783, 22, 149, 4, 22141, 2253, 2, 1893, 34, 17, 933, 109, 555, 78, 12, 16, 8, 338, 34, 29, 933, 199, 34, 5, 338, 219, 2, 38, 404, 2, 356, 16, 4009, 380, 7292, 28, 26, 98, 137, 3, 1944, 677, 9, 555, 78, 163, 1022, 44, 3081, 59, 3, 630, 26, 16, 1336, 6, 707]",693.0,28515256,429
Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancer.,Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,Radiother Oncol,2017-05-01,"To test the hypothesis that atlas-based active bone marrow (ABM)-sparing intensity modulated radiation therapy (IMRT) yields similar dosimetric results compared to custom ABM-sparing IMRT for cervical cancer patients. We sampled 62 cervical cancer patients with pre-treatment FDG-PET/CT in training (n=32) or test (n=30) sets. ABM was defined as the subvolume of the pelvic bone marrow (PBM) with standardized uptake value (SUV) above the mean on the average FDG-PET image (ABM<sub>Atlas</sub>) vs. the individual's PET (ABM<sub>Custom</sub>). Both were deformed to the planning CT. Overlap between the two subvolumes was measured using the Dice coefficient. Three IMRT plans designed to spare PBM, ABM<sub>Atlas</sub>, or ABM<sub>Custom</sub> were compared for 30 test patients. Dosimetric parameters were used to evaluate plan quality. ABM<sub>Atlas</sub> and ABM<sub>Custom</sub> volumes were not significantly different (p=0.90), with a mean Dice coefficient of 0.75, indicating good agreement. Compared to IMRT plans designed to spare PBM and ABM<sub>Custom</sub>, ABM<sub>Atlas</sub>-sparing IMRT plans achieved excellent target coverage and normal tissue sparing, without reducing dose to ABM<sub>Custom</sub> (mean ABM<sub>Custom</sub> dose 29.4Gy vs. 27.1Gyvs. 26.9Gy, respectively; p=0.10); however, PTV coverage and bowel sparing were slightly reduced. Atlas-based ABM sparing IMRT is clinically feasible and may obviate the need for customized ABM-sparing as a strategy to reduce hematologic toxicity.",Journal Article,995.0,9.0,To test the hypothesis that atlas-based active marrow ABM -sparing intensity modulated radiation therapy IMRT yields similar dosimetric results compared to custom ABM-sparing IMRT for cancer patients We sampled 62 cancer patients with pre-treatment FDG-PET/CT in training n=32 or test n=30 sets ABM was defined as the subvolume of the pelvic marrow PBM with standardized uptake value SUV above the mean on the average FDG-PET image ABM sub Atlas /sub vs. the individual 's PET ABM sub Custom /sub Both were deformed to the planning CT Overlap between the two subvolumes was measured using the Dice coefficient Three IMRT plans designed to spare PBM ABM sub Atlas /sub or ABM sub Custom /sub were compared for 30 test patients Dosimetric parameters were used to evaluate plan quality ABM sub Atlas /sub and ABM sub Custom /sub volumes were not significantly different p=0.90 with a mean Dice coefficient of 0.75 indicating good agreement Compared to IMRT plans designed to spare PBM and ABM sub Custom /sub ABM sub Atlas /sub -sparing IMRT plans achieved excellent target coverage and normal tissue sparing without reducing dose to ABM sub Custom /sub mean ABM sub Custom /sub dose 29.4Gy vs. 27.1Gyvs 26.9Gy respectively p=0.10 however PTV coverage and bowel sparing were slightly reduced Atlas-based ABM sparing IMRT is clinically feasible and may obviate the need for customized ABM-sparing as a strategy to reduce hematologic toxicity,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 412, 3, 1492, 17, 2643, 90, 544, 581, 14380, 1851, 837, 1757, 121, 36, 964, 4788, 288, 3187, 99, 72, 6, 6980, 14380, 1851, 964, 9, 12, 7, 21, 5919, 744, 12, 7, 5, 671, 24, 1285, 495, 425, 4, 1741, 78, 531, 15, 412, 78, 201, 2270, 14380, 10, 395, 22, 3, 24103, 1, 3, 1110, 581, 9215, 5, 1670, 1135, 549, 2217, 2090, 3, 313, 23, 3, 1011, 1285, 495, 1482, 14380, 551, 2643, 551, 105, 3, 797, 292, 495, 14380, 551, 6980, 551, 110, 11, 19169, 6, 3, 1349, 425, 4526, 59, 3, 100, 13719, 10, 644, 75, 3, 13685, 3200, 169, 964, 1853, 1114, 6, 8539, 9215, 14380, 551, 2643, 551, 15, 14380, 551, 6980, 551, 11, 72, 9, 201, 412, 7, 3187, 1038, 11, 95, 6, 376, 2242, 372, 14380, 551, 2643, 551, 2, 14380, 551, 6980, 551, 2225, 11, 44, 97, 338, 19, 13, 424, 5, 8, 313, 13685, 3200, 1, 13, 481, 1716, 1178, 2024, 72, 6, 964, 1853, 1114, 6, 8539, 9215, 2, 14380, 551, 6980, 551, 14380, 551, 2643, 551, 1851, 964, 1853, 513, 1503, 283, 2139, 2, 295, 246, 1851, 187, 1818, 61, 6, 14380, 551, 6980, 551, 313, 14380, 551, 6980, 551, 61, 462, 17384, 105, 428, 70421, 432, 40256, 106, 19, 13, 79, 137, 3303, 2139, 2, 1659, 1851, 11, 3223, 405, 2643, 90, 14380, 1851, 964, 16, 505, 1313, 2, 68, 14808, 3, 594, 9, 8959, 14380, 1851, 22, 8, 692, 6, 969, 813, 155]",1437.0,28528206,347
Genotype-specific methylation of HPV in cervical intraepithelial neoplasia.,Journal of gynecologic oncology,J Gynecol Oncol,2017-07-01,"Hypermethylation of human papillomavirus (HPV) and host genes has been reported in cervical cancer. However, the degree of methylation of different HPV types relative to the severity of the cervical lesions remains controversial. Studies of the degree of methylation associated with the host gene and the HPV genome to the severity of cervical lesions are rare. We examined the association of methylation status between host genes and late gene 1 (L1) regions of HPV16, 18, 52, and 58 in cervical brushings. Cervical brushings from 147 HPV-infected patients were obtained. The samples comprised normal (n=28), cervical intraepithelial neoplasia (CIN) 1 (n=45), CIN2 (n=13), and CIN3/carcinoma in situ (n=61). The methylation status of HPV and host genes was measured using bisulfite pyrosequencing and quantitative methylation-specific polymerase chain reaction (PCR). The degree of methylation of L1 in HPV16, 18, and 52 was associated with the severity of the cervical lesion. In HPV52, C-phosphate-G (CpG) sites 6368m, 6405m, and 6443m showed significantly higher methylation in lesions CIN3 (p=0.005, 0.003, and 0.026, respectively). Methylation of most HPV types except HPV52 (r<-0.1) was positively correlated with the degree of methylation of host genes including PAX1 and SOX1 (0.4r0.7). Combining HPV methylation with PAX1 methylation improved the clustering for CIN2. Our study showed that the degree of L1 methylation of HPV16, 18, and 52 but not 58 is associated with the severity of cervical lesions. The association between HPV methylation and host gene methylation suggests different responses of host cellular epigenetic machinery to different HPV genotypes.",Journal Article,934.0,6.0,Hypermethylation of human papillomavirus HPV and host genes has been reported in cancer However the degree of methylation of different HPV types relative to the severity of the lesions remains controversial Studies of the degree of methylation associated with the host gene and the HPV genome to the severity of lesions are rare We examined the association of methylation status between host genes and late gene 1 L1 regions of HPV16 18 52 and 58 in brushings brushings from 147 HPV-infected patients were obtained The samples comprised normal n=28 intraepithelial neoplasia CIN 1 n=45 CIN2 n=13 and CIN3/carcinoma in situ n=61 The methylation status of HPV and host genes was measured using bisulfite pyrosequencing and quantitative methylation-specific polymerase chain reaction PCR The degree of methylation of L1 in HPV16 18 and 52 was associated with the severity of the lesion In HPV52 C-phosphate-G CpG sites 6368m 6405m and 6443m showed significantly higher methylation in lesions CIN3 p=0.005 0.003 and 0.026 respectively Methylation of most HPV types except HPV52 r -0.1 was positively correlated with the degree of methylation of host genes including PAX1 and SOX1 0.4r0.7 Combining HPV methylation with PAX1 methylation improved the clustering for CIN2 Our study showed that the degree of L1 methylation of HPV16 18 and 52 but not 58 is associated with the severity of lesions The association between HPV methylation and host gene methylation suggests different responses of host cellular epigenetic machinery to different HPV genotypes,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2575, 1, 171, 3242, 933, 2, 1204, 214, 71, 85, 210, 4, 12, 137, 3, 1444, 1, 569, 1, 338, 933, 630, 580, 6, 3, 1702, 1, 3, 406, 469, 2010, 94, 1, 3, 1444, 1, 569, 41, 5, 3, 1204, 145, 2, 3, 933, 898, 6, 3, 1702, 1, 406, 32, 622, 21, 409, 3, 248, 1, 569, 156, 59, 1204, 214, 2, 807, 145, 14, 729, 1374, 1, 4048, 203, 653, 2, 717, 4, 14515, 14515, 29, 4961, 933, 3369, 7, 11, 683, 3, 347, 2603, 295, 78, 339, 4153, 2298, 4652, 14, 78, 512, 12870, 78, 233, 2, 10346, 134, 4, 957, 78, 713, 3, 569, 156, 1, 933, 2, 1204, 214, 10, 644, 75, 6181, 6031, 2, 1156, 569, 112, 1451, 1260, 1329, 604, 3, 1444, 1, 569, 1, 729, 4, 4048, 203, 2, 653, 10, 41, 5, 3, 1702, 1, 3, 1180, 4, 41408, 256, 4849, 499, 2075, 633, 70446, 70447, 2, 70448, 224, 97, 142, 569, 4, 406, 70449, 19, 13, 1614, 13, 1421, 2, 13, 4554, 106, 569, 1, 96, 933, 630, 2187, 41408, 668, 13, 14, 10, 2375, 438, 5, 3, 1444, 1, 569, 1, 1204, 214, 141, 35805, 2, 43680, 13, 70450, 67, 1525, 933, 569, 5, 35805, 569, 231, 3, 3147, 9, 70451, 114, 45, 224, 17, 3, 1444, 1, 729, 569, 1, 4048, 203, 2, 653, 84, 44, 717, 16, 41, 5, 3, 1702, 1, 406, 3, 248, 59, 933, 569, 2, 1204, 145, 569, 844, 338, 253, 1, 1204, 763, 1418, 6415, 6, 338, 933, 2071]",1552.0,28541643,67
Evaluating Intensity Modulated Proton Therapy Relative to Passive Scattering Proton Therapy for Increased Vertebral Column Sparing in Craniospinal Irradiation in Growing Pediatric Patients.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2017-02-01,"At present, proton craniospinal irradiation (CSI) for growing children is delivered to the whole vertebral body (WVB) to avoid asymmetric growth. We aimed to demonstrate the feasibility and potential clinical benefit of delivering vertebral body sparing (VBS) versus WVB CSI with passively scattered (PS) and intensity modulated proton therapy (IMPT) in growing children treated for medulloblastoma. Five plans were generated for medulloblastoma patients, who had been previously treated with CSI PS proton radiation therapy: (1) single posteroanterior (PA) PS field covering the WVB (PS-PA-WVB); (2) single PA PS field that included only the thecal sac in the target volume (PS-PA-VBS); (3) single PA IMPT field covering the WVB (IMPT-PA-WVB); (4) single PA IMPT field, target volume including thecal sac only (IMPT-PA-VBS); and (5) 2 posterior-oblique (-35, +35) IMPT fields, with the target volume including the thecal sac only (IMPT2F-VBS). For all cases, 23.4Gy (relative biologic effectiveness [RBE]) was prescribed to 95% of the spinal canal. The dose, linear energy transfer, and variable-RBE-weighted dose distributions were calculated for all plans using the tool for particle simulation, version 2, Monte Carlo system. IMPT VBS techniques efficiently spared the anterior vertebral bodies (AVBs), even when accounting for potential higher variable RBE predicted by linear energy transfer distributions. Assuming an RBE of 1.1, the V10Gy(RBE) decreased from 100% for the WVB techniques to 59.5% to 76.8% for the cervical, 29.9% to 34.6% for the thoracic, and 20.6% to 25.1% for the lumbar AVBs, and the V20Gy(RBE) decreased from 99.0% to 17.8% to 20.0% for the cervical, 7.2% to 7.6% for the thoracic, and 4.0% to 4.6% for the lumbar AVBs when IMPT VBS techniques were applied. The corresponding percentages for the PS VBS technique were higher. Advanced proton techniques can sufficiently reduce the dose to the vertebral body and allow for vertebral column growth for children with central nervous system tumors requiring CSI. This was true even when considering variable RBE values. A clinical trial is planned for VBS to the thoracic and lumbosacral spine in growing children.",Evaluation Study,1084.0,7.0,At present proton craniospinal irradiation CSI for growing children is delivered to the whole vertebral body WVB to avoid asymmetric growth We aimed to demonstrate the feasibility and potential clinical benefit of delivering vertebral body sparing VBS versus WVB CSI with passively scattered PS and intensity modulated proton therapy IMPT in growing children treated for medulloblastoma Five plans were generated for medulloblastoma patients who had been previously treated with CSI PS proton radiation therapy 1 single posteroanterior PA PS field covering the WVB PS-PA-WVB 2 single PA PS field that included only the thecal sac in the target volume PS-PA-VBS 3 single PA IMPT field covering the WVB IMPT-PA-WVB 4 single PA IMPT field target volume including thecal sac only IMPT-PA-VBS and 5 2 posterior-oblique -35 +35 IMPT fields with the target volume including the thecal sac only IMPT2F-VBS For all cases 23.4 Gy relative biologic effectiveness RBE was prescribed to 95 of the spinal canal The dose linear energy transfer and variable-RBE-weighted dose distributions were calculated for all plans using the tool for particle simulation version 2 Monte Carlo system IMPT VBS techniques efficiently spared the anterior vertebral bodies AVBs even when accounting for potential higher variable RBE predicted by linear energy transfer distributions Assuming an RBE of 1.1 the V10 Gy RBE decreased from 100 for the WVB techniques to 59.5 to 76.8 for the 29.9 to 34.6 for the thoracic and 20.6 to 25.1 for the lumbar AVBs and the V20 Gy RBE decreased from 99.0 to 17.8 to 20.0 for the 7.2 to 7.6 for the thoracic and 4.0 to 4.6 for the lumbar AVBs when IMPT VBS techniques were applied The corresponding percentages for the PS VBS technique were higher Advanced proton techniques can sufficiently reduce the dose to the vertebral body and allow for vertebral column growth for children with central nervous system tumors requiring CSI This was true even when considering variable RBE values A clinical trial is planned for VBS to the thoracic and lumbosacral spine in growing children,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[28, 364, 2095, 5748, 1104, 4293, 9, 1921, 541, 16, 1623, 6, 3, 902, 4731, 642, 27617, 6, 3085, 14877, 129, 21, 1295, 6, 608, 3, 1437, 2, 174, 38, 247, 1, 4790, 4731, 642, 1851, 18014, 185, 27617, 4293, 5, 16075, 9638, 1511, 2, 837, 1757, 2095, 36, 5534, 4, 1921, 541, 73, 9, 2714, 365, 1853, 11, 1419, 9, 2714, 7, 54, 42, 85, 373, 73, 5, 4293, 1511, 2095, 121, 36, 14, 226, 22374, 3118, 1511, 1067, 9296, 3, 27617, 1511, 3118, 27617, 18, 226, 3118, 1511, 1067, 17, 159, 158, 3, 17060, 7948, 4, 3, 283, 433, 1511, 3118, 18014, 27, 226, 3118, 5534, 1067, 9296, 3, 27617, 5534, 3118, 27617, 39, 226, 3118, 5534, 1067, 283, 433, 141, 17060, 7948, 158, 5534, 3118, 18014, 2, 33, 18, 3028, 19506, 50423, 50423, 5534, 3130, 5, 3, 283, 433, 141, 3, 17060, 7948, 158, 70518, 18014, 9, 62, 140, 382, 39, 381, 580, 1283, 1236, 7037, 10, 2746, 6, 48, 1, 3, 1499, 5614, 3, 61, 1646, 2803, 2602, 2, 1347, 7037, 2337, 61, 4477, 11, 981, 9, 62, 1853, 75, 3, 1515, 9, 5997, 4026, 2256, 18, 7990, 7991, 398, 5534, 18014, 1092, 4143, 6830, 3, 2882, 4731, 7442, 41786, 871, 198, 3116, 9, 174, 142, 1347, 7037, 783, 20, 1646, 2803, 2602, 4477, 7242, 35, 7037, 1, 14, 14, 3, 10724, 381, 7037, 340, 29, 394, 9, 3, 27617, 1092, 6, 728, 33, 6, 846, 66, 9, 3, 462, 83, 6, 562, 49, 9, 3, 2098, 2, 179, 49, 6, 243, 14, 9, 3, 6187, 41786, 2, 3, 8120, 381, 7037, 340, 29, 1058, 13, 6, 269, 66, 6, 179, 13, 9, 3, 67, 18, 6, 67, 49, 9, 3, 2098, 2, 39, 13, 6, 39, 49, 9, 3, 6187, 41786, 198, 5534, 18014, 1092, 11, 1498, 3, 1734, 5504, 9, 3, 1511, 18014, 1312, 11, 142, 131, 2095, 1092, 122, 5938, 969, 3, 61, 6, 3, 4731, 642, 2, 1700, 9, 4731, 9004, 129, 9, 541, 5, 854, 1880, 398, 57, 1888, 4293, 26, 10, 2501, 871, 198, 3075, 1347, 7037, 1030, 8, 38, 160, 16, 1465, 9, 18014, 6, 3, 2098, 2, 15598, 2342, 4, 1921, 541]",2086.0,28587051,185
"Isolation, Detection, and Quantification of Cancer Biomarkers in HPV-Associated Malignancies.",Scientific reports,Sci Rep,2017-06-12,"Human Papillomavirus (HPV) infection has been recognized as the main etiologic factor in the development of various cancers including penile, vulva, oropharyngeal and cervical cancers. In the development of cancer, persistent HPV infections induce E6 and E7 oncoproteins, which promote cell proliferation and carcinogenesis resulting elevated levels of host antibodies (e.g., anti-HPV16 E7 antibody). Currently, these cancers are clinically diagnosed using invasive biopsy-based tests, which are performed only in centralized labs by experienced clinical staff using time-consuming and expensive tools and technologies. Therefore, these obstacles constrain their utilization at primary care clinics and in remote settings, where resources are limited. Here, we present a rapid, inexpensive, reliable, easy-to-use, customized immunoassay platform following a microfluidic filter device to detect and quantify anti-HPV16 E7 antibodies from whole blood as a non-invasive assisting technology for diagnosis of HPV-associated malignancies, especially, at primary healthcare and remote settings. The platform can detect and quantify anti-HPV16 E7 antibody down to 2.87ng/mL. We further validated our immunoassay in clinical patient samples and it provided significantly high responses as compared to control samples. Thus, it can be potentially implemented as a pretesting tool to identify high-risk groups for broad monitoring of HPV-associated cancers in resource-constrained settings.",Journal Article,953.0,7.0,Human Papillomavirus HPV infection has been recognized as the main etiologic factor in the development of various cancers including vulva and cancers In the development of cancer persistent HPV infections induce E6 and E7 oncoproteins which promote cell proliferation and carcinogenesis resulting elevated levels of host antibodies e.g. anti-HPV16 E7 antibody Currently these cancers are clinically diagnosed using invasive biopsy-based tests which are performed only in centralized labs by experienced clinical staff using time-consuming and expensive tools and technologies Therefore these obstacles constrain their utilization at primary care clinics and in remote settings where resources are limited Here we present a rapid inexpensive reliable easy-to-use customized immunoassay platform following a microfluidic filter device to detect and quantify anti-HPV16 E7 antibodies from whole blood as a non-invasive assisting technology for diagnosis of HPV-associated malignancies especially at primary healthcare and remote settings The platform can detect and quantify anti-HPV16 E7 antibody down to 2.87 ng/mL We further validated our immunoassay in clinical patient samples and it provided significantly high responses as compared to control samples Thus it can be potentially implemented as a pretesting tool to identify high-risk groups for broad monitoring of HPV-associated cancers in resource-constrained settings,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 3242, 933, 930, 71, 85, 1904, 22, 3, 1895, 6604, 161, 4, 3, 193, 1, 747, 163, 141, 9263, 2, 163, 4, 3, 193, 1, 12, 1882, 933, 1875, 1290, 4837, 2, 4540, 8241, 92, 1617, 31, 457, 2, 1719, 1113, 804, 148, 1, 1204, 890, 563, 499, 312, 4048, 4540, 548, 694, 46, 163, 32, 505, 265, 75, 416, 411, 90, 895, 92, 32, 173, 158, 4, 10826, 18754, 20, 592, 38, 5898, 75, 98, 7117, 2, 6038, 1896, 2, 2590, 673, 46, 7140, 28101, 136, 1961, 28, 86, 165, 4736, 2, 4, 9879, 1947, 1257, 2892, 32, 383, 467, 21, 364, 8, 1321, 8168, 2450, 6261, 6, 119, 8959, 9006, 2243, 366, 8, 9401, 7578, 4472, 6, 1426, 2, 3091, 312, 4048, 4540, 890, 29, 902, 315, 22, 8, 220, 416, 16194, 2033, 9, 147, 1, 933, 41, 441, 1093, 28, 86, 2819, 2, 9879, 1947, 3, 2243, 122, 1426, 2, 3091, 312, 4048, 4540, 548, 1328, 6, 18, 912, 997, 542, 21, 195, 938, 114, 9006, 4, 38, 69, 347, 2, 192, 1052, 97, 64, 253, 22, 72, 6, 182, 347, 631, 192, 122, 40, 751, 3426, 22, 8, 32298, 1515, 6, 255, 64, 43, 271, 9, 2094, 1315, 1, 933, 41, 163, 4, 3069, 9133, 1947]",1423.0,28607383,530
Medicaid Expansions and Cervical Cancer Screening for Low-Income Women.,Health services research,Health Serv Res,2017-06-30,"Medicaid coverage for low-income women may play an important role in ensuring access to preventive care. This study examines how Medicaid eligibility expansions to nonelderly adults impact cervical cancer screening among low-income women. We use data from the Behavioral Risk Factor Surveillance System from 2000 to 2010. The primary outcome of interest is whether women in the relevant guideline consistent age range reported having a Pap test in the previous year. We use a difference-in-differences approach with matched treatment and comparison states and a simulated eligibility approach based on a continuous measure of Medicaid generosity. Our results indicate that cervical cancer screening increased among low-income women in expansion states relative to comparison states. Increases in screening rates are largest among low-income Hispanic women. Medicaid expansions during the period from 2000 to 2010 were associated with improved cervical cancer screening rates, which is critical for early cervical cancer detection and prevention of cancer morbidity and mortality in women. The results suggest that more widespread Medicaid expansions may have positive effects on preventive health care for women.",Journal Article,935.0,7.0,Medicaid coverage for low-income women may play an important role in ensuring access to preventive care This study examines how Medicaid eligibility expansions to nonelderly adults impact cancer screening among low-income women We use data from the Behavioral Risk Factor Surveillance System from 2000 to 2010 The primary outcome of interest is whether women in the relevant guideline consistent age range reported having a Pap test in the previous year We use a difference-in-differences approach with matched treatment and comparison states and a simulated eligibility approach based on a continuous measure of Medicaid generosity Our results indicate that cancer screening increased among low-income women in expansion states relative to comparison states Increases in screening rates are largest among low-income Hispanic women Medicaid expansions during the period from 2000 to 2010 were associated with improved cancer screening rates which is critical for early cancer detection and prevention of cancer morbidity and mortality in women The results suggest that more widespread Medicaid expansions may have positive effects on preventive health care for women,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2843, 2139, 9, 154, 2306, 117, 68, 1343, 35, 305, 200, 4, 8397, 1655, 6, 3494, 165, 26, 45, 4468, 832, 2843, 2317, 12384, 6, 15008, 857, 345, 12, 453, 107, 154, 2306, 117, 21, 119, 74, 29, 3, 4166, 43, 161, 617, 398, 29, 1081, 6, 1120, 3, 86, 228, 1, 1333, 16, 317, 117, 4, 3, 867, 2009, 925, 89, 184, 210, 1041, 8, 4290, 412, 4, 3, 698, 111, 21, 119, 8, 523, 4, 362, 353, 5, 655, 24, 2, 1155, 907, 2, 8, 5872, 2317, 353, 90, 23, 8, 1314, 1463, 1, 2843, 41365, 114, 99, 1008, 17, 12, 453, 101, 107, 154, 2306, 117, 4, 1422, 907, 580, 6, 1155, 907, 1106, 4, 453, 151, 32, 2166, 107, 154, 2306, 1776, 117, 2843, 12384, 190, 3, 727, 29, 1081, 6, 1120, 11, 41, 5, 231, 12, 453, 151, 92, 16, 740, 9, 191, 12, 638, 2, 1070, 1, 12, 787, 2, 282, 4, 117, 3, 99, 309, 17, 80, 3029, 2843, 12384, 68, 47, 109, 176, 23, 3494, 341, 165, 9, 117]",1166.0,28664993,107
XPNPEP2 is overexpressed in cervical cancer and promotes cervical cancer metastasis.,Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,Tumour Biol.,2017-07-01,"XPNPEP2 is a proline hydrolytic enzyme that hydrolyzes several biologically active peptides and causes a loss of substrate activity. However, its function in cancer is still unknown. Our study showed that XPNPEP2 expression was significantly upregulated in cervical cancer tissues compared with normal cervical tissues and cervical intraepithelial neoplasm tissues. Statistical analysis showed that XPNPEP2 expression was associated with the International Federation of Gynecology and Obstetrics stage and lymph node metastasis. Overexpression of XPNPEP2 in SiHa and HeLa cells promoted cell invasion and migration without affecting cell proliferation and apoptosis. Mechanistically, we found that XPNPEP2 facilitated cervical cancer cell invasion and migration by inducing epithelial-mesenchymal transition. Furthermore, we demonstrated that XPNPEP2 had significant effects on the metastasis of xenografted tumors in vivo. Collectively, our findings identify the novel function of XPNPEP2 in the metastasis of cervical cancer and suggest that XPNPEP2 could be a novel potential therapeutic target for the treatment of cervical cancer.",Journal Article,934.0,5.0,XPNPEP2 is a proline hydrolytic enzyme that hydrolyzes several biologically active peptides and causes a loss of substrate activity However its function in cancer is still unknown Our study showed that XPNPEP2 expression was significantly upregulated in cancer tissues compared with normal tissues and intraepithelial neoplasm tissues Statistical analysis showed that XPNPEP2 expression was associated with the International Federation of Gynecology and Obstetrics stage and lymph node metastasis Overexpression of XPNPEP2 in SiHa and HeLa cells promoted cell invasion and migration without affecting cell proliferation and apoptosis Mechanistically we found that XPNPEP2 facilitated cancer cell invasion and migration by inducing epithelial-mesenchymal transition Furthermore we demonstrated that XPNPEP2 had significant effects on the metastasis of xenografted tumors in vivo Collectively our findings identify the novel function of XPNPEP2 in the metastasis of cancer and suggest that XPNPEP2 could be a novel potential therapeutic target for the treatment of cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[25822, 16, 8, 13850, 30570, 1644, 17, 29421, 392, 2665, 544, 2491, 2, 1626, 8, 407, 1, 4235, 128, 137, 211, 343, 4, 12, 16, 1234, 860, 114, 45, 224, 17, 25822, 55, 10, 97, 2684, 4, 12, 742, 72, 5, 295, 742, 2, 4153, 2131, 742, 1050, 65, 224, 17, 25822, 55, 10, 41, 5, 3, 944, 7303, 1, 6429, 2, 7407, 82, 2, 263, 289, 278, 851, 1, 25822, 4, 19043, 2, 8466, 37, 2992, 31, 578, 2, 1381, 187, 2319, 31, 457, 2, 351, 4187, 21, 204, 17, 25822, 4667, 12, 31, 578, 2, 1381, 20, 1958, 701, 1569, 1970, 798, 21, 264, 17, 25822, 42, 93, 176, 23, 3, 278, 1, 8047, 57, 4, 386, 2535, 114, 272, 255, 3, 229, 343, 1, 25822, 4, 3, 278, 1, 12, 2, 309, 17, 25822, 359, 40, 8, 229, 174, 189, 283, 9, 3, 24, 1, 12]",1069.0,28670957,282
A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.,Gynecologic oncology,Gynecol. Oncol.,2017-07-18,"Brivanib is an oral, tyrosine kinase inhibitor against vascular endothelial growth factor (VEGF) and fibroblast growth factor receptor (FGFR). We studied its efficacy and tolerability in persistent or recurrent cervical cancer patients. Eligible patients had at least one prior cytotoxic regimen for recurrence and with measurable disease. Brivanib 800mg was administered orally every day (1cycle=28days) until disease progression or prohibitive toxicity. Primary endpoints were progression-free survival (PFS) >6months and objective tumor response. Of 28 eligible and evaluable women enrolled, 11 (39%) had primary surgery and 25 (89%) had prior radiation. Eighteen (64%) received one prior cytotoxic treatment and 10 (36%) had 2 prior regimens. Twelve (43%) had >2cycles of brivanib with 4 (14%) receiving >10cycles (range: 1-20). Seven (25%) patients had PFS >6months (90% CI: 7.3%-33.9%). Two (7%) (90% CI: 1.3%-20.8%) patients had partial tumor response with duration of 8 and 22months and 12 (43%) had stable disease. The median PFS was 3.2months (90% CI: 2.1-4.4). The median overall survival was 7.9months (90% CI: 6.1-11.7). More common grade 3 adverse events were hypertension, anemia, hyponatremia, hyperglycemia, elevated liver enzymes, nausea, headache, and colon hemorrhage. Grade 4 adverse events included sepsis and hypertension. Based on early results of this phase II trial, brivanib was well tolerated and demonstrated sufficient activity after first stage but trial was stopped due to lack of drug availability.","Clinical Trial, Phase II",917.0,3.0,Brivanib is an oral tyrosine kinase inhibitor against vascular endothelial growth factor VEGF and fibroblast growth factor receptor FGFR We studied its efficacy and tolerability in persistent or recurrent cancer patients Eligible patients had at least one prior cytotoxic regimen for recurrence and with measurable disease Brivanib 800mg was administered orally every day 1cycle=28days until disease progression or prohibitive toxicity Primary endpoints were progression-free survival PFS 6months and objective tumor response Of 28 eligible and evaluable women enrolled 11 39 had primary surgery and 25 89 had prior radiation Eighteen 64 received one prior cytotoxic treatment and 10 36 had 2 prior regimens Twelve 43 had 2cycles of brivanib with 4 14 receiving 10cycles range 1-20 Seven 25 patients had PFS 6months 90 CI 7.3 -33.9 Two 7 90 CI 1.3 -20.8 patients had partial tumor response with duration of 8 and 22months and 12 43 had stable disease The median PFS was 3.2months 90 CI 2.1-4.4 The median overall survival was 7.9months 90 CI 6.1-11.7 More common grade 3 adverse events were hypertension anemia hyponatremia hyperglycemia elevated enzymes nausea headache and hemorrhage Grade 4 adverse events included sepsis and hypertension Based on early results of this phase II trial brivanib was well tolerated and demonstrated sufficient activity after first stage but trial was stopped due to lack of drug availability,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[9827, 16, 35, 518, 564, 216, 230, 480, 756, 845, 129, 161, 618, 2, 3758, 129, 161, 153, 4453, 21, 656, 211, 209, 2, 1543, 4, 1882, 15, 387, 12, 7, 625, 7, 42, 28, 506, 104, 324, 759, 477, 9, 146, 2, 5, 1884, 34, 9827, 24111, 10, 468, 1428, 454, 218, 47162, 27430, 1100, 34, 91, 15, 10784, 155, 86, 1387, 11, 91, 115, 25, 300, 14695, 2, 461, 30, 51, 1, 339, 625, 2, 859, 117, 346, 175, 587, 42, 86, 152, 2, 243, 887, 42, 324, 121, 3195, 660, 103, 104, 324, 759, 24, 2, 79, 511, 42, 18, 324, 472, 2544, 601, 42, 70855, 1, 9827, 5, 39, 213, 357, 41183, 184, 14, 179, 648, 243, 7, 42, 300, 14695, 424, 58, 67, 27, 466, 83, 100, 67, 424, 58, 14, 27, 179, 66, 7, 42, 450, 30, 51, 5, 654, 1, 66, 2, 41086, 2, 133, 601, 42, 585, 34, 3, 52, 300, 10, 27, 15030, 424, 58, 18, 14, 39, 39, 3, 52, 63, 25, 10, 67, 16988, 424, 58, 49, 14, 175, 67, 80, 186, 88, 27, 290, 281, 11, 1824, 1545, 6672, 3992, 804, 3039, 1218, 4538, 2, 3599, 88, 39, 290, 281, 159, 4227, 2, 1824, 90, 23, 191, 99, 1, 26, 124, 215, 160, 9827, 10, 149, 421, 2, 264, 1952, 128, 50, 157, 82, 84, 160, 10, 4403, 520, 6, 926, 1, 234, 2550]",1425.0,28728751,63
"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).","Lancet (London, England)",Lancet,2017-07-27,"On Aug 14, 2014, the US Food and Drug Administration approved the antiangiogenesis drug bevacizumab for women with advanced cervical cancer on the basis of improved overall survival (OS) after the second interim analysis (in 2012) of 271 deaths in the Gynecologic Oncology Group (GOG) 240 trial. In this study, we report the prespecified final analysis of the primary objectives, OS and adverse events. In this randomised, controlled, open-label, phase 3 trial, we recruited patients with metastatic, persistent, or recurrent cervical carcinoma from 81 centres in the USA, Canada, and Spain. Inclusion criteria included a GOG performance status score of 0 or 1; adequate renal, hepatic, and bone marrow function; adequately anticoagulated thromboembolism; a urine protein to creatinine ratio of less than 1; and measurable disease. Patients who had received chemotherapy for recurrence and those with non-healing wounds or active bleeding conditions were ineligible. We randomly allocated patients 1:1:1:1 (blocking used; block size of four) to intravenous chemotherapy of either cisplatin (50 mg/m<sup>2</sup> on day 1 or 2) plus paclitaxel (135 mg/m<sup>2</sup> or 175 mg/m<sup>2</sup> on day 1) or topotecan (075 mg/m<sup>2</sup> on days 1-3) plus paclitaxel (175 mg/m<sup>2</sup> on day 1) with or without intravenous bevacizumab (15 mg/kg on day 1) in 21 day cycles until disease progression, unacceptable toxic effects, voluntary withdrawal by the patient, or complete response. We stratified randomisation by GOG performance status (0 vs 1), previous radiosensitising platinum-based chemotherapy, and disease status (recurrent or persistent vs metastatic). We gave treatment open label. Primary outcomes were OS (analysed in the intention-to-treat population) and adverse events (analysed in all patients who received treatment and submitted adverse event information), assessed at the second interim and final analysis by the masked Data and Safety Monitoring Board. The cutoff for final analysis was 450 patients with 346 deaths. This trial is registered with ClinicalTrials.gov, number NCT00803062. Between April 6, 2009, and Jan 3, 2012, we enrolled 452 patients (225 [50%] in the two chemotherapy-alone groups and 227 [50%] in the two chemotherapy plus bevacizumab groups). By March 7, 2014, 348 deaths had occurred, meeting the prespecified cutoff for final analysis. The chemotherapy plus bevacizumab groups continued to show significant improvement in OS compared with the chemotherapy-alone groups: 168 months in the chemotherapy plus bevacizumab groups versus 133 months in the chemotherapy-alone groups (hazard ratio 077 [95% CI 062-095]; p=0007). Final OS among patients not receiving previous pelvic radiotherapy was 245 months versus 168 months (064 [037-110]; p=011). Postprogression OS was not significantly different between the chemotherapy plus bevacizumab groups (84 months) and chemotherapy-alone groups (71 months; 083 [066-105]; p=006). Fistula (any grade) occurred in 32 (15%) of 220 patients in the chemotherapy plus bevacizumab groups (all previously irradiated) versus three (1%) of 220 in the chemotherapy-alone groups (all previously irradiated). Grade 3 fistula developed in 13 (6%) versus one (<1%). No fistulas resulted in surgical emergencies, sepsis, or death. The benefit conferred by incorporation of bevacizumab is sustained with extended follow-up as evidenced by the overall survival curves remaining separated. After progression while receiving bevacizumab, we did not observe a negative rebound effect (ie, shorter survival after bevacizumab is stopped than after chemotherapy alone is stopped). These findings represent proof-of-concept of the efficacy and tolerability of antiangiogenesis therapy in advanced cervical cancer. National Cancer Institute.","Clinical Trial, Phase III",908.0,71.0,On Aug 14 2014 the US Food and Drug Administration approved the antiangiogenesis drug bevacizumab for women with advanced cancer on the basis of improved overall survival OS after the second interim analysis in 2012 of 271 deaths in the Gynecologic Oncology Group GOG 240 trial In this study we report the prespecified final analysis of the primary objectives OS and adverse events In this randomised controlled open-label phase 3 trial we recruited patients with metastatic persistent or recurrent carcinoma from 81 centres in the USA Canada and Spain Inclusion criteria included a GOG performance status score of 0 or 1 adequate hepatic and marrow function adequately anticoagulated thromboembolism a urine protein to creatinine ratio of less than 1 and measurable disease Patients who had received chemotherapy for recurrence and those with non-healing wounds or active bleeding conditions were ineligible We randomly allocated patients 1:1:1:1 blocking used block size of four to intravenous chemotherapy of either cisplatin 50 mg/m sup 2 /sup on day 1 or 2 plus paclitaxel 135 mg/m sup 2 /sup or 175 mg/m sup 2 /sup on day 1 or topotecan 075 mg/m sup 2 /sup on days 1-3 plus paclitaxel 175 mg/m sup 2 /sup on day 1 with or without intravenous bevacizumab 15 mg/kg on day 1 in 21 day cycles until disease progression unacceptable toxic effects voluntary withdrawal by the patient or complete response We stratified randomisation by GOG performance status 0 vs 1 previous radiosensitising platinum-based chemotherapy and disease status recurrent or persistent vs metastatic We gave treatment open label Primary outcomes were OS analysed in the intention-to-treat population and adverse events analysed in all patients who received treatment and submitted adverse event information assessed at the second interim and final analysis by the masked Data and Safety Monitoring Board The cutoff for final analysis was 450 patients with 346 deaths This trial is registered with ClinicalTrials.gov number NCT00803062 Between April 6 2009 and Jan 3 2012 we enrolled 452 patients 225 50 in the two chemotherapy-alone groups and 227 50 in the two chemotherapy plus bevacizumab groups By March 7 2014 348 deaths had occurred meeting the prespecified cutoff for final analysis The chemotherapy plus bevacizumab groups continued to show significant improvement in OS compared with the chemotherapy-alone groups 168 months in the chemotherapy plus bevacizumab groups versus 133 months in the chemotherapy-alone groups hazard ratio 077 95 CI 062-095 p=0007 Final OS among patients not receiving previous pelvic radiotherapy was 245 months versus 168 months 064 037-110 p=011 Postprogression OS was not significantly different between the chemotherapy plus bevacizumab groups 84 months and chemotherapy-alone groups 71 months 083 066-105 p=006 Fistula any grade occurred in 32 15 of 220 patients in the chemotherapy plus bevacizumab groups all previously irradiated versus three 1 of 220 in the chemotherapy-alone groups all previously irradiated Grade 3 fistula developed in 13 6 versus one 1 No fistulas resulted in surgical emergencies sepsis or death The benefit conferred by incorporation of bevacizumab is sustained with extended follow-up as evidenced by the overall survival curves remaining separated After progression while receiving bevacizumab we did not observe a negative rebound effect ie shorter survival after bevacizumab is stopped than after chemotherapy alone is stopped These findings represent proof-of-concept of the efficacy and tolerability of antiangiogenesis therapy in advanced cancer National Cancer Institute,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[23, 10497, 213, 1409, 3, 843, 1773, 2, 234, 634, 850, 3, 7351, 234, 599, 9, 117, 5, 131, 12, 23, 3, 877, 1, 231, 63, 25, 118, 50, 3, 419, 2914, 65, 4, 1195, 1, 8957, 1043, 4, 3, 1512, 413, 87, 4760, 4263, 160, 4, 26, 45, 21, 414, 3, 4075, 1457, 65, 1, 3, 86, 2409, 118, 2, 290, 281, 4, 26, 2827, 1149, 1020, 1756, 124, 27, 160, 21, 2619, 7, 5, 113, 1882, 15, 387, 134, 29, 865, 4496, 4, 3, 2706, 4740, 2, 13629, 1680, 371, 159, 8, 4760, 528, 156, 368, 1, 13, 15, 14, 1658, 939, 2, 581, 343, 4215, 26039, 3501, 8, 2646, 178, 6, 3177, 197, 1, 299, 76, 14, 2, 1884, 34, 7, 54, 42, 103, 56, 9, 146, 2, 135, 5, 220, 4706, 24951, 15, 544, 2294, 1298, 11, 3773, 21, 1108, 6682, 7, 14, 14, 14, 14, 2521, 95, 2381, 444, 1, 294, 6, 1262, 56, 1, 361, 540, 212, 81, 188, 172, 18, 172, 23, 218, 14, 15, 18, 349, 490, 3978, 81, 188, 172, 18, 172, 15, 3300, 81, 188, 172, 18, 172, 23, 218, 14, 15, 2129, 16992, 81, 188, 172, 18, 172, 23, 162, 14, 27, 349, 490, 3300, 81, 188, 172, 18, 172, 23, 218, 14, 5, 15, 187, 1262, 599, 167, 81, 503, 23, 218, 14, 4, 239, 218, 410, 1100, 34, 91, 3215, 1812, 176, 14814, 3683, 20, 3, 69, 15, 236, 51, 21, 1173, 5204, 20, 4760, 528, 156, 13, 105, 14, 698, 35764, 828, 90, 56, 2, 34, 156, 387, 15, 1882, 105, 113, 21, 6421, 24, 1020, 1756, 86, 123, 11, 118, 3141, 4, 3, 3205, 6, 943, 266, 2, 290, 281, 3141, 4, 62, 7, 54, 103, 24, 2, 5118, 290, 774, 487, 275, 28, 3, 419, 2914, 2, 1457, 65, 20, 3, 7415, 74, 2, 367, 1315, 2620, 3, 2779, 9, 1457, 65, 10, 5669, 7, 5, 9184, 1043, 26, 160, 16, 1653, 5, 1252, 1239, 207, 40623, 59, 2292, 49, 1238, 2, 7555, 27, 1195, 21, 346, 12638, 7, 4011, 212, 4, 3, 100, 56, 279, 271, 2, 7132, 212, 4, 3, 100, 56, 349, 599, 271, 20, 2363, 67, 1409, 9935, 1043, 42, 489, 2238, 3, 4075, 2779, 9, 1457, 65, 3, 56, 349, 599, 271, 1351, 6, 514, 93, 767, 4, 118, 72, 5, 3, 56, 279, 271, 36317, 53, 4, 3, 56, 349, 599, 271, 185, 25594, 53, 4, 3, 56, 279, 271, 360, 197, 18645, 48, 58, 19270, 23965, 19, 35768, 1457, 118, 107, 7, 44, 357, 698, 1110, 310, 10, 36297, 53, 185, 36317, 53, 18602, 35865, 21797, 19, 39821, 12039, 118, 10, 44, 97, 338, 59, 3, 56, 349, 599, 271, 23913, 53, 2, 56, 279, 271, 22727, 53, 22746, 16123, 27191, 19, 25281, 4920, 500, 88, 489, 4, 531, 167, 1, 6211, 7, 4, 3, 56, 349, 599, 271, 62, 373, 2398, 185, 169, 14, 1, 6211, 4, 3, 56, 279, 271, 62, 373, 2398, 88, 27, 4920, 276, 4, 233, 49, 185, 104, 14, 77, 13244, 627, 4, 221, 31618, 4227, 15, 273, 3, 247, 3851, 20, 2838, 1, 599, 16, 2275, 5, 1747, 166, 126, 22, 4728, 20, 3, 63, 25, 2400, 1844, 4910, 50, 91, 369, 357, 599, 21, 205, 44, 4635, 8, 199, 12309, 254, 2523, 985, 25, 50, 599, 16, 4403, 76, 50, 56, 279, 16, 4403, 46, 272, 1231, 3840, 1, 2545, 1, 3, 209, 2, 1543, 1, 7351, 36, 4, 131, 12, 657, 12, 1377]",3643.0,28756902,265
Prospective screening with the validated Opioid Risk Tool demonstrates gynecologic oncology patients are at low risk for opioid misuse.,Gynecologic oncology,Gynecol. Oncol.,2017-08-12,"To characterize risk for opioid misuse among gynecologic oncology patients. The Opioid Risk Tool (ORT), a validated screen for opioid misuse risk, was administered to a convenience sample of patients with gynecologic cancer receiving opioid prescriptions in gynecologic oncology or palliative care clinics from January 2012-June 2016. Demographic and clinical information was abstracted on chart review. The primary outcome was ORT risk level (low vs. moderate or high). Chi-square tests were performed for categorical variables. A total of 118 women were screened. Most women were Caucasian (79%) with a median age of 57years. Ovarian cancer patients comprised 46% of the cohort with fewer endometrial (25%), cervical (23%), vulvar (4%), and vaginal (2%) cancer patients. The median ORT score was 1.0 (range, 0-10) out of a possible 26. Overall, 87% of patients were categorized as low-risk for opioid misuse, 7% as moderate-risk, and 6% as high-risk. Patients who were at moderate or high-risk of opioid misuse were significantly younger (47 vs. 58years, p=0.02), more likely to have cervical cancer (p=0.02), be smokers (p=0.01) and be uninsured or on Medicare (p=0.03). Most gynecologic oncology patients in our cohort were low-risk for opioid misuse (87%). Cervical cancer patients were more likely to be moderate to high-risk for misuse. Future screening efforts for opioid misuse may have the highest utility in this subset of patients.",Journal Article,892.0,5.0,To characterize risk for opioid misuse among gynecologic oncology patients The Opioid Risk Tool ORT a validated screen for opioid misuse risk was administered to a convenience sample of patients with gynecologic cancer receiving opioid prescriptions in gynecologic oncology or palliative care clinics from January 2012-June 2016 Demographic and clinical information was abstracted on chart review The primary outcome was ORT risk level low vs. moderate or high Chi-square tests were performed for categorical variables A total of 118 women were screened Most women were Caucasian 79 with a median age of 57years cancer patients comprised 46 of the cohort with fewer 25 23 4 and 2 cancer patients The median ORT score was 1.0 range 0-10 out of a possible 26 Overall 87 of patients were categorized as low-risk for opioid misuse 7 as moderate-risk and 6 as high-risk Patients who were at moderate or high-risk of opioid misuse were significantly younger 47 vs. 58years p=0.02 more likely to have cancer p=0.02 be smokers p=0.01 and be uninsured or on Medicare p=0.03 Most gynecologic oncology patients in our cohort were low-risk for opioid misuse 87 cancer patients were more likely to be moderate to high-risk for misuse Future screening efforts for opioid misuse may have the highest utility in this subset of patients,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 1507, 43, 9, 2742, 13739, 107, 1512, 413, 7, 3, 2742, 43, 1515, 19957, 8, 938, 2413, 9, 2742, 13739, 43, 10, 468, 6, 8, 8184, 1000, 1, 7, 5, 1512, 12, 357, 2742, 7654, 4, 1512, 413, 15, 994, 165, 4736, 29, 1024, 1195, 1924, 1390, 1540, 2, 38, 487, 10, 4106, 23, 2937, 206, 3, 86, 228, 10, 19957, 43, 301, 154, 105, 1163, 15, 64, 3163, 3219, 895, 11, 173, 9, 5982, 682, 8, 181, 1, 4002, 117, 11, 2261, 96, 117, 11, 3229, 842, 5, 8, 52, 89, 1, 32414, 12, 7, 2603, 641, 1, 3, 180, 5, 1497, 243, 382, 39, 2, 18, 12, 7, 3, 52, 19957, 368, 10, 14, 13, 184, 13, 79, 1205, 1, 8, 899, 432, 63, 912, 1, 7, 11, 2320, 22, 154, 43, 9, 2742, 13739, 67, 22, 1163, 43, 2, 49, 22, 64, 43, 7, 54, 11, 28, 1163, 15, 64, 43, 1, 2742, 13739, 11, 97, 773, 662, 105, 71018, 19, 13, 588, 80, 322, 6, 47, 12, 19, 13, 588, 40, 1485, 19, 13, 355, 2, 40, 4955, 15, 23, 1378, 19, 13, 680, 96, 1512, 413, 7, 4, 114, 180, 11, 154, 43, 9, 2742, 13739, 912, 12, 7, 11, 80, 322, 6, 40, 1163, 6, 64, 43, 9, 13739, 508, 453, 1413, 9, 2742, 13739, 68, 47, 3, 1076, 1207, 4, 26, 697, 1, 7]",1319.0,28807366,5
Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted <sup>18</sup>F-DCFPyL in peripheral ganglia.,Annals of nuclear medicine,Ann Nucl Med,2017-08-22,"Radiotracers targeting prostate-specific membrane antigen (PSMA) have increasingly been recognized as showing uptake in a number of normal structures, anatomic variants, and non-prostate-cancer pathologies. We aimed to explore the frequency and degree of uptake in peripheral ganglia in patients undergoing PET with the PSMA-targeted agent <sup>18</sup>F-DCFPyL. A total of 98 patients who underwent <sup>18</sup>F-DCFPyL PET/CT imaging were retrospectively analyzed. This included 76 men with prostate cancer (PCa) and 22 patients with renal cell carcinoma (RCC; 13 men, 9 women). Scans were evaluated for uptake in the cervical, stellate, celiac, lumbar and sacral ganglia. Maximum standardized uptake value corrected to body weight (SUV<sub>max</sub>), and maximum standardized uptake value corrected to lean body mass (SUL<sub>max</sub>) were recorded for all ganglia with visible uptake above background. Ganglia-to-background ratios were calculated by dividing the SUV<sub>max</sub> and SUL<sub>max</sub> values by the mean uptake in the ascending aorta (Aorta<sub>mean</sub>) and the right gluteus muscle (Gluteus<sub>mean</sub>). Overall, 95 of 98 (96.9%) patients demonstrated uptake in at least one of the evaluated peripheral ganglia. With regard to the PCa cohort, the most frequent sites of radiotracer accumulation were lumbar ganglia (55/76, 72.4%), followed by the cervical ganglia (51/76, 67.1%). Bilateral uptake was found in the majority of cases [lumbar 44/55 (80%) and cervical 30/51 (58.8%)]. Additionally, discernible radiotracer uptake was recorded in 50/76 (65.8%) of the analyzed stellate ganglia and in 45/76 (59.2%) of the celiac ganglia, whereas only 5/76 (6.6%) of the sacral ganglia demonstrated <sup>18</sup>F-DCFPyL accumulation. Similar findings were observed for patients with RCC, with the most frequent locations of radiotracer uptake in both the lumbar (20/22, 90.9%) and cervical ganglia (19/22, 86.4%). No laterality preference was found in mean PSMA-ligand uptake for either the PCa or RCC cohorts. As PSMA-targeted agents become more widely disseminated, the patterns of uptake in structures that are not directly relevant to patients' cancers must be understood. This is the first systematic evaluation of the uptake of <sup>18</sup>F-DCFPyL in ganglia demonstrating a general trend with a descending frequency of radiotracer accumulation in lumbar, cervical, stellate, celiac, and sacral ganglia. The underlying biology that leads to variability of PSMA-targeted radiotracers in peripheral ganglia is not currently understood, but may provide opportunities for future research.",Journal Article,882.0,14.0,Radiotracers targeting prostate-specific membrane antigen PSMA have increasingly been recognized as showing uptake in a number of normal structures anatomic variants and non-prostate-cancer pathologies We aimed to explore the frequency and degree of uptake in peripheral ganglia in patients undergoing PET with the PSMA-targeted agent sup 18 /sup F-DCFPyL A total of 98 patients who underwent sup 18 /sup F-DCFPyL PET/CT imaging were retrospectively analyzed This included 76 men with cancer PCa and 22 patients with cell carcinoma RCC 13 men 9 women Scans were evaluated for uptake in the stellate celiac lumbar and sacral ganglia Maximum standardized uptake value corrected to body weight SUV sub max /sub and maximum standardized uptake value corrected to lean body mass SUL sub max /sub were recorded for all ganglia with visible uptake above background Ganglia-to-background ratios were calculated by dividing the SUV sub max /sub and SUL sub max /sub values by the mean uptake in the ascending aorta Aorta sub mean /sub and the right gluteus muscle Gluteus sub mean /sub Overall 95 of 98 96.9 patients demonstrated uptake in at least one of the evaluated peripheral ganglia With regard to the PCa cohort the most frequent sites of radiotracer accumulation were lumbar ganglia 55/76 72.4 followed by the ganglia 51/76 67.1 Bilateral uptake was found in the majority of cases lumbar 44/55 80 and 30/51 58.8 Additionally discernible radiotracer uptake was recorded in 50/76 65.8 of the analyzed stellate ganglia and in 45/76 59.2 of the celiac ganglia whereas only 5/76 6.6 of the sacral ganglia demonstrated sup 18 /sup F-DCFPyL accumulation Similar findings were observed for patients with RCC with the most frequent locations of radiotracer uptake in both the lumbar 20/22 90.9 and ganglia 19/22 86.4 No laterality preference was found in mean PSMA-ligand uptake for either the PCa or RCC cohorts As PSMA-targeted agents become more widely disseminated the patterns of uptake in structures that are not directly relevant to patients cancers must be understood This is the first systematic evaluation of the uptake of sup 18 /sup F-DCFPyL in ganglia demonstrating a general trend with a descending frequency of radiotracer accumulation in lumbar stellate celiac and sacral ganglia The underlying biology that leads to variability of PSMA-targeted radiotracers in peripheral ganglia is not currently understood but may provide opportunities for future research,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[13626, 529, 1364, 112, 1905, 448, 3588, 47, 1635, 85, 1904, 22, 2069, 1135, 4, 8, 207, 1, 295, 2414, 2745, 839, 2, 220, 1364, 12, 10456, 21, 1295, 6, 1645, 3, 675, 2, 1444, 1, 1135, 4, 672, 15381, 4, 7, 479, 495, 5, 3, 3588, 238, 420, 172, 203, 172, 1068, 10385, 8, 181, 1, 1096, 7, 54, 208, 172, 203, 172, 1068, 10385, 495, 425, 270, 11, 894, 311, 26, 159, 846, 325, 5, 12, 1265, 2, 350, 7, 5, 31, 134, 796, 233, 325, 83, 117, 1441, 11, 194, 9, 1135, 4, 3, 9528, 6932, 6187, 2, 7943, 15381, 689, 1670, 1135, 549, 3848, 6, 642, 924, 2217, 551, 2649, 551, 2, 689, 1670, 1135, 549, 3848, 6, 6949, 642, 782, 16874, 551, 2649, 551, 11, 1872, 9, 62, 15381, 5, 4822, 1135, 2090, 2426, 15381, 6, 2426, 1137, 11, 981, 20, 9515, 3, 2217, 551, 2649, 551, 2, 16874, 551, 2649, 551, 1030, 20, 3, 313, 1135, 4, 3, 14404, 14164, 14164, 551, 313, 551, 2, 3, 1913, 50529, 1502, 50529, 551, 313, 551, 63, 48, 1, 1096, 921, 83, 7, 264, 1135, 4, 28, 506, 104, 1, 3, 194, 672, 15381, 5, 2539, 6, 3, 1265, 180, 3, 96, 908, 633, 1, 7610, 1835, 11, 6187, 15381, 614, 846, 720, 39, 370, 20, 3, 15381, 725, 846, 598, 14, 1607, 1135, 10, 204, 4, 3, 686, 1, 140, 6187, 584, 614, 493, 2, 201, 725, 717, 66, 1724, 19070, 7610, 1135, 10, 1872, 4, 212, 846, 556, 66, 1, 3, 311, 9528, 15381, 2, 4, 512, 846, 728, 18, 1, 3, 6932, 15381, 547, 158, 33, 846, 49, 49, 1, 3, 7943, 15381, 264, 172, 203, 172, 1068, 10385, 1835, 288, 272, 11, 164, 9, 7, 5, 796, 5, 3, 96, 908, 4069, 1, 7610, 1135, 4, 110, 3, 6187, 179, 350, 424, 83, 2, 15381, 326, 350, 868, 39, 77, 9915, 3863, 10, 204, 4, 313, 3588, 1232, 1135, 9, 361, 3, 1265, 15, 796, 736, 22, 3588, 238, 183, 1417, 80, 1792, 3605, 3, 764, 1, 1135, 4, 2414, 17, 32, 44, 1606, 867, 6, 7, 163, 1642, 40, 1784, 26, 16, 3, 157, 1556, 451, 1, 3, 1135, 1, 172, 203, 172, 1068, 10385, 4, 15381, 2219, 8, 1083, 853, 5, 8, 13478, 675, 1, 7610, 1835, 4, 6187, 9528, 6932, 2, 7943, 15381, 3, 1181, 891, 17, 1940, 6, 1982, 1, 3588, 238, 13626, 4, 672, 15381, 16, 44, 694, 1784, 84, 68, 377, 2605, 9, 508, 389]",2464.0,28831739,205
Immunotherapy in Gynecologic Cancers: Are We There Yet?,Current treatment options in oncology,Curr Treat Options Oncol,2017-08-24,"Immune-targeted therapies have demonstrated durable responses in many tumor types with limited treatment options and poor overall prognosis. This has led to enthusiasm for expanding such therapies to other tumor types including gynecologic malignancies. The use of immunotherapy in gynecologic malignancies is in the early stages and is an active area of ongoing clinical research. Both cancer vaccines and immune checkpoint inhibitor therapy continue to be extensively studied in gynecologic malignancies. Immune checkpoint inhibitors, in particular, hold promising potential in specific subsets of endometrial cancer that express microsatellite instability. The key to successful treatment with immunotherapy involves identification of the subgroup of patients that will derive benefit. The number of ongoing trials in cervical, ovarian, and endometrial cancer will help to recognize these patients and make treatment more directed. Additionally, a number of studies are combining immunotherapy with standard treatment options and will help to determine combinations that will enhance responses to standard therapy. Overall, there is much enthusiasm for immunotherapy approaches in gynecologic malignancies. However, the emerging data shows that with the exception of microsatellite unstable tumors, the use of single-agent immune checkpoint inhibitors is associated with response rates of 10-15%. More effective and likely combinatorial approaches are needed and will be informed by the findings of ongoing trials.",Journal Article,880.0,19.0,Immune-targeted therapies have demonstrated durable responses in many tumor types with limited treatment options and poor overall prognosis This has led to enthusiasm for expanding such therapies to other tumor types including gynecologic malignancies The use of immunotherapy in gynecologic malignancies is in the early stages and is an active area of ongoing clinical research Both cancer vaccines and immune checkpoint inhibitor therapy continue to be extensively studied in gynecologic malignancies Immune checkpoint inhibitors in particular hold promising potential in specific subsets of cancer that express microsatellite instability The key to successful treatment with immunotherapy involves identification of the subgroup of patients that will derive benefit The number of ongoing trials in and cancer will help to recognize these patients and make treatment more directed Additionally a number of studies are combining immunotherapy with standard treatment options and will help to determine combinations that will enhance responses to standard therapy Overall there is much enthusiasm for immunotherapy approaches in gynecologic malignancies However the emerging data shows that with the exception of microsatellite unstable tumors the use of single-agent immune checkpoint inhibitors is associated with response rates of 10-15 More effective and likely combinatorial approaches are needed and will be informed by the findings of ongoing trials,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[250, 238, 235, 47, 264, 1480, 253, 4, 445, 30, 630, 5, 383, 24, 838, 2, 334, 63, 356, 26, 71, 836, 6, 8582, 9, 4304, 225, 235, 6, 127, 30, 630, 141, 1512, 441, 3, 119, 1, 726, 4, 1512, 441, 16, 4, 3, 191, 1153, 2, 16, 35, 544, 965, 1, 942, 38, 389, 110, 12, 1842, 2, 250, 986, 230, 36, 1906, 6, 40, 3576, 656, 4, 1512, 441, 250, 986, 222, 4, 1454, 4164, 721, 174, 4, 112, 1890, 1, 12, 17, 1669, 2226, 1753, 3, 825, 6, 1401, 24, 5, 726, 2921, 911, 1, 3, 1363, 1, 7, 17, 303, 3823, 247, 3, 207, 1, 942, 143, 4, 2, 12, 303, 987, 6, 4237, 46, 7, 2, 2378, 24, 80, 1166, 1724, 8, 207, 1, 94, 32, 1525, 726, 5, 260, 24, 838, 2, 303, 987, 6, 223, 1247, 17, 303, 1304, 253, 6, 260, 36, 63, 125, 16, 1802, 8582, 9, 726, 611, 4, 1512, 441, 137, 3, 1478, 74, 1949, 17, 5, 3, 4188, 1, 2226, 7705, 57, 3, 119, 1, 226, 420, 250, 986, 222, 16, 41, 5, 51, 151, 1, 79, 167, 80, 323, 2, 322, 3866, 611, 32, 575, 2, 303, 40, 2767, 20, 3, 272, 1, 942, 143]",1456.0,28840453,89
American Brachytherapy Society recurrent carcinoma of the endometrium task force patterns of care and review of the literature.,Brachytherapy,Brachytherapy,2017-09-06,"The purpose of this American Brachytherapy Society task force is to present a literature review and patterns of care by a panel of experts for the management of vaginal recurrence of endometrial cancer. In 2016, the American Brachytherapy Society Board selected a panel of experts in gynecologic brachytherapy to update our current state of knowledge for managing vaginal recurrence of endometrial cancer. Practice patterns were evaluated via an online survey and clinical updates occurred through a combination of literature review and clinical experience and/or expertise. There are various retrospective series of patients treated with radiation for vaginal recurrence of endometrial cancer, which include a varied group of patients, multiple treatment techniques, and a range of total doses and demonstrate a wide scope of local control and overall survival outcomes. In the era of image-guided brachytherapy, high local control rates with low significant late-term morbidities can be achieved. Lower rates of local control and higher late-term toxicity are reported in the retreatment setting. In patients with no previous history of radiation treatment, external beam radiation therapy followed by brachytherapy boost should be used. There are varying practices with regard to the definition and appropriate doses of both the high-risk clinical target volume and the intermediate-risk clinical target volume in the setting of vaginal recurrence of endometrial cancer. There are limited data to provide appropriate dose constraints for some organs at risk with the majority of guidance taken from the definitive cervical cancer literature. A summary of literature and expert practice patterns for patient selection, dose recommendations, and constraints are provided as guidance for practitioners.",Consensus Development Conference,867.0,6.0,The purpose of this American Brachytherapy Society task force is to present a literature review and patterns of care by a panel of experts for the management of recurrence of cancer In 2016 the American Brachytherapy Society Board selected a panel of experts in gynecologic brachytherapy to update our current state of knowledge for managing recurrence of cancer Practice patterns were evaluated via an online survey and clinical updates occurred through a combination of literature review and clinical experience and/or expertise There are various retrospective series of patients treated with radiation for recurrence of cancer which include a varied group of patients multiple treatment techniques and a range of total doses and demonstrate a wide scope of local control and overall survival outcomes In the era of image-guided brachytherapy high local control rates with low significant late-term morbidities can be achieved Lower rates of local control and higher late-term toxicity are reported in the retreatment setting In patients with no previous history of radiation treatment external beam radiation therapy followed by brachytherapy boost should be used There are varying practices with regard to the definition and appropriate doses of both the high-risk clinical target volume and the intermediate-risk clinical target volume in the setting of recurrence of cancer There are limited data to provide appropriate dose constraints for some organs at risk with the majority of guidance taken from the definitive cancer literature A summary of literature and expert practice patterns for patient selection dose recommendations and constraints are provided as guidance for practitioners,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 743, 1, 26, 597, 1536, 1174, 3488, 4380, 16, 6, 364, 8, 789, 206, 2, 764, 1, 165, 20, 8, 993, 1, 3186, 9, 3, 284, 1, 146, 1, 12, 4, 1390, 3, 597, 1536, 1174, 2620, 715, 8, 993, 1, 3186, 4, 1512, 1536, 6, 2991, 114, 291, 1309, 1, 922, 9, 3969, 146, 1, 12, 758, 764, 11, 194, 847, 35, 4123, 1407, 2, 38, 5454, 489, 298, 8, 150, 1, 789, 206, 2, 38, 730, 2, 15, 4935, 125, 32, 747, 459, 988, 1, 7, 73, 5, 121, 9, 146, 1, 12, 92, 643, 8, 2051, 87, 1, 7, 232, 24, 1092, 2, 8, 184, 1, 181, 415, 2, 608, 8, 1019, 7924, 1, 293, 182, 2, 63, 25, 123, 4, 3, 1713, 1, 1482, 1808, 1536, 64, 293, 182, 151, 5, 154, 93, 807, 337, 5655, 122, 40, 513, 280, 151, 1, 293, 182, 2, 142, 807, 337, 155, 32, 210, 4, 3, 6291, 546, 4, 7, 5, 77, 698, 532, 1, 121, 24, 1455, 1345, 121, 36, 370, 20, 1536, 2569, 257, 40, 95, 125, 32, 2990, 2634, 5, 2539, 6, 3, 2470, 2, 870, 415, 1, 110, 3, 64, 43, 38, 283, 433, 2, 3, 919, 43, 38, 283, 433, 4, 3, 546, 1, 146, 1, 12, 125, 32, 383, 74, 6, 377, 870, 61, 4879, 9, 476, 2285, 28, 43, 5, 3, 686, 1, 2753, 1633, 29, 3, 1057, 12, 789, 8, 1962, 1, 789, 2, 2005, 758, 764, 9, 69, 881, 61, 883, 2, 4879, 32, 1052, 22, 2753, 9, 6323]",1695.0,28888417,384
Genistein Induces Alterations of Epigenetic Modulatory Signatures in Human Cervical Cancer Cells.,Anti-cancer agents in medicinal chemistry,Anticancer Agents Med Chem,2018-01-01,"Epidemiological studies indicate that diet rich in fruits and vegetables is associated with decreased cancer risk thereby indicating that dietary polyphenols can be potential chemo-preventive agents. The reversible nature of epigenetic modifications makes them a favorable target for cancer prevention. Polyphenols have been shown to reverse aberrant epigenetic patterns by targeting the regulatory enzymes, DNA methyltransferases (DNMTs) and histone deacetylases (HDACs). In vitro and in silico studies of DNMTs and HDACs were planned to examine genistein's role as a natural epigenetic modifier in human cervical cancer cells, HeLa. Expression of the tumour suppressor genes (TSGs) [MGMT, RAR, p21, E-cadherin, DAPK1] as well the methylation status of their promoters were examined alongwith the activity levels of DNMT and HDAC enzymes after treatment with genistein. Expression of DNMTs and HDACs was also studied. In-silico studies were performed to determine the interaction of genistein with DNMTs and HDACs. Genistein treatment significantly reduced the expression and enzymatic activity of both DNMTs and HDACs in a time-dependent way. Molecular modeling data suggest that genistein can interact with various members of DNMT and HDAC families and support genistein mediated inhibition of their activity. Timedependent exposure of genistein reversed the promoter region methylation of the TSGs and re-established their expression. In this study, we find that genistein is able to reinstate the expression of the TSGs studied by inhibiting the action of DNMTs and HDACs. This shows that genistein could be an important arsenal in the development of epigenetic based cancer therapy.",Journal Article,750.0,15.0,Epidemiological studies indicate that diet rich in fruits and vegetables is associated with decreased cancer risk thereby indicating that dietary polyphenols can be potential chemo-preventive agents The reversible nature of epigenetic modifications makes them a favorable target for cancer prevention Polyphenols have been shown to reverse aberrant epigenetic patterns by targeting the regulatory enzymes DNA methyltransferases DNMTs and histone deacetylases HDACs In vitro and in silico studies of DNMTs and HDACs were planned to examine genistein 's role as a natural epigenetic modifier in human cancer cells HeLa Expression of the tumour suppressor genes TSGs MGMT RAR p21 E-cadherin DAPK1 as well the methylation status of their promoters were examined alongwith the activity levels of DNMT and HDAC enzymes after treatment with genistein Expression of DNMTs and HDACs was also studied In-silico studies were performed to determine the interaction of genistein with DNMTs and HDACs Genistein treatment significantly reduced the expression and enzymatic activity of both DNMTs and HDACs in a time-dependent way Molecular modeling data suggest that genistein can interact with various members of DNMT and HDAC families and support genistein mediated inhibition of their activity Timedependent exposure of genistein reversed the promoter region methylation of the TSGs and re-established their expression In this study we find that genistein is able to reinstate the expression of the TSGs studied by inhibiting the action of DNMTs and HDACs This shows that genistein could be an important arsenal in the development of epigenetic based cancer therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4614, 94, 1008, 17, 2453, 3697, 4, 7896, 2, 6024, 16, 41, 5, 340, 12, 43, 2267, 1716, 17, 2013, 14831, 122, 40, 174, 3341, 3494, 183, 3, 2786, 2202, 1, 1418, 2916, 4677, 1370, 8, 913, 283, 9, 12, 1070, 14831, 47, 85, 443, 6, 1772, 1898, 1418, 764, 20, 529, 3, 1253, 3039, 261, 11494, 16486, 2, 1508, 9758, 7803, 4, 439, 2, 4, 6648, 94, 1, 16486, 2, 7803, 11, 1465, 6, 1004, 7395, 292, 200, 22, 8, 1504, 1418, 8833, 4, 171, 12, 37, 8466, 55, 1, 3, 770, 1245, 214, 13876, 2661, 50607, 2657, 563, 2154, 11503, 22, 149, 3, 569, 156, 1, 136, 4347, 11, 409, 50608, 3, 128, 148, 1, 10229, 2, 2654, 3039, 50, 24, 5, 7395, 55, 1, 16486, 2, 7803, 10, 120, 656, 4, 6648, 94, 11, 173, 6, 223, 3, 915, 1, 7395, 5, 16486, 2, 7803, 7395, 24, 97, 405, 3, 55, 2, 5226, 128, 1, 110, 16486, 2, 7803, 4, 8, 98, 470, 2255, 219, 2057, 74, 309, 17, 7395, 122, 4491, 5, 747, 1684, 1, 10229, 2, 2654, 1954, 2, 538, 7395, 517, 297, 1, 136, 128, 71243, 645, 1, 7395, 3682, 3, 973, 1053, 569, 1, 3, 13876, 2, 1491, 635, 136, 55, 4, 26, 45, 21, 2469, 17, 7395, 16, 1665, 6, 71244, 3, 55, 1, 3, 13876, 656, 20, 2062, 3, 1578, 1, 16486, 2, 7803, 26, 1949, 17, 7395, 359, 40, 35, 305, 13325, 4, 3, 193, 1, 1418, 90, 12, 36]",1654.0,28925878,0
Role of Radiation Therapy in the Multidisciplinary Management of Uterine Carcinosarcoma.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2018-01-01,"This study aimed to evaluate the impact of radiation therapy on outcomes for patients with uterine carcinosarcoma (UC). We retrospectively reviewed the records of 155 women with stage I (98), II (11), or III (46) UC who underwent total abdominal hysterectomy/bilateral salpingo-oophorectomy at our institution between 1990 and 2011. Survival rates were assessed using the Kaplan-Meier method and log-rank test. Univariate and multivariate Cox regression analyses were performed. Seventy-six patients (49%) received radiation therapy: 38 (50%) had vaginal cuff brachytherapy (VBT) alone and 38 had external beam radiation therapy (EBRT)  VBT. Seventy patients (45%) received chemotherapy (12 concurrent, 49 adjuvant, 9 both). The 5-year overall survival rate was 48.6% (stage I, 53.8%; II, 30.0%; and III, 42.5%). The disease-specific survival (DSS) rate was 57.2% (stage I, 60.9%; II, 44.4%; and III, 51.8%). Patients treated with EBRT had a higher 5-year pelvic disease control rate (88.3%) than did patients treated with VBT only (67.4%) or no radiation (71.2%; P = 0.04). In stage III patients, EBRT was associated with higher 5-year pelvic disease control (90.0% vs 55.5%, P = 0.046), DSS (64.6% vs 46.4%, P = 0.13), and overall survival (64.6% vs 34.0%, P = 0.04) rates. For all 155 patients, age at least 65 years, cervical involvement, and lymph vascular space invasion were correlated with lower DSS on univariate and multivariate analyses. In addition, treatment with concurrent chemoradiation therapy was independently associated with a higher DSS rate on multivariate analysis. Patients with UC have a high rate of relapse in the regional nodes and distant sites. External beam radiation therapy improves locoregional control in all stages and may improve survival in stage III patients who are at the highest risk of pelvic relapse.",Journal Article,750.0,2.0,This study aimed to evaluate the impact of radiation therapy on outcomes for patients with carcinosarcoma UC We retrospectively reviewed the records of 155 women with stage I 98 II 11 or III 46 UC who underwent total abdominal hysterectomy/bilateral salpingo-oophorectomy at our institution between 1990 and 2011 Survival rates were assessed using the Kaplan-Meier method and log-rank test Univariate and multivariate Cox regression analyses were performed Seventy-six patients 49 received radiation therapy 38 50 had cuff brachytherapy VBT alone and 38 had external beam radiation therapy EBRT  VBT Seventy patients 45 received chemotherapy 12 concurrent 49 adjuvant 9 both The 5-year overall survival rate was 48.6 stage I 53.8 II 30.0 and III 42.5 The disease-specific survival DSS rate was 57.2 stage I 60.9 II 44.4 and III 51.8 Patients treated with EBRT had a higher 5-year pelvic disease control rate 88.3 than did patients treated with VBT only 67.4 or no radiation 71.2 P 0.04 In stage III patients EBRT was associated with higher 5-year pelvic disease control 90.0 vs 55.5 P 0.046 DSS 64.6 vs 46.4 P 0.13 and overall survival 64.6 vs 34.0 P 0.04 rates For all 155 patients age at least 65 years involvement and lymph vascular space invasion were correlated with lower DSS on univariate and multivariate analyses In addition treatment with concurrent chemoradiation therapy was independently associated with a higher DSS rate on multivariate analysis Patients with UC have a high rate of relapse in the regional nodes and distant sites External beam radiation therapy improves locoregional control in all stages and may improve survival in stage III patients who are at the highest risk of pelvic relapse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[26, 45, 1295, 6, 376, 3, 345, 1, 121, 36, 23, 123, 9, 7, 5, 5623, 2417, 21, 894, 446, 3, 1064, 1, 3735, 117, 5, 82, 70, 1096, 215, 175, 15, 316, 641, 2417, 54, 208, 181, 1467, 2622, 1607, 5690, 3470, 28, 114, 731, 59, 2289, 2, 1132, 25, 151, 11, 275, 75, 3, 876, 882, 596, 2, 1066, 1026, 412, 880, 2, 331, 418, 320, 318, 11, 173, 2073, 437, 7, 739, 103, 121, 36, 519, 212, 42, 11445, 1536, 15050, 279, 2, 519, 42, 1455, 1345, 121, 36, 1883, 810, 15050, 2073, 7, 512, 103, 56, 133, 750, 739, 249, 83, 110, 3, 33, 111, 63, 25, 116, 10, 576, 49, 82, 70, 699, 66, 215, 201, 13, 2, 316, 595, 33, 3, 34, 112, 25, 1788, 116, 10, 696, 18, 82, 70, 335, 83, 215, 584, 39, 2, 316, 725, 66, 7, 73, 5, 1883, 42, 8, 142, 33, 111, 1110, 34, 182, 116, 889, 27, 76, 205, 7, 73, 5, 15050, 158, 598, 39, 15, 77, 121, 792, 18, 19, 13, 755, 4, 82, 316, 7, 1883, 10, 41, 5, 142, 33, 111, 1110, 34, 182, 424, 13, 105, 614, 33, 19, 13, 4902, 1788, 660, 49, 105, 641, 39, 19, 13, 233, 2, 63, 25, 660, 49, 105, 562, 13, 19, 13, 755, 151, 9, 62, 3735, 7, 89, 28, 506, 556, 60, 799, 2, 263, 756, 3865, 578, 11, 438, 5, 280, 1788, 23, 880, 2, 331, 318, 4, 352, 24, 5, 750, 975, 36, 10, 1042, 41, 5, 8, 142, 1788, 116, 23, 331, 65, 7, 5, 2417, 47, 8, 64, 116, 1, 429, 4, 3, 951, 502, 2, 626, 633, 1455, 1345, 121, 36, 1804, 1325, 182, 4, 62, 1153, 2, 68, 401, 25, 4, 82, 316, 7, 54, 32, 28, 3, 1076, 43, 1, 1110, 429]",1714.0,28930812,877
Mutational signatures efficiently identify different mutational processes underlying cancers with similar somatic mutation spectra.,Mutation research,Mutat. Res.,2017-07-19,"Compared to analyzing mutations with conventional spectra, deciphering mutational signatures provides much greater resolution of biological processes that generate somatic mutations during cancer development. Previous studies of bladder urothelial cancer (BLCA) and cervical squamous cell carcinoma (CESC) mutational signatures failed to uncover different mutational processes underlying the two cancers, which diminishes the capability of mutational signature to differentiate between the two cancers. In this study, we deciphered and compared the mutational signatures of BLCA and CESC. Four BLCA mutational signatures were deciphered from 37,098 somatic mutations of 130 exomes. Five CESC mutational signatures were deciphered from 44,206 somatic mutations of 194 exomes. Three BLCA mutational signatures were very similar to the three CESC signatures. These mutational signatures exhibited common endogenous mutational processes during BLCA and CESC development. The respective BLCA and CESC mutational signature 4 revealed the role of viral infection in both cancers. Noticeably, CESC mutational signature 4 is a novel one that has not been described in other studies. In summary, we have demonstrated the similarities and differences between BLCA and CESC by deciphering mutational signatures. This study will shed light on the use of mutational signatures to clarify the mechanisms of endogenous and exogenous carcinogens that cause somatic mutations in human cancers.",Journal Article,916.0,1.0,"Compared to analyzing mutations with conventional spectra deciphering mutational signatures provides much greater resolution of biological processes that generate somatic mutations during cancer development Previous studies of urothelial cancer BLCA and squamous cell carcinoma CESC mutational signatures failed to uncover different mutational processes underlying the two cancers which diminishes the capability of mutational signature to differentiate between the two cancers In this study we deciphered and compared the mutational signatures of BLCA and CESC Four BLCA mutational signatures were deciphered from 37,098 somatic mutations of 130 exomes Five CESC mutational signatures were deciphered from 44,206 somatic mutations of 194 exomes Three BLCA mutational signatures were very similar to the three CESC signatures These mutational signatures exhibited common endogenous mutational processes during BLCA and CESC development The respective BLCA and CESC mutational signature 4 revealed the role of viral infection in both cancers Noticeably CESC mutational signature 4 is a novel one that has not been described in other studies In summary we have demonstrated the similarities and differences between BLCA and CESC by deciphering mutational signatures This study will shed light on the use of mutational signatures to clarify the mechanisms of endogenous and exogenous carcinogens that cause somatic mutations in human cancers",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,"[72, 6, 4449, 138, 5, 809, 7683, 27305, 1619, 2210, 777, 1802, 378, 2125, 1, 1037, 1849, 17, 2562, 1119, 138, 190, 12, 193, 698, 94, 1, 1472, 12, 20111, 2, 691, 31, 134, 24303, 1619, 2210, 1551, 6, 6281, 338, 1619, 1849, 1181, 3, 100, 163, 92, 14436, 3, 6188, 1, 1619, 1651, 6, 3723, 59, 3, 100, 163, 4, 26, 45, 21, 26761, 2, 72, 3, 1619, 2210, 1, 20111, 2, 24303, 294, 20111, 1619, 2210, 11, 26761, 29, 567, 17765, 1119, 138, 1, 3431, 12233, 365, 24303, 1619, 2210, 11, 26761, 29, 584, 5956, 1119, 138, 1, 5434, 12233, 169, 20111, 1619, 2210, 11, 923, 288, 6, 3, 169, 24303, 2210, 46, 1619, 2210, 1416, 186, 2682, 1619, 1849, 190, 20111, 2, 24303, 193, 3, 3847, 20111, 2, 24303, 1619, 1651, 39, 553, 3, 200, 1, 1667, 930, 4, 110, 163, 28130, 24303, 1619, 1651, 39, 16, 8, 229, 104, 17, 71, 44, 85, 1027, 4, 127, 94, 4, 1962, 21, 47, 264, 3, 6089, 2, 362, 59, 20111, 2, 24303, 20, 27305, 1619, 2210, 26, 45, 303, 5816, 1691, 23, 3, 119, 1, 1619, 2210, 6, 3968, 3, 483, 1, 2682, 2, 4181, 8850, 17, 708, 1119, 138, 4, 171, 163]",1438.0,28942182,131
Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2017-10-28,"Survival rates for women with metastatic cervical cancer are low, with limited management options. Definitive radiation therapy (RT) for oligometastatic disease has led to prolonged survival in other malignancies, but this approach has yet to be systematically studied for cervical cancer. We evaluated 38 patients who received definitive RT to oligometastatic sites of cervical cancer at a single institution from 2002 to 2015. Patients presented with synchronous (n=9) or metachronous (n=15) oligometastatic disease to supraclavicular (SCV) nodes, or with recurrent disease in mediastinum (n=10) or lung (n=7). Three patients were treated for both SCV and mediastinal sites, and six patients were treated for para-aortic or pelvic recurrences along with oligometastatic sites. Most received chemotherapy: induction (n=5), concurrent (n=24), or adjuvant (n=5). Outcomes were evaluated via Kaplan-Meier, and associations were examined via Cox proportional hazards modeling. Median follow-up was 35.2months (range 3.1-94.7). Median overall survival (OS) was 50.7months from end of RT, with 2-year and 3-year OS rates of 74% and 65%. Median progression-free survival (PFS) was 21.7months, with 1-year and 2-year PFS rates of 63% and 48%. Of the 38 patients, 21 (55%) experienced progression, at a median time of 24.8months. There was one in-field failure. Other relapses occurred regionally (n=10) and distally (n=12), with two patients experiencing both. The most common site of recurrence following treatment of SCV disease was mediastinum (n=7). The incidence of grade3 toxicity from treatment of oligometastatic sites was <3%. Definitive RT to sites of oligometastatic cervical cancer can result in excellent local control, favorable outcomes, and even achieve long-term survival for carefully selected patients, with minimal RT-associated toxicity.",Journal Article,815.0,14.0,Survival rates for women with metastatic cancer are low with limited management options Definitive radiation therapy RT for oligometastatic disease has led to prolonged survival in other malignancies but this approach has yet to be systematically studied for cancer We evaluated 38 patients who received definitive RT to oligometastatic sites of cancer at a single institution from 2002 to 2015 Patients presented with synchronous n=9 or metachronous n=15 oligometastatic disease to supraclavicular SCV nodes or with recurrent disease in mediastinum n=10 or n=7 Three patients were treated for both SCV and mediastinal sites and six patients were treated for para-aortic or pelvic recurrences along with oligometastatic sites Most received chemotherapy induction n=5 concurrent n=24 or adjuvant n=5 Outcomes were evaluated via Kaplan-Meier and associations were examined via Cox proportional hazards modeling Median follow-up was 35.2months range 3.1-94.7 Median overall survival OS was 50.7months from end of RT with 2-year and 3-year OS rates of 74 and 65 Median progression-free survival PFS was 21.7months with 1-year and 2-year PFS rates of 63 and 48 Of the 38 patients 21 55 experienced progression at a median time of 24.8months There was one in-field failure Other relapses occurred regionally n=10 and distally n=12 with two patients experiencing both The most common site of recurrence following treatment of SCV disease was mediastinum n=7 The incidence of grade3 toxicity from treatment of oligometastatic sites was 3 Definitive RT to sites of oligometastatic cancer can result in excellent local control favorable outcomes and even achieve long-term survival for carefully selected patients with minimal RT-associated toxicity,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[25, 151, 9, 117, 5, 113, 12, 32, 154, 5, 383, 284, 838, 1057, 121, 36, 240, 9, 4101, 34, 71, 836, 6, 1069, 25, 4, 127, 441, 84, 26, 353, 71, 1145, 6, 40, 3390, 656, 9, 12, 21, 194, 519, 7, 54, 103, 1057, 240, 6, 4101, 633, 1, 12, 28, 8, 226, 731, 29, 1544, 6, 1483, 7, 917, 5, 2734, 78, 83, 15, 4796, 78, 167, 4101, 34, 6, 5804, 13661, 502, 15, 5, 387, 34, 4, 7156, 78, 79, 15, 78, 67, 169, 7, 11, 73, 9, 110, 13661, 2, 2626, 633, 2, 437, 7, 11, 73, 9, 4615, 3938, 15, 1110, 1593, 1510, 5, 4101, 633, 96, 103, 56, 504, 78, 33, 750, 78, 259, 15, 249, 78, 33, 123, 11, 194, 847, 876, 882, 2, 685, 11, 409, 847, 418, 831, 1017, 2057, 52, 166, 126, 10, 465, 15030, 184, 27, 14, 960, 67, 52, 63, 25, 118, 10, 212, 20665, 29, 396, 1, 240, 5, 18, 111, 2, 27, 111, 118, 151, 1, 794, 2, 556, 52, 91, 115, 25, 300, 10, 239, 20665, 5, 14, 111, 2, 18, 111, 300, 151, 1, 676, 2, 576, 1, 3, 519, 7, 239, 614, 592, 91, 28, 8, 52, 98, 1, 259, 29806, 125, 10, 104, 4, 1067, 496, 127, 3713, 489, 8183, 78, 79, 2, 17743, 78, 133, 5, 100, 7, 2985, 110, 3, 96, 186, 606, 1, 146, 366, 24, 1, 13661, 34, 10, 7156, 78, 67, 3, 287, 1, 14659, 155, 29, 24, 1, 4101, 633, 10, 27, 1057, 240, 6, 633, 1, 4101, 12, 122, 757, 4, 1503, 293, 182, 913, 123, 2, 871, 1359, 319, 337, 25, 9, 3900, 715, 7, 5, 1048, 240, 41, 155]",1740.0,29089122,153
3T multiparametric MRI-guided high-dose-rate combined intracavitary and interstitial adaptive brachytherapy for the treatment of cervical cancer with a novel split-ring applicator.,Brachytherapy,Brachytherapy,2017-10-31,"To evaluate the role of 3T-MRI-guided adaptive high-dose-rate (HDR) combined intracavitary and interstitial brachytherapy for cervical cancer using a novel intracavitary split-ring (ICSR) applicator adapter. We retrospectively reviewed all HDR brachytherapy cases from 2013 to 2015 using an ICSR applicator. Initial optimization was performed using 3T multiparametric MRI (mpMRI) series with an applicator in place. The mpMRI series were discretionarily acquired before subsequent fractions for possible target adaptation. When necessary, interstitial needles (ISNs) were inserted through a novel ICSR adapter or freehand. Dosimetric parameters, clinical outcomes, and toxicities were compared between groups. Seventeen patients were included, with a mean followup of 32months. An mpMRI series preceded each initial fraction and 52.9% of patients underwent 1 additional pretreatment mpMRI. Among these subsequent fractions, the high-risk clinical target volume was reduced in 80% vs. 41% without pretreatment mpMRI. Five patients had ISN placement (seven insertions) to improve extracervical target coverage. Mean D<sub>90</sub> (Gy) per fraction to the high-risk clinical target volume and intermediate-risk clinical target volume with and without an ISN were 7.51  1.07 vs. 6.14  0.52 (p= 0.028) and 6.35  0.75 vs. 5.21  0.49 (p= 0.007), respectively. Mean fractional D<sub>2cc</sub> (Gy) for organs at risk was comparable. No Grades 3-4 toxicity was reported. Disease-free survival and local control for the ICSR-ISN and ICSR-alone groups were 29.8months/80.0% and 31.2months/83.3%, respectively. The mpMRI acquisition with ICSR applicator in place immediately before HDR brachytherapy for cervical cancer guided successful adaptive treatment optimization and delivery. Our initial experience with a novel interstitial adapter for the split-ring applicator demonstrated excellent target coverage without compromising organs at risk, resulting in good local control and disease-free survival.",Journal Article,812.0,2.0,To evaluate the role of 3T-MRI-guided adaptive high-dose-rate HDR combined intracavitary and interstitial brachytherapy for cancer using a novel intracavitary split-ring ICSR applicator adapter We retrospectively reviewed all HDR brachytherapy cases from 2013 to 2015 using an ICSR applicator Initial optimization was performed using 3T multiparametric MRI mpMRI series with an applicator in place The mpMRI series were discretionarily acquired before subsequent fractions for possible target adaptation When necessary interstitial needles ISNs were inserted through a novel ICSR adapter or freehand Dosimetric parameters clinical outcomes and toxicities were compared between groups Seventeen patients were included with a mean followup of 32 months An mpMRI series preceded each initial fraction and 52.9 of patients underwent 1 additional pretreatment mpMRI Among these subsequent fractions the high-risk clinical target volume was reduced in 80 vs. 41 without pretreatment mpMRI Five patients had ISN placement seven insertions to improve extracervical target coverage Mean D sub 90 /sub Gy per fraction to the high-risk clinical target volume and intermediate-risk clinical target volume with and without an ISN were 7.51  1.07 vs. 6.14  0.52 p 0.028 and 6.35  0.75 vs. 5.21  0.49 p 0.007 respectively Mean fractional D sub 2cc /sub Gy for organs at risk was comparable No Grades 3-4 toxicity was reported Disease-free survival and local control for the ICSR-ISN and ICSR-alone groups were 29.8 months/80.0 and 31.2 months/83.3 respectively The mpMRI acquisition with ICSR applicator in place immediately before HDR brachytherapy for cancer guided successful adaptive treatment optimization and delivery Our initial experience with a novel interstitial adapter for the split-ring applicator demonstrated excellent target coverage without compromising organs at risk resulting in good local control and disease-free survival,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 3, 200, 1, 17828, 704, 1808, 2454, 64, 61, 116, 5309, 397, 9122, 2, 4543, 1536, 9, 12, 75, 8, 229, 9122, 6240, 4091, 29933, 8789, 23192, 21, 894, 446, 62, 5309, 1536, 140, 29, 1346, 6, 1483, 75, 35, 29933, 8789, 388, 3980, 10, 173, 75, 17828, 8347, 704, 9719, 988, 5, 35, 8789, 4, 3536, 3, 9719, 988, 11, 71477, 1294, 348, 706, 1550, 9, 899, 283, 7275, 198, 1493, 4543, 14393, 45508, 11, 9882, 298, 8, 229, 29933, 23192, 15, 36307, 3187, 1038, 38, 123, 2, 385, 11, 72, 59, 271, 3591, 7, 11, 159, 5, 8, 313, 3569, 1, 531, 53, 35, 9719, 988, 6083, 296, 388, 1509, 2, 653, 83, 1, 7, 208, 3567, 402, 1194, 9719, 107, 46, 706, 1550, 3, 64, 43, 38, 283, 433, 10, 405, 4, 493, 105, 605, 187, 1194, 9719, 365, 7, 42, 41893, 2613, 648, 6315, 6, 401, 38497, 283, 2139, 313, 427, 551, 424, 551, 381, 379, 1509, 6, 3, 64, 43, 38, 283, 433, 2, 919, 43, 38, 283, 433, 5, 2, 187, 35, 41893, 11, 67, 725, 810, 14, 1615, 105, 49, 213, 810, 13, 653, 19, 13, 4836, 2, 49, 465, 810, 13, 481, 105, 33, 239, 810, 13, 739, 19, 13, 1999, 106, 313, 7528, 427, 551, 71478, 551, 381, 9, 2285, 28, 43, 10, 1279, 77, 2276, 27, 39, 155, 10, 210, 34, 115, 25, 2, 293, 182, 9, 3, 29933, 41893, 2, 29933, 279, 271, 11, 462, 66, 53, 493, 13, 2, 456, 18, 53, 852, 27, 106, 3, 9719, 3405, 5, 29933, 8789, 4, 3536, 3467, 348, 5309, 1536, 9, 12, 1808, 1401, 2454, 24, 3980, 2, 989, 114, 388, 730, 5, 8, 229, 4543, 23192, 9, 3, 6240, 4091, 8789, 264, 1503, 283, 2139, 187, 6102, 2285, 28, 43, 1113, 4, 1178, 293, 182, 2, 34, 115, 25]",1933.0,29097137,223
Skull base plasmacytoma: A unique case of POEMS syndrome with a plasmacytoma causing craniocervical instability.,Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,J Clin Neurosci,2017-10-31,"Plasmacytomas, considered to be the solitary counterparts of multiple myeloma, are neoplastic monoclonal plasma cell proliferations within soft tissue or bone. Plasmacytomas often present as a collection of findings known as POEMS-syndrome (Polyneuropathy, Organomegaly, Endocrinopathy, M-Protein spike, and Skin changes). We present a report of a 47 yo male diagnosed with POEMS-syndrome secondary to a skull base plasmacytoma. The mass resulted in marked instability of the cranio-cervical junction due to bony erosion. Following an induction course of chemotherapy, he showed clinical improvement with a marked reduction in tumor size and underwent an autologous peripheral blood stem cell transplant for systemic treatment of his POEMS-syndrome. Following completion of systemic treatment, he then underwent a definitive occipital-cervical fusion without complications. His neurologic exam upon dismissal was stable with subjective improvement in left upper extremity strength. Postoperative radiographs confirmed spinal alignment and pathological examination of a small biopsy from C1 revealed benign fibrous tissue. To the best of our knowledge, this is the first report of a skull-base plasmacytoma associated with POEMS-syndrome, causing cranio-cervical instability. The approach of systemic therapy combined with temporary external fixation, followed by definitive occipital cervical fusion resulted in a good outcome for this patient.",Case Reports,812.0,0.0,Plasmacytomas considered to be the solitary counterparts of multiple are neoplastic monoclonal plasma cell proliferations within soft tissue or Plasmacytomas often present as a collection of findings known as POEMS-syndrome Polyneuropathy Organomegaly Endocrinopathy M-Protein spike and changes We present a report of a 47 yo male diagnosed with POEMS-syndrome secondary to a skull base plasmacytoma The mass resulted in marked instability of the cranio-cervical junction due to bony erosion Following an induction course of chemotherapy he showed clinical improvement with a marked reduction in tumor size and underwent an autologous peripheral blood stem cell transplant for systemic treatment of his POEMS-syndrome Following completion of systemic treatment he then underwent a definitive occipital-cervical fusion without complications His neurologic exam upon dismissal was stable with subjective improvement in left upper extremity strength Postoperative radiographs confirmed spinal alignment and pathological examination of a small biopsy from C1 revealed benign fibrous tissue To the best of our knowledge this is the first report of a skull-base plasmacytoma associated with POEMS-syndrome causing cranio-cervical instability The approach of systemic therapy combined with temporary external fixation followed by definitive occipital fusion resulted in a good outcome for this patient,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,"[13279, 515, 6, 40, 3, 3144, 3953, 1, 232, 32, 2000, 848, 554, 31, 14432, 262, 1214, 246, 15, 13279, 629, 364, 22, 8, 2442, 1, 272, 440, 22, 12007, 681, 14469, 16738, 13011, 188, 178, 10712, 2, 400, 21, 364, 8, 414, 1, 8, 662, 29207, 1045, 265, 5, 12007, 681, 568, 6, 8, 5054, 1782, 9426, 3, 782, 627, 4, 2003, 1753, 1, 3, 34721, 18237, 3322, 520, 6, 6552, 14547, 366, 35, 504, 906, 1, 56, 3174, 224, 38, 767, 5, 8, 2003, 628, 4, 30, 444, 2, 208, 35, 1028, 672, 315, 452, 31, 941, 9, 403, 24, 1, 3224, 12007, 681, 366, 1438, 1, 403, 24, 3174, 818, 208, 8, 1057, 17945, 18237, 1212, 187, 521, 3224, 2543, 6747, 1548, 44733, 10, 585, 5, 5571, 767, 4, 1712, 1726, 2678, 3671, 573, 8921, 557, 1499, 8097, 2, 1301, 1385, 1, 8, 302, 411, 29, 6801, 553, 1002, 5870, 246, 6, 3, 824, 1, 114, 922, 26, 16, 3, 157, 414, 1, 8, 5054, 1782, 9426, 41, 5, 12007, 681, 3440, 34721, 18237, 1753, 3, 353, 1, 403, 36, 397, 5, 7579, 1455, 8574, 370, 20, 1057, 17945, 1212, 627, 4, 8, 1178, 228, 9, 26, 69]",1394.0,29100675,11
Serum Immune Profiling for Early Detection of Cervical Disease.,Theranostics,Theranostics,2017-08-23,"The most recent (2012) worldwide estimates from International Agency for Research on Cancer indicate that approximately 528,000 new cases and 270,000 deaths per year are attributed to cervical cancer worldwide. The disease is preventable with HPV vaccination and with early detection and treatment of pre-invasive cervical intraepithelial neoplasia, CIN. Antibodies (Abs) to HPV proteins are under investigation as potential biomarkers for early detection. To detect circulating HPV-specific IgG Abs, we developed programmable protein arrays (NAPPA) that display the proteomes of two low-risk HPV types (HPV6 and 11) and ten oncogenic high-risk HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52 and 58). Arrays were probed with sera from women with CIN 0/I (n=78), CIN II/III (n=84), or invasive cervical cancer (ICC, n=83). Abs to any early (E) HPV protein were detected less frequently in women with CIN 0/I (23.7%) than women with CIN II/III (39.0%) and ICC (46.1%, p<0.04). Of the E Abs, anti-E7 Abs were the most frequently detected (6.6%, 19.5%, and 30.3%, respectively). The least frequently detected Abs were E1 and E2-Abs in CIN 0/I (1.3%) and E1-Abs in CIN II/III (1.2%) and ICC (7.9%). HPV16-specific Abs correlated with HPV16 DNA detected in the cervix in 0% of CIN 0/I, 21.2% of CIN II/III, and 45.5% of ICC. A significant number (29 - 73%) of E4, E7, L1, and L2 Abs had cross-reactivity between HPV types. HPV protein arrays provide a valuable high-throughput tool for measuring the breadth, specificity, and heterogeneity of the serologic response to HPV in cervical disease.",Journal Article,881.0,5.0,"The most recent 2012 worldwide estimates from International Agency for Research on Cancer indicate that approximately 528,000 new cases and 270,000 deaths per year are attributed to cancer worldwide The disease is preventable with HPV vaccination and with early detection and treatment of pre-invasive intraepithelial neoplasia CIN Antibodies Abs to HPV proteins are under investigation as potential biomarkers for early detection To detect circulating HPV-specific IgG Abs we developed programmable protein arrays NAPPA that display the proteomes of two low-risk HPV types HPV6 and 11 and ten oncogenic high-risk HPV types HPV16 18 31 33 35 39 45 51 52 and 58 Arrays were probed with sera from women with CIN 0/I n=78 CIN II/III n=84 or invasive cancer ICC n=83 Abs to any early E HPV protein were detected less frequently in women with CIN 0/I 23.7 than women with CIN II/III 39.0 and ICC 46.1 p 0.04 Of the E Abs anti-E7 Abs were the most frequently detected 6.6 19.5 and 30.3 respectively The least frequently detected Abs were E1 and E2-Abs in CIN 0/I 1.3 and E1-Abs in CIN II/III 1.2 and ICC 7.9 HPV16-specific Abs correlated with HPV16 DNA detected in the cervix in 0 of CIN 0/I 21.2 of CIN II/III and 45.5 of ICC A significant number 29 73 of E4 E7 L1 and L2 Abs had cross-reactivity between HPV types HPV protein arrays provide a valuable high-throughput tool for measuring the breadth specificity and heterogeneity of the serologic response to HPV in disease",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 96, 435, 1195, 2358, 1423, 29, 944, 8613, 9, 389, 23, 12, 1008, 17, 705, 12595, 984, 217, 140, 2, 6666, 984, 1043, 379, 111, 32, 3073, 6, 12, 2358, 3, 34, 16, 7936, 5, 933, 1915, 2, 5, 191, 638, 2, 24, 1, 671, 416, 4153, 2298, 4652, 890, 7723, 6, 933, 652, 32, 669, 940, 22, 174, 582, 9, 191, 638, 6, 1426, 1033, 933, 112, 3630, 7723, 21, 276, 13410, 178, 3923, 34999, 17, 3640, 3, 34764, 1, 100, 154, 43, 933, 630, 41407, 2, 175, 2, 1618, 1302, 64, 43, 933, 630, 4048, 203, 456, 466, 465, 587, 512, 725, 653, 2, 717, 3923, 11, 16218, 5, 4210, 29, 117, 5, 4652, 13, 70, 78, 833, 4652, 215, 316, 78, 874, 15, 416, 12, 2259, 78, 852, 7723, 6, 500, 191, 563, 933, 178, 11, 530, 299, 746, 4, 117, 5, 4652, 13, 70, 382, 67, 76, 117, 5, 4652, 215, 316, 587, 13, 2, 2259, 641, 14, 19, 13, 755, 1, 3, 563, 7723, 312, 4540, 7723, 11, 3, 96, 746, 530, 49, 49, 326, 33, 2, 201, 27, 106, 3, 506, 746, 530, 7723, 11, 6778, 2, 5036, 7723, 4, 4652, 13, 70, 14, 27, 2, 6778, 7723, 4, 4652, 215, 316, 14, 18, 2, 2259, 67, 83, 4048, 112, 7723, 438, 5, 4048, 261, 530, 4, 3, 3629, 4, 13, 1, 4652, 13, 70, 239, 18, 1, 4652, 215, 316, 2, 512, 33, 1, 2259, 8, 93, 207, 462, 803, 1, 22245, 4540, 729, 2, 5111, 7723, 42, 1383, 4601, 59, 933, 630, 933, 178, 3923, 377, 8, 2926, 64, 3643, 1515, 9, 2978, 3, 13945, 1121, 2, 1144, 1, 3, 7850, 51, 6, 933, 4, 34]",1468.0,29109779,772
Cancer incidence and mortality among young adults aged 20-39 years worldwide in 2012: a population-based study.,The Lancet. Oncology,Lancet Oncol.,2017-10-27,"To date, the burden of cancer among young adults has rarely been studied in depth. Our aim was to describe the scale and profile of cancer incidence and mortality worldwide among 20-39 year-olds, highlighting major patterns by age, sex, development level, and geographical region. We did a population-based study to quantify the burden of young adult cancers worldwide. We defined young adult cancers as those occurring between the ages of 20 and 39 years because these individuals will have passed puberty and adolescence, but not yet experienced the effects of hormonal decline, immune response deterioration, or organ dysfunction associated with chronic health conditions. Global, regional, and country-specific (n=184) data estimates of the number of new cancer cases and cancer-associated deaths that occurred in 2012 among young adults were extracted in four 5-year bands from the International Agency for Research on Cancer's GLOBOCAN 2012 for all cancers combined and for 27 major types as defined by the International Classification of Disease, tenth revision. We report the number of new cancer cases and cancer-associated deaths overall and by sex alongside corresponding age-standardised rates (ASR) per 100000 people per year. We also present results using four levels of the Human Development Index (HDI; low [least developed], medium, high, and very high [most developed]), which is a composite indicator for socioeconomic development comprising life expectancy, education, and gross national income. 975396 new cancer cases and 358392 cancer-associated deaths occurred among young adults worldwide in 2012, which equated to an ASR of 433 new cancer cases per 100000 people per year and 159 cancer-associated deaths per 100000 people per year. The burden was disproportionally greater among women and the most common cancer types overall in terms of new cases were female breast cancer, cervical cancer, thyroid cancer, leukaemia, and colorectal cancer; in terms of deaths, female breast cancer, liver cancer, leukaemia, and cervical cancer were the main contributors. When assessed by development level and geographical region, the cancer profile varied substantially; generally, the burden of infection-associated cancers was greater in regions under transition. Cancer incidence was elevated in very high-HDI regions compared with low-HDI regions (ASR 645 vs 462 cancer cases per 100000 people per year); however, the mortality burden was 3 times higher in low-HDI regions (ASR 254 vs 92 cancer-associated deaths per 100000 people per year), reflecting differences in cancer profiles and inferior outcomes. The global cancer burden among 20-39 year-olds differs from that seen in younger or older ages and varies substantially by age, sex, development level, and geographical region. Although the cancer burden is lower in this age group than that observed in older ages, the societal and economic effects remain great given the major effects of premature morbidity and mortality. Targeted surveillance, prevention, and treatment are needed to reduce the cancer burden in this underserved age group. International Agency for Research on Cancer (IARC) and European Commission's FP-7 Marie Curie Actions-People-COFUND.",Journal Article,816.0,73.0,To date the burden of cancer among young adults has rarely been studied in depth Our aim was to describe the scale and profile of cancer incidence and mortality worldwide among 20-39 year-olds highlighting major patterns by age sex development level and geographical region We did a population-based study to quantify the burden of young adult cancers worldwide We defined young adult cancers as those occurring between the ages of 20 and 39 years because these individuals will have passed puberty and adolescence but not yet experienced the effects of hormonal decline immune response deterioration or organ dysfunction associated with chronic health conditions Global regional and country-specific n=184 data estimates of the number of new cancer cases and cancer-associated deaths that occurred in 2012 among young adults were extracted in four 5-year bands from the International Agency for Research on Cancer 's GLOBOCAN 2012 for all cancers combined and for 27 major types as defined by the International Classification of Disease tenth revision We report the number of new cancer cases and cancer-associated deaths overall and by sex alongside corresponding age-standardised rates ASR per 100 000 people per year We also present results using four levels of the Human Development Index HDI low least developed medium high and very high most developed which is a composite indicator for socioeconomic development comprising life expectancy education and gross national income 975 396 new cancer cases and 358 392 cancer-associated deaths occurred among young adults worldwide in 2012 which equated to an ASR of 433 new cancer cases per 100 000 people per year and 159 cancer-associated deaths per 100 000 people per year The burden was disproportionally greater among women and the most common cancer types overall in terms of new cases were female cancer cancer cancer leukaemia and cancer in terms of deaths female cancer cancer leukaemia and cancer were the main contributors When assessed by development level and geographical region the cancer profile varied substantially generally the burden of infection-associated cancers was greater in regions under transition Cancer incidence was elevated in very high-HDI regions compared with low-HDI regions ASR 645 vs 462 cancer cases per 100 000 people per year however the mortality burden was 3 times higher in low-HDI regions ASR 254 vs 92 cancer-associated deaths per 100 000 people per year reflecting differences in cancer profiles and inferior outcomes The global cancer burden among 20-39 year-olds differs from that seen in younger or older ages and varies substantially by age sex development level and geographical region Although the cancer burden is lower in this age group than that observed in older ages the societal and economic effects remain great given the major effects of premature morbidity and mortality Targeted surveillance prevention and treatment are needed to reduce the cancer burden in this underserved age group International Agency for Research on Cancer IARC and European Commission 's FP-7 Marie Curie Actions-People-COFUND,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[6, 1244, 3, 892, 1, 12, 107, 1169, 857, 71, 2416, 85, 656, 4, 2436, 114, 1130, 10, 6, 897, 3, 1124, 2, 800, 1, 12, 287, 2, 282, 2358, 107, 179, 587, 111, 12801, 4051, 458, 764, 20, 89, 1035, 193, 301, 2, 8767, 1053, 21, 205, 8, 266, 90, 45, 6, 3091, 3, 892, 1, 1169, 780, 163, 2358, 21, 395, 1169, 780, 163, 22, 135, 1821, 59, 3, 2165, 1, 179, 2, 587, 60, 408, 46, 869, 303, 47, 11814, 10302, 2, 6964, 84, 44, 1145, 592, 3, 176, 1, 1761, 1858, 250, 51, 4451, 15, 1259, 1527, 41, 5, 442, 341, 1298, 1648, 951, 2, 5978, 112, 78, 5894, 74, 1423, 1, 3, 207, 1, 217, 12, 140, 2, 12, 41, 1043, 17, 489, 4, 1195, 107, 1169, 857, 11, 2484, 4, 294, 33, 111, 13759, 29, 3, 944, 8613, 9, 389, 23, 12, 292, 31818, 1195, 9, 62, 163, 397, 2, 9, 428, 458, 630, 22, 395, 20, 3, 944, 947, 1, 34, 27227, 5646, 21, 414, 3, 207, 1, 217, 12, 140, 2, 12, 41, 1043, 63, 2, 20, 1035, 10150, 1734, 89, 14041, 151, 29727, 379, 394, 984, 3788, 379, 111, 21, 120, 364, 99, 75, 294, 148, 1, 3, 171, 193, 558, 6676, 154, 506, 276, 3759, 64, 2, 923, 64, 96, 276, 92, 16, 8, 3308, 3287, 9, 3331, 193, 3538, 358, 3399, 1848, 2, 1789, 657, 2306, 16842, 9987, 217, 12, 140, 2, 8396, 11353, 12, 41, 1043, 489, 107, 1169, 857, 2358, 4, 1195, 92, 28625, 6, 35, 29727, 1, 32597, 217, 12, 140, 379, 394, 984, 3788, 379, 111, 2, 25416, 12, 41, 1043, 379, 394, 984, 3788, 379, 111, 3, 892, 10, 20708, 378, 107, 117, 2, 3, 96, 186, 12, 630, 63, 4, 1794, 1, 217, 140, 11, 1061, 12, 12, 12, 2001, 2, 12, 4, 1794, 1, 1043, 1061, 12, 12, 2001, 2, 12, 11, 3, 1895, 9680, 198, 275, 20, 193, 301, 2, 8767, 1053, 3, 12, 800, 2051, 2109, 1228, 3, 892, 1, 930, 41, 163, 10, 378, 4, 1374, 669, 1970, 12, 287, 10, 804, 4, 923, 64, 6676, 1374, 72, 5, 154, 6676, 1374, 29727, 71495, 105, 50334, 12, 140, 379, 394, 984, 3788, 379, 111, 137, 3, 282, 892, 10, 27, 1072, 142, 4, 154, 6676, 1374, 29727, 48866, 105, 17489, 12, 41, 1043, 379, 394, 984, 3788, 379, 111, 4777, 362, 4, 12, 1241, 2, 1663, 123, 3, 1648, 12, 892, 107, 179, 587, 111, 12801, 4990, 29, 17, 527, 4, 773, 15, 434, 2165, 2, 4037, 2109, 20, 89, 1035, 193, 301, 2, 8767, 1053, 242, 3, 12, 892, 16, 280, 4, 26, 89, 87, 76, 17, 164, 4, 434, 2165, 3, 9378, 2, 3875, 176, 918, 2797, 447, 3, 458, 176, 1, 5682, 787, 2, 282, 238, 617, 1070, 2, 24, 32, 575, 6, 969, 3, 12, 892, 4, 26, 6960, 89, 87, 944, 8613, 9, 389, 23, 12, 21501, 2, 1865, 7258, 292, 6434, 67, 23208, 21260, 5592, 3788, 71496]",3121.0,29111259,167
Predictors of quality of life improvement after surgery for metastatic tumors of the spine: prospective cohort study.,The spine journal : official journal of the North American Spine Society,Spine J,2017-11-06,"Surgical decompression and stabilization followed by radiosurgery represents an effective method for local tumor control and neurologic preservation for patients with metastatic epidural spinal cord compression (MESCC). We have previously demonstrated improvement in health-related quality of life (HrQOL) after this combined modality treatment (""hybrid therapy""). The current analysis focuses on delineation of patient-specific prognostic factors predictive of HrQOL change after combined surgery-stereotactic radiosurgery (SRS) treatment of MESCC. This is a prospective, single-center, cohort study. One hundred and eleven patients with MESCC who underwent separation surgery followed by SRS were included. Prognostic factors associated with improved patient-reported outcome (PRO) measures. Patient-reported outcome tools, that is, Brief Pain Inventory (BPI) and MD Anderson Symptom Inventory-Spine Tumor (MDASI-SP), both validated in the cancer population, were prospectively collected. Numeric prognostic factors were correlated with PRO measures using the Spearman rank correlation coefficient. Categorical prognostic factors were correlated with PRO measures using the Wilcoxon two-sample test (for two categories) or the Kruskal-Wallis test (for three or more categories). All statistical tests were two-sided with a level of significance <.05 for correlation of prognostic factors with PRO constructs and a level of significance <.0014 for correlation of prognostic factors with PRO items. Statistical analyses were done in SAS (version 9.4, Cary, NC, USA). One hundred and eleven patients were included in this analysis. Patients with lower preoperative Medical Research Council (MRC) motor scores experienced a greater decrease in symptom interference (BPI interference construct (p=.03) and individual functional measures including general activity (p=.001), walking (p=.001), and normal work (p=.006)). Lumbar location was associated with better outcomes than cervical or thoracic as noted on the BPI pain experience construct (p=.03) and MDASI-SP interference (p=.01) and core symptom (p=.002) constructs. Patients with American Spinal Injury Association (ASIA) scores of C or D benefit more than those with ASIA E on BPI interference construct (p=.04). Patients with higher Eastern Cooperative Oncology Group (ECOG) scores at presentation benefit more than those with low ECOG scores on MDASI-SP interference construct (p=.03). Women benefit more than men on BPI interference (p=.03) and pain experience (p=.04) constructs. Patients with prior spinal surgery at the current level of interest benefit less than those who are nave surgical patients in MDASI-SP interference construct (p=.04). Delineation of patient characteristics associated with HrQOL improvement provides crucial information for patient selection, patient education, and setting treatment expectations. For patients with MESCC treated with hybrid therapy using surgery and radiosurgery, the presence of neurologic deficits and diminished performance status, lumbar tumor level, and female gender were associated with greater PRO improvement.",Journal Article,806.0,9.0,Surgical decompression and stabilization followed by radiosurgery represents an effective method for local tumor control and neurologic preservation for patients with metastatic epidural spinal cord compression MESCC We have previously demonstrated improvement in health-related quality of life HrQOL after this combined modality treatment `` hybrid therapy '' The current analysis focuses on delineation of patient-specific prognostic factors predictive of HrQOL change after combined surgery-stereotactic radiosurgery SRS treatment of MESCC This is a prospective single-center cohort study One hundred and eleven patients with MESCC who underwent separation surgery followed by SRS were included Prognostic factors associated with improved patient-reported outcome PRO measures Patient-reported outcome tools that is Brief Pain Inventory BPI and MD Anderson Symptom Inventory-Spine Tumor MDASI-SP both validated in the cancer population were prospectively collected Numeric prognostic factors were correlated with PRO measures using the Spearman rank correlation coefficient Categorical prognostic factors were correlated with PRO measures using the Wilcoxon two-sample test for two categories or the Kruskal-Wallis test for three or more categories All statistical tests were two-sided with a level of significance .05 for correlation of prognostic factors with PRO constructs and a level of significance .0014 for correlation of prognostic factors with PRO items Statistical analyses were done in SAS version 9.4 Cary NC USA One hundred and eleven patients were included in this analysis Patients with lower preoperative Medical Research Council MRC motor scores experienced a greater decrease in symptom interference BPI interference construct p=.03 and individual functional measures including general activity p=.001 walking p=.001 and normal work p=.006 Lumbar location was associated with better outcomes than or thoracic as noted on the BPI pain experience construct p=.03 and MDASI-SP interference p=.01 and core symptom p=.002 constructs Patients with American Spinal Injury Association ASIA scores of C or D benefit more than those with ASIA E on BPI interference construct p=.04 Patients with higher Eastern Cooperative Oncology Group ECOG scores at presentation benefit more than those with low ECOG scores on MDASI-SP interference construct p=.03 Women benefit more than men on BPI interference p=.03 and pain experience p=.04 constructs Patients with prior spinal surgery at the current level of interest benefit less than those who are nave surgical patients in MDASI-SP interference construct p=.04 Delineation of patient characteristics associated with HrQOL improvement provides crucial information for patient selection patient education and setting treatment expectations For patients with MESCC treated with hybrid therapy using surgery and radiosurgery the presence of neurologic deficits and diminished performance status lumbar tumor level and female gender were associated with greater PRO improvement,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[221, 7638, 2, 3184, 370, 20, 2192, 1449, 35, 323, 596, 9, 293, 30, 182, 2, 2543, 2224, 9, 7, 5, 113, 5844, 1499, 1885, 3481, 9001, 21, 47, 373, 264, 767, 4, 341, 139, 372, 1, 358, 2534, 50, 26, 397, 1396, 24, 4542, 36, 522, 3, 291, 65, 3026, 23, 5529, 1, 69, 112, 177, 130, 464, 1, 2534, 707, 50, 397, 152, 1729, 2192, 1429, 24, 1, 9001, 26, 16, 8, 482, 226, 574, 180, 45, 104, 1128, 2, 2627, 7, 5, 9001, 54, 208, 5422, 152, 370, 20, 1429, 11, 159, 177, 130, 41, 5, 231, 69, 210, 228, 1805, 1018, 69, 210, 228, 1896, 17, 16, 3190, 559, 3818, 9699, 2, 2244, 1929, 934, 3818, 2342, 30, 5288, 4074, 110, 938, 4, 3, 12, 266, 11, 1143, 786, 10090, 177, 130, 11, 438, 5, 1805, 1018, 75, 3, 5061, 1026, 816, 3200, 5982, 177, 130, 11, 438, 5, 1805, 1018, 75, 3, 3896, 100, 1000, 412, 9, 100, 1996, 15, 3, 8800, 8875, 412, 9, 169, 15, 80, 1996, 62, 1050, 895, 11, 100, 1689, 5, 8, 301, 1, 724, 474, 9, 816, 1, 177, 130, 5, 1805, 5500, 2, 8, 301, 1, 724, 11408, 9, 816, 1, 177, 130, 5, 1805, 2980, 1050, 318, 11, 1822, 4, 8265, 2256, 83, 39, 23376, 5480, 2706, 104, 1128, 2, 2627, 7, 11, 159, 4, 26, 65, 7, 5, 280, 498, 484, 389, 9474, 10976, 3482, 703, 592, 8, 378, 775, 4, 934, 3182, 9699, 3182, 3883, 19, 680, 2, 797, 583, 1018, 141, 1083, 128, 19, 144, 7467, 19, 144, 2, 295, 1357, 19, 1861, 6187, 1147, 10, 41, 5, 380, 123, 76, 15, 2098, 22, 1051, 23, 3, 9699, 559, 730, 3883, 19, 680, 2, 5288, 4074, 3182, 19, 355, 2, 1793, 934, 19, 1111, 5500, 7, 5, 597, 1499, 2730, 248, 5958, 703, 1, 256, 15, 427, 247, 80, 76, 135, 5, 5958, 563, 23, 9699, 3182, 3883, 19, 755, 7, 5, 142, 2118, 1690, 413, 87, 2351, 703, 28, 1031, 247, 80, 76, 135, 5, 154, 2351, 703, 23, 5288, 4074, 3182, 3883, 19, 680, 117, 247, 80, 76, 325, 23, 9699, 3182, 19, 680, 2, 559, 730, 19, 755, 5500, 7, 5, 324, 1499, 152, 28, 3, 291, 301, 1, 1333, 247, 299, 76, 135, 54, 32, 2809, 221, 7, 4, 5288, 4074, 3182, 3883, 19, 755, 5529, 1, 69, 374, 41, 5, 2534, 767, 777, 2653, 487, 9, 69, 881, 69, 1848, 2, 546, 24, 5591, 9, 7, 5, 9001, 73, 5, 4542, 36, 75, 152, 2, 2192, 3, 463, 1, 2543, 2752, 2, 2849, 528, 156, 6187, 30, 301, 2, 1061, 1632, 11, 41, 5, 378, 1805, 767]",3030.0,29122701,761
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma.,JAMA oncology,JAMA Oncol,2018-07-12,"Based on evidence of human papillomavirus (HPV)-induced immune evasion, immunotherapy may be an attractive strategy in cervical cancer. Ipilimumab is a fully humanized monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4), which acts to downregulate the T-cell immune response. To assess the safety and antitumor activity of ipilimumab in recurrent cervical cancer. A multicenter trial was designed for patients with metastatic cervical cancer (squamous cell carcinoma or adenocarcinoma) with measurable disease and progression after at least 1 line of platinum chemotherapy. A run-in safety cohort using ipilimumab, 3 mg/kg, every 21 days for 4 cycles in 6 patients was followed by a phase II cohort of ipilimumab, 10 mg/kg, every 21 days for 4 cycles and then 4 cycles of maintenance therapy every 12 weeks for patients demonstrating radiologic response or stabilization. Immune correlative studies were performed on peripheral blood before and after therapy on archival tissue and fresh tumor obtained prior to registration and 7 days after cycle 2. The study was conducted from December 3, 2012, to September 15, 2014. The data were analyzed from April 2016 to June 2016 and in July 2017. The primary end points were safety and objective response rate. Immune analyses were performed on blood and tumor tissue. A total of 42 women (median age, 49 years; range, 23-78 years) were enrolled (29 [69%] squamous cell cervical cancer and 13 [31%] adenocarcinoma; 37 [93%] of 40 patients with tissue available for analysis had HPV-positive confirmation; there was no archival tissue for 2 women). Grade 3 toxic effects included diarrhea in 4 patients, 3 of whom had colitis. Of 34 patients evaluated for best response (Response Evaluation Criteria in Solid Tumors, version 1.1), 1 patient had partial response and 10 had stable disease. The median progression-free survival and overall survival were 2.5 months (95% CI, 2.1-3.2 months) and 8.5 months (95% CI, 3.6-not reached; 1 patient was still alive), respectively. Intratumoral pretreatment CD3, CD4, CD8, FoxP3, indoleamine 2,3-dioxygenase, and programmed cell death ligand 1 (PD-L1) expression was not predictive of benefit and did not significantly change with treatment. Multicolor flow cytometry on peripheral lymphocytes revealed a treatment-dependent increase of inducible T-cell costimulator, human leukocyte antigen-antigen D related, and PD-1 during initial treatment, which returned to baseline during maintenance. Ipilimumab was tolerable in this population but did not show significant single-agent activity. Immune changes were induced by anti-CTLA-4 therapy but did not correlate with clinical activity. Changes in these markers may guide further treatment strategies.",Journal Article,558.0,21.0,"Based on evidence of human papillomavirus HPV -induced immune evasion immunotherapy may be an attractive strategy in cancer Ipilimumab is a fully humanized monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 CTLA-4 which acts to downregulate the T-cell immune response To assess the safety and antitumor activity of ipilimumab in recurrent cancer A multicenter trial was designed for patients with metastatic cancer squamous cell carcinoma or adenocarcinoma with measurable disease and progression after at least 1 line of platinum chemotherapy A run-in safety cohort using ipilimumab 3 mg/kg every 21 days for 4 cycles in 6 patients was followed by a phase II cohort of ipilimumab 10 mg/kg every 21 days for 4 cycles and then 4 cycles of maintenance therapy every 12 weeks for patients demonstrating radiologic response or stabilization Immune correlative studies were performed on peripheral blood before and after therapy on archival tissue and fresh tumor obtained prior to registration and 7 days after cycle 2 The study was conducted from December 3 2012 to September 15 2014 The data were analyzed from April 2016 to June 2016 and in July 2017 The primary end points were safety and objective response rate Immune analyses were performed on blood and tumor tissue A total of 42 women median age 49 years range 23-78 years were enrolled 29 69 squamous cell cancer and 13 31 adenocarcinoma 37 93 of 40 patients with tissue available for analysis had HPV-positive confirmation there was no archival tissue for 2 women Grade 3 toxic effects included diarrhea in 4 patients 3 of whom had colitis Of 34 patients evaluated for best response Response Evaluation Criteria in Solid Tumors version 1.1 1 patient had partial response and 10 had stable disease The median progression-free survival and overall survival were 2.5 months 95 CI 2.1-3.2 months and 8.5 months 95 CI 3.6-not reached 1 patient was still alive respectively Intratumoral pretreatment CD3 CD4 CD8 FoxP3 indoleamine 2,3-dioxygenase and programmed cell death ligand 1 PD-L1 expression was not predictive of benefit and did not significantly change with treatment Multicolor flow cytometry on peripheral lymphocytes revealed a treatment-dependent increase of inducible T-cell costimulator human leukocyte antigen-antigen D related and PD-1 during initial treatment which returned to baseline during maintenance Ipilimumab was tolerable in this population but did not show significant single-agent activity Immune changes were induced by anti-CTLA-4 therapy but did not correlate with clinical activity Changes in these markers may guide further treatment strategies",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[90, 23, 241, 1, 171, 3242, 933, 277, 250, 5351, 726, 68, 40, 35, 3059, 692, 4, 12, 1306, 16, 8, 1910, 3619, 848, 548, 17, 2860, 759, 102, 1448, 448, 39, 2127, 39, 92, 4459, 6, 10261, 3, 102, 31, 250, 51, 6, 423, 3, 367, 2, 579, 128, 1, 1306, 4, 387, 12, 8, 1570, 160, 10, 1114, 9, 7, 5, 113, 12, 691, 31, 134, 15, 449, 5, 1884, 34, 2, 91, 50, 28, 506, 14, 328, 1, 828, 56, 8, 7726, 4, 367, 180, 75, 1306, 27, 81, 503, 454, 239, 162, 9, 39, 410, 4, 49, 7, 10, 370, 20, 8, 124, 215, 180, 1, 1306, 79, 81, 503, 454, 239, 162, 9, 39, 410, 2, 818, 39, 410, 1, 1146, 36, 454, 133, 244, 9, 7, 2219, 2812, 51, 15, 3184, 250, 3679, 94, 11, 173, 23, 672, 315, 348, 2, 50, 36, 23, 3967, 246, 2, 4329, 30, 683, 324, 6, 3169, 2, 67, 162, 50, 417, 18, 3, 45, 10, 426, 29, 1397, 27, 1195, 6, 2636, 167, 1409, 3, 74, 11, 311, 29, 2292, 1390, 6, 1924, 1390, 2, 4, 2066, 1759, 3, 86, 396, 862, 11, 367, 2, 461, 51, 116, 250, 318, 11, 173, 23, 315, 2, 30, 246, 8, 181, 1, 595, 117, 52, 89, 739, 60, 184, 382, 833, 60, 11, 346, 462, 790, 691, 31, 12, 2, 233, 456, 449, 567, 966, 1, 327, 7, 5, 246, 390, 9, 65, 42, 933, 109, 3551, 125, 10, 77, 3967, 246, 9, 18, 117, 88, 27, 1812, 176, 159, 1172, 4, 39, 7, 27, 1, 953, 42, 4132, 1, 562, 7, 194, 9, 824, 51, 51, 451, 371, 4, 537, 57, 2256, 14, 14, 14, 69, 42, 450, 51, 2, 79, 42, 585, 34, 3, 52, 91, 115, 25, 2, 63, 25, 11, 18, 33, 53, 48, 58, 18, 14, 27, 18, 53, 2, 66, 33, 53, 48, 58, 27, 49, 44, 1300, 14, 69, 10, 1234, 1701, 106, 2074, 1194, 3117, 1440, 968, 3548, 10566, 18, 27, 9175, 2, 1846, 31, 273, 1232, 14, 333, 729, 55, 10, 44, 464, 1, 247, 2, 205, 44, 97, 707, 5, 24, 11920, 1412, 1914, 23, 672, 1594, 553, 8, 24, 470, 344, 1, 2877, 102, 31, 23705, 171, 3627, 448, 448, 427, 139, 2, 333, 14, 190, 388, 24, 92, 5157, 6, 330, 190, 1146, 1306, 10, 2668, 4, 26, 266, 84, 205, 44, 514, 93, 226, 420, 128, 250, 400, 11, 277, 20, 312, 2127, 39, 36, 84, 205, 44, 1513, 5, 38, 128, 400, 4, 46, 525, 68, 1597, 195, 24, 422]",2642.0,29145543,413
Development of a goat model for evaluation of withaferin A: Cervical implants for the treatment of cervical intraepithelial neoplasia.,Experimental and molecular pathology,Exp. Mol. Pathol.,2017-11-21,"Cervical cancer is caused by human papillomavirus (HPV). The disease develops over many years through a series of precancerous lesions. Cervical cancer can be prevented by HPV-vaccination, screening and treatment of precancer before development of cervical cancer. The treatment of high-grade cervical dysplasia (CIN <sup>2+</sup>) has traditionally been by cervical conization. Surgical procedures are associated with increased risk of undesirable side effects including bleeding, infection, scarring (stenosis), infertility and complications in later pregnancies. An inexpensive, non-invasive method of delivering therapeutics locally will be favorable to treat precancerous cervical lesions without damaging healthy tissue. The feasibility and safety of a sustained, continuous drug-releasing cervical polymeric implant for use in clinical trials was studied using a large animal model. The goat (Capra hircus), non-pregnant adult female Boer goats, was chosen due to similarities in cervical dimensions to the human. Estrus was induced with progesterone CIDR vaginal implants for 14days followed by the administration of chorionic gonadotropins 48h prior to removal of the progesterone implants to relax the cervix to allow for the placement of the cervical implant. Cervical implants, containing 2% and 4% withaferin A (WFA), with 8 coats of blank polymer, provided sustained release for a long duration and were used for the animal study. The 'mushroom'-shaped cervical polymeric implant, originally designed for women required redesigning to be accommodated within the goat cervix. The cervical implants were well tolerated by the animals with no obvious evidence of discomfort, systemic or local inflammation or toxicity. In addition, we developed a new method to analyze tissue WFA levels by solvent extractions and LS/MS-MS. WFA was found to be localized to the target and adjacent tissues with 12-16ng WFA/g tissue, with essentially no detectable WFA in distant tissues. This study suggests that the goat is a good large animal model for the future development and evaluation of therapeutic efficacy of continuous local drug delivery by cervical polymeric implants to treat precancerous cervical lesions.",Journal Article,791.0,1.0,cancer is caused by human papillomavirus HPV The disease develops over many years through a series of precancerous lesions cancer can be prevented by HPV-vaccination screening and treatment of precancer before development of cancer The treatment of high-grade dysplasia CIN sup 2+ /sup has traditionally been by conization Surgical procedures are associated with increased risk of undesirable side effects including bleeding infection scarring stenosis infertility and complications in later pregnancies An inexpensive non-invasive method of delivering therapeutics locally will be favorable to treat precancerous lesions without damaging healthy tissue The feasibility and safety of a sustained continuous drug-releasing polymeric implant for use in clinical trials was studied using a large animal model The goat Capra hircus non-pregnant adult female Boer goats was chosen due to similarities in dimensions to the human Estrus was induced with progesterone CIDR implants for 14days followed by the administration of chorionic gonadotropins 48h prior to removal of the progesterone implants to relax the cervix to allow for the placement of the implant implants containing 2 and 4 withaferin A WFA with 8 coats of blank polymer provided sustained release for a long duration and were used for the animal study The 'mushroom'-shaped polymeric implant originally designed for women required redesigning to be accommodated within the goat cervix The implants were well tolerated by the animals with no obvious evidence of discomfort systemic or local inflammation or toxicity In addition we developed a new method to analyze tissue WFA levels by solvent extractions and LS/MS-MS. WFA was found to be localized to the target and adjacent tissues with 12-16ng WFA/g tissue with essentially no detectable WFA in distant tissues This study suggests that the goat is a good large animal model for the future development and evaluation of therapeutic efficacy of continuous local drug delivery by polymeric implants to treat precancerous lesions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 1546, 20, 171, 3242, 933, 3, 34, 4734, 252, 445, 60, 298, 8, 988, 1, 6605, 406, 12, 122, 40, 3902, 20, 933, 1915, 453, 2, 24, 1, 12380, 348, 193, 1, 12, 3, 24, 1, 64, 88, 2253, 4652, 172, 18, 172, 71, 4206, 85, 20, 8755, 221, 1369, 32, 41, 5, 101, 43, 1, 13572, 1152, 176, 141, 2294, 930, 13542, 6935, 5901, 2, 521, 4, 1559, 8746, 35, 8168, 220, 416, 596, 1, 4790, 1943, 795, 303, 40, 913, 6, 943, 6605, 406, 187, 4904, 1331, 246, 3, 1437, 2, 367, 1, 8, 2275, 1314, 234, 5586, 9770, 4194, 9, 119, 4, 38, 143, 10, 656, 75, 8, 375, 2026, 202, 3, 29075, 29617, 71604, 220, 6086, 780, 1061, 71605, 27348, 10, 4695, 520, 6, 6089, 4, 6190, 6, 3, 171, 71606, 10, 277, 5, 2143, 71607, 5966, 9, 50088, 370, 20, 3, 634, 1, 10420, 34749, 41659, 324, 6, 2829, 1, 3, 2143, 5966, 6, 34731, 3, 3629, 6, 1700, 9, 3, 2613, 1, 3, 4194, 5966, 1101, 18, 2, 39, 21604, 8, 14381, 5, 66, 49907, 1, 16024, 5570, 1052, 2275, 2008, 9, 8, 319, 654, 2, 11, 95, 9, 3, 2026, 45, 3, 71608, 8902, 9770, 4194, 5045, 1114, 9, 117, 616, 41909, 6, 40, 50705, 262, 3, 29075, 3629, 3, 5966, 11, 149, 421, 20, 3, 2258, 5, 77, 6228, 241, 1, 7381, 403, 15, 293, 1815, 15, 155, 4, 352, 21, 276, 8, 217, 596, 6, 1992, 246, 14381, 148, 20, 10614, 20462, 2, 3153, 2307, 2307, 14381, 10, 204, 6, 40, 909, 6, 3, 283, 2, 2086, 742, 5, 133, 71609, 14381, 499, 246, 5, 7257, 77, 2083, 14381, 4, 626, 742, 26, 45, 844, 17, 3, 29075, 16, 8, 1178, 375, 2026, 202, 9, 3, 508, 193, 2, 451, 1, 189, 209, 1, 1314, 293, 234, 989, 20, 9770, 5966, 6, 943, 6605, 406]",2039.0,29157955,158
Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2017-11-27,"Purpose To update the guideline recommendations on the use of larynx-preservation strategies in the treatment of laryngeal cancer. Methods An Expert Panel updated the systematic review of the literature for the period from January 2005 to May 2017. Results The panel confirmed that the use of a larynx-preservation approach for appropriately selected patients does not compromise survival. No larynx-preservation approach offered a survival advantage compared with total laryngectomy and adjuvant therapy as indicated. Changes were supported for the use of endoscopic surgical resection in patients with limited disease (T1, T2) and for initial total laryngectomy in patients with T4a disease or with severe pretreatment laryngeal dysfunction. New recommendations for positron emission tomography imaging for the evaluation of regional nodes after treatment and best measures for evaluating voice and swallowing function were added. Recommendations Patients with T1, T2 laryngeal cancer should be treated initially with intent to preserve the larynx by using endoscopic resection or radiation therapy, with either leading to similar outcomes. For patients with locally advanced (T3, T4) disease, organ-preservation surgery, combined chemotherapy and radiation, or radiation alone offer the potential for larynx preservation without compromising overall survival. For selected patients with extensive T3 or large T4a lesions and/or poor pretreatment laryngeal function, better survival rates and quality of life may be achieved with total laryngectomy. Patients with clinically involved regional cervical nodes (N+) who have a complete clinical and radiologic imaging response after chemoradiation do not require elective neck dissection. All patients should undergo a pretreatment baseline assessment of voice and swallowing function and receive counseling with regard to the potential impact of treatment options on voice, swallowing, and quality of life. Additional information is available at www.asco.org/head-neck-cancer-guidelines and www.asco.org/guidelineswiki .",Journal Article,785.0,27.0,Purpose To update the guideline recommendations on the use of larynx-preservation strategies in the treatment of cancer Methods An Expert Panel updated the systematic review of the literature for the period from January 2005 to May 2017 Results The panel confirmed that the use of a larynx-preservation approach for appropriately selected patients does not compromise survival No larynx-preservation approach offered a survival advantage compared with total laryngectomy and adjuvant therapy as indicated Changes were supported for the use of endoscopic surgical resection in patients with limited disease T1 T2 and for initial total laryngectomy in patients with T4a disease or with severe pretreatment dysfunction New recommendations for positron emission tomography imaging for the evaluation of regional nodes after treatment and best measures for evaluating voice and swallowing function were added Recommendations Patients with T1 T2 cancer should be treated initially with intent to preserve the larynx by using endoscopic resection or radiation therapy with either leading to similar outcomes For patients with locally advanced T3 T4 disease organ-preservation surgery combined chemotherapy and radiation or radiation alone offer the potential for larynx preservation without compromising overall survival For selected patients with extensive T3 or large T4a lesions and/or poor pretreatment function better survival rates and quality of life may be achieved with total laryngectomy Patients with clinically involved regional nodes N+ who have a complete clinical and radiologic imaging response after chemoradiation do not require elective dissection All patients should undergo a pretreatment baseline assessment of voice and swallowing function and receive counseling with regard to the potential impact of treatment options on voice swallowing and quality of life Additional information is available at www.asco.org/head-neck-cancer-guidelines and www.asco.org/guidelineswiki,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[743, 6, 2991, 3, 2009, 883, 23, 3, 119, 1, 4308, 2224, 422, 4, 3, 24, 1, 12, 636, 35, 2005, 993, 2939, 3, 1556, 206, 1, 3, 789, 9, 3, 727, 29, 1024, 1242, 6, 68, 1759, 99, 3, 993, 557, 17, 3, 119, 1, 8, 4308, 2224, 353, 9, 4544, 715, 7, 1097, 44, 4665, 25, 77, 4308, 2224, 353, 2216, 8, 25, 1874, 72, 5, 181, 8391, 2, 249, 36, 22, 1103, 400, 11, 2708, 9, 3, 119, 1, 2056, 221, 170, 4, 7, 5, 383, 34, 1534, 1786, 2, 9, 388, 181, 8391, 4, 7, 5, 10626, 34, 15, 5, 905, 1194, 1527, 217, 883, 9, 1900, 1799, 872, 270, 9, 3, 451, 1, 951, 502, 50, 24, 2, 824, 1018, 9, 1435, 6284, 2, 6129, 343, 11, 1953, 883, 7, 5, 1534, 1786, 12, 257, 40, 73, 1625, 5, 1697, 6, 6783, 3, 4308, 20, 75, 2056, 170, 15, 121, 36, 5, 361, 1049, 6, 288, 123, 9, 7, 5, 795, 131, 2065, 2463, 34, 1259, 2224, 152, 397, 56, 2, 121, 15, 121, 279, 1918, 3, 174, 9, 4308, 2224, 187, 6102, 63, 25, 9, 715, 7, 5, 1344, 2065, 15, 375, 10626, 406, 2, 15, 334, 1194, 343, 380, 25, 151, 2, 372, 1, 358, 68, 40, 513, 5, 181, 8391, 7, 5, 505, 646, 951, 502, 78, 54, 47, 8, 236, 38, 2, 2812, 270, 51, 50, 975, 1022, 44, 1353, 4700, 1161, 62, 7, 257, 1251, 8, 1194, 330, 455, 1, 6284, 2, 6129, 343, 2, 560, 2011, 5, 2539, 6, 3, 174, 345, 1, 24, 838, 23, 6284, 6129, 2, 372, 1, 358, 402, 487, 16, 390, 28, 3064, 2697, 5598, 718, 4606, 12, 677, 2, 3064, 2697, 5598, 16590]",1987.0,29172863,580
Cervical Cancer Screening and Follow-Up Procedures in Women Age <21 Years Following New Screening Guidelines.,The Journal of adolescent health : official publication of the Society for Adolescent Medicine,J Adolesc Health,2017-11-22,"The 2009 American College of Obstetricians and Gynecologists guidelines recommended no cervical cancer screening before age 21 years. We examined changes in screening, diagnostic, and treatment procedures for cervical dysplasia after guideline introduction, and cost implications. We studied Davidson County women aged 18-20 years, enrolled in Tennessee Medicaid, 2006-2014. We identified those with at least one Papanicolaou (Pap) test, human papillomavirus detection test, colposcopy, or excisional dysplasia treatment annually via Current Procedural Terminology coding. We used rate ratios with 95% confidence intervals to compare annual changes in procedure and treatment rates from 2014 to 2006. We counted total outcomes to estimate annual costs based on 2014 average procedural costs. From 2006 to 2014, about 3,800 Davidson County women aged 18-20 years were enrolled in Medicaid annually. From 2006 to 2014, there were declines in Pap tests from 55.6 to 15.2 per 100 women (rate ratio .27, 95% confidence interval .25-.3); human papillomavirus tests from 13.8 to 5.9 per 100 (.42, .36-.5); colposcopy from 9.4 to 1.1 per 100 (.12, .08-.17); and dysplasia treatment from 1.1 to 0 per 100. The estimated cost of screening and procedures fell from $53 to $8 per enrolled woman, not accounting for changes in visits or complications associated with these procedures. The 2009 screening guidelines were associated with major declines in screening, diagnostic, and treatment procedures for cervical dysplasia. Minimum estimated procedure and treatment costs saved were $45 per enrolled woman age 18-20 years.",Journal Article,790.0,0.0,"The 2009 American College of Obstetricians and Gynecologists guidelines recommended no cancer screening before age 21 years We examined changes in screening diagnostic and treatment procedures for dysplasia after guideline introduction and cost implications We studied Davidson County women aged 18-20 years enrolled in Tennessee Medicaid 2006-2014 We identified those with at least one Papanicolaou Pap test human papillomavirus detection test colposcopy or excisional dysplasia treatment annually via Current Procedural Terminology coding We used rate ratios with 95 confidence intervals to compare annual changes in procedure and treatment rates from 2014 to 2006 We counted total outcomes to estimate annual costs based on 2014 average procedural costs From 2006 to 2014 about 3,800 Davidson County women aged 18-20 years were enrolled in Medicaid annually From 2006 to 2014 there were declines in Pap tests from 55.6 to 15.2 per 100 women rate ratio .27 95 confidence interval .25-.3 human papillomavirus tests from 13.8 to 5.9 per 100 .42 .36-.5 colposcopy from 9.4 to 1.1 per 100 .12 .08-.17 and dysplasia treatment from 1.1 to 0 per 100 The estimated cost of screening and procedures fell from 53 to 8 per enrolled woman not accounting for changes in visits or complications associated with these procedures The 2009 screening guidelines were associated with major declines in screening diagnostic and treatment procedures for dysplasia Minimum estimated procedure and treatment costs saved were 45 per enrolled woman age 18-20 years",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1238, 597, 2979, 1, 21015, 2, 14854, 677, 793, 77, 12, 453, 348, 89, 239, 60, 21, 409, 400, 4, 453, 752, 2, 24, 1369, 9, 2253, 50, 2009, 2456, 2, 835, 1268, 21, 656, 28744, 5152, 117, 1032, 203, 179, 60, 346, 4, 23319, 2843, 1324, 1409, 21, 108, 135, 5, 28, 506, 104, 10416, 4290, 412, 171, 3242, 638, 412, 9946, 15, 6488, 2253, 24, 4226, 847, 291, 8492, 3462, 3097, 21, 95, 116, 1137, 5, 48, 307, 1582, 6, 932, 2114, 400, 4, 1299, 2, 24, 151, 29, 1409, 6, 1324, 21, 12252, 181, 123, 6, 1191, 2114, 1201, 90, 23, 1409, 1011, 8492, 1201, 29, 1324, 6, 1409, 545, 27, 2796, 28744, 5152, 117, 1032, 203, 179, 60, 11, 346, 4, 2843, 4226, 29, 1324, 6, 1409, 125, 11, 4264, 4, 4290, 895, 29, 614, 49, 6, 167, 18, 379, 394, 117, 116, 197, 428, 48, 307, 268, 243, 27, 171, 3242, 895, 29, 233, 66, 6, 33, 83, 379, 394, 595, 511, 33, 9946, 29, 83, 39, 6, 14, 14, 379, 394, 133, 1592, 269, 2, 2253, 24, 29, 14, 14, 6, 13, 379, 394, 3, 661, 835, 1, 453, 2, 1369, 7689, 29, 699, 6, 66, 379, 346, 2854, 44, 3116, 9, 400, 4, 2690, 15, 521, 41, 5, 46, 1369, 3, 1238, 453, 677, 11, 41, 5, 458, 4264, 4, 453, 752, 2, 24, 1369, 9, 2253, 2499, 661, 1299, 2, 24, 1201, 11806, 11, 512, 379, 346, 2854, 89, 203, 179, 60]",1541.0,29174874,78
Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study.,British journal of cancer,Br. J. Cancer,2017-11-28,"Based primarily on studies concerning early-stage tumours (treated surgically), and locally advanced disease (treated with chemoradiation), the prognosis for women with adenocarcinoma (AC) or adenosquamous (AS) carcinoma has been reported to be poorer than those with squamous cell carcinoma (SCCA) of the cervix. It is unclear whether differences in prognosis also persist in the setting of recurrent or metastatic disease treated using chemotherapy doublets with or without bevacizumab. Cases were pooled from three Gynaecologic Oncology Group randomised phase III trials of chemotherapy doublets. Pearson's test was used to evaluate response rate (RR) of AC/AS vs SCCA, Kaplan-Meier method to estimate progression-free survival (PFS) and overall survival (OS), and Cox proportional hazards model to estimate the impact of histology on PFS and OS. Of 781 evaluable patients, 77% (N=599) had SCCA and 23% (N=182) AC/AS. There were no significant differences in RRs between histologic subgroups. The adjusted hazard ratio (HR) for death for SCCA vs AC/AS was 1.13 (95% CI 0.93, 1.38 P=0.23). When comparing SC/AS (N=661, 85%) to AC alone (N=120, 15%), the adjusted HR for death was 1.23 (95% CI 0.97, 1.57, P=0.09). AC/AS and SCCA have similar survival in recurrent or metastatic cervical carcinoma when treated with chemotherapy doublets.",Journal Article,784.0,2.0,Based primarily on studies concerning early-stage tumours treated surgically and locally advanced disease treated with chemoradiation the prognosis for women with adenocarcinoma AC or adenosquamous AS carcinoma has been reported to be poorer than those with squamous cell carcinoma SCCA of the cervix It is unclear whether differences in prognosis also persist in the setting of recurrent or metastatic disease treated using chemotherapy doublets with or without bevacizumab Cases were pooled from three Gynaecologic Oncology Group randomised phase III trials of chemotherapy doublets Pearson 's test was used to evaluate response rate RR of AC/AS vs SCCA Kaplan-Meier method to estimate progression-free survival PFS and overall survival OS and Cox proportional hazards model to estimate the impact of histology on PFS and OS Of 781 evaluable patients 77 N=599 had SCCA and 23 N=182 AC/AS There were no significant differences in RRs between histologic subgroups The adjusted hazard ratio HR for death for SCCA vs AC/AS was 1.13 95 CI 0.93 1.38 P=0.23 When comparing SC/AS N=661 85 to AC alone N=120 15 the adjusted HR for death was 1.23 95 CI 0.97 1.57 P=0.09 AC/AS and SCCA have similar survival in recurrent or metastatic carcinoma when treated with chemotherapy doublets,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[90, 1561, 23, 94, 4243, 191, 82, 1319, 73, 2350, 2, 795, 131, 34, 73, 5, 975, 3, 356, 9, 117, 5, 449, 1948, 15, 8067, 22, 134, 71, 85, 210, 6, 40, 1769, 76, 135, 5, 691, 31, 134, 6372, 1, 3, 3629, 192, 16, 1200, 317, 362, 4, 356, 120, 5589, 4, 3, 546, 1, 387, 15, 113, 34, 73, 75, 56, 9097, 5, 15, 187, 599, 140, 11, 1830, 29, 169, 23316, 413, 87, 2827, 124, 316, 143, 1, 56, 9097, 4720, 292, 412, 10, 95, 6, 376, 51, 116, 861, 1, 1948, 22, 105, 6372, 876, 882, 596, 6, 1191, 91, 115, 25, 300, 2, 63, 25, 118, 2, 418, 831, 1017, 202, 6, 1191, 3, 345, 1, 784, 23, 300, 2, 118, 1, 11486, 859, 7, 849, 78, 13029, 42, 6372, 2, 382, 78, 5160, 1948, 22, 125, 11, 77, 93, 362, 4, 4739, 59, 884, 1453, 3, 586, 360, 197, 168, 9, 273, 9, 6372, 105, 1948, 22, 10, 14, 233, 48, 58, 13, 966, 14, 519, 19, 13, 382, 198, 1430, 2969, 22, 78, 12745, 772, 6, 1948, 279, 78, 2031, 167, 3, 586, 168, 9, 273, 10, 14, 382, 48, 58, 13, 1015, 14, 696, 19, 13, 1730, 1948, 22, 2, 6372, 47, 288, 25, 4, 387, 15, 113, 134, 198, 73, 5, 56, 9097]",1275.0,29182608,491
The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings.,Journal of gynecologic oncology,J Gynecol Oncol,2018-01-01,"We hypothesized that DNA methylation of development-related genes may occur in endometrial cancer (EC)/ovarian cancer (OC) and may be detected in cervical scrapings. We tested methylation status by quantitative methylation-specific polymerase chain reaction for 14 genes in DNA pools of endometrial and OC tissues. Tissues of EC/normal endometrium, OC/normal ovary, were verified in training set using cervical scrapings of 10 EC/10 OC patients and 10 controls, and further validated in the testing set using independent cervical scrapings in 30 EC/30 OC patients and 30 controls. We generated cutoff values of methylation index (M-index) from cervical scrapings to distinguish between cancer patients and control. Sensitivity/specificity of DNA methylation biomarkers in detecting EC and OC was calculated. Of 14 genes, 4 (PTGDR, HS3ST2, POU4F3, MAGI2) showed hypermethylation in EC and OC tissues, and were verified in training set. POU4F3 and MAGI2 exhibited hypermethylation in training set were validated in independent cases. The mean M-index of POU4F3 is 78.28 in EC and 20.36 in OC, which are higher than that in controls (6.59; p<0.001 and p=0.100, respectively), and that of MAGI2 is 246.0 in EC and 12.2 in OC, which is significantly higher that than in controls (2.85; p<0.001 and p=0.480, respectively). Sensitivity and specificity of POU4F3/MAGI2 were 83%-90% and 69%-75% for detection of EC, and 61% and 62%-69% for the detection of OC. The findings demonstrate the potential of EC/OC detection through testing for DNA methylation in cervical scrapings.",Evaluation Study,750.0,7.0,We hypothesized that DNA methylation of development-related genes may occur in cancer EC /ovarian cancer OC and may be detected in scrapings We tested methylation status by quantitative methylation-specific polymerase chain reaction for 14 genes in DNA pools of and OC tissues Tissues of EC/normal OC/normal ovary were verified in training set using scrapings of 10 EC/10 OC patients and 10 controls and further validated in the testing set using independent scrapings in 30 EC/30 OC patients and 30 controls We generated cutoff values of methylation index M-index from scrapings to distinguish between cancer patients and control Sensitivity/specificity of DNA methylation biomarkers in detecting EC and OC was calculated Of 14 genes 4 PTGDR HS3ST2 POU4F3 MAGI2 showed hypermethylation in EC and OC tissues and were verified in training set POU4F3 and MAGI2 exhibited hypermethylation in training set were validated in independent cases The mean M-index of POU4F3 is 78.28 in EC and 20.36 in OC which are higher than that in controls 6.59 p 0.001 and p=0.100 respectively and that of MAGI2 is 246.0 in EC and 12.2 in OC which is significantly higher that than in controls 2.85 p 0.001 and p=0.480 respectively Sensitivity and specificity of POU4F3/MAGI2 were 83 -90 and 69 -75 for detection of EC and 61 and 62 -69 for the detection of OC The findings demonstrate the potential of EC/OC detection through testing for DNA methylation in scrapings,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[21, 1237, 17, 261, 569, 1, 193, 139, 214, 68, 1271, 4, 12, 2180, 6301, 12, 2950, 2, 68, 40, 530, 4, 26433, 21, 650, 569, 156, 20, 1156, 569, 112, 1451, 1260, 1329, 9, 213, 214, 4, 261, 9090, 1, 2, 2950, 742, 742, 1, 2180, 295, 2950, 295, 3631, 11, 4815, 4, 1741, 916, 75, 26433, 1, 79, 2180, 79, 2950, 7, 2, 79, 535, 2, 195, 938, 4, 3, 471, 916, 75, 306, 26433, 4, 201, 2180, 201, 2950, 7, 2, 201, 535, 21, 1419, 2779, 1030, 1, 569, 558, 188, 558, 29, 26433, 6, 3081, 59, 12, 7, 2, 182, 485, 1121, 1, 261, 569, 582, 4, 2502, 2180, 2, 2950, 10, 981, 1, 213, 214, 39, 71681, 32393, 36509, 31751, 224, 2575, 4, 2180, 2, 2950, 742, 2, 11, 4815, 4, 1741, 916, 36509, 2, 31751, 1416, 2575, 4, 1741, 916, 11, 938, 4, 306, 140, 3, 313, 188, 558, 1, 36509, 16, 833, 339, 4, 2180, 2, 179, 511, 4, 2950, 92, 32, 142, 76, 17, 4, 535, 49, 728, 19, 13, 144, 2, 19, 13, 394, 106, 2, 17, 1, 31751, 16, 6907, 13, 4, 2180, 2, 133, 18, 4, 2950, 92, 16, 97, 142, 17, 76, 4, 535, 18, 772, 19, 13, 144, 2, 19, 13, 9108, 106, 485, 2, 1121, 1, 36509, 31751, 11, 852, 424, 2, 790, 481, 9, 638, 1, 2180, 2, 713, 2, 744, 790, 9, 3, 638, 1, 2950, 3, 272, 608, 3, 174, 1, 2180, 2950, 638, 298, 471, 9, 261, 569, 4, 26433]",1446.0,29185275,500
Tuberculosis in Pap samples with emphasis on LBC: Caught only when thought.,Diagnostic cytopathology,Diagn. Cytopathol.,2017-11-28,"Despite being a commonly encountered infection, the clinical diagnosis of tuberculosis of the uterine cervix is elusive. Though a straightforward diagnosis on tissue sections, identification of typical features of tubercular infection on cervical Pap samples is challenging. In our experience, the infrequent pale staining collections of epithelioid cells are difficult to pick up on Pap stained smears, particularly LBC samples. In this series, 2 of the three samples were reported as atypical squamous cells of undetermined significance while 1 was reported as inflammatory at the initial diagnosis. Scattered Langhans' type giant cells may be seen as a subtle clue which should prompt the search for epithelioid cell granulomas. These cases may have a mass lesion clinically while no obvious signs of malignancy on the cervical samples.",Journal Article,784.0,0.0,Despite being a commonly encountered infection the clinical diagnosis of tuberculosis of the cervix is elusive Though a straightforward diagnosis on tissue sections identification of typical features of tubercular infection on Pap samples is challenging In our experience the infrequent pale staining collections of epithelioid cells are difficult to pick up on Pap stained smears particularly LBC samples In this series 2 of the three samples were reported as atypical squamous cells of undetermined significance while 1 was reported as inflammatory at the initial diagnosis Scattered Langhans type giant cells may be seen as a subtle clue which should prompt the search for epithelioid cell granulomas These cases may have a mass lesion clinically while no obvious signs of malignancy on the samples,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[550, 486, 8, 841, 3903, 930, 3, 38, 147, 1, 20584, 1, 3, 3629, 16, 5327, 2471, 8, 12753, 147, 23, 246, 3013, 911, 1, 3476, 404, 1, 71702, 930, 23, 4290, 347, 16, 1950, 4, 114, 730, 3, 4475, 17678, 1029, 8394, 1, 3838, 37, 32, 1740, 6, 23483, 126, 23, 4290, 3386, 8916, 823, 28439, 347, 4, 26, 988, 18, 1, 3, 169, 347, 11, 210, 22, 1973, 691, 37, 1, 5206, 724, 369, 14, 10, 210, 22, 1291, 28, 3, 388, 147, 9638, 71703, 267, 6470, 37, 68, 40, 527, 22, 8, 7543, 12360, 92, 257, 4776, 3, 1901, 9, 3838, 31, 22821, 46, 140, 68, 47, 8, 782, 1180, 505, 369, 77, 6228, 3408, 1, 710, 23, 3, 347]",801.0,29193907,54
Impact of HPV 16/18 infection on clinical outcomes in locally advanced cervical cancers treated with radical radio (chemo) therapy - A prospective observational study.,Gynecologic oncology,Gynecol. Oncol.,2017-12-06,"With an aim to investigate the impact of Human Papilloma Virus (HPV) 16/18 infection on clinical outcomes in locally advanced cervical cancers treated with radical radio (chemo) therapy, we undertook this prospective study. Between May 2010 and April 2012, 150 histologically proven cervical cancer patients treated with radio (chemo) therapy were accrued. Cervical biopsies/brushings were collected at pre-treatment, end of treatment and at 3 monthly intervals up to 24months. Quantitative estimation of HPV 16/18 was done using real-time polymerase chain reaction (RT-PCR) and correlated with various clinical end-points. Out of 150 patients accrued, 135 patients were considered for final analysis. Pre-treatment HPV16/18 DNA was detected in 126 (93%) patients, with HPV-16 present in 91%. The mean log (SD) HPV-16 and HPV-18 viral load at pre-treatment was 4.76 (2.5) and 0.14 (2.1) copies/10ng of DNA, respectively. Though significant decline in viral load was observed on follow-ups (p<0.0001); by 9-month follow-up, 89 (66%) patients had persistence of HPV infection. Patients with persistent HPV 16/18 infection had a significantly higher overall and loco-regional relapses [44/89 (49%) and 29/89 (32%)] as compared to HPV clearance by 9months [12/43 (28%) and 5/43 (11%)] with p=0.024 and p=0.02, respectively. Also, persistent HPV infection by 24-month showed a significant impact on loco-regional control (LRC) and recurrence-free survival (RFS). In locally advanced cervical cancers treated with radical radio (chemo) therapy, persistent HPV 16/18 infection is significantly high in immediate post-treatment period and correlated with higher loco-regional, overall relapses and was also associated with early relapses.",Journal Article,776.0,4.0,With an aim to investigate the impact of Human Papilloma Virus HPV 16/18 infection on clinical outcomes in locally advanced cancers treated with radical radio chemo therapy we undertook this prospective study Between May 2010 and April 2012 150 histologically proven cancer patients treated with radio chemo therapy were accrued biopsies/brushings were collected at pre-treatment end of treatment and at 3 monthly intervals up to 24months Quantitative estimation of HPV 16/18 was done using real-time polymerase chain reaction RT-PCR and correlated with various clinical end-points Out of 150 patients accrued 135 patients were considered for final analysis Pre-treatment HPV16/18 DNA was detected in 126 93 patients with HPV-16 present in 91 The mean log SD HPV-16 and HPV-18 viral load at pre-treatment was 4.76 2.5 and 0.14 2.1 copies/10ng of DNA respectively Though significant decline in viral load was observed on follow-ups p 0.0001 by 9-month follow-up 89 66 patients had persistence of HPV infection Patients with persistent HPV 16/18 infection had a significantly higher overall and loco-regional relapses 44/89 49 and 29/89 32 as compared to HPV clearance by 9months 12/43 28 and 5/43 11 with p=0.024 and p=0.02 respectively Also persistent HPV infection by 24-month showed a significant impact on loco-regional control LRC and recurrence-free survival RFS In locally advanced cancers treated with radical radio chemo therapy persistent HPV 16/18 infection is significantly high in immediate post-treatment period and correlated with higher loco-regional overall relapses and was also associated with early relapses,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[5, 35, 1130, 6, 963, 3, 345, 1, 171, 7017, 1450, 933, 245, 203, 930, 23, 38, 123, 4, 795, 131, 163, 73, 5, 711, 6477, 3341, 36, 21, 5418, 26, 482, 45, 59, 68, 1120, 2, 2292, 1195, 1577, 2161, 1930, 12, 7, 73, 5, 6477, 3341, 36, 11, 3198, 1154, 14515, 11, 786, 28, 671, 24, 396, 1, 24, 2, 28, 27, 3889, 1582, 126, 6, 41924, 1156, 4470, 1, 933, 245, 203, 10, 1822, 75, 1589, 98, 1451, 1260, 1329, 240, 604, 2, 438, 5, 747, 38, 396, 862, 1205, 1, 1577, 7, 3198, 3978, 7, 11, 515, 9, 1457, 65, 671, 24, 4048, 203, 261, 10, 530, 4, 3927, 966, 7, 5, 933, 245, 364, 4, 970, 3, 313, 1066, 22658, 933, 245, 2, 933, 203, 1667, 3800, 28, 671, 24, 10, 39, 846, 22627, 33, 2, 13, 213, 22627, 14, 5127, 35377, 1, 261, 106, 2471, 93, 1858, 4, 1667, 3800, 10, 164, 23, 166, 6106, 19, 13, 488, 20, 83, 811, 166, 126, 887, 700, 7, 42, 4108, 1, 933, 930, 7, 5, 1882, 933, 245, 203, 930, 42, 8, 97, 142, 63, 2, 7214, 951, 3713, 584, 887, 739, 2, 462, 887, 531, 22, 72, 6, 933, 1960, 20, 16988, 133, 601, 339, 2, 33, 601, 175, 5, 19, 13, 4247, 2, 19, 13, 588, 106, 120, 1882, 933, 930, 20, 259, 811, 224, 8, 93, 345, 23, 7214, 951, 182, 4000, 2, 146, 115, 25, 1272, 4, 795, 131, 163, 73, 5, 711, 6477, 3341, 36, 1882, 933, 245, 203, 930, 16, 97, 64, 4, 2181, 539, 24, 727, 2, 438, 5, 142, 7214, 951, 63, 3713, 2, 10, 120, 41, 5, 191, 3713]",1629.0,29203175,71
Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study.,Journal of the National Cancer Institute,J. Natl. Cancer Inst.,2018-05-01,"Family history of bladder cancer confers an increased risk for concordant and discordant cancers in relatives. However, previous studies investigating this relationship lack any correction for smoking status of family members. We conducted a population-based study of cancer risks in relatives of bladder cancer patients and matched controls with exclusion of variant subtypes to improve the understanding of familial cancer clustering. Case subjects with urothelial carcinoma were identified using the Utah Cancer Registry and matched 1:5 to cancer-free controls from the Utah Population Database. Cox regression was used to determine the risk of cancer in first-degree relatives, second-degree relatives, first cousins, and spouses. A total of 229 251 relatives of case subjects and 1 197 552 relatives of matched control subjects were analyzed. To correct for smoking status, we performed a secondary analysis excluding families with elevated rates of smoking-related cancers. All statistical tests were two-sided. First- and second-degree relatives of case subjects had an increased risk for any cancer diagnosis (hazard ratio [HR] = 1.06, 95% confidence interval [CI] = 1.03 to 1.09, P < .001; HR=1.04, 95% CI=1.02 to 1.07, P = .001) and urothelial cancer (HR=1.73, 95% CI=1.50 to 1.99, P < .001; HR=1.35, 95% CI=1.21 to 1.51, P < .001). Site-specific analysis found increased risk for bladder (HR=1.69, 95% CI=1.47 to 1.95, P < .001), kidney (HR=1.30, 95% CI=1.08 to 1.57, P = .006), cervical (HR=1.25, 95% CI=1.06 to 1.49, P = .01), and lung cancer (HR=1.34, 95% CI=1.19 to 1.51, P < .001) in first-degree relatives. Second-degree relatives had increased risk for bladder (HR=1.35, 95% CI=1.2 to 1.5, P < .001) and thyroid cancer (HR=1.18, 95% CI=1.03 to 1.35, P = .02). Spouses showed an increased risk for laryngeal (HR=2.68, 95% CI=1.02 to 7.05, P = .04) and cervical cancer (HR=1.57, 95% CI=1.13 to 2.17, P = .007). These results did not substantively change after correction for suspected smoking behaviors. Our results suggest familial urothelial cancer clustering independent of smoking, with increased risk in relatives for both concordant and discordant cancers, suggesting shared genetic or environmental roots. Identifying families with statistically significant risks for non-smoking-related urothelial cancer would be extremely informative for genetic linkage studies.",Journal Article,630.0,2.0,Family history of cancer confers an increased risk for concordant and discordant cancers in relatives However previous studies investigating this relationship lack any correction for smoking status of family members We conducted a population-based study of cancer risks in relatives of cancer patients and matched controls with exclusion of variant subtypes to improve the understanding of familial cancer clustering Case subjects with urothelial carcinoma were identified using the Utah Cancer Registry and matched 1:5 to cancer-free controls from the Utah Population Database Cox regression was used to determine the risk of cancer in first-degree relatives second-degree relatives first cousins and spouses A total of 229 251 relatives of case subjects and 1 197 552 relatives of matched control subjects were analyzed To correct for smoking status we performed a secondary analysis excluding families with elevated rates of smoking-related cancers All statistical tests were two-sided First- and second-degree relatives of case subjects had an increased risk for any cancer diagnosis hazard ratio HR 1.06 95 confidence interval CI 1.03 to 1.09 P .001 HR 1.04 95 CI 1.02 to 1.07 P .001 and urothelial cancer HR 1.73 95 CI 1.50 to 1.99 P .001 HR 1.35 95 CI 1.21 to 1.51 P .001 Site-specific analysis found increased risk for HR 1.69 95 CI 1.47 to 1.95 P .001 HR 1.30 95 CI 1.08 to 1.57 P .006 HR 1.25 95 CI 1.06 to 1.49 P .01 and cancer HR 1.34 95 CI 1.19 to 1.51 P .001 in first-degree relatives Second-degree relatives had increased risk for HR 1.35 95 CI 1.2 to 1.5 P .001 and cancer HR 1.18 95 CI 1.03 to 1.35 P .02 Spouses showed an increased risk for HR 2.68 95 CI 1.02 to 7.05 P .04 and cancer HR 1.57 95 CI 1.13 to 2.17 P .007 These results did not substantively change after correction for suspected smoking behaviors Our results suggest familial urothelial cancer clustering independent of smoking with increased risk in relatives for both concordant and discordant cancers suggesting shared genetic or environmental roots Identifying families with statistically significant risks for non-smoking-related urothelial cancer would be extremely informative for genetic linkage studies,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,"[607, 532, 1, 12, 4020, 35, 101, 43, 9, 3610, 2, 4570, 163, 4, 3335, 137, 698, 94, 3103, 26, 858, 926, 500, 5360, 9, 979, 156, 1, 607, 1684, 21, 426, 8, 266, 90, 45, 1, 12, 1098, 4, 3335, 1, 12, 7, 2, 655, 535, 5, 4721, 1, 1142, 814, 6, 401, 3, 612, 1, 2200, 12, 3147, 473, 976, 5, 1472, 134, 11, 108, 75, 3, 10940, 12, 1608, 2, 655, 14, 33, 6, 12, 115, 535, 29, 3, 10940, 266, 609, 418, 320, 10, 95, 6, 223, 3, 43, 1, 12, 4, 157, 1444, 3335, 419, 1444, 3335, 157, 26226, 2, 10080, 8, 181, 1, 7584, 7288, 3335, 1, 473, 976, 2, 14, 6114, 10097, 3335, 1, 655, 182, 976, 11, 311, 6, 4883, 9, 979, 156, 21, 173, 8, 568, 65, 3207, 1954, 5, 804, 151, 1, 979, 139, 163, 62, 1050, 895, 11, 100, 1689, 157, 2, 419, 1444, 3335, 1, 473, 976, 42, 35, 101, 43, 9, 500, 12, 147, 360, 197, 168, 14, 1460, 48, 307, 268, 58, 14, 680, 6, 14, 1730, 19, 144, 168, 14, 755, 48, 58, 14, 588, 6, 14, 1615, 19, 144, 2, 1472, 12, 168, 14, 803, 48, 58, 14, 212, 6, 14, 1058, 19, 144, 168, 14, 465, 48, 58, 14, 239, 6, 14, 725, 19, 144, 606, 112, 65, 204, 101, 43, 9, 168, 14, 790, 48, 58, 14, 662, 6, 14, 48, 19, 144, 168, 14, 201, 48, 58, 14, 1592, 6, 14, 696, 19, 1861, 168, 14, 243, 48, 58, 14, 1460, 6, 14, 739, 19, 355, 2, 12, 168, 14, 562, 48, 58, 14, 326, 6, 14, 725, 19, 144, 4, 157, 1444, 3335, 419, 1444, 3335, 42, 101, 43, 9, 168, 14, 465, 48, 58, 14, 18, 6, 14, 33, 19, 144, 2, 12, 168, 14, 203, 48, 58, 14, 680, 6, 14, 465, 19, 588, 10080, 224, 35, 101, 43, 9, 168, 18, 806, 48, 58, 14, 588, 6, 67, 474, 19, 755, 2, 12, 168, 14, 696, 48, 58, 14, 233, 6, 18, 269, 19, 1999, 46, 99, 205, 44, 31252, 707, 50, 5360, 9, 2768, 979, 3704, 114, 99, 309, 2200, 1472, 12, 3147, 306, 1, 979, 5, 101, 43, 4, 3335, 9, 110, 3610, 2, 4570, 163, 802, 2664, 336, 15, 3766, 19672, 1386, 1954, 5, 712, 93, 1098, 9, 220, 979, 139, 1472, 12, 688, 40, 2938, 4189, 9, 336, 4820, 94]",2193.0,29228305,290
"Upregulation of the BDNF/TrKB pathway promotes epithelial-mesenchymal transition, as well as the migration and invasion of cervical cancer.",International journal of oncology,Int. J. Oncol.,2017-12-19,"Brain-derived neurotrophic factor(BDNF) has previously been demonstrated to be associated with several types of cancer. In addition, its receptor, tropomyosin related kinaseB(TrkB) is involved in tumor invasion and metastasis. Epithelial-mesenchymal transition(EMT) is associated with metastasis in cancers. Thus, The aim of the present study was to examine whether BDNF/TrKB expression is linked to a poor survival and the acquisition of the EMT phenotype in cervical cancer. We found that a high positive expression of BDNF/TrKB was associated with poor survival in cervical cancer. Our results revealed that high expression levels of BDNF/TrKB were observed in cervical cancer compared to normal cells. Importantly, we demonstrated that the silencing of TrKB suppressed the activation of EMT via the downregulation of N-cadherin, vimentin, matrix metalloproteinase(MMP)2 and MMP9, and the upregulation of E-cadherin and tissue inhibitor of metalloproteinases(TIMP)2, which resulted in suppressed cell proliferation, migration and invasion. Furthermore, high phosphorylation levels of ERK and Akt were observed in the cervical cancer cells, while these levels were decreased in the cells in which TrKB was knocked down. On the whole, these findings suggest that the BDNF/TrKB pathway is a promising target for the prevention of tumor proliferation, invasion, metastasis and EMT in cervical cancer cells.",Journal Article,763.0,7.0,Brain-derived neurotrophic factor BDNF has previously been demonstrated to be associated with several types of cancer In addition its receptor tropomyosin related kinase B TrkB is involved in tumor invasion and metastasis Epithelial-mesenchymal transition EMT is associated with metastasis in cancers Thus The aim of the present study was to examine whether BDNF/TrKB expression is linked to a poor survival and the acquisition of the EMT phenotype in cancer We found that a high positive expression of BDNF/TrKB was associated with poor survival in cancer Our results revealed that high expression levels of BDNF/TrKB were observed in cancer compared to normal cells Importantly we demonstrated that the silencing of TrKB suppressed the activation of EMT via the downregulation of N-cadherin vimentin matrix metalloproteinase MMP 2 and MMP9 and the upregulation of E-cadherin and tissue inhibitor of metalloproteinases TIMP 2 which resulted in suppressed cell proliferation migration and invasion Furthermore high phosphorylation levels of ERK and Akt were observed in the cancer cells while these levels were decreased in the cells in which TrKB was knocked down On the whole these findings suggest that the BDNF/TrKB pathway is a promising target for the prevention of tumor proliferation invasion metastasis and EMT in cancer cells,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[342, 526, 12967, 161, 12934, 71, 373, 85, 264, 6, 40, 41, 5, 392, 630, 1, 12, 4, 352, 211, 153, 20408, 139, 216, 132, 8880, 16, 646, 4, 30, 578, 2, 278, 701, 1569, 1970, 2208, 16, 41, 5, 278, 4, 163, 631, 3, 1130, 1, 3, 364, 45, 10, 6, 1004, 317, 12934, 8880, 55, 16, 1199, 6, 8, 334, 25, 2, 3, 3405, 1, 3, 2208, 1005, 4, 12, 21, 204, 17, 8, 64, 109, 55, 1, 12934, 8880, 10, 41, 5, 334, 25, 4, 12, 114, 99, 553, 17, 64, 55, 148, 1, 12934, 8880, 11, 164, 4, 12, 72, 6, 295, 37, 1859, 21, 264, 17, 3, 2077, 1, 8880, 1908, 3, 363, 1, 2208, 847, 3, 2475, 1, 78, 2154, 4840, 2248, 4914, 2151, 18, 2, 10356, 2, 3, 2218, 1, 563, 2154, 2, 246, 230, 1, 8834, 5272, 18, 92, 627, 4, 1908, 31, 457, 1381, 2, 578, 798, 64, 982, 148, 1, 1819, 2, 649, 11, 164, 4, 3, 12, 37, 369, 46, 148, 11, 340, 4, 3, 37, 4, 92, 8880, 10, 10237, 1328, 23, 3, 902, 46, 272, 309, 17, 3, 12934, 8880, 308, 16, 8, 721, 283, 9, 3, 1070, 1, 30, 457, 578, 278, 2, 2208, 4, 12, 37]",1335.0,29345295,149
Lymph node ratio as a prognostic factor in metastatic cutaneous head and neck squamous cell carcinoma.,Head & neck,Head Neck,2018-01-23,The prognostic impact of the size and number of nodal metastases in head and neck cutaneous squamous cell carcinoma (SCC) is well established. The purpose of this study was to validate the prognostic significance of the lymph node ratio in metastatic head and neck cutaneous SCC. A retrospective review of 326 patients with head and neck cutaneous SCC with parotid and/or cervical nodal metastases was performed. The primary endpoints were overall survival (OS) and disease-free survival (DFS). The minimal-P approach was used to investigate the optimal lymph node ratio threshold. Our data included 77 recurrences and 101 deaths. A lymph node ratio of 6% was a significant predictor of shorter DFS (hazard ratio [HR] 1.62; 95% confidence interval [CI] 1.11-2.38; P=.01) and OS (HR 1.63; 95% CI 1.03-2.58; P=0.04) on multivariable analysis. The lymph node ratio is an independent prognosticator of survival outcomes in patients presenting with metastatic head and neck cutaneous SCC. A lymph node ratio >6% is a significant threshold to categorize patients into low and high risk.,Journal Article,728.0,6.0,The prognostic impact of the size and number of nodal metastases in head and cutaneous squamous cell carcinoma SCC is well established The purpose of this study was to validate the prognostic significance of the lymph node ratio in metastatic head and cutaneous SCC A retrospective review of 326 patients with head and cutaneous SCC with parotid and/or nodal metastases was performed The primary endpoints were overall survival OS and disease-free survival DFS The minimal-P approach was used to investigate the optimal lymph node ratio threshold Our data included 77 recurrences and 101 deaths A lymph node ratio of 6 was a significant predictor of shorter DFS hazard ratio HR 1.62 95 confidence interval CI 1.11-2.38 P .01 and OS HR 1.63 95 CI 1.03-2.58 P 0.04 on multivariable analysis The lymph node ratio is an independent prognosticator of survival outcomes in patients presenting with metastatic head and cutaneous SCC A lymph node ratio 6 is a significant threshold to categorize patients into low and high risk,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 177, 345, 1, 3, 444, 2, 207, 1, 779, 196, 4, 718, 2, 1486, 691, 31, 134, 1791, 16, 149, 635, 3, 743, 1, 26, 45, 10, 6, 2183, 3, 177, 724, 1, 3, 263, 289, 197, 4, 113, 718, 2, 1486, 1791, 8, 459, 206, 1, 9588, 7, 5, 718, 2, 1486, 1791, 5, 5838, 2, 15, 779, 196, 10, 173, 3, 86, 1387, 11, 63, 25, 118, 2, 34, 115, 25, 1010, 3, 1048, 19, 353, 10, 95, 6, 963, 3, 665, 263, 289, 197, 2390, 114, 74, 159, 849, 1593, 2, 2338, 1043, 8, 263, 289, 197, 1, 49, 10, 8, 93, 980, 1, 985, 1010, 360, 197, 168, 14, 744, 48, 307, 268, 58, 14, 175, 18, 519, 19, 355, 2, 118, 168, 14, 676, 48, 58, 14, 680, 18, 717, 19, 13, 755, 23, 658, 65, 3, 263, 289, 197, 16, 35, 306, 9655, 1, 25, 123, 4, 7, 1656, 5, 113, 718, 2, 1486, 1791, 8, 263, 289, 197, 49, 16, 8, 93, 2390, 6, 10440, 7, 237, 154, 2, 64, 43]",1019.0,29360276,450
Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2018-02-09,"Annual cervical cancer screening with Papanicolaou (Pap) and human papillomavirus (HPV) testing after stem cell transplant (SCT) is recommended, but the uptake is unknown. We aimed to determine the prevalence and predictors of cervical cancer screening in patients with hematologic malignancies. We searched MarketScan Commercial Claims database for women who underwent allogeneic or autologous SCT. The primary outcome was cervical cancer screening, defined as procedures or abnormal results for HPV and/or Pap testing according administrative codes within 2 years after SCT. A multivariable logistic regression model was fitted with cancer type, SCT year, age, geographic area, insurance plan, comorbidity, and presence of graft-versus-host disease (GVHD).The study included 1484 patients; 1048 patients (70.6%) had autologous and 436 (29.4%) allogeneic SCT. Mean age was 52.5 years. Overall, 660 patients (44.5%) had screening within 2 years after SCT, 214 (49.1%) with allogeneic SCT and 446 (42.6%) with autologous SCT (P=.02). In the allogeneic SCT group, patients with GVHD had a lower rate of screening than patients without GVHD (42.5% versus 55.4%, P<.01), and GVHD was associated with lower odds of screening (odds ratio, .50; 95% confidence interval, .32 to .79). In the autologous SCT group, patients with comorbid medical conditions had a lower rate of screening than patients without comorbidity (36.0% versus 45.7%, P<.01). In both allogeneic and autologous SCT groups older patients had lower odds of screening. Cervical cancer screening rates after SCT are low, particularly in patients with GVHD, who are at significant risk of second malignancies. Future work is needed to develop strategies to increase uptake.",Journal Article,711.0,1.0,Annual cancer screening with Papanicolaou Pap and human papillomavirus HPV testing after stem cell transplant SCT is recommended but the uptake is unknown We aimed to determine the prevalence and predictors of cancer screening in patients with hematologic malignancies We searched MarketScan Commercial Claims database for women who underwent allogeneic or autologous SCT The primary outcome was cancer screening defined as procedures or abnormal results for HPV and/or Pap testing according administrative codes within 2 years after SCT A multivariable logistic regression model was fitted with cancer type SCT year age geographic area insurance plan comorbidity and presence of graft-versus-host disease GVHD .The study included 1484 patients 1048 patients 70.6 had autologous and 436 29.4 allogeneic SCT Mean age was 52.5 years Overall 660 patients 44.5 had screening within 2 years after SCT 214 49.1 with allogeneic SCT and 446 42.6 with autologous SCT P .02 In the allogeneic SCT group patients with GVHD had a lower rate of screening than patients without GVHD 42.5 versus 55.4 P .01 and GVHD was associated with lower odds of screening odds ratio .50 95 confidence interval .32 to .79 In the autologous SCT group patients with comorbid medical conditions had a lower rate of screening than patients without comorbidity 36.0 versus 45.7 P .01 In both allogeneic and autologous SCT groups older patients had lower odds of screening cancer screening rates after SCT are low particularly in patients with GVHD who are at significant risk of second malignancies Future work is needed to develop strategies to increase uptake,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2114, 12, 453, 5, 10416, 4290, 2, 171, 3242, 933, 471, 50, 452, 31, 941, 1988, 16, 793, 84, 3, 1135, 16, 860, 21, 1295, 6, 223, 3, 1078, 2, 674, 1, 12, 453, 4, 7, 5, 813, 441, 21, 3080, 10246, 4860, 2770, 609, 9, 117, 54, 208, 1063, 15, 1028, 1988, 3, 86, 228, 10, 12, 453, 395, 22, 1369, 15, 1668, 99, 9, 933, 2, 15, 4290, 471, 768, 6723, 5271, 262, 18, 60, 50, 1988, 8, 658, 812, 320, 202, 10, 7315, 5, 12, 267, 1988, 111, 89, 3466, 965, 1935, 2242, 1879, 2, 463, 1, 1599, 185, 1204, 34, 1562, 3, 45, 159, 41106, 7, 37396, 7, 431, 49, 42, 1028, 2, 10601, 462, 39, 1063, 1988, 313, 89, 10, 653, 33, 60, 63, 10639, 7, 584, 33, 42, 453, 262, 18, 60, 50, 1988, 6900, 739, 14, 5, 1063, 1988, 2, 9849, 595, 49, 5, 1028, 1988, 19, 588, 4, 3, 1063, 1988, 87, 7, 5, 1562, 42, 8, 280, 116, 1, 453, 76, 7, 187, 1562, 595, 33, 185, 614, 39, 19, 355, 2, 1562, 10, 41, 5, 280, 610, 1, 453, 610, 197, 212, 48, 307, 268, 531, 6, 842, 4, 3, 1028, 1988, 87, 7, 5, 3952, 484, 1298, 42, 8, 280, 116, 1, 453, 76, 7, 187, 1879, 511, 13, 185, 512, 67, 19, 355, 4, 110, 1063, 2, 1028, 1988, 271, 434, 7, 42, 280, 610, 1, 453, 12, 453, 151, 50, 1988, 32, 154, 823, 4, 7, 5, 1562, 54, 32, 28, 93, 43, 1, 419, 441, 508, 1357, 16, 575, 6, 690, 422, 6, 344, 1135]",1627.0,29378304,441
Society of Gynecologic Oncology Clinical Outcomes Registry: From small beginnings come great things.,Gynecologic oncology,Gynecol. Oncol.,2018-02-01,"Clinical registries within medical societies have demonstrated the capacity to promote quality improvement. Opportunities for well-designed data repositories could yield reliable national standards for informing reimbursement, determining adherence to care guidelines, maintaining board certification, and developing bundled payment models. Looking to the future, we set out to develop a gynecologic cancer registry serving the members of the Society of Gynecologic Oncology (SGO). The SGO Clinical Outcomes Registry (COR) initiated a web-based data entry platform as a foray into developing a functional registry, compiling data elements specific to gynecologic oncology. Endometrial and ovarian cancer patients began enrollment in early 2014. Within one year, 19 sites were participating with the addition of cervical cancer patients in January 2015. To date, >6500 patients are currently entered from 29 sites, and the COR is being queried to address topics of quality improvement, disparities, and cancer outcomes. The SGO COR has proven the feasibility of developing a functional gynecologic cancer registry, with high uptake, rapid accrual, and ability to investigate topics of quality and outcome using the COR.",Editorial,719.0,1.0,Clinical registries within medical societies have demonstrated the capacity to promote quality improvement Opportunities for well-designed data repositories could yield reliable national standards for informing reimbursement determining adherence to care guidelines maintaining board certification and developing bundled payment models Looking to the future we set out to develop a gynecologic cancer registry serving the members of the Society of Gynecologic Oncology SGO The SGO Clinical Outcomes Registry COR initiated a web-based data entry platform as a foray into developing a functional registry compiling data elements specific to gynecologic oncology and cancer patients began enrollment in early 2014 Within one year 19 sites were participating with the addition of cancer patients in January 2015 To date 6500 patients are currently entered from 29 sites and the COR is being queried to address topics of quality improvement disparities and cancer outcomes The SGO COR has proven the feasibility of developing a functional gynecologic cancer registry with high uptake rapid accrual and ability to investigate topics of quality and outcome using the COR,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[38, 3768, 262, 484, 10600, 47, 264, 3, 2162, 6, 1617, 372, 767, 2605, 9, 149, 1114, 74, 19548, 359, 2309, 2450, 657, 3371, 9, 10603, 6642, 2196, 2149, 6, 165, 677, 3284, 2620, 17377, 2, 931, 27383, 9066, 274, 9095, 6, 3, 508, 21, 916, 1205, 6, 690, 8, 1512, 12, 1608, 6823, 3, 1684, 1, 3, 1174, 1, 1512, 413, 12063, 3, 12063, 38, 123, 1608, 16897, 1917, 8, 3469, 90, 74, 3001, 2243, 22, 8, 72082, 237, 931, 8, 583, 1608, 41080, 74, 2531, 112, 6, 1512, 413, 2, 12, 7, 4603, 1798, 4, 191, 1409, 262, 104, 111, 326, 633, 11, 3052, 5, 3, 352, 1, 12, 7, 4, 1024, 1483, 6, 1244, 37097, 7, 32, 694, 2836, 29, 462, 633, 2, 3, 16897, 16, 486, 3547, 6, 1539, 4461, 1, 372, 767, 2227, 2, 12, 123, 3, 12063, 16897, 71, 1930, 3, 1437, 1, 931, 8, 583, 1512, 12, 1608, 5, 64, 1135, 1321, 2262, 2, 801, 6, 963, 4461, 1, 372, 2, 228, 75, 3, 16897]",1163.0,29395312,203
Variable response of CNS hemangioblastomas to Pazopanib in a single patient with von Hippel-Lindau disease: Case report.,Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia,J Clin Neurosci,2018-02-01,"Von Hippel-Lindau (VHL) disease is a multisystem genetic disease, the cardinal manifestations of which include central nervous system hemangioblastomas (CNS HB), renal cell carcinomas (RCC), and pheochromocytoma. Tumorigenesis in VHL of both RCC and CNS HB occurs secondary to downstream effects of a mutated or absent VHL protein. Treatment of RCCs with tyrosine kinase inhibitors (TKIs) such as Pazopanib is now first line therapy, but their effect on VHL-associated CNS HBs remains unknown. We report the use of Pazopanib in a patient with VHL disease for treatment of RCC who also harbored multiple CNS HBs. Following initiation of treatment, a large cervical and a lumbar spinal HB regressed in size while the remaining CNS HBs exhibited stable or progressive disease. These findings highlight the multiplicity of factors contributing to hemangioblastoma development, even among tumors with a common germline mutation, and the potential limitations of TKIs, but additionally this report supports the conservative management of asymptomatic VHL patients with spinal HBs whereby tumor response to TKI treatment may alleviate or postpone the need for surgery.",Case Reports,719.0,4.0,Von Hippel-Lindau VHL disease is a multisystem genetic disease the cardinal manifestations of which include central nervous system hemangioblastomas CNS HB cell carcinomas RCC and Tumorigenesis in VHL of both RCC and CNS HB occurs secondary to downstream effects of a mutated or absent VHL protein Treatment of RCCs with tyrosine kinase inhibitors TKIs such as Pazopanib is now first line therapy but their effect on VHL-associated CNS HBs remains unknown We report the use of Pazopanib in a patient with VHL disease for treatment of RCC who also harbored multiple CNS HBs Following initiation of treatment a large and a lumbar spinal HB regressed in size while the remaining CNS HBs exhibited stable or progressive disease These findings highlight the multiplicity of factors contributing to hemangioblastoma development even among tumors with a common germline mutation and the potential limitations of TKIs but additionally this report supports the conservative management of asymptomatic VHL patients with spinal HBs whereby tumor response to TKI treatment may alleviate or postpone the need for surgery,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6430, 7703, 7704, 3808, 34, 16, 8, 17333, 336, 34, 3, 17228, 4282, 1, 92, 643, 854, 1880, 398, 23838, 1025, 5753, 31, 826, 796, 2, 1565, 4, 3808, 1, 110, 796, 2, 1025, 5753, 1780, 568, 6, 1489, 176, 1, 8, 1185, 15, 3269, 3808, 178, 24, 1, 8195, 5, 564, 216, 222, 1671, 225, 22, 2576, 16, 1134, 157, 328, 36, 84, 136, 254, 23, 3808, 41, 1025, 14773, 469, 860, 21, 414, 3, 119, 1, 2576, 4, 8, 69, 5, 3808, 34, 9, 24, 1, 796, 54, 120, 3253, 232, 1025, 14773, 366, 1118, 1, 24, 8, 375, 2, 8, 6187, 1499, 5753, 12579, 4, 444, 369, 3, 1844, 1025, 14773, 1416, 585, 15, 1014, 34, 46, 272, 1817, 3, 8641, 1, 130, 3156, 6, 29643, 193, 871, 107, 57, 5, 8, 186, 1009, 258, 2, 3, 174, 1939, 1, 1671, 84, 1724, 26, 414, 2304, 3, 4476, 284, 1, 2100, 3808, 7, 5, 1499, 14773, 6131, 30, 51, 6, 1379, 24, 68, 8193, 15, 29352, 3, 594, 9, 152]",1107.0,29396065,405
Phosphatidylinositol 3-Kinase -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2018-02-05,"Purpose We report the first-in-human phase Ia study to our knowledge ( ClinicalTrials.gov identifier: NCT01219699) identifying the maximum tolerated dose and assessing safety and preliminary efficacy of single-agent alpelisib (BYL719), an oral phosphatidylinositol 3-kinase  (PI3K)-selective inhibitor. Patients and Methods In the dose-escalation phase, patients with PIK3CA-altered advanced solid tumors received once-daily or twice-daily oral alpelisib on a continuous schedule. In the dose-expansion phase, patients with PIK3CA-altered solid tumors and PIK3CA-wild-type, estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer received alpelisib 400 mg once daily. Results One hundred thirty-four patients received treatment. Alpelisib maximum tolerated doses were established as 400 mg once daily and 150 mg twice daily. Nine patients (13.2%) in the dose-escalation phase had dose-limiting toxicities of hyperglycemia (n = 6), nausea (n = 2), and both hyperglycemia and hypophosphatemia (n = 1). Frequent all-grade, treatment-related adverse events included hyperglycemia (51.5%), nausea (50.0%), decreased appetite (41.8%), diarrhea (40.3%), and vomiting (31.3%). Alpelisib was rapidly absorbed; half-life was 7.6 hours at 400 mg once daily with minimal accumulation. Objective tumor responses were observed at doses  270 mg once daily; overall response rate was 6.0% (n = 8; one patient with endometrial cancer had a complete response, and seven patients with cervical, breast, endometrial, colon, and rectal cancers had partial responses). Stable disease was achieved in 70 (52.2%) patients and was maintained > 24 weeks in 13 (9.7%) patients; disease control rate (complete and partial responses and stable disease) was 58.2%. In patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer, median progression-free survival was 5.5 months. Frequently mutated genes ( 10% tumors) included TP53 (51.3%), APC (23.7%), KRAS (22.4%), ARID1A (13.2%), and FBXW7 (10.5%). Conclusion Alpelisib demonstrated a tolerable safety profile and encouraging preliminary activity in patients with PIK3CA-altered solid tumors, supporting the rationale for selective PI3K inhibition in combination with other agents for the treatment of PIK3CA-mutant tumors.","Clinical Trial, Phase I",715.0,65.0,Purpose We report the first-in-human phase Ia study to our knowledge ClinicalTrials.gov identifier NCT01219699 identifying the maximum tolerated dose and assessing safety and preliminary efficacy of single-agent alpelisib BYL719 an oral phosphatidylinositol 3-kinase PI3K -selective inhibitor Patients and Methods In the dose-escalation phase patients with PIK3CA-altered advanced solid tumors received once-daily or twice-daily oral alpelisib on a continuous schedule In the dose-expansion phase patients with PIK3CA-altered solid tumors and PIK3CA-wild-type estrogen receptor-positive/human epidermal growth factor receptor 2-negative cancer received alpelisib 400 mg once daily Results One hundred thirty-four patients received treatment Alpelisib maximum tolerated doses were established as 400 mg once daily and 150 mg twice daily Nine patients 13.2 in the dose-escalation phase had dose-limiting toxicities of hyperglycemia n 6 nausea n 2 and both hyperglycemia and hypophosphatemia n 1 Frequent all-grade treatment-related adverse events included hyperglycemia 51.5 nausea 50.0 decreased appetite 41.8 diarrhea 40.3 and vomiting 31.3 Alpelisib was rapidly absorbed half-life was 7.6 hours at 400 mg once daily with minimal accumulation Objective tumor responses were observed at doses  270 mg once daily overall response rate was 6.0 n 8 one patient with cancer had a complete response and seven patients with and cancers had partial responses Stable disease was achieved in 70 52.2 patients and was maintained 24 weeks in 13 9.7 patients disease control rate complete and partial responses and stable disease was 58.2 In patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative cancer median progression-free survival was 5.5 months Frequently mutated genes  10 tumors included TP53 51.3 APC 23.7 KRAS 22.4 ARID1A 13.2 and FBXW7 10.5 Conclusion Alpelisib demonstrated a tolerable safety profile and encouraging preliminary activity in patients with PIK3CA-altered solid tumors supporting the rationale for selective PI3K inhibition in combination with other agents for the treatment of PIK3CA-mutant tumors,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,"[743, 21, 414, 3, 157, 4, 171, 124, 3302, 45, 6, 114, 922, 1252, 1239, 3719, 72101, 1386, 3, 689, 421, 61, 2, 1977, 367, 2, 1676, 209, 1, 226, 420, 21850, 19337, 35, 518, 3415, 27, 216, 17552, 1094, 230, 7, 2, 636, 4, 3, 61, 1125, 124, 7, 5, 1506, 1495, 131, 537, 57, 103, 1059, 391, 15, 936, 391, 518, 21850, 23, 8, 1314, 1055, 4, 3, 61, 1422, 124, 7, 5, 1506, 1495, 537, 57, 2, 1506, 955, 267, 808, 153, 109, 171, 829, 129, 161, 153, 18, 199, 12, 103, 21850, 1524, 81, 1059, 391, 99, 104, 1128, 977, 294, 7, 103, 24, 21850, 689, 421, 415, 11, 635, 22, 1524, 81, 1059, 391, 2, 1577, 81, 936, 391, 762, 7, 233, 18, 4, 3, 61, 1125, 124, 42, 61, 817, 385, 1, 3992, 78, 49, 1218, 78, 18, 2, 110, 3992, 2, 8021, 78, 14, 908, 62, 88, 24, 139, 290, 281, 159, 3992, 725, 33, 1218, 212, 13, 340, 4062, 605, 66, 1172, 327, 27, 2, 1966, 456, 27, 21850, 10, 1755, 5249, 1303, 358, 10, 67, 49, 1459, 28, 1524, 81, 1059, 391, 5, 1048, 1835, 461, 30, 253, 11, 164, 28, 415, 749, 6666, 81, 1059, 391, 63, 51, 116, 10, 49, 13, 78, 66, 104, 69, 5, 12, 42, 8, 236, 51, 2, 648, 7, 5, 2, 163, 42, 450, 253, 585, 34, 10, 513, 4, 431, 653, 18, 7, 2, 10, 1955, 259, 244, 4, 233, 83, 67, 7, 34, 182, 116, 236, 2, 450, 253, 2, 585, 34, 10, 717, 18, 4, 7, 5, 808, 153, 109, 171, 829, 129, 161, 153, 18, 199, 12, 52, 91, 115, 25, 10, 33, 33, 53, 746, 1185, 214, 749, 79, 57, 159, 1206, 725, 27, 2528, 382, 67, 723, 350, 39, 5430, 233, 18, 2, 8352, 79, 33, 1221, 21850, 264, 8, 2668, 367, 800, 2, 2269, 1676, 128, 4, 7, 5, 1506, 1495, 537, 57, 1912, 3, 1728, 9, 1094, 17552, 297, 4, 150, 5, 127, 183, 9, 3, 24, 1, 1506, 620, 57]",2152.0,29401002,142
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.,Nature,Nature,2018-01-31,"Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, 'basket' trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.",Clinical Trial,720.0,133.0,Somatic mutations of ERBB2 and ERBB3 which encode HER2 and HER3 respectively are found in a wide range of cancers Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation but most remain biologically uncharacterized Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology genomically selected 'basket trial using the pan-HER kinase inhibitor neratinib SUMMIT clinicaltrials.gov identifier NCT01953926 Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models with the greatest activity seen in and biliary cancers and with tumours that contain kinase domain missense mutations This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1119, 138, 1, 2186, 2, 6573, 92, 6924, 354, 2, 4885, 106, 32, 204, 4, 8, 1019, 184, 1, 163, 693, 10812, 844, 17, 8, 697, 1, 46, 138, 1122, 6, 3178, 354, 363, 84, 96, 918, 2665, 10607, 467, 21, 1107, 3, 1037, 2, 189, 1187, 1, 440, 1302, 354, 2, 4885, 138, 2, 839, 1, 860, 1037, 1187, 20, 6018, 8, 1414, 784, 7218, 715, 41675, 160, 75, 3, 3055, 1084, 216, 230, 6379, 12396, 1252, 1239, 3719, 72118, 209, 4, 354, 620, 163, 2051, 22, 8, 343, 1, 110, 770, 267, 2, 620, 1254, 6, 8, 1444, 44, 783, 20, 693, 274, 5, 3, 2199, 128, 527, 4, 2, 2532, 163, 2, 5, 1319, 17, 3725, 216, 1398, 4007, 138, 26, 45, 1902, 832, 8, 2372, 1621, 38, 160, 122, 40, 95, 6, 5003, 114, 1037, 612, 1, 110, 765, 2, 217, 572, 593, 5, 174, 2094, 5412, 9, 5155, 3, 2431, 1, 898, 1621, 413]",1076.0,29420467,228
"Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2018-02-12,"Purpose We compared the efficacy and toxicity of neoadjuvant chemotherapy followed by radical surgery versus standard cisplatin-based chemoradiation in patients with locally advanced squamous cervical cancer. Patients and Methods This was a single-center, phase III, randomized controlled trial ( ClinicalTrials.gov identifier: NCT00193739). Eligible patients were between 18 and 65 years old and had stage IB2, IIA, or IIB squamous cervical cancer. They were randomly assigned, after stratification by stage, to receive either three cycles of neoadjuvant chemotherapy using paclitaxel and carboplatin once every 3 weeks followed by radical hysterectomy or standard radiotherapy with concomitant cisplatin once every week for 5 weeks. Patients in the neoadjuvant group received postoperative adjuvant radiation or concomitant chemotherapy and radiotherapy, if indicated. The primary end point was disease-free survival (DFS), defined as survival without relapse or death related to cancer, and secondary end points included overall survival and toxicity. Results Between September 2003 and February 2015, 635 patients were randomly assigned, of whom 633 (316 patients in the neoadjuvant chemotherapy plus surgery group and 317 patients in the concomitant chemoradiation group) were included in the final analysis, with a median follow-up time of 58.5 months. The 5-year DFS in the neoadjuvant chemotherapy plus surgery group was 69.3% compared with 76.7% in the concomitant chemoradiation group (hazard ratio, 1.38; 95% CI, 1.02 to 1.87; P = .038), whereas the corresponding 5-year OS rates were 75.4% and 74.7%, respectively (hazard ratio, 1.025; 95% CI, 0.752 to 1.398; P = .87). The delayed toxicities at 24 months or later after treatment completion in the neoadjuvant chemotherapy plus surgery group versus the concomitant chemoradiation group were rectal (2.2% v 3.5%, respectively), bladder (1.6% v 3.5%, respectively), and vaginal (12.0% v 25.6%, respectively). Conclusion Cisplatin-based concomitant chemoradiation resulted in superior DFS compared with neoadjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer.","Clinical Trial, Phase III",708.0,61.0,Purpose We compared the efficacy and toxicity of neoadjuvant chemotherapy followed by radical surgery versus standard cisplatin-based chemoradiation in patients with locally advanced squamous cancer Patients and Methods This was a single-center phase III randomized controlled trial ClinicalTrials.gov identifier NCT00193739 Eligible patients were between 18 and 65 years old and had stage IB2 IIA or IIB squamous cancer They were randomly assigned after stratification by stage to receive either three cycles of neoadjuvant chemotherapy using paclitaxel and carboplatin once every 3 weeks followed by radical hysterectomy or standard radiotherapy with concomitant cisplatin once every week for 5 weeks Patients in the neoadjuvant group received postoperative adjuvant radiation or concomitant chemotherapy and radiotherapy if indicated The primary end point was disease-free survival DFS defined as survival without relapse or death related to cancer and secondary end points included overall survival and toxicity Results Between September 2003 and February 2015 635 patients were randomly assigned of whom 633 316 patients in the neoadjuvant chemotherapy plus surgery group and 317 patients in the concomitant chemoradiation group were included in the final analysis with a median follow-up time of 58.5 months The 5-year DFS in the neoadjuvant chemotherapy plus surgery group was 69.3 compared with 76.7 in the concomitant chemoradiation group hazard ratio 1.38 95 CI 1.02 to 1.87 P .038 whereas the corresponding 5-year OS rates were 75.4 and 74.7 respectively hazard ratio 1.025 95 CI 0.752 to 1.398 P .87 The delayed toxicities at 24 months or later after treatment completion in the neoadjuvant chemotherapy plus surgery group versus the concomitant chemoradiation group were 2.2 v 3.5 respectively 1.6 v 3.5 respectively and 12.0 v 25.6 respectively Conclusion Cisplatin-based concomitant chemoradiation resulted in superior DFS compared with neoadjuvant chemotherapy followed by radical surgery in locally advanced cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,"[743, 21, 72, 3, 209, 2, 155, 1, 536, 56, 370, 20, 711, 152, 185, 260, 540, 90, 975, 4, 7, 5, 795, 131, 691, 12, 7, 2, 636, 26, 10, 8, 226, 574, 124, 316, 384, 1149, 160, 1252, 1239, 3719, 72140, 625, 7, 11, 59, 203, 2, 556, 60, 1095, 2, 42, 82, 9537, 4088, 15, 3884, 691, 12, 491, 11, 1108, 896, 50, 1541, 20, 82, 6, 560, 361, 169, 410, 1, 536, 56, 75, 490, 2, 927, 1059, 454, 27, 244, 370, 20, 711, 2622, 15, 260, 310, 5, 1781, 540, 1059, 454, 647, 9, 33, 244, 7, 4, 3, 536, 87, 103, 573, 249, 121, 15, 1781, 56, 2, 310, 492, 1103, 3, 86, 396, 741, 10, 34, 115, 25, 1010, 395, 22, 25, 187, 429, 15, 273, 139, 6, 12, 2, 568, 396, 862, 159, 63, 25, 2, 155, 99, 59, 2636, 1522, 2, 3010, 1483, 12254, 7, 11, 1108, 896, 1, 953, 11967, 8500, 7, 4, 3, 536, 56, 349, 152, 87, 2, 7869, 7, 4, 3, 1781, 975, 87, 11, 159, 4, 3, 1457, 65, 5, 8, 52, 166, 126, 98, 1, 717, 33, 53, 3, 33, 111, 1010, 4, 3, 536, 56, 349, 152, 87, 10, 790, 27, 72, 5, 846, 67, 4, 3, 1781, 975, 87, 360, 197, 14, 519, 48, 58, 14, 588, 6, 14, 912, 19, 5215, 547, 3, 1734, 33, 111, 118, 151, 11, 481, 39, 2, 794, 67, 106, 360, 197, 14, 4067, 48, 58, 13, 11611, 6, 14, 8336, 19, 912, 3, 1612, 385, 28, 259, 53, 15, 1559, 50, 24, 1438, 4, 3, 536, 56, 349, 152, 87, 185, 3, 1781, 975, 87, 11, 18, 18, 603, 27, 33, 106, 14, 49, 603, 27, 33, 106, 2, 133, 13, 603, 243, 49, 106, 1221, 540, 90, 1781, 975, 627, 4, 1123, 1010, 72, 5, 536, 56, 370, 20, 711, 152, 4, 795, 131, 12]",2031.0,29432076,197
Insurance status and cancer treatment mediate the association between race/ethnicity and cervical cancer survival.,PloS one,PLoS ONE,2018-02-15,"Cervical cancer outcomes remain poor among disadvantaged populations, including ethnic minorities, low-income, and underinsured women. The aim of this study was to evaluate the mechanisms that underlie the observed association between race/ethnicity and cervical cancer survival. We identified 13,698 women, ages 21 to 64 years, diagnosed with stages I-III primary cervical cancer between 2007-2013 in Surveillance, Epidemiology, and End Results (SEER). Multivariable Cox proportional hazards regression models evaluated associations between race/ethnicity (Non-Hispanic White, Non-Hispanic Black, Hispanic, Other) and cervical cancer-specific mortality. We conducted mediation analysis to calculate the mediation proportion and its 95% confidence interval. Non-Hispanic black women had an increased risk of cervical cancer-specific mortality (HR: 1.23, 95% CI: 1.08-1.39), and Hispanic women a decreased risk of dying from their disease (HR: 0.82, 95% CI: 0.72-0.93), compared with non-Hispanic white. The estimated proportion of excess cervical cancer mortality for non-Hispanic black women relative to non-Hispanic white women that was mediated by insurance was 18.6% and by treatment was 47.2%. Furthermore, non-Hispanic black women were more likely to receive radiation and less likely to receive surgery for early-stage disease. In this population-based study we found that some of the excess cervical cancer-specific mortality for non-Hispanic black women is mediated by factors such as insurance status and treatment. These findings suggest that enhancing existing insurance coverage and ensuring equal and adequate treatment in all women may be a key strategy for improving cervical cancer outcomes.",Journal Article,705.0,3.0,"cancer outcomes remain poor among disadvantaged populations including ethnic minorities low-income and underinsured women The aim of this study was to evaluate the mechanisms that underlie the observed association between race/ethnicity and cancer survival We identified 13,698 women ages 21 to 64 years diagnosed with stages I-III primary cancer between 2007-2013 in Surveillance Epidemiology and End Results SEER Multivariable Cox proportional hazards regression models evaluated associations between race/ethnicity Non-Hispanic White Non-Hispanic Black Hispanic Other and cancer-specific mortality We conducted mediation analysis to calculate the mediation proportion and its 95 confidence interval Non-Hispanic black women had an increased risk of cancer-specific mortality HR 1.23 95 CI 1.08-1.39 and Hispanic women a decreased risk of dying from their disease HR 0.82 95 CI 0.72-0.93 compared with non-Hispanic white The estimated proportion of excess cancer mortality for non-Hispanic black women relative to non-Hispanic white women that was mediated by insurance was 18.6 and by treatment was 47.2 Furthermore non-Hispanic black women were more likely to receive radiation and less likely to receive surgery for early-stage disease In this population-based study we found that some of the excess cancer-specific mortality for non-Hispanic black women is mediated by factors such as insurance status and treatment These findings suggest that enhancing existing insurance coverage and ensuring equal and adequate treatment in all women may be a key strategy for improving cancer outcomes",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 123, 918, 334, 107, 16700, 1184, 141, 2871, 6727, 154, 2306, 2, 25156, 117, 3, 1130, 1, 26, 45, 10, 6, 376, 3, 483, 17, 5875, 3, 164, 248, 59, 1047, 2091, 2, 12, 25, 21, 108, 233, 14072, 117, 2165, 239, 6, 660, 60, 265, 5, 1153, 70, 316, 86, 12, 59, 1307, 1346, 4, 617, 1284, 2, 396, 99, 1605, 658, 418, 831, 1017, 320, 274, 194, 685, 59, 1047, 2091, 220, 1776, 886, 220, 1776, 1445, 1776, 127, 2, 12, 112, 282, 21, 426, 13484, 65, 6, 3232, 3, 13484, 920, 2, 211, 48, 307, 268, 220, 1776, 1445, 117, 42, 35, 101, 43, 1, 12, 112, 282, 168, 14, 382, 48, 58, 14, 1592, 14, 587, 2, 1776, 117, 8, 340, 43, 1, 4536, 29, 136, 34, 168, 13, 878, 48, 58, 13, 720, 13, 966, 72, 5, 220, 1776, 886, 3, 661, 920, 1, 2612, 12, 282, 9, 220, 1776, 1445, 117, 580, 6, 220, 1776, 886, 117, 17, 10, 517, 20, 1935, 10, 203, 49, 2, 20, 24, 10, 662, 18, 798, 220, 1776, 1445, 117, 11, 80, 322, 6, 560, 121, 2, 299, 322, 6, 560, 152, 9, 191, 82, 34, 4, 26, 266, 90, 45, 21, 204, 17, 476, 1, 3, 2612, 12, 112, 282, 9, 220, 1776, 1445, 117, 16, 517, 20, 130, 225, 22, 1935, 156, 2, 24, 46, 272, 309, 17, 2430, 1692, 1935, 2139, 2, 8397, 2997, 2, 1658, 24, 4, 62, 117, 68, 40, 8, 825, 692, 9, 1673, 12, 123]",1594.0,29447263,435
Clinicopathologic characteristics of poorly differentiated chordoma.,"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",Mod. Pathol.,2018-02-26,"Chordoma is a rare malignant tumor of bone with high morbidity and mortality. Recently, aggressive pediatric poorly differentiated chordoma with SMARCB1 loss has been described. This study summarizes the clinicopathologic features of poorly differentiated chordoma with SMARCB1 loss in the largest series to date. A search of records between 1990-2017 at MGH identified 19 patients with poorly differentiated chordoma. Immunohistochemical stains were evaluated. Kaplan-Meier survival statistics and log-rank (Mantel Cox) tests compared survival with other subtypes. The patients (n=19) were diagnosed at a median age of 11 years (range: 1-29). Tumors arose in the skull base and clivus (n=10/19; 53%); cervical spine (n=6/19; 32%); and sacrum or coccyx (n=3/19; 16%). The clinical stage of these patients (AJCC 7e) was stage 2A (n=7/16; 44%); stage 2B (n=6/16; 38%); stage 4A (n=1/16; 6%); and stage 4B (n=2/16; 13%). The tumors were composed of sheets of epithelioid cells with nuclear pleomorphism, abundant eosinophilic cytoplasm, and increased mitoses. Tumors were positive for cytokeratin (n=18/18; 100%) and brachyury (n=18/18; 100%). Patients were treated with a combination of excision, radiation therapy, and chemotherapy. No difference in overall survival, progression free survival, local control time, and metastasis free survival was identified between poorly differentiated chordoma of the skull base and of the spine. Compared to other chordoma subtypes, poorly differentiated chordoma has a significantly decreased mean overall survival after stratification by site (p=0.037). Pediatric poorly differentiated chordoma has a distinct clinical and immunohistochemical profile, with characteristic SMARCB1 loss and decreased survival compared to conventional/chondroid chordoma. Recognition of this subtype is important because these malignancies should be treated aggressively with multimodality therapy.",Journal Article,694.0,10.0,Chordoma is a rare malignant tumor of with high morbidity and mortality Recently aggressive pediatric poorly differentiated chordoma with SMARCB1 loss has been described This study summarizes the clinicopathologic features of poorly differentiated chordoma with SMARCB1 loss in the largest series to date A search of records between 1990-2017 at MGH identified 19 patients with poorly differentiated chordoma Immunohistochemical stains were evaluated Kaplan-Meier survival statistics and log-rank Mantel Cox tests compared survival with other subtypes The patients n 19 were diagnosed at a median age of 11 years range 1-29 Tumors arose in the skull base and clivus n 10/19 53 spine n 6/19 32 and sacrum or coccyx n 3/19 16 The clinical stage of these patients AJCC 7e was stage 2A n 7/16 44 stage 2B n 6/16 38 stage 4A n 1/16 6 and stage 4B n 2/16 13 The tumors were composed of sheets of epithelioid cells with nuclear pleomorphism abundant eosinophilic cytoplasm and increased mitoses Tumors were positive for cytokeratin n 18/18 100 and brachyury n 18/18 100 Patients were treated with a combination of excision radiation therapy and chemotherapy No difference in overall survival progression free survival local control time and metastasis free survival was identified between poorly differentiated chordoma of the skull base and of the spine Compared to other chordoma subtypes poorly differentiated chordoma has a significantly decreased mean overall survival after stratification by site p 0.037 Pediatric poorly differentiated chordoma has a distinct clinical and immunohistochemical profile with characteristic SMARCB1 loss and decreased survival compared to conventional/chondroid chordoma Recognition of this subtype is important because these malignancies should be treated aggressively with multimodality therapy,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3911, 16, 8, 622, 393, 30, 1, 5, 64, 787, 2, 282, 761, 571, 815, 1240, 1442, 3911, 5, 5952, 407, 71, 85, 1027, 26, 45, 2869, 3, 1399, 404, 1, 1240, 1442, 3911, 5, 5952, 407, 4, 3, 2166, 988, 6, 1244, 8, 1901, 1, 1064, 59, 2289, 1759, 28, 10704, 108, 326, 7, 5, 1240, 1442, 3911, 1382, 7742, 11, 194, 876, 882, 25, 3065, 2, 1066, 1026, 11618, 418, 895, 72, 25, 5, 127, 814, 3, 7, 78, 326, 11, 265, 28, 8, 52, 89, 1, 175, 60, 184, 14, 462, 57, 7268, 4, 3, 5054, 1782, 2, 29835, 78, 79, 326, 699, 2342, 78, 49, 326, 531, 2, 11629, 15, 43903, 78, 27, 326, 245, 3, 38, 82, 1, 46, 7, 2271, 22893, 10, 82, 4707, 78, 67, 245, 584, 82, 3381, 78, 49, 245, 519, 82, 14820, 78, 14, 245, 49, 2, 82, 16030, 78, 18, 245, 233, 3, 57, 11, 3317, 1, 13568, 1, 3838, 37, 5, 928, 14152, 4834, 9757, 4558, 2, 101, 7246, 57, 11, 109, 9, 4292, 78, 203, 203, 394, 2, 19979, 78, 203, 203, 394, 7, 11, 73, 5, 8, 150, 1, 1366, 121, 36, 2, 56, 77, 523, 4, 63, 25, 91, 115, 25, 293, 182, 98, 2, 278, 115, 25, 10, 108, 59, 1240, 1442, 3911, 1, 3, 5054, 1782, 2, 1, 3, 2342, 72, 6, 127, 3911, 814, 1240, 1442, 3911, 71, 8, 97, 340, 313, 63, 25, 50, 1541, 20, 606, 19, 13, 5171, 815, 1240, 1442, 3911, 71, 8, 834, 38, 2, 1382, 800, 5, 2037, 5952, 407, 2, 340, 25, 72, 6, 809, 15590, 3911, 2335, 1, 26, 875, 16, 305, 408, 46, 441, 257, 40, 73, 8503, 5, 2425, 36]",1826.0,29483606,387
A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes-Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2018-05-01,"A global unmet medical need exists for effective treatments for persistent, recurrent, or metastatic cervical cancer, as patients have a short life expectancy. Recently, immunotherapies have shown promising survival benefits for patients with advanced forms of cancer. Axalimogene filolisbac (ADXS11-001), a Listeria monocytogenes immunotherapy with a broad effect on the immune system, is under investigation for treatment of human papillomavirus-associated cancers including cervical cancer. This phase 2 study evaluated the safety and efficacy of ADXS11-001, administered with or without cisplatin, in patients with recurrent/refractory cervical cancer following prior chemotherapy and/or radiotherapy. A total of 109 patients were treated, and 69 were evaluable for tumor response at equal to or more than 3 months postbaseline. Median overall survival (OS) was comparable between treatment groups (ADXS11-001: 8.28 months; 95% confidence interval [CI], 5.85-10.5 months; ADXS11-001 + cisplatin: 8.78 months; 95% CI, 7.4-13.3 months). The 12- and 18-month milestone OS rates were 30.9% versus 38.9%, and 23.6% versus 25.9% for each group, respectively (34.9% and 24.8% combined). Median progression-free survival (6.10 vs 6.08 months) and the overall response rate (17.1% vs 14.7%) were similar for both groups. ADXS11-001 was generally well tolerated; adverse events were predominantly mild to moderate in severity and not related to treatment. More adverse events were reported in the combination group (429 vs 275). These promising safety and efficacy results, including the encouraging 12-month 34.9% combined OS rate, warrant further investigation of ADXS11-001 for treatment of recurrent/refractory cervical cancer.","Clinical Trial, Phase II",630.0,14.0,A global unmet medical need exists for effective treatments for persistent recurrent or metastatic cancer as patients have a short life expectancy Recently immunotherapies have shown promising survival benefits for patients with advanced forms of cancer Axalimogene filolisbac ADXS11-001 a Listeria monocytogenes immunotherapy with a broad effect on the immune system is under investigation for treatment of human papillomavirus-associated cancers including cancer This phase 2 study evaluated the safety and efficacy of ADXS11-001 administered with or without cisplatin in patients with recurrent/refractory cancer following prior chemotherapy and/or radiotherapy A total of 109 patients were treated and 69 were evaluable for tumor response at equal to or more than 3 months postbaseline Median overall survival OS was comparable between treatment groups ADXS11-001 8.28 months 95 confidence interval CI 5.85-10.5 months ADXS11-001 cisplatin 8.78 months 95 CI 7.4-13.3 months The 12- and 18-month milestone OS rates were 30.9 versus 38.9 and 23.6 versus 25.9 for each group respectively 34.9 and 24.8 combined Median progression-free survival 6.10 vs 6.08 months and the overall response rate 17.1 vs 14.7 were similar for both groups ADXS11-001 was generally well tolerated adverse events were predominantly mild to moderate in severity and not related to treatment More adverse events were reported in the combination group 429 vs 275 These promising safety and efficacy results including the encouraging 12-month 34.9 combined OS rate warrant further investigation of ADXS11-001 for treatment of recurrent/refractory cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[8, 1648, 3715, 484, 594, 2481, 9, 323, 640, 9, 1882, 387, 15, 113, 12, 22, 7, 47, 8, 978, 358, 3399, 761, 2811, 47, 443, 721, 25, 1141, 9, 7, 5, 131, 2377, 1, 12, 72370, 72371, 20057, 144, 8, 14582, 16023, 726, 5, 8, 2094, 254, 23, 3, 250, 398, 16, 669, 940, 9, 24, 1, 171, 3242, 41, 163, 141, 12, 26, 124, 18, 45, 194, 3, 367, 2, 209, 1, 20057, 144, 468, 5, 15, 187, 540, 4, 7, 5, 387, 430, 12, 366, 324, 56, 2, 15, 310, 8, 181, 1, 3486, 7, 11, 73, 2, 790, 11, 859, 9, 30, 51, 28, 2997, 6, 15, 80, 76, 27, 53, 14958, 52, 63, 25, 118, 10, 1279, 59, 24, 271, 20057, 144, 66, 339, 53, 48, 307, 268, 58, 33, 772, 79, 33, 53, 20057, 144, 540, 66, 833, 53, 48, 58, 67, 39, 233, 27, 53, 3, 133, 2, 203, 811, 12821, 118, 151, 11, 201, 83, 185, 519, 83, 2, 382, 49, 185, 243, 83, 9, 296, 87, 106, 562, 83, 2, 259, 66, 397, 52, 91, 115, 25, 49, 79, 105, 49, 1592, 53, 2, 3, 63, 51, 116, 269, 14, 105, 213, 67, 11, 288, 9, 110, 271, 20057, 144, 10, 1228, 149, 421, 290, 281, 11, 2117, 1980, 6, 1163, 4, 1702, 2, 44, 139, 6, 24, 80, 290, 281, 11, 210, 4, 3, 150, 87, 8406, 105, 5620, 46, 721, 367, 2, 209, 99, 141, 3, 2269, 133, 811, 562, 83, 397, 118, 116, 2946, 195, 940, 1, 20057, 144, 9, 24, 1, 387, 430, 12]",1628.0,29538258,580
Knowledge and attitude of women attending Subharti Medical College towards Pap smear.,Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology,J Obstet Gynaecol,2018-03-19,"The aim of this prospective study was to assess the knowledge and attitude of women towards the Pap smear. It was carried out on the women coming to the Department of Obstetrics and Gynaecology at our University, with the help of a pre-formed questionnaire. We found that only 33% of the women were aware of the Pap smear, and of these hardly (10%) had the correct information. Sixty-five percent of the women said that they would have gotten the Pap smear done, if they had known about it earlier. Unless this knowledge amongst women is improved and their attitude is changed, the indices of cervical cancer cannot be improved. Impact statement What is already known on this subject? A Pap smear is used as a screening test to detect not only early stages of cervical cancer but also the precancerous conditions. A Pap smear is done every three years for routine screening, or every five years along with an HPV DNA test. What do the results of this study add? Despite the efforts from the medical fraternity and governments, the number of women undergoing this test in Uttar Pradesh is very minimal. This study analysed the knowledge and attitude of women towards the Pap smear. What are the implications of these findings for clinical practice and/or further research? The results have brought into light the many factors hindering an effective cervical cancer screening in India. Further actions need to be directed in the direction to address these issues.",Journal Article,673.0,1.0,The aim of this prospective study was to assess the knowledge and attitude of women towards the Pap smear It was carried out on the women coming to the Department of Obstetrics and Gynaecology at our University with the help of a pre-formed questionnaire We found that only 33 of the women were aware of the Pap smear and of these hardly 10 had the correct information Sixty-five percent of the women said that they would have gotten the Pap smear done if they had known about it earlier Unless this knowledge amongst women is improved and their attitude is changed the indices of cancer can not be improved Impact statement What is already known on this subject A Pap smear is used as a screening test to detect not only early stages of cancer but also the precancerous conditions A Pap smear is done every three years for routine screening or every five years along with an HPV DNA test What do the results of this study add Despite the efforts from the medical fraternity and governments the number of women undergoing this test in Uttar Pradesh is very minimal This study analysed the knowledge and attitude of women towards the Pap smear What are the implications of these findings for clinical practice and/or further research The results have brought into light the many factors hindering an effective cancer screening in India Further actions need to be directed in the direction to address these issues,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1130, 1, 26, 482, 45, 10, 6, 423, 3, 922, 2, 18476, 1, 117, 3113, 3, 4290, 8379, 192, 10, 2629, 1205, 23, 3, 117, 10671, 6, 3, 4271, 1, 7407, 2, 72388, 28, 114, 1652, 5, 3, 987, 1, 8, 671, 3516, 1770, 21, 204, 17, 158, 466, 1, 3, 117, 11, 4749, 1, 3, 4290, 8379, 2, 1, 46, 26009, 79, 42, 3, 4883, 487, 1746, 365, 714, 1, 3, 117, 12159, 17, 491, 688, 47, 43495, 3, 4290, 8379, 1822, 492, 491, 42, 440, 545, 192, 1677, 6179, 26, 922, 7212, 117, 16, 231, 2, 136, 18476, 16, 2368, 3, 3824, 1, 12, 122, 44, 40, 231, 345, 5914, 2067, 16, 3298, 440, 23, 26, 2974, 8, 4290, 8379, 16, 95, 22, 8, 453, 412, 6, 1426, 44, 158, 191, 1153, 1, 12, 84, 120, 3, 6605, 1298, 8, 4290, 8379, 16, 1822, 454, 169, 60, 9, 1311, 453, 15, 454, 365, 60, 1510, 5, 35, 933, 261, 412, 2067, 1022, 3, 99, 1, 26, 45, 4178, 550, 3, 1413, 29, 3, 484, 50940, 2, 24055, 3, 207, 1, 117, 479, 26, 412, 4, 72389, 72390, 16, 923, 1048, 26, 45, 3141, 3, 922, 2, 18476, 1, 117, 3113, 3, 4290, 8379, 2067, 32, 3, 1268, 1, 46, 272, 9, 38, 758, 2, 15, 195, 389, 3, 99, 47, 6681, 237, 1691, 3, 445, 130, 19607, 35, 323, 12, 453, 4, 7776, 195, 5592, 594, 6, 40, 1166, 4, 3, 4651, 6, 1539, 46, 1553]",1411.0,29553837,300
The impact of daily bladder filling on small bowel dose for intensity modulated radiation therapy for cervical cancer.,Medical dosimetry : official journal of the American Association of Medical Dosimetrists,Med Dosim,2018-03-21,"Research demonstrates that instructing patients to have a full bladder for pelvic radiotherapy results in highly variable bladder volumes at daily treatment. We aimed to determine bladder volume variation in patients with intact cervical cancer treated with intensity-modulated radiotherapy (IMRT) on an empty bladder and estimate the difference in radiation dose to the small bowel compared to treating on a full bladder. We identified 29 patients treated with IMRT from 2010 to 2013 who underwent 2 planning computed tomography (CT) scans, 1 with a full bladder followed by 1 with an empty bladder. Interfractional variation in bladder volume was measured using 782 daily cone beam computed tomography (CBCT) scans. To estimate dose to small bowel, radiation plans were created on both empty and full bladder CT scans using an automated knowledge-based planning modeling program. Mean bladder volume with empty bladder instructions was 6726cc compared to 9143cc for no bladder instructions and 15454cc for full bladder instructions (p<0.001). There was a significant reduction in the absolute bladder volume variation in patients given empty bladder instructions compared to full bladder instructions (p<0.05) The intraclass correlation coefficient showed low reliability of bladder filling across all groups (p=0.6). The average bowel V45 for the empty bladder plans was 188cc, compared to 139cc for the full bladder plans (p<0.05). More plans created on an empty bladder exceeded Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) guidelines but this was not significant (31% vs 14%, p=0.12). Reliability of bladder volume at the time of radiation treatment is low, regardless of bladder filling instructions, although an empty bladder reduces absolute variation in bladder volume. Radiation planning on an empty bladder predicts a larger volume of small bowel receiving 45Gy compared to a full bladder, although bowel dose on average is still within QUANTEC guidelines (V45 < 195cc).",Journal Article,671.0,2.0,Research demonstrates that instructing patients to have a full for pelvic radiotherapy results in highly variable volumes at daily treatment We aimed to determine volume variation in patients with intact cancer treated with intensity-modulated radiotherapy IMRT on an empty and estimate the difference in radiation dose to the small bowel compared to treating on a full We identified 29 patients treated with IMRT from 2010 to 2013 who underwent 2 planning computed tomography CT scans 1 with a full followed by 1 with an empty Interfractional variation in volume was measured using 782 daily cone beam computed tomography CBCT scans To estimate dose to small bowel radiation plans were created on both empty and full CT scans using an automated knowledge-based planning modeling program Mean volume with empty instructions was 67  26 cc compared to 91  43 cc for no instructions and 154  54 cc for full instructions p 0.001 There was a significant reduction in the absolute volume variation in patients given empty instructions compared to full instructions p 0.05 The intraclass correlation coefficient showed low reliability of filling across all groups p 0.6 The average bowel V45 for the empty plans was 188 cc compared to 139 cc for the full plans p 0.05 More plans created on an empty exceeded Quantitative Analyses of Normal Tissue Effects in the Clinic QUANTEC guidelines but this was not significant 31 vs 14 p 0.12 Reliability of volume at the time of radiation treatment is low regardless of filling instructions although an empty reduces absolute variation in volume Radiation planning on an empty predicts a larger volume of small bowel receiving 45 Gy compared to a full although bowel dose on average is still within QUANTEC guidelines V45 195 cc,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,"[389, 1902, 17, 72431, 7, 6, 47, 8, 1647, 9, 1110, 310, 99, 4, 561, 1347, 2225, 28, 391, 24, 21, 1295, 6, 223, 433, 1380, 4, 7, 5, 2964, 12, 73, 5, 837, 1757, 310, 964, 23, 35, 9436, 2, 1191, 3, 523, 4, 121, 61, 6, 3, 302, 1659, 72, 6, 1367, 23, 8, 1647, 21, 108, 462, 7, 73, 5, 964, 29, 1120, 6, 1346, 54, 208, 18, 1349, 1220, 872, 425, 1441, 14, 5, 8, 1647, 370, 20, 14, 5, 35, 9436, 15640, 1380, 4, 433, 10, 644, 75, 13587, 391, 6939, 1345, 1220, 872, 5187, 1441, 6, 1191, 61, 6, 302, 1659, 121, 1853, 11, 2466, 23, 110, 9436, 2, 1647, 425, 1441, 75, 35, 3235, 922, 90, 1349, 2057, 1243, 313, 433, 5, 9436, 14875, 10, 598, 810, 432, 1951, 72, 6, 970, 810, 601, 1951, 9, 77, 14875, 2, 4838, 810, 667, 1951, 9, 1647, 14875, 19, 13, 144, 125, 10, 8, 93, 628, 4, 3, 1766, 433, 1380, 4, 7, 447, 9436, 14875, 72, 6, 1647, 14875, 19, 13, 474, 3, 10892, 816, 3200, 224, 154, 4217, 1, 13930, 716, 62, 271, 19, 13, 49, 3, 1011, 1659, 16984, 9, 3, 9436, 1853, 10, 5664, 1951, 72, 6, 4929, 1951, 9, 3, 1647, 1853, 19, 13, 474, 80, 1853, 2466, 23, 35, 9436, 4726, 1156, 318, 1, 295, 246, 176, 4, 3, 1188, 25788, 677, 84, 26, 10, 44, 93, 456, 105, 213, 19, 13, 133, 4217, 1, 433, 28, 3, 98, 1, 121, 24, 16, 154, 1583, 1, 13930, 14875, 242, 35, 9436, 2389, 1766, 1380, 4, 433, 121, 1349, 23, 35, 9436, 2623, 8, 1077, 433, 1, 302, 1659, 357, 512, 381, 72, 6, 8, 1647, 242, 1659, 61, 23, 1011, 16, 1234, 262, 25788, 677, 16984, 5786, 1951]",1765.0,29573921,171
Racial and ethnic disparities over time in the treatment and mortality of women with gynecological malignancies.,Gynecologic oncology,Gynecol. Oncol.,2018-04-01,"To examine temporal trends in treatment and survival among black, Asian, Hispanic, and white women diagnosed with endometrial, ovarian, cervical, and vulvar cancer. Using the National Cancer Database (2004-2014), we identified women diagnosed with endometrial, ovarian, cervical, and vulvar cancer. For each disease site, we analyzed race/ethnicity-specific trends in receipt of evidence-based practices. Professional societies' recommendations were used to define these practices. Using data from the Surveillance, Epidemiology, and End Results Program (2000-2009) we analyzed trends in 5-year survival. Throughout the study period black (64.8%) and Hispanic (68.3%) women were less likely to undergo lymphadenectomy for stage I ovarian cancer compared to Asian (79.5%) and white patients (74.6%). Black women were the least likely group to undergo lymphadenectomy in all periods. Among patients with stage II-IV ovarian cancer, 76.6% of white and Asian women received both surgery and chemotherapy, compared to 70.8% of black and 73.9% Hispanic women. Hispanic women with deeply invasive or high-grade stage I endometrial cancer underwent lymphadenectomy less frequently (74.5%) than all other groups (80.7%). Black women were less likely to have chemo-radiotherapy for stage IIB-IVA cervical cancer (75.6% versus 80.4% of all others). Black women were also less likely to have a surgical lymph node evaluation for vulvar cancer (58.8% versus 63.5% of all others). Among women diagnosed with ovarian, endometrial, and cervical cancer, black women had lower five-year survival than other groups. Significant racial disparities persist in the delivery of evidence-based care. Black women with ovarian, endometrial, and cervical cancer continue to experience higher cancer-specific mortality than other groups.",Journal Article,660.0,10.0,To examine temporal trends in treatment and survival among black Asian Hispanic and white women diagnosed with and cancer Using the National Cancer Database 2004-2014 we identified women diagnosed with and cancer For each disease site we analyzed race/ethnicity-specific trends in receipt of evidence-based practices Professional societies recommendations were used to define these practices Using data from the Surveillance Epidemiology and End Results Program 2000-2009 we analyzed trends in 5-year survival Throughout the study period black 64.8 and Hispanic 68.3 women were less likely to undergo lymphadenectomy for stage I cancer compared to Asian 79.5 and white patients 74.6 Black women were the least likely group to undergo lymphadenectomy in all periods Among patients with stage II-IV cancer 76.6 of white and Asian women received both surgery and chemotherapy compared to 70.8 of black and 73.9 Hispanic women Hispanic women with deeply invasive or high-grade stage I cancer underwent lymphadenectomy less frequently 74.5 than all other groups 80.7 Black women were less likely to have chemo-radiotherapy for stage IIB-IVA cancer 75.6 versus 80.4 of all others Black women were also less likely to have a surgical lymph node evaluation for cancer 58.8 versus 63.5 of all others Among women diagnosed with and cancer black women had lower five-year survival than other groups Significant racial disparities persist in the delivery of evidence-based care Black women with and cancer continue to experience higher cancer-specific mortality than other groups,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 1004, 3264, 1963, 4, 24, 2, 25, 107, 1445, 2399, 1776, 2, 886, 117, 265, 5, 2, 12, 75, 3, 657, 12, 609, 1131, 1409, 21, 108, 117, 265, 5, 2, 12, 9, 296, 34, 606, 21, 311, 1047, 2091, 112, 1963, 4, 1699, 1, 241, 90, 2634, 5341, 10600, 883, 11, 95, 6, 1107, 46, 2634, 75, 74, 29, 3, 617, 1284, 2, 396, 99, 1243, 1081, 1238, 21, 311, 1963, 4, 33, 111, 25, 2432, 3, 45, 727, 1445, 660, 66, 2, 1776, 806, 27, 117, 11, 299, 322, 6, 1251, 2048, 9, 82, 70, 12, 72, 6, 2399, 842, 33, 2, 886, 7, 794, 49, 1445, 117, 11, 3, 506, 322, 87, 6, 1251, 2048, 4, 62, 3338, 107, 7, 5, 82, 215, 478, 12, 846, 49, 1, 886, 2, 2399, 117, 103, 110, 152, 2, 56, 72, 6, 431, 66, 1, 1445, 2, 803, 83, 1776, 117, 1776, 117, 5, 16394, 416, 15, 64, 88, 82, 70, 12, 208, 2048, 299, 746, 794, 33, 76, 62, 127, 271, 493, 67, 1445, 117, 11, 299, 322, 6, 47, 3341, 310, 9, 82, 3884, 5900, 12, 481, 49, 185, 493, 39, 1, 62, 1749, 1445, 117, 11, 120, 299, 322, 6, 47, 8, 221, 263, 289, 451, 9, 12, 717, 66, 185, 676, 33, 1, 62, 1749, 107, 117, 265, 5, 2, 12, 1445, 117, 42, 280, 365, 111, 25, 76, 127, 271, 93, 2257, 2227, 5589, 4, 3, 989, 1, 241, 90, 165, 1445, 117, 5, 2, 12, 1906, 6, 730, 142, 12, 112, 282, 76, 127, 271]",1567.0,29605048,819
Improving cancer care for American Indians with cervical cancer in the Indian Health Service (IHS) system - Navigation may not be enough.,Gynecologic oncology,Gynecol. Oncol.,2018-04-01,"Patient navigation programs have been shown to positively impact cancer outcomes for minority populations. Little is known regarding the effects of these programs on American Indian (AI) populations. The purpose of this study is to characterize the impact of a patient navigation program on AI cervical cancer patients at a tertiary care center. A retrospective review of all AI cervical cancer patients receiving navigation services and a cohort of AI patients treated prior to navigation services was performed. Additional comparisons were made between those with and without Indian Health Service (IHS) funding. Summary statistics were used to describe demographic, clinical characteristics, treatment, and survivorship across groups. Of 55 patients identified, 34 received navigation and 21 did not. In navigated patients, median age was 46years (27-80years) compared with 42years (17-68years) in pre-navigation patients (p=0.53). There was no difference between stage at diagnosis (p=0.73). No difference was noted in treatment received between groups (p=0.48). Distance traveled for treatment between groups did not differ (p=0.46). Median time to initiation of treatment was not different between groups, 30.5days vs. 27.5days (p=0.18). Among patients with IHS funding, navigation services did not alter time to initiation of treatment (p=0.57), and there was no difference in completion of prescribed therapy between groups (92% navigated vs 100% pre-navigation). Navigation services for AI cervical cancer patients did not alter initiation or completion of treatment. Navigation programs may provide less tangible benefits to AI cervical cancer patients and further study is warranted.",Journal Article,660.0,0.0,Patient navigation programs have been shown to positively impact cancer outcomes for minority populations Little is known regarding the effects of these programs on American Indian AI populations The purpose of this study is to characterize the impact of a patient navigation program on AI cancer patients at a tertiary care center A retrospective review of all AI cancer patients receiving navigation services and a cohort of AI patients treated prior to navigation services was performed Additional comparisons were made between those with and without Indian Health Service IHS funding Summary statistics were used to describe demographic clinical characteristics treatment and survivorship across groups Of 55 patients identified 34 received navigation and 21 did not In navigated patients median age was 46years 27-80years compared with 42years 17-68years in pre-navigation patients p=0.53 There was no difference between stage at diagnosis p=0.73 No difference was noted in treatment received between groups p=0.48 Distance traveled for treatment between groups did not differ p=0.46 Median time to initiation of treatment was not different between groups 30.5days vs. 27.5days p=0.18 Among patients with IHS funding navigation services did not alter time to initiation of treatment p=0.57 and there was no difference in completion of prescribed therapy between groups 92 navigated vs 100 pre-navigation Navigation services for AI cancer patients did not alter initiation or completion of treatment Navigation programs may provide less tangible benefits to AI cancer patients and further study is warranted,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[69, 5604, 2251, 47, 85, 443, 6, 2375, 345, 12, 123, 9, 2652, 1184, 1215, 16, 440, 666, 3, 176, 1, 46, 2251, 23, 597, 7968, 2247, 1184, 3, 743, 1, 26, 45, 16, 6, 1507, 3, 345, 1, 8, 69, 5604, 1243, 23, 2247, 12, 7, 28, 8, 2557, 165, 574, 8, 459, 206, 1, 62, 2247, 12, 7, 357, 5604, 2142, 2, 8, 180, 1, 2247, 7, 73, 324, 6, 5604, 2142, 10, 173, 402, 2213, 11, 1229, 59, 135, 5, 2, 187, 7968, 341, 3086, 37085, 5468, 1962, 3065, 11, 95, 6, 897, 1540, 38, 374, 24, 2, 2560, 716, 271, 1, 614, 7, 108, 562, 103, 5604, 2, 239, 205, 44, 4, 15373, 7, 52, 89, 10, 72485, 428, 72486, 72, 5, 72487, 269, 35777, 4, 671, 5604, 7, 19, 13, 699, 125, 10, 77, 523, 59, 82, 28, 147, 19, 13, 803, 77, 523, 10, 1051, 4, 24, 103, 59, 271, 19, 13, 576, 3019, 12590, 9, 24, 59, 271, 205, 44, 1505, 19, 13, 641, 52, 98, 6, 1118, 1, 24, 10, 44, 338, 59, 271, 201, 29680, 105, 428, 29680, 19, 13, 203, 107, 7, 5, 37085, 5468, 5604, 2142, 205, 44, 2688, 98, 6, 1118, 1, 24, 19, 13, 696, 2, 125, 10, 77, 523, 4, 1438, 1, 2746, 36, 59, 271, 937, 15373, 105, 394, 671, 5604, 5604, 2142, 9, 2247, 12, 7, 205, 44, 2688, 1118, 15, 1438, 1, 24, 5604, 2251, 68, 377, 299, 19079, 1141, 6, 2247, 12, 7, 2, 195, 45, 16, 1197]",1611.0,29605056,91
Spermidineinduced growth inhibition and apoptosis via autophagic activation in cervical cancer.,Oncology reports,Oncol. Rep.,2018-04-18,"Cervical cancer is the most common malignancy of the female reproductive tract, and the poor response to prophylactic vaccines and the toxicity of highdose chemotherapeutic drugs have limited their clinical application. Spermidine, a natural polyamine detected in all eukaryotic organisms, exhibits functions that promote longevity in multiple model systems and may constitute a promising agent for cancer treatment. However, the potential effectiveness of spermidine in cervical cancer has not yet been fully elucidated, and the underlying molecular mechanisms remain unclear. In the present study, we aimed to assess the effects of spermidine on proliferation and apoptosis of HeLa cells (a cervical cancer cell line). Firstly, CCK8 and flow cytometric assays revealed that spermidine reduced the proliferation of HeLa cells in a dosedependent fashion by arresting the cell cycle at the Sphase. Secondly, flow cytometry incorporating AnnexinVFITC/PIstaining revealed that spermidine promoted the apoptosis of HeLa cells, and western blot analysis revealed that spermidine activated autophagy. Finally, spermidineactivated autophagy mediated the inhibition of cell proliferation by spermidine and spermidineinduced apoptosis in HeLa cells. Collectively, these results revealed a novel function for spermidine in inhibiting cellular proliferation and inducing apoptosis of HeLa cells by activating autophagy, which may have important implications for the use of spermidine in cervical cancer therapy.",Journal Article,643.0,1.0,cancer is the most common malignancy of the female reproductive tract and the poor response to prophylactic vaccines and the toxicity of highdose chemotherapeutic drugs have limited their clinical application Spermidine a natural polyamine detected in all eukaryotic organisms exhibits functions that promote longevity in multiple model systems and may constitute a promising agent for cancer treatment However the potential effectiveness of spermidine in cancer has not yet been fully elucidated and the underlying molecular mechanisms remain unclear In the present study we aimed to assess the effects of spermidine on proliferation and apoptosis of HeLa cells a cancer cell line Firstly CCK8 and flow cytometric assays revealed that spermidine reduced the proliferation of HeLa cells in a dosedependent fashion by arresting the cell cycle at the S phase Secondly flow cytometry incorporating Annexin VFITC/PIstaining revealed that spermidine promoted the apoptosis of HeLa cells and western blot analysis revealed that spermidine activated autophagy Finally spermidineactivated autophagy mediated the inhibition of cell proliferation by spermidine and spermidineinduced apoptosis in HeLa cells Collectively these results revealed a novel function for spermidine in inhibiting cellular proliferation and inducing apoptosis of HeLa cells by activating autophagy which may have important implications for the use of spermidine in cancer therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 3, 96, 186, 710, 1, 3, 1061, 3705, 1696, 2, 3, 334, 51, 6, 1862, 1842, 2, 3, 155, 1, 72614, 1573, 600, 47, 383, 136, 38, 1581, 15528, 8, 1504, 11433, 530, 4, 62, 8374, 9694, 4273, 1681, 17, 1617, 15187, 4, 232, 202, 1530, 2, 68, 4999, 8, 721, 420, 9, 12, 24, 137, 3, 174, 1236, 1, 15528, 4, 12, 71, 44, 1145, 85, 1910, 3901, 2, 3, 1181, 219, 483, 918, 1200, 4, 3, 364, 45, 21, 1295, 6, 423, 3, 176, 1, 15528, 23, 457, 2, 351, 1, 8466, 37, 8, 12, 31, 328, 16535, 72615, 2, 1412, 6226, 1013, 553, 17, 15528, 405, 3, 457, 1, 8466, 37, 4, 8, 48387, 3240, 20, 18265, 3, 31, 417, 28, 3, 695, 124, 18904, 1412, 1914, 2570, 4850, 72616, 72617, 553, 17, 15528, 2992, 3, 351, 1, 8466, 37, 2, 1521, 2639, 65, 553, 17, 15528, 735, 2240, 1368, 72618, 2240, 517, 3, 297, 1, 31, 457, 20, 15528, 2, 72619, 351, 4, 8466, 37, 2535, 46, 99, 553, 8, 229, 343, 9, 15528, 4, 2062, 763, 457, 2, 1958, 351, 1, 8466, 37, 20, 1616, 2240, 92, 68, 47, 305, 1268, 9, 3, 119, 1, 15528, 4, 12, 36]",1451.0,29693131,424
HPV: Molecular pathways and targets.,Current problems in cancer,Curr Probl Cancer,2018-04-05,"Infection of high-risk human papillomaviruses (HPVs) is a prerequisite for the development of cervical carcinoma. HPV infections are also implicated in the development of other types of carcinomas. Chronic or persistent infection of HPV is essential but HPV alone is inadequate, additional endogenous or exogenous cues are needed along with HPV to induce cervical carcinogenesis. The strategies that high-risk HPVs have developed in differentiating epithelial cells to reach a DNA-synthesis competent state leading to tumorigenic transformation are basically due to overexpression of the E6 and E7 oncoproteins and the activation of diverse cellular regulatory or signaling pathways that are targeted by them. Moreover, the Wnt/-catenin/Notch and phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathways are deregulated in various cancers, and have also been implicated in HPV-induced cancers. These are basically related to the ""cancer hallmarks,"" and include sustaining proliferative signals, the evasion of growth suppression and immune destruction, replicative immortality, inflammation, invasion, metastasis and angiogenesis, as well as genome instability, resisting cell death, and deregulation of cellular energetics. These information could eventually aid in identifying or developing new diagnostic, prognostic biomarkers, and may contribute to design more effective targeted therapeutics and treatment strategies. Although surgery, chemotherapy and radiotherapy can cure more than 90% of women with early stage cervical cancer, the recurrent and metastatic disease remains a major cause of cancer mortality. Numerous efforts have been made to design new drugs and develop gene therapies to treat cervical cancer. In recent years, research on treatment strategies has proposed several options, including the role of HPV E5, E6, and E7 oncogenes, which are retained and overexpressed in most of the cervical cancers and whose respective oncoproteins are critical to the induction and maintenance of the malignant phenotype. Other efforts have been focused on antitumor immunotherapy strategies. It is known that during the development of cervical cancer, a cascade of abnormal events is induced, including disruption of cell cycle control, perturbation of antitumor immune response, alteration of gene expression, deregulation of microRNA and cancer stem cell and stemness related markers expression could serve as novel molecular targets for reliable diagnosis and treatment of HPV-positive cancers. However, the search for new proposals for disease control and prevention has brought new findings and approaches in the context of molecular biology indicating innovations and perspectives in the early detection and prevention of the disease. Thus, in this article, we discuss molecular signaling pathways activated by HPV and potential targets or biomarkers for early detection or prevention and the treatment of HPV-associated cancers.",Journal Article,656.0,13.0,Infection of high-risk human papillomaviruses HPVs is a prerequisite for the development of carcinoma HPV infections are also implicated in the development of other types of carcinomas Chronic or persistent infection of HPV is essential but HPV alone is inadequate additional endogenous or exogenous cues are needed along with HPV to induce carcinogenesis The strategies that high-risk HPVs have developed in differentiating epithelial cells to reach a DNA-synthesis competent state leading to tumorigenic transformation are basically due to overexpression of the E6 and E7 oncoproteins and the activation of diverse cellular regulatory or signaling pathways that are targeted by them Moreover the Wnt/-catenin/Notch and phosphoinositide 3-kinase PI3K /protein kinase B Akt pathways are deregulated in various cancers and have also been implicated in HPV-induced cancers These are basically related to the `` cancer hallmarks '' and include sustaining proliferative signals the evasion of growth suppression and immune destruction replicative immortality inflammation invasion metastasis and angiogenesis as well as genome instability resisting cell death and deregulation of cellular energetics These information could eventually aid in identifying or developing new diagnostic prognostic biomarkers and may contribute to design more effective targeted therapeutics and treatment strategies Although surgery chemotherapy and radiotherapy can cure more than 90 of women with early stage cancer the recurrent and metastatic disease remains a major cause of cancer mortality Numerous efforts have been made to design new drugs and develop gene therapies to treat cancer In recent years research on treatment strategies has proposed several options including the role of HPV E5 E6 and E7 oncogenes which are retained and overexpressed in most of the cancers and whose respective oncoproteins are critical to the induction and maintenance of the malignant phenotype Other efforts have been focused on antitumor immunotherapy strategies It is known that during the development of cancer a cascade of abnormal events is induced including disruption of cell cycle control perturbation of antitumor immune response alteration of gene expression deregulation of microRNA and cancer stem cell and stemness related markers expression could serve as novel molecular targets for reliable diagnosis and treatment of HPV-positive cancers However the search for new proposals for disease control and prevention has brought new findings and approaches in the context of molecular biology indicating innovations and perspectives in the early detection and prevention of the disease Thus in this article we discuss molecular signaling pathways activated by HPV and potential targets or biomarkers for early detection or prevention and the treatment of HPV-associated cancers,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[930, 1, 64, 43, 171, 14731, 13477, 16, 8, 12088, 9, 3, 193, 1, 134, 933, 1875, 32, 120, 1771, 4, 3, 193, 1, 127, 630, 1, 826, 442, 15, 1882, 930, 1, 933, 16, 1452, 84, 933, 279, 16, 3358, 402, 2682, 15, 4181, 15209, 32, 575, 1510, 5, 933, 6, 1290, 1719, 3, 422, 17, 64, 43, 13477, 47, 276, 4, 5209, 701, 37, 6, 3690, 8, 261, 2525, 6299, 1309, 1049, 6, 3795, 1392, 32, 27664, 520, 6, 851, 1, 3, 4837, 2, 4540, 8241, 2, 3, 363, 1, 1867, 763, 1253, 15, 314, 460, 17, 32, 238, 20, 1370, 1393, 3, 2112, 1458, 1778, 3193, 2, 4497, 27, 216, 974, 178, 216, 132, 649, 460, 32, 5415, 4, 747, 163, 2, 47, 120, 85, 1771, 4, 933, 277, 163, 46, 32, 27664, 139, 6, 3, 12, 7693, 522, 2, 643, 10100, 2441, 2312, 3, 5351, 1, 129, 1332, 2, 250, 4572, 14529, 32520, 1815, 578, 278, 2, 1056, 22, 149, 22, 898, 1753, 39053, 31, 273, 2, 4765, 1, 763, 29395, 46, 487, 359, 3124, 2427, 4, 1386, 15, 931, 217, 752, 177, 582, 2, 68, 1248, 6, 771, 80, 323, 238, 1943, 2, 24, 422, 242, 152, 56, 2, 310, 122, 1722, 80, 76, 424, 1, 117, 5, 191, 82, 12, 3, 387, 2, 113, 34, 469, 8, 458, 708, 1, 12, 282, 2331, 1413, 47, 85, 1229, 6, 771, 217, 600, 2, 690, 145, 235, 6, 943, 12, 4, 435, 60, 389, 23, 24, 422, 71, 1587, 392, 838, 141, 3, 200, 1, 933, 16072, 4837, 2, 4540, 3326, 92, 32, 3532, 2, 1711, 4, 96, 1, 3, 163, 2, 1310, 3847, 8241, 32, 740, 6, 3, 504, 2, 1146, 1, 3, 393, 1005, 127, 1413, 47, 85, 1649, 23, 579, 726, 422, 192, 16, 440, 17, 190, 3, 193, 1, 12, 8, 4678, 1, 1668, 281, 16, 277, 141, 3220, 1, 31, 417, 182, 10564, 1, 579, 250, 51, 2611, 1, 145, 55, 4765, 1, 3213, 2, 12, 452, 31, 2, 6591, 139, 525, 55, 359, 1833, 22, 229, 219, 637, 9, 2450, 147, 2, 24, 1, 933, 109, 163, 137, 3, 1901, 9, 217, 11913, 9, 34, 182, 2, 1070, 71, 6681, 217, 272, 2, 611, 4, 3, 1533, 1, 219, 891, 1716, 10081, 2, 5856, 4, 3, 191, 638, 2, 1070, 1, 3, 34, 631, 4, 26, 946, 21, 1139, 219, 314, 460, 735, 20, 933, 2, 174, 637, 15, 582, 9, 191, 638, 15, 1070, 2, 3, 24, 1, 933, 41, 163]",2856.0,29706467,238
Underutilization of brachytherapy and disparities in survival for patients with cervical cancer in California.,Gynecologic oncology,Gynecol. Oncol.,2018-04-27,"The treatment for locally advanced cervical cancer is external beam radiation (EBRT), concurrent chemotherapy, and brachytherapy (BT). We investigated demographic and socioeconomic factors that influence trends in BT utilization and disparities in survival. Using the California Cancer Registry, cervical cancer patients FIGO IB2-IVA from 2004 to 2014 were identified. We collected tumor, demographic and socioeconomic (SES) factors. We used multivariable logistic regression analysis to determine predictors of use of BT. Using Cox proportional hazards, we examined the impact of BT vs EBRT boost on cause specific (CSS) and overall survival (OS). We identified 4783 patients with FIGO stage 11% IB2; 32% II, 54% III, 3% IVA. Nearly half (45%) of patients were treated with BT, 18% were treated with a EBRT boost, and 37% had no boost. Stage II and III were more likely to be treated with BT (p=0.002 and p=0.0168) vs Stage IB2. As patients aged, the use of BT decreased. Using multivariate analysis, BT impacted CCS (HR 1.16, p=0.0330) and OS (HR 1.14, p=0.0333). Worse CSS was observed for black patients (p=0.0002), low SES (p=0.0263), stage III and IVA (p<0.0001. Black patients, low and middle SES had worse OS, (p=0.0003). The utilization of BT in locally advanced cervical cancer was low at 45%, with a decrease in CSS and OS. Black patients and those in low SES had worse CSS. As we strive for outcome improvement in cervical cancer, we need to target increasing access and disparities for quality and value.",Journal Article,634.0,6.0,The treatment for locally advanced cancer is external beam radiation EBRT concurrent chemotherapy and brachytherapy BT We investigated demographic and socioeconomic factors that influence trends in BT utilization and disparities in survival Using the California Cancer Registry cancer patients FIGO IB2-IVA from 2004 to 2014 were identified We collected tumor demographic and socioeconomic SES factors We used multivariable logistic regression analysis to determine predictors of use of BT Using Cox proportional hazards we examined the impact of BT vs EBRT boost on cause specific CSS and overall survival OS We identified 4783 patients with FIGO stage 11 IB2 32 II 54 III 3 IVA Nearly half 45 of patients were treated with BT 18 were treated with a EBRT boost and 37 had no boost Stage II and III were more likely to be treated with BT p 0.002 and p 0.0168 vs Stage IB2 As patients aged the use of BT decreased Using multivariate analysis BT impacted CCS HR 1.16 p 0.0330 and OS HR 1.14 p 0.0333 Worse CSS was observed for black patients p 0.0002 low SES p 0.0263 stage III and IVA p 0.0001 Black patients low and middle SES had worse OS p 0.0003 The utilization of BT in locally advanced cancer was low at 45 with a decrease in CSS and OS Black patients and those in low SES had worse CSS As we strive for outcome improvement in cancer we need to target increasing access and disparities for quality and value,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 24, 9, 795, 131, 12, 16, 1455, 1345, 121, 1883, 750, 56, 2, 1536, 3641, 21, 565, 1540, 2, 3331, 130, 17, 1054, 1963, 4, 3641, 1961, 2, 2227, 4, 25, 75, 3, 4355, 12, 1608, 12, 7, 3837, 9537, 5900, 29, 1131, 6, 1409, 11, 108, 21, 786, 30, 1540, 2, 3331, 5699, 130, 21, 95, 658, 812, 320, 65, 6, 223, 674, 1, 119, 1, 3641, 75, 418, 831, 1017, 21, 409, 3, 345, 1, 3641, 105, 1883, 2569, 23, 708, 112, 2687, 2, 63, 25, 118, 21, 108, 20538, 7, 5, 3837, 82, 175, 9537, 531, 215, 667, 316, 27, 5900, 1857, 1303, 512, 1, 7, 11, 73, 5, 3641, 203, 11, 73, 5, 8, 1883, 2569, 2, 567, 42, 77, 2569, 82, 215, 2, 316, 11, 80, 322, 6, 40, 73, 5, 3641, 19, 13, 1111, 2, 19, 13, 72647, 105, 82, 9537, 22, 7, 1032, 3, 119, 1, 3641, 340, 75, 331, 65, 3641, 4619, 5688, 168, 14, 245, 19, 13, 72648, 2, 118, 168, 14, 213, 19, 13, 34187, 639, 2687, 10, 164, 9, 1445, 7, 19, 13, 3531, 154, 5699, 19, 13, 51027, 82, 316, 2, 5900, 19, 13, 488, 1445, 7, 154, 2, 3897, 5699, 42, 639, 118, 19, 13, 4418, 3, 1961, 1, 3641, 4, 795, 131, 12, 10, 154, 28, 512, 5, 8, 775, 4, 2687, 2, 118, 1445, 7, 2, 135, 4, 154, 5699, 42, 639, 2687, 22, 21, 16837, 9, 228, 767, 4, 12, 21, 594, 6, 283, 602, 1655, 2, 2227, 9, 372, 2, 549]",1412.0,29709291,183
The role of bevacizumab on tumour angiogenesis and in the management of gynaecological cancers: A review.,Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,Biomed. Pharmacother.,2018-04-05,"The study aims to analyze the effectiveness of bevacizumab in addressing the complications associated with gynecological cancers and evaluates effective treatments for various gynecological cancers. The study follows a systematic review approach that has been implemented to analyze the qualitative published data from previous studies. Studies related with the trials of angiogenesis and bevacizumab were selected in the review. In general, the management of gynecological cancers include chemotherapy, surgery and radiation therapy. Results suggest bevacizumab as an effective treatment modality for cervical and several other cancers. Overall, bevacizumab showed promising results in improving the overall survival rate of gynecological cancer patients through the combination of bevacizumab with other chemotherapeutic agents. Bevacizumab possess less documented adverse effects when compared to other chemotherapeutic agents. The manifestation and severity of adverse effects reported varied according to the chemotherapeutic agent(s) that were used with bevacizumab in combination therapy. Overall, bevacizumab effectively improved the survival rate in patients with several gynaecological cancers.",Journal Article,656.0,13.0,The study aims to analyze the effectiveness of bevacizumab in addressing the complications associated with gynecological cancers and evaluates effective treatments for various gynecological cancers The study follows a systematic review approach that has been implemented to analyze the qualitative published data from previous studies Studies related with the trials of angiogenesis and bevacizumab were selected in the review In general the management of gynecological cancers include chemotherapy surgery and radiation therapy Results suggest bevacizumab as an effective treatment modality for and several other cancers Overall bevacizumab showed promising results in improving the overall survival rate of gynecological cancer patients through the combination of bevacizumab with other chemotherapeutic agents Bevacizumab possess less documented adverse effects when compared to other chemotherapeutic agents The manifestation and severity of adverse effects reported varied according to the chemotherapeutic agent s that were used with bevacizumab in combination therapy Overall bevacizumab effectively improved the survival rate in patients with several gynaecological cancers,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 45, 2970, 6, 1992, 3, 1236, 1, 599, 4, 3432, 3, 521, 41, 5, 6324, 163, 2, 4941, 323, 640, 9, 747, 6324, 163, 3, 45, 2962, 8, 1556, 206, 353, 17, 71, 85, 3426, 6, 1992, 3, 3926, 983, 74, 29, 698, 94, 94, 139, 5, 3, 143, 1, 1056, 2, 599, 11, 715, 4, 3, 206, 4, 1083, 3, 284, 1, 6324, 163, 643, 56, 152, 2, 121, 36, 99, 309, 599, 22, 35, 323, 24, 1396, 9, 2, 392, 127, 163, 63, 599, 224, 721, 99, 4, 1673, 3, 63, 25, 116, 1, 6324, 12, 7, 298, 3, 150, 1, 599, 5, 127, 1573, 183, 599, 5766, 299, 1405, 290, 176, 198, 72, 6, 127, 1573, 183, 3, 6746, 2, 1702, 1, 290, 176, 210, 2051, 768, 6, 3, 1573, 420, 695, 17, 11, 95, 5, 599, 4, 150, 36, 63, 599, 1856, 231, 3, 25, 116, 4, 7, 5, 392, 18832, 163]",1181.0,29710531,159
"Graphene oxide sensitizes cancer cells to chemotherapeutics by inducing early autophagy events, promoting nuclear trafficking and necrosis.",Theranostics,Theranostics,2018-03-28,"<b>Rationale:</b> Cisplatin (CDDP) is a broad-spectrum anticancer drug but chemoresistance to CDDP impedes its wide use for cancer therapy. Autophagy is an event occurring in the cytoplasm and cytoplasmic LC3 puncta formation is a hallmark of autophagy. Graphene oxide (GO) is a nanomaterial that provokes autophagy in CT26 colon cancer cells and confers antitumor effects. Here we aimed to evaluate whether combined use of GO with CDDP (GO/CDDP) overcomes chemoresistance in different cancer cells and uncover the underlying mechanism. <b>Methods:</b> We treated different cancer cells with GO/CDDP and evaluated the cytotoxicity, death mechanism, autophagy induction and nuclear entry of CDDP. We further knocked down genes essential for autophagic flux and deciphered which step is critical to nuclear import and cell death. Finally, we performed immunoprecipitation, mass spectrometry and immunofluorescence labeling to evaluate the association of LC3 and CDDP. <b>Results:</b> We uncovered that combination of GO and CDDP (GO/CDDP) promoted the killing of not only CT26 cells, but also ovarian, cervical and prostate cancer cells. In the highly chemosensitized Skov-3 cells, GO/CDDP significantly enhanced concurrent nuclear import of CDDP and autophagy marker LC3 and elevated cell necrosis, which required autophagy initiation and progression but did not necessitate late autophagy events (e.g., autophagosome completion and autolysosome formation). The GO/CDDP-elicited nuclear trafficking and cell death also required importin /, and LC3 also co-migrated with CDDP and histone H1/H4 into the nucleus. In particular, GO/CDDP triggered histone H4 acetylation in the nucleus, which could decondense the chromosome and enable CDDP to more effectively access chromosomal DNA to trigger cell death. <b>Conclusion:</b> These findings shed light on the mechanisms of GO/CDDP-induced chemosensitization and implicate the potential applications of GO/CDDP to treat multiple cancers.",Journal Article,664.0,9.0,b Rationale /b Cisplatin CDDP is a broad-spectrum anticancer drug but chemoresistance to CDDP impedes its wide use for cancer therapy Autophagy is an event occurring in the cytoplasm and cytoplasmic LC3 puncta formation is a hallmark of autophagy Graphene oxide GO is a nanomaterial that provokes autophagy in CT26 cancer cells and confers antitumor effects Here we aimed to evaluate whether combined use of GO with CDDP GO/CDDP overcomes chemoresistance in different cancer cells and uncover the underlying mechanism b Methods /b We treated different cancer cells with GO/CDDP and evaluated the cytotoxicity death mechanism autophagy induction and nuclear entry of CDDP We further knocked down genes essential for autophagic flux and deciphered which step is critical to nuclear import and cell death Finally we performed immunoprecipitation mass spectrometry and immunofluorescence labeling to evaluate the association of LC3 and CDDP b Results /b We uncovered that combination of GO and CDDP GO/CDDP promoted the killing of not only CT26 cells but also and cancer cells In the highly chemosensitized Skov-3 cells GO/CDDP significantly enhanced concurrent nuclear import of CDDP and autophagy marker LC3 and elevated cell necrosis which required autophagy initiation and progression but did not necessitate late autophagy events e.g. autophagosome completion and autolysosome formation The GO/CDDP-elicited nuclear trafficking and cell death also required importin / and LC3 also co-migrated with CDDP and histone H1/H4 into the nucleus In particular GO/CDDP triggered histone H4 acetylation in the nucleus which could decondense the chromosome and enable CDDP to more effectively access chromosomal DNA to trigger cell death b Conclusion /b These findings shed light on the mechanisms of GO/CDDP-induced chemosensitization and implicate the potential applications of GO/CDDP to treat multiple cancers,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[132, 1728, 132, 540, 5820, 16, 8, 2094, 1873, 1475, 234, 84, 3782, 6, 5820, 20745, 211, 1019, 119, 9, 12, 36, 2240, 16, 35, 774, 1821, 4, 3, 4558, 2, 2828, 7568, 23706, 1264, 16, 8, 4683, 1, 2240, 23607, 6608, 3537, 16, 8, 24016, 17, 24597, 2240, 4, 9564, 12, 37, 2, 4020, 579, 176, 467, 21, 1295, 6, 376, 317, 397, 119, 1, 3537, 5, 5820, 3537, 5820, 8510, 3782, 4, 338, 12, 37, 2, 6281, 3, 1181, 670, 132, 636, 132, 21, 73, 338, 12, 37, 5, 3537, 5820, 2, 194, 3, 1408, 273, 670, 2240, 504, 2, 928, 3001, 1, 5820, 21, 195, 10237, 1328, 214, 1452, 9, 8810, 9876, 2, 26761, 92, 2458, 16, 740, 6, 928, 13849, 2, 31, 273, 1368, 21, 173, 4857, 782, 3680, 2, 4130, 3383, 6, 376, 3, 248, 1, 7568, 2, 5820, 132, 99, 132, 21, 5601, 17, 150, 1, 3537, 2, 5820, 3537, 5820, 2992, 3, 3003, 1, 44, 158, 9564, 37, 84, 120, 2, 12, 37, 4, 3, 561, 72676, 12393, 27, 37, 3537, 5820, 97, 651, 750, 928, 13849, 1, 5820, 2, 2240, 952, 7568, 2, 804, 31, 1523, 92, 616, 2240, 1118, 2, 91, 84, 205, 44, 12084, 807, 2240, 281, 563, 499, 21388, 1438, 2, 72677, 1264, 3, 3537, 5820, 5179, 928, 6105, 2, 31, 273, 120, 616, 22683, 2014, 1458, 2, 7568, 120, 1269, 15487, 5, 5820, 2, 1508, 5199, 7812, 237, 3, 4262, 4, 1454, 3537, 5820, 4173, 1508, 7812, 4145, 4, 3, 4262, 92, 359, 72678, 3, 1170, 2, 3047, 5820, 6, 80, 1856, 1655, 1860, 261, 6, 5781, 31, 273, 132, 1221, 132, 46, 272, 5816, 1691, 23, 3, 483, 1, 3537, 5820, 277, 13594, 2, 5545, 3, 174, 2911, 1, 3537, 5820, 6, 943, 232, 163]",1905.0,29721093,55
Trends in Place of Death Among Patients With Gynecologic Cancer in the United States.,Obstetrics and gynecology,Obstet Gynecol,2018-06-01,"To describe the change over time in place of death (hospital, home, hospice) among all women in the United States who died of gynecologic malignancies and compare them with other leading causes of female cancer deaths. This is a retrospective cross-sectional study using national death certificate data from the Mortality Multiple Cause-of-Death Public Use Record Data. All women who died from gynecologic, breast, lung, and colorectal cancers were identified according to International Classification of Diseases, 10 Revision, cause of death from 2003 to 2015. Regression analyses with ordinary least-squares linear probability modeling were used to test for differences in location of death over time, and differences in trends by cancer type, while controlling for age, race, ethnicity, marital status, and education status. From 2003 to 2015, 2,133,056 women died from gynecologic, lung, breast, and colorectal malignancies in the United States. A total of 359,340 died from gynecologic malignancies, including ovarian cancer (n=188,366 [52.4%]), uterine cancer (n=106,454 [29.6%]), cervical cancer (n=52,320 [14.6%]), and vulvar cancer (n=12,200 [3.4%]). Overall, 49.2% (n=176,657) of gynecologic cancer deaths occurred at home or in hospice. The relative increase from 2003 to 2015 in the rate of deaths at home or in hospice was 47.2% for gynecologic cancer deaths (40.5% in 2003 to 59.5% in 2015). In adjusted analyses, the trend in the percentage of deaths at home or in hospice increased at a rate of 1.6 percentage points per year for gynecologic cancer deaths (95% CI 1.5-1.6) vs 1.5 (95% CI 1.4-1.5, P<.001), 1.4 (95% CI 1.4-1.5, P<.001), and 1.5 (95% CI 1.4-1.5, P=.09) percentage points per year for lung, breast, and colorectal cancer deaths, respectively. Between 2003 and 2015, there was a 47.2% increase (40.5-59.5%) in the rates of gynecologic cancer deaths occurring at home or in hospice. This trend may represent an increase in advance care planning and value-based treatment decisions.",Journal Article,599.0,2.0,"To describe the change over time in place of death hospital home hospice among all women in the United States who died of gynecologic malignancies and compare them with other leading causes of female cancer deaths This is a retrospective cross-sectional study using national death certificate data from the Mortality Multiple Cause-of-Death Public Use Record Data All women who died from gynecologic and cancers were identified according to International Classification of Diseases 10 Revision cause of death from 2003 to 2015 Regression analyses with ordinary least-squares linear probability modeling were used to test for differences in location of death over time and differences in trends by cancer type while controlling for age race ethnicity marital status and education status From 2003 to 2015 2,133,056 women died from gynecologic and malignancies in the United States A total of 359,340 died from gynecologic malignancies including cancer n=188,366 52.4 cancer n=106,454 29.6 cancer n=52,320 14.6 and cancer n=12,200 3.4 Overall 49.2 n=176,657 of gynecologic cancer deaths occurred at home or in hospice The relative increase from 2003 to 2015 in the rate of deaths at home or in hospice was 47.2 for gynecologic cancer deaths 40.5 in 2003 to 59.5 in 2015 In adjusted analyses the trend in the percentage of deaths at home or in hospice increased at a rate of 1.6 percentage points per year for gynecologic cancer deaths 95 CI 1.5-1.6 vs 1.5 95 CI 1.4-1.5 P .001 1.4 95 CI 1.4-1.5 P .001 and 1.5 95 CI 1.4-1.5 P=.09 percentage points per year for and cancer deaths respectively Between 2003 and 2015 there was a 47.2 increase 40.5-59.5 in the rates of gynecologic cancer deaths occurring at home or in hospice This trend may represent an increase in advance care planning and value-based treatment decisions",1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 897, 3, 707, 252, 98, 4, 3536, 1, 273, 702, 3249, 2490, 107, 62, 117, 4, 3, 1088, 907, 54, 1016, 1, 1512, 441, 2, 932, 1370, 5, 127, 1049, 1626, 1, 1061, 12, 1043, 26, 16, 8, 459, 1383, 2832, 45, 75, 657, 273, 17216, 74, 29, 3, 282, 232, 708, 1, 273, 3067, 119, 3237, 74, 62, 117, 54, 1016, 29, 1512, 2, 163, 11, 108, 768, 6, 944, 947, 1, 1342, 79, 5646, 708, 1, 273, 29, 1522, 6, 1483, 320, 318, 5, 19493, 506, 11938, 1646, 1320, 2057, 11, 95, 6, 412, 9, 362, 4, 1147, 1, 273, 252, 98, 2, 362, 4, 1963, 20, 12, 267, 369, 1893, 9, 89, 1047, 2091, 5345, 156, 2, 1848, 156, 29, 1522, 6, 1483, 18, 5026, 9556, 117, 1016, 29, 1512, 2, 441, 4, 3, 1088, 907, 8, 181, 1, 10791, 7264, 1016, 29, 1512, 441, 141, 12, 78, 5664, 9797, 653, 39, 12, 78, 3251, 11026, 462, 49, 12, 78, 653, 5904, 213, 49, 2, 12, 78, 133, 1250, 27, 39, 63, 739, 18, 78, 5800, 13141, 1, 1512, 12, 1043, 489, 28, 3249, 15, 4, 2490, 3, 580, 344, 29, 1522, 6, 1483, 4, 3, 116, 1, 1043, 28, 3249, 15, 4, 2490, 10, 662, 18, 9, 1512, 12, 1043, 327, 33, 4, 1522, 6, 728, 33, 4, 1483, 4, 586, 318, 3, 853, 4, 3, 1150, 1, 1043, 28, 3249, 15, 4, 2490, 101, 28, 8, 116, 1, 14, 49, 1150, 862, 379, 111, 9, 1512, 12, 1043, 48, 58, 14, 33, 14, 49, 105, 14, 33, 48, 58, 14, 39, 14, 33, 19, 144, 14, 39, 48, 58, 14, 39, 14, 33, 19, 144, 2, 14, 33, 48, 58, 14, 39, 14, 33, 19, 1730, 1150, 862, 379, 111, 9, 2, 12, 1043, 106, 59, 1522, 2, 1483, 125, 10, 8, 662, 18, 344, 327, 33, 728, 33, 4, 3, 151, 1, 1512, 12, 1043, 1821, 28, 3249, 15, 4, 2490, 26, 853, 68, 1231, 35, 344, 4, 3148, 165, 1349, 2, 549, 90, 24, 1526]",1819.0,29742673,91
Brain-stem hemangioblastomas: The seemingly innocuous lesion in a perilous location.,Neurology India,Neurol India,,"Hemangioblastomas [75% sporadic, 25% with Von Hippel Lindau (VHL) disease] are highly vascular, benign lesions. The surgical nuances, management, and complication avoidance in brain-stem hemangioblastomas (BHs) have been studied. Over 18 years, 27(mean age: 29 years; range 15-60 years) consecutive cases of BH underwent microsurgical excision. All patients were assessed clinico-radiologically for neurological deficits and screened for VHL disease. Outcome of the patients was based on Karnofsky Performance Status scale (KPS). 12 out of 19 (70.4%) patients with hydrocephalus underwent a cerebrospinal fluid (CSF) diversion procedure. Lower cranial nerve palsy was present in 10 (37%) patients and motor weakness in 13 (48%). The tumours [mean size 3.34  1.06 cm, range: 1.4-5.5 cm; 11 solid, rest solid-cystic; 18 (66.7%) subpial and 9 (33.33%) intramedullary] were divided into four categories based on size: A: <2 cm (n = 5,18.5%); B: 2-3 cm (n = 10,37%); C: 3-4 cm (n = 6,22.2%); D: >4 cm (n = 6,22.2%). Their location was at posterior cervicomedullary junction (n = 12); pontomedullary junction (n = 7); pons (n = 3), medulla (n = 3) and ponto-mesencephalic region (n = 2). Multiple flow voids were seen in >50% patients with tumour >2 cm. 5 patients had syringomyelia; and, 8 had diffuse cervical cord expansion. Two patients with a large vascular tumour underwent preoperative embolization. Six patients had VHL disease; one underwent bilateral adrenalectomy for refractory hypertension; and, the another, nephrectomy for renal cell carcinoma. Twenty-six patients underwent a midline suboccipital craniectomy; and, 1 with a cerebellopontine angle tumour, a retromastoid craniectomy. 15 patients underwent total excision; 10 patients, near-total (<10% remaining) excision, and 2 patients, a subtotal (>10% remaining)) excision. Three patients (2 with VHL disease) expired due to exsanguinating hemorrhage, spreading venous thrombosis and aspiration pneumonitis, respectively. At follow-up visit (median: 25  interquartile range 2-56months), 17 patients had improved KPS, 4 remained in same status and 3 (recently operated, on tracheostomy) had worsened KPS. Significant improvement is achievable in neurological status in patients following successful extirpation of a brain-stem hemangioblastoma, despite a turbulent perioperative period. Leaving tumour capsule adherent to the brain-stem often helps in preserving brain-stem function. Postoperatively, the patients should be monitored for their respiratory and lower cranial nerve status to prevent aspiration pneumonitis.",Journal Article,,3.0,"Hemangioblastomas 75 sporadic 25 with Von Hippel Lindau VHL disease are highly vascular benign lesions The surgical nuances management and complication avoidance in brain-stem hemangioblastomas BHs have been studied Over 18 years 27 mean age 29 years range 15-60 years consecutive cases of BH underwent microsurgical excision All patients were assessed clinico-radiologically for neurological deficits and screened for VHL disease Outcome of the patients was based on Karnofsky Performance Status scale KPS 12 out of 19 70.4 patients with hydrocephalus underwent a cerebrospinal fluid CSF diversion procedure Lower cranial nerve palsy was present in 10 37 patients and motor weakness in 13 48 The tumours mean size 3.34  1.06 cm range 1.4-5.5 cm 11 solid rest solid-cystic 18 66.7 subpial and 9 33.33 intramedullary were divided into four categories based on size A 2 cm n 5,18.5 B 2-3 cm n 10,37 C 3-4 cm n 6,22.2 D 4 cm n 6,22.2 Their location was at posterior cervicomedullary junction n 12 pontomedullary junction n 7 pons n 3 medulla n 3 and ponto-mesencephalic region n 2 Multiple flow voids were seen in 50 patients with tumour 2 cm 5 patients had syringomyelia and 8 had diffuse cord expansion Two patients with a large vascular tumour underwent preoperative embolization Six patients had VHL disease one underwent bilateral adrenalectomy for refractory hypertension and the another nephrectomy for cell carcinoma Twenty-six patients underwent a midline suboccipital craniectomy and 1 with a cerebellopontine angle tumour a retromastoid craniectomy 15 patients underwent total excision 10 patients near-total 10 remaining excision and 2 patients a subtotal 10 remaining excision Three patients 2 with VHL disease expired due to exsanguinating hemorrhage spreading venous thrombosis and aspiration pneumonitis respectively At follow-up visit median 25  interquartile range 2-56months 17 patients had improved KPS 4 remained in same status and 3 recently operated on tracheostomy had worsened KPS Significant improvement is achievable in neurological status in patients following successful extirpation of a brain-stem hemangioblastoma despite a turbulent perioperative period Leaving tumour capsule adherent to the brain-stem often helps in preserving brain-stem function Postoperatively the patients should be monitored for their respiratory and lower cranial nerve status to prevent aspiration pneumonitis",0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[23838, 481, 1928, 243, 5, 6430, 7703, 7704, 3808, 34, 32, 561, 756, 1002, 406, 3, 221, 15967, 284, 2, 1447, 5863, 4, 342, 452, 23838, 26781, 47, 85, 656, 252, 203, 60, 428, 313, 89, 462, 60, 184, 167, 335, 60, 935, 140, 1, 17932, 208, 14615, 1366, 62, 7, 11, 275, 8688, 9579, 9, 3622, 2752, 2, 2261, 9, 3808, 34, 228, 1, 3, 7, 10, 90, 23, 2857, 528, 156, 1124, 2988, 133, 1205, 1, 326, 431, 39, 7, 5, 9250, 208, 8, 5156, 2357, 1211, 6067, 1299, 280, 2565, 2476, 18801, 10, 364, 4, 79, 567, 7, 2, 3482, 6408, 4, 233, 576, 3, 1319, 313, 444, 27, 562, 810, 14, 1460, 494, 184, 14, 39, 33, 33, 494, 175, 537, 3677, 537, 2965, 203, 700, 67, 47377, 2, 83, 466, 466, 8686, 11, 2176, 237, 294, 1996, 90, 23, 444, 8, 18, 494, 78, 33, 203, 33, 132, 18, 27, 494, 78, 79, 567, 256, 27, 39, 494, 78, 49, 350, 18, 427, 39, 494, 78, 49, 350, 18, 136, 1147, 10, 28, 3028, 51065, 3322, 78, 133, 72775, 3322, 78, 67, 18216, 78, 27, 20187, 78, 27, 2, 72776, 72777, 1053, 78, 18, 232, 1412, 51043, 11, 527, 4, 212, 7, 5, 770, 18, 494, 33, 7, 42, 51066, 2, 66, 42, 1388, 1885, 1422, 100, 7, 5, 8, 375, 756, 770, 208, 498, 4232, 437, 7, 42, 3808, 34, 104, 208, 1607, 6647, 9, 430, 1824, 2, 3, 1809, 1738, 9, 31, 134, 737, 437, 7, 208, 8, 8677, 33194, 25038, 2, 14, 5, 8, 36603, 8939, 770, 8, 72778, 25038, 167, 7, 208, 181, 1366, 79, 7, 1829, 181, 79, 1844, 1366, 2, 18, 7, 8, 5503, 79, 1844, 1366, 169, 7, 18, 5, 3808, 34, 13758, 520, 6, 72779, 3599, 8153, 2167, 2839, 2, 3256, 2949, 106, 28, 166, 126, 2807, 52, 243, 810, 2899, 184, 18, 72780, 269, 7, 42, 231, 2988, 39, 958, 4, 827, 156, 2, 27, 761, 7297, 23, 15648, 42, 5890, 2988, 93, 767, 16, 6171, 4, 3622, 156, 4, 7, 366, 1401, 11945, 1, 8, 342, 452, 29643, 550, 8, 45973, 1547, 727, 7806, 770, 5474, 7010, 6, 3, 342, 452, 629, 6484, 4, 4972, 342, 452, 343, 3541, 3, 7, 257, 40, 2909, 9, 136, 2718, 2, 280, 2565, 2476, 156, 6, 1682, 3256, 2949]",2416.0,29766943,308
Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival.,Gynecologic oncology,Gynecol. Oncol.,2018-07-01,"Standard surgical treatment for women with stage IB1 cervical cancer consists of radical hysterectomy. This study assesses survival outcomes of those treated with less radical surgery (LRS; conization, trachelectomy, simple hysterectomy) compared to more radical surgery (MRS; modified radical, radical hysterectomy). Using the Surveillance, Epidemiology and End Results database, we identified women <45years with FIGO stage IB1 cervical cancer diagnosed from 1/1998 to 12/2012. Only those who underwent lymph node (LN) assessment were analyzed. Disease-specific survivals (DSSs) of LRS were compared with those of MRS. Of 2571 patients, 807 underwent LRS and 1764 underwent MRS, all with LN assessment. For LRS vs. MRS, 28% vs. 23% were diagnosed with adenocarcinoma (p=0.024), 31% vs. 39% had G3 disease (p<0.001), 40% vs. 45% had tumor size >2cm (p<0.001), and 27% vs. 29% received adjuvant radiation therapy (p=0.005). Median follow-up was 79months (range, 0-179). Ten-year DSS for LRS vs. MRS was 93.5% vs. 92.3% (p=0.511). There was no difference in 10-year DSS when stratified by tumor size 2cm (LRS 95.1% vs. MRS 95.6%, p=0.80) or>2cm (LRS 90.1% vs. MRS 88.2%, p=0.48). Factors independently associated with increased risk of death included adenosquamous histology (HR 2.37), G3 disease (HR 2.86), tumors >2cm (HR 1.82), and LN positivity (HR 2.42). Compared to MRS, LRS was not associated with a higher risk of death. In a select group of young women with stage IB1 cervical cancer, LRS compared to MRS does not appear to compromise DSS.",Journal Article,569.0,6.0,Standard surgical treatment for women with stage IB1 cancer consists of radical hysterectomy This study assesses survival outcomes of those treated with less radical surgery LRS conization trachelectomy simple hysterectomy compared to more radical surgery MRS modified radical radical hysterectomy Using the Surveillance Epidemiology and End Results database we identified women 45 years with FIGO stage IB1 cancer diagnosed from 1/1998 to 12/2012 Only those who underwent lymph node LN assessment were analyzed Disease-specific survivals DSSs of LRS were compared with those of MRS. Of 2571 patients 807 underwent LRS and 1764 underwent MRS all with LN assessment For LRS vs. MRS 28 vs. 23 were diagnosed with adenocarcinoma p 0.024 31 vs. 39 had G3 disease p 0.001 40 vs. 45 had tumor size 2 cm p 0.001 and 27 vs. 29 received adjuvant radiation therapy p 0.005 Median follow-up was 79 months range 0-179 Ten-year DSS for LRS vs. MRS was 93.5 vs. 92.3 p 0.511 There was no difference in 10-year DSS when stratified by tumor size 2 cm LRS 95.1 vs. MRS 95.6 p 0.80 or 2 cm LRS 90.1 vs. MRS 88.2 p 0.48 Factors independently associated with increased risk of death included adenosquamous histology HR 2.37 G3 disease HR 2.86 tumors 2 cm HR 1.82 and LN positivity HR 2.42 Compared to MRS LRS was not associated with a higher risk of death In a select group of young women with stage IB1 cancer LRS compared to MRS does not appear to compromise DSS,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[260, 221, 24, 9, 117, 5, 82, 8111, 12, 5132, 1, 711, 2622, 26, 45, 7777, 25, 123, 1, 135, 73, 5, 299, 711, 152, 9301, 8755, 5760, 2763, 2622, 72, 6, 80, 711, 152, 6087, 1230, 711, 711, 2622, 75, 3, 617, 1284, 2, 396, 99, 609, 21, 108, 117, 512, 60, 5, 3837, 82, 8111, 12, 265, 29, 14, 1850, 6, 133, 1195, 158, 135, 54, 208, 263, 289, 1763, 455, 11, 311, 34, 112, 3794, 72817, 1, 9301, 11, 72, 5, 135, 1, 6087, 1, 72818, 7, 12831, 208, 9301, 2, 28453, 208, 6087, 62, 5, 1763, 455, 9, 9301, 105, 6087, 339, 105, 382, 11, 265, 5, 449, 19, 13, 4247, 456, 105, 587, 42, 5578, 34, 19, 13, 144, 327, 105, 512, 42, 30, 444, 18, 494, 19, 13, 144, 2, 428, 105, 462, 103, 249, 121, 36, 19, 13, 1614, 52, 166, 126, 10, 842, 53, 184, 13, 5977, 1618, 111, 1788, 9, 9301, 105, 6087, 10, 966, 33, 105, 937, 27, 19, 13, 10532, 125, 10, 77, 523, 4, 79, 111, 1788, 198, 1173, 20, 30, 444, 6006, 494, 9301, 48, 14, 105, 6087, 48, 49, 19, 13, 493, 15, 18, 494, 9301, 424, 14, 105, 6087, 889, 18, 19, 13, 576, 130, 1042, 41, 5, 101, 43, 1, 273, 159, 8067, 784, 168, 18, 567, 5578, 34, 168, 18, 868, 57, 18, 494, 168, 14, 878, 2, 1763, 1887, 168, 18, 595, 72, 6, 6087, 9301, 10, 44, 41, 5, 8, 142, 43, 1, 273, 4, 8, 1717, 87, 1, 1169, 117, 5, 82, 8111, 12, 9301, 72, 6, 6087, 1097, 44, 1322, 6, 4665, 1788]",1445.0,29776598,430
Comprehensive pharmacogenomic profiling of human papillomavirus-positive and -negative squamous cell carcinoma identifies sensitivity to aurora kinase inhibition in KMT2D mutants.,Cancer letters,Cancer Lett.,2018-05-25,"To address the unmet need for effective biomarker-driven targeted therapy for human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) and cervical cancer, we conducted a high-throughput drug screen using 1122 compounds in 13 HPV-positive and 11 matched HPV-negative cell lines. The most effective drug classes were inhibitors of polo-like kinase, proteasomes, histone deacetylase, and Aurora kinases. Treatment with a pan-Aurora inhibitor, danusertib, led to G2M arrest and apoptosis in vitro. Furthermore, danusertib decreased tumor size compared with controls in patient derived xenograft models of HNSCC. To identify biomarkers predicting response, we determined associations between mutations and drug sensitivity. Our data and the Genomics of Drug Sensitivity in Cancer database showed that cancer cells with KMT2D mutations were more sensitive to Aurora kinase inhibitors than were cells without mutations. Knockdown of KMT2D in wild-type cells led to increased Aurora kinase inhibitor-induced apoptosis. We identified Aurora kinase inhibitors as effective and understudied drugs in HNSCC and CESC. This is the first published study to demonstrate that mutations in KMT2D, which are common in many cancers, correlate with drug sensitivity in two independent datasets.",Journal Article,606.0,6.0,To address the unmet need for effective biomarker-driven targeted therapy for human papillomavirus HPV -associated head and squamous cell carcinoma HNSCC and cancer we conducted a high-throughput drug screen using 1122 compounds in 13 HPV-positive and 11 matched HPV-negative cell lines The most effective drug classes were inhibitors of polo-like kinase proteasomes histone deacetylase and Aurora kinases Treatment with a pan-Aurora inhibitor danusertib led to G2M arrest and apoptosis in vitro Furthermore danusertib decreased tumor size compared with controls in patient derived xenograft models of HNSCC To identify biomarkers predicting response we determined associations between mutations and drug sensitivity Our data and the Genomics of Drug Sensitivity in Cancer database showed that cancer cells with KMT2D mutations were more sensitive to Aurora kinase inhibitors than were cells without mutations Knockdown of KMT2D in wild-type cells led to increased Aurora kinase inhibitor-induced apoptosis We identified Aurora kinase inhibitors as effective and understudied drugs in HNSCC and CESC This is the first published study to demonstrate that mutations in KMT2D which are common in many cancers correlate with drug sensitivity in two independent datasets,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1539, 3, 3715, 594, 9, 323, 901, 1621, 238, 36, 9, 171, 3242, 933, 41, 718, 2, 691, 31, 134, 1209, 2, 12, 21, 426, 8, 64, 3643, 234, 2413, 75, 23306, 2411, 4, 233, 933, 109, 2, 175, 655, 933, 199, 31, 285, 3, 96, 323, 234, 3211, 11, 222, 1, 12635, 733, 216, 24715, 1508, 2732, 2, 4095, 1549, 24, 5, 8, 3055, 4095, 230, 20672, 836, 6, 26151, 1854, 2, 351, 4, 439, 798, 20672, 340, 30, 444, 72, 5, 535, 4, 69, 526, 1330, 274, 1, 1209, 6, 255, 582, 1434, 51, 21, 509, 685, 59, 138, 2, 234, 485, 114, 74, 2, 3, 4229, 1, 234, 485, 4, 12, 609, 224, 17, 12, 37, 5, 14715, 138, 11, 80, 745, 6, 4095, 216, 222, 76, 11, 37, 187, 138, 1563, 1, 14715, 4, 955, 267, 37, 836, 6, 101, 4095, 216, 230, 277, 351, 21, 108, 4095, 216, 222, 22, 323, 2, 8207, 600, 4, 1209, 2, 24303, 26, 16, 3, 157, 983, 45, 6, 608, 17, 138, 4, 14715, 92, 32, 186, 4, 445, 163, 1513, 5, 234, 485, 4, 100, 306, 3455]",1265.0,29807113,481
Disparities Predict for Higher Rates of Cut-through Hysterectomies in Locally Advanced Cervical Cancer.,American journal of clinical oncology,Am. J. Clin. Oncol.,2019-01-01,"The treatment of choice for locally advanced cervical cancer is definitive chemoradiation (CRT). Hysterectomy is not indicated due to higher-rates of cut-through resections leaving gross disease behind, requiring additional therapy with increasing morbidity and no benefit in overall survival (OS). The objectives of this study were to determine factors associated with cut-through hysterectomies and evaluate OS outcomes. The National Cancer Database (NCDB) was queried for patients 18 years and older with clinical Federation of Gynecology and Obstetrics stage IB2 to IVA. All patients underwent upfront hysterectomy and had known margin status. Cut-through hysterectomy was classified as presence of microscopic or macroscopic disease at the margin. A total of 11,638 patients were included; 993 (8.5%) had positive margins. In patients with positive margins, 560 (56.4%) received postoperative CRT and 148 (14.9%) underwent postoperative radiation. Five-year OS was worse for those with cut-through resections when compared with those with negative margins, 66.0% versus 86.7%, respectively (hazard ratios, 3.08; P<0.001). Under multiple logistic regression, African American race (odds ratio [OR], 1.45; P=0.001), older age (OR per year increase, 1.03; P<0.001), patients with government insurance (OR, 1.21; P=0.019), and those treated at community practices (OR, 1.31; P=0.001) were more likely to undergo cut-through hysterectomies. A review of national patterns of care over the past decade confirms women with positive margins after hysterectomy for cervical cancer have significantly worse OS. Disparities in surgical results for women with cervical cancer exist. In response, further causality evaluation and corrective action are warranted to address these inequalities.",Journal Article,385.0,1.0,"The treatment of choice for locally advanced cancer is definitive chemoradiation CRT Hysterectomy is not indicated due to higher-rates of cut-through resections leaving gross disease behind requiring additional therapy with increasing morbidity and no benefit in overall survival OS The objectives of this study were to determine factors associated with cut-through hysterectomies and evaluate OS outcomes The National Cancer Database NCDB was queried for patients 18 years and older with clinical Federation of Gynecology and Obstetrics stage IB2 to IVA All patients underwent upfront hysterectomy and had known margin status Cut-through hysterectomy was classified as presence of microscopic or macroscopic disease at the margin A total of 11,638 patients were included 993 8.5 had positive margins In patients with positive margins 560 56.4 received postoperative CRT and 148 14.9 underwent postoperative radiation Five-year OS was worse for those with cut-through resections when compared with those with negative margins 66.0 versus 86.7 respectively hazard ratios 3.08 P 0.001 Under multiple logistic regression African American race odds ratio OR 1.45 P=0.001 older age OR per year increase 1.03 P 0.001 patients with government insurance OR 1.21 P=0.019 and those treated at community practices OR 1.31 P=0.001 were more likely to undergo cut-through hysterectomies A review of national patterns of care over the past decade confirms women with positive margins after hysterectomy for cancer have significantly worse OS Disparities in surgical results for women with cancer exist In response further causality evaluation and corrective action are warranted to address these inequalities",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 24, 1, 1866, 9, 795, 131, 12, 16, 1057, 975, 1089, 2622, 16, 44, 1103, 520, 6, 142, 151, 1, 3554, 298, 2185, 7806, 1789, 34, 5219, 1888, 402, 36, 5, 602, 787, 2, 77, 247, 4, 63, 25, 118, 3, 2409, 1, 26, 45, 11, 6, 223, 130, 41, 5, 3554, 298, 15266, 2, 376, 118, 123, 3, 657, 12, 609, 4315, 10, 3547, 9, 7, 203, 60, 2, 434, 5, 38, 7303, 1, 6429, 2, 7407, 82, 9537, 6, 5900, 62, 7, 208, 2941, 2622, 2, 42, 440, 959, 156, 3554, 298, 2622, 10, 1373, 22, 463, 1, 2984, 15, 5897, 34, 28, 3, 959, 8, 181, 1, 175, 11864, 7, 11, 159, 18828, 66, 33, 42, 109, 1012, 4, 7, 5, 109, 1012, 7356, 664, 39, 103, 573, 1089, 2, 4647, 213, 83, 208, 573, 121, 365, 111, 118, 10, 639, 9, 135, 5, 3554, 298, 2185, 198, 72, 5, 135, 5, 199, 1012, 700, 13, 185, 868, 67, 106, 360, 1137, 27, 1592, 19, 13, 144, 669, 232, 812, 320, 1410, 597, 1047, 610, 197, 15, 14, 512, 19, 13, 144, 434, 89, 15, 379, 111, 344, 14, 680, 19, 13, 144, 7, 5, 7608, 1935, 15, 14, 239, 19, 13, 4049, 2, 135, 73, 28, 1714, 2634, 15, 14, 456, 19, 13, 144, 11, 80, 322, 6, 1251, 3554, 298, 15266, 8, 206, 1, 657, 764, 1, 165, 252, 3, 1219, 2025, 5120, 117, 5, 109, 1012, 50, 2622, 9, 12, 47, 97, 639, 118, 2227, 4, 221, 99, 9, 117, 5, 12, 1923, 4, 51, 195, 10107, 451, 2, 26329, 1578, 32, 1197, 6, 1539, 46, 28859]",1694.0,29889138,204
"A compact, low-cost, quantitative and multiplexed fluorescence detection platform for point-of-care applications.",Biosensors & bioelectronics,Biosens Bioelectron,2018-04-04,"An effective method of combating infectious diseases is the deployment of hand-held devices at the point-of-care (POC) for screening or self-monitoring applications. There is a need for very sensitive, low-cost and quantitative diagnostic devices. In this study, we present a low-cost, multiplexed fluorescence detection platform that has a high sensitivity and wide dynamic range. Our system features inexpensive 33mm interference filters with a high stopband rejection, sharp transition edges, and greater than 90% transmission in the passband. In addition to the filters, we improve signal-to-noise ratio by leveraging time for accuracy using a charge-integration-based readout. The fluorescence sensing platform provides a sensitivity to photon flux of 110<sup>4</sup>photons/mm<sup>2</sup>sec and has the potential for 2-3 orders of magnitude improvement in sensitivity over standard colorimetric detection that uses colored latex microspheres. We also detail the design, development, and characterization of our low-cost fluorescence detection platform and demonstrate 100% and 97.96% reduction in crosstalk probability and filter cost, respectively. This is achieved by reducing filter dimensions and ensuring appropriate channel isolation in a 22 array configuration. Practical considerations with low-cost interference filter system design, analysis, and system performance are also discussed. The performance of our platform is compared to that of a standard laboratory array scanner. We also demonstrate the detection of antibodies to human papillomavirus (HPV16) E7 protein, as a potential biomarker for early cervical cancer detection in human plasma.",Journal Article,657.0,11.0,An effective method of combating infectious diseases is the deployment of hand-held devices at the point-of-care POC for screening or self-monitoring applications There is a need for very sensitive low-cost and quantitative diagnostic devices In this study we present a low-cost multiplexed fluorescence detection platform that has a high sensitivity and wide dynamic range Our system features inexpensive 3 3 mm interference filters with a high stopband rejection sharp transition edges and greater than 90 transmission in the passband In addition to the filters we improve signal-to-noise ratio by leveraging time for accuracy using a charge-integration-based readout The fluorescence sensing platform provides a sensitivity to photon flux of 110 sup 4 /sup photons/mm sup 2 /sup sec and has the potential for 2-3 orders of magnitude improvement in sensitivity over standard colorimetric detection that uses colored latex microspheres We also detail the design development and characterization of our low-cost fluorescence detection platform and demonstrate 100 and 97.96 reduction in crosstalk probability and filter cost respectively This is achieved by reducing filter dimensions and ensuring appropriate channel isolation in a 2 2 array configuration Practical considerations with low-cost interference filter system design analysis and system performance are also discussed The performance of our platform is compared to that of a standard laboratory array scanner We also demonstrate the detection of antibodies to human papillomavirus HPV16 E7 protein as a potential biomarker for early cancer detection in human plasma,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[35, 323, 596, 1, 16964, 3398, 1342, 16, 3, 13512, 1, 2833, 4033, 6497, 28, 3, 741, 1, 165, 12224, 9, 453, 15, 1074, 1315, 2911, 125, 16, 8, 594, 9, 923, 745, 154, 835, 2, 1156, 752, 6497, 4, 26, 45, 21, 364, 8, 154, 835, 7734, 1591, 638, 2243, 17, 71, 8, 64, 485, 2, 1019, 2540, 184, 114, 398, 404, 8168, 27, 27, 321, 3182, 10788, 5, 8, 64, 73003, 4772, 9978, 1970, 19874, 2, 378, 76, 424, 8151, 4, 3, 73004, 4, 352, 6, 3, 10788, 21, 401, 1235, 6, 7556, 197, 20, 15023, 98, 9, 1190, 75, 8, 11812, 2676, 90, 18589, 3, 1591, 8350, 2243, 777, 8, 485, 6, 4216, 9876, 1, 73005, 172, 39, 172, 7862, 321, 172, 18, 172, 13678, 2, 71, 3, 174, 9, 18, 27, 8502, 1, 3131, 767, 4, 485, 252, 260, 16308, 638, 17, 4025, 28300, 45008, 7321, 21, 120, 5000, 3, 771, 193, 2, 2136, 1, 114, 154, 835, 1591, 638, 2243, 2, 608, 394, 2, 1015, 921, 628, 4, 8119, 1320, 2, 7578, 835, 106, 26, 16, 513, 20, 1818, 7578, 6190, 2, 8397, 870, 8240, 5019, 4, 8, 18, 18, 1926, 13796, 3320, 3891, 5, 154, 835, 3182, 7578, 398, 771, 65, 2, 398, 528, 32, 120, 1588, 3, 528, 1, 114, 2243, 16, 72, 6, 17, 1, 8, 260, 1624, 1926, 10437, 21, 120, 608, 3, 638, 1, 890, 6, 171, 3242, 4048, 4540, 178, 22, 8, 174, 901, 9, 191, 12, 638, 4, 171, 554]",1630.0,29894852,198
"Results of Cervical Cancer Screening in the Rural Population of Lucknow West, India, through a Camp Approach.",Acta cytologica,Acta Cytol.,2018-06-13,"Cytological screening was carried out in rural women of Lucknow West, India, through a camp approach to detect cervical cancer in its preinvasive phase and to see whether the primitive living conditions in the villages have any effect on the incidence of precancer and carcinoma of the cervix and the associated predisposing factors of cervical carcinogenesis. During a span of 4 years (May 2013 to March 2017), a total of 135 camps were organized under the auspice of Era's Lucknow Medical College and Hospital (Lucknow, India). Only 4,269 (31.2%) out of 13,500 women who were motivated and counseled attended the camp and 2,369 (55.1%) of them underwent a Pap smear examination. The incidence of squamous intraepithelial lesions of the cervix (SIL) was found to be very high (18.2%) in the 2,369 women who were screened, but the majority of them were of a low grade. The SIL incidence was very high for all predisposing factors like gynaecological symptoms, age, and clinical lesions of the cervix. However, the SIL rate showed a rise with increasing parity. Candida albicans was more common in rural women (4.7%) than Trichomonas vaginalis (1.1%), and a low incidence of viral sexually transmitted diseases (STD) was seen. Organizing camps in the villages through proper counseling and motivation may help in the screening of larger numbers of women for early detection of cervical cancer, the adequate treatment of which will check the progression of the disease and thus minimize the incidence of carcinoma of the cervix and its associated mortality in the rural population of India.",Journal Article,587.0,1.0,"Cytological screening was carried out in rural women of Lucknow West India through a camp approach to detect cancer in its preinvasive phase and to see whether the primitive living conditions in the villages have any effect on the incidence of precancer and carcinoma of the cervix and the associated predisposing factors of carcinogenesis During a span of 4 years May 2013 to March 2017 a total of 135 camps were organized under the auspice of Era 's Lucknow Medical College and Hospital Lucknow India Only 4,269 31.2 out of 13,500 women who were motivated and counseled attended the camp and 2,369 55.1 of them underwent a Pap smear examination The incidence of squamous intraepithelial lesions of the cervix SIL was found to be very high 18.2 in the 2,369 women who were screened but the majority of them were of a low grade The SIL incidence was very high for all predisposing factors like gynaecological symptoms age and clinical lesions of the cervix However the SIL rate showed a rise with increasing parity Candida albicans was more common in rural women 4.7 than Trichomonas vaginalis 1.1 and a low incidence of viral sexually transmitted diseases STD was seen Organizing camps in the villages through proper counseling and motivation may help in the screening of larger numbers of women for early detection of cancer the adequate treatment of which will check the progression of the disease and thus minimize the incidence of carcinoma of the cervix and its associated mortality in the rural population of India",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[9019, 453, 10, 2629, 1205, 4, 5291, 117, 1, 42083, 7261, 7776, 298, 8, 10837, 353, 6, 1426, 12, 4, 211, 10796, 124, 2, 6, 3764, 317, 3, 5594, 2798, 1298, 4, 3, 42084, 47, 500, 254, 23, 3, 287, 1, 12380, 2, 134, 1, 3, 3629, 2, 3, 41, 6885, 130, 1, 1719, 190, 8, 7165, 1, 39, 60, 68, 1346, 6, 2363, 1759, 8, 181, 1, 3978, 42085, 11, 7511, 669, 3, 73007, 1, 1713, 292, 42083, 484, 2979, 2, 702, 42083, 7776, 158, 39, 8639, 456, 18, 1205, 1, 233, 1666, 117, 54, 11, 9252, 2, 10411, 10893, 3, 10837, 2, 18, 8718, 614, 14, 1, 1370, 208, 8, 4290, 8379, 1385, 3, 287, 1, 691, 4153, 406, 1, 3, 3629, 10858, 10, 204, 6, 40, 923, 64, 203, 18, 4, 3, 18, 8718, 117, 54, 11, 2261, 84, 3, 686, 1, 1370, 11, 1, 8, 154, 88, 3, 10858, 287, 10, 923, 64, 9, 62, 6885, 130, 733, 18832, 507, 89, 2, 38, 406, 1, 3, 3629, 137, 3, 10858, 116, 224, 8, 3693, 5, 602, 5754, 13321, 24644, 10, 80, 186, 4, 5291, 117, 39, 67, 76, 73008, 27693, 14, 14, 2, 8, 154, 287, 1, 1667, 13588, 12959, 1342, 15759, 10, 527, 15917, 42085, 4, 3, 42084, 298, 4576, 2011, 2, 9806, 68, 987, 4, 3, 453, 1, 1077, 1870, 1, 117, 9, 191, 638, 1, 12, 3, 1658, 24, 1, 92, 303, 9565, 3, 91, 1, 3, 34, 2, 631, 3241, 3, 287, 1, 134, 1, 3, 3629, 2, 211, 41, 282, 4, 3, 5291, 266, 1, 7776]",1521.0,29898440,339
Metastatic gynecologic malignancies: advances in treatment and management.,Clinical & experimental metastasis,Clin. Exp. Metastasis,2018-06-21,"Gynecologic cancers comprise of mostly uterine, ovarian, and cervical malignancies and are responsible for 95,000 new cases annually in the United States. Uterine cancer is the most common and the number of new cases and mortality has been increasing. Cervical cancer has decreased due to screening, early detection, and treatment of pre-invasive cancers. However, ovarian cancer remains the most lethal because of advanced stage at diagnosis and drug resistance. The metastatic spread pattern differs amongst these cancers, with uterine and cervical cancer found mostly in the primary organ and ovarian cancer disseminating throughout the peritoneum and upper abdomen at presentation. The primary treatment of ovarian cancer typically involves surgery followed by systemic therapy for more advanced disease. Previously, systemic chemotherapy with platinums, taxanes, doxorubicin, topotecan, and gemcitabine has been the standard in either upfront or recurrent setting. With molecular and genetic breakthroughs, we now have over eight new indications and five novel biologic therapies including antiangiogenics, poly ADP ribose polymerase inhibitors, and immunotherapies approved over the last 3years. In this review, we will examine the biology of gynecologic cancer metastasis and focus on new treatment options for these cancers with a focus on ovarian cancer.",Journal Article,579.0,3.0,"Gynecologic cancers comprise of mostly and malignancies and are responsible for 95,000 new cases annually in the United States cancer is the most common and the number of new cases and mortality has been increasing cancer has decreased due to screening early detection and treatment of pre-invasive cancers However cancer remains the most lethal because of advanced stage at diagnosis and drug resistance The metastatic spread pattern differs amongst these cancers with and cancer found mostly in the primary organ and cancer disseminating throughout the peritoneum and upper abdomen at presentation The primary treatment of cancer typically involves surgery followed by systemic therapy for more advanced disease Previously systemic chemotherapy with platinums taxanes doxorubicin topotecan and gemcitabine has been the standard in either upfront or recurrent setting With molecular and genetic breakthroughs we now have over eight new indications and five novel biologic therapies including antiangiogenics poly ADP ribose polymerase inhibitors and immunotherapies approved over the last 3 years In this review we will examine the biology of gynecologic cancer metastasis and focus on new treatment options for these cancers with a focus on cancer",0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[1512, 163, 5238, 1, 2754, 2, 441, 2, 32, 2327, 9, 48, 984, 217, 140, 4226, 4, 3, 1088, 907, 12, 16, 3, 96, 186, 2, 3, 207, 1, 217, 140, 2, 282, 71, 85, 602, 12, 71, 340, 520, 6, 453, 191, 638, 2, 24, 1, 671, 416, 163, 137, 12, 469, 3, 96, 2266, 408, 1, 131, 82, 28, 147, 2, 234, 251, 3, 113, 2579, 1177, 4990, 7212, 46, 163, 5, 2, 12, 204, 2754, 4, 3, 86, 1259, 2, 12, 17703, 2432, 3, 6699, 2, 1726, 4036, 28, 1031, 3, 86, 24, 1, 12, 1969, 2921, 152, 370, 20, 403, 36, 9, 80, 131, 34, 373, 403, 56, 5, 18919, 2961, 856, 2129, 2, 679, 71, 85, 3, 260, 4, 361, 2941, 15, 387, 546, 5, 219, 2, 336, 9985, 21, 1134, 47, 252, 659, 217, 2406, 2, 365, 229, 1283, 235, 141, 25449, 2699, 3638, 3507, 1451, 222, 2, 2811, 850, 252, 3, 1060, 27, 60, 4, 26, 206, 21, 303, 1004, 3, 891, 1, 1512, 12, 278, 2, 1222, 23, 217, 24, 838, 9, 46, 163, 5, 8, 1222, 23, 12]",1249.0,29931499,188
Cervical cancer care in rural Virginia: The impact of distance from an academic medical center on outcomes & the role of non-specialized radiation centers.,Gynecologic oncology,Gynecol. Oncol.,2018-06-21,"To determine whether distance to a tertiary care facility affects outcomes for locally advanced cervical cancer and to evaluate the impact of receiving care at non-specialized centers in rural communities. Retrospective, single institution study of patients with locally advanced cervical cancer managed with chemo-radiation from January 1, 2000 to June 1, 2014. Kaplan-Meier survival curves and Cox proportional hazard models were used to compare progression free and overall survival for patients by median distance to the tertiary care facility (<72miles or >72miles) and facility where treatment was received. 180 patients met inclusion criteria. There was no difference in PFS or OS between the travel distance cohorts. When compared by location of external beam radiation, patients treated at outside facilities were older (p=0.02) and significantly more likely to be insured (95.6% versus 71.7%, p<0.0002). There were more recurrences among patients treated at outside facilities (31.1% versus 15.8%) but this was non-significant (p=0.24). On multivariable analysis, FIGO stage and insurance status were associated with overall survival. Uninsured patients had a significantly increased hazard risk of death as compared to privately insured patients (HR 3.85 95% CI 3.07-4.64, p=0.0008). Median distance to a tertiary care facility had no significant impact on PFS or OS, however treating facility for radiation may influence recurrence rates. Having non-private insurance or being uninsured is significantly associated with increased risk of death and speaks to the many barriers these patients face.",Journal Article,579.0,4.0,To determine whether distance to a tertiary care facility affects outcomes for locally advanced cancer and to evaluate the impact of receiving care at non-specialized centers in rural communities Retrospective single institution study of patients with locally advanced cancer managed with chemo-radiation from January 1 2000 to June 1 2014 Kaplan-Meier survival curves and Cox proportional hazard models were used to compare progression free and overall survival for patients by median distance to the tertiary care facility 72 miles or 72 miles and facility where treatment was received 180 patients met inclusion criteria There was no difference in PFS or OS between the travel distance cohorts When compared by location of external beam radiation patients treated at outside facilities were older p 0.02 and significantly more likely to be insured 95.6 versus 71.7 p 0.0002 There were more recurrences among patients treated at outside facilities 31.1 versus 15.8 but this was non-significant p 0.24 On multivariable analysis FIGO stage and insurance status were associated with overall survival Uninsured patients had a significantly increased hazard risk of death as compared to privately insured patients HR 3.85 95 CI 3.07-4.64 p 0.0008 Median distance to a tertiary care facility had no significant impact on PFS or OS however treating facility for radiation may influence recurrence rates Having non-private insurance or being uninsured is significantly associated with increased risk of death and speaks to the many barriers these patients face,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 317, 3019, 6, 8, 2557, 165, 3483, 2561, 123, 9, 795, 131, 12, 2, 6, 376, 3, 345, 1, 357, 165, 28, 220, 4791, 1168, 4, 5291, 7651, 459, 226, 731, 45, 1, 7, 5, 795, 131, 12, 2231, 5, 3341, 121, 29, 1024, 14, 1081, 6, 1924, 14, 1409, 876, 882, 25, 2400, 2, 418, 831, 360, 274, 11, 95, 6, 932, 91, 115, 2, 63, 25, 9, 7, 20, 52, 3019, 6, 3, 2557, 165, 3483, 720, 7886, 15, 720, 7886, 2, 3483, 1257, 24, 10, 103, 3172, 7, 543, 1680, 371, 125, 10, 77, 523, 4, 300, 15, 118, 59, 3, 6793, 3019, 736, 198, 72, 20, 1147, 1, 1455, 1345, 121, 7, 73, 28, 2513, 4351, 11, 434, 19, 13, 588, 2, 97, 80, 322, 6, 40, 4291, 48, 49, 185, 792, 67, 19, 13, 3531, 125, 11, 80, 1593, 107, 7, 73, 28, 2513, 4351, 456, 14, 185, 167, 66, 84, 26, 10, 220, 93, 19, 13, 259, 23, 658, 65, 3837, 82, 2, 1935, 156, 11, 41, 5, 63, 25, 4955, 7, 42, 8, 97, 101, 360, 43, 1, 273, 22, 72, 6, 9901, 4291, 7, 168, 27, 772, 48, 58, 27, 1615, 39, 660, 19, 13, 7044, 52, 3019, 6, 8, 2557, 165, 3483, 42, 77, 93, 345, 23, 300, 15, 118, 137, 1367, 3483, 9, 121, 68, 1054, 146, 151, 1041, 220, 4745, 1935, 15, 486, 4955, 16, 97, 41, 5, 101, 43, 1, 273, 2, 50713, 6, 3, 445, 2160, 46, 7, 3376]",1554.0,29935911,89
Esthesioneuroblastoma with widespread distant metastasis: Case report and literature review.,"Ear, nose, & throat journal",Ear Nose Throat J,,"Esthesioneuroblastoma (ENB) is an uncommon sinonasal tract tumor, and it is even more uncommon among all neoplasms. Literature regarding the incidence and spread of the disease is limited. The prognosis of metastatic disease is poor. In this report, we present a case of recurrent ENB in a young woman involving metastasis to the neck, lungs, and ovary. Metastasis to the cervical lymph nodes is relatively common, but metastasis to the lungs is rare. Furthermore, to our knowledge, no cases of ovarian metastases of ENB have been reported. This case highlights the potential for widespread metastatic disease, suggesting the need for more frequent and thorough surveillance of patients diagnosed with recurrences of this tumor.",Case Reports,,0.0,ENB is an uncommon sinonasal tract tumor and it is even more uncommon among all neoplasms Literature regarding the incidence and spread of the disease is limited The prognosis of metastatic disease is poor In this report we present a case of recurrent ENB in a young woman involving metastasis to the lungs and ovary Metastasis to the lymph nodes is relatively common but metastasis to the lungs is rare Furthermore to our knowledge no cases of metastases of ENB have been reported This case highlights the potential for widespread metastatic disease suggesting the need for more frequent and thorough surveillance of patients diagnosed with recurrences of this tumor,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[11490, 16, 35, 2052, 7605, 1696, 30, 2, 192, 16, 871, 80, 2052, 107, 62, 1179, 789, 666, 3, 287, 2, 2579, 1, 3, 34, 16, 383, 3, 356, 1, 113, 34, 16, 334, 4, 26, 414, 21, 364, 8, 473, 1, 387, 11490, 4, 8, 1169, 2854, 1267, 278, 6, 3, 4465, 2, 3631, 278, 6, 3, 263, 502, 16, 1352, 186, 84, 278, 6, 3, 4465, 16, 622, 798, 6, 114, 922, 77, 140, 1, 196, 1, 11490, 47, 85, 210, 26, 473, 2527, 3, 174, 9, 3029, 113, 34, 802, 3, 594, 9, 80, 908, 2, 5506, 617, 1, 7, 265, 5, 1593, 1, 26, 30]",667.0,29940688,16
Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years.,Gynecologic oncology,Gynecol. Oncol.,2018-06-27,"Since 1970, the Gynecologic Oncology Group (GOG) has been at the forefront of evaluating and helping to implement ground breaking and paradigm changing research in the management of cervical cancer. While the most dramatic example of this impact was a series of clinical trials published in 1999 that evaluated chemoradiation therapy versus radiation therapy alone for patients with various clinical scenarios, including both locally advanced as well as post radical hysterectomy patients, investigation has continued to further refine and improve therapy. In 2014, based on the results of GOG protocol 240, bevacizumab became the first approved targeted therapy in a gynecologic cancer in the United States. Most recently, clinical trial work from the GOG is changing the standard of care for all clinical scenarios. Finally, an emphasis on survivorship and special populations are now top priorities.",Historical Article,573.0,3.0,Since 1970 the Gynecologic Oncology Group GOG has been at the forefront of evaluating and helping to implement ground breaking and paradigm changing research in the management of cancer While the most dramatic example of this impact was a series of clinical trials published in 1999 that evaluated chemoradiation therapy versus radiation therapy alone for patients with various clinical scenarios including both locally advanced as well as post radical hysterectomy patients investigation has continued to further refine and improve therapy In 2014 based on the results of GOG protocol 240 bevacizumab became the first approved targeted therapy in a gynecologic cancer in the United States Most recently clinical trial work from the GOG is changing the standard of care for all clinical scenarios Finally an emphasis on survivorship and special populations are now top priorities,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1192, 4868, 3, 1512, 413, 87, 4760, 71, 85, 28, 3, 11747, 1, 1435, 2, 7188, 6, 6207, 9808, 13869, 2, 2431, 3600, 389, 4, 3, 284, 1, 12, 369, 3, 96, 3079, 2685, 1, 26, 345, 10, 8, 988, 1, 38, 143, 983, 4, 2043, 17, 194, 975, 36, 185, 121, 36, 279, 9, 7, 5, 747, 38, 3964, 141, 110, 795, 131, 22, 149, 22, 539, 711, 2622, 7, 940, 71, 1351, 6, 195, 5003, 2, 401, 36, 4, 1409, 90, 23, 3, 99, 1, 4760, 1182, 4263, 599, 3451, 3, 157, 850, 238, 36, 4, 8, 1512, 12, 4, 3, 1088, 907, 96, 761, 38, 160, 1357, 29, 3, 4760, 16, 3600, 3, 260, 1, 165, 9, 62, 38, 3964, 1368, 35, 3136, 23, 2560, 2, 3714, 1184, 32, 1134, 3150, 6513]",879.0,29954593,9
Proliferative role of BDNF/TrkB signaling is associated with anoikis resistance in cervical cancer.,Oncology reports,Oncol. Rep.,2018-06-20,"Brainderived neurotrophic factor (BDNF) is known as one of the members of the neurotropin family. BDNFinduced activation of its receptor tyrosine kinase B (TrkB) is associated with anoikis tolerance, tumor progression and poor prognosis in many types of malignancy. However, to the best of our knowledge, there are no reports describing the contribution of the BDNF/TrkB axis to cervical cancer. BDNF and TrKB expression in cervical cancer (CC) tissues and adjacent normal tissues from 87 patients were analyzed by immunohistochemistry, western blot analysis and quantitative PCR assays and the results showed that they were significantly higher in cancer tissues than that in normal adjacent tissues, respectively. Higher expression rates of BDNF and TrKB were observed in stageIIB or higher and BDNF expression was positively associated with lymph node metastasis. Notably, a high expression of TrKB may be contributed to poor survival time, which confirmed by KaplanMeier analysis. Compared to the corresponding CC cell lines, HeLa, SiHa, CASKI, C41 and C33a, BDNF and TrKB expression was enhanced in anoikislike apoptotic tolerance (AAT), a cell model established from cervical cancer cell lines. AAT cells showed a higher proliferation activity compared with CC cell lines, which was confirmed by a shorter G0/G1 phase, elevated cyclinA, cyclinD1 and cmyc, decreased caspase3 and Bax, and increased Bcl2. By contrast, the knockdown of TrKB expression reversed these changes in AAT cells, induced G0/G1 arrest and suppressed proliferation activity. The results of the present study show that PI3K/Akt signaling is involved in the BDNF/TrKBinduced proliferation of AAT cells in cervical cancer. These findings indicate that BDNF/TrKB pathway is a potential target for the treatment of cervical cancer.",Journal Article,580.0,2.0,Brainderived neurotrophic factor BDNF is known as one of the members of the neurotropin family BDNFinduced activation of its receptor tyrosine kinase B TrkB is associated with anoikis tolerance tumor progression and poor prognosis in many types of malignancy However to the best of our knowledge there are no reports describing the contribution of the BDNF/TrkB axis to cancer BDNF and TrKB expression in cancer CC tissues and adjacent normal tissues from 87 patients were analyzed by immunohistochemistry western blot analysis and quantitative PCR assays and the results showed that they were significantly higher in cancer tissues than that in normal adjacent tissues respectively Higher expression rates of BDNF and TrKB were observed in stage IIB or higher and BDNF expression was positively associated with lymph node metastasis Notably a high expression of TrKB may be contributed to poor survival time which confirmed by KaplanMeier analysis Compared to the corresponding CC cell lines HeLa SiHa CASKI C41 and C33a BDNF and TrKB expression was enhanced in anoikislike apoptotic tolerance AAT a cell model established from cancer cell lines AAT cells showed a higher proliferation activity compared with CC cell lines which was confirmed by a shorter G0/G1 phase elevated cyclin A cyclin D1 and cmyc decreased caspase3 and Bax and increased Bcl2 By contrast the knockdown of TrKB expression reversed these changes in AAT cells induced G0/G1 arrest and suppressed proliferation activity The results of the present study show that PI3K/Akt signaling is involved in the BDNF/TrKBinduced proliferation of AAT cells in cancer These findings indicate that BDNF/TrKB pathway is a potential target for the treatment of cancer,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[73201, 12967, 161, 12934, 16, 440, 22, 104, 1, 3, 1684, 1, 3, 73202, 607, 73203, 363, 1, 211, 153, 564, 216, 132, 8880, 16, 41, 5, 7817, 2614, 30, 91, 2, 334, 356, 4, 445, 630, 1, 710, 137, 6, 3, 824, 1, 114, 922, 125, 32, 77, 1198, 4950, 3, 2925, 1, 3, 12934, 8880, 2310, 6, 12, 12934, 2, 8880, 55, 4, 12, 1951, 742, 2, 2086, 295, 742, 29, 912, 7, 11, 311, 20, 888, 1521, 2639, 65, 2, 1156, 604, 1013, 2, 3, 99, 224, 17, 491, 11, 97, 142, 4, 12, 742, 76, 17, 4, 295, 2086, 742, 106, 142, 55, 151, 1, 12934, 2, 8880, 11, 164, 4, 82, 3884, 15, 142, 2, 12934, 55, 10, 2375, 41, 5, 263, 289, 278, 2552, 8, 64, 55, 1, 8880, 68, 40, 3447, 6, 334, 25, 98, 92, 557, 20, 36322, 65, 72, 6, 3, 1734, 1951, 31, 285, 8466, 19043, 27417, 73204, 2, 73205, 12934, 2, 8880, 55, 10, 651, 4, 73206, 1631, 2614, 19665, 8, 31, 202, 635, 29, 12, 31, 285, 19665, 37, 224, 8, 142, 457, 128, 72, 5, 1951, 31, 285, 92, 10, 557, 20, 8, 985, 8588, 3344, 124, 804, 1226, 8, 1226, 2146, 2, 73207, 340, 51153, 2, 3119, 2, 101, 42103, 20, 748, 3, 1563, 1, 8880, 55, 3682, 46, 400, 4, 19665, 37, 277, 8588, 3344, 1854, 2, 1908, 457, 128, 3, 99, 1, 3, 364, 45, 514, 17, 974, 649, 314, 16, 646, 4, 3, 12934, 73208, 457, 1, 19665, 37, 4, 12, 46, 272, 1008, 17, 12934, 8880, 308, 16, 8, 174, 283, 9, 3, 24, 1, 12]",1733.0,29989647,559
Patient-Reported Toxicity During Pelvic Intensity-Modulated Radiation Therapy: NRG Oncology-RTOG 1203.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2018-07-10,"Purpose NRG Oncology/RTOG 1203 was designed to compare patient-reported acute toxicity and health-related quality of life during treatment with standard pelvic radiation or intensity-modulated radiation therapy (IMRT) in women with cervical and endometrial cancer. Methods Patients were randomly assigned to standard four-field radiation therapy (RT) or IMRT radiation treatment. The primary end point was change in patient-reported acute GI toxicity from baseline to the end of RT, measured with the bowel domain of the Expanded Prostate Cancer Index Composite (EPIC). Secondary end points included change in patient-reported urinary toxicity, change in GI toxicity measured with the Patient-Reported Outcome Common Terminology Criteria for Adverse Events, and quality of life measured with the Trial Outcome Index. Results From 2012 to 2015, 289 patients were enrolled, of whom 278 were eligible. Between baseline and end of RT, the mean EPIC bowel score declined 23.6 points in the standard RT group and 18.6 points in the IMRT group ( P = .048), the mean EPIC urinary score declined 10.4 points in the standard RT group and 5.6 points in the IMRT group ( P = .03), and the mean Trial Outcome Index score declined 12.8 points in the standard RT group and 8.8 points in the IMRT group ( P = .06). At the end of RT, 51.9% of women who received standard RT and 33.7% who received IMRT reported frequent or almost constant diarrhea ( P = .01), and more patients who received standard RT were taking antidiarrheal medications four or more times daily (20.4% v 7.8%; P = .04). Conclusion Pelvic IMRT was associated with significantly less GI and urinary toxicity than standard RT from the patient's perspective.","Clinical Trial, Phase III",560.0,21.0,Purpose NRG Oncology/RTOG 1203 was designed to compare patient-reported acute toxicity and health-related quality of life during treatment with standard pelvic radiation or intensity-modulated radiation therapy IMRT in women with and cancer Methods Patients were randomly assigned to standard four-field radiation therapy RT or IMRT radiation treatment The primary end point was change in patient-reported acute GI toxicity from baseline to the end of RT measured with the bowel domain of the Expanded Cancer Index Composite EPIC Secondary end points included change in patient-reported urinary toxicity change in GI toxicity measured with the Patient-Reported Outcome Common Terminology Criteria for Adverse Events and quality of life measured with the Trial Outcome Index Results From 2012 to 2015 289 patients were enrolled of whom 278 were eligible Between baseline and end of RT the mean EPIC bowel score declined 23.6 points in the standard RT group and 18.6 points in the IMRT group P .048 the mean EPIC urinary score declined 10.4 points in the standard RT group and 5.6 points in the IMRT group P .03 and the mean Trial Outcome Index score declined 12.8 points in the standard RT group and 8.8 points in the IMRT group P .06 At the end of RT 51.9 of women who received standard RT and 33.7 who received IMRT reported frequent or almost constant diarrhea P .01 and more patients who received standard RT were taking antidiarrheal medications four or more times daily 20.4 v 7.8 P .04 Conclusion Pelvic IMRT was associated with significantly less GI and urinary toxicity than standard RT from the patient 's perspective,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[743, 8828, 413, 3931, 31119, 10, 1114, 6, 932, 69, 210, 286, 155, 2, 341, 139, 372, 1, 358, 190, 24, 5, 260, 1110, 121, 15, 837, 1757, 121, 36, 964, 4, 117, 5, 2, 12, 636, 7, 11, 1108, 896, 6, 260, 294, 1067, 121, 36, 240, 15, 964, 121, 24, 3, 86, 396, 741, 10, 707, 4, 69, 210, 286, 2104, 155, 29, 330, 6, 3, 396, 1, 240, 644, 5, 3, 1659, 1398, 1, 3, 2064, 12, 558, 3308, 8995, 568, 396, 862, 159, 707, 4, 69, 210, 1660, 155, 707, 4, 2104, 155, 644, 5, 3, 69, 210, 228, 186, 3462, 371, 9, 290, 281, 2, 372, 1, 358, 644, 5, 3, 160, 228, 558, 99, 29, 1195, 6, 1483, 9080, 7, 11, 346, 1, 953, 9128, 11, 625, 59, 330, 2, 396, 1, 240, 3, 313, 8995, 1659, 368, 3054, 382, 49, 862, 4, 3, 260, 240, 87, 2, 203, 49, 862, 4, 3, 964, 87, 19, 4969, 3, 313, 8995, 1660, 368, 3054, 79, 39, 862, 4, 3, 260, 240, 87, 2, 33, 49, 862, 4, 3, 964, 87, 19, 680, 2, 3, 313, 160, 228, 558, 368, 3054, 133, 66, 862, 4, 3, 260, 240, 87, 2, 66, 66, 862, 4, 3, 964, 87, 19, 1460, 28, 3, 396, 1, 240, 725, 83, 1, 117, 54, 103, 260, 240, 2, 466, 67, 54, 103, 964, 210, 908, 15, 2214, 4982, 1172, 19, 355, 2, 80, 7, 54, 103, 260, 240, 11, 2727, 26911, 2679, 294, 15, 80, 1072, 391, 179, 39, 603, 67, 66, 19, 755, 1221, 1110, 964, 10, 41, 5, 97, 299, 2104, 2, 1660, 155, 76, 260, 240, 29, 3, 69, 292, 3727]",1626.0,29989857,602
HGT-ID: an efficient and sensitive workflow to detect human-viral insertion sites using next-generation sequencing data.,BMC bioinformatics,BMC Bioinformatics,2018-07-17,"Transfer of genetic material from microbes or viruses into the host genome is known as horizontal gene transfer (HGT). The integration of viruses into the human genome is associated with multiple cancers, and these can now be detected using next-generation sequencing methods such as whole genome sequencing and RNA-sequencing. We designed a novel computational workflow, HGT-ID, to identify the integration of viruses into the human genome using the sequencing data. The HGT-ID workflow primarily follows a four-step procedure: i) pre-processing of unaligned reads, ii) virus detection using subtraction approach, iii) identification of virus integration site using discordant and soft-clipped reads and iv) HGT candidates prioritization through a scoring function. Annotation and visualization of the events, as well as primer design for experimental validation, are also provided in the final report. We evaluated the tool performance with the well-understood cervical cancer samples. The HGT-ID workflow accurately detected known human papillomavirus (HPV) integration sites with high sensitivity and specificity compared to previous HGT methods. We applied HGT-ID to The Cancer Genome Atlas (TCGA) whole-genome sequencing data (WGS) from liver tumor-normal pairs. Multiple hepatitis B virus (HBV) integration sites were identified in TCGA liver samples and confirmed by HGT-ID using the RNA-Seq data from the matched liver pairs. This shows the applicability of the method in both the data types and cross-validation of the HGT events in liver samples. We also processed 220 breast tumor WGS data through the workflow; however, there were no HGT events detected in those samples. HGT-ID is a novel computational workflow to detect the integration of viruses in the human genome using the sequencing data. It is fast and accurate with functions such as prioritization, annotation, visualization and primer design for future validation of HGTs. The HGT-ID workflow is released under the MIT License and available at http://kalarikrlab.org/Software/HGT-ID.html .",Journal Article,553.0,1.0,Transfer of genetic material from microbes or viruses into the host genome is known as horizontal gene transfer HGT The integration of viruses into the human genome is associated with multiple cancers and these can now be detected using next-generation sequencing methods such as whole genome sequencing and RNA-sequencing We designed a novel computational workflow HGT-ID to identify the integration of viruses into the human genome using the sequencing data The HGT-ID workflow primarily follows a four-step procedure i pre-processing of unaligned reads ii virus detection using subtraction approach iii identification of virus integration site using discordant and soft-clipped reads and iv HGT candidates prioritization through a scoring function Annotation and visualization of the events as well as primer design for experimental validation are also provided in the final report We evaluated the tool performance with the well-understood cancer samples The HGT-ID workflow accurately detected known human papillomavirus HPV integration sites with high sensitivity and specificity compared to previous HGT methods We applied HGT-ID to The Cancer Genome Atlas TCGA whole-genome sequencing data WGS from tumor-normal pairs Multiple hepatitis B virus HBV integration sites were identified in TCGA samples and confirmed by HGT-ID using the RNA-Seq data from the matched pairs This shows the applicability of the method in both the data types and cross-validation of the HGT events in samples We also processed 220 tumor WGS data through the workflow however there were no HGT events detected in those samples HGT-ID is a novel computational workflow to detect the integration of viruses in the human genome using the sequencing data It is fast and accurate with functions such as prioritization annotation visualization and primer design for future validation of HGTs The HGT-ID workflow is released under the MIT License and available at http //kalarikrlab.org/Software/HGT-ID.html,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2602, 1, 336, 3692, 29, 14266, 15, 4405, 237, 3, 1204, 898, 16, 440, 22, 17376, 145, 2602, 20123, 3, 2676, 1, 4405, 237, 3, 171, 898, 16, 41, 5, 232, 163, 2, 46, 122, 1134, 40, 530, 75, 1305, 914, 615, 636, 225, 22, 902, 898, 615, 2, 893, 615, 21, 1114, 8, 229, 5368, 8825, 20123, 4937, 6, 255, 3, 2676, 1, 4405, 237, 3, 171, 898, 75, 3, 615, 74, 3, 20123, 4937, 8825, 1561, 2962, 8, 294, 2458, 1299, 70, 671, 3325, 1, 73241, 11062, 215, 1450, 638, 75, 13956, 353, 316, 911, 1, 1450, 2676, 606, 75, 4570, 2, 1214, 12681, 11062, 2, 478, 20123, 1931, 10343, 298, 8, 2504, 343, 8407, 2, 6234, 1, 3, 281, 22, 149, 22, 9684, 771, 9, 1560, 929, 32, 120, 1052, 4, 3, 1457, 414, 21, 194, 3, 1515, 528, 5, 3, 149, 1784, 12, 347, 3, 20123, 4937, 8825, 2141, 530, 440, 171, 3242, 933, 2676, 633, 5, 64, 485, 2, 1121, 72, 6, 698, 20123, 636, 21, 1498, 20123, 4937, 6, 3, 12, 898, 2643, 2959, 902, 898, 615, 74, 11881, 29, 30, 295, 2773, 232, 3002, 132, 1450, 3427, 2676, 633, 11, 108, 4, 2959, 347, 2, 557, 20, 20123, 4937, 75, 3, 893, 4185, 74, 29, 3, 655, 2773, 26, 1949, 3, 5412, 1, 3, 596, 4, 110, 3, 74, 630, 2, 1383, 929, 1, 3, 20123, 281, 4, 347, 21, 120, 5232, 6211, 30, 11881, 74, 298, 3, 8825, 137, 125, 11, 77, 20123, 281, 530, 4, 135, 347, 20123, 4937, 16, 8, 229, 5368, 8825, 6, 1426, 3, 2676, 1, 4405, 4, 3, 171, 898, 75, 3, 615, 74, 192, 16, 5830, 2, 1481, 5, 1681, 225, 22, 10343, 8407, 6234, 2, 9684, 771, 9, 508, 929, 1, 73242, 3, 20123, 4937, 8825, 16, 5394, 669, 3, 11455, 15289, 2, 390, 28, 5196, 73243, 5598, 3639, 20123, 4937, 23629]",1983.0,30016933,203
Kinetics of Intratumoral Immune Cell Activation During Chemoradiation for Cervical Cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2018-07-12,"Radiation therapy has direct cytotoxic effects on tumor-infiltrating lymphocytes, but it also has immune stimulatory effects that increase immune cell infiltration. The dynamics of these competing effects on immune cells at the site of the tumor are poorly characterized during chemoradiation treatment (CRT) because of the difficulty of obtaining consecutive tumor biopsies. We used a minimally invasive cervical cytobrushing method to analyze the kinetics of intratumoral immune cell changes in patients with cervical cancer during CRT. Cervical brushings were obtained from 20 patients with cervical cancer at baseline and during fractionated radiation therapy and cisplatin (weeks 1, 3, and 5). Matching peripheral blood mononuclear cells were obtained from 9 patients at the same time points. Cells were analyzed using multispectral flow cytometry to identify T cell and myeloid cell subsets and their activation status. Changes in immune cell subsets throughout treatment were calculated using matched-pair analysis with Wilcoxon rank sum test. We observed a significant decline in CD3+ total T cells, as well as CD8+ and CD4+ T-cell subsets in the first week of treatment from baseline, followed by variable expansion at weeks 3 and 5. This coincided with higher levels of proliferating CD8+ T cells expressing Ki67 at week 3 of treatment. The percentages of activated CD8+ T cells expressing CD69 continuously increased over the course of treatment, whereas the percentage of activated CD11c+CD11b- dendritic cells was highest during the first week. Many of these changes were not observed in the blood. Our results identified immune dynamic changes during CRT, indicating that CRT may be immune activating at the site of the tumor. This study also suggests the importance of sequential analyses of the local tumor microenvironment in addition to peripheral blood.",Journal Article,558.0,2.0,Radiation therapy has direct cytotoxic effects on tumor-infiltrating lymphocytes but it also has immune stimulatory effects that increase immune cell infiltration The dynamics of these competing effects on immune cells at the site of the tumor are poorly characterized during chemoradiation treatment CRT because of the difficulty of obtaining consecutive tumor biopsies We used a minimally invasive cytobrushing method to analyze the kinetics of intratumoral immune cell changes in patients with cancer during CRT brushings were obtained from 20 patients with cancer at baseline and during fractionated radiation therapy and cisplatin weeks 1 3 and 5 Matching peripheral blood mononuclear cells were obtained from 9 patients at the same time points Cells were analyzed using multispectral flow cytometry to identify T cell and myeloid cell subsets and their activation status Changes in immune cell subsets throughout treatment were calculated using matched-pair analysis with Wilcoxon rank sum test We observed a significant decline in CD3+ total T cells as well as CD8+ and CD4+ T-cell subsets in the first week of treatment from baseline followed by variable expansion at weeks 3 and 5 This coincided with higher levels of proliferating CD8+ T cells expressing Ki67 at week 3 of treatment The percentages of activated CD8+ T cells expressing CD69 continuously increased over the course of treatment whereas the percentage of activated CD11c+CD11b- dendritic cells was highest during the first week Many of these changes were not observed in the blood Our results identified immune dynamic changes during CRT indicating that CRT may be immune activating at the site of the tumor This study also suggests the importance of sequential analyses of the local tumor microenvironment in addition to peripheral blood,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[121, 36, 71, 1196, 759, 176, 23, 30, 2097, 1594, 84, 192, 120, 71, 250, 6708, 176, 17, 344, 250, 31, 2084, 3, 5193, 1, 46, 2573, 176, 23, 250, 37, 28, 3, 606, 1, 3, 30, 32, 1240, 765, 190, 975, 24, 1089, 408, 1, 3, 4035, 1, 5244, 935, 30, 1154, 21, 95, 8, 2144, 416, 73247, 596, 6, 1992, 3, 3839, 1, 2074, 250, 31, 400, 4, 7, 5, 12, 190, 1089, 14515, 11, 683, 29, 179, 7, 5, 12, 28, 330, 2, 190, 3950, 121, 36, 2, 540, 244, 14, 27, 2, 33, 2616, 672, 315, 3041, 37, 11, 683, 29, 83, 7, 28, 3, 827, 98, 862, 37, 11, 311, 75, 18997, 1412, 1914, 6, 255, 102, 31, 2, 533, 31, 1890, 2, 136, 363, 156, 400, 4, 250, 31, 1890, 2432, 24, 11, 981, 75, 655, 4767, 65, 5, 3896, 1026, 3216, 412, 21, 164, 8, 93, 1858, 4, 3117, 181, 102, 37, 22, 149, 22, 968, 2, 1440, 102, 31, 1890, 4, 3, 157, 647, 1, 24, 29, 330, 370, 20, 1347, 1422, 28, 244, 27, 2, 33, 26, 13050, 5, 142, 148, 1, 5639, 968, 102, 37, 1046, 3654, 28, 647, 27, 1, 24, 3, 5504, 1, 735, 968, 102, 37, 1046, 16337, 4285, 101, 252, 3, 906, 1, 24, 547, 3, 1150, 1, 735, 12513, 6861, 2464, 37, 10, 1076, 190, 3, 157, 647, 445, 1, 46, 400, 11, 44, 164, 4, 3, 315, 114, 99, 108, 250, 2540, 400, 190, 1089, 1716, 17, 1089, 68, 40, 250, 1616, 28, 3, 606, 1, 3, 30, 26, 45, 120, 844, 3, 1187, 1, 1787, 318, 1, 3, 293, 30, 995, 4, 352, 6, 672, 315]",1812.0,30017792,684
Conservative management of cervical cancer: Current status and obstetrical implications.,Best practice & research. Clinical obstetrics & gynaecology,Best Pract Res Clin Obstet Gynaecol,2018-06-28,"Recent advances in screening and early diagnosis have decreased cervical cancer incidence and mortality rates in high-resource settings. The postponement of childbearing, combined with an increased number of cervical cancer survivors, has yielded new paradigms in patient care. In recent years, radical surgery has been challenged as the standard of care for early-stage cervical cancer owing to its significant morbidity and fertility impairment. Attention has been directed to assessing more conservative procedures that can reduce treatment-induced morbidity without compromising oncologic safety and reproductive potential of patients with early-stage disease. In those with more advanced disease, neoadjuvant chemotherapy followed by conservative surgery has also been considered. These conservative treatment modalities including cervical conization, simple trachelectomy, and simple hysterectomy have been studied in various settings. In this chapter, we discuss the role of conservative surgery in the management of cervical cancer and the resulting obstetrical outcomes.",Journal Article,572.0,3.0,Recent advances in screening and early diagnosis have decreased cancer incidence and mortality rates in high-resource settings The postponement of childbearing combined with an increased number of cancer survivors has yielded new paradigms in patient care In recent years radical surgery has been challenged as the standard of care for early-stage cancer owing to its significant morbidity and fertility impairment Attention has been directed to assessing more conservative procedures that can reduce treatment-induced morbidity without compromising oncologic safety and reproductive potential of patients with early-stage disease In those with more advanced disease neoadjuvant chemotherapy followed by conservative surgery has also been considered These conservative treatment modalities including conization simple trachelectomy and simple hysterectomy have been studied in various settings In this chapter we discuss the role of conservative surgery in the management of cancer and the resulting obstetrical outcomes,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[435, 954, 4, 453, 2, 191, 147, 47, 340, 12, 287, 2, 282, 151, 4, 64, 3069, 1947, 3, 40908, 1, 10278, 397, 5, 35, 101, 207, 1, 12, 332, 71, 2178, 217, 4887, 4, 69, 165, 4, 435, 60, 711, 152, 71, 85, 6389, 22, 3, 260, 1, 165, 9, 191, 82, 12, 3421, 6, 211, 93, 787, 2, 2954, 2315, 2111, 71, 85, 1166, 6, 1977, 80, 4476, 1369, 17, 122, 969, 24, 277, 787, 187, 6102, 1998, 367, 2, 3705, 174, 1, 7, 5, 191, 82, 34, 4, 135, 5, 80, 131, 34, 536, 56, 370, 20, 4476, 152, 71, 120, 85, 515, 46, 4476, 24, 1558, 141, 8755, 2763, 5760, 2, 2763, 2622, 47, 85, 656, 4, 747, 1947, 4, 26, 6366, 21, 1139, 3, 200, 1, 4476, 152, 4, 3, 284, 1, 12, 2, 3, 1113, 21031, 123]",1020.0,30029960,131
Long-Term Oncologic Outcomes of Uterine-Preserving Surgery in Young Women With Stage Ib1 Cervical Cancer.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2018-09-01,"This study aimed to evaluate oncologic outcomes of women with stage IB1 cervical cancer treated with uterine-preserving surgery (UPS) (defined as conization or trachelectomy) versus non-UPS (defined as hysterectomy of any type). The Surveillance, Epidemiology, and End Results (SEER) database was used to identify women younger than 45 years diagnosed with stage IB1 cervical cancer from 1998 to 2012. Only those who underwent lymph node (LN) assessment were included. Outcomes of UPS versus non-UPS were analyzed. Among 2717 patients, 125 were treated with UPS and 2592 were treated with non-UPS. Those in the UPS group were younger (median age 33 vs 37 years, P < 0.001), less commonly had tumor size greater than 2 cm (27% vs 45%, P < 0.001), and less commonly received adjuvant radiation therapy (18% vs 29%, P = 0.006). There was no difference in distribution of tumor grade, histology, or rate of LN positivity. Median follow-up was 79 months (range, 0-179). There was no difference in 5-year disease-specific survival (DSS) between the UPS versus non-UPS groups (93% vs 94%, respectively, P = 0.755). When stratified by tumor size, DSS for UPS versus non-UPS was as follows: tumors 2 cm or less, 96.8% versus 96.3% (P = 0.683); tumors greater than 2 cm, 82.4% versus 90.4% (P = 0.112). Factors independently associated with worsened survival included adenosquamous histology (hazard ratio [HR] 2.29, 95% confidence interval [CI]1.51-3.47), G3 disease (HR 2.44, 95% CI 1.01-5.89), tumor size greater than 2 cm (HR 1.93, 95% CI 1.36-2.75) and LN positivity (HR 2.29, 95% CI 1.64-3.22). The UPS was not associated with a higher risk of death. The UPS does not seem to compromise oncologic outcomes in a select group of young women with stage IB1 cervical cancer, especially in the setting of tumors 2 cm or less. Further studies are needed to clarify the role of UPS in tumors greater than 2 cm.",Journal Article,507.0,3.0,This study aimed to evaluate oncologic outcomes of women with stage IB1 cancer treated with uterine-preserving surgery UPS defined as conization or trachelectomy versus non-UPS defined as hysterectomy of any type The Surveillance Epidemiology and End Results SEER database was used to identify women younger than 45 years diagnosed with stage IB1 cancer from 1998 to 2012 Only those who underwent lymph node LN assessment were included Outcomes of UPS versus non-UPS were analyzed Among 2717 patients 125 were treated with UPS and 2592 were treated with non-UPS Those in the UPS group were younger median age 33 vs 37 years P 0.001 less commonly had tumor size greater than 2 cm 27 vs 45 P 0.001 and less commonly received adjuvant radiation therapy 18 vs 29 P 0.006 There was no difference in distribution of tumor grade histology or rate of LN positivity Median follow-up was 79 months range 0-179 There was no difference in 5-year disease-specific survival DSS between the UPS versus non-UPS groups 93 vs 94 respectively P 0.755 When stratified by tumor size DSS for UPS versus non-UPS was as follows tumors 2 cm or less 96.8 versus 96.3 P 0.683 tumors greater than 2 cm 82.4 versus 90.4 P 0.112 Factors independently associated with worsened survival included adenosquamous histology hazard ratio HR 2.29 95 confidence interval CI 1.51-3.47 G3 disease HR 2.44 95 CI 1.01-5.89 tumor size greater than 2 cm HR 1.93 95 CI 1.36-2.75 and LN positivity HR 2.29 95 CI 1.64-3.22 The UPS was not associated with a higher risk of death The UPS does not seem to compromise oncologic outcomes in a select group of young women with stage IB1 cancer especially in the setting of tumors 2 cm or less Further studies are needed to clarify the role of UPS in tumors greater than 2 cm,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[26, 45, 1295, 6, 376, 1998, 123, 1, 117, 5, 82, 8111, 12, 73, 5, 16369, 4972, 152, 6106, 395, 22, 8755, 15, 5760, 185, 220, 6106, 395, 22, 2622, 1, 500, 267, 3, 617, 1284, 2, 396, 99, 1605, 609, 10, 95, 6, 255, 117, 773, 76, 512, 60, 265, 5, 82, 8111, 12, 29, 1850, 6, 1195, 158, 135, 54, 208, 263, 289, 1763, 455, 11, 159, 123, 1, 6106, 185, 220, 6106, 11, 311, 107, 73298, 7, 1731, 11, 73, 5, 6106, 2, 39264, 11, 73, 5, 220, 6106, 135, 4, 3, 6106, 87, 11, 773, 52, 89, 466, 105, 567, 60, 19, 13, 144, 299, 841, 42, 30, 444, 378, 76, 18, 494, 428, 105, 512, 19, 13, 144, 2, 299, 841, 103, 249, 121, 36, 203, 105, 462, 19, 13, 1861, 125, 10, 77, 523, 4, 1395, 1, 30, 88, 784, 15, 116, 1, 1763, 1887, 52, 166, 126, 10, 842, 53, 184, 13, 5977, 125, 10, 77, 523, 4, 33, 111, 34, 112, 25, 1788, 59, 3, 6106, 185, 220, 6106, 271, 966, 105, 960, 106, 19, 13, 14753, 198, 1173, 20, 30, 444, 1788, 9, 6106, 185, 220, 6106, 10, 22, 2962, 57, 18, 494, 15, 299, 921, 66, 185, 921, 27, 19, 13, 15677, 57, 378, 76, 18, 494, 878, 39, 185, 424, 39, 19, 13, 3726, 130, 1042, 41, 5, 5890, 25, 159, 8067, 784, 360, 197, 168, 18, 462, 48, 307, 268, 58, 14, 725, 27, 662, 5578, 34, 168, 18, 584, 48, 58, 14, 355, 33, 887, 30, 444, 378, 76, 18, 494, 168, 14, 966, 48, 58, 14, 511, 18, 481, 2, 1763, 1887, 168, 18, 462, 48, 58, 14, 660, 27, 350, 3, 6106, 10, 44, 41, 5, 8, 142, 43, 1, 273, 3, 6106, 1097, 44, 3233, 6, 4665, 1998, 123, 4, 8, 1717, 87, 1, 1169, 117, 5, 82, 8111, 12, 1093, 4, 3, 546, 1, 57, 18, 494, 15, 299, 195, 94, 32, 575, 6, 3968, 3, 200, 1, 6106, 4, 57, 378, 76, 18, 494]",1770.0,30036225,173
National Cancer Grid of India Consensus Guidelines on the Management of Cervical Cancer.,Journal of global oncology,J Glob Oncol,2018-07-01,"Standard guidelines for the management of early and locally advanced cervical cancer are available from various academic consortiums nationally and internationally. However, implementing standard-of-care treatment poses unique challenges within low- and middle-income countries, such as India, where diverse clinical care practices may exist. The National Cancer Grid, a consortium of 108 institutions in India, aims to homogenize care for patients with cervical cancer by achieving consensus on not only imaging and management, but also in addressing potential solutions to prevalent challenges that affect the homogenous implementation of standard-of-care treatment. These guidelines therefore represent a consensus statement of the National Cancer Grid gynecologic cancer expert group and will assist in homogenization of the therapeutic management of patients with cervical cancer in India.",Journal Article,569.0,4.0,Standard guidelines for the management of early and locally advanced cancer are available from various academic consortiums nationally and internationally However implementing standard-of-care treatment poses unique challenges within low- and middle-income countries such as India where diverse clinical care practices may exist The National Cancer Grid a consortium of 108 institutions in India aims to homogenize care for patients with cancer by achieving consensus on not only imaging and management but also in addressing potential solutions to prevalent challenges that affect the homogenous implementation of standard-of-care treatment These guidelines therefore represent a consensus statement of the National Cancer Grid gynecologic cancer expert group and will assist in homogenization of the therapeutic management of patients with cancer in India,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[260, 677, 9, 3, 284, 1, 191, 2, 795, 131, 12, 32, 390, 29, 747, 1916, 35947, 7685, 2, 12828, 137, 6436, 260, 1, 165, 24, 7056, 991, 1427, 262, 154, 2, 3897, 2306, 2115, 225, 22, 7776, 1257, 1867, 38, 165, 2634, 68, 1923, 3, 657, 12, 17491, 8, 2404, 1, 3590, 1764, 4, 7776, 2970, 6, 73378, 165, 9, 7, 5, 12, 20, 1785, 1391, 23, 44, 158, 270, 2, 284, 84, 120, 4, 3432, 174, 6947, 6, 2485, 1427, 17, 1158, 3, 10408, 2393, 1, 260, 1, 165, 24, 46, 677, 673, 1231, 8, 1391, 5914, 1, 3, 657, 12, 17491, 1512, 12, 2005, 87, 2, 303, 3425, 4, 73379, 1, 3, 189, 284, 1, 7, 5, 12, 4, 7776]",857.0,30085891,0
Standard Chemoradiation and Conventional Brachytherapy for Locally Advanced Cervical Cancer: Is It Still Applicable in the Era of Magnetic Resonance-Based Brachytherapy?,Journal of global oncology,J Glob Oncol,2018-07-01,"Purpose Recent guidelines recommend magnetic resonance imaging-based brachytherapy (MRBT) for locally advanced cervical cancer. However, its implementation is challenging within the developing world. This article reports the outcomes of patients with locally advanced cervical cancer treated with chemoradiation and point A-based brachytherapy (BT) using x-ray- or computed tomography-based planning. Methods Patients treated between January 2014 and December 2015 were included. Patients underwent x-ray- or computed tomography-based BT planning with an aim to deliver equivalent doses in 2 Gy (EQD2) > 84 Gy<sub>10</sub> to point A while minimizing maximum dose received by rectum or bladder to a point or 2 cc volume to < 75 Gy EQD2 and < 90 Gy EQD2, respectively<sub>.</sub> The impact of known prognostic factors was evaluated. Results A total of 339 patients were evaluated. Median age was 52 (32 to 81) years; 52% of patients had stage IB2 to IIB and 48% had stage III to IVA disease. There was 85% compliance with chemoradiation, and 87% of patients received four or more cycles. Median point A dose was 84 (64.8 to 89.7) Gy. The median rectal and bladder doses were 73.5 (69.6 to 78.4) Gy<sub>3</sub> and 83 (73.2 to 90.0) Gy<sub>3</sub>, respectively. At a median follow-up of 28 (4 to 45) months, the 3-year local, disease-free, and overall survival for stage IB to IIB disease was 94.1%, 83.3%, and 82.7%, respectively. The corresponding rates for stage III to IVA were 85.1%, 60.7%, and 69.6%. Grade III to IV proctitis and cystitis were observed in 4.7% and 0% of patients, respectively. Conclusion This audit demonstrates good 3-year outcomes that are comparable to published MRBT series. Conventional BT with selective use of interstitial needles and MRBT should continue as standard procedures until level-I evidence for MRBT becomes available.",Journal Article,569.0,5.0,Purpose Recent guidelines recommend magnetic resonance imaging-based brachytherapy MRBT for locally advanced cancer However its implementation is challenging within the developing world This article reports the outcomes of patients with locally advanced cancer treated with chemoradiation and point A-based brachytherapy BT using x-ray- or computed tomography-based planning Methods Patients treated between January 2014 and December 2015 were included Patients underwent x-ray- or computed tomography-based BT planning with an aim to deliver equivalent doses in 2 Gy EQD2 84 Gy sub 10 /sub to point A while minimizing maximum dose received by rectum or to a point or 2 cc volume to 75 Gy EQD2 and 90 Gy EQD2 respectively sub /sub The impact of known prognostic factors was evaluated Results A total of 339 patients were evaluated Median age was 52 32 to 81 years 52 of patients had stage IB2 to IIB and 48 had stage III to IVA disease There was 85 compliance with chemoradiation and 87 of patients received four or more cycles Median point A dose was 84 64.8 to 89.7 Gy The median and doses were 73.5 69.6 to 78.4 Gy sub 3 /sub and 83 73.2 to 90.0 Gy sub 3 /sub respectively At a median follow-up of 28 4 to 45 months the 3-year local disease-free and overall survival for stage IB to IIB disease was 94.1 83.3 and 82.7 respectively The corresponding rates for stage III to IVA were 85.1 60.7 and 69.6 Grade III to IV proctitis and cystitis were observed in 4.7 and 0 of patients respectively Conclusion This audit demonstrates good 3-year outcomes that are comparable to published MRBT series Conventional BT with selective use of interstitial needles and MRBT should continue as standard procedures until level-I evidence for MRBT becomes available,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,"[743, 435, 677, 2237, 1484, 1535, 270, 90, 1536, 36649, 9, 795, 131, 12, 137, 211, 2393, 16, 1950, 262, 3, 931, 1956, 26, 946, 1198, 3, 123, 1, 7, 5, 795, 131, 12, 73, 5, 975, 2, 741, 8, 90, 1536, 3641, 75, 1006, 5520, 15, 1220, 872, 90, 1349, 636, 7, 73, 59, 1024, 1409, 2, 1397, 1483, 11, 159, 7, 208, 1006, 5520, 15, 1220, 872, 90, 3641, 1349, 5, 35, 1130, 6, 3392, 2017, 415, 4, 18, 381, 10010, 874, 381, 551, 79, 551, 6, 741, 8, 369, 4501, 689, 61, 103, 20, 3660, 15, 6, 8, 741, 15, 18, 1951, 433, 6, 481, 381, 10010, 2, 424, 381, 10010, 106, 551, 551, 3, 345, 1, 440, 177, 130, 10, 194, 99, 8, 181, 1, 7881, 7, 11, 194, 52, 89, 10, 653, 531, 6, 865, 60, 653, 1, 7, 42, 82, 9537, 6, 3884, 2, 576, 42, 82, 316, 6, 5900, 34, 125, 10, 772, 3336, 5, 975, 2, 912, 1, 7, 103, 294, 15, 80, 410, 52, 741, 8, 61, 10, 874, 660, 66, 6, 887, 67, 381, 3, 52, 2, 415, 11, 803, 33, 790, 49, 6, 833, 39, 381, 551, 27, 551, 2, 852, 803, 18, 6, 424, 13, 381, 551, 27, 551, 106, 28, 8, 52, 166, 126, 1, 339, 39, 6, 512, 53, 3, 27, 111, 293, 34, 115, 2, 63, 25, 9, 82, 3180, 6, 3884, 34, 10, 960, 14, 852, 27, 2, 878, 67, 106, 3, 1734, 151, 9, 82, 316, 6, 5900, 11, 772, 14, 335, 67, 2, 790, 49, 88, 316, 6, 478, 17612, 2, 13032, 11, 164, 4, 39, 67, 2, 13, 1, 7, 106, 1221, 26, 15639, 1902, 1178, 27, 111, 123, 17, 32, 1279, 6, 983, 36649, 988, 809, 3641, 5, 1094, 119, 1, 4543, 14393, 2, 36649, 257, 1906, 22, 260, 1369, 1100, 301, 70, 241, 9, 36649, 5366, 390]",1751.0,30085892,207
"Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2018-08-01,"People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment disparities. Lack of guidelines and provider education has led to substandard cancer care being offered to PLWH. To fill that gap, the NCCN Guidelines for Cancer in PLWH were developed; they provide treatment recommendations for PLWH who develop non-small cell lung cancer, anal cancer, Hodgkin lymphoma, and cervical cancer. In addition, the NCCN Guidelines outline advice regarding HIV management during cancer therapy; drug-drug interactions between antiretroviral treatments and cancer therapies; and workup, radiation therapy, surgical management, and supportive care in PLWH who have cancer.",Journal Article,538.0,6.0,People living with HIV PLWH are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses advanced cancer stage comorbidities immunosuppression and cancer treatment disparities Lack of guidelines and provider education has led to substandard cancer care being offered to PLWH To fill that gap the NCCN Guidelines for Cancer in PLWH were developed they provide treatment recommendations for PLWH who develop cell cancer cancer and cancer In addition the NCCN Guidelines outline advice regarding HIV management during cancer therapy drug-drug interactions between antiretroviral treatments and cancer therapies and workup radiation therapy surgical management and supportive care in PLWH who have cancer,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3788, 2798, 5, 1942, 32908, 32, 265, 5, 12, 28, 35, 101, 116, 252, 3, 1083, 266, 2, 1228, 47, 8, 142, 282, 520, 6, 1612, 2403, 131, 12, 82, 1909, 3646, 2, 12, 24, 2227, 926, 1, 677, 2, 3094, 1848, 71, 836, 6, 26213, 12, 165, 486, 2216, 6, 32908, 6, 11476, 17, 5285, 3, 1944, 677, 9, 12, 4, 32908, 11, 276, 491, 377, 24, 883, 9, 32908, 54, 690, 31, 12, 12, 2, 12, 4, 352, 3, 1944, 677, 5277, 11144, 666, 1942, 284, 190, 12, 36, 234, 234, 1286, 59, 6564, 640, 2, 12, 235, 2, 4755, 121, 36, 221, 284, 2, 1877, 165, 4, 32908, 54, 47, 12]",777.0,30099375,194
Frozen Section for Detection of Lymph Nodes After Cervical Injection with Indocyanine Green (ICG) for Sentinel Lymph Node Technique in Endometrial Cancer Staging.,Annals of surgical oncology,Ann. Surg. Oncol.,2018-08-16,"The aim of this study was to assess the role of frozen section (FS) in identifying an absence of lymph nodes during sentinel lymph node (SLN) biopsy for apparent early-stage endometrial cancer (EC). Consecutive apparent early-stage EC patients who had SLNs removed after cervical injection with indocyanine green (ICG) from 1 June 2014 to 30 June 2016 were analyzed. An empty node (EN) was defined as an SLN specimen without evidence of lymph node(s). The association of tumor and patient characteristics with an EN was evaluated, and trend analysis to compare the rate of ENs over calendar quarters was performed. A decision-tree model was then created to compare the use of FS versus no FS for SLN evaluation in the hypothetical cohort affected by early-stage EC in the US each year. Over the study period, 300 patients met the inclusion criteria. FS revealed ENs in 24 (8%) patients. No association between patient demographic characteristics (age, body mass index, prior abdominopelvic surgery, international federation of gynecology and obstetrics (FIGO) stage, histology, myometrial invasion, cervical stromal invasion) and presence of ENs was observed. The rate of ENs at FS did not change over time (p=0.68). The hypothetical analysis showed a 4.3% decrease of inappropriately staged patients with the use of FS on the SLN (95% confidence interval 4.1-4.5). ENs during SLN biopsy for EC staging is not a rare event and can be easily detected with FS. The implementation of FS of SLN might reduce inadequate staging of EC. Individual institutions may want to examine their own EN rates and determine if this would assist them in their SLN practices for EC.",Clinical Trial,523.0,8.0,The aim of this study was to assess the role of frozen section FS in identifying an absence of lymph nodes during sentinel lymph node SLN biopsy for apparent early-stage cancer EC Consecutive apparent early-stage EC patients who had SLNs removed after injection with indocyanine green ICG from 1 June 2014 to 30 June 2016 were analyzed An empty node EN was defined as an SLN specimen without evidence of lymph node s The association of tumor and patient characteristics with an EN was evaluated and trend analysis to compare the rate of ENs over calendar quarters was performed A decision-tree model was then created to compare the use of FS versus no FS for SLN evaluation in the hypothetical cohort affected by early-stage EC in the US each year Over the study period 300 patients met the inclusion criteria FS revealed ENs in 24 8 patients No association between patient demographic characteristics age body mass index prior abdominopelvic surgery international federation of gynecology and obstetrics FIGO stage histology myometrial invasion stromal invasion and presence of ENs was observed The rate of ENs at FS did not change over time p 0.68 The hypothetical analysis showed a 4.3 decrease of inappropriately staged patients with the use of FS on the SLN 95 confidence interval 4.1-4.5 ENs during SLN biopsy for EC staging is not a rare event and can be easily detected with FS The implementation of FS of SLN might reduce inadequate staging of EC Individual institutions may want to examine their own EN rates and determine if this would assist them in their SLN practices for EC,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,"[3, 1130, 1, 26, 45, 10, 6, 423, 3, 200, 1, 3015, 2917, 4110, 4, 1386, 35, 1127, 1, 263, 502, 190, 1323, 263, 289, 1099, 411, 9, 2235, 191, 82, 12, 2180, 935, 2235, 191, 82, 2180, 7, 54, 42, 2642, 2264, 50, 1754, 5, 18903, 4658, 9118, 29, 14, 1924, 1409, 6, 201, 1924, 1390, 11, 311, 35, 9436, 289, 4375, 10, 395, 22, 35, 1099, 2360, 187, 241, 1, 263, 289, 695, 3, 248, 1, 30, 2, 69, 374, 5, 35, 4375, 10, 194, 2, 853, 65, 6, 932, 3, 116, 1, 32909, 252, 11236, 14497, 10, 173, 8, 948, 4899, 202, 10, 818, 2466, 6, 932, 3, 119, 1, 4110, 185, 77, 4110, 9, 1099, 451, 4, 3, 7045, 180, 1424, 20, 191, 82, 2180, 4, 3, 843, 296, 111, 252, 3, 45, 727, 2036, 7, 543, 3, 1680, 371, 4110, 553, 32909, 4, 259, 66, 7, 77, 248, 59, 69, 1540, 374, 89, 642, 782, 558, 324, 12147, 152, 944, 7303, 1, 6429, 2, 7407, 3837, 82, 784, 7327, 578, 1126, 578, 2, 463, 1, 32909, 10, 164, 3, 116, 1, 32909, 28, 4110, 205, 44, 707, 252, 98, 19, 13, 806, 3, 7045, 65, 224, 8, 39, 27, 775, 1, 13254, 2930, 7, 5, 3, 119, 1, 4110, 23, 3, 1099, 48, 307, 268, 39, 14, 39, 33, 32909, 190, 1099, 411, 9, 2180, 632, 16, 44, 8, 622, 774, 2, 122, 40, 4697, 530, 5, 4110, 3, 2393, 1, 4110, 1, 1099, 822, 969, 3358, 632, 1, 2180, 797, 1764, 68, 9651, 6, 1004, 136, 4165, 4375, 151, 2, 223, 492, 26, 688, 3425, 1370, 4, 136, 1099, 2634, 9, 2180]",1588.0,30116949,242
Characteristics and outcomes of reproductive-aged women with early-stage cervical cancer: trachelectomy vs hysterectomy.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2018-08-21,"Trachelectomy is the treatment of choice for reproductive-aged women with early-stage cervical cancer who desire future fertility. Comprehensive population-based statistics have been missing to date. We sought to compare characteristics and survival of reproductive-aged women who underwent trachelectomy for early-stage cervical cancer to those who had hysterectomy. This is a retrospective observational study examining the Surveillance, Epidemiology, and End Results program from 1998 through 2014. Women <45 years of age with stage IA and IB1 (tumor size 2 cm) cervical cancer who underwent trachelectomy were compared to those who underwent hysterectomy. Multivariable models were used to identify clinicopathological factors associated with trachelectomy. Survival was compared between the 2 groups after propensity score matching. Among 6359 women, 190 (3.0%; 95% confidence interval, 2.6-3.4) underwent trachelectomy. The median age of the trachelectomy group was 31 years (interquartile range, 28-34). The proportion of women who underwent trachelectomy significantly increased during the study period (1.2% in 1998 through 2002, 3.0% in 2003 through 2008, and 4.5% in 2009 through 2014, P < .001). Younger age, nonblack race, single marital status, eastern registry area, recent disease diagnosis, nonsquamous histology, and higher stage were independent factors associated with trachelectomy use (all, adjusted P < .05). After propensity score matching, 5-year cause-specific survival (96.9% vs 96.6%; hazard ratio, 0.73; 95% confidence interval, 0.23-2.30; P= .59) and overall survival (96.1% vs 96.6%; hazard ratio, 0.76; 95% confidence interval, 0.26-2.20; P= .61) were similar between the trachelectomy group and the hysterectomy group. Our study found that there was a significant increase in the proportion of reproductive-aged women with stage IA or IB1 (2 cm) cervical cancer who underwent trachelectomy in recent years. Survival with trachelectomy was similar to those who had hysterectomy in this population.",Comparative Study,518.0,4.0,Trachelectomy is the treatment of choice for reproductive-aged women with early-stage cancer who desire future fertility Comprehensive population-based statistics have been missing to date We sought to compare characteristics and survival of reproductive-aged women who underwent trachelectomy for early-stage cancer to those who had hysterectomy This is a retrospective observational study examining the Surveillance Epidemiology and End Results program from 1998 through 2014 Women 45 years of age with stage IA and IB1 tumor size 2 cm cancer who underwent trachelectomy were compared to those who underwent hysterectomy Multivariable models were used to identify clinicopathological factors associated with trachelectomy Survival was compared between the 2 groups after propensity score matching Among 6359 women 190 3.0 95 confidence interval 2.6-3.4 underwent trachelectomy The median age of the trachelectomy group was 31 years interquartile range 28-34 The proportion of women who underwent trachelectomy significantly increased during the study period 1.2 in 1998 through 2002 3.0 in 2003 through 2008 and 4.5 in 2009 through 2014 P .001 Younger age nonblack race single marital status eastern registry area recent disease diagnosis nonsquamous histology and higher stage were independent factors associated with trachelectomy use all adjusted P .05 After propensity score matching 5-year cause-specific survival 96.9 vs 96.6 hazard ratio 0.73 95 confidence interval 0.23-2.30 P .59 and overall survival 96.1 vs 96.6 hazard ratio 0.76 95 confidence interval 0.26-2.20 P .61 were similar between the trachelectomy group and the hysterectomy group Our study found that there was a significant increase in the proportion of reproductive-aged women with stage IA or IB1 2 cm cancer who underwent trachelectomy in recent years Survival with trachelectomy was similar to those who had hysterectomy in this population,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[5760, 16, 3, 24, 1, 1866, 9, 3705, 1032, 117, 5, 191, 82, 12, 54, 5278, 508, 2954, 949, 266, 90, 3065, 47, 85, 4593, 6, 1244, 21, 990, 6, 932, 374, 2, 25, 1, 3705, 1032, 117, 54, 208, 5760, 9, 191, 82, 12, 6, 135, 54, 42, 2622, 26, 16, 8, 459, 2495, 45, 3282, 3, 617, 1284, 2, 396, 99, 1243, 29, 1850, 298, 1409, 117, 512, 60, 1, 89, 5, 82, 3302, 2, 8111, 30, 444, 6006, 494, 12, 54, 208, 5760, 11, 72, 6, 135, 54, 208, 2622, 658, 274, 11, 95, 6, 255, 2721, 130, 41, 5, 5760, 25, 10, 72, 59, 3, 18, 271, 50, 1925, 368, 2616, 107, 73462, 117, 5974, 27, 13, 48, 307, 268, 18, 49, 27, 39, 208, 5760, 3, 52, 89, 1, 3, 5760, 87, 10, 456, 60, 2899, 184, 339, 562, 3, 920, 1, 117, 54, 208, 5760, 97, 101, 190, 3, 45, 727, 14, 18, 4, 1850, 298, 1544, 27, 13, 4, 1522, 298, 1375, 2, 39, 33, 4, 1238, 298, 1409, 19, 144, 773, 89, 18496, 1047, 226, 5345, 156, 2118, 1608, 965, 435, 34, 147, 6218, 784, 2, 142, 82, 11, 306, 130, 41, 5, 5760, 119, 62, 586, 19, 474, 50, 1925, 368, 2616, 33, 111, 708, 112, 25, 921, 83, 105, 921, 49, 360, 197, 13, 803, 48, 307, 268, 13, 382, 18, 201, 19, 728, 2, 63, 25, 921, 14, 105, 921, 49, 360, 197, 13, 846, 48, 307, 268, 13, 432, 18, 179, 19, 713, 11, 288, 59, 3, 5760, 87, 2, 3, 2622, 87, 114, 45, 204, 17, 125, 10, 8, 93, 344, 4, 3, 920, 1, 3705, 1032, 117, 5, 82, 3302, 15, 8111, 6006, 494, 12, 54, 208, 5760, 4, 435, 60, 25, 5, 5760, 10, 288, 6, 135, 54, 42, 2622, 4, 26, 266]",1920.0,30138618,295
Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging Seventh and Eighth Editions.,Thyroid : official journal of the American Thyroid Association,Thyroid,2018-10-01,"The American Joint Committee on Cancer Cancer Staging System for differentiated thyroid cancer has been recently revised. The purpose of this study was to compare survival prognostication between the seventh and eighth editions. We retrospectively reviewed 2579 differentiated thyroid cancer patients who underwent surgery at MD Anderson Cancer Center between 2000 and 2015. Disease-specific survival (DSS) and overall survival were estimated using the Kaplan-Meier method and compared using log rank test. The effect of potential predictor was estimated using Cox proportional hazards model. Power of survival prediction was estimated using Harrell's C concordance index (C-index), and predictive capacities for DSS were estimated using proportion of variance explained (PVE). Revision of tumor-node-metastasis (TNM) categories, age cutoff, and stage reassignment in the 8<sup>th</sup> edition caused reclassification of overall stage compared with the seventh edition. The proportion of patients in stage I and II increased from 62% to 83% and 5% to 12%, respectively, while the proportion of patients in stage III and IV decreased from 20% to 2% and 14% to 3%, respectively. Ten-year DSS for stages I-IV based on the seventh edition were 100%, 97.5%, 98.3%, and 82.6%, respectively, while 10-year DSS for the corresponding stage in the eighth edition were 99.8%, 88.3%, 72.4%, and 71.9%, respectively. In multivariate analysis for both seventh edition (C-index 0.94, PVE 4.6%) and eighth edition (C-index 0.94, PVE 4.8%), the factors predictive of worse outcome for DSS were older age, advanced tumor size category, and distant metastasis while cervical lymph node metastases did not predict worse survival. For the eighth edition, patients <55 years of age with stage II disease had significantly worse DSS (p<0.001) than patients 55 years with stage II disease but appeared to be similar to patients 55 years with stage III (p=0.742) and IV disease (p=0.566). Patients 55 years old with T3a and T3b disease had 10-year DSS of 67% and 92%, respectively (p=0.390). The AJCC eighth edition is similar to the seventh edition in disease-specific survival prediction. Potential modifications that may improve disease-specific survival prediction in future renditions include reconsideration of T3b tumor category and upstaging classification of patients <55 years of age with distant metastases.",Journal Article,477.0,10.0,The American Joint Committee on Cancer Cancer Staging System for differentiated cancer has been recently revised The purpose of this study was to compare survival prognostication between the seventh and eighth editions We retrospectively reviewed 2579 differentiated cancer patients who underwent surgery at MD Anderson Cancer Center between 2000 and 2015 Disease-specific survival DSS and overall survival were estimated using the Kaplan-Meier method and compared using log rank test The effect of potential predictor was estimated using Cox proportional hazards model Power of survival prediction was estimated using Harrell 's C concordance index C-index and predictive capacities for DSS were estimated using proportion of variance explained PVE Revision of tumor-node-metastasis TNM categories age cutoff and stage reassignment in the 8 sup th /sup edition caused reclassification of overall stage compared with the seventh edition The proportion of patients in stage I and II increased from 62 to 83 and 5 to 12 respectively while the proportion of patients in stage III and IV decreased from 20 to 2 and 14 to 3 respectively Ten-year DSS for stages I-IV based on the seventh edition were 100 97.5 98.3 and 82.6 respectively while 10-year DSS for the corresponding stage in the eighth edition were 99.8 88.3 72.4 and 71.9 respectively In multivariate analysis for both seventh edition C-index 0.94 PVE 4.6 and eighth edition C-index 0.94 PVE 4.8 the factors predictive of worse outcome for DSS were older age advanced tumor size category and distant metastasis while lymph node metastases did not predict worse survival For the eighth edition patients 55 years of age with stage II disease had significantly worse DSS p 0.001 than patients 55 years with stage II disease but appeared to be similar to patients 55 years with stage III p 0.742 and IV disease p 0.566 Patients 55 years old with T3a and T3b disease had 10-year DSS of 67 and 92 respectively p 0.390 The AJCC eighth edition is similar to the seventh edition in disease-specific survival prediction Potential modifications that may improve disease-specific survival prediction in future renditions include reconsideration of T3b tumor category and upstaging classification of patients 55 years of age with distant metastases,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,"[3, 597, 2093, 2002, 23, 12, 12, 632, 398, 9, 1442, 12, 71, 85, 761, 4218, 3, 743, 1, 26, 45, 10, 6, 932, 25, 4260, 59, 3, 8114, 2, 7732, 17465, 21, 894, 446, 34150, 1442, 12, 7, 54, 208, 152, 28, 2244, 1929, 12, 574, 59, 1081, 2, 1483, 34, 112, 25, 1788, 2, 63, 25, 11, 661, 75, 3, 876, 882, 596, 2, 72, 75, 1066, 1026, 412, 3, 254, 1, 174, 980, 10, 661, 75, 418, 831, 1017, 202, 2349, 1, 25, 1590, 10, 661, 75, 11214, 292, 256, 1827, 558, 256, 558, 2, 464, 14866, 9, 1788, 11, 661, 75, 920, 1, 4446, 3672, 5726, 5646, 1, 30, 289, 278, 2918, 1996, 89, 2779, 2, 82, 51212, 4, 3, 66, 172, 4517, 172, 3580, 1546, 10101, 1, 63, 82, 72, 5, 3, 8114, 3580, 3, 920, 1, 7, 4, 82, 70, 2, 215, 101, 29, 744, 6, 852, 2, 33, 6, 133, 106, 369, 3, 920, 1, 7, 4, 82, 316, 2, 478, 340, 29, 179, 6, 18, 2, 213, 6, 27, 106, 1618, 111, 1788, 9, 1153, 70, 478, 90, 23, 3, 8114, 3580, 11, 394, 1015, 33, 1096, 27, 2, 878, 49, 106, 369, 79, 111, 1788, 9, 3, 1734, 82, 4, 3, 7732, 3580, 11, 1058, 66, 889, 27, 720, 39, 2, 792, 83, 106, 4, 331, 65, 9, 110, 8114, 3580, 256, 558, 13, 960, 5726, 39, 49, 2, 7732, 3580, 256, 558, 13, 960, 5726, 39, 66, 3, 130, 464, 1, 639, 228, 9, 1788, 11, 434, 89, 131, 30, 444, 2169, 2, 626, 278, 369, 263, 289, 196, 205, 44, 678, 639, 25, 9, 3, 7732, 3580, 7, 614, 60, 1, 89, 5, 82, 215, 34, 42, 97, 639, 1788, 19, 13, 144, 76, 7, 15425, 60, 5, 82, 215, 34, 84, 2121, 6, 40, 288, 6, 7, 15425, 60, 5, 82, 316, 19, 13, 12585, 2, 478, 34, 19, 13, 14539, 7, 15425, 60, 1095, 5, 12844, 2, 14499, 34, 42, 79, 111, 1788, 1, 598, 2, 937, 106, 19, 13, 7992, 3, 2271, 7732, 3580, 16, 288, 6, 3, 8114, 3580, 4, 34, 112, 25, 1590, 174, 2916, 17, 68, 401, 34, 112, 25, 1590, 4, 508, 73464, 643, 23110, 1, 14499, 30, 2169, 2, 6335, 947, 1, 7, 614, 60, 1, 89, 5, 626, 196]",2294.0,30141373,147
Locally advanced cervical cancer: A study of 5-year outcomes.,Indian journal of cancer,Indian J Cancer,,"Cervical cancer is the second most common cancer among Indian women. This present retrospective study was conducted to report patient outcomes with locally advanced cervical cancer treated in the year 2010. Case records of cervical cancer patients registered from January 1, 2010, to December 31, 2010 were retrieved. A total of 1200 patients were registered, of which 583 received either definitive or adjuvant radiotherapy (RT). Of these, 345 patients who received complete treatment at our hospital were included for outcome analysis. Descriptive statistics were used to summarize patient- and treatment-related variables, and Kaplan-Meier analysis was performed for survival analysis. The median age was 56 years (range: 33-90). Squamous carcinoma was the most common histology (91.4%) and the majority were FIGO Stage III (45.4%). Median follow-up of the cohort was 44 months (1-85 months). The 5-year disease-free survival (DFS) across stages was 50%. Most important predictor of DFS was FIGO staging (Stage II vs. Stage III: 62% vs. 45%) and use of concurrent chemoradiotherapy (CTRT) l (RT vs. CTRT: 32% vs. 57%, respectively). Patients aged >70 years had a significantly poor DFS at 5 years; however, did not have any effect on survival. Grade 3 or more late toxicity was seen in only 5% of the patients. Five-year DFS of 62% and 45% of Stage II and III patients treated under routine care represents comparable stage-matched results to the rest of the world, respectively.",Journal Article,,5.0,cancer is the second most common cancer among Indian women This present retrospective study was conducted to report patient outcomes with locally advanced cancer treated in the year 2010 Case records of cancer patients registered from January 1 2010 to December 31 2010 were retrieved A total of 1200 patients were registered of which 583 received either definitive or adjuvant radiotherapy RT Of these 345 patients who received complete treatment at our hospital were included for outcome analysis Descriptive statistics were used to summarize patient- and treatment-related variables and Kaplan-Meier analysis was performed for survival analysis The median age was 56 years range 33-90 Squamous carcinoma was the most common histology 91.4 and the majority were FIGO Stage III 45.4 Median follow-up of the cohort was 44 months 1-85 months The 5-year disease-free survival DFS across stages was 50 Most important predictor of DFS was FIGO staging Stage II vs Stage III 62 vs. 45 and use of concurrent chemoradiotherapy CTRT l RT vs. CTRT 32 vs. 57 respectively Patients aged 70 years had a significantly poor DFS at 5 years however did not have any effect on survival Grade 3 or more late toxicity was seen in only 5 of the patients Five-year DFS of 62 and 45 of Stage II and III patients treated under routine care represents comparable stage-matched results to the rest of the world respectively,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 3, 419, 96, 186, 12, 107, 7968, 117, 26, 364, 459, 45, 10, 426, 6, 414, 69, 123, 5, 795, 131, 12, 73, 4, 3, 111, 1120, 473, 1064, 1, 12, 7, 1653, 29, 1024, 14, 1120, 6, 1397, 456, 1120, 11, 4539, 8, 181, 1, 6847, 7, 11, 1653, 1, 92, 12876, 103, 361, 1057, 15, 249, 310, 240, 1, 46, 9005, 7, 54, 103, 236, 24, 28, 114, 702, 11, 159, 9, 228, 65, 3778, 3065, 11, 95, 6, 2479, 69, 2, 24, 139, 682, 2, 876, 882, 65, 10, 173, 9, 25, 65, 3, 52, 89, 10, 664, 60, 184, 466, 424, 691, 134, 10, 3, 96, 186, 784, 970, 39, 2, 3, 686, 11, 3837, 82, 316, 512, 39, 52, 166, 126, 1, 3, 180, 10, 584, 53, 14, 772, 53, 3, 33, 111, 34, 115, 25, 1010, 716, 1153, 10, 212, 96, 305, 980, 1, 1010, 10, 3837, 632, 82, 215, 105, 82, 316, 744, 105, 512, 2, 119, 1, 750, 1464, 10329, 805, 240, 105, 10329, 531, 105, 696, 106, 7, 1032, 431, 60, 42, 8, 97, 334, 1010, 28, 33, 60, 137, 205, 44, 47, 500, 254, 23, 25, 88, 27, 15, 80, 807, 155, 10, 527, 4, 158, 33, 1, 3, 7, 365, 111, 1010, 1, 744, 2, 512, 1, 82, 215, 2, 316, 7, 73, 669, 1311, 165, 1449, 1279, 82, 655, 99, 6, 3, 3677, 1, 3, 1956, 106]",1398.0,30147092,139
A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study.,Gynecologic oncology,Gynecol. Oncol.,2018-08-31,"Chemo-radiation (chemoRT) has improved the overall survival for locally advanced cervical cancer (LACC) though women whose disease involves the para-aortic nodes (PAN) experience recurrence rates and worse survival outcomes compared to those without PAN involvement. This Phase I study determined if additional cycles of systemic chemotherapy could be safely added to extended field chemoRT in this population of patients. Women with LACC and documented positive PAN were eligible for treatment. All women were treated with extended field radiation and brachytherapy and concurrent cisplatin 40mg/m<sup>2</sup> weekly for six weeks. Four to six weeks after completion of chemoRT, patients were treated with four cycles of paclitaxel 135mg/m<sup>2</sup> and escalating doses of carboplatin (Dose Level (DL) 1=AUC 4, DL2=AUC 5). Eleven women were entered on study and 9 were evaluable for dose limiting toxicities (DLT). Two women (1 in each of 2 DLs) did not complete chemoRT and so were not evaluable for DLT. Three women completed all 10cycles at DL 1 with no DLTs. Six women were then treated at DL 2. For the 10 patients evaluable for response, the ORR was 60% (CR+PR). PFS and OS at 12months were 60% and 90%, respectively. The predominant grade 3 or 4 acute toxicities were hematologic. There were no grade 5 events. Extended field chemoRT followed by paclitaxel 135mg/m<sup>2</sup> and carboplatin AUC 5 is feasible in women with LACC and positive PAN.","Clinical Trial, Phase I",508.0,2.0,Chemo-radiation chemoRT has improved the overall survival for locally advanced cancer LACC though women whose disease involves the para-aortic nodes PAN experience recurrence rates and worse survival outcomes compared to those without PAN involvement This Phase I study determined if additional cycles of systemic chemotherapy could be safely added to extended field chemoRT in this population of patients Women with LACC and documented positive PAN were eligible for treatment All women were treated with extended field radiation and brachytherapy and concurrent cisplatin 40 mg/m sup 2 /sup weekly for six weeks Four to six weeks after completion of chemoRT patients were treated with four cycles of paclitaxel 135 mg/m sup 2 /sup and escalating doses of carboplatin Dose Level DL 1 AUC 4 DL2 AUC 5 Eleven women were entered on study and 9 were evaluable for dose limiting toxicities DLT Two women 1 in each of 2 DLs did not complete chemoRT and so were not evaluable for DLT Three women completed all 10 cycles at DL 1 with no DLTs Six women were then treated at DL 2 For the 10 patients evaluable for response the ORR was 60 CR PR PFS and OS at 12 months were 60 and 90 respectively The predominant grade 3 or 4 acute toxicities were hematologic There were no grade 5 events Extended field chemoRT followed by paclitaxel 135 mg/m sup 2 /sup and carboplatin AUC 5 is feasible in women with LACC and positive PAN,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3341, 121, 13704, 71, 231, 3, 63, 25, 9, 795, 131, 12, 24255, 2471, 117, 1310, 34, 2921, 3, 4615, 3938, 502, 3055, 730, 146, 151, 2, 639, 25, 123, 72, 6, 135, 187, 3055, 799, 26, 124, 70, 45, 509, 492, 402, 410, 1, 403, 56, 359, 40, 2268, 1953, 6, 1747, 1067, 13704, 4, 26, 266, 1, 7, 117, 5, 24255, 2, 1405, 109, 3055, 11, 625, 9, 24, 62, 117, 11, 73, 5, 1747, 1067, 121, 2, 1536, 2, 750, 540, 327, 81, 188, 172, 18, 172, 709, 9, 437, 244, 294, 6, 437, 244, 50, 1438, 1, 13704, 7, 11, 73, 5, 294, 410, 1, 490, 3978, 81, 188, 172, 18, 172, 2, 2922, 415, 1, 927, 61, 301, 1826, 14, 1376, 39, 16133, 1376, 33, 2627, 117, 11, 2836, 23, 45, 2, 83, 11, 859, 9, 61, 817, 385, 2059, 100, 117, 14, 4, 296, 1, 18, 15038, 205, 44, 236, 13704, 2, 1743, 11, 44, 859, 9, 2059, 169, 117, 781, 62, 79, 410, 28, 1826, 14, 5, 77, 2506, 437, 117, 11, 818, 73, 28, 1826, 18, 9, 3, 79, 7, 859, 9, 51, 3, 1735, 10, 335, 684, 998, 300, 2, 118, 28, 133, 53, 11, 335, 2, 424, 106, 3, 2750, 88, 27, 15, 39, 286, 385, 11, 813, 125, 11, 77, 88, 33, 281, 1747, 1067, 13704, 370, 20, 490, 3978, 81, 188, 172, 18, 172, 2, 927, 1376, 33, 16, 1313, 4, 117, 5, 24255, 2, 109, 3055]",1414.0,30174176,511
Acute hematological toxicity during post-operative bowel sparing image-guided intensity modulated radiation with concurrent cisplatin.,The British journal of radiology,Br J Radiol,2018-10-03,"To report acute hematological toxicity (HT) in patients receiving post-operative bowel sparing intensity-modulated radiotherapy (IMRT) and cisplatin and its dosimetric predictors. Clinical database of Phase III trial (NCT01279135), that randomized patients to post-operative conformal or intensity modulated radiation therapy, was searched to select patient strata that received bowel sparing IMRT (50 Gy/25#/5 wks) and concurrent cisplatin (40 mg m<sup>-</sup><sup>2</sup>). Pelvic bone marrow (BM) was retrospectively delineated in two sets: whole bone (WB), and freehand (FH) inner cavity of bone. Dose volume histograms (DVH) of BM were obtained. Receiver operating characteristic (ROC) curve identified DVH thresholds that predicted for Grade II HT with highest specificity. Univariate and multivariate analysis was performed. Overall 75 patients received concurrent cisplatin. Grades I-V HT was observed in 38.7%, 42.7%, 14.7%, 0%, and 0% patients, respectively. Grade  II leukopenia, neutropenia, anemia, and thrombocytopenia were observed in 26%, 40%, 26.5%, and 1.4% respectively. None of the HT resulted in treatment break. On univariate analysis, whole pelvis+ lumbar FH V30 >55% & V40>35%, whole pelvis WB and FH V40 > 35%, and lower pelvis WB and FH V40 >20% correlated for Grade  II leucopenia and neutropenia. None of the BM dose volume constraints predicted for overall HT or neutropenia on multivariate analysis. The IMRT arm of NCT01279135 (PARCER study) that employed strict bowel constraints had unintentional but desirable BM sparing. None of the BM subvolume DVH parameters could be validated on multivariate analysis. The prospective study reports feasibility of bone marrow sparing with bowel sparing post-operative pelvic IMRT and concurrent chemotherapy for cervical cancer. The present study reports low incidence of hematological and gastrointestinal toxicity during post-operative chemoradiation with IMRT. As both whole bone and freehand pelvis BM contours predicted for HT, hence an easier method of whole bone contouring should continue to be used till further validation of more specific BM subvolumes becomes available. The study results highlight the need for further research into dose volume constraints during post-operative IMRT.","Clinical Trial, Phase III",475.0,1.0,To report acute hematological toxicity HT in patients receiving post-operative bowel sparing intensity-modulated radiotherapy IMRT and cisplatin and its dosimetric predictors Clinical database of Phase III trial NCT01279135 that randomized patients to post-operative conformal or intensity modulated radiation therapy was searched to select patient strata that received bowel sparing IMRT 50 Gy/25 /5 wks and concurrent cisplatin 40 mg m sup /sup sup 2 /sup Pelvic marrow BM was retrospectively delineated in two sets whole WB and freehand FH inner cavity of Dose volume histograms DVH of BM were obtained Receiver operating characteristic ROC curve identified DVH thresholds that predicted for Grade II HT with highest specificity Univariate and multivariate analysis was performed Overall 75 patients received concurrent cisplatin Grades I-V HT was observed in 38.7 42.7 14.7 0 and 0 patients respectively Grade  II leukopenia neutropenia anemia and thrombocytopenia were observed in 26 40 26.5 and 1.4 respectively None of the HT resulted in treatment break On univariate analysis whole pelvis+ lumbar FH V30 55 V40 35 whole pelvis WB and FH V40 35 and lower pelvis WB and FH V40 20 correlated for Grade  II leucopenia and neutropenia None of the BM dose volume constraints predicted for overall HT or neutropenia on multivariate analysis The IMRT arm of NCT01279135 PARCER study that employed strict bowel constraints had unintentional but desirable BM sparing None of the BM subvolume DVH parameters could be validated on multivariate analysis The prospective study reports feasibility of marrow sparing with bowel sparing post-operative pelvic IMRT and concurrent chemotherapy for cancer The present study reports low incidence of hematological and toxicity during post-operative chemoradiation with IMRT As both whole and freehand pelvis BM contours predicted for HT hence an easier method of whole contouring should continue to be used till further validation of more specific BM subvolumes becomes available The study results highlight the need for further research into dose volume constraints during post-operative IMRT,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 414, 286, 2890, 155, 3152, 4, 7, 357, 539, 1208, 1659, 1851, 837, 1757, 310, 964, 2, 540, 2, 211, 3187, 674, 38, 609, 1, 124, 316, 160, 51220, 17, 384, 7, 6, 539, 1208, 2972, 15, 837, 1757, 121, 36, 10, 3080, 6, 1717, 69, 5758, 17, 103, 1659, 1851, 964, 212, 381, 243, 33, 16820, 2, 750, 540, 327, 81, 188, 172, 172, 172, 18, 172, 1110, 581, 1246, 10, 894, 5610, 4, 100, 2270, 902, 7126, 2, 36307, 5348, 7938, 2405, 1, 61, 433, 8638, 8255, 1, 1246, 11, 683, 3185, 2584, 2037, 3783, 1496, 108, 8255, 4634, 17, 783, 9, 73506, 215, 3152, 5, 1076, 1121, 880, 2, 331, 65, 10, 173, 63, 481, 7, 103, 750, 540, 2276, 70, 603, 3152, 10, 164, 4, 519, 67, 595, 67, 213, 67, 13, 2, 13, 7, 106, 88, 749, 215, 3904, 778, 1545, 2, 1340, 11, 164, 4, 432, 327, 432, 33, 2, 14, 39, 106, 1292, 1, 3, 3152, 627, 4, 24, 4338, 23, 880, 65, 902, 3270, 6187, 5348, 14613, 614, 12454, 465, 902, 3270, 7126, 2, 5348, 12454, 465, 2, 280, 3270, 7126, 2, 5348, 12454, 179, 438, 9, 88, 749, 215, 10317, 2, 778, 1292, 1, 3, 1246, 61, 433, 4879, 783, 9, 63, 3152, 15, 778, 23, 331, 65, 3, 964, 475, 1, 51220, 73507, 45, 17, 2516, 8043, 1659, 4879, 42, 17350, 84, 7365, 1246, 1851, 1292, 1, 3, 1246, 24103, 8255, 1038, 359, 40, 938, 23, 331, 65, 3, 482, 45, 1198, 1437, 1, 581, 1851, 5, 1659, 1851, 539, 1208, 1110, 964, 2, 750, 56, 9, 12, 3, 364, 45, 1198, 154, 287, 1, 2890, 2, 155, 190, 539, 1208, 975, 5, 964, 22, 110, 902, 2, 36307, 3270, 1246, 6137, 783, 9, 3152, 3665, 35, 12734, 596, 1, 902, 7997, 257, 1906, 6, 40, 95, 20528, 195, 929, 1, 80, 112, 1246, 13719, 5366, 390, 3, 45, 99, 1817, 3, 594, 9, 195, 389, 237, 61, 433, 4879, 190, 539, 1208, 964]",2133.0,30179056,794
"Cancer Stem Cells, CD44, and Outcomes Following Chemoradiation in Locally Advanced Cervical Cancer: Results From a Prospective Study.","International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2018-09-11,"Although cancer stem cells (CSCs) have been reported across solid tumors, there is a dearth of data regarding CSC and its impact on outcomes of cervical cancer. From October 2013 to December 2015, patients with squamous cancer of the cervix (stage IB2-IVA) were included. Pretreatment and posttreatment biopsy was obtained and immunohistochemistry was performed for SOX-2, OCT-4, Nanog, CD44, and Podoplanin. All patients received concurrent radiation and brachytherapy to an equivalent dose of 80 to 84Gy to point A with concurrent weekly cisplatin. Correlation of CSC expression was performed with known prognostic factors. The effect of stem cell expression on disease outcomes was tested within multivariate analysis. One hundred fifty patients were included. The median dose to point A was 83Gy (46-89Gy) and a median of 4 cycles (range, 0-6 cycles) of chemotherapy was administered. At baseline, moderate to strong immunohistochemical expression of SOX-2, OCT-4, Nanog, CD44, and Podoplanin was observed in 12.8%, 4.8%, 24.4%, 15.5%, and 1.3% of patients, respectively. At median follow-up of 30months (range, 3-51months), locoregional and distant relapse was observed in 12.2% and 23.1% of patients, of whom 4.7% had both local and distant relapse. The 3-year disease-free survival rate was 87%. On multivariate analysis, moderate to high CSC expression and CD44 low status (hazard ratio [HR]=8.8; 95% confidence interval [CI], 1.0-77.2; P<.04) independently predicted for locoregional relapse-free survival. International Federation of Gynecology and Obstetrics stage (HR=2.6; 95% CI, 1.3-5.4; P=.004) and presence of residual tumor after external radiation (HR=3.5; 95% CI, 1.8-6.5; P=.0001) predicted for a detriment in disease-free survival. The presence of stem cell proteins and loss of CD44 independently predicts for reduced locoregional control in locally advanced cervical cancer. Further investigation into the interaction of stem cell and CD44 biology is warranted.",Journal Article,497.0,1.0,Although cancer stem cells CSCs have been reported across solid tumors there is a dearth of data regarding CSC and its impact on outcomes of cancer From October 2013 to December 2015 patients with squamous cancer of the cervix stage IB2-IVA were included Pretreatment and posttreatment biopsy was obtained and immunohistochemistry was performed for SOX-2 OCT-4 Nanog CD44 and Podoplanin All patients received concurrent radiation and brachytherapy to an equivalent dose of 80 to 84 Gy to point A with concurrent weekly cisplatin Correlation of CSC expression was performed with known prognostic factors The effect of stem cell expression on disease outcomes was tested within multivariate analysis One hundred fifty patients were included The median dose to point A was 83 Gy 46-89 Gy and a median of 4 cycles range 0-6 cycles of chemotherapy was administered At baseline moderate to strong immunohistochemical expression of SOX-2 OCT-4 Nanog CD44 and Podoplanin was observed in 12.8 4.8 24.4 15.5 and 1.3 of patients respectively At median follow-up of 30 months range 3-51 months locoregional and distant relapse was observed in 12.2 and 23.1 of patients of whom 4.7 had both local and distant relapse The 3-year disease-free survival rate was 87 On multivariate analysis moderate to high CSC expression and CD44 low status hazard ratio HR 8.8 95 confidence interval CI 1.0-77.2 P .04 independently predicted for locoregional relapse-free survival International Federation of Gynecology and Obstetrics stage HR 2.6 95 CI 1.3-5.4 P .004 and presence of residual tumor after external radiation HR 3.5 95 CI 1.8-6.5 P .0001 predicted for a detriment in disease-free survival The presence of stem cell proteins and loss of CD44 independently predicts for reduced locoregional control in locally advanced cancer Further investigation into the interaction of stem cell and CD44 biology is warranted,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[242, 12, 452, 37, 4059, 47, 85, 210, 716, 537, 57, 125, 16, 8, 14224, 1, 74, 666, 4234, 2, 211, 345, 23, 123, 1, 12, 29, 2551, 1346, 6, 1397, 1483, 7, 5, 691, 12, 1, 3, 3629, 82, 9537, 5900, 11, 159, 1194, 2, 3149, 411, 10, 683, 2, 888, 10, 173, 9, 27111, 18, 5137, 39, 11851, 3035, 2, 16036, 62, 7, 103, 750, 121, 2, 1536, 6, 35, 2017, 61, 1, 493, 6, 874, 381, 6, 741, 8, 5, 750, 709, 540, 816, 1, 4234, 55, 10, 173, 5, 440, 177, 130, 3, 254, 1, 452, 31, 55, 23, 34, 123, 10, 650, 262, 331, 65, 104, 1128, 1461, 7, 11, 159, 3, 52, 61, 6, 741, 8, 10, 852, 381, 641, 887, 381, 2, 8, 52, 1, 39, 410, 184, 13, 49, 410, 1, 56, 10, 468, 28, 330, 1163, 6, 1082, 1382, 55, 1, 27111, 18, 5137, 39, 11851, 3035, 2, 16036, 10, 164, 4, 133, 66, 39, 66, 259, 39, 167, 33, 2, 14, 27, 1, 7, 106, 28, 52, 166, 126, 1, 201, 53, 184, 27, 725, 53, 1325, 2, 626, 429, 10, 164, 4, 133, 18, 2, 382, 14, 1, 7, 1, 953, 39, 67, 42, 110, 293, 2, 626, 429, 3, 27, 111, 34, 115, 25, 116, 10, 912, 23, 331, 65, 1163, 6, 64, 4234, 55, 2, 3035, 154, 156, 360, 197, 168, 66, 66, 48, 307, 268, 58, 14, 13, 849, 18, 19, 755, 1042, 783, 9, 1325, 429, 115, 25, 944, 7303, 1, 6429, 2, 7407, 82, 168, 18, 49, 48, 58, 14, 27, 33, 39, 19, 1520, 2, 463, 1, 753, 30, 50, 1455, 121, 168, 27, 33, 48, 58, 14, 66, 49, 33, 19, 488, 783, 9, 8, 13334, 4, 34, 115, 25, 3, 463, 1, 452, 31, 652, 2, 407, 1, 3035, 1042, 2623, 9, 405, 1325, 182, 4, 795, 131, 12, 195, 940, 237, 3, 915, 1, 452, 31, 2, 3035, 891, 16, 1197]",1894.0,30213750,634
"Disparities in Breast, Lung, and Cervical Cancer Trials Worldwide.",Journal of global oncology,J Glob Oncol,2018-09-01,"As cancer burden has risen worldwide, physicians, patients, and their advocates have become aware that the clinical cancer trial research paradigm is not ubiquitous. Furthermore, the number and characteristics of trials that are registered in low- and middle-income countries (LMICs) compared with that in high-income countries (HICs) are unknown. We collected retrospective data on trials for breast, lung, and cervical cancer registered in ClinicalTrials.gov or with the WHO International Clinical Trial Registry Platform between 2010 and 2017. The data were then classified as trials within LMICs or HICs using definitions from the World Bank. Included in these analyses were 6,710 trials, of which 3,164 (47%) were breast cancer trials, 3,283 (49%) were lung cancer trials, and 263 (4%) were cervical cancer trials. There were 1,951 (29%) trials from LMICs and 4,759 (71%) trials from HICs ( P < .001). Although the proportion of phase III trials in HICs versus LMICs was similar (18% v 17%; P = .66), the number of phase I trials in LMICs was significantly lower than that of HICs (20% v 2%; P < .001). For several LMICs with the highest mortality-to-incidence ratios for breast, lung, or cervical cancer, there were no cancer trials registered in the registration data bases searched for this work. There are differences in access to cancer clinical trials in LMICs compared with HICs. Several factors, such as excessive cost and a lack of infrastructure and expertise, may explain these differences.",Journal Article,507.0,4.0,"As cancer burden has risen worldwide physicians patients and their advocates have become aware that the clinical cancer trial research paradigm is not ubiquitous Furthermore the number and characteristics of trials that are registered in low- and middle-income countries LMICs compared with that in high-income countries HICs are unknown We collected retrospective data on trials for and cancer registered in ClinicalTrials.gov or with the WHO International Clinical Trial Registry Platform between 2010 and 2017 The data were then classified as trials within LMICs or HICs using definitions from the World Bank Included in these analyses were 6,710 trials of which 3,164 47 were cancer trials 3,283 49 were cancer trials and 263 4 were cancer trials There were 1,951 29 trials from LMICs and 4,759 71 trials from HICs P .001 Although the proportion of phase III trials in HICs versus LMICs was similar 18 v 17 P .66 the number of phase I trials in LMICs was significantly lower than that of HICs 20 v 2 P .001 For several LMICs with the highest mortality-to-incidence ratios for or cancer there were no cancer trials registered in the registration data bases searched for this work There are differences in access to cancer clinical trials in LMICs compared with HICs Several factors such as excessive cost and a lack of infrastructure and expertise may explain these differences",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[22, 12, 892, 71, 16347, 2358, 1261, 7, 2, 136, 7781, 47, 1417, 4749, 17, 3, 38, 12, 160, 389, 2431, 16, 44, 8577, 798, 3, 207, 2, 374, 1, 143, 17, 32, 1653, 4, 154, 2, 3897, 2306, 2115, 13457, 72, 5, 17, 4, 64, 2306, 2115, 20833, 32, 860, 21, 786, 459, 74, 23, 143, 9, 2, 12, 1653, 4, 1252, 1239, 15, 5, 3, 54, 944, 38, 160, 1608, 2243, 59, 1120, 2, 1759, 3, 74, 11, 818, 1373, 22, 143, 262, 13457, 15, 20833, 75, 3833, 29, 3, 1956, 10213, 159, 4, 46, 318, 11, 49, 9232, 143, 1, 92, 27, 5279, 662, 11, 12, 143, 27, 9078, 739, 11, 12, 143, 2, 6098, 39, 11, 12, 143, 125, 11, 14, 16530, 462, 143, 29, 13457, 2, 39, 13812, 792, 143, 29, 20833, 19, 144, 242, 3, 920, 1, 124, 316, 143, 4, 20833, 185, 13457, 10, 288, 203, 603, 269, 19, 700, 3, 207, 1, 124, 70, 143, 4, 13457, 10, 97, 280, 76, 17, 1, 20833, 179, 603, 18, 19, 144, 9, 392, 13457, 5, 3, 1076, 282, 6, 287, 1137, 9, 15, 12, 125, 11, 77, 12, 143, 1653, 4, 3, 3169, 74, 9412, 3080, 9, 26, 1357, 125, 32, 362, 4, 1655, 6, 12, 38, 143, 4, 13457, 72, 5, 20833, 392, 130, 225, 22, 4529, 835, 2, 8, 926, 1, 6219, 2, 4935, 68, 2943, 46, 362]",1380.0,30241268,600
Rising Rates of Upfront Surgery in Early Locally Advanced Cervical Cancer: What Factors Predict for This Treatment Paradigm?,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2018-10-01,"In this study, we analyzed patterns of care for patients with locally advanced cervical cancer to identify predictors for upfront surgery compared with definitive chemoradiation (CRT). The National Cancer Database was queried for patients aged 18 years or older with Federation of Gynecology and Obstetrics IB2-IIB cervical cancer. All patients underwent either upfront hysterectomy with or without postoperative radiation therapy versus definitive CRT. Logistic regression was used to assess variables associated with modality of treatment (surgery vs CRT). Of the 9494 patients included, 2151 (22.7%) underwent upfront surgery. Of those undergoing surgery, 380 (17.7%) had positive margins, 478 (22.2%) had positive nodes, and 458 (21.3%) had pathologic involvement of the parametrium. Under multiple logistic regression, rates of surgery significantly increased from 2004 (12.2%) to 2012 (31.2%) (odds ratio [OR] per year increase, 1.15; confidence interval [CI], 1.12-1.17; P < 0.001). Upfront surgery was more commonly performed in urban (OR, 1.21; 95% CI, 1.03-1.41; P = 0.018) and rural counties (OR, 1.79; 95% CI, 1.24-2.58; P = 0.002), for adenocarcinoma (OR, 2.14; 1.88-2.44; P < 0.001) and adenosquamous (OR, 2.69; 2.11-3.43; P < 0.001) histologies, and in patients from higher median income communities (ORs, 1.19-1.37). Upfront surgery was less common at academic centers (OR, 0.73; 95% CI, 0.58-0.93; P = 0.011). Rates of upfront surgery relative to definitive CRT have increased significantly over the past decade. In the setting of level 1 evidence supporting the use of definitive CRT alone for these women, the rising rates of upfront surgery raises concern for both unnecessary surgical procedures with higher rates of treatment-related morbidity and greater health care costs.",Comparative Study,477.0,2.0,In this study we analyzed patterns of care for patients with locally advanced cancer to identify predictors for upfront surgery compared with definitive chemoradiation CRT The National Cancer Database was queried for patients aged 18 years or older with Federation of Gynecology and Obstetrics IB2-IIB cancer All patients underwent either upfront hysterectomy with or without postoperative radiation therapy versus definitive CRT Logistic regression was used to assess variables associated with modality of treatment surgery vs CRT Of the 9494 patients included 2151 22.7 underwent upfront surgery Of those undergoing surgery 380 17.7 had positive margins 478 22.2 had positive nodes and 458 21.3 had pathologic involvement of the parametrium Under multiple logistic regression rates of surgery significantly increased from 2004 12.2 to 2012 31.2 odds ratio OR per year increase 1.15 confidence interval CI 1.12-1.17 P 0.001 Upfront surgery was more commonly performed in urban OR 1.21 95 CI 1.03-1.41 P 0.018 and rural counties OR 1.79 95 CI 1.24-2.58 P 0.002 for adenocarcinoma OR 2.14 1.88-2.44 P 0.001 and adenosquamous OR 2.69 2.11-3.43 P 0.001 histologies and in patients from higher median income communities ORs 1.19-1.37 Upfront surgery was less common at academic centers OR 0.73 95 CI 0.58-0.93 P 0.011 Rates of upfront surgery relative to definitive CRT have increased significantly over the past decade In the setting of level 1 evidence supporting the use of definitive CRT alone for these women the rising rates of upfront surgery raises concern for both unnecessary surgical procedures with higher rates of treatment-related morbidity and greater health care costs,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4, 26, 45, 21, 311, 764, 1, 165, 9, 7, 5, 795, 131, 12, 6, 255, 674, 9, 2941, 152, 72, 5, 1057, 975, 1089, 3, 657, 12, 609, 10, 3547, 9, 7, 1032, 203, 60, 15, 434, 5, 7303, 1, 6429, 2, 7407, 9537, 3884, 12, 62, 7, 208, 361, 2941, 2622, 5, 15, 187, 573, 121, 36, 185, 1057, 1089, 812, 320, 10, 95, 6, 423, 682, 41, 5, 1396, 1, 24, 152, 105, 1089, 1, 3, 73644, 7, 159, 50912, 350, 67, 208, 2941, 152, 1, 135, 479, 152, 8389, 269, 67, 42, 109, 1012, 11017, 350, 18, 42, 109, 502, 2, 12072, 239, 27, 42, 510, 799, 1, 3, 30751, 669, 232, 812, 320, 151, 1, 152, 97, 101, 29, 1131, 133, 18, 6, 1195, 456, 18, 610, 197, 15, 379, 111, 344, 14, 167, 307, 268, 58, 14, 133, 14, 269, 19, 13, 144, 2941, 152, 10, 80, 841, 173, 4, 5532, 15, 14, 239, 48, 58, 14, 680, 14, 605, 19, 13, 4047, 2, 5291, 8257, 15, 14, 842, 48, 58, 14, 259, 18, 717, 19, 13, 1111, 9, 449, 15, 18, 213, 14, 889, 18, 584, 19, 13, 144, 2, 8067, 15, 18, 790, 18, 175, 27, 601, 19, 13, 144, 3489, 2, 4, 7, 29, 142, 52, 2306, 7651, 3694, 14, 326, 14, 567, 2941, 152, 10, 299, 186, 28, 1916, 1168, 15, 13, 803, 48, 58, 13, 717, 13, 966, 19, 13, 3651, 151, 1, 2941, 152, 580, 6, 1057, 1089, 47, 101, 97, 252, 3, 1219, 2025, 4, 3, 546, 1, 301, 14, 241, 1912, 3, 119, 1, 1057, 1089, 279, 9, 46, 117, 3, 3699, 151, 1, 2941, 152, 5789, 2893, 9, 110, 4224, 221, 1369, 5, 142, 151, 1, 24, 139, 787, 2, 378, 341, 165, 1201]",1680.0,30247249,375
Imaging and Quantitative Detection of Lipid Droplets by Yellow Fluorescent Probes in Liver Sections of Plasmodium Infected Mice and Third Stage Human Cervical Cancer Tissues.,Bioconjugate chemistry,Bioconjug. Chem.,2018-10-10,"The diagnosis and prognosis of the disease associated with lipid irregularity are areas of extreme significance. In this direction, fluoranthene based yellow fluorescent probes (FLUN-550, FLUN-552, FLUN-547) were designed and synthesized by conjugating the ethanolamine headgroup of the phospholipid phosphatidyl-ethanolamine present in biological membranes. Owing to unique photophysical properties and aqueous compatibility, these probes were successfully employed for staining lipid droplets (LDs) in preadipocytes and Leishmania donovani promastigotes. Furthermore, using the fluorescent probes FLUN-550 and FLUN-552 we successfully imaged and quantitatively detected the excess accumulation of lipids in a liver section of Plasmodium yoelii MDR infected mice (3- to 4-fold) and the tissue sections of third stage human cervical cancer patients (1.5- to 2-fold) compared to normal tissues. To the best of our knowledge, this is the first report of yellow fluorescent probes for imaging and quantitative detection of LDs in human cervical cancer tissues. These new yellow fluorescent lipid probes (FLUN-550 and FLUN-552) showed great potential for diagnosis of cervical cancer patients.",Journal Article,468.0,4.0,The diagnosis and prognosis of the disease associated with lipid irregularity are areas of extreme significance In this direction fluoranthene based yellow fluorescent probes FLUN-550 FLUN-552 FLUN-547 were designed and synthesized by conjugating the ethanolamine headgroup of the phospholipid phosphatidyl-ethanolamine present in biological membranes Owing to unique photophysical properties and aqueous compatibility these probes were successfully employed for staining lipid droplets LDs in preadipocytes and Leishmania donovani promastigotes Furthermore using the fluorescent probes FLUN-550 and FLUN-552 we successfully imaged and quantitatively detected the excess accumulation of lipids in a section of Plasmodium yoelii MDR infected mice 3- to 4-fold and the tissue sections of third stage human cancer patients 1.5- to 2-fold compared to normal tissues To the best of our knowledge this is the first report of yellow fluorescent probes for imaging and quantitative detection of LDs in human cancer tissues These new yellow fluorescent lipid probes FLUN-550 and FLUN-552 showed great potential for diagnosis of cancer patients,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 147, 2, 356, 1, 3, 34, 41, 5, 3121, 15200, 32, 1361, 1, 5611, 724, 4, 26, 4651, 73645, 90, 17826, 2910, 3701, 27707, 7935, 27707, 10097, 27707, 11110, 11, 1114, 2, 5134, 20, 19164, 3, 32259, 51259, 1, 3, 13476, 15628, 32259, 364, 4, 1037, 10255, 3421, 6, 991, 51260, 1571, 2, 13152, 22539, 46, 3701, 11, 1878, 2516, 9, 1029, 3121, 25209, 29855, 4, 28374, 2, 47859, 73646, 73647, 798, 75, 3, 2910, 3701, 27707, 7935, 2, 27707, 10097, 21, 1878, 5903, 2, 5889, 530, 3, 2612, 1835, 1, 9176, 4, 8, 2917, 1, 73648, 73649, 4186, 3369, 399, 27, 6, 39, 1116, 2, 3, 246, 3013, 1, 1282, 82, 171, 12, 7, 14, 33, 6, 18, 1116, 72, 6, 295, 742, 6, 3, 824, 1, 114, 922, 26, 16, 3, 157, 414, 1, 17826, 2910, 3701, 9, 270, 2, 1156, 638, 1, 29855, 4, 171, 12, 742, 46, 217, 17826, 2910, 3121, 3701, 27707, 7935, 2, 27707, 10097, 224, 2797, 174, 9, 147, 1, 12, 7]",1134.0,30247899,858
Relationship between type of smokeless tobacco & risk of cancer: A systematic review.,The Indian journal of medical research,Indian J. Med. Res.,2018-07-01,"Causative linkages of smokeless tobacco (SLT) use with oral potentially malignant disorders and cancers of oral cavity, oesophagus and pancreas have been reported. Published meta-analyses have provided pooled risk estimates for major cancers caused by SLT, both on global and regional levels. This systematic review was aimed at summarizing the available studies on occurrence and mortality risk of common cancers due to various SLT products. PubMed and Google Scholar databases were systematically searched from 1985 till January 2018 for observational studies on SLT and cancer. The included studies were evaluated and data were extracted and reviewed. The review included 80 studies providing 121 risk estimates for various cancers. Majority of the studies from South-East Asian Region (SEAR) and Eastern Mediterranean Region (EMR) showed a significant positive association of SLT use with oral [odds ratio (OR) ranging from 1.48 to 27.4] and oesophageal cancers (OR between 2.06 and 12.8), while studies from European Region (EUR) reported a positive association with pancreatic cancer (OR between 1.6 and 2.1). Cancer-related mortality was evaluated in a few reports with higher risk of mortality for lung (OR between 2.0 and 9.1), cervical (OR 2.0) and prostate (OR 2.1) cancers. A wide variation was noted in the association of various cancers and specific SLT products based on their nature, methods of use and inherent toxicity. The majority of chewing tobacco products displayed higher risk for oral and oesophageal cancers while the same was not observed for snus. This review emphasizes on the significantly positive association of SLT use with oral and oesophageal cancers in SEAR and EMR and pancreatic cancer in EUR. Mortality estimates for SLT-associated cancers need further analysis. Risk analysis for cancers of other sites in SLT users also requires multicentric well-designed studies.",Journal Article,569.0,4.0,Causative linkages of smokeless tobacco SLT use with oral potentially malignant disorders and cancers of oral cavity oesophagus and have been reported Published meta-analyses have provided pooled risk estimates for major cancers caused by SLT both on global and regional levels This systematic review was aimed at summarizing the available studies on occurrence and mortality risk of common cancers due to various SLT products PubMed and Google Scholar databases were systematically searched from 1985 till January 2018 for observational studies on SLT and cancer The included studies were evaluated and data were extracted and reviewed The review included 80 studies providing 121 risk estimates for various cancers Majority of the studies from South-East Asian Region SEAR and Eastern Mediterranean Region EMR showed a significant positive association of SLT use with oral odds ratio OR ranging from 1.48 to 27.4 and oesophageal cancers OR between 2.06 and 12.8 while studies from European Region EUR reported a positive association with cancer OR between 1.6 and 2.1 Cancer-related mortality was evaluated in a few reports with higher risk of mortality for OR between 2.0 and 9.1 OR 2.0 and OR 2.1 cancers A wide variation was noted in the association of various cancers and specific SLT products based on their nature methods of use and inherent toxicity The majority of chewing tobacco products displayed higher risk for oral and oesophageal cancers while the same was not observed for snus This review emphasizes on the significantly positive association of SLT use with oral and oesophageal cancers in SEAR and EMR and cancer in EUR Mortality estimates for SLT-associated cancers need further analysis Risk analysis for cancers of other sites in SLT users also requires multicentric well-designed studies,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[8088, 21149, 1, 18412, 2607, 11330, 119, 5, 518, 751, 393, 1997, 2, 163, 1, 518, 2405, 16966, 2, 47, 85, 210, 983, 1742, 318, 47, 1052, 1830, 43, 1423, 9, 458, 163, 1546, 20, 11330, 110, 23, 1648, 2, 951, 148, 26, 1556, 206, 10, 1295, 28, 15693, 3, 390, 94, 23, 2291, 2, 282, 43, 1, 186, 163, 520, 6, 747, 11330, 2766, 3161, 2, 11897, 16945, 2348, 11, 3390, 3080, 29, 4675, 20528, 1024, 2982, 9, 2495, 94, 23, 11330, 2, 12, 3, 159, 94, 11, 194, 2, 74, 11, 2484, 2, 446, 3, 206, 159, 493, 94, 1736, 4141, 43, 1423, 9, 747, 163, 686, 1, 3, 94, 29, 5452, 6633, 2399, 1053, 51266, 2, 2118, 29096, 1053, 7617, 224, 8, 93, 109, 248, 1, 11330, 119, 5, 518, 610, 197, 15, 2223, 29, 14, 576, 6, 428, 39, 2, 8618, 163, 15, 59, 18, 1460, 2, 133, 66, 369, 94, 29, 1865, 1053, 32713, 210, 8, 109, 248, 5, 12, 15, 59, 14, 49, 2, 18, 14, 12, 139, 282, 10, 194, 4, 8, 1021, 1198, 5, 142, 43, 1, 282, 9, 15, 59, 18, 13, 2, 83, 14, 15, 18, 13, 2, 15, 18, 14, 163, 8, 1019, 1380, 10, 1051, 4, 3, 248, 1, 747, 163, 2, 112, 11330, 2766, 90, 23, 136, 2202, 636, 1, 119, 2, 4943, 155, 3, 686, 1, 14244, 2607, 2766, 2507, 142, 43, 9, 518, 2, 8618, 163, 369, 3, 827, 10, 44, 164, 9, 73686, 26, 206, 7519, 23, 3, 97, 109, 248, 1, 11330, 119, 5, 518, 2, 8618, 163, 4, 51266, 2, 7617, 2, 12, 4, 32713, 282, 1423, 9, 11330, 41, 163, 594, 195, 65, 43, 65, 9, 163, 1, 127, 633, 4, 11330, 2735, 120, 1706, 8388, 149, 1114, 94]",1811.0,30264755,52
Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy.,Frontiers in immunology,Front Immunol,2018-09-19,"Although there has been significant progress in prevention and treatment of cervical cancer, this malignancy is still a leading cause of cancer death for women. Anti-angiogenesis and immunotherapy approaches have been providing survival benefits, however, response rates and durability of response need to be improved. There is a clear need for combination therapies that increase effectiveness of these agents and further improve patient outcome. Previous studies have largely focused on gene expression and molecular pathways in untreated cervix cancer. The goal of this study was to evaluate cancer-specific molecular pathways and their correlation with tumor immune profile in recurrent cervical cancer. Tumor and adjacent normal tissues were used to identify potential combination therapy targets. We found that DNA damage repair pathway genes were significantly overexpressed in the tumor. Based on our results and other recent investigations, we suggest that combination immune checkpoint and PARP inhibitor therapy is a high priority consideration for patients with recurrent, previously treated cervical cancer. We also show that multiple epithelial-mesenchymal transition-related genes, including MAP2K4, ID2, JAK1, FGF2, PIK3R1, AKT3, FGF13, and STAT3 may be potential targets. Interestingly, high-throughput analysis of Cancer Genome Atlas data identified distinct targets, including Fatty acid synthase FASN and Matrix Metallopeptidase 1 MMP1 as novel, promising combination therapy partners.",Journal Article,489.0,2.0,Although there has been significant progress in prevention and treatment of cancer this malignancy is still a leading cause of cancer death for women Anti-angiogenesis and immunotherapy approaches have been providing survival benefits however response rates and durability of response need to be improved There is a clear need for combination therapies that increase effectiveness of these agents and further improve patient outcome Previous studies have largely focused on gene expression and molecular pathways in untreated cervix cancer The goal of this study was to evaluate cancer-specific molecular pathways and their correlation with tumor immune profile in recurrent cancer Tumor and adjacent normal tissues were used to identify potential combination therapy targets We found that DNA damage repair pathway genes were significantly overexpressed in the tumor Based on our results and other recent investigations we suggest that combination immune checkpoint and PARP inhibitor therapy is a high priority consideration for patients with recurrent previously treated cancer We also show that multiple epithelial-mesenchymal transition-related genes including MAP2K4 ID2 JAK1 FGF2 PIK3R1 AKT3 FGF13 and STAT3 may be potential targets Interestingly high-throughput analysis of Cancer Genome Atlas data identified distinct targets including Fatty acid synthase FASN and Matrix Metallopeptidase 1 MMP1 as novel promising combination therapy partners,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[242, 125, 71, 85, 93, 1466, 4, 1070, 2, 24, 1, 12, 26, 710, 16, 1234, 8, 1049, 708, 1, 12, 273, 9, 117, 312, 1056, 2, 726, 611, 47, 85, 1736, 25, 1141, 137, 51, 151, 2, 6867, 1, 51, 594, 6, 40, 231, 125, 16, 8, 885, 594, 9, 150, 235, 17, 344, 1236, 1, 46, 183, 2, 195, 401, 69, 228, 698, 94, 47, 1733, 1649, 23, 145, 55, 2, 219, 460, 4, 1278, 3629, 12, 3, 1326, 1, 26, 45, 10, 6, 376, 12, 112, 219, 460, 2, 136, 816, 5, 30, 250, 800, 4, 387, 12, 30, 2, 2086, 295, 742, 11, 95, 6, 255, 174, 150, 36, 637, 21, 204, 17, 261, 1350, 972, 308, 214, 11, 97, 1711, 4, 3, 30, 90, 23, 114, 99, 2, 127, 435, 2492, 21, 309, 17, 150, 250, 986, 2, 2041, 230, 36, 16, 8, 64, 4690, 2415, 9, 7, 5, 387, 373, 73, 12, 21, 120, 514, 17, 232, 701, 1569, 1970, 139, 214, 141, 26816, 13296, 8075, 18541, 12936, 12429, 73724, 2, 1439, 68, 40, 174, 637, 2873, 64, 3643, 65, 1, 12, 898, 2643, 74, 108, 834, 637, 141, 4038, 971, 3522, 5728, 2, 2248, 31661, 14, 20559, 22, 229, 721, 150, 36, 4005]",1452.0,30283446,442
Lymphoepithelioma-Like Carcinoma of the Uterine Cervix: A Pathologic Study of Eight Cases With Emphasis on the Association With Human Papillomavirus.,American journal of clinical pathology,Am. J. Clin. Pathol.,2019-01-01,"Lymphoepithelioma-like carcinoma (LELC) of the uterine cervix is a rare tumor. The goal of this study was to evaluate a series of cases of cervical LELC and to investigate possible association with human papillomavirus (HPV) and/or Epstein-Barr virus (EBV). Immunohistochemistry for p63, p16, human leukocyte antigen-D related (HLA-DR), and B-cell lymphoma 2 (BCL-2); in situ hybridization (ISH) for EBV and HPV; and polymerase chain reaction (PCR) genotyping were performed. Mismatch repair (MMR) studies and PD-L1 status were obtained. We found eight cases of LELC. Tumors demonstrated sheets of cells containing vesicular nuclei, amphiphilic cytoplasm, and dense peri- and intratumoral lymphocytic infiltrates. All tumors stained for p63, p16, and HLA-DR; two also stained for BCL-2. When combining ISH and PCR results, seven tumors were HPV positive; they were all Epstein-Barr encoding region negative. All cases were MMR intact, and most overexpressed PD-L1. This study shows that cervical LELCs are associated with HPV and not EBV.",Journal Article,385.0,0.0,Lymphoepithelioma-like carcinoma LELC of the cervix is a rare tumor The goal of this study was to evaluate a series of cases of LELC and to investigate possible association with human papillomavirus HPV and/or Epstein-Barr virus EBV Immunohistochemistry for p63 p16 human leukocyte antigen-D related HLA-DR and B-cell 2 BCL-2 in situ hybridization ISH for EBV and HPV and polymerase chain reaction PCR genotyping were performed Mismatch repair MMR studies and PD-L1 status were obtained We found eight cases of LELC Tumors demonstrated sheets of cells containing vesicular nuclei amphiphilic cytoplasm and dense peri- and intratumoral lymphocytic infiltrates All tumors stained for p63 p16 and HLA-DR two also stained for BCL-2 When combining ISH and PCR results seven tumors were HPV positive they were all Epstein-Barr encoding region negative All cases were MMR intact and most overexpressed PD-L1 This study shows that LELCs are associated with HPV and not EBV,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[28091, 733, 134, 42174, 1, 3, 3629, 16, 8, 622, 30, 3, 1326, 1, 26, 45, 10, 6, 376, 8, 988, 1, 140, 1, 42174, 2, 6, 963, 899, 248, 5, 171, 3242, 933, 2, 15, 5212, 5190, 1450, 2672, 888, 9, 7147, 1932, 171, 3627, 448, 427, 139, 1160, 3436, 2, 132, 31, 18, 1044, 18, 4, 957, 1554, 6321, 9, 2672, 2, 933, 2, 1451, 1260, 1329, 604, 2686, 11, 173, 2617, 972, 2205, 94, 2, 333, 729, 156, 11, 683, 21, 204, 659, 140, 1, 42174, 57, 264, 13568, 1, 37, 1101, 11117, 4725, 23411, 4558, 2, 3076, 6164, 2, 2074, 1193, 5942, 62, 57, 3386, 9, 7147, 1932, 2, 1160, 3436, 100, 120, 3386, 9, 1044, 18, 198, 1525, 6321, 2, 604, 99, 648, 57, 11, 933, 109, 491, 11, 62, 5212, 5190, 2362, 1053, 199, 62, 140, 11, 2205, 2964, 2, 96, 1711, 333, 729, 26, 45, 1949, 17, 73793, 32, 41, 5, 933, 2, 44, 2672]",964.0,30321260,42
Cytologic patterns of cervical adenocarcinomas with emphasis on factors associated with underdiagnosis.,Cancer cytopathology,Cancer Cytopathol,2018-10-23,"New cervical cancers continue to be diagnosed despite the success of Papanicolaou (Pap) tests. In an effort to identify pitfalls that limit the diagnosis of adenocarcinoma, the authors reviewed the cytologic characteristics of endocervical adenocarcinomas in their patient population. Liquid-based cytology slides from 45 women who had concurrent, histologically confirmed cervical adenocarcinomas were reviewed retrospectively and semiquantitatively for 25 key cytologic traits. The original sign-out diagnosis, available clinical findings, and high-risk human papillomavirus (HR HPV) results also were noted. Abundant tumor cellularity, nuclear size from 3 to 6 times normal, abundant 3-dimensional tumor cell groups, round cell shape, and cytoplasmic neutrophils characterized the 23 cases that were identified correctly as adenocarcinomas. Key reasons for undercalls included low tumor cellularity and low-grade columnar morphology; these also tended to correlate with low-grade or unusual adenocarcinoma variants on histology. Overall, 73% of adenocarcinomas had a concurrent positive HR HPV test. Most endocervical adenocarcinomas can be diagnosed accurately in cases with classical features, but some cases continue to be problematic when evaluated based on cytologic features alone. Reflex HPV testing may help increase Pap test sensitivity for challenging cases that have atypical glandular cells of undetermined significance. Occasional cases with negative HR HPV test results remain of concern.",Journal Article,455.0,2.0,New cancers continue to be diagnosed despite the success of Papanicolaou Pap tests In an effort to identify pitfalls that limit the diagnosis of adenocarcinoma the authors reviewed the cytologic characteristics of endocervical adenocarcinomas in their patient population Liquid-based cytology slides from 45 women who had concurrent histologically confirmed adenocarcinomas were reviewed retrospectively and semiquantitatively for 25 key cytologic traits The original sign-out diagnosis available clinical findings and high-risk human papillomavirus HR HPV results also were noted Abundant tumor cellularity nuclear size from 3 to 6 times normal abundant 3-dimensional tumor cell groups round cell shape and cytoplasmic neutrophils characterized the 23 cases that were identified correctly as adenocarcinomas Key reasons for undercalls included low tumor cellularity and low-grade columnar morphology these also tended to correlate with low-grade or unusual adenocarcinoma variants on histology Overall 73 of adenocarcinomas had a concurrent positive HR HPV test Most endocervical adenocarcinomas can be diagnosed accurately in cases with classical features but some cases continue to be problematic when evaluated based on cytologic features alone Reflex HPV testing may help increase Pap test sensitivity for challenging cases that have atypical glandular cells of undetermined significance Occasional cases with negative HR HPV test results remain of concern,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[217, 163, 1906, 6, 40, 265, 550, 3, 1825, 1, 10416, 4290, 895, 4, 35, 2919, 6, 255, 9631, 17, 2385, 3, 147, 1, 449, 3, 738, 446, 3, 4195, 374, 1, 10174, 1586, 4, 136, 69, 266, 3165, 90, 2045, 3830, 29, 512, 117, 54, 42, 750, 2161, 557, 1586, 11, 446, 894, 2, 19562, 9, 243, 825, 4195, 8546, 3, 2279, 7636, 1205, 147, 390, 38, 272, 2, 64, 43, 171, 3242, 168, 933, 99, 120, 11, 1051, 4834, 30, 6363, 928, 444, 29, 27, 6, 49, 1072, 295, 4834, 27, 2201, 30, 31, 271, 4436, 31, 5465, 2, 2828, 5700, 765, 3, 382, 140, 17, 11, 108, 4911, 22, 1586, 825, 2325, 9, 73838, 159, 154, 30, 6363, 2, 154, 88, 16500, 2567, 46, 120, 3886, 6, 1513, 5, 154, 88, 15, 4015, 449, 839, 23, 784, 63, 803, 1, 1586, 42, 8, 750, 109, 168, 933, 412, 96, 10174, 1586, 122, 40, 265, 2141, 4, 140, 5, 3781, 404, 84, 476, 140, 1906, 6, 40, 6594, 198, 194, 90, 23, 4195, 404, 279, 10265, 933, 471, 68, 987, 344, 4290, 412, 485, 9, 1950, 140, 17, 47, 1973, 6170, 37, 1, 5206, 724, 9753, 140, 5, 199, 168, 933, 412, 99, 918, 1, 2893]",1461.0,30351473,413
Use of Preventive Health Services Among Cancer Survivors in the U.S.,American journal of preventive medicine,Am J Prev Med,2018-10-21,"With improvements in early detection and treatment, a growing proportion of the population now lives with a personal history of a cancer. Although many cancer survivors are in excellent health, the underlying risk factors and side effects of cancer treatment increase the risk of medical complications and secondary malignancies. The 2013 National Health Interview Survey was utilized to assess the association between personal history of cancer and receipt of U.S. Preventive Services Task Force-recommended services, comprising three cancer screening tests (mammography, colonoscopy, and Pap smear) and six general medical preventive care services (aspirin for prevention of cardiovascular disease; blood pressure, cholesterol, and diabetes screening; diet/activity counseling; and tobacco use counseling). For each preventive service, patients with a history that would preclude that test were excluded. One to three matching of cancer survivors to controls was performed using propensity scores generated from patient-level demographic variables. Conditional logistic regression models were employed to compare odds of screening between matched cohorts of cancer survivors and controls. The years of analysis were 2015 and 2017. A total of 2,639 cancer patients and 31,885 controls were extracted from the merged 2013 National Health Interview Survey. In the propensity score-matched cohorts of eligible adults, only one of the three cancer screening tests, colorectal, was more common in cancer survivors (OR=1.52, 95% CI=1.32, 1.75, p<0.001), whereas breast and cervical cancer screening were not more common in survivors. By contrast, all of the medical screening tests, with the exception of diabetes screening, were more common among cancer survivors. The association between receipt of recommended preventive medical care and personal history of cancer varied, depending on the preventive service in question, but in the majority of preventive services assessed, cancer survivors had more frequent screening compared with non-cancer survivors.",Journal Article,457.0,0.0,"With improvements in early detection and treatment a growing proportion of the population now lives with a personal history of a cancer Although many cancer survivors are in excellent health the underlying risk factors and side effects of cancer treatment increase the risk of medical complications and secondary malignancies The 2013 National Health Interview Survey was utilized to assess the association between personal history of cancer and receipt of U.S. Preventive Services Task Force-recommended services comprising three cancer screening tests mammography colonoscopy and Pap smear and six general medical preventive care services aspirin for prevention of cardiovascular disease blood pressure cholesterol and diabetes screening diet/activity counseling and tobacco use counseling For each preventive service patients with a history that would preclude that test were excluded One to three matching of cancer survivors to controls was performed using propensity scores generated from patient-level demographic variables Conditional logistic regression models were employed to compare odds of screening between matched cohorts of cancer survivors and controls The years of analysis were 2015 and 2017 A total of 2,639 cancer patients and 31,885 controls were extracted from the merged 2013 National Health Interview Survey In the propensity score-matched cohorts of eligible adults only one of the three cancer screening tests was more common in cancer survivors OR=1.52 95 CI=1.32 1.75 p 0.001 whereas and cancer screening were not more common in survivors By contrast all of the medical screening tests with the exception of diabetes screening were more common among cancer survivors The association between receipt of recommended preventive medical care and personal history of cancer varied depending on the preventive service in question but in the majority of preventive services assessed cancer survivors had more frequent screening compared with non-cancer survivors",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[5, 1474, 4, 191, 638, 2, 24, 8, 1921, 920, 1, 3, 266, 1134, 6407, 5, 8, 3008, 532, 1, 8, 12, 242, 445, 12, 332, 32, 4, 1503, 341, 3, 1181, 43, 130, 2, 1152, 176, 1, 12, 24, 344, 3, 43, 1, 484, 521, 2, 568, 441, 3, 1346, 657, 341, 4313, 1407, 10, 2080, 6, 423, 3, 248, 59, 3008, 532, 1, 12, 2, 1699, 1, 1767, 695, 3494, 2142, 3488, 4380, 793, 2142, 3538, 169, 12, 453, 895, 2446, 3996, 2, 4290, 8379, 2, 437, 1083, 484, 3494, 165, 2142, 2085, 9, 1070, 1, 2179, 34, 315, 3738, 5020, 2, 1978, 453, 2453, 128, 2011, 2, 2607, 119, 2011, 9, 296, 3494, 3086, 7, 5, 8, 532, 17, 688, 6064, 17, 412, 11, 1800, 104, 6, 169, 2616, 1, 12, 332, 6, 535, 10, 173, 75, 1925, 703, 1419, 29, 69, 301, 1540, 682, 3212, 812, 320, 274, 11, 2516, 6, 932, 610, 1, 453, 59, 655, 736, 1, 12, 332, 2, 535, 3, 60, 1, 65, 11, 1483, 2, 1759, 8, 181, 1, 18, 14553, 12, 7, 2, 456, 14962, 535, 11, 2484, 29, 3, 11267, 1346, 657, 341, 4313, 1407, 4, 3, 1925, 368, 655, 736, 1, 625, 857, 158, 104, 1, 3, 169, 12, 453, 895, 10, 80, 186, 4, 12, 332, 15, 14, 653, 48, 58, 14, 531, 14, 481, 19, 13, 144, 547, 2, 12, 453, 11, 44, 80, 186, 4, 332, 20, 748, 62, 1, 3, 484, 453, 895, 5, 3, 4188, 1, 1978, 453, 11, 80, 186, 107, 12, 332, 3, 248, 59, 1699, 1, 793, 3494, 484, 165, 2, 3008, 532, 1, 12, 2051, 3221, 23, 3, 3494, 3086, 4, 2840, 84, 4, 3, 686, 1, 3494, 2142, 275, 12, 332, 42, 80, 908, 453, 72, 5, 220, 12, 332]",1984.0,30352719,100
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.,The New England journal of medicine,N. Engl. J. Med.,2018-10-31,"There are limited data from retrospective studies regarding whether survival outcomes after laparoscopic or robot-assisted radical hysterectomy (minimally invasive surgery) are equivalent to those after open abdominal radical hysterectomy (open surgery) among women with early-stage cervical cancer. In this trial involving patients with stage IA1 (lymphovascular invasion), IA2, or IB1 cervical cancer and a histologic subtype of squamous-cell carcinoma, adenocarcinoma, or adenosquamous carcinoma, we randomly assigned patients to undergo minimally invasive surgery or open surgery. The primary outcome was the rate of disease-free survival at 4.5 years, with noninferiority claimed if the lower boundary of the two-sided 95% confidence interval of the between-group difference (minimally invasive surgery minus open surgery) was greater than -7.2 percentage points (i.e., closer to zero). A total of 319 patients were assigned to minimally invasive surgery and 312 to open surgery. Of the patients who were assigned to and underwent minimally invasive surgery, 84.4% underwent laparoscopy and 15.6% robot-assisted surgery. Overall, the mean age of the patients was 46.0 years. Most patients (91.9%) had stage IB1 disease. The two groups were similar with respect to histologic subtypes, the rate of lymphovascular invasion, rates of parametrial and lymph-node involvement, tumor size, tumor grade, and the rate of use of adjuvant therapy. The rate of disease-free survival at 4.5 years was 86.0% with minimally invasive surgery and 96.5% with open surgery, a difference of -10.6 percentage points (95% confidence interval [CI], -16.4 to -4.7). Minimally invasive surgery was associated with a lower rate of disease-free survival than open surgery (3-year rate, 91.2% vs. 97.1%; hazard ratio for disease recurrence or death from cervical cancer, 3.74; 95% CI, 1.63 to 8.58), a difference that remained after adjustment for age, body-mass index, stage of disease, lymphovascular invasion, and lymph-node involvement; minimally invasive surgery was also associated with a lower rate of overall survival (3-year rate, 93.8% vs. 99.0%; hazard ratio for death from any cause, 6.00; 95% CI, 1.77 to 20.30). In this trial, minimally invasive radical hysterectomy was associated with lower rates of disease-free survival and overall survival than open abdominal radical hysterectomy among women with early-stage cervical cancer. (Funded by the University of Texas M.D. Anderson Cancer Center and Medtronic; LACC ClinicalTrials.gov number, NCT00614211 .).","Clinical Trial, Phase III",447.0,174.0,There are limited data from retrospective studies regarding whether survival outcomes after laparoscopic or robot-assisted radical hysterectomy minimally invasive surgery are equivalent to those after open abdominal radical hysterectomy open surgery among women with early-stage cancer In this trial involving patients with stage IA1 lymphovascular invasion IA2 or IB1 cancer and a histologic subtype of squamous-cell carcinoma adenocarcinoma or adenosquamous carcinoma we randomly assigned patients to undergo minimally invasive surgery or open surgery The primary outcome was the rate of disease-free survival at 4.5 years with noninferiority claimed if the lower boundary of the two-sided 95 confidence interval of the between-group difference minimally invasive surgery minus open surgery was greater than -7.2 percentage points i.e. closer to zero A total of 319 patients were assigned to minimally invasive surgery and 312 to open surgery Of the patients who were assigned to and underwent minimally invasive surgery 84.4 underwent laparoscopy and 15.6 robot-assisted surgery Overall the mean age of the patients was 46.0 years Most patients 91.9 had stage IB1 disease The two groups were similar with respect to histologic subtypes the rate of lymphovascular invasion rates of parametrial and lymph-node involvement tumor size tumor grade and the rate of use of adjuvant therapy The rate of disease-free survival at 4.5 years was 86.0 with minimally invasive surgery and 96.5 with open surgery a difference of -10.6 percentage points 95 confidence interval CI -16.4 to -4.7 Minimally invasive surgery was associated with a lower rate of disease-free survival than open surgery 3-year rate 91.2 vs. 97.1 hazard ratio for disease recurrence or death from cancer 3.74 95 CI 1.63 to 8.58 a difference that remained after adjustment for age body-mass index stage of disease lymphovascular invasion and lymph-node involvement minimally invasive surgery was also associated with a lower rate of overall survival 3-year rate 93.8 vs. 99.0 hazard ratio for death from any cause 6.00 95 CI 1.77 to 20.30 In this trial minimally invasive radical hysterectomy was associated with lower rates of disease-free survival and overall survival than open abdominal radical hysterectomy among women with early-stage cancer Funded by the University of Texas M.D Anderson Cancer Center and Medtronic LACC ClinicalTrials.gov number NCT00614211,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[125, 32, 383, 74, 29, 459, 94, 666, 317, 25, 123, 50, 1964, 15, 6589, 2927, 711, 2622, 2144, 416, 152, 32, 2017, 6, 135, 50, 1020, 1467, 711, 2622, 1020, 152, 107, 117, 5, 191, 82, 12, 4, 26, 160, 1267, 7, 5, 82, 14517, 2933, 578, 16725, 15, 8111, 12, 2, 8, 884, 875, 1, 691, 31, 134, 449, 15, 8067, 134, 21, 1108, 896, 7, 6, 1251, 2144, 416, 152, 15, 1020, 152, 3, 86, 228, 10, 3, 116, 1, 34, 115, 25, 28, 39, 33, 60, 5, 7386, 22459, 492, 3, 280, 8920, 1, 3, 100, 1689, 48, 307, 268, 1, 3, 59, 87, 523, 2144, 416, 152, 12297, 1020, 152, 10, 378, 76, 67, 18, 1150, 862, 70, 563, 6576, 6, 5115, 8, 181, 1, 9052, 7, 11, 896, 6, 2144, 416, 152, 2, 8187, 6, 1020, 152, 1, 3, 7, 54, 11, 896, 6, 2, 208, 2144, 416, 152, 874, 39, 208, 3553, 2, 167, 49, 6589, 2927, 152, 63, 3, 313, 89, 1, 3, 7, 10, 641, 13, 60, 96, 7, 970, 83, 42, 82, 8111, 34, 3, 100, 271, 11, 288, 5, 2184, 6, 884, 814, 3, 116, 1, 2933, 578, 151, 1, 8726, 2, 263, 289, 799, 30, 444, 30, 88, 2, 3, 116, 1, 119, 1, 249, 36, 3, 116, 1, 34, 115, 25, 28, 39, 33, 60, 10, 868, 13, 5, 2144, 416, 152, 2, 921, 33, 5, 1020, 152, 8, 523, 1, 79, 49, 1150, 862, 48, 307, 268, 58, 245, 39, 6, 39, 67, 2144, 416, 152, 10, 41, 5, 8, 280, 116, 1, 34, 115, 25, 76, 1020, 152, 27, 111, 116, 970, 18, 105, 1015, 14, 360, 197, 9, 34, 146, 15, 273, 29, 12, 27, 794, 48, 58, 14, 676, 6, 66, 717, 8, 523, 17, 958, 50, 1852, 9, 89, 642, 782, 558, 82, 1, 34, 2933, 578, 2, 263, 289, 799, 2144, 416, 152, 10, 120, 41, 5, 8, 280, 116, 1, 63, 25, 27, 111, 116, 966, 66, 105, 1058, 13, 360, 197, 9, 273, 29, 500, 708, 49, 2038, 48, 58, 14, 849, 6, 179, 201, 4, 26, 160, 2144, 416, 711, 2622, 10, 41, 5, 280, 151, 1, 34, 115, 25, 2, 63, 25, 76, 1020, 1467, 711, 2622, 107, 117, 5, 191, 82, 12, 3827, 20, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 2, 73892, 24255, 1252, 1239, 207, 73893]",2427.0,30380365,31
Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy.,Journal for immunotherapy of cancer,J Immunother Cancer,2018-12-12,"Novel approaches with checkpoint inhibitors in immunotherapy continue to be essential in the treatment of non-small cell lung cancer (NSCLC). However, the low rate of primary response and the development of acquired resistance during the immunotherapy limit their long-term effectiveness. The underlying cause of acquired resistance is poorly understood; potential management strategies for patients with acquired resistance are even less clear. Here, we report the case of a 75-year-old female smoker with cough, fatigue, and weight loss that was found to have an 8.6cm right upper lobe lung lesion with local invasion, adenopathy, and a malignant pericardial effusion. This lesion was biopsied and identified to be cT3N3M1b squamous cell cancer of the lung without any recognizable PD-L1 expression on tumor cells. For her metastatic NSCLC, the patient underwent two lines of conventional chemotherapy before initiation of combination immunotherapy with an anti-PD-L1 and anti-CTLA-4 antibody. Though she initially achieved a response, she thereafter progressed and developed immunotherapy resistant lymph nodal metastasis. While cervical lymph nodes could be surgically removed, another metastasis in an aortocaval area required a more sensitive therapy like thermal ablation. The aortocaval node was partially treated with a single treatment of cryotherapy and demonstrated durable complete response. Cryotherapy for checkpoint immunotherapy resistant metastasis appears to be a safe and feasible treatment for treating metastatic disease in non-small cell lung cancer. The prospect of cryotherapy adjuvancy may enable local control of metastatic disease after initial response to immune checkpoint immunotherapy and may impact on overall outcomes.",Case Reports,405.0,1.0,Novel approaches with checkpoint inhibitors in immunotherapy continue to be essential in the treatment of cell cancer NSCLC However the low rate of primary response and the development of acquired resistance during the immunotherapy limit their long-term effectiveness The underlying cause of acquired resistance is poorly understood potential management strategies for patients with acquired resistance are even less clear Here we report the case of a 75-year-old female smoker with cough fatigue and weight loss that was found to have an 8.6 cm right upper lobe lesion with local invasion adenopathy and a malignant pericardial effusion This lesion was biopsied and identified to be cT3N3M1b squamous cell cancer of the without any recognizable PD-L1 expression on tumor cells For her metastatic NSCLC the patient underwent two lines of conventional chemotherapy before initiation of combination immunotherapy with an anti-PD-L1 and anti-CTLA-4 antibody Though she initially achieved a response she thereafter progressed and developed immunotherapy resistant lymph nodal metastasis While lymph nodes could be surgically removed another metastasis in an aortocaval area required a more sensitive therapy like thermal ablation The aortocaval node was partially treated with a single treatment of cryotherapy and demonstrated durable complete response Cryotherapy for checkpoint immunotherapy resistant metastasis appears to be a safe and feasible treatment for treating metastatic disease in cell cancer The prospect of cryotherapy adjuvancy may enable local control of metastatic disease after initial response to immune checkpoint immunotherapy and may impact on overall outcomes,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[229, 611, 5, 986, 222, 4, 726, 1906, 6, 40, 1452, 4, 3, 24, 1, 31, 12, 304, 137, 3, 154, 116, 1, 86, 51, 2, 3, 193, 1, 1294, 251, 190, 3, 726, 2385, 136, 319, 337, 1236, 3, 1181, 708, 1, 1294, 251, 16, 1240, 1784, 174, 284, 422, 9, 7, 5, 1294, 251, 32, 871, 299, 885, 467, 21, 414, 3, 473, 1, 8, 481, 111, 1095, 1061, 9082, 5, 6546, 613, 2, 924, 407, 17, 10, 204, 6, 47, 35, 66, 49, 494, 1913, 1726, 4940, 1180, 5, 293, 578, 7741, 2, 8, 393, 6657, 4433, 26, 1180, 10, 6775, 2, 108, 6, 40, 74168, 691, 31, 12, 1, 3, 187, 500, 13908, 333, 729, 55, 23, 30, 37, 9, 1084, 113, 304, 3, 69, 208, 100, 285, 1, 809, 56, 348, 1118, 1, 150, 726, 5, 35, 312, 333, 729, 2, 312, 2127, 39, 548, 2471, 3109, 1625, 513, 8, 51, 3109, 3972, 1839, 2, 276, 726, 436, 263, 779, 278, 369, 263, 502, 359, 40, 2350, 2264, 1809, 278, 4, 35, 17414, 965, 616, 8, 80, 745, 36, 733, 6244, 1650, 3, 17414, 289, 10, 2995, 73, 5, 8, 226, 24, 1, 8610, 2, 264, 1480, 236, 51, 8610, 9, 986, 726, 436, 278, 1233, 6, 40, 8, 1165, 2, 1313, 24, 9, 1367, 113, 34, 4, 31, 12, 3, 10869, 1, 8610, 74169, 68, 3047, 293, 182, 1, 113, 34, 50, 388, 51, 6, 250, 986, 726, 2, 68, 345, 23, 63, 123]",1681.0,30541627,129
"Relationship between social support, quality of life, and Th2 cytokines in a biobehavioral cancer survivorship trial.",Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,Support Care Cancer,2019-01-05,"Benefits of social support (SS) during cancer survivorship are complex. This study examines change in SS over time in cervical cancer (CXCA) survivors who have completed definitive treatment and how changing SS impacts quality of life (QOL) and T-helper type 2 (Th2) cytokines. We conducted a randomized trial in 204 CXCA survivors to test if psychosocial telephone counseling (PTC) could improve QOL compared to usual care (UC). Although PTC did not target SS, data were collected at baseline, 4 and 9months post-enrollment using the Medical Outcomes Survey Social Support scale. Biospecimens were collected to investigate associations with patient-reported outcomes. Data were analyzed using multivariate linear models and stepwise regression. Participants' mean age was 43. PTC participants experienced increasing SS compared to UC at 4months (PTC-UC=5.1; p=0.055) and 9months (PTC-UC=6.0; p=0.046). Higher baseline SS and increasing SS were independently associated with improved QOL at 4 and 9months after adjusting for patient characteristics (p<0.05). Differences between study arms were not statistically significant. Improvements in QOL at 4months were observed with increases in emotional/informational and tangible SS. Increasing SS predicted significant longitudinal decreases in IL-4 and IL-13 at 4months that were larger in the PTC arm (interactions p=0.041 and p=0.057, respectively). Improved SS was significantly associated with improved QOL independent of patient characteristics and study arm. Decreasing Th2 cytokines with increasing SS and QOL are consistent with a biobehavioral paradigm in which modulation of the chronic stress response is associated with shifts in immune stance.",Journal Article,381.0,0.0,Benefits of social support SS during cancer survivorship are complex This study examines change in SS over time in cancer CXCA survivors who have completed definitive treatment and how changing SS impacts quality of life QOL and T-helper type 2 Th2 cytokines We conducted a randomized trial in 204 CXCA survivors to test if psychosocial telephone counseling PTC could improve QOL compared to usual care UC Although PTC did not target SS data were collected at baseline 4 and 9 months post-enrollment using the Medical Outcomes Survey Social Support scale Biospecimens were collected to investigate associations with patient-reported outcomes Data were analyzed using multivariate linear models and stepwise regression Participants mean age was 43 PTC participants experienced increasing SS compared to UC at 4 months PTC-UC 5.1 p 0.055 and 9 months PTC-UC 6.0 p 0.046 Higher baseline SS and increasing SS were independently associated with improved QOL at 4 and 9 months after adjusting for patient characteristics p 0.05 Differences between study arms were not statistically significant Improvements in QOL at 4 months were observed with increases in emotional/informational and tangible SS Increasing SS predicted significant longitudinal decreases in IL-4 and IL-13 at 4 months that were larger in the PTC arm interactions p 0.041 and p 0.057 respectively Improved SS was significantly associated with improved QOL independent of patient characteristics and study arm Decreasing Th2 cytokines with increasing SS and QOL are consistent with a biobehavioral paradigm in which modulation of the chronic stress response is associated with shifts in immune stance,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1141, 1, 2032, 538, 4417, 190, 12, 2560, 32, 840, 26, 45, 4468, 707, 4, 4417, 252, 98, 4, 12, 27479, 332, 54, 47, 781, 1057, 24, 2, 832, 3600, 4417, 4719, 372, 1, 358, 1001, 2, 102, 5539, 267, 18, 8358, 1886, 21, 426, 8, 384, 160, 4, 5996, 27479, 332, 6, 412, 492, 2322, 4258, 2011, 3748, 359, 401, 1001, 72, 6, 3521, 165, 2417, 242, 3748, 205, 44, 283, 4417, 74, 11, 786, 28, 330, 39, 2, 83, 53, 539, 1798, 75, 3, 484, 123, 1407, 2032, 538, 1124, 12419, 11, 786, 6, 963, 685, 5, 69, 210, 123, 74, 11, 311, 75, 331, 1646, 274, 2, 5497, 320, 776, 313, 89, 10, 601, 3748, 776, 592, 602, 4417, 72, 6, 2417, 28, 39, 53, 3748, 2417, 33, 14, 19, 13, 9186, 2, 83, 53, 3748, 2417, 49, 13, 19, 13, 4902, 142, 330, 4417, 2, 602, 4417, 11, 1042, 41, 5, 231, 1001, 28, 39, 2, 83, 53, 50, 1358, 9, 69, 374, 19, 13, 474, 362, 59, 45, 1335, 11, 44, 712, 93, 1474, 4, 1001, 28, 39, 53, 11, 164, 5, 1106, 4, 2671, 12156, 2, 19079, 4417, 602, 4417, 783, 93, 2380, 2140, 4, 501, 39, 2, 501, 233, 28, 39, 53, 17, 11, 1077, 4, 3, 3748, 475, 1286, 19, 13, 5937, 2, 19, 13, 10807, 106, 231, 4417, 10, 97, 41, 5, 231, 1001, 306, 1, 69, 374, 2, 45, 475, 2777, 8358, 1886, 5, 602, 4417, 2, 1001, 32, 925, 5, 8, 21332, 2431, 4, 92, 2356, 1, 3, 442, 1531, 51, 16, 41, 5, 5906, 4, 250, 34448]",1661.0,30612237,530
Factors influencing the adoption of the sentinel lymph node technique for endometrial cancer staging: an international survey of gynecologic oncologists.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2019-01-01,"To explore the factors influencing adoption of the sentinel lymph node (SLN) technique for endometrial cancer staging among gynecologic oncologists. A self-administered, web-based survey was sent via email (April 20 through May 21, 2017) to all members of European Society of Gynecologic Oncologists, International Gynecologic Cancer Society, and Society of Gynecologic Oncologists. Surgical and pathologic practices related to SLN and reasons for not adopting this technique were investigated. Overall, 489 attending physicians or consultants in gynecologic oncology from 69 countries responded: 201 (41.1%), 118 (24.1%), and 117 (23.9%) from Europe, the USA, and other countries, respectively (10.8% did not report a country). SLN was adopted by 246 (50.3%) respondents, with 93.1% injecting the cervix and 62.6 % using indocyanine green dye. The National Comprehensive Cancer Network SLN algorithm was followed by 160 (65.0%) respondents (USA 74.4%, Europe 55.4%, other countries 71.4%). However, 66.7% completed a backup lymphadenectomy in high-risk patients. When SLN biopsy revealed isolated tumor cells, 13.8% of respondents recommended adjuvant therapy. This percentage increased to 52% if micrometastases were detected. Among the 243 not adopting SLN, 50.2% cited lack of evidence and 45.3% stated that inadequate instrumentation fueled their decisions. SLN with a cervical injection is gaining widespread acceptance for staging of endometrial cancer among gynecologic oncologists worldwide. Standardization of the surgical approach with the National Comprehensive Care Network algorithm is applied by most users. Management of isolated tumor cells and the role of backup lymphadenectomy for 'high-risk' cases remain areas of investigation.",Journal Article,385.0,3.0,To explore the factors influencing adoption of the sentinel lymph node SLN technique for cancer staging among gynecologic oncologists A self-administered web-based survey was sent via email April 20 through May 21 2017 to all members of European Society of Gynecologic Oncologists International Gynecologic Cancer Society and Society of Gynecologic Oncologists Surgical and pathologic practices related to SLN and reasons for not adopting this technique were investigated Overall 489 attending physicians or consultants in gynecologic oncology from 69 countries responded 201 41.1 118 24.1 and 117 23.9 from Europe the USA and other countries respectively 10.8 did not report a country SLN was adopted by 246 50.3 respondents with 93.1 injecting the cervix and 62.6 using indocyanine green dye The National Comprehensive Cancer Network SLN algorithm was followed by 160 65.0 respondents USA 74.4 Europe 55.4 other countries 71.4 However 66.7 completed a backup lymphadenectomy in high-risk patients When SLN biopsy revealed isolated tumor cells 13.8 of respondents recommended adjuvant therapy This percentage increased to 52 if micrometastases were detected Among the 243 not adopting SLN 50.2 cited lack of evidence and 45.3 stated that inadequate instrumentation fueled their decisions SLN with a injection is gaining widespread acceptance for staging of cancer among gynecologic oncologists worldwide Standardization of the surgical approach with the National Comprehensive Care Network algorithm is applied by most users Management of isolated tumor cells and the role of backup lymphadenectomy for 'high-risk cases remain areas of investigation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 1645, 3, 130, 4743, 4350, 1, 3, 1323, 263, 289, 1099, 1312, 9, 12, 632, 107, 1512, 1339, 8, 1074, 468, 3469, 90, 1407, 10, 6325, 847, 23856, 2292, 179, 298, 68, 239, 1759, 6, 62, 1684, 1, 1865, 1174, 1, 1512, 1339, 944, 1512, 12, 1174, 2, 1174, 1, 1512, 1339, 221, 2, 510, 2634, 139, 6, 1099, 2, 2325, 9, 44, 10096, 26, 1312, 11, 565, 63, 12283, 6895, 1261, 15, 45057, 4, 1512, 413, 29, 790, 2115, 2211, 4766, 605, 14, 4002, 259, 14, 2, 3843, 382, 83, 29, 3934, 3, 2706, 2, 127, 2115, 106, 79, 66, 205, 44, 414, 8, 5978, 1099, 10, 4457, 20, 6907, 212, 27, 3122, 5, 966, 14, 17121, 3, 3629, 2, 744, 49, 75, 18903, 4658, 3796, 3, 657, 949, 12, 1801, 1099, 2124, 10, 370, 20, 3457, 556, 13, 3122, 2706, 794, 39, 3934, 614, 39, 127, 2115, 792, 39, 137, 700, 67, 781, 8, 28321, 2048, 4, 64, 43, 7, 198, 1099, 411, 553, 1355, 30, 37, 233, 66, 1, 3122, 793, 249, 36, 26, 1150, 101, 6, 653, 492, 5485, 11, 530, 107, 3, 6346, 44, 10096, 1099, 212, 18, 7068, 926, 1, 241, 2, 512, 27, 8245, 17, 3358, 9166, 14767, 136, 1526, 1099, 5, 8, 1754, 16, 7312, 3029, 5080, 9, 632, 1, 12, 107, 1512, 1339, 2358, 6213, 1, 3, 221, 353, 5, 3, 657, 949, 165, 1801, 2124, 16, 1498, 20, 96, 2735, 284, 1, 1355, 30, 37, 2, 3, 200, 1, 28321, 2048, 9, 24717, 43, 140, 918, 1361, 1, 940]",1650.0,30640685,10
Trends in Risks for Second Primary Cancers Associated With Index Human Papillomavirus-Associated Cancers.,JAMA network open,JAMA Netw Open,2018-09-07,"In the last 4 decades, survival among patients with human papillomavirus (HPV)-associated cancers has improved, while the incidence of these cancers has increased among younger cohorts. Among survivors of HPV-associated cancers, persistent HPV infection may remain a risk factor for preventable HPV-associated second primary cancers (HPV-SPCs). To investigate the risk of HPV-SPCs among survivors of HPV-associated index cancers and to test the hypothesis that the HPV-SPC risk among these persons has increased over the last 4 decades. A retrospective cohort study of 9 cancer registries of the Surveillance, Epidemiology, and End Results (SEER) database was conducted to identify patients with HPV-associated (cervical, vaginal, vulvar, oropharyngeal, anal, and penile) cancers diagnosed from January 1, 1973, through December 31, 2014. The dates of analysis were July 1, 2017, to January 31, 2018. The HPV-SPC risk was quantified by calculating standard incidence ratios (SIRs) and excess absolute risks (EARs) per 10 000 person-years at risk (PYR). The HPV-SPC risk by time was estimated using Poisson regression. From 113 272 (73 085 female and 40 187 male) survivors of HPV-associated cancers, 1397 women and 1098 men developed HPV-SPCs. The SIRs for HPV-SPCs were 6.2 (95% CI, 5.9-6.6) among women and 15.8 (95% CI, 14.9-16.8) among men. The EARs were 18.2 per 10000 PYR for women and 53.5 per 10000 PYR for men. Among both women and men, those who had index oropharyngeal cancers had the highest HPV-SPC risk (SIR, 19.8 [95% CI, 18.4-21.4] and EAR, 80.6 per 10000 PYR among women; SIR, 18.0 [95% CI, 16.9-19.1] and EAR, 61.5 per 10000 PYR among men). Women who had index cervical cancers and men who had index anal cancers had the lowest HPV-SPC risk (SIR, 2.4 [95% CI, 2.2-2.7] and EAR, 4.5 per 10000 PYR among women; SIR, 6.5 [95% CI, 4.7-8.8] and EAR, 18.5 per 10000 PYR among men). Both women and men who had index HPV-associated cancers of any kind had a significantly higher risk of oropharyngeal HPV-SPCs. Over the last 4 decades, the risk of developing most types of HPV-SPCs after index cervical, vaginal, and vulvar cancers increased. According to this study, the HPV-SPC risk among survivors of HPV-associated cancers is significant, implying that persistent HPV infection at multiple sites may be associated with HPV-SPCs. These findings have the potential to inform surveillance recommendations for survivors of HPV-associated cancers.",Journal Article,501.0,4.0,In the last 4 decades survival among patients with human papillomavirus HPV -associated cancers has improved while the incidence of these cancers has increased among younger cohorts Among survivors of HPV-associated cancers persistent HPV infection may remain a risk factor for preventable HPV-associated second primary cancers HPV-SPCs To investigate the risk of HPV-SPCs among survivors of HPV-associated index cancers and to test the hypothesis that the HPV-SPC risk among these persons has increased over the last 4 decades A retrospective cohort study of 9 cancer registries of the Surveillance Epidemiology and End Results SEER database was conducted to identify patients with HPV-associated and cancers diagnosed from January 1 1973 through December 31 2014 The dates of analysis were July 1 2017 to January 31 2018 The HPV-SPC risk was quantified by calculating standard incidence ratios SIRs and excess absolute risks EARs per 10 000 person-years at risk PYR The HPV-SPC risk by time was estimated using Poisson regression From 113 272 73 085 female and 40 187 male survivors of HPV-associated cancers 1397 women and 1098 men developed HPV-SPCs The SIRs for HPV-SPCs were 6.2 95 CI 5.9-6.6 among women and 15.8 95 CI 14.9-16.8 among men The EARs were 18.2 per 10 000 PYR for women and 53.5 per 10 000 PYR for men Among both women and men those who had index cancers had the highest HPV-SPC risk SIR 19.8 95 CI 18.4-21.4 and EAR 80.6 per 10 000 PYR among women SIR 18.0 95 CI 16.9-19.1 and EAR 61.5 per 10 000 PYR among men Women who had index cancers and men who had index cancers had the lowest HPV-SPC risk SIR 2.4 95 CI 2.2-2.7 and EAR 4.5 per 10 000 PYR among women SIR 6.5 95 CI 4.7-8.8 and EAR 18.5 per 10 000 PYR among men Both women and men who had index HPV-associated cancers of any kind had a significantly higher risk of HPV-SPCs Over the last 4 decades the risk of developing most types of HPV-SPCs after index and cancers increased According to this study the HPV-SPC risk among survivors of HPV-associated cancers is significant implying that persistent HPV infection at multiple sites may be associated with HPV-SPCs These findings have the potential to inform surveillance recommendations for survivors of HPV-associated cancers,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4, 3, 1060, 39, 1968, 25, 107, 7, 5, 171, 3242, 933, 41, 163, 71, 231, 369, 3, 287, 1, 46, 163, 71, 101, 107, 773, 736, 107, 332, 1, 933, 41, 163, 1882, 933, 930, 68, 918, 8, 43, 161, 9, 7936, 933, 41, 419, 86, 163, 933, 25885, 6, 963, 3, 43, 1, 933, 25885, 107, 332, 1, 933, 41, 558, 163, 2, 6, 412, 3, 1492, 17, 3, 933, 13490, 43, 107, 46, 4327, 71, 101, 252, 3, 1060, 39, 1968, 8, 459, 180, 45, 1, 83, 12, 3768, 1, 3, 617, 1284, 2, 396, 99, 1605, 609, 10, 426, 6, 255, 7, 5, 933, 41, 2, 163, 265, 29, 1024, 14, 4756, 298, 1397, 456, 1409, 3, 9561, 1, 65, 11, 2066, 14, 1759, 6, 1024, 456, 2982, 3, 933, 13490, 43, 10, 2790, 20, 8408, 260, 287, 1137, 7120, 2, 2612, 1766, 1098, 19743, 379, 79, 984, 2719, 60, 28, 43, 17475, 3, 933, 13490, 43, 20, 98, 10, 661, 75, 7668, 320, 29, 4259, 6905, 803, 13639, 1061, 2, 327, 5568, 1045, 332, 1, 933, 41, 163, 30993, 117, 2, 39715, 325, 276, 933, 25885, 3, 7120, 9, 933, 25885, 11, 49, 18, 48, 58, 33, 83, 49, 49, 107, 117, 2, 167, 66, 48, 58, 213, 83, 245, 66, 107, 325, 3, 19743, 11, 203, 18, 379, 79, 984, 17475, 9, 117, 2, 699, 33, 379, 79, 984, 17475, 9, 325, 107, 110, 117, 2, 325, 135, 54, 42, 558, 163, 42, 3, 1076, 933, 13490, 43, 3636, 326, 66, 48, 58, 203, 39, 239, 39, 2, 7815, 493, 49, 379, 79, 984, 17475, 107, 117, 3636, 203, 13, 48, 58, 245, 83, 326, 14, 2, 7815, 713, 33, 379, 79, 984, 17475, 107, 325, 117, 54, 42, 558, 163, 2, 325, 54, 42, 558, 163, 42, 3, 2101, 933, 13490, 43, 3636, 18, 39, 48, 58, 18, 18, 18, 67, 2, 7815, 39, 33, 379, 79, 984, 17475, 107, 117, 3636, 49, 33, 48, 58, 39, 67, 66, 66, 2, 7815, 203, 33, 379, 79, 984, 17475, 107, 325, 110, 117, 2, 325, 54, 42, 558, 933, 41, 163, 1, 500, 11968, 42, 8, 97, 142, 43, 1, 933, 25885, 252, 3, 1060, 39, 1968, 3, 43, 1, 931, 96, 630, 1, 933, 25885, 50, 558, 2, 163, 101, 768, 6, 26, 45, 3, 933, 13490, 43, 107, 332, 1, 933, 41, 163, 16, 93, 7885, 17, 1882, 933, 930, 28, 232, 633, 68, 40, 41, 5, 933, 25885, 46, 272, 47, 3, 174, 6, 2295, 617, 883, 9, 332, 1, 933, 41, 163]",2254.0,30646145,840
Data-Derived Treatment Duration Goal for Cervical Cancer: Should 8 Weeks Remain the Target in the Era of Concurrent Chemoradiation?,JCO clinical cancer informatics,JCO Clin Cancer Inform,2017-11-01,"Prior studies have demonstrated the importance of treatment duration (TD) in radiation therapy (RT) for cervical cancer, with an 8-week goal based primarily on RT alone. This study uses a contemporary cohort to estimate the time point by which completion of chemoradiation therapy is most critical. The National Cancer Database was queried for women with nonmetastatic cervical cancer diagnosed from 2004 to 2012 who underwent chemotherapy, external beam RT, and brachytherapy. Data-derived TD cut points for overall survival (OS) were computed by using recursive partitioning analysis with bootstrapped aggregation (bagging) and 10-fold cross-validation. Models were independently trained with 70% of the population and validated on 30% of the population by log-rank test with and without propensity matching. Multivariable Cox proportional hazards regression was performed for the entire cohort. In all, 7,355 women were identified with a median TD of 57 days. Bagged recursive partitioning analysis converged to a mean cut point of 66.6 days (median, 64.5 days; interquartile range, 63.5 to 68.5 days). Cross-validation yielded a cut point of 63.3 days. Both cut points differentiated OS in validation. Younger age, recent diagnosis, geographic region, nongovernment insurance, shorter distance to treatment facility, metropolitan location, lower comorbidity, squamous cell carcinoma, lower stage, negative lymph nodes, and shorter TD were independently associated with longer OS. With adjustment, TD within the mean cut point (64.9 days; hazard ratio, 0.79; 95% CI, 0.73 to 0.87) and 56 days (hazard ratio, 0.87; 95% CI, 0.80 to 0.95) were associated with longer OS. Exploratory stratification suggested increasing OS detriment beyond 64 days. Shorter chemoradiation TD in cervical cancer is associated with longer survival, and TD should be minimized as much as possible. The data-derived cut point was distributed around 64 days, with a continuous relationship between shorter TD and longer OS.",Journal Article,811.0,3.0,"Prior studies have demonstrated the importance of treatment duration TD in radiation therapy RT for cancer with an 8-week goal based primarily on RT alone This study uses a contemporary cohort to estimate the time point by which completion of chemoradiation therapy is most critical The National Cancer Database was queried for women with nonmetastatic cancer diagnosed from 2004 to 2012 who underwent chemotherapy external beam RT and brachytherapy Data-derived TD cut points for overall survival OS were computed by using recursive partitioning analysis with bootstrapped aggregation bagging and 10-fold cross-validation Models were independently trained with 70 of the population and validated on 30 of the population by log-rank test with and without propensity matching Multivariable Cox proportional hazards regression was performed for the entire cohort In all 7,355 women were identified with a median TD of 57 days Bagged recursive partitioning analysis converged to a mean cut point of 66.6 days median 64.5 days interquartile range 63.5 to 68.5 days Cross-validation yielded a cut point of 63.3 days Both cut points differentiated OS in validation Younger age recent diagnosis geographic region nongovernment insurance shorter distance to treatment facility metropolitan location lower comorbidity squamous cell carcinoma lower stage negative lymph nodes and shorter TD were independently associated with longer OS With adjustment TD within the mean cut point 64.9 days hazard ratio 0.79 95 CI 0.73 to 0.87 and 56 days hazard ratio 0.87 95 CI 0.80 to 0.95 were associated with longer OS Exploratory stratification suggested increasing OS detriment beyond 64 days Shorter chemoradiation TD in cancer is associated with longer survival and TD should be minimized as much as possible The data-derived cut point was distributed around 64 days with a continuous relationship between shorter TD and longer OS",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[324, 94, 47, 264, 3, 1187, 1, 24, 654, 8325, 4, 121, 36, 240, 9, 12, 5, 35, 66, 647, 1326, 90, 1561, 23, 240, 279, 26, 45, 4025, 8, 2667, 180, 6, 1191, 3, 98, 741, 20, 92, 1438, 1, 975, 36, 16, 96, 740, 3, 657, 12, 609, 10, 3547, 9, 117, 5, 2683, 12, 265, 29, 1131, 6, 1195, 54, 208, 56, 1455, 1345, 240, 2, 1536, 74, 526, 8325, 3554, 862, 9, 63, 25, 118, 11, 1220, 20, 75, 4493, 4515, 65, 5, 22879, 6598, 38748, 2, 79, 1116, 1383, 929, 274, 11, 1042, 5946, 5, 431, 1, 3, 266, 2, 938, 23, 201, 1, 3, 266, 20, 1066, 1026, 412, 5, 2, 187, 1925, 2616, 658, 418, 831, 1017, 320, 10, 173, 9, 3, 1797, 180, 4, 62, 67, 8370, 117, 11, 108, 5, 8, 52, 8325, 1, 696, 162, 51407, 4493, 4515, 65, 20267, 6, 8, 313, 3554, 741, 1, 700, 49, 162, 52, 660, 33, 162, 2899, 184, 676, 33, 6, 806, 33, 162, 1383, 929, 2178, 8, 3554, 741, 1, 676, 27, 162, 110, 3554, 862, 1442, 118, 4, 929, 773, 89, 435, 147, 3466, 1053, 74325, 1935, 985, 3019, 6, 24, 3483, 8737, 1147, 280, 1879, 691, 31, 134, 280, 82, 199, 263, 502, 2, 985, 8325, 11, 1042, 41, 5, 589, 118, 5, 1852, 8325, 262, 3, 313, 3554, 741, 660, 83, 162, 360, 197, 13, 842, 48, 58, 13, 803, 6, 13, 912, 2, 664, 162, 360, 197, 13, 912, 48, 58, 13, 493, 6, 13, 48, 11, 41, 5, 589, 118, 2386, 1541, 1148, 602, 118, 13334, 1654, 660, 162, 985, 975, 8325, 4, 12, 16, 41, 5, 589, 25, 2, 8325, 257, 40, 9243, 22, 1802, 22, 899, 3, 74, 526, 3554, 741, 10, 4737, 3337, 660, 162, 5, 8, 1314, 858, 59, 985, 8325, 2, 589, 118]",1913.0,30657372,593
Brachytherapy: A critical component of primary radiation therapy for cervical cancer: From the Society of Gynecologic Oncology (SGO) and the American Brachytherapy Society (ABS).,Gynecologic oncology,Gynecol. Oncol.,2019-01-18,Brachytherapy is well-established as an integral component in the standard of care for treatment of patients receiving primary radiotherapy for cervical cancer. A decline in brachytherapy has been associated with negative impacts on survival in the era of modern EBRT techniques. Conformal external beam therapies such intensity modulated radiation therapy (IMRT) or stereotactic body radiation therapy (SBRT) should not be used as alternatives to brachytherapy in patients undergoing primary curative-intent radiation therapy for cervical cancer. Computed tomography or magnetic resonance image-guided adaptive brachytherapy is evolving as the preferred brachytherapy method. With careful care coordination EBRT and brachytherapy can be successfully delivered at different treatment centers without compromising treatment time and outcome in areas where access to brachytherapy maybe limited.,Journal Article,368.0,5.0,Brachytherapy is well-established as an integral component in the standard of care for treatment of patients receiving primary radiotherapy for cancer A decline in brachytherapy has been associated with negative impacts on survival in the era of modern EBRT techniques Conformal external beam therapies such intensity modulated radiation therapy IMRT or stereotactic body radiation therapy SBRT should not be used as alternatives to brachytherapy in patients undergoing primary curative-intent radiation therapy for cancer Computed tomography or magnetic resonance image-guided adaptive brachytherapy is evolving as the preferred brachytherapy method With careful care coordination EBRT and brachytherapy can be successfully delivered at different treatment centers without compromising treatment time and outcome in areas where access to brachytherapy maybe limited,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1536, 16, 149, 635, 22, 35, 4450, 1249, 4, 3, 260, 1, 165, 9, 24, 1, 7, 357, 86, 310, 9, 12, 8, 1858, 4, 1536, 71, 85, 41, 5, 199, 4719, 23, 25, 4, 3, 1713, 1, 2366, 1883, 1092, 2972, 1455, 1345, 235, 225, 837, 1757, 121, 36, 964, 15, 1729, 642, 121, 36, 1415, 257, 44, 40, 95, 22, 6295, 6, 1536, 4, 7, 479, 86, 1075, 1697, 121, 36, 9, 12, 1220, 872, 15, 1484, 1535, 1482, 1808, 2454, 1536, 16, 3276, 22, 3, 2514, 1536, 596, 5, 3465, 165, 6373, 1883, 2, 1536, 122, 40, 1878, 1623, 28, 338, 24, 1168, 187, 6102, 24, 98, 2, 228, 4, 1361, 1257, 1655, 6, 1536, 16817, 383]",866.0,30665615,415
Brachytherapy: A critical component of primary radiation therapy for cervical cancer: From the Society of Gynecologic Oncology (SGO) and the American Brachytherapy Society (ABS).,Brachytherapy,Brachytherapy,2019-01-18,Brachytherapy is well-established as an integral component in the standard of care for treatment of patients receiving primary radiotherapy for cervical cancer. A decline in brachytherapy has been associated with negative impacts on survival in the era of modern EBRT techniques. Conformal external beam therapies such intensity modulated radiation therapy (IMRT) or stereotactic body radiation therapy (SBRT) should not be used as alternatives to brachytherapy in patients undergoing primary curative-intent radiation therapy for cervical cancer. Computed tomography or magnetic resonance image-guided adaptive brachytherapy is evolving as the preferred brachytherapy method. With careful care coordination EBRT and brachytherapy can be successfully delivered at different treatment centers without compromising treatment time and outcome in areas where access to brachytherapy maybe limited.,Journal Article,368.0,6.0,Brachytherapy is well-established as an integral component in the standard of care for treatment of patients receiving primary radiotherapy for cancer A decline in brachytherapy has been associated with negative impacts on survival in the era of modern EBRT techniques Conformal external beam therapies such intensity modulated radiation therapy IMRT or stereotactic body radiation therapy SBRT should not be used as alternatives to brachytherapy in patients undergoing primary curative-intent radiation therapy for cancer Computed tomography or magnetic resonance image-guided adaptive brachytherapy is evolving as the preferred brachytherapy method With careful care coordination EBRT and brachytherapy can be successfully delivered at different treatment centers without compromising treatment time and outcome in areas where access to brachytherapy maybe limited,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1536, 16, 149, 635, 22, 35, 4450, 1249, 4, 3, 260, 1, 165, 9, 24, 1, 7, 357, 86, 310, 9, 12, 8, 1858, 4, 1536, 71, 85, 41, 5, 199, 4719, 23, 25, 4, 3, 1713, 1, 2366, 1883, 1092, 2972, 1455, 1345, 235, 225, 837, 1757, 121, 36, 964, 15, 1729, 642, 121, 36, 1415, 257, 44, 40, 95, 22, 6295, 6, 1536, 4, 7, 479, 86, 1075, 1697, 121, 36, 9, 12, 1220, 872, 15, 1484, 1535, 1482, 1808, 2454, 1536, 16, 3276, 22, 3, 2514, 1536, 596, 5, 3465, 165, 6373, 1883, 2, 1536, 122, 40, 1878, 1623, 28, 338, 24, 1168, 187, 6102, 24, 98, 2, 228, 4, 1361, 1257, 1655, 6, 1536, 16817, 383]",866.0,30665713,416
Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2019-02-02,"The impact of pathologic features of a cone biopsy on the management of women with early stage cervical cancer is understudied. Our objective was to evaluate the additive value of pathologic features of a cone biopsy toward identifying patients with high risk tumors for which adjuvant therapy may be indicated. Patients with early stage cervical cancer undergoing a conization followed by radical hysterectomy from 1995 to 2016 were retrospectively identified. Clinical and pathologic data were abstracted from patient medical records. A total of 115 patients were identified. Based on final pathology, 70.5% were low risk, 10.4% intermediate risk, and 19.1% were high risk. The additive pathologic features of the conization specimen would have reclassified five patients from low into the intermediate risk group. Though depth of invasion did not correlate with final pathology results, when lymphovascular space invasion (LVSI) was present in the conization specimen, 51.2% of patients were noted to meet intermediate/high risk; compared to only 9.5% without LVSI. In women with early stage cervical cancer, additive pathology of the conization and hysterectomy specimen did not significantly impact risk stratification, only affecting 4.3% of patients. However, presence of LVSI in the conization was associated with intermediate risk criteria in 60% of cases and high risk criteria in 37% of cases. As patients with intermediate/high risk criteria would meet recommendations for adjuvant therapy, the evaluation of LVSI in conization specimens may influence the selection of primary treatment for women with cervical cancer.",Journal Article,353.0,1.0,The impact of pathologic features of a cone biopsy on the management of women with early stage cancer is understudied Our objective was to evaluate the additive value of pathologic features of a cone biopsy toward identifying patients with high risk tumors for which adjuvant therapy may be indicated Patients with early stage cancer undergoing a conization followed by radical hysterectomy from 1995 to 2016 were retrospectively identified Clinical and pathologic data were abstracted from patient medical records A total of 115 patients were identified Based on final pathology 70.5 were low risk 10.4 intermediate risk and 19.1 were high risk The additive pathologic features of the conization specimen would have reclassified five patients from low into the intermediate risk group Though depth of invasion did not correlate with final pathology results when lymphovascular space invasion LVSI was present in the conization specimen 51.2 of patients were noted to meet intermediate/high risk compared to only 9.5 without LVSI In women with early stage cancer additive pathology of the conization and hysterectomy specimen did not significantly impact risk stratification only affecting 4.3 of patients However presence of LVSI in the conization was associated with intermediate risk criteria in 60 of cases and high risk criteria in 37 of cases As patients with intermediate/high risk criteria would meet recommendations for adjuvant therapy the evaluation of LVSI in conization specimens may influence the selection of primary treatment for women with cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 345, 1, 510, 404, 1, 8, 6939, 411, 23, 3, 284, 1, 117, 5, 191, 82, 12, 16, 8207, 114, 461, 10, 6, 376, 3, 3396, 549, 1, 510, 404, 1, 8, 6939, 411, 1317, 1386, 7, 5, 64, 43, 57, 9, 92, 249, 36, 68, 40, 1103, 7, 5, 191, 82, 12, 479, 8, 8755, 370, 20, 711, 2622, 29, 2323, 6, 1390, 11, 894, 108, 38, 2, 510, 74, 11, 4106, 29, 69, 484, 1064, 8, 181, 1, 3670, 7, 11, 108, 90, 23, 1457, 1117, 431, 33, 11, 154, 43, 79, 39, 919, 43, 2, 326, 14, 11, 64, 43, 3, 3396, 510, 404, 1, 3, 8755, 2360, 688, 47, 7864, 365, 7, 29, 154, 237, 3, 919, 43, 87, 2471, 2436, 1, 578, 205, 44, 1513, 5, 1457, 1117, 99, 198, 2933, 3865, 578, 8004, 10, 364, 4, 3, 8755, 2360, 725, 18, 1, 7, 11, 1051, 6, 3362, 919, 64, 43, 72, 6, 158, 83, 33, 187, 8004, 4, 117, 5, 191, 82, 12, 3396, 1117, 1, 3, 8755, 2, 2622, 2360, 205, 44, 97, 345, 43, 1541, 158, 2319, 39, 27, 1, 7, 137, 463, 1, 8004, 4, 3, 8755, 10, 41, 5, 919, 43, 371, 4, 335, 1, 140, 2, 64, 43, 371, 4, 567, 1, 140, 22, 7, 5, 919, 64, 43, 371, 688, 3362, 883, 9, 249, 36, 3, 451, 1, 8004, 4, 8755, 623, 68, 1054, 3, 881, 1, 86, 24, 9, 117, 5, 12]",1563.0,30718123,585
A Study of Pap Smears in HIV-Positive and HIV-Negative Women from a Tertiary Care Center in South India.,Acta cytologica,Acta Cytol.,2019-02-05,"The aim of this work was to study the spectrum of epithelial abnormalities on Pap smears of HIV-positive women categorized as per the Bethesda System of Reporting Cervical Cytology, to correlate them with CD4 lymphocyte counts, and to compare them with the spectrum of abnormalities seen in a HIV-negative control group. Study Design and Methodology: The present study was a 6-year retrospective study conducted in the Department of Pathology at Kasturba Medical College, Mangalore, which included 150 Pap smears from HIV-positive and HIV-negative women, respectively. The Pap-stained slides of the cases were retrieved and studied. The data collected were tabulated and analyzed. A statistical study was performed using SPSS software. The 2 test was used to analyze the data and a p value < 0.05 was considered to be significant. Pap smear abnormalities were twice as high in HIV-infected women (12%) as compared with HIV-negative women (6%; p = 0.006, RR = 2). Negative for intraepithelial lesion/malignancy was the most common finding (88%), which was further subdivided into inflammatory, atrophic smear, non-specific, candidiasis, and bacterial vaginitis groups. The percentage of epithelial abnormalities was 12%, including: atypical squamous cells of undetermined significance, 5.55%; atypical squamous cells, cannot exclude HSIL, 16.66%; low-grade squamous intraepithelial lesion, 5.55%; high-grade squamous intraepithelial lesion (HSIL), 61.11%, and squamous cell carcinoma, 11.11%. The highest incidence of intraepithelial lesions in HIV-positive females was in the age group of 34-49 years. CD4 cell counts fell in the range of 200-500 cells/mm3 in most of the HIV-positive patients (68.75%), but was not found to be statistically significant. Routine Pap smear examination is advocated in women with HIV as the prevalence of epithelial cell abnormalities was found to be 12%, which was twice as high as compared to the HIV-negative control group. Although there was no correlation of epithelial cell abnormalities with CD4 counts, a higher rate of the cases with epithelial abnormalities were observed to have CD4 cell counts of 200-500 cells/mm3.",Journal Article,350.0,0.0,The aim of this work was to study the spectrum of epithelial abnormalities on Pap smears of HIV-positive women categorized as per the Bethesda System of Reporting Cytology to correlate them with CD4 lymphocyte counts and to compare them with the spectrum of abnormalities seen in a HIV-negative control group Study Design and Methodology The present study was a 6-year retrospective study conducted in the Department of Pathology at Kasturba Medical College Mangalore which included 150 Pap smears from HIV-positive and HIV-negative women respectively The Pap-stained slides of the cases were retrieved and studied The data collected were tabulated and analyzed A statistical study was performed using SPSS software The 2 test was used to analyze the data and a p value 0.05 was considered to be significant Pap smear abnormalities were twice as high in HIV-infected women 12 as compared with HIV-negative women 6 p 0.006 RR 2 Negative for intraepithelial lesion/malignancy was the most common finding 88 which was further subdivided into inflammatory atrophic smear non-specific candidiasis and bacterial vaginitis groups The percentage of epithelial abnormalities was 12 including atypical squamous cells of undetermined significance 5.55 atypical squamous cells can not exclude HSIL 16.66 low-grade squamous intraepithelial lesion 5.55 high-grade squamous intraepithelial lesion HSIL 61.11 and squamous cell carcinoma 11.11 The highest incidence of intraepithelial lesions in HIV-positive females was in the age group of 34-49 years CD4 cell counts fell in the range of 200-500 cells/mm3 in most of the HIV-positive patients 68.75 but was not found to be statistically significant Routine Pap smear examination is advocated in women with HIV as the prevalence of epithelial cell abnormalities was found to be 12 which was twice as high as compared to the HIV-negative control group Although there was no correlation of epithelial cell abnormalities with CD4 counts a higher rate of the cases with epithelial abnormalities were observed to have CD4 cell counts of 200-500 cells/mm3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1130, 1, 26, 1357, 10, 6, 45, 3, 1873, 1, 701, 1171, 23, 4290, 8916, 1, 1942, 109, 117, 2320, 22, 379, 3, 8222, 398, 1, 1760, 2045, 6, 1513, 1370, 5, 1440, 1448, 1911, 2, 6, 932, 1370, 5, 3, 1873, 1, 1171, 527, 4, 8, 1942, 199, 182, 87, 45, 771, 2, 3209, 3, 364, 45, 10, 8, 49, 111, 459, 45, 426, 4, 3, 4271, 1, 1117, 28, 74375, 484, 2979, 74376, 92, 159, 1577, 4290, 8916, 29, 1942, 109, 2, 1942, 199, 117, 106, 3, 4290, 3386, 3830, 1, 3, 140, 11, 4539, 2, 656, 3, 74, 786, 11, 9903, 2, 311, 8, 1050, 45, 10, 173, 75, 11461, 3639, 3, 20721, 412, 10, 95, 6, 1992, 3, 74, 2, 8, 19, 549, 13, 474, 10, 515, 6, 40, 93, 4290, 8379, 1171, 11, 936, 22, 64, 4, 1942, 3369, 117, 133, 22, 72, 5, 1942, 199, 117, 49, 19, 13, 1861, 861, 18, 199, 9, 4153, 1180, 710, 10, 3, 96, 186, 1567, 889, 92, 10, 195, 10676, 237, 1291, 6294, 8379, 220, 112, 30874, 2, 5117, 46490, 271, 3, 1150, 1, 701, 1171, 10, 133, 141, 1973, 691, 37, 1, 5206, 724, 33, 614, 1973, 691, 37, 122, 44, 6262, 16067, 245, 700, 154, 88, 691, 4153, 1180, 33, 614, 64, 88, 691, 4153, 1180, 16067, 713, 175, 2, 691, 31, 134, 175, 175, 3, 1076, 287, 1, 4153, 406, 4, 1942, 109, 2451, 10, 4, 3, 89, 87, 1, 562, 739, 60, 1440, 31, 1911, 7689, 4, 3, 184, 1, 1250, 1666, 37, 8434, 4, 96, 1, 3, 1942, 109, 7, 806, 481, 84, 10, 44, 204, 6, 40, 712, 93, 1311, 4290, 8379, 1385, 16, 8866, 4, 117, 5, 1942, 22, 3, 1078, 1, 701, 31, 1171, 10, 204, 6, 40, 133, 92, 10, 936, 22, 64, 22, 72, 6, 3, 1942, 199, 182, 87, 242, 125, 10, 77, 816, 1, 701, 31, 1171, 5, 1440, 1911, 8, 142, 116, 1, 3, 140, 5, 701, 1171, 11, 164, 6, 47, 1440, 31, 1911, 1, 1250, 1666, 37, 8434]",2084.0,30721904,294
A mobile-phone based high-resolution microendoscope to image cervical precancer.,PloS one,PLoS ONE,2019-02-06,"Nearly 90% of cervical cancer cases and deaths occur in low- and middle-income countries that lack comprehensive national HPV immunization and cervical cancer screening programs. In these settings, it is difficult to implement screening programs due to a lack of infrastructure and shortage of trained personnel. Screening programs based on visual inspection with acetic acid (VIA) have been successfully implemented in some low-resource settings. However, VIA has poor specificity and up to 90% of patients receiving treatment based on a positive VIA exam are over-treated. A number of studies have suggested that high-resolution cervical imaging to visualize nuclear morphology in vivo can improve specificity by better distinguishing precancerous and benign lesions. To enable high-resolution imaging in low-resource settings, we developed a portable, low-cost, high-resolution microendoscope that uses a mobile phone to detect and display images of cervical epithelium in vivo with subcellular resolution. The device was fabricated for less than $2,000 using commercially available optical components including filters, an LED and triplet lenses assembled in a 3D-printed opto-mechanical mount. We show that the mobile high-resolution microendoscope achieves similar resolution and signal-to-background ratio as previously reported high-resolution microendoscope systems using traditional cameras and computers to detect and display images. Finally, we demonstrate the ability of the mobile high-resolution microendoscope to image normal and precancerous squamous epithelium of the cervix in vivo in a gynecological referral clinic in Barretos, Brazil.",Journal Article,349.0,1.0,"Nearly 90 of cancer cases and deaths occur in low- and middle-income countries that lack comprehensive national HPV immunization and cancer screening programs In these settings it is difficult to implement screening programs due to a lack of infrastructure and shortage of trained personnel Screening programs based on visual inspection with acetic acid VIA have been successfully implemented in some low-resource settings However VIA has poor specificity and up to 90 of patients receiving treatment based on a positive VIA exam are over-treated A number of studies have suggested that high-resolution imaging to visualize nuclear morphology in vivo can improve specificity by better distinguishing precancerous and benign lesions To enable high-resolution imaging in low-resource settings we developed a portable low-cost high-resolution microendoscope that uses a mobile phone to detect and display images of epithelium in vivo with subcellular resolution The device was fabricated for less than 2,000 using commercially available optical components including filters an LED and triplet lenses assembled in a 3D-printed opto-mechanical mount We show that the mobile high-resolution microendoscope achieves similar resolution and signal-to-background ratio as previously reported high-resolution microendoscope systems using traditional cameras and computers to detect and display images Finally we demonstrate the ability of the mobile high-resolution microendoscope to image normal and precancerous squamous epithelium of the cervix in vivo in a gynecological referral clinic in Barretos Brazil",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1857, 424, 1, 12, 140, 2, 1043, 1271, 4, 154, 2, 3897, 2306, 2115, 17, 926, 949, 657, 933, 4835, 2, 12, 453, 2251, 4, 46, 1947, 192, 16, 1740, 6, 6207, 453, 2251, 520, 6, 8, 926, 1, 6219, 2, 14326, 1, 5946, 13966, 453, 2251, 90, 23, 3046, 11746, 5, 16812, 971, 847, 47, 85, 1878, 3426, 4, 476, 154, 3069, 1947, 137, 847, 71, 334, 1121, 2, 126, 6, 424, 1, 7, 357, 24, 90, 23, 8, 109, 847, 6747, 32, 252, 73, 8, 207, 1, 94, 47, 1148, 17, 64, 2125, 270, 6, 9360, 928, 2567, 4, 386, 122, 401, 1121, 20, 380, 4508, 6605, 2, 1002, 406, 6, 3047, 64, 2125, 270, 4, 154, 3069, 1947, 21, 276, 8, 17302, 154, 835, 64, 2125, 19487, 17, 4025, 8, 7489, 8772, 6, 1426, 2, 3640, 1572, 1, 2781, 4, 386, 5, 7153, 2125, 3, 4472, 10, 18894, 9, 299, 76, 18, 984, 75, 5262, 390, 4303, 1628, 141, 10788, 35, 836, 2, 7706, 45418, 6154, 4, 8, 2265, 16310, 74379, 6065, 9652, 21, 514, 17, 3, 7489, 64, 2125, 19487, 6358, 288, 2125, 2, 1235, 6, 2426, 197, 22, 373, 210, 64, 2125, 19487, 1530, 75, 1847, 24716, 2, 16480, 6, 1426, 2, 3640, 1572, 1368, 21, 608, 3, 801, 1, 3, 7489, 64, 2125, 19487, 6, 1482, 295, 2, 6605, 691, 2781, 1, 3, 3629, 4, 386, 4, 8, 6324, 2096, 1188, 4, 32336, 10452]",1598.0,30726252,641
A proposal for updating the staging of endometrial cancer.,International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,Int J Gynaecol Obstet,2019-03-06,"Since the last update of the International Federation of Gynecology and Obstetrics (FIGO) staging for corpus uteri cancer in 2009, a number of new insights into pathology, molecular genetics, and prognostic factors that justify a revision have been made. We recommend incorporation of histotype and grade along with depth of myometrial invasion to define stage I endometrial cancer, a change from 3-tier grading to binary grading, and inclusion of lymph node status (negative vs not removed) in the definition of stage I disease. Elimination of cervical involvement to define stage II and inclusion of positive peritoneal cytology to upstage otherwise stage I cancers to stage IIA is also recommended. Extrauterine pelvic involvement should be classified as stage IIB disease, and stage III should be reclassified based exclusively on retroperitoneal pelvic and/or para-aortic lymph node involvement. If feasible, molecular staging by immunohistochemistry (mismatch repair proteins and p53) as well as POLE exonuclease sequencing may be carried out in order to assign one of the four categories from The Cancer Genome Atlas.",Journal Article,321.0,0.0,Since the last update of the International Federation of Gynecology and Obstetrics FIGO staging for corpus uteri cancer in 2009 a number of new insights into pathology molecular genetics and prognostic factors that justify a revision have been made We recommend incorporation of histotype and grade along with depth of myometrial invasion to define stage I cancer a change from 3-tier grading to binary grading and inclusion of lymph node status negative vs not removed in the definition of stage I disease Elimination of involvement to define stage II and inclusion of positive peritoneal cytology to upstage otherwise stage I cancers to stage IIA is also recommended Extrauterine pelvic involvement should be classified as stage IIB disease and stage III should be reclassified based exclusively on retroperitoneal pelvic and/or para-aortic lymph node involvement If feasible molecular staging by immunohistochemistry mismatch repair proteins and p53 as well as POLE exonuclease sequencing may be carried out in order to assign one of the four categories from The Cancer Genome Atlas,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[1192, 3, 1060, 2991, 1, 3, 944, 7303, 1, 6429, 2, 7407, 3837, 632, 9, 7758, 18980, 12, 4, 1238, 8, 207, 1, 217, 1957, 237, 1117, 219, 2894, 2, 177, 130, 17, 6665, 8, 5646, 47, 85, 1229, 21, 2237, 2838, 1, 16958, 2, 88, 1510, 5, 2436, 1, 7327, 578, 6, 1107, 82, 70, 12, 8, 707, 29, 27, 8377, 3452, 6, 6405, 3452, 2, 1680, 1, 263, 289, 156, 199, 105, 44, 2264, 4, 3, 2470, 1, 82, 70, 34, 3730, 1, 799, 6, 1107, 82, 215, 2, 1680, 1, 109, 1639, 2045, 6, 19328, 2632, 82, 70, 163, 6, 82, 4088, 16, 120, 793, 12115, 1110, 799, 257, 40, 1373, 22, 82, 3884, 34, 2, 82, 316, 257, 40, 7864, 90, 4437, 23, 2591, 1110, 2, 15, 4615, 3938, 263, 289, 799, 492, 1313, 219, 632, 20, 888, 2617, 972, 652, 2, 624, 22, 149, 22, 9119, 32364, 615, 68, 40, 2629, 1205, 4, 1732, 6, 11295, 104, 1, 3, 294, 1996, 29, 3, 12, 898, 2643]",1085.0,30776091,497
Cervical cancer screening in rural India: Status & current concepts.,The Indian journal of medical research,Indian J. Med. Res.,2018-12-01,"Cervical carcinoma is one of the most common and dreaded diseases of women, and in India, it accounts for 16 per cent of total cervical cancer cases occurring globally. The situation is more alarming in the rural areas where the majority of women are illiterate and ignorant about the hazards of cervical cancer. Different screening strategies such as rural cancer registries and camp approach for cancer detection have been found useful in minimizing the problem of cervical cancer in the villages. Various screening techniques such as visual inspection with acetic acid, visual inspection with Lugol's iodine, visual inspection with magnification devices-magnavisualizer, Pap smear and HPV-DNA testing have been suggested and tried under low-resource settings of our country, and cervical cytology screening has been found effective in reducing incidence of the disease. In the present review, feasibility of different screening methods has been assessed to find out the most suitable mode applicable at the rural level. Single lifetime screening particularly of high-risk women along with analysis of cost-effective tumour markers such as Argyrophilic nucleolar organizer regions (AgNOR) counts to discriminate high-risk dysplasia cases appears to be an appropriate approach in fighting against cervical cancer.",Journal Article,416.0,1.0,carcinoma is one of the most common and dreaded diseases of women and in India it accounts for 16 per cent of total cancer cases occurring globally The situation is more alarming in the rural areas where the majority of women are illiterate and ignorant about the hazards of cancer Different screening strategies such as rural cancer registries and camp approach for cancer detection have been found useful in minimizing the problem of cancer in the villages Various screening techniques such as visual inspection with acetic acid visual inspection with Lugol 's iodine visual inspection with magnification devices-magnavisualizer Pap smear and HPV-DNA testing have been suggested and tried under low-resource settings of our country and cytology screening has been found effective in reducing incidence of the disease In the present review feasibility of different screening methods has been assessed to find out the most suitable mode applicable at the rural level Single lifetime screening particularly of high-risk women along with analysis of cost-effective tumour markers such as Argyrophilic nucleolar organizer regions AgNOR counts to discriminate high-risk dysplasia cases appears to be an appropriate approach in fighting against cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[134, 16, 104, 1, 3, 96, 186, 2, 23386, 1342, 1, 117, 2, 4, 7776, 192, 4162, 9, 245, 379, 6548, 1, 181, 12, 140, 1821, 6873, 3, 7747, 16, 80, 23611, 4, 3, 5291, 1361, 1257, 3, 686, 1, 117, 32, 43385, 2, 74445, 545, 3, 1017, 1, 12, 338, 453, 422, 225, 22, 5291, 12, 3768, 2, 10837, 353, 9, 12, 638, 47, 85, 204, 999, 4, 4501, 3, 2497, 1, 12, 4, 3, 42084, 747, 453, 1092, 225, 22, 3046, 11746, 5, 16812, 971, 3046, 11746, 5, 37920, 292, 4287, 3046, 11746, 5, 22145, 6497, 74446, 4290, 8379, 2, 933, 261, 471, 47, 85, 1148, 2, 13780, 669, 154, 3069, 1947, 1, 114, 5978, 2, 2045, 453, 71, 85, 204, 323, 4, 1818, 287, 1, 3, 34, 4, 3, 364, 206, 1437, 1, 338, 453, 636, 71, 85, 275, 6, 2469, 1205, 3, 96, 2884, 4530, 3801, 28, 3, 5291, 301, 226, 2898, 453, 823, 1, 64, 43, 117, 1510, 5, 65, 1, 835, 323, 770, 525, 225, 22, 74447, 11328, 51441, 1374, 74448, 1911, 6, 5696, 64, 43, 2253, 140, 1233, 6, 40, 35, 870, 353, 4, 32814, 480, 12]",1246.0,30778002,35
Cervical congenital infantile fibrosarcoma: a case report.,Journal of medical case reports,J Med Case Rep,2019-02-24,"Congenital infantile fibrosarcoma is a rare mesenchymal tumor seen in children as well as adults. The congenital variety is rare and out of the reported cases only one case sited in the neck has been reported so far. Another such case is presented here who was successfully managed. A 3-month-old Hindu baby boy presented with a congenital neck swelling. The apparent clinical diagnosis was lympho-venous malformation. With a remote possibility of malignancy, an excisional biopsy was done. Histopathology revealed congenital infantile fibrosarcoma. A successful excision of cervical congenital infantile fibrosarcoma has not been reported. This diagnosis should be kept as a possibility in all congenital cervical swellings. These are commonly misdiagnosed as lympho-venous malformations and histopathology is confirmatory.",Case Reports,331.0,0.0,Congenital infantile fibrosarcoma is a rare mesenchymal tumor seen in children as well as adults The congenital variety is rare and out of the reported cases only one case sited in the has been reported so far Another such case is presented here who was successfully managed A 3-month-old Hindu baby boy presented with a congenital swelling The apparent clinical diagnosis was lympho-venous malformation With a remote possibility of malignancy an excisional biopsy was done Histopathology revealed congenital infantile fibrosarcoma A successful excision of congenital infantile fibrosarcoma has not been reported This diagnosis should be kept as a possibility in all congenital swellings These are commonly misdiagnosed as lympho-venous malformations and histopathology is confirmatory,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6711, 15935, 8378, 16, 8, 622, 1569, 30, 527, 4, 541, 22, 149, 22, 857, 3, 6711, 1362, 16, 622, 2, 1205, 1, 3, 210, 140, 158, 104, 473, 74475, 4, 3, 71, 85, 210, 1743, 3272, 1809, 225, 473, 16, 917, 467, 54, 10, 1878, 2231, 8, 27, 811, 1095, 74476, 25200, 10802, 917, 5, 8, 6711, 6967, 3, 2235, 38, 147, 10, 20183, 2167, 14595, 5, 8, 9879, 2526, 1, 710, 35, 6488, 411, 10, 1822, 3831, 553, 6711, 15935, 8378, 8, 1401, 1366, 1, 6711, 15935, 8378, 71, 44, 85, 210, 26, 147, 257, 40, 11322, 22, 8, 2526, 4, 62, 6711, 74477, 46, 32, 841, 10688, 22, 20183, 2167, 11756, 2, 3831, 16, 5697]",785.0,30797242,824
Simple Hysterectomy for Cervical Cancer: Risk Factors for Failed Screening and Deviation From Screening Guidelines.,Journal of lower genital tract disease,J Low Genit Tract Dis,2019-04-01,"The aim of this study is to describe risk factors associated with either false-negative cervical cancer screening or deviations from screening guidelines that result in incidentally found invasive cervical cancer at the time of simple hysterectomy for benign indications. This is a retrospective review from 1990 to 2017 of subjects with incidental cervical cancer. Baseline demographics, preoperative evaluations, surgical data, and histopathologic characteristics were recorded. Deviations from screening guidelines or false-negative screenings were identified. Associations of independent risk factors according to age, insurance status, and histology were assessed. Fifty-nine subjects with a median age of 43 years were found. Abnormal uterine bleeding was the most common indication for hysterectomy (61%, n = 36) and cervical dysplasia was present in 42% (n = 25) of these cases. Of those with inappropriate screening, 38% (n = 17) did not have documented Pap test, 22% (n = 10) had Pap that was not triaged appropriately, 18% (n = 8) received Pap and colposcopy but no indicated excisional procedure, and 22% (n = 10) had an excisional procedure that was not managed according to guidelines. False-negative screening occurred in 25% subjects (n = 15). There was no significant association between age, insurance status, or histology and risk of false-negative screening or inadequate screening. The most common cause of incidental cervical cancer at the time of simple hysterectomy was failure to properly adhere to screening guidelines. Less frequently, false-negative screening was the cause. No independent risk factor in either group was identified in this single institutional study. Illustrated is the importance of continuing education of surgeons about adequate screening in the preoperative evaluation for benign hysterectomy.",Journal Article,295.0,0.0,The aim of this study is to describe risk factors associated with either false-negative cancer screening or deviations from screening guidelines that result in incidentally found invasive cancer at the time of simple hysterectomy for benign indications This is a retrospective review from 1990 to 2017 of subjects with incidental cancer Baseline demographics preoperative evaluations surgical data and histopathologic characteristics were recorded Deviations from screening guidelines or false-negative screenings were identified Associations of independent risk factors according to age insurance status and histology were assessed Fifty-nine subjects with a median age of 43 years were found Abnormal bleeding was the most common indication for hysterectomy 61 n 36 and dysplasia was present in 42 n 25 of these cases Of those with inappropriate screening 38 n 17 did not have documented Pap test 22 n 10 had Pap that was not triaged appropriately 18 n 8 received Pap and colposcopy but no indicated excisional procedure and 22 n 10 had an excisional procedure that was not managed according to guidelines False-negative screening occurred in 25 subjects n 15 There was no significant association between age insurance status or histology and risk of false-negative screening or inadequate screening The most common cause of incidental cancer at the time of simple hysterectomy was failure to properly adhere to screening guidelines Less frequently false-negative screening was the cause No independent risk factor in either group was identified in this single institutional study Illustrated is the importance of continuing education of surgeons about adequate screening in the preoperative evaluation for benign hysterectomy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 1130, 1, 26, 45, 16, 6, 897, 43, 130, 41, 5, 361, 2133, 199, 12, 453, 15, 7810, 29, 453, 677, 17, 757, 4, 5925, 204, 416, 12, 28, 3, 98, 1, 2763, 2622, 9, 1002, 2406, 26, 16, 8, 459, 206, 29, 2289, 6, 1759, 1, 976, 5, 4490, 12, 330, 2221, 498, 3816, 221, 74, 2, 2630, 374, 11, 1872, 7810, 29, 453, 677, 15, 2133, 199, 14317, 11, 108, 685, 1, 306, 43, 130, 768, 6, 89, 1935, 156, 2, 784, 11, 275, 1461, 762, 976, 5, 8, 52, 89, 1, 601, 60, 11, 204, 1668, 2294, 10, 3, 96, 186, 3607, 9, 2622, 713, 78, 511, 2, 2253, 10, 364, 4, 595, 78, 243, 1, 46, 140, 1, 135, 5, 5148, 453, 519, 78, 269, 205, 44, 47, 1405, 4290, 412, 350, 78, 79, 42, 4290, 17, 10, 44, 20774, 4544, 203, 78, 66, 103, 4290, 2, 9946, 84, 77, 1103, 6488, 1299, 2, 350, 78, 79, 42, 35, 6488, 1299, 17, 10, 44, 2231, 768, 6, 677, 2133, 199, 453, 489, 4, 243, 976, 78, 167, 125, 10, 77, 93, 248, 59, 89, 1935, 156, 15, 784, 2, 43, 1, 2133, 199, 453, 15, 3358, 453, 3, 96, 186, 708, 1, 4490, 12, 28, 3, 98, 1, 2763, 2622, 10, 496, 6, 6785, 11898, 6, 453, 677, 299, 746, 2133, 199, 453, 10, 3, 708, 77, 306, 43, 161, 4, 361, 87, 10, 108, 4, 26, 226, 1115, 45, 8508, 16, 3, 1187, 1, 4346, 1848, 1, 1613, 545, 1658, 453, 4, 3, 498, 451, 9, 1002, 2622]",1728.0,30817687,502
Prevalence of high-grade anal dysplasia among women with high-grade lower genital tract dysplasia or cancer: Results of a pilot study.,Gynecologic oncology,Gynecol. Oncol.,2019-03-01,"To estimate the prevalence of high-grade anal dysplasia in women with high-grade dysplasia or carcinoma of the cervix, vagina or vulva. In this cross-sectional study, participants underwent anal cytology, anal HPV testing with Cervista HPV16/18 and high-resolution anoscopy (HRA). Patients with HSIL (high-grade squamous cell intraepithelial lesion) or greater on anal cytology or anal biopsy were referred to a colorectal surgery specialist for further evaluation. Seventy-five women were enrolled in the study, including 47 with cervical (cervix group), 10 with vaginal (vagina group), 15 with vulvar (vulva group), 1 with cervical and vaginal, and 2 with vulvar and vaginal disease. The median age in the cervix group (40years (range 26-69)) was substantially younger than in the vagina (60years (38-69)) and the vulva (59years (36-75)) groups. Anal HSIL based on composite endpoints of the most severe cytology or histology result was diagnosed in 6 patients (8.0%). Anal cytology revealed HSIL in 2 (2.7%), atypical squamous cells of undetermined significance (ASCUS) in 12 (16.0%), low-grade squamous cell intraepithelial lesion (LSIL) in 2 (2.7%), and was normal in 59 (78.7%) patients. Anal HPV16/18 test was positive in 15 (20.0%), negative in 48 (64.0%) and insufficient in 12 (16.0%) patients. Of the 6 women with high-grade anal dysplasia, three (50%) had a positive anal HPV16/18 test. No case of anal cancer was observed. Our results suggest that the prevalence of anal HSIL is elevated among women with HPV-related lower genital tract dysplasia or cancer. To further support the inclusion of this high-risk group into screening guidelines for anal dysplasia, further studies are necessary to determine what screening strategy is suited to this population.",Journal Article,326.0,2.0,To estimate the prevalence of high-grade dysplasia in women with high-grade dysplasia or carcinoma of the cervix vagina or vulva In this cross-sectional study participants underwent cytology HPV testing with Cervista HPV16/18 and high-resolution anoscopy HRA Patients with HSIL high-grade squamous cell intraepithelial lesion or greater on cytology or biopsy were referred to a surgery specialist for further evaluation Seventy-five women were enrolled in the study including 47 with cervix group 10 with vagina group 15 with vulva group 1 with and and 2 with and disease The median age in the cervix group 40 years range 26-69 was substantially younger than in the vagina 60 years 38-69 and the vulva 59 years 36-75 groups HSIL based on composite endpoints of the most severe cytology or histology result was diagnosed in 6 patients 8.0 cytology revealed HSIL in 2 2.7 atypical squamous cells of undetermined significance ASCUS in 12 16.0 low-grade squamous cell intraepithelial lesion LSIL in 2 2.7 and was normal in 59 78.7 patients HPV16/18 test was positive in 15 20.0 negative in 48 64.0 and insufficient in 12 16.0 patients Of the 6 women with high-grade dysplasia three 50 had a positive HPV16/18 test No case of cancer was observed Our results suggest that the prevalence of HSIL is elevated among women with HPV-related lower genital tract dysplasia or cancer To further support the inclusion of this high-risk group into screening guidelines for dysplasia further studies are necessary to determine what screening strategy is suited to this population,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1191, 3, 1078, 1, 64, 88, 2253, 4, 117, 5, 64, 88, 2253, 15, 134, 1, 3, 3629, 7553, 15, 9263, 4, 26, 1383, 2832, 45, 776, 208, 2045, 933, 471, 5, 74507, 4048, 203, 2, 64, 2125, 21979, 20959, 7, 5, 16067, 64, 88, 691, 31, 4153, 1180, 15, 378, 23, 2045, 15, 411, 11, 1995, 6, 8, 152, 6554, 9, 195, 451, 2073, 365, 117, 11, 346, 4, 3, 45, 141, 662, 5, 3629, 87, 79, 5, 7553, 87, 167, 5, 9263, 87, 14, 5, 2, 2, 18, 5, 2, 34, 3, 52, 89, 4, 3, 3629, 87, 327, 60, 184, 432, 790, 10, 2109, 773, 76, 4, 3, 7553, 335, 60, 519, 790, 2, 3, 9263, 728, 60, 511, 481, 271, 16067, 90, 23, 3308, 1387, 1, 3, 96, 905, 2045, 15, 784, 757, 10, 265, 4, 49, 7, 66, 13, 2045, 553, 16067, 4, 18, 18, 67, 1973, 691, 37, 1, 5206, 724, 21337, 4, 133, 245, 13, 154, 88, 691, 31, 4153, 1180, 17849, 4, 18, 18, 67, 2, 10, 295, 4, 728, 833, 67, 7, 4048, 203, 412, 10, 109, 4, 167, 179, 13, 199, 4, 576, 660, 13, 2, 3027, 4, 133, 245, 13, 7, 1, 3, 49, 117, 5, 64, 88, 2253, 169, 212, 42, 8, 109, 4048, 203, 412, 77, 473, 1, 12, 10, 164, 114, 99, 309, 17, 3, 1078, 1, 16067, 16, 804, 107, 117, 5, 933, 139, 280, 8226, 1696, 2253, 15, 12, 6, 195, 538, 3, 1680, 1, 26, 64, 43, 87, 237, 453, 677, 9, 2253, 195, 94, 32, 1493, 6, 223, 2067, 453, 692, 16, 7247, 6, 26, 266]",1562.0,30827725,866
A comparative analysis of quality of life after postoperative intensity-modulated radiotherapy or three-dimensional conformal radiotherapy for cervical cancer.,Indian journal of cancer,Indian J Cancer,,"The aim of this study is to compare the quality of life (QOL) between adjuvant three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiotherapy (IMRT) for cervical cancer. QOL assessment was done at the baseline and then longitudinally after completing (chemo) radiation. All patients completed EORTC QLQ-C30 and EORTC QLQ Cx-24 modules. Independent-sample t-test was used to compare the mean scores between the two groups. Analysis of variance was used to compare differences in QOL measures over the six time points (baseline, post-RT, 3, 6, 9, and 12 months after treatment) and between treatment groups (3DCRT vs. IMRT). Linear mixed model was also performed to account for attrition. Overall, 64 patients (image-guided IMRT, n = 40 and 3DCRT, n = 24) completed QOL assessment. The median age and follow-up period were 48 years and 15.5 months, respectively. General QOL domains such as emotional (at 12 months, P = 0.04) and social (at 3 months, P = 0.02 and 12 months, P = 0.03) were better with IMRT. Pain (12 months, P = 0.03); fatigue (12 months, P = 0.05); nausea and vomiting (12 months, P = 0.03); insomnia (post-RT, P = 0.05 and 12 months, P = 0.03); appetite loss (post-RT and 12 months, P = 0.04); and diarrhea (6 months, P = 0.02 and 12 months, P = 0.003) scores were significantly better with IMRT. On linear mixed model analysis, there was a significant interaction between treatment cohort and assessment intervals for physical, emotional, and social functioning, appetite loss, diarrhea, lymphedema, and menopausal symptom scores were significantly better with IMRT. Treatment technique (IMRT vs. 3DCRT) impacts early QOL in undergoing adjuvant radiation for cervical cancer.",Comparative Study,,1.0,The aim of this study is to compare the quality of life QOL between adjuvant three-dimensional conformal radiotherapy 3DCRT or intensity-modulated radiotherapy IMRT for cancer QOL assessment was done at the baseline and then longitudinally after completing chemo radiation All patients completed EORTC QLQ-C30 and EORTC QLQ Cx-24 modules Independent-sample t-test was used to compare the mean scores between the two groups Analysis of variance was used to compare differences in QOL measures over the six time points baseline post-RT 3 6 9 and 12 months after treatment and between treatment groups 3DCRT vs. IMRT Linear mixed model was also performed to account for attrition Overall 64 patients image-guided IMRT n 40 and 3DCRT n 24 completed QOL assessment The median age and follow-up period were 48 years and 15.5 months respectively General QOL domains such as emotional at 12 months P 0.04 and social at 3 months P 0.02 and 12 months P 0.03 were better with IMRT Pain 12 months P 0.03 fatigue 12 months P 0.05 nausea and vomiting 12 months P 0.03 insomnia post-RT P 0.05 and 12 months P 0.03 appetite loss post-RT and 12 months P 0.04 and diarrhea 6 months P 0.02 and 12 months P 0.003 scores were significantly better with IMRT On linear mixed model analysis there was a significant interaction between treatment cohort and assessment intervals for physical emotional and social functioning appetite loss diarrhea lymphedema and menopausal symptom scores were significantly better with IMRT Treatment technique IMRT vs. 3DCRT impacts early QOL in undergoing adjuvant radiation for cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1130, 1, 26, 45, 16, 6, 932, 3, 372, 1, 358, 1001, 59, 249, 169, 2201, 2972, 310, 8295, 15, 837, 1757, 310, 964, 9, 12, 1001, 455, 10, 1822, 28, 3, 330, 2, 818, 9278, 50, 4144, 3341, 121, 62, 7, 781, 4359, 5144, 6273, 2, 4359, 5144, 13627, 259, 11153, 306, 1000, 102, 412, 10, 95, 6, 932, 3, 313, 703, 59, 3, 100, 271, 65, 1, 4446, 10, 95, 6, 932, 362, 4, 1001, 1018, 252, 3, 437, 98, 862, 330, 539, 240, 27, 49, 83, 2, 133, 53, 50, 24, 2, 59, 24, 271, 8295, 105, 964, 1646, 1739, 202, 10, 120, 173, 6, 1967, 9, 9174, 63, 660, 7, 1482, 1808, 964, 78, 327, 2, 8295, 78, 259, 781, 1001, 455, 3, 52, 89, 2, 166, 126, 727, 11, 576, 60, 2, 167, 33, 53, 106, 1083, 1001, 2703, 225, 22, 2671, 28, 133, 53, 19, 13, 755, 2, 2032, 28, 27, 53, 19, 13, 588, 2, 133, 53, 19, 13, 680, 11, 380, 5, 964, 559, 133, 53, 19, 13, 680, 613, 133, 53, 19, 13, 474, 1218, 2, 1966, 133, 53, 19, 13, 680, 8055, 539, 240, 19, 13, 474, 2, 133, 53, 19, 13, 680, 4062, 407, 539, 240, 2, 133, 53, 19, 13, 755, 2, 1172, 49, 53, 19, 13, 588, 2, 133, 53, 19, 13, 1421, 703, 11, 97, 380, 5, 964, 23, 1646, 1739, 202, 65, 125, 10, 8, 93, 915, 59, 24, 180, 2, 455, 1582, 9, 900, 2671, 2, 2032, 2702, 4062, 407, 1172, 3063, 2, 3565, 934, 703, 11, 97, 380, 5, 964, 24, 1312, 964, 105, 8295, 4719, 191, 1001, 4, 479, 249, 121, 9, 12]",1595.0,30829265,808
Minimally Invasive Esophageal Cancer Surgery.,Surgical oncology clinics of North America,Surg. Oncol. Clin. N. Am.,2019-02-02,"Laparoscopic and thoracoscopic or robotic-assisted minimally invasive esophagectomy offers benefits in decreased postoperative complications and faster recovery. The choice of operation depends on patient and surgeon factors. McKeown or 3-field esophagectomy requires dissection in the abdomen, chest, and neck, with a cervical anastomosis. Ivor Lewis esophagectomy is performed with abdominal and right chest dissection and intrathoracic anastomosis. Transhiatal or transmediastinal esophagectomy is performed with abdominal and cervical dissections and a cervical anastomosis and is preferential in patients with significant pulmonary risk factors. Preparation and operative conduct for laparoscopic and robotic approaches for these operations, and the expected postoperative recovery are detailed.",Journal Article,353.0,0.0,Laparoscopic and thoracoscopic or robotic-assisted minimally invasive esophagectomy offers benefits in decreased postoperative complications and faster recovery The choice of operation depends on patient and surgeon factors McKeown or 3-field esophagectomy requires dissection in the abdomen chest and with a anastomosis Ivor Lewis esophagectomy is performed with abdominal and right chest dissection and intrathoracic anastomosis Transhiatal or transmediastinal esophagectomy is performed with abdominal and dissections and a anastomosis and is preferential in patients with significant pulmonary risk factors Preparation and operative conduct for laparoscopic and robotic approaches for these operations and the expected postoperative recovery are detailed,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1964, 2, 5752, 15, 2895, 2927, 2144, 416, 3617, 2339, 1141, 4, 340, 573, 521, 2, 5308, 1602, 3, 1866, 1, 2589, 3828, 23, 69, 2, 1897, 130, 36229, 15, 27, 1067, 3617, 1706, 1161, 4, 3, 4036, 1662, 2, 5, 8, 5519, 14776, 9449, 3617, 16, 173, 5, 1467, 2, 1913, 1662, 1161, 2, 7359, 5519, 14120, 15, 74547, 3617, 16, 173, 5, 1467, 2, 6894, 2, 8, 5519, 2, 16, 6629, 4, 7, 5, 93, 1087, 43, 130, 4824, 2, 1208, 4073, 9, 1964, 2, 2895, 611, 9, 46, 3867, 2, 3, 1336, 573, 1602, 32, 2455]",758.0,30851822,550
"Four percent formalin application for the management of radiation proctitis in carcinoma cervix patients: An effective, safe, and economical practice.",Journal of cancer research and therapeutics,J Cancer Res Ther,,"Radiotherapy is a very effective treatment modality for pelvic malignancies such as carcinoma of the cervix. However, it is quite common for chronic radiation proctitis (CRP) to manifest after radical radiotherapy. CRP is a source of significant morbidity, and there is a lack of effective treatment modalities. There also exists a general lack of guidelines on management of CRP. To assess the benefit from 4% formalin application for the treatment of Grade >2 CRP among patients previously treated with radical radiotherapy for cervical carcinoma. This retrospective descriptive study involved 29 eligible patients who were treated from November 2010 - November 2015 for CRP with 4% formalin application. Of the 1864 patients of carcinoma cervix treated during the said patients, 29 patients fulfilled the eligibility criteria. Eligible patients were invited telephonically for follow-up and were assessed for response and complications of the procedure. The treatment of hemorrhagic radiation proctitis with local formalin instillation is effective, well tolerated and safe procedure. The procedure is inexpensive, technically simple and can be done on an outpatient basis. 62% patients had complete freedom from rectal bleed, while 34.5% patients had partial benefit. Only one patient required diversion colostomy for persistent bleeding.",Journal Article,,0.0,Radiotherapy is a very effective treatment modality for pelvic malignancies such as carcinoma of the cervix However it is quite common for chronic radiation proctitis CRP to manifest after radical radiotherapy CRP is a source of significant morbidity and there is a lack of effective treatment modalities There also exists a general lack of guidelines on management of CRP To assess the benefit from 4 formalin application for the treatment of Grade 2 CRP among patients previously treated with radical radiotherapy for carcinoma This retrospective descriptive study involved 29 eligible patients who were treated from November 2010 November 2015 for CRP with 4 formalin application Of the 1864 patients of carcinoma cervix treated during the said patients 29 patients fulfilled the eligibility criteria Eligible patients were invited telephonically for follow-up and were assessed for response and complications of the procedure The treatment of hemorrhagic radiation proctitis with local formalin instillation is effective well tolerated and safe procedure The procedure is inexpensive technically simple and can be done on an outpatient basis 62 patients had complete freedom from bleed while 34.5 patients had partial benefit Only one patient required diversion colostomy for persistent bleeding,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,"[310, 16, 8, 923, 323, 24, 1396, 9, 1110, 441, 225, 22, 134, 1, 3, 3629, 137, 192, 16, 6223, 186, 9, 442, 121, 17612, 3162, 6, 7633, 50, 711, 310, 3162, 16, 8, 2353, 1, 93, 787, 2, 125, 16, 8, 926, 1, 323, 24, 1558, 125, 120, 2481, 8, 1083, 926, 1, 677, 23, 284, 1, 3162, 6, 423, 3, 247, 29, 39, 3265, 1581, 9, 3, 24, 1, 88, 18, 3162, 107, 7, 373, 73, 5, 711, 310, 9, 134, 26, 459, 3778, 45, 646, 462, 625, 7, 54, 11, 73, 29, 2868, 1120, 2868, 1483, 9, 3162, 5, 39, 3265, 1581, 1, 3, 27870, 7, 1, 134, 3629, 73, 190, 3, 12159, 7, 462, 7, 9091, 3, 2317, 371, 625, 7, 11, 7594, 74574, 9, 166, 126, 2, 11, 275, 9, 51, 2, 521, 1, 3, 1299, 3, 24, 1, 6998, 121, 17612, 5, 293, 3265, 13561, 16, 323, 149, 421, 2, 1165, 1299, 3, 1299, 16, 8168, 6093, 2763, 2, 122, 40, 1822, 23, 35, 2379, 877, 744, 7, 42, 236, 3060, 29, 19502, 369, 562, 33, 7, 42, 450, 247, 158, 104, 69, 616, 6067, 7635, 9, 1882, 2294]",1299.0,30880761,48
Reproductive counseling and pregnancy outcomes after radical trachelectomy for early stage cervical cancer.,Journal of gynecologic oncology,J Gynecol Oncol,2019-05-01,"To evaluate patient perceptions of preoperative reproductive counseling and to evaluate complications and pregnancy outcomes in women who had radical trachelectomy (RT) for early stage cervical cancer. Patients who underwent RT from January 1, 2004, through July 31, 2017, and had been cancer free for more than 1 year after RT were eligible; consented patients were sent a 16-item online survey. Of the 58 eligible patients, 39 patients (67%) completed the questionnaire. Eighteen patients (46%) reported receiving reproductive counseling and 26 (68%) reported receiving counseling about pregnancy risks and complications prior to RT, mainly delivered by gynecologic oncologists. Twenty-nine patients (74%) reported having a complication after RT, and cervical stenosis was the most common complication, occurring in 13 patients (33%). Twenty-four patients actively attempted to conceive after RT, and 20 pregnancies were achieved in 13 patients for a pregnancy rate of 54%. Eight pregnancies were spontaneous and 12 required a fertility treatment. There were 5 spontaneous first-trimester miscarriages; 14 of the 20 pregnancies (70%) resulted in live births. The median time to conception was 13.5 months (range, 1-120). A significant proportion of women with early stage cervical cancer do not receive adequate reproductive counseling before RT, and many women undergoing RT experience complications that can negatively impact their fertility. We recommend a preoperative consultation with a reproductive endocrinologist for all patients considering RT.",Journal Article,265.0,2.0,To evaluate patient perceptions of preoperative reproductive counseling and to evaluate complications and pregnancy outcomes in women who had radical trachelectomy RT for early stage cancer Patients who underwent RT from January 1 2004 through July 31 2017 and had been cancer free for more than 1 year after RT were eligible consented patients were sent a 16-item online survey Of the 58 eligible patients 39 patients 67 completed the questionnaire Eighteen patients 46 reported receiving reproductive counseling and 26 68 reported receiving counseling about pregnancy risks and complications prior to RT mainly delivered by gynecologic oncologists Twenty-nine patients 74 reported having a complication after RT and stenosis was the most common complication occurring in 13 patients 33 Twenty-four patients actively attempted to conceive after RT and 20 pregnancies were achieved in 13 patients for a pregnancy rate of 54 Eight pregnancies were spontaneous and 12 required a fertility treatment There were 5 spontaneous first-trimester miscarriages 14 of the 20 pregnancies 70 resulted in live births The median time to conception was 13.5 months range 1-120 A significant proportion of women with early stage cancer do not receive adequate reproductive counseling before RT and many women undergoing RT experience complications that can negatively impact their fertility We recommend a preoperative consultation with a reproductive endocrinologist for all patients considering RT,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 69, 3746, 1, 498, 3705, 2011, 2, 6, 376, 521, 2, 2290, 123, 4, 117, 54, 42, 711, 5760, 240, 9, 191, 82, 12, 7, 54, 208, 240, 29, 1024, 14, 1131, 298, 2066, 456, 1759, 2, 42, 85, 12, 115, 9, 80, 76, 14, 111, 50, 240, 11, 625, 8199, 7, 11, 6325, 8, 245, 3471, 4123, 1407, 1, 3, 717, 625, 7, 587, 7, 598, 781, 3, 1770, 3195, 7, 641, 210, 357, 3705, 2011, 2, 432, 806, 210, 357, 2011, 545, 2290, 1098, 2, 521, 324, 6, 240, 2615, 1623, 20, 1512, 1339, 737, 762, 7, 794, 210, 1041, 8, 1447, 50, 240, 2, 6935, 10, 3, 96, 186, 1447, 1821, 4, 233, 7, 466, 737, 294, 7, 4489, 4098, 6, 34874, 50, 240, 2, 179, 8746, 11, 513, 4, 233, 7, 9, 8, 2290, 116, 1, 667, 659, 8746, 11, 3280, 2, 133, 616, 8, 2954, 24, 125, 11, 33, 3280, 157, 12693, 22124, 213, 1, 3, 179, 8746, 431, 627, 4, 3812, 9951, 3, 52, 98, 6, 17273, 10, 233, 33, 53, 184, 14, 2031, 8, 93, 920, 1, 117, 5, 191, 82, 12, 1022, 44, 560, 1658, 3705, 2011, 348, 240, 2, 445, 117, 479, 240, 730, 521, 17, 122, 2723, 345, 136, 2954, 21, 2237, 8, 498, 2981, 5, 8, 3705, 25277, 9, 62, 7, 3075, 240]",1482.0,30887762,363
"Cervical, Vaginal, and Vulvar Cancer Costs Incurred by the Medicaid Program in Publicly Insured Patients in Texas.",Journal of lower genital tract disease,J Low Genit Tract Dis,2019-04-01,"To determine from the perspective of the State of Texas, the direct medical care costs associated with cervical, vaginal, and vulvar cancers in Texas Medicaid enrollees. We conducted a case-control study and searched Texas Medicaid databases between 2008 and 2012 for eligible cancer patients. A comparison group was selected for each cancer site using a 2-step 1:1 propensity score matching method. Patients were followed for 2 years after cancer diagnosis to estimate monthly and yearly direct medical costs. For each cancer site, the differential cost between patients and the matched comparison individuals was the estimated cost associated with cancer. The study included 583 cervical, 62 vaginal, and 137 vulvar cancer patients and equal numbers of cancer-free comparison individuals. Among the cases, 322 cervical cancer patients, 46 vaginal cancer patients, and 102 vulvar cancer patients were Medicaid-Medicare dual eligible enrollees. For Medicaid-only enrollees, the adjusted first- and second-year mean total differential costs were US $19,859 and $3,110 for cervical cancer, US $19,627 and $4,582 for vaginal cancer, and US $7,631 and $777 for vulvar cancer patients, respectively. For Medicaid-Medicare dual eligible enrollees, adjusted first- and second-year mean total differential costs incurred by Medicaid were US $2,565 and $792 for cervical cancer, US $1,293 and $181 for vaginal cancer, and US $1,774 and $1,049 for vulvar cancer patients, respectively. The direct medical costs associated with cervical, vaginal, and vulvar cancers in Texas Medicaid were substantial in the first 2 years after cancer diagnosis, but dual eligibility for Medicare coverage attenuated Medicaid costs.",Journal Article,295.0,0.0,"To determine from the perspective of the State of Texas the direct medical care costs associated with and cancers in Texas Medicaid enrollees We conducted a case-control study and searched Texas Medicaid databases between 2008 and 2012 for eligible cancer patients A comparison group was selected for each cancer site using a 2-step 1:1 propensity score matching method Patients were followed for 2 years after cancer diagnosis to estimate monthly and yearly direct medical costs For each cancer site the differential cost between patients and the matched comparison individuals was the estimated cost associated with cancer The study included 583 62 and 137 cancer patients and equal numbers of cancer-free comparison individuals Among the cases 322 cancer patients 46 cancer patients and 102 cancer patients were Medicaid-Medicare dual eligible enrollees For Medicaid-only enrollees the adjusted first- and second-year mean total differential costs were US 19,859 and 3,110 for cancer US 19,627 and 4,582 for cancer and US 7,631 and 777 for cancer patients respectively For Medicaid-Medicare dual eligible enrollees adjusted first- and second-year mean total differential costs incurred by Medicaid were US 2,565 and 792 for cancer US 1,293 and 181 for cancer and US 1,774 and 1,049 for cancer patients respectively The direct medical costs associated with and cancers in Texas Medicaid were substantial in the first 2 years after cancer diagnosis but dual eligibility for Medicare coverage attenuated Medicaid costs",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 29, 3, 3727, 1, 3, 1309, 1, 2738, 3, 1196, 484, 165, 1201, 41, 5, 2, 163, 4, 2738, 2843, 9888, 21, 426, 8, 473, 182, 45, 2, 3080, 2738, 2843, 2348, 59, 1375, 2, 1195, 9, 625, 12, 7, 8, 1155, 87, 10, 715, 9, 296, 12, 606, 75, 8, 18, 2458, 14, 14, 1925, 368, 2616, 596, 7, 11, 370, 9, 18, 60, 50, 12, 147, 6, 1191, 3889, 2, 9460, 1196, 484, 1201, 9, 296, 12, 606, 3, 1777, 835, 59, 7, 2, 3, 655, 1155, 869, 10, 3, 661, 835, 41, 5, 12, 3, 45, 159, 12876, 744, 2, 4352, 12, 7, 2, 2997, 1870, 1, 12, 115, 1155, 869, 107, 3, 140, 8024, 12, 7, 641, 12, 7, 2, 2867, 12, 7, 11, 2843, 1378, 1828, 625, 9888, 9, 2843, 158, 9888, 3, 586, 157, 2, 419, 111, 313, 181, 1777, 1201, 11, 843, 326, 20149, 2, 27, 3129, 9, 12, 843, 326, 13598, 2, 39, 13909, 9, 12, 2, 843, 67, 14576, 2, 12021, 9, 12, 7, 106, 9, 2843, 1378, 1828, 625, 9888, 586, 157, 2, 419, 111, 313, 181, 1777, 1201, 11172, 20, 2843, 11, 843, 18, 10852, 2, 13760, 9, 12, 843, 14, 7541, 2, 5540, 9, 12, 2, 843, 14, 11927, 2, 14, 5121, 9, 12, 7, 106, 3, 1196, 484, 1201, 41, 5, 2, 163, 4, 2738, 2843, 11, 1281, 4, 3, 157, 18, 60, 50, 12, 147, 84, 1828, 2317, 9, 1378, 2139, 2656, 2843, 1201]",1518.0,30907776,122
The Extent of Neck Dissection Among Patients Who Receive Adjuvant Radiotherapy for HNSCC and Its Effect on Disease-Specific and Overall Survival.,"Ear, nose, & throat journal",Ear Nose Throat J,2019-04-04,"The study objective was to assess if the extent of neck dissection among patients who receive adjuvant radiotherapy affects regional recurrence and survival. This was a retrospective study of patients who had clinical metastatic mucosal primary squamous cell carcinoma (SCC) to cervical lymph nodes done at Roswell Park Comprehensive Cancer Center, Buffalo, New York from 2004 to 2015. Patients with previous radiotherapy and/or chemotherapy were excluded. All patients had surgery to the primary tumor and the neck followed by adjuvant (chemo) radiation. Patients have been divided into 2 groups according to type of neck dissection as either selective neck dissection (SND) or comprehensive neck dissection (CND). The extent of neck dissection was determined by surgeon preference. All patients received postoperative radiotherapy to the primary tumor bed and to the neck with or without chemotherapy. Main outcomes were measured in regional recurrence and overall survival. In our study, 74 patients were included. Among the 2 groups of patients, 3-year outcomes for regional recurrence occurred in 4 (7.1%) of 56 patients in the SND group and 2 (11.1%) of 18 patients in the CND group. Overall survival was 29 (51.8%) of 56 patients in the SND group and 11 (61.1%) of 18 patients in the CND group ( P = .497). Among patients who died in each cohort, disease-specific death was 20 (74.1%) of 27 patients in the SND group and 5 (71.4%) of 7 patients in the CND group ( P = .79).The overall and disease-specific survival differences between the SND and CND cohorts were not statistically significant. In conclusion, SND, combined with proper adjuvant treatment, achieved regional control and survival rates comparable to CND.",Journal Article,292.0,0.0,The study objective was to assess if the extent of dissection among patients who receive adjuvant radiotherapy affects regional recurrence and survival This was a retrospective study of patients who had clinical metastatic mucosal primary squamous cell carcinoma SCC to lymph nodes done at Roswell Park Comprehensive Cancer Center Buffalo New York from 2004 to 2015 Patients with previous radiotherapy and/or chemotherapy were excluded All patients had surgery to the primary tumor and the followed by adjuvant chemo radiation Patients have been divided into 2 groups according to type of dissection as either selective dissection SND or comprehensive dissection CND The extent of dissection was determined by surgeon preference All patients received postoperative radiotherapy to the primary tumor bed and to the with or without chemotherapy Main outcomes were measured in regional recurrence and overall survival In our study 74 patients were included Among the 2 groups of patients 3-year outcomes for regional recurrence occurred in 4 7.1 of 56 patients in the SND group and 2 11.1 of 18 patients in the CND group Overall survival was 29 51.8 of 56 patients in the SND group and 11 61.1 of 18 patients in the CND group P .497 Among patients who died in each cohort disease-specific death was 20 74.1 of 27 patients in the SND group and 5 71.4 of 7 patients in the CND group P .79 .The overall and disease-specific survival differences between the SND and CND cohorts were not statistically significant In conclusion SND combined with proper adjuvant treatment achieved regional control and survival rates comparable to CND,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 45, 461, 10, 6, 423, 492, 3, 1039, 1, 1161, 107, 7, 54, 560, 249, 310, 2561, 951, 146, 2, 25, 26, 10, 8, 459, 45, 1, 7, 54, 42, 38, 113, 3068, 86, 691, 31, 134, 1791, 6, 263, 502, 1822, 28, 9970, 9151, 949, 12, 574, 22061, 217, 5050, 29, 1131, 6, 1483, 7, 5, 698, 310, 2, 15, 56, 11, 1800, 62, 7, 42, 152, 6, 3, 86, 30, 2, 3, 370, 20, 249, 3341, 121, 7, 47, 85, 2176, 237, 18, 271, 768, 6, 267, 1, 1161, 22, 361, 1094, 1161, 15314, 15, 949, 1161, 14287, 3, 1039, 1, 1161, 10, 509, 20, 1897, 3863, 62, 7, 103, 573, 310, 6, 3, 86, 30, 2929, 2, 6, 3, 5, 15, 187, 56, 1895, 123, 11, 644, 4, 951, 146, 2, 63, 25, 4, 114, 45, 794, 7, 11, 159, 107, 3, 18, 271, 1, 7, 27, 111, 123, 9, 951, 146, 489, 4, 39, 67, 14, 1, 664, 7, 4, 3, 15314, 87, 2, 18, 175, 14, 1, 203, 7, 4, 3, 14287, 87, 63, 25, 10, 462, 725, 66, 1, 664, 7, 4, 3, 15314, 87, 2, 175, 713, 14, 1, 203, 7, 4, 3, 14287, 87, 19, 11178, 107, 7, 54, 1016, 4, 296, 180, 34, 112, 273, 10, 179, 794, 14, 1, 428, 7, 4, 3, 15314, 87, 2, 33, 792, 39, 1, 67, 7, 4, 3, 14287, 87, 19, 842, 3, 63, 2, 34, 112, 25, 362, 59, 3, 15314, 2, 14287, 736, 11, 44, 712, 93, 4, 1221, 15314, 397, 5, 4576, 249, 24, 513, 951, 182, 2, 25, 151, 1279, 6, 14287]",1626.0,30943803,200
Molecular mechanisms in progression of HPV-associated cervical carcinogenesis.,Journal of biomedical science,J. Biomed. Sci.,2019-04-23,"Cervical cancer is the fourth most frequent cancer in women worldwide and a major cause of mortality in developing countries. Persistent infection with high-risk human papillomavirus (HPV) is a necessary cause for the development of cervical cancer. In addition, genetic and epigenetic alterations in host cell genes are crucial for progression of cervical precancerous lesions to invasive cancer. Although much progress has been made in understanding the life cycle of HPV and it's role in the development of cervical cancer, there is still a critical need for accurate surveillance strategies and targeted therapeutic options to eradicate these cancers in patients. Given the widespread nature of HPV infection and the type specificity of currently available HPV vaccines, it is crucial that molecular details of the natural history of HPV infection as well as the biological activities of viral oncoproteins be elucidated. A better understanding of the mechanisms involved in oncogenesis can provide novel insights and opportunities for designing effective therapeutic approaches against HPV-associated malignancies. In this review, we briefly summarize epigenetic alterations and events that cause alterations in host genomes inducing cell cycle deregulation, aberrant proliferation and genomic instability contributing to tumorigenesis.",Journal Article,273.0,3.0,cancer is the fourth most frequent cancer in women worldwide and a major cause of mortality in developing countries Persistent infection with high-risk human papillomavirus HPV is a necessary cause for the development of cancer In addition genetic and epigenetic alterations in host cell genes are crucial for progression of precancerous lesions to invasive cancer Although much progress has been made in understanding the life cycle of HPV and it 's role in the development of cancer there is still a critical need for accurate surveillance strategies and targeted therapeutic options to eradicate these cancers in patients Given the widespread nature of HPV infection and the type specificity of currently available HPV vaccines it is crucial that molecular details of the natural history of HPV infection as well as the biological activities of viral oncoproteins be elucidated A better understanding of the mechanisms involved in oncogenesis can provide novel insights and opportunities for designing effective therapeutic approaches against HPV-associated malignancies In this review we briefly summarize epigenetic alterations and events that cause alterations in host genomes inducing cell cycle deregulation aberrant proliferation and genomic instability contributing to tumorigenesis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 16, 3, 3608, 96, 908, 12, 4, 117, 2358, 2, 8, 458, 708, 1, 282, 4, 931, 2115, 1882, 930, 5, 64, 43, 171, 3242, 933, 16, 8, 1493, 708, 9, 3, 193, 1, 12, 4, 352, 336, 2, 1418, 593, 4, 1204, 31, 214, 32, 2653, 9, 91, 1, 6605, 406, 6, 416, 12, 242, 1802, 1466, 71, 85, 1229, 4, 612, 3, 358, 417, 1, 933, 2, 192, 292, 200, 4, 3, 193, 1, 12, 125, 16, 1234, 8, 740, 594, 9, 1481, 617, 422, 2, 238, 189, 838, 6, 5650, 46, 163, 4, 7, 447, 3, 3029, 2202, 1, 933, 930, 2, 3, 267, 1121, 1, 694, 390, 933, 1842, 192, 16, 2653, 17, 219, 3791, 1, 3, 1504, 532, 1, 933, 930, 22, 149, 22, 3, 1037, 2042, 1, 1667, 8241, 40, 3901, 8, 380, 612, 1, 3, 483, 646, 4, 4503, 122, 377, 229, 1957, 2, 2605, 9, 5048, 323, 189, 611, 480, 933, 41, 441, 4, 26, 206, 21, 6277, 2479, 1418, 593, 2, 281, 17, 708, 593, 4, 1204, 5085, 1958, 31, 417, 4765, 1898, 457, 2, 572, 1753, 3156, 6, 1565]",1292.0,31014351,167
"Cervical Cancer Screening Services at Tertiary Healthcare
Facility: An Alternative Approach",Asian Pacific journal of cancer prevention : APJCP,Asian Pac. J. Cancer Prev.,2019-04-29,"Introduction: India fights massive cervical cancer burden. This article highlights an innovative feasible approach
enabling tertiary hospitals to contribute to cancer prevention without compromising their primary mandate to provide
treatment. Methodology: Since 1979, National Institute of Cancer Prevention and Research (NICPR) support a tertiary
hospital in cervical cancer screening through a satellite clinic. Record review of 5328 attendees of this clinic between
January-December 2016 was done. Pap-smear testing and reporting were performed by trained NICPR personnel. Patients
demographics, reproductive history, Pap-test date, cytology results were recorded and results were communicated to
respective units for further management. Results: Among 5328 women screened, 2% (96/5328) had abnormal cytology,
which included malignancy(33%; 32/96), Atypical Squamous Cells-Undetermined Significance(ASC-US) (20%;
19/96), Atypical Glandular Cells(AGC) (23%; 22/96) with complaints of pain in lower abdomen 65.6%(59/90), white
discharge per vaginum 46.7%(42/90) and backache 23.3%(21/90). In which, Muslims- 67% (65/96), illiterates- 58%
(56/96). Age>35(p<0.001), parity>3(p<0.05), illiteracy (p<0.05), Muslim women (p<0.05) had positive association with
abnormal cytology. Conclusion: Awareness about cervical cancer screening is the immediate need in resource-limited
countries. Government hospitals in such countries should house dedicated preventive oncology unit for cancer screening.",Journal Article,267.0,1.0,Introduction India fights massive cancer burden This article highlights an innovative feasible approach enabling tertiary hospitals to contribute to cancer prevention without compromising their primary mandate to provide treatment Methodology Since 1979 National Institute of Cancer Prevention and Research NICPR support a tertiary hospital in cancer screening through a satellite clinic Record review of 5328 attendees of this clinic between January-December 2016 was done Pap-smear testing and reporting were performed by trained NICPR personnel Patients demographics reproductive history Pap-test date cytology results were recorded and results were communicated to respective units for further management Results Among 5328 women screened 2 96/5328 had abnormal cytology which included malignancy 33 32/96 Atypical Squamous Cells-Undetermined Significance ASC-US 20 19/96 Atypical Glandular Cells AGC 23 22/96 with complaints of pain in lower abdomen 65.6 59/90 white discharge per vaginum 46.7 42/90 and backache 23.3 21/90 In which Muslims- 67 65/96 illiterates- 58 56/96 Age 35 p 0.001 parity 3 p 0.05 illiteracy p 0.05 Muslim women p 0.05 had positive association with abnormal cytology Conclusion Awareness about cancer screening is the immediate need in resource-limited countries Government hospitals in such countries should house dedicated preventive oncology unit for cancer screening,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2456, 7776, 51512, 7929, 12, 892, 26, 946, 2527, 35, 4019, 1313, 353, 5257, 2557, 1987, 6, 1248, 6, 12, 1070, 187, 6102, 136, 86, 12493, 6, 377, 24, 3209, 1192, 9444, 657, 1377, 1, 12, 1070, 2, 389, 51513, 538, 8, 2557, 702, 4, 12, 453, 298, 8, 10193, 1188, 3237, 206, 1, 36751, 13670, 1, 26, 1188, 59, 1024, 1397, 1390, 10, 1822, 4290, 8379, 471, 2, 1760, 11, 173, 20, 5946, 51513, 13966, 7, 2221, 3705, 532, 4290, 412, 1244, 2045, 99, 11, 1872, 2, 99, 11, 15175, 6, 3847, 2960, 9, 195, 284, 99, 107, 36751, 117, 2261, 18, 921, 36751, 42, 1668, 2045, 92, 159, 710, 466, 531, 921, 1973, 691, 37, 5206, 724, 5203, 843, 179, 326, 921, 1973, 6170, 37, 10490, 382, 350, 921, 5, 6938, 1, 559, 4, 280, 4036, 556, 49, 728, 424, 886, 2993, 379, 74730, 641, 67, 595, 424, 2, 45383, 382, 27, 239, 424, 4, 92, 74731, 598, 556, 921, 51514, 717, 664, 921, 89, 465, 19, 13, 144, 5754, 27, 19, 13, 474, 51515, 19, 13, 474, 41495, 117, 19, 13, 474, 42, 109, 248, 5, 1668, 2045, 1221, 3310, 545, 12, 453, 16, 3, 2181, 594, 4, 3069, 383, 2115, 7608, 1987, 4, 225, 2115, 257, 10087, 4827, 3494, 413, 2712, 9, 12, 453]",1398.0,31030504,522
Interpreting Randomized Clinical Trials in Gynecologic Oncology Surgery: Does One Size Fit All?,American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting,Am Soc Clin Oncol Educ Book,2019-05-17,"Randomized clinical trials (RCTs) are considered the gold standard of clinical research. They are designed to eliminate bias and to produce objective and generalizable results about new treatment paradigms. Although RCTs have recognized limitations, including long completion time and high cost, they also have transformed clinical research and improved the quality of health care by rigorously evaluating countless new treatment options. Surgical RCTs present their own unique set of limitations including an inability to standardize surgical technique and expertise; an inability to overcome enrollment bias by enrolling surgeons; and a lack of generalizability with respect to institutional resources and abilities. Here, we discuss surgical RCTs in two domains: upfront management of advanced ovarian cancer and surgical management of early-stage cervical cancer. Familiarity with the abundant retrospective data available for both of these clinical scenarios as well as recognition of the strengths and limitations of surgical RCTs are critical to determine the best treatment for an individual patient.",Journal Article,249.0,,Randomized clinical trials RCTs are considered the gold standard of clinical research They are designed to eliminate bias and to produce objective and generalizable results about new treatment paradigms Although RCTs have recognized limitations including long completion time and high cost they also have transformed clinical research and improved the quality of health care by rigorously evaluating countless new treatment options Surgical RCTs present their own unique set of limitations including an inability to standardize surgical technique and expertise an inability to overcome enrollment bias by enrolling surgeons and a lack of generalizability with respect to institutional resources and abilities Here we discuss surgical RCTs in two domains upfront management of advanced cancer and surgical management of early-stage cancer Familiarity with the abundant retrospective data available for both of these clinical scenarios as well as recognition of the strengths and limitations of surgical RCTs are critical to determine the best treatment for an individual patient,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[384, 38, 143, 4335, 32, 515, 3, 4159, 260, 1, 38, 389, 491, 32, 1114, 6, 4964, 2947, 2, 6, 2410, 461, 2, 12313, 99, 545, 217, 24, 4887, 242, 4335, 47, 1904, 1939, 141, 319, 1438, 98, 2, 64, 835, 491, 120, 47, 2423, 38, 389, 2, 231, 3, 372, 1, 341, 165, 20, 10347, 1435, 26289, 217, 24, 838, 221, 4335, 364, 136, 4165, 991, 916, 1, 1939, 141, 35, 4985, 6, 9211, 221, 1312, 2, 4935, 35, 4985, 6, 1768, 1798, 2947, 20, 6280, 1613, 2, 8, 926, 1, 10214, 5, 2184, 6, 1115, 2892, 2, 7965, 467, 21, 1139, 221, 4335, 4, 100, 2703, 2941, 284, 1, 131, 12, 2, 221, 284, 1, 191, 82, 12, 10322, 5, 3, 4834, 459, 74, 390, 9, 110, 1, 46, 38, 3964, 22, 149, 22, 2335, 1, 3, 9127, 2, 1939, 1, 221, 4335, 32, 740, 6, 223, 3, 824, 24, 9, 35, 797, 69]",1077.0,31099641,275
Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy.,Gynecologic oncology,Gynecol. Oncol.,2019-05-16,"Women with endometrial or cervical cancer at risk for recurrence receive postoperative radiation therapy (RT). A patient reported outcomes (PRO) instrument to assess bowel and urinary toxicities is the Expanded Prostate Cancer Index Composite (EPIC), which has been validated in men with prostate cancer. As this instrument specifically measures bowel toxicity and the degree to which this is a problem, it was used in NRG Oncology/RTOG 1203 to compare intensity modulated RT (IMRT) to standard RT. This paper reports on the expanded validation of EPIC for use in women receiving pelvic RT. In addition to the EPIC bowel domain, urinary toxicity (EPIC urinary domain), patient reported bowel toxicities (PRO-CTCAE) and quality of life (Functional Assessment of Cancer Therapy (FACT)) were completed before, during and after treatment. Sensitivity, reliability and concurrent validity were assessed. Mean bowel and urinary scores among 278 women enrolled were significantly worse during treatment and differed between groups. Acceptable to good reliability for bowel and urinary domain scores were obtained at all time points with the exception of one at baseline. Correlations between function and bother scores within the bowel and urinary domains were consistently stronger than those across domains. Correlations between bowel domain scores and PRO-CTCAE during treatment were stronger than those with the FACT. Correlations within and among the instruments indicate EPIC bowel and urinary domains are measuring conceptually discrete components of health. These EPIC domains are valid, reliable and sensitive instruments to measure PRO among women undergoing pelvic radiation.",Journal Article,250.0,1.0,Women with or cancer at risk for recurrence receive postoperative radiation therapy RT A patient reported outcomes PRO instrument to assess bowel and urinary toxicities is the Expanded Cancer Index Composite EPIC which has been validated in men with cancer As this instrument specifically measures bowel toxicity and the degree to which this is a problem it was used in NRG Oncology/RTOG 1203 to compare intensity modulated RT IMRT to standard RT This paper reports on the expanded validation of EPIC for use in women receiving pelvic RT In addition to the EPIC bowel domain urinary toxicity EPIC urinary domain patient reported bowel toxicities PRO-CTCAE and quality of life Functional Assessment of Cancer Therapy FACT were completed before during and after treatment Sensitivity reliability and concurrent validity were assessed Mean bowel and urinary scores among 278 women enrolled were significantly worse during treatment and differed between groups Acceptable to good reliability for bowel and urinary domain scores were obtained at all time points with the exception of one at baseline Correlations between function and bother scores within the bowel and urinary domains were consistently stronger than those across domains Correlations between bowel domain scores and PRO-CTCAE during treatment were stronger than those with the FACT Correlations within and among the instruments indicate EPIC bowel and urinary domains are measuring conceptually discrete components of health These EPIC domains are valid reliable and sensitive instruments to measure PRO among women undergoing pelvic radiation,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[117, 5, 15, 12, 28, 43, 9, 146, 560, 573, 121, 36, 240, 8, 69, 210, 123, 1805, 3877, 6, 423, 1659, 2, 1660, 385, 16, 3, 2064, 12, 558, 3308, 8995, 92, 71, 85, 938, 4, 325, 5, 12, 22, 26, 3877, 1225, 1018, 1659, 155, 2, 3, 1444, 6, 92, 26, 16, 8, 2497, 192, 10, 95, 4, 8828, 413, 3931, 31119, 6, 932, 837, 1757, 240, 964, 6, 260, 240, 26, 2817, 1198, 23, 3, 2064, 929, 1, 8995, 9, 119, 4, 117, 357, 1110, 240, 4, 352, 6, 3, 8995, 1659, 1398, 1660, 155, 8995, 1660, 1398, 69, 210, 1659, 385, 1805, 3898, 2, 372, 1, 358, 583, 455, 1, 12, 36, 1991, 11, 781, 348, 190, 2, 50, 24, 485, 4217, 2, 750, 3099, 11, 275, 313, 1659, 2, 1660, 703, 107, 9128, 117, 346, 11, 97, 639, 190, 24, 2, 2512, 59, 271, 1595, 6, 1178, 4217, 9, 1659, 2, 1660, 1398, 703, 11, 683, 28, 62, 98, 862, 5, 3, 4188, 1, 104, 28, 330, 2553, 59, 343, 2, 9873, 703, 262, 3, 1659, 2, 1660, 2703, 11, 2433, 3355, 76, 135, 716, 2703, 2553, 59, 1659, 1398, 703, 2, 1805, 3898, 190, 24, 11, 3355, 76, 135, 5, 3, 1991, 2553, 262, 2, 107, 3, 4730, 1008, 8995, 1659, 2, 1660, 2703, 32, 2978, 13825, 5447, 1628, 1, 341, 46, 8995, 2703, 32, 4406, 2450, 2, 745, 4730, 6, 1463, 1805, 107, 117, 479, 1110, 121]",1605.0,31104905,819
"Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.",Gynecologic oncology,Gynecol. Oncol.,2019-05-20,"Improved treatment for advanced cervical cancer is needed; currently, treatment options include combined chemotherapy and bevacizumab or pembrolizumab monotherapy for PD-L1 positive disease. PIK3CA and KRAS mutations have been reported in cervical cancers; this study therefore tested dual inhibition of PI3K and RAS signaling by combining the MEK inhibitor trametinib and the AKT inhibitor GSK2141795 in recurrent cervical cancer. This was an investigator-initiated phase II study combining trametinib and GSK2141795 in patients with recurrent cervical cancer. Primary endpoint was best tumor response; secondary endpoints included progression free survival, overall survival, and safety assessment. Translational objectives included characterization of molecular alterations in PI3K and RAS signaling pathway genes. Planned accrual was 35 patients; 14 patients were enrolled and received at least one dose of study drug before the study was terminated due to discontinuation of GSK2141795 development. There were no confirmed responses; 1 patient had an unconfirmed PR, 8 had stable disease, 3 had progression as best response, and 2 were unevaluable. Toxicities were mostly grade 1 and 2, although 57% of patients experienced grade 3/4 adverse events and 50% patients required a dose reduction. The combination of trametinib and GSK2141795 was feasible but required dose holds and modifications for adverse events; however, anti-cancer activity was minimal, even in patients with PI3K or RAS pathway alterations. Although the study was terminated early after GSK2141795 development was halted, the findings in these 14 patients do not support further development of this combination in cervical cancer.","Clinical Trial, Phase II",246.0,0.0,Improved treatment for advanced cancer is needed currently treatment options include combined chemotherapy and bevacizumab or pembrolizumab monotherapy for PD-L1 positive disease PIK3CA and KRAS mutations have been reported in cancers this study therefore tested dual inhibition of PI3K and RAS signaling by combining the MEK inhibitor trametinib and the AKT inhibitor GSK2141795 in recurrent cancer This was an investigator-initiated phase II study combining trametinib and GSK2141795 in patients with recurrent cancer Primary endpoint was best tumor response secondary endpoints included progression free survival overall survival and safety assessment Translational objectives included characterization of molecular alterations in PI3K and RAS signaling pathway genes Planned accrual was 35 patients 14 patients were enrolled and received at least one dose of study drug before the study was terminated due to discontinuation of GSK2141795 development There were no confirmed responses 1 patient had an unconfirmed PR 8 had stable disease 3 had progression as best response and 2 were unevaluable Toxicities were mostly grade 1 and 2 although 57 of patients experienced grade 3/4 adverse events and 50 patients required a dose reduction The combination of trametinib and GSK2141795 was feasible but required dose holds and modifications for adverse events however anti-cancer activity was minimal even in patients with PI3K or RAS pathway alterations Although the study was terminated early after GSK2141795 development was halted the findings in these 14 patients do not support further development of this combination in cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[231, 24, 9, 131, 12, 16, 575, 694, 24, 838, 643, 397, 56, 2, 599, 15, 2233, 1411, 9, 333, 729, 109, 34, 1506, 2, 723, 138, 47, 85, 210, 4, 163, 26, 45, 673, 650, 1828, 297, 1, 974, 2, 1102, 314, 20, 1525, 3, 1693, 230, 3858, 2, 3, 649, 230, 18719, 4, 387, 12, 26, 10, 35, 3464, 1917, 124, 215, 45, 1525, 3858, 2, 18719, 4, 7, 5, 387, 12, 86, 1138, 10, 824, 30, 51, 568, 1387, 159, 91, 115, 25, 63, 25, 2, 367, 455, 2460, 2409, 159, 2136, 1, 219, 593, 4, 974, 2, 1102, 314, 308, 214, 1465, 2262, 10, 465, 7, 213, 7, 11, 346, 2, 103, 28, 506, 104, 61, 1, 45, 234, 348, 3, 45, 10, 5640, 520, 6, 2007, 1, 18719, 193, 125, 11, 77, 557, 253, 14, 69, 42, 35, 5971, 998, 66, 42, 585, 34, 27, 42, 91, 22, 824, 51, 2, 18, 11, 18257, 385, 11, 2754, 88, 14, 2, 18, 242, 696, 1, 7, 592, 88, 27, 39, 290, 281, 2, 212, 7, 616, 8, 61, 628, 3, 150, 1, 3858, 2, 18719, 10, 1313, 84, 616, 61, 5253, 2, 2916, 9, 290, 281, 137, 312, 12, 128, 10, 1048, 871, 4, 7, 5, 974, 15, 1102, 308, 593, 242, 3, 45, 10, 5640, 191, 50, 18719, 193, 10, 9473, 3, 272, 4, 46, 213, 7, 1022, 44, 538, 195, 193, 1, 26, 150, 4, 12]",1632.0,31118140,638
Development and Implementation of a Simulation-Based Educational Workshop on Gynecological Brachytherapy: Pilot Study at a National Meeting.,Practical radiation oncology,Pract Radiat Oncol,2019-05-22,"Despite the importance of brachytherapy in the curative treatment of locally advanced cervical cancer, reviews of practice patterns in the United States have identified a decline in brachytherapy use in clinically appropriate patient populations. A survey of radiation oncologists identified lack of time and lack of guidance as barriers. To address these barriers, the purpose of this study was to develop a simulation-based educational (SBE) gynecologic brachytherapy workshop. The SBE gynecologic brachytherapy workshop was developed with expertise from 2 institutions, combining procedural simulation with a practical discussion of brachytherapy applicator insertion techniques. The primary outcome was feasibility of workshop deployment, defined as completion of all workshop components in the time allotted. Preworkshop and postworkshop surveys were also administered to assess efficacy, a secondary outcome. The workshop took place at a national radiation oncology meeting, and all workshop components were completed in the 2hours allotted. SBE stations focused on (1) fiducial placement, (2-3) applicator selection, (4) suturing, and (5) pelvic examination and applicator placement. Fourteen participants completed surveys. Respondents included residents and attending physicians. More than 50% of respondents were from academic practices and practiced gynecologic brachytherapy weekly or more. Curricular objectives for this workshop were for 20% trainees to report increased confidence in practice and 20% of trainees to report increased familiarity with applicators. After participation in the workshop, confidence in applicator choice improved in 9 of 13 participants (69%), confidence in complication management improved in 8 of 13 participants (62%), and familiarity with applicators improved in 7 of 13 participants (54%). These differences were statistically significant at =.05. This study demonstrated feasibility in using simulation for gynecologic brachytherapy education at a national meeting. Although most respondents were experienced in brachytherapy, more than half reported increased confidence and familiarity with aspects of the procedure after the workshop. Future work should address interstitial needle placement and improved time management of workshop stations.",Journal Article,244.0,1.0,Despite the importance of brachytherapy in the curative treatment of locally advanced cancer reviews of practice patterns in the United States have identified a decline in brachytherapy use in clinically appropriate patient populations A survey of radiation oncologists identified lack of time and lack of guidance as barriers To address these barriers the purpose of this study was to develop a simulation-based educational SBE gynecologic brachytherapy workshop The SBE gynecologic brachytherapy workshop was developed with expertise from 2 institutions combining procedural simulation with a practical discussion of brachytherapy applicator insertion techniques The primary outcome was feasibility of workshop deployment defined as completion of all workshop components in the time allotted Preworkshop and postworkshop surveys were also administered to assess efficacy a secondary outcome The workshop took place at a national radiation oncology meeting and all workshop components were completed in the 2 hours allotted SBE stations focused on 1 fiducial placement 2-3 applicator selection 4 suturing and 5 pelvic examination and applicator placement Fourteen participants completed surveys Respondents included residents and attending physicians More than 50 of respondents were from academic practices and practiced gynecologic brachytherapy weekly or more Curricular objectives for this workshop were for 20 trainees to report increased confidence in practice and 20 of trainees to report increased familiarity with applicators After participation in the workshop confidence in applicator choice improved in 9 of 13 participants 69 confidence in complication management improved in 8 of 13 participants 62 and familiarity with applicators improved in 7 of 13 participants 54 These differences were statistically significant at .05 This study demonstrated feasibility in using simulation for gynecologic brachytherapy education at a national meeting Although most respondents were experienced in brachytherapy more than half reported increased confidence and familiarity with aspects of the procedure after the workshop Future work should address interstitial needle placement and improved time management of workshop stations,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[550, 3, 1187, 1, 1536, 4, 3, 1075, 24, 1, 795, 131, 12, 2004, 1, 758, 764, 4, 3, 1088, 907, 47, 108, 8, 1858, 4, 1536, 119, 4, 505, 870, 69, 1184, 8, 1407, 1, 121, 1339, 108, 926, 1, 98, 2, 926, 1, 2753, 22, 2160, 6, 1539, 46, 2160, 3, 743, 1, 26, 45, 10, 6, 690, 8, 4026, 90, 3624, 19514, 1512, 1536, 4014, 3, 19514, 1512, 1536, 4014, 10, 276, 5, 4935, 29, 18, 1764, 1525, 8492, 4026, 5, 8, 3320, 2488, 1, 1536, 8789, 5099, 1092, 3, 86, 228, 10, 1437, 1, 4014, 13512, 395, 22, 1438, 1, 62, 4014, 1628, 4, 3, 98, 31441, 51535, 2, 74823, 3666, 11, 120, 468, 6, 423, 209, 8, 568, 228, 3, 4014, 5060, 3536, 28, 8, 657, 121, 413, 2238, 2, 62, 4014, 1628, 11, 781, 4, 3, 18, 1459, 31441, 19514, 9105, 1649, 23, 14, 8416, 2613, 18, 27, 8789, 881, 39, 35601, 2, 33, 1110, 1385, 2, 8789, 2613, 3225, 776, 781, 3666, 3122, 159, 5662, 2, 6895, 1261, 80, 76, 212, 1, 3122, 11, 29, 1916, 2634, 2, 11121, 1512, 1536, 709, 15, 80, 74824, 2409, 9, 26, 4014, 11, 9, 8076, 11695, 6, 414, 101, 307, 4, 758, 2, 8076, 1, 11695, 6, 414, 101, 10322, 5, 11800, 50, 2599, 4, 3, 4014, 307, 4, 8789, 1866, 231, 4, 83, 1, 233, 776, 790, 307, 4, 1447, 284, 231, 4, 66, 1, 233, 776, 744, 2, 10322, 5, 11800, 231, 4, 67, 1, 233, 776, 667, 46, 362, 11, 712, 93, 28, 474, 26, 45, 264, 1437, 4, 75, 4026, 9, 1512, 1536, 1848, 28, 8, 657, 2238, 242, 96, 3122, 11, 592, 4, 1536, 80, 76, 1303, 210, 101, 307, 2, 10322, 5, 2695, 1, 3, 1299, 50, 3, 4014, 508, 1357, 257, 1539, 4543, 2177, 2613, 2, 231, 98, 284, 1, 4014, 9105]",2235.0,31128303,101
Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes.,Gynecologic oncology,Gynecol. Oncol.,2019-06-14,"The Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) is a national survey of inpatient experience. This study evaluated the association between HCAHPS survey results and outcomes in gynecologic cancer surgery. This observational study used HCAHPS survey data from 2009 to 2011 to assign hospitals into score terciles. The Nationwide Inpatient Sample (NIS) database was used to identify admissions during the same time period for gynecologic cancer-specific surgeries. Data sources were linked at the hospital level. Postoperative complications, mortality, and prolonged length of stay were compared between higher and lower scoring hospitals. Complications were grouped as 'surgical', 'medical', or 'care team'. Mixed effects models were used to evaluate the associations between hospitals' HCAHPS scores and outcomes after adjustment for patient and hospital-level variables. 17,509 linked encounters in 651 hospitals across the U.S. were identified, with 51% uterine, 40% ovarian, and 9% cervical cancer surgical admissions. In-hospital mortality was lower in hospitals in the top HCAHPS score terciles compared to bottom HCAHPS score tercile (odds ratio (OR) 0.54, 95% CI: 0.31-0.94). Surgery in higher scoring HCAHPS hospitals was associated with less 'surgical' complications (OR 0.82, 95% CI 0.69-0.98). No association was found between 'medical', 'care team', overall complications, or prolonged hospitalization (p>0.05) and HCAHPS scores. Gynecologic oncology surgeries performed in top HCAHPS tercile hospitals were associated with lower in-hospital mortality and surgical complications compared to surgeries performed in bottom tercile hospitals. Associations between HCAHPS scores and other adverse events were not seen.",Journal Article,221.0,0.0,"The Hospital Consumer Assessment of Healthcare Providers and Systems HCAHPS is a national survey of inpatient experience This study evaluated the association between HCAHPS survey results and outcomes in gynecologic cancer surgery This observational study used HCAHPS survey data from 2009 to 2011 to assign hospitals into score terciles The Nationwide Inpatient Sample NIS database was used to identify admissions during the same time period for gynecologic cancer-specific surgeries Data sources were linked at the hospital level Postoperative complications mortality and prolonged length of stay were compared between higher and lower scoring hospitals Complications were grouped as 'surgical 'medical or 'care team Mixed effects models were used to evaluate the associations between hospitals HCAHPS scores and outcomes after adjustment for patient and hospital-level variables 17,509 linked encounters in 651 hospitals across the U.S. were identified with 51 40 and 9 cancer surgical admissions In-hospital mortality was lower in hospitals in the top HCAHPS score terciles compared to bottom HCAHPS score tercile odds ratio OR 0.54 95 CI 0.31-0.94 Surgery in higher scoring HCAHPS hospitals was associated with less 'surgical complications OR 0.82 95 CI 0.69-0.98 No association was found between 'medical 'care team overall complications or prolonged hospitalization p 0.05 and HCAHPS scores Gynecologic oncology surgeries performed in top HCAHPS tercile hospitals were associated with lower in-hospital mortality and surgical complications compared to surgeries performed in bottom tercile hospitals Associations between HCAHPS scores and other adverse events were not seen",0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 702, 14003, 455, 1, 2819, 1994, 2, 1530, 23034, 16, 8, 657, 1407, 1, 2420, 730, 26, 45, 194, 3, 248, 59, 23034, 1407, 99, 2, 123, 4, 1512, 12, 152, 26, 2495, 45, 95, 23034, 1407, 74, 29, 1238, 6, 1132, 6, 11295, 1987, 237, 368, 29078, 3, 5405, 2420, 1000, 7228, 609, 10, 95, 6, 255, 5565, 190, 3, 827, 98, 727, 9, 1512, 12, 112, 5305, 74, 3375, 11, 1199, 28, 3, 702, 301, 573, 521, 282, 2, 1069, 1318, 1, 2020, 11, 72, 59, 142, 2, 280, 2504, 1987, 521, 11, 3706, 22, 51543, 51544, 15, 51545, 2870, 1739, 176, 274, 11, 95, 6, 376, 3, 685, 59, 1987, 23034, 703, 2, 123, 50, 1852, 9, 69, 2, 702, 301, 682, 269, 8727, 1199, 8525, 4, 13114, 1987, 716, 3, 1767, 695, 11, 108, 5, 725, 327, 2, 83, 12, 221, 5565, 4, 702, 282, 10, 280, 4, 1987, 4, 3, 3150, 23034, 368, 29078, 72, 6, 9288, 23034, 368, 36657, 610, 197, 15, 13, 667, 48, 58, 13, 456, 13, 960, 152, 4, 142, 2504, 23034, 1987, 10, 41, 5, 299, 51543, 521, 15, 13, 878, 48, 58, 13, 790, 13, 1096, 77, 248, 10, 204, 59, 51544, 51545, 2870, 63, 521, 15, 1069, 2826, 19, 13, 474, 2, 23034, 703, 1512, 413, 5305, 173, 4, 3150, 23034, 36657, 1987, 11, 41, 5, 280, 4, 702, 282, 2, 221, 521, 72, 6, 5305, 173, 4, 9288, 36657, 1987, 685, 59, 23034, 703, 2, 127, 290, 281, 11, 44, 527]",1680.0,31208738,39
Intraspinal Degenerative Cyst Causing Compression Of Cervicomedullary Junction.,World neurosurgery,World Neurosurg,2019-06-26,"Intraspinal degenerative cysts in the cervical region are rare disorders that may cause myelopathy or radiculopathy. Most of the intraspinal degenerative cysts reported are extradural cysts. This case report includes the neuroimaging, intraoperative, pathologic, and postoperative findings obtained in a patient with a degenerative intradural cyst at the craniovertebral (CV) junction. We report a patient presenting with progressive spastic quadriparesis resulting from compressive myelopathy due to intradural degenerative cyst at the CV junction. Preoperative magnetic resonance imaging showed the intradural cyst at the cervicomedullary junction with degenerative changes causing myelopathy. We performed decompression of the CV junction, and histopathology of the cyst revealed degenerative cyst. Postoperatively the symptoms were relieved with no apparent complication. Intraspinal degenerative cysts causing compressive myelopathy are rare. To the best of our knowledge, this is the first case of intradural degenerative cyst at the CV junction. In this case report, we demonstrated the clinical, imaging, intraoperative, and pathologic features of a degenerative intraspinal cyst at the CV junction that was intradural in location. Compression of the spinal cord resulted in a gradually progressive myelopathy that showed remarkable improvement immediately after decompression by cystectomy.",Case Reports,209.0,0.0,Intraspinal degenerative cysts in the region are rare disorders that may cause myelopathy or radiculopathy Most of the intraspinal degenerative cysts reported are extradural cysts This case report includes the neuroimaging intraoperative pathologic and postoperative findings obtained in a patient with a degenerative intradural cyst at the craniovertebral CV junction We report a patient presenting with progressive spastic quadriparesis resulting from compressive myelopathy due to intradural degenerative cyst at the CV junction Preoperative magnetic resonance imaging showed the intradural cyst at the cervicomedullary junction with degenerative changes causing myelopathy We performed decompression of the CV junction and histopathology of the cyst revealed degenerative cyst Postoperatively the symptoms were relieved with no apparent complication Intraspinal degenerative cysts causing compressive myelopathy are rare To the best of our knowledge this is the first case of intradural degenerative cyst at the CV junction In this case report we demonstrated the clinical imaging intraoperative and pathologic features of a degenerative intraspinal cyst at the CV junction that was intradural in location Compression of the spinal cord resulted in a gradually progressive myelopathy that showed remarkable improvement immediately after decompression by cystectomy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[18329, 16344, 4395, 4, 3, 1053, 32, 622, 1997, 17, 68, 708, 10415, 15, 16642, 96, 1, 3, 18329, 16344, 4395, 210, 32, 42290, 4395, 26, 473, 414, 1920, 3, 7468, 1720, 510, 2, 573, 272, 683, 4, 8, 69, 5, 8, 16344, 14288, 3364, 28, 3, 31589, 6249, 3322, 21, 414, 8, 69, 1656, 5, 1014, 51549, 74899, 1113, 29, 33928, 10415, 520, 6, 14288, 16344, 3364, 28, 3, 6249, 3322, 498, 1484, 1535, 270, 224, 3, 14288, 3364, 28, 3, 51065, 3322, 5, 16344, 400, 3440, 10415, 21, 173, 7638, 1, 3, 6249, 3322, 2, 3831, 1, 3, 3364, 553, 16344, 3364, 3541, 3, 507, 11, 14429, 5, 77, 2235, 1447, 18329, 16344, 4395, 3440, 33928, 10415, 32, 622, 6, 3, 824, 1, 114, 922, 26, 16, 3, 157, 473, 1, 14288, 16344, 3364, 28, 3, 6249, 3322, 4, 26, 473, 414, 21, 264, 3, 38, 270, 1720, 2, 510, 404, 1, 8, 16344, 18329, 3364, 28, 3, 6249, 3322, 17, 10, 14288, 4, 1147, 3481, 1, 3, 1499, 1885, 627, 4, 8, 8092, 1014, 10415, 17, 224, 3813, 767, 3467, 50, 7638, 20, 1750]",1368.0,31254712,65
"Low-cost, high-resolution imaging for detecting cervical precancer in medically-underserved areas of Texas.",Gynecologic oncology,Gynecol. Oncol.,2019-07-06,"Cervical cancer rates in the United States have declined since the 1940's, however, cervical cancer incidence remains elevated in medically-underserved areas, especially in the Rio Grande Valley (RGV) along the Texas-Mexico border. High-resolution microendoscopy (HRME) is a low-cost, in vivo imaging technique that can identify high-grade precancerous cervical lesions (CIN2+) at the point-of-care. The goal of this study was to evaluate the performance of HRME in medically-underserved areas in Texas, comparing results to a tertiary academic medical center. HRME was evaluated in five different outpatient clinical settings, two in Houston and three in the RGV, with medical providers of varying skill and training. Colposcopy, followed by HRME imaging, was performed on eligible women. The sensitivity and specificity of traditional colposcopy and colposcopy followed by HRME to detect CIN2+ were compared and HRME image quality was evaluated. 174 women (227 cervical sites) were included in the final analysis, with 12% (11% of cervical sites) diagnosed with CIN2+ on histopathology. On a per-site basis, a colposcopic impression of low-grade precancer or greater had a sensitivity of 84% and a specificity of 45% to detect CIN2+. While there was no significant difference in sensitivity (76%, p=0.62), the specificity when using HRME was significantly higher than that of traditional colposcopy (56%, p=0.01). There was no significant difference in HRME image quality between clinical sites (p=0.77) or medical providers (p=0.33). HRME imaging increased the specificity for detecting CIN2+ when compared to traditional colposcopy. HRME image quality remained consistent across different clinical settings.",Journal Article,199.0,0.0,cancer rates in the United States have declined since the 1940 's however cancer incidence remains elevated in medically-underserved areas especially in the Rio Grande Valley RGV along the Texas-Mexico border High-resolution microendoscopy HRME is a low-cost in vivo imaging technique that can identify high-grade precancerous lesions CIN2+ at the point-of-care The goal of this study was to evaluate the performance of HRME in medically-underserved areas in Texas comparing results to a tertiary academic medical center HRME was evaluated in five different outpatient clinical settings two in Houston and three in the RGV with medical providers of varying skill and training Colposcopy followed by HRME imaging was performed on eligible women The sensitivity and specificity of traditional colposcopy and colposcopy followed by HRME to detect CIN2+ were compared and HRME image quality was evaluated 174 women 227 sites were included in the final analysis with 12 11 of sites diagnosed with CIN2+ on histopathology On a per-site basis a colposcopic impression of low-grade precancer or greater had a sensitivity of 84 and a specificity of 45 to detect CIN2+ While there was no significant difference in sensitivity 76 p 0.62 the specificity when using HRME was significantly higher than that of traditional colposcopy 56 p 0.01 There was no significant difference in HRME image quality between clinical sites p 0.77 or medical providers p 0.33 HRME imaging increased the specificity for detecting CIN2+ when compared to traditional colposcopy HRME image quality remained consistent across different clinical settings,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 151, 4, 3, 1088, 907, 47, 3054, 1192, 3, 23303, 292, 137, 12, 287, 469, 804, 4, 4381, 6960, 1361, 1093, 4, 3, 44833, 44834, 17624, 36706, 1510, 3, 2738, 10109, 11793, 64, 2125, 24180, 12049, 16, 8, 154, 835, 4, 386, 270, 1312, 17, 122, 255, 64, 88, 6605, 406, 12870, 28, 3, 741, 1, 165, 3, 1326, 1, 26, 45, 10, 6, 376, 3, 528, 1, 12049, 4, 4381, 6960, 1361, 4, 2738, 1430, 99, 6, 8, 2557, 1916, 484, 574, 12049, 10, 194, 4, 365, 338, 2379, 38, 1947, 100, 4, 6212, 2, 169, 4, 3, 36706, 5, 484, 1994, 1, 2990, 11180, 2, 1741, 9946, 370, 20, 12049, 270, 10, 173, 23, 625, 117, 3, 485, 2, 1121, 1, 1847, 9946, 2, 9946, 370, 20, 12049, 6, 1426, 12870, 11, 72, 2, 12049, 1482, 372, 10, 194, 5811, 117, 7132, 633, 11, 159, 4, 3, 1457, 65, 5, 133, 175, 1, 633, 265, 5, 12870, 23, 3831, 23, 8, 379, 606, 877, 8, 14131, 8925, 1, 154, 88, 12380, 15, 378, 42, 8, 485, 1, 874, 2, 8, 1121, 1, 512, 6, 1426, 12870, 369, 125, 10, 77, 93, 523, 4, 485, 846, 19, 13, 744, 3, 1121, 198, 75, 12049, 10, 97, 142, 76, 17, 1, 1847, 9946, 664, 19, 13, 355, 125, 10, 77, 93, 523, 4, 12049, 1482, 372, 59, 38, 633, 19, 13, 849, 15, 484, 1994, 19, 13, 466, 12049, 270, 101, 3, 1121, 9, 2502, 12870, 198, 72, 6, 1847, 9946, 12049, 1482, 372, 958, 925, 716, 338, 38, 1947]",1617.0,31288949,263
Comparison of the AV Magnivisualizer device with colposcopy to detect cervical intraepithelial neoplasia using the Swede scoring system.,International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics,Int J Gynaecol Obstet,2019-08-13,"To compare the AV Magnivisualizer with colposcopy to detect cervical intraepithelial neoplasia (CIN) using the Swede scoring system. Cross-sectional study conducted in a tertiary care hospital from May 2017 to March 2018. One hundred women with positive results at visual inspection with acetic acid underwent cervical inspection using the Magnivisualizer followed by a colposcope. Biopsies were taken if the Swede score was greater than 4. Pregnant women, women with an obvious cervical growth, acute cervicitis, or prior cervical surgery were excluded. Diagnostic accuracy of the Magnivisualizer and colposcope was calculated for high-grade lesions (CIN2/CIN2+) and agreement was compared between the two modalities. The sensitivity, specificity, and positive and negative predictive values of the Magnivisualizer were 88.2%, 70.0%, 50.0%, and 94.6%, respectively, to detect high-grade lesions at a Swede score cutoff of 5 or more. The area under the curve for the Magnivisualizer was 0.80 (95% CI, 0.67-0.92), which was comparable with colposcopy (AUC 0.86; 95% CI, 0.76-0.96). There was very good agreement between the Magnivisualizer and colposcopy (=0.865, P<0.001) for high-grade lesions. The Magnivisualizer had high diagnostic accuracy to detect high-grade CIN in screen-positive women, which was comparable with colposcopy.",Comparative Study,161.0,0.0,To compare the AV Magnivisualizer with colposcopy to detect intraepithelial neoplasia CIN using the Swede scoring system Cross-sectional study conducted in a tertiary care hospital from May 2017 to March 2018 One hundred women with positive results at visual inspection with acetic acid underwent inspection using the Magnivisualizer followed by a colposcope Biopsies were taken if the Swede score was greater than 4 Pregnant women women with an obvious growth acute cervicitis or prior surgery were excluded Diagnostic accuracy of the Magnivisualizer and colposcope was calculated for high-grade lesions CIN 2/CIN 2+ and agreement was compared between the two modalities The sensitivity specificity and positive and negative predictive values of the Magnivisualizer were 88.2 70.0 50.0 and 94.6 respectively to detect high-grade lesions at a Swede score cutoff of 5 or more The area under the curve for the Magnivisualizer was 0.80 95 CI 0.67-0.92 which was comparable with colposcopy AUC 0.86 95 CI 0.76-0.96 There was very good agreement between the Magnivisualizer and colposcopy =0.865 P 0.001 for high-grade lesions The Magnivisualizer had high diagnostic accuracy to detect high-grade CIN in screen-positive women which was comparable with colposcopy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 932, 3, 19679, 27737, 5, 9946, 6, 1426, 4153, 2298, 4652, 75, 3, 42295, 2504, 398, 1383, 2832, 45, 426, 4, 8, 2557, 165, 702, 29, 68, 1759, 6, 2363, 2982, 104, 1128, 117, 5, 109, 99, 28, 3046, 11746, 5, 16812, 971, 208, 11746, 75, 3, 27737, 370, 20, 8, 51558, 1154, 11, 1633, 492, 3, 42295, 368, 10, 378, 76, 39, 6086, 117, 117, 5, 35, 6228, 129, 286, 74930, 15, 324, 152, 11, 1800, 752, 1190, 1, 3, 27737, 2, 51558, 10, 981, 9, 64, 88, 406, 4652, 18, 4652, 18, 2, 2024, 10, 72, 59, 3, 100, 1558, 3, 485, 1121, 2, 109, 2, 199, 464, 1030, 1, 3, 27737, 11, 889, 18, 431, 13, 212, 13, 2, 960, 49, 106, 6, 1426, 64, 88, 406, 28, 8, 42295, 368, 2779, 1, 33, 15, 80, 3, 965, 669, 3, 1496, 9, 3, 27737, 10, 13, 493, 48, 58, 13, 598, 13, 937, 92, 10, 1279, 5, 9946, 1376, 13, 868, 48, 58, 13, 846, 13, 921, 125, 10, 923, 1178, 2024, 59, 3, 27737, 2, 9946, 4627, 13, 13419, 19, 13, 144, 9, 64, 88, 406, 3, 27737, 42, 64, 752, 1190, 6, 1426, 64, 88, 4652, 4, 2413, 109, 117, 92, 10, 1279, 5, 9946]",1258.0,31353466,75
Sentinel lymph node biopsy with cervical injection of indocyanine green in apparent early-stage endometrial cancer: predictors of unsuccessful mapping.,Gynecologic oncology,Gynecol. Oncol.,2019-08-08,"To identify predictors of unsuccessful sentinel lymph node (SLN) mapping in patients with apparent early-stage endometrial cancer (EC) undergoing surgical staging with cervical injection of indocyanine green and SLN biopsy. We retrospectively identified consecutive patients with EC with attempted SLN biopsy between June 2014 and June 2016 at our institution. Patients were grouped according to whether they had a successful procedure, defined as the bilateral identification of SLNs, or an unsuccessful procedure, defined as unilateral or no SLN mapping. Logistic regression was used to evaluate predictors of an unsuccessful procedure. Among 327 patients included in the analysis, 256 (78.3%) had a successful procedure and 71 (21.7%) had an unsuccessful procedure (15.0% unilateral SLN mapping, 6.7% no mapping). The rate of successful procedure increased from 57.7% to 83.3% between the first and last quarters of the 2-year study period, which represented the learning curve for the technique. The mean (SD) operative time decreased from 164 (55) to 137 (37) minutes. By multivariable analysis, lysis of adhesions at the beginning of surgery (odds ratio, 3.07; 95% CI, 1.56-6.07) and the presence of enlarged lymph nodes (odds ratio, 4.69; 95% CI, 1.82-12.11) were independently associated with an unsuccessful procedure. Lysis of adhesions at the beginning of surgery and the presence of enlarged lymph nodes independently affect the bilateral detection of SLNs.",Journal Article,166.0,0.0,To identify predictors of unsuccessful sentinel lymph node SLN mapping in patients with apparent early-stage cancer EC undergoing surgical staging with injection of indocyanine green and SLN biopsy We retrospectively identified consecutive patients with EC with attempted SLN biopsy between June 2014 and June 2016 at our institution Patients were grouped according to whether they had a successful procedure defined as the bilateral identification of SLNs or an unsuccessful procedure defined as unilateral or no SLN mapping Logistic regression was used to evaluate predictors of an unsuccessful procedure Among 327 patients included in the analysis 256 78.3 had a successful procedure and 71 21.7 had an unsuccessful procedure 15.0 unilateral SLN mapping 6.7 no mapping The rate of successful procedure increased from 57.7 to 83.3 between the first and last quarters of the 2-year study period which represented the learning curve for the technique The mean SD operative time decreased from 164 55 to 137 37 minutes By multivariable analysis lysis of adhesions at the beginning of surgery odds ratio 3.07 95 CI 1.56-6.07 and the presence of enlarged lymph nodes odds ratio 4.69 95 CI 1.82-12.11 were independently associated with an unsuccessful procedure Lysis of adhesions at the beginning of surgery and the presence of enlarged lymph nodes independently affect the bilateral detection of SLNs,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 255, 674, 1, 7581, 1323, 263, 289, 1099, 2568, 4, 7, 5, 2235, 191, 82, 12, 2180, 479, 221, 632, 5, 1754, 1, 18903, 4658, 2, 1099, 411, 21, 894, 108, 935, 7, 5, 2180, 5, 4098, 1099, 411, 59, 1924, 1409, 2, 1924, 1390, 28, 114, 731, 7, 11, 3706, 768, 6, 317, 491, 42, 8, 1401, 1299, 395, 22, 3, 1607, 911, 1, 2642, 15, 35, 7581, 1299, 395, 22, 3208, 15, 77, 1099, 2568, 812, 320, 10, 95, 6, 376, 674, 1, 35, 7581, 1299, 107, 7749, 7, 159, 4, 3, 65, 7162, 833, 27, 42, 8, 1401, 1299, 2, 792, 239, 67, 42, 35, 7581, 1299, 167, 13, 3208, 1099, 2568, 49, 67, 77, 2568, 3, 116, 1, 1401, 1299, 101, 29, 696, 67, 6, 852, 27, 59, 3, 157, 2, 1060, 14497, 1, 3, 18, 111, 45, 727, 92, 3324, 3, 3434, 1496, 9, 3, 1312, 3, 313, 1270, 1208, 98, 340, 29, 5279, 614, 6, 4352, 567, 2511, 20, 658, 65, 4783, 1, 13233, 28, 3, 2948, 1, 152, 610, 197, 27, 1615, 48, 58, 14, 664, 49, 1615, 2, 3, 463, 1, 7547, 263, 502, 610, 197, 39, 790, 48, 58, 14, 878, 133, 175, 11, 1042, 41, 5, 35, 7581, 1299, 4783, 1, 13233, 28, 3, 2948, 1, 152, 2, 3, 463, 1, 7547, 263, 502, 1042, 1158, 3, 1607, 638, 1, 2642]",1398.0,31402166,29
Effects of green synthesised silver nanoparticles (ST06-AgNPs) using curcumin derivative (ST06) on human cervical cancer cells (HeLa) in vitro and EAC tumor bearing mice models.,International journal of nanomedicine,Int J Nanomedicine,2019-07-16,"In recent years, green synthesized silver nanoparticles have been increasingly investigated for their anti-cancer potential. In the present study, we aimed at the biosynthesis of silver nanoparticles (AgNPs) using a curcumin derivative, ST06. Although, the individual efficacies of silver nanoparticles or curcumin derivatives have been studied previously, the synergistic cytotoxic effects of curcumin derivative and silver nanoparticles in a single nanoparticulate formulation have not been studied earlier specifically on animal models. This makes this study novel compared to the earlier synthesized curcumin derivative or silver nanoparticles studies. The aim of the study was to synthesize ST06 coated silver nanoparticles (ST06-AgNPs) using ST06 as both reducing and coating agent. The synthesized nanoparticles AgNPs and ST06-AgNPs were characterised for the particle size distribution, morphology, optical properties and surface charge by using UV-visible spectroscopy, dynamic light scattering (DLS) and transmission electron microscopy (TEM). Elemental composition and structural properties were studied by energy dispersive X-ray spectroscopy (EDX) and X-ray diffraction spectroscopy (XRD). The presence of ST06 as capping agent was demonstrated by Fourier transform infrared spectroscopy (FTIR). The synthesized nanoparticles (ST06-AgNPs) were spherical and had a size distribution in the range of 50-100nm. UV-Vis spectroscopy displayed a specific silver plasmon peak at 410nm. The in vitro cytotoxicity effects of ST06 and ST06-AgNPs, as assessed by MTT assay, showed significant growth inhibition of human cervical cancer cell line (HeLa). In addition, studies carried out in EAC tumor-induced mouse model (Ehrlich Ascites carcinoma) using ST06-AgNPs, revealed that treatment of the animals with these nanoparticles resulted in a significant reduction in the tumor growth, compared to the control group animals. In conclusion, green synthesized ST06-AgNPs exhibited superior anti-tumor efficacy than the free ST06 or AgNPs with no acute toxicity under both in vitro and in vivo conditions. The tumor suppression is associated with the intrinsic apoptotic pathway. Together, the results of this study suggest that ST06-AgNPs could be considered as a potential option for the treatment of solid tumors.",Journal Article,189.0,0.0,In recent years green synthesized silver nanoparticles have been increasingly investigated for their anti-cancer potential In the present study we aimed at the biosynthesis of silver nanoparticles AgNPs using a curcumin derivative ST06 Although the individual efficacies of silver nanoparticles or curcumin derivatives have been studied previously the synergistic cytotoxic effects of curcumin derivative and silver nanoparticles in a single nanoparticulate formulation have not been studied earlier specifically on animal models This makes this study novel compared to the earlier synthesized curcumin derivative or silver nanoparticles studies The aim of the study was to synthesize ST06 coated silver nanoparticles ST06-AgNPs using ST06 as both reducing and coating agent The synthesized nanoparticles AgNPs and ST06-AgNPs were characterised for the particle size distribution morphology optical properties and surface charge by using UV-visible spectroscopy dynamic light scattering DLS and transmission electron microscopy TEM Elemental composition and structural properties were studied by energy dispersive X-ray spectroscopy EDX and X-ray diffraction spectroscopy XRD The presence of ST06 as capping agent was demonstrated by Fourier transform infrared spectroscopy FTIR The synthesized nanoparticles ST06-AgNPs were spherical and had a size distribution in the range of 50-100 nm UV-Vis spectroscopy displayed a specific silver plasmon peak at 410 nm The in vitro cytotoxicity effects of ST06 and ST06-AgNPs as assessed by MTT assay showed significant growth inhibition of human cancer cell line HeLa In addition studies carried out in EAC tumor-induced mouse model Ehrlich Ascites carcinoma using ST06-AgNPs revealed that treatment of the animals with these nanoparticles resulted in a significant reduction in the tumor growth compared to the control group animals In conclusion green synthesized ST06-AgNPs exhibited superior anti-tumor efficacy than the free ST06 or AgNPs with no acute toxicity under both in vitro and in vivo conditions The tumor suppression is associated with the intrinsic apoptotic pathway Together the results of this study suggest that ST06-AgNPs could be considered as a potential option for the treatment of solid tumors,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4, 435, 60, 4658, 5134, 17924, 2889, 47, 85, 1635, 565, 9, 136, 312, 12, 174, 4, 3, 364, 45, 21, 1295, 28, 3, 6225, 1, 17924, 2889, 23035, 75, 8, 3775, 4819, 20130, 242, 3, 797, 14198, 1, 17924, 2889, 15, 3775, 6490, 47, 85, 656, 373, 3, 1806, 759, 176, 1, 3775, 4819, 2, 17924, 2889, 4, 8, 226, 18067, 3583, 47, 44, 85, 656, 1677, 1225, 23, 2026, 274, 26, 4677, 26, 45, 229, 72, 6, 3, 1677, 5134, 3775, 4819, 15, 17924, 2889, 94, 3, 1130, 1, 3, 45, 10, 6, 11254, 20130, 8248, 17924, 2889, 20130, 23035, 75, 20130, 22, 110, 1818, 2, 14737, 420, 3, 5134, 2889, 23035, 2, 20130, 23035, 11, 10715, 9, 3, 5997, 444, 1395, 2567, 4303, 1571, 2, 1255, 11812, 20, 75, 6640, 4822, 5326, 2540, 1691, 7841, 15038, 2, 8151, 4560, 3804, 9594, 24899, 3761, 2, 3281, 1571, 11, 656, 20, 2803, 34656, 1006, 5520, 5326, 23036, 2, 1006, 5520, 32629, 5326, 51510, 3, 463, 1, 20130, 22, 19476, 420, 10, 264, 20, 29367, 7136, 6765, 5326, 51563, 3, 5134, 2889, 20130, 23035, 11, 13312, 2, 42, 8, 444, 1395, 4, 3, 184, 1, 212, 394, 2878, 6640, 18504, 5326, 2507, 8, 112, 17924, 21387, 2944, 28, 7690, 2878, 3, 4, 439, 1408, 176, 1, 20130, 2, 20130, 23035, 22, 275, 20, 4988, 719, 224, 93, 129, 297, 1, 171, 12, 31, 328, 8466, 4, 352, 94, 2629, 1205, 4, 3378, 30, 277, 830, 202, 24203, 3819, 134, 75, 20130, 23035, 553, 17, 24, 1, 3, 2258, 5, 46, 2889, 627, 4, 8, 93, 628, 4, 3, 30, 129, 72, 6, 3, 182, 87, 2258, 4, 1221, 4658, 5134, 20130, 23035, 1416, 1123, 312, 30, 209, 76, 3, 115, 20130, 15, 23035, 5, 77, 286, 155, 669, 110, 4, 439, 2, 4, 386, 1298, 3, 30, 1332, 16, 41, 5, 3, 2354, 1631, 308, 1162, 3, 99, 1, 26, 45, 309, 17, 20130, 23035, 359, 40, 515, 22, 8, 174, 1501, 9, 3, 24, 1, 537, 57]",2259.0,31409988,391
PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.,Gynecologic oncology,Gynecol. Oncol.,2019-08-18,"Cervical cancer (CC) remains a major health problem worldwide. Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors (PARPi) have emerged as a promising class of chemotherapeutics in ovarian cancer. We explored the preclinical in vitro and in vivo activity of olaparib against multiple primary whole exome sequenced (WES) CC cells lines and xenografts. Olaparib cell-cycle, apoptosis, homologous-recombination-deficiency (HRD), PARP trapping and cytotoxicity activity was evaluated against 9 primary CC cell lines in vitro. PARP and PAR expression were analyzed by Western blot assays. Finally, olaparib in vivo antitumor activity was tested against CC xenografts. While none of the cell lines demonstrated HRD, three out of 9 (33.3%) primary CC cell lines showed strong PARylation activity and demonstrated high sensitivity to olaparib in vitro treatment (cutoff IC<sub>50</sub> values<2M, p=0.0012). Olaparib suppressed CC cell growth through cell cycle arrest in the G2/M phase and caused apoptosis (p<0.0001). Olaparib activity in CC involved both PARP enzyme inhibition and trapping. In vivo, olaparib significantly impaired CC xenografts tumor growth (p=0.0017) and increased overall animal survival (p=0.008). A subset of CC primary cell lines is highly responsive to olaparib treatment in vitro and in vivo. High level of PARylation correlated with olaparib preclinical activity and may represent a useful biomarker for the identification of CC patients benefitting the most from PARPi.",Journal Article,156.0,0.0,cancer CC remains a major health problem worldwide Poly adenosine diphosphate ADP -ribose polymerase PARP inhibitors PARPi have emerged as a promising class of chemotherapeutics in cancer We explored the preclinical in vitro and in vivo activity of olaparib against multiple primary whole exome sequenced WES CC cells lines and xenografts Olaparib cell-cycle apoptosis homologous-recombination-deficiency HRD PARP trapping and cytotoxicity activity was evaluated against 9 primary CC cell lines in vitro PARP and PAR expression were analyzed by Western blot assays Finally olaparib in vivo antitumor activity was tested against CC xenografts While none of the cell lines demonstrated HRD three out of 9 33.3 primary CC cell lines showed strong PARylation activity and demonstrated high sensitivity to olaparib in vitro treatment cutoff IC sub 50 /sub values 2 M p 0.0012 Olaparib suppressed CC cell growth through cell cycle arrest in the G2/M phase and caused apoptosis p 0.0001 Olaparib activity in CC involved both PARP enzyme inhibition and trapping In vivo olaparib significantly impaired CC xenografts tumor growth p 0.0017 and increased overall animal survival p 0.008 A subset of CC primary cell lines is highly responsive to olaparib treatment in vitro and in vivo High level of PARylation correlated with olaparib preclinical activity and may represent a useful biomarker for the identification of CC patients benefitting the most from PARPi,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 1951, 469, 8, 458, 341, 2497, 2358, 2699, 4938, 8762, 3638, 3507, 1451, 2041, 222, 5828, 47, 2054, 22, 8, 721, 1040, 1, 6097, 4, 12, 21, 1443, 3, 693, 4, 439, 2, 4, 386, 128, 1, 4024, 480, 232, 86, 902, 2865, 4040, 9148, 1951, 37, 285, 2, 1348, 4024, 31, 417, 351, 3894, 4017, 2299, 9149, 2041, 12140, 2, 1408, 128, 10, 194, 480, 83, 86, 1951, 31, 285, 4, 439, 2041, 2, 7112, 55, 11, 311, 20, 1521, 2639, 1013, 1368, 4024, 4, 386, 579, 128, 10, 650, 480, 1951, 1348, 369, 1292, 1, 3, 31, 285, 264, 9149, 169, 1205, 1, 83, 466, 27, 86, 1951, 31, 285, 224, 1082, 51565, 128, 2, 264, 64, 485, 6, 4024, 4, 439, 24, 2779, 2340, 551, 212, 551, 1030, 18, 4810, 19, 13, 10095, 4024, 1908, 1951, 31, 129, 298, 31, 417, 1854, 4, 3, 3774, 188, 124, 2, 1546, 351, 19, 13, 488, 4024, 128, 4, 1951, 646, 110, 2041, 1644, 297, 2, 12140, 4, 386, 4024, 97, 2364, 1951, 1348, 30, 129, 19, 13, 15849, 2, 101, 63, 2026, 25, 19, 13, 2155, 8, 697, 1, 1951, 86, 31, 285, 16, 561, 2443, 6, 4024, 24, 4, 439, 2, 4, 386, 64, 301, 1, 51565, 438, 5, 4024, 693, 128, 2, 68, 1231, 8, 999, 901, 9, 3, 911, 1, 1951, 7, 29542, 3, 96, 29, 5828]",1452.0,31434613,65
Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls.,Gynecologic oncology,Gynecol. Oncol.,2019-09-26,"The aim of this study was to characterize variation in the gut microbiome of women with locally advanced cervical cancer and compare it to healthy controls. We characterized the 16S rDNA fecal microbiome in 42 cervical cancer patients and 46 healthy female controls. Shannon diversity index (SDI) was used to evaluate alpha (within sample) diversity. Beta (between sample) diversity was examined using principle coordinate analysis (PCoA) of unweighted Unifrac distances. Relative abundance of microbial taxa was compared between samples using Linear Discriminant Analysis Effect Size (LEfSe). Within cervical cancer patients, bacterial alpha diversity was positively correlated with age (p=0.22) but exhibited an inverse relationship in control subjects (p<0.01). Alpha diversity was significantly higher in cervical cancer patients as compared to controls (p<0.05), though stratification by age suggested this relationship was restricted to older women (>50years; p<0.01). Beta diversity (unweighted Unifrac; p<0.01) also significantly differed between cervical cancer patients and controls. Based on age- and race-adjusted LEfSe analysis, multiple taxa significantly differed between cervical cancer patients and controls. Prevotella, Porphyromonas, and Dialister were significantly enriched in cervical cancer patients, while Bacteroides, Alistipes and members of the Lachnospiracea family were significantly enriched in healthy subjects. Our study suggests differences in gut microbiota diversity and composition between cervical cancer patients and controls. Associations within the gut microbiome by age may reflect etiologic/clinical differences. These findings provide rationale for further study of the gut microbiome in cervical cancer.",Journal Article,117.0,0.0,The aim of this study was to characterize variation in the gut microbiome of women with locally advanced cancer and compare it to healthy controls We characterized the 16S rDNA fecal microbiome in 42 cancer patients and 46 healthy female controls Shannon diversity index SDI was used to evaluate alpha within sample diversity Beta between sample diversity was examined using principle coordinate analysis PCoA of unweighted Unifrac distances Relative abundance of microbial taxa was compared between samples using Linear Discriminant Analysis Effect Size LEfSe Within cancer patients bacterial alpha diversity was positively correlated with age p 0.22 but exhibited an inverse relationship in control subjects p 0.01 Alpha diversity was significantly higher in cancer patients as compared to controls p 0.05 though stratification by age suggested this relationship was restricted to older women 50 years p 0.01 Beta diversity unweighted Unifrac p 0.01 also significantly differed between cancer patients and controls Based on age- and race-adjusted LEfSe analysis multiple taxa significantly differed between cancer patients and controls Prevotella Porphyromonas and Dialister were significantly enriched in cancer patients while Bacteroides Alistipes and members of the Lachnospiracea family were significantly enriched in healthy subjects Our study suggests differences in gut microbiota diversity and composition between cancer patients and controls Associations within the gut microbiome by age may reflect etiologic/clinical differences These findings provide rationale for further study of the gut microbiome in cancer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1130, 1, 26, 45, 10, 6, 1507, 1380, 4, 3, 7600, 7675, 1, 117, 5, 795, 131, 12, 2, 932, 192, 6, 1331, 535, 21, 765, 3, 17009, 19933, 6784, 7675, 4, 595, 12, 7, 2, 641, 1331, 1061, 535, 32714, 3653, 558, 16495, 10, 95, 6, 376, 950, 262, 1000, 3653, 1090, 59, 1000, 3653, 10, 409, 75, 4968, 9767, 65, 50764, 1, 17875, 36373, 11022, 580, 4778, 1, 9138, 21861, 10, 72, 59, 347, 75, 1646, 12371, 65, 254, 444, 51579, 262, 12, 7, 5117, 950, 3653, 10, 2375, 438, 5, 89, 19, 13, 350, 84, 1416, 35, 2931, 858, 4, 182, 976, 19, 13, 355, 950, 3653, 10, 97, 142, 4, 12, 7, 22, 72, 6, 535, 19, 13, 474, 2471, 1541, 20, 89, 1148, 26, 858, 10, 2016, 6, 434, 117, 212, 60, 19, 13, 355, 1090, 3653, 17875, 36373, 19, 13, 355, 120, 97, 2512, 59, 12, 7, 2, 535, 90, 23, 89, 2, 1047, 586, 51579, 65, 232, 21861, 97, 2512, 59, 12, 7, 2, 535, 32453, 40225, 2, 75056, 11, 97, 2220, 4, 12, 7, 369, 15744, 75057, 2, 1684, 1, 3, 75058, 607, 11, 97, 2220, 4, 1331, 976, 114, 45, 844, 362, 4, 7600, 7287, 3653, 2, 3761, 59, 12, 7, 2, 535, 685, 262, 3, 7600, 7675, 20, 89, 68, 2694, 6604, 38, 362, 46, 272, 377, 1728, 9, 195, 45, 1, 3, 7600, 7675, 4, 12]",1624.0,31500892,326
GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE).,Gynecologic oncology,Gynecol. Oncol.,2019-10-31,"To explore whether patient-reported lymphedema-related symptoms, as measured by the Gynecologic Cancer Lymphedema Questionnaire (GCLQ), are associated with a patient-reported diagnosis of lymphedema of the lower extremity (LLE) and limb volume change (LVC) in patients who have undergone radical surgery, including lymphadenectomy, for endometrial, cervical, or vulvar cancer on Gynecologic Oncology Group (GOG) study 244. Patients completed the baseline and at least one post-surgery GCLQ and LVC assessment. The 20-item GCLQ measures seven symptom clusters-aching, heaviness, infection-related, numbness, physical functioning, general swelling, and limb swelling. LLE was defined as a patient self-reported LLE diagnosis on the GCLQ. LVC was measured by volume calculations based on circumferential measurements. A linear mixed model was fitted for change in symptom cluster scores and GCLQ total score and adjusted for disease sites and assessment time. Of 987 eligible patients, 894 were evaluable (endometrial, 719; cervical, 136; vulvar, 39). Of these, 14% reported an LLE diagnosis (endometrial, 11%; cervical, 18%; vulvar, 38%). Significantly more patients diagnosed versus not diagnosed with LLE reported 4-point increase from baseline on the GCLQ total score (p<0.001). Changes from baseline were significantly larger on all GCLQ symptom cluster scores in patients with LLE compared to those without LLE. An LVC increment of >10% was significantly associated with reported general swelling (p<0.001), heaviness (p=0.005), infection-related symptoms (p=0.002), and physical function (p=0.006). Patient-reported symptoms, as measured by the GCLQ, discerned those with and without a patient-reported LLE diagnosis and demonstrated predictive value. The GCLQ combined with LVC may enhance our ability to identify LLE.",Journal Article,82.0,0.0,To explore whether patient-reported lymphedema-related symptoms as measured by the Gynecologic Cancer Lymphedema Questionnaire GCLQ are associated with a patient-reported diagnosis of lymphedema of the lower extremity LLE and limb volume change LVC in patients who have undergone radical surgery including lymphadenectomy for or cancer on Gynecologic Oncology Group GOG study 244 Patients completed the baseline and at least one post-surgery GCLQ and LVC assessment The 20-item GCLQ measures seven symptom clusters-aching heaviness infection-related numbness physical functioning general swelling and limb swelling LLE was defined as a patient self-reported LLE diagnosis on the GCLQ LVC was measured by volume calculations based on circumferential measurements A linear mixed model was fitted for change in symptom cluster scores and GCLQ total score and adjusted for disease sites and assessment time Of 987 eligible patients 894 were evaluable 719 136 39 Of these 14 reported an LLE diagnosis 11 18 38 Significantly more patients diagnosed versus not diagnosed with LLE reported 4-point increase from baseline on the GCLQ total score p 0.001 Changes from baseline were significantly larger on all GCLQ symptom cluster scores in patients with LLE compared to those without LLE An LVC increment of 10 was significantly associated with reported general swelling p 0.001 heaviness p 0.005 infection-related symptoms p 0.002 and physical function p 0.006 Patient-reported symptoms as measured by the GCLQ discerned those with and without a patient-reported LLE diagnosis and demonstrated predictive value The GCLQ combined with LVC may enhance our ability to identify LLE,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 1645, 317, 69, 210, 3063, 139, 507, 22, 644, 20, 3, 1512, 12, 3063, 1770, 24352, 32, 41, 5, 8, 69, 210, 147, 1, 3063, 1, 3, 280, 2678, 24353, 2, 3930, 433, 707, 15022, 4, 7, 54, 47, 1989, 711, 152, 141, 2048, 9, 15, 12, 23, 1512, 413, 87, 4760, 45, 6567, 7, 781, 3, 330, 2, 28, 506, 104, 539, 152, 24352, 2, 15022, 455, 3, 179, 3471, 24352, 1018, 648, 934, 3780, 36769, 22328, 930, 139, 8655, 900, 2702, 1083, 6967, 2, 3930, 6967, 24353, 10, 395, 22, 8, 69, 1074, 210, 24353, 147, 23, 3, 24352, 15022, 10, 644, 20, 433, 8229, 90, 23, 7937, 1685, 8, 1646, 1739, 202, 10, 7315, 9, 707, 4, 934, 3132, 703, 2, 24352, 181, 368, 2, 586, 9, 34, 633, 2, 455, 98, 1, 16906, 625, 7, 13341, 11, 859, 16012, 4829, 587, 1, 46, 213, 210, 35, 24353, 147, 175, 203, 519, 97, 80, 7, 265, 185, 44, 265, 5, 24353, 210, 5915, 741, 344, 29, 330, 23, 3, 24352, 181, 368, 19, 13, 144, 400, 29, 330, 11, 97, 1077, 23, 62, 24352, 934, 3132, 703, 4, 7, 5, 24353, 72, 6, 135, 187, 24353, 35, 15022, 9705, 1, 79, 10, 97, 41, 5, 210, 1083, 6967, 19, 13, 144, 22328, 19, 13, 1614, 930, 139, 507, 19, 13, 1111, 2, 900, 343, 19, 13, 1861, 69, 210, 507, 22, 644, 20, 3, 24352, 19767, 135, 5, 2, 187, 8, 69, 210, 24353, 147, 2, 264, 464, 549, 3, 24352, 397, 5, 15022, 68, 1304, 114, 801, 6, 255, 24353]",1670.0,31679787,388
Technical considerations in the application of intensity-modulated radiotherapy as a concomitant integrated boost for locally-advanced cervix cancer.,Medical dosimetry : official journal of the American Association of Medical Dosimetrists,Med Dosim,2002-01-01,"The technical aspects of IMRT applied to cervix cancer are discussed in this paper, as well as issues related to tumor delineation, target volume definitions, inverse planning, and IMRT delivery. A theoretical example illustrating how IMRT can accurately mimic dose distributions obtained using conventional planning plus HDR brachytherapy is also shown. The notion of clinical optimization parameters is introduced to account for the radiation delivery variables, which affect the overall treatment time. This is especially relevant to the possible introduction of intrafractional movement and resulting inaccuracy, as well as facility efficiency.",Journal Article,6594.0,20.0,The technical aspects of IMRT applied to cervix cancer are discussed in this paper as well as issues related to tumor delineation target volume definitions inverse planning and IMRT delivery A theoretical example illustrating how IMRT can accurately mimic dose distributions obtained using conventional planning plus HDR brachytherapy is also shown The notion of clinical optimization parameters is introduced to account for the radiation delivery variables which affect the overall treatment time This is especially relevant to the possible introduction of intrafractional movement and resulting inaccuracy as well as facility efficiency,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 3359, 2695, 1, 964, 1498, 6, 3629, 12, 32, 1588, 4, 26, 2817, 22, 149, 22, 1553, 139, 6, 30, 5529, 283, 433, 3833, 2931, 1349, 2, 964, 989, 8, 7060, 2685, 12819, 832, 964, 122, 2141, 5356, 61, 4477, 683, 75, 809, 1349, 349, 5309, 1536, 16, 120, 443, 3, 6691, 1, 38, 3980, 1038, 16, 3955, 6, 1967, 9, 3, 121, 989, 682, 92, 1158, 3, 63, 24, 98, 26, 16, 1093, 867, 6, 3, 899, 2456, 1, 16809, 7950, 2, 1113, 22289, 22, 149, 22, 3483, 2904]",,12074470,54
Induction of caspase-dependent and -independent apoptosis in response to methionine restriction.,International journal of oncology,Int. J. Oncol.,2003-02-01,"Tumor cells are more sensitive to methionine restriction than normal tissues, a phenomenon known as methionine auxotrophy. Previous studies have demonstrated that methionine restriction causes tumor cell growth arrest and eventually apoptosis. The current studies were undertaken to elucidate the molecular pathways leading to apoptosis induced by methionine restriction. We found that methionine restriction induced formation of oligonucleosomal DNA fragment and cytochrome c release from mitochondria in methionine-dependent PC3 and Hela cells. Methionine restriction also led to cleavage and activation of initiator and effector caspases in Hela cells but not PC3 cells. Furthermore, methionine restriction resulted in cleavage of BID and reduction in Bcl-2 levels in both cell lines. These data suggest that apoptosis induced by methionine restriction is mitochondria-dependent. Methionine restriction induced caspase-independent cell death in PC3 cells, whereas it stimulated caspase-dependent cell death in Hela cells. Cleavage of BID and decreased expression of Bcl-2 upon methionine deprivation may be the underlying mechanism to stimulate release of cytochrome c from mitochondria.",Journal Article,6198.0,18.0,Tumor cells are more sensitive to methionine restriction than normal tissues a phenomenon known as methionine auxotrophy Previous studies have demonstrated that methionine restriction causes tumor cell growth arrest and eventually apoptosis The current studies were undertaken to elucidate the molecular pathways leading to apoptosis induced by methionine restriction We found that methionine restriction induced formation of oligonucleosomal DNA fragment and cytochrome c release from mitochondria in methionine-dependent PC3 and Hela cells Methionine restriction also led to cleavage and activation of initiator and effector caspases in Hela cells but not PC3 cells Furthermore methionine restriction resulted in cleavage of BID and reduction in Bcl-2 levels in both cell lines These data suggest that apoptosis induced by methionine restriction is mitochondria-dependent Methionine restriction induced caspase-independent cell death in PC3 cells whereas it stimulated caspase-dependent cell death in Hela cells Cleavage of BID and decreased expression of Bcl-2 upon methionine deprivation may be the underlying mechanism to stimulate release of cytochrome c from mitochondria,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[30, 37, 32, 80, 745, 6, 5686, 4575, 76, 295, 742, 8, 3936, 440, 22, 5686, 27858, 698, 94, 47, 264, 17, 5686, 4575, 1626, 30, 31, 129, 1854, 2, 3124, 351, 3, 291, 94, 11, 2789, 6, 3061, 3, 219, 460, 1049, 6, 351, 277, 20, 5686, 4575, 21, 204, 17, 5686, 4575, 277, 1264, 1, 75225, 261, 5245, 2, 4155, 256, 2008, 29, 5443, 4, 5686, 470, 4505, 2, 8466, 37, 5686, 4575, 120, 836, 6, 3155, 2, 363, 1, 21101, 2, 2070, 7629, 4, 8466, 37, 84, 44, 4505, 37, 798, 5686, 4575, 627, 4, 3155, 1, 2793, 2, 628, 4, 1044, 18, 148, 4, 110, 31, 285, 46, 74, 309, 17, 351, 277, 20, 5686, 4575, 16, 5443, 470, 5686, 4575, 277, 1469, 306, 31, 273, 4, 4505, 37, 547, 192, 2816, 1469, 470, 31, 273, 4, 8466, 37, 3155, 1, 2793, 2, 340, 55, 1, 1044, 18, 1548, 5686, 1868, 68, 40, 3, 1181, 670, 6, 4223, 2008, 1, 4155, 256, 29, 5443]",,12527942,75
CT image-guided intensity-modulated therapy for paraspinal tumors using stereotactic immobilization.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2003-03-01,"To design and implement a noninvasive stereotactic immobilization technique with daily CT image-guided positioning to treat patients with paraspinal lesions accurately and to quantify the systematic and random patient setup errors occurring with this method. A stereotactic body frame (SBF) was developed for ""rigid"" immobilization of paraspinal patients. The inherent accuracy of this system for stereotactic CT-guided treatment was evaluated with phantom studies. Seven patients with thoracic and lumbar spine lesions were immobilized with the SBF and positioned for 33 treatment fractions using daily CT scans. For all 7 patients, the daily setup errors, as assessed from the daily CT scans, were corrected at each treatment fraction. A retrospective analysis was also performed to assess what the impact on patient treatment would have been without the CT-based corrections (i.e., if patient setup had been performed only with the SBF). The average magnitude of systematic and random errors from uncorrected patient setups using the SBF was approximately 2 mm and 1.5 mm (1 SD), respectively. For fixed phantom targets, the system accuracy for the SBF localization and treatment was shown to be within 1 mm (1 SD) in any direction. Dose-volume histograms incorporating these uncertainties for an intensity-modulated radiotherapy plan for lumbar spine lesions were generated, and the effects on the dose-volume histograms were studied. We demonstrated a very accurate and precise method of patient immobilization and treatment delivery based on a noninvasive SBF and daily image guidance for paraspinal lesions. The SBF provides excellent immobilization for paraspinal targets, with setup accuracy better than 2 mm (1 SD). However, for highly conformal paraspinal treatments, uncorrected systematic and random errors of 2 mm in magnitude can result in a significantly greater (>100%) dose to the spinal cord than planned, even though the planned target coverage may not change substantially. With daily CT guidance using the SBF, we showed that the maximal spinal cord dose is ensured to be within 10-15% of the planned value.",Journal Article,6170.0,72.0,To design and implement a noninvasive stereotactic immobilization technique with daily CT image-guided positioning to treat patients with paraspinal lesions accurately and to quantify the systematic and random patient setup errors occurring with this method A stereotactic body frame SBF was developed for `` rigid '' immobilization of paraspinal patients The inherent accuracy of this system for stereotactic CT-guided treatment was evaluated with phantom studies Seven patients with thoracic and lumbar spine lesions were immobilized with the SBF and positioned for 33 treatment fractions using daily CT scans For all 7 patients the daily setup errors as assessed from the daily CT scans were corrected at each treatment fraction A retrospective analysis was also performed to assess what the impact on patient treatment would have been without the CT-based corrections i.e. if patient setup had been performed only with the SBF The average magnitude of systematic and random errors from uncorrected patient setups using the SBF was approximately 2 mm and 1.5 mm 1 SD respectively For fixed phantom targets the system accuracy for the SBF localization and treatment was shown to be within 1 mm 1 SD in any direction Dose-volume histograms incorporating these uncertainties for an intensity-modulated radiotherapy plan for lumbar spine lesions were generated and the effects on the dose-volume histograms were studied We demonstrated a very accurate and precise method of patient immobilization and treatment delivery based on a noninvasive SBF and daily image guidance for paraspinal lesions The SBF provides excellent immobilization for paraspinal targets with setup accuracy better than 2 mm 1 SD However for highly conformal paraspinal treatments uncorrected systematic and random errors of 2 mm in magnitude can result in a significantly greater 100 dose to the spinal cord than planned even though the planned target coverage may not change substantially With daily CT guidance using the SBF we showed that the maximal spinal cord dose is ensured to be within 10-15 of the planned value,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 771, 2, 6207, 8, 2957, 1729, 10161, 1312, 5, 391, 425, 1482, 1808, 7172, 6, 943, 7, 5, 9282, 406, 2141, 2, 6, 3091, 3, 1556, 2, 2324, 69, 4333, 4612, 1821, 5, 26, 596, 8, 1729, 642, 5331, 20077, 10, 276, 9, 12782, 522, 10161, 1, 9282, 7, 3, 4943, 1190, 1, 26, 398, 9, 1729, 425, 1808, 24, 10, 194, 5, 6755, 94, 648, 7, 5, 2098, 2, 6187, 2342, 406, 11, 15093, 5, 3, 20077, 2, 14240, 9, 466, 24, 1550, 75, 391, 425, 1441, 9, 62, 67, 7, 3, 391, 4333, 4612, 22, 275, 29, 3, 391, 425, 1441, 11, 3848, 28, 296, 24, 1509, 8, 459, 65, 10, 120, 173, 6, 423, 2067, 3, 345, 23, 69, 24, 688, 47, 85, 187, 3, 425, 90, 10737, 70, 563, 492, 69, 4333, 42, 85, 173, 158, 5, 3, 20077, 3, 1011, 3131, 1, 1556, 2, 2324, 4612, 29, 18332, 69, 23549, 75, 3, 20077, 10, 705, 18, 321, 2, 14, 33, 321, 14, 1270, 106, 9, 1959, 6755, 637, 3, 398, 1190, 9, 3, 20077, 2145, 2, 24, 10, 443, 6, 40, 262, 14, 321, 14, 1270, 4, 500, 4651, 61, 433, 8638, 2570, 46, 7387, 9, 35, 837, 1757, 310, 2242, 9, 6187, 2342, 406, 11, 1419, 2, 3, 176, 23, 3, 61, 433, 8638, 11, 656, 21, 264, 8, 923, 1481, 2, 3260, 596, 1, 69, 10161, 2, 24, 989, 90, 23, 8, 2957, 20077, 2, 391, 1482, 2753, 9, 9282, 406, 3, 20077, 777, 1503, 10161, 9, 9282, 637, 5, 4333, 1190, 380, 76, 18, 321, 14, 1270, 137, 9, 561, 2972, 9282, 640, 18332, 1556, 2, 2324, 4612, 1, 18, 321, 4, 3131, 122, 757, 4, 8, 97, 378, 394, 61, 6, 3, 1499, 1885, 76, 1465, 871, 2471, 3, 1465, 283, 2139, 68, 44, 707, 2109, 5, 391, 425, 2753, 75, 3, 20077, 21, 224, 17, 3, 2725, 1499, 1885, 61, 16, 23296, 6, 40, 262, 79, 167, 1, 3, 1465, 549]",,12573745,125
Transperitoneal laparoscopic pelvic and para-aortic lymph node dissection using the argon-beam coagulator and monopolar instruments: an 8-year study and description of technique.,Gynecologic oncology,Gynecol. Oncol.,2003-06-01,"The objective was to describe the results, technique, and complications of transperitoneal laparoscopic (LSC) pelvic and aortic lymph node dissection (LND) using the argon-beam coagulator (ABC) and monopolar electrosurgical instruments in women with gynecologic malignancies. A retrospective chart review of 114 patients who underwent LSC pelvic and/or aortic LND in addition to other LSC procedures between 1/1994 and 12/2001 was conducted. All intraoperative complications and complications that occurred within the first 30 postoperative days were included. Complications were graded according to an institutional surgical secondary events reference. During the same time period, 89 patients underwent LSC followed immediately by laparotomy that included LND, resulting in a total of 203 cases. These 203 total cases are used as a denominator to determine the etiology of cases converted from LSC to laparotomy. Monopolar electrosurgical instruments or the 10-mm ABC (Conmed) set at 70 W with argon flow of 3-4 L/m min were used for laparoscopic nodal dissection. Sixty-one of 114 (53%) patients underwent pelvic LND, 35 (31%) underwent both pelvic and aortic LND, and 18 (16%) underwent aortic LND only. Mean patient age and body mass index were 53.3 years (range, 16 to 87 years) and 25 (range, 16 to 40), respectively. In addition, the mean number of pelvic and aortic lymph nodes removed was 10.7 (range, 1 to 39) and 5.7 (range, 0 to 21), respectively. The mean estimated blood loss was 151 mL (range, 25 to 600 ml) and the mean hospital stay was 2.8 days (range, 0 to 35 days). Overall, complications occurred in eight (7%) cases. There were no fatal complications, and no patient required conversion to laparotomy due to uncontrollable bleeding from the laparoscopic nodal dissection. Only 17 of 203 (8%) patients required conversion to laparotomy secondary to adhesions and unsatisfactory exposure. Laparoscopic pelvic and aortic LND for gynecologic malignancies can be satisfactorily performed in the majority of patients, with only 8% of patients requiring conversion to laparotomy due to adhesions or unsatisfactory exposure. The overall complication rate was 7% and was limited to grade 3 or less.",Journal Article,6078.0,54.0,The objective was to describe the results technique and complications of transperitoneal laparoscopic LSC pelvic and aortic lymph node dissection LND using the argon-beam coagulator ABC and monopolar electrosurgical instruments in women with gynecologic malignancies A retrospective chart review of 114 patients who underwent LSC pelvic and/or aortic LND in addition to other LSC procedures between 1/1994 and 12/2001 was conducted All intraoperative complications and complications that occurred within the first 30 postoperative days were included Complications were graded according to an institutional surgical secondary events reference During the same time period 89 patients underwent LSC followed immediately by laparotomy that included LND resulting in a total of 203 cases These 203 total cases are used as a denominator to determine the etiology of cases converted from LSC to laparotomy Monopolar electrosurgical instruments or the 10-mm ABC Conmed set at 70 W with argon flow of 3-4 L/m min were used for laparoscopic nodal dissection Sixty-one of 114 53 patients underwent pelvic LND 35 31 underwent both pelvic and aortic LND and 18 16 underwent aortic LND only Mean patient age and body mass index were 53.3 years range 16 to 87 years and 25 range 16 to 40 respectively In addition the mean number of pelvic and aortic lymph nodes removed was 10.7 range 1 to 39 and 5.7 range 0 to 21 respectively The mean estimated blood loss was 151 mL range 25 to 600 ml and the mean hospital stay was 2.8 days range 0 to 35 days Overall complications occurred in eight 7 cases There were no fatal complications and no patient required conversion to laparotomy due to uncontrollable bleeding from the laparoscopic nodal dissection Only 17 of 203 8 patients required conversion to laparotomy secondary to adhesions and unsatisfactory exposure Laparoscopic pelvic and aortic LND for gynecologic malignancies can be satisfactorily performed in the majority of patients with only 8 of patients requiring conversion to laparotomy due to adhesions or unsatisfactory exposure The overall complication rate was 7 and was limited to grade 3 or less,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 461, 10, 6, 897, 3, 99, 1312, 2, 521, 1, 12145, 1964, 6643, 1110, 2, 3938, 263, 289, 1161, 3400, 75, 3, 26069, 1345, 43424, 5106, 2, 25116, 24548, 4730, 4, 117, 5, 1512, 441, 8, 459, 2937, 206, 1, 3803, 7, 54, 208, 6643, 1110, 2, 15, 3938, 3400, 4, 352, 6, 127, 6643, 1369, 59, 14, 3023, 2, 133, 1758, 10, 426, 62, 1720, 521, 2, 521, 17, 489, 262, 3, 157, 201, 573, 162, 11, 159, 521, 11, 3468, 768, 6, 35, 1115, 221, 568, 281, 2482, 190, 3, 827, 98, 727, 887, 7, 208, 6643, 370, 3467, 20, 3274, 17, 159, 3400, 1113, 4, 8, 181, 1, 5426, 140, 46, 5426, 181, 140, 32, 95, 22, 8, 26534, 6, 223, 3, 2855, 1, 140, 4764, 29, 6643, 6, 3274, 25116, 24548, 4730, 15, 3, 79, 321, 5106, 75280, 916, 28, 431, 5444, 5, 26069, 1412, 1, 27, 39, 805, 188, 1538, 11, 95, 9, 1964, 779, 1161, 1746, 104, 1, 3803, 699, 7, 208, 1110, 3400, 465, 456, 208, 110, 1110, 2, 3938, 3400, 2, 203, 245, 208, 3938, 3400, 158, 313, 69, 89, 2, 642, 782, 558, 11, 699, 27, 60, 184, 245, 6, 912, 60, 2, 243, 184, 245, 6, 327, 106, 4, 352, 3, 313, 207, 1, 1110, 2, 3938, 263, 502, 2264, 10, 79, 67, 184, 14, 6, 587, 2, 33, 67, 184, 13, 6, 239, 106, 3, 313, 661, 315, 407, 10, 5075, 542, 184, 243, 6, 2383, 542, 2, 3, 313, 702, 2020, 10, 18, 66, 162, 184, 13, 6, 465, 162, 63, 521, 489, 4, 659, 67, 140, 125, 11, 77, 3034, 521, 2, 77, 69, 616, 3111, 6, 3274, 520, 6, 26396, 2294, 29, 3, 1964, 779, 1161, 158, 269, 1, 5426, 66, 7, 616, 3111, 6, 3274, 568, 6, 13233, 2, 9573, 645, 1964, 1110, 2, 3938, 3400, 9, 1512, 441, 122, 40, 33968, 173, 4, 3, 686, 1, 7, 5, 158, 66, 1, 7, 1888, 3111, 6, 3274, 520, 6, 13233, 15, 9573, 645, 3, 63, 1447, 116, 10, 67, 2, 10, 383, 6, 88, 27, 15, 299]",,12798719,164
Postconization surveillance of cervical adenocarcinoma in situ. A prospective trial.,The Journal of reproductive medicine,J Reprod Med,2003-10-01,"To conduct a surveillance trial after conization to prospectively determine the outcome of conservative management of adenocarcinoma in situ (AIS). Women diagnosed with AIS were prospectively enrolled from September 2000 to September 2001. Eligibility criteria included patient age younger than 40 years, prior conization with negative margins and the desire to preserve fertility. Each cone biopsy specimen was secondarily reviewed. Postconization surveillance consisted of a liquid-based Pap test and endocervical curettage (ECC) every 4 months. Follow-up ended in September 2002. Ten women with a median age of 32 years (range, 26-37) were enrolled. Six were nulliparous and 2 primiparous. Seven patients were clinically free of disease after a median of 21 months (range, 5-24), 2 were lost to follow-up, and 1 was excluded when AIS could not be confirmed on the original specimen. Twenty-eight Pap smears and 18 ECCs were performed, but no additional surgical procedures were required due to abnormal cytopathology. This prospective trial on postconization surveillance demonstrated the safety of conservative management for AIS patients desiring to preserve fertility.",Journal Article,5956.0,15.0,To conduct a surveillance trial after conization to prospectively determine the outcome of conservative management of adenocarcinoma in situ AIS Women diagnosed with AIS were prospectively enrolled from September 2000 to September 2001 Eligibility criteria included patient age younger than 40 years prior conization with negative margins and the desire to preserve fertility Each cone biopsy specimen was secondarily reviewed Postconization surveillance consisted of a liquid-based Pap test and endocervical curettage ECC every 4 months Follow-up ended in September 2002 Ten women with a median age of 32 years range 26-37 were enrolled Six were nulliparous and 2 primiparous Seven patients were clinically free of disease after a median of 21 months range 5-24 2 were lost to follow-up and 1 was excluded when AIS could not be confirmed on the original specimen Twenty-eight Pap smears and 18 ECCs were performed but no additional surgical procedures were required due to abnormal cytopathology This prospective trial on postconization surveillance demonstrated the safety of conservative management for AIS patients desiring to preserve fertility,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 4073, 8, 617, 160, 50, 8755, 6, 1143, 223, 3, 228, 1, 4476, 284, 1, 449, 4, 957, 3826, 117, 265, 5, 3826, 11, 1143, 346, 29, 2636, 1081, 6, 2636, 1758, 2317, 371, 159, 69, 89, 773, 76, 327, 60, 324, 8755, 5, 199, 1012, 2, 3, 5278, 6, 6783, 2954, 296, 6939, 411, 2360, 10, 12974, 446, 35603, 617, 1695, 1, 8, 3165, 90, 4290, 412, 2, 10174, 12529, 18238, 454, 39, 53, 166, 126, 8909, 4, 2636, 1544, 1618, 117, 5, 8, 52, 89, 1, 531, 60, 184, 432, 567, 11, 346, 437, 11, 9475, 2, 18, 37943, 648, 7, 11, 505, 115, 1, 34, 50, 8, 52, 1, 239, 53, 184, 33, 259, 18, 11, 3009, 6, 166, 126, 2, 14, 10, 1800, 198, 3826, 359, 44, 40, 557, 23, 3, 2279, 2360, 737, 659, 4290, 8916, 2, 203, 43105, 11, 173, 84, 77, 402, 221, 1369, 11, 616, 520, 6, 1668, 21569, 26, 482, 160, 23, 35603, 617, 264, 3, 367, 1, 4476, 284, 9, 3826, 7, 20520, 6, 6783, 2954]",,14619639,428
Phase II study of cisplatin and vinorelbine in squamous cell carcinoma of the cervix: a gynecologic oncology group study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2004-08-01,"To evaluate the efficacy and toxicity of intravenous cisplatin and vinorelbine as combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the cervix. Between August 1997 and January 2001, 73 patients with advanced or recurrent squamous cell carcinoma of the cervix were entered onto this study. Eligible patients had received no prior therapeutic chemotherapy, except when administered concurrent with primary radiation therapy. The initial doses administered were cisplatin 75 mg/m(2) every 4 weeks and vinorelbine 30 mg/m(2) weekly. Subsequent doses were unchanged, reduced, escalated, or omitted according to observed toxicity and protocol guidelines. Patients were evaluated for response and toxicity using standard Gynecologic Oncology Group criteria. Of 73 patients, 67 were eligible and assessable. The overall response rate was 30% (five complete and 15 partial responses). The overall median response duration was 5.5+ months. The major toxicity was neutropenia, with 16% grade 3 and 67% grade 4 reported. Gastrointestinal and neurotoxicity were infrequent and mild. The combination of cisplatin and vinorelbine has moderate activity in advanced or recurrent squamous cell carcinoma of the cervix. Additional study of this regimen in a phase III setting is justified in this patient population.",Clinical Trial,5651.0,51.0,To evaluate the efficacy and toxicity of intravenous cisplatin and vinorelbine as combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the cervix Between August 1997 and January 2001 73 patients with advanced or recurrent squamous cell carcinoma of the cervix were entered onto this study Eligible patients had received no prior therapeutic chemotherapy except when administered concurrent with primary radiation therapy The initial doses administered were cisplatin 75 mg/m 2 every 4 weeks and vinorelbine 30 mg/m 2 weekly Subsequent doses were unchanged reduced escalated or omitted according to observed toxicity and protocol guidelines Patients were evaluated for response and toxicity using standard Gynecologic Oncology Group criteria Of 73 patients 67 were eligible and assessable The overall response rate was 30 five complete and 15 partial responses The overall median response duration was 5.5+ months The major toxicity was neutropenia with 16 grade 3 and 67 grade 4 reported and neurotoxicity were infrequent and mild The combination of cisplatin and vinorelbine has moderate activity in advanced or recurrent squamous cell carcinoma of the cervix Additional study of this regimen in a phase III setting is justified in this patient population,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 376, 3, 209, 2, 155, 1, 1262, 540, 2, 3676, 22, 150, 56, 4, 7, 5, 131, 15, 387, 691, 31, 134, 1, 3, 3629, 59, 2480, 2341, 2, 1024, 1758, 803, 7, 5, 131, 15, 387, 691, 31, 134, 1, 3, 3629, 11, 2836, 3301, 26, 45, 625, 7, 42, 103, 77, 324, 189, 56, 2187, 198, 468, 750, 5, 86, 121, 36, 3, 388, 415, 468, 11, 540, 481, 81, 188, 18, 454, 39, 244, 2, 3676, 201, 81, 188, 18, 709, 706, 415, 11, 4639, 405, 2842, 15, 7138, 768, 6, 164, 155, 2, 1182, 677, 7, 11, 194, 9, 51, 2, 155, 75, 260, 1512, 413, 87, 371, 1, 803, 7, 598, 11, 625, 2, 3120, 3, 63, 51, 116, 10, 201, 365, 236, 2, 167, 450, 253, 3, 63, 52, 51, 654, 10, 33, 33, 53, 3, 458, 155, 10, 778, 5, 245, 88, 27, 2, 598, 88, 39, 210, 2, 3561, 11, 4475, 2, 1980, 3, 150, 1, 540, 2, 3676, 71, 1163, 128, 4, 131, 15, 387, 691, 31, 134, 1, 3, 3629, 402, 45, 1, 26, 477, 4, 8, 124, 316, 546, 16, 6860, 4, 26, 69, 266]",,15310778,379
Metastatic spinal cord compression by solid tumors.,Seminars in neurology,Semin Neurol,2004-12-01,"As the survival of cancer patients continues to improve, physicians in the 21st century face the challenge of early detection of metastatic spinal cord compression. Prompt diagnosis and intervention increase the likelihood of functional recovery. Because the epidural space is the most common site of spinal cord metastasis from solid tumors, this article will review the epidemiology, relevant anatomy, pathophysiology, clinical presentation, diagnostic evaluation, treatment, and prognosis for metastatic epidural spinal cord compression. Special attention will be given to the various modalities available for management of metastatic epidural spinal cord compression to maintain or restore normal spinal cord function and relieve pain. These treatment options will be considered according to patients' disease burden, life expectancy, and values. Intramedullary metastasis will be briefly discussed.",Journal Article,5529.0,44.0,As the survival of cancer patients continues to improve physicians in the 21st century face the challenge of early detection of metastatic spinal cord compression Prompt diagnosis and intervention increase the likelihood of functional recovery Because the epidural space is the most common site of spinal cord metastasis from solid tumors this article will review the epidemiology relevant anatomy pathophysiology clinical presentation diagnostic evaluation treatment and prognosis for metastatic epidural spinal cord compression Special attention will be given to the various modalities available for management of metastatic epidural spinal cord compression to maintain or restore normal spinal cord function and relieve pain These treatment options will be considered according to patients disease burden life expectancy and values Intramedullary metastasis will be briefly discussed,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[22, 3, 25, 1, 12, 7, 2274, 6, 401, 1261, 4, 3, 17245, 7981, 3376, 3, 1745, 1, 191, 638, 1, 113, 1499, 1885, 3481, 4776, 147, 2, 788, 344, 3, 1420, 1, 583, 1602, 408, 3, 5844, 3865, 16, 3, 96, 186, 606, 1, 1499, 1885, 278, 29, 537, 57, 26, 946, 303, 206, 3, 1284, 867, 5081, 4320, 38, 1031, 752, 451, 24, 2, 356, 9, 113, 5844, 1499, 1885, 3481, 3714, 2111, 303, 40, 447, 6, 3, 747, 1558, 390, 9, 284, 1, 113, 5844, 1499, 1885, 3481, 6, 3040, 15, 6075, 295, 1499, 1885, 343, 2, 9635, 559, 46, 24, 838, 303, 40, 515, 768, 6, 7, 34, 892, 358, 3399, 2, 1030, 8686, 278, 303, 40, 6277, 1588]",,15637649,364
Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.,Obstetrics and gynecology,Obstet Gynecol,2005-05-01,"To compare the efficacy of dalteparin, a low-molecular-weight heparin, to unfractionated heparin (UFH) in the prevention of deep venous thrombosis (DVT) and pulmonary embolism in patients after surgery for gynecologic malignancy. The medical records of all patients undergoing major surgery on the Gynecologic Oncology Service at the Massachusetts General Hospital from July 2002 through April 2003 were reviewed. Patients with confirmed malignancy were included. Between July 1, 2002, and November 15, 2002, dalteparin (5,000 U subcutaneously each day) was used for postoperative prophylaxis for DVT and pulmonary embolus. After November 15, 2002, the method of prophylaxis was changed to UFH (5,000 U subcutaneously every 8 hours) exclusively. Patients were evaluated for DVT or pulmonary embolus based on clinical suspicion using computed tomographic angiography, ventilation and perfusion scan, or lower extremity doppler. A total of 214 patients were identified who met study criteria. Dalteparin was administered to 103 patients, and UFH was administered to 111. The rates of clinically significant DVT or pulmonary embolus in patients receiving dalteparin and UFH were 8.9% and 1.2%, respectively (P = .009). Major risk factors for DVT or pulmonary embolus, including age, obesity, duration of surgery, and type of malignancy, did not differ between groups. There were no significant differences in bleeding complications or transfusion requirements between groups. The low-molecular-weight heparin dalteparin dosed 5,000 U daily is inadequate postoperative prophylaxis in women undergoing surgery for gynecologic cancer. In addition, heparin administered every 8 hours was not associated with increased bleeding complications. The use of dalteparin at the doses used in this study should be questioned until a large randomized trial shows efficacy in these high-risk patients.",Comparative Study,5378.0,13.0,"To compare the efficacy of dalteparin a low-molecular-weight heparin to unfractionated heparin UFH in the prevention of deep venous thrombosis DVT and pulmonary embolism in patients after surgery for gynecologic malignancy The medical records of all patients undergoing major surgery on the Gynecologic Oncology Service at the Massachusetts General Hospital from July 2002 through April 2003 were reviewed Patients with confirmed malignancy were included Between July 1 2002 and November 15 2002 dalteparin 5,000 U subcutaneously each day was used for postoperative prophylaxis for DVT and pulmonary embolus After November 15 2002 the method of prophylaxis was changed to UFH 5,000 U subcutaneously every 8 hours exclusively Patients were evaluated for DVT or pulmonary embolus based on clinical suspicion using computed tomographic angiography ventilation and perfusion scan or lower extremity doppler A total of 214 patients were identified who met study criteria Dalteparin was administered to 103 patients and UFH was administered to 111 The rates of clinically significant DVT or pulmonary embolus in patients receiving dalteparin and UFH were 8.9 and 1.2 respectively P .009 Major risk factors for DVT or pulmonary embolus including age obesity duration of surgery and type of malignancy did not differ between groups There were no significant differences in bleeding complications or transfusion requirements between groups The low-molecular-weight heparin dalteparin dosed 5,000 U daily is inadequate postoperative prophylaxis in women undergoing surgery for gynecologic cancer In addition heparin administered every 8 hours was not associated with increased bleeding complications The use of dalteparin at the doses used in this study should be questioned until a large randomized trial shows efficacy in these high-risk patients",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 932, 3, 209, 1, 16667, 8, 154, 219, 924, 7309, 6, 16341, 7309, 32994, 4, 3, 1070, 1, 2369, 2167, 2839, 6311, 2, 1087, 5475, 4, 7, 50, 152, 9, 1512, 710, 3, 484, 1064, 1, 62, 7, 479, 458, 152, 23, 3, 1512, 413, 3086, 28, 3, 5459, 1083, 702, 29, 2066, 1544, 298, 2292, 1522, 11, 446, 7, 5, 557, 710, 11, 159, 59, 2066, 14, 1544, 2, 2868, 167, 1544, 16667, 33, 984, 1767, 3928, 296, 218, 10, 95, 9, 573, 2049, 9, 6311, 2, 1087, 12738, 50, 2868, 167, 1544, 3, 596, 1, 2049, 10, 2368, 6, 32994, 33, 984, 1767, 3928, 454, 66, 1459, 4437, 7, 11, 194, 9, 6311, 15, 1087, 12738, 90, 23, 38, 5782, 75, 1220, 6158, 8078, 7845, 2, 3018, 1657, 15, 280, 2678, 10644, 8, 181, 1, 6900, 7, 11, 108, 54, 543, 45, 371, 16667, 10, 468, 6, 3283, 7, 2, 32994, 10, 468, 6, 3167, 3, 151, 1, 505, 93, 6311, 15, 1087, 12738, 4, 7, 357, 16667, 2, 32994, 11, 66, 83, 2, 14, 18, 106, 19, 2376, 458, 43, 130, 9, 6311, 15, 1087, 12738, 141, 89, 1661, 654, 1, 152, 2, 267, 1, 710, 205, 44, 1505, 59, 271, 125, 11, 77, 93, 362, 4, 2294, 521, 15, 2785, 4230, 59, 271, 3, 154, 219, 924, 7309, 16667, 6268, 33, 984, 1767, 391, 16, 3358, 573, 2049, 4, 117, 479, 152, 9, 1512, 12, 4, 352, 7309, 468, 454, 66, 1459, 10, 44, 41, 5, 101, 2294, 521, 3, 119, 1, 16667, 28, 3, 415, 95, 4, 26, 45, 257, 40, 9089, 1100, 8, 375, 384, 160, 1949, 209, 4, 46, 64, 43, 7]",,15863537,243
Using navigators to improve care of underserved patients: current practices and approaches.,Cancer,Cancer,2005-08-01,"Logistic, cultural, educational, and other barriers can impede the delivery of high-quality cancer care to underserved patients. Patient navigation services represent one innovation for addressing perceived barriers to care encountered by disadvantaged patients. In this report, the authors have 1) defined patient navigation, distinguishing it from other cancer support services; 2) described how programs are organized; and 3) discussed the need for research on program effectiveness. Information was examined on navigation programs published in the scientific literature and on line. Qualitative research also was conducted, consisting of direct observation of patient care in cancer clinics with and without navigators in northern California, in-person interviews with personnel and patients in the clinics observed, and telephone interviews with navigators at four sites across the United States. The authors found that navigation services have been implemented at all stages of cancer care: prevention, screening, treatment, and survival. Navigators differ from other cancer support personnel in their orientation toward flexible problem solving to overcome perceived barriers to care rather than the provision of a predefined set of services. There are no rigorous demonstrations of the effects and effectiveness of navigation, although such studies are underway. Currently, patient navigation is understudied, and literature documenting its effects and effectiveness is scant. Rigorous studies are needed of the navigator role and program costs and benefits. Such studies will facilitate an assessment of program effectiveness, feasibility across a range of health care settings, and performance relative to alternative approaches for addressing barriers to care among the underserved.",Journal Article,5286.0,302.0,Logistic cultural educational and other barriers can impede the delivery of high-quality cancer care to underserved patients Patient navigation services represent one innovation for addressing perceived barriers to care encountered by disadvantaged patients In this report the authors have 1 defined patient navigation distinguishing it from other cancer support services 2 described how programs are organized and 3 discussed the need for research on program effectiveness Information was examined on navigation programs published in the scientific literature and on line Qualitative research also was conducted consisting of direct observation of patient care in cancer clinics with and without navigators in northern California in-person interviews with personnel and patients in the clinics observed and telephone interviews with navigators at four sites across the United States The authors found that navigation services have been implemented at all stages of cancer care prevention screening treatment and survival Navigators differ from other cancer support personnel in their orientation toward flexible problem solving to overcome perceived barriers to care rather than the provision of a predefined set of services There are no rigorous demonstrations of the effects and effectiveness of navigation although such studies are underway Currently patient navigation is understudied and literature documenting its effects and effectiveness is scant Rigorous studies are needed of the navigator role and program costs and benefits Such studies will facilitate an assessment of program effectiveness feasibility across a range of health care settings and performance relative to alternative approaches for addressing barriers to care among the underserved,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[812, 8587, 3624, 2, 127, 2160, 122, 11290, 3, 989, 1, 64, 372, 12, 165, 6, 6960, 7, 69, 5604, 2142, 1231, 104, 13091, 9, 3432, 2588, 2160, 6, 165, 3903, 20, 16700, 7, 4, 26, 414, 3, 738, 47, 14, 395, 69, 5604, 4508, 192, 29, 127, 12, 538, 2142, 18, 1027, 832, 2251, 32, 7511, 2, 27, 1588, 3, 594, 9, 389, 23, 1243, 1236, 487, 10, 409, 23, 5604, 2251, 983, 4, 3, 3138, 789, 2, 23, 328, 3926, 389, 120, 10, 426, 2273, 1, 1196, 1664, 1, 69, 165, 4, 12, 4736, 5, 2, 187, 15368, 4, 7088, 4355, 4, 2719, 4053, 5, 13966, 2, 7, 4, 3, 4736, 164, 2, 4258, 4053, 5, 15368, 28, 294, 633, 716, 3, 1088, 907, 3, 738, 204, 17, 5604, 2142, 47, 85, 3426, 28, 62, 1153, 1, 12, 165, 1070, 453, 24, 2, 25, 15368, 1505, 29, 127, 12, 538, 13966, 4, 136, 11604, 1317, 6940, 2497, 18471, 6, 1768, 2588, 2160, 6, 165, 1832, 76, 3, 6832, 1, 8, 5944, 916, 1, 2142, 125, 32, 77, 6496, 33995, 1, 3, 176, 2, 1236, 1, 5604, 242, 225, 94, 32, 3948, 694, 69, 5604, 16, 8207, 2, 789, 9255, 211, 176, 2, 1236, 16, 11578, 6496, 94, 32, 575, 1, 3, 18560, 200, 2, 1243, 1201, 2, 1141, 225, 94, 303, 1876, 35, 455, 1, 1243, 1236, 1437, 716, 8, 184, 1, 341, 165, 1947, 2, 528, 580, 6, 1091, 611, 9, 3432, 2160, 6, 165, 107, 3, 6960]",,16010658,68
Intrathoracic leaks following esophagectomy are no longer associated with increased mortality.,Annals of surgery,Ann. Surg.,2005-09-01,"Assess outcomes following intrathoracic leaks after esophagectomy from 1970 to 2004 to evaluate the impact of evolving surgical and perioperative techniques on leak-associated mortality (LAM). An intrathoracic leak following esophagectomy has historically been considered a catastrophic event, with mortality as high as 71%. Concerns about this complication often affect choice of surgical approach for esophagectomy. A retrospective review of all esophagectomies for cancer from 1970 to 2004 (n = 1223) was performed. Outcomes following intrathoracic anastomoses (n = 621) were analyzed by era: historical 1970-1986 (n = 145) and modern 1987-2004 (n = 476). There was no difference in the frequency of leak between the time intervals (4.8% versus 6.3%, P = 0.5). Despite a significant increase in the use of preoperative chemoradiation (1% versus 42%, P < 0.001) in the historical versus modern era, the overall mortality decreased from 11% to 2.5% (P < 0.001). The LAM was markedly reduced from 43% to 3.3% (P = 0.016). Factors associated with LAM included failure to use enteral nutrition (HR 13.22, CI 1.8-96.8) and era in which the surgery was performed (HR 18.3, 1.9-180). Other differences included an increased proportion of successful reoperations for leak control (11/30 versus 0/7, P = 0.08) and use of reinforcing muscle flaps (7/11). In the modern era, perioperative mortality is not significantly different for patients with or without intrathoracic leaks (3.3% versus 2.5%, P = 0.55), nor is long-term survival (P = 0.16). Modern surgical management of intrathoracic leaks results in no increased mortality and has no impact on long-term survival. Clinical decisions regarding the use of intrathoracic anastomoses should not be affected by concerns of increased mortality from leak.",Journal Article,5255.0,93.0,Assess outcomes following intrathoracic leaks after esophagectomy from 1970 to 2004 to evaluate the impact of evolving surgical and perioperative techniques on leak-associated mortality LAM An intrathoracic leak following esophagectomy has historically been considered a catastrophic event with mortality as high as 71 Concerns about this complication often affect choice of surgical approach for esophagectomy A retrospective review of all esophagectomies for cancer from 1970 to 2004 n 1223 was performed Outcomes following intrathoracic anastomoses n 621 were analyzed by era historical 1970-1986 n 145 and modern 1987-2004 n 476 There was no difference in the frequency of leak between the time intervals 4.8 versus 6.3 P 0.5 Despite a significant increase in the use of preoperative chemoradiation 1 versus 42 P 0.001 in the historical versus modern era the overall mortality decreased from 11 to 2.5 P 0.001 The LAM was markedly reduced from 43 to 3.3 P 0.016 Factors associated with LAM included failure to use enteral nutrition HR 13.22 CI 1.8-96.8 and era in which the surgery was performed HR 18.3 1.9-180 Other differences included an increased proportion of successful reoperations for leak control 11/30 versus 0/7 P 0.08 and use of reinforcing muscle flaps 7/11 In the modern era perioperative mortality is not significantly different for patients with or without intrathoracic leaks 3.3 versus 2.5 P 0.55 nor is long-term survival P 0.16 Modern surgical management of intrathoracic leaks results in no increased mortality and has no impact on long-term survival Clinical decisions regarding the use of intrathoracic anastomoses should not be affected by concerns of increased mortality from leak,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[423, 123, 366, 7359, 9674, 50, 3617, 29, 4868, 6, 1131, 6, 376, 3, 345, 1, 3276, 221, 2, 1547, 1092, 23, 4238, 41, 282, 10501, 35, 7359, 4238, 366, 3617, 71, 3578, 85, 515, 8, 16253, 774, 5, 282, 22, 64, 22, 792, 2061, 545, 26, 1447, 629, 1158, 1866, 1, 221, 353, 9, 3617, 8, 459, 206, 1, 62, 25338, 9, 12, 29, 4868, 6, 1131, 78, 75591, 10, 173, 123, 366, 7359, 13311, 78, 12202, 11, 311, 20, 1713, 2252, 4868, 3751, 78, 4058, 2, 2366, 5450, 1131, 78, 10652, 125, 10, 77, 523, 4, 3, 675, 1, 4238, 59, 3, 98, 1582, 39, 66, 185, 49, 27, 19, 13, 33, 550, 8, 93, 344, 4, 3, 119, 1, 498, 975, 14, 185, 595, 19, 13, 144, 4, 3, 2252, 185, 2366, 1713, 3, 63, 282, 340, 29, 175, 6, 18, 33, 19, 13, 144, 3, 10501, 10, 2195, 405, 29, 601, 6, 27, 27, 19, 13, 3820, 130, 41, 5, 10501, 159, 496, 6, 119, 14781, 5260, 168, 233, 350, 58, 14, 66, 921, 66, 2, 1713, 4, 92, 3, 152, 10, 173, 168, 203, 27, 14, 83, 3172, 127, 362, 159, 35, 101, 920, 1, 1401, 10691, 9, 4238, 182, 175, 201, 185, 13, 67, 19, 13, 1592, 2, 119, 1, 18356, 1502, 9039, 67, 175, 4, 3, 2366, 1713, 1547, 282, 16, 44, 97, 338, 9, 7, 5, 15, 187, 7359, 9674, 27, 27, 185, 18, 33, 19, 13, 614, 2110, 16, 319, 337, 25, 19, 13, 245, 2366, 221, 284, 1, 7359, 9674, 99, 4, 77, 101, 282, 2, 71, 77, 345, 23, 319, 337, 25, 38, 1526, 666, 3, 119, 1, 7359, 13311, 257, 44, 40, 1424, 20, 2061, 1, 101, 282, 29, 4238]",,16135925,326
Fertility-sparing options for patients with gynecologic malignancies.,The oncologist,Oncologist,2005-09-01,"Gynecologic malignancies are most often diagnosed in postmenopausal women, but these malignancies also arise in premenopausal women, in whom issues of fertility can be a major concern. An increasing number of women are delaying childbearing. This has led to a significant increase in the number of women diagnosed with a gynecologic malignancy before desired completion of childbearing. Many of the standard treatments for these malignancies result in permanent sterility; however, there are now options for select young women who desire to preserve fertility. Patients should be told that data on fertility-sparing procedures are limited and that many of these options are of an experimental, nonstandard nature. The care of these patients is challenging and complex and requires a multidisciplinary approach, which should include gynecologic oncologists, reproductive endocrinologists, and perinatologists.",Journal Article,5255.0,29.0,Gynecologic malignancies are most often diagnosed in postmenopausal women but these malignancies also arise in premenopausal women in whom issues of fertility can be a major concern An increasing number of women are delaying childbearing This has led to a significant increase in the number of women diagnosed with a gynecologic malignancy before desired completion of childbearing Many of the standard treatments for these malignancies result in permanent sterility however there are now options for select young women who desire to preserve fertility Patients should be told that data on fertility-sparing procedures are limited and that many of these options are of an experimental nonstandard nature The care of these patients is challenging and complex and requires a multidisciplinary approach which should include gynecologic oncologists reproductive endocrinologists and perinatologists,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[1512, 441, 32, 96, 629, 265, 4, 1679, 117, 84, 46, 441, 120, 3043, 4, 2710, 117, 4, 953, 1553, 1, 2954, 122, 40, 8, 458, 2893, 35, 602, 207, 1, 117, 32, 7151, 10278, 26, 71, 836, 6, 8, 93, 344, 4, 3, 207, 1, 117, 265, 5, 8, 1512, 710, 348, 6115, 1438, 1, 10278, 445, 1, 3, 260, 640, 9, 46, 441, 757, 4, 4377, 30680, 137, 125, 32, 1134, 838, 9, 1717, 1169, 117, 54, 5278, 6, 6783, 2954, 7, 257, 40, 14786, 17, 74, 23, 2954, 1851, 1369, 32, 383, 2, 17, 445, 1, 46, 838, 32, 1, 35, 1560, 18798, 2202, 3, 165, 1, 46, 7, 16, 1950, 2, 840, 2, 1706, 8, 1643, 353, 92, 257, 643, 1512, 1339, 3705, 42331, 2, 51730]",,16177285,2
Quality of life and gynecologic malignancies.,Current oncology reports,Curr Oncol Rep,2005-11-01,"In 2005, an estimated 79,480 new cases of gynecologic malignancies will be diagnosed, and almost 29,000 women will die. Treatment of gynecologic malignancies involves a combination of surgery, chemotherapy, and/or radiotherapy, all of which may affect a woman's physical, social, and emotional well-being. Although specific effects on quality of life (QOL) depend on disease site, treatment-, and patient-specific factors, common QOL issues include changes in physical functioning due to side effects of treatment, psychological distress due to fear and anxiety of recurrence, sexual dysfunction associated with anatomic and physiologic changes of treatment, and, for younger women, loss of childbearing potential. As new diagnostic and treatment strategies for gynecologic malignancies are developed, research efforts should include QOL consequences. Further studies are needed to develop strategies for identifying women at risk for serious QOL disruption so that effective interventions to assist these women can be designed.",Journal Article,5194.0,,"In 2005 an estimated 79,480 new cases of gynecologic malignancies will be diagnosed and almost 29,000 women will die Treatment of gynecologic malignancies involves a combination of surgery chemotherapy and/or radiotherapy all of which may affect a woman 's physical social and emotional well-being Although specific effects on quality of life QOL depend on disease site treatment- and patient-specific factors common QOL issues include changes in physical functioning due to side effects of treatment psychological distress due to fear and anxiety of recurrence sexual dysfunction associated with anatomic and physiologic changes of treatment and for younger women loss of childbearing potential As new diagnostic and treatment strategies for gynecologic malignancies are developed research efforts should include QOL consequences Further studies are needed to develop strategies for identifying women at risk for serious QOL disruption so that effective interventions to assist these women can be designed",0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[4, 1242, 35, 661, 842, 9108, 217, 140, 1, 1512, 441, 303, 40, 265, 2, 2214, 462, 984, 117, 303, 3384, 24, 1, 1512, 441, 2921, 8, 150, 1, 152, 56, 2, 15, 310, 62, 1, 92, 68, 1158, 8, 2854, 292, 900, 2032, 2, 2671, 149, 486, 242, 112, 176, 23, 372, 1, 358, 1001, 4533, 23, 34, 606, 24, 2, 69, 112, 130, 186, 1001, 1553, 643, 400, 4, 900, 2702, 520, 6, 1152, 176, 1, 24, 2624, 1462, 520, 6, 6443, 2, 2021, 1, 146, 2232, 1527, 41, 5, 2745, 2, 4628, 400, 1, 24, 2, 9, 773, 117, 407, 1, 10278, 174, 22, 217, 752, 2, 24, 422, 9, 1512, 441, 32, 276, 389, 1413, 257, 643, 1001, 3255, 195, 94, 32, 575, 6, 690, 422, 9, 1386, 117, 28, 43, 9, 1762, 1001, 3220, 1743, 17, 323, 1151, 6, 3425, 46, 117, 122, 40, 1114]",,16221383,14
Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2006-04-01,"The purpose of this study was to assess the value of preoperative lymphoscintigraphy before intraoperative lymphatic mapping for sentinel lymph node identification during radical hysterectomy. Fifty patients underwent intraoperative lymphatic mapping on our institutional review board-approved protocol. The location of sentinel lymph nodes that were found on lymphoscintigraphy and intraoperative lymphatic mapping were compared. Fifteen of 21 patients (71%) with solitary sentinel lymph nodes that were found on lymphoscintigraphy had multiple sentinel lymph node basins found during the operation. Thirteen of 25 patients (52%) with unilateral sentinel lymph node basins that were found on lymphoscintigraphy had bilateral sentinel lymph nodes at intraoperative lymphatic mapping. Of 15 patients with 2 sentinel lymph node locations that were identified on lymphoscintigraphy, 12 patients (80%) had > or = 3 found during the operation. Of the sentinel lymph nodes that were located on the external iliac basin (n = 47) on lymphoscintigraphy, only 20 lymph nodes (43%) were found at that location during the operation. Concordance between the 2 methods was poor. Seven of the 9 patients with lymph node metastases had disease that was limited to the sentinel lymph nodes. Preoperative lymphoscintigraphy adds little value over intraoperative lymphatic mapping for sentinel lymph node identification during radical hysterectomy.",Journal Article,5043.0,31.0,The purpose of this study was to assess the value of preoperative lymphoscintigraphy before intraoperative lymphatic mapping for sentinel lymph node identification during radical hysterectomy Fifty patients underwent intraoperative lymphatic mapping on our institutional review board-approved protocol The location of sentinel lymph nodes that were found on lymphoscintigraphy and intraoperative lymphatic mapping were compared Fifteen of 21 patients 71 with solitary sentinel lymph nodes that were found on lymphoscintigraphy had multiple sentinel lymph node basins found during the operation Thirteen of 25 patients 52 with unilateral sentinel lymph node basins that were found on lymphoscintigraphy had bilateral sentinel lymph nodes at intraoperative lymphatic mapping Of 15 patients with 2 sentinel lymph node locations that were identified on lymphoscintigraphy 12 patients 80 had or 3 found during the operation Of the sentinel lymph nodes that were located on the external iliac basin n 47 on lymphoscintigraphy only 20 lymph nodes 43 were found at that location during the operation Concordance between the 2 methods was poor Seven of the 9 patients with lymph node metastases had disease that was limited to the sentinel lymph nodes Preoperative lymphoscintigraphy adds little value over intraoperative lymphatic mapping for sentinel lymph node identification during radical hysterectomy,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 423, 3, 549, 1, 498, 6849, 348, 1720, 2936, 2568, 9, 1323, 263, 289, 911, 190, 711, 2622, 1461, 7, 208, 1720, 2936, 2568, 23, 114, 1115, 206, 2620, 850, 1182, 3, 1147, 1, 1323, 263, 502, 17, 11, 204, 23, 6849, 2, 1720, 2936, 2568, 11, 72, 3057, 1, 239, 7, 792, 5, 3144, 1323, 263, 502, 17, 11, 204, 23, 6849, 42, 232, 1323, 263, 289, 7847, 204, 190, 3, 2589, 3170, 1, 243, 7, 653, 5, 3208, 1323, 263, 289, 7847, 17, 11, 204, 23, 6849, 42, 1607, 1323, 263, 502, 28, 1720, 2936, 2568, 1, 167, 7, 5, 18, 1323, 263, 289, 4069, 17, 11, 108, 23, 6849, 133, 7, 493, 42, 15, 27, 204, 190, 3, 2589, 1, 3, 1323, 263, 502, 17, 11, 2308, 23, 3, 1455, 6692, 6969, 78, 662, 23, 6849, 158, 179, 263, 502, 601, 11, 204, 28, 17, 1147, 190, 3, 2589, 1827, 59, 3, 18, 636, 10, 334, 648, 1, 3, 83, 7, 5, 263, 289, 196, 42, 34, 17, 10, 383, 6, 3, 1323, 263, 502, 498, 6849, 6659, 1215, 549, 252, 1720, 2936, 2568, 9, 1323, 263, 289, 911, 190, 711, 2622]",,16580331,740
Intensity-modulated radiation therapy in gynecologic malignancies: current status and future directions.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2006-05-01,"Radiation therapy is used as either definitive or adjuvant therapy following surgery in many gynecologic malignancies. Though effective, radiation therapy is limited by the adverse sequelae that result from normal tissues receiving external-beam radiation. A novel approach, intensity-modulated radiation therapy, can overcome these limitations by sparing the tissue surrounding the malignancy through conforming the dose to the shape of the target in three dimensions. This review provides an overview of current use, published research, and ongoing studies of intensity-modulated radiation therapy.",Journal Article,5013.0,7.0,Radiation therapy is used as either definitive or adjuvant therapy following surgery in many gynecologic malignancies Though effective radiation therapy is limited by the adverse sequelae that result from normal tissues receiving external-beam radiation A novel approach intensity-modulated radiation therapy can overcome these limitations by sparing the tissue surrounding the malignancy through conforming the dose to the shape of the target in three dimensions This review provides an overview of current use published research and ongoing studies of intensity-modulated radiation therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[121, 36, 16, 95, 22, 361, 1057, 15, 249, 36, 366, 152, 4, 445, 1512, 441, 2471, 323, 121, 36, 16, 383, 20, 3, 290, 4156, 17, 757, 29, 295, 742, 357, 1455, 1345, 121, 8, 229, 353, 837, 1757, 121, 36, 122, 1768, 46, 1939, 20, 1851, 3, 246, 2976, 3, 710, 298, 39383, 3, 61, 6, 3, 5465, 1, 3, 283, 4, 169, 6190, 26, 206, 777, 35, 2901, 1, 291, 119, 983, 389, 2, 942, 94, 1, 837, 1757, 121, 36]",,16728946,686
A novel model of intramedullary spinal cord tumors in rats: functional progression and histopathological characterization.,Neurosurgery,Neurosurgery,2006-07-01,"Intramedullary spinal cord tumors are difficult lesions to treat given their recurrence rate and limited treatment options. The absence of an adequate animal model, however, has hindered the development of new treatment paradigms. In this study, we describe the technique for intramedullary injection of two experimental rodent gliomas (9L and F98) and present the methodology for functional and histopathological analysis of tumor progression. F344 rats (n = 24) were randomized into three groups. Group 1 (n = 8) received a 5 microl intramedullary injection of Dulbecco's modified Eagle medium, Group 2 received a 5 microl intramedullary injection of 9L gliosarcoma (100,000) cells, and Group 3 received a 5 microl intramedullary injection of F98 glioma (100,000) cells. The animals were anesthetized, a 2 cm incision was made in the dorsal mid-thoracic region, and the spinous process of the T5 vertebrae was removed to expose the intervertebral space. The ligamentum flavum was removed, and an intramedullary injection was made into the spinal cord. The animals were evaluated daily for signs of paralysis using the Basso, Beattie, and Bresnahan scale and sacrificed after the onset of deficits for histopathological analysis. Animals injected with 9L-gliosarcoma had a median onset of hind limb paresis at 12 +/- 2.9 days. Animals injected with F98 glioma had a median onset of hind limb paresis at 19 +/- 3 days. Animals injected with Dulbecco's modified Eagle medium did not show neurological deficits. Hematoxylin-eosin cross sections confirmed the presence of intramedullary 9L and F98 tumor invading the spinal cord. Control animals had no significant histopathological findings. Animals injected with 9L or F98 consistently developed hind limb paresis in a reliable and reproducible manner. The progression of neurological deficits is similar to that seen in patients with intramedullary spinal cord tumors. These findings suggest that this model mimics the behavior of intramedullary spinal cord tumors in humans and may be used to examine the efficacy of new treatment options for both low- and high-grade intramedullary tumors.",Journal Article,4952.0,19.0,"Intramedullary spinal cord tumors are difficult lesions to treat given their recurrence rate and limited treatment options The absence of an adequate animal model however has hindered the development of new treatment paradigms In this study we describe the technique for intramedullary injection of two experimental rodent gliomas 9L and F98 and present the methodology for functional and histopathological analysis of tumor progression F344 rats n 24 were randomized into three groups Group 1 n 8 received a 5 microl intramedullary injection of Dulbecco 's modified Eagle medium Group 2 received a 5 microl intramedullary injection of 9L gliosarcoma 100,000 cells and Group 3 received a 5 microl intramedullary injection of F98 glioma 100,000 cells The animals were anesthetized a 2 cm incision was made in the dorsal mid-thoracic region and the spinous process of the T5 vertebrae was removed to expose the intervertebral space The ligamentum flavum was removed and an intramedullary injection was made into the spinal cord The animals were evaluated daily for signs of paralysis using the Basso Beattie and Bresnahan scale and sacrificed after the onset of deficits for histopathological analysis Animals injected with 9L-gliosarcoma had a median onset of hind limb paresis at 12 +/- 2.9 days Animals injected with F98 glioma had a median onset of hind limb paresis at 19 +/- 3 days Animals injected with Dulbecco 's modified Eagle medium did not show neurological deficits Hematoxylin-eosin cross sections confirmed the presence of intramedullary 9L and F98 tumor invading the spinal cord Control animals had no significant histopathological findings Animals injected with 9L or F98 consistently developed hind limb paresis in a reliable and reproducible manner The progression of neurological deficits is similar to that seen in patients with intramedullary spinal cord tumors These findings suggest that this model mimics the behavior of intramedullary spinal cord tumors in humans and may be used to examine the efficacy of new treatment options for both low- and high-grade intramedullary tumors",0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,"[8686, 1499, 1885, 57, 32, 1740, 406, 6, 943, 447, 136, 146, 116, 2, 383, 24, 838, 3, 1127, 1, 35, 1658, 2026, 202, 137, 71, 9981, 3, 193, 1, 217, 24, 4887, 4, 26, 45, 21, 897, 3, 1312, 9, 8686, 1754, 1, 100, 1560, 7713, 1287, 7963, 2, 13389, 2, 364, 3, 3209, 9, 583, 2, 4370, 65, 1, 30, 91, 23362, 3765, 78, 259, 11, 384, 237, 169, 271, 87, 14, 78, 66, 103, 8, 33, 5128, 8686, 1754, 1, 29979, 292, 1230, 32875, 3759, 87, 18, 103, 8, 33, 5128, 8686, 1754, 1, 7963, 7536, 394, 984, 37, 2, 87, 27, 103, 8, 33, 5128, 8686, 1754, 1, 13389, 945, 394, 984, 37, 3, 2258, 11, 51041, 8, 18, 494, 7538, 10, 1229, 4, 3, 12891, 4863, 2098, 1053, 2, 3, 34753, 1129, 1, 3, 30493, 7565, 10, 2264, 6, 17100, 3, 75723, 3865, 3, 75724, 75725, 10, 2264, 2, 35, 8686, 1754, 10, 1229, 237, 3, 1499, 1885, 3, 2258, 11, 194, 391, 9, 3408, 1, 11737, 75, 3, 33857, 33858, 2, 33859, 1124, 2, 15470, 50, 3, 1707, 1, 2752, 9, 4370, 65, 2258, 2651, 5, 7963, 7536, 42, 8, 52, 1707, 1, 15899, 3930, 20429, 28, 133, 18, 83, 162, 2258, 2651, 5, 13389, 945, 42, 8, 52, 1707, 1, 15899, 3930, 20429, 28, 326, 27, 162, 2258, 2651, 5, 29979, 292, 1230, 32875, 3759, 205, 44, 514, 3622, 2752, 6209, 5975, 1383, 3013, 557, 3, 463, 1, 8686, 7963, 2, 13389, 30, 8653, 3, 1499, 1885, 182, 2258, 42, 77, 93, 4370, 272, 2258, 2651, 5, 7963, 15, 13389, 2433, 276, 15899, 3930, 20429, 4, 8, 2450, 2, 4172, 1708, 3, 91, 1, 3622, 2752, 16, 288, 6, 17, 527, 4, 7, 5, 8686, 1499, 1885, 57, 46, 272, 309, 17, 26, 202, 7557, 3, 1710, 1, 8686, 1499, 1885, 57, 4, 3218, 2, 68, 40, 95, 6, 1004, 3, 209, 1, 217, 24, 838, 9, 110, 154, 2, 64, 88, 8686, 57]",,16823316,130
Predicting absolute risk of CIN3 during post-colposcopic follow-up: results from the ASCUS-LSIL Triage Study (ALTS).,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2006-08-01,"At present, clinical management of women referred to colposcopy but found to have <CIN2 remains unclear. Using data from the ASCUS-LSIL Triage Study (ALTS) to inform clinical management, we calculated the absolute risk for developing CIN3 within 2 years of referral to an enrollment colposcopy. Women included in the analyses: (1) were initially referred to ALTS with a community cytologic interpretation of atypical squamous cell of undetermined significance (ASCUS) or low-grade squamous intraepithelial lesions (LSIL); (2) had a colposcopic evaluation and biopsy, if indicated, resulting in a diagnosis <CIN2; and, therefore (3) were followed without treatment. Results from subsequent human papillomavirus (HPV) testing, liquid-based cytology interpretations, and a second colposcopic evaluation at least 6 months after and within 2 years of the first colposcopic evaluation were used to calculate absolute risks for CIN3. Women with HPV-negative test results were at low risk for CIN3 regardless of other test results. Among HPV-positive women, increasing absolute risks of CIN3 were observed with increasing cytology severity: 7% (normal), 11% (ASCUS and LSIL), and 45% (HSIL). The highest absolute risk for CIN3 (67%) was observed for HPV-positive women with HSIL and a colposcopic impression of high-grade/cancer on the second colposcopy. In the ALTS population, after the first colposcopic diagnosis of <CIN2, clear risk stratification for CIN3 outcomes was obtained among women with a subsequent HPV-positive test. Because absolute risk for histologic CIN3 outcomes was high for women with HPV positive tests, HSIL cytology, and a high-grade impression at second colposcopy, it is worth considering whether this combination of findings might warrant immediate excisional therapy in some circumstances.",Journal Article,4921.0,55.0,At present clinical management of women referred to colposcopy but found to have CIN2 remains unclear Using data from the ASCUS-LSIL Triage Study ALTS to inform clinical management we calculated the absolute risk for developing CIN3 within 2 years of referral to an enrollment colposcopy Women included in the analyses 1 were initially referred to ALTS with a community cytologic interpretation of atypical squamous cell of undetermined significance ASCUS or low-grade squamous intraepithelial lesions LSIL 2 had a colposcopic evaluation and biopsy if indicated resulting in a diagnosis CIN2 and therefore 3 were followed without treatment Results from subsequent human papillomavirus HPV testing liquid-based cytology interpretations and a second colposcopic evaluation at least 6 months after and within 2 years of the first colposcopic evaluation were used to calculate absolute risks for CIN3 Women with HPV-negative test results were at low risk for CIN3 regardless of other test results Among HPV-positive women increasing absolute risks of CIN3 were observed with increasing cytology severity 7 normal 11 ASCUS and LSIL and 45 HSIL The highest absolute risk for CIN3 67 was observed for HPV-positive women with HSIL and a colposcopic impression of high-grade/cancer on the second colposcopy In the ALTS population after the first colposcopic diagnosis of CIN2 clear risk stratification for CIN3 outcomes was obtained among women with a subsequent HPV-positive test Because absolute risk for histologic CIN3 outcomes was high for women with HPV positive tests HSIL cytology and a high-grade impression at second colposcopy it is worth considering whether this combination of findings might warrant immediate excisional therapy in some circumstances,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[28, 364, 38, 284, 1, 117, 1995, 6, 9946, 84, 204, 6, 47, 12870, 469, 1200, 75, 74, 29, 3, 21337, 17849, 9059, 45, 26252, 6, 2295, 38, 284, 21, 981, 3, 1766, 43, 9, 931, 10346, 262, 18, 60, 1, 2096, 6, 35, 1798, 9946, 117, 159, 4, 3, 318, 14, 11, 1625, 1995, 6, 26252, 5, 8, 1714, 4195, 3037, 1, 1973, 691, 31, 1, 5206, 724, 21337, 15, 154, 88, 691, 4153, 406, 17849, 18, 42, 8, 14131, 451, 2, 411, 492, 1103, 1113, 4, 8, 147, 12870, 2, 673, 27, 11, 370, 187, 24, 99, 29, 706, 171, 3242, 933, 471, 3165, 90, 2045, 11158, 2, 8, 419, 14131, 451, 28, 506, 49, 53, 50, 2, 262, 18, 60, 1, 3, 157, 14131, 451, 11, 95, 6, 3232, 1766, 1098, 9, 10346, 117, 5, 933, 199, 412, 99, 11, 28, 154, 43, 9, 10346, 1583, 1, 127, 412, 99, 107, 933, 109, 117, 602, 1766, 1098, 1, 10346, 11, 164, 5, 602, 2045, 1702, 67, 295, 175, 21337, 2, 17849, 2, 512, 16067, 3, 1076, 1766, 43, 9, 10346, 598, 10, 164, 9, 933, 109, 117, 5, 16067, 2, 8, 14131, 8925, 1, 64, 88, 12, 23, 3, 419, 9946, 4, 3, 26252, 266, 50, 3, 157, 14131, 147, 1, 12870, 885, 43, 1541, 9, 10346, 123, 10, 683, 107, 117, 5, 8, 706, 933, 109, 412, 408, 1766, 43, 9, 884, 10346, 123, 10, 64, 9, 117, 5, 933, 109, 895, 16067, 2045, 2, 8, 64, 88, 8925, 28, 419, 9946, 192, 16, 9498, 3075, 317, 26, 150, 1, 272, 822, 2946, 2181, 6488, 36, 4, 476, 7684]",,16890545,230
"Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study.",Gynecologic oncology,Gynecol. Oncol.,2006-10-17,"To evaluate the anti-tumor activity and adverse events of capecitabine in advanced, persistent or recurrent squamous cell carcinoma of the cervix, and to explore biomarkers with the potential to predict capecitabine response and toxicity. Eligible, consenting patients were treated with a starting dose of 2500 mg/m(2)/day or 1800 mg/m(2)/day (divided into two doses given every 12 h) for 14 days of each 21-day cycle. Prior chemotherapy was allowed only in the context of radiation ""sensitization"". Genotyping in the 5' and 3' ends of thymidylate synthase (TS) was performed in DNA from pretreatment blood. Relative gene expression of TS, dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) was quantified in RNA extracted from paraffin-embedded tumor. All patients had prior radiotherapy and 22 received a radiation sensitizer. A partial response was observed in 4 of 26 (15%) evaluable patients. An additional 35% of patients achieved stable disease while 42% experienced increasing disease. The most common serious non-hematological toxicities were gastrointestinal and dermatologic. Exploratory analyses suggested that: a germline polymorphism in the 3' or the 5' end of TS was not associated with TS gene expression, relative tumor expression of TS, DPD and TP were not correlated, and relative tumor expression of TP may predict severe anemia. Based on the modest response rate, this trial was closed without a second stage of accrual; single agent capecitabine was not selected for further study in advanced persistent or recurrent squamous cell carcinoma of the cervix previously treated with radiation or chemoradiation.","Clinical Trial, Phase II",4844.0,24.0,To evaluate the anti-tumor activity and adverse events of capecitabine in advanced persistent or recurrent squamous cell carcinoma of the cervix and to explore biomarkers with the potential to predict capecitabine response and toxicity Eligible consenting patients were treated with a starting dose of 2500 mg/m 2 /day or 1800 mg/m 2 /day divided into two doses given every 12 h for 14 days of each 21-day cycle Prior chemotherapy was allowed only in the context of radiation `` sensitization '' Genotyping in the 5 and 3 ends of thymidylate synthase TS was performed in DNA from pretreatment blood Relative gene expression of TS dihydropyrimidine dehydrogenase DPD and thymidine phosphorylase TP was quantified in RNA extracted from paraffin-embedded tumor All patients had prior radiotherapy and 22 received a radiation sensitizer A partial response was observed in 4 of 26 15 evaluable patients An additional 35 of patients achieved stable disease while 42 experienced increasing disease The most common serious non-hematological toxicities were and dermatologic Exploratory analyses suggested that a germline polymorphism in the 3 or the 5 end of TS was not associated with TS gene expression relative tumor expression of TS DPD and TP were not correlated and relative tumor expression of TP may predict severe anemia Based on the modest response rate this trial was closed without a second stage of accrual single agent capecitabine was not selected for further study in advanced persistent or recurrent squamous cell carcinoma of the cervix previously treated with radiation or chemoradiation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 3, 312, 30, 128, 2, 290, 281, 1, 1629, 4, 131, 1882, 15, 387, 691, 31, 134, 1, 3, 3629, 2, 6, 1645, 582, 5, 3, 174, 6, 678, 1629, 51, 2, 155, 625, 11932, 7, 11, 73, 5, 8, 1723, 61, 1, 11735, 81, 188, 18, 218, 15, 13507, 81, 188, 18, 218, 2176, 237, 100, 415, 447, 454, 133, 555, 9, 213, 162, 1, 296, 239, 218, 417, 324, 56, 10, 2313, 158, 4, 3, 1533, 1, 121, 6272, 522, 2686, 4, 3, 33, 2, 27, 10894, 1, 6205, 3522, 3527, 10, 173, 4, 261, 29, 1194, 315, 580, 145, 55, 1, 3527, 14398, 2374, 14142, 2, 6403, 10658, 5907, 10, 2790, 4, 893, 2484, 29, 2487, 2505, 30, 62, 7, 42, 324, 310, 2, 350, 103, 8, 121, 13806, 8, 450, 51, 10, 164, 4, 39, 1, 432, 167, 859, 7, 35, 402, 465, 1, 7, 513, 585, 34, 369, 595, 592, 602, 34, 3, 96, 186, 1762, 220, 2890, 385, 11, 2, 4722, 2386, 318, 1148, 17, 8, 1009, 1907, 4, 3, 27, 15, 3, 33, 396, 1, 3527, 10, 44, 41, 5, 3527, 145, 55, 580, 30, 55, 1, 3527, 14142, 2, 5907, 11, 44, 438, 2, 580, 30, 55, 1, 5907, 68, 678, 905, 1545, 90, 23, 3, 1721, 51, 116, 26, 160, 10, 3745, 187, 8, 419, 82, 1, 2262, 226, 420, 1629, 10, 44, 715, 9, 195, 45, 4, 131, 1882, 15, 387, 691, 31, 134, 1, 3, 3629, 373, 73, 5, 121, 15, 975]",,17049588,25
Sexual function after gynecologic cancer.,Obstetrics and gynecology clinics of North America,Obstet. Gynecol. Clin. North Am.,2006-12-01,"Sexual functioning is the most enduringly compromised quality of life issue women face after treatment gynecologic cancer. As the population of cancer survivors continues to grow, more attention needs to be given to women who have such concerns. It is vital to increase the awareness of sexual health after gynecologic cancer. We must work together with our patients to address and treat sexual concerns.",Journal Article,4799.0,45.0,Sexual functioning is the most enduringly compromised quality of life issue women face after treatment gynecologic cancer As the population of cancer survivors continues to grow more attention needs to be given to women who have such concerns It is vital to increase the awareness of sexual health after gynecologic cancer We must work together with our patients to address and treat sexual concerns,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[2232, 2702, 16, 3, 96, 75770, 4867, 372, 1, 358, 2537, 117, 3376, 50, 24, 1512, 12, 22, 3, 266, 1, 12, 332, 2274, 6, 6265, 80, 2111, 1891, 6, 40, 447, 6, 117, 54, 47, 225, 2061, 192, 16, 3511, 6, 344, 3, 3310, 1, 2232, 341, 50, 1512, 12, 21, 1642, 1357, 1162, 5, 114, 7, 6, 1539, 2, 943, 2232, 2061]",,17116505,290
Religiousness and spiritual support among advanced cancer patients and associations with end-of-life treatment preferences and quality of life.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2007-02-01,"Religion and spirituality play a role in coping with illness for many cancer patients. This study examined religiousness and spiritual support in advanced cancer patients of diverse racial/ethnic backgrounds and associations with quality of life (QOL), treatment preferences, and advance care planning. The Coping With Cancer study is a federally funded, multi-institutional investigation examining factors associated with advanced cancer patient and caregiver well-being. Patients with an advanced cancer diagnosis and failure of first-line chemotherapy were interviewed at baseline regarding religiousness, spiritual support, QOL, treatment preferences, and advance care planning. Most (88%) of the study population (N = 230) considered religion to be at least somewhat important. Nearly half (47%) reported that their spiritual needs were minimally or not at all supported by a religious community, and 72% reported that their spiritual needs were supported minimally or not at all by the medical system. Spiritual support by religious communities or the medical system was significantly associated with patient QOL (P = .0003). Religiousness was significantly associated with wanting all measures to extend life (odds ratio, 1.96; 95% CI, 1.08 to 3.57). Many advanced cancer patients' spiritual needs are not supported by religious communities or the medical system, and spiritual support is associated with better QOL. Religious individuals more frequently want aggressive measures to extend life.",Journal Article,4737.0,492.0,Religion and spirituality play a role in coping with illness for many cancer patients This study examined religiousness and spiritual support in advanced cancer patients of diverse racial/ethnic backgrounds and associations with quality of life QOL treatment preferences and advance care planning The Coping With Cancer study is a federally funded multi-institutional investigation examining factors associated with advanced cancer patient and caregiver well-being Patients with an advanced cancer diagnosis and failure of first-line chemotherapy were interviewed at baseline regarding religiousness spiritual support QOL treatment preferences and advance care planning Most 88 of the study population N 230 considered religion to be at least somewhat important Nearly half 47 reported that their spiritual needs were minimally or not at all supported by a religious community and 72 reported that their spiritual needs were supported minimally or not at all by the medical system Spiritual support by religious communities or the medical system was significantly associated with patient QOL P .0003 Religiousness was significantly associated with wanting all measures to extend life odds ratio 1.96 95 CI 1.08 to 3.57 Many advanced cancer patients spiritual needs are not supported by religious communities or the medical system and spiritual support is associated with better QOL Religious individuals more frequently want aggressive measures to extend life,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[16851, 2, 8007, 1343, 8, 200, 4, 4276, 5, 2973, 9, 445, 12, 7, 26, 45, 409, 22871, 2, 3573, 538, 4, 131, 12, 7, 1, 1867, 2257, 2871, 10681, 2, 685, 5, 372, 1, 358, 1001, 24, 2875, 2, 3148, 165, 1349, 3, 4276, 5, 12, 45, 16, 8, 22523, 3827, 1414, 1115, 940, 3282, 130, 41, 5, 131, 12, 69, 2, 4828, 149, 486, 7, 5, 35, 131, 12, 147, 2, 496, 1, 157, 328, 56, 11, 6713, 28, 330, 666, 22871, 3573, 538, 1001, 24, 2875, 2, 3148, 165, 1349, 96, 889, 1, 3, 45, 266, 78, 6136, 515, 16851, 6, 40, 28, 506, 6122, 305, 1857, 1303, 662, 210, 17, 136, 3573, 1891, 11, 2144, 15, 44, 28, 62, 2708, 20, 8, 6942, 1714, 2, 720, 210, 17, 136, 3573, 1891, 11, 2708, 2144, 15, 44, 28, 62, 20, 3, 484, 398, 3573, 538, 20, 6942, 7651, 15, 3, 484, 398, 10, 97, 41, 5, 69, 1001, 19, 4418, 22871, 10, 97, 41, 5, 21164, 62, 1018, 6, 4087, 358, 610, 197, 14, 921, 48, 58, 14, 1592, 6, 27, 696, 445, 131, 12, 7, 3573, 1891, 32, 44, 2708, 20, 6942, 7651, 15, 3, 484, 398, 2, 3573, 538, 16, 41, 5, 380, 1001, 6942, 869, 80, 746, 9651, 571, 1018, 6, 4087, 358]",,17290065,16
Reproductive issues in the gynecologic cancer patient.,"Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2007-04-01,"Clinicians, researchers, and survivorship communities are beginning to recognize the late effects of cancer treatment, such as infertility, and the negative impact this can have on cancer survivorship. Reproductive concerns that emerge within cancer experiences have been shown to be negatively associated with quality of life. Gynecologic cancer can present before childbearing has been started or completed, during pregnancy, or can even arise out of pregnancy, as is the case with gestational trophoblastic disease. Parenthood has been cited as an important aspect of cancer survivorship. As a result, interest concerning fertility preservation, reproductive concerns, and family-building options in cancer survivorship has increased, in addition to awareness of the emotional ramifications of cancer-related infertility. Education and support are clearly an essential component of cancer survivorship. Furthermore, more attention and investigation is still needed about the reproductive issues of gynecologic cancer survivors in the future.",Journal Article,4678.0,6.0,Clinicians researchers and survivorship communities are beginning to recognize the late effects of cancer treatment such as infertility and the negative impact this can have on cancer survivorship Reproductive concerns that emerge within cancer experiences have been shown to be negatively associated with quality of life Gynecologic cancer can present before childbearing has been started or completed during pregnancy or can even arise out of pregnancy as is the case with gestational trophoblastic disease Parenthood has been cited as an important aspect of cancer survivorship As a result interest concerning fertility preservation reproductive concerns and family-building options in cancer survivorship has increased in addition to awareness of the emotional ramifications of cancer-related infertility Education and support are clearly an essential component of cancer survivorship Furthermore more attention and investigation is still needed about the reproductive issues of gynecologic cancer survivors in the future,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1490, 4211, 2, 2560, 7651, 32, 2948, 6, 4237, 3, 807, 176, 1, 12, 24, 225, 22, 5901, 2, 3, 199, 345, 26, 122, 47, 23, 12, 2560, 3705, 2061, 17, 6371, 262, 12, 4031, 47, 85, 443, 6, 40, 2723, 41, 5, 372, 1, 358, 1512, 12, 122, 364, 348, 10278, 71, 85, 3461, 15, 781, 190, 2290, 15, 122, 871, 3043, 1205, 1, 2290, 22, 16, 3, 473, 5, 9383, 11355, 34, 34872, 71, 85, 7068, 22, 35, 305, 7416, 1, 12, 2560, 22, 8, 757, 1333, 4243, 2954, 2224, 3705, 2061, 2, 607, 5808, 838, 4, 12, 2560, 71, 101, 4, 352, 6, 3310, 1, 3, 2671, 15575, 1, 12, 139, 5901, 1848, 2, 538, 32, 2536, 35, 1452, 1249, 1, 12, 2560, 798, 80, 2111, 2, 940, 16, 1234, 575, 545, 3, 3705, 1553, 1, 1512, 12, 332, 4, 3, 508]",,17536344,2
Epidermodysplasia verruciformis in the setting of graft-versus-host disease.,Journal of the American Academy of Dermatology,J. Am. Acad. Dermatol.,2007-11-01,"We report a case of epidermodysplasia verruciformis (EV)-like lesions in a patient with graft-versus-host disease after peripheral blood stem cell transplantation from his HLA-matched brother. The patient presented with a diffuse papular eruption that was clinically consistent with graft-versus-host disease; however, histopathology demonstrated viral cytopathic changes and polymerase chain reaction confirmed EV human papillomavirus types 8 and 20. Repeated biopsy specimen showed both human papillomavirus cytopathic effect and graft-versus-host disease, and further workup revealed ocular and hepatic involvement. This progressed to a lupuslike syndrome with lichenoid, violaceous, flat-topped papules in a malar distribution and positive antinuclear autoantibodies. Although EV-like lesions have been reported in patients who are immunocompromised, the incidence is low, and may be linked to EV-related haplotypes.",Case Reports,4464.0,24.0,We report a case of epidermodysplasia verruciformis EV -like lesions in a patient with graft-versus-host disease after peripheral blood stem cell transplantation from his HLA-matched brother The patient presented with a diffuse papular eruption that was clinically consistent with graft-versus-host disease however histopathology demonstrated viral cytopathic changes and polymerase chain reaction confirmed EV human papillomavirus types 8 and 20 Repeated biopsy specimen showed both human papillomavirus cytopathic effect and graft-versus-host disease and further workup revealed ocular and hepatic involvement This progressed to a lupuslike syndrome with lichenoid violaceous flat-topped papules in a malar distribution and positive antinuclear autoantibodies Although EV-like lesions have been reported in patients who are immunocompromised the incidence is low and may be linked to EV-related haplotypes,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,"[21, 414, 8, 473, 1, 47692, 47693, 10123, 733, 406, 4, 8, 69, 5, 1599, 185, 1204, 34, 50, 672, 315, 452, 31, 497, 29, 3224, 1160, 655, 25085, 3, 69, 917, 5, 8, 1388, 31443, 15219, 17, 10, 505, 925, 5, 1599, 185, 1204, 34, 137, 3831, 264, 1667, 15502, 400, 2, 1451, 1260, 1329, 557, 10123, 171, 3242, 630, 66, 2, 179, 2113, 411, 2360, 224, 110, 171, 3242, 15502, 254, 2, 1599, 185, 1204, 34, 2, 195, 4755, 553, 4345, 2, 939, 799, 26, 1839, 6, 8, 75936, 681, 5, 17575, 31434, 7767, 75937, 20577, 4, 8, 75938, 1395, 2, 109, 75939, 7613, 242, 10123, 733, 406, 47, 85, 210, 4, 7, 54, 32, 7796, 3, 287, 16, 154, 2, 68, 40, 1199, 6, 10123, 139, 5940]",,17938030,90
Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2007-11-01,"The objective of the study was to confirm that concurrent cisplatin (CT) with radiation therapy (RT) is associated with improved long-term progression-free survival (PFS) and overall survival (OS), compared with RT alone in stage IB bulky carcinoma of the cervix, when both groups' therapy is followed by hysterectomy. Three hundred seventy-four patients entered this trial. There were 369 evaluable patients; 186 were randomly allocated to receive RT alone and 183 to receive CT plus RT. Radiation dosage was 45 Gray (Gy) in 20 fractions followed by low dose-rate intracavitary application(s) of 30 Gy to point A. Chemotherapy consisted of intravenous cisplatin 40 mg/m2 every week for up to 6 weekly cycles. Total extrafascial hysterectomy followed the completion of RT by 6-8 weeks. Preliminary results have been published, at which time there were 292 censored observations, and median duration of follow-up was only 36 months. Patient and tumor characteristics were well balanced between the regimens. The median patient age was 41.5 years; 81% had squamous tumors; 59% were white. Median follow-up is now 101 months. The relative risk for progression was 0.61 favoring CT plus RT (95% confidence interval [CI] 0.43 to 0.85, P < .004). At 72 months, 71% of patients receiving CT plus RT were predicted to be alive and disease free when adjusting for age and tumor size, compared with 60% of those receiving RT alone. The adjusted death hazard ratio was 0.63 (95% CI 0.43 to 0.91, P < .015) favoring CT plus RT. At 72 months, 78% of CT plus RT patients were predicted to be alive, compared with 64% of RT patients. An increased rate of early hematologic and gastrointestinal toxicity was seen with CT plus RT. There was no detectable difference in the frequency of late adverse events. Concurrent weekly cisplatin with RT significantly improves long-term PFS and OS when compared with RT alone. Serious late effects were not increased. The inclusion of hysterectomy has been discontinued on the basis of another trial. Pending further trials, weekly cisplatin with radiation is the standard against which other regimens should be compared.",Journal Article,4464.0,89.0,The objective of the study was to confirm that concurrent cisplatin CT with radiation therapy RT is associated with improved long-term progression-free survival PFS and overall survival OS compared with RT alone in stage IB bulky carcinoma of the cervix when both groups therapy is followed by hysterectomy Three hundred seventy-four patients entered this trial There were 369 evaluable patients 186 were randomly allocated to receive RT alone and 183 to receive CT plus RT Radiation dosage was 45 Gray Gy in 20 fractions followed by low dose-rate intracavitary application s of 30 Gy to point A Chemotherapy consisted of intravenous cisplatin 40 mg/m2 every week for up to 6 weekly cycles Total extrafascial hysterectomy followed the completion of RT by 6-8 weeks Preliminary results have been published at which time there were 292 censored observations and median duration of follow-up was only 36 months Patient and tumor characteristics were well balanced between the regimens The median patient age was 41.5 years 81 had squamous tumors 59 were white Median follow-up is now 101 months The relative risk for progression was 0.61 favoring CT plus RT 95 confidence interval CI 0.43 to 0.85 P .004 At 72 months 71 of patients receiving CT plus RT were predicted to be alive and disease free when adjusting for age and tumor size compared with 60 of those receiving RT alone The adjusted death hazard ratio was 0.63 95 CI 0.43 to 0.91 P .015 favoring CT plus RT At 72 months 78 of CT plus RT patients were predicted to be alive compared with 64 of RT patients An increased rate of early hematologic and toxicity was seen with CT plus RT There was no detectable difference in the frequency of late adverse events Concurrent weekly cisplatin with RT significantly improves long-term PFS and OS when compared with RT alone Serious late effects were not increased The inclusion of hysterectomy has been discontinued on the basis of another trial Pending further trials weekly cisplatin with radiation is the standard against which other regimens should be compared,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 461, 1, 3, 45, 10, 6, 1843, 17, 750, 540, 425, 5, 121, 36, 240, 16, 41, 5, 231, 319, 337, 91, 115, 25, 300, 2, 63, 25, 118, 72, 5, 240, 279, 4, 82, 3180, 4112, 134, 1, 3, 3629, 198, 110, 271, 36, 16, 370, 20, 2622, 169, 1128, 2073, 294, 7, 2836, 26, 160, 125, 11, 8718, 859, 7, 5869, 11, 1108, 6682, 6, 560, 240, 279, 2, 6348, 6, 560, 425, 349, 240, 121, 3323, 10, 512, 4163, 381, 4, 179, 1550, 370, 20, 154, 61, 116, 9122, 1581, 695, 1, 201, 381, 6, 741, 8, 56, 1695, 1, 1262, 540, 327, 81, 821, 454, 647, 9, 126, 6, 49, 709, 410, 181, 25094, 2622, 370, 3, 1438, 1, 240, 20, 49, 66, 244, 1676, 99, 47, 85, 983, 28, 92, 98, 125, 11, 8155, 7534, 2172, 2, 52, 654, 1, 166, 126, 10, 158, 511, 53, 69, 2, 30, 374, 11, 149, 4115, 59, 3, 472, 3, 52, 69, 89, 10, 605, 33, 60, 865, 42, 691, 57, 728, 11, 886, 52, 166, 126, 16, 1134, 2338, 53, 3, 580, 43, 9, 91, 10, 13, 713, 6238, 425, 349, 240, 48, 307, 268, 58, 13, 601, 6, 13, 772, 19, 1520, 28, 720, 53, 792, 1, 7, 357, 425, 349, 240, 11, 783, 6, 40, 1701, 2, 34, 115, 198, 1358, 9, 89, 2, 30, 444, 72, 5, 335, 1, 135, 357, 240, 279, 3, 586, 273, 360, 197, 10, 13, 676, 48, 58, 13, 601, 6, 13, 970, 19, 3433, 6238, 425, 349, 240, 28, 720, 53, 833, 1, 425, 349, 240, 7, 11, 783, 6, 40, 1701, 72, 5, 660, 1, 240, 7, 35, 101, 116, 1, 191, 813, 2, 155, 10, 527, 5, 425, 349, 240, 125, 10, 77, 2083, 523, 4, 3, 675, 1, 807, 290, 281, 750, 709, 540, 5, 240, 97, 1804, 319, 337, 300, 2, 118, 198, 72, 5, 240, 279, 1762, 807, 176, 11, 44, 101, 3, 1680, 1, 2622, 71, 85, 2402, 23, 3, 877, 1, 1809, 160, 9453, 195, 143, 709, 540, 5, 121, 16, 3, 260, 480, 92, 127, 472, 257, 40, 72]",,17980189,261
Frozen-section evaluation of cervical adenocarcinoma at time of radical trachelectomy: pathologic pitfalls and the application of an objective scoring system.,Gynecologic oncology,Gynecol. Oncol.,2008-07-17,"To analyze the incidence of diagnostic discrepancy between frozen-section and final diagnosis of the endocervical margin at time of radical trachelectomy and to apply an objective scoring system to non-invasive endocervical glandular atypia to determine its utility in distinguishing benign from malignant lesions. Histologic slides from 19 cases of radical trachelectomy performed for invasive endocervical adenocarcinoma were evaluated for correlation between the frozen and permanent sections of the endocervical margin. An objective scoring system for grading non-invasive endocervical glandular lesions proposed by Ioffe et al. was also applied to the frozen and permanent section slides and compared to the final diagnosis. There was 84% concordance between the frozen-section and final diagnosis using histology alone, vs. 95% concordance using the Ioffe scoring system. One trachelectomy was converted to completion hysterectomy for what was presumed to be adenocarcinoma in situ at the margin, which in retrospect, was a benign lesion and was correctly classified using the Ioffe system. Most of the discrepancies were due to misinterpretation of tubal metaplasia, tubo-endometrioid metaplasia, and atypical tubal metaplasia as adenocarcinoma in situ. Benign mimics of endocervical adenocarcinoma in situ can be difficult to distinguish from malignant lesions, especially during frozen-section evaluation of the trachelectomy. Correctly diagnosing the margin status intraoperatively has great clinical impact and the application of an objective scoring system, like that proposed by Ioffe et al., can increase diagnostic accuracy when applied to frozen-section slides and better correlates with final diagnosis when compared to histology alone.",Journal Article,4205.0,15.0,To analyze the incidence of diagnostic discrepancy between frozen-section and final diagnosis of the endocervical margin at time of radical trachelectomy and to apply an objective scoring system to non-invasive endocervical glandular atypia to determine its utility in distinguishing benign from malignant lesions Histologic slides from 19 cases of radical trachelectomy performed for invasive endocervical adenocarcinoma were evaluated for correlation between the frozen and permanent sections of the endocervical margin An objective scoring system for grading non-invasive endocervical glandular lesions proposed by Ioffe et al was also applied to the frozen and permanent section slides and compared to the final diagnosis There was 84 concordance between the frozen-section and final diagnosis using histology alone vs. 95 concordance using the Ioffe scoring system One trachelectomy was converted to completion hysterectomy for what was presumed to be adenocarcinoma in situ at the margin which in retrospect was a benign lesion and was correctly classified using the Ioffe system Most of the discrepancies were due to misinterpretation of tubal metaplasia tubo-endometrioid metaplasia and atypical tubal metaplasia as adenocarcinoma in situ Benign mimics of endocervical adenocarcinoma in situ can be difficult to distinguish from malignant lesions especially during frozen-section evaluation of the trachelectomy Correctly diagnosing the margin status intraoperatively has great clinical impact and the application of an objective scoring system like that proposed by Ioffe et al. can increase diagnostic accuracy when applied to frozen-section slides and better correlates with final diagnosis when compared to histology alone,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 1992, 3, 287, 1, 752, 7916, 59, 3015, 2917, 2, 1457, 147, 1, 3, 10174, 959, 28, 98, 1, 711, 5760, 2, 6, 4930, 35, 461, 2504, 398, 6, 220, 416, 10174, 6170, 3598, 6, 223, 211, 1207, 4, 4508, 1002, 29, 393, 406, 884, 3830, 29, 326, 140, 1, 711, 5760, 173, 9, 416, 10174, 449, 11, 194, 9, 816, 59, 3, 3015, 2, 4377, 3013, 1, 3, 10174, 959, 35, 461, 2504, 398, 9, 3452, 220, 416, 10174, 6170, 406, 1587, 20, 36839, 2022, 2171, 10, 120, 1498, 6, 3, 3015, 2, 4377, 2917, 3830, 2, 72, 6, 3, 1457, 147, 125, 10, 874, 1827, 59, 3, 3015, 2917, 2, 1457, 147, 75, 784, 279, 105, 48, 1827, 75, 3, 36839, 2504, 398, 104, 5760, 10, 4764, 6, 1438, 2622, 9, 2067, 10, 5472, 6, 40, 449, 4, 957, 28, 3, 959, 92, 4, 41875, 10, 8, 1002, 1180, 2, 10, 4911, 1373, 75, 3, 36839, 398, 96, 1, 3, 7631, 11, 520, 6, 22357, 1, 6674, 6054, 36350, 3151, 6054, 2, 1973, 6674, 6054, 22, 449, 4, 957, 1002, 7557, 1, 10174, 449, 4, 957, 122, 40, 1740, 6, 3081, 29, 393, 406, 1093, 190, 3015, 2917, 451, 1, 3, 5760, 4911, 5798, 3, 959, 156, 6595, 71, 2797, 38, 345, 2, 3, 1581, 1, 35, 461, 2504, 398, 733, 17, 1587, 20, 36839, 2022, 2171, 122, 344, 752, 1190, 198, 1498, 6, 3015, 2917, 3830, 2, 380, 1871, 5, 1457, 147, 198, 72, 6, 784, 279]",,18635252,640
Laparoscopic colostomy in gynecologic cancer.,Journal of minimally invasive gynecology,J Minim Invasive Gynecol,,"The purpose of our study was to report on our case series of 7 patients with gynecologic cancer who underwent laparoscopic colostomy for elective fecal diversion. Our aim was to retrospectively estimate feasibility, safety, and efficacy of the laparoscopic approach in the setting of gynecologic malignancy, given the high incidence of earlier abdominal surgery and pelvic radiation treatment in this select population. Retrospective chart review (Canadian Task Force classification I). University of Texas, M.D. Anderson Cancer Center. All patients with a history of gynecologic cancers who underwent laparoscopic colostomy during the study period. We retrospectively reviewed all patients who underwent elective laparoscopic diverting colostomy in our department of gynecologic oncology. Surgical indications, medical history, operative and stomal complications, estimated blood loss, return of bowel function, and length of hospital stay were collected. Seven patients underwent laparoscopic colostomy during the study period. Six of these patients underwent an end descending colostomy, and 1 patient underwent a loop colostomy. Indications included rectovaginal fistula (n = 5), colonic/pelvic fistula (n = 1), or large bowel obstruction (n = 1). No intraoperative or postoperative complications occurred, nor did any conversions to laparotomy. The median blood loss was 50 mL (range 10-75). Median operative time was 102 minutes (range 69-159). Six (86%) patients had a history of pelvic radiation. In addition, 3 (43%) patients had a history of laparotomy. The median patient weight was 59.8 kg (range 47.1-82.2). The median time to tolerance of a regular diet was 2 days (range 1-3) and the median length of hospital stay was 3 days (range 2-4). No immediate or delayed stomal complications were noted with a median follow-up of 6 months (range 1-15). Laparoscopic colostomy in advanced gynecologic cancer may be a safe and feasible technique with minimal morbidity, rapid return of bowel function, and short hospital stay.",Journal Article,,1.0,The purpose of our study was to report on our case series of 7 patients with gynecologic cancer who underwent laparoscopic colostomy for elective fecal diversion Our aim was to retrospectively estimate feasibility safety and efficacy of the laparoscopic approach in the setting of gynecologic malignancy given the high incidence of earlier abdominal surgery and pelvic radiation treatment in this select population Retrospective chart review Canadian Task Force classification I University of Texas M.D Anderson Cancer Center All patients with a history of gynecologic cancers who underwent laparoscopic colostomy during the study period We retrospectively reviewed all patients who underwent elective laparoscopic diverting colostomy in our department of gynecologic oncology Surgical indications medical history operative and stomal complications estimated blood loss return of bowel function and length of hospital stay were collected Seven patients underwent laparoscopic colostomy during the study period Six of these patients underwent an end descending colostomy and 1 patient underwent a loop colostomy Indications included rectovaginal fistula n 5 colonic/pelvic fistula n 1 or large bowel obstruction n 1 No intraoperative or postoperative complications occurred nor did any conversions to laparotomy The median blood loss was 50 mL range 10-75 Median operative time was 102 minutes range 69-159 Six 86 patients had a history of pelvic radiation In addition 3 43 patients had a history of laparotomy The median patient weight was 59.8 kg range 47.1-82.2 The median time to tolerance of a regular diet was 2 days range 1-3 and the median length of hospital stay was 3 days range 2-4 No immediate or delayed stomal complications were noted with a median follow-up of 6 months range 1-15 Laparoscopic colostomy in advanced gynecologic cancer may be a safe and feasible technique with minimal morbidity rapid return of bowel function and short hospital stay,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,"[3, 743, 1, 114, 45, 10, 6, 414, 23, 114, 473, 988, 1, 67, 7, 5, 1512, 12, 54, 208, 1964, 7635, 9, 4700, 6784, 6067, 114, 1130, 10, 6, 894, 1191, 1437, 367, 2, 209, 1, 3, 1964, 353, 4, 3, 546, 1, 1512, 710, 447, 3, 64, 287, 1, 1677, 1467, 152, 2, 1110, 121, 24, 4, 26, 1717, 266, 459, 2937, 206, 7170, 3488, 4380, 947, 70, 1652, 1, 2738, 188, 427, 1929, 12, 574, 62, 7, 5, 8, 532, 1, 1512, 163, 54, 208, 1964, 7635, 190, 3, 45, 727, 21, 894, 446, 62, 7, 54, 208, 4700, 1964, 15107, 7635, 4, 114, 4271, 1, 1512, 413, 221, 2406, 484, 532, 1208, 2, 28126, 521, 661, 315, 407, 4656, 1, 1659, 343, 2, 1318, 1, 702, 2020, 11, 786, 648, 7, 208, 1964, 7635, 190, 3, 45, 727, 437, 1, 46, 7, 208, 35, 396, 13478, 7635, 2, 14, 69, 208, 8, 4432, 7635, 2406, 159, 22569, 4920, 78, 33, 3663, 1110, 4920, 78, 14, 15, 375, 1659, 3191, 78, 14, 77, 1720, 15, 573, 521, 489, 2110, 205, 500, 13112, 6, 3274, 3, 52, 315, 407, 10, 212, 542, 184, 79, 481, 52, 1208, 98, 10, 2867, 2511, 184, 790, 5917, 437, 868, 7, 42, 8, 532, 1, 1110, 121, 4, 352, 27, 601, 7, 42, 8, 532, 1, 3274, 3, 52, 69, 924, 10, 728, 66, 503, 184, 662, 14, 878, 18, 3, 52, 98, 6, 2614, 1, 8, 3316, 2453, 10, 18, 162, 184, 14, 27, 2, 3, 52, 1318, 1, 702, 2020, 10, 27, 162, 184, 18, 39, 77, 2181, 15, 1612, 28126, 521, 11, 1051, 5, 8, 52, 166, 126, 1, 49, 53, 184, 14, 167, 1964, 7635, 4, 131, 1512, 12, 68, 40, 8, 1165, 2, 1313, 1312, 5, 1048, 787, 1321, 4656, 1, 1659, 343, 2, 978, 702, 2020]",,18971136,224
Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2008-11-18,"We sought to determine the value of conization margin status in predicting residual and recurrent adenocarcinoma in situ (ACIS) of the cervix. In all, 33 studies (1278 patients) were identified. Metaanalysis with pooled Mantel-Haenszel odds ratio (OR) was used to compare the risk of residual and recurrent disease according to margin status. A repeated excisional procedure was performed in 607 patients; a positive conization margin was associated with a significant increase in the risk of residual disease (OR, 4.01; 95% confidence interval [CI], 2.62-6.33; P < .001). Of the 671 patients followed up with surveillance only, 2.6% with negative margins and 19.4% with positive margins developed a recurrence (OR, 2.48; 95% CI, 1.05-6.22; P < .001). Invasive adenocarcinoma was more commonly associated with positive margins (5.2%) compared with negative margins (0.1%). After conization for ACIS, patients with positive margins are significantly more likely to have residual or recurrent disease, whereas those with negative margins may be treated conservatively.",Journal Article,4081.0,54.0,We sought to determine the value of conization margin status in predicting residual and recurrent adenocarcinoma in situ ACIS of the cervix In all 33 studies 1278 patients were identified Metaanalysis with pooled Mantel-Haenszel odds ratio OR was used to compare the risk of residual and recurrent disease according to margin status A repeated excisional procedure was performed in 607 patients a positive conization margin was associated with a significant increase in the risk of residual disease OR 4.01 95 confidence interval CI 2.62-6.33 P .001 Of the 671 patients followed up with surveillance only 2.6 with negative margins and 19.4 with positive margins developed a recurrence OR 2.48 95 CI 1.05-6.22 P .001 Invasive adenocarcinoma was more commonly associated with positive margins 5.2 compared with negative margins 0.1 After conization for ACIS patients with positive margins are significantly more likely to have residual or recurrent disease whereas those with negative margins may be treated conservatively,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 990, 6, 223, 3, 549, 1, 8755, 959, 156, 4, 1434, 753, 2, 387, 449, 4, 957, 21274, 1, 3, 3629, 4, 62, 466, 94, 47926, 7, 11, 108, 19810, 5, 1830, 11618, 14496, 610, 197, 15, 10, 95, 6, 932, 3, 43, 1, 753, 2, 387, 34, 768, 6, 959, 156, 8, 2113, 6488, 1299, 10, 173, 4, 12311, 7, 8, 109, 8755, 959, 10, 41, 5, 8, 93, 344, 4, 3, 43, 1, 753, 34, 15, 39, 355, 48, 307, 268, 58, 18, 744, 49, 466, 19, 144, 1, 3, 12522, 7, 370, 126, 5, 617, 158, 18, 49, 5, 199, 1012, 2, 326, 39, 5, 109, 1012, 276, 8, 146, 15, 18, 576, 48, 58, 14, 474, 49, 350, 19, 144, 416, 449, 10, 80, 841, 41, 5, 109, 1012, 33, 18, 72, 5, 199, 1012, 13, 14, 50, 8755, 9, 21274, 7, 5, 109, 1012, 32, 97, 80, 322, 6, 47, 753, 15, 387, 34, 547, 135, 5, 199, 1012, 68, 40, 73, 10296]",,19019325,218
Activation of Akt as a mechanism for tumor immune evasion.,Molecular therapy : the journal of the American Society of Gene Therapy,Mol. Ther.,2008-12-23,"Immune evasion is an important reason why the immune system cannot control tumor growth. To elucidate the mechanism for tumor immune evasion, we generated an immune-resistant human papillomavirus type 16 (HPV-16) E7-expressing tumor cell line by subjecting a susceptible tumor cell line to multiple rounds of in vivo immune selection with an E7-specific vaccine. Comparison of parental and immune-resistant tumors revealed that Akt is highly activated in the immune-resistant tumors. Retroviral transfer of a constitutively active form of Akt into the parental tumor significantly increased its resistance against E7-specific CD8(+) T-cell mediated apoptosis. The observed resistance against apoptosis was found to be associated with the upregulation of antiapoptotic molecules. We also observed that intratumoral injection of an Akt inhibitor enhanced the therapeutic efficacy of E7-specific vaccine or E7-specific CD8(+) T-cell adoptive transfer against the immune-resistant tumors. Thus, our data indicate that the activation of PI3K/Akt pathway represents a new mechanism of immune escape and has important implications for the development of a novel strategy in cancer immunotherapy against immune-resistant tumor cells.",Journal Article,4046.0,59.0,Immune evasion is an important reason why the immune system can not control tumor growth To elucidate the mechanism for tumor immune evasion we generated an immune-resistant human papillomavirus type 16 HPV-16 E7-expressing tumor cell line by subjecting a susceptible tumor cell line to multiple rounds of in vivo immune selection with an E7-specific vaccine Comparison of parental and immune-resistant tumors revealed that Akt is highly activated in the immune-resistant tumors Retroviral transfer of a constitutively active form of Akt into the parental tumor significantly increased its resistance against E7-specific CD8 T-cell mediated apoptosis The observed resistance against apoptosis was found to be associated with the upregulation of antiapoptotic molecules We also observed that intratumoral injection of an Akt inhibitor enhanced the therapeutic efficacy of E7-specific vaccine or E7-specific CD8 T-cell adoptive transfer against the immune-resistant tumors Thus our data indicate that the activation of PI3K/Akt pathway represents a new mechanism of immune escape and has important implications for the development of a novel strategy in cancer immunotherapy against immune-resistant tumor cells,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[250, 5351, 16, 35, 305, 3852, 5283, 3, 250, 398, 122, 44, 182, 30, 129, 6, 3061, 3, 670, 9, 30, 250, 5351, 21, 1419, 35, 250, 436, 171, 3242, 267, 245, 933, 245, 4540, 1046, 30, 31, 328, 20, 39186, 8, 4012, 30, 31, 328, 6, 232, 7001, 1, 4, 386, 250, 881, 5, 35, 4540, 112, 1274, 1155, 1, 3418, 2, 250, 436, 57, 553, 17, 649, 16, 561, 735, 4, 3, 250, 436, 57, 8658, 2602, 1, 8, 2818, 544, 1297, 1, 649, 237, 3, 3418, 30, 97, 101, 211, 251, 480, 4540, 112, 968, 102, 31, 517, 351, 3, 164, 251, 480, 351, 10, 204, 6, 40, 41, 5, 3, 2218, 1, 4176, 1598, 21, 120, 164, 17, 2074, 1754, 1, 35, 649, 230, 651, 3, 189, 209, 1, 4540, 112, 1274, 15, 4540, 112, 968, 102, 31, 3159, 2602, 480, 3, 250, 436, 57, 631, 114, 74, 1008, 17, 3, 363, 1, 974, 649, 308, 1449, 8, 217, 670, 1, 250, 3776, 2, 71, 305, 1268, 9, 3, 193, 1, 8, 229, 692, 4, 12, 726, 480, 250, 436, 30, 37]",,19107122,266
Predictive value of a proposed subclassification of stages I and II cervical cancer based on clinical tumor diameter.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2009-01-01,"Hospital records of 4490 patients treated for International Federation of Gynecology and Obstetrics (FIGO) stage IB, IIA, or IIB carcinoma of the cervix between 1960 and 2001 at 1 institution were reviewed. Outcomes were estimated using the Kaplan-Meier method and compared using the log-rank method. A proportional hazards regression model was used to evaluate the relative importance of predictive factors. The rates of disease-specific survival and pelvic disease control were strongly correlated with tumor diameter, FIGO stage, histological subtype, and clinical node status. Regression analysis demonstrated that a diameter of greater than 4 cm, a diameter of greater than 6 cm, FIGO stage II (vs IB), the presence and level of lymph node involvement, and histological subtype were all highly significant independent predictors of poor disease-specific survival. Intermediate tumor-diameter categories (>5 cm or >7 cm) and FIGO stage IIB (vs IB or IIA) did not contribute significant additional information to the model. Only a tumor diameter of greater than 4 cm, a diameter of greater than 6 cm, the presence of lymph node involvement, and histological subtype were independent predictors of pelvic disease control. On the basis of these results, we propose dividing each of the FIGO categories IB, IIA, and IIB into 3 groups according to clinical tumor diameter: (1) less than or equal to 4 cm, (2) 4.1 to 6 cm, and (3) greater than 6 cm. The proposed modified system would provide more accurate prognostic information, facilitate comparisons, and maintain continuity with the current staging system.",Journal Article,4037.0,20.0,Hospital records of 4490 patients treated for International Federation of Gynecology and Obstetrics FIGO stage IB IIA or IIB carcinoma of the cervix between 1960 and 2001 at 1 institution were reviewed Outcomes were estimated using the Kaplan-Meier method and compared using the log-rank method A proportional hazards regression model was used to evaluate the relative importance of predictive factors The rates of disease-specific survival and pelvic disease control were strongly correlated with tumor diameter FIGO stage histological subtype and clinical node status Regression analysis demonstrated that a diameter of greater than 4 cm a diameter of greater than 6 cm FIGO stage II vs IB the presence and level of lymph node involvement and histological subtype were all highly significant independent predictors of poor disease-specific survival Intermediate tumor-diameter categories 5 cm or 7 cm and FIGO stage IIB vs IB or IIA did not contribute significant additional information to the model Only a tumor diameter of greater than 4 cm a diameter of greater than 6 cm the presence of lymph node involvement and histological subtype were independent predictors of pelvic disease control On the basis of these results we propose dividing each of the FIGO categories IB IIA and IIB into 3 groups according to clinical tumor diameter 1 less than or equal to 4 cm 2 4.1 to 6 cm and 3 greater than 6 cm The proposed modified system would provide more accurate prognostic information facilitate comparisons and maintain continuity with the current staging system,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[702, 1064, 1, 40359, 7, 73, 9, 944, 7303, 1, 6429, 2, 7407, 3837, 82, 3180, 4088, 15, 3884, 134, 1, 3, 3629, 59, 10391, 2, 1758, 28, 14, 731, 11, 446, 123, 11, 661, 75, 3, 876, 882, 596, 2, 72, 75, 3, 1066, 1026, 596, 8, 831, 1017, 320, 202, 10, 95, 6, 376, 3, 580, 1187, 1, 464, 130, 3, 151, 1, 34, 112, 25, 2, 1110, 34, 182, 11, 1327, 438, 5, 30, 2549, 3837, 82, 1831, 875, 2, 38, 289, 156, 320, 65, 264, 17, 8, 2549, 1, 378, 76, 39, 494, 8, 2549, 1, 378, 76, 49, 494, 3837, 82, 215, 105, 3180, 3, 463, 2, 301, 1, 263, 289, 799, 2, 1831, 875, 11, 62, 561, 93, 306, 674, 1, 334, 34, 112, 25, 919, 30, 2549, 1996, 33, 494, 15, 67, 494, 2, 3837, 82, 3884, 105, 3180, 15, 4088, 205, 44, 1248, 93, 402, 487, 6, 3, 202, 158, 8, 30, 2549, 1, 378, 76, 39, 494, 8, 2549, 1, 378, 76, 49, 494, 3, 463, 1, 263, 289, 799, 2, 1831, 875, 11, 306, 674, 1, 1110, 34, 182, 23, 3, 877, 1, 46, 99, 21, 2548, 9515, 296, 1, 3, 3837, 1996, 3180, 4088, 2, 3884, 237, 27, 271, 768, 6, 38, 30, 2549, 14, 299, 76, 15, 2997, 6, 39, 494, 18, 39, 14, 6, 49, 494, 2, 27, 378, 76, 49, 494, 3, 1587, 1230, 398, 688, 377, 80, 1481, 177, 487, 1876, 2213, 2, 3040, 12253, 5, 3, 291, 632, 398]",,19258933,534
A prospective randomized trial comparing patient-controlled epidural analgesia to patient-controlled intravenous analgesia on postoperative pain control and recovery after major open gynecologic cancer surgery.,Gynecologic oncology,Gynecol. Oncol.,2009-04-23,"To determine the effect of perioperative patient-controlled epidural analgesia (PCEA) compared to postoperative intravenous (IV) patient-controlled analgesia (PCA) on postoperative recovery parameters after major open gynecologic surgery. A randomized controlled clinical trial included women undergoing laparotomy for a gynecologic disorder. Patients were randomized to postoperative IV morphine PCA (control arm) or to postoperative morphine-bupivacaine PCEA (treatment arm). Postoperative outcomes such as pain, and length of hospital stay were compared with an intention-to-treat analysis. The primary endpoint was postoperative pain at rest and when coughing--assessed by a 10-point visual analog scale (VAS). Between 9/04 and 6/07, 153 patients were randomized and 135 were evaluable (PCEA=67; PCA=68). Over 75% of the women in this study had gynecologic cancer. Patients in the PCEA arm had significantly less postoperative pain at rest on Day 1 and during the first 3 postoperative days when coughing compared to the PCA arm (P<0.05). The mean pain score at rest on Day 1 was 3.3 for the PCEA group compared to 4.3 for the PCA group (P=0.01). Overall, postoperative pain at rest and while coughing in the first 6 days was less in women treated with PCEA compared to PCA (P<0.003). PCEA offers superior postoperative pain control after laparotomy for gynecologic surgery compared to traditional IV PCA. Women requiring major open surgery for gynecologic cancer should be offered PCEA for postoperative pain management if there are no contraindications.",Journal Article,3925.0,35.0,To determine the effect of perioperative patient-controlled epidural analgesia PCEA compared to postoperative intravenous IV patient-controlled analgesia PCA on postoperative recovery parameters after major open gynecologic surgery A randomized controlled clinical trial included women undergoing laparotomy for a gynecologic disorder Patients were randomized to postoperative IV morphine PCA control arm or to postoperative morphine-bupivacaine PCEA treatment arm Postoperative outcomes such as pain and length of hospital stay were compared with an intention-to-treat analysis The primary endpoint was postoperative pain at rest and when coughing -- assessed by a 10-point visual analog scale VAS Between 9/04 and 6/07 153 patients were randomized and 135 were evaluable PCEA=67 PCA=68 Over 75 of the women in this study had gynecologic cancer Patients in the PCEA arm had significantly less postoperative pain at rest on Day 1 and during the first 3 postoperative days when coughing compared to the PCA arm P 0.05 The mean pain score at rest on Day 1 was 3.3 for the PCEA group compared to 4.3 for the PCA group P=0.01 Overall postoperative pain at rest and while coughing in the first 6 days was less in women treated with PCEA compared to PCA P 0.003 PCEA offers superior postoperative pain control after laparotomy for gynecologic surgery compared to traditional IV PCA Women requiring major open surgery for gynecologic cancer should be offered PCEA for postoperative pain management if there are no contraindications,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 223, 3, 254, 1, 1547, 69, 1149, 5844, 7737, 22615, 72, 6, 573, 1262, 478, 69, 1149, 7737, 1265, 23, 573, 1602, 1038, 50, 458, 1020, 1512, 152, 8, 384, 1149, 38, 160, 159, 117, 479, 3274, 9, 8, 1512, 2645, 7, 11, 384, 6, 573, 478, 5896, 1265, 182, 475, 15, 6, 573, 5896, 31226, 22615, 24, 475, 573, 123, 225, 22, 559, 2, 1318, 1, 702, 2020, 11, 72, 5, 35, 3205, 6, 943, 65, 3, 86, 1138, 10, 573, 559, 28, 3677, 2, 198, 19762, 275, 20, 8, 79, 741, 3046, 3497, 1124, 8458, 59, 83, 755, 2, 49, 1615, 4251, 7, 11, 384, 2, 3978, 11, 859, 22615, 598, 1265, 806, 252, 481, 1, 3, 117, 4, 26, 45, 42, 1512, 12, 7, 4, 3, 22615, 475, 42, 97, 299, 573, 559, 28, 3677, 23, 218, 14, 2, 190, 3, 157, 27, 573, 162, 198, 19762, 72, 6, 3, 1265, 475, 19, 13, 474, 3, 313, 559, 368, 28, 3677, 23, 218, 14, 10, 27, 27, 9, 3, 22615, 87, 72, 6, 39, 27, 9, 3, 1265, 87, 19, 13, 355, 63, 573, 559, 28, 3677, 2, 369, 19762, 4, 3, 157, 49, 162, 10, 299, 4, 117, 73, 5, 22615, 72, 6, 1265, 19, 13, 1421, 22615, 2339, 1123, 573, 559, 182, 50, 3274, 9, 1512, 152, 72, 6, 1847, 478, 1265, 117, 1888, 458, 1020, 152, 9, 1512, 12, 257, 40, 2216, 22615, 9, 573, 559, 284, 492, 125, 32, 77, 8511]",,19395071,144
Safety and feasibility of robotic radical trachelectomy in patients with early-stage cervical cancer.,Gynecologic oncology,Gynecol. Oncol.,2009-11-26,"This study aimed to determine the safety and feasibility of robotic radical trachelectomy and bilateral pelvic lymphadenectomy. We also describe our surgical technique. This is a retrospective review of all patients who underwent robotic radical trachelectomy and bilateral pelvic lymphadenectomy from October 2008 to May 2009. We analyzed our data to evaluate the safety and feasibility of this surgery. This analysis included 4 patients with early-stage squamous cell carcinoma of the cervix. The median body mass index was 27.1 kg/m(2) (range, 22.7 to 39.1). Three patients had stage IA2 adenocarcinoma; 1 patient had stage IA1 adenocarcinoma with lymph-vascular space invasion. The median operative time was 339.5 min (range, 245 to 416). The median console time was 282.5 min (range, 217 to 338). The median estimated blood loss was 62.5 ml (range, 50 to 75). There were no conversions to laparotomy. There were no intraoperative complications. No patient required blood transfusion. The median length of hospital stay was 1.5 days (range, 1 to 2). One patient experienced a postoperative complication, transient left lower extremity sensory neuropathy. No patient had residual tumor in the trachelectomy specimen, and no patient underwent adjuvant therapy. The median number of pelvic lymph nodes removed was 20 (range, 18 to 27). The median time to a successful voiding trial was 8 days (range, 7 to 9). The median follow-up was 105 days (range, 82 to 217). There were no recurrences. Robotic radical trachelectomy and bilateral pelvic lymphadenectomy is feasible and safe and should be considered for patients desiring fertility-sparing surgery.",Journal Article,3708.0,66.0,This study aimed to determine the safety and feasibility of robotic radical trachelectomy and bilateral pelvic lymphadenectomy We also describe our surgical technique This is a retrospective review of all patients who underwent robotic radical trachelectomy and bilateral pelvic lymphadenectomy from October 2008 to May 2009 We analyzed our data to evaluate the safety and feasibility of this surgery This analysis included 4 patients with early-stage squamous cell carcinoma of the cervix The median body mass index was 27.1 kg/m 2 range 22.7 to 39.1 Three patients had stage IA2 adenocarcinoma 1 patient had stage IA1 adenocarcinoma with lymph-vascular space invasion The median operative time was 339.5 min range 245 to 416 The median console time was 282.5 min range 217 to 338 The median estimated blood loss was 62.5 ml range 50 to 75 There were no conversions to laparotomy There were no intraoperative complications No patient required blood transfusion The median length of hospital stay was 1.5 days range 1 to 2 One patient experienced a postoperative complication transient left lower extremity sensory neuropathy No patient had residual tumor in the trachelectomy specimen and no patient underwent adjuvant therapy The median number of pelvic lymph nodes removed was 20 range 18 to 27 The median time to a successful voiding trial was 8 days range 7 to 9 The median follow-up was 105 days range 82 to 217 There were no recurrences Robotic radical trachelectomy and bilateral pelvic lymphadenectomy is feasible and safe and should be considered for patients desiring fertility-sparing surgery,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[26, 45, 1295, 6, 223, 3, 367, 2, 1437, 1, 2895, 711, 5760, 2, 1607, 1110, 2048, 21, 120, 897, 114, 221, 1312, 26, 16, 8, 459, 206, 1, 62, 7, 54, 208, 2895, 711, 5760, 2, 1607, 1110, 2048, 29, 2551, 1375, 6, 68, 1238, 21, 311, 114, 74, 6, 376, 3, 367, 2, 1437, 1, 26, 152, 26, 65, 159, 39, 7, 5, 191, 82, 691, 31, 134, 1, 3, 3629, 3, 52, 642, 782, 558, 10, 428, 14, 503, 188, 18, 184, 350, 67, 6, 587, 14, 169, 7, 42, 82, 16725, 449, 14, 69, 42, 82, 14517, 449, 5, 263, 756, 3865, 578, 3, 52, 1208, 98, 10, 7881, 33, 1538, 184, 7373, 6, 10695, 3, 52, 34479, 98, 10, 8219, 33, 1538, 184, 6499, 6, 9982, 3, 52, 661, 315, 407, 10, 744, 33, 542, 184, 212, 6, 481, 125, 11, 77, 13112, 6, 3274, 125, 11, 77, 1720, 521, 77, 69, 616, 315, 2785, 3, 52, 1318, 1, 702, 2020, 10, 14, 33, 162, 184, 14, 6, 18, 104, 69, 592, 8, 573, 1447, 2473, 1712, 280, 2678, 4148, 1751, 77, 69, 42, 753, 30, 4, 3, 5760, 2360, 2, 77, 69, 208, 249, 36, 3, 52, 207, 1, 1110, 263, 502, 2264, 10, 179, 184, 203, 6, 428, 3, 52, 98, 6, 8, 1401, 16280, 160, 10, 66, 162, 184, 67, 6, 83, 3, 52, 166, 126, 10, 3263, 162, 184, 878, 6, 6499, 125, 11, 77, 1593, 2895, 711, 5760, 2, 1607, 1110, 2048, 16, 1313, 2, 1165, 2, 257, 40, 515, 9, 7, 20520, 2954, 1851, 152]",,19944451,571
Incremental value of using Medicaid claim files to study comorbid conditions and treatments in dually eligible beneficiaries.,Medical care,Med Care,2010-01-01,"Although investigations using Medicare claims files are ubiquitous in the health services research literature, Medicaid claims files are used less frequently. Nonetheless, Medicaid is the major payer for healthcare among low-income persons. To assess the added value of Medicaid claim files for identifying comorbid conditions and cancer treatments in a dually eligible sample. Data were obtained from linked statewide tumor registries from 2 contiguous Midwestern states (Michigan and Ohio), Medicare and Medicaid enrollment files, and Medicare and Medicaid claims files. We estimated the prevalence of Charlson Comorbidity Index conditions by counting the number of patients with these conditions in the Medicare claims files alone. We then estimate the expected percent increase in the prevalence of comorbid conditions (along with the 95% confidence interval) that could be obtained by using both Medicare and Medicaid claim files. We followed a similar procedure to identify treatments provided to dually eligible patients. Medicaid claims added very few individuals with comorbid conditions over those identified through Medicare claim files. The increase in the prevalence of comorbid conditions was between 0% and 2.5%. Likewise, Medicaid claims identified few individuals with cancer treatments who were not already identified through Medicare claim files, although variations were noted between the 2 states. This study suggests that the incremental value of Medicaid inpatient, outpatient, and carrier claims is relatively small over what can be obtained from Medicare claims data.",Journal Article,3672.0,3.0,Although investigations using Medicare claims files are ubiquitous in the health services research literature Medicaid claims files are used less frequently Nonetheless Medicaid is the major payer for healthcare among low-income persons To assess the added value of Medicaid claim files for identifying comorbid conditions and cancer treatments in a dually eligible sample Data were obtained from linked statewide tumor registries from 2 contiguous Midwestern states Michigan and Ohio Medicare and Medicaid enrollment files and Medicare and Medicaid claims files We estimated the prevalence of Charlson Comorbidity Index conditions by counting the number of patients with these conditions in the Medicare claims files alone We then estimate the expected percent increase in the prevalence of comorbid conditions along with the 95 confidence interval that could be obtained by using both Medicare and Medicaid claim files We followed a similar procedure to identify treatments provided to dually eligible patients Medicaid claims added very few individuals with comorbid conditions over those identified through Medicare claim files The increase in the prevalence of comorbid conditions was between 0 and 2.5 Likewise Medicaid claims identified few individuals with cancer treatments who were not already identified through Medicare claim files although variations were noted between the 2 states This study suggests that the incremental value of Medicaid inpatient outpatient and carrier claims is relatively small over what can be obtained from Medicare claims data,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[242, 2492, 75, 1378, 2770, 7530, 32, 8577, 4, 3, 341, 2142, 389, 789, 2843, 2770, 7530, 32, 95, 299, 746, 4648, 2843, 16, 3, 458, 7433, 9, 2819, 107, 154, 2306, 4327, 6, 423, 3, 1953, 549, 1, 2843, 10429, 7530, 9, 1386, 3952, 1298, 2, 12, 640, 4, 8, 11409, 625, 1000, 74, 11, 683, 29, 1199, 13749, 30, 3768, 29, 18, 10941, 24671, 907, 9432, 2, 10009, 1378, 2, 2843, 1798, 7530, 2, 1378, 2, 2843, 2770, 7530, 21, 661, 3, 1078, 1, 4670, 1879, 558, 1298, 20, 9479, 3, 207, 1, 7, 5, 46, 1298, 4, 3, 1378, 2770, 7530, 279, 21, 818, 1191, 3, 1336, 714, 344, 4, 3, 1078, 1, 3952, 1298, 1510, 5, 3, 48, 307, 268, 17, 359, 40, 683, 20, 75, 110, 1378, 2, 2843, 10429, 7530, 21, 370, 8, 288, 1299, 6, 255, 640, 1052, 6, 11409, 625, 7, 2843, 2770, 1953, 923, 1021, 869, 5, 3952, 1298, 252, 135, 108, 298, 1378, 10429, 7530, 3, 344, 4, 3, 1078, 1, 3952, 1298, 10, 59, 13, 2, 18, 33, 6269, 2843, 2770, 108, 1021, 869, 5, 12, 640, 54, 11, 44, 3298, 108, 298, 1378, 10429, 7530, 242, 2293, 11, 1051, 59, 3, 18, 907, 26, 45, 844, 17, 3, 3648, 549, 1, 2843, 2420, 2379, 2, 4715, 2770, 16, 1352, 302, 252, 2067, 122, 40, 683, 29, 1378, 2770, 74]",,20050352,0
Dose perturbation due to the polysulfone cap surrounding a Fletcher-Williamson colpostat.,Journal of applied clinical medical physics,J Appl Clin Med Phys,2010-01-28,"We conducted a metrological evaluation of the dosimetric impact due to the polysulfone cap used with the Fletcher-Williamson (FW) colpostat for 192Ir high-dose rate and pulsed-dose rate intracavitary brachytherapy using Monte Carlo simulations. Polysulfone caps with diameter of 30 mm, 25 mm, 20 mm, and 16 mm (mini-ovoid) were simulated and the absorbed dose rate in the surrounding water was calculated and compared to the dose rate for a bare 192Ir source in water. The dose perturbation depended on the cap diameter, distance away from the cap surface, and angular position around the cap. The largest dose rate reductions were found to be in the direction of the tumor bed where the cap is thickest. The range of perturbation over all depths and cap diameters was +2.8% (dose enhancement) to -6.8% (dose reduction). The FW colpostat cap's material composition should be modified to reduce this dosimetric effect or brachytherapy treatment planning dose algorithms should be improved to account for this perturbation.",Journal Article,3645.0,4.0,We conducted a metrological evaluation of the dosimetric impact due to the polysulfone cap used with the Fletcher-Williamson FW colpostat for 192Ir high-dose rate and pulsed-dose rate intracavitary brachytherapy using Monte Carlo simulations Polysulfone caps with diameter of 30 mm 25 mm 20 mm and 16 mm mini-ovoid were simulated and the absorbed dose rate in the surrounding water was calculated and compared to the dose rate for a bare 192Ir source in water The dose perturbation depended on the cap diameter distance away from the cap surface and angular position around the cap The largest dose rate reductions were found to be in the direction of the tumor bed where the cap is thickest The range of perturbation over all depths and cap diameters was +2.8 dose enhancement to -6.8 dose reduction The FW colpostat cap 's material composition should be modified to reduce this dosimetric effect or brachytherapy treatment planning dose algorithms should be improved to account for this perturbation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[21, 426, 8, 76390, 451, 1, 3, 3187, 345, 520, 6, 3, 51935, 3204, 95, 5, 3, 28459, 39216, 51936, 35627, 9, 28360, 64, 61, 116, 2, 5695, 61, 116, 9122, 1536, 75, 7990, 7991, 7490, 51935, 20413, 5, 2549, 1, 201, 321, 243, 321, 179, 321, 2, 245, 321, 7313, 15300, 11, 5872, 2, 3, 5249, 61, 116, 4, 3, 2976, 4388, 10, 981, 2, 72, 6, 3, 61, 116, 9, 8, 28770, 28360, 2353, 4, 4388, 3, 61, 10564, 9020, 23, 3, 3204, 2549, 3019, 6565, 29, 3, 3204, 1255, 2, 22212, 3559, 3337, 3, 3204, 3, 2166, 61, 116, 2153, 11, 204, 6, 40, 4, 3, 4651, 1, 3, 30, 2929, 1257, 3, 3204, 16, 76391, 3, 184, 1, 10564, 252, 62, 17764, 2, 3204, 10390, 10, 18, 66, 61, 2461, 6, 49, 66, 61, 628, 3, 51936, 35627, 3204, 292, 3692, 3761, 257, 40, 1230, 6, 969, 26, 3187, 254, 15, 1536, 24, 1349, 61, 3529, 257, 40, 231, 6, 1967, 9, 26, 10564]",,20160700,9
Technique of minimally invasive Ivor Lewis esophagogastrectomy with intrathoracic stapled side-to-side anastomosis.,Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract,J. Gastrointest. Surg.,2010-06-08,"An intrathoracic linear stapled side-to-side anastomosis for gastroesophageal junction malignancy is feasible, results in low leak rates and less stenosis. Retrospective case series. University tertiary care center. Between March 2008 and January 2009, six patients with gastroesophageal junction malignancy undergoing minimally invasive esophagectomy with an intrathoracic linear stapled side-to-side anastomosis were identified and their clinicopathological data analyzed. Technique of a 6-cm side-to-side stapled intrathoracic esophagogastric anastomosis. Six patients underwent a minimally invasive esophagectomy with a side-to-side stapled intrathoracic esophagogastric anastomosis. Median age was 61.5years. All patients had gastroesophageal junction adenocarcinoma and completed neoadjuvant chemoradiation therapy. The median operative time was 360min. No patient received a blood transfusion. The 30-day mortality was 0. The median length of hospital stay was 8days. The median number of nodes harvested was 18. At a median follow-up of 9months, all patients were alive. There have been no anastomotic strictures to date. A 6-cm side-to-side stapled intrathoracic esophagogastric anastomosis is feasible and is associated with a low anastomotic leak rate.",Journal Article,3514.0,41.0,An intrathoracic linear stapled side-to-side anastomosis for gastroesophageal junction malignancy is feasible results in low leak rates and less stenosis Retrospective case series University tertiary care center Between March 2008 and January 2009 six patients with gastroesophageal junction malignancy undergoing minimally invasive esophagectomy with an intrathoracic linear stapled side-to-side anastomosis were identified and their clinicopathological data analyzed Technique of a 6-cm side-to-side stapled intrathoracic esophagogastric anastomosis Six patients underwent a minimally invasive esophagectomy with a side-to-side stapled intrathoracic esophagogastric anastomosis Median age was 61.5 years All patients had gastroesophageal junction adenocarcinoma and completed neoadjuvant chemoradiation therapy The median operative time was 360 min No patient received a blood transfusion The 30-day mortality was 0 The median length of hospital stay was 8 days The median number of nodes harvested was 18 At a median follow-up of 9 months all patients were alive There have been no anastomotic strictures to date A 6-cm side-to-side stapled intrathoracic esophagogastric anastomosis is feasible and is associated with a low anastomotic leak rate,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,"[35, 7359, 1646, 9911, 1152, 6, 1152, 5519, 9, 3227, 3322, 710, 16, 1313, 99, 4, 154, 4238, 151, 2, 299, 6935, 459, 473, 988, 1652, 2557, 165, 574, 59, 2363, 1375, 2, 1024, 1238, 437, 7, 5, 3227, 3322, 710, 479, 2144, 416, 3617, 5, 35, 7359, 1646, 9911, 1152, 6, 1152, 5519, 11, 108, 2, 136, 2721, 74, 311, 1312, 1, 8, 49, 494, 1152, 6, 1152, 9911, 7359, 6330, 5519, 437, 7, 208, 8, 2144, 416, 3617, 5, 8, 1152, 6, 1152, 9911, 7359, 6330, 5519, 52, 89, 10, 713, 33, 60, 62, 7, 42, 3227, 3322, 449, 2, 781, 536, 975, 36, 3, 52, 1208, 98, 10, 6739, 1538, 77, 69, 103, 8, 315, 2785, 3, 201, 218, 282, 10, 13, 3, 52, 1318, 1, 702, 2020, 10, 66, 162, 3, 52, 207, 1, 502, 6503, 10, 203, 28, 8, 52, 166, 126, 1, 83, 53, 62, 7, 11, 1701, 125, 47, 85, 77, 4818, 7860, 6, 1244, 8, 49, 494, 1152, 6, 1152, 9911, 7359, 6330, 5519, 16, 1313, 2, 16, 41, 5, 8, 154, 4818, 4238, 116]",,20532663,697
Repeat decompression surgery for recurrent spinal metastases.,Journal of neurosurgery. Spine,J Neurosurg Spine,2010-07-01,"OBJECT In this paper, the authors' goal was to determine the outcome of reoperation for recurrent epidural spinal cord compression in patients with metastatic spine disease. METHODS A retrospective chart review was conducted of all patients who underwent spine surgery at the Memorial Sloan-Kettering Cancer Center between 1996 and 2007. Thirty-nine patients who underwent reoperation of the spine at the level previously treated with surgery were identified. Only patients whose reoperation was performed because of tumor recurrence leading to high-grade epidural spinal cord compression or recurrence with no further radiation options were included in the study. Patients who underwent reoperations exclusively for instrumentation failure were excluded. All patients underwent additional decompression via a posterolateral approach without removal of the spinal instrumentation. RESULTS Patients underwent 1-4 reoperations at the same level. A median survival time of 12.4 months was noted after the first reoperation, and a median survival time of 9.1 months was noted after the last reoperation. At last follow-up 22 (65%) of 34 patients were ambulatory at the time of last follow-up or death, and the median time between loss-of-ambulation and death was 1 month. Functional status was maintained or improved by one Eastern Cooperative Oncology Group grade in 97% of patients. A major surgical complication rate of 5% was noted. CONCLUSIONS Reoperation represents a viable option in patients with high-grade epidural spinal cord compression who have recurrent metastatic tumors at previously operated spinal levels. In carefully selected patients, reoperation can prolong ambulation and result in good functional and neurological outcomes.",Journal Article,3491.0,21.0,OBJECT In this paper the authors goal was to determine the outcome of reoperation for recurrent epidural spinal cord compression in patients with metastatic spine disease METHODS A retrospective chart review was conducted of all patients who underwent spine surgery at the Memorial Sloan-Kettering Cancer Center between 1996 and 2007 Thirty-nine patients who underwent reoperation of the spine at the level previously treated with surgery were identified Only patients whose reoperation was performed because of tumor recurrence leading to high-grade epidural spinal cord compression or recurrence with no further radiation options were included in the study Patients who underwent reoperations exclusively for instrumentation failure were excluded All patients underwent additional decompression via a posterolateral approach without removal of the spinal instrumentation RESULTS Patients underwent 1-4 reoperations at the same level A median survival time of 12.4 months was noted after the first reoperation and a median survival time of 9.1 months was noted after the last reoperation At last follow-up 22 65 of 34 patients were ambulatory at the time of last follow-up or death and the median time between loss-of-ambulation and death was 1 month Functional status was maintained or improved by one Eastern Cooperative Oncology Group grade in 97 of patients A major surgical complication rate of 5 was noted CONCLUSIONS Reoperation represents a viable option in patients with high-grade epidural spinal cord compression who have recurrent metastatic tumors at previously operated spinal levels In carefully selected patients reoperation can prolong ambulation and result in good functional and neurological outcomes,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12381, 4, 26, 2817, 3, 738, 1326, 10, 6, 223, 3, 228, 1, 5077, 9, 387, 5844, 1499, 1885, 3481, 4, 7, 5, 113, 2342, 34, 636, 8, 459, 2937, 206, 10, 426, 1, 62, 7, 54, 208, 2342, 152, 28, 3, 2563, 2783, 2784, 12, 574, 59, 2648, 2, 1307, 977, 762, 7, 54, 208, 5077, 1, 3, 2342, 28, 3, 301, 373, 73, 5, 152, 11, 108, 158, 7, 1310, 5077, 10, 173, 408, 1, 30, 146, 1049, 6, 64, 88, 5844, 1499, 1885, 3481, 15, 146, 5, 77, 195, 121, 838, 11, 159, 4, 3, 45, 7, 54, 208, 10691, 4437, 9, 9166, 496, 11, 1800, 62, 7, 208, 402, 7638, 847, 8, 13000, 353, 187, 2829, 1, 3, 1499, 9166, 99, 7, 208, 14, 39, 10691, 28, 3, 827, 301, 8, 52, 25, 98, 1, 133, 39, 53, 10, 1051, 50, 3, 157, 5077, 2, 8, 52, 25, 98, 1, 83, 14, 53, 10, 1051, 50, 3, 1060, 5077, 28, 1060, 166, 126, 350, 556, 1, 562, 7, 11, 4154, 28, 3, 98, 1, 1060, 166, 126, 15, 273, 2, 3, 52, 98, 59, 407, 1, 13952, 2, 273, 10, 14, 811, 583, 156, 10, 1955, 15, 231, 20, 104, 2118, 1690, 413, 87, 88, 4, 1015, 1, 7, 8, 458, 221, 1447, 116, 1, 33, 10, 1051, 2130, 5077, 1449, 8, 2663, 1501, 4, 7, 5, 64, 88, 5844, 1499, 1885, 3481, 54, 47, 387, 113, 57, 28, 373, 7297, 1499, 148, 4, 3900, 715, 7, 5077, 122, 3615, 13952, 2, 757, 4, 1178, 583, 2, 3622, 123]",,20594025,179
Symptom research in gynecologic oncology: a review of available measurement tools.,Gynecologic oncology,Gynecol. Oncol.,2010-08-04,"Cancer and its treatment produce multiple symptoms that significantly distress patients and impair function. Effective symptom management requires effective symptom assessment. A variety of measurement instruments have been created to identify symptoms in oncology practice. Here we review symptom assessment measures available for gynecologic cancers. A systematic literature search was performed to identify articles on symptom assessment and quality-of-life instruments in gynecologic oncology. Articles were accessed through searches performed in PubMed, MEDLINE, CINAHL Plus, and the Cochrane Library. Studies were selected if they described development of symptom assessment tools for diagnosis and measurement of symptoms of gynecologic cancers and treatments. We also included studies using quality-of-life measurement tools that contained symptom items. Nine studies examined symptom assessment, quality-of-life assessment, or symptom indexes for various gynecologic cancers. Studies varied in design, patient profiles, symptoms assessed, and outcomes measured. Meta-analysis was not performed due to heterogeneity in the studies. Although pain is well-studied and well-characterized, other disease-specific and general systemic symptoms of gynecologic cancers need better understanding and assessment. Accordingly, assessment of symptoms throughout the course of disease is crucial for treatment decisions and outcomes monitoring for patients with gynecologic cancer. This is especially true for survivors of gynecologic cancer, for patients whose treatment was unsuccessful, or for choosing between treatments with comparable survival outcomes. However, measurement and assessment of cancer-related symptoms is challenging because of the complex interaction between disease progression, multi-modality treatments, and symptoms. In this review, we evaluate the currently available symptom assessment tools for gynecologic cancers, along with quality-of-life assessment tools that include symptom items, and we give recommendations for further research.",Journal Article,3457.0,13.0,Cancer and its treatment produce multiple symptoms that significantly distress patients and impair function Effective symptom management requires effective symptom assessment A variety of measurement instruments have been created to identify symptoms in oncology practice Here we review symptom assessment measures available for gynecologic cancers A systematic literature search was performed to identify articles on symptom assessment and quality-of-life instruments in gynecologic oncology Articles were accessed through searches performed in PubMed MEDLINE CINAHL Plus and the Cochrane Library Studies were selected if they described development of symptom assessment tools for diagnosis and measurement of symptoms of gynecologic cancers and treatments We also included studies using quality-of-life measurement tools that contained symptom items Nine studies examined symptom assessment quality-of-life assessment or symptom indexes for various gynecologic cancers Studies varied in design patient profiles symptoms assessed and outcomes measured Meta-analysis was not performed due to heterogeneity in the studies Although pain is well-studied and well-characterized other disease-specific and general systemic symptoms of gynecologic cancers need better understanding and assessment Accordingly assessment of symptoms throughout the course of disease is crucial for treatment decisions and outcomes monitoring for patients with gynecologic cancer This is especially true for survivors of gynecologic cancer for patients whose treatment was unsuccessful or for choosing between treatments with comparable survival outcomes However measurement and assessment of cancer-related symptoms is challenging because of the complex interaction between disease progression multi-modality treatments and symptoms In this review we evaluate the currently available symptom assessment tools for gynecologic cancers along with quality-of-life assessment tools that include symptom items and we give recommendations for further research,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[12, 2, 211, 24, 2410, 232, 507, 17, 97, 1462, 7, 2, 6267, 343, 323, 934, 284, 1706, 323, 934, 455, 8, 1362, 1, 2204, 4730, 47, 85, 2466, 6, 255, 507, 4, 413, 758, 467, 21, 206, 934, 455, 1018, 390, 9, 1512, 163, 8, 1556, 789, 1901, 10, 173, 6, 255, 2384, 23, 934, 455, 2, 372, 1, 358, 4730, 4, 1512, 413, 2384, 11, 11276, 298, 6769, 173, 4, 3161, 3388, 14657, 349, 2, 3, 4956, 4157, 94, 11, 715, 492, 491, 1027, 193, 1, 934, 455, 1896, 9, 147, 2, 2204, 1, 507, 1, 1512, 163, 2, 640, 21, 120, 159, 94, 75, 372, 1, 358, 2204, 1896, 17, 3070, 934, 2980, 762, 94, 409, 934, 455, 372, 1, 358, 455, 15, 934, 11480, 9, 747, 1512, 163, 94, 2051, 4, 771, 69, 1241, 507, 275, 2, 123, 644, 1742, 65, 10, 44, 173, 520, 6, 1144, 4, 3, 94, 242, 559, 16, 149, 656, 2, 149, 765, 127, 34, 112, 2, 1083, 403, 507, 1, 1512, 163, 594, 380, 612, 2, 455, 4705, 455, 1, 507, 2432, 3, 906, 1, 34, 16, 2653, 9, 24, 1526, 2, 123, 1315, 9, 7, 5, 1512, 12, 26, 16, 1093, 2501, 9, 332, 1, 1512, 12, 9, 7, 1310, 24, 10, 7581, 15, 9, 5065, 59, 640, 5, 1279, 25, 123, 137, 2204, 2, 455, 1, 12, 139, 507, 16, 1950, 408, 1, 3, 840, 915, 59, 34, 91, 1414, 1396, 640, 2, 507, 4, 26, 206, 21, 376, 3, 694, 390, 934, 455, 1896, 9, 1512, 163, 1510, 5, 372, 1, 358, 455, 1896, 17, 643, 934, 2980, 2, 21, 4978, 883, 9, 195, 389]",,20688364,799
Ethics consultation on a gynecologic oncology service: an opportunity for physician education.,Journal of cancer education : the official journal of the American Association for Cancer Education,J Cancer Educ,2011-03-01,"The purpose of this study is to understand the features of gynecologic oncology patients who receive ethics consults in order to identify areas for physician education and improve patient care. A review of ethics consults for gynecologic oncology patients from 1993 to 2008 was performed. Information on all gynecologic oncology patients treated during the study interval was also collected to define a base population for comparison. Forty-one consults were performed. Compared to the base population, a greater proportion of consult patients had pregnancy-related malignancies (7.9% vs. 0.8%, p < 0.0001) and were African American (33.3% vs. 10.9%, p < 0.0001). The most common clinical case types involved identifying levels of appropriate treatment. Support of the health care team and complex family dynamics were key underlying issues. Ethics consultation provides a substantial resource in identifying relevant issues experienced by gynecologic oncology patients upon which physician educational initiatives may be based.",Journal Article,3248.0,2.0,The purpose of this study is to understand the features of gynecologic oncology patients who receive ethics consults in order to identify areas for physician education and improve patient care A review of ethics consults for gynecologic oncology patients from 1993 to 2008 was performed Information on all gynecologic oncology patients treated during the study interval was also collected to define a base population for comparison Forty-one consults were performed Compared to the base population a greater proportion of consult patients had pregnancy-related malignancies 7.9 vs. 0.8 p 0.0001 and were African American 33.3 vs. 10.9 p 0.0001 The most common clinical case types involved identifying levels of appropriate treatment Support of the health care team and complex family dynamics were key underlying issues Ethics consultation provides a substantial resource in identifying relevant issues experienced by gynecologic oncology patients upon which physician educational initiatives may be based,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 743, 1, 26, 45, 16, 6, 1640, 3, 404, 1, 1512, 413, 7, 54, 560, 16560, 12725, 4, 1732, 6, 255, 1361, 9, 1473, 1848, 2, 401, 69, 165, 8, 206, 1, 16560, 12725, 9, 1512, 413, 7, 29, 3343, 6, 1375, 10, 173, 487, 23, 62, 1512, 413, 7, 73, 190, 3, 45, 268, 10, 120, 786, 6, 1107, 8, 1782, 266, 9, 1155, 1213, 104, 12725, 11, 173, 72, 6, 3, 1782, 266, 8, 378, 920, 1, 11907, 7, 42, 2290, 139, 441, 67, 83, 105, 13, 66, 19, 13, 488, 2, 11, 1410, 597, 466, 27, 105, 79, 83, 19, 13, 488, 3, 96, 186, 38, 473, 630, 646, 1386, 148, 1, 870, 24, 538, 1, 3, 341, 165, 2870, 2, 840, 607, 5193, 11, 825, 1181, 1553, 16560, 2981, 777, 8, 1281, 3069, 4, 1386, 867, 1553, 592, 20, 1512, 413, 7, 1548, 92, 1473, 3624, 6328, 68, 40, 90]",,20835927,0
Building capacity to assess cancer care in the Medicaid population in New York State.,Health services research,Health Serv Res,2010-12-15,"To link data from a central cancer registry with Medicaid enrollment and claims files in order to assess cancer care in an economically disadvantaged population. Over 500,000 cancer patients diagnosed between 2002 and 2006 reported to the New York State Cancer Registry were linked with New York State Medicaid enrollment and claims records. A probabilistic linkage was performed between the two data sources. The resulting Medicaid and non-Medicaid populations were compared in terms of demographics and stage at diagnosis. Existing databases were used. One-quarter of cancer patients were enrolled in Medicaid at or near the time of cancer diagnosis. The Medicaid cohort was younger, more likely to be an ethnic minority, foreign born, never married, live in either an inner-city or remote rural area, and have a higher stage at diagnosis. The linked dataset will permit detailed analysis of cancer treatment and cancer treatment disparities among historically understudied groups. The linkage has also resulted in improvements in Cancer Registry quality through the identification of errors and missing values. The linkage did present technical challenges in the form of immense file sizes not easily adaptable to desktop computers.",Journal Article,3324.0,22.0,"To link data from a central cancer registry with Medicaid enrollment and claims files in order to assess cancer care in an economically disadvantaged population Over 500,000 cancer patients diagnosed between 2002 and 2006 reported to the New York State Cancer Registry were linked with New York State Medicaid enrollment and claims records A probabilistic linkage was performed between the two data sources The resulting Medicaid and non-Medicaid populations were compared in terms of demographics and stage at diagnosis Existing databases were used One-quarter of cancer patients were enrolled in Medicaid at or near the time of cancer diagnosis The Medicaid cohort was younger more likely to be an ethnic minority foreign born never married live in either an inner-city or remote rural area and have a higher stage at diagnosis The linked dataset will permit detailed analysis of cancer treatment and cancer treatment disparities among historically understudied groups The linkage has also resulted in improvements in Cancer Registry quality through the identification of errors and missing values The linkage did present technical challenges in the form of immense file sizes not easily adaptable to desktop computers",1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 3460, 74, 29, 8, 854, 12, 1608, 5, 2843, 1798, 2, 2770, 7530, 4, 1732, 6, 423, 12, 165, 4, 35, 18514, 16700, 266, 252, 1666, 984, 12, 7, 265, 59, 1544, 2, 1324, 210, 6, 3, 217, 5050, 1309, 12, 1608, 11, 1199, 5, 217, 5050, 1309, 2843, 1798, 2, 2770, 1064, 8, 7889, 4820, 10, 173, 59, 3, 100, 74, 3375, 3, 1113, 2843, 2, 220, 2843, 1184, 11, 72, 4, 1794, 1, 2221, 2, 82, 28, 147, 1692, 2348, 11, 95, 104, 8034, 1, 12, 7, 11, 346, 4, 2843, 28, 15, 1829, 3, 98, 1, 12, 147, 3, 2843, 180, 10, 773, 80, 322, 6, 40, 35, 2871, 2652, 9950, 8234, 1737, 5365, 3812, 4, 361, 35, 7938, 7235, 15, 9879, 5291, 965, 2, 47, 8, 142, 82, 28, 147, 3, 1199, 3014, 303, 5634, 2455, 65, 1, 12, 24, 2, 12, 24, 2227, 107, 3578, 8207, 271, 3, 4820, 71, 120, 627, 4, 1474, 4, 12, 1608, 372, 298, 3, 911, 1, 4612, 2, 4593, 1030, 3, 4820, 205, 364, 3359, 1427, 4, 3, 1297, 1, 17980, 12339, 4131, 44, 4697, 16474, 6, 29723, 16480]",,21158856,20
"Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.",Gynecologic oncology,Gynecol. Oncol.,2011-02-16,"The purpose of this study was to evaluate the safety and efficacy of cetuximab (C225), an antibody that inhibits epidermal growth factor receptor (EGFR) activity, with cisplatin and to explore associations between EGFR protein expression with patient demographics or clinical outcome. Women with advanced, persistent, or recurrent carcinoma of the cervix were eligible. The women received cisplatin at 30mg/m(2) on days 1 and 8 with a loading dose of cetuximab at 400mg/m(2) followed by 250mg/m(2) on days 1, 8, and 15 in a 21day cycle. Adverse events were assessed with CTCAE v 3.0. Primary measure of efficacy was tumor response by RECIST. The study was stratified by prior chemotherapy (CT). EGFR protein expression in pre-treatment tumor was analyzed by immunohistochemistry. Between September 2004 and March 2008, 76 patients were enrolled. Of these, 69 were eligible and evaluable; 44 (64%) received prior chemotherapy. There were 4 responses in each group, prior chemotherapy and no chemotherapy, 9% and 16%, respectively. Grade 4 toxicities included anemia (1), allergy (1), metabolic (1), and vascular (1). The most common grade 3 toxicities were metabolic (15), dermatologic (8), fatigue (6), and gastrointestinal (6). EGFR protein was expressed in 47/48 (98%) of tumors analyzed with a median cellular expression of 81%. Exploratory analyses revealed a trend between the percentage of cells expressing EGFR protein and PFS (hazard ratio=1.76, 95% confidence interval=0.96-3.21). The combination of cetuximab with cisplatin was adequately tolerated but did not indicate additional benefit beyond cisplatin therapy.","Clinical Trial, Phase II",3261.0,64.0,The purpose of this study was to evaluate the safety and efficacy of cetuximab C225 an antibody that inhibits epidermal growth factor receptor EGFR activity with cisplatin and to explore associations between EGFR protein expression with patient demographics or clinical outcome Women with advanced persistent or recurrent carcinoma of the cervix were eligible The women received cisplatin at 30mg/m 2 on days 1 and 8 with a loading dose of cetuximab at 400mg/m 2 followed by 250mg/m 2 on days 1 8 and 15 in a 21day cycle Adverse events were assessed with CTCAE v 3.0 Primary measure of efficacy was tumor response by RECIST The study was stratified by prior chemotherapy CT EGFR protein expression in pre-treatment tumor was analyzed by immunohistochemistry Between September 2004 and March 2008 76 patients were enrolled Of these 69 were eligible and evaluable 44 64 received prior chemotherapy There were 4 responses in each group prior chemotherapy and no chemotherapy 9 and 16 respectively Grade 4 toxicities included anemia 1 allergy 1 metabolic 1 and vascular 1 The most common grade 3 toxicities were metabolic 15 dermatologic 8 fatigue 6 and 6 EGFR protein was expressed in 47/48 98 of tumors analyzed with a median cellular expression of 81 Exploratory analyses revealed a trend between the percentage of cells expressing EGFR protein and PFS hazard ratio=1.76 95 confidence interval=0.96-3.21 The combination of cetuximab with cisplatin was adequately tolerated but did not indicate additional benefit beyond cisplatin therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 376, 3, 367, 2, 209, 1, 1175, 7913, 35, 548, 17, 1576, 829, 129, 161, 153, 227, 128, 5, 540, 2, 6, 1645, 685, 59, 227, 178, 55, 5, 69, 2221, 15, 38, 228, 117, 5, 131, 1882, 15, 387, 134, 1, 3, 3629, 11, 625, 3, 117, 103, 540, 28, 30285, 188, 18, 23, 162, 14, 2, 66, 5, 8, 4717, 61, 1, 1175, 28, 14632, 188, 18, 370, 20, 22452, 188, 18, 23, 162, 14, 66, 2, 167, 4, 8, 49034, 417, 290, 281, 11, 275, 5, 3898, 603, 27, 13, 86, 1463, 1, 209, 10, 30, 51, 20, 1834, 3, 45, 10, 1173, 20, 324, 56, 425, 227, 178, 55, 4, 671, 24, 30, 10, 311, 20, 888, 59, 2636, 1131, 2, 2363, 1375, 846, 7, 11, 346, 1, 46, 790, 11, 625, 2, 859, 584, 660, 103, 324, 56, 125, 11, 39, 253, 4, 296, 87, 324, 56, 2, 77, 56, 83, 2, 245, 106, 88, 39, 385, 159, 1545, 14, 9842, 14, 1436, 14, 2, 756, 14, 3, 96, 186, 88, 27, 385, 11, 1436, 167, 4722, 66, 613, 49, 2, 49, 227, 178, 10, 570, 4, 662, 576, 1096, 1, 57, 311, 5, 8, 52, 763, 55, 1, 865, 2386, 318, 553, 8, 853, 59, 3, 1150, 1, 37, 1046, 227, 178, 2, 300, 360, 197, 14, 846, 48, 307, 268, 13, 921, 27, 239, 3, 150, 1, 1175, 5, 540, 10, 4215, 421, 84, 205, 44, 1008, 402, 247, 1654, 540, 36]",,21329967,716
Concurrent sulforaphane and eugenol induces differential effects on human cervical cancer cells.,Integrative cancer therapies,Integr Cancer Ther,2011-03-07,"The concept of combination of chemoprevention holds great potential for cancer management as lower, clinically tolerable doses of individual agents could be achieved through therapeutic synergy. However, elucidation of their possible interactions--additive, synergistic, or antagonistic--must be thoroughly studied before considering for clinical use. To evaluate the effect of combination treatment of sulforaphane (SFN) and eugenol on HeLa cells, the authors performed cell viability assay, apoptosis assay, and reverse transcription polymerase chain reaction for gene expression analysis. Calculations of combination effects were expressed as a combination index (CI) with CI < 1, CI = 1, or CI > 1 representing synergism, additivity, or antagonism, respectively. Simultaneous treatment with variable dose combinations of SFN and eugenol resulted in differential effects with an antagonistic effect at lower and synergistic at higher sub-lethal doses as reflected in cell cytotoxicity and apoptosis induction. Importantly, gemcitabine used in conjunction with the low- and high-dose combinations showed no significant cell death at lower doses suggesting that cell cytotoxicity is proportional to gemcitabine alone, whereas at higher sublethal doses of SFN and eugenol, it was found to act in a synergistic manner with gemcitabine. Furthermore, SFN and eugenol combinations at synergistic dose significantly downregulated the expression of Bcl-2, COX-2 and IL- but not the antagonistic combinations. This study clearly indicates that 2 (or more) chemopreventive agents can act antagonistically or synergistically necessitating elucidation of possible mechanistic interactions for favorable and reliable outcomes of dietary components in the field of cancer prevention.",Journal Article,3242.0,24.0,The concept of combination of chemoprevention holds great potential for cancer management as lower clinically tolerable doses of individual agents could be achieved through therapeutic synergy However elucidation of their possible interactions -- additive synergistic or antagonistic -- must be thoroughly studied before considering for clinical use To evaluate the effect of combination treatment of sulforaphane SFN and eugenol on HeLa cells the authors performed cell viability assay apoptosis assay and reverse transcription polymerase chain reaction for gene expression analysis Calculations of combination effects were expressed as a combination index CI with CI 1 CI 1 or CI 1 representing synergism additivity or antagonism respectively Simultaneous treatment with variable dose combinations of SFN and eugenol resulted in differential effects with an antagonistic effect at lower and synergistic at higher sub-lethal doses as reflected in cell cytotoxicity and apoptosis induction Importantly gemcitabine used in conjunction with the low- and high-dose combinations showed no significant cell death at lower doses suggesting that cell cytotoxicity is proportional to gemcitabine alone whereas at higher sublethal doses of SFN and eugenol it was found to act in a synergistic manner with gemcitabine Furthermore SFN and eugenol combinations at synergistic dose significantly downregulated the expression of Bcl-2 COX-2 and IL- but not the antagonistic combinations This study clearly indicates that 2 or more chemopreventive agents can act antagonistically or synergistically necessitating elucidation of possible mechanistic interactions for favorable and reliable outcomes of dietary components in the field of cancer prevention,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 2545, 1, 150, 1, 2886, 5253, 2797, 174, 9, 12, 284, 22, 280, 505, 2668, 415, 1, 797, 183, 359, 40, 513, 298, 189, 3439, 137, 7481, 1, 136, 899, 1286, 3396, 1806, 15, 9863, 1642, 40, 11576, 656, 348, 3075, 9, 38, 119, 6, 376, 3, 254, 1, 150, 24, 1, 9510, 10481, 2, 20743, 23, 8466, 37, 3, 738, 173, 31, 2120, 719, 351, 719, 2, 1772, 866, 1451, 1260, 1329, 9, 145, 55, 65, 8229, 1, 150, 176, 11, 570, 22, 8, 150, 558, 58, 5, 58, 14, 58, 14, 15, 58, 14, 2861, 6494, 22390, 15, 7537, 106, 2824, 24, 5, 1347, 61, 1247, 1, 10481, 2, 20743, 627, 4, 1777, 176, 5, 35, 9863, 254, 28, 280, 2, 1806, 28, 142, 551, 2266, 415, 22, 4686, 4, 31, 1408, 2, 351, 504, 1859, 679, 95, 4, 3357, 5, 3, 154, 2, 64, 61, 1247, 224, 77, 93, 31, 273, 28, 280, 415, 802, 17, 31, 1408, 16, 831, 6, 679, 279, 547, 28, 142, 17219, 415, 1, 10481, 2, 20743, 192, 10, 204, 6, 2559, 4, 8, 1806, 1708, 5, 679, 798, 10481, 2, 20743, 1247, 28, 1806, 61, 97, 3315, 3, 55, 1, 1044, 18, 418, 18, 2, 501, 1458, 84, 44, 3, 9863, 1247, 26, 45, 2536, 2640, 17, 18, 15, 80, 4401, 183, 122, 2559, 48526, 15, 4240, 8365, 7481, 1, 899, 2716, 1286, 9, 913, 2, 2450, 123, 1, 2013, 1628, 4, 3, 1067, 1, 12, 1070]",,21382956,370
Long-term outcome of pleuropneumonectomy for Masaoka stage IVa thymoma.,European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,Eur J Cardiothorac Surg,2011-03-21,"Because pleuropneumonectomy is associated with a high mortality rate, its indication for the treatment of Masaoka stage IVa thymoma is debated. We reviewed retrospectively our single-center experience in order to determine if the benefits warrant the risk of such procedure. Between 1970 and 2009, 17 patients (12 men and 5 women) with a mean age of 44 years (range, 25-62 years) underwent a pleuropneumonectomy for a Masaoka stage IVa thymoma in our institution. Eight patients had recurrent thymoma after a mean postoperative period of 47  28 months, and nine patients presented de novo with stage IVa disease. A multimodality treatment including chemotherapy, radiotherapy, or both was performed in 14 (82%) patients. Eight patients (47%) experienced a major postoperative complication, including four broncho-pleural fistulae (23%). There were no operative deaths and the 30-day mortality was 17.6% (3/17). But two patients died at 2 and 3 months, increasing the postoperative mortality to 29.4% (5/17). Complete resection was achieved in 11 (65%) patients. By univariate analysis, myasthenia gravis was the only risk factor for broncho-pleural fistulae. With a median survival of 76 months and median follow-up of 59 months (range, 1-262 months), 5-year and 10-year survivals were 60% and 30%, respectively. During follow-up, a recurrence occurred in two patients at 26 and 87 months, respectively, which was treated medically without success. Pleuropneumonectomy for Masaoka stage IVa thymoma is associated with a high morbid-mortality rate. However, included in a multimodality strategy and in highly selected patients this procedure may provide good long-term survival.",Journal Article,3228.0,30.0,Because pleuropneumonectomy is associated with a high mortality rate its indication for the treatment of Masaoka stage IVa thymoma is debated We reviewed retrospectively our single-center experience in order to determine if the benefits warrant the risk of such procedure Between 1970 and 2009 17 patients 12 men and 5 women with a mean age of 44 years range 25-62 years underwent a pleuropneumonectomy for a Masaoka stage IVa thymoma in our institution Eight patients had recurrent thymoma after a mean postoperative period of 47  28 months and nine patients presented de novo with stage IVa disease A multimodality treatment including chemotherapy radiotherapy or both was performed in 14 82 patients Eight patients 47 experienced a major postoperative complication including four broncho-pleural fistulae 23 There were no operative deaths and the 30-day mortality was 17.6 3/17 But two patients died at 2 and 3 months increasing the postoperative mortality to 29.4 5/17 Complete resection was achieved in 11 65 patients By univariate analysis myasthenia gravis was the only risk factor for broncho-pleural fistulae With a median survival of 76 months and median follow-up of 59 months range 1-262 months 5-year and 10-year survivals were 60 and 30 respectively During follow-up a recurrence occurred in two patients at 26 and 87 months respectively which was treated medically without success Pleuropneumonectomy for Masaoka stage IVa thymoma is associated with a high morbid-mortality rate However included in a multimodality strategy and in highly selected patients this procedure may provide good long-term survival,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[408, 42493, 16, 41, 5, 8, 64, 282, 116, 211, 3607, 9, 3, 24, 1, 9313, 82, 5900, 5070, 16, 7755, 21, 446, 894, 114, 226, 574, 730, 4, 1732, 6, 223, 492, 3, 1141, 2946, 3, 43, 1, 225, 1299, 59, 4868, 2, 1238, 269, 7, 133, 325, 2, 33, 117, 5, 8, 313, 89, 1, 584, 60, 184, 243, 744, 60, 208, 8, 42493, 9, 8, 9313, 82, 5900, 5070, 4, 114, 731, 659, 7, 42, 387, 5070, 50, 8, 313, 573, 727, 1, 662, 810, 339, 53, 2, 762, 7, 917, 1566, 2018, 5, 82, 5900, 34, 8, 2425, 24, 141, 56, 310, 15, 110, 10, 173, 4, 213, 878, 7, 659, 7, 662, 592, 8, 458, 573, 1447, 141, 294, 25126, 2164, 17809, 382, 125, 11, 77, 1208, 1043, 2, 3, 201, 218, 282, 10, 269, 49, 27, 269, 84, 100, 7, 1016, 28, 18, 2, 27, 53, 602, 3, 573, 282, 6, 462, 39, 33, 269, 236, 170, 10, 513, 4, 175, 556, 7, 20, 880, 65, 18197, 18198, 10, 3, 158, 43, 161, 9, 25126, 2164, 17809, 5, 8, 52, 25, 1, 846, 53, 2, 52, 166, 126, 1, 728, 53, 184, 14, 7801, 53, 33, 111, 2, 79, 111, 3794, 11, 335, 2, 201, 106, 190, 166, 126, 8, 146, 489, 4, 100, 7, 28, 432, 2, 912, 53, 106, 92, 10, 73, 4381, 187, 1825, 42493, 9, 9313, 82, 5900, 5070, 16, 41, 5, 8, 64, 8188, 282, 116, 137, 159, 4, 8, 2425, 692, 2, 4, 561, 715, 7, 26, 1299, 68, 377, 1178, 319, 337, 25]",,21420311,168
Animal models and molecular imaging tools to investigate lymph node metastases.,"Journal of molecular medicine (Berlin, Germany)",J. Mol. Med.,2011-05-10,"Lymph node metastasis is a strong predictor of poor outcome in cancer patients. Animal studies of lymph node metastasis are constrained by difficulties in the establishment of appropriate animal models, limitations in the noninvasive monitoring of lymph node metastasis progression, and challenges in the pathologic confirmation of lymph node metastases. In this comprehensive review, we summarize available preclinical animal cancer models for noninvasive imaging and identification of lymph node metastases of non-hematogenous cancers. Furthermore, we discuss the strengths and weaknesses of common noninvasive imaging modalities used to identify tumor-bearing lymph nodes and provide guidelines for their pathological confirmation.",Journal Article,3178.0,12.0,Lymph node metastasis is a strong predictor of poor outcome in cancer patients Animal studies of lymph node metastasis are constrained by difficulties in the establishment of appropriate animal models limitations in the noninvasive monitoring of lymph node metastasis progression and challenges in the pathologic confirmation of lymph node metastases In this comprehensive review we summarize available preclinical animal cancer models for noninvasive imaging and identification of lymph node metastases of non-hematogenous cancers Furthermore we discuss the strengths and weaknesses of common noninvasive imaging modalities used to identify tumor-bearing lymph nodes and provide guidelines for their pathological confirmation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[263, 289, 278, 16, 8, 1082, 980, 1, 334, 228, 4, 12, 7, 2026, 94, 1, 263, 289, 278, 32, 9133, 20, 4679, 4, 3, 5346, 1, 870, 2026, 274, 1939, 4, 3, 2957, 1315, 1, 263, 289, 278, 91, 2, 1427, 4, 3, 510, 3551, 1, 263, 289, 196, 4, 26, 949, 206, 21, 2479, 390, 693, 2026, 12, 274, 9, 2957, 270, 2, 911, 1, 263, 289, 196, 1, 220, 9792, 163, 798, 21, 1139, 3, 9127, 2, 12165, 1, 186, 2957, 270, 1558, 95, 6, 255, 30, 1894, 263, 502, 2, 377, 677, 9, 136, 1301, 3551]",,21556810,1
Willingness of pregnant women to vaccinate themselves and their newborns with the HPV vaccine.,Vaccine,Vaccine,2011-05-08,"To evaluate the willingness of pregnant women to accept the HPV vaccine for their newborns as well as themselves. An 18-item questionnaire was distributed to antepartum women. Demographic data about the respondent's current pregnancy and her knowledge of HPV and the HPV vaccine was collected. Information about the respondent's HPV and HPV vaccine status as well as her acceptance of the vaccine for herself during pregnancy and her newborn son and/or daughter after delivery was also collected. Three hundred surveys were completed and available for review. Only 6 respondents (2%) had received the HPV vaccine. Despite the small group of patients who had previously been vaccinated, 112 respondents (37.3%) stated that they would receive the HPV vaccine during pregnancy if recommended by an obstetrician. 99 respondents (33%) stated that they would vaccinate their newborn female infant and 83 (27.7%) stated would vaccinate their male infants. Providing the HPV vaccine to pregnant women as well as newborns could be an important way to increase the patient population who is protected against HPV. A percentage of pregnant women are willing to accept the vaccine for themselves and their newborns.",Journal Article,3180.0,1.0,To evaluate the willingness of pregnant women to accept the HPV vaccine for their newborns as well as themselves An 18-item questionnaire was distributed to antepartum women Demographic data about the respondent 's current pregnancy and her knowledge of HPV and the HPV vaccine was collected Information about the respondent 's HPV and HPV vaccine status as well as her acceptance of the vaccine for herself during pregnancy and her newborn son and/or daughter after delivery was also collected Three hundred surveys were completed and available for review Only 6 respondents 2 had received the HPV vaccine Despite the small group of patients who had previously been vaccinated 112 respondents 37.3 stated that they would receive the HPV vaccine during pregnancy if recommended by an obstetrician 99 respondents 33 stated that they would vaccinate their newborn female infant and 83 27.7 stated would vaccinate their male infants Providing the HPV vaccine to pregnant women as well as newborns could be an important way to increase the patient population who is protected against HPV A percentage of pregnant women are willing to accept the vaccine for themselves and their newborns,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 376, 3, 5268, 1, 6086, 117, 6, 11485, 3, 933, 1274, 9, 136, 24844, 22, 149, 22, 5374, 35, 203, 3471, 1770, 10, 4737, 6, 33882, 117, 1540, 74, 545, 3, 15190, 292, 291, 2290, 2, 1084, 922, 1, 933, 2, 3, 933, 1274, 10, 786, 487, 545, 3, 15190, 292, 933, 2, 933, 1274, 156, 22, 149, 22, 1084, 5080, 1, 3, 1274, 9, 29239, 190, 2290, 2, 1084, 24749, 28165, 2, 15, 15254, 50, 989, 10, 120, 786, 169, 1128, 3666, 11, 781, 2, 390, 9, 206, 158, 49, 3122, 18, 42, 103, 3, 933, 1274, 550, 3, 302, 87, 1, 7, 54, 42, 373, 85, 5130, 3726, 3122, 567, 27, 8245, 17, 491, 688, 560, 3, 933, 1274, 190, 2290, 492, 793, 20, 35, 23084, 1058, 3122, 466, 8245, 17, 491, 688, 25022, 136, 24749, 1061, 8027, 2, 852, 428, 67, 8245, 688, 25022, 136, 1045, 5585, 1736, 3, 933, 1274, 6, 6086, 117, 22, 149, 22, 24844, 359, 40, 35, 305, 2255, 6, 344, 3, 69, 266, 54, 16, 5541, 480, 933, 8, 1150, 1, 6086, 117, 32, 7820, 6, 11485, 3, 1274, 9, 5374, 2, 136, 24844]",,21557976,17
Combination of pet imaging with viral vectors for identification of cancer metastases.,Advanced drug delivery reviews,Adv. Drug Deliv. Rev.,2011-04-30,"There are three main ways for dissemination of solid tumors: direct invasion, lymphatic spread and hematogenic spread. The presence of metastases is the most significant factor in predicting prognosis and therefore evidence of metastases will influence decision-making regarding treatment. Conventional imaging techniques are limited in the evaluation and localization of metastases due to their restricted ability to identify subcentimeter neoplastic disease. Hence, there is a need for an effective noninvasive modality that can accurately identify occult metastases in cancer patients. One such method is the combination of positron emission tomography (PET) with vectors designed for delivery of reporter genes into target cells. Vectors expressing the herpes simplex virus-1 thymidine kinase (HSV1-tk) reporter system have recently been shown to allow localization of micrometastases in animal models of cancer using non invasive imaging. Combination of HSV1-tk and PET imaging is based on the virtues of vectors which can carry and selectively express the HSV1-tk reporter gene in a variety of cancer cells but not in normal tissue. A radioactive tracer which is applied systemically is phosphorylated by the HSV1-tk enzyme, and as a consequence, the tracer accumulates in proportion to the level of HSV1-tk expression which can be imaged by PET. In this paper we review the recent developments in molecular imaging of micrometastases using replication-competent viral or nonviral vectors carrying the HSV1-tk gene using PET imaging. These diagnostic paradigms introduce an advantageous new concept in noninvasive molecular imaging with the potential benefits for improving patient care by providing guidance for therapy to patients with risk for metastases.",Journal Article,3188.0,8.0,There are three main ways for dissemination of solid tumors direct invasion lymphatic spread and hematogenic spread The presence of metastases is the most significant factor in predicting prognosis and therefore evidence of metastases will influence decision-making regarding treatment Conventional imaging techniques are limited in the evaluation and localization of metastases due to their restricted ability to identify subcentimeter neoplastic disease Hence there is a need for an effective noninvasive modality that can accurately identify occult metastases in cancer patients One such method is the combination of positron emission tomography PET with vectors designed for delivery of reporter genes into target cells Vectors expressing the herpes simplex virus-1 thymidine kinase HSV1-tk reporter system have recently been shown to allow localization of micrometastases in animal models of cancer using non invasive imaging Combination of HSV1-tk and PET imaging is based on the virtues of vectors which can carry and selectively express the HSV1-tk reporter gene in a variety of cancer cells but not in normal tissue A radioactive tracer which is applied systemically is phosphorylated by the HSV1-tk enzyme and as a consequence the tracer accumulates in proportion to the level of HSV1-tk expression which can be imaged by PET In this paper we review the recent developments in molecular imaging of micrometastases using replication-competent viral or nonviral vectors carrying the HSV1-tk gene using PET imaging These diagnostic paradigms introduce an advantageous new concept in noninvasive molecular imaging with the potential benefits for improving patient care by providing guidance for therapy to patients with risk for metastases,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[125, 32, 169, 1895, 4245, 9, 3430, 1, 537, 57, 1196, 578, 2936, 2579, 2, 76677, 2579, 3, 463, 1, 196, 16, 3, 96, 93, 161, 4, 1434, 356, 2, 673, 241, 1, 196, 303, 1054, 948, 1079, 666, 24, 809, 270, 1092, 32, 383, 4, 3, 451, 2, 2145, 1, 196, 520, 6, 136, 2016, 801, 6, 255, 16262, 2000, 34, 3665, 125, 16, 8, 594, 9, 35, 323, 2957, 1396, 17, 122, 2141, 255, 2879, 196, 4, 12, 7, 104, 225, 596, 16, 3, 150, 1, 1900, 1799, 872, 495, 5, 5453, 1114, 9, 989, 1, 3674, 214, 237, 283, 37, 5453, 1046, 3, 4716, 7241, 1450, 14, 6403, 216, 20276, 5067, 3674, 398, 47, 761, 85, 443, 6, 1700, 2145, 1, 5485, 4, 2026, 274, 1, 12, 75, 220, 416, 270, 150, 1, 20276, 5067, 2, 495, 270, 16, 90, 23, 3, 35359, 1, 5453, 92, 122, 3542, 2, 2382, 1669, 3, 20276, 5067, 3674, 145, 4, 8, 1362, 1, 12, 37, 84, 44, 4, 295, 246, 8, 4741, 6160, 92, 16, 1498, 6327, 16, 2365, 20, 3, 20276, 5067, 1644, 2, 22, 8, 4177, 3, 6160, 14390, 4, 920, 6, 3, 301, 1, 20276, 5067, 55, 92, 122, 40, 5903, 20, 495, 4, 26, 2817, 21, 206, 3, 435, 3703, 4, 219, 270, 1, 5485, 75, 2079, 6299, 1667, 15, 18434, 5453, 2934, 3, 20276, 5067, 145, 75, 495, 270, 46, 752, 4887, 7630, 35, 10650, 217, 2545, 4, 2957, 219, 270, 5, 3, 174, 1141, 9, 1673, 69, 165, 20, 1736, 2753, 9, 36, 6, 7, 5, 43, 9, 196]",,21565234,108
Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations.,American journal of obstetrics and gynecology,Am. J. Obstet. Gynecol.,2011-06-01,"Although gynecologic cancers account for only 10% of all new cancer cases in women, these cancers account for 20% of all female cancer survivors. Improvements in cancer care have resulted in almost 10 million cancer survivors, and this number is expected to grow. Therefore, determining the most cost-effective clinical surveillance for detection of recurrence is critical. Unfortunately, there has been a paucity of research in what are the most cost-effective strategies for surveillance once patients have achieved a complete response. Currently, most recommendations are based on retrospective studies and expert opinion. Taking a thorough history, performing a thorough examination, and educating cancer survivors about concerning symptoms is the most effective method for the detection of most gynecologic cancer recurrences. There is very little evidence that routine cytologic procedures or imaging improves the ability to detect gynecologic cancer recurrence at a stage that will impact cure or response rates to salvage therapy. This article will review the most recent data on surveillance for gynecologic cancer recurrence in women who have had a complete response to primary cancer therapy.",Journal Article,3156.0,221.0,Although gynecologic cancers account for only 10 of all new cancer cases in women these cancers account for 20 of all female cancer survivors Improvements in cancer care have resulted in almost 10 million cancer survivors and this number is expected to grow Therefore determining the most cost-effective clinical surveillance for detection of recurrence is critical Unfortunately there has been a paucity of research in what are the most cost-effective strategies for surveillance once patients have achieved a complete response Currently most recommendations are based on retrospective studies and expert opinion Taking a thorough history performing a thorough examination and educating cancer survivors about concerning symptoms is the most effective method for the detection of most gynecologic cancer recurrences There is very little evidence that routine cytologic procedures or imaging improves the ability to detect gynecologic cancer recurrence at a stage that will impact cure or response rates to salvage therapy This article will review the most recent data on surveillance for gynecologic cancer recurrence in women who have had a complete response to primary cancer therapy,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[242, 1512, 163, 1967, 9, 158, 79, 1, 62, 217, 12, 140, 4, 117, 46, 163, 1967, 9, 179, 1, 62, 1061, 12, 332, 1474, 4, 12, 165, 47, 627, 4, 2214, 79, 3346, 12, 332, 2, 26, 207, 16, 1336, 6, 6265, 673, 2196, 3, 96, 835, 323, 38, 617, 9, 638, 1, 146, 16, 740, 3869, 125, 71, 85, 8, 4832, 1, 389, 4, 2067, 32, 3, 96, 835, 323, 422, 9, 617, 1059, 7, 47, 513, 8, 236, 51, 694, 96, 883, 32, 90, 23, 459, 94, 2, 2005, 3564, 2727, 8, 5506, 532, 3620, 8, 5506, 1385, 2, 14452, 12, 332, 545, 4243, 507, 16, 3, 96, 323, 596, 9, 3, 638, 1, 96, 1512, 12, 1593, 125, 16, 923, 1215, 241, 17, 1311, 4195, 1369, 15, 270, 1804, 3, 801, 6, 1426, 1512, 12, 146, 28, 8, 82, 17, 303, 345, 1722, 15, 51, 151, 6, 992, 36, 26, 946, 303, 206, 3, 96, 435, 74, 23, 617, 9, 1512, 12, 146, 4, 117, 54, 47, 42, 8, 236, 51, 6, 86, 12, 36]",,21752752,692
Radical hysterectomy: a comparison of surgical approaches after adoption of robotic surgery in gynecologic oncology.,Gynecologic oncology,Gynecol. Oncol.,2011-08-27,"To compare intra-operative, postoperative and pathologic outcomes of three surgical approaches to radical hysterectomy and bilateral pelvic lymph node dissection over a three year time period during which all three approaches were used. We reviewed all patients who underwent radical hysterectomy with pelvic lymph node dissection between 1/2007 and 11/2010. Comparison was made between robotic, laparoscopic and open procedures in regard to surgical times, complication rates, and pathologic findings. A total of 95 radical hysterectomy procedures were performed during the study period: 30 open (RAH), 31 laparoscopic (LRH) and 34 robotic (RRH). There were no differences in age, body mass index or other demographic factors between the groups. Operative time was significantly shorter in the RAH compared to LRH and RRH (265 vs 338 vs 328min, p=0.002). Estimated blood loss was significantly lower in LRH and RRH compared with RAH (100 vs 100 vs 350mL, p<0.001). Thirteen (24%) of RAH required blood transfusion. Conversion rates were higher in the LRH (16%) compared to RRH (3%) although not significant (p=0.10). Median length of stay was significantly shorter in RRH (1day) vs LRH or RAH (2 vs 4days, p<0.01). Pathologic findings were similar among all groups. Minimally invasive surgery has made a significant impact on patients undergoing radical hysterectomy including decrease in blood loss and transfusion rates however; operative times were significantly longer compared to open radical hysterectomy. Our findings suggest that the robotic approach may have the added benefit of even shorter length of stay compared to traditional laparoscopy.",Comparative Study,3069.0,89.0,To compare intra-operative postoperative and pathologic outcomes of three surgical approaches to radical hysterectomy and bilateral pelvic lymph node dissection over a three year time period during which all three approaches were used We reviewed all patients who underwent radical hysterectomy with pelvic lymph node dissection between 1/2007 and 11/2010 Comparison was made between robotic laparoscopic and open procedures in regard to surgical times complication rates and pathologic findings A total of 95 radical hysterectomy procedures were performed during the study period 30 open RAH 31 laparoscopic LRH and 34 robotic RRH There were no differences in age body mass index or other demographic factors between the groups Operative time was significantly shorter in the RAH compared to LRH and RRH 265 vs 338 vs 328min p=0.002 Estimated blood loss was significantly lower in LRH and RRH compared with RAH 100 vs 100 vs 350mL p 0.001 Thirteen 24 of RAH required blood transfusion Conversion rates were higher in the LRH 16 compared to RRH 3 although not significant p=0.10 Median length of stay was significantly shorter in RRH 1day vs LRH or RAH 2 vs 4days p 0.01 Pathologic findings were similar among all groups Minimally invasive surgery has made a significant impact on patients undergoing radical hysterectomy including decrease in blood loss and transfusion rates however operative times were significantly longer compared to open radical hysterectomy Our findings suggest that the robotic approach may have the added benefit of even shorter length of stay compared to traditional laparoscopy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 932, 2392, 1208, 573, 2, 510, 123, 1, 169, 221, 611, 6, 711, 2622, 2, 1607, 1110, 263, 289, 1161, 252, 8, 169, 111, 98, 727, 190, 92, 62, 169, 611, 11, 95, 21, 446, 62, 7, 54, 208, 711, 2622, 5, 1110, 263, 289, 1161, 59, 14, 1307, 2, 175, 1120, 1155, 10, 1229, 59, 2895, 1964, 2, 1020, 1369, 4, 2539, 6, 221, 1072, 1447, 151, 2, 510, 272, 8, 181, 1, 48, 711, 2622, 1369, 11, 173, 190, 3, 45, 727, 201, 1020, 33042, 456, 1964, 19053, 2, 562, 2895, 21738, 125, 11, 77, 362, 4, 89, 642, 782, 558, 15, 127, 1540, 130, 59, 3, 271, 1208, 98, 10, 97, 985, 4, 3, 33042, 72, 6, 19053, 2, 21738, 7298, 105, 9982, 105, 76759, 19, 13, 1111, 661, 315, 407, 10, 97, 280, 4, 19053, 2, 21738, 72, 5, 33042, 394, 105, 394, 105, 76760, 19, 13, 144, 3170, 259, 1, 33042, 616, 315, 2785, 3111, 151, 11, 142, 4, 3, 19053, 245, 72, 6, 21738, 27, 242, 44, 93, 19, 13, 79, 52, 1318, 1, 2020, 10, 97, 985, 4, 21738, 29690, 105, 19053, 15, 33042, 18, 105, 49139, 19, 13, 355, 510, 272, 11, 288, 107, 62, 271, 2144, 416, 152, 71, 1229, 8, 93, 345, 23, 7, 479, 711, 2622, 141, 775, 4, 315, 407, 2, 2785, 151, 137, 1208, 1072, 11, 97, 589, 72, 6, 1020, 711, 2622, 114, 272, 309, 17, 3, 2895, 353, 68, 47, 3, 1953, 247, 1, 871, 985, 1318, 1, 2020, 72, 6, 1847, 3553]",,21872911,348
New biologic agents for the treatment of gynecologic cancers.,Hematology/oncology clinics of North America,Hematol. Oncol. Clin. North Am.,2012-02-01,"The discovery of new biologic targeted agents and appropriately matching them to specific gynecologic tumor types either based on histology or the genetic make-up of the cancer is an exciting new chapter in the treatment of gynecologic malignancies. Therapeutic targets of multiple pathways are currently in study, and combinations with chemotherapy as well as combinations of pathway inhibitors are currently in development.",Journal Article,2911.0,5.0,The discovery of new biologic targeted agents and appropriately matching them to specific gynecologic tumor types either based on histology or the genetic make-up of the cancer is an exciting new chapter in the treatment of gynecologic malignancies Therapeutic targets of multiple pathways are currently in study and combinations with chemotherapy as well as combinations of pathway inhibitors are currently in development,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 1574, 1, 217, 1283, 238, 183, 2, 4544, 2616, 1370, 6, 112, 1512, 30, 630, 361, 90, 23, 784, 15, 3, 336, 2378, 126, 1, 3, 12, 16, 35, 4963, 217, 6366, 4, 3, 24, 1, 1512, 441, 189, 637, 1, 232, 460, 32, 694, 4, 45, 2, 1247, 5, 56, 22, 149, 22, 1247, 1, 308, 222, 32, 694, 4, 193]",,22244666,10
Quality of laparoscopic radical hysterectomy in developing countries: a comparison of surgical and oncologic outcomes between a comprehensive cancer center in the United States and a cancer center in Colombia.,Gynecologic oncology,Gynecol. Oncol.,2012-01-16,"To help determine whether global collaborations for prospective gynecologic surgery trials should include hospitals in developing countries, we compared surgical and oncologic outcomes of patients undergoing laparoscopic radical hysterectomy at a large comprehensive cancer center in the United States and a cancer center in Colombia. Records of the first 50 consecutive patients who underwent laparoscopic radical hysterectomy at The University of Texas MD Anderson Cancer Center in Houston (between April 2004 and July 2007) and the first 50 consecutive patients who underwent the same procedure at the Instituto de Cancerologa-Clnica las Amricas in Medelln (between December 2008 and October 2010) were retrospectively reviewed. Surgical and oncologic outcomes were compared between the 2 groups. There was no significant difference in median patient age (US 41.9 years [range 23-73] vs. Colombia 44.5 years [range 24-75], P=0.09). Patients in Colombia had a lower median body mass index than patients in the US (24.4 kg/m(2) vs. 28.7 kg/m(2), P=0.002). Compared to patients treated in Colombia, patients who underwent surgery in the US had a greater median estimated blood loss (200 mL vs. 79 mL, P<0.001), longer median operative time (328.5 min vs. 235 min, P<0.001), and longer postoperative hospital stay (2 days vs. 1 day, P<0.001). Surgical and oncologic outcomes of laparoscopic radical hysterectomy were not worse at a cancer center in a developing country than at a large comprehensive cancer center in the United States. These results support consideration of developing countries for inclusion in collaborations for prospective surgical studies.",Comparative Study,2927.0,13.0,To help determine whether global collaborations for prospective gynecologic surgery trials should include hospitals in developing countries we compared surgical and oncologic outcomes of patients undergoing laparoscopic radical hysterectomy at a large comprehensive cancer center in the United States and a cancer center in Colombia Records of the first 50 consecutive patients who underwent laparoscopic radical hysterectomy at The University of Texas MD Anderson Cancer Center in Houston between April 2004 and July 2007 and the first 50 consecutive patients who underwent the same procedure at the Instituto de Cancerologa-Clnica las Amricas in Medelln between December 2008 and October 2010 were retrospectively reviewed Surgical and oncologic outcomes were compared between the 2 groups There was no significant difference in median patient age US 41.9 years range 23-73 vs. Colombia 44.5 years range 24-75 P=0.09 Patients in Colombia had a lower median body mass index than patients in the US 24.4 kg/m 2 vs. 28.7 kg/m 2 P=0.002 Compared to patients treated in Colombia patients who underwent surgery in the US had a greater median estimated blood loss 200 mL vs. 79 mL P 0.001 longer median operative time 328.5 min vs. 235 min P 0.001 and longer postoperative hospital stay 2 days vs. 1 day P 0.001 Surgical and oncologic outcomes of laparoscopic radical hysterectomy were not worse at a cancer center in a developing country than at a large comprehensive cancer center in the United States These results support consideration of developing countries for inclusion in collaborations for prospective surgical studies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 987, 223, 317, 1648, 10493, 9, 482, 1512, 152, 143, 257, 643, 1987, 4, 931, 2115, 21, 72, 221, 2, 1998, 123, 1, 7, 479, 1964, 711, 2622, 28, 8, 375, 949, 12, 574, 4, 3, 1088, 907, 2, 8, 12, 574, 4, 23932, 1064, 1, 3, 157, 212, 935, 7, 54, 208, 1964, 711, 2622, 28, 3, 1652, 1, 2738, 2244, 1929, 12, 574, 4, 6212, 59, 2292, 1131, 2, 2066, 1307, 2, 3, 157, 212, 935, 7, 54, 208, 3, 827, 1299, 28, 3, 34364, 1566, 38587, 51578, 42304, 76884, 4, 76885, 59, 1397, 1375, 2, 2551, 1120, 11, 894, 446, 221, 2, 1998, 123, 11, 72, 59, 3, 18, 271, 125, 10, 77, 93, 523, 4, 52, 69, 89, 843, 605, 83, 60, 184, 382, 803, 105, 23932, 584, 33, 60, 184, 259, 481, 19, 13, 1730, 7, 4, 23932, 42, 8, 280, 52, 642, 782, 558, 76, 7, 4, 3, 843, 259, 39, 503, 188, 18, 105, 339, 67, 503, 188, 18, 19, 13, 1111, 72, 6, 7, 73, 4, 23932, 7, 54, 208, 152, 4, 3, 843, 42, 8, 378, 52, 661, 315, 407, 1250, 542, 105, 842, 542, 19, 13, 144, 589, 52, 1208, 98, 8584, 33, 1538, 105, 6465, 1538, 19, 13, 144, 2, 589, 573, 702, 2020, 18, 162, 105, 14, 218, 19, 13, 144, 221, 2, 1998, 123, 1, 1964, 711, 2622, 11, 44, 639, 28, 8, 12, 574, 4, 8, 931, 5978, 76, 28, 8, 375, 949, 12, 574, 4, 3, 1088, 907, 46, 99, 538, 2415, 1, 931, 2115, 9, 1680, 4, 10493, 9, 482, 221, 94]",,22261300,69
"Cancer screening in the United States, 2012: A review of current American Cancer Society guidelines and current issues in cancer screening.",CA: a cancer journal for clinicians,CA Cancer J Clin,2012-01-19,"Each year the American Cancer Society (ACS) publishes a summary of its recommendations for early cancer detection, a report on data and trends in cancer screening rates, and select issues related to cancer screening. In this issue of the journal, current ACS cancer screening guidelines are summarized, as are the latest data on the use of cancer screening from the National Health Interview Survey.",Journal Article,2924.0,113.0,Each year the American Cancer Society ACS publishes a summary of its recommendations for early cancer detection a report on data and trends in cancer screening rates and select issues related to cancer screening In this issue of the journal current ACS cancer screening guidelines are summarized as are the latest data on the use of cancer screening from the National Health Interview Survey,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[296, 111, 3, 597, 12, 1174, 6004, 22457, 8, 1962, 1, 211, 883, 9, 191, 12, 638, 8, 414, 23, 74, 2, 1963, 4, 12, 453, 151, 2, 1717, 1553, 139, 6, 12, 453, 4, 26, 2537, 1, 3, 6685, 291, 6004, 12, 453, 677, 32, 3989, 22, 32, 3, 5923, 74, 23, 3, 119, 1, 12, 453, 29, 3, 657, 341, 4313, 1407]",,22261986,28
Frailty: an outcome predictor for elderly gynecologic oncology patients.,Gynecologic oncology,Gynecol. Oncol.,2012-04-19,"The objective of this pilot study was to determine if frailty predicts surgical complications among elderly women undergoing gynecologic oncology procedures. A cohort of gynecologic oncology patients age  65, undergoing surgery between March and December 2011 was identified. Frailty was evaluated using a validated assessment tool. The primary outcome measure was 30 day postoperative complication rate. Forty women were approached for study entry and 37 (92%) enrolled. The mean age was 73 years (range 65-95). The majority of women had a malignancy and underwent a major abdominal surgical procedure. Twenty-one women (57%) were not frail, 10 (27%) were intermediately frail and 6 (16%) were frail. There was no difference in age or prevalence of medical comorbidities between groups. Frail women had a significantly higher BMI compared to intermediately frail and not frail women, (36.0, 31.5 and 26.1 kg/m(2), p=0.02). The rate of 30-day surgical complications increased with frailty score and was 24%, versus 67% for women who were not frail as compared to the frail (p=0.04). Pre-operative frailty assessment is well accepted by gynecologic oncology patients and feasible in a clinic setting. Frail women had a higher BMI, indicating that low body weight is not a marker for frailty, and had a significantly higher rate of 30-day postoperative complications in this pilot study. Initial findings support the concept of measuring frailty as a possible predictor for postoperative morbidity that will allow for improved patient counseling and decision making.",Journal Article,2833.0,64.0,The objective of this pilot study was to determine if frailty predicts surgical complications among elderly women undergoing gynecologic oncology procedures A cohort of gynecologic oncology patients age  65 undergoing surgery between March and December 2011 was identified Frailty was evaluated using a validated assessment tool The primary outcome measure was 30 day postoperative complication rate Forty women were approached for study entry and 37 92 enrolled The mean age was 73 years range 65-95 The majority of women had a malignancy and underwent a major abdominal surgical procedure Twenty-one women 57 were not frail 10 27 were intermediately frail and 6 16 were frail There was no difference in age or prevalence of medical comorbidities between groups Frail women had a significantly higher BMI compared to intermediately frail and not frail women 36.0 31.5 and 26.1 kg/m 2 p=0.02 The rate of 30-day surgical complications increased with frailty score and was 24 versus 67 for women who were not frail as compared to the frail p=0.04 Pre-operative frailty assessment is well accepted by gynecologic oncology patients and feasible in a clinic setting Frail women had a higher BMI indicating that low body weight is not a marker for frailty and had a significantly higher rate of 30-day postoperative complications in this pilot study Initial findings support the concept of measuring frailty as a possible predictor for postoperative morbidity that will allow for improved patient counseling and decision making,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 461, 1, 26, 2281, 45, 10, 6, 223, 492, 5289, 2623, 221, 521, 107, 1216, 117, 479, 1512, 413, 1369, 8, 180, 1, 1512, 413, 7, 89, 749, 556, 479, 152, 59, 2363, 2, 1397, 1132, 10, 108, 5289, 10, 194, 75, 8, 938, 455, 1515, 3, 86, 228, 1463, 10, 201, 218, 573, 1447, 116, 1213, 117, 11, 5738, 9, 45, 3001, 2, 567, 937, 346, 3, 313, 89, 10, 803, 60, 184, 556, 48, 3, 686, 1, 117, 42, 8, 710, 2, 208, 8, 458, 1467, 221, 1299, 737, 104, 117, 696, 11, 44, 7226, 79, 428, 11, 26921, 7226, 2, 49, 245, 11, 7226, 125, 10, 77, 523, 4, 89, 15, 1078, 1, 484, 1909, 59, 271, 7226, 117, 42, 8, 97, 142, 1140, 72, 6, 26921, 7226, 2, 44, 7226, 117, 511, 13, 456, 33, 2, 432, 14, 503, 188, 18, 19, 13, 588, 3, 116, 1, 201, 218, 221, 521, 101, 5, 5289, 368, 2, 10, 259, 185, 598, 9, 117, 54, 11, 44, 7226, 22, 72, 6, 3, 7226, 19, 13, 755, 671, 1208, 5289, 455, 16, 149, 3058, 20, 1512, 413, 7, 2, 1313, 4, 8, 1188, 546, 7226, 117, 42, 8, 142, 1140, 1716, 17, 154, 642, 924, 16, 44, 8, 952, 9, 5289, 2, 42, 8, 97, 142, 116, 1, 201, 218, 573, 521, 4, 26, 2281, 45, 388, 272, 538, 3, 2545, 1, 2978, 5289, 22, 8, 899, 980, 9, 573, 787, 17, 303, 1700, 9, 231, 69, 2011, 2, 948, 1079]",,22522190,53
Biology of human papillomavirus infection and immune therapy for HPV-related head and neck cancers.,Otolaryngologic clinics of North America,Otolaryngol. Clin. North Am.,2012-08-01,This article outlines the biology of human papillomavirus (HPV) infection of human mucosa and the cellular pathways that are altered through viral infection. The article provides a conceptual framework with which to understand the 2 major immunologic strategies to address HPV-related diseases: (1) prevention of primary HPV infection through the use of prophylactic vaccines and (2) treatment of established infection and diseases through therapeutic vaccines. Nonimmunologic therapy that targets cellular dysregulation induced by HPV infection is also discussed. The challenges in actualizing these conceptually attractive therapies on both a societal and biological level are examined.,Journal Article,2729.0,23.0,This article outlines the biology of human papillomavirus HPV infection of human mucosa and the cellular pathways that are altered through viral infection The article provides a conceptual framework with which to understand the 2 major immunologic strategies to address HPV-related diseases 1 prevention of primary HPV infection through the use of prophylactic vaccines and 2 treatment of established infection and diseases through therapeutic vaccines Nonimmunologic therapy that targets cellular dysregulation induced by HPV infection is also discussed The challenges in actualizing these conceptually attractive therapies on both a societal and biological level are examined,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[26, 946, 6510, 3, 891, 1, 171, 3242, 933, 930, 1, 171, 2713, 2, 3, 763, 460, 17, 32, 1495, 298, 1667, 930, 3, 946, 777, 8, 8329, 2586, 5, 92, 6, 1640, 3, 18, 458, 3042, 422, 6, 1539, 933, 139, 1342, 14, 1070, 1, 86, 933, 930, 298, 3, 119, 1, 1862, 1842, 2, 18, 24, 1, 635, 930, 2, 1342, 298, 189, 1842, 39362, 36, 17, 637, 763, 3935, 277, 20, 933, 930, 16, 120, 1588, 3, 1427, 4, 77025, 46, 13825, 3059, 235, 23, 110, 8, 9378, 2, 1037, 301, 32, 409]",,22793854,65
"A prospective study of the feasibility and acceptability of a Web-based, electronic patient-reported outcome system in assessing patient recovery after major gynecologic cancer surgery.",Gynecologic oncology,Gynecol. Oncol.,2012-08-04,"The purposes of this study are to evaluate the feasibility of capturing patient-reported outcomes (PROs) electronically and to identify the most common distressing symptoms in women recovering from major gynecologic cancer surgery. This was a prospective, single-arm pilot study. Eligible participants included those scheduled for a laparotomy for presumed or known gynecologic malignancy. Patients completed a Web-based ""STAR"" (Symptom Tracking and Reporting for Patients) questionnaire once preoperatively and weekly during the 6-week postoperative period. The questionnaire consisted of the patient adaptation of the NCI CTCAE 3.0 and EORTC QLQ-C30 3.0. When a patient submitted a response that was concerning, an automated email alert was sent to the clinician. The patient's assessment of STAR's usefulness was measured via an exit survey. Forty-nine patients completed the study. The procedures included the following: hysterectomystaging (67%), resection of tumor (22%), salpingo-oophorectomy (6%), and other (4%). Most patients (82%) completed at least 4 sessions in STAR. The CTC generated 43 alerts. These alerts resulted in 25 telephone contacts with patients, 2 ER referrals, one new appointment, and one pharmaceutical prescription. The 3 most common patient-reported symptoms generating an alert were as follows: poor performance status (19%), nausea (18%), and fatigue (17%). Most patients found STAR useful (80%) and would recommend it to others (85%). Application of a Web-based, electronic STAR system is feasible in the postoperative period, highly accepted by patients, and warrants further study. Poor performance status, nausea, and fatigue were the most common distressing patient-reported symptoms.",Clinical Trial,2726.0,23.0,The purposes of this study are to evaluate the feasibility of capturing patient-reported outcomes PROs electronically and to identify the most common distressing symptoms in women recovering from major gynecologic cancer surgery This was a prospective single-arm pilot study Eligible participants included those scheduled for a laparotomy for presumed or known gynecologic malignancy Patients completed a Web-based `` STAR '' Symptom Tracking and Reporting for Patients questionnaire once preoperatively and weekly during the 6-week postoperative period The questionnaire consisted of the patient adaptation of the NCI CTCAE 3.0 and EORTC QLQ-C30 3.0 When a patient submitted a response that was concerning an automated email alert was sent to the clinician The patient 's assessment of STAR 's usefulness was measured via an exit survey Forty-nine patients completed the study The procedures included the following hysterectomystaging 67 resection of tumor 22 salpingo-oophorectomy 6 and other 4 Most patients 82 completed at least 4 sessions in STAR The CTC generated 43 alerts These alerts resulted in 25 telephone contacts with patients 2 ER referrals one new appointment and one pharmaceutical prescription The 3 most common patient-reported symptoms generating an alert were as follows poor performance status 19 nausea 18 and fatigue 17 Most patients found STAR useful 80 and would recommend it to others 85 Application of a Web-based electronic STAR system is feasible in the postoperative period highly accepted by patients and warrants further study Poor performance status nausea and fatigue were the most common distressing patient-reported symptoms,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 4624, 1, 26, 45, 32, 6, 376, 3, 1437, 1, 10492, 69, 210, 123, 4660, 14980, 2, 6, 255, 3, 96, 186, 7787, 507, 4, 117, 17752, 29, 458, 1512, 12, 152, 26, 10, 8, 482, 226, 475, 2281, 45, 625, 776, 159, 135, 4394, 9, 8, 3274, 9, 5472, 15, 440, 1512, 710, 7, 781, 8, 3469, 90, 12215, 522, 934, 7447, 2, 1760, 9, 7, 1770, 1059, 3888, 2, 709, 190, 3, 49, 647, 573, 727, 3, 1770, 1695, 1, 3, 69, 7275, 1, 3, 2580, 3898, 27, 13, 2, 4359, 5144, 6273, 27, 13, 198, 8, 69, 5118, 8, 51, 17, 10, 4243, 35, 3235, 23856, 12781, 10, 6325, 6, 3, 3744, 3, 69, 292, 455, 1, 12215, 292, 5235, 10, 644, 847, 35, 11909, 1407, 1213, 762, 7, 781, 3, 45, 3, 1369, 159, 3, 366, 77047, 598, 170, 1, 30, 350, 5690, 3470, 49, 2, 127, 39, 96, 7, 878, 781, 28, 506, 39, 4390, 4, 12215, 3, 1775, 1419, 601, 21757, 46, 21757, 627, 4, 243, 4258, 13291, 5, 7, 18, 516, 6902, 104, 217, 9698, 2, 104, 6278, 3584, 3, 27, 96, 186, 69, 210, 507, 3997, 35, 12781, 11, 22, 2962, 334, 528, 156, 326, 1218, 203, 2, 613, 269, 96, 7, 204, 12215, 999, 493, 2, 688, 2237, 192, 6, 1749, 772, 1581, 1, 8, 3469, 90, 3098, 12215, 398, 16, 1313, 4, 3, 573, 727, 561, 3058, 20, 7, 2, 2782, 195, 45, 334, 528, 156, 1218, 2, 613, 11, 3, 96, 186, 7787, 69, 210, 507]",,22871467,859
Inhibitory effect of genistein on the invasive potential of human cervical cancer cells via modulation of matrix metalloproteinase-9 and tissue inhibitors of matrix metalloproteinase-1 expression.,Cancer epidemiology,Cancer Epidemiol,2012-08-11,"One of the most challenging stumbling blocks for the treatment of cancer is the ability of cancer cells to break the natural barriers and spread from its site of origin to non-adjacent regional and distant sites, accounting for high cancer mortality rates. Gamut experimental and epidemiological data advocate the use of pharmacological or nutritional interventions to inhibit or delay various stage(s) of cancer such as invasion and metastasis. Genistein, a promising chemopreventive agent, has gained considerable attention for its powerful anti-carcinogenic, anti-angiogenic and chemosensitizing activities. In this study, the cytotoxic potential of genistein on HeLa cells by cell viability assay and the mode of cell death induced by genistein were determined by nuclear morphological examination, DNA laddering assay and cell cycle analysis. Moreover, to establish its inhibitory effect on migration of HeLa cells, scratch wound assay was performed and these results were correlated with the expression of genes involved in invasion and migration (MMP-9 and TIMP-1) by RT-PCR. The exposure of HeLa cells to genistein resulted in significant dose- and time-dependent growth inhibition, which was found to be mediated by apoptosis and cell cycle arrest at G(2)/M phase. In addition, it induced migration-inhibition in a time-dependent manner by modulating the expression of MMP-9 and TIMP-1. Our results signify that genistein may be an effective anti-neoplastic agent to prevent cancer cell growth and invasion and metastasis. Therefore therapeutic strategies utilizing genistein could be developed to substantially reduce cancer morbidity and mortality.",Journal Article,2719.0,37.0,One of the most challenging stumbling blocks for the treatment of cancer is the ability of cancer cells to break the natural barriers and spread from its site of origin to non-adjacent regional and distant sites accounting for high cancer mortality rates Gamut experimental and epidemiological data advocate the use of pharmacological or nutritional interventions to inhibit or delay various stage s of cancer such as invasion and metastasis Genistein a promising chemopreventive agent has gained considerable attention for its powerful anti-carcinogenic anti-angiogenic and chemosensitizing activities In this study the cytotoxic potential of genistein on HeLa cells by cell viability assay and the mode of cell death induced by genistein were determined by nuclear morphological examination DNA laddering assay and cell cycle analysis Moreover to establish its inhibitory effect on migration of HeLa cells scratch wound assay was performed and these results were correlated with the expression of genes involved in invasion and migration MMP-9 and TIMP-1 by RT-PCR The exposure of HeLa cells to genistein resulted in significant dose- and time-dependent growth inhibition which was found to be mediated by apoptosis and cell cycle arrest at G 2 /M phase In addition it induced migration-inhibition in a time-dependent manner by modulating the expression of MMP-9 and TIMP-1 Our results signify that genistein may be an effective anti-neoplastic agent to prevent cancer cell growth and invasion and metastasis Therefore therapeutic strategies utilizing genistein could be developed to substantially reduce cancer morbidity and mortality,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[104, 1, 3, 96, 1950, 37449, 2860, 9, 3, 24, 1, 12, 16, 3, 801, 1, 12, 37, 6, 4338, 3, 1504, 2160, 2, 2579, 29, 211, 606, 1, 1938, 6, 220, 2086, 951, 2, 626, 633, 3116, 9, 64, 12, 282, 151, 31244, 1560, 2, 4614, 74, 8912, 3, 119, 1, 3419, 15, 5082, 1151, 6, 1433, 15, 1984, 747, 82, 695, 1, 12, 225, 22, 578, 2, 278, 7395, 8, 721, 4401, 420, 71, 3711, 2658, 2111, 9, 211, 3757, 312, 7483, 312, 2068, 2, 16829, 2042, 4, 26, 45, 3, 759, 174, 1, 7395, 23, 8466, 37, 20, 31, 2120, 719, 2, 3, 4530, 1, 31, 273, 277, 20, 7395, 11, 509, 20, 928, 4268, 1385, 261, 33768, 719, 2, 31, 417, 65, 1393, 6, 1811, 211, 1810, 254, 23, 1381, 1, 8466, 37, 18385, 2689, 719, 10, 173, 2, 46, 99, 11, 438, 5, 3, 55, 1, 214, 646, 4, 578, 2, 1381, 2151, 83, 2, 5272, 14, 20, 240, 604, 3, 645, 1, 8466, 37, 6, 7395, 627, 4, 93, 61, 2, 98, 470, 129, 297, 92, 10, 204, 6, 40, 517, 20, 351, 2, 31, 417, 1854, 28, 499, 18, 188, 124, 4, 352, 192, 277, 1381, 297, 4, 8, 98, 470, 1708, 20, 3712, 3, 55, 1, 2151, 83, 2, 5272, 14, 114, 99, 19016, 17, 7395, 68, 40, 35, 323, 312, 2000, 420, 6, 1682, 12, 31, 129, 2, 578, 2, 278, 673, 189, 422, 2600, 7395, 359, 40, 276, 6, 2109, 969, 12, 787, 2, 282]",,22884883,663
Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study.,Gynecologic oncology,Gynecol. Oncol.,2012-09-14,"Metastatic and recurrent, platinum resistant cervix cancer has an extremely poor prognosis. The Gynecologic Oncology Group has studied >20 cytotoxic drugs or drug combinations in the second-line, phase II setting of advanced, drug resistant cervix cancer. Nanoparticle, albumin-bound paclitaxel (nab-paclitaxel) was administered at 125 mg/m(2) IV over 30 minutes on days 1, 8 and 15 of each 28 day cycle to 37 women with metastatic or recurrent cervix cancer that had progressed or relapsed following first-line cytotoxic drug treatment. A flexible, 2-stage accrual design that allowed stopping early for lack of treatment activity was utilized. Because of slow patient accrual, the second stage was not completed. Of 37 patients enrolled, 2 were ineligible due to no prior cytotoxic chemotherapy, which left 35 eligible patients evaluable for response and tolerability. All of the eligible patients had 1 prior chemotherapy regimen and 27 of them had prior radiation therapy with concomitant cisplatin. The median number of nab-paclitaxel cycles were 4 (range 1-15). Ten (28.6%; CI 14.6%-46.3%) of the 35 patients had a partial response and another 15 patients (42.9%) had stable disease. The median progression-free and overall survival were 5.0 and 9.4 months, respectively. The only NCI CTCAE grade 4 event was neutropenia in 2 patients (5.7%) which resolved following dose reduction. Grade 3 neurotoxicity was reported in 1 (2.9%) patient and resolved to grade 2 following dose discontinuation. Nab-paclitaxel has considerable activity and moderate toxicity in the treatment of drug resistant, metastatic and recurrent cervix cancer.","Clinical Trial, Phase II",2685.0,24.0,Metastatic and recurrent platinum resistant cervix cancer has an extremely poor prognosis The Gynecologic Oncology Group has studied 20 cytotoxic drugs or drug combinations in the second-line phase II setting of advanced drug resistant cervix cancer Nanoparticle albumin-bound paclitaxel nab-paclitaxel was administered at 125 mg/m 2 IV over 30 minutes on days 1 8 and 15 of each 28 day cycle to 37 women with metastatic or recurrent cervix cancer that had progressed or relapsed following first-line cytotoxic drug treatment A flexible 2-stage accrual design that allowed stopping early for lack of treatment activity was utilized Because of slow patient accrual the second stage was not completed Of 37 patients enrolled 2 were ineligible due to no prior cytotoxic chemotherapy which left 35 eligible patients evaluable for response and tolerability All of the eligible patients had 1 prior chemotherapy regimen and 27 of them had prior radiation therapy with concomitant cisplatin The median number of nab-paclitaxel cycles were 4 range 1-15 Ten 28.6 CI 14.6 -46.3 of the 35 patients had a partial response and another 15 patients 42.9 had stable disease The median progression-free and overall survival were 5.0 and 9.4 months respectively The only NCI CTCAE grade 4 event was neutropenia in 2 patients 5.7 which resolved following dose reduction Grade 3 neurotoxicity was reported in 1 2.9 patient and resolved to grade 2 following dose discontinuation Nab-paclitaxel has considerable activity and moderate toxicity in the treatment of drug resistant metastatic and recurrent cervix cancer,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[113, 2, 387, 828, 436, 3629, 12, 71, 35, 2938, 334, 356, 3, 1512, 413, 87, 71, 656, 179, 759, 600, 15, 234, 1247, 4, 3, 419, 328, 124, 215, 546, 1, 131, 234, 436, 3629, 12, 4483, 2799, 2951, 490, 3139, 490, 10, 468, 28, 1731, 81, 188, 18, 478, 252, 201, 2511, 23, 162, 14, 66, 2, 167, 1, 296, 339, 218, 417, 6, 567, 117, 5, 113, 15, 387, 3629, 12, 17, 42, 1839, 15, 591, 366, 157, 328, 759, 234, 24, 8, 6940, 18, 82, 2262, 771, 17, 2313, 6811, 191, 9, 926, 1, 24, 128, 10, 2080, 408, 1, 3645, 69, 2262, 3, 419, 82, 10, 44, 781, 1, 567, 7, 346, 18, 11, 3773, 520, 6, 77, 324, 759, 56, 92, 1712, 465, 625, 7, 859, 9, 51, 2, 1543, 62, 1, 3, 625, 7, 42, 14, 324, 56, 477, 2, 428, 1, 1370, 42, 324, 121, 36, 5, 1781, 540, 3, 52, 207, 1, 3139, 490, 410, 11, 39, 184, 14, 167, 1618, 339, 49, 58, 213, 49, 641, 27, 1, 3, 465, 7, 42, 8, 450, 51, 2, 1809, 167, 7, 595, 83, 42, 585, 34, 3, 52, 91, 115, 2, 63, 25, 11, 33, 13, 2, 83, 39, 53, 106, 3, 158, 2580, 3898, 88, 39, 774, 10, 778, 4, 18, 7, 33, 67, 92, 3862, 366, 61, 628, 88, 27, 3561, 10, 210, 4, 14, 18, 83, 69, 2, 3862, 6, 88, 18, 366, 61, 2007, 3139, 490, 71, 2658, 128, 2, 1163, 155, 4, 3, 24, 1, 234, 436, 113, 2, 387, 3629, 12]",,22986144,502
Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies.,Gynecologic oncology,Gynecol. Oncol.,2012-11-28,"To compare the incidence of venous thromboembolism (VTE) before and after the implementation of standardized extended duration prophylaxis guidelines in women undergoing laparotomy for gynecologic cancer. In October 2009, departmental practice guidelines were implemented for VTE prevention. Patients undergoing laparotomy for gynecologic cancer were started on low molecular weight heparin (LMWH) within 24h of surgery and it was continued for a total of 28 days postoperatively. The incidence of VTE diagnosed within 30 and 90 days of surgery was determined and compared to a historic cohort of patients who underwent surgery prior to implementation of the guidelines. The incidence of VTE within 30 days of surgery decreased from 2.7% (8/300) to 0.6% (2/334) following implementation of VTE prevention guidelines (78% reduction, p=0.040). However, when the pre and post-guideline implementation groups were compared for the development of VTE within 90 days of surgery, there was no significant difference (11/300 (3.7%) vs. 10/334 (3.0%) respectively, p=0.619). The median time between surgery and VTE diagnosis was 12 days in the pre-guideline implementation group, compared with 57 days in the post-guideline implementation group (p=0.012). Patients receiving extended duration LMWH were found to have significantly lower rates of VTE within 30 days of surgery when compared with similar patients who did not receive extended duration LMWH. However, this effect was not sustained when the groups were compared for VTE diagnosis within 90 days of surgery. Additional study is needed to further reduce long-term VTE rates in this high-risk population.",Journal Article,2610.0,38.0,To compare the incidence of venous thromboembolism VTE before and after the implementation of standardized extended duration prophylaxis guidelines in women undergoing laparotomy for gynecologic cancer In October 2009 departmental practice guidelines were implemented for VTE prevention Patients undergoing laparotomy for gynecologic cancer were started on low molecular weight heparin LMWH within 24h of surgery and it was continued for a total of 28 days postoperatively The incidence of VTE diagnosed within 30 and 90 days of surgery was determined and compared to a historic cohort of patients who underwent surgery prior to implementation of the guidelines The incidence of VTE within 30 days of surgery decreased from 2.7 8/300 to 0.6 2/334 following implementation of VTE prevention guidelines 78 reduction p=0.040 However when the pre and post-guideline implementation groups were compared for the development of VTE within 90 days of surgery there was no significant difference 11/300 3.7 vs. 10/334 3.0 respectively p=0.619 The median time between surgery and VTE diagnosis was 12 days in the pre-guideline implementation group compared with 57 days in the post-guideline implementation group p=0.012 Patients receiving extended duration LMWH were found to have significantly lower rates of VTE within 30 days of surgery when compared with similar patients who did not receive extended duration LMWH However this effect was not sustained when the groups were compared for VTE diagnosis within 90 days of surgery Additional study is needed to further reduce long-term VTE rates in this high-risk population,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 932, 3, 287, 1, 2167, 3501, 1779, 348, 2, 50, 3, 2393, 1, 1670, 1747, 654, 2049, 677, 4, 117, 479, 3274, 9, 1512, 12, 4, 2551, 1238, 14560, 758, 677, 11, 3426, 9, 1779, 1070, 7, 479, 3274, 9, 1512, 12, 11, 3461, 23, 154, 219, 924, 7309, 8214, 262, 12551, 1, 152, 2, 192, 10, 1351, 9, 8, 181, 1, 339, 162, 3541, 3, 287, 1, 1779, 265, 262, 201, 2, 424, 162, 1, 152, 10, 509, 2, 72, 6, 8, 6875, 180, 1, 7, 54, 208, 152, 324, 6, 2393, 1, 3, 677, 3, 287, 1, 1779, 262, 201, 162, 1, 152, 340, 29, 18, 67, 66, 2036, 6, 13, 49, 18, 9376, 366, 2393, 1, 1779, 1070, 677, 833, 628, 19, 13, 6824, 137, 198, 3, 671, 2, 539, 2009, 2393, 271, 11, 72, 9, 3, 193, 1, 1779, 262, 424, 162, 1, 152, 125, 10, 77, 93, 523, 175, 2036, 27, 67, 105, 79, 9376, 27, 13, 106, 19, 13, 14277, 3, 52, 98, 59, 152, 2, 1779, 147, 10, 133, 162, 4, 3, 671, 2009, 2393, 87, 72, 5, 696, 162, 4, 3, 539, 2009, 2393, 87, 19, 13, 3499, 7, 357, 1747, 654, 8214, 11, 204, 6, 47, 97, 280, 151, 1, 1779, 262, 201, 162, 1, 152, 198, 72, 5, 288, 7, 54, 205, 44, 560, 1747, 654, 8214, 137, 26, 254, 10, 44, 2275, 198, 3, 271, 11, 72, 9, 1779, 147, 262, 424, 162, 1, 152, 402, 45, 16, 575, 6, 195, 969, 319, 337, 1779, 151, 4, 26, 64, 43, 266]",,23200912,202
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2013-06-01,"It is well documented that recurrence after pelvic exenteration remains high (up to 50%), and patients may require a prolonged period of recuperation following this aggressive surgery. We conducted a retrospective review to evaluate the feasibility of administering adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies. We reviewed the medical records of patients with any gynecologic cancer who underwent exenterative surgery between January 2005 and February 2011 at our institution. Patients were referred for postexenteration adjuvant chemotherapy based on surgeon's discretion and/or presence of high-risk features: positive margins, positive lymph nodes, and/or lymphovascular space invasion. Suitability for chemotherapy was assessed by a gynecologic medical oncologist. Regimens consisted of 4 to 6 cycles of platinum-based doublet chemotherapy. Chemotherapy-related toxicities were assessed using the Common Terminology Criteria for Adverse Events version 4. We identified 42 patients who underwent pelvic exenteration during the study period. Eleven (26%) were referred for adjuvant chemotherapy. Three (27%) of the 11 patients did not receive chemotherapy because of delayed postoperative recovery or physician choice. Seven (88%) of the remaining 8 patients completed all scheduled chemotherapy. Grade 2 toxicities or greater were documented in 6 patients (75%), the most common being neutropenia, neuropathy, and fatigue. Median follow-up time was 25 months (range, 6-56 months). The 3-year progression-free and overall survival rates of the 8 patients who received chemotherapy were 58% (95% confidence interval, 18%-84%) and 54% (95% confidence interval, 13%- 83%), respectively. The administration of adjuvant chemotherapy is feasible for a select group of patients after pelvic exenteration for gynecologic malignancies. Our results need to be interpreted with caution because of the small and heterogeneous cohort of patients included.",Journal Article,2425.0,1.0,It is well documented that recurrence after pelvic exenteration remains high up to 50 and patients may require a prolonged period of recuperation following this aggressive surgery We conducted a retrospective review to evaluate the feasibility of administering adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies We reviewed the medical records of patients with any gynecologic cancer who underwent exenterative surgery between January 2005 and February 2011 at our institution Patients were referred for postexenteration adjuvant chemotherapy based on surgeon 's discretion and/or presence of high-risk features positive margins positive lymph nodes and/or lymphovascular space invasion Suitability for chemotherapy was assessed by a gynecologic medical oncologist Regimens consisted of 4 to 6 cycles of platinum-based doublet chemotherapy Chemotherapy-related toxicities were assessed using the Common Terminology Criteria for Adverse Events version 4 We identified 42 patients who underwent pelvic exenteration during the study period Eleven 26 were referred for adjuvant chemotherapy Three 27 of the 11 patients did not receive chemotherapy because of delayed postoperative recovery or physician choice Seven 88 of the remaining 8 patients completed all scheduled chemotherapy Grade 2 toxicities or greater were documented in 6 patients 75 the most common being neutropenia neuropathy and fatigue Median follow-up time was 25 months range 6-56 months The 3-year progression-free and overall survival rates of the 8 patients who received chemotherapy were 58 95 confidence interval 18 -84 and 54 95 confidence interval 13 83 respectively The administration of adjuvant chemotherapy is feasible for a select group of patients after pelvic exenteration for gynecologic malignancies Our results need to be interpreted with caution because of the small and heterogeneous cohort of patients included,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[192, 16, 149, 1405, 17, 146, 50, 1110, 5668, 469, 64, 126, 6, 212, 2, 7, 68, 1353, 8, 1069, 727, 1, 77281, 366, 26, 571, 152, 21, 426, 8, 459, 206, 6, 376, 3, 1437, 1, 5776, 249, 56, 50, 1110, 5668, 9, 1512, 441, 21, 446, 3, 484, 1064, 1, 7, 5, 500, 1512, 12, 54, 208, 23501, 152, 59, 1024, 1242, 2, 3010, 1132, 28, 114, 731, 7, 11, 1995, 9, 77282, 249, 56, 90, 23, 1897, 292, 7772, 2, 15, 463, 1, 64, 43, 404, 109, 1012, 109, 263, 502, 2, 15, 2933, 3865, 578, 10163, 9, 56, 10, 275, 20, 8, 1512, 484, 2709, 472, 1695, 1, 39, 6, 49, 410, 1, 828, 90, 4872, 56, 56, 139, 385, 11, 275, 75, 3, 186, 3462, 371, 9, 290, 281, 2256, 39, 21, 108, 595, 7, 54, 208, 1110, 5668, 190, 3, 45, 727, 2627, 432, 11, 1995, 9, 249, 56, 169, 428, 1, 3, 175, 7, 205, 44, 560, 56, 408, 1, 1612, 573, 1602, 15, 1473, 1866, 648, 889, 1, 3, 1844, 66, 7, 781, 62, 4394, 56, 88, 18, 385, 15, 378, 11, 1405, 4, 49, 7, 481, 3, 96, 186, 486, 778, 1751, 2, 613, 52, 166, 126, 98, 10, 243, 53, 184, 49, 664, 53, 3, 27, 111, 91, 115, 2, 63, 25, 151, 1, 3, 66, 7, 54, 103, 56, 11, 717, 48, 307, 268, 203, 874, 2, 667, 48, 307, 268, 233, 852, 106, 3, 634, 1, 249, 56, 16, 1313, 9, 8, 1717, 87, 1, 7, 50, 1110, 5668, 9, 1512, 441, 114, 99, 594, 6, 40, 5047, 5, 5526, 408, 1, 3, 302, 2, 1564, 180, 1, 7, 159]",,23698798,265
Survivorship planning in gynecologic cancer patients.,Gynecologic oncology,Gynecol. Oncol.,2013-05-23,"There are over one million survivors from gynecologic malignancies currently living in the United States and this population is expected to increase by 33% over the next decade. Identifying the needs of these cancer survivors is often understudied and overlooked. A literature review using MEDLINE was searched for research articles published in English from 1967 to 2013 focusing on survivorship care in women with gynecologic malignancies. For women with gynecologic malignancies, the survivorship period requires management of several aspects of care. Improved coordination of care between providers that may be addressed with the use of survivorship care plans and should include surveillance recommendations. Providers should conduct a focused evaluation of late and long-term effects of cancer that may continue to effect patients during and after treatment. Opportunities to improve lifestyle behaviors and continue general health maintenance should also be maximized. The survivorship period incorporates the following: prevention of new cancer diagnoses, surveillance for recurrence, assessment and management of side effects from cancer and cancer treatment, and the coordination of care between patients and healthcare providers. Focusing on these components may improve quality of life as it allows for a seamless transition for cancer survivors and their caregivers.",Journal Article,2434.0,19.0,There are over one million survivors from gynecologic malignancies currently living in the United States and this population is expected to increase by 33 over the next decade Identifying the needs of these cancer survivors is often understudied and overlooked A literature review using MEDLINE was searched for research articles published in English from 1967 to 2013 focusing on survivorship care in women with gynecologic malignancies For women with gynecologic malignancies the survivorship period requires management of several aspects of care Improved coordination of care between providers that may be addressed with the use of survivorship care plans and should include surveillance recommendations Providers should conduct a focused evaluation of late and long-term effects of cancer that may continue to effect patients during and after treatment Opportunities to improve lifestyle behaviors and continue general health maintenance should also be maximized The survivorship period incorporates the following prevention of new cancer diagnoses surveillance for recurrence assessment and management of side effects from cancer and cancer treatment and the coordination of care between patients and healthcare providers Focusing on these components may improve quality of life as it allows for a seamless transition for cancer survivors and their caregivers,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[125, 32, 252, 104, 3346, 332, 29, 1512, 441, 694, 2798, 4, 3, 1088, 907, 2, 26, 266, 16, 1336, 6, 344, 20, 466, 252, 3, 1305, 2025, 1386, 3, 1891, 1, 46, 12, 332, 16, 629, 8207, 2, 12549, 8, 789, 206, 75, 3388, 10, 3080, 9, 389, 2384, 983, 4, 4201, 29, 14902, 6, 1346, 3312, 23, 2560, 165, 4, 117, 5, 1512, 441, 9, 117, 5, 1512, 441, 3, 2560, 727, 1706, 284, 1, 392, 2695, 1, 165, 231, 6373, 1, 165, 59, 1994, 17, 68, 40, 2814, 5, 3, 119, 1, 2560, 165, 1853, 2, 257, 643, 617, 883, 1994, 257, 4073, 8, 1649, 451, 1, 807, 2, 319, 337, 176, 1, 12, 17, 68, 1906, 6, 254, 7, 190, 2, 50, 24, 2605, 6, 401, 3487, 3704, 2, 1906, 1083, 341, 1146, 257, 120, 40, 14440, 3, 2560, 727, 6175, 3, 366, 1070, 1, 217, 12, 2403, 617, 9, 146, 455, 2, 284, 1, 1152, 176, 29, 12, 2, 12, 24, 2, 3, 6373, 1, 165, 59, 7, 2, 2819, 1994, 3312, 23, 46, 1628, 68, 401, 372, 1, 358, 22, 192, 2333, 9, 8, 29295, 1970, 9, 12, 332, 2, 136, 2771]",,23707666,87
Incidence of trocar site herniation following robotic gynecologic surgery.,Gynecologic oncology,Gynecol. Oncol.,2013-08-27,"Trocar site herniation is a recognized complication of minimally invasive surgery, but published data on trocar site herniation after robotic surgery are scarce. We sought to determine the incidence of trocar site herniation in women undergoing robotic surgery for gynecologic disease. A retrospective review of robotic surgeries performed from January 1, 2006, through December 31, 2012, was conducted. Postoperative trocar site herniations were identified, along with time to presentation, location of herniation, and management. Patients were excluded if surgery was converted to laparotomy or traditional laparoscopy. The Wilcoxon rank-sum test was used to compare patients with and without herniation with respect to continuous variables, and Fisher's exact test was used to compare these 2 groups with respect to categorical variables. The study included 500 patients, 3 of whom experienced herniation at a single trocar site. The patients with and without herniation did not differ with respect to age, body mass index, smoking status, medical comorbidities, operating time, or estimated blood loss. All 3 herniations occurred at 12-mm trocar sites. Two herniations occurred at assistant port sites, and 1 occurred at the umbilical camera port site. The median time to herniation was 21 days (range, 8-38 days). One patient required immediate surgical intervention; the other 2 patients had conservative management. Trocar site herniation is a rare complication following robotic surgery. The most important risk factor for trocar site herniation appears to be larger trocar size, as all herniations occurred at 12-mm port sites.",Journal Article,2338.0,16.0,Trocar site herniation is a recognized complication of minimally invasive surgery but published data on trocar site herniation after robotic surgery are scarce We sought to determine the incidence of trocar site herniation in women undergoing robotic surgery for gynecologic disease A retrospective review of robotic surgeries performed from January 1 2006 through December 31 2012 was conducted Postoperative trocar site herniations were identified along with time to presentation location of herniation and management Patients were excluded if surgery was converted to laparotomy or traditional laparoscopy The Wilcoxon rank-sum test was used to compare patients with and without herniation with respect to continuous variables and Fisher 's exact test was used to compare these 2 groups with respect to categorical variables The study included 500 patients 3 of whom experienced herniation at a single trocar site The patients with and without herniation did not differ with respect to age body mass index smoking status medical comorbidities operating time or estimated blood loss All 3 herniations occurred at 12-mm trocar sites Two herniations occurred at assistant port sites and 1 occurred at the umbilical camera port site The median time to herniation was 21 days range 8-38 days One patient required immediate surgical intervention the other 2 patients had conservative management Trocar site herniation is a rare complication following robotic surgery The most important risk factor for trocar site herniation appears to be larger trocar size as all herniations occurred at 12-mm port sites,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[11980, 606, 15352, 16, 8, 1904, 1447, 1, 2144, 416, 152, 84, 983, 74, 23, 11980, 606, 15352, 50, 2895, 152, 32, 8113, 21, 990, 6, 223, 3, 287, 1, 11980, 606, 15352, 4, 117, 479, 2895, 152, 9, 1512, 34, 8, 459, 206, 1, 2895, 5305, 173, 29, 1024, 14, 1324, 298, 1397, 456, 1195, 10, 426, 573, 11980, 606, 33052, 11, 108, 1510, 5, 98, 6, 1031, 1147, 1, 15352, 2, 284, 7, 11, 1800, 492, 152, 10, 4764, 6, 3274, 15, 1847, 3553, 3, 3896, 1026, 3216, 412, 10, 95, 6, 932, 7, 5, 2, 187, 15352, 5, 2184, 6, 1314, 682, 2, 3135, 292, 2472, 412, 10, 95, 6, 932, 46, 18, 271, 5, 2184, 6, 5982, 682, 3, 45, 159, 1666, 7, 27, 1, 953, 592, 15352, 28, 8, 226, 11980, 606, 3, 7, 5, 2, 187, 15352, 205, 44, 1505, 5, 2184, 6, 89, 642, 782, 558, 979, 156, 484, 1909, 2584, 98, 15, 661, 315, 407, 62, 27, 33052, 489, 28, 133, 321, 11980, 633, 100, 33052, 489, 28, 24422, 3083, 633, 2, 14, 489, 28, 3, 5998, 14823, 3083, 606, 3, 52, 98, 6, 15352, 10, 239, 162, 184, 66, 519, 162, 104, 69, 616, 2181, 221, 788, 3, 127, 18, 7, 42, 4476, 284, 11980, 606, 15352, 16, 8, 622, 1447, 366, 2895, 152, 3, 96, 305, 43, 161, 9, 11980, 606, 15352, 1233, 6, 40, 1077, 11980, 444, 22, 62, 33052, 489, 28, 133, 321, 3083, 633]",,23988416,38
Intraoperative neurophysiologic monitoring and neurologic outcomes in patients with epidural spine tumors.,Clinical neurology and neurosurgery,Clin Neurol Neurosurg,2013-08-12,"Multimodal intraoperative neurophysiologic monitoring (IOM) provides assessment of spinal cord pathways during neurosurgery. Despite widespread use, few data exist regarding sensitivity and specificity of IOM in predicting neurologic outcome during decompression and instrumentation for epidural spine tumors. Retrospective analysis evaluated consecutive spine procedures involving IOM modalities (somatosensory evoked potentials [SSEP], motor evoked potentials [MEP], and electromyography [(EMG]) from 2007 to 2009. Demographic and surgical information, intraoperative neurophysiologic data, and pre- and postoperative neurologic status were collected. All cases involved neoplastic epidural spinal cord compression by a primary or metastatic tumor and included posterolateral decompression and instrumented fusion. Two-hundred and eight consecutive patients had spine surgery during this time period and one hundred and fifty-two met inclusion criteria. All patients had SSEP monitoring, with 4 having transient changes and 7 persistent changes. One hundred and twenty-two patients had combined SSEP and MEP monitoring, with 3 having transient changes and 4 persistent changes in MEP signals. Two patients had neurophysiologic changes associated with hypotension and correction led to normalization. One developed new neurologic deficits after surgery. Two from the total cohort had new postoperative neurologic deficits. One had a transient decrease in MEP amplitude while the other had no intraoperative changes. These cases are often long with significant blood loss, and stability of multiple IOM modalities provides reassurance that spinal cord function remains intact. Signal changes should result in scrutiny of blood pressure, surgical technique and anesthesia. Preserved IOM signals are suggestive of preserved neurologic outcome.",Journal Article,2353.0,17.0,Multimodal intraoperative neurophysiologic monitoring IOM provides assessment of spinal cord pathways during neurosurgery Despite widespread use few data exist regarding sensitivity and specificity of IOM in predicting neurologic outcome during decompression and instrumentation for epidural spine tumors Retrospective analysis evaluated consecutive spine procedures involving IOM modalities somatosensory evoked potentials SSEP motor evoked potentials MEP and electromyography EMG from 2007 to 2009 Demographic and surgical information intraoperative neurophysiologic data and pre- and postoperative neurologic status were collected All cases involved neoplastic epidural spinal cord compression by a primary or metastatic tumor and included posterolateral decompression and instrumented fusion Two-hundred and eight consecutive patients had spine surgery during this time period and one hundred and fifty-two met inclusion criteria All patients had SSEP monitoring with 4 having transient changes and 7 persistent changes One hundred and twenty-two patients had combined SSEP and MEP monitoring with 3 having transient changes and 4 persistent changes in MEP signals Two patients had neurophysiologic changes associated with hypotension and correction led to normalization One developed new neurologic deficits after surgery Two from the total cohort had new postoperative neurologic deficits One had a transient decrease in MEP amplitude while the other had no intraoperative changes These cases are often long with significant blood loss and stability of multiple IOM modalities provides reassurance that spinal cord function remains intact Signal changes should result in scrutiny of blood pressure surgical technique and anesthesia Preserved IOM signals are suggestive of preserved neurologic outcome,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[4122, 1720, 26837, 1315, 17015, 777, 455, 1, 1499, 1885, 460, 190, 13272, 550, 3029, 119, 1021, 74, 1923, 666, 485, 2, 1121, 1, 17015, 4, 1434, 2543, 228, 190, 7638, 2, 9166, 9, 5844, 2342, 57, 459, 65, 194, 935, 2342, 1369, 1267, 17015, 1558, 36398, 22008, 13328, 42553, 3482, 22008, 13328, 29044, 2, 40429, 40430, 29, 1307, 6, 1238, 1540, 2, 221, 487, 1720, 26837, 74, 2, 671, 2, 573, 2543, 156, 11, 786, 62, 140, 646, 2000, 5844, 1499, 1885, 3481, 20, 8, 86, 15, 113, 30, 2, 159, 13000, 7638, 2, 29539, 1212, 100, 1128, 2, 659, 935, 7, 42, 2342, 152, 190, 26, 98, 727, 2, 104, 1128, 2, 1461, 100, 543, 1680, 371, 62, 7, 42, 42553, 1315, 5, 39, 1041, 2473, 400, 2, 67, 1882, 400, 104, 1128, 2, 737, 100, 7, 42, 397, 42553, 2, 29044, 1315, 5, 27, 1041, 2473, 400, 2, 39, 1882, 400, 4, 29044, 2312, 100, 7, 42, 26837, 400, 41, 5, 6577, 2, 5360, 836, 6, 5924, 104, 276, 217, 2543, 2752, 50, 152, 100, 29, 3, 181, 180, 42, 217, 573, 2543, 2752, 104, 42, 8, 2473, 775, 4, 29044, 11283, 369, 3, 127, 42, 77, 1720, 400, 46, 140, 32, 629, 319, 5, 93, 315, 407, 2, 2769, 1, 232, 17015, 1558, 777, 14491, 17, 1499, 1885, 343, 469, 2964, 1235, 400, 257, 757, 4, 11323, 1, 315, 3738, 221, 1312, 2, 6433, 5797, 17015, 2312, 32, 3832, 1, 5797, 2543, 228]",,24012272,196
Referrals to phase I clinical trials in a gynecologic oncology unit.,Gynecologic oncology,Gynecol. Oncol.,2013-09-14,"Previous reviews of phase I clinical trials report limited response rates. Development of novel biologic agents and trials designs have increased these rates. A contemporary appraisal of phase I clinical trials in gynecologic malignancies could help validate these findings. Retrospectively reviewed records for 410 patients with gynecologic malignancies treated in a phase I unit, January 1999 to October 2012. Patient characteristics and treatment outcomes were abstracted and analyzed. Patients enrolled in 43 different phase I trials, 17 phase Ia, 17 phase Ib dose escalation and 9 dose expansion. 9 trials (21%) investigated unique cytotoxic delivery methods, 15 (35%) conventional cytotoxic plus novel agents and 19 (44%) novel agents alone. For patients treated in the first-line setting, 90 (74.4%) achieved CR, 20 (16.5%) PR, 9 (7.4%) SD and 2 (1.7%) PD, yielding an overall response rate of 90.9%. In patients treated for recurrent disease, 2 (1.6%) achieved CR, 11 (8.9%) PR, 57 (46.0%) SD and 54 (43.5%) PD, yielding a response rate of 11% and an overall clinical benefit rate of 57%. Response rate for molecular targeted therapies was 11.5% with an overall clinical benefit rate of 46.2%. Patients with prior anti-angiogenic exposure had comparable median PFS to those who had not been previously exposed (3.5 vs. 4.0 months, p = 0.29). Results support referral of gynecologic cancer patients for phase I clinical trials. Patients with advanced, heavily pretreated disease fare at least as well as they do on phase II trials and a proportion of them can attain an objective response or stabilization of their disease.",Journal Article,2320.0,0.0,Previous reviews of phase I clinical trials report limited response rates Development of novel biologic agents and trials designs have increased these rates A contemporary appraisal of phase I clinical trials in gynecologic malignancies could help validate these findings Retrospectively reviewed records for 410 patients with gynecologic malignancies treated in a phase I unit January 1999 to October 2012 Patient characteristics and treatment outcomes were abstracted and analyzed Patients enrolled in 43 different phase I trials 17 phase Ia 17 phase Ib dose escalation and 9 dose expansion 9 trials 21 investigated unique cytotoxic delivery methods 15 35 conventional cytotoxic plus novel agents and 19 44 novel agents alone For patients treated in the first-line setting 90 74.4 achieved CR 20 16.5 PR 9 7.4 SD and 2 1.7 PD yielding an overall response rate of 90.9 In patients treated for recurrent disease 2 1.6 achieved CR 11 8.9 PR 57 46.0 SD and 54 43.5 PD yielding a response rate of 11 and an overall clinical benefit rate of 57 Response rate for molecular targeted therapies was 11.5 with an overall clinical benefit rate of 46.2 Patients with prior anti-angiogenic exposure had comparable median PFS to those who had not been previously exposed 3.5 vs. 4.0 months p 0.29 Results support referral of gynecologic cancer patients for phase I clinical trials Patients with advanced heavily pretreated disease fare at least as well as they do on phase II trials and a proportion of them can attain an objective response or stabilization of their disease,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[698, 2004, 1, 124, 70, 38, 143, 414, 383, 51, 151, 193, 1, 229, 1283, 183, 2, 143, 4120, 47, 101, 46, 151, 8, 2667, 10477, 1, 124, 70, 38, 143, 4, 1512, 441, 359, 987, 2183, 46, 272, 894, 446, 1064, 9, 7690, 7, 5, 1512, 441, 73, 4, 8, 124, 70, 2712, 1024, 2043, 6, 2551, 1195, 69, 374, 2, 24, 123, 11, 4106, 2, 311, 7, 346, 4, 601, 338, 124, 70, 143, 269, 124, 3302, 269, 124, 3180, 61, 1125, 2, 83, 61, 1422, 83, 143, 239, 565, 991, 759, 989, 636, 167, 465, 809, 759, 349, 229, 183, 2, 326, 584, 229, 183, 279, 9, 7, 73, 4, 3, 157, 328, 546, 424, 794, 39, 513, 684, 179, 245, 33, 998, 83, 67, 39, 1270, 2, 18, 14, 67, 333, 4949, 35, 63, 51, 116, 1, 424, 83, 4, 7, 73, 9, 387, 34, 18, 14, 49, 513, 684, 175, 66, 83, 998, 696, 641, 13, 1270, 2, 667, 601, 33, 333, 4949, 8, 51, 116, 1, 175, 2, 35, 63, 38, 247, 116, 1, 696, 51, 116, 9, 219, 238, 235, 10, 175, 33, 5, 35, 63, 38, 247, 116, 1, 641, 18, 7, 5, 324, 312, 2068, 645, 42, 1279, 52, 300, 6, 135, 54, 42, 44, 85, 373, 2234, 27, 33, 105, 39, 13, 53, 19, 13, 462, 99, 538, 2096, 1, 1512, 12, 7, 9, 124, 70, 38, 143, 7, 5, 131, 2447, 2193, 34, 11470, 28, 506, 22, 149, 22, 491, 1022, 23, 124, 215, 143, 2, 8, 920, 1, 1370, 122, 10719, 35, 461, 51, 15, 3184, 1, 136, 34]",,24041878,558
Use of social media to conduct a cross-sectional epidemiologic and quality of life survey of patients with neuroendocrine carcinoma of the cervix: a feasibility study.,Gynecologic oncology,Gynecol. Oncol.,2013-10-19,"To determine the feasibility of using social media to perform cross-sectional epidemiologic and quality-of-life research on patients with rare gynecologic tumors, we performed a survey of patients with neuroendocrine tumors of the cervix using Facebook. After approval from our Institutional Review Board, a support group of patients with neuroendocrine tumors of the cervix was identified on Facebook. Group members were asked to complete a survey comprising 84 questions evaluating clinical presentation; treatment; recurrence; quality of life; and sexual function. The survey was posted for 30 days, during which 57 women responded from 8 countries across 4 continents treated at 51 centers. All respondents provided a detailed clinical and tumor history. The mean age was 38.5 years. The stage distribution was stage I, 36 patients (63%); II, 13 (23%); III, 2 (4%); and IV, 6 (11%). Forty-nine patients (86%) had small cell and 8 (14%) had large cell tumors. Forty-five of the respondents (79%) had completed primary therapy and were without evidence of disease. Five (9%) had recurrence, 3 (5%) had persistent disease after therapy, and 4 (7%) were still under treatment. Forty-one patients (72%) reported symptoms at time of presentation. Thirty-seven patients (65%) received multimodality primary therapy. Quality of life instruments demonstrated high scores for anxiety and a negative impact of anxiety and cancer on functional and emotional well-being. Sexual function scores did not differ significantly between respondents and the PROMIS reference population. Use of a social media network to perform epidemiologic and quality of life research on patients with rare gynecologic tumors is feasible and permits such research to be conducted efficiently and rapidly.",Journal Article,2285.0,23.0,To determine the feasibility of using social media to perform cross-sectional epidemiologic and quality-of-life research on patients with rare gynecologic tumors we performed a survey of patients with neuroendocrine tumors of the cervix using Facebook After approval from our Institutional Review Board a support group of patients with neuroendocrine tumors of the cervix was identified on Facebook Group members were asked to complete a survey comprising 84 questions evaluating clinical presentation treatment recurrence quality of life and sexual function The survey was posted for 30 days during which 57 women responded from 8 countries across 4 continents treated at 51 centers All respondents provided a detailed clinical and tumor history The mean age was 38.5 years The stage distribution was stage I 36 patients 63 II 13 23 III 2 4 and IV 6 11 Forty-nine patients 86 had small cell and 8 14 had large cell tumors Forty-five of the respondents 79 had completed primary therapy and were without evidence of disease Five 9 had recurrence 3 5 had persistent disease after therapy and 4 7 were still under treatment Forty-one patients 72 reported symptoms at time of presentation Thirty-seven patients 65 received multimodality primary therapy Quality of life instruments demonstrated high scores for anxiety and a negative impact of anxiety and cancer on functional and emotional well-being Sexual function scores did not differ significantly between respondents and the PROMIS reference population Use of a social media network to perform epidemiologic and quality of life research on patients with rare gynecologic tumors is feasible and permits such research to be conducted efficiently and rapidly,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 1437, 1, 75, 2032, 4769, 6, 2715, 1383, 2832, 3609, 2, 372, 1, 358, 389, 23, 7, 5, 622, 1512, 57, 21, 173, 8, 1407, 1, 7, 5, 1542, 57, 1, 3, 3629, 75, 52168, 50, 1814, 29, 114, 1115, 206, 2620, 8, 538, 87, 1, 7, 5, 1542, 57, 1, 3, 3629, 10, 108, 23, 52168, 87, 1684, 11, 3732, 6, 236, 8, 1407, 3538, 874, 1937, 1435, 38, 1031, 24, 146, 372, 1, 358, 2, 2232, 343, 3, 1407, 10, 17878, 9, 201, 162, 190, 92, 696, 117, 2211, 29, 66, 2115, 716, 39, 17130, 73, 28, 725, 1168, 62, 3122, 1052, 8, 2455, 38, 2, 30, 532, 3, 313, 89, 10, 519, 33, 60, 3, 82, 1395, 10, 82, 70, 511, 7, 676, 215, 233, 382, 316, 18, 39, 2, 478, 49, 175, 1213, 762, 7, 868, 42, 302, 31, 2, 66, 213, 42, 375, 31, 57, 1213, 365, 1, 3, 3122, 842, 42, 781, 86, 36, 2, 11, 187, 241, 1, 34, 365, 83, 42, 146, 27, 33, 42, 1882, 34, 50, 36, 2, 39, 67, 11, 1234, 669, 24, 1213, 104, 7, 720, 210, 507, 28, 98, 1, 1031, 977, 648, 7, 556, 103, 2425, 86, 36, 372, 1, 358, 4730, 264, 64, 703, 9, 2021, 2, 8, 199, 345, 1, 2021, 2, 12, 23, 583, 2, 2671, 149, 486, 2232, 343, 703, 205, 44, 1505, 97, 59, 3122, 2, 3, 10929, 2482, 266, 119, 1, 8, 2032, 4769, 1801, 6, 2715, 3609, 2, 372, 1, 358, 389, 23, 7, 5, 622, 1512, 57, 16, 1313, 2, 8504, 225, 389, 6, 40, 426, 4143, 2, 1755]",,24145111,622
Cognitive impairment in gynecologic cancers: a systematic review of current approaches to diagnosis and treatment.,Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,Support Care Cancer,2013-11-10,"To review the etiology and assessment of chemotherapy-related cognitive impairment (CRCI). To explore current treatment and prevention strategies for CRCI and propose future research goals in the field of gynecologic oncology. Computerized searches in PubMed of cognitive impairment in cancer between 2000 and 2012 were conducted. The inclusion criteria were randomized control trials evaluating treatment of CRCI and search terms 'cognitive function, cognitive impairment, cognitive decline, chemobrain, chemofog, and cancer'. To date, numerous modalities have been utilized for assessing CRCI in patients undergoing therapy. It has been proposed to move towards web-based assessment modalities as a possible standard. Few studies have aimed to elucidate possible treatment and prevention options for CRCI; even less in the field of gynecologic oncology. Only seven of these studies were subjected to randomized control trials. Only one of these studies looked at treatment in patients with gynecologic cancers. The etiology of CRCI is multi-factorial. Following from this, there is no consensus on the best way to assess CRCI although objective measures are more reliable. One must extrapolate data from the non-gynecologic cancer literature, even venturing to non-cancer literature, to explore the treatment and prevention of CRCI. The methods found in these areas of research have not yet been applied to CRCI in gynecologic oncology.",Journal Article,2263.0,,To review the etiology and assessment of chemotherapy-related cognitive impairment CRCI To explore current treatment and prevention strategies for CRCI and propose future research goals in the field of gynecologic oncology Computerized searches in PubMed of cognitive impairment in cancer between 2000 and 2012 were conducted The inclusion criteria were randomized control trials evaluating treatment of CRCI and search terms 'cognitive function cognitive impairment cognitive decline chemobrain chemofog and cancer To date numerous modalities have been utilized for assessing CRCI in patients undergoing therapy It has been proposed to move towards web-based assessment modalities as a possible standard Few studies have aimed to elucidate possible treatment and prevention options for CRCI even less in the field of gynecologic oncology Only seven of these studies were subjected to randomized control trials Only one of these studies looked at treatment in patients with gynecologic cancers The etiology of CRCI is multi-factorial Following from this there is no consensus on the best way to assess CRCI although objective measures are more reliable One must extrapolate data from the non-gynecologic cancer literature even venturing to non-cancer literature to explore the treatment and prevention of CRCI The methods found in these areas of research have not yet been applied to CRCI in gynecologic oncology,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 206, 3, 2855, 2, 455, 1, 56, 139, 1863, 2315, 16170, 6, 1645, 291, 24, 2, 1070, 422, 9, 16170, 2, 2548, 508, 389, 2802, 4, 3, 1067, 1, 1512, 413, 4912, 6769, 4, 3161, 1, 1863, 2315, 4, 12, 59, 1081, 2, 1195, 11, 426, 3, 1680, 371, 11, 384, 182, 143, 1435, 24, 1, 16170, 2, 1901, 1794, 77439, 343, 1863, 2315, 1863, 1858, 34367, 77440, 2, 12, 6, 1244, 2331, 1558, 47, 85, 2080, 9, 1977, 16170, 4, 7, 479, 36, 192, 71, 85, 1587, 6, 6759, 3113, 3469, 90, 455, 1558, 22, 8, 899, 260, 1021, 94, 47, 1295, 6, 3061, 899, 24, 2, 1070, 838, 9, 16170, 871, 299, 4, 3, 1067, 1, 1512, 413, 158, 648, 1, 46, 94, 11, 4325, 6, 384, 182, 143, 158, 104, 1, 46, 94, 13058, 28, 24, 4, 7, 5, 1512, 163, 3, 2855, 1, 16170, 16, 1414, 11613, 366, 29, 26, 125, 16, 77, 1391, 23, 3, 824, 2255, 6, 423, 16170, 242, 461, 1018, 32, 80, 2450, 104, 1642, 19750, 74, 29, 3, 220, 1512, 12, 789, 871, 77441, 6, 220, 12, 789, 6, 1645, 3, 24, 2, 1070, 1, 16170, 3, 636, 204, 4, 46, 1361, 1, 389, 47, 44, 1145, 85, 1498, 6, 16170, 4, 1512, 413]",,24212261,509
Fellowship learning curve associated with completing a robotic assisted total laparoscopic hysterectomy.,Gynecologic oncology,Gynecol. Oncol.,2013-11-18,"To describe the learning curve associated with training fellows in completing robotic assisted total laparoscopic hysterectomies. All patients scheduled to undergo a robotic procedure at our institution from 5/15/07 to 5/22/12 were identified. Fellow participation per procedure was documented. The learning curve of fellows for the time to complete a hysterectomy (from initiation of developing the retroperitoneal space to the completion of the colpotomy) was analyzed. Of the 1754 planned robotic cases, 1626 were completed robotically and 128 were converted to laparotomy. Fifty-seven fellows participated in 99.7% of the cases. Eleven gynecologic oncology fellows completed at least 1 robotic assisted total laparoscopic hysterectomy. From 7/7/08 to 5/21/12, 981 hysterectomies were completed robotically, 254 of these (25.9%) by the 11 fellows. Prior to completing a hysterectomy, the median number of hysterectomies in which a fellow participated was 16 (range, 11-40). Median amount of time for a fellow to complete a hysterectomy decreased from 60 min in 2009 (N=27 cases) to 31 min in 2011 (N=148 cases). Based on the recorded completion times in which the 11 fellows completed a hysterectomy, it required ~33 cases per fellow to be able to perform the hysterectomy and overcome the learning curve. The learning curve associated with hysterectomy requires completion of ~33 cases by the fellow after an initial median experience of 16 cases. Our data suggest that a minimum of 50 total cases is required during fellowship to complete a robotic hysterectomy.",Journal Article,2255.0,20.0,To describe the learning curve associated with training fellows in completing robotic assisted total laparoscopic hysterectomies All patients scheduled to undergo a robotic procedure at our institution from 5/15/07 to 5/22/12 were identified Fellow participation per procedure was documented The learning curve of fellows for the time to complete a hysterectomy from initiation of developing the retroperitoneal space to the completion of the colpotomy was analyzed Of the 1754 planned robotic cases 1626 were completed robotically and 128 were converted to laparotomy Fifty-seven fellows participated in 99.7 of the cases Eleven gynecologic oncology fellows completed at least 1 robotic assisted total laparoscopic hysterectomy From 7/7/08 to 5/21/12 981 hysterectomies were completed robotically 254 of these 25.9 by the 11 fellows Prior to completing a hysterectomy the median number of hysterectomies in which a fellow participated was 16 range 11-40 Median amount of time for a fellow to complete a hysterectomy decreased from 60 min in 2009 N=27 cases to 31 min in 2011 N=148 cases Based on the recorded completion times in which the 11 fellows completed a hysterectomy it required ~33 cases per fellow to be able to perform the hysterectomy and overcome the learning curve The learning curve associated with hysterectomy requires completion of ~33 cases by the fellow after an initial median experience of 16 cases Our data suggest that a minimum of 50 total cases is required during fellowship to complete a robotic hysterectomy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 897, 3, 3434, 1496, 41, 5, 1741, 7813, 4, 4144, 2895, 2927, 181, 1964, 15266, 62, 7, 4394, 6, 1251, 8, 2895, 1299, 28, 114, 731, 29, 33, 167, 1615, 6, 33, 350, 133, 11, 108, 10526, 2599, 379, 1299, 10, 1405, 3, 3434, 1496, 1, 7813, 9, 3, 98, 6, 236, 8, 2622, 29, 1118, 1, 931, 3, 2591, 3865, 6, 3, 1438, 1, 3, 77454, 10, 311, 1, 3, 38682, 1465, 2895, 140, 49305, 11, 781, 15573, 2, 3990, 11, 4764, 6, 3274, 1461, 648, 7813, 3025, 4, 1058, 67, 1, 3, 140, 2627, 1512, 413, 7813, 781, 28, 506, 14, 2895, 2927, 181, 1964, 2622, 29, 67, 67, 1592, 6, 33, 239, 133, 17946, 15266, 11, 781, 15573, 7691, 1, 46, 243, 83, 20, 3, 175, 7813, 324, 6, 4144, 8, 2622, 3, 52, 207, 1, 15266, 4, 92, 8, 10526, 3025, 10, 245, 184, 175, 327, 52, 3108, 1, 98, 9, 8, 10526, 6, 236, 8, 2622, 340, 29, 335, 1538, 4, 1238, 78, 428, 140, 6, 456, 1538, 4, 1132, 78, 4647, 140, 90, 23, 3, 1872, 1438, 1072, 4, 92, 3, 175, 7813, 781, 8, 2622, 192, 616, 466, 140, 379, 10526, 6, 40, 1665, 6, 2715, 3, 2622, 2, 1768, 3, 3434, 1496, 3, 3434, 1496, 41, 5, 2622, 1706, 1438, 1, 466, 140, 20, 3, 10526, 50, 35, 388, 52, 730, 1, 245, 140, 114, 74, 309, 17, 8, 2499, 1, 212, 181, 140, 16, 616, 190, 9289, 6, 236, 8, 2895, 2622]",,24262878,401
"Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2014-01-06,"This prospective, randomized phase III intergroup trial of the Gynecologic Oncology Group and National Cancer Institute of Canada Clinical Trials Group was designed to test the effectiveness and safety of adding the hypoxic cell sensitizer tirapazamine (TPZ) to standard cisplatin (CIS) chemoradiotherapy in locally advanced cervix cancer. Patients with locally advanced cervix cancer were randomly assigned to CIS chemoradiotherapy versus CIS/TPZ chemoradiotherapy. Primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS) and tolerability. PFS was evaluable in 387 of 402 patients randomly assigned over 36 months, with enrollment ending in September 2009. Because of the lack of TPZ supply, the study did not reach its original target accrual goal. At median follow-up of 28.3 months, PFS and OS were similar in both arms. Three-year PFS for the TPZ/CIS/RT and CIS/RT arms were 63.0% and 64.4%, respectively (log-rank P = .7869). Three-year OS for the TPZ/CIS/RT and CIS/RT arms were 70.5% and 70.6%, respectively (log-rank P = .8333). A scheduled interim safety analysis led to a reduction in the starting dose for the TPZ/CIS arm, with resulting tolerance in both treatment arms. TPZ/CIS chemoradiotherapy was not superior to CIS chemoradiotherapy in either PFS or OS, although definitive commentary was limited by an inadequate number of events (progression or death). TPZ/CIS chemoradiotherapy was tolerable at a modified starting dose.","Clinical Trial, Phase III",2206.0,59.0,This prospective randomized phase III intergroup trial of the Gynecologic Oncology Group and National Cancer Institute of Canada Clinical Trials Group was designed to test the effectiveness and safety of adding the hypoxic cell sensitizer tirapazamine TPZ to standard cisplatin CIS chemoradiotherapy in locally advanced cervix cancer Patients with locally advanced cervix cancer were randomly assigned to CIS chemoradiotherapy versus CIS/TPZ chemoradiotherapy Primary end point was progression-free survival PFS Secondary end points included overall survival OS and tolerability PFS was evaluable in 387 of 402 patients randomly assigned over 36 months with enrollment ending in September 2009 Because of the lack of TPZ supply the study did not reach its original target accrual goal At median follow-up of 28.3 months PFS and OS were similar in both arms Three-year PFS for the TPZ/CIS/RT and CIS/RT arms were 63.0 and 64.4 respectively log-rank P .7869 Three-year OS for the TPZ/CIS/RT and CIS/RT arms were 70.5 and 70.6 respectively log-rank P .8333 A scheduled interim safety analysis led to a reduction in the starting dose for the TPZ/CIS arm with resulting tolerance in both treatment arms TPZ/CIS chemoradiotherapy was not superior to CIS chemoradiotherapy in either PFS or OS although definitive commentary was limited by an inadequate number of events progression or death TPZ/CIS chemoradiotherapy was tolerable at a modified starting dose,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[26, 482, 384, 124, 316, 4839, 160, 1, 3, 1512, 413, 87, 2, 657, 12, 1377, 1, 4740, 38, 143, 87, 10, 1114, 6, 412, 3, 1236, 2, 367, 1, 2726, 3, 4744, 31, 13806, 14512, 16889, 6, 260, 540, 1927, 1464, 4, 795, 131, 3629, 12, 7, 5, 795, 131, 3629, 12, 11, 1108, 896, 6, 1927, 1464, 185, 1927, 16889, 1464, 86, 396, 741, 10, 91, 115, 25, 300, 568, 396, 862, 159, 63, 25, 118, 2, 1543, 300, 10, 859, 4, 9513, 1, 9422, 7, 1108, 896, 252, 511, 53, 5, 1798, 16412, 4, 2636, 1238, 408, 1, 3, 926, 1, 16889, 6296, 3, 45, 205, 44, 3690, 211, 2279, 283, 2262, 1326, 28, 52, 166, 126, 1, 339, 27, 53, 300, 2, 118, 11, 288, 4, 110, 1335, 169, 111, 300, 9, 3, 16889, 1927, 240, 2, 1927, 240, 1335, 11, 676, 13, 2, 660, 39, 106, 1066, 1026, 19, 77486, 169, 111, 118, 9, 3, 16889, 1927, 240, 2, 1927, 240, 1335, 11, 431, 33, 2, 431, 49, 106, 1066, 1026, 19, 77487, 8, 4394, 2914, 367, 65, 836, 6, 8, 628, 4, 3, 1723, 61, 9, 3, 16889, 1927, 475, 5, 1113, 2614, 4, 110, 24, 1335, 16889, 1927, 1464, 10, 44, 1123, 6, 1927, 1464, 4, 361, 300, 15, 118, 242, 1057, 4662, 10, 383, 20, 35, 3358, 207, 1, 281, 91, 15, 273, 16889, 1927, 1464, 10, 2668, 28, 8, 1230, 1723, 61]",,24395863,497
"Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening.",CA: a cancer journal for clinicians,CA Cancer J Clin,2014-01-09,"Answer questions and earn CME/CNE Each year the American Cancer Society publishes a summary of its guidelines for early cancer detection, a report on data and trends in cancer screening rates, and select issues related to cancer screening. In this issue of the journal, we summarize current American Cancer Society cancer screening guidelines. In addition, the latest data on the use of cancer screening from the National Health Interview Survey is described, as are several issues related to screening coverage under the Patient Protection and Affordable Care Act, including the expansion of the Medicaid program.",Journal Article,2203.0,133.0,Answer questions and earn CME/CNE Each year the American Cancer Society publishes a summary of its guidelines for early cancer detection a report on data and trends in cancer screening rates and select issues related to cancer screening In this issue of the journal we summarize current American Cancer Society cancer screening guidelines In addition the latest data on the use of cancer screening from the National Health Interview Survey is described as are several issues related to screening coverage under the Patient Protection and Affordable Care Act including the expansion of the Medicaid program,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6634, 1937, 2, 17339, 12919, 18408, 296, 111, 3, 597, 12, 1174, 22457, 8, 1962, 1, 211, 677, 9, 191, 12, 638, 8, 414, 23, 74, 2, 1963, 4, 12, 453, 151, 2, 1717, 1553, 139, 6, 12, 453, 4, 26, 2537, 1, 3, 6685, 21, 2479, 291, 597, 12, 1174, 12, 453, 677, 4, 352, 3, 5923, 74, 23, 3, 119, 1, 12, 453, 29, 3, 657, 341, 4313, 1407, 16, 1027, 22, 32, 392, 1553, 139, 6, 453, 2139, 669, 3, 69, 3525, 2, 8216, 165, 2559, 141, 3, 1422, 1, 3, 2843, 1243]",,24408568,2
Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2014-02-01,"To determine the incidence of duodenal toxicity in patients receiving intensity modulated radiation therapy (IMRT) for treatment of para-aortic nodes and to identify dosimetric parameters predictive of late duodenal toxicity. We identified 105 eligible patients with gynecologic malignancies who were treated with IMRT for gross metastatic disease in the para-aortic nodes from January 1, 2005, through December 31, 2009. Patients were treated to a nodal clinical target volume to 45 to 50.4Gy with a boost to 60 to 66Gy. The duodenum was contoured, and dosimetric data were exported for analysis. Duodenal toxicity was scored according to Radiation Therapy Oncology Group criteria. Univariate Cox proportional hazards analysis and recursive partitioning analysis were used to determine associations between dosimetric variables and time to toxicity and to identify the optimal threshold that separated patients according to risk of toxicity. Nine of the 105 patients experienced grade 2 to grade 5 duodenal toxicity, confirmed by endoscopy in all cases. The 3-year actuarial rate of any duodenal toxicity was 11.7%. A larger volume of the duodenum receiving 55Gy (V55) was associated with higher rates of duodenal toxicity. The 3-year actuarial rates of duodenal toxicity with V55 above and below 15cm(3) were 48.6% and 7.4%, respectively (P<.01). In Cox univariate analysis of dosimetric variables, V55 was associated with duodenal toxicity (P=.029). In recursive partitioning analysis, V55 less than 13.94% segregated all patients with duodenal toxicity. Dose-escalated IMRT can safely and effectively treat para-aortic nodal disease in gynecologic malignancies, provided that care is taken to limit the dose to the duodenum to reduce the risk of late duodenal toxicity. Limiting V55 to below 15cm(3) may reduce the risk of duodenal complications. In cases where the treatment cannot be delivered within these constraints, consideration should be given to other treatment approaches such as resection or initial chemotherapy.",Journal Article,2180.0,29.0,To determine the incidence of duodenal toxicity in patients receiving intensity modulated radiation therapy IMRT for treatment of para-aortic nodes and to identify dosimetric parameters predictive of late duodenal toxicity We identified 105 eligible patients with gynecologic malignancies who were treated with IMRT for gross metastatic disease in the para-aortic nodes from January 1 2005 through December 31 2009 Patients were treated to a nodal clinical target volume to 45 to 50.4 Gy with a boost to 60 to 66 Gy The duodenum was contoured and dosimetric data were exported for analysis Duodenal toxicity was scored according to Radiation Therapy Oncology Group criteria Univariate Cox proportional hazards analysis and recursive partitioning analysis were used to determine associations between dosimetric variables and time to toxicity and to identify the optimal threshold that separated patients according to risk of toxicity Nine of the 105 patients experienced grade 2 to grade 5 duodenal toxicity confirmed by endoscopy in all cases The 3-year actuarial rate of any duodenal toxicity was 11.7 A larger volume of the duodenum receiving 55 Gy V55 was associated with higher rates of duodenal toxicity The 3-year actuarial rates of duodenal toxicity with V55 above and below 15 cm 3 were 48.6 and 7.4 respectively P .01 In Cox univariate analysis of dosimetric variables V55 was associated with duodenal toxicity P=.029 In recursive partitioning analysis V55 less than 13.94 segregated all patients with duodenal toxicity Dose-escalated IMRT can safely and effectively treat para-aortic nodal disease in gynecologic malignancies provided that care is taken to limit the dose to the duodenum to reduce the risk of late duodenal toxicity Limiting V55 to below 15 cm 3 may reduce the risk of duodenal complications In cases where the treatment can not be delivered within these constraints consideration should be given to other treatment approaches such as resection or initial chemotherapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,"[6, 223, 3, 287, 1, 4748, 155, 4, 7, 357, 837, 1757, 121, 36, 964, 9, 24, 1, 4615, 3938, 502, 2, 6, 255, 3187, 1038, 464, 1, 807, 4748, 155, 21, 108, 3263, 625, 7, 5, 1512, 441, 54, 11, 73, 5, 964, 9, 1789, 113, 34, 4, 3, 4615, 3938, 502, 29, 1024, 14, 1242, 298, 1397, 456, 1238, 7, 11, 73, 6, 8, 779, 38, 283, 433, 6, 512, 6, 212, 39, 381, 5, 8, 2569, 6, 335, 6, 700, 381, 3, 8401, 10, 6476, 2, 3187, 74, 11, 16961, 9, 65, 4748, 155, 10, 3179, 768, 6, 121, 36, 413, 87, 371, 880, 418, 831, 1017, 65, 2, 4493, 4515, 65, 11, 95, 6, 223, 685, 59, 3187, 682, 2, 98, 6, 155, 2, 6, 255, 3, 665, 2390, 17, 4910, 7, 768, 6, 43, 1, 155, 762, 1, 3, 3263, 7, 592, 88, 18, 6, 88, 33, 4748, 155, 557, 20, 4199, 4, 62, 140, 3, 27, 111, 2361, 116, 1, 500, 4748, 155, 10, 175, 67, 8, 1077, 433, 1, 3, 8401, 357, 614, 381, 29521, 10, 41, 5, 142, 151, 1, 4748, 155, 3, 27, 111, 2361, 151, 1, 4748, 155, 5, 29521, 2090, 2, 2736, 167, 494, 27, 11, 576, 49, 2, 67, 39, 106, 19, 355, 4, 418, 880, 65, 1, 3187, 682, 29521, 10, 41, 5, 4748, 155, 19, 4770, 4, 4493, 4515, 65, 29521, 299, 76, 233, 960, 11324, 62, 7, 5, 4748, 155, 61, 2842, 964, 122, 2268, 2, 1856, 943, 4615, 3938, 779, 34, 4, 1512, 441, 1052, 17, 165, 16, 1633, 6, 2385, 3, 61, 6, 3, 8401, 6, 969, 3, 43, 1, 807, 4748, 155, 817, 29521, 6, 2736, 167, 494, 27, 68, 969, 3, 43, 1, 4748, 521, 4, 140, 1257, 3, 24, 122, 44, 40, 1623, 262, 46, 4879, 2415, 257, 40, 447, 6, 127, 24, 611, 225, 22, 170, 15, 388, 56]",,24411609,317
"Adolescent and young adult oncology, version 2.2014.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2014-01-01,"The NCCN Guidelines Insights on Adolescent and Young Adult (AYA) Oncology discuss the fertility and endocrine issues that are relevant to the management of AYA patients with cancer. Fertility preservation should be an essential part in the treatment of AYA patients with cancer. The NCCN Guidelines recommend discussion of fertility preservation and contraception before the start of treatment. Oophoropexy and embryo cryopreservation are the 2 established options for fertility preservation in women. Semen cryopreservation before the start of treatment is the most reliable and well-established method of preserving fertility in men. AYA women with cancer also have unique contraception needs, depending on the type of cancer, its treatment, and treatment-related complications. Management of cancer during pregnancy poses significant diagnostic and therapeutic challenges for both the patient and the physician. AYA women diagnosed with cancer during pregnancy require individualized treatment from a multidisciplinary team involving medical, surgical, radiation, and gynecologic oncologists; obstetricians; and perinatologists. ",Journal Article,2211.0,65.0,The NCCN Guidelines Insights on Adolescent and Young Adult AYA Oncology discuss the fertility and endocrine issues that are relevant to the management of AYA patients with cancer Fertility preservation should be an essential part in the treatment of AYA patients with cancer The NCCN Guidelines recommend discussion of fertility preservation and contraception before the start of treatment Oophoropexy and embryo cryopreservation are the 2 established options for fertility preservation in women Semen cryopreservation before the start of treatment is the most reliable and well-established method of preserving fertility in men AYA women with cancer also have unique contraception needs depending on the type of cancer its treatment and treatment-related complications Management of cancer during pregnancy poses significant diagnostic and therapeutic challenges for both the patient and the physician AYA women diagnosed with cancer during pregnancy require individualized treatment from a multidisciplinary team involving medical surgical radiation and gynecologic oncologists obstetricians and perinatologists,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[3, 1944, 677, 1957, 23, 3678, 2, 1169, 780, 4598, 413, 1139, 3, 2954, 2, 1293, 1553, 17, 32, 867, 6, 3, 284, 1, 4598, 7, 5, 12, 2954, 2224, 257, 40, 35, 1452, 760, 4, 3, 24, 1, 4598, 7, 5, 12, 3, 1944, 677, 2237, 2488, 1, 2954, 2224, 2, 21441, 348, 3, 2435, 1, 24, 23371, 2, 12803, 10270, 32, 3, 18, 635, 838, 9, 2954, 2224, 4, 117, 21792, 10270, 348, 3, 2435, 1, 24, 16, 3, 96, 2450, 2, 149, 635, 596, 1, 4972, 2954, 4, 325, 4598, 117, 5, 12, 120, 47, 991, 21441, 1891, 3221, 23, 3, 267, 1, 12, 211, 24, 2, 24, 139, 521, 284, 1, 12, 190, 2290, 7056, 93, 752, 2, 189, 1427, 9, 110, 3, 69, 2, 3, 1473, 4598, 117, 265, 5, 12, 190, 2290, 1353, 2596, 24, 29, 8, 1643, 2870, 1267, 484, 221, 121, 2, 1512, 1339, 21015, 2, 51730]",,24453290,725
HPV vaccine use among African American girls: qualitative formative research using a participatory social marketing approach.,Gynecologic oncology,Gynecol. Oncol.,2014-01-31,"To generate recommendations for framing messages to promote HPV vaccination, specifically for African American adolescents and their parents who have not yet made a decision about the vaccine (the ""Undecided"" market segment). Focus groups and interviews were conducted with African American girls ages 11-18 (N=34) and their mothers (N=31), broken into market segments based on daughter's vaccination status and mother's intent to vaccinate. Findings suggested that the HPV vaccine should be presented to ""Undecided"" mothers and adolescents as a routine vaccine (just like other vaccines) that helps prevent cancer. Within the ""Undecided"" segment, we identified two sub-segments based on barriers to HPV vaccination and degree of reluctance. The ""Undecided/Ready If Offered"" segment would easily accept HPV vaccine if given the opportunity, with basic information and a healthcare provider recommendation. The ""Undecided/Skeptical"" segment would need more in-depth information to allay concerns about vaccine safety, mistrust of drug companies, and recommended age. Some mothers and girls had the erroneous perception that girls do not need the vaccine until they become sexually active. African American adolescents and their mothers overwhelmingly thought campaigns should target both girls and boys for HPV vaccination. In addition, campaigns and messages may need to be tailored for pre-teens (ages 9-12) versus teens (ages 13-18) and their parents. Findings pointed to the need to ""normalize"" the perception of HPV vaccine as just another routine vaccine (e.g., part of pre-teen vaccine package). Findings can inform social marketing campaigns targeting Undecided or ethnically diverse families.",Journal Article,2181.0,25.0,To generate recommendations for framing messages to promote HPV vaccination specifically for African American adolescents and their parents who have not yet made a decision about the vaccine the `` Undecided '' market segment Focus groups and interviews were conducted with African American girls ages 11-18 N=34 and their mothers N=31 broken into market segments based on daughter 's vaccination status and mother 's intent to vaccinate Findings suggested that the HPV vaccine should be presented to `` Undecided '' mothers and adolescents as a routine vaccine just like other vaccines that helps prevent cancer Within the `` Undecided '' segment we identified two sub-segments based on barriers to HPV vaccination and degree of reluctance The `` Undecided/Ready If Offered '' segment would easily accept HPV vaccine if given the opportunity with basic information and a healthcare provider recommendation The `` Undecided/Skeptical '' segment would need more in-depth information to allay concerns about vaccine safety mistrust of drug companies and recommended age Some mothers and girls had the erroneous perception that girls do not need the vaccine until they become sexually active African American adolescents and their mothers overwhelmingly thought campaigns should target both girls and boys for HPV vaccination In addition campaigns and messages may need to be tailored for pre-teens ages 9-12 versus teens ages 13-18 and their parents Findings pointed to the need to `` normalize '' the perception of HPV vaccine as just another routine vaccine e.g. part of pre-teen vaccine package Findings can inform social marketing campaigns targeting Undecided or ethnically diverse families,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 2562, 883, 9, 31317, 12610, 6, 1617, 933, 1915, 1225, 9, 1410, 597, 3101, 2, 136, 2418, 54, 47, 44, 1145, 1229, 8, 948, 545, 3, 1274, 3, 20502, 522, 9763, 4610, 1222, 271, 2, 4053, 11, 426, 5, 1410, 597, 5989, 2165, 175, 203, 78, 562, 2, 136, 8605, 78, 456, 17656, 237, 9763, 5138, 90, 23, 15254, 292, 1915, 156, 2, 9733, 292, 1697, 6, 25022, 272, 1148, 17, 3, 933, 1274, 257, 40, 917, 6, 20502, 522, 8605, 2, 3101, 22, 8, 1311, 1274, 4673, 733, 127, 1842, 17, 6484, 1682, 12, 262, 3, 20502, 522, 4610, 21, 108, 100, 551, 5138, 90, 23, 2160, 6, 933, 1915, 2, 1444, 1, 13872, 3, 20502, 11307, 492, 2216, 522, 4610, 688, 4697, 11485, 933, 1274, 492, 447, 3, 2666, 5, 2795, 487, 2, 8, 2819, 3094, 3347, 3, 20502, 50958, 522, 4610, 688, 594, 80, 4, 2436, 487, 6, 37339, 2061, 545, 1274, 367, 34245, 1, 234, 11275, 2, 793, 89, 476, 8605, 2, 5989, 42, 3, 17725, 4886, 17, 5989, 1022, 44, 594, 3, 1274, 1100, 491, 1417, 13588, 544, 1410, 597, 3101, 2, 136, 8605, 18890, 2739, 24508, 257, 283, 110, 5989, 2, 12958, 9, 933, 1915, 4, 352, 24508, 2, 12610, 68, 594, 6, 40, 3632, 9, 671, 28707, 2165, 83, 133, 185, 28707, 2165, 233, 203, 2, 136, 2418, 272, 15342, 6, 3, 594, 6, 13633, 522, 3, 4886, 1, 933, 1274, 22, 4673, 1809, 1311, 1274, 563, 499, 760, 1, 671, 27478, 1274, 8913, 272, 122, 2295, 2032, 13362, 24508, 529, 20502, 15, 12771, 1867, 1954]",,24491412,218
Predictors of palliative care consultation on an inpatient gynecologic oncology service: are we following ASCO recommendations?,Gynecologic oncology,Gynecol. Oncol.,2014-03-01,"Determine predictors of inpatient palliative care (PC) consultation and characterize PC referral patterns with respect to recommendations from the American Society of Clinical Oncology (ASCO). Women with a gynecologic malignancy admitted to the gynecologic oncology service 3/2012-8/2012 were identified. Demographic information, disease and treatment details and date of death were abstracted from medical records. Student's t-test, Fischer's exact test or (2)-test was used for univariate analysis. Binomial logistic regression was used for multivariate analysis. Of 340 patients analyzed, 82 (24%) had PC consultation. Univariate predictors of PC consultation included race, cancer type and stage, recurrent disease, admission frequency, admission for symptom management or malignant bowel obstruction (MBO), discharge to skilled nursing facility (SNF) and number of lines of chemotherapy. On multivariate analysis, significant predictors of PC consultation were recurrent disease (OR 2.4, 95% CI 1.1-5.3), number of admissions ( 3, OR 10.9, 95% CI 3.4-34.9), admission for symptom management (OR 19.4, 95% CI 7.5-50.1), discharge to SNF (OR 5, 95% CI 1.9-13.5) and death within 6 months (OR 16.5, 95% CI 6.9-39.5). Of patients considered to meet ASCO guidelines, 53% (63/118) had PC referral. Of patients referred to PC, 51.2% (42/82) died within 6 months of last admission. Patients referred to inpatient PC have high disease and symptom burden and poor prognosis. High-risk patients, including those meeting ASCO recommendations, are not captured comprehensively. We continue to use PC referrals primarily for patients near the end of life, rather than utilizing early integration as recommended by ASCO.",Journal Article,2152.0,12.0,Determine predictors of inpatient palliative care PC consultation and characterize PC referral patterns with respect to recommendations from the American Society of Clinical Oncology ASCO Women with a gynecologic malignancy admitted to the gynecologic oncology service 3/2012-8/2012 were identified Demographic information disease and treatment details and date of death were abstracted from medical records Student 's t-test Fischer 's exact test or  2 -test was used for univariate analysis Binomial logistic regression was used for multivariate analysis Of 340 patients analyzed 82 24 had PC consultation Univariate predictors of PC consultation included race cancer type and stage recurrent disease admission frequency admission for symptom management or malignant bowel obstruction MBO discharge to skilled nursing facility SNF and number of lines of chemotherapy On multivariate analysis significant predictors of PC consultation were recurrent disease OR 2.4 95 CI 1.1-5.3 number of admissions  3 OR 10.9 95 CI 3.4-34.9 admission for symptom management OR 19.4 95 CI 7.5-50.1 discharge to SNF OR 5 95 CI 1.9-13.5 and death within 6 months OR 16.5 95 CI 6.9-39.5 Of patients considered to meet ASCO guidelines 53 63/118 had PC referral Of patients referred to PC 51.2 42/82 died within 6 months of last admission Patients referred to inpatient PC have high disease and symptom burden and poor prognosis High-risk patients including those meeting ASCO recommendations are not captured comprehensively We continue to use PC referrals primarily for patients near the end of life rather than utilizing early integration as recommended by ASCO,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[223, 674, 1, 2420, 994, 165, 1341, 2981, 2, 1507, 1341, 2096, 764, 5, 2184, 6, 883, 29, 3, 597, 1174, 1, 38, 413, 2697, 117, 5, 8, 1512, 710, 4319, 6, 3, 1512, 413, 3086, 27, 1195, 66, 1195, 11, 108, 1540, 487, 34, 2, 24, 3791, 2, 1244, 1, 273, 11, 4106, 29, 484, 1064, 6390, 292, 102, 412, 13218, 292, 2472, 412, 15, 5112, 18, 412, 10, 95, 9, 880, 65, 8538, 812, 320, 10, 95, 9, 331, 65, 1, 7264, 7, 311, 878, 259, 42, 1341, 2981, 880, 674, 1, 1341, 2981, 159, 1047, 12, 267, 2, 82, 387, 34, 3411, 675, 3411, 9, 934, 284, 15, 393, 1659, 3191, 11098, 2993, 6, 11918, 5652, 3483, 5071, 2, 207, 1, 285, 1, 56, 23, 331, 65, 93, 674, 1, 1341, 2981, 11, 387, 34, 15, 18, 39, 48, 58, 14, 14, 33, 27, 207, 1, 5565, 749, 27, 15, 79, 83, 48, 58, 27, 39, 562, 83, 3411, 9, 934, 284, 15, 326, 39, 48, 58, 67, 33, 212, 14, 2993, 6, 5071, 15, 33, 48, 58, 14, 83, 233, 33, 2, 273, 262, 49, 53, 15, 245, 33, 48, 58, 49, 83, 587, 33, 1, 7, 515, 6, 3362, 2697, 677, 699, 676, 4002, 42, 1341, 2096, 1, 7, 1995, 6, 1341, 725, 18, 595, 878, 1016, 262, 49, 53, 1, 1060, 3411, 7, 1995, 6, 2420, 1341, 47, 64, 34, 2, 934, 892, 2, 334, 356, 64, 43, 7, 141, 135, 2238, 2697, 883, 32, 44, 4954, 5627, 21, 1906, 6, 119, 1341, 6902, 1561, 9, 7, 1829, 3, 396, 1, 358, 1832, 76, 2600, 191, 2676, 22, 793, 20, 2697]",,24594073,872
Single-incision laparoscopic surgery through an ostomy site: a natural approach by an unnatural orifice.,"Surgical laparoscopy, endoscopy & percutaneous techniques",Surg Laparosc Endosc Percutan Tech,2015-02-01,"Single-incision laparoscopic surgery (SILS) is gaining popularity for a wide variety of surgical operations and capitalizes on the benefits of traditional laparoscopic surgery without incurring multiple incision sites. Traditionally, SILS is performed by a midline periumbilical approach. However, such a minimally invasive approach may be utilized in patients who already have an abdominal incision. Our series retrospectively reviews 7 cases in which we utilized the fascial defect at the time of after ostomy reversal as our SILS incision site. In turn, we performed a variety of concurrent intra-abdominal procedures with excellent technical success and outcomes. Our study is the largest single-institution case series of this novel approach and suggests that utilizing an existing ostomy-site abdominal incision is a safe and effective location for SILS port placement and should be considered in patients undergoing concurrent procedures. ",Clinical Study,1815.0,4.0,Single-incision laparoscopic surgery SILS is gaining popularity for a wide variety of surgical operations and capitalizes on the benefits of traditional laparoscopic surgery without incurring multiple incision sites Traditionally SILS is performed by a midline periumbilical approach However such a minimally invasive approach may be utilized in patients who already have an abdominal incision Our series retrospectively reviews 7 cases in which we utilized the fascial defect at the time of after ostomy reversal as our SILS incision site In turn we performed a variety of concurrent intra-abdominal procedures with excellent technical success and outcomes Our study is the largest single-institution case series of this novel approach and suggests that utilizing an existing ostomy-site abdominal incision is a safe and effective location for SILS port placement and should be considered in patients undergoing concurrent procedures,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[226, 7538, 1964, 152, 36930, 16, 7312, 11393, 9, 8, 1019, 1362, 1, 221, 3867, 2, 37608, 23, 3, 1141, 1, 1847, 1964, 152, 187, 24775, 232, 7538, 633, 4206, 36930, 16, 173, 20, 8, 8677, 77570, 353, 137, 225, 8, 2144, 416, 353, 68, 40, 2080, 4, 7, 54, 3298, 47, 35, 1467, 7538, 114, 988, 894, 2004, 67, 140, 4, 92, 21, 2080, 3, 15027, 5398, 28, 3, 98, 1, 50, 15565, 5933, 22, 114, 36930, 7538, 606, 4, 3854, 21, 173, 8, 1362, 1, 750, 2392, 1467, 1369, 5, 1503, 3359, 1825, 2, 123, 114, 45, 16, 3, 2166, 226, 731, 473, 988, 1, 26, 229, 353, 2, 844, 17, 2600, 35, 1692, 15565, 606, 1467, 7538, 16, 8, 1165, 2, 323, 1147, 9, 36930, 3083, 2613, 2, 257, 40, 515, 4, 7, 479, 750, 1369]",,24743670,262
Survivorship in gynecologic cancer: enduring the treatment toward a new normal.,American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting,Am Soc Clin Oncol Educ Book,2014-01-01,"Women are living longer after a cancer diagnosis because of advances in early detection and treatment. However, although our ability to effectively treat gynecologic malignancies has improved, survivors of gynecologic cancer often face profound physical, emotional, sexual, and psychosocial challenges as a result of their cancer diagnosis and treatment. In this article, we discuss how patient comorbidities (i.e., obesity) and cancer treatment effects may adversely affect sexual health outcomes, gastrointestinal function, and general health among survivors of gynecologic cancer. The importance of a multidisciplinary, patient-centered approach to survivorship care is emphasized. ",Journal Article,2211.0,1.0,Women are living longer after a cancer diagnosis because of advances in early detection and treatment However although our ability to effectively treat gynecologic malignancies has improved survivors of gynecologic cancer often face profound physical emotional sexual and psychosocial challenges as a result of their cancer diagnosis and treatment In this article we discuss how patient comorbidities i.e. obesity and cancer treatment effects may adversely affect sexual health outcomes function and general health among survivors of gynecologic cancer The importance of a multidisciplinary patient-centered approach to survivorship care is emphasized,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[117, 32, 2798, 589, 50, 8, 12, 147, 408, 1, 954, 4, 191, 638, 2, 24, 137, 242, 114, 801, 6, 1856, 943, 1512, 441, 71, 231, 332, 1, 1512, 12, 629, 3376, 4399, 900, 2671, 2232, 2, 2322, 1427, 22, 8, 757, 1, 136, 12, 147, 2, 24, 4, 26, 946, 21, 1139, 832, 69, 1909, 70, 563, 1661, 2, 12, 24, 176, 68, 4311, 1158, 2232, 341, 123, 343, 2, 1083, 341, 107, 332, 1, 1512, 12, 3, 1187, 1, 8, 1643, 69, 4846, 353, 6, 2560, 165, 16, 8585]",,24857115,184
Complications of pelvic radiation in patients treated for gynecologic malignancies.,Cancer,Cancer,2014-07-23,"Radiation therapy is a critical treatment modality in the management of patients with gynecologic tumors. New highly conformal external-beam and brachytherapy techniques have led to important reductions in recurrence and patient morbidity and mortality. However, patients who receive pelvic radiation for gynecologic malignancies may experience a unique constellation of toxicity because of the anatomic locations, combination with concurrent chemotherapy and/or surgery, as well as potential surgical interventions. Although side effects are often categorized into acute versus late toxicities, several late toxicities represent continuation and evolution of the same pathologic process. Comorbidities and radiation dose can significantly increase the risk of morbidity. Current understanding of the incidence of various morbidities in patients treated with current radiation techniques for gynecologic malignancies, the impact of chemotherapy and surgery, treatment options for those effects, and future areas of research are highlighted.",Journal Article,2008.0,50.0,Radiation therapy is a critical treatment modality in the management of patients with gynecologic tumors New highly conformal external-beam and brachytherapy techniques have led to important reductions in recurrence and patient morbidity and mortality However patients who receive pelvic radiation for gynecologic malignancies may experience a unique constellation of toxicity because of the anatomic locations combination with concurrent chemotherapy and/or surgery as well as potential surgical interventions Although side effects are often categorized into acute versus late toxicities several late toxicities represent continuation and evolution of the same pathologic process Comorbidities and radiation dose can significantly increase the risk of morbidity Current understanding of the incidence of various morbidities in patients treated with current radiation techniques for gynecologic malignancies the impact of chemotherapy and surgery treatment options for those effects and future areas of research are highlighted,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[121, 36, 16, 8, 740, 24, 1396, 4, 3, 284, 1, 7, 5, 1512, 57, 217, 561, 2972, 1455, 1345, 2, 1536, 1092, 47, 836, 6, 305, 2153, 4, 146, 2, 69, 787, 2, 282, 137, 7, 54, 560, 1110, 121, 9, 1512, 441, 68, 730, 8, 991, 13862, 1, 155, 408, 1, 3, 2745, 4069, 150, 5, 750, 56, 2, 15, 152, 22, 149, 22, 174, 221, 1151, 242, 1152, 176, 32, 629, 2320, 237, 286, 185, 807, 385, 392, 807, 385, 1231, 6870, 2, 2554, 1, 3, 827, 510, 1129, 1909, 2, 121, 61, 122, 97, 344, 3, 43, 1, 787, 291, 612, 1, 3, 287, 1, 747, 5655, 4, 7, 73, 5, 291, 121, 1092, 9, 1512, 441, 3, 345, 1, 56, 2, 152, 24, 838, 9, 135, 176, 2, 508, 1361, 1, 389, 32, 3681]",,25056522,671
"Pemetrexed and cisplatin for the treatment of advanced, persistent, or recurrent carcinoma of the cervix: a limited access phase II trial of the gynecologic oncology group.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2014-07-28,"To estimate the antitumor activity of pemetrexed and cisplatin with objective tumor response (partial and complete) in patients with advanced, persistent, or recurrent carcinoma of the cervix and to determine the nature and degree of toxicity of this regimen. Secondarily, this study will determine the effects of this regimen on progression-free survival and overall survival. Eligible, consenting patients received pemetrexed 500 mg/m(2) and cisplatin 50 mg/m(2) intravenously repeated every 21 days until disease progression or adverse events prohibited further therapy. Patients received no prior therapeutic chemotherapy, except when administered concurrently with primary radiation therapy. Subsequent doses were adjusted according to observed toxicity and protocol guidelines. Adverse events were assessed with Common Terminology Criteria for Adverse Events v 3.0. The primary measure of efficacy was tumor response according to Response Evaluation Criteria in Solid Tumors. The study was stratified by prior radiation therapy. From September 2008 to November 2011, 55 patients were enrolled by five Gynecologic Oncology Group member institutions; of those, 54 patients were eligible and assessable. The regimen was well tolerated with 26% receiving more than nine cycles. The most common greater than grade 2 toxicities were neutropenia 35%, leukopenia 28%, and metabolic 28%. The overall response rate was 31% (one complete and 16 partial). The median progression-free survival was 5.7 months, and overall survival was 12.3 months. Pemetrexed in combination with cisplatin demonstrates activity in the treatment of advanced, persistent, or recurrent carcinoma of the cervix.","Clinical Trial, Phase II",2003.0,15.0,To estimate the antitumor activity of pemetrexed and cisplatin with objective tumor response partial and complete in patients with advanced persistent or recurrent carcinoma of the cervix and to determine the nature and degree of toxicity of this regimen Secondarily this study will determine the effects of this regimen on progression-free survival and overall survival Eligible consenting patients received pemetrexed 500 mg/m 2 and cisplatin 50 mg/m 2 intravenously repeated every 21 days until disease progression or adverse events prohibited further therapy Patients received no prior therapeutic chemotherapy except when administered concurrently with primary radiation therapy Subsequent doses were adjusted according to observed toxicity and protocol guidelines Adverse events were assessed with Common Terminology Criteria for Adverse Events v 3.0 The primary measure of efficacy was tumor response according to Response Evaluation Criteria in Solid Tumors The study was stratified by prior radiation therapy From September 2008 to November 2011 55 patients were enrolled by five Gynecologic Oncology Group member institutions of those 54 patients were eligible and assessable The regimen was well tolerated with 26 receiving more than nine cycles The most common greater than grade 2 toxicities were neutropenia 35 leukopenia 28 and metabolic 28 The overall response rate was 31 one complete and 16 partial The median progression-free survival was 5.7 months and overall survival was 12.3 months Pemetrexed in combination with cisplatin demonstrates activity in the treatment of advanced persistent or recurrent carcinoma of the cervix,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[6, 1191, 3, 579, 128, 1, 2046, 2, 540, 5, 461, 30, 51, 450, 2, 236, 4, 7, 5, 131, 1882, 15, 387, 134, 1, 3, 3629, 2, 6, 223, 3, 2202, 2, 1444, 1, 155, 1, 26, 477, 12974, 26, 45, 303, 223, 3, 176, 1, 26, 477, 23, 91, 115, 25, 2, 63, 25, 625, 11932, 7, 103, 2046, 1666, 81, 188, 18, 2, 540, 212, 81, 188, 18, 1672, 2113, 454, 239, 162, 1100, 34, 91, 15, 290, 281, 19105, 195, 36, 7, 103, 77, 324, 189, 56, 2187, 198, 468, 3294, 5, 86, 121, 36, 706, 415, 11, 586, 768, 6, 164, 155, 2, 1182, 677, 290, 281, 11, 275, 5, 186, 3462, 371, 9, 290, 281, 603, 27, 13, 3, 86, 1463, 1, 209, 10, 30, 51, 768, 6, 51, 451, 371, 4, 537, 57, 3, 45, 10, 1173, 20, 324, 121, 36, 29, 2636, 1375, 6, 2868, 1132, 614, 7, 11, 346, 20, 365, 1512, 413, 87, 2693, 1764, 1, 135, 667, 7, 11, 625, 2, 3120, 3, 477, 10, 149, 421, 5, 432, 357, 80, 76, 762, 410, 3, 96, 186, 378, 76, 88, 18, 385, 11, 778, 465, 3904, 339, 2, 1436, 339, 3, 63, 51, 116, 10, 456, 104, 236, 2, 245, 450, 3, 52, 91, 115, 25, 10, 33, 67, 53, 2, 63, 25, 10, 133, 27, 53, 2046, 4, 150, 5, 540, 1902, 128, 4, 3, 24, 1, 131, 1882, 15, 387, 134, 1, 3, 3629]",,25071133,583
"Outpatient rapid 4-step desensitization for gynecologic oncology patients with mild to low-risk, moderate hypersensitivity reactions to carboplatin/cisplatin.",Gynecologic oncology,Gynecol. Oncol.,2014-08-07,"The primary objective of this study is to assess the efficacy and safety of an outpatient, 4-step, one-solution desensitization protocol in gynecologic oncology patients with history of mild to low-risk, moderate hypersensitivity reactions (HSRs) to platinums (carboplatin and cisplatin). This was a single institutional retrospective review. Gynecologic oncology patients with a documented history of mild or low-risk, moderate immediate HSRs to carboplatin/cisplatin and continued treatment with 4-step, one-solution desensitization protocols in the outpatient infusion center were included. Patients with delayed HSRs or immediate high-risk, moderate or severe HSRs were excluded. The primary end point was the rate of successful administrations of each course of platinums. From January 2011 to June 2013, eighteen eligible patients were evaluated for outpatient 4-step, one-solution desensitization. Thirteen patients had a history of HSRs to carboplatin and 5 with HSRs to cisplatin. All of 18 patients successfully completed 94 (98.9%) of 95 desensitization courses in the outpatient infusion center. Eight of 8 (100%) patients with initial mild HSRs completed 29/29 (100%) desensitization courses, and 9 of 10 (90%) of patients with initial moderate HSRs completed 65/66 (94%) desensitization courses. In total, 65/95 (68%) desensitizations resulted in no breakthrough reactions, and mild, moderate and severe breakthrough reactions were seen in 19%, 12% and 1% desensitizations, respectively. No patients were hospitalized during desensitization. The outpatient rapid, 4-step, one-solution desensitization protocol was effective and appeared safe among gynecologic oncology patients who experienced mild to low-risk, moderate HSRs to carboplatin/cisplatin.",Journal Article,1993.0,14.0,The primary objective of this study is to assess the efficacy and safety of an outpatient 4-step one-solution desensitization protocol in gynecologic oncology patients with history of mild to low-risk moderate hypersensitivity reactions HSRs to platinums carboplatin and cisplatin This was a single institutional retrospective review Gynecologic oncology patients with a documented history of mild or low-risk moderate immediate HSRs to carboplatin/cisplatin and continued treatment with 4-step one-solution desensitization protocols in the outpatient infusion center were included Patients with delayed HSRs or immediate high-risk moderate or severe HSRs were excluded The primary end point was the rate of successful administrations of each course of platinums From January 2011 to June 2013 eighteen eligible patients were evaluated for outpatient 4-step one-solution desensitization Thirteen patients had a history of HSRs to carboplatin and 5 with HSRs to cisplatin All of 18 patients successfully completed 94 98.9 of 95 desensitization courses in the outpatient infusion center Eight of 8 100 patients with initial mild HSRs completed 29/29 100 desensitization courses and 9 of 10 90 of patients with initial moderate HSRs completed 65/66 94 desensitization courses In total 65/95 68 desensitizations resulted in no breakthrough reactions and mild moderate and severe breakthrough reactions were seen in 19 12 and 1 desensitizations respectively No patients were hospitalized during desensitization The outpatient rapid 4-step one-solution desensitization protocol was effective and appeared safe among gynecologic oncology patients who experienced mild to low-risk moderate HSRs to carboplatin/cisplatin,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,"[3, 86, 461, 1, 26, 45, 16, 6, 423, 3, 209, 2, 367, 1, 35, 2379, 39, 2458, 104, 5829, 9293, 1182, 4, 1512, 413, 7, 5, 532, 1, 1980, 6, 154, 43, 1163, 4034, 2428, 10915, 6, 18919, 927, 2, 540, 26, 10, 8, 226, 1115, 459, 206, 1512, 413, 7, 5, 8, 1405, 532, 1, 1980, 15, 154, 43, 1163, 2181, 10915, 6, 927, 540, 2, 1351, 24, 5, 39, 2458, 104, 5829, 9293, 2189, 4, 3, 2379, 904, 574, 11, 159, 7, 5, 1612, 10915, 15, 2181, 64, 43, 1163, 15, 905, 10915, 11, 1800, 3, 86, 396, 741, 10, 3, 116, 1, 1401, 10306, 1, 296, 906, 1, 18919, 29, 1024, 1132, 6, 1924, 1346, 3195, 625, 7, 11, 194, 9, 2379, 39, 2458, 104, 5829, 9293, 3170, 7, 42, 8, 532, 1, 10915, 6, 927, 2, 33, 5, 10915, 6, 540, 62, 1, 203, 7, 1878, 781, 960, 1096, 83, 1, 48, 9293, 1993, 4, 3, 2379, 904, 574, 659, 1, 66, 394, 7, 5, 388, 1980, 10915, 781, 462, 462, 394, 9293, 1993, 2, 83, 1, 79, 424, 1, 7, 5, 388, 1163, 10915, 781, 556, 700, 960, 9293, 1993, 4, 181, 556, 48, 806, 26337, 627, 4, 77, 6022, 2428, 2, 1980, 1163, 2, 905, 6022, 2428, 11, 527, 4, 326, 133, 2, 14, 26337, 106, 77, 7, 11, 4795, 190, 9293, 3, 2379, 1321, 39, 2458, 104, 5829, 9293, 1182, 10, 323, 2, 2121, 1165, 107, 1512, 413, 7, 54, 592, 1980, 6, 154, 43, 1163, 10915, 6, 927, 540]",,25110329,37
Cancer immunoprevention--the next frontier.,"Cancer prevention research (Philadelphia, Pa.)",Cancer Prev Res (Phila),2014-09-22,"Cancer immunotherapy is a rapidly developing field, but limited in its success by a high tumor burden and immune tolerance. In contrast, immunoprevention has the potential to prevent cancer before the development of immune tolerance, and to prevent cancer recurrence in the setting of minimal residual disease. Although immunoprevention for viral-induced cancers has been successful in the setting of hepatitis B and human papillomavirus vaccination, primary prevention of nonviral-induced cancers is in its infancy. In contrast, prevention of cancer recurrence after adjuvant treatment (secondary prevention) is gaining steam. This review provides an overview of the scope of research in cancer immunoprevention over the last three years and directions for future research.",Journal Article,1947.0,14.0,Cancer immunotherapy is a rapidly developing field but limited in its success by a high tumor burden and immune tolerance In contrast immunoprevention has the potential to prevent cancer before the development of immune tolerance and to prevent cancer recurrence in the setting of minimal residual disease Although immunoprevention for viral-induced cancers has been successful in the setting of hepatitis B and human papillomavirus vaccination primary prevention of nonviral-induced cancers is in its infancy In contrast prevention of cancer recurrence after adjuvant treatment secondary prevention is gaining steam This review provides an overview of the scope of research in cancer immunoprevention over the last three years and directions for future research,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[12, 726, 16, 8, 1755, 931, 1067, 84, 383, 4, 211, 1825, 20, 8, 64, 30, 892, 2, 250, 2614, 4, 748, 23738, 71, 3, 174, 6, 1682, 12, 348, 3, 193, 1, 250, 2614, 2, 6, 1682, 12, 146, 4, 3, 546, 1, 1048, 753, 34, 242, 23738, 9, 1667, 277, 163, 71, 85, 1401, 4, 3, 546, 1, 3002, 132, 2, 171, 3242, 1915, 86, 1070, 1, 18434, 277, 163, 16, 4, 211, 12069, 4, 748, 1070, 1, 12, 146, 50, 249, 24, 568, 1070, 16, 7312, 44416, 26, 206, 777, 35, 2901, 1, 3, 7924, 1, 389, 4, 12, 23738, 252, 3, 1060, 169, 60, 2, 3540, 9, 508, 389]",,25245763,150
Perioperative blood transfusion in gynecologic oncology surgery: analysis of the National Surgical Quality Improvement Program Database.,Gynecologic oncology,Gynecol. Oncol.,2014-11-14,"To use a large-scale multi-institutional dataset to quantify the prevalence of packed red blood cell transfusions and examine the associations between transfusion and perioperative outcomes in gynecologic cancer surgery. The American College of Surgeons National Surgical Quality Improvement Program (NSQIP) participant use file was queried for all gynecologic cancer cases between 2010 and 2012. Demographic, preoperative and intraoperative variables were compared between transfusion and non-transfusion groups using chi-squared, Fisher's exact and Wilcoxon rank-sum tests. The primary endpoint was 30-day composite morbidity. Secondary endpoints included composite surgical site infections, mortality and length of stay. A total of 8519 patients were analyzed, and 13.8% received a packed red blood cell transfusion. In the multivariate analysis, after adjusting for key clinical and perioperative factors, including preoperative anemia and case magnitude, transfusion was associated with higher composite morbidity (OR = 1.85, 95% CI 1.5-2.24), surgical site infections (OR 1.80, 95% CI 1.39-2.35), mortality (OR 3.38, 95% CI 1.80-6.36) and length of hospital stay (3.02 days v. 7.17 days, P < 0.001). Blood transfusions are associated with increased surgical wound infections, composite morbidity and mortality. Based on our analysis of the NSQIP database, transfusion practices in gynecologic cancer should be scrutinized. Examination of institutional practices and creation of transfusion guidelines for gynecologic malignancies could potentially result in better utilization of blood bank resources and clinical outcomes among patients.",Journal Article,1894.0,26.0,To use a large-scale multi-institutional dataset to quantify the prevalence of packed red blood cell transfusions and examine the associations between transfusion and perioperative outcomes in gynecologic cancer surgery The American College of Surgeons National Surgical Quality Improvement Program NSQIP participant use file was queried for all gynecologic cancer cases between 2010 and 2012 Demographic preoperative and intraoperative variables were compared between transfusion and non-transfusion groups using chi-squared Fisher 's exact and Wilcoxon rank-sum tests The primary endpoint was 30-day composite morbidity Secondary endpoints included composite surgical site infections mortality and length of stay A total of 8519 patients were analyzed and 13.8 received a packed red blood cell transfusion In the multivariate analysis after adjusting for key clinical and perioperative factors including preoperative anemia and case magnitude transfusion was associated with higher composite morbidity OR 1.85 95 CI 1.5-2.24 surgical site infections OR 1.80 95 CI 1.39-2.35 mortality OR 3.38 95 CI 1.80-6.36 and length of hospital stay 3.02 days v. 7.17 days P 0.001 Blood transfusions are associated with increased surgical wound infections composite morbidity and mortality Based on our analysis of the NSQIP database transfusion practices in gynecologic cancer should be scrutinized Examination of institutional practices and creation of transfusion guidelines for gynecologic malignancies could potentially result in better utilization of blood bank resources and clinical outcomes among patients,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 119, 8, 375, 1124, 1414, 1115, 3014, 6, 3091, 3, 1078, 1, 14203, 3422, 315, 31, 4987, 2, 1004, 3, 685, 59, 2785, 2, 1547, 123, 4, 1512, 12, 152, 3, 597, 2979, 1, 1613, 657, 221, 372, 767, 1243, 8280, 5705, 119, 12339, 10, 3547, 9, 62, 1512, 12, 140, 59, 1120, 2, 1195, 1540, 498, 2, 1720, 682, 11, 72, 59, 2785, 2, 220, 2785, 271, 75, 3163, 8515, 3135, 292, 2472, 2, 3896, 1026, 3216, 895, 3, 86, 1138, 10, 201, 218, 3308, 787, 568, 1387, 159, 3308, 221, 606, 1875, 282, 2, 1318, 1, 2020, 8, 181, 1, 77836, 7, 11, 311, 2, 233, 66, 103, 8, 14203, 3422, 315, 31, 2785, 4, 3, 331, 65, 50, 1358, 9, 825, 38, 2, 1547, 130, 141, 498, 1545, 2, 473, 3131, 2785, 10, 41, 5, 142, 3308, 787, 15, 14, 772, 48, 58, 14, 33, 18, 259, 221, 606, 1875, 15, 14, 493, 48, 58, 14, 587, 18, 465, 282, 15, 27, 519, 48, 58, 14, 493, 49, 511, 2, 1318, 1, 702, 2020, 27, 588, 162, 603, 67, 269, 162, 19, 13, 144, 315, 4987, 32, 41, 5, 101, 221, 2689, 1875, 3308, 787, 2, 282, 90, 23, 114, 65, 1, 3, 8280, 609, 2785, 2634, 4, 1512, 12, 257, 40, 21084, 1385, 1, 1115, 2634, 2, 7560, 1, 2785, 677, 9, 1512, 441, 359, 751, 757, 4, 380, 1961, 1, 315, 10213, 2892, 2, 38, 123, 107, 7]",,25451693,774
[18F]-Fluoromisonidazole positron emission tomography/computed tomography visualization of tumor hypoxia in patients with chordoma of the mobile and sacrococcygeal spine.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2014-12-01,"To investigate [18F]-fluoromisonidazole positron emission tomography/computed tomography (FMISO-PET/CT) detection of targetable hypoxic subvolumes (HSVs) in chordoma of the mobile or sacrococcygeal spine. A prospective, pilot study of 20 patients with primary or locally recurrent chordoma of the mobile or sacrococcygeal spine treated with proton or combined proton/photon radiation therapy (RT) with or without surgery was completed. The FMISO-PET/CT was performed before RT and after 19.8-34.2 GyRBE (relative biologic effectiveness). Gross tumor volumes were delineated and HSVs defined including voxels with standardized uptake values 1.4 times the muscle mean. Clinical characteristics and treatments received were compared between patients with and without HSVs. The FMISO-PET/CT detected HSVs in 12 of 20 patients (60%). Baseline and interval HSV spatial concordance varied (0%-94%). Eight HSVs were sufficiently large (5 cm(3)) to potentially allow an intensity modulated proton therapy boost. Patients with HSVs had significantly larger gross tumor volumes (median 410.0 cm(3) vs 63.4 cm(3); P=.02) and were significantly more likely to have stage T2 tumors (5 of 12 vs 0 of 8; P=.04). After a median follow-up of 1.8 years (range, 0.2-4.4 years), a local recurrence has yet to be observed. Three patients developed metastatic disease, 2 with HSVs. Detection of targetable HSVs by FMISO-PET/CT within patients undergoing RT with or without surgery for treatment of chordoma of the mobile and sacrococcygeal spine is feasible. The study's inability to attribute interval HSV changes to treatment, rapidly changing hypoxic physiology, or imaging inconsistencies is a limitation. Further study of double-baseline FMISO-PET/CT and hypoxia-directed RT dose escalation, particularly in patients at high risk for local recurrence, is warranted.","Clinical Trial, Phase I",1877.0,7.0,To investigate 18F -fluoromisonidazole positron emission tomography/computed tomography FMISO-PET/CT detection of targetable hypoxic subvolumes HSVs in chordoma of the mobile or sacrococcygeal spine A prospective pilot study of 20 patients with primary or locally recurrent chordoma of the mobile or sacrococcygeal spine treated with proton or combined proton/photon radiation therapy RT with or without surgery was completed The FMISO-PET/CT was performed before RT and after 19.8-34.2 GyRBE relative biologic effectiveness Gross tumor volumes were delineated and HSVs defined including voxels with standardized uptake values 1.4 times the muscle mean Clinical characteristics and treatments received were compared between patients with and without HSVs The FMISO-PET/CT detected HSVs in 12 of 20 patients 60 Baseline and interval HSV spatial concordance varied 0 -94 Eight HSVs were sufficiently large 5 cm 3 to potentially allow an intensity modulated proton therapy boost Patients with HSVs had significantly larger gross tumor volumes median 410.0 cm 3 vs 63.4 cm 3 P=.02 and were significantly more likely to have stage T2 tumors 5 of 12 vs 0 of 8 P=.04 After a median follow-up of 1.8 years range 0.2-4.4 years a local recurrence has yet to be observed Three patients developed metastatic disease 2 with HSVs Detection of targetable HSVs by FMISO-PET/CT within patients undergoing RT with or without surgery for treatment of chordoma of the mobile and sacrococcygeal spine is feasible The study 's inability to attribute interval HSV changes to treatment rapidly changing hypoxic physiology or imaging inconsistencies is a limitation Further study of double-baseline FMISO-PET/CT and hypoxia-directed RT dose escalation particularly in patients at high risk for local recurrence is warranted,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[6, 963, 4751, 22578, 1900, 1799, 872, 1220, 872, 10504, 495, 425, 638, 1, 3985, 4744, 13719, 20396, 4, 3911, 1, 3, 7489, 15, 24260, 2342, 8, 482, 2281, 45, 1, 179, 7, 5, 86, 15, 795, 387, 3911, 1, 3, 7489, 15, 24260, 2342, 73, 5, 2095, 15, 397, 2095, 4216, 121, 36, 240, 5, 15, 187, 152, 10, 781, 3, 10504, 495, 425, 10, 173, 348, 240, 2, 50, 326, 66, 562, 18, 27365, 580, 1283, 1236, 1789, 30, 2225, 11, 5610, 2, 20396, 395, 141, 8784, 5, 1670, 1135, 1030, 3567, 39, 1072, 3, 1502, 313, 38, 374, 2, 640, 103, 11, 72, 59, 7, 5, 2, 187, 20396, 3, 10504, 495, 425, 530, 20396, 4, 133, 1, 179, 7, 335, 330, 2, 268, 4702, 5104, 1827, 2051, 13, 960, 659, 20396, 11, 5938, 375, 4126, 494, 27, 6, 751, 1700, 35, 837, 1757, 2095, 36, 2569, 7, 5, 20396, 42, 97, 1077, 1789, 30, 2225, 52, 7690, 13, 494, 27, 105, 676, 39, 494, 27, 19, 588, 2, 11, 97, 80, 322, 6, 47, 82, 1786, 57, 33, 1, 133, 105, 13, 1, 66, 19, 755, 50, 8, 52, 166, 126, 1, 14, 66, 60, 184, 13, 18, 39, 39, 60, 8, 293, 146, 71, 1145, 6, 40, 164, 169, 7, 276, 113, 34, 18, 5, 20396, 638, 1, 3985, 20396, 20, 10504, 495, 425, 262, 7, 479, 240, 5, 15, 187, 152, 9, 24, 1, 3911, 1, 3, 7489, 2, 24260, 2342, 16, 1313, 3, 45, 292, 4985, 6, 13530, 268, 4702, 400, 6, 24, 1755, 3600, 4744, 7206, 15, 270, 14974, 16, 8, 5039, 195, 45, 1, 1627, 330, 10504, 495, 425, 2, 1823, 1166, 240, 61, 1125, 823, 4, 7, 28, 64, 43, 9, 293, 146, 16, 1197]",,25539367,544
Gynecologic Oncologist as surgical consultant: intraoperative consultations during general gynecologic surgery as an important focus of gynecologic oncology training.,Gynecologic oncology,Gynecol. Oncol.,2015-01-21,"The aim of this study is to explore the previously unexamined role of the Gynecologic Oncologist as an intraoperative consultant during general gynecologic surgery. Demographic and clinical data were collected on 98 major gynecologic surgeries that included both a general Gynecologist and a Gynecologic Oncologist between October 2010 and August 2014. Data were analyzed using XLSTAT-Prov2014.2.02. Of 794 major gynecologic surgeries, 98 (12.3%) cases that involved an intraoperative consultation were identified. There were 36 (37%) planned consults and 62 (63%) unplanned consults. Significantly more planned consults were during laparoscopy (100% v 58%; p<0.01) and significantly more unplanned consults were during laparotomy (42% v 0%; p<0.01). The majority of planned consults were for surgical training (86%) and the most common reasons for unplanned consults were adhesions (40%), bowel injury (19%), inability to identify ureter (19%), and cancer (11%). The most common interventions performed during unplanned consults were identification of anatomy (55%), lysis of adhesions (42%), and retroperitoneal dissection (27%). Average surgeon years in practice were significantly lower for unplanned consults (9 v 15; p<0.01). A total of 25 major adverse events occurred in 15 cases with the majority occurring in cases with unplanned consults (23% v 3%; p<0.01). After controlling for laparotomy, unplanned consultation was not significantly associated with major events (OR=6.67, 95%CI 0.69-64.39; p=0.10). Gynecologic Oncologists play a pivotal role in the support of generalist colleagues during pelvic surgery. In this series, Gynecologic Oncologists were consulted frequently for complex major benign surgeries. It is important to incorporate the skills required of an intraoperative consultant into Gynecologic Oncology fellowship training.",Journal Article,1826.0,6.0,The aim of this study is to explore the previously unexamined role of the Gynecologic Oncologist as an intraoperative consultant during general gynecologic surgery Demographic and clinical data were collected on 98 major gynecologic surgeries that included both a general Gynecologist and a Gynecologic Oncologist between October 2010 and August 2014 Data were analyzed using XLSTAT-Prov2014.2.02 Of 794 major gynecologic surgeries 98 12.3 cases that involved an intraoperative consultation were identified There were 36 37 planned consults and 62 63 unplanned consults Significantly more planned consults were during laparoscopy 100 v 58 p 0.01 and significantly more unplanned consults were during laparotomy 42 v 0 p 0.01 The majority of planned consults were for surgical training 86 and the most common reasons for unplanned consults were adhesions 40 bowel injury 19 inability to identify ureter 19 and cancer 11 The most common interventions performed during unplanned consults were identification of anatomy 55 lysis of adhesions 42 and retroperitoneal dissection 27 Average surgeon years in practice were significantly lower for unplanned consults 9 v 15 p 0.01 A total of 25 major adverse events occurred in 15 cases with the majority occurring in cases with unplanned consults 23 v 3 p 0.01 After controlling for laparotomy unplanned consultation was not significantly associated with major events OR=6.67 95 CI 0.69-64.39 p=0.10 Gynecologic Oncologists play a pivotal role in the support of generalist colleagues during pelvic surgery In this series Gynecologic Oncologists were consulted frequently for complex major benign surgeries It is important to incorporate the skills required of an intraoperative consultant into Gynecologic Oncology fellowship training,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 1130, 1, 26, 45, 16, 6, 1645, 3, 373, 52248, 200, 1, 3, 1512, 2709, 22, 35, 1720, 23651, 190, 1083, 1512, 152, 1540, 2, 38, 74, 11, 786, 23, 1096, 458, 1512, 5305, 17, 159, 110, 8, 1083, 21947, 2, 8, 1512, 2709, 59, 2551, 1120, 2, 2480, 1409, 74, 11, 311, 75, 77890, 77891, 18, 588, 1, 13085, 458, 1512, 5305, 1096, 133, 27, 140, 17, 646, 35, 1720, 2981, 11, 108, 125, 11, 511, 567, 1465, 12725, 2, 744, 676, 5851, 12725, 97, 80, 1465, 12725, 11, 190, 3553, 394, 603, 717, 19, 13, 355, 2, 97, 80, 5851, 12725, 11, 190, 3274, 595, 603, 13, 19, 13, 355, 3, 686, 1, 1465, 12725, 11, 9, 221, 1741, 868, 2, 3, 96, 186, 2325, 9, 5851, 12725, 11, 13233, 327, 1659, 2730, 326, 4985, 6, 255, 9775, 326, 2, 12, 175, 3, 96, 186, 1151, 173, 190, 5851, 12725, 11, 911, 1, 5081, 614, 4783, 1, 13233, 595, 2, 2591, 1161, 428, 1011, 1897, 60, 4, 758, 11, 97, 280, 9, 5851, 12725, 83, 603, 167, 19, 13, 355, 8, 181, 1, 243, 458, 290, 281, 489, 4, 167, 140, 5, 3, 686, 1821, 4, 140, 5, 5851, 12725, 382, 603, 27, 19, 13, 355, 50, 1893, 9, 3274, 5851, 2981, 10, 44, 97, 41, 5, 458, 281, 15, 49, 598, 48, 58, 13, 790, 660, 587, 19, 13, 79, 1512, 1339, 1343, 8, 3754, 200, 4, 3, 538, 1, 39338, 6367, 190, 1110, 152, 4, 26, 988, 1512, 1339, 11, 12824, 746, 9, 840, 458, 1002, 5305, 192, 16, 305, 6, 3360, 3, 5909, 616, 1, 35, 1720, 23651, 237, 1512, 413, 9289, 1741]",,25617772,93
A 20-year-old man with back pain and lower extremity weakness.,JAMA neurology,JAMA Neurol,2015-03-01,"A 20-year-old man presented with 1 week of low back pain and progressive lower extremity weakness. Results of cerebrospinal fluid analysis demonstrated elevated total protein and a mildly elevated white blood cell count with lymphocytic predominance. Findings from imaging studies revealed a multifocal, heterogeneously enhancing, intramedullary lesion involving the cervicothoracic spinal cord and nodular enhancement of the cauda equina. The patient eventually underwent spinal surgery for tissue diagnosis. The differential diagnosis, pathologic findings, and diagnosis are discussed. ",Case Reports,1787.0,0.0,A 20-year-old man presented with 1 week of low back pain and progressive lower extremity weakness Results of cerebrospinal fluid analysis demonstrated elevated total protein and a mildly elevated white blood cell count with lymphocytic predominance Findings from imaging studies revealed a multifocal heterogeneously enhancing intramedullary lesion involving the cervicothoracic spinal cord and nodular enhancement of the cauda equina The patient eventually underwent spinal surgery for tissue diagnosis The differential diagnosis pathologic findings and diagnosis are discussed,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[8, 179, 111, 1095, 3628, 917, 5, 14, 647, 1, 154, 4636, 559, 2, 1014, 280, 2678, 6408, 99, 1, 5156, 2357, 65, 264, 804, 181, 178, 2, 8, 9443, 804, 886, 315, 31, 1276, 5, 1193, 7593, 272, 29, 270, 94, 553, 8, 3492, 13394, 2430, 8686, 1180, 1267, 3, 26738, 1499, 1885, 2, 4481, 2461, 1, 3, 19791, 20537, 3, 69, 3124, 208, 1499, 152, 9, 246, 147, 3, 1777, 147, 510, 272, 2, 147, 32, 1588]",,25621865,418
FDG PET-CT of gynecologic cancers: pearls and pitfalls.,Abdominal imaging,Abdom Imaging,2015-10-01,"FDG PET-CT plays an important role in treatment planning and in prognosis assessment of gynecologic cancer patients. Detection of hypermetabolic tissue with FDG PET, when combined with the high spatial resolution of CT, results in improved cancer detection and localization not afforded by either modality independently. This article is a primer for a radiologist performing PET-CT on gynecologic cancer patients and includes the imaging protocol, normal pattern of FDG distribution in the female pelvis and the lymph node drainage pathways from the gynecologic organs. Clinically relevant imaging findings that should be included in the report are discussed. Case examples illustrate how potential errors in exam interpretation can be avoided by concurrently performing a high-quality diagnostic CT with the FDG PET scan and by analyzing both the stand-alone and the fusion images. ",Journal Article,1573.0,10.0,FDG PET-CT plays an important role in treatment planning and in prognosis assessment of gynecologic cancer patients Detection of hypermetabolic tissue with FDG PET when combined with the high spatial resolution of CT results in improved cancer detection and localization not afforded by either modality independently This article is a primer for a radiologist performing PET-CT on gynecologic cancer patients and includes the imaging protocol normal pattern of FDG distribution in the female pelvis and the lymph node drainage pathways from the gynecologic organs Clinically relevant imaging findings that should be included in the report are discussed Case examples illustrate how potential errors in exam interpretation can be avoided by concurrently performing a high-quality diagnostic CT with the FDG PET scan and by analyzing both the stand-alone and the fusion images,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[1285, 495, 425, 1698, 35, 305, 200, 4, 24, 1349, 2, 4, 356, 455, 1, 1512, 12, 7, 638, 1, 16049, 246, 5, 1285, 495, 198, 397, 5, 3, 64, 5104, 2125, 1, 425, 99, 4, 231, 12, 638, 2, 2145, 44, 9150, 20, 361, 1396, 1042, 26, 946, 16, 8, 9684, 9, 8, 6247, 3620, 495, 425, 23, 1512, 12, 7, 2, 1920, 3, 270, 1182, 295, 1177, 1, 1285, 1395, 4, 3, 1061, 3270, 2, 3, 263, 289, 3528, 460, 29, 3, 1512, 2285, 505, 867, 270, 272, 17, 257, 40, 159, 4, 3, 414, 32, 1588, 473, 4416, 4746, 832, 174, 4612, 4, 6747, 3037, 122, 40, 5617, 20, 3294, 3620, 8, 64, 372, 752, 425, 5, 3, 1285, 495, 1657, 2, 20, 4449, 110, 3, 9959, 279, 2, 3, 1212, 1572]",,25680500,6
The Risk Factors of Readmission in Postoperative Gynecologic Oncology Patients at a Single Institution.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2015-11-01,"Hospital readmission rates are an important measure of quality care and have recently been tied to reimbursement. This study seeks to identify the risk factors for postoperative readmission in patients treated by a gynecologic oncology service. A 7-year retrospective review (2007-2013) of all patients operated on by the University of Virginia gynecologic oncology service who were readmitted within 30 days of discharge was performed. Abstracted data included demographics, dates of surgery, operative details, cancer history, and relevant medical history. The readmitted patients (n = 166) were compared with randomly selected controls (n = 168) from the same service in a matching time frame and analyzed using univariate and multivariate models. In the study period, 2993 operations were performed. One hundred sixty-six unique patients (5.5%) were readmitted within 30 days of discharge from their operative procedure. On multivariate analysis, the factors that were associated with a higher risk of readmission were a history of psychiatric disease, postoperative complication, type of insurance, surgical modality, and lysis of adhesions at the time of surgery. The most common readmission diagnoses were infection (44%), nausea/vomiting (28%), thrombosis (6%), bowel leak (4%), and bleeding (4%). Postoperative readmissions are a common problem and are increasingly important as a measure of quality. Although patients were generally admitted for infections or gastrointestinal complaints, we also found that individual factors such as mental health and socioeconomic status also contributed. Our data suggest that we can preoperatively identify high-risk individuals for whom extra resources can be directed postoperatively to avoid unnecessary readmissions.",Journal Article,1542.0,8.0,Hospital readmission rates are an important measure of quality care and have recently been tied to reimbursement This study seeks to identify the risk factors for postoperative readmission in patients treated by a gynecologic oncology service A 7-year retrospective review 2007-2013 of all patients operated on by the University of Virginia gynecologic oncology service who were readmitted within 30 days of discharge was performed Abstracted data included demographics dates of surgery operative details cancer history and relevant medical history The readmitted patients n 166 were compared with randomly selected controls n 168 from the same service in a matching time frame and analyzed using univariate and multivariate models In the study period 2993 operations were performed One hundred sixty-six unique patients 5.5 were readmitted within 30 days of discharge from their operative procedure On multivariate analysis the factors that were associated with a higher risk of readmission were a history of psychiatric disease postoperative complication type of insurance surgical modality and lysis of adhesions at the time of surgery The most common readmission diagnoses were infection 44 nausea/vomiting 28 thrombosis 6 bowel leak 4 and bleeding 4 Postoperative readmissions are a common problem and are increasingly important as a measure of quality Although patients were generally admitted for infections or complaints we also found that individual factors such as mental health and socioeconomic status also contributed Our data suggest that we can preoperatively identify high-risk individuals for whom extra resources can be directed postoperatively to avoid unnecessary readmissions,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[702, 3146, 151, 32, 35, 305, 1463, 1, 372, 165, 2, 47, 761, 85, 15945, 6, 6642, 26, 45, 10086, 6, 255, 3, 43, 130, 9, 573, 3146, 4, 7, 73, 20, 8, 1512, 413, 3086, 8, 67, 111, 459, 206, 1307, 1346, 1, 62, 7, 7297, 23, 20, 3, 1652, 1, 11457, 1512, 413, 3086, 54, 11, 8351, 262, 201, 162, 1, 2993, 10, 173, 4106, 74, 159, 2221, 9561, 1, 152, 1208, 3791, 12, 532, 2, 867, 484, 532, 3, 8351, 7, 78, 5812, 11, 72, 5, 1108, 715, 535, 78, 5359, 29, 3, 827, 3086, 4, 8, 2616, 98, 5331, 2, 311, 75, 880, 2, 331, 274, 4, 3, 45, 727, 24976, 3867, 11, 173, 104, 1128, 1746, 437, 991, 7, 33, 33, 11, 8351, 262, 201, 162, 1, 2993, 29, 136, 1208, 1299, 23, 331, 65, 3, 130, 17, 11, 41, 5, 8, 142, 43, 1, 3146, 11, 8, 532, 1, 6563, 34, 573, 1447, 267, 1, 1935, 221, 1396, 2, 4783, 1, 13233, 28, 3, 98, 1, 152, 3, 96, 186, 3146, 2403, 11, 930, 584, 1218, 1966, 339, 2839, 49, 1659, 4238, 39, 2, 2294, 39, 573, 5319, 32, 8, 186, 2497, 2, 32, 1635, 305, 22, 8, 1463, 1, 372, 242, 7, 11, 1228, 4319, 9, 1875, 15, 6938, 21, 120, 204, 17, 797, 130, 225, 22, 3031, 341, 2, 3331, 156, 120, 3447, 114, 74, 309, 17, 21, 122, 3888, 255, 64, 43, 869, 9, 953, 3420, 2892, 122, 40, 1166, 3541, 6, 3085, 4224, 5319]",,26332390,311
Cyclometalated Ruthenium(II) Anthraquinone Complexes Exhibit Strong Anticancer Activity in Hypoxic Tumor Cells.,"Chemistry (Weinheim an der Bergstrasse, Germany)",Chemistry,2015-09-04,"Hypoxia is the critical feature of the tumor microenvironment that is known to lead to resistance to many chemotherapeutic drugs. Six novel ruthenium(II) anthraquinone complexes were designed and synthesized; they exhibit similar or superior cytotoxicity compared to cisplatin in hypoxic HeLa, A549, and multidrug-resistant (A549R) tumor cell lines. Their anticancer activities are related to their lipophilicity and cellular uptake; therefore, these physicochemical properties of the complexes can be changed by modifying the ligands to obtain better anticancer candidates. Complex 1, the most potent member of the series, is highly active against hypoxic HeLa cancer cells (IC50 =0.53M). This complex likely has 46-fold better activity than cisplatin (IC50 =24.62M) in HeLa cells. This complex tends to accumulate in the mitochondria and the nucleus of hypoxic HeLa cells. Further mechanistic studies show that complex 1 induced cell apoptosis during hypoxia through multiple pathways, including those of DNA damage, mitochondrial dysfunction, and the inhibition of DNA replication and HIF-1 expression, making it an outstanding candidate for further in vivo studies.",Journal Article,1600.0,12.0,Hypoxia is the critical feature of the tumor microenvironment that is known to lead to resistance to many chemotherapeutic drugs Six novel ruthenium II anthraquinone complexes were designed and synthesized they exhibit similar or superior cytotoxicity compared to cisplatin in hypoxic HeLa A549 and multidrug-resistant A549R tumor cell lines Their anticancer activities are related to their lipophilicity and cellular uptake therefore these physicochemical properties of the complexes can be changed by modifying the ligands to obtain better anticancer candidates Complex 1 the most potent member of the series is highly active against hypoxic HeLa cancer cells IC50 =0.53 M This complex likely has 46-fold better activity than cisplatin IC50 =24.62 M in HeLa cells This complex tends to accumulate in the mitochondria and the nucleus of hypoxic HeLa cells Further mechanistic studies show that complex 1 induced cell apoptosis during hypoxia through multiple pathways including those of DNA damage mitochondrial dysfunction and the inhibition of DNA replication and HIF-1 expression making it an outstanding candidate for further in vivo studies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1823, 16, 3, 740, 2705, 1, 3, 30, 995, 17, 16, 440, 6, 1122, 6, 251, 6, 445, 1573, 600, 437, 229, 20133, 215, 49888, 3817, 11, 1114, 2, 5134, 491, 2239, 288, 15, 1123, 1408, 72, 6, 540, 4, 4744, 8466, 4105, 2, 4814, 436, 78146, 30, 31, 285, 136, 1475, 2042, 32, 139, 6, 136, 26111, 2, 763, 1135, 673, 46, 16312, 1571, 1, 3, 3817, 122, 40, 2368, 20, 4898, 3, 3123, 6, 3140, 380, 1475, 1931, 840, 14, 3, 96, 1157, 2693, 1, 3, 988, 16, 561, 544, 480, 4744, 8466, 12, 37, 5211, 13, 699, 4810, 26, 840, 322, 71, 641, 1116, 380, 128, 76, 540, 5211, 259, 744, 4810, 4, 8466, 37, 26, 840, 11488, 6, 7859, 4, 3, 5443, 2, 3, 4262, 1, 4744, 8466, 37, 195, 2716, 94, 514, 17, 840, 14, 277, 31, 351, 190, 1823, 298, 232, 460, 141, 135, 1, 261, 1350, 2019, 1527, 2, 3, 297, 1, 261, 2079, 2, 2940, 3305, 55, 1079, 192, 35, 14565, 1609, 9, 195, 4, 386, 94]",,26338207,268
American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2016-04-11,"American Society of Clinical Oncology (ASCO), the leading medical professional oncology society, is committed to lessening the burden of cancer and as such will promote underused interventions that have the potential to save millions of lives through cancer prevention. As the main providers of cancer care worldwide, our patients, their families, and our communities look to us for guidance regarding all things cancer related, including cancer prevention. Through this statement and accompanying recommendations, ASCO hopes to increase awareness of the tremendous global impact of human papillomavirus (HPV) -caused cancers, refocus the discussion of HPV vaccination on its likely ability to prevent millions of cancer deaths, and increase HPV vaccination uptake via greater involvement of oncology professionals in ensuring accurate public discourse about HPV vaccination and calling for the implementation of concrete strategies to address barriers to vaccine access and acceptance.",Journal Article,1380.0,46.0,American Society of Clinical Oncology ASCO the leading medical professional oncology society is committed to lessening the burden of cancer and as such will promote underused interventions that have the potential to save millions of lives through cancer prevention As the main providers of cancer care worldwide our patients their families and our communities look to us for guidance regarding all things cancer related including cancer prevention Through this statement and accompanying recommendations ASCO hopes to increase awareness of the tremendous global impact of human papillomavirus HPV -caused cancers refocus the discussion of HPV vaccination on its likely ability to prevent millions of cancer deaths and increase HPV vaccination uptake via greater involvement of oncology professionals in ensuring accurate public discourse about HPV vaccination and calling for the implementation of concrete strategies to address barriers to vaccine access and acceptance,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[597, 1174, 1, 38, 413, 2697, 3, 1049, 484, 5341, 413, 1174, 16, 9552, 6, 23627, 3, 892, 1, 12, 2, 22, 225, 303, 1617, 11166, 1151, 17, 47, 3, 174, 6, 14447, 13616, 1, 6407, 298, 12, 1070, 22, 3, 1895, 1994, 1, 12, 165, 2358, 114, 7, 136, 1954, 2, 114, 7651, 5316, 6, 843, 9, 2753, 666, 62, 22150, 12, 139, 141, 12, 1070, 298, 26, 5914, 2, 9503, 883, 2697, 10442, 6, 344, 3310, 1, 3, 6678, 1648, 345, 1, 171, 3242, 933, 1546, 163, 78390, 3, 2488, 1, 933, 1915, 23, 211, 322, 801, 6, 1682, 13616, 1, 12, 1043, 2, 344, 933, 1915, 1135, 847, 378, 799, 1, 413, 3409, 4, 8397, 1481, 3067, 20009, 545, 933, 1915, 2, 14558, 9, 3, 2393, 1, 17441, 422, 6, 1539, 2160, 6, 1274, 1655, 2, 5080]",,27069078,144
Primary Placement of Incisional Negative Pressure Wound Therapy at Time of Laparotomy for Gynecologic Malignancies.,International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,Int. J. Gynecol. Cancer,2016-10-01,"Wound complications are an important cause of postoperative morbidity amongst patient with gynecologic malignancies. We evaluated whether the placement of prophylactic negative pressure wound therapy (NPWT) at the time of laparotomy for gynecologic cancer surgery reduces wound complication rates. A retrospective analysis of patients undergoing laparotomy with primary wound closure performed by a gynecologic oncologist at a single academic institution over a 5-year study period was performed. Patients who had placement of prophylactic NPWT dressing were compared with patients with a standard closure. Postoperative outcomes were examined. A total of 230 patients were identified: 208 women received standard wound care, 22 received NPWT. Groups were similar in age, prevalence of diabetes, tobacco use, and number of previous abdominal procedures. Intraoperative factors including length of procedure and transfusion requirements were similar. Body mass index for patients receiving standard treatment was 30.67 compared with 41.29 for NPWT group (P < 0.001). Incidence of all wound complications was 19.7% for those receiving standard treatment versus 27.3% for NPWT group (P = 0.40). Length of hospital stay was similar between the 2 groups (5.25 vs 6.22 days, P = 0.20). There were 3 hospital readmissions for wound complications-none occurred in women with a prophylactic NPWT dressing. Despite significantly higher obesity rates, patients with prophylactic NPWT dressing placement had similar rates of wound complications. Our findings suggest a potential therapeutic benefit in the use of prophylactic NPWT for the reduction of wound complications in this high-risk gynecologic oncology patient population.",Journal Article,1207.0,8.0,Wound complications are an important cause of postoperative morbidity amongst patient with gynecologic malignancies We evaluated whether the placement of prophylactic negative pressure wound therapy NPWT at the time of laparotomy for gynecologic cancer surgery reduces wound complication rates A retrospective analysis of patients undergoing laparotomy with primary wound closure performed by a gynecologic oncologist at a single academic institution over a 5-year study period was performed Patients who had placement of prophylactic NPWT dressing were compared with patients with a standard closure Postoperative outcomes were examined A total of 230 patients were identified 208 women received standard wound care 22 received NPWT Groups were similar in age prevalence of diabetes tobacco use and number of previous abdominal procedures Intraoperative factors including length of procedure and transfusion requirements were similar Body mass index for patients receiving standard treatment was 30.67 compared with 41.29 for NPWT group P 0.001 Incidence of all wound complications was 19.7 for those receiving standard treatment versus 27.3 for NPWT group P 0.40 Length of hospital stay was similar between the 2 groups 5.25 vs 6.22 days P 0.20 There were 3 hospital readmissions for wound complications-none occurred in women with a prophylactic NPWT dressing Despite significantly higher obesity rates patients with prophylactic NPWT dressing placement had similar rates of wound complications Our findings suggest a potential therapeutic benefit in the use of prophylactic NPWT for the reduction of wound complications in this high-risk gynecologic oncology patient population,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[2689, 521, 32, 35, 305, 708, 1, 573, 787, 7212, 69, 5, 1512, 441, 21, 194, 317, 3, 2613, 1, 1862, 199, 3738, 2689, 36, 22467, 28, 3, 98, 1, 3274, 9, 1512, 12, 152, 2389, 2689, 1447, 151, 8, 459, 65, 1, 7, 479, 3274, 5, 86, 2689, 4830, 173, 20, 8, 1512, 2709, 28, 8, 226, 1916, 731, 252, 8, 33, 111, 45, 727, 10, 173, 7, 54, 42, 2613, 1, 1862, 22467, 23302, 11, 72, 5, 7, 5, 8, 260, 4830, 573, 123, 11, 409, 8, 181, 1, 6136, 7, 11, 108, 5920, 117, 103, 260, 2689, 165, 350, 103, 22467, 271, 11, 288, 4, 89, 1078, 1, 1978, 2607, 119, 2, 207, 1, 698, 1467, 1369, 1720, 130, 141, 1318, 1, 1299, 2, 2785, 4230, 11, 288, 642, 782, 558, 9, 7, 357, 260, 24, 10, 201, 598, 72, 5, 605, 462, 9, 22467, 87, 19, 13, 144, 287, 1, 62, 2689, 521, 10, 326, 67, 9, 135, 357, 260, 24, 185, 428, 27, 9, 22467, 87, 19, 13, 327, 1318, 1, 702, 2020, 10, 288, 59, 3, 18, 271, 33, 243, 105, 49, 350, 162, 19, 13, 179, 125, 11, 27, 702, 5319, 9, 2689, 521, 1292, 489, 4, 117, 5, 8, 1862, 22467, 23302, 550, 97, 142, 1661, 151, 7, 5, 1862, 22467, 23302, 2613, 42, 288, 151, 1, 2689, 521, 114, 272, 309, 8, 174, 189, 247, 4, 3, 119, 1, 1862, 22467, 9, 3, 628, 1, 2689, 521, 4, 26, 64, 43, 1512, 413, 69, 266]",,27488215,84
Safety and Local Control of Radiation Therapy for Chordoma of the Spine and Sacrum: A Systematic Review.,Spine,Spine,2016-10-01,"Systematic literature review. To assess the toxicity, common radiation doses, and local control (LC) rates of radiation therapy for chordoma of the spine and sacrum and identify the difference in LC and toxicity between adjuvant, salvage, and primary therapy using radiation. Chordoma of the spine is typically a low-grade malignant tumor thought to be relatively radioresistant with a high rate of local recurrence and the potential for metastases. Improved results of modern radiation therapy in the treatment of chordoma support exploration of its role in the management of primary/de novo chordoma or recurrent chordoma. We conducted a systematic literature review using PubMed and Embase databases to assess information available regarding the toxicity, LC rates, and overall survival (OS) rates for adjuvant, salvage, and primary radiation therapy for spinal and sacral chordoma. A total of 40 articles were reviewed. Evidence quality was low or very low. The highest rates of LC and OS were with early adjuvant RT for primary/de novo disease. Salvage RT for recurrent disease has very small cohorts and thus strong conclusions were not able be made. The use of pre- and/or post-operative photon image-guided radiotherapy (IGRT), proton or carbon ion therapy should be considered for patients undergoing surgery for the treatment of primary and recurrent chordomas in the mobile spine and sacrum, since these RT modalities may improve local control. Preoperative evaluation by the surgeon and radiation oncologist should be used to formulate a cohesive treatment plan.The use of photon IGRT or carbon ion therapy as the primary treatment of chordoma, when currently in its developmental stage, shows promise and requires clear delineation of toxicity profile and long-term local control. 2.",Journal Article,1207.0,33.0,Systematic literature review To assess the toxicity common radiation doses and local control LC rates of radiation therapy for chordoma of the spine and sacrum and identify the difference in LC and toxicity between adjuvant salvage and primary therapy using radiation Chordoma of the spine is typically a low-grade malignant tumor thought to be relatively radioresistant with a high rate of local recurrence and the potential for metastases Improved results of modern radiation therapy in the treatment of chordoma support exploration of its role in the management of primary/de novo chordoma or recurrent chordoma We conducted a systematic literature review using PubMed and Embase databases to assess information available regarding the toxicity LC rates and overall survival OS rates for adjuvant salvage and primary radiation therapy for spinal and sacral chordoma A total of 40 articles were reviewed Evidence quality was low or very low The highest rates of LC and OS were with early adjuvant RT for primary/de novo disease Salvage RT for recurrent disease has very small cohorts and thus strong conclusions were not able be made The use of pre- and/or post-operative photon image-guided radiotherapy IGRT proton or carbon ion therapy should be considered for patients undergoing surgery for the treatment of primary and recurrent chordomas in the mobile spine and sacrum since these RT modalities may improve local control Preoperative evaluation by the surgeon and radiation oncologist should be used to formulate a cohesive treatment plan.The use of photon IGRT or carbon ion therapy as the primary treatment of chordoma when currently in its developmental stage shows promise and requires clear delineation of toxicity profile and long-term local control 2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[1556, 789, 206, 6, 423, 3, 155, 186, 121, 415, 2, 293, 182, 1837, 151, 1, 121, 36, 9, 3911, 1, 3, 2342, 2, 11629, 2, 255, 3, 523, 4, 1837, 2, 155, 59, 249, 992, 2, 86, 36, 75, 121, 3911, 1, 3, 2342, 16, 1969, 8, 154, 88, 393, 30, 2739, 6, 40, 1352, 7092, 5, 8, 64, 116, 1, 293, 146, 2, 3, 174, 9, 196, 231, 99, 1, 2366, 121, 36, 4, 3, 24, 1, 3911, 538, 3370, 1, 211, 200, 4, 3, 284, 1, 86, 1566, 2018, 3911, 15, 387, 3911, 21, 426, 8, 1556, 789, 206, 75, 3161, 2, 4995, 2348, 6, 423, 487, 390, 666, 3, 155, 1837, 151, 2, 63, 25, 118, 151, 9, 249, 992, 2, 86, 121, 36, 9, 1499, 2, 7943, 3911, 8, 181, 1, 327, 2384, 11, 446, 241, 372, 10, 154, 15, 923, 154, 3, 1076, 151, 1, 1837, 2, 118, 11, 5, 191, 249, 240, 9, 86, 1566, 2018, 34, 992, 240, 9, 387, 34, 71, 923, 302, 736, 2, 631, 1082, 2130, 11, 44, 1665, 40, 1229, 3, 119, 1, 671, 2, 15, 539, 1208, 4216, 1482, 1808, 310, 7901, 2095, 15, 5183, 7714, 36, 257, 40, 515, 9, 7, 479, 152, 9, 3, 24, 1, 86, 2, 387, 6790, 4, 3, 7489, 2342, 2, 11629, 1192, 46, 240, 1558, 68, 401, 293, 182, 498, 451, 20, 3, 1897, 2, 121, 2709, 257, 40, 95, 6, 10992, 8, 21497, 24, 2242, 3, 119, 1, 4216, 7901, 15, 5183, 7714, 36, 22, 3, 86, 24, 1, 3911, 198, 694, 4, 211, 4566, 82, 1949, 1783, 2, 1706, 885, 5529, 1, 155, 800, 2, 319, 337, 293, 182, 18]",,27509195,206
An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations.,Gynecologic oncology,Gynecol. Oncol.,2017-03-31,"Gynecologic cancers account for ~12% of all new cancer cases in women and ~15% of all female cancer survivors. Current and continued advances within the field have resulted in long-term outcomes and a high rate of survivors. Therefore determining the most cost-effective clinical surveillance for detection of recurrence is critical. Unfortunately, there has been a paucity of research regarding the most effective strategies for surveillance after patients have achieved a complete response. Currently, most recommendations are based on retrospective studies and expert opinion. Taking a thorough history, performing a thorough examination, and educating cancer survivors about concerning symptoms are the most effective methods for the detection of most gynecologic cancer recurrences. There is very little evidence that routine cytology or imaging improves the ability to detect gynecologic cancer recurrence that will impact cure or response rates to salvage therapy. This article provides an update on surveillance for gynecologic cancer recurrence in women who have had a complete response to primary cancer therapy.",Journal Article,1026.0,41.0,Gynecologic cancers account for ~12 of all new cancer cases in women and ~15 of all female cancer survivors Current and continued advances within the field have resulted in long-term outcomes and a high rate of survivors Therefore determining the most cost-effective clinical surveillance for detection of recurrence is critical Unfortunately there has been a paucity of research regarding the most effective strategies for surveillance after patients have achieved a complete response Currently most recommendations are based on retrospective studies and expert opinion Taking a thorough history performing a thorough examination and educating cancer survivors about concerning symptoms are the most effective methods for the detection of most gynecologic cancer recurrences There is very little evidence that routine cytology or imaging improves the ability to detect gynecologic cancer recurrence that will impact cure or response rates to salvage therapy This article provides an update on surveillance for gynecologic cancer recurrence in women who have had a complete response to primary cancer therapy,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[1512, 163, 1967, 9, 133, 1, 62, 217, 12, 140, 4, 117, 2, 167, 1, 62, 1061, 12, 332, 291, 2, 1351, 954, 262, 3, 1067, 47, 627, 4, 319, 337, 123, 2, 8, 64, 116, 1, 332, 673, 2196, 3, 96, 835, 323, 38, 617, 9, 638, 1, 146, 16, 740, 3869, 125, 71, 85, 8, 4832, 1, 389, 666, 3, 96, 323, 422, 9, 617, 50, 7, 47, 513, 8, 236, 51, 694, 96, 883, 32, 90, 23, 459, 94, 2, 2005, 3564, 2727, 8, 5506, 532, 3620, 8, 5506, 1385, 2, 14452, 12, 332, 545, 4243, 507, 32, 3, 96, 323, 636, 9, 3, 638, 1, 96, 1512, 12, 1593, 125, 16, 923, 1215, 241, 17, 1311, 2045, 15, 270, 1804, 3, 801, 6, 1426, 1512, 12, 146, 17, 303, 345, 1722, 15, 51, 151, 6, 992, 36, 26, 946, 777, 35, 2991, 23, 617, 9, 1512, 12, 146, 4, 117, 54, 47, 42, 8, 236, 51, 6, 86, 12, 36]",,28372871,753
High-Risk Human Papillomavirus E7 Alters Host DNA Methylome and Represses HLA-E Expression in Human Keratinocytes.,Scientific reports,Sci Rep,2017-06-16,"Human papillomavirus (HPV) infection distinctly alters methylation patterns in HPV-associated cancer. We have recently reported that HPV E7-dependent promoter hypermethylation leads to downregulation of the chemokine CXCL14 and suppression of antitumor immune responses. To investigate the extent of gene expression dysregulated by HPV E7-induced DNA methylation, we analyzed parallel global gene expression and DNA methylation using normal immortalized keratinocyte lines, NIKS, NIKS-16, NIKS-18, and NIKS-16E7. We show that expression of the MHC class I genes is downregulated in HPV-positive keratinocytes in an E7-dependent manner. Methylome analysis revealed hypermethylation at a distal CpG island (CGI) near the HLA-E gene in NIKS-16 cells compared to either NIKS cells or NIKS-16E7 cells, which lack E7 expression. The HLA-E CGI functions as an active promoter element which is dramatically repressed by DNA methylation. HLA-E protein expression on cell surface is downregulated by high-risk HPV16 and HPV18 E7 expression, but not by low-risk HPV6 and HPV11 E7 expression. Conversely, demethylation at the HLA-E CGI restores HLA-E protein expression in HPV-positive keratinocytes. Because HLA-E plays an important role in antiviral immunity by regulating natural killer and CD8<sup>+</sup> T cells, epigenetic downregulation of HLA-E by high-risk HPV E7 may contribute to virus-induced immune evasion during HPV persistence.",Journal Article,949.0,15.0,Human papillomavirus HPV infection distinctly alters methylation patterns in HPV-associated cancer We have recently reported that HPV E7-dependent promoter hypermethylation leads to downregulation of the chemokine CXCL14 and suppression of antitumor immune responses To investigate the extent of gene expression dysregulated by HPV E7-induced DNA methylation we analyzed parallel global gene expression and DNA methylation using normal immortalized keratinocyte lines NIKS NIKS-16 NIKS-18 and NIKS-16E7 We show that expression of the MHC class I genes is downregulated in HPV-positive keratinocytes in an E7-dependent manner Methylome analysis revealed hypermethylation at a distal CpG island CGI near the HLA-E gene in NIKS-16 cells compared to either NIKS cells or NIKS-16E7 cells which lack E7 expression The HLA-E CGI functions as an active promoter element which is dramatically repressed by DNA methylation HLA-E protein expression on cell surface is downregulated by high-risk HPV16 and HPV18 E7 expression but not by low-risk HPV6 and HPV11 E7 expression Conversely demethylation at the HLA-E CGI restores HLA-E protein expression in HPV-positive keratinocytes Because HLA-E plays an important role in antiviral immunity by regulating natural killer and CD8 sup /sup T cells epigenetic downregulation of HLA-E by high-risk HPV E7 may contribute to virus-induced immune evasion during HPV persistence,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[171, 3242, 933, 930, 9452, 6745, 569, 764, 4, 933, 41, 12, 21, 47, 761, 210, 17, 933, 4540, 470, 973, 2575, 1940, 6, 2475, 1, 3, 3596, 18390, 2, 1332, 1, 579, 250, 253, 6, 963, 3, 1039, 1, 145, 55, 4288, 20, 933, 4540, 277, 261, 569, 21, 311, 2755, 1648, 145, 55, 2, 261, 569, 75, 295, 6090, 14065, 285, 27814, 27814, 245, 27814, 203, 2, 27814, 52478, 21, 514, 17, 55, 1, 3, 3658, 1040, 70, 214, 16, 3315, 4, 933, 109, 9587, 4, 35, 4540, 470, 1708, 11362, 65, 553, 2575, 28, 8, 2107, 2075, 3454, 18180, 1829, 3, 1160, 563, 145, 4, 27814, 245, 37, 72, 6, 361, 27814, 37, 15, 27814, 52478, 37, 92, 926, 4540, 55, 3, 1160, 563, 18180, 1681, 22, 35, 544, 973, 4467, 92, 16, 2729, 6654, 20, 261, 569, 1160, 563, 178, 55, 23, 31, 1255, 16, 3315, 20, 64, 43, 4048, 2, 33514, 4540, 55, 84, 44, 20, 154, 43, 41407, 2, 78976, 4540, 55, 3154, 6800, 28, 3, 1160, 563, 18180, 8489, 1160, 563, 178, 55, 4, 933, 109, 9587, 408, 1160, 563, 1698, 35, 305, 200, 4, 6264, 1604, 20, 2681, 1504, 3458, 2, 968, 172, 172, 102, 37, 1418, 2475, 1, 1160, 563, 20, 64, 43, 933, 4540, 68, 1248, 6, 1450, 277, 250, 5351, 190, 933, 4108]",,28623356,548
Modified En Bloc Spondylectomy for Tumors of the Thoracic and Lumbar Spine: Surgical Technique and Outcomes.,The Journal of bone and joint surgery. American volume,J Bone Joint Surg Am,2017-09-01,"Total en bloc spondylectomy (TES) for the treatment of spinal tumors decreases local recurrence and improves survival compared with intralesional resection. TES approaches vary in both the number of stages to complete the procedure and instruments with which osteotomies are performed. We describe a 2-stage technique that employs the use of threadwire saws. We performed a retrospective review of cases of primary tumors and solitary metastases involving the thoracic or lumbar spine treated with use of our modified technique at our institution between 2010 and 2016, identifying eligible patients by searching for specific phrases in operative reports found in our oncologic database. Clinical notes, operative notes, imaging reports, and pathology reports were reviewed for all patients. Thirty-three patients underwent our modified technique, in which we pass a threadwire saw between the vertebral body and the thecal sac. The most common tumor type was chordoma (64%), and tumors were most commonly located in the lumbar spine (61%). There were no intraoperative injuries to the spinal cord or great vessels. One patient experienced a dural tear secondary to the passage of a saw. Seventeen (52%) of the patients had perioperative complications, with 1 death. Seven (22%) of the patients had complications occurring within 90 days after discharge, and 8 (25%) had complications occurring >90 days after discharge. Instrumentation failure was observed in 8 cases (25%). Negative margins were obtained in 94% of the cases. Local recurrence was observed in 2 cases (6%). The majority of patients had normal motor function at the time of the most recent follow-up. Our modified en bloc spondylectomy represents an effective technique for the resection of spinal tumors in selected patients, allowing for visualization of vessels anterior to the spine and the avoidance of spinal cord injury. Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.",Journal Article,872.0,7.0,Total en bloc spondylectomy TES for the treatment of spinal tumors decreases local recurrence and improves survival compared with intralesional resection TES approaches vary in both the number of stages to complete the procedure and instruments with which osteotomies are performed We describe a 2-stage technique that employs the use of threadwire saws We performed a retrospective review of cases of primary tumors and solitary metastases involving the thoracic or lumbar spine treated with use of our modified technique at our institution between 2010 and 2016 identifying eligible patients by searching for specific phrases in operative reports found in our oncologic database Clinical notes operative notes imaging reports and pathology reports were reviewed for all patients Thirty-three patients underwent our modified technique in which we pass a threadwire saw between the vertebral body and the thecal sac The most common tumor type was chordoma 64 and tumors were most commonly located in the lumbar spine 61 There were no intraoperative injuries to the spinal cord or great vessels One patient experienced a dural tear secondary to the passage of a saw Seventeen 52 of the patients had perioperative complications with 1 death Seven 22 of the patients had complications occurring within 90 days after discharge and 8 25 had complications occurring 90 days after discharge Instrumentation failure was observed in 8 cases 25 Negative margins were obtained in 94 of the cases Local recurrence was observed in 2 cases 6 The majority of patients had normal motor function at the time of the most recent follow-up Our modified en bloc spondylectomy represents an effective technique for the resection of spinal tumors in selected patients allowing for visualization of vessels anterior to the spine and the avoidance of spinal cord injury Therapeutic Level IV See Instructions for Authors for a complete description of levels of evidence,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[181, 4375, 5590, 52493, 21037, 9, 3, 24, 1, 1499, 57, 2140, 293, 146, 2, 1804, 25, 72, 5, 7549, 170, 21037, 611, 2825, 4, 110, 3, 207, 1, 1153, 6, 236, 3, 1299, 2, 4730, 5, 92, 79066, 32, 173, 21, 897, 8, 18, 82, 1312, 17, 15151, 3, 119, 1, 52494, 79067, 21, 173, 8, 459, 206, 1, 140, 1, 86, 57, 2, 3144, 196, 1267, 3, 2098, 15, 6187, 2342, 73, 5, 119, 1, 114, 1230, 1312, 28, 114, 731, 59, 1120, 2, 1390, 1386, 625, 7, 20, 10082, 9, 112, 34516, 4, 1208, 1198, 204, 4, 114, 1998, 609, 38, 8192, 1208, 8192, 270, 1198, 2, 1117, 1198, 11, 446, 9, 62, 7, 977, 169, 7, 208, 114, 1230, 1312, 4, 92, 21, 10152, 8, 52494, 9257, 59, 3, 4731, 642, 2, 3, 17060, 7948, 3, 96, 186, 30, 267, 10, 3911, 660, 2, 57, 11, 96, 841, 2308, 4, 3, 6187, 2342, 713, 125, 11, 77, 1720, 13063, 6, 3, 1499, 1885, 15, 2797, 3102, 104, 69, 592, 8, 11124, 17639, 568, 6, 3, 7740, 1, 8, 9257, 3591, 653, 1, 3, 7, 42, 1547, 521, 5, 14, 273, 648, 350, 1, 3, 7, 42, 521, 1821, 262, 424, 162, 50, 2993, 2, 66, 243, 42, 521, 1821, 424, 162, 50, 2993, 9166, 496, 10, 164, 4, 66, 140, 243, 199, 1012, 11, 683, 4, 960, 1, 3, 140, 293, 146, 10, 164, 4, 18, 140, 49, 3, 686, 1, 7, 42, 295, 3482, 343, 28, 3, 98, 1, 3, 96, 435, 166, 126, 114, 1230, 4375, 5590, 52493, 1449, 35, 323, 1312, 9, 3, 170, 1, 1499, 57, 4, 715, 7, 2952, 9, 6234, 1, 3102, 2882, 6, 3, 2342, 2, 3, 5863, 1, 1499, 1885, 2730, 189, 301, 478, 3764, 14875, 9, 738, 9, 8, 236, 5263, 1, 148, 1, 241]",,28872530,463
Postoperative Complications Drive Unplanned Readmissions After Esophagectomy for Cancer.,The Annals of thoracic surgery,Ann. Thorac. Surg.,2018-01-31,"Hospital readmissions are increasingly viewed as a marker of inferior health care quality and penalized with decreased reimbursement. The timing of, and reasons for, readmissions after esophagectomy for cancer are not well understood. We examined the association of complications to 30-day postoperative-related, unplanned readmission to identify opportunities for improvement in patient care. We analyzed the American College of Surgeons National Surgical Quality Improvement Program database (2012 to 2015) to characterize 30-day postoperative unplanned readmissions after esophagectomy for cancer using descriptive statistics. Type and timing of readmission after discharge was assessed. A Cox proportional hazards model was developed to identify predictors of readmission. Of 3,723 patients who underwent esophagectomy for cancer, 1,419 (38.1%) experienced 1 complication within 30 days. A total of 400 patients (10.7%) experienced related, unplanned readmissions within 30 days of the operation, and postoperative complications were documented in 263 (65.8%). Leading causes of readmission were infectious, pulmonary, and gastrointestinal complications. Of these patients, 155 (59%) were readmitted within 7 days and 236 (90%) within 14 days of discharge. The Cox proportional hazards model identified readmission being associated with occurrence of postdischarge infectious, pulmonary, venous thromboembolic, and urinary tract infection complications, in-hospital urinary tract infection complications, and log-transformation of length of stay (representing increasing length of stay) (all p < 0.05). Postoperative occurrence of common complications and prolonged length of stay are associated with unplanned readmission after esophagectomy. Most patients are readmitted within 1 week of discharge. Earlier follow-up after discharge may identify patients with complications and facilitate outpatient intervention to prevent readmission.",Journal Article,720.0,13.0,"Hospital readmissions are increasingly viewed as a marker of inferior health care quality and penalized with decreased reimbursement The timing of and reasons for readmissions after esophagectomy for cancer are not well understood We examined the association of complications to 30-day postoperative-related unplanned readmission to identify opportunities for improvement in patient care We analyzed the American College of Surgeons National Surgical Quality Improvement Program database 2012 to 2015 to characterize 30-day postoperative unplanned readmissions after esophagectomy for cancer using descriptive statistics Type and timing of readmission after discharge was assessed A Cox proportional hazards model was developed to identify predictors of readmission Of 3,723 patients who underwent esophagectomy for cancer 1,419 38.1 experienced 1 complication within 30 days A total of 400 patients 10.7 experienced related unplanned readmissions within 30 days of the operation and postoperative complications were documented in 263 65.8 Leading causes of readmission were infectious pulmonary and complications Of these patients 155 59 were readmitted within 7 days and 236 90 within 14 days of discharge The Cox proportional hazards model identified readmission being associated with occurrence of postdischarge infectious pulmonary venous thromboembolic and urinary tract infection complications in-hospital urinary tract infection complications and log-transformation of length of stay representing increasing length of stay all p 0.05 Postoperative occurrence of common complications and prolonged length of stay are associated with unplanned readmission after esophagectomy Most patients are readmitted within 1 week of discharge Earlier follow-up after discharge may identify patients with complications and facilitate outpatient intervention to prevent readmission",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,"[702, 5319, 32, 1635, 7879, 22, 8, 952, 1, 1663, 341, 165, 372, 2, 19806, 5, 340, 6642, 3, 1972, 1, 2, 2325, 9, 5319, 50, 3617, 9, 12, 32, 44, 149, 1784, 21, 409, 3, 248, 1, 521, 6, 201, 218, 573, 139, 5851, 3146, 6, 255, 2605, 9, 767, 4, 69, 165, 21, 311, 3, 597, 2979, 1, 1613, 657, 221, 372, 767, 1243, 609, 1195, 6, 1483, 6, 1507, 201, 218, 573, 5851, 5319, 50, 3617, 9, 12, 75, 3778, 3065, 267, 2, 1972, 1, 3146, 50, 2993, 10, 275, 8, 418, 831, 1017, 202, 10, 276, 6, 255, 674, 1, 3146, 1, 27, 14555, 7, 54, 208, 3617, 9, 12, 14, 10469, 519, 14, 592, 3567, 1447, 262, 201, 162, 8, 181, 1, 1524, 7, 79, 67, 592, 139, 5851, 5319, 262, 201, 162, 1, 3, 2589, 2, 573, 521, 11, 1405, 4, 6098, 556, 66, 1049, 1626, 1, 3146, 11, 3398, 1087, 2, 521, 1, 46, 7, 3735, 728, 11, 8351, 262, 67, 162, 2, 6383, 424, 262, 213, 162, 1, 2993, 3, 418, 831, 1017, 202, 108, 3146, 486, 41, 5, 2291, 1, 15407, 3398, 1087, 2167, 4703, 2, 1660, 1696, 930, 521, 4, 702, 1660, 1696, 930, 521, 2, 1066, 1392, 1, 1318, 1, 2020, 2861, 602, 1318, 1, 2020, 62, 19, 13, 474, 573, 2291, 1, 186, 521, 2, 1069, 1318, 1, 2020, 32, 41, 5, 5851, 3146, 50, 3617, 96, 7, 32, 8351, 262, 14, 647, 1, 2993, 1677, 166, 126, 50, 2993, 68, 255, 7, 5, 521, 2, 1876, 2379, 788, 6, 1682, 3146]",,29373825,849
An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers.,Clinical therapeutics,Clin Ther,2018-03-09,"The goal of this study was to compile a review of topics pertinent to the use of immune checkpoint inhibitors in gynecologic malignancies, including foundation for use, current agents available and trials in gynecologic cancers, special populations of interest, identification and management of toxicities, and considerations in predictive biomarkers and response assessment. A literature review of selected topics in reference to immune checkpoint inhibitors and gynecologic cancers was conducted on PubMed and the US Food and Drug Administration drug search application. A review of current and ongoing clinical trials was performed in clinicaltrials.gov, and selected preliminary results reported in PubMed abstracts and through the American Society of Clinical Oncologists were compiled. Although immunotherapy in gynecologic malignancy is relatively new, 7 agents are currently approved for use in other oncologic indications, and a multitude of trials in gynecologic cancer are ongoing. Immunotherapy has a specific set of drug toxicities that manifest and are managed unlike traditional cytotoxic therapies. Application of the knowledge of immune checkpoint inhibitor use in gynecologic cancers will improve care for women with cancers of the female reproductive tract. As more complex and newer immunotherapies evolve, it will be vital to accurately characterize each specific drug class and management thereof.",Journal Article,683.0,8.0,The goal of this study was to compile a review of topics pertinent to the use of immune checkpoint inhibitors in gynecologic malignancies including foundation for use current agents available and trials in gynecologic cancers special populations of interest identification and management of toxicities and considerations in predictive biomarkers and response assessment A literature review of selected topics in reference to immune checkpoint inhibitors and gynecologic cancers was conducted on PubMed and the US Food and Drug Administration drug search application A review of current and ongoing clinical trials was performed in clinicaltrials.gov and selected preliminary results reported in PubMed abstracts and through the American Society of Clinical Oncologists were compiled Although immunotherapy in gynecologic malignancy is relatively new 7 agents are currently approved for use in other oncologic indications and a multitude of trials in gynecologic cancer are ongoing Immunotherapy has a specific set of drug toxicities that manifest and are managed unlike traditional cytotoxic therapies Application of the knowledge of immune checkpoint inhibitor use in gynecologic cancers will improve care for women with cancers of the female reproductive tract As more complex and newer immunotherapies evolve it will be vital to accurately characterize each specific drug class and management thereof,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3, 1326, 1, 26, 45, 10, 6, 26528, 8, 206, 1, 4461, 5799, 6, 3, 119, 1, 250, 986, 222, 4, 1512, 441, 141, 3247, 9, 119, 291, 183, 390, 2, 143, 4, 1512, 163, 3714, 1184, 1, 1333, 911, 2, 284, 1, 385, 2, 3891, 4, 464, 582, 2, 51, 455, 8, 789, 206, 1, 715, 4461, 4, 2482, 6, 250, 986, 222, 2, 1512, 163, 10, 426, 23, 3161, 2, 3, 843, 1773, 2, 234, 634, 234, 1901, 1581, 8, 206, 1, 291, 2, 942, 38, 143, 10, 173, 4, 1252, 1239, 2, 715, 1676, 99, 210, 4, 3161, 5159, 2, 298, 3, 597, 1174, 1, 38, 1339, 11, 8535, 242, 726, 4, 1512, 710, 16, 1352, 217, 67, 183, 32, 694, 850, 9, 119, 4, 127, 1998, 2406, 2, 8, 9540, 1, 143, 4, 1512, 12, 32, 942, 726, 71, 8, 112, 916, 1, 234, 385, 17, 7633, 2, 32, 2231, 4246, 1847, 759, 235, 1581, 1, 3, 922, 1, 250, 986, 230, 119, 4, 1512, 163, 303, 401, 165, 9, 117, 5, 163, 1, 3, 1061, 3705, 1696, 22, 80, 840, 2, 2246, 2811, 4800, 192, 303, 40, 3511, 6, 2141, 1507, 296, 112, 234, 1040, 2, 284, 13902]",,29530456,724
Consideration of older patients for enrollment in phase 1 clinical trials: Exploring treatment related toxicities and outcomes.,Gynecologic oncology,Gynecol. Oncol.,2018-04-01,"Age imposes a disparity in the treatment of and outcomes with gynecologic cancer. Older patients are underrepresented in primary treatment trials, but little is known about their ability to withstand trial-based treatment for recurrent or refractory disease. This study sought to examine treatment-related toxicities and outcomes of older versus younger patients participating in phase 1 clinical trials. A retrospective analysis of patients enrolled in phase 1 clinical trials for gynecologic malignancies from 2010 to 2016 was performed. Demographic and clinic-pathologic data was abstracted. Toxicities were defined as either grade III or IV by CTCAE criteria. Best response was calculated using RECIST criteria. Associations between categorical variables were determined using Fisher's exact test and continuous variables using Wilcoxon rank sum test. Survival was estimated using the Kaplan-Meier method. 237 patients were included with 22% (n=51) comprising the older cohort (70years). The vast majority (98%) were treated for recurrent disease. Older patients incurred similar grade III/IV hematologic (21% vs 16%, p=0.38) and non-hematologic toxicities (26% vs 29%, p=0.64). Older patients discontinued treatment due to toxicity only 8% of the time. Median survival was 13.0 and 10.3months in the <70 and 70 groups, respectively (p=0.35). 63% of patients 70 achieved clinical benefit. Although historically older patients have not been routinely considered for enrollment in phase 1 trials, our data demonstrates similar toxicity profiles to that of younger patients and 63% clinical benefit rate. Thus, with careful selection, patients 70 should be considered when facing recurrent or refractory gynecologic cancer.",Journal Article,660.0,3.0,Age imposes a disparity in the treatment of and outcomes with gynecologic cancer Older patients are underrepresented in primary treatment trials but little is known about their ability to withstand trial-based treatment for recurrent or refractory disease This study sought to examine treatment-related toxicities and outcomes of older versus younger patients participating in phase 1 clinical trials A retrospective analysis of patients enrolled in phase 1 clinical trials for gynecologic malignancies from 2010 to 2016 was performed Demographic and clinic-pathologic data was abstracted Toxicities were defined as either grade III or IV by CTCAE criteria Best response was calculated using RECIST criteria Associations between categorical variables were determined using Fisher 's exact test and continuous variables using Wilcoxon rank sum test Survival was estimated using the Kaplan-Meier method 237 patients were included with 22 n=51 comprising the older cohort 70years The vast majority 98 were treated for recurrent disease Older patients incurred similar grade III/IV hematologic 21 vs 16 p=0.38 and non-hematologic toxicities 26 vs 29 p=0.64 Older patients discontinued treatment due to toxicity only 8 of the time Median survival was 13.0 and 10.3months in the 70 and 70 groups respectively p=0.35 63 of patients 70 achieved clinical benefit Although historically older patients have not been routinely considered for enrollment in phase 1 trials our data demonstrates similar toxicity profiles to that of younger patients and 63 clinical benefit rate Thus with careful selection patients 70 should be considered when facing recurrent or refractory gynecologic cancer,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[89, 35670, 8, 4326, 4, 3, 24, 1, 2, 123, 5, 1512, 12, 434, 7, 32, 9900, 4, 86, 24, 143, 84, 1215, 16, 440, 545, 136, 801, 6, 21330, 160, 90, 24, 9, 387, 15, 430, 34, 26, 45, 990, 6, 1004, 24, 139, 385, 2, 123, 1, 434, 185, 773, 7, 3052, 4, 124, 14, 38, 143, 8, 459, 65, 1, 7, 346, 4, 124, 14, 38, 143, 9, 1512, 441, 29, 1120, 6, 1390, 10, 173, 1540, 2, 1188, 510, 74, 10, 4106, 385, 11, 395, 22, 361, 88, 316, 15, 478, 20, 3898, 371, 824, 51, 10, 981, 75, 1834, 371, 685, 59, 5982, 682, 11, 509, 75, 3135, 292, 2472, 412, 2, 1314, 682, 75, 3896, 1026, 3216, 412, 25, 10, 661, 75, 3, 876, 882, 596, 7296, 7, 11, 159, 5, 350, 78, 725, 3538, 3, 434, 180, 24115, 3, 4337, 686, 1096, 11, 73, 9, 387, 34, 434, 7, 11172, 288, 88, 316, 478, 813, 239, 105, 245, 19, 13, 519, 2, 220, 813, 385, 432, 105, 462, 19, 13, 660, 434, 7, 2402, 24, 520, 6, 155, 158, 66, 1, 3, 98, 52, 25, 10, 233, 13, 2, 79, 18669, 4, 3, 431, 2, 6146, 271, 106, 19, 13, 465, 676, 1, 7, 6146, 513, 38, 247, 242, 3578, 434, 7, 47, 44, 85, 3066, 515, 9, 1798, 4, 124, 14, 143, 114, 74, 1902, 288, 155, 1241, 6, 17, 1, 773, 7, 2, 676, 38, 247, 116, 631, 5, 3465, 881, 7, 6146, 257, 40, 515, 198, 7917, 387, 15, 430, 1512, 12]",,29605046,193
"Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas.",Cell reports,Cell Rep,2018-04-01,"This integrated, multiplatform PanCancer Atlas study co-mapped and identified distinguishing molecular features of squamous cell carcinomas (SCCs) from five sites associated with smoking and/or human papillomavirus (HPV). SCCs harbor 3q, 5p, and other recurrent chromosomal copy-number alterations (CNAs), DNA mutations, and/or aberrant methylation of genes and microRNAs, which are correlated with the expression of multi-gene programs linked to squamous cell stemness, epithelial-to-mesenchymal differentiation, growth, genomic integrity, oxidative damage, death, and inflammation. Low-CNA SCCs tended to be HPV(+) and display hypermethylation with repression of TET1 demethylase and FANCF, previously linked to predisposition to SCC, or harbor mutations affecting CASP8, RAS-MAPK pathways, chromatin modifiers, and immunoregulatory molecules. We uncovered hypomethylation of the alternative promoter that drives expression of the Np63 oncogene and embedded miR944. Co-expression of immune checkpoint, T-regulatory, and Myeloid suppressor cells signatures may explain reduced efficacyof immune therapy. These findings support possibilities for molecular classification and therapeutic approaches.",Journal Article,660.0,41.0,This integrated multiplatform PanCancer Atlas study co-mapped and identified distinguishing molecular features of squamous cell carcinomas SCCs from five sites associated with smoking and/or human papillomavirus HPV SCCs harbor 3q 5p and other recurrent chromosomal copy-number alterations CNAs DNA mutations and/or aberrant methylation of genes and microRNAs which are correlated with the expression of multi-gene programs linked to squamous cell stemness epithelial-to-mesenchymal differentiation growth genomic integrity oxidative damage death and inflammation Low-CNA SCCs tended to be HPV and display hypermethylation with repression of TET1 demethylase and FANCF previously linked to predisposition to SCC or harbor mutations affecting CASP8 RAS-MAPK pathways chromatin modifiers and immunoregulatory molecules We uncovered hypomethylation of the alternative promoter that drives expression of the Np63 oncogene and embedded miR944 Co-expression of immune checkpoint T-regulatory and Myeloid suppressor cells signatures may explain reduced efficacy of immune therapy These findings support possibilities for molecular classification and therapeutic approaches,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[26, 2102, 16542, 29788, 2643, 45, 1269, 6224, 2, 108, 4508, 219, 404, 1, 691, 31, 826, 6334, 29, 365, 633, 41, 5, 979, 2, 15, 171, 3242, 933, 6334, 2760, 18200, 4534, 2, 127, 387, 1860, 1337, 207, 593, 7452, 261, 138, 2, 15, 1898, 569, 1, 214, 2, 3515, 92, 32, 438, 5, 3, 55, 1, 1414, 145, 2251, 1199, 6, 691, 31, 6591, 701, 6, 1569, 910, 129, 572, 4797, 3495, 1350, 273, 2, 1815, 154, 8986, 6334, 3886, 6, 40, 933, 2, 3640, 2575, 5, 5255, 1, 20655, 11869, 2, 15910, 373, 1199, 6, 2863, 6, 1791, 15, 2760, 138, 2319, 9212, 1102, 1748, 460, 2287, 5663, 2, 11288, 1598, 21, 5601, 4441, 1, 3, 1091, 973, 17, 5267, 55, 1, 3, 23999, 1836, 2, 2505, 79445, 1269, 55, 1, 250, 986, 102, 1253, 2, 533, 1245, 37, 2210, 68, 2943, 405, 209, 1, 250, 36, 46, 272, 538, 10433, 9, 219, 947, 2, 189, 611]",,29617660,23
Clinical trial methodology in rare gynecologic tumor research: Strategies for success.,Gynecologic oncology,Gynecol. Oncol.,2018-04-24,"Performing clinical trials in rare gynecologic cancers presents specific challenges. Strategies for improving accrual and modifications in clinical trial design are outlined. The literature was reviewed in order to present statistical designs pertinent to the study of rare gynecologic cancers. The experience of the Gynecologic Oncology Group/NRG Oncology is outlined as it relates to rare gynecologic cancer clinical trial development. Significant progress has been made in studying rare tumors, both nationally and in gynecologic oncology, but challenges inherent to the study of uncommon diseases remain. Important components of these trials include establishing the standard of care, utilizing the appropriate clinical trial design to effectively answer the question in the trial, accurately estimating sample size, choosing modified and realistic endpoints, and avoiding pitfalls specific to rare tumors. Adaptive trial design and statistical modifications are important components of clinical trial design in rare tumors. Strategies for effective study of rare gynecologic cancers must be implemented when designing clinical trials for these patients.",Journal Article,637.0,1.0,Performing clinical trials in rare gynecologic cancers presents specific challenges Strategies for improving accrual and modifications in clinical trial design are outlined The literature was reviewed in order to present statistical designs pertinent to the study of rare gynecologic cancers The experience of the Gynecologic Oncology Group/NRG Oncology is outlined as it relates to rare gynecologic cancer clinical trial development Significant progress has been made in studying rare tumors both nationally and in gynecologic oncology but challenges inherent to the study of uncommon diseases remain Important components of these trials include establishing the standard of care utilizing the appropriate clinical trial design to effectively answer the question in the trial accurately estimating sample size choosing modified and realistic endpoints and avoiding pitfalls specific to rare tumors Adaptive trial design and statistical modifications are important components of clinical trial design in rare tumors Strategies for effective study of rare gynecologic cancers must be implemented when designing clinical trials for these patients,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,"[3620, 38, 143, 4, 622, 1512, 163, 2740, 112, 1427, 422, 9, 1673, 2262, 2, 2916, 4, 38, 160, 771, 32, 6394, 3, 789, 10, 446, 4, 1732, 6, 364, 1050, 4120, 5799, 6, 3, 45, 1, 622, 1512, 163, 3, 730, 1, 3, 1512, 413, 87, 8828, 413, 16, 6394, 22, 192, 9228, 6, 622, 1512, 12, 38, 160, 193, 93, 1466, 71, 85, 1229, 4, 4559, 622, 57, 110, 7685, 2, 4, 1512, 413, 84, 1427, 4943, 6, 3, 45, 1, 2052, 1342, 918, 305, 1628, 1, 46, 143, 643, 4431, 3, 260, 1, 165, 2600, 3, 870, 38, 160, 771, 6, 1856, 6634, 3, 2840, 4, 3, 160, 2141, 4563, 1000, 444, 5065, 1230, 2, 7661, 1387, 2, 6048, 9631, 112, 6, 622, 57, 2454, 160, 771, 2, 1050, 2916, 32, 305, 1628, 1, 38, 160, 771, 4, 622, 57, 422, 9, 323, 45, 1, 622, 1512, 163, 1642, 40, 3426, 198, 5048, 38, 143, 9, 46, 7]",,29699802,36
Immunohistochemical evaluation of tumor angiogenesis and the role of mast cells in oral squamous cell carcinoma.,Journal of cancer research and therapeutics,J Cancer Res Ther,,"Increased angiogenesis has been associated with neoplastic progression, metastasis and outcome in several studies and in a number of malignancies. Among the various host immune cells, mast cells have been implicated in tumor progression by promoting angiogenesis. The aim of this study is to examine the relationship between angiogenesis, mast cells with that of the normal oral mucosa (NOM) and oral squamous cell carcinoma (OSCC). The study was conducted using routine haematoxylin and eosin staining procedure and included immunohistochemical staining for microvessels and toluidine blue staining for mast cells. The microvessel density (MVD) and mast cell density (MCD) of two groups (NOM and OSCC). The MVD and MCD in OSCC ranged from 59.18 to 263.31 microvessel/mm <sup>2</sup> and 41.65 to 193.28 cells/mm <sup>2</sup> respectively with mean (standard deviation) 161.73  48.27 microvessel/mm <sup>2</sup> and 83.59  40.67 cells/mm <sup>2</sup>. In both NOM and OSCC, the mean MCD was comparatively lower as compared to respective MVD (MCD < MVD) and comparatively lower in NOM as compared to OSCC (normal < OSCC). A significant correlation is present between MCD and MVD in OSCC and also that both these entities are significantly increased in the disease process when compared to that of the NOM.",Journal Article,,3.0,Increased angiogenesis has been associated with neoplastic progression metastasis and outcome in several studies and in a number of malignancies Among the various host immune cells mast cells have been implicated in tumor progression by promoting angiogenesis The aim of this study is to examine the relationship between angiogenesis mast cells with that of the normal oral mucosa NOM and oral squamous cell carcinoma OSCC The study was conducted using routine haematoxylin and eosin staining procedure and included immunohistochemical staining for microvessels and toluidine blue staining for mast cells The microvessel density MVD and mast cell density MCD of two groups NOM and OSCC The MVD and MCD in OSCC ranged from 59.18 to 263.31 microvessel/mm sup 2 /sup and 41.65 to 193.28 cells/mm sup 2 /sup respectively with mean standard deviation 161.73  48.27 microvessel/mm sup 2 /sup and 83.59  40.67 cells/mm sup 2 /sup In both NOM and OSCC the mean MCD was comparatively lower as compared to respective MVD MCD MVD and comparatively lower in NOM as compared to OSCC normal OSCC A significant correlation is present between MCD and MVD in OSCC and also that both these entities are significantly increased in the disease process when compared to that of the NOM,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[101, 1056, 71, 85, 41, 5, 2000, 91, 278, 2, 228, 4, 392, 94, 2, 4, 8, 207, 1, 441, 107, 3, 747, 1204, 250, 37, 5563, 37, 47, 85, 1771, 4, 30, 91, 20, 2388, 1056, 3, 1130, 1, 26, 45, 16, 6, 1004, 3, 858, 59, 1056, 5563, 37, 5, 17, 1, 3, 295, 518, 2713, 12240, 2, 518, 691, 31, 134, 3785, 3, 45, 10, 426, 75, 1311, 26849, 2, 5975, 1029, 1299, 2, 159, 1382, 1029, 9, 15132, 2, 52559, 3352, 1029, 9, 5563, 37, 3, 4269, 1263, 6066, 2, 5563, 31, 1263, 16479, 1, 100, 271, 12240, 2, 3785, 3, 6066, 2, 16479, 4, 3785, 1869, 29, 728, 203, 6, 6098, 456, 4269, 321, 172, 18, 172, 2, 605, 556, 6, 5744, 339, 37, 321, 172, 18, 172, 106, 5, 313, 27406, 3348, 5377, 803, 810, 576, 428, 4269, 321, 172, 18, 172, 2, 852, 728, 810, 327, 598, 37, 321, 172, 18, 172, 4, 110, 12240, 2, 3785, 3, 313, 16479, 10, 11584, 280, 22, 72, 6, 3847, 6066, 16479, 6066, 2, 11584, 280, 4, 12240, 22, 72, 6, 3785, 295, 3785, 8, 93, 816, 16, 364, 59, 16479, 2, 6066, 4, 3785, 2, 120, 17, 110, 46, 4613, 32, 97, 101, 4, 3, 34, 1129, 198, 72, 6, 17, 1, 3, 12240]",,29893305,2
Mutation allele frequency threshold does not affect prognostic analysis using next-generation sequencing in oral squamous cell carcinoma.,BMC cancer,BMC Cancer,2018-07-24,"With the development of sequencing technologies, there may be some disputes on sequencing analysis. The aim of this study was to investigate different allele frequency thresholds of mutations in targeted genes on prognostic analyses using a panel of cancer associated gene exons (CAGE) in oral squamous cell carcinoma (OSCC). Forty-six patients were included in this study. Twelve genes were sequenced and analyzed using next-generation sequencing from formalin-fixed paraffin-embedded tissues. Allele frequency thresholds of 10, 5, and 3% were used for prognostic analyses. With a mean sequence depth of 3199-fold, 99% of CAGE were represented by at least 10 reads. Ninety-four non-synonymous (missense [70.2%], nonsense [11.7%], splice site [10.6%], and insertion/deletion [7.5%]) mutations were detected in 40 OSCC patients with an allele frequency threshold of 10%. TP53 (78.3%), NOTCH1 (30.4%), CASP8 (13.0%), CDKN2A (10.9%), and CDH1 (6.5%) were the most frequently mutated genes. Using allele frequency thresholds of 10, 5, and 3%, there were no significant differences in clinical outcomes between patients with non-synonymous mutations and wild type genotypes. TP53, NOTCH1, CASP8, CDKN2A, and CDH1 are the most frequently mutated genes in OSCC patients. The allele frequency threshold used in this study does not affect the results of clinical outcome analysis.",Journal Article,546.0,0.0,With the development of sequencing technologies there may be some disputes on sequencing analysis The aim of this study was to investigate different allele frequency thresholds of mutations in targeted genes on prognostic analyses using a panel of cancer associated gene exons CAGE in oral squamous cell carcinoma OSCC Forty-six patients were included in this study Twelve genes were sequenced and analyzed using next-generation sequencing from formalin-fixed paraffin-embedded tissues Allele frequency thresholds of 10 5 and 3 were used for prognostic analyses With a mean sequence depth of 3199-fold 99 of CAGE were represented by at least 10 reads Ninety-four non-synonymous missense 70.2 nonsense 11.7 splice site 10.6 and insertion/deletion 7.5 mutations were detected in 40 OSCC patients with an allele frequency threshold of 10 TP53 78.3 NOTCH1 30.4 CASP8 13.0 CDKN2A 10.9 and CDH1 6.5 were the most frequently mutated genes Using allele frequency thresholds of 10 5 and 3 there were no significant differences in clinical outcomes between patients with non-synonymous mutations and wild type genotypes TP53 NOTCH1 CASP8 CDKN2A and CDH1 are the most frequently mutated genes in OSCC patients The allele frequency threshold used in this study does not affect the results of clinical outcome analysis,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[5, 3, 193, 1, 615, 2590, 125, 68, 40, 476, 79672, 23, 615, 65, 3, 1130, 1, 26, 45, 10, 6, 963, 338, 1254, 675, 4634, 1, 138, 4, 238, 214, 23, 177, 318, 75, 8, 993, 1, 12, 41, 145, 3885, 9493, 4, 518, 691, 31, 134, 3785, 1213, 437, 7, 11, 159, 4, 26, 45, 2544, 214, 11, 4040, 2, 311, 75, 1305, 914, 615, 29, 3265, 1959, 2487, 2505, 742, 1254, 675, 4634, 1, 79, 33, 2, 27, 11, 95, 9, 177, 318, 5, 8, 313, 1532, 2436, 1, 79673, 1116, 1058, 1, 9493, 11, 3324, 20, 28, 506, 79, 11062, 2493, 294, 220, 9287, 4007, 431, 18, 9168, 175, 67, 4371, 606, 79, 49, 2, 5099, 1528, 67, 33, 138, 11, 530, 4, 327, 3785, 7, 5, 35, 1254, 675, 2390, 1, 79, 1206, 833, 27, 4607, 201, 39, 9212, 233, 13, 3175, 79, 83, 2, 5813, 49, 33, 11, 3, 96, 746, 1185, 214, 75, 1254, 675, 4634, 1, 79, 33, 2, 27, 125, 11, 77, 93, 362, 4, 38, 123, 59, 7, 5, 220, 9287, 138, 2, 955, 267, 2071, 1206, 4607, 9212, 3175, 2, 5813, 32, 3, 96, 746, 1185, 214, 4, 3785, 7, 3, 1254, 675, 2390, 95, 4, 26, 45, 1097, 44, 1158, 3, 99, 1, 38, 228, 65]",,30041611,0
Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV<sup>+</sup> Oral Cancers.,Cancer research,Cancer Res.,2018-07-27,"High-risk human papillomavirus (HPV)-associated squamous cell carcinomas of the oropharynx (SCCOP) are among the fastest growing cancers. After standard-of-care treatment, however, patients with HPV<sup>+</sup> SCCOP have better overall and disease-specific survival than patients with HPV<sup>-</sup> SCCOP, suggesting the importance of HPV-specific immunity. We reasoned that therapeutic vaccination targeting the HPV-16 E6 and E7 oncogenes could elicit high-affinity, high-frequency tumor antigen-specific T-cell responses, which could then be augmented and shielded from suppression in the tumor microenvironment by immune checkpoint modulation. In this study, we used a preclinical syngeneic mouse model of oral cancer comprised of mouse tonsil-derived epithelial cells stably expressing HPV-16 E6 and E7 genes along with H-ras oncogene (mEER) to identify combinations of vaccination and checkpoint antibodies capable of promoting tumor regression. Intranasal HPV E6/E7 peptide vaccination and single checkpoint antibodies failed to elicit responses in more than half of animals; however, 4-1BB agonist antibody along with either CD40 agonist antibody or CTLA-4 blockade eliminated the majority of established mEER tumors. The combination of intranasal HPV peptide vaccine and 4-1BB and CTLA-4 antibodies produced curative efficacy and a better safety profile against orally implanted mEER tumors. Correlates of protective immunity included enhanced intratumoral levels of CD8 T cells relative to immunosuppressive regulatory T cells and myeloid-derived suppressor cells. Overall, our results demonstrate combination vaccine-immunotherapy modalities as novel treatment options for HPV<sup>+</sup> SCCOP.<b>Significance:</b> Combinations of vaccine and checkpoint modulation are effective and safe treatment options for HPV<sup>+</sup> oral cancers. <i>Cancer Res; 78(18); 5327-39. 2018 AACR</i>.",Journal Article,543.0,4.0,High-risk human papillomavirus HPV -associated squamous cell carcinomas of the oropharynx SCCOP are among the fastest growing cancers After standard-of-care treatment however patients with HPV sup /sup SCCOP have better overall and disease-specific survival than patients with HPV sup /sup SCCOP suggesting the importance of HPV-specific immunity We reasoned that therapeutic vaccination targeting the HPV-16 E6 and E7 oncogenes could elicit high-affinity high-frequency tumor antigen-specific T-cell responses which could then be augmented and shielded from suppression in the tumor microenvironment by immune checkpoint modulation In this study we used a preclinical syngeneic mouse model of oral cancer comprised of mouse tonsil-derived epithelial cells stably expressing HPV-16 E6 and E7 genes along with H-ras oncogene mEER to identify combinations of vaccination and checkpoint antibodies capable of promoting tumor regression Intranasal HPV E6/E7 peptide vaccination and single checkpoint antibodies failed to elicit responses in more than half of animals however 4-1BB agonist antibody along with either CD40 agonist antibody or CTLA-4 blockade eliminated the majority of established mEER tumors The combination of intranasal HPV peptide vaccine and 4-1BB and CTLA-4 antibodies produced curative efficacy and a better safety profile against orally implanted mEER tumors Correlates of protective immunity included enhanced intratumoral levels of CD8 T cells relative to immunosuppressive regulatory T cells and myeloid-derived suppressor cells Overall our results demonstrate combination vaccine-immunotherapy modalities as novel treatment options for HPV sup /sup SCCOP. b Significance /b Combinations of vaccine and checkpoint modulation are effective and safe treatment options for HPV sup /sup oral cancers i Cancer Res 78 18 5327-39 2018 AACR /i,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[64, 43, 171, 3242, 933, 41, 691, 31, 826, 1, 3, 5333, 28796, 32, 107, 3, 18177, 1921, 163, 50, 260, 1, 165, 24, 137, 7, 5, 933, 172, 172, 28796, 47, 380, 63, 2, 34, 112, 25, 76, 7, 5, 933, 172, 172, 28796, 802, 3, 1187, 1, 933, 112, 1604, 21, 15577, 17, 189, 1915, 529, 3, 933, 245, 4837, 2, 4540, 3326, 359, 5487, 64, 3601, 64, 675, 30, 448, 112, 102, 31, 253, 92, 359, 818, 40, 4277, 2, 17327, 29, 1332, 4, 3, 30, 995, 20, 250, 986, 2356, 4, 26, 45, 21, 95, 8, 693, 5174, 830, 202, 1, 518, 12, 2603, 1, 830, 10226, 526, 701, 37, 5834, 1046, 933, 245, 4837, 2, 4540, 214, 1510, 5, 555, 1102, 1836, 42757, 6, 255, 1247, 1, 1915, 2, 986, 890, 2787, 1, 2388, 30, 320, 24906, 933, 4837, 4540, 1389, 1915, 2, 226, 986, 890, 1551, 6, 5487, 253, 4, 80, 76, 1303, 1, 2258, 137, 39, 6521, 3821, 548, 1510, 5, 361, 5040, 3821, 548, 15, 2127, 39, 1189, 6173, 3, 686, 1, 635, 42757, 57, 3, 150, 1, 24906, 933, 1389, 1274, 2, 29153, 6521, 2, 39639, 39, 890, 1687, 1075, 209, 2, 8, 380, 367, 800, 480, 1428, 3416, 42757, 57, 1871, 1, 2864, 1604, 159, 651, 2074, 148, 1, 968, 102, 37, 580, 6, 2989, 1253, 102, 37, 2, 533, 526, 1245, 37, 63, 114, 99, 608, 150, 1274, 726, 1558, 22, 229, 24, 838, 9, 933, 172, 172, 28796, 132, 724, 132, 1247, 1, 1274, 2, 986, 2356, 32, 323, 2, 1165, 24, 838, 9, 933, 172, 172, 518, 163, 70, 12, 1936, 833, 203, 30841, 587, 4281, 1630, 70]",,30054333,10
Intramedullary Capillary Hemangioma Presenting with Hydrocephalus and Spastic Paraparesis in 2-Month-Old Infant.,World neurosurgery,World Neurosurg,2019-01-24,"Intramedullary capillary hemangiomas are rare lesions with only 14 cases reported so far and are found in middle-aged persons. Until now only a single case has been reported in the pediatric population. Ours was the second pediatric case and the youngest of all to be diagnosed with an intramedullary capillary hemangioma. We are reporting the case of a 2-month male child who presented with features of hydrocephalus and spastic paraparesis. On magnetic resonance imaging he had features suggestive of a D10-11 intradural extramedullary lesion and hydrocephalus. We did a ventriculoperitoneal shunt followed by excision of the lesion in the same sitting. Intraoperatively it was found to be an intramedullary lesion, and histopathologic examination showed features suggestive of capillary hemangioma. Postoperatively he recovered well and there is no recurrence 18 months after surgery. Intramedullary capillary hemangiomas are extremely rare lesions in infants but should be kept in mind while treating any patient with the spinal lesion. Further reporting of similar cases will help in understanding the natural history, pathogenesis, and management.",Case Reports,362.0,0.0,Intramedullary capillary hemangiomas are rare lesions with only 14 cases reported so far and are found in middle-aged persons Until now only a single case has been reported in the pediatric population Ours was the second pediatric case and the youngest of all to be diagnosed with an intramedullary capillary hemangioma We are reporting the case of a 2-month male child who presented with features of hydrocephalus and spastic paraparesis On magnetic resonance imaging he had features suggestive of a D10-11 intradural extramedullary lesion and hydrocephalus We did a ventriculoperitoneal shunt followed by excision of the lesion in the same sitting Intraoperatively it was found to be an intramedullary lesion and histopathologic examination showed features suggestive of capillary hemangioma Postoperatively he recovered well and there is no recurrence 18 months after surgery Intramedullary capillary hemangiomas are extremely rare lesions in infants but should be kept in mind while treating any patient with the spinal lesion Further reporting of similar cases will help in understanding the natural history pathogenesis and management,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[8686, 8943, 11984, 32, 622, 406, 5, 158, 213, 140, 210, 1743, 3272, 2, 32, 204, 4, 3897, 1032, 4327, 1100, 1134, 158, 8, 226, 473, 71, 85, 210, 4, 3, 815, 266, 23206, 10, 3, 419, 815, 473, 2, 3, 13042, 1, 62, 6, 40, 265, 5, 35, 8686, 8943, 12712, 21, 32, 1760, 3, 473, 1, 8, 18, 811, 1045, 2566, 54, 917, 5, 404, 1, 9250, 2, 51549, 28373, 23, 1484, 1535, 270, 3174, 42, 404, 3832, 1, 8, 29034, 175, 14288, 5508, 1180, 2, 9250, 21, 205, 8, 16283, 8637, 370, 20, 1366, 1, 3, 1180, 4, 3, 827, 18459, 6595, 192, 10, 204, 6, 40, 35, 8686, 1180, 2, 2630, 1385, 224, 404, 3832, 1, 8943, 12712, 3541, 3174, 5784, 149, 2, 125, 16, 77, 146, 203, 53, 50, 152, 8686, 8943, 11984, 32, 2938, 622, 406, 4, 5585, 84, 257, 40, 11322, 4, 8090, 369, 1367, 500, 69, 5, 3, 1499, 1180, 195, 1760, 1, 288, 140, 303, 987, 4, 612, 3, 1504, 532, 1384, 2, 284]",,30685376,10
Smokeless tobacco use and oral neoplasia among urban Indian women.,Oral diseases,Oral Dis,2019-08-19,"Oral cavity cancers are fourth most common cancers among Indian women. The objectives were to create cancer awareness (CA) and screen tobacco-using women for oral cavity cancers. A community-based CA and screening programme was conducted among women in Mumbai, India. The tobacco-using women participated in CA and oral cavity screening by oral visual inspection (OVI). All screen-positive women were referred to nodal hospital and assisted for diagnostic confirmation and treatment completion. Twelve slum clusters comprising of 138,383 population and 13,492 tobacco-using women have been covered. Among them, 11,895 (88.2%) participated in CA and 11,768 (87.2%) in OVI. A total of 377 (3.2%) women were screened positive, 275 (72.9%) complied with referral and 207 oral precancers [173 leukoplakia, 9 erythroplakia, 3 erythroleukoplakia and 41 sub-mucus fibrosis (SMF) including 35 women with multiple precancers] and 7 oral cancers were diagnosed. The detection rate of oral precancerous lesions and oral cancers was 17.6 and 0.6 per 1,000 screened women. Thirty-five women had multiple oral precancerous lesions. The results of multivariate analysis indicate dose-response relationship between tobacco use and risk of oral precancers. Good participation rates (>85%) for cancer awareness and OVI were seen among urban slum women in India. Many oral precancer and cancer cases were detected and were managed at the nodal hospital.",Journal Article,155.0,0.0,"Oral cavity cancers are fourth most common cancers among Indian women The objectives were to create cancer awareness CA and screen tobacco-using women for oral cavity cancers A community-based CA and screening programme was conducted among women in Mumbai India The tobacco-using women participated in CA and oral cavity screening by oral visual inspection OVI All screen-positive women were referred to nodal hospital and assisted for diagnostic confirmation and treatment completion Twelve slum clusters comprising of 138,383 population and 13,492 tobacco-using women have been covered Among them 11,895 88.2 participated in CA and 11,768 87.2 in OVI A total of 377 3.2 women were screened positive 275 72.9 complied with referral and 207 oral precancers 173 leukoplakia 9 erythroplakia 3 erythroleukoplakia and 41 sub-mucus fibrosis SMF including 35 women with multiple precancers and 7 oral cancers were diagnosed The detection rate of oral precancerous lesions and oral cancers was 17.6 and 0.6 per 1,000 screened women Thirty-five women had multiple oral precancerous lesions The results of multivariate analysis indicate dose-response relationship between tobacco use and risk of oral precancers Good participation rates 85 for cancer awareness and OVI were seen among urban slum women in India Many oral precancer and cancer cases were detected and were managed at the nodal hospital",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,"[518, 2405, 163, 32, 3608, 96, 186, 163, 107, 7968, 117, 3, 2409, 11, 6, 3736, 12, 3310, 1568, 2, 2413, 2607, 75, 117, 9, 518, 2405, 163, 8, 1714, 90, 1568, 2, 453, 11410, 10, 426, 107, 117, 4, 33733, 7776, 3, 2607, 75, 117, 3025, 4, 1568, 2, 518, 2405, 453, 20, 518, 3046, 11746, 42791, 62, 2413, 109, 117, 11, 1995, 6, 779, 702, 2, 2927, 9, 752, 3551, 2, 24, 1438, 2544, 52657, 3780, 3538, 1, 4478, 10574, 266, 2, 233, 11628, 2607, 75, 117, 47, 85, 4306, 107, 1370, 175, 15241, 889, 18, 3025, 4, 1568, 2, 175, 15188, 912, 18, 4, 42791, 8, 181, 1, 8211, 27, 18, 117, 11, 2261, 109, 5620, 720, 83, 26387, 5, 2096, 2, 5292, 518, 18753, 5785, 15359, 83, 80047, 27, 80048, 2, 605, 551, 20605, 3000, 80049, 141, 465, 117, 5, 232, 18753, 2, 67, 518, 163, 11, 265, 3, 638, 116, 1, 518, 6605, 406, 2, 518, 163, 10, 269, 49, 2, 13, 49, 379, 14, 984, 2261, 117, 977, 365, 117, 42, 232, 518, 6605, 406, 3, 99, 1, 331, 65, 1008, 61, 51, 858, 59, 2607, 119, 2, 43, 1, 518, 18753, 1178, 2599, 151, 772, 9, 12, 3310, 2, 42791, 11, 527, 107, 5532, 52657, 117, 4, 7776, 445, 518, 12380, 2, 12, 140, 11, 530, 2, 11, 2231, 28, 3, 779, 702]",,31348589,191
